<SEC-DOCUMENT>0001326110-24-000037.txt : 20240319
<SEC-HEADER>0001326110-24-000037.hdr.sgml : 20240319
<ACCEPTANCE-DATETIME>20240319163153
ACCESSION NUMBER:		0001326110-24-000037
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		124
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240319
DATE AS OF CHANGE:		20240319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunityBio, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		24763912

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(844) 696-5235

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NantKwest, Inc.
		DATE OF NAME CHANGE:	20150713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ibrx-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1fd74a66-0ec9-47b3-a3a2-77069a10a521,g:7ebe44e2-bf98-46f1-8b70-fddc2baf2bbb,d:f7eeec8e66644046bbbe3c0a87df2c46-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ibrx="http://www.immunitybio.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ibrx-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001326110</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-1044">http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="c-10" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1125">http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-370" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-1163">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="c-370" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="f-1165">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1170">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1171">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1178">http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1179">http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1184">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1185">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-1722">zero</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-1723">zero</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-668" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-1922">0.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-669" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-1923">0.5</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ibrx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantKwestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibrx:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:AdvancesToRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ibrx:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>ibrx:security</xbrli:measure></xbrli:unit><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-25</xbrli:startDate><xbrli:endDate>2023-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015AmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:AmyrisIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="licenseagreement"><xbrli:measure>ibrx:licenseAgreement</xbrli:measure></xbrli:unit><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:ViractaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:ViractaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:ViractaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-14</xbrli:startDate><xbrli:endDate>2022-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-14</xbrli:startDate><xbrli:endDate>2022-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-14</xbrli:startDate><xbrli:endDate>2022-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="renewal_options"><xbrli:measure>ibrx:renewal_options</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>ibrx:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:DrSoonShiongAndRelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-09</xbrli:startDate><xbrli:endDate>2022-07-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-08</xbrli:startDate><xbrli:endDate>2022-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">ibrx:CGMPBatchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">ibrx:SoftwareLicenseSubscriptionFeesAndImplementationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">ibrx:LaboratoryCleanroomServiceCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:InitialPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:InitialPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:SecondPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:SecondPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:InitialPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:SecondPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-30</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:EmbeddedDerivativeRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-30</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:CommonStockRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-30</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-30</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Tranche1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Tranche1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-17</xbrli:startDate><xbrli:endDate>2021-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="advance"><xbrli:measure>ibrx:advance</xbrli:measure></xbrli:unit><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-13</xbrli:startDate><xbrli:endDate>2023-06-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-11</xbrli:startDate><xbrli:endDate>2023-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-11</xbrli:startDate><xbrli:endDate>2023-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputExpectedMarketYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:RelatedPartyFixedRateNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:VariousMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:VariousMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-03</xbrli:startDate><xbrli:endDate>2023-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>ibrx:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SeptemberTwentyNineteenLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:JulyTwentyNineteenLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-27</xbrli:startDate><xbrli:endDate>2021-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-20</xbrli:startDate><xbrli:endDate>2023-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLLCMemberMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:A2014PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-09</xbrli:startDate><xbrli:endDate>2021-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-25</xbrli:startDate><xbrli:endDate>2023-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ibrx:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-25</xbrli:startDate><xbrli:endDate>2023-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-25</xbrli:startDate><xbrli:endDate>2023-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#254;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>,&#160;2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#168;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from                     to     </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-37507</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">IMMUNITYBIO,&#160;INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">43-1979754</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">3530 John Hopkins Court</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">844</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">696-5235</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.152%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">IBRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#168;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#168;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#254;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#254;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#168;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15&#160;U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-26">&#168;</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#168;</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#168;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s voting and non-voting common equity held by non-affiliates, computed based on the closing price of shares of common stock on the Nasdaq Global Select Market on June&#160;30,&#160;2023 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">315.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s common stock outstanding as of March&#160;14,&#160;2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">673,952,278</ix:nonFraction> (excluding 163,800&#160;shares held by a majority owned subsidiary of ours that are treated as treasury shares for accounting purposes).</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted herein, the information called for by Part&#160;III of this Annual Report is incorporated by reference to specified portions of the registrant&#8217;s definitive proxy statement to be filed in conjunction with the registrant&#8217;s 2024&#160;Annual Meeting of Stockholders, which is expected to be filed not later than 120&#160;days after the registrant&#8217;s fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> December&#160;31,&#160;2023.</span></div></ix:nonNumeric><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNITYBIO, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEAR ENDED DECEMBER&#160;31,&#160;2023</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.511%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">PART I</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_16">Business.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 1A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_49">Risk Factors.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_49">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 1B.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_52">Unresolved Staff Comments.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_52">106</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 1C.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_926">Cybersecurity.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_926">107</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_55">Properties.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_55">109</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_58">Legal Proceedings.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_58">109</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_61">Mine Safety Disclosures.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_61">110</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">PART II</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 5.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_67">Issuer Purchases of Equity Securities.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_67">111</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_70">Reserved.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_70">112</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 7.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_73">113</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 7A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_124">Quantitative and Qualitative Disclosures About Market Risk.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_124">135</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 8.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_127">Financial Statements and Supplementary Data.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_127">137</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 9.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_244">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_244">206</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 9A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_247">Controls and Procedures.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_247">206</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 9B.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_250">Other Information.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_250">207</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 9C.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_253">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_253">207</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">PART III</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 10.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_259">Directors, Executive Officers and Corporate Governance.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_259">208</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 11.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_262">Executive Compensation.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_262">208</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 12.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_265">Security Ownership of Certain Beneficial Owners and Management and </a></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_265">Related Stockholder Matters.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_265">208</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 13.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:25.37pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_268">Certain Relationships and Related Transactions, and Director Independence.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_268">208</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 14.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:25.37pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_271">Principal Accountant Fees and Services.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_271">208</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">PART IV</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 15.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_277">Exhibits and Financial Statement Schedules.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_277">209</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Item 16.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_280">Form 10-K Summary.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_280">215</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_283">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_283">216</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Defined Terms</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless expressly indicated or the context required otherwise, the terms &#8220;ImmunityBio,&#8221; &#8220;the&#160;company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this Annual Report refer to ImmunityBio,&#160;Inc., a Delaware corporation, and, where appropriate, its subsidiaries. We have also used several other terms in this Report, the consolidated financial statements and accompanying notes included herein, most of which are defined below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definition</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantKwest, Inc. 2014 Equity Incentive Plan</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmunityBio, Inc. 2015 Equity Incentive Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Share Repurchase Program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board of Directors-approved share repurchase program </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3M&#160;IPC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3M Innovative Properties Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401(k) Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401(k) retirement and savings plan</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AAHI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Access to Advanced Health Institute</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affordable Care Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADCC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">antibody-dependent cellular cytotoxicity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altor BioScience, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">America Invents Act</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leahy-Smith America Invents Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AML</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acute myeloid leukemia</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amyris</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amyris, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anktiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proposed proprietary name for N-803, our novel antibody-cytokine fusion protein (nogapendekin&#160;alfa inbakicept-pmln) in the non-muscle invasive bladder cancer indication. The FDA has not yet approved this proposed proprietary name for such use, and this proposed proprietary name will be approved at the time the BLA is approved, if at all.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual Report</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual Report on Form&#160;10-K</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ART</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">anti-retroviral therapy</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting Standards Codification</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASCO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Society of Clinical Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting Standards Update</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Athenex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Athenex, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;at-the-market&#8221; sales agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Taxpayer Relief Act of 2012</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biomedical Advanced Research and Development Authority</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BCG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bacillus Calmette-Gu&#233;rin</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beike</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shenzhen Beike Biotechnology Co. Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BICR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">blinded independent central review</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics License Application</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BPCIA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics Price Competition and Innovation Act of 2009</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bNAbs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">broadly-neutralizing antibodies</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brink</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brink Biologics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge Equities, LP</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chimeric antigen receptor</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CCPA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Consumer Privacy Act of 2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chief executive officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CFO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chief financial officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cGMP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">current Good Manufacturing Practice</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">when used in connection with the RIPA, People&#8217;s Republic of China, Hong Kong and any territories controlled by the People&#8217;s Republic of China</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definition</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">confidence interval</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">chief information officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">carcinoma in situ</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-Oncology Clinic, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing Date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">when used in connection with the RIPA, December&#160;29,&#160;2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chemistry, Manufacturing and Controls</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">contract manufacturing organization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Code</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal Revenue Code of 1986, as amended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">common stock, par value $0.0001&#160;per share, of the company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CPRA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Privacy Rights Act of 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">complete response</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRADA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cooperative Research and Development Agreement</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">complete response letter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">contract research organization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CVR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">contingent value right</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cynviloq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IG-101 (paclitaxel nanoparticle polymeric micelle)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DGCL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware General Corporation Law</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DSCSA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug Supply Chain Security Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duley Road</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duley Road, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunkirk Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a leasehold interest in a cGMP ISO Class&#160;5 pharmaceutical manufacturing space in <br/>&#160;&#160;&#160;western New&#160;York</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EGFR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">epidermal growth factor receptor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ERM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise Risk Management</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Etubics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Etubics Corporation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">emergency use authorization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange Act</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange Ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a right to receive&#160;0.8190 newly issued shares of Company Common Stock</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exyte</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exyte&#160;U.S., Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FCA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">False Claims Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Foreign Corrupt Practices Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FD&amp;C Act</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Food, Drug, and Cosmetic Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FDASIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food and Drug Administration Safety and Innovation Act of 2012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FSMC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fort Schuyler Management Corporation, a not-for-profit corporation affiliated with the <br/>&#160;&#160;&#160;state of New York </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal Trade Commission</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">freedom-to-operate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FVO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">fair value option</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">glioblastoma multiforme</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definition</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GCP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Good Clinical Practice</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GDPR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Data Protection Regulation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GlobeImmune</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GlobeImmune, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GLP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Good Laboratory Practice</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GMP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Good Manufacturing Practice</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">hAd5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">human adenovirus serotype&#160;5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hatch-Waxman Act</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug Price Competition and Patent Term Restoration Act of 1984</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCW</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCW&#160;Biologics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HHS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Department of Health and Human Services</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIPAA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Insurance Portability and Accountability Act of 1996</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HITECH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Information Technology for Economic and Clinical Health Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">human immunodeficiency virus</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">immune checkpoint blockade</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investigational Device Exemption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IDRI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infectious Disease Research Institute</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IgDraSol</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IgDraSol,&#160;Inc., a subsidiary of the company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IL-15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">novel interleukin 15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">investigational new drug</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infinity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infinity&#160;SA LLC, as purchaser agent for affiliates of Oberland</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Institutional review boards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LadRx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LadRx Corporation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMIC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">low- and middle-income countries</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung-MAP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lung Cancer Master Protocol</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M-ceNK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">memory-like cytokine-enhanced NK cells</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">mAbs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">monoclonal antibodies</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MDSC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">myeloid-derived suppressor cells</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">majors histocompatability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MNC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">mononuclear cells</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nant Capital, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantBio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantBio, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCell,&#160;Inc., a subsidiary of the company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NANTibody</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunotherapy NANTibody,&#160;LLC, a subsidiary of the company</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantKwest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantKwest, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantMobile, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantPharma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantPharma, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantWorks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantWorks, LLC, a related-party</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NC 2015 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCell, Inc. 2015 Stock Incentive Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Cancer Institute</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCSC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NantCancerStemCell, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NCTN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Clinical Trials Network</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definition</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">named executive officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NHP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-human primate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIAID</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Institute of Allergy and Infectious Diseases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIDCD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Institute on Deafness and Other Communication Disorders</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">National Institutes of Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIH Guidelines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIH Guidelines for Research Involving Recombinant DNA Molecules</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">natural killer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">nanostructured lipid carrier</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NMIBC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-muscle invasive bladder cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net operating loss</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OBA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NIH Office of Biotechnology Activities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oberland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oberland Capital Management LLC and its affiliates (including Purchasers as <br/>&#160;&#160;&#160;defined in the RIPA)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OFAC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Control</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OSHA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupational Safety and Health Administration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OWS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operation Warp Speed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PCAOB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public Company Accounting Oversight Board (United States)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDMA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Prescription Drug Marketing Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDUFA date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">user fee goal date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">physical function</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protected Health Information</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHSA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public Health Service Act</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PIK</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">paid-in-kind</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">premarket approval</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PREA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pediatric Research Equity Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient Recorded Outcomes</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proxy Statement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 14A in connection with our 2024 Annual Meeting of Stockholders</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QMSR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality Management System Regulation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QSR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality System Regulation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">research and development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;E</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">research and experimental expenditures</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recombinant DNA Advisory Committee</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RECIST</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">response evaluation criteria in solid tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REMS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Evaluation and Mitigation Strategy</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIPA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Purchase Agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riptide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riptide Bioscience, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">restricted stock unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarbanes-Oxley</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarbanes-Oxley Act of 2002</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">saRNA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">self-amplifying RNA</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SARS-CoV-2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">novel strain of the coronavirus (COVID-19)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definition</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SBRT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">stereotactic body radiotherapy</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 404</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 404 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Act</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Act of 1933, as amended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCLC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">small cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sorrento</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sorrento Therapeutics,&#160;Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPOA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Purchase and Option Agreement </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SRLY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">separate return limitation year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SWOG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SWOG Cancer Research Network</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">tumor-associated antigen</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TCJA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Cuts and Jobs Act of 2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term SOFR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Secured Overnight Financing Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Test Date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">when used in connection with the RIPA, December&#160;31,&#160;2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">toll-like receptor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory T cells</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. GAAP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">accounting principles generally accepted in the United States of America</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USPTO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Patent and Trademark Office</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VBC Holdings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VBC Holdings,&#160;LLC, a subsidiary of the company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable interest entity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viracta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viracta Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VivaBioCell</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VivaBioCell, S.p.A., a wholly-owned subsidiary of VBC Holdings</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">v</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_16"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. &#160;&#160;&#160;&#160;BUSINESS.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_19"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional financing to fund our operations and complete the development and commercialization of our various product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not the FDA will ultimately determine that the BLA resubmission and related actions successfully address and resolve the issues identified in the CRL;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and the ability of our third-party CMOs, to adequately address the issues raised in the FDA&#8217;s CRL;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the FDA approval milestone after which Oberland may purchase $100.0&#160;million in Revenue Interests will be achieved; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet our payment obligations under the RIPA and to service the interest on our related-party promissory notes and repay such notes, to the extent required;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the terms, conditions, covenants, restrictions, and obligations set forth in the RIPA and related transaction documents;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the potential benefits of our strategy and technology;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to forecast operating results and make period-to-period comparisons predictive of future performance due to fluctuations in warrant values;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the operation and effectiveness of our product candidates and related benefits;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize multiple modes to induce cell death;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">details regarding our strategic vision and planned product candidate pipeline;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the success, cost and timing of our product candidate development activities and current and future clinical trials and studies, including study design and the enrollment of patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of the development and commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to utilize the Phase&#160;I/II aNK and haNK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials data to support the development of our product candidates, including our haNK, taNK, t&#8209;haNK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MSC, and M-ceNK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the development, application, commercialization, marketing, prospects and use generally of our product candidates, including Anktiva, hAd5 and saRNA constructs, and PD-L1 t&#8209;haNK and M-ceNK;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned IND, BLA or NDA filings or pursuit of accelerated regulatory approval pathways or orphan drug status and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem, including being able to regularly add neoepitopes and subsequently formulate new product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of strategic collaborators to share our vision and effectively work with us to achieve our goals;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of various third parties to engage in R&amp;D activities involving our product candidates, and our ability to leverage those activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract additional third-party collaborators;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the ease of administration associated with our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding patient compatibility associated with our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the potential markets for our product candidates and our ability to serve those markets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the timing of enrollment and submission of our clinical trials, and protocols related to such trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to produce an antibody-cytokine fusion protein, a DNA, RNA, or recombinant protein vaccine, or a cell therapy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our third-party CMOs&#8217; abilities to follow cGMP standards to scale up the production of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans regarding our manufacturing facilities and our belief that our manufacturing is capable of being conducted in&#8209;house;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief in the potential of our antibody-cytokine fusion proteins, DNA, RNA, or recombinant protein vaccines, or cell therapies, and the fact that our business is based upon the success individually and collectively of these platforms;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief regarding the magnitude or duration for additional clinical testing of our antibody-cytokine fusion proteins, DNA, RNA or recombinant protein vaccines, or cell therapies, along with other product candidate families;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">even if we successfully develop and commercialize specific product candidates like our N-803 or PD-L1 t&#8209;haNK, our ability to develop and commercialize our other product candidates either alone or in combination with other therapeutic agents;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize any approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of any approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding our future revenue, as well as our future operating expenses, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for our product candidates and technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and conditions of licenses granted to us and our ability to license additional intellectual property relating to our product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any government shutdown, which could adversely affect the U.S. and global economies, and materially and adversely affect our business and/or our BLA submission;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on us, if any, if the CVRs held by former Altor stockholders become due and payable in accordance with their terms; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements include statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;goal,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;scheduled,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;indicate,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;strategy,&#8221; and variations of such words or similar expressions. and the negatives of those terms. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. These statements are based upon information available to us as of the date of this Annual Report, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Item&#160;1A. &#8220;Risk Factors&#8221; of this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Annual Report.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ImmunityBio, NantKwest, Anktiva, VesAnktiva, ThAnktiva, NK-92, ceNK, M-ceNK, haNK, taNK, t-haNK, GlobeImmune, Tarmogen, VivaBioCell, Nant001, NantXL, Nant Cancer Vaccine, QUILT, IPRT, Outsmart Your Disease, Smart Therapies for Difficult Diseases, and Nature&#8217;s First Responder are trademarks of ImmunityBio, Inc., its subsidiaries, or its affiliates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our product candidates, including N-803, are investigational agents that are restricted by federal law to investigational use only. Safety and efficacy have not been established by any agency, including the FDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report contains references to our trademarks and trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We&#160;do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us, by any other companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Using our proprietary platforms that amplify both the innate and adaptive branches of the immune system, our teams of clinical, scientific, and manufacturing experts, advance novel therapies and vaccines aimed at defeating urologic and other cancers, as well as infectious diseases. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations and is currently under review by the FDA for treatment in combination with BCG of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease and has a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including&#8212;NK cells, dendritic cells, and macrophages, as well as&#8212;the adaptive immune system comprising&#8212;B&#160;and T&#160;cells,&#8212;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally-infected. Our ultimate goal is to overcome the limitations of current treatments, such as checkpoint inhibitors, and/or reduce the need for standard high-dose chemotherapy in cancer by employing this coordinated approach to establish &#8220;immunological memory&#8221; that confers long-term benefit for the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary platforms for the development of biologic product candidates include: (i)&#160;antibody-cytokine fusion proteins, (ii)&#160;DNA, RNA, and recombinant protein vaccines, and (iii)&#160;cell therapies. These platforms have generated 9&#160;novel therapeutic agents for which clinical trials are either underway or planned in solid and liquid tumors. Specifically, our clinical focus includes bladder, lung, and colorectal cancers and GBM, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. In May&#160;2022, we announced the submission of a BLA to the FDA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. The CRL did not request new preclinical studies or Phase&#160;III clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company&#8217;s resubmission, as well as a safety update. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. As part of our resubmission, we provided an update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG unresponsive subjects with high-risk CIS disease. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further late-stage efforts for Anktiva are in development within the broader bladder cancer space, including BCG-na&#239;ve NMIBC. In addition, data from multiple clinical trials suggest N-803 has potential to enhance the activity of therapeutic mAbs, including checkpoint inhibitors (e.g., pembrolizumab/Keytruda), across a wide range of tumor types. We believe there is potential for N-803 to become a therapeutic foundation across all phases of treatment, including in adjunctive therapy, to amplify, reactivate or extend the efficacy of standard of care. In addition to N-803, we have active clinical programs evaluating therapeutic candidates from our DNA and RNA vaccine technology platforms and our NK&#160;cell-based therapy platforms in oncology and infectious disease indications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests (as defined in the RIPA) from us for a gross purchase price of $200.0&#160;million paid on closing, less certain transaction expenses. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including following the receipt of approval by the FDA of the company&#8217;s BLA for N-803 in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease on or before June&#160;30,&#160;2024 (the Second Payment). Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $10.0&#160;million of our common stock at $4.1103&#160;per share in a private placement. Oberland also has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. </span></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:20.61pt">Our Strategy</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to become a leading global immunological therapeutics company by creating next-generation immuno- and cell therapies to address serious unmet needs within urologic and other cancers as well as infectious diseases. To achieve this goal, the key elements of our strategy include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advancing the approval and commercialization of our lead IL-15 superagonist antibody-cytokine fusion protein, N-803, as an integral component of immunotherapy combinations, including those with checkpoint inhibitors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continuously scrutinizing our clinical pipeline;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerating product candidates generated from our immunotherapy platforms with registrational intent to address difficult-to-treat oncological and infectious disease indications;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continuing to prospect, license, and acquire technologies to complement and strengthen our platforms and product candidates, both as single agent and combination therapies, in order to optimize responses of the innate and adaptive immune systems to generate cellular memory against multiple tumor types and infectious diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investing in our discovery, development, and manufacturing capabilities for our next-generation product candidates in both oncology and infectious disease; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultivating new and expanding existing collaborations for our multi-stage pipeline to reach global scale efficiently.</span></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">II.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.72pt">Our Next-Generation Platforms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody-Cytokine Fusion Proteins</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibody-cytokine fusion proteins, such as N-803, are a novel class of biologics that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. N-803 is an IL-15 superagonist fusion protein consisting of high-affinity mutant IL-15N72D fused to the IL-15 receptor&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#945;&#160;sushi subunit and linked to the Fc&#160;portion of IgG1&#160;Fc that exerts its effects via enhanced IL-2 receptor </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#946;&#160;site binding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N-803 specifically increases proliferation and activation of two&#160;critical cell types of the immune system &#8211; NK&#160;cells and cytotoxic (tumor cell killing) CD8+T-cells &#8211; but not immunosuppressive T-reg&#160;cells, leading to the establishment of memory T&#160;cells. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anktiva </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations by the FDA for the treatment of BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease as well as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation for BCG-unresponsive NMIBC papillary and BCG-na&#239;ve NMIBC with CIS. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We note such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, on October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that other N-803 indications with registration potential include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG-unresponsive papillary, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG-na&#239;ve CIS and BCG-na&#239;ve papillary, lung and colorectal cancers, and GBM in oncology and HIV in infectious diseases. </span></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:19pt;font-weight:700;line-height:120%">N-803</span></div><div style="margin-top:12pt;text-align:center"><img src="ibrx-20231231_g1.jpg" alt="04-IL-15.jpg" style="height:558px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to N-803, we are developing bi-specific fusion proteins targeting PD-L1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IL-12, and TGF-&#223; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enhance NK and T-cell activation directed to the infectious disease or tumor microenvironment, and to modulate the systemic and local immune response to accelerate immunogenic cell death. Prioritized product candidates in preclinical development include antibody-cytokine fusion proteins </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N-809 (targeting PD-L1), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N-812 (delivering IL-12 to necrotic tumor cells), and N-830 (delivering a TGF-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#223;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Trap to necrotic tumor cells). </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA, RNA, and Recombinant Protein Vaccines</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and/or acquired rights to multiple vaccine delivery technologies for oncology to deliver common TAAs, and neoepitopes (expressed only by cancer cells) and for infectious diseases to target key viruses, including SARS-CoV-2. These technologies can deliver DNA, saRNA, and subunit proteins to induce B- and T-cell memory due to the activation of both CD4+ and CD8+ T&#160;cells along with antibody (humoral) responses. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key vaccine delivery technologies include:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Second-generation hAd5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> vector</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adenovirus is a well-established viral vector and can be utilized as a vaccine platform to stimulate the immune system. Our hAd5 technology has unique deletions in the early&#160;1, (E1), early&#160;2 (E2b) and early&#160;3 (E3) regions (hAd5 [E1-, E2b-, E3-]), which allows it to be effective in the presence of pre-existing adenovirus immunity and lowers the risk of generating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vector-directed immunity. We have developed several hAd5 product candidates that have been studied in multiple clinical trials as potential vaccines for the treatment of infectious diseases and certain cancers. Importantly, these product candidates have shown an ability to overcome previous adenovirus immunity in preclinical models and in cancer patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In oncology, we are exploring the delivery of N-803 in combination with hAd5 TAAs like CEA, MUC1, Brachyury, [E6/E7] and PSA, which we believe could yield immunological memory.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">saRNA in an NLC formulation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Synthetic RNA technology has quickly come to the forefront for use in prophylactic and therapeutic vaccines in part because it allows for rapid, scalable, and cell-free manufacturing as evidenced by the adoption of SARS-CoV-2 RNA&#160;vaccines. Our saRNA technology (licensed from AAHI, formerly known as IDRI), includes an NLC formulation that protects the saRNA cargo and is important for thermal stability. The platform technology facilitates substitution of genetic sequences to generate novel vaccines and has an ability to vaccinate with multivalent strains.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The self-replicating capability allows for increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potency </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintaining auto-replicative activity derived from the RNA virus vector, while the self-amplifying capability may increase the duration and breadth of immunity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies in small animal and NHP models have shown that NLC saRNA delivery elicits potent humoral and cell-based immunogenicity. Phase&#160;I first-in-human trials of saRNA for COVID-19 began in 2022. Results to date have demonstrated limited adverse events of the saRNA&#160;S construct and are being analyzed to inform future studies in oncology and infectious disease.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.07pt">Recombinant protein vaccine platforms</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our yeast vaccine platforms have been studied in both oncology and infectious diseases, including our Tarmogen platform (licensed from our subsidiary GlobeImmune), which has been administered to over </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400&#160;patients with cancer or infectious diseases in FDA-regulated clinical trials. This platform technology consists of a heat-killed, recombinant S&#160;cerevisiae yeast-based vaccine engineered to express immunogens such as TAAs, pathogen antigens, and tumor-specific neoepitopes. Immunization with this platform elicits CD4+ and CD8+ T&#160;cell responses capable of eliminating tumor cells or pathogen-infected cells. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have one of the most comprehensive clinical-stage cell-based platforms in development. Our engineered NK&#160;cells have demonstrated the ability to induce cell death in cancers and virally-infected cells through a variety of concurrent mechanisms including innate killing, antibody-mediated killing, CAR-directed killing, and a combination of the latter. </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Off-the-shelf NK&#160;cells</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NK&#160;cells are a type of cytotoxic lymphocyte critical to the innate immune system. NK&#160;cells show spontaneous cytolytic activity against cells under stress such as tumor cells and virally-infected cells. After activation, NK&#160;cells secrete several cytokines such as interferon-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#947; (IFN-&#947;), tumor necrosis factor-&#945; (TNF-&#945;), granulocyte macrophage colony-stimulating factor (GM&#8209;CSF), and chemokines that can modulate the function of other</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> innate and adaptive immune cells. Our NK-92 cytotoxic cell line was established from a patient with clonal NK-cell lymphoma. These NK&#160;cells can be expanded in culture in the presence of cytokines (IL-2, IL-15). Our &#8220;off-the-shelf&#8221; aNK&#160;cell platform has been molecularly engineered in a variety of ways to boost its killing capabilities against cancers and virally-infected cells. Unlike normal NK cells,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our aNK&#160;c</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ells do not express the key inhibitory receptors that diseased cells often exploit to turn off the killing function of NK&#160;cells and escape elimination.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Further, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e have genetically engineered our aNK&#160;cell platform to overexpress high-affinity CD16&#160;receptors that bind to antibodies. These antibody-targeted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> haNK&#160;cel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ls are designed to directly bind to IgG1-type antibodies, such as avelumab, trastuzumab, cetuximab, and rituximab, with the intention of enhancing the cancer-killing efficacy of these antibodies by boosting the population of competent NK&#160;cells that can kill cancer cells through ADCC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced off-the-shelf NK&#160;cell, t-haNK, is an innovative, bioengineered cell line that incorporates all the features of our haNK platform together with a CAR, such as programmed PD-L1. Product candidates under this platform have three&#160;modes of killing: innate, antibody-mediated, and CAR-directed killing. These product candidates also include one or more additional expression elements such as functional cytokines, chemokines, and trafficking factors. These product candidates are intended to be combined with commercially-available therapeutic antibodies to effectively target either two&#160;different epitopes of the same cancer-specific protein or two&#160;entirely different cancer-specific proteins.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical trials to assess o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8209;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">haNK product candidates were initiated&#8212;PD-L1 t-haNK in a&#160;Phase&#160;I trial in triple-negative breast cancer, and a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase&#160;II </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial in pancreatic cancer&#8212;and CD19 t-haNK has been cleared to commence Phase&#160;I testing. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Findings from a preclinical study performed in collaboration with the NCI demonstrated our PD-L1 t-haNK cells exert potent antitumor effects against MDSC and overcome T&#160;cell escape in multiple types of resistant tumors. The contribution of PD-L1 t&#8209;haNK to antitumor efficacy is further evidenced by data reported at the ASCO meeting in June&#160;2022 and updated at ASCO&#160;GI in January&#160;2023 from the QUILT&#160;88 trial of patients with advanced pancreatic cancer who were administered PD-L1 t-haNK, aldoxorubicin and N-803. The multi-modal therapy resulted in a median overall survival of 6.3&#160;months (95% CI:&#160;5.0, 7.2&#160;months) in patients who had progressed after two&#160;prior lines of therapy, more than doubling the historical survival rate. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our pipeline that includes t-haNK cells engineered to express other CARs, including those targeting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EGFR,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is advancing through clinical-enabling studies, will facilitate our ability to potentially address an even broader range of cancers as part of a chemotherapy-free combination regimen. </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Autologous and allogeneic M-ceNK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M-ceNK cells are generated from lymphocytes collected from donors that are then pre-activated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex-vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by exposure to interleukins-12 (IL-12), -15 and -18, which results in differentiation and acquisition of enhanced responses to cytokine re-stimulation. M-ceNK have increased antitumor characteristics, including enhanced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFN-&#947;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> production and cytotoxicity against leukemic cell lines. M-ceNK cells are further distinguished by their unique cell-surface marker profile and their highly desirable feature of immune-memory, marked by their pronounced anti-cancer activity for weeks to months in duration, which has made these cells a research focus for more than a decade.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a unique ability to generate a portfolio of distinct M-ceNK cell products through the application of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our proprietary technology and cytokines and our proprietary methods and overall expertise in scale manufacturing of NK&#160;cell-based products. A Phase&#160;I first-in-human trial is open and actively enrolling patients </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to study the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M-ceNK</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform in solid tumors (QUILT&#160;3076). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate commencement of Phase&#160;II trials of M-ceNK plus N-803 in patients with AML (QUILT&#160;102) and platinum-resistant ovarian cancer (QUILT&#160;108) in the near term.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">III.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.83pt">Our Pipeline</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;2024, our platforms have generated 9&#160;first-in-human therapeutic agents that are currently being or planned to be studied in 24&#160;clinical trials across 12&#160;indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and GBM. These indications are among the most frequent and lethal cancer types for which there are high failure rates for existing standards of care or, in some cases, no available effective treatment. We are constantly monitoring and prioritizing clinical development based upon the availability of our resources and the efficacy and market developments of our competitors&#8217; products and product candidates, among other factors.</span></div><div style="margin-top:12pt;text-align:center"><img src="ibrx-20231231_g2.jpg" alt="IBRX Pipeline March 2024.jpg" style="height:414px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bladder Cancer</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., bladder cancer is the fourth most commonly-diagnosed solid malignancy in men. The American Cancer Society estimates there will be 83,190&#160;new cases and 16,840&#160;deaths from bladder cancer in 2024. There is an urgent, unmet need to treat NMIBC and avoid radical cystectomy of the bladder in an attempt to control the disease. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations by the FDA for the treatment of BCG-unresponsive NMIBC with CIS (Cohort&#160;A) with or without Ta or T1&#160;disease as well as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation for BCG-unresponsive NMIBC papillary (Cohort&#160;B) and BCG-na&#239;ve NMIBC with CIS. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our QUILT&#160;3032 trial, the company reported in November&#160;2022, as published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEJM Evidence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the primary end points were met for both BCG-unresponsive NMIBC with CIS with a complete response rate of 71%, and BCG-unresponsive NMIBC papillary with a 12-month disease-free rate of 55%. As presented at ASCO&#160;2022, the combination of BCG plus N-803 (as measured in BCG-unresponsive NMIBC patients, Cohorts&#160;A and B combined) was well-tolerated with 1%&#160;treatment-related serious adverse events, 0%&#160;immune-related serious adverse events, and 100%&#160;bladder cancer-specific overall survival at 24&#160;months. Low-grade treatment-related adverse events include dysuria (22%), pollakiuria (20%), hematuria&#160;(17%), fatigue (16%), and urgency (12%), and all other treatment-related adverse events were seen at 7% or less. Seminal patents covering intravesical administration of BCG and N-803 were issued providing term coverage until 2035.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCG Unresponsive NMIBC CIS (Cohort A) &#8211; QUILT 3032</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Phase&#160;II/III open-label multi-center trial of BCG-unresponsive high grade NMIBC patients, the patients are receiving BCG plus N-803 weekly for six&#160;consecutive weeks during induction. The patients also receive additional treatment including three&#160;weekly maintenance instillations every three&#160;months for up to 12&#160;months and then at month&#160;18. Patients with no disease or low-grade Ta&#160;disease at months&#160;24, 30, and 36 are eligible for continued BCG plus N-803 (Cohort&#160;A) or N-803 alone (Cohort&#160;C) treatment (3&#160;weekly instillations), at the principal investigators&#8217; discretion. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the BCG-unresponsive NMIBC with CIS trial is a complete response rate at any time equal to or greater than&#160;30% and the lower bound of the 95%&#160;CI must be greater than or equal to&#160;20% for success. Complete response, or the disappearance of measurable disease in response to treatment, is evaluated at three&#160;months or six&#160;months following initial administration of BCG plus N-803 (and every three&#160;months thereafter until 24&#160;months). This endpoint would be achieved once at least 24&#160;of the 80&#160;patients in the trial achieve a complete response.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A data cutoff occurred in January&#160;2022, which provided a median follow-up in Cohort&#160;A of approximately 24&#160;months. Data as published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEJM Evidence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November&#160;2022 showed a complete response in 58 of 82&#160;patients with a 71%&#160;complete response rate (95%&#160;CI: 59.6, 80.3) and a median duration of CR of 26.6&#160;months (95%&#160;CI: 9.9, [upper bound not reached]). At 24&#160;months in patients with a complete response, the probability of avoiding cystectomy and disease-specific survival was&#160;91.4% and 100%, respectively. Also, at 24&#160;months in all patients in Cohort&#160;A, the probability of avoiding cystectomy and of disease-specific survival was 84.1% and 100%, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of planned analyses, BCG-unresponsive patients in the QUILT&#160;3032 trial of N-803 plus BCG completed PRO&#160;questionnaires, which revealed stability of both mean physical function and global health from baseline to 24&#160;months on-study for those participants who had reached the 24-month assessment. Further, at month&#160;6, Cohort&#160;A (CIS disease) patients that achieved a complete response reported higher physical function scores than those without a CR (P&#160;=&#160;0.0659). Summary scores for the NMIBC-specific questionnaire also remained stable. These PROs, taken together with efficacy findings from both the NEJM&#160;Evidence report and subsequent follow-up, suggest a favorable risk-benefit ratio for the novel therapeutic combination.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2022, we submitted a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for which we received a target PDUFA action date of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. The CRL did not request new preclinical studies or clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company&#8217;s resubmission, as well as a safety update.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. As part of our resubmission, we provided an update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG-unresponsive subjects with high-risk CIS disease. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCG Unresponsive NMIBC Papillary (Cohort B) &#8211; QUILT 3032</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Phase&#160;II, open-label multi-center trial of BCG-unresponsive high grade NMIBC papillary patients (Cohort&#160;B), the patients are receiving BCG plus N-803 weekly for six&#160;consecutive weeks during induction. The patients also receive additional treatment including three&#160;weekly maintenance instillations every three&#160;months for up to 12&#160;months and then every nine&#160;months for up to 24&#160;months. The primary endpoint of the trial is a 12-month disease free rate greater than or equal to 30% and the lower bound of the 95%&#160;CI must be greater than or equal to&#160;20% for success. To meet the primary endpoint, 24 out of 80&#160;patients must be disease free at 12&#160;months. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A data cutoff occurred in January&#160;2022, which provided a median follow-up in Cohort&#160;B of approximately 21&#160;months. Data as published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEJM Evidence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November&#160;2022 showed a 12-month disease-free survival rate of 55% (95%&#160;CI: 42.0, 66.8), with median disease-free survival of 19.3&#160;months (95%&#160;CI: 7.4, [upper bound not reached]). At the cutoff date 67 of 72&#160;patients, 93.1%, had not progressed to radical cystectomy and the 24-month disease-free survival rate was&#160;97.7%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We met with the FDA in December&#160;2022, and the FDA advised us that when there is a time-to-event endpoint a randomized trial is required. We are continuing to evaluate trial designs while we work with the FDA on BCG-unresponsive CIS pending approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCG-N</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a&#239;ve &#8211; QUILT&#160;2005</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, Anktiva</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been awarded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation by the FDA for the treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BCG-na&#239;ve NMIBC with CIS. We are currently enrolling patients in our Phase&#160;IIb blinded, randomized, two-cohort, open-label, multi-center trial of intravesical BCG plus N-803 versus BCG alone, in BCG-na&#239;ve patients with high-grade NMIBC with CIS (Cohort&#160;A) and NMIBC papillary (Cohort&#160;B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Planned enrollment for Cohort&#160;A (CIS) and Cohort&#160;B (papillary) is 366&#160;patients and 230&#160;patients, respectively. As part of our October&#160;2023 BLA resubmission for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, we provided an update on the long-term follow-up (QUILT&#160;205) of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG-na&#239;ve </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subjects in QUILT&#160;2005 receiving N-803 plus BCG for CIS&#177; Ta/T1 in the Phase&#160;Ib trial, examining the survival of the 9&#160;subjects who entered the trial since 2014. As initially reported in 2021, all 9&#160;subjects (100%) achieved a complete response, and in an 8-year follow up, the 6&#160;evaluable patients remain disease-free (two&#160;were deceased from causes other than bladder cancer and one&#160;was lost to follow-up) with bladder preservation over a median survival period of 8.8&#160;years.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lung Cancer</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the American Cancer Society, lung cancer is the second most common cancer in the U.S. In&#160;2024, it is estimated that 234,580&#160;new cases of lung cancer will be diagnosed in the U.S. and 125,070&#160;deaths will be attributed to the disease. NSCLC accounts for about 80% to 85% of all lung cancers diagnoses and there are very few successful treatment options for these patients once the cancer spreads beyond the lungs. The development of checkpoint inhibitors in NSCLC has been revolutionary, doubling the median overall survival in some settings; however, patient response may be short lived, due to late response and/or progression after achieving an initial response. As with bladder cancer, N-803 enhances the proliferation and activation of NK and T&#160;cells critical for targeting and killing lung cancer cells. There is therefore a strong rationale to evaluate N-803 in addition to an anti-PD-1 or anti-PD-L1 checkpoint inhibitor for patients with NSCLC who have relapsed after achieving an initial response to PD-1 or PD-L1 checkpoint inhibitor therapy. SCLC accounts for about 10% to 15% of all lung cancers. About two-thirds of patients with SCLC are diagnosed with extensive-stage disease, which is associated with especially poor prognosis, and a median survival of 10&#8211;13&#160;months. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of pooled data from a Phase&#160;I/II trial conducted from January&#160;2016 to June&#160;2017 in 23&#160;patients, and a subsequent investigator-initiated Phase&#160;II trial conducted by the Medical University of South Carolina, yielded confirmation of activity of the combination of checkpoint inhibitors and N-803 in relapsed NSCLC. In 15&#160;patients with PD-L1 greater than 50%, the overall response rate was&#160;38% and the median overall survival rate was 17.1&#160;months. These preliminary findings were favorable relative to the historical response rate seen in this patient population in the first-line setting with checkpoint inhibitor therapy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Small Cell Lung Cancer &#8211; QUILT 3055</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of these findings discussed above, we initiated a single-arm Phase&#160;IIb multi-cohort basket trial of N-803 and checkpoint inhibitor combinations in patients who have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors per an FDA-approved indication. Patients enrolled in this trial were eligible if actively progressing on checkpoint inhibitor therapy. Upon enrollment, patients continued on the same checkpoint inhibitor but with the addition of N-803. Despite progressing on checkpoint inhibitor therapy upon entry into the trial, the majority of patients reverted to stable disease and demonstrated durability of stable disease, some extending as long as nine&#160;months. Data presented at the ASCO Annual Meeting in 2021 showed that despite the patients&#8217; prior progression on checkpoint inhibitor therapy alone, upon entry into the trial the majority of patients experienced clinical benefit either as stable disease (49%) or a partial response (9%). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among 140&#160;patients enrolled in QUILT&#160;3055, the common N-803 attributed grade&#160;1 and 2 adverse events included: injection-site reaction (71%), chills (34%), fatigue (27%), pyrexia (24%), flu-like illness (13%), and decreased appetite (10%). A&#160;total of 18&#160;grade&#160;3 and 4&#160;adverse events attributed to N-803 have been reported among 16&#160;patients (12%) in the trial as of February&#160;2021. All reported grade&#160;3 and 4&#160;adverse events occurred at a frequency of 5% or less; two&#160;patients reported increased alanine amino transferase, increased aspartate amino transferase or increased blood alkaline phosphatase, anemia, injection-site reaction, or injection-site pain. All other occurrences of grade&#160;3 or 4 adverse events that the clinical trial site investigators reported as suspected as being due to N-803 include: decreased lymphocyte count; weight loss; influenza-like illness; injection-site pruritus; cellulitis; injection-site cellulitis; sepsis; deep vein thrombosis; hypovolemic shock; colitis; diarrhea; delirium; respiratory failure; and maculopapular rash. Although further studies are warranted, based on this relatively well-tolerated adverse event profile, coupled with NK and CD8+ T&#160;cell stimulatory effects, we believe that N-803 has the potential to become a standard in combination with other immunotherapies for multiple indications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2023, we reviewed the updated QUILT&#160;3055 data, through February&#160;5,&#160;2023, from several cohorts of NSCLC patients who have progressed after check point inhibitor therapy. These cohorts are:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1a &#8211; NSCLC patients with initial response on single-agent checkpoint inhibitor therapy and subsequently progressed on or after that therapy.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 &#8211; NSCLC patients having high PD-L1 expression (tumor proportion score &#8805;50%) and disease progression on a PD-1/PD-L1 checkpoint inhibitor after experiencing an initial response when received checkpoint inhibitor as a single-agent for first-line treatment.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 &#8211; NSCLC patients with initial response but subsequently relapsed on maintenance PD-1/PD-L1 checkpoint inhibitor therapy when initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 4 &#8211; NSCLC patients currently receiving PD-1/PD-L1 checkpoint inhibitor therapy that progressed after experiencing stable disease for at least 6&#160;months during previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results are listed in the table below:</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUILT 3055: Overall Survival &#8211; NSCLC Subjects Safety Population</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Variable</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cohort&#160;1a<br/>(N=19)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cohort 2<br/>(N=9)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cohort 3<br/>(N=20)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cohort 4<br/>(N=38)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Subjects</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(N=86)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Deaths</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 (68%)</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 (67%)</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 (75%)</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 (55%)</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 (64%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Median Survival (months)</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.9</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95% CI for Median Survival</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7, 28.7</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1, &#8211;</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5, 24.9</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8, 25.5</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7, 17.4</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These results show a median overall survival of 13.9&#160;months in the 86&#160;patients in the pooled analysis. This is in contrast to the overall survival of 6.1&#160;months reported by Freeman et al. for patients who received any therapy post-checkpoint inhibitor therapy progression or an overall survival of 7.5&#160;months, as reported by Brueckl et al., for patients who received docetaxel plus ramucirumab after initial failure of first-line chemotherapy plus checkpoint inhibitor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Small Cell Lung Cancer &#8211; QUILT&#160;211 </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently approved therapeutics for SCLC include checkpoint inhibitors in combination with platinum-based chemotherapy as first-line and lurbinectedin for second-line therapy. Nonetheless, only a subset of patients respond, a limit attributed to low MHC class&#160;I expression in SCLC. NK&#160;cells do not require such expression and preclinical studies have demonstrated M-ceNK are effective in killing SCLC&#160;cells of all subtypes as well as neuroendocrine prostate cancer. Based on these and similar findings, a Phase&#160;III, open-label, randomized clinical trial of N-803 and M-ceNK in combination with standard of care versus standard of care alone for previously treated patients with extensive-stage SCLC was designed, with enrollment expected to commence in 2024. The primary endpoint is the objective response rate with secondary endpoints of progression-free survival, overall survival, duration of response and disease control rate based on RECIST&#160;1.1 criteria, and quality of life based on PROs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Colorectal Cancer</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the American Cancer Society, colorectal cancer is the third-leading cause of cancer-related deaths in the U.S. in men and the fourth-leading cause in women, but it is the second most common cause of cancer deaths when numbers for men and women are combined. Colorectal cancer is expected to cause about 53,010&#160;deaths during 2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynch syndrome is the most common cause of hereditary colorectal cancer. People with this syndrome are at high risk of developing colorectal cancer. Lynch syndrome causes about 4,300 colorectal cancers per year. These cancers are more likely to develop at earlier ages, often before the age of 50. If someone has Lynch syndrome, it means that their close relatives (parents, siblings, and children) have a 50%&#160;chance of having the mutation that causes it too. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lynch Syndrome (NCI) &#8211; QUILT 5015</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lynch syndrome trial, sponsored by the NCI, focuses on the ability of Tri-Ad5&#8211;a combination of three&#160;vaccines targeting different TAAs&#8211;used in combination with N-803 to reduce the incidence of onset of cancer. People with Lynch syndrome harbor mutations in mismatch repair genes that put them at high risk for development of cancer, particularly colon cancer. Recently, we announced full accrual of participants in the first two open-label phases of the Lynch syndrome trial. The trial plans to enroll up to 186&#160;participants, and the randomized controlled portion of the trial is now recruiting.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glioblastoma Multiforme</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the American Association of Neurological Surgeons, GBM is the most common malignant brain tumor accounting for approximately 48% of all primary brain tumors. GBM has a low survival rate of approximately 40% in the first&#160;year after diagnosis and only 17% in the second&#160;year. In a preclinical study, we evaluated the activity of N-803 alone and in combination with an anti-PD-1 antibody or stereotactic radiosurgery in a murine GL261-luc GBM model and demonstrated that N-803 as mono-or combination therapy exhibits a robust antitumor immune response resulting in prolonged survival including complete remission in tumor bearing mice. In addition, N-803 treatment resulted in long-term immune memory against GBM tumor rechallenge. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recurrent or Progressive GBM &#8211; QUILT&#160;3078</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A multi-center, open-label Phase&#160;II/III trial has been developed to evaluate the safety and efficacy of combination therapy with N-803, PD-L1 t-haNK, and bevacizumab in patients with recurrent or progressive GBM. In Phase&#160;II, safety of the combination will be assessed prior to Phase&#160;III wherein participants will be randomized to either combination therapy or bevacizumab monotherapy as the current standard of care. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pilot (Part A).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Enrollment will initiate with a single-arm study of 10&#160;patients to receive N-803, PD-L1 t-haNK, and bevacizumab combination therapy. Continued development of the experimental arm in Part&#160;B will be based on the overall risk/benefit of the combined treatment regimen observed in Part&#160;A.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Randomized Comparison of Combination Therapy versus Bevacizumab Monotherapy (Part B).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part&#160;B will enroll patients to be randomly assigned (1:1) to the experimental arm or to the control arm. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ovarian Cancer</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to estimates from the American Cancer Society, in 2024 about 19,680&#160;women will receive a new diagnosis of ovarian cancer and about 12,740&#160;women will die from ovarian cancer. A woman&#8217;s risk of getting ovarian cancer in her lifetime is about 1 in 87 and her chance of dying from ovarian cancer is about 1 in 130. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Platinum-Resistant Ovarian Cancer &#8211; QUILT&#160;108</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An open-label Phase&#160;II trial of M-ceNK plus N-803 in patients with platinum-resistant ovarian cancer has been designed. In this trial, patients with platinum-resistant high-grade ovarian cancer will receive M-ceNK adoptive cell therapy in combination with N-803 and gemcitabine or investigator&#8217;s choice chemotherapy. The study consists of two&#160;arms, with participants in the control arm receiving investigator&#8217;s choice chemotherapy such as pegylated liposomal doxorubicin or gemcitabine, and participants in the experimental arm receiving M-ceNK adoptive cell therapy in combination with N-803 and gemcitabine. Only </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the experimental arm participants will undergo mononuclear cell collection for M-ceNK generation, day&#160;8 induction and every 28-day (if M-ceNK are available) maintenance dosing, along with N-803. The goal for enrollment has not been established, and is pending statistician recommendation. The primary endpoint is tumor response by BICR using RECIST&#160;1.1 criteria and secondary endpoints are overall survival, overall response rate, duration of response, disease control rate, and CA-125&#160;levels, with safety endpoints of adverse events, treatment-emergent adverse events and significant adverse events, graded using NCI Common Terminology Criteria for Adverse Events Version&#160;5.0.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acute Myeloid Leukemia</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to estimates from the American Cancer Society, in 2024 there will be about 20,800&#160;new cases of AML (mostly in adults) and about 11,220&#160;people will die from AML (almost all in adults). AML is one of the most common types of leukemia in adults but is fairly rare overall, accounting for only about 1% of all cancers. The average age of people when they are first diagnosed is about 68. People above 60&#160;years of age generally don&#8217;t respond as well as younger people to conventional treatment as they often have trouble tolerating intensive treatment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned AML &#8211; QUILT&#160;102</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An open-label Phase&#160;II trial of M-ceNK plus N-803 in patients with AML has been designed. In this trial, patients either between 2- and 15-years of age (Cohort&#160;1) or patients 16&#160;years or older (Cohort&#160;2) with relapsed/refractory AML will receive subcutaneous N-803 and M-ceNK following hematopoietic stem cell transplant. N-803 will be given both before collection of mononuclear cells and M-ceNK generation, and after M-ceNK infusion to activate NK/M-ceNK cells. Participants will also receive standard graft versus host disease prophylaxis. Up to 200&#160;participants will be enrolled in each cohort. The primary endpoints are overall survival and leukemia-free survival rates, and incidence of relapse in those that achieve a complete response. Secondary endpoints are incidence of significant adverse events and overall adverse events.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infectious Disease Indications</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the trials listed above in oncology, we are exploring or pursuing several other company-sponsored and investigator-initiated studies of our product candidates in infectious diseases, including HIV. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HIV </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV affects tens of millions of people globally and while ART has increased survival of infected HIV individuals, there is currently no cure. One strategy for curing HIV is known as the &#8220;kick and kill&#8221; approach. The &#8220;kick&#8221; is to induce HIV out of its latent resting state in T&#160;cells, revealing infected cells to the immune system, and the &#8220;kill&#8221; is to eliminate the infected cells via an immune response or immunotherapy. N-803 is a promising molecule to elicit &#8220;kick and kill&#8221; because of its ability to activate viral transcription in CD4+ T&#160;cells (&#8220;kick&#8221;) while strongly activating CD8+ effector memory cells and NK&#160;cells important for recognizing and killing HIV infected cells (&#8220;kill&#8221;), as well as directing these cells to sites of viral reservoirs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIV Cure Studies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2021, we announced the opening of a clinical trial sponsored by the AIDS Clinical Trials Group and the NIAID (the&#160;HIV Cure Study) that will evaluate whether N-803 alone or together with bNAbs can control HIV following interruption of ART. The Phase&#160;I open-label, randomized trial will enroll 46&#160;people living with HIV whose virus has been suppressed by ART for approximately two&#160;years, including at least 30% cisgender women or transgender men. An additional and companion trial utilizing N-803 and 2&#160;different bNAbs sponsored by The Rockefeller University opened in December&#160;2022. Both of these trials are actively enrolling as of January&#160;2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Thai Red Cross and the U.S. Military HIV Research Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2021, we announced the launch of a Phase&#160;II trial sponsored by the Thai Red Cross and the U.S.&#160;Military HIV Research Program. The trial enrolled 14&#160;patients and was designed to investigate the safety, tolerability and immunostimulatory effects of administering N-803 during acute HIV infection. N-803 was administered subcutaneously at weeks&#160;zero, three and six&#160;(for a total of three&#160;doses) and was initiated together with antiretroviral therapy in order to determine if the immunostimulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects of N-803 will reduce the amount of HIV present during acute infection. The trial duration for individual participants was approximately 12&#160;weeks. It is hypothesized that N-803 initiated with anti-retroviral therapy during acute HIV infection will not result in complications or additional toxicities compared with anti-retroviral therapy alone, and may result in a reduced viral load in these patients by inhibiting early establishment of HIV&#160;reservoirs in infected individuals. The trial was recently completed and data analyses are ongoing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NIAID University of Minnesota Trials</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the hypothesis </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that in HIV-infected individuals treated with N-803</span><span style="background-color:#ffffdd;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD8+ T&#160;cells will migrate to B&#160;cell follicles and reduce the frequency of cells with an inducible HIV provirus, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Phase&#160;I proof-of-concept non-randomized, open-label dose-escalation clinical trial sponsored by the University of Minnesota in collaboration with the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NIAID was conducted. The primary assessment is the safety of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> N-803 in ART-suppressed people living with HIV, along with exploratory analysis of effects on the HIV reservoir. In a 2022&#160;report, no significant laboratory adverse events attributable to N-803 were recorded and N-803 was associated with proliferation and/or activation of CD4+ and CD8+ T cells and NK cells, with a small but significant decrease in the frequency of peripheral blood mononuclear cells with an inducible HIV provirus. The trial results are complete and a publication is expected during late 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A separate small HIV Cure Phase&#160;I trial evaluating N-803 in combination with haploidentical NK&#160;cells in HIV-infected patients was completed in 2023. Reported data from the study validate the hypothesis that N-803 combined with NK&#160;cells has the potential to reduce viral load in people living with HIV, showing a marked decrease in HIV-producing cells in lymph nodes. The approach was well tolerated with no unexpected adverse events. The trial is complete and results were published online in January&#160;2024, with print edition expected in March&#160;2024. A follow-on trial is being planned to further investigate the above regimen in additional patients.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Infectious Diseases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously developed COVID-19 vaccine candidates based on our hAd5 and NLC-saRNA platforms that delivered DNA or RNA, respectively, for SARS-CoV-2 spike (S) and nucleocapsid (N) proteins that underwent early clinical testing in the U.S. and South Africa. These trials demonstrated the tolerability of the platforms, which elicited no severe adverse events, and provided evidence of effective antigen delivery. Given the development and adoption of other approved vaccine candidates, we have prioritized our pipeline to focus on delivery of TAAs with these platforms for cancer indications. Our latest TAA vaccine is currently being tested with the NCI as discussed above. </span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Distribution</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a strategic position to be vertically integrated and develop our products according to the FDA&#8217;s GMP standards for large-scale manufacturing, even during Phase&#160;II clinical trial development. Biological upstream and downstream manufacturing capabilities, with its attendant know-how and regulatory compliance for approval, have long lead times. We have adopted an approach for preparedness to provide our vaccine, immunotherapy, and cell therapy products at a global scale. As such, we have established our own plants and have access to facilities on a global basis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to create an efficient manufacturing process and supply chain will be important in enabling us to develop novel therapies. Our strategy is to anticipate the needs of our early-stage research and development initiatives for preclinical and eventual clinical product candidates with a focus on rapid capability to produce at scale fusion proteins, hAd5, saRNA, subunit proteins, toll receptor activators, and NK&#160;cell products. We believe members of our management team, many of whom have experience in both nanoparticle commercialization and large-scale injectable drug production, are capable of constructing the processes and commissioning the facilities necessary to meet our development and commercialization goals. For well-known processes, we currently work, and plan to continue working, with established third-party CMOs to produce drug substance and drug products. In addition, we plan to further enhance our in-house manufacturing capabilities for drug substances, drug products, and labeling and packaging. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of our Manufacturing Model </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing capabilities include advanced technology facilities to produce and test various drug substances and drug products. Our experienced operations and quality team focuses on internal manufacturing and testing with a constant endeavor to create robust, high quality, efficient and consistent supply that meets target product profiles. Our Phase&#160;I manufacturing process is designed to efficiently scale-up through all phases of clinical development to commercial manufacturing to drive successful commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial cGMP Production</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our N-803 product candidate, we have contracted with multiple multi-national biologics manufacturers with several cGMP-compliant facilities in the U.S., Europe and Asia for our current clinical trials and future commercial sales, if approved. We believe the facilities have robust process development and validation and quality oversight with high-capacity production suites operating multiple 2,000-20,000L production bioreactors and high-capacity fill lines. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial GMP Antibody and Fusion Protein Production </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are establishing a cGMP-compliant multi-platform facility in California, which includes a large space for the production of antibodies and fusion proteins (including N-803) to treat cancers and infectious diseases. This facility will include fully integrated biologic upstream and downstream production suites and a quality assurance/quality control release laboratory for high-capacity antibody and fusion protein production.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial GMP saRNA, Adenovirus, and Yeast Production</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established other cGMP-compliant facilities for saRNA, adenovirus, and yeast production in multiple sites in California and a site in Colorado for oncology and infectious diseases. One of our sites in California is dedicated to adenovirus product candidates for the production of vaccine candidates to treat infectious diseases and oncology TAAs. These facilities generally have fully-integrated biologic upstream and downstream production suites and quality assurance/quality control release laboratories for high capacity, continuous, or personalized just-in-time vaccine production.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial GMP NK&#160;Cell Therapy Production</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established other cGMP-compliant facilities for NK&#160;cell therapy product production in multiple sites in California for oncology. One of our sites in California is dedicated to our off-the-shelf product candidates (including PD-L1 t&#8209;haNK), while another is primarily focused on our M-ceNK product candidates, including a training lab for our second-generation offerings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cGMP ISO Class&#160;5 Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;14,&#160;2022, we acquired a leasehold interest in the Dunkirk&#160;Facility. This facility has construction needs that may require an additional 12&#160;to&#160;18&#160;months to complete in order for it to be used as intended, and which needs remain as a result of an ongoing dispute with the Dunkirk&#160;Facility&#8217;s general contractor and a stay in resolving the dispute related to Athenex&#8217;s ongoing bankruptcy proceedings. See Item&#160;1A. Risk Factors </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545338">&#8220;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545338">We are party to a public-private partnership regarding our manufacturing facility in Dunkirk, New</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545338">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545338">York, and if we or our counterparties fail to meet the obligations of those agreements, it could materially impact our development, operations and prospects</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545338">&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information. We believe this facility will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our existing manufacturing capacity in the U.S. and the ability to scale production associated with certain of our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacture of Platform Product Candidates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio&#8217;s diverse product candidate portfolio and pipeline requires a broad knowledge of various manufacturing and quality assurance methods. We have invested heavily in the processes, systems, and technology to build an extensive range of manufacturing programs spanning various levels of development from IND-enablement through BLA preparation of our first&#160;commercial product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our plan to selectively use third-party CMOs for certain of our assets at various stages, coupled with internal development, will give us assurance that any products will have backup manufacturing options.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when our lead product candidate, or another one of our product candidates is approved for commercial sale, we plan to work with a leading third-party logistic provider in a title model while we finish establishing direct licenses in the remaining states where we cannot receive a license until after our first approval. We also plan on contracting with the large specialty distributors to make our product available across relevant clinics, hospitals, infusion centers, and government entities.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, convenience, cost, market access, level of promotional activity devoted to them, competitive intensity, and intellectual property protection. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have focused our efforts on urologic and other oncological and infectious disease indications that are difficult to treat and with large unmet needs, and we believe our platform will be broadly applicable across multiple tumor types and infections. Based on the breadth and depth of our platforms, we believe our competitors will range from large pharmaceutical companies to emerging novel biotechnology companies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody-Cytokine Fusion Proteins. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This platform primarily competes with large pharmaceutical companies marketing checkpoint inhibitors. However, the potential exists for some of these large pharmaceutical companies to seek collaboration for combination of N-803 with their marketed checkpoint inhibitor. This platform will also compete with immunotherapy fusion protein companies developing similar approaches, including Nektar&#160;Therapeutics, Neoleukin Therapeutics,&#160;Inc., Novartis International&#160;AG (Novartis), F.&#160;Hoffmann-La&#160;Roche&#160;AG (Roche), Sanofi,&#160;S.A. (Sanofi), Xencor,&#160;Inc., and in the context of NMIBC, CG Oncology&#160;Inc., Ferring Pharmaceuticals, Janssen Pharmaceuticals, Inc. (Janssen)/Johnson &amp; Johnson, and Merck &amp; Co.,&#160;Inc. (Merck). </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">DNA, RNA, and Recombinant Protein Vaccines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This platform and the associated product candidates will likely compete with other cancer vaccines. Other potential cancer vaccine competitors include Achilles&#160;Therapeutics, BioNTech&#160;SE (BioNTech), Geneos&#160;Therapeutics,&#160;Inc., Hangzhou Neoantigen Therapeutics,&#160;Inc., Gritstone Bio,&#160;Inc., Merck, Moderna,&#160;Inc., and Roche. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cell Therapies.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This platform&#8217;s product candidates (haNK, taNK, t&#8209;haNK and M-ceNK) face competition from several companies focused on NK&#160;cell-based approaches, including Artiva Biotherapeutics Inc./Merck, Catamaran Bio&#160;Inc., Celularity,&#160;Inc. (Celularity), Century Therapeutics,&#160;Inc., Fate&#160;Therapeutics,&#160;Inc., Gamida Cell,&#160;Ltd., INmune Bio&#160;Inc., Nkarta&#160;Therapeutics,&#160;Inc., NKGen Biotech,&#160;Inc., Sanofi, Shoreline Biosciences,&#160;Inc., and Takeda&#160;Pharmaceutical Company Limited (Takeda). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our NK&#160;cell product candidates compete with other cell and molecule-based immunotherapy approaches using or targeting NK cells, NKT&#160;cells, T&#160;cells, macrophages, and dendritic cells. There are currently six&#160;approved T&#160;cell-based treatments marketed by Bristol-Myers Squibb Company (BMS) (two&#160;marketed products), Gilead&#160;Sciences,&#160;Inc. (Gilead)/Kite Pharma (two&#160;marketed products), Janssen/Johnson &amp; Johnson, and Novartis. Additional companies focused on CAR T-related treatment approaches include Allogene Therapeutics,&#160;Inc., BMS, Cellectis&#160;SA, Celularity, Gilead, Janssen, Novartis, Pfizer,&#160;Inc., Poseida, and Takeda. Competitor companies focused on other T&#160;cell-based approaches include Adaptimmune&#160;Ltd., Adicet&#160;Bio,&#160;Inc., Autolus Therapeutics,&#160;plc, Beam&#160;Therapeutics&#160;Inc., BioNTech, GlaxoSmithKline&#160;plc., Precision&#160;Biosciences,&#160;Inc., Sensei&#160;Biotherapeutics,&#160;Inc., Senti Biosciences,&#160;Inc., and TCR&#178; Therapeutics&#160;Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other potential immunotherapy competitors in oncology include Affimed&#160;GmbH, MiNK Therapeutics,&#160;Inc., Appia&#160;Bio,&#160;Inc., Compass Therapeutics,&#160;Inc., Glycostem Therapeutics&#160;BV, GT&#160;Biopharma,&#160;Inc., and Lyell Immunopharma,&#160;Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Infectious Diseases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our infectious disease product candidates are primarily focused on HIV. In this space, we have product candidates that use N-803 that will likely compete with companies who have approved therapeutics for HIV, including Gilead&#160;Sciences, ViiV Healthcare Limited (a joint venture between GSK, Pfizer, and Shionogi,&#160;Inc.), Merck &amp; Co., BMS, and Janssen&#160;Pharmaceuticals (a subsidiary of Johnson &amp; Johnson).</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the U.S. and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of cancer therapeutics and immunotherapy. We expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available, as well as on regulatory protection afforded through orphan drug designations. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our product candidates, technology, inventions, and improvements; to preserve the confidentiality of our trade secrets; to maintain our licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including our patents; and to operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and other proprietary rights of third parties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed, acquired, and in-licensed patents and patent applications across platforms as previously described for: (1)&#160;activated NK and T&#160;cells; (2)&#160;memory T&#160;cell activation; and (3)&#160;activated tumoricidal macrophages. With respect to activated NK and T&#160;cells, we have developed N-803, an N72D variant IL-15 complexed to a dimeric IL-15Ra/Fc fusion protein; with respect to memory T&#160;cell activation, we have developed adenoviral and yeast immunotherapies expressing tumor antigens such as CEA, MUC1, and Brachyury, and in-licensed saRNA technologies; and with respect to activated tumoricidal macrophages, we have in-licensed intellectual property licensed to aldoxorubicin, a tumor-targeted doxorubicin conjugate, from LadRx.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own patents and patent applications related to the development and commercialization of N-803. As of December&#160;31,&#160;2023, our owned patent portfolio directed to N-803, methods of use of N-803, and combinations with additional therapeutics consists of approximately 27&#160;issued U.S.&#160;patents and 14&#160;pending U.S.&#160;patent applications, as well as approximately 82&#160;patents issued in jurisdictions outside of the U.S., including Europe, China, Japan, Canada, and Australia. Excluding any patent term adjustment and patent term extension, the issued U.S.&#160;patents directed to N-803, methods of use of N-803 and combinations with additional therapeutics are expected to expire from 2028 to 2040. Excluding any applicable extensions, the issued foreign </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents are expected to expire from 2028 to 2039. If patents issue from our pending U.S.&#160;patent applications, excluding any patent term adjustment and patent term extension, such patents will be expected to expire from 2031 to 2043. The validity of one of our European patents, EP&#160;Patent No.&#160;3601363, is being challenged in an opposition proceeding. This patent is directed to methods of using N-803-based combination therapy with anti-CD38 antibodies to treat cancer, which does not directly relate to any of our current programs. We intend to defend our patent and believe we have meritorious defenses against this opposition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, these patents and patent applications include claims directed to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">N-803 compositions of matter;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uses of N-803 in methods of treating cancers;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uses of N-803 in treating HIV; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">combination treatments using N-803 and additional therapeutics.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own, co-own, and in-license patents and patent applications related to the development and commercialization of cell-based therapies. As of December&#160;31,&#160;2023, our owned and co-owned patent portfolio directed to NK, haNK, and t-haNK cell lines, methods of use of these cells, and combinations with additional therapeutics consists of approximately 19&#160;issued U.S.&#160;patents and 23&#160;pending U.S.&#160;patent applications, as well as approximately 58&#160;patents issued in jurisdictions outside of the U.S., including Europe, China, Japan, and Australia. As of December&#160;31,&#160;2023, our in-licensed patent portfolio directed to NK, haNK, and t-haNK lines, methods of use of these cells, and combinations with additional therapeutics consists of approximately 4&#160;issued U.S.&#160;patents, as well as approximately 41&#160;patents issued in jurisdictions outside of the U.S., including Europe, Canada, and Australia. Excluding any patent term adjustment and patent term extension, the issued U.S.&#160;patents directed to these cell therapies, methods of use, and combinations with additional therapeutics are expected to expire from 2025 to 2040. Excluding any applicable extensions, the issued foreign patents are expected to expire from 2025 to 2040. If patents issue from our pending U.S.&#160;patent applications, excluding any patent term adjustment and patent term extension, such patents will be expected to expire from 2034 to 2042. For example, these patents and patent applications include claims directed to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NK&#160;cells;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">haNK&#160;cells;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EGFR t-haNK&#160;cells;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CD19&#160;t-haNK&#160;cells; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HER2 t-haNK&#160;cells; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PD-L1 t-haNK&#160;cells.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own patents and patent applications related to development and commercialization of N-820, N-809, N-812, and N-830. As of December&#160;31,&#160;2023, our owned patent portfolio directed to N-820, N-809, N-812, and N-830 and methods of use of N-820, N-809, N-812, and N-830 consists of approximately 15&#160;issued U.S.&#160;patents and 3&#160;pending U.S.&#160;patent applications, as well as approximately 57&#160;patents issued in jurisdictions outside of the U.S. Excluding any patent term adjustment and patent term extension, the issued U.S.&#160;patents directed to N-820, N-809, N-812, and N-830 are expected to expire from 2028 to 2039. If patents issue from our pending U.S.&#160;patent applications, excluding any patent term adjustment and patent term extension, these patents will be expected to expire from 2028 to 2038. For example, these patents and patent applications include claims directed to fusions of checkpoint inhibitor and TAA antibodies and binding molecules with IL-15/IL-15Ra/Fc fusion proteins complexes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We co-own and exclusively in-license patents and patent applications from LadRx related to the development and commercialization of aldoxorubicin. As of December&#160;31,&#160;2023, our licensed patent portfolio directed to aldoxorubicin and methods of use of aldoxorubicin consists of approximately 4&#160;issued U.S.&#160;patents, as well as approximately 23&#160;patents issued in jurisdictions outside of the U.S., including Europe, Japan, Korea, and Australia. Excluding any patent term adjustment and patent term extension, the issued U.S.&#160;patents directed to aldoxorubicin are expected to expire from 2030 to 2034. Excluding any applicable extensions, the issued foreign patents are expected to expire from 2033 to 2034. For example, these patents and this patent application include claims directed to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aldoxorubicin formulations; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aldoxorubicin formulations for use in treating cancer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclusively own, and co-own with and in-license from the HHS, patents and patent applications related to the development and commercialization of adenovirus-based cancer and viral immunotherapies. As of December&#160;31,&#160;2023, our patent portfolio directed to adenovirus and methods of use of adenovirus in treating or preventing cancer and viral diseases consists of approximately 30&#160;issued U.S.&#160;patents and approximately 8&#160;pending U.S.&#160;patent applications, as well as approximately 88&#160;patents issued in jurisdictions outside of the U.S. Excluding any patent term adjustment and patent term extension, the issued U.S.&#160;patents directed to adenovirus-based cancer and viral immunotherapies are expected to expire from 2024 to 2039. If patents issue from our pending U.S.&#160;patent applications, excluding any patent term adjustment and patent term extension, such patents will be expected to expire from 2028 to 2041. For example, these patents and patent applications include claims directed to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adenovirus vectors and virus particles comprising TAAs; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uses of adenovirus vectors and virus particles in methods of treating cancers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own, co-own with HHS and in-license from HHS and the University of Colorado, patents and patent applications related to the development and commercialization of yeast-based cancer and viral immunotherapies. As of December&#160;31,&#160;2023, our patent portfolio directed to yeast-based cancer and viral immunotherapies and methods of use of yeast-based cancer and viral immunotherapies in treating or preventing cancer and viral diseases consists of approximately 21&#160;issued U.S.&#160;patents and approximately 4&#160;pending U.S.&#160;patent applications, as well as approximately 155&#160;patents issued in jurisdictions outside of the U.S. Excluding any patent term adjustment and patent term extension, the issued U.S.&#160;patents directed to yeast-based cancer and viral immunotherapies are expected to expire from 2027 to 2036. If any patents issue from our pending U.S.&#160;patent applications, excluding any patent term adjustment and patent term extension, such patents will be expected to expire from 2030 to 2039. For example, these patents and patent applications include claims directed to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">yeast and yeast vehicles expressing TAAs and neoepitopes; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uses of yeast and yeast vehicles expressing TAAs and neoepitopes in methods of treating cancers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own approximately 2&#160;issued&#160;U.S. patents and 3&#160;pending U.S.&#160;patent applications directed to therapeutics for COVID-19. Some of these patent applications are directed to the use of our adenovirus and yeast technologies for a COVID-19 vaccine. Excluding any patent term adjustment and patent term extension, the issued U.S. patents directed to therapeutics for COVID-19 expire in 2040. If any patents issue from our pending U.S.&#160;patent applications, excluding any patent term adjustment and patent term extension, such patents will be expected to expire from 2040 to 2042.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We in-license patents and patent applications from AAHI related to the development and commercialization of adjuvant formulations and saRNA&#160;based vaccines. As of December&#160;31,&#160;2023, our licensed patent portfolio directed to adjuvant formulations and saRNA vaccine platforms consists of approximately 5&#160;issued U.S. patents and approximately 5&#160;pending U.S.&#160;patent applications, as well as 1&#160;issued patent in jurisdictions outside of the U.S. Excluding any patent term adjustment and patent term extension, the issued U.S. patents directed to adjuvant formulations and saRNA-based vaccines are expected to expire from 2027 to 2038. If any patents issue from our pending U.S. patent applications, excluding any patent term adjustment and patent term extension, such patents will be expected to expire from 2033 to 2038. In November&#160;2023, the validity of one of our in-licensed issued European patents, EP&#160;Patent No.&#160;2068918, previously challenged in an opposition proceeding was upheld upon appeal. This patent is directed to vaccine compositions comprising certain lipid adjuvants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own patents and patent applications related to the development and commercialization of GMP-in-a-Box. As of December&#160;31,&#160;2023, our patent portfolio directed to GMP-in-a-Box consists of approximately 8&#160;issued U.S.&#160;patents and approximately 2&#160;pending U.S.&#160;patent applications as well as approximately 65&#160;patents issued in jurisdictions outside of the U.S. Excluding any patent term adjustment and patent term extension, the issued U.S.&#160;patents directed to GMP-in-a-Box are expected to expire in 2030 and 2037. If patents issue from our pending patent applications, excluding any patent term adjustment and patent term extension, such patents will be expected to expire in 2035 and 2039. For example, these patents and patent applications include claims directed to methods, bioreactors, and apparatuses for monitoring and culturing cells.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the U.S. are effective for 20&#160;years from the earliest effective filing date of a non-provisional patent application. The patent term may be adjusted to compensate for delayed patent issuance when such delays are caused by the USPTO or successful appeals against USPTO actions. There is no statutory limit on this patent term adjustment, which is generally the length of any such delays caused by the USPTO. In addition, in certain instances, a patent term can be extended to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The restoration period cannot be longer than five years, the total patent term, including the restoration period, must not exceed 14&#160;years following FDA approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. While we plan to seek such patent term adjustments and extensions where applicable, there is no guarantee that the USPTO and/or FDA will agree with our assessment of whether such adjustments or extensions should be granted, and if granted, the length of such adjustments or extensions. The duration of patents outside of the U.S. varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product and country-to-country basis and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of immunotherapy has emerged in the U.S. The patent situation outside of the U.S. is even more uncertain. Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and owned intellectual property, we cannot be sure that patents will be granted with respect to any current pending patent applications or with respect to any patent applications filed in the future, nor can we be sure that any existing patents or any patents that may be granted in the future will be commercially useful in protecting our product candidates and the methods used to manufacture those product candidates. Moreover, even our issued patents do not guarantee us the right to practice our technology in relation to the commercialization of our product candidates. The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our technology. Our issued patents and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or limit the length of the term of patent protection that we may have for our product candidates. In addition, the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies. For these reasons, we may have competition for our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product candidate, it is possible that, before any particular product candidate can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered trademark portfolio currently contains approximately 23&#160;registered trademarks in the U.S., approximately 217&#160;registered trademarks in foreign jurisdictions, approximately 42&#160;pending trademark applications in the U.S., and approximately 64&#160;pending trademark applications in foreign jurisdictions. We may also rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We seek to protect our trade secrets and other proprietary information, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, contractors, consultants, collaborators, and advisors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or may be independently discovered by competitors. To the extent that our employees, contractors, consultants, collaborators, or advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. See Item&#160;1A. Risk Factors &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_444150">Risks Related to Intellectual Property</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and Item&#160;3.&#160;&#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_58">Legal Proceedings</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of this Annual Report for risks related to our proprietary technology, inventions, improvements, and products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that strategic collaborations will continue to be an integral part of our operations, providing opportunities to leverage our partners&#8217; expertise and capabilities to gain access to new technologies and further expand the potential of our technologies and product candidates across relevant platforms. We believe we are well positioned to become a leader in immunotherapy due to our broad and vertically-integrated platforms and through complementary strategic partnerships. Agreements shown below have been arranged in alphabetical order.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of certain of our collaboration and license agreements is not a comprehensive listing of all such agreements to which we are a party, and the inclusion of a description of any collaboration or license agreement is not an indication that we consider such agreement(s) to be material to our business and operations as a whole, which is a dynamic and evolving analysis and may change over time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amyris Joint Venture</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2021, Immunity Bio and Amyris entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture was to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine platform license. As part of the limited liability agreement, Amyris agreed to contribute, in part, rights to its license agreement with AAHI for an RNA platform for the field of COVID-19, and ImmunityBio agreed to contribute, in part, priority access to its manufacturing capacity for the joint venture product. In August&#160;2023, Amyris announced that it filed for Chapter&#160;11 bankruptcy protection. The Amyris bankruptcy case remains ongoing, and there can be no assurance that we will receive any recovery on account of our claims against Amyris, including for Amyris&#8217; portion of expenses incurred by the joint venture. As of December&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was zero. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Cancer Institute </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company and its subsidiaries began their relationship with HHS, as represented by the NCI of the NIH in 2015. Pursuant to the CRADAs, the NCI provides scientific staff and other support necessary to conduct research and related activities as described in the CRADAs. During the term of the initial and amended CRADAs, we collaborated with the NCI on the preclinical and clinical development of an adenovirus technology expressing TAAs for cancer immunotherapy, the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing TAAs, and the proprietary adenovirus technology expressing TAAs for cancer immunotherapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the CRADA was amended and the research plan was modified to include the preclinical and clinical development of ImmunityBio&#8217;s proprietary adenovirus platform expressing TAAs; proprietary yeast platform expressing TAAs; proprietary agent&#160;N-803 and derivatives, agent&#160;N-809 and derivatives, and/or TxM&#160;product candidates; proprietary recombinant NK&#160;cells and mAbs; proprietary RNA vaccines and adjuvants; and other proprietary agents owned or controlled by ImmunityBio for cancer immunotherapy. The term of the CRADA was extended through May&#160;2026. Under this agreement, we agreed to pay NCI funding totaling $1.3&#160;million per year, payable in semi-annual installments each year through 2025. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3M IPC and AAHI License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M&#160;IPC and its affiliates and AAHI. In November&#160;2021 we obtained nonexclusive rights in the field of SARS-CoV-2 and in June&#160;2022 we modified those rights and expanded the scope of the license to include (1)&#160;SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than LMIC, and (2)&#160;oncology applications, when used in combination with our proprietary technology and/or IL-15 agonists. Adjuvants are either synthetic or naturally occurring molecules that activate TLRs thereby enhancing the humoral and cell-mediated immune response of vaccines. There are 10&#160;human TLRs expressed either on the inside or outside of the immune cell and their function is to recognize foreign substances expressed by pathogens. Once activated, these TLRs stimulate danger signals to the immune cells </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiating an immune response. The synthetic imidazoquinolinone 3M-052 is structurally similar to resiquimod. The 3M-052/Alum adjuvant formulation is in Phase&#160;I trials in the U.S. with an HIV antigen and has been well-tolerated and immunogenic. In consideration for the license, we agreed to make certain periodic license payments, including $2.25&#160;million each year through June&#160;2025. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. Beginning in April&#160;2026, the annual minimum licensing payment is $1.0&#160;million, which can be credited against any royalty payments due under this agreement. We may terminate this license for any reason after providing 3M and AAHI sixty (60)&#160;days written notice. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAHI License Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into two&#160;license agreements with the AAHI pursuant to which we received a license to certain patents and know-how relating to AAHI&#8217;s (i)&#160;adjuvant formulations for the treatment, prevention and/or diagnosis of SARS-CoV-2 (the AAHI&#160;Adjuvant Formulation License Agreement) and (ii)&#160;RNA vaccine platform as further described below (the AAHI RNA License Agreement). Under both agreements, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $2.0&#160;million. In addition, under the AAHI Adjuvant Formulation License Agreement we owe milestone payments to a total of up to $2.5&#160;million based on the achievement of certain development and regulatory milestones for the first&#160;licensed product and royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low-single digit percentage, subject to certain royalty-reduction provisions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we amended and restated the AAHI RNA License Agreement, pursuant to which AAHI granted us an exclusive, worldwide, sublicensable license to AAHI&#8217;s rights to an RNA&#160;vaccine platform for the development and commercialization of certain therapeutic, diagnostic, or prophylactic products for the prevention, treatment or diagnosis of any indication, other than those subject to pre-existing third-party license grants, including, without limitation, SARS-CoV-2. Pursuant to the terms of the amended and restated AAHI RNA License Agreement, we made an additional one-time, non-creditable, non-refundable, upfront payment to AAHI of $1.5&#160;million. We paid a license fee of $3.0&#160;million in 2022 and $5.5&#160;million in 2023. We are also required to pay a license maintenance fee to AAHI of $5.5&#160;million annually from 2024 through 2030. The company may terminate the restated agreement without cause by paying AAHI a $10.0&#160;million one-time early termination fee. In addition, the milestone payments to AAHI based on the achievement of certain development and regulatory milestones for the first&#160;licensed product were amended to a total of up to $4.0&#160;million. We are required to pay royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low- to mid-single digit percentage. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the license agreements, in May&#160;2021 we also entered into a sponsored research agreement with AAHI pursuant to which we will fund continued research of at least $2.0&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlobeImmune, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into an exclusive licensing agreement with GlobeImmune, a consolidated entity of the company, pursuant to which we obtained worldwide, exclusive licenses under certain patents, know-how, and other intellectual property to use, research, develop and commercialize products with GlobeImmune&#8217;s COVID-19 vaccine program, other Tarmogen-based programs, and neoepitopes programs in exchange for a license fee for the first&#160;two years of the agreement totaling $1.2&#160;million, up to $345.0&#160;million in milestone payments related to the successful completion of clinical and regulatory milestones and up to $240.0&#160;million in total milestone payments based on licensed product net sales milestones, and a royalty on net sales of licensed products, on a product-by-product basis ranging in percentage from the mid-single digits to the mid-teens. We may terminate this agreement, in whole or on a licensed-product-by-licensed-product and/or country-by-country basis, at any time upon sixty&#160;(60)&#160;days written notice to GlobeImmune. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LadRx Corporation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with LadRx pursuant to which we obtained a royalty-bearing, exclusive, worldwide license, with the right to sublicense, LadRx&#8217;s applicable intellectual property to research, develop and commercialize aldoxorubicin for all indications. Under the terms of the license agreement, LadRx is entitled to receive milestone payments of up to $345.7&#160;million related to regulatory approvals and commercial milestones for aldoxorubicin. In addition, LadRx will receive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increasing low double-digit percentage royalties on net sales of aldoxorubicin for the treatment of soft tissue sarcomas and mid-to-high single-digit percentage royalties on net sales of aldoxorubicin for all other indications. We may terminate the agreement in its entirety at any time upon twelve (12)&#160;months written notice to LadRx. Upon termination of the agreement, any licenses granted to us under the agreement are terminated, and we must cease the development, manufacture, and commercialization of aldoxorubicin. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanford Health</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, and as amended in November&#160;2021, we entered into a license agreement with Sanford pursuant to which we obtained a worldwide, exclusive license under Sanford&#8217;s applicable patent and know-how rights to use, make, have made, sell, offer to sell, export and import products for all uses and applications of polynucleotides encoding mutant E16&#160;antigen (mutant HPV16 E6 antigen + mutant HPV16 E7 antigen) and the encoded mutant E16 antigen, in exchange for consideration that includes the amount equal to the patent prosecution costs incurred by Sanford for the prosecution of the licensed patent rights, milestone payments payable upon the achievement of certain contractual and regulatory milestones of up to $2.0&#160;million, a low single-digit percentage royalty on net sales of the resulting licensed products, and a low to high-teen percentage share of non-royalty sublicensing revenue. Our obligation to pay royalties continues, on a licensed product-by-licensed product and country-by-country basis, until the date on which such licensed product is no longer covered by a valid claim of a patent licensed pursuant to the agreement in such country. We must use commercially reasonable efforts to develop and commercialize the licensed products. Sanford is responsible for the prosecution and maintenance of the patents licensed pursuant to the agreement. We are required to use commercially reasonable efforts to develop and make available the licensed products, which include achieving certain regulatory objectives within certain specific time periods. We have the first right to enforce the patents licensed pursuant to the agreement, subject to Sanford&#8217;s ability to exercise such right if we fail to do so. We may terminate this agreement at any time upon 60&#160;days&#8217; written notice to Sanford. Sanford may terminate the agreement in the event of an uncured material breach by us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2023, we filed an IND for QUILT&#160;3100 exploring the use of an hAd5 [E6/E7] construct known as IBRX-042 in a Phase&#160;I open-label trial to evaluate safety and determine the maximum tolerated dose in subjects with HPV-associated tumors. During the second&#160;half of 2023, we received correspondence from the FDA that it was placing the IND on clinical hold, and requesting additional toxicology studies. The company submitted a complete response to the hold letter in 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shenzhen Beike Biotechnology Co. Ltd. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, Altor entered into a license, development and commercialization agreement with Beike, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license under certain of its intellectual property rights in order to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses, in exchange for consideration that includes up to $195.5&#160;million in total milestone payments based on the successful completion of regulatory and sales milestones for each resulting product, and a royalty on net sales of licensed products, on a product-by-product basis ranging in percentage from the mid-single digits to the mid-teens. Beike&#8217;s obligation to pay royalties continues, on a licensed product-by-licensed product basis, until the later of (i)&#160;the date on which such licensed product is no longer covered by a valid claim of a patent licensed pursuant to the agreement in China and (ii)&#160;ten&#160;years after the first commercial sale of such licensed product in China. Altor has the sole right to prosecute and maintain the patents licensed pursuant to the agreement. Altor has the first right to enforce the patents licensed pursuant to the agreement, subject to Beike&#8217;s ability to exercise such right if Altor fails to do so. Altor and Beike each have the right to terminate the agreement in the event of a material breach by the other party. In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Beike asserting breach of contract under our subsidiary Altor&#8217;s license agreement with them. See Item&#160;3. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_58">Legal Proceedings</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viracta Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with Viracta under which we were granted exclusive worldwide rights to Viracta&#8217;s Phase&#160;II drug candidate, nanatinostat, for use in combination with our platform of NK&#160;cell therapies. In consideration for the license, we are obligated to pay Viracta mid-single digit percentage royalties on net sales of licensed products for therapeutic use and milestone payments ranging from $10.0&#160;million to $25.0&#160;million up to an aggregate maximum of $100.0&#160;million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, at our sole discretion, in whole or on a product-by-product and/or country-by-country basis, at any time upon 90&#160;days&#8217; prior written notice. In addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates biopharmaceuticals under the FD&amp;C&#160;Act and the PHSA. Biopharmaceuticals also are subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.&#160;requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any FDA or judicial enforcement action could have a material adverse effect on us. Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of small molecule and biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various , and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before biopharmaceutical product candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s GLP guidelines;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent IRB or ethics committee for each clinical site before the clinical trial is begun;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety, purity, and potency of the proposed biologic product candidate for its intended purpose; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation of and submission to the FDA of a BLA or NDA, after completion of all required clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60&#160;days of its receipt of a BLA/NDA to file the application for review;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods, and controls are adequate to preserve the product candidates&#8217; continued safety, quality, purity and potency or efficacy, and of selected clinical investigational sites to assess compliance with GCP guidelines; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA or NDA to permit commercial marketing of the product for particular indications for use in the U.S.; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with any post-approval requirements, including the potential requirement to implement a REMS, and the potential requirement to conduct post-approval studies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all. Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an IND product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. The IND also includes results of animal and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a clinical trial using genetically engineered cells is conducted at, or sponsored by, institutions receiving NIH funding for wild-type DNA research, prior to the submission of an IND to the FDA, a protocol and related documentation is submitted to and the study is registered with the OBA pursuant to the NIH Guidelines. Compliance with the NIH Guidelines is mandatory for investigators at institutions receiving NIH funds for research involving wild-type DNA, and many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. The NIH is responsible for convening the RAC, a federal advisory committee that discusses protocols that raise novel or particularly important scientific, safety, or ethical considerations at one of its quarterly public meetings. The OBA will notify the FDA of the RAC&#8217;s decision regarding the necessity for full public review of a protocol. RAC proceedings and reports are posted to the OBA web site and may be accessed by the public. If the FDA allows the IND to proceed, but the RAC decides that full public review of the protocol is warranted, the FDA will request at the completion of its IND review that sponsors delay initiation of the protocol until after completion of the RAC review process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP guidelines, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A&#160;separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB, for each site proposing to conduct the clinical trial, must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of BLA or NDA approval, human clinical trials are typically conducted in three&#160;sequential phases that may overlap:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The investigational product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, the initial human testing is often conducted in patients.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase II. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investigational product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy or potency of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage, and dosing schedule.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase III. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are undertaken to further evaluate dosage, clinical efficacy or potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase IV. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies may voluntarily pursue additional clinical trials after a product is approved to gain more information about the product for that approved indication. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may require an additional trial after a product is approved, and these so-called Phase&#160;IV trials may be a condition to approval of the BLA or NDA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase&#160;I, Phase&#160;II, and Phase&#160;III testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA/NDA Submission and Review by the FDA</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA for a biologic product candidate or an NDA for a small molecule product candidate requesting approval to market the product for one or more indications. Unless agreed to in advance with the FDA, the BLA/NDA must include all data from pertinent preclinical and clinical trials, including negative or ambiguous results, as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of the product or from a number of alternative sources, including studies initiated by investigators, including government agencies (e.g., NIH). The submission of a BLA/NDA requires payment of a substantial user fee to the FDA, and the sponsor of an approved BLA/NDA is subject to annual product and establishment user fees. These fees typically increase annually. A waiver of user fees may be obtained under certain limited circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60&#160;days following submission of the application, the FDA reviews a BLA/NDA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA or NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA/NDA must be resubmitted with the additional information. Once a BLA/NDA has been submitted, the FDA&#8217;s goal is to review the application within ten&#160;months after it accepts the application for filing, or, if the application relates to an unmet medical need in a serious or life-threatening indication, the FDA may review the application six&#160;months after the FDA accepts the application for filing. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA/NDA to determine, among other things, whether a product is safe and effective, or safe, pure, and potent for the proposed indication(s) and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency or efficacy. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA/NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. If applicable, FDA regulations also require tissue establishments to register and list their human cells, tissues, and cellular and tissue-based products with the FDA and to evaluate donors through screening and testing. Additionally, before approving a BLA/NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP guidelines. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing and approval process require substantial time, effort, and financial resources, and each may take several years to complete. The FDA may not grant approval on a timely basis, or at all, and we may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing our product candidates. After the FDA evaluates a BLA/NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application is not ready for approval. A CRL may request additional information or clarification. The FDA may delay or refuse approval of a BLA/NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA/NDA with a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or other restrictions to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase&#160;IV post-market trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our product candidates under development.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, the FDA may consider sections of the BLA/NDA for review on a rolling basis before the complete application is submitted if relevant criteria are met. A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designated product candidate may also qualify for priority review. Priority review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria are not met for priority review, the application is subject to the standard FDA review period. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the accelerated approval program, the FDA may approve a BLA/NDA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the product&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. The Food and Drug Omnibus Reform Act made several changes to the FDA&#8217;s authorities and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a product on an expedited basis for non-compliance with post-approval requirements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDASIA established </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation. A sponsor may seek FDA designation of its product candidate as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors may request the FDA to designate a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of, or any time after, the submission of an IND, but ideally before an end-of-Phase&#160;II meeting with the FDA. If the FDA designates a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller or more efficient clinical trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation also allows the sponsor to file sections of the BLA/NDA for review on a rolling basis. We may seek designation as a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for some or all of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations and priority review do not change the standards for approval. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receipt of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the PREA requires a sponsor to conduct pediatric clinical trials for certain drugs and biological products, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs/BLAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the product candidate is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drugs</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000&#160;individuals in the U.S., or a patient population greater than 200,000&#160;individuals in the U.S. and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the U.S. will be recovered from sales in the U.S. for that drug or biologic. Orphan drug designation must be requested before submitting a BLA or NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA or NDA, to market the same biologic or drug product for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approval are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record keeping, reporting of adverse experiences, periodic reporting, distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. Biopharmaceutical manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and any third-party manufacturers that we may decide to use. Changes to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us, and any third-party manufacturers, that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. We cannot be certain that we or our present or future suppliers will be able to comply with cGMP regulations and other FDA regulatory requirements. If our present or future suppliers are not able to comply with these requirements, the FDA may, among other things, halt our clinical trials, require us to recall a product from distribution, or withdraw approval of the BLA or NDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., once a drug is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. FDA&#160;regulations require that drugs be manufactured in specific facilities per the BLA or NDA approval and in accordance with cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural, and documentation requirements with respect to manufacturing and quality assurance activities. BLA or NDA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute drugs manufactured, processed, or tested by them. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer, or holder of an approved BLA or NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Marketing Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new drug, a biopharmaceutical company and the approved drug are subject to continuing regulation by the FDA, including, among other things, establishment registration and drug listing, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the drug, providing the regulatory authorities with updated safety and efficacy information, drug sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., once a drug is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. FDA regulations require that drugs be manufactured in specific facilities per the NDA approval and in accordance with cGMP. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of its drugs in accordance with cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural, and documentation requirements with respect to manufacturing and quality assurance activities. NDA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute drugs manufactured, processed, or tested by them. Discovery of problems with a drug after approval may result in restrictions on a drug, manufacturer, or holder of an approved NDA, including, among other things, recall or withdrawal of the drug from the market, and may require substantial resources to correct.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require post-approval testing, sometimes referred to as Phase&#160;IV testing, risk minimization action plans, and post-marketing surveillance to monitor the effects of an approved drug or place conditions on an approval that could restrict the distribution or use of the drug. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics or drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties, and exclusion from participation in governmental health programs, like Medicare and Medicaid. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling. Modifications or enhancements to the drug or its labeling or changes of the site or process of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prescription drug advertising is subject to federal, state, and foreign regulations. In the U.S., the FDA regulates prescription drug promotion, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drugs and pharmaceutical samples must comply with the U.S.&#160;PDMA, a part of the FD&amp;C Act. The DSCSA, enacted in 2013, aims to build an electronic system to identify and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trace certain prescription drugs distributed in the U.S. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers. The law&#8217;s requirements include the quarantine and prompt investigation of a suspect product to determine if it is illegitimate and notifying trading partners and the FDA of any illegitimate product. Drug manufacturers and their collaborators are also required to place a unique product identifier on prescription drug packages. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premarket Clearance and Approval Requirements for Medical Devices</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each medical device we seek to commercially distribute in the U.S., including our bioreactors, will require a prior 510(k)&#160;clearance, unless it has received a PMA from the FDA. Generally, if a new device has a predicate that is already on the market under a 510(k) clearance, the FDA will allow that new device to be marketed under a 510(k) clearance; otherwise, a PMA is required. Medical devices are classified into one of three classes: Class&#160;1, Class&#160;2, or Class&#160;3, depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurance of safety and effectiveness. Class&#160;1 devices are deemed to be low risk and are subject to the general controls of the FD&amp;C Act, such as provisions that relate to: adulteration; misbranding; registration and listing; notification, including repair, replacement, or refund; records and reports; and good manufacturing practices. Most Class&#160;1 devices are classified as exempt from premarket notification under section 510(k)&#160;of the FD&amp;C Act, and therefore may be commercially distributed without obtaining 510(k)&#160;clearance from the FDA. Class&#160;2 devices are subject to both general controls and special controls to provide reasonable assurance of safety and effectiveness. Special controls include performance standards, post market surveillance, patient registries and guidance documents. A manufacturer may be required to submit to the FDA a premarket notification requesting permission to commercially distribute some Class&#160;2 devices. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k)&#160;device, are placed in Class&#160;3. A Class&#160;3 device cannot be marketed in the U.S. unless the FDA approves the device after submission of a PMA. However, there are some Class&#160;3 devices for which FDA has not yet called for a PMA. For these devices, the manufacturer must submit a premarket notification and obtain 510(k)&#160;clearance in orders to commercially distribute these devices. The FDA can also impose sales, marketing, or other restrictions on devices in order to assure that they are used in a safe and effective manner.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">510(k) Clearance Pathway</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a 510(k) clearance is required, we must submit a premarket notification to the FDA demonstrating that our proposed device is substantially equivalent to a predicate device, which is a previously cleared and legally marketed 510(k)&#160;device or a device that was in commercial distribution before May&#160;28,&#160;1976. By regulation, a premarket notification must be submitted to the FDA at least 90&#160;days before we intend to distribute a device. As a practical matter, clearance often takes significantly longer. To demonstrate substantial equivalence, the manufacturer must show that the proposed device has the same intended use as the predicate device, and it either has the same technological characteristics, or different technological characteristics and the information in the premarket notification demonstrates that the device is equally safe and effective and does not raise different questions of safety and effectiveness. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence. If the FDA determines that the device, or its intended use, is not substantially equivalent to a previously cleared device or use, the FDA will place the device into Class&#160;3.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three types of 510(k)s: traditional; special; and abbreviated. Special 510(k)s are for devices that are modified and the modification needs a new 510(k) but does not affect the intended use or alter the fundamental scientific technology of the device. Abbreviated 510(k)s&#160;are for devices that conform to a recognized standard. The special and abbreviated&#160;510(k)s are intended to streamline review, and the FDA intends to process special&#160;510(k)s within 30&#160;days of receipt.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De Novo Classification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical device types that the FDA has not previously classified as Class&#160;1, 2 or 3 are automatically classified into Class&#160;3 regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class&#160;3 due to the absence of a predicate device, called the Request for Evaluation of Automatic Class&#160;3 Designation (or the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Classification Process).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This procedure allows a manufacturer whose novel device is automatically classified into Class&#160;3 to request down-classification of its medical device into Class&#160;1 or Class&#160;2 on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the FDASIA, a medical device could only be eligible for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. The FDASIA streamlined the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification pathway by permitting manufacturers to request </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. Under the FDASIA, the FDA is required to classify the device within 120&#160;days following receipt of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> application. If the manufacturer seeks reclassification into Class&#160;2, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premarket Approval Pathway</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A PMA application must be submitted to the FDA for Class&#160;3 devices for which the FDA has required a PMA. The PMA application process is much more demanding than the 510(k) premarket notification process. A PMA application must be supported by extensive data, including but not limited to technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction reasonable evidence of safety and effectiveness of the device.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a PMA application is submitted, the FDA has 45&#160;days to determine whether the application is sufficiently complete to permit a substantive review and thus whether the FDA will file the application for review. The FDA has 180&#160;days to review a filed PMA application, although the review of an application generally occurs over a significantly longer period of time and can take up to several years. During this review period, the FDA may request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the FDA is not bound by the advisory panel decision, the panel&#8217;s recommendations are important to the FDA&#8217;s overall decision making process. In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the QSR. The agency also may inspect one or more clinical sites to assure compliance with FDA&#8217;s regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the PMA review, the FDA may: (i)&#160;approve the PMA application which authorizes commercial marketing with specific prescribing information for one or more indications, which can be more limited than those originally sought; (ii)&#160;issue an approvable letter which indicates the FDA&#8217;s belief that the PMA application is approvable and states what additional information the FDA requires or the post-approval commitments that must be agreed to prior to approval; (iii)&#160;issue a not approvable letter which outlines steps required for approval, but which are typically more onerous than those in an approvable letter, and may require additional clinical trials that are often expensive and time consuming and can delay approval for months or even years; or (iv)&#160;deny the application. If the FDA issues an approvable or not approvable letter, the applicant has 180&#160;days to respond, after which the FDA&#8217;s review clock is reset.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are almost always required to support PMA and are sometimes required for 510(k) clearance. In the U.S., for significant risk devices, these trials require submission of an application for an IDE to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved in advance by the FDA for a specific number of patients at specified trial sites. During the trial, the sponsor must comply with the FDA&#8217;s IDE requirements for investigator selection, trial monitoring, reporting and recordkeeping. The investigators must obtain patient informed consent, rigorously follow the investigational plan, and trial protocol, control the disposition of investigational devices and comply with all reporting and recordkeeping requirements. Clinical trials for significant risk devices may not begin until the IDE application is approved by the FDA and the appropriate IRBs at the clinical trial sites. An IRB is an appropriately constituted group that has been formally designated to review and monitor medical research involving subjects and which has the authority to approve, require modifications in, or disapprove research to protect the rights, safety, and welfare of human research subjects. A nonsignificant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk device does not require FDA approval of an IDE; however, the clinical trial must still be conducted in compliance with various requirements of FDA&#8217;s IDE regulations and be approved by an IRB at the clinical trial sites. The FDA or the IRB at each site at which a clinical trial is being performed may withdraw approval of a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits or a failure to comply with FDA or IRB requirements. Even if a trial is completed, the results of clinical testing may not demonstrate the safety and effectiveness of the device, may be equivocal or may otherwise not be sufficient to obtain approval or clearance of the product. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials of devices are required to register with clinical trials.gov, a public database of clinical trial information. Information related to the device, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ongoing Medical Device Regulation by the FDA</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a device receives clearance or approval and is placed on the market, numerous regulatory requirements apply. These include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment registration and device listing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the manufacturing process;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labeling regulations and the FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses and other requirements related to promotional activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical device reporting regulations, which require that manufactures report to the FDA if their device may have caused or contributed to a death or serious injury, or if their device malfunctioned and the device or a similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">corrections and removal reporting regulations, which require that manufactures report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the FD&amp;C Act that may present a risk to health; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post market surveillance regulations, which apply to certain Class&#160;2 or 3 devices when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new clearance or possibly a PMA. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacture&#8217;s determination. If the FDA disagrees with our determination not to seek a new 510(k) clearance, the FDA may retroactively require us to seek 510(k) clearance or possibly a PMA. The FDA could also require manufacturer to cease marketing and distribution and/or recall the modified device until 510(k) clearance or PMA is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines and penalties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some changes to an approved PMA device, including changes in indications, labeling or manufacturing processes or facilities, require submission and FDA approval of a new PMA application or PMA supplement, as appropriate, before the change can be implemented. Supplements to a PMA application often require the submission of the same type of information required for an original PMA application, except that the supplement is generally limited to that information needed to support the proposed change from the device covered by the original PMA. The FDA uses the same procedures and actions in reviewing PMA supplements as it does in reviewing original PMA applications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA regulations require us to register as a medical device manufacturer with the FDA. Additionally, some states require us to register as a medical device manufacturer within the state. Because of this, the FDA and similar state agencies may inspect us on a routine basis for compliance with the QSR. In February&#160;2024, the FDA issued a final rule replacing the QSR with the QMSR, which incorporates by reference the quality management system requirements of ISO&#160;13485:2016. The FDA has stated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the standards contained in ISO&#160;13485:216 are substantially similar to those set forth in the existing QSR. This final rule does not go into effect until February&#160;2026. These regulations require that the manufacturer maintain proper documentation in a prescribed manner with respect to manufacturing, testing and control activities. Further, the FDA requires medical device manufacturers to comply with various FDA regulations regarding labeling. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or by our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or state authorities, which may include any of the following sanctions:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer notifications, voluntary or mandatory recall or seizure of our medical device product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions, partial suspension, or total shutdown of production;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in processing submissions or applications for new products or modifications to existing products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawing approvals that have already been granted; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Device Reporting laws and regulations require medical device manufacturers to provide information to the FDA when they receive or otherwise become aware of information that reasonably suggests the device may have caused or contributed to a death or serious injury as well as a device malfunction that likely would cause or contribute to death or serious injury if the malfunction were to recur. In addition, the FDA prohibits an approved device from being marketed for off-label use. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory clearance or approval of our medical device product candidates under development. Medical device manufacturers are also subject to other federal, state, and local laws and regulations relating to safe working conditions, laboratory and manufacturing practices.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing, sales, promotion, and other activities following drug approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the U.S., CMS, other divisions of HHS, the Drug Enforcement Administration for controlled substances, the Consumer Product Safety Commission, the FTC, Occupational Safety and Health Administration, the Environmental Protection Agency, and state and local governments. In the U.S., sales, marketing, and scientific/educational programs must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Patient Protection and Affordable Care Act as amended by the ACA. If drugs are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Drugs must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion, and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign, federal, state, and local environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. In addition, our leasing and operation of real property may subject us to liability pursuant to certain U.S. environmental laws and regulations, under which current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly, and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of pharmaceutical drugs is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical drugs. The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines, or other penalties, injunctions, voluntary recall, or seizure of drugs, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales, promotion, medical education, clinical research, and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the U.S. in addition to the FDA, including potentially the FTC, the Department of Justice, the CMS, other divisions of HHS and state and local governments. Our promotional and scientific/educational programs must comply with the AKS, the FCA, physician payment transparency laws, privacy laws, security laws, and additional federal and state laws similar to the foregoing. If drugs are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Drugs must meet applicable child-resistant packaging requirements under the U.S.&#160;Poison Prevention Packaging Act. Manufacturing, sales, promotion, and other activities are also potentially subject to federal and state consumer protection and unfair competition laws. Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AKS prohibits, among other things, the knowing and willing, direct or indirect offer, receipt, solicitation, or payment of remuneration in exchange for or to induce the referral of patients, including the purchase, order or lease of any good, facility, item or service that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the AKS has been violated. The government has enforced the AKS to reach large settlements with healthcare companies based on sham research or consulting and other financial arrangements with physicians. Further, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Many states have similar laws that apply to their state health care programs, as well as private payors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal false claims and false statement laws, including the FCA, imposes liability on persons or entities that, among other things, knowingly present or cause to be presented claims that are false or fraudulent or not provided as claimed for payment or approval by a federal health care program. The FCA has been used to prosecute persons or entities that cause the submission of claims for payment that are inaccurate or fraudulent, by, for example, providing inaccurate billing or coding information to customers, promoting a product off-label, submitting claims for services not provided as claimed, or submitting claims for services that were provided but not medically necessary. Actions under the FCA may be brought by the Attorney General, or as a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qui tam action by a private individual, in the name of the government. Violations of the FCA can result in significant monetary penalties and treble damages. The federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other illegal sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the FCA in addition to individual criminal convictions under applicable criminal statutes. In addition, certain companies that were found to be in violation of the FCA have been forced to implement extensive corrective action plans and have often become subject to consent decrees or corporate integrity agreements, restricting the manner in which they conduct their business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors; knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; and willfully obstructing a criminal investigation of a healthcare offense. Like the AKS, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws. In addition, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to the extent that our product candidates, once commercialized, are sold in a foreign country, we may be subject to similar foreign laws.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers and teaching hospitals. The ACA, among other things, under the federal Physician Payment Sunshine Act, imposed reporting requirements on certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, for payments or other transfers of value made by them to certain covered recipients, including physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January&#160;1,&#160;2022, these reporting obligations with respect to covered recipients have been extended to include payments and transfers of value made to non-physician providers such as physician assistants and nurse practitioners. Covered manufacturers are required to collect and report detailed payment data and submit legal attestation to the accuracy of such data to the government each year. Failure to submit required information may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission. Additionally, entities that do not comply with mandatory reporting requirements may be subject to a corporate integrity agreement. Certain states also mandate implementation of commercial compliance programs, impose restrictions on covered manufacturers&#8217; marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and other healthcare professionals.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by HITECH and their respective implementing regulations, impose specified requirements on certain health care providers, plans, and clearinghouses, or collectively, covered entities, and their business associates, relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, which includes independent contractors or agents of covered entities that create, receive, maintain, or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain states have their own laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other and/or HIPAA in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, contractual damages, reputational harm, and diminished profits and future earnings, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other providers, independent contractors, or entities with whom we do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing health care laws, we are also subject to the FCPA and similar worldwide anti-bribery laws, which generally prohibit companies and their intermediaries from making improper payments to government officials or private-sector recipients for the purpose of obtaining or retaining business. The anti-corruption policy mandates compliance with the FCPA and similar anti-bribery laws applicable to our business throughout the world. However, we cannot assure you that such a policy or procedures implemented to enforce such a policy will protect us from intentional, reckless, or negligent acts committed by our employees, distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products depend significantly on the extent to which coverage and adequate reimbursement are provided by third-party payors. Third-party payors include state and federal government health care programs, managed care providers, private health insurers and other organizations. Although we currently believe that third-party payors will provide coverage and reimbursement for our product candidates, if approved, we cannot be certain of this. Third-party payors are increasingly challenging the price, examining the cost-effectiveness, and reducing reimbursement for medical products and services. In the U.S., no uniform policy of coverage and reimbursement for drugs or biological products exists, and one payor&#8217;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will make a similar determination. In the U.S., the principal decisions about reimbursement for new medicines are typically made by the CMS, an agency within the HHS, as the CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private third-party payors tend to follow Medicare coverage and reimbursement limitations to a substantial degree, but also have their own methods and approval process apart from Medicare determinations. Significant uncertainty exists as to the reimbursement status of newly approved healthcare products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S.&#160;government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures could further limit our revenues and results. We may need to conduct expensive clinical trials to demonstrate the comparative cost-effectiveness of our product candidates. The product candidates that we develop may not be considered cost-effective and thus may not be covered or sufficiently reimbursed. It is time consuming and expensive for us to seek coverage and reimbursement from third-party payors, as each payor will make its own determination as to whether to cover a product and at what level of reimbursement. Thus, one payor&#8217;s decision to provide coverage and adequate reimbursement for a product does not assure that another payor will provide coverage or that the reimbursement levels will be adequate. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement may not be available or sufficient to allow us to sell our product candidates on a competitive and profitable basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our product candidates profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March 2010, the ACA was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our potential product candidates are:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include, among others, the Budget Control Act of 2011, which mandates aggregate reductions to Medicare payments to providers of up to 2% per fiscal year effective April&#160;1,&#160;2013, and, due to subsequent legislative amendments, will remain in effect through 2032. In January&#160;2013, President Obama signed into law the ATRA, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and, accordingly, our financial operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the American Rescue Plan Act of 2021, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs was eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. Further, in July&#160;2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at increasing competition for prescription drugs. In August&#160;2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part&#160;B and Part&#160;D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part&#160;D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Various industry stakeholders have initiated lawsuits against the U.S. government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of these judicial challenges, legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. The impact of these regulations and any future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is currently unknown. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the enactment of the ACA, there have been judicial and Congressional challenges to certain aspects of the ACA. In June&#160;2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how additional challenges and healthcare reform measures of the Biden administration will impact the ACA. Complying with any new legislation or changes in healthcare regulation could be time-intensive and expensive, resulting in material adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products. For example, the FDA recently authorized the state of Florida to import certain prescription drugs from Canada for a period of two&#160;years to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida. These measures could reduce the demand for our products, if approved, or impose additional pricing pressures on how much we can charge for our products if approved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. Furthermore, the current presidential administration and Congress may continue to attempt broad sweeping changes to the current health care laws. We face uncertainties that might result from modifications or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the pharmaceutical and biotechnology industries as a whole is currently unknown. However, any changes to the ACA are likely to have an impact on our results of operations and may have a material adverse effect on our results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect any future legislation or regulation in the U.S. may have on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Regulation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates to the extent we choose to develop or sell any product candidates outside of the U.S. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Human Capital talent strategy relies on attracting, retaining and developing top talent that align with our culture and mission to &#8220;Outsmart Your Disease.&#8221; We promote a culture that is focused on delivering treatments utilizing natural immunities, and we seek to harness our science first focus to deliver solutions to patients and families. As of December&#160;31,&#160;2023, we had 628&#160;employees located across the U.S. and Italy. Among our employees, 40%&#160;are focused on research and development, 34%&#160;on manufacturing and quality, and 26%&#160;on general and administrative functions. We have not been subject to labor action or union activities, and our management considers its relationships with employees to be good.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that fostering a workplace that celebrates differences and strengths creates an environment that supports the inclusion and value of diverse thoughts, backgrounds and perspectives. A well rounded culture allows for ongoing dialogue and discussions that challenge the status quo and create a learning environment that supports diversity, equity and inclusion. As part of our commitment, we continue to encourage a culture where employees can freely ask questions and raise concerns. Our annual performance review process helps support our commitment to develop and retain top talent by providing an opportunity to have open dialogue, establish goals, discuss milestones and continue to engage in opportunities to develop and cultivate the talent. Additionally, our management team makes themselves available to all employees including 1:1s, Department Meetings and Town&#160;Hall events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing success will continue to depend on our ability to attract, engage and retain top talent in an ever growing competitive market. We offer a competitive compensation package to help meet the needs of our employees. In addition to salaries, these programs include the potential to receive annual bonuses and equity awards, and a 401(k)&#160;plan, healthcare and insurance benefits, flexible spending accounts, paid time off, family leave, flexible work schedules, and an employee assistance program, among others. We work to ensure pay equity by assessing our compensation practices and working with external benchmarks and compensation consultants to design and benchmark our programs.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Development of ImmunityBio, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio,&#160;Inc. was established following a series of mergers and name changes. We were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporated in Illinois on October&#160;7,&#160;2002 under the name ZelleRx&#160;Corporation. Our name was later changed to Conkwest,&#160;Inc., and we were reincorporated in the state of Delaware in March&#160;2014. On July&#160;10,&#160;2015, we changed our name to NantKwest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NantCell, LLC was originally organized as a Delaware limited liability company in November&#160;2014. In April&#160;2015, it&#160;was converted to a Delaware corporation, NantCell,&#160;Inc., and in May&#160;2019 changed its name to ImmunityBio,&#160;Inc. (a private company). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;21,&#160;2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NantKwest and NantCell entered into an Agreement and Plan of Merger (the Merger Agreement), pursuant to which NantKwest and NantCell agreed to combine their businesses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the Merger), with NantCell surviving the Merger as a wholly-owned subsidiary of the company. We believe that the Merger, which closed on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;9,&#160;2021, combined two&#160;companies to create a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio is incorporated in Delaware and its principal executive offices are located in San&#160;Diego, California. </span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about our company is available on our website at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.immunitybio.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available on our website, free of charge, copies of our Annual Report, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it, to the SEC. All reports we file with the SEC are available free of charge via EDGAR through the SEC website at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.sec.gov</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have included the web addresses of ImmunityBio and the SEC as inactive textual references only. Except as specifically incorporated by reference into this Annual Report, information on these websites is not part of this filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, any of which may be relevant to decisions regarding an investment in or ownership of our stock. The occurrence of any of these risks could have a significant adverse effect on our reputation, business, financial condition, results of operations, growth, and ability to accomplish our strategic objectives. We have organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with a limited operating history and no products approved for commercial sale. We have a history of operating losses, and we expect to continue to incur losses and may never be profitable, which together with our limited operating history, makes it difficult to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We anticipate needing additional financing to fund our operations and complete the development and commercialization of our various product candidates, and if we are unable to obtain such financing when needed, or on acceptable terms, we may be unable to complete the development and commercialization of our product candidates. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The RIPA imposes Revenue Interest Payments (as defined in the RIPA) obligations, which may adversely affect our financial position and results of operations, as well as affirmative and negative covenants, which restrict our business operations. The breach of our obligations under the RIPA could give rise to a default, triggering a Put Option (as defined in the RIPA) and/or foreclosure on our assets.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our debt and revenue interest liability could adversely affect our cash flows and limit our flexibility to raise additional capital.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The value of our warrants outstanding and the revenue interest liability are subject to potentially material increases and decreases based on fluctuations in the price of our common stock or projected sales and the probability of specific events, which may affect our results of operations and financial position and could adversely affect our stock price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Commercialization of our Product Candidates</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The CRL we received from the FDA for the BLA has delayed, and may decrease the likelihood of, ultimate approval and successful commercialization of our lead product candidate in the U.S. and potentially other markets. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied and will continue to rely on third parties and related parties to conduct many of our preclinical studies and clinical trials, manufacture products, and perform many essential services for any products that we commercialize. Any failure by a third party, related party, or by us to perform as expected, to comply with legal and regulatory requirements or to conduct the clinical trials according to GCP&#160;guidelines, and in a timely manner, may delay or prevent our ability to seek or obtain regulatory approval for or commercialization of our product candidates and subject us to regulatory sanctions.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If third-party manufacturers, wholesalers and distributors fail to perform as expected, or fail to devote sufficient time and resources to our product candidates, our clinical development may be delayed, our costs may be higher than expected or our product candidates may fail to be approved, or we may fail to commercialize any product candidates if approved.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use the Clinic, a related party, in some of our clinical trials which may expose us to significant regulatory risks. If our data for this site is not sufficiently robust or if there are any data integrity issues, we may be required to repeat such studies or contract with other clinical trial sites, which could delay and/or increase the cost of our development plans.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third&#160;parties or additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements. Conflicts may arise between us and our collaborators or strategic partners, and such strategic alliances, collaborations or licensing arrangements may not be successful.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare and Other Government Regulations</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our product candidates. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval for our lead product candidate or any other product candidates, we will continue to be subject to ongoing regulatory requirements, which may result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to adequately establish sales, marketing and distribution capabilities, we may not be successful commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems related to large-scale commercial manufacturing could cause delays in product launches, an increase in costs, product recalls or product shortages.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain, maintain, protect and enforce patent protection and other proprietary rights for our product candidates and technologies, we may not be able to compete effectively or operate profitably and our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our licensors, collaborators, or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other intellectual property or the patents or other intellectual property of our licensors, all of which could be expensive, time-consuming and unsuccessful, may delay or prevent the development and commercialization of our product candidates, or may put our patents and other proprietary rights at risk.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock and CVRs</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dr.&#160;Soon-Shiong, our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, has significant interests in other companies which may conflict with our interests.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dr.&#160;Soon-Shiong, through his voting control of the company, has the ability to control actions that require stockholder approval. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conversion of certain related-party promissory notes, exercise of outstanding warrants and options to purchase our common stock, the achievement of the milestone under our outstanding CVRs, and potential additional equity issuances may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and may continue to be volatile, and investors may have difficulty selling their shares.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">clinical-stage biotechnology</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> company with a limited operating history and no products approved for commercial sale. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of operating losses, and we expect to continue to incur losses and may never be profitable, which together with our limited operating history, makes it difficult to assess our future viability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with a limited operating history upon which you can evaluate our business and prospects, and we have a broad portfolio of product candidates at various stages of development. None of our products have been approved for commercial sale, and we have not generated any revenue from product sales, although we have generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry, including in connection with obtaining marketing approvals, manufacturing a commercial-scale product or arranging for a third&#160;party to do so on our behalf or conducting sales and marketing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities necessary for successful product commercialization. Because of the numerous risks and uncertainties associated with our product development efforts, we are unable to predict when we may become profitable, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the commencement of our operations, we have incurred significant losses each year, and, as of December&#160;31,&#160;2023, we had an accumulated deficit of $3.0&#160;billion. We expect to continue to incur significant expenses as we seek to expand our business, including in connection with conducting research and development across multiple therapeutic areas, participating in clinical trial activities, continuing to acquire or in-license technologies, maintaining, protecting and expanding our intellectual property, seeking regulatory approvals, increasing our manufacturing capabilities and, upon successful receipt of FDA approval, commercializing our products. Moreover, if our lead product candidate is not approved, we do not expect to have significant product sales or revenue in the near term, if ever. Furthermore, even if approved, the timing and magnitude of product sales and revenue remain uncertain, and may take a significant amount of time to materialize, if ever.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required by the FDA or any equivalent foreign regulatory authority to perform clinical trials or studies in addition to those we currently expect to conduct, or if there are any delays in completing the clinical trials of our product candidates, our expenses could increase substantially. We have submitted a BLA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all, for commercialization and even if approved, the resulting revenue may not enable us to achieve profitability. Even if we obtain regulatory approval to market a product candidate, our future revenues will depend upon the size of any markets in which our product candidates have received approval, and our ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share for our product candidates in those markets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses and net losses to increase significantly as we prepare to potentially commercialize our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, if approved by the FDA, continue our development of, and seek regulatory approvals for, our other product candidates, and begin to commercialize other approved products, if any, as well as hire additional personnel, protect our intellectual property and incur additional costs associated with operating as a public company. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical studies and trials, associated manufacturing needs, commercialization activities if our product candidates are approved and our expenditures on other research and development activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our research and development efforts are successful, we may also face the risks associated with the shift from development to commercialization of new products based on innovative technologies. Our ability to achieve profitability, if ever, is dependent upon, among other things, obtaining regulatory approvals for our product candidates and successfully commercializing our product candidates alone or with third&#160;parties. However, our operations may not be profitable even if one or more of our product candidates under development are successfully developed and produced and thereafter commercialized. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. As a result, it may be more difficult for you to assess our future viability than it could be if we had a longer operating history.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We anticipate needing additional financing to fund our operations and complete the development and commercialization of our various product candidates, and if we are unable to obtain such financing when needed, or on acceptable terms, we may be unable to complete the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception. A significant portion of our funding had been in the form of promissory notes totaling $735.0&#160;million in indebtedness (consisting of related-party promissory notes and accrued and unpaid interest) outstanding as of December&#160;31,&#160;2023 held by entities affiliated with Dr.&#160;Soon-Shiong.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, we held cash, cash equivalents and marketable securities totaling $267.4&#160;million. We will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our product candidates. Changing circumstances may cause us to increase our spending significantly faster than we currently anticipate and we may need to raise additional funds sooner than we presently anticipate. Moreover, research and development and our operating costs and fixed expenses such as rent and other contractual commitments, including those for our research collaborations, are substantial and are expected to increase in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless and until we can generate a sufficient amount of revenue, we may finance future cash needs through public or private equity offerings, license agreements, debt financings, collaborations, strategic alliances, marketing or distribution arrangements, or exchange additional future Revenue Interests for the Second Payment in the RIPA agreement. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or equity-linked securities (including warrants), convertible debt or under the&#160;ATM, our shelf registration statement, or other offerings, or if any of our current debt is converted into equity or if our existing warrants are exercised, your ownership interest will be diluted, and the liquidation or other preferences may adversely affect your rights as a stockholder. If we incur additional indebtedness, our fixed payment obligations will increase and we may have to comply with certain restrictive covenants that are similar to those associated with the revenue interest liability, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third&#160;parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us, or exercise our Call Option (as defined in the RIPA) to purchase the outstanding revenue interest liability which will require us to generate a significant amount of cash flow to offset these outflows. Absent the Second Payment under the RIPA, subject to satisfaction of certain conditions specified in the RIPA, we have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545397">&#8220;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545397">&#8212;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545397">Our payment obligations under the RIPA may adversely affect our financial position and results of operations and our ability to raise additional capital which in turn may increase our vulnerability to adverse regulatory developments or economic or business downturns</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545397">&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the &#8220;Notes to the Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span id="if7b491d5c1d6441fa17129e6f403e298_545397"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our payment obligations under the RIPA may adversely affect our financial position and results of operations and our ability to raise additional capital which in turn may increase our vulnerability to adverse regulatory developments or economic or business downturns.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing, less certain transaction expenses. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment subject to certain conditions specified in the RIPA, including following the receipt of approval by the FDA of the company&#8217;s BLA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on or before June&#160;30,&#160;2024. As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, our worldwide net sales, excluding those in China, which will be tiered payments initially ranging from 3.00% to 7.00% (or after funding of the Second Payment, 4.50% to 10.00%), subject to increase or decrease, following December&#160;31,&#160;2029 depending on whether the aggregate payments made to Oberland as of that date met or exceeded the Cumulative Purchaser Payments (as defined in the RIPA). In addition, if the aggregate payments to Oberland as of December&#160;31,&#160;2029 do not equal or exceed the amount of the Cumulative Purchaser Payments, then we are obligated to make a one-time payment to Oberland in an amount equal to 100% of the Cumulative Purchaser Payments, less the aggregate amount of our previous payments to Oberland as of December&#160;31,&#160;2029 (the True-Up Payment, as defined in the RIPA). See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to the Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA and our payment obligations to Oberland could have important negative consequences to holders of our securities. For example, a portion of our cash flow from operations will be needed to make required payments to Oberland and will not be available to fund future operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment requirements under the RIPA will increase our cash outflows. Our future operating performance is subject to market conditions and business factors that are beyond our control. If our cash inflows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay capital expenditures, sell assets or seek additional capital. If we raise funds by selling additional equity, such sale would result in dilution to our stockholders. There is no assurance that if we are required to secure funding we can do so on terms acceptable to us, or at all. Failure to pay amounts owed to Oberland when due would result in a default under the RIPA and could result in foreclosure on all or substantially all of our assets, which would have a material adverse effect.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The RIPA contains affirmative and negative operational covenants and events of default, which may prevent us from capitalizing on business opportunities and taking some corporate actions, and gives rise to a Put Option in favor of Oberland, which could have a material adverse effect on our financial condition and business operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA contains affirmative and negative covenants and events of default, including covenants and restrictions that, among other things, restrict our ability to incur liens, incur additional indebtedness, make loans and investments, enter into transactions with affiliates, engage in mergers and acquisitions, engage in asset sales and exclusive licensing arrangements, and declare dividends to our stockholders, in each case, subject to certain exceptions set forth in the RIPA. Additionally, Oberland has a Put Option enabling them to terminate the RIPA and to require the company to repurchase the Revenue Interests upon enumerated events such as a bankruptcy event, failure to make a payment, an uncured material breach, default on certain third-party agreements, a breach or default under any subordination agreements with respect to indebtedness to existing stockholders, any right to repurchase or accelerate debt instruments like permitted convertible notes, existing stockholder indebtedness, or subordinated notes during certain time periods, judgments in excess of certain amounts against us, a material adverse effect, the loss of regulatory approval of our product candidates or a change of control. The triggering of the Put Option, including by our failure to comply with these covenants, would permit Oberland to declare certain amounts to be immediately due and payable. If we were to default under the terms of the RIPA, including by failure to make such accelerated payments, Oberland could exercise remedies, including initiating foreclosure proceedings against all or substantially all of our assets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oberland&#8217;s right to repayment is senior to the rights of the holders of our common stock. Any triggering of the Put Option or other declaration by Oberland of an event of default under the RIPA could significantly harm our financial condition, business and prospects and could cause the price of our common stock to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our debt and revenue interest liability could adversely affect our cash flows and limit our flexibility to raise additional capital.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant amount of debt and revenue interest liability and may need to incur additional debt to support our growth. As of December&#160;31,&#160;2023, our indebtedness totaled $735.0&#160;million, (consisting of related-party promissory notes and accrued and unpaid interest), held by entities affiliated with Dr.&#160;Soon-Shiong along with a $200.0&#160;million revenue interest liability with Oberland.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our substantial amount of debt could have important consequences and could:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to dedicate a substantial portion of our cash and cash equivalents to make interest and principal payments on our debt and revenue interest liability payments, reducing the availability of our cash and cash equivalents and cash flow from operations to fund future capital expenditures, working capital, execution of our strategy and other general corporate requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our cost of borrowing and even limit our ability to access additional debt to fund future growth;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to general adverse economic and industry conditions and adverse changes in governmental regulations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and industry, which may place us at a disadvantage compared with our competitors; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds, even when necessary to maintain adequate liquidity, which would also limit our ability to further expand our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the foregoing factors could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the company&#8217;s ability to make scheduled payments of the principal of, potential Test&#160;Date payments of, to pay interest or royalties on, or to refinance any current or future indebtedness, including the related-party promissory notes or the revenue interest liability, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flows from operations in the future to service our indebtedness, pay the revenue interest liability, and make necessary capital expenditures. If we are unable to generate such cash flows, we may be required to adopt one or more alternatives, such as selling assets, restructuring indebtedness, including the revenue interest liability, or obtaining additional equity or equity-linked capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness, including the revenue interest liability, at maturity or otherwise, will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we can refinance the related-party promissory notes or revenue interest liability or what terms will be available in the market at the time of refinancing. Furthermore, if prevailing interest rates or other factors at the time of refinancing result in higher interest rates upon refinancing, then the interest expense relating to the refinancing would increase. These risks could materially adversely affect our financial condition, cash flows and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The value of our warrants outstanding and the revenue interest liability are subject to potentially material increases and decreases based on fluctuations in the price of our common stock or projected sales and the probability of specific events, which may affect our results of operations and financial position and could adversely affect our stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our registered direct offerings, during the years ended December&#160;31,&#160;2023 and 2022 we entered into warrant agreements with certain institutional investors that allows such investors to purchase up to an aggregate total of 37,732,820&#160;shares of our common stock at exercise prices ranging from $3.2946&#160;per share to $6.60&#160;share. As of December&#160;31,&#160;2023, all of the warrants were exercisable and had expiration dates ranging from December&#160;12,&#160;2024 to July&#160;24,&#160;2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the warrants as derivative instruments, and changes in the fair value of the warrants are included in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations for each reporting period. At December&#160;31,&#160;2023, the fair value of warrant liabilities included in the consolidated balance sheet was $118.8&#160;million. We use the Black-Scholes option pricing model </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to determine the fair value of the warrants. As a result, the valuation of these derivative instruments is subjective, and the Black-Scholes option pricing model requires the input of subjective assumptions, including the expected stock price volatility and probability of a fundamental transaction (a strategic merger or sale). Changes in these assumptions can materially affect the fair value estimate. We could, at any point in time, ultimately incur amounts different than the carrying value, which could have a significant impact on our results of operations and financial position.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the revenue interest liability as a liability, net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on the liability and the underlying value of the bifurcated embedded derivative may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales, and in the case of the derivative, specific probabilities associated with RIPA Put/Call events or Test&#160;Date payments underlying our Monte Carlo analysis. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability and/or the bifurcated embedded derivative, interest expense, and the time period for repayment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in warrant, revenue interest liability, and derivative values and changes in the assumptions and factors used in the model may impact our operating results, making it difficult to forecast our operating results and making period-to-period comparisons less predictive of future performance. In one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price of our common stock could decline. In addition, the market price of our common stock may fluctuate or decline regardless of our operating performance</span><span style="color:#373739;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accounting method for convertible debt securities could have a material effect on our reported financial results.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC&#160;Topic&#160;470-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Modifications and Extinguishments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;470-50), we recorded amendments to our related-party promissory notes entered into on September&#160;11,&#160;2023 under the debt modification accounting model, as the amendments were not substantially different than the terms of the promissory notes prior to the amendment. Under this model, the unamortized debt discounts from the promissory notes are amortized as an adjustment of interest expense over the remaining term of modified promissory notes using the effective interest rate method. Also, the increase in fair value of the embedded conversion feature from the debt modification was accounted for as a debt discount to the $200.0&#160;million convertible note that is not recorded at fair value with a corresponding increase in additional paid-in capital. In addition, we recorded amendments to our related-party promissory notes entered into on December&#160;29,&#160;2023 under the debt extinguishment model, and as a result recognized a total net gain on extinguishment of $36.1&#160;million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit, as the debt was acquired from entities under common control. As a result of the debt amendments, we will be required to record a greater amount of non-cash interest expense in current periods presented as a result of the amortization of the discount associated with certain promissory notes. We will either report lower net income or a higher net loss in our consolidated financial results because FASB ASC&#160;Topic&#160;470-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires interest to include both the current period&#8217;s amortization of the debt discount and the instrument&#8217;s coupon interest, which could adversely affect our reported or future financial results and the trading price of our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We invest our cash on hand in various financial instruments which are subject to risks that could adversely affect our business, results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have typically invested our cash in a variety of financial instruments, including investment-grade short- to intermediate-term corporate debt securities, government-sponsored securities and European bonds; however, after our entry into the RIPA, we can no longer invest our excess funds in corporate or European bonds. Certain of our investments are subject to credit, liquidity, market, and interest rate risk. Such risks, including the failure or severe financial distress of the financial institutions that hold our cash, cash equivalents and investments, may result in a loss of liquidity, impairment to our investments, realization of substantial future losses, or a complete loss of the investments in the long-term, which may have a material adverse effect on our business, results of operations, liquidity and financial condition. To manage the risk to our investments, we maintain an investment policy that, among other things, limits the amount that we may invest in any one issue or any single issuer and requires us to only invest in high credit quality securities to preserve liquidity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use NOLs and research and development credits to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Sections&#160;382 and 383 of the Code, a corporation that undergoes an ownership change is subject to limitations on its ability to utilize its pre-change NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5%&#160;of a corporation&#8217;s stock increases its ownership by more than 50&#160;percentage points over its lowest ownership percentage within a specified testing period. We have not conducted a complete study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If we have experienced a change of control, as defined by Section&#160;382, at any time since inception (including as a result of the March&#160;2021 merger which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursuant to which NantKwest and NantCell combined their businesses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization. In addition, our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we will need to raise substantial additional funding to finance our operations, we may experience further ownership changes in the future, some of which may be outside of our control. Limits on our ability to use our pre-change NOLs or credits to offset U.S.&#160;federal taxable income could potentially result in increased future tax liability to us if we earn net taxable income in the future. In addition, under the legislation commonly referred to as the TCJA, as modified by the Coronavirus Aid, Relief, and Economic Security Act, the amount of NOLs generated in taxable periods beginning after December&#160;31,&#160;2017, that we are permitted to deduct in any taxable year beginning after December&#160;31,&#160;2020 is limited to 80%&#160;of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. The TCJA allows post-2017 unused NOLs to be carried forward indefinitely. Similar rules may apply under state tax laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our transfer pricing policies may be subject to challenge by the IRS or other taxing authorities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intercompany relationships are subject to complex transfer pricing regulations administered by taxing authorities in various jurisdictions. The relevant taxing authorities may disagree with our determinations as to the value of assets sold or acquired or income and expenses attributable to specific jurisdictions. If such a disagreement were to occur, and our position were not sustained, we could be required to pay additional taxes, interest and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. We believe that our consolidated financial statements reflect adequate reserves to cover such a contingency, but there can be no assurances in that regard.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could expose us to greater than anticipated tax liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax laws applicable to our business, including the laws of the U.S. and other jurisdictions, are subject to interpretation and certain jurisdictions may aggressively interpret their laws in an effort to raise additional tax revenue. It is possible that tax authorities may disagree with certain positions we have taken, are currently taking or will take, and any adverse outcome of such a review or audit could have a negative effect on our financial position and results of operations. Further, the determination of our provision for income taxes and other tax liabilities requires significant judgment by management, and there are transactions where the ultimate tax determination is uncertain. Although we believe that our estimates are reasonable, the ultimate tax outcome may differ from the amounts recorded on the consolidated financial statements and may materially affect our financial results in the period or periods for which such determination is made.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. For example, in August&#160;2022, the U.S. enacted the IRA, which imposes a 15%&#160;minimum tax on the adjusted financial statement income of certain large corporations, as well as a 1%&#160;percent excise tax on corporate stock repurchases by publicly-traded companies. Additionally, for taxable years beginning on or after January&#160;1,&#160;2022, the Code eliminated the right to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize U.S. and foreign research and development expenditures over&#160;5 and 15&#160;tax years, respectively. These updates, as well as any other changes to tax laws that are enacted, could adversely affect our tax liability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development and Commercialization of our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will successfully complete development, receive regulatory approval or be successfully commercialized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Annual Report, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from product candidates that are under development. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;2022, we announced the submission of a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the development of our main product candidates, N-803, our novel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> antibody-cytokine fusion protein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">econd-generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hAd5 and saRNA vaccine candidates, and our NK&#160;cell therapy candidates. Our product candidates will require additional clinical and non-clinical development, regulatory approval, commercial manufacturing arrangements, enhancement of our commercial organization and service providers, significant marketing efforts, and further investment before we can generate any revenues from product sales. We expect to invest heavily in these product candidates as well as in our other existing product candidates and in any future product candidates that we may develop. Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected adverse events or failure to achieve primary endpoints in clinical trials. Furthermore, we cannot assure you that we will meet our timelines for current or future clinical trials, which may be delayed or not completed for a number of reasons. Additionally, our ability to generate revenues from our combination therapy products will also depend on the availability of the other therapies, including BCG, with which our products are intended to be used. We currently generate no meaningful revenues from the sale of any product candidates, and we may never be able to develop or commercialize a product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The CRL we received from the FDA for the BLA has delayed, and may decrease the likelihood of, ultimate approval and successful commercialization of our lead product candidate in the U.S. and potentially other markets. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2022, we announced the submission of a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. In July&#160;2022, we announced that the FDA had accepted our BLA for review and set a target PDUFA action date of May&#160;23,&#160;2023. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that it had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the FDA will ultimately agree that the issues raised in the CRL have been successfully addressed and resolved in the BLA resubmission. Further, any inability to successfully work with the FDA to find a satisfactory solution to address any concerns in a timely manner or at all during the review process for the BLA, including any inability to provide the FDA with data, analysis or other information sufficient to support an approval of the BLA, may adversely impact the prospects for FDA approval. In addition, the results from any FDA re-inspection of any facility including those of our third-party CMOs may further delay, or adversely impact, potential approval. It is unclear when the FDA will approve our BLA, if at all. The CRL and any subsequent resulting delay in the development and approval of such product candidate may prevent, decrease and/or delay expected revenue. Any of these risks could have a material impact on our business, operating results, and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing product candidates in combination with other therapies, which exposes us to additional risks.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing product candidates in combination with one or more other therapies. We are studying N-803&#160;therapy along with other products and product candidates, such as BCG, PD-L1 t-haNK, hAd5 and yeast TAAs, and aldoxorubicin. If we choose to develop a product candidate for use in combination with an approved therapy, we are subject to the risk that the FDA, EMA or comparable foreign regulatory authorities in other jurisdictions could revoke approval of, or that safety, efficacy, manufacturing or supply issues could arise with the therapy used in combination with our product candidate. The FDA may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. To the extent that we do not have rights to already approved products, this may require us to work with another company to satisfy such a requirement or increase our cost of development. It is possible that the results of these trials could show that any positive results are attributable to the already approved product. Following product approval, the FDA may require that products used in conjunction with each other be cross labeled for combined use. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, unapproved therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delays in clinical trials and lack of FDA approval. If the FDA or comparable foreign regulatory authorities do not approve or revoke their approval of these other therapies, or if safety, efficacy, quality, manufacturing or supply issues arise with, the therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain approval of or market such combination therapy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development programs are at various stages of development. The clinical trials of our product candidates as well as the manufacturing and marketing of our product candidates will be subject to extensive and rigorous review and regulation by numerous government authorities in the U.S. and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit profile required for product licensure will vary depending on these factors and may include not only the ability to show tumor shrinkage, but also adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response rates from the use of our product candidates or their contribution of effect, may not be sufficient to obtain regulatory approval unless we can also show an adequate duration of response. The clinical trials for our product candidates under development may not be completed on schedule and regulatory authorities may ultimately disagree with our chosen endpoints or may find that our studies or study results do not support product approval and we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do or accept the therapeutic effects as valid endpoints in clinical trials necessary for market approval or they may find that our clinical trial design or conduct does not meet the applicable approval requirement and more trials could be required before we submit our product candidates for approval. Success in early clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. Product candidates in later stages of clinical trials may fail to show the desired safety, tolerability and efficacy traits despite having progressed through preclinical studies and initial clinical trials and after reviewing test results, we or our collaborators may abandon projects that we might previously have believed to be promising. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we do not have data on possible harmful long-term effects of our product candidates and do not expect to have this data in the near future. As a result, our ability to generate clinical safety and effectiveness data sufficient to support submission of a marketing application or commercialization of our product candidates is uncertain and is subject to significant risk.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing shortage of BCG may adversely impact market uptake of our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, if such product candidate receives regulatory approval and it may delay our ability to execute our clinical trials or seek new approvals. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an ongoing shortage of BCG, which may adversely impact market uptake of our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, if such product candidate receives regulatory approval. The BCG shortage may impact the number of patients who are treated with BCG for NMIBC with CIS with or without Ta or T1&#160;disease, therefore limiting the pool of BCG-unresponsive patients who may be candidates for our product, if approved. In addition, the BCG shortage may also constrain the number of patients we can treat with our product since our product, if approved, will be administered along with BCG. In addition, Anktiva was awarded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation by the FDA for the treatment of BCG-na&#239;ve NMIBC with CIS. We are currently enrolling patients in our Phase&#160;IIb blinded, randomized, two-cohort, open-label, multi-center trial of intravesical BCG plus Anktiva versus BCG alone, in BCG-na&#239;ve patients with high-grade NMIBC with CIS (Cohort A) and NMIBC papillary (Cohort B), which is impacted by the availability of BGC. If we do not complete new trials timely, our ability to generate clinical safety and effectiveness data sufficient to support submission of a marketing application or commercialization of our product candidates in new indications could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may choose to expend our limited resources on programs that do not yield successful product candidates as opposed to indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have sufficient resources to pursue development of all or even a substantial portion of the potential opportunities that we believe will be afforded to us by our product candidates. Because we have limited resources and access to capital to fund our operations, our management must make strategic decisions as to which product candidates and indications to pursue and how much of our resources to allocate to each. Our management must also evaluate the benefits of developing in&#8209;licensed or jointly-owned technologies, which in some circumstances we may be contractually obligated to pursue, relative to developing other product candidates, indications or programs. Our management has broad discretion to suspend, scale down, or discontinue any or all of these development efforts, or to initiate new programs to treat other diseases. If we select and commit resources to opportunities that we are unable to successfully develop, or we forego more promising opportunities, our business, financial condition and results of operations will be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products, if approved, may be smaller than we estimate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our current product candidates and any future product candidates will represent novel approaches to treating various conditions, it may be difficult, in any event, to accurately estimate the potential revenues from these product candidates. Accordingly, we may spend significant capital trying to obtain approval for product candidates that have an uncertain commercial market. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our beliefs and estimates, and estimates of the therapeutic benefit and adverse event profile of our product candidates. These estimates, which have been derived from a variety of sources, including scientific literature, preclinical and clinical studies, surveys of clinics, patient foundations, or market research by third parties, may prove to be incorrect. Further, new studies or approvals of new therapeutics may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates and may also be limited by the cost of our treatments and the reimbursement of those treatment costs by third-party payors. Even if we obtain significant market share for our product candidates, because the potential target populations may be small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will complete a strategic partnership transaction on acceptable terms in accordance with our anticipated timeline, or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our BLA resubmission, we continue to explore potential global strategic partnership transactions for commercialization of N-803 for certain indications. There is a risk that our ability to enter into such a strategic partnership transaction may be impacted by the CRL and BLA resubmission and associated review process. Further, there are other factors that may impact our ability, or decision, to enter into such a strategic partnership, including without limitation the put/call features of the RIPA that may be triggered by entry into a strategic partnership depending on its scope and terms, and ultimately there can be no assurance that we will complete a transaction on acceptable terms, or at all. If we do not execute a strategic partnership transaction in the near-term, it would eliminate a potential source of near-term funding, and may impact our ability to raise additional funds to meet our business needs. In addition, there are significant risks involved with building and managing a commercial infrastructure on a stand-alone basis, which could materialize in the event we do not execute a strategic partnership transaction, or depending on the geographic scope of any executed transaction.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, initial, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary, interim or top-line data from our preclinical studies and clinical trials, which are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease, or as inclusion and exclusion criteria is discussed with regulators. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may not be initiated or completed when we expect, or at all, they may take longer and cost more to complete than we project, our clinical trial costs may be higher than for more conventional therapeutic technologies or drug products, and we may be required to conduct additional clinical trials or modify current or future clinical trials based on feedback we receive from the FDA.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any current or future clinical trials will be conducted as planned or completed on schedule, if at all, or that any of our product candidates will receive regulatory approval. A failure of one or more clinical trials can occur at any stage of the clinical trial process, other events may cause us to stop a clinical trial temporarily or permanently, and our future clinical trials may not be successful. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our product candidates include, and we expect our future product candidates to include, candidates based on advanced therapy technologies, we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, costs to treat patients and to treat potential side effects that may result from our product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates can be significant. Some clinical trial sites may not bill, or obtain coverage from Medicare, Medicaid, or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and clinical trial sites outside of the U.S. may not reimburse for costs typically covered by third-party payors in the U.S., and as a result we may be required by those trial sites to pay such costs. Accordingly, our clinical trial costs are likely to be significantly higher per patient than those of more conventional therapeutic technologies or drug products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations with other entities may be subject to additional delays because of the management of the trials, contract negotiations, the need to obtain agreement from multiple parties and the necessity of obtaining additional approvals for therapeutics used in the combination trials. These combination therapies will require additional testing and clinical trials will require additional FDA approval and will increase our future costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete preclinical and clinical development could result in additional costs to us, slow down our product development and approval process or impair our ability to commence product sales and generate revenues. In addition, if we make manufacturing changes to our product candidates, we may be required to, or we may elect to, conduct additional trials to bridge our modified product candidates to earlier versions. These changes may require FDA approval or notification and may not have their desired effect. The FDA may also not accept data from prior versions of the product to support an application, delaying our clinical trials or programs or necessitating additional clinical trials or preclinical studies. We may find that this change has unintended consequences that necessitates additional development and manufacturing work, additional clinical and preclinical studies, or that results in refusal to file or non-approval of a BLA and/or NDA.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial delays could shorten any periods during which our product candidates have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, we have in the past experienced clinical holds imposed upon certain of our or investigator-led clinical trials for various reasons, and we may experience further clinical trial holds in the future. If we fail to commence or complete, or experience delays in, any of our planned clinical trials, our stock price and our ability to conduct our business as currently planned could be harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if one of our product candidates is approved and commercialized, we may not become profitable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved for marketing by applicable regulatory authorities, our ability to generate revenues from our product candidates will depend on our ability to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price our product candidates competitively such that third-party and government reimbursement leads to broad product adoption;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prepare a broad network of clinical sites for administration of our product;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create market demand for our product candidates through our own or our partner&#8217;s marketing and sales activities, and any other arrangements to promote these product candidates that we may otherwise establish;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive regulatory approval for the targeted patient population(s) and claims that are necessary or desirable for successful marketing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture product candidates through third-party CMOs or in our own manufacturing facilities or facilities owned by entities affiliated with Dr.&#160;Soon-Shiong in sufficient quantities and at acceptable quality and manufacturing cost to meet regulatory requirements and commercial demand at launch and thereafter;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and maintain agreements with wholesalers, distributors, pharmacies, and group purchasing organizations on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain, maintain, protect and enforce patent and other intellectual property protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully commercialize any of our product candidates that receive regulatory approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain compliance with applicable laws, regulations, and guidance specific to commercialization including interactions with health care professionals, patient advocacy groups, and communication of health care economic information to payors and formularies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve market acceptance of our product candidates by patients, the medical community, and third-party payors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve appropriate reimbursement for our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain a distribution and logistics network capable of product storage within our specifications and regulatory guidelines, and further capable of timely product delivery to commercial clinical sites;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively compete with other therapies or competitors; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">following launch, ensure that our product will be used as directed and that additional unexpected safety risks will not arise.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves N-803 for certain indications or in combination with other therapeutic products, and even if we obtain significant market share for it, because the potential target population may be small, we may never achieve profitability without obtaining regulatory approval for additional indications. The FDA often approves new therapies initially only for use in patients with relapsed and/or refractory metastatic disease, which may limit our patient population. Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide net sales of N-803 exceed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0&#160;billion prior to December&#160;31,&#160;2026 with amounts payable in cash or shares of our common stock or a combination thereof. As of December&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his related party hold approximately $139.8&#160;million of net sales CVRs, and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. If this were to occur, we may need to seek additional sources of capital and any such financing activities may be restricted by the covenants included in the terms of the RIPA. As such, we may face difficulties raising additional capital and may have to accept unfavorable terms and as a result, we may not be able to achieve profitability or positive cash flow.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our financing in December&#160;2023, we entered into the RIPA with Infinity and Oberland. Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, our worldwide net sales, excluding those in China, which will be tiered payments initially ranging from 3.00% to 7.00% (or after funding of the Second Payment, 4.50% to 10.00%), subject to increase or decrease, following the Test&#160;Date depending on whether our aggregate payments made to Oberland as of the Test&#160;Date have met or exceeded the Cumulative Purchaser Payments. In addition, if our aggregate payments made as of the Test&#160;Date to Oberland do not equal or exceed the amount of the Cumulative Purchaser Payments as of such date, then we are obligated to make a one-time payment True-Up Payment as described above. In addition to other considerations of the RIPA and the associated impact to our profitability and cash flow, if we were required to make a True-Up Payment, we may need to seek additional sources of capital, and we may not be able to achieve profitability or positive cash flow. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter delays or difficulties enrolling and/or maintaining patients in our clinical trials, our clinical development activities and receipt of necessary marketing approvals could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties or delays in patient enrollment and retention in our clinical trials for a variety of reasons.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the number of qualified clinical investigators is limited, we may need to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. In addition, in the past we have engaged, and we intend to continue to engage, in clinical trial efforts outside of the U.S., which gives rise to additional potential complexity and challenges, and further reliance upon third parties in foreign jurisdictions. Moreover, because our product candidates represent a departure from more commonly used methods for cancer and/or viral disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and approved immunotherapies that have established safety and efficacy profiles, rather than enroll patients in any future clinical trial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays or failures in planned patient enrollment or retention may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates or could render further development impossible.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of our trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. Combination immunotherapy that includes our current product candidates may be associated with more frequent adverse events or additional adverse events. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials or order our clinical trials to be placed on clinical hold, and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications. The FDA or comparable foreign regulatory authorities may also require additional data, clinical trials, or preclinical studies should unacceptable toxicities arise. We may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective. Even if we were to receive product approval, such approval could be contingent on inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or requirements for costly post marketing testing and surveillance, or other requirements, including a REMS to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of our current or future product candidates. In addition, these serious adverse effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates are not normally encountered in the general patient population and by medical personnel. They may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials and which could jeopardize regulatory approval. Any of these occurrences may materially harm our business, financial condition and prospects. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development, quality control, or scaling-up of our manufacturing capabilities. If we or our related parties, or any of our third-party manufacturers encounter such difficulties, our ability to gain approval, or to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of our product candidates involves complex processes, especially for our biologics, vectors and cell therapy product candidates, which are complex, highly regulated and subject to multiple risks. As a result of the complexities, the cost to manufacture biologics, vectors and cell therapies is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. The manufacture of fusion proteins, DNA and RNA constructs, and cell therapy products require significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel and compliance with strictly enforced federal, state, local and foreign regulations. We may also find that the manufacture of our product candidates is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical trials or, if approved, commercial supply. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. Our product candidates are manufactured using processes developed or modified by us, our affiliates or by our third-party collaborators that we may not utilize for more advanced clinical trials or commercialization. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently we manufacture our product candidates in our own manufacturing facilities, facilities owned by entities affiliated with Dr.&#160;Soon-Shiong, or through third-party CMOs. Our clinical trials will need to be conducted with product candidates and materials that were produced under cGMP and/or Good Tissue Practice regulations, which are enforced by regulatory authorities. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. Moreover, because of the complexity and novelty of our manufacturing process, there are only a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing our product candidates </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for us and willing to do so. If our third-party CMOs should cease manufacturing for us, we would experience delays in obtaining sufficient quantities of our product candidates for clinical trials and, if approved, commercial supply. Further, our third-party CMOs may breach, terminate, or not renew our agreements with them. If we were to need to find alternative manufacturing facilities or transfer between existing facilities it may take us significant time to find a replacement, if we are able to find a replacement at all and it would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. The commercial terms of any new arrangement could be less favorable than our existing arrangements and the expenses relating to the transfer of necessary technology and processes could be significant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply or our third-party CMOs&#8217; failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory review process. We may not be able to demonstrate sufficient comparability between products manufactured in different runs at the same or at different facilities to allow for inclusion of the clinical results from patients treated with products from these different runs, in our product registrations or to assure a cGMP process to qualify our product candidates. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so could result in enforcement actions and adverse publicity.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails exposure to risks to which we would not be subject if we manufactured the product candidate ourselves, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to negotiate manufacturing and quality agreements with third&#160;parties under commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced day-to-day control over the manufacturing process for our product candidates as a result of using third-party manufacturers for all aspects of manufacturing activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control over the protection of our trade secrets, know-how and other proprietary information from misappropriation or inadvertent disclosure or from being used in such a way as to expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third&#160;parties in a manner or at a time that may be costly or damaging to us or result in delays in the development or commercialization of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy or personnel turnover at the manufacturer or supplier.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, any problems or delays we or our third-party CMOs experience in preparing for commercial scale manufacturing of a product candidate may result in a delay in the FDA approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and could adversely affect our business. Furthermore, if we or our third-party CMOs fail to deliver the required commercial quantities of our product candidates on a timely basis and at reasonable costs, we would likely be unable to meet demand for our products and we would lose potential revenues. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing process and facilities for any products that we may develop are subject to FDA and foreign regulatory authority approval processes, and we or our third-party CMOs will need to meet all applicable FDA and foreign regulatory authority requirements, including cGMP, on an ongoing basis. cGMP requirements include quality control, quality assurance and the maintenance of records and documentation. The FDA and other regulatory authorities enforce these requirements through facility inspections. Manufacturing facilities must submit to pre-approval inspections by the FDA that will be conducted after we submit our marketing applications, including BLAs and NDAs, to the FDA. Manufacturers are also subject to continuing FDA and other regulatory authority inspections following marketing approval. Further, we and our third-party CMOs must supply all necessary CMC documentation in support of a BLA or NDA on a timely basis. Our or our third-party CMOs&#8217; manufacturing facilities may be unable to comply with our specifications, cGMP, and with other FDA, state, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign regulatory requirements, and there is no guarantee that we or our third-party CMOs will be able to successfully pass all aspects of a pre-approval inspection by the FDA or other foreign regulatory authorities. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. Further, the results from any FDA re-inspection of any facility, including those of our third-party CMOs, may further delay, or adversely impact, potential approval. It is unclear when the FDA will approve our BLA, if at all. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of product candidates that may not be detectable in final product testing. If microbial, viral, environmental or other contaminants are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination which could delay clinical trials and adversely harm our business. If we or our third-party CMOs are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, or in accordance with the strict regulatory requirements, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our third-party CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Deviations from manufacturing requirements may further require remedial measures that may be costly and/or time-consuming for us or a third&#160;party to implement and may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third&#160;parties with whom we contract could materially harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenues.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we use third-party CMOs, we are ultimately responsible for the manufacture of our products, if approved, and product candidates. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the biologic, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the federal civil FCA, corporate integrity agreements, consent decrees, or withdrawal of product approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in managing the build-out of our manufacturing facilities and associated costs or satisfying manufacturing-related regulatory requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into facility leases for our planned manufacturing operations and related activities under which we are responsible for the build-out of the facility space and associated costs. The build-out of these facilities and related equipment purchases are complex and specialized and will involve substantial capital expenditure, and it could take longer, and cost more, than currently expected. Significant delays and/or cost overruns would result in higher expenditures and could be disruptive to operations, any of which could have a negative impact on our financial condition or results of operations. For example, during the first&#160;quarter of 2022 we acquired a leasehold interest in the 409,000&#160;square foot Dunkirk Facility as described below. While we believe that governmental funding will assist in funding a small portion of the further build-out of the Dunkirk Facility, we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, it is possible that, once built, the leased facilities may prove to be less conducive to our operations than is currently anticipated, resulting in operational inefficiencies or similar difficulties that could prove difficult or impossible to remediate and result in an adverse impact on our financial condition or results of operations. We also may not successfully realize the anticipated benefits from the capital expenditure at such facilities based on factors such as delays and uncertainties regarding development, regulatory approval and commercialization of our product candidates, as well as the potential to lose access to the leased facilities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in the future if we transition from our current third-party CMOs to our own manufacturing facilities, or to alternative third-party CMOs, for one or more of our product candidates, including our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG&#8209;unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, we may need to conduct additional preclinical, analytical or clinical trials and obtain FDA approval before such manufacturing changes are implemented. If we are unsuccessful in demonstrating the comparability of supplies before and after a manufacturing change, such manufacturing change can result in a delay or disruption in our clinical development plan or our ability to commercialize any approved product. Any production shortfall that impairs the supply of our product candidates could negatively impact our ability to complete clinical trials, obtain regulatory approval and commercialize our product candidates. If our product candidates receive approval, a product shortfall could have a material adverse effect on our business, financial condition and results of operations and adversely affect our ability to satisfy demand for our product candidates, which could materially and adversely affect our revenue and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our planned operations, including our development, testing and future manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that may have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. Failure to successfully complete our build-outs and successfully operate our planned manufacturing facilities and satisfy manufacturing-related regulatory requirements could adversely affect the commercial viability of our product candidates and our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies and biologics rely on the availability of reagents, specialized equipment and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products, if approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on a small number of suppliers for some of the materials used in, and processes required to develop, our product candidates. For some of these reagents, equipment and materials used in the manufacture of our product candidates, we rely, and we may in the future rely, on sole source vendors or a limited number of vendors. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing. An inability to continue to source product from any of these suppliers could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we seek to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical testing, the change may require us to perform both </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our current product candidates represent, and our other potential product candidates will represent, novel approaches to the treatment of disease, there are many uncertainties regarding the development, market acceptance, public opinion, third-party reimbursement coverage and the commercial potential of our product candidates, which may impact public perception of us and our product candidates and which may adversely affect our ability to conduct our business and implement our business plans.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human immunotherapy products are a new category of therapeutics. We use relatively novel technologies involving N-803, hAd5, saRNA and yeast constructs, and cell-based therapies, and our NK&#160;cell platform utilizes a relatively novel technology involving the genetic modification of human cells and utilization of those modified cells in other individuals. Because this is a relatively new and expanding area of novel therapeutic interventions, there are many uncertainties related to development, marketing, reimbursement and the commercial potential for our product candidates. There can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of immunotherapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval. Adverse public attitudes may adversely impact our ability to enroll patients in clinical trials. The FDA may take longer than usual to come to a decision on any BLA and/or NDA that we submit and may ultimately determine that there is not enough data, information, or experience with our product candidates to support an approval decision. The FDA may also require that we conduct additional post-marketing studies or implement risk management programs, such as REMS, until more experience with our product candidates is obtained. Finally, after increased usage, we may find that our product candidates do not have the intended effect, do not work with other combination therapies or have unanticipated side effects, potentially jeopardizing initial or continuing regulatory approval and commercial prospects. More restrictive government regulations or negative public opinion could have an adverse effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the approaches offered by our product candidates will gain broad acceptance among doctors or patients or that governmental agencies or third-party medical insurers will be willing to provide reimbursement coverage for our proposed product candidates. Public perception may be influenced by claims, such as claims that our technologies are unsafe, unethical or immoral and, consequently, our approach may not gain the acceptance of the public or the medical community. Negative public reaction to cell-based immunotherapy in general could result in greater government regulation and stricter labeling requirements of immunotherapy products, including our product candidates, and could cause a decrease in the demand for any products we may develop. Moreover, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing, and their patients being willing to receive treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. The market for any products that we successfully develop will also depend on the cost of the product. Aside from our lead product candidate, where costs could materially change, we do not yet have sufficient information to reliably estimate what it will cost to commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. Our goal is to reduce the cost of manufacturing and providing our therapies. However, unless we can reduce those costs to an acceptable amount, we may never be able to develop a commercially viable product. If we do not successfully develop and commercialize products based upon our approach or find suitable and economical sources for materials used in the production of our potential products, we will not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become profitable, which would materially and adversely affect the value of our common stock. Our N-803 therapies and our other therapies may be provided to patients in combination with other agents provided by third&#160;parties or our affiliates. The cost of such combination therapy may increase the overall cost of therapy and may result in issues regarding the allocation of reimbursements between our therapy and the other agents, all of which may affect our ability to obtain reimbursement coverage for the combination therapy from governmental or private third-party medical insurers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical development, testing and manufacturing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Large judgements have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a regulatory investigation of the safety and effectiveness of our products, our third-party manufacturer&#8217;s manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, including limitations on the approved indications for which our product candidates may be used or suspension or withdrawal of approvals, decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to product liability claims for which we have no coverage. While we have obtained clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will face significant competition from other biotechnology and pharmaceutical companies and from non-profit institutions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in the field of cancer and infectious disease therapy is intense and is accentuated by the rapid pace of technological development. We compete with a variety of multi-national biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. These competitors have developed, may develop and are developing product candidates and processes competitive with our product candidates. Research and discoveries by others may result in breakthroughs which may render our product candidates obsolete even before they generate any revenues. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing product candidates. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the U.S. and internationally. Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical, and human resources than we do, as well as significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful in obtaining approval of treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive, possibly even before we are able to enter the market. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third&#160;parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our therapies. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from other methods of treatment to our product, or if physicians switch to other new therapies, drugs or biologic products or choose to reserve our product candidates for use in limited circumstances. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug status or Breakthrough Therapy or Fast Track designations or other designation for one or more of our product candidates, but even if any such designation or status is granted, it may not lead to a faster development process or regulatory review and may not increase the likelihood that our product candidates will receive marketing approval, and we may be unable to maintain any benefits associated with such designations or status, including market exclusivity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, the FDA established a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation, which is intended to expedite, although there is no guarantee, the development and review of products that treat serious or life-threatening conditions. We have been awarded, and may seek in the future, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation for current or future product candidates. Receipt of a designation to facilitate product candidate development is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the product candidates no longer meet the designation conditions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available the drug or biologic will be recovered from sales in the U.S. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA to market the same drug or biologic for the same indication for seven&#160;years, except in limited circumstances. We may seek orphan drug status for one or more of our product candidates, but exclusive marketing rights in the U.S. may be lost if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In response to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Catalyst Pharms.,&#160;Inc. v.&#160;Becerra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 14&#160;F.4th 1299 (11th Cir.&#160;2021), the FDA clarified in a January&#160;2023 notice that it intends to continue to apply its longstanding interpretation of the regulations to matters outside of the scope of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Catalyst </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">order&#160;&#8211;&#160;that is, the agency will continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that have not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of the orphan drug exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a condition of approval, the FDA may require that we implement various post-marketing requirements and conduct post-marketing studies, any of which would require a substantial investment of time, effort, and money, and which may limit our commercial prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of biologic licensing, the FDA is authorized to require that sponsors of approved BLAs implement various post-market requirements, including REMS and Phase&#160;IV trials. For example, in connection with FDA approval of another company&#8217;s drug, the FDA required significant post-marketing commitments, including a Phase&#160;IV trial, revalidation of a test method, and a substantial REMS program that included, among other requirements, the certification of hospitals and their associated clinics that dispensed the drug, including the implementation of a training program and limited distribution only to certified hospitals and their associated clinics. If we receive approval of our product candidates, the FDA may determine that similar or additional or more burdensome post-approval requirements are necessary to ensure that our product candidates are safe, pure and potent. To the extent that we are required to establish and implement any post-approval requirements, we will likely need to invest a significant amount of time, effort and money. Such post-approval requirements may also limit the commercial prospects of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never commercialized a product candidate before, and we may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators. We may be unable to establish effective marketing and sales capabilities or enter into agreements with third&#160;parties or related parties to market and sell our product candidates, if they are approved, and as a result, we may be unable to generate product revenues.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have little to no prior experience in, and currently have a limited commercial infrastructure for, the marketing, sale and distribution of biopharmaceutical products. To achieve commercial success for the product candidates, which we may license to others, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights and marketing approval, if approved, in order to commercialize our product candidates, we must continue to build out our marketing, sales and distribution capabilities, including a comprehensive healthcare compliance program, and/or arrange with third&#160;parties to perform these services, which will continue to take time and require significant financial expenditures and could delay any product launch and we may not be successful in doing so. There are significant risks involved with building and managing a commercial infrastructure. We, or our collaborators and third-party contractors, will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, manage and retain medical affairs, marketing, sales and commercial support personnel. Recruiting, training and retaining a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we or our third-party contractors recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have incurred these commercialization expenses prematurely or unnecessarily. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In the event we are unable to develop a commercial infrastructure, we may not be able to commercialize our current or future product candidates, which would limit our ability to generate product revenues. Even if we and/or our third-party contractors are able to effectively establish a sales force and develop a marketing and sales infrastructure, such sales force and marketing teams may not be successful in commercializing our current or future product candidates. To the extent we rely on third&#160;parties to commercialize any products for which we obtain regulatory approval, which we intend to do to a certain extent in connection with our initial product launch, if approved, we would have less control over their sales efforts and could be held liable if they failed to comply with applicable legal or regulatory requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not commercialized a product candidate for any indication. Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors and others in the medical community. If any product candidate for which we obtain regulatory approval does not gain an adequate level of market acceptance, we may not generate significant product revenues or become profitable. Market acceptance of our product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. Even if the medical community accepts that our product candidates are safe and effective for their approved indications, physicians and patients may not immediately be receptive to such product candidates and may be slow to adopt them as an accepted treatment of the approved indications. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of any of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse events associated with such product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the products are approved and the approved claims that we may make for the products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the product&#8217;s FDA-approved labeling, including potential limitations or warnings for such products that may be more restrictive than other competitive products or distribution and use restrictions imposed by the FDA with respect to such product candidates or to which we agree as part of a mandatory REMS or voluntary risk management plan;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for such product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative difficulty of administration of such product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer such product candidates for sale at competitive prices, including the cost of treatment versus economic and clinical benefit in relation to alternative treatments or therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate coverage or reimbursement by third&#160;parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and strength of our marketing and distribution of such product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety, efficacy and other potential advantages over, and availability of, alternative treatments already used or that may later be approved for any of our intended indications;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of such product candidates, as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and strength of our third-party manufacturer and supplier support;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity about the product or favorable publicity about competitive products; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product liability claims.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may face competition sooner than anticipated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of the BPCIA created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, the FDA cannot make an approval of an application for a biosimilar product effective until 12&#160;years after the original branded product was approved under a BLA. Certain changes, however, and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest or other related entity do not qualify for the 12-year exclusivity period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may qualify for the BPCIA&#8217;s 12-year period of exclusivity. There is a risk that any product candidates we may develop that are approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any product candidates we may develop to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not block companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Even if we receive a period of BPCIA exclusivity for our first licensed product, if subsequent products do not include a modification to the structure of the product that impacts safety, purity, or potency, we may not receive additional periods of exclusivity for those products. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference product candidates in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Medicare Part&#160;B encourages use of biosimilars by paying the provider the same percentage of the reference product average sale price as a mark-up, regardless of which product is reimbursed. It is also possible that payors will give reimbursement preference to biosimilars even over reference biologics absent a determination of interchangeability.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our small molecular product candidates, if qualified, the regulatory exclusivity period is less than for our biologic product candidates. The FD&amp;C Act provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a drug where the FDA has not previously approved any other new drug containing the same active molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated NDA or a 505(b)(2)&#160;NDA submitted by another company for a generic version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four&#160;years if it contains a certification of patent invalidity or non-infringement. The FD&amp;C Act also provides three&#160;years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, which were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. As such, we may face competition from generic versions of our small molecule product candidates, which will negatively impact our long-term business prospects and marketing opportunities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to obtain FDA approval of any proposed branded product names, and any failure or delay associated with such approval may adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any name we intend to use for our product candidates in the U.S. will require approval from the FDA regardless of whether we have secured a formal trademark registration from the USPTO including, without limitation, Anktiva. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. The FDA may also object to a product name if it believes the name inappropriately implies medical claims or contributes to an overstatement of efficacy. If the FDA objects to any of our proposed product names, we may be required to adopt alternative names for our product candidates. If we adopt alternative names, we will lose the benefit of any existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe or otherwise violate the existing rights of third&#160;parties, and be acceptable to the FDA. We may be unable to build a successful brand identity for a new product name in a timely manner or at all, which would limit our ability to commercialize our product candidates.</span></div><div style="margin-top:12pt"><span id="if7b491d5c1d6441fa17129e6f403e298_444148"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our systems, infrastructure or data, or those used by our CROs, CMOs, clinical sites or other contractors or consultants, may or may be perceived to fail or suffer a cyberattack, security breach or other incident, including a breakdown or compromise of the confidentiality, integrity and availability of our systems, networks or data, which could adversely affect the operation of our business and reputation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and will be dependent upon information technology systems, infrastructure and data. In the ordinary course of our business, we will directly or indirectly collect, store, transmit, and otherwise process sensitive and confidential information, including intellectual property, preclinical and clinical trial data, proprietary business information, and personal information of our clinical trial patients and employees, including in our data centers and on our systems and networks or on those of third&#160;parties. The secure maintenance, transmission, and processing of data is critical to our operations. The multitude and complexity of our systems and those of our CROs, CMOs, clinical sites or other contractors or consultants may subject them to various threats, including interruption, destruction, malicious intrusion, and random attack. Privacy or security breaches or other incidents, including by third&#160;parties, employees, contractors or others, may pose a risk that sensitive or confidential information, including our intellectual property, trade secrets or personal information of our employees, patients, or other business partners may be exposed to unauthorized persons or to the public. Further, as many of our employees work remotely, our reliance on our and third-party systems has increased substantially and is expected to continue to increase.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our systems, infrastructure and data, and those of our CROs, CMOs, clinical sites and other contractors and consultants, are subject to risks relating to cyberattacks, security breaches, or other incidents, including through viruses and other malware, employee error, unauthorized access, natural disasters, terrorism, war, fire, telecommunication and electrical failures, denial of service attacks, social engineering (including phishing attacks) and other means. As the cyberthreat landscape evolves, these cyberattacks are increasing in their frequency, sophistication and intensity and are becoming increasingly difficult to detect. The techniques used by cybercriminals change frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Cyberattacks affect service reliability and threaten data confidentiality, integrity and availability. While we and our shared services partner, NantWorks, have invested, and continue to invest, in the protection of our data, systems, and infrastructure, there can be no assurance that our efforts, or the efforts of our partners, vendors, CROs, CMOs, clinical sites and other contractors and consultants, will be successful. Any failure or perceived failure in our systems, infrastructure or data, or to identify or prevent cyberattacks, security breaches or other incidents, including service interruptions could adversely affect our business and operations, result in the loss, unavailability, misuse, unauthorized use or acquisition, or other unauthorized processing of critical or sensitive information, and result in financial, legal, business or reputational harm. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to any such failures, security breaches, cyberattacks or other incidents.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any such event were to occur, it could also cause interruptions in our operations, including a disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data or may limit our ability to effectively execute a product recall, if required. Any such event could result in liability, delays in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the development and commercialization of product candidates, claims, demands or proceedings initiated by regulatory authorities or private parties, violations of laws, including laws that protect the privacy or security of personal information, significant liabilities, including regulatory penalties, and damage to our reputation and a loss of confidence in us and our ability to conduct clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, or the perception of its effects, may materially and adversely affect our business, operations and financial condition.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health outbreaks, such as epidemics or pandemics may significantly disrupt our business. Such outbreaks pose the risk that we or our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time due to the spread of the disease, due to shutdowns that may be requested or mandated by federal, state, and local governmental authorities or certain employers, or due to the economic consequences associated with the pandemic. Business disruptions could include disruptions or restrictions on our ability to travel, as well as temporary closures of our facilities and the facilities of our partners, clinical trial sites, service providers, suppliers, or contract manufacturers. For example, the COVID-19 pandemic caused a temporary disruption in our ability to recruit participants for our clinical trials in the calendar year&#160;2020 and the first&#160;quarter of 2021. While it is not possible to predict whether another pandemic, epidemic, or infectious disease outbreak similar to COVID-19 will materialize, any measures taken by governments and local authorities in response to such future health crises have the potential to disrupt and delay the initiation of new clinical trials, the progress of our ongoing clinical trials and our preclinical activities, and potentially the manufacture or shipment of both drug substance and finished drug product of our product candidates for preclinical testing and clinical trials, and commercial product, if approved, as well as adversely impact our business, financial condition, or operating results.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied and will continue to rely on third parties and related parties to conduct many of our preclinical studies and clinical trials, manufacture products, and perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection and adverse event reporting. Any failure by a third party, related party, or by us to perform as expected, to comply with legal and regulatory requirements or to conduct the clinical trials according to GCP&#160;guidelines, and in a timely manner, may delay or prevent our ability to seek or obtain regulatory approval for or commercialization of our product candidates and our ability to commercialize our current or future product candidates will be significantly impacted and we may be subject to regulatory sanctions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied and will continue to rely on third parties and related parties to conduct many of our preclinical studies and clinical trials, manufacture products, and perform many essential services for any products that we commercialize. Any failure by a third party, related party, or by us to perform as expected, to comply with legal and regulatory requirements or to conduct the clinical trials according to GCP&#160;guidelines, and in a timely manner, may delay or prevent our ability to seek or obtain regulatory approval for or commercialization of our product candidates and subject us to regulatory sanctions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large-scale clinical trials require significant financial and management resources. We expect to be heavily reliant on third and related parties, including medical institutions, academic institutions, clinical investigators or CROs to conduct, supervise or monitor some or all aspects of our clinical trials, and in some cases, third-party CMOs to manufacture products, which may force us to encounter delays and challenges that are outside of our control. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable trial protocol and legal, regulatory and scientific standards, and our reliance on CROs, clinical trial sites, and other third parties does not relieve us of these responsibilities. Our CROs and other third&#160;parties must communicate and coordinate with one another in order for our trials to be successful. We have a limited history of conducting clinical trials and have limited experience as a company in submitting and supporting the applications necessary to gain marketing approvals. Our relative lack of experience conducting clinical trials may contribute to our planned clinical trials not beginning or completing on time, if at all. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, applicable regulatory authorities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and for ensuring that our preclinical studies are conducted in accordance with GLP guidelines, as appropriate. Moreover, the FDA and comparable foreign regulatory authorities require us and the third parties upon which we intend to rely for conducting our clinical trials to comply with GCP guidelines for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections (including pre-approval inspections once a BLA or NDA is filed with the FDA) of trial sponsors, clinical investigators, trial sites and certain third parties including CMOs. If we, our CROs, clinical trial sites, or other third parties fail to comply with applicable GCP guidelines or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable and have to be repeated, and our submission of marketing applications may be delayed or the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP&#160;guidelines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties to manufacture, package, label and ship some of our product candidates for the clinical trials that we conduct. Any performance failure on the part of these third parties could delay clinical development or marketing approval of our product candidates or commercialization of our product candidates, if approved, producing additional losses and depriving us of potential product revenues. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs, clinical trial sites and other third parties may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting clinical trials or other therapeutic development activities that could harm our competitive position. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with them, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If these third parties conducting our clinical trials (i)&#160;do not successfully carry out their contractual duties, (ii)&#160;do not meet expected deadlines, (iii)&#160;experience work stoppages, (iv)&#160;do not conduct our clinical trials in accordance with regulatory requirements or our stated protocols, (v)&#160;need to be replaced, (vi)&#160;experience financial hardships or (vii)&#160;terminate their agreements with us or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical trial protocols, GCP guidelines or other regulatory requirements or for other reasons, our trials may need to be repeated, extended, delayed or terminated, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates or we or they may be subject to regulatory enforcement actions. Additionally, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties, which we may not be able to do on commercially reasonable terms, or at all and which may involve additional cost and time and require management time and focus. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Furthermore, if any of the third parties conducting our clinical trials experience any financial hardships due to difficulties relating to the operation of their business, it could damage our business, financial condition, results of operations and prospects. In addition, if an agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay the continued development of our product candidates using the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to retain third-party service providers to perform a variety of functions related to the sale of our current or future product candidates, key aspects of which will be out of our direct control. These service providers may provide key services related to sales, market access, distribution, customer service, accounts receivable management, state reporting, compliance support, and cash collection. If we retain a service provider, we will substantially rely on it as well as other third-party providers that perform services for us, including entrusting our inventories of products to their care and handling. If these third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines or otherwise do not carry out their contractual duties to us, or encounter physical or natural damage at their facilities, our ability to deliver product to meet commercial demand would be significantly impaired and we may be subject to regulatory enforcement action. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may engage in the future with third parties to perform various other services for us relating to adverse event reporting, safety database management, fulfillment of requests for medical information regarding our product candidates and related services. If the quality or accuracy of the data maintained by these service providers is insufficient, or these third parties otherwise fail to comply with regulatory requirements related to adverse event reporting, we could be subject to regulatory sanctions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may contract in the future with a third party to calculate and report pricing information mandated by various government programs. If a third party fails to timely report or adjust prices as required or errs in calculating government pricing information from transactional data in our financial records, it could impact our discount and rebate liability, and potentially subject us to regulatory sanctions or FCA lawsuits.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third and related parties can also present intellectual property-related risks. For example, collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to our product candidates or technology or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property-related proceedings, including proceedings challenging the scope, ownership, validity and enforceability of our intellectual property. Collaborators may also own or co-own intellectual property covering our product candidates or technology that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or technology. Collaborators may also gain access to our trade secrets or formulations and impact our ability to commercialize proprietary technology. We may also need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also anticipate that part of our strategy for pursuing the wide range of indications potentially addressed by N-803 will involve further investigator-led clinical trials. While these trials generally provide us with valuable clinical data that can inform our future development strategy, we generally have less control over not only the conduct but also the design of these clinical trials. Third-party investigators may design clinical trials involving our product candidates with clinical endpoints that are more difficult to achieve or in other ways that increase the risk of negative clinical trial results compared to clinical trials we may design on our own. Negative results from investigator-led clinical trials, regardless of how the clinical trial was designed or conducted, could have a material adverse effect on our business and the perception of our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party manufacturers, wholesalers and distributors fail to perform as expected, or fail to devote sufficient time and resources to our product candidates, our clinical development may be delayed, our costs may be higher than expected or our product candidates may fail to be approved, or we may fail to commercialize any product candidates if approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers, wholesalers and distributors exposes us to the following risks, any of which could delay FDA approval of our product candidates and commercialization of our product candidates if approved, result in higher costs, or deprive us of potential product revenues:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy commercial demand, may experience technical issues that impact quality or compliance with applicable and strictly enforced regulations governing the manufacture of pharmaceutical products, and may experience shortages of qualified personnel to adequately staff production operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our wholesalers and distributors could become unable to sell and deliver our product candidates for regulatory, compliance and other reasons;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, wholesalers and distributors could breach or default on their agreements with us to meet our requirements for commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, wholesalers and distributors may not perform as agreed or may not remain in business for the time required to successfully produce, store, sell and distribute our product candidates and we may incur additional cost;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CMOs, wholesalers and distributors may misappropriate our proprietary information; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our CMOs, wholesalers and distributors were to terminate our arrangements or fail to meet their contractual obligations, we may be forced to delay our commercial programs. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties reduces our control over our product candidate development activities but does not relieve us of our responsibility to ensure compliance with all required legal, regulatory and industry standards. For example, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP requirements. Any failure by our third-party manufacturers to comply with cGMP or maintain a compliance status acceptable to the FDA or other regulatory authorities or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all. In addition, our third-party manufacturers will be subject to periodic inspections by the FDA and other regulatory authorities, and failure to comply with cGMP could be the basis for the FDA to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including a request to recall or seize product candidates, total or partial suspension of production, suspension of clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of product candidates, injunction, imposing civil penalties or pursuing criminal prosecution.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as we scale up manufacturing of our product candidates and conduct required stability testing, we may encounter additional challenges or cGMP issues. These issues may require refinement or resolution in order to proceed with commercial marketing of our product candidates if approved. In addition, quality issues may arise during scale-up and validation of commercial manufacturing processes. Any issues in our manufacturing process could result in increased scrutiny by regulatory authorities, delays in our regulatory review process, increases in our operating expenses, or failure to obtain or maintain approval for our product candidates. If such issues relate to an approved product, we may not be able to commercialize the approved product as we planned or fail to meet commercial demand, any of which can materially and adversely affect our position in the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use the Clinic, a related party, in some of our clinical trials which may expose us to significant regulatory risks. If our data for this site is not sufficiently robust or if there are any data integrity issues, we may be required to repeat such studies or contract with other clinical trial sites, which could delay and/or increase the cost of our development plans.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Clinic has conducted, is currently conducting, and in the future may conduct, clinical trials involving our product candidates. The Clinic is a related party as it is owned by an officer of the company and additionally, NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30,&#160;2019, one of the company&#8217;s officers was an investigator or sub&#8209;investigator for certain of the company&#8217;s trials conducted at the Clinic. NantWorks, which is wholly owned by our Executive Chairman and Global Chief Scientific and Medical Officer, Dr.&#160;Soon&#8209;Shiong, provides certain administrative services (and has loaned money) to the Clinic. Under certain circumstances, we may be required to report some of these relationships to the FDA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relying on a related-party clinical site to develop data that is used as the basis to support regulatory approval can expose us to significant regulatory risks. The FDA may conclude that a financial relationship between us, the Clinic and/or a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. If any data integrity, or regulatory non-compliance issues occur during the study, we may not be able to use the data for our regulatory approval. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have formed, and may in the future form or seek, strategic alliances or enter into collaborations with third&#160;parties or additional licensing arrangements, and we may not realize the benefits of such alliances or licensing arrangements. Conflicts may arise between us and our collaborators or strategic partners, and such strategic alliances, collaborations or licensing arrangements may not be successful</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have formed, and may in the future form or seek, strategic alliances, or enter into collaborations with third parties or additional licensing arrangements that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. We plan to collaborate with governmental, academic and corporate partners, including affiliates, to improve and develop N-803, hAd5, saRNA and yeast constructs, and other cell therapies for new indications for use in combination with other therapies and to improve and develop other product candidates, which may expose us to additional risks, or we may not realize the benefits of such collaborations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because some of our collaborations are conducted at outside laboratories, and we do not have complete control over how the studies are conducted or reported, the results of such studies, which we may use as the basis for our conclusions, projections or decisions with respect to our current or future product candidates, may be incorrect or unreliable, or may have a negative impact on us if the results of such studies are imputed to our product candidates or proposed indications, even if such imputation is improper. Additionally, we may use third&#8209;party data to analyze, reach conclusions or make predictions or decisions with respect to our product candidates that may be incomplete, inaccurate or otherwise unreliable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to collaborate with governmental, academic and corporate partners, including affiliates, to improve and develop N-803, hAd5, saRNA and yeast constructs, cell therapies and other therapies for new indications for use in combination with other therapies and to improve and develop other product candidates, which may expose us to additional risks, or we may not realize the benefits of such collaborations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conflicts</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may arise between us and our collaborators or strategic partners, and such strategic alliances, collaborations or licensing arrangements may result in litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For example, in 2019 Sorrento, with which we jointly established a new entity called NANTibody as a stand-alone biotechnology company, commenced litigation against us and certain of our officers and directors, alleging that we improperly caused NANTibody to acquire IgDraSol. Additionally, in 2020 we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Beike asserting breach of contract under our subsidiary Altor&#8217;s license agreement with them. See Item&#160;3. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_58">Legal Proceedings</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information regarding these disputes. Any such developments could harm our product development efforts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, collaborations involving our product candidates will be subject to numerous risks, which may include the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators, including their related or affiliated companies, may be entitled to receive exclusive rights for or involving our products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third&#160;parties, products that compete directly or indirectly with our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain, defend or enforce our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if an agreement with any collaborator terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates using the collaborator&#8217;s technology or intellectual property or require us to stop development of those product candidates completely; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our product candidates or technology that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, if we enter into collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. Additionally, exclusive rights that we may grant in connection with collaboration agreements may limit our ability to enter into new or additional collaboration agreements or strategic partnerships if we experience issues with existing collaborations. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third&#160;parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Some of our existing academic collaborators and strategic partners are conducting multiple product development efforts. Such current or future collaborators or strategic partners could become our competitors in the future and could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of our product candidates. Competing product candidates, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of our collaborator&#8217;s or partner&#8217;s support for our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of joint ventures, strategic partnerships and alliances may expose us to risks associated with jointly owned investments.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may operate parts of our business through joint ventures, strategic partnerships and/or alliances with other companies. While such arrangements may, in some cases, give us access to technologies that we may not otherwise have or may give us access to capital, they involve risks not otherwise present in our own investments, including: (i)&#160;we may not control the venture, and it </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may divert management time and resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii)&#160;the partner(s) may not agree to distributions that we believe are appropriate; (iii)&#160;we may experience impasses or disputes with such partner(s) on certain decisions, which could require us to expend additional resources to resolve such impasses or disputes, including litigation or arbitration; (iv)&#160;our partner(s) may become insolvent or bankrupt, fail to fund their share of required capital contributions or fail to fulfil their obligations as a venture partner; (v)&#160;the arrangements governing these relationships may contain certain conditions or milestone events that may never be satisfied or achieved; (vi)&#160;our partner(s) may have business or economic interests that are inconsistent with our interests and may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take actions contrary to our interests; (vii)&#160;we may suffer losses as a result of actions taken by the partner(s); and (viii)&#160;it may be difficult for us to exit if an impasse arises or if we desire to sell our interest for any reason. For example, in December&#160;2021 we established a joint venture with Amyris. However, in August&#160;2023, Amyris announced that it had filed for Chapter&#160;11 bankruptcy protection. As of December&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was zero. There can be no guarantee that the strategic partnerships that we currently have or may enter into will be successful. Furthermore, we may, in certain circumstances, be liable for the actions of our partners. Any of the foregoing risks could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on our senior management, particularly Dr. Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer, and a loss of a member of our senior management team in the future, even if only temporary, could harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations will be dependent upon the services of our executives and our employees who are engaged in research and development. If we lose the services of members of our senior management, particularly Dr.&#160;Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer, for a short or an extended time, for any reason, we may not be able to find appropriate replacements on a timely basis, and our business, financial condition and results of operations could be materially adversely affected. Our existing operations and our future development depend to a significant extent upon the performance and active participation of certain key individuals, particularly Dr.&#160;Soon-Shiong. Although Dr.&#160;Soon-Shiong focuses heavily on our matters and is highly active in our management, he does devote a significant amount of his time to a number of different endeavors and companies, including NantHealth,&#160;Inc., NantMedia Holdings,&#160;LLC (which operates the Los&#160;Angeles Times) and NantWorks, which is a collection of multiple companies in the healthcare and technology space. The risks related to our dependence upon Dr.&#160;Soon-Shiong are particularly acute given his ownership percentage, the commercial and other relationships that we have with entities affiliated with him, his role in our company and his public reputation. We may also be dependent on additional funding from Dr.&#160;Soon-Shiong and his affiliates, which may not be available when needed and which he is under no obligation to provide.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided, and plan to continue providing, equity incentive awards that vest over time. The value to employees of equity incentive awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. We do not have employment agreements with our NEOs and do not maintain &#8220;key man&#8221; insurance policies on the lives of most of the members of our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of their attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. In order to develop our business in accordance with our business plan, we will have to hire additional qualified personnel, including in the areas of research, manufacturing, clinical trials management, regulatory affairs, and sales and marketing. We are continuing our efforts to recruit and hire the necessary employees to support our planned operations in the near term. However, competition for qualified personnel in the biotechnology and pharmaceuticals industry is intense due to the limited number of individuals who possess the skills and experience required, and no assurance can be given that we will be able attract, hire, retain and motivate the highly skilled employees that we need, on acceptable terms or at all. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining, and motivating additional employees;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third&#160;parties; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems, and procedures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future we expect to rely, in substantial part, on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements on economically reasonable terms, or at all. In addition, if we are unable to effectively manage our outsourced activities or if the quality, compliance or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development, and commercialization goals on a timely basis, or at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, intellectual property, and products of an acquired company or product, including difficulties associated with integrating new personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of our managements&#8217; attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant upfront milestone and/or royalty payments from which we may not realize the anticipated benefits;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenues from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the size and nature of future strategic acquisitions, we may acquire assets or businesses that require us to raise additional capital or to operate or manage businesses in which we have limited experience. Making larger acquisitions that require us to raise additional capital to fund the acquisition will expose us to the risks associated with capital raising activities. Acquiring and thereafter operating larger new businesses will also increase our management, operating and reporting costs and burdens (including increased cash requirements). In addition, if we undertake acquisitions, we may issue dilutive equity securities, assume or incur additional debt obligations or contingent liabilities, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements in foreign countries;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the FCPA or comparable foreign regulations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of public health epidemics on the global economy, such as the coronavirus pandemic; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:12pt"><span id="if7b491d5c1d6441fa17129e6f403e298_545338"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are party to a public-private partnership regarding our manufacturing facility in Dunkirk, New York, and if we or our counterparties fail to meet the obligations of those agreements, it could materially impact our development, operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;14,&#160;2022, we acquired a leasehold interest in the Dunkirk Facility from Athenex with a lease term that commenced on October&#160;1,&#160;2021 (the Commencement Date), which we believe will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our manufacturing capacity in the U.S. and the ability to scale production associated with certain of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid approximately $40.0&#160;million to Athenex, and the leasehold interest in the Dunkirk Facility was transferred to us. Our annual lease payment will be $2.00&#160;per year for an initial 10-year term, with an option to renew the lease under substantially the same terms and conditions for an additional 10-year term. As part of the transaction, we assumed obligations under various third-party agreements, and committed to spend $1.52&#160;billion on operational expenses during the initial term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for the additional 10-year term. We also committed to hiring 450&#160;employees at the Dunkirk Facility within the first five years following the Commencement Date, with 300&#160;such employees to be hired within the first 2.5 years following the Commencement Date. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe that the Dunkirk Facility has construction needs that may require approximately 12 to 18&#160;months to complete in order for it to be used as intended, and which needs remain as a result of an ongoing dispute with the Dunkirk Facility&#8217;s general contractor and stay related to Athenex&#8217;s ongoing bankruptcy proceedings, as described below. Consequently, during the third&#160;quarter of 2022, we determined to conduct a reduction-in-force of a significant portion of the then-current employees at the Dunkirk Facility, which became effective in late December&#160;2022. The construction period and reduction-in-force may adversely affect our ability to satisfy certain operational obligations described above. In addition, while we believe we are in compliance with all applicable laws and agreements implicated by the reduction-in-force, we could become subject to litigation in connection with these measures. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to satisfy the obligations over the lease term, including the milestones we have committed to achieve, may give rise to certain rights and remedies of the lessor and other governmental authorities including, for example, termination of the lease agreement and other related agreements and potential recoupment of a percentage of the grant funding received by Athenex for construction of the Dunkirk Facility and other benefits received, subject to the terms and conditions of the applicable agreements. If we lose access to the Dunkirk Facility and related leased equipment, it could disrupt our operations and manufacturing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities, cause us to divert resources to finding alternative facilities, which would not have any subsidies, and could have a significant impact on our operations and financial performance. We may also be subject to lawsuits or claims for damages against us if we are unable to comply with our obligations under these arrangements or in connection with other aspects of the Dunkirk Facility, which could materially and adversely affect our business, results of operations and financial condition. For example, we were named as a defendant in a lawsuit filed during the fourth&#160;quarter of 2022 by Exyte, the general contractor for the Dunkirk Facility, in New York state court arising from a construction agreement Exyte entered with Athenex pertaining to construction of the Dunkirk Facility. We believe we are entitled to defense costs and indemnification and, accordingly, we have provided notice to Athenex. On May&#160;14,&#160;2023, Athenex, together with certain of its subsidiaries, filed voluntary petitions for relief under Chapter&#160;11 of the United States Bankruptcy Court for the Southern District of Texas. The lawsuit with Exyte has remained stayed as a result of Athenex&#8217;s bankruptcy proceedings and the construction needs of the Dunkirk Facility remain. The extent of the impact of the Athenex Proceedings and its automatic stay will have on any continuing obligations Athenex may have under the purchase agreement remain unclear. We further believe Exyte&#8217;s claims against us are without merit, and we intend to defend the claims vigorously. Furthermore, there is no guarantee that the counterparties to our public-private partnerships will comply with the terms of the agreements, including that their ability to fund their capital commitments under the agreements may be subject to their ability to raise additional capital and that further construction or operational timetables may not be met. Public-private partnerships are also subject to risks associated with government and government agency counterparties, including risks related to government relations compliance, sovereign immunity, shifts in the political environment, changing economic and legal conditions and social dynamics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our contractors and subcontractors may place liens on our projects, and if they then successfully foreclose on such projects, we may not be able to use such assets for our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under general property law, any contractor or subcontractor doing work on a project may attach a lien on the property with respect to which it does work to secure the dollar value of all labor and material furnished to the project. A valid lien holder could, after the lien is perfected, institute a collection suit, according to the lien, and if it were successful in obtaining a judgment, the real property and the equipment thereon could be foreclosed upon. If a contractor were to successfully foreclose on such liens, we may not then be able to use such assets to manufacture our products, and our business could be materially harmed. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare and Other Government Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates. We are, and if we receive regulatory approval of our product candidates, will continue to be subject to ongoing extensive regulation, regulatory obligations and continued regulatory review, which may result in significant additional expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are subject to extensive governmental regulations relating to, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory review process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, lengthy, time-consuming, uncertain and subject to unanticipated delays and can vary substantially based upon the type, complexity and novelty of the products involved. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;2022, we announced the submission of a BLA to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease. On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection is required before the BLA would be approved. At the time, the FDA further provided recommendations specific to additional CMC&#160;issues and assays to be resolved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. There can be no assurance that the FDA will ultimately agree that the issues raised in the CRL have been successfully addressed and resolved in the BLA resubmission. Further, any inability to successfully work with the FDA to find a satisfactory solution to address any </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concerns in a timely manner or at all during the review process for the BLA, including any inability to provide the FDA with data, analysis or other information sufficient to support an approval of the BLA, may adversely impact the prospects for FDA approval. In addition, to the extent the FDA requires a re-inspection of any facility including those of our third-party CMOs or otherwise may further delay, or adversely impact, potential approval. Further, the FDA may not accept the data and results as included in our BLA resubmission at levels consistent with the published results, or at all. Accordingly, even if we receive FDA approval for the BLA, which we may not, it is possible that any data accepted for use on any approved label will differ from data previously published in peer review publications or announced by the company in press releases or other forms of communication, which may have an adverse impact on the commercial prospects for our product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not submitted any other marketing or drug approval applications to the FDA or comparable foreign authorities, for any other product candidate, and we may never receive such regulatory approval for any of our product candidates or regulatory approval that will allow us to successfully commercialize our product candidates. In addition, regulatory agencies may lack experience with our technologies and products, which may lengthen the regulatory review process, increase our development costs and delay or prevent their commercialization.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other research. The number and types of preclinical studies and clinical trials that will be required for regulatory approval also vary depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in completing development or obtaining, or failing to obtain, required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, be subject to other regulatory enforcement action, and we may not achieve or sustain profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, however a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory review process in others. Approval policies, procedures and requirements may vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our product candidates is also subject to approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for our lead product candidate or any other product candidates, we will continue to be subject to ongoing regulatory requirements, which may result in significant additional expenses. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed, or to conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to monitor safety and efficacy. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for any approved product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, including reporting of certain adverse events as well as continued compliance with cGMP for the drug products, and GCP guidelines for any clinical trials that we conduct post-approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency, or with manufacturing operations or processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">holds on clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a REMS, which may include distribution or use restrictions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct additional post-market clinical trials to assess the safety of the product;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us, or withdrawal of product approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of product candidates; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or are not able to maintain regulatory compliance, we may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of implementing our sales and marketing personnel hiring plan and building out key commercialization infrastructure. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales and marketing team.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to build a focused sales and marketing infrastructure to market our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, and potentially other product candidates in the U.S., if and when they are approved, including by partnering with experienced third party contractors. There are risks involved with establishing our own sales, marketing and distribution capabilities and entering </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, including failure to receive marketing approval from the FDA, we would have prematurely or unnecessarily incurred these commercialization expenses. For example, we had hired sales and marketing personnel for a launch of our lead product candidate, but we received a CRL from the FDA in May 2023. We may also inaccurately estimate the number of representatives needed to build our sales force, which may result in unnecessary expense or the inability to scale as quickly as needed. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates, if approved, on our own include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or increase market acceptable of our approved product;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of reimbursement professionals to negotiate arrangements for coverage or adequate reimbursement by payors for our approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to price our product candidates at a sufficient price point to ensure an adequate and attractive level of profitability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted or closed distribution channels that make it difficult to distribute our product candidates to segments of the patient population; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third&#160;parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Problems related to large-scale commercial manufacturing could cause delays in product launches, an increase in product reclass or costs, product recalls or product shortages.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing finished drug products, especially in large quantities, is complex. If our product candidates receive regulatory approval, they will require several manufacturing steps and may involve complex techniques to ensure quality and sufficient quantity, especially as the manufacturing scale increases. Our product candidates will need to be made consistently and in compliance with a clearly defined manufacturing process pursuant to FDA regulations. Accordingly, it will be essential to be able to validate and control the manufacturing process to assure that it is reproducible. Slight deviations anywhere in the manufacturing process, including obtaining materials, filling, labeling, packaging, storage, shipping, quality control and testing, may result in lot failures, delay in the release of lots, product recalls or spoilage. Success rates can vary dramatically at different stages of the manufacturing process, which can lower yields and increase costs. We may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and cause us to fail to satisfy contractual commitments, cause recalls, lead to delays in our clinical trials or result in litigation or regulatory action. Such actions would hinder our ability to meet contractual obligations and could cause material adverse consequences for our business.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. For example, our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> GMP-in-a-Box may be regulated by the FDA as a medical device, and regulatory compliance for medical devices is expensive, complex and uncertain, and a failure to comply could lead to enforcement actions against us and other negative consequences for our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar agencies regulate medical devices. All of our potential medical device products and material modifications will be subject to extensive regulation and clearance or approval from the FDA and non-U.S.&#160;regulatory agencies prior to commercial sale and distribution as well as after clearance or approval. Complying with these regulations is costly, time&#8209;consuming, complex and uncertain. For instance, before a new medical device, or a new intended use for an existing device, can be marketed in the U.S., a company must first submit a premarket submission, such as a premarket notification (510(k)), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De&#160;Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> request, or PMA, and receive clearance, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De&#160;Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grant, or approval from the FDA, unless an exemption applies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our drug product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA and similar agencies have significant pre- and post-market authority, including requirements related to product design, development, testing, laboratory and preclinical studies, clinical trials approval, manufacturing processes and quality (including suppliers), labeling, packaging, distribution, adverse event and deviation reporting, storage, shipping, premarket clearance or approval, advertising, marketing, promotion, sale, import, export, product change, recalls, submissions of safety and effectiveness, post-market surveillance and reporting of deaths or serious injuries and certain malfunctions, and other post-marketing information and reports such as deviation reports, registration, product listing, annual user fees, and recordkeeping for our product candidates. The FDA may also require a REMS to approve our product candidates, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The FDA may also require post-approval Phase&#160;4 trials. Moreover, the FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices regulated by the FDA are subject to general controls which include: registration with the FDA; listing commercially distributed products with the FDA; complying with cGMP under QSR; filing reports with the FDA of and keeping records relative to certain types of adverse events associated with devices under the medical device reporting regulation; assuring that device labeling complies with device labeling requirements; and reporting certain device field removals and corrections to the FDA. In addition to the general controls, some Class&#160;2 medical devices are also subject to special controls. Most medical devices that require premarket review by the FDA, including most Class&#160;2 medical devices, require the submission of a 510(k) or a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De&#160;Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> request and obtaining 510(k) clearance or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De&#160;Novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grant prior to marketing the device. Some devices known as 510(k)-exempt devices can be marketed without prior clearance or approval from the FDA. Most Class&#160;3 devices are subject to the FDA&#8217;s PMA requirement. Further, in February&#160;2024, the FDA issued a final rule replacing the QSR with the QMSR, which incorporates by reference the quality management system requirements of ISO&#160;13485:2016. The FDA has stated that the standards contained in ISO&#160;13485:216 are substantially similar to those set forth in the existing QSR. This final rule does not go into effect until February&#160;2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA can also refuse to clear or approve premarket submissions for any medical device we develop. We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, for any medical device products we develop, which could harm our business. Furthermore, even if we are granted regulatory clearances or approvals for any medical device products, they may include significant limitations on the indicated uses for the product, which may limit the market for the product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we, our contractors, and our collaborators are and will remain responsible for FDA compliance. We and any of our collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with regulatory requirements. Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes. The cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or comparable foreign regulatory authorities become aware of new safety information or previously unknown problems after approval of any of our product candidates, including: (i)&#160;adverse events of unanticipated severity or frequency, (ii)&#160;that the product is less effective than previously thought, (iii)&#160;problems with our third-party manufacturers or manufacturing processes or (iv)&#160;failure to comply with regulatory requirements, or if we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may face a number of regulatory consequences, including fines, warnings or untitled letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions or partial suspension or total shutdown of production, injunctions, consent decrees, civil penalties and criminal prosecution, among other consequences. Additionally, we may face unanticipated expenditures to address or defend such actions and customer notifications for repair, replacement or refunds. Any such restrictions could limit sales of the product. Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our stock price and could significantly harm our business, financial condition, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also regulates the advertising and promotion of medical devices to ensure that the claims are consistent with their regulatory clearances or approvals, that there are adequate and reasonable data to substantiate the claims and that the promotional labeling and advertising is neither false nor misleading in any respect. If the FDA determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. Failure to comply with applicable U.S.&#160;requirements regarding, for example, promoting, manufacturing, or labeling our medical device products, may subject us to a variety of administrative or judicial actions and sanctions, such as Form&#160;483 observations, warning letters, untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. If any of our medical device products cause or contribute to a death or a serious injury or malfunction in certain ways, we will be required to report under applicable medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, it would have a material and adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting pre-approval promotion and the promotion of off-label uses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA prohibits the pre-approval promotion of drugs as safe and effective for the purposes for which they are under investigation. Similarly, the FDA prohibits the promotion of approved drugs for new or unapproved indications. If the FDA finds that we have engaged in pre-approval promotion of our future product candidates, or if any of our future product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our future product candidates, if approved. In particular, an approved product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label, which is within their purview as part of their practice of medicine. If we are found to have promoted such off-label uses, however, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. The FDA may also issue a public warning letter or untitled letter to the company. If we cannot successfully manage the promotion of our future approved products, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results for any patient who receives compassionate use access to our product candidates should not be viewed as representative of how the product candidate will perform in a well-controlled clinical trial and cannot be used to establish safety or efficacy for regulatory approval. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often receive requests for compassionate use access to our investigational drugs by patients that do not meet the entry criteria for enrollment into our clinical trials. Generally, patients requesting compassionate use have no other treatment alternatives for life-threatening conditions. We evaluate each compassionate use request on an individual basis, and in some cases grant access to our investigational product candidates outside of our sponsored clinical trials if a physician certifies that the patient receiving treatment is critically ill and does not meet the entry criteria for one of our open clinical trials. Individual patient results from compassionate use access may not be used to support submission of a regulatory application, may not support approval of a product candidate, and should not be considered to be indicative of results from any ongoing or future well-controlled clinical trial. Before we can seek regulatory approval for any of our product candidates, we must demonstrate in well-controlled clinical trials statistically significant evidence that the product candidate is both safe and effective for the indication for which we are seeking approval. The results of our compassionate use program may not be used to establish safety or efficacy or regulatory approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are and will be subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal and/or civil liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates will be subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations and various economic and trade sanctions regulations administered by the OFAC, the FCPA, the U.S.&#160;domestic bribery statute contained in 18&#160;U.S.C.&#160;&#167;201, the U.S.&#160;Travel Act, the USA&#160;PATRIOT Act and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We use CROs abroad for clinical trials. In addition, we may engage third-party intermediaries to sell our product candidates and solutions abroad once we enter a commercialization phase for our product candidates and/or to obtain necessary permits, licenses, and other regulatory approvals. We or our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted an anti-corruption policy, which mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, there can be no assurance that our employees and third-party intermediaries will comply with this policy or such anti-corruption laws. Non-compliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other investigations, or other enforcement actions. If such actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor, which can result in added costs and administrative burdens.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is currently significant uncertainty about the future relationship between the U.S. and various other countries, most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. The U.S.&#160;government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers&#8217; ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the U.S. and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation. If we are unable to obtain or use services from existing service providers or become unable to export or sell our products to any of our customers, our business, liquidity, financial condition, and/or results of operations would be materially and adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with state, national and/or international privacy and security laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous laws and regulations at the federal and state levels addressing privacy and security concerns, and some state laws apply more broadly than HIPAA and associated regulations. For example, the CCPA, which went into effect on January&#160;1,&#160;2020, provides, among other things, new privacy and security obligations for covered companies and new privacy rights to California consumers, including the right to opt out of certain sales of their personal information. The CCPA also provides for civil penalties as well as a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the CCPA includes limited exceptions, including for certain personal information collected as part of certain clinical trials or other biomedical research studies, it may regulate or impact our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">processing of personal information depending on the context. Additionally, the CPRA was approved by California voters in November&#160;2020. The CPRA significantly modifies the CCPA, which may require us to modify our practices and policies and may further increase our compliance costs and potential liability. Certain states have also enacted or proposed privacy laws governing health information, including for example, Washington&#8217;s My Health, My Data Act and Nevada&#8217;s Senate Bill&#160;370, and all 50&#160;states have enacted laws imposing obligations to provide notification of certain security breaches of personal information. Additionally, several states have enacted or proposed laws similar to the CCPA, such as in New York, Virginia, Colorado, Utah, Connecticut, Iowa, Indiana, Montana, Tennessee, Oregon, Florida, Delaware, and Texas. These laws could mark the beginning of a further trend toward more stringent privacy laws in the U.S. and have prompted a number of proposals for new federal and state-level privacy laws. We cannot yet determine the impact these laws or changes may have on our business and operations, but anticipate they could increase our compliance costs and potential liability, impair our ability to collect, use or otherwise process personal information, expose us to greater liability and require us to modify our practices and policies in an effort to comply.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also various laws and regulations in other jurisdictions relating to privacy and security. For example, EU&#160;member states and other foreign jurisdictions, including the UK and Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations on us. The collection, use, and other processing of personal data, including patient or health data, in the EU, may be governed by the GDPR. The GDPR, which is wide-ranging in scope and applies extraterritorially, imposes, among other things, requirements relating to the consent of the individuals to whom the personal data relates, the notices provided to such individuals, the security and confidentiality of personal data, data breach notification, the adoption of appropriate privacy governance, including policies, procedures, training and audits, and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU, including to the U.S., provides data protection authorities with enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20&#160;million or up to 4%&#160;of the total worldwide annual global revenues of the noncompliant entity, whichever is greater. GDPR requirements apply not only to third-party personal data transfers, but also to transfers of personal data between us and our subsidiaries, including employee information. In addition, in January&#160;2021, following its exit from the EU, the UK transposed the GDPR into its domestic law with its own version of the&#160;GDPR (combining the GDPR and the UK Data Protection Act of 2018), which currently imposes the same obligations as the GDPR in most material respects and provides for fines of up &#163;17.5&#160;million or up to 4%&#160;of the total worldwide annual global revenues of the noncompliant entity, whichever is greater.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with numerous, complex, and changing laws and regulations is expensive and difficult. Any actual or alleged failure to comply with any privacy or security law or regulation, or security breach or other incident, including those involving the misappropriation, loss, or other unauthorized use, disclosure or other processing of sensitive or confidential patient, consumer or other personal information, whether by us, one of our CROs or business associates or another third party, could adversely affect our business, financial condition, and results of operations, and could subject us to investigations, litigation, and other proceedings, material fines and penalties, compensatory, special, punitive and statutory damages, consent orders regarding our privacy and security practices, requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals, adverse actions against our licenses to do business, reputational damage, and injunctive relief. The enactment of, and changes to, privacy and security laws and regulations have increased our responsibility and potential liability, including in relation to the personal data that we process and our clinical trials, and we may be required to put in place additional mechanisms in an effort to comply with applicable laws and regulations, which could divert management&#8217;s attention and increase our cost of doing business. In addition, any new law or regulation relating to privacy and security, or any applicable industry standard, may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and security in the U.S., the UK, the EU, and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that our CROs or other third-party service providers with access to our or our customers&#8217;, suppliers&#8217;, trial patients&#8217; and employees&#8217; personal information or other sensitive or confidential information will not breach applicable laws or regulations or contractual obligations imposed by us, or that they will not experience security breaches or incidents, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy and security laws and regulations and/or which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that the measures and safeguards we have taken will protect us from the foregoing risks, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our third-party contractors must comply with environmental, health and safety laws and regulations. A failure to comply with these laws and regulations could expose us to significant costs or liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any of our third-party contract manufacturers or suppliers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, generation, manufacture, storage, treatment and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with such environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability, which could exceed our assets and resources.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we will maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of biological or hazardous materials or wastes arising out of and in the course of employment, this insurance may not provide adequate coverage against potential liabilities. We do not maintain comprehensive insurance coverage for liabilities arising from medical or hazardous materials, environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts, which could harm our business, prospects, financial condition or results of operations. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of our collaborators to sell our product candidates profitably. In addition, third&#8209;party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. Obtaining coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenues from our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of our collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we, or our collaborators, may not be able to successfully commercialize our product candidates. Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Moreover, the factors noted above have continued to be the focus of policy and regulatory debate that has, thus far, shown the potential for movement towards permanent policy changes; this trend is likely to continue, and may result in more or less favorable impacts on pricing. The recent and ongoing series of congressional hearings relating to drug pricing has presented heightened attention to the biopharmaceutical industry, creating the potential for political and public pressure, while the potential for resulting legislative or policy changes presents uncertainty. Congress has considered and may continue to consider legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases. The impact of these regulations and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is currently unknown. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices paid for a drug also vary depending on the class of trade. Prices charged to government customers are subject to price controls, including ceilings, and private institutions obtain discounts through group purchasing organizations. Net prices for drugs may be further reduced by mandatory discounts or rebates required by government healthcare programs and demanded by private payors. It is also not uncommon for market conditions to warrant multiple discounts to different customers on the same unit, such as purchase discounts to institutional care providers and rebates to the health plans that pay them, which reduces the net realization on the original sale.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, federal programs impose penalties on manufacturers of drugs marketed under a BLA or NDA, in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices. For example, under the American Rescue Plan Act of 2021, effective January&#160;1,&#160;2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. In August&#160;2022, Congress passed the IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part&#160;B and Part&#160;D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part&#160;D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Various industry stakeholders, including certain pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of these judicial challenges, legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. Cost control initiatives could cause us, or our collaborators, to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the realized prices for our product candidates, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenues and profitability will suffer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain coverage for a given product, the resulting approved reimbursement payment rates might not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments or achieve or sustain profitability or may require co-payments that patients find unacceptably high. If payors subject our product candidates to maximum payment amounts or impose limitations that make it difficult to obtain reimbursement, providers may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">choose to use therapies which are less expensive when compared to our product candidates. Additionally, if payors require high co-payments, beneficiaries may decline our therapies and seek alternative therapies. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of physicians and other target customers and third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and our collaborators, cannot be sure that coverage will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. A possible challenge for our product candidates arises from the fact that they may potentially be used in an inpatient setting. Inpatient reimbursement generally relies on stringent packaging rules that may mean that there is no separate payment for our product candidates. Additionally, data used to set the payment rates for inpatient admissions is usually several years old and would not take into account all of the additional therapy costs associated with the administration of our product candidates. If special rules are not created for reimbursement for immunotherapy treatments such as our product candidates, hospitals might not receive enough reimbursement to cover their costs of treatment, which will have a negative effect on their adoption of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased revenues from our biopharmaceutical product candidates, decreased potential returns from our development efforts, and additional downward pressure on the price that we, or our collaborators, may receive for any approved products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA in 2010, in both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates profitably. These changes included aggregate reductions of Medicare payments to providers of up to 2%&#160;per fiscal year, effective April&#160;1,&#160;2013, which, due to subsequent legislative amendments, will stay in effect through 2032, with the exception of a temporary suspension implemented under various COVID&#8209;19 relief legislation. In January&#160;2013, the ATRA was approved which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government to recover overpayments to providers from three to five&#160;years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our financial operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, various portions of the ACA have been subject to judicial and constitutional challenges. In June&#160;2021, the U.S. Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this Supreme Court decision, future litigation, or healthcare measures promulgated by the Biden administration will impact our business, financial condition and results of operations. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenues, attain profitability or commercialize our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals may also be made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. Further, if the Supreme Court reverses or curtails the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> doctrine, which gives deference to regulatory agencies in litigation against the FDA and other agencies, more companies may bring lawsuits against the FDA to challenge longstanding decisions and policies of the FDA, which could undermine the FDA&#8217;s authority, lead to uncertainties in the industry, and disrupt FDA&#8217;s normal operations, which could delay the FDA&#8217;s review of our marketing applications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been increasing legislative efforts and enforcement interest in the U.S. with respect to drug pricing practices, including Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. As discussed above, in August&#160;2022, Congress passed the IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part&#160;B and Part&#160;D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part&#160;D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Various stakeholders have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of these judicial challenges, legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, the FDA recently authorized the state of Florida to import certain prescription drugs from Canada for a period of two&#160;years to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the future course of federal or state healthcare legislation in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The ACA and any further changes in the law or regulatory framework that reduce our revenues or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current product candidates and any future product candidates or additional pricing pressures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In international markets, reimbursement and health care payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost&#8209;effectiveness of our product candidate to other available therapies. There can be no assurance that our product candidates will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be available, or that the third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners, principal investigators, CROs, suppliers and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those product candidates in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws and regulations designed to prevent fraud, kickbacks, self&#8209;dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter misconduct or other improper activities by our employees or third&#160;parties that we engage for our business operations and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions, including exclusion from government healthcare programs, and serious harm to our reputation. In addition, the approval and commercialization of any of our product candidates outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with health care professionals, institutional providers, principal investigators, consultants, potential customers and third-party payors are, and will continue to be, subject, directly and indirectly, to federal and state health care fraud and abuse, false claims, marketing expenditure tracking and disclosure, government price reporting, and privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face significant penalties and liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly or indirectly subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal FCA. If we obtain FDA approval for any of our product candidates and begin commercializing those product candidates in the U.S., our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to laws of the federal government and state governments in which we conduct our business relating to privacy and security with respect to patient or health data. The laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal false claims and civil monetary penalties laws, including the federal civil FCA, which prohibit, among other things, individuals or entities from knowingly presenting or causing to be presented, claims for payment by government funded programs such as Medicare or Medicaid that are false or fraudulent, and which may apply to us by virtue of statements and representations made to customers or third parties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud healthcare programs, as well as;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by HITECH, which imposes requirements on certain types of people and entities relating to the privacy, security, and transmission of PHI, and requires notification to affected individuals and regulatory authorities of certain breaches of the privacy or security of PHI, and other U.S. laws and foreign laws that govern the privacy or security of health or patient data; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, to report annually to the CMS information related to payments and other transfers of value to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare providers (such as physician assistants and nurse practitioners) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members, which is published in a searchable form on an annual basis; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making, or causing to be made, false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FCPA, the U.K. Bribery Act of 2010, and other local anti-corruption laws that apply to our international activities; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws that may be broader in scope and also apply to commercial insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to patient or health data, privacy or security. Other state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur increased costs of compliance with such laws and regulations as they continue to evolve. If we or our contractors are unable to comply, or have not fully complied, with such laws, we could face penalties, including, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal and state health care programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations. Any of these could adversely affect our business, financial condition, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to grow our business and expand our sales organization or rely on distributors outside of the U.S., we would be at increased risk of violating these laws or our internal policies and procedures. The risk of us being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions, which could negatively impact our business and the approval of our BLA submission, as well as adversely affect the U.S. and global economy and our liquidity, financial condition and earnings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and related government shutdowns, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely is subject to the impacts of political events, which are inherently fluid and unpredictable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies, including disruptions due to public health concerns, resurgence of COVID-19 cases, travel restrictions, or staffing shortages, may slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which could adversely affect our business. For example, over the last several years, the U.S.&#160;government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs in the future, including as a result of any failure by the U.S. federal government to increase the debt ceiling, it could significantly impact the ability of the FDA and the SEC to timely review and process our submissions, as well as cause interest rates and borrowing costs to further increase, which may negatively impact our ability to access the debt markets, including the corporate bond markets, on favorable terms, which could have a material adverse effect on our business, financial condition and results of operations and/or our BLA submission.</span></div><div style="margin-top:18pt"><span id="if7b491d5c1d6441fa17129e6f403e298_444150"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain, maintain, protect and enforce patent protection and other proprietary rights for our product candidates and technologies, we may not be able to compete effectively or operate profitably and our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent in large part on our obtaining, maintaining, protecting and enforcing patents and other proprietary rights in the U.S. and other countries with respect to our product candidates and technology and on our ability to avoid infringing the intellectual property and other proprietary rights of others. Certain of our intellectual property rights are licensed from other entities, and as such the preparation and prosecution of any such patents and patent applications was not performed by us or under our control. Furthermore, patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving and, consequently, patent positions in our industry may not be as strong as in other more well-established fields. The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. As a result, the issuance, scope, validity, enforceability, or commercial value of our patent rights remain highly uncertain.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, any of our issued or granted patents will not later be found to be invalid or unenforceable, or any issued or granted patents will include claims sufficiently broad to cover our product candidates and technology, or to provide meaningful protection from our competitors. Our owned or in-licensed pending and future patent applications may not result in patents being issued that protect our N-803, hAd5, saRNA and yeast technologies and constructs, cell-based therapies, aldoxorubicin or other product candidates and technologies or that effectively prevent others from commercializing competitive technologies and product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third&#160;parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged, narrowed, circumvented, or invalidated by third&#160;parties. Consequently, we do not know whether our N-803, hAd5, saRNA and yeast technologies and constructs, cell-based therapies or other product candidates and technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third&#160;parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it is uncertain how much protection, if any, will be provided by our patents, including if they are challenged in the courts or patent offices or in other proceedings, such as re-examinations or oppositions, which may be brought in the U.S. or foreign jurisdictions to challenge the validity of a patent. A third&#160;party may challenge the validity or enforceability of a patent after its issuance. It is possible that a competitor may successfully challenge our patents or that a challenge will result in limiting their coverage. Moreover, it is possible that competitors may infringe our patents or successfully avoid the patented technology through design innovation. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time&#8209;consuming, even if we were successful in stopping the violation of our patent rights.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, or interference proceedings or other similar proceedings challenging our owned or licensed patent rights. Should third&#160;parties file patent applications, or be issued patents claiming technology also used or claimed by our licensor(s) or by us in any future patent application, we, or one of our licensors, may be required to participate in interference proceedings in the USPTO to determine priority of invention for those patents or patent applications that are subject to the first-to-invent law in the U.S., or may be required to participate in derivation proceedings in the USPTO for those patents or patent applications that are subject to the first-inventor-to-file law in the U.S. We may be required to participate in such interference or derivation proceedings involving our issued patents and pending applications. We may also be required to participate in post-grant challenge proceedings, such as oppositions in a foreign patent office, which challenge our or our licensor&#8217;s priority of invention or other features of patentability with respect to our owned or in&#8209;licensed patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our N-803, hAd5, saRNA and yeast technologies and constructs, cell-based therapies or other product candidates and technologies. For example, the validity of one of our European patents, EP&#160;Patent No.&#160;3601363, is being challenged in an opposition proceeding. This patent is directed to methods of using N-803-based combination therapy with anti-CD38 antibodies to treat cancer, which does not directly relate to any of our current programs. We intend to defend our patent and believe we have meritorious defenses against this opposition. An adverse determination in any of the type of submissions described above, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our owned or in&#8209;licensed patent rights, allow third&#160;parties to commercialize our N-803, hAd5, saRNA and yeast technologies and constructs, cell-based therapies or other product candidates or technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to cease using the technology or to obtain and maintain license rights from prevailing third&#160;parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. A prevailing party in that case may not offer us a license on commercially acceptable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third&#160;parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third&#160;parties. In addition, certain of our licensors co-own the patents and patent applications we in-license with other third&#160;parties with whom we do not have a direct relationship. Our exclusive rights to certain of these patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third&#160;parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third&#160;parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our owned or in-licensed patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third&#160;parties. The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third&#160;parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, collaborators, or any future strategic partners may become subject to third-</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">to protect or enforce our patents or other intellectual property or the patents or other intellectual property of our licensors, all of which could be expensive, time-consuming and unsuccessful, may delay or prevent the development and commercialization of our product candidates, or may put our patents and other proprietary rights at risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensors initiate legal proceedings against a third&#160;party to enforce a patent covering one of our product candidates or other technologies, the defendant could counterclaim that the patent is invalid and/or unenforceable or that we infringe their patents. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third&#160;party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or other applicable body, or made a misleading statement, during prosecution. Third&#160;parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our licensor, our or our licensor&#8217;s patent counsel and the patent examiner were unaware during prosecution. Moreover, even if our patents were to survive such a litigation challenge to their validity, the patents might still be held to be valid but unenforceable if a court were to decide that the patents are being enforced in a manner inconsistent with the antitrust laws, or that the patents were obtained through deceit during patent office examination or other such failure of sufficient candor to the patent office. If a third&#160;party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects. The validity of one of our European patents, EP&#160;Patent No.&#160;3601363, is being challenged in an opposition proceeding. We intend to defend our patent and believe we have meritorious defenses against this opposition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources, including our scientists and management, from our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse result in any litigation or defense proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable, or interpreted narrowly, and could put our patent applications at risk of not being issued. Such proceedings could result in revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our product candidates or technologies. If the outcome of litigation is adverse to us, third&#160;parties may be able to use our patented invention without payment to us. In addition, in an infringement proceeding, there is a risk that a court may decide that one or more of our patents is not valid or is unenforceable and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of our patents were upheld, a court would refuse to stop the other party on the grounds that its activities are not covered by, that is, do not infringe, our patents. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be better able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use of our technology and product candidates could potentially conflict with the rights of others, and third-party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our product candidates and technologies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our, our licensors&#8217; and our collaborators&#8217; ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third&#160;parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biopharmaceutical industry. Our potential competitors or other parties may have, develop or acquire patent or other intellectual property rights that they could assert against us. If they do so, then we may be required to alter our product candidates, pay licensing fees or cease our development and commercialization activities with respect to the applicable product candidates or technologies. If our product candidates conflict with patent or other intellectual property rights of others, such parties could bring legal actions against us or our collaborators, licensees, suppliers or customers, claiming damages and seeking to enjoin manufacturing, use and marketing of the affected products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have conducted FTO analyses of the patent landscape with respect to our lead product candidates and continue to undertake FTO analyses of our manufacturing processes, our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, and contemplated future processes and products, because patent applications do not publish for 18&#160;months, and because the claims of patent applications </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">can change over time, no FTO analysis can be considered exhaustive. We may not be aware of patents that have already been issued and that a competitor or other third&#160;party might assert are infringed by our current or future product candidates or technologies. It is also possible that we could be found to have infringed patents owned by third&#160;parties of which we are aware, but which we do not believe are relevant to our product candidates or technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or technologies may infringe. Furthermore, patent and other intellectual property rights in biotechnology remains an evolving area with many risks and uncertainties. As such, we may not be able to ensure that we can market our product candidates without conflict with the rights of others.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If intellectual property-related legal actions asserted against us are successful, in addition to any potential liability for damages (including treble damages and attorneys&#8217; fees for willful infringement), we could be enjoined from, or required to obtain a license to continue, manufacturing, promoting the use of or marketing the affected products. We may not prevail in any legal action and a required license under the applicable patent or other intellectual property may not be available on acceptable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third&#160;parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be required to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other immunotherapy and biopharmaceutical companies, our success is dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing wide-ranging patent reform legislation. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March&#160;2013, under the America Invents Act enacted in September&#160;2011, the U.S. transitioned to a first-to-file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third&#160;party was the first to invent the claimed invention. A third&#160;party that files a patent application in the USPTO after March&#160;2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before such third&#160;party made it. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our product candidates or other technologies or invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s review, and derivation proceedings. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, U.S.&#160;Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. While we do not believe that any of the patents owned or licensed by us will be found invalid based on the foregoing, we cannot predict how future decisions by Congress, the federal courts or the USPTO may impact the value of our patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent. The USPTO and various foreign governmental patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensors to pay these fees and take the necessary actions to comply with these requirements. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical products or technology, which would have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates and technologies are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will rely on licenses to certain patent rights and proprietary technology from third&#160;parties that are important or necessary to the development of aldoxorubicin as well as products enabled by our adenoviral, saRNA and yeast (including Tarmogen), vaccine technologies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License agreements may not provide exclusive rights to use certain licensed intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. As a result, we may not be able to prevent competitors or other third&#160;parties from developing and commercializing competitive products that also utilize technology that we have in-licensed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, subject to the terms of any such license agreements, we do not have the right to control the preparation, filing, prosecution and maintenance, and we may not have the right to control the enforcement, and defense of patents and patent applications covering the technology that we license from third&#160;parties. We cannot be certain that our in-licensed or out-licensed patents and patent applications that are controlled by our licensors or licensees will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors or licensees fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize N-803 and any of our product candidates that are subject of such licensed rights could be adversely affected, and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third&#160;parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third&#160;parties. For example, certain of our in-licensed intellectual property was funded in part by the U.S.&#160;government. As a result, the U.S.&#160;government may have certain rights to such intellectual property. When new technologies are developed with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.&#160;government funding, the U.S.&#160;government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S.&#160;government to use the invention or to have others use the invention on its behalf. The U.S.&#160;government&#8217;s rights may also permit it to disclose the funded inventions and technology to third&#160;parties and to exercise march-in rights to use or allow third&#160;parties to use the technology we have licensed that was developed using U.S.&#160;government funding. The U.S.&#160;government may exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S.&#160;industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the U.S. in certain circumstances if this requirement is not waived. Any exercise by the U.S.&#160;government of such rights or by any third&#160;party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third&#160;parties or otherwise experience disruptions to our business relationships with our licensors, we may be required to pay damages and we could lose license rights that are important to our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into license agreements with third&#160;parties and may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates. We may be unable to obtain certain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates or continue to utilize our existing technology, which could harm our business, financial condition, results of operations and growth prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third&#160;parties, which could be significant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each of our license agreements, and we expect our future agreements, will impose various development, diligence, commercialization, and other obligations on us. Certain of our license agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third&#160;parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates or of N-803. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third&#160;parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and growth prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights in various jurisdictions throughout the world.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third&#160;parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third&#160;parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third&#160;parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third&#160;parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed trade secrets or other confidential information of third&#160;parties or claims asserting ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third&#160;parties and their employees and contractors. In addition, we plan to employ and contract with individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed the trade secrets or other confidential information of these third&#160;parties or our employees&#8217; former employers. Litigation may be necessary to defend against or pursue these claims. Even if we are successful in resolving these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants and independent contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third&#160;parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to license or acquire new or necessary intellectual property rights or technology from third&#160;parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An element of our intellectual property strategy is to license intellectual property rights and technologies from third&#160;parties and/or our affiliates. Other parties, including our competitors or our affiliates, may have patents relevant to our business, may have already filed patent applications relevant to our business, and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these patents, we may find it necessary or prudent to obtain licenses to such patents from such parties. In addition, with respect to any patents we co-own with other parties, including our affiliates, we may require licenses to such co-owners&#8217; interest to such patents. The licensing or acquisition of intellectual property rights is a competitive area, and other more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. No&#160;assurance can be given that we will be successful in licensing any additional rights or technologies from third&#160;parties and/or our affiliates. Our inability to license the rights and technologies that we have identified, or that we may in the future identify, could have a material adverse impact on our ability to complete the development of our product candidates or to develop additional product candidates. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third&#160;parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. Failure to obtain any necessary rights or licenses may detrimentally affect our planned development of our current or future additional product candidates and could increase the cost, and extend the timelines associated with our development, of such other products, and we may have to abandon development of the relevant program or product candidate. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or in-licensed U.S.&#160;patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Only one patent may be extended per new drug, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the U.S. and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and growth prospects could be materially harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging rights in our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, collaborators or other third&#160;parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property, including as an inventor or co-inventor. For example, we or our licensors may have disputes arising from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventorship, or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for N-803, hAd5, saRNA and yeast technologies and constructs, cell therapies, and other product candidates and technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect these trade secrets and other proprietary technology, in part, by entering into nondisclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors, and other third&#160;parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third&#160;party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third&#160;party, our competitive position would be materially and adversely harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third&#160;parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third&#160;parties;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors or other third&#160;parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third&#160;party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock and CVRs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dr. Soon-Shiong, our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, has significant interests in other companies which may conflict with our interests.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, Dr.&#160;Soon-Shiong, is the founder of NantWorks. The various NantWorks companies are currently exploring opportunities in the immunotherapy, oncology, infectious disease and inflammatory disease fields. In particular, we have agreements with a number of related parties that provide services, technology and equipment for use in their efforts to develop their product pipelines. Dr.&#160;Soon-Shiong holds a controlling interest, either directly or indirectly, in these entities. Consequently, Dr.&#160;Soon-Shiong&#8217;s interests may not be aligned with our other stockholders, and he may from time to time be incentivized to take certain actions that benefit his other interests and that our other stockholders do not view as being in their interest as investors in our company. In addition, other companies affiliated with Dr.&#160;Soon-Shiong may compete with us for business opportunities or, in the future, develop products that are competitive with ours (including products in other therapeutic fields which we may target in the future). Moreover, even if they do not directly relate to us, actions taken by Dr.&#160;Soon-Shiong and the companies with which he is involved could impact us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also pursuing supply arrangements for various investigational agents controlled by affiliates to be used in their clinical trials. If Dr.&#160;Soon-Shiong were to cease his affiliation with us or NantWorks, these entities may be unwilling to continue these relationships with us on commercially reasonable terms, or at all, and as a result may impede our ability to control the supply chain for our combination therapies. These collaboration agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenues that is at least proportional to the costs that we will incur in commercializing the product candidate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into shared services agreements with NantWorks, pursuant to which NantWorks and its affiliates provide corporate, general and administrative and other support services to us. If Dr.&#160;Soon-Shiong was to cease his affiliation with us or with NantWorks, we may be unable to establish or maintain this relationship with NantWorks on a commercially reasonable basis, if at all. As a result, we could experience a lack of business continuity due to loss of historical and institutional knowledge and a lack of familiarity of new employees and/or new service providers with business processes, operating requirements, policies and procedures, and we may incur additional costs as new employees and/or service providers gain necessary experience. In addition, the loss of the services of NantWorks might significantly delay or prevent the development of our product candidates or achievement of other business objectives by diverting management&#8217;s attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dr. Soon-Shiong, through his voting control of the company, has the ability to control actions that require stockholder approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Soon-Shiong, through his direct and indirect ownership of the company&#8217;s common stock, has voting control of the company. As of December&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his affiliates own approximately 79.4% of the company&#8217;s common stock outstanding. Dr.&#160;Soon-Shiong and his affiliates also own all of our outstanding convertible promissory notes, certain warrants and stock options to purchase shares of our common stock, and certain CVRs as described under </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">&#8220;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">&#8212;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">Conversion</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349"> of certain related-party </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">promissory </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">notes, exercise of outstanding warrants </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">and o</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">ptions </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">to purchase our common stock, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">the achievement of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">the milestone under our outstanding </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">CVRs</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">, and po</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">tential additional equity issuances</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349"> may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_545349">&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Soon-Shiong is in a position to control the outcome of corporate actions that require, or may be accomplished by, stockholder approval, including amending the bylaws of the company, the election or removal of directors and transactions involving a change of control. Dr.&#160;Soon-Shiong&#8217;s controlling ownership could limit the ability of the remaining stockholders of the company to influence corporate matters, and the interests of Dr.&#160;Soon-Shiong may not coincide with the company&#8217;s interests or the interests of its remaining stockholders. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Nominating Agreement between us and Cambridge, an entity that Dr.&#160;Soon-Shiong controls, Cambridge has the ability to designate one director to be nominated for election to the Board of Directors for as long as Cambridge continues to hold at least 20%&#160;of the issued and outstanding shares of our common stock. Dr.&#160;Soon-Shiong was selected by Cambridge to hold this board seat. Dr.&#160;Soon-Shiong and his affiliates will therefore have significant influence over management and significant control over matters requiring stockholder approval, including the annual election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets, for the foreseeable future. This control will limit stockholders&#8217; ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. As a result, the market price of our common stock could be adversely affected.</span></div><div style="margin-top:12pt"><span id="if7b491d5c1d6441fa17129e6f403e298_545349"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of certain related-party promissory notes, exercise of outstanding warrants and options to purchase our common stock, the achievement of the milestone under our outstanding CVRs, and potential additional equity issuances may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the company had outstanding promissory notes representing an aggregate of $610.0&#160;million principal amount held by entities affiliated with Dr.&#160;Soon-Shiong that are convertible into shares of our common stock under certain circumstances, including the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $380.0&#160;million principal amount of Tranche&#160;2 of our convertible promissory note due December&#160;31,&#160;2025 bearing interest at 3-month Term&#160;SOFR plus 7.5%&#160;per annum, which provides that the noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $8.2690&#160;per share (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event);</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $200.0&#160;million principal amount convertible promissory note due September&#160;11,&#160;2026 bearing interest at 1-month Term&#160;SOFR plus 8.0%&#160;per annum provides that the noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $1.9350&#160;per share (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event); and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $30.0&#160;million principal amount convertible promissory note due December&#160;31,&#160;2025 bearing interest at 3-month Term&#160;SOFR plus 8.0%&#160;per annum, which provides that the noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $2.28&#160;per share (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December&#160;31,&#160;2023, we had outstanding warrants and stock options covering the sale of up to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">9,090,909&#160;shares of our common stock at an exercise price of $6.60&#160;per share, which are currently exercisable with an expiration date of December&#160;12,&#160;2024 (these warrants were issued to certain institutional investors);</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">28,641,911&#160;shares of our common stock at an exercise price of $3.2946&#160;per share, which are currently exercisable with an expiration date of July&#160;24,&#160;2026 (these warrants were issued to certain institutional investors);</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$10.0&#160;million of the company&#8217;s common stock at a price per share to be determined by the 30-day trailing volume weighted-average price of our common stock, calculated from the date of exercise. The option is exercisable by Oberland any time after the closing of the SPOA, until the earliest of (i)&#160;December&#160;29,&#160;2028, (ii)&#160;a change of control of the company, or (iii)&#160;a sale of substantially all of the company&#8217;s assets; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,626,064&#160;stock options issued to Dr.&#160;Soon-Shiong that are outstanding as of December&#160;31,&#160;2023, of which 1,159,398 are vested and exercisable and 466,666&#160;are unvested and unexercisable; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,638,000&#160;shares of our common stock at an exercise price of $3.24&#160;per share exercisable from the 30th&#160;day following the achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates (which has not yet been satisfied) with an expiration date on the tenth&#160;anniversary of such initial exercise date (this warrant was issued to an affiliate of Dr.&#160;Soon-Shiong).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December&#160;31,&#160;2023, we had outstanding an aggregate of approximately $300.6&#160;million of CVRs issued to the former stockholders of Altor, including Dr.&#160;Soon-Shiong and certain affiliates, which such stockholders may choose to receive either in cash or shares of our common stock based upon an average of closing prices on a 20-trading day trailing period, upon the first calendar year prior to December&#160;31,&#160;2026 in which worldwide net sales of N-803 exceed $1.0&#160;billion. N-803 is not currently approved for commercial sale, and there can be no assurance that such sales milestone will be achieved. Dr.&#160;Soon-Shiong and his related party hold approximately $139.8&#160;million of such CVRs, and have irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs.</span></div><div style="margin-top:12pt;text-indent:49pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion or exchange of some or all of our outstanding promissory notes into shares of our common stock, the exercise of any of our outstanding warrants and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the decision of the holders of our CVRs to receive shares of our common stock could dilute the ownership interests of existing stockholders. Any sales in the public market of our outstanding promissory notes or warrants, or our common stock issuable upon conversion of the promissory notes or exercise of the warrants, could adversely affect prevailing market prices of our common stock. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been and may continue to be volatile, and investors may have difficulty selling their shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in our regulatory submissions for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such submissions, including without limitation the FDA&#8217;s issuance of a CRL or a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or delays in clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our quarterly operating results, including those driven by liability accounting associated with embedded derivatives;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our liquidity position, RIPA liability covenants and the amount and nature of any debt we may incur;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements that our revenue or income are below or that costs or losses are greater than analysts&#8217; expectations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of large blocks of our common stock;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in stock market prices and volumes;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of our clinical trial results by retail investors, which investors may be subject to the influence of information provided by third&#160;party investor websites and independent authors distributing information on the internet;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic slowdowns;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government-imposed lockdowns, supply chain disruptions, and adverse economic effects from a potential pandemic, epidemic, or outbreak of an infectious disease, in the U.S. and abroad;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical tensions and war, including the war in Ukraine and ongoing conflicts in Gaza and Yemen;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinated actions by independent third-party actors to affect the price of certain stocks, coordinated via the internet and otherwise; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to securities class action litigation and may be subject to similar or other litigation in the future, all of which will require significant management time and attention, result in significant legal expenses and may result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and may in the future become, subject to various legal proceedings and claims that arise in or outside the ordinary course of business. For example, on June&#160;30,&#160;2023, a putative securities class action complaint, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salzman&#160;v.&#160;ImmunityBio, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No.&#160;3:23-cv-01216-BEN-WVG, was filed in the U.S.&#160;District Court for the Southern District of California against the company and three&#160;of its officers and/or directors, asserting violations of Sections&#160;10(b) and 20(a) of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Act stemming from the company&#8217;s disclosure on May&#160;11,&#160;2023 that it had received an FDA CRL stating, among other things, that it could not approve the company&#8217;s original BLA submission for its product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, in its initial form due to deficiencies related to its pre-license inspection of the company&#8217;s third-party CMOs. The complaint alleges that the defendants had previously made materially false and misleading statements and/or omitted material adverse facts regarding its third-party clinical manufacturing organizations and the prospects for regulatory approval of the BLA. On September&#160;27,&#160;2023, the court appointed a lead plaintiff, approved their selection of lead counsel, and re-captioned the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. ImmunityBio, Inc. Securities Litigation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No.&#160;3:23-cv-01216. On November&#160;17,&#160;2023, lead plaintiff filed an amended complaint, which named the same defendants and asserted the same claims as the previous complaint. On January&#160;8,&#160;2024, defendants filed a motion to dismiss the amended complaint. A hearing on the motion is currently scheduled for April&#160;23,&#160;2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the securities class action lawsuit, and any future legal proceedings cannot be predicted with certainty. Also, our insurance coverage may be insufficient, our assets may be insufficient to cover any amounts that exceed our insurance coverage, and we may have to pay damage awards or otherwise may enter into a settlement arrangement in connection with such claim. Any such payments or settlement arrangements in current or future litigation could have a material adverse effect on our business, operating results or financial condition. Even if the plaintiffs&#8217; claims are not successful, current or future litigation could result in substantial costs and significantly and adversely impact our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock. In addition, such lawsuits may make it more difficult to finance our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell substantial amounts of our common stock in the public market, including shares obtained from the conversion or exchange of our convertible promissory notes, exercise of our warrants, satisfaction of our CVRs, or the exercise or settlement of our equity incentive awards, the market price of our common stock could decline significantly. In addition, our Executive Chairman and Global Chief Scientific and Medical Officer, Dr.&#160;Soon-Shiong, and his affiliates owned approximately 79.4%&#160;of our outstanding shares of common stock as of December&#160;31,&#160;2023. Sales of stock by Dr.&#160;Soon-Shiong and his affiliates could have an adverse effect on the trading price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain holders of our common stock are entitled to certain rights with respect to the registration of their shares under the Securities Act, including the shares purchased by affiliates of Oberland in connection with our entry into the RIPA. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule&#160;144 under the Securities Act. Any sales of securities by these stockholders could have an adverse effect on the market price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect that additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, regulatory approval efforts, pre-commercialization and commercialization activities, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, including as part of the ATM, convertible securities or other equity securities (including warrants) in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, existing investors may be materially diluted, and new investors could gain rights, preferences and privileges senior to the holders of our common stock. The issuance of additional shares of common stock or warrants to purchase common stock, perception that such issuances may occur, or the exercise of outstanding warrants or other equity securities will have a material dilutive impact on existing stockholders and could have a material negative effect on the market price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal control over financial reporting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the U.S., we have incurred and will continue to incur significant additional legal, accounting and other expenses as a result of operating as a public company. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including Sarbanes-Oxley and regulations implemented by the SEC and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to create a larger finance function with additional personnel to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company in the U.S., we are required, pursuant to Section&#160;404 to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. The controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business our controls and procedures may become inadequate because of changes in conditions or the degree of compliance with these policies or procedures may deteriorate and material weaknesses in our internal control over financial reporting may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, can provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no absolute assurance that all control issues have been or will be detected. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To fully comply with Section&#160;404, we will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In addition, in the process of evaluating our internal control over financial reporting, we expect that certain of our internal control practices will need to be updated to comply with the requirements of Section&#160;404 and the regulations promulgated thereunder, and we may not be able to do so on a timely basis, or at all. In the event that we are not able to demonstrate compliance with Section&#160;404 in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or Nasdaq, and investors may lose confidence in our operating results and the price of our common stock could decline. Furthermore, if we are unable to certify that our internal control over financial reporting is effective and in compliance with Section&#160;404, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or stock exchanges, and investors could lose confidence in the accuracy and completeness of our financial reports, which could hurt our business, the price of our common stock and our ability to access the capital markets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating as a public company makes it more expensive for us to obtain directors&#8217; and officers&#8217; liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified persons to serve on the Board of Directors, on committees of the Board of Directors, or as members of senior management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a restatement of our consolidated financial statements were to occur, our stockholders&#8217; confidence in the company&#8217;s financial reporting in the future may be affected, which could in turn have a material adverse effect on our business and stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements, and we could be required to restate our financial results. In addition, if we are unable to successfully remediate any future material weaknesses in our internal controls or if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected, and we may be unable to maintain compliance with applicable stock exchange listing requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends for the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as the Board of Directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are relying on the exemptions from corporate governance requirements as a result of being a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman and Global Chief Scientific and Medical Officer, Dr.&#160;Soon-Shiong, and entities affiliated with him, control a majority of our common stock. As a result, we are a controlled company within the meaning of the Nasdaq listing standards. Under these rules, a company of which more than 50%&#160;of the voting power is held by an individual, a group or another company is a controlled company and may elect not to comply with certain Nasdaq corporate governance requirements, including (1)&#160;the requirement that a majority of the Board of Directors consist of independent directors, and (2)&#160;the requirement that we have a Nominating and Corporate Governance Committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Accordingly, you do not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements. However, our Board of Directors is currently comprised of a majority of independent directors, and we currently have a Nominating and Corporate Governance Committee and the majority of the members of such committee are independent directors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock and the value of our warrants will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts&#8217; cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of our CVRs that are payable contingent upon us achieving certain milestones may not receive any further consideration. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026. N-803 is not currently approved for commercial sale, and there can be no assurance that such sales milestone will be achieved. Accordingly, holders of our CVRs that are payable contingent upon us achieving the aforementioned milestones may not receive any further consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not subject to the provisions of Section 203 of the DGCL, which could negatively affect your investment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected in our Amended and Restated Certificate of Incorporation to not be subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three&#160;years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns (or, in certain cases, within three&#160;years prior, did own) 15%&#160;or more of the corporation&#8217;s voting stock. Our decision not to be subject to Section&#160;203 will allow, for example, our Executive Chairman and Global Chief Scientific and Medical Officer (who, with members of his immediate family and entities affiliated with him, owned, in the aggregate, approximately 79.4% of our common stock as of December&#160;31,&#160;2023) to transfer shares in excess of 15%&#160;of our voting stock to a third-party free of the restrictions imposed by Section&#160;203. This may make us more vulnerable to takeovers that are completed without the approval of our Board of Directors and/or without giving us the ability to prohibit or delay such takeovers as effectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, as well as provisions of Delaware law, could make it more difficult for a third&#160;party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that special meetings of stockholders be called only by the board of directors, president or chief executive officer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice requirements for stockholder proposals and nominations for election to the board of directors; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These anti-takeover provisions and other provisions in our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by the then-current Board of Directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section&#160;145 of the DGCL, our Amended and Restated Bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are not obligated pursuant to our Amended and Restated Bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees except with respect to proceedings authorized by our Board of Directors or brought to enforce a right to indemnification.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our Amended and Restated Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. &#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">106</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_926"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C. &#160;&#160;&#160;&#160;CYBERSECURITY.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Assessment and Management</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly assess risks from cybersecurity threats; monitor our information systems for potential vulnerabilities; and test those systems pursuant to our cybersecurity policies, processes, and practices, which are integrated into our overall risk management program. To protect our information systems from cybersecurity threats, we use various security tools that are designed to help identify, escalate, investigate, resolve, and recover from security incidents in a timely manner. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has an ERM program to identify, evaluate, and manage risks. Cybersecurity risks are evaluated alongside other critical business risks under the ERM program to align cybersecurity efforts with the company&#8217;s broader business goals and objectives. We believe that integrating cybersecurity risks into our ERM program fosters a proactive and holistic approach to cybersecurity, which helps safeguard the company&#8217;s operations, financial condition, and reputation in an ever-evolving threat landscape.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company maintains a cybersecurity program that is designed to identify, protect from, detect, respond to, and recover from cybersecurity threats and risks, and protect the confidentiality, integrity, and availability of its information systems, including the information residing on such systems</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity threats, including those resulting from any previous cybersecurity incidents, had not materially affected the company, including our business strategy, results of operations, or financial condition. We do not believe that cybersecurity threats resulting from any previous cybersecurity incidents of which we are aware are reasonably likely to materially affect our company. See Item&#160;1A. Risk Factors &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_444148">Our systems, infrastructure or data, or those used by our CROs, CMOs, clinical sites or other contractors or consultants, may or may be perceived to fail or suffer a cyberattack, security breach or other incident, including a breakdown or compromise of the confidentiality, integrity and availability of our system</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_444148">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_444148">, network</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_444148">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_444148"> or data, which could adversely affect the operation of our business and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7b491d5c1d6441fa17129e6f403e298_444148">reputation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information regarding cybersecurity risks and the potential impact on the company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incident Response</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has a dedicated incident management team responsible for managing and coordinating its cybersecurity incident response efforts. This team also collaborates closely with other teams in identifying, protecting from, detecting, responding to, and recovering from cybersecurity incidents. Cybersecurity incidents that meet certain thresholds are escalated to the executive incident team and cross-functional teams on an as-needed basis for support and guidance. Additionally, this team tracks cybersecurity incidents to help identify and analyze them. The company&#8217;s incident response team partners with other key stakeholders as appropriate to respond to cybersecurity incidents. The company maintains a cybersecurity and incident response program to prepare for and respond to cybersecurity incidents, which includes standard processes for reporting and escalating cybersecurity incidents to the executive incident team. Additionally, the company conducts at least one&#160;incident response test exercise on an annual basis, where members of a cross-functional team engage in a simulated incident scenario. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board Oversight Role</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors oversees our risk management process, including as it pertains to cybersecurity risks, directly and through its committees. The Audit Committee (the Committee) of the Board of Directors oversees our cybersecurity and data privacy. The Committee meets periodically to review and discuss with management risks relating to significant cybersecurity matters and concerns involving the company, including information security, data privacy, backup of information systems and related regulatory matters and compliance. The Committee regularly reports to the Board of Directors with respect to the Committee&#8217;s activities and recommendations, including those relating to cybersecurity matters and concerns. The CIO provides quarterly reports to the Committee on information security matters, including the adequacy and effectiveness of the company&#8217;s information security policies and practices and the internal controls regarding information security, and notifies the chairperson of the Committee as soon as practicable of significant information security matters and concerns as they arise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Role</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has a dedicated cybersecurity organization within its technology department that focuses on current and emerging cybersecurity matters. The company&#8217;s cybersecurity function is led by the company&#8217;s director of information security, who reports to the CIO. The director of information security and CIO (collectively, the Cybersecurity Leaders) are actively involved in assessing and managing cybersecurity risks, and are responsible for implementing cybersecurity policies, programs, procedures, and strategies. The responsibilities and relevant experience of each of the Cybersecurity Leaders are as follows:</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIO provides leadership for the company&#8217;s technology department. She holds a Bachelor of Science, Communication from Arizona State University, has served in various roles in information technology for over 25&#160;years, holds multiple certifications, and has been actively involved in the information security and cybersecurity domains for over 20&#160;years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The director of information security is responsible for all aspects of cybersecurity across the company&#8217;s locations and data centers, including security engineering, security operations, incident response, threat intelligence, risk and compliance, and vulnerability management. He holds a Bachelor of Science in Business Administration, Management Information Systems from the University of Arizona, holds various certifications, and has served in various roles in information technology for over 25&#160;years at numerous technology companies and consulting firms.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company&#8217;s cybersecurity department is comprised of teams that engage in a range of cybersecurity activities such as threat intelligence, security architecture, and incident response. These teams conduct vulnerability management and penetration testing to identify, classify, prioritize, remediate, and mitigate vulnerabilities. Leaders from each team regularly meet with the Cybersecurity Leaders to provide visibility to major issues and seek alignment with strategy. As discussed above, the company&#8217;s cybersecurity incident response plan includes standard processes for reporting and escalating cybersecurity incidents to senior management. Cybersecurity incidents that meet certain thresholds are escalated to the Cybersecurity Leaders and cross-functional teams on an as-needed basis for support and guidance. The company&#8217;s incident response team also coordinates with external legal advisors, communication specialists, and other key stakeholders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cybersecurity Service Providers and Third-Party Consultants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company engages cybersecurity consultants and other third parties to assess and enhance its cybersecurity practices. These third parties conduct assessments and penetration testing to identify weaknesses and recommend improvements. Additionally, the company leverages a number of third-party tools and technologies as part of its efforts to enhance cybersecurity functions, including a managed security service provider to augment the company&#8217;s internal resources, an endpoint detection and response system for continuous monitoring, detection, and response capabilities, and a security information and event management solution to automate real-time threat detection, investigation, and prioritization of high-fidelity alerts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oversight of Third-Party Service Providers</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company also uses third-party service providers to support its operations and many of its technology initiatives, and evaluates its third-party service providers from a cybersecurity risk perspective, which may include an assessment of that service provider&#8217;s cybersecurity posture or a recommendation of specific mitigation controls. Following such evaluation, the company determines and prioritizes service provider risk based on the potential threat impact and likelihood, and such risk determination drives the level of due diligence and ongoing compliance monitoring required for each service provider.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">108</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. &#160;&#160;&#160;&#160;PROPERTIES.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease property in multiple facilities across the U.S. and Italy, including facilities located in El&#160;Segundo and Culver&#160;City,&#160;CA that are leased from related parties. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information about our related-party leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal properties under lease as of December&#160;31,&#160;2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration <br/>Year (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Rentable<br/>Square Feet (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Primary Function(s)</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dunkirk, NY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future Manufacturing Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">El Segundo, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 &#8211; 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory &#8211; Research &amp; Manufacturing</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisville, CO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory &#8211; Research</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Culver City, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Month to Month</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory &#8211; Research &amp; Manufacturing</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory &#8211; Research &amp; Corporate Office</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Woburn, MA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory &#8211; Research &amp; Office</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seattle, WA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory &#8211; Research</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 &#8211; 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory &#8211; Research &amp; Office</span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:3.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expiration years shown are per the lease agreements in effect as of December&#160;31,&#160;2023 and do not reflect contractual options to extend the term of the lease available to us under the lease agreements. For locations with multiple leases, the first and last expiration year are shown.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts shown represent the total approximate rentable square feet for all buildings located in each city.</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities are adequate to meet our current and future needs and that we will be able to renew existing leases and obtain additional commercial space as needed.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. &#160;&#160;&#160;&#160;LEGAL PROCEEDINGS.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shenzhen Beike Biotechnology Co. Ltd. Arbitration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement (standstill agreement) under which, among other things, the parties affirmed they will perform certain of their obligations under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement could be terminated by any party on ten&#160;calendar days&#8217; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We served an Answer and Counterclaims on May&#160;19,&#160;2023. Beike served a Reply to our counterclaims on June&#160;21,&#160;2023. Beike&#8217;s Statement of Claim is due on March&#160;22,&#160;2024, and the company&#8217;s Statement of Defense and Counterclaim is due on June&#160;21,&#160;2024. The hearing in the arbitration is scheduled to begin on June&#160;9,&#160;2025. Given that no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims asserted against the company lack merit and intend to defend the case, and to pursue our counterclaims, vigorously.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;30,&#160;2023, a putative securities class action complaint, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salzman v. ImmunityBio, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No.&#160;3:23-cv-01216-BEN-WVG, was filed in the U.S.&#160;District Court for the Southern District of California against the company and three&#160;of its officers and/or directors, asserting violations of Sections&#160;10(b) and 20(a) of the Exchange Act. Stemming from the company&#8217;s disclosure on May&#160;11,&#160;2023 that it had received an FDA CRL stating, among other things, that it could not approve the company&#8217;s BLA for its product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, in its present form due to deficiencies related to its pre-license inspection of the company&#8217;s third-party CMOs, the complaint alleges that the defendants had previously made materially false and misleading statements and/or omitted material adverse facts regarding its third-party clinical manufacturing organizations and the prospects for regulatory approval of the BLA. On September&#160;27,&#160;2023, the court appointed a lead plaintiff, approved their selection of lead counsel, and re-captioned the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. ImmunityBio, Inc. Securities Litigation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No.&#160;3:23-cv-01216. On November&#160;17,&#160;2023, lead plaintiff filed an amended complaint, which named the same defendants and asserted the same claims as the previous complaint. On January&#160;8, 2024, defendants filed a motion to dismiss the amended complaint. A hearing on the motion is currently scheduled for April&#160;23,&#160;2024. The company believes the lawsuit is without merit and intends to defend the case vigorously. The company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in this action. If an unfavorable outcome were to occur, it is possible that the impact could be material to the company&#8217;s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience, LLC, and NantCell, Inc. Matters Against Dr. Hing Wong and HCW Biologics, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;23,&#160;2022, Altor and NantCell filed an arbitration demand against Dr.&#160;Hing Wong, former CEO of Altor and NantCell. The demand asserts claims for breach of Dr.&#160;Wong&#8217;s contracts with the companies, breach of the covenant of good faith and fair dealing, conversion, fraudulent concealment, unjust enrichment, breach of fiduciary duty, and replevin. The same day, Dr.&#160;Wong filed an arbitration demand seeking a declaratory judgment finding that Dr.&#160;Wong is not liable to Altor or NantCell for any of their claims. The parties have agreed to consolidate the arbitration filings in one proceeding, and on January&#160;23,&#160;2023, Dr.&#160;Wong filed an Answering Statement denying the claims.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on December&#160;23,&#160;2022 Altor and NantCell filed a complaint in the United States District Court for the Southern District of Florida against HCW, Dr.&#160;Wong&#8217;s new company. Altor&#8217;s and NantCell&#8217;s complaint asserts claims for misappropriation of trade secrets under both Florida and federal law, inducement of breach of contract, tortious interference with contractual relations, inducement of breach of fiduciary duty, conversion, unjust enrichment, replevin, request for assignment of patents and patent applications, and establishment of a constructive trust. On January&#160;31,&#160;2023, HCW filed motions to compel arbitration of Altor&#8217;s and NantCell&#8217;s claims, or in the alternative to stay or dismiss them. Altor and NantCell filed an opposition to the motions on February&#160;14,&#160;2023, and HCW filed reply papers on February&#160;21,&#160;2023. At a hearing on April&#160;18,&#160;2023, the court heard argument and requested supplemental briefing. After the hearing, the parties reached an agreement to consolidate all claims in a single arbitration proceeding. On May&#160;1,&#160;2023, we filed our arbitration demand asserting the same claims against HCW that were asserted in the federal court complaint. On May&#160;15,&#160;2023, HCW filed an Answering Statement denying the claims. The parties are currently engaged in discovery. The hearing in the consolidated arbitration is scheduled to begin on May&#160;20,&#160;2024.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_67"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded under the ticker symbol &#8220;IBRX&#8221; on the Nasdaq Global Select Market.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;14,&#160;2024, there were approximately 91&#160;stockholders of record of our common stock. The actual number of stockholders is greater than the number of record holders and includes stockholders who are beneficial owners but whose shares are held in &#8220;street name&#8221; by brokers and other nominees. The number of stockholders of record also does not include stockholders whose shares may be held in trust or by other entities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock for the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as the Board of Directors may consider relevant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule&#160;14A in connection with our Proxy Statement, which is expected to be filed not later than 120&#160;days after the end of our fiscal year ended December&#160;31,&#160;2023, and is incorporated herein by reference.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total return on our common stock, the Russell&#160;2000 Index, and the Nasdaq&#160;Biotechnology Index over the five-year period ending December&#160;31,&#160;2023. The graph assumes that $100 was invested on December&#160;31,&#160;2018 in our common stock or the comparative indices, including reinvestment of dividends. The returns shown are based on historical results and are not indicative of, or intended to forecast, future performance of our common stock or the comparative indices. This performance graph shall not be deemed filed for purposes of Section&#160;18 of the Exchange Act or incorporated by reference into any filing of ImmunityBio, Inc. under the Securities Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Among ImmunityBio, Inc., the Russell 2000 Index</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">and the Nasdaq Biotechnology Index</span></div><div style="margin-top:12pt;text-align:center"><img src="ibrx-20231231_g3.jpg" alt="3253" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:690px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No shares of our common stock were repurchased during the three&#160;months&#160;ended December&#160;31,&#160;2023 under the 2015&#160;Share Repurchase Program. As of December&#160;31,&#160;2023, $18.3&#160;million remained authorized to use for share repurchases under the program. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">Note&#160;13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Stockholders&#8217; Deficit,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding the 2015&#160;Share Repurchase Program.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. &#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. </span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_76"></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the description of our business that appears in Part&#160;I, Item&#160;1. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_16">Business</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; and the consolidated financial statements and related notes thereto in Part&#160;II, Item&#160;8. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_127">Financial Statements and Supplementary Data</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; of this Annual Report. This discussion contains forward-looking statements as a result of many factors, including those set forth under Part&#160;I, Item&#160;1.&#160;&#8220;Business&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_19">Forward-Looking Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; and Item&#160;1A. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_49">Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,&#8221; and elsewhere in this Annual Report. These statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Actual results could differ materially from those discussed in or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Part&#160;I, Item&#160;1A. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_49">Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#8221; Except as required by law, we do not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any document, whether as a result of new information, future events, or otherwise. </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Using our proprietary platforms that amplify both the innate and adaptive branches of the immune system, our teams of clinical, scientific, and manufacturing experts, advance novel therapies and vaccines aimed at defeating urologic and other cancers, as well as infectious diseases. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations and is currently under review by the FDA for treatment in combination with BCG of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease and has a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including&#8212;NK cells, dendritic cells, and macrophages, as well as&#8212;the adaptive immune system comprising&#8212;B&#160;and T&#160;cells,&#8212;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally-infected. Our ultimate goal is to overcome the limitations of current treatments, such as checkpoint inhibitors, and/or reduce the need for standard high-dose chemotherapy in cancer by employing this coordinated approach to establish &#8220;immunological memory&#8221; that confers long-term benefit for the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary platforms for the development of biologic product candidates include: (i)&#160;antibody-cytokine fusion proteins, (ii)&#160;DNA, RNA, and recombinant protein vaccines, and (iii)&#160;cell therapies. These platforms have generated 9&#160;novel therapeutic agents for which clinical trials are either underway or planned in solid and liquid tumors. Specifically, our clinical focus includes bladder, lung, and colorectal cancers and GBM, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. In May&#160;2022, we announced the submission of a BLA to the FDA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. The CRL did not request new preclinical studies or Phase&#160;III clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company&#8217;s resubmission, as well as a safety update. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. As part of our resubmission, we provided an update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG unresponsive subjects with high-risk CIS disease. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further late-stage efforts for Anktiva are in development within the broader bladder cancer space, including BCG-na&#239;ve NMIBC. In addition, data from multiple clinical trials suggests N-803 has potential to enhance the activity of therapeutic mAbs, including checkpoint inhibitors (e.g., pembrolizumab/Keytruda), across a wide range of tumor types. We believe there is potential for N-803 to become a therapeutic foundation across all phases of treatment, including in adjunctive therapy, to amplify, reactivate or extend the efficacy of standard of care. In addition to N-803, we have active clinical programs evaluating therapeutic candidates from our DNA and RNA vaccine technology platforms and our NK&#160;cell-based therapy platforms in oncology and infectious disease indications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing, less certain transaction expenses. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including following the receipt of approval by the FDA of the company&#8217;s BLA for N-803 in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease on or before June&#160;30,&#160;2024. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $10.0&#160;million of our common stock at $4.1103&#160;per share in a private placement. Oberland also has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;21,&#160;2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NantKwest and NantCell entered into the Merger Agreement, pursuant to which NantKwest and NantCell agreed to combine their businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell, with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;9,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the Effective Time), each share of NantCell common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $0.001&#160;per share, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically using the Exchange Ratio into newly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued shares of Company Common Stock, with cash paid in lieu of any fractional shares.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, RSU or warrant to purchase NantCell common stock was converted using the Exchange Ratio into an option, RSU or warrant, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Effective Time, the former stockholders of NantCell held approximately 71.5%&#160;of the outstanding shares of Company Common Stock and the stockholders of NantKwest as of immediately prior to the Merger held approximately 28.5%&#160;of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Chairman and Global Chief Scientific and Medical Officer,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and his affiliates beneficially owned, in the aggregate, approximately 81.8%&#160;of the outstanding shares of Company Common Stock. Following the consummation of the Merger, the symbol for shares of the company&#8217;s common stock was changed to &#8220;IBRX.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.0&#160;million of costs </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the Merger consisting of financial advisory, legal and other professional fees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Treatment of the Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger represents a business combination pursuant to FASB ASC Topic&#160;805-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mergers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC&#160;805-50), which was accounted for as a transaction between entities under common control as Dr.&#160;Soon&#8209;Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We recast our prior period financial statements for the year ended December&#160;31,&#160;2021 to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the consolidated financial statements presented in Part&#160;II, Item&#160;8. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_127">Financial Statements and Supplementary Data</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of this Annual Report. All material intercompany accounts and transactions have been eliminated in consolidation.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a public health and economic challenge around the world. Through the date of this Annual Report, we have not seen a material adverse impact to our business from the pandemic. However, given the continuously evolving nature of the pandemic, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the impact of COVID-19 on our business, including our clinical trials, manufacturing facilities and capabilities, and ability to access necessary resources. For a discussion of the risks presented by the COVID-19 pandemic to our results of operations and financial condition, see Part&#160;I, Item&#160;1A. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_49">Risk Factors.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Results</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Annual Report, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. We have incurred net losses in each year since our inception and, as of December&#160;31,&#160;2023, we had an accumulated deficit of $3.0&#160;billion. During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> years ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31,&#160;2023, 2022 and 2021, net losses attributable to ImmunityBio common stockholders were $583.2&#160;million, $416.6&#160;million, and $346.8&#160;million, respectively. Substantially all of our net losses resulted principally from costs incurred in connection with our ongoing clinical trials and operations, our research and development programs, and from selling, general and administrative costs associated with our operations, including stock-based compensation expense. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, we had 628&#160;employees. Personnel of related companies who provide corporate, general and administrative, certain research and development, a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other support services under our shared services agreement with NantWorks are not included in this number. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information. In anticipation of the commercialization of select drug candidates, we expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. See &#8220;&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idc92d124152645ee9f76a518f486ff29_28076">Future Funding Requirements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below for a discussion of our anticipated expenditures and sources of capital we expect to access to fund these expenditures.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that strategic collaborations will continue to be an integral part of our operations, providing opportunities to leverage our partners&#8217; expertise and capabilities to gain access to new technologies and further expand the potential of our technologies and product candidates across relevant platforms. We believe we are well positioned to become a leader in immunotherapy due to our broad and vertically-integrated platforms and through complementary strategic partnerships.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our innovative approach to orchestrate and combine therapies for optimal immune system response will become a therapeutic foundation across multiple indications. Additionally, we believe that data from multiple clinical trials indicates N-803 has broad potential to enhance the activity of therapeutic mAbs, including checkpoint inhibitors, across a wide range of tumor types. We may also enter into supply arrangements for various investigational agents to be used in our clinical trials. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_184">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements and Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding our collaboration and license agreements.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreements with Related Parties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. We have entered into arrangements with NantWorks, and certain affiliates of NantWorks. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman and Global Chief Scientific and Medical Officer.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Debt</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion of the company&#8217;s related-party promissory notes does not purport to be complete and is qualified in its entirety by reference to the full text of the notes, copies of which are incorporated by reference in Part&#160;IV, Item&#160;15. </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_277">&#8220;Exhibits and Financial Statement Schedules&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Promissory Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC (collectively, the &#8220;related-party purchasers&#8221;), which are entities affiliated with Dr.&#160;Soon-Shiong, pursuant to which the related-party purchasers exchanged outstanding fixed-rate promissory notes held by such related-party purchasers, representing approximately $270.0&#160;million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936&#160;shares of common stock at an exchange price of $1.29&#160;per share. As a result of the exchange, the company is forever released and discharged from all its obligations and liabilities under these notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company executed a $200.0&#160;million convertible promissory note with Nant&#160;Capital. The note bears interest at Term&#160;SOFR plus&#160;8.0%&#160;per annum. The accrued interest shall be payable monthly commencing on September&#160;30,&#160;2023. The outstanding principal amount and any accrued and unpaid interest are due on the earlier of (i)&#160;September&#160;11,&#160;2026 or (ii)&#160;upon the occurrence and during the continuance of an &#8220;event of default&#8221; (as defined in the note). We&#160;may prepay the outstanding principal amount, together with any accrued interest, at any time, in whole or in part, without premium or penalty upon five&#160;(5) days&#8217; written notice to the noteholder. The noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $1.9350&#160;per share. We received net proceeds of approximately $199.0&#160;million from this financing, net of a $1.0&#160;million origination fee paid to the noteholder. On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into a letter amendment whereby this promissory note became subordinated to the RIPA payment obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Convertible Note at Fair Value</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital. This note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum. The outstanding principal amount and any accrued and unpaid interest are due on the earlier of December&#160;31,&#160;2023 or upon the occurrence and continuation of an event of default (as defined in the note). The interest on this note is paid on a quarterly basis beginning on June&#160;30,&#160;2023. The company may prepay the outstanding principal amount and any accrued and unpaid interest of the promissory note, at any time, in whole or in part, without penalty. Upon receipt of a written notice of prepayment from the company, the noteholder has the right, at its option, to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon (as specified in the notice of prepayment) into shares of the company&#8217;s common stock at a price of $2.28&#160;per share. Additionally, the whole promissory note and any accrued interest may be converted into shares of the company&#8217;s common stock at a conversion price of $2.28&#160;per share (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event), at the option of the noteholder. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of approximately $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the noteholder, which we used, together with other available funds, to progress our pre-commercialization efforts and clinical development programs, to fund other research and development activities, for capital expenditures, and for other general corporate purposes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of this promissory note was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of this promissory note was extended to December&#160;31,&#160;2025, and the note became subordinated to the RIPA payment obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note was accounted for under the ASC&#160;825-10-15-4 FVO election </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until it was amended on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023. Under the FVO&#160;election, the note was initially measured at its issuance date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. With each such remeasurement, the note was adjusted to fair value, with the change in fair value recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Nonconvertible Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;13,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital. The company was able to request up to three&#160;(3) advances of $10.0&#160;million each pursuant to the note. The principal amount of each advance bears interest at Term&#160;SOFR plus 8.0%&#160;per annum. The accrued interest on any advance is payable quarterly on the last business day of June, September and December. The outstanding principal amount and any accrued and unpaid interest on advances were due on the earlier of (i)&#160;December&#160;31,&#160;2023 or (ii)&#160;upon the occurrence and during the continuance of an event of default (as defined in the note). We may prepay the outstanding principal amount, together with any accrued interest, on any then-outstanding advances, at any time, in whole or in part, without premium or penalty, and without the prior consent of the noteholder, upon five&#160;(5)&#160;days written notice to the noteholder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of approximately $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to Nant&#160;Capital, which we used, together with other available funds, to progress our regulatory approval efforts, pre-commercialization activities and clinical development programs, to fund other research and development activities, for capital expenditures, and for other general corporate purposes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a series of letter agreements pursuant to which the maturity date of related-party nonconvertible promissory notes totaling $505.0&#160;million in principal were extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing $30.0&#160;million promissory note, along with other existing related-party nonconvertible promissory notes, was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note. The Tranche&#160;2 of the promissory note has a principal amount of $380.0&#160;million, a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Based on the terms of the amended and restated promissory note, the noteholder, at its sole discretion, may convert all of the $380.0&#160;million principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. The new note became subordinated to the RIPA payment obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding our related-party debt.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mmuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple agreements with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Clinic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. While we have not yet finalized the potential transition, we continue discussions with potential partners around such alternative structures. During</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023, 2022 and 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recorded $2.2&#160;million, $2.4&#160;million and $1.6&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations related to clinical trial and transition services provided by the Clinic.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">605 Doug St, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2023, we exercised the option to extend the lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for one&#160;additional three-year term through July&#160;2026. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">23 Alaska, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August&#160;31, 2023, we executed a lease termination agreement with 23&#160;Alaska,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duley Road, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October&#160;3, 2023, we exercised the first option to extend the lease agreement with Duley Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for one&#160;additional five-year term through October&#160;31, 2029. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding our related-party agreements.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Annual Report, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally classify our operating expenses into research and development, and selling, general and administrative expenses. Personnel costs, including salaries, benefits, bonuses, and stock-based compensation expense comprise a significant component of our research and development, and selling, general and administrative expense categories. We allocate expenses associated with our facilities and information technology costs between these two&#160;categories, primarily based on the nature of each cost.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our technology and product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory submissions for product candidates. We recognize research and development expenses as they are incurred. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses primarily consist of:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial and regulatory-related costs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under collaborative agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and testing costs and related supplies and materials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and stock-based compensation; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility expenses dedicated to research and development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classifies its research and development expenses as either external or internal. The&#160;company&#8217;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#8217;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#8217;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase significantly for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates and conducting our ongoing and planned clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of sites included in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the countries in which the clinical trials are conducted;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients that participate in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of comparative agents used in clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration of patient follow-up; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety profile and efficacy of the product candidate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only one product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, for which we submitted a BLA to the FDA in May&#160;2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. There can be no assurance that our product candidate will be approved for commercial sale by the FDA in the near term, if ever. We do not expect any of our other product candidates to be commercially available for the foreseeable future, if ever. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation, for employees performing functions other than research and development. This includes personnel in executive, finance, human resources, information technology, legal, and administrative support functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for auditing, tax and legal services, advertising costs, expenses associated with strategic business transactions and business development efforts, obtaining and maintaining patents, consulting costs, royalties and licensing costs, and costs of our information systems.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our selling, general and administrative expense will increase for the foreseeable future as we expand operations, build out information systems and increase our headcount to support continued research activities and the development of our clinical programs. We have incurred and expect that we will continue to incur in the future, additional costs associated with operating as a public company, including costs to comply with stock exchange listing and SEC requirements, future funding efforts, corporate governance, internal controls, investor relations, disclosure and similar requirements applicable to public companies. Additionally, if and when we believe that a regulatory approval of a product candidate appears likely, we expect to incur significant increases in our selling, general and administrative expense relating to the sales and marketing of the approved product candidate.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists primarily of interest and investment income, interest expense (including amortization of debt discounts), unrealized gains and losses from investments in equity securities and equity-method investments, changes in fair value of warrants, derivative liabilities, and a convertible note, realized gains and losses on debt and equity securities, and gains and losses on foreign currency transactions.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California and other states. From inception through December&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated NOLs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Consolidated Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31,&#160;2023 and 2022</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (including amounts<br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (including amounts<br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,872&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,538&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,334&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362,250)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351,298)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,952)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and investment income (loss), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (including amounts with related parties)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,060)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net (including amounts <br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,642)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,988)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,654)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes and noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(583,892)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,286)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,606)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(583,852)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,320)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,532)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $0.4&#160;million during the year ended December&#160;31,&#160;2023, as compared to the year ended December&#160;31,&#160;2022. The increase was primarily driven by higher grant revenue received in 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased $15.8&#160;million during the year ended December&#160;31,&#160;2023, as compared to the year ended December&#160;31,&#160;2022. The following table summarizes our research and development expenses during the years ended December&#160;31,&#160;2023 and 2022, together with the changes in those items (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, depreciation, and facility costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total internal research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,154&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,036&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,882)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,783)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased $15.8&#160;million primarily attributable to the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A $5.1&#160;million increase in external research and development expenses that was primarily due to higher qualification and testing costs, pre-licensing inspection costs, and outside consulting fees relating to regulatory and compliance services for the resubmission of the BLA, partially offset by a decrease in clinical trial costs and initial BLA submission fees;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A $7.3&#160;million decrease in personnel-related costs that was primarily due to the write off of accrued discretionary bonuses for 2022 not paid and a reduction in headcount, partially offset by an increase in stock-based compensation costs associated with new retention awards granted to existing employees; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A $2.1&#160;million decrease in equipment, depreciation, and facility costs that was primarily due to a reduction in activities related to facility expansion that occurred in the prior year, which resulted in lower expenditures for equipment qualification and certification, as well as lower expenses for sanitary services, partially offset by higher equipment maintenance costs; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An $11.5&#160;million decrease in other research and development costs, primarily attributable to reductions in laboratory and test supplies and material supplies used for internal manufacturing, and no impairment costs from long-lived assets in the current year compared to the prior year, as well as an increase in collaboration costs allocated to a joint venture. Additionally, the write down of right-of-use assets from a lease used for R&amp;D contributed to an additional decrease in other R&amp;D expenses. The reduction in costs were partially offset by higher R&amp;D activities and increased costs related to R&amp;D licenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase significantly for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates and conducting our ongoing and planned clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense increased $26.9&#160;million during the year ended December&#160;31,&#160;2023, as compared to the year ended December&#160;31,&#160;2022. The rise in expenses was primarily due to a $28.9&#160;million increase in legal expenses, which was driven by higher defense costs and general legal services, as well as fewer legal insurance reimbursements received compared to the prior year. Additionally, there was a $1.1&#160;million increase in personnel-related costs resulting from higher stock-based compensation expenses and travel costs, a $0.6&#160;million increase in IT and security license fees, and a $0.2&#160;million increase in marketing costs for pre-commercialization activities. These increases were partially offset by a $2.7&#160;million reduction in consulting services from ERP implementations and professional fees from accounting and tax services, and a $1.2&#160;million reduction in insurance expenses and other operating costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of intangible assets increased $0.2&#160;million during the year ended December&#160;31,&#160;2023, compared to the year&#160;ended December&#160;31,&#160;2022, due to an impairment charge of $0.9&#160;million related to indefinite-lived intangible assets associated with the Tarmogen platform as the research and development program was limited in the current year. The $0.7&#160;million write off of the organized workforce with definite lives during 2022 was as a result of the workforce reduction at the Dunkirk Facility.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net increased $155.7&#160;million during the year ended December&#160;31,&#160;2023, as compared to the year ended December&#160;31,&#160;2022, due to a $65.7&#160;million increase in interest expense driven by higher related-party borrowings, an increase in the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term&#160;SOFR</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> rate, and higher amortization of related-party notes discounts. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there was a total increase in expense of $97.3&#160;million driven by the change in the fair value of warrant liabilities and the change in the fair value of a related-party convertible note, and a $1.5&#160;million increase in expense due to higher issuance costs associated with our registered direct offerings, and an increase in other expenses. These changes were partially offset by a $4.6&#160;million lower loss on equity method investments and a $4.2&#160;million increase in investment income. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31,&#160;2022 to 2021</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item 7. &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our Annual Report filed with the SEC on March&#160;1,&#160;2023 for a discussion of the company&#8217;s results of operations during the year ended December&#160;31,&#160;2022 compared to the year ended December&#160;31,&#160;2021.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have funded our operations primarily through proceeds from the issuance of related-party promissory notes and sales of our common stock under the ATM and our shelf registration statement, and through registered direct offerings. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA to support the commercialization of Anktiva for the treatment of BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, the further development of our other product platforms, and to provide for other working capital needs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Marketable Securities on Hand</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, we had cash and cash equivalents, and marketable securities of $267.4&#160;million compared to $108.0&#160;million as of December&#160;31,&#160;2022. We have typically invested our cash in a variety of financial instruments and classified these investments as available-for-sale. However, after our entry into the RIPA we can no longer invest our excess funds in corporate or European bonds. Certain of our investments are subject to credit, liquidity, market, and interest-rate risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from the ATM</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we received net proceeds of approximately $16.1&#160;million from the issuance of 5,605,323&#160;shares under the&#160;ATM. We used the net proceeds from this offering, together with other available funds, to progress our regulatory approval efforts, pre-commercialization activities and clinical development programs, to fund other research and development activities, for capital expenditures, and for other general corporate purposes. As of December&#160;31,&#160;2023, we had $208.8&#160;million available for future stock issuances under the&#160;ATM.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February&#160;2023, we filed a $750.0&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. During the year ended December&#160;31,&#160;2023, we sold shares of our common stock and warrants valued at $184.4&#160;million under the shelf. As of December&#160;31,&#160;2023, we had $565.6&#160;million available for use under the shelf. This available shelf is in addition to the ATM. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceeds from Registered Direct Offerings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15,&#160;2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,072,615&#160;shares of our common stock, as well as warrants (the February&#160;2023 Warrants) that allow such investors to purchase an additional 14,072,615&#160;shares of common stock at an exercise price of $4.2636&#160;per share, for a purchase price of $3.5530&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other offering costs. Pursuant to the terms of a letter agreement dated July&#160;25,&#160;2023, the company and the investors agreed to reduce the exercise price of the outstanding February&#160;2023 Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extend the expiration date of the warrants until July&#160;24,&#160;2026. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;20, 2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,569,296&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,569,296&#160;shares of common stock at an exercise price of $3.2946&#160;per share, for a purchase price of $2.7455&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $37.5&#160;million, after deducting placement agent fees and other offering costs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the net proceeds from these registered direct offerings, together with other available funds, to progress our regulatory approval efforts, pre-commercialization activities and clinical development programs, to fund other research and development activities, for capital expenditures, and for other general corporate purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Promissory Notes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the noteholders exchanged promissory notes totaling approximately $270.0&#160;million in aggregate principal amount and accrued and unpaid interest for an aggregate of 209,291,936&#160;shares of common stock at an exchange price of $1.29&#160;per share. As a result of the exchange, the company was forever released and discharged from all its obligations and liabilities under the notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a series of letter agreements pursuant to which the maturity date of the related-party nonconvertible notes described above totaling $505.0&#160;million in principal was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. In addition, the company entered into a $200.0&#160;million September&#160;2023 promissory note with Nant&#160;Capital. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note and a letter amendment for the following outstanding promissory notes. Pursuant to the terms of the amended and restated promissory note, the amended $505.0&#160;million December&#160;2023 promissory note is comprised of a Tranche&#160;1 principal amount of $125.0&#160;million, which was previously the $125.0&#160;million August&#160;2022 promissory note before amendment, and a Tranche&#160;2 with principal amount of $380.0&#160;million, which is made up of the previous $300.0&#160;million December&#160;2021 promissory note, $50.0&#160;million December&#160;2022 promissory note, and $30.0&#160;million June&#160;2023 promissory note. In addition, the amendment allows Nant&#160;Capital, in its sole discretion, to convert all the Tranche&#160;2 principal amount of $380.0&#160;million of the amended promissory note into shares of the company&#8217;s common stock. The conversion price was determined subsequently at $8.2690&#160;per share based on the agreement. The maturity date of the amended promissory note is December&#160;31,&#160;2025. Pursuant to the terms of the letter amendment, the maturity date of the $30.0&#160;million March&#160;2023 promissory note was extended from December&#160;31,&#160;2024 to December&#160;31,&#160;2025. Also, in connection with the RIPA transaction, all outstanding related-party promissory notes became subordinated to the RIPA payment obligations. After the amendment, the interest rates for the Tranche&#160;1 principal amount and Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note were Term&#160;SOFR plus&#160;8.0% and Term&#160;SOFR plus&#160;7.5%, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding our related-party debt.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing, less certain transaction expenses. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including following the receipt of approval by the FDA of the company&#8217;s BLA for N-803 in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease on or before June&#160;30,&#160;2024. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $10.0&#160;million of our common stock at $4.1103&#160;per share in a private placement. Oberland also has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uses of Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the cash used to fund our operating activities discussed in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#idc92d124152645ee9f76a518f486ff29_28076">&#8212;Future Funding Requirements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below, we will require cash to settle the following obligations:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December&#160;31,&#160;2023, our indebtedness payable at maturity totaled $735.0&#160;million (excluding unamortized related-party notes discounts), held by entities affiliated with Dr.&#160;Soon-Shiong. In connection with the RIPA, all of our related-party promissory notes are now general unsecured obligations of the company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the RIPA, the Revenue Interests issued pursuant to such agreement, and refinancing of the foregoing. In addition, the terms of promissory notes totaling $535.0&#160;million were amended and restated to extend the maturity date by one&#160;year to December&#160;31,&#160;2025. The remaining $200.0&#160;million promissory note and any accrued and unpaid interest are due on the earlier of (i)&#160;September&#160;11,&#160;2026 or (ii)&#160;upon the occurrence and during the continuance of an event of default (as defined in the note). </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Pursuant to the terms of the amended and restated promissory note, the amended $505.0&#160;million December&#160;2023 promissory note is comprised of the Tranche&#160;1 principal amount of $125.0&#160;million and the Tranche&#160;2 principal amount of $380.0&#160;million. All Tranche&#160;2 principal amount of $380.0&#160;million and any accrued and unpaid interest can be converted into shares of the company&#8217;s stock at $8.2690&#160;per share at the option of the noteholder. The interest rates for the Tranche&#160;1 principal amount and Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note were Term&#160;SOFR plus 8.0%&#160;per annum and Term&#160;SOFR plus 7.5%&#160;per annum, respectively. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The $200.0&#160;million convertible promissory note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum. The noteholder has the sole option to convert all of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $1.9350&#160;per share. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The $30.0&#160;million convertible promissory note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum. The noteholder has the sole option to convert all of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $2.28&#160;per share.</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the company can refinance these promissory notes or what terms will be available in the market at the time of refinancing. Furthermore, if prevailing interest rates or other factors at the time of refinancing result in higher interest rates upon refinancing, then the interest expense relating to the refinanced indebtedness would increase. These risks could materially adversely affect the company&#8217;s financial condition, cash flows and results of operations.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we entered into the RIPA with Infinity and Oberland. Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, our worldwide net sales, excluding those in China, which will be tiered payments initially ranging from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.00%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.00%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (or after funding of the Second Payment, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.50%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.00%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), subject to increase or decrease, following </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2029</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the Test Date) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depending on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether our aggregate payments made to Oberland as of the Test Date have met or exceeded the Cumulative Purchaser Payments. In addition, if our aggregate payments made as of the Test Date to Oberland do not equal or exceed the amount of the Cumulative Purchaser Payments as of such date, then we are obligated to make a one-time True-Up Payment to Oberland in an amount equal to 100% of the Cumulative Purchaser Payments as of the Test Date, less the aggregate amount of our previous payments to Oberland as of the Test Date. See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note 9</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding the RIPA.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. As of December&#160;31,&#160;2023, Dr.&#160;Soon-Shiong and his related party hold approximately $139.8&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. We may need to seek additional sources of capital to satisfy the CVR obligations if they are achieved.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with our acquisition of VivaBioCell, we are obligated to pay the former owners approximately $2.2&#160;million of contingent consideration upon the achievement of a regulatory milestone relating to the GMP-in-a-Box technology.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Consolidated Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion of ImmunityBio&#8217;s cash flows is based on the consolidated statements of cash flows in Part&#160;II,&#160;Item 8. &#8220;Financial Statements and Supplementary Data&#8221; and is not meant to be an all&#8209;inclusive discussion of the changes in its cash flows for the years presented below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our primary sources and uses of cash for the years indicated (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects of exchange rate changes on cash, cash equivalents, <br/>&#160;&#160;&#160;and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,822&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,315)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, net cash used in operating activities of $366.8&#160;million consisted of a net loss of $583.9&#160;million, partially offset by $213.1&#160;million in adjustments for non-cash items and $3.9&#160;million of cash provided by net working capital. Adjustments for non-cash items primarily consisted of $49.2&#160;million in stock-based compensation expense, $47.6&#160;million in change in fair value of warrant liabilities, $42.4&#160;million in amortization of debt issuance costs and accretion of discounts, $36.2&#160;million in change in fair value of convertible notes, $18.5&#160;million in depreciation and amortization expense, $9.2&#160;million in non-cash interest primarily related to related-party promissory notes, $6.1&#160;million in non-cash lease expense related to operating lease right&#8209;of&#8209;use assets, $2.0&#160;million of transaction costs allocable to warrant liabilities, $1.6&#160;million in unrealized losses on equity securities driven by a decrease in the value of our investments, $0.9&#160;million in loss on impairment of intangible assets, partially offset by $0.5&#160;million in other items, and a decrease of $0.1&#160;million in amortization of premiums, net of discounts on marketable debt securities. The changes in net working capital consisted primarily of an increase of $6.7&#160;million in accrued expenses, a decrease of $5.9&#160;million in prepaid expenses and other current assets, and a decrease of $1.9&#160;million in other assets, partially offset by a decrease of $6.5&#160;million in accounts payable, a decrease of $3.0&#160;million in operating lease liabilities, and a decrease of $1.1&#160;million in due to related parties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, net cash used in operating activities of $337.5&#160;million consisted of a net loss of $417.3&#160;million and $8.0&#160;million of cash used in net working capital, partially offset by $87.8&#160;million in adjustments for non-cash items. The changes in net working capital consisted primarily of an increase of $16.6&#160;million in prepaid and other current assets, and decreases of $4.3&#160;million in operating lease liabilities and $1.2&#160;million with related parties, partially offset by an increase of $8.0&#160;million in accounts payable, an increase of $4.1&#160;million in accrued expenses and other liabilities, and a decrease of $2.0&#160;million in investment and other assets. Adjustments for non-cash items primarily consisted of $40.2&#160;million in stock-based compensation expense, $18.3&#160;million in depreciation and amortization expense, $16.3&#160;million in amortization of debt issuance costs and accretion of discounts, $11.7&#160;million in non-cash interest primarily related to related-party promissory notes, $5.9&#160;million in non&#8209;cash lease expense related to operating lease right-of-use assets, $4.2&#160;million in unrealized losses on equity securities driven by a decrease in the value of our investments, $1.3&#160;million in loss on impairment of fixed assets, $1.3&#160;million in amortization of premiums, net of discounts, on marketable debt securities, $1.1&#160;million in transaction costs allocable to a warrant liability, a non-cash $0.7&#160;million loss on the impairment of intangible assets, and $0.3&#160;million in other non-cash items, reduced by a $13.5&#160;million change in fair value of a warrant liability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically experienced negative cash flows from operating activities, with such negative cash flows likely to continue for the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, net cash used in investing activities was $30.5&#160;million, which included cash outflows of $30.6&#160;million in purchases of property, plant and equipment (including construction in progress and the completion of a warehouse facility), and $10.4&#160;million in purchases of marketable debt securities, partially offset by cash inflows of $10.5&#160;million from maturities and sales of marketable debt and equity securities. Our investments in property, plant and equipment are primarily related to acquisitions of equipment that will be used for the manufacturing of our product candidates and expenditures related to the build out of our manufacturing facilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, net cash provided by investing activities was $27.3&#160;million, which included cash inflows of $162.0&#160;million from maturities and sales of marketable debt and equity securities, partially offset by $78.2&#160;million of purchases of property, plant and equipment (including construction in progress and depreciable property acquired in the Dunkirk acquisition), $34.3&#160;million of purchases of marketable debt securities, $21.2&#160;million for purchase of intangible assets (related to the Dunkirk acquisition), and a $1.0&#160;million investment in a joint venture. Our investments in property, plant and equipment are primarily related to acquisitions of equipment that will be used for the manufacturing of our product candidates and expenditures related to the build out of our manufacturing facilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to accelerate our capital spending as we scale our cGMP&#160;manufacturing capabilities, which will require significant capital for the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, net cash provided by financing activities was $558.3&#160;million, which consisted of $258.7&#160;million in net proceeds from issuances of related-party promissory notes, $192.8&#160;million in net proceeds from payments received pursuant to the RIPA, $84.4&#160;million in net proceeds from registered direct offerings, $16.1&#160;million in net proceeds from the ATM offering, $9.5&#160;million in net proceeds from issuance of common stock in connection with the RIPA, and $0.3&#160;million in proceeds from the exercise of stock options, partially offset by $3.4&#160;million used for payment of payroll tax withholding in connection with the net share settlement of vested RSUs, and $0.1&#160;million used for principal payments of finance leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2022, net cash provided by financing activities was $233.6&#160;million, which consisted of $174.1&#160;million in net proceeds from issuances of related-party promissory notes, $47.3&#160;million in net proceeds from a registered direct offering, and $13.1&#160;million in net proceeds from the ATM offering, partially offset by $0.6&#160;million related to net share settlement of vested RSUs for payment of payroll tax withholding and a $0.3&#160;million used in other financing activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise additional capital to fund our future cash needs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31,&#160;2022 to 2021</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part&#160;II, Item&#160;7. &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our Annual Report filed with the SEC on March&#160;1,&#160;2023 for a discussion of the company&#8217;s consolidated cash flows for the year ended December&#160;31,&#160;2022 compared to the year ended December&#160;31,&#160;2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span id="idc92d124152645ee9f76a518f486ff29_28076"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through the date of this Annual Report we have generated minimal revenue, we have no clinical products approved for commercial sale, and we have not generated any revenue from therapeutic and vaccine product candidates that are under development. We do not expect to generate significant revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, this will occur. In addition, we expect our operating expenses to significantly increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. We have also incurred and expect that we will continue to incur in the future additional costs associated with operating as a public company as well as costs related to future fundraising efforts. In addition, subject to obtaining regulatory approval of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our operating expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue research and development, including preclinical and clinical development of our existing product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially seek regulatory approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to discover and develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to comply with regulatory standards and laws;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, leverage and expand our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire clinical, manufacturing, scientific and other personnel to support our product candidates&#8217; development and future commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating as a public company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of our common stock that may be issued and sold under the&#160;ATM, of which we had $208.8&#160;million available for future issuance as of December&#160;31,&#160;2023, and a February&#160;2023 shelf registration statement, of which we had $565.6&#160;million available for future offerings as of December&#160;31,&#160;2023), and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility, issue other debt in compliance with the terms of the RIPA, or engage in strategic partnership transactions. However, we may not be able to secure such external financing in a timely manner or on favorable terms, if at all. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we may need additional funds to meet our needs sooner than planned.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our product candidates. Changing circumstances may cause us to increase our spending significantly faster than we currently anticipate and we may need to raise additional funds sooner than we presently anticipate. Moreover, research and development and our operating costs and fixed expenses such as rent and other contractual commitments, including those for our research collaborations, are substantial and are expected to increase in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress, timing, number, scope and costs of researching and developing our product candidates and our ongoing, planned and potential clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">time and cost of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize any product candidates, if approved and the costs of such commercialization activities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue from product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest and principal payments on our related-party promissory notes, and payment of Revenue Interests, the Second Payment and Test Date payments due under the RIPA;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost of building, staffing and validating our own manufacturing facilities in the U.S., including having a product candidate successfully manufactured consistent with FDA and EMA regulations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terms, timing and costs of our current and any potential future collaborations, business or product acquisitions, CVRs, milestones, royalties, licensing or other arrangements that we have established or may establish;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">time and cost necessary to respond to technological, regulatory, political and market developments; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless and until we can generate a sufficient amount of revenues, we may finance future cash needs through public or private equity offerings, license agreements, debt financings, collaborations, strategic alliances and marketing or distribution arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all, including but not limited to the offering, issuance and sale by us of our common stock that may be issued and sold under the ATM.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or equity-linked securities (including warrants), convertible debt or under the&#160;ATM, our shelf registration statement, or other offerings, or if any of our current debt is converted into equity or if our existing warrants are exercised, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of additional indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third&#160;parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">129</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have material cash requirements to pay related-party affiliates and third parties under various contractual obligations discussed below:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are obligated to make payments to several related-party affiliates under written agreements and other informal arrangements. We are also obligated to pay interest and to repay principal under our related-party promissory notes. For&#160;information regarding our financing obligations, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are obligated to make payments to Oberland associated with our revenue interest liability, which do not have a fixed repayment schedule. Oberland&#8217;s right to receive payments under the RIPA shall terminate when Oberland has received maximum payments (including any True-Up Payment) equal to&#160;195.0% of the then Cumulative Purchaser Payments unless the RIPA is terminated prior to such date. </span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, prior to the Test Date, every $100.0&#160;million of worldwide net sales, excluding those in China, of less than or equal to $600.0&#160;million in a calendar year would result in a tiered Revenue Interest Payment of approximately $7.0&#160;million or 7.0% (or $10.0&#160;million or 10.0% after funding of the Second Payment). Worldwide net sales, excluding those in China, for a calendar year exceeding $600.0&#160;million would result in a tiered Revenue Interest Payment of approximately $3.0&#160;million or 3.0% (or $4.5&#160;million or 4.5% after funding of the Second Payment) for every $100.0&#160;million of worldwide net sales, excluding those in China, above the threshold. </span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, cumulative worldwide net sales, excluding those in China, levels up to the Test Date will determine whether or not we are required to make a True-Up Payment and implement modified payment rates. The amount of the obligation and timing of payment is likely to change</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue Interest Purchase Agreement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding the RIPA. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are obligated to make payments under our operating leases, which primarily consist of facility leases. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_199">Note&#160;8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lease Arrangements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appear in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for&#160;information regarding our lease obligations. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with the acquisitions of Altor and VivaBioCell, we are obligated to pay contingent consideration upon the achievement of certain milestones. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_190">Note&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Commitments and Contingencies&#8212;Contingent Consideration Related to Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for information regarding our contingent consideration obligations.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have contractual obligations to make payments to related-party affiliates and third parties under unconditional purchase arrangements. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_190">Note&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Commitments and Contingencies&#8212;Unconditional Purchase Obligations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for information on these unconditional purchase obligations. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have certain contractual commitments that are expected to be paid in fiscal year 2024, depending on the progress of build outs, completion of services, and the realization of milestones associated with third-party agreements. This amounts totals $60.8&#160;million and is primarily related to capital expenditures, open purchase orders as of December&#160;31,&#160;2023 for the acquisition of goods and services in the ordinary course of business, and near-term upfront milestone payments to third parties. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, we have contractual commitments that are expected to be paid in fiscal year 2025 and beyond based on the achievement of various development, regulatory and commercial milestones for agreements with third parties. These payments may not be realized or may be modified and are contingent upon the occurrence of various future events, substantially all of which have a high degree of uncertainty of occurring. As of December&#160;31,&#160;2023, the maximum amount that may be payable related to these commitments is $769.3&#160;million. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In connection with our leasehold interest in the Dunkirk Facility, we committed to spend an aggregate of $1.52&#160;billion on operational expenses during the initial 10-year term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for the additional 10-year term. These amounts are not included in the discussion above. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_184">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements and Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8.&#160;&#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information on these obligations.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. The preparation of consolidated financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, revenue interest liability, preclinical and clinical trial accruals, impairment assessments, CVR measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants and convertible promissory notes, fair value measurements, asset acquisition, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that any ongoing pandemic could have on our significant accounting estimates. Actual results could differ from those estimates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in the notes accompanying our consolidated financial statements that appear in Part&#160;II, Item 8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our consolidated financial statements:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have primarily generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. The nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies grant them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines. We have generated revenues from product sales of our proprietary GMP-in-a-Box bioreactors and related consumables, primarily to related parties. Additionally, we also generated revenues from grant programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreements with customers, we typically promise to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. Research and development data are provided throughout the term of the contract when and if available.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have sold our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies. The arrangements typically include delivery of bioreactors, consumables, and providing installation service and perpetual software licenses for using the equipment. We recognize revenue when customers obtain control and can benefit from the promised goods or services, generally upon installation of the bioreactors, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. Upfront payments and fees are recorded as deferred revenue upon receipt and recognized as revenue when we satisfy our performance obligations under these arrangements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue is typically paid for reimbursable costs incurred over the duration of the associated research project or clinical trial and is recognized either when expenses reimbursable under the grants have been incurred and payments under the grants become contractually due or when cash is received, depending on the certainty of payment and other factors specific to each grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Interest Liability</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter. The RIPA is considered a sale of future revenues and is accounted for as a liability net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability, interest expense, and the time period for repayment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Embedded derivatives that are required to be bifurcated from the underlying debt instrument that do not meet the derivative scope exception and equity classification criteria are accounted for and valued as separate financial instruments. The terms of an embedded derivative related to a contingent exercisable prepayment feature of a convertible note have been evaluated and deemed to require bifurcation. This embedded derivative will be initially measured at fair value and will be remeasured to fair value at each reporting date until the derivative is settled. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains certain features that meet the definition of being an embedded derivative requiring bifurcation as a separate compound financial instrument apart from the RIPA. The derivative liability is initially measured at fair value upon issuance and is subject to remeasurement at each reporting period with changes in fair value recognized in other expense, net, on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing the consolidated financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate clinical trial and research agreement-related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research-related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials costs, including CROs and related clinical manufacturing, including third-party CMOs, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classifies its research and development expenses as either external or internal. The&#160;company&#8217;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#8217;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#8217;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the preclinical studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates. We adjust the accruals in the period when actual costs become known.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC Topic&#160;480, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;480) and FASB ASC Topic&#160;815, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC&#160;815). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indexed to the&#160;company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther expense, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounted for a convertible note issued on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the&#160;FVO&#160;election of ASC&#160;825 until it was amended and restated on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023. Prior to its extinguishment on December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the convertible note was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issuance-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of this convertible note were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations, except that changes in estimated fair value caused by changes in the instrument-specific credit risk were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with ASC&#160;470-50, when the convertible note was extinguished on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the cumulative amount previously recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting from changes in the instrument-specific credit risk were reclassified and reported in current earnings on the consolidated statement of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Modification and Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company evaluates amendments to its debt instruments in accordance with ASC&#160;470-50. This evaluation includes comparing (1)&#160;if applicable, the net present value of future cash flows of the amended debt to that of the original debt and (2)&#160;the change in fair value of an embedded conversion feature to that of the carrying amount of the debt immediately prior to amendment to determine, in each case, if a change greater than 10% occurred. In instances where the net present value of future cash flows or the fair value of an embedded conversion feature, if any, changed more than 10%, the company applies extinguishment accounting. In instances where the net present value of future cash flows and the fair value of an embedded conversion feature, if any, changed less than 10%, the company accounts for the amendment to the debt as a debt modification. Gains and losses on debt amendments that are considered extinguishments are recognized in current earnings or in additional paid-in capital if the transactions are with entities under common control. Debt amendments that are considered debt modifications are accounted for prospectively through yield adjustments, based on the revised terms. The increase in fair value of the embedded conversion feature from the debt modification was accounted for as an increase in debt discount with a corresponding increase in additional paid-in capital. Legal fees and other costs incurred with third parties that are directly related to debt modifications are expensed as incurred. Amounts paid by the company to the lenders, are reflected as additional debt discount and amortized as an adjustment of interest expense over remaining term of modified debt using the effective interest rate method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC&#160;718). We estimate fair value of each stock option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions, including, but not limited to, expected stock price volatility over the term of the awards and the expected term of the stock options. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method of accounting in accordance with ASC&#160;805-50. These standards require that the total cost of acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition, with the excess purchase price recorded as goodwill. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration incurred in connection with a business combination are recorded at their fair values on the acquisition date and re-measured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations and comprehensive income (loss). Changes in fair values reflect changes to our assumptions regarding probabilities of successful achievement of related milestones, the timing in which the milestones are expected to be achieved, and the discount rate used to estimate the fair value of the obligation.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4643e1a07ce0428bbdfe8baf8b53beac_102909">Note&#160;2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the &#8220;Notes to Consolidated Financial Statements&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding recent accounting pronouncements or changes in accounting pronouncements that are of significance, or potential significance, to us.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk for changes in interest rates relates primarily to interest earned on our cash equivalents, investments and variable interest rate debt. The primary objective of our investment activities is to preserve our capital to fund operations. A secondary objective is to maximize income from our investments without assuming significant risk. Our investment policy provides for investments in low-risk, investment-grade debt instruments. As of December&#160;31,&#160;2023, we had $265.5&#160;million in cash and cash equivalents and $1.9&#160;million in our investment portfolio. Our cash equivalents are short-term investments with maturities of 90&#160;days or less at the time of purchase. We maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits. However, we believe that we are not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. As of December&#160;31,&#160;2023, our investment portfolio was comprised of available-for-sale securities, and we did not hold or issue financial instruments for trading purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk &#8211; Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the cash discussed above, our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S&#160;interest rates. However, we do not believe a sudden change in the interest rates would have a material impact on our financial condition or results of operations due to the short-term maturities of our cash equivalents. A hypothetical 100&#160;basis point change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk &#8211; Cash Equivalents and Investment Portfolio</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest a portion of our cash in a number of diversified fixed-and floating-rate securities, consisting of marketable debt securities and debt funds that are subject to interest rate risk. Changes in the general level of interest rates can affect the fair value of our investment portfolio. If interest rates in the general economy were to rise, our holdings could lose value. At December&#160;31,&#160;2023, a hypothetical increase in interest rates of 100&#160;basis points across the entire yield curve on our holdings would not have resulted in a material impact on the fair value of our portfolio.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk &#8211; Variable-Rate Debt</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our use of variable-rate debt exposes us to interest rate risk as changes in interest rates would affect interest expense. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have variable-rate loans outstanding totaling $735.0&#160;million, of which:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$380.0&#160;million matures on December&#160;31,&#160;2025 and bears interest at 3-month Term&#160;SOFR plus 7.5%&#160;per annum;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$155.0&#160;million matures on December&#160;31,&#160;2025 and bears interest at 3-month Term&#160;SOFR plus 8.0%&#160;per annum; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$200.0&#160;million matures on September&#160;11,&#160;2026 and bears interest at 1-month Term&#160;SOFR plus 8.0%&#160;per annum.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the weighted-average interest rate on these loans was 13.09%. A </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hypothetical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100-basis point increase in the Term&#160;SOFR rate as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would increase our future interest payments by $16.1&#160;million. Similarly, a hypothetical 100-basis point decrease in the Term&#160;SOFR rate as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would decrease our future interest payment by $16.1&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk &#8211; RIPA</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a revenue interest purchase agreement. Our primary exposure to market risk is that the interest rate on the revenue interest liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability, interest expense, and the time period for repayment. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; that appears in Part&#160;II, Item&#160;8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report for more information regarding the terms of the RIPA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to foreign currency exchange rate risk inherent in conducting business globally in numerous currencies. We contract with clinical research organizations, investigational sites and suppliers in foreign countries. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, therefore, subject to fluctuations in foreign currency rates in connection with these agreements. We have not entered into any material foreign currency hedging contracts although we may do so in the future. From inception through the date of this Annual Report, we have not incurred any material effects from foreign currency changes on these contracts. The effect of a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10% adverse change in exchange rates on foreign currency denominated cash and payables as of December&#160;31,&#160;2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would not have been material</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, fluctuations in currency exchange rates could harm our business in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to foreign currency fluctuations related to the operations of our subsidiary in Italy whose financial statements are denominated in the Euro. We translate all assets and liabilities denominated in foreign currency into U.S.&#160;dollars using the exchange rate as of the end of the reporting period, while the operating results are translated into U.S.&#160;dollars using the average exchange rates for the reporting periods. Gains and losses resulting from translating the financial statements from our subsidiary&#8217;s functional currency to U.S.&#160;dollars are recognized as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of comprehensive loss. Foreign currency exchange rate fluctuations affect our reported net loss and can make comparisons from period to period more difficult. Our foreign operations are not material to our operations as a whole. As such, we currently do not enter into currency forward exchange or option contracts to hedge foreign currency exposures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market Ris<span id="i84811bef2c984971a876b6880e1034b5_6013"></span>k</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, 37,732,820 warrants from our direct registered offerings remained outstanding at a fair value of $118.8&#160;million. The fair value of the warrant liabilities is determined using the Black-Scholes option pricing model and is therefore sensitive to changes in the market price and volatility of our common stock among other factors. In the event of a hypothetical&#160;10% increase in the market price of our common stock ($5.52 based on the $5.02 market price of our stock at December&#160;31,&#160;2023) on which the December&#160;31,&#160;2023 valuation was based, the fair value of the warrant liabilities would have increased by $15.6&#160;million. Similarly, based on the fair value of the warrants outstanding as of December&#160;31,&#160;2023, a hypo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thetical decrease of 10% in the market price of our common stock would have the fair value of the warrant liabilities decreased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.5&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. S</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uch increase or decrease would have been reflected as a change in fair value of warrant liabilities in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation may affect us by increasing our cost of labor, clinical trial, and other costs. We do not believe that inflation has had a material effect on our business, financial condition or results of operations for any period presented herein.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. &#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.658%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_130">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-36">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_130">138</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_133">Consolidated Balance Sheets as of December 31, 2023 and 2022</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_133">140</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_136">Consolidated Statements of Operations for the years ended </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_136">December 31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_136">141</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_139">Consolidated Statements of Comprehensive Loss for the years ended </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_139">December 31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_139">142</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_142">Consolidated Statements of Stockholders&#8217; Deficit for the years ended </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_142">December 31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_142">143</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_145">Consolidated Statements of Cash Flows for the years ended </a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_145">December 31, 2023, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_145">145</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_148">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if7eeec8e66644046bbbe3c0a87df2c46_148">148</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of ImmunityBio, Inc. and Subsidiaries</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of ImmunityBio, Inc. and Subsidiaries (the&#160;Company) as of December&#160;31,&#160;2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; deficit and cash flows for each of the three&#160;years in the period ended December&#160;31,&#160;2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31,&#160;2023 and 2022, and the results of its operations and its cash flows for each of the three&#160;years in the period ended December&#160;31,&#160;2023, in conformity with U.S.&#160;generally accepted accounting principles.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1)&#160;relates to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.780%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related party transactions and disclosures</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the <br/>Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes&#160;10 and 11 to the consolidated financial statements, the Company&#8217;s Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder Dr.&#160;Patrick Soon-Shiong has a controlling interest in certain entities with which the Company has entered into material transactions including related party debt transactions with Nant Capital, LLC, NantWorks, NantMobile, LLC and NantCancerStemCell. Affiliates of such entities are also affiliates of the Company due to the common control of the Company&#8217;s Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assessing the sufficiency of procedures performed to identify related parties and significant related party transactions and determining the identified significant related party transactions were properly recorded, presented and disclosed was challenging due to the nature, volume and the significance of related party transactions.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed <br/>the Matter in Our <br/>Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the Company&#8217;s related party process. This included testing controls over management&#8217;s identification, review, recognition and disclosure of significant related party transactions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit procedures we performed included, among others, testing the completeness and accuracy of the listing of related parties identified and significant related party transactions provided by management, and testing the manner in which significant related party transactions were recorded, presented and disclosed. We performed journal entry searches of identified related parties to verify completeness and accuracy of the Company&#8217;s significant related party transactions. We inquired of management, members of the Company&#8217;s audit committee, and the Company&#8217;s related party transaction committee chair regarding the completeness of the significant related party transactions identified. We also inspected questionnaires received from the Company&#8217;s directors and officers, read minutes of the meetings of Board of Directors and its various Committees, read employment and compensation contracts, proxy statements and other relevant filings with the Securities and Exchange Commission that relate to the Company&#8217;s financial relationships and transactions with the Company&#8217;s executive officers and with other entities controlled by the Company&#8217;s Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder. We confirmed the significant transactions and/or balances, as applicable, with the related parties. We also obtained the underlying agreements for significant related party transactions and assessed the associated accounting and recognition. We involved valuation specialists to assist in evaluating the appropriateness of the valuation methodologies and reasonableness of the assumptions used in the valuation of the related party debt including underlying conversion features and embedded derivatives, as deemed necessary, as described in Note&#160;10 to the consolidated financial statements.</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-37">Ernst &amp; Young LLP</ix:nonNumeric> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2016.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-38">Los Angeles, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;19,&#160;2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">139</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">265,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">104,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">2,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Due from related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets (including amounts with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">25,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">31,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">294,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">140,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities, noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="f-49">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="f-50">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-51">146,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-52">143,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-53">17,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-54">20,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Convertible note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:ConvertibleNoteReceivableNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">6,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:ConvertibleNoteReceivableNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">6,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right-of-use assets, net (including amounts with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-57">36,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-58">45,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-61">504,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-62">362,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">9,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">21,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">42,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">41,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Related-party promissory notes, net of discounts and deferred issuance costs (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">431,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Due to related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">3,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">58,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">500,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Related-party nonconvertible note, net of discount (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-75">104,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Related-party convertible notes and accrued interest, net of discount (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-77">576,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-78">241,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue interest liability (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-79">155,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liabilities (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" format="ixt:num-dot-decimal" scale="3" id="f-81">35,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">39,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">47,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-85">118,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-86">21,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-88">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-89">1,090,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-90">812,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_190">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-91"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-92"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stockholders&#8217; deficit:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-93"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-94">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-95">1,350,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-96">900,000,000</ix:nonFraction>&#160;shares authorized </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;as of December&#160;31,&#160;2023 and 2022, respectively; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98">670,867,344</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-100">421,569,115</ix:nonFraction></ix:nonFraction> shares </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;issued and outstanding as of December&#160;31,&#160;2023 and 2022, respectively; </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;&#160;&#160;excluding <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-102">163,800</ix:nonFraction></ix:nonFraction>&#160;treasury stock shares outstanding as of December&#160;31,&#160;2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-103">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-104">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-105">2,374,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-106">1,930,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-107">2,961,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-108">2,378,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-109">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-110">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total ImmunityBio stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">586,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">447,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-113">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-114">2,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">585,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-116">449,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">504,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-118">362,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_136"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-119">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-120">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-121">934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (including amounts <br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">232,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">248,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">195,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (including amounts<br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-125">129,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">102,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">135,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="f-128">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="f-129">681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-131">362,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-132">351,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-133">331,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">362,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">351,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">330,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and investment income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-137">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-138">3,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-139">4,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (including amounts with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-140">129,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-141">63,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-142">14,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-143">7,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-144">12,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="f-145">803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-146">47,600</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-147">13,460</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-148">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of related-party convertible note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="f-149">36,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:fixed-zero" scale="3" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:fixed-zero" scale="3" id="f-151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net (including amounts <br/>&#160;&#160;&#160;with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">2,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-153">736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-154">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">221,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">65,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-157">19,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">583,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-159">417,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-160">349,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-161">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-162">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-163">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">583,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">417,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">349,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-167">656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-168">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-169">3,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to ImmunityBio common stockholders</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">583,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">416,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">346,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per ImmunityBio common share &#8211; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-173"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174">1.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-175"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-176">1.04</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-177"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-178">0.89</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in computing<br/>&#160;&#160;&#160;net loss per share &#8211; basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-179"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-180">508,635,592</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-182">399,900,374</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-184">389,234,156</ix:nonFraction></ix:nonFraction></span></td></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">141</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">583,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">417,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">349,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of income taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="f-188">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="f-189">183</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="3" id="f-190">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of net realized gains (losses) on<br/>&#160;&#160;&#160;available-for-sale securities included in net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="f-191">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="f-192">124</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-194">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-195">238</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-196">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-197">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-198">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-199">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-200">584,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-201">417,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-202">349,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-203">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-204">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">3,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to ImmunityBio <br/>&#160;&#160;&#160;common stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-206">583,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-207">416,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-208">346,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">142</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Deficit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.920%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Other <br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>ImmunityBio<br/>Stockholders&#8217;<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-209">382,243,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-210">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-211">1,495,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">1,615,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-213">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">119,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-215">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-216">118,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock &#8220;at-the-market&#8221; </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;offering, net of commissions and </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-217">4,674</ix:nonFraction> (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">&#160;13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-218">13,295,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-219">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-220">164,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-221">164,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-222">164,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-223">57,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-224">57,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-225">57,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-226">1,695,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-227">5,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-228">5,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-229">5,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-230">873,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net share settlement for RSUs vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-231">277,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-232">4,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-233">4,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-234">4,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of assets to an entity under common control</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-235">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-236">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-237">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-238">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-239">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-240">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-241">346,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-242">346,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">3,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">349,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31,&#160;2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-245">397,830,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-246">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-247">1,719,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-248">1,961,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-249">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-250">242,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-251">1,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-252">243,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock &#8220;at-the-market&#8221; </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;offering, net of commissions and </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-253">302</ix:nonFraction> (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">&#160;13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-254">2,051,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-255">13,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-256">13,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-257">13,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of related-party convertible note and </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;accrued interest, net of unamortized debt discount, </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;into equity (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-258">9,986,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-259">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-260">51,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-261">51,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-262">51,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares in a registered direct offering,</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;net of discount and offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-263">1,897</ix:nonFraction> </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;and value ascribed to associated warrants (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_220">Note 12</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-264">9,090,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-265">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-266">13,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-267">13,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-268">13,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-269">40,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-270">40,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-271">40,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-272">14,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-273">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-274">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-275">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-276">521,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net share settlement for RSUs vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-277">156,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-278">616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-279">616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-280">616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued pursuant to litigation settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="ibrx:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="f-281">2,229,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ibrx:StockIssuedDuringPeriodValueLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="f-282">10,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="ibrx:StockIssuedDuringPeriodValueLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="f-283">10,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:StockIssuedDuringPeriodValueLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="f-284">10,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Deficit (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.920%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Other <br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>ImmunityBio<br/>Stockholders&#8217;<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on extinguishment of debt with related parties<br/>&#160;&#160;&#160;under common control</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-285">82,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-286">82,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-287">82,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-288">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-289">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-290">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-291">416,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-292">416,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-293">753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-294">417,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-295">421,569,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-296">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-297">1,930,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-298">2,378,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-299">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-300">447,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-301">2,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-302">449,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock &#8220;at-the market&#8221; </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;offering, net of commissions and </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-303">457</ix:nonFraction> (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">Note &#160;13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-304">5,605,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-305">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-306">16,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-307">16,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-308">16,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in exchange for notes </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;payable (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-309">209,291,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-310">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-311">269,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-312">269,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-313">269,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares in a registered direct offerings,</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;net of discounts and offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-314">3,535</ix:nonFraction> </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;and value ascribed to associated warrants (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_220">Note 12</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-315">28,641,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-316">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-317">36,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-318">36,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-319">36,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the RIPA, </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;net of transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-320">473</ix:nonFraction> (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-321">2,432,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-322">11,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-323">11,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-324">11,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on debt extinguishment with related-parties </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;under common control (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl" format="ixt:num-dot-decimal" scale="3" id="f-325">36,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl" format="ixt:num-dot-decimal" scale="3" id="f-326">36,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl" format="ixt:num-dot-decimal" scale="3" id="f-327">36,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in fair value of embedded conversion feature </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;from debt modification with entities under common</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;control (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" format="ixt:num-dot-decimal" scale="3" id="f-328">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" format="ixt:num-dot-decimal" scale="3" id="f-329">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" format="ixt:num-dot-decimal" scale="3" id="f-330">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-331">49,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-332">49,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-333">49,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-334">184,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-335">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-336">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-337">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="f-338">4,545,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net share settlement for RSUs vesting</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-339">1,403,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-340">3,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-341">3,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-342">3,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in ownership interest in a joint venture due to</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;legal settlement (</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_190">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" format="ixt:num-dot-decimal" scale="3" id="f-343">4,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" format="ixt:num-dot-decimal" scale="3" id="f-344">4,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" format="ixt:num-dot-decimal" scale="3" id="f-345">4,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-347">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-348">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-349">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-350">583,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-351">583,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-352">656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-353">583,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31,&#160;2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-354">670,867,344</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-355">67</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-356">2,374,620</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-357">2,961,684</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-358">10</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-359">586,987</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-360">1,050</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-361">585,937</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">144</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-362">583,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-363">417,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-364">349,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-365">49,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-366">40,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-367">57,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-368">47,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-369">13,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-371">42,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-372">16,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-373">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="f-374">36,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-377">18,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-378">18,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-379">14,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest items, net (including amounts with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-380">9,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-381">11,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-382">12,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense related to operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-383">6,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-384">5,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-385">4,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs allocated to warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:TransactionCostsWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-386">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:TransactionCostsWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-387">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:TransactionCostsWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-389">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-390">4,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-391">4,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="f-392">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="f-393">681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums, net of discounts, on marketable <br/>&#160;&#160;&#160;debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-395">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-396">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-397">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-399">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-401">407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-402">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-403">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-404">5,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-405">16,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-406">2,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-407">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-408">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-409">3,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-410">6,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-411">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="3" id="f-412">3,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-413">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-414">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-415">5,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-416">1,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-417">1,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-418">10,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-419">2,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-420">4,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-421">4,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-422">366,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-423">337,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-424">274,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-425">30,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-426">78,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-427">33,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-429">21,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-433">20,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable debt securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-434">10,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-435">34,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-436">141,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable debt securities, available for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-437">10,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-438">128,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-439">56,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt and equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="f-440">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-441">33,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-442">13,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in joint venture &#8211; an equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInJointVenture" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInJointVenture" format="ixt:num-dot-decimal" scale="3" id="f-444">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInJointVenture" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-446">30,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-447">27,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-448">84,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (Continued)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of related-party promissory notes <br/>net of issuance costs paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-449">258,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-450">174,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="3" id="f-451">338,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the RIPA, net of transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-452">192,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from equity offerings, <br/>&#160;&#160;&#160;net of discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-455">100,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-456">60,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-457">164,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock issuance in connection with the RIPA, <br/>&#160;&#160;&#160;net of transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-458">9,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-461">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-462">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-463">5,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net share settlement for RSUs vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-464">3,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-465">616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-466">4,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-467">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-468">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of assets to an entity under common control</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-472">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment for contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="f-474">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="f-475">419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-476">558,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-477">233,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-478">505,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and<br/>&#160;&#160;&#160;restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-479">292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-480">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-481">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-482">160,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-483">76,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-484">146,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-485">104,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-486">181,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-487">35,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-488">265,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-489">104,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-490">181,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (Continued)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents, and restricted cash, <br/>&#160;&#160;&#160;end of year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-491">265,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-492">104,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-493">181,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4643e1a07ce0428bbdfe8baf8b53beac_51425">(Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="f-494">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="f-495">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="f-496">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, end of year</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-497">265,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-498">104,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-499">181,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-500">77,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-501">35,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-502">2,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-503">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-504">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-505">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of related-party convertible notes and accrued interest,<br/>&#160;&#160;&#160;net of unamortized discount, into equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="f-506">269,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="f-507">51,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial measurement of warrants issued in connection with <br/>&#160;&#160;&#160;registered direct offerings accounted for as liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:IssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-509">49,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:IssuanceOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-510">35,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:IssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt with related parties under <br/>&#160;&#160;&#160;common control</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-512">36,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-513">82,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" format="ixt:fixed-zero" scale="3" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value of embedded conversion feature from <br/>&#160;&#160;&#160;debt modification</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative" format="ixt:num-dot-decimal" scale="3" id="f-515">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative" format="ixt:fixed-zero" scale="3" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative" format="ixt:fixed-zero" scale="3" id="f-517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issuance discount related to the revenue interest liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:CommonStockDiscountOnSharesRevenueInterestLiability" format="ixt:num-dot-decimal" scale="3" id="f-518">2,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:CommonStockDiscountOnSharesRevenueInterestLiability" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:CommonStockDiscountOnSharesRevenueInterestLiability" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment purchases included in accounts payable, <br/>&#160;&#160;&#160;accrued expenses and due to related parties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-521">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-522">12,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-523">11,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for <br/>&#160;&#160;&#160;operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-525">14,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-526">23,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets disposed in exchange for <br/>&#160;&#160;&#160;operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-527">3,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued pursuant to litigation settlement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-531">10,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid offering and transaction costs included in accounts payable<br/>&#160;&#160;&#160;and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="f-533">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" scale="3" id="f-534">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" format="ixt:fixed-zero" scale="3" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashless exercise of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:StockIssuedCashlessExerciseOfStockOptions" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:StockIssuedCashlessExerciseOfStockOptions" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:StockIssuedCashlessExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-538">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued investment in joint venture</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:InvestmentsInJointVentureIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:InvestmentsInJointVentureIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:InvestmentsInJointVentureIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-541">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">147</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunityBio, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_151"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-542" continuedAt="f-542-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-542-1" continuedAt="f-542-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to the consolidated financial statements, the terms &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio and subsidiaries.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Using our proprietary platforms that amplify both the innate and adaptive branches of the immune system, our teams of clinical, scientific, and manufacturing experts, advance novel therapies and vaccines aimed at defeating urologic and other cancers, as well as infectious diseases. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations and is currently under review by the FDA for treatment in combination with BCG of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease and has a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including&#8212;NK cells, dendritic cells, and macrophages, as well as&#8212;the adaptive immune system comprising&#8212;B&#160;and T&#160;cells,&#8212;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally-infected. Our ultimate goal is to overcome the limitations of current treatments, such as checkpoint inhibitors, and/or reduce the need for standard high-dose chemotherapy in cancer by employing this coordinated approach to establish &#8220;immunological memory&#8221; that confers long-term benefit for the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary platforms for the development of biologic product candidates include: (i)&#160;antibody-cytokine fusion proteins, (ii)&#160;DNA, RNA, and recombinant protein vaccines, and (iii)&#160;cell therapies. These platforms have generated 9&#160;novel therapeutic agents for which clinical trials are either underway or planned in solid and liquid tumors. Specifically, our clinical focus includes bladder, lung, and colorectal cancers and GBM, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. In May&#160;2022, we announced the submission of a BLA to the FDA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. The CRL did not request new preclinical studies or Phase&#160;III clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company&#8217;s resubmission, as well as a safety update. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. As part of our resubmission, we provided an update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG unresponsive subjects with high-risk CIS disease. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-542-2" continuedAt="f-542-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;21,&#160;2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NantKwest and NantCell,&#160;Inc. (formerly known as ImmunityBio,&#160;Inc., a private company) (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NantCell)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into an Agreement and Plan of Merger (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), pursuant to which NantKwest and NantCell agreed to combine their businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;9,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the Effective Time), each share of NantCell common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-543">0.001</ix:nonFraction>&#160;per share, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted auto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matically </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the Exchange Ratio into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">newly issued shares of Company Common Stock, with cash paid in lieu of any fractional shares.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, RSU or warrant to purchase NantCell common stock was converted using the Exchange Ratio into an option, RSU or warrant, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="3" name="ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" scale="-2" id="f-544">71.5</ix:nonFraction>% </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the outstanding shares of Company Common Stock and the stockholders of NantKwest as of immediately prior to the Merger held approximately&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="3" name="ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" scale="-2" id="f-545">28.5</ix:nonFraction>% o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Chairman and Global Chief Scientific and Medical Officer,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and his affiliates beneficially owned, in the aggregate, approxim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ately&#160;<ix:nonFraction unitRef="number" contextRef="c-88" decimals="3" name="ibrx:OwnershipPercentageByKeyExecutives" scale="-2" id="f-546">81.8</ix:nonFraction>% of th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e outstanding shares of Company Common Stock. Following the consummation of the Merger, the symbol for shares of the company&#8217;s common stock was changed to &#8220;IBRX.&#8221;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:PaymentsForMergerRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-547">13.0</ix:nonFraction>&#160;million of costs </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the Merger in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations, consisting of financial advisory, legal and other professional fees.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" id="f-548" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Treatment of the Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger represents a business combination pursuant to ASC&#160;805-50, which was accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We recast our prior period financial statements for the year ended December&#160;31,&#160;2021 to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the consolidated financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="f-549" escape="true"><ix:continuation id="f-542-3"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the impact of the change in reporting entity on our unaudited condensed consolidated statement of operations for the three&#160;months&#160;ended March&#160;31,&#160;2021 (in&#160;thousands):</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:50.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NantCell</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NantKwest</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intercompany<br/>Eliminations</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">ImmunityBio,<br/>Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-550">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="f-552">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-553">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (including amounts<br/>with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-554">21,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-555">19,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" sign="-" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-556">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-557">41,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (including amounts<br/>with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-558">24,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-559">20,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-560">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-561">45,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-562">45,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-563">40,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-564">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-565">86,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net (including amounts <br/>with related parties)</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-566">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-567">6,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-569">5,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-571">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-573">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-574">46,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-575">33,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="f-576">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-577">80,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="if7eeec8e66644046bbbe3c0a87df2c46_154"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-578" continuedAt="f-578-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-578-1" continuedAt="f-578-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-579" continuedAt="f-579-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-579-1">The consolidated financial statements have been prepared in accordance with U.S.&#160;GAAP and pursuant to the rules and regulations of the SEC. Certain items in the prior years&#8217; consolidated financial statements have been reclassified to conform to the current presentation. These reclassifications had no effect on the reported results of operations. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-580" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a VIE for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities in which we have less than 100% ownership, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net loss attributable to noncontrolling interests, net of tax,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impacts the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the entity is within the scope of the variable interest model and meets the definition of a VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-2" continuedAt="f-578-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="f-581">3.0</ix:nonFraction>&#160;billion. We also had negative cash flows from operations of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-582">366.8</ix:nonFraction>&#160;million during the year ended December&#160;31,&#160;2023. The company will likely need additional capital to further fund the development of, and to seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of our common stock under the ATM, of which we had $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="f-583">208.8</ix:nonFraction>&#160;million available for future issuance as of December&#160;31,&#160;2023, and a February&#160;2023 shelf registration statement, of which we had $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="f-584">565.6</ix:nonFraction>&#160;million available for future offerings as of December&#160;31,&#160;2023), a potential $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment" format="ixt:num-dot-decimal" scale="6" id="f-585">100.0</ix:nonFraction>&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including upon approval of N-803 before June&#160;30,&#160;2024, and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek to sell additional equity, through one or more follow-on offerings, or in separate financings, or obtain incremental subordinated debt in compliance with our existing revenue interest liability. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the potential commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-586" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, CVR&#160;measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants, stock options, derivative liabilities, and convertible promissory notes, fair value measurements, revenue interest liability, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain judgments to determine whether transactions should be accounted for as acquisitions of assets or as business combinations. If it is determined that substantially all of the fair value of gross assets acquired in a transaction is concentrated in a single asset (or a group of similar assets), the transaction is treated as an acquisition of assets. We evaluate the inputs, processes, and outputs associated with the acquired set of activities and assets. If the assets in a transaction include an input and a substantive process that together significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-3" continuedAt="f-578-4"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which requires that assets acquired and liabilities assumed generally be recorded at their fair values as of the acquisition date. Excess of consideration over the fair value of net assets acquired is recorded as goodwill. Estimating fair value requires us to make significant judgments and assumptions. We perform impairment testing of goodwill annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions accounted for as asset acquisitions, the cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. In an asset acquisition, upfront payments allocated to in-process research and development projects at the acquisition date are expensed unless there is an alternative future use. In addition, product development milestones are expensed upon achievement. Any contingent consideration, such as payments upon achievement of various developmental, regulatory, and commercial milestones, generally is not recognized at the acquisition date.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-587" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-588" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attempt to minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also monitor the creditworthiness of the borrower of the convertible promissory note. We believe that any concentration of credit risk in its convertible note receivable was mitigated in part by our ability to convert, if necessary, at the qualifying financing event or upon a payment default into shares of the senior class of equity securities of the borrower.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates developed by us will require approvals or clearances from the&#160;FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-589" continuedAt="f-589-1" escape="true"><div style="margin-top:12pt"><span id="i4643e1a07ce0428bbdfe8baf8b53beac_51425"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include highly liquid investments with an original maturity of three&#160;months or less from the date of purchase.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-4" continuedAt="f-578-5"><ix:continuation id="f-589-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes a certificate of deposit held as a substitute letter of credit for one of our leased properties. This certificate of deposit is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash is included on the consolidated statements of cash flows as of December&#160;31,&#160;2023, 2022 and 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-590" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Other Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have typically invested our cash in a variety of financial instruments, including investment-grade short- to intermediate-term corporate debt securities, government-sponsored securities and European bonds; however, after our entry into the RIPA, we can no longer invest our excess funds in corporate or European bonds. Certain of our investments are subject to credit, liquidity, market, and interest-rate risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive income,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest and investment income (loss), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. Realized gains and losses from sales of securities and the amounts, net of tax, reclassified out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if any, are determined on a specific identification basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in mutual funds and equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and any unrealized gains and losses are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. Realized gains and losses from the sale of the securities are determined on a specific identification basis and the amounts are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluating Investments for Other-than-Temporary Impairments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether we have plans to sell the security or whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfInvestments" format="ixt:fixed-zero" scale="0" id="f-591"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="INF" name="us-gaap:ImpairmentOfInvestments" format="ixt:fixed-zero" scale="0" id="f-592"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:ImpairmentOfInvestments" format="ixt:fixed-zero" scale="0" id="f-593">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> other-than-temporary impairments recorded during the years ended December&#160;31,&#160;2023, 2022 and 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-594" continuedAt="f-594-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method of Accounting</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="f-594-1" continuedAt="f-594-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, we record our share of the income or loss of the other company as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">loss on equity method investment</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-594-2">, in our consolidated statement of operations.</ix:continuation> </span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-595" continuedAt="f-595-1" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-5" continuedAt="f-578-6"><ix:continuation id="f-595-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to operating expenses during the financial period in which they are incurred. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-596" continuedAt="f-596-1" escape="true">Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:</ix:nonNumeric></span></div><ix:continuation id="f-596-1" continuedAt="f-596-2"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-97" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-597">39</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-98" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-598">3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-99" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-599">5</ix:nonNumeric> to <ix:nonNumeric contextRef="c-100" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-600">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-601">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IT equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-102" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-602">3</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The lesser of the lease term or life of the asset</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal of property, plant and equipment, the cost and related accumulated depreciation are removed from the consolidated financial statements and the net amount, less any proceeds, is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="f-603" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review impairment of property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-604" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method of accounting in accordance with ASC&#160;805-50. These standards require that the total cost of acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition, with the excess purchase price recorded as goodwill. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration incurred in connection with a business combination are recorded at their fair values on the acquisition date and re-measured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair value are recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations and comprehensive loss. Changes in fair value reflect changes to our assumptions regarding probabilities of successful achievement of related milestones, the timing in which the milestones are expected to be achieved, and the discount rate used to estimate the fair value of the obligation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ibrx:CommonControlTransactionPolicyPolicyTextBlock" id="f-605" continuedAt="f-605-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Control Transactions</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-605-1">Transactions between us and entities where Dr.&#160;Soon-Shiong and his affiliates are the controlling stockholders are accounted for as common control transactions whereby the net assets acquired or transferred are accounted at their carrying value. Any difference between the carrying value and consideration recognized is treated as a capital transaction. Cash consideration up to the carrying value of the net assets acquired or transferred is presented as an investing activity on the consolidated statement of cash flows. Cash consideration in excess of the carrying value of the net assets acquired or transferred is presented as a financing activity on the consolidated statement of cash flows.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-606" continuedAt="f-606-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired in a business combination or an asset acquisition are initially recognized at their fair value on the acquisition date. Acquired indefinite-lived assets, such as IPR&amp;D, are not amortized until they become definite-lived assets, upon the successful completion of the associated research and development effort. At that time, we evaluate whether the recorded </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-6" continuedAt="f-578-7"><ix:continuation id="f-606-1" continuedAt="f-606-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are impaired and make any necessary adjustments, and then determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned, the related IPR&amp;D assets is written-off and an impairment charge recorded. </span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="f-606-2" continuedAt="f-606-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired definite-lived intangible assets are amortized using the straight-line method over their respective estimated useful lives. The amortization of these intangible assets is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-606-3"> on the consolidated statement of operations. Intangible assets are tested for impairment at least annually or more frequently if indicators of potential impairment exist.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LegalCostsPolicyTextBlock" id="f-607" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent costs, including related legal costs, are expensed as incurred and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-608" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three tiers are defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities, and corporate bonds, as well as foreign municipal securities.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, no transfers were made into or out of the Level&#160;1, 2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-609" continuedAt="f-609-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of FASB ASC Topic&#160;808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;808). A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. To the extent the collaboration agreement is within the scope of ASC&#160;808, we also assess whether the arrangement contains multiple elements that are within the scope of other accounting literature. If we conclude that some or all aspects of the agreement are distinct and represent a transaction with a customer, we account for those aspects of the arrangement within the scope of FASB ASC Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;606). Amounts that are owed by collaboration partners within the scope of ASC&#160;808 are recognized as an offset to research and development expense as such amounts are incurred by the collaboration partner. The amounts owed to a collaboration partner are classified as research and development expense.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-7" continuedAt="f-578-8"><ix:continuation id="f-609-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration arrangements require us to acquire certain equipment for exclusive use in the joint operating activities. These equipment purchases do not have an alternative use and are therefore expensed as incurred within research and development expense.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration arrangements are further discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_184">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements and Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="c-1" name="ibrx:PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" id="f-610" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing the consolidated financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate clinical trial and research agreement-related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research-related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ibrx:RelatedPartyTransactionsPolicyPolicyTextBlock" id="f-611" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Related Parties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have various agreements with related parties. These arrangements can be billed and settled in cash monthly, billed quarterly and settled in cash the following month, or estimated in advance and collected or paid upfront based on expected utilization. Monthly accruals are made for all quarterly billing arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-612" continuedAt="f-612-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases other than short-term leases, at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At the commencement date, lease right-of-use assets and lease liabilities are determined based on the present value of lease payments to be made over the lease term. Leases are classified as either finance leases or operating leases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the rate implicit in lease contracts are not readily determinable, we utilize its incremental borrowing rate as a discount rate for purposes of determining the present value of lease payments, which is based on the estimated interest rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, we will remeasure the lease liability at the net present value of the remaining lease payments using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, the exercise of renewal is only assured for five&#160;of our cGMP facilities where we have made significant improvements or extended the lease.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We combine our lease components (e.g.,&#160;fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g.,&#160;common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term. The lease term includes the non-cancellable period of the lease and any additional periods covered by either options to renew or not to terminate when the company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-8" continuedAt="f-578-9"><ix:nonNumeric contextRef="c-1" name="ibrx:WarrantsPolicyTextBlock" id="f-613" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC&#160;480 and ASC&#160;815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther expense, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ibrx:ConvertibleNotesFairValueOptionElectionPolicyTextBlock" id="f-614" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounted for a convertible note issued on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the&#160;FVO&#160;election of ASC&#160;825 until it was amended and restated on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023. Prior to its extinguishment on December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the convertible note was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issuance-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of this convertible note were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations, except that changes in estimated fair value caused by changes in the instrument-specific credit risk were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with ASC&#160;470-50, when the convertible note was extinguished on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the cumulative amount previously recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting from changes in the instrument-specific credit risk were reclassified and reported in current earnings on the consolidated statement of operations. See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note</a><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">&#160;10</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-615" continuedAt="f-615-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Modification and Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company evaluates amendments to its debt instruments in accordance with ASC&#160;470-50. This evaluation includes comparing (1)&#160;if applicable, the net present value of future cash flows of the amended debt to that of the original debt and (2)&#160;the change in fair value of an embedded conversion feature to that of the carrying amount of the debt immediately prior to amendment to determine, in each case, if a change greater than 10% occurred. In instances where the net present value of future cash flows or the fair value of an embedded conversion feature, if any, changed more than 10%, the company applies extinguishment accounting. In instances where the net present value of future cash flows and the fair value of an embedded conversion feature, if any, changed less than 10%, the company accounts for the amendment to the debt as a debt modification. Gains and losses on debt amendments that are considered extinguishments are recognized in current earnings or in additional paid-in capital if the transactions are with entities under common control. Debt amendments that are considered debt modifications are accounted for prospectively through yield adjustments, based on the revised terms. The increase in fair value of the embedded conversion feature from the debt modification was accounted for as an increase in debt discount with a corresponding increase in additional paid-in capital. Legal fees and other costs incurred with third parties that are directly related to debt modifications are expensed as incurred. Amounts paid by the company to the lenders, are reflected as additional debt discount and amortized as an adjustment of interest expense over remaining term of modified debt using the effective interest rate method.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">157</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-9" continuedAt="f-578-10"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-616" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize uncertain tax positions when the position will more likely than not be upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax benefit (expense),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31,&#160;2023 and 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ibrx:StockRepurchaseProgramPolicyPolicyTextBlock" id="f-617" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program. As it is our intent for the repurchased shares to be retired, we have elected to account for the shares repurchased using the constructive retirement method. For shares repurchased in excess of par, we record the purchase price in excess of par value in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheet.</span></div></ix:nonNumeric><ix:continuation id="f-615-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Interest Liability</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="ibrx:PurchaseAgreementTotalInvestmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-618">200.0</ix:nonFraction>&#160;million paid on closing. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment" format="ixt:num-dot-decimal" scale="6" id="f-619">100.0</ix:nonFraction>&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter. The RIPA is considered a sale of future revenues and is accounted for as a liability net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability, interest expense, and the time period for repayment.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesEmbeddedDerivatives" id="f-620" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Embedded derivatives that are required to be bifurcated from the underlying debt instrument that do not meet the derivative scope exception and equity classification criteria are accounted for and valued as separate financial instruments. The terms of an embedded derivative related to a contingent exercisable prepayment feature of a convertible note have been evaluated and deemed to require bifurcation. This embedded derivative will be initially measured at fair value and will be remeasured to fair value at each reporting date until the derivative is settled. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains certain features that meet the definition of being an embedded derivative requiring bifurcation as a separate compound financial instrument apart from the RIPA. The derivative liability is initially measured at fair value upon issuance and is subject to remeasurement at each reporting period with changes in fair value recognized in other expense, net, on the consolidated statement of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-10" continuedAt="f-578-11"><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-621" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have primarily generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. The nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies grant them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines. We have generated revenues from product sales of our proprietary GMP-in-a-Box bioreactors and related consumables, primarily to related parties. Additionally, we also generated revenues from grant programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreements with customers, we typically promise to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. Research and development data are provided throughout the term of the contract when and if available.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be <ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-622">zero</ix:nonFraction> and, as such, <ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="f-623">no</ix:nonFraction> revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have sold our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies. The arrangements typically include delivery of bioreactors, consumables, and providing installation service and perpetual software licenses for using the equipment. We recognize revenue when customers obtain control and can benefit from the promised goods or services, generally upon installation of the bioreactors, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. Upfront payments and fees are recorded as deferred revenue upon receipt and recognized as revenue when we satisfy our performance obligations under these arrangements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue is typically paid for reimbursable costs incurred over the duration of the associated research project or clinical trial and is recognized either when expenses reimbursable under the grants have been incurred and payments under the grants become contractually due or when cash is received, depending on the certainty of payment and other factors specific to each grant.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31,&#160;2023, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-624" continuedAt="f-624-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials costs, including CROs and related clinical manufacturing, including third-party CMOs, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-11" continuedAt="f-578-12"><ix:continuation id="f-624-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classifies its research and development expenses as either external or internal. The&#160;company&#8217;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#8217;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#8217;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the preclinical studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates. We adjust the accruals in the period when actual costs become known.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-625" continuedAt="f-625-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="f-625-1" continuedAt="f-625-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation under the provisions of ASC&#160;718. We estimate fair value of each stock option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions, including, but not limited to, expected stock price volatility over the term of the awards and the expected term of the stock options. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_226">Note&#160;14</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-625-2">, for more information.</ix:continuation> </span></div><ix:continuation id="f-612-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale-Leaseback Transaction</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sale-leaseback transaction occurs when an entity sells an asset it owns and immediately leases the asset back from the buyer. The seller then becomes the lessee and the buyer becomes the lessor. When entering into a sale-leaseback transaction as a seller-lessee, the requirements in ASC&#160;606, and all related ASUs to such Topic are applied in determining whether the transfer of an asset shall be accounted for as a sale of the asset by assessing whether it satisfies a performance obligation under the contract by transferring control of an asset. If the company transfers control of an asset to the buyer-lessor, the transfer is accounted for as a sale and the company derecognizes the transferred asset. The subsequent leaseback of the asset is accounted for in accordance with FASB ASC&#160;Topic&#160;842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same manner as any third-party lease. If the company does not transfer control of an asset to the buyer-lessor, the sale-leaseback transaction is accounted for as a financing arrangement.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-626" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net (loss) income and other comprehensive (loss) income. Our other comprehensive income or loss consists of net unrealized gains (losses) on marketable debt securities classified as available-for-sale, net of income taxes and foreign currency translation adjustments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-627" continuedAt="f-627-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests are recorded for the entities that we consolidate but are not wholly-owned by the company. Noncontrolling interests are classified as a separate component of equity on the consolidated balance sheet and consolidated statement of stockholders&#8217; deficit. Additionally, net loss attributable to noncontrolling interests is reflected separately from consolidated net loss on the consolidated statement of operations and the consolidated statement of stockholders&#8217; deficit. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">160</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-12" continuedAt="f-578-13"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-627-1">We record the noncontrolling interests&#8217; share of loss based on the percentage of ownership interest retained by the respective noncontrolling interest holders.</ix:continuation> Noncontrolling interests recorded on the consolidated financial statements result from the company&#8217;s share of GlobeImmune, of which we controlled <ix:nonFraction unitRef="number" contextRef="c-105" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-628"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-629"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-630">69.1</ix:nonFraction></ix:nonFraction></ix:nonFraction>% as of December&#160;31,&#160;2023, 2022 and 2021, respectively, and NANTibody, of which we controlled <ix:nonFraction unitRef="number" contextRef="c-108" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-631">100.0</ix:nonFraction>% as of December&#160;31,&#160;2023 and <ix:nonFraction unitRef="number" contextRef="c-109" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-632"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-633">60.0</ix:nonFraction></ix:nonFraction>% as of December&#160;31,&#160;2022 and 2021, respectively. Noncontrolling interest stockholders are common stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GlobeImmune was determined to be a VIE as it does not have sufficient equity investment at risk to finance its operations without additional subordinated financial support and we are deemed the primary beneficiary of GlobeImmune and, accordingly, consolidate GlobeImmune into the company&#8217;s consolidated financial statements under the VIE model. The company also supports GlobeImmune through a promissory note agreement, in which the company provides advances to GlobeImmune from time to time up to $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="f-634">6.0</ix:nonFraction>&#160;million with a per annum interest rate of five&#160;percent (<ix:nonFraction unitRef="number" contextRef="c-112" decimals="INF" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="f-635">5</ix:nonFraction>%). As of December&#160;31,&#160;2023 and 2022, there were <ix:nonFraction unitRef="usd" contextRef="c-113" decimals="INF" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-636"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="INF" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-637">no</ix:nonFraction></ix:nonFraction> outstanding advances due from GlobeImmune under the promissory note agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022, and 2021, GlobeImmune recognized <ix:nonFraction unitRef="usd" contextRef="c-112" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-638"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-639"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-640">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue, respectively, and recognized $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-641">0.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-642">0.5</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-643">0.7</ix:nonFraction>&#160;million of operating expenses, respectively, during the years ended December&#160;31,&#160;2023, 2022 and 2021. As of both December&#160;31,&#160;2023 and 2022, the consolidated balance sheets included approximately $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-644"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-645">1.4</ix:nonFraction></ix:nonFraction>&#160;million of total assets that can only be used to settle obligations of GlobeImmune, and <ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:Liabilities" format="ixt-sec:numwordsen" scale="6" id="f-646"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:Liabilities" format="ixt-sec:numwordsen" scale="6" id="f-647">no</ix:nonFraction></ix:nonFraction>&#160;liabilities, respectively, related to GlobeImmune. The creditors of GlobeImmune do not have recourse to the general credit of the primary beneficiary.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-648" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and hold assets in Italy and South Korea. The functional currency of the subsidiary in Italy is the Euro, based on the nature of the transactions occurring within this entity, and accordingly, assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates prevailing as of the balance sheet dates, while the operating results are translated into U.S.&#160;dollars using the average exchange rates for the period correlating with those operating results. Adjustments resulting from translating the financial statements of the foreign subsidiary into U.S.&#160;dollars are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of comprehensive loss. Transaction gains and losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-649" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-650" continuedAt="f-650-1" escape="true">The following table details those securities that have been excluded from the computation of potentially dilutive securities:</ix:nonNumeric></span></div><ix:continuation id="f-650-1"><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-651">162,471,837</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-652">46,274,965</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-653">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding third-party warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-654">37,732,820</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-655">9,090,909</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-656">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-657">9,820,435</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-658">9,262,926</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-659">4,124,930</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-660">7,503,979</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-661">6,551,388</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-662">6,515,889</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding related-party warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-663">1,638,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-664">1,638,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-665">1,638,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-666">219,167,071</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-667">72,818,188</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-668">12,278,819</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">161</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-578-13"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dilutive securities exclude the option to purchase up to $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="ibrx:SaleOfStockAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="f-669">10.0</ix:nonFraction>&#160;million of the company&#8217;s common stock pursuant to the SPOA entered in connection with the RIPA, as the exercise price is not yet determined. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_223">13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Deficit,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-670" continuedAt="f-670-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-670-1">We operate in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-671"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-672">one</ix:nonFraction></ix:nonFraction> reporting segment focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Our CEO is the chief operating decision-maker of the company, and manages and allocates resources to our operations on a company-wide basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future-period financial results, allocating resources, and setting incentive targets.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-673" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate a portion of our revenues from outside of the U.S. Information about our revenues by geographic region is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-674">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-675">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-676">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-677">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-678">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-679">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-680">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-681">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-682">934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-683" escape="true"><div style="margin-top:12pt"><span id="i4643e1a07ce0428bbdfe8baf8b53beac_102909"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2023, the FASB issued ASU&#160;2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic&#160;740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1)&#160;disclose specific categories in the rate reconciliation, (2)&#160;provide additional information for reconciling items that meet a quantitative threshold, and (3)&#160;disclose more detailed information about income taxes paid, including by jurisdiction; pretax income (or loss) from continuing operations; and income tax expense (or benefit). The ASU is effective for fiscal years beginning after December&#160;15,&#160;2024, and interim periods beginning after December&#160;15,&#160;2025, with early adoption permitted. We are currently evaluating the impact of this standard on our disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2023, the FASB issued ASU&#160;2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic&#160;280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, and interim periods within fiscal years beginning after December&#160;15,&#160;2024 on a retrospective basis. We are currently evaluating the impact of this standard on our disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2023, the FASB issued ASU 2023-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations-Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a joint venture to initially measure all contributions received upon its formation at fair value. This ASU is applicable to joint venture entities with a formation date on or after January&#160;1,&#160;2025 on a prospective basis. We will apply this guidance prospectively in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2023, the FASB issued ASU&#160;2023-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Common Control Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC) and the SEC during the year ended December&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">162</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-684" continuedAt="f-684-1" escape="true">Financial Statement Details</ix:nonNumeric></span></div><ix:continuation id="f-684-1" continuedAt="f-684-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="f-685" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-686">7,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-687">11,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:PrepaidServices" format="ixt:num-dot-decimal" scale="3" id="f-688">5,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:PrepaidServices" format="ixt:num-dot-decimal" scale="3" id="f-689">8,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="f-690">2,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="f-691">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid software license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:PrepaidSoftwareLicenseFees" format="ixt:num-dot-decimal" scale="3" id="f-692">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:PrepaidSoftwareLicenseFees" format="ixt:num-dot-decimal" scale="3" id="f-693">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance premium financing asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:InsurancePremiumFinancingAsset" format="ixt:num-dot-decimal" scale="3" id="f-694">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:InsurancePremiumFinancingAsset" format="ixt:num-dot-decimal" scale="3" id="f-695">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance claims receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-696">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InsuranceSettlementsReceivableCurrent" format="ixt:fixed-zero" scale="3" id="f-697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid equipment maintenance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:PrepaidEquipmentMaintenance" format="ixt:num-dot-decimal" scale="3" id="f-698">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:PrepaidEquipmentMaintenance" scale="3" id="f-699">833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ERP system implementation cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-700">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" scale="3" id="f-701">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Supplies" format="ixt:fixed-zero" scale="3" id="f-702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Supplies" format="ixt:num-dot-decimal" scale="3" id="f-703">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-705">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-706">25,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-707">31,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><ix:continuation id="f-596-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-708">72,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-709">68,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-710">69,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-711">67,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-712">84,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-713">72,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-714">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-715">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture &amp; fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-716">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-717">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-718">230,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-719">212,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-720">84,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-721">69,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-722">146,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-723">143,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, depreciation expense related to property, plant and equipment totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-724">16.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-725">16.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-726">14.2</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">163</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-684-2" continuedAt="f-684-3"><div><span id="i5152da74782c4119b27351f18d5b573b_17470"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-727" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Definite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-147" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-728">8.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-729">20,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-730">3,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-732">16,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-733">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:IndefiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="f-734">886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-735">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-736">21,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-737">3,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:IntangibleAssetsAccumulatedImpairment" scale="3" id="f-738">886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-739">17,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-148" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-740">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-741">20,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-742">1,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" format="ixt:fixed-zero" scale="3" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-744">18,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Organized workforce</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-745">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-746">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="f-747">681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-749">21,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-750">1,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="f-751">681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-752">18,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-753">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-754">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-755">22,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-756">1,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:IntangibleAssetsAccumulatedImpairment" scale="3" id="f-757">681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-758">20,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definite-Lived Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the Dunkirk Facility in 2022, we acquired definite-lived intangibles consisting of favorable leasehold rights and an organized workforce. During the year ended December&#160;31,&#160;2022, we wrote off the entire unamortized organized workforce intangible asset totaling $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-759">0.7</ix:nonFraction>&#160;million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> impairment of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_184">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements and Acquisition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023 and 2022, we recorded amortization expense of definite-lived intangible assets totaling $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-760">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-761">1.9</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we discontinued the research and development program associated with the&#160;Tarmogen platform based on results gathered from clinical data. We recorded a charge totaling $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-762">0.9</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">impairment of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations in connection with the writedown of the carrying value of Tarmogen to zero. <ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-763"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt-sec:numwordsen" scale="0" id="f-764">No</ix:nonFraction></ix:nonFraction> such impairments were recorded during the years&#160;ended December&#160;31,&#160;2022 and 2021. As of December&#160;31,&#160;2023 and 2022, the company had indefinite-lived IPR&amp;D intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-765">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-766">1.4</ix:nonFraction>&#160;million, respectively, which were obtained from business acquisitions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">164</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-684-3" continuedAt="f-684-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-767" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense associated with our definite-lived intangible assets is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Definite-lived</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intangible</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-768">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-769">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-770">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-771">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-772">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-773">6,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-774">16,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Note Receivable</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we executed a convertible promissory note pursuant to which we advanced Riptide a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="ibrx:ConvertibleNoteReceivableNonCurrent" format="ixt:num-dot-decimal" scale="6" id="f-775">5.0</ix:nonFraction>&#160;million. The note bears interest at a per annum rate of five percent&#160;(<ix:nonFraction unitRef="number" contextRef="c-157" decimals="INF" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-776">5</ix:nonFraction>%). Concurrent with the transaction, we entered into an exclusive license agreement with Riptide to obtain worldwide exclusive rights, with the right to sublicense, certain know-how related to RP-182, RP-233 and RP-183. We are required to pay a single-digit royalty on net sales of the licensed products on a country-by-country basis. Pursuant to the license agreement, we are also required to make cash milestone payments upon successful completion of certain clinical, regulatory and commercial milestones up to an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentPayableAmount" format="ixt:num-dot-decimal" scale="6" id="f-777">47.0</ix:nonFraction>&#160;million for the first three&#160;indications of the licensed product with a maximum payment amount of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-778">100.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a first amendment to the convertible promissory note with Riptide. Under the agreement, we extended the maturity of the promissory note to the earlier of (a)&#160;the later of (i)&#160;the completion of non-clinical IND enabling studies by the company, or (ii)&#160;December&#160;31,&#160;2020; and (b)&#160;when we accelerate the maturity of the note upon the occurrence of an event of default. No other terms and conditions of the promissory note were modified. Concurrently, we also entered into a first&#160;amendment to the exclusive license agreement with Riptide and extended the achievement dates for certain clinical trial milestones related to the licensed products. This option for receiving a <ix:nonFraction unitRef="number" contextRef="c-4" decimals="2" name="ibrx:ConvertibleNoteReceivableDiscountOptionPercent" scale="0" id="f-779">25</ix:nonFraction>%&#160;discount was determined to have an immaterial value at inception and life-to-date of the note, as the probability of a future qualifying event is remote. The convertible note receivable balance was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ibrx:ConvertibleNoteReceivableNonCurrent" format="ixt:num-dot-decimal" scale="6" id="f-780">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ibrx:ConvertibleNoteReceivableNonCurrent" format="ixt:num-dot-decimal" scale="6" id="f-781">6.6</ix:nonFraction>&#160;million, which included accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="f-782">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="f-783">1.6</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-784" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-785">11,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-786">12,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional and service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-787">9,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-788">6,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:AccruedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-789">7,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:AccruedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-790">1,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-791">6,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-792">6,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued preclinical and clinical trial costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" format="ixt:num-dot-decimal" scale="3" id="f-793">4,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" format="ixt:num-dot-decimal" scale="3" id="f-794">4,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing obligation &#8211; current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:FinancingObligationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-795">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:FinancingObligationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-796">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued construction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConstructionPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-797">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ConstructionPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-798">7,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-799">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-800">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-801">42,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-802">41,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">165</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-684-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Investment Income (Loss), Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InterestAndOtherIncomeTableTextBlock" id="f-803" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and investment income (loss), net consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses from equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-804">1,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-805">4,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-806">4,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="f-807">863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-808">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="f-809">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment accretion income (amortization expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-810">1,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-811">1,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="f-812">488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="f-813">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="f-814">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="f-815">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and investment income (loss), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-816">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-817">3,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-818">4,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes interest from marketable securities, convertible notes receivable, other assets, and on bank deposits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="f-819" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on related-party notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-820">86,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-821">47,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-822">14,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:AmortizationOfDebtDiscountPremiumRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-823">42,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:AmortizationOfDebtDiscountPremiumRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-824">16,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:AmortizationOfDebtDiscountPremiumRelatedParty" scale="3" id="f-825">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseOther" scale="3" id="f-826">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestExpenseOther" scale="3" id="f-827">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestExpenseOther" scale="3" id="f-828">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-829">129,198</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-830">63,515</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-831">14,849</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if7eeec8e66644046bbbe3c0a87df2c46_175"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentTextBlock" id="f-832" continuedAt="f-832-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-832-1" continuedAt="f-832-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Debt Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-833" continuedAt="f-833-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-163" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" format="ixt-sec:duryear" id="f-834">0.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-835">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-838">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-839">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-841">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-842">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-843">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-845">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-846">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-167" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" format="ixt-sec:duryear" id="f-847">3.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-848">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-850">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-851">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-852">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-854">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-855">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">166</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-832-2"><ix:continuation id="f-833-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:34.007%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;<br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-856">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-858">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-859">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-170" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" format="ixt-sec:duryear" id="f-860">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-861">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-863">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-864">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="f-865">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-867">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-868">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, <ix:nonFraction unitRef="security" contextRef="c-4" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-869">12</ix:nonFraction>&#160;of the securities were in an unrealized loss position. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-870" continuedAt="f-870-1" escape="true">Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): </ix:nonNumeric></span></div><ix:continuation id="f-870-1"><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="f-871">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-872">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="f-875">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-876">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="f-879">930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-880">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="f-883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="f-885">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-886">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="f-887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="f-889">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-890">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="3" id="f-891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="3" id="f-893">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-894">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, we evaluated our securities for other-than-temporary impairment and did <ix:nonFraction unitRef="usd" contextRef="c-176" decimals="INF" name="us-gaap:ImpairmentOfInvestments" format="ixt:fixed-zero" scale="3" id="f-895"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="INF" name="us-gaap:ImpairmentOfInvestments" format="ixt:fixed-zero" scale="3" id="f-896"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="INF" name="us-gaap:ImpairmentOfInvestments" format="ixt:fixed-zero" scale="3" id="f-897">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> recognize any other-than-temporary impairment losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, we held investments in marketable equity securities with readily determinable fair values of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-898">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-899">2.5</ix:nonFraction>&#160;million, respectively. During the years ended December&#160;31,&#160;2023, 2022 and 2021, unrealized losses recorded on these securities totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-900">1.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-901">4.2</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-902">4.6</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest and investment income (loss), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="f-903" continuedAt="f-903-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-903-1" continuedAt="f-903-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurring Valuations</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-904" continuedAt="f-904-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-905">265,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-906">265,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-909">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-910">916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-913">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-915">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-917">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-918">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-921">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-922">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-923">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-925">267,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-926">266,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-927">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-929">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-931">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-932">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock option purchase liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-933">819</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-934">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-936">819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-937">35,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-940">35,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-941">118,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-944">118,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-945">154,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-948">154,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-949">104,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-950">63,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-951">40,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-953">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-954">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-957">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-958">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-961">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-963">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-965">108,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-966">66,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-967">41,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-969">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-972">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-973">21,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-976">21,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-977">21,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-980">21,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">168</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-904-1" continuedAt="f-904-2"><ix:continuation id="f-903-2" continuedAt="f-903-3"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration is recorded at estimated fair value and revalued each reporting period until the related contingency is resolved. The fair value measurement is based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_190">Note</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_190">&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Contingent Consideration Related to Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the carrying amount of contingent consideration were as follows (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:60.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-981">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-982">409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-983">972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="f-985">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="f-986">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (increase) decrease in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-987">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-988">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-989">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-990">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-991">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-992">409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock Option Purchase Liability</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the RIPA, we entered into an SPOA pursuant to which Oberland has an option to purchase up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-993">10.0</ix:nonFraction>&#160;million of our common stock, at a price to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability at its fair value upon issuance. The fair value was estimated using probability-weighted scenarios over the likelihood of this option being exercised. As of December&#160;31,&#160;2023, the stock purchase option was outstanding. The fair value of the stock purchase option was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="ibrx:EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" format="ixt:num-dot-decimal" scale="6" id="f-994">0.8</ix:nonFraction> million at issuance. Due to the proximity of the inception date of the SPOA to December&#160;31,&#160;2023, the change in fair value was immaterial. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The debt incurred pursuant to the RIPA entered on December&#160;29,&#160;2023 contains embedded derivatives requiring bifurcation as a single compound derivative instrument. The company estimated the fair value of the derivative liability using a &#8220;with-and-without&#8221; method. The with-and-without methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the individual embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the derivative liability, which is estimated at $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="f-995">34.5</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023. The estimated probability and timing of underlying events triggering the exercisability of the Put Option contained in the RIPA, forecasted cash flows and the discount rate are significant unobservable inputs used to determine the estimated fair value of the entire instrument with the embedded derivative. As of December&#160;31,&#160;2023, the discount rate used for valuation of the derivative liability was <ix:nonFraction unitRef="number" contextRef="c-254" decimals="3" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" scale="-2" id="f-996">12.1</ix:nonFraction>%. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">N</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">ote</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_952">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;2023 debt extinguishment, the company identified an embedded derivative related to a contingently exercisable prepayment feature of the amended $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-997">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note, which allows the noteholder to request up to a $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="ibrx:DebtInstrumentPrepaymentAndAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-998">50.0</ix:nonFraction>&#160;million prepayment and accrued interest upon occurrence of a specified transaction (defined in the promissory note). This embedded derivative is recorded as a derivative liability on the consolidated balance sheet and is measured at fair value. Changes in the fair value of the derivative liability are reported as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">change in fair value of derivative,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. The fair value of the derivative liability is determined at each period end using a with and without method, which assesses the likelihood and timing of a specified transaction that if triggered could result in a repayment. The fair value of the embedded derivative is estimated at $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="f-999">0.8</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023, and will be remeasured to fair value at each reporting date until the derivative is settled.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">169</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-904-2" continuedAt="f-904-3"><ix:continuation id="f-903-3" continuedAt="f-903-4"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-Party Warrant Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;12,&#160;2022 registered direct offering of common stock, the company issued <ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1000">9,090,909</ix:nonFraction>&#160;warrants (December&#160;2022&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023 and 2022, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-257" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-1001">6.60</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-258" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-1002">6.60</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-259" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="f-1003">1.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-260" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="f-1004">2.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-261" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1005">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-262" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1006">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-1007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-264" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-1008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1009">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-266" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1010">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the February&#160;15,&#160;2023 registered direct offering of common stock, the company issued <ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1011">14,072,615</ix:nonFraction>&#160;warrants. The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">February&#160;17,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-268" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-1012">3.2946</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-269" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-1013">4.2636</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-270" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="f-1014">2.6</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-271" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="f-1015">2.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-272" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1016">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-273" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1017">97.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-274" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-1018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-275" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-1019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-276" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1020">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1021">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, the company reduced the exercise price of the outstanding February&#160;2023&#160;Warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1022">4.2636</ix:nonFraction>&#160;per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1023">3.2946</ix:nonFraction>&#160;per share and extended the expiration date of the warrants until July&#160;24,&#160;2026. The effect of amending the terms of the warrants is reflected in a change in the fair value of warrant liability of $<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-1024">7.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">July 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the July&#160;20, 2023 registered direct offering of common stock, the company issued <ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1025">14,569,296</ix:nonFraction>&#160;warrants (July&#160;2023&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">July&#160;25,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-282" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-1026">3.2946</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-1027">3.2946</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-284" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="f-1028">2.6</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-285" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="f-1029">3.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-286" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1030">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-287" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1031">121.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-288" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-289" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-1033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-290" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1034">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-1035">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">170</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-903-4" continuedAt="f-903-5"><ix:continuation id="f-904-3" continuedAt="f-904-4"><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying amount of the warrant liabilities was as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:46.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.456%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2022<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">February&#160;2023<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July&#160;2023<br/>Warrants</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1036">21,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1037">21,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-1038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-1039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-1040">49,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-1041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-1042">23,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-1043">25,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1044">Change in fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1045">47,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1046">4,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1047">26,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1048">25,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1049">118,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1050">17,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1051">49,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1052">51,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;2022<br/>Warrants</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value at issuance, December&#160;12,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-1053">35,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1054">13,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1055">21,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1056">32.0</ix:nonFraction>&#160;million in U.S.&#160;government agency securities and $<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1057">8.8</ix:nonFraction>&#160;million in corporate debt securities with original maturities of less than 90&#160;days.</span></div></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Recurring Valuations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. Except for the impairments discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5152da74782c4119b27351f18d5b573b_17470">Note&#160;3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Details&#8212;Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were no other material non-financial assets or liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the years ended December&#160;31,&#160;2023, 2022 and 2021.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="f-903-5" continuedAt="f-903-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the promissory notes before and after amendments that were entered on December&#160;29,&#160;2023 and August&#160;31,&#160;2022, as they were accounted for under the debt extinguishment accounting model. We used discounted cash flow analyses for promissory notes without a holder conversion option and used binomial lattice models for promissory notes with a holder conversion option. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be a Level&#160;3 valuation. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_202">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Debt,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-903-6"> for more information.</ix:continuation> </span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_184"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="f-1058" continuedAt="f-1058-1" escape="true">Collaboration and License Agreements and Acquisition</ix:nonNumeric></span></div><ix:continuation id="f-1058-1" continuedAt="f-1058-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Cancer Institute </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2015 NCI CRADA</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2015, Etubics entered into a CRADA with the HHS as represented by the NCI of the NIH to collaborate on the preclinical and clinical development of an adenovirus technology expressing TAAs for cancer immunotherapy. In January&#160;2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;2018, our subsidiary NantCell assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing TAAs and proprietary adenovirus technology expressing TAAs for cancer immunotherapy. Pursuant to the CRADA, the NCI provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA. During the term of the CRADA, we were required to make annual payments of $<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" format="ixt:num-dot-decimal" scale="6" id="f-1059">0.6</ix:nonFraction>&#160;million to the NCI for support of research activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2021, NantCell entered into a third&#160;amendment to the CRADA, which was effective as of March&#160;16,&#160;2021. The principal changes effected by the third&#160;amendment are the following: (i)&#160;assignment of the CRADA from NantCell to ImmunityBio; (ii)&#160;modification of the research plan; (iii)&#160;extension of the CRADA term through May&#160;2026; and (iv)&#160;an increase in funding for a total of $<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="ibrx:CollaborationAgreementsAnnualProjectFundingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1060">1.3</ix:nonFraction>&#160;million per year, payable in semi-annual installments from 2022 through 2025. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">171</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1058-2" continuedAt="f-1058-3"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded R&amp;D expense of $<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities" format="ixt:num-dot-decimal" scale="6" id="f-1061">1.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities" format="ixt:num-dot-decimal" scale="6" id="f-1062">1.2</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities" format="ixt:num-dot-decimal" scale="6" id="f-1063">1.1</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the updated CRADA research plan, NCI and ImmunityBio will collaborate on the preclinical and clinical development of ImmunityBio&#8217;s proprietary adenovirus platform expressing TAAs; proprietary yeast platform expressing TAAs; proprietary agent N-803</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and derivatives, agent N-809 and derivatives, and/or TxM&#160;product candidates; proprietary recombinant NK&#160;cells and mAbs; proprietary RNA vaccines and adjuvants; and other proprietary agents owned or controlled by ImmunityBio as contemplated in the research plan, for cancer immunotherapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under any of the CRADAs, any party may unilaterally terminate the agreement by providing timely advance written notice to the other party before the desired termination date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of any of the CRADAs. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amyris Joint Venture</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2021, ImmunityBio and Amyris entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture is to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine-platform. As part of the limited liability agreement, Amyris contributed $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-1064">1.0</ix:nonFraction>&#160;million in cash and rights to its license agreement with AAHI for an RNA platform for the field of COVID-19. ImmunityBio contributed $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-1065">1.0</ix:nonFraction>&#160;million in cash and priority access to its manufacturing capacity for the joint venture product. Both parties agreed to enter into a separate manufacturing and supply agreement and a sublicense agreement following the execution of the joint venture agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint venture agreement stipulates the initial terms for equal representation in the management of the newly-formed joint venture. The joint venture is managed by a board of directors consisting of four&#160;directors: two appointed by the company and two&#160;appointed by Amyris. Both parties agreed to make additional capital contributions in cash, in proportion to their respective interests, as determined by the board of directors of the joint venture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered the joint venture entity as a VIE and determined that we are not the primary beneficiary of the VIE. We account for our investment in the joint venture using the equity method of accounting. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded our <ix:nonFraction unitRef="number" contextRef="c-311" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-1066">50</ix:nonFraction>%&#160;share of net losses from the joint venture totaling $<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1067">7.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1068">12.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1069">0.8</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. During the years ended December&#160;31,&#160;2023 and 2022, such losses incurred included $<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1070">7.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1071">11.9</ix:nonFraction>&#160;million, respectively, attributable to expenses incurred by us on behalf of the joint venture. We are not obligated to fund the joint venture&#8217;s potential future losses. In August&#160;2023, Amyris announced that it filed for Chapter&#160;11 bankruptcy protection. The Amyris bankruptcy case remains ongoing, and there can be no assurance that we will receive any recovery on account of our claims against Amyris, including for Amyris&#8217; portion of expenses incurred by the joint venture. As of December&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was <ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:fixed-zero" scale="6" id="f-1072">zero</ix:nonFraction>.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3M IPC and AAHI License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M&#160;IPC and its affiliates and AAHI. In November&#160;2021 we obtained nonexclusive rights in the field of SARS-CoV-2 and in June&#160;2022 we modified those rights and expanded the scope of the license to include (1)&#160;SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than LMIC, and (2)&#160;oncology applications, when used in combination with our proprietary technology and/or IL-15 agonists. In consideration for the license, we agreed to make certain periodic license payments, including $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-4" name="ibrx:CollaborationAgreementsPeriodicLicensePayments" format="ixt:num-dot-decimal" scale="6" id="f-1073">2.25</ix:nonFraction>&#160;million each year through June&#160;2025. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. Beginning in April&#160;2026, the annual minimum licensing payment is $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="ibrx:CollaborationAgreementsAnnualMinimumLicensingPayment" format="ixt:num-dot-decimal" scale="6" id="f-1074">1.0</ix:nonFraction>&#160;million, which can be credited against any royalty payments due under this agreement. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">172</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1058-3" continuedAt="f-1058-4"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2023 and 2022, we made annual license maintenance fee payments of $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-4" name="ibrx:CollaborationAgreementsPeriodicLicensePayments" format="ixt:num-dot-decimal" scale="6" id="f-1075">2.25</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-4" name="ibrx:CollaborationAgreementsLicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="6" id="f-1076">1.75</ix:nonFraction>&#160;million, respectively. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we expensed $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1077">2.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1078">1.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1079">0.5</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAHI License Agreements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into <ix:nonFraction unitRef="licenseagreement" contextRef="c-320" decimals="INF" name="ibrx:CollaborationAgreementsNumberOfLicenseAgreements" format="ixt-sec:numwordsen" id="f-1080">two</ix:nonFraction>&#160;license agreements with AAHI pursuant to which we received a license to certain patents and know-how relating to AAHI&#8217;s (i)&#160;adjuvant formulations for the treatment, prevention and/or diagnosis of SARS-CoV-2 (the AAHI&#160;Adjuvant Formulation License Agreement) and (ii)&#160;RNA vaccine platform as further described below (the&#160;AAHI RNA License Agreement). Under both agreements, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="ibrx:CollaborationAgreementsNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1081">2.0</ix:nonFraction>&#160;million. In addition, under the AAHI Adjuvant Formulation License Agreement we owe milestone payments to a total of up to $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum" format="ixt:num-dot-decimal" scale="6" id="f-1082">2.5</ix:nonFraction>&#160;million based on the achievement of certain development and regulatory milestones for the first&#160;licensed product and royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low-single digit percentage, subject to certain royalty-reduction provisions. During the years ended December&#160;31,&#160;2023 and 2022, <ix:nonFraction unitRef="usd" contextRef="c-322" decimals="INF" name="ibrx:CollaborationAgreementsMilestoneFees" format="ixt:fixed-zero" scale="0" id="f-1083"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="INF" name="ibrx:CollaborationAgreementsMilestoneFees" format="ixt:fixed-zero" scale="0" id="f-1084">no</ix:nonFraction></ix:nonFraction>&#160;milestone fees were incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we amended and restated the AAHI RNA License Agreement, pursuant to which AAHI granted us an exclusive, worldwide, sublicensable license to AAHI&#8217;s rights to an RNA&#160;vaccine platform for the development and commercialization of certain therapeutic, diagnostic, or prophylactic products for the prevention, treatment or diagnosis of any indication, other than those subject to pre-existing third-party license grants, including, without limitation, SARS-CoV-2. Pursuant to the terms of the amended and restated AAHI RNA License Agreement, we made a one-time, non-creditable, non-refundable, upfront payment to AAHI of $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="ibrx:CollaborationAgreementsNonrefundableUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1085">1.5</ix:nonFraction>&#160;million and a license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="ibrx:CollaborationAgreementsLicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="6" id="f-1086">3.0</ix:nonFraction>&#160;million in June&#160;2022. The company is required to pay license maintenance fees to AAHI of $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="ibrx:CollaborationAgreementsLicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="6" id="f-1087">5.5</ix:nonFraction>&#160;million annually from 2023 through 2030. The company may terminate the restated agreement without cause by paying AAHI a $<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="ibrx:CollaborationAgreementsTerminationFee" format="ixt:num-dot-decimal" scale="6" id="f-1088">10.0</ix:nonFraction>&#160;million one-time early termination fee. In addition, the milestone payments to AAHI based on the achievement of certain development and regulatory milestones for the first&#160;licensed product were amended to a total of up to $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum" format="ixt:num-dot-decimal" scale="6" id="f-1089">4.0</ix:nonFraction>&#160;million. We are required to pay royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low to mid-single digit percentage. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1090">4.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1091">1.8</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1092">1.5</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the license agreements, in May&#160;2021 we also entered into a sponsored research agreement with AAHI pursuant to which we will fund continued research of at least $<ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5" name="ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" format="ixt:num-dot-decimal" scale="6" id="f-1093">2.0</ix:nonFraction>&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. As of December&#160;31,&#160;2023, $<ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-3" name="ibrx:CollaborationAgreementsLicenseMaintenanceFeesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1094">0.5</ix:nonFraction>&#160;million payable to AAHI in connection with the sponsored research agreement was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheet. During the year ended December&#160;31,&#160;2023, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1095">1.2</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1096">3.7</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">loss on equity method investment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December&#160;31,&#160;2022, respectively, on the consolidated statements of operations related to the sponsored research agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viracta License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with Viracta under which we were granted exclusive worldwide rights to Viracta&#8217;s Phase&#160;II drug candidate, VRx-3996 (nanatinostat), for use in combination with our platform of NK&#160;cell therapies. In&#160;consideration for the license, we are obligated to pay Viracta mid-single digit percentage royalties on net sales of licensed products for therapeutic use and milestone payments ranging from $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1097">10.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1098">25.0</ix:nonFraction>&#160;million up to an aggregate maximum of $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum" format="ixt:num-dot-decimal" scale="6" id="f-1099">100.0</ix:nonFraction> million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, at our sole discretion, in whole or on a product by product and/or country by country basis, at any time upon 90&#160;days&#8217; prior written notice. In&#160;addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party. To&#160;date, we have not had incurred any royalty or milestone payment obligations under this agreement, including during the years ended December&#160;31,&#160;2023, 2022 and 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">173</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1058-4" continuedAt="f-1058-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dunkirk Facility Leasehold Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;14,&#160;2022, we completed the acquisition of the Dunkirk Facility (approximately <ix:nonFraction unitRef="sqft" contextRef="c-339" decimals="INF" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1100">409,000</ix:nonFraction> rentable square feet) from Athenex, which we believe will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our existing manufacturing capacity in the U.S. and the ability to scale production associated with certain of our product candidates. The company accounted for the transaction as an asset acquisition because the Dunkirk Facility&#8217;s integrated set of assets and activities does not meet the definition of a business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the acquisition was approximately $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-1101">40.5</ix:nonFraction>&#160;million, including a cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-1102">40.0</ix:nonFraction>&#160;million, and transaction costs of approximately $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="f-1103">0.5</ix:nonFraction>&#160;million. <ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionTableTextBlock" id="f-1104" continuedAt="f-1104-1" escape="true">The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):</ix:nonNumeric></span></div><ix:continuation id="f-1104-1" continuedAt="f-1104-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-1105">10,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-1106">6,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1107">21,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other depreciable assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1108">2,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="ibrx:AssetAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="f-1109">40,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">_______________</span></div></ix:continuation><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-1104-2" continuedAt="f-1104-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"><ix:continuation id="f-1104-3">Definite-lived intangible assets consist of favorable leasehold rights totaling $<ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-1110">20.4</ix:nonFraction>&#160;million and organized workforce totaling $<ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-1111">0.8</ix:nonFraction>&#160;million as of the acquisition date.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort&#160;Schuyler Management Corporation Lease, dated October&#160;1,&#160;2021 and as amended as of the February&#160;14,&#160;2022 closing date (as amended, the Dunkirk Lease), with the FSMC as landlord. The Dunkirk Facility, as well as certain equipment, is owned by the FSMC and is leased to us under the Dunkirk Lease. Our annual lease payment will be $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="INF" name="ibrx:LeaseOperatingLeaseAnnualLeasePayment" scale="0" id="f-1112">2.00</ix:nonFraction> per year&#160;for an initial <ix:nonNumeric contextRef="c-339" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-1113">10-year</ix:nonNumeric> term, with <ix:nonFraction unitRef="renewal_options" contextRef="c-339" decimals="INF" name="ibrx:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="f-1114">one</ix:nonFraction>&#160;option to renew the lease under substantially the same terms and conditions for an additional <ix:nonNumeric contextRef="c-339" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1115">10-year</ix:nonNumeric> term. As part of the transaction, we assumed certain of Athenex&#8217;s obligations under various third-party agreements (the Facility Agreements), subject to the terms and conditions of the purchase agreement by and between the company and Athenex dated as of January&#160;7,&#160;2022, and committed to spend an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-7" name="ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" format="ixt:num-dot-decimal" scale="9" id="f-1116">1.52</ix:nonFraction>&#160;billion on operational expenses during the initial term, and an additional $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-7" name="ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" format="ixt:num-dot-decimal" scale="9" id="f-1117">1.50</ix:nonFraction>&#160;billion on operational expenses if we elect to renew the lease for <ix:nonFraction unitRef="renewal_options" contextRef="c-339" decimals="INF" name="ibrx:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="f-1118">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-339" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1119">10-year</ix:nonNumeric> term. We also committed to hiring <ix:nonFraction unitRef="employee" contextRef="c-339" decimals="INF" name="ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" scale="0" id="f-1120">450</ix:nonFraction>&#160;employees at the Dunkirk Facility within the first five years following the Commencement Date, with <ix:nonFraction unitRef="employee" contextRef="c-339" decimals="INF" name="ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" scale="0" id="f-1121">300</ix:nonFraction>&#160;such employees to be hired within the first 2.5 years following the Commencement Date. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above. Failure to satisfy the obligations over the lease term may give rise to certain rights and remedies of governmental authorities including, for example, termination of the Dunkirk Lease and other Facility Agreements and potential recoupment of a percentage of the grant funding received by Athenex for construction of the facility and other benefits received, subject to the terms and conditions of the applicable agreements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that governmental funding will assist in funding a portion of the further build-out of the Dunkirk Facility, which we estimate to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="ibrx:LeaseholdInterestGovernmentFundingAvailable" format="ixt:num-dot-decimal" scale="6" id="f-1122">8.0</ix:nonFraction>&#160;million&#160;to $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="ibrx:LeaseholdInterestGovernmentFundingAvailable" format="ixt:num-dot-decimal" scale="6" id="f-1123">10.0</ix:nonFraction>&#160;million of governmental funding remaining available as of December&#160;31,&#160;2023, there can be no assurance as to the final acceptance and timing of the requests for governmental funding that we submit, and we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, any future governmental funding will be subject to the eligibility of submitted expenses, as well as our compliance with the obligations that we are subject to pursuant to the agreements with parties regarding the Dunkirk Facility as described above. Further, on May&#160;14,&#160;2023, Athenex, together with certain of its subsidiaries, filed voluntary petitions for relief under Chapter&#160;11 of the United States Bankruptcy Court for the Southern District of Texas (the Athenex Proceedings). We do not know what, if any, impact the Athenex Proceedings will have on any portion of the potential governmental funding remaining for the Dunkirk Facility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1058-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dunkirk Facility Workforce Reduction</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2022, the company initiated a workforce reduction at the Dunkirk Facility and recorded severance and retention benefits for the terminated employees totaling $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1124">1.0</ix:nonFraction>&#160;million during the year ended December&#160;31,&#160;2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1125">selling, general and administrative expense</span>, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations. The terminated employees were not required to render service through their termination date in December&#160;2022 to receive these benefits.</span></div></ix:continuation><div id="if7eeec8e66644046bbbe3c0a87df2c46_190"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1126" continuedAt="f-1126-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-1126-1" continuedAt="f-1126-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VivaBioCell, S.p.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2015, NantWorks, a related party, acquired a <ix:nonFraction unitRef="number" contextRef="c-346" decimals="INF" name="ibrx:PercentageOfWhollyOwnedSubsidiary" scale="-2" id="f-1127">100</ix:nonFraction>% interest in VivaBioCell through its wholly-owned subsidiary, VBC Holdings for $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-1128">0.7</ix:nonFraction>&#160;million, less working capital adjustments. In June&#160;2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of VBC, we are obligated to pay the former owners contingent consideration upon the achievement of certain milestones related to the GMP-in-a-Box technology. A clinical milestone totaling $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="ibrx:BusinessCombinationContingentConsiderationArrangementsEarned" format="ixt:num-dot-decimal" scale="6" id="f-1129">0.8</ix:nonFraction>&#160;million was earned by the former owners of VivaBioCell, of which $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements" format="ixt:num-dot-decimal" scale="6" id="f-1130">0.4</ix:nonFraction>&#160;million was paid during the year ended December&#160;31,&#160;2021, with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements" format="ixt:num-dot-decimal" scale="6" id="f-1131">0.3</ix:nonFraction>&#160;million clinical obligation, net of foreign exchange adjustment, settled during the year ended December&#160;31,&#160;2022. If a government agency unconditionally approves the GMP-in-a-Box technology for commercial sale (the regulatory milestone) in the future, we will be obligated to pay an additional approximately $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" format="ixt:num-dot-decimal" scale="6" id="f-1132">2.2</ix:nonFraction>&#160;million to the former owners.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="ibrx:ContingentValueRightsObligations" format="ixt:num-dot-decimal" scale="6" id="f-1133">304.0</ix:nonFraction>&#160;million of contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-8" name="ibrx:MinimumNetSalesMilestoneContingentValueRightsObligation" format="ixt:num-dot-decimal" scale="9" id="f-1134">1.0</ix:nonFraction>&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable. As of December&#160;31,&#160;2023, Dr.&#160;Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer, and his related party hold approximately $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="ibrx:ContingentValueRightsObligations" format="ixt:num-dot-decimal" scale="6" id="f-1135">139.8</ix:nonFraction>&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="ibrx:ContingentValueRightsObligations" format="ixt:num-dot-decimal" scale="6" id="f-1136">164.2</ix:nonFraction>&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience, LLC Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, NantCell announced it had entered into a definitive merger agreement to acquire Altor. An action captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gray v.&#160;Soon-Shiong, et&#160;al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (Gray) and Adam&#160;R.&#160;Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">175</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1126-2" continuedAt="f-1126-3"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara&#160;Sturm Waldman and Douglas E. Henderson (Henderson)) filed a second&#160;amended complaint, including appraisal claims, and which the defendants subsequently moved to dismiss. In a second&#160;action, Dyad Pharmaceutical Corporation (Dyad) filed a petition in Delaware Chancery Court for appraisal in connection with the merger. The defendants moved to dismiss the appraisal petition in 2018. The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor from the action. The following claims remained: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the court issued a written order implementing its ruling on the defendants&#8217; motions (the Implementing Order). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o&#160;C. Boyden Gray, were dismissed. The plaintiffs then moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the court granted the plaintiffs&#8217; motion, and the plaintiffs filed the third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counterclaims against the plaintiffs. The defendants sought damages for attorneys&#8217; fees and costs incurred as a result of the breaches of &#8220;standstill&#8221; agreements and of stockholder releases. The plaintiffs filed an answer denying the counterclaims and asserting defenses. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the former Altor stockholders seeking appraisal met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date, given that those shares were the subject of the above-described appraisal claims. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March&#160;2022, the company agreed to the terms of a settlement with the appraisal petitioners, without any admission of liability or fault. The settlement provided that in exchange for complete releases, the appraisal petitioners, who as a group held <ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="ibrx:NumberOfDissentingShares" format="ixt:num-dot-decimal" scale="0" id="f-1137">3,167,565</ix:nonFraction>&#160;dissenting Altor shares, collectively would receive an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="ibrx:LitigationSettlementNumberOfSharesToBeIssued" format="ixt:num-dot-decimal" scale="0" id="f-1138">2,229,296</ix:nonFraction>&#160;shares of the company&#8217;s common stock issued in a private placement, plus an aggregate of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="INF" name="ibrx:SharesIssuedCashDistributedInLieuOfFractionalShares" scale="0" id="f-1139">21.13</ix:nonFraction>&#160;in cash in lieu of fractional shares. The company&#8217;s Board of Directors approved the settlement and stock issuance in April&#160;2022, and the court approved the settlement and dismissed the appraisal petitioners&#8217; claims on July&#160;9,&#160;2022. On July&#160;9,&#160;2022, the company issued <ix:nonFraction unitRef="shares" contextRef="c-356" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1140">2,229,296</ix:nonFraction>&#160;shares of its common stock with an aggregate market value of $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="f-1141">10.7</ix:nonFraction>&#160;million, based on the closing price of its common stock on the Nasdaq as of July&#160;8,&#160;2022, to the appraisal petitioners pursuant to the court-approved settlement agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late April&#160;2022, the company also agreed to the terms of a settlement with the putative class plaintiffs without any admission of liability or fault. In exchange for class-wide releases, the company committed to make a settlement payment of $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="f-1142">5.0</ix:nonFraction>&#160;million in cash by December&#160;31,&#160;2022. On December&#160;8,&#160;2022, the Delaware Court of Chancery entered a final judgment approving the settlement, and the company timely made the $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-1143">5.0</ix:nonFraction>&#160;million settlement payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sorrento Therapeutics, Inc. Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sorrento, derivatively on behalf of NANTibody, filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company&#8217;s subsidiary NantCell, Dr.&#160;Soon-Shiong, and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol from NantPharma and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. Trial had been set to commence in Sorrento&#8217;s Superior Court action on August&#160;7,&#160;2023, but on July&#160;24,&#160;2023 the Superior Court vacated the August&#160;7,&#160;2023 trial date at the parties&#8217; request in light of the pending settlement discussed below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#8217;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">176</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1126-3" continuedAt="f-1126-4"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April&#160;2021 and concluded in early August&#160;2021. After post-hearing briefing was concluded, the parties were notified on November&#160;30,&#160;2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February&#160;25,&#160;2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July&#160;2022, and summations took place on August&#160;2,&#160;2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two&#160;exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1144">156.8</ix:nonFraction> million and NANTibody approximately $<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1145">16.7</ix:nonFraction> million, plus post-award interest accruing at a daily rate. On December&#160;21,&#160;2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January&#160;16,&#160;2023, Sorrento filed a response to the petitions and moved to vacate the award. On February&#160;7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento&#8217;s motion to vacate. The Superior Court entered judgments against Sorrento in the aggregate amount of approximately $<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1146">176.4</ix:nonFraction>&#160;million plus <ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF" name="ibrx:LitigationSettlementInterestPercent" scale="-2" id="f-1147">10</ix:nonFraction>% post-judgment interest, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1148">159.4</ix:nonFraction>&#160;million was payable to NantCell, and the remainder of which was payable to NANTibody. On February&#160;13,&#160;2023, Sorrento informed counsel to the company that it had filed a Chapter&#160;11 proceeding in the U.S. District Court for the Southern District of Texas, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In&#160;re:&#160;Sorrento Therapeutics,&#160;Inc., et&#160;al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No.&#160;23-90085 (DRJ), Docket Entry&#160;810. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;6,&#160;2023, Sorrento filed a motion in its Chapter&#160;11 proceeding for entry of an order approving and implementing a mediation settlement reached with the company and other entities. The settlement involved two&#160;possible scenarios: Either, if Sorrento were to raise an amount needed to pay its debtor in possession lender and its unsecured creditors by August&#160;31,&#160;2023, Sorrento would pay those obligations, including the judgments held by NantCell and NANTibody, by 2:00&#160;p.m.&#160;ET on August&#160;31,&#160;2023 and be free to proceed with pending litigation; or, failing that, the judgments would be released, the litigation claims would be released, including, without limitation, the Superior Court action discussed above, Sorrento would relinquish its interests in NANTibody and certain other entities, Sorrento would forfeit its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell (rights to PD-L1), and certain other provisions not impacting the company would be implemented as described in the motion. On August&#160;14,&#160;2023, the United States Bankruptcy Court for the Southern District of Texas issued an order approving the settlement described above, such that the settlement became binding on the parties. As of 2:00&#160;p.m. ET on August&#160;31,&#160;2023, Sorrento had not paid the judgments held by NantCell and NANTibody. Accordingly, in relevant part to the company and NantCell, a mutual release of claims became effective such that the aforementioned judgments were released, the litigation claims were released including, without limitation, the derivative litigation against NantCell described above, Sorrento relinquished its interests in NANTibody, and Sorrento forfeited its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell, including any royalties associated with the company&#8217;s engineered NK&#160;cell therapy in Phase&#160;II clinical trials, PD-L1 t-haNK. As a result of the settlement, the parties filed dismissals of the litigation matters discussed above. After the settlement, the company&#8217;s ownership in NANTibody increased from <ix:nonFraction unitRef="number" contextRef="c-364" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-1149">60</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-365" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-1150">100</ix:nonFraction>%, and, as a result, the carrying amount of the noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="6" id="f-1151">4.2</ix:nonFraction>&#160;million was adjusted and recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to the company, on the consolidated statement of stockholders&#8217; deficit. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shenzhen Beike Biotechnology Co. Ltd. Arbitration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill agreement under which, among other things, the parties affirmed they would perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration were indefinitely extended. The standstill agreement could be terminated by any party on ten&#160;calendar days&#8217; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">177</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1126-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We served an Answer and Counterclaims on May&#160;19,&#160;2023. Beike served a Reply to our counterclaims on June&#160;21,&#160;2023. Beike&#8217;s Statement of Claim is due on March&#160;22,&#160;2024, and the company&#8217;s Statement of Defense and Counterclaim is due on June&#160;21,&#160;2024. The hearing in the arbitration is scheduled to begin on June&#160;9,&#160;2025. Given that no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims asserted against the company lack merit and intend to defend the case, and to pursue or counterclaims, vigorously.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;30,&#160;2023, a putative securities class action complaint, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salzman v. ImmunityBio, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:23-cv-01216-BEN-WVG, was filed in the U.S.&#160;District Court for the Southern District of California against the company and three&#160;of its officers and/or directors, asserting violations of Sections&#160;10(b) and 20(a) of the Exchange Act. Stemming from the&#160;company&#8217;s disclosure on May&#160;11,&#160;2023 that it had received an FDA CRL stating, among other things, that it could not approve the company&#8217;s BLA for its product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, in its present form due to deficiencies related to its pre-license inspection of the company&#8217;s third-party CMOs, the complaint alleges that the defendants had previously made materially false and misleading statements and/or omitted material adverse facts regarding its third-party clinical manufacturing organizations and the prospects for regulatory approval of the BLA. On September&#160;27,&#160;2023, the court appointed a lead plaintiff, approved their selection of lead counsel, and re-captioned the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. ImmunityBio, Inc. Securities Litigation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No.&#160;3:23-cv-01216. On November&#160;17,&#160;2023, lead plaintiff filed an amended complaint, which named the same defendants and asserted the same claims as the previous complaint. On January&#160;8, 2024, defendants filed a motion to dismiss the amended complaint. A hearing on the motion is currently scheduled for April&#160;23,&#160;2024.The company believes the lawsuit is without merit and intends to defend the case vigorously. The company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in this action. If an unfavorable outcome were to occur, it is possible that the impact could be material to the company&#8217;s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconditional Purchase Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unconditional purchase obligations are defined as an agreement to purchase goods or services that are enforceable and legally binding (non-cancelable, or cancelable only in certain circumstances). In the normal course of business, we enter into unconditional purchase obligation arrangements with a third-party CMO to reserve manufacturing slots in its cGMP manufacturing facility for the manufacture and supply of cGMP batches per FDA and EMA regulations for commercial use. The total amount of future non-cancelable purchase commitments related to the manufacture of cGMP batches is $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1152">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="6" id="f-1153">0.9</ix:nonFraction>&#160;million for the years&#160;ending December&#160;31,&#160;2024 and 2025, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our total unconditional purchase obligation related to hosted software license subscription fees and implementation costs at $<ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-1154">5.2</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023. Payments by year are estimated as follows: 2024&#160;($<ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1155">1.6</ix:nonFraction>&#160;million), 2025&#160;($<ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="6" id="f-1156">1.8</ix:nonFraction>&#160;million) and 2026&#160;($<ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="6" id="f-1157">1.8</ix:nonFraction>&#160;million). Additionally, our total unconditional purchase obligation for laboratory cleanroom service costs are estimated at $<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-1158">1.9</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023. Payments by year are estimated as follows: 2024&#160;($<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1159">0.5</ix:nonFraction>&#160;million) and 2025&#160;($<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="6" id="f-1160">1.4</ix:nonFraction>&#160;million). The purchase obligation amounts do not represent the entire anticipated purchases in the future, but represent only those items for which we are contractually obligated. The majority of our goods and services are purchased as needed, with no unconditional commitment. For this reason, these amounts do not provide an indication of our expected future cash outflows related to purchases.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we did not enter into any significant contracts or material unconditional purchase commitments, other than those disclosed in these consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">178</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_199"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-1162" continuedAt="f-1162-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1161" continuedAt="f-1161-1" escape="true">Lease Arrangements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-1162-1" continuedAt="f-1162-2"><ix:continuation id="f-1161-1" continuedAt="f-1161-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease property in multiple facilities across the U.S. and Italy, including facilities located in El&#160;Segundo,&#160;CA and the Dunkirk Facility in upstate New&#160;York. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rentals at the Dunkirk Facility. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information about our related-party leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:f-1163">two</span> to <ix:nonNumeric contextRef="c-371" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-1164">ten years</ix:nonNumeric> and often include one or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:f-1165">one</span> to <ix:nonNumeric contextRef="c-371" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1166">ten years</ix:nonNumeric>, and are included in the lease term when it is reasonably certain that we will exercise the option.</span></div><ix:nonNumeric contextRef="c-1" name="ibrx:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-1167" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:33.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1168">36,543</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1169">45,788</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1170"><span style="-sec-ix-hidden:f-1171">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-1172">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-1173">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1174">36,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1175">45,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1176">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1177">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1178"><span style="-sec-ix-hidden:f-1179">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1180">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1181">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1182">39,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1183">47,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1184"><span style="-sec-ix-hidden:f-1185">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-1187">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1188">45,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1189">50,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1190" continuedAt="f-1190-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:71.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.541%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 7pt 0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1191">6.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1192">6.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1193">0.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1194">1.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1195">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1196">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1197">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1198">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">179</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1162-2"><ix:continuation id="f-1161-2"><ix:continuation id="f-1190-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:60.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1199">11,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1200">11,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1201">7,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1202">4,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1203">3,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="f-1204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including right-of-use asset <br/>&#160;&#160;&#160;amortization and interest expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" scale="3" id="f-1205">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" scale="3" id="f-1206">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" format="ixt:fixed-zero" scale="3" id="f-1207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1208">3,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1209">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1210">2,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1211">18,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1212">18,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1213">10,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:59.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1214">9,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1215">10,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1216">9,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-1217">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-1218">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="f-1219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-1220">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-1221">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:fixed-zero" scale="3" id="f-1222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of December&#160;31,&#160;2023, including $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" format="ixt:num-dot-decimal" scale="6" id="f-1223">11.5</ix:nonFraction>&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1224" escape="true"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1225">10,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-1226">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearOne" format="ixt:num-dot-decimal" scale="3" id="f-1227">10,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1228">10,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:fixed-zero" scale="3" id="f-1229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1230">10,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1231">8,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="f-1232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1233">8,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1234">8,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-1235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1236">8,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1237">8,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="f-1238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityToBePaidYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1239">8,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1240">16,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityToBePaidAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1242">16,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1243">62,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-1244">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityToBePaid" format="ixt:num-dot-decimal" scale="3" id="f-1245">63,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1246">17,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-1247">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityUndiscountedExcessInterest" format="ixt:num-dot-decimal" scale="3" id="f-1248">17,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" scale="3" id="f-1249">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" format="ixt:fixed-zero" scale="3" id="f-1250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiabilityTenantImprovementAllowanceReceivable" scale="3" id="f-1251">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1252">45,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-1253">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1254">45,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we extended some existing related-party leases and terminated an existing related-party lease. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information regarding our related-party leases.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">180</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_952"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1255" continuedAt="f-1255-1" escape="true">Revenue Interest Purchase Agreement</ix:nonNumeric></span></div><ix:continuation id="f-1255-1" continuedAt="f-1255-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland, to support the commercialization of Anktiva, our lead product candidate, to further the development of our product platforms, and to provide for other working capital needs. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="ibrx:PurchaseAgreementTotalInvestmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1256">200.0</ix:nonFraction>&#160;million paid on closing, less certain transaction expenses. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment" format="ixt:num-dot-decimal" scale="6" id="f-1257">100.0</ix:nonFraction>&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including following the receipt of approval by the FDA of the company&#8217;s BLA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on or before June&#160;30,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales during such quarter, which will be tiered payments initially ranging from <ix:nonFraction unitRef="number" contextRef="c-372" decimals="2" name="ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" scale="-2" id="f-1258">3.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-373" decimals="2" name="ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" scale="-2" id="f-1259">7.00</ix:nonFraction>% (or after funding of the Second&#160;Payment, <ix:nonFraction unitRef="number" contextRef="c-374" decimals="3" name="ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" scale="-2" id="f-1260">4.50</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-375" decimals="1" name="ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" scale="-2" id="f-1261">10.00</ix:nonFraction>%) of the company&#8217;s worldwide net sales, excluding those in China. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the aggregate Revenue Interest Payments made to Oberland as of December&#160;31,&#160;2029 equal or exceed the Cumulative Purchaser Payments as of that date, the initially tiered revenue interest rate will be decreased to a single rate of <ix:nonFraction unitRef="number" contextRef="c-376" decimals="3" name="ibrx:RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" scale="-2" id="f-1262">1.50</ix:nonFraction>% (or after the funding of the Second Payment, <ix:nonFraction unitRef="number" contextRef="c-377" decimals="4" name="ibrx:RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" scale="-2" id="f-1263">2.25</ix:nonFraction>%) of the company&#8217;s worldwide net sales, excluding those in China. If the aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then following the Test Date the initially tiered revenue interest rate will increase to a rate that, had such increased rate applied during the period from December&#160;29,&#160;2023 through December&#160;31,&#160;2029, it would have resulted in Oberland receiving aggregate Revenue Interest Payments (excluding certain payments detailed in the RIPA) equal to the Cumulative Purchaser Payments as of the Test Date. In addition, if aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then the company must make the True-Up Payment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oberland&#8217;s rights to receive Revenue Interest Payments under the RIPA shall terminate when Oberland has received payments (including any True-Up Payment) equal to <ix:nonFraction unitRef="number" contextRef="c-378" decimals="2" name="ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage" scale="-2" id="f-1264">195.0</ix:nonFraction>% of the then Cumulative Purchaser Payments unless the RIPA is terminated prior to such date. If Oberland has not received total payments (including any True-Up Payment) equal to <ix:nonFraction unitRef="number" contextRef="c-378" decimals="2" name="ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage" scale="-2" id="f-1265">195.0</ix:nonFraction>% of the then Cumulative Purchaser Payments on or before the twelfth&#160;anniversary of the RIPA, then the company shall be obligated to pay to Oberland an amount equal to <ix:nonFraction unitRef="number" contextRef="c-378" decimals="2" name="ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage" scale="-2" id="f-1266">195.0</ix:nonFraction>% of the then Cumulative Purchaser Payments less the aggregate payments (including any True-Up Payments) made as of such date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA, the company has a Call Option to terminate the RIPA and repurchase the Revenue Interests at any time upon advance written notice, subject to certain limitations set forth in the RIPA. Additionally, Oberland has a Put Option enabling them to terminate the RIPA and to require the company to repurchase the Revenue Interests upon enumerated events, such as a bankruptcy event, failure to make a payment, an uncured material breach, default in certain third-party agreements, a breach or default under any subordination agreements with respect to indebtedness to existing stockholders, or subordinated notes during certain time periods, judgments in excess of certain amounts against the company, a material adverse effect, the loss of regulatory approval of our product candidates or a change of control. The required purchase price with respect to the Call Option and/or Put Option, as applicable, shall be (a)&#160;<ix:nonFraction unitRef="number" contextRef="c-379" decimals="4" name="ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" scale="-2" id="f-1267">120.0</ix:nonFraction>% of the Cumulative Purchaser Payments as of such date, if Oberland exercises the Put Option (other than in connection with a change of control) on or prior to the first anniversary the Closing Date, (b)&#160;<ix:nonFraction unitRef="number" contextRef="c-380" decimals="4" name="ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" scale="-2" id="f-1268">135.0</ix:nonFraction>% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised in connection with a change of control on or prior to the date that is eighteen (18)&#160;months after the Closing Date, and (c)&#160;in all other cases, (i)&#160;<ix:nonFraction unitRef="number" contextRef="c-381" decimals="4" name="ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" scale="-2" id="f-1269">175.0</ix:nonFraction>% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised no later than the date that is thirty&#160;six (36)&#160;months after the Closing Date, and (ii)&#160;<ix:nonFraction unitRef="number" contextRef="c-382" decimals="4" name="ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" scale="-2" id="f-1270">195.0</ix:nonFraction>% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised later than the date that is thirty&#160;six (36)&#160;months after the Closing Date, minus, in each case, the total payments made to Oberland on or prior to such date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company&#8217;s obligations under the RIPA are guaranteed by certain of its subsidiaries meeting materiality thresholds set forth in the RIPA. To secure the company&#8217;s obligations under the RIPA and the subsidiary guarantors&#8217; obligations under the guarantees, each of the company and the subsidiary guarantors has granted a security interest in substantially all its assets, subject to certain exceptions and limitations. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">181</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1255-2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA contains affirmative and negative covenants and events of default, including covenants and restrictions that, among other things, restrict our ability to incur additional liens, incur additional indebtedness, make loans and investments, enter into transactions with affiliates, engage in mergers and acquisitions, engage in asset sales and exclusive licensing arrangements, and declare dividends to our stockholders, in each case, subject to certain exceptions set forth in the RIPA. As of December&#160;31,&#160;2023, the company was in compliance with all covenants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA is considered a sale of future revenues and accounted for as long-term debt recorded at amortized cost using the effective interest rate method.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on December&#160;29,&#160;2023 and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1271">10.0</ix:nonFraction>&#160;million of our common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-383" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1272">4.1103</ix:nonFraction>&#160;per share in a private placement. Oberland also has an option to purchase up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="ibrx:SaleOfStockAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="f-1273">10.0</ix:nonFraction>&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability estimated at fair value at issuance. The $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="ibrx:PurchaseAgreementTotalInvestmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-1274">200.0</ix:nonFraction>&#160;million received pursuant to the&#160;RIPA and $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1275">10.0</ix:nonFraction>&#160;million received pursuant to the SPOA were allocated among the resulting financial instruments on a relative fair value basis, with $<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1276">197.1</ix:nonFraction>&#160;million allocated to the debt under the RIPA, $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1277">12.0</ix:nonFraction>&#160;million allocated to the common stock issued under the SPOA, and $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1278">0.8</ix:nonFraction>&#160;million allocated to the stock purchase option. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Put Option under the RIPA that is exercisable by Oberland upon certain contingent events and the Call Option that is exercisable by the company upon a change of control were determined to be embedded derivatives requiring bifurcation and separately accounted for as a single compound derivative instrument. The company recorded the initial fair value of the derivative liability of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="f-1279">34.5</ix:nonFraction>&#160;million as a debt discount, which will be amortized to interest expense over the expected term of the debt using the effective interest rate method.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the RIPA, as of December&#160;31,&#160;2023 $<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1280">155.4</ix:nonFraction>&#160;million was recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">revenue interest liability,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales may materially impact the revenue interest liability, interest expense, other income, and the time period for repayment. During the year ended December&#160;31,&#160;2023, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-1281">0.3</ix:nonFraction>&#160;million of interest expense related to this arrangement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company incurred $<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1282">7.5</ix:nonFraction>&#160;million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the debt.</span></div><ix:nonNumeric contextRef="c-1" name="ibrx:SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" id="f-1283" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the year ended December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability at inception</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="f-1284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the RIPA, gross</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="ibrx:ProceedsFromIssuanceOfSecuredDebtGross" format="ixt:num-dot-decimal" scale="3" id="f-1285">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1286">7,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the RIPA, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-1287">192,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded contingent derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-3" name="ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod" format="ixt:num-dot-decimal" scale="3" id="f-1288">34,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-3" name="ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod" format="ixt:num-dot-decimal" scale="3" id="f-1289">2,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock purchase option</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" name="ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod" scale="3" id="f-1290">819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="f-1291">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability as of December&#160;31,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1292">155,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">182</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_202"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1293" continuedAt="f-1293-1" escape="true">Related-Party Debt </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" id="f-1294" continuedAt="f-1294-1" escape="true"><ix:continuation id="f-1293-1" continuedAt="f-1293-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.405%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1295">505</ix:nonFraction> million December 2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-391" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1296">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1297">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1298">20,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1299">104,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1300">300</ix:nonFraction> million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1301">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1302">26,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1303">273,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1304">50</ix:nonFraction> million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1305">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1306">4,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1307">45,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1308">30</ix:nonFraction> million June&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1309">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1310">2,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1311">27,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1312">505</ix:nonFraction> million December 2023 Promissory Note Tranche 2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-403" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="0" id="f-1313">7.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1314">380,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1315">33,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1316">346,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1317">30</ix:nonFraction> million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-407" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1318">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1319">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="f-1320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1321">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1322">200</ix:nonFraction> million September&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-411" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1323">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1324">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="f-1325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1326">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1327">610,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1328">33,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1329">576,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued PIK<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized<br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1330">300</ix:nonFraction> million December&#160;2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-414" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1331">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1332">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1334">35,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1335">264,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1336">125</ix:nonFraction> million August&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-417" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1337">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1338">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1340">7,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1341">117,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1342">50</ix:nonFraction> million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-419" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1343">8.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1344">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="f-1346">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1347">49,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party nonconvertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1348">475,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1350">43,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1351">431,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2015 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-422" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1352">5.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1353">55,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1354">9,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1355">5,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1356">59,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2020 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-424" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1357">6.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1358">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1359">7,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1360">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1361">52,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2021 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-426" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1362">6.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1363">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1365">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1366">37,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NantMobile Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-428" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1367">3.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1368">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1369">5,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1370">5,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1371">54,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCSC Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-430" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1372">5.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1373">33,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1374">7,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1375">3,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1376">37,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1377">233,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1378">29,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1379">21,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1380">241,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-2" continuedAt="f-1293-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1381">300.0</ix:nonFraction>&#160;million December 2021 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;17,&#160;2021, the company executed a $<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1382">300.0</ix:nonFraction>&#160;million promissory note with N</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ant&#160;Capital, an af</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filiated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. The note bore an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-433" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1383">5.4</ix:nonFraction>%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances were due on December&#160;17,&#160;2022. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into shares of the company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-434" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1384">5.67</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company and Nant&#160;Capital entered into an amended and restated promissory note, pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2023 and the interest rate was amended to Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-435" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1385">8.0</ix:nonFraction>%&#160;per annum. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which this existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1386">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-436" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1387">7.5</ix:nonFraction>%&#160;per annum. Based on the terms of the amended and restated promissory note, the noteholder, at its sole discretion, may convert all of the Tranche&#160;2 $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1388">380.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal amount into shares of common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-437" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1389">8.2690</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1390">125.0</ix:nonFraction>&#160;million August 2022 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company executed a $<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1391">125.0</ix:nonFraction>&#160;million promissory note with Nant&#160;Capital. The note bears an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-438" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1392">8.0</ix:nonFraction>%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note letter agreement pursuant to which the existing promissory note was amended to be included in the Tranche&#160;1 principal amount of the amended $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1393">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025 and an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-438" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1394">8.0</ix:nonFraction>% per annum. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1395">50.0</ix:nonFraction>&#160;million December 2022 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12,&#160;2022, the company executed a $<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1396">50.0</ix:nonFraction>&#160;million promissory note with Nant&#160;Capital. The note bore an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-439" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1397">8.0</ix:nonFraction>%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a specified transaction (as defined in the note), the noteholder can request the outstanding principal and interest due on the loan to be repaid in full upon consummation of such specified transaction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1398">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-440" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1399">7.5</ix:nonFraction>%&#160;per annum. Pursuant to the terms of the amended and restated promissory note, the investor, in its sole discretion may convert all of the outstanding Tranche&#160;2 principal amount into shares of common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-441" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1400">8.2690</ix:nonFraction>&#160;per share. The noteholder can request up to $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="ibrx:DebtInstrumentPrepaymentAndAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1401">50.0</ix:nonFraction>&#160;million of the Tranche&#160;2 principal amount and accrued interest to be repaid upon consummation of such specified transaction.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">184</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-3" continuedAt="f-1293-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1402">30.0</ix:nonFraction>&#160;million March 2023 Promissory Note </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31,&#160;2023, the company executed a $<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1403">30.0</ix:nonFraction>&#160;million promissory note with Nant&#160;Capital. This note bears interest at Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-407" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1404">8.0</ix:nonFraction>%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest was originally due on December&#160;31,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. Upon receipt of a written notice of prepayment from the company, the noteholder may choose to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon into shares of the company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-443" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1405">2.28</ix:nonFraction>&#160;per share. Additionally, the noteholder may at its option convert the entire outstanding principal amount of the promissory note and accrued interest into shares of the company&#8217;s common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-443" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1406">2.28</ix:nonFraction> per share, at the option of the noteholder. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="f-1407">29.9</ix:nonFraction>&#160;million from this financing, net of a $<ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-1408">0.1</ix:nonFraction>&#160;million origination fee paid to the noteholder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of the $<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1409">30.0</ix:nonFraction>&#160;million promissory note described above was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of this promissory note was extended to December&#160;31,&#160;2025. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1410">30.0</ix:nonFraction>&#160;million June 2023 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;13,&#160;2023, the company executed a $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1411">30.0</ix:nonFraction>&#160;million promissory note with Nant&#160;Capital, pursuant to which, the company could request up to <ix:nonFraction unitRef="advance" contextRef="c-400" decimals="INF" name="ibrx:DebtInstrumentNumberOfAdvances" format="ixt-sec:numwordsen" scale="0" id="f-1412">three</ix:nonFraction>&#160;(3) advances of $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="ibrx:DebtInstrumentFaceAmountPerTranche" format="ixt:num-dot-decimal" scale="6" id="f-1413">10.0</ix:nonFraction>&#160;million each. The principal amount of each advance bore interest rate at Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-445" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1414">8.0</ix:nonFraction>%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances was originally due on December&#160;31,&#160;2023. We may prepay the outstanding principal amount, together with any accrued interest, on any then-outstanding advances, at any time, in whole or in part, without premium or penalty, and without the prior consent of the noteholder upon five&#160;(5) days written notice to the noteholder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="f-1415">29.9</ix:nonFraction>&#160;million from this promissory note, net of a $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-1416">0.1</ix:nonFraction>&#160;million origination fee paid to Nant&#160;Capital. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1417">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-447" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1418">7.5</ix:nonFraction>%&#160;per annum. Pursuant to the terms of the amended and restated promissory note the investor, in its sole discretion may convert all of the Tranche&#160;2 $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1419">380.0</ix:nonFraction>&#160;million principal amount into shares of common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-448" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1420">8.2690</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1421">200.0</ix:nonFraction>&#160;million September 2023 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company executed a $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1422">200.0</ix:nonFraction>&#160;million convertible promissory note with Nant&#160;Capital. The note bears interest at Term&#160;SOFR plus <ix:nonFraction unitRef="number" contextRef="c-449" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1423">8.0</ix:nonFraction>%&#160;per annum, payable on a monthly basis. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;11,&#160;2026. We may prepay the outstanding principal amount, together with any accrued interest, at any time, in whole or in part, without premium or penalty upon five&#160;(5) days written notice to the noteholder. The noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-410" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1424">1.9350</ix:nonFraction>&#160;per share. The company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-5" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="6" id="f-1425">199.0</ix:nonFraction>&#160;million from this financing, net of a $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-1426">1.0</ix:nonFraction>&#160;million origination fee paid to the noteholder. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">185</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-4" continuedAt="f-1293-5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Footnotes to Related-Party Debt Tables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Modification and Debt Extinguishments</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">August 2022 Debt Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company amended and restated the above fixed-rate notes payables held by Nant&#160;Capital, NantWorks, NantMobile and NCSC, which are entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and thereafter continued to bear interest at a per annum rate ranging from <ix:nonFraction unitRef="number" contextRef="c-451" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1427">3.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-452" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1428">6.0</ix:nonFraction>%, provided that the outstanding principal was and thereafter continued to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continued to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and thereafter continued to be able to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the noteholder, subject to an advance notice period of at least five business days during which the noteholder could convert the amount requested to be prepaid by the company into shares of the company&#8217;s common stock, as part of the amendment and restatement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gave each noteholder, at its sole option, at any time (other than when the noteholder is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-453" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1429">5.67</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above promissory notes were entered into or amended at the same time and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. ASC&#160;470-50 provides that a modification or an exchange that adds or eliminates a substantive conversion option as of the conversion date would always be considered substantial and require extinguishment accounting. Accordingly, as a result of the addition of the conversion feature to the fixed-rate promissory notes, the fixed-rate promissory notes and the variable-rate promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments. Under this model, the company calculated a gain on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="f-1430">82.9</ix:nonFraction>&#160;million, representing the difference between the fair value of the new and amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts plus the cash proceeds from the new promissory note. Since the debt was obtained from entities under common control, such gain was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022. Also, the difference between the face values of the new and amended promissory notes (and accrued interest on the date of the amendment) and the fair values of the new and restated promissory notes was recorded as a debt discount to be amortized to interest expense over the remaining term (or until conversion in the case of fixed-rate promissory notes) of the respective promissory notes. During the year ended December&#160;31,&#160;2022, we recorded amortization of related-party notes discounts totaling $<ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="f-1431">16.3</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the promissory notes without a holder conversion option were estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair values of the fixed-rate promissory notes, which were each modified to include a holder conversion option, were determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included market yields from <ix:nonFraction unitRef="number" contextRef="c-455" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1432">18.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-456" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1433">24.8</ix:nonFraction>% and a risk-free rate of <ix:nonFraction unitRef="number" contextRef="c-457" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1434">4.1</ix:nonFraction>%, and the significant unobservable inputs used for the binomial lattice model included a volatility of <ix:nonFraction unitRef="number" contextRef="c-458" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1435">84.9</ix:nonFraction>%, a market yield of <ix:nonFraction unitRef="number" contextRef="c-459" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1436">17.4</ix:nonFraction>% and a risk-free rate of <ix:nonFraction unitRef="number" contextRef="c-460" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1437">3.5</ix:nonFraction>%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, the company received written notice from NantWorks, the holder of an existing convertible promissory note of NantCell, a wholly-owned subsidiary of the company, of its election to convert the NantCell promissory note into shares of the company&#8217;s common stock. As of such date, the holder of the NantCell note converted the entire $<ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="ibrx:LongTermDebtGrossIncludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1438">56.6</ix:nonFraction>&#160;million of outstanding principal and accrued and unpaid interest due under the note into <ix:nonFraction unitRef="shares" contextRef="c-462" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-1439">9,986,920</ix:nonFraction>&#160;shares of the company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-463" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1440">5.67</ix:nonFraction>&#160;per share in accordance with the terms of the promissory note. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">186</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-5" continuedAt="f-1293-6"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">September&#160;11,&#160;2023 Debt Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the holders exchanged promissory notes totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="ibrx:LongTermDebtGrossIncludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1441">270.0</ix:nonFraction>&#160;million in aggregate principal amount and accrued and unpaid interest for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-465" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1442">209,291,936</ix:nonFraction>&#160;shares of common stock at an exchange price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-466" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1443">1.29</ix:nonFraction>&#160;per share. As a result of the exchange, the company was forever released and discharged from all its obligations and liabilities under the notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a series of letter agreements pursuant to which the maturity date of the related-party nonconvertible notes described above totaling $<ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1444">505.0</ix:nonFraction>&#160;million in principal was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. In addition, the company entered into the $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1445">200.0</ix:nonFraction>&#160;million September 2023 promissory note with Nant&#160;Capital. No other material terms or conditions of these promissory notes were modified.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above promissory notes were entered into or amended at the same time on September&#160;11,&#160;2023 and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Pursuant to ASC&#160;470-50, as the terms of the amendment were not substantially different than the terms of the promissory notes prior to the amendment, the amendment was accounted for as a debt modification. The unamortized debt discounts from the promissory notes are being amortized as an adjustment to interest expense over the remaining term of modified promissory notes that are not recorded at fair value using the effective interest rate method. Also, a $<ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="f-1446">29.6</ix:nonFraction>&#160;million increase in fair value of the embedded conversion feature from the debt modification was accounted for as a debt discount to the $<ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1447">200.0</ix:nonFraction>&#160;million convertible note that is not recorded at fair value, and a $<ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="f-1448">1.6</ix:nonFraction>&#160;million increase in fair value of the embedded conversion feature related to the promissory note recorded at fair value was accounted for as interest expense during the year ended December&#160;31,&#160;2023. Such increase in fair values of the embedded conversion features totaling $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" format="ixt:num-dot-decimal" scale="6" id="f-1449">31.2</ix:nonFraction>&#160;million has been recorded with a corresponding increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit.</span></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">December&#160;29,&#160;2023 Debt Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note and a letter amendment for the following outstanding promissory notes. Pursuant to the terms of the amended and restated promissory note, the amended $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1450">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note is comprised of a Tranche&#160;1 with principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1451">125.0</ix:nonFraction>&#160;million which was previously the $<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1452">125.0</ix:nonFraction>&#160;million August&#160;2022 promissory note before amendment, and a Tranche&#160;2 with principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1453">380.0</ix:nonFraction>&#160;million, which is made up of the previous $<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1454">300.0</ix:nonFraction>&#160;million December&#160;2021 promissory note, $<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1455">50.0</ix:nonFraction>&#160;million December 2022 promissory note and $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1456">30.0</ix:nonFraction>&#160;million June&#160;2023 promissory note. In addition, the amendment allows Nant&#160;Capital, in its sole discretion, to convert all the Tranche&#160;2 principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1457">380.0</ix:nonFraction>&#160;million of the amended promissory note into shares of common stock. The conversion price was subsequently determined at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-448" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1458">8.2690</ix:nonFraction>&#160;per share based on the agreement. The maturity date of the amended promissory note is December&#160;31,&#160;2025. Pursuant to the terms of the letter amendment, the maturity date of the $<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1459">30.0</ix:nonFraction>&#160;million March&#160;2023 promissory note was extended from December&#160;31,&#160;2024 to December&#160;31,&#160;2025. Also, in connection with the RIPA transaction, all outstanding related-party promissory notes became subordinated to the RIPA payment obligations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1294-1" continuedAt="f-1294-2"><ix:continuation id="f-1293-6" continuedAt="f-1293-7"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes before the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1460">125</ix:nonFraction> million August&#160;2022 Promissory Note </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1461">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-438" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1462">8.0</ix:nonFraction>%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1463">300</ix:nonFraction> million December&#160;2021 Promissory Note </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1464">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-435" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1465">8.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1466">50</ix:nonFraction> million December&#160;2022 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1467">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-439" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1468">8.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1469">30</ix:nonFraction> million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1470">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-445" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1471">8.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1472">30</ix:nonFraction> million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1473">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-408" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1474">2.2800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-407" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1475">8.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1476">200</ix:nonFraction> million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1477">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-472" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1478">1.9350</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes<br/>&#160;&#160;&#160;before amendments</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1479">735,000</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes after the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1480">505</ix:nonFraction> million December&#160;2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1481">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-391" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1482">8.0</ix:nonFraction>%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1483">300</ix:nonFraction> million December&#160;2021 Promissory Note</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1484">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1485">50</ix:nonFraction> million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1486">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1487">30</ix:nonFraction> million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1488">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1489">505</ix:nonFraction> million December&#160;2023 Promissory Note &#8211; </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 2</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1490">380,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-404" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1491">8.2690</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-403" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="0" id="f-1492">7.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1493">505</ix:nonFraction> million December&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1494">505,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1495">30</ix:nonFraction> million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1496">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-478" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1497">2.2800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-407" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1498">8.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1499">200</ix:nonFraction> million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1500">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-472" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1501">1.9350</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+<ix:nonFraction unitRef="number" contextRef="c-411" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1502">8.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes <br/>&#160;&#160;&#160;after amendments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1503">735,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-7" continuedAt="f-1293-8"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above outstanding promissory notes were amended at the same time, with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Also, in accordance with ASC 470-50 the company used the debt terms that existed before the September&#160;11,&#160;2023 modification to determine whether the current modification is substantially different, as the September&#160;11,&#160;2023 modification was within a year of the current transaction, and the promissory notes, at that time, had been modified without being deemed to be substantially different. As the modifications (September&#160;11,&#160;2023 and December&#160;29,&#160;2023 on a cumulative basis) added a substantive conversion feature to the promissory notes, these promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of all the promissory notes before and after amendments. Under this model, the company calculated a loss on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1504">318.8</ix:nonFraction>&#160;million, representing the difference between the fair value of the amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts. Since the debt was obtained from entities under common control, such loss was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, a debt premium totaling $<ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="6" id="f-1505">354.9</ix:nonFraction>&#160;million, calculated as the difference between the fair values of certain promissory notes after modifications and their respective face values, was also recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collectively, net gain on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl" format="ixt:num-dot-decimal" scale="6" id="f-1506">36.1</ix:nonFraction>&#160;million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit for the year ended December&#160;31,&#160;2023. Also, the difference between face values of certain new and amended promissory notes and their respective fair values of $<ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="f-1507">53.1</ix:nonFraction>&#160;million was recorded as a debt discount to be amortized as interest expense over the remaining term. During the year&#160;ended December&#160;31,&#160;2023, we recorded amortization of related-party notes discounts totaling $<ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="f-1508">0.5</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations related to the new and amended promissory notes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regard to the Tranche&#160;2 principal amount of the $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1509">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note, the company identified an embedded derivative related to a contingent exercisable prepayment feature of the promissory note, which allows the noteholder to request up to a $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="ibrx:DebtInstrumentPrepaymentAndAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1510">50.0</ix:nonFraction>&#160;million prepayment of the promissory note and accrued interest upon the occurrence of a specified transaction. After the debt extinguishment, the company concluded that this promissory note was issued at a substantial discount, so the embedded derivative that is contingent exercisable was required to be bifurcated and accounted separately from the debt host instrument. The fair value of the embedded derivative was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="f-1511">0.8</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023, using a with and without method, which assesses the likelihood and timing of the specified transaction to be triggered and result in a repayment. Significant unobservable inputs used for the valuation included a volatility of <ix:nonFraction unitRef="number" contextRef="c-483" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1512">118.0</ix:nonFraction>%, a market yield of <ix:nonFraction unitRef="number" contextRef="c-484" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1513">23.2</ix:nonFraction>% and a risk-free rate of <ix:nonFraction unitRef="number" contextRef="c-485" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1514">4.8</ix:nonFraction>%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Tranche&#160;1 principal amount of the amended $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1515">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note, which had no noteholder conversion option, was estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair value of Tranche&#160;2 of the amended promissory note, which was modified to include a noteholder conversion option, was determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed were considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included a market yield of <ix:nonFraction unitRef="number" contextRef="c-486" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1516">23.2</ix:nonFraction>% and the significant unobservable inputs used for the binomial lattice model included a volatility of <ix:nonFraction unitRef="number" contextRef="c-487" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1517">118.0</ix:nonFraction>%, a market yield of <ix:nonFraction unitRef="number" contextRef="c-488" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1518">23.2</ix:nonFraction>% and a risk-free rate of <ix:nonFraction unitRef="number" contextRef="c-489" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1519">4.4</ix:nonFraction>%. The effective unamortized debt discount rate of the amended Tranche&#160;1 and Tranche&#160;2 principal amount of the $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1520">505.0</ix:nonFraction>&#160;million December&#160;2023 promissory note is <ix:nonFraction unitRef="number" contextRef="c-490" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1521">23.65</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-491" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1522">18.04</ix:nonFraction>%, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1523">200.0</ix:nonFraction>&#160;million September 2023 promissory note was determined using the binomial lattice model. Significant unobservable inputs used for the valuation included a volatility of <ix:nonFraction unitRef="number" contextRef="c-492" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1524">119.3</ix:nonFraction>%, a market yield of <ix:nonFraction unitRef="number" contextRef="c-493" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1525">23.3</ix:nonFraction>% and a risk-free rate of <ix:nonFraction unitRef="number" contextRef="c-494" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="f-1526">5.2</ix:nonFraction>%.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">189</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-8" continuedAt="f-1293-9"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to December&#160;29,&#160;2023, the $<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1527">30.0</ix:nonFraction>&#160;million March&#160;2023 promissory note was accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the note was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. <ix:continuation id="f-904-4" continuedAt="f-904-5">The estimated fair value of the convertible note was computed using the binomial lattice model with the following observable assumptions before it was modified on December&#160;29,&#160;2023. After the debt extinguishment, the note is accounted for under the amortized cost basis. </ix:continuation></span></div><ix:continuation id="f-904-5"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-495" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1528">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-496" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1529">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-497" decimals="3" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="f-1530">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of this note was as follows (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value at issuance date, March&#160;31,&#160;2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-1531">29,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1532">36,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on debt extinguishment with entities under common control</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1533">36,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying value, December&#160;29,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-1534">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:continuation id="f-1294-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense for our related-party promissory notes during the year ended December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.026%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Expense</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt<br/>Discount<br/>Amortization</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1535">300</ix:nonFraction> million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1536">39,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-1537">27,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1538">125</ix:nonFraction> million August&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1539">16,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-1540">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1541">50</ix:nonFraction> million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1542">6,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-1543">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1544">30</ix:nonFraction> million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1545">4,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:fixed-zero" scale="3" id="f-1546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1547">30</ix:nonFraction> million June&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1548">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="f-1549">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1550">200</ix:nonFraction> million September&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1551">8,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-1552">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related-Party Fixed-Rate Promissory Notes </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1553">8,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-1554">5,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1555">86,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-1556">42,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balances include the amortization of debt discount totaling $<ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="f-1557">0.5</ix:nonFraction>&#160;million recorded during the period from December&#160;29,&#160;2023 to December&#160;31,&#160;2023. The interest expense recorded during this period was $<ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="f-1558">0.4</ix:nonFraction>&#160;million.</span></div></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="f-1559" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"/><td style="width:33.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-1560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-1561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1562">79,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1563">16,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1564">96,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1565">410,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1566">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1567">79,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1568">16,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1569">631,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1570">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="f-1571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1572">18,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="3" id="f-1573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1574">218,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1575">610,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1576">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1577">177,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1578">33,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1579">946,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:3.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our promissory notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The weighted-average interest rate on our promissory notes as of December&#160;31,&#160;2023 was <ix:nonFraction unitRef="number" contextRef="c-513" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1580">13.09</ix:nonFraction>%.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">190</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_205"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:continuation id="f-1293-9" continuedAt="f-1293-10">Related-Party Agreements</ix:continuation></span></div><ix:continuation id="f-1293-10" continuedAt="f-1293-11"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business with several affiliates under written agreements and informal arrangements. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-1581" continuedAt="f-1581-1" escape="true">Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):</ix:nonNumeric></span></div><ix:continuation id="f-1581-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1582">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1583">1,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-1584">541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from related party&#8211;Brink</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-1586">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-1587">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-1588">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="f-1589">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1590">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1591">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-1592">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-1593">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-1594">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1595">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;the Clinic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-1596">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-1597">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-1599">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1600">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1601">3,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantWorks, LLC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shared Services Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated shared services agreement dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for these services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1602">3.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1603">3.8</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1604">4.4</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1605">2.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1606">0.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1607">0.4</ix:nonFraction>&#160;million, respectively, of expense reimbursements under this arrangement in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, we had a receivable of $<ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1608">0.5</ix:nonFraction>&#160;million and a payable of $<ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1609">1.0</ix:nonFraction>&#160;million, respectively, for all agreements with NantWorks, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due from/due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. We also recorded $<ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1610">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1611">2.0</ix:nonFraction>&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of December&#160;31,&#160;2023 and 2022, respectively, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a facility license agreement with NantWorks for approximately <ix:nonFraction unitRef="sqft" contextRef="c-534" decimals="-2" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1612">9,500</ix:nonFraction>&#160;rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In 2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing January&#160;1,&#160;2022, the license fee increased by <ix:nonFraction unitRef="number" contextRef="c-535" decimals="2" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1613">3</ix:nonFraction>% to approximately $<ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-1" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1614">56,120</ix:nonFraction> per month. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">191</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-11" continuedAt="f-1293-12"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by <ix:nonFraction unitRef="sqft" contextRef="c-536" decimals="INF" name="ibrx:IncreaseToNumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1615">36,830</ix:nonFraction>&#160;rentable square feet to an aggregate total of <ix:nonFraction unitRef="sqft" contextRef="c-536" decimals="INF" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1616">46,330</ix:nonFraction>&#160;rentable square feet. Effective May&#160;1,&#160;2022, the license fee was approximately $<ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-2" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1617">273,700</ix:nonFraction> per month and was subject to a <ix:nonFraction unitRef="number" contextRef="c-537" decimals="INF" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1618">3</ix:nonFraction>%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#8217; prior written notice to the other party. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded license fee expense for this facility totaling $<ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1619">3.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1620">2.4</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1621">0.7</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple agreements with t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that a previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we wrote down the remaining value of our prepaid asset and recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-5" name="ibrx:PrepaidExpenseWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-1622">4.4</ix:nonFraction>&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. While we have not yet finalized the potential transition, we continue discussions with potential partners around such alternative structures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1623">2.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1624">2.4</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1625">1.6</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, we owed the&#160;Clinic $<ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1626"><ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1627">0.1</ix:nonFraction></ix:nonFraction>&#160;million, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brink Biologics, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into an agreement with Brink whereby we granted Brink worldwide exclusive licenses for the use of certain cell lines and intellectual property in non-clinical laboratory testing. Brink is a related party as our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, and our Chief Corporate Affairs Officer and member of our Board of Directors, collectively own more than 50%&#160;of Brink&#8217;s outstanding shares. During the years ended December&#160;31,&#160;2023 and 2022, we recognized revenue of an immaterial amount, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1628">0.4</ix:nonFraction>&#160;million during the year ended December&#160;31,&#160;2021 related to this license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantBio, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a supply agreement with NCSC, a 100%&#160;owned subsidiary of NantBio. Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement had an initial term of <ix:nonNumeric contextRef="c-547" name="ibrx:SupplyAgreementTermOfContract" format="ixt-sec:durwordsen" id="f-1629">five years</ix:nonNumeric> and renews automatically for successive <ix:nonNumeric contextRef="c-548" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1630">one-year</ix:nonNumeric> terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#8217; prior written notice by NCSC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized <ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-5" name="ibrx:NantBioRevenue" format="ixt:fixed-zero" scale="6" id="f-1631"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" name="ibrx:NantBioRevenue" format="ixt:fixed-zero" scale="6" id="f-1632">no</ix:nonFraction></ix:nonFraction>&#160;revenue, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-5" name="ibrx:NantBioRevenue" format="ixt:num-dot-decimal" scale="6" id="f-1633">0.3</ix:nonFraction>&#160;million of revenue during the year ended December&#160;31,&#160;2021. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-1634"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-1635">0.1</ix:nonFraction></ix:nonFraction>&#160;million of deferred revenue for bioreactors that were delivered but not installed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1636"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1637">0.9</ix:nonFraction></ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets related to this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">192</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-12" continuedAt="f-1293-13"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits related to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded a receivable from NantBio of $<ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1638"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1639">1.3</ix:nonFraction></ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due from related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Doug St, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately <ix:nonFraction unitRef="sqft" contextRef="c-556" decimals="-1" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1640">24,250</ix:nonFraction>&#160;rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease term was from July&#160;2016 through July&#160;2023. In June&#160;2023, we exercised the option to extend the lease for <ix:nonFraction unitRef="renewal_options" contextRef="c-557" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="f-1641">one</ix:nonFraction>&#160;additional <ix:nonNumeric contextRef="c-557" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1642">three-year</ix:nonNumeric> term through July&#160;2026. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="c-557" decimals="0" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1643">72,385</ix:nonFraction> per month, with annual increases of <ix:nonFraction unitRef="number" contextRef="c-557" decimals="2" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1644">3</ix:nonFraction>% that began in July&#160;2017. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded lease expense for this facility of $<ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1645"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1646"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1647">0.9</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duley Road, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately <ix:nonFraction unitRef="sqft" contextRef="c-561" decimals="-1" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1648">11,980</ix:nonFraction>&#160;rentable square feet of office and cGMP&#160;manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for <ix:nonFraction unitRef="renewal_options" contextRef="c-562" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="f-1649">two</ix:nonFraction>&#160;consecutive <ix:nonNumeric contextRef="c-562" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1650">five-year</ix:nonNumeric> periods through October&#160;2034. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-2" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1651">40,700</ix:nonFraction> per month, with annual increases of&#160;<ix:nonFraction unitRef="number" contextRef="c-562" decimals="2" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1652">3</ix:nonFraction>% that began in November&#160;2018. Effective October&#160;3, 2023, we exercised the first option to extend the lease for <ix:nonFraction unitRef="renewal_options" contextRef="c-563" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="f-1653">one</ix:nonFraction>&#160;additional <ix:nonNumeric contextRef="c-563" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1654">five-year</ix:nonNumeric> term through October&#160;31, 2029. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in 2019, we entered into <ix:nonFraction unitRef="lease" contextRef="c-564" decimals="INF" name="ibrx:NumberOfLeases" format="ixt-sec:numwordsen" id="f-1655">two</ix:nonFraction>&#160;lease agreements with Duley&#160;Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately <ix:nonFraction unitRef="sqft" contextRef="c-565" decimals="-1" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1656">5,650</ix:nonFraction>&#160;rentable square feet. The lease has a <ix:nonNumeric contextRef="c-565" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-1657">seven-year</ix:nonNumeric> term that commenced in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately <ix:nonFraction unitRef="sqft" contextRef="c-566" decimals="0" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1658">6,488</ix:nonFraction>&#160;rentable square feet. The lease has a <ix:nonNumeric contextRef="c-566" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-1659">seven-year</ix:nonNumeric> term that commenced in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for <ix:nonFraction unitRef="renewal_options" contextRef="c-564" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="f-1660">two</ix:nonFraction>&#160;consecutive <ix:nonNumeric contextRef="c-564" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1661">five-year</ix:nonNumeric> periods through 2036. The base rent for the <ix:nonFraction unitRef="lease" contextRef="c-564" decimals="INF" name="ibrx:NumberOfLeases" format="ixt-sec:numwordsen" scale="0" id="f-1662">two</ix:nonFraction>&#160;leases is approximately $<ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-2" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1663">35,800</ix:nonFraction> per month, with annual increases of&#160;<ix:nonFraction unitRef="number" contextRef="c-564" decimals="2" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1664">3</ix:nonFraction>% per year.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded rent expense for these leases totaling $<ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1665">0.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1666">0.8</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1667">1.0</ix:nonFraction>&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-5" name="ibrx:LeaseRelatedPayables" format="ixt:num-dot-decimal" scale="6" id="f-1668">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-5" name="ibrx:LeaseRelatedPayables" format="ixt:num-dot-decimal" scale="6" id="f-1669">1.4</ix:nonFraction>&#160;million of lease-related payables to Duley&#160;Road, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Nash, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but effective on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately <ix:nonFraction unitRef="sqft" contextRef="c-572" decimals="0" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1670">6,883</ix:nonFraction>&#160;rentable square feet (the Initial Premises) in a two&#160;story mixed use building containing approximately 64,643&#160;rentable square feet at 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2027</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and includes an option to extend the lease for <ix:nonFraction unitRef="renewal_options" contextRef="c-573" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="f-1671">one</ix:nonFraction> <ix:nonNumeric contextRef="c-573" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1672">three-year</ix:nonNumeric> term through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2030</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-2" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1673">20,300</ix:nonFraction> per month with an annual increase of <ix:nonFraction unitRef="number" contextRef="c-573" decimals="2" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1674">3</ix:nonFraction>%&#160;on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year during the initial term, and if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">193</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-13" continuedAt="f-1293-14"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately <ix:nonFraction unitRef="sqft" contextRef="c-574" decimals="-1" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1675">57,760</ix:nonFraction>&#160;rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has <ix:nonFraction unitRef="renewal_options" contextRef="c-575" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="f-1676">one</ix:nonFraction>&#160;option to extend the initial term for <ix:nonNumeric contextRef="c-575" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1677">three years</ix:nonNumeric>. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $<ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-2" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1678">170,400</ix:nonFraction>&#160;per month with annual increases of <ix:nonFraction unitRef="number" contextRef="c-575" decimals="2" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1679">3</ix:nonFraction>% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included the options to extend the lease term of both the Initial and Expansion Premises for <ix:nonNumeric contextRef="c-575" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1680">three years</ix:nonNumeric> as part of the initial term of the leases as it is reasonably certain that we will exercise the options, which implies expiration of both leases in December&#160;2030. During the years ended December&#160;31,&#160;2023, 2022, and 2021, we recorded rent expense for the Initial and Expansion Premises leases totaling $<ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1681"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1682"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1683">2.2</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million, respectively, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations. The terms of initial and amended leases provided for tenant improvement allowances totaling $<ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-5" name="us-gaap:IncentiveFromLessor" format="ixt:num-dot-decimal" scale="6" id="f-1684">2.9</ix:nonFraction>&#160;million for costs and expenses related to improvements made by us to the Initial and Expansion Premises, which were received from the landlord during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">557 Doug St, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a Membership Interest Purchase Agreement with Nant&#160;Capital (the Purchase Agreement). Nant&#160;Capital is a related party controlled by Dr.&#160;Soon-Shiong. The Purchase Agreement transferred all outstanding membership interests in 557 Doug St,&#160;LLC from the company to Nant&#160;Capital. The only asset owned by 557&#160;Doug St, LLC is the improved property located at 557&#160;South Douglas Street, El&#160;Segundo, California with a building area of approximately <ix:nonFraction unitRef="sqft" contextRef="c-580" decimals="INF" name="ibrx:NumberOfSquareFootOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1685">36,434</ix:nonFraction>&#160;rentable square feet (the Douglas Property).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price under the purchase agreement was $<ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-5" name="ibrx:SaleLeasebackTransactionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-1686">22.0</ix:nonFraction>&#160;million, and after the offset prorated property taxes of $<ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-5" name="ibrx:SaleLeasebackTransactionPropertyTaxes" format="ixt:num-dot-decimal" scale="6" id="f-1687">0.1</ix:nonFraction>&#160;million, the net proceeds from the sale were $<ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-5" name="ibrx:SaleLeasebackTransactionNetProceeds" format="ixt:num-dot-decimal" scale="6" id="f-1688">21.9</ix:nonFraction>&#160;million. An independent appraisal of the Douglas Property assigned the Douglas Property a value of $<ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-5" name="us-gaap:SaleLeasebackTransactionHistoricalCost" format="ixt:num-dot-decimal" scale="6" id="f-1689">22.0</ix:nonFraction>&#160;million. The net carrying value of the property was $<ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-5" name="us-gaap:SaleLeasebackTransactionNetBookValue" format="ixt:num-dot-decimal" scale="6" id="f-1690">20.5</ix:nonFraction>&#160;million as of the closing date. We accounted for the transfer as a sale of an asset to an entity under common control, recorded the transfer at book value and recognized the excess of net consideration over carrying book value of $<ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="f-1691">1.4</ix:nonFraction>&#160;million as a capital contribution received from Nant&#160;Capital in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we entered into a lease agreement with Nant&#160;Capital under which we leased back 557&#160;South Douglas Street for an initial lease term of <ix:nonNumeric contextRef="c-583" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1692">seven years</ix:nonNumeric>, which commenced on September&#160;27,&#160;2021. The monthly base rent under the lease was approximately $<ix:nonFraction unitRef="usd" contextRef="c-583" decimals="0" name="ibrx:BaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="f-1693">81,976</ix:nonFraction> per month with an annual increase of&#160;<ix:nonFraction unitRef="number" contextRef="c-583" decimals="2" name="ibrx:AnnualPercentageIncreasesToBaseRent" scale="-2" id="f-1694">3</ix:nonFraction>% on October&#160;1 of each year beginning in 2022 during the initial term. For the first <ix:nonNumeric contextRef="c-583" name="ibrx:PeriodOfRentFreeLeaseTerm" format="ixt-sec:durwordsen" id="f-1695">two years</ix:nonNumeric> under the lease, we would not be charged rent; we would begin paying rent on October&#160;1,&#160;2023 at the current monthly base rent. We prepaid the first&#160;month rent and security deposit totaling $<ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-5" name="ibrx:LesseeOperatingLeasePrepaidExpense" format="ixt:num-dot-decimal" scale="6" id="f-1696">0.2</ix:nonFraction>&#160;million upon the execution of the lease. The lease was classified as an operating lease. During the year ended December&#160;31,&#160;2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-585" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1697">0.3</ix:nonFraction>&#160;million of rent expense for the lease, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May&#160;31,&#160;2022, we executed a lease termination agreement with Nant&#160;Capital under which we received a full refund of the first month&#8217;s rent and security deposit totaling $<ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-5" name="ibrx:LesseeOperatingLeasePrepaidExpense" format="ixt:num-dot-decimal" scale="6" id="f-1698">0.2</ix:nonFraction>&#160;million that we paid upon execution of the lease. Prior to the termination of the lease, we recorded rent expense of $<ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1699">0.4</ix:nonFraction>&#160;million during the year ended December&#160;31,&#160;2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. During the year ended December&#160;31,&#160;2022, we recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-5" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:num-dot-decimal" scale="6" id="f-1700">0.6</ix:nonFraction>&#160;million on the disposal of this lease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">420 Nash, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately <ix:nonFraction unitRef="sqft" contextRef="c-588" decimals="0" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1701">19,125</ix:nonFraction> rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">194</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1293-14"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $<ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-1" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1702">38,250</ix:nonFraction> per month with an annual increase of <ix:nonFraction unitRef="number" contextRef="c-589" decimals="INF" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1703">3</ix:nonFraction>% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. We received a rent abatement for the first month of the lease, and a one-time improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-3" name="us-gaap:IncentiveFromLessor" format="ixt:num-dot-decimal" scale="0" id="f-1704">15,000</ix:nonFraction> from the landlord that was credited against base rent obligations for the second month of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has options to extend the lease term for <ix:nonFraction unitRef="renewal_options" contextRef="c-589" decimals="INF" name="ibrx:OptionsToExtendNumberOfTerms" format="ixt-sec:numwordsen" scale="0" id="f-1705">two</ix:nonFraction>&#160;additional consecutive periods of <ix:nonNumeric contextRef="c-589" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1706">five years</ix:nonNumeric> each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of <ix:nonFraction unitRef="number" contextRef="c-589" decimals="INF" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1707">3</ix:nonFraction>% during the option term. We have included the first&#160;option to extend the lease term for <ix:nonNumeric contextRef="c-589" name="ibrx:PeriodOfExtendedLeaseTerm" format="ixt-sec:durwordsen" id="f-1708">five years</ix:nonNumeric> as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. During the years ended December&#160;31,&#160;2023 and 2022, we recorded rent expense for this lease totaling $<ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1709"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1710">0.5</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1711">0.1</ix:nonFraction>&#160;million during the year ended December&#160;31,&#160;2021 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23&#160;Alaska, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a <ix:nonFraction unitRef="sqft" contextRef="c-593" decimals="INF" name="ibrx:NumberOfSquareFeetOfFacilityLeased" format="ixt:num-dot-decimal" scale="0" id="f-1712">47,265</ix:nonFraction>&#160;rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the lease term began on May&#160;1,&#160;2022 and was to expire on April&#160;30,&#160;2027. The base rent was approximately $<ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-2" name="ibrx:MonthlyLicenseFee" format="ixt:num-dot-decimal" scale="0" id="f-1713">139,400</ix:nonFraction>&#160;per month with an annual increase of <ix:nonFraction unitRef="number" contextRef="c-594" decimals="INF" name="ibrx:AnnualPercentageIncreaseToLicenseFee" scale="-2" id="f-1714">3</ix:nonFraction>% on May&#160;1 of each year beginning in 2023 during the initial term. We were also required to pay $<ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-2" name="ibrx:MonthlyBaseRentParking" format="ixt:num-dot-decimal" scale="0" id="f-1715">7,600</ix:nonFraction>&#160;per month for parking during the initial term. The company was responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company was responsible for the costs associated with the build-out of the premises and was to receive a one-time tenant improvement allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:IncentiveFromLessor" format="ixt:num-dot-decimal" scale="6" id="f-1716">0.9</ix:nonFraction>&#160;million from the landlord. As of December&#160;31,&#160;2022, we re-evaluated plans for the future development of the facility and deemed it unlikely to claim any of the allowance during the reimbursement time frame. As such, during the year ended December&#160;31,&#160;2022 we wrote off the entire allowance receivable of $<ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" name="us-gaap:IncentiveFromLessor" format="ixt:num-dot-decimal" scale="6" id="f-1717">0.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August&#160;31, 2023, we executed a lease termination agreement with the lessor under which we received a full refund of the security deposit totaling $<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-1718">0.1</ix:nonFraction>&#160;million that we paid upon execution of the lease. During the years ended December&#160;31,&#160;2023 and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1719"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-1720">1.2</ix:nonFraction></ix:nonFraction>&#160;million of rent expense for this lease, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. During the year&#160;ended December&#160;31,&#160;2023, we recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-5" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:num-dot-decimal" scale="6" id="f-1721">0.6</ix:nonFraction>&#160;million on the disposal of this lease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div></ix:continuation><div id="if7eeec8e66644046bbbe3c0a87df2c46_220"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ibrx:WarrantLiabilityTextBlock" id="f-1724" continuedAt="f-1724-1" escape="true">Warrant Liabilities</ix:nonNumeric></span></div><ix:continuation id="f-1724-1" continuedAt="f-1724-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12,&#160;2022, in connection with the sale of <ix:nonFraction unitRef="shares" contextRef="c-602" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1725">9,090,909</ix:nonFraction>&#160;shares of our common stock to an institutional investor, we entered into a warrant agreement that allows such investor to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1726">9,090,909</ix:nonFraction>&#160;shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-603" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1727">6.60</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of the warrants was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1728">35.1</ix:nonFraction>&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1729">3.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-5" name="ibrx:TransactionCostsWarrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-1730">1.1</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was allocated to the warrants and recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations on the date of the transaction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, all <ix:nonFraction unitRef="shares" contextRef="c-606" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1731"><ix:nonFraction unitRef="shares" contextRef="c-607" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1732">9,090,909</ix:nonFraction></ix:nonFraction>&#160;underlying warrants were outstanding. As of December&#160;31,&#160;2023 and 2022, the estimated fair value of the warrants were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1733">17.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1734">21.6</ix:nonFraction>&#160;million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the year ended December&#160;31,&#160;2023, a decrease in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1735">4.5</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">195</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1724-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15,&#160;2023, in connection with the sale of <ix:nonFraction unitRef="shares" contextRef="c-608" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1736">14,072,615</ix:nonFraction>&#160;shares of our common stock to certain institutional investors, we entered into a warrant agreement that allows such investors to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-609" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1737">14,072,615</ix:nonFraction>&#160;shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1738">4.2636</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1739">23.7</ix:nonFraction>&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling $<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1740">3.0</ix:nonFraction>&#160;million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-5" name="ibrx:TransactionCostsWarrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-1741">1.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was allocated to the warrants </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the date of the transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, the company amended the terms of the warrant, reducing the exercise price of the warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1742">4.2636</ix:nonFraction>&#160;per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1743">3.2946</ix:nonFraction>&#160;per share and extending the expiration date of the warrants until July&#160;24,&#160;2026. Since the warrants were classified as liabilities and measured at fair value, we recognized the change of $<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="f-1744">7.3</ix:nonFraction>&#160;million in fair value of warrant liability in earnings due to the warrant modification.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, all <ix:nonFraction unitRef="shares" contextRef="c-613" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1745"><ix:nonFraction unitRef="shares" contextRef="c-614" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1746">14,072,615</ix:nonFraction></ix:nonFraction>&#160;underlying warrants were outstanding, with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1747">50.0</ix:nonFraction>&#160;million. During the year ended December&#160;31,&#160;2023, an increase in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1748">26.3</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">July&#160;2023 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;20, 2023, in connection with the sale of <ix:nonFraction unitRef="shares" contextRef="c-615" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1749">14,569,296</ix:nonFraction>&#160;shares of our common stock to certain institutional investors, we entered into a warrant agreement that allows such investors to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1750">14,569,296</ix:nonFraction>&#160;shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1751">3.2946</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1752">25.8</ix:nonFraction>&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling $<ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1753">2.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" name="ibrx:TransactionCostsWarrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-1754">1.0</ix:nonFraction>&#160;million was allocated to the warrants </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the date of the transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, all <ix:nonFraction unitRef="shares" contextRef="c-619" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1755">14,569,296</ix:nonFraction>&#160;underlying warrants were outstanding, with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-1756">51.7</ix:nonFraction>&#160;million. During the year ended December&#160;31,&#160;2023, an increase in fair value of $<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="f-1757">25.9</ix:nonFraction>&#160;million was recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div></ix:continuation><div id="if7eeec8e66644046bbbe3c0a87df2c46_223"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1758" continuedAt="f-1758-1" escape="true">Stockholders&#8217; Deficit</ix:nonNumeric></span></div><ix:continuation id="f-1758-1" continuedAt="f-1758-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Authorized for Issuance</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the company was authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1759">1,350,000,000</ix:nonFraction>&#160;shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1760">0.0001</ix:nonFraction>&#160;per share, and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1761">20,000,000</ix:nonFraction>&#160;shares of our preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1762"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1763">0.0001</ix:nonFraction></ix:nonFraction>&#160;per share. As of December&#160;31,&#160;2023, there were <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1764"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1765">670,867,344</ix:nonFraction></ix:nonFraction>&#160;shares of our common stock outstanding (excluding <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-1766">163,800</ix:nonFraction>&#160;shares held by a majority owned subsidiary of the company that are treated as treasury shares for accounting purposes).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October&#160;18,&#160;2023, we amended and restated our Amended and Restated Certificate of Incorporation to increase the number of shares that the company is authorized to issue from <ix:nonFraction unitRef="shares" contextRef="c-620" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1767">900,000,000</ix:nonFraction>&#160;shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1768"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1769">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value per share, to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1770">1,350,000,000</ix:nonFraction>&#160;shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1771"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1772">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value per share. The number of shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1773"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1774">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value per share, that the company is authorized to issue remained unchanged at <ix:nonFraction unitRef="shares" contextRef="c-620" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1775">20,000,000</ix:nonFraction>&#160;shares. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">196</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1758-2" continuedAt="f-1758-3"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Issued in Connection with the Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1776">0.001</ix:nonFraction>&#160;per share, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive <ix:nonFraction unitRef="number" contextRef="c-621" decimals="INF" name="ibrx:MergerExchangeRatio" scale="0" id="f-1777">0.8190</ix:nonFraction>&#160;newly issued shares of common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-622" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1778">0.0001</ix:nonFraction>&#160;per share, resulting in the issuance of approximately <ix:nonFraction unitRef="shares" contextRef="c-621" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-1779">273.7</ix:nonFraction>&#160;million shares of Company Common Stock.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Merger was accounted for as a transaction between entities under common control, the outstanding shares presented on the consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock during the period ended December&#160;31,&#160;2021, and in connection with the conversion, those shares of common stock were recorded at the company&#8217;s par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-622" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1780">0.0001</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2015 Share Repurchase Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program, which allows our CEO or CFO, to repurchase on behalf of the company, from time to time in the open market or in privately negotiated transactions, up to $<ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1781">50.0</ix:nonFraction>&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups, or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements, and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through approval of the Board of Directors upon repurchase. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="c-624" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="f-1782"><ix:nonFraction unitRef="shares" contextRef="c-625" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="f-1783"><ix:nonFraction unitRef="shares" contextRef="c-626" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="f-1784">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares of our common stock were repurchased under the program. Since the plan&#8217;s inception, we have repurchased a total of <ix:nonFraction unitRef="shares" contextRef="c-627" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-1785">6,403,489</ix:nonFraction>&#160;shares at a total cost of $<ix:nonFraction unitRef="usd" contextRef="c-627" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-1786">31.7</ix:nonFraction>&#160;million. As of December&#160;31,&#160;2023, $<ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1787">18.3</ix:nonFraction>&#160;million remained authorized to use for share repurchases under the program. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February&#160;2023, we filed a $<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" name="ibrx:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="f-1788">750.0</ix:nonFraction>&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. During the year ended December&#160;31,&#160;2023, we sold shares of our common stock and warrants valued at $<ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1789">184.4</ix:nonFraction>&#160;million under the shelf. As of December&#160;31,&#160;2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="f-1790">565.6</ix:nonFraction>&#160;million available for use under the shelf. This available shelf is in addition to the Open Market Sale Agreement described below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sale Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2021, we entered into the&#160;ATM under which we may offer and sell, from time to time at our sole discretion, shares of our common stock through our sales agent. We pay our sales agent a commission of up to <ix:nonFraction unitRef="number" contextRef="c-630" decimals="3" name="ibrx:PercentageOfSalesAgentCommission" scale="-2" id="f-1791">3.0</ix:nonFraction>%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the ATM, and also have provided them with customary indemnification and contribution rights. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, we received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1792">16.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1793">13.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-633" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1794">164.5</ix:nonFraction>&#160;million, respectively, from the issuance of shares under the&#160;ATM. As of December&#160;31,&#160;2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="ibrx:CommonStockValueAvailableForFutureStockIssuance" format="ixt:num-dot-decimal" scale="6" id="f-1795">208.8</ix:nonFraction>&#160;million available for future issuances under the ATM.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">197</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1758-3" continuedAt="f-1758-4"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances and shall automatically terminate upon the issuance and sale of all of the shares.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Direct Offerings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Offerings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15,&#160;2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of <ix:nonFraction unitRef="shares" contextRef="c-634" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1796">14,072,615</ix:nonFraction>&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional <ix:nonFraction unitRef="shares" contextRef="c-609" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1797">14,072,615</ix:nonFraction>&#160;shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1798">4.2636</ix:nonFraction>&#160;per share, for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-611" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1799">3.5530</ix:nonFraction>&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1800">47.0</ix:nonFraction>&#160;million, after deducting placement agent fees and other offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1801">3.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1802">2.0</ix:nonFraction>&#160;million was allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2023. The warrants became immediately exercisable on February&#160;17,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, pursuant to the terms of a letter amendment, the company and the investors agreed to reduce the exercise price of the outstanding February&#160;2023 Warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-278" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1803">4.2636</ix:nonFraction>&#160;per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1804">3.2946</ix:nonFraction>&#160;per share and extend the expiration date of the warrants to July&#160;24,&#160;2026. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_220">Note&#160;</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_220">12</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">July 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;20, 2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of <ix:nonFraction unitRef="shares" contextRef="c-615" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1805">14,569,296</ix:nonFraction>&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional <ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1806">14,569,296</ix:nonFraction>&#160;shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1807">3.2946</ix:nonFraction>&#160;per share, for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-281" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1808">2.7455</ix:nonFraction>&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1809">37.5</ix:nonFraction>&#160;million, after deducting placement agent fees and other estimated offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1810">2.5</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1811">12.7</ix:nonFraction>&#160;million was allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2023. The warrants became immediately exercisable on July&#160;25,&#160;2023 and expire on July&#160;24,&#160;2026.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Offering</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12,&#160;2022, we entered into a securities purchase agreement with an institutional investor for the sale of <ix:nonFraction unitRef="shares" contextRef="c-602" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1812">9,090,909</ix:nonFraction>&#160;shares of our common stock, as well as warrants that allow such investor to purchase an additional <ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1813">9,090,909</ix:nonFraction>&#160;shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-603" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1814">6.60</ix:nonFraction>&#160;per share, for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-604" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1815">5.50</ix:nonFraction>&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1816">47.0</ix:nonFraction>&#160;million, after deducting placement agent fees and other offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1817">3.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1818">1.9</ix:nonFraction>&#160;million was allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase and Option Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1819">10.0</ix:nonFraction>&#160;million of our common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-383" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1820">4.1103</ix:nonFraction>&#160;per share in a private placement, which resulted in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-636" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1821">2,432,894</ix:nonFraction>&#160;shares of common stock. We received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1822">9.5</ix:nonFraction>&#160;million, after deducting offering costs of $<ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1823">0.5</ix:nonFraction>&#160;million, which were allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oberland also has an option to purchase up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-5" name="ibrx:SaleOfStockAdditionalPurchaseOption" format="ixt:num-dot-decimal" scale="6" id="f-1824">10.0</ix:nonFraction>&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock, calculated from the date of exercise. The option is exercisable by Oberland any time after the closing of the SPOA, until the earliest of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">198</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1758-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;December&#160;29,&#160;2028, (ii)&#160;a change of control of the company, or (iii)&#160;a sale of substantially all of the company&#8217;s assets. Among other limitations, the option may only be exercised to the extent that the common stock issuable pursuant to such exercise would not exceed <ix:nonFraction unitRef="number" contextRef="c-132" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="f-1825">19.9</ix:nonFraction>%&#160;of the common stock outstanding immediately after giving effect to such exercise. We have agreed to file a shelf registration statement allowing for the resale of the common stock acquired under the SPOA and to cause the registration statement to be effective no later than May&#160;15,&#160;2024, or if the SEC decides to review such registration statement, no later than June&#160;30,&#160;2024. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Promissory Notes into Common Stock </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the related-party purchasers exchanged all such fixed-rate promissory notes, representing approximately $<ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="ibrx:LongTermDebtGrossIncludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1826">270.0</ix:nonFraction>&#160;million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-465" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1827">209,291,936</ix:nonFraction>&#160;shares of common stock at an exchange price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-466" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1828">1.29</ix:nonFraction>&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, the company received written notice from NantWorks, the holder of the existing note, of its election to convert the entire outstanding principal and accrued interest under the existing note into shares of the company&#8217;s common stock. As of such date, the entire outstanding principal amount and accrued and unpaid interest due under the existing note of approximately $<ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-5" name="ibrx:LongTermDebtGrossIncludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="f-1829">56.6</ix:nonFraction>&#160;million and an unamortized debt discount of $<ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="f-1830">4.7</ix:nonFraction>&#160;million were converted into <ix:nonFraction unitRef="shares" contextRef="c-462" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-1831">9,986,920</ix:nonFraction>&#160;shares of the company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-463" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1832">5.67</ix:nonFraction>&#160;per share in accordance with the terms of the Existing Note. We recorded a net increase of $<ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-1833">51.9</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet related to this transaction.</span></div></ix:continuation><div id="if7eeec8e66644046bbbe3c0a87df2c46_226"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1834" continuedAt="f-1834-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-1834-1" continuedAt="f-1834-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors adopted, and our stockholders approved, the 2015&#160;Plan. The 2015&#160;Plan, as amended, permits the grant of incentive stock options to the company&#8217;s employees, and the grant of non-statutory stock options, restricted stock, RSUs, stock appreciation rights, performance units and performance shares to the company&#8217;s employees, directors, and consultants. In addition, the number of shares reserved for future grant under the 2015&#160;Plan include shares subject to stock options granted under the 2014&#160;Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2014&#160;Plan that are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2015&#160;Plan pursuant to this provision is approximately <ix:nonFraction unitRef="shares" contextRef="c-642" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-1835">346,840</ix:nonFraction>&#160;shares as of December&#160;31,&#160;2023). Pursuant to the Merger, we assumed <ix:nonFraction unitRef="shares" contextRef="c-643" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1836">7,121,110</ix:nonFraction>&#160;RSUs (adjusted for the Exchange Ratio) issued under the NC&#160;2015 Plan. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the 2015&#160;Plan is the only equity plan available for grant of equity awards to employees, directors, and consultants of the company. As of December&#160;31,&#160;2023, approximately <ix:nonFraction unitRef="shares" contextRef="c-644" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1837">13.1</ix:nonFraction>&#160;million&#160;shares were available for future grants under the 2015&#160;Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1838" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation included on the consolidated statements of operations (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1839">13,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1840">13,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1841">11,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1842">35,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1843">26,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1844">45,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1845">49,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1846">40,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1847">57,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense in operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1848">17,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1849">11,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1850">18,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1851">31,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1852">28,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1853">38,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1854">49,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1855">40,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1856">57,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">199</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1834-2" continuedAt="f-1834-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1857" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity and related information for the year ended December&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intrinsic</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in years)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1858">9,262,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1859">9.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1860">4,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-10" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1861">7.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1862">949,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1863">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1864">184,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1865">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1866">207,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1867">5.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1868">9,820,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1869">9.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1870">6,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1871">6.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and exercisable as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1872">5,867,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1873">11.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1874">4,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1875">5.4</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the unrecognized compensation cost related to outstanding stock options was $<ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1876">8.4</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="c-657" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1877">1.0</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, the total intrinsic value of stock options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1878">0.3</ix:nonFraction>&#160;million. During the years ended December&#160;31,&#160;2023, 2022 and 2021, cash proceeds received from stock option exercises were $<ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1879">0.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1880">0.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1881">5.4</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, a total of <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1882">3,445,499</ix:nonFraction>&#160;vested and exercisable stock options were outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1883" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-657" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1884">5.50</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-658" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1885">5.69</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-659" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1886">5.90</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-657" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1887">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-658" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1888">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-659" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1889">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-657" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1890">116.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-658" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1891">101.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-659" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1892">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-657" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-658" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-659" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-657" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1896">2.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-658" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1897">4.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-659" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1898">16.80</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S.&#160;Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends for the foreseeable future.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1834-3" continuedAt="f-1834-4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-1899" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the year ended December&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:71.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Units</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance as of December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-660" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1900">6,551,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-660" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1901">18.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-648" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1902">6,407,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-648" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1903">1.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-648" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1904">4,545,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-648" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1905">7.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-648" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1906">909,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-648" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1907">7.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-661" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1908">7,503,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-661" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1909">12.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1910">38.2</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-648" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1911">2.2</ix:nonNumeric>&#160;years. During the year ended December&#160;31,&#160;2023, the total intrinsic value of RSUs vested was $<ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-1912">11.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of August&#160;25,&#160;2023, the Compensation Committee of the Board of Directors granted <ix:nonFraction unitRef="shares" contextRef="c-662" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1913">5,727,159</ix:nonFraction>&#160;RSUs to eligible employees of the company, with the intention of retaining such employees (the &#8220;retention award&#8221;). The retention award vests according to the following schedule: &#189;&#160;(one-half) was to vest and vested on September&#160;1,&#160;2023 and &#189;&#160;(one-half) will vest on January&#160;31,&#160;2024, subject to the recipients continuing to be a &#8220;service provider&#8221; (as defined in the 2015&#160;Plan) through each applicable vesting date. With respect to RSUs granted, compensation cost was measured using the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-662" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1914">1.65</ix:nonFraction>&#160;per share, the closing price of the company&#8217;s common stock on August&#160;25,&#160;2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded to employees and consultants of affiliated companies are accounted for as stock-based compensation in accordance with FASB ASU 2018-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation (Topic&#160;718)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_205">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" name="ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1915">4.0</ix:nonFraction>&#160;million. During the years ended December&#160;31,&#160;2023 and 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="f-1916"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="f-1917">0.4</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="f-1918">0.9</ix:nonFraction>&#160;million of deemed dividends during the year ended December&#160;31,&#160;2021 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets, with a corresponding credit to stock-based compensation expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Warrants</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1834-4">In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#8217;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of <ix:nonFraction unitRef="shares" contextRef="c-667" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1919">1,638,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-667" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1920">3.24</ix:nonFraction>&#160;per share were outstanding as of December&#160;31,&#160;2023. The fair value of $<ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-5" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1921">18.0</ix:nonFraction>&#160;million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">201</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_232"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1924" continuedAt="f-1924-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-1924-1" continuedAt="f-1924-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California, and other states. From inception through December&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated NOLs. Our federal returns for tax years 2020 through 2022 remain open to examination, and our state returns remain subject to examination for tax years 2019 through 2022. The Italian and South Korean returns for tax years 2018 through 2022 remain open to examination. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the IRS or other respective tax authorities. No income tax returns are currently under examination by taxing authorities. There are no cumulative earnings in our Italian and South Korean subsidiaries as of December&#160;31,&#160;2023 that would be subject to U.S.&#160;income tax or foreign withholding tax. We plan to indefinitely reinvest any future earnings of our foreign subsidiaries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;9,&#160;2021, the company completed the Merger with NantCell. The Merger is accounted for as a transaction between entities under common control, and is considered a nontaxable transaction for U.S.&#160;income tax purposes, as it is intended to qualify as a &#8220;reorganization&#8221; (within the meaning of Section&#160;368(a) of the Code).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1925" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss before income taxes is as follows (in&#160;thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. loss before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1926">581,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1927">413,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1928">347,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1929">2,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1930">3,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1931">2,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1932">583,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1933">417,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1934">349,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1935" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense) consists of the following (in&#160;thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1939">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1940">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1941">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1945">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1946">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1947">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-1948">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-1949">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1951">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1952">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ibrx:DeferredIncomeTaxExpenseBenefitNet" scale="3" id="f-1957">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="ibrx:DeferredIncomeTaxExpenseBenefitNet" scale="3" id="f-1958">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ibrx:DeferredIncomeTaxExpenseBenefitNet" format="ixt:fixed-zero" scale="3" id="f-1959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit (expense)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1960">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1961">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1962">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">202</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1924-2" continuedAt="f-1924-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1963" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components that comprise our net deferred tax liabilities consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1964">420,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1965">362,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;E capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1966">87,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1967">50,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1968">56,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1969">40,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1970">39,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1971">19,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1972">22,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1973">20,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1974">16,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:fixed-zero" scale="3" id="f-1975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" format="ixt:num-dot-decimal" scale="3" id="f-1976">11,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" format="ixt:num-dot-decimal" scale="3" id="f-1977">12,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ibrx:DeferredTaxAssetsValuationDiscount" format="ixt:num-dot-decimal" scale="3" id="f-1978">9,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ibrx:DeferredTaxAssetsValuationDiscount" format="ixt:fixed-zero" scale="3" id="f-1979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1980">7,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1981">5,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1982">3,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1983">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1984">3,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1985">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1986">2,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1987">1,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-1988">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-1989">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1990">682,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1991">523,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1992">23,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1993">16,527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1994">9,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-1995">11,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1996">1,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1997">3,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="f-1998">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="f-1999">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2000">34,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2001">31,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-2002">648,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-2003">491,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-2004">648,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-2005">491,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-2006">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-2007">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, we have federal NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="9" id="f-2008">1.6</ix:nonFraction>&#160;billion, state NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="9" id="f-2009">2.0</ix:nonFraction>&#160;billion, and foreign NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="f-2010">14.3</ix:nonFraction>&#160;million. Of the $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="9" id="f-2011">1.6</ix:nonFraction>&#160;billion in federal NOLs, $<ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="9" id="f-2012">1.2</ix:nonFraction>&#160;billion do not expire and will be able to be used to offset 80% of taxable income in future years. Of the $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="9" id="f-2013">2.0</ix:nonFraction>&#160;billion in state NOLs, $<ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-2014">50.7</ix:nonFraction>&#160;million do not expire and will be able to be used to offset 80% of taxable income in future years. The remaining federal NOL carryforwards expire beginning in 2024, the remaining state NOL carryforwards expire beginning in 2024, the South Korean NOL carryforwards expire beginning in 2024, and the Italian NOLs do not expire. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some or all of our deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of economic conditions, we recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-2015">648.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-2016">491.8</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023 and 2022, respectively. During the years ended December&#160;31,&#160;2023 and 2022, the valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-2017">156.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-2018">116.6</ix:nonFraction>&#160;million, respectively, which was mainly driven by losses from which we cannot benefit. The portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ibrx:DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" format="ixt:num-dot-decimal" scale="6" id="f-2019">0.2</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">203</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1924-3" continuedAt="f-1924-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-2020" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory income tax rate to our effective income tax rate is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-2021">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-2022">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-2023">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-2024">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-2025">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-2026">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" scale="-2" id="f-2027">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" scale="-2" id="f-2028">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" format="ixt:fixed-zero" scale="-2" id="f-2029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" scale="-2" id="f-2030">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" format="ixt:fixed-zero" scale="-2" id="f-2031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" format="ixt:fixed-zero" scale="-2" id="f-2032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" scale="-2" id="f-2033">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" format="ixt:fixed-zero" scale="-2" id="f-2034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" format="ixt:fixed-zero" scale="-2" id="f-2035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" format="ixt:fixed-zero" scale="-2" id="f-2036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-2037">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-2038">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-2039">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-2040">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-2041">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-2042">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-2043">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-2044">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-2045">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-2046">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-2047">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" scale="-2" id="f-2048">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" sign="-" name="ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" scale="-2" id="f-2049">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" format="ixt:fixed-zero" scale="-2" id="f-2050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-2051">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-2052">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-2053">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-2054">30.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-2055">33.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-2056">32.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-2057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-2058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-2059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections&#160;382 and 383 of the Code, annual use of our net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We have not recognized the deferred tax assets for federal and state NOLs and credits of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ibrx:DeferredTaxAssetNotRecognizedSection382383Limitations" format="ixt:num-dot-decimal" scale="6" id="f-2060">274.1</ix:nonFraction>&#160;million from our deferred tax asset schedules as of December&#160;31,&#160;2023 due to Section&#160;382/383 limitations. There is no impact to tax expense for the derecognition of net operating losses, and federal and state research and development credits due to the valuation allowance recorded against our deferred tax assets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, we also had federal research tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="f-2061">47.7</ix:nonFraction>&#160;million and state research tax credits of $<ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="f-2062">29.6</ix:nonFraction>&#160;million. The federal research tax credit carryforwards expire beginning in 2032 and certain state research tax credit carryforwards expire beginning in 2030. Our California research tax credits can be carried forward indefinitely. As of December&#160;31,&#160;2023, we also had federal other tax credits carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="6" id="f-2063">1.3</ix:nonFraction>&#160;million and the tax credit carryforwards expire beginning in 2036 </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credits also are limited when there is a SRLY. These rules generally limit the use of the acquired or departing members&#8217; net operating loss and tax credit carryovers to the amount of taxable income such entity contributes to consolidated taxable income. The 80%&#160;limitation also applies to SRLY NOL carryovers and tax credits. Therefore, any SRLY NOLs and tax credits will be subject to this limitation, as well as Section&#160;382 and 383 limitations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, we have $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ibrx:DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" format="ixt:num-dot-decimal" scale="6" id="f-2064">164.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ibrx:DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" format="ixt:num-dot-decimal" scale="6" id="f-2065">77.6</ix:nonFraction>&#160;million of interest, respectively, that is temporarily disallowed pursuant to Section&#160;163(j) of the Code. This interest can be carried forward indefinitely and will be deductible when the company generates sufficient adjusted taxable income.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-2066" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of changes to the amount of unrecognized tax benefits is as follows (in&#160;thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2067">16,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2068">13,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2069">20,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-2070">18,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-2071">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-2072">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-2073">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-2074">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-2075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-2076">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-2077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-2078">7,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2079">35,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2080">16,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2081">13,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><ix:continuation id="f-1924-4" continuedAt="f-1924-5"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of December&#160;31,&#160;2023 is $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="ibrx:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-2082">15.1</ix:nonFraction>&#160;million that, if recognized, would not impact our income tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. We do not expect that the unrecognized tax benefits will change within 12&#160;months of December&#160;31,&#160;2023. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact our effective tax rate. We have not incurred any material interest or penalties as of the current reporting date with respect to income tax matters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Reduction Act of 2022</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1924-5">The Inflation Reduction Act 2022, which incorporates a corporate alternative minimum tax, was signed on August&#160;16,&#160;2022. The changes are effective for the tax years beginning after December&#160;31,&#160;2022. The new tax will require companies to compute two&#160;separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The company will be monitoring the impact of the act to determine if it will have an impact on the company for years beginning after December&#160;31,&#160;2022. We currently do not expect this act will have a material effect on our consolidated financial statements.</ix:continuation> </span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_235"></div><div style="margin-top:18pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="f-2083" continuedAt="f-2083-1" escape="true">Employee Benefits</ix:nonNumeric></span></div><ix:continuation id="f-2083-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, we adopted a 401(k)&#160;Plan covering all employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The company, at its discretion, may make certain contributions to the 401(k)&#160;Plan. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we made contributions totaling $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-2084">2.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-2085">2.7</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="f-2086">1.7</ix:nonFraction>&#160;million, respectively, to the 401(k)&#160;Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensated Absences</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our vacation policy, salaried employees are provided unlimited vacation leave. Therefore, we do not record an accrual for paid leave related to these employees since we are unable to reasonably estimate the compensated absences that these employees will take.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">205</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_244"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. &#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_247"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. There is no assurance that our disclosure controls and procedures will operate effectively under all circumstances.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31,&#160;2023. The term &#8220;disclosure controls and procedures&#8221; (as defined in Rule&#160;13a-15(e) of the Exchange Act) means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31,&#160;2023, our CEO and CFO have concluded that, as of December&#160;31,&#160;2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule&#160;13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our CEO and CFO, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; and (ii)&#160;provide reasonable assurance (a)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, (b)&#160;that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (c)&#160;regarding the prevention or timely detection of the unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). Based on this evaluation, our management concluded that, as of December&#160;31,&#160;2023, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our registered independent public accounting firm pursuant to the rules of the SEC that permit us to provide only management&#8217;s report in this Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">206</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended December&#160;31,&#160;2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_250"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_253"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. &#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">207</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_256"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_259"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. &#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule&#160;14A in connection with our Proxy Statement, which is expected to be filed not later than 120&#160;days after the end of our fiscal year ended December&#160;31,&#160;2023, and is incorporated herein by reference.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_262"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Executive Compensation,&#8221; &#8220;Executive Compensation Tables,&#8221; and &#8220;Director Compensation,&#8221; and is incorporated herein by reference.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_265"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. &#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information,&#8221; and is incorporated herein by reference.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_268"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. &#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Certain Relationships and Related-Party Transactions&#8221; and &#8220;Corporate Governance,&#8221; and is incorporated herein by reference.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_271"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. &#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the heading &#8220;Fees Paid to Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">208</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_274"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_277"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. &#160;&#160;&#160;&#160;EXHIBIT AND FINANCIAL STATEMENT SCHEDULES.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements, financial statement schedules and exhibits filed as part of this Annual Report are as follows:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Financial Statements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the consolidated financial statements identified in the &#8220;Index to Financial Statements&#8221; under Part&#160;II, Item&#160;8. </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_127">&#8220;Financial Statements and Supplementary Data&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Financial Statement Schedules for the Years Ended December&#160;31,&#160;2023, 2022 and 2021 </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because the information required to be set forth therein is not applicable or is otherwise included in the consolidated financial statements or notes thereto. See Part&#160;II, Item&#160;8. </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_127">&#8220;Financial Statements and Supplementary Data&#8221;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Exhibits </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The documents listed below are incorporated by reference or filed or furnished with this Annual Report, in each case as indicated therein (numbered in accordance with Item&#160;601 of Regulation&#160;S-K).</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.031%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.498%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;2.1+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312520323766/d21044dex21.htm">Agreement and Plan of Merger, dated December&#160;21,&#160;2020, by and among ImmunityBio, Inc. (f/k/a NantKwest, Inc.), NantCell, Inc. (f/k/a ImmunityBio, Inc.) and Nectarine Merger Sub, Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515275314/d158803dex31.htm">Amended and Restated Certificate of Incorporation of ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521075243/d307217dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio,&#160;Inc. dated March&#160;9,&#160;2021.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522061324/d283375dex33.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio, Inc. dated February&#160;1,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POSASR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-255699</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit34.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio, Inc. dated October&#160;18,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">Amended and Restated Bylaws of ImmunityBio, Inc. effective as of March</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">10,</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">&#160;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex32_717.htm">2021.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 12, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex41.htm">Nominating Agreement by and between the Registrant and Cambridge Equities, LP, dated June&#160;18,&#160;2015.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 19, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex42.htm">Form of Registration Rights Agreement by and between the Registrant and the Purchasers of Common Stock, dated June&#160;2015.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 19, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex43.htm">Registration Rights Agreement by and between the Registrant and Cambridge Equities, LP, dated December&#160;23,&#160;2014.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 19, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.031%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.498%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex45.htm">Form of Subscription and Securities Purchase Agreement among the Registrant and the Subscribers of Series&#160;C Preferred Stock, dated as of April&#160;1,&#160;2014.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 19, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex46.htm">Registration Rights Agreement, among the Registrant and the purchasers of Series&#160;B Preferred Stock, dated as of June&#160;20,&#160;2013.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 19, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521169432/d162734dex41.htm">Specimen Common Stock Certificate.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8 POS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 21, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.7*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit47.htm">Description of Registrant&#8217;s Securities.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.8+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1013.htm">Common Stock Purchase Warrant, dated June&#160;30,&#160;2016, issued by the Company to NantWorks,&#160;LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex41.htm">Form of December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex41.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex41.htm">2022 Common Stock Purchase Warrant.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 12, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit41.htm">Amended Form of February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit41.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit41.htm">2023 Common Stock Purchase Warrant.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/d489429dex41.htm">Form of July</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/d489429dex41.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/d489429dex41.htm">2023 Common Stock Purchase Warrant.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 21, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312520323766/d21044dex101.htm">Voting Agreement, dated as of December&#160;21,&#160;2020, by and among ImmunityBio,&#160;Inc., NantKwest,&#160;Inc. and the NantKwest,&#160;Inc. stockholders party thereto.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312520323766/d21044dex102.htm">Voting Agreement, dated as of December&#160;21,&#160;2020, by and among ImmunityBio, Inc., NantKwest, Inc. and the ImmunityBio, Inc. stockholders party thereto.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 22, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.3+*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx20231231-10kexhibit103.htm">Revenue Interest Purchase Agreement dated as of December&#160;29,&#160;2023 among ImmunityBio, Inc., the Purchasers from time to time party hereto and Infinity SA LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.4+*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx20231231-10kexhibit104.htm">Security and Pledge Agreement as of December&#160;29,&#160;2023 among ImmunityBio, Inc., the Subsidiary Guarantors listed on the signature pages hereto, such other parties that may become Grantors hereunder after the date hereof and Infinity SA LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.5+*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx20231231-10kexhibit105.htm">Stock Purchase and Option Agreement dated December&#160;29,&#160;2023 by and between the Investors and ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit103.htm">Stock Purchase Agreement, dated September&#160;11,&#160;2023, by and among ImmunityBio,&#160;Inc., NantCell,&#160;Inc., Nant&#160;Capital,&#160;LLC, NantMobile,&#160;LLC, and NantCancerStemCell,&#160;LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523190800/d489429dex101.htm">Securities Purchase Agreement dated as of July&#160;20,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 21, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex101.htm">Securities Purchase Agreement dated as of February</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex101.htm">15,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex101.htm">2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312523039833/d644968dex101.htm">.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.031%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.498%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex101.htm">Securities Purchase Agreement, dated as of December&#160;12,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 12, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521146472/d176034dex101.htm">Open Market Sale Agreement dated April&#160;30,&#160;2021, by and between ImmunityBio,&#160;Inc. and Jefferies LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.11+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex104.htm">Agreement and Plan of Merger, dated May&#160;19,&#160;2017, by and among the Company, Altor Acquisition LLC, Altor BioScience Corporation and Shareholder Representative Services LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1012.htm">Sales Milestone Contingent Value Rights Agreement, dated as of July&#160;31,&#160;2017, by and between the Company and Shareholder Representative Services LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.13*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx20231231-10kexhibit1013.htm">Letter Amendment dated December&#160;29,&#160;2023 to the Convertible Promissory Notes dated March&#160;31,&#160;2023 (as amended on September&#160;11,&#160;2023) and September&#160;30,&#160;2023 issued by ImmunityBio, Inc. to Nant&#160;Capital, LLC</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx20231231-10kexhibit1013.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx20231231-10kexhibit1013.htm"> </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit104.htm">Convertible Promissory Note between ImmunityBio,&#160;Inc. and Nant&#160;Capital,&#160;LLC dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit104.htm">September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit104.htm">&#160;1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit104.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit104.htm">,&#160;202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit104.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit104.htm">.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit108.htm">Letter of Amendment dated as of September&#160;11,&#160;2023 to the Convertible Promissory Note issued by ImmunityBio,&#160;Inc. to Nant&#160;Capital, LLC dated March&#160;31,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000028/ibrx-20233318xkexhibit101.htm">Convertible Promissory Note by and between ImmunityBio,&#160;Inc. and Nant&#160;Capital, LLC dated March&#160;31,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.17*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx20231231-10kexhibit1017.htm">Amended and Restated Promissory Note between ImmunityBio,&#160;Inc. and Nant&#160;Capital,&#160;LLC dated December&#160;29,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">Letter of Amendment dated as of September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">11,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">2023 to the Promissory Note issued by ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">Inc. to Nant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">Capital, LLC dated December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">12,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit107.htm">2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex102.htm">Promissory Note between ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex102.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex102.htm">Inc. and Nant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex102.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739dex102.htm">Capital, LLC dated December&#160;12,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 12, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">Letter of Amendment dated as of September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">11,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">2023 to the Promissory Note issued by ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">Inc. to Nant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">Capital, LLC dated August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">31,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit106.htm">2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit101.htm">Promissory Note between ImmunityBio,&#160;Inc. and Nant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit101.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit101.htm">Capital, LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">Letter of Amendment dated as of September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">11,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">2023 to the Promissory Note issued by ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">Inc. to Nant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">Capital, LLC dated June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">13,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit109.htm">2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">211</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.031%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.498%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/ibrx-2023613x8kexhibit101.htm">Promissory Note between ImmunityBio,&#160;Inc. and Nant&#160;Capital, LLC dated June&#160;13,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit105.htm">Letter of Amendment dated as of September&#160;11, 2023 to the Amended and Restated Promissory Note issued by ImmunityBio,&#160;Inc. to Nant&#160;Capital, LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit102.htm">Amended and Restated Promissory Note between ImmunityBio,&#160;Inc. and Nant&#160;Capital,&#160;LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit103.htm">Amended and Restated Convertible Promissory Note between ImmunityBio,&#160;Inc. and Nant&#160;Capital,&#160;LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit104.htm">Amended and Restated Convertible Promissory Note between ImmunityBio,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit104.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit104.htm">Inc. and Nant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit104.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit104.htm">Capital, LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit105.htm">Second Amended and Restated Convertible Promissory Note between ImmunityBio,&#160;Inc. and Nant&#160;Capital,&#160;LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit107.htm">Second Amended and Restated Convertible Promissory Note between ImmunityBio,&#160;Inc. and NantCancerStemCell,&#160;LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000074/ibrx-20220930x10qexhibit108.htm">Second Amended and Restated Convertible Promissory Note between ImmunityBio,&#160;Inc. and NantMobile,&#160;LLC dated August&#160;31,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000095012315007692/d917371dex1019.htm">Lease Agreement by and between ARE-JOHN HOPKINS COURT, LLC and the Company, dated June&#160;19,&#160;2015.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 27, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000058/ibrx-20220630x10qexhibit106.htm">First Amendment to Lease dated July&#160;16,&#160;2015 by and between ARE-JOHN HOPKINS COURT, LLC and Conkwest,&#160;Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000058/ibrx-20220630x10qexhibit107.htm">Second Amendment to Lease effective as of June&#160;18,&#160;2016 by and between ARE-JOHN HOPKINS COURT, LLC and NantKwest,&#160;Inc., fka Conkwest,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000058/ibrx-20220630x10qexhibit108.htm">Third Amendment to Lease dated April&#160;12,&#160;2022 by and between ARE-JOHN HOPKINS COURT, LLC and ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459016015596/nk-ex1023_1729.htm">Facility License Agreement by and between NantWorks, LLC and the Company, dated as of November&#160;6,&#160;2015.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 30, 2016</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">212</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.031%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.498%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459020052488/nk-ex102_93.htm">First Amendment to Facility License Agreement by and between NantWorks,&#160;LLC and the Company, dated as of September&#160;14,&#160;2020.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000058/ibrx-20220630x10qexhibit104.htm">Second Amendment to Facility License Agreement, effective as of May&#160;1,&#160;2022, by and between NantWorks,&#160;LLC, the Licensor, and ImmunityBio,&#160;Inc., the Licensee.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459016028905/nk-ex101_159.htm">Commercial Lease by and between 605&#160;Doug&#160;St, LLC and the Company, dated&#160;September&#160;15,&#160;2016.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2016</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000098/ibrx-20230630x10qexhibit102.htm">Extension of Commercial Lease by and between 605&#160;Doug St, LLC and ImmunityBio,&#160;Inc., dated June&#160;30,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.40+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1027.htm">Commercial Lease by and between Duley&#160;Road, LLC and Altor BioScience Manufacturing Company, LLC, dated February&#160;1,&#160;2017.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.41*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kex1041.htm">Extension of Commercial Lease by and between Duley&#160;Road, LLC and Altor BioScience Manufacturing Company, LLC, dated October&#160;3,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.42+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1028.htm">Commercial Lease by and between Duley&#160;Road, LLC and the Company, dated January&#160;28,&#160;2019.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.43+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1029.htm">Commercial Lease by and between Duley&#160;Road, LLC and the Company, dated January&#160;28,&#160;2019.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459020052488/nk-ex103_94.htm">Sublease Agreement between Altor BioScience Manufacturing Company,&#160;LLC and the Company, dated as of September&#160;30,&#160;2020.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021010945/nk-ex1035_433.htm">Commercial Lease between 605&#160;Nash,&#160;LLC and the Company, dated February&#160;11,&#160;2021.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.46</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459021044008/ibrx-ex101_955.htm">First Amendment to Lease (Expansion &amp; Extension) made and entered into as of May&#160;28,&#160;2021 by and between 605&#160;Nash,&#160;LLC and ImmunityBio,&#160;Inc. </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 12, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611021000009/ibrx-20210930x10qexhibit102.htm">Membership Interest Purchase Agreement entered into as of September&#160;27,&#160;2021 by and among Nant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611021000009/ibrx-20210930x10qexhibit102.htm">&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611021000009/ibrx-20210930x10qexhibit102.htm">Capital,&#160;LLC and ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611021000009/ibrx-20210930x10qexhibit103.htm">Industrial/Commercial Lease Agreement dated September&#160;27,&#160;2021 by and between 557&#160;Doug St, LLC and ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000058/ibrx-20220630x10qexhibit109.htm">Lease Termination Agreement effective May&#160;31,&#160;2022 by and between ImmunityBio,&#160;Inc. and 557&#160;Doug St., LLC.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611021000009/ibrx-20210930x10qexhibit104.htm">Commercial Lease Agreement dated September&#160;27,&#160;2021 by and between 420&#160;Nash, LLC and ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 12, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">213</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.031%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.498%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000027/ibrx-20220331x10qexhibit102.htm">Fort Schuyler Management Corporation Lease, effective as of October&#160;1,&#160;2021, between Fort Schuyler Management Corporation, as Landlord, and Athenex,&#160;Inc., as Tenant.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000027/ibrx-20220331x10qexhibit103.htm">First Amendment to Lease, effective as of February&#160;14,&#160;2022, by and among Fort&#160;Schuyler Management Corporation and ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000058/ibrx-20220630x10qexhibit.htm">Industrial/Commercial Lease Agreement dated May&#160;1,&#160;2022 by and between 23&#160;Alaska,&#160;LLC and ImmunityBio,&#160;Inc.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">L</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">ease Termination Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">dated as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm"> August&#160;31,&#160;2023 by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">I</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">mmunityBio</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">,&#160;Inc. and 23&#160;Alaska,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">&#160;LLC</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611023000147/ibrx-2023930x10qexhibit102.htm">.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.55+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312522007333/d276464dex101.htm">Purchase Agreement by and between Athenex,&#160;Inc. and ImmunityBio,&#160;Inc. dated January&#160;7,&#160;2022.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 12, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.56+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459019029330/nk-ex104_267.htm">Letter Agreement effective as of July&#160;1,&#160;2019 between Immuno-Oncology Clinic,&#160;Inc. and the Company.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459020024168/nk-ex101_98.htm">First Amendment to the July&#160;1,&#160;2019 Letter Agreement by and between Immuno-Oncology Clinic,&#160;Inc. and the Company, dated March&#160;31,&#160;2020.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459016024275/nk-ex101_112.htm">Amended and Restated Shared Services Agreement by and between NantKwest,&#160;Inc. and NantWorks,&#160;LLC, dated June&#160;28,&#160;2016.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 15, 2016</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.59#+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000156459020052488/nk-ex104_390.htm">Offer Letter between the Company and Richard Adcock, dated October&#160;26,&#160;2020.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37507</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.60#+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1031.htm">Offer Letter, dated August&#160;3,&#160;2020, between ImmunityBio,&#160;Inc. and David Sachs.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252232</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex101.htm">Form of Indemnification Agreement between ImmunityBio,&#160;Inc. and each of its Directors and Executive Officers.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 19, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.62#</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515252847/d917371dex104.htm">Executive Incentive Compensation Plan.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.63#</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312515229037/d917371dex102.htm">2014 NantKwest, Inc. Equity Incentive Plan and forms of agreement thereunder.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205124</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 19, 2015</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.64#</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611022000040/ibrx-20220614xs8exhibit101.htm">ImmunityBio, Inc. 2015 Equity Incentive Plan and forms of agreement thereunder.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-265599</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;10.65#</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1014.htm">NantCell, Inc. 2015 Stock Incentive Plan and forms of agreement thereunder.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252332</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 19, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;21.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit211.htm">Subsidiaries of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;23.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit231.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;24.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (Contained in Signature Page to this Annual Report).</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">214</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:8.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.031%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.498%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;31.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit311.htm">Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15(d)-14(a) of the Securities Act, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;31.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit312.htm">Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15(d)-14(a) of the Securities Act, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;32.1**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit321.htm">Certification of Principal Executive Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;32.2**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit322.htm">Certification of Principal Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;97.1#+*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ibrx-20231231x10kexhibit971.htm">ImmunityBio, Inc. Compensation Recovery Policy as adopted or most recently updated on November&#160;29,&#160;2023.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit&#160;101).</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*  &#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**  &#160;&#160;&#160;&#160;The certifications attached as Exhibits&#160;32.1 and 32.2 that accompany this Annual Report are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of ImmunityBio,&#160;Inc. under the Securities&#160;Act or the Exchange&#160;Act, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">#  &#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">+  &#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some information has been redacted pursuant to Item&#160;601of Regulation&#160;S-K. The company agrees to furnish to the SEC a copy of any redacted information upon request.</span></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_280"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. &#160;&#160;&#160;&#160;FORM 10-K SUMMARY.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">215</span></div></div></div><div id="if7eeec8e66644046bbbe3c0a87df2c46_283"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.922%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.999%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">IMMUNITYBIO, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">Registrant</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: March&#160;19,&#160;2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Richard Adcock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Adcock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: March&#160;19,&#160;2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ David C. Sachs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David C. Sachs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Financial Officer)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: March&#160;19,&#160;2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Regan J. Lauer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Regan J. Lauer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">(Principal Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Table of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if7eeec8e66644046bbbe3c0a87df2c46_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose signature appears below constitutes and appoints Richard Adcock, David C. Sachs and Jason&#160;Liljestrom, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Patrick Soon-Shiong</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Chief Scientific and Medical Officer, and <br/>Executive Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patrick Soon-Shiong</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard Adcock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard Adcock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David C. Sachs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David C. Sachs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Regan J. Lauer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regan J. Lauer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Barry J. Simon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Corporate Affairs Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Barry J. Simon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Blaszyk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael D. Blaszyk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Owen Brennan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Owen Brennan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Wesley Clark</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wesley Clark</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Cheryl L. Cohen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Independent Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cheryl L. Cohen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Linda Maxwell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Linda Maxwell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christobel Selecky</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;19,&#160;2024</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christobel Selecky</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">217</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>ibrx-20231231x10kexhibit47.htm
<DESCRIPTION>EX-4.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1de069e1abff4a0caea2fa3dd7a68184_35"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">EXHIBIT 4.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">ImmunityBio, Inc. has one class of securities registered under Section&#160;12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our common stock.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Description of Capital Stock</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation (our &#8220;Certificate of Incorporation&#8221;) and our Amended and Restated Bylaws (our &#8220;Bylaws&#8221;), each of which are incorporated by reference as an exhibit to the Annual Report on Form&#160;10-K of which this Exhibit&#160;4.7 is a part. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law, for additional information.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">We are authorized to issue up to a total of 1,350,0</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">00,000&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">shares of common stock, par value </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">$0.0001&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. Further, holders of our common stock have no preemptive, conversion, redemption or subscription rights and there are no sinking fund provisions applicable to our common stock. Upon our liquidation, dissolution or winding-up, holders of our common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of our assets which are legally available.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Our board of directors is authorized, subject to certain limitations prescribed by law, to designate and issue up to a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">20,000,000&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">shares of preferred stock, par value </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">$0.0001&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">per share, without stockholder approval. The board may issue preferred stock from time to time in one or more series and fix the designations, preferences and rights of the shares of each such series and any qualifications, limitations or restrictions on the shares of each such series, including dividend rights and rates, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any such series.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could harm the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might harm the market price of our common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Certain provisions of the Delaware General Corporation Law, our Certificate of Incorporation and our Bylaws may have the effect of delaying, deferring or discouraging another person from acquiring</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaw Provisions</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Our Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our management team, including the following&#58;</font></div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.33pt">Board of directors vacancies. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Our Certificate of Incorporation and Bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by our board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.33pt">Advance notice requirements for stockholder proposals and director nominations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Our Bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.33pt">No cumulative voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our Certificate of Incorporation does not provide for cumulative voting.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.33pt">Amendment of charter provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders of at least two-thirds of our then outstanding voting securities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.33pt">Issuance of undesignated preferred stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Our board of directors has the authority, without further action by the stockholders, to issue up to 20,000,000&#160;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.33pt">Exclusive forum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our Certificate of Incorporation or our Bylaws, or (iv)&#160;any action asserting a claim against us governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Listing</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;IBRX.&#8221;</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. They can be reached by mail at EQ, PO Box&#160;500, Newark, New Jersey 07101 or by email at helpAST&#64;equiniti.com. The transfer agent&#8217;s telephone number is (800)&#160;937-5449.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>ibrx20231231-10kexhibit103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibdce341a54074590ae0418afe4e58f16_93"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.3</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY &#91;*****&#93; IS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE THE REGISTRANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ACTUALLY TREATS THAT INFORMATION AS CONFIDENTIAL&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVENUE INTEREST PURCHASE AGREEMENT</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">dated as of December 29, 2023</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">among</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNITYBIO, INC.,</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as the Company,</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">the Purchasers from time to time party hereto</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">and</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFINITY SA LLC, as Purchaser Agent</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ibdce341a54074590ae0418afe4e58f16_77"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TABLE OF CONTENTS</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:21.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I DEFINITIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definitions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II PURCHASE OF REVENUE INTERESTS&#59; PAYMENTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase of Revenue Interests.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Section 2.02</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payments by the Company.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Section 2.03</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchaser Payments&#59; Conditions Precedent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Section 2.04</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Assumed Obligations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.02</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorization.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.03</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Enforceability.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.04</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Reserved&#93;.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.05</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ownership.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.06</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements&#59; No Material Adverse Effect.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.07</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Undisclosed Liabilities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.08</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Solvency&#59; No Fraudulent Transfer.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.09</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compliance with Laws.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conflicts&#59; Adverse Agreements.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Approvals&#59; Anktiva.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Contracts.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.15</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Perfection Certificate.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.16</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers and Suppliers.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.17</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Perfection&#59; Subordination.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.18</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.19</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.20</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Reports.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.21</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Company Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.22</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC&#59; Anti-Terrorism Laws.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.23</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Broker&#8217;s Fees.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.24</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Put Option Event.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.25</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.26</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ERISA Compliance, Employee and Labor Matters&#59; Pension Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.02</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorization.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.03</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Broker&#8217;s Fees.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.04</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conflicts.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.05</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE V COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices&#59; Access&#59; Information.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.02</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reports.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:21.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.03</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compliance with Law&#59; Existence and Maintenance of Properties&#59; Payment of Obligations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.04</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Confidentiality&#59; Public Announcement.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.05</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security Interest.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.06</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Further Assurances&#59; Creation&#47;Acquisition of Subsidiaries&#59; Additional Collateral&#59; Control Agreements.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.07</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Put Option&#59; Call Option.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.08</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.09</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property&#59; Regulatory Approvals.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Protective Covenants.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Contracts.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee and Pension Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VI TERMINATION</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Termination Date.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.02</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect of Termination.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VII PURCHASER AGENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Appointment and Authority.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.02</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rights as a Purchaser.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.03</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exculpatory Provisions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.04</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reliance by Purchaser Agent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.05</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delegation of Duties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.06</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Resignation of Purchaser Agent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.07</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Reliance on Purchaser Agent and Other Purchasers.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.08</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collateral and Guaranty Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.09</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement by Purchasers.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VIII MISCELLANEOUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.01</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Damages.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.02</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.03</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successors and Assigns.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.04</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.05</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No Implied Representations and Warranties&#59; Survival of Representations and Warranties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.06</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Nature of Relationship.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.07</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entire Agreement.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.08</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendments&#59; No Waivers.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.09</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interpretation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.10</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Headings and Captions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">79</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.11</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Counterparts&#59; Effectiveness&#59; Electronic Signature.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.12</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Severability.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.13</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.14</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law&#59; Jurisdiction.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.15</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Waiver of Jury Trial.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULES</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="15" style="padding:0 1pt 0 19pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule 1.01(b)</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;Purchaser Commitments</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit A</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;Form of Compliance Certificate</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit B</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;Form of Guaranty</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit C</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;Form of Payment Notice</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit D</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;Customary Subordination Terms</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</font></div></div></div><div id="ibdce341a54074590ae0418afe4e58f16_35"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVENUE INTEREST PURCHASE AGREEMENT </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVENUE INTEREST PURCHASE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (as amended, supplemented or otherwise modified from time to time, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of December&#160;29,&#160;2023, by and among ImmunityBio, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Purchasers from time to time party hereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company wishes to obtain financing to support the further development and commercialization of the Included Products (as hereinafter defined) and other general corporate purposes&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Purchasers wish to purchase the Revenue Interests (as hereinafter defined) from the Company, and the Company wishes to sell, collaterally assign and transfer the Revenue Interests to the Purchasers in consideration for its payment of the Purchaser Payments (as hereinafter defined) all upon and subject to the terms and conditions hereinafter set forth.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in consideration of the mutual covenants, agreements, representations and warranties set forth herein, the parties hereto agree as follows&#58; </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.92pt;text-decoration:underline">Definitions.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following terms that are defined in the UCC (as hereinafter defined) are used in this Agreement as so defined (and, in the event any such term is defined differently for purposes of Article&#160;9 of the UCC than for any other purpose or purposes of the UCC, the Article&#160;9 definition shall govern)&#58; Account, Chattel Paper, Commercial Tort Claim, Commodity Account, Commodity Intermediary, Deposit Accounts, Documents, Electronic Chattel Paper, Equipment, General Intangibles, Goods, Instruments, Inventory, Investment Property, Letter of Credit Rights, Proceeds, Securities Account, Securities Intermediary and Tangible Chattel Paper. In addition, the following, as used herein, shall have the following meanings&#58; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a take-over bid, tender offer, amalgamation, merger, purchase of assets or similar transaction having the same effect as any of the foregoing, (i)&#160;acquires any business, product, business line or product line or all or substantially all of the assets of any Person, business, product, business line or product line, division or other unit operation of any Person, (ii)&#160;acquires control of securities of a Person engaged in a business representing more than&#160;50% of the ordinary voting power for the election of directors or other governing body if the business affairs of such Person are managed by a board of directors or other governing body or (iii)&#160;acquires control of more than&#160;50% of the ownership interest in any Person engaged in any business that is not managed by a board of directors or other governing body and (b)&#160;any In-License.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means consideration paid or payable for an Acquisition (including, without limitation, all milestone, maintenance and&#47;or similar payments, earnouts (whether earned or contingent), deferred purchase price and any other contractual commitment, whether fixed or contingent). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Person that Controls, is Controlled by, or is under common Control with another Person. Unless the context otherwise requires, &#8220;Affiliate&#8221; refers to an Affiliate of the Company (and includes any Subsidiary of the Company).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (x)&#160;that certain Amended and Restated Shared Services Agreement, dated as of June&#160;28,&#160;2016, as amended, supplemented or otherwise modified from time to time in compliance with this Agreement and (y)&#160;other arrangements between the Obligors and their Affiliates existing on the Closing Date and disclosed on Schedule&#160;5.11(a)(xiii)(1) to the Disclosure Letter (and any amendment thereto or replacement thereof to the extent such an amendment or replacement is (i)&#160;at least as favorable in all material respects to the Company and its Subsidiaries as was the original transaction and (ii)&#160;not adverse to the interests of the Purchasers).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the first paragraph hereof. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all laws, rules, regulations and orders of Governmental Authorities applicable to such Person or any of its properties or assets.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any calendar year, the amount of Net Sales of all Included Products for such calendar year.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anktiva</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product or treatment comprising or containing the interleukin-15 superagonist complex named N-803 (or ALT-803), in any formulation, dose or dosage form, under any brand name, including Anktiva</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or as an authorized generic product, and any derivative, improvement, enhancement, modification or subsequent iteration of any of the foregoing.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means,</font></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">as of any date of determination for any full or partial calendar year occurring prior to the Second Purchaser Payment Date, the percentage based on the applicable portion of Annual Net Sales for such calendar year as set forth in the chart below&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tier</font></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portion of Annual<br>Net Sales</font></td><td colspan="9" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Percentage</font></td></tr><tr><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">At all times prior to<br>the Test Date&#58;</font></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">At all times from and<br>after the Test Date, if a<br>Test Date Shortfall has<br>not occurred&#58;</font></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">At all times from and<br>after the Test Date, if a<br>Test Date Shortfall has <br>occurred&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tier 1</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to <br>Annual Net Sales of<br>$600,000,000 or less.</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00%</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To be calculated<br>pursuant to the <br>subsequent proviso.</font></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tier 2</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to<br>Annual Net Sales in<br>excess of<br>$600,000,000.</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To be calculated<br>pursuant to the<br>subsequent proviso.</font></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">as of any date of determination for any full or partial calendar year occurring after the Second Purchaser Payment Date during the Term, the percentage based on the applicable portion of Annual Net Sales for such calendar year as set forth in the chart below&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tier</font></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portion of Annual<br>Net Sales</font></td><td colspan="9" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Percentage</font></td></tr><tr><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">At all times prior to<br>the Test Date&#58;</font></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">At all times from and<br>after the Test Date, if a<br>Test Date Shortfall has<br>not occurred&#58;</font></td><td colspan="3" style="background-color:#8ab6cc;border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">At all times from and<br>after the Test Date, if a<br>Test Date Shortfall has <br>occurred&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tier 1</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to <br>Annual Net Sales of<br>$600,000,000 or less.</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.00%</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.25%</font></td><td colspan="3" style="border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To be calculated<br>pursuant to the <br>subsequent proviso.</font></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tier 2</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to<br>Annual Net Sales in<br>excess of<br>$600,000,000.</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.50%</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.25%</font></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #b6b6b6;border-left:1pt solid #b6b6b6;border-right:1pt solid #b6b6b6;border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To be calculated<br>pursuant to the<br>subsequent proviso.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, in each case of clauses&#160;(a) and (b),&#160;if a Test Date Shortfall has occurred, then as of and following the Test Date, the Applicable Percentage for Tiers&#160;1 and 2 shall be increased for all subsequent calendar years beginning on January&#160;1,&#160;2030 to a single defined rate (with no separate Tiers) that, had such increased rate applied to the applicable &#8220;Tier 1&#8221; during the period from the Closing Date through and including the Test Date, would have provided the Purchasers with aggregate Revenue Interest Payments (excluding any Revenue Interest Payments made with respect to amounts treated as Net Sales of the Included Products pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.09(c)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and&#47;or with respect to upfront payments, milestone payments or other lump sum payments made under Out-Licenses) in an amount equal to the Cumulative Purchaser Payments as of the Test Date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Audited Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the definition of &#8220;Financial Statements&#8221;.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bankruptcy Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following&#58; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Company or any Subsidiary commences any case, proceeding or other action (i)&#160;under any Bankruptcy Law, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, administration, protection, liquidation or dissolution (other than a solvent winding-up, dissolution or liquidation of a Subsidiary into an Obligor), composition or other relief with respect to it or its debts, or (ii)&#160;seeking appointment of a receiver, interim receiver, receiver and manager, trustee, administrator, administrative receiver, custodian or other similar official for it or for all or any portion of its assets, or the Company or any Subsidiary makes a general assignment for the benefit of its creditors or enter into a composition, compromise, assignment or arrangement with any of its creditors (whether by way of a voluntary arrangement, scheme of arrangement, deed of compromise or otherwise)&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">there is commenced against the Company or any Subsidiary any case, proceeding or other action seeking to adjudicate it bankrupt or insolvent, or seeking dissolution, liquidation, administration, winding up, reorganization, arrangement, adjustment, protection, relief of debtors, or seeking the entry of an order for relief or the appointment of a receiver, interim receiver, receiver and manager, trustee, administrator, administrative receiver, custodian or other similar official for any such Person or for any substantial part of its property, and either such proceeding remains undismissed or unstayed for a period of thirty&#160;(30) days or any of the actions sought in such proceeding (including, without limitation, the entry of an order for relief against any such Person or the appointment of a receiver, interim receiver, receiver and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manager, trustee, administrator, administrative receiver, custodian or other similar official for it or for any substantial part of its property) occurs&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">the Company or any Subsidiary is generally not paying its debts as such debts become due or shall admit in writing its inability to pay its debts generally&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">a receiver, interim receiver, receiver and manager, trustee, administrator, administrative receiver, custodian or other similar official is appointed, either voluntarily or involuntarily, to or in respect of the Company or any Subsidiary or the whole or any part of the property, assets or undertaking of the Company or any Subsidiary&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">there is commenced against the Company or any Subsidiary any case, proceeding or other action seeking issuance of a warrant of attachment, execution, distraint or similar process against (i)&#160;all or a substantial portion of its assets and&#47;or (ii)&#160;any Included Product or any Collateral, which results in the entry of an order for any such relief which shall not have been vacated, discharged, stayed, satisfied or bonded pending appeal within thirty&#160;(30) days from the entry thereof&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">the Company or any Subsidiary is insolvent as defined in any statute of the United States Bankruptcy Code or in the fraudulent conveyance or fraudulent transfer statutes of the State of Delaware or other applicable jurisdiction of organization&#59; or</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">an affirmative vote by the applicable Board to commence any case, proceeding or other action described in clause&#160;(a) above or any other action by the Company or any Subsidiary to otherwise cause, consent to, approve or acquiesce in any of the acts described in clauses&#160;(a) through (f) inclusive above.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bankruptcy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, in any jurisdiction, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer, or other similar Applicable Laws affecting the enforcement of creditors&#8217; rights generally.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Beike License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that certain Amended and Restated License, Development and Commercialization Agreement, dated as of September&#160;30,&#160;2017, by and between Altor BioScience, LLC, a Delaware limited liability company and Subsidiary Guarantor, and Shenzhen Beike Biotechnology Co., Ltd., a limited liability company organized under the laws of the People&#8217;s Republic of China.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Biologics License Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an application submitted pursuant to Section&#160;351 of the PHSA requesting permission from the FDA to introduce, or deliver for introduction, a biologic product into interstate commerce in the United States.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the board of directors or similar governing body of the Company or any Subsidiary, as applicable.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of the State of New York, or any day on which banking institutions located in the State of New York are required by law or other governmental action to close. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Call Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.07(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Call Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.07(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Call Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.07(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cap Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of the date of determination thereof, the amount equal to the product of (i)&#160;1.95&#160;and (ii)&#160;the Cumulative Purchaser Payments as of such date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (i)&#160;securities issued or unconditionally guaranteed or insured by the United States of America or any agency or instrumentality thereof, backed by the full faith and credit of the United States of America and maturing within one year from the date of acquisition, (ii)&#160;commercial paper issued by any Person organized under the laws of the United States of America maturing within 360&#160;days from the date of acquisition and, at the time of acquisition, having a rating of at least&#160;A-1 or the equivalent thereof by Standard &#38; Poor&#8217;s Ratings Services or at least P-1 or the equivalent thereof by Moody&#8217;s Investors Service, Inc., or F-1 or better by Fitch Investor Services, (iii)&#160;time deposits and certificates of deposit maturing within 360&#160;days from the date of issuance (A)&#160;that are unconditionally guaranteed or insured by the United States of America or any agency or instrumentality thereof, backed by the full faith and credit of the United States of America or (B)&#160;that are issued by a bank or trust company organized under the laws of the United States of America (or any state thereof) (1)&#160;that has combined capital and surplus of at least $500,000,000 or (2)&#160;that has (or is a subsidiary of a bank holding company that has) a long-term unsecured debt rating of at least&#160;A or the equivalent thereof by Standard &#38; Poor&#8217;s Ratings Services or at least A2 or the equivalent thereof by Moody&#8217;s Investors Service, Inc. or&#160;A or better by Fitch Investor Services, (iv)&#160;investment funds investing at least ninety-five&#160;(95%) of their assets in securities of the types described in clauses&#160;(i)&#160;through (iii) and (v)&#160;below, and (v)&#160;money market funds that are SEC registered&#160;2a-7 eligible only, have assets in excess of $1,000,000,000, offer a daily purchase&#47;redemption feature and seek to maintain a constant share price&#59; provided that, the Obligors will invest only in &#8216;no-load&#8217; funds which have a constant&#160;$1.00 net asset value target.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, at any time, the occurrence of any of the following events or circumstances&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">the acquisition by any &#8220;person&#8221; or &#8220;group&#8221; (within the meaning of Sections&#160;13(d)(3) or 14(d)(2) of the Exchange Act), other than a Permitted Holder, of beneficial ownership of any Equity Interests of the Company, if after such acquisition, such &#8220;person&#8221; or &#8220;group&#8221;, other than a Permitted Holder, would be the &#8220;beneficial owner&#8221; (as defined in Rule&#160;13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than forty-nine percent&#160;(49%) of the combined voting power of the Company&#8217;s then outstanding securities entitled to vote generally in the election of directors&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">a merger or consolidation of the Company with any other Person, other than a merger or consolidation of the Company in which the Company is the surviving Person and which results in the Company&#8217;s voting securities outstanding immediately prior thereto continuing to represent more than fifty percent&#160;(50%) of the combined voting power of the Company&#8217;s voting securities outstanding immediately after such merger or consolidation&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">the Transfer of all or substantially all of the Company&#8217;s assets in any transaction or series of related transactions&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">any Transfer by the Company or any of its Subsidiaries of any Primary Product Assets (other than a Transfer permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.11(a)(x)(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.11(a)(x)(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Patrick Soon-Shiong (together with his Immediate Family Members, Affiliates and funds, investments, Persons, vehicles or accounts that are managed, sponsored, or advised by him or his Affiliates) ceases to beneficially own&#160;35% or more of the Equity Interests of the Company entitled to vote for members of its Board on a fully diluted basis&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">the occurrence of a change of control, &#8220;fundamental change&#8221; or other similar provision, as defined in any agreement or instrument evidencing any Indebtedness in excess of prior to the Milestone, $5,000,000, and from and after the occurrence of the Milestone, $10,000,000, triggering a default, a mandatory prepayment or other obligation to repurchase, redeem or repay such Indebtedness. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any clinical trial or investigation and any non-clinical investigations of the Included Products conducted by or on behalf of the Company or any Subsidiary.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trial Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any application or submission to any Regulatory Agency for authorization of the investigation of any product in any country or group of countries.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to each ongoing or proposed Clinical Trial, a summary of (a)&#160;the current status of enrollment, (b)&#160;the estimated completion date, (c)&#160;the status of any clinical hold imposed, or threatened to be imposed, by any Regulatory Agency, (d)&#160;any unexpected fatal or life-threatening suspected adverse reaction, as that term is defined in 21&#160;CFR&#160;312.32 (or comparable regulations under other Applicable Law), and (e)&#160;any other material information and developments with respect to such Clinical Trial, including any change or modification to or termination of such Clinical Trial&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to any Clinical Trial not related to Anktiva, copies of updates provided to the Board of the Company shall be sufficient to constitute Clinical Updates.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means December&#160;29,&#160;2023.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Security Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commercial Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means material information and developments with respect to the Obligors&#8217; Commercialization plans and prospects for the Included Products.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">means any and all activities, other than manufacturing, directed to the preparation for sale of, or sale of the Included Products, including activities related to marketing, promoting, distributing, and importing the Included Products, and interacting with Regulatory Agencies regarding any of the foregoing. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">to Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means to engage in Commercialization, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commercialized</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has a corresponding meaning.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the first paragraph hereof. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, at any time of determination, any Person (and each other Person that owns or controls, directly or indirectly, such Person, or that controls or is controlled by or is under common control with such Person) that is an operating company and that directly and primarily engaged in the same, substantially the same, or similar line of business as the Company and its Subsidiaries, taken as a whole, as of such time. As used in this definition, &#8220;control&#8221; means (a)&#160;direct or indirect beneficial ownership of at least fifty&#160;percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in a Person or (b)&#160;the power to direct or cause the direction of the management of such Person by contract or otherwise.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that certain certificate in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all confidential and&#47;or proprietary financial (including term sheets, transaction structures and draft agreements or amendments to a Transaction Document and any discussions or negotiations related thereto), business, marketing, operations, regulatory, strategic and&#47;or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientific information (including all originals, copies, digests and summaries thereof) of any Disclosing Party and&#47;or its affiliates that is known to such Disclosing Party and&#47;or its affiliates prior to or after the date hereof. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise provided that with respect to any Intellectual Property, &#8220;control&#8221; means that the applicable Person owns or has a license to such item or right and has the ability to grant to a party a license, sublicense, or rights of access and use under such item or right without (a)&#160;violating the terms or conditions of any agreement or other arrangement between such Person and any Third Party in existence as of the time such party would be required hereunder to grant such license, sublicense, or rights of access and use, and (b)&#160;paying any consideration to any Third Party. &#8220;Controlling&#8221; and &#8220;Controlled&#8221; have meanings correlative thereto.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Control Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any deposit account, any securities account, commodity account, securities entitlement or commodity contract, an agreement, in form and substance reasonably satisfactory to the Purchaser Agent, among the Purchaser Agent, the financial institution or other Person at which such account is maintained or with which such entitlement or contract is carried and the Obligor maintaining such account, effective to grant &#8220;control&#8221; (as defined under the relevant Uniform Commercial Code) over such account to the Purchaser Agent.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Benefit Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Guaranty or the grant or perfection of any security interest by any Foreign Guarantor, any limitations on such Guaranty or such grant or perfection imposed pursuant to Applicable Law (other than limitations that do not impair the rights and remedies of the Secured Parties more than analogous restrictions imposed under the laws of the United States as reasonably determined by Purchaser Agent).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the entire world, excluding the People&#8217;s Republic of China, Hong Kong and any territories controlled by the People&#8217;s Republic of China.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cumulative Purchaser Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean (a)&#160;if the Purchasers have made the First&#160;Payment, $200,000,000 and (b)&#160;if the Purchasers have made the First&#160;Payment and the Second&#160;Payment, $300,000,000.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the electronic data room materials accessible to the Purchaser Agent in the rooms &#91;*****&#93; and maintained by the Obligors in connection with the transactions contemplated under this Agreement, as such materials existed as of 5&#58;00&#160;p.m. EST on the date that is one&#160;calendar day prior to the Closing Date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all activities related to discovery, research, development, creation and prosecution of Intellectual Property, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance&#47;quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Agency as a condition or in support of obtaining or maintaining a Regulatory Approval. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means to engage in Development.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the disclosure letter, dated as of the Closing Date, as may be supplemented from time to time by the Company in accordance with the terms of this Agreement and the other Transaction Documents, delivered by the Company and the other Obligors to Purchase Agent for the benefit of the Purchasers.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disqualified Equity Interests&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means Equity Interests that, by their terms (or by the terms of any security or other Equity Interest into which they are convertible or for which they are exchangeable), or upon the happening of any event or condition, (a)&#160;mature (excluding any maturity as the result of an optional redemption by the issuer thereof) or are mandatorily redeemable (other than solely for Qualified Equity Interests and&#47;or cash in lieu of fractional shares of such Equity Interests), pursuant to a sinking fund obligation or otherwise, or are redeemable at the option of the holder thereof (other than solely for Qualified Equity Interests and&#47;or cash in lieu of fractional shares of such Equity Interests), in whole or in part, (b)&#160;are convertible into or exchangeable for (i)&#160;Indebtedness or (ii)&#160;any Equity Interests referred to in clause&#160;(a) above, (c)&#160;contain any repurchase obligation or (d)&#160;contain any repurchase obligation or provides for mandatory distributions or the payment of cash dividends or distributions, in the case of each of the foregoing clauses&#160;(a), (b), (c) and (d), prior to the date that is 91&#160;days after the Maturity Date in effect at the time of the issuance thereof&#59; provided that if such Equity Interests are issued pursuant to a plan or compensatory stand-alone agreement for the benefit of the Company or any Subsidiary or their directors, officers, employees and&#47;or consultants or by any such plan or agreement to directors, officers, employees or consultants of the Company or any Subsidiary, such Equity Interests shall not constitute Disqualified Equity Interests solely because they may be required to be repurchased by the Company or any Subsidiary in order to satisfy applicable statutory or regulatory obligations or as a result of such director, officer, employee or consultant&#8217;s termination of service, death or disability. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Drug Approval Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a New Drug Application submitted pursuant to Section&#160;505 of the FFDCA, a Biologics License Application, or any corresponding foreign application (in each case, including any amendment or supplement thereto) for an Included Product.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dunkirk Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that certain Fort Schuyler Management Corporation Lease, dated October&#160;1,&#160;2021, by and among Fort Schuyler Management Corporation, a not-for-profit corporation existing under the laws of the State of New&#160;York, and the Company (as assignee of Athenex, Inc.), as amended by that certain First&#160;Amendment to Lease, effective as of February&#160;14,&#160;2022, and related transaction documents, each as amended, supplemented or otherwise modified from time to time in any manner (i)&#160;not adverse to the Company, Purchaser Agent or the Purchasers or (ii)&#160;approved in writing by Purchaser Agent.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Electronic Signature</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an electronic sound, symbol or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is (i)&#160;any Purchaser, (ii)&#160;any Affiliate of a Purchaser or any fund or investment vehicle managed by a Purchaser or an Affiliate of a Purchaser or under common management with a Purchaser and (iii)&#160;any Person that, to the knowledge of the Purchaser Agent, is a &#8220;qualified institutional buyer&#8221; (as defined in Rule&#160;144A under the Securities Act of 1933, as amended) or an &#8220;accredited investor&#8221; (as defined in Rule&#160;501(a)(1), (2), (3) or (7)) with assets under management (together with its Affiliates) of at least $150,000,000, as determined by the Purchaser Agent in its good faith discretion&#59; provided that, notwithstanding the foregoing, &#8220;Eligible Assignee&#8221; shall not include, unless a Put Option Event, or any event that with the giving of notice or passage of time would constitute a Put Option Event, has occurred and is continuing, (x)&#160;any Competitor identified by the Company in writing as such from time to time, (y)&#160;any Person identified to the Purchaser Agent by an Obligor in writing on or prior to the Closing Date, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in case any Affiliate thereof that is identifiable as such by name (or otherwise known to any Purchaser to be an Affiliate of such Person), or (z)&#160;any hedge fund primarily focused on stockholder activism or distressed investments (as determined in good faith by Purchaser Agent).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any and all federal, state, local, foreign and other applicable statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any and all shares, interests, participations or other equivalents (however designated) of equity interests of a corporation, any and all equivalent ownership interests in a Person other than a corporation (including, without limitation, partnership interests, membership interests and similar ownership interests), any and all warrants, rights or options to purchase or other arrangements or rights to acquire any of the foregoing, and all other ownership or profit interests in a Person (including partnership, member or trusts interests in such Person), in each case whether voting or non-voting and whether or not outstanding on any date of determination&#59; provided that Equity Interests shall not include any Permitted Convertible Notes or Existing Subordinated Indebtedness.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Person, trade or business (whether or not incorporated) under common control with any Obligor within the meaning of Section&#160;414(b) or (c) of the Code (and Sections&#160;414(b), (c), (m) and (o) of the Code for purposes or Section&#160;4001(b) of ERISA.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;a Reportable Event (as defined in ERISA) with respect to a Pension Plan&#59; (b)&#160;the failure by an Obligor or any ERISA Affiliate to meet all applicable requirements under the Pension Funding Rules or the filing of an application for the waiver of the minimum funding standards under the Pension Funding Rules&#59; (c)&#160;the incurrence by an Obligor or any ERISA Affiliate of any liability pursuant to Section&#160;4063 or 4064 of ERISA or a cessation of operations with respect to a Pension Plan within the meaning of Section&#160;4062(e) of ERISA&#59; (d)&#160;a complete or partial withdrawal by an Obligor or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization or insolvent (within the meaning of Title&#160;IV of ERISA)&#59; (e)&#160;the filing of a notice of intent to terminate a Pension Plan under, or the treatment of a Pension Plan amendment as a termination under, Section&#160;4041 of ERISA&#59; (f)&#160;the institution by the PBGC of proceedings to terminate a Pension Plan&#59; (g)&#160;any event or condition that constitutes grounds under Section&#160;4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan&#59; (h)&#160;the determination that any Pension Plan is in at-risk status (within the meaning of Section&#160;430 of the Code or Section&#160;303 of ERISA) or that a Multiemployer Plan is in endangered or critical status (within the meaning of Section&#160;432 of the Code or Section&#160;305 of ERISA)&#59; (i)&#160;the imposition or incurrence of any liability under Title&#160;IV of ERISA, other than for PBGC premiums due but not delinquent under Section&#160;4007 of ERISA, upon any Obligor or any ERISA Affiliate&#59; (j)&#160;the engagement by any Obligor or any ERISA Affiliate in a transaction that could be subject to Section&#160;4069 or Section&#160;4212(c) of ERISA&#59; (k)&#160;the imposition of a lien upon any Obligor pursuant to Section&#160;430(k) of the Code or Section&#160;303(k) of ERISA&#59; (l)&#160;the making of an amendment to a Pension Plan that could result in the posting of bond or security under Section&#160;436(f)(1) of the Code&#59; or (m)&#160;a Foreign Plan Event.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;any deposit accounts solely used for (i)&#160;funding payroll or segregating payroll taxes or funding other employee wage or benefit payments, (ii)&#160;segregating 401(k)&#160;contributions or contributions to an employee stock purchase plan and other health and benefit plans, in each case for payment in accordance with Applicable Laws, and (iii)&#160;containing solely cash secured by a Permitted Lien under clauses&#160;(b), (m), (n), (o) and&#47;or (w) thereof and (b)&#160;withholding tax, fiduciary accounts, trust accounts and escrow accounts (including customer reserve or deposit accounts), (c)&#160;zero balance accounts, (d)&#160;worker&#8217;s compensation and health savings accounts, (e)&#160;deposit accounts, securities accounts and commodity accounts exclusively used for withholding taxes, goods and services taxes and sales taxes, and (f)&#160;other accounts holding cash and&#47;or Cash Equivalents in an aggregate amount not in excess of (i)&#160;$500,000 for each such account and (ii)&#160;$1,000,000 for all such accounts.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;any Foreign Subsidiary that is prohibited by Applicable Law or by any contractual obligation existing on the date of acquisition or formation of such Subsidiary (provided such contractual obligation was not entered into in contemplation thereof) from guaranteeing the Obligations or any Subsidiary that would require the approval of any Governmental Authority in order to guarantee the Obligations unless such approval has been received or can be obtained by the Subsidiary through the use of commercially reasonable efforts, (b)&#160;any Immaterial Subsidiary and (c)&#160;GlobeImmune, Inc.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any of the following Taxes, (a)&#160;Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i)&#160;imposed as a result of the Person liable for such Tax being organized under the laws of, or having its principal office or applicable office located in the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii)&#160;that are Other Connection Taxes, (b)&#160;U.S. federal, state or local withholding Taxes imposed in respect of a Person with respect to an applicable interest in the Obligations or Purchaser Commitment pursuant to a law in effect on the date on which (i)&#160;such Person acquires such interest in the Obligations or Purchaser Commitment or (ii)&#160;such Person changes its applicable office, (c)&#160;Taxes attributable to a Purchaser&#8217;s failure to comply with Section&#160;5.12(d), (d)&#160;any withholding Taxes imposed under FATCA and (e)&#160;non-U.S. Taxes. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Stockholder Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the indebtedness of the Company evidenced by the agreements set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2.03(b)(i)(M)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter and any modifications, refinancings, refundings, replacements, exchanges, renewals, extensions and&#47;or restatements thereof pursuant to clause&#160;(o) of the definition of Permitted Indebtedness.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Sections&#160;1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section&#160;1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.22(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States Food and Drug Administration or any successor federal agency thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FDA Approval Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the date on which the FDA has granted approval for</font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Anktiva in combination with BCG (Bacillus Calmette-Gu&#233;rin) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1&#160;disease </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with a label that is substantially similar to the label included in the Biologics License Application&#160;761336 submitted for approval to the FDA on or around October&#160;20,&#160;2023 in response to the complete response letter delivered by the FDA to the Company on May&#160;9,&#160;2023.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FFDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, together with any regulations promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;the audited consolidated balance sheets of the Company and its Subsidiaries as of December&#160;31,&#160;2022 and December&#160;31,&#160;2021 and the related consolidated statements of operations, comprehensive loss and stockholders&#8217; equity (deficit) and cash flows for the years then ended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Audited Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (b)&#160;the unaudited balance sheets of the Company as of September&#160;30,&#160;2023 and the related consolidated statements of operations, comprehensive loss and stockholders&#8217; equity (deficit) and cash flows for the three&#160;(3) month and nine&#160;(9) month periods then ended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interim Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and (c)&#160;each financial statement delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.02(a)(i) and 5.02(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means $200,000,000, which shall be paid by the Purchasers on the Closing Date in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.03(a)(i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Subsidiary Guarantor that is a Foreign Subsidiary.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any employee benefit plan, program, policy, arrangement or agreement maintained, sponsored or contributed to, or for which there is an obligation to contribute to, by any Obligor or any ERISA Affiliate that is subject to any requirements of Applicable Law other than, or in addition to, the laws of the United States or any state thereof or the laws of the District of Columbia.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Plan Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Foreign Plan, (a)&#160;the existence of unfunded liabilities in excess of the amount permitted under any requirements of Applicable Law, or in excess of the amount that would be permitted absent a waiver from a Governmental Authority, (b)&#160;the failure to make any required contribution or payment under any requirements of Applicable Law within the time permitted by any requirement of Applicable Law for such contributions or payments, (c)&#160;the receipt of a notice from a Governmental Authority relating to the intention to terminate any such Foreign Plan or to appoint a trustee or similar official to administer any such Foreign Plan, or alleging the insolvency of any such Foreign Plan.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Subsidiary that is that is not an entity organized under the laws of the United States or any state or territory thereof.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Full Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Subsidiary Guarantor that is not a Limited Guarantor.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Funding Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means generally accepted accounting principles in the United States in effect from time to time. Notwithstanding anything in this Agreement to the contrary, for all purposes hereunder, any obligations of a Person in respect of leases that would have been treated as operating leases prior to the implementation of Accounting Standards Codification&#160;842 (regardless of whether or not then in effect) shall be treated as operating leases for purposes of all financial definitions, calculations and covenants, without giving effect to Accounting Standards Codification&#160;842 requiring operating lease obligations to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalized, except that financial statements delivered pursuant to Section&#160;5.01 may be prepared in accordance with GAAP (including giving effect to Accounting Standards Codification&#160;842 as in effect at the time of such delivery).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Globally Systemically Important Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a banking institution designated as a &#8220;Globally Systemically Important Bank&#8221; or &#8220;G-SIB&#8221; by the Financial Stability Board and their Affiliates and branch offices.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any government, court, regulatory or administrative agency or commission, or other governmental authority, agency or instrumentality, whether foreign, federal, state, local or supranational (domestic or foreign), including each Patent Office, the FDA or the United States National Institutes of Health. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of or by any Person (the &#8220;guarantor&#8221;) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the &#8220;primary obligor&#8221;) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a)&#160;to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b)&#160;to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (c)&#160;to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation&#59; provided that the term Guarantee shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the Indebtedness in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a guaranty agreement made by each Subsidiary Guarantor in favor of Purchaser Agent and the Purchasers substantially in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Immaterial Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date, any Subsidiary of the Company for which (a)&#160;the consolidated total assets (determined in accordance with GAAP) of such Subsidiary and its Subsidiaries constitute less than&#160;1.0% of consolidated total assets (determined in accordance with GAAP) of the Company and its Subsidiaries and (b)&#160;the consolidated revenues (determined in accordance with GAAP) of such Subsidiary and its Subsidiaries constitute less than&#160;1.0% of the consolidated revenues (determined in accordance with GAAP) of the Company and its Subsidiaries, in each case, as of the last day of and for the most recently ended four&#160;fiscal quarter period for which financial statements have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (and for the avoidance of doubt, each excluding intercompany payables)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if the consolidated revenues or consolidated assets of all Subsidiaries that would otherwise be an Immaterial Subsidiary pursuant to clauses&#160;(a) and (b) above equals or exceeds&#160;2.0% of the consolidated revenues or consolidated assets, as applicable, of the Company and its Subsidiaries as of the last day of the most recent fiscal quarter for which financial statements of the Company were delivered or required to be delivered, then the Company shall designate in writing to the Purchaser Agent one or more of such Subsidiaries that would otherwise be Immaterial Subsidiaries to be excluded as Immaterial Subsidiaries until such 2.0%&#160;threshold is met. Notwithstanding the foregoing, until such time as which VivaBioCell, S.p.A. and its Subsidiaries&#8217; consolidated total revenue exceeds $10,000,000 on a trailing four fiscal quarter basis or consolidated total assets exceeds $15,000,000 as of the last day of a fiscal quarter period, VivaBioCell, S.p.A. shall be considered an Immaterial Subsidiary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Immediate Family Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means with respect to any individual, such individual&#8217;s child, stepchild, grandchild or more remote descendant, parent, stepparent, grandparent, spouse, former spouse, domestic partner, former domestic partner, sibling, mother-in-law, father-in-law, son-in-law or daughter-in-law (including adoptive relationships), any trust, partnership or other bona fide estate-planning vehicle the only beneficiaries of which are any of the foregoing individuals, such individual&#8217;s estate (or an executor, administrator, heir or legatee, in each case, acting on their behalf) or any private foundation or fund that is controlled by any of the foregoing individuals or any donor-advised fund of which any such individual is the donor.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Included Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;Anktiva, (b)&#160;all other compounds, chemical entities, biologic or pharmaceutical products being designed, Developed, owned, licensed, acquired, Manufactured or Commercialized by the Company or any of its Subsidiaries from time to time, or (c)&#160;any derivative, improvement, enhancement, modification, combination or subsequent iteration of any of the foregoing described in clause&#160;(a) or (b).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means with respect to any Person&#58; (a)&#160;any liability or obligation of such Person (i)&#160;for borrowed money, (ii)&#160;evidenced by a bond, note, debenture, or similar instrument, (iii)&#160;in respect of the deferred purchase price of property or services, including a purchase money obligation given in connection with the acquisition of any businesses, properties or assets of any kind, (iv)&#160;under conditional sale or other title retention agreements relating to property acquired by such Person, (v)&#160;&#91;reserved&#93;, (vi)&#160;contingent or otherwise, in respect of bankers&#8217; acceptances, letters of credit or similar extensions of credit, (vii)&#160;in respect of hedging agreements and other derivative contracts (for the net amount owed by such Person thereunder), (viii)&#160;for the payment of money relating to any obligations under any capital lease of real or personal property which are required to be recorded as a capitalized lease obligation in accordance with GAAP, (ix)&#160;under guaranteed minimum purchase, take or pay or similar performance requirement contracts required to be listed as a liability on a balance sheet of such Person in accordance with GAAP, (x)&#160;&#91;reserved&#93;, (xi)&#160;under receivables factoring, receivable sales or similar transactions or under synthetic lease, tax ownership&#47;operating lease, off balance sheet financing or similar financing, (xii)&#160;for contingent milestone payments, royalty payments, upfront payments, license payments and similar payments pursuant to any License Agreement or other license agreement, research and development agreement, collaboration or development agreement, in each case, which payments are contingent and not yet fixed or determinable or (xiii)&#160;arising under revenue interest agreements, royalty financing agreements or similar financings&#59; (b)&#160;all Disqualified Equity Interests of such Person&#59; (c)&#160;any Guarantee by such Person of Indebtedness of any other Person&#59; and (d)&#160;(without duplication) any amendment, supplement, modification, deferral, renewal, extension or refunding of any liability of the types referred to in clauses&#160;(a), (b) and (c) above. &#8220;Indebtedness&#8221; of any Person shall include (A)&#160;all Indebtedness referred to in clauses&#160;(a) through (d) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property (including, without limitation, accounts and contract rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such Indebtedness&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the amount of the Indebtedness of any such Person for purposes of this clause&#160;(A) shall be deemed to be equal to the lesser of (x)&#160;the aggregate unpaid amount of such Indebtedness and (y)&#160;the fair market value of the property encumbered thereby as determined by such Person in good faith and (B)&#160;the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person&#8217;s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor. &#8220;Indebtedness&#8221; of any Person shall not include (i)&#160;prepaid or deferred revenue arising in the ordinary course of business, (ii)&#160;current trade payables and current liabilities arising in the ordinary course of business and outstanding for not more than 120&#160;days after the date such payable or liabilities first became due and owing, (iii)&#160;purchase price holdbacks, amounts in respect of purchase price adjustments, escrowed purchase price amounts, and similar arrangements, customary indemnification and&#47;or reimbursement obligations, and&#47;or other deferred payment amounts (including contingent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations such as earn-outs and amounts described in clause&#160;(xii)&#160;of the definition of Indebtedness), in each case, to the extent included in Acquisition Cost and incurred in connection with a Permitted Acquisition, unless such obligations have not been paid within fifteen&#160;(15) Business Days following the date on which such amounts first became due and payable, (iv)&#160;Qualified Equity Interests, (v)&#160;intercompany liabilities consisting of allocated overhead and expenses (other than intercompany Indebtedness and Investments) that would be eliminated on the consolidated balance sheet of the Company and its consolidated Subsidiaries, (vi)&#160;any obligations in respect of workers&#8217; compensation claims, early retirement or termination obligations (unless in respect of Disqualified Equity Interests, in which case such items shall constitute Indebtedness), deferred compensatory or employee or director equity plans (unless in respect of Disqualified Equity Interests, in which case such items shall constitute Indebtedness), pension fund obligations or contributions or similar claims, obligations or contributions or social security or wage taxes, and (vii)&#160;obligations of the Company in respect of Permitted Bond Hedging Agreements.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, all Excluded Liabilities and any and all liabilities, obligations, losses, assessments, awards, causes of action, damages, penalties, claims, charges, fines, judgments, costs, expenses and disbursements of any kind or nature whatsoever (including reasonable expenses of investigation and the reasonable and documented fees and disbursements of counsel for Indemnified Parties), whether direct, indirect or consequential, whether based on any federal, state or foreign laws, statutes, rules or regulations (including securities and commercial laws, statutes, rules or regulations), on common law or equitable cause or on contract or otherwise, imposed on, incurred by, or asserted against any such Indemnified Party, in any manner relating to or arising out of this Agreement or the other Transaction Documents or the transactions contemplated hereby or thereby (including any enforcement of any of the Transaction Documents (including any sale of, collection from, or other realization upon any of the Collateral)).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.04(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any license or other agreement between the Company or any Affiliate and any Third Party pursuant to which the Company or a Subsidiary obtains a license or sublicense of, covenant not to sue under, or other similar rights to, any Intellectual Property of such Third Party (other than (i)&#160;off-the-shelf software licenses, (ii)&#160;shrink-wrap or click-wrap licenses, and (iii)&#160;non-exclusive licenses of Intellectual Property that does not constitute Product Intellectual Property). </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all intellectual property and other proprietary rights of any kind or nature, whether registered or unregistered and whether registrable or not, protected, created or arising under any law, including any and all rights in&#58; proprietary information&#59; technical data&#59; laboratory notebooks&#59; clinical data&#59; priority rights&#59; trade secrets&#59; know-how&#59; confidential information&#59; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application)&#59; Patents&#59; registered or unregistered trademarks, trade names, service marks, trade dress, logos, slogans, including all goodwill associated therewith&#59; domain names&#59; registered and unregistered copyrights and all applications thereof and all rights in works of authorship of any type, in all forms or media, designs rights, registered designs, database rights and rights in compilations of data.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a summary of any new Patents, trademarks or copyrights issued or patent, trademark or copyright applications filed, amended or supplemented, constituting Product Intellectual Property (in form sufficient to allow Purchaser Agent to prepare appropriate filings in respect thereof to protect its Liens thereon), together with any material information or developments with respect to the Material Patents.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interim Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the definition of &#8220;Financial Statements.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;any beneficial ownership interest in any Person (including Equity Interests or other securities), (b)&#160;any loan, advance, extension of credit, capital contribution or similar payment to, or Guarantee of the obligations of, any Person, (c)&#160;any Acquisition, and (d)&#160;any investment in any other items that are or would be classified as investments on a balance sheet of such Person prepared in accordance with GAAP. The amount of any Investment shall be the amount actually invested (or in the case of an Acquisition, the Acquisition Cost thereof) plus the cost of all additions thereto, less any return of capital thereon, without any adjustments for increases or decreases in value, or write-ups, write-downs or write-offs with respect to such Investment.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;Patrick Soon-Shiong and (b)&#160;Cambridge Equities, LP, in each case, together with their Affiliates and funds, investments, Persons, vehicles or accounts that are managed, sponsored, or advised by it or its Affiliates.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">IRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States Internal Revenue Service or any successor federal agency thereto.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the actual knowledge, after reasonable inquiry of a Person.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Knowledge of the Obligors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Knowledge of any Knowledge Person.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Knowledge Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any of the persons listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, and any individual who succeeds such person in the role identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all Out-Licenses and all In-Licenses.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Licensees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, Third Parties to which the Company or any Subsidiary grants or has granted the right to Commercialize any Included Product, including, without limitation, any licensees and sublicensees under any Out-License related to an Included Product&#59; each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all liens, encumbrances, deeds of trust, hypothecations, pledges, charges, security interests, mortgages or other encumbrances of any kind.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limited Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Subsidiary Guarantor whose Guaranty, or the grant or perfection of a security interest in whose assets, are limited by Corporate Benefit Limitations.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, supply, and holding of any Included Product, or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, tissue engineering, product characterization, stability testing, quality assurance, and quality control.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to an Included Product, the Regulatory Approval required by Applicable Law to market or sell such Included Product in a country or region, including, to the extent required by Applicable Law for the sale of such Included Product, all pricing approvals and government reimbursement approvals.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;a material adverse change in the business, operations, assets, prospects or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole, (b)&#160;an adverse effect in any material respect on the validity or enforceability of any of the Transaction Documents, (c)&#160;a material adverse effect on the ability of any Obligor to perform any of its material obligations under the Transaction Documents, (d)&#160;an adverse effect in any material respect on the rights or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remedies of the Purchaser Agent or any Purchaser under any of the Transaction Documents, (e) a material adverse effect on the Included Products, taken as a whole, or on Anktiva, on the Product Intellectual Property, taken as a whole, or on the ability of any Obligor or a Person acting on behalf of such Obligor to Develop, Commercialize or Manufacture the Included Products, taken as a whole or to Develop, Commercialize or Manufacture Anktiva, (f) a Put Option Event, (g) an adverse effect in any material respect on the timing, amount or duration of the Revenue Interest Payments or (h) an adverse effect in any material respect on the validity, perfection (except to the extent permitted under the Security Agreement) or first priority (subject to Permitted Priority Liens) of Liens in favor of the Purchaser Agent for the benefit of the Secured Parties (except to the extent resulting solely from any actions or inactions on the part of the Secured Parties despite timely receipt of information regarding the Company and its Subsidiaries as required by this Agreement). </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Material Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) any &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K of the Securities Act, other than those agreements and arrangements described in Item 601(b)(10)(iii) and other than the Dunkirk Lease and the Beike License Agreement) with respect to the Company or its Subsidiaries&#59; (b) any development agreement, collaboration agreement, marketing agreement, co-promotion agreement, license agreement, option agreement, supply agreement, distribution agreement, partnering agreement or similar agreement with respect to Anktiva (but excluding (i) non-exclusive research licenses for the use of Anktiva in the ordinary course of business in each case granting no rights to sell, offer to sell, or otherwise Commercialize Anktiva and (ii) the Beike License Agreement)&#59; (c) any material agreement with respect to the Company or any of its Subsidiaries relating to any Material Patent, including any license, option, assignment, or agreement related to control of such Material Patent (but excluding the Beike License Agreement)&#59; or (d) any agreement (other than the Dunkirk Lease and the Beike License Agreement) with consideration or other payments in excess of (i)  prior to the Milestone, $2,500,000 per fiscal year and (ii) from and after the occurrence of the Milestone, $10,000,000 per fiscal year or agreement evidencing any Indebtedness in an amount exceeding $2,500,000.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Material Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the twelfth (12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) anniversary of the Closing Date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the first date on which (i) twelve-month trailing Net Sales from Anktiva for treatment of bladder cancer in the Covered Territory are greater than or equal to the Cumulative Purchaser Payments and (ii) the Company delivers written notice to the Purchaser Agent, including calculations in reasonable detail (based on figures contained in the audited or unaudited financial statements most recently delivered to the Purchaser Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), establishing the foregoing.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MNPI Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MNPI Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any period designated as such by Purchaser Agent by written notice to the Obligors. Each MNPI Notice Period will commence five Business Days following Purchaser Agent&#8217;s written notice to the Obligors of such MNPI Notice Period (or any later date specified by Purchaser Agent in such notice), and will end five Business Days  following written notice from Purchaser Agent to the Obligors that such MNPI Notice Period is terminated.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which any Obligor or any ERISA Affiliate makes or is obligated to make contributions, during the preceding five plan years has made or been obligated to make contributions, or has any liability.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, for any relevant fiscal period, consolidated net revenue of the Company and its Subsidiaries properly recognized and reported under GAAP, as applicable, consistently applied, during </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, upon the occurrence of a Test Date Shortfall, from and after the Test Date, &#8220;Net Sales&#8221; shall also include, for any relevant fiscal period, without duplication of amounts already included in consolidated net revenue for such fiscal period or any prior period, with respect to each Included Product, the aggregate gross invoiced sales prices from the sale or disposition of such Included Product by the Company, any Affiliate and any Licensee to Third Parties, less the following deductions without duplication, but solely to the extent included in the gross amount invoiced with respect to such sale or disposition of such Included Product and to the extent such deductions are in accordance with GAAP&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">trade, quantity and cash discounts, credits or allowances actually given&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">allowances for returns or rejections (due to spoilage, damage, expiration of useful life or otherwise)&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">freight and insurance, if separately identified on the invoice&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">mandatory discounts or rebates imposed by any Governmental Authority against the Company, any Affiliate or any Licensee, as applicable, including any claw-backs or similar pharmaceutical taxes directly related to such Included Product and paid directly by the Company, such Affiliate or such Licensee, as applicable, or, in the case of claw-backs related to aggregate sales of the Company, such Affiliate or such Licensee, as applicable, such portion of the claw-back as shall be reasonably determined by the Company, such Affiliate or such Licensee, as applicable, based on the proportion between the share of Net Sales hereunder and aggregate sales of the Company, such Affiliate or such Licensee, as applicable&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Third Party rebates, chargebacks, hospital buying group&#47;group purchasing organization administration fees or managed care organization rebates actually given&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">rebates and similar payments made with respect to sales paid for by any Governmental Authority or Regulatory Agency such as federal or state Medicaid, Medicare or similar state program&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">value-added tax, sales, use or turnover taxes, excise taxes and customs duties assessed by Governmental Authorities on the sale of such Included Product&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">retroactive price reductions or billing corrections.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of calculating Net Sales pursuant to the proviso above&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">In the case of any sale or other disposal for value, such as barter or counter-trade, of an Included Product, or part thereof, other than in an arm&#8217;s length transaction exclusively for cash, Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of such Included Product in the country of sale or disposal, as determined in accordance with GAAP&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Sales of Included Products between the Company, any Affiliate and&#47;or any Licensee for resale shall be excluded from the computation of Net Sales, provided that the subsequent resale of such Included Products to a Third Party are included in the computation of Net Sales&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">The Transfer, disposal or use of Included Products, without consideration, for marketing, regulatory, development or charitable purposes, such as clinical trials, compassionate use, named patient use, or indigent patient programs shall not be deemed a sale hereunder&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">In no event shall Net Sales for any period be less than worldwide net revenue for the Included Products for such period as reported in the Company&#8217;s financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, for purposes of determining consolidated net revenues, the proceeds of public or private grants and&#47;or government financial assistance programs shall be excluded to the extent such grants and&#47;or financial assistance and the inclusion thereof in Net Sales would, as demonstrated to Purchaser Agent in its reasonable satisfaction, violate or result in a Third Party&#8217;s right of termination under any agreement relating to such program.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, without duplication, all obligations of the Obligors in respect of the Revenue Interests, including all obligations to make Revenue Interest Payments, to make the True-Up Payment and to pay the Put&#47;Call Price, and all present and future Indebtedness, taxes, liabilities, obligations, covenants, duties, and debts, Indemnified Liabilities owing by the Obligors to the Purchasers, in each case, arising under or pursuant to the Transaction Documents, including all Reimbursable Expenses (and including any interest, fees and other charges that would accrue but for the filing of any bankruptcy action by an Obligor, whether or not such claim is allowed in such bankruptcy action). Without limiting the foregoing, the Obligations of the Obligors under the Transaction Documents exclude any obligations in respect of the Option Agreement or any Equity Interests in the Company. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obligors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Company and each Subsidiary Guarantor.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control and any successor thereto.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means that certain Option Agreement, dated as of the date hereof, between the Company and the Purchasers.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Organization Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction), (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement, and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, Taxes imposed as a result of a present or former connection between such Person and the jurisdiction imposing such Tax (other than connections arising from such Person having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced this Agreement, or sold or assigned an interest in any Obligation or this Agreement).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Out-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any license or other agreement between the Company, any Affiliate and&#47;or any Third Party pursuant to which the Company or any Subsidiary grants to such Third Party a license or sublicense with respect to, covenant not to sue under, or other similar rights under any Product Intellectual Property. For clarity, the Out-Licenses existing as of the Closing Date include the Beike License Agreement.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the respective patent office, including the United States Patent and Trademark Office, the European Patent Office and any comparable patent office in any other jurisdiction, for any Patents.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all issued national, regional and international patents and patent applications (and any patents that issue as a result of those patent applications or from an application claiming priority from</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of those and which for the purposes of this Agreement, shall be deemed to include all certificates of invention and applications for certificates of invention) and any renewals, restorations, reissues, reexaminations or other post-grant proceedings, extensions, continuations, continuations-in-part, divisions, revisions, certificates of invention, registrations, revalidations, utility models, supplemental protection certificates, patent term extensions, pediatric exclusivity periods and substitutions relating to any of the issued patents and patent applications, in any jurisdiction.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means each March 31, June 30, September 30 and December 31, commencing on March 31, 2024&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if any such date shall occur on a day that is not a Business Day, the applicable Payment Date shall be the immediately preceding Business Day.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is that certain form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PBGC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Pension Benefit Guaranty Corporation.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pension Funding Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the rules of the Code and ERISA regarding minimum funding standards and minimum required contributions (including any installment payment thereof) to Pension Plans and Multiemployer Plans and set forth in, with respect to plan years ending prior to the effective date of the Pension Act, Section 412 of the Code and Section 302 of ERISA, each as in effect prior to the Pension Act and, thereafter, Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pension Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any employee pension benefit plan (including a multiple employer plan that is an employee pension benefit plan, but excluding a Multiemployer Plan) that is maintained, sponsored or contributed to by any Obligor or any ERISA Affiliate, or for which any Obligor or any ERISA Affiliate could be considered an &#8220;employer&#8221; as defined in Section 3(5) of ERISA, and is either covered by Section 302 or Title IV of ERISA, or is subject to the minimum funding standards under Section 412 of the Code.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a perfection certificate signed by an officer of the Company, as updated from time to time (without retroactive effect), subject to the review and approval of Purchaser Agent, in accordance with the terms of this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Acquisition with respect to which all parties involved (other than the applicable Obligor) are non-Affiliates, provided that&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)        for any Acquisition with an aggregate Acquisition Cost in excess of (i) prior to the Milestone, $2,500,000 and (ii) from and after the occurrence of the Milestone, $10,000,000, the Obligors shall have delivered written notice of such Acquisition to the Purchaser Agent, on behalf of the Purchasers, not less than ten (10) Business Days prior to the execution of a definitive agreement for such Acquisition (or such shorter period as may be specified by the Purchaser Agent in its sole discretion) together with a due diligence package consisting of the Board package(s) provided in connection with such Acquisition, including without limitation, with regard to the Acquisition of the applicable target, business product or In-License (together with any material updates available from time to time prior to the closing of such Acquisition), a summary of the development program for all relevant products, a summary of Intellectual Property related to such product or products, a cash forecast, pro forma for the acquisition (inflows and outflows), a description of the sources and uses for financing the Acquisition, and to the extent available, quarterly and annual audited financial statements of the Person whose Equity Interests or assets are being acquired for the twelve (12) month period immediately prior to such proposed Acquisition&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)        for any Acquisition with an aggregate Acquisition Cost in excess of (i) prior to the Milestone, $2,500,000 and (ii) from and after the occurrence of the Milestone, $10,000,000, Purchaser</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agent, on behalf of the Purchasers, shall have received, (i) not less than five (5) Business Days prior to the execution of a definitive agreement for such Acquisition (or such shorter period as may be specified by the Purchaser Agent in its sole discretion), drafts of any acquisition agreements, disclosure schedules, and other material agreements related to the Acquisition and (ii) substantially concurrently with the execution of the definitive documentation relating to such Acquisition, fully executed acquisition agreements and other material agreements with all attachments and schedules&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)        immediately prior to, and after giving effect to such Acquisition, no Event of Default nor Put Option Event, nor any event that, with the giving of notice or passage of time, would constitute an Event of Default or Put Option Event, shall have occurred and be continuing or would reasonably be expected to result therefrom&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)        all transactions in connection with such Acquisition shall be consummated, in all material respects, in accordance with Applicable Law&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)        in the case of the purchase or other acquisition of Equity Interests, (i) all of the Equity Interests (except for any such Equity Interest in the nature of directors&#8217; qualifying shares required pursuant to Applicable Law) acquired or otherwise issued by such Person or any newly formed Subsidiary in connection with such Acquisition shall be wholly owned by the Company or a Full Guarantor and (ii) all Persons whose Equity Interests are being acquired shall become Obligors to the extent required by Section 5.06</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)        the aggregate amount of cash consideration in the Acquisition Cost for such Acquisition, combined with the aggregate amount of cash used in the Acquisition Cost for all other Permitted Acquisitions entered into after the Closing Date and on or prior to the date of such Acquisition, shall not exceed at any time (x) prior to the Milestone, 10.00% of the market capitalization of the Company determined as of the date on which the definitive documentation for such Acquisition is executed and (y) from and after the occurrence of the Milestone, 20.00% of the market capitalization of the Company determined as of the date on which the definitive documentation for such Acquisition is executed&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)        no Change of Control shall result from the consummation of such Acquisition&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)         no breach or contravention of any Material Contract shall result from such transaction and to the extent such Permitted Acquisition is an In-License, such In-License shall not constitute a Restricted License&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)         such Acquisition shall be consensual and, if required under Applicable Law or the organizational documents of the target, shall have been approved by the target&#8217;s board of directors&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)        the Person whose Equity Interests, business or line of business are being acquired shall be engaged in, or the asset acquired shall be used to engage in, or any In-License shall be in relation to, the same line of business as the Company and&#47;or its Subsidiaries or a line of business incidental, complementary or reasonably related thereto, or a reasonable extension thereof&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)         for any Acquisition with an aggregate Acquisition Cost in excess of (i) prior to the Milestone, $2,500,000 and (ii) from and after the occurrence of the Milestone, $10,000,000, on a pro forma basis for such Acquisition, without regard to any subsequent financing transactions of the Obligors, as demonstrated by projections (taking into account the terms of such transaction and all Acquisition Cost incurred or expected to be incurred in connection with or as a result of, such transaction), the Obligors shall have sufficient liquidity to pay their projected expenses and all debt service when due for a period of six (6) months after the consummation of such Acquisition (after giving effect to such Acquisition), as set forth </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in reasonably detailed projections delivered by the Obligors to the Purchaser Agent at least five (5) Business Days prior to the execution of the definitive agreement for such Acquisition.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or prior to the date of any such Acquisition, Purchaser Agent shall have received, in form and substance reasonably satisfactory to Purchaser Agent, a certificate signed by the chief financial officer of the Company certifying compliance with the foregoing requirements contained in this definition of &#8220;Permitted Acquisition&#8221; and with the other terms of the Transaction Documents (before and after giving effect to such Acquisition).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;Permitted Bond Hedging Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means any forward purchase agreement, call option or other equity derivative transaction relating to the equity interests of the Company (or other securities or property that the common stock of the Company is converted into following a merger event or other change of the common stock of the Company) executed in connection with the issuance of any Permitted Convertible Notes (or deemed executed therewith)&#59; provided that no cash payment (other than cash in lieu of fractional shares) by the Company (or any of its Subsidiaries) shall be required in connection with the exercise, unwinding, settlement or termination of such Permitted Bond Hedging Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;Permitted Convertible Notes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means senior subordinated unsecured notes issued by the Company, following a bona fide marketing process, that are convertible into a fixed number (subject to customary anti-dilution adjustments, &#8220;make-whole&#8221; increases and other customary changes thereto) of common stock of the Company (or other securities or property following a merger event, reclassification or other change of the common stock of the Company, but for the avoidance of doubt excluding Disqualified Equity Interests), cash or a combination thereof and cash in lieu of fractional shares of common stock of the Company&#59; provided, that, (a) no Subsidiary shall guarantee such Permitted Convertible Notes, (b) such Permitted Convertible Notes shall (i) not include any financial maintenance or negative covenants (other than customary covenants regarding stay, extension and usury laws, and regarding mergers and sales of assets), (ii) have other terms, conditions, covenants and defaults that are, taken as a whole, not more restrictive on the Company and its Subsidiaries than the covenants and defaults set forth in the Transaction Documents and which terms, including conversion, redemption and fundamental change provisions, are customary for public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A of the Securities Act, in each case, as determined by the board of directors of the Company in good faith), and (iii) permit physical settlement (and cash in lieu of fractional shares) upon conversion (and the Company shall not elect cash or combination settlement upon conversion without the Purchaser Agent&#8217;s prior written consent), (c) no Put Option Event shall have occurred and be continuing at the time of incurrence of such Permitted Convertible Notes or could result upon such incurrence, (d) such Permitted Convertible Notes shall (x) contain subordination terms for underwritten or Rule 144A offerings of senior subordinated convertible notes substantially the same form and substance as set forth on Exhibit D and (y) specifically designate this Agreement and all Obligations as &#8220;designated senior indebtedness&#8221; or similar term so that the subordination terms referred to in clause (d) of this definition specifically refer to such notes as being subordinated to the Obligations pursuant to such subordination terms, (e) no scheduled or mandatory principal payments, repayments, prepayments, cash settlements, repurchases, redemptions or sinking fund or like payments (but excluding, for the avoidance of doubt, regularly scheduled cash interest payments) of such Permitted Convertible Notes shall be required at any time on or prior to the stated maturity date thereof (other than upon a &#8220;change of control&#8221; or &#8220;fundamental change&#8221;), (f) such Permitted Convertible Notes shall have a cash interest rate of less than 10% per annum and (g) the Company shall have delivered to the Purchaser Agent an officer&#8217;s certificate signed by a senior executive of the Company certifying as to the foregoing.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Debt Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">regularly scheduled payments of interest&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the exchange or conversion of any Indebtedness for, into or with,  the Company&#8217;s Equity Interests (other than Disqualified Equity Interests), together with cash payments in lieu of any fractional shares and in respect of any accrued and unpaid interest&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">so long as the Company&#8217;s market capitalization as of the date of any such payment is at least Two Billion Five Hundred Million Dollars ($2,500,000,000), the redemption or repurchase of any Permitted Convertible Notes or Existing Stockholder Indebtedness solely with (X) the net proceeds of a substantially concurrent offering of the Company&#8217;s Equity Interests (other than Disqualified Equity Interests and other than proceeds from an &#8220;at the market&#8221; offering) where such use of proceeds was specifically disclosed to the investors in such offering and (Y) from and after the occurrence of the Milestone, the net proceeds of any sale of the Company&#8217;s Equity Interests (other than Disqualified Equity Interests) pursuant to a concurrent &#8220;at the market&#8221; offering&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">payments in respect of Indebtedness described in clauses (a), (c), (d), (e) (provided that payments in respect of the Indebtedness underlying the applicable guarantee are otherwise permitted), (f), (g), (h), (i), (j), (k), (l), (m), (p), (q), (r) and (s) (to the extent such payments are permitted under the applicable subordination agreement) of the definition of &#8220;Permitted Indebtedness,&#8221; in each case in the ordinary course of the Company&#8217;s business&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">so long as (i) no Put Option Event has occurred and is continuing, and (ii) either (A) Net Sales for the most recently completed four fiscal quarter period for which financial statements have been delivered pursuant to Section 5.02(a) exceed the product of Cumulative Purchaser Payments and 1.5 or (B) the Total Revenue Interest Payments as of such date exceed the Cumulative Purchaser Payments, other payments in respect of Existing Stockholder Indebtedness&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">so long as (i) no Put Option Event has occurred and is continuing, (ii) the FDA Approval Date shall have occurred, and (iii) the Second Payment shall have been made, principal payments in respect of Existing Stockholder Indebtedness in an aggregate amount not to exceed $100,000,000&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">so long as no Put Option Event has occurred and is continuing, the prepayment of $50,000,000 of Tranche 2 Principal Amount (as defined therein) outstanding under that certain Amended and Restated Promissory Note, dated December 29, 2023, issued by the Company to Nant Capital, LLC, pursuant to Section 1(d) of such Amended and Restated Promissory Note, using solely the concurrent net proceeds of a Specified Transaction (as defined in such Amended and Restated Promissory Note)&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">any required repurchase of Permitted Convertible Notes upon a &#8220;change of control&#8221; or &#8220;fundamental change&#8221; (as defined in such Permitted Convertible Notes)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the Purchasers exercise the Put Option in connection with such event, the Company indefeasibly pays the Put&#47;Call Price prior to such repurchase.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any of (a) the Investors (and, with respect to any Investor that is a natural person, his or her Immediate Family Members) and (b) any group (within the meaning of Section 13(d) or 14(d) of the Exchange Act) of which the Investors are members and any other member of such group&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Investors, without giving effect to the existence of such group or any other group, collectively beneficially own, directly or indirectly, Equity Interests constituting a majority of the aggregate ordinary voting power represented by the then issued and outstanding Equity Securities of the Company (or any direct or indirect parent of the Company) owned by such group.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Indebtedness owed to the Purchasers and the Purchaser Agent under this Agreement and the other Transaction Documents&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Indebtedness existing on the Closing Date and disclosed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.11(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter and, solely with respect to the items listed as numbers 10 and 11 on such schedule, any modifications, refinancings, refundings, replacements, exchanges, renewals, extensions, and&#47;or restatements of such Indebtedness so long as the principal amount thereof does not exceed the principal amount  of the Indebtedness so modified, refinanced, refunded, replaced, exchanged, renewed, extended or restated&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">unsecured Indebtedness to trade creditors incurred in the ordinary course of business&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Indebtedness constituting Permitted Investments under clause (f) thereof&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Guarantees by the Company and&#47;or any of its Subsidiaries in respect of Indebtedness and other obligations of the Company and&#47;or any of its Subsidiaries otherwise permitted hereunder&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Indebtedness incurred by the Company or its Subsidiaries to finance the payment of insurance premiums&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Indebtedness owed to any Person providing worker&#8217;s compensation, health, disability or other employee benefits or property, casualty or liability insurance to the Company or any Subsidiary incurred in connection with such Person providing such benefits or insurance pursuant to customary reimbursement or indemnification obligations to such Person&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Guarantees (or liabilities as a surety, endorser, accommodation endorser or otherwise) in respect of performance, surety, statutory, appeal or similar obligations incurred in the ordinary course of business but excluding guaranties with respect to any obligations for borrowed money&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Indebtedness in respect of letters of credit, bank guarantees, bankers acceptances and&#47;or similar obligations in an aggregate principal amount not to exceed (x)&#160;$2,500,000 at any time outstanding prior to the Milestone and (y) from and after the occurrence of the Milestone, $10,000,000 at any time outstanding&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Indebtedness in respect of payment processing services, netting services, overdrafts and other liabilities in connection with deposit accounts and&#47;or securities accounts (including Indebtedness resulting from the honoring by a bank or other financial institution of a check, draft or similar instrument drawn against insufficient funds) and&#47;or otherwise arising from treasury, depositary and cash management services&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Indebtedness in respect of business credit card programs, debit cards, stored value cards, and&#47;or commercial cards (including &#8220;purchase cards,&#8221; &#8220;procurement cards,&#8221; or &#8220;p-cards&#8221;) in an aggregate principal amount not to exceed (x) $2,500,000 at any time outstanding prior to the Milestone and (y) from and after the occurrence of the Milestone, $10,000,000 at any time outstanding&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Indebtedness consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by the Company or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made), and (ii) such Indebtedness is in an aggregate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal amount outstanding at any time not to exceed (x) prior to the Milestone, $5,000,000 and (y) from and after the occurrence of the Milestone, $25,000,000&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Indebtedness in respect of hedging agreements entered into for bona fide hedging purposes in the ordinary course and not for speculative purposes&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Permitted Convertible Notes&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Existing Stockholder Indebtedness so long as it remains subject to an enforceable subordination agreement delivered to Purchaser Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03(b)(i)(L)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any modifications, refinancings, refundings, replacements, exchanges, renewals, extensions, and&#47;or restatements of such Indebtedness so long as (i) the principal amount thereof does not exceed the principal amount of the Indebtedness so modified, refinanced, refunded, replaced, exchanged, renewed, extended or restated, except by an amount equal to unpaid accrued interest thereon plus fees and expenses reasonably incurred, in connection therewith, (ii) the terms thereof (including, without limitation, interest rates, fees, payment terms and covenants) are in no way more onerous or restrictive than the terms of the Indebtedness so modified, refinanced, refunded, replaced, exchanged, renewed, extended or restated, (iii) such modification, refinancing, refunding, replacement, exchange, renewal, extension or restatement involves the exact same parties as the original Existing Stockholder Indebtedness and involves no additional parties, and (iv) for the avoidance of doubt, such modification, refinancing, refunding, replacement, exchange, renewal, extension or restatement is subject to the subordination agreement delivered to Purchaser Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03(b)(i)(L)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or another subordination agreement satisfactory to Purchaser Agent in its sole and absolute discretion&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">endorsements of instruments for deposit or collection in the ordinary course of business&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Indebtedness of a Person that is acquired in a Permitted Acquisition and&#47;or Indebtedness assumed by the Company or any of its Subsidiaries in connection with a Permitted Acquisition or Permitted Investment permitted hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (I) such Indebtedness is not incurred in connection with, or in contemplation of, such Acquisition or Investment and (II) unless such Indebtedness consists solely of Indebtedness in respect of letters of credit or capital leases of real or personal property, such Indebtedness is subject to a subordination agreement satisfactory in Purchaser Agent&#8217;s sole and absolute discretion&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that such Indebtedness is in an aggregate amount outstanding at any time not to exceed (x) prior to the Milestone, $5,000,000 and (y) from and after the occurrence of the Milestone, $10,000,000&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">unsecured Indebtedness arising as a result of judgments, orders, awards or decrees, in each case which do not constitute an Event of Default&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.45pt">Subordinated Debt&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">other unsecured Indebtedness not otherwise permitted under clauses (a) through (r) in an aggregate outstanding principal amount not to exceed at any time (x) prior to the Milestone, $2,500,000 and (y) from and after the occurrence of the Milestone, $10,000,000.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03(c)(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Investments existing on, or contractually committed on, the Closing Date and listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.11(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Investments consisting of cash and Cash Equivalents&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, (ii) loans to employees, officers or directors relating to the purchase of Equity Interests of the Company pursuant to employee stock purchase plans or agreements approved by the Board of the Company, (iii) advances in connection with indemnification agreements in the ordinary course of business and (iv) non-cash loans to employees, officers or directors relating to the purchase of Equity Interests of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (x) Investments described in prongs (i) and (ii) of this clause (c) shall be in an amount not to exceed $2,000,000 in any fiscal year of the Company and (y) no Investments described in this clause (c) may be made to Patrick Soon-Shiong or any Immediate Family Member of Patrick Soon-Shiong&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Investments consisting of accounts receivable of, notes receivable of, or prepaid royalties and other credit extensions (including trade credit and prepayment of expenses), to customers and suppliers who are not Affiliates, in the ordinary course of business&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Investments (i) in the Company and the Full Guarantors&#59; (ii) by Limited Guarantors and Subsidiaries that are not Obligors, in Limited Guarantors&#59; (iii) by Subsidiaries that are not Obligors in other such Subsidiaries&#59; (iv) by the Company and the Full Guarantors in Limited Guarantors in an aggregate amount at any time outstanding not to exceed (x) prior to the Milestone, $5,000,000 and (y) from and after the occurrence of the Milestone, $10,000,000&#59; (v)  in VivaBioCell, S.p.A. in an aggregate amount not to exceed $5,000,000 per calendar year&#59; and (vi) by any Obligor in any Subsidiary that is not an Obligor (other than VivaBioCell, S.p.A.) in an aggregate amount not to exceed $1,000,000 per calendar year&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Permitted Acquisitions&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Investments held by any Person acquired in any Permitted Acquisition at the time of such Permitted Acquisition (and not acquired in contemplation of the Permitted Acquisition)&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Guarantees of obligations of any Subsidiary of the Company incurred in the ordinary course of business and not constituting Indebtedness in an aggregate amount at any time outstanding not to exceed (I) prior to the Milestone, $2,500,000 and (II) from and after the occurrence of the Milestone, $5,000,000&#59;   </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Investments in the ordinary course of business consisting of endorsements for collection&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Investments consisting of hedging agreements not entered into for speculative purposes&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Investments (other than Acquisitions) to the extent that payment for such Investments is made solely with the proceeds of a substantially contemporaneous issuance of Equity Interests (other than Disqualified Equity Interests) of the Company and no Put Option Event has occurred and is continuing at the time of such Investment or would immediately result therefrom&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Investments in joint ventures and similar arrangements to the extent such Investments are made with non-Affiliates (provided, for the avoidance of doubt, that the joint venture may itself constitute an Affiliate), in an arm&#8217;s length transaction and on terms that are no worse than those which could be obtained in an arm&#8217;s length transaction (as determined by the Board of the Company in good faith), and provided that the aggregate amount of all such Investments at any time outstanding does not exceed (i) prior to the Milestone, $2,500,000 and (ii) from and after the occurrence of the Milestone, $10,000,000&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">(i) the purchase of any Permitted Bond Hedging Agreement in connection with the issuance of Permitted Convertible Notes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to this clause (i), the aggregate purchase price for such Permitted Bond Hedging Agreement, net of any proceeds relating to any concurrent sale or termination of any Permitted Bond Hedging Agreement, in respect of any Permitted Convertible Notes does not exceed 15% of the gross cash proceeds from such issuance of Permitted Convertible Notes and (ii) the acquisition of Equity Interests of the Company in connection with the exercise, settlement or performance of any Permitted Bond Hedging Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to this clause (ii), no additional cash payments are made upon such exercise or settlement (other than cash in lieu of fractional shares)&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">other Investments in an aggregate amount not to exceed at any time outstanding (x) prior to the Milestone, $2,500,000 and (y) from and after the occurrence of the Milestone, $10,000,000.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) any Out-License with a non-Affiliate for the Development, Manufacture and&#47;or Commercialization of (x) an Included Product (other than Anktiva for the treatment of bladder cancer) within the United States and (y)&#160;an Included Product exclusively outside of the United States&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, in each case, (i) such Out-License is not a Restricted License and constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property, and (ii) all upfront payments, royalties, milestone payments or other proceeds arising from such Out-License that are payable to any Obligor or Affiliate are paid to a deposit account that is subject to a Control Agreement or in which Purchaser Agent otherwise has a first-priority perfected security interest on terms and pursuant to documentation satisfactory to Purchaser Agent in its sole discretion&#59; (b) any license granted to any Third Party non-Affiliate for the Manufacture of any Included Product or otherwise granted to a vendor or service provider in order to provide services for the benefit of the Obligors or their Affiliates but granting no rights to sell, offer to sell or otherwise Commercialize any Included Product&#59; (c) intercompany non-exclusive licenses or grants of rights for Development, Manufacture, production, Commercialization (including commercial sales to end users), marketing, sale, research, co-promotion, or distribution among the Obligors and their Subsidiaries&#59; (d) non-exclusive research licenses and other licenses for the use of the property of the Obligors or their Subsidiaries in the ordinary course of business but in each case granting no rights to sell, offer to sell or otherwise Commercialize any Included Product&#59; (e) any Out-License existing on the Closing Date which is shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.11(a)(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter&#59; and (f) any other licenses or similar agreements with Third Parties that do not constitute Out-Licenses.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Liens in favor of the Purchaser Agent and&#47;or the Purchasers created by or otherwise existing under or in connection with the Transaction Documents&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens in existence as of the date hereof and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.11(a)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Liens imposed by provisions of law of landlords, carriers, warehousemen, bailees, mechanics and materialmen incurred in the ordinary course of business for sums that (i) are not yet delinquent, or (ii) are being contested in good faith by appropriate proceedings&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens (other than those imposed by ERISA) incurred in the ordinary course of business in connection with worker&#8217;s compensation, unemployment insurance or other forms of governmental insurance or benefits, insurance, surety bonds, or other obligations of a like nature or to secure the performance of letters of credit, banker&#8217;s acceptances, bids, tenders, statutory obligations, leases and contracts (other than for borrowed money) entered into in the ordinary course of business&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Liens for Taxes that are not delinquent or remain payable without any penalty or that are being contested in good faith and with due diligence by appropriate proceedings and for which adequate reserves have been established in accordance with GAAP&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">(i) banker&#8217;s Liens for collection or rights of set off or similar rights and remedies as to deposit accounts or other funds maintained with depositary institutions&#59; provided that such deposit accounts or funds are not established or deposited for the purpose of providing collateral for any Indebtedness and are not subject to restrictions on access by the Company or any Subsidiary in excess of those required by applicable banking regulations&#59; (ii) customary Liens incurred in the ordinary course of business to secure obligations in respect of payment processing services, netting services, overdrafts and similar obligations arising from treasury, depositary and cash management services&#59; and (iii) contractual Liens in favor of the applicable depository bank solely to the extent the applicable deposit account is an Excluded Account or subject to a valid Control Agreement&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens on insurance policies, premiums and proceeds thereof, or other deposits, to secure insurance premium financings with respect to unearned premiums and other liabilities to insurance carriers&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens securing Indebtedness permitted under clause (l) of the definition of Permitted Indebtedness&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (i) such Liens exist prior to the acquisition of, or attach substantially simultaneous with, or within ninety (90) days after the, acquisition, lease, repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii) such Liens do not extend to any property of the Company or any Subsidiary other than the property (and any improvements, accessions, proceeds, dividends, or distributions, in respect thereof) acquired, leased or built, or the improvements or repairs, financed by such Indebtedness&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Liens on specific items of inventory or other goods (and the proceeds thereof) of the Company or any Subsidiary securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into in the ordinary course of business&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods in the ordinary course of business&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">(i) Liens consisting of the interests of licensors and of licensees in respect of In-Licenses and Permitted Licenses, (ii) leases and subleases of property (other than Intellectual Property) granted to others that do not (x) interfere in any material respect with the business of the Company and its Subsidiaries, taken as a whole or (y) secure any Indebtedness, and (iii) any interest or title of a lessor under leases (other than leases constituting Indebtedness) entered into by any of the Company and&#47;or its Subsidiaries in the ordinary course of business&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Liens on deposits or other amounts held in escrow to secure payments (contingent or otherwise) payable by the Company or any Subsidiary with respect to (i) the settlement, satisfaction, compromise or resolution or judgments, litigation, arbitration or other disputes and (ii) any commercial contracts for manufacturing, production and other service arrangements entered into in the ordinary course of business or other obligations in respect of any Permitted Acquisition or Transfer expressly permitted hereunder&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens on cash deposits securing (i) Indebtedness permitted pursuant to clause (i) of the definition of &#8220;Permitted Indebtedness&#8221;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the amount of such cash deposits in respect of any letter of credit does not exceed 105% of the face amount thereof with respect to any U.S. dollar denominated letters of credit and 110% of the face amount thereof with respect to any letter of credit denominated in a foreign currency and (ii) Indebtedness permitted pursuant to clause (k) of the definition of &#8220;Permitted Indebtedness&#8221;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the amount of such cash deposits do not exceed (I) prior to the Milestone, $2,500,000 and (II) from and after the occurrence of the Milestone, $10,000,000&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">any Lien existing on any property or asset prior to the acquisition thereof by the Company or any of its Subsidiaries or existing on any property or asset of any Person that is merged or consolidated with or into the Company or any of its Subsidiaries or becomes a Subsidiary after the Closing Date prior to the time such Person is so merged or consolidated or becomes a Subsidiary&#59; provided that (i) such Lien is not created in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as the case may be&#59; (ii) such Lien shall not apply to any other property or assets of the Company or any of its Subsidiaries (other than improvements, accessions, proceeds, dividends or distributions in respect thereof and assets fixed or appurtenant thereto)&#59; and (iii) such Lien shall secure only those obligations which it secures on the date of such acquisition or the date such Person becomes a Subsidiary, as the case may be, and any modifications, refinancings, refundings, replacements, exchanges, renewals, extensions, and&#47;or restatements of such Indebtedness so long as (x) the principal amount (or accreted value, if applicable) thereof does not exceed the principal amount (or accreted value, if applicable) of the Indebtedness so modified, refinanced, refunded, replaced, exchanged, renewed, extended or restated, except by an amount equal to unpaid accrued interest and&#47;or premiums thereon plus other reasonable amounts paid, and fees and expenses reasonably incurred, in connection with such modification, refinancing, replacements, exchange, renewal, extension, or restatement thereon and (y) the terms thereof (including, without limitation, interest rates, fees, payment terms and covenants) are in no way more onerous or restrictive than the terms of the Indebtedness so modified, refinanced, refunded, replaced, exchanged, renewed, extended or restated&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens on Equity Interests in a joint venture imposed pursuant to the operative documents governing such joint venture&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens in favor of a seller solely on any cash earnest money deposits made by the Company or any of its Subsidiaries in connection with any letter of intent or purchase agreement with respect to any Permitted Acquisition or other Permitted Investment&#59; provided that the obligations secured by such Liens do not exceed (I) prior to the Milestone, $2,000,000 and (II) from and after the occurrence of the Milestone, $4,000,000&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Liens of a collection bank arising under Section 4-208 or Section 4-210 of the UCC on items in the course of collection&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.45pt">precautionary UCC filings in connection with leases not constituting Indebtedness or bailee arrangements, in each case, in the ordinary course of business&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt"> with respect to any real property, servitudes, easements, rights-of-way, covenants, conditions, restrictions (including zoning and building restrictions) or other restrictions imposed by any applicable Law and other rights reserved to or vested in any Governmental Authority, encroachments, protrusions and other similar charges, encumbrances and title defects affecting real property, or such defects or encroachments as might be revealed by an up-to-date survey of such real property, that, in the aggregate, do not in any case materially interfere with the ordinary conduct of the business of the Company and its respective Subsidiaries taken as a whole, or the use of the property for its intended purpose, and any other exceptions to title on the mortgage policies accepted by the Purchase Agent, in its reasonable discretion, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordance with this Agreement&#59; deposits incurred in the ordinary course of business to secure the performance of leases (other than Indebtedness) or as security for the payment of rent&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">non-consensual restrictions on the transfer or pledge of assets imposed by any Governmental Authority or comparable state or local legislation, regulations or ordinances or otherwise imposed by Applicable Law&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens arising from attachments or judgments, orders, or decrees in circumstances not constituting a Put Option Event&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">Liens on cash in an amount not to exceed $2,500,000 at any time securing &#8220;hedging agreements&#8221; permitted under clause (m) of &#8220;Permitted Indebtedness&#8221;&#59; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">other Liens incurred by the Company and&#47;or its Subsidiaries so long as (i) such Liens do not secure Indebtedness and (ii) at the time of incurrence of the obligations secured thereby the aggregate outstanding principal amount of obligations secured thereby does not exceed (x) prior to the Milestone, $5,000,000 and (y) from and after the occurrence of the Milestone, $10,000,000&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Liens imposed on the underlying fee interest in real property leased, subleased or licensed by the Company and&#47;or its Subsidiaries (other than any such Liens incurred or caused by the Company and&#47;or its Subsidiaries).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Priority Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Permitted Liens identified in clauses (b), (c), (d),(e), (f), (g), (h), (i), (k), (m), (n), (o), (p), (q), (r), (t), (u), (v), (w) and (y) of the definition thereof.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, but not including a government or political subdivision or any agency or instrumentality of such government or political subdivision.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PHSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States Public Health Service Act, as amended from time to time, together with any regulations promulgated thereunder (including all additions, supplements, extensions, and modifications thereto).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any employee benefit plan within the meaning of Section 3(3) of ERISA, maintained for employees of the Company or any of its Subsidiaries, or any such plan to which the Company or any of its Subsidiaries required to contribute on behalf of any of its employees or with respect to which the Company or such Subsidiary has any liability.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a press release mutually agreed upon by the Obligors and Purchaser Agent in respect of the transactions contemplated by the Transaction Documents.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Primary Product Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Product Assets necessary for the Development, Manufacturing and&#47;or Commercialization of Anktiva.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, for any day, the per annum rate of interest in effect for such day quoted by the Wall Street Journal as the &#8220;prime rate&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Portion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Purchaser, the sum of the unfunded Purchaser Commitment of such Purchaser and Purchaser Payments made by such Purchaser divided by the sum of all unfunded Purchaser Commitments and all Purchaser Payments made by the Purchasers. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) all Product Intellectual Property, (b) each Material Contract, (c) all Regulatory Approvals and (d) any other assets that are owned by, licensed to, or otherwise Controlled by the Company or any Subsidiary that are necessary for, or used or reasonably useful for, the Development, Commercialization, Manufacture, formulation, use, or sale of any Included Products.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all Intellectual Property that is necessary, used for or material to the Development, Commercialization, and&#47;or Manufacture, or other exploitation, of any Included Product that is owned, licensed or otherwise controlled by any Obligor as of the Closing Date or acquired by an Obligor thereafter, including, without limitation, the Patents identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the first paragraph hereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the first paragraph hereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Purchaser, the commitment of such Purchaser to purchase its Pro Rata Portion of the Revenue Interests and pay the Purchaser Payments in an aggregate amount up to the amount set forth opposite such Purchaser&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means each of the First Payment and the Second Payment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Option Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Option Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any one of the following events&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">any Change of Control&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the occurrence of any Event of Default, subject to any applicable grace periods set forth in the definition thereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put&#47;Call Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, the Put&#47;Call Price shall be an amount equal to&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">if the Purchasers exercise a Put Option, other than pursuant to clause (a) of the definition of &#8220;Put Option Event&#8221;, on or prior to the date that is twelve (12) months after the Closing Date, 120.0% of the Cumulative Purchaser Payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">if the Purchasers exercise a Put Option pursuant to clause (a) of the definition of &#8220;Put Option Event&#8221; or if the Company exercises the Call Option in connection with a Change of Control, in each case on or prior to the date that is eighteen (18) months after the Closing Date, 135.0% of the Cumulative Purchaser Payments&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">in the event that neither of clauses (a) or (b) applies, if the Put&#47;Call Price is received in full by the Purchasers no later than the date that is thirty six (36) months after the Closing Date, 175.0% of the Cumulative Purchaser Payments&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">following the date that is thirty six (36) months after the Closing Date, an amount equal to 195.0% of the Cumulative Purchaser Payments&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">minus, in each case, the Total Revenue Interest Payments made on or prior to such date&#59; provided that the Put&#47;Call Price shall not be less than zero.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Qualified Equity Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of any Person means Equity Interests of such Person that are not Disqualified Equity Interests.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Quarterly Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reconciliation Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to the relevant calendar quarter or calendar year, (a) a report showing Net Sales for the Included Products for such calendar period, reconciled, in each case, to the most applicable line item in the Company&#8217;s statements of operations for the applicable calendar period and (b) a reconciliation of all payments made by the Company to the Purchasers pursuant to this Agreement during such calendar period.  The Reconciliation Report for a calendar year shall also include the foregoing information with respect to the fourth quarter of such calendar year. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the FDA and any other Governmental Authority with responsibility for the approval of the marketing and sale of pharmaceuticals or biologics or other regulation of pharmaceuticals or biologics.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all approvals (including, without limitation, where applicable, Drug Approval Applications, pricing and reimbursement approval, labeling approval and schedule classifications), licenses, registrations, certificates, permits or authorizations (including, without limitation, pre- and post-approval Marketing Authorizations) of any Governmental Authority necessary for the manufacture, use, storage, import, export, transport, offer for sale, or sale of each Included Product, together with all amendments, supplements and updates thereto and all benefits arising therefrom, including any orphan drug exclusivities or other non-patent exclusivities.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all applications, filings, dossiers and the like submitted to a Regulatory Agency for the purpose of obtaining Regulatory Approval from that Regulatory Agency. Regulatory Filings shall include, but not be limited to, all Drug Approval Applications.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means material information and developments with respect to any Regulatory Filing&#59; provided, that with respect to any Regulatory Filing not related to Anktiva, copies of updates provided to the Board of the Company shall be sufficient to constitute Regulatory Updates.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursable Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all reasonable and documented costs and expenses (including attorneys&#8217; fees and expenses, as well as appraisal fees, consulting fees, advisory fees, fees incurred on account of lien searches, inspection fees and filing fees) incurred as a result of or arising from or relating to or in connection with preparing, amending, executing, negotiating, administering, defending and enforcing the Transaction Documents (including, without limitation, those incurred in connection with appeals or any Bankruptcy Event) or otherwise incurred by the Purchaser Agent and&#47;or the Purchasers in connection with the Transaction Documents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Required Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Purchasers whose aggregate Pro Rata Portions exceed 50%. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (i) any Out-License that provides for or results in the legal transfer by any Obligor or its Subsidiaries of any title in or to any Intellectual Property, (ii) any License Agreement that cannot be collaterally assigned to secure the Obligations or otherwise contains provisions that restrict or penalize the granting of a security interest in or Lien on such License Agreement or the related Intellectual Property or, if entered into after the Closing Date, does not recognize the collateral assignment thereof to secure the Obligations, in each case, to the extent such provisions would validly prevent the granting of a security interest or collateral assignment to Purchaser Agent and&#47;or the Purchasers after giving effect to Applicable Laws (including Section 9-407, 9-408, and 9-409 of the UCC), (iii) any License Agreement that restricts assignment of such License Agreement to the applicable purchaser upon the sale or other disposition of all or substantially all of the assets to which such License Agreement relates (other than customary provisions requiring the assumption by the applicable purchaser of all obligations under such License Agreement), or (iv) any License Agreement that does not permit the disclosure of information to be provided thereunder to Purchaser Agent and the Purchasers, to any purchaser or prospective purchaser in a foreclosure or other Transfer of all or any portion of the Collateral (subject to customary confidentiality obligations). For the avoidance of doubt, no agreement pursuant to which the Company or any Subsidiary obtains an off-the-shelf software license, a shrink-wrap license, a click-wrap license or a non-exclusive license of Intellectual Property that does not constitute Product Intellectual Property, in each case in the ordinary course of business, shall be a Restricted License.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a) any dividend or other distribution, direct or indirect, on account of any shares (or equivalent) of any class of Equity Interests of any Person or any of its Subsidiaries, now or hereafter outstanding, (b) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of (i) any shares (or equivalent) of any class of Equity Interests of any Person or any of its Subsidiaries, now or hereafter outstanding or (ii)&#160;any call option on any shares (or equivalent) of any class of Equity Interests or any Person or any of its Subsidiaries (irrespective of whether such call option can be cash, net share or physically settled), (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Equity Interests of any Person or any of its Subsidiaries, now or hereafter outstanding, (d) any payment made in cash to the holders of Existing Stockholder Indebtedness or Subordinated Debt and (e) payments pursuant to the Affiliate Agreements and any other payment of management, advisory, consulting or other similar fees and expenses to Affiliates (in each case with respect to this clause (e), excluding rent payments (and payments for the use of real estate substantially identical to rent) to Affiliates in respect of real estate operating leases (or licenses to use real estate) entered into in the ordinary course of business).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Interest Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to each calendar quarter during the Revenue Interest Period, the amount payable by the Company to the Purchasers equal to the Net Sales in the Covered Territory for such calendar quarter multiplied by the Applicable Percentage, subject to the terms and conditions set forth in this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, with respect to any calendar quarter, that the Total Revenue Interest Payments will not exceed the Cap Amount applicable at such time.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Interest Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the period from and including the Closing Date through and including the date on which the Purchasers have received Total Revenue Interest Payments equal to the applicable Cap Amount as of such date, unless earlier terminated or expired, as applicable, upon the indefeasible payment of the Put&#47;Call Price upon (i) the Purchasers&#8217; exercise, or deemed automatic exercise, of the Put Option in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ii) the Company&#8217;s exercise of the Call Option in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or (iii) the Maturity Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means all of the Obligors&#8217; right, title and interest in and to that portion of the accounts and payment intangibles arising out of sales and licenses of the Included Products and the Product Assets equal to the Revenue Interest Payments for each calendar quarter (or portion thereof) during the Revenue Interest Period.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Safety Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any recalls, field notifications, market withdrawals, warnings, &#8220;dear doctor&#8221; letters, investigator notices, safety alerts or other notices of action issued or instigated by the Company, any Subsidiary of the Company or any Governmental Authority relating to an alleged lack of safety or regulatory compliance of any Included Product.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.22(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctions Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the U.S. government (including U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control and the U.S. Department of State), the United Nations Security Council, His Majesty&#8217;s Treasury, the European Union, any European Union member state or any other applicable sanctions authority.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities and Exchange Commission or any successor federal agency thereto.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means $100,000,000, which shall be paid by the Purchasers on the Second Purchaser Payment Date in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03(a)(ii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Payment Date Disclosure Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a notice delivered by the Obligors on or prior to the Second Purchaser Payment Date, which shall detail any exceptions to the making of representations and warranties by the Obligors as of the Second Purchaser Payment Date required in the judgment of the Obligors to make the representations and warranties in connection with the Second Payment comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03(b)(iii)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Purchaser Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the date specified in the Payment Notice with regards to the Second Payment (or such earlier date as may be agreed by Purchaser Agent and the Purchasers in their sole discretion).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Security Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Security Agreement among the Company, each Subsidiary Guarantor and the Purchaser Agent, dated as of the Closing Date, providing for, among other things, the grant by the Obligors in favor of the Purchaser Agent, for the benefit of the Secured Parties, of a valid continuing, perfected first priority (subject to Permitted Priority Liens) Lien on and security interest in the Collateral described therein.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Purchase Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Option (as defined in the Option Agreement) granted by the Company to the Purchasers pursuant to Section 1(a) of the Option Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Shares (as defined in the Option Agreement) issued or issuable to the Purchasers upon the exercise of the Share Purchase Option pursuant to and in accordance with the Option Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subordinated Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means Indebtedness of any Obligor that is expressly subordinated to the Obligations on terms and pursuant to documentation satisfactory to Purchaser Agent in its sole and absolute discretion (provided subordination to the Obligations on terms and pursuant to documentation consistent with the subordination agreement entered into on the Closing Date by the holders of the Existing Stockholder Indebtedness shall be satisfactory to Purchase Agent)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (i) such subordinated Indebtedness is provided by Patrick Soon-Shiong or an Affiliate or fund, investment, Person, vehicle or account that is managed, sponsored, or advised by Patrick Soon-Shiong or his Affiliates&#59; (ii) such subordinated Indebtedness shall only be guaranteed by the Company or its Subsidiaries that are Obligors hereunder, (iii) (A) the terms of such subordinated Indebtedness (including, without limitation, interest rates, fees, payment terms and covenants) shall be no more onerous or restrictive than those contained in the Existing Stockholder Indebtedness, (B) such subordinated Indebtedness shall have a cash interest rate of less than 10% per annum and (C) no scheduled principal payments, redemptions or sinking fund or like payments of any such subordinated Indebtedness shall be required prior to the date at least 91 days after the Maturity Date), and  (iv) no Put Option Event shall exist immediately before and after giving effect to the incurrence of such subordinated Indebtedness and the use of proceeds therefrom on such date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means with respect to any Person (i) any corporation of which the outstanding Equity Interests having at least a majority of votes entitled to be cast in the election of directors under ordinary circumstances is at the time owned, directly or indirectly, by such Person or (ii) any other Person of which at least a majority voting interest under ordinary circumstances is at the time, directly or indirectly, owned by such Person.  Unless the context otherwise requires, &#8220;Subsidiary&#8221; refers to a direct or indirect Subsidiary of the Company.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Subsidiary that is a guarantor of the Obligations under the Guaranty (or under another guaranty agreement in form and substance satisfactory to the Purchaser Agent) and has granted to the Purchaser Agent, on behalf of the Purchasers, a Lien upon and security interest in its right, title and interest in, to and under the Collateral pursuant to the Security Agreement or other Transaction Document. No Excluded Subsidiary shall be required to become a Subsidiary Guarantor. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any federal, state, local or foreign tax, levy, impost, duty, assessment, fee, deduction or withholding or other charge, including all excise, sales, use, value added, transfer, stamp, documentary, filing, recordation and other fees imposed by any taxing authority (and interest, fines, penalties and additions related thereto). </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any report, return, form (including elections, declarations, statements, amendments, claims for refund, schedules, information returns or attachments thereto) or other information supplied or required to be supplied to a Governmental Authority with respect to Taxes.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Test Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the last Business Day of the calendar year 2029.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Test Date Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Person other than the Purchaser Agent, any Purchaser, the Company or any Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, for purposes of the Net Sales definition, &#8220;Third Party&#8221; means any Person other than the Company, its Affiliates and any Licensee. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any claim, action, suit or proceeding by a Third Party, excluding any lender, officer, directors, employee or agent or other representative of a party to this Agreement, including any investigation by any Governmental Authority.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Revenue Interest Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination, the aggregate amount of all Revenue Interest Payments and any True-Up Payment indefeasibly paid by the Company and actually received by the Purchasers pursuant to this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, this Agreement, each Guaranty, the Security Agreement, the Control Agreements, each intellectual property security agreement, any mortgages, deeds of trust or deeds to secure debt that encumbers real property, any foreign collateral documents or other collateral documents or subordination agreements entered into in connection with this Agreement, the Perfection Certificate, each Compliance Certificate, each Payment Notice, the Option Agreement, and any related ancillary documents or agreements, in each case, for the benefit of the Secured Parties in connection with this Agreement, all as amended, amended and restated, supplemented or otherwise modified from time to time.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the sale, conveyance, transfer, license, sublicense, lease or other disposition of any property, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">True-Up Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">UCC Financing Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the UCC-1 financing statements, in form and substance reasonably satisfactory to the Purchaser Agent, that shall be filed by the Purchaser Agent at or promptly following the Closing Date, as well as any additional UCC-1 financing statements or amendments thereto as reasonably requested from time to time, to perfect the Purchaser Agent&#8217;s security interest in the Collateral.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States of America. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURCHASE OF REVENUE INTERESTS&#59; PAYMENTS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase of Revenue Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the terms and subject to the conditions set forth in this Agreement, the Company agrees to sell, assign and transfer to each Purchaser, and each Purchaser agrees to purchase and accept from the Company, free and clear of all Liens, such Purchaser&#8217;s Pro Rata Portion of the Revenue Interests.  The Purchasers&#8217; interest in the Revenue Interests shall vest immediately upon the Company&#8217;s receipt of payment of the First Payment pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subject to the termination provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Payments by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Payments in Respect of the Revenue Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">In consideration of the Purchaser Payments made by the Purchasers, the Purchasers shall be entitled to receive, and the Company shall pay to the Purchasers, on each applicable Payment Date, the Revenue Interest Payments during the Revenue Interest Period and, upon the exercise (or deemed exercise) by the respective party of the Call Option or the Put Option, as the case may be, the Put&#47;Call Price in respect thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">With respect to each calendar quarter commencing with the first Payment Date, the Company shall pay to the Purchasers, the Revenue Interest Payment for such calendar quarter on the Payment Date at the end of such calendar quarter with Net Sales for such payment to be calculated using the Company&#8217;s good faith estimate of gross cash receipts for such calendar quarter&#59; provided that all payments in respect of any calendar quarter shall be subject to reconciliation based on (A) the final Net Sales for the applicable calendar quarter on the Payment Date for the subsequent calendar quarter and (B) the final Net Sales for the applicable calendar year in which such calendar quarter occurs based on the audited financial statements for such calendar year on the Payment Date for the first calendar quarter of the subsequent calendar year, in each case of (A) and (B), with such reconciliation to be prepared by the Company and delivered to the Purchasers and the Purchaser Agent in the form of a Reconciliation Report in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to each reconciliation, any overpayments shall be credited against, and any underpayments shall be added to, the subsequent payments in respect of the Revenue Interests. For the avoidance of doubt, the Purchasers shall not be required to refund any Revenue Interest Payments.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">True-Up Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  If, as of the Test Date, the Total Revenue Interest Payments are less than 100% of the Cumulative Purchaser Payments (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Test Date Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then the Company will, on the Test Date, make a one-time payment to each Purchaser in accordance with its Pro Rata Portion of the Revenue Interests, by wire transfer of immediately available funds to the account or accounts designated by such Purchaser, in an amount equal to 100% of the Cumulative Purchaser Payments as of the Test Date less the Total Revenue Interest Payments as of the Test Date (such amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">True-Up Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Upon the Maturity Date, the Company shall pay to each Purchaser in accordance with its Pro Rata Portion of the Revenue Interests, by wire transfer of immediately available funds to the account or accounts designated by such Purchaser, an amount equal to 195.0% of the Cumulative Purchaser Payments minus the Total Revenue Interest Payments as of such date. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Reimbursable Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company shall pay to the Purchaser Agent all Reimbursable Expenses (including attorneys&#8217; fees and expenses for documentation and negotiation of this Agreement) incurred through and after the Closing Date, when due. It is the intention of the parties hereto that the Company shall pay Reimbursable Expenses directly&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, at the discretion of the Purchasers, Reimbursable Expenses may be deducted from the Purchaser Payments to the extent invoiced at least two (2) Business Days (or one (1) Business Day in the case of the First Payment) prior to such Purchaser Payment. In the event the Purchaser Agent or any Purchaser pays any of such expenses directly, the Company will promptly following invoice by Purchaser Agent or such Purchaser reimburse the Purchaser Agent or such Purchaser for such expenses.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Payment Procedure&#59; Currency Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any payments to be made by the Obligors to the Purchasers and&#47;or Purchaser Agent hereunder or under any other Transaction Document shall be made in United States dollars by wire transfer of immediately available funds. All Revenue Interest Payments and other payments by the Obligors (other than payments in respect of Reimbursable Expenses and indemnification obligations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) shall be made to each Purchaser in accordance with its Pro Rata Portion.  If any currency conversion shall be required in connection with the calculation of amounts payable hereunder, such conversion shall be made using the average of the buying and selling rates on the last five (5) Business Days of the calendar quarter to which such amounts pertain, as published by The Wall Street Journal, Internet Edition at www.wsj.com. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt;text-decoration:underline">Late Payments.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Revenue Interests and any other Obligations required to be paid to the Purchasers on each Payment Date but not paid when due (other than good faith underpayments subject to reconciliation pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) shall bear interest at a rate of the Prime Rate plus four percent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.00%) per annum (calculated on the basis of a three hundred sixty (360) day year and actual days elapsed) from the due date until paid in full or, if less, the maximum interest rate permitted by Applicable Law.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Payments&#59; Conditions Precedent.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Purchaser Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In each case subject to the applicable conditions precedent in clause (b), which may be waived by the Required Purchasers in their sole discretion&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">On the Closing Date, each Purchaser shall pay to the Company, and the Company shall accept, such Purchaser&#8217;s Pro Rata Portion of the First Payment (less any then unpaid Reimbursable Expenses) by wire transfer of immediately available funds.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">On the Second Purchaser Payment Date, each Purchaser shall pay to the Company, and the Company shall accept, such Purchaser&#8217;s Pro Rata Portion of the Second Payment (less any then unpaid Reimbursable Expenses) by wire transfer of immediately available funds.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Conditions Precedent to the Closing Date and First Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company and each other Obligor, as applicable, shall have delivered to the Purchaser Agent&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">this Agreement, the Security Agreement, the Guaranty, the Disclosure Letter and any other Transaction Documents, duly executed by each applicable Obligor&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">an irrevocable Payment Notice in respect of the First Payment&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">insurance certificates in form and substance satisfactory to Purchaser Agent with respect to all property and general liability insurance policies of the Obligors&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">&#91;reserved&#93;&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.24pt"> &#91;reserved&#93;&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">a secretary&#8217;s certificate executed by an officer of each Obligor attaching certified organizational documents, certificates of good standing and incumbency certificates of each Obligor and resolutions of the governing body of each Obligor authorizing such Obligor to enter into the Transaction Documents and perform the transactions contemplated thereby (including resolutions of the shareholders, if necessary under the applicable organizational documents to approve entry by an Obligor into the Transaction Documents)&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">all other consents required (if any) by the Obligors under any Material Contracts Applicable Law, the organizational documents of the Obligors and Governmental Authorities&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">UCC Financing Statements in proper form for filing against each Obligor&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">short-form security agreements in respect of the Intellectual Property of each Obligor&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(J)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.45pt">one or more legal opinions of counsel to the Obligors&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(K)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">a completed Perfection Certificate, duly executed by the Company&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(L)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.24pt">the Option Agreement, duly executed by the Company&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(M)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.45pt">subordination agreement(s) in form and substance satisfactory to the Purchaser Agent in its sole discretion from the holders of the Existing Stockholder Indebtedness&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(N)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">copies of all Material Contracts, all amendments of such Material Contracts as of and through the Closing Date, the Dunkirk Lease and all documentation related or ancillary to the Dunkirk Lease and the Beike License Agreement&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(O)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">&#91;reserved&#93;&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(P)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">evidence that (i) all Liens (other than Permitted Liens) will be terminated and (ii) the documents and&#47;or filings evidencing the perfection of such Liens, including without limitation any financing statements, control agreements and&#47;or landlord consents and bailee waivers, have or will, concurrently with the making of the First Payment on the Closing Date, be terminated&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">such other items as the Purchaser Agent may reasonably request, in each case in form and substance satisfactory to the Purchaser Agent and duly executed by all parties thereto. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Conditions Precedent to the Second Payment. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">The First Payment shall have occurred&#59; </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">The FDA Approval Date shall have occurred on or prior to June 30, 2024&#59; and</font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">If the Obligors elect to deliver a Second Payment Date Disclosure Notice, such Second Payment Date Disclosure Notice shall be satisfactory to the Purchaser Agent and the Purchasers in their sole discretion.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">Conditions Precedent to each Purchaser Payment. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">The representations and warranties in Article III hereof shall be true, correct and complete in all material respects on the date of the Payment Notice (except with respect to any Payment Notice delivered prior to the Closing Date) and on the date of the applicable payment (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof)&#59; provided, further, that those representations and warranties expressly referring to a specific date shall be true, correct and complete in all material respects as of such date (except that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> solely in respect of the Second Payment, such representations and warranties shall be qualified by the matters disclosed in the Second Payment Date Disclosure Notice&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">No Put Option Event, nor event or circumstance that with the giving of notice or passage of time or both would constitute a Put Option Event, shall have occurred and be continuing&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.68pt">To the extent not deducted from the applicable Purchaser Payment, the Company shall have paid all Reimbursable Expenses then due in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">With respect to the Second Payment, by 12&#58;00 noon Eastern time fifteen (15) Business Days (or such shorter period as may be determined by Purchaser Agent and the Purchasers in their sole discretion) prior to the Second Purchaser Payment Date, the Company shall have delivered to Purchaser Agent a duly executed Payment Notice&#59;     </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.24pt">Each of Purchaser Agent and the Purchasers determine to its satisfaction that there has not been any Material Adverse Effect&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Company shall have provided (i) updates to the information in the Perfection Certificate since the Closing Date or the most recent update thereto and (ii) all financial statements, reports or notices required to have been delivered under the Transaction Documents, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Agreement&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">The Company shall have delivered to Purchaser Agent an officer&#8217;s certificate certifying as to the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03(b)(iii)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.12pt">The Purchaser Commitments shall not have expired.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchaser Commitments shall terminate to the extent funded and shall terminate on the earliest of (A) the Second Purchaser Payment Date and (B)(1) if the FDA Approval Date has not occurred on or prior to June 30, 2024, June 30, 2024 or (2) if the FDA Approval Date has occurred on or prior to June 30, 2024, the date which is thirty (30) Business Days after the FDA Approval Date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing and anything else to the contrary herein, (A) promptly following the FDA Approval Date, the Company shall deliver to Purchaser Agent the items described in the preceding clauses (D), (F)(i) and (G) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.03(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and (B) Purchaser Agent and the Purchasers may at any time in their sole discretion, by written notice (such notice, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Funding Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to the Company with five (5) Business Days prior notice (or such shorter period to which the Company may agree in its sole discretion), designate the Second Purchaser Payment Date and fund the Second Payment, as applicable, on such date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Post-Closing Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Within 30 days of the Closing Date, duly executed Control Agreements (or, with respect to any bank account of an Obligor located outside of the United States, other documentation satisfactory to Purchaser Agent in its sole discretion in order to provide Purchaser Agent with a first-priority perfected security interest in such account) in respect of each of the deposit accounts and securities accounts of each Obligor other than Excluded Accounts.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Within 10 Business Days of the Closing Date, additional insured or lenders&#8217; loss payee endorsements, as applicable, in each case in favor of Purchaser Agent and in form and substance satisfactory to Purchaser Agent with respect to all property and general liability insurance policies of the Obligors.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">Within 30 days of the Closing Date, a permanent record, in form reasonably satisfactory to Purchaser Agent, of all documents and materials uploaded to the Data Room related to the transactions contemplated by this Agreement prior to the Closing Date (e.g., a USB drive containing copies of such documents and deliverables).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Without limiting the application of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.06(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within 90 days of the Closing Date, the Obligors as of the Closing Date shall hold all of their cash and Cash Equivalents in bank accounts maintained at Globally Systemically Important Banks.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">For a period of at least 180 days following the Closing Date, the Company and its Subsidiaries shall use their commercially reasonable best efforts to deliver to Purchaser Agent a landlord waiver and collateral access agreement with regard to each of the Obligors&#8217; locations set forth in the Perfection Certificate, except for the property located at 3805 Lake Shore Drive E, Dunkirk, NY 14048.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Within 90 days of the Closing Date, the Company and its Subsidiaries shall deliver to Purchaser Agent a leasehold mortgage or deed of trust, as applicable, in form and substance reasonably satisfactory to Purchaser Agent in favor of the Purchaser Agent for the benefit of the Purchasers with respect to the properties listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.03(c)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> such mortgages and deeds of trust shall not (i) require the Company and its Subsidiaries to restate (or bringdown) the representations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Agreement (other than representations and warranties customary for mortgages and deeds of trust) or (ii) include representations, covenants or conditions that conflict with or contravene the provisions of this Agreement.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">Within 180 days of the Closing Date, the Company shall sell for cash the corporate bonds and European bonds listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.11(a)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 2.04&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Assumed Obligations. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any provision in this Agreement or any other writing to the contrary, the Purchasers are acquiring only the Revenue Interests and are not assuming any liability or obligation of the Company or any Affiliate of whatever nature, whether presently in existence or arising or asserted hereafter, whether under any Transaction Document or otherwise.  All such liabilities and obligations shall be retained by and remain obligations and liabilities of the Company or their Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> REPRESENTATIONS AND WARRANTIES OF THE COMPANY</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company hereby represents and warrants to the Purchaser Agent and the Purchasers, that, except as disclosed in the Disclosure Letter and any Second Payment Date Disclosure Notice, as applicable, as of the Closing Date and the Second Purchaser Payment Date, as applicable, the following&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Obligor is a corporation, limited liability company or other corporate entity, as applicable, duly organized or incorporated (as applicable), validly existing, and (to the extent the concept is applicable in such jurisdiction) in good standing under the laws of its respective jurisdiction of organization. Each Obligor has all requisite corporate, limited liability company or other power, as applicable, licenses, authorizations, consents and approvals required to carry on its respective business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents. Each Obligor is duly qualified to do business as a foreign corporation, foreign limited liability company or other foreign entity, as applicable, and (to the extent the concept is applicable in such jurisdiction) is in good standing in every jurisdiction (other than its jurisdiction of organization) in which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the failure to do so would be reasonably expected to have a Material Adverse Effect. As of the Closing Date, the Subsidiaries of the Company are listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Obligor has all requisite corporate, limited liability company or other organizational power and authority to execute and deliver, and perform its obligations under, this Agreement, the Security Agreement and each other Transaction Document to which it is a party and to consummate the transactions contemplated hereunder and thereunder, as applicable. The execution, delivery, and performance of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated by this Agreement and the other Transaction Documents, have been duly authorized by all necessary corporate, limited liability company or other organizational action on the part of such Obligor. Each Obligor has provided the Purchaser Agent with a copy of resolutions adopted by such Obligor&#8217;s Board authorizing the execution, delivery, and performance by such Obligor of this Agreement, the Security Agreement and each other Transaction Document and the consummation by such Obligor of the transactions contemplated by this Agreement, the Security Agreement and the other Transaction Documents. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enforceability.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement, the Security Agreement and the other Transaction Documents have been duly authorized, executed and delivered by each Obligor party thereto and constitute the valid and binding obligation of such entity, enforceable against such entity in accordance with its respective terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;Reserved&#93;. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors exclusively own all of the Product Intellectual Property, Regulatory Filings and the Regulatory Approvals related to Anktiva free and clear of all Liens (other than Permitted Liens), and no license or covenant not to sue under any such Product Intellectual Property, or right of reference under any such Regulatory Filings, has been granted by any Obligor to any Third Party, except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.05(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter. In addition, the Obligors own or hold a valid license granting rights to use, or have other rights to use, all of the Product Intellectual Property, Regulatory Filings and the Regulatory Approvals related to each other Included Product free and clear of all Liens (other than Permitted Liens), and no license or covenant not to sue under any such Product Intellectual Property, or right of reference under any such Regulatory Filings, has been granted by any Obligor to any Third Party, except for Permitted Licenses or as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.05(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter. Any exclusive or commercial rights granted under the agreements listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter are notated as such on such schedule.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.05(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter or as permitted pursuant to this Agreement, no Obligor has Transferred or granted any Lien in respect of or agreed to Transfer or grant any Lien in respect of, any portion of the Revenue Interests or the Collateral. Except for the sale of the Revenue Interests pursuant hereto and as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.05(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, no Person other than the Company has any right to receive any payments in respect of Net Sales or revenues of the Included Products. The Company has the full right to sell, transfer, convey and assign to the Purchasers all of the Company&#8217;s rights, title and interests in and to the Revenue Interests pursuant to this Agreement without any requirement to obtain the consent of any Person, except such consents as are obtained at or prior to the Closing Date.  At the Closing Date, Purchaser Agent shall have acquired good </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and valid rights and interests in and to all of the Revenue Interests, free and clear of any and all Liens, subject to the terms of this Agreement. Any agreements related to Anktiva and listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.05(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter are notated as such on such schedule. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Statements&#59; No Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Audited Financial Statements and the Interim Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein (and except, in the case of the Interim Financial Statements, for the absence of footnotes and subject to year-end adjustments) and (ii) fairly present in all material respects the financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein (and except, in the case of the Interim Financial Statements, for the absence of footnotes and subject to year-end adjustments).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#91;reserved&#93;.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">From the date of the Audited Financial Statements to and including the Closing Date, there has been no Transfer by the Company or any Subsidiary, voluntary or involuntary, of any material part of the business or property of the Company or any Subsidiary, and no purchase or other acquisition by any of them of any business or property (including any Equity Interests of any other Person) material to the Company or any Subsidiary, in each case, which is not reflected in the foregoing financial statements or in the notes thereto and has not otherwise been disclosed in writing to Purchaser Agent and the Purchasers on or prior to the Closing Date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The financial statements delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been prepared in accordance with GAAP (except as may otherwise be permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and present fairly in all material respects (on the basis disclosed in the footnotes to such financial statements) the consolidated financial condition, results of operations and cash flows of the Company and its Subsidiaries as of the dates thereof and for the periods covered thereby.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Since the date of the Audited Financial Statements, there has been no event or circumstance, either individually or in the aggregate, that has had or could reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Undisclosed Liabilities. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for (a) those liabilities identified in the Financial Statements (including the notes thereto) and&#47;or in any current or periodic filing made by the Company with the SEC or incurred in the ordinary course of business since the date of the most recent Financial Statements&#59; (b) Indebtedness permitted hereunder&#59; or (c) those liabilities in connection with the Obligations under the Transaction Documents, there are no material liabilities of the Company or its Subsidiaries related to any Included Product, of any kind whatsoever, whether accrued, contingent, absolute, determined or determinable.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency&#59; No Fraudulent Transfer. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its Subsidiaries, taken as a whole, are not insolvent as defined in any statute of the United States Bankruptcy Code, the fraudulent conveyance or fraudulent transfer statutes of the State of Delaware or any other Bankruptcy Laws.  After giving effect to the applicable Purchaser Payment on the Closing Date or the Second Purchaser Payment Date, as applicable, (a) the present fair saleable value of the Company&#8217;s and the Subsidiaries&#8217; assets, taken as a whole, is greater than the total amount of liabilities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company and the Subsidiaries, taken as a whole, as such liabilities mature, (b) the Company and the Subsidiaries, taken as a whole, do not have unreasonably small capital with which to engage in their business, and (c) the Company and the Subsidiaries, taken as a whole, have not incurred, nor do they have present plans to or intend to incur, debts or liabilities beyond their ability to pay such debts or liabilities as they become absolute and matured.  No transfer of property was or is being made by any Obligor and no obligation was or is being incurred by any Obligor in connection with the transactions contemplated by this Agreement or the other Transaction Documents with the intent to hinder, delay, or defraud either present or future creditors of such Obligor.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I) Other than as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.09(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, no Obligor is a party to or has received any written notice of (a) any action, suit, arbitration proceeding, claim, investigation or other proceeding (whether administrative, judicial or otherwise) pending or, to the Knowledge of the Obligors, threatened against the Company or any of its Subsidiaries, or (b) any governmental inquiry pending or, to the Knowledge of the Obligors, threatened against the Company or any of its Subsidiaries, in each case with respect to clauses (a) and (b) above, which would, individually or in the aggregate, if determined adversely, reasonably be expected to have a Material Adverse Effect and (II) other than as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.09(II)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, there is no action, suit, arbitration proceeding, claim, investigation, governmental inquiry or other proceeding (whether administrative, judicial or otherwise) pending or, to the Knowledge of the Obligors, threatened against the Company, any Subsidiary or any other Person relating to the Revenue Interests, any Included Product or any other Product Asset.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither the Company nor any Subsidiary (a) is in violation of, has violated, or to the Knowledge of the Obligors, is under investigation with respect to, or (b) has been threatened to be charged with or been given notice of any violation of any law, rule, ordinance or regulation of, or any judgment, order, writ, decree, permit or license entered by any Governmental Authority applicable to, the Company or any of its Subsidiaries, the Revenue Interests or the Included Products or any other Product Asset, in each case which could reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conflicts&#59; Adverse Agreements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, neither the execution and delivery of any of this Agreement or the other Transaction Documents to which any Obligor is a party nor the performance or consummation of the transactions contemplated hereby or thereby will&#58; (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of&#58; (i) any law, rule, ordinance or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which the Company or any Subsidiary or any of their respective assets or properties may be subject or bound&#59; or (ii) any contract, agreement, commitment or instrument to which the Company or any Subsidiary is a party or by which the Company or its Subsidiary or any of their respective assets or properties is bound or committed&#59; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the articles or certificate of incorporation or bylaws (or other organizational or constitutional documents) of the Company or any Subsidiary&#59; (c) except for the filing of the UCC Financing Statements and any other notices of security or notices of charge required hereunder and filings with the United States Patent and Trademark Office and&#47;or the United States Copyright Office, require any notification to, filing with, or consent of, any Person or Governmental Authority, except such consents that are obtained, notices provided, and&#47;or filings made, in each case, at or prior to the Closing Date&#59; (d) give rise to any right of termination, cancellation or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceleration of any right or obligation of the Company, any Subsidiary or any other Person or&#59; (e) give rise to any loss of any benefit relating to the Revenue Interests&#59; or (f) other than pursuant to this Agreement or any other Transaction Document, result in the creation or imposition of any Lien on (i) the assets or properties of the Company or any Subsidiaries or (ii) the Revenue Interests or any Collateral except, in the case of the foregoing clauses (a), (c) or (d), as could not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.  No Obligor or any of its Subsidiaries is a party to any contractual obligation or subject to any restriction or limitation in any organizational document or any judgment, order, regulation, ruling or other requirement of a court or other Governmental Authority, which (either individually or in the aggregate) has, or in the future could reasonably be expected (either individually or in the aggregate) to have, a Material Adverse Effect. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Schedule 3.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter sets forth, as of the Closing Date, true, correct and complete list of all (i) Patents and utility models, (ii) trade names, registered trademarks, registered service marks, and applications for trademark registration or service mark registration, (iii) registered copyrights and (iv) domain name registrations and websites, in each case with respect to clauses (i), (ii), (iii) and (iv) above in this clause (a) that are material Product Intellectual Property.  Except as disclosed therein, to the Knowledge of the Obligors, each issued Patent and trademark listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter is valid, enforceable and subsisting and has not lapsed, expired, been cancelled or become abandoned, except in the ordinary course of business or where such lapse or abandonment would not reasonably be likely to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Except for Product Intellectual Property licensed to or owned by any Obligor and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, to the Knowledge of the Obligors, no other Intellectual Property is necessary to use, Develop, Manufacture, import or Commercialize the Included Products.  To the Knowledge of the Obligors, the use, Development, Manufacture, import or Commercialization of the Included Products do not and will not infringe any Patents or misappropriate any other Intellectual Property that is owned or controlled by a Third Party.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">To the Knowledge of the Obligors, there are no unpaid maintenance, annuity or renewal fees currently overdue for any of the Patents that constitute Product Intellectual Property or which claim or cover compositions of matter, formulation, method of use, method of manufacture and&#47;or processes which relate to the Included Products, or that are otherwise material to the business of the Obligors and their Subsidiaries, and that are owned by or licensed to any Obligor or Subsidiary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Material Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.12(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, there is, and has been, no pending, decided or settled opposition, interference proceeding, reexamination proceeding, cancellation proceeding, injunction, claim, lawsuit, declaratory judgment, administrative post-grant review proceeding, other administrative or judicial proceeding, hearing, investigation, complaint, arbitration, mediation, International Trade Commission investigation, decree, or any other filed claim (collectively referred to hereinafter as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) related to any of the Material Patents nor has any such Dispute been threatened in writing challenging the legality, validity, enforceability or ownership of any Material Patents.  There are no Disputes by any Person or Third Party against any Obligor or any of their respective Subsidiaries, and no Obligor nor any Subsidiary thereof has received any written notice or claim of any such Dispute as pertaining to the Included Products. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors and their Subsidiaries have taken commercially reasonable measures and precautions to protect and maintain (i) the confidentiality of all trade secrets with respect to the Included Products that it owns or exclusively licenses and (ii) the value of all Intellectual Property related to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included Products, except where such failure to take action would not reasonably be expected to have a Material Adverse Effect.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">No material trade secret of the Obligors or any of their respective Subsidiaries with respect to the Included Products has been published or disclosed to any Person except pursuant to a written agreement requiring such Person to keep such trade secret confidential, except where such disclosure would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Approvals&#59; Anktiva</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors and their Subsidiaries have made available to Purchaser Agent any written reports or other written communications received by them or, to the actual knowledge of the Knowledge Persons, by any Affiliates and Licensees of the Obligors and their Subsidiaries, from a Governmental Authority that would indicate that any Regulatory Agency (i) is likely to revise or revoke any current Clinical Trial Application filed with any Regulatory Agency with respect to Anktiva or Regulatory Approval granted by any Regulatory Agency with respect to Anktiva, or may reject any filing of a Clinical Trial Application or not grant Regulatory Approval for Anktiva, (ii) is likely to pursue any material compliance actions against any Obligor or any of the Obligors&#8217; Affiliates or Licensees, or (iii) except as would not reasonably be expected to result in a Material Adverse Effect, has any concerns with Anktiva.  To the Knowledge of the Obligors there are no other facts or circumstances that could reasonably be expected to (A) indicate that any of the events specified in the immediately preceding clauses (i), (ii) or (iii) may occur or (B) cause the Obligors or any of their respective Affiliates or Licensees to voluntarily revise, withdraw or not apply for any Clinical Trial Application or Regulatory Approval for Anktiva.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Obligors and their Subsidiaries possess all Clinical Trial Applications and Regulatory Approvals issued or required by the Regulatory Agency, which are necessary to conduct the business relating to Anktiva, including to conduct the current Clinical Trials relating to Anktiva, and no Obligor nor any of the Obligors&#8217; Subsidiaries, nor, to the actual knowledge of the Knowledge Persons, any of the Obligors&#8217; Affiliates or Licensees, has received any notice of proceedings relating to, and there are no facts or circumstances to the Knowledge of the Obligors that could reasonably be expected to lead to, the revocation, suspension, termination or modification of any such Clinical Trial Applications or Regulatory Approvals. All Clinical Trial Applications and applications, notifications, submissions, information, claims, reports and statistics and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Regulatory Approval from the FDA or other Regulatory Agency relating to the Obligors or any of their Subsidiaries, their business operations and Anktiva, when submitted to the FDA or other Regulatory Agency were true, complete and correct in all material respects as of the date of submission or any necessary or required updates, changes, corrections or modifications to such applications, submissions, information and data have been submitted to the FDA or other Regulatory Agency. None of the officers or directors, or, to the Knowledge of the Obligors, employees or Affiliates of any Obligor or any Affiliate or Licensee of any Obligor or any agent or consultant of any such Person has (i) made an untrue statement of material fact or fraudulent statement to any Regulatory Agency or failed to disclose a material fact required to be disclosed to a Regulatory Agency&#59; or (ii) committed an act, made a statement, or failed to make a statement that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#8221; set forth in 56 Fed. Reg. 46191 (September 10, 1991).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors and their Subsidiaries and, to the actual knowledge of the Knowledge Persons, the Obligors&#8217; Affiliates and Licensees, are in compliance with, and have complied with, all applicable federal, state, local and foreign laws, rules, regulations, standards, orders and decrees governing its business, including all regulations promulgated by each Regulatory Agency, the failure of compliance with which could reasonably be expected to result in a Material Adverse Effect&#59; the Obligors and their</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries and, to the actual knowledge of the Knowledge Persons, the Obligors&#8217; Affiliates and Licensees, have not received any notice citing action or inaction by any of them that would constitute any non-compliance with any applicable federal, state, local and foreign laws, rules, regulations, or standards, which could reasonably be expected to result in a Material Adverse Effect&#59; and to the Knowledge of the Obligors, no prospective change in any applicable federal, state, local or foreign laws, rules, regulations or standards has been adopted which, when made effective, could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.13(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, (i) all preclinical and Clinical Trials conducted by or on behalf of the Obligors or their Subsidiaries or, to the actual knowledge of the Knowledge Persons, the Obligors&#8217; Affiliates or Licensees, relating to Anktiva were conducted in all material respects in compliance with Applicable Law and, in all material respects, in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards, (ii) the descriptions and the results of such trials provided to Purchaser Agent are accurate in all material respects and (iii) no Obligor nor any of their Subsidiaries nor, to the actual knowledge of the Knowledge Persons, the Obligors&#8217; Affiliates and Licensees, has received any notices or correspondence from any Regulatory Agency or comparable authority requiring the termination, suspension, or modification or clinical hold of any Clinical Trials conducted by or on behalf of such Obligor or its Affiliates and Licensees.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">No Obligor nor any of the Obligors&#8217; Subsidiaries nor, to the actual knowledge of the Knowledge Persons, the Obligors&#8217; Affiliates or Licensees, have received any notices from, or had any written or oral communications with, (i) any Governmental Authority or (ii) any pricing and reimbursement representative of any Person, in each case exercising authority with respect to pricing and reimbursement for Anktiva, that have resulted in, or could reasonably be expected to result in, any non-coverage decision in respect of, or material reduction in the expected pricing of, Anktiva.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.13(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, all manufacturing operations conducted by or on behalf of the Obligors and their Subsidiaries and, to the actual knowledge of the Knowledge Persons, the Obligors&#8217; Affiliates and Licensees, relating to Anktiva have been and are being conducted in compliance with, as applicable, current good manufacturing practices set forth in 21 C.F.R. Parts 210 and 211 and applicable FDA guidance documents. Without limiting the generality of the foregoing, as of the Closing Date, to the Knowledge of the Obligors, neither any Obligor nor any of their Subsidiaries nor, to the actual knowledge of the Knowledge Persons, any Affiliate or Licensee of the Obligors has received any written notice from any applicable Governmental Authority, including the FDA, that such Governmental Authority is conducting an investigation or review of (i) the Obligors&#8217; and their Affiliates&#8217; or Licensees&#8217; (or any third party contractors therefor) manufacturing facilities, manufacturing or other processes, or marketing and sales, in each case which have identified any material deficiencies or violations of Applicable Laws or the permits related to the manufacture, marketing and&#47;or sales of Anktiva that could reasonably be expected to result in a Material Adverse Effect, or (ii) any such Regulatory Approval that could be reasonably expected to result in a revocation or withdrawal of such Regulatory Approval, nor has any such Governmental Authority issued any order or recommendation stating that the development, testing, manufacturing, marketing or sales of Anktiva by any Obligor or any of the Obligors&#8217; Affiliates or Licensees should cease or that Anktiva should be withdrawn from the marketplace. No Obligor nor any Subsidiary nor, to the actual knowledge of the Knowledge Persons, any Affiliate or Licensee of any Obligor, has experienced any significant failures in manufacturing Anktiva for commercial sale or use in Clinical Trials that has had or could reasonably be expected to have, if such failure occurred again, a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">No Obligor, nor any Subsidiary of any Obligor, nor their respective officers, employees or agents, nor, to the actual knowledge of the Knowledge Persons, any Affiliate or Licensee of any Obligor, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been convicted of any crime or engaged in any conduct for which (i) debarment is mandated by 21 U.S.C. &#167; 335a(a) or authorized by 21 U.S.C. &#167; 335a(b)&#59; or (ii) exclusion is required pursuant to 42 U.S.C. &#167; 1320a-7b and related regulations, nor is any such debarment or exclusion threatened or pending. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">No Obligor, nor any Subsidiary of any Obligor, nor, to the actual knowledge of the Knowledge Persons, any Affiliate or Licensee of any Obligor, has received from the FDA, a warning letter, Form FDA-483, &#8220;Untitled Letter,&#8221; or similar written correspondence or notice alleging violations of laws and regulations enforced by the FDA, or any comparable correspondence from any other Governmental Authority, the subject of which communication is unresolved and if determined adversely to such Obligor, Affiliate or Licensee could reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">(i) There have been no Safety Notices, (ii) to the Knowledge of the Obligors, there are no unresolved material product complaints which could reasonably be expected to have a Material Adverse Effect, and (iii) to the Knowledge of the Obligors, there are no facts that would be reasonably likely to result in (A) a material Safety Notice, (B) a material change in the labeling of Anktiva, or (C) a termination or suspension of marketing of Anktiva.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">The Obligors and their Subsidiaries and, to the actual knowledge of the Knowledge Persons, the Obligors&#8217; Affiliates and Licensees, are in material compliance with all applicable federal, state and local laws and regulations regarding the privacy and security of health information and electronic transactions, including the Health Insurance Portability and Accountability Act (HIPAA), and has implemented adequate policies, procedures and training designed to assure continued compliance and to detect non-compliance. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Obligors have made available to the Purchaser Agent all Clinical Trial Applications and Regulatory Approvals and all material correspondence with Governmental Authorities (including the FDA) with respect to such Clinical Trial Applications and Regulatory Approvals, in each case with respect to Anktiva for treatment of BCG-unresponsive non-muscle invasive bladder carcinoma in situ and all requested documents related to Anktiva for treatment of BCG-unresponsive non-muscle invasive bladder carcinoma in situ, in each case in the possession and control of the Obligors or their Subsidiaries. The Obligors have not withheld any document or information that could reasonably be considered to be material to the Purchasers&#8217; decision to provide the financing contemplated by this Agreement.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Material Contracts.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Disclosure Letter (which may be updated by the Obligors from time to time by written notice to the Purchaser Agent) sets forth a true and complete list of all Material Contracts.  The Obligors have made available to Purchaser Agent correct and complete copies of all Material Contracts, the Beike License Agreement, and of the Dunkirk Lease and all documents related or ancillary thereto.  Neither the Company nor any Subsidiary of the Company is in breach of any Material Contract or in default under any Material Contract which breach or default, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.  There is no event or circumstance that with notice or lapse of time, or both, could reasonably be expected to (a) constitute a material breach or default by the Company and&#47;or its Subsidiaries or (to the Knowledge of the Obligors) any other party under any Material Contract, (b) give any other party to any Material Contract the right to accelerate the maturity or performance of any Material Contract or (c) give any Person the right to cancel, terminate or modify any Material Contract. To the Knowledge of the Obligors, nothing has occurred and no condition exists that would permit any other party thereto to terminate any Material Contract. Neither the Company nor its Subsidiaries has received any notice or, to the Knowledge of the Obligors, any threat of termination of any such Material Contract. To the Knowledge of the Obligors, no other party to a Material Contract is in material breach of or in material default under such Material Contract. All Material Contracts are valid and binding on the Company and its</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries, as applicable and, to the Knowledge of the Obligors, on each other party thereto, and are in full force and effect. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Perfection Certificate.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Agreement, the Company on behalf of itself and each other Obligor has delivered to Purchaser Agent a completed Perfection Certificate.  The Perfection Certificate accurately sets forth (a) each Obligor&#8217;s exact legal name, organization type and jurisdiction, and organizational or company identification number (or accurately states that such Obligor has none)&#59; and (b) each Obligor&#8217;s place of business, or, if more than one, its chief executive office or principal place of business, as applicable, as well as each Obligor&#8217;s mailing address (if different than its chief executive office). Except as noted in the Perfection Certificate, each Obligor (and each of its respective predecessors) have not, in the past five (5) years, changed its jurisdiction of organization or incorporation, organizational structure or type, or any organizational or company number assigned by its jurisdiction. All other information set forth on the Perfection Certificate pertaining to the Obligors and the Subsidiaries, is true, correct and complete in all material respects.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Customers and Suppliers.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There exists no actual or, to the Knowledge of the Obligors, threatened (in writing) termination, cancellation or limitation of, or modification to or change in, the business relationship between (i) any Obligor, on the one hand, and any customer or any group thereof, on the other hand, or (ii) any Obligor, on the one hand, and any supplier or any group thereof, on the other hand, in either case, which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Perfection&#59; Subordination.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Transaction Documents create valid security interests in, and Liens on, the Collateral purported to be covered thereby, securing the Obligations, which security interests and Liens will be, upon the timely and proper filings, deliveries, notations and other actions contemplated in the Transaction Documents perfected security interests and Liens (to the extent that such security interests and Liens can be perfected by such filings, deliveries, notations and other actions).  The claims and rights of the Purchaser Agent and the Purchasers created by any Transaction Document are not and shall not be subordinated to any creditor of any Obligor or any other Person, and the Liens created pursuant to the Transaction Documents will have first ranking priority and will not be subject to any prior ranking or pari passu ranking Lien other than Permitted Priority Liens.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are in full force and effect insurance policies maintained by reputable insurance companies in accordance with standards customary for companies such as the Obligors, with coverage of the Company and each of its Subsidiaries in amounts customary for companies of comparable size and condition similarly situated in the same industry as, subject only to such exclusions and deductible items as are usual and customary in insurance policies of such type. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tax.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company and its Subsidiaries has timely filed all Tax Returns and has paid all Taxes prior to delinquency, except to the extent such Tax Returns or Taxes (a) are being contested in good faith by appropriate proceedings diligently conducted and with appropriate reserves in accordance with GAAP or (b) to the extent that the failure to do so could not reasonably be expected to have a Material Adverse </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect.  There are no Liens in respect of Taxes applicable to the Company or any of its Subsidiaries except Permitted Liens.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Reports. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All reports required to be filed by the Company under the Exchange Act have been duly filed, were in substantial compliance with the requirements of their respective forms, and did not, as of the date filed, contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements made therein in light of the circumstances under which they were made not misleading. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Company Act. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the Company or any of its Subsidiaries is required to register as an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company,&#8221; within the meaning of the Investment Company Act of 1940.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">OFAC&#59; Anti-Terrorism Laws.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">None of the Company, any Subsidiary of the Company nor, to the Knowledge of the Obligors, any Affiliate is a Person that is, or is owned or controlled by persons that are (i) the subject of any economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by the Sanctions Authority (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or (ii) located, organized or resident in a country or territory that is the subject of Sanctions.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Each of the Company, its Subsidiaries and respective directors, officers and employees and, to the Knowledge of the Obligors, the agents and Affiliates of the Company and its Subsidiaries are in compliance with the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and are in compliance in all material respects with all applicable Sanctions and any other applicable anti-corruption law. The Company and its Subsidiaries have instituted and maintain policies and procedures designed to ensure continued compliance with applicable Sanctions, the FCPA and any other applicable anti-corruption law.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Broker&#8217;s Fees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for any commission or broker&#8217;s fee set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 3.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, the Company and its Subsidiaries have not taken any action that would entitle any Person to any commission or broker&#8217;s fee in connection with this Agreement.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Option Event.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No Put Option Event has occurred and is continuing, and no event has occurred and is continuing which, with the giving of notice or passage of time, or both, would constitute a Put Option Event.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Obligors have disclosed to the Purchasers all agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that, in each case, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. All information heretofore furnished to the Purchaser Agent or any Purchaser by or on behalf of the Company for purposes of or in connection with any Transaction Document or any transaction contemplated hereby, including with respect to Clinical Trial Applications and Regulatory Approvals, after giving effect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to all supplements thereto made prior to the Closing Date or the Second Purchaser Payment Date, as applicable, is or will be, true, complete and correct in every material respect, and no report, financial statement, certificate or other information furnished (whether written or oral) by or on behalf of the Company or its Subsidiaries to the Purchasers in connection with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or under any other Transaction Document (in each case, as modified or supplemented by other information so furnished) contains any material misstatement of fact or omits to state any fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each case, as of the time so made or furnished&#59; provided, that, with respect to financial projections, estimates, budgets or other forward-looking information, the Company and its Subsidiaries represent only that such information was prepared in good faith based upon assumptions believed by the Obligors to be reasonable at the time such information was prepared (it being understood that (a) such information is as to future events, is not to be viewed as facts, and is subject to significant uncertainties and contingencies, many of which are beyond the control of the Company and its Subsidiaries, (b) no assurance can be given that any particular projection, estimate, budget or forecast will be realized and (c) actual results during the period or periods covered by any such projections, estimate, budgets or forecasts may differ significantly from the projected results and such differences may be material).</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 3.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Compliance, Employee and Labor Matters&#59; Pension Matters. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Except as could not reasonably be expected, either individually or in the aggregate, to result in a Material Adverse Effect, (i) each Plan is in compliance with the applicable provisions of ERISA, the Code and other federal or state laws and (ii) each Plan that is intended to be a qualified plan under Section 401(a) of the Code has received a favorable determination letter from the IRS to the effect that the form of such Plan is qualified under Section 401(a) of the Code and the trust related thereto has been determined by the IRS to be exempt from federal income tax under Section 501(a) of the Code, or an application for such a letter is currently being processed by the IRS, and, to the Knowledge of the Obligors, nothing has occurred that would prevent or cause the loss of such tax-qualified status.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">There are no pending or, to the Knowledge of the Obligors, threatened or contemplated claims, actions or lawsuits, or action by any Governmental Authority, with respect to any Plan that, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.  There has been no prohibited transaction or violation of the fiduciary responsibility rules with respect to any Plan that, either individually or in the aggregate, has had or could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">No ERISA Event has occurred, and no Obligor nor any ERISA Affiliate is aware of any fact, event or circumstance that, either individually or in the aggregate, could reasonably be expected to constitute or result in an ERISA Event with respect to any Pension Plan that, either individually or in the aggregate, has had or could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The present value of all accrued benefits under each Pension Plan (based on those assumptions used to fund such Pension Plan) did not, as of the last annual valuation date prior to the date on which this representation is made or deemed made, exceed the value of the assets of such Pension Plan allocable to such accrued benefits by a material amount.  As of the most recent valuation date for each Multiemployer Plan, the potential liability of any Obligor or any ERISA Affiliate for a complete withdrawal from such Multiemployer Plan (within the meaning of Section 4203 or Section 4205 of ERISA), when aggregated with such potential liability for a complete withdrawal from all Multiemployer Plans, is zero.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">To the extent applicable, each Foreign Plan has been maintained in compliance with its terms and with the requirements of any and all Applicable Law and has been maintained, where required, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in good standing with applicable regulatory authorities, except to the extent that the failure so to comply could not reasonably be expected, either individually or in the aggregate, to result in a Material Adverse Effect.  Neither the Company nor any of its Subsidiaries has incurred or could reasonably be expected to incur any material obligation in connection with the termination of or withdrawal from any Foreign Plan.  The present value of the accrued benefit liabilities (whether or not vested) under each Foreign Plan that is funded, determined as of the end of the most recently ended fiscal year of the Company or any of its Subsidiaries, as applicable, on the basis of actuarial assumptions, each of which is reasonable, did not exceed the current value of the property of such Foreign Plan by a material amount, and for each Foreign Plan that is not funded, the obligations of such Foreign Plan are properly accrued.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Neither the Company nor any of its Subsidiaries has any liability under ERISA or the Code with respect to any citizen of the United States who performs services outside of the United States.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As of the Closing Date, and except as disclosed to Purchaser Agent in writing after the Closing Date, there are no collective bargaining agreements covering employees of any Obligor or any of its Subsidiaries. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IV</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Purchaser represents and warrants to the Company, as of the Closing Date and on the Second Purchaser Payment Date, the following&#58; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Organization.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such Purchaser is a duly organized and validly existing under the laws of its jurisdiction of organization.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorization.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such Purchaser has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder.  The Transaction Documents have been duly authorized, executed and delivered by such Purchaser and each Transaction Document constitutes the valid and binding obligation of such Purchaser, enforceable against such Purchaser in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally or general equitable principles. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Broker&#8217;s Fees.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such Purchaser has not taken any action that would entitle any Person to any commission or broker&#8217;s fee in connection with the transactions contemplated by the Transaction Documents. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conflicts.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither the execution and delivery of this Agreement or any other Transaction Document to which such Purchaser is a party nor the performance or consummation of the transactions contemplated hereby or thereby will&#58; (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of&#58; (i) any law, rule or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which such Purchaser or any of its assets or properties may be subject or bound&#59; or (ii) any contract, agreement, commitment or instrument to which such Purchaser is a party or by which such Purchaser or any of its assets or properties is bound or committed&#59; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the organizational or constitutional documents of such Purchaser&#59; or (c) require any notification to, filing with, or consent of, any Person or Governmental Authority, except, in the case of the foregoing clauses&#160;(a) or (c), as would not, individually or in the aggregate, have a material adverse effect on the ability of such Purchaser to perform any of its obligations under the Transaction Documents. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 4.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Purchaser has sufficient funds (or sufficient commitments from its investors to provide funds) available to make its Pro Rata Portion of the Purchaser Payments. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE V</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> COVENANTS</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the date hereof through and including the end of the Revenue Interest Period, the following covenants shall apply&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notices&#59; Access&#59; Information.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Obligors shall provide the written notice to the Purchaser Agent and the Purchasers of the following events&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Promptly (and in any event within two (2) Business Days) upon Knowledge thereof, the occurrence of any Put Option Event, any event which, with the giving of notice or passage of time, or both, would constitute a Put Option Event, or any breach or default by any Obligor or Subsidiary of any covenant, agreement or other provision of this Agreement or any other Transaction Document&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Promptly (and in any event within two (2) Business Days) upon Knowledge thereof, the occurrence of any Material Adverse Effect or any event which could reasonably be expected to have a Material Adverse Effect&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">Within five (5) Business Days upon (A) entry into any new Material Contract or amendment to any Material Contract, the Beike License Agreement or the Dunkirk Lease, which notice shall attach a copy of such Material Contract or amendment and, unless the Obligors have already publicly disclosed such information, set forth the material terms of such Material Contract or amendment with a description of its likely impact on the Company&#8217;s and its Subsidiaries&#8217; business or financial condition or (B) (x) receipt of written notice of, or otherwise obtaining Knowledge of, any default or event of default under, or (y) any termination (other than expiration in accordance with its terms) of, any Material Contract, the Beike License Agreement or the Dunkirk Lease&#59;  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Promptly (and in any event within five (5) Business Days) upon Knowledge thereof, any litigation or proceedings to which the Company or any Subsidiary is a party or which could reasonably be expected to have a Material Adverse Effect or which challenge the validity of the Transaction Documents or any of the transactions contemplated therein</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Promptly (and in any event within five (5) Business Days) upon Knowledge thereof, the occurrence of (i) a manufacturing disruption which has had, or could reasonably be expected to have, individually or in the aggregate, a material adverse effect on the level of Net Sales of the Included Products or (ii) any circumstance, event or condition that has resulted in, or could reasonably be expected to result in, a recall of any Included Product&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Promptly (and in any event within five (5) Business Days) (A) upon Knowledge thereof, (i) any infringement by any Included Product of any Intellectual Property of a Third Party, (ii) any infringement by any Third Party of any Product Intellectual Property and (iii) any infringement by a Third Party of any other Intellectual Property material to the conduct of the Obligors&#8217; business, and (B) after receipt of any written notice from a Third Party alleging or claiming that the making, having made, using, importing, offering for sale, or selling of any Included Product in the Covered Territory infringes any Patents of such Third Party, a copy of such notice&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">Promptly (and in any event within five (5) Business Days of the occurrence thereof), the Company&#8217;s submission to the FDA (or any foreign equivalent) of any application for any Regulatory Approval of an Included Product in the Covered Territory, and&#47;or the acceptance for review by the FDA (or such foreign equivalent) of such application&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">Promptly (and in any event within five (5) Business Days of the occurrence thereof), the FDA Approval Date or any Obligor&#8217;s receipt of any other Regulatory Approval of an Included Product in the Covered Territory&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Promptly (and in any event within five (5) Business Days) of the receipt, (a) prior to the Milestone, any material written communication from the FDA, and (b) from and after the occurrence of the Milestone, any material written communication from the FDA regarding Anktiva&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Promptly (and in any event within five (5) Business Days), (a) prior to the Milestone, receipt of material data with respect to any Clinical Trial, or any other material update with respect to any Clinical Trial, together with a copy of such data and any other relevant materials, and (b) from and after the occurrence of the Milestone, receipt of material data with respect to any Clinical Trial regarding Anktiva, or any other material update with respect to any Clinical Trial regarding Anktiva, together with a copy of such data and any other relevant materials&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Not less than ten (10) calendar days prior thereto, any change in, or amendment or alteration of, any Obligor&#8217;s legal name, form of legal entity or jurisdiction of organization, or any change in the address for the chief executive office of any Obligor&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">To the extent permitted by Applicable Law, promptly following receipt by any Obligor or any Subsidiary of any written notice, claim or demand challenging the legality, validity, enforceability or ownership of any Intellectual Property of any Obligor or Subsidiary or pursuant to which any Third Party commences or threatens any action, suit or other proceeding against such Obligor or Subsidiary and relating to (a) prior to the Milestone, any Included Product, and (b) from and after the occurrence of the Milestone, Anktiva, the Obligors shall (i) inform the Purchasers in writing of such receipt and (ii) furnish the Purchasers with a copy of such notice, claim or demand, or if such notice is not in writing, furnish to the Purchasers a written summary describing in reasonable detail the contents thereof&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">Promptly (and in any event, within five (5) Business Days), any material change in accounting policies or financial reporting practices by the Company or any Subsidiary&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.57pt">As soon as possible, and in any event within ten (10) Business Days after the occurrence of any ERISA Event that, either individually or together with any other ERISA Events, could reasonably be expected to result in liability of the Company and its Subsidiaries in an aggregate amount exceeding $2,500,000&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">Not less than fifteen (15) Business Days prior thereto, any Change of Control.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any documents required to be delivered pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which the Obligors have (A) posted such documents on an electronic data room to which Purchaser Agent and the Purchasers have sole access and the contents of which Purchaser Agent and the Purchasers have unrestricted ability to view, download and print and (B) notified Purchaser Agent and the Purchasers in writing of the availability of each such document, including a detailed description of the location of such document in the data room and which specific provision(s) and&#47;or requirement(s) of this Agreement such document relates. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Maintenance of Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each of the Obligors shall keep and maintain, cause its Subsidiaries to keep and maintain, and use commercially reasonable efforts to cause its Affiliates and Licensees to keep and maintain, at all times, full and accurate books of account and records adequate to correctly reflect (and in sufficient detail to permit the Purchaser Agent to confirm the accuracy of) all payments paid and&#47;or payable with respect to the Revenue Interests.  Such records shall be kept and maintained for a minimum of seven (7) years from the end of the calendar year to which they pertain.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Inspections and Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Obligors shall, and shall cause their Subsidiaries to, at the sole cost of the Obligors, allow Purchaser Agent, during regular business hours upon reasonable prior written notice, to visit and inspect any of the Obligors&#8217; and their Subsidiaries&#8217; offices and properties where the Obligors and their Subsidiaries keep and maintain their books and records relating or pertaining to the Revenue Interests and the Collateral for purposes of conducting an audit of such books and records, to examine and make abstracts or copies from any such books and records, to conduct a collateral audit and analysis of its operations and the Collateral and to conduct an audit of Net Sales.  Such audits shall be conducted no more often than once every year unless (and more frequently if) a Put Option Event has occurred and is continuing. The Obligors shall include in all Out-Licenses it enters into after the Closing Date provisions permitting them to audit such Licensee and shall use commercially reasonable efforts to include terms and conditions consistent in all material respects with the Purchasers&#8217; rights to audit Company set forth in this Section 5.01(c), and each Obligor will exercise all applicable rights under such provisions, and share with Purchaser Agent the results of such inspections and audits, promptly upon written request from Purchaser Agent to do so.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Purchaser Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the Revenue Interest Period, the Purchasers shall be entitled to a quarterly update call or meeting (in person, via teleconference or videoconference or at a location designated by the Purchaser Agent) to discuss the reports delivered by the Obligors pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the progress of sales and product development and marketing efforts made by the Obligors, the status and the historical and potential performance of the Included Products, any regulatory developments or such other matters that the Purchasers deem appropriate. Notwithstanding the foregoing, after the occurrence and during the continuance of a Put Option Event, the Required Purchasers shall have the right, as often, at such times and with such prior notice, as the Required Purchasers shall determine, in their reasonable discretion, to have such update meetings or inspect any records and operations of the Obligors and their Subsidiaries. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reports.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Periodic Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Obligors shall deliver to the Purchaser Agent the following financial statements, reports and certificates&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">as soon as available, but no later than forty-five (45) days after the last day of the first three calendar quarters of each fiscal year, (A) a company prepared unaudited balance sheet of the Company and its Subsidiaries as of such quarter end and the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock (if applicable), redeemable common stock (if applicable) and stockholders&#8217; equity (deficit) and cash flows for the three (3) month period then ended certified by the chief financial officer of the Company, all prepared in accordance with GAAP, subject to normal year-end audit adjustments and the absence of disclosures normally made in footnotes, (B) a statement, on a country-by-country and Included Product-by-Included Product basis, of the amount of gross sales and Net Sales of Included Products during the applicable fiscal quarter (including details of the deductions from gross sales taken in accordance with the definition of Net Sales), the calculation of the Applicable Percentage, the calculation of the amount of Revenue Interest Payment due on such sales for such fiscal quarter, and the exchange rates used, if applicable and (C) a duly completed Compliance Certificate signed by the chief financial officer of the Company&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">as soon as available, but no later than ninety (90) days after the last day of each calendar year, audited consolidated balance sheets of the Company as of such year end and the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock (if applicable), redeemable common stock (if applicable) and stockholders&#8217; equity (deficit) and cash flows for the year then ended, prepared under GAAP, consistently applied, together with a report and opinion on the financial statements and on internal controls and procedures, if available, from any &#8220;Big 4&#8221; accounting firm or any other independent certified public accounting firm acceptable to the Purchaser Agent in its reasonable discretion (which report and opinion shall be prepared in accordance with GAAP and shall not be subject to any qualification, emphasis of matter or statement as to &#8220;going concern&#8221; or scope of audit, except for qualifications or statements relating to (i) such qualification, emphasis of matter or statement related to the impending maturity of the Obligations and&#47;or (ii) changes in accounting principles or practices reflecting changes in GAAP and required or approved by the Company&#8217;s independent certified public accountants), together with a duly completed Compliance Certificate signed by the chief financial officer of the Company&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">promptly following the end of each calendar quarter, but in any event, in each case, no later than forty-five (45) calendar days after the end of such calendar quarter, as applicable, a reasonably detailed quarterly report (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Quarterly Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) setting forth, with respect to such same period, (a) the Clinical Updates, the Regulatory Updates, the Commercial Updates, the Intellectual Property Updates, and any transactions with Affiliates, (b) updates to the Perfection Certificate to reflect any amendments, modifications and updates, if any, to the information in the Perfection Certificate since the Closing Date or the most recent update thereto (to the extent not covered in the Intellectual Property Update), (c) cash flow projections for the four quarter period following such fiscal quarter set forth in a quarter by quarter format, and (d) a financial &#8220;DashBoard&#8221; report which shall include unrestricted cash and Cash Equivalents, marketable securities, revenue for the reporting quarter, and year-to-date revenue (provided that the Obligors shall also provide Purchaser Agent with such additional information regarding the updates included in each such Quarterly Report as Purchaser Agent may reasonably request from time to time). The Obligors shall prepare and maintain and shall use commercially reasonable efforts to cause their respective Licensees to prepare and maintain reasonably complete and accurate records of the information to be disclosed in each Quarterly Report. In addition, the Obligors shall provide the Purchaser Agent with a written or telephonic update within ten (10) Business Days following (1) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any material development with respect to any prior (i) Clinical Update, (ii) the Regulatory Update, (iii) Commercial Update or (iv) Intellectual Property Update and (2) any serious adverse event in the Clinical Trials&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">as soon as practicable, and in any event not later than forty-five (45) days after the commencement of each fiscal year of the Company, beginning with the fiscal year commencing January 1, 2024, an annual business plan and budget of the Company and its Subsidiaries on a consolidated basis for the then current fiscal year containing, among other things, projections for each quarter of such fiscal year, all approved by the Board of the Company&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">no later than five (5) days after each regularly-scheduled quarterly meeting of the Board of the Company or any Subsidiary, the board kit and other materials delivered to the directors in connection with any such meeting&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (1) such materials may be redacted to information relating to the potential refinancing of the obligations under this Agreement or repurchase of the Revenue Interests, and (2) if the Obligors, upon the advice of counsel, reasonably determine that any such information constitutes attorney-client privileged information and the disclosure thereof would adversely impair the attorney-client privilege between the Obligors and such counsel with respect to such information, then the Obligors will permit the Purchaser Agent and the Purchasers to enter into a customary common interest agreement with respect to such information and, unless and until the Purchaser Agent and the Purchasers have entered into such agreement, the Obligors shall be entitled to withhold delivery of, or redact, any such information (and only such information) from the Purchaser Agent and the Purchasers&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Obligors shall disclose that the information is being withheld on the foregoing basis&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">without limiting the generality of the above </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">clause (v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, promptly after any reasonable request by the Purchaser, copies of any detailed audit reports, management letters or recommendations submitted to the Board (or the audit committee of the Board) by independent accountants in connection with the accounts or books of the Company or any Subsidiary, or any audit of any of them&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">promptly after the furnishing thereof, copies of any material statement or report furnished to any holder of debt securities of the Company or any Subsidiary pursuant to the terms of any indenture, loan or credit or similar agreement&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">promptly, and in any event within five (5) Business Days after receipt thereof by the Company or any Subsidiary thereof, copies of each written notice or other correspondence received from the SEC (or comparable agency in any applicable non-U.S. jurisdiction) concerning any investigation or possible investigation or other material inquiry by such agency regarding financial or other operational results of the Company or any Subsidiary&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">as soon as practicable upon the reasonable request of the Purchasers, copies of the most recent monthly statements for each deposit account, securities account and other bank account of the Company and its Subsidiaries&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">promptly upon request, such other information as Purchaser Agent may from time to time reasonably request&#59; provided that, if the Obligors, upon the advice of counsel, reasonably determine that any such information constitutes attorney-client privileged information and the disclosure thereof would adversely impair the attorney-client privilege between the Obligors and such counsel with respect to such information, then the Obligors will permit the Purchaser Agent and the Purchasers to enter into a customary common interest agreement with respect to such information and, unless and until the Purchaser Agent and the Purchasers have entered into such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, the Obligors shall be entitled to withhold delivery of, or redact, any such information (and only such information) from the Purchaser Agent and the Purchasers&#59; provided that the Obligors shall disclose that the information is being withheld on the foregoing basis.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any documents required to be delivered pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which (A) the Obligors posts such documents, or provides a link thereto, on their website on the internet at their website address or (B) such documents are posted on the Obligors&#8217; behalf on the internet or an intranet website, if any, to which Purchaser Agent and the Purchasers have access.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Reconciliation Reports&#59; Updates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Concurrently with the delivery of financial statements pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 5.02(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above, the Obligors shall produce and deliver to the Purchaser Agent&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">a Reconciliation Report for such quarter or year, together with a certificate signed by the chief financial officer of the Company, certifying that to the Knowledge of the Obligors (i) such Reconciliation Report is a true and complete copy and (ii) any statements and any data and information therein prepared by the Obligors are true, correct and complete in all material respects. Upon request by Purchaser Agent, the Obligors and Purchaser Agent shall meet in person or by teleconference to discuss each Reconciliation Report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">the insurance binder or other evidence of insurance for any insurance coverage of the Company or any Subsidiary that was renewed, replaced or modified during the period covered by such Quarterly Report&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">within a reasonable time after the receipt by the Purchaser Agent or the Purchasers of any report or notice from the Obligors or upon the occurrence of any material event affecting the Obligors, the Obligors shall provide such other information about such report, notice or material event as any Purchaser or the Purchaser Agent may from time to time reasonably request.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything set forth above to the contrary, during any MNPI Notice Period, the Obligors shall deliver all notices and reports required to be furnished pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or otherwise pursuant to any Transaction Documents (any such notice, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MNPI Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Oberland Capital Management LLC (at kwiggert&#64;oberlandcapital.com, attention&#58; Kristian Wiggert (or such other person as specified by Purchaser Agent in writing from time to time)), in which case the Obligors&#8217; obligations to deliver or pay any such MNPI Notice under any Transaction Document, whether under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or otherwise shall be deemed satisfied as to the Purchaser Agent or Purchasers otherwise entitled to receive such MNPI Notice, as applicable.   </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Law&#59; Existence and Maintenance of Properties&#59; Payment of Obligations. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors shall, and shall cause their Subsidiaries to, (i) comply with all material federal, state, local and foreign laws, regulations and orders applicable to the Obligors or any Subsidiary or any of their respective assets, including all Environmental Laws, (ii) obtain and maintain any and all material licenses, permits, franchises, governmental authorizations, Intellectual Property or other rights necessary for the ownership of its properties and the advantageous conduct of its business and as may be required from time to time by Applicable Law and (iii) maintain each material Regulatory Approval necessary to sell the Included Products within the Covered Territory, except in the case of (i) or (ii) where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Obligors shall, and shall cause their Subsidiaries to, (i) (x) maintain and preserve in full force and effect its legal existence, (y) maintain its good standing (to the extent the concept is applicable under such jurisdiction) under the laws of the jurisdiction of its incorporation or formation, as the case may be, and (z) maintain its qualification to do business in every other jurisdiction where the nature of its business or its properties makes such qualification necessary (except, in the case of clause (z), where the failure to be so qualified or licensed would not reasonably be expected to have a Material Adverse Effect)&#59; and (ii) maintain all material tangible properties in good working order and condition (normal wear and tear and damage by casualty excepted) and from time to time make all necessary repairs to and renewals and replacements of such properties, except to the extent that the failure to do so would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Each Obligor and each Subsidiary shall pay and discharge all its obligations and liabilities, including (i) prior to the date on which penalties attach thereto, all federal and state and other material Taxes imposed upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by such Obligor or Subsidiary, (ii) as the same shall become due and payable, all lawful claims which, if unpaid, would by law become a Lien upon its property (other than Permitted Liens), and (iii) prior to the date on which such Indebtedness shall become delinquent or in default, all Indebtedness, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Confidentiality&#59; Public Announcement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Non-Disclosure and Non-Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (x) In handling any Confidential Information of the Obligors and their Subsidiaries, the Purchaser Agent and the Purchasers and (y) in handling any confidential information of the Purchaser Agent and the Purchasers, the Obligors and their Subsidiaries (in either case, as applicable, the party receiving Confidential Information, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, the party disclosing such Confidential Information, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) shall, in each case, exercise the same degree of care that they exercise for their own proprietary information (but in no event less than a reasonable standard of care).  The Receiving Party agrees to&#58; (a) hold any Confidential Information received in confidence&#59; (b) use or permit the use of the Confidential Information solely in connection with preparing, amending, executing, negotiating, administering, defending and enforcing the Transaction Documents (the &#8220;Permitted Purpose&#8221;)&#59; and (c) except as otherwise permitted herein, not disclose the Confidential Information to any person or entity not a party to this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement&#58; (a)either Receiving Party may disclose such Confidential Information  (i) to its Affiliates and to the Receiving Party&#8217;s and its Affiliates&#8217; directors, officers (including managing members or partners), limited partners, directors, employees, accountants, attorneys, financial advisors or consultants (together, &#8220;Representatives&#8221;) who (A) have a need to know the Confidential Information for the Permitted Purpose, (B) are apprised of the confidential nature of the Confidential Information and (C) are under written or professional obligations of confidentiality, non-disclosure and non-use in respect of Confidential Information to Receiving Party at least as stringent as those contained herein or (ii) as required by law, regulation, subpoena or court order or otherwise in connection with a judicial, administrative or governmental proceeding, provided that, in the event that the Receiving Party is required or requested to make such disclosure, the Receiving Party shall, to the extent legally permissible, notify the Disclosing Party in advance of the disclosure so as to allow the Disclosing Party an opportunity to seek (at the Disclosing Party&#8217;s sole expense) a protective order or other appropriate remedy&#59; in the case of disclosures of information pertaining to the Purchaser Agent and&#47;or the Purchasers, provided, further, that such notice and opportunity shall not be required in respect of (A) disclosures required pursuant to the Securities Act, the Exchange Act, or the listing rules of the Nasdaq Capital Market, the Nasdaq Global Select Market, the Nasdaq Global Market or the New York Stock Exchange (or any nationally recognized securities exchange that is a successor to any of the foregoing)  on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the Company&#8217;s common stock is listed or (B) disclosures to any regulatory or self-regulatory authority as required by Applicable Law in connection with an examination, audit, inspection, inquiry, request or general supervisory oversight, and (b) the Purchaser and Purchaser Agent may disclose such Confidential Information (i) so long as such Persons are subject to customary confidentiality obligations, in connection with a Purchaser&#8217;s own financing or securitization transactions and upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction, (ii) to prospective transferees (other than those identified in the immediately preceding clause (i)) or purchasers of any interest in the Revenue Interests (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the Purchasers and Purchaser Agent shall obtain such prospective transferee&#8217;s or purchaser&#8217;s agreement to the terms of this provision or to similar confidentiality terms), (iii) as Purchaser Agent reasonably considers appropriate in exercising remedies under the Transaction Documents or (iv) to any actual or potential investors, co-investors, members, and partners or their Affiliates so long as such Persons are subject to confidentiality, non-use and non-disclosure obligations in respect of such Confidential Information at least as restrictive as those contained herein.  The Receiving Party shall be responsible for any breaches of this Section by its Representatives. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">In addition, subject to the foregoing, the prohibitions on disclosure in this Section shall not apply to information that the Receiving Party can demonstrate&#58; (i) is in the public domain or in the Receiving Party&#8217;s possession when disclosed to the Receiving Party, or becomes part of the public domain after disclosure to the Receiving Party&#59; or (ii) is disclosed to the Receiving Party by a third party, if the Receiving Party does not know that the third party is prohibited from disclosing the information.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Notwithstanding anything herein to the contrary, (i) the Purchasers and Purchaser Agent may use Confidential Information for the development of client databases, reporting purposes and market analysis, (ii) after the Closing Date, any Purchaser may disclose the transaction contemplated by the Transaction Documents on its website and in marketing materials (which may include use of logos of one or more of the Obligors) and (iii) on the Closing Date or such other date mutually agreed to by the Company and Purchaser Agent, the Obligors shall issue the Press Release.  Except as otherwise provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a party may not use the name, likeness or trademarks of the other party or its Representatives for any purpose, including without limitation, to express or imply any relationship or affiliation between the parties, or any endorsement of any product or service, without the other party&#8217;s prior written consent. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The agreements provided under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Security Interest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Revenue Interest Period, and at all times until the Obligations are paid and performed in full (other than inchoate indemnity obligations for which no claim has been made), each Obligor shall grant in favor of the Purchaser Agent, for the benefit of the Purchasers, a valid, continuing, first priority (subject to Permitted Priority Liens) perfected lien on and security interest in the Collateral described in the Security Agreement. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Further Assurances&#59; Creation&#47;Acquisition of Subsidiaries&#59; Additional Collateral&#59; Control Agreements.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Without limiting the obligations of the Obligors in the Security Agreement or in the other Transaction Documents, each Obligor hereby agrees to take such action and execute, acknowledge and deliver, and cause each of its Subsidiaries to take such action and execute, acknowledge and deliver, at its sole cost and expense, such agreements, instruments or other documents as the Purchaser Agent may reasonably request from time to time in order (i) to carry out more effectively the purposes of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement and the other Transaction Documents, (ii) to subject to valid and perfected first priority Liens any of the Collateral or any other property of any Obligor and its Subsidiaries (other than Excluded Subsidiaries so long as such Subsidiaries remain Excluded Subsidiaries) intended to be Collateral hereunder free and clear of Liens (other than Permitted Liens) and to assign the Revenue Interests to the Purchasers, (iii) to establish and maintain the validity and effectiveness of any of the Transaction Documents and the validity, perfection and priority of the Liens intended to be created thereby (including, without limitation, making all filings and registrations), and (iv) to better assure, convey, grant, assign, transfer and confirm unto each Purchaser the rights now or hereafter intended to be granted to it under this Agreement or any other Transaction Document.  In furtherance of the foregoing, to the maximum extent permitted by Applicable Law, each Obligor (i) authorizes the Purchaser Agent to execute any such agreements, instruments or other documents in each Obligor&#8217;s name and to file such agreements, instruments or other documents in any appropriate filing office if any Obligor refuses or fails to execute or deliver any of the above reasonably requested agreements, instruments or documents within ten (10) days of the Purchaser Agent&#8217;s request to do so and (ii) authorizes the Purchaser Agent to file any financing statement required hereunder or under any other Transaction Document, and any continuation statement or amendment with respect thereto, in any appropriate filing office without the signature of such Obligor.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Obligors and the Purchasers shall cooperate and provide assistance as reasonably requested by the other party hereto, at the expense of such other party hereto (except as otherwise set forth herein), in connection with any litigation, arbitration, investigation or other proceeding (whether threatened, existing, initiated or contemplated prior to, on or after the date hereof) to which the other party hereto, any of its Affiliates or controlling persons or any of their respective officers, directors, equityholders, controlling persons, managers, agents or employees is or may become a party or is or may become otherwise directly or indirectly affected or as to which any such Persons have a direct or indirect interest, in each case relating to any Transaction Document, the transactions contemplated herein or therein or the Revenue Interests but in all cases excluding any litigation brought by the Company or its Affiliates against the Purchasers or Purchaser Agent or brought by the Purchasers or Purchaser Agent (for itself or on behalf of any Indemnified Party) against any Obligor.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">In the event (x) the Company or any of its Subsidiaries creates or acquires any Subsidiary (other than an Excluded Subsidiary) or (y) any Excluded Subsidiary ceases to be an Excluded Subsidiary, the Company shall provide prompt written notice to the Purchaser Agent of the creation or acquisition of such new Subsidiary or of such Excluded Subsidiary ceasing to be an Excluded Subsidiary, as applicable, and, promptly (and in any event no later than the earlier of any Transfer of any assets to such Subsidiary and thirty (30) days after the creation or acquisition thereof or any such Subsidiary ceasing to be an Excluded Subsidiary, as applicable), take all such action as may be reasonably required by the Purchaser Agent or any Purchaser to cause such Subsidiary to become a Subsidiary Guarantor, including without limitation by executing and delivering a Guaranty (or a joinder thereto), becoming a party to the Security Agreement (or delivering a foreign security agreement in form and substance reasonably satisfactory to Purchaser Agent) and delivering such proof of corporate action, incumbency of officers, opinions of counsel and other documents as requested by the Purchaser Agent.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">With respect to any Collateral acquired after the Closing Date by any Obligor that is not already subject to the Lien created by any of the Transaction Documents or specifically excluded from the requirement to be subject to such Lien in the Transaction Documents, the Obligors shall promptly (and in any event within thirty (30)days after the acquisition thereof) (i) execute and deliver to the Purchaser Agent such amendments or supplements to the relevant Transaction Documents or such other documents as the Purchaser Agent shall deem necessary or advisable to grant for its benefit, a Lien on such property subject to no Liens other than Permitted Liens, and (ii) take all actions necessary to cause such Lien to be duly perfected in accordance with all applicable requirements of Applicable Law, including the filing of financing statements in such jurisdictions as may be reasonably requested by the Purchaser Agent. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Obligor shall otherwise take such actions and execute and&#47;or deliver to the Purchaser Agent such documents as the Purchaser Agent shall reasonably require to confirm the validity, perfection and priority of the Lien of the Security Agreement on such after-acquired properties.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors (excluding VivaBioCell, S.p.A. (to the extent it becomes an Obligor)) shall not establish or maintain any bank account except for bank accounts with Globally Systemically Important Banks&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Obligors may maintain the bank accounts set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.06(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter as of the Closing Date (which bank accounts constitute all of the deposit accounts, securities accounts or other similar accounts maintained by the Obligors on the Closing Date that are not held with Globally Systemically Important Banks) until the date that is ninety (90) days following the Closing Date. In addition, no Obligor will establish or maintain any bank account unless (x) Purchaser Agent is provided at least ten&#160;(10) Business Days&#8217; prior written notice of the establishment of such account and (y) (I) with respect to any bank account located in the United States, Purchaser Agent, such Obligor and the bank or other financial institution at which the account is to be opened or maintained enter into a Control Agreement regarding such bank account prior to depositing any funds into such new bank account and in any event within fifteen (15) days following the opening of such new bank account and (II) with respect to any bank account located outside of the United States, such Obligor provide Purchaser Agent with documentation satisfactory to Purchaser Agent in its sole discretion to provide Purchaser Agent with a first-priority perfected security interest in such new bank account&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the foregoing requirement to deliver a Control Agreement or applicable foreign law documentation shall not apply to any Excluded Account, whether now existing or opened hereafter&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the event that any Excluded Account cease to be an Excluded Account it shall be subject to the requirement to deliver a Control Agreement or applicable foreign law documentation as if such account was opened on the day it ceased to be an Excluded Account.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Each Obligor shall keep its and its Subsidiaries&#8217; business and the Collateral insured for risks and in amounts customary for companies in the Obligors&#8217; industry and location. Insurance policies shall be in a form, with companies, and in amounts that are customary for companies in the Obligors&#8217; industry and location&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> such insurance shall at all times be at least as comprehensive as, and in amounts no lower than, the insurance that is in effect on the Closing Date. All property policies applicable to any Obligor shall have a lender&#8217;s loss payable endorsement showing Purchaser Agent as lender loss payee and waive subrogation against Purchaser Agent, and all liability policies applicable to any Obligor shall show, or have endorsements showing, Purchaser Agent as additional insured. Purchaser Agent shall be named as lender loss payee and&#47;or additional insured with respect to any such insurance providing coverage in respect of any Collateral, and Obligors shall endeavor to cause each provider of any such insurance to agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to Purchaser Agent, that it will give Purchaser Agent thirty (30) days prior written notice before any such policy or policies shall be materially diminished or canceled&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if any such provider does not agree to provide such notice, then the applicable Obligor or Subsidiary shall not materially diminish or cancel any such policy or policies without giving Purchaser Agent thirty (30) days prior written notice. At Purchaser Agent&#8217;s request, the Obligors shall deliver certified copies of policies and evidence of all premium payments.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Option&#59; Call Option.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Put Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Upon the occurrence and during the continuance of a Put Option Event, the Purchasers, or the Purchaser Agent on behalf of the Purchasers, will have the option to accelerate and require the Company to repurchase all, but not less than all, of the Revenue Interests and to terminate the Purchaser Commitments for a payment equal to the then-current Put&#47;Call Price as of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the date of the Put Option Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The Purchasers or the Purchaser Agent may exercise the Put Option at any time after the occurrence and during the continuance of a Put Option Event by delivering to the Company written notice thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  If Purchasers (or the Purchaser Agent) exercise the Put Option, then on the date specified in the Put Notice (which may be immediate) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Put Option Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company will pay the Put&#47;Call Price to the Purchaser by wire transfer of immediately available funds to the account or accounts designated by the Purchaser Agent.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Notwithstanding anything to the contrary contained herein, (A) immediately upon the occurrence of a Bankruptcy Event, the Purchasers shall be deemed to have automatically and simultaneously elected to require the Company to repurchase the Revenue Interests and to terminate the Purchaser Commitments and the Put&#47;Call Price shall be immediately due and payable and the Purchaser Commitments shall be immediately terminated, without any further action or notice by any party, and (B) in the case of a Put Option Event constituting a Change of Control, the Purchasers (or Purchaser Agent) may deliver a Put Notice in advance of a Change of Control specifying that the Put Option is exercised contingent upon such Change of Control and that the Put Option Closing Date shall be the date of such Change of Control. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">For the avoidance of doubt, (A) the Purchasers&#8217; election not to exercise the Put Option with respect to a given Put Option Event will not preclude the Purchasers from exercising the Put Option with respect to a continuing or subsequent Put Option Event, (B) a Put Option Event shall be deemed to exist at all times during the period commencing on the date that such Put Option Event occurs to the date on which such Put Option Event is waived in writing pursuant to this Agreement, and (C) a Put Option Event shall &#8220;continue&#8221; or be &#8220;continuing&#8221; until such Put Option Event has been waived in writing by the Purchasers.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Upon the occurrence and during the continuance of a Put Option Event, unless payment of the Put&#47;Call Price has been made when due, the Purchasers and the Purchaser Agent, on behalf of the Purchasers, may exercise all rights and remedies available to the Purchasers or the Purchaser Agent as creditors hereunder and under the other Transaction Documents and Applicable Law (which exercise may be determined in its sole discretion and which such exercise shall not constitute an election of remedies), including enforcement of the Liens created thereby. For the avoidance of doubt, the parties hereto intend for the Revenue Interests to constitute a debt obligation of the Company arising out of a loan made by the Purchasers pursuant to this Agreement in the amount of the Cumulative Purchaser Payments and, in consideration for such loan, the Put&#47;Call Price shall be due and payable at any time the Put Option or the Call Option is exercised or the Obligations are otherwise accelerated hereunder for any reason, whether due to acceleration pursuant to the terms of this Agreement, by operation of law or otherwise (including where bankruptcy filings or the exercise of any bankruptcy right or power, whether in any plan of reorganization or otherwise, results or would result in a payment, discharge, modification or other treatment of the Revenue Interests that would otherwise evade, avoid, or otherwise disappoint the expectations of the Purchasers in receiving the full benefit of the bargained-for Put&#47;Call Price). The Company and the Purchasers acknowledge and agree that none of the Put&#47;Call Price shall constitute unmatured interest, whether under Section 502(b)(2) of the United States Bankruptcy Code or otherwise (except as required for any Tax purpose), but instead is reasonably calculated to ensure that the Purchasers receive the benefit of their bargain under the terms of this Agreement. The Company acknowledges and agrees that the Purchasers shall be entitled to recover the full amount of the Put&#47;Call Price in each and every circumstance such amount is due pursuant to or in connection with this Agreement, including in the case of any Bankruptcy Event, so that the Purchasers shall receive the benefit of its bargain hereunder and otherwise receive full recovery as agreed under every possible circumstance, and, to the fullest extent permitted by maximum law, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise.  The Company further acknowledges and agrees, and, to the fullest extent permitted by Applicable Law, waives any argument to the contrary, that payment of such amounts does not constitute a penalty or an otherwise unenforceable or invalid obligation. Any damages that the Purchasers may suffer or incur resulting from or arising in connection with any breach hereof or thereof by the Company shall constitute secured Obligations.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Call Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  At any time during the Term (but subject to the last sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company will have the option to repurchase all, but not less than all of, the Revenue Interests for a payment equal to the then-current Put&#47;Call Price (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Call Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The Company may exercise the Call Option by delivering to the Purchaser Agent written notice thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Call Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  If the Company exercises the Call Option, then within ten (10) days following the date of delivery of the Call Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Call Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Company will pay the then-current Put&#47;Call Price to the Purchasers by wire transfer of immediately available funds to the account or accounts designated by the Purchaser Agent.  Effective as of the Call Closing Date, all Purchaser Commitments shall immediately terminate. Notwithstanding anything to the contrary contained in this Agreement, the Company may rescind any Call Notice (or make such Call Notice, by its terms, conditioned on the occurrence or non-occurrence of subsequent events) and payment pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must provide the Purchaser Agent with a new notice at least five (5) days prior to any Call Closing Date if the Company has rescinded the notice.  Notwithstanding the foregoing, if the Purchaser Agent and&#47;or Purchasers have issued a Funding Election Notice, the Company will not be permitted to exercise the Call Option (and no Call Closing Date will occur) during the period commencing on the FDA Approval Date through, and including, the earlier of (a) the Second Purchaser Payment Date and (b) thirty (30) days following the FDA Approval Date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Right of Set-off&#59; Sharing of Set-off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any amount payable hereunder is not paid as and when due, each Obligor irrevocably authorizes the Purchasers to proceed, to the fullest extent permitted by Applicable Law, without prior notice, by right of set-off, counterclaim or otherwise, against any assets of such Obligor in any currency that may at any time be in the possession of the Purchaser Agent, any Purchaser or any of their respective Affiliates, to the full extent of all amounts payable to the Purchasers hereunder&#59; provided, however, that the Purchaser Agent shall notify the Obligors of the exercise of such right promptly following such exercise. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Rights Not Exclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The rights provided for herein are cumulative and are not exclusive of any other rights, powers, privileges or remedies provided by this Agreement or Applicable Law.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Obligations of Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In connection with the consummation of a repurchase of the Revenue Interests pursuant to the Put Option or the Call Option, the Purchaser Agent agrees that it will, at the sole cost and expense of the Obligors, after each Purchaser has received payment in full of its Pro Rata Portion of the Put&#47;Call Price, execute and deliver to the Obligors such UCC termination statements and other documents, and take such other actions, as may be necessary and reasonably requested by the Obligors to release (or evidence the release of) the Purchaser Agent&#8217;s Lien on the Collateral and otherwise give effect to such repurchase.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Events of Default.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any one of the following shall constitute an event of default (an &#8220;Event of Default&#8221;) under this Agreement&#58; </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Company fails to make&#58; (i) any payment of the Put&#47;Call Price when due, or (ii) any other payment when due under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or under the other Transaction Documents&#59; provided, with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to this clause (ii), that no more than one time in any twelve consecutive month period, such failure shall not constitute a Put Option Event if the Company makes such payment within three Business Days of the applicable due date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">(i) The Company or any Subsidiary breaches any term, covenant or agreement in any Transaction Document (other than a breach of this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which such breach, if capable of cure, is not cured within ten (10) Business Days of the occurrence thereof, or (ii) the Company or any Subsidiary breaches </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Any Bankruptcy Event.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">There is a default in any agreement to which the Company or any of its Subsidiaries is a party with any Third Party that could entitle or permit such Third Party, after the giving of notice or the expiration of any applicable grace periods, to accelerate the maturity of any Indebtedness in an aggregate amount in excess of (X) prior to the Milestone, $5,000,000 and (Y) from and after the occurrence of the Milestone, $10,000,000 (in either case, even if such Third Party is restricted from accelerating the maturity of such Indebtedness, including pursuant to the terms of a subordination or other similar agreement).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">A default or breach occurs under any subordination, intercreditor or other similar agreement with respect to any Existing Stockholder Indebtedness. For the avoidance of doubt, material defaults or breaches for the purposes of this clause (e) shall include breaches of payment, enforcement and subordination provisions or restrictions.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">If any Permitted Convertible Notes, Existing Stockholder Indebtedness or Subordinated Debt is outstanding at such time, the earlier of (i) 91 days prior to the maturity date of such Permitted Convertible Notes or Existing Stockholder Indebtedness, as applicable, and (ii) the occurrence of any &#8220;fundamental change,&#8221; &#8220;event of default&#8221; or similar event under the terms of such Permitted Convertible Notes or Existing Stockholder Indebtedness, as applicable, giving the holders thereof the right to require the repurchase of, or to accelerate, such Permitted Convertibles Notes or Existing Stockholder Indebtedness.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">One or more judgments, orders, or awards (or any settlement of any claim that, if breached, could result in a judgment, order or award) for the payment of money in an amount, individually or in the aggregate, of at least (i)&#160;$5,000,000 prior to the Milestone and (ii)&#160;$10,000,000 from and after the occurrence of the Milestone  shall be rendered against the Company or any of its Subsidiaries and shall remain unsatisfied, unvacated or unstayed for a period of thirty (30) days after the entry thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that any such judgment, order, award or settlement shall not give rise to a Put Option Event under this Section if and for so long as (A) the amount of such judgment, order, award or settlement is covered by a valid and binding policy of insurance between the defendant and the insurer covering full payment thereof and (B) such insurer has been notified, and has not disputed the claim made for payment, of the amount of such judgment, order, award or settlement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any representation, warranty or statement made or deemed made by or on behalf of any Obligor in any Transaction Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with any Transaction Document or any amendment or modification hereof or thereof, shall&#58; (i) prove to have been incorrect when made or deemed made to the extent that such representation, warranty or statement contains any materiality or Material Adverse Effect qualifier&#59; or (ii) prove to have been incorrect in any material respect when made or deemed made to the extent that such representation, warranty or statement does not otherwise contain any materiality or Material Adverse Effect qualifier.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Any material provision of any Transaction Document shall for any reason cease to be valid and binding on or enforceable against any Obligor, or any Obligor shall so state in writing or bring an action to limit its obligations or liabilities thereunder&#59; or the Security Agreement, the Control Agreements or any other Transaction Document, which purports to create a validly perfected security interest, shall for any reason (other than pursuant to the terms thereof) cease to create a valid security interest in any material portion of the Collateral purported to be covered thereby or such security interest shall for any reason (other than pursuant to the terms of the Transaction Documents) cease to be a perfected and first priority security interest in any material portion of the Collateral subject thereto, subject only to Permitted Liens, in each case, other than as a direct result of any action by the Purchaser Agent or the Purchasers or failure of the Purchaser Agent or any Purchaser to perform an obligation thereof under the Transaction Documents.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">The Company shall fail to issue and deliver, and consummate the sale by the Company and the purchase by the Purchasers of, the Shares upon the exercise by the Purchasers of the Share Purchase Option in accordance with the Option Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company&#8217;s common stock ceases to be listed or admitted for trading on the Nasdaq Capital Market, the Nasdaq Global Select Market, the Nasdaq Global Market or the New York Stock Exchange (or any nationally recognized securities exchange that is a successor to any of the foregoing) and, solely in the case of a voluntary delisting of the Company&#8217;s common stock that is not effected as a result of the failure, or expected failure, to meet applicable listing criteria, the Company&#8217;s common stock continues to not be so listed or admitted for longer than fifteen (15) consecutive Business Days from the occurrence thereof (it being agreed that if the Company&#8217;s common stock is no longer so listed or admitted for any other reason, an immediate Event of Default shall occur).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Following the receipt of Regulatory Approval to Commercialize or Develop Anktiva, (i) the loss of Regulatory Approval to Commercialize or Develop Anktiva (whether voluntary or involuntary), or (ii) the receipt by the Company or any Subsidiary of the Company of any written notice from the FDA or any other Regulatory Authority of pending recommendation or final decision to withdraw Regulatory Approval to Commercialize or Develop Anktiva, in each case, with respect to the United States, which withdrawal or removal will last, or is reasonably expected to last, more than one hundred eighty (180) days.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property&#59; Regulatory Approvals.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Each Obligor shall, at its sole expense, either directly or by causing any Subsidiary to do so, use commercially reasonable efforts (including taking legal action to specifically enforce the applicable terms of any License Agreement) to prepare, execute, deliver and file any and all agreements, documents or instruments which are necessary to diligently prosecute and maintain the Material Patents with the intent to protect the Included Products. Each Obligor shall, at its sole expense without any reduction in the Revenue Interests, either directly or by causing a Subsidiary to do so, use commercially reasonable efforts to diligently defend or assert all Product Intellectual Property against infringement or interference by any other Persons, and against any claims of invalidity or unenforceability (including, without limitation, by bringing any legal action for infringement or defending any claim of invalidity or action of a Third Party for declaratory judgment of non-infringement or non-enforceability), except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect. The Obligors shall not, shall cause its Subsidiaries not to, and shall use their commercially reasonable efforts to cause any Licensee not to, disclaim or abandon, or fail to take any action necessary to prevent the disclaimer or abandonment of, the Material Patents, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">In the event that any Obligor becomes aware that the Development, use, Manufacture or Commercialization of any Included Product infringes or violates any Intellectual Property that is owned or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">controlled by a Third Party, such Obligor shall use commercially reasonable efforts to attempt to secure the right to use such Intellectual Property on behalf of itself and any affected Licensee, as applicable, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect, and shall pay all reasonable costs and amounts associated with obtaining any such license, without any reduction in the Revenue Interests.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">If any Obligor or Subsidiary recovers monetary damages from a Third Party in an action brought for such Third Party&#8217;s infringement of any Product Intellectual Property in connection with the exploitation of any product, therapy, or service that actually or prospectively competes with any Included Product or the market for such Included Product in the Covered Territory, where such damages (whether in the form of judgment or settlement) are awarded for loss of sales of such Included Product in the Covered Territory, then (i) such damages will be allocated first to the reimbursement of any expenses incurred by such Obligor or Subsidiary in bringing such action (including reasonable attorney&#8217;s fees) not already reimbursed from other damages awarded under the same action, (ii) any remaining amount of such damages will be reduced, if applicable, to comply with any required allocation of recovered damages with such Obligor&#8217;s or Subsidiary&#8217;s licensors or (sub)licensees, and (iii) any residual amount of such damages after application of clauses (i) and (ii) will be treated as Net Sales of the Included Products for purposes of calculating Revenue Interest Payments under this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Each Obligor shall directly, or through an Affiliate or Licensee, take any and all actions and prepare, execute, deliver and file any and all agreements, documents or instruments to secure and maintain, all applicable Regulatory Approvals, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall use the proceeds of the Purchaser Payments solely as working capital, for general corporate purposes and to fund its general business requirements (including, but not limited to, progressing regulatory approval efforts, pre-commercialization activities and clinical development programs, funding other research and development activities and for capital expenditures) in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Protective Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">No Obligor nor any of their Subsidiaries shall, without the prior written consent of the Purchaser Agent&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">forgive, release or compromise any amount owed to such Obligor or Subsidiary and relating to the Revenue Interests, other than the forgiveness, release or compromise in connection with the collection, settlement or compromise thereof in the ordinary course of business&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">hold any Anktiva Collateral (as defined in the Security Agreement) at any location leased under the Dunkirk Lease, or conduct any Development, Manufacture and&#47;or Commercialization of Anktiva at any location leased under the Dunkirk Lease&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">create, incur, assume or suffer to exist any Indebtedness, except for Permitted Indebtedness&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">create, incur, assume or suffer to exist any Lien upon any of its property or assets of any kind (real or personal, tangible or intangible), except for Permitted Liens&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">make or permit to exist any Investment, except for Permitted Investments, or make any Investment after the Closing Date in AccessBioScience, LLC&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">declare or make, directly or indirectly, any Restricted Payment, or incur any obligation (contingent or otherwise) to do so, except that (A) each Subsidiary may make Restricted Payments to holders of Equity Interests on a ratable basis, (B) the Company may declare and make dividend payments or other distributions payable solely in its Qualified Equity Interests, (C) the Company may make repurchases of Equity Interests to the extent deemed to occur upon the withholding of a portion of the Equity Interests granted or awarded to the holder thereof to pay for the taxes payable by such person upon such grant or award (or upon vesting, exercise or settlement thereof) or in connection with an equity award exchange or option repricing program approved by the Board with respect to compensatory Equity Interests held by any current or former officer, director, employee or consultant of the Company or any Subsidiary, (D) the Company may (i) pay cash in lieu of fractional shares of its Equity Interests in connection with issuance of Qualified Equity Interests of the Company pursuant to Permitted Acquisitions and (ii) pay cash in lieu of fractional shares upon the exercise of warrants, options or other securities convertible into or exercisable for Qualified Equity Interests of the Company, (E) the Company and its Subsidiaries may make Restricted Payments constituting Permitted Debt Payments, (F) the Company and its Subsidiaries may make Restricted Payments consisting of the repurchase, redemption or other acquisition or retirement for value of any Qualified Equity Interests of the Company held by any employee, director or consultant of the Company or any Subsidiary of the Company (other than any Permitted Holder) pursuant to any employee equity agreement, stock option agreement, stock ownership arrangement or other benefit plan upon the death, disability retirement or termination of employment of such employee, director, consultant or officer&#59; provided, that the amount of Restricted Payments made pursuant to this clause (F) shall not exceed (i) $2,500,000 during any fiscal year prior to the Milestone and (ii) $10,000,000 during any fiscal year from and after the occurrence of the Milestone, (G) the Company may pay fees and expenses to Affiliates in respect of corporate, general and administrative and other support services provided pursuant to the Affiliate Agreements&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amounts paid by the Company pursuant to this clause (G) during any fiscal year, net of any payments received by Obligors from Affiliates that are not Subsidiaries during such fiscal year, shall not exceed (i) prior to the Milestone, $7,500,000 and (ii) from and after the occurrence of the Milestone, $20,000,000, (H) the purchase of Permitted Bond Hedging Agreements solely to the extent permitted under clause (n) of the definition of &#8220;Permitted Investments,&#8221; and any settlement, unwinding or termination of such Permitted Bond Hedging Agreements, whether according to their terms or otherwise&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> any such settlement or termination shall not require any additional cash payments (on a net basis after taking into account any cash received in respect of a concurrent unwind of other Permitted Bond Hedging Agreements and excluding any cash in lieu of fractional shares) by the Company or any Subsidiary, and (I) so long as no Put Option Event has occurred and is continuing and the Existing Stockholder Indebtedness has been repaid in full or converted or exchanged for or into Qualified Equity Interests of the Company, in either case in accordance with this Agreement, the Company and its Subsidiaries may make other Restricted Payments in an aggregate amount not to exceed, prior to the Milestone, $5,000,000 per fiscal year of the Company and, from and after the occurrence of the Milestone, $10,000,000 per fiscal year of the Company&#59;  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">make (or give any notice or make any election with respect thereto) any payment  (including payments of interest) or prepayment or redemption, settlement  or acquisition for value of (including without limitation, by way of depositing money or securities with the trustee with respect thereto before due for the purpose of paying when due), refund, refinance or exchange of any Indebtedness of the Obligors or any Subsidiary (other than the Indebtedness arising under the Transaction Documents and Permitted Debt Payments)&#59;  </font></div><div style="margin-top:12pt;text-indent:54pt"><font><br></font></div><div style="margin-top:12pt;text-indent:54pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">engage in any material line of business substantially different from those lines of business conducted by the Obligors and their Subsidiaries on the Closing Date or any business reasonably related, incidental, or complementary thereto or a reasonable extension thereof&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">amend, modify or change its Organization Documents in a manner materially adverse to the rights or remedies of the Purchaser Agent or the Purchasers under the Transaction Documents (other than in their capacity as a holder of Equity Interests or other rights under the Option Agreement, so long as any such amendment, modification or change does not disproportionately affect Purchaser Agent or the Purchasers in such capacity)&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Transfer any Collateral, other than (A) Transfers of cash and Cash Equivalents, Transfers of inventory and&#47;or the Transfer of obsolete, worn-out or surplus equipment, in each case in the ordinary course of business, (B) Permitted Liens, (C) Permitted Licenses, (D) Permitted Investments, (E) Transfers among Subsidiaries that are not Subsidiary Guarantors, (F) Transfers to an Obligor, provided that (X) in the case of a Transfer from an Obligor such Transfer does not impair the Liens of the Purchaser Agent in the Collateral subject to such Transfer and (Y) any Transfer from a Full Guarantor must be to the Company or a Full Guarantor, (G) Transfers to Subsidiaries that are not Subsidiary Guarantors so long as (X) no material Intellectual Property is Transferred pursuant to this clause (G), (Y) the aggregate amount of such Transfers pursuant to this clause (G) does not exceed (I) prior to the Milestone, $5,000,000 and (II) from and after the occurrence of the Milestone, $10,000,000 and (Z) all Transfers pursuant to this clause (G) be made for fair market value and for consideration consisting solely of cash and Cash Equivalents, (H) Transfers of equipment in exchange for credit against the purchase price of similar replacement equipment or where the proceeds of such Transfer are promptly applied to the purchase of similar or replacement equipment, (I) any Transfer resulting from casualty, loss, condemnation, eminent domain, seizure, nationalization or other similar actions, (J) the surrender or waiver of obligations or rights pursuant to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of any credit or customer, (K) Transfers consisting of the sale or discount of receivables in the ordinary course of business in connection with the compromise or collection thereof, (L) to the extent constituting Transfers, Permitted Debt Payments, (M) to the extent constituting Transfers, Restricted Payments made in accordance with Section 5.11(a)(vi), (N) the unwinding or termination of hedging arrangements not prohibited hereunder, (O) the surrender, compromise, settlement, or release of contract, tort, or other litigation claims, arbitration, or other disputes, which, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, (P) Transfers of investments in joint ventures to the extent required by, or made pursuant to customary buy&#47;sell arrangements or rights of first refusal between, the joint venture parties set forth in joint venture arrangements or similar binding arrangements, (Q) the sale of disposition of nominal amounts of Qualified Equity Interests to where required under Applicable Law to qualify directors, and&#47;or (R) to the extent constituting Transfers, termination of contracts in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">consummate any Restricted Licenses&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">change the fiscal year end (other than, in the case of the Company or any Subsidiary, to conform to the Company&#8217;s fiscal year end)&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">directly or indirectly enter into or permit to exist any transaction or series of transactions with any Affiliate of the Company or any of its Subsidiaries with a fair market value in excess of $120,000, except for (a) the Affiliate Agreements&#59; (b) transactions between or among Obligors and Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, except for Permitted Investments pursuant to clauses (c), (f)(v) and (f)(vi) of the definition thereof, Permitted Indebtedness pursuant to clauses (d), (e) and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o) of the definition thereof, Permitted Debt Payments pursuant to clauses (e) and (f) thereof, and Restricted Payments permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11(a)(vi)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, any transactions with Subsidiaries that are not Obligors are in the ordinary course of the Company&#8217;s and the applicable Subsidiary&#8217;s (or Subsidiaries&#8217;) business, upon fair, customary and reasonable terms that are no less favorable to the Obligors than would be obtained in an arm&#8217;s length transaction with a nonaffiliated Person&#59; (c)&#160;customary compensation, service, severance and indemnification of, and other employment arrangements with, directors and officers of the Company and its Subsidiaries, and reimbursements of expenses of current or former directors and officers, in each case in the ordinary course of business, upon fair, customary and reasonable terms that, with respect to any such arrangements with Affiliates of the Company or any Subsidiary, are no less favorable to the Company and its Subsidiaries than would be obtained in an arm&#8217;s length transaction with a non-affiliated Person&#59; (d) the issuance of Equity Interests of the Company to Affiliates in exchange for cash&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of such transaction are no less favorable to the Company than those that would be obtained in a comparable arm&#8217;s length transaction with a Person that is not an Affiliate&#59; (e) any transaction expressly permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11(a)(vi)(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11(a)(vi)(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11(a)(vi)(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11(a)(x)(Q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, clauses (b), (e), (n), (o), (r) and (s) of the definition of &#8220;Permitted Indebtedness&#8221;, and clause (c) of the definition of &#8220;Permitted Investments&#8221;&#59; (f) transactions that do not involve Investments, License Agreements, Restricted Payments or Transfers and that are made (i) in the ordinary course of the Company&#8217;s and the applicable Subsidiary&#8217;s (or Subsidiaries&#8217;) business, upon fair, customary and reasonable terms that are no less favorable to the Obligors than would be obtained in an arm&#8217;s length transaction with a nonaffiliated Person and (ii) approved by the Related Party Transaction Committee of the Company&#8217;s Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consideration paid by the Company and its Subsidiaries during any fiscal year in connection with transactions entered into under this clause (f), net of any payments received from Affiliates that are not Subsidiaries in connection with such transactions during such fiscal year, shall not exceed (X) prior to the Milestone, $5,000,000 and (Y) from and after the occurrence of the Milestone, $10,000,000&#59; (g) the payment of reasonable out-of-pocket costs and expenses relating to registration rights and indemnities provided to holders of Equity Interests of the Company pursuant to any stockholders&#8217; agreement or registration and participation rights agreement and (h) agreements existing on the Closing Date and listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.11(a)(xiii)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">No Obligor may take any action or engage in any transaction (or series of actions or transactions), whether by reorganization, Transfer of assets, merger, dissolution, amendment of organizational documents or otherwise, the primary purpose of which is to evade, avoid or seek to avoid the performance or observance of the covenants, agreements or obligations of the Obligors under the Transaction Documents.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Each Obligor shall timely file (taking into account all extensions of due dates) all income and all other material Tax Returns required to be filed by it and will pay all material Taxes required to be paid with such returns.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Purchaser Agent, each Purchaser and each Obligor agree that (a) the transactions contemplated by this agreement are intended to constitute and shall be treated by the parties as a debt instrument for U.S. federal and applicable state and local income tax purposes and (b) the payments of interest under such debt instrument are intended to qualify as &#8220;portfolio interest&#8221; within the meaning of Section 871(h)(2) of the Code (provided that the requirements of Sections 871(h)(3), 871(h)(5), 881(c)(3) and 881(c)(5) of the Code, as applicable, are satisfied) or to be eligible for the benefits of Section 1 of Article 11 of the income tax treaty between the United States and Ireland. None of the Purchasers nor any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligor shall take any Tax position inconsistent with the foregoing unless otherwise required by a determination within the meaning of Section 1313(a) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">&#91;reserved&#93;.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">On or prior to the Closing Date (or the date that any Purchaser acquires an interest in the Obligations or Purchaser Commitment), each Purchaser shall deliver to the Company a duly completed and valid IRS Form W-9 certifying that such Purchaser is a United States person and exempt from U.S. federal backup withholding (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">IRS Withholding Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and each Purchaser shall provide an updated IRS Withholding Form to the Company throughout the Revenue Interest Period whenever required in order for the Company to have on file a duly completed and valid IRS Withholding Form.  Each Purchaser represents that it is not participating in a &#8220;conduit financing arrangement&#8221; within the meaning of Treasury regulation section 1.881-3 with respect to the Obligations or Purchaser Commitments.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors covenant to each Purchaser that all amounts payable hereunder shall be paid by the Obligors without deduction or withholding for any Taxes, except as required pursuant to any Applicable Law.  If any Applicable Law (as determined in the good faith discretion of an applicable withholding agent) requires the deduction or withholding of any Tax from any payment in respect of this Agreement by a withholding agent (including a Purchaser), then the applicable withholding agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Applicable Law, and, if such Tax is not an Excluded Tax, then the sum payable by Obligors to Purchasers shall be increased as necessary so that after such deduction or withholding has been made (including any such deduction and withholding by a Purchaser as a withholding agent and such deductions and withholdings applicable to additional sums payable under this Section 5.12(e)) the Purchasers receive an amount equal to what they would have received had no deduction or withholding been made.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Material Contracts.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Obligor and its Subsidiaries shall comply with all material terms and conditions of and fulfill all of its obligations under all the Material Contracts. No Obligor nor any of their respective Subsidiaries shall, without the prior consent of the Purchaser Agent, which shall not be unreasonably withheld, conditioned or delayed, enter into any material amendment or waiver to or material modification of any Material Contract, or take or omit to take any action that results in the termination of any Material Contract or that permits a Material Contract to be terminated by any counterparty thereto prior to its stated date of expiration, in either case that could reasonably be expected to (i) result in a Material Adverse Effect or (ii) have any adverse impact on Purchaser Agent&#8217;s or the Purchasers&#8217; rights and remedies under this Agreement. Upon the occurrence of a breach of any Material Contract by any other party thereto, each Obligor shall seek to enforce all of its (and cause its Subsidiaries to seek to enforce all of their) rights and remedies thereunder.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 5.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee and Pension Matters.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than a customary 401(k) plan, no Obligor nor any ERISA Affiliate shall sponsor, establish, maintain, participate in or incur any liability in respect of any &#8220;employee benefit plan&#8221; as defined in Section 3(3) of ERISA and that is intended to be a tax-qualified plan under Section 401 of the Code and is subject to ERISA which is, or within the preceding six years was, sponsored, maintained or contributed to by, or required to be contributed by, any member of the Company and its Subsidiaries or any of their respective ERISA Affiliates </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VI</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TERMINATION</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, this Agreement shall terminate upon expiration of the Revenue Interest Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If any payments are required to be made by one of the parties hereunder after that date, this Agreement shall remain in full force and effect until any and all such payments have been made in full, and (except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) solely for that purpose. In addition, this Agreement shall sooner terminate if the Purchasers shall have exercised the Put Option in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or the Company shall have exercised the Call Option in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.07(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in each case upon the payment of the Put&#47;Call Price and any other Obligations (other than contingent indemnity obligations for which no claim has been made).</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the termination of this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, this Agreement shall forthwith become void and have no effect without any liability on the part of any party hereto or its Affiliates, directors, officers, stockholders, partners, managers or members other than the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof, which shall survive any termination indefinitely. Nothing contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall relieve any party from liability for any breach of this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VII</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURCHASER AGENT</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Appointment and Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Each of the Purchasers hereby irrevocably appoints Infinity SA LLC (together with any successor Purchaser Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) as the Purchaser Agent hereunder and authorizes Purchaser Agent to (i)&#160;execute and deliver the Transaction Documents and accept delivery thereof on its behalf from the Obligors and their Subsidiaries, (ii) take such action on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to the Purchaser Agent under such Transaction Documents, (iii) act as agent of such Purchaser for purposes of acquiring, holding, enforcing and perfecting all Liens granted by the Obligors on the Collateral to secure any of the Obligations and (iv) exercise such powers as are reasonably incidental thereto.  Except for the last paragraph of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the provisions of this Article VII are solely for the benefit of the Purchaser Agent and the Purchasers, and neither the Company nor any other Obligor shall have rights as a third-party beneficiary of any of such provisions.  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, any action required or permitted to be taken by the Purchaser Agent hereunder shall be taken with the prior approval of the Required Purchasers.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rights as a Purchaser.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The Person serving as the Purchaser Agent hereunder shall have the same rights (including under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and powers, and shall be subject to the same obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as any other Purchaser and may exercise the same as though it were not the Purchaser Agent and the term &#8220;Purchaser&#8221; or &#8220;Purchasers&#8221; shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Purchaser Agent hereunder.  Such Person and its Affiliates may lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with any Obligor or any Subsidiary or other Affiliate thereof as if such Person were not the Purchaser Agent hereunder and without any duty to account therefor to the Purchasers.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exculpatory Provisions.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Purchaser Agent shall not have any duties or obligations except those expressly set forth herein and in the other Transaction Documents to which it is a party.  Without limiting the generality of the foregoing, the Purchaser Agent&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">shall not be subject to any fiduciary or other implied duties, regardless of whether a default, breach by any Obligor of the Transaction Documents or Put Option Event, or any event that, with the giving of notice or passage of time, would constitute a Put Option Event, has occurred and is continuing&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Transaction Documents to which it is a party that the Purchaser Agent is required to exercise as directed in writing by the Required Purchasers (or such other number or percentage of the Purchasers as shall be expressly provided for herein or in such other Transaction Documents), provided that the Purchaser Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Purchaser Agent to liability or that is contrary to any Transaction Document or Applicable Law&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">shall not, except as expressly set forth herein and in the other Transaction Documents to which it is a party, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Obligor or any of its Affiliates that is communicated to or obtained by the Person serving as the Purchaser Agent or any of its Affiliates in any capacity.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Purchaser Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Purchasers (or such other number or percentage of the Purchasers as shall be necessary, or as the Purchaser Agent shall believe in good faith shall be necessary, under the circumstances as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and non-appealable judgment.  The Purchaser Agent shall be deemed not to have knowledge of any default, breach by the Obligors of the Transaction Documents, or Put Option Event unless and until notice describing such default, breach of the Transaction Documents or Put Option Event is given to the Purchaser Agent in writing by the Obligors or a Purchaser.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Purchaser Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Transaction Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default, breach of the Transaction Documents or Put Option Event, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Transaction Document or any other agreement, instrument or document or (v)&#160;the satisfaction of any condition set forth in Article II or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Purchaser Agent.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Notwithstanding anything to the contrary herein, the Purchaser Agent&#8217;s sole duty with respect to the custody, safekeeping and physical preservation of the Collateral in its possession, under the UCC or otherwise, shall be to deal with it in the same manner as the Purchaser Agent deals with similar property for its own account, and the Purchaser Agent shall be deemed to have exercised reasonable care in the custody and preservation of the Collateral in its possession if the Collateral is accorded treatment substantially equal to that which comparable secured parties accord comparable collateral. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">In addition to and not in limitation of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under no circumstances shall the Purchaser Agent have any duty or obligation to take any actions hereunder, even if instructed to do so by the Required Purchasers, if the Purchaser Agent determines, in its sole and absolute discretion, that such actions would subject it to liability or expense for which indemnity or security satisfactory to it has not been provided hereunder or otherwise or would be contrary to the Transactions Documents or requirements of Applicable Law.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reliance by Purchaser Agent.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchaser Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person.  The Purchaser Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon.  The Purchaser Agent may consult with legal counsel (who may be counsel for the Obligors), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delegation of Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Purchaser Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Transaction Document by or through any one or more sub-agents appointed by the Purchaser Agent.  The Purchaser Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates.  The exculpatory provisions of this Article VII shall apply to any such sub-agent and to the Affiliates of the Purchaser Agent and any such sub-agent.  The Purchaser Agent shall not be responsible for the negligence or misconduct of any sub-agent except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Purchaser Agent acted with gross negligence or willful misconduct in the selection of such sub-agent.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Resignation of Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Purchaser Agent may at any time give notice of its resignation to the Purchasers and the Company upon thirty (30) days written notice.  Upon the receipt of any such notice of resignation, the Required Purchasers shall have the right, in consultation with the Company so long as no default, breach by the Obligors of the Transaction Documents or Put Option Event has occurred and is continuing, to appoint a successor.  If no successor shall have been so appointed by the Required Purchasers and shall have accepted such appointment within thirty (30) days after the retiring Purchaser Agent gives notice of its resignation, then the retiring Purchaser Agent may, on behalf of the Purchasers, appoint a successor Purchaser Agent&#59; provided that, whether or not a successor has been appointed or has accepted such appointment, such resignation shall become effective upon delivery of the notice thereof.  Upon the acceptance of a successor&#8217;s appointment as Purchaser Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Purchaser Agent, and the retiring Purchaser Agent shall be discharged from all of its duties and obligations under the Transaction Documents (if not already discharged therefrom as provided above in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).  After the retiring Purchaser Agent&#8217;s resignation, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Article VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall continue in effect for the benefit of such retiring Purchaser Agent, its sub-agents and their respective Affiliates in respect of any actions taken or omitted to be taken by any of them while the retiring Purchaser Agent was acting as Purchaser Agent.  Upon any resignation by the Purchaser Agent, all payments (if any), communications and determinations provided to be made by, to or through the Purchaser Agent shall instead be made by, to or through each Purchaser directly, until such time as a Person accepts an appointment as Purchaser Agent in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Reliance on Purchaser Agent and Other Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Purchaser acknowledges that it has, independently and without reliance upon the Purchaser Agent or any other Purchaser or any of their Affiliates and based on such documents and information as it has deemed appropriate, made its own </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit analysis and decision to enter into this Agreement and purchase the Revenue Interests hereunder.  Each Purchaser also acknowledges that it will, independently and without reliance upon the Purchaser Agent or any other Purchaser or any of their Affiliates and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Transaction Document or any related agreement or any document furnished hereunder or thereunder.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral and Guaranty Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Each Purchaser agrees that any action taken by the Purchaser Agent or the Required Purchasers in accordance with the provisions of this Agreement or of the other Transaction Documents, and the exercise by the Purchaser Agent or Required Purchasers of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Purchasers. Without limiting the generality of the foregoing, the Purchasers irrevocably authorize the Purchaser Agent, at its option and in its discretion&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">to release any Lien on any property granted to or held by the Purchaser Agent under any Transaction Document (A) upon the discharge of the Obligations (other than contingent indemnity obligations for which no claim has been made), (B) that is sold, transferred, disposed or to be sold, transferred, disposed as part of or in connection with any sale, transfer or other disposition (other than any sale to an Obligor&#59; provided, however that the Purchaser Agent may make any filings necessary to reflect the transfer of Collateral from one Obligor to another) permitted hereunder or otherwise becomes an Excluded Property (as defined in the Security Agreement), (C) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if approved, authorized or ratified in writing by the Required Purchasers or (D) to the extent such property is owned by a Subsidiary Guarantor upon the release of such Subsidiary Guarantor from its obligations under its Guaranty pursuant to clause (c) below&#59;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">to release any Subsidiary Guarantor from its obligations under the Guaranty if such Person ceases to be a Subsidiary as a result of a transaction permitted hereunder&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">to enter into non-disturbance and similar agreements in connection with the licensing of Intellectual Property permitted pursuant to the terms of this Agreement in form and substance reasonably satisfactory to the Purchaser Agent and the applicable licensor.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon request by the Purchaser Agent at any time, the Required Purchasers will confirm in writing the Purchaser Agent&#8217;s authority to release or subordinate its interest in particular types or items of property, or to release any Subsidiary Guarantor from its obligations under the Guaranty pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each case as specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Purchaser Agent will (and each Purchaser irrevocably authorizes the Purchaser Agent to), at the Obligors&#8217; expense, execute and deliver to the applicable Obligor such documents as such Obligor may reasonably request (i) to evidence the release or subordination of such item of collateral from the assignment and security interest granted under the Transaction Documents, (ii) to enter into non-disturbance or similar agreements in connection with the licensing of Intellectual Property, (iii) to evidence the release of such Subsidiary Guarantor from its obligations under the Guaranty, in each case in accordance with the terms of the Transaction Documents and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in form and substance reasonably acceptable to the Purchaser Agent.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchaser Agent shall deliver to the Purchasers notice of any action taken by it under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as soon as reasonably practicable after the taking thereof&#59; provided, that delivery of or failure to deliver any such notice shall not affect the Purchaser Agent&#8217;s rights, powers, privileges and protections under this Article VII.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 7.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement by Purchasers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  To the extent that the Obligors for any reason fail to indefeasibly pay any amount required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be paid by them to the Purchaser Agent (or any sub-agent thereof) or any Affiliate of any of the foregoing, each Purchaser severally agrees to pay to the Purchaser Agent (or any such sub-agent) or such Affiliate, as the case may be, such Purchaser&#8217;s Pro Rata Portion of such unpaid amount&#59; provided that the unreimbursed expense or indemnified loss, damage, liability or related expense, as the case may be, was incurred by or asserted against the Purchaser Agent (or any such sub-agent) in its capacity as such or against any Affiliate of any of the foregoing acting for the Purchaser Agent (or any sub-agent) in connection with such capacity.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VIII</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MISCELLANEOUS</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations on Damages. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement or any other Transaction Document, in no event shall any party hereto be liable for special, indirect, incidental, punitive or consequential damages of any other party, whether or not caused by or resulting from the actions of such party or the breach of its covenants, agreements, representations or warranties under the Transaction Documents, even if such party has been advised of the possibility of such damages&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nothing contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall limit the Obligors&#8217; indemnification obligations hereunder to the extent such special, indirect, consequential or punitive damages are included in any third party claim in connection with which such Indemnified Party is entitled to indemnification under any Transaction Document. In connection with the foregoing, the parties hereto acknowledge and agree that (i) Purchaser Agent&#8217;s and the Purchasers&#8217; damages, if any, for any such action or claim will typically include losses for payments that the Purchasers were entitled to receive in respect of their ownership of the Revenue Interests but did not receive timely or at all due to such indemnifiable event and (ii) Purchaser Agent and the Purchasers shall be entitled to make claims for all such missing or delayed Revenue Interests as losses hereunder, and such missing or delayed Revenue Interests shall not be deemed special, indirect, incidental, punitive or consequential damages.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All notices, consents, waivers and communications under this Agreement or any other Transaction Document given by any party to the other shall be in writing and delivered personally, by a recognized overnight courier, or by dispatching the same by certified or registered mail, return receipt requested, with postage prepaid, or by email, in each case addressed (with a copy by email)&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.685%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to the Company&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ImmunityBio, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3530 John Hopkins Court</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Jason Liljestrom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Telephone&#58; (310) 913-3804</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; Jason.Liljestrom&#64;Immunitybio.com</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to the Purchaser Agent&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c&#47;o Oberland Capital Management LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1700 Broadway, 37th Floor</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York, NY 10019</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.685%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Kristian Wiggert</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Telephone&#58; (212) 257-5850</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; kwiggert&#64;oberlandcapital.com</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with a copy to&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cooley LLP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embarcadero Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20th Floor</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Francisco, CA 94111-4004</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Gian-Michele a Marca</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; gmamarca&#64;cooley.com</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to any Purchaser&#58; As specified on the applicable signature page hereto.</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or to such other address or addresses as the Purchaser Agent, any Purchaser or the Company may from time to time designate by notice as provided herein, except that notices of changes of address shall be effective only upon receipt. All such notices, consents, waivers and communications shall&#58; (a) when posted by certified or registered mail, postage prepaid, return receipt requested, be effective three (3) Business Days after dispatch, unless such communication is sent trans-Atlantic, in which case they shall be deemed effective five (5) Business Days after dispatch, (b) when delivered by a recognized overnight courier or in person, be effective upon receipt when hand delivered or (c) any notice, if transmitted by email, shall be deemed given upon the earlier of (x) confirmation of receipt by the recipient and (y) the opening of business on the next Business Day for the recipient. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.  The Obligors shall not be entitled to assign any of their obligations and rights under the Transaction Documents without the prior written consent of the Purchaser Agent and the Required Purchasers. The Purchaser Agent and any Purchaser shall not assign any of their obligations and rights under the Transaction Documents without the prior written consent of the Company, except that Purchaser Agent and any Purchaser may assign any of its rights under the Transaction Documents (other than the Option Agreement) without restriction (i) to any Eligible Assignee&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to any assignment under this clause (i), if Affiliates of Oberland Capital Management LLC constitute the Required Purchasers prior to such assignment, then Affiliates of Oberland Capital Management LLC shall continue to constitute the Required Purchasers after giving effect to such assignment and (ii) after the occurrence and during the continuance of a Put Option Event, to any Person&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, except to the extent such Purchaser retains its obligations to make its Pro Rata Portion of future Purchaser Payments, such Eligible Assignee shall assume in writing all such Purchaser&#8217;s obligation to make future Purchaser Payments&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the Purchaser shall provide the Company with written notice of any assignment. The Company shall maintain a &#8220;register&#8221; for the recordation of the names and addresses of, and the Purchaser Commitments of, and amounts owing to, each Purchaser and assignee owning Revenue Interest Payments. Any purported assignment not in compliance with the foregoing requirement shall be null and void.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section  8.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The Obligors hereby indemnify and hold the Purchaser Agent, each Purchaser and their respective Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) harmless from and against any and all Indemnified Liabilities, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in all cases, arising, in whole or in part, out of or relating to any claim, notice, suit or proceeding commenced or threatened in writing (including, without limitation, by electronic means) by any Person (including any Governmental Authority)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (i) the Obligors shall not have any obligation to any Indemnified Party hereunder with respect to any Indemnified Liabilities to the extent such Indemnified Liabilities arise from the bad faith, gross negligence or willful misconduct of such Indemnified Party or the breach by such Indemnified Party of its obligations to pay its Purchaser Payments hereunder and (ii) such indemnity shall not, as to any Indemnified Party, be available to the extent that such Indemnified Liabilities arise out of any claim, litigation, investigation or proceeding brought by any such Indemnifying Party against another Indemnifying Party that does not involve any act or omission by the Obligors or any of their Subsidiaries.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">If any Third Party Claim shall be brought or alleged against an Indemnified Party in respect of which indemnity is to be sought against an indemnifying party pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Indemnified Party shall, promptly after receipt of notice of the commencement of any such Third Party Claim, notify the indemnifying party in writing of the commencement thereof, enclosing a copy of all papers served, if any&#59; provided, that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unless, and only to the extent that, the indemnifying party is actually prejudiced by such omission.  In the event that any Third Party Claim is brought against an Indemnified Party and it notifies the indemnifying party of the commencement thereof in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the indemnifying party will be entitled, at the indemnifying party&#8217;s sole cost and expense, to participate therein and, to the extent that it may wish, to assume the defense thereof, with counsel reasonably satisfactory to such Indemnified Party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such Indemnified Party of its election so to assume the defense thereof, the indemnifying party will not, subject to the immediately succeeding sentence, be liable to such indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation.  In any such Third Party Claim, an Indemnified Party shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the sole cost and expense of such Indemnified Party unless (i) the indemnifying party and the Indemnified Party shall have mutually agreed to the retention of such counsel, (ii) the indemnifying party has assumed the defense of such proceeding and has failed within a reasonable time to retain counsel reasonably satisfactory to such Indemnified Party or (iii) the named parties to any such Third Party Claim (including any impleaded parties) include both the indemnifying party and the Indemnified Party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of counsel to the indemnifying party.  It is agreed that the indemnifying party shall not, in connection with any Third Party Claim or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to local counsel where necessary) for all such Indemnified Parties.  The indemnifying party shall not be liable for any settlement of any Third Party Claim effected without its written consent, but, if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the Indemnified Party from and against any Indemnified Liabilities by reason of such settlement or judgment.  No indemnifying party shall, without the prior written consent of the Indemnified Party, effect any settlement, compromise or discharge of any pending or threatened Third Party Claim in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement, compromise or discharge, as the case may be, (i) includes an unconditional written release of such Indemnified Party, in form and substance reasonably satisfactory to the Indemnified Party, from all liability on claims that are the subject matter of such claim or proceeding, (ii) does not include any statement as to an admission of fault, culpability or failure to act by or on behalf of any Indemnified Party and (iii) does not impose any continuing material obligation or restrictions on such Indemnified Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">A claim by an Indemnified Party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for any matter not involving a Third Party Claim and in respect of which such Indemnified Party seeks indemnification hereunder may be made by delivering, in good faith, a written notice of demand to the indemnifying party, which notice shall contain (i) a description and the amount of any Indemnified Liabilities incurred or suffered or reasonably expected to be incurred or suffered by the Indemnified Party, (ii) a statement that the Indemnified Party is entitled to indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for such Indemnified Liabilities and a reasonable explanation of the basis therefor, and (iii) a demand for payment in the amount of such Indemnified Liabilities.  Within thirty (30) days after receipt by the indemnifying party of any such notice, the indemnifying party may deliver to the Indemnified Party that delivered the notice a written response in which the indemnifying party (i) agrees that the Indemnified Party is entitled to the full amount of the Indemnified Liabilities claimed in the notice from the Indemnified Party&#59; (ii) agrees that the Indemnified Party is entitled to part, but not all, of the amount of the Indemnified Liabilities claimed in the notice from the Indemnified Party&#59; or (iii) indicates that the indemnifying party disputes the entire amount of the Indemnified Liabilities claimed in the notice from the Indemnified Party.  If the Indemnified Party does not receive such a response from the indemnifying party within such thirty (30)-day period, then the indemnifying party shall be conclusively deemed to have agreed that the Indemnified Party is entitled to the full amount.  If the indemnifying party and the Indemnified Party are unable to resolve any dispute relating to any amount of the Indemnified Liabilities claimed in the notice from the Indemnified Party within thirty (30) days after the delivery of the response to such notice from the indemnifying party, then the parties shall be entitled to resort to any legal remedy available to such party to resolve such dispute that is provided for in this Agreement, subject to all the terms, conditions and limitations of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Implied Representations and Warranties&#59; Survival of Representations and Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party acknowledges and agrees that, other than the representations and warranties specifically contained in any of the Transaction Documents, there are no representations or warranties of either party or any other Person either expressed or implied with respect to the Revenue Interests or the transactions contemplated hereby. Without limiting the foregoing, the Purchaser Agent and each Purchasers acknowledges and agrees that the Purchaser Agent, each Purchaser and their respective Affiliates, together with their representatives, have made their own investigation of each Included Product and are not relying on any implied warranties or upon any representation or warranty whatsoever as to the future amount or potential amount of the Revenue Interests or as to the creditworthiness of the Company. All representations and warranties by the parties contained in this Agreement shall survive the execution, delivery and acceptance thereof by the parties and the closing of the transactions described in this Agreement and continue in effect until payment of all amounts due to the Purchasers under the Transaction Documents and the termination of this Agreement pursuant to its terms.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Nature of Relationship. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The relationship between the Company, the other Obligors and the Subsidiaries, on the one hand, and the Purchaser Agent and the Purchasers, on the other, is solely that of seller and purchaser, and for U.S. federal income Tax purposes, that of debtor and creditor, and neither the Purchaser Agent and the Purchasers, on the one hand, nor the Obligors and their Subsidiaries, on the other, has any fiduciary or other special relationship with the other or any of their respective Affiliates. Nothing contained herein or in any other Transaction Document shall be deemed to constitute the Company or their Subsidiaries and the Purchaser Agent and the Purchasers as a partnership, an association, a joint venture or other kind of entity or legal form for any purposes, including for any Tax purposes.   </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">No officer or employee or agent of the Purchaser Agent or any Purchaser will be located at the premises of the Company or any of its Affiliates, except in connection with an inspection or audit performed pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or in connection with the enforcement of remedies as contemplated by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Transaction Documents. No officer, manager or employee of the Purchaser Agent or any Purchaser shall engage in any commercial activity with the Company or any of its Affiliates other than as contemplated herein and in the other Transaction Documents.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement, together with the Exhibits and Schedules hereto (which are incorporated herein by reference), and the other Transaction Documents constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings and negotiations, both written and oral, between the parties with respect to the subject matter of this Agreement. No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits, Schedules or other Transaction Documents) has been made or relied upon by either party hereto. None of this Agreement, nor any provision hereof, is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments&#59; No Waivers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.08(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, this Agreement, the other Transaction Documents or any term or provision hereof or thereof may not be amended, changed or modified except with the written consent of the Company, the Purchaser Agent and the Required Purchasers. No waiver of any right hereunder shall be effective unless such waiver is signed in writing by the party against whom such waiver is sought to be enforced.  </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Without the prior written consent of each Purchaser that would be affected thereby, no amendment, modification, termination or consent shall be effective if the effect thereof would&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">waive, reduce or postpone any Revenue Interest Payment&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">amend, modify, terminate or waive any provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">amend the definition of &#8220;Required Purchasers&#8221; or &#8220;Pro Rata Portion&#8221;&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">release all or any material portion of the Collateral or release any Obligor from any of its rights and obligations under any Transaction Document (except as expressly provided in the Transaction Documents).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section  8.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a reference is made in this Agreement to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Articles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such reference shall be to an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Article</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Agreement unless otherwise indicated. The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation&#8221;. Neither party hereto shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one party or the other. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Headings and Captions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The headings and captions in this Agreement are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts&#59; Effectiveness&#59; Electronic Signature. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original. The words &#8216;execution&#8217;, &#8216;signed&#8217;, &#8216;signature&#8217;, &#8216;delivery&#8217; and words of like import in or relating to any document to be signed in connection with this Agreement or any other Transaction Document and the transactions contemplated hereby shall be deemed to include Electronic Signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar State laws based on the Uniform Electronic Transactions Act&#59; provided, that nothing herein shall require any Person to accept electronic signatures in any form or format without its prior written consent.  Without limiting the generality of the foregoing, the parties hereto hereby (a) agree that, for all purposes, including in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among the Purchasers and the Obligors, electronic images of this Agreement or any other Transaction Document (in each case, including with respect to any signature pages thereto) shall have the same legal effect, validity and enforceability as any paper original, and (b) waive any argument, defense or right to contest the validity or enforceability of the Transaction Documents based solely on the lack of paper original copies of any Transaction Documents, including with respect to any signature pages thereto.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Obligors will pay all of their own fees and expenses in connection with entering into and consummating the transactions contemplated by this Agreement.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Governing Law&#59; Jurisdiction. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of New York, without giving effect to the principles of conflicts of law thereof.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any legal action or proceeding with respect to this Agreement or any other Transaction Document may be brought in any state or federal court of competent jurisdiction in the State of New York, County of New York. By execution and delivery of this Agreement, each party hereto hereby irrevocably consents to and accepts, for itself and in respect of its property, generally and unconditionally the non-exclusive jurisdiction of such courts. Each party hereto hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens, which it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of any Transaction Document.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Each party hereto hereby irrevocably consents to the service of process out of any of the courts referred to in clause (b) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this Agreement.  Each party hereto hereby irrevocably waives any objection to such service of process and further irrevocably waives and agrees not to plead or claim in any suit, action or proceeding commenced hereunder or under any other Transaction Document that service of process was in any way invalid or ineffective. Nothing herein shall affect the right of a party to serve process on the other party in any other manner permitted by law.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 8.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Jury Trial.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM ARISING OUT OF OR RELATING TO ANY TRANSACTION DOCUMENT OR THE TRANSACTIONS CONTEMPLATED UNDER ANY TRANSACTION DOCUMENT. THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO ANY TRANSACTION DOCUMENT.</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</font></div></div></div><div id="ibdce341a54074590ae0418afe4e58f16_41"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">COMPANY&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">IMMUNITYBIO, INC.</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Sachs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">PURCHASER AGENT&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">INFINITY SA LLC</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Dubinsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Authorized Signatory</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">PURCHASERS&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TPC INVESTMENTS II LP</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; David Dubinksy</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Authorized Signatory</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TPC INVESTMENTS III LP</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; David Dubinksy</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Authorized Signatory</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TPC INVESTMENTS SOLUTIONS LLC</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; David Dubinksy</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Authorized Signatory</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">TPC INVESTMENTS SOLUTIONS CO INVEST LP</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; David Dubinksy</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Authorized Signatory</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Revenue Interest Purchase Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>ibrx20231231-10kexhibit104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8363cd9747ad47ca9d764fff43ec1d15_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 10.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITY AND PLEDGE AGREEMENT</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS SECURITY AND PLEDGE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is entered into as of December&#160;29,&#160;2023 among ImmunityBio, Inc., a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Subsidiary Guarantors listed on the signature pages hereto, such other parties that may become Grantors hereunder after the date hereof (together with the Company and the Subsidiary Guarantors, each individually a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Infinity SA LLC, a Delaware limited liability company, in its capacity as agent (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the Secured Parties.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, pursuant to that certain Revenue Interest Purchase Agreement, dated as of the date hereof (as amended, restated, amended and restated, renewed, replaced, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) among the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company, the Purchasers party thereto and the Purchaser Agent, the Purchasers have agreed to purchase the Revenue Interests upon the terms and subject to the conditions set forth therein&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, this Agreement is required by the terms of the Purchase Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of these premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase Agreement. Capitalized terms used and not otherwise defined either herein or in the Purchase Agreement shall have the meanings ascribed to such terms under the UCC. With reference to this Agreement, unless otherwise specified herein&#58; (i)&#160;the definitions of terms herein shall apply equally to the singular and plural forms of the terms defined, (ii)&#160;whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms, (iii)&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (iv)&#160;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (v)&#160;any definition of, or reference to, any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document, as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (vi)&#160;any reference herein to any Person shall be construed to include such Person&#8217;s permitted successors and assigns, (vii)&#160;the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (viii)&#160;all references herein to Sections, Exhibits and Schedules shall be construed to refer to Sections of, and Exhibits and Schedules to, this Agreement, (ix)&#160;the words &#8220;asset&#8221; and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights, (x)&#160;the term &#8220;documents&#8221; includes any and all instruments, documents, agreements, certificates, notices, reports, financial statements and other writings, however evidenced, whether in physical or electronic form, (xi)&#160;in the computation of periods of time from a specified date to a later specified date, the word &#8220;from&#8221; means &#8220;from and including,&#8221; the words &#8220;to&#8221; and &#8220;until&#8221; each mean &#8220;to but excluding,&#8221; and the word &#8220;through&#8221; means &#8220;to and including&#8221;, (xii)&#160;Section headings herein are included for convenience of reference only and shall not affect the interpretation of this Agreement and (xiii)&#160;where the context requires, terms relating to the Collateral or any part thereof, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when used in relation to a Grantor, shall refer to such Grantor&#8217;s Collateral or the relevant part thereof.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#91;Reserved&#93;.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">In addition, the following terms shall have the meanings set forth below&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anktiva Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (i)&#160;any Product Assets relating to, or necessary, used or reasonably useful for, the Development, Manufacturing and&#47;or Commercialization of Anktiva and (ii)&#160;any and all products, rents, royalties, profits, claims, substitutions, additions, attachments, accessories, accessions and improvements to and replacements of or from any and all of the foregoing, and books and records relating to the foregoing. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment of Claims Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Assignment of Claims Act of 1940 (41&#160;U.S.C. Section&#160;15, 31 U.S.C. Section&#160;3737, and 31&#160;U.S.C. Section&#160;3727), including all amendments thereto and regulations promulgated thereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;all Accounts (including health&#8209;care receivables), Chattel Paper, Contracts, Commercial Tort Claims (including, without limitation, those listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter), Documents, Fixtures, General Intangibles (including all Intellectual Property), Equipment, Goods, Instruments, Inventory, Investment Property, Payment Intangibles, Letter of Credit Rights and Supporting Obligations, (b)&#160;all Pledged Equity and Pledged Investment Property, Deposit Accounts, Securities Accounts, cash or Cash Equivalents, wherever located and (c)&#160;any and all Proceeds, products, rents, royalties, profits, claims, substitutions, additions, attachments, accessories, accessions and improvements to and replacements of or from any and all of the foregoing, and books and records relating to the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, for the avoidance of doubt, the definition of &#8220;Collateral&#8221; and definitions of and references to asset categories in the definition of Collateral and elsewhere in this Agreement or any agreement entered into or pursuant to this Agreement shall not include, Excluded Property.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, all of the following of any Grantor&#58; (i)&#160;all copyrights, works protectable by copyright, copyright registrations and copyright applications anywhere in the world, (ii)&#160;all derivative works, counterparts, extensions and renewals of any of the foregoing, (iii)&#160;all income, royalties, damages and payments now or hereafter due and&#47;or payable under any of the foregoing or with respect to any of the foregoing, including, without limitation, damages or payments for past, present and future infringements, violations or misappropriations of any of the foregoing, (iv)&#160;the right to sue for past, present and future infringements, violations or misappropriations of any of the foregoing and (v)&#160;all rights corresponding to any of the foregoing throughout the world.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Grantor&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">assets for which a pledge thereof or a security interest therein is prohibited by Applicable Laws after giving effect to the applicable anti-assignment provisions of the UCC and other Applicable Law </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other than to the extent that any such prohibition would be rendered ineffective pursuant to the UCC or any other Applicable Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">any contract, lease, license or other agreements, or any goods or other property subject to a purchase money security interest, finance lease or similar arrangement, in each case, to the extent permitted under the Transaction Documents, to the extent that a pledge thereof or a security interest therein would (i)&#160;result in (A)&#160;a breach of the terms of, or constitute a default under, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such contract, lease, license or other agreement or (B)&#160;the abandonment, invalidation, or unenforceability of any material right, title or interest of a Grantor under such contract, lease, license or other agreement, or (ii)&#160;create a right of termination in favor of any other party thereto (other than the Company and its Subsidiaries), in each case, after giving effect to the applicable anti-assignment clauses of the UCC, Applicable Laws or principles of equity, other than the proceeds thereof the assignment of which is expressly deemed effective under Applicable Laws notwithstanding such prohibition&#59;</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">any governmental licenses (but not the proceeds thereof) or state or local franchises, charters and authorizations, to the extent security interests in favor of the Purchaser Agent in such licenses, franchises, charters or authorizations are prohibited or restricted thereby&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that (i)&#160;any such limitation described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">clause&#160;(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the security interests granted shall only apply to the extent that any such prohibition or restriction could not be rendered ineffective pursuant to the UCC of any applicable jurisdiction or any other Applicable Law or principles of equity and shall not apply to any proceeds or receivables thereof, the assignment of which is expressly deemed effective under the UCC notwithstanding such prohibition and (ii)&#160;in the event of the termination or elimination of any such prohibition or restriction contained in any applicable license, franchise, charter or authorization, a security interest in such licenses, franchises, charters or authorizations shall be automatically and simultaneously granted under the applicable Transaction Documents and such licenses, franchises, charters or authorizations shall be included as Collateral&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Excluded Accounts&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">the Dunkirk Lease&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Equity Interests in AccessBioScience, LLC, to the extent a Lien thereon is prohibited by or requires consent (which has not been obtained) under the organizational documents of AccessBioScience, LLC&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">United States intent-to-use trademark or service mark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark or service mark application under federal law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that after such period, each Grantor acknowledges that such interest in such trademark or service mark application shall be subject to a security interest in favor of the Purchaser Agent and shall be included in the Collateral&#59;</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the Collateral shall at all times include (and &#8220;Excluded Property&#8221; shall not include) all proceeds arising from the sale or transfer of any of the foregoing Excluded Property to the extent such proceeds do not otherwise constitute Excluded Property. </font></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Government Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a contract between any Grantor and an agency, department or instrumentality of the United States or any state, municipal or local Governmental Authority located in the United States or all obligations of any such Governmental Authority arising under any Account now or hereafter owing by any such Governmental Authority, as Account Debtor, to any Grantor.</font></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning provided in the Purchase Agreement.</font></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Issuer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the issuer of any Pledged Equity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Anktiva Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any assets of the Grantors that do not constitute Anktiva Collateral.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning provided in the Purchase Agreement.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pledged Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, with respect to each Grantor, 100% of the issued and outstanding Equity Interests of each Subsidiary of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that is directly owned by such Grantor, including the Equity Interests of the Subsidiaries owned by such Grantor as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter (as updated from time to time in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in each case together with the certificates (or other agreements or instruments), if any, representing such shares, and all options and other rights, contractual or otherwise, with respect thereto, including, but not limited to, the following&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">all Equity Interests representing a dividend thereon, or representing a distribution or return of capital upon or in respect thereof, or resulting from a stock split, revision, reclassification or other exchange therefor, and any subscriptions, warrants, rights or options issued to the holder thereof, or otherwise in respect thereof&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">in the event of any consolidation or merger involving any Issuer and in which such Issuer is not the surviving Person, all shares of each class of the Equity Interests of the successor Person formed by or resulting from such consolidation or merger, to the extent that such successor Person is a direct Subsidiary of a Grantor.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Purchasers and the Purchaser Agent.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means, collectively, all of the following of any Grantor&#58; (i)&#160;all trademarks, trade names, corporate names, company names, business names, fictitious business names, internet domain names, trade styles, service marks, logos, other business identifiers, whether registered or unregistered, all registrations and recordings thereof, and all applications in connection therewith (other than each United States application to register any trademark or service mark prior to the filing under Applicable Law of a verified statement of use for such trademark or service mark) anywhere in the world, (ii)&#160;all counterparts, extensions and renewals of any of the foregoing, (iii)&#160;all income, royalties, damages and payments now or hereafter due and&#47;or payable under any of the foregoing or with respect to any of the foregoing, including, without limitation, damages or payments for past, present or future infringements, violations, dilutions or misappropriations of any of the foregoing, (iv)&#160;the right to sue for past, present or future infringements, violations, dilutions or misappropriations of any of the foregoing and (v)&#160;all rights corresponding to any of the foregoing (including the goodwill) throughout the world.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the Uniform Commercial Code as in effect from time to time in the state of New York except as such term may be used in connection with the perfection of the Collateral and then the applicable jurisdiction with respect to such affected Collateral shall apply.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">USPTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States Patent and Trademark Office.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vessel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any watercraft or other artificial contrivance used, or capable of being used, as a means of transportation on water (including, without limitation, those whose primary purpose is the maritime transportation of cargo or which are otherwise engaged, used or useful in any business activities of the Grantors) which are owned by and registered (or to be owned and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registered) in the name of any of the Grantors, including, without limitation, any Vessel leased or otherwise registered in the foregoing parties&#8217; names, pursuant to a lease or other operating agreement constituting a capital lease obligation, in each case together with all related spares, equipment and any additional improvements, vessel owned, bareboat chartered or operated by a Grantor other than Vessels owned by an entity other than a Grantor and which are managed under Vessel management agreements.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Grant of Security Interest in the Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To secure the prompt payment and performance in full when due, whether by lapse of time, acceleration, mandatory prepayment or otherwise, of the Obligations, each Grantor hereby grants to the Purchaser Agent, for the benefit of the Secured Parties, a continuing security interest in, and a right to set off against, any and all right, title and interest of such Grantor in and to the Collateral, whether now owned or existing or owned, acquired, or arising hereafter.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Grantors and the Purchaser Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest created hereby in the Collateral (A)&#160;constitutes continuing collateral security for all of the Obligations, whether now existing or hereafter arising, and (B)&#160;is not to be construed as an assignment of any Intellectual Property.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Grantor hereby represents and warrants to the Purchaser Agent, for the benefit of the Secured Parties, that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Grantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter sets forth as of the Closing Date (i)&#160;the name (within the meaning of Section&#160;9-503 of the UCC) and jurisdiction of organization of each Grantor, (ii)&#160;the address for the chief executive office of each Grantor, and (iii)&#160;tax identification numbers, if any, and organizational identification numbers, if any, for each Grantor.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Grantor is the legal and beneficial owner of its Collateral and has the right to pledge, sell, assign or transfer the same. There exists no Adverse Claim with respect to the Pledged Equity of such Grantor.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Security Interest&#47;Priority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement creates a valid security interest in favor of the Purchaser Agent, for the benefit of the Secured Parties, in the Collateral of such Grantor and, when properly perfected by filing, shall constitute a valid and perfected, first priority (subject to Permitted Priority Liens) security interest in such Collateral (including all uncertificated Pledged Equity consisting of partnership or limited liability company interests that do not constitute Securities), to the extent such security interest can be perfected by filing a financing statement under the UCC, free and clear of all Liens except for Permitted Liens. No Grantor has authenticated any agreement authorizing any secured party thereunder to file a financing statement, except to perfect Permitted Liens. The taking of possession by the Purchaser Agent of the certificated securities (if any) evidencing the Pledged Equity and any other Instruments constituting Collateral will perfect and establish the first priority of the Purchaser Agent&#8217;s security interest in all the Pledged Equity evidenced by such certificated securities and such Instruments. With respect to any Collateral consisting of a Deposit Account, Securities Entitlement or held in a Securities Account, upon execution and delivery by the applicable Grantor, the applicable depository institution or Securities Intermediary and the Purchaser Agent of a Control Agreement to the extent required under the Purchase Agreement, the Purchaser Agent shall have a valid and perfected, first priority security interest in such Collateral, subject to Permitted Priority Liens.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Types of Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. None of the Collateral consists of, or is the Proceeds of, (i)&#160;As-Extracted Collateral, (ii)&#160;Consumer Goods, (iii)&#160;Farm Products, (iv)&#160;Manufactured Homes, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;standing timber, (vi)&#160;an aircraft, airframe, aircraft engine or related property, (vii)&#160;an aircraft leasehold interest, (viii)&#160;a Vessel or (ix)&#160;any other interest in or to any of the foregoing.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (i)&#160;Each Account of the Grantors and the papers and documents relating thereto are genuine and in all material respects what they purport to be, (ii)&#160;each Account arises out of (A)&#160;a bona fide sale of goods sold and delivered by such Grantor (or is in the process of being delivered) or (B)&#160;services theretofore actually rendered by such Grantor to, the Account Debtor named therein, (iii)&#160;no Account of a Grantor is evidenced by any Instrument or Chattel Paper unless such Instrument or Chattel Paper, to the extent requested by the Purchaser Agent, has been endorsed over and delivered to, or submitted to the control of, the Purchaser Agent, (iv)&#160;no surety bond was required or given in connection with any Account of a Grantor or the contracts or purchase orders out of which they arose, (v)&#160;the right to receive payment under each Account is assignable and (vi)&#160;no Account Debtor has any defense, set-off, claim or counterclaim against any Grantor that can be asserted against the Purchaser Agent, whether in any proceeding to enforce the Purchaser Agent&#8217;s rights in the Collateral or otherwise, except defenses, setoffs, claims or counterclaims that are not, in the aggregate, material to the value of the Accounts.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt;text-decoration:underline">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to any Inventory of a Grantor, each such Grantor has exclusive possession and control of such Inventory except for (i)&#160;Inventory in transit with common carriers or (ii)&#160;Inventory in the possession or control of a warehouseman, bailee or any agent, contract manufacturers or processor of such Grantor. No Inventory of a Grantor is held by a Person other than a Grantor pursuant to consignment, sale or return, sale on approval or similar arrangement. Collateral consisting of Inventory is of good and merchantable quality, free from material defects. None of such Inventory is subject to any licensing, Patent, Trademark, trade name or Copyright with any Person that restricts any Grantor&#8217;s ability to use, manufacture, lease, sell or otherwise dispose of such Inventory. The completion of the manufacturing process of such Inventory by a Person other than the applicable Grantor would be permitted under any contract to which such Grantor is a party or to which the Inventory is subject.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Authorization of Pledged Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All Pledged Equity in a Subsidiary of a Grantor (i)&#160;is duly authorized and validly issued, (ii)is fully paid and, to the extent applicable, nonassessable and is not subject to the preemptive rights of any Person, (iii)&#160;is beneficially owned as of record by a Grantor and (iv)&#160;constitute all the issued and outstanding shares of all classes of the equity of such Issuer issued to such Grantor, to the extent required to be pledged hereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">No Other Equity Interests, Instruments, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (1)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter (as updated from time to time by written notice to the Purchaser Agent) sets forth each Person whose Equity Interests are pledged hereunder, the number of shares of each class of Equity Interests of such Person, the certificate number and percentage ownership of outstanding shares of each class of Equity Interests of such Person and the class or nature of such Equity Interests (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.,&#160;voting, non-voting, preferred, etc.) and (2)&#160;no Grantor owns any certificated Equity Interests in any Subsidiary that are required to be pledged and delivered to the Purchaser Agent hereunder except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter (as updated from time to time by written notice to the Purchaser Agent). No Grantor holds any Instruments, Documents or Chattel Paper required to be pledged and delivered to the Purchaser Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other than as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter (as updated from time to time by written notice to the Purchaser Agent) hereto. All such certificated securities, Instruments, Documents and Chattel Paper have been delivered to the Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the extent required by the terms of this Agreement and the other Transaction Documents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Partnership and Limited Liability Company Interests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as previously disclosed to the Purchaser Agent, none of the Collateral consisting of an interest in a partnership or a limited liability company (i)&#160;is dealt in or traded on a securities exchange or in a securities market, (ii)&#160;by its terms expressly provides that it is a Security governed by Article&#160;8 of the UCC, (iii)&#160;is a &#8220;security&#8221; within the meaning of the Investment Company Act of 1940 (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Company Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (iv)&#160;is held in a Securities Account or (v)&#160;constitutes a Security or a Financial Asset.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Consents&#59; Etc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No approval, consent, exemption, authorization or other action by, notice to, or filing with, any Regulatory Agency or other Governmental Authority or any other Person (including, without limitation, any stockholder, member or creditor of such Grantor), is necessary or required for (i)&#160;the grant by such Grantor of the security interest in the Collateral granted hereby or for the execution, delivery or performance of this Agreement by such Grantor, (ii)&#160;the perfection of such security interest (to the extent such security interest can be perfected by filing under the UCC, the granting of control (to the extent required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or by filing an appropriate notice with the USPTO or the United States Copyright Office) or (iii)&#160;the exercise by the Purchaser Agent or the Secured Parties of the rights and remedies provided for in this Agreement (including, without limitation, as against any Issuer), except for (A)&#160;the filing or recording of UCC financing statements or other filings under the Assignment of Claims Act, (B)&#160;the filing of appropriate notices with the USPTO and the United States Copyright Office, (C)&#160;obtaining control to perfect the Liens created by this Agreement (to the extent required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), (D)&#160;such actions as may be required by Applicable Laws affecting the offering and sale of securities, (E)&#160;such actions as may be required by applicable foreign laws affecting the pledge of the Pledged Equity of Subsidiaries not formed under the laws of the United States and (F)&#160;consents, authorizations, filings or other actions which have been obtained or made.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Commercial Tort Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No Grantor has any Commercial Tort Claims seeking damages, or with respect to which damages could reasonably be expected to be, in excess of $2,000,000 other than as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt;text-decoration:underline">Deposit Accounts, Securities Accounts and Commodity Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter is a description of all Deposit Accounts, Securities Accounts and Commodity Accounts of the Grantors, including the name of (A)&#160;the applicable Grantor, (B)&#160;in the case of a Deposit Account, the depository institution and whether such account is an Excluded Account (and, if so, under which clause of the definition of &#8220;Excluded Account&#8221;), (C)&#160;in the case of a Securities Account, the Securities Intermediary or issuer, as applicable, and (D)&#160;in the case of a Commodity Account, the Commodity Intermediary or issuer, as applicable. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Copyrights, Patents and Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">To the knowledge of each Grantor, as of the Closing Date, each issued material Patent and Trademark of such Grantor that is listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;3.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter of the Purchase Agreement is valid, subsisting, unexpired, enforceable and has not been abandoned, except in the ordinary course of business or where such lapse or abandonment would not reasonably be likely to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">No holding, decision or judgment has been rendered by any Governmental Authority that would limit, cancel or question the validity of any material Patent of any Grantor.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">To the knowledge of each Grantor, all applications pertaining to the material Copyrights, and material Patents and Trademarks of each Grantor have been duly and properly filed, and all registrations or letters pertaining to such material Copyrights, Patents and Trademarks have been duly and properly filed and issued, and that there are no unpaid maintenance, annuity or renewal currently overdue for any of the material Patents or Trademarks.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">No Grantor has made any assignment or agreement in conflict with the security interest in the Intellectual Property of any Grantor hereunder.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Each Grantor and each of its Subsidiaries, owns, or possesses the right to use, all of the Intellectual Property that is used in or reasonably necessary for the operation of their respective businesses, without known infringement or misappropriation of or conflict with the rights of any other Person.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">To the knowledge of each Grantor, neither the conduct of the business of such Grantor and each of its Subsidiaries nor any slogan or other advertising device, product, process, method, substance, part or other material now employed, or now contemplated to be employed by such Grantor or any of its Subsidiaries is known to infringe, misappropriate, dilute or otherwise violate any rights held by any other Person.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5.11(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, no Grantor or any Subsidiary thereof pays or owes any milestone payments, royalty payments, upfront payments, license payments and similar payments to any Person with respect to any Intellectual Property.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">As of the Closing Date, no proceeding, claim or litigation regarding any of the foregoing is pending or threatened in writing.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Grantor covenants that until the termination of the Purchase Agreement in accordance with the terms of Section&#160;6.01 of the Purchase Agreement (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), such Grantor shall&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Maintenance of Perfected Security Interest&#59; Further Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Maintain the security interest created by this Agreement as a first priority perfected security interest (subject only to Permitted Priority Liens) and shall defend such security interest against the claims and demands of all Persons whomsoever (other than the holders of Permitted Priority Liens).</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">From time to time furnish to the Purchaser Agent upon the Purchaser Agent&#8217;s or any Purchaser&#8217;s reasonable request, statements and schedules further identifying and describing the assets and property of such Grantor and such other reports in connection therewith as the Purchaser Agent or such Purchaser may reasonably request, all in reasonable detail.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Required Notifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Grantor shall promptly notify the Purchaser Agent, in writing, of&#58; (i)&#160;any Lien (other than Permitted Liens) on any of the Collateral which would adversely affect the ability of the Purchaser Agent to exercise any of its remedies hereunder, and (ii)&#160;the occurrence of any other event which could reasonably be expected to have a material </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment on any material portion of the value of the Collateral or on the security interests created hereby.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Perfection through Possession and Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">To the extent not previously delivered, deliver to the Purchaser Agent, concurrently with the delivery of each Quarterly Report pursuant to Section&#160;5.02(a)(iii) of the Purchase Agreement, all certificates and instruments constituting Pledged Equity and a supplement to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter to describe such Pledged Equity&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the issuer of any Pledged Equity becomes a Subsidiary Guarantor pursuant to Section&#160;5.06(c) of the Purchase Agreement, then on or before the date such issuer of such Pledged Equity becomes a Subsidiary Guarantor, the Grantor of such Pledged Equity shall deliver to the Purchaser Agent all certificates and instruments constituting such Pledged Equity and a supplement to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter to describe such Pledged Equity. Prior to delivery to the Purchaser Agent, all such certificates constituting Pledged Equity shall be held in trust by such Grantor for the benefit of the Purchaser Agent pursuant hereto. All such certificates representing Pledged Equity shall be delivered in suitable form for transfer by delivery or shall be accompanied by duly executed instruments of transfer or assignment in blank, substantially in the form provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereto or other form acceptable to the Purchaser Agent.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">(1)&#160;To the extent not previously delivered, deliver to the Purchaser Agent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concurrently with the delivery of each Quarterly Report pursuant to Section&#160;5.02(a)(iii) of the Purchase Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all Instruments, Supporting Obligations, Investment Property, Documents and Chattel Paper (and with respect to Electronic Chattel Paper, take all steps reasonably necessary to grant the Purchaser Agent control of all such Electronic Chattel Paper in accordance with the UCC and all &#8220;transferable records&#8221; as that term is defined in Section&#160;16 of the Uniform Electronic Transaction Act and Section&#160;201 of the federal Electronic Signatures in Global and National Commerce Act as in effect in any relevant jurisdiction), in each case, with an individual face amount or value (whichever is higher) in excess of $2,000,000 and to the extent constituting Collateral, which shall be in form suitable for transfer by delivery, together with appropriate endorsements or other necessary instruments of registration, transfer or assignment, duly executed and in form and substance reasonably satisfactory to the Purchaser Agent, and in each case together with such other instruments or documents as the Purchaser Agent may reasonably request and (2)&#160;supplement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;2B</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter to describe any such Instrument, Chattel Paper, Investment Property, Supporting Obligations, Documents and Chattel Paper. Such Grantor shall ensure that any Collateral consisting of Chattel Paper is, if requested by the Purchaser Agent, marked with a legend reasonably acceptable to the Purchaser Agent indicating the Purchaser Agent&#8217;s security interest in such Chattel Paper. Each Grantor will, at its own cost and expense, cooperate with the Purchaser Agent in obtaining a control agreement, in form and substance reasonably satisfactory to the Purchaser Agent, and in taking such other actions as may be reasonably requested by the Purchaser Agent from time to time with respect to any Investment Property constituting Collateral or other Collateral in which a security interest may be perfected only by control under the UCC (or other Applicable Law).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Filing of Financing Statements, Notices, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Grantor shall execute and deliver to the Purchaser Agent and&#47;or file such agreements, assignments or instruments (including affidavits, notices, reaffirmations and amendments and restatements of existing documents, as the Purchaser Agent may reasonably request) and do all such other things as the Purchaser Agent may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably deem necessary (i)&#160;to perfect and maintain the security interests granted hereunder in accordance with the UCC or other Applicable Law, including, without limitation, (A)&#160;financing statements (including continuation statements), (B)&#160;with regard to Copyrights included in the Collateral, a Notice of Grant of Security Interest in Copyrights for filing in the United States Copyright Office substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or other form reasonably acceptable to the Purchaser Agent, (C)&#160;with regard to Patents included in the Collateral, a Notice of Grant of Security Interest in Patents for filing with the USPTO substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or other form reasonably acceptable to the Purchaser Agent and (D)&#160;with regard to Trademarks included in the Collateral, a Notice of Grant of Security Interest in Trademarks for filing with the USPTO substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or other form reasonably acceptable to the Purchaser Agent, (ii)&#160;to consummate the transactions contemplated hereby and (iii)&#160;to otherwise protect and assure the Purchaser Agent of its rights and interests hereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Collateral Held by Warehouseman, Bailee, Etc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Without limiting the generality of any other provision of this Agreement, each Grantor agrees that it shall not permit any Collateral valued in excess of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)&#160;prior to the Milestone, $2,500,000 and (y)&#160;from and after the occurrence of the Milestone, $10,000,000 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be in the possession of any bailee, warehouseman, agent, processor or other third party at any time unless such bailee or other Person shall have been notified of the security interest created by this Agreement (or, if required under Applicable Law in order to perfect the Purchaser Agent&#8217;s security interest in such Collateral, such bailee or other Person shall have acknowledged to the Purchaser Agent in writing that it is holding such Collateral for the benefit of the Purchaser Agent and subject to such security interest and to the instructions of the Purchaser Agent) and such Grantor shall have exercised its commercially reasonable best efforts to obtain from such bailee or other Person, at such Grantor&#8217;s sole cost and expense, (1)&#160;the written acknowledgement described above (if not already required by Applicable Law to perfect the Purchaser Agent&#8217;s security interest) and agreement to waive and release any Lien (whether arising by operation of Applicable Law or otherwise) it may have with respect to such Collateral, such agreement to be in form and substance reasonably satisfactory to the Purchaser Agent and (2)&#160;such other documentation required by the Purchaser Agent or the Purchaser Agent (including, without limitation, subordination and access agreements in respect of such location). </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">At the Purchaser Agent&#8217;s reasonable request, perfect and protect such Grantor&#8217;s ownership interests in all Inventory stored with a consignee against creditors of the consignee by filing and maintaining financing statements against the consignee reflecting the consignment arrangement filed in all appropriate filing offices, providing any written notices required by the UCC to notify any prior creditors of the consignee of the consignment arrangement, and taking such other actions as may be appropriate to perfect and protect such Grantor&#8217;s interests in such inventory under Section&#160;2-326, Section&#160;9-103, Section&#160;9-324 and Section&#160;9-505 of the UCC or otherwise, which such financing statements filed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4(e)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be assigned to the Purchaser Agent, for the benefit of the Secured Parties.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt;text-decoration:underline">Landlord Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Use its commercially reasonable best efforts to deliver to Purchaser Agent a landlord waiver and collateral access agreement with respect to each Grantor&#8217;s (i)&#160;locations set forth in the Perfection Certificate as of the Closing Date and (ii)&#160;any other leased location at which Collateral is stored from time to time with an aggregate value in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">excess of, or with a per annum rental rate in excess of, in each case, (x)&#160;prior to the Milestone, $2,500,000 and (y)&#160;from and after the occurrence of the Milestone, $10,000,000&#59; provided, that the requirement set forth in this sentence shall not apply to the property located at 3805&#160;Lake Shore Drive&#160;E, Dunkirk,&#160;NY 14048.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">In the event such Grantor leases any real property from any Affiliate after the Closing Date, substantially concurrently with its entry into the applicable lease, deliver to Purchaser Agent a leasehold mortgage in form and substance reasonably satisfactory to Purchaser Agent in favor of the Purchaser Agent for the benefit of the Purchasers with respect to such real property.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Commercial Tort Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Execute and deliver such statements, documents and notices and do and cause to be done all such things as may be required by law to create, preserve, perfect and maintain the Purchaser Agent&#8217;s security interest in any Commercial Tort Claims set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter initiated by or in favor of any Grantor. If the Grantors (or any of them) obtain Commercial Tort Claims seeking damages, or with respect to which damages could reasonably be expected to be, in excess of $2,000,000 that are not described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter, then the applicable Grantor or Grantors shall (x)&#160;concurrently with the delivery of each Quarterly Report pursuant to Section&#160;5.02(a)(iii) of the Purchase Agreement, notify the Purchaser Agent thereof and (y)&#160;after written request by the Purchaser Agent, supplement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter to describe such Commercial Tort Claims in a manner that reasonably identifies such Commercial Tort Claims and which is otherwise reasonably satisfactory to the Purchaser Agent, and hereby authorizes the filing of additional financing statements or amendments to existing financing statements describing such Commercial Tort Claims, and agrees to do such other acts or things reasonably deemed necessary by the Purchaser Agent to give Purchaser Agent, on behalf of the Secured Parties, a first priority perfected security interest (subject to Permitted Priority Liens) in any such Commercial Tort Claim.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to the Inventory of each Grantor&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#91;reserved&#93;.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Produce, use, store and maintain the Inventory in accordance in all material respects with applicable standards of any insurance and in conformity in all material respects with Applicable Laws (including the requirements of the Federal Fair Labor Standards Act of 1938, as amended and all rules, regulations and orders related thereto).</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cause each Issuer of Pledged Equity to mark its books and records to reflect the security interest granted pursuant to this Agreement.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Nature of Collateral.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At all times maintain the Collateral as personal property and not affix any Collateral that is material to the business of the Grantors or otherwise of any material value, or any Anktiva Collateral, to any real property in a manner which would change its nature from personal property to real property or a Fixture to real property, unless the Purchaser Agent shall have a perfected Lien on such Fixture or real property.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Issuance or Acquisition of Equity Interests in Partnerships or Limited Liability Companies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Without first executing and delivering, or causing to be executed and delivered, to the Purchaser Agent such agreements, documents and instruments as the Purchaser Agent may reasonably require, no Grantor will issue or acquire any Pledged Equity consisting of an interest in a partnership or a limited liability company that (A)&#160;is dealt in or traded on a securities exchange or in a securities market, (B)&#160;by its terms expressly provides that it is a Security governed by Article&#160;8 of the UCC, (C)&#160;is an Investment Company Security, (D)&#160;is held in a Securities Account or (E)&#160;constitutes a Security or a Financial Asset.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Without the prior written consent of the Purchaser Agent, no Grantor will (A)&#160;vote to enable, or take any other action to permit, any applicable Issuer to issue any Investment Property or Equity Interests consisting of Collateral and constituting partnership or limited liability company interests, except for additional Investment Property or Equity Interests constituting partnership or limited liability company interests that will be subject to the security interest granted herein in favor of the Secured Parties, or (B)&#160;enter into any agreement or undertaking, except to the extent permitted under the Purchase Agreement, restricting the right or ability of such Grantor or the Purchaser Agent to sell, assign or transfer any Investment Property or Pledged Equity or Proceeds thereof. The Grantors will defend the right, title and interest of the Purchaser Agent in and to any Investment Property and Pledged Equity against the claims and demands of all Persons whomsoever, other than claims constituting Permitted Liens under clause&#160;(p) thereof.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">If any Grantor shall become entitled to receive or shall receive (A)&#160;any Certificated Securities (including, without limitation, any certificate representing a stock dividend or a distribution in connection with any reclassification, increase or reduction of capital or any certificate issued in connection with any reorganization), option or rights in respect of the ownership interests of any Issuer, whether in addition to, in substitution of, as a conversion of, or in exchange for, any Investment Property, or otherwise in respect thereof, or (B)&#160;any sums paid upon or in respect of any Investment Property upon the liquidation or dissolution of any Issuer, in each case, to the extent constituting Collateral, such Grantor shall accept the same as the agent of the Secured Parties, hold the same in trust for the Secured Parties, segregated from other funds of such Grantor, and promptly deliver the same to the Purchaser Agent, on behalf of the Secured Parties, in accordance with the terms hereof.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Not do any act or omit to do any act whereby any material Copyright may become invalidated and (A)&#160;not do any act, or omit to do any act, whereby any material Copyright may become injected into the public domain&#59; (B)&#160;notify the Purchaser Agent immediately if it knows that any material Copyright may become injected into the public domain or of any materially adverse determination or development (including, without limitation, the institution of, or any such determination or development in, any court or tribunal in the United States or any other country) regarding a Grantor&#8217;s ownership of any such Copyright or its validity&#59; (C)&#160;take all necessary steps as it shall deem appropriate under the circumstances, to maintain and pursue each application (and to obtain the relevant registration) of each material Copyright owned by a Grantor and to maintain each registration of each material Copyright owned by a Grantor including, without limitation, filing of applications for renewal where necessary&#59; and (D)&#160;promptly upon becoming aware, notify the Purchaser Agent of any material infringement, misappropriation, dilution or impairment of any material Copyright of a Grantor of which it becomes aware and take </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such actions as such Grantor shall reasonably deem appropriate under the circumstances to protect such Copyright, including, where appropriate, the bringing of suit for infringement, dilution or impairment or seeking injunctive relief and seeking to recover any and all damages for such infringement, misappropriation, dilution or impairment.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">&#91;Reserved.&#93;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">(A)&#160;Continue to maintain each material Trademark in full force free from any claim of abandonment for non-use, (B)&#160;maintain as in the past the quality of products and services offered under such material Trademark, (C)&#160;employ such material Trademark with the appropriate notice of registration, if applicable, (D)&#160;&#91;reserved&#93;, and (E)&#160;not (and not permit any licensee or sublicensee thereof to) do any act or omit to do any act whereby any such material Trademark may become invalidated.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Not do any act, or omit to do any act, whereby any material Patent may become abandoned, invalidated or dedicated to the public.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Promptly notify the Purchaser Agent if it knows that any application or registration relating to any material Patent or material Trademark may become abandoned or dedicated, or of any materially adverse determination or development (including, without limitation, the institution of, or any such determination or development in, any proceeding in the USPTO or any court or tribunal in any country) regarding such Grantor&#8217;s ownership of any such material Patent or material Trademark or its right to register the same or to keep, maintain and enforce the same.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Take all commercially reasonable steps, including, without limitation, in any proceeding before the USPTO, or any similar office or agency in any other country or any political subdivision thereof, to maintain and pursue each application (and to obtain the relevant registration) and to maintain each registration of each material Patent and material Trademark, including, without limitation, filing of applications for renewal, affidavits of use and affidavits of incontestability.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">Promptly notify the Purchaser Agent after it learns that any material Patent or material Trademark included in the Collateral is infringed, misappropriated, diluted or impaired by a third party, and take such actions as such Grantor shall reasonably deem appropriate under the circumstances and&#47;or that Purchaser Agent reasonably requests to protect such Patent or Trademark, including, without limitation, the bringing of suit for infringement, dilution or impairment or seeking injunctive relief and seeking to recover any and all damages for such infringement, misappropriation, dilution or impairment.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">Not make any assignment or agreement in conflict with the security interest in the Patents or Trademarks of each Grantor hereunder (except as permitted by the Purchase Agreement).</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">&#91;Reserved&#93;.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#91;Reserved&#93;.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xi)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Execute and deliver to the Purchaser Agent on the date hereof fully completed assignments in the forms of Exhibits&#160;B, C&#160;and D, as applicable, for recordation in the United States Copyright Office or the USPTO, as applicable, with regard to any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collateral constituting Copyrights, Patents or Trademarks, as the case may be, in existence as of the Closing Date and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter. In the event that after the date hereof any Grantor shall acquire any registered Copyright, Patent or Trademark constituting Collateral, or effect any registration of any Copyright, Patent or Trademark constituting Collateral or file any application for registration thereof, whether within the United States or any other country or jurisdiction, such Grantor shall provide written notice to the Purchaser Agent thereof concurrently with the delivery of a Quarterly Report for such calendar quarter pursuant to Section&#160;5.02(a)(iii) of the Purchase Agreement, together with any additional information reasonably requested by, and sufficient to permit the Purchaser Agent, upon its receipt of such notice, to (and each Grantor hereby authorizes the Purchaser Agent to) modify this Agreement, as appropriate, by amending </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Disclosure Letter or to add additional exhibits hereto to include any Copyright, Patent or Trademark that becomes part of the Collateral under this Agreement, and such Grantor shall additionally, at its own expense, execute and deliver to the Purchaser Agent, as promptly as possible (but in any event within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ten&#160;(1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0) days after the date of any request therefor with regard to United States Patents, Trademarks and Copyrights constituting Collateral), fully completed assignments in the forms of Exhibits&#160;B, C&#160;and D, as applicable, for recordation in the United States Copyright Office or the USPTO as more fully described hereinabove, together in all instances with any other agreements, instruments and documents that the Purchaser Agent may reasonably request from time to time to further effect and confirm the assignment and security interest created by this Agreement in such Copyrights, Patents and Trademarks, and each Grantor hereby appoints the Purchaser Agent its attorney-in-fact to execute, deliver and record any and all such agreements, instruments and documents for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed and such power, being coupled with an interest, shall be irrevocable for so long as this Agreement shall be in effect with respect to such Grantor. Upon the occurrence and during the continuance of a Put Option Event, upon request of the Purchaser Agent, each Grantor shall use commercially reasonable efforts to obtain all requisite consents or approvals from the licensor of each In-License with respect to Grantor&#8217;s material Copyrights, material Patents or material Trademarks constituting Collateral to effect the assignment of all of such Grantor&#8217;s right, title and interest thereunder to the Purchaser Agent or its designee.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt;text-decoration:underline">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Maintain each item of Equipment in good working order and condition (reasonable wear and tear and obsolescence excepted), except to the extent that the failure to do so would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Government Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent notice to the Purchaser Agent has not already been provided, promptly notify the Purchaser Agent, in writing, if it enters into any contract with a Governmental Authority under which such Governmental Authority, as Account Debtor, owes a monetary obligation to any Grantor under any Account.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">&#91;Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Promptly upon the request of the Purchaser Agent, and at the sole expense of the Grantors, duly execute and deliver, and have recorded, such further instruments and documents and take such further actions as the Purchaser Agent may reasonably request for the purpose of obtaining or preserving the full benefits of this Agreement and of the rights and powers herein granted, including, without limitation, all applications, certificates, instruments, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registration statements, and all other documents and papers the Purchaser Agent may reasonably request and as may be required by law in connection with the obtaining of any consent, approval, registration, qualification, or authorization of any Person deemed necessary or appropriate for the effective exercise of any rights under this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Authorization to File Financing Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Grantor hereby authorizes the Purchaser Agent to prepare and file (and, to the extent applicable, sign) in the name of such Grantor such financing statements (including continuation statements) or amendments thereof or supplements thereto or other instruments as the Purchaser Agent may from time to time deem necessary or appropriate in order to perfect and maintain the security interests granted hereunder in accordance with the UCC (or other Applicable Law), which such financing statements may describe the Collateral in the same manner as described herein or may contain an indication or description of Collateral that describes such property in any other manner as the Purchaser Agent may determine, in its sole discretion, is necessary, advisable or prudent to ensure the perfection of the security interest in the Collateral granted herein, including, without limitation, describing such property as &#8220;all assets, whether now owned or hereafter acquired&#8221; or &#8220;all personal property, whether now owned or hereafter acquired.&#8221;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Advances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent may, at its sole option and in its sole discretion, perform </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any obligations hereunder of any Grantor on behalf of such Grantor necessary to preserve the value of the Collateral,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and in so doing may expend such sums as the Purchaser Agent may reasonably deem advisable in the performance thereof, including, without limitation, the payment of any insurance premiums, the payment of any taxes, a payment to obtain a release of a Lien or potential Lien, expenditures made in defending against any adverse claim and all other expenditures which the Purchaser Agent may make for the protection of the security hereof or which may be compelled to make by operation of Applicable Law. All such sums and amounts so expended shall be repayable by the Grantors on a joint and several basis promptly upon timely notice thereof and demand therefor, shall constitute additional Obligations and shall bear interest from the date said amounts are expended at the rate set forth in Section&#160;2.02(f) of the Purchase Agreement. No such performance of any covenant or agreement by the Purchaser Agent on behalf of any Grantor, and no such advance or expenditure therefor, shall relieve the Grantors of any Put Option Event. The Purchaser Agent may make any payment hereby authorized in accordance with any bill, statement or estimate procured from the appropriate public office or holder of the claim to be discharged without inquiry into the accuracy of such bill, statement or estimate or into the validity of any tax assessment, sale, forfeiture, tax lien, title or claim except to the extent such payment is being contested in good faith by a Grantor in appropriate proceedings and against which adequate reserves are being maintained in accordance with GAAP.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">General Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent on behalf of the Secured Parties shall have, in addition to the rights and remedies provided herein, in the Transaction Documents, in any other documents relating to the Obligations, or by any Applicable Law (including, but not limited to, levy of attachment, garnishment and the rights and remedies set forth in the UCC of the jurisdiction applicable to the affected Collateral), the rights and remedies of a secured party under the UCC (regardless of whether the UCC is the law of the jurisdiction where the rights and remedies are asserted and regardless of whether the UCC applies to the affected Collateral), and further, the Purchaser Agent may, with or without judicial process or the aid and assistance of others, (i)&#160;enter on any premises on which any of the Collateral may be located and, without resistance or interference by the Grantors, take possession of the Collateral, (ii)&#160;dispose of any Collateral on any such premises, (iii)&#160;require the Grantors to assemble and make available to the Purchaser Agent at the expense of the Grantors any Collateral at any place and time designated by the Purchaser Agent which is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably convenient to both parties, (iv)&#160;remove any Collateral from any such premises for the purpose of effecting sale or other disposition thereof, (v)&#160;without demand and without advertisement, notice, hearing or process of law, all of which each of the Grantors hereby waives to the fullest extent permitted by Applicable Law, at any place and time or times, sell, lease, assign, give option or options to purchase, or otherwise dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels of any or all Collateral held by or for it at public or private sale (which in the case of a private sale of Pledged Equity, shall be to a restricted group of purchasers who will be obligated to agree, among other things, to acquire such securities for their own account, for investment and not with a view to the distribution or resale thereof), at any exchange or broker&#8217;s board or elsewhere, by one or more contracts, in one or more parcels, for money, upon credit or otherwise, at such prices and upon such terms as the Purchaser Agent deems advisable, in its sole discretion (subject in all cases to any and all mandatory legal requirements) and&#47;or (vi)&#160;complete and tender each internet domain name transfer document in its own name, place and stead of the Grantor in order to effect the transfer of any internet domain name registration, either to the Purchaser Agent or to another transferee, as the case may be and maintain, obtain access to, and continue to operate, in its own name or in the name, place and stead of such Grantor, such Grantor&#8217;s internet website and the contents thereof, and all related advertising, linking and technology licensing and other contractual relationships, in each case in connection with the maintenance, preservation, operation, sale or other disposition of the Collateral or for any other purpose permitted under the Transaction Documents or by Applicable Law. Each Grantor acknowledges that any such private sale may be at prices and on terms less favorable to the seller than the prices and other terms which might have been obtained at a public sale and, notwithstanding the foregoing, agrees that such private sale shall be deemed to have been made in a commercially reasonable manner and, in the case of a sale of Pledged Equity, that the Purchaser Agent shall have no obligation to delay sale of any such securities for the period of time necessary to permit the Issuer of such securities to register such securities for public sale under the Securities Act of 1933. The Purchaser Agent or any other Secured Party shall have the right upon any such public sale or sales, and, to the extent permitted by Applicable Law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold. Neither the Purchaser Agent&#8217;s compliance with Applicable Law nor its disclaimer of warranties relating to the Collateral shall be considered to adversely affect the commercial reasonableness of any sale. To the extent the rights of notice cannot be legally waived hereunder, each Grantor agrees that any requirement of reasonable notice shall be met if such notice, specifying the place of any public sale or the time after which any private sale is to be made, is personally served on or mailed, postage prepaid, to the Company</font><font style="color:#7030a0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with the notice provisions of Section&#160;8.02 of the Purchase Agreement at least ten&#160;(10) days before the time of sale or other event giving rise to the requirement of such notice. Each Grantor further acknowledges and agrees that any offer to sell any Pledged Equity which has been (A) publicly advertised on a bona fide basis in a newspaper or other publication of general circulation in the financial community of New York, New York (to the extent that such offer may be advertised without prior registration under the Securities Act of 1933), or (B)&#160;made privately in the manner described above shall be deemed to involve a &#8220;public sale&#8221; under the UCC, notwithstanding that such sale may not constitute a &#8220;public offering&#8221; under the Securities Act of 1933, and the Purchaser Agent may, in such event, bid for the purchase of such securities. The Purchaser Agent shall not be obligated to make any sale or other disposition of the Collateral regardless of notice having been given. To the extent permitted by Applicable Law, any Secured Party may be a purchaser at any such sale. To the extent permitted by Applicable Law, each of the Grantors hereby waives all of its rights of redemption with respect to any such sale. Subject to the provisions of Applicable Law, the Purchaser Agent may postpone or cause the postponement of the sale of all or any portion of the Collateral by announcement at the time and place of such sale, and such sale may, without further notice, to the extent permitted by Applicable Law, be made at the time and place to which the sale was postponed, or the Purchaser Agent may further postpone </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such sale by announcement made at such time and place. To the extent permitted by Applicable Law, each Grantor waives all claims, damages and demands it may acquire against the Purchaser Agent or any Secured Party arising out of the exercise by them of any rights hereunder except to the extent any such claims, damages or demands result solely from the gross negligence or willful misconduct of the Purchaser Agent or any other Secured Party as determined by a final non-appealable judgment of a court of competent jurisdiction, in each case against whom such claim is asserted. Each Grantor agrees that the internet shall constitute a &#8220;place&#8221; for purposes of Section&#160;9-610(b) of the UCC and that any sale of Collateral to a licensor pursuant to the terms of a license agreement between such licensor and a Grantor is sufficient to constitute a commercially reasonable sale (including as to method, terms, manner, and time) within the meaning of Section&#160;9-610 of the UCC.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Remedies Relating to Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Upon the occurrence and during the continuance of a Put Option Event, whether or not the Purchaser Agent has exercised any or all of its rights and remedies hereunder, (A)&#160;upon request of the Purchaser Agent, each Grantor shall notify (such notice to be in form and substance satisfactory to the Purchaser Agent) its Account Debtors and parties to the Material Contracts subject to a security interest hereunder that such Accounts and the Material Contracts have been assigned to the Purchaser Agent, for the benefit of the Secured Parties and promptly upon request of the Purchaser Agent, instruct all Account Debtors to remit all payments in respect of Accounts to a mailing location selected by the Purchaser Agent and (B)&#160;the Purchaser Agent shall have the right to enforce any Grantor&#8217;s rights against its customers and Account Debtors, and the Purchaser Agent or its designee may notify any Grantor&#8217;s customers and Account Debtors that the Accounts of such Grantor have been assigned to the Purchaser Agent or of the Purchaser Agent&#8217;s security interest therein, and may (either in its own name or in the name of a Grantor or both) demand, collect (including without limitation by way of a lockbox arrangement), receive, take receipt for, sell, sue for, compound, settle, compromise and give acquittance for any and all amounts due or to become due on any Account, and, in the Purchaser Agent&#8217;s discretion, file any claim or take any other action or proceeding to protect and realize upon the security interest of the Secured Parties in the Accounts.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Each Grantor acknowledges and agrees that the Proceeds of its Accounts remitted to or on behalf of the Purchaser Agent in accordance with the provisions hereof shall be solely for the Purchaser Agent&#8217;s own convenience and that such Grantor shall not have any right, title or interest in such Accounts or in any such other amounts except as expressly provided herein. Neither the Purchaser Agent nor the Secured Parties shall have any liability or responsibility to any Grantor for acceptance of a check, draft or other order for payment of money bearing the legend &#8220;payment in full&#8221; or words of similar import or any other restrictive legend or endorsement or be responsible for determining the correctness of any remittance.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">Upon the occurrence and during the continuance of a Put Option Event, (A)&#160;the Purchaser Agent shall have the right, but not the obligation, to make test verifications of the Accounts in any manner and through any medium that it reasonably considers advisable, and the Grantors shall furnish all such assistance and information as the Purchaser Agent may require in connection with such test verifications, (B)&#160;upon the Purchaser Agent&#8217;s request and at the expense of the Grantors, the Grantors shall cause independent public accountants or others satisfactory to the Purchaser Agent to furnish to the Purchaser Agent reports showing reconciliations, aging and test verifications of, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial balances for, the Accounts and (C)&#160;the Purchaser Agent in its own name or in the name of others may communicate with Account Debtors on the Accounts to verify with them to the Purchaser Agent&#8217;s satisfaction the existence, amount and terms of any Accounts.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Upon the occurrence and during the continuance of a Put Option Event, and upon the request of the Purchaser Agent, each Grantor shall forward to the Purchaser Agent, on the last Business Day of each week, deposit slips related to all cash, money, checks or any other similar items of payment received by the Grantor during such week, and, if requested by the Purchaser Agent, copies of such checks or any other similar items of payment, together with a statement showing the application of all payments on the Collateral during such week and a collection report with regard thereto, in form and substance satisfactory to the Purchaser Agent.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Deposit Accounts&#47;Commodity Accounts&#47;Securities Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent may prevent withdrawals or other dispositions of funds in Deposit Accounts, Commodity Accounts and Securities Accounts subject to Control Agreements or held with any Secured Party.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Investment Property&#47;Pledged Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to receive any and all cash dividends, payments or distributions made in respect of any Investment Property or Pledged Equity or other Proceeds paid in respect of any Investment Property or Pledged Equity, and any or all of any Investment Property or Pledged Equity may, at the option of the Purchaser Agent, be registered in the name of the Purchaser Agent or its nominee, and the Purchaser Agent or its nominee may thereafter exercise (i) all voting, corporate and other rights pertaining to such Investment Property, or any such Pledged Equity at any meeting of shareholders, partners or members of the relevant Issuers or otherwise and (ii) any and all rights of conversion, exchange and subscription and any other rights, privileges or options pertaining to such Investment Property or Pledged Equity as if it were the absolute owner thereof (including, without limitation, the right to exchange at its discretion any and all of the Investment Property or Pledged Equity upon the merger, consolidation, reorganization, recapitalization or other fundamental change in the corporate, partnership or limited liability company structure of any Issuer or upon the exercise by any Grantor or the Purchaser Agent of any right, privilege or option pertaining to such Investment Property or Pledged Equity, and in connection therewith, the right to deposit and deliver any and all of the Investment Property or Pledged Equity with any committee, depositary, transfer agent, registrar or other designated agency upon such terms and conditions as the Purchaser Agent may determine), all without liability except to account for property actually received by it&#59; but the Purchaser Agent shall have no duty to any Grantor to exercise any such right, privilege or option and the Purchaser Agent and the other Secured Parties shall not be responsible for any failure to do so or delay in so doing. In furtherance thereof, each Grantor hereby authorizes and instructs each Issuer with respect to any Collateral consisting of Investment Property and&#47;or Pledged Equity to (A)&#160;comply with any instruction received by it from the Purchaser Agent in writing that (1)&#160;states that a Put Option Event has occurred and is continuing and (2)&#160;is otherwise in accordance with the terms of this Agreement, without any other or further instructions from such Grantor, and each Grantor agrees that each Issuer shall be fully protected in so complying following receipt of such notice and prior to notice that such Put Option Event has been waived in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Purchase Agreement, and (B)&#160;except as consented in writing by the Purchaser Agent or otherwise expressly permitted hereby, until such Put Option Event shall have been waived by the Purchaser Agent in accordance with Section&#160;8.08 of the Purchase Agreement, pay any dividends, distributions or other payments with respect to any Investment Property or Pledged Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directly to the Purchaser Agent. Unless the Purchaser Agent shall have given notice to the relevant Grantor </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Purchaser Agent&#8217;s intent to exercise its corresponding rights pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, each Grantor shall be permitted to receive all cash dividends, payments or other distributions made in respect of any Investment Property and any Pledged Equity, in each case paid in the normal course of business of the relevant Issuer and consistent with past practice, to the extent not prohibited in the Purchase Agreement, and to exercise all voting and other corporate, company and partnership rights with respect to any Investment Property and Pledged Equity to the extent not prohibited with the terms of this Agreement and the other Transaction Documents.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Material Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall be entitled to (but shall not be required to)&#58; (i)&#160;proceed to perform any and all obligations of the applicable Grantor under any Material Contract and exercise all rights of such Grantor thereunder as fully as such Grantor itself could, (ii)&#160;do all other acts which the Purchaser Agent may deem necessary or proper to protect its security interest granted hereunder, provided such acts are not inconsistent with or in violation of the terms of any of the Purchase Agreement, of the other Transaction Documents or Applicable Law, and (iii)&#160;sell, assign or otherwise transfer any Material Contract in accordance with the Purchase Agreement, the other Transaction Documents and Applicable Law, subject, however, to the prior approval of each other party to such Material Contract, to the extent required under such Material Contract.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt;text-decoration:underline">Access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the rights and remedies hereunder, upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to enter and remain upon the various premises of the Grantors without cost or charge to the Purchaser Agent, and use the same, together with materials, supplies, books and records of the Grantors for the purpose of collecting and liquidating the Collateral, or for preparing for sale and conducting the sale of the Collateral, whether by foreclosure, auction or otherwise. In addition, upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent may remove Collateral, or any part thereof, from such premises and&#47;or any records with respect thereto, in order to effectively collect or liquidate such Collateral. If the Purchaser Agent exercises its right to take possession of the Collateral, each Grantor shall also at its expense perform any and all other steps reasonably requested by the Purchaser Agent to preserve and protect the security interest hereby granted in the Collateral, such as placing and maintaining signs indicating the security interest of the Purchaser Agent, appointing overseers for the Collateral and maintaining inventory records.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Nonexclusive Nature of Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Failure by the Purchaser Agent or the Secured Parties to exercise any right, remedy or option under this Agreement, any other Transaction Document, any other document relating to the Obligations, or as provided by Applicable Law, or any delay by the Purchaser Agent or the Secured Parties in exercising the same, shall not operate as a waiver of any such right, remedy or option. No waiver of any provision hereunder shall be effective unless it satisfies the requirements set forth in Section&#160;8.08 of the Purchase Agreement. To the extent permitted by Applicable Law, neither the Purchaser Agent, the Secured Parties, nor any party acting as attorney for the Purchaser Agent or the Secured Parties, shall be liable hereunder for any acts or omissions or for any error of judgment or mistake of fact or law other than their gross negligence or willful misconduct hereunder as determined by a final non-appealable judgment of a court of competent jurisdiction. The rights and remedies of the Purchaser Agent and the Secured Parties under this Agreement shall be cumulative and not exclusive of any other right or remedy which the Purchaser Agent or the Secured Parties may have.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Retention of Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the rights and remedies hereunder, the Purchaser Agent may, in compliance with Sections&#160;9-620 and 9-621 of the UCC or otherwise in compliance with the requirements of Applicable Law of the relevant jurisdiction, accept or retain the Collateral in satisfaction of the Obligations. Unless and until the Purchaser Agent shall have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided such notices, however, the Purchaser Agent shall not be deemed to have retained any Collateral in satisfaction of any Obligations for any reason.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Waiver&#59; Deficiency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Grantor hereby waives, to the extent permitted by Applicable Laws, all rights of redemption, appraisement, valuation, stay, extension or moratorium now or hereafter in force under any Applicable Laws in order to prevent or delay the enforcement of this Agreement or the absolute sale of the Collateral or any portion thereof. In the event that the proceeds of any sale, collection or realization are insufficient to pay all amounts to which the Purchaser Agent or the Secured Parties are legally entitled, the Grantors shall be jointly and severally liable for the deficiency, together with interest thereon at the rate set forth in Section&#160;2.02(f) of the Purchase Agreement, together with the costs of collection and the fees, charges and disbursements of counsel. Any surplus remaining after the full payment and satisfaction of the Obligations shall be returned to the Grantors or to whomsoever a court of competent jurisdiction shall determine to be entitled thereto.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">For the purpose of enabling the Purchaser Agent to, upon the occurrence and during the continuance of a Put Option Event, exercise rights and remedies under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, license out, convey, transfer or grant options to purchase any Collateral), each Grantor hereby grants to the Purchaser Agent, for the benefit of the Purchasers and all other Secured Parties, an irrevocable (until the Termination Date), nonexclusive, worldwide, assignable license (which license may be exercised only upon the occurrence during the continuance of a Put Option Event, without payment of royalty or other compensation to any Grantor or any Subsidiary thereof), to practice, use, sublicense or otherwise exploit any Intellectual Property now owned or hereafter acquired by such Grantor or any of its Subsidiaries or licensed or sublicensed to such Grantor or any of its Subsidiaries, and wherever the same may be located, and including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof to the extent that such non-exclusive license (A)&#160;does not violate the express terms of any agreement between a Grantor or any of its Subsidiaries and a third party governing such Intellectual Property existing as of the Closing Date, or gives such third party any right of acceleration, modification, termination or cancellation therein and (B)&#160;is not prohibited by any Applicable Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that such license and sublicenses with respect to Trademarks shall be subject to the maintenance of quality standards with respect to the goods and services on which such Trademarks are used sufficient to preserve the validity of such Trademarks. The exercise of such license by the Purchaser Agent may be exercised solely upon the occurrence and during the continuance of a Put Option Event and solely for the purpose of exercising remedies in accordance with the Purchase Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that any license, sublicense or other transaction entered into by the Purchaser Agent in accordance with the provisions of this Agreement shall be binding upon the Grantors and each of their respective Subsidiaries, notwithstanding any subsequent waiver in accordance with Section&#160;8.08 of the Purchase Agreement of a Put Option Event.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Rights of the Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Power of Attorney</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to other powers of attorney contained herein, each Grantor hereby designates and appoints the Purchaser Agent, on behalf of the Secured Parties, and each of its designees or agents, as attorney-in-fact of such Grantor, irrevocably and with power of substitution, with authority to take any or all of the following actions solely upon the occurrence and during the continuance of a Put Option Event&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that such power of attorney shall terminated automatically upon the Termination Date without any action by any Person&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">to demand, collect, settle, compromise, adjust, give discharges and releases, all as the Purchaser Agent may reasonably determine&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">to commence and prosecute any actions at any court for the purposes of collecting any Collateral and enforcing any other right in respect thereof&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">to defend, settle or compromise any action brought and, in connection therewith, give such discharge or release as the Purchaser Agent may deem reasonably appropriate&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">to receive, open and dispose of mail addressed to a Grantor and endorse checks, notes, drafts, acceptances, money orders, bills of lading, warehouse receipts or other instruments or documents evidencing payment, shipment or storage of the goods giving rise to the Collateral of such Grantor on behalf of and in the name of such Grantor, or securing, or relating to such Collateral&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">to sell, assign, transfer, make any agreement in respect of, or otherwise deal with or exercise rights in respect of, any Collateral or the goods or services which have given rise thereto, as fully and completely as though the Purchaser Agent were the absolute owner thereof for all purposes&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">to adjust and settle claims under any insurance policy relating thereto&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">to execute and deliver all assignments, conveyances, statements, financing statements, continuation financing statements, security agreements, affidavits, notices and other agreements, instruments and documents that the Purchaser Agent may determine necessary in order to perfect and maintain the security interests and liens granted in this Agreement and in order to fully consummate all of the transactions contemplated herein&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">to institute any foreclosure proceedings that the Purchaser Agent may deem appropriate&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">to sign and endorse any drafts, assignments, proxies, stock powers, verifications, notices and other documents relating to the Collateral&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">to exchange any of the Pledged Equity or other property upon any merger, consolidation, reorganization, recapitalization or other readjustment of the Issuer thereof and, in connection therewith, deposit any of the Pledged Equity with any committee, depository, transfer agent, registrar or other designated agency upon such terms as the Purchaser Agent may reasonably deem appropriate&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">to vote for a shareholder resolution, or to sign an instrument in writing, sanctioning the transfer of any or all of the Pledged Equity into the name of the Purchaser </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agent or one or more of the Secured Parties or into the name of any transferee to whom the Pledged Equity or any part thereof may be sold pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.8pt">to pay or discharge taxes, liens, security interests or other encumbrances levied or placed on or threatened against the Collateral&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.03pt">to direct any parties liable for any payment in connection with any of the Collateral to make payment of any and all monies due and to become due thereunder directly to the Purchaser Agent or as the Purchaser Agent shall direct&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.57pt">to receive payment of and receipt for any and all monies, claims, and other amounts due and to become due at any time in respect of or arising out of any Collateral&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.34pt">in the case of any Intellectual Property, execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as the Purchaser Agent may request to evidence the security interests created hereby in such Intellectual Property and the goodwill and General Intangibles of such Grantor relating thereto or represented thereby&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(xvi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.57pt">do and perform all such other acts and things as the Purchaser Agent may reasonably deem to be necessary, proper or convenient in connection with the foregoing.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This power of attorney is a power coupled with an interest and shall be irrevocable until the Termination Date. The Purchaser Agent shall be under no duty to exercise or withhold the exercise of any of the rights, powers, privileges and options expressly or implicitly granted to the Purchaser Agent in this Agreement, and shall not be liable for any failure to do so or any delay in doing so. The Purchaser Agent shall not be liable for any act or omission or for any error of judgment or any mistake of fact or law in its individual capacity or its capacity as attorney-in-fact except acts or omissions resulting from its gross negligence or willful misconduct as determined by a final non-appealable judgment of a court of competent jurisdiction. This power of attorney is conferred on the Purchaser Agent solely to protect, preserve and realize upon its security interest in the Collateral and shall not impose any duty upon the Purchaser Agent or any other Secured Party to exercise any such powers.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Assignment by the Purchaser Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Purchaser Agent may from time to time assign the Obligations to a successor Purchaser Agent appointed in accordance with the Purchase Agreement, and such successor shall be entitled to all of the rights and remedies of the Purchaser Agent under this Agreement in relation thereto.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">The Purchaser Agent&#8217;s Duty of Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other than the exercise of reasonable care to assure the safe custody of the Collateral while being held by the Purchaser Agent hereunder, the Purchaser Agent shall have no duty or liability to preserve rights pertaining thereto, it being understood and agreed that the Grantors shall be responsible for preservation of all rights in the Collateral, and the Purchaser Agent shall be relieved of all responsibility for the Collateral upon surrendering it or tendering the surrender of it to the Grantors. The Purchaser Agent shall be deemed to have exercised reasonable care in the custody and preservation of the Collateral in its possession if the Collateral is accorded treatment substantially equal to that which the Purchaser Agent accords its own property, which shall be no less than the treatment employed by a reasonable and prudent agent in the industry, it being understood that the Purchaser Agent shall not have responsibility for taking any necessary steps to preserve rights against any parties with respect to any of the Collateral. In the event of a public or private sale of Collateral pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hereof, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchaser Agent shall have no responsibility for (i)&#160;ascertaining or taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relating to any Collateral, whether or not the Purchaser Agent has or is deemed to have knowledge of such matters, or (ii)&#160;taking any steps to clean, repair or otherwise prepare the Collateral for sale.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;text-decoration:underline">Liability with Respect to Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Anything herein to the contrary notwithstanding, each of the Grantors shall remain liable under each of the Accounts to observe and perform all the conditions and obligations to be observed and performed by it thereunder, all in accordance with the terms of any agreement giving rise to each such Account. Neither the Purchaser Agent nor any Secured Party shall have any obligation or liability under any Account (or any agreement giving rise thereto) by reason of or arising out of this Agreement or the receipt by the Purchaser Agent or any Secured Party of any payment relating to such Account pursuant hereto, nor shall the Purchaser Agent or any Secured Party be obligated in any manner to perform any of the obligations of a Grantor under or pursuant to any Account (or any agreement giving rise thereto), to make any payment, to make any inquiry as to the nature or the sufficiency of any payment received by it or as to the sufficiency of any performance by any party under any Account (or any agreement giving rise thereto), to present or file any claim, to take any action to enforce any performance or to collect the payment of any amounts which may have been assigned to it or to which it may be entitled at any time or times.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;text-decoration:underline">Voting and Payment Rights in Respect of the Pledged Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">So long as no Put Option Event shall exist, each Grantor may (A)&#160;exercise any and all voting and other consensual rights pertaining to the Pledged Equity of such Grantor or any part thereof for any purpose not inconsistent with the terms of this Agreement or the Purchase Agreement and (B)&#160;receive and retain any and all dividends (other than stock dividends and other dividends constituting Collateral which are addressed hereinabove), principal or interest paid in respect of the Pledged Equity to the extent they are allowed under the Purchase Agreement&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">Upon the occurrence and during the continuance of a Put Option Event, (A)&#160;all rights of a Grantor to exercise the voting and other consensual rights which it would otherwise be entitled to exercise pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">clause&#160;(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above shall cease and all such rights shall thereupon become vested in the Purchaser Agent which shall then have the sole right to exercise such voting and other consensual rights, (B) all rights of a Grantor to receive the dividends, principal and interest payments which it would otherwise be authorized to receive and retain pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">clause&#160;(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above shall cease and all such rights shall thereupon be vested in the Purchaser Agent which shall then have the sole right to receive and hold as Collateral such dividends, principal and interest payments, and (C)&#160;all dividends, principal and interest payments which are received by a Grantor contrary to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">clause&#160;(ii)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above shall be received in trust for the benefit of the Purchaser Agent, shall be segregated from other property or funds of such Grantor, and shall be forthwith paid over to the Purchaser Agent as Collateral in the exact form received, to be held by the Purchaser Agent as Collateral and as further collateral security for the Obligations.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt;text-decoration:underline">Releases of Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">If any Collateral shall be sold, assigned, conveyed, transferred or otherwise disposed of by any Grantor in a transaction permitted by the Purchase Agreement, then the Purchaser Agent, at the request and sole expense of such Grantor, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall promptly execute and deliver to such Grantor all releases, filings, and other documents, and take such other action, reasonably necessary for the release of the Liens created hereby or by any other Transaction Document on such Collateral.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Purchaser Agent may release any of the Pledged Equity from this Agreement or may substitute any of the Pledged Equity for other Pledged Equity without altering, varying or diminishing in any way the force, effect, lien, pledge or security interest of this Agreement as to any Pledged Equity not expressly released or substituted, and this Agreement shall continue as a first priority lien on all Pledged Equity not expressly released or substituted.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt">Upon the occurrence of the Milestone, all Liens of the Purchaser Agent in the Non-Anktiva Collateral shall automatically be deemed terminated and released and the Purchaser Agent, at the request and sole expense of such Grantor, shall promptly execute and deliver to such Grantor all releases (including, without limitation, UCC-3 termination statements, notices of termination to be filed with the USPTO and the United States Copyright Office, and control agreement terminations) filings, and other documents (including, without limitation, a statement of the Purchaser Agent that any released collateral is no longer subject to a Lien under this Agreement), and take such other action, reasonably necessary for the release of the Liens created hereby or by any other Transaction Document on such Non-Anktiva Collateral. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt;text-decoration:underline">Application of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any payments in respect of the Obligations and any proceeds of the Collateral, when received by the Purchaser Agent or any Secured Party, will be applied in reduction of the Obligations in the order determined by Purchaser Agent in its sole and absolute discretion.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Continuing Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">This Agreement shall remain in full force and effect until the Termination Date, at which time this Agreement (other than obligations under this Agreement which expressly survive termination) and the Liens created hereby shall automatically be deemed terminated and released and the Purchaser Agent, at the request and sole expense of such Grantor, shall promptly execute and deliver to such Grantor all releases, filings, and other documents, and take such other action, reasonably necessary for the release of the Liens created hereby or by any other Transaction Document, and shall duly assign, transfer and deliver to such Grantor such of the Collateral as may be in the possession of Purchaser Agent and as has not theretofore been sold or otherwise applied or released pursuant to this Agreement.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">This Agreement shall continue to be effective or be automatically reinstated, as the case may be, if at any time payment, in whole or in part, of any of the Obligations is rescinded or must otherwise be restored or returned by the Purchaser Agent or any Secured Party as a preference, fraudulent conveyance or otherwise under any Bankruptcy Laws, all as though such payment had not been made&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that in the event payment of all or any part of the Obligations is rescinded or must be restored or returned, all reasonable costs and expenses (including without limitation any reasonable legal fees and disbursements) incurred by the Purchaser Agent or any Secured Party in defending and enforcing such reinstatement shall be deemed to be included as a part of the Obligations.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Amendments&#59; Waivers&#59; Modifications, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement and the provisions hereof may not be amended, waived, modified, changed, discharged or terminated except as set forth in Section&#160;8.08 of the Purchase Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Successors in Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement shall be binding upon each Grantor, its successors and assigns and shall inure, together with the rights and remedies of the Purchaser Agent and the Secured Parties hereunder, to the benefit of the Purchaser Agent and the Secured Parties and their successors and permitted assigns.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All notices required or permitted to be given under this Agreement shall be in conformance with Section&#160;8.02 of the Purchase Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that notices and communications to any Grantor shall be directed to such Grantor, care of the Company, at the address of the Company set forth on Section&#160;8.02 of the Purchase Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement may be executed in any number of counterparts, each of which where so executed and delivered shall be an original, but all of which shall constitute one and the same instrument. It shall not be necessary in making proof of this Agreement to produce or account for more than one such counterpart. Delivery of an executed counterpart of a signature page of this Agreement by fax transmission or other electronic mail transmission (e.g. &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this Agreement. Without limiting the foregoing, to the extent a manually executed counterpart is not specifically required to be delivered, upon the request of any party, such fax transmission or electronic mail transmission shall be promptly followed by such manually executed counterpart.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The headings of the sections hereof are provided for convenience only and shall not in any way affect the meaning or construction of any provision of this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Governing Law&#59; Submission to Jurisdiction&#59; Venue&#59; Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of New York, without giving effect to the principles of conflicts of law thereof. The terms of Sections&#160;8.14(b), 8.14(c) and 8.15 of the Purchase Agreement with respect to submission to jurisdiction, venue and waiver of jury trial are incorporated herein by reference, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the parties hereto agree to such terms.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any provision of this Agreement is determined to be illegal, invalid or unenforceable, such provision shall be fully severable and the remaining provisions shall remain in full force and effect and shall be construed without giving effect to the illegal, invalid or unenforceable provisions.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Entirety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Agreement, the other Transaction Documents and the other documents relating to the Obligations represent the entire agreement of the parties hereto and thereto, and supersede all prior agreements and understandings, oral or written, if any, including any commitment letters or correspondence relating to the Transaction Documents, any other documents relating to the Obligations, or the transactions contemplated herein and therein.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Other Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent that any of the Obligations are now or hereafter secured by property other than the Collateral (including, without limitation, real property and securities owned by a Grantor), or by a guarantee, endorsement or property of any other Person, then the Purchaser Agent shall have the right to proceed against such other property, guarantee or endorsement upon the occurrence and during the continuance of any Put Option Event, and the Purchaser Agent shall have the right, in its sole discretion, to determine which rights, security, liens, security interests or remedies the Purchaser Agent shall at any time pursue, relinquish, subordinate, modify or take with respect thereto, without in any way modifying or affecting any of them or the Obligations or any of the rights of the Purchaser Agent or the Secured Parties under this Agreement, under any other of the Transaction Documents or under any other document relating to the Obligations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Joinder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At any time after the date of this Agreement, one or more additional Persons may become party hereto by executing and delivering to the Purchaser Agent a Joinder Agreement in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Immediately upon such execution and delivery of such Joinder Agreement (and without any further action), each such additional Person will become a party to this Agreement as an &#8220;Grantor&#8221; and have all of the rights and obligations of a Grantor hereunder and this Agreement and the schedules hereto shall be deemed amended by such Joinder Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Consent of Issuers of Pledged Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any Grantor that is an Issuer hereby acknowledges, consents and agrees to the grant of the security interests in such Pledged Equity by the applicable Grantors pursuant to this Agreement, together with all rights accompanying such security interest as provided by this Agreement and Applicable Law, notwithstanding any anti-assignment provisions in any operating agreement, limited partnership agreement or similar organizational or governance documents of such Issuer.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Joint and Several Obligations of Grantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Each of the Grantors is accepting joint and several liability hereunder in consideration of the financial accommodations to be provided by the Purchasers under the Purchase Agreement, for the mutual benefit, directly and indirectly, of each of the Grantors and in consideration of the undertakings of each of the Grantors to accept joint and several liability for the obligations of each of them.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Each of the Grantors jointly and severally hereby irrevocably and unconditionally accepts, not merely as a surety but also as a primary obligor, joint and several liability with the other Grantors with respect to the payment and performance of all of the Obligations, it being the intention of the parties hereto that (i)&#160;all the Obligations shall be the joint and several obligations of each of the Grantors without preferences or distinction among them and (ii)&#160;a separate action may be brought against each Grantor to enforce this Agreement whether or not the Company, any other Grantor or any other person or entity is joined as a party.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Notwithstanding any provision to the contrary contained herein, in any other of the Transaction Documents, to the extent the obligations of a Grantor shall be adjudicated to be invalid or unenforceable for any reason (including, without limitation, because of any applicable state or federal law relating to fraudulent conveyances or transfers) then the obligations of such Grantor hereunder shall be limited to the maximum amount that is permissible under Applicable Law (whether federal or state and including, without limitation, Bankruptcy Laws).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Marshaling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Purchaser Agent shall not be required to marshal any present or future collateral security (including but not limited to the Collateral) for, or other assurances of payment of, the Obligations or any of them or to resort to such collateral security or other assurances of payment in any particular order, and all of its rights and remedies hereunder and in respect of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights and remedies, however existing or arising. To the extent that it lawfully may, each Grantor hereby agrees that it will not invoke any law relating to the marshaling of collateral which might cause delay in or impede the enforcement of the Purchaser Agent&#8217;s rights and remedies under this Agreement or under any other instrument creating or evidencing any of the Obligations or under which any of the Obligations is outstanding or by which any of the Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, each Grantor hereby irrevocably waives the benefits of all such laws.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Each Grantor recognizes that, in the event such Grantor fails to perform, observe or discharge any of its obligations or liabilities under this Agreement or any other Transaction Document, any remedy of law may prove to be inadequate relief to the Purchaser Agent and the other Secured Parties. Therefore, each Grantor agrees that the Purchaser Agent and the other Secured Parties, at the option of the Purchaser Agent and the other Secured Parties, shall be entitled to temporary and permanent injunctive relief in any such case without the necessity of proving actual damages.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Purchaser Agent, the other Secured Parties and each Grantor hereby agree that no such Person shall have a remedy of punitive or exemplary damages against any other party to a Transaction Document and each such Person hereby waives any right or claim to punitive or exemplary damages that they may now have or may arise in the future in connection with any dispute under this Agreement or any other Transaction Document, whether such dispute is resolved through arbitration or judicially.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i8363cd9747ad47ca9d764fff43ec1d15_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the parties hereto has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">GRANTORS&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">IMMUNITYBIO, INC.</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">INFACELL THERAPEUTIICS, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">NANTCELL, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ETUBICS CORPORATION</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ALTOR BIOSCIENCE, LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ALTOR BIOSCIENCE MANUFACTURING <br>COMPANY, LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manager</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;Signature Page to Security and Pledge Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">RECEPTOME, INC.</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">IGDRASOL, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">MCLR PARENT LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manager</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">MARIPOSA CLINIC CO LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manager</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">MARIPOSA LAB CO LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manager</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">MARIPOSA RADIOLOGY CO LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manager</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;Signature Page to Security and Pledge Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">VBC HOLDINGS LLC</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">IMMUNOTHERAPY NANTIBODY, LLC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manager</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;Signature Page to Security and Pledge Agreement&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accepted and agreed to as of the date first above written.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.596%"><tr><td style="width:1.0%"></td><td style="width:20.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INFINITY SA LLC,</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as Purchaser Agent</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Dubinsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Dubinsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized Signatory</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;Signature Page to Security and Pledge Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>ibrx20231231-10kexhibit105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib67646ccdb0e4b978ee0e5aa765c267f_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.5</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">STOCK PURCHASE AND OPTION AGREEMENT</font></div><div style="margin-top:15pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">This STOCK PURCHASE AND OPTION AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), is made and entered as of December&#160;29,&#160;2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between (i)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TPC INVESTMENTS II&#160;LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware limited partnership, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TPC INVESTMENTS III LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware limited partnership, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TPC&#160;INVESTMENTS SOLUTIONS LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware limited liability company, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TPC&#160;INVESTMENTS SOLUTIONS CO-INVEST LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware limited partnership, (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (ii)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMMUNITYBIO, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Investors and the Company are referred to herein, collectively, as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and each, individually, as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, contemporaneously with the execution of this Agreement, each of the Parties (or their respective Affiliates (as defined in the Revenue Interest Purchase Agreement)) have executed that certain Revenue Interest Purchase Agreement with each of the other signatories thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Revenue Interest Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of and in connection with the Revenue Interest Purchase Agreement, the Company and the Investors desire to sell and purchase shares of the Company&#8217;s common stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the Company desires to grant to the Investors the right to purchase additional shares of Common Stock, pursuant to the terms and conditions set forth herein.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of the foregoing and the covenants set forth herein, the Parties agree as follows&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Purchase and Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Subject to the terms and conditions of this Agreement, each Investor agrees to purchase, and the Company agrees to sell and issue to each Investor, at the Closing (as defined below) that number of shares of Common Stock set forth opposite each Investor&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, at a purchase price of $4.1103&#160;per share. The shares of Common Stock issued to the Investors at the Closing or pursuant to any exercise of the Option (as defined below) shall be referred to in this Agreement as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The purchase and sale of Shares at the Closing shall take place remotely via the exchange of documents and signatures, on the date of this Agreement at such time as is mutually </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">agreed upon, orally or in writing, by the Company and the Investors (which time and place are designated as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">At the Closing, the Company shall deliver to each Investor a certificate or evidence of book-entry position (as determined by such Investor) with the Company&#8217;s transfer agent representing the Shares being purchased by such Investor at the Closing against payment of the purchase price therefor by wire transfer to an account designated by the Company in immediately available funds.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company hereby grants to each of the Investors, or its registered assigns (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the right to purchase at any time and from time to time after the Closing and on or prior to the expiration date set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;2(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(such purchase right, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) up to a number of newly issued Shares equal to an aggregate of $10,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Total Option Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) divided by the Exercise Price (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#59; provided, however, a Holder or the Holders may not partially exercise the Option for a dollar amount of Shares that is less than $5,000,000 unless (a)&#160;such lesser amount is necessary to prevent such Holder or Holders from acquiring a number of shares of Common Stock that would exceed the Maximum Percentage (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">below) or (b)&#160;it is the final exercise and such final exercise is for the remaining, unexercised portion of the Total Option Amount. For the avoidance of doubt, the maximum aggregate number of Shares that can be purchased pursuant to the Option by all Holders is that number of Shares issuable for an aggregate Exercise Price for all Holders of approximately $10,000,000, subject to the terms and conditions set forth herein.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The Option shall be exercisable by the Holders at any time after the Closing and from time to time until exercised in full until the earlier of (as applicable, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Option Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (i)&#160;the close of business on December&#160;31,&#160;2028 and (ii)&#160;the closing date of a Corporate Reorganization. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Corporate Reorganization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any (i)&#160;merger, consolidation or reorganization or other similar transaction or series of related transactions which results in the holders of the voting securities of the Company outstanding immediately prior thereto representing the owners, either directly or indirectly, of 50%&#160;or less of the combined voting power of the voting securities of and economic interests in the Company or such surviving or acquiring entity outstanding immediately after such merger, consolidation or reorganization&#59; (ii)&#160;the distribution of assets (by any method) to the holders of the Company&#8217;s equity securities following the completion of a sale, lease, exclusive license, transfer, conveyance or other disposition of all or substantially all of the assets of the Company&#59; or (iii)&#160;sale of shares of equity securities of the Company by then-existing stockholders of the Company, in a single transaction or series of related transactions to a single person or entity, representing at least 50%&#160;of the voting power of the voting securities of and economic interests in the Company&#59; provided, that with respect to subsections (i)&#160;and (iii)&#160;hereof, options and value appreciation or similar rights shall be excluded from such calculations for all purposes. The Company shall notify the Holders in writing at least 21&#160;days&#8217; prior to the closing of (or, in the case of subsection&#160;(ii) above, the record date for being entitled to participate in the distribution of assets) any Corporate Reorganization, which notice may be satisfied pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or pursuant to the Company&#8217;s filing of a Current Report on Form&#160;8-K with the U.S.&#160;Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Securities and Exchange Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Option is exercisable by the Holders by delivery of the notice of exercise attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit&#160;B </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Notice of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) together with an amount equal to (i)&#160;the number of Shares as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to which the Option is being exercised, multiplied by (ii)&#160;the Exercise Price (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exercise Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), paid by wire transfer to an account designated by the Company in immediately available funds.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Upon delivery of the Notice of Exercise to the Company at its address for notice set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and upon payment of the Exercise Amount for the Shares being purchased, the Company shall promptly issue and deliver to the applicable Holder (or its designee) a certificate or evidence of book-entry position with the Company&#8217;s transfer agent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">book-entry position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as determined by such Holder, for the Shares issuable upon such exercise, such delivery to be made promptly, but in any case within two&#160;(2) Business Days (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) of the Date of Exercise (as defined below), or such fewer number of Business Days comprising the Standard Settlement Period (as defined below in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In lieu of delivery of a certificate or book-entry position and subject to applicable law, a Holder may direct the Company by written notice to have the Shares deposited in an account designated by such Holder&#59; provided, however, that such Holder demonstrates compliance with applicable securities laws in connection with any such notice (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">). Any person so designated by a Holder to receive Shares shall be deemed to have become holder of record of such Shares and shall be treated as a stockholder of the Company for all purposes as of the Date of Exercise of the Option. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Standard Settlement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the standard settlement period, expressed in a number of Business Days, on the primary trading market or exchange for the Common Stock. As used in this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Date of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the date on which the Holder shall have delivered to the Company (i)&#160;the Notice of Exercise attached hereto, appropriately completed and duly signed and (ii)&#160;payment of the Exercise Amount for the Shares being purchased.</font></div><div style="margin-top:12pt;padding-left:0.01pt;text-indent:66.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:35.99pt">If the Company fails to deliver the Shares pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;2(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by the Share Delivery Date, then the applicable Holder will have the right to rescind such exercise.</font></div><div style="margin-top:12pt;padding-left:1.01pt;text-indent:63.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.99pt">In addition to any other rights available to the Holders, if the Company fails to deliver the Shares in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;2(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">above pursuant to an exercise on or before the Share Delivery Date, and if after such date the applicable Holder is required by its broker to purchase (in an open market transaction or otherwise) or such Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Shares which such Holder anticipated receiving upon such exercise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the Company shall (A)&#160;pay in cash to the Holder the amount, if any, by which (x)&#160;the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&#160;the amount obtained by multiplying (1)&#160;the number of Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)&#160;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&#160;at the option of the Holder, either reinstate the portion of the Option and equivalent amount of Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of the Option for Shares with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&#160;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s failure to timely deliver Shares upon exercise of the Option as required pursuant to the terms hereof.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">No fractional Shares will be issued in connection with any exercise of the Option.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">Issuance and delivery of the Shares upon exercise of the Option shall be made without charge to the applicable Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect of such issuance, all of which taxes and expenses shall be paid by the Company&#59; provided, however, that the Company shall not be required to pay any capital gains tax or income tax that may be imposed on such Holder&#59; provided further that if Shares are to be registered in a name or names other than the name of the applicable Holder, funds sufficient to pay all transfer taxes payable as a result of such transfer shall be paid by such Holder.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">If this Agreement is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Agreement, a New Option (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. Applicants for a New Option under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">In the event a Holder exercises the Option, the purchase price per share at which such Holder shall be required to purchase the Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be equal to the trailing 30-day volume-weighted average price of the Common Stock (as reported by Bloomberg&#160;L.P., based on a Trading Day from 9&#58;30&#160;a.m. (New York City time) to 4&#58;00&#160;p.m. (New York City time)) measured from the date the Notice of Exercise is delivered to the Company&#59; provided, however, that if the number of Shares to be purchased pursuant to the relevant Notice of Exercise, together with all prior issuances of Shares pursuant to this Agreement, is greater than 132,911,740&#160;Shares, then the weighted-average purchase price of all Shares previously purchased and to be purchased pursuant to the current Notice of Exercise must not be less than $4.712&#160;(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Minimum Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and if necessary to achieve the Minimum Price the Holder may proceed with the exercise of the Option that is subject to the current Notice of Exercise by increasing the Exercise Price for such current exercise to a price that results in either (i)&#160;the total number of Shares to be purchased pursuant to the Notice of Exercise, plus all previously issued Shares, being fewer than 132,911,740&#160;Shares or (ii)&#160;the weighted-average purchase price of all Shares purchased under the Agreement to be not less than the Minimum Price.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Registration of Option&#59; Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company shall register the Option in a record to be maintained by the Company for that purpose (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Option Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in the name of the Holders. The Company may deem and treat the Holders, collectively, as the absolute owners hereof for the purpose of any exercise hereof and for all other purposes, absent actual notice to the contrary.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and compliance with the relevant securities laws, this Agreement may be transferred in its entirety and not in part and the Company shall register such transfer of the Option</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in the Option Register, upon surrender of this Agreement, together with the Form of Assignment attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, duly completed and signed, to the Company at its address for notice set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon any such transfer, a new Option to purchase Shares, in substantially the form of this Agreement (any such new Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">New Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), shall be issued to the transferee. The acceptance of the New Option by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of the Option.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Option and the Shares may only be disposed of or otherwise transferred in compliance with state and federal securities laws.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each certificate or book-entry position for Shares issued upon exercise of the Option shall bear the following legend, unless at the time of exercise such Shares (1)&#160;are registered for resale under the Securities Act of&#160;1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and are sold pursuant to the Plan of Distribution set forth in the registration statement relating thereto, or (2)&#160;have been sold pursuant to Rule&#160;144 of the Securities Act or another exemption from the registration requirements of the Securities&#160;Act that would permit the removal of the legend set forth below&#58;</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any certificate or book-entry position for Shares issued at any time in exchange or substitution for any certificate bearing such legend or to be issued in connection with a request made by a Holder pursuant to the first paragraph of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;4(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(unless at that time such Shares are registered for resale under the Securities Act and are sold pursuant to the Plan of Distribution set forth in the registration statement relating thereto or are being sold under Rule&#160;144 of the Securities Act) shall also bear such legend unless, in the written opinion of counsel selected by a Holder (who may be an employee of such Holder) which counsel and opinion shall be acceptable to the Company, the Shares represented thereby need no longer be subject to restrictions on resale under the Securities Act.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With respect to any Shares bearing a restrictive legend, the Company agrees that following such time as the restrictive legend is no longer required because the Shares (1)&#160;are registered for resale under the Securities Act and have been sold pursuant to the Plan of Distribution set forth in the registration statement relating thereto, (2)&#160;can be sold pursuant to Rule&#160;144(b)(1) of the Securities Act without regard to the requirements in paragraph&#160;(c)(1) of Rule&#160;144 of the Securities Act, or (3)&#160;have been sold pursuant to Rule&#160;144 of the Securities Act or another exemption from the registration requirements of the Securities Act that would permit the removal of the legend set forth above, upon the applicable Holder&#8217;s written request the Company shall deliver a certificate or book-entry position representing such Shares that is free from all restrictive and other legends or, at such Holder&#8217;s election, deliver such Shares to an account designated by such Holder. In connection with any request by a Holder that any Shares not bear a restrictive legend, Holder shall promptly provide such additional information or certificates that the Company may reasonably deem necessary to remove the restrictive legend or issue the Shares without restrictive legend&#59; provided, however, that in connection with any sale of Shares pursuant to an effective registration statement under the Securities Act or pursuant to Rule&#160;144 under the Securities Act, Holder shall not be required to provide anything pursuant to this sentence other than (i)&#160;a confirmation that such Shares have been sold pursuant to</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Plan of Distribution section of such registration statement or (ii)&#160;if the Shares have been sold pursuant to Rule&#160;144 under the Securities Act or another exemption from the registration requirements of the Securities Act, a certificate reasonably satisfactory to the Company setting forth customary non-affiliate representations to support the delivery of a legal opinion to the Company's transfer agent (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Rule&#160;144 Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), provided, however, that if Holder does not have a representative serving as a director on the Company&#8217;s Board of Directors and Holder confirms to the Company in writing that it does not hold any shares of Common Stock or securities convertible into Common Stock other than the Option or any shares of Common Stock issued pursuant to the Option, then no such Rule&#160;144 Certificate will be required.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event the Company is obligated to deliver Shares to a Holder without restrictive legend pursuant to this Agreement, the Company will, no later than the later of (A)&#160;the earlier of (i)&#160;two (2)&#160;Business Days and (ii)&#160;the number of Business Days comprising the Standard Settlement Period following the request by the Holder to deliver Shares without restrictive legend pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;4(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and (B)&#160;if Holder is required to deliver a Rule&#160;144 Certificate pursuant to the immediately preceding paragraph, the date Holder delivers a Rule&#160;144 Certificate to the Company (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legend Removal Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), deliver or cause to be delivered to such Holder a certificate or book-entry position representing such Shares that is free from all restrictive and other legends or, at such Holder&#8217;s election, deliver such Shares to an account designated by such Holder. Notwithstanding anything to the contrary set forth herein, in the event the Holder has been issued a certificate representing Shares that bears a restrictive legend and the Holder submits a request to have the legends from such certificate removed in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then the Legend Removal Date shall be the later of (i)&#160;the time specified in the definition above and (ii)&#160;the date Holder delivers the certificate representing the relevant Shares to the Company or its transfer agent, or, if the certificate has been lost, delivers an executed affidavit of loss to the Company or its transfer agent.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to such Holder&#8217;s other available remedies, if the Company fails to deliver unlegended Shares to the Holder by the Legend Removal Date as required by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company shall pay to the Holder, in cash, (i)&#160;as partial liquidated damages and not as a penalty, for each&#160;$1,000 of Shares (based on the volume-weighted average price of the Common Stock on the Nasdaq Stock Market or other domestic securities exchange on which the Common Stock may at the time be listed on the date Holder requests pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;4(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that such unlegended Shares be delivered) subject to the request, $10&#160;per Business Day (increasing to $20&#160;per Business Day on the third&#160;Business Day after the Legend Removal Date) for each Business Day after the Legend Removal Date until such certificate or book-entry position is delivered without a restrictive or other legend or such Shares are delivered to an account designated by the Holder and (ii)&#160;if the Company fails to (a)&#160;issue and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate or book-entry position representing the Shares to be delivered to such Holder that is free from all restrictive and other legends or to deliver Shares to an account designated by such Holder and (b)&#160;if after the Legend Removal Date such Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of Shares that such Holder anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of such Holder&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Buy- In Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) over the product of (A)&#160;such number of Shares that the Company was required to deliver to Holder by the Legend Removal Date multiplied by (B)&#160;the lowest closing sale price of the Common Stock on any Business Day during the period commencing on the date of such Holder&#8217;s request to the Company to deliver the applicable Shares (or, if applicable, the date such Holder delivers to the Company or its</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">transfer agent the certificate representing the applicable Shares) and ending on the date of such delivery and payment under this paragraph.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Representations and Warranties of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company hereby represents and warrants to the Investors and Holders as of the Execution Date, the Closing and each Date of Exercise (with the exception of clause&#160;(d) below, which shall only be as of the Execution Date and the Closing Date) that&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure so to qualify would have a material adverse effect on its business or properties&#59; and</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">This Agreement has been duly authorized, validly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company enforceable against it in accordance with its terms, except as such enforceability may be limited by (i)&#160;bankruptcy, insolvency, reorganization, moratorium or similar laws or equitable principles affecting the enforcement of creditors&#8217; rights generally or (ii)&#160;laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Shares have been duly reserved for issuance and when issued, sold and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under applicable state and federal securities laws (subject to the terms of this Agreement) and liens or encumbrances created by or imposed by an Investor or Holder (if any).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Except as otherwise disclosed to the Investors and Holders or sales in connection with the payment or withholding of income taxes due to the vesting&#47;settlement of equity awards, the Company is not aware of any pending, planned or contemplated significant sale or other disposition of shares of Common Stock by any of the Company&#8217;s Affiliates, including any of its Section&#160;16 officers and directors and their family members or Affiliates.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Representations and Warranties of the Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the Holders hereby represents and warrants to the Company as of the Execution Date, the Closing and each Date of Exercise that&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">(i)&#160;It is an accredited investor as defined in Rule&#160;501(a) of Regulation&#160;D promulgated under the Securities Act, and it is acquiring the Option and the Shares for its own account for investment purposes and not with the view to any sale or distribution, (ii)&#160;it will not offer, sell or otherwise dispose of the Option or the Shares except under circumstances as will not result in a violation of applicable securities laws, (iii)&#160;it has had such opportunity as it has deemed adequate to ask questions of the Company and its representatives and to otherwise obtain from the Company such information regarding the Company, along with copies of all information from the Company that it deems necessary to permit it to evaluate the merits of accepting the Option, (iv)&#160;it has such knowledge, sophistication and experience in business and financial matters to be able to evaluate the merits, risks and other considerations relating to the acquisition of the Option&#59; and (v)&#160;it understands and acknowledges that the Option involves a high degree of risk&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">It understands that the Shares will not be registered under the Securities Act at the time of issuance, that the Shares will be &#8220;restricted securities&#8221; under applicable U.S. federal and state securities laws and that, pursuant to these laws, it must hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Covenants of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue the Shares upon exercise of the Option, the number of shares of Common Stock that would be likely be issued and delivered upon the exercise of the Option at such time, such shares to be free from preemptive rights or any other contingent purchase rights of persons other than the Holders.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The Company covenants that the Shares, when issued, sold and delivered in accordance with the terms set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than applicable state and federal securities laws and liens or encumbrances created by or imposed by the Holders.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company shall use its reasonable best efforts to cause the Shares to be admitted for trading on each securities exchange on which the Common Stock is listed on the date hereof and the Date of Exercise or, if the Common Stock is not then listed, take such actions to cause the Shares to be eligible to be traded on the OTC Bulletin Board, the Pink OTC Markets or similar quotation system or association on such date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The Holders and the Company shall each take all actions as may be reasonably necessary to consummate the transactions contemplated by this Agreement, including, without limitation, entering into agreements and delivering certificates and instruments and consents as may be deemed necessary or appropriate.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Company shall not knowingly effect the exercise of the Option, and a Holder shall not have the right to exercise the Option, to the extent that, after giving effect to such exercise, such Holder (together with its Affiliates) would beneficially own in excess of 9.9%&#160;of the Common Stock outstanding immediately after giving effect to such exercise (or such higher or lower amount as such Holder may specify with at least 61&#160;days&#8217; written notice to the Company, but which in no event may exceed 19.9%&#160;of the Common Stock outstanding immediately after giving effect to such exercise) (as&#160;applicable, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Maximum Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by a Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of the Option with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Holder and its Affiliates (including, without limitation, any convertible notes or convertible shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Securities Exchange Act of 1934, as amended. For</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purposes of the Option, in determining the number of outstanding shares of Common Stock, the Holders may rely on the number of outstanding shares of Common Stock as reflected in the most recent of (i)&#160;the Company&#8217;s Annual Report on Form&#160;10-K, Quarterly Report on Form&#160;10-Q or other public filing with the Securities and Exchange Commission, as the case may be, (ii)&#160;a more recent public announcement by the Company or (iii)&#160;any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder, the Company shall promptly (and no later than two&#160;(2) Business Days following such request) confirm to such Holder the number of shares of Common Stock then outstanding. Furthermore, upon the written request of the Company, each Holder shall confirm to the Company its then current beneficial ownership with respect to the Company&#8217;s Common Stock.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">The Company shall prepare and file with the Securities and Exchange Commission after the Execution Date a shelf registration statement under the Securities Act which covers, permits, and allows for the resale by the Holders (or any of the Holders&#8217; assigns pursuant to this Agreement, and together with the Holders, each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investor Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), on a delayed or continuous basis and pursuant to the plan or method of distribution elected by the Investor Party, of the Shares (including the Shares issued and issuable to the Investor Parties upon the exercise of the Option) and names such Investor Parties as the selling stockholders of such Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Prior to the filing of the Registration Statement, if requested by the Company, the Investors shall notify the Company the allocation of the shares to be issued upon exercise of the Option amongst the Holders (it being agreed that nothing herein shall restrict the Investors from reallocating the Option amongst the Holders from time to time). The Company shall cause such Registration Statement to be declared effective (or become automatically effective) by the SEC no later than May&#160;15,&#160;2024, provided however, that if the SEC decides to review the Registration Statement then the Company shall have until June&#160;30,&#160;2024 for it to become effective. The Company shall maintain the effectiveness of the Registration Statement until the earliest of (i)&#160;two&#160;years following the expiration of the Option Term and (ii)&#160;the closing of a Corporate Reorganization. Each Investor Party shall promptly provide such information as may reasonably be requested by the Company, in connection with the preparation of any Registration Statement, including amendments and supplements thereto, in order to effect the registration of the Shares for resale under the Securities Act and in connection with the Company&#8217;s obligation to comply with federal and applicable state securities laws. The Company shall cooperate with the Investor Parties to file, maintain, and make effective such Registration Statement and shall cooperate with each of the Investor Parties to facilitate the sale of the Shares by the Investor Parties pursuant to the Registration Statement. At any time upon the written request from an Investor Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Shelf Takedown Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the Company to effect a resale of all of a portion of such Investor Party&#8217;s Shares registered under the Registration Statement, the Company shall file a prospectus supplement as soon as practicable to add, amend and supplement the prospectus as contained in the Registration Statement as necessary for such purpose. There is no limit on the number of the Shelf Takedown Requests the Investor Party may make. In the event that the Registration Statement is no longer effective or may otherwise not be used by the Investor Parties to sell such Shares (except pursuant to a permitted Suspension Event, as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), the Company shall promptly file a new Registration Statement (or a post-effective amendment thereto, including any prospectus supplements to the applicable prospectus contained in the new Registration Statement or the post-effective amendment) that permits the resale of such Shares by the Investor Parties and shall cause such Registration Statement (or post-effective amendment) to be effective as soon as reasonable practicable after filing and to remain effective pursuant to the terms of this provision set forth above. The Registration Statement shall be on Form&#160;S-3, if the Company is eligible to use such form, and the Company shall use its commercially reasonable efforts to qualify and remain qualified to</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">register the offer and sale of securities under the Securities Act pursuant to a Registration Statement on Form&#160;S-3 or any successor form thereto.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The Company agrees that, in the event that (i)&#160;the Registration Statement has not been declared effective by the SEC by May&#160;15,&#160;2024 or (ii)&#160;after such Registration Statement is declared effective by the SEC, is suspended by the Company or ceases to remain continuously effective as to all Shares for which it is required to be effective, other than, in each case, within the time period(s) permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(h) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(each such event referred to in clauses (i), (ii) and (iii), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Registration Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), for more than 20&#160;consecutive days or more than 40&#160;days in any period of 360&#160;days during which the Registration Default remains uncured, the Company shall pay to each Holder the greater of (a)&#160;1.0% of the dollar amount of all Shares purchased under this Agreement and (b)&#160;1.0% of $15,000,000, for each 30-day period (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Penalty Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (provided the payment amount shall increase by&#160;1.0% of the applicable foregoing amount for each subsequent 30-day period following the initial 30-day period), or pro rata for any portion thereof, during which the Registration Default remains uncured&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if a Holder fails to provide the Company with any information that is required to be provided in such Registration Statement with respect to such Holder as set forth herein, then the commencement of the Penalty Period described above shall be extended until two&#160;(2) Business Days following the later of (1)&#160;the date of receipt by the Company of such required information and (2)&#160;the later of (A)&#160;the date on which Company no longer has stale financial statements and (B)&#160;the deadline under the Exchange Act for filing financial statements for the relevant fiscal period with the SEC&#59; and provided, further, that in no event shall the Company be required hereunder to pay to any Holder pursuant to this Agreement more than the greater of (a)&#160;3.0% of the dollar amount of all Shares purchased under this Agreement and (b)&#160;3.0% of $15,000,000, in any Penalty Period and in no event shall the Company be required hereunder to pay to any Holder pursuant to this Agreement an aggregate amount that exceeds the greater of (a)&#160;10.0% of the dollar amount of all Shares purchased under this Agreement and (b)&#160;10.0% of $15,000,000. The Company shall deliver said cash payment to the applicable Holder by the fifth&#160;Business Day after the end of such Penalty Period.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Notwithstanding anything to the contrary contained herein, the Company may delay or postpone filing of such Registration Statement, and from time to time require an Investor Party not to sell under the Registration Statement or suspend the use of any such Registration Statement, if the board of directors of the Company determines in good faith that either in order for the Registration Statement to not contain a material misstatement or omission, an amendment thereto would be needed, or if such filing or use could materially affect a bona fide business or financing transaction of the Company or would require premature disclosure of information that could materially adversely affect the Company (each such circumstance, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Suspension Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, that, (i)&#160;the Company shall not so delay filing or so suspend the use of the Registration Statement on more than two&#160;occasions or for a period of more than 45&#160;consecutive days or more than a total of 60&#160;calendar days, in each case in any 360-day period and (ii)&#160;the Company shall use commercially reasonable efforts to make such Registration Statement available for the sale by the Investor Parties of such securities as soon as practicable thereafter.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">Upon receipt of any written notice from the Company (which notice shall not contain any material non-public information regarding the Company) of the happening of a Suspension Event during the period that the Registration Statement is effective or if as a result of a Suspension Event the Registration Statement or related prospectus contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made (in the case of the prospectus) not misleading, each Investor Party agrees that (1)&#160;it will immediately discontinue offers and sales of the Shares under the Registration</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Statement (excluding, for the avoidance of doubt, sales conducted pursuant to Rule&#160;144) until the Investor Parties receive copies of a supplemental or amended prospectus (which the Company agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and receives notice that any post- effective amendment has become effective or unless otherwise notified by the Company that it may resume such offers and sales, and (2)&#160;it will maintain the confidentiality of any information included in such written notice delivered by the Company except (A)&#160;for disclosure to the Investor&#8217;s employees, agents and professional advisers who need to know such information and are obligated to keep it confidential, (B)&#160;for disclosures to the extent required in order to comply with reporting obligations to its limited partners who have agreed to keep such information confidential and (C)&#160;as required by law or subpoena.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">The Company may request from each Investor Party such additional information as the Company may deem necessary to register the resale of the Shares and evaluate the eligibility of the Holder to acquire the Shares, and the Holder shall promptly provide such information as may reasonably be requested.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">At any time during the period commencing from the six&#160;(6) month anniversary of the purchase of any Shares hereunder, if the Company fails to satisfy any condition set forth in Rule&#160;144(c)(1) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Public Information Failure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) then, in addition to such Holder&#8217;s other available remedies, the Company shall pay to such Holder, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Shares, an amount in cash equal to two&#160;percent (2.0%) of the Exercise Amount(s) of such Holder&#8217;s Shares on the day of a Public Information Failure and on every 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">day (prorated for periods totaling less than 30&#160;days) thereafter until the earlier of (a)&#160;the date such Public Information Failure is cured and (b)&#160;such time that such public information is no longer required for Holder to transfer the Shares pursuant to Rule&#160;144. The payments to which a Holder shall be entitled pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(k) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">are referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Public Information Failure Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221; Public Information Failure Payments shall be paid on the earlier of (i)&#160;the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii)&#160;the third&#160;(3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5%&#160;per month (prorated for partial months) until paid in full. Nothing herein shall limit such Holder&#8217;s right to pursue actual damages for the Public Information Failure, and such Holder shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief.</font></div><div style="margin-top:12pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:30.13pt">To the extent permitted by law, the Company shall indemnify each Holder and each person, individual, corporation, limited liability company, partnership or trust (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) controlling such Holder within the meaning of Section&#160;15 of the Securities Act, with respect to which any registration that has been effected pursuant to this Agreement, against all claims, losses, damages and liabilities (or action in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(n) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">below), arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any Registration Statement, prospectus, any amendment or supplement thereof, or other document incident to any such registration, qualification or compliance or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in light of the circumstances in which they were made, or any violation by the Company of any rule or regulation promulgated by the Securities Act applicable to the Company and relating to any action or inaction required of the Company in connection with any such registration, qualification or compliance, and will reimburse each Holder and each Person</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">controlling such Holder, for reasonable and documented legal and other out-of-pocket expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action as incurred&#59; provided that the Company will not be liable in any such case to the extent that any untrue statement or omission or allegation thereof is made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Holder for use in preparation of any Registration Statement, prospectus, amendment or supplement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that the Company will not be liable in any such case where the claim, loss, damage or liability arises out of or is related to the failure of such Holder to comply with the covenants and agreements contained in this Agreement respecting sales of Shares.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.13pt">Each Holder will severally, and not jointly, indemnify the Company, each of its directors and officers, and each Person who controls the Company within the meaning of Section&#160;15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(n) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">below), arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any Registration Statement, prospectus, or any amendment or supplement thereof, incident to any such registration, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in light of the circumstances in which they were made, and will reimburse the Company, such directors and officers, and each Person controlling the Company for reasonable and documented legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability or action as incurred, in each case to the extent, but only to the extent, that such untrue statement or omission or allegation thereof is made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Holder for use in preparation of any Registration Statement, prospectus, amendment or supplement. Notwithstanding the foregoing, a Holder&#8217;s aggregate liability pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(m) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7(o) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be limited to the net amount actually received by the Holder from the sale of its Shares.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each party entitled to indemnification under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall give notice to the party required to provide indemnification (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party (at its expense) to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld, conditioned or delayed), and the Indemnified Party may participate in such defense at such Indemnified Party&#8217;s expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Agreement, unless such failure is materially prejudicial to the Indemnifying Party in defending such claim or litigation. An Indemnifying Party shall not be liable for any settlement of an action or claim effected without its written consent (which consent will not be unreasonably withheld, conditioned or delayed). No Indemnifying Party, in its defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">If the indemnification provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expense referred to therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party thereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions which resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each Investor agrees that, prior to the Maturity Date (as defined in the Revenue Interest Purchase Agreement), neither it nor any of its controlled Affiliates will knowingly lend any Shares to a third party for purposes of a covering such third party&#8217;s short position in the Common Stock.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a)&#160;when delivered by hand (with written confirmation of receipt)&#59; (b)&#160;when received by the addressee if sent by a nationally recognized overnight courier (receipt requested)&#59; (c)&#160;at the time of transmission if sent by facsimile or e- mail (with confirmation of transmission)&#59; or (d)&#160;on the third&#160;day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective Parties at the addresses indicated below (or at such other address for a Party as shall be specified in a notice given in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to the Investors</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Infinity SA LLC<br>c&#47;o Oberland Capital Management LLC <br>1700 Broadway, 37th Floor<br>New York, NY 10019 <br>Attention&#58; Kristian Wiggert <br>Telephone&#58; (202) 257-5850<br>Email&#58; kwiggert&#64;oberlandcapital.com</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If to the Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ImmunityBio, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3530 John Hopkins Court </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">San Diego, CA 92121</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Attention&#58; David C. Sachs</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:116%">Email&#58;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:116%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:116%">David.Sachs&#64;Immunitybio.com</font></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:29.56pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">Successor and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns. The Company may not assign (including through a merger) or transfer any of its rights or obligations under this Agreement without the prior written consent of the Holders. A Holder may not assign or transfer any of its rights or obligations</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">under this Agreement without the prior written consent of the Company, except that a Holder may assign any of its rights or obligations under this Agreement (i)&#160;to any Affiliate of a Holder or any fund or investment vehicle managed by a Holder or an Affiliate of a Holder or under common management with a Holder, and (ii)&#160;after the occurrence and during the continuance of a Put Option Event (as defined in the Revenue Interest Purchase Agreement), to any Person. Any assignment or transfer in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be null and void ab initio.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement is for the sole benefit of the Parties and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">Amendment and Modification&#59; Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by the Company and the Holders. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof&#59; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">Governing Law&#59; Submission to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of New York. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America or the courts of the State of New York in each case located in New York City, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of process, summons, notice or other document by mail to such Party&#8217;s address set forth herein shall be effective service of process for any suit, action or other proceeding brought in any such court. The Parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such courts and irrevocably waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement or the transactions contemplated hereby. Each Party certifies and acknowledges that (a)&#160;no representative of any other Party has represented, expressly or otherwise, that such other Party would not seek to enforce the foregoing waiver in the event of a legal action&#59; (b)&#160;such Party has considered the implications of this waiver&#59; (c)&#160;such Party makes this waiver voluntarily&#59; and (d) such Party has been induced to enter into this Agreement by, among other things, the mutual waivers and certifications in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which shall together be deemed to be one and the same agreement. This Agreement may also be executed and delivered by facsimile signature, PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g.,&#160;www.docusign.com), each of which will have the same legal effect as delivery of an original signed copy of this Agreement.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:24.06pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the Parties, and no presumption or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature Pages Follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="ib67646ccdb0e4b978ee0e5aa765c267f_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties hereto have executed this Stock Purchase and Option Agreement on the Execution Date.</font></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.192%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TPC INVESTMENTS II LP</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Bubinsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Authorized Signatory</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TPC INVESTMENTS III LP</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Bubinsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Authorized Signatory</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TPC INVESTMENTS SOLUTIONS LLC</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Bubinsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Authorized Signatory</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TPC INVESTMENTS SOLUTIONS CO-<br>INVEST LP</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">David Dubinsky</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Bubinsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Authorized Signatory</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties hereto have executed this Stock Purchase and Option Agreement on the Execution Date.</font></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.192%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">IMMUNITYBIO, INC.,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">a Delaware Corporation</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Stock Purchase and Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>6
<FILENAME>ibrx20231231-10kexhibit1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i587cfe8d1bb24d32ac489fb56208729b_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 10.13</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nant&#160;Capital, LLC </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450 Duley Road</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">El Segundo, California 90245</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attn&#58; Robert Morse, Chief Financial Officer </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear Nant&#160;Capital, LLC&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to (a)&#160;that certain Convertible Promissory Note issued by ImmunityBio,&#160;Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Nant&#160;Capital, LLC, a Delaware limited liability company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated March&#160;31,&#160;2023 in the stated principal amount of $30,000,000 (as amended from time to time, including by that certain letter amendment dated September&#160;11,&#160;2023, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 2023 Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and (b)&#160;that certain Convertible Promissory Note issued by the Company to the Holder dated September&#160;11,&#160;2023 in the stated principal amount of $200,000,000 (as amended from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 2023 Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms used but not defined herein are used as defined in the March&#160;2023&#160;Note.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This letter amendment confirms our mutual agreement that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The first paragraph of the March&#160;2023&#160;Note is hereby amended by replacing the phrase &#8220;December&#160;31,&#160;2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturity&#160;Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#8221; therein with the phrase &#8220;December&#160;31,&#160;2025 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maturity&#160;Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#8221;.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Each of the March&#160;2023&#160;Note and September&#160;2023&#160;Note (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) are hereby amended to include the following legend at the top of each of each such Note&#58;</font></div><div style="margin-top:12pt;padding-left:63pt;padding-right:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS NOTE AND THE RIGHTS AND OBLIGATIONS EVIDENCED HEREBY ARE SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN THAT CERTAIN SUBORDINATION AGREEMENT (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SUBORDINATION AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), DATED AS OF DECEMBER&#160;29,&#160;2023, BETWEEN INFINITY&#160;SA LLC, A DELAWARE LIMITED LIABILITY COMPANY, AS SENIOR AGENT, AND INVESTOR (AS DEFINED BELOW), AS SUBORDINATED CREDITOR, AND ACKNOWLEDGED BY THE COMPANY (AS DEFINED BELOW) AND EACH HOLDER OF THIS INSTRUMENT, BY ITS ACCEPTANCE HEREOF, SHALL BE BOUND BY THE PROVISIONS OF THE SUBORDINATION AGREEMENT.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as expressly set forth herein, the provisions of each Note shall remain unchanged and in full force and effect and the parties hereto hereby ratify and reaffirm each and every term, covenant and condition set forth in each Note as of the date hereof, as amended by this letter amendment.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS LETTER AMENDMENT SHALL BE GOVERNED BY THE LAW OF THE STATE OF CALIFORNIA (WITHOUT GIVING EFFECT TO THE CONFLICT OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAW OF A DIFFERENT JURISDICTION).</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This letter amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. This letter amendment and the Notes constitute the entire agreement among the parties hereto relating to the subject matter hereof and thereof and supersede any and all previous discussions, correspondence, agreements and other understandings, whether oral or written, relating to the subject matter hereof or thereof. This letter amendment may be executed in any number of counterparts, each of which shall be deemed to be an original and shall be binding upon all parties hereto, and their successors and assigns. Any signatures delivered by a party hereto by facsimile transmission or by electronic transmission shall be deemed an original signature hereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i587cfe8d1bb24d32ac489fb56208729b_75"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please indicate your agreement to the foregoing by signing in the space indicated below.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.192%"><tr><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sincerely,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">IMMUNITYBIO, INC.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer and President</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline">CONSENTED TO AND AGREED&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">NANT CAPITAL, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Charles N. Kenworthy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Charles N. Kenworthy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Letter Amendment to Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>7
<FILENAME>ibrx20231231-10kexhibit1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id2f0bbada57149b1a7bba908c373a84f_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.17</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ACT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THIS NOTE AND THE RIGHTS AND OBLIGATIONS EVIDENCED HEREBY ARE SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN THAT CERTAIN SUBORDINATION AGREEMENT (THE &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">SUBORDINATION AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), DATED AS OF DECEMBER 29, 2023, BETWEEN INFINITY SA LLC, A DELAWARE LIMITED LIABILITY COMPANY, AS SENIOR AGENT, AND INVESTOR (AS DEFINED BELOW), AS SUBORDINATED CREDITOR, AND ACKNOWLEDGED BY THE COMPANY (AS DEFINED BELOW) AND EACH HOLDER OF THIS INSTRUMENT, BY ITS ACCEPTANCE HEREOF, SHALL BE BOUND BY THE PROVISIONS OF THE SUBORDINATION AGREEMENT.</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMMUNITYBIO, INC.</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDED AND RESTATED PROMISSORY NOTE</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:22.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$505,000,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 29, 2023</font></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOR VALUE RECEIVED, IMMUNITYBIO, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) promises to pay to NANT&#160;CAPITAL, LLC or its registered assigns (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), in lawful money of the United States of America, the principal sum of FIVE HUNDRED AND FIVE MILLION Dollars ($505,000,000), or such lesser amount as shall equal the outstanding principal amount hereof, together with interest from the date of this Amended and Restated Promissory Note (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) on the unpaid principal balance at a rate equal to the Tranche&#160;1&#160;Rate or the Tranche&#160;2&#160;Rate (each, as defined below), as applicable, computed on the basis of the actual number of days elapsed and a year of 365&#160;days. All unpaid principal, together with any then unpaid and accrued interest and other amounts payable hereunder, shall be due and payable on the earlier of (i)&#160;December&#160;31,&#160;2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), or (ii)&#160;when, upon the occurrence and during the continuance of an Event of Default, such amounts are declared due and payable by Investor or made automatically due and payable, in each case, in accordance with the terms hereof.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Note amends, restates, and supersedes in its entirety, (a)&#160;that certain Promissory Note, dated as of August&#160;31,&#160;2022, by and between the Company and Investor in the stated principal amount of One&#160;Hundred Twenty Five Million Dollars ($125,000,000), as amended from time to time, (b)&#160;that certain Amended and Restated Promissory Note, dated as of August&#160;31,&#160;2022, by and between the Company and Investor in the stated principal amount of Three Hundred Million Dollars ($300,000,000), as amended from time to time, (c)&#160;that certain Promissory Note, dated as of June&#160;13,&#160;2023, by and between the Company and Investor in the stated principal amount of Thirty Million Dollars ($30,000,000), as amended from time to time, and (d)&#160;that certain Promissory Note, dated as of December&#160;12,&#160;2022, by and between the Company and Investor in the stated principal amount of Fifty Million Dollars ($50,000,000), as amended from time to time (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Existing Non-Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-1-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a statement of the rights of Investor and the conditions to which this Note is subject, and to which Investor, by the acceptance of this Note, agrees&#58;</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.8pt">Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Interest on the Tranche&#160;1 Principal Amount shall accrue at a per annum rate equal to the Term&#160;SOFR Rate plus eight&#160;percent (8.00%) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Tranche&#160;1&#160;Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Interest on the Tranche&#160;2 Principal Amount shall accrue interest at a per annum rate equal to the Term&#160;SOFR Rate plus seven&#160;and one-half of one&#160;percent (7.50%) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Tranche&#160;2&#160;Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Interest. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued interest on this Note shall be payable quarterly, in arrears, on each Interest Payment Date.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.8pt">Voluntary Prepayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon five&#160;Business Days&#8217; prior written notice to Investor, the Company may prepay any outstanding Obligations under this Note in whole or in part without premium or penalty and without the prior consent of Investor, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that any such prepayment will be applied first to the payment of accrued but unpaid interest on this Note and second, if the amount of prepayment exceeds the amount of all such interest, to the payment of outstanding principal of this Note. Any such prepayment may be applied to the Tranche&#160;2 Obligations, the Tranche&#160;1 Obligations, or both in such amounts and in such proportions as determined by the Company in its sole discretion.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Mandatory Prepayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of a Specified Transaction, and only upon the written request of the Investor (in the Investor&#8217;s sole discretion), up to Fifty Million Dollars ($50,000,000) of the Tranche&#160;2 Principal Amount, together with all accrued but unpaid interest thereon shall be due and payable upon the consummation of such Specified Transaction.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The occurrence of any of the following shall constitute an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; under this Note.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.8pt">Failure to Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company shall fail to pay the principal payment, plus any accrued and unpaid interest, on the Maturity Date&#59;</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Voluntary Bankruptcy or Insolvency Proceedings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall (i)&#160;apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii)&#160;admit in writing its inability to pay its debts generally as they mature, (iii)&#160;make a general assignment for the benefit of its or any of its creditors, (iv)&#160;be dissolved or liquidated, (v)&#160;commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against it, or (vi)&#160;take any action for the purpose of effecting any of the foregoing&#59; or</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.8pt">Involuntary Bankruptcy or Insolvency Proceedings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proceedings for the appointment of a receiver, trustee, liquidator or custodian of the Company, or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect to the Company or any of its subsidiaries, if any, or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered or such proceeding shall not be dismissed or discharged within 45&#160;days of commencement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Rights of Investor upon Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the occurrence of any Event of Default (other than an Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;2(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and at any time thereafter during the continuance of such Event of Default, Investor may, by written notice to the Company, declare all outstanding Obligations payable by the Company hereunder to be immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to the contrary notwithstanding. Upon the occurrence of any Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;2(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, immediately and without notice, all outstanding Obligations payable by the Company hereunder shall automatically become immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence and during the continuance of any Event of Default, Investor may exercise any other right, power or remedy otherwise permitted to it by law, either by suit in equity or by action at law, or both.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Voluntary Conversion at Investor&#8217;s Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Investor has the right, at Investor&#8217;s option, at any time after the Conversion Date and on or before the Maturity Date (other than any time period beginning on receipt of a notice of prepayment pursuant to Section&#160;1(c) hereof and ending on the proposed prepayment date specified in such notice of prepayment), to convert all (but not less than all) of the outstanding Tranche&#160;2 Principal Amount into fully paid and nonassessable shares of the Company&#8217;s common stock at a price per share equal to the Conversion Price. The total combined number of shares of common stock to be issued upon voluntary conversion pursuant to this Section&#160;4(a) shall equal (x)&#160;the outstanding Tranche&#160;2 Principal Amount , divided by (y)&#160;the Conversion Price.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Voluntary Conversion upon Notice of Prepayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon receipt of a written notice of prepayment of all or any portion of the Tranche&#160;2 Principal Amount from the Company pursuant to Section&#160;1(c) hereof following the Conversion Date, Investor has the right, at Investor&#8217;s option and upon written notice from Investor to the Company, at any time prior to the proposed prepayment date specified in such notice of prepayment, to convert the outstanding Tranche&#160;2 Principal Amount designated to be so prepaid (as specified in such notice of prepayment) into fully paid and nonassessable shares of the Company&#8217;s common stock at a price per share equal to the Conversion Price. The total combined number of shares of common stock to be issued upon voluntary conversion pursuant to this Section&#160;4(b) shall equal (x)&#160;the outstanding Tranche&#160;2 Principal Amount so converted, divided by (y)&#160;the Conversion Price.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Conversion Pursuant to Section 4(a) or 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Before Investor shall be entitled to convert outstanding Tranche&#160;2 Principal Amount into shares of common stock, it shall give written notice to the Company at its principal corporate offices of the election to convert the same pursuant to Section&#160;4(a) or 4(b), and shall state therein the amount of the outstanding Tranche&#160;2 Principal Amount to be converted, together with all accrued and unpaid interest thereon. The Company shall, as soon as practicable thereafter, issue and deliver to Investor a certificate or certificates, or evidence of the applicable book entry or entries, for the number of shares to which Investor shall be entitled upon such conversion, including a check payable to Investor for any cash amounts payable as described in Section&#160;4(d). Any conversion of the outstanding Tranche&#160;2 Principal Amount pursuant to Section&#160;4(a) or 4(b) shall be deemed to have been made upon the satisfaction of all of the conditions set forth in this Section&#160;4(c) and on and after such date the Persons entitled to receive the shares issuable upon such conversion shall be treated for all purposes as the record holder of such shares.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt;text-decoration:underline">Fractional Shares&#59; Interest&#59; Effect of Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No fractional shares shall be issued upon conversion of the outstanding Tranche&#160;2 Principal Amount. In lieu of the Company issuing any fractional shares to the Investor upon the conversion of the outstanding Tranche&#160;2 Principal Amount, the Company shall pay to Investor an amount equal to the product obtained by multiplying the applicable Conversion Price by the fraction of a share not issued pursuant to the previous sentence. In addition, to the extent not converted into shares of capital stock, the Company shall pay to Investor any interest accrued on the amount converted and on the amount to be paid by the Company pursuant to the previous sentence. Upon conversion of this Note in full and the payment of the amounts specified in this paragraph, the Company shall be forever released from all its obligations and liabilities in respect of the Tranche&#160;2 Obligations. The conversion of any portion of the Tranche&#160;2 Principal Amount shall be equivalent to prepayment in full in cash of such Obligations for all purposes of this Note and, once converted, such amounts shall be deemed paid in full and no longer outstanding hereunder.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt;text-decoration:underline">Reservation of Stock Issuable Upon Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. After the Conversion Date, the Company shall at all times reserve and keep available out of its authorized but unissued shares of common stock solely for the purpose of effecting the conversion of the outstanding Tranche&#160;2 Principal Amount such number of its shares of common stock as shall from time to time be sufficient to effect the conversion of the outstanding Tranche&#160;2 Principal Amount&#59; and if at any time the number of authorized but unissued shares of common stock shall not be sufficient to effect the conversion of the entire outstanding Tranche&#160;2 Principal Amount, without limitation of such other remedies as shall be available to the holder of this Note, the Company will use its reasonable efforts to take such corporate action as may, in the opinion of counsel, be necessary to increase its authorized but unissued shares of common stock to such number of shares as shall be sufficient for such purposes.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Representations and Warranties of Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. By acceptance of this Note, Investor represents and warrants to the Company that Investor has full legal capacity, power and authority to execute and deliver this Note and to perform its obligations hereunder. This Note constitutes valid and binding obligations of Investor, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors&#8217; rights generally and general principles of equity.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As used in this Note, the following capitalized terms have the following meanings&#58;</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day (other than a Saturday or a Sunday) on which banks are open for business in New York City.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CME Term SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means CME Group Benchmark Administration Limited as administrator of the forward-looking term Secured Overnight Financing Rate (SOFR) (or a successor administrator).</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Conversion Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the price per share equal to the greater of (a) the product of (i)&#160;the price for one share of common stock of the Company on the NASDAQ Global Select Market as of the close of trading on the date that is two&#160;full Trading Days following the date on which the execution and effectiveness of this Note is publicly announced, multiplied by (ii)&#160;1.75 and (b)&#160;the &#8220;Minimum Price&#8221; (as defined in Listing Rule&#160;5635(d) of the NASDAQ Listing Rules), as determined after the close of trading on the date hereof.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Conversion Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the close of market trading on the date that is two&#160;full Trading Days following the date on which the execution and effectiveness of this Note is publicly </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">announced.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning given in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section&#160;2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereof.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Person specified in the introductory paragraph of this Note or any Person who shall at the time be the registered holder of this Note.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the last Business Day of each March, June, September and December, commencing with December&#160;31,&#160;2023.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Interest Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a)&#160;the period commencing on the date of this Note and ending on December&#160;31,&#160;2023 and (b)&#160;each three-month period thereafter ending on an Interest Payment Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (i)&#160;if any Interest Period would end on a day other than a U.S.&#160;Government Securities Business Day, such Interest Period shall be extended to the next succeeding U.S.&#160;Government Securities Business Day unless such next succeeding U.S.&#160;Government Securities Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding U.S.&#160;Government Securities Business Day, and (ii)&#160;any Interest Period that commences on the last U.S.&#160;Government Securities Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest Period) shall end on the last U.S.&#160;Government Securities Business Day of the last calendar month of such Interest Period.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means and include all loans, advances, debts, liabilities and obligations, howsoever arising, owed by the Company to Investor of every kind and description, now existing or hereafter arising under or pursuant to the terms of this Note, including, all interest, fees, charges, expenses, attorneys&#8217; fees and costs and accountants&#8217; fees and costs chargeable to and payable by the Company hereunder and thereunder, in each case, whether direct or indirect, absolute or contingent, due or to become due, and whether or not arising after the commencement of a proceeding under Title&#160;11 of the United States Code (11&#160;U. S. C. Section&#160;101 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">et&#160;seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.), as amended from time to time (including post- petition interest) and whether or not allowed or allowable as a claim in any such proceeding.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means and include an individual, a partnership, a corporation (including a business trust), a joint stock company, a limited liability company, an unincorporated association, a joint venture or other entity or a governmental authority.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Specified Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the successful closing of a strategic partnering transaction with a large biopharmaceutical company.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it under the definition of Term&#160;SOFR Reference Rate.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any tenor comparable to the applicable Interest Period, the Term SOFR Reference Rate at approximately 5&#58;00&#160;a.m., Chicago time, two&#160;U.S.&#160;Government Securities Business Days prior to the commencement of such tenor comparable to the applicable Interest Period, as such rate is published by the CME Term&#160;SOFR Administrator.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Term SOFR Reference Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any day and time (such day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Term&#160;SOFR Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), for any tenor comparable to the applicable Interest Period, the rate per annum reasonably determined by the Company as the forward-looking term rate based on SOFR. If by 5&#58;00&#160;pm (New York City time) on the fifth&#160;(5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) U.S.&#160;Government Securities Business Day immediately following any Term&#160;SOFR Determination Day, the &#8220;Term&#160;SOFR Reference Rate&#8221; for the applicable</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">tenor has not been published by the CME Term&#160;SOFR Administrator, then the Term&#160;SOFR Reference Rate for such Term&#160;SOFR Determination Day will be the Term&#160;SOFR Reference Rate as published in respect of the first preceding U.S.&#160;Government Securities Business Day for which such Term&#160;SOFR Reference Rate was published by the CME Term&#160;SOFR Administrator.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a day on which (i)&#160;trading in the Company&#8217;s common stock generally occurs on the Nasdaq Global Select Market and (ii)&#160;a last reported sale price for the Company&#8217;s common stock is available on the Nasdaq Global Select Market.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Tranche 1 Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Tranche&#160;1 Principal Amount, plus all accrued and unpaid interest thereon.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Tranche 2 Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Tranche&#160;2 Principal Amount, plus all accrued and unpaid interest thereon.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Tranche 1 Principal Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean One Hundred Twenty Five Million Dollars ($125,000,000) or such lesser amount as shall then remain outstanding as of any applicable date of determination.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Tranche 2 Principal Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Three Hundred Eighty Million Dollars ($380,000,000) or such lesser amount as shall then remain outstanding as of any applicable date of determination.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">U.S. Government Securities Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day except for (i)&#160;a Saturday, (ii)&#160;a Sunday or (iii)&#160;a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.8pt">Waiver and Amendment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any provision of this Note may be amended, waived or modified upon the written consent of the Company and Investor.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to Investor) or otherwise delivered by hand, messenger or courier service addressed&#58;</font></div><div style="margin-top:9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">if to Investor, to Investor&#8217;s address, facsimile number or electronic mail address as shown in the Company&#8217;s records, as may be updated in accordance with the provisions hereof, or, until such holder so furnishes an address, facsimile number or electronic mail address to the Company, then to the address, facsimile number or electronic mail address of the last holder of this Note for which the Company has contact information in its records&#59; or</font></div><div style="margin-top:9pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">if to the Company, to the attention of the Chief Executive Officer or Chief Financial Officer of the Company at 3530&#160;John Hopkins Court, San&#160;Diego, CA&#160;92121, or at such other current address as the Company shall have furnished to Investor, with a copy (which shall not constitute notice) to Martin&#160;J.&#160;Waters, Wilson Sonsini Goodrich &#38; Rosati,&#160;P.C., 12235&#160;El Camino Real, Suite&#160;200, San&#160;Diego, CA&#160;92130-3002.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each such notice or other communication shall for all purposes of this Note be treated as effective or having been given (i)&#160;if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next- business-day delivery, one Business Day after deposit with the courier), or (ii)&#160;if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii)&#160;if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#8217;s next Business Day. In the event of any conflict between the Company&#8217;s books and records and this Note or any notice delivered hereunder, the Company&#8217;s books and records will control absent fraud or error.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.8pt">Payment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless converted into the Company&#8217;s equity securities pursuant to the terms hereof, payment shall be made in lawful tender of the United States.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Default Rate&#59;Usury. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During any period prior to the Maturity Date in which a non- payment by the Company of the interest earned on the Note has occurred and is continuing, or an Event of Default has occurred and is continuing, the Company shall pay interest on the unpaid principal balance hereof at a rate per annum equal to the rate otherwise applicable hereunder plus two&#160;percent (2%) per annum. In the event any interest is paid on this Note which is deemed to be in excess of the then legal maximum rate, then that portion of the interest payment representing an amount in excess of the then legal maximum rate shall be deemed a payment of principal and applied against the principal of this Note.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.8pt">Waivers. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company hereby waives notice of default, presentment or demand for payment, protest or notice of nonpayment or dishonor and all other notices or demands relative to this instrument.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:25.02pt">Governing Law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Note and all actions arising out of or in connection with this Note shall be governed by and construed in accordance with the laws of the State of California, without regard to the conflicts of law provisions of the State of California, or of any other state.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Restriction on Transferability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Note and the rights and obligations hereunder may not be assigned by either the Investor or the Company without the prior written consent of the other party.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company or its agent will keep books for the registration and registration of transfer of the Note. Subject to this section and any other restrictions on or conditions to transfer set forth in the Note, the Note may be transferred only upon its surrender to the Company for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Prior to registration of any such transfer, the Company shall treat the person in whose name the Note is registered as the owner and holder of the Note for all purposes, including payment of principal and interest, and the Company shall not be affected by notice to the contrary.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:25.63pt">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding any other provision to the contrary, the Company shall be entitled to deduct and withhold from any amounts payable or otherwise deliverable with respect to this Note such amounts as may be required to be deducted or withheld therefrom under any provision of applicable law, and to be provided any necessary tax forms and information, including Internal Revenue Service Form W&#160;9 or appropriate version of IRS Form W&#160;8, as applicable, from each</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">beneficial owner of the Note. To the extent such amounts are so deducted or withheld and paid over to the appropriate taxing authority, such amounts shall be treated for all purposes as having been paid to the person to whom such amounts otherwise would have been paid.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:25.63pt">Surrender of Note for Cancellation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon payment or conversion, as applicable, in full of the Tranche&#160;1 Obligations and the Tranche&#160;2 Obligations, Investor shall surrender this Note (or a notice to the effect that the original Note has been lost, stolen or destroyed and an agreement acceptable to the Company whereby the holder agrees to indemnify the Company from any loss incurred by it in connection with this Note) to the Company for cancellation. Any failure of Investor to comply with the foregoing sentence shall not impact the discharge and termination of the obligations under this Note upon payment or conversion, as applicable, in full of the Tranche&#160;1 Obligations and the Tranche&#160;2 Obligations.</font></div><div style="margin-top:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.18pt">Amendment and Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Note amends and restates in its entirety the Existing Non-Convertible Notes issued by the Company in favor of Investor&#59; and the Company confirms that the Existing Non-Convertible Notes have at all times, since the date of the execution and delivery of such Existing Non-Convertible Notes, remained in full force and effect. The Obligations hereunder are a continuation of the Obligations under (and as such term is defined in) each of the Existing Non-Convertible Notes. The Company and the Investor acknowledge and agree that the amendment and restatement of the Existing Non-Convertible Notes by this Note is not intended to constitute, nor does it constitute, a novation, interruption, suspension of continuity, satisfaction, discharge or termination of the obligations, liabilities, or indebtedness under the Existing Non- Convertible Notes.</font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-8-</font></div></div></div><div id="id2f0bbada57149b1a7bba908c373a84f_71"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has caused this Note to be issued as of the date first written above.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">IMMUNITYBIO, INC.,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">a Delaware corporation</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#47;s&#47; Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Chief Executive Officer and President</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Signature page for Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">)</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:7.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%;text-decoration:underline">CONSENTED TO AND AGREED BY&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">NANT CAPITAL, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#47;s&#47; Charles N. Kenworthy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Charles N. Kenworthy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Signature page for Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">)</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>8
<FILENAME>ibrx-20231231x10kex1041.htm
<DESCRIPTION>EX-10.41
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i49fd51940ef64ce8b5e6dda7829da823_34"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.41</font></div></div><div><img alt="ib_logoxfinalxcolorx02x2021a.jpg" src="ib_logoxfinalxcolorx02x2021a.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">October&#160;3,&#160;2023</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Duley Road, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9922 Jefferson Boulevard</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Culver City, CA 90232</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; Charles N. Kenworthy</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Re&#58; Building #3 at 400 Duley Road</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear Mr. Kenworthy&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reference is made to that certain Commercial Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) dated February&#160;1,&#160;2017 by and between Duley Road, LLC  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Altor Bioscience Manufacturing Company, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) whereby Tenant leases from Landlord certain premises commonly known as Building&#160;#3 at 400&#160;Duley&#160;Road, El Segundo, California&#160;90245. Capitalized terms that are undefined herein shall have meanings given to them in the Lease.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant hereby elects to exercise its option to extend the Term of the Lease for an additional period of five&#160;(5) years through October&#160;31,&#160;2029 pursuant to the terms of Section&#160;1.2 of the Lease. The parties hereto further agree that all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this letter agreement. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sincerely,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David Sachs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David Sachs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ACKNOWLEDGED AND AGREED</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Duley Road, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Charles N. Kenworthy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Charles N. Kenworthy, Manager</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>ibrx-20231231x10kexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6884a323811645178f88dfb9c3d962f2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">EXHIBIT 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUBSIDIARIES OF IMMUNITYBIO, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jurisdiction of<br>Organization</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Percentage of <br>Voting Securities <br>Owned Directly <br>or Indirectly by <br>ImmunityBio, Inc.</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Infacell Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inex Bio, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NantCell, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Etubics Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Altor BioScience, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Altor BioScience Manufacturing Company, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Receptome, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">VBC Holdings LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">92.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">VivaBioCell, S.p.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Italy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GlobeImmune, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69.1%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Immunotherapy NANTibody, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IgDraSol, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MCLR Parent LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mariposa Clinic Co LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mariposa Lab Co LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mariposa Radiology Co LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100.0%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AccessBio LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">50.0%</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">__________</font></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Note&#58;&#160;&#160;&#160;&#160;All of the subsidiaries shown above are included in our consolidated financial statements. Inactive subsidiaries have not been included in the above list.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>ibrx-20231231x10kexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i63918a65806b4d23bce888b0ada1bfd7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EXHIBIT 23.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-top:9pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.68pt">Registration Statement (Form&#160;S-8 No.&#160;333-205942) pertaining to the 2014&#160;Equity Incentive Plan and 2015 Equity Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-top:6pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.68pt">Registration Statement (Form&#160;S-8 No.&#160;333-233082) pertaining to the 2015&#160;Equity Incentive Plan as Amended and Restated&#59;</font></div><div style="margin-top:6pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.68pt">Registration Statement (Form&#160;S-8 No.&#160;333-243725) pertaining to the 2015&#160;Equity Incentive Plan as Amended and Restated&#59; </font></div><div style="margin-top:6pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.68pt">Registration Statement (Post-Effective Amendment No.&#160;1 on Form&#160;S-8 to Form&#160;S-4 No.&#160;333-252232) for the registration of common stock reserved for issuance pursuant to the Amended and Restated ImmunityBio,&#160;Inc. 2015&#160;Stock Incentive Plan&#59;</font></div><div style="margin-top:6pt;padding-left:49pt;text-indent:-24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.68pt">Registration Statement (Form&#160;S-3 No.&#160;333-255699) of ImmunityBio, Inc. for the registration of common stock, preferred stock, debt securities, warrants and units, as amended by Post-Effective Amendment No.&#160;1 on&#160;Form&#160;S-3, Post-Effective Amendment No.&#160;2 on Form S-3, and Post-Effective Amendment No. 3 on Form S-3&#59;</font></div><div style="margin-top:6pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.68pt">Registration Statement (Form&#160;S-8 No.&#160;333-265599) pertaining to the 2015 Equity Incentive Plan, as Amended&#59; and</font></div><div style="margin-top:6pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.68pt">Registration Statement (Form&#160;S-3 No. 333-269608) of ImmunityBio, Inc. for the registration of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, and units.</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of our report dated March&#160;19,&#160;2024, with respect to the consolidated financial statements of ImmunityBio,&#160;Inc. and Subsidiaries included in this Annual Report (Form&#160;10-K) for the year ended December&#160;31,&#160;2023.</font></div><div style="margin-top:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-top:18pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Los Angeles, California</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March&#160;19,&#160;2024</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>ibrx-20231231x10kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i32207741fadb43f2a4619f73c5e79767_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard Adcock, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form&#160;10-K of ImmunityBio, Inc.&#894;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;  March&#160;19,&#160;2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>ibrx-20231231x10kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i456ea94b748a46f1bcb99cf5298a54eb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;302 OF </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David C. Sachs, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form&#160;10-K of ImmunityBio, Inc.&#894;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:45.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;  March&#160;19,&#160;2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Principal Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>ibrx-20231231x10kexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i80a604c9ae4e4f80aaae75066a7eafa2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 32.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. &#167; 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18&#160;U.S.C.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#167;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, I,&#160;Richard&#160;Adcock, the chief executive officer of ImmunityBio, Inc. (the &#8220;Company&#8221;), hereby certify, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the Annual Report of the Company on Form&#160;10-K for the year ended December&#160;31,&#160;2023 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#894; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:40.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;19,&#160;2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Adcock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>ibrx-20231231x10kexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="idb47628a1e614619bcc3e0fa9ec78663_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 32.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. &#167; 1350, AS ADOPTED </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18&#160;U.S.C.&#160;&#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, I,&#160;David&#160;C.&#160;Sachs, the chief financial officer of ImmunityBio, Inc. (the &#8220;Company&#8221;), hereby certify, that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the Annual Report of the Company on Form&#160;10-K for the year ended December&#160;31,&#160;2023 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#894; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;19,&#160;2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David C. Sachs</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>15
<FILENAME>ibrx-20231231x10kexhibit971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4ddce53fad284a12ba12d60abc689d7f_34"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;97.1</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNITYBIO, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPENSATION RECOVERY POLICY</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As adopted or most recently amended on November&#160;29,&#160;2023</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is committed to strong corporate governance. As part of this commitment, the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) has adopted this clawback policy called the Compensation Recovery Policy (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Policy is intended to further the Company&#8217;s pay-for-performance philosophy and to comply with applicable laws by providing rules relating to the reasonably prompt recovery of certain compensation received by Covered Executives in the event of an Accounting Restatement. The application of the Policy to Covered Executives is not discretionary, except to the limited extent provided below, and applies without regard to whether a Covered Executive was at fault. Capitalized terms used in the Policy are defined below, and the definitions have substantive impact on its application so reviewing them carefully is important to your understanding.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Policy is intended to comply with, and will be interpreted in a manner consistent with, Section&#160;10D of the Securities Exchange Act of 1934 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), with Exchange Act Rule 10D-1 and with the listing standards of the national securities exchange (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on which the securities of the Company are listed, including any official interpretive guidance.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Persons Covered by the Policy</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Policy is binding and enforceable against all &#8220;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covered Executives.</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; A Covered Executive is each individual who is or was ever designated as an &#8220;officer&#8221; by the Board in accordance with Exchange Act Rule&#160;16a-1(f) (a &#8220;</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;16 Officer</font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Committee may (but is not obligated to) request or require a Covered Executive to sign and return to the Company an acknowledgement that such Covered Executive will be bound by the terms and comply with the Policy. The Policy is binding on each Covered Executive whether or not the Covered Executive signs and&#47;or returns any acknowledgment.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Administration of the Policy</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board shall delegate authority to administer the Policy to a committee of the Board made up of independent members of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board shall delegate authority to administer the Policy to a committee of the Board made up of independent members of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Restatements Requiring Application of the Policy</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then the Committee must determine the Excess Compensation, if any, that must be recovered. The Company&#8217;s obligation to recover Excess Compensation is not dependent on if or when restated financial statements are filed.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Covered by the Policy</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Policy applies to certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (certain terms used in this Section are defined below) that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on or after October&#160;2,&#160;2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), during the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covered Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> while the Company has a class of securities listed on a national securities exchange. Such Incentive-Based Compensation is considered &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clawback Eligible Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; if the Incentive-Based Compensation is Received by a person after such person became a Section&#160;16 Officer and the person served as a Section&#160;16 Officer at any time during the performance period for the Incentive-Based Compensation. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excess Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the amount of Clawback Eligible Incentive-Based Compensation that exceeds the amount of Clawback Eligible Incentive-Based Compensation that otherwise would have been Received had such Clawback Eligible Incentive-Based Compensation been determined based on the restated amounts. Excess Compensation must be computed without regard to any taxes paid and is referred to in the listings standards as &#8220;erroneously awarded compensation&#8221;.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the amount of Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received and the Company must maintain documentation of the determination of that reasonable estimate and provide that documentation to the Exchange.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. For the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company&#8217;s right to recover under the Policy has lapsed. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; are measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incentive-Based Compensation is &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; under the Policy in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment, vesting, settlement or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to the Effective Date.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covered Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Determination Date. In addition, Covered Period can include certain transition periods resulting from a change in the Company&#8217;s fiscal year. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Restatement Determination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the earliest to occur of&#58; (a)&#160;the date the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement&#59; and (b)&#160;the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repayment of Excess Compensation</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must recover Excess Compensation reasonably promptly and Covered Executives are required to repay Excess Compensation to the Company. Subject to applicable law, the Company may recover Excess Compensation by requiring the Covered Executive to repay such amount to the Company by direct payment to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not need to be identical as to each Covered Executive). These means include (but are not limited to)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">requiring reimbursement of cash Incentive-Based Compensation previously paid&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation or vest based on the achievement of performance goals&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or any affiliate of the Company to the Covered Executive, including (but not limited to) payments of severance that might otherwise be due in connection with a Covered Executive&#8217;s termination of employment and without regard to whether such amounts are Incentive-Based Compensation&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">cancelling outstanding vested or unvested equity awards (including, but not limited to, time-based vesting awards), without regard to whether such awards are Incentive-Based Compensation&#59; and&#47;or </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">taking any other remedial and recovery action permitted by law, as determined by the Committee. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of Excess Compensation must be made by a Covered Executive notwithstanding any Covered Executive&#8217;s belief (whether or not legitimate) that the Excess Compensation had been previously earned under applicable law and therefore is not subject to clawback. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce a Covered Executive&#8217;s obligations to the Company or to discipline a Covered Executive. Failure of a Covered Executive to comply with their obligations under the Policy may result in (without limitation) termination of that Covered Executive&#8217;s employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities or change in role. The decision to take any actions described in the preceding sentence will not be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company. For avoidance of doubt, any decisions of the Company or the Covered Executive&#8217;s employer to discipline a Covered Executive or terminate the employment of a Covered Executive are independent of determinations under this Policy. For example, if a Covered Executive was involved in activities that led to an Accounting Restatement, the Company&#8217;s decision as to whether or not to terminate such Covered Executive&#8217;s employment would be made under its employment arrangements with such Covered Executive and the requirement to apply this no-fault and non-discretionary clawback policy will not be determinative of whether any such termination is for cause, although failure to comply with the Policy might be something that could result in a termination for cause depending on the terms of such arrangements.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limited Exceptions to the Policy</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must recover the Excess Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below is met, and the Committee determines that recovery of the Excess Compensation would be impracticable&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover such Excess Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Important Information in the Policy</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer, as well as any other applicable laws, regulatory requirements, rules, or pursuant to the terms of any existing Company policy or agreement providing for the recovery of compensation.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the terms of any of the Company&#8217;s organizational documents (including, but not limited to, the Company&#8217;s bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify or provide advancement for any Covered Executive against any loss of Excess Compensation. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event that the Company is required to recover Excess Compensation pursuant to the Policy from a Covered Executive who is no longer an employee, the Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement that individual may have signed. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the terms of any of the Company&#8217;s organizational documents (including, but not limited to, the&#160;Company&#8217;s bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify or provide advancement for any Covered Executive against any loss of Excess Compensation. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event that the Company is required to recover Excess Compensation pursuant to the Policy from a Covered Executive who is no longer an employee, the&#160;Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement that individual may have signed. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee or Board may review and modify the Policy from time to time.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any provision of the Policy or the application of any such provision to any Covered Executive is adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of the Policy or the application of such provision to another Covered Executive, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Policy will terminate and no longer be enforceable when the Company ceases to be listed issuer within the meaning of Section&#160;10D of the Exchange Act.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>ibrx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1fd74a66-0ec9-47b3-a3a2-77069a10a521,g:7ebe44e2-bf98-46f1-8b70-fddc2baf2bbb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ibrx="http://www.immunitybio.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.immunitybio.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.immunitybio.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.immunitybio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.immunitybio.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersDeficit" roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersDeficitParenthetical" roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Stockholders' Deficit Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.immunitybio.com/role/DescriptionofBusiness">
        <link:definition>0000010 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetails" roleURI="http://www.immunitybio.com/role/FinancialStatementDetails">
        <link:definition>0000012 - Disclosure - Financial Statement Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.immunitybio.com/role/FinancialInstruments">
        <link:definition>0000013 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.immunitybio.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisition" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition">
        <link:definition>0000015 - Disclosure - Collaboration and License Agreements and Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.immunitybio.com/role/CommitmentsandContingencies">
        <link:definition>0000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangements" roleURI="http://www.immunitybio.com/role/LeaseArrangements">
        <link:definition>0000017 - Disclosure - Lease Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueInterestPurchaseAgreement" roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreement">
        <link:definition>0000018 - Disclosure - Revenue Interest Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebt" roleURI="http://www.immunitybio.com/role/RelatedPartyDebt">
        <link:definition>0000019 - Disclosure - Related-Party Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreements" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreements">
        <link:definition>0000020 - Disclosure - Related-Party Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilities" roleURI="http://www.immunitybio.com/role/WarrantLiabilities">
        <link:definition>0000021 - Disclosure - Warrant Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://www.immunitybio.com/role/StockholdersDeficit">
        <link:definition>0000022 - Disclosure - Stockholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.immunitybio.com/role/StockBasedCompensation">
        <link:definition>0000023 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.immunitybio.com/role/IncomeTaxes">
        <link:definition>0000024 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://www.immunitybio.com/role/EmployeeBenefits">
        <link:definition>0000025 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessTables" roleURI="http://www.immunitybio.com/role/DescriptionofBusinessTables">
        <link:definition>9954472 - Disclosure - Description of Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954473 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsTables" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsTables">
        <link:definition>9954474 - Disclosure - Financial Statement Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsTables">
        <link:definition>9954475 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.immunitybio.com/role/FairValueMeasurementsTables">
        <link:definition>9954476 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionTables" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables">
        <link:definition>9954477 - Disclosure - Collaboration and License Agreements and Acquisition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsTables" roleURI="http://www.immunitybio.com/role/LeaseArrangementsTables">
        <link:definition>9954478 - Disclosure - Lease Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueInterestPurchaseAgreementTables" roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementTables">
        <link:definition>9954479 - Disclosure - Revenue Interest Purchase Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtTables" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtTables">
        <link:definition>9954480 - Disclosure - Related-Party Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsTables" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsTables">
        <link:definition>9954481 - Disclosure - Related-Party Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.immunitybio.com/role/StockBasedCompensationTables">
        <link:definition>9954482 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.immunitybio.com/role/IncomeTaxesTables">
        <link:definition>9954483 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>9954484 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail" roleURI="http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail">
        <link:definition>9954485 - Disclosure - Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Consolidated Statements of Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails">
        <link:definition>9954487 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail">
        <link:definition>9954488 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails" roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails">
        <link:definition>9954489 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail">
        <link:definition>9954490 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail">
        <link:definition>9954491 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail">
        <link:definition>9954492 - Disclosure - Financial Statement Details - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsIntangibleAssetsNetDetails" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails">
        <link:definition>9954493 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsIntangibleAssetsNetDetails_1" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1">
        <link:definition>9954493 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail">
        <link:definition>9954494 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail">
        <link:definition>9954495 - Disclosure - Financial Statement Details - Interest and Investment Income (Loss), Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialStatementDetailsInterestExpenseDetails" roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails">
        <link:definition>9954496 - Disclosure - Financial Statement Details - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail">
        <link:definition>9954497 - Disclosure - Financial Instruments - Available-for-Sale Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail">
        <link:definition>9954498 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail">
        <link:definition>9954499 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>9954500 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>9954501 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>9954502 - Disclosure - Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail">
        <link:definition>9954503 - Disclosure - Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails">
        <link:definition>9954504 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails" roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails">
        <link:definition>9954505 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail">
        <link:definition>9954506 - Disclosure - Commitments and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLitigationAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail">
        <link:definition>9954507 - Disclosure - Commitments and Contingencies - Litigation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails" roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails">
        <link:definition>9954508 - Disclosure - Commitments and Contingencies - Unconditional Purchase Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail">
        <link:definition>9954509 - Disclosure - Lease Arrangements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSupplementalBalanceSheetInformationDetails" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails">
        <link:definition>9954510 - Disclosure - Lease Arrangements - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofInformationRegardingLeasesDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail">
        <link:definition>9954511 - Disclosure - Lease Arrangements - Summary of Information Regarding Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsComponentsofLeaseExpenseDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail">
        <link:definition>9954512 - Disclosure - Lease Arrangements - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail">
        <link:definition>9954513 - Disclosure - Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail">
        <link:definition>9954514 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1">
        <link:definition>9954514 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2">
        <link:definition>9954514 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueInterestPurchaseAgreementAdditionalInformationDetails" roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails">
        <link:definition>9954515 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails" roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails">
        <link:definition>9954516 - Disclosure - Revenue Interest Purchase Agreement - Summary of the Revenue Interest Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail">
        <link:definition>9954517 - Disclosure - Related-Party Debt - Summary of Related-Party Promissory Notes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtAdditionalInformationDetails" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails">
        <link:definition>9954518 - Disclosure - Related-Party Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails">
        <link:definition>9954519 - Disclosure - Related Party Debt - Estimated Fair Value of Convertible Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtRelatedPartyPromissoryNotesDetails" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails">
        <link:definition>9954520 - Disclosure - Related Party Debt - Related Party Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" roleURI="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails">
        <link:definition>9954521 - Disclosure - Related-Party Debt - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail">
        <link:definition>9954522 - Disclosure - Related-Party Agreements - Outstanding Balances of Related-Party Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyAgreementsAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail">
        <link:definition>9954523 - Disclosure - Related-Party Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantLiabilitiesDetails" roleURI="http://www.immunitybio.com/role/WarrantLiabilitiesDetails">
        <link:definition>9954524 - Disclosure - Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail">
        <link:definition>9954525 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>9954526 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail">
        <link:definition>9954527 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expenses Related to Statement of Operations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail">
        <link:definition>9954528 - Disclosure - Stock-Based Compensation - Stock Option Activity and Related Information under Equity Plans (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail">
        <link:definition>9954529 - Disclosure - Stock-Based Compensation - Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRSUActivityunderEquityPlansDetail" roleURI="http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail">
        <link:definition>9954530 - Disclosure - Stock-Based Compensation - RSU Activity under Equity Plans (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossBeforeTaxesDomesticandForeignDetails" roleURI="http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails">
        <link:definition>9954531 - Disclosure - Income Taxes - Loss Before Taxes, Domestic and Foreign (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails" roleURI="http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails">
        <link:definition>9954532 - Disclosure - Income Taxes - Components of Income Tax Benefit (Provision) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954533 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>9954534 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" roleURI="http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails">
        <link:definition>9954535 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails" roleURI="http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails">
        <link:definition>9954536 - Disclosure - Income Taxes - Changes to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsDetails" roleURI="http://www.immunitybio.com/role/EmployeeBenefitsDetails">
        <link:definition>9954537 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" abstract="false" name="IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RiptideBioscienceIncMember" abstract="true" name="RiptideBioscienceIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_InsurancePremiumFinancingAsset" abstract="false" name="InsurancePremiumFinancingAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LitigationSettlementNumberOfSharesToBeIssued" abstract="false" name="LitigationSettlementNumberOfSharesToBeIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ibrx_SixZeroFiveDougStLLCMember" abstract="true" name="SixZeroFiveDougStLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AltorBioScienceLLCMember" abstract="true" name="AltorBioScienceLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_ImmunoOncologyClinicMember" abstract="true" name="ImmunoOncologyClinicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_DrSoonShiongAndRelatedPartyMember" abstract="true" name="DrSoonShiongAndRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" abstract="false" name="ConvertibleNotesFairValueOptionElectionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ibrx_MeasurementInputMarketYieldMember" abstract="true" name="MeasurementInputMarketYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_SaleOfStockAdditionalPurchaseOption" abstract="false" name="SaleOfStockAdditionalPurchaseOption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" abstract="false" name="LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_RevenueInterestPurchaseAgreementAbstract" abstract="true" name="RevenueInterestPurchaseAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_SeptemberTwentyNineteenLeaseMember" abstract="true" name="SeptemberTwentyNineteenLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_A50MillionDecember2022PromissoryNoteMember" abstract="true" name="A50MillionDecember2022PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_BaseMonthlyRent" abstract="false" name="BaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" abstract="false" name="ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_PromissoryNotesPayableMember" abstract="true" name="PromissoryNotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" abstract="false" name="OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_NantKwestMember" abstract="true" name="NantKwestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_PeriodOneMember" abstract="true" name="PeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_DebtInstrumentNumberOfAdvances" abstract="false" name="DebtInstrumentNumberOfAdvances" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_A505MillionPromissoryNoteDecember2023Member" abstract="true" name="A505MillionPromissoryNoteDecember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_SixZeroFiveNashLLCMember" abstract="true" name="SixZeroFiveNashLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_AccountingPoliciesLineItems" abstract="true" name="AccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" abstract="false" name="APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_TransactionCostsWarrantLiability" abstract="false" name="TransactionCostsWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_StockOptionPurchaseLiabilityMember" abstract="true" name="StockOptionPurchaseLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_StockPurchaseAndOptionAgreementMember" abstract="true" name="StockPurchaseAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_PrivatePlacementAndAtTheMarketOfferingsMember" abstract="true" name="PrivatePlacementAndAtTheMarketOfferingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" abstract="false" name="FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" abstract="false" name="IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsLicenseMaintenanceFees" abstract="false" name="CollaborationAgreementsLicenseMaintenanceFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_PeriodOfExtendedLeaseTerm" abstract="false" name="PeriodOfExtendedLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_PrepaidSoftwareLicenseFees" abstract="false" name="PrepaidSoftwareLicenseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_WarrantsPolicyTextBlock" abstract="false" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_ConvertibleNoteReceivableDiscountOptionPercent" abstract="false" name="ConvertibleNoteReceivableDiscountOptionPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_February2023WarrantsMember" abstract="true" name="February2023WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_MonthlyBaseRentParking" abstract="false" name="MonthlyBaseRentParking" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_FinancingObligationCurrent" abstract="false" name="FinancingObligationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaid" abstract="false" name="LeaseLiabilityToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_TieredPaymentsAxis" abstract="true" name="TieredPaymentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" abstract="true" name="ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_OrganizedWorkforceMember" abstract="true" name="OrganizedWorkforceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_NantCapitalOneMember" abstract="true" name="NantCapitalOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_VariousMember" abstract="true" name="VariousMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_TwoThousandFifteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member" abstract="true" name="A505MillionPromissoryNoteDecember2023Tranche1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_AnnualPercentageIncreaseToLicenseFee" abstract="false" name="AnnualPercentageIncreaseToLicenseFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" abstract="false" name="UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage" abstract="false" name="RevenueInterestPurchaseAgreementPaymentReceivedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AssetAcquisitionFairValueOfAssetsAcquired" abstract="false" name="AssetAcquisitionFairValueOfAssetsAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" abstract="true" name="SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_CurrentLiabilitiesMember" abstract="true" name="CurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AdvancesToRelatedPartyMember" abstract="true" name="AdvancesToRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_PrepaidEquipmentMaintenance" abstract="false" name="PrepaidEquipmentMaintenance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SaleLeasebackTransactionPropertyTaxes" abstract="false" name="SaleLeasebackTransactionPropertyTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CommonStockRevenueInterestPurchaseAgreementMember" abstract="true" name="CommonStockRevenueInterestPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_PercentageOfWhollyOwnedSubsidiary" abstract="false" name="PercentageOfWhollyOwnedSubsidiary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_TieredPaymentsDomain" abstract="true" name="TieredPaymentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" abstract="false" name="SharesIssuedCashDistributedInLieuOfFractionalShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ibrx_NantCapitalMember" abstract="true" name="NantCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LeaseOperatingLeaseAnnualLeasePayment" abstract="false" name="LeaseOperatingLeaseAnnualLeasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_JulyTwentyNineteenLeaseMember" abstract="true" name="JulyTwentyNineteenLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" abstract="false" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ProceedsFromIssuanceOfSecuredDebtGross" abstract="false" name="ProceedsFromIssuanceOfSecuredDebtGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ContingentValueRightsObligationSalesMilestoneMember" abstract="true" name="ContingentValueRightsObligationSalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidAbstract" abstract="true" name="LeaseLiabilityToBePaidAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" abstract="false" name="RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_DebtInstrumentPrepaymentAndAccruedInterest" abstract="false" name="DebtInstrumentPrepaymentAndAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsSettlements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A200MillionSeptember2023PromissoryNoteMember" abstract="true" name="A200MillionSeptember2023PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" abstract="false" name="FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AnnualPercentageIncreasesToBaseRent" abstract="false" name="AnnualPercentageIncreasesToBaseRent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_LeaseholdInterestGovernmentFundingAvailable" abstract="false" name="LeaseholdInterestGovernmentFundingAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" abstract="false" name="CollaborationAgreementsAnnualMinimumLicensingPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RelatedPartyFixedRateNotesMember" abstract="true" name="RelatedPartyFixedRateNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LicensingAgreementTable" abstract="true" name="LicensingAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ContingentValueRightsObligations" abstract="false" name="ContingentValueRightsObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NationalCancerInstituteMember" abstract="true" name="NationalCancerInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_InitialAndExpansionPremisesMember" abstract="true" name="InitialAndExpansionPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" abstract="true" name="ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_DerivativeLiabilitiesMember" abstract="true" name="DerivativeLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" abstract="false" name="LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_StockRepurchaseProgramPolicyPolicyTextBlock" abstract="false" name="StockRepurchaseProgramPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_FinancialStatementDetailsLineItems" abstract="true" name="FinancialStatementDetailsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_NoncurrentAssetsMember" abstract="true" name="NoncurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AccruedResearchAndDevelopmentCosts" abstract="false" name="AccruedResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl" abstract="false" name="GainOnDebtExtinguishmentEntitiesUnderCommonControl" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A3MIPCAndAAHIAgreementMember" abstract="true" name="A3MIPCAndAAHIAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_FinancialStatementDetailsAbstract" abstract="true" name="FinancialStatementDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_IssuanceOfWarrants" abstract="false" name="IssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A30MillionJune2023PromissoryNoteMember" abstract="true" name="A30MillionJune2023PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_RevenueInterestPurchaseAgreementMember" abstract="true" name="RevenueInterestPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_SupplyAgreementTermOfContract" abstract="false" name="SupplyAgreementTermOfContract" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_LongTermDebtGrossIncludingAccruedInterest" abstract="false" name="LongTermDebtGrossIncludingAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_GlobeImmuneIncMember" abstract="true" name="GlobeImmuneIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_FiveFiveSevenDougStLLCMember" abstract="true" name="FiveFiveSevenDougStLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" abstract="false" name="RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_WarrantLiabilityTextBlock" abstract="false" name="WarrantLiabilityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" abstract="false" name="DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsMilestonePaymentPayableAmount" abstract="false" name="CollaborationAgreementsMilestonePaymentPayableAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SorrentoTherapeuticsIncLitigationMember" abstract="true" name="SorrentoTherapeuticsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_PrepaidServices" abstract="false" name="PrepaidServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_StockIssuedCashlessExerciseOfStockOptions" abstract="false" name="StockIssuedCashlessExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AccountingPoliciesTable" abstract="true" name="AccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_SaleLeasebackTransactionNetProceeds" abstract="false" name="SaleLeasebackTransactionNetProceeds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LitigationTable" abstract="true" name="LitigationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_LesseeOperatingLeasePrepaidExpense" abstract="false" name="LesseeOperatingLeasePrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LitigationLineItems" abstract="true" name="LitigationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_NumberOfLeases" abstract="false" name="NumberOfLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment" abstract="false" name="PurchaseAgreementAdditionalRevenueInterestsSecondPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearTwo" abstract="false" name="LeaseLiabilityToBePaidYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ValuationTechniqueBinomialLatticeModelMember" abstract="true" name="ValuationTechniqueBinomialLatticeModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_SharedServicesAgreementMember" abstract="true" name="SharedServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_February2023ShelfRegistrationStatementMember" abstract="true" name="February2023ShelfRegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_StockIssuedDuringPeriodValueLitigationSettlement" abstract="false" name="StockIssuedDuringPeriodValueLitigationSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsTerminationFee" abstract="false" name="CollaborationAgreementsTerminationFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantBioRevenue" abstract="false" name="NantBioRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SponsoredResearchAgreementMember" abstract="true" name="SponsoredResearchAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_MergerExchangeRatio" abstract="false" name="MergerExchangeRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ibrx_NANTibodyLLCMember" abstract="true" name="NANTibodyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_NantCapitalThreeMember" abstract="true" name="NantCapitalThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_NantWorksLLCMember" abstract="true" name="NantWorksLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_NantCellTwoThousandAndFifteenPlanMember" abstract="true" name="NantCellTwoThousandAndFifteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" abstract="false" name="AmortizationOfDebtDiscountPremiumRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsNumberOfLicenseAgreements" abstract="false" name="CollaborationAgreementsNumberOfLicenseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_InitialPremisesMember" abstract="true" name="InitialPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" abstract="false" name="AvailableForSaleSecuritiesDebtSecuritiesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_StateOfNewYorkMember" abstract="true" name="StateOfNewYorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_ExpansionPremisesMember" abstract="true" name="ExpansionPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_NantCapitalTwoMember" abstract="true" name="NantCapitalTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_DebtInstrumentFaceAmountPerTranche" abstract="false" name="DebtInstrumentFaceAmountPerTranche" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AltorStockholdersMember" abstract="true" name="AltorStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" abstract="false" name="DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearFour" abstract="false" name="LeaseLiabilityToBePaidYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A2014PlanMember" abstract="true" name="A2014PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_CooperativeResearchAndDevelopmentAgreement2015Member" abstract="true" name="CooperativeResearchAndDevelopmentAgreement2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LeaseLiabilityUndiscountedExcessInterest" abstract="false" name="LeaseLiabilityUndiscountedExcessInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_PrepaidExpenseWriteDown" abstract="false" name="PrepaidExpenseWriteDown" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember" abstract="true" name="A505MillionPromissoryNoteDecember2023TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantKwestInc.Member" abstract="true" name="NantKwestInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" abstract="false" name="LeaseLiabilityTenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" abstract="false" name="CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A300MillionDecember2021PromissoryNoteMember" abstract="true" name="A300MillionDecember2021PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_A125MillionAugust2022PromissoryNoteMember" abstract="true" name="A125MillionAugust2022PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" abstract="true" name="ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_NantWorksLLCMemberMember" abstract="true" name="NantWorksLLCMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_OptionsToExtendNumberOfTerms" abstract="false" name="OptionsToExtendNumberOfTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_MonthlyLicenseFee" abstract="false" name="MonthlyLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_DuleyRoadLLCMember" abstract="true" name="DuleyRoadLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_VivaBioCellMember" abstract="true" name="VivaBioCellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AccruedPreclinicalAndClinicalTrialCosts" abstract="false" name="AccruedPreclinicalAndClinicalTrialCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RelatedPartyNotesPrincipalMember" abstract="true" name="RelatedPartyNotesPrincipalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_RelatedPartyWarrantsMember" abstract="true" name="RelatedPartyWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" abstract="true" name="FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_December2022WarrantsMember" abstract="true" name="December2022WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" abstract="false" name="RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_OwnershipPercentageByKeyExecutives" abstract="false" name="OwnershipPercentageByKeyExecutives" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsMilestoneFees" abstract="false" name="CollaborationAgreementsMilestoneFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsAnnualProjectFundingAmount" abstract="false" name="CollaborationAgreementsAnnualProjectFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LitigationSettlementInterestPercent" abstract="false" name="LitigationSettlementInterestPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_InitialPaymentMember" abstract="true" name="InitialPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" abstract="false" name="FiniteLivedIntangibleAssetsAccumulatedImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CommonStockValueAvailableForFutureStockIssuance" abstract="false" name="CommonStockValueAvailableForFutureStockIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock" abstract="false" name="RelatedPartyTransactionsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" abstract="false" name="MinimumNetSalesMilestoneContingentValueRightsObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_PrepaidResearchAndDevelopmentCosts" abstract="false" name="PrepaidResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_A30MillionMarch2023PromissoryNoteMember" abstract="true" name="A30MillionMarch2023PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_FourTwoZeroNashLLCMember" abstract="true" name="FourTwoZeroNashLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_RelatedPartyNotesMember" abstract="true" name="RelatedPartyNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_ViractaMember" abstract="true" name="ViractaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_A23AlaskaLLCMember" abstract="true" name="A23AlaskaLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LeaseRelatedPayables" abstract="false" name="LeaseRelatedPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CommonStockDiscountOnSharesRevenueInterestLiability" abstract="false" name="CommonStockDiscountOnSharesRevenueInterestLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_AmyrisIncMember" abstract="true" name="AmyrisIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_PurchaseAgreementTotalInvestmentAmount" abstract="false" name="PurchaseAgreementTotalInvestmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantMobileMember" abstract="true" name="NantMobileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_IntangibleAssetsAccumulatedImpairment" abstract="false" name="IntangibleAssetsAccumulatedImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ConvertibleNoteReceivableNonCurrent" abstract="false" name="ConvertibleNoteReceivableNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CGMPBatchesMember" abstract="true" name="CGMPBatchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities" abstract="false" name="CollaborationAgreementsPaymentForSupportOfResearchActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NumberOfSquareFeetOfFacilityLeased" abstract="false" name="NumberOfSquareFeetOfFacilityLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" abstract="true" name="NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NumberOfDissentingShares" abstract="false" name="NumberOfDissentingShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ibrx_DeferredTaxAssetsValuationDiscount" abstract="false" name="DeferredTaxAssetsValuationDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" abstract="false" name="SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" abstract="true" name="EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NumberOfSquareFootOfFacilityLeased" abstract="false" name="NumberOfSquareFootOfFacilityLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="ibrx_AtTheMarketOfferingProgramMember" abstract="true" name="AtTheMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" abstract="false" name="LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearOne" abstract="false" name="LeaseLiabilityToBePaidYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" abstract="false" name="CollaborationAgreementsMilestonePaymentAggregateMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantCancerStemCellMember" abstract="true" name="NantCancerStemCellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_SecondPaymentMember" abstract="true" name="SecondPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" abstract="false" name="EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_PeriodFourMember" abstract="true" name="PeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_PeriodThreeMember" abstract="true" name="PeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" abstract="true" name="NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" abstract="false" name="EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_BrinkBiologicsIncMember" abstract="true" name="BrinkBiologicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_NantWorksMember" abstract="true" name="NantWorksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_PercentageOfSalesAgentCommission" abstract="false" name="PercentageOfSalesAgentCommission" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_InvestmentsInJointVentureIncurredButNotYetPaid" abstract="false" name="InvestmentsInJointVentureIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearThree" abstract="false" name="LeaseLiabilityToBePaidYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_TwoThousandFifteenShareRepurchasePlanMember" abstract="true" name="TwoThousandFifteenShareRepurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AmyrisJointVentureMember" abstract="true" name="AmyrisJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_July2023WarrantsMember" abstract="true" name="July2023WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" abstract="true" name="CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_AAHIMember" abstract="true" name="AAHIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" abstract="false" name="RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsPeriodicLicensePayments" abstract="false" name="CollaborationAgreementsPeriodicLicensePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_DeferredIncomeTaxExpenseBenefitNet" abstract="false" name="DeferredIncomeTaxExpenseBenefitNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" abstract="false" name="LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ibrx_MeasurementInputExpectedMarketYieldMember" abstract="true" name="MeasurementInputExpectedMarketYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_StockIssuedDuringPeriodSharesLitigationSettlement" abstract="false" name="StockIssuedDuringPeriodSharesLitigationSettlement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ibrx_PeriodTwoMember" abstract="true" name="PeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_CommonControlTransactionPolicyPolicyTextBlock" abstract="false" name="CommonControlTransactionPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_WarrantsMember" abstract="true" name="WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_IPRDMember" abstract="true" name="IPRDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" abstract="false" name="OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidAfterYearFive" abstract="false" name="LeaseLiabilityToBePaidAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_FinancialStatementDetailsTable" abstract="true" name="FinancialStatementDetailsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_CurrentAssetsMember" abstract="true" name="CurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" abstract="false" name="EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_SaleLeasebackTransactionConsiderationTransferred" abstract="false" name="SaleLeasebackTransactionConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_DuleyRoadMember" abstract="true" name="DuleyRoadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_NoncurrentLiabilitiesMember" abstract="true" name="NoncurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" abstract="true" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" abstract="false" name="EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ibrx_ImmunoOncologyClinicIncMember" abstract="true" name="ImmunoOncologyClinicIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_OptionPeriodDomain" abstract="true" name="OptionPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NantCellInc.Member" abstract="true" name="NantCellInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" abstract="false" name="CollaborationAgreementsNonrefundableUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" abstract="false" name="PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ibrx_LeaseLiabilityToBePaidYearFive" abstract="false" name="LeaseLiabilityToBePaidYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_NantBioInc.Member" abstract="true" name="NantBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable" abstract="false" name="CollaborationAgreementsLicenseMaintenanceFeesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_ReimbursementsMember" abstract="true" name="ReimbursementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_OptionPeriodAxis" abstract="true" name="OptionPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_DueToRelatedPartiesMember" abstract="true" name="DueToRelatedPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_LaboratoryCleanroomServiceCostsMember" abstract="true" name="LaboratoryCleanroomServiceCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" abstract="false" name="NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod" abstract="false" name="DebtInstrumentDebtDiscountRecordedInThePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_LicensingAgreementLineItems" abstract="true" name="LicensingAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ibrx_CollaborationAgreementsMilestonePaymentAmount" abstract="false" name="CollaborationAgreementsMilestonePaymentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment" abstract="false" name="IndefiniteLivedIntangibleAssetsAccumulatedImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ibrx_RelatedPartyConvertibleNotesMember" abstract="true" name="RelatedPartyConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ibrx_DunkirkFacilityMember" abstract="true" name="DunkirkFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_PeriodOfRentFreeLeaseTerm" abstract="false" name="PeriodOfRentFreeLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ibrx_RelatedPartyNotesInterestMember" abstract="true" name="RelatedPartyNotesInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" abstract="false" name="IncreaseToNumberOfSquareFootOfFacilityLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations" abstract="false" name="DeferredTaxAssetNotRecognizedSection382383Limitations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>ibrx-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1fd74a66-0ec9-47b3-a3a2-77069a10a521,g:7ebe44e2-bf98-46f1-8b70-fddc2baf2bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b4c36d3-dc40-4d60-baf5-8a3b99c4f96b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0774dc65-2030-4829-8a94-d41e26493b41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b4c36d3-dc40-4d60-baf5-8a3b99c4f96b" xlink:to="loc_us-gaap_AccountsPayableCurrent_0774dc65-2030-4829-8a94-d41e26493b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a61ab02b-8b9b-4af8-9035-b6ba627dbe30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b4c36d3-dc40-4d60-baf5-8a3b99c4f96b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a61ab02b-8b9b-4af8-9035-b6ba627dbe30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_12ff1c0a-4474-4634-8730-1c5c729cdfad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b4c36d3-dc40-4d60-baf5-8a3b99c4f96b" xlink:to="loc_us-gaap_NotesPayableCurrent_12ff1c0a-4474-4634-8730-1c5c729cdfad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9356770d-9ad3-45d5-8b05-6eefa3593a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b4c36d3-dc40-4d60-baf5-8a3b99c4f96b" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_9356770d-9ad3-45d5-8b05-6eefa3593a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a97c6fb4-ce8e-4239-8e36-f39b422a16cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2effcff1-4b41-4d44-8479-78176fb753fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a97c6fb4-ce8e-4239-8e36-f39b422a16cf" xlink:to="loc_us-gaap_CommonStockValue_2effcff1-4b41-4d44-8479-78176fb753fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ce02cc2e-3b0a-4f9c-bde1-a0a311b2a213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a97c6fb4-ce8e-4239-8e36-f39b422a16cf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ce02cc2e-3b0a-4f9c-bde1-a0a311b2a213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_240341cb-7d05-4276-be46-900716cec2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a97c6fb4-ce8e-4239-8e36-f39b422a16cf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_240341cb-7d05-4276-be46-900716cec2cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ac7cc21-db2d-451c-bced-ccbea60702be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a97c6fb4-ce8e-4239-8e36-f39b422a16cf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ac7cc21-db2d-451c-bced-ccbea60702be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_943675ee-e212-4a7c-a622-e77d61cfd5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1023c5e4-78d3-4ed8-be15-5ba42290dd78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_943675ee-e212-4a7c-a622-e77d61cfd5b9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1023c5e4-78d3-4ed8-be15-5ba42290dd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8b577f7a-4243-4f64-a318-14cff307b909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_943675ee-e212-4a7c-a622-e77d61cfd5b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8b577f7a-4243-4f64-a318-14cff307b909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bb7c1ed7-aff8-4435-ac8a-c48101e89ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_943675ee-e212-4a7c-a622-e77d61cfd5b9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bb7c1ed7-aff8-4435-ac8a-c48101e89ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ea6b7420-9849-46f2-94e7-3ee6a36ed538" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_943675ee-e212-4a7c-a622-e77d61cfd5b9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ea6b7420-9849-46f2-94e7-3ee6a36ed538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e8d465ab-2f95-438b-9187-7663453f14a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:to="loc_us-gaap_AssetsCurrent_e8d465ab-2f95-438b-9187-7663453f14a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_30f76bc4-44b7-41d6-89bf-1a821b8dee98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_30f76bc4-44b7-41d6-89bf-1a821b8dee98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2416df7-453a-44f0-addc-5f15d7da190b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2416df7-453a-44f0-addc-5f15d7da190b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a2ee498-b5e1-489b-8397-40b5ee50a990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a2ee498-b5e1-489b-8397-40b5ee50a990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_3fc363c6-da29-40ef-8623-dffba71f5a06" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_3fc363c6-da29-40ef-8623-dffba71f5a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a5dbaa54-6445-49f4-972a-d9ee66d64b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a5dbaa54-6445-49f4-972a-d9ee66d64b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f44d4b8b-13ee-4768-b993-d6b4c94d8415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56d70a11-a0fa-4751-8bda-8251df5c67f2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f44d4b8b-13ee-4768-b993-d6b4c94d8415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8cc0230-20e9-4072-9308-b7d34f28d86a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2ed6932e-15e0-48c6-b25f-8b3fc34380a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8cc0230-20e9-4072-9308-b7d34f28d86a" xlink:to="loc_us-gaap_StockholdersEquity_2ed6932e-15e0-48c6-b25f-8b3fc34380a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b0b45f6b-7ca2-4ee5-99dd-206c07f372e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8cc0230-20e9-4072-9308-b7d34f28d86a" xlink:to="loc_us-gaap_MinorityInterest_b0b45f6b-7ca2-4ee5-99dd-206c07f372e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9665d02b-8c59-4af6-8d6f-6cf91978ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9665d02b-8c59-4af6-8d6f-6cf91978ee40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b6f07796-cbd2-43a7-b7b4-0fcc7da6436a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b6f07796-cbd2-43a7-b7b4-0fcc7da6436a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_74f6ccd9-727f-4fdd-b28e-9c41f8487c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_74f6ccd9-727f-4fdd-b28e-9c41f8487c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_3df33ef2-d5d1-4e84-bade-5f3246ec1e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_SecuredLongTermDebt_3df33ef2-d5d1-4e84-bade-5f3246ec1e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_0eb8fcb2-23d5-47a1-8d76-4bf64b72068b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_0eb8fcb2-23d5-47a1-8d76-4bf64b72068b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_3c92fd24-cf5c-4fcc-98d9-a71e1fa2064f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_3c92fd24-cf5c-4fcc-98d9-a71e1fa2064f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_6baa67bd-2b6d-44ce-a7fe-bf713d578af0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_6baa67bd-2b6d-44ce-a7fe-bf713d578af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4b266675-9458-48d4-9780-8dda3849b9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8ad119b-121b-4799-87b5-7393e4f8fb07" xlink:to="loc_us-gaap_LiabilitiesCurrent_4b266675-9458-48d4-9780-8dda3849b9ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a980e195-39d2-41f2-b606-43fa4e11f721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_709302b9-cabc-486c-abc5-fdf5e50007e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a980e195-39d2-41f2-b606-43fa4e11f721" xlink:to="loc_us-gaap_Liabilities_709302b9-cabc-486c-abc5-fdf5e50007e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bb8efcd3-54ca-4ebb-a3ae-4bbb044c0940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a980e195-39d2-41f2-b606-43fa4e11f721" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bb8efcd3-54ca-4ebb-a3ae-4bbb044c0940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b36f24ca-dcd2-41c3-9250-cda2ebc2c0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a980e195-39d2-41f2-b606-43fa4e11f721" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b36f24ca-dcd2-41c3-9250-cda2ebc2c0b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3b6894ce-18d9-4a32-b6ce-c117559327cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_64830e7a-f8a3-4b20-9f3b-8cd39756a11d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3b6894ce-18d9-4a32-b6ce-c117559327cc" xlink:to="loc_us-gaap_OperatingIncomeLoss_64830e7a-f8a3-4b20-9f3b-8cd39756a11d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8b993d82-04f5-4596-bb8f-06b3d8c0eb74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3b6894ce-18d9-4a32-b6ce-c117559327cc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8b993d82-04f5-4596-bb8f-06b3d8c0eb74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_141095bf-86d7-47a9-8b8b-5b2db64042ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1e7cea4-7808-423e-8507-f5f56e8e9f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_141095bf-86d7-47a9-8b8b-5b2db64042ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1e7cea4-7808-423e-8507-f5f56e8e9f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a8ecc17a-a49b-4082-bd8c-8a0f21522271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_141095bf-86d7-47a9-8b8b-5b2db64042ab" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a8ecc17a-a49b-4082-bd8c-8a0f21522271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c042a31f-85cc-4715-8532-fae4da1afb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2dd66fc8-5c2f-4372-af0b-5e7f29ed2c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c042a31f-85cc-4715-8532-fae4da1afb2f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2dd66fc8-5c2f-4372-af0b-5e7f29ed2c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d34d6e50-f01a-42cd-afb7-cdadf2e7bc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c042a31f-85cc-4715-8532-fae4da1afb2f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d34d6e50-f01a-42cd-afb7-cdadf2e7bc1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_16fd821f-6159-479f-b7c6-fdad3eb41e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c042a31f-85cc-4715-8532-fae4da1afb2f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_16fd821f-6159-479f-b7c6-fdad3eb41e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_533b7b1c-5440-4845-9ca5-be388b315a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5774099d-2715-4d55-a6bc-e1ab10c7d626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_533b7b1c-5440-4845-9ca5-be388b315a6a" xlink:to="loc_us-gaap_ProfitLoss_5774099d-2715-4d55-a6bc-e1ab10c7d626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8a6a290-bca3-4813-836e-7fd1aa876957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_533b7b1c-5440-4845-9ca5-be388b315a6a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e8a6a290-bca3-4813-836e-7fd1aa876957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c734b151-d496-4612-94ff-9aaa19538f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ac4e6ac5-9648-4cf0-b0f4-270b7143da01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c734b151-d496-4612-94ff-9aaa19538f7b" xlink:to="loc_us-gaap_Revenues_ac4e6ac5-9648-4cf0-b0f4-270b7143da01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f24d174a-853f-4539-a16a-9fa1301d9f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c734b151-d496-4612-94ff-9aaa19538f7b" xlink:to="loc_us-gaap_OperatingExpenses_f24d174a-853f-4539-a16a-9fa1301d9f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cf0ffd72-be24-4f16-976b-4dc1a35c5d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_089c369b-9c3a-4b5e-86f3-a3b71e1663cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cf0ffd72-be24-4f16-976b-4dc1a35c5d2f" xlink:to="loc_us-gaap_InterestExpense_089c369b-9c3a-4b5e-86f3-a3b71e1663cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1743727d-b78f-49b4-b89d-a605eeede270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cf0ffd72-be24-4f16-976b-4dc1a35c5d2f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1743727d-b78f-49b4-b89d-a605eeede270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_dbe12667-11ff-480c-9a54-7cc9e61a32cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cf0ffd72-be24-4f16-976b-4dc1a35c5d2f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_dbe12667-11ff-480c-9a54-7cc9e61a32cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_88dd4f29-4cfd-4a2b-bc7c-05a4ad45e3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cf0ffd72-be24-4f16-976b-4dc1a35c5d2f" xlink:to="loc_us-gaap_GainLossOnInvestments_88dd4f29-4cfd-4a2b-bc7c-05a4ad45e3bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_669fa9ae-6ef6-435b-a5a5-8416d28ce5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cf0ffd72-be24-4f16-976b-4dc1a35c5d2f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_669fa9ae-6ef6-435b-a5a5-8416d28ce5fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_9cd046e4-401d-4ac2-ac02-3454964870ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cf0ffd72-be24-4f16-976b-4dc1a35c5d2f" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_9cd046e4-401d-4ac2-ac02-3454964870ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7312ebe2-1721-4b86-9f0c-6b918c321dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ed1fd6da-4825-42e1-a42d-a5a4aa8a2c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7312ebe2-1721-4b86-9f0c-6b918c321dd2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ed1fd6da-4825-42e1-a42d-a5a4aa8a2c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6203453d-a9e8-4bdc-9b6a-2d37765418b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7312ebe2-1721-4b86-9f0c-6b918c321dd2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6203453d-a9e8-4bdc-9b6a-2d37765418b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc8eb601-4a41-4860-8bad-a24d083472ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_fb042f14-7bae-494f-b49e-c1f42548fd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc8eb601-4a41-4860-8bad-a24d083472ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_fb042f14-7bae-494f-b49e-c1f42548fd9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_774d9fc8-7ce9-4a0a-b1f4-5720ab92124e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc8eb601-4a41-4860-8bad-a24d083472ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_774d9fc8-7ce9-4a0a-b1f4-5720ab92124e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_47ea839f-ac68-4da9-8118-ca2682f59e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc8eb601-4a41-4860-8bad-a24d083472ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_47ea839f-ac68-4da9-8118-ca2682f59e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9dacf5df-c1d7-4365-9eee-092664be1338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d6cc6ff1-7e39-4b94-8bba-df4c79111eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9dacf5df-c1d7-4365-9eee-092664be1338" xlink:to="loc_us-gaap_ProfitLoss_d6cc6ff1-7e39-4b94-8bba-df4c79111eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_50eb5024-c826-417a-a2b6-c80fd78685c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9dacf5df-c1d7-4365-9eee-092664be1338" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_50eb5024-c826-417a-a2b6-c80fd78685c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_923561d2-2c0b-4335-8d48-d8df61dbbad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fdb4fd87-0d86-4e58-ad10-fbbd2bcc67bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_923561d2-2c0b-4335-8d48-d8df61dbbad6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fdb4fd87-0d86-4e58-ad10-fbbd2bcc67bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8036ec3b-5254-4c23-a9d6-6292fa79eeff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_923561d2-2c0b-4335-8d48-d8df61dbbad6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8036ec3b-5254-4c23-a9d6-6292fa79eeff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_cda79c60-ce6c-4b22-9eee-57bc68241895" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_923561d2-2c0b-4335-8d48-d8df61dbbad6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_cda79c60-ce6c-4b22-9eee-57bc68241895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a184311-2930-43f5-b996-681f9ba66ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_923561d2-2c0b-4335-8d48-d8df61dbbad6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a184311-2930-43f5-b996-681f9ba66ec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e3b116d3-282a-4d3b-9a74-3ed3ba4323ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e3b116d3-282a-4d3b-9a74-3ed3ba4323ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_4c7ae66f-0a88-4d9d-99ae-2c5d0aa31708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_4c7ae66f-0a88-4d9d-99ae-2c5d0aa31708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3dfcfcff-a806-4227-bf82-c94fc7dcc0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3dfcfcff-a806-4227-bf82-c94fc7dcc0a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a71cecc2-c144-49aa-b02f-855c18b92409" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a71cecc2-c144-49aa-b02f-855c18b92409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_2f33c374-4907-41b4-91ae-7ba3276834d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_2f33c374-4907-41b4-91ae-7ba3276834d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_d8b4f446-45d3-48df-b86e-363c02c2ead5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_d8b4f446-45d3-48df-b86e-363c02c2ead5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_c30dc849-b3c8-4942-8ba2-5ab7bd31bcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_c30dc849-b3c8-4942-8ba2-5ab7bd31bcf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e68bfefc-cace-47a5-874e-d8d8679e6f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0778170f-4e41-4008-8b21-7be1419980ab" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e68bfefc-cace-47a5-874e-d8d8679e6f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c936a0f8-21ee-457b-af4b-db727482d37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0f510420-3d78-40b4-8a56-dbe4906b3215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c936a0f8-21ee-457b-af4b-db727482d37e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0f510420-3d78-40b4-8a56-dbe4906b3215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e483d3a7-c5d9-44e3-a807-9eed7e6874f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_c936a0f8-21ee-457b-af4b-db727482d37e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e483d3a7-c5d9-44e3-a807-9eed7e6874f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_3fa41435-9f6e-4beb-92be-19194d23e70c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_3fa41435-9f6e-4beb-92be-19194d23e70c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8e4b676a-e417-489f-ac00-e9884c64c770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8e4b676a-e417-489f-ac00-e9884c64c770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_01493c9e-f4e5-4f2c-a4a7-88721ab525a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_01493c9e-f4e5-4f2c-a4a7-88721ab525a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2a9ef8f4-65d8-41b3-8ed9-ea800ec92824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2a9ef8f4-65d8-41b3-8ed9-ea800ec92824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_79705361-d4fa-4ff8-afd7-df53d866adaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_79705361-d4fa-4ff8-afd7-df53d866adaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4cbfe61f-1173-4916-970b-003a067e31b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4cbfe61f-1173-4916-970b-003a067e31b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5df3daa-3f13-44d5-91bd-737849481329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32780ac9-3cef-43e0-a8d0-ba7190c9a5d7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5df3daa-3f13-44d5-91bd-737849481329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a0f4a6a4-0d5b-41f1-9cd3-a94970421388" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a0f4a6a4-0d5b-41f1-9cd3-a94970421388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_caa10c12-a1ba-4c92-a43c-0218c408e1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_PaidInKindInterest_caa10c12-a1ba-4c92-a43c-0218c408e1ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_508985ca-2601-4cf6-85ec-fd5fb52601cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_ProfitLoss_508985ca-2601-4cf6-85ec-fd5fb52601cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9b82e906-732a-4916-83b6-e3f0407555ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_ShareBasedCompensation_9b82e906-732a-4916-83b6-e3f0407555ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_e97ed4e0-1520-4889-8483-fe0f8ede7b7b" xlink:href="ibrx-20231231.xsd#ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_e97ed4e0-1520-4889-8483-fe0f8ede7b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1bdcc4a4-ecce-45c0-9700-7cd20c89e6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1bdcc4a4-ecce-45c0-9700-7cd20c89e6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f0e22c46-e1fd-493a-afd2-72cf1e2e7b50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f0e22c46-e1fd-493a-afd2-72cf1e2e7b50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_98f0002f-0bd0-45eb-85bd-876b51e9f8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_98f0002f-0bd0-45eb-85bd-876b51e9f8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_cf6c1da6-3d8c-4bfc-a193-520080d22c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_cf6c1da6-3d8c-4bfc-a193-520080d22c98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_42978589-0b14-46d8-a99c-ef2b4515f57d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_42978589-0b14-46d8-a99c-ef2b4515f57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_effaa517-55d7-4713-8d20-54952db497e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_effaa517-55d7-4713-8d20-54952db497e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a5292782-55e5-4aca-ad89-96d23fbeba05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a5292782-55e5-4aca-ad89-96d23fbeba05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8dc12a2d-a37b-473e-b8d4-8206217eee10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8dc12a2d-a37b-473e-b8d4-8206217eee10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a92a6cd8-affd-493a-9e86-b05aabe13987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a92a6cd8-affd-493a-9e86-b05aabe13987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6eddba7a-9767-4c76-851a-b8cb21892718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6eddba7a-9767-4c76-851a-b8cb21892718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_c31fb0ae-4d1c-4692-b137-a43e52678c76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_c31fb0ae-4d1c-4692-b137-a43e52678c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_f164ddc7-e48f-4024-b048-c5cb089df504" xlink:href="ibrx-20231231.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_f164ddc7-e48f-4024-b048-c5cb089df504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b1fbf832-e4ed-43b1-ae2a-9f8483df3564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b1fbf832-e4ed-43b1-ae2a-9f8483df3564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_70fb8a9a-7465-427b-8ddd-1ca06e4a049b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_70fb8a9a-7465-427b-8ddd-1ca06e4a049b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_415141a1-2e47-4f31-b5ee-e276f6b05606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6b38b2d-766c-42e3-8d23-9cdfaef314a3" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_415141a1-2e47-4f31-b5ee-e276f6b05606" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39f297c2-3cc1-41bd-9fe5-9ca57056642c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a09c0aa7-7dd4-4b32-b250-11a63ae8d1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_39f297c2-3cc1-41bd-9fe5-9ca57056642c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a09c0aa7-7dd4-4b32-b250-11a63ae8d1d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ed430a69-bf8a-40c5-a521-7a065577c93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_39f297c2-3cc1-41bd-9fe5-9ca57056642c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ed430a69-bf8a-40c5-a521-7a065577c93e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cfa86655-e532-4e56-864d-4845c4af38d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_39f297c2-3cc1-41bd-9fe5-9ca57056642c" xlink:to="loc_us-gaap_Revenues_cfa86655-e532-4e56-864d-4845c4af38d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c15a544a-b0ab-4cf9-992d-c1656f233c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9bfe8272-7f81-41d6-b4af-60dadd78eb12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c15a544a-b0ab-4cf9-992d-c1656f233c82" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9bfe8272-7f81-41d6-b4af-60dadd78eb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7fecceb1-a72e-4547-bd66-d58e40c72720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c15a544a-b0ab-4cf9-992d-c1656f233c82" xlink:to="loc_us-gaap_OperatingIncomeLoss_7fecceb1-a72e-4547-bd66-d58e40c72720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b6a522bb-0633-43f4-97d7-8a49b0287998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c15a544a-b0ab-4cf9-992d-c1656f233c82" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b6a522bb-0633-43f4-97d7-8a49b0287998" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InsurancePremiumFinancingAsset_48510227-73a1-4b65-b098-3c6c382436f0" xlink:href="ibrx-20231231.xsd#ibrx_InsurancePremiumFinancingAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_ibrx_InsurancePremiumFinancingAsset_48510227-73a1-4b65-b098-3c6c382436f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_19f861f5-2da4-4ede-a5c9-a016ca6c1b93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_us-gaap_PrepaidInsurance_19f861f5-2da4-4ede-a5c9-a016ca6c1b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidEquipmentMaintenance_24a83a6e-fe23-43db-93dd-244f78397a8e" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidEquipmentMaintenance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_ibrx_PrepaidEquipmentMaintenance_24a83a6e-fe23-43db-93dd-244f78397a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_8ff9168e-8568-40a6-88b0-47ab808901bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Supplies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_us-gaap_Supplies_8ff9168e-8568-40a6-88b0-47ab808901bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidResearchAndDevelopmentCosts_d2ce72a7-515b-4415-a998-2239fed8e264" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidResearchAndDevelopmentCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_ibrx_PrepaidResearchAndDevelopmentCosts_d2ce72a7-515b-4415-a998-2239fed8e264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_8552ce79-289d-490a-9981-d7933731d54a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_8552ce79-289d-490a-9981-d7933731d54a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_606a9643-fc39-4c2e-8be1-3abaa97e1a83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_us-gaap_OtherAssetsCurrent_606a9643-fc39-4c2e-8be1-3abaa97e1a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidServices_40fe7fc6-1559-4156-89a8-6a6ed02257fc" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidServices"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_ibrx_PrepaidServices_40fe7fc6-1559-4156-89a8-6a6ed02257fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidSoftwareLicenseFees_1a257944-ec89-4693-b816-cf71fd04b277" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidSoftwareLicenseFees"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_ibrx_PrepaidSoftwareLicenseFees_1a257944-ec89-4693-b816-cf71fd04b277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_2a13317d-466a-40ea-a779-4a5ca597584a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f891590-ae07-47a9-83fa-212eb39a74a1" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_2a13317d-466a-40ea-a779-4a5ca597584a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_95596492-ede0-481b-8e9b-86e289db9c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_50b67b1b-9d19-4dc1-a28d-ea095264d165" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_95596492-ede0-481b-8e9b-86e289db9c4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_50b67b1b-9d19-4dc1-a28d-ea095264d165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c90f8ff-2aee-4e6c-8375-39efbb4bd786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_95596492-ede0-481b-8e9b-86e289db9c4a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4c90f8ff-2aee-4e6c-8375-39efbb4bd786" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38efd142-7e24-4727-acd4-09726cbb99ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_275ce8ad-5cd4-4828-9bda-df03e6035f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38efd142-7e24-4727-acd4-09726cbb99ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_275ce8ad-5cd4-4828-9bda-df03e6035f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2d550063-3d53-489d-a1a5-01683507e75d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38efd142-7e24-4727-acd4-09726cbb99ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2d550063-3d53-489d-a1a5-01683507e75d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d2f5b133-36fc-4e95-8ea7-9630b7e43c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38efd142-7e24-4727-acd4-09726cbb99ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d2f5b133-36fc-4e95-8ea7-9630b7e43c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_272da03c-5981-4484-b671-fb8b6769668f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38efd142-7e24-4727-acd4-09726cbb99ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_272da03c-5981-4484-b671-fb8b6769668f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6fd85361-4fb3-401f-9270-b2f6b26fbf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38efd142-7e24-4727-acd4-09726cbb99ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6fd85361-4fb3-401f-9270-b2f6b26fbf5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_318271f6-2ec2-4006-b04c-d5c2bd27283b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_38efd142-7e24-4727-acd4-09726cbb99ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_318271f6-2ec2-4006-b04c-d5c2bd27283b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3d79ff04-35ef-4ed2-a6a2-626149594471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fa714d2f-927d-4ba5-8468-03d0d4c9f08f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3d79ff04-35ef-4ed2-a6a2-626149594471" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fa714d2f-927d-4ba5-8468-03d0d4c9f08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e9fad337-9563-4579-b9d0-75af5fe778b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3d79ff04-35ef-4ed2-a6a2-626149594471" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e9fad337-9563-4579-b9d0-75af5fe778b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b7aebd8b-7b33-404b-a9ef-e0c48892858e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_0afd614b-0846-436e-8914-7fe421eee67f" xlink:href="ibrx-20231231.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b7aebd8b-7b33-404b-a9ef-e0c48892858e" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_0afd614b-0846-436e-8914-7fe421eee67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_00daf376-5ec2-4169-b679-e07e3aa41577" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b7aebd8b-7b33-404b-a9ef-e0c48892858e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_00daf376-5ec2-4169-b679-e07e3aa41577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_af1b87ae-2a22-43c1-b02c-fbc356e2f0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b7aebd8b-7b33-404b-a9ef-e0c48892858e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_af1b87ae-2a22-43c1-b02c-fbc356e2f0d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fc71ba18-b860-4996-92e0-dca22255c935" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_81044c19-8004-463d-88f4-b5ee3b470ed6" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fc71ba18-b860-4996-92e0-dca22255c935" xlink:to="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_81044c19-8004-463d-88f4-b5ee3b470ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_db9d2662-495c-44ba-afcd-4e303bd691c8" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fc71ba18-b860-4996-92e0-dca22255c935" xlink:to="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_db9d2662-495c-44ba-afcd-4e303bd691c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IntangibleAssetsAccumulatedImpairment_36f342a5-4c39-4d39-ae48-28a06e74cc4c" xlink:href="ibrx-20231231.xsd#ibrx_IntangibleAssetsAccumulatedImpairment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_b1318510-6c41-4e05-9442-761fbda328ab" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_IntangibleAssetsAccumulatedImpairment_36f342a5-4c39-4d39-ae48-28a06e74cc4c" xlink:to="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_b1318510-6c41-4e05-9442-761fbda328ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_29271de0-1ffc-4d54-b265-87740b2704a1" xlink:href="ibrx-20231231.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_IntangibleAssetsAccumulatedImpairment_36f342a5-4c39-4d39-ae48-28a06e74cc4c" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_29271de0-1ffc-4d54-b265-87740b2704a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails_1"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f597b5e-6e73-4e34-a5ee-f6197f9e58cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_458eaf23-0995-4da0-a56b-f2e161bcdb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f597b5e-6e73-4e34-a5ee-f6197f9e58cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_458eaf23-0995-4da0-a56b-f2e161bcdb01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7df6aeab-e5c4-481d-98be-faa977605f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f597b5e-6e73-4e34-a5ee-f6197f9e58cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7df6aeab-e5c4-481d-98be-faa977605f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_ba458703-aff4-4583-80b7-0e91ca55fe08" xlink:href="ibrx-20231231.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f597b5e-6e73-4e34-a5ee-f6197f9e58cc" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_ba458703-aff4-4583-80b7-0e91ca55fe08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_32eb87a9-2bb6-4bcd-ac52-3272d97f8c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_795bf716-5a52-4be8-821d-65deceb8bfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_32eb87a9-2bb6-4bcd-ac52-3272d97f8c96" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_795bf716-5a52-4be8-821d-65deceb8bfbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4fbd7ea9-94ca-4459-b0c2-5313d785cb03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_32eb87a9-2bb6-4bcd-ac52-3272d97f8c96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4fbd7ea9-94ca-4459-b0c2-5313d785cb03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_bedddd61-db4d-4f11-b5e6-6536ff89b444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_us-gaap_AccruedBonusesCurrent_bedddd61-db4d-4f11-b5e6-6536ff89b444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_00d99d99-2cb6-4ce6-8290-553a07bba777" xlink:href="ibrx-20231231.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_00d99d99-2cb6-4ce6-8290-553a07bba777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ecf82043-7446-49fd-9f62-c9c8b079fd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ecf82043-7446-49fd-9f62-c9c8b079fd1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_2ec249aa-0ace-427a-9af6-1c0bf10a1904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_us-gaap_ConstructionPayableCurrent_2ec249aa-0ace-427a-9af6-1c0bf10a1904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9495bdb7-430c-4960-b7a3-44d431b81b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9495bdb7-430c-4960-b7a3-44d431b81b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedResearchAndDevelopmentCosts_86db9537-6a0c-4c76-b783-4dd16b52e43d" xlink:href="ibrx-20231231.xsd#ibrx_AccruedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_ibrx_AccruedResearchAndDevelopmentCosts_86db9537-6a0c-4c76-b783-4dd16b52e43d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancingObligationCurrent_2cc596b9-da4d-4dcb-91c2-f08a1db3b445" xlink:href="ibrx-20231231.xsd#ibrx_FinancingObligationCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_ibrx_FinancingObligationCurrent_2cc596b9-da4d-4dcb-91c2-f08a1db3b445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_4a357bc2-6e7d-4ce9-822a-5d20fafeab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e27a027c-c2cc-4706-bd56-5c16c44aa1ab" xlink:to="loc_us-gaap_AccruedSalariesCurrent_4a357bc2-6e7d-4ce9-822a-5d20fafeab2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_efdda8ee-86e3-4635-bb25-d418f541a894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_a2222c31-02ab-4a9b-b20f-e06d22282a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_efdda8ee-86e3-4635-bb25-d418f541a894" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_a2222c31-02ab-4a9b-b20f-e06d22282a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_df6d878a-ae12-4b7c-b6a6-072525686522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_efdda8ee-86e3-4635-bb25-d418f541a894" xlink:to="loc_us-gaap_InterestAndOtherIncome_df6d878a-ae12-4b7c-b6a6-072525686522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_dde132ec-c48b-49b8-91b9-6fbf2e04e360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_efdda8ee-86e3-4635-bb25-d418f541a894" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_dde132ec-c48b-49b8-91b9-6fbf2e04e360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_7cdb3de4-ebb1-4578-aed2-f551989e6d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GainLossOnInvestments_efdda8ee-86e3-4635-bb25-d418f541a894" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_7cdb3de4-ebb1-4578-aed2-f551989e6d43" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2147becd-8ecd-4e47-8162-0ead2778a310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_6daf54ce-6b29-4548-b226-87c596869cf9" xlink:href="ibrx-20231231.xsd#ibrx_AmortizationOfDebtDiscountPremiumRelatedParty"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_2147becd-8ecd-4e47-8162-0ead2778a310" xlink:to="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_6daf54ce-6b29-4548-b226-87c596869cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_26a96ce9-2ae3-4b61-8103-e54d3084ff94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_2147becd-8ecd-4e47-8162-0ead2778a310" xlink:to="loc_us-gaap_InterestExpenseOther_26a96ce9-2ae3-4b61-8103-e54d3084ff94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_840cbdc1-3771-4ff1-b244-158641f9824c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_2147becd-8ecd-4e47-8162-0ead2778a310" xlink:to="loc_us-gaap_InterestExpenseDebt_840cbdc1-3771-4ff1-b244-158641f9824c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28f250bf-d2d2-448f-be74-3a6e5672be1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aba800bc-c0cb-4320-920c-6cd7345081d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28f250bf-d2d2-448f-be74-3a6e5672be1a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_aba800bc-c0cb-4320-920c-6cd7345081d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2a8f72fc-619b-482a-95e2-e13bd429c810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28f250bf-d2d2-448f-be74-3a6e5672be1a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2a8f72fc-619b-482a-95e2-e13bd429c810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_872dd0ff-cbe6-4f93-9c2d-7071b24c5861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_28f250bf-d2d2-448f-be74-3a6e5672be1a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_872dd0ff-cbe6-4f93-9c2d-7071b24c5861" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_060c0eb1-07ca-44af-82ff-bf9fceaadde0" xlink:href="ibrx-20231231.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_ca2a2ccb-94cb-465c-ad0c-3e16249204b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_060c0eb1-07ca-44af-82ff-bf9fceaadde0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_ca2a2ccb-94cb-465c-ad0c-3e16249204b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_b2bc81d5-e573-4c06-9efc-0501c427d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_060c0eb1-07ca-44af-82ff-bf9fceaadde0" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_b2bc81d5-e573-4c06-9efc-0501c427d7e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_800cee9f-c6dc-468c-a954-997c6dc98a93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_060c0eb1-07ca-44af-82ff-bf9fceaadde0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_800cee9f-c6dc-468c-a954-997c6dc98a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_0c9cee83-ea80-4a2f-b491-f6619cfb90ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_060c0eb1-07ca-44af-82ff-bf9fceaadde0" xlink:to="loc_us-gaap_ConstructionInProgressGross_0c9cee83-ea80-4a2f-b491-f6619cfb90ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRightOfUseAsset_36a07f09-3896-4b31-9367-873d201d727f" xlink:href="ibrx-20231231.xsd#ibrx_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1ac53eff-0b29-4c87-8ad1-766d30a09e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseRightOfUseAsset_36a07f09-3896-4b31-9367-873d201d727f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1ac53eff-0b29-4c87-8ad1-766d30a09e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_58f7c357-b841-4dea-ab40-3427c7353bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseRightOfUseAsset_36a07f09-3896-4b31-9367-873d201d727f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_58f7c357-b841-4dea-ab40-3427c7353bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_36c21c8e-2aa0-47f5-9d2a-00d25153181e" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2bd32c8c-5539-43eb-9ab2-d2047f581eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_36c21c8e-2aa0-47f5-9d2a-00d25153181e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2bd32c8c-5539-43eb-9ab2-d2047f581eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ab1a6e90-c281-46a5-ba44-445879ae320d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_36c21c8e-2aa0-47f5-9d2a-00d25153181e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ab1a6e90-c281-46a5-ba44-445879ae320d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e22fe5de-1692-4df7-bde3-f019d8866964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_36c21c8e-2aa0-47f5-9d2a-00d25153181e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e22fe5de-1692-4df7-bde3-f019d8866964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e9c25c3d-f5ba-4b4e-89c9-17fc9b6535c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_36c21c8e-2aa0-47f5-9d2a-00d25153181e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e9c25c3d-f5ba-4b4e-89c9-17fc9b6535c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsComponentsofLeaseExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_418a4dc8-85f0-479f-ac3a-55ab005be5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a6dea832-e135-4cb3-a243-b95eff677525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_418a4dc8-85f0-479f-ac3a-55ab005be5b7" xlink:to="loc_us-gaap_ShortTermLeaseCost_a6dea832-e135-4cb3-a243-b95eff677525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_141465a6-5d35-43b4-bc35-69331daa532d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_418a4dc8-85f0-479f-ac3a-55ab005be5b7" xlink:to="loc_us-gaap_OperatingLeaseCost_141465a6-5d35-43b4-bc35-69331daa532d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ba406020-97e2-456e-8940-dbd39f654d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_418a4dc8-85f0-479f-ac3a-55ab005be5b7" xlink:to="loc_us-gaap_VariableLeaseCost_ba406020-97e2-456e-8940-dbd39f654d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_5de02647-1c40-4bd2-9ca2-31a750f51f30" xlink:href="ibrx-20231231.xsd#ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_418a4dc8-85f0-479f-ac3a-55ab005be5b7" xlink:to="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_5de02647-1c40-4bd2-9ca2-31a750f51f30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fe121a9-e77e-4f2d-aef0-0fa5b9898a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9fd6786c-e654-4db5-8b89-2a28b3a79a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fe121a9-e77e-4f2d-aef0-0fa5b9898a08" xlink:to="loc_us-gaap_OperatingLeaseLiability_9fd6786c-e654-4db5-8b89-2a28b3a79a3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bf4b2281-601c-4979-9608-616066d75363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fe121a9-e77e-4f2d-aef0-0fa5b9898a08" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bf4b2281-601c-4979-9608-616066d75363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_5deb8b6b-4f09-4bbd-a8d5-cd1216b3dac0" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fe121a9-e77e-4f2d-aef0-0fa5b9898a08" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_5deb8b6b-4f09-4bbd-a8d5-cd1216b3dac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c11fc47-1283-4fb9-836b-cb316d2abfae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_74ca9973-06be-424d-b25f-262e4ea12567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c11fc47-1283-4fb9-836b-cb316d2abfae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_74ca9973-06be-424d-b25f-262e4ea12567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b113c2bd-98e3-4929-8258-5370ebe43303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c11fc47-1283-4fb9-836b-cb316d2abfae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_b113c2bd-98e3-4929-8258-5370ebe43303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_24257f69-5a92-4918-9e85-3c9d84c0df98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c11fc47-1283-4fb9-836b-cb316d2abfae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_24257f69-5a92-4918-9e85-3c9d84c0df98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7c1bcf05-414d-4581-8669-da6acf705c93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c11fc47-1283-4fb9-836b-cb316d2abfae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7c1bcf05-414d-4581-8669-da6acf705c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1be08cb4-e0a5-44c0-a851-1f0db91b71d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c11fc47-1283-4fb9-836b-cb316d2abfae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1be08cb4-e0a5-44c0-a851-1f0db91b71d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_51879a8c-5836-4ba7-ba5d-35bea3ebdc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_8c11fc47-1283-4fb9-836b-cb316d2abfae" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_51879a8c-5836-4ba7-ba5d-35bea3ebdc0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_b2b34c44-2ce1-450b-a7c7-cfc129e17f00" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87e3a2d0-b903-4b7d-b933-7fb44f3432c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_b2b34c44-2ce1-450b-a7c7-cfc129e17f00" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87e3a2d0-b903-4b7d-b933-7fb44f3432c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_48f3532b-42ea-49ee-a176-1dc88780c85f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_b2b34c44-2ce1-450b-a7c7-cfc129e17f00" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_48f3532b-42ea-49ee-a176-1dc88780c85f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive_fec3a2c7-a10b-4ffb-ba1b-9c56ea4df2b2" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9e91ddc-a297-41cd-9377-f47655a0b525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive_fec3a2c7-a10b-4ffb-ba1b-9c56ea4df2b2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9e91ddc-a297-41cd-9377-f47655a0b525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3a9a8321-36f1-4c74-be63-b3bc6d9be20c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive_fec3a2c7-a10b-4ffb-ba1b-9c56ea4df2b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3a9a8321-36f1-4c74-be63-b3bc6d9be20c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_977f466a-d026-44a5-911d-46b50570bd68" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_2d6cc224-0c7b-46f0-a8b8-4726f71698bd" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_977f466a-d026-44a5-911d-46b50570bd68" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_2d6cc224-0c7b-46f0-a8b8-4726f71698bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_1dc2db88-336d-465d-9460-acb5b3b6b099" xlink:href="ibrx-20231231.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_977f466a-d026-44a5-911d-46b50570bd68" xlink:to="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_1dc2db88-336d-465d-9460-acb5b3b6b099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_c54ad039-600f-4f41-8940-cb588f133491" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64ce7547-7b12-4993-972d-8cb7b49b60d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_c54ad039-600f-4f41-8940-cb588f133491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64ce7547-7b12-4993-972d-8cb7b49b60d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_449b4706-b984-40f5-90f8-089b77790096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_c54ad039-600f-4f41-8940-cb588f133491" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_449b4706-b984-40f5-90f8-089b77790096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo_76a1bd53-278c-48fb-a4b7-c2e5f68abea3" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_90622ce8-a055-4ecf-97d6-75f9be561552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearTwo_76a1bd53-278c-48fb-a4b7-c2e5f68abea3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_90622ce8-a055-4ecf-97d6-75f9be561552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d7c9b29e-13c6-4063-ac3c-f1c9aa0fcb85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearTwo_76a1bd53-278c-48fb-a4b7-c2e5f68abea3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_d7c9b29e-13c6-4063-ac3c-f1c9aa0fcb85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour_048699b2-205c-4cfb-8ad3-cade6007a64e" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_713f3141-efc3-4c42-9d4a-58d60fa133f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFour_048699b2-205c-4cfb-8ad3-cade6007a64e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_713f3141-efc3-4c42-9d4a-58d60fa133f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9de02bcc-9378-41c9-b591-395b809dc847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFour_048699b2-205c-4cfb-8ad3-cade6007a64e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9de02bcc-9378-41c9-b591-395b809dc847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne_83dc7422-377c-4303-af54-e2592427bd1f" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_931b892e-a75f-47a4-a70b-75f04f11fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearOne_83dc7422-377c-4303-af54-e2592427bd1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_931b892e-a75f-47a4-a70b-75f04f11fa54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dced9025-33c1-4ca1-b43d-c17cde984799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearOne_83dc7422-377c-4303-af54-e2592427bd1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dced9025-33c1-4ca1-b43d-c17cde984799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFive_f8f6be63-d67c-4244-98b7-864441be1358" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFive"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9866ddd0-1ced-4aad-9ef6-ccc60eaaacd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFive_f8f6be63-d67c-4244-98b7-864441be1358" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9866ddd0-1ced-4aad-9ef6-ccc60eaaacd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cc572d73-3c2e-4c96-98a6-7d77e68c8093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFive_f8f6be63-d67c-4244-98b7-864441be1358" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cc572d73-3c2e-4c96-98a6-7d77e68c8093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_d9a01a12-98ac-4e6a-8992-3076fbcaa82d" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5f82f7c8-3cce-4cab-afad-ee5d5afdf65d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_d9a01a12-98ac-4e6a-8992-3076fbcaa82d" xlink:to="loc_us-gaap_OperatingLeaseLiability_5f82f7c8-3cce-4cab-afad-ee5d5afdf65d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f1fd7f90-7ab5-4659-979c-abea77a97cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiability_d9a01a12-98ac-4e6a-8992-3076fbcaa82d" xlink:to="loc_us-gaap_FinanceLeaseLiability_f1fd7f90-7ab5-4659-979c-abea77a97cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree_cea1d14f-3339-445e-b3f4-82ef0431e25b" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ffcf395c-48de-4e3c-a4ad-9b194afc12a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearThree_cea1d14f-3339-445e-b3f4-82ef0431e25b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ffcf395c-48de-4e3c-a4ad-9b194afc12a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bdad1c5c-553f-49ca-be08-d3dcc899d168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearThree_cea1d14f-3339-445e-b3f4-82ef0431e25b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bdad1c5c-553f-49ca-be08-d3dcc899d168" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_85c1fc4e-f1c9-480e-91f8-8e0d64b0316a" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour_295fa923-ab05-409f-80e7-72760a8deaa2" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_85c1fc4e-f1c9-480e-91f8-8e0d64b0316a" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearFour_295fa923-ab05-409f-80e7-72760a8deaa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne_b8f8aaad-f794-4927-8c67-0896c1688c3a" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_85c1fc4e-f1c9-480e-91f8-8e0d64b0316a" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearOne_b8f8aaad-f794-4927-8c67-0896c1688c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive_2e282ce7-e7e4-4ba3-b6a8-76b85e8b62e2" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_85c1fc4e-f1c9-480e-91f8-8e0d64b0316a" xlink:to="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive_2e282ce7-e7e4-4ba3-b6a8-76b85e8b62e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFive_eca04197-6f5a-42ec-a52d-73c2cb066079" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_85c1fc4e-f1c9-480e-91f8-8e0d64b0316a" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearFive_eca04197-6f5a-42ec-a52d-73c2cb066079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo_ba72d5a3-9bb6-4cd8-9dd4-3530a10cf62c" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_85c1fc4e-f1c9-480e-91f8-8e0d64b0316a" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearTwo_ba72d5a3-9bb6-4cd8-9dd4-3530a10cf62c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree_cb8b3cf8-0dc7-4d88-ae25-8b955379a58f" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_85c1fc4e-f1c9-480e-91f8-8e0d64b0316a" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearThree_cb8b3cf8-0dc7-4d88-ae25-8b955379a58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4694a821-432b-4e89-b154-4c255934f61c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_7faa1568-91df-4ccb-8e73-52a8ed527fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4694a821-432b-4e89-b154-4c255934f61c" xlink:to="loc_us-gaap_FinanceLeaseLiability_7faa1568-91df-4ccb-8e73-52a8ed527fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_5aab364f-a759-4d5c-9e1e-c9f4397d481a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4694a821-432b-4e89-b154-4c255934f61c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_5aab364f-a759-4d5c-9e1e-c9f4397d481a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_2db0a2cd-304a-48a7-8433-8e5cad95d5ae" xlink:href="ibrx-20231231.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4694a821-432b-4e89-b154-4c255934f61c" xlink:to="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_2db0a2cd-304a-48a7-8433-8e5cad95d5ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84d976ea-6a78-44d7-9727-b6c11be36271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_898144da-a32c-4d3e-85a3-3793edf2107b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84d976ea-6a78-44d7-9727-b6c11be36271" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_898144da-a32c-4d3e-85a3-3793edf2107b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09c4ed8e-2321-471b-a78c-ec18aaf06f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84d976ea-6a78-44d7-9727-b6c11be36271" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09c4ed8e-2321-471b-a78c-ec18aaf06f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fbb09d08-ae86-45bc-8d9f-d13c460fa154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84d976ea-6a78-44d7-9727-b6c11be36271" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fbb09d08-ae86-45bc-8d9f-d13c460fa154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0e905a67-fab1-43f1-95d9-4c428ed6c043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84d976ea-6a78-44d7-9727-b6c11be36271" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0e905a67-fab1-43f1-95d9-4c428ed6c043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a58cc15b-7e5c-4b92-94f0-a85d9748799f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84d976ea-6a78-44d7-9727-b6c11be36271" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a58cc15b-7e5c-4b92-94f0-a85d9748799f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4578594e-b2b6-4672-80a8-54724d5b21d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84d976ea-6a78-44d7-9727-b6c11be36271" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4578594e-b2b6-4672-80a8-54724d5b21d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_842b7d18-621f-4c95-9347-90b4350dfe28" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_1531f975-f2b5-4cd3-b18e-22991bce44dd" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_842b7d18-621f-4c95-9347-90b4350dfe28" xlink:to="loc_ibrx_LeaseLiability_1531f975-f2b5-4cd3-b18e-22991bce44dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_9b0e677d-592d-4cf9-a377-ca3ece897f43" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_842b7d18-621f-4c95-9347-90b4350dfe28" xlink:to="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_9b0e677d-592d-4cf9-a377-ca3ece897f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_f4d5308c-dfe4-4b9b-acae-750bcb7e42aa" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_LeaseLiabilityToBePaid_842b7d18-621f-4c95-9347-90b4350dfe28" xlink:to="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_f4d5308c-dfe4-4b9b-acae-750bcb7e42aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_14863559-c125-439c-b894-dc1ae08355b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_b0101a6d-cf50-480a-be6e-9e7be040ab28" xlink:href="ibrx-20231231.xsd#ibrx_ProceedsFromIssuanceOfSecuredDebtGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_14863559-c125-439c-b894-dc1ae08355b7" xlink:to="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_b0101a6d-cf50-480a-be6e-9e7be040ab28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ee4c108d-41a4-428e-896d-03d9ca837517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_14863559-c125-439c-b894-dc1ae08355b7" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ee4c108d-41a4-428e-896d-03d9ca837517" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_991e8edd-4835-46a1-897f-a0ebc1f246ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_63da78a6-d61a-43b3-8232-36d16c3b8014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_991e8edd-4835-46a1-897f-a0ebc1f246ab" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_63da78a6-d61a-43b3-8232-36d16c3b8014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_2469c403-3767-46ba-8bad-b9f4e80d6f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_991e8edd-4835-46a1-897f-a0ebc1f246ab" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_2469c403-3767-46ba-8bad-b9f4e80d6f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7c56b5bf-939f-4c81-b303-56286cf1885e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_991e8edd-4835-46a1-897f-a0ebc1f246ab" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7c56b5bf-939f-4c81-b303-56286cf1885e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e0b76eec-7f45-4e6f-b0c9-26a24236e4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c0e3b8fa-7e3e-4ce9-9ea0-17c8c9dfdda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e0b76eec-7f45-4e6f-b0c9-26a24236e4f4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c0e3b8fa-7e3e-4ce9-9ea0-17c8c9dfdda5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cda68823-d91d-4025-83df-ce23ce93a7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e0b76eec-7f45-4e6f-b0c9-26a24236e4f4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cda68823-d91d-4025-83df-ce23ce93a7ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ce9703eb-dd1c-412d-b66a-9f69ae1018e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e0b76eec-7f45-4e6f-b0c9-26a24236e4f4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ce9703eb-dd1c-412d-b66a-9f69ae1018e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesLossBeforeTaxesDomesticandForeignDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_821f2570-d53c-466a-9329-2cb6b27277d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_39e8fd78-26ae-4cfc-be33-c3cef0ea985c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_821f2570-d53c-466a-9329-2cb6b27277d7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_39e8fd78-26ae-4cfc-be33-c3cef0ea985c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c776d349-8584-4c15-96cd-6cb60cb22778" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_821f2570-d53c-466a-9329-2cb6b27277d7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c776d349-8584-4c15-96cd-6cb60cb22778" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_158ce1d4-352c-4de1-800f-5c7bcb26df12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0828f880-ea8b-4e18-8755-db63182df009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_158ce1d4-352c-4de1-800f-5c7bcb26df12" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0828f880-ea8b-4e18-8755-db63182df009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_652a7b15-21f1-4896-9829-4b64a5732052" xlink:href="ibrx-20231231.xsd#ibrx_DeferredIncomeTaxExpenseBenefitNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_158ce1d4-352c-4de1-800f-5c7bcb26df12" xlink:to="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_652a7b15-21f1-4896-9829-4b64a5732052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_197e5ac6-4e0f-4231-9bc0-ee6703db2013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_795df9fd-d024-4e5f-bcd6-bdb712ab6253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_197e5ac6-4e0f-4231-9bc0-ee6703db2013" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_795df9fd-d024-4e5f-bcd6-bdb712ab6253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_95867f1b-e26d-4db0-b5d0-812d072d304d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_197e5ac6-4e0f-4231-9bc0-ee6703db2013" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_95867f1b-e26d-4db0-b5d0-812d072d304d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_95c4fe85-0621-4060-b33b-e2c74751a772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_197e5ac6-4e0f-4231-9bc0-ee6703db2013" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_95c4fe85-0621-4060-b33b-e2c74751a772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_2eb8e74b-1e48-4103-95f3-74682178b47d" xlink:href="ibrx-20231231.xsd#ibrx_DeferredIncomeTaxExpenseBenefitNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_029796ee-6674-4244-b3b6-ae2a6209a6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_2eb8e74b-1e48-4103-95f3-74682178b47d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_029796ee-6674-4244-b3b6-ae2a6209a6ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_edfc4acc-bd9b-405f-a6f1-ee3ae9873f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_2eb8e74b-1e48-4103-95f3-74682178b47d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_edfc4acc-bd9b-405f-a6f1-ee3ae9873f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1f34a43d-0c31-4f53-97a6-5c5fee8255c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_2eb8e74b-1e48-4103-95f3-74682178b47d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1f34a43d-0c31-4f53-97a6-5c5fee8255c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d5661361-4b3d-4de4-8a23-06b2a1477cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_eda6bf4b-a849-4278-9bca-35eef43b689a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d5661361-4b3d-4de4-8a23-06b2a1477cba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_eda6bf4b-a849-4278-9bca-35eef43b689a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_17dc95c1-b9b8-4612-8e14-8849b46d1414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d5661361-4b3d-4de4-8a23-06b2a1477cba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_17dc95c1-b9b8-4612-8e14-8849b46d1414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f069ca0b-328b-4dae-b2bf-999ad7188bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d5661361-4b3d-4de4-8a23-06b2a1477cba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f069ca0b-328b-4dae-b2bf-999ad7188bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_f2a65eb8-b8bc-44ee-a8f3-b61dd401932b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_d5661361-4b3d-4de4-8a23-06b2a1477cba" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_f2a65eb8-b8bc-44ee-a8f3-b61dd401932b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_525d0604-dfcd-449a-9a74-6ed5b771db06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d92486cf-f206-4d59-88cc-ddba7dbf8d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_525d0604-dfcd-449a-9a74-6ed5b771db06" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d92486cf-f206-4d59-88cc-ddba7dbf8d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a5453f99-5901-4140-b414-2271a47333f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_525d0604-dfcd-449a-9a74-6ed5b771db06" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a5453f99-5901-4140-b414-2271a47333f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_68314804-3ac0-43e8-83eb-ad0cb7b6457a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_656dc67f-5b55-446d-a0f4-ca20193fd3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_68314804-3ac0-43e8-83eb-ad0cb7b6457a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_656dc67f-5b55-446d-a0f4-ca20193fd3d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_51e4ba9f-a924-42ca-a7c6-8e4b863b6593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_68314804-3ac0-43e8-83eb-ad0cb7b6457a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_51e4ba9f-a924-42ca-a7c6-8e4b863b6593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9cda6343-6b0f-40b3-9883-d5df3007feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9cda6343-6b0f-40b3-9883-d5df3007feb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_3e734759-2e3b-4bb1-af2c-9ba5f12bc7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_3e734759-2e3b-4bb1-af2c-9ba5f12bc7fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d6bea898-efc6-4892-8874-fb60b8991da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d6bea898-efc6-4892-8874-fb60b8991da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d252c12c-c175-487f-88dc-19f8d028d426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d252c12c-c175-487f-88dc-19f8d028d426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_0359760f-39f0-458f-9a1a-30b6cddccf82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_0359760f-39f0-458f-9a1a-30b6cddccf82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b8e65d15-4d6f-4f6e-a211-a1b8af1466c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b8e65d15-4d6f-4f6e-a211-a1b8af1466c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_df6e9df2-9d02-4873-8b4c-072c11c24127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_df6e9df2-9d02-4873-8b4c-072c11c24127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_f6225a5d-b36f-4a65-85fb-4dcd7562c760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_f6225a5d-b36f-4a65-85fb-4dcd7562c760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6571eb2f-df05-481f-b3db-3374d0819825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6571eb2f-df05-481f-b3db-3374d0819825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_617758f4-51c4-4c97-9971-602b375dfa47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_617758f4-51c4-4c97-9971-602b375dfa47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_165798ef-88ac-40a9-b12f-ca4fa363e88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_165798ef-88ac-40a9-b12f-ca4fa363e88b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_3f828adf-53e9-495b-881d-80a54b120be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_3f828adf-53e9-495b-881d-80a54b120be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetsValuationDiscount_f1f86930-7660-46f0-a8d2-23f94544f588" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetsValuationDiscount"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03c94e78-2dc6-4348-86e1-1c896d7bd954" xlink:to="loc_ibrx_DeferredTaxAssetsValuationDiscount_f1f86930-7660-46f0-a8d2-23f94544f588" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2e667604-9414-4ef1-88fe-085c7e3b441a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2e667604-9414-4ef1-88fe-085c7e3b441a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent_f2759097-b45e-4bb8-a6ad-3a71c5233b05" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent_f2759097-b45e-4bb8-a6ad-3a71c5233b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f2b43cfa-9ffe-47e9-ae9a-d1922220a066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f2b43cfa-9ffe-47e9-ae9a-d1922220a066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue_736fb307-f101-4963-8749-fa261b113029" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue_736fb307-f101-4963-8749-fa261b113029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_04f44cdb-385c-47f0-bd47-23a2f056d4de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_04f44cdb-385c-47f0-bd47-23a2f056d4de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8073a0bd-61a9-4a06-ac3c-c6889cd886cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8073a0bd-61a9-4a06-ac3c-c6889cd886cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue_628b63b1-9168-4c39-9bc6-819e75cfd924" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue_628b63b1-9168-4c39-9bc6-819e75cfd924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_e29bd85c-57f5-41b8-af43-4e97c9b9b705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_e29bd85c-57f5-41b8-af43-4e97c9b9b705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_54648902-00d8-4920-a87e-5bc90d1efe66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_54648902-00d8-4920-a87e-5bc90d1efe66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss_ebd8071f-33e1-4f2e-8dfd-14735ad82e4d" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss_ebd8071f-33e1-4f2e-8dfd-14735ad82e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f3b49c92-fb8a-4d57-8f2e-b4f9d4c312d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f3b49c92-fb8a-4d57-8f2e-b4f9d4c312d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e354f75-4944-49e6-83f2-ebc56a29788e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_07694c2d-cfaf-4e47-aec5-28618d39f625" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e354f75-4944-49e6-83f2-ebc56a29788e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>ibrx-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1fd74a66-0ec9-47b3-a3a2-77069a10a521,g:7ebe44e2-bf98-46f1-8b70-fddc2baf2bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9771a41d-9391-47a8-bd8c-631582c17caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:to="loc_us-gaap_StatementTable_9771a41d-9391-47a8-bd8c-631582c17caf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d499a27e-2a27-4f9e-b1f0-b35970849c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9771a41d-9391-47a8-bd8c-631582c17caf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d499a27e-2a27-4f9e-b1f0-b35970849c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d499a27e-2a27-4f9e-b1f0-b35970849c9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d499a27e-2a27-4f9e-b1f0-b35970849c9a" xlink:to="loc_us-gaap_RelatedPartyDomain_d499a27e-2a27-4f9e-b1f0-b35970849c9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d499a27e-2a27-4f9e-b1f0-b35970849c9a" xlink:to="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_c372f993-bb4a-44d3-abe8-79d904686fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:to="loc_us-gaap_NonrelatedPartyMember_c372f993-bb4a-44d3-abe8-79d904686fd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5e93416d-1715-49ee-9f49-330e4ecd6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:to="loc_us-gaap_RelatedPartyMember_5e93416d-1715-49ee-9f49-330e4ecd6fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:to="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e2e88ab-e565-4838-ba87-601edb0d90a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e2e88ab-e565-4838-ba87-601edb0d90a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c62e1694-dc8b-4852-a598-95d9e5d08414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c62e1694-dc8b-4852-a598-95d9e5d08414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1341f19d-9c7d-4c79-9201-50d511e4ae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1341f19d-9c7d-4c79-9201-50d511e4ae4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_71b50090-18cb-42b0-a8dd-ede4078b3fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_71b50090-18cb-42b0-a8dd-ede4078b3fcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e62f4d69-4f96-4fcb-b6e3-84440c65115a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_AssetsCurrent_e62f4d69-4f96-4fcb-b6e3-84440c65115a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f39c4fcd-a924-4f44-abd7-9fb204640eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f39c4fcd-a924-4f44-abd7-9fb204640eab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2c8fcb8a-4ed7-4864-9789-05c61ca27f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2c8fcb8a-4ed7-4864-9789-05c61ca27f7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52f2ef1e-f322-41de-817c-1de876020f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52f2ef1e-f322-41de-817c-1de876020f21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_3eff4f33-12e5-4f4c-8043-d1a48454b582" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_3eff4f33-12e5-4f4c-8043-d1a48454b582" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5fbbe7e-a8d5-4de7-abb8-4763f1b40e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5fbbe7e-a8d5-4de7-abb8-4763f1b40e8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_efece56f-6001-496e-bd7b-064607056644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_efece56f-6001-496e-bd7b-064607056644" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_273ddc04-3433-4f87-96b9-b387aeb997e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_Assets_273ddc04-3433-4f87-96b9-b387aeb997e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2ca9eebe-ca74-4e6b-8d5c-299731e00ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_AccountsPayableCurrent_2ca9eebe-ca74-4e6b-8d5c-299731e00ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3e06d228-541a-4803-a07f-12dd2ae6a062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3e06d228-541a-4803-a07f-12dd2ae6a062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f7ae9949-a8b7-47b5-b35c-9ed93ca98fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_NotesPayableCurrent_f7ae9949-a8b7-47b5-b35c-9ed93ca98fb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4b67ec5-831d-4593-ba42-a0f1e5ad6a75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4b67ec5-831d-4593-ba42-a0f1e5ad6a75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fbc8fd95-f67a-4dc7-84c4-07e162b00f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_LiabilitiesCurrent_fbc8fd95-f67a-4dc7-84c4-07e162b00f42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_89101227-b310-474b-956e-45e761498942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_89101227-b310-474b-956e-45e761498942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_19b091c9-7a36-4910-8cae-0a931974baf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_19b091c9-7a36-4910-8cae-0a931974baf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_da305422-8b9a-4a6c-9744-d9d531456aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_SecuredLongTermDebt_da305422-8b9a-4a6c-9744-d9d531456aa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_7a835401-73ca-4e77-b490-8f45e88aaeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_7a835401-73ca-4e77-b490-8f45e88aaeb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2d435ef6-5ff5-4dfa-a036-7511e1da0240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2d435ef6-5ff5-4dfa-a036-7511e1da0240" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_56cb08e3-e549-4b13-b2e9-ac9617aaf23c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_56cb08e3-e549-4b13-b2e9-ac9617aaf23c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3d36d943-19c2-4250-95f1-6365396a8c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3d36d943-19c2-4250-95f1-6365396a8c0d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d8c7a5f9-9e09-434d-862b-d945e3a22a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_Liabilities_d8c7a5f9-9e09-434d-862b-d945e3a22a5b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_66493037-ebb3-441e-a0da-cbf9ca1532ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_66493037-ebb3-441e-a0da-cbf9ca1532ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dfda0393-eefd-4442-845c-95adad771fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_CommonStockValue_dfda0393-eefd-4442-845c-95adad771fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b89c8dd5-a9b9-4210-bf8c-dc76cccf05db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b89c8dd5-a9b9-4210-bf8c-dc76cccf05db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31025eeb-41b8-4b2a-9ae3-f425e7f62bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31025eeb-41b8-4b2a-9ae3-f425e7f62bbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5cc11a8-966b-45d0-972b-de4eeb170a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5cc11a8-966b-45d0-972b-de4eeb170a2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c0298c8-f12f-46e0-9b6d-b39d66a7997b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_StockholdersEquity_4c0298c8-f12f-46e0-9b6d-b39d66a7997b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1b03c4de-1735-4547-aa13-c77e46870695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_MinorityInterest_1b03c4de-1735-4547-aa13-c77e46870695" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_433b4898-f8c1-41c5-82fa-7034b3a27e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_433b4898-f8c1-41c5-82fa-7034b3a27e61" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_618b4b0c-8967-40ba-857b-37d8deb0010b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_618b4b0c-8967-40ba-857b-37d8deb0010b" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofStockholdersDeficit"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f9b0bc7-2d96-4add-9d8c-4ce33016866b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5f9b0bc7-2d96-4add-9d8c-4ce33016866b" xlink:to="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5b351892-28b8-4a5b-9f3d-aec2fd7df866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5b351892-28b8-4a5b-9f3d-aec2fd7df866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5b351892-28b8-4a5b-9f3d-aec2fd7df866_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5b351892-28b8-4a5b-9f3d-aec2fd7df866" xlink:to="loc_us-gaap_EquityComponentDomain_5b351892-28b8-4a5b-9f3d-aec2fd7df866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5b351892-28b8-4a5b-9f3d-aec2fd7df866" xlink:to="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:to="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e51c64ba-d621-443e-9d91-9479011317ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_CommonStockMember_e51c64ba-d621-443e-9d91-9479011317ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41d4e1f1-15f8-40f3-93d5-d00e7e8ab8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41d4e1f1-15f8-40f3-93d5-d00e7e8ab8a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_30f8eb66-05e6-4d8b-8c8c-7ad4daf26931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_RetainedEarningsMember_30f8eb66-05e6-4d8b-8c8c-7ad4daf26931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3a4b218-11bc-464f-83e1-1a68676d5ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3a4b218-11bc-464f-83e1-1a68676d5ff5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_03fcf0e1-cee8-4fb6-921f-d9e416e1caeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:to="loc_us-gaap_NoncontrollingInterestMember_03fcf0e1-cee8-4fb6-921f-d9e416e1caeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b1e3f309-3efc-4040-b3e9-b3da6bec6096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b1e3f309-3efc-4040-b3e9-b3da6bec6096" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1e3f309-3efc-4040-b3e9-b3da6bec6096_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b1e3f309-3efc-4040-b3e9-b3da6bec6096" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1e3f309-3efc-4040-b3e9-b3da6bec6096_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b1e3f309-3efc-4040-b3e9-b3da6bec6096" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_d7853fee-b979-45dc-889f-218bffea61f8" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_d7853fee-b979-45dc-889f-218bffea61f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_7e532aed-4443-4ada-b8c6-c5b586792dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:to="loc_us-gaap_PrivatePlacementMember_7e532aed-4443-4ada-b8c6-c5b586792dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_f6b7d934-c790-45d9-9d04-38c2bff92bf6" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_f6b7d934-c790-45d9-9d04-38c2bff92bf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5f9b0bc7-2d96-4add-9d8c-4ce33016866b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ae21512f-9ec9-4072-836d-3dc6f6b5f47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ae21512f-9ec9-4072-836d-3dc6f6b5f47f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3823b8c-5102-4f1e-826c-68121839f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3823b8c-5102-4f1e-826c-68121839f28f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0449abed-6e09-42ce-be80-219d969f91c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0449abed-6e09-42ce-be80-219d969f91c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31101b1b-bd43-40a7-bc2b-7478565e31d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31101b1b-bd43-40a7-bc2b-7478565e31d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_becbd23d-cc1c-4bcd-b2ad-1907979a5776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_becbd23d-cc1c-4bcd-b2ad-1907979a5776" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69576d17-849a-48b2-9e5a-11775ff7cd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69576d17-849a-48b2-9e5a-11775ff7cd22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_9f14f063-b5a9-4b7f-b8cb-1fc8cec95037" xlink:href="ibrx-20231231.xsd#ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_9f14f063-b5a9-4b7f-b8cb-1fc8cec95037" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_149416a8-ffa5-4f7f-b0f0-012fc55b7507" xlink:href="ibrx-20231231.xsd#ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_149416a8-ffa5-4f7f-b0f0-012fc55b7507" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dd250c4-301a-4658-bc66-9f12abf24d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dd250c4-301a-4658-bc66-9f12abf24d82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c12d4db2-9210-464f-b4ff-59e284675973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c12d4db2-9210-464f-b4ff-59e284675973" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_715934e9-5e9e-412e-89b9-0841a404a708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_715934e9-5e9e-412e-89b9-0841a404a708" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4c73016b-ecc1-43f0-8661-0eb0cab3c1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4c73016b-ecc1-43f0-8661-0eb0cab3c1e6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_1697b940-da46-46a6-b0d4-3b4f35f19526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_1697b940-da46-46a6-b0d4-3b4f35f19526" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_24330844-b8cf-45bb-8173-fba0f11af063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_24330844-b8cf-45bb-8173-fba0f11af063" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement_5a8b0d36-5e55-48fe-99a8-cfbc849206ec" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement_5a8b0d36-5e55-48fe-99a8-cfbc849206ec" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedDuringPeriodValueLitigationSettlement_cd13c58c-d1fe-48fc-af20-0c3a644ad7f5" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedDuringPeriodValueLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_StockIssuedDuringPeriodValueLitigationSettlement_cd13c58c-d1fe-48fc-af20-0c3a644ad7f5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8c190507-34db-4db1-9b03-a656d5a978a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8c190507-34db-4db1-9b03-a656d5a978a4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_35f3efee-b190-4758-bbb5-dfbdbb40a61f" xlink:href="ibrx-20231231.xsd#ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_35f3efee-b190-4758-bbb5-dfbdbb40a61f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement_6eb84b07-3676-4a37-8d91-fe53f5f75887" xlink:href="ibrx-20231231.xsd#ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement_6eb84b07-3676-4a37-8d91-fe53f5f75887" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f3a54d8-119e-46e7-ad86-9ef325613b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f3a54d8-119e-46e7-ad86-9ef325613b1c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8b2b20d2-7407-4fb2-8619-14266cbbabeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_ProfitLoss_8b2b20d2-7407-4fb2-8619-14266cbbabeb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ba6b8493-c17b-413d-8b81-92da779a4589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_697fb2e6-8317-4222-baeb-e64f763d2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofStockholdersDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f729d0d4-d663-4d26-9aff-407ea3264563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ea9c5c0a-3991-45c5-8821-0b083e64afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f729d0d4-d663-4d26-9aff-407ea3264563" xlink:to="loc_us-gaap_StatementTable_ea9c5c0a-3991-45c5-8821-0b083e64afa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6320a420-a31c-4902-9620-d6486d63bb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ea9c5c0a-3991-45c5-8821-0b083e64afa6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6320a420-a31c-4902-9620-d6486d63bb62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6320a420-a31c-4902-9620-d6486d63bb62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6320a420-a31c-4902-9620-d6486d63bb62" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6320a420-a31c-4902-9620-d6486d63bb62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6320a420-a31c-4902-9620-d6486d63bb62" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_65f66172-1e98-4f8b-95b6-4069250d5898" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_65f66172-1e98-4f8b-95b6-4069250d5898" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_1dc8e0f7-0472-4037-832a-1711822313c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:to="loc_us-gaap_PrivatePlacementMember_1dc8e0f7-0472-4037-832a-1711822313c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_00645b09-e222-46a1-bd9b-3195010b8be2" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_00645b09-e222-46a1-bd9b-3195010b8be2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_13450f55-a5c5-49d0-8d7c-e95a7627a8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f729d0d4-d663-4d26-9aff-407ea3264563" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_13450f55-a5c5-49d0-8d7c-e95a7627a8e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_09c05d5c-8fd6-4710-bed0-f59ffafa0185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_StatementTable_09c05d5c-8fd6-4710-bed0-f59ffafa0185" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09c05d5c-8fd6-4710-bed0-f59ffafa0185" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_18f8d4d5-6cba-47c8-b2fd-99583e6d3d81" xlink:href="ibrx-20231231.xsd#ibrx_PrivatePlacementAndAtTheMarketOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:to="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_18f8d4d5-6cba-47c8-b2fd-99583e6d3d81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_73dd7ca8-ccae-4a27-9425-c5de623ce8b9" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_73dd7ca8-ccae-4a27-9425-c5de623ce8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a2e71d4-9c56-4b50-9e36-958e07434af6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:to="loc_us-gaap_ProfitLoss_6a2e71d4-9c56-4b50-9e36-958e07434af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0d35eb16-47ea-4471-9ba5-f51198c570aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_ShareBasedCompensation_0d35eb16-47ea-4471-9ba5-f51198c570aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_49527f10-47bd-4f1a-b489-80af06c83ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_49527f10-47bd-4f1a-b489-80af06c83ba4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_86f74ffc-3afe-4737-bdb8-68fc8fc6bac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_86f74ffc-3afe-4737-bdb8-68fc8fc6bac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_f4951522-0055-4a1a-86d9-e6f1e90ac65d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_f4951522-0055-4a1a-86d9-e6f1e90ac65d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_59270a79-022b-4876-a3d3-5090f545be88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_59270a79-022b-4876-a3d3-5090f545be88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_3f2a326f-f7f8-4628-860d-a46e2f82f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_PaidInKindInterest_3f2a326f-f7f8-4628-860d-a46e2f82f55c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_8e12b585-2a4a-4dd0-ac0e-39f565b6d2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_8e12b585-2a4a-4dd0-ac0e-39f565b6d2d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_fac553be-3a70-4ec6-99db-976ebdc9ca65" xlink:href="ibrx-20231231.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_fac553be-3a70-4ec6-99db-976ebdc9ca65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2d2427a9-d744-44a1-91d2-252a128e24d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2d2427a9-d744-44a1-91d2-252a128e24d2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6ae75c7f-01fc-4373-bfb9-9c92a2132680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6ae75c7f-01fc-4373-bfb9-9c92a2132680" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a8861b7c-555b-4ede-85cf-1230783ba0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a8861b7c-555b-4ede-85cf-1230783ba0bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_8d44f579-eaa6-4f2c-a2aa-a485fd954bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_8d44f579-eaa6-4f2c-a2aa-a485fd954bc4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0015439e-e28b-4e54-9d84-5f50f87f1581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0015439e-e28b-4e54-9d84-5f50f87f1581" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85ed492e-d743-479a-b556-67ef1c976d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85ed492e-d743-479a-b556-67ef1c976d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2eff93fb-87f8-49c4-8af3-21fc78cd4a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2eff93fb-87f8-49c4-8af3-21fc78cd4a03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_31eed9e0-1da2-4ded-8ddd-4b2c27c4358f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_31eed9e0-1da2-4ded-8ddd-4b2c27c4358f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fd542e35-41d0-4e33-a3f9-6b4cd4bb6a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fd542e35-41d0-4e33-a3f9-6b4cd4bb6a56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_be4c8dcd-ce8b-4b9a-8373-f8e6343ccd06" xlink:href="ibrx-20231231.xsd#ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_be4c8dcd-ce8b-4b9a-8373-f8e6343ccd06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_eaf2feed-2d58-4583-958b-37acec5608f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_eaf2feed-2d58-4583-958b-37acec5608f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1180724-0341-45e0-923f-611ab2a47617" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1180724-0341-45e0-923f-611ab2a47617" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e62819f5-f0d9-43c3-a518-365916983c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e62819f5-f0d9-43c3-a518-365916983c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9e96a303-d5bf-4011-a1d4-d561901438cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9e96a303-d5bf-4011-a1d4-d561901438cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3280b147-3864-48c5-a24a-ab9676662469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3280b147-3864-48c5-a24a-ab9676662469" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_aeb122e7-bfa7-4028-94cb-ad787aac81d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_aeb122e7-bfa7-4028-94cb-ad787aac81d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5379a036-fd77-4bdc-98ca-a88a04d7e524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5379a036-fd77-4bdc-98ca-a88a04d7e524" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_52c7f349-8947-40d2-bffc-aac3bc65eacd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_52c7f349-8947-40d2-bffc-aac3bc65eacd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_b62a8d65-2d0d-4df8-8c8e-cf3874dd53e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_b62a8d65-2d0d-4df8-8c8e-cf3874dd53e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f55bed91-d186-4673-a0fd-9ebc6eea3cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f55bed91-d186-4673-a0fd-9ebc6eea3cf2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_03aef210-d92d-45f1-86e7-2d99431940e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_03aef210-d92d-45f1-86e7-2d99431940e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_075cda15-aa73-4c02-8465-0ee449829987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_075cda15-aa73-4c02-8465-0ee449829987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dfe87def-7cf8-47ea-951d-ff5a406328fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dfe87def-7cf8-47ea-951d-ff5a406328fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e6c83284-8003-4f52-a77d-0664fadf5bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e6c83284-8003-4f52-a77d-0664fadf5bd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dbe8897c-1e1c-4f5f-a0ab-fc7ea126cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dbe8897c-1e1c-4f5f-a0ab-fc7ea126cf50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_24f8f8ae-3c78-401e-93d2-14dcdd461b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_24f8f8ae-3c78-401e-93d2-14dcdd461b8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_e58cc3eb-a825-48c8-b660-43a2015bc59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_e58cc3eb-a825-48c8-b660-43a2015bc59e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3b122ae0-4b11-48c2-a1ac-fe165b500bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3b122ae0-4b11-48c2-a1ac-fe165b500bdd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8db42ee-5e8b-4641-91e3-a8a02f5be2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8db42ee-5e8b-4641-91e3-a8a02f5be2f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0be156bd-d849-46ca-adcb-1d42c50a143f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0be156bd-d849-46ca-adcb-1d42c50a143f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c42cbb0b-26b8-4be4-bb64-470da1ea50a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c42cbb0b-26b8-4be4-bb64-470da1ea50a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_18446a64-4721-4471-b944-270f76b3c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_18446a64-4721-4471-b944-270f76b3c21d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9e7a4524-77a9-4d21-9f65-49004b4059f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86a37788-d6a5-4f3f-9ca9-d4b0e97ee323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86a37788-d6a5-4f3f-9ca9-d4b0e97ee323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8f8a0f8b-12cd-4a6d-96e7-2150d4e1d08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8f8a0f8b-12cd-4a6d-96e7-2150d4e1d08b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_334adaf4-3eea-4b15-ba4c-e388ea51d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a8dbb9e6-7349-4021-870a-dcb91f80060f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:to="loc_us-gaap_InterestPaidNet_a8dbb9e6-7349-4021-870a-dcb91f80060f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_55069140-8c2e-4c13-ad09-bee17cf60c68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_55069140-8c2e-4c13-ad09-bee17cf60c68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_210114d6-d5f2-48c2-be1b-92a40c2c3c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_210114d6-d5f2-48c2-be1b-92a40c2c3c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfWarrants_d8129847-3bae-4652-87c6-df0768f9f7f2" xlink:href="ibrx-20231231.xsd#ibrx_IssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_IssuanceOfWarrants_d8129847-3bae-4652-87c6-df0768f9f7f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b853f60a-dbc6-4741-a315-0c5335cf18c8" xlink:href="ibrx-20231231.xsd#ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b853f60a-dbc6-4741-a315-0c5335cf18c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative_f19eb9e7-d6f0-434e-9043-41330a95673c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative_f19eb9e7-d6f0-434e-9043-41330a95673c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability_19fb2078-d34c-4555-9fb9-bf263de1b3cc" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockDiscountOnSharesRevenueInterestLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability_19fb2078-d34c-4555-9fb9-bf263de1b3cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_37f47b50-f275-4d9f-8bf9-f54b7729fa67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_37f47b50-f275-4d9f-8bf9-f54b7729fa67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f4d90d0-a36c-4823-8bd5-49583f824b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f4d90d0-a36c-4823-8bd5-49583f824b92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability_3f869311-085e-4158-b518-e3e5091696ee" xlink:href="ibrx-20231231.xsd#ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability_3f869311-085e-4158-b518-e3e5091696ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_777fe448-a80b-4136-935c-bbedebed85fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_StockIssued1_777fe448-a80b-4136-935c-bbedebed85fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses_16aa1dbd-f869-4574-bfb9-e2be104c8b18" xlink:href="ibrx-20231231.xsd#ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses_16aa1dbd-f869-4574-bfb9-e2be104c8b18" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedCashlessExerciseOfStockOptions_705a1bb4-1654-43ed-be13-899fe6b002a4" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedCashlessExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_StockIssuedCashlessExerciseOfStockOptions_705a1bb4-1654-43ed-be13-899fe6b002a4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid_8de23ced-a0d2-4a5e-a077-effc69520216" xlink:href="ibrx-20231231.xsd#ibrx_InvestmentsInJointVentureIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid_8de23ced-a0d2-4a5e-a077-effc69520216" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:href="ibrx-20231231.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:href="ibrx-20231231.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c1e11460-150d-45e1-aa5e-fd1f380d931f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c1e11460-150d-45e1-aa5e-fd1f380d931f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1e11460-150d-45e1-aa5e-fd1f380d931f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c1e11460-150d-45e1-aa5e-fd1f380d931f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c1e11460-150d-45e1-aa5e-fd1f380d931f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8ad9939-2b59-4410-9f6e-fc9430173671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c1e11460-150d-45e1-aa5e-fd1f380d931f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8ad9939-2b59-4410-9f6e-fc9430173671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_70af44b3-9277-4eb4-b7c4-db06e072cc6c" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8ad9939-2b59-4410-9f6e-fc9430173671" xlink:to="loc_ibrx_NantCellInc.Member_70af44b3-9277-4eb4-b7c4-db06e072cc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3942b874-0f84-4da8-97e1-346b9cfe21ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_srt_OwnershipAxis_3942b874-0f84-4da8-97e1-346b9cfe21ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3942b874-0f84-4da8-97e1-346b9cfe21ea_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3942b874-0f84-4da8-97e1-346b9cfe21ea" xlink:to="loc_srt_OwnershipDomain_3942b874-0f84-4da8-97e1-346b9cfe21ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e77480bf-3629-4b82-811f-7d0f68b0c023" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3942b874-0f84-4da8-97e1-346b9cfe21ea" xlink:to="loc_srt_OwnershipDomain_e77480bf-3629-4b82-811f-7d0f68b0c023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantKwestMember_87e3361f-2653-4934-a811-e4ddbf7d8732" xlink:href="ibrx-20231231.xsd#ibrx_NantKwestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e77480bf-3629-4b82-811f-7d0f68b0c023" xlink:to="loc_ibrx_NantKwestMember_87e3361f-2653-4934-a811-e4ddbf7d8732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_84e21dfe-575e-4613-9202-61e70f913525" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_srt_TitleOfIndividualAxis_84e21dfe-575e-4613-9202-61e70f913525" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_84e21dfe-575e-4613-9202-61e70f913525_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_84e21dfe-575e-4613-9202-61e70f913525" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_84e21dfe-575e-4613-9202-61e70f913525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5492846b-3b57-4aab-9303-6b64a304fb22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_84e21dfe-575e-4613-9202-61e70f913525" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5492846b-3b57-4aab-9303-6b64a304fb22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember_3d75e9e5-4bac-4d67-83ad-f574023f072c" xlink:href="ibrx-20231231.xsd#ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5492846b-3b57-4aab-9303-6b64a304fb22" xlink:to="loc_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember_3d75e9e5-4bac-4d67-83ad-f574023f072c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_78b9cbdf-a4af-4976-9b78-2545f2857c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_78b9cbdf-a4af-4976-9b78-2545f2857c35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_78b9cbdf-a4af-4976-9b78-2545f2857c35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_78b9cbdf-a4af-4976-9b78-2545f2857c35" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_78b9cbdf-a4af-4976-9b78-2545f2857c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20bd1758-30e2-4adb-9d56-78887f41b8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_78b9cbdf-a4af-4976-9b78-2545f2857c35" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20bd1758-30e2-4adb-9d56-78887f41b8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2448be92-93d9-4d2a-91bc-67d080b1ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20bd1758-30e2-4adb-9d56-78887f41b8bd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2448be92-93d9-4d2a-91bc-67d080b1ab50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8824fc44-7e22-4f48-9c73-cff52d0d8e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8824fc44-7e22-4f48-9c73-cff52d0d8e23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_38ab5f91-f7e1-42c6-9ec0-b6ae4b899726" xlink:href="ibrx-20231231.xsd#ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_38ab5f91-f7e1-42c6-9ec0-b6ae4b899726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OwnershipPercentageByKeyExecutives_d394cf98-a92e-444a-9e23-c612a5aa5b22" xlink:href="ibrx-20231231.xsd#ibrx_OwnershipPercentageByKeyExecutives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_ibrx_OwnershipPercentageByKeyExecutives_d394cf98-a92e-444a-9e23-c612a5aa5b22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts_90d71e91-707a-4fbe-9bfd-89523872c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_us-gaap_PaymentsForMergerRelatedCosts_90d71e91-707a-4fbe-9bfd-89523872c21d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NameChangeEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NameChangeEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_824955ee-a61d-46db-beb7-75b030e14387" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:to="loc_srt_ConsolidationItemsAxis_824955ee-a61d-46db-beb7-75b030e14387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_824955ee-a61d-46db-beb7-75b030e14387_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_824955ee-a61d-46db-beb7-75b030e14387" xlink:to="loc_srt_ConsolidationItemsDomain_824955ee-a61d-46db-beb7-75b030e14387_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_824955ee-a61d-46db-beb7-75b030e14387" xlink:to="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableLegalEntitiesMember_d87347c4-0e6f-4cc1-895a-27afc5d347c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ReportableLegalEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:to="loc_srt_ReportableLegalEntitiesMember_d87347c4-0e6f-4cc1-895a-27afc5d347c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_0195d046-f581-4e71-a77c-ca0d42996ae4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:to="loc_srt_ConsolidationEliminationsMember_0195d046-f581-4e71-a77c-ca0d42996ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8716dd5a-c880-4f56-8cd2-de96a983d18c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8716dd5a-c880-4f56-8cd2-de96a983d18c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8716dd5a-c880-4f56-8cd2-de96a983d18c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8716dd5a-c880-4f56-8cd2-de96a983d18c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8716dd5a-c880-4f56-8cd2-de96a983d18c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8716dd5a-c880-4f56-8cd2-de96a983d18c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_bc382749-8f3b-494f-9195-5794fb15f079" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:to="loc_ibrx_NantCellInc.Member_bc382749-8f3b-494f-9195-5794fb15f079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantKwestInc.Member_dbf7abed-30ae-4302-a181-4fc696bb55d1" xlink:href="ibrx-20231231.xsd#ibrx_NantKwestInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:to="loc_ibrx_NantKwestInc.Member_dbf7abed-30ae-4302-a181-4fc696bb55d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_01954894-7285-4844-89bf-eaf2ef861ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_Revenues_01954894-7285-4844-89bf-eaf2ef861ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49007055-e750-4960-90a3-0411f47a916a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49007055-e750-4960-90a3-0411f47a916a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2216e8ca-5ef7-451a-906f-e60849249b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2216e8ca-5ef7-451a-906f-e60849249b10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ba80b27-f000-46cd-a880-ce8db26a458d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_OperatingIncomeLoss_2ba80b27-f000-46cd-a880-ce8db26a458d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_06671352-a127-44dc-99f8-5ce4a5fd5156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_06671352-a127-44dc-99f8-5ce4a5fd5156" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01075ded-25ac-4deb-a973-f3358c7dd8af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01075ded-25ac-4deb-a973-f3358c7dd8af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2e7c80a7-b5a3-488a-be49-65614f0ec850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_ProfitLoss_2e7c80a7-b5a3-488a-be49-65614f0ec850" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:href="ibrx-20231231.xsd#ibrx_AccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:href="ibrx-20231231.xsd#ibrx_AccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_775b7b0b-d017-40ab-841b-ce7f9559115d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_TypeOfArrangementAxis_775b7b0b-d017-40ab-841b-ce7f9559115d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_775b7b0b-d017-40ab-841b-ce7f9559115d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_775b7b0b-d017-40ab-841b-ce7f9559115d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_775b7b0b-d017-40ab-841b-ce7f9559115d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_775b7b0b-d017-40ab-841b-ce7f9559115d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_3cafec9b-b6dc-4b3e-9fa0-fb7146de33fc" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_3cafec9b-b6dc-4b3e-9fa0-fb7146de33fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicenseAgreementMember_26bd6f66-5410-408f-9330-df35131943c0" xlink:href="ibrx-20231231.xsd#ibrx_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:to="loc_ibrx_LicenseAgreementMember_26bd6f66-5410-408f-9330-df35131943c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ca5457ed-376d-4b16-bad0-5b4f3c7125d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ca5457ed-376d-4b16-bad0-5b4f3c7125d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca5457ed-376d-4b16-bad0-5b4f3c7125d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ca5457ed-376d-4b16-bad0-5b4f3c7125d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca5457ed-376d-4b16-bad0-5b4f3c7125d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ca5457ed-376d-4b16-bad0-5b4f3c7125d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_2f1c07d4-17c7-4367-b042-d0a69a61ca7e" xlink:href="ibrx-20231231.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_2f1c07d4-17c7-4367-b042-d0a69a61ca7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_dfe97f22-623d-4884-b3d9-2aa76eaa2c68" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_dfe97f22-623d-4884-b3d9-2aa76eaa2c68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_81458158-e9bb-4650-a727-287303405ec4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_srt_OwnershipAxis_81458158-e9bb-4650-a727-287303405ec4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_81458158-e9bb-4650-a727-287303405ec4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_81458158-e9bb-4650-a727-287303405ec4" xlink:to="loc_srt_OwnershipDomain_81458158-e9bb-4650-a727-287303405ec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_81458158-e9bb-4650-a727-287303405ec4" xlink:to="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GlobeImmuneIncMember_9b0a8d3b-c2bc-4681-a3d9-d7bd2f009205" xlink:href="ibrx-20231231.xsd#ibrx_GlobeImmuneIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:to="loc_ibrx_GlobeImmuneIncMember_9b0a8d3b-c2bc-4681-a3d9-d7bd2f009205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_7402af23-7d10-4a3f-a584-eccc3c91cd91" xlink:href="ibrx-20231231.xsd#ibrx_NANTibodyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:to="loc_ibrx_NANTibodyLLCMember_7402af23-7d10-4a3f-a584-eccc3c91cd91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_srt_ConsolidatedEntitiesAxis_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82" xlink:to="loc_srt_ConsolidatedEntitiesDomain_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c2927337-2268-44de-9704-1ac98c5eaa82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c2927337-2268-44de-9704-1ac98c5eaa82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GlobeImmuneIncMember_d88329a2-7b6f-4bf9-b8dc-0fd09d299cfc" xlink:href="ibrx-20231231.xsd#ibrx_GlobeImmuneIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c2927337-2268-44de-9704-1ac98c5eaa82" xlink:to="loc_ibrx_GlobeImmuneIncMember_d88329a2-7b6f-4bf9-b8dc-0fd09d299cfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_640e3d8f-cdbe-4dd0-8e31-142d28c1a1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_640e3d8f-cdbe-4dd0-8e31-142d28c1a1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdvancesToRelatedPartyMember_dac48efc-7427-420e-83dd-669994adfd87" xlink:href="ibrx-20231231.xsd#ibrx_AdvancesToRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_640e3d8f-cdbe-4dd0-8e31-142d28c1a1d0" xlink:to="loc_ibrx_AdvancesToRelatedPartyMember_dac48efc-7427-420e-83dd-669994adfd87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_180229c3-2d10-4c58-b173-c9966ea9efe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_180229c3-2d10-4c58-b173-c9966ea9efe5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_180229c3-2d10-4c58-b173-c9966ea9efe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_180229c3-2d10-4c58-b173-c9966ea9efe5" xlink:to="loc_us-gaap_RelatedPartyDomain_180229c3-2d10-4c58-b173-c9966ea9efe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4c207bd9-9923-49aa-af40-7e15a7fb30e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_180229c3-2d10-4c58-b173-c9966ea9efe5" xlink:to="loc_us-gaap_RelatedPartyDomain_4c207bd9-9923-49aa-af40-7e15a7fb30e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c65eedaf-fd98-43fc-b240-1591dae9c313" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4c207bd9-9923-49aa-af40-7e15a7fb30e0" xlink:to="loc_srt_AffiliatedEntityMember_c65eedaf-fd98-43fc-b240-1591dae9c313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e26138f-f30c-4e23-90d5-2b01d506245a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e26138f-f30c-4e23-90d5-2b01d506245a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e26138f-f30c-4e23-90d5-2b01d506245a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e26138f-f30c-4e23-90d5-2b01d506245a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e26138f-f30c-4e23-90d5-2b01d506245a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ee1c135-d4da-471d-8e48-45146ca2d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e26138f-f30c-4e23-90d5-2b01d506245a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ee1c135-d4da-471d-8e48-45146ca2d4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_7c42d6ea-fef7-4a98-8031-56b03d6284a8" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ee1c135-d4da-471d-8e48-45146ca2d4dd" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_7c42d6ea-fef7-4a98-8031-56b03d6284a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384692f2-8ecb-48dc-855a-285adcc1ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384692f2-8ecb-48dc-855a-285adcc1ff77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e6f7a0d8-3766-4a3d-bd3c-35b1228bffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e6f7a0d8-3766-4a3d-bd3c-35b1228bffbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_566226b0-fb36-46ba-a6ca-fab7e50f48f4" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_566226b0-fb36-46ba-a6ca-fab7e50f48f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_04c2d96f-bfed-4e90-8385-275370d5d7ee" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementTotalInvestmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_04c2d96f-bfed-4e90-8385-275370d5d7ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_483f8159-9718-4cc9-8099-e2e7906d1884" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_483f8159-9718-4cc9-8099-e2e7906d1884" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_dbf3f911-fd02-4ced-b53e-c46ed32b48a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_ImpairmentOfInvestments_dbf3f911-fd02-4ced-b53e-c46ed32b48a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_475967fe-29c0-4b73-920c-88a0f892a931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_Revenues_475967fe-29c0-4b73-920c-88a0f892a931" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2e89bdfb-1689-4205-938f-8deebafe3f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2e89bdfb-1689-4205-938f-8deebafe3f3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_baa33d1f-4d25-4575-b4c8-af602c5fadcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_baa33d1f-4d25-4575-b4c8-af602c5fadcd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_7fc010f1-97c6-4a40-adb4-723f4f835797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_7fc010f1-97c6-4a40-adb4-723f4f835797" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2ec74ff7-7442-42ad-b52a-7e9484f9660c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2ec74ff7-7442-42ad-b52a-7e9484f9660c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2aff4584-e553-431d-9fd0-660935b3eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_OperatingExpenses_2aff4584-e553-431d-9fd0-660935b3eec4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9e91e6f0-ebc2-41e4-92c7-23025f0e55f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_Assets_9e91e6f0-ebc2-41e4-92c7-23025f0e55f7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a36f6164-03be-43ea-a628-bb4969f0d6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_Liabilities_a36f6164-03be-43ea-a628-bb4969f0d6f2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAdditionalPurchaseOption_6d60ca7e-72d7-4cd2-a60a-9f0e307d80e2" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_SaleOfStockAdditionalPurchaseOption_6d60ca7e-72d7-4cd2-a60a-9f0e307d80e2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5c6cc338-a1a7-47d2-b0c4-36d00f850ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5c6cc338-a1a7-47d2-b0c4-36d00f850ade" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ed20e73d-4c8b-4cf6-abfa-a070aa33549a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_NumberOfReportableSegments_ed20e73d-4c8b-4cf6-abfa-a070aa33549a" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7923e4b7-d0d3-4dd8-b85d-33395809c5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7923e4b7-d0d3-4dd8-b85d-33395809c5bc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16773141-4342-4ac3-97a1-a7a88eaff312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16773141-4342-4ac3-97a1-a7a88eaff312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16773141-4342-4ac3-97a1-a7a88eaff312_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16773141-4342-4ac3-97a1-a7a88eaff312" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_16773141-4342-4ac3-97a1-a7a88eaff312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16773141-4342-4ac3-97a1-a7a88eaff312" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_63c40455-be21-4acd-8b85-43e32707c6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_BuildingMember_63c40455-be21-4acd-8b85-43e32707c6d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_869cff8c-1f80-477d-a413-af60e1d2e0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_869cff8c-1f80-477d-a413-af60e1d2e0cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LaboratoryEquipmentMember_f2a7050e-23e9-495b-a947-b5a92f932e92" xlink:href="ibrx-20231231.xsd#ibrx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_ibrx_LaboratoryEquipmentMember_f2a7050e-23e9-495b-a947-b5a92f932e92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ef2e5792-5453-4f62-9c1c-34098dcff1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ef2e5792-5453-4f62-9c1c-34098dcff1b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_67379b2e-435a-48af-8e60-3af4219e9d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_ComputerEquipmentMember_67379b2e-435a-48af-8e60-3af4219e9d12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:to="loc_srt_RangeAxis_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e" xlink:to="loc_srt_RangeMember_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e" xlink:to="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f632730e-5515-4335-8a97-8dcd286d8083" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:to="loc_srt_MinimumMember_f632730e-5515-4335-8a97-8dcd286d8083" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cc1b9a57-5eee-4455-98cb-58158ca788eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:to="loc_srt_MaximumMember_cc1b9a57-5eee-4455-98cb-58158ca788eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4282c9b8-d4a8-4b2e-87c9-44fcef20b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7923e4b7-d0d3-4dd8-b85d-33395809c5bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4282c9b8-d4a8-4b2e-87c9-44fcef20b8a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ddec6dff-0ee2-4d94-a404-c2a80ca5e128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b24055-beb1-45c9-9248-e279b693cac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ddec6dff-0ee2-4d94-a404-c2a80ca5e128" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b24055-beb1-45c9-9248-e279b693cac3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b24055-beb1-45c9-9248-e279b693cac3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember_91946394-ac40-4d64-970c-92ccad229ae4" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_ibrx_RelatedPartyConvertibleNotesMember_91946394-ac40-4d64-970c-92ccad229ae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ad891642-6439-4bac-948b-332deac9483d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_us-gaap_WarrantMember_ad891642-6439-4bac-948b-332deac9483d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d1464985-93b2-4991-b008-1de462d7d586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d1464985-93b2-4991-b008-1de462d7d586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bee58446-11ee-4428-9a29-e3120510a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bee58446-11ee-4428-9a29-e3120510a03c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyWarrantsMember_78bc6931-c249-45a6-b4af-648603deaa6b" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_ibrx_RelatedPartyWarrantsMember_78bc6931-c249-45a6-b4af-648603deaa6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4b21030e-3747-4921-a34b-8c2a0b23c878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ddec6dff-0ee2-4d94-a404-c2a80ca5e128" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4b21030e-3747-4921-a34b-8c2a0b23c878" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_127280bf-5e3d-43d5-87a1-d8d8c2a57a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_25923cb7-5430-44df-b254-d3df5737ca42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_127280bf-5e3d-43d5-87a1-d8d8c2a57a9a" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_25923cb7-5430-44df-b254-d3df5737ca42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_25923cb7-5430-44df-b254-d3df5737ca42" xlink:to="loc_srt_StatementGeographicalAxis_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5" xlink:to="loc_srt_SegmentGeographicalDomain_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5" xlink:to="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6e54d658-5238-4fe4-98b7-572c80e1f9ca" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:to="loc_country_US_6e54d658-5238-4fe4-98b7-572c80e1f9ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dd7ee681-a3f8-418b-8966-bf07435b5937" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:to="loc_srt_EuropeMember_dd7ee681-a3f8-418b-8966-bf07435b5937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_193a9bc3-b4e3-4741-914f-5e78df37c507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_127280bf-5e3d-43d5-87a1-d8d8c2a57a9a" xlink:to="loc_us-gaap_Revenues_193a9bc3-b4e3-4741-914f-5e78df37c507" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_89ae7e4e-1e9b-4cba-ad4c-ddba78eebaae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_89ae7e4e-1e9b-4cba-ad4c-ddba78eebaae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4e8be96c-262a-44e4-b16e-7927b00fd0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_89ae7e4e-1e9b-4cba-ad4c-ddba78eebaae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4e8be96c-262a-44e4-b16e-7927b00fd0e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e8be96c-262a-44e4-b16e-7927b00fd0e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4e8be96c-262a-44e4-b16e-7927b00fd0e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e8be96c-262a-44e4-b16e-7927b00fd0e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4e8be96c-262a-44e4-b16e-7927b00fd0e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_930960f8-5260-47b6-bd3b-dd54ae667368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_930960f8-5260-47b6-bd3b-dd54ae667368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a95e594d-cbbd-4bd3-b73b-fd0832f78db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_EquipmentMember_a95e594d-cbbd-4bd3-b73b-fd0832f78db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_114680dc-32be-4f8b-861c-5d90513035a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_ConstructionInProgressMember_114680dc-32be-4f8b-861c-5d90513035a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_40e962ea-671e-417d-af05-dab1a8e62f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_40e962ea-671e-417d-af05-dab1a8e62f39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a6063480-5492-4cde-bcff-c5edda07f5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a6063480-5492-4cde-bcff-c5edda07f5a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8287a911-24f6-4df0-baa9-52befe36ca93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8287a911-24f6-4df0-baa9-52befe36ca93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_79cb4e5a-458e-4d5d-b4de-84707cdea3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_79cb4e5a-458e-4d5d-b4de-84707cdea3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b560b0b1-66ac-4432-8ffd-b1fdcb5838f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b560b0b1-66ac-4432-8ffd-b1fdcb5838f5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_85121683-b6bc-4ed4-97b0-eb2d221ff66a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_us-gaap_AssetAcquisitionAxis_85121683-b6bc-4ed4-97b0-eb2d221ff66a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_85121683-b6bc-4ed4-97b0-eb2d221ff66a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_85121683-b6bc-4ed4-97b0-eb2d221ff66a" xlink:to="loc_us-gaap_AssetAcquisitionDomain_85121683-b6bc-4ed4-97b0-eb2d221ff66a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_06dcc03f-e82e-42dd-9198-08c89075bf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_85121683-b6bc-4ed4-97b0-eb2d221ff66a" xlink:to="loc_us-gaap_AssetAcquisitionDomain_06dcc03f-e82e-42dd-9198-08c89075bf8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_f83c0542-3340-44ba-8f95-adf7b450acd5" xlink:href="ibrx-20231231.xsd#ibrx_DunkirkFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_06dcc03f-e82e-42dd-9198-08c89075bf8a" xlink:to="loc_ibrx_DunkirkFacilityMember_f83c0542-3340-44ba-8f95-adf7b450acd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4115a2d8-e511-4bc6-873d-48eec9e94a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4115a2d8-e511-4bc6-873d-48eec9e94a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_9e298a80-9ba9-4de4-92ad-9b303dad15a6" xlink:href="ibrx-20231231.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4115a2d8-e511-4bc6-873d-48eec9e94a5f" xlink:to="loc_ibrx_OrganizedWorkforceMember_9e298a80-9ba9-4de4-92ad-9b303dad15a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_763f6788-259f-4b9a-a348-49bb29cfd90f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_763f6788-259f-4b9a-a348-49bb29cfd90f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_763f6788-259f-4b9a-a348-49bb29cfd90f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_763f6788-259f-4b9a-a348-49bb29cfd90f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_763f6788-259f-4b9a-a348-49bb29cfd90f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5d48d69b-aa82-4ed8-a2d5-21cced6b2f7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_763f6788-259f-4b9a-a348-49bb29cfd90f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5d48d69b-aa82-4ed8-a2d5-21cced6b2f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RiptideBioscienceIncMember_01f30c82-c374-44c7-b32a-6e9b8b46e82b" xlink:href="ibrx-20231231.xsd#ibrx_RiptideBioscienceIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5d48d69b-aa82-4ed8-a2d5-21cced6b2f7d" xlink:to="loc_ibrx_RiptideBioscienceIncMember_01f30c82-c374-44c7-b32a-6e9b8b46e82b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bff8e638-3e22-41da-ac81-6f5f0258d4fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_srt_RangeAxis_bff8e638-3e22-41da-ac81-6f5f0258d4fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bff8e638-3e22-41da-ac81-6f5f0258d4fb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bff8e638-3e22-41da-ac81-6f5f0258d4fb" xlink:to="loc_srt_RangeMember_bff8e638-3e22-41da-ac81-6f5f0258d4fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c03d55fe-7915-405f-b790-e7736d6fc6e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bff8e638-3e22-41da-ac81-6f5f0258d4fb" xlink:to="loc_srt_RangeMember_c03d55fe-7915-405f-b790-e7736d6fc6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_abe90ad1-2ba7-4dce-9135-94bf46616283" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c03d55fe-7915-405f-b790-e7736d6fc6e9" xlink:to="loc_srt_MaximumMember_abe90ad1-2ba7-4dce-9135-94bf46616283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25b345d5-0486-4f25-8925-01fd9f00442f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25b345d5-0486-4f25-8925-01fd9f00442f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_25b345d5-0486-4f25-8925-01fd9f00442f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25b345d5-0486-4f25-8925-01fd9f00442f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_25b345d5-0486-4f25-8925-01fd9f00442f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_53b1002b-6eed-4845-a8aa-32dbeefc5de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25b345d5-0486-4f25-8925-01fd9f00442f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_53b1002b-6eed-4845-a8aa-32dbeefc5de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IPRDMember_78b5920a-eda1-42ad-8eb8-8bb20b338da5" xlink:href="ibrx-20231231.xsd#ibrx_IPRDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_53b1002b-6eed-4845-a8aa-32dbeefc5de6" xlink:to="loc_ibrx_IPRDMember_78b5920a-eda1-42ad-8eb8-8bb20b338da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f115b4e3-dbd0-4b54-bdc1-8deecab0063c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_Depreciation_f115b4e3-dbd0-4b54-bdc1-8deecab0063c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_80226c3d-2569-405f-a9f9-3e82d9da5134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_80226c3d-2569-405f-a9f9-3e82d9da5134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_faac4793-5f92-412d-989a-1adbc29207c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_faac4793-5f92-412d-989a-1adbc29207c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_930f1555-0af3-4510-acac-06a6a9ed186f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_930f1555-0af3-4510-acac-06a6a9ed186f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3450ea55-bebe-4bd8-9130-dbdf419f1ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3450ea55-bebe-4bd8-9130-dbdf419f1ac4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableDiscountOptionPercent_c950e1c6-c43f-4803-90d2-aa572d084c26" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableDiscountOptionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_ConvertibleNoteReceivableDiscountOptionPercent_c950e1c6-c43f-4803-90d2-aa572d084c26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_2586afd0-6592-4c93-ac41-00ad7a8a0006" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_2586afd0-6592-4c93-ac41-00ad7a8a0006" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_3d3b769b-1bee-4f50-b1df-8994eea394f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_InvestmentInterestRate_3d3b769b-1bee-4f50-b1df-8994eea394f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount_8d86d253-7204-4186-98db-31db2bcd251a" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentPayableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount_8d86d253-7204-4186-98db-31db2bcd251a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_2bbd160d-cb52-4518-89a2-8bdaa65c8ab9" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_2bbd160d-cb52-4518-89a2-8bdaa65c8ab9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_6b28529f-20b5-43cf-a0d9-0a245fdf5152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_InterestReceivable_6b28529f-20b5-43cf-a0d9-0a245fdf5152" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_f6996493-5bcd-4b9a-a110-7a441dec746e" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_ibrx_FinancialStatementDetailsTable_f6996493-5bcd-4b9a-a110-7a441dec746e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a42338d9-28eb-4765-81dc-3523e9a6146b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_f6996493-5bcd-4b9a-a110-7a441dec746e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a42338d9-28eb-4765-81dc-3523e9a6146b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a42338d9-28eb-4765-81dc-3523e9a6146b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a42338d9-28eb-4765-81dc-3523e9a6146b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a42338d9-28eb-4765-81dc-3523e9a6146b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a42338d9-28eb-4765-81dc-3523e9a6146b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_7eabc1d6-1cc5-462d-8161-b5c874221462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_7eabc1d6-1cc5-462d-8161-b5c874221462" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_064454ff-95fa-4bae-a4e1-38c945f10715" xlink:href="ibrx-20231231.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:to="loc_ibrx_OrganizedWorkforceMember_064454ff-95fa-4bae-a4e1-38c945f10715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0faad156-93e5-40fa-8865-058d874ac553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0faad156-93e5-40fa-8865-058d874ac553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_04ce1ce7-286a-4086-b385-0587de6a6d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_04ce1ce7-286a-4086-b385-0587de6a6d7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d04620a4-1210-4559-bc3a-c260f6e8fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d04620a4-1210-4559-bc3a-c260f6e8fc7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_91965e59-3b0f-4114-9c40-08999f8dce4d" xlink:href="ibrx-20231231.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_91965e59-3b0f-4114-9c40-08999f8dce4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a7fd9bf-8f72-4061-a43c-6a4b0d75d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a7fd9bf-8f72-4061-a43c-6a4b0d75d97d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_1e561268-1e29-48e3-a131-2acdfc5d8477" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:to="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_1e561268-1e29-48e3-a131-2acdfc5d8477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_de4c5528-7a49-4963-b9a5-a520acfc3c6f" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:to="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_de4c5528-7a49-4963-b9a5-a520acfc3c6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f2121b1-bb75-424a-863e-c0d78c398a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f2121b1-bb75-424a-863e-c0d78c398a0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9b413b9a-d6d7-4306-b404-c6427925a8da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9b413b9a-d6d7-4306-b404-c6427925a8da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IntangibleAssetsAccumulatedImpairment_843a25fa-47c9-4510-9849-defda07c54b0" xlink:href="ibrx-20231231.xsd#ibrx_IntangibleAssetsAccumulatedImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_ibrx_IntangibleAssetsAccumulatedImpairment_843a25fa-47c9-4510-9849-defda07c54b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9f8d4bf2-1d09-45da-9b73-e54b17ce9a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9f8d4bf2-1d09-45da-9b73-e54b17ce9a0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_747b8092-d058-4252-afbe-8bd2174f34d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_747b8092-d058-4252-afbe-8bd2174f34d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a34a13c0-5c9e-4d30-ad97-5a96a04f1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a34a13c0-5c9e-4d30-ad97-5a96a04f1bf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dfe228c7-da46-4674-9284-0e6b89643822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dfe228c7-da46-4674-9284-0e6b89643822" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_50377998-5dd2-4636-9ed6-2af0adb490d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_50377998-5dd2-4636-9ed6-2af0adb490d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_23a56972-57f3-4c67-bf13-8900ea813595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_23a56972-57f3-4c67-bf13-8900ea813595" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dcbf9645-ca87-4464-8114-3bcd598769fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dcbf9645-ca87-4464-8114-3bcd598769fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e53fe248-2b4d-45d5-a1a1-b1700dd4708d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_f11e3170-1742-4c04-a469-e746945134ee" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_ibrx_FinancialStatementDetailsTable_f11e3170-1742-4c04-a469-e746945134ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_552692f2-3b9b-414c-a00e-8c92d3c6fb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_FinancialStatementDetailsTable_f11e3170-1742-4c04-a469-e746945134ee" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_552692f2-3b9b-414c-a00e-8c92d3c6fb9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_552692f2-3b9b-414c-a00e-8c92d3c6fb9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_552692f2-3b9b-414c-a00e-8c92d3c6fb9d" xlink:to="loc_us-gaap_RelatedPartyDomain_552692f2-3b9b-414c-a00e-8c92d3c6fb9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cb7cf288-2db8-4a02-a443-e035ed8798d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_552692f2-3b9b-414c-a00e-8c92d3c6fb9d" xlink:to="loc_us-gaap_RelatedPartyDomain_cb7cf288-2db8-4a02-a443-e035ed8798d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_87f655b3-8bf4-43bb-a2f0-ad3dcf69a2a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cb7cf288-2db8-4a02-a443-e035ed8798d1" xlink:to="loc_srt_AffiliatedEntityMember_87f655b3-8bf4-43bb-a2f0-ad3dcf69a2a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_133dfc50-910b-4edc-b5a6-0913153fe2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_us-gaap_InterestExpenseDebt_133dfc50-910b-4edc-b5a6-0913153fe2e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_27bde068-c73a-4150-ae92-89a68c2f2b78" xlink:href="ibrx-20231231.xsd#ibrx_AmortizationOfDebtDiscountPremiumRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_27bde068-c73a-4150-ae92-89a68c2f2b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_8ed47a9f-0bb0-4fe4-ae38-2ad47993e732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_us-gaap_InterestExpenseOther_8ed47a9f-0bb0-4fe4-ae38-2ad47993e732" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4978022e-646f-4b5d-be56-62fdd3c4b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_us-gaap_InterestExpense_4978022e-646f-4b5d-be56-62fdd3c4b9db" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e0e1034a-938c-4a29-91c5-0c13a6281c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e0e1034a-938c-4a29-91c5-0c13a6281c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e0e1034a-938c-4a29-91c5-0c13a6281c90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e0e1034a-938c-4a29-91c5-0c13a6281c90" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e0e1034a-938c-4a29-91c5-0c13a6281c90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e0e1034a-938c-4a29-91c5-0c13a6281c90" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_2b10a301-f1e7-4f8b-8fc3-4599aca00006" xlink:href="ibrx-20231231.xsd#ibrx_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:to="loc_ibrx_CurrentAssetsMember_2b10a301-f1e7-4f8b-8fc3-4599aca00006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_76fac8eb-1c86-4def-93eb-b6194aa8daff" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:to="loc_ibrx_NoncurrentAssetsMember_76fac8eb-1c86-4def-93eb-b6194aa8daff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c59881c3-8f19-435f-a7ca-2cc9b20a8d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c59881c3-8f19-435f-a7ca-2cc9b20a8d21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c59881c3-8f19-435f-a7ca-2cc9b20a8d21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c59881c3-8f19-435f-a7ca-2cc9b20a8d21" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c59881c3-8f19-435f-a7ca-2cc9b20a8d21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c59881c3-8f19-435f-a7ca-2cc9b20a8d21" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_8843b3a4-6a48-42a4-a288-8d80b3544ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_8843b3a4-6a48-42a4-a288-8d80b3544ab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_1646f120-464b-4018-9533-68c02839b29b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:to="loc_us-gaap_MutualFundMember_1646f120-464b-4018-9533-68c02839b29b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_089709ac-1940-43ec-9e5c-96b465db1013" xlink:href="ibrx-20231231.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_089709ac-1940-43ec-9e5c-96b465db1013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084e8ecf-7526-48be-a039-25ef47a3bbba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084e8ecf-7526-48be-a039-25ef47a3bbba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_72820ba1-0560-4407-879d-d37496b7ac4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_72820ba1-0560-4407-879d-d37496b7ac4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d2f9a0b-b06b-46c7-89d3-dc96f3947dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d2f9a0b-b06b-46c7-89d3-dc96f3947dc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3b55442e-bbc5-4545-a409-62ba074eb37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3b55442e-bbc5-4545-a409-62ba074eb37f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_85d99d80-cf24-4ca2-93e7-e27f7bea84fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_85d99d80-cf24-4ca2-93e7-e27f7bea84fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85d99d80-cf24-4ca2-93e7-e27f7bea84fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85d99d80-cf24-4ca2-93e7-e27f7bea84fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85d99d80-cf24-4ca2-93e7-e27f7bea84fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85d99d80-cf24-4ca2-93e7-e27f7bea84fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_e946d3ba-4774-473f-9d79-0ab36cb3a962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:to="loc_us-gaap_MutualFundMember_e946d3ba-4774-473f-9d79-0ab36cb3a962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_df716037-660f-4d3c-afc9-6e210c5a8581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_df716037-660f-4d3c-afc9-6e210c5a8581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_58a4da1a-2b37-474f-8687-927f47c6bea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:to="loc_us-gaap_DebtSecuritiesMember_58a4da1a-2b37-474f-8687-927f47c6bea1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f3e81995-55b6-4e98-b333-3645f6d14947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f3e81995-55b6-4e98-b333-3645f6d14947" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f3e81995-55b6-4e98-b333-3645f6d14947_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f3e81995-55b6-4e98-b333-3645f6d14947" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f3e81995-55b6-4e98-b333-3645f6d14947_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_89490991-9565-429e-8831-9c5afa45b1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f3e81995-55b6-4e98-b333-3645f6d14947" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_89490991-9565-429e-8831-9c5afa45b1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_f83d57cf-4b60-4105-8a8b-70885279d369" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_89490991-9565-429e-8831-9c5afa45b1fc" xlink:to="loc_ibrx_NoncurrentAssetsMember_f83d57cf-4b60-4105-8a8b-70885279d369" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_082e9633-5a1a-4a24-bdba-847f0f9a46e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_082e9633-5a1a-4a24-bdba-847f0f9a46e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e612b43a-ae98-4430-989d-972e7e4ed5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e612b43a-ae98-4430-989d-972e7e4ed5ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_26b911d7-2454-459a-a35c-8d741f3e0696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_26b911d7-2454-459a-a35c-8d741f3e0696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f7d724ad-87d7-4ec1-90cb-47358a4d1dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f7d724ad-87d7-4ec1-90cb-47358a4d1dc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_7e3d4d94-2b39-4149-a6b0-67bf04713a7c" xlink:href="ibrx-20231231.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_7e3d4d94-2b39-4149-a6b0-67bf04713a7c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c9f2f48-6207-42a1-8013-f8bd21bb3854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c9f2f48-6207-42a1-8013-f8bd21bb3854" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_041ef6f9-80f0-4519-b3b6-39e92373809f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c9f2f48-6207-42a1-8013-f8bd21bb3854" xlink:to="loc_us-gaap_FinancialInstrumentAxis_041ef6f9-80f0-4519-b3b6-39e92373809f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_041ef6f9-80f0-4519-b3b6-39e92373809f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_041ef6f9-80f0-4519-b3b6-39e92373809f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_041ef6f9-80f0-4519-b3b6-39e92373809f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69e56084-f629-4403-9f69-1c62574b4048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_041ef6f9-80f0-4519-b3b6-39e92373809f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69e56084-f629-4403-9f69-1c62574b4048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_a0dd7685-7534-4a9f-a9dc-b395d7b41e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69e56084-f629-4403-9f69-1c62574b4048" xlink:to="loc_us-gaap_DebtSecuritiesMember_a0dd7685-7534-4a9f-a9dc-b395d7b41e24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_308864e6-ed68-4c53-b9ca-c442450a6dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:to="loc_us-gaap_ImpairmentOfInvestments_308864e6-ed68-4c53-b9ca-c442450a6dc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_d3fb99d2-92bf-4d4a-9207-1aed4e87be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:to="loc_us-gaap_MarketableSecurities_d3fb99d2-92bf-4d4a-9207-1aed4e87be7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b4204ca7-3afc-41f4-8532-9d54bbb509d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b4204ca7-3afc-41f4-8532-9d54bbb509d3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_89399ca6-f0f5-44ae-8d65-83224711a71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_89399ca6-f0f5-44ae-8d65-83224711a71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_89399ca6-f0f5-44ae-8d65-83224711a71a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_89399ca6-f0f5-44ae-8d65-83224711a71a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_89399ca6-f0f5-44ae-8d65-83224711a71a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dce6d9f7-814b-4148-82c0-f64be2e70ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_89399ca6-f0f5-44ae-8d65-83224711a71a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dce6d9f7-814b-4148-82c0-f64be2e70ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_06a90aa2-3e1e-4ca8-9823-598972b8d595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dce6d9f7-814b-4148-82c0-f64be2e70ebb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_06a90aa2-3e1e-4ca8-9823-598972b8d595" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffbf0f40-9498-41f7-84a7-8e4e79d03575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffbf0f40-9498-41f7-84a7-8e4e79d03575" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffbf0f40-9498-41f7-84a7-8e4e79d03575_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffbf0f40-9498-41f7-84a7-8e4e79d03575" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffbf0f40-9498-41f7-84a7-8e4e79d03575_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffbf0f40-9498-41f7-84a7-8e4e79d03575" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_20bc4653-3253-4b25-b421-0135f5779aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_20bc4653-3253-4b25-b421-0135f5779aee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11efc248-ec6d-4ed6-8585-6cc2b6f0262d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11efc248-ec6d-4ed6-8585-6cc2b6f0262d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_997684ef-af27-495c-a303-3a284fc26fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_997684ef-af27-495c-a303-3a284fc26fd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_ecb85d5c-accb-4952-9456-40e30c0f5e76" xlink:href="ibrx-20231231.xsd#ibrx_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_CurrentAssetsMember_ecb85d5c-accb-4952-9456-40e30c0f5e76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_fee9e7b8-0237-4ecc-ad34-e31039c2932e" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_NoncurrentAssetsMember_fee9e7b8-0237-4ecc-ad34-e31039c2932e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentLiabilitiesMember_305241fa-e92e-4e4b-8660-e60d61597d96" xlink:href="ibrx-20231231.xsd#ibrx_CurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_CurrentLiabilitiesMember_305241fa-e92e-4e4b-8660-e60d61597d96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentLiabilitiesMember_9fd31c96-82da-4ea2-b77f-d0d38d34b57c" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_NoncurrentLiabilitiesMember_9fd31c96-82da-4ea2-b77f-d0d38d34b57c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5e570383-221b-4bac-9292-c53cd39e6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5e570383-221b-4bac-9292-c53cd39e6e2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5e570383-221b-4bac-9292-c53cd39e6e2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5e570383-221b-4bac-9292-c53cd39e6e2c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5e570383-221b-4bac-9292-c53cd39e6e2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_772707e2-926b-41da-9e89-468cff005d31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5e570383-221b-4bac-9292-c53cd39e6e2c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_772707e2-926b-41da-9e89-468cff005d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5e170616-5edc-4082-8019-1cba3c7e8353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_772707e2-926b-41da-9e89-468cff005d31" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5e170616-5edc-4082-8019-1cba3c7e8353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_494b78d2-01ea-4bd2-88c3-cedc97f1ba43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_InvestmentTypeAxis_494b78d2-01ea-4bd2-88c3-cedc97f1ba43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_494b78d2-01ea-4bd2-88c3-cedc97f1ba43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_494b78d2-01ea-4bd2-88c3-cedc97f1ba43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_494b78d2-01ea-4bd2-88c3-cedc97f1ba43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_494b78d2-01ea-4bd2-88c3-cedc97f1ba43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d1bd8627-eb45-4447-b90c-9f644d1d8dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:to="loc_us-gaap_EquitySecuritiesMember_d1bd8627-eb45-4447-b90c-9f644d1d8dce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_4102f6a6-7a01-4f48-aa08-3d75c368602a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_4102f6a6-7a01-4f48-aa08-3d75c368602a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_d7090d75-965c-47ef-b6cc-39bb00d064b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:to="loc_us-gaap_MutualFundMember_d7090d75-965c-47ef-b6cc-39bb00d064b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember_5036474e-57e5-4ef0-9091-aee5b03edcd6" xlink:href="ibrx-20231231.xsd#ibrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_ibrx_ContingentConsiderationMember_5036474e-57e5-4ef0-9091-aee5b03edcd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockOptionPurchaseLiabilityMember_56406e67-e181-4c2d-8efa-f6fc6e81c2f8" xlink:href="ibrx-20231231.xsd#ibrx_StockOptionPurchaseLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_ibrx_StockOptionPurchaseLiabilityMember_56406e67-e181-4c2d-8efa-f6fc6e81c2f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DerivativeLiabilitiesMember_ec9c7582-2ab4-4ef6-8e9e-d33587544b61" xlink:href="ibrx-20231231.xsd#ibrx_DerivativeLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_ibrx_DerivativeLiabilitiesMember_ec9c7582-2ab4-4ef6-8e9e-d33587544b61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_572ca0ed-b418-43c5-a073-745ec03c08cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_us-gaap_WarrantMember_572ca0ed-b418-43c5-a073-745ec03c08cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6f4bcd9e-ae1d-4b83-8f8a-d513f0e982db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6f4bcd9e-ae1d-4b83-8f8a-d513f0e982db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_63e45a77-1d05-4b3e-be04-91b4bbc8cc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6f4bcd9e-ae1d-4b83-8f8a-d513f0e982db" xlink:to="loc_us-gaap_WarrantMember_63e45a77-1d05-4b3e-be04-91b4bbc8cc6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ab1b7f30-cc59-4989-b9a1-6dd2e2e000b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ab1b7f30-cc59-4989-b9a1-6dd2e2e000b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_75943b91-f904-40cf-ae0e-cf5512c1746e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_75943b91-f904-40cf-ae0e-cf5512c1746e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_139bc2fc-2485-46a5-9ce7-711c16855168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_139bc2fc-2485-46a5-9ce7-711c16855168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_139bc2fc-2485-46a5-9ce7-711c16855168_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_139bc2fc-2485-46a5-9ce7-711c16855168" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_139bc2fc-2485-46a5-9ce7-711c16855168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17f699-f471-4ba3-8c9e-e86664560e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_139bc2fc-2485-46a5-9ce7-711c16855168" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17f699-f471-4ba3-8c9e-e86664560e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a085ee83-efd7-4b3a-b04c-0aeede56306d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17f699-f471-4ba3-8c9e-e86664560e34" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a085ee83-efd7-4b3a-b04c-0aeede56306d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_81a30058-f2a9-4d7b-8925-54d50d075296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_81a30058-f2a9-4d7b-8925-54d50d075296" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_81a30058-f2a9-4d7b-8925-54d50d075296_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81a30058-f2a9-4d7b-8925-54d50d075296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_81a30058-f2a9-4d7b-8925-54d50d075296_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81a30058-f2a9-4d7b-8925-54d50d075296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_3832db03-141f-40c0-9c71-c44fb935e7d6" xlink:href="ibrx-20231231.xsd#ibrx_December2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:to="loc_ibrx_December2022WarrantsMember_3832db03-141f-40c0-9c71-c44fb935e7d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_20078eaa-00dd-4233-bb79-babd9dafdd22" xlink:href="ibrx-20231231.xsd#ibrx_February2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:to="loc_ibrx_February2023WarrantsMember_20078eaa-00dd-4233-bb79-babd9dafdd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_July2023WarrantsMember_dff357b4-6619-44db-be9e-75721e85e0e8" xlink:href="ibrx-20231231.xsd#ibrx_July2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:to="loc_ibrx_July2023WarrantsMember_dff357b4-6619-44db-be9e-75721e85e0e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_990b8803-936f-4fb7-b7f4-4fd4a280a576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_990b8803-936f-4fb7-b7f4-4fd4a280a576" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_990b8803-936f-4fb7-b7f4-4fd4a280a576_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_990b8803-936f-4fb7-b7f4-4fd4a280a576" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_990b8803-936f-4fb7-b7f4-4fd4a280a576_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_990b8803-936f-4fb7-b7f4-4fd4a280a576" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f0f182c0-a53c-4d0d-8de7-136603d210cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f0f182c0-a53c-4d0d-8de7-136603d210cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_7e06ba09-2e86-4c6b-bc7e-a032a9bd31ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_7e06ba09-2e86-4c6b-bc7e-a032a9bd31ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_af3dc347-1a03-40ba-a72b-103f4d95e902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_af3dc347-1a03-40ba-a72b-103f4d95e902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d39e5d32-8f6e-4933-acc5-28305b32a5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d39e5d32-8f6e-4933-acc5-28305b32a5d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_54ad3f93-59fe-48b1-8fd2-2b5aedb0373c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_54ad3f93-59fe-48b1-8fd2-2b5aedb0373c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b28b24ec-e7db-4ef7-ad88-5757810a8f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b28b24ec-e7db-4ef7-ad88-5757810a8f42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e5783699-3237-42fa-8c69-2cb6339021f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e5783699-3237-42fa-8c69-2cb6339021f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5783699-3237-42fa-8c69-2cb6339021f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5783699-3237-42fa-8c69-2cb6339021f8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5783699-3237-42fa-8c69-2cb6339021f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5783699-3237-42fa-8c69-2cb6339021f8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_38f50ae9-1d6d-4434-ba8a-97e4f8e5d0a5" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_38f50ae9-1d6d-4434-ba8a-97e4f8e5d0a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_8d25cde7-6788-44c2-9653-5f200c0b7259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:to="loc_us-gaap_PrivatePlacementMember_8d25cde7-6788-44c2-9653-5f200c0b7259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a04960b2-7bc1-44fa-9e47-f8ee01b35cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a04960b2-7bc1-44fa-9e47-f8ee01b35cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_ea567cc5-d436-4b23-b3de-4b251a95e15c" xlink:href="ibrx-20231231.xsd#ibrx_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a04960b2-7bc1-44fa-9e47-f8ee01b35cbe" xlink:to="loc_ibrx_CurrentAssetsMember_ea567cc5-d436-4b23-b3de-4b251a95e15c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9e04becb-18d1-4528-b506-655b4b99fb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9e04becb-18d1-4528-b506-655b4b99fb9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9e04becb-18d1-4528-b506-655b4b99fb9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9e04becb-18d1-4528-b506-655b4b99fb9c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9e04becb-18d1-4528-b506-655b4b99fb9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9e04becb-18d1-4528-b506-655b4b99fb9c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_fbf9a1f7-f6eb-4762-a564-8839dfad4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:to="loc_us-gaap_AgencySecuritiesMember_fbf9a1f7-f6eb-4762-a564-8839dfad4ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_26af5aaa-9ee0-453a-9e6a-1e1a3e4f9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_26af5aaa-9ee0-453a-9e6a-1e1a3e4f9c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39cbce9a-4bb8-4eef-adcc-b69182c5f992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39cbce9a-4bb8-4eef-adcc-b69182c5f992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c6a2e6f9-45d2-40c2-8cb2-dc69adb44bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39cbce9a-4bb8-4eef-adcc-b69182c5f992" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c6a2e6f9-45d2-40c2-8cb2-dc69adb44bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d474fe3a-497f-40ec-8a74-c4072780cc81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d474fe3a-497f-40ec-8a74-c4072780cc81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d474fe3a-497f-40ec-8a74-c4072780cc81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d474fe3a-497f-40ec-8a74-c4072780cc81" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d474fe3a-497f-40ec-8a74-c4072780cc81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4e1043fd-5fe8-4f9a-b276-76482bf25367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d474fe3a-497f-40ec-8a74-c4072780cc81" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4e1043fd-5fe8-4f9a-b276-76482bf25367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember_ec5b9242-b702-43c5-966a-9f8584b98166" xlink:href="ibrx-20231231.xsd#ibrx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4e1043fd-5fe8-4f9a-b276-76482bf25367" xlink:to="loc_ibrx_ContingentConsiderationMember_ec5b9242-b702-43c5-966a-9f8584b98166" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_86b39f32-776f-48db-bfed-3e45f5399bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_86b39f32-776f-48db-bfed-3e45f5399bb2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86b39f32-776f-48db-bfed-3e45f5399bb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_86b39f32-776f-48db-bfed-3e45f5399bb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_86b39f32-776f-48db-bfed-3e45f5399bb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3344a4-7d99-4575-a925-970914c66632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_86b39f32-776f-48db-bfed-3e45f5399bb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3344a4-7d99-4575-a925-970914c66632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f81758cf-dda5-447d-9914-8949027efa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3344a4-7d99-4575-a925-970914c66632" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f81758cf-dda5-447d-9914-8949027efa4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ec254ff4-e81d-4460-a8f3-34da1a5e1b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ec254ff4-e81d-4460-a8f3-34da1a5e1b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_04cc5a76-cb17-4df4-b894-5ebf44fe8591" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ec254ff4-e81d-4460-a8f3-34da1a5e1b21" xlink:to="loc_ibrx_PromissoryNotesPayableMember_04cc5a76-cb17-4df4-b894-5ebf44fe8591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2054c9a9-718f-4090-a349-cb5ce95cff67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2054c9a9-718f-4090-a349-cb5ce95cff67" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2054c9a9-718f-4090-a349-cb5ce95cff67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2054c9a9-718f-4090-a349-cb5ce95cff67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2054c9a9-718f-4090-a349-cb5ce95cff67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1289cae4-b267-4f19-ad39-8881c2ee3005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2054c9a9-718f-4090-a349-cb5ce95cff67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1289cae4-b267-4f19-ad39-8881c2ee3005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_5a223486-4196-4d5d-b4a0-d14d0e169ed2" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1289cae4-b267-4f19-ad39-8881c2ee3005" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_5a223486-4196-4d5d-b4a0-d14d0e169ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2227840a-6f80-478c-93db-3846b52b9508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2227840a-6f80-478c-93db-3846b52b9508" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2227840a-6f80-478c-93db-3846b52b9508_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2227840a-6f80-478c-93db-3846b52b9508" xlink:to="loc_us-gaap_RelatedPartyDomain_2227840a-6f80-478c-93db-3846b52b9508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_baff1a5c-65ce-476d-9742-f731c650b6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2227840a-6f80-478c-93db-3846b52b9508" xlink:to="loc_us-gaap_RelatedPartyDomain_baff1a5c-65ce-476d-9742-f731c650b6f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cb6df630-b534-4fbd-a054-f301f2f29675" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_baff1a5c-65ce-476d-9742-f731c650b6f6" xlink:to="loc_srt_AffiliatedEntityMember_cb6df630-b534-4fbd-a054-f301f2f29675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_846bffbe-62df-4547-9766-e4a16d7f28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_846bffbe-62df-4547-9766-e4a16d7f28ac" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_846bffbe-62df-4547-9766-e4a16d7f28ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_846bffbe-62df-4547-9766-e4a16d7f28ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_846bffbe-62df-4547-9766-e4a16d7f28ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07c3716a-c0c3-48ed-822e-22b0d50b52d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_846bffbe-62df-4547-9766-e4a16d7f28ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07c3716a-c0c3-48ed-822e-22b0d50b52d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_00a7e908-9193-408a-b99d-ca15d9eb20ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07c3716a-c0c3-48ed-822e-22b0d50b52d3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_00a7e908-9193-408a-b99d-ca15d9eb20ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f5f0bb3-1402-45d0-a949-6c634580e874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f5f0bb3-1402-45d0-a949-6c634580e874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_56625d12-fbf4-4ff6-b79e-83ad20e4a9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_56625d12-fbf4-4ff6-b79e-83ad20e4a9d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_723496e4-6a74-4d5f-95f5-bcbd2438b799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_723496e4-6a74-4d5f-95f5-bcbd2438b799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fcab38b3-c817-4047-a347-34e3e93d92bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_9ac88178-c42d-4154-a6d1-0f04bbe9e622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_9ac88178-c42d-4154-a6d1-0f04bbe9e622" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d8484da9-0195-46d5-8852-75cb925d9792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d8484da9-0195-46d5-8852-75cb925d9792" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue_04938d7e-5c62-4bac-b139-e60c512e89a6" xlink:href="ibrx-20231231.xsd#ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue_04938d7e-5c62-4bac-b139-e60c512e89a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_bed5d12d-8833-403d-b877-09d662b8b582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_bed5d12d-8833-403d-b877-09d662b8b582" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ed0d8585-d9de-433c-8d7b-3a5e0432018a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ed0d8585-d9de-433c-8d7b-3a5e0432018a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_02e8f481-fc2d-4d07-ad4e-abde80da1db8" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentPrepaymentAndAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_02e8f481-fc2d-4d07-ad4e-abde80da1db8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_ad1a346a-5ab5-4543-aa27-5cbeb0de0849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_ad1a346a-5ab5-4543-aa27-5cbeb0de0849" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_880e3a6e-0a62-4fc1-a508-e1b93ade4705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_880e3a6e-0a62-4fc1-a508-e1b93ade4705" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c6c265dd-c5cd-4b80-9432-7d4e59bd745b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c6c265dd-c5cd-4b80-9432-7d4e59bd745b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7d55af0e-e730-4518-8a93-b0f28f043196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7d55af0e-e730-4518-8a93-b0f28f043196" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3f3d5760-7443-45df-b53c-2ce40c19decb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3f3d5760-7443-45df-b53c-2ce40c19decb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c46d5da8-be31-45e5-8773-947cc9c301d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c46d5da8-be31-45e5-8773-947cc9c301d2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_699b4023-965d-4486-8acd-37f2943791e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_699b4023-965d-4486-8acd-37f2943791e2" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:href="ibrx-20231231.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:href="ibrx-20231231.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_0560dd85-6f69-4415-9807-5f9f2c27acba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_0560dd85-6f69-4415-9807-5f9f2c27acba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_0560dd85-6f69-4415-9807-5f9f2c27acba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_0560dd85-6f69-4415-9807-5f9f2c27acba" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_0560dd85-6f69-4415-9807-5f9f2c27acba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_5dcacba7-2c7a-4e65-967c-84d1bd15d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_0560dd85-6f69-4415-9807-5f9f2c27acba" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_5dcacba7-2c7a-4e65-967c-84d1bd15d4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NationalCancerInstituteMember_2c8e9915-9002-4154-9663-4a05b2fd0691" xlink:href="ibrx-20231231.xsd#ibrx_NationalCancerInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_5dcacba7-2c7a-4e65-967c-84d1bd15d4df" xlink:to="loc_ibrx_NationalCancerInstituteMember_2c8e9915-9002-4154-9663-4a05b2fd0691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_418d7307-f047-44c3-ba66-ba4825b33924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_us-gaap_TypeOfArrangementAxis_418d7307-f047-44c3-ba66-ba4825b33924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_418d7307-f047-44c3-ba66-ba4825b33924_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_418d7307-f047-44c3-ba66-ba4825b33924" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_418d7307-f047-44c3-ba66-ba4825b33924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c312811-cb8e-4e65-910f-0ed411137fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_418d7307-f047-44c3-ba66-ba4825b33924" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c312811-cb8e-4e65-910f-0ed411137fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_06ac1c91-0e84-43ab-9438-290e76f497af" xlink:href="ibrx-20231231.xsd#ibrx_CooperativeResearchAndDevelopmentAgreement2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c312811-cb8e-4e65-910f-0ed411137fd8" xlink:to="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_06ac1c91-0e84-43ab-9438-290e76f497af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember_b57b6dc1-c7bc-47b1-bf5a-0f7c8d86356d" xlink:href="ibrx-20231231.xsd#ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_06ac1c91-0e84-43ab-9438-290e76f497af" xlink:to="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember_b57b6dc1-c7bc-47b1-bf5a-0f7c8d86356d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f73c0ebe-0390-49fe-8478-6b373ec8b344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f73c0ebe-0390-49fe-8478-6b373ec8b344" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f73c0ebe-0390-49fe-8478-6b373ec8b344_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f73c0ebe-0390-49fe-8478-6b373ec8b344" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f73c0ebe-0390-49fe-8478-6b373ec8b344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c3042ed7-28f1-4084-b815-7a9bfc5c4f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f73c0ebe-0390-49fe-8478-6b373ec8b344" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c3042ed7-28f1-4084-b815-7a9bfc5c4f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebddbc2d-ea94-4429-ae2e-e1dd478ad6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3042ed7-28f1-4084-b815-7a9bfc5c4f0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebddbc2d-ea94-4429-ae2e-e1dd478ad6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_09f336ef-bbd2-43a6-b126-dd75f443fb20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_09f336ef-bbd2-43a6-b126-dd75f443fb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisJointVentureMember_5a07e099-bc84-4cba-8621-504fef4d13b4" xlink:href="ibrx-20231231.xsd#ibrx_AmyrisJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09f336ef-bbd2-43a6-b126-dd75f443fb20" xlink:to="loc_ibrx_AmyrisJointVentureMember_5a07e099-bc84-4cba-8621-504fef4d13b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_dei_LegalEntityAxis_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70" xlink:to="loc_dei_EntityDomain_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8d16a3a3-07c8-44c9-aa8d-584c13bb1c93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70" xlink:to="loc_dei_EntityDomain_8d16a3a3-07c8-44c9-aa8d-584c13bb1c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisIncMember_b05b7521-4f49-4758-a152-0ac8de2a674a" xlink:href="ibrx-20231231.xsd#ibrx_AmyrisIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8d16a3a3-07c8-44c9-aa8d-584c13bb1c93" xlink:to="loc_ibrx_AmyrisIncMember_b05b7521-4f49-4758-a152-0ac8de2a674a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_13462e25-0bc9-4c54-b626-cf356e66d070" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_13462e25-0bc9-4c54-b626-cf356e66d070" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualProjectFundingAmount_f9d8fdcd-b89d-4ed7-8859-beea903073af" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualProjectFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_ibrx_CollaborationAgreementsAnnualProjectFundingAmount_f9d8fdcd-b89d-4ed7-8859-beea903073af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities_413cfa97-8172-4768-aaee-5a3030321bf8" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities_413cfa97-8172-4768-aaee-5a3030321bf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_354079dd-a3bb-4755-8236-a8fa77997086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_354079dd-a3bb-4755-8236-a8fa77997086" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8934a659-d6f6-4b1a-8218-b50f50b0a002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8934a659-d6f6-4b1a-8218-b50f50b0a002" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_854a355d-65d0-4ea7-b504-312c2bf5ba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_854a355d-65d0-4ea7-b504-312c2bf5ba5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_90f285a5-0d44-4af3-9171-25f7e75429ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_90f285a5-0d44-4af3-9171-25f7e75429ec" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:href="ibrx-20231231.xsd#ibrx_LicensingAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:href="ibrx-20231231.xsd#ibrx_LicensingAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A3MIPCAndAAHIAgreementMember_596fca9c-475f-406a-90a3-e579e26f562b" xlink:href="ibrx-20231231.xsd#ibrx_A3MIPCAndAAHIAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:to="loc_ibrx_A3MIPCAndAAHIAgreementMember_596fca9c-475f-406a-90a3-e579e26f562b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AAHIMember_4b15855c-dca8-41fc-9fe8-f37a94faf043" xlink:href="ibrx-20231231.xsd#ibrx_AAHIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:to="loc_ibrx_AAHIMember_4b15855c-dca8-41fc-9fe8-f37a94faf043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ViractaMember_c3423bb9-4dc5-4d71-b133-59ea1b7ff199" xlink:href="ibrx-20231231.xsd#ibrx_ViractaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:to="loc_ibrx_ViractaMember_c3423bb9-4dc5-4d71-b133-59ea1b7ff199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_943d371b-760f-425b-8c6e-ae49de9c9e60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_943d371b-760f-425b-8c6e-ae49de9c9e60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_943d371b-760f-425b-8c6e-ae49de9c9e60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_943d371b-760f-425b-8c6e-ae49de9c9e60" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_943d371b-760f-425b-8c6e-ae49de9c9e60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_943d371b-760f-425b-8c6e-ae49de9c9e60" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_74863a73-43c8-4ef1-bda5-d427060f9866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_74863a73-43c8-4ef1-bda5-d427060f9866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SponsoredResearchAgreementMember_9f6efdc5-81dc-46cf-a2ad-130071280827" xlink:href="ibrx-20231231.xsd#ibrx_SponsoredResearchAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:to="loc_ibrx_SponsoredResearchAgreementMember_9f6efdc5-81dc-46cf-a2ad-130071280827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicenseAgreementMember_4969dff4-81ac-4f09-aff1-4b1801686f01" xlink:href="ibrx-20231231.xsd#ibrx_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:to="loc_ibrx_LicenseAgreementMember_4969dff4-81ac-4f09-aff1-4b1801686f01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_srt_RangeAxis_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa" xlink:to="loc_srt_RangeMember_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa" xlink:to="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bc81c1c-8a40-4b14-be85-76e2c6af5e08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:to="loc_srt_MinimumMember_7bc81c1c-8a40-4b14-be85-76e2c6af5e08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da07088f-1d49-47b4-aace-3daa9157b1ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:to="loc_srt_MaximumMember_da07088f-1d49-47b4-aace-3daa9157b1ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_1f0c235d-7c92-4a03-a56b-f843b93617e9" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_1f0c235d-7c92-4a03-a56b-f843b93617e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_1f0c235d-7c92-4a03-a56b-f843b93617e9_default" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_1f0c235d-7c92-4a03-a56b-f843b93617e9" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_1f0c235d-7c92-4a03-a56b-f843b93617e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_1f0c235d-7c92-4a03-a56b-f843b93617e9" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_66861e89-c569-427d-94b2-beed02cb5836" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_66861e89-c569-427d-94b2-beed02cb5836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_b2af0e8c-3d53-4726-bc84-d8b78c3567fe" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_b2af0e8c-3d53-4726-bc84-d8b78c3567fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_b7df4e2a-bd3e-4c7a-86f1-b3a3ce2ae8cb" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsPeriodicLicensePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_b7df4e2a-bd3e-4c7a-86f1-b3a3ce2ae8cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_f8e36f6d-61a1-421e-bcd1-d414283ce200" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_f8e36f6d-61a1-421e-bcd1-d414283ce200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_56760ac8-cbec-49f1-b167-1d18bdff0c08" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_56760ac8-cbec-49f1-b167-1d18bdff0c08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_66bed66c-afd8-4d81-a217-6a92407c7489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_66bed66c-afd8-4d81-a217-6a92407c7489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNumberOfLicenseAgreements_e8c6f65b-7f31-4544-901c-c0a866b94752" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsNumberOfLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsNumberOfLicenseAgreements_e8c6f65b-7f31-4544-901c-c0a866b94752" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_a48afc40-aa02-48cf-b773-6cfe92bdc1aa" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsNonrefundableUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_a48afc40-aa02-48cf-b773-6cfe92bdc1aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_47804c8f-f617-46a2-b6a2-b81b95f2505b" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_47804c8f-f617-46a2-b6a2-b81b95f2505b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestoneFees_c6dc4a66-f600-4306-aeca-fafb6952a1be" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestoneFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsMilestoneFees_c6dc4a66-f600-4306-aeca-fafb6952a1be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsTerminationFee_786b7a81-169b-4fcc-b471-67a36d87d7e5" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsTerminationFee_786b7a81-169b-4fcc-b471-67a36d87d7e5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable_d14953ce-8c5a-4c47-bbaa-c1bcfbb46ffe" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable_d14953ce-8c5a-4c47-bbaa-c1bcfbb46ffe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_1d9801be-e88e-4e5e-853a-27cb2531c7ba" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_1d9801be-e88e-4e5e-853a-27cb2531c7ba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f0542f8-4cb2-43a5-9fbd-a6ee6f8d3ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f0542f8-4cb2-43a5-9fbd-a6ee6f8d3ea7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_44d13aa9-bb50-4dea-b8f2-edd0296e3e25" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_44d13aa9-bb50-4dea-b8f2-edd0296e3e25" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_293add47-1ab7-4d41-a179-a805927307a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:to="loc_us-gaap_AssetAcquisitionAxis_293add47-1ab7-4d41-a179-a805927307a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_293add47-1ab7-4d41-a179-a805927307a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_293add47-1ab7-4d41-a179-a805927307a7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_293add47-1ab7-4d41-a179-a805927307a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e4dfead6-ffc8-4cb6-8328-889519fe62ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_293add47-1ab7-4d41-a179-a805927307a7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e4dfead6-ffc8-4cb6-8328-889519fe62ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_00be56a5-ba53-4a5e-bdbb-188a7f5c74c4" xlink:href="ibrx-20231231.xsd#ibrx_DunkirkFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e4dfead6-ffc8-4cb6-8328-889519fe62ef" xlink:to="loc_ibrx_DunkirkFacilityMember_00be56a5-ba53-4a5e-bdbb-188a7f5c74c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d48d5042-3671-4b90-848d-27ffe90ea7e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:to="loc_srt_CounterpartyNameAxis_d48d5042-3671-4b90-848d-27ffe90ea7e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d48d5042-3671-4b90-848d-27ffe90ea7e1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d48d5042-3671-4b90-848d-27ffe90ea7e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d48d5042-3671-4b90-848d-27ffe90ea7e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c1cc837-d2ed-4ae4-bb2f-bc9326b662e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d48d5042-3671-4b90-848d-27ffe90ea7e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c1cc837-d2ed-4ae4-bb2f-bc9326b662e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StateOfNewYorkMember_fdd82a25-630a-40dc-ba62-ebd8bc80f75b" xlink:href="ibrx-20231231.xsd#ibrx_StateOfNewYorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c1cc837-d2ed-4ae4-bb2f-bc9326b662e8" xlink:to="loc_ibrx_StateOfNewYorkMember_fdd82a25-630a-40dc-ba62-ebd8bc80f75b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b73136b8-af13-4ab9-8f06-4da27e9a448e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:to="loc_srt_RangeAxis_b73136b8-af13-4ab9-8f06-4da27e9a448e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b73136b8-af13-4ab9-8f06-4da27e9a448e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b73136b8-af13-4ab9-8f06-4da27e9a448e" xlink:to="loc_srt_RangeMember_b73136b8-af13-4ab9-8f06-4da27e9a448e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b73136b8-af13-4ab9-8f06-4da27e9a448e" xlink:to="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_421360bc-991a-4f26-8e53-c93fed00e583" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:to="loc_srt_MinimumMember_421360bc-991a-4f26-8e53-c93fed00e583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89ce5b20-de6f-47ff-a800-64f7965ac653" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:to="loc_srt_MaximumMember_89ce5b20-de6f-47ff-a800-64f7965ac653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_53891ddd-09bb-41f9-9e96-fecf7f51fece" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFeetOfFacilityLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_53891ddd-09bb-41f9-9e96-fecf7f51fece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_f847de23-e528-4182-959f-d9a51ad8f952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_f847de23-e528-4182-959f-d9a51ad8f952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_51508dc4-4df9-436b-9880-0ff44d1e0283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_51508dc4-4df9-436b-9880-0ff44d1e0283" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_3aae7b7d-0ec5-439f-b4ee-ced12f81865c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_3aae7b7d-0ec5-439f-b4ee-ced12f81865c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_6882f730-678e-4d1a-a07e-884e53ee68fc" xlink:href="ibrx-20231231.xsd#ibrx_LeaseOperatingLeaseAnnualLeasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_6882f730-678e-4d1a-a07e-884e53ee68fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cb36a00-c312-4b55-89b8-0a24ef67f349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cb36a00-c312-4b55-89b8-0a24ef67f349" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions_a41a6885-5394-4525-8fcc-f9a6a582c168" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions_a41a6885-5394-4525-8fcc-f9a6a582c168" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b17f055d-9d22-4efc-b5a3-bfd45889d860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b17f055d-9d22-4efc-b5a3-bfd45889d860" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_b282ad3c-d32e-4a47-8e5b-ba68ff7bbe64" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_b282ad3c-d32e-4a47-8e5b-ba68ff7bbe64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_ca75a459-72f5-41ba-8776-2b1747c7b320" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_ca75a459-72f5-41ba-8776-2b1747c7b320" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_db397731-472d-4357-b6c0-0196433abc1c" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_db397731-472d-4357-b6c0-0196433abc1c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_41d7ea77-09a6-4ca4-a071-40dad388de28" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_41d7ea77-09a6-4ca4-a071-40dad388de28" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestGovernmentFundingAvailable_54830af5-0b8b-48c6-86d3-af8a23a580b9" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestGovernmentFundingAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestGovernmentFundingAvailable_54830af5-0b8b-48c6-86d3-af8a23a580b9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d47ee854-8f43-46fc-b8a0-fd4704f83cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_RestructuringCharges_d47ee854-8f43-46fc-b8a0-fd4704f83cab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_63462a03-7209-4be3-8608-36d91ceedefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_63462a03-7209-4be3-8608-36d91ceedefc" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_103bf308-97fb-4c9f-9f2b-8f95263ff3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_103bf308-97fb-4c9f-9f2b-8f95263ff3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_103bf308-97fb-4c9f-9f2b-8f95263ff3dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_103bf308-97fb-4c9f-9f2b-8f95263ff3dd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_103bf308-97fb-4c9f-9f2b-8f95263ff3dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ffb34095-a3c8-4e95-8249-3469325dcf90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_103bf308-97fb-4c9f-9f2b-8f95263ff3dd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ffb34095-a3c8-4e95-8249-3469325dcf90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_446dce84-807b-4e04-87ce-8b268f92b5d1" xlink:href="ibrx-20231231.xsd#ibrx_DunkirkFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ffb34095-a3c8-4e95-8249-3469325dcf90" xlink:to="loc_ibrx_DunkirkFacilityMember_446dce84-807b-4e04-87ce-8b268f92b5d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_731fcb61-add9-4d9b-a42c-b68b2d94e2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_731fcb61-add9-4d9b-a42c-b68b2d94e2ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_1a23c6a7-6ef2-4bff-88c9-5177a421fb83" xlink:href="ibrx-20231231.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:to="loc_ibrx_OrganizedWorkforceMember_1a23c6a7-6ef2-4bff-88c9-5177a421fb83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_46322a86-9482-49dd-ae45-e027bfcf1b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_ConstructionInProgressGross_46322a86-9482-49dd-ae45-e027bfcf1b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_727ef976-3e96-426b-ac88-5400a4eb7178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_727ef976-3e96-426b-ac88-5400a4eb7178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_355da6f8-1e40-4192-90d7-4c7d3cf7a44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_355da6f8-1e40-4192-90d7-4c7d3cf7a44e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_a0482ce8-ba94-426c-8b9d-d9f539f6dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_a0482ce8-ba94-426c-8b9d-d9f539f6dfa5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_99e4811a-a6bf-46b4-9f60-a704821d9ee5" xlink:href="ibrx-20231231.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_99e4811a-a6bf-46b4-9f60-a704821d9ee5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1c5b473b-4652-4dde-a38f-a24305075698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1c5b473b-4652-4dde-a38f-a24305075698" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_64185063-98ba-4f4d-ac23-e992e765df3c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_dei_LegalEntityAxis_64185063-98ba-4f4d-ac23-e992e765df3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_64185063-98ba-4f4d-ac23-e992e765df3c_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_64185063-98ba-4f4d-ac23-e992e765df3c" xlink:to="loc_dei_EntityDomain_64185063-98ba-4f4d-ac23-e992e765df3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c61077b2-225d-43b8-8df5-bf85b21d2bc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_64185063-98ba-4f4d-ac23-e992e765df3c" xlink:to="loc_dei_EntityDomain_c61077b2-225d-43b8-8df5-bf85b21d2bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VivaBioCellMember_35e96ef8-77cb-4e63-b9a6-79a403e2d78c" xlink:href="ibrx-20231231.xsd#ibrx_VivaBioCellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c61077b2-225d-43b8-8df5-bf85b21d2bc8" xlink:to="loc_ibrx_VivaBioCellMember_35e96ef8-77cb-4e63-b9a6-79a403e2d78c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9c57757a-fbcf-4d7e-b936-2c18afad5168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9c57757a-fbcf-4d7e-b936-2c18afad5168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c57757a-fbcf-4d7e-b936-2c18afad5168_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c57757a-fbcf-4d7e-b936-2c18afad5168" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9c57757a-fbcf-4d7e-b936-2c18afad5168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d28a84b5-b14a-4e4a-98d0-1ec2f66ba746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c57757a-fbcf-4d7e-b936-2c18afad5168" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d28a84b5-b14a-4e4a-98d0-1ec2f66ba746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember_c6d5bc02-951b-4a73-878a-a1b35dffd765" xlink:href="ibrx-20231231.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d28a84b5-b14a-4e4a-98d0-1ec2f66ba746" xlink:to="loc_ibrx_AltorBioScienceLLCMember_c6d5bc02-951b-4a73-878a-a1b35dffd765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09049093-770b-4eba-995b-23f148f02e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09049093-770b-4eba-995b-23f148f02e1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_09049093-770b-4eba-995b-23f148f02e1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09049093-770b-4eba-995b-23f148f02e1e" xlink:to="loc_us-gaap_RelatedPartyDomain_09049093-770b-4eba-995b-23f148f02e1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09049093-770b-4eba-995b-23f148f02e1e" xlink:to="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DrSoonShiongAndRelatedPartyMember_64fb4b73-599b-4043-8c81-28d3cbd8a6e4" xlink:href="ibrx-20231231.xsd#ibrx_DrSoonShiongAndRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:to="loc_ibrx_DrSoonShiongAndRelatedPartyMember_64fb4b73-599b-4043-8c81-28d3cbd8a6e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorStockholdersMember_8fe5e9a7-c8c6-43f9-b7cb-da1df131b515" xlink:href="ibrx-20231231.xsd#ibrx_AltorStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:to="loc_ibrx_AltorStockholdersMember_8fe5e9a7-c8c6-43f9-b7cb-da1df131b515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_649855e8-41a3-4534-b54a-19f3331b47f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_649855e8-41a3-4534-b54a-19f3331b47f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_649855e8-41a3-4534-b54a-19f3331b47f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_649855e8-41a3-4534-b54a-19f3331b47f4" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_649855e8-41a3-4534-b54a-19f3331b47f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_fb088bad-ff16-4565-b069-4b27a98340bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_649855e8-41a3-4534-b54a-19f3331b47f4" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_fb088bad-ff16-4565-b069-4b27a98340bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_75b4a383-c2c4-4f49-9e32-8065a7c34cbc" xlink:href="ibrx-20231231.xsd#ibrx_ContingentValueRightsObligationSalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_fb088bad-ff16-4565-b069-4b27a98340bd" xlink:to="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_75b4a383-c2c4-4f49-9e32-8065a7c34cbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_fba88ec4-a1c2-4dc0-a980-62df393cbbda" xlink:href="ibrx-20231231.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_fba88ec4-a1c2-4dc0-a980-62df393cbbda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e2c3ff2a-0a97-4da2-86cd-a2a89f71a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e2c3ff2a-0a97-4da2-86cd-a2a89f71a48d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_ae909009-044b-43bf-bd64-281065c0417a" xlink:href="ibrx-20231231.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_ae909009-044b-43bf-bd64-281065c0417a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_7c1d9aa0-a35f-4d8e-9e47-e36aaaca73c4" xlink:href="ibrx-20231231.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_7c1d9aa0-a35f-4d8e-9e47-e36aaaca73c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_8fcc7658-89f0-47f9-9bae-27eaaab8718c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_8fcc7658-89f0-47f9-9bae-27eaaab8718c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligations_a5c1d4af-5b44-4432-a20c-ec46075f09ab" xlink:href="ibrx-20231231.xsd#ibrx_ContingentValueRightsObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_ContingentValueRightsObligations_a5c1d4af-5b44-4432-a20c-ec46075f09ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_a28040cd-4510-4300-95d8-c9b8d5c6981b" xlink:href="ibrx-20231231.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_a28040cd-4510-4300-95d8-c9b8d5c6981b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CommitmentsandContingenciesLitigationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:href="ibrx-20231231.xsd#ibrx_LitigationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:href="ibrx-20231231.xsd#ibrx_LitigationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4559428-8d68-4655-887e-86af27026523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4559428-8d68-4655-887e-86af27026523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember_5435cb3e-d72c-4436-9214-a0ded68aa980" xlink:href="ibrx-20231231.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4559428-8d68-4655-887e-86af27026523" xlink:to="loc_ibrx_AltorBioScienceLLCMember_5435cb3e-d72c-4436-9214-a0ded68aa980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_44582f36-ed47-411f-8543-729d4feff8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_44582f36-ed47-411f-8543-729d4feff8a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44582f36-ed47-411f-8543-729d4feff8a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44582f36-ed47-411f-8543-729d4feff8a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44582f36-ed47-411f-8543-729d4feff8a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12205356-e9c3-4704-986c-abfe11359aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44582f36-ed47-411f-8543-729d4feff8a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12205356-e9c3-4704-986c-abfe11359aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_2bd00846-4132-4a29-9c2b-f5debab478f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12205356-e9c3-4704-986c-abfe11359aac" xlink:to="loc_us-gaap_PrivatePlacementMember_2bd00846-4132-4a29-9c2b-f5debab478f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_srt_LitigationCaseAxis_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f" xlink:to="loc_srt_LitigationCaseTypeDomain_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dcbd6c64-ea3d-4cc3-b0f4-90294b2dd18c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f" xlink:to="loc_srt_LitigationCaseTypeDomain_dcbd6c64-ea3d-4cc3-b0f4-90294b2dd18c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_3fa043ca-e1dc-471b-9873-3224a141cd50" xlink:href="ibrx-20231231.xsd#ibrx_SorrentoTherapeuticsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_dcbd6c64-ea3d-4cc3-b0f4-90294b2dd18c" xlink:to="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_3fa043ca-e1dc-471b-9873-3224a141cd50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c00e7147-e675-4c73-9ae2-d2ee7d826456" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c00e7147-e675-4c73-9ae2-d2ee7d826456" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c00e7147-e675-4c73-9ae2-d2ee7d826456_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c00e7147-e675-4c73-9ae2-d2ee7d826456" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c00e7147-e675-4c73-9ae2-d2ee7d826456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c00e7147-e675-4c73-9ae2-d2ee7d826456" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_aa187f20-0462-4760-997c-0edf1620a9de" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:to="loc_ibrx_NantCellInc.Member_aa187f20-0462-4760-997c-0edf1620a9de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_1d3cedbc-1599-4045-b7ee-cb6f424101ad" xlink:href="ibrx-20231231.xsd#ibrx_NANTibodyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:to="loc_ibrx_NANTibodyLLCMember_1d3cedbc-1599-4045-b7ee-cb6f424101ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ffa97845-6249-4d7e-bcea-af70739bd056" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_srt_OwnershipAxis_ffa97845-6249-4d7e-bcea-af70739bd056" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ffa97845-6249-4d7e-bcea-af70739bd056_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_ffa97845-6249-4d7e-bcea-af70739bd056" xlink:to="loc_srt_OwnershipDomain_ffa97845-6249-4d7e-bcea-af70739bd056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ed4c0139-9db3-4178-92bb-194785a97406" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_ffa97845-6249-4d7e-bcea-af70739bd056" xlink:to="loc_srt_OwnershipDomain_ed4c0139-9db3-4178-92bb-194785a97406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_2abce382-5d98-4f17-b199-c29fa74f6fd6" xlink:href="ibrx-20231231.xsd#ibrx_NANTibodyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ed4c0139-9db3-4178-92bb-194785a97406" xlink:to="loc_ibrx_NANTibodyLLCMember_2abce382-5d98-4f17-b199-c29fa74f6fd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfDissentingShares_2712d1cf-60fa-4fb6-8dd0-1bdc4623a0a0" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfDissentingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_NumberOfDissentingShares_2712d1cf-60fa-4fb6-8dd0-1bdc4623a0a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_0949741c-8dea-4a2b-bec6-df2c4e40dff0" xlink:href="ibrx-20231231.xsd#ibrx_LitigationSettlementNumberOfSharesToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_0949741c-8dea-4a2b-bec6-df2c4e40dff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_0e6c3bd9-3463-4210-89ca-cc529cb97fd8" xlink:href="ibrx-20231231.xsd#ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_0e6c3bd9-3463-4210-89ca-cc529cb97fd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_2ba67055-0a7c-4863-b6a1-b67b519237dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_SharesIssued_2ba67055-0a7c-4863-b6a1-b67b519237dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_e6ed3f5d-d3bb-408a-a87c-06c6171348f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_e6ed3f5d-d3bb-408a-a87c-06c6171348f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_4e31e322-1aaa-4f2b-bc50-b9ea18b8f270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_LitigationReserve_4e31e322-1aaa-4f2b-bc50-b9ea18b8f270" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_f411352b-c29e-46f6-96b1-d9bb1d39ba71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_f411352b-c29e-46f6-96b1-d9bb1d39ba71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_5daabbac-d194-4f7c-a6ca-6b5e702ffc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_5daabbac-d194-4f7c-a6ca-6b5e702ffc3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementInterestPercent_051795ea-74a5-4d0a-a0ad-b0512626a826" xlink:href="ibrx-20231231.xsd#ibrx_LitigationSettlementInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_LitigationSettlementInterestPercent_051795ea-74a5-4d0a-a0ad-b0512626a826" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_04e938eb-aa43-4033-9eb0-a4ae79a17f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_04e938eb-aa43-4033-9eb0-a4ae79a17f38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2ed91c2b-e59f-443c-87de-8162e25f08fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_MinorityInterest_2ed91c2b-e59f-443c-87de-8162e25f08fd" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_80808d1a-00ad-45df-9f30-207ead34943b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_80808d1a-00ad-45df-9f30-207ead34943b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_a6902b3d-c7dd-4edb-bfbe-404705a16c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_80808d1a-00ad-45df-9f30-207ead34943b" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_a6902b3d-c7dd-4edb-bfbe-404705a16c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_a6902b3d-c7dd-4edb-bfbe-404705a16c56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_a6902b3d-c7dd-4edb-bfbe-404705a16c56" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_a6902b3d-c7dd-4edb-bfbe-404705a16c56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_a6902b3d-c7dd-4edb-bfbe-404705a16c56" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CGMPBatchesMember_713de1f1-e3be-4bcd-9c35-163851bf263b" xlink:href="ibrx-20231231.xsd#ibrx_CGMPBatchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:to="loc_ibrx_CGMPBatchesMember_713de1f1-e3be-4bcd-9c35-163851bf263b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember_2c093a83-c6cf-4983-8ef1-dabd41359be6" xlink:href="ibrx-20231231.xsd#ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:to="loc_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember_2c093a83-c6cf-4983-8ef1-dabd41359be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LaboratoryCleanroomServiceCostsMember_b206cf5a-a9c4-42dc-9c11-73b41fa860bf" xlink:href="ibrx-20231231.xsd#ibrx_LaboratoryCleanroomServiceCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:to="loc_ibrx_LaboratoryCleanroomServiceCostsMember_b206cf5a-a9c4-42dc-9c11-73b41fa860bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6699aad8-0b0a-43cb-81c8-b04cd4b84b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6699aad8-0b0a-43cb-81c8-b04cd4b84b99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_e10bab2e-e808-4e58-a897-c384705fe5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_e10bab2e-e808-4e58-a897-c384705fe5b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_6cd5f35f-4e85-43a4-8e2d-9c85e484e16e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_6cd5f35f-4e85-43a4-8e2d-9c85e484e16e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_bd023147-1f1e-4204-89ab-1d9668b834ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligation_bd023147-1f1e-4204-89ab-1d9668b834ac" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_912baf6a-60cb-475c-b236-388ebed155c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_912baf6a-60cb-475c-b236-388ebed155c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97db1652-0ec9-49c4-8742-bb657c28536c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_912baf6a-60cb-475c-b236-388ebed155c5" xlink:to="loc_srt_RangeAxis_97db1652-0ec9-49c4-8742-bb657c28536c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97db1652-0ec9-49c4-8742-bb657c28536c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_97db1652-0ec9-49c4-8742-bb657c28536c" xlink:to="loc_srt_RangeMember_97db1652-0ec9-49c4-8742-bb657c28536c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_97db1652-0ec9-49c4-8742-bb657c28536c" xlink:to="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60cdfd6e-943c-4a1f-9ae2-9a5465064038" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:to="loc_srt_MinimumMember_60cdfd6e-943c-4a1f-9ae2-9a5465064038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f0a9ff6-aad2-4203-a7d4-a1ffe105e299" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:to="loc_srt_MaximumMember_5f0a9ff6-aad2-4203-a7d4-a1ffe105e299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61659863-25c6-4c9b-9e28-c3a62f55ac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61659863-25c6-4c9b-9e28-c3a62f55ac5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_22a31a5c-5999-4fff-b674-2095737c8630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_22a31a5c-5999-4fff-b674-2095737c8630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_0084e2fa-ced3-48c5-a52a-660a995b55cd" xlink:href="ibrx-20231231.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:to="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_0084e2fa-ced3-48c5-a52a-660a995b55cd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RevenueInterestPurchaseAgreementAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TieredPaymentsAxis_38a876e9-91ab-4483-8beb-c17556e6c052" xlink:href="ibrx-20231231.xsd#ibrx_TieredPaymentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_ibrx_TieredPaymentsAxis_38a876e9-91ab-4483-8beb-c17556e6c052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TieredPaymentsDomain_38a876e9-91ab-4483-8beb-c17556e6c052_default" xlink:href="ibrx-20231231.xsd#ibrx_TieredPaymentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ibrx_TieredPaymentsAxis_38a876e9-91ab-4483-8beb-c17556e6c052" xlink:to="loc_ibrx_TieredPaymentsDomain_38a876e9-91ab-4483-8beb-c17556e6c052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:href="ibrx-20231231.xsd#ibrx_TieredPaymentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ibrx_TieredPaymentsAxis_38a876e9-91ab-4483-8beb-c17556e6c052" xlink:to="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPaymentMember_c32316d6-97c3-4d4e-b8d5-f583610e97ef" xlink:href="ibrx-20231231.xsd#ibrx_InitialPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:to="loc_ibrx_InitialPaymentMember_c32316d6-97c3-4d4e-b8d5-f583610e97ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecondPaymentMember_a3ed15a4-4c7c-4c9e-91b6-21b39fc65b76" xlink:href="ibrx-20231231.xsd#ibrx_SecondPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:to="loc_ibrx_SecondPaymentMember_a3ed15a4-4c7c-4c9e-91b6-21b39fc65b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d946992e-1f81-490c-bf8d-d732357b2c0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_srt_RangeAxis_d946992e-1f81-490c-bf8d-d732357b2c0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d946992e-1f81-490c-bf8d-d732357b2c0f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d946992e-1f81-490c-bf8d-d732357b2c0f" xlink:to="loc_srt_RangeMember_d946992e-1f81-490c-bf8d-d732357b2c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d946992e-1f81-490c-bf8d-d732357b2c0f" xlink:to="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4e7e1898-4be3-44ef-8c5a-9ed67de2eca7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:to="loc_srt_MinimumMember_4e7e1898-4be3-44ef-8c5a-9ed67de2eca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_649d97bc-21f1-4505-ad2b-ca98012a6055" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:to="loc_srt_MaximumMember_649d97bc-21f1-4505-ad2b-ca98012a6055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_80612a63-520c-4c73-a1ce-36ca2fd671c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_80612a63-520c-4c73-a1ce-36ca2fd671c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_80612a63-520c-4c73-a1ce-36ca2fd671c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_80612a63-520c-4c73-a1ce-36ca2fd671c9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_80612a63-520c-4c73-a1ce-36ca2fd671c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72b1007a-8874-4998-9704-e5b774a97cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_80612a63-520c-4c73-a1ce-36ca2fd671c9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72b1007a-8874-4998-9704-e5b774a97cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_68f2c46b-46a0-4fbf-b2bd-54c20fc7ca1c" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72b1007a-8874-4998-9704-e5b774a97cb5" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_68f2c46b-46a0-4fbf-b2bd-54c20fc7ca1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_154bad0d-14b8-4d17-8713-cbca1c13ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_154bad0d-14b8-4d17-8713-cbca1c13ce9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_154bad0d-14b8-4d17-8713-cbca1c13ce9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_154bad0d-14b8-4d17-8713-cbca1c13ce9f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_154bad0d-14b8-4d17-8713-cbca1c13ce9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccf3cf67-f046-4eb1-bd8b-10dc440dcac0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_154bad0d-14b8-4d17-8713-cbca1c13ce9f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccf3cf67-f046-4eb1-bd8b-10dc440dcac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_cbb97fe5-79b3-4d64-b377-6b279988ba3c" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccf3cf67-f046-4eb1-bd8b-10dc440dcac0" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_cbb97fe5-79b3-4d64-b377-6b279988ba3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b1f315e6-ac03-4949-acaf-554e7344bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b1f315e6-ac03-4949-acaf-554e7344bedd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b1f315e6-ac03-4949-acaf-554e7344bedd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b1f315e6-ac03-4949-acaf-554e7344bedd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b1f315e6-ac03-4949-acaf-554e7344bedd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99c10abc-9340-46fb-8c31-d9789ea4af81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b1f315e6-ac03-4949-acaf-554e7344bedd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99c10abc-9340-46fb-8c31-d9789ea4af81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_3fda054c-3165-44e1-b4b0-bdd4de176830" xlink:href="ibrx-20231231.xsd#ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99c10abc-9340-46fb-8c31-d9789ea4af81" xlink:to="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_3fda054c-3165-44e1-b4b0-bdd4de176830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionPeriodAxis_524e1136-95e3-4b1a-9b2a-c4875457de97" xlink:href="ibrx-20231231.xsd#ibrx_OptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_ibrx_OptionPeriodAxis_524e1136-95e3-4b1a-9b2a-c4875457de97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionPeriodDomain_524e1136-95e3-4b1a-9b2a-c4875457de97_default" xlink:href="ibrx-20231231.xsd#ibrx_OptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ibrx_OptionPeriodAxis_524e1136-95e3-4b1a-9b2a-c4875457de97" xlink:to="loc_ibrx_OptionPeriodDomain_524e1136-95e3-4b1a-9b2a-c4875457de97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:href="ibrx-20231231.xsd#ibrx_OptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ibrx_OptionPeriodAxis_524e1136-95e3-4b1a-9b2a-c4875457de97" xlink:to="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOneMember_31014b5e-666e-47b1-a20f-170b40cf0a49" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodOneMember_31014b5e-666e-47b1-a20f-170b40cf0a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodTwoMember_e79850c9-cdb4-4f0c-b66e-779f5a863cc9" xlink:href="ibrx-20231231.xsd#ibrx_PeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodTwoMember_e79850c9-cdb4-4f0c-b66e-779f5a863cc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodThreeMember_382dcafe-a00a-4af8-ad0e-83c887d96874" xlink:href="ibrx-20231231.xsd#ibrx_PeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodThreeMember_382dcafe-a00a-4af8-ad0e-83c887d96874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodFourMember_f0d362bd-267b-493b-8c45-9af5c19b278c" xlink:href="ibrx-20231231.xsd#ibrx_PeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodFourMember_f0d362bd-267b-493b-8c45-9af5c19b278c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_aa141af7-0789-4bfa-a27a-d3c900dc2cac" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementTotalInvestmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_aa141af7-0789-4bfa-a27a-d3c900dc2cac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_ed0f8c62-3449-4aab-9f4b-062fe9e46496" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_ed0f8c62-3449-4aab-9f4b-062fe9e46496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales_a945de1e-734d-4c04-887d-f6667e49f011" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales_a945de1e-734d-4c04-887d-f6667e49f011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage_652044b7-fe38-4fa0-b841-d8a86a321d10" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage_652044b7-fe38-4fa0-b841-d8a86a321d10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage_6efd0af2-7da8-4c92-a89f-11960371e9e5" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage_6efd0af2-7da8-4c92-a89f-11960371e9e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice_b3032c17-40c5-4f23-923f-fa79c77063dc" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice_b3032c17-40c5-4f23-923f-fa79c77063dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_309b2f7b-6c67-48fb-990a-bc5c806d7ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_309b2f7b-6c67-48fb-990a-bc5c806d7ff0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2911d328-4cfb-4fc5-94e5-23e9cc24c0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2911d328-4cfb-4fc5-94e5-23e9cc24c0ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAdditionalPurchaseOption_f3acb0af-9530-4381-9bee-83e40d013dad" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_SaleOfStockAdditionalPurchaseOption_f3acb0af-9530-4381-9bee-83e40d013dad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction_05682b8c-525f-44e8-8e8d-8f7ac1af1f64" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction_05682b8c-525f-44e8-8e8d-8f7ac1af1f64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0e0f6809-4f21-4f95-8a94-937f6953f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0e0f6809-4f21-4f95-8a94-937f6953f0b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_4ed8061b-ae70-42ef-b9dc-a664e64d38df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_SecuredLongTermDebt_4ed8061b-ae70-42ef-b9dc-a664e64d38df" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b8d57434-e3ca-4892-9a22-783a94fc9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_InterestExpense_b8d57434-e3ca-4892-9a22-783a94fc9b56" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_10f5bef2-ea2b-4cd8-8f87-377563d9b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_10f5bef2-ea2b-4cd8-8f87-377563d9b9fc" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_46b850a9-b827-42b8-94da-5c2d59d1bafd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:to="loc_us-gaap_DebtInstrumentAxis_46b850a9-b827-42b8-94da-5c2d59d1bafd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_46b850a9-b827-42b8-94da-5c2d59d1bafd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_46b850a9-b827-42b8-94da-5c2d59d1bafd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_46b850a9-b827-42b8-94da-5c2d59d1bafd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa9a8ac2-613a-414a-94b2-1b24a689d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_46b850a9-b827-42b8-94da-5c2d59d1bafd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa9a8ac2-613a-414a-94b2-1b24a689d02b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_f5c2bc1e-175f-405e-9f24-d437e146ae03" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9a8ac2-613a-414a-94b2-1b24a689d02b" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_f5c2bc1e-175f-405e-9f24-d437e146ae03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_985e712a-f296-4f14-83f0-29f22a2f1652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_985e712a-f296-4f14-83f0-29f22a2f1652" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_985e712a-f296-4f14-83f0-29f22a2f1652_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_985e712a-f296-4f14-83f0-29f22a2f1652" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_985e712a-f296-4f14-83f0-29f22a2f1652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_985e712a-f296-4f14-83f0-29f22a2f1652" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember_c8f57d5d-a4af-4805-8b22-6591f6ebf6f9" xlink:href="ibrx-20231231.xsd#ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:to="loc_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember_c8f57d5d-a4af-4805-8b22-6591f6ebf6f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockRevenueInterestPurchaseAgreementMember_fd39df88-a256-49c0-ab50-fc4218d9c848" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockRevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:to="loc_ibrx_CommonStockRevenueInterestPurchaseAgreementMember_fd39df88-a256-49c0-ab50-fc4218d9c848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_e1ca2260-8628-4c6a-803a-b910e0287f62" xlink:href="ibrx-20231231.xsd#ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:to="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_e1ca2260-8628-4c6a-803a-b910e0287f62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c1d4370-0bc4-4e31-a2a4-43100111870d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_LongTermDebt_4c1d4370-0bc4-4e31-a2a4-43100111870d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_f3800076-b08c-4967-b2b1-3e288296cb94" xlink:href="ibrx-20231231.xsd#ibrx_ProceedsFromIssuanceOfSecuredDebtGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_f3800076-b08c-4967-b2b1-3e288296cb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a5ced560-3992-414c-9e39-717a651b0886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a5ced560-3992-414c-9e39-717a651b0886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a39f60da-f0af-4d20-bcca-f4ecd2087bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a39f60da-f0af-4d20-bcca-f4ecd2087bc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod_806b8193-3921-44f7-84d4-10b110e79ac0" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod_806b8193-3921-44f7-84d4-10b110e79ac0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_e9675f6b-eab7-42e5-8604-1b7ce6eec6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_InterestExpenseDebt_e9675f6b-eab7-42e5-8604-1b7ce6eec6c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_59bc4072-3b3c-4ce2-b3c4-34d684a5ebbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ca4d4f52-a39e-460b-a755-cd67309db98e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ca4d4f52-a39e-460b-a755-cd67309db98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ca4d4f52-a39e-460b-a755-cd67309db98e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca4d4f52-a39e-460b-a755-cd67309db98e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ca4d4f52-a39e-460b-a755-cd67309db98e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca4d4f52-a39e-460b-a755-cd67309db98e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_dac296e1-acd9-49ae-bf92-3e214595ded5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_dac296e1-acd9-49ae-bf92-3e214595ded5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_6d0a0054-bebf-4114-9a5b-7a15b6801463" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:to="loc_ibrx_PromissoryNotesPayableMember_6d0a0054-bebf-4114-9a5b-7a15b6801463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_28b59ec9-3b3c-4097-bb33-4ace2ebd8084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_28b59ec9-3b3c-4097-bb33-4ace2ebd8084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_28b59ec9-3b3c-4097-bb33-4ace2ebd8084_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_28b59ec9-3b3c-4097-bb33-4ace2ebd8084" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_28b59ec9-3b3c-4097-bb33-4ace2ebd8084_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_28b59ec9-3b3c-4097-bb33-4ace2ebd8084" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member_415fb8fa-4022-4933-96e2-43cb7692089b" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member_415fb8fa-4022-4933-96e2-43cb7692089b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_ad6f626b-3d5b-4453-a53a-bc63e087a009" xlink:href="ibrx-20231231.xsd#ibrx_A300MillionDecember2021PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_ad6f626b-3d5b-4453-a53a-bc63e087a009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_1dd936d1-b0b4-4c9d-8456-3f34e7d1778a" xlink:href="ibrx-20231231.xsd#ibrx_A50MillionDecember2022PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_1dd936d1-b0b4-4c9d-8456-3f34e7d1778a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionJune2023PromissoryNoteMember_719dab54-34e5-433d-9294-7231df859804" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionJune2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A30MillionJune2023PromissoryNoteMember_719dab54-34e5-433d-9294-7231df859804" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember_c7a17a13-c319-4f85-a6ae-a9c0e9cc15e8" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember_c7a17a13-c319-4f85-a6ae-a9c0e9cc15e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_5c153a4f-f9ed-401b-a4b0-d23f408ff8d5" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionMarch2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_5c153a4f-f9ed-401b-a4b0-d23f408ff8d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_4a88fbc3-1225-48fa-a956-4a0dfb21a01a" xlink:href="ibrx-20231231.xsd#ibrx_A200MillionSeptember2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_4a88fbc3-1225-48fa-a956-4a0dfb21a01a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_c894319b-d1ce-4f62-86cd-d32bc3803e10" xlink:href="ibrx-20231231.xsd#ibrx_A125MillionAugust2022PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_c894319b-d1ce-4f62-86cd-d32bc3803e10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_c414f28a-9000-4906-ba6d-d57e5e037e02" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCapitalMember_c414f28a-9000-4906-ba6d-d57e5e037e02" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalOneMember_2e8b716b-918a-4580-9591-a9a12653846d" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCapitalOneMember_2e8b716b-918a-4580-9591-a9a12653846d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember_8a74b3d9-d85b-4da1-a61c-45a5913618c0" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCapitalTwoMember_8a74b3d9-d85b-4da1-a61c-45a5913618c0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantMobileMember_faa70331-7a45-4483-a7e9-18fb1ac3526b" xlink:href="ibrx-20231231.xsd#ibrx_NantMobileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantMobileMember_faa70331-7a45-4483-a7e9-18fb1ac3526b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCancerStemCellMember_82a9c18c-eeec-4c09-9ab3-64737d70beef" xlink:href="ibrx-20231231.xsd#ibrx_NantCancerStemCellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCancerStemCellMember_82a9c18c-eeec-4c09-9ab3-64737d70beef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_2d05d6b5-81b0-4b19-97e9-e1b01df06581" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_2d05d6b5-81b0-4b19-97e9-e1b01df06581" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2f356948-3302-47d6-b21b-4aa33b02d5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2f356948-3302-47d6-b21b-4aa33b02d5cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2f356948-3302-47d6-b21b-4aa33b02d5cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2f356948-3302-47d6-b21b-4aa33b02d5cf" xlink:to="loc_us-gaap_RelatedPartyDomain_2f356948-3302-47d6-b21b-4aa33b02d5cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c9e1ba69-b216-4ca7-a66d-92979a293931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2f356948-3302-47d6-b21b-4aa33b02d5cf" xlink:to="loc_us-gaap_RelatedPartyDomain_c9e1ba69-b216-4ca7-a66d-92979a293931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_3ce5da5c-2d70-49e1-9647-b4be6cd89614" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c9e1ba69-b216-4ca7-a66d-92979a293931" xlink:to="loc_srt_AffiliatedEntityMember_3ce5da5c-2d70-49e1-9647-b4be6cd89614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_12888fea-afff-47a5-a588-d96436f1185c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_VariableRateAxis_12888fea-afff-47a5-a588-d96436f1185c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_12888fea-afff-47a5-a588-d96436f1185c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_12888fea-afff-47a5-a588-d96436f1185c" xlink:to="loc_us-gaap_VariableRateDomain_12888fea-afff-47a5-a588-d96436f1185c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_347fa156-d65c-429e-9e5f-1ba25438b027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_12888fea-afff-47a5-a588-d96436f1185c" xlink:to="loc_us-gaap_VariableRateDomain_347fa156-d65c-429e-9e5f-1ba25438b027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_5796e3c8-db9c-49a3-b583-afec1008a047" xlink:href="ibrx-20231231.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_347fa156-d65c-429e-9e5f-1ba25438b027" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_5796e3c8-db9c-49a3-b583-afec1008a047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ebf1c5b8-f18c-4f74-8ea2-b76850fb29db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ebf1c5b8-f18c-4f74-8ea2-b76850fb29db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f0e3060f-e05c-4539-93ac-4072fd11c853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f0e3060f-e05c-4539-93ac-4072fd11c853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5e97bf4b-8225-4025-a891-b94aabc146d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_LongTermDebt_5e97bf4b-8225-4025-a891-b94aabc146d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_f0f155f0-040d-4284-95cc-3b29182391c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_f0f155f0-040d-4284-95cc-3b29182391c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_280b5946-fb58-4430-8664-c82fbe5015d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_280b5946-fb58-4430-8664-c82fbe5015d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_739db45f-0fd0-4fc5-8269-7c0c8e8d6989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_739db45f-0fd0-4fc5-8269-7c0c8e8d6989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_45b167be-92ed-4571-95fe-a6610493177e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_45b167be-92ed-4571-95fe-a6610493177e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_68ed2e44-8f18-411a-967e-e993de2f805a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_68ed2e44-8f18-411a-967e-e993de2f805a" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9322bb1-953e-4562-9051-330b5226ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9322bb1-953e-4562-9051-330b5226ce79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e9322bb1-953e-4562-9051-330b5226ce79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9322bb1-953e-4562-9051-330b5226ce79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e9322bb1-953e-4562-9051-330b5226ce79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9322bb1-953e-4562-9051-330b5226ce79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_7e09d7b1-151c-47aa-b355-a51c9aff66e1" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:to="loc_ibrx_PromissoryNotesPayableMember_7e09d7b1-151c-47aa-b355-a51c9aff66e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1083ccb4-510d-40ae-991f-d1c281b73669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1083ccb4-510d-40ae-991f-d1c281b73669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ef784eaf-9c31-493c-b0b6-826c7b19357b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ef784eaf-9c31-493c-b0b6-826c7b19357b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ef784eaf-9c31-493c-b0b6-826c7b19357b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ef784eaf-9c31-493c-b0b6-826c7b19357b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ef784eaf-9c31-493c-b0b6-826c7b19357b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ef784eaf-9c31-493c-b0b6-826c7b19357b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_47fb943b-3c8a-4a9e-99a6-8e6fb64ee23a" xlink:href="ibrx-20231231.xsd#ibrx_A300MillionDecember2021PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_47fb943b-3c8a-4a9e-99a6-8e6fb64ee23a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_be3ba60b-8259-4660-8028-03be6ccf067c" xlink:href="ibrx-20231231.xsd#ibrx_A125MillionAugust2022PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_be3ba60b-8259-4660-8028-03be6ccf067c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_81aa5aed-f102-49dc-aca7-2a0a692ab4c2" xlink:href="ibrx-20231231.xsd#ibrx_A50MillionDecember2022PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_81aa5aed-f102-49dc-aca7-2a0a692ab4c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_410a7dea-c5c1-438c-a9aa-8aadb858b403" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionMarch2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_410a7dea-c5c1-438c-a9aa-8aadb858b403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionJune2023PromissoryNoteMember_6db06e5a-2098-4fad-a4f2-9537f9190495" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionJune2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A30MillionJune2023PromissoryNoteMember_6db06e5a-2098-4fad-a4f2-9537f9190495" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_900c7b17-df33-4557-ba31-5a3aefa161a4" xlink:href="ibrx-20231231.xsd#ibrx_A200MillionSeptember2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_900c7b17-df33-4557-ba31-5a3aefa161a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member_dd96cacf-328b-4400-a28d-16e7300343e3" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member_dd96cacf-328b-4400-a28d-16e7300343e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_dcd00247-976e-44ed-b449-051ab8f7b9f5" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_dcd00247-976e-44ed-b449-051ab8f7b9f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_3882b298-b19d-4c79-81ac-e2ce7dfdd2a6" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantWorksMember_3882b298-b19d-4c79-81ac-e2ce7dfdd2a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_9a034b22-40dc-4c47-9c54-6b7fc7f157d2" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantCapitalMember_9a034b22-40dc-4c47-9c54-6b7fc7f157d2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_d6dca311-12b5-4db3-89b8-da4ed39584d9" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_d6dca311-12b5-4db3-89b8-da4ed39584d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02f4f036-ac76-4041-a4ce-75993da077ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02f4f036-ac76-4041-a4ce-75993da077ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_02f4f036-ac76-4041-a4ce-75993da077ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02f4f036-ac76-4041-a4ce-75993da077ab" xlink:to="loc_us-gaap_RelatedPartyDomain_02f4f036-ac76-4041-a4ce-75993da077ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b967fe7d-04f1-4310-a07b-667c11d6d15f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02f4f036-ac76-4041-a4ce-75993da077ab" xlink:to="loc_us-gaap_RelatedPartyDomain_b967fe7d-04f1-4310-a07b-667c11d6d15f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_a6297976-f970-4071-a631-8851ba4ead3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b967fe7d-04f1-4310-a07b-667c11d6d15f" xlink:to="loc_srt_AffiliatedEntityMember_a6297976-f970-4071-a631-8851ba4ead3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_VariableRateAxis_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1" xlink:to="loc_us-gaap_VariableRateDomain_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e9a3b3c9-bb49-4957-b7a9-1dbecd6cb03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1" xlink:to="loc_us-gaap_VariableRateDomain_e9a3b3c9-bb49-4957-b7a9-1dbecd6cb03a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_f759c621-486b-4ba6-94e6-69483edbcb9c" xlink:href="ibrx-20231231.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e9a3b3c9-bb49-4957-b7a9-1dbecd6cb03a" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_f759c621-486b-4ba6-94e6-69483edbcb9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5587dc34-3a0d-4155-bb74-029508d572a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_srt_RangeAxis_5587dc34-3a0d-4155-bb74-029508d572a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5587dc34-3a0d-4155-bb74-029508d572a8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5587dc34-3a0d-4155-bb74-029508d572a8" xlink:to="loc_srt_RangeMember_5587dc34-3a0d-4155-bb74-029508d572a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5587dc34-3a0d-4155-bb74-029508d572a8" xlink:to="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a5122bf3-6b60-48c4-b531-1f1a0ffaa6d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:to="loc_srt_MinimumMember_a5122bf3-6b60-48c4-b531-1f1a0ffaa6d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd8bbd0f-e5a6-4990-9442-4316d3fa6276" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:to="loc_srt_MaximumMember_dd8bbd0f-e5a6-4990-9442-4316d3fa6276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b1699c3d-c231-45e5-a73d-5e902eb09056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b1699c3d-c231-45e5-a73d-5e902eb09056" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b1699c3d-c231-45e5-a73d-5e902eb09056_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b1699c3d-c231-45e5-a73d-5e902eb09056" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b1699c3d-c231-45e5-a73d-5e902eb09056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b1699c3d-c231-45e5-a73d-5e902eb09056" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputMarketYieldMember_651721ef-a057-41eb-b138-7758117be0dc" xlink:href="ibrx-20231231.xsd#ibrx_MeasurementInputMarketYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:to="loc_ibrx_MeasurementInputMarketYieldMember_651721ef-a057-41eb-b138-7758117be0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e4c0e03e-fba3-4ad6-8b5d-9a2e46b4f30c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e4c0e03e-fba3-4ad6-8b5d-9a2e46b4f30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_abecea56-86a3-4330-8325-7b316565962a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_abecea56-86a3-4330-8325-7b316565962a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_511ccbc4-8058-4f6b-a4f2-40713e1aaebd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_511ccbc4-8058-4f6b-a4f2-40713e1aaebd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ValuationTechniqueBinomialLatticeModelMember_570dfdc6-dc13-4f20-aac1-04fcd6e660f4" xlink:href="ibrx-20231231.xsd#ibrx_ValuationTechniqueBinomialLatticeModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:to="loc_ibrx_ValuationTechniqueBinomialLatticeModelMember_570dfdc6-dc13-4f20-aac1-04fcd6e660f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_6ae9d3fb-0777-4c3a-9ba6-588e14f49012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_6ae9d3fb-0777-4c3a-9ba6-588e14f49012" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_6ae9d3fb-0777-4c3a-9ba6-588e14f49012_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_6ae9d3fb-0777-4c3a-9ba6-588e14f49012" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_6ae9d3fb-0777-4c3a-9ba6-588e14f49012_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_be016726-1b39-4ee4-8f82-dd2525d1fa07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_6ae9d3fb-0777-4c3a-9ba6-588e14f49012" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_be016726-1b39-4ee4-8f82-dd2525d1fa07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_a8439e55-9c2b-4ec6-a31f-524b77f4fb10" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_be016726-1b39-4ee4-8f82-dd2525d1fa07" xlink:to="loc_ibrx_PromissoryNotesPayableMember_a8439e55-9c2b-4ec6-a31f-524b77f4fb10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_VestingAxis_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421" xlink:to="loc_us-gaap_VestingDomain_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421" xlink:to="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0b9de12b-05af-4f61-a51b-88dbfc8dff46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0b9de12b-05af-4f61-a51b-88dbfc8dff46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a8e3f6ae-8856-4603-b2db-f8a90a72c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a8e3f6ae-8856-4603-b2db-f8a90a72c1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_80af554e-f7ca-4ce2-ae20-208fa37be132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_80af554e-f7ca-4ce2-ae20-208fa37be132" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_80af554e-f7ca-4ce2-ae20-208fa37be132_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_80af554e-f7ca-4ce2-ae20-208fa37be132" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_80af554e-f7ca-4ce2-ae20-208fa37be132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc38c812-d18b-446a-bc00-77dcb16db968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_80af554e-f7ca-4ce2-ae20-208fa37be132" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc38c812-d18b-446a-bc00-77dcb16db968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_5e04e79f-8b34-4de5-9863-3af1b4c689ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc38c812-d18b-446a-bc00-77dcb16db968" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_5e04e79f-8b34-4de5-9863-3af1b4c689ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ee11800-cfe9-47c9-94b6-198649b3bd28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ee11800-cfe9-47c9-94b6-198649b3bd28" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ee11800-cfe9-47c9-94b6-198649b3bd28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ee11800-cfe9-47c9-94b6-198649b3bd28" xlink:to="loc_us-gaap_EquityComponentDomain_5ee11800-cfe9-47c9-94b6-198649b3bd28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fe2a186-8f80-4073-b978-c1c07dd9fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ee11800-cfe9-47c9-94b6-198649b3bd28" xlink:to="loc_us-gaap_EquityComponentDomain_6fe2a186-8f80-4073-b978-c1c07dd9fb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1606edb0-78e7-41e7-a756-d3ad482b6054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fe2a186-8f80-4073-b978-c1c07dd9fb99" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1606edb0-78e7-41e7-a756-d3ad482b6054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c8d11d5c-48c7-4f0a-b3b1-2baee5b9e4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c8d11d5c-48c7-4f0a-b3b1-2baee5b9e4c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28883dc9-d939-4ff8-aa93-4643b962879c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28883dc9-d939-4ff8-aa93-4643b962879c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1d6b0d9b-52cb-44c3-a726-151c70eb9719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1d6b0d9b-52cb-44c3-a726-151c70eb9719" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_aeaad7c4-1078-4bac-997a-bcdc406c0208" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentPrepaymentAndAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_aeaad7c4-1078-4bac-997a-bcdc406c0208" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_f62e66dd-adf2-4a32-860a-ad88321f4c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_f62e66dd-adf2-4a32-860a-ad88321f4c8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_fe700926-4a2c-4b51-acd5-cd3ebbed6c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_fe700926-4a2c-4b51-acd5-cd3ebbed6c14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentNumberOfAdvances_85675198-9366-4a0a-9fe2-765753ccafb6" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentNumberOfAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_DebtInstrumentNumberOfAdvances_85675198-9366-4a0a-9fe2-765753ccafb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentFaceAmountPerTranche_ceb7f6c1-056a-4e4f-bc30-61995ace66f4" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentFaceAmountPerTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_DebtInstrumentFaceAmountPerTranche_ceb7f6c1-056a-4e4f-bc30-61995ace66f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19caf8e4-5b54-4d9e-bd41-426324650097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19caf8e4-5b54-4d9e-bd41-426324650097" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b4496821-686d-46e1-ba84-b4896e06c3ff" xlink:href="ibrx-20231231.xsd#ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b4496821-686d-46e1-ba84-b4896e06c3ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f827cb88-cb61-4e3e-a855-52763add4987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_InterestExpenseDebt_f827cb88-cb61-4e3e-a855-52763add4987" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_43aa4c2f-4580-4850-b0a2-ac71469f710f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_43aa4c2f-4580-4850-b0a2-ac71469f710f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_8ab193dc-7f44-446f-9225-2de718bbdc6e" xlink:href="ibrx-20231231.xsd#ibrx_LongTermDebtGrossIncludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_8ab193dc-7f44-446f-9225-2de718bbdc6e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_95b11184-0695-4b55-bb96-1176edf563ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_95b11184-0695-4b55-bb96-1176edf563ac" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_527a8980-374f-449c-9dde-434b1815da30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_527a8980-374f-449c-9dde-434b1815da30" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4018d87b-6251-4298-996e-f0c414c61e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4018d87b-6251-4298-996e-f0c414c61e16" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ac3b5cec-08f7-4232-913d-9d3e0eb7deba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ac3b5cec-08f7-4232-913d-9d3e0eb7deba" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_ab4325f7-968a-44df-a78b-06e017a3c707" xlink:href="ibrx-20231231.xsd#ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_ab4325f7-968a-44df-a78b-06e017a3c707" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ee3424b2-196c-4e97-8cc6-12eaf31c849f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ee3424b2-196c-4e97-8cc6-12eaf31c849f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_bb2401a8-4edf-4a91-82ef-330cd661ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_bb2401a8-4edf-4a91-82ef-330cd661ccd2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_51981117-7dba-4dd1-a133-c7efd1a84e56" xlink:href="ibrx-20231231.xsd#ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_51981117-7dba-4dd1-a133-c7efd1a84e56" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_cc88c3a2-41d0-46e8-901d-62cafe5b2d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_cc88c3a2-41d0-46e8-901d-62cafe5b2d1b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_04e8afeb-fbba-4340-9574-d8018c9602b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_04e8afeb-fbba-4340-9574-d8018c9602b4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3ccd10af-f291-4904-a518-4a826b384aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3ccd10af-f291-4904-a518-4a826b384aad" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_60eb8c13-b94f-4817-8630-53e5de5ed127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_60eb8c13-b94f-4817-8630-53e5de5ed127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_38223963-62fc-41e6-84f1-82b224ec0ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_60eb8c13-b94f-4817-8630-53e5de5ed127" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_38223963-62fc-41e6-84f1-82b224ec0ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e8002688-12a9-4196-a1d1-ff613f6a5a79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e8002688-12a9-4196-a1d1-ff613f6a5a79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e8002688-12a9-4196-a1d1-ff613f6a5a79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e8002688-12a9-4196-a1d1-ff613f6a5a79" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e8002688-12a9-4196-a1d1-ff613f6a5a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e8002688-12a9-4196-a1d1-ff613f6a5a79" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputExpectedMarketYieldMember_e67846aa-929b-4702-8ddc-295c9ad49b63" xlink:href="ibrx-20231231.xsd#ibrx_MeasurementInputExpectedMarketYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:to="loc_ibrx_MeasurementInputExpectedMarketYieldMember_e67846aa-929b-4702-8ddc-295c9ad49b63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_ec40552b-65e5-4661-aca1-6e6a5c0adfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_ec40552b-65e5-4661-aca1-6e6a5c0adfcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2ee1db34-09e1-41e6-a363-905dc71be810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2ee1db34-09e1-41e6-a363-905dc71be810" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_45e73485-6b84-456b-b101-aec085b5a427" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_45e73485-6b84-456b-b101-aec085b5a427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c5e2fb63-80d7-4859-a7cb-559e69e32680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_45e73485-6b84-456b-b101-aec085b5a427" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c5e2fb63-80d7-4859-a7cb-559e69e32680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_b68b7b08-129d-474f-ac01-bad5d0a32c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_b68b7b08-129d-474f-ac01-bad5d0a32c2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a53a144-6fb0-4efa-8f78-63eecd133185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a53a144-6fb0-4efa-8f78-63eecd133185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_267b4585-420f-4744-81b5-5f5ee3247002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_267b4585-420f-4744-81b5-5f5ee3247002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5342aef0-ce2e-4bfd-b7b0-04039b81bf74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5342aef0-ce2e-4bfd-b7b0-04039b81bf74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a4c91f88-15cc-4dc5-b6b2-46de1a308fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a4c91f88-15cc-4dc5-b6b2-46de1a308fe8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtRelatedPartyPromissoryNotesDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6cab3735-5b7d-4d88-9438-13a8b2ed1a06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6cab3735-5b7d-4d88-9438-13a8b2ed1a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6cab3735-5b7d-4d88-9438-13a8b2ed1a06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6cab3735-5b7d-4d88-9438-13a8b2ed1a06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6cab3735-5b7d-4d88-9438-13a8b2ed1a06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68b0dacf-79d1-4f7b-ae2a-c6d22a010f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6cab3735-5b7d-4d88-9438-13a8b2ed1a06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68b0dacf-79d1-4f7b-ae2a-c6d22a010f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_1807c321-5031-4267-bcd6-ad5a37d3e934" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68b0dacf-79d1-4f7b-ae2a-c6d22a010f85" xlink:to="loc_ibrx_PromissoryNotesPayableMember_1807c321-5031-4267-bcd6-ad5a37d3e934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c32fdfea-23a4-465a-9a65-a420741750b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c32fdfea-23a4-465a-9a65-a420741750b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c32fdfea-23a4-465a-9a65-a420741750b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c32fdfea-23a4-465a-9a65-a420741750b8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c32fdfea-23a4-465a-9a65-a420741750b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c32fdfea-23a4-465a-9a65-a420741750b8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_75b8e8a6-8976-48f8-ac8a-d65ac507f9a2" xlink:href="ibrx-20231231.xsd#ibrx_A300MillionDecember2021PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_75b8e8a6-8976-48f8-ac8a-d65ac507f9a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_b948059d-49bc-4f95-8fd6-042ca364ca8e" xlink:href="ibrx-20231231.xsd#ibrx_A125MillionAugust2022PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_b948059d-49bc-4f95-8fd6-042ca364ca8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_05beff0e-943a-4bba-92b5-8bb3dbcaed0b" xlink:href="ibrx-20231231.xsd#ibrx_A50MillionDecember2022PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_05beff0e-943a-4bba-92b5-8bb3dbcaed0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_4db0046a-c225-45e2-acb0-74f8cafe9702" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionMarch2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_4db0046a-c225-45e2-acb0-74f8cafe9702" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionJune2023PromissoryNoteMember_945f629a-e0a9-4272-b46d-912ce2aaa2c7" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionJune2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A30MillionJune2023PromissoryNoteMember_945f629a-e0a9-4272-b46d-912ce2aaa2c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_5636488b-cc21-4040-b73f-ba0cddae8afa" xlink:href="ibrx-20231231.xsd#ibrx_A200MillionSeptember2023PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_5636488b-cc21-4040-b73f-ba0cddae8afa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyFixedRateNotesMember_ba679868-3987-4f52-a88a-d4a0b2d07a40" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyFixedRateNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_RelatedPartyFixedRateNotesMember_ba679868-3987-4f52-a88a-d4a0b2d07a40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b614745-fc86-4c52-98c2-5bde6d22087e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b614745-fc86-4c52-98c2-5bde6d22087e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b614745-fc86-4c52-98c2-5bde6d22087e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b614745-fc86-4c52-98c2-5bde6d22087e" xlink:to="loc_us-gaap_RelatedPartyDomain_5b614745-fc86-4c52-98c2-5bde6d22087e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ca724064-3d52-48e8-893b-7af1d41659db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b614745-fc86-4c52-98c2-5bde6d22087e" xlink:to="loc_us-gaap_RelatedPartyDomain_ca724064-3d52-48e8-893b-7af1d41659db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_0f134f5a-0310-468c-81cd-28bb5f3a2ae1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ca724064-3d52-48e8-893b-7af1d41659db" xlink:to="loc_srt_AffiliatedEntityMember_0f134f5a-0310-468c-81cd-28bb5f3a2ae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a7b2a095-ceda-4ef0-a573-21e264c59ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:to="loc_us-gaap_InterestExpenseDebt_a7b2a095-ceda-4ef0-a573-21e264c59ae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9bad7dc4-0a42-42cc-bcd1-a03dd8bf1ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9bad7dc4-0a42-42cc-bcd1-a03dd8bf1ca7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f09b0fbf-da52-4996-b82d-1ab884bd55ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f09b0fbf-da52-4996-b82d-1ab884bd55ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f09b0fbf-da52-4996-b82d-1ab884bd55ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f09b0fbf-da52-4996-b82d-1ab884bd55ae" xlink:to="loc_us-gaap_RelatedPartyDomain_f09b0fbf-da52-4996-b82d-1ab884bd55ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c4cf39e-909f-4f90-9ee7-cfb9b0edd849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f09b0fbf-da52-4996-b82d-1ab884bd55ae" xlink:to="loc_us-gaap_RelatedPartyDomain_3c4cf39e-909f-4f90-9ee7-cfb9b0edd849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_2cf81b97-fa43-42c4-8406-f6cd1da1e318" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3c4cf39e-909f-4f90-9ee7-cfb9b0edd849" xlink:to="loc_srt_AffiliatedEntityMember_2cf81b97-fa43-42c4-8406-f6cd1da1e318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b33a9b6a-9f8a-45a0-8618-ae58b787d406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_DebtInstrumentAxis_b33a9b6a-9f8a-45a0-8618-ae58b787d406" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b33a9b6a-9f8a-45a0-8618-ae58b787d406_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b33a9b6a-9f8a-45a0-8618-ae58b787d406" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b33a9b6a-9f8a-45a0-8618-ae58b787d406_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc232eab-5994-46f3-be10-ea25f4cb5586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b33a9b6a-9f8a-45a0-8618-ae58b787d406" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc232eab-5994-46f3-be10-ea25f4cb5586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc232eab-5994-46f3-be10-ea25f4cb5586" xlink:to="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPrincipalMember_1afcae29-137a-4ce5-aaa3-7b09caac8b2d" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesPrincipalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:to="loc_ibrx_RelatedPartyNotesPrincipalMember_1afcae29-137a-4ce5-aaa3-7b09caac8b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesInterestMember_1f545723-5ec3-4903-9e0d-dc9804f55471" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:to="loc_ibrx_RelatedPartyNotesInterestMember_1f545723-5ec3-4903-9e0d-dc9804f55471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_49c0bc42-652f-438e-a26e-f01f86990945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_49c0bc42-652f-438e-a26e-f01f86990945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_febb7b55-7bee-46d1-91b4-1e5e78d75605" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:to="loc_ibrx_PromissoryNotesPayableMember_febb7b55-7bee-46d1-91b4-1e5e78d75605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9c1d6920-71c6-40e7-9cde-501e91e634da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9c1d6920-71c6-40e7-9cde-501e91e634da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalThreeMember_3d895afe-0733-46d5-9c0e-576f06aeaf0b" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9c1d6920-71c6-40e7-9cde-501e91e634da" xlink:to="loc_ibrx_NantCapitalThreeMember_3d895afe-0733-46d5-9c0e-576f06aeaf0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bf858c0b-dc9c-4a86-903a-3a4fefbf1a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bf858c0b-dc9c-4a86-903a-3a4fefbf1a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_dd41ff7b-c7a8-41d7-ad7c-0fd21ea41276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_dd41ff7b-c7a8-41d7-ad7c-0fd21ea41276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0d15d1db-6f06-4d42-9c9b-1a5d8f2bf401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0d15d1db-6f06-4d42-9c9b-1a5d8f2bf401" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c3d0eb95-e38a-41e5-a892-a8cba2349e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebt_c3d0eb95-e38a-41e5-a892-a8cba2349e76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c4dedda-a785-4a3d-9399-88b872bb3953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c4dedda-a785-4a3d-9399-88b872bb3953" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8e5f4d02-867f-4451-9677-41bf3c26a129" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:to="loc_srt_CounterpartyNameAxis_8e5f4d02-867f-4451-9677-41bf3c26a129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5f4d02-867f-4451-9677-41bf3c26a129_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8e5f4d02-867f-4451-9677-41bf3c26a129" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5f4d02-867f-4451-9677-41bf3c26a129_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8e5f4d02-867f-4451-9677-41bf3c26a129" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioInc.Member_7a2e8406-189c-41f1-8381-f37638bb1032" xlink:href="ibrx-20231231.xsd#ibrx_NantBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_NantBioInc.Member_7a2e8406-189c-41f1-8381-f37638bb1032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_5fd63d44-eb71-4854-b00c-cd661a133eea" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_NantWorksMember_5fd63d44-eb71-4854-b00c-cd661a133eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember_1686ac2f-3e5e-4425-8843-763b9dfc9806" xlink:href="ibrx-20231231.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_BrinkBiologicsIncMember_1686ac2f-3e5e-4425-8843-763b9dfc9806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VariousMember_45349142-3a47-42af-80cd-883fb6837473" xlink:href="ibrx-20231231.xsd#ibrx_VariousMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_VariousMember_45349142-3a47-42af-80cd-883fb6837473" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadMember_50c4485c-86a2-4c45-8675-3f80863ed2b3" xlink:href="ibrx-20231231.xsd#ibrx_DuleyRoadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_DuleyRoadMember_50c4485c-86a2-4c45-8675-3f80863ed2b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicMember_a0b51694-2a62-4a1d-942e-dbed7a1eff33" xlink:href="ibrx-20231231.xsd#ibrx_ImmunoOncologyClinicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_ImmunoOncologyClinicMember_a0b51694-2a62-4a1d-942e-dbed7a1eff33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c49383a-2e8f-4392-8d73-7db5c5eeb68f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c49383a-2e8f-4392-8d73-7db5c5eeb68f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5c49383a-2e8f-4392-8d73-7db5c5eeb68f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c49383a-2e8f-4392-8d73-7db5c5eeb68f" xlink:to="loc_us-gaap_RelatedPartyDomain_5c49383a-2e8f-4392-8d73-7db5c5eeb68f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_327c889b-17ca-4eb7-8090-4236247fb987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c49383a-2e8f-4392-8d73-7db5c5eeb68f" xlink:to="loc_us-gaap_RelatedPartyDomain_327c889b-17ca-4eb7-8090-4236247fb987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5762838b-f1e1-4725-861c-34949d579072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_327c889b-17ca-4eb7-8090-4236247fb987" xlink:to="loc_us-gaap_RelatedPartyMember_5762838b-f1e1-4725-861c-34949d579072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7005853c-2891-4b92-acf4-348d376cb907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7005853c-2891-4b92-acf4-348d376cb907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1a10a704-83d7-4152-85da-1c6054dcd8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:to="loc_us-gaap_AccountsPayableCurrent_1a10a704-83d7-4152-85da-1c6054dcd8fb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22fb7e53-5943-431a-8975-2e2cfaae24ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_srt_CounterpartyNameAxis_22fb7e53-5943-431a-8975-2e2cfaae24ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22fb7e53-5943-431a-8975-2e2cfaae24ca_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_22fb7e53-5943-431a-8975-2e2cfaae24ca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22fb7e53-5943-431a-8975-2e2cfaae24ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_22fb7e53-5943-431a-8975-2e2cfaae24ca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_000ad4b1-7758-448c-ba07-aad04927595c" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_NantWorksMember_000ad4b1-7758-448c-ba07-aad04927595c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember_d2fe3f41-46da-4f89-8422-c9d34961f6b7" xlink:href="ibrx-20231231.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_ImmunoOncologyClinicIncMember_d2fe3f41-46da-4f89-8422-c9d34961f6b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember_ee41d185-6a65-4cc2-a609-e09e11ea2b09" xlink:href="ibrx-20231231.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_BrinkBiologicsIncMember_ee41d185-6a65-4cc2-a609-e09e11ea2b09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioInc.Member_57e3d294-d59f-4dea-b4d6-2e39d1808d39" xlink:href="ibrx-20231231.xsd#ibrx_NantBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_NantBioInc.Member_57e3d294-d59f-4dea-b4d6-2e39d1808d39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveDougStLLCMember_85f52ead-25a5-42ef-a65a-bec968c8f4d1" xlink:href="ibrx-20231231.xsd#ibrx_SixZeroFiveDougStLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_SixZeroFiveDougStLLCMember_85f52ead-25a5-42ef-a65a-bec968c8f4d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadLLCMember_acaee542-a11a-4deb-827a-e5e55b2a16d9" xlink:href="ibrx-20231231.xsd#ibrx_DuleyRoadLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_DuleyRoadLLCMember_acaee542-a11a-4deb-827a-e5e55b2a16d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveNashLLCMember_655eba33-a9ff-4ada-9994-2493fa907112" xlink:href="ibrx-20231231.xsd#ibrx_SixZeroFiveNashLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_SixZeroFiveNashLLCMember_655eba33-a9ff-4ada-9994-2493fa907112" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_08261290-c6a2-4a9d-a4ef-c0f0d10d4788" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_NantCapitalMember_08261290-c6a2-4a9d-a4ef-c0f0d10d4788" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FourTwoZeroNashLLCMember_a765bc01-b602-4c76-a538-c3f063b31c83" xlink:href="ibrx-20231231.xsd#ibrx_FourTwoZeroNashLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_FourTwoZeroNashLLCMember_a765bc01-b602-4c76-a538-c3f063b31c83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A23AlaskaLLCMember_d42ac68d-cd6c-4731-8e32-17b070f48193" xlink:href="ibrx-20231231.xsd#ibrx_A23AlaskaLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_A23AlaskaLLCMember_d42ac68d-cd6c-4731-8e32-17b070f48193" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e6dc9f-7e4d-4782-852e-7ace003235a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e6dc9f-7e4d-4782-852e-7ace003235a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c5e6dc9f-7e4d-4782-852e-7ace003235a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e6dc9f-7e4d-4782-852e-7ace003235a0" xlink:to="loc_us-gaap_RelatedPartyDomain_c5e6dc9f-7e4d-4782-852e-7ace003235a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0a3e1ace-ab61-4769-9b97-e9d0e1f49dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e6dc9f-7e4d-4782-852e-7ace003235a0" xlink:to="loc_us-gaap_RelatedPartyDomain_0a3e1ace-ab61-4769-9b97-e9d0e1f49dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_443e16a4-0711-4a32-a9ee-263657d04957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0a3e1ace-ab61-4769-9b97-e9d0e1f49dc9" xlink:to="loc_us-gaap_RelatedPartyMember_443e16a4-0711-4a32-a9ee-263657d04957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afe9b74e-57b7-4ee6-8b8a-e45fef158152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afe9b74e-57b7-4ee6-8b8a-e45fef158152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe9b74e-57b7-4ee6-8b8a-e45fef158152_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afe9b74e-57b7-4ee6-8b8a-e45fef158152" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afe9b74e-57b7-4ee6-8b8a-e45fef158152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60b65a7-523e-4767-a3d4-f57d32a1cfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afe9b74e-57b7-4ee6-8b8a-e45fef158152" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60b65a7-523e-4767-a3d4-f57d32a1cfa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharedServicesAgreementMember_cf0c615a-dd8a-469c-8926-9644f00f16da" xlink:href="ibrx-20231231.xsd#ibrx_SharedServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60b65a7-523e-4767-a3d4-f57d32a1cfa8" xlink:to="loc_ibrx_SharedServicesAgreementMember_cf0c615a-dd8a-469c-8926-9644f00f16da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_bc86a7c6-970e-418b-b030-399c92316e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_TransactionTypeAxis_bc86a7c6-970e-418b-b030-399c92316e3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_bc86a7c6-970e-418b-b030-399c92316e3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_bc86a7c6-970e-418b-b030-399c92316e3f" xlink:to="loc_us-gaap_TransactionDomain_bc86a7c6-970e-418b-b030-399c92316e3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_fc9156fd-36f2-42db-84a7-6385ddf76ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_bc86a7c6-970e-418b-b030-399c92316e3f" xlink:to="loc_us-gaap_TransactionDomain_fc9156fd-36f2-42db-84a7-6385ddf76ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ReimbursementsMember_310242eb-00c9-4604-b88a-071af015b41a" xlink:href="ibrx-20231231.xsd#ibrx_ReimbursementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_fc9156fd-36f2-42db-84a7-6385ddf76ad4" xlink:to="loc_ibrx_ReimbursementsMember_310242eb-00c9-4604-b88a-071af015b41a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_20882699-22ac-4d93-b5a1-27c4cc8a5d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_20882699-22ac-4d93-b5a1-27c4cc8a5d30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20882699-22ac-4d93-b5a1-27c4cc8a5d30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20882699-22ac-4d93-b5a1-27c4cc8a5d30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20882699-22ac-4d93-b5a1-27c4cc8a5d30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20882699-22ac-4d93-b5a1-27c4cc8a5d30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc59728b-f27c-4f60-b2c8-7d43b4d66740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc59728b-f27c-4f60-b2c8-7d43b4d66740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_55306700-d6bc-4da9-a1df-195e20a7518a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_55306700-d6bc-4da9-a1df-195e20a7518a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1f2ecac2-2926-4f69-b1d8-08cfeb699674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1f2ecac2-2926-4f69-b1d8-08cfeb699674" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1f2ecac2-2926-4f69-b1d8-08cfeb699674_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1f2ecac2-2926-4f69-b1d8-08cfeb699674" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1f2ecac2-2926-4f69-b1d8-08cfeb699674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1f2ecac2-2926-4f69-b1d8-08cfeb699674" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCancerStemCellMember_cd1f4965-8731-49bc-aaca-7ccf06e209dc" xlink:href="ibrx-20231231.xsd#ibrx_NantCancerStemCellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:to="loc_ibrx_NantCancerStemCellMember_cd1f4965-8731-49bc-aaca-7ccf06e209dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiveFiveSevenDougStLLCMember_bd5a95ed-ffa8-4f44-bd94-52e322da529e" xlink:href="ibrx-20231231.xsd#ibrx_FiveFiveSevenDougStLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:to="loc_ibrx_FiveFiveSevenDougStLLCMember_bd5a95ed-ffa8-4f44-bd94-52e322da529e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_46dad45b-6be1-45cc-9c93-c20e18aee155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_LeaseContractualTermAxis_46dad45b-6be1-45cc-9c93-c20e18aee155" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_46dad45b-6be1-45cc-9c93-c20e18aee155_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_46dad45b-6be1-45cc-9c93-c20e18aee155" xlink:to="loc_us-gaap_LeaseContractualTermDomain_46dad45b-6be1-45cc-9c93-c20e18aee155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_46dad45b-6be1-45cc-9c93-c20e18aee155" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SeptemberTwentyNineteenLeaseMember_37b56202-8715-4123-9ee2-66ebeeb98ba4" xlink:href="ibrx-20231231.xsd#ibrx_SeptemberTwentyNineteenLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_SeptemberTwentyNineteenLeaseMember_37b56202-8715-4123-9ee2-66ebeeb98ba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_JulyTwentyNineteenLeaseMember_34c121ae-5434-4c92-88a2-a21018f81755" xlink:href="ibrx-20231231.xsd#ibrx_JulyTwentyNineteenLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_JulyTwentyNineteenLeaseMember_34c121ae-5434-4c92-88a2-a21018f81755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPremisesMember_5c528815-5195-4079-a82c-bd70d99adec8" xlink:href="ibrx-20231231.xsd#ibrx_InitialPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_InitialPremisesMember_5c528815-5195-4079-a82c-bd70d99adec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExpansionPremisesMember_e6780fbc-52e1-4857-9d9d-1e20b662859a" xlink:href="ibrx-20231231.xsd#ibrx_ExpansionPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_ExpansionPremisesMember_e6780fbc-52e1-4857-9d9d-1e20b662859a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialAndExpansionPremisesMember_a83cac63-0af2-4164-916d-db7b5bcc0cbb" xlink:href="ibrx-20231231.xsd#ibrx_InitialAndExpansionPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_InitialAndExpansionPremisesMember_a83cac63-0af2-4164-916d-db7b5bcc0cbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0b040686-1317-4d31-a3b8-7eac46d2b07d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0b040686-1317-4d31-a3b8-7eac46d2b07d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0b040686-1317-4d31-a3b8-7eac46d2b07d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0b040686-1317-4d31-a3b8-7eac46d2b07d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0b040686-1317-4d31-a3b8-7eac46d2b07d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f6d0cab-8cd7-41e3-b638-132fa2be7d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0b040686-1317-4d31-a3b8-7eac46d2b07d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f6d0cab-8cd7-41e3-b638-132fa2be7d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DueToRelatedPartiesMember_2b261743-0f4f-4239-b059-0915e66b11df" xlink:href="ibrx-20231231.xsd#ibrx_DueToRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f6d0cab-8cd7-41e3-b638-132fa2be7d56" xlink:to="loc_ibrx_DueToRelatedPartiesMember_2b261743-0f4f-4239-b059-0915e66b11df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bb6a228-966b-433c-922a-dd3541fe149c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bb6a228-966b-433c-922a-dd3541fe149c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0a2f63cb-897b-4e60-b717-656d338433bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0a2f63cb-897b-4e60-b717-656d338433bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_07d3b251-b3ab-442a-a663-f28cbd58fe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_07d3b251-b3ab-442a-a663-f28cbd58fe7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c276457d-3ae7-431f-8b76-c50dcc556712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_AccountsPayableCurrent_c276457d-3ae7-431f-8b76-c50dcc556712" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_643af4e0-3bd9-44d0-b0f6-dce876932a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_643af4e0-3bd9-44d0-b0f6-dce876932a35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_bcbb1f52-0288-4ffd-a11c-bb9e325d98d5" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFeetOfFacilityLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_bcbb1f52-0288-4ffd-a11c-bb9e325d98d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreaseToLicenseFee_3fa0b825-48d5-4e51-bbad-66608be11242" xlink:href="ibrx-20231231.xsd#ibrx_AnnualPercentageIncreaseToLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_AnnualPercentageIncreaseToLicenseFee_3fa0b825-48d5-4e51-bbad-66608be11242" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MonthlyLicenseFee_2b52eb8c-bc59-4b3f-9396-2e7fdc9f077f" xlink:href="ibrx-20231231.xsd#ibrx_MonthlyLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_MonthlyLicenseFee_2b52eb8c-bc59-4b3f-9396-2e7fdc9f077f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_17b1bbc9-ab63-4355-92f7-31e9ea26d4e6" xlink:href="ibrx-20231231.xsd#ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_17b1bbc9-ab63-4355-92f7-31e9ea26d4e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_46ab1e69-8eba-4c01-a63c-9231a41ea915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_OperatingLeaseExpense_46ab1e69-8eba-4c01-a63c-9231a41ea915" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidExpenseWriteDown_1dbbe565-742e-4d8e-8981-6f3b2def762d" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidExpenseWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_PrepaidExpenseWriteDown_1dbbe565-742e-4d8e-8981-6f3b2def762d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_721d6271-e7ce-43ef-b63c-f23f9aaccd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_Revenues_721d6271-e7ce-43ef-b63c-f23f9aaccd8c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementTermOfContract_661fffbf-b01f-4641-a871-ff145f29efa0" xlink:href="ibrx-20231231.xsd#ibrx_SupplyAgreementTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SupplyAgreementTermOfContract_661fffbf-b01f-4641-a871-ff145f29efa0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfExtendedLeaseTerm_c84958c4-2467-4413-9ce2-e177750351df" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOfExtendedLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_PeriodOfExtendedLeaseTerm_c84958c4-2467-4413-9ce2-e177750351df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioRevenue_2dc6073d-d32b-42ff-b2a2-866547ad365e" xlink:href="ibrx-20231231.xsd#ibrx_NantBioRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NantBioRevenue_2dc6073d-d32b-42ff-b2a2-866547ad365e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ca227d42-f7c3-4709-b0ed-64ea28ab85ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ca227d42-f7c3-4709-b0ed-64ea28ab85ae" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionsToExtendNumberOfTerms_4225b0a4-3113-4069-a875-c53edfeb48d3" xlink:href="ibrx-20231231.xsd#ibrx_OptionsToExtendNumberOfTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_OptionsToExtendNumberOfTerms_4225b0a4-3113-4069-a875-c53edfeb48d3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfLeases_d1c9ec1f-e051-4a95-95ec-668ebd5131b4" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NumberOfLeases_d1c9ec1f-e051-4a95-95ec-668ebd5131b4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0a5a4852-9183-4ee3-ace4-6985ecffc6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0a5a4852-9183-4ee3-ace4-6985ecffc6ce" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRelatedPayables_3c8e4312-40db-465a-9e30-0b194e109b4d" xlink:href="ibrx-20231231.xsd#ibrx_LeaseRelatedPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_LeaseRelatedPayables_3c8e4312-40db-465a-9e30-0b194e109b4d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_5e310466-3193-423c-94e0-9faac0172c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_IncentiveFromLessor_5e310466-3193-423c-94e0-9faac0172c42" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased_7bec5370-470a-48f2-95da-7e56dcbba400" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NumberOfSquareFootOfFacilityLeased_7bec5370-470a-48f2-95da-7e56dcbba400" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionConsiderationTransferred_dc13afb8-dc08-435d-9116-92a929a3762e" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SaleLeasebackTransactionConsiderationTransferred_dc13afb8-dc08-435d-9116-92a929a3762e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionPropertyTaxes_d4a5353c-8e77-46d0-b0b0-6fc338dbb1bc" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionPropertyTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SaleLeasebackTransactionPropertyTaxes_d4a5353c-8e77-46d0-b0b0-6fc338dbb1bc" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionNetProceeds_fb413e78-8204-43c2-8418-83fd66aa59ad" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionNetProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SaleLeasebackTransactionNetProceeds_fb413e78-8204-43c2-8418-83fd66aa59ad" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionHistoricalCost_abf72c89-5265-4412-ae32-df538ba6e8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionHistoricalCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SaleLeasebackTransactionHistoricalCost_abf72c89-5265-4412-ae32-df538ba6e8c6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue_4bd65d9c-9566-4a77-80c0-ba61b18293b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SaleLeasebackTransactionNetBookValue_4bd65d9c-9566-4a77-80c0-ba61b18293b8" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_878915e4-2249-4c0d-a78e-71df25f9e32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_878915e4-2249-4c0d-a78e-71df25f9e32c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRent_040642ee-d848-46b8-a176-9e079c78d89e" xlink:href="ibrx-20231231.xsd#ibrx_BaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_BaseMonthlyRent_040642ee-d848-46b8-a176-9e079c78d89e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreasesToBaseRent_a39ea233-6d52-4bce-9679-829c4675bc05" xlink:href="ibrx-20231231.xsd#ibrx_AnnualPercentageIncreasesToBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_AnnualPercentageIncreasesToBaseRent_a39ea233-6d52-4bce-9679-829c4675bc05" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfRentFreeLeaseTerm_d1bae3f6-86d0-40f0-aaa9-4c9446082ba9" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOfRentFreeLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_PeriodOfRentFreeLeaseTerm_d1bae3f6-86d0-40f0-aaa9-4c9446082ba9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeasePrepaidExpense_9d7c7f79-7da2-4eba-89aa-436269979a79" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeasePrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_LesseeOperatingLeasePrepaidExpense_9d7c7f79-7da2-4eba-89aa-436269979a79" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_b3c57d02-dba9-489a-86ac-e914b8cdb635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_b3c57d02-dba9-489a-86ac-e914b8cdb635" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MonthlyBaseRentParking_d30f268b-8c96-4d4c-bc21-f00e3ef9f7e7" xlink:href="ibrx-20231231.xsd#ibrx_MonthlyBaseRentParking"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_MonthlyBaseRentParking_d30f268b-8c96-4d4c-bc21-f00e3ef9f7e7" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_b64f8e8e-5c3b-4b8b-b039-ec57f72ed4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SecurityDeposit_b64f8e8e-5c3b-4b8b-b039-ec57f72ed4d5" xlink:type="arc" order="34"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#WarrantLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0d7aae0a-541c-4d00-99df-bfda9cf42a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0d7aae0a-541c-4d00-99df-bfda9cf42a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d7aae0a-541c-4d00-99df-bfda9cf42a2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0d7aae0a-541c-4d00-99df-bfda9cf42a2c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d7aae0a-541c-4d00-99df-bfda9cf42a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38a04b1b-198e-484a-8745-571e79e8717b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0d7aae0a-541c-4d00-99df-bfda9cf42a2c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38a04b1b-198e-484a-8745-571e79e8717b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_2bb13e6f-b301-4cd1-bf45-2ef0612aab75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38a04b1b-198e-484a-8745-571e79e8717b" xlink:to="loc_us-gaap_PrivatePlacementMember_2bb13e6f-b301-4cd1-bf45-2ef0612aab75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_bed3b47c-223a-4182-b904-3883b031ebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_bed3b47c-223a-4182-b904-3883b031ebe3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bed3b47c-223a-4182-b904-3883b031ebe3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_bed3b47c-223a-4182-b904-3883b031ebe3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bed3b47c-223a-4182-b904-3883b031ebe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_bed3b47c-223a-4182-b904-3883b031ebe3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_46783b48-5529-4c53-8784-af41294ea092" xlink:href="ibrx-20231231.xsd#ibrx_December2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:to="loc_ibrx_December2022WarrantsMember_46783b48-5529-4c53-8784-af41294ea092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_f1cb8a31-e535-46b4-81d7-e59774a44e3a" xlink:href="ibrx-20231231.xsd#ibrx_February2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:to="loc_ibrx_February2023WarrantsMember_f1cb8a31-e535-46b4-81d7-e59774a44e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_July2023WarrantsMember_bfaf8c69-6b72-4fdc-8094-d33fabcd6d8e" xlink:href="ibrx-20231231.xsd#ibrx_July2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:to="loc_ibrx_July2023WarrantsMember_bfaf8c69-6b72-4fdc-8094-d33fabcd6d8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9f3aaaea-1def-4c94-a8b7-0a1e286ab7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9f3aaaea-1def-4c94-a8b7-0a1e286ab7d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c2136f89-3fa8-4ba5-a362-bf78173d60da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c2136f89-3fa8-4ba5-a362-bf78173d60da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6621a6ad-569d-4403-b7f5-156099998e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6621a6ad-569d-4403-b7f5-156099998e6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_280660a3-a18c-4920-825e-069fc5bf8a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_280660a3-a18c-4920-825e-069fc5bf8a65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_737e09c5-561d-4e60-af0c-c353a2ce9791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_DeferredOfferingCosts_737e09c5-561d-4e60-af0c-c353a2ce9791" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_01fed098-f45a-4444-a3b8-cc5e9f39be29" xlink:href="ibrx-20231231.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_01fed098-f45a-4444-a3b8-cc5e9f39be29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7e683b1a-42a6-4384-9690-45192ca807b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7e683b1a-42a6-4384-9690-45192ca807b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_475f1106-934e-4074-bec3-468d85454ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_475f1106-934e-4074-bec3-468d85454ad3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d985f867-a012-4edc-a814-8fdc8f70fd46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d985f867-a012-4edc-a814-8fdc8f70fd46" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec253984-a410-43d4-b3ef-46c4b7b62d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec253984-a410-43d4-b3ef-46c4b7b62d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec253984-a410-43d4-b3ef-46c4b7b62d05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec253984-a410-43d4-b3ef-46c4b7b62d05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec253984-a410-43d4-b3ef-46c4b7b62d05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d5c43ca-4e51-40c2-9156-1993d0190fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec253984-a410-43d4-b3ef-46c4b7b62d05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d5c43ca-4e51-40c2-9156-1993d0190fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_514d7bf5-f112-4d45-ae8a-a7ae9caf09a4" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d5c43ca-4e51-40c2-9156-1993d0190fce" xlink:to="loc_ibrx_NantCellInc.Member_514d7bf5-f112-4d45-ae8a-a7ae9caf09a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4b93c467-ae3f-4f97-96bf-fffb064ee7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_PlanNameAxis_4b93c467-ae3f-4f97-96bf-fffb064ee7ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4b93c467-ae3f-4f97-96bf-fffb064ee7ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4b93c467-ae3f-4f97-96bf-fffb064ee7ba" xlink:to="loc_us-gaap_PlanNameDomain_4b93c467-ae3f-4f97-96bf-fffb064ee7ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3ab5e1a3-19c7-4f8c-a5ae-3eac43749759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4b93c467-ae3f-4f97-96bf-fffb064ee7ba" xlink:to="loc_us-gaap_PlanNameDomain_3ab5e1a3-19c7-4f8c-a5ae-3eac43749759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_b5470bcd-a6a9-43bd-8c1b-88f7151edeaf" xlink:href="ibrx-20231231.xsd#ibrx_TwoThousandFifteenShareRepurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3ab5e1a3-19c7-4f8c-a5ae-3eac43749759" xlink:to="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_b5470bcd-a6a9-43bd-8c1b-88f7151edeaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f06894ff-e93f-4937-a0ff-d1009af419ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f06894ff-e93f-4937-a0ff-d1009af419ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f06894ff-e93f-4937-a0ff-d1009af419ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f06894ff-e93f-4937-a0ff-d1009af419ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f06894ff-e93f-4937-a0ff-d1009af419ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f06894ff-e93f-4937-a0ff-d1009af419ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_2c534532-abea-4ed8-b09b-52befa6fae65" xlink:href="ibrx-20231231.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_2c534532-abea-4ed8-b09b-52befa6fae65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_904d7e00-19fd-4676-bd7d-4ebb5ead9b48" xlink:href="ibrx-20231231.xsd#ibrx_PrivatePlacementAndAtTheMarketOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_904d7e00-19fd-4676-bd7d-4ebb5ead9b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_1cefbef4-9075-4bde-b4a9-ed943853e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_us-gaap_PrivatePlacementMember_1cefbef4-9075-4bde-b4a9-ed943853e4c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_5c17f285-dc54-4ba1-b2e1-5b55b4a34670" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_5c17f285-dc54-4ba1-b2e1-5b55b4a34670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6a1ff11-98e7-4f38-8e0f-395f490a61d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_srt_RangeAxis_b6a1ff11-98e7-4f38-8e0f-395f490a61d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6a1ff11-98e7-4f38-8e0f-395f490a61d3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b6a1ff11-98e7-4f38-8e0f-395f490a61d3" xlink:to="loc_srt_RangeMember_b6a1ff11-98e7-4f38-8e0f-395f490a61d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dceeaa8-b956-4869-a69a-2bdb3824c4aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b6a1ff11-98e7-4f38-8e0f-395f490a61d3" xlink:to="loc_srt_RangeMember_0dceeaa8-b956-4869-a69a-2bdb3824c4aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f9aca63e-2ef2-415a-97c4-5a8c693b8fcf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0dceeaa8-b956-4869-a69a-2bdb3824c4aa" xlink:to="loc_srt_MaximumMember_f9aca63e-2ef2-415a-97c4-5a8c693b8fcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3bb70744-633e-477a-af3c-1b76386eefa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3bb70744-633e-477a-af3c-1b76386eefa6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3bb70744-633e-477a-af3c-1b76386eefa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3bb70744-633e-477a-af3c-1b76386eefa6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3bb70744-633e-477a-af3c-1b76386eefa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c3b20f8-1533-4028-a564-d45c4c39b38e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3bb70744-633e-477a-af3c-1b76386eefa6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c3b20f8-1533-4028-a564-d45c4c39b38e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_fd498fd1-2858-44b9-b9f1-f01b6e739e1a" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c3b20f8-1533-4028-a564-d45c4c39b38e" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_fd498fd1-2858-44b9-b9f1-f01b6e739e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_31b89cf8-34d1-44dd-8e7b-abd2464dfc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_31b89cf8-34d1-44dd-8e7b-abd2464dfc83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_31b89cf8-34d1-44dd-8e7b-abd2464dfc83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_31b89cf8-34d1-44dd-8e7b-abd2464dfc83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_31b89cf8-34d1-44dd-8e7b-abd2464dfc83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_31b89cf8-34d1-44dd-8e7b-abd2464dfc83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_82bcd0c8-a5fc-456a-a573-ee8e2d7b9aa1" xlink:href="ibrx-20231231.xsd#ibrx_February2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:to="loc_ibrx_February2023WarrantsMember_82bcd0c8-a5fc-456a-a573-ee8e2d7b9aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_July2023WarrantsMember_31d3c53d-f6fa-448c-b9fc-4888706646fd" xlink:href="ibrx-20231231.xsd#ibrx_July2023WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:to="loc_ibrx_July2023WarrantsMember_31d3c53d-f6fa-448c-b9fc-4888706646fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_807a8983-74ba-4366-bba1-fc18967245ba" xlink:href="ibrx-20231231.xsd#ibrx_December2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:to="loc_ibrx_December2022WarrantsMember_807a8983-74ba-4366-bba1-fc18967245ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_73c813a5-9f16-4ce2-acd4-40b4746a350d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_73c813a5-9f16-4ce2-acd4-40b4746a350d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_73c813a5-9f16-4ce2-acd4-40b4746a350d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_73c813a5-9f16-4ce2-acd4-40b4746a350d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_73c813a5-9f16-4ce2-acd4-40b4746a350d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7faf2eb4-f8a5-42b6-b9bd-d4f9f40b1e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_73c813a5-9f16-4ce2-acd4-40b4746a350d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7faf2eb4-f8a5-42b6-b9bd-d4f9f40b1e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_71721223-89f3-40cd-9224-e8bc2b6ebce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7faf2eb4-f8a5-42b6-b9bd-d4f9f40b1e86" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_71721223-89f3-40cd-9224-e8bc2b6ebce0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0960a639-803e-43c0-9b7f-551b1612ee15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0960a639-803e-43c0-9b7f-551b1612ee15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0960a639-803e-43c0-9b7f-551b1612ee15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0960a639-803e-43c0-9b7f-551b1612ee15" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0960a639-803e-43c0-9b7f-551b1612ee15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0960a639-803e-43c0-9b7f-551b1612ee15" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_18118bfb-360e-491c-84b0-16213ad7d3aa" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_18118bfb-360e-491c-84b0-16213ad7d3aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksLLCMember_39ac9f9d-2a01-42a0-9b54-4ad505d99668" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantWorksLLCMember_39ac9f9d-2a01-42a0-9b54-4ad505d99668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_64a7c4ef-9ce4-45f2-a12d-aafcdbbc9abb" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantWorksMember_64a7c4ef-9ce4-45f2-a12d-aafcdbbc9abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksLLCMemberMember_c787e260-dbac-45d5-9436-2b94a3ca340d" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksLLCMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantWorksLLCMemberMember_c787e260-dbac-45d5-9436-2b94a3ca340d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40b7a099-1fba-4f27-b73f-587523d70348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40b7a099-1fba-4f27-b73f-587523d70348" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_40b7a099-1fba-4f27-b73f-587523d70348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40b7a099-1fba-4f27-b73f-587523d70348" xlink:to="loc_us-gaap_RelatedPartyDomain_40b7a099-1fba-4f27-b73f-587523d70348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_36a5aa4b-ede9-4303-9970-ca789a479834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40b7a099-1fba-4f27-b73f-587523d70348" xlink:to="loc_us-gaap_RelatedPartyDomain_36a5aa4b-ede9-4303-9970-ca789a479834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_fd637ec9-4640-45a4-940c-bb812e4c4329" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_36a5aa4b-ede9-4303-9970-ca789a479834" xlink:to="loc_srt_AffiliatedEntityMember_fd637ec9-4640-45a4-940c-bb812e4c4329" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ab096025-1740-4784-91bd-32edf1d87e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ab096025-1740-4784-91bd-32edf1d87e1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_58dd1353-018f-43bd-8220-01be924158f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_58dd1353-018f-43bd-8220-01be924158f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6aa5c87b-038d-455b-b4e5-3a55809e9668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6aa5c87b-038d-455b-b4e5-3a55809e9668" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e68c3b33-14a9-40de-bc15-bb2b257d1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockSharesIssued_e68c3b33-14a9-40de-bc15-bb2b257d1cf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dfede270-5bd7-450b-b133-678b36453876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dfede270-5bd7-450b-b133-678b36453876" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_3bfaab4a-3cbf-4030-9d99-48be911b30b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_TreasuryStockCommonShares_3bfaab4a-3cbf-4030-9d99-48be911b30b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MergerExchangeRatio_07655f5d-cb58-4bed-8c1a-02296c8467e2" xlink:href="ibrx-20231231.xsd#ibrx_MergerExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_MergerExchangeRatio_07655f5d-cb58-4bed-8c1a-02296c8467e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93900498-708d-4360-acf6-7976c620c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93900498-708d-4360-acf6-7976c620c23a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_320bac97-9e5f-47ef-b178-9ec25b907e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_320bac97-9e5f-47ef-b178-9ec25b907e03" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4e84bea5-589a-43f4-943f-9a8daea70716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4e84bea5-589a-43f4-943f-9a8daea70716" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11568e7b-a276-4517-9faf-0b83377315fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11568e7b-a276-4517-9faf-0b83377315fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1c1bf15f-2211-4161-aa10-3ee10f382426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1c1bf15f-2211-4161-aa10-3ee10f382426" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_8b3f0a50-6d06-46f9-a3f0-c54617aab652" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_8b3f0a50-6d06-46f9-a3f0-c54617aab652" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3b59ddc8-bcf7-4096-aa35-d2ee26941441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3b59ddc8-bcf7-4096-aa35-d2ee26941441" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_e2f1f4ff-efdf-492e-a3f6-d6ed4b017954" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_e2f1f4ff-efdf-492e-a3f6-d6ed4b017954" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfSalesAgentCommission_aea9c37f-1672-4eba-aab1-66fd369f5d44" xlink:href="ibrx-20231231.xsd#ibrx_PercentageOfSalesAgentCommission"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_PercentageOfSalesAgentCommission_aea9c37f-1672-4eba-aab1-66fd369f5d44" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ac282b7-2621-4008-b2e1-e8e01606a025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ac282b7-2621-4008-b2e1-e8e01606a025" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_70b0ad9b-1be9-449d-9dd2-aab0aa0f6938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_70b0ad9b-1be9-449d-9dd2-aab0aa0f6938" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_313edc9a-04b5-4b25-bae2-071bb686548a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_313edc9a-04b5-4b25-bae2-071bb686548a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40911659-77cd-4e01-ae6f-10e7dcce6b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40911659-77cd-4e01-ae6f-10e7dcce6b85" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c0d2c2d1-ece2-45fb-a017-201bab1a3238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c0d2c2d1-ece2-45fb-a017-201bab1a3238" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_10d400cf-c536-48e6-86d0-7b9588f31116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DeferredOfferingCosts_10d400cf-c536-48e6-86d0-7b9588f31116" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0ba5891b-51a9-41d1-a6c1-4acf0d0eb28f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0ba5891b-51a9-41d1-a6c1-4acf0d0eb28f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAdditionalPurchaseOption_36d0d130-1d2d-48ea-a229-4816d5e10521" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAdditionalPurchaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_SaleOfStockAdditionalPurchaseOption_36d0d130-1d2d-48ea-a229-4816d5e10521" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_cbbc5e96-38f9-4f7a-904a-b5b366682830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_cbbc5e96-38f9-4f7a-904a-b5b366682830" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_9e09a6e0-45f1-4393-a7fc-52604dc834a8" xlink:href="ibrx-20231231.xsd#ibrx_LongTermDebtGrossIncludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_9e09a6e0-45f1-4393-a7fc-52604dc834a8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7ea7edf-3b2d-4b58-be8c-87de51383422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7ea7edf-3b2d-4b58-be8c-87de51383422" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0dc010fd-f427-40a1-91ce-fc5580dce2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0dc010fd-f427-40a1-91ce-fc5580dce2de" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8e566468-e981-4408-8725-e0ec804a470b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8e566468-e981-4408-8725-e0ec804a470b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a54b9f96-ab20-47d8-82e0-a74160a06974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a54b9f96-ab20-47d8-82e0-a74160a06974" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8be9f5c4-ea5f-4153-a102-20210d988431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8be9f5c4-ea5f-4153-a102-20210d988431" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_912d7f42-e496-4629-8c58-683e731c9ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_PlanNameAxis_912d7f42-e496-4629-8c58-683e731c9ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_912d7f42-e496-4629-8c58-683e731c9ad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_912d7f42-e496-4629-8c58-683e731c9ad9" xlink:to="loc_us-gaap_PlanNameDomain_912d7f42-e496-4629-8c58-683e731c9ad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_912d7f42-e496-4629-8c58-683e731c9ad9" xlink:to="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A2014PlanMember_7d6b4e23-5d56-4ee6-818a-8332cd787dc1" xlink:href="ibrx-20231231.xsd#ibrx_A2014PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:to="loc_ibrx_A2014PlanMember_7d6b4e23-5d56-4ee6-818a-8332cd787dc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellTwoThousandAndFifteenPlanMember_e7e23637-c2e1-4aec-98f9-fb77d479eee1" xlink:href="ibrx-20231231.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:to="loc_ibrx_NantCellTwoThousandAndFifteenPlanMember_e7e23637-c2e1-4aec-98f9-fb77d479eee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_6b315248-52af-4787-8244-2be43b5eda2e" xlink:href="ibrx-20231231.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:to="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_6b315248-52af-4787-8244-2be43b5eda2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6eafd773-a302-45ae-85a4-74de2a5050ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6eafd773-a302-45ae-85a4-74de2a5050ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6eafd773-a302-45ae-85a4-74de2a5050ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6eafd773-a302-45ae-85a4-74de2a5050ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6eafd773-a302-45ae-85a4-74de2a5050ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f517bd0-8adf-45e8-a96f-b5db52d77ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6eafd773-a302-45ae-85a4-74de2a5050ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f517bd0-8adf-45e8-a96f-b5db52d77ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_f6ad1065-f51c-4d55-8eb5-2ff0addc9ac5" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f517bd0-8adf-45e8-a96f-b5db52d77ec2" xlink:to="loc_ibrx_NantCellInc.Member_f6ad1065-f51c-4d55-8eb5-2ff0addc9ac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f813fa9e-a173-4e5d-ac38-180001258d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_AwardTypeAxis_f813fa9e-a173-4e5d-ac38-180001258d84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f813fa9e-a173-4e5d-ac38-180001258d84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f813fa9e-a173-4e5d-ac38-180001258d84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f813fa9e-a173-4e5d-ac38-180001258d84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f813fa9e-a173-4e5d-ac38-180001258d84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7f6b8668-8496-4138-a155-5d8ebe4ec808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7f6b8668-8496-4138-a155-5d8ebe4ec808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d5f16825-1d78-4f87-9fb9-60486561d02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d5f16825-1d78-4f87-9fb9-60486561d02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsMember_ab0d18f5-b8ef-4828-9bfa-f59ec7d3950d" xlink:href="ibrx-20231231.xsd#ibrx_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:to="loc_ibrx_WarrantsMember_ab0d18f5-b8ef-4828-9bfa-f59ec7d3950d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2ed847f0-513c-4365-8de1-5ead84f6a0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2ed847f0-513c-4365-8de1-5ead84f6a0bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2ed847f0-513c-4365-8de1-5ead84f6a0bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ed847f0-513c-4365-8de1-5ead84f6a0bc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2ed847f0-513c-4365-8de1-5ead84f6a0bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_91025211-7b66-419f-8f52-9cc1204a85ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ed847f0-513c-4365-8de1-5ead84f6a0bc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_91025211-7b66-419f-8f52-9cc1204a85ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3101d62b-d16e-42e4-915d-d0b129125fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_91025211-7b66-419f-8f52-9cc1204a85ae" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3101d62b-d16e-42e4-915d-d0b129125fae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34760a06-adb3-4d4e-b1a2-93a585556d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34760a06-adb3-4d4e-b1a2-93a585556d60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_34760a06-adb3-4d4e-b1a2-93a585556d60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34760a06-adb3-4d4e-b1a2-93a585556d60" xlink:to="loc_us-gaap_RelatedPartyDomain_34760a06-adb3-4d4e-b1a2-93a585556d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc0e4417-c437-4be2-b72a-225d936be9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34760a06-adb3-4d4e-b1a2-93a585556d60" xlink:to="loc_us-gaap_RelatedPartyDomain_cc0e4417-c437-4be2-b72a-225d936be9e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_de98fd56-f526-4865-bf49-8d1d6dbd1822" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cc0e4417-c437-4be2-b72a-225d936be9e6" xlink:to="loc_ibrx_NantWorksMember_de98fd56-f526-4865-bf49-8d1d6dbd1822" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_VestingAxis_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71" xlink:to="loc_us-gaap_VestingDomain_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71" xlink:to="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_663b4680-6945-43f9-ad26-68fc7739ee27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_663b4680-6945-43f9-ad26-68fc7739ee27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_eae10ed8-33d9-460a-9be9-e49c47804d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_eae10ed8-33d9-460a-9be9-e49c47804d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_167a7243-83ee-4474-b3a1-c965eba2b59d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_167a7243-83ee-4474-b3a1-c965eba2b59d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b50b8130-fb5e-427c-b113-813e40631c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b50b8130-fb5e-427c-b113-813e40631c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_011bad8a-cf12-4fda-8598-db12110a122e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_011bad8a-cf12-4fda-8598-db12110a122e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0c3034d0-d275-4687-8156-66518977c89e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0c3034d0-d275-4687-8156-66518977c89e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_038eb8d9-cd0c-414c-80ea-0c2e93fa7fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_038eb8d9-cd0c-414c-80ea-0c2e93fa7fa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c8f68c72-4e6c-4fe3-afd3-b8993365ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c8f68c72-4e6c-4fe3-afd3-b8993365ea6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9445033b-cf8e-4d22-b9a9-21e191faac43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9445033b-cf8e-4d22-b9a9-21e191faac43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6af0183d-d1b1-4532-828f-9b0600a9e44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6af0183d-d1b1-4532-828f-9b0600a9e44f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fe2172f0-4920-4f42-bf4d-739f0203896c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fe2172f0-4920-4f42-bf4d-739f0203896c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_22853d25-2135-4082-9ac2-f34d567b9985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_22853d25-2135-4082-9ac2-f34d567b9985" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d4663a06-9f8a-4437-836e-98991fb2c761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d4663a06-9f8a-4437-836e-98991fb2c761" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb5c97cc-140d-4e83-b2ff-3816ea456a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb5c97cc-140d-4e83-b2ff-3816ea456a73" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_c31e947f-6a7b-45ae-905d-c73f3d948cb7" xlink:href="ibrx-20231231.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_c31e947f-6a7b-45ae-905d-c73f3d948cb7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_b921072d-20f6-4876-b88e-8ba1d7fffb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_Dividends_b921072d-20f6-4876-b88e-8ba1d7fffb8d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37685dec-91e3-4961-9a94-2a24ab682e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37685dec-91e3-4961-9a94-2a24ab682e43" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_756179e0-e3eb-4191-9257-97cf17be7304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_756179e0-e3eb-4191-9257-97cf17be7304" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ceae677d-3cbb-45bd-9d98-504959290c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ceae677d-3cbb-45bd-9d98-504959290c89" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d7ccefe-70e8-4d74-9f46-c49b61529127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d7ccefe-70e8-4d74-9f46-c49b61529127" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6c623fb-59a0-410f-83fe-2cf2561ba596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:to="loc_us-gaap_AwardTypeAxis_b6c623fb-59a0-410f-83fe-2cf2561ba596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6c623fb-59a0-410f-83fe-2cf2561ba596_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b6c623fb-59a0-410f-83fe-2cf2561ba596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6c623fb-59a0-410f-83fe-2cf2561ba596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b6c623fb-59a0-410f-83fe-2cf2561ba596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b73c33b8-f953-45af-8840-7da15a29fce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:to="loc_us-gaap_StockOptionMember_b73c33b8-f953-45af-8840-7da15a29fce2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_58a07a9e-36c3-4a73-bd0e-112c2236e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_58a07a9e-36c3-4a73-bd0e-112c2236e6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f0491f3b-7c33-4939-95d2-28abedcc305a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f0491f3b-7c33-4939-95d2-28abedcc305a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f0491f3b-7c33-4939-95d2-28abedcc305a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f0491f3b-7c33-4939-95d2-28abedcc305a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f0491f3b-7c33-4939-95d2-28abedcc305a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f0491f3b-7c33-4939-95d2-28abedcc305a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f65b7631-0284-4ac1-a028-6bc6d25318bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f65b7631-0284-4ac1-a028-6bc6d25318bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b17fe36-f405-4752-a230-28c091a0b104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b17fe36-f405-4752-a230-28c091a0b104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39953509-2957-488c-9a65-f6f46159d90f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d7ccefe-70e8-4d74-9f46-c49b61529127" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39953509-2957-488c-9a65-f6f46159d90f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7310335-c3ef-4c24-a64c-e2b9bdfd9ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7310335-c3ef-4c24-a64c-e2b9bdfd9ae2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c7f399f-df99-4303-83cd-635c2fa00f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7310335-c3ef-4c24-a64c-e2b9bdfd9ae2" xlink:to="loc_us-gaap_AwardTypeAxis_7c7f399f-df99-4303-83cd-635c2fa00f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c7f399f-df99-4303-83cd-635c2fa00f4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7c7f399f-df99-4303-83cd-635c2fa00f4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c7f399f-df99-4303-83cd-635c2fa00f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d3f3559-c7e5-4348-9acc-6c2327ab0c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7c7f399f-df99-4303-83cd-635c2fa00f4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d3f3559-c7e5-4348-9acc-6c2327ab0c9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab6eb71b-b6ee-4366-b709-c7062176bd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d3f3559-c7e5-4348-9acc-6c2327ab0c9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab6eb71b-b6ee-4366-b709-c7062176bd22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eeac2859-a9f3-4f40-adb4-6559a02f60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eeac2859-a9f3-4f40-adb4-6559a02f60ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a9dc603-65b4-4403-aea3-0a5bb3d0ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a9dc603-65b4-4403-aea3-0a5bb3d0ae48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f0c24ae8-62b5-4dee-b7e5-7af9fdf0bde3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f0c24ae8-62b5-4dee-b7e5-7af9fdf0bde3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd8a8ab8-b0c1-434e-bc85-86555f787a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd8a8ab8-b0c1-434e-bc85-86555f787a36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e3dcd73-f140-4079-8481-46b730617d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e3dcd73-f140-4079-8481-46b730617d5d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationRSUActivityunderEquityPlansDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d6fcc6-8f4e-45ae-8466-4af9b59e39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d6fcc6-8f4e-45ae-8466-4af9b59e39a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69948394-94bf-49b2-865c-ef269b5b6ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d6fcc6-8f4e-45ae-8466-4af9b59e39a5" xlink:to="loc_us-gaap_AwardTypeAxis_69948394-94bf-49b2-865c-ef269b5b6ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69948394-94bf-49b2-865c-ef269b5b6ecb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_69948394-94bf-49b2-865c-ef269b5b6ecb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_69948394-94bf-49b2-865c-ef269b5b6ecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0865baf-3a8f-49d0-b993-efebdce7b909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_69948394-94bf-49b2-865c-ef269b5b6ecb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0865baf-3a8f-49d0-b993-efebdce7b909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_05dc78c5-1c2a-445a-8510-7a22340bb917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0865baf-3a8f-49d0-b993-efebdce7b909" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_05dc78c5-1c2a-445a-8510-7a22340bb917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c817dc37-3e6a-486b-b6fc-774796159591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c817dc37-3e6a-486b-b6fc-774796159591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e57fa07-66f3-40c5-a783-9173cbcd2cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e57fa07-66f3-40c5-a783-9173cbcd2cd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0af7b66e-522f-4407-b91e-23da64b4ec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0af7b66e-522f-4407-b91e-23da64b4ec4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_38a945e6-aab3-4c4d-a3cc-443e0aaa1e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_38a945e6-aab3-4c4d-a3cc-443e0aaa1e11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a13ae78b-c6a6-4f9f-ab31-966799f81140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595769b1-f592-4f87-96bf-280370555af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595769b1-f592-4f87-96bf-280370555af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_edc31c9a-3413-4fac-b8b4-d45a79b1d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_edc31c9a-3413-4fac-b8b4-d45a79b1d6df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5591f925-e9a6-4d37-9e77-39fdbbc12bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5591f925-e9a6-4d37-9e77-39fdbbc12bbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6fcd53f-4e2b-44ea-a1b6-5e9f19876ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6fcd53f-4e2b-44ea-a1b6-5e9f19876ef8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_669efe52-4acc-494d-87a5-f9d5c81a360a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:href="ibrx-20231231.xsd#ibrx_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxTable_85fbf8e9-0176-4c95-9023-ee94edcc50f3" xlink:href="ibrx-20231231.xsd#ibrx_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_IncomeTaxTable_85fbf8e9-0176-4c95-9023-ee94edcc50f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0d3f2da3-1700-4c9c-affa-cbac4b40fc85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ibrx_IncomeTaxTable_85fbf8e9-0176-4c95-9023-ee94edcc50f3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0d3f2da3-1700-4c9c-affa-cbac4b40fc85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0d3f2da3-1700-4c9c-affa-cbac4b40fc85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0d3f2da3-1700-4c9c-affa-cbac4b40fc85" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0d3f2da3-1700-4c9c-affa-cbac4b40fc85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0d3f2da3-1700-4c9c-affa-cbac4b40fc85" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c91e3836-bf73-4c02-b633-c99a2261d406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:to="loc_us-gaap_DomesticCountryMember_c91e3836-bf73-4c02-b633-c99a2261d406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_03332962-3588-49c0-b001-3e1b2c4e10b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_03332962-3588-49c0-b001-3e1b2c4e10b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7d835fcd-be9d-438b-8465-42cd3bea7b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7d835fcd-be9d-438b-8465-42cd3bea7b97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_506a783d-eea1-443a-b953-3054a0ec7e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_506a783d-eea1-443a-b953-3054a0ec7e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_2d353781-1da7-4222-8a0b-fec17f68bc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_2d353781-1da7-4222-8a0b-fec17f68bc3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_6d2459c2-6055-462d-8ed8-db0e02cfd529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_6d2459c2-6055-462d-8ed8-db0e02cfd529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_245c05d0-84ec-4987-936a-ba17e59db2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_245c05d0-84ec-4987-936a-ba17e59db2fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b1be6992-346d-4635-bc54-ca86adb425f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b1be6992-346d-4635-bc54-ca86adb425f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital_7ae93655-6c47-4f92-8c09-5fda2cff6607" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital_7ae93655-6c47-4f92-8c09-5fda2cff6607" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations_ec1dd91d-d97c-455d-8922-160fbe9e59e2" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations_ec1dd91d-d97c-455d-8922-160fbe9e59e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0d97797f-7693-44db-aab6-74baf6ef6f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0d97797f-7693-44db-aab6-74baf6ef6f2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_3f0b7dc6-1e6b-4c09-9004-59e6f617a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_3f0b7dc6-1e6b-4c09-9004-59e6f617a2a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed_34e4062a-3474-48cc-848d-b5ebf292bdd1" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed_34e4062a-3474-48cc-848d-b5ebf292bdd1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_645775bb-9258-4026-b5bd-cbf1d941c86a" xlink:href="ibrx-20231231.xsd#ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_645775bb-9258-4026-b5bd-cbf1d941c86a" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>ibrx-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1fd74a66-0ec9-47b3-a3a2-77069a10a521,g:7ebe44e2-bf98-46f1-8b70-fddc2baf2bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_5f9976e4-ba5e-4750-8d38-d39c280d8a5d_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment to spend, operational expenses, initial lease term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:to="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsTerminationFee_61dad9e8-66f3-4236-b5d9-c706a2f9d3ac_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination fee</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsTerminationFee_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Termination Fee</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsTerminationFee_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsTerminationFee" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsTerminationFee" xlink:to="lab_ibrx_CollaborationAgreementsTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales_74f0f602-1e2e-4e1b-8d18-42c8cf07c933_terseLabel_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments as a percentage of net sales</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales_label_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales_documentation_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" xlink:to="lab_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed_835ee633-823c-4248-b326-cda809f6bc04_terseLabel_en-US" xlink:label="lab_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, interest expense temporarily disallowed</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed_label_en-US" xlink:label="lab_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset Not Recognized, Interest Expense Temporarily Disallowed</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed_documentation_en-US" xlink:label="lab_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset Not Recognized, Interest Expense Temporarily Disallowed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" xlink:to="lab_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0f26d10b-f4a5-49de-b659-f51667cb5e4b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LaboratoryCleanroomServiceCostsMember_d3ee87f6-f3fa-493d-9b65-0d391744b01b_terseLabel_en-US" xlink:label="lab_ibrx_LaboratoryCleanroomServiceCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Cleanroom Service Costs</link:label>
    <link:label id="lab_ibrx_LaboratoryCleanroomServiceCostsMember_label_en-US" xlink:label="lab_ibrx_LaboratoryCleanroomServiceCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Cleanroom Service Costs [Member]</link:label>
    <link:label id="lab_ibrx_LaboratoryCleanroomServiceCostsMember_documentation_en-US" xlink:label="lab_ibrx_LaboratoryCleanroomServiceCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Cleanroom Service Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LaboratoryCleanroomServiceCostsMember" xlink:href="ibrx-20231231.xsd#ibrx_LaboratoryCleanroomServiceCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LaboratoryCleanroomServiceCostsMember" xlink:to="lab_ibrx_LaboratoryCleanroomServiceCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ebb22ffd-4bea-4173-a565-5af42cc7b537_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_99e18d0d-c733-45ce-8e53-b654f4464f68_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5e975119-b4a9-44c1-b692-6b4abb6beb11_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent_8e79f9fb-3d62-4fc8-b38e-cbdef2b4536b_terseLabel_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 162(m) limitation</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent_label_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Nondeductible Expense, Section 162(m) Limitation, Percent</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent_documentation_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Nondeductible Expense, Section 162(m) Limitation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" xlink:to="lab_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_e40d2c52-e82e-407a-a4ec-c6a6bbb430a3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a416ddd1-291d-40dd-8ee6-a2841e2bf55b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_2350d9fa-48cb-465d-8c15-ecb3793a296c_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3b4bbef3-614d-4568-a010-29f2c1858b87_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment accretion income (amortization expense), net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4026fae2-e355-4508-8877-b0a5a605e2db_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_13c8b4b4-03bf-431c-a21d-28f6ba025c33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_08783f22-e0ff-4db4-9b7d-a3491875f937_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares to be issued in private placement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_2d419d8a-4f66-4b91-9727-40fdeaf6b23f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net, Impairment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AtTheMarketOfferingProgramMember_7831546c-6e28-4ad9-b4cc-7164759d2f62_terseLabel_en-US" xlink:label="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Offering Program</link:label>
    <link:label id="lab_ibrx_AtTheMarketOfferingProgramMember_fcb3d31b-65f9-4824-bd02-df221c424853_verboseLabel_en-US" xlink:label="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">At-the-Market</link:label>
    <link:label id="lab_ibrx_AtTheMarketOfferingProgramMember_label_en-US" xlink:label="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Program [Member]</link:label>
    <link:label id="lab_ibrx_AtTheMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market offering program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AtTheMarketOfferingProgramMember" xlink:to="lab_ibrx_AtTheMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NANTibodyLLCMember_3f7d16da-8db9-4534-8a1b-d099a2da0b16_terseLabel_en-US" xlink:label="lab_ibrx_NANTibodyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NANTibody, LLC</link:label>
    <link:label id="lab_ibrx_NANTibodyLLCMember_label_en-US" xlink:label="lab_ibrx_NANTibodyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NANTibody, LLC [Member]</link:label>
    <link:label id="lab_ibrx_NANTibodyLLCMember_documentation_en-US" xlink:label="lab_ibrx_NANTibodyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NANTibody, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_NANTibodyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NANTibodyLLCMember" xlink:to="lab_ibrx_NANTibodyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidResearchAndDevelopmentCosts_7318becf-4a44-4681-994c-228f34159b94_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development costs</link:label>
    <link:label id="lab_ibrx_PrepaidResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:label id="lab_ibrx_PrepaidResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:to="lab_ibrx_PrepaidResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember_12f6c6ee-716f-4686-a7c5-962ffa9306a9_terseLabel_en-US" xlink:label="lab_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Embedded contingent derivative liability</link:label>
    <link:label id="lab_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember_label_en-US" xlink:label="lab_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Revenue Interest Purchase Agreement [Member]</link:label>
    <link:label id="lab_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Revenue Interest Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" xlink:to="lab_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_48d54bf1-5010-4cd6-b19c-ba193cc91138_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember_941b944a-9d52-4a0d-a0ab-88b8736c7653_terseLabel_en-US" xlink:label="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Equity Incentive Plan</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand fifteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:href="ibrx-20231231.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_8abdce3c-7660-4999-beea-361e769eede7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected average volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StockIssuedDuringPeriodValueLitigationSettlement_140db7b8-6b4c-45c4-ba4f-28bc0e41cfa2_terseLabel_en-US" xlink:label="lab_ibrx_StockIssuedDuringPeriodValueLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to litigation settlement</link:label>
    <link:label id="lab_ibrx_StockIssuedDuringPeriodValueLitigationSettlement_label_en-US" xlink:label="lab_ibrx_StockIssuedDuringPeriodValueLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Litigation Settlement</link:label>
    <link:label id="lab_ibrx_StockIssuedDuringPeriodValueLitigationSettlement_documentation_en-US" xlink:label="lab_ibrx_StockIssuedDuringPeriodValueLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedDuringPeriodValueLitigationSettlement" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedDuringPeriodValueLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StockIssuedDuringPeriodValueLitigationSettlement" xlink:to="lab_ibrx_StockIssuedDuringPeriodValueLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1695e8f5-bd7b-4975-a75d-630f0773ca70_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OrganizedWorkforceMember_a1b64415-f232-4524-8da5-f1848f826744_terseLabel_en-US" xlink:label="lab_ibrx_OrganizedWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organized workforce</link:label>
    <link:label id="lab_ibrx_OrganizedWorkforceMember_label_en-US" xlink:label="lab_ibrx_OrganizedWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organized Workforce [Member]</link:label>
    <link:label id="lab_ibrx_OrganizedWorkforceMember_documentation_en-US" xlink:label="lab_ibrx_OrganizedWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organized Workforce</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember" xlink:href="ibrx-20231231.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OrganizedWorkforceMember" xlink:to="lab_ibrx_OrganizedWorkforceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ef296494-a0e3-46f0-842c-72dd188a4bf3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_f4d02b58-b89e-49d8-adf8-7192f229df6e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember_1e36f7a1-2f99-4996-ac8c-8a47ea466d6a_terseLabel_en-US" xlink:label="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Share Repurchase Plan</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember_label_en-US" xlink:label="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Share Repurchase Plan [Member]</link:label>
    <link:label id="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember_documentation_en-US" xlink:label="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 share repurchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:href="ibrx-20231231.xsd#ibrx_TwoThousandFifteenShareRepurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:to="lab_ibrx_TwoThousandFifteenShareRepurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_88275b46-08cc-45d4-8025-4764e9d7bc17_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9ed32a81-2dfc-4aa1-af76-5130e89d1ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_730f009d-bf41-4796-9781-bbb4f3d97e87_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bd0477d8-8121-4a33-bdfb-8020f10139fe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_443af35a-73e8-4d6f-81ce-a417b25fbcc5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseRelatedPayables_ccaf503f-5aa6-4f18-9f46-49127a19224d_terseLabel_en-US" xlink:label="lab_ibrx_LeaseRelatedPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease-related payables</link:label>
    <link:label id="lab_ibrx_LeaseRelatedPayables_label_en-US" xlink:label="lab_ibrx_LeaseRelatedPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Related Payables</link:label>
    <link:label id="lab_ibrx_LeaseRelatedPayables_documentation_en-US" xlink:label="lab_ibrx_LeaseRelatedPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease-related payables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRelatedPayables" xlink:href="ibrx-20231231.xsd#ibrx_LeaseRelatedPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseRelatedPayables" xlink:to="lab_ibrx_LeaseRelatedPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_WarrantLiabilityTextBlock_b059034c-cfd7-4f7a-a860-8e0ea3e53218_terseLabel_en-US" xlink:label="lab_ibrx_WarrantLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liabilities</link:label>
    <link:label id="lab_ibrx_WarrantLiabilityTextBlock_label_en-US" xlink:label="lab_ibrx_WarrantLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Text Block]</link:label>
    <link:label id="lab_ibrx_WarrantLiabilityTextBlock_documentation_en-US" xlink:label="lab_ibrx_WarrantLiabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantLiabilityTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_WarrantLiabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_WarrantLiabilityTextBlock" xlink:to="lab_ibrx_WarrantLiabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_649efd7b-9812-442b-8a7c-20506febc788_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e5727d30-29a9-4149-b018-f71a07853c13_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per ImmunityBio common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_17468130-6f73-4031-aecb-de91183fa659_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_319a7ef3-9f45-422c-a612-8509baca9bf6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccruedResearchAndDevelopmentCosts_b3610a90-b106-4c90-926c-2a06eedd7406_terseLabel_en-US" xlink:label="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development costs</link:label>
    <link:label id="lab_ibrx_AccruedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs</link:label>
    <link:label id="lab_ibrx_AccruedResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedResearchAndDevelopmentCosts" xlink:href="ibrx-20231231.xsd#ibrx_AccruedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccruedResearchAndDevelopmentCosts" xlink:to="lab_ibrx_AccruedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PeriodOfRentFreeLeaseTerm_1e05c116-c7d7-44d5-bbf8-b894d8e0a418_terseLabel_en-US" xlink:label="lab_ibrx_PeriodOfRentFreeLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of rent free lease term</link:label>
    <link:label id="lab_ibrx_PeriodOfRentFreeLeaseTerm_label_en-US" xlink:label="lab_ibrx_PeriodOfRentFreeLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Rent Free Lease Term</link:label>
    <link:label id="lab_ibrx_PeriodOfRentFreeLeaseTerm_documentation_en-US" xlink:label="lab_ibrx_PeriodOfRentFreeLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Rent Free Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfRentFreeLeaseTerm" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOfRentFreeLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PeriodOfRentFreeLeaseTerm" xlink:to="lab_ibrx_PeriodOfRentFreeLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_979a4da6-19c3-414b-9dff-0d97bba91a96_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements and Acquisition</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AuditInformationAbstract_label_en-US" xlink:label="lab_ibrx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ibrx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ibrx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AuditInformationAbstract" xlink:href="ibrx-20231231.xsd#ibrx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AuditInformationAbstract" xlink:to="lab_ibrx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_5c9340f1-d32f-4cee-aed0-ee5db758cd26_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1a3622c6-47fa-4739-bf26-0f35e6167797_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7a61dddf-2cf2-4a07-b0cd-8d7c99675d75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_a13ea3c8-8401-4391-b209-a60b6fc06795_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ebf775f1-c92f-4870-857d-3e2d17c1d6bb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_fd65a774-fa4c-4d70-bc26-2cac7fcc144d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b7671e33-af86-4e9c-8780-7c346b5d1c26_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_311bdb76-adef-42d0-886b-270eae942a93_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_c05b55f2-af8b-479f-838a-a6293ac18561_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2a33f057-6811-44b7-88bd-c4cc2ff5be9e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8779a108-9bf9-48fd-8611-e74a1c119ecb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_499b7e47-6170-43b9-9f38-8fc93ac7922a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax rate adjustment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a414246d-6ed5-48a6-a482-9062a395753d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes to Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_60bf63bc-2072-4da7-ba01-2d9b0a3b43ea_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable_d2d607d0-cb4f-4a97-987f-6740ad907fc5_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License payable</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, License Maintenance Fees Payable</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, License Maintenance Fees Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable" xlink:to="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_774477f0-8322-4a38-92cb-1cc6c8b135f9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_0d6acb57-dca8-41b5-a41c-9a318ead4e35_totalLabel_en-US" xlink:label="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_label_en-US" xlink:label="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Fair Value Of Assets Acquired</link:label>
    <link:label id="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_documentation_en-US" xlink:label="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Fair Value Of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:href="ibrx-20231231.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:to="lab_ibrx_AssetAcquisitionFairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_ed19669a-15e9-4229-ad7a-12a9943dc417_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_9b017fd0-c65e-4a2d-b486-8334e69822a9_terseLabel_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration arrangements, paid</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_label_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Settlements</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_documentation_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:href="ibrx-20231231.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:to="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9c3d21cd-0968-4a13-94f5-6217107f7b51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember_60fabb30-12be-4734-bc2e-33d77ba0dbce_terseLabel_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$505 Million Promissory Note, December 2023, Tranche Two</link:label>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember_label_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$505 Million Promissory Note, December 2023, Tranche Two [Member]</link:label>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember_documentation_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$505 Million Promissory Note, December 2023, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember" xlink:to="lab_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_349d337b-5fc1-4bee-9980-cccba9db2b27_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_db97e593-984e-4e5c-a0b7-7a2cc0e8e805_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForMergerRelatedCosts_ccedc186-051b-40a5-9f12-ac514e2960d5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger-related costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForMergerRelatedCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Merger Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForMergerRelatedCosts" xlink:to="lab_us-gaap_PaymentsForMergerRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative_ba5dce92-2553-4d55-b865-e7f0b44071ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of embedded conversion feature from debt modification</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain on Embedded Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative" xlink:to="lab_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_94cebe3b-6732-4619-a400-d9b814301eb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_5f0c3198-0c6b-450f-8012-41d1cd64b8cb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4f1b6dd9-76b9-4fe0-87cc-c932deed68eb_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Useful Lives of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_43e58dcc-e4bb-472e-9706-b18d7666f9dc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_38b4fa1d-65cb-4a28-b487-57989619b773_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total ImmunityBio Stockholders&#8217; (Deficit) Equity</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b20bbc90-1c06-4256-9022-f43788c9cc9f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5b0316bc-d5b6-447e-a048-598598e9bee7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fd969203-e7c0-4d36-8a8c-2f2e16625cc7_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5170f047-52de-4418-8a63-e53bec4a4622_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SorrentoTherapeuticsIncLitigationMember_c13ff5f7-f99d-49ea-ad2f-a453c02a0a9c_terseLabel_en-US" xlink:label="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sorrento Therapeutics, Inc. Litigation</link:label>
    <link:label id="lab_ibrx_SorrentoTherapeuticsIncLitigationMember_label_en-US" xlink:label="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sorrento Therapeutics, Inc. Litigation [Member]</link:label>
    <link:label id="lab_ibrx_SorrentoTherapeuticsIncLitigationMember_documentation_en-US" xlink:label="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sorrento Therapeutics, Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:href="ibrx-20231231.xsd#ibrx_SorrentoTherapeuticsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:to="lab_ibrx_SorrentoTherapeuticsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_db00898c-d325-45b5-8026-7dc57ed4357b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3ad76c04-5dec-4941-bc7e-691f3b498f6c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77e2856d-4c84-40c3-8279-3a60d797032a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0735ca92-296b-4abd-9516-ebafbabd58a0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IntangibleAssetsAccumulatedImpairment_5aee508f-72e9-497d-8577-1f7c3ee2786c_negatedTotalLabel_en-US" xlink:label="lab_ibrx_IntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ibrx_IntangibleAssetsAccumulatedImpairment_label_en-US" xlink:label="lab_ibrx_IntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Accumulated Impairment</link:label>
    <link:label id="lab_ibrx_IntangibleAssetsAccumulatedImpairment_documentation_en-US" xlink:label="lab_ibrx_IntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Accumulated Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IntangibleAssetsAccumulatedImpairment" xlink:href="ibrx-20231231.xsd#ibrx_IntangibleAssetsAccumulatedImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IntangibleAssetsAccumulatedImpairment" xlink:to="lab_ibrx_IntangibleAssetsAccumulatedImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a88cf044-7cbd-4ccf-9ab6-1f84329ea923_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_28a638ff-bf58-4cad-be76-ebd1d74e7b62_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyConvertibleNotesMember_fe0b0066-d6ff-40e1-a905-5ef03ecc080f_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-party convertible notes</link:label>
    <link:label id="lab_ibrx_RelatedPartyConvertibleNotesMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Convertible Notes [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyConvertibleNotesMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyConvertibleNotesMember" xlink:to="lab_ibrx_RelatedPartyConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ccad10f5-484f-47a3-9d26-e4e78bfd160f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SharedServicesAgreementMember_0ef75f18-54aa-4db6-a2fa-71a6587e4789_terseLabel_en-US" xlink:label="lab_ibrx_SharedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shared Services Agreement</link:label>
    <link:label id="lab_ibrx_SharedServicesAgreementMember_label_en-US" xlink:label="lab_ibrx_SharedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shared Services Agreement [Member]</link:label>
    <link:label id="lab_ibrx_SharedServicesAgreementMember_documentation_en-US" xlink:label="lab_ibrx_SharedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shared services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharedServicesAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_SharedServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SharedServicesAgreementMember" xlink:to="lab_ibrx_SharedServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2b52945d-ed48-4205-8c2a-929d9cf4e3d8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_590c3be4-7cab-4173-b70c-e96995d3b773_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual payment for support of research activities</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Annual Payment For Support Of Research Activities</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual payment for support of research activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:to="lab_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_c9f5782d-7113-4011-b29a-9ffbecc75f23_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_357be082-b659-4b5d-a672-8b1ba1607981_terseLabel_en-US" xlink:label="lab_ibrx_ProceedsFromIssuanceOfSecuredDebtGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the RIPA, gross</link:label>
    <link:label id="lab_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_label_en-US" xlink:label="lab_ibrx_ProceedsFromIssuanceOfSecuredDebtGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Secured Debt, Gross</link:label>
    <link:label id="lab_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_documentation_en-US" xlink:label="lab_ibrx_ProceedsFromIssuanceOfSecuredDebtGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Secured Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross" xlink:href="ibrx-20231231.xsd#ibrx_ProceedsFromIssuanceOfSecuredDebtGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross" xlink:to="lab_ibrx_ProceedsFromIssuanceOfSecuredDebtGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DebtInstrumentFaceAmountPerTranche_94b91fd9-ccfb-4cb2-a439-f66e50026dcb_terseLabel_en-US" xlink:label="lab_ibrx_DebtInstrumentFaceAmountPerTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount, per tranche</link:label>
    <link:label id="lab_ibrx_DebtInstrumentFaceAmountPerTranche_label_en-US" xlink:label="lab_ibrx_DebtInstrumentFaceAmountPerTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Per Tranche</link:label>
    <link:label id="lab_ibrx_DebtInstrumentFaceAmountPerTranche_documentation_en-US" xlink:label="lab_ibrx_DebtInstrumentFaceAmountPerTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Per Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentFaceAmountPerTranche" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentFaceAmountPerTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DebtInstrumentFaceAmountPerTranche" xlink:to="lab_ibrx_DebtInstrumentFaceAmountPerTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtMember_8cd4bab7-1f22-4ad0-8681-cf716f1e66f7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Government Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a4e7ee9e-ffc7-4b9b-bbf8-6251fad018b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_eff25b3a-8d87-404a-8284-112c06219c17_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_39d68226-d5ec-4702-8d22-bd5fe6a808bc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_442f7089-d43b-4f46-8a94-4aeff937118d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ef3196af-5a95-482d-aa66-5d65bd84f34c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_fd3435b7-1d2e-4dea-b10f-ae25ebab2c3b_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Contractual Obligations for Related-Party Notes Payable</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncomeTaxTable_c866eae8-4407-4f56-b91f-527c372e2c68_terseLabel_en-US" xlink:label="lab_ibrx_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_ibrx_IncomeTaxTable_label_en-US" xlink:label="lab_ibrx_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_ibrx_IncomeTaxTable_documentation_en-US" xlink:label="lab_ibrx_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxTable" xlink:href="ibrx-20231231.xsd#ibrx_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncomeTaxTable" xlink:to="lab_ibrx_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionTypeAxis_3126d9a9-191d-457c-b436-e46d42e033e0_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Type</link:label>
    <link:label id="lab_us-gaap_TransactionTypeAxis_label_en-US" xlink:label="lab_us-gaap_TransactionTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3c31f012-c9c1-44a5-a141-a4637ca9e447_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e705b1f2-759b-40e5-9ef4-f392726b23f7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a7500f4d-7fde-4d96-b47d-b0ac4314b174_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net share settlement for RSUs vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ba71894e-5b88-4443-ac0d-d3c437565727_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_8b95e32c-7bc5-43ed-881f-8820ccb62473_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_a2938a30-3524-4c5b-a0ce-a7f416f160de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_11f28198-4dc6-4090-bcd5-e78bf6f58b26_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_fdce04cc-5240-4f55-918f-16dc2385da9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bbaf5dec-f132-4d0b-b58f-f2640a64b66e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Securities Excluded from the Computation of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_57a4576a-3567-4c2b-b408-747b54e6d1dc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on related-party notes payable</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_cc16df9b-dc9c-42a4-9548-df1fa7350a08_terseLabel_en-US" xlink:label="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_03685e4e-2851-4ff5-99a0-fc06e1816306_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_583f776f-875e-4e04-934c-ee11bd7ef62a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PeriodTwoMember_432777cb-b42c-4fe5-919d-1589b2a9a6ac_terseLabel_en-US" xlink:label="lab_ibrx_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_ibrx_PeriodTwoMember_label_en-US" xlink:label="lab_ibrx_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Two [Member]</link:label>
    <link:label id="lab_ibrx_PeriodTwoMember_documentation_en-US" xlink:label="lab_ibrx_PeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodTwoMember" xlink:href="ibrx-20231231.xsd#ibrx_PeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PeriodTwoMember" xlink:to="lab_ibrx_PeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_14f707f6-c5a4-4710-91ed-c757bddcb843_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_33308069-bca0-4e69-8664-33c867d30af4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_GlobeImmuneIncMember_ed691818-e37e-4c85-8576-264dcf333006_terseLabel_en-US" xlink:label="lab_ibrx_GlobeImmuneIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlobeImmune, Inc.</link:label>
    <link:label id="lab_ibrx_GlobeImmuneIncMember_label_en-US" xlink:label="lab_ibrx_GlobeImmuneIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlobeImmune, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_GlobeImmuneIncMember_documentation_en-US" xlink:label="lab_ibrx_GlobeImmuneIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GlobeImmune, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GlobeImmuneIncMember" xlink:href="ibrx-20231231.xsd#ibrx_GlobeImmuneIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_GlobeImmuneIncMember" xlink:to="lab_ibrx_GlobeImmuneIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ff3561a1-abe8-4c74-8034-cb0c7a0b2798_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants of restricted stock (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1ce8ed67-eb28-43fe-aa7f-47997c5a5aea_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationLineItems_1a40eb25-14c0-48bb-861d-86913c408ae8_terseLabel_en-US" xlink:label="lab_ibrx_LitigationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation [Line Items]</link:label>
    <link:label id="lab_ibrx_LitigationLineItems_label_en-US" xlink:label="lab_ibrx_LitigationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation [Line Items]</link:label>
    <link:label id="lab_ibrx_LitigationLineItems_documentation_en-US" xlink:label="lab_ibrx_LitigationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationLineItems" xlink:href="ibrx-20231231.xsd#ibrx_LitigationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationLineItems" xlink:to="lab_ibrx_LitigationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_d19c944e-83f0-404e-89e2-ecae7ace39b4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_527b1a6b-0cba-4fa4-8add-4421e707a290_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_160608f0-e9cb-4d86-9585-7b8c92eec251_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_7b9832c3-199b-4345-b572-9593d2eefd80_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_3af19aa8-bf11-4735-a638-4cb3bfcd5f83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8f365c6f-2d02-492f-bb9d-c519d04029cc_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_166b68cb-5a4a-4244-9adc-a4619f1c4d27_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Debt</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_62ed7154-de4c-4bc3-96ef-9bcc84b6c465_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Agreements</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_323c64cf-5dc0-461c-9a81-061b05d66d4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseRightOfUseAsset_81c1b38e-46d3-4a6f-8077-cab4e3af802d_totalLabel_en-US" xlink:label="lab_ibrx_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease assets</link:label>
    <link:label id="lab_ibrx_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_ibrx_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ibrx_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ibrx_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRightOfUseAsset" xlink:href="ibrx-20231231.xsd#ibrx_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseRightOfUseAsset" xlink:to="lab_ibrx_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_27d1f43e-9194-4b08-ae15-679c10e4fe84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangements</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a35e8ea5-0532-48dc-aedb-d5e0819a2f58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Benefit (Provision)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BaseMonthlyRent_e208c4ca-18b6-4bbe-9044-a02d63f12bc2_terseLabel_en-US" xlink:label="lab_ibrx_BaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base rent - monthly</link:label>
    <link:label id="lab_ibrx_BaseMonthlyRent_label_en-US" xlink:label="lab_ibrx_BaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Monthly Rent</link:label>
    <link:label id="lab_ibrx_BaseMonthlyRent_documentation_en-US" xlink:label="lab_ibrx_BaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Base monthly rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRent" xlink:href="ibrx-20231231.xsd#ibrx_BaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BaseMonthlyRent" xlink:to="lab_ibrx_BaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023Member_922cc6b1-34ae-45c0-8ad4-af4ef422eba5_terseLabel_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$505&#160;million December 2023 Promissory Note</link:label>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023Member_label_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$505 Million Promissory Note, December 2023 [Member]</link:label>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023Member_documentation_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$505 Million Promissory Note, December 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Member" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A505MillionPromissoryNoteDecember2023Member" xlink:to="lab_ibrx_A505MillionPromissoryNoteDecember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ContingentConsiderationMember_fdcd8824-5751-46a0-a52c-a404c3f8f40d_terseLabel_en-US" xlink:label="lab_ibrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_ibrx_ContingentConsiderationMember_label_en-US" xlink:label="lab_ibrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_ibrx_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_ibrx_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember" xlink:href="ibrx-20231231.xsd#ibrx_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ContingentConsiderationMember" xlink:to="lab_ibrx_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_89c132a9-743f-4f66-b251-427c1581456a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_115f330c-2f00-4c9d-bf92-eb2af9fb2156_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ff9f9327-3518-4b91-90b8-45b70e2f46ee_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantWorksLLCMemberMember_0f00a68c-efe3-4c76-a57c-1cbd6bcb712f_terseLabel_en-US" xlink:label="lab_ibrx_NantWorksLLCMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantWorks, LLC Member</link:label>
    <link:label id="lab_ibrx_NantWorksLLCMemberMember_label_en-US" xlink:label="lab_ibrx_NantWorksLLCMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantWorks, LLC Member [Member]</link:label>
    <link:label id="lab_ibrx_NantWorksLLCMemberMember_documentation_en-US" xlink:label="lab_ibrx_NantWorksLLCMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantWorks, LLC Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksLLCMemberMember" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksLLCMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantWorksLLCMemberMember" xlink:to="lab_ibrx_NantWorksLLCMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_23c421fb-c018-4c11-b8ce-8e783ce184ad_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum milestone payment due if certain conditions are met</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StockIssuedCashlessExerciseOfStockOptions_4ddec127-ea62-4f41-ae9c-046354afd2d3_terseLabel_en-US" xlink:label="lab_ibrx_StockIssuedCashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise of stock options</link:label>
    <link:label id="lab_ibrx_StockIssuedCashlessExerciseOfStockOptions_label_en-US" xlink:label="lab_ibrx_StockIssuedCashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued, Cashless Exercise Of Stock Options</link:label>
    <link:label id="lab_ibrx_StockIssuedCashlessExerciseOfStockOptions_documentation_en-US" xlink:label="lab_ibrx_StockIssuedCashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued, Cashless Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedCashlessExerciseOfStockOptions" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedCashlessExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StockIssuedCashlessExerciseOfStockOptions" xlink:to="lab_ibrx_StockIssuedCashlessExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7306963d-db2d-4034-a1f9-3e54fcb81d8f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0366278a-d721-4d62-a296-7a214dbfe0d5_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3daad5d4-d3ed-4e8e-863c-7b9ba90b852e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_87dde365-a715-4cf1-b4ed-0a67178f6640_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A23AlaskaLLCMember_6779810b-62a7-410f-a48d-7b64fd2d3e0c_terseLabel_en-US" xlink:label="lab_ibrx_A23AlaskaLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">23 Alaska, LLC</link:label>
    <link:label id="lab_ibrx_A23AlaskaLLCMember_label_en-US" xlink:label="lab_ibrx_A23AlaskaLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">23 Alaska, LLC [Member]</link:label>
    <link:label id="lab_ibrx_A23AlaskaLLCMember_documentation_en-US" xlink:label="lab_ibrx_A23AlaskaLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">23 Alaska, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A23AlaskaLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_A23AlaskaLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A23AlaskaLLCMember" xlink:to="lab_ibrx_A23AlaskaLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_c4221dba-e93c-4264-8b82-af08eace916c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A125MillionAugust2022PromissoryNoteMember_e64601c8-74b1-4f89-9d9a-1a340a713c44_terseLabel_en-US" xlink:label="lab_ibrx_A125MillionAugust2022PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$125 Million August 2022 Promissory Note</link:label>
    <link:label id="lab_ibrx_A125MillionAugust2022PromissoryNoteMember_label_en-US" xlink:label="lab_ibrx_A125MillionAugust2022PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$125 Million August 2022 Promissory Note [Member]</link:label>
    <link:label id="lab_ibrx_A125MillionAugust2022PromissoryNoteMember_documentation_en-US" xlink:label="lab_ibrx_A125MillionAugust2022PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$125 Million August 2022 Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A125MillionAugust2022PromissoryNoteMember" xlink:href="ibrx-20231231.xsd#ibrx_A125MillionAugust2022PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A125MillionAugust2022PromissoryNoteMember" xlink:to="lab_ibrx_A125MillionAugust2022PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_479a17ea-0599-45e0-b41a-fdf36cba8fe8_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentInterestRate_3c66f800-4d71-488e-b5ed-cd637c787d26_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_InvestmentInterestRate_label_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentInterestRate" xlink:to="lab_us-gaap_InvestmentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d9d6bd18-5e39-431b-860d-bbeff1753d6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8c115d28-6c2f-459e-9282-f7bf4ae38db0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_764d67bc-c0f4-437d-969c-63e108a2ddcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss Before Taxes, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5e5bcb3f-eefd-445d-8395-9523c9f03131_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock issued in transaction (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_9afa794d-ef4b-4568-9260-febb4362b7d6_verboseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_6adb58cd-bfd6-4781-ba88-8815b555832d_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_01352903-8785-4d90-9d68-d31c7ed9ec2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock_8f14360c-af41-467d-8cc8-dd263201f57a_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with Related Parties</link:label>
    <link:label id="lab_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:to="lab_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_fd09ed89-89ba-4fa0-8efd-8996e1d42c4d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f67630c7-06da-409e-b616-8c4895c08716_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_8a27db8b-ad21-49e7-a232-f62b1cd877df_terseLabel_en-US" xlink:label="lab_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of embedded conversion feature from debt modification with entities under common control (Note 10)</link:label>
    <link:label id="lab_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_label_en-US" xlink:label="lab_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Debt Instrument, Convertible, Increase In Fair Value Of Embedded Conversion Feature</link:label>
    <link:label id="lab_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_documentation_en-US" xlink:label="lab_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">APIC, Debt Instrument, Convertible, Increase In Fair Value Of Embedded Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" xlink:href="ibrx-20231231.xsd#ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" xlink:to="lab_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_477fe979-c114-4bad-b86a-391f63ab2392_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearTwo_4a604d64-5ad6-4d4f-b357-49697bab4cb7_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearTwo_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Two</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearTwo_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2d7d60c3-4cd9-4bbf-8add-f3f481c5196b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7198a361-bfb8-4099-ae4b-f82cf5746abf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9c225472-4487-47dd-ab2c-edf66273b0b1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6f144122-f195-4326-979c-2626cacb56cd_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_666e9a92-1586-4588-8fc1-5eea457a117d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiability_063e8062-c166-4105-b06a-486809379c0b_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_ibrx_LeaseLiability_label_en-US" xlink:label="lab_ibrx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_ibrx_LeaseLiability_documentation_en-US" xlink:label="lab_ibrx_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiability" xlink:to="lab_ibrx_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue_89bd99fa-d724-46d3-a3bc-d1ec9b1ad333_terseLabel_en-US" xlink:label="lab_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value stock purchase option</link:label>
    <link:label id="lab_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue_label_en-US" xlink:label="lab_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value Of Stock Purchase Option At Issuance And Change In Fair Value</link:label>
    <link:label id="lab_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue_documentation_en-US" xlink:label="lab_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Fair Value Of Stock Purchase Option At Issuance And Change In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" xlink:href="ibrx-20231231.xsd#ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" xlink:to="lab_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A200MillionSeptember2023PromissoryNoteMember_066635d7-e5eb-4ae0-a09d-a81088ce4cd7_terseLabel_en-US" xlink:label="lab_ibrx_A200MillionSeptember2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$200 Million September 2023 Promissory Note</link:label>
    <link:label id="lab_ibrx_A200MillionSeptember2023PromissoryNoteMember_label_en-US" xlink:label="lab_ibrx_A200MillionSeptember2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$200 Million September 2023 Promissory Note [Member]</link:label>
    <link:label id="lab_ibrx_A200MillionSeptember2023PromissoryNoteMember_documentation_en-US" xlink:label="lab_ibrx_A200MillionSeptember2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$200 Million September 2023 Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember" xlink:href="ibrx-20231231.xsd#ibrx_A200MillionSeptember2023PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember" xlink:to="lab_ibrx_A200MillionSeptember2023PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_6e0f4110-9bca-4dce-8ed1-a3ff193debd2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NumberOfSquareFeetOfFacilityLeased_cecb698a-117b-47dd-a845-a369f72d4161_terseLabel_en-US" xlink:label="lab_ibrx_NumberOfSquareFeetOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of square foot of facility leased</link:label>
    <link:label id="lab_ibrx_NumberOfSquareFeetOfFacilityLeased_label_en-US" xlink:label="lab_ibrx_NumberOfSquareFeetOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Square Feet Of Facility Leased</link:label>
    <link:label id="lab_ibrx_NumberOfSquareFeetOfFacilityLeased_documentation_en-US" xlink:label="lab_ibrx_NumberOfSquareFeetOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of square feet of facility leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFeetOfFacilityLeased" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFeetOfFacilityLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NumberOfSquareFeetOfFacilityLeased" xlink:to="lab_ibrx_NumberOfSquareFeetOfFacilityLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_cb906ea0-0034-4fe9-a0c6-9d08c1167fc0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b4da0008-f5c8-426a-a777-06e8f7a32e57_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_044c4165-5caa-4062-9f9d-b3272d64fe9d_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_120f59ee-c1b8-4471-b6a5-4fe5b5161253_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Balances of Related Party Agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_02bab83d-0438-4c77-97d8-d62258231514_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_7639eb20-a736-4e12-92d5-4776e0afb135_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Embedded derivative</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_fe981388-5997-474a-8722-3c7efa2c52bf_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront cash payments</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Nonrefundable Upfront Payment</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nonrefundable upfront payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsNonrefundableUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:to="lab_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_cfed2c50-8dcf-4529-b82b-d6a9a6922b0c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4bd27b38-f5a9-4cbd-a725-1725343ab5b5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636d46b5-2943-4065-8db8-b8dd5056c595_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3b9b0375-6f77-494c-ac0c-c23c0a570647_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7a2059be-1a28-4ae6-9fc6-97d16fd0043b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AnnualPercentageIncreaseToLicenseFee_5441187d-269a-4116-ac9c-c90e5f7ea679_terseLabel_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreaseToLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage increase to base rent</link:label>
    <link:label id="lab_ibrx_AnnualPercentageIncreaseToLicenseFee_label_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreaseToLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Percentage Increase to License Fee</link:label>
    <link:label id="lab_ibrx_AnnualPercentageIncreaseToLicenseFee_documentation_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreaseToLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual percentage increase to base rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreaseToLicenseFee" xlink:href="ibrx-20231231.xsd#ibrx_AnnualPercentageIncreaseToLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AnnualPercentageIncreaseToLicenseFee" xlink:to="lab_ibrx_AnnualPercentageIncreaseToLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SeptemberTwentyNineteenLeaseMember_cf63474d-1278-43a1-9181-c613f6072884_terseLabel_en-US" xlink:label="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 2019 Lease</link:label>
    <link:label id="lab_ibrx_SeptemberTwentyNineteenLeaseMember_label_en-US" xlink:label="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">September Twenty Nineteen Lease [Member]</link:label>
    <link:label id="lab_ibrx_SeptemberTwentyNineteenLeaseMember_documentation_en-US" xlink:label="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">September twenty nineteen lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:href="ibrx-20231231.xsd#ibrx_SeptemberTwentyNineteenLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:to="lab_ibrx_SeptemberTwentyNineteenLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_cfefd1b5-c8ad-4503-9f45-16a418243868_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FiveFiveSevenDougStLLCMember_5993d67a-f1f3-49da-bc8f-f1290adbc7f1_terseLabel_en-US" xlink:label="lab_ibrx_FiveFiveSevenDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">557 Doug St, LLC</link:label>
    <link:label id="lab_ibrx_FiveFiveSevenDougStLLCMember_label_en-US" xlink:label="lab_ibrx_FiveFiveSevenDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five Five Seven Doug St, LLC [Member]</link:label>
    <link:label id="lab_ibrx_FiveFiveSevenDougStLLCMember_documentation_en-US" xlink:label="lab_ibrx_FiveFiveSevenDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Five Five Seven Doug St, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiveFiveSevenDougStLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_FiveFiveSevenDougStLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FiveFiveSevenDougStLLCMember" xlink:to="lab_ibrx_FiveFiveSevenDougStLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4d24df79-3dea-4a04-86e4-99c94b274b53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_ac56cc61-7b90-4e6e-bdc5-338c968832b0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NumberOfSquareFootOfFacilityLeased_b8086e9d-c2d1-46f4-806e-d09799429c47_terseLabel_en-US" xlink:label="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of square foot of facility leased</link:label>
    <link:label id="lab_ibrx_NumberOfSquareFootOfFacilityLeased_label_en-US" xlink:label="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Square Foot Of Facility Leased</link:label>
    <link:label id="lab_ibrx_NumberOfSquareFootOfFacilityLeased_documentation_en-US" xlink:label="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of square foot of facility leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:to="lab_ibrx_NumberOfSquareFootOfFacilityLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NumberOfDissentingShares_29dd8751-6368-4745-ac4c-b323b4bcb47b_terseLabel_en-US" xlink:label="lab_ibrx_NumberOfDissentingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dissenting shares to be released (in shares)</link:label>
    <link:label id="lab_ibrx_NumberOfDissentingShares_label_en-US" xlink:label="lab_ibrx_NumberOfDissentingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Dissenting Shares</link:label>
    <link:label id="lab_ibrx_NumberOfDissentingShares_documentation_en-US" xlink:label="lab_ibrx_NumberOfDissentingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Dissenting Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfDissentingShares" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfDissentingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NumberOfDissentingShares" xlink:to="lab_ibrx_NumberOfDissentingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a832cab8-007a-4b09-9021-6909896775ab_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_b0822d1f-b9a7-4b40-9a45-1e79cb275084_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount awarded from other party in litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_ecf8a545-2828-4281-9bf5-febf6ed0a787_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_04b4098c-032a-4b0a-a3c9-71e8c4f407b7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c3df628d-6303-4a34-b3f6-6dd7e336c8b3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c358ec19-f255-4145-9964-88b762b2945f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_871f1242-5bd9-4174-9ab1-eb8bc745f359_totalLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_5f87e5f2-8dd5-44ba-9982-c4a8872073a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ad679ee-3e79-4330-b7f1-a5ee08b56725_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b34a53e3-6641-4301-8f16-27f6b50ae2ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SupplyAgreementTermOfContract_12128c45-b26b-4d64-95bb-5037c4bc5a88_terseLabel_en-US" xlink:label="lab_ibrx_SupplyAgreementTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supply agreement, term of contract</link:label>
    <link:label id="lab_ibrx_SupplyAgreementTermOfContract_label_en-US" xlink:label="lab_ibrx_SupplyAgreementTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supply Agreement, Term Of Contract</link:label>
    <link:label id="lab_ibrx_SupplyAgreementTermOfContract_documentation_en-US" xlink:label="lab_ibrx_SupplyAgreementTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supply Agreement, Term Of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementTermOfContract" xlink:href="ibrx-20231231.xsd#ibrx_SupplyAgreementTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SupplyAgreementTermOfContract" xlink:to="lab_ibrx_SupplyAgreementTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ReportableLegalEntitiesMember_d46e8273-296f-422f-bfc8-49d07d3bb79c_terseLabel_en-US" xlink:label="lab_srt_ReportableLegalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Legal Entities</link:label>
    <link:label id="lab_srt_ReportableLegalEntitiesMember_label_en-US" xlink:label="lab_srt_ReportableLegalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Legal Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableLegalEntitiesMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ReportableLegalEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableLegalEntitiesMember" xlink:to="lab_srt_ReportableLegalEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_478ade95-4491-482b-8ecd-53630da6dfe5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2212a11e-ee84-4b62-bc36-e7d3a957d6f4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_04610355-9385-46dd-a76e-0eb1ddc1837e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MonthlyLicenseFee_da5faad5-75a6-41c2-9221-a1ff01fdb237_terseLabel_en-US" xlink:label="lab_ibrx_MonthlyLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly base rent</link:label>
    <link:label id="lab_ibrx_MonthlyLicenseFee_label_en-US" xlink:label="lab_ibrx_MonthlyLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monthly License Fee</link:label>
    <link:label id="lab_ibrx_MonthlyLicenseFee_documentation_en-US" xlink:label="lab_ibrx_MonthlyLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monthly base rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MonthlyLicenseFee" xlink:href="ibrx-20231231.xsd#ibrx_MonthlyLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MonthlyLicenseFee" xlink:to="lab_ibrx_MonthlyLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_edce26a7-8b6f-473e-9112-a3c0fd7b7074_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_87f295d0-5aca-4efb-a506-650031e1465d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_083883d7-66ee-446c-a34f-030b63a81969_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fc0926a0-4a97-421f-b2ae-d65329b7df9a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7e989312-0a14-4f52-aaf4-2e18ae69c159_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_fd3e78c6-4e06-47d6-9c9a-68fa06003e11_terseLabel_en-US" xlink:label="lab_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets, Gross, Excluding Goodwill</link:label>
    <link:label id="lab_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_documentation_en-US" xlink:label="lab_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets, Gross, Excluding Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_3f7d2a58-8b02-4bb8-bf3d-6e044057477e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_358c4eac-18df-49af-9f4a-b06ae7bb7d72_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_ec7f238c-b922-4f95-ac79-b6dc788c2f06_terseLabel_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Arrangements With Federal Government [Table]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_label_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangements With Federal Government [Table]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_documentation_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Arrangements With Federal Government [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:href="ibrx-20231231.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:to="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_9b66751c-214f-43ac-bdd7-e32a2fba2ddf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_c22d1681-e836-4409-9a2a-d0f95546cdca_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b2b71e2b-5761-4c20-a9b9-c85848dce3b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyWarrantsMember_b84f95a6-8bf7-4e75-a6b8-8e2ae875dfa1_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding related-party warrants</link:label>
    <link:label id="lab_ibrx_RelatedPartyWarrantsMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Warrants [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyWarrantsMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyWarrantsMember" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyWarrantsMember" xlink:to="lab_ibrx_RelatedPartyWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ReimbursementsMember_97a89a8e-3573-45b0-a72f-9b64c2e28358_terseLabel_en-US" xlink:label="lab_ibrx_ReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursements</link:label>
    <link:label id="lab_ibrx_ReimbursementsMember_label_en-US" xlink:label="lab_ibrx_ReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursements [Member]</link:label>
    <link:label id="lab_ibrx_ReimbursementsMember_documentation_en-US" xlink:label="lab_ibrx_ReimbursementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ReimbursementsMember" xlink:href="ibrx-20231231.xsd#ibrx_ReimbursementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ReimbursementsMember" xlink:to="lab_ibrx_ReimbursementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAfterYearFive_72dad573-e534-4e5c-8c3f-de6800a9424a_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAfterYearFive_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, After Year Five</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAfterYearFive_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive" xlink:to="lab_ibrx_LeaseLiabilityToBePaidAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3ee7abcf-d0dc-44a1-92d1-04cd80431906_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidEquipmentMaintenance_55a00948-9f69-420d-aa96-b998f3754b52_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidEquipmentMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid equipment maintenance</link:label>
    <link:label id="lab_ibrx_PrepaidEquipmentMaintenance_label_en-US" xlink:label="lab_ibrx_PrepaidEquipmentMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Equipment Maintenance</link:label>
    <link:label id="lab_ibrx_PrepaidEquipmentMaintenance_documentation_en-US" xlink:label="lab_ibrx_PrepaidEquipmentMaintenance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid equipment maintenance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidEquipmentMaintenance" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidEquipmentMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidEquipmentMaintenance" xlink:to="lab_ibrx_PrepaidEquipmentMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b7115f06-0a2b-46bf-b3e2-7385374d1526_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_d918880f-643f-4625-ac5a-58315e835716_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposits</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement_87704989-233b-4263-93ad-61557b24b09f_terseLabel_en-US" xlink:label="lab_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued pursuant to litigation settlement (in shares)</link:label>
    <link:label id="lab_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement_label_en-US" xlink:label="lab_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Litigation Settlement</link:label>
    <link:label id="lab_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement_documentation_en-US" xlink:label="lab_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:to="lab_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_240aa900-c50e-433b-99b4-510fb3135420_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c3192b8e-35cd-45da-b13e-0aaaf7a5ac14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_bb406b84-2c7b-46b3-a1a7-6e8eda676c44_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PromissoryNotesPayableMember_0cfb1d1c-392f-40d8-8991-1fdf57965a76_terseLabel_en-US" xlink:label="lab_ibrx_PromissoryNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory Notes</link:label>
    <link:label id="lab_ibrx_PromissoryNotesPayableMember_label_en-US" xlink:label="lab_ibrx_PromissoryNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promissory Notes Payable [Member]</link:label>
    <link:label id="lab_ibrx_PromissoryNotesPayableMember_documentation_en-US" xlink:label="lab_ibrx_PromissoryNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Promissory Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PromissoryNotesPayableMember" xlink:to="lab_ibrx_PromissoryNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_533514e4-d687-483a-b7b9-159b96ee91d8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_89453183-5a9a-4c0c-aa97-a3ef2ceeb252_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_7ae282d4-f8c1-4da4-ae35-5df103194b33_terseLabel_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated benefit at grant date fair value</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_label_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_documentation_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:href="ibrx-20231231.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:to="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_07180a4e-094b-4767-a3c4-f314bbff24ca_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment, 2024</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d5f1ca6a-7aee-44c8-bebb-0fb0679beb6d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9e5dbd18-6f7c-4f61-8f2b-c80de37f086c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating leases (excluding variable lease costs)</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_460b2562-6421-4046-a363-ec098c3b9178_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5f9d6d74-4fe4-4503-982b-f53162bf6c94_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f6cefc13-0574-4b72-9c6b-c2bd1ff9d979_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OptionPeriodDomain_732c3800-5cf2-4b20-b4d6-fd69f19bc762_terseLabel_en-US" xlink:label="lab_ibrx_OptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Period [Domain]</link:label>
    <link:label id="lab_ibrx_OptionPeriodDomain_label_en-US" xlink:label="lab_ibrx_OptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Period [Domain]</link:label>
    <link:label id="lab_ibrx_OptionPeriodDomain_documentation_en-US" xlink:label="lab_ibrx_OptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionPeriodDomain" xlink:href="ibrx-20231231.xsd#ibrx_OptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OptionPeriodDomain" xlink:to="lab_ibrx_OptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_6b33ca78-af09-419e-808e-57dc2740759e_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2d1c44f3-28d1-44c8-b0b1-438676b30007_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_cab63930-0b34-40fe-a3a4-1884230386d9_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_3169f8e6-5860-45fc-864c-2b8631a07027_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_9e0194c9-588e-4c74-85fc-dbe9a18a38d8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyFixedRateNotesMember_6b06d31f-3ec5-436b-a96b-01ed05e366e5_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyFixedRateNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Fixed Rate Notes</link:label>
    <link:label id="lab_ibrx_RelatedPartyFixedRateNotesMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyFixedRateNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Fixed Rate Notes [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyFixedRateNotesMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyFixedRateNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Fixed Rate Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyFixedRateNotesMember" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyFixedRateNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyFixedRateNotesMember" xlink:to="lab_ibrx_RelatedPartyFixedRateNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6020810b-9f89-4fad-829f-2bc737425c18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_0bd15b38-c30a-45a8-8b41-509f0fee17fd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod_c6775775-eea4-4fd8-9d62-c78fe99fb890_negatedLabel_en-US" xlink:label="lab_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod_label_en-US" xlink:label="lab_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Discount Recorded In The Period</link:label>
    <link:label id="lab_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod_documentation_en-US" xlink:label="lab_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Discount Recorded In The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod" xlink:to="lab_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9aa2fd32-cab2-4f3b-ae6d-905cc164104d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_56b8be04-a27d-45eb-a5dd-bf555a9c2a88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, unrealized loss position, number of positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5bc648f6-0c3f-478b-bccf-16f0213561e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_1996dae1-e4a7-4945-86f2-af740f2de04a_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_7830f20f-fd52-4a23-a882-c9d88502da31_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_c839a265-a2e0-43b7-836e-d9b45ddc6be7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses from equity securities</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt and Equity Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f6da7eb2-aff3-4ea6-836a-c72e63061a8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c891b1a3-67d2-415b-8005-cb5e0280f640_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_8263a4d6-3d16-4841-bbc9-fe9fb3517d27_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_56c0f5b8-9bbc-4925-9834-274fd6a6d2a1_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82a34ca9-179f-4d63-bc44-8e89f360772d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidSoftwareLicenseFees_ad1dd8ee-d596-420e-a8c1-c0b5eab66af7_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid software license fees</link:label>
    <link:label id="lab_ibrx_PrepaidSoftwareLicenseFees_label_en-US" xlink:label="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Software License Fees</link:label>
    <link:label id="lab_ibrx_PrepaidSoftwareLicenseFees_documentation_en-US" xlink:label="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid software license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidSoftwareLicenseFees" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidSoftwareLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidSoftwareLicenseFees" xlink:to="lab_ibrx_PrepaidSoftwareLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b15928b5-6664-418f-ac1e-0ef8f7261b79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_473c3127-fd5a-4e6b-868e-77cd2549ec44_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0a9202cf-0618-47f5-9b3a-8dbadfafea2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 R&amp;E capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9c7f6fd-32de-4ad6-a458-809977ee996b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1074c028-2267-4fbd-babc-f12d1ebe8477_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment_85c3688f-e778-44e3-9d73-546080b106fe_terseLabel_en-US" xlink:label="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual lease payment</link:label>
    <link:label id="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment_label_en-US" xlink:label="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Operating Lease, Annual Lease Payment</link:label>
    <link:label id="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment_documentation_en-US" xlink:label="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Operating Lease, Annual Lease Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:href="ibrx-20231231.xsd#ibrx_LeaseOperatingLeaseAnnualLeasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:to="lab_ibrx_LeaseOperatingLeaseAnnualLeasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability_fb0d627c-8856-4574-a571-1e310ede8d06_negatedTerseLabel_en-US" xlink:label="lab_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets disposed in exchange for operating lease liabilities</link:label>
    <link:label id="lab_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Disposed In Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Disposed In Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" xlink:href="ibrx-20231231.xsd#ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" xlink:to="lab_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_37b1873c-bfef-4a3a-ae6f-ce78dac8c833_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Other Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_546442d7-a3cc-4a42-9730-bc2108e5c2cf_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SaleOfStockAdditionalPurchaseOption_3d714086-d17f-4bd8-ba99-3b67156cf2ac_terseLabel_en-US" xlink:label="lab_ibrx_SaleOfStockAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, additional purchase option</link:label>
    <link:label id="lab_ibrx_SaleOfStockAdditionalPurchaseOption_label_en-US" xlink:label="lab_ibrx_SaleOfStockAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Additional Purchase Option</link:label>
    <link:label id="lab_ibrx_SaleOfStockAdditionalPurchaseOption_documentation_en-US" xlink:label="lab_ibrx_SaleOfStockAdditionalPurchaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Additional Purchase Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAdditionalPurchaseOption" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAdditionalPurchaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SaleOfStockAdditionalPurchaseOption" xlink:to="lab_ibrx_SaleOfStockAdditionalPurchaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0492d5a7-b353-4263-891d-3c538cd99408_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StockPurchaseAndOptionAgreementMember_332845e9-6563-4e4a-a695-cea5ac0e03ae_terseLabel_en-US" xlink:label="lab_ibrx_StockPurchaseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Purchase and Option Agreement</link:label>
    <link:label id="lab_ibrx_StockPurchaseAndOptionAgreementMember_label_en-US" xlink:label="lab_ibrx_StockPurchaseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase And Option Agreement [Member]</link:label>
    <link:label id="lab_ibrx_StockPurchaseAndOptionAgreementMember_documentation_en-US" xlink:label="lab_ibrx_StockPurchaseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase And Option Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StockPurchaseAndOptionAgreementMember" xlink:to="lab_ibrx_StockPurchaseAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_e3595568-c705-4f4e-93b5-5d67ff186c4c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional and service fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4c403d97-ec49-4101-b910-59200c0be9c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_f803c6d9-8f19-4a13-99a4-62116c83a83b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a8e33acd-2a58-4a27-bbb0-6acbe1a349e1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_56e5ecbb-b3b5-4e6d-be93-f35c2f6d812d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances to support operations</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_e472a510-73e5-422b-962b-eb6ac9e2768b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_66b544d7-b6fe-4b8d-8252-ed34b699c137_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_c3a09f2b-c7e8-450a-b0db-fde650727b72_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unconditional purchase obligation commitment</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock_851b5f50-7d8e-4f6b-aaad-d885aa8c8823_terseLabel_en-US" xlink:label="lab_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchases</link:label>
    <link:label id="lab_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_StockRepurchaseProgramPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock" xlink:to="lab_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d78b140e-2938-4445-8fbe-e2fa1460b24d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member_4844fa8d-94d5-4bfe-a0cc-b57c67d7d4e8_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023</link:label>
    <link:label id="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member_label_en-US" xlink:label="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023 [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member_documentation_en-US" xlink:label="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" xlink:to="lab_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_68dafb76-338c-4798-84b5-36697664dcaf_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aa4a3b5e-3f0c-4334-afc5-a60502329871_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_019a28d6-df48-4d62-8c89-dea0276d1668_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7e79395a-8bb9-416f-91d3-48e7301b9f3b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_VariousMember_54a01e26-a3cd-400a-a30b-466e821f1b9f_terseLabel_en-US" xlink:label="lab_ibrx_VariousMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various</link:label>
    <link:label id="lab_ibrx_VariousMember_label_en-US" xlink:label="lab_ibrx_VariousMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various [Member]</link:label>
    <link:label id="lab_ibrx_VariousMember_documentation_en-US" xlink:label="lab_ibrx_VariousMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VariousMember" xlink:href="ibrx-20231231.xsd#ibrx_VariousMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_VariousMember" xlink:to="lab_ibrx_VariousMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantKwestInc.Member_84c12e41-dbc5-4811-92d0-ab9c52acaa06_terseLabel_en-US" xlink:label="lab_ibrx_NantKwestInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantKwest</link:label>
    <link:label id="lab_ibrx_NantKwestInc.Member_label_en-US" xlink:label="lab_ibrx_NantKwestInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantKwest, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_NantKwestInc.Member_documentation_en-US" xlink:label="lab_ibrx_NantKwestInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantKwest, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantKwestInc.Member" xlink:href="ibrx-20231231.xsd#ibrx_NantKwestInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantKwestInc.Member" xlink:to="lab_ibrx_NantKwestInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c9227e64-3c9a-4274-83a4-0d3e9eef890a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f54cb777-8dbe-43c4-a65c-4ff1dde70159_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DebtInstrumentNumberOfAdvances_92a19377-93ed-4c67-a9dd-b5eedc9e677d_terseLabel_en-US" xlink:label="lab_ibrx_DebtInstrumentNumberOfAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of advances</link:label>
    <link:label id="lab_ibrx_DebtInstrumentNumberOfAdvances_label_en-US" xlink:label="lab_ibrx_DebtInstrumentNumberOfAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Advances</link:label>
    <link:label id="lab_ibrx_DebtInstrumentNumberOfAdvances_documentation_en-US" xlink:label="lab_ibrx_DebtInstrumentNumberOfAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentNumberOfAdvances" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentNumberOfAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DebtInstrumentNumberOfAdvances" xlink:to="lab_ibrx_DebtInstrumentNumberOfAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_144434c6-9325-499b-ab70-f7d6a86b6686_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_1d1dde6f-36cc-478e-848f-59f98ac577eb_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_14779b00-8260-4f96-bab6-460ae6b9c17f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ce8326b-e44b-45a9-92f7-9d791aa44055_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_79e8055c-5c73-4678-830a-e14a26499a9f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a65f3305-8151-4b8b-94ae-46e8b7645654_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_19209b64-2733-492e-ac6d-a1a423af3d59_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_0c2b303b-05f1-499b-bbdd-af73ec5141b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementAbstract_label_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement [Abstract]</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementAbstract_documentation_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementAbstract" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementAbstract" xlink:to="lab_ibrx_RevenueInterestPurchaseAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NameChangeEventLineItems_dd86e345-2b0c-40d6-a55c-63009fcc6bf4_terseLabel_en-US" xlink:label="lab_dei_NameChangeEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name Change Event [Line Items]</link:label>
    <link:label id="lab_dei_NameChangeEventLineItems_label_en-US" xlink:label="lab_dei_NameChangeEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name Change Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NameChangeEventLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NameChangeEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NameChangeEventLineItems" xlink:to="lab_dei_NameChangeEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_78e4b5f3-44b5-4137-bbaa-5b5a829aa8c8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermNotesPayable_9b9f800d-c83a-4efb-b3f9-28da82dc02c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-party nonconvertible note, net of discount (Note 10)</link:label>
    <link:label id="lab_us-gaap_OtherLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermNotesPayable" xlink:to="lab_us-gaap_OtherLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_70974eac-8cec-40b3-ac60-7c874bdf3aad_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture &amp; fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_8f24feac-0f17-4921-b62a-dd7e4c088a43_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalTwoMember_68eabd84-b00e-4c4a-bbcb-41894cc2b52e_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nant Capital 2021 Note Payable</link:label>
    <link:label id="lab_ibrx_NantCapitalTwoMember_label_en-US" xlink:label="lab_ibrx_NantCapitalTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Capital Two [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalTwoMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nant capital two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalTwoMember" xlink:to="lab_ibrx_NantCapitalTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_83a803b7-6583-4961-8ff2-c0a7cc2302a8_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Legal Entities</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MergerExchangeRatio_dedcb4e4-4d07-4b2d-95cb-aef981e62149_terseLabel_en-US" xlink:label="lab_ibrx_MergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger exchange ratio</link:label>
    <link:label id="lab_ibrx_MergerExchangeRatio_label_en-US" xlink:label="lab_ibrx_MergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merger Exchange Ratio</link:label>
    <link:label id="lab_ibrx_MergerExchangeRatio_documentation_en-US" xlink:label="lab_ibrx_MergerExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merger exchange ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MergerExchangeRatio" xlink:href="ibrx-20231231.xsd#ibrx_MergerExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MergerExchangeRatio" xlink:to="lab_ibrx_MergerExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_7cc2a7fb-7a70-4776-81ae-3939ba697799_negatedTerseLabel_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_label_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Impairment</link:label>
    <link:label id="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_documentation_en-US" xlink:label="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:href="ibrx-20231231.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:to="lab_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_5f47798b-3be7-4df1-a376-68ae0ab2d656_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8e002ae7-f73f-4e18-a92f-ab4a5c01b674_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f76767e8-7751-419b-8105-7436a7f7a78d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8665d45-e7bf-4b71-9fa0-537e1e7ad3dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_9d8ee43e-4ae2-416f-828a-037f583dc9ef_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_276c4e65-76fb-4e54-8d16-b8ed5a116ed3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_d5f3c17c-405c-404d-872c-aa9733d0e821_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Embedded derivative</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33f14c82-cd3a-4ebc-aa0c-490b581f0043_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalThreeMember_22060769-992f-4210-926b-7e828b522ea4_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nant Capital Three</link:label>
    <link:label id="lab_ibrx_NantCapitalThreeMember_label_en-US" xlink:label="lab_ibrx_NantCapitalThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Capital Three [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalThreeMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nant Capital Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalThreeMember" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalThreeMember" xlink:to="lab_ibrx_NantCapitalThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0b67b343-1349-4c6a-bd08-e39c49873702_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AmyrisJointVentureMember_03cf1527-321e-479d-a6a7-8b1f9655c5b4_terseLabel_en-US" xlink:label="lab_ibrx_AmyrisJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amyris Joint Venture</link:label>
    <link:label id="lab_ibrx_AmyrisJointVentureMember_label_en-US" xlink:label="lab_ibrx_AmyrisJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amyris Joint Venture [Member]</link:label>
    <link:label id="lab_ibrx_AmyrisJointVentureMember_documentation_en-US" xlink:label="lab_ibrx_AmyrisJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amyris Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisJointVentureMember" xlink:href="ibrx-20231231.xsd#ibrx_AmyrisJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AmyrisJointVentureMember" xlink:to="lab_ibrx_AmyrisJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_0f5e1d29-a7d3-404f-bda2-87aab0fd816c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a29f4750-016c-4ce3-9f50-98d50c89d2c5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8accfef4-cc00-45de-b14e-32aee554ab58_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_739af251-9d96-423e-ac76-2447bbb4b4b5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SaleLeasebackTransactionNetProceeds_0bc660b0-cdde-4313-8ecf-d3725d927046_terseLabel_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionNetProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale leaseback transaction, net proceeds</link:label>
    <link:label id="lab_ibrx_SaleLeasebackTransactionNetProceeds_label_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionNetProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Net Proceeds</link:label>
    <link:label id="lab_ibrx_SaleLeasebackTransactionNetProceeds_documentation_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionNetProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Net Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionNetProceeds" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionNetProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SaleLeasebackTransactionNetProceeds" xlink:to="lab_ibrx_SaleLeasebackTransactionNetProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_96a211d2-036a-4a2b-9f99-cf5a61360483_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment to hire, number of employees, first five years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Commitment To Hire, Number Of Employees, First Five Years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Commitment To Hire, Number Of Employees, First Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:to="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4927384-e6e8-426c-8341-8482e2c66c12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_ab8e68cf-80f1-4f77-b5c8-f7cd9a0d19d2_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment to spend, operational expenses, renewal lease term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:to="lab_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0cb6c135-4063-4b1d-beb3-2edcc5421e6f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_d27188ae-9fc5-4013-bc10-96e68dadc8b2_verboseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest items, net (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d458af21-939f-429e-a038-963f85480b12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_09f5146b-28d0-43c5-8aaa-89fb2eba1818_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_81eb6491-414b-4cbd-8db8-8aa129def6ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_8778842e-934b-46d6-9693-704d6b658018_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual minimum licensing payment</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Annual Minimum Licensing Payment</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Annual Minimum Licensing Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:to="lab_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_897c016e-e216-46fa-a371-eb2b4ac386f6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounted cash flow analysis</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantWorksLLCMember_0060c05f-6044-49fa-baf8-4e5bc8ab6364_terseLabel_en-US" xlink:label="lab_ibrx_NantWorksLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantWorks, LLC</link:label>
    <link:label id="lab_ibrx_NantWorksLLCMember_label_en-US" xlink:label="lab_ibrx_NantWorksLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantWorks, LLC [Member]</link:label>
    <link:label id="lab_ibrx_NantWorksLLCMember_documentation_en-US" xlink:label="lab_ibrx_NantWorksLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantWorks, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantWorksLLCMember" xlink:to="lab_ibrx_NantWorksLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e60da671-7770-452c-96d0-efa080777bac_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fd83acda-ffdd-4aed-8a15-b8d291b6dbf7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7af7535f-87c0-4139-af7b-41ab6951ebdb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cac8c325-5eda-4aa8-b07d-f1f1588a90d1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_00ebcf3a-1211-4743-a21c-9d2c5ddcf968_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_238ac996-b3cd-40f2-9983-6c2c5ce1b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9467fafd-0404-46fc-963a-576a564c2e1f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid_cfc102ca-890f-4501-ba21-eeb91bd59423_terseLabel_en-US" xlink:label="lab_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued investment in joint venture</link:label>
    <link:label id="lab_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid_label_en-US" xlink:label="lab_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments In Joint Venture, Incurred But Not Yet Paid</link:label>
    <link:label id="lab_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Joint Venture, Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid" xlink:href="ibrx-20231231.xsd#ibrx_InvestmentsInJointVentureIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid" xlink:to="lab_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_571ccfe1-421c-4f71-9f99-edcad6d2a5b3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4828dc6b-adfd-4a37-85d1-6b88adc2405e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a377b22d-2af5-411c-a851-9f12ed5a29aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5fcabec8-977a-4aee-93c9-3511f583f6ab_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fb65fbb5-f22f-4399-a535-e8706fac9838_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb9a829c-0cad-48e2-ad2d-23130fa2ee6b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net share settlement for RSUs vesting</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_38774a7f-f1c2-46c3-abe6-44f6c29b7abd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d11fc4e-6692-4326-968b-0fd673046922_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_8296e47a-6773-46a0-9c4d-9a6670c02bd0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1561863f-0969-48a4-94fa-369e737ca9ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_f68cd079-6696-4c97-be53-94ddd574fa2c_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, discount rate</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantKwestMember_ac3c2021-a18f-4b3c-8bb7-5241dcb24cba_terseLabel_en-US" xlink:label="lab_ibrx_NantKwestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantKwest</link:label>
    <link:label id="lab_ibrx_NantKwestMember_label_en-US" xlink:label="lab_ibrx_NantKwestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantKwest [Member]</link:label>
    <link:label id="lab_ibrx_NantKwestMember_documentation_en-US" xlink:label="lab_ibrx_NantKwestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantKwest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantKwestMember" xlink:href="ibrx-20231231.xsd#ibrx_NantKwestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantKwestMember" xlink:to="lab_ibrx_NantKwestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9e7ec08d-d5af-49f2-9f8f-fc0113381c2f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit&#160;</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableNonCurrent_eb1426f7-88c7-42a3-b90a-105847791806_terseLabel_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note receivable</link:label>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableNonCurrent_label_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Note Receivable Non Current</link:label>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableNonCurrent_documentation_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible note receivable, non-current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:to="lab_ibrx_ConvertibleNoteReceivableNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_a22d23a8-3461-4036-b1b3-a1ea9f3bb867_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_a5c41866-5410-4fad-b6ff-69c76d9a083a_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_72cf8c33-fca0-4742-9051-dd2da3e60f5e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per ImmunityBio common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c4e0c2f4-c649-4353-bed6-c6f79cba142f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_cdb8b103-6165-4209-a321-3b5e9ce8285f_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_f2076151-c3f8-4a8c-9054-33f900563fdb_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC</link:label>
    <link:label id="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_label_en-US" xlink:label="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:to="lab_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestoneFees_7d220a6b-dc4b-4833-847d-5a0bc3fd5233_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestoneFees_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Milestone Fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestoneFees_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Milestone Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestoneFees" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestoneFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsMilestoneFees" xlink:to="lab_ibrx_CollaborationAgreementsMilestoneFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_08ca7e90-d788-4c3e-a381-8a50137a3ce1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_45c78c2b-cc6a-426f-a6bc-76d038d81c6b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCancerStemCellMember_e5133a6a-bdf3-4183-94e7-a543d3442215_terseLabel_en-US" xlink:label="lab_ibrx_NantCancerStemCellMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">N C S C</link:label>
    <link:label id="lab_ibrx_NantCancerStemCellMember_label_en-US" xlink:label="lab_ibrx_NantCancerStemCellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantCancerStemCell [Member]</link:label>
    <link:label id="lab_ibrx_NantCancerStemCellMember_documentation_en-US" xlink:label="lab_ibrx_NantCancerStemCellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NCSC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCancerStemCellMember" xlink:href="ibrx-20231231.xsd#ibrx_NantCancerStemCellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCancerStemCellMember" xlink:to="lab_ibrx_NantCancerStemCellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_3e46c280-da9d-4d3b-9bea-170d75c568c7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b2c79d7b-69e5-422a-884a-05ceb06f0817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of stock option exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c55c1804-c6eb-4024-a0f2-e7dbf35832d5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCellInc.Member_190465fd-d8cb-49be-b1d2-9ef5df57d7cb_terseLabel_en-US" xlink:label="lab_ibrx_NantCellInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantCell</link:label>
    <link:label id="lab_ibrx_NantCellInc.Member_label_en-US" xlink:label="lab_ibrx_NantCellInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantCell, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_NantCellInc.Member_documentation_en-US" xlink:label="lab_ibrx_NantCellInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantCell, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCellInc.Member" xlink:to="lab_ibrx_NantCellInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_6899770a-7dd7-45d5-a34d-75a894b35f0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_fd3f0b3c-2ef6-4e70-8ed6-aac4c791ba7e_terseLabel_en-US" xlink:label="lab_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage held by stockholders upon consummation of merger</link:label>
    <link:label id="lab_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_label_en-US" xlink:label="lab_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage Acquired On Fully Diluted Bases Upon Consummation Of Merger</link:label>
    <link:label id="lab_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_documentation_en-US" xlink:label="lab_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership percentage acquired on fully diluted bases upon consummation of merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:href="ibrx-20231231.xsd#ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:to="lab_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_b8c53ab7-ee08-40fa-9b54-b2ddb4983654_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued pursuant to litigation settlement</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StockOptionPurchaseLiabilityMember_ec57c2ce-7c0f-4fb9-8746-abd2236bf68a_terseLabel_en-US" xlink:label="lab_ibrx_StockOptionPurchaseLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option purchase liability</link:label>
    <link:label id="lab_ibrx_StockOptionPurchaseLiabilityMember_label_en-US" xlink:label="lab_ibrx_StockOptionPurchaseLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Purchase Liability [Member]</link:label>
    <link:label id="lab_ibrx_StockOptionPurchaseLiabilityMember_documentation_en-US" xlink:label="lab_ibrx_StockOptionPurchaseLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Option Purchase Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockOptionPurchaseLiabilityMember" xlink:href="ibrx-20231231.xsd#ibrx_StockOptionPurchaseLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StockOptionPurchaseLiabilityMember" xlink:to="lab_ibrx_StockOptionPurchaseLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_0fc035e4-b600-4f21-9acd-08e1611027b1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_dd49d9f3-c55d-4f4b-befd-e82a8b84bf01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options, Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f372453a-3bd3-4bce-ad5b-6ade955e3b87_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4b48bf29-933b-4b75-845e-2876101b1251_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a0a27011-8561-4927-8ac3-e04ee227a052_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DunkirkFacilityMember_895be7ce-0101-4cce-9501-ceb937e87869_terseLabel_en-US" xlink:label="lab_ibrx_DunkirkFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dunkirk Facility</link:label>
    <link:label id="lab_ibrx_DunkirkFacilityMember_label_en-US" xlink:label="lab_ibrx_DunkirkFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dunkirk Facility [Member]</link:label>
    <link:label id="lab_ibrx_DunkirkFacilityMember_documentation_en-US" xlink:label="lab_ibrx_DunkirkFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dunkirk Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember" xlink:href="ibrx-20231231.xsd#ibrx_DunkirkFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DunkirkFacilityMember" xlink:to="lab_ibrx_DunkirkFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_f6d28fcc-da0c-407b-aca4-914b05d16970_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_62b567d4-138a-4f1a-bef3-7b86cc2d9acf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_ea8ce1f8-81ba-45b3-b698-3351c3ff5dcb_terseLabel_en-US" xlink:label="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related-Party Promissory Notes</link:label>
    <link:label id="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_label_en-US" xlink:label="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Related-Party Promissory Notes Table [Table Text Block]</link:label>
    <link:label id="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_documentation_en-US" xlink:label="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of related party notes payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:to="lab_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_910a5084-4635-497f-ad00-cdede09b54e7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations_6ef72f54-5258-425a-95d0-c571bb2d8c38_terseLabel_en-US" xlink:label="lab_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets not recognized due to limitations</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations_label_en-US" xlink:label="lab_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset Not Recognized, Section 382/383 Limitations</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations_documentation_en-US" xlink:label="lab_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset Not Recognized, Section 382/383 Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations" xlink:to="lab_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fb8e1763-32f2-4927-96e1-d128df399ce4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_cfcf2685-7002-472f-86d6-c0ece2899c93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantBioRevenue_8a49f270-85ba-4fb5-9c35-cb161913e798_terseLabel_en-US" xlink:label="lab_ibrx_NantBioRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantBio revenue recognized</link:label>
    <link:label id="lab_ibrx_NantBioRevenue_label_en-US" xlink:label="lab_ibrx_NantBioRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantBio Revenue</link:label>
    <link:label id="lab_ibrx_NantBioRevenue_documentation_en-US" xlink:label="lab_ibrx_NantBioRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantBio Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioRevenue" xlink:href="ibrx-20231231.xsd#ibrx_NantBioRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantBioRevenue" xlink:to="lab_ibrx_NantBioRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_71e26db0-571f-4944-bb18-56260a1f93df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DeferredIncomeTaxExpenseBenefitNet_e2c5272d-9a5d-4119-bcb1-01aae48276d9_negatedTotalLabel_en-US" xlink:label="lab_ibrx_DeferredIncomeTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_ibrx_DeferredIncomeTaxExpenseBenefitNet_label_en-US" xlink:label="lab_ibrx_DeferredIncomeTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net</link:label>
    <link:label id="lab_ibrx_DeferredIncomeTaxExpenseBenefitNet_documentation_en-US" xlink:label="lab_ibrx_DeferredIncomeTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet" xlink:href="ibrx-20231231.xsd#ibrx_DeferredIncomeTaxExpenseBenefitNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet" xlink:to="lab_ibrx_DeferredIncomeTaxExpenseBenefitNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a8f37a8b-b59e-4bc2-a244-adda30508cbb_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NoncurrentAssetsMember_8f457706-18d4-4d78-864d-1418749b8cf8_terseLabel_en-US" xlink:label="lab_ibrx_NoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent Assets</link:label>
    <link:label id="lab_ibrx_NoncurrentAssetsMember_label_en-US" xlink:label="lab_ibrx_NoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Assets [Member]</link:label>
    <link:label id="lab_ibrx_NoncurrentAssetsMember_documentation_en-US" xlink:label="lab_ibrx_NoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NoncurrentAssetsMember" xlink:to="lab_ibrx_NoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFour_337c6cc2-988f-4200-98a0-e811105632c8_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFour_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Four</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFour_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFour" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CommonStockRevenueInterestPurchaseAgreementMember_e1f380ac-e1fe-414f-905d-5ffed91aba42_terseLabel_en-US" xlink:label="lab_ibrx_CommonStockRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_ibrx_CommonStockRevenueInterestPurchaseAgreementMember_label_en-US" xlink:label="lab_ibrx_CommonStockRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Revenue Interest Purchase Agreement [Member]</link:label>
    <link:label id="lab_ibrx_CommonStockRevenueInterestPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ibrx_CommonStockRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Revenue Interest Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockRevenueInterestPurchaseAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockRevenueInterestPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CommonStockRevenueInterestPurchaseAgreementMember" xlink:to="lab_ibrx_CommonStockRevenueInterestPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_992a8c0a-b8c9-4c0c-952f-fe76c043d042_terseLabel_en-US" xlink:label="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_label_en-US" xlink:label="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_documentation_en-US" xlink:label="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:href="ibrx-20231231.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_4b6f961b-0683-4fa0-ab48-3f81002804d0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_cf0ab988-205b-4576-8543-c5777b04f017_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PeriodThreeMember_b44a8835-9f6a-4ff6-ba40-10a2cc3c16ac_terseLabel_en-US" xlink:label="lab_ibrx_PeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Three</link:label>
    <link:label id="lab_ibrx_PeriodThreeMember_label_en-US" xlink:label="lab_ibrx_PeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Three [Member]</link:label>
    <link:label id="lab_ibrx_PeriodThreeMember_documentation_en-US" xlink:label="lab_ibrx_PeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodThreeMember" xlink:href="ibrx-20231231.xsd#ibrx_PeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PeriodThreeMember" xlink:to="lab_ibrx_PeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7f2baffd-c20b-4cab-b941-6c257dd8ae88_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_aae658b2-95da-4dbc-8a07-ca69851529b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fedf2d19-5f07-4557-b03b-e635346feae4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationEliminationsMember_a6c03489-b1a4-4360-9322-59774a0903bb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intercompany Eliminations</link:label>
    <link:label id="lab_srt_ConsolidationEliminationsMember_label_en-US" xlink:label="lab_srt_ConsolidationEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationEliminationsMember" xlink:to="lab_srt_ConsolidationEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8d752e14-6dfe-4e86-a835-c8051b422c26_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_84792145-91a4-4f36-8d60-613f2fb03d4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember_10ba9c14-a46e-43ed-b5ae-371370c8645c_terseLabel_en-US" xlink:label="lab_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Chairman and Global Chief Scientific and Medical Officer</link:label>
    <link:label id="lab_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember_label_en-US" xlink:label="lab_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Chairman And Global Chief Scientific And Medical Officer [Member]</link:label>
    <link:label id="lab_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember_documentation_en-US" xlink:label="lab_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Executive Chairman and principal stockholder, and affiliates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" xlink:href="ibrx-20231231.xsd#ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" xlink:to="lab_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice_3172c7bd-fbda-4690-ba78-1755f72ee296_terseLabel_en-US" xlink:label="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum offering</link:label>
    <link:label id="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_ibrx_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_fe5c6188-0ffe-46a4-9172-e843cb4c563e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_0f5a07ba-03a0-4d09-bada-f13bd63237e1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_b6d7d1b9-558b-4819-9644-d6866ab94960_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyNotesPrincipalMember_e63cd725-3269-4523-8213-7b150aff6633_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Notes - Principal</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesPrincipalMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Notes - Principal [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesPrincipalMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Notes - Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPrincipalMember" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesPrincipalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyNotesPrincipalMember" xlink:to="lab_ibrx_RelatedPartyNotesPrincipalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0031bc58-7335-4859-b35e-e9db5bc30eb8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_0dd5a35c-c4c5-4bd3-85f1-8205cec37088_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method of Accounting</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_39358a75-e22b-46f7-8331-862330c5426a_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement And Arrangement Other Than Collaborative, Fee Schedule [Domain]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e77f6064-c309-435b-a658-3f98d763f085_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_088c9a0c-7be0-4d6b-82b4-d16c8a51c2e2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_125b14e7-27fa-4783-aa7e-8daa01a44d89_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue_643645ce-1d47-4d15-8e2f-ffa9bcbf01bd_terseLabel_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible notes</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue_label_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Convertible Notes, Change In Fair Value</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue_documentation_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Convertible Notes, Change In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" xlink:to="lab_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CurrentLiabilitiesMember_7a0706b6-f851-4027-b5ae-e399cfc4a29d_terseLabel_en-US" xlink:label="lab_ibrx_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_ibrx_CurrentLiabilitiesMember_label_en-US" xlink:label="lab_ibrx_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:label id="lab_ibrx_CurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_ibrx_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentLiabilitiesMember" xlink:href="ibrx-20231231.xsd#ibrx_CurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CurrentLiabilitiesMember" xlink:to="lab_ibrx_CurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember_a489eb48-6975-4604-be3a-336c0a8c2519_terseLabel_en-US" xlink:label="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 CRADA, Amendment</link:label>
    <link:label id="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember_label_en-US" xlink:label="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cooperative Research And Development Agreement, 2015 Amendment [Member]</link:label>
    <link:label id="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember_documentation_en-US" xlink:label="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cooperative Research And Development Agreement, 2015 Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" xlink:href="ibrx-20231231.xsd#ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" xlink:to="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d3eaf60b-fd77-4863-a28a-ad40bdd2f07e_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MeasurementInputMarketYieldMember_de6f844a-8955-4e5d-b0c0-a1cf578f6239_terseLabel_en-US" xlink:label="lab_ibrx_MeasurementInputMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market yield</link:label>
    <link:label id="lab_ibrx_MeasurementInputMarketYieldMember_label_en-US" xlink:label="lab_ibrx_MeasurementInputMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Market Yield [Member]</link:label>
    <link:label id="lab_ibrx_MeasurementInputMarketYieldMember_documentation_en-US" xlink:label="lab_ibrx_MeasurementInputMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Market Yield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputMarketYieldMember" xlink:href="ibrx-20231231.xsd#ibrx_MeasurementInputMarketYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MeasurementInputMarketYieldMember" xlink:to="lab_ibrx_MeasurementInputMarketYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ff027e57-3a05-4729-9540-ed70aeca2bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_98a9bf62-623d-4b2c-bafd-4960072726eb_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionHistoricalCost_428dc36c-2960-478d-b1ef-0055dd100ef0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale leaseback transaction, independent appraisal value</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionHistoricalCost_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Historical Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionHistoricalCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:to="lab_us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b5050e7d-e92a-4a39-96ab-505f0e0c74ba_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancingObligationCurrent_ed6437d1-8f58-4583-a21b-40eb1b9f7b3f_terseLabel_en-US" xlink:label="lab_ibrx_FinancingObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing obligation &#8211; current portion</link:label>
    <link:label id="lab_ibrx_FinancingObligationCurrent_label_en-US" xlink:label="lab_ibrx_FinancingObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Obligation, Current</link:label>
    <link:label id="lab_ibrx_FinancingObligationCurrent_documentation_en-US" xlink:label="lab_ibrx_FinancingObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancingObligationCurrent" xlink:href="ibrx-20231231.xsd#ibrx_FinancingObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancingObligationCurrent" xlink:to="lab_ibrx_FinancingObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_6ff86022-c64e-438f-a326-8de85f21aadf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate, Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_0b64f456-240c-4691-98fe-055701afaa83_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_9645d110-1c1e-4392-bc04-68f43043dfe5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MonthlyBaseRentParking_0ae09366-5551-436d-a8dd-3704897433d8_terseLabel_en-US" xlink:label="lab_ibrx_MonthlyBaseRentParking" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly base rent, parking</link:label>
    <link:label id="lab_ibrx_MonthlyBaseRentParking_label_en-US" xlink:label="lab_ibrx_MonthlyBaseRentParking" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monthly Base Rent, Parking</link:label>
    <link:label id="lab_ibrx_MonthlyBaseRentParking_documentation_en-US" xlink:label="lab_ibrx_MonthlyBaseRentParking" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monthly Base Rent, Parking</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MonthlyBaseRentParking" xlink:href="ibrx-20231231.xsd#ibrx_MonthlyBaseRentParking"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MonthlyBaseRentParking" xlink:to="lab_ibrx_MonthlyBaseRentParking" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_6e16cedb-b4db-4128-bbe3-f22825b06279_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction_d44e8d44-6571-4b84-a9bf-c18bc8017e23_terseLabel_en-US" xlink:label="lab_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price allocation</link:label>
    <link:label id="lab_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction</link:label>
    <link:label id="lab_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" xlink:to="lab_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_a1a5ca1f-1860-41fe-90b0-a90936ef722e_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement And Arrangement Other Than Collaborative, Fee One [Member]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement And Arrangement Other Than Collaborative, Fee One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6ddbb228-6b81-421d-a74c-a33ffad3c2de_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4d5ac6ab-8a67-41d2-aac5-ec0b325c0bc8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e1ea8f4e-1844-4c88-8137-8e9664b7e189_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_61e80124-5218-4a80-9d96-6bda153c50e7_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_a1d13c8a-15b8-413e-8473-1739f82e2ea7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_cc37765a-6827-4ac0-9ce8-d8bd9d589fe5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_e196d394-074f-46da-b0c9-1dd63af20b42_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement Terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7e2dae9b-ab8a-4e72-b1be-fff4f6506e18_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_2ea484ae-f30f-4053-a873-800ef0c84b91_terseLabel_en-US" xlink:label="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease payments related to options to extend lease terms</link:label>
    <link:label id="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_label_en-US" xlink:label="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Payments Related To Options To Extend Lease Terms</link:label>
    <link:label id="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_documentation_en-US" xlink:label="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease payments related to options to extend lease terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:href="ibrx-20231231.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:to="lab_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_c6c66aa0-9947-4b50-9f26-c9fbc7ddf7fa_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for legal settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_94939a25-dc30-4325-8db7-5f996f893000_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">More than 12 months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b9738025-e8d6-4ad8-960d-f165e3a7581f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd4062db-300d-45fe-aec5-668924c9714f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_01630e85-3319-46d2-920a-2f31d08ce1e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of net realized gains (losses) on available-for-sale securities included in net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a58d1c9a-39bf-4a36-8a48-fe6f3806478c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term, Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ebe93941-e72b-4da0-8a9d-af5e31652894_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_be29b37b-b2c6-4a5e-a585-3e2775a4e799_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total due from related parties</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OptionsToExtendNumberOfTerms_1994bfd7-40fd-43dd-9cf1-c864d70b8c7e_terseLabel_en-US" xlink:label="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to extend number of terms</link:label>
    <link:label id="lab_ibrx_OptionsToExtendNumberOfTerms_label_en-US" xlink:label="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options To Extend Number Of Terms</link:label>
    <link:label id="lab_ibrx_OptionsToExtendNumberOfTerms_documentation_en-US" xlink:label="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to extend number of terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionsToExtendNumberOfTerms" xlink:href="ibrx-20231231.xsd#ibrx_OptionsToExtendNumberOfTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OptionsToExtendNumberOfTerms" xlink:to="lab_ibrx_OptionsToExtendNumberOfTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_51839f81-1717-4aa6-b1eb-5b8a6d1d9a2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9c520e51-0628-4110-9517-77860b4a3d70_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_33a2e4a9-711b-4164-b582-9c58747e68ce_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4b1d3233-a5e3-4651-8fb1-16bc778c48c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net share settlement for RSUs vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c27268b9-96bf-4907-915c-489dadf9b5c5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8af87795-60aa-45d2-969a-ccb222cff56e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_5ec04c00-5e09-42a3-be9f-99197119debc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DueToRelatedPartiesMember_c730e15a-629f-4549-bad7-dbebe2b90f06_terseLabel_en-US" xlink:label="lab_ibrx_DueToRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_ibrx_DueToRelatedPartiesMember_label_en-US" xlink:label="lab_ibrx_DueToRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due To Related Parties [Member]</link:label>
    <link:label id="lab_ibrx_DueToRelatedPartiesMember_documentation_en-US" xlink:label="lab_ibrx_DueToRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Due to related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DueToRelatedPartiesMember" xlink:href="ibrx-20231231.xsd#ibrx_DueToRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DueToRelatedPartiesMember" xlink:to="lab_ibrx_DueToRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage_60f8deb6-d7b8-40db-846b-1f81163719ef_terseLabel_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue interest purchase agreement, tiered revenue interest rate percentage</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage_label_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage_documentation_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" xlink:to="lab_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f9391bba-3899-4eab-a4a7-1fa04d3e037e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_9350fdb6-31bc-49c0-9521-5dca5211dbb1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bbf9842b-6a6b-4734-88c7-9e548636bcc7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7119956a-293a-44d8-acc8-57e5d48bfc86_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_240496b6-1f8b-4819-98cf-a4c8081155cc_terseLabel_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangements with Federal Government [Line Items]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_label_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Arrangements With Federal Government [Line Items]</link:label>
    <link:label id="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_documentation_en-US" xlink:label="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development arrangements with the federal government.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:href="ibrx-20231231.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:to="lab_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_a6339659-6e1d-4a4a-b37d-cc8e6318abb0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss_fe385389-b41b-4418-9da7-b9045557df4e_terseLabel_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment loss</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss_label_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Investment Loss</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss_documentation_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Investment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" xlink:to="lab_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_13c5eae6-fa2c-4986-84d8-d3b475b74940_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_51bddddc-594d-4934-89ee-35d3d10a0e02_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5e926dd1-e9f5-4527-b764-5a264baadda8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_db9e7f2a-4b33-4765-9cf7-b931c31ca41b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_151dd3aa-3939-4c89-8c6c-1958b8cede88_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_bba2510b-e6a6-4cda-b2ba-a1cea9925f0c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_259511eb-a4ec-4cb2-bc04-a8dc66cd2e21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7a54f4f2-7027-4d76-856a-192d382e80c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_df361fdf-ee7b-4cb5-a04e-f66cbb8a4cf0_terseLabel_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Tenant improvement allowance receivable</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:to="lab_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f03c1baf-0d26-44da-9a79-d50e501df037_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1686f990-84f8-4294-b25f-65632d469019_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_f467882f-23ae-4cf1-91b6-d53da491e375_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs, Level 3 valuations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_cba71249-5c0a-422b-b498-9c15d9439171_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3ca7037c-e099-4237-a5f4-2010ec562739_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_47c810bd-f5ac-4616-87cb-3e3718eb8ca6_terseLabel_en-US" xlink:label="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual&#160;Life (in years)</link:label>
    <link:label id="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_label_en-US" xlink:label="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Securities Period</link:label>
    <link:label id="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_documentation_en-US" xlink:label="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available for sale securities debt securities period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:href="ibrx-20231231.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:to="lab_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_97b130b5-a131-46bb-b975-138ef1933ed8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions_00ffabfd-11ad-439f-ba9d-ce877238ac5e_terseLabel_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1c60ecee-b4ee-4ac8-9f1e-118939e24b2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_d7c78e9d-1312-484a-aeac-558ddc80ca93_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities (Note&#160;9 and Note&#160;10)</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_fccef3e5-21c7-4bad-a110-c8429958e65c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d620177-3c2e-490e-b97f-1854e58ec2e9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TransactionCostsWarrantLiability_eff5c994-7517-457a-a287-f175c00b0e7a_terseLabel_en-US" xlink:label="lab_ibrx_TransactionCostsWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs allocated to warrant liabilities</link:label>
    <link:label id="lab_ibrx_TransactionCostsWarrantLiability_label_en-US" xlink:label="lab_ibrx_TransactionCostsWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs, Warrant Liability</link:label>
    <link:label id="lab_ibrx_TransactionCostsWarrantLiability_documentation_en-US" xlink:label="lab_ibrx_TransactionCostsWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Costs, Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability" xlink:href="ibrx-20231231.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TransactionCostsWarrantLiability" xlink:to="lab_ibrx_TransactionCostsWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_005864e6-4168-453c-9631-ede7310d45c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_4ef8dc4a-e672-40df-9889-e9cb27451ca7_terseLabel_en-US" xlink:label="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum net sales milestone contingent value rights obligation</link:label>
    <link:label id="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_label_en-US" xlink:label="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Net Sales Milestone Contingent Value Rights Obligation</link:label>
    <link:label id="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_documentation_en-US" xlink:label="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum net sales milestone contingent value rights obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:href="ibrx-20231231.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:to="lab_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AdvancesToRelatedPartyMember_7dff285f-b6a0-4bd5-854d-f738c3e90156_terseLabel_en-US" xlink:label="lab_ibrx_AdvancesToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances To Related Party</link:label>
    <link:label id="lab_ibrx_AdvancesToRelatedPartyMember_label_en-US" xlink:label="lab_ibrx_AdvancesToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances To Related Party [Member]</link:label>
    <link:label id="lab_ibrx_AdvancesToRelatedPartyMember_documentation_en-US" xlink:label="lab_ibrx_AdvancesToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advances To Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdvancesToRelatedPartyMember" xlink:href="ibrx-20231231.xsd#ibrx_AdvancesToRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AdvancesToRelatedPartyMember" xlink:to="lab_ibrx_AdvancesToRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_99e6ff58-ca87-47da-82d6-2ccf54218e6e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7fd9bf4b-1032-4f2d-b6ba-3100f7d7f9ca_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_1b2801a7-4870-4e7c-af66-016e27a86f19_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NumberOfLeases_125367f4-2f22-4601-bf1c-e19e6aab8ab2_terseLabel_en-US" xlink:label="lab_ibrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_ibrx_NumberOfLeases_label_en-US" xlink:label="lab_ibrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Leases</link:label>
    <link:label id="lab_ibrx_NumberOfLeases_documentation_en-US" xlink:label="lab_ibrx_NumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfLeases" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NumberOfLeases" xlink:to="lab_ibrx_NumberOfLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b155530b-3e0b-438c-b0cd-49f376d8b8eb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cf32f05f-7053-4098-a3e5-ac0477438537_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Optional extended lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c2f84552-a02d-4073-b9b8-c0c9da31e7a8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_289ea1b3-1105-4bad-ba55-6375abc367df_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_2fff3579-63e4-438d-91c0-68ac62abd847_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_04a12a55-b873-4511-b1ab-864a6779949c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fed717bd-1c93-4842-9f21-82b5a6b47753_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SaleLeasebackTransactionPropertyTaxes_091ff466-7652-4084-aa7f-d54bc852b79c_terseLabel_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionPropertyTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale-leaseback transaction, property taxes</link:label>
    <link:label id="lab_ibrx_SaleLeasebackTransactionPropertyTaxes_label_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionPropertyTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale-leaseback Transaction, Property Taxes</link:label>
    <link:label id="lab_ibrx_SaleLeasebackTransactionPropertyTaxes_documentation_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionPropertyTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale-leaseback Transaction, Property Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionPropertyTaxes" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionPropertyTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SaleLeasebackTransactionPropertyTaxes" xlink:to="lab_ibrx_SaleLeasebackTransactionPropertyTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_a66003eb-85a5-4328-976d-f7bba260d263_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net realized gains (losses) on investments</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_827e19fc-1200-4420-9388-6ef0c67ca6e6_terseLabel_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored securities</link:label>
    <link:label id="lab_us-gaap_AgencySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AgencySecuritiesMember" xlink:to="lab_us-gaap_AgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_89852033-2a1d-41a0-9a86-c7ecf6769d93_terseLabel_en-US" xlink:label="lab_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement and At The Market Offerings</link:label>
    <link:label id="lab_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_label_en-US" xlink:label="lab_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement And At The Market Offerings [Member]</link:label>
    <link:label id="lab_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_documentation_en-US" xlink:label="lab_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement And At The Market Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember" xlink:href="ibrx-20231231.xsd#ibrx_PrivatePlacementAndAtTheMarketOfferingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember" xlink:to="lab_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_da604630-9dc0-4954-9886-87c9ad89bc7a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_c71d1a11-e774-41fe-ba49-dbd56be8eec7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_4a1b2281-2a28-4ec0-91f2-a7cb30b5e6ae_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_61a14c8e-e443-42c7-b0e8-a7aeca8b06de_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other depreciable assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalMember_2402b443-09da-413d-a988-9c25a87e96e6_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nant Capital 2015 Note Payable</link:label>
    <link:label id="lab_ibrx_NantCapitalMember_label_en-US" xlink:label="lab_ibrx_NantCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Capital [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantCapital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalMember" xlink:to="lab_ibrx_NantCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LicensingAgreementLineItems_1df071f8-7927-482d-bab6-43d5f47ff641_terseLabel_en-US" xlink:label="lab_ibrx_LicensingAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement [Line Items]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementLineItems_label_en-US" xlink:label="lab_ibrx_LicensingAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreement [Line Items]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementLineItems_documentation_en-US" xlink:label="lab_ibrx_LicensingAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementLineItems" xlink:href="ibrx-20231231.xsd#ibrx_LicensingAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LicensingAgreementLineItems" xlink:to="lab_ibrx_LicensingAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a1f5b5c1-00b7-4f23-84b7-5c5b3a6c5325_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_15be26d3-5c13-425a-b5b5-57bc66b1a1ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of income taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_fdb52e34-8c07-44a1-ac86-661fc85d8451_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock_bb1a1bfa-900a-43ff-9aaf-50e958ec945d_terseLabel_en-US" xlink:label="lab_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical and Clinical Trial Accruals</link:label>
    <link:label id="lab_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preclinical and Clinical Trial Accruals, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preclinical and Clinical Trial Accruals, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:to="lab_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_dd744ac2-fa38-48c5-b904-93056fa6c50c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Anniversary</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ExpansionPremisesMember_b9f92b94-f59a-4705-b2e1-a474ec5581cb_terseLabel_en-US" xlink:label="lab_ibrx_ExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expansion Premises</link:label>
    <link:label id="lab_ibrx_ExpansionPremisesMember_label_en-US" xlink:label="lab_ibrx_ExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expansion Premises [Member]</link:label>
    <link:label id="lab_ibrx_ExpansionPremisesMember_documentation_en-US" xlink:label="lab_ibrx_ExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amendment for expansion of premises, lease term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExpansionPremisesMember" xlink:href="ibrx-20231231.xsd#ibrx_ExpansionPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ExpansionPremisesMember" xlink:to="lab_ibrx_ExpansionPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_fb1aa6be-6cea-4f56-b17f-04d2b9317393_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_12f3258a-e974-48d4-be66-002a482d195c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_03ab0979-64ce-41eb-936c-c8bf13dc7895_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_00c24001-a78d-4275-b4be-11c12a13f601_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7d28563f-a771-45b0-8367-ce2812939afb_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b7f42760-c612-450e-be99-f0d282c4ea53_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8ba7d27c-3b9b-4962-9c10-356fcb8d71bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning balance (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_be4a1da7-7633-4f9d-9136-cf1128afc85c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, ending balance (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OwnershipPercentageByKeyExecutives_36d34beb-6538-422d-a8d0-549efd66b4b4_terseLabel_en-US" xlink:label="lab_ibrx_OwnershipPercentageByKeyExecutives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage of outstanding shares of company</link:label>
    <link:label id="lab_ibrx_OwnershipPercentageByKeyExecutives_label_en-US" xlink:label="lab_ibrx_OwnershipPercentageByKeyExecutives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Percentage By Key Executives</link:label>
    <link:label id="lab_ibrx_OwnershipPercentageByKeyExecutives_documentation_en-US" xlink:label="lab_ibrx_OwnershipPercentageByKeyExecutives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership percentage by key executives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OwnershipPercentageByKeyExecutives" xlink:href="ibrx-20231231.xsd#ibrx_OwnershipPercentageByKeyExecutives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OwnershipPercentageByKeyExecutives" xlink:to="lab_ibrx_OwnershipPercentageByKeyExecutives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7d1a699c-60db-4574-8c45-399ad133ad98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_000be8d5-c997-4a74-8584-558eb86c313c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_0ef0dd26-c273-42ce-8d03-9c663b1972c2_terseLabel_en-US" xlink:label="lab_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional revenue interests, second payment</link:label>
    <link:label id="lab_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_label_en-US" xlink:label="lab_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Additional Revenue Interests, Second Payment</link:label>
    <link:label id="lab_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_documentation_en-US" xlink:label="lab_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Additional Revenue Interests, Second Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment" xlink:to="lab_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_d2faf629-5fb9-43b7-9df8-b9870ed1bd90_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8b7cbe61-bc67-4f8c-9b2f-c1e6692d00f5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_6f6e6293-24ab-45e0-8cd4-2d8f7fd86046_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discretionary contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1220332-9930-465e-9af8-4381a4c600b3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write off of remaining unamortized organized workforce intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SixZeroFiveNashLLCMember_80c36ebe-0470-4aa7-a575-4d65a4ad66da_terseLabel_en-US" xlink:label="lab_ibrx_SixZeroFiveNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">605 Nash, LLC</link:label>
    <link:label id="lab_ibrx_SixZeroFiveNashLLCMember_label_en-US" xlink:label="lab_ibrx_SixZeroFiveNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Six Zero Five Nash, LLC [Member]</link:label>
    <link:label id="lab_ibrx_SixZeroFiveNashLLCMember_documentation_en-US" xlink:label="lab_ibrx_SixZeroFiveNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Six Zero Five Nash, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveNashLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_SixZeroFiveNashLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SixZeroFiveNashLLCMember" xlink:to="lab_ibrx_SixZeroFiveNashLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_9fef1602-cdca-4cae-aa50-625701253e3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_215a1ca8-371d-46d9-9bb5-59b0a9b2faba_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total due to related parties</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DeferredTaxAssetsValuationDiscount_0dd514dc-620b-4c38-b545-9924cc7a3d4b_terseLabel_en-US" xlink:label="lab_ibrx_DeferredTaxAssetsValuationDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation discount</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetsValuationDiscount_label_en-US" xlink:label="lab_ibrx_DeferredTaxAssetsValuationDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Discount</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetsValuationDiscount_documentation_en-US" xlink:label="lab_ibrx_DeferredTaxAssetsValuationDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetsValuationDiscount" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetsValuationDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DeferredTaxAssetsValuationDiscount" xlink:to="lab_ibrx_DeferredTaxAssetsValuationDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_b08b6c6c-3fd7-41a5-905d-d0dcafd34e2b_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IT equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_2033896f-eee5-4ebe-a417-af716882ab3f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e17b3792-973e-4def-8077-9929261315ba_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_635c3af6-8dbc-44ed-b8ac-3d50631017a4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementMember_5972ce9c-cd27-44c9-b0e4-1f0437d9acde_terseLabel_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementMember_label_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement [Member]</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementMember" xlink:to="lab_ibrx_RevenueInterestPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7f5aec50-d24d-4c7a-a530-05801f6137ea_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_94b7e215-1562-455f-9dfc-3399ea1b72b1_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11ebd171-f97c-4f4f-a343-e7a113a5f6e5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ae26f7f4-6e39-43be-b985-9dce83191968_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2a7089bb-afd2-42aa-a783-448d26960f92_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_4ed1ece4-065d-47a1-b2bd-83eb25049d54_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableDiscountOptionPercent_4cac9986-ccf5-4420-8711-61634e764a86_terseLabel_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableDiscountOptionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note receivable, discount option, percent</link:label>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableDiscountOptionPercent_label_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableDiscountOptionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Note Receivable, Discount Option, Percent</link:label>
    <link:label id="lab_ibrx_ConvertibleNoteReceivableDiscountOptionPercent_documentation_en-US" xlink:label="lab_ibrx_ConvertibleNoteReceivableDiscountOptionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Note Receivable, Discount Option, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableDiscountOptionPercent" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableDiscountOptionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ConvertibleNoteReceivableDiscountOptionPercent" xlink:to="lab_ibrx_ConvertibleNoteReceivableDiscountOptionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccountingPoliciesLineItems_6dff05f1-f62c-437e-8385-ddd6f0fb1180_terseLabel_en-US" xlink:label="lab_ibrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesLineItems_label_en-US" xlink:label="lab_ibrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ibrx_AccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesLineItems" xlink:href="ibrx-20231231.xsd#ibrx_AccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccountingPoliciesLineItems" xlink:to="lab_ibrx_AccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_da3c4e5f-10c8-4861-af85-07f39b4815bd_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSU Activity under Equity Plans</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IssuanceOfWarrants_7a38c497-0521-4c7e-ad71-1662e54489d3_terseLabel_en-US" xlink:label="lab_ibrx_IssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial measurement of warrants issued in connection with registered direct offerings accounted for as liabilities</link:label>
    <link:label id="lab_ibrx_IssuanceOfWarrants_label_en-US" xlink:label="lab_ibrx_IssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Warrants</link:label>
    <link:label id="lab_ibrx_IssuanceOfWarrants_documentation_en-US" xlink:label="lab_ibrx_IssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfWarrants" xlink:href="ibrx-20231231.xsd#ibrx_IssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IssuanceOfWarrants" xlink:to="lab_ibrx_IssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2f5a026b-7f06-42d3-b000-24cae7763ca8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_77389be3-7134-4f1c-b34b-883af9bb1c4c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_341fb8cd-35e0-406d-8bbc-6d08f011c74c_terseLabel_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Tenant improvement allowance receivable</link:label>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:href="ibrx-20231231.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:to="lab_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c4b67d65-00c8-4cab-8ee4-401f794e48f7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7f035a86-aadd-4601-9a9e-ba00477ad81d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_27999978-bd01-4c1c-a124-db5a48c7e771_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_04cc7ad0-fd65-4d76-8491-68b4870e487b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Treatment of the Merger</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:to="lab_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_7413ceff-1fb4-4965-9955-955ac9b9ef76_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash (Note 2)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_556bac6e-4071-4ac7-994d-d9d67ca0fde7_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AAHIMember_69be6e41-5261-47f7-953f-435d49b22b98_terseLabel_en-US" xlink:label="lab_ibrx_AAHIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Access to Advanced Health Institute (AAHI)</link:label>
    <link:label id="lab_ibrx_AAHIMember_label_en-US" xlink:label="lab_ibrx_AAHIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AAHI [Member]</link:label>
    <link:label id="lab_ibrx_AAHIMember_documentation_en-US" xlink:label="lab_ibrx_AAHIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AAHI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AAHIMember" xlink:href="ibrx-20231231.xsd#ibrx_AAHIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AAHIMember" xlink:to="lab_ibrx_AAHIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_658cd081-0c48-4912-80cb-ac8e584cbe87_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_4ab5af2a-6b59-4e83-a733-a03eac622e2f_terseLabel_en-US" xlink:label="lab_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of stock purchase option</link:label>
    <link:label id="lab_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_label_en-US" xlink:label="lab_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement [Member]</link:label>
    <link:label id="lab_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" xlink:to="lab_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_9a047666-c7ae-4a65-9c28-03a3d1dfe990_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4c00ec00-0be2-490d-9c94-d76d55a0e48a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1325059d-31b5-4575-bbb1-92edee0607b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7acb1e91-bed9-4059-826e-43783616237e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment for contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InitialPremisesMember_57ef3c64-be76-4f8b-b7aa-7d264364b3b1_terseLabel_en-US" xlink:label="lab_ibrx_InitialPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Premises</link:label>
    <link:label id="lab_ibrx_InitialPremisesMember_label_en-US" xlink:label="lab_ibrx_InitialPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Premises [Member]</link:label>
    <link:label id="lab_ibrx_InitialPremisesMember_documentation_en-US" xlink:label="lab_ibrx_InitialPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Premises.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPremisesMember" xlink:href="ibrx-20231231.xsd#ibrx_InitialPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InitialPremisesMember" xlink:to="lab_ibrx_InitialPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_79bfe102-7842-4a24-99db-3afec68402dc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4691f22b-b6e7-4f5c-9815-1fd6ad67aec0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AnnualPercentageIncreasesToBaseRent_926ef111-7e62-4314-b57f-aa4561726317_terseLabel_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of annual increases of base rent</link:label>
    <link:label id="lab_ibrx_AnnualPercentageIncreasesToBaseRent_label_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Percentage Increases To Base Rent</link:label>
    <link:label id="lab_ibrx_AnnualPercentageIncreasesToBaseRent_documentation_en-US" xlink:label="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual percentage increases to base rent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:href="ibrx-20231231.xsd#ibrx_AnnualPercentageIncreasesToBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:to="lab_ibrx_AnnualPercentageIncreasesToBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6589f4f5-eda5-4214-b027-e31ebe9a48a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price, Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9f256b69-12e5-4431-aac9-1081acf8a056_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability_705079b0-f7df-4d3b-91e0-fa77f1c83c78_terseLabel_en-US" xlink:label="lab_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issuance discount related to the revenue interest liability</link:label>
    <link:label id="lab_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability_label_en-US" xlink:label="lab_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Discount On Shares, Revenue Interest Liability</link:label>
    <link:label id="lab_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability_documentation_en-US" xlink:label="lab_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Discount On Shares, Revenue Interest Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockDiscountOnSharesRevenueInterestLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability" xlink:to="lab_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_14a2e345-533d-4597-8219-a2731aeaf7d6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cee7896a-1812-4b5a-bb1d-c05058168686_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f890dbfd-0038-46e1-8d80-22688a68f61f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_2a46abbf-fa24-42a2-9c94-df2b779d4498_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e14ff8f2-52c5-4340-a158-ecb72bd79a85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_5b64f452-2d97-4f24-ac9a-feae66a7f356_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_b426fcae-092c-4e0a-91c1-67070bfae536_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6f8cd007-ea65-4ace-8d0a-ccac33ef893c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9c7f1cb3-758a-454e-beda-6113e5419c95_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to ImmunityBio common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AltorStockholdersMember_e7334565-421c-4f85-b273-d80d4062bc49_terseLabel_en-US" xlink:label="lab_ibrx_AltorStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Altor Stockholders</link:label>
    <link:label id="lab_ibrx_AltorStockholdersMember_label_en-US" xlink:label="lab_ibrx_AltorStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Altor Stockholders [Member]</link:label>
    <link:label id="lab_ibrx_AltorStockholdersMember_documentation_en-US" xlink:label="lab_ibrx_AltorStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Altor Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorStockholdersMember" xlink:href="ibrx-20231231.xsd#ibrx_AltorStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AltorStockholdersMember" xlink:to="lab_ibrx_AltorStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4f02856a-8afd-43c2-af59-f503d6b63650_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_7d64c250-3d42-4563-9eec-989cb1fe6711_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_681c25c3-dda7-4a34-b30e-f0e4a1a760a4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4744400c-0d75-4fa9-bb0b-f0f9a41a694b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_8b28b699-a451-4cc6-806d-3166db20b53a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_3d891b42-c09c-4363-85ef-2d70c827b5c4_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares to be issued in private placement (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09628b90-4037-4f0b-9053-8f03e1425280_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:to="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_882ee658-2cc7-40c5-9030-de2646cb4f86_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27ca2404-9d9f-4e56-aabb-8f1bec6ca2f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bd69b25b-e9b0-4aaa-8c4f-cbe90614bb88_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BrinkBiologicsIncMember_28840d5b-a58f-45b1-9386-f0ba0a0cd6d7_terseLabel_en-US" xlink:label="lab_ibrx_BrinkBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brink Biologics, Inc.</link:label>
    <link:label id="lab_ibrx_BrinkBiologicsIncMember_label_en-US" xlink:label="lab_ibrx_BrinkBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brink Biologics, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_BrinkBiologicsIncMember_documentation_en-US" xlink:label="lab_ibrx_BrinkBiologicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Brink Biologics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember" xlink:href="ibrx-20231231.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BrinkBiologicsIncMember" xlink:to="lab_ibrx_BrinkBiologicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_df423750-2e78-4ffe-8b0c-4ebc1f381c42_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-party convertible notes and accrued interest, net of discount (Note 10)</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5ebf3c7e-65a2-4679-bf41-1eee9e0afaca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1b3b536c-2839-4b1f-ba23-6af94e99738a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NoncurrentLiabilitiesMember_a66b89df-636d-4b9f-84b2-50d7668b7dbb_terseLabel_en-US" xlink:label="lab_ibrx_NoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent Liabilities</link:label>
    <link:label id="lab_ibrx_NoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_ibrx_NoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_ibrx_NoncurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_ibrx_NoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentLiabilitiesMember" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NoncurrentLiabilitiesMember" xlink:to="lab_ibrx_NoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7fd330ad-bbc8-49b1-9758-c99f80dc6f77_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ViractaMember_6a55a4d2-87e6-4a83-8eb7-ad250c1850a8_terseLabel_en-US" xlink:label="lab_ibrx_ViractaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Viracta</link:label>
    <link:label id="lab_ibrx_ViractaMember_label_en-US" xlink:label="lab_ibrx_ViractaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Viracta [Member]</link:label>
    <link:label id="lab_ibrx_ViractaMember_documentation_en-US" xlink:label="lab_ibrx_ViractaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Viracta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ViractaMember" xlink:href="ibrx-20231231.xsd#ibrx_ViractaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ViractaMember" xlink:to="lab_ibrx_ViractaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_04ab35a2-01f7-434d-94cd-d680c2220338_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_0c14526b-188f-44a7-a0a8-c0a68ad3be06_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_c3cd9fdc-7753-4c39-ac24-f1adce4f87ea_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransactionDomain_d81e9bcc-7d89-4eb8-a7df-7262c46c88ea_terseLabel_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction</link:label>
    <link:label id="lab_us-gaap_TransactionDomain_label_en-US" xlink:label="lab_us-gaap_TransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8275906d-9e4b-47c2-a12f-987a487a213c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_97bf2f85-b10a-4c5a-930a-47710125f9d2_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AltorBioScienceLLCMember_a4f3de90-3d21-4403-b670-4cb18d44407f_terseLabel_en-US" xlink:label="lab_ibrx_AltorBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Altor BioScience, LLC</link:label>
    <link:label id="lab_ibrx_AltorBioScienceLLCMember_label_en-US" xlink:label="lab_ibrx_AltorBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Altor BioScience, LLC [Member]</link:label>
    <link:label id="lab_ibrx_AltorBioScienceLLCMember_documentation_en-US" xlink:label="lab_ibrx_AltorBioScienceLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Altor BioScience, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AltorBioScienceLLCMember" xlink:to="lab_ibrx_AltorBioScienceLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveFromLessor_eca70775-7f2e-4524-a3d5-218367a5a049_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvements incentive</link:label>
    <link:label id="lab_us-gaap_IncentiveFromLessor_label_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive from Lessor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveFromLessor" xlink:to="lab_us-gaap_IncentiveFromLessor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8f6ddb66-e01f-403e-8530-19c44f7b2509_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration paid</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_95c213c0-1a38-4318-b5f1-32573bfdb7dc_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding third-party warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_2edb75cd-8071-4c36-aaf8-cd0e222fb423_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember_6a30dabe-c3ab-4233-9cfb-311cdc46dae9_terseLabel_en-US" xlink:label="lab_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software License Subscription Fees and Implementation Costs</link:label>
    <link:label id="lab_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember_label_en-US" xlink:label="lab_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software License Subscription Fees And Implementation Costs [Member]</link:label>
    <link:label id="lab_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember_documentation_en-US" xlink:label="lab_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software License Subscription Fees And Implementation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" xlink:href="ibrx-20231231.xsd#ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" xlink:to="lab_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d9baa0ed-d03f-4970-b40b-51ac825ee9ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, less current portion (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_637b47f9-a0a6-4062-870a-adeee585eaa2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_8223250d-2069-49fd-a3ed-2b568b793ac6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b3ef5a57-ba67-41dd-bcb5-fb96b117ec36_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_726a8796-d93d-4a25-9db2-3084712ba552_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1bf80a57-443b-4a07-a09c-78b7be5ffd5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RiptideBioscienceIncMember_9ee982bc-4029-44aa-a9d9-82c680a8f9e1_terseLabel_en-US" xlink:label="lab_ibrx_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Riptide Bioscience, Inc.</link:label>
    <link:label id="lab_ibrx_RiptideBioscienceIncMember_label_en-US" xlink:label="lab_ibrx_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Riptide Bioscience, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_RiptideBioscienceIncMember_documentation_en-US" xlink:label="lab_ibrx_RiptideBioscienceIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Riptide Bioscience, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RiptideBioscienceIncMember" xlink:href="ibrx-20231231.xsd#ibrx_RiptideBioscienceIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RiptideBioscienceIncMember" xlink:to="lab_ibrx_RiptideBioscienceIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_924f2af2-d34e-46aa-b966-764f7fee8a79_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_1893d406-91dd-4edc-8032-15a8627aa7bc_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ContingentValueRightsObligations_58d594a4-fce0-48cb-a622-14483cddf811_terseLabel_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent value rights obligations</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligations_label_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Rights Obligations</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligations_documentation_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent value rights obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligations" xlink:href="ibrx-20231231.xsd#ibrx_ContingentValueRightsObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ContingentValueRightsObligations" xlink:to="lab_ibrx_ContingentValueRightsObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_430d659b-7978-45bc-8c56-6731a4132a98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_5ba81b3a-ae60-443e-a087-7a203343119a_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 through 2030</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement And Arrangement Other Than Collaborative, Fee, Tranche Two [Member]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement And Arrangement Other Than Collaborative, Fee, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_654443fb-da2f-4452-a594-da6edc1f1f04_terseLabel_en-US" xlink:label="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of related-party notes discounts</link:label>
    <link:label id="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_label_en-US" xlink:label="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Debt Discount (Premium), Related Party</link:label>
    <link:label id="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_documentation_en-US" xlink:label="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Debt Discount (Premium), Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:href="ibrx-20231231.xsd#ibrx_AmortizationOfDebtDiscountPremiumRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:to="lab_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_a15df2d3-90cb-4da6-83e7-a173026b9bd0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a7cd3212-70f2-4bac-a9fa-7d982deeb063_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PercentageOfWhollyOwnedSubsidiary_7e808c72-a95e-4bf8-a34c-d0c58dc9d1bc_terseLabel_en-US" xlink:label="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage acquired</link:label>
    <link:label id="lab_ibrx_PercentageOfWhollyOwnedSubsidiary_label_en-US" xlink:label="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Wholly Owned Subsidiary</link:label>
    <link:label id="lab_ibrx_PercentageOfWhollyOwnedSubsidiary_documentation_en-US" xlink:label="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of wholly-owned subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:href="ibrx-20231231.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:to="lab_ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_0ff3dbf5-e6b8-4fcf-81a0-e216db5bde28_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_840b6333-9107-456d-ba3f-3fc5b7e2a86e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_48638c96-18e2-45ab-8def-b3401112110d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_f89a3206-6d95-438e-bd27-3ce9982ebd71_terseLabel_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration arrangements, earned</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_label_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Earned</link:label>
    <link:label id="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_documentation_en-US" xlink:label="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:href="ibrx-20231231.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:to="lab_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_ec391fe0-14a2-462f-9b11-e9205376ee5e_terseLabel_en-US" xlink:label="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash distributed in lieu of fractional shares (in dollars per share)</link:label>
    <link:label id="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_label_en-US" xlink:label="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Cash Distributed In Lieu Of Fractional Shares</link:label>
    <link:label id="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_documentation_en-US" xlink:label="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued, Cash Distributed In Lieu Of Fractional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:href="ibrx-20231231.xsd#ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:to="lab_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_20f9b87c-830e-49f5-bfec-df33ddad9ee3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Information Regarding Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85d8a389-77d9-4f6f-ab1a-04ec96d3e391_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_8d72fa9f-e96c-4ce1-aef0-786683038288_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of related-party convertible note</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_6f4140d3-fc7e-435d-b063-c3d43226786d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible note</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_af4a7da1-c503-4701-9d5d-11a238bfca3a_terseLabel_en-US" xlink:label="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_label_en-US" xlink:label="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_documentation_en-US" xlink:label="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:href="ibrx-20231231.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_43c1bd28-c665-4144-bf5c-9954029495e8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f123c326-d715-4fc2-9fd3-cd9acb6649e2_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_InterestExpense_58ece911-e502-4545-a6e9-cc2c18b20207_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_06a6df18-e30b-490e-9695-ca0b50acbe6f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_239161b0-cfe8-4bca-a40e-a54a4795aac8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualProjectFundingAmount_1e853909-6924-409a-a5ea-aa3109f7374f_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualProjectFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual project funding amount</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualProjectFundingAmount_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualProjectFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Annual Project Funding Amount</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsAnnualProjectFundingAmount_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsAnnualProjectFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Annual Project Funding Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualProjectFundingAmount" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualProjectFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsAnnualProjectFundingAmount" xlink:to="lab_ibrx_CollaborationAgreementsAnnualProjectFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_764867ff-9a04-415e-b1b7-4622f701eed6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment purchases included in accounts payable, accrued expenses and due to related parties</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d633781c-4b2f-40d0-ac09-146d30a2db6c_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_dc893b11-e56d-48ce-9d45-de92a21bc8c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment with entities under common control</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9ef4d6ca-0231-4847-99cf-dfca7b72a128_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Details</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_138d9012-3f42-4654-bf5b-a21f0bc6584a_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9d2ff5e2-c322-4402-9b53-614293cadecf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_79abcdc0-b352-4541-a613-198b99fa7cd7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of assets to an entity under common control</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_7c0c814a-acc4-4d34-a975-ec4f93d8f121_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital_fc515065-ece6-4f9e-bd58-68cd278d572a_terseLabel_en-US" xlink:label="lab_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion of valuation allowance credited directly to contributed capital</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital_label_en-US" xlink:label="lab_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Tax Benefits Credited To Contributed Capital</link:label>
    <link:label id="lab_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital_documentation_en-US" xlink:label="lab_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Tax Benefits Credited To Contributed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" xlink:to="lab_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PeriodFourMember_91502237-5461-492c-aee9-aa93f3e157c8_terseLabel_en-US" xlink:label="lab_ibrx_PeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period Four</link:label>
    <link:label id="lab_ibrx_PeriodFourMember_label_en-US" xlink:label="lab_ibrx_PeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Four [Member]</link:label>
    <link:label id="lab_ibrx_PeriodFourMember_documentation_en-US" xlink:label="lab_ibrx_PeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodFourMember" xlink:href="ibrx-20231231.xsd#ibrx_PeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PeriodFourMember" xlink:to="lab_ibrx_PeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bb4adf4f-3f1e-425e-9432-290a6da7bd26_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_974c537a-0615-45d3-8cdb-78e4c35ff607_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_01b5e73a-e737-42e7-86d1-3eaeba47037d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_06573bdc-0176-4c26-bd09-2d35e6849411_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived: Favorable leasehold rights</link:label>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_label_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Off-Market Favorable Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:to="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_VivaBioCellMember_eefe62dd-1728-4b29-ae40-a7584c39d56a_terseLabel_en-US" xlink:label="lab_ibrx_VivaBioCellMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VivaBioCell</link:label>
    <link:label id="lab_ibrx_VivaBioCellMember_label_en-US" xlink:label="lab_ibrx_VivaBioCellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Viva Bio Cell [Member]</link:label>
    <link:label id="lab_ibrx_VivaBioCellMember_documentation_en-US" xlink:label="lab_ibrx_VivaBioCellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VivaBioCell.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VivaBioCellMember" xlink:href="ibrx-20231231.xsd#ibrx_VivaBioCellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_VivaBioCellMember" xlink:to="lab_ibrx_VivaBioCellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_bc0db55c-0372-49dd-9991-f47657dc18d2_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_a8d1dbf6-e507-44d4-9fe8-94e9a7693629_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Unamortized Discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8d828f3c-6d53-4837-8b70-d249f14c30a3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_26afdbd4-0cc3-4235-86d2-07f0e2881e34_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afa31dc8-675b-4d26-8f07-404bb4a3535b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_4274729f-6e7a-4e86-974e-d97e1c867758_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement agent fees and other offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DuleyRoadLLCMember_f5843ece-b7fe-4683-9ed9-1ead4cad3f15_terseLabel_en-US" xlink:label="lab_ibrx_DuleyRoadLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duley Road, LLC</link:label>
    <link:label id="lab_ibrx_DuleyRoadLLCMember_label_en-US" xlink:label="lab_ibrx_DuleyRoadLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Duley Road, LLC [Member]</link:label>
    <link:label id="lab_ibrx_DuleyRoadLLCMember_documentation_en-US" xlink:label="lab_ibrx_DuleyRoadLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Duley Road, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_DuleyRoadLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DuleyRoadLLCMember" xlink:to="lab_ibrx_DuleyRoadLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b318dd7d-c9f3-46ec-80c2-d5cb10e6c2b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TieredPaymentsDomain_2e9164dc-d761-4408-b405-0de497aadf57_terseLabel_en-US" xlink:label="lab_ibrx_TieredPaymentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tiered Payments [Domain]</link:label>
    <link:label id="lab_ibrx_TieredPaymentsDomain_label_en-US" xlink:label="lab_ibrx_TieredPaymentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tiered Payments [Domain]</link:label>
    <link:label id="lab_ibrx_TieredPaymentsDomain_documentation_en-US" xlink:label="lab_ibrx_TieredPaymentsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tiered Payments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TieredPaymentsDomain" xlink:href="ibrx-20231231.xsd#ibrx_TieredPaymentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TieredPaymentsDomain" xlink:to="lab_ibrx_TieredPaymentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_4e9aae45-0769-4a66-841b-64f2926a4341_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_189c8bd4-ecd7-4145-ac21-28eef2fccd47_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2bf9fbea-d366-47f3-94ad-d65902238a6d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Supplies_22be31f9-f0d8-4277-a80c-51c984bb88cb_terseLabel_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid supplies</link:label>
    <link:label id="lab_us-gaap_Supplies_label_en-US" xlink:label="lab_us-gaap_Supplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Supplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Supplies" xlink:to="lab_us-gaap_Supplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9ca40ffd-6264-4489-961b-a8bdc3aa8aa7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidServices_7fb725d8-0286-4474-a896-535245a7e8c1_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid services</link:label>
    <link:label id="lab_ibrx_PrepaidServices_label_en-US" xlink:label="lab_ibrx_PrepaidServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Services</link:label>
    <link:label id="lab_ibrx_PrepaidServices_documentation_en-US" xlink:label="lab_ibrx_PrepaidServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidServices" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidServices" xlink:to="lab_ibrx_PrepaidServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_60dc05cb-eee8-4720-a67f-bc40b107e77d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8c3d3a9f-54da-4526-8ef8-1ada00da0e43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue_059c1e77-ac60-439b-8cb7-5f9a807d667d_terseLabel_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue_label_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Warrants, Change In Fair Value</link:label>
    <link:label id="lab_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue_documentation_en-US" xlink:label="lab_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Warrants, Change In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" xlink:to="lab_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_d3074cf8-e11a-417f-912c-9237fb7376f7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_354dad9d-4e30-4df7-b31e-ea8681827f51_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_fd44b747-1b45-414f-a89e-e24df1b16e57_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_460c3201-22c5-4e48-a7c8-2d2403148539_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 12 months, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1c82357d-c1b2-4dc2-ab63-fd848113bc61_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_379cca9d-7f5a-4eda-a1e4-f8dc61312b17_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in units)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAbstract_78c97e58-c5a3-4510-86ee-00af805cecdf_terseLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAbstract_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid [Abstract]</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidAbstract_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAbstract" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract" xlink:to="lab_ibrx_LeaseLiabilityToBePaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_bdd839e0-b1c3-4135-adc5-28a51d47e785_periodStartLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Revenue interest liability at inception</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_4b35a714-12f6-4926-9c23-10af09579ef9_periodEndLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Revenue interest liability at end of period</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_05605f8b-f616-4697-9116-a0eee64cdd25_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9a4238f9-a63c-4264-a76a-b348f060f717_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6769c23e-a10b-4cfa-abea-b374f1cceaeb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of stock issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f6a6606e-4644-4020-8c92-e165a35593d5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bfe51ff8-2d56-47da-a711-6edfb8e54cfc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to ImmunityBio common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncomeTaxLineItems_84477d6f-2a8a-442f-ae38-124201ea47c3_terseLabel_en-US" xlink:label="lab_ibrx_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_ibrx_IncomeTaxLineItems_label_en-US" xlink:label="lab_ibrx_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_ibrx_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_ibrx_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxLineItems" xlink:href="ibrx-20231231.xsd#ibrx_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncomeTaxLineItems" xlink:to="lab_ibrx_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_2fe6b63c-ed06-4f3a-897a-7c5c1c624796_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e39ecc3f-bef1-4075-a8fa-bfdd4387c681_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A2014PlanMember_e4640d08-e017-451e-9eb6-662266adb604_terseLabel_en-US" xlink:label="lab_ibrx_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_ibrx_A2014PlanMember_label_en-US" xlink:label="lab_ibrx_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2014 Plan [Member]</link:label>
    <link:label id="lab_ibrx_A2014PlanMember_documentation_en-US" xlink:label="lab_ibrx_A2014PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2014 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A2014PlanMember" xlink:href="ibrx-20231231.xsd#ibrx_A2014PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A2014PlanMember" xlink:to="lab_ibrx_A2014PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_7f67a6ae-f781-46b6-9929-ba63d6a227fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_fa511680-f1e6-4a9d-a12f-3de552260fc2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest and Investment (Loss) Income, Net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:to="lab_us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_24fd2dce-5fff-4874-ba68-bb1169c6bc99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearOne_848ff35c-1893-4dfe-93a3-bda2a39b496a_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearOne_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year One</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearOne_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearOne" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_3ae91338-b872-4641-8b79-6304197477e6_terseLabel_en-US" xlink:label="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Option Election</link:label>
    <link:label id="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes, Fair Value Option Election [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Notes, Fair Value Option Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:to="lab_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_6591ae09-ca71-4ea8-9f7d-93fb4285ef18_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership interest by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionNetBookValue_a22894c2-5721-4e17-8c29-74cae1962fbc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale leaseback transaction, net carrying value</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionNetBookValue_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Net Book Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:to="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_13fdcdc2-087f-48e2-95a5-89a47f2f0c75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_9b3d5344-2e84-4da4-a100-4f6629057e24_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e3358378-04b5-4abb-94cd-a15bbd32e925_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DuleyRoadMember_ee27486c-0071-4da4-a333-a64d1a28b590_terseLabel_en-US" xlink:label="lab_ibrx_DuleyRoadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duley Road, LLC</link:label>
    <link:label id="lab_ibrx_DuleyRoadMember_label_en-US" xlink:label="lab_ibrx_DuleyRoadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Duley Road [Member]</link:label>
    <link:label id="lab_ibrx_DuleyRoadMember_documentation_en-US" xlink:label="lab_ibrx_DuleyRoadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Duley Road.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadMember" xlink:href="ibrx-20231231.xsd#ibrx_DuleyRoadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DuleyRoadMember" xlink:to="lab_ibrx_DuleyRoadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A50MillionDecember2022PromissoryNoteMember_6fa3a674-f86a-461e-bd0d-a6714e27b648_terseLabel_en-US" xlink:label="lab_ibrx_A50MillionDecember2022PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$50 Million December 2022 Promissory Note</link:label>
    <link:label id="lab_ibrx_A50MillionDecember2022PromissoryNoteMember_label_en-US" xlink:label="lab_ibrx_A50MillionDecember2022PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$50 Million December 2022 Promissory Note [Member]</link:label>
    <link:label id="lab_ibrx_A50MillionDecember2022PromissoryNoteMember_documentation_en-US" xlink:label="lab_ibrx_A50MillionDecember2022PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$50 Million December 2022 Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A50MillionDecember2022PromissoryNoteMember" xlink:href="ibrx-20231231.xsd#ibrx_A50MillionDecember2022PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A50MillionDecember2022PromissoryNoteMember" xlink:to="lab_ibrx_A50MillionDecember2022PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_July2023WarrantsMember_fb416865-b55e-4543-82dc-500dfa799533_terseLabel_en-US" xlink:label="lab_ibrx_July2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 2023 Warrants</link:label>
    <link:label id="lab_ibrx_July2023WarrantsMember_label_en-US" xlink:label="lab_ibrx_July2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July 2023 Warrants [Member]</link:label>
    <link:label id="lab_ibrx_July2023WarrantsMember_documentation_en-US" xlink:label="lab_ibrx_July2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July 2023 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_July2023WarrantsMember" xlink:href="ibrx-20231231.xsd#ibrx_July2023WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_July2023WarrantsMember" xlink:to="lab_ibrx_July2023WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LongTermDebtGrossIncludingAccruedInterest_8aecb272-531d-4fe2-9eab-a32428a6928b_terseLabel_en-US" xlink:label="lab_ibrx_LongTermDebtGrossIncludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal and accrued interest</link:label>
    <link:label id="lab_ibrx_LongTermDebtGrossIncludingAccruedInterest_label_en-US" xlink:label="lab_ibrx_LongTermDebtGrossIncludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross, Including Accrued Interest</link:label>
    <link:label id="lab_ibrx_LongTermDebtGrossIncludingAccruedInterest_documentation_en-US" xlink:label="lab_ibrx_LongTermDebtGrossIncludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross, Including Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest" xlink:href="ibrx-20231231.xsd#ibrx_LongTermDebtGrossIncludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest" xlink:to="lab_ibrx_LongTermDebtGrossIncludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_8d38052d-3007-4408-8de8-c0521759d977_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionRate_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionRate" xlink:to="lab_us-gaap_RelatedPartyTransactionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_faa06c86-23f0-4a55-aca5-c76f9672cd30_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8567b619-2865-4f11-9de5-37f92ae66315_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_fc4b6efd-3b8d-44c9-950b-b9be43708aa3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_526f2245-0fa2-4452-9841-a4b922a2a450_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_5e9338d7-c113-41b1-ad37-0dcdb8ab2d2e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_MeasurementInputExpectedMarketYieldMember_e842dcf3-3bf9-441e-b1cd-d9e1108a6ce0_terseLabel_en-US" xlink:label="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected market yield</link:label>
    <link:label id="lab_ibrx_MeasurementInputExpectedMarketYieldMember_label_en-US" xlink:label="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Market Yield [Member]</link:label>
    <link:label id="lab_ibrx_MeasurementInputExpectedMarketYieldMember_documentation_en-US" xlink:label="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Market Yield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:href="ibrx-20231231.xsd#ibrx_MeasurementInputExpectedMarketYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:to="lab_ibrx_MeasurementInputExpectedMarketYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_4804a5b9-805b-4851-98b6-cd902ce62b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFive_762f4ae7-b3dc-4420-9add-ce0166e24c2a_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFive_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Five</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearFive_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFive" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearFive" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage_0de36dcb-5605-4f72-830d-e2366cc809dd_terseLabel_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue interest purchase agreement, payment received percentage</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage_label_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Payment Received Percentage</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage_documentation_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Payment Received Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage" xlink:to="lab_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a6268a2e-67d0-4a8b-af5e-a423ba9d8142_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PercentageOfSalesAgentCommission_85ba7ba2-74ce-402a-afe0-fbe986a6ea4c_terseLabel_en-US" xlink:label="lab_ibrx_PercentageOfSalesAgentCommission" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of sales agent commission</link:label>
    <link:label id="lab_ibrx_PercentageOfSalesAgentCommission_label_en-US" xlink:label="lab_ibrx_PercentageOfSalesAgentCommission" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Sales Agent Commission</link:label>
    <link:label id="lab_ibrx_PercentageOfSalesAgentCommission_documentation_en-US" xlink:label="lab_ibrx_PercentageOfSalesAgentCommission" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Sales Agent Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfSalesAgentCommission" xlink:href="ibrx-20231231.xsd#ibrx_PercentageOfSalesAgentCommission"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PercentageOfSalesAgentCommission" xlink:to="lab_ibrx_PercentageOfSalesAgentCommission" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_7c0b6cbc-e4d5-44d7-a3c8-47049fd65713_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_64d5df35-bbd8-4cdb-a165-d2ca4a6e49f5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_ac003379-27ae-4a99-9fe8-fc5ab7a03adb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of related-party convertible notes and accrued interest, net of unamortized discount, into equity</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts_76b136f1-ec15-45c5-9dfc-25c349f01f1d_terseLabel_en-US" xlink:label="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued preclinical and clinical trial costs</link:label>
    <link:label id="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts_label_en-US" xlink:label="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Preclinical And Clinical Trial Costs</link:label>
    <link:label id="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts_documentation_en-US" xlink:label="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued preclinical and clinical trial costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:href="ibrx-20231231.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:to="lab_ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_6c6c2f2d-ecbe-48a0-940b-b912f41979ae_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments_14156c03-1d6c-4150-8b6c-16535cd1495e_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic license payments</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Periodic License Payments</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Periodic License Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsPeriodicLicensePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:to="lab_ibrx_CollaborationAgreementsPeriodicLicensePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DerivativeLiabilitiesMember_64dbc9df-95d6-49ad-b784-d346bceb367e_terseLabel_en-US" xlink:label="lab_ibrx_DerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_ibrx_DerivativeLiabilitiesMember_label_en-US" xlink:label="lab_ibrx_DerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liabilities [Member]</link:label>
    <link:label id="lab_ibrx_DerivativeLiabilitiesMember_documentation_en-US" xlink:label="lab_ibrx_DerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DerivativeLiabilitiesMember" xlink:href="ibrx-20231231.xsd#ibrx_DerivativeLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DerivativeLiabilitiesMember" xlink:to="lab_ibrx_DerivativeLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_01289379-7c9a-4f70-b731-cbae5fcecabc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6c3e10da-cd1a-4c77-bb1f-272bec98a41f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_9cac6111-6ef5-491a-8786-4ee89691135b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7458cf4c-3995-47aa-b0f1-f9ca7af3e053_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash, end of year:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_71410436-4e68-4e05-b5d7-7d5830368c52_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancialStatementDetailsTable_9e38d19b-b286-4c5d-92b1-d9adfee70073_terseLabel_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Table]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsTable_label_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Table]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsTable_documentation_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancialStatementDetailsTable" xlink:to="lab_ibrx_FinancialStatementDetailsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0931039b-60fb-46b6-8293-f822a9c3c267_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ValuationTechniqueBinomialLatticeModelMember_3405d3f3-3ab4-4ab7-b5d6-0bf23e00eb86_terseLabel_en-US" xlink:label="lab_ibrx_ValuationTechniqueBinomialLatticeModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Binomial lattice model</link:label>
    <link:label id="lab_ibrx_ValuationTechniqueBinomialLatticeModelMember_label_en-US" xlink:label="lab_ibrx_ValuationTechniqueBinomialLatticeModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Binomial Lattice Model [Member]</link:label>
    <link:label id="lab_ibrx_ValuationTechniqueBinomialLatticeModelMember_documentation_en-US" xlink:label="lab_ibrx_ValuationTechniqueBinomialLatticeModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Technique, Binomial Lattice Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ValuationTechniqueBinomialLatticeModelMember" xlink:href="ibrx-20231231.xsd#ibrx_ValuationTechniqueBinomialLatticeModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ValuationTechniqueBinomialLatticeModelMember" xlink:to="lab_ibrx_ValuationTechniqueBinomialLatticeModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_e427389f-a2be-4d75-86ba-70d1b1a0b88a_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total ImmunityBio Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_eb2661ae-509c-4af0-bd77-7d25c64b0c2e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_3762b2dc-4540-4035-a9f8-1e0b6eba5ca3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationTable_b9cf54b5-8ce6-4a1d-a3ae-225d9c7994e0_terseLabel_en-US" xlink:label="lab_ibrx_LitigationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation [Table]</link:label>
    <link:label id="lab_ibrx_LitigationTable_label_en-US" xlink:label="lab_ibrx_LitigationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation [Table]</link:label>
    <link:label id="lab_ibrx_LitigationTable_documentation_en-US" xlink:label="lab_ibrx_LitigationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationTable" xlink:href="ibrx-20231231.xsd#ibrx_LitigationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationTable" xlink:to="lab_ibrx_LitigationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9281c124-87fd-4427-a992-350f736375b0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7bab833b-25a6-4487-a277-e45d2605906b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (RSUs) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_86f2e650-6475-4b5b-b5ff-4394c42159aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7d300bb6-da4f-4820-897e-ea0e46f4d473_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3a2706fa-434f-46d9-b95b-71317ad4aa3b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_45b5d259-52bf-4b77-b05a-3bdadea326ac_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fd1e2118-a558-4245-b1a3-18a1bbfa055f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_c6a831e3-cb34-4a39-aeaf-ccdd419a211a_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b8df1190-a677-4e70-a452-7041e39f1927_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2c9f6d42-9edd-4e55-af51-d6d26f1bc033_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_20155291-793c-455a-b946-179bed277d89_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2442211b-535d-4bb2-9f21-ff505475f015_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4b2e412e-d70c-4477-a6b6-bb683bbf1b30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice_64985026-433d-4e69-9934-cd7eb702285d_terseLabel_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required purchase price, as a percent</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice_label_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price</link:label>
    <link:label id="lab_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice_documentation_en-US" xlink:label="lab_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" xlink:to="lab_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_26a821cf-797e-4744-862a-ce8cad18280f_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impact of Change in Reporting Entity on Unaudited Consolidated Statements of Operations</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Income Statement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_fb89ee33-3e0a-4859-b1b7-87300598e123_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of common stock outstanding after option exercise, maximum</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantMobileMember_f779d16b-19d2-4a56-9e57-c74545b83b1a_terseLabel_en-US" xlink:label="lab_ibrx_NantMobileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantMobile</link:label>
    <link:label id="lab_ibrx_NantMobileMember_label_en-US" xlink:label="lab_ibrx_NantMobileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Mobile [Member]</link:label>
    <link:label id="lab_ibrx_NantMobileMember_documentation_en-US" xlink:label="lab_ibrx_NantMobileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nant Mobile.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantMobileMember" xlink:href="ibrx-20231231.xsd#ibrx_NantMobileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantMobileMember" xlink:to="lab_ibrx_NantMobileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b4fa2787-8e1a-4c04-85b8-54a8b2e514f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationSettlementInterestPercent_c8c30dcc-064a-4baa-8be9-d458684193f9_terseLabel_en-US" xlink:label="lab_ibrx_LitigationSettlementInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest related to litigation settlement, as a percent</link:label>
    <link:label id="lab_ibrx_LitigationSettlementInterestPercent_label_en-US" xlink:label="lab_ibrx_LitigationSettlementInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement Interest, Percent</link:label>
    <link:label id="lab_ibrx_LitigationSettlementInterestPercent_documentation_en-US" xlink:label="lab_ibrx_LitigationSettlementInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement Interest, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementInterestPercent" xlink:href="ibrx-20231231.xsd#ibrx_LitigationSettlementInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationSettlementInterestPercent" xlink:to="lab_ibrx_LitigationSettlementInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5794ea09-2af8-4828-8031-1b0610121421_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCellTwoThousandAndFifteenPlanMember_c2901d3c-f64b-461c-bf59-7f26523c0cdd_terseLabel_en-US" xlink:label="lab_ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NC 2015 Plan</link:label>
    <link:label id="lab_ibrx_NantCellTwoThousandAndFifteenPlanMember_label_en-US" xlink:label="lab_ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Cell Two Thousand And Fifteen Plan [Member]</link:label>
    <link:label id="lab_ibrx_NantCellTwoThousandAndFifteenPlanMember_documentation_en-US" xlink:label="lab_ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantCell two thousand and fifteen plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:href="ibrx-20231231.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:to="lab_ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_WarrantsPolicyTextBlock_e92da4b3-1d89-470d-a28c-b08ccb62d88c_terseLabel_en-US" xlink:label="lab_ibrx_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ibrx_WarrantsPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_WarrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_WarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsPolicyTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_WarrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_WarrantsPolicyTextBlock" xlink:to="lab_ibrx_WarrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fd8cf78c-125c-4309-8190-dde9dc895dda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_66fc1cc7-3fc8-4f56-95ff-06505bda0f26_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f0b9eff8-d0aa-4d25-a237-133418c613fe_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9dfacec7-c312-4e49-9da4-a41a99bc3527_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_96b0afac-8fcf-408e-9bd1-da6f968a08ae_terseLabel_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_label_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement And Arrangement Other Than Collaborative, Fee Schedule [Axis]</link:label>
    <link:label id="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_documentation_en-US" xlink:label="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement And Arrangement Other Than Collaborative, Fee Schedule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:to="lab_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CGMPBatchesMember_0ded5826-99e9-4408-8227-5a6f2d14d29f_terseLabel_en-US" xlink:label="lab_ibrx_CGMPBatchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">cGMP Batches</link:label>
    <link:label id="lab_ibrx_CGMPBatchesMember_label_en-US" xlink:label="lab_ibrx_CGMPBatchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cGMP Batches [Member]</link:label>
    <link:label id="lab_ibrx_CGMPBatchesMember_documentation_en-US" xlink:label="lab_ibrx_CGMPBatchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">cGMP Batches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CGMPBatchesMember" xlink:href="ibrx-20231231.xsd#ibrx_CGMPBatchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CGMPBatchesMember" xlink:to="lab_ibrx_CGMPBatchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_13d51166-c08f-401e-992e-f8b21d81a04f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d9372f98-40f0-4e81-85a9-91526efbd190_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_ffb04f79-eaac-46be-8658-e9ad10751838_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0cbc5f9-568a-4d3e-8524-4874878db44e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9a8d5240-44ed-42a8-b87e-326801b9b1d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember_f074dea7-7085-44ed-a96d-b511028a7f63_terseLabel_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Value Rights Obligation, Sales Milestone</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember_label_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Value Rights Obligation, Sales Milestone [Member]</link:label>
    <link:label id="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember_documentation_en-US" xlink:label="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent value rights obligation before December 31, 2026.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:href="ibrx-20231231.xsd#ibrx_ContingentValueRightsObligationSalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:to="lab_ibrx_ContingentValueRightsObligationSalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_February2023ShelfRegistrationStatementMember_b6715fa2-7d40-4d37-b063-f627f98b4004_terseLabel_en-US" xlink:label="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">February 2023 Shelf Registration Statement</link:label>
    <link:label id="lab_ibrx_February2023ShelfRegistrationStatementMember_label_en-US" xlink:label="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February 2023 Shelf Registration Statement [Member]</link:label>
    <link:label id="lab_ibrx_February2023ShelfRegistrationStatementMember_documentation_en-US" xlink:label="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">February 2023 Shelf Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember" xlink:href="ibrx-20231231.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_February2023ShelfRegistrationStatementMember" xlink:to="lab_ibrx_February2023ShelfRegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SponsoredResearchAgreementMember_cb3e0e86-dd9f-45f4-a2f8-f6ee00526c63_terseLabel_en-US" xlink:label="lab_ibrx_SponsoredResearchAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sponsored Research Agreement</link:label>
    <link:label id="lab_ibrx_SponsoredResearchAgreementMember_label_en-US" xlink:label="lab_ibrx_SponsoredResearchAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sponsored Research Agreement [Member]</link:label>
    <link:label id="lab_ibrx_SponsoredResearchAgreementMember_documentation_en-US" xlink:label="lab_ibrx_SponsoredResearchAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sponsored research agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SponsoredResearchAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_SponsoredResearchAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SponsoredResearchAgreementMember" xlink:to="lab_ibrx_SponsoredResearchAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CurrentAssetsMember_90d70a10-09a5-4b99-a4e6-240ca7b923db_terseLabel_en-US" xlink:label="lab_ibrx_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_ibrx_CurrentAssetsMember_label_en-US" xlink:label="lab_ibrx_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:label id="lab_ibrx_CurrentAssetsMember_documentation_en-US" xlink:label="lab_ibrx_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember" xlink:href="ibrx-20231231.xsd#ibrx_CurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CurrentAssetsMember" xlink:to="lab_ibrx_CurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_050994c1-f821-4285-9999-03e5a291190b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6dac3f5f-8081-499e-8d96-c48e04b8a1d2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NationalCancerInstituteMember_daec059a-4395-489e-82c9-2bfcc141bb91_terseLabel_en-US" xlink:label="lab_ibrx_NationalCancerInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">National Cancer Institute (NCI)</link:label>
    <link:label id="lab_ibrx_NationalCancerInstituteMember_label_en-US" xlink:label="lab_ibrx_NationalCancerInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Cancer Institute [Member]</link:label>
    <link:label id="lab_ibrx_NationalCancerInstituteMember_documentation_en-US" xlink:label="lab_ibrx_NationalCancerInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">National Cancer Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NationalCancerInstituteMember" xlink:href="ibrx-20231231.xsd#ibrx_NationalCancerInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NationalCancerInstituteMember" xlink:to="lab_ibrx_NationalCancerInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_49f1fcd9-90e1-43bb-99bc-efedb92d520e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f8f7133b-556d-4e6c-af0a-f15bc1e6ed0b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001&#160;par value; 1,350,000,000 and 900,000,000&#160;shares authorized as of December&#160;31,&#160;2023 and 2022, respectively; 670,867,344 and 421,569,115 shares issued and outstanding as of December&#160;31,&#160;2023 and 2022, respectively; excluding 163,800&#160;treasury stock shares outstanding as of December&#160;31,&#160;2023 and 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_639fbcda-b0a5-4a7e-a6ae-33d2796031f4_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1bef6884-95ab-48e4-bb27-d5044bf610fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense related to operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e16d1e1b-b98b-42d6-b2a3-46974481e37d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_9a2af1b8-1b3a-436c-b3b8-32ca251930cf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued PIK Interest Added to Note</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f8e5739d-634d-488e-892c-213653de30f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_e490c97c-16de-465b-8b6a-4cc47aade410_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash flow from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestGovernmentFundingAvailable_213cefdc-9dca-4789-9cd8-124e5c4c665f_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestGovernmentFundingAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government funding for leasehold build-out</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestGovernmentFundingAvailable_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestGovernmentFundingAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Government Funding Available</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestGovernmentFundingAvailable_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestGovernmentFundingAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Government Funding Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestGovernmentFundingAvailable" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestGovernmentFundingAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestGovernmentFundingAvailable" xlink:to="lab_ibrx_LeaseholdInterestGovernmentFundingAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_d52fe5ad-988a-4f3b-ba77-00beedf0cff0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Operating Activities Lessee [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_December2022WarrantsMember_4b95f70e-8248-473f-8310-2dedac29f1c6_terseLabel_en-US" xlink:label="lab_ibrx_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2022 Warrants</link:label>
    <link:label id="lab_ibrx_December2022WarrantsMember_label_en-US" xlink:label="lab_ibrx_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2022 Warrants [Member]</link:label>
    <link:label id="lab_ibrx_December2022WarrantsMember_documentation_en-US" xlink:label="lab_ibrx_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2022 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember" xlink:href="ibrx-20231231.xsd#ibrx_December2022WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_December2022WarrantsMember" xlink:to="lab_ibrx_December2022WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_830f165c-2939-4506-9570-b3e6a05f1739_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e6b3360c-1942-45b7-baa3-70cd15754493_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_76c2fb24-a9e0-4a3d-aaa4-9348b75eb420_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4865fc1b-de7d-46b5-96f9-9341ee66deaf_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_c85bf91d-a672-4d79-9d63-68ee5f906b62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the RIPA, net of transaction costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_70e7687d-9fa0-4f56-9b95-1b9e1d90a7c4_totalLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the RIPA, net of transaction costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8eedc273-1ee7-477f-b555-20a940fa9c7f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_bf206919-f8f2-4ae6-bd3f-6e8cb7943a53_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue interest liability (Note&#160;9)</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_512b1151-2302-4041-9b6c-4d3d077a1ac1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_050c9df8-3a72-4db2-968e-261a66aa794e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6857caf1-a829-4ba8-b5d9-0e06745650cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_StateOfNewYorkMember_dbd801e9-2d16-41d0-86a1-9f3716ac2d34_terseLabel_en-US" xlink:label="lab_ibrx_StateOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State Of New York</link:label>
    <link:label id="lab_ibrx_StateOfNewYorkMember_label_en-US" xlink:label="lab_ibrx_StateOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State Of New York [Member]</link:label>
    <link:label id="lab_ibrx_StateOfNewYorkMember_documentation_en-US" xlink:label="lab_ibrx_StateOfNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">State Of New York</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StateOfNewYorkMember" xlink:href="ibrx-20231231.xsd#ibrx_StateOfNewYorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_StateOfNewYorkMember" xlink:to="lab_ibrx_StateOfNewYorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fe6e145f-bb1a-4572-b3ff-9f061ea6b6f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_987d3771-250f-49da-b789-1abf0f90c552_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_e0453de0-a7e9-4f3a-88f9-c6b410ebf131_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FourTwoZeroNashLLCMember_4522c76b-8ee7-4ebe-b3eb-e8b01303f178_terseLabel_en-US" xlink:label="lab_ibrx_FourTwoZeroNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">420 Nash, LLC</link:label>
    <link:label id="lab_ibrx_FourTwoZeroNashLLCMember_label_en-US" xlink:label="lab_ibrx_FourTwoZeroNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Two Zero Nash, LLC [Member]</link:label>
    <link:label id="lab_ibrx_FourTwoZeroNashLLCMember_documentation_en-US" xlink:label="lab_ibrx_FourTwoZeroNashLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Two Zero Nash, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FourTwoZeroNashLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_FourTwoZeroNashLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FourTwoZeroNashLLCMember" xlink:to="lab_ibrx_FourTwoZeroNashLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_a1aa2989-b4aa-40f0-8a4b-d29b10e2c6a2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_536d7839-f910-4916-8074-5306e833efe0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Modification and Extinguishment</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_54d98b41-e934-4440-aac7-a8e3852fa703_terseLabel_en-US" xlink:label="lab_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would not impact effective tax rate</link:label>
    <link:label id="lab_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_label_en-US" xlink:label="lab_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</link:label>
    <link:label id="lab_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_documentation_en-US" xlink:label="lab_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:href="ibrx-20231231.xsd#ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="lab_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_73b2b9a9-1efd-44f3-9a9c-8b0f7cbf50b2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_February2023WarrantsMember_cb3b9c33-cc4f-4bba-a290-cc7a4982f966_terseLabel_en-US" xlink:label="lab_ibrx_February2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">February 2023 Warrants</link:label>
    <link:label id="lab_ibrx_February2023WarrantsMember_label_en-US" xlink:label="lab_ibrx_February2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February 2023 Warrants [Member]</link:label>
    <link:label id="lab_ibrx_February2023WarrantsMember_documentation_en-US" xlink:label="lab_ibrx_February2023WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">February 2023 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember" xlink:href="ibrx-20231231.xsd#ibrx_February2023WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_February2023WarrantsMember" xlink:to="lab_ibrx_February2023WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_143a06d6-cace-495b-a4e3-088b79a58288_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_00792055-adda-4393-bd83-2cac2d3ef148_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LesseeOperatingLeasePrepaidExpense_33828b40-5ba3-4723-bba5-e7abdba21fa1_terseLabel_en-US" xlink:label="lab_ibrx_LesseeOperatingLeasePrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment of first month rent and security deposit</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeasePrepaidExpense_label_en-US" xlink:label="lab_ibrx_LesseeOperatingLeasePrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Prepaid Expense</link:label>
    <link:label id="lab_ibrx_LesseeOperatingLeasePrepaidExpense_documentation_en-US" xlink:label="lab_ibrx_LesseeOperatingLeasePrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeasePrepaidExpense" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeasePrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LesseeOperatingLeasePrepaidExpense" xlink:to="lab_ibrx_LesseeOperatingLeasePrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyNotesInterestMember_0908c6bc-6793-4b8f-8ca9-3d0d57f9ab49_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payments</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesInterestMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyNotesInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Notes - Interest [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesInterestMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyNotesInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Notes - Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesInterestMember" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyNotesInterestMember" xlink:to="lab_ibrx_RelatedPartyNotesInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseOther_24bf172d-2482-4ab1-8891-a3e78ea91c76_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseOther_label_en-US" xlink:label="lab_us-gaap_InterestExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOther" xlink:to="lab_us-gaap_InterestExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ImmunoOncologyClinicMember_b9df9dec-9f69-4a09-b81a-c80340b704be_terseLabel_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immuno-Oncology Clinic, Inc.</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicMember_label_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immuno Oncology Clinic [Member]</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicMember_documentation_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immuno-Oncology Clinic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicMember" xlink:href="ibrx-20231231.xsd#ibrx_ImmunoOncologyClinicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ImmunoOncologyClinicMember" xlink:to="lab_ibrx_ImmunoOncologyClinicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_a4da730b-033c-42ee-8e3e-c0d2864d6bb2_terseLabel_en-US" xlink:label="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt with related parties under common control</link:label>
    <link:label id="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_244fcce0-68ee-4010-9fb5-261f4abcdf92_verboseLabel_en-US" xlink:label="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt with related parties under common control</link:label>
    <link:label id="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_label_en-US" xlink:label="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Gain (Loss) On Extinguishment Of Debt With Related Party</link:label>
    <link:label id="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_documentation_en-US" xlink:label="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Gain (Loss) On Extinguishment Of Debt With Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" xlink:href="ibrx-20231231.xsd#ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" xlink:to="lab_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ef68053c-31c0-4a47-a7c0-e9b63dc2ae40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_0ab3bf24-2020-4bc7-bd68-2f803600ee4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_c0abd636-ff26-4a40-a906-99c9067e2782_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_OptionPeriodAxis_d1084aec-6b99-4aec-acad-d42f464fb565_terseLabel_en-US" xlink:label="lab_ibrx_OptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Period [Axis]</link:label>
    <link:label id="lab_ibrx_OptionPeriodAxis_label_en-US" xlink:label="lab_ibrx_OptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Period [Axis]</link:label>
    <link:label id="lab_ibrx_OptionPeriodAxis_documentation_en-US" xlink:label="lab_ibrx_OptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionPeriodAxis" xlink:href="ibrx-20231231.xsd#ibrx_OptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_OptionPeriodAxis" xlink:to="lab_ibrx_OptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_731556fa-d7a1-4ddc-82aa-e87d80038c30_terseLabel_en-US" xlink:label="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_label_en-US" xlink:label="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Due To Related Parties Current And Non Current</link:label>
    <link:label id="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_documentation_en-US" xlink:label="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in due to related parties current and non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:href="ibrx-20231231.xsd#ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:to="lab_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_e5ad352a-10c9-4811-9483-a38db39e914d_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CommonControlTransactionPolicyPolicyTextBlock_01205291-e031-4696-bb66-a0481f2162b1_terseLabel_en-US" xlink:label="lab_ibrx_CommonControlTransactionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Control Transactions</link:label>
    <link:label id="lab_ibrx_CommonControlTransactionPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ibrx_CommonControlTransactionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Control Transaction, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ibrx_CommonControlTransactionPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ibrx_CommonControlTransactionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Control Transaction, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonControlTransactionPolicyPolicyTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_CommonControlTransactionPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CommonControlTransactionPolicyPolicyTextBlock" xlink:to="lab_ibrx_CommonControlTransactionPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_00bd0bc4-7c70-48c6-a170-e40dd0a3220a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_34705041-30d3-4f11-b33f-44365ad29e61_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_729c06e1-c26d-48b5-9fcf-bceeda494efe_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total ImmunityBio stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount_07da683b-4689-49b8-932e-1c92a40c408b_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment, payable amount</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Milestone Payment, Payable Amount</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentPayableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount" xlink:to="lab_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_TieredPaymentsAxis_17b96d56-d99a-458f-94d2-e4645bc8feec_terseLabel_en-US" xlink:label="lab_ibrx_TieredPaymentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tiered Payments [Axis]</link:label>
    <link:label id="lab_ibrx_TieredPaymentsAxis_label_en-US" xlink:label="lab_ibrx_TieredPaymentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tiered Payments [Axis]</link:label>
    <link:label id="lab_ibrx_TieredPaymentsAxis_documentation_en-US" xlink:label="lab_ibrx_TieredPaymentsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tiered Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TieredPaymentsAxis" xlink:href="ibrx-20231231.xsd#ibrx_TieredPaymentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_TieredPaymentsAxis" xlink:to="lab_ibrx_TieredPaymentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_af6483e6-82d8-4877-9f91-cb7952db4052_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bf49c08-0b4e-40d3-8a3a-b386bce30152_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2fd99498-afc1-4177-acb5-7f15ea0021d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaid_eb7265f0-f6b8-4db1-9999-b8694961f079_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaid_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaid_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaid" xlink:to="lab_ibrx_LeaseLiabilityToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_46bba03e-b39d-4878-86f3-a25bc4c7147f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_97257d03-92fb-4e4d-8d24-9d948423111f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_68652c90-4ec9-4934-aa49-d2b151581eb8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SixZeroFiveDougStLLCMember_078d044c-e136-4891-99f5-b07054d80d85_terseLabel_en-US" xlink:label="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">605 Doug St, LLC</link:label>
    <link:label id="lab_ibrx_SixZeroFiveDougStLLCMember_label_en-US" xlink:label="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Six Zero Five Doug St, LLC [Member]</link:label>
    <link:label id="lab_ibrx_SixZeroFiveDougStLLCMember_documentation_en-US" xlink:label="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Six Zero Five Doug St, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveDougStLLCMember" xlink:href="ibrx-20231231.xsd#ibrx_SixZeroFiveDougStLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SixZeroFiveDougStLLCMember" xlink:to="lab_ibrx_SixZeroFiveDougStLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_5103bd1b-dfae-41c3-8ffb-0be36c8c44ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_5df43e7b-a40f-4408-8e8d-a2e80155832d_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IPRDMember_dc8ce351-eee5-43a8-a8e2-3cf6904485a3_terseLabel_en-US" xlink:label="lab_ibrx_IPRDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_ibrx_IPRDMember_label_en-US" xlink:label="lab_ibrx_IPRDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPR&amp;D [Member]</link:label>
    <link:label id="lab_ibrx_IPRDMember_documentation_en-US" xlink:label="lab_ibrx_IPRDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IPRDMember" xlink:href="ibrx-20231231.xsd#ibrx_IPRDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IPRDMember" xlink:to="lab_ibrx_IPRDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_4c61bbc0-0d85-4912-a25a-485a2678c5ec_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of fixed assets</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_59f07123-e054-449a-addc-d6c0fee0f025_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in exchange for notes payable (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2334fa56-6859-4858-8e49-531ef8a10bdb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_6620dead-3b52-4830-8f06-7491711b20d3_terseLabel_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ibrx-20231231.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_ImmunoOncologyClinicIncMember_7886d506-814e-4080-aa57-63ae6c68947d_terseLabel_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Immuno-Oncology Clinic, Inc.</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicIncMember_label_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immuno Oncology Clinic Inc [Member]</link:label>
    <link:label id="lab_ibrx_ImmunoOncologyClinicIncMember_documentation_en-US" xlink:label="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Immuno Oncology Clinic Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember" xlink:href="ibrx-20231231.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_ImmunoOncologyClinicIncMember" xlink:to="lab_ibrx_ImmunoOncologyClinicIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_6818eb9e-be95-4cae-827a-faa8c5d6834e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payment to acquire assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities_25a353c2-3382-46a5-8857-0ec5fedaf882_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for support of research activities</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Payment For Support Of Research Activities</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Payment For Support Of Research Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities" xlink:to="lab_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a2bb5132-1f53-4823-90f9-957252b16653_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AmyrisIncMember_c252c17f-4866-443f-bdd7-c9731367b5bf_terseLabel_en-US" xlink:label="lab_ibrx_AmyrisIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amyris, Inc.</link:label>
    <link:label id="lab_ibrx_AmyrisIncMember_label_en-US" xlink:label="lab_ibrx_AmyrisIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amyris, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_AmyrisIncMember_documentation_en-US" xlink:label="lab_ibrx_AmyrisIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amyris, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisIncMember" xlink:href="ibrx-20231231.xsd#ibrx_AmyrisIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AmyrisIncMember" xlink:to="lab_ibrx_AmyrisIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_075fffe0-2f1d-409e-aad6-24ebc96b2733_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ac29b3bd-5caa-4fc0-b2b0-5ad67c343cdf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Statements of Stockholders&#8217; Deficit [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a740f078-d26f-4f6b-8f8d-84c6207baabe_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3faa9310-272d-4513-ad14-7ec57f82098a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b0ae35a3-31e4-4956-a91b-6a2df958cb03_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_87cb75ed-8243-4b8e-a07d-16a15fff9309_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46f0efd4-25ac-4a89-9cde-db81362a64f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_05a0897c-7404-4d60-a8ce-029c9b42f4a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f953568c-fe43-4867-9826-302b26a97a76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_2c64deaf-bc5a-404c-8cff-afacec31c1c8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PrepaidExpenseWriteDown_ccc361d3-4f46-4ad2-9001-80643b918085_terseLabel_en-US" xlink:label="lab_ibrx_PrepaidExpenseWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partial write down of prepaid expense</link:label>
    <link:label id="lab_ibrx_PrepaidExpenseWriteDown_label_en-US" xlink:label="lab_ibrx_PrepaidExpenseWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Write Down</link:label>
    <link:label id="lab_ibrx_PrepaidExpenseWriteDown_documentation_en-US" xlink:label="lab_ibrx_PrepaidExpenseWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidExpenseWriteDown" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidExpenseWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PrepaidExpenseWriteDown" xlink:to="lab_ibrx_PrepaidExpenseWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesEmbeddedDerivatives_ad412f06-ea81-4999-9196-050c51f41f2e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesEmbeddedDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesEmbeddedDerivatives_label_en-US" xlink:label="lab_us-gaap_DerivativesEmbeddedDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Embedded Derivatives [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesEmbeddedDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesEmbeddedDerivatives" xlink:to="lab_us-gaap_DerivativesEmbeddedDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e46cd27b-a67a-4018-a9f1-28d01608f4c9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancialStatementDetailsAbstract_0a683a95-b947-410f-9276-de06442d5025_terseLabel_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Abstract]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsAbstract_label_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Abstract]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsAbstract_documentation_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial statement details.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract" xlink:to="lab_ibrx_FinancialStatementDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_e7d04477-a3ef-4f39-93a5-1d5162d63202_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_66d376a2-6dbc-484b-a810-def43f267ea8_verboseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a1e45452-efb0-4974-a55e-4583580723f5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantBioInc.Member_0b6cf70c-69ff-41c3-a654-f66c3185a60d_terseLabel_en-US" xlink:label="lab_ibrx_NantBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantBio</link:label>
    <link:label id="lab_ibrx_NantBioInc.Member_label_en-US" xlink:label="lab_ibrx_NantBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantBio, Inc. [Member]</link:label>
    <link:label id="lab_ibrx_NantBioInc.Member_documentation_en-US" xlink:label="lab_ibrx_NantBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantBio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioInc.Member" xlink:href="ibrx-20231231.xsd#ibrx_NantBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantBioInc.Member" xlink:to="lab_ibrx_NantBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9a7ac5f6-02d0-44d0-bcd4-3fca83999e27_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial term of lease arrangement</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_f326ec57-3c17-414a-960b-4f8f8742e007_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8bce3f3a-4df2-4411-ba62-262fa32b8f00_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e0851d7c-b3e6-4dc8-ade4-cb1796f55ca6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity and Related Information under Equity Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_db1150fc-7327-422b-83f4-d1db78e2bb26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_WarrantsMember_47f2fb8a-6aaf-4914-9dd5-39e72e6f8794_terseLabel_en-US" xlink:label="lab_ibrx_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ibrx_WarrantsMember_label_en-US" xlink:label="lab_ibrx_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Member]</link:label>
    <link:label id="lab_ibrx_WarrantsMember_documentation_en-US" xlink:label="lab_ibrx_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsMember" xlink:href="ibrx-20231231.xsd#ibrx_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_WarrantsMember" xlink:to="lab_ibrx_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_a93fea53-72ea-4db6-90f0-6e71917fe0e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in joint venture &#8211; an equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LicensingAgreementTable_7a823e49-1144-4c0f-b6e1-b4a26ed0c2fc_terseLabel_en-US" xlink:label="lab_ibrx_LicensingAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement [Table]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementTable_label_en-US" xlink:label="lab_ibrx_LicensingAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreement [Table]</link:label>
    <link:label id="lab_ibrx_LicensingAgreementTable_documentation_en-US" xlink:label="lab_ibrx_LicensingAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementTable" xlink:href="ibrx-20231231.xsd#ibrx_LicensingAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LicensingAgreementTable" xlink:to="lab_ibrx_LicensingAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A300MillionDecember2021PromissoryNoteMember_0a6ef703-7699-4bed-9b43-a7afce6719b6_terseLabel_en-US" xlink:label="lab_ibrx_A300MillionDecember2021PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$300 Million December 2021 Promissory Note</link:label>
    <link:label id="lab_ibrx_A300MillionDecember2021PromissoryNoteMember_label_en-US" xlink:label="lab_ibrx_A300MillionDecember2021PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$300 Million December 2021 Promissory Note [Member]</link:label>
    <link:label id="lab_ibrx_A300MillionDecember2021PromissoryNoteMember_documentation_en-US" xlink:label="lab_ibrx_A300MillionDecember2021PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$300 Million December 2021 Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A300MillionDecember2021PromissoryNoteMember" xlink:href="ibrx-20231231.xsd#ibrx_A300MillionDecember2021PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A300MillionDecember2021PromissoryNoteMember" xlink:to="lab_ibrx_A300MillionDecember2021PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExercisePriceMember_f9b7709a-aa54-4cf6-b4fd-b0310efaf649_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price per share</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExercisePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_65953c1c-a1dd-4e23-9580-b41159f2deca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A30MillionJune2023PromissoryNoteMember_396eeabe-62f3-4cd4-8c1a-2062ecbf2d22_terseLabel_en-US" xlink:label="lab_ibrx_A30MillionJune2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$30 Million June 2023 Promissory Note</link:label>
    <link:label id="lab_ibrx_A30MillionJune2023PromissoryNoteMember_label_en-US" xlink:label="lab_ibrx_A30MillionJune2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$30 Million June 2023 Promissory Note [Member]</link:label>
    <link:label id="lab_ibrx_A30MillionJune2023PromissoryNoteMember_documentation_en-US" xlink:label="lab_ibrx_A30MillionJune2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$30 Million June 2023 Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionJune2023PromissoryNoteMember" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionJune2023PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A30MillionJune2023PromissoryNoteMember" xlink:to="lab_ibrx_A30MillionJune2023PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_b8f6e8c3-eee3-4246-8452-28dcd5ee7538_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance claims receivable</link:label>
    <link:label id="lab_us-gaap_InsuranceSettlementsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Settlements Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="lab_us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_266adb8f-efe8-4e18-ab1f-703df6cae1c4_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_347dc5bc-3237-4673-bcf8-3ec34966c160_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_112625a6-312d-4cb5-98cc-4c3628b783ab_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4eb12d08-da55-4c57-ab20-c6d8751759d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_4791a8f1-0301-4705-b208-48ddf4cb5e70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_6b598a13-6af4-411a-bf98-388264816cfe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9f9c4a6d-98c8-4e70-86ed-2c5279ce53bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expenses Related to Statement of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_22490e14-4da2-4901-a178-e4b4deb54ffc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums, net of discounts, on marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_94ee1a90-6652-4026-ad2f-7aa60532309d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8f7e30c3-15f2-4e39-90a4-3f0efa8bd15d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6e62a557-050a-44e2-87aa-df4c4f4029e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0841e4ba-27c7-4b69-8d40-c58ddf51a437_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_a83cce13-2434-4d41-a6f1-7bf4e3a282fb_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_c427fc60-a668-4818-84fe-b3c0c6e76fcc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_19469876-29c9-456e-a0c6-5bb79568035d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f73012ef-bbea-49e3-8099-cd92334f78e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, net (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_728abbcd-2a19-4b1c-a814-f14c524c96a1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_8a875cbc-81c8-4213-86f3-67e98ae9d9f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction costs</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_448d7a94-f4c8-44c9-8646-9a94d3b40672_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees_e98dc7db-758d-4083-9c7b-caf9227e76dc_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, License Maintenance Fees</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:to="lab_ibrx_CollaborationAgreementsLicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinancialStatementDetailsLineItems_fe6a892e-7895-42f8-a111-6889b1c2e572_terseLabel_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Line Items]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsLineItems_label_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Line Items]</link:label>
    <link:label id="lab_ibrx_FinancialStatementDetailsLineItems_documentation_en-US" xlink:label="lab_ibrx_FinancialStatementDetailsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Statement Details [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems" xlink:to="lab_ibrx_FinancialStatementDetailsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LaboratoryEquipmentMember_ed71c174-a2c4-4d4c-acb7-275ffb2acd0e_terseLabel_en-US" xlink:label="lab_ibrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_ibrx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_ibrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_ibrx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_ibrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LaboratoryEquipmentMember" xlink:href="ibrx-20231231.xsd#ibrx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LaboratoryEquipmentMember" xlink:to="lab_ibrx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_cfc170ea-c41c-4f18-bac4-9f6519f1bd89_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other than temporary impairment losses</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments" xlink:to="lab_us-gaap_ImpairmentOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_546d3d24-8612-4dc4-a2a7-11a8b6fcb06b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance_788a583d-f6a5-4715-bb2b-be3dcb7ec68e_terseLabel_en-US" xlink:label="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available for future stock issuance</link:label>
    <link:label id="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance_label_en-US" xlink:label="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Value Available For Future Stock Issuance</link:label>
    <link:label id="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance_documentation_en-US" xlink:label="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock value available for future stock issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:to="lab_ibrx_CommonStockValueAvailableForFutureStockIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8f74ca4d-dabb-40a1-b484-46784f268966_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_5b5875d2-49cc-4a58-a3e7-2c4f86e4f739_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_68bdb6fb-0091-4409-8a23-e6a3e00e3cbe_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment, 2025</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_f9348724-cfb3-442c-ad91-03b30d58e249_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued_d7a7720a-eafd-4653-9a61-105c8537ecd1_terseLabel_en-US" xlink:label="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for litigation settlement (in shares)</link:label>
    <link:label id="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued_label_en-US" xlink:label="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Number Of Shares To Be Issued</link:label>
    <link:label id="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued_documentation_en-US" xlink:label="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Number Of Shares To Be Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:href="ibrx-20231231.xsd#ibrx_LitigationSettlementNumberOfSharesToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:to="lab_ibrx_LitigationSettlementNumberOfSharesToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_29aa70dc-d5f4-4b11-a7f3-1736b7de53d1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment, 2026</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d598f3b9-69f0-435d-972d-fb18c1d5d923_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance and retention benefits</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearThree_f5e65547-5f79-4d32-b4f9-99515769e34e_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearThree_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Three</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityToBePaidYearThree_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, To Be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityToBePaidYearThree" xlink:to="lab_ibrx_LeaseLiabilityToBePaidYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0f572aea-6449-40e4-a2e8-56660b1a4107_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c62a4175-8a75-44b6-9f76-e2d47693c5f4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_a0f2cce4-0365-4d46-aa17-cde53e5bc2e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3d535f4d-8b15-49ed-8f18-a3992e0e571c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a79bc3e5-865e-46e7-8966-2505bf2690e9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1270caa6-3247-4d4d-935e-4c18e6840076_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NameChangeEventTable_75f23e47-33b5-43da-9cd5-4432b01d42cb_terseLabel_en-US" xlink:label="lab_dei_NameChangeEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name Change Event [Table]</link:label>
    <link:label id="lab_dei_NameChangeEventTable_label_en-US" xlink:label="lab_dei_NameChangeEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name Change Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NameChangeEventTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NameChangeEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NameChangeEventTable" xlink:to="lab_dei_NameChangeEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_5056ed28-7b12-4fda-bc80-0190e696d1ef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of assets to an entity under common control</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_df174bbf-b3dd-404b-94b9-fef222ffb747_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73980285-fcc9-4938-8cc4-1333f4d6f358_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3efde11c-9e2d-413b-bd11-a1b57b3acc0c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d0379710-3b7c-453c-be74-4baab898365e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_64af2edb-f2f0-496e-bf42-ccd2b1ee5208_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-party promissory notes, net of discounts and deferred issuance costs (Note&#160;10)</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_f92d14b3-fde7-469d-9289-f7f38c4b28ce_terseLabel_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ERP system implementation costs</link:label>
    <link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:to="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_211aee65-8426-4b5d-94fc-0266a9e2a525_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_1acf1153-0409-4389-8a90-cdebd00e0e53_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InitialPaymentMember_3c0f6950-a2cb-4996-b213-9aa16b1803d0_terseLabel_en-US" xlink:label="lab_ibrx_InitialPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Payment</link:label>
    <link:label id="lab_ibrx_InitialPaymentMember_label_en-US" xlink:label="lab_ibrx_InitialPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Payment [Member]</link:label>
    <link:label id="lab_ibrx_InitialPaymentMember_documentation_en-US" xlink:label="lab_ibrx_InitialPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPaymentMember" xlink:href="ibrx-20231231.xsd#ibrx_InitialPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InitialPaymentMember" xlink:to="lab_ibrx_InitialPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3e726d85-b99a-4b93-9553-dc49347da87c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_80c6b05d-2ee1-44fa-b999-a6b723ef7450_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and investment income (loss), net</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_6f723574-6530-4ddb-a9d0-c7ca013923cf_totalLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Interest and investment income (loss), net</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_58fe5612-840d-4804-9fa1-cd33f8172cb4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsNumberOfLicenseAgreements_a362cf47-3ccb-49c4-82ed-15002018ea52_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of license agreements</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsNumberOfLicenseAgreements_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Number Of License Agreements</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsNumberOfLicenseAgreements_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsNumberOfLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Number Of License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNumberOfLicenseAgreements" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsNumberOfLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsNumberOfLicenseAgreements" xlink:to="lab_ibrx_CollaborationAgreementsNumberOfLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_bd7ccdb6-3070-4dc8-8c03-7b5712d18ade_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Less: Tenant improvement allowance receivable</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, Tenant Improvement Allowance Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:to="lab_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_26c2f2a7-f7a0-45e4-95a3-9bd29ba4cc4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_dfa22b79-7237-4280-be1b-83c3bdecf33a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b2b3889-0fc1-461b-a99c-dd1b91989b57_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07b3e783-d832-4b67-a4b9-f6b7b8ea8e44_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets (including amounts with related parties)</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0333a4eb-e1f0-4b4c-86b1-5efbff4dc00c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_5247f0a6-f23f-46bb-8940-504a705672fa_terseLabel_en-US" xlink:label="lab_ibrx_DebtInstrumentPrepaymentAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment and accrued interest upon specified transaction</link:label>
    <link:label id="lab_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_label_en-US" xlink:label="lab_ibrx_DebtInstrumentPrepaymentAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment And Accrued Interest</link:label>
    <link:label id="lab_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_documentation_en-US" xlink:label="lab_ibrx_DebtInstrumentPrepaymentAndAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment And Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentPrepaymentAndAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest" xlink:to="lab_ibrx_DebtInstrumentPrepaymentAndAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SaleLeasebackTransactionConsiderationTransferred_5a4d090e-f013-443b-8e8c-8ce1d4cc368e_terseLabel_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale-leaseback transaction, consideration transferred</link:label>
    <link:label id="lab_ibrx_SaleLeasebackTransactionConsiderationTransferred_label_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale-leaseback Transaction, Consideration Transferred</link:label>
    <link:label id="lab_ibrx_SaleLeasebackTransactionConsiderationTransferred_documentation_en-US" xlink:label="lab_ibrx_SaleLeasebackTransactionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale-leaseback Transaction, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionConsiderationTransferred" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SaleLeasebackTransactionConsiderationTransferred" xlink:to="lab_ibrx_SaleLeasebackTransactionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock_6e5ac350-7b60-4926-978d-44e1e183f1a0_terseLabel_en-US" xlink:label="lab_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarizes the Revenue Interest Liability Activity</link:label>
    <link:label id="lab_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock_label_en-US" xlink:label="lab_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summarizes the Revenue Interest Liability Activity [Table Text Block]</link:label>
    <link:label id="lab_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock_documentation_en-US" xlink:label="lab_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summarizes the Revenue Interest Liability Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" xlink:href="ibrx-20231231.xsd#ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" xlink:to="lab_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7788df8-dbd8-4fdd-a5c6-86f1a1687bce_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cc5b26c1-a2ac-4a7f-beba-3d56bc577104_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2bbdcc5b-d7f2-466c-976c-56d4d21fed50_verboseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_45a88e0b-e3af-4308-9b0b-337f4cde3530_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f55fc6d7-3afd-4ffb-a0cf-4a177fca1f61_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_81f90e16-acf9-442b-8419-549ef7068557_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_4310713e-b7ca-4d02-a030-39f6a0c6a0c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Anniversary</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bca2ff63-7827-4dbd-ba92-0e57e2ccfb28_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_9f21ce8b-bd4f-43a2-9f49-69c0c674e54d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c38b88a9-dedd-488b-a4e9-ae015673607d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InitialAndExpansionPremisesMember_6e8d9754-f6f2-42f8-87ba-5897729451e1_terseLabel_en-US" xlink:label="lab_ibrx_InitialAndExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial And Expansion Premises</link:label>
    <link:label id="lab_ibrx_InitialAndExpansionPremisesMember_label_en-US" xlink:label="lab_ibrx_InitialAndExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial And Expansion Premises [Member]</link:label>
    <link:label id="lab_ibrx_InitialAndExpansionPremisesMember_documentation_en-US" xlink:label="lab_ibrx_InitialAndExpansionPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial And Expansion Premises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialAndExpansionPremisesMember" xlink:href="ibrx-20231231.xsd#ibrx_InitialAndExpansionPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InitialAndExpansionPremisesMember" xlink:to="lab_ibrx_InitialAndExpansionPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PeriodOneMember_e2f4e787-88dd-4c1b-ae70-de77ba875783_terseLabel_en-US" xlink:label="lab_ibrx_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_ibrx_PeriodOneMember_label_en-US" xlink:label="lab_ibrx_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period One [Member]</link:label>
    <link:label id="lab_ibrx_PeriodOneMember_documentation_en-US" xlink:label="lab_ibrx_PeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOneMember" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PeriodOneMember" xlink:to="lab_ibrx_PeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_2642703e-f4e2-4152-8c46-e015a6da3b5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of related-party promissory notes net of issuance costs paid</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a2bb3449-9661-49b9-90d6-97c8fc5d2e51_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PurchaseAgreementTotalInvestmentAmount_bc8c01af-b5a1-415f-b4d7-593a08170439_terseLabel_en-US" xlink:label="lab_ibrx_PurchaseAgreementTotalInvestmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross purchase price</link:label>
    <link:label id="lab_ibrx_PurchaseAgreementTotalInvestmentAmount_label_en-US" xlink:label="lab_ibrx_PurchaseAgreementTotalInvestmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Total Investment Amount</link:label>
    <link:label id="lab_ibrx_PurchaseAgreementTotalInvestmentAmount_documentation_en-US" xlink:label="lab_ibrx_PurchaseAgreementTotalInvestmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Agreement, Total Investment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementTotalInvestmentAmount" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementTotalInvestmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PurchaseAgreementTotalInvestmentAmount" xlink:to="lab_ibrx_PurchaseAgreementTotalInvestmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_AccountingPoliciesTable_4c4a6196-7747-4393-8be0-8a5ba46bf61a_terseLabel_en-US" xlink:label="lab_ibrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesTable_label_en-US" xlink:label="lab_ibrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_ibrx_AccountingPoliciesTable_documentation_en-US" xlink:label="lab_ibrx_AccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesTable" xlink:href="ibrx-20231231.xsd#ibrx_AccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_AccountingPoliciesTable" xlink:to="lab_ibrx_AccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_040f20fa-dadc-46cf-9997-97e2964b0bf8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8a64e8fc-7235-474a-8250-39b8be87519b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest_61ddf0f9-cec3-48a0-899c-2af83e0431ae_totalLabel_en-US" xlink:label="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest_label_en-US" xlink:label="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, Undiscounted Excess Interest</link:label>
    <link:label id="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest_documentation_en-US" xlink:label="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, Undiscounted Excess Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:to="lab_ibrx_LeaseLiabilityUndiscountedExcessInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A30MillionMarch2023PromissoryNoteMember_9d89f11a-6f17-4bfb-8812-f1cb1aa45881_terseLabel_en-US" xlink:label="lab_ibrx_A30MillionMarch2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$30 Million March 2023 Promissory Note</link:label>
    <link:label id="lab_ibrx_A30MillionMarch2023PromissoryNoteMember_label_en-US" xlink:label="lab_ibrx_A30MillionMarch2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$30 Million March 2023 Promissory Note [Member]</link:label>
    <link:label id="lab_ibrx_A30MillionMarch2023PromissoryNoteMember_documentation_en-US" xlink:label="lab_ibrx_A30MillionMarch2023PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$30 Million March 2023 Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionMarch2023PromissoryNoteMember" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionMarch2023PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A30MillionMarch2023PromissoryNoteMember" xlink:to="lab_ibrx_A30MillionMarch2023PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_999de1f3-ab0b-43b2-b95c-afc818ea2528_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_73a45a99-9a29-4e09-a40a-43f64977b2eb_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of related-party notes discounts</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member_10ab8a19-e23e-43c4-9290-5c33dac4007b_terseLabel_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$505 Million December 2023 Promissory Note - Tranche 1</link:label>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member_label_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">$505 Million Promissory Note, December 2023, Tranche 1 [Member]</link:label>
    <link:label id="lab_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member_documentation_en-US" xlink:label="lab_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">$505 Million Promissory Note, December 2023, Tranche 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member" xlink:to="lab_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_RelatedPartyNotesMember_0cd80547-0b3e-4bf7-a43f-3e6609f4f710_terseLabel_en-US" xlink:label="lab_ibrx_RelatedPartyNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Notes</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesMember_label_en-US" xlink:label="lab_ibrx_RelatedPartyNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Notes [Member]</link:label>
    <link:label id="lab_ibrx_RelatedPartyNotesMember_documentation_en-US" xlink:label="lab_ibrx_RelatedPartyNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesMember" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_RelatedPartyNotesMember" xlink:to="lab_ibrx_RelatedPartyNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6e09a226-6490-4ecd-8323-9ab529051a52_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d2db3ab6-c9ed-48a7-bed1-771bd0107437_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_066a5cde-ebd0-4222-842c-12f33da52a68_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_d532a18d-c187-44b1-94ca-87876ca871a7_terseLabel_en-US" xlink:label="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease costs (including right-of-use asset amortization and interest expense)</link:label>
    <link:label id="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_label_en-US" xlink:label="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense</link:label>
    <link:label id="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_documentation_en-US" xlink:label="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:href="ibrx-20231231.xsd#ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:to="lab_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_24dc8853-5983-4452-9d2e-ea5e25bf0017_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses_68da6e46-e16d-44aa-91a1-0df7df49471f_terseLabel_en-US" xlink:label="lab_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid offering and transaction costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unpaid Offering and Transaction Costs Included in Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unpaid Offering and Transaction Costs Included in Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="ibrx-20231231.xsd#ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6d835bc2-7a21-4c58-9b32-03405ad9cf97_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SecuredOvernightFinancingRateSOFRMember_a406d545-7246-4cae-8fa6-fec84ecb0d59_terseLabel_en-US" xlink:label="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_ibrx_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_ibrx_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:href="ibrx-20231231.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_ibrx_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ec1d9db5-708f-486b-823d-6d26904204a6_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c2d745f8-0b51-4e59-b18a-815aea3d45c8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b76e615f-5fb0-4c73-96a1-322b8fe430d6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_2702eebe-4364-4eae-b051-847d94ecc488_terseLabel_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment to hire, number of employees, first two and a half years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_label_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Commitment To Hire, Number Of Employees, First Two And A Half Years</link:label>
    <link:label id="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_documentation_en-US" xlink:label="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Interest, Commitment To Hire, Number Of Employees, First Two And A Half Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:to="lab_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_2f08a032-2507-4c61-b5fb-d2093c1145cf_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_20023540-5ce0-49e3-8018-a84ba6423d43_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_ed4dc2cb-b782-409a-8573-8a2d005567a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1d49a196-4b6c-4959-abde-b1f8ede244e8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_02e5be5d-6d06-4790-83eb-fb1a73c484c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate, Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_2813d611-cafd-4409-93c6-66ee54ec8a19_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_fc91bf8c-6ed6-4dfb-8180-45f3203540e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_607d3957-22d7-49f8-9053-7b36080c1f10_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_5d17262e-f909-4602-b1ce-6cf5e26b5896_terseLabel_en-US" xlink:label="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expansion of leased premises (in square feet)</link:label>
    <link:label id="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_label_en-US" xlink:label="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to Number Of Square Foot Of Facility Leased</link:label>
    <link:label id="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_documentation_en-US" xlink:label="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase to Number Of Square Foot Of Facility Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:href="ibrx-20231231.xsd#ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:to="lab_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_c5fcc87c-ae72-4076-84ea-3cd11cb29939_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_InsurancePremiumFinancingAsset_d5cd43bf-1be4-4921-9d93-85ef03c09c5a_terseLabel_en-US" xlink:label="lab_ibrx_InsurancePremiumFinancingAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance premium financing asset</link:label>
    <link:label id="lab_ibrx_InsurancePremiumFinancingAsset_label_en-US" xlink:label="lab_ibrx_InsurancePremiumFinancingAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Premium Financing Asset</link:label>
    <link:label id="lab_ibrx_InsurancePremiumFinancingAsset_documentation_en-US" xlink:label="lab_ibrx_InsurancePremiumFinancingAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance premium financing asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InsurancePremiumFinancingAsset" xlink:href="ibrx-20231231.xsd#ibrx_InsurancePremiumFinancingAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_InsurancePremiumFinancingAsset" xlink:to="lab_ibrx_InsurancePremiumFinancingAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1c706c95-0524-4f5b-93ec-bd77970ab871_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term, Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_83839430-ecd2-4b06-a4b5-82c60d95e115_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5d80f9df-0448-431b-9fc5-910e6c75b741_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_264d17b1-33e6-4c69-8bd6-ca1930bd104c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0bb5670a-1533-4d93-b800-0c595f96f792_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ed4c8481-6443-4e26-bbdc-74750b15ed99_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_A3MIPCAndAAHIAgreementMember_f81b5da7-33c0-4f21-b60b-be85f9c6c370_terseLabel_en-US" xlink:label="lab_ibrx_A3MIPCAndAAHIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3M IPC and Access to Advanced Health Institute License Agreement</link:label>
    <link:label id="lab_ibrx_A3MIPCAndAAHIAgreementMember_label_en-US" xlink:label="lab_ibrx_A3MIPCAndAAHIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3M IPC and AAHI Agreement [Member]</link:label>
    <link:label id="lab_ibrx_A3MIPCAndAAHIAgreementMember_documentation_en-US" xlink:label="lab_ibrx_A3MIPCAndAAHIAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3M IPC and AAHI Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A3MIPCAndAAHIAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_A3MIPCAndAAHIAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_A3MIPCAndAAHIAgreementMember" xlink:to="lab_ibrx_A3MIPCAndAAHIAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_SecondPaymentMember_212df3cb-5058-459e-9265-3af7d2dae24f_terseLabel_en-US" xlink:label="lab_ibrx_SecondPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Payment</link:label>
    <link:label id="lab_ibrx_SecondPaymentMember_label_en-US" xlink:label="lab_ibrx_SecondPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Payment [Member]</link:label>
    <link:label id="lab_ibrx_SecondPaymentMember_documentation_en-US" xlink:label="lab_ibrx_SecondPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecondPaymentMember" xlink:href="ibrx-20231231.xsd#ibrx_SecondPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_SecondPaymentMember" xlink:to="lab_ibrx_SecondPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2921d78c-8e20-4a23-93ec-66bfcfb85961_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_82872018-f880-45b8-b30e-623732e788da_negatedTerseLabel_en-US" xlink:label="lab_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_label_en-US" xlink:label="lab_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Accumulated Impairment</link:label>
    <link:label id="lab_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_documentation_en-US" xlink:label="lab_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Accumulated Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:to="lab_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4e92e237-ee69-4fd7-be6f-343e9ef71df7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_PeriodOfExtendedLeaseTerm_96e380b6-1a9b-41d2-a20f-d51dc65c1346_terseLabel_en-US" xlink:label="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Optional extended lease term</link:label>
    <link:label id="lab_ibrx_PeriodOfExtendedLeaseTerm_label_en-US" xlink:label="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Extended Lease Term</link:label>
    <link:label id="lab_ibrx_PeriodOfExtendedLeaseTerm_documentation_en-US" xlink:label="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of extended lease term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfExtendedLeaseTerm" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOfExtendedLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_PeriodOfExtendedLeaseTerm" xlink:to="lab_ibrx_PeriodOfExtendedLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c0db017f-25e0-4ccb-a0d5-7fd80ddf3703_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_0fb360ff-4911-4a54-89b7-36f53457b032_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dc0494d1-9091-4683-bfad-84093491d411_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAmount_4b91fabd-d35e-48f5-802b-0aedd8efb4eb_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment, amount</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAmount_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Milestone Payment, Amount</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAmount_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Milestone Payment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount" xlink:to="lab_ibrx_CollaborationAgreementsMilestonePaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_1c41bcd7-0940-4f3c-9eb5-2e9c963744a6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_b8936d10-5c62-4cbe-aff1-801874136bcc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_a03a7ae1-236a-4e89-ac4f-e0689165e673_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d6d2eb92-d984-4496-af93-6094504033ed_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Life, Vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5ffc503c-3e4f-42e1-a8ac-ed69c8270ef3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_29094973-6a93-4ab3-ae1a-8d21cc758696_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d8f7ccbd-b58e-4d28-b16b-c89a3baf7756_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_DrSoonShiongAndRelatedPartyMember_70da7446-fb13-4658-a445-8a97b5220c71_terseLabel_en-US" xlink:label="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dr Soon Shiong And Related Party</link:label>
    <link:label id="lab_ibrx_DrSoonShiongAndRelatedPartyMember_label_en-US" xlink:label="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr Soon Shiong And Related Party [Member]</link:label>
    <link:label id="lab_ibrx_DrSoonShiongAndRelatedPartyMember_documentation_en-US" xlink:label="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dr. Soon-Shiong and related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:href="ibrx-20231231.xsd#ibrx_DrSoonShiongAndRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:to="lab_ibrx_DrSoonShiongAndRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_9eb0c576-bc99-47d2-8b11-6daa08c478ee_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_775b54ff-e4ef-485d-a237-0d629bb51b95_terseLabel_en-US" xlink:label="lab_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment with related-parties under common control (Note 10)</link:label>
    <link:label id="lab_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_label_en-US" xlink:label="lab_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain On Debt Extinguishment, Entities Under Common Control</link:label>
    <link:label id="lab_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_documentation_en-US" xlink:label="lab_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain On Debt Extinguishment, Entities Under Common Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl" xlink:href="ibrx-20231231.xsd#ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl" xlink:to="lab_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_6b5b3ff2-e387-4528-86be-e4b6c6298d4e_terseLabel_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment, aggregate maximum</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_label_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Milestone Payment, Aggregate Maximum</link:label>
    <link:label id="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_documentation_en-US" xlink:label="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Milestone Payment, Aggregate Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:to="lab_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03395e52-ee46-4191-ae77-213215fce945_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_4b10fa3f-00b3-401f-8c58-ba815f730db1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in marketable equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a4ba8055-cb2e-42dd-956b-a0b14e2254dc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_41d789e2-6462-4fd2-9b85-b15d4d65732d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2c6185d6-374b-44dd-9a86-d214246937a7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f193ab12-6099-4ee5-a20d-c24e1c83e3fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantWorksMember_0331d50d-9556-4ece-ab94-7c9361592f40_terseLabel_en-US" xlink:label="lab_ibrx_NantWorksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NantWorks</link:label>
    <link:label id="lab_ibrx_NantWorksMember_label_en-US" xlink:label="lab_ibrx_NantWorksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NantWorks [Member]</link:label>
    <link:label id="lab_ibrx_NantWorksMember_documentation_en-US" xlink:label="lab_ibrx_NantWorksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NantWorks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantWorksMember" xlink:to="lab_ibrx_NantWorksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_LicenseAgreementMember_e661a7ca-7675-4c7a-9938-64e2e237e2a0_terseLabel_en-US" xlink:label="lab_ibrx_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_ibrx_LicenseAgreementMember_label_en-US" xlink:label="lab_ibrx_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_ibrx_LicenseAgreementMember_documentation_en-US" xlink:label="lab_ibrx_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicenseAgreementMember" xlink:href="ibrx-20231231.xsd#ibrx_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_LicenseAgreementMember" xlink:to="lab_ibrx_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6bbf1637-b5f2-43ff-a774-a2394ac11983_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_575f6c61-789e-4755-b553-96b39084d2cf_terseLabel_en-US" xlink:label="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 CRADA</link:label>
    <link:label id="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_label_en-US" xlink:label="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cooperative Research And Development Agreement, 2015 [Member]</link:label>
    <link:label id="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_documentation_en-US" xlink:label="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cooperative research and development agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member" xlink:href="ibrx-20231231.xsd#ibrx_CooperativeResearchAndDevelopmentAgreement2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member" xlink:to="lab_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_JulyTwentyNineteenLeaseMember_be322463-1d30-424f-8f8b-d5b2fa78699d_terseLabel_en-US" xlink:label="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 2019 Lease</link:label>
    <link:label id="lab_ibrx_JulyTwentyNineteenLeaseMember_label_en-US" xlink:label="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July Twenty Nineteen Lease [Member]</link:label>
    <link:label id="lab_ibrx_JulyTwentyNineteenLeaseMember_documentation_en-US" xlink:label="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July twenty nineteen lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_JulyTwentyNineteenLeaseMember" xlink:href="ibrx-20231231.xsd#ibrx_JulyTwentyNineteenLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_JulyTwentyNineteenLeaseMember" xlink:to="lab_ibrx_JulyTwentyNineteenLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_94f0d861-1ca6-4f40-9ba1-1012b6727720_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_820b994a-72cb-46d4-8cb4-933b76240646_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_eeed2ad6-ad17-4726-8b98-47eacae023ef_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_96ee90d8-4e64-49e2-ad60-89919a24be21_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in exchange for notes payable (Note&#160;10)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NantCapitalOneMember_27665e33-aea7-49a6-974f-9fe36d2506ed_terseLabel_en-US" xlink:label="lab_ibrx_NantCapitalOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nant Capital 2020 Note Payable</link:label>
    <link:label id="lab_ibrx_NantCapitalOneMember_label_en-US" xlink:label="lab_ibrx_NantCapitalOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nant Capital One [Member]</link:label>
    <link:label id="lab_ibrx_NantCapitalOneMember_documentation_en-US" xlink:label="lab_ibrx_NantCapitalOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nant capital one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalOneMember" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NantCapitalOneMember" xlink:to="lab_ibrx_NantCapitalOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a8f9790c-3805-43de-b633-86dfe8f3a93b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement_9072654c-c41c-4caa-b942-aa8f6b811dca_terseLabel_en-US" xlink:label="lab_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in ownership interest in a joint venture due to legal settlement (Note 7)</link:label>
    <link:label id="lab_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement_label_en-US" xlink:label="lab_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) From Legal Settlement</link:label>
    <link:label id="lab_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement_documentation_en-US" xlink:label="lab_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) From Legal Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" xlink:href="ibrx-20231231.xsd#ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" xlink:to="lab_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_8589c776-ba33-4da4-aa6b-ab26d7b0296a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>ibrx-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1fd74a66-0ec9-47b3-a3a2-77069a10a521,g:7ebe44e2-bf98-46f1-8b70-fddc2baf2bbb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.immunitybio.com/role/CoverPage" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1c9c05ff-ee0d-4849-980f-858476d66b0e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentType_1c9c05ff-ee0d-4849-980f-858476d66b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_05de77e8-06cc-41d2-9119-4172a1a77300" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentAnnualReport_05de77e8-06cc-41d2-9119-4172a1a77300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6fa8116e-f80e-4d52-bd8b-b1c7c0b604a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentPeriodEndDate_6fa8116e-f80e-4d52-bd8b-b1c7c0b604a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_242a4b49-6aea-485b-89ba-d38f20629d4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_CurrentFiscalYearEndDate_242a4b49-6aea-485b-89ba-d38f20629d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b660b9cc-86cf-49b8-a49f-e65c81794b66" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentTransitionReport_b660b9cc-86cf-49b8-a49f-e65c81794b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_42daa7ee-65d4-458c-a370-3cfb176c3c22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityFileNumber_42daa7ee-65d4-458c-a370-3cfb176c3c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_731bf129-de3b-4747-b7fe-10caa78a5121" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityRegistrantName_731bf129-de3b-4747-b7fe-10caa78a5121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7f803cbf-84be-4f7b-8a45-9f0521d7f405" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7f803cbf-84be-4f7b-8a45-9f0521d7f405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_61ed72cc-d0aa-4cac-aae1-80049111eda8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityTaxIdentificationNumber_61ed72cc-d0aa-4cac-aae1-80049111eda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7aee8104-7b85-45b7-a0a9-c91f625a9b08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityAddressAddressLine1_7aee8104-7b85-45b7-a0a9-c91f625a9b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_34af879d-33b1-4171-98f5-cdd164e671c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityAddressCityOrTown_34af879d-33b1-4171-98f5-cdd164e671c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b66338ca-feab-476b-89ed-bc47eff827ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityAddressStateOrProvince_b66338ca-feab-476b-89ed-bc47eff827ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_26056cff-9350-41a4-9f43-ea29b7a273e1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityAddressPostalZipCode_26056cff-9350-41a4-9f43-ea29b7a273e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bfd665f9-da74-4daa-8a8d-b89969e281a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_CityAreaCode_bfd665f9-da74-4daa-8a8d-b89969e281a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_05a78e9f-30a5-4ef4-a284-029472b00e8b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_LocalPhoneNumber_05a78e9f-30a5-4ef4-a284-029472b00e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_82503921-cf41-41a8-8b61-24a7fc3c5252" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_Security12bTitle_82503921-cf41-41a8-8b61-24a7fc3c5252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_835b55ea-b739-45a4-8ddb-721de4a6090a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_TradingSymbol_835b55ea-b739-45a4-8ddb-721de4a6090a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_98152044-94c2-4867-b13b-bacb418b9ae9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_SecurityExchangeName_98152044-94c2-4867-b13b-bacb418b9ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8319ef3a-9a89-4a97-b10e-7352f751d272" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8319ef3a-9a89-4a97-b10e-7352f751d272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_157cc7e0-a216-4464-a871-fbb91b481e85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityVoluntaryFilers_157cc7e0-a216-4464-a871-fbb91b481e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9d5e4751-ef4a-449a-9693-7cfb47eec87e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityCurrentReportingStatus_9d5e4751-ef4a-449a-9693-7cfb47eec87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e575a953-50e2-406f-9314-3ddf2981701d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityInteractiveDataCurrent_e575a953-50e2-406f-9314-3ddf2981701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_92e3ba87-9201-4498-a2dc-e5c5ca4c4219" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityFilerCategory_92e3ba87-9201-4498-a2dc-e5c5ca4c4219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3a79d947-f6c6-41cd-95fe-19bc4ef918a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntitySmallBusiness_3a79d947-f6c6-41cd-95fe-19bc4ef918a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_663e6f32-516b-4dd2-98d7-903bf7b90caa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityEmergingGrowthCompany_663e6f32-516b-4dd2-98d7-903bf7b90caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_efb12871-aa9c-4d4a-87ce-e5037ffd45fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_efb12871-aa9c-4d4a-87ce-e5037ffd45fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_43f629fd-c023-4e5e-8840-d6654c4ef6ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_43f629fd-c023-4e5e-8840-d6654c4ef6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_be2b8beb-2ec9-4c1c-8b89-91d1f4ba6b5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityShellCompany_be2b8beb-2ec9-4c1c-8b89-91d1f4ba6b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f3634a32-d350-4965-b38e-14e983a891d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityPublicFloat_f3634a32-d350-4965-b38e-14e983a891d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ad5ca2b8-e232-4215-9661-f34087973787" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ad5ca2b8-e232-4215-9661-f34087973787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_de19588c-c1d1-4666-867b-d929c4ddda55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_de19588c-c1d1-4666-867b-d929c4ddda55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_edf667c4-ce4e-492a-afcd-dcaa3fbc3f21" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_AmendmentFlag_edf667c4-ce4e-492a-afcd-dcaa3fbc3f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b2a143e6-7ade-40e4-96ec-5fd63d37c066" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentFiscalYearFocus_b2a143e6-7ade-40e4-96ec-5fd63d37c066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7184542e-e83e-44d3-ba71-058588c50fc7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7184542e-e83e-44d3-ba71-058588c50fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f7c9f9bc-58e6-4149-81ba-4bd77c6719bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6d36613e-e75a-48fe-877c-2d92a14f35e6" xlink:to="loc_dei_EntityCentralIndexKey_f7c9f9bc-58e6-4149-81ba-4bd77c6719bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/AuditInformation" xlink:type="simple" xlink:href="ibrx-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AuditInformationAbstract_5cc7bf90-7139-4ec0-8e65-8c2150f9295a" xlink:href="ibrx-20231231.xsd#ibrx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1995d59c-5890-46d2-8c8f-a2246102a055" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AuditInformationAbstract_5cc7bf90-7139-4ec0-8e65-8c2150f9295a" xlink:to="loc_dei_AuditorFirmId_1995d59c-5890-46d2-8c8f-a2246102a055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_3c48d2fa-8c6d-44d0-805d-03aba23d8229" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AuditInformationAbstract_5cc7bf90-7139-4ec0-8e65-8c2150f9295a" xlink:to="loc_dei_AuditorName_3c48d2fa-8c6d-44d0-805d-03aba23d8229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_ecb296bd-6176-45d7-a3b7-8de90cc6fcb3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AuditInformationAbstract_5cc7bf90-7139-4ec0-8e65-8c2150f9295a" xlink:to="loc_dei_AuditorLocation_ecb296bd-6176-45d7-a3b7-8de90cc6fcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_50f2bf7b-892e-4f27-9013-0bd7a57d21bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9771a41d-9391-47a8-bd8c-631582c17caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50f2bf7b-892e-4f27-9013-0bd7a57d21bf" xlink:to="loc_us-gaap_StatementTable_9771a41d-9391-47a8-bd8c-631582c17caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d499a27e-2a27-4f9e-b1f0-b35970849c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9771a41d-9391-47a8-bd8c-631582c17caf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d499a27e-2a27-4f9e-b1f0-b35970849c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d499a27e-2a27-4f9e-b1f0-b35970849c9a" xlink:to="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_c372f993-bb4a-44d3-abe8-79d904686fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:to="loc_us-gaap_NonrelatedPartyMember_c372f993-bb4a-44d3-abe8-79d904686fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5e93416d-1715-49ee-9f49-330e4ecd6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0bb20b74-04dc-40de-a631-2fb6ebddfa4e" xlink:to="loc_us-gaap_RelatedPartyMember_5e93416d-1715-49ee-9f49-330e4ecd6fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9771a41d-9391-47a8-bd8c-631582c17caf" xlink:to="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:to="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e2e88ab-e565-4838-ba87-601edb0d90a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e2e88ab-e565-4838-ba87-601edb0d90a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c62e1694-dc8b-4852-a598-95d9e5d08414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c62e1694-dc8b-4852-a598-95d9e5d08414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1341f19d-9c7d-4c79-9201-50d511e4ae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1341f19d-9c7d-4c79-9201-50d511e4ae4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_71b50090-18cb-42b0-a8dd-ede4078b3fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_71b50090-18cb-42b0-a8dd-ede4078b3fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e62f4d69-4f96-4fcb-b6e3-84440c65115a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9571fd33-7fab-40fa-9cc3-4f3f203b1696" xlink:to="loc_us-gaap_AssetsCurrent_e62f4d69-4f96-4fcb-b6e3-84440c65115a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f39c4fcd-a924-4f44-abd7-9fb204640eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f39c4fcd-a924-4f44-abd7-9fb204640eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2c8fcb8a-4ed7-4864-9789-05c61ca27f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2c8fcb8a-4ed7-4864-9789-05c61ca27f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52f2ef1e-f322-41de-817c-1de876020f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52f2ef1e-f322-41de-817c-1de876020f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_3eff4f33-12e5-4f4c-8043-d1a48454b582" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_3eff4f33-12e5-4f4c-8043-d1a48454b582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5fbbe7e-a8d5-4de7-abb8-4763f1b40e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e5fbbe7e-a8d5-4de7-abb8-4763f1b40e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_efece56f-6001-496e-bd7b-064607056644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_efece56f-6001-496e-bd7b-064607056644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_273ddc04-3433-4f87-96b9-b387aeb997e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cbbf1b8e-aeb9-4a3a-ab4b-dea338caa504" xlink:to="loc_us-gaap_Assets_273ddc04-3433-4f87-96b9-b387aeb997e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_078b3770-3844-4ab6-9d45-b3cdab56aaa1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2ca9eebe-ca74-4e6b-8d5c-299731e00ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_AccountsPayableCurrent_2ca9eebe-ca74-4e6b-8d5c-299731e00ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3e06d228-541a-4803-a07f-12dd2ae6a062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_3e06d228-541a-4803-a07f-12dd2ae6a062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f7ae9949-a8b7-47b5-b35c-9ed93ca98fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_NotesPayableCurrent_f7ae9949-a8b7-47b5-b35c-9ed93ca98fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4b67ec5-831d-4593-ba42-a0f1e5ad6a75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b4b67ec5-831d-4593-ba42-a0f1e5ad6a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fbc8fd95-f67a-4dc7-84c4-07e162b00f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd5d11a9-cf2c-43c8-8fae-81433b8020ed" xlink:to="loc_us-gaap_LiabilitiesCurrent_fbc8fd95-f67a-4dc7-84c4-07e162b00f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_89101227-b310-474b-956e-45e761498942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_89101227-b310-474b-956e-45e761498942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_19b091c9-7a36-4910-8cae-0a931974baf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_19b091c9-7a36-4910-8cae-0a931974baf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_da305422-8b9a-4a6c-9744-d9d531456aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_SecuredLongTermDebt_da305422-8b9a-4a6c-9744-d9d531456aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_7a835401-73ca-4e77-b490-8f45e88aaeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_7a835401-73ca-4e77-b490-8f45e88aaeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2d435ef6-5ff5-4dfa-a036-7511e1da0240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2d435ef6-5ff5-4dfa-a036-7511e1da0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_56cb08e3-e549-4b13-b2e9-ac9617aaf23c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_56cb08e3-e549-4b13-b2e9-ac9617aaf23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3d36d943-19c2-4250-95f1-6365396a8c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3d36d943-19c2-4250-95f1-6365396a8c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d8c7a5f9-9e09-434d-862b-d945e3a22a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_Liabilities_d8c7a5f9-9e09-434d-862b-d945e3a22a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_66493037-ebb3-441e-a0da-cbf9ca1532ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_66493037-ebb3-441e-a0da-cbf9ca1532ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dfda0393-eefd-4442-845c-95adad771fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_CommonStockValue_dfda0393-eefd-4442-845c-95adad771fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b89c8dd5-a9b9-4210-bf8c-dc76cccf05db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b89c8dd5-a9b9-4210-bf8c-dc76cccf05db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31025eeb-41b8-4b2a-9ae3-f425e7f62bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_31025eeb-41b8-4b2a-9ae3-f425e7f62bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5cc11a8-966b-45d0-972b-de4eeb170a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5cc11a8-966b-45d0-972b-de4eeb170a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c0298c8-f12f-46e0-9b6d-b39d66a7997b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7b0b3187-4fdd-4b00-ae66-ae48e22b03f4" xlink:to="loc_us-gaap_StockholdersEquity_4c0298c8-f12f-46e0-9b6d-b39d66a7997b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1b03c4de-1735-4547-aa13-c77e46870695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_MinorityInterest_1b03c4de-1735-4547-aa13-c77e46870695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_433b4898-f8c1-41c5-82fa-7034b3a27e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_433b4898-f8c1-41c5-82fa-7034b3a27e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_618b4b0c-8967-40ba-857b-37d8deb0010b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d14be134-9b88-4d60-9c90-9bf19a70517f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_618b4b0c-8967-40ba-857b-37d8deb0010b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a86697ec-f43c-42ea-860e-d14833e7f0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e8f1f1f-eb56-452b-b61e-e51fc15f4ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a86697ec-f43c-42ea-860e-d14833e7f0d3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4e8f1f1f-eb56-452b-b61e-e51fc15f4ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e4c98aae-b154-44da-b85f-ca754537b239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a86697ec-f43c-42ea-860e-d14833e7f0d3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e4c98aae-b154-44da-b85f-ca754537b239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_12bf993e-dcbb-477d-87b2-980b898688dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a86697ec-f43c-42ea-860e-d14833e7f0d3" xlink:to="loc_us-gaap_CommonStockSharesIssued_12bf993e-dcbb-477d-87b2-980b898688dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_626c1df9-0b8c-4d6c-8e37-d8f3c51ac8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a86697ec-f43c-42ea-860e-d14833e7f0d3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_626c1df9-0b8c-4d6c-8e37-d8f3c51ac8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_ffa41dca-63d6-4169-ba95-a2a04afc3691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a86697ec-f43c-42ea-860e-d14833e7f0d3" xlink:to="loc_us-gaap_TreasuryStockCommonShares_ffa41dca-63d6-4169-ba95-a2a04afc3691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_11a18bce-6fe8-465e-b77d-442da69de681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_Revenues_11a18bce-6fe8-465e-b77d-442da69de681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d454e25e-d0f2-40ec-8218-90fe7e98f8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d454e25e-d0f2-40ec-8218-90fe7e98f8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c0bc3228-fe88-4d9f-915d-6e1fb0c0e9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d454e25e-d0f2-40ec-8218-90fe7e98f8ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c0bc3228-fe88-4d9f-915d-6e1fb0c0e9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6871a70d-8bb7-4fe5-9f50-04d33d408302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d454e25e-d0f2-40ec-8218-90fe7e98f8ac" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6871a70d-8bb7-4fe5-9f50-04d33d408302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7ed3da07-06b1-4414-9142-028ef9a67de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d454e25e-d0f2-40ec-8218-90fe7e98f8ac" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_7ed3da07-06b1-4414-9142-028ef9a67de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4f7d2ba4-cef0-4a75-a5f0-d71103714b96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d454e25e-d0f2-40ec-8218-90fe7e98f8ac" xlink:to="loc_us-gaap_OperatingExpenses_4f7d2ba4-cef0-4a75-a5f0-d71103714b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8514e6b6-cb15-4428-99a3-10f4ca6472cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_OperatingIncomeLoss_8514e6b6-cb15-4428-99a3-10f4ca6472cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_d02929e0-0f04-4a8d-a652-013a1ff80695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:to="loc_us-gaap_GainLossOnInvestments_d02929e0-0f04-4a8d-a652-013a1ff80695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6cecd161-6b6c-459b-9368-9676d293c186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:to="loc_us-gaap_InterestExpense_6cecd161-6b6c-459b-9368-9676d293c186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8986e5d0-c428-4cce-a66c-7a2051d056ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8986e5d0-c428-4cce-a66c-7a2051d056ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_0f1e731a-811f-4f77-bed9-1709a35147cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_0f1e731a-811f-4f77-bed9-1709a35147cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_58a1cf1d-7542-4c8a-9280-44758834b5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_58a1cf1d-7542-4c8a-9280-44758834b5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e74ce982-f3bf-4844-a8b2-9323ed495f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e74ce982-f3bf-4844-a8b2-9323ed495f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0c707e22-1871-4fe4-b365-3e6ea6b08c28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2785f8d9-a2d0-4c10-968a-1e90a325e9bd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0c707e22-1871-4fe4-b365-3e6ea6b08c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18d87b6a-a970-4170-8180-407f219dbb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18d87b6a-a970-4170-8180-407f219dbb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3889e2de-f47e-4bd4-92a1-61602d955e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3889e2de-f47e-4bd4-92a1-61602d955e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_318e7183-49ee-45f4-844d-6d24d3b58aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_ProfitLoss_318e7183-49ee-45f4-844d-6d24d3b58aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f21407e7-0987-4aa8-ac31-c538e1528980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f21407e7-0987-4aa8-ac31-c538e1528980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18d1a3c4-b5f6-424e-bd8f-84dec9fb7351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_NetIncomeLoss_18d1a3c4-b5f6-424e-bd8f-84dec9fb7351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c3c1f433-1e8a-4c8a-b311-a153ff357876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_EarningsPerShareBasic_c3c1f433-1e8a-4c8a-b311-a153ff357876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4c5f58bd-a608-41c4-8e4b-e913704588c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4c5f58bd-a608-41c4-8e4b-e913704588c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6f74798-0d3e-4c92-a4b7-0b258b114a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6f74798-0d3e-4c92-a4b7-0b258b114a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d9ec7502-45d9-40b3-8a04-fdae4b7c8df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a12abbc4-867c-481f-9e9a-8c144f7aedd8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d9ec7502-45d9-40b3-8a04-fdae4b7c8df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1589b4b1-98f2-4898-936a-747bb7019916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9b440f0d-5aac-41c1-8d31-32813103ab0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1589b4b1-98f2-4898-936a-747bb7019916" xlink:to="loc_us-gaap_ProfitLoss_9b440f0d-5aac-41c1-8d31-32813103ab0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ff661a5a-a1fc-4f4b-80c2-273705db1f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1589b4b1-98f2-4898-936a-747bb7019916" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ff661a5a-a1fc-4f4b-80c2-273705db1f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3594b3d3-9b73-4801-aae3-774227a780e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ff661a5a-a1fc-4f4b-80c2-273705db1f85" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3594b3d3-9b73-4801-aae3-774227a780e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_a31c4a34-a557-4b6b-babe-7a806bba585a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ff661a5a-a1fc-4f4b-80c2-273705db1f85" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_a31c4a34-a557-4b6b-babe-7a806bba585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_33fb9012-1831-4508-8ef8-80438d8672bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ff661a5a-a1fc-4f4b-80c2-273705db1f85" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_33fb9012-1831-4508-8ef8-80438d8672bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d5087d7c-149a-4f56-a898-880348d99e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ff661a5a-a1fc-4f4b-80c2-273705db1f85" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d5087d7c-149a-4f56-a898-880348d99e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8ea2d206-9c7c-4a21-9dcb-4dbf91785b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1589b4b1-98f2-4898-936a-747bb7019916" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8ea2d206-9c7c-4a21-9dcb-4dbf91785b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7572fbce-3c2e-4b56-b5d9-316c422fc370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1589b4b1-98f2-4898-936a-747bb7019916" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7572fbce-3c2e-4b56-b5d9-316c422fc370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_049f5eeb-00d5-4464-92f8-9860d4800aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1589b4b1-98f2-4898-936a-747bb7019916" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_049f5eeb-00d5-4464-92f8-9860d4800aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_63dbe8f4-4e61-42a8-98e7-c01868d0f5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_63dbe8f4-4e61-42a8-98e7-c01868d0f5f4" xlink:to="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5b351892-28b8-4a5b-9f3d-aec2fd7df866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5b351892-28b8-4a5b-9f3d-aec2fd7df866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5b351892-28b8-4a5b-9f3d-aec2fd7df866" xlink:to="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:to="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e51c64ba-d621-443e-9d91-9479011317ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_CommonStockMember_e51c64ba-d621-443e-9d91-9479011317ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41d4e1f1-15f8-40f3-93d5-d00e7e8ab8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41d4e1f1-15f8-40f3-93d5-d00e7e8ab8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_30f8eb66-05e6-4d8b-8c8c-7ad4daf26931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_RetainedEarningsMember_30f8eb66-05e6-4d8b-8c8c-7ad4daf26931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3a4b218-11bc-464f-83e1-1a68676d5ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_5c7fa10a-2e18-4e52-860f-f5401ce011ad" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3a4b218-11bc-464f-83e1-1a68676d5ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_03fcf0e1-cee8-4fb6-921f-d9e416e1caeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d60820a2-51d1-4345-bf9e-0d258fe6e056" xlink:to="loc_us-gaap_NoncontrollingInterestMember_03fcf0e1-cee8-4fb6-921f-d9e416e1caeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b1e3f309-3efc-4040-b3e9-b3da6bec6096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b1e3f309-3efc-4040-b3e9-b3da6bec6096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b1e3f309-3efc-4040-b3e9-b3da6bec6096" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_d7853fee-b979-45dc-889f-218bffea61f8" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_d7853fee-b979-45dc-889f-218bffea61f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_7e532aed-4443-4ada-b8c6-c5b586792dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:to="loc_us-gaap_PrivatePlacementMember_7e532aed-4443-4ada-b8c6-c5b586792dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_f6b7d934-c790-45d9-9d04-38c2bff92bf6" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0095d5c4-4e8d-4f04-b067-107c90b0c8fc" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_f6b7d934-c790-45d9-9d04-38c2bff92bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5f9b0bc7-2d96-4add-9d8c-4ce33016866b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2b9a4edb-d73a-4287-b28f-08dcec7c5f7b" xlink:to="loc_us-gaap_StatementLineItems_5f9b0bc7-2d96-4add-9d8c-4ce33016866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5f9b0bc7-2d96-4add-9d8c-4ce33016866b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ae21512f-9ec9-4072-836d-3dc6f6b5f47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ae21512f-9ec9-4072-836d-3dc6f6b5f47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3823b8c-5102-4f1e-826c-68121839f28f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3823b8c-5102-4f1e-826c-68121839f28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0449abed-6e09-42ce-be80-219d969f91c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0449abed-6e09-42ce-be80-219d969f91c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31101b1b-bd43-40a7-bc2b-7478565e31d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31101b1b-bd43-40a7-bc2b-7478565e31d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_becbd23d-cc1c-4bcd-b2ad-1907979a5776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_becbd23d-cc1c-4bcd-b2ad-1907979a5776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69576d17-849a-48b2-9e5a-11775ff7cd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_69576d17-849a-48b2-9e5a-11775ff7cd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_9f14f063-b5a9-4b7f-b8cb-1fc8cec95037" xlink:href="ibrx-20231231.xsd#ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_9f14f063-b5a9-4b7f-b8cb-1fc8cec95037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_149416a8-ffa5-4f7f-b0f0-012fc55b7507" xlink:href="ibrx-20231231.xsd#ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_149416a8-ffa5-4f7f-b0f0-012fc55b7507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dd250c4-301a-4658-bc66-9f12abf24d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8dd250c4-301a-4658-bc66-9f12abf24d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c12d4db2-9210-464f-b4ff-59e284675973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c12d4db2-9210-464f-b4ff-59e284675973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_715934e9-5e9e-412e-89b9-0841a404a708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_715934e9-5e9e-412e-89b9-0841a404a708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4c73016b-ecc1-43f0-8661-0eb0cab3c1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4c73016b-ecc1-43f0-8661-0eb0cab3c1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_1697b940-da46-46a6-b0d4-3b4f35f19526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_1697b940-da46-46a6-b0d4-3b4f35f19526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_24330844-b8cf-45bb-8173-fba0f11af063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_24330844-b8cf-45bb-8173-fba0f11af063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement_5a8b0d36-5e55-48fe-99a8-cfbc849206ec" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement_5a8b0d36-5e55-48fe-99a8-cfbc849206ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedDuringPeriodValueLitigationSettlement_cd13c58c-d1fe-48fc-af20-0c3a644ad7f5" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedDuringPeriodValueLitigationSettlement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_StockIssuedDuringPeriodValueLitigationSettlement_cd13c58c-d1fe-48fc-af20-0c3a644ad7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8c190507-34db-4db1-9b03-a656d5a978a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_8c190507-34db-4db1-9b03-a656d5a978a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_35f3efee-b190-4758-bbb5-dfbdbb40a61f" xlink:href="ibrx-20231231.xsd#ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_35f3efee-b190-4758-bbb5-dfbdbb40a61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement_6eb84b07-3676-4a37-8d91-fe53f5f75887" xlink:href="ibrx-20231231.xsd#ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement_6eb84b07-3676-4a37-8d91-fe53f5f75887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f3a54d8-119e-46e7-ad86-9ef325613b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f3a54d8-119e-46e7-ad86-9ef325613b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8b2b20d2-7407-4fb2-8619-14266cbbabeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_ProfitLoss_8b2b20d2-7407-4fb2-8619-14266cbbabeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ba6b8493-c17b-413d-8b81-92da779a4589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ba6b8493-c17b-413d-8b81-92da779a4589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_697fb2e6-8317-4222-baeb-e64f763d2b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5fe1e3-9d6d-4f5d-aade-82e94ad50e63" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_697fb2e6-8317-4222-baeb-e64f763d2b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofStockholdersDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9c98385a-9bed-478a-913e-663144a8e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ea9c5c0a-3991-45c5-8821-0b083e64afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9c98385a-9bed-478a-913e-663144a8e4b3" xlink:to="loc_us-gaap_StatementTable_ea9c5c0a-3991-45c5-8821-0b083e64afa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6320a420-a31c-4902-9620-d6486d63bb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ea9c5c0a-3991-45c5-8821-0b083e64afa6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6320a420-a31c-4902-9620-d6486d63bb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6320a420-a31c-4902-9620-d6486d63bb62" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_65f66172-1e98-4f8b-95b6-4069250d5898" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_65f66172-1e98-4f8b-95b6-4069250d5898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_1dc8e0f7-0472-4037-832a-1711822313c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:to="loc_us-gaap_PrivatePlacementMember_1dc8e0f7-0472-4037-832a-1711822313c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_00645b09-e222-46a1-bd9b-3195010b8be2" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9d2664eb-c47b-4321-b295-c57288d6826b" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_00645b09-e222-46a1-bd9b-3195010b8be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f729d0d4-d663-4d26-9aff-407ea3264563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ea9c5c0a-3991-45c5-8821-0b083e64afa6" xlink:to="loc_us-gaap_StatementLineItems_f729d0d4-d663-4d26-9aff-407ea3264563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_13450f55-a5c5-49d0-8d7c-e95a7627a8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f729d0d4-d663-4d26-9aff-407ea3264563" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_13450f55-a5c5-49d0-8d7c-e95a7627a8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ibrx-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1424af02-71dc-453c-83d7-d1468aba2143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_09c05d5c-8fd6-4710-bed0-f59ffafa0185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1424af02-71dc-453c-83d7-d1468aba2143" xlink:to="loc_us-gaap_StatementTable_09c05d5c-8fd6-4710-bed0-f59ffafa0185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09c05d5c-8fd6-4710-bed0-f59ffafa0185" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4f5a2073-9615-4b8d-b1ce-ff03d577ae0f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_18f8d4d5-6cba-47c8-b2fd-99583e6d3d81" xlink:href="ibrx-20231231.xsd#ibrx_PrivatePlacementAndAtTheMarketOfferingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:to="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_18f8d4d5-6cba-47c8-b2fd-99583e6d3d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_73dd7ca8-ccae-4a27-9425-c5de623ce8b9" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f2457590-1086-44e0-93a0-eb2e021f49c7" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_73dd7ca8-ccae-4a27-9425-c5de623ce8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09c05d5c-8fd6-4710-bed0-f59ffafa0185" xlink:to="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a2e71d4-9c56-4b50-9e36-958e07434af6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:to="loc_us-gaap_ProfitLoss_6a2e71d4-9c56-4b50-9e36-958e07434af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6ed9680f-e3c9-4436-9e32-7fb91d541dc3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0d35eb16-47ea-4471-9ba5-f51198c570aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_ShareBasedCompensation_0d35eb16-47ea-4471-9ba5-f51198c570aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_49527f10-47bd-4f1a-b489-80af06c83ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_49527f10-47bd-4f1a-b489-80af06c83ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_86f74ffc-3afe-4737-bdb8-68fc8fc6bac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_86f74ffc-3afe-4737-bdb8-68fc8fc6bac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_f4951522-0055-4a1a-86d9-e6f1e90ac65d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_f4951522-0055-4a1a-86d9-e6f1e90ac65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_59270a79-022b-4876-a3d3-5090f545be88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_59270a79-022b-4876-a3d3-5090f545be88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_3f2a326f-f7f8-4628-860d-a46e2f82f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_PaidInKindInterest_3f2a326f-f7f8-4628-860d-a46e2f82f55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_8e12b585-2a4a-4dd0-ac0e-39f565b6d2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_8e12b585-2a4a-4dd0-ac0e-39f565b6d2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_fac553be-3a70-4ec6-99db-976ebdc9ca65" xlink:href="ibrx-20231231.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_fac553be-3a70-4ec6-99db-976ebdc9ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2d2427a9-d744-44a1-91d2-252a128e24d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2d2427a9-d744-44a1-91d2-252a128e24d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6ae75c7f-01fc-4373-bfb9-9c92a2132680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6ae75c7f-01fc-4373-bfb9-9c92a2132680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a8861b7c-555b-4ede-85cf-1230783ba0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a8861b7c-555b-4ede-85cf-1230783ba0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_8d44f579-eaa6-4f2c-a2aa-a485fd954bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_8d44f579-eaa6-4f2c-a2aa-a485fd954bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0015439e-e28b-4e54-9d84-5f50f87f1581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0015439e-e28b-4e54-9d84-5f50f87f1581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8ce9b7b9-724f-4135-bf74-3a01ab7e6ed4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85ed492e-d743-479a-b556-67ef1c976d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85ed492e-d743-479a-b556-67ef1c976d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2eff93fb-87f8-49c4-8af3-21fc78cd4a03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2eff93fb-87f8-49c4-8af3-21fc78cd4a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_31eed9e0-1da2-4ded-8ddd-4b2c27c4358f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_31eed9e0-1da2-4ded-8ddd-4b2c27c4358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fd542e35-41d0-4e33-a3f9-6b4cd4bb6a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_fd542e35-41d0-4e33-a3f9-6b4cd4bb6a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_be4c8dcd-ce8b-4b9a-8373-f8e6343ccd06" xlink:href="ibrx-20231231.xsd#ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent_be4c8dcd-ce8b-4b9a-8373-f8e6343ccd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_eaf2feed-2d58-4583-958b-37acec5608f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_eaf2feed-2d58-4583-958b-37acec5608f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1180724-0341-45e0-923f-611ab2a47617" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2908ccec-0c70-47a2-ad05-a9d9e3c9016a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1180724-0341-45e0-923f-611ab2a47617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e62819f5-f0d9-43c3-a518-365916983c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e62819f5-f0d9-43c3-a518-365916983c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9e96a303-d5bf-4011-a1d4-d561901438cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9e96a303-d5bf-4011-a1d4-d561901438cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3280b147-3864-48c5-a24a-ab9676662469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3280b147-3864-48c5-a24a-ab9676662469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_aeb122e7-bfa7-4028-94cb-ad787aac81d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_aeb122e7-bfa7-4028-94cb-ad787aac81d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5379a036-fd77-4bdc-98ca-a88a04d7e524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_5379a036-fd77-4bdc-98ca-a88a04d7e524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_52c7f349-8947-40d2-bffc-aac3bc65eacd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_52c7f349-8947-40d2-bffc-aac3bc65eacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_b62a8d65-2d0d-4df8-8c8e-cf3874dd53e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInJointVenture_b62a8d65-2d0d-4df8-8c8e-cf3874dd53e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f55bed91-d186-4673-a0fd-9ebc6eea3cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6fc82e82-64be-4cfe-a9c0-5672640eefd2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f55bed91-d186-4673-a0fd-9ebc6eea3cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_03aef210-d92d-45f1-86e7-2d99431940e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_03aef210-d92d-45f1-86e7-2d99431940e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_075cda15-aa73-4c02-8465-0ee449829987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_075cda15-aa73-4c02-8465-0ee449829987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dfe87def-7cf8-47ea-951d-ff5a406328fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dfe87def-7cf8-47ea-951d-ff5a406328fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e6c83284-8003-4f52-a77d-0664fadf5bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e6c83284-8003-4f52-a77d-0664fadf5bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dbe8897c-1e1c-4f5f-a0ab-fc7ea126cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dbe8897c-1e1c-4f5f-a0ab-fc7ea126cf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_24f8f8ae-3c78-401e-93d2-14dcdd461b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_24f8f8ae-3c78-401e-93d2-14dcdd461b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_e58cc3eb-a825-48c8-b660-43a2015bc59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_e58cc3eb-a825-48c8-b660-43a2015bc59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3b122ae0-4b11-48c2-a1ac-fe165b500bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3b122ae0-4b11-48c2-a1ac-fe165b500bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8db42ee-5e8b-4641-91e3-a8a02f5be2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d22fbab-e2ac-46bd-85db-8f59ff5a4dc3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8db42ee-5e8b-4641-91e3-a8a02f5be2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0be156bd-d849-46ca-adcb-1d42c50a143f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0be156bd-d849-46ca-adcb-1d42c50a143f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c42cbb0b-26b8-4be4-bb64-470da1ea50a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c42cbb0b-26b8-4be4-bb64-470da1ea50a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_18446a64-4721-4471-b944-270f76b3c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_18446a64-4721-4471-b944-270f76b3c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9e7a4524-77a9-4d21-9f65-49004b4059f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_9e7a4524-77a9-4d21-9f65-49004b4059f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86a37788-d6a5-4f3f-9ca9-d4b0e97ee323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86a37788-d6a5-4f3f-9ca9-d4b0e97ee323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8f8a0f8b-12cd-4a6d-96e7-2150d4e1d08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8f8a0f8b-12cd-4a6d-96e7-2150d4e1d08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_334adaf4-3eea-4b15-ba4c-e388ea51d4da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_334adaf4-3eea-4b15-ba4c-e388ea51d4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_5c34e4f0-4867-4cc3-9c8b-d1f816a9b9b3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_a8dbb9e6-7349-4021-870a-dcb91f80060f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:to="loc_us-gaap_InterestPaidNet_a8dbb9e6-7349-4021-870a-dcb91f80060f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_55069140-8c2e-4c13-ad09-bee17cf60c68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_461ded62-612a-4fd3-95db-5656435cb444" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_55069140-8c2e-4c13-ad09-bee17cf60c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6fe1af-7b43-4441-bf85-8f1037d1006d" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_210114d6-d5f2-48c2-be1b-92a40c2c3c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_210114d6-d5f2-48c2-be1b-92a40c2c3c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IssuanceOfWarrants_d8129847-3bae-4652-87c6-df0768f9f7f2" xlink:href="ibrx-20231231.xsd#ibrx_IssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_IssuanceOfWarrants_d8129847-3bae-4652-87c6-df0768f9f7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b853f60a-dbc6-4741-a315-0c5335cf18c8" xlink:href="ibrx-20231231.xsd#ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b853f60a-dbc6-4741-a315-0c5335cf18c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative_f19eb9e7-d6f0-434e-9043-41330a95673c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative_f19eb9e7-d6f0-434e-9043-41330a95673c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability_19fb2078-d34c-4555-9fb9-bf263de1b3cc" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockDiscountOnSharesRevenueInterestLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability_19fb2078-d34c-4555-9fb9-bf263de1b3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_37f47b50-f275-4d9f-8bf9-f54b7729fa67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_37f47b50-f275-4d9f-8bf9-f54b7729fa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f4d90d0-a36c-4823-8bd5-49583f824b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f4d90d0-a36c-4823-8bd5-49583f824b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability_3f869311-085e-4158-b518-e3e5091696ee" xlink:href="ibrx-20231231.xsd#ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability_3f869311-085e-4158-b518-e3e5091696ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_777fe448-a80b-4136-935c-bbedebed85fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_us-gaap_StockIssued1_777fe448-a80b-4136-935c-bbedebed85fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses_16aa1dbd-f869-4574-bfb9-e2be104c8b18" xlink:href="ibrx-20231231.xsd#ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses_16aa1dbd-f869-4574-bfb9-e2be104c8b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockIssuedCashlessExerciseOfStockOptions_705a1bb4-1654-43ed-be13-899fe6b002a4" xlink:href="ibrx-20231231.xsd#ibrx_StockIssuedCashlessExerciseOfStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_StockIssuedCashlessExerciseOfStockOptions_705a1bb4-1654-43ed-be13-899fe6b002a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid_8de23ced-a0d2-4a5e-a077-effc69520216" xlink:href="ibrx-20231231.xsd#ibrx_InvestmentsInJointVentureIncurredButNotYetPaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_de848356-2b2e-4de7-b7c4-c00315a60315" xlink:to="loc_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid_8de23ced-a0d2-4a5e-a077-effc69520216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ibrx-20231231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9bd9ea4-2dce-4220-b79a-2014475eee1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_3091f2bf-3f8e-47df-9f2b-26561dc66cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9bd9ea4-2dce-4220-b79a-2014475eee1d" xlink:to="loc_us-gaap_NatureOfOperations_3091f2bf-3f8e-47df-9f2b-26561dc66cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3df6c663-a42e-4bc2-9390-25ec78493245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93a6ae17-1d99-4489-9195-f1a9b6547572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3df6c663-a42e-4bc2-9390-25ec78493245" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_93a6ae17-1d99-4489-9195-f1a9b6547572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_9e123afb-325d-44c6-af9e-10b775eb66d7" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9118449b-52a9-4d93-aa7d-d6a820578869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_9e123afb-325d-44c6-af9e-10b775eb66d7" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9118449b-52a9-4d93-aa7d-d6a820578869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstruments" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6e1836b-5512-400f-83e2-46dd08d29f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_a894585f-2205-425d-b8a5-e6a06bfe04d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e6e1836b-5512-400f-83e2-46dd08d29f72" xlink:to="loc_us-gaap_InvestmentTextBlock_a894585f-2205-425d-b8a5-e6a06bfe04d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ee03bc00-351c-4b3c-9741-f0053d7f7629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_4cc04bbf-7a2f-438d-b5a6-a59b2199b660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ee03bc00-351c-4b3c-9741-f0053d7f7629" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_4cc04bbf-7a2f-438d-b5a6-a59b2199b660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisition"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_0e332aa8-a1a9-470b-8a21-6ba0d8307e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_f1edf240-5e0d-4404-b1ce-00eb2df59523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_0e332aa8-a1a9-470b-8a21-6ba0d8307e78" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_f1edf240-5e0d-4404-b1ce-00eb2df59523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bf677a5-7c58-4611-9062-32c4c0346e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fb84d4ae-033d-4ba2-b992-02ac4505eb68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bf677a5-7c58-4611-9062-32c4c0346e16" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fb84d4ae-033d-4ba2-b992-02ac4505eb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangements" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangements"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_900be371-3cdb-44a4-82bd-1532dc599818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9fb18fa6-a538-4633-bbeb-da190ef4f117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_900be371-3cdb-44a4-82bd-1532dc599818" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9fb18fa6-a538-4633-bbeb-da190ef4f117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_fcad47bf-8d12-430a-93b0-e3715032d820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_900be371-3cdb-44a4-82bd-1532dc599818" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_fcad47bf-8d12-430a-93b0-e3715032d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreement" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RevenueInterestPurchaseAgreement"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_103ed21d-35dc-4bd2-97bf-a7bd0e1a0548" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_eec123ce-ebdc-4da4-b268-33749aca2d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_103ed21d-35dc-4bd2-97bf-a7bd0e1a0548" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_eec123ce-ebdc-4da4-b268-33749aca2d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebt" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebt"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_54c0a66b-3027-4bc8-8246-3b20efff5b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5782aca2-57d9-46ee-9085-9fac12231714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_54c0a66b-3027-4bc8-8246-3b20efff5b3f" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5782aca2-57d9-46ee-9085-9fac12231714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreements" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyAgreements"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_319a9a8d-13e0-492b-9ef3-724aeae48ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2fa4db04-f097-4101-afa0-e6a7589b5968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_319a9a8d-13e0-492b-9ef3-724aeae48ca9" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2fa4db04-f097-4101-afa0-e6a7589b5968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/WarrantLiabilities" xlink:type="simple" xlink:href="ibrx-20231231.xsd#WarrantLiabilities"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/WarrantLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1649db01-065e-4db3-90c8-0ba188452759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantLiabilityTextBlock_8bc43ed3-5323-432b-ad97-fde8c32996d8" xlink:href="ibrx-20231231.xsd#ibrx_WarrantLiabilityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1649db01-065e-4db3-90c8-0ba188452759" xlink:to="loc_ibrx_WarrantLiabilityTextBlock_8bc43ed3-5323-432b-ad97-fde8c32996d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0298edc7-a1f2-4d68-a29a-afe8523a9ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5967eefb-98e5-4b1f-b498-1b5819c3be2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0298edc7-a1f2-4d68-a29a-afe8523a9ae6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5967eefb-98e5-4b1f-b498-1b5819c3be2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55e4f229-a2ca-4fa7-9de7-5c2dad2f335f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ef1ba704-05d5-47c0-9789-d0f055195ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55e4f229-a2ca-4fa7-9de7-5c2dad2f335f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ef1ba704-05d5-47c0-9789-d0f055195ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf62893-6c15-4f25-8fa1-ae82b5aebcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3d298407-3e0e-41f5-bd50-f96e48d79b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7bf62893-6c15-4f25-8fa1-ae82b5aebcdf" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3d298407-3e0e-41f5-bd50-f96e48d79b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="ibrx-20231231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_2aa93393-119c-469c-8ecf-d92dc36f6b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_d428f984-0237-4727-bf2c-5c0c619a4460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_2aa93393-119c-469c-8ecf-d92dc36f6b20" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_d428f984-0237-4727-bf2c-5c0c619a4460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_241e067a-1fd1-4982-9b7b-52ed252b1002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock_241e067a-1fd1-4982-9b7b-52ed252b1002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3f44f88-efaf-438f-a4c1-cbf3fbecedc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3f44f88-efaf-438f-a4c1-cbf3fbecedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d5d18da4-316b-46bd-a261-18b09fa2ce0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d5d18da4-316b-46bd-a261-18b09fa2ce0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0c480aff-d093-4e7a-a6cd-3adadd83af23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_UseOfEstimates_0c480aff-d093-4e7a-a6cd-3adadd83af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e40b608f-851c-4534-a675-64ed592fe4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_e40b608f-851c-4534-a675-64ed592fe4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_f02502ca-23fb-4ad9-b111-5988103cfb53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_f02502ca-23fb-4ad9-b111-5988103cfb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0d586194-97fd-4dd3-9d93-e1de8b403762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0d586194-97fd-4dd3-9d93-e1de8b403762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_3ff1a537-9093-4f89-86b4-8a854648af22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_3ff1a537-9093-4f89-86b4-8a854648af22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_dea58419-30c4-466f-88ae-9dc91c2c11c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_dea58419-30c4-466f-88ae-9dc91c2c11c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c5d22dfe-abbd-495e-8471-36165dc10561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c5d22dfe-abbd-495e-8471-36165dc10561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_baff4dfa-2510-4777-883b-2cf5a28085ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_baff4dfa-2510-4777-883b-2cf5a28085ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_f270d6b8-2408-4df7-8024-471d3f0c09d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_f270d6b8-2408-4df7-8024-471d3f0c09d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonControlTransactionPolicyPolicyTextBlock_02fd8859-19ff-4734-b7f2-d0facabe4cef" xlink:href="ibrx-20231231.xsd#ibrx_CommonControlTransactionPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_ibrx_CommonControlTransactionPolicyPolicyTextBlock_02fd8859-19ff-4734-b7f2-d0facabe4cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_33720f38-431f-4862-a483-0c996ce459ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_33720f38-431f-4862-a483-0c996ce459ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_295f8e76-4abe-4fff-b7ad-ae2120641d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_295f8e76-4abe-4fff-b7ad-ae2120641d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3d40dcf5-0622-4059-b67c-3f33ca35dbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3d40dcf5-0622-4059-b67c-3f33ca35dbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_23125822-75f0-456f-a7b7-f66dd9eb3e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_23125822-75f0-456f-a7b7-f66dd9eb3e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock_6f927355-3c8c-460b-9c1e-aa742e3a6e5c" xlink:href="ibrx-20231231.xsd#ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock_6f927355-3c8c-460b-9c1e-aa742e3a6e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock_a367a6d2-c80c-4392-8b0e-378a6dd506d4" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock_a367a6d2-c80c-4392-8b0e-378a6dd506d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4300daf4-1818-47b4-9206-f7634b197364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4300daf4-1818-47b4-9206-f7634b197364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsPolicyTextBlock_db5b18bc-1b4d-4ed8-b923-e67bc37bdd63" xlink:href="ibrx-20231231.xsd#ibrx_WarrantsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_ibrx_WarrantsPolicyTextBlock_db5b18bc-1b4d-4ed8-b923-e67bc37bdd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_d32b965f-79ab-4a69-97b1-38e034ff872c" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock_d32b965f-79ab-4a69-97b1-38e034ff872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_051546ac-37ef-4a67-9eee-5259e9d900f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_DebtPolicyTextBlock_051546ac-37ef-4a67-9eee-5259e9d900f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f2e1b779-cb6a-4883-aad0-db4a20219dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f2e1b779-cb6a-4883-aad0-db4a20219dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock_9a4826d3-2ce2-4a78-b29a-32c7e3c86654" xlink:href="ibrx-20231231.xsd#ibrx_StockRepurchaseProgramPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock_9a4826d3-2ce2-4a78-b29a-32c7e3c86654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesEmbeddedDerivatives_9fff56c5-44d4-45a9-b2aa-90530b5b41be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_DerivativesEmbeddedDerivatives_9fff56c5-44d4-45a9-b2aa-90530b5b41be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0605bb6e-ce15-42be-86dc-c6cffb9beae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0605bb6e-ce15-42be-86dc-c6cffb9beae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_88e24296-d4d7-44a4-89d7-9e3fe67e7890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_88e24296-d4d7-44a4-89d7-9e3fe67e7890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_7079ab5d-88bf-4b76-b215-e9952846a8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_7079ab5d-88bf-4b76-b215-e9952846a8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_753e0524-dd08-4bac-ab00-b1a4eadcd0da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_753e0524-dd08-4bac-ab00-b1a4eadcd0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_94a8a76b-c1cd-4ad8-9116-d6580cab2d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_94a8a76b-c1cd-4ad8-9116-d6580cab2d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3341a3ec-6602-409b-b883-629747671cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3341a3ec-6602-409b-b883-629747671cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ad7417ee-4b11-4df7-89b5-ad3eb7119b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ad7417ee-4b11-4df7-89b5-ad3eb7119b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_65022de7-d894-41be-8558-619d2a299036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_65022de7-d894-41be-8558-619d2a299036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5a48cf6a-5254-4ad9-a9f4-058bb8b2a077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82cee6b6-642e-4012-b308-1486a5c2cb2f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5a48cf6a-5254-4ad9-a9f4-058bb8b2a077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusinessTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#DescriptionofBusinessTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusinessTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d8017cf-2a25-4bef-a169-8a00fc35df54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_c7756e1b-97a7-47ad-be78-1e0a3244ec38" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d8017cf-2a25-4bef-a169-8a00fc35df54" xlink:to="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_c7756e1b-97a7-47ad-be78-1e0a3244ec38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_24d59b39-c590-4384-a3f6-f5c411feb623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1bee576c-f3c9-4866-8573-c2749a5ed78e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24d59b39-c590-4384-a3f6-f5c411feb623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1bee576c-f3c9-4866-8573-c2749a5ed78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3b85f443-d7b5-4a42-a488-c5ba1cc8329c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24d59b39-c590-4384-a3f6-f5c411feb623" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3b85f443-d7b5-4a42-a488-c5ba1cc8329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_f58977d5-0a52-44fc-9f33-1a74f8b40e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_24d59b39-c590-4384-a3f6-f5c411feb623" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_f58977d5-0a52-44fc-9f33-1a74f8b40e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_09259753-424d-4179-a415-03ba9539f786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_09259753-424d-4179-a415-03ba9539f786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2e52665a-b4bc-411f-909b-ae6ded5b6084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2e52665a-b4bc-411f-909b-ae6ded5b6084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_17597d70-1603-4c3f-94a1-d303b29cb3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_17597d70-1603-4c3f-94a1-d303b29cb3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9e02eeea-d88f-4b32-8f86-764d02e6c708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9e02eeea-d88f-4b32-8f86-764d02e6c708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_722379b7-9c34-40a4-a5b3-85ca10a4d504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_722379b7-9c34-40a4-a5b3-85ca10a4d504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_58591799-e541-4af5-92f3-b9179f356730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:to="loc_us-gaap_InterestAndOtherIncomeTableTextBlock_58591799-e541-4af5-92f3-b9179f356730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_af94e550-afa0-43ee-98c1-fb1a9d1ca0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_3b4059b4-b0ee-4181-afb8-38689c1324c6" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_af94e550-afa0-43ee-98c1-fb1a9d1ca0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6b395393-89d2-4cdf-9394-64a72ebf59c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_61659246-48ab-4a80-b6bd-f218a7dae21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6b395393-89d2-4cdf-9394-64a72ebf59c5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_61659246-48ab-4a80-b6bd-f218a7dae21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_9beb8afb-1b55-44e9-9077-992178a784d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6b395393-89d2-4cdf-9394-64a72ebf59c5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_9beb8afb-1b55-44e9-9077-992178a784d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cd4b8e73-c6a7-4b6c-a1e3-914a06102c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_987fa714-9953-47a5-9454-7fa6c5ce78f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cd4b8e73-c6a7-4b6c-a1e3-914a06102c9f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_987fa714-9953-47a5-9454-7fa6c5ce78f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_b32d7800-74d2-4899-aa91-7f5477e08776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_1f6d2642-8777-4a07-96fb-7ded0d7fd5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_b32d7800-74d2-4899-aa91-7f5477e08776" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_1f6d2642-8777-4a07-96fb-7ded0d7fd5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cea75090-693c-493a-b8e9-30640ecbf80c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_8c8d3074-10f4-49ba-8e87-843d111b3733" xlink:href="ibrx-20231231.xsd#ibrx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cea75090-693c-493a-b8e9-30640ecbf80c" xlink:to="loc_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock_8c8d3074-10f4-49ba-8e87-843d111b3733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b09b0055-cfdf-4633-9769-0bf5681564f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cea75090-693c-493a-b8e9-30640ecbf80c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b09b0055-cfdf-4633-9769-0bf5681564f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2dfdd6a3-d002-4de0-ba4f-368f2419201b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cea75090-693c-493a-b8e9-30640ecbf80c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2dfdd6a3-d002-4de0-ba4f-368f2419201b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RevenueInterestPurchaseAgreementTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_b6d19df6-08cc-40fa-89d9-7c1e8454ce82" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock_95cd9434-68af-4599-b3ec-90f66d4ea19d" xlink:href="ibrx-20231231.xsd#ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_b6d19df6-08cc-40fa-89d9-7c1e8454ce82" xlink:to="loc_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock_95cd9434-68af-4599-b3ec-90f66d4ea19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_93f96697-502d-4929-86ba-ccb40a669998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_023dadb5-fc0e-4a5c-8d4f-9a8edf7458df" xlink:href="ibrx-20231231.xsd#ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_93f96697-502d-4929-86ba-ccb40a669998" xlink:to="loc_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock_023dadb5-fc0e-4a5c-8d4f-9a8edf7458df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_52ae9fae-a9af-495b-a704-53f28cb4e155" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_93f96697-502d-4929-86ba-ccb40a669998" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_52ae9fae-a9af-495b-a704-53f28cb4e155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d2a8572f-2abf-4e8c-800f-01cfa0b5fd54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_93f96697-502d-4929-86ba-ccb40a669998" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d2a8572f-2abf-4e8c-800f-01cfa0b5fd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1228bdbd-dcd4-4b8a-b064-62c397890262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_45045b3a-e2ee-4ba7-b76d-da8c79a1605d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1228bdbd-dcd4-4b8a-b064-62c397890262" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_45045b3a-e2ee-4ba7-b76d-da8c79a1605d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b57669f1-9551-4f18-bdc8-139b76c0371d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_33aa635c-3672-439a-a5b8-594a3772c2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b57669f1-9551-4f18-bdc8-139b76c0371d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_33aa635c-3672-439a-a5b8-594a3772c2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_89a17eb6-3d67-4f33-bd7a-b65a3dad2110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b57669f1-9551-4f18-bdc8-139b76c0371d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_89a17eb6-3d67-4f33-bd7a-b65a3dad2110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_89c4f57b-8fb6-499c-adcf-480ec4230114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b57669f1-9551-4f18-bdc8-139b76c0371d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_89c4f57b-8fb6-499c-adcf-480ec4230114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_8136b7cf-620b-41c8-9086-001a5e6528aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b57669f1-9551-4f18-bdc8-139b76c0371d" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_8136b7cf-620b-41c8-9086-001a5e6528aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6bb3b3ce-e257-4a5f-b305-cb22e9bf9526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4dd54965-f127-4bf7-99a6-3c2b882013e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6bb3b3ce-e257-4a5f-b305-cb22e9bf9526" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4dd54965-f127-4bf7-99a6-3c2b882013e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_90ff0bee-8b8f-44a1-bcaa-2cfd7c441cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6bb3b3ce-e257-4a5f-b305-cb22e9bf9526" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_90ff0bee-8b8f-44a1-bcaa-2cfd7c441cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_717daf98-fa3e-4453-b502-c2fcdc698471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6bb3b3ce-e257-4a5f-b305-cb22e9bf9526" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_717daf98-fa3e-4453-b502-c2fcdc698471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_22a2d624-761b-4551-b850-ce3596349560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6bb3b3ce-e257-4a5f-b305-cb22e9bf9526" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_22a2d624-761b-4551-b850-ce3596349560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b2414679-90c9-452d-90e4-47d42fc812ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6bb3b3ce-e257-4a5f-b305-cb22e9bf9526" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b2414679-90c9-452d-90e4-47d42fc812ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96e591d5-c54d-44d9-9c1f-ae89e89271d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:href="ibrx-20231231.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96e591d5-c54d-44d9-9c1f-ae89e89271d8" xlink:to="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c1e11460-150d-45e1-aa5e-fd1f380d931f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c1e11460-150d-45e1-aa5e-fd1f380d931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8ad9939-2b59-4410-9f6e-fc9430173671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c1e11460-150d-45e1-aa5e-fd1f380d931f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8ad9939-2b59-4410-9f6e-fc9430173671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_70af44b3-9277-4eb4-b7c4-db06e072cc6c" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8ad9939-2b59-4410-9f6e-fc9430173671" xlink:to="loc_ibrx_NantCellInc.Member_70af44b3-9277-4eb4-b7c4-db06e072cc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3942b874-0f84-4da8-97e1-346b9cfe21ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_srt_OwnershipAxis_3942b874-0f84-4da8-97e1-346b9cfe21ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e77480bf-3629-4b82-811f-7d0f68b0c023" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3942b874-0f84-4da8-97e1-346b9cfe21ea" xlink:to="loc_srt_OwnershipDomain_e77480bf-3629-4b82-811f-7d0f68b0c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantKwestMember_87e3361f-2653-4934-a811-e4ddbf7d8732" xlink:href="ibrx-20231231.xsd#ibrx_NantKwestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e77480bf-3629-4b82-811f-7d0f68b0c023" xlink:to="loc_ibrx_NantKwestMember_87e3361f-2653-4934-a811-e4ddbf7d8732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_84e21dfe-575e-4613-9202-61e70f913525" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_srt_TitleOfIndividualAxis_84e21dfe-575e-4613-9202-61e70f913525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5492846b-3b57-4aab-9303-6b64a304fb22" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_84e21dfe-575e-4613-9202-61e70f913525" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5492846b-3b57-4aab-9303-6b64a304fb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember_3d75e9e5-4bac-4d67-83ad-f574023f072c" xlink:href="ibrx-20231231.xsd#ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5492846b-3b57-4aab-9303-6b64a304fb22" xlink:to="loc_ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember_3d75e9e5-4bac-4d67-83ad-f574023f072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_78b9cbdf-a4af-4976-9b78-2545f2857c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_78b9cbdf-a4af-4976-9b78-2545f2857c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20bd1758-30e2-4adb-9d56-78887f41b8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_78b9cbdf-a4af-4976-9b78-2545f2857c35" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20bd1758-30e2-4adb-9d56-78887f41b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2448be92-93d9-4d2a-91bc-67d080b1ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20bd1758-30e2-4adb-9d56-78887f41b8bd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2448be92-93d9-4d2a-91bc-67d080b1ab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:href="ibrx-20231231.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_58d33009-bc8b-4cd9-8315-672d6431a0d0" xlink:to="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8824fc44-7e22-4f48-9c73-cff52d0d8e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8824fc44-7e22-4f48-9c73-cff52d0d8e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_38ab5f91-f7e1-42c6-9ec0-b6ae4b899726" xlink:href="ibrx-20231231.xsd#ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_38ab5f91-f7e1-42c6-9ec0-b6ae4b899726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OwnershipPercentageByKeyExecutives_d394cf98-a92e-444a-9e23-c612a5aa5b22" xlink:href="ibrx-20231231.xsd#ibrx_OwnershipPercentageByKeyExecutives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_ibrx_OwnershipPercentageByKeyExecutives_d394cf98-a92e-444a-9e23-c612a5aa5b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForMergerRelatedCosts_90d71e91-707a-4fbe-9bfd-89523872c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_b06ce54e-6d86-4870-b425-70726a9772df" xlink:to="loc_us-gaap_PaymentsForMergerRelatedCosts_90d71e91-707a-4fbe-9bfd-89523872c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8cfd63d-b5b6-48a2-b436-400db93a4be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NameChangeEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f8cfd63d-b5b6-48a2-b436-400db93a4be4" xlink:to="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_824955ee-a61d-46db-beb7-75b030e14387" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:to="loc_srt_ConsolidationItemsAxis_824955ee-a61d-46db-beb7-75b030e14387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_824955ee-a61d-46db-beb7-75b030e14387" xlink:to="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableLegalEntitiesMember_d87347c4-0e6f-4cc1-895a-27afc5d347c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ReportableLegalEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:to="loc_srt_ReportableLegalEntitiesMember_d87347c4-0e6f-4cc1-895a-27afc5d347c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_0195d046-f581-4e71-a77c-ca0d42996ae4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_c35f72fb-a724-444e-bfdd-4d700acb368a" xlink:to="loc_srt_ConsolidationEliminationsMember_0195d046-f581-4e71-a77c-ca0d42996ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8716dd5a-c880-4f56-8cd2-de96a983d18c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8716dd5a-c880-4f56-8cd2-de96a983d18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8716dd5a-c880-4f56-8cd2-de96a983d18c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_bc382749-8f3b-494f-9195-5794fb15f079" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:to="loc_ibrx_NantCellInc.Member_bc382749-8f3b-494f-9195-5794fb15f079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantKwestInc.Member_dbf7abed-30ae-4302-a181-4fc696bb55d1" xlink:href="ibrx-20231231.xsd#ibrx_NantKwestInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_b0ae783f-e255-4589-9fc9-9ea5935e4763" xlink:to="loc_ibrx_NantKwestInc.Member_dbf7abed-30ae-4302-a181-4fc696bb55d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NameChangeEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventTable_329d50fd-ba14-46fc-8061-61be63b4e246" xlink:to="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_01954894-7285-4844-89bf-eaf2ef861ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_Revenues_01954894-7285-4844-89bf-eaf2ef861ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49007055-e750-4960-90a3-0411f47a916a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49007055-e750-4960-90a3-0411f47a916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2216e8ca-5ef7-451a-906f-e60849249b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4b42ed17-c880-4469-a16c-cb3f16ba6808" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2216e8ca-5ef7-451a-906f-e60849249b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ba80b27-f000-46cd-a880-ce8db26a458d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_OperatingIncomeLoss_2ba80b27-f000-46cd-a880-ce8db26a458d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_06671352-a127-44dc-99f8-5ce4a5fd5156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_06671352-a127-44dc-99f8-5ce4a5fd5156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01075ded-25ac-4deb-a973-f3358c7dd8af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01075ded-25ac-4deb-a973-f3358c7dd8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2e7c80a7-b5a3-488a-be49-65614f0ec850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_NameChangeEventLineItems_fe06fdea-2ab9-48e8-8af8-a166712e6e36" xlink:to="loc_us-gaap_ProfitLoss_2e7c80a7-b5a3-488a-be49-65614f0ec850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cce08d66-72fd-43d9-bb7d-0da2433cefe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:href="ibrx-20231231.xsd#ibrx_AccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cce08d66-72fd-43d9-bb7d-0da2433cefe7" xlink:to="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_775b7b0b-d017-40ab-841b-ce7f9559115d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_TypeOfArrangementAxis_775b7b0b-d017-40ab-841b-ce7f9559115d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_775b7b0b-d017-40ab-841b-ce7f9559115d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_3cafec9b-b6dc-4b3e-9fa0-fb7146de33fc" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_3cafec9b-b6dc-4b3e-9fa0-fb7146de33fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicenseAgreementMember_26bd6f66-5410-408f-9330-df35131943c0" xlink:href="ibrx-20231231.xsd#ibrx_LicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14cde7b9-3235-464b-9e99-959af0d44ee5" xlink:to="loc_ibrx_LicenseAgreementMember_26bd6f66-5410-408f-9330-df35131943c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ca5457ed-376d-4b16-bad0-5b4f3c7125d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ca5457ed-376d-4b16-bad0-5b4f3c7125d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ca5457ed-376d-4b16-bad0-5b4f3c7125d3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_2f1c07d4-17c7-4367-b042-d0a69a61ca7e" xlink:href="ibrx-20231231.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_2f1c07d4-17c7-4367-b042-d0a69a61ca7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_dfe97f22-623d-4884-b3d9-2aa76eaa2c68" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e700c464-bdc6-4606-b420-9d8a3c69b8a3" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_dfe97f22-623d-4884-b3d9-2aa76eaa2c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_81458158-e9bb-4650-a727-287303405ec4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_srt_OwnershipAxis_81458158-e9bb-4650-a727-287303405ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_81458158-e9bb-4650-a727-287303405ec4" xlink:to="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GlobeImmuneIncMember_9b0a8d3b-c2bc-4681-a3d9-d7bd2f009205" xlink:href="ibrx-20231231.xsd#ibrx_GlobeImmuneIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:to="loc_ibrx_GlobeImmuneIncMember_9b0a8d3b-c2bc-4681-a3d9-d7bd2f009205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_7402af23-7d10-4a3f-a584-eccc3c91cd91" xlink:href="ibrx-20231231.xsd#ibrx_NANTibodyLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_4beddfaa-9ac7-4d5f-8d7a-87f9ff59af74" xlink:to="loc_ibrx_NANTibodyLLCMember_7402af23-7d10-4a3f-a584-eccc3c91cd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_srt_ConsolidatedEntitiesAxis_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c2927337-2268-44de-9704-1ac98c5eaa82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_49f9a424-6a7a-4dc2-8ce7-d26a0cef5e82" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c2927337-2268-44de-9704-1ac98c5eaa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GlobeImmuneIncMember_d88329a2-7b6f-4bf9-b8dc-0fd09d299cfc" xlink:href="ibrx-20231231.xsd#ibrx_GlobeImmuneIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c2927337-2268-44de-9704-1ac98c5eaa82" xlink:to="loc_ibrx_GlobeImmuneIncMember_d88329a2-7b6f-4bf9-b8dc-0fd09d299cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_640e3d8f-cdbe-4dd0-8e31-142d28c1a1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_74ed064a-8f9e-42b5-bdb0-c9eac4a7fb14" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_640e3d8f-cdbe-4dd0-8e31-142d28c1a1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdvancesToRelatedPartyMember_dac48efc-7427-420e-83dd-669994adfd87" xlink:href="ibrx-20231231.xsd#ibrx_AdvancesToRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_640e3d8f-cdbe-4dd0-8e31-142d28c1a1d0" xlink:to="loc_ibrx_AdvancesToRelatedPartyMember_dac48efc-7427-420e-83dd-669994adfd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_180229c3-2d10-4c58-b173-c9966ea9efe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_180229c3-2d10-4c58-b173-c9966ea9efe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4c207bd9-9923-49aa-af40-7e15a7fb30e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_180229c3-2d10-4c58-b173-c9966ea9efe5" xlink:to="loc_us-gaap_RelatedPartyDomain_4c207bd9-9923-49aa-af40-7e15a7fb30e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c65eedaf-fd98-43fc-b240-1591dae9c313" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4c207bd9-9923-49aa-af40-7e15a7fb30e0" xlink:to="loc_srt_AffiliatedEntityMember_c65eedaf-fd98-43fc-b240-1591dae9c313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e26138f-f30c-4e23-90d5-2b01d506245a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e26138f-f30c-4e23-90d5-2b01d506245a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ee1c135-d4da-471d-8e48-45146ca2d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e26138f-f30c-4e23-90d5-2b01d506245a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ee1c135-d4da-471d-8e48-45146ca2d4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_7c42d6ea-fef7-4a98-8031-56b03d6284a8" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ee1c135-d4da-471d-8e48-45146ca2d4dd" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_7c42d6ea-fef7-4a98-8031-56b03d6284a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:href="ibrx-20231231.xsd#ibrx_AccountingPoliciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesTable_c713cd8e-d788-4aba-bc9d-e81971556a25" xlink:to="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384692f2-8ecb-48dc-855a-285adcc1ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_384692f2-8ecb-48dc-855a-285adcc1ff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e6f7a0d8-3766-4a3d-bd3c-35b1228bffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e6f7a0d8-3766-4a3d-bd3c-35b1228bffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_566226b0-fb36-46ba-a6ca-fab7e50f48f4" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_566226b0-fb36-46ba-a6ca-fab7e50f48f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_04c2d96f-bfed-4e90-8385-275370d5d7ee" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementTotalInvestmentAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_04c2d96f-bfed-4e90-8385-275370d5d7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_483f8159-9718-4cc9-8099-e2e7906d1884" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_483f8159-9718-4cc9-8099-e2e7906d1884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_dbf3f911-fd02-4ced-b53e-c46ed32b48a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_ImpairmentOfInvestments_dbf3f911-fd02-4ced-b53e-c46ed32b48a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_475967fe-29c0-4b73-920c-88a0f892a931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_Revenues_475967fe-29c0-4b73-920c-88a0f892a931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2e89bdfb-1689-4205-938f-8deebafe3f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2e89bdfb-1689-4205-938f-8deebafe3f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_baa33d1f-4d25-4575-b4c8-af602c5fadcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_baa33d1f-4d25-4575-b4c8-af602c5fadcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionRate_7fc010f1-97c6-4a40-adb4-723f4f835797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_RelatedPartyTransactionRate_7fc010f1-97c6-4a40-adb4-723f4f835797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2ec74ff7-7442-42ad-b52a-7e9484f9660c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2ec74ff7-7442-42ad-b52a-7e9484f9660c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2aff4584-e553-431d-9fd0-660935b3eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_OperatingExpenses_2aff4584-e553-431d-9fd0-660935b3eec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9e91e6f0-ebc2-41e4-92c7-23025f0e55f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_Assets_9e91e6f0-ebc2-41e4-92c7-23025f0e55f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a36f6164-03be-43ea-a628-bb4969f0d6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_Liabilities_a36f6164-03be-43ea-a628-bb4969f0d6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAdditionalPurchaseOption_6d60ca7e-72d7-4cd2-a60a-9f0e307d80e2" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAdditionalPurchaseOption"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_ibrx_SaleOfStockAdditionalPurchaseOption_6d60ca7e-72d7-4cd2-a60a-9f0e307d80e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_5c6cc338-a1a7-47d2-b0c4-36d00f850ade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_5c6cc338-a1a7-47d2-b0c4-36d00f850ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ed20e73d-4c8b-4cf6-abfa-a070aa33549a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_AccountingPoliciesLineItems_a112f808-03b2-4054-b600-5af78e16deb3" xlink:to="loc_us-gaap_NumberOfReportableSegments_ed20e73d-4c8b-4cf6-abfa-a070aa33549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bdf01033-9d1b-4256-b673-3f4072dd9d94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bdf01033-9d1b-4256-b673-3f4072dd9d94" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16773141-4342-4ac3-97a1-a7a88eaff312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16773141-4342-4ac3-97a1-a7a88eaff312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_16773141-4342-4ac3-97a1-a7a88eaff312" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_63c40455-be21-4acd-8b85-43e32707c6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_BuildingMember_63c40455-be21-4acd-8b85-43e32707c6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_869cff8c-1f80-477d-a413-af60e1d2e0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_869cff8c-1f80-477d-a413-af60e1d2e0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LaboratoryEquipmentMember_f2a7050e-23e9-495b-a947-b5a92f932e92" xlink:href="ibrx-20231231.xsd#ibrx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_ibrx_LaboratoryEquipmentMember_f2a7050e-23e9-495b-a947-b5a92f932e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_ef2e5792-5453-4f62-9c1c-34098dcff1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_ef2e5792-5453-4f62-9c1c-34098dcff1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_67379b2e-435a-48af-8e60-3af4219e9d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a06e5a65-d2f1-433e-8b74-6f2b0b32ee58" xlink:to="loc_us-gaap_ComputerEquipmentMember_67379b2e-435a-48af-8e60-3af4219e9d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:to="loc_srt_RangeAxis_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8824ce5e-eacb-4f21-a31c-d5276ee5cf4e" xlink:to="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f632730e-5515-4335-8a97-8dcd286d8083" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:to="loc_srt_MinimumMember_f632730e-5515-4335-8a97-8dcd286d8083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cc1b9a57-5eee-4455-98cb-58158ca788eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae7a065a-e99e-4c45-9ec7-ce519ddf7bd6" xlink:to="loc_srt_MaximumMember_cc1b9a57-5eee-4455-98cb-58158ca788eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7923e4b7-d0d3-4dd8-b85d-33395809c5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dfe6bac9-b324-41c4-a0cc-eb8e4cfe9997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7923e4b7-d0d3-4dd8-b85d-33395809c5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4282c9b8-d4a8-4b2e-87c9-44fcef20b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7923e4b7-d0d3-4dd8-b85d-33395809c5bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4282c9b8-d4a8-4b2e-87c9-44fcef20b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_38e28a67-47cb-487c-944c-6c83f8312f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b24055-beb1-45c9-9248-e279b693cac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38e28a67-47cb-487c-944c-6c83f8312f38" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b24055-beb1-45c9-9248-e279b693cac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b24055-beb1-45c9-9248-e279b693cac3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9f6ad0b5-6c30-4fae-aa25-afe6e7f92b26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyConvertibleNotesMember_91946394-ac40-4d64-970c-92ccad229ae4" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_ibrx_RelatedPartyConvertibleNotesMember_91946394-ac40-4d64-970c-92ccad229ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ad891642-6439-4bac-948b-332deac9483d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_us-gaap_WarrantMember_ad891642-6439-4bac-948b-332deac9483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d1464985-93b2-4991-b008-1de462d7d586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d1464985-93b2-4991-b008-1de462d7d586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bee58446-11ee-4428-9a29-e3120510a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bee58446-11ee-4428-9a29-e3120510a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyWarrantsMember_78bc6931-c249-45a6-b4af-648603deaa6b" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_817827ef-8752-44c5-bc3d-871677b6cecc" xlink:to="loc_ibrx_RelatedPartyWarrantsMember_78bc6931-c249-45a6-b4af-648603deaa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ddec6dff-0ee2-4d94-a404-c2a80ca5e128" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4b24055-beb1-45c9-9248-e279b693cac3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ddec6dff-0ee2-4d94-a404-c2a80ca5e128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4b21030e-3747-4921-a34b-8c2a0b23c878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ddec6dff-0ee2-4d94-a404-c2a80ca5e128" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4b21030e-3747-4921-a34b-8c2a0b23c878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d76444ab-4154-40ab-8aba-60d5fcd07893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_25923cb7-5430-44df-b254-d3df5737ca42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d76444ab-4154-40ab-8aba-60d5fcd07893" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_25923cb7-5430-44df-b254-d3df5737ca42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_25923cb7-5430-44df-b254-d3df5737ca42" xlink:to="loc_srt_StatementGeographicalAxis_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6e8031b3-a0fd-4949-bdaf-e16f8b4c55c5" xlink:to="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6e54d658-5238-4fe4-98b7-572c80e1f9ca" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:to="loc_country_US_6e54d658-5238-4fe4-98b7-572c80e1f9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dd7ee681-a3f8-418b-8966-bf07435b5937" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_124de7c5-9118-4272-8761-053dc5cb53be" xlink:to="loc_srt_EuropeMember_dd7ee681-a3f8-418b-8966-bf07435b5937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_127280bf-5e3d-43d5-87a1-d8d8c2a57a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_25923cb7-5430-44df-b254-d3df5737ca42" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_127280bf-5e3d-43d5-87a1-d8d8c2a57a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_193a9bc3-b4e3-4741-914f-5e78df37c507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_127280bf-5e3d-43d5-87a1-d8d8c2a57a9a" xlink:to="loc_us-gaap_Revenues_193a9bc3-b4e3-4741-914f-5e78df37c507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidResearchAndDevelopmentCosts_a3d3e39a-b46f-49c2-b2aa-ebb5e70abe3b" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_ibrx_PrepaidResearchAndDevelopmentCosts_a3d3e39a-b46f-49c2-b2aa-ebb5e70abe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidServices_a6af5244-bf71-4de0-9b1f-e6df4e2a3ddc" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_ibrx_PrepaidServices_a6af5244-bf71-4de0-9b1f-e6df4e2a3ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_c552a571-f484-4ce1-b815-a42414027130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_us-gaap_PrepaidInsurance_c552a571-f484-4ce1-b815-a42414027130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidSoftwareLicenseFees_b703cc03-b427-463a-b8a2-86440f6c4010" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidSoftwareLicenseFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_ibrx_PrepaidSoftwareLicenseFees_b703cc03-b427-463a-b8a2-86440f6c4010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InsurancePremiumFinancingAsset_b3784dff-c858-4adb-ba5c-c7531db4f493" xlink:href="ibrx-20231231.xsd#ibrx_InsurancePremiumFinancingAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_ibrx_InsurancePremiumFinancingAsset_b3784dff-c858-4adb-ba5c-c7531db4f493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceSettlementsReceivableCurrent_100ad659-84fe-49c3-9562-b0e3f2b4ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceSettlementsReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_us-gaap_InsuranceSettlementsReceivableCurrent_100ad659-84fe-49c3-9562-b0e3f2b4ef29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidEquipmentMaintenance_f2d739a9-631b-4a4b-bddb-58a3ff7a8275" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidEquipmentMaintenance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_ibrx_PrepaidEquipmentMaintenance_f2d739a9-631b-4a4b-bddb-58a3ff7a8275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_4838b8d3-7e4f-47a1-80d4-5c60b68e908e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_4838b8d3-7e4f-47a1-80d4-5c60b68e908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Supplies_c1043b42-8711-4522-a1cf-faae0c2d71e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Supplies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_us-gaap_Supplies_c1043b42-8711-4522-a1cf-faae0c2d71e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1a54512f-aefb-41f1-a038-58e0897fd272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_us-gaap_OtherAssetsCurrent_1a54512f-aefb-41f1-a038-58e0897fd272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc956ee3-411a-4f59-a166-7f8dcd358033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b189c796-a83e-4d3c-b85c-b6b5ed7d4af8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc956ee3-411a-4f59-a166-7f8dcd358033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_08ff5a7d-e21a-4c47-88aa-621c67ba86c8" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_89ae7e4e-1e9b-4cba-ad4c-ddba78eebaae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_08ff5a7d-e21a-4c47-88aa-621c67ba86c8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_89ae7e4e-1e9b-4cba-ad4c-ddba78eebaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4e8be96c-262a-44e4-b16e-7927b00fd0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_89ae7e4e-1e9b-4cba-ad4c-ddba78eebaae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4e8be96c-262a-44e4-b16e-7927b00fd0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4e8be96c-262a-44e4-b16e-7927b00fd0e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_930960f8-5260-47b6-bd3b-dd54ae667368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_930960f8-5260-47b6-bd3b-dd54ae667368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a95e594d-cbbd-4bd3-b73b-fd0832f78db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_EquipmentMember_a95e594d-cbbd-4bd3-b73b-fd0832f78db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_114680dc-32be-4f8b-861c-5d90513035a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_ConstructionInProgressMember_114680dc-32be-4f8b-861c-5d90513035a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_40e962ea-671e-417d-af05-dab1a8e62f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_40e962ea-671e-417d-af05-dab1a8e62f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a6063480-5492-4cde-bcff-c5edda07f5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_efe92d75-9a23-4445-9156-11c289eab0a7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a6063480-5492-4cde-bcff-c5edda07f5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_89ae7e4e-1e9b-4cba-ad4c-ddba78eebaae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8287a911-24f6-4df0-baa9-52befe36ca93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8287a911-24f6-4df0-baa9-52befe36ca93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_79cb4e5a-458e-4d5d-b4de-84707cdea3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_79cb4e5a-458e-4d5d-b4de-84707cdea3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b560b0b1-66ac-4432-8ffd-b1fdcb5838f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_93c22fa9-c8bb-490a-aa4d-3d1cf9f4a68f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b560b0b1-66ac-4432-8ffd-b1fdcb5838f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_b6639dbc-2c1b-405c-93ef-ac59fe937ec2" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_b6639dbc-2c1b-405c-93ef-ac59fe937ec2" xlink:to="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_85121683-b6bc-4ed4-97b0-eb2d221ff66a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_us-gaap_AssetAcquisitionAxis_85121683-b6bc-4ed4-97b0-eb2d221ff66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_06dcc03f-e82e-42dd-9198-08c89075bf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_85121683-b6bc-4ed4-97b0-eb2d221ff66a" xlink:to="loc_us-gaap_AssetAcquisitionDomain_06dcc03f-e82e-42dd-9198-08c89075bf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_f83c0542-3340-44ba-8f95-adf7b450acd5" xlink:href="ibrx-20231231.xsd#ibrx_DunkirkFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_06dcc03f-e82e-42dd-9198-08c89075bf8a" xlink:to="loc_ibrx_DunkirkFacilityMember_f83c0542-3340-44ba-8f95-adf7b450acd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4115a2d8-e511-4bc6-873d-48eec9e94a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eeddcb3-cf0e-4a7f-8bc7-bea31dd40566" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4115a2d8-e511-4bc6-873d-48eec9e94a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_9e298a80-9ba9-4de4-92ad-9b303dad15a6" xlink:href="ibrx-20231231.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4115a2d8-e511-4bc6-873d-48eec9e94a5f" xlink:to="loc_ibrx_OrganizedWorkforceMember_9e298a80-9ba9-4de4-92ad-9b303dad15a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_763f6788-259f-4b9a-a348-49bb29cfd90f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_763f6788-259f-4b9a-a348-49bb29cfd90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5d48d69b-aa82-4ed8-a2d5-21cced6b2f7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_763f6788-259f-4b9a-a348-49bb29cfd90f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5d48d69b-aa82-4ed8-a2d5-21cced6b2f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RiptideBioscienceIncMember_01f30c82-c374-44c7-b32a-6e9b8b46e82b" xlink:href="ibrx-20231231.xsd#ibrx_RiptideBioscienceIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_5d48d69b-aa82-4ed8-a2d5-21cced6b2f7d" xlink:to="loc_ibrx_RiptideBioscienceIncMember_01f30c82-c374-44c7-b32a-6e9b8b46e82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bff8e638-3e22-41da-ac81-6f5f0258d4fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_srt_RangeAxis_bff8e638-3e22-41da-ac81-6f5f0258d4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c03d55fe-7915-405f-b790-e7736d6fc6e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bff8e638-3e22-41da-ac81-6f5f0258d4fb" xlink:to="loc_srt_RangeMember_c03d55fe-7915-405f-b790-e7736d6fc6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_abe90ad1-2ba7-4dce-9135-94bf46616283" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c03d55fe-7915-405f-b790-e7736d6fc6e9" xlink:to="loc_srt_MaximumMember_abe90ad1-2ba7-4dce-9135-94bf46616283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25b345d5-0486-4f25-8925-01fd9f00442f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25b345d5-0486-4f25-8925-01fd9f00442f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_53b1002b-6eed-4845-a8aa-32dbeefc5de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_25b345d5-0486-4f25-8925-01fd9f00442f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_53b1002b-6eed-4845-a8aa-32dbeefc5de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IPRDMember_78b5920a-eda1-42ad-8eb8-8bb20b338da5" xlink:href="ibrx-20231231.xsd#ibrx_IPRDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_53b1002b-6eed-4845-a8aa-32dbeefc5de6" xlink:to="loc_ibrx_IPRDMember_78b5920a-eda1-42ad-8eb8-8bb20b338da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_a570d8f5-7ed9-43aa-8ad7-976dfb28598c" xlink:to="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f115b4e3-dbd0-4b54-bdc1-8deecab0063c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_Depreciation_f115b4e3-dbd0-4b54-bdc1-8deecab0063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_80226c3d-2569-405f-a9f9-3e82d9da5134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_80226c3d-2569-405f-a9f9-3e82d9da5134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_faac4793-5f92-412d-989a-1adbc29207c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_faac4793-5f92-412d-989a-1adbc29207c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_930f1555-0af3-4510-acac-06a6a9ed186f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_930f1555-0af3-4510-acac-06a6a9ed186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3450ea55-bebe-4bd8-9130-dbdf419f1ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3450ea55-bebe-4bd8-9130-dbdf419f1ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableDiscountOptionPercent_c950e1c6-c43f-4803-90d2-aa572d084c26" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableDiscountOptionPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_ConvertibleNoteReceivableDiscountOptionPercent_c950e1c6-c43f-4803-90d2-aa572d084c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ConvertibleNoteReceivableNonCurrent_2586afd0-6592-4c93-ac41-00ad7a8a0006" xlink:href="ibrx-20231231.xsd#ibrx_ConvertibleNoteReceivableNonCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_ConvertibleNoteReceivableNonCurrent_2586afd0-6592-4c93-ac41-00ad7a8a0006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_3d3b769b-1bee-4f50-b1df-8994eea394f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_InvestmentInterestRate_3d3b769b-1bee-4f50-b1df-8994eea394f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount_8d86d253-7204-4186-98db-31db2bcd251a" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentPayableAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount_8d86d253-7204-4186-98db-31db2bcd251a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_2bbd160d-cb52-4518-89a2-8bdaa65c8ab9" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_2bbd160d-cb52-4518-89a2-8bdaa65c8ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_6b28529f-20b5-43cf-a0d9-0a245fdf5152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_e3412561-7dbc-4073-8699-8138c68a8787" xlink:to="loc_us-gaap_InterestReceivable_6b28529f-20b5-43cf-a0d9-0a245fdf5152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_385145cb-ef1a-46c4-873f-74db3563a14e" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_f6996493-5bcd-4b9a-a110-7a441dec746e" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_385145cb-ef1a-46c4-873f-74db3563a14e" xlink:to="loc_ibrx_FinancialStatementDetailsTable_f6996493-5bcd-4b9a-a110-7a441dec746e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a42338d9-28eb-4765-81dc-3523e9a6146b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_f6996493-5bcd-4b9a-a110-7a441dec746e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a42338d9-28eb-4765-81dc-3523e9a6146b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a42338d9-28eb-4765-81dc-3523e9a6146b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_7eabc1d6-1cc5-462d-8161-b5c874221462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_7eabc1d6-1cc5-462d-8161-b5c874221462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_064454ff-95fa-4bae-a4e1-38c945f10715" xlink:href="ibrx-20231231.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d16d687a-5ebb-41f5-88f9-21a29cce56be" xlink:to="loc_ibrx_OrganizedWorkforceMember_064454ff-95fa-4bae-a4e1-38c945f10715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_f6996493-5bcd-4b9a-a110-7a441dec746e" xlink:to="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0faad156-93e5-40fa-8865-058d874ac553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0faad156-93e5-40fa-8865-058d874ac553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_04ce1ce7-286a-4086-b385-0587de6a6d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_04ce1ce7-286a-4086-b385-0587de6a6d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d04620a4-1210-4559-bc3a-c260f6e8fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d04620a4-1210-4559-bc3a-c260f6e8fc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_91965e59-3b0f-4114-9c40-08999f8dce4d" xlink:href="ibrx-20231231.xsd#ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment_91965e59-3b0f-4114-9c40-08999f8dce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a7fd9bf-8f72-4061-a43c-6a4b0d75d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_094543c6-023c-4e20-8615-11154e3cce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8a7fd9bf-8f72-4061-a43c-6a4b0d75d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_1e561268-1e29-48e3-a131-2acdfc5d8477" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:to="loc_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill_1e561268-1e29-48e3-a131-2acdfc5d8477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_de4c5528-7a49-4963-b9a5-a520acfc3c6f" xlink:href="ibrx-20231231.xsd#ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:to="loc_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment_de4c5528-7a49-4963-b9a5-a520acfc3c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f2121b1-bb75-424a-863e-c0d78c398a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_27bdef93-b91a-4b17-a5e6-2f6997851df6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4f2121b1-bb75-424a-863e-c0d78c398a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9b413b9a-d6d7-4306-b404-c6427925a8da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9b413b9a-d6d7-4306-b404-c6427925a8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IntangibleAssetsAccumulatedImpairment_843a25fa-47c9-4510-9849-defda07c54b0" xlink:href="ibrx-20231231.xsd#ibrx_IntangibleAssetsAccumulatedImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_ibrx_IntangibleAssetsAccumulatedImpairment_843a25fa-47c9-4510-9849-defda07c54b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9f8d4bf2-1d09-45da-9b73-e54b17ce9a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9f8d4bf2-1d09-45da-9b73-e54b17ce9a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_9416ec45-ac41-4c47-9293-feac96d55837" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_747b8092-d058-4252-afbe-8bd2174f34d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_747b8092-d058-4252-afbe-8bd2174f34d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a34a13c0-5c9e-4d30-ad97-5a96a04f1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a34a13c0-5c9e-4d30-ad97-5a96a04f1bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dfe228c7-da46-4674-9284-0e6b89643822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dfe228c7-da46-4674-9284-0e6b89643822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_50377998-5dd2-4636-9ed6-2af0adb490d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_50377998-5dd2-4636-9ed6-2af0adb490d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_23a56972-57f3-4c67-bf13-8900ea813595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_23a56972-57f3-4c67-bf13-8900ea813595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dcbf9645-ca87-4464-8114-3bcd598769fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dcbf9645-ca87-4464-8114-3bcd598769fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e53fe248-2b4d-45d5-a1a1-b1700dd4708d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_890e4bee-8fd7-4562-a9ea-41cd31aec949" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e53fe248-2b4d-45d5-a1a1-b1700dd4708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsIntangibleAssetsNetDetails_1"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_944816f4-7a08-499a-b3af-35deb7809b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_us-gaap_AccruedBonusesCurrent_944816f4-7a08-499a-b3af-35deb7809b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_7538446b-7e80-40aa-aa60-f608f6e4cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_7538446b-7e80-40aa-aa60-f608f6e4cffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedResearchAndDevelopmentCosts_8429729e-5609-4b98-b8ea-ba8ff102d231" xlink:href="ibrx-20231231.xsd#ibrx_AccruedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_ibrx_AccruedResearchAndDevelopmentCosts_8429729e-5609-4b98-b8ea-ba8ff102d231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_1e65813b-a7a9-4455-bf49-80b88e649a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_us-gaap_AccruedSalariesCurrent_1e65813b-a7a9-4455-bf49-80b88e649a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_92bc1fcb-ba57-4b15-b342-c3aac0fd636a" xlink:href="ibrx-20231231.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_ibrx_AccruedPreclinicalAndClinicalTrialCosts_92bc1fcb-ba57-4b15-b342-c3aac0fd636a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancingObligationCurrent_4986c64f-06b9-4807-bf47-715117d13ec1" xlink:href="ibrx-20231231.xsd#ibrx_FinancingObligationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_ibrx_FinancingObligationCurrent_4986c64f-06b9-4807-bf47-715117d13ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_f8270e64-bd97-4c5a-8319-d1e5d78efe26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_us-gaap_ConstructionPayableCurrent_f8270e64-bd97-4c5a-8319-d1e5d78efe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_896e60ce-2d68-42ad-8e88-bcce230cc9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_896e60ce-2d68-42ad-8e88-bcce230cc9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dd6c0cd3-0a06-4a67-9dc2-44945f8febb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_d877892a-27e0-40f1-9065-3a6ab457c0b5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dd6c0cd3-0a06-4a67-9dc2-44945f8febb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_7c6ec70a-334b-45bf-aa80-bffbb2032fc5" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_3d70b4aa-a61e-4f3b-8fa8-740024f7e338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_7c6ec70a-334b-45bf-aa80-bffbb2032fc5" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_3d70b4aa-a61e-4f3b-8fa8-740024f7e338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_ae8513b8-a30f-4ed5-b2a0-cac62e9f9511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_7c6ec70a-334b-45bf-aa80-bffbb2032fc5" xlink:to="loc_us-gaap_InterestAndOtherIncome_ae8513b8-a30f-4ed5-b2a0-cac62e9f9511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_16693236-93b7-4660-b412-cb377835b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_7c6ec70a-334b-45bf-aa80-bffbb2032fc5" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_16693236-93b7-4660-b412-cb377835b68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_46f71272-6114-422e-bf07-fb05cfe81ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_7c6ec70a-334b-45bf-aa80-bffbb2032fc5" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_46f71272-6114-422e-bf07-fb05cfe81ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_69281b58-c1b2-4b9f-8b78-3d8a9e663b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_7c6ec70a-334b-45bf-aa80-bffbb2032fc5" xlink:to="loc_us-gaap_GainLossOnInvestments_69281b58-c1b2-4b9f-8b78-3d8a9e663b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialStatementDetailsInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsAbstract_717dc643-07c5-430a-99f7-edf138b6a58e" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsTable_f11e3170-1742-4c04-a469-e746945134ee" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsAbstract_717dc643-07c5-430a-99f7-edf138b6a58e" xlink:to="loc_ibrx_FinancialStatementDetailsTable_f11e3170-1742-4c04-a469-e746945134ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_552692f2-3b9b-414c-a00e-8c92d3c6fb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_f11e3170-1742-4c04-a469-e746945134ee" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_552692f2-3b9b-414c-a00e-8c92d3c6fb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cb7cf288-2db8-4a02-a443-e035ed8798d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_552692f2-3b9b-414c-a00e-8c92d3c6fb9d" xlink:to="loc_us-gaap_RelatedPartyDomain_cb7cf288-2db8-4a02-a443-e035ed8798d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_87f655b3-8bf4-43bb-a2f0-ad3dcf69a2a7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cb7cf288-2db8-4a02-a443-e035ed8798d1" xlink:to="loc_srt_AffiliatedEntityMember_87f655b3-8bf4-43bb-a2f0-ad3dcf69a2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:href="ibrx-20231231.xsd#ibrx_FinancialStatementDetailsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsTable_f11e3170-1742-4c04-a469-e746945134ee" xlink:to="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_133dfc50-910b-4edc-b5a6-0913153fe2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_us-gaap_InterestExpenseDebt_133dfc50-910b-4edc-b5a6-0913153fe2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_27bde068-c73a-4150-ae92-89a68c2f2b78" xlink:href="ibrx-20231231.xsd#ibrx_AmortizationOfDebtDiscountPremiumRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty_27bde068-c73a-4150-ae92-89a68c2f2b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOther_8ed47a9f-0bb0-4fe4-ae38-2ad47993e732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_us-gaap_InterestExpenseOther_8ed47a9f-0bb0-4fe4-ae38-2ad47993e732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4978022e-646f-4b5d-be56-62fdd3c4b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_FinancialStatementDetailsLineItems_0e52b7f4-0076-4cd9-9e90-176567dc97f0" xlink:to="loc_us-gaap_InterestExpense_4978022e-646f-4b5d-be56-62fdd3c4b9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e728543d-02ff-42cd-8257-06e23da634cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e728543d-02ff-42cd-8257-06e23da634cb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e0e1034a-938c-4a29-91c5-0c13a6281c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e0e1034a-938c-4a29-91c5-0c13a6281c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e0e1034a-938c-4a29-91c5-0c13a6281c90" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_2b10a301-f1e7-4f8b-8fc3-4599aca00006" xlink:href="ibrx-20231231.xsd#ibrx_CurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:to="loc_ibrx_CurrentAssetsMember_2b10a301-f1e7-4f8b-8fc3-4599aca00006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_76fac8eb-1c86-4def-93eb-b6194aa8daff" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_256e4bf7-b3de-48cf-a278-b7cfe83c8d50" xlink:to="loc_ibrx_NoncurrentAssetsMember_76fac8eb-1c86-4def-93eb-b6194aa8daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c59881c3-8f19-435f-a7ca-2cc9b20a8d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c59881c3-8f19-435f-a7ca-2cc9b20a8d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c59881c3-8f19-435f-a7ca-2cc9b20a8d21" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_8843b3a4-6a48-42a4-a288-8d80b3544ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_8843b3a4-6a48-42a4-a288-8d80b3544ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_1646f120-464b-4018-9533-68c02839b29b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3cd5a0ca-a436-47c3-b63c-c0be35e1606b" xlink:to="loc_us-gaap_MutualFundMember_1646f120-464b-4018-9533-68c02839b29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e9bfb1f-5fd1-42ff-be5f-7a47c7b24745" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_089709ac-1940-43ec-9e5c-96b465db1013" xlink:href="ibrx-20231231.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_089709ac-1940-43ec-9e5c-96b465db1013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084e8ecf-7526-48be-a039-25ef47a3bbba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_084e8ecf-7526-48be-a039-25ef47a3bbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_72820ba1-0560-4407-879d-d37496b7ac4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_72820ba1-0560-4407-879d-d37496b7ac4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d2f9a0b-b06b-46c7-89d3-dc96f3947dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d2f9a0b-b06b-46c7-89d3-dc96f3947dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3b55442e-bbc5-4545-a409-62ba074eb37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d52dbc1-b8eb-451e-a9e6-6344f4369be3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3b55442e-bbc5-4545-a409-62ba074eb37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3350466a-5ca5-44be-b55a-8ee2142499c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_22bd42ba-ac87-4367-9ac8-21deaeae5692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3350466a-5ca5-44be-b55a-8ee2142499c1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_22bd42ba-ac87-4367-9ac8-21deaeae5692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3350466a-5ca5-44be-b55a-8ee2142499c1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_85d99d80-cf24-4ca2-93e7-e27f7bea84fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_85d99d80-cf24-4ca2-93e7-e27f7bea84fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85d99d80-cf24-4ca2-93e7-e27f7bea84fc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_e946d3ba-4774-473f-9d79-0ab36cb3a962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:to="loc_us-gaap_MutualFundMember_e946d3ba-4774-473f-9d79-0ab36cb3a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_df716037-660f-4d3c-afc9-6e210c5a8581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_df716037-660f-4d3c-afc9-6e210c5a8581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_58a4da1a-2b37-474f-8687-927f47c6bea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97c8ab1d-3a04-476c-9fae-51e20fe9dad5" xlink:to="loc_us-gaap_DebtSecuritiesMember_58a4da1a-2b37-474f-8687-927f47c6bea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f3e81995-55b6-4e98-b333-3645f6d14947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f3e81995-55b6-4e98-b333-3645f6d14947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_89490991-9565-429e-8831-9c5afa45b1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f3e81995-55b6-4e98-b333-3645f6d14947" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_89490991-9565-429e-8831-9c5afa45b1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_f83d57cf-4b60-4105-8a8b-70885279d369" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_89490991-9565-429e-8831-9c5afa45b1fc" xlink:to="loc_ibrx_NoncurrentAssetsMember_f83d57cf-4b60-4105-8a8b-70885279d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9b5b5838-3b5d-4c3f-97f9-31d4eaad43d6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_082e9633-5a1a-4a24-bdba-847f0f9a46e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_082e9633-5a1a-4a24-bdba-847f0f9a46e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e612b43a-ae98-4430-989d-972e7e4ed5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e612b43a-ae98-4430-989d-972e7e4ed5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_26b911d7-2454-459a-a35c-8d741f3e0696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_26b911d7-2454-459a-a35c-8d741f3e0696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f7d724ad-87d7-4ec1-90cb-47358a4d1dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f7d724ad-87d7-4ec1-90cb-47358a4d1dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_7e3d4d94-2b39-4149-a6b0-67bf04713a7c" xlink:href="ibrx-20231231.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a955fb24-679d-4c99-8da9-31c0f7674371" xlink:to="loc_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_7e3d4d94-2b39-4149-a6b0-67bf04713a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FinancialInstrumentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f846a7c3-5600-4f94-ae63-3623cdffef2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c9f2f48-6207-42a1-8013-f8bd21bb3854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f846a7c3-5600-4f94-ae63-3623cdffef2e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c9f2f48-6207-42a1-8013-f8bd21bb3854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_041ef6f9-80f0-4519-b3b6-39e92373809f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c9f2f48-6207-42a1-8013-f8bd21bb3854" xlink:to="loc_us-gaap_FinancialInstrumentAxis_041ef6f9-80f0-4519-b3b6-39e92373809f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69e56084-f629-4403-9f69-1c62574b4048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_041ef6f9-80f0-4519-b3b6-39e92373809f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69e56084-f629-4403-9f69-1c62574b4048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_a0dd7685-7534-4a9f-a9dc-b395d7b41e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69e56084-f629-4403-9f69-1c62574b4048" xlink:to="loc_us-gaap_DebtSecuritiesMember_a0dd7685-7534-4a9f-a9dc-b395d7b41e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2c9f2f48-6207-42a1-8013-f8bd21bb3854" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_308864e6-ed68-4c53-b9ca-c442450a6dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:to="loc_us-gaap_ImpairmentOfInvestments_308864e6-ed68-4c53-b9ca-c442450a6dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_d3fb99d2-92bf-4d4a-9207-1aed4e87be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:to="loc_us-gaap_MarketableSecurities_d3fb99d2-92bf-4d4a-9207-1aed4e87be7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b4204ca7-3afc-41f4-8532-9d54bbb509d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_83fd6343-c4ea-417e-81fc-7a5009cc98ef" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_b4204ca7-3afc-41f4-8532-9d54bbb509d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a0453fe0-4640-40c0-8634-aef10ddd34db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a0453fe0-4640-40c0-8634-aef10ddd34db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_89399ca6-f0f5-44ae-8d65-83224711a71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_89399ca6-f0f5-44ae-8d65-83224711a71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dce6d9f7-814b-4148-82c0-f64be2e70ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_89399ca6-f0f5-44ae-8d65-83224711a71a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dce6d9f7-814b-4148-82c0-f64be2e70ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_06a90aa2-3e1e-4ca8-9823-598972b8d595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dce6d9f7-814b-4148-82c0-f64be2e70ebb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_06a90aa2-3e1e-4ca8-9823-598972b8d595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffbf0f40-9498-41f7-84a7-8e4e79d03575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffbf0f40-9498-41f7-84a7-8e4e79d03575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffbf0f40-9498-41f7-84a7-8e4e79d03575" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_20bc4653-3253-4b25-b421-0135f5779aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_20bc4653-3253-4b25-b421-0135f5779aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11efc248-ec6d-4ed6-8585-6cc2b6f0262d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11efc248-ec6d-4ed6-8585-6cc2b6f0262d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_997684ef-af27-495c-a303-3a284fc26fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f347c104-a247-47e8-831e-db64bf3457bf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_997684ef-af27-495c-a303-3a284fc26fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5fb2c1f1-231d-48b6-9ed8-9d8db44a85f9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_ecb85d5c-accb-4952-9456-40e30c0f5e76" xlink:href="ibrx-20231231.xsd#ibrx_CurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_CurrentAssetsMember_ecb85d5c-accb-4952-9456-40e30c0f5e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentAssetsMember_fee9e7b8-0237-4ecc-ad34-e31039c2932e" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_NoncurrentAssetsMember_fee9e7b8-0237-4ecc-ad34-e31039c2932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentLiabilitiesMember_305241fa-e92e-4e4b-8660-e60d61597d96" xlink:href="ibrx-20231231.xsd#ibrx_CurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_CurrentLiabilitiesMember_305241fa-e92e-4e4b-8660-e60d61597d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NoncurrentLiabilitiesMember_9fd31c96-82da-4ea2-b77f-d0d38d34b57c" xlink:href="ibrx-20231231.xsd#ibrx_NoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2952c49d-5cf9-4aab-b447-ee3d624b7c47" xlink:to="loc_ibrx_NoncurrentLiabilitiesMember_9fd31c96-82da-4ea2-b77f-d0d38d34b57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_5e570383-221b-4bac-9292-c53cd39e6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_5e570383-221b-4bac-9292-c53cd39e6e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_772707e2-926b-41da-9e89-468cff005d31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_5e570383-221b-4bac-9292-c53cd39e6e2c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_772707e2-926b-41da-9e89-468cff005d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5e170616-5edc-4082-8019-1cba3c7e8353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_772707e2-926b-41da-9e89-468cff005d31" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5e170616-5edc-4082-8019-1cba3c7e8353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_494b78d2-01ea-4bd2-88c3-cedc97f1ba43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_InvestmentTypeAxis_494b78d2-01ea-4bd2-88c3-cedc97f1ba43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_494b78d2-01ea-4bd2-88c3-cedc97f1ba43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d1bd8627-eb45-4447-b90c-9f644d1d8dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:to="loc_us-gaap_EquitySecuritiesMember_d1bd8627-eb45-4447-b90c-9f644d1d8dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtMember_4102f6a6-7a01-4f48-aa08-3d75c368602a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignGovernmentDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:to="loc_us-gaap_ForeignGovernmentDebtMember_4102f6a6-7a01-4f48-aa08-3d75c368602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_d7090d75-965c-47ef-b6cc-39bb00d064b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a53b4c91-d60f-4149-8b7d-421248c376c3" xlink:to="loc_us-gaap_MutualFundMember_d7090d75-965c-47ef-b6cc-39bb00d064b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_f48a9c26-8cbc-46d1-969c-cd3d9d9c9169" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember_5036474e-57e5-4ef0-9091-aee5b03edcd6" xlink:href="ibrx-20231231.xsd#ibrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_ibrx_ContingentConsiderationMember_5036474e-57e5-4ef0-9091-aee5b03edcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockOptionPurchaseLiabilityMember_56406e67-e181-4c2d-8efa-f6fc6e81c2f8" xlink:href="ibrx-20231231.xsd#ibrx_StockOptionPurchaseLiabilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_ibrx_StockOptionPurchaseLiabilityMember_56406e67-e181-4c2d-8efa-f6fc6e81c2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DerivativeLiabilitiesMember_ec9c7582-2ab4-4ef6-8e9e-d33587544b61" xlink:href="ibrx-20231231.xsd#ibrx_DerivativeLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_ibrx_DerivativeLiabilitiesMember_ec9c7582-2ab4-4ef6-8e9e-d33587544b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_572ca0ed-b418-43c5-a073-745ec03c08cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6026ded2-8a6f-4cf2-8e68-c017e8e82f3b" xlink:to="loc_us-gaap_WarrantMember_572ca0ed-b418-43c5-a073-745ec03c08cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6f4bcd9e-ae1d-4b83-8f8a-d513f0e982db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8c35efcc-36bc-4be6-a6ff-3dcfef0c4606" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6f4bcd9e-ae1d-4b83-8f8a-d513f0e982db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_63e45a77-1d05-4b3e-be04-91b4bbc8cc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6f4bcd9e-ae1d-4b83-8f8a-d513f0e982db" xlink:to="loc_us-gaap_WarrantMember_63e45a77-1d05-4b3e-be04-91b4bbc8cc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_69e48cb8-858b-41e4-bce6-4bf182c94acb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ab1b7f30-cc59-4989-b9a1-6dd2e2e000b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ab1b7f30-cc59-4989-b9a1-6dd2e2e000b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_75943b91-f904-40cf-ae0e-cf5512c1746e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4a31083-5c4d-43ba-83b0-2293cceb6aa6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_75943b91-f904-40cf-ae0e-cf5512c1746e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_230264d7-f5a6-4076-bc64-2e2806881c68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_230264d7-f5a6-4076-bc64-2e2806881c68" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_139bc2fc-2485-46a5-9ce7-711c16855168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_139bc2fc-2485-46a5-9ce7-711c16855168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17f699-f471-4ba3-8c9e-e86664560e34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_139bc2fc-2485-46a5-9ce7-711c16855168" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17f699-f471-4ba3-8c9e-e86664560e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a085ee83-efd7-4b3a-b04c-0aeede56306d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d17f699-f471-4ba3-8c9e-e86664560e34" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a085ee83-efd7-4b3a-b04c-0aeede56306d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_81a30058-f2a9-4d7b-8925-54d50d075296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_81a30058-f2a9-4d7b-8925-54d50d075296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_81a30058-f2a9-4d7b-8925-54d50d075296" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_3832db03-141f-40c0-9c71-c44fb935e7d6" xlink:href="ibrx-20231231.xsd#ibrx_December2022WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:to="loc_ibrx_December2022WarrantsMember_3832db03-141f-40c0-9c71-c44fb935e7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_20078eaa-00dd-4233-bb79-babd9dafdd22" xlink:href="ibrx-20231231.xsd#ibrx_February2023WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:to="loc_ibrx_February2023WarrantsMember_20078eaa-00dd-4233-bb79-babd9dafdd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_July2023WarrantsMember_dff357b4-6619-44db-be9e-75721e85e0e8" xlink:href="ibrx-20231231.xsd#ibrx_July2023WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2ef7de4b-67f5-45c1-bf02-a2bceb0a327d" xlink:to="loc_ibrx_July2023WarrantsMember_dff357b4-6619-44db-be9e-75721e85e0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_990b8803-936f-4fb7-b7f4-4fd4a280a576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_990b8803-936f-4fb7-b7f4-4fd4a280a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_990b8803-936f-4fb7-b7f4-4fd4a280a576" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f0f182c0-a53c-4d0d-8de7-136603d210cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f0f182c0-a53c-4d0d-8de7-136603d210cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_7e06ba09-2e86-4c6b-bc7e-a032a9bd31ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_7e06ba09-2e86-4c6b-bc7e-a032a9bd31ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_af3dc347-1a03-40ba-a72b-103f4d95e902" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_af3dc347-1a03-40ba-a72b-103f4d95e902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d39e5d32-8f6e-4933-acc5-28305b32a5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d39e5d32-8f6e-4933-acc5-28305b32a5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_54ad3f93-59fe-48b1-8fd2-2b5aedb0373c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_54ad3f93-59fe-48b1-8fd2-2b5aedb0373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b28b24ec-e7db-4ef7-ad88-5757810a8f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_647e434f-4129-4a05-83db-7f1cf9abe97d" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b28b24ec-e7db-4ef7-ad88-5757810a8f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e5783699-3237-42fa-8c69-2cb6339021f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e5783699-3237-42fa-8c69-2cb6339021f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5783699-3237-42fa-8c69-2cb6339021f8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_38f50ae9-1d6d-4434-ba8a-97e4f8e5d0a5" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_38f50ae9-1d6d-4434-ba8a-97e4f8e5d0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_8d25cde7-6788-44c2-9653-5f200c0b7259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43626216-748d-4301-9ab3-664f83c094d3" xlink:to="loc_us-gaap_PrivatePlacementMember_8d25cde7-6788-44c2-9653-5f200c0b7259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a04960b2-7bc1-44fa-9e47-f8ee01b35cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2affa9c6-fbf2-4214-a13e-9b89a60f7bcf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a04960b2-7bc1-44fa-9e47-f8ee01b35cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CurrentAssetsMember_ea567cc5-d436-4b23-b3de-4b251a95e15c" xlink:href="ibrx-20231231.xsd#ibrx_CurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a04960b2-7bc1-44fa-9e47-f8ee01b35cbe" xlink:to="loc_ibrx_CurrentAssetsMember_ea567cc5-d436-4b23-b3de-4b251a95e15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9e04becb-18d1-4528-b506-655b4b99fb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9e04becb-18d1-4528-b506-655b4b99fb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9e04becb-18d1-4528-b506-655b4b99fb9c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AgencySecuritiesMember_fbf9a1f7-f6eb-4762-a564-8839dfad4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AgencySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:to="loc_us-gaap_AgencySecuritiesMember_fbf9a1f7-f6eb-4762-a564-8839dfad4ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_26af5aaa-9ee0-453a-9e6a-1e1a3e4f9c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ee6b5d8a-1fa2-4826-984e-5a3f8d052491" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_26af5aaa-9ee0-453a-9e6a-1e1a3e4f9c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39cbce9a-4bb8-4eef-adcc-b69182c5f992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_d7d8c8ce-22b0-45cb-ab3f-d1643af576c5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39cbce9a-4bb8-4eef-adcc-b69182c5f992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_c6a2e6f9-45d2-40c2-8cb2-dc69adb44bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39cbce9a-4bb8-4eef-adcc-b69182c5f992" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_c6a2e6f9-45d2-40c2-8cb2-dc69adb44bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d474fe3a-497f-40ec-8a74-c4072780cc81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d474fe3a-497f-40ec-8a74-c4072780cc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4e1043fd-5fe8-4f9a-b276-76482bf25367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d474fe3a-497f-40ec-8a74-c4072780cc81" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4e1043fd-5fe8-4f9a-b276-76482bf25367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentConsiderationMember_ec5b9242-b702-43c5-966a-9f8584b98166" xlink:href="ibrx-20231231.xsd#ibrx_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4e1043fd-5fe8-4f9a-b276-76482bf25367" xlink:to="loc_ibrx_ContingentConsiderationMember_ec5b9242-b702-43c5-966a-9f8584b98166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_86b39f32-776f-48db-bfed-3e45f5399bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_86b39f32-776f-48db-bfed-3e45f5399bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3344a4-7d99-4575-a925-970914c66632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_86b39f32-776f-48db-bfed-3e45f5399bb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3344a4-7d99-4575-a925-970914c66632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f81758cf-dda5-447d-9914-8949027efa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e3344a4-7d99-4575-a925-970914c66632" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f81758cf-dda5-447d-9914-8949027efa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ec254ff4-e81d-4460-a8f3-34da1a5e1b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2145ac77-64a9-4bf2-b2ff-ad0bea89ea0b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ec254ff4-e81d-4460-a8f3-34da1a5e1b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_04cc5a76-cb17-4df4-b894-5ebf44fe8591" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ec254ff4-e81d-4460-a8f3-34da1a5e1b21" xlink:to="loc_ibrx_PromissoryNotesPayableMember_04cc5a76-cb17-4df4-b894-5ebf44fe8591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2054c9a9-718f-4090-a349-cb5ce95cff67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2054c9a9-718f-4090-a349-cb5ce95cff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1289cae4-b267-4f19-ad39-8881c2ee3005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2054c9a9-718f-4090-a349-cb5ce95cff67" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1289cae4-b267-4f19-ad39-8881c2ee3005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_5a223486-4196-4d5d-b4a0-d14d0e169ed2" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1289cae4-b267-4f19-ad39-8881c2ee3005" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_5a223486-4196-4d5d-b4a0-d14d0e169ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2227840a-6f80-478c-93db-3846b52b9508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2227840a-6f80-478c-93db-3846b52b9508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_baff1a5c-65ce-476d-9742-f731c650b6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2227840a-6f80-478c-93db-3846b52b9508" xlink:to="loc_us-gaap_RelatedPartyDomain_baff1a5c-65ce-476d-9742-f731c650b6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cb6df630-b534-4fbd-a054-f301f2f29675" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_baff1a5c-65ce-476d-9742-f731c650b6f6" xlink:to="loc_srt_AffiliatedEntityMember_cb6df630-b534-4fbd-a054-f301f2f29675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_846bffbe-62df-4547-9766-e4a16d7f28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_846bffbe-62df-4547-9766-e4a16d7f28ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07c3716a-c0c3-48ed-822e-22b0d50b52d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_846bffbe-62df-4547-9766-e4a16d7f28ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07c3716a-c0c3-48ed-822e-22b0d50b52d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_00a7e908-9193-408a-b99d-ca15d9eb20ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07c3716a-c0c3-48ed-822e-22b0d50b52d3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_00a7e908-9193-408a-b99d-ca15d9eb20ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c0fca751-3c04-41a2-8f80-ee97e666ae0c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f5f0bb3-1402-45d0-a949-6c634580e874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f5f0bb3-1402-45d0-a949-6c634580e874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_56625d12-fbf4-4ff6-b79e-83ad20e4a9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_56625d12-fbf4-4ff6-b79e-83ad20e4a9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_723496e4-6a74-4d5f-95f5-bcbd2438b799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_723496e4-6a74-4d5f-95f5-bcbd2438b799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fcab38b3-c817-4047-a347-34e3e93d92bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fcab38b3-c817-4047-a347-34e3e93d92bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_9ac88178-c42d-4154-a6d1-0f04bbe9e622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_9ac88178-c42d-4154-a6d1-0f04bbe9e622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d8484da9-0195-46d5-8852-75cb925d9792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d8484da9-0195-46d5-8852-75cb925d9792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue_04938d7e-5c62-4bac-b139-e60c512e89a6" xlink:href="ibrx-20231231.xsd#ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue_04938d7e-5c62-4bac-b139-e60c512e89a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_bed5d12d-8833-403d-b877-09d662b8b582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_bed5d12d-8833-403d-b877-09d662b8b582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ed0d8585-d9de-433c-8d7b-3a5e0432018a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ed0d8585-d9de-433c-8d7b-3a5e0432018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_02e8f481-fc2d-4d07-ad4e-abde80da1db8" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentPrepaymentAndAccruedInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_02e8f481-fc2d-4d07-ad4e-abde80da1db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_ad1a346a-5ab5-4543-aa27-5cbeb0de0849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_ad1a346a-5ab5-4543-aa27-5cbeb0de0849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_880e3a6e-0a62-4fc1-a508-e1b93ade4705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_880e3a6e-0a62-4fc1-a508-e1b93ade4705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c6c265dd-c5cd-4b80-9432-7d4e59bd745b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c6c265dd-c5cd-4b80-9432-7d4e59bd745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7d55af0e-e730-4518-8a93-b0f28f043196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7d55af0e-e730-4518-8a93-b0f28f043196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3f3d5760-7443-45df-b53c-2ce40c19decb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3f3d5760-7443-45df-b53c-2ce40c19decb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c46d5da8-be31-45e5-8773-947cc9c301d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c46d5da8-be31-45e5-8773-947cc9c301d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_699b4023-965d-4486-8acd-37f2943791e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3a83bdbb-0c6f-4474-bd9f-ca39c25df02c" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_699b4023-965d-4486-8acd-37f2943791e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_251d68b7-6718-4f7e-b48c-03baceb16a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:href="ibrx-20231231.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_251d68b7-6718-4f7e-b48c-03baceb16a37" xlink:to="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_0560dd85-6f69-4415-9807-5f9f2c27acba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_0560dd85-6f69-4415-9807-5f9f2c27acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_5dcacba7-2c7a-4e65-967c-84d1bd15d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_0560dd85-6f69-4415-9807-5f9f2c27acba" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_5dcacba7-2c7a-4e65-967c-84d1bd15d4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NationalCancerInstituteMember_2c8e9915-9002-4154-9663-4a05b2fd0691" xlink:href="ibrx-20231231.xsd#ibrx_NationalCancerInstituteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_5dcacba7-2c7a-4e65-967c-84d1bd15d4df" xlink:to="loc_ibrx_NationalCancerInstituteMember_2c8e9915-9002-4154-9663-4a05b2fd0691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_418d7307-f047-44c3-ba66-ba4825b33924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_us-gaap_TypeOfArrangementAxis_418d7307-f047-44c3-ba66-ba4825b33924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c312811-cb8e-4e65-910f-0ed411137fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_418d7307-f047-44c3-ba66-ba4825b33924" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c312811-cb8e-4e65-910f-0ed411137fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_06ac1c91-0e84-43ab-9438-290e76f497af" xlink:href="ibrx-20231231.xsd#ibrx_CooperativeResearchAndDevelopmentAgreement2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c312811-cb8e-4e65-910f-0ed411137fd8" xlink:to="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_06ac1c91-0e84-43ab-9438-290e76f497af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember_b57b6dc1-c7bc-47b1-bf5a-0f7c8d86356d" xlink:href="ibrx-20231231.xsd#ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015Member_06ac1c91-0e84-43ab-9438-290e76f497af" xlink:to="loc_ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember_b57b6dc1-c7bc-47b1-bf5a-0f7c8d86356d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f73c0ebe-0390-49fe-8478-6b373ec8b344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f73c0ebe-0390-49fe-8478-6b373ec8b344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c3042ed7-28f1-4084-b815-7a9bfc5c4f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f73c0ebe-0390-49fe-8478-6b373ec8b344" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c3042ed7-28f1-4084-b815-7a9bfc5c4f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebddbc2d-ea94-4429-ae2e-e1dd478ad6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3042ed7-28f1-4084-b815-7a9bfc5c4f0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebddbc2d-ea94-4429-ae2e-e1dd478ad6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_09f336ef-bbd2-43a6-b126-dd75f443fb20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_821a4921-e2d2-4c31-bfa6-eb7f2ed981f3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_09f336ef-bbd2-43a6-b126-dd75f443fb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisJointVentureMember_5a07e099-bc84-4cba-8621-504fef4d13b4" xlink:href="ibrx-20231231.xsd#ibrx_AmyrisJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_09f336ef-bbd2-43a6-b126-dd75f443fb20" xlink:to="loc_ibrx_AmyrisJointVentureMember_5a07e099-bc84-4cba-8621-504fef4d13b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_dei_LegalEntityAxis_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8d16a3a3-07c8-44c9-aa8d-584c13bb1c93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4ea2e6b8-59a9-4a6e-8c92-1a38ef4c7c70" xlink:to="loc_dei_EntityDomain_8d16a3a3-07c8-44c9-aa8d-584c13bb1c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AmyrisIncMember_b05b7521-4f49-4758-a152-0ac8de2a674a" xlink:href="ibrx-20231231.xsd#ibrx_AmyrisIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8d16a3a3-07c8-44c9-aa8d-584c13bb1c93" xlink:to="loc_ibrx_AmyrisIncMember_b05b7521-4f49-4758-a152-0ac8de2a674a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:href="ibrx-20231231.xsd#ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable_71803b5d-cf88-4864-af1a-278223efda40" xlink:to="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_13462e25-0bc9-4c54-b626-cf356e66d070" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_13462e25-0bc9-4c54-b626-cf356e66d070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualProjectFundingAmount_f9d8fdcd-b89d-4ed7-8859-beea903073af" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualProjectFundingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_ibrx_CollaborationAgreementsAnnualProjectFundingAmount_f9d8fdcd-b89d-4ed7-8859-beea903073af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities_413cfa97-8172-4768-aaee-5a3030321bf8" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities_413cfa97-8172-4768-aaee-5a3030321bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_354079dd-a3bb-4755-8236-a8fa77997086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_354079dd-a3bb-4755-8236-a8fa77997086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8934a659-d6f6-4b1a-8218-b50f50b0a002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8934a659-d6f6-4b1a-8218-b50f50b0a002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_854a355d-65d0-4ea7-b504-312c2bf5ba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_854a355d-65d0-4ea7-b504-312c2bf5ba5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_90f285a5-0d44-4af3-9171-25f7e75429ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems_6b5736d6-21be-444e-96f6-7edab3fc307c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_90f285a5-0d44-4af3-9171-25f7e75429ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_c7c11574-e40b-4c55-89c1-af6c5d2f9694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:href="ibrx-20231231.xsd#ibrx_LicensingAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_c7c11574-e40b-4c55-89c1-af6c5d2f9694" xlink:to="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d45ff0fb-cdcb-4e15-9ad1-eb2b9b1d6004" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A3MIPCAndAAHIAgreementMember_596fca9c-475f-406a-90a3-e579e26f562b" xlink:href="ibrx-20231231.xsd#ibrx_A3MIPCAndAAHIAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:to="loc_ibrx_A3MIPCAndAAHIAgreementMember_596fca9c-475f-406a-90a3-e579e26f562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AAHIMember_4b15855c-dca8-41fc-9fe8-f37a94faf043" xlink:href="ibrx-20231231.xsd#ibrx_AAHIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:to="loc_ibrx_AAHIMember_4b15855c-dca8-41fc-9fe8-f37a94faf043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ViractaMember_c3423bb9-4dc5-4d71-b133-59ea1b7ff199" xlink:href="ibrx-20231231.xsd#ibrx_ViractaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ca3e559-466e-4400-8efd-56afded65c6f" xlink:to="loc_ibrx_ViractaMember_c3423bb9-4dc5-4d71-b133-59ea1b7ff199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_943d371b-760f-425b-8c6e-ae49de9c9e60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_943d371b-760f-425b-8c6e-ae49de9c9e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_943d371b-760f-425b-8c6e-ae49de9c9e60" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_74863a73-43c8-4ef1-bda5-d427060f9866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_74863a73-43c8-4ef1-bda5-d427060f9866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SponsoredResearchAgreementMember_9f6efdc5-81dc-46cf-a2ad-130071280827" xlink:href="ibrx-20231231.xsd#ibrx_SponsoredResearchAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:to="loc_ibrx_SponsoredResearchAgreementMember_9f6efdc5-81dc-46cf-a2ad-130071280827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicenseAgreementMember_4969dff4-81ac-4f09-aff1-4b1801686f01" xlink:href="ibrx-20231231.xsd#ibrx_LicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8d3c301c-0957-4ab8-ba1e-a405053afbee" xlink:to="loc_ibrx_LicenseAgreementMember_4969dff4-81ac-4f09-aff1-4b1801686f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_srt_RangeAxis_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c0eef22-bc0b-4527-9b3c-cca178bfa5aa" xlink:to="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7bc81c1c-8a40-4b14-be85-76e2c6af5e08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:to="loc_srt_MinimumMember_7bc81c1c-8a40-4b14-be85-76e2c6af5e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_da07088f-1d49-47b4-aace-3daa9157b1ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_820c998b-f07d-4713-8e4f-91c40506ce76" xlink:to="loc_srt_MaximumMember_da07088f-1d49-47b4-aace-3daa9157b1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_1f0c235d-7c92-4a03-a56b-f843b93617e9" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_1f0c235d-7c92-4a03-a56b-f843b93617e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis_1f0c235d-7c92-4a03-a56b-f843b93617e9" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_66861e89-c569-427d-94b2-beed02cb5836" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember_66861e89-c569-427d-94b2-beed02cb5836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_b2af0e8c-3d53-4726-bc84-d8b78c3567fe" xlink:href="ibrx-20231231.xsd#ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain_3c6e4cca-2574-4de1-ad04-74033dd2956a" xlink:to="loc_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember_b2af0e8c-3d53-4726-bc84-d8b78c3567fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:href="ibrx-20231231.xsd#ibrx_LicensingAgreementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementTable_26aba144-3cfd-4dbf-be1d-7f351f8a3515" xlink:to="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_b7df4e2a-bd3e-4c7a-86f1-b3a3ce2ae8cb" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsPeriodicLicensePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsPeriodicLicensePayments_b7df4e2a-bd3e-4c7a-86f1-b3a3ce2ae8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_f8e36f6d-61a1-421e-bcd1-d414283ce200" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment_f8e36f6d-61a1-421e-bcd1-d414283ce200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_56760ac8-cbec-49f1-b167-1d18bdff0c08" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFees_56760ac8-cbec-49f1-b167-1d18bdff0c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_66bed66c-afd8-4d81-a217-6a92407c7489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_66bed66c-afd8-4d81-a217-6a92407c7489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNumberOfLicenseAgreements_e8c6f65b-7f31-4544-901c-c0a866b94752" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsNumberOfLicenseAgreements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsNumberOfLicenseAgreements_e8c6f65b-7f31-4544-901c-c0a866b94752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_a48afc40-aa02-48cf-b773-6cfe92bdc1aa" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsNonrefundableUpfrontPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment_a48afc40-aa02-48cf-b773-6cfe92bdc1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_47804c8f-f617-46a2-b6a2-b81b95f2505b" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum_47804c8f-f617-46a2-b6a2-b81b95f2505b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestoneFees_c6dc4a66-f600-4306-aeca-fafb6952a1be" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestoneFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsMilestoneFees_c6dc4a66-f600-4306-aeca-fafb6952a1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsTerminationFee_786b7a81-169b-4fcc-b471-67a36d87d7e5" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsTerminationFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsTerminationFee_786b7a81-169b-4fcc-b471-67a36d87d7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable_d14953ce-8c5a-4c47-bbaa-c1bcfbb46ffe" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable_d14953ce-8c5a-4c47-bbaa-c1bcfbb46ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_1d9801be-e88e-4e5e-853a-27cb2531c7ba" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities_1d9801be-e88e-4e5e-853a-27cb2531c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f0542f8-4cb2-43a5-9fbd-a6ee6f8d3ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f0542f8-4cb2-43a5-9fbd-a6ee6f8d3ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_44d13aa9-bb50-4dea-b8f2-edd0296e3e25" xlink:href="ibrx-20231231.xsd#ibrx_CollaborationAgreementsMilestonePaymentAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LicensingAgreementLineItems_6a856c2e-def1-457a-bf50-b9ed26d27dfc" xlink:to="loc_ibrx_CollaborationAgreementsMilestonePaymentAmount_44d13aa9-bb50-4dea-b8f2-edd0296e3e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_eb3db995-ce3b-477e-a403-3977613dec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_eb3db995-ce3b-477e-a403-3977613dec7d" xlink:to="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_293add47-1ab7-4d41-a179-a805927307a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:to="loc_us-gaap_AssetAcquisitionAxis_293add47-1ab7-4d41-a179-a805927307a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e4dfead6-ffc8-4cb6-8328-889519fe62ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_293add47-1ab7-4d41-a179-a805927307a7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e4dfead6-ffc8-4cb6-8328-889519fe62ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_00be56a5-ba53-4a5e-bdbb-188a7f5c74c4" xlink:href="ibrx-20231231.xsd#ibrx_DunkirkFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e4dfead6-ffc8-4cb6-8328-889519fe62ef" xlink:to="loc_ibrx_DunkirkFacilityMember_00be56a5-ba53-4a5e-bdbb-188a7f5c74c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d48d5042-3671-4b90-848d-27ffe90ea7e1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:to="loc_srt_CounterpartyNameAxis_d48d5042-3671-4b90-848d-27ffe90ea7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c1cc837-d2ed-4ae4-bb2f-bc9326b662e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d48d5042-3671-4b90-848d-27ffe90ea7e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c1cc837-d2ed-4ae4-bb2f-bc9326b662e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StateOfNewYorkMember_fdd82a25-630a-40dc-ba62-ebd8bc80f75b" xlink:href="ibrx-20231231.xsd#ibrx_StateOfNewYorkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c1cc837-d2ed-4ae4-bb2f-bc9326b662e8" xlink:to="loc_ibrx_StateOfNewYorkMember_fdd82a25-630a-40dc-ba62-ebd8bc80f75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b73136b8-af13-4ab9-8f06-4da27e9a448e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:to="loc_srt_RangeAxis_b73136b8-af13-4ab9-8f06-4da27e9a448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b73136b8-af13-4ab9-8f06-4da27e9a448e" xlink:to="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_421360bc-991a-4f26-8e53-c93fed00e583" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:to="loc_srt_MinimumMember_421360bc-991a-4f26-8e53-c93fed00e583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89ce5b20-de6f-47ff-a800-64f7965ac653" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_913ed02d-d3b8-4105-b5b4-539639f9802a" xlink:to="loc_srt_MaximumMember_89ce5b20-de6f-47ff-a800-64f7965ac653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_e7f2d690-cfd6-4438-ab3e-ff3b732cd520" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_53891ddd-09bb-41f9-9e96-fecf7f51fece" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFeetOfFacilityLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_53891ddd-09bb-41f9-9e96-fecf7f51fece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_f847de23-e528-4182-959f-d9a51ad8f952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_f847de23-e528-4182-959f-d9a51ad8f952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_51508dc4-4df9-436b-9880-0ff44d1e0283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_51508dc4-4df9-436b-9880-0ff44d1e0283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_3aae7b7d-0ec5-439f-b4ee-ced12f81865c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_3aae7b7d-0ec5-439f-b4ee-ced12f81865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_6882f730-678e-4d1a-a07e-884e53ee68fc" xlink:href="ibrx-20231231.xsd#ibrx_LeaseOperatingLeaseAnnualLeasePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseOperatingLeaseAnnualLeasePayment_6882f730-678e-4d1a-a07e-884e53ee68fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cb36a00-c312-4b55-89b8-0a24ef67f349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_8cb36a00-c312-4b55-89b8-0a24ef67f349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions_a41a6885-5394-4525-8fcc-f9a6a582c168" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions_a41a6885-5394-4525-8fcc-f9a6a582c168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b17f055d-9d22-4efc-b5a3-bfd45889d860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b17f055d-9d22-4efc-b5a3-bfd45889d860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_b282ad3c-d32e-4a47-8e5b-ba68ff7bbe64" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm_b282ad3c-d32e-4a47-8e5b-ba68ff7bbe64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_ca75a459-72f5-41ba-8776-2b1747c7b320" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm_ca75a459-72f5-41ba-8776-2b1747c7b320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_db397731-472d-4357-b6c0-0196433abc1c" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears_db397731-472d-4357-b6c0-0196433abc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_41d7ea77-09a6-4ca4-a071-40dad388de28" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears_41d7ea77-09a6-4ca4-a071-40dad388de28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseholdInterestGovernmentFundingAvailable_54830af5-0b8b-48c6-86d3-af8a23a580b9" xlink:href="ibrx-20231231.xsd#ibrx_LeaseholdInterestGovernmentFundingAvailable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_ibrx_LeaseholdInterestGovernmentFundingAvailable_54830af5-0b8b-48c6-86d3-af8a23a580b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d47ee854-8f43-46fc-b8a0-fd4704f83cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_RestructuringCharges_d47ee854-8f43-46fc-b8a0-fd4704f83cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_63462a03-7209-4be3-8608-36d91ceedefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_76fbd946-effa-41dc-80d4-ecffe3c5ee2b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_63462a03-7209-4be3-8608-36d91ceedefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_b4e3f2c7-bd02-4103-b667-cf641a96c446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_b4e3f2c7-bd02-4103-b667-cf641a96c446" xlink:to="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_103bf308-97fb-4c9f-9f2b-8f95263ff3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_103bf308-97fb-4c9f-9f2b-8f95263ff3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ffb34095-a3c8-4e95-8249-3469325dcf90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_103bf308-97fb-4c9f-9f2b-8f95263ff3dd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ffb34095-a3c8-4e95-8249-3469325dcf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DunkirkFacilityMember_446dce84-807b-4e04-87ce-8b268f92b5d1" xlink:href="ibrx-20231231.xsd#ibrx_DunkirkFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ffb34095-a3c8-4e95-8249-3469325dcf90" xlink:to="loc_ibrx_DunkirkFacilityMember_446dce84-807b-4e04-87ce-8b268f92b5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ec5bea3-95cc-4be8-9c0a-d5f0c810da67" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_731fcb61-add9-4d9b-a42c-b68b2d94e2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_731fcb61-add9-4d9b-a42c-b68b2d94e2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OrganizedWorkforceMember_1a23c6a7-6ef2-4bff-88c9-5177a421fb83" xlink:href="ibrx-20231231.xsd#ibrx_OrganizedWorkforceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_41e77ec1-b90e-4f38-b274-011c62a2376e" xlink:to="loc_ibrx_OrganizedWorkforceMember_1a23c6a7-6ef2-4bff-88c9-5177a421fb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_a5056235-69c7-49d4-9a44-f0ca1d7405f8" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_46322a86-9482-49dd-ae45-e027bfcf1b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_ConstructionInProgressGross_46322a86-9482-49dd-ae45-e027bfcf1b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_727ef976-3e96-426b-ac88-5400a4eb7178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_727ef976-3e96-426b-ac88-5400a4eb7178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_355da6f8-1e40-4192-90d7-4c7d3cf7a44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_355da6f8-1e40-4192-90d7-4c7d3cf7a44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_a0482ce8-ba94-426c-8b9d-d9f539f6dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_a0482ce8-ba94-426c-8b9d-d9f539f6dfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_99e4811a-a6bf-46b4-9f60-a704821d9ee5" xlink:href="ibrx-20231231.xsd#ibrx_AssetAcquisitionFairValueOfAssetsAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_ibrx_AssetAcquisitionFairValueOfAssetsAcquired_99e4811a-a6bf-46b4-9f60-a704821d9ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1c5b473b-4652-4dde-a38f-a24305075698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a49bd829-1239-4076-aede-3326ee8b683a" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1c5b473b-4652-4dde-a38f-a24305075698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c757eae8-cd8d-45dc-ba04-7528b1d24199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c757eae8-cd8d-45dc-ba04-7528b1d24199" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_64185063-98ba-4f4d-ac23-e992e765df3c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_dei_LegalEntityAxis_64185063-98ba-4f4d-ac23-e992e765df3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c61077b2-225d-43b8-8df5-bf85b21d2bc8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_64185063-98ba-4f4d-ac23-e992e765df3c" xlink:to="loc_dei_EntityDomain_c61077b2-225d-43b8-8df5-bf85b21d2bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VivaBioCellMember_35e96ef8-77cb-4e63-b9a6-79a403e2d78c" xlink:href="ibrx-20231231.xsd#ibrx_VivaBioCellMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c61077b2-225d-43b8-8df5-bf85b21d2bc8" xlink:to="loc_ibrx_VivaBioCellMember_35e96ef8-77cb-4e63-b9a6-79a403e2d78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9c57757a-fbcf-4d7e-b936-2c18afad5168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9c57757a-fbcf-4d7e-b936-2c18afad5168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d28a84b5-b14a-4e4a-98d0-1ec2f66ba746" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9c57757a-fbcf-4d7e-b936-2c18afad5168" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d28a84b5-b14a-4e4a-98d0-1ec2f66ba746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember_c6d5bc02-951b-4a73-878a-a1b35dffd765" xlink:href="ibrx-20231231.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d28a84b5-b14a-4e4a-98d0-1ec2f66ba746" xlink:to="loc_ibrx_AltorBioScienceLLCMember_c6d5bc02-951b-4a73-878a-a1b35dffd765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09049093-770b-4eba-995b-23f148f02e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09049093-770b-4eba-995b-23f148f02e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_09049093-770b-4eba-995b-23f148f02e1e" xlink:to="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DrSoonShiongAndRelatedPartyMember_64fb4b73-599b-4043-8c81-28d3cbd8a6e4" xlink:href="ibrx-20231231.xsd#ibrx_DrSoonShiongAndRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:to="loc_ibrx_DrSoonShiongAndRelatedPartyMember_64fb4b73-599b-4043-8c81-28d3cbd8a6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorStockholdersMember_8fe5e9a7-c8c6-43f9-b7cb-da1df131b515" xlink:href="ibrx-20231231.xsd#ibrx_AltorStockholdersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_856da5d1-eb98-4771-98e7-4d877b0b1743" xlink:to="loc_ibrx_AltorStockholdersMember_8fe5e9a7-c8c6-43f9-b7cb-da1df131b515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_649855e8-41a3-4534-b54a-19f3331b47f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_649855e8-41a3-4534-b54a-19f3331b47f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_fb088bad-ff16-4565-b069-4b27a98340bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_649855e8-41a3-4534-b54a-19f3331b47f4" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_fb088bad-ff16-4565-b069-4b27a98340bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_75b4a383-c2c4-4f49-9e32-8065a7c34cbc" xlink:href="ibrx-20231231.xsd#ibrx_ContingentValueRightsObligationSalesMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_fb088bad-ff16-4565-b069-4b27a98340bd" xlink:to="loc_ibrx_ContingentValueRightsObligationSalesMilestoneMember_75b4a383-c2c4-4f49-9e32-8065a7c34cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_60afc172-dc23-47ad-b77d-196f5e2dd6b9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_fba88ec4-a1c2-4dc0-a980-62df393cbbda" xlink:href="ibrx-20231231.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_PercentageOfWhollyOwnedSubsidiary_fba88ec4-a1c2-4dc0-a980-62df393cbbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e2c3ff2a-0a97-4da2-86cd-a2a89f71a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e2c3ff2a-0a97-4da2-86cd-a2a89f71a48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_ae909009-044b-43bf-bd64-281065c0417a" xlink:href="ibrx-20231231.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned_ae909009-044b-43bf-bd64-281065c0417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_7c1d9aa0-a35f-4d8e-9e47-e36aaaca73c4" xlink:href="ibrx-20231231.xsd#ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements_7c1d9aa0-a35f-4d8e-9e47-e36aaaca73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_8fcc7658-89f0-47f9-9bae-27eaaab8718c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_8fcc7658-89f0-47f9-9bae-27eaaab8718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ContingentValueRightsObligations_a5c1d4af-5b44-4432-a20c-ec46075f09ab" xlink:href="ibrx-20231231.xsd#ibrx_ContingentValueRightsObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_ContingentValueRightsObligations_a5c1d4af-5b44-4432-a20c-ec46075f09ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_a28040cd-4510-4300-95d8-c9b8d5c6981b" xlink:href="ibrx-20231231.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50a59c66-adc5-4b71-a9a2-2a7e0c6a48d3" xlink:to="loc_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation_a28040cd-4510-4300-95d8-c9b8d5c6981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CommitmentsandContingenciesLitigationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d6aa819-1052-4eb5-baa7-5eaedd10db50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:href="ibrx-20231231.xsd#ibrx_LitigationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d6aa819-1052-4eb5-baa7-5eaedd10db50" xlink:to="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4559428-8d68-4655-887e-86af27026523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0eef44fd-1fbf-4039-9fa9-4eb42c08e0ed" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4559428-8d68-4655-887e-86af27026523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AltorBioScienceLLCMember_5435cb3e-d72c-4436-9214-a0ded68aa980" xlink:href="ibrx-20231231.xsd#ibrx_AltorBioScienceLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4559428-8d68-4655-887e-86af27026523" xlink:to="loc_ibrx_AltorBioScienceLLCMember_5435cb3e-d72c-4436-9214-a0ded68aa980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_44582f36-ed47-411f-8543-729d4feff8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_44582f36-ed47-411f-8543-729d4feff8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12205356-e9c3-4704-986c-abfe11359aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44582f36-ed47-411f-8543-729d4feff8a7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12205356-e9c3-4704-986c-abfe11359aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_2bd00846-4132-4a29-9c2b-f5debab478f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12205356-e9c3-4704-986c-abfe11359aac" xlink:to="loc_us-gaap_PrivatePlacementMember_2bd00846-4132-4a29-9c2b-f5debab478f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_srt_LitigationCaseAxis_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dcbd6c64-ea3d-4cc3-b0f4-90294b2dd18c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_1f82a07c-ca25-44e2-8728-c0b8d64a5e2f" xlink:to="loc_srt_LitigationCaseTypeDomain_dcbd6c64-ea3d-4cc3-b0f4-90294b2dd18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_3fa043ca-e1dc-471b-9873-3224a141cd50" xlink:href="ibrx-20231231.xsd#ibrx_SorrentoTherapeuticsIncLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_dcbd6c64-ea3d-4cc3-b0f4-90294b2dd18c" xlink:to="loc_ibrx_SorrentoTherapeuticsIncLitigationMember_3fa043ca-e1dc-471b-9873-3224a141cd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c00e7147-e675-4c73-9ae2-d2ee7d826456" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c00e7147-e675-4c73-9ae2-d2ee7d826456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c00e7147-e675-4c73-9ae2-d2ee7d826456" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_aa187f20-0462-4760-997c-0edf1620a9de" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:to="loc_ibrx_NantCellInc.Member_aa187f20-0462-4760-997c-0edf1620a9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_1d3cedbc-1599-4045-b7ee-cb6f424101ad" xlink:href="ibrx-20231231.xsd#ibrx_NANTibodyLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_f6e43325-12fc-436a-9c2f-04a26dc4591e" xlink:to="loc_ibrx_NANTibodyLLCMember_1d3cedbc-1599-4045-b7ee-cb6f424101ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ffa97845-6249-4d7e-bcea-af70739bd056" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_srt_OwnershipAxis_ffa97845-6249-4d7e-bcea-af70739bd056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ed4c0139-9db3-4178-92bb-194785a97406" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_ffa97845-6249-4d7e-bcea-af70739bd056" xlink:to="loc_srt_OwnershipDomain_ed4c0139-9db3-4178-92bb-194785a97406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NANTibodyLLCMember_2abce382-5d98-4f17-b199-c29fa74f6fd6" xlink:href="ibrx-20231231.xsd#ibrx_NANTibodyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ed4c0139-9db3-4178-92bb-194785a97406" xlink:to="loc_ibrx_NANTibodyLLCMember_2abce382-5d98-4f17-b199-c29fa74f6fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:href="ibrx-20231231.xsd#ibrx_LitigationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationTable_a62f1163-5aa4-4054-ad11-72bbc8fae5a1" xlink:to="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfDissentingShares_2712d1cf-60fa-4fb6-8dd0-1bdc4623a0a0" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfDissentingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_NumberOfDissentingShares_2712d1cf-60fa-4fb6-8dd0-1bdc4623a0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_0949741c-8dea-4a2b-bec6-df2c4e40dff0" xlink:href="ibrx-20231231.xsd#ibrx_LitigationSettlementNumberOfSharesToBeIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_LitigationSettlementNumberOfSharesToBeIssued_0949741c-8dea-4a2b-bec6-df2c4e40dff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_0e6c3bd9-3463-4210-89ca-cc529cb97fd8" xlink:href="ibrx-20231231.xsd#ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares_0e6c3bd9-3463-4210-89ca-cc529cb97fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_2ba67055-0a7c-4863-b6a1-b67b519237dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_SharesIssued_2ba67055-0a7c-4863-b6a1-b67b519237dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_e6ed3f5d-d3bb-408a-a87c-06c6171348f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_e6ed3f5d-d3bb-408a-a87c-06c6171348f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_4e31e322-1aaa-4f2b-bc50-b9ea18b8f270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_LitigationReserve_4e31e322-1aaa-4f2b-bc50-b9ea18b8f270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_f411352b-c29e-46f6-96b1-d9bb1d39ba71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_f411352b-c29e-46f6-96b1-d9bb1d39ba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_5daabbac-d194-4f7c-a6ca-6b5e702ffc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_5daabbac-d194-4f7c-a6ca-6b5e702ffc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LitigationSettlementInterestPercent_051795ea-74a5-4d0a-a0ad-b0512626a826" xlink:href="ibrx-20231231.xsd#ibrx_LitigationSettlementInterestPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_ibrx_LitigationSettlementInterestPercent_051795ea-74a5-4d0a-a0ad-b0512626a826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_04e938eb-aa43-4033-9eb0-a4ae79a17f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_04e938eb-aa43-4033-9eb0-a4ae79a17f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2ed91c2b-e59f-443c-87de-8162e25f08fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LitigationLineItems_e2d5e4be-ee65-4886-bfec-aa2a098b794e" xlink:to="loc_us-gaap_MinorityInterest_2ed91c2b-e59f-443c-87de-8162e25f08fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11b34660-9296-4473-ad1d-e9f42f8e6c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_80808d1a-00ad-45df-9f30-207ead34943b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11b34660-9296-4473-ad1d-e9f42f8e6c66" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_80808d1a-00ad-45df-9f30-207ead34943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_a6902b3d-c7dd-4edb-bfbe-404705a16c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_80808d1a-00ad-45df-9f30-207ead34943b" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_a6902b3d-c7dd-4edb-bfbe-404705a16c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_a6902b3d-c7dd-4edb-bfbe-404705a16c56" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CGMPBatchesMember_713de1f1-e3be-4bcd-9c35-163851bf263b" xlink:href="ibrx-20231231.xsd#ibrx_CGMPBatchesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:to="loc_ibrx_CGMPBatchesMember_713de1f1-e3be-4bcd-9c35-163851bf263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember_2c093a83-c6cf-4983-8ef1-dabd41359be6" xlink:href="ibrx-20231231.xsd#ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:to="loc_ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember_2c093a83-c6cf-4983-8ef1-dabd41359be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LaboratoryCleanroomServiceCostsMember_b206cf5a-a9c4-42dc-9c11-73b41fa860bf" xlink:href="ibrx-20231231.xsd#ibrx_LaboratoryCleanroomServiceCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_fcac1393-61da-400b-8364-e2c1c6071bd1" xlink:to="loc_ibrx_LaboratoryCleanroomServiceCostsMember_b206cf5a-a9c4-42dc-9c11-73b41fa860bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_80808d1a-00ad-45df-9f30-207ead34943b" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6699aad8-0b0a-43cb-81c8-b04cd4b84b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_6699aad8-0b0a-43cb-81c8-b04cd4b84b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_e10bab2e-e808-4e58-a897-c384705fe5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_e10bab2e-e808-4e58-a897-c384705fe5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_6cd5f35f-4e85-43a4-8e2d-9c85e484e16e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_6cd5f35f-4e85-43a4-8e2d-9c85e484e16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_bd023147-1f1e-4204-89ab-1d9668b834ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_28edfa3d-3c61-4f4d-b29f-f24c54635cc8" xlink:to="loc_us-gaap_PurchaseObligation_bd023147-1f1e-4204-89ab-1d9668b834ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e89d5c21-175e-4b69-ad59-ae16c2d120e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_912baf6a-60cb-475c-b236-388ebed155c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e89d5c21-175e-4b69-ad59-ae16c2d120e1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_912baf6a-60cb-475c-b236-388ebed155c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97db1652-0ec9-49c4-8742-bb657c28536c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_912baf6a-60cb-475c-b236-388ebed155c5" xlink:to="loc_srt_RangeAxis_97db1652-0ec9-49c4-8742-bb657c28536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_97db1652-0ec9-49c4-8742-bb657c28536c" xlink:to="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_60cdfd6e-943c-4a1f-9ae2-9a5465064038" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:to="loc_srt_MinimumMember_60cdfd6e-943c-4a1f-9ae2-9a5465064038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f0a9ff6-aad2-4203-a7d4-a1ffe105e299" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_591ba71e-9e2e-4566-be7e-bf53c1c4e104" xlink:to="loc_srt_MaximumMember_5f0a9ff6-aad2-4203-a7d4-a1ffe105e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_912baf6a-60cb-475c-b236-388ebed155c5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61659863-25c6-4c9b-9e28-c3a62f55ac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_61659863-25c6-4c9b-9e28-c3a62f55ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_22a31a5c-5999-4fff-b674-2095737c8630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_22a31a5c-5999-4fff-b674-2095737c8630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_0084e2fa-ced3-48c5-a52a-660a995b55cd" xlink:href="ibrx-20231231.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_54584898-45a4-4357-881d-b1c225f92d1a" xlink:to="loc_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_0084e2fa-ced3-48c5-a52a-660a995b55cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_09881d67-cc2e-4eec-89c8-9a2bbd228fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_09881d67-cc2e-4eec-89c8-9a2bbd228fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_bf3f1035-f8c4-4a17-b6ce-2d04f7300979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_bf3f1035-f8c4-4a17-b6ce-2d04f7300979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRightOfUseAsset_3a1ad81e-e083-4d4b-96ae-a12e7b0bc687" xlink:href="ibrx-20231231.xsd#ibrx_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_ibrx_LeaseRightOfUseAsset_3a1ad81e-e083-4d4b-96ae-a12e7b0bc687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fe4d88ee-1afe-42e2-a6ac-45b83b44c62e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fe4d88ee-1afe-42e2-a6ac-45b83b44c62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5e879cec-9faf-4749-ba78-7ce5b50b447b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5e879cec-9faf-4749-ba78-7ce5b50b447b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a53b1e06-540b-474f-b4b0-5050f63c2e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a53b1e06-540b-474f-b4b0-5050f63c2e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ff838d11-b43d-4bd8-a82c-80e7a20852b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ff838d11-b43d-4bd8-a82c-80e7a20852b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_34b7abfd-0f04-4199-8ae6-596ae9dbc9db" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_ibrx_LeaseLiability_34b7abfd-0f04-4199-8ae6-596ae9dbc9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_70adb00c-050f-455a-af01-4011a5949b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_70adb00c-050f-455a-af01-4011a5949b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_02fcfdd6-7449-4847-9c7d-706a7179287c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_02fcfdd6-7449-4847-9c7d-706a7179287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f59bc944-75bd-4582-934f-11bf5c05055e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d784c4c6-82dc-48e4-bbfe-a2c168be7643" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f59bc944-75bd-4582-934f-11bf5c05055e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSummaryofInformationRegardingLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f870eca2-8ae0-4217-9798-80dd62e4cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3f25e0d2-02bc-4962-ab0a-b7532c40f26e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f870eca2-8ae0-4217-9798-80dd62e4cdc0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3f25e0d2-02bc-4962-ab0a-b7532c40f26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_005d26fd-4d08-47c7-b235-ec501d4b7be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f870eca2-8ae0-4217-9798-80dd62e4cdc0" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_005d26fd-4d08-47c7-b235-ec501d4b7be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cfc6e2dd-68dd-4344-99f0-8f42a776925f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f870eca2-8ae0-4217-9798-80dd62e4cdc0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cfc6e2dd-68dd-4344-99f0-8f42a776925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0cd356c6-a266-4973-a07e-239c1967c783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f870eca2-8ae0-4217-9798-80dd62e4cdc0" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0cd356c6-a266-4973-a07e-239c1967c783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsComponentsofLeaseExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_95d73cc5-0728-45e0-8924-8ee128d1a2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_18f84807-2a6b-4384-bf31-fd8e08d2e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_95d73cc5-0728-45e0-8924-8ee128d1a2c4" xlink:to="loc_us-gaap_OperatingLeaseCost_18f84807-2a6b-4384-bf31-fd8e08d2e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_0ad50738-811d-4c8e-8bf7-baee9dd6c6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_95d73cc5-0728-45e0-8924-8ee128d1a2c4" xlink:to="loc_us-gaap_ShortTermLeaseCost_0ad50738-811d-4c8e-8bf7-baee9dd6c6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_467c7a2a-3773-48bd-9252-2fcf8150ccf4" xlink:href="ibrx-20231231.xsd#ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_95d73cc5-0728-45e0-8924-8ee128d1a2c4" xlink:to="loc_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense_467c7a2a-3773-48bd-9252-2fcf8150ccf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ba847245-f2f6-4c58-9807-f8f6266f21f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_95d73cc5-0728-45e0-8924-8ee128d1a2c4" xlink:to="loc_us-gaap_VariableLeaseCost_ba847245-f2f6-4c58-9807-f8f6266f21f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_922cebf6-0322-4b5a-9c1a-7b421c1a3503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_95d73cc5-0728-45e0-8924-8ee128d1a2c4" xlink:to="loc_us-gaap_LeaseCost_922cebf6-0322-4b5a-9c1a-7b421c1a3503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c8b2feee-841b-46e8-85ec-595415146274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9d5c880a-a3a1-460d-acdb-ae352b03bc69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c8b2feee-841b-46e8-85ec-595415146274" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9d5c880a-a3a1-460d-acdb-ae352b03bc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_70fc06b7-531c-41e0-b32a-a6be679f2e21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9d5c880a-a3a1-460d-acdb-ae352b03bc69" xlink:to="loc_us-gaap_OperatingLeasePayments_70fc06b7-531c-41e0-b32a-a6be679f2e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_5d4a343b-8937-44ef-bada-cfdfaa59dda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9d5c880a-a3a1-460d-acdb-ae352b03bc69" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_5d4a343b-8937-44ef-bada-cfdfaa59dda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1eb6855f-6909-4148-8122-3e3407b99a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_9d5c880a-a3a1-460d-acdb-ae352b03bc69" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1eb6855f-6909-4148-8122-3e3407b99a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f023ed3f-a647-4a16-a772-ed9ed6baac90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f023ed3f-a647-4a16-a772-ed9ed6baac90" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_011ec7a2-5a40-4e3a-9c53-76d04ec692b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_011ec7a2-5a40-4e3a-9c53-76d04ec692b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a7892118-93ab-4343-a207-40188a35c997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a7892118-93ab-4343-a207-40188a35c997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_94dae782-4556-4a2b-8d77-152f81ef6d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_94dae782-4556-4a2b-8d77-152f81ef6d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0fe10447-4ddd-46bf-838c-266fa4bd95c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0fe10447-4ddd-46bf-838c-266fa4bd95c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f09d57a1-6095-4eaa-8c44-3408fd165c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f09d57a1-6095-4eaa-8c44-3408fd165c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9107242d-0f0f-48f4-846a-c94daa3d3485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9107242d-0f0f-48f4-846a-c94daa3d3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a5ca3a5a-ba89-4ea3-aa86-b5228d764215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a5ca3a5a-ba89-4ea3-aa86-b5228d764215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_26cfda7d-8e7a-4b91-9fc5-bf39a8e0000f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_26cfda7d-8e7a-4b91-9fc5-bf39a8e0000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_5b1ea70b-95f7-4ae4-8d6a-4f8a66500b50" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable_5b1ea70b-95f7-4ae4-8d6a-4f8a66500b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f7750021-58ad-4d57-9078-f7910f3c4840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ce2fa222-30e0-47a3-96f5-4f3b770750e3" xlink:to="loc_us-gaap_OperatingLeaseLiability_f7750021-58ad-4d57-9078-f7910f3c4840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f023ed3f-a647-4a16-a772-ed9ed6baac90" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c2b95647-1371-4598-af83-d9c81e0fc86f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c2b95647-1371-4598-af83-d9c81e0fc86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_79a416b6-00b1-4161-a632-bbf831310e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_79a416b6-00b1-4161-a632-bbf831310e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5db51f9a-4e4f-4015-8b01-1e14f2a799e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5db51f9a-4e4f-4015-8b01-1e14f2a799e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c1ad3756-6898-48aa-b83f-ef19f5a83f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c1ad3756-6898-48aa-b83f-ef19f5a83f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_6a96b11c-a39c-45ae-bd4e-ffb534a46c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_6a96b11c-a39c-45ae-bd4e-ffb534a46c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b8ee58ae-f5e0-4ee1-9985-6ca19f877ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b8ee58ae-f5e0-4ee1-9985-6ca19f877ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c35a225-b3f1-4ffc-8f94-ce7dc7c10622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c35a225-b3f1-4ffc-8f94-ce7dc7c10622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a701f47c-3ef9-42aa-b5a1-f46c4e5f1934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a701f47c-3ef9-42aa-b5a1-f46c4e5f1934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_e38645e5-d2f8-46b1-a117-3e4aa732d4bf" xlink:href="ibrx-20231231.xsd#ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable_e38645e5-d2f8-46b1-a117-3e4aa732d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d2b0be49-f111-4969-8a44-5aa415193a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_4a72b1e0-5a1f-4ac4-bd4e-6e2a30f9d76d" xlink:to="loc_us-gaap_FinanceLeaseLiability_d2b0be49-f111-4969-8a44-5aa415193a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f023ed3f-a647-4a16-a772-ed9ed6baac90" xlink:to="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearOne_9ea6780d-aa30-45e4-ad96-349fd0f06a42" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearOne_9ea6780d-aa30-45e4-ad96-349fd0f06a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearTwo_7e1bd3e0-418e-497e-91b5-bde55840e62b" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearTwo_7e1bd3e0-418e-497e-91b5-bde55840e62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearThree_651d491e-ac46-4f25-9b50-c32eb333672d" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearThree_651d491e-ac46-4f25-9b50-c32eb333672d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFour_211be68d-01a3-40db-b1f5-317908b2fefb" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearFour_211be68d-01a3-40db-b1f5-317908b2fefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidYearFive_94b1cbaa-e58d-43f2-9bff-1f2405154276" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityToBePaidYearFive_94b1cbaa-e58d-43f2-9bff-1f2405154276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive_8c64a1d4-e04a-4e02-af09-6e53576ebc9b" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaidAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityToBePaidAfterYearFive_8c64a1d4-e04a-4e02-af09-6e53576ebc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityToBePaid_c0b6313b-7938-48ec-86ef-af62a578fd6d" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityToBePaid_c0b6313b-7938-48ec-86ef-af62a578fd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_76db5ece-66e0-4156-966d-b135e50feec3" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityUndiscountedExcessInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityUndiscountedExcessInterest_76db5ece-66e0-4156-966d-b135e50feec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_581f34ea-81eb-44d7-a890-cfd927f2758a" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable_581f34ea-81eb-44d7-a890-cfd927f2758a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseLiability_13874a93-7061-4e6a-bf33-f7d595a34bbe" xlink:href="ibrx-20231231.xsd#ibrx_LeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_LeaseLiabilityToBePaidAbstract_32222e2f-1d68-4f2f-8656-b6b9e9d70872" xlink:to="loc_ibrx_LeaseLiability_13874a93-7061-4e6a-bf33-f7d595a34bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="simple" xlink:href="ibrx-20231231.xsd#LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RevenueInterestPurchaseAgreementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_01c62048-35b1-482e-a3c2-6cd5315df519" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_01c62048-35b1-482e-a3c2-6cd5315df519" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TieredPaymentsAxis_38a876e9-91ab-4483-8beb-c17556e6c052" xlink:href="ibrx-20231231.xsd#ibrx_TieredPaymentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_ibrx_TieredPaymentsAxis_38a876e9-91ab-4483-8beb-c17556e6c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:href="ibrx-20231231.xsd#ibrx_TieredPaymentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_TieredPaymentsAxis_38a876e9-91ab-4483-8beb-c17556e6c052" xlink:to="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPaymentMember_c32316d6-97c3-4d4e-b8d5-f583610e97ef" xlink:href="ibrx-20231231.xsd#ibrx_InitialPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:to="loc_ibrx_InitialPaymentMember_c32316d6-97c3-4d4e-b8d5-f583610e97ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecondPaymentMember_a3ed15a4-4c7c-4c9e-91b6-21b39fc65b76" xlink:href="ibrx-20231231.xsd#ibrx_SecondPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_TieredPaymentsDomain_884ce732-3df4-4ae3-8d05-4df143cfae78" xlink:to="loc_ibrx_SecondPaymentMember_a3ed15a4-4c7c-4c9e-91b6-21b39fc65b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d946992e-1f81-490c-bf8d-d732357b2c0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_srt_RangeAxis_d946992e-1f81-490c-bf8d-d732357b2c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d946992e-1f81-490c-bf8d-d732357b2c0f" xlink:to="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4e7e1898-4be3-44ef-8c5a-9ed67de2eca7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:to="loc_srt_MinimumMember_4e7e1898-4be3-44ef-8c5a-9ed67de2eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_649d97bc-21f1-4505-ad2b-ca98012a6055" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_91cf4461-4a9f-41e0-8f65-3f9fd56de9d3" xlink:to="loc_srt_MaximumMember_649d97bc-21f1-4505-ad2b-ca98012a6055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_80612a63-520c-4c73-a1ce-36ca2fd671c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_80612a63-520c-4c73-a1ce-36ca2fd671c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72b1007a-8874-4998-9704-e5b774a97cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_80612a63-520c-4c73-a1ce-36ca2fd671c9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72b1007a-8874-4998-9704-e5b774a97cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_68f2c46b-46a0-4fbf-b2bd-54c20fc7ca1c" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72b1007a-8874-4998-9704-e5b774a97cb5" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_68f2c46b-46a0-4fbf-b2bd-54c20fc7ca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_154bad0d-14b8-4d17-8713-cbca1c13ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_154bad0d-14b8-4d17-8713-cbca1c13ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccf3cf67-f046-4eb1-bd8b-10dc440dcac0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_154bad0d-14b8-4d17-8713-cbca1c13ce9f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccf3cf67-f046-4eb1-bd8b-10dc440dcac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_cbb97fe5-79b3-4d64-b377-6b279988ba3c" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ccf3cf67-f046-4eb1-bd8b-10dc440dcac0" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_cbb97fe5-79b3-4d64-b377-6b279988ba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b1f315e6-ac03-4949-acaf-554e7344bedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b1f315e6-ac03-4949-acaf-554e7344bedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99c10abc-9340-46fb-8c31-d9789ea4af81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b1f315e6-ac03-4949-acaf-554e7344bedd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99c10abc-9340-46fb-8c31-d9789ea4af81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_3fda054c-3165-44e1-b4b0-bdd4de176830" xlink:href="ibrx-20231231.xsd#ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99c10abc-9340-46fb-8c31-d9789ea4af81" xlink:to="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_3fda054c-3165-44e1-b4b0-bdd4de176830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionPeriodAxis_524e1136-95e3-4b1a-9b2a-c4875457de97" xlink:href="ibrx-20231231.xsd#ibrx_OptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_ibrx_OptionPeriodAxis_524e1136-95e3-4b1a-9b2a-c4875457de97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:href="ibrx-20231231.xsd#ibrx_OptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OptionPeriodAxis_524e1136-95e3-4b1a-9b2a-c4875457de97" xlink:to="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOneMember_31014b5e-666e-47b1-a20f-170b40cf0a49" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodOneMember_31014b5e-666e-47b1-a20f-170b40cf0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodTwoMember_e79850c9-cdb4-4f0c-b66e-779f5a863cc9" xlink:href="ibrx-20231231.xsd#ibrx_PeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodTwoMember_e79850c9-cdb4-4f0c-b66e-779f5a863cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodThreeMember_382dcafe-a00a-4af8-ad0e-83c887d96874" xlink:href="ibrx-20231231.xsd#ibrx_PeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodThreeMember_382dcafe-a00a-4af8-ad0e-83c887d96874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodFourMember_f0d362bd-267b-493b-8c45-9af5c19b278c" xlink:href="ibrx-20231231.xsd#ibrx_PeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_OptionPeriodDomain_d3327104-9b45-4c71-bf62-31afea81a9d9" xlink:to="loc_ibrx_PeriodFourMember_f0d362bd-267b-493b-8c45-9af5c19b278c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_69d0451e-964a-4e66-bf3d-e6bd268204fe" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_aa141af7-0789-4bfa-a27a-d3c900dc2cac" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementTotalInvestmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_PurchaseAgreementTotalInvestmentAmount_aa141af7-0789-4bfa-a27a-d3c900dc2cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_ed0f8c62-3449-4aab-9f4b-062fe9e46496" xlink:href="ibrx-20231231.xsd#ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment_ed0f8c62-3449-4aab-9f4b-062fe9e46496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales_a945de1e-734d-4c04-887d-f6667e49f011" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales_a945de1e-734d-4c04-887d-f6667e49f011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage_652044b7-fe38-4fa0-b841-d8a86a321d10" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage_652044b7-fe38-4fa0-b841-d8a86a321d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage_6efd0af2-7da8-4c92-a89f-11960371e9e5" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage_6efd0af2-7da8-4c92-a89f-11960371e9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice_b3032c17-40c5-4f23-923f-fa79c77063dc" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice_b3032c17-40c5-4f23-923f-fa79c77063dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_309b2f7b-6c67-48fb-990a-bc5c806d7ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_309b2f7b-6c67-48fb-990a-bc5c806d7ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2911d328-4cfb-4fc5-94e5-23e9cc24c0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2911d328-4cfb-4fc5-94e5-23e9cc24c0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAdditionalPurchaseOption_f3acb0af-9530-4381-9bee-83e40d013dad" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAdditionalPurchaseOption"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_SaleOfStockAdditionalPurchaseOption_f3acb0af-9530-4381-9bee-83e40d013dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction_05682b8c-525f-44e8-8e8d-8f7ac1af1f64" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction_05682b8c-525f-44e8-8e8d-8f7ac1af1f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0e0f6809-4f21-4f95-8a94-937f6953f0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_0e0f6809-4f21-4f95-8a94-937f6953f0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_4ed8061b-ae70-42ef-b9dc-a664e64d38df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_SecuredLongTermDebt_4ed8061b-ae70-42ef-b9dc-a664e64d38df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b8d57434-e3ca-4892-9a22-783a94fc9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_InterestExpense_b8d57434-e3ca-4892-9a22-783a94fc9b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_10f5bef2-ea2b-4cd8-8f87-377563d9b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_f0924c0b-14f6-499b-ab0a-9e6cefa51c51" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_10f5bef2-ea2b-4cd8-8f87-377563d9b9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_f8d1f65b-ccd1-4015-aa6d-1176c1390671" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RevenueInterestPurchaseAgreementAbstract_f8d1f65b-ccd1-4015-aa6d-1176c1390671" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_46b850a9-b827-42b8-94da-5c2d59d1bafd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:to="loc_us-gaap_DebtInstrumentAxis_46b850a9-b827-42b8-94da-5c2d59d1bafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa9a8ac2-613a-414a-94b2-1b24a689d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_46b850a9-b827-42b8-94da-5c2d59d1bafd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa9a8ac2-613a-414a-94b2-1b24a689d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RevenueInterestPurchaseAgreementMember_f5c2bc1e-175f-405e-9f24-d437e146ae03" xlink:href="ibrx-20231231.xsd#ibrx_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9a8ac2-613a-414a-94b2-1b24a689d02b" xlink:to="loc_ibrx_RevenueInterestPurchaseAgreementMember_f5c2bc1e-175f-405e-9f24-d437e146ae03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_985e712a-f296-4f14-83f0-29f22a2f1652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_985e712a-f296-4f14-83f0-29f22a2f1652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_985e712a-f296-4f14-83f0-29f22a2f1652" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember_c8f57d5d-a4af-4805-8b22-6591f6ebf6f9" xlink:href="ibrx-20231231.xsd#ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:to="loc_ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember_c8f57d5d-a4af-4805-8b22-6591f6ebf6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockRevenueInterestPurchaseAgreementMember_fd39df88-a256-49c0-ab50-fc4218d9c848" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockRevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:to="loc_ibrx_CommonStockRevenueInterestPurchaseAgreementMember_fd39df88-a256-49c0-ab50-fc4218d9c848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_e1ca2260-8628-4c6a-803a-b910e0287f62" xlink:href="ibrx-20231231.xsd#ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_36dce49f-f24d-4298-bc38-ad45052edb03" xlink:to="loc_ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember_e1ca2260-8628-4c6a-803a-b910e0287f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_1da7c52a-740a-474c-8791-4942c03f026f" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4c1d4370-0bc4-4e31-a2a4-43100111870d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_LongTermDebt_4c1d4370-0bc4-4e31-a2a4-43100111870d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_f3800076-b08c-4967-b2b1-3e288296cb94" xlink:href="ibrx-20231231.xsd#ibrx_ProceedsFromIssuanceOfSecuredDebtGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_ibrx_ProceedsFromIssuanceOfSecuredDebtGross_f3800076-b08c-4967-b2b1-3e288296cb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a5ced560-3992-414c-9e39-717a651b0886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a5ced560-3992-414c-9e39-717a651b0886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a39f60da-f0af-4d20-bcca-f4ecd2087bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_a39f60da-f0af-4d20-bcca-f4ecd2087bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod_806b8193-3921-44f7-84d4-10b110e79ac0" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod_806b8193-3921-44f7-84d4-10b110e79ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_e9675f6b-eab7-42e5-8604-1b7ce6eec6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_InterestExpenseDebt_e9675f6b-eab7-42e5-8604-1b7ce6eec6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_59bc4072-3b3c-4ce2-b3c4-34d684a5ebbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_1bc0097f-8dbb-491c-82fd-d656dc6c5dc6" xlink:to="loc_us-gaap_LongTermDebt_59bc4072-3b3c-4ce2-b3c4-34d684a5ebbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b44e543b-7781-4dcb-9556-cfb8b8a17612" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b44e543b-7781-4dcb-9556-cfb8b8a17612" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ca4d4f52-a39e-460b-a755-cd67309db98e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ca4d4f52-a39e-460b-a755-cd67309db98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ca4d4f52-a39e-460b-a755-cd67309db98e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_dac296e1-acd9-49ae-bf92-3e214595ded5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_dac296e1-acd9-49ae-bf92-3e214595ded5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_6d0a0054-bebf-4114-9a5b-7a15b6801463" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_110c61b7-363b-4690-91a5-ee0aecd002b4" xlink:to="loc_ibrx_PromissoryNotesPayableMember_6d0a0054-bebf-4114-9a5b-7a15b6801463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_28b59ec9-3b3c-4097-bb33-4ace2ebd8084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_28b59ec9-3b3c-4097-bb33-4ace2ebd8084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_28b59ec9-3b3c-4097-bb33-4ace2ebd8084" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member_415fb8fa-4022-4933-96e2-43cb7692089b" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member_415fb8fa-4022-4933-96e2-43cb7692089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_ad6f626b-3d5b-4453-a53a-bc63e087a009" xlink:href="ibrx-20231231.xsd#ibrx_A300MillionDecember2021PromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_ad6f626b-3d5b-4453-a53a-bc63e087a009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_1dd936d1-b0b4-4c9d-8456-3f34e7d1778a" xlink:href="ibrx-20231231.xsd#ibrx_A50MillionDecember2022PromissoryNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_1dd936d1-b0b4-4c9d-8456-3f34e7d1778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionJune2023PromissoryNoteMember_719dab54-34e5-433d-9294-7231df859804" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionJune2023PromissoryNoteMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A30MillionJune2023PromissoryNoteMember_719dab54-34e5-433d-9294-7231df859804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember_c7a17a13-c319-4f85-a6ae-a9c0e9cc15e8" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember_c7a17a13-c319-4f85-a6ae-a9c0e9cc15e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_5c153a4f-f9ed-401b-a4b0-d23f408ff8d5" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionMarch2023PromissoryNoteMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_5c153a4f-f9ed-401b-a4b0-d23f408ff8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_4a88fbc3-1225-48fa-a956-4a0dfb21a01a" xlink:href="ibrx-20231231.xsd#ibrx_A200MillionSeptember2023PromissoryNoteMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_4a88fbc3-1225-48fa-a956-4a0dfb21a01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_c894319b-d1ce-4f62-86cd-d32bc3803e10" xlink:href="ibrx-20231231.xsd#ibrx_A125MillionAugust2022PromissoryNoteMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_c894319b-d1ce-4f62-86cd-d32bc3803e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_c414f28a-9000-4906-ba6d-d57e5e037e02" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCapitalMember_c414f28a-9000-4906-ba6d-d57e5e037e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalOneMember_2e8b716b-918a-4580-9591-a9a12653846d" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalOneMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCapitalOneMember_2e8b716b-918a-4580-9591-a9a12653846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalTwoMember_8a74b3d9-d85b-4da1-a61c-45a5913618c0" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalTwoMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCapitalTwoMember_8a74b3d9-d85b-4da1-a61c-45a5913618c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantMobileMember_faa70331-7a45-4483-a7e9-18fb1ac3526b" xlink:href="ibrx-20231231.xsd#ibrx_NantMobileMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantMobileMember_faa70331-7a45-4483-a7e9-18fb1ac3526b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCancerStemCellMember_82a9c18c-eeec-4c09-9ab3-64737d70beef" xlink:href="ibrx-20231231.xsd#ibrx_NantCancerStemCellMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_NantCancerStemCellMember_82a9c18c-eeec-4c09-9ab3-64737d70beef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_2d05d6b5-81b0-4b19-97e9-e1b01df06581" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_55e7a8e9-d955-4749-a755-63a8c407faf7" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_2d05d6b5-81b0-4b19-97e9-e1b01df06581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2f356948-3302-47d6-b21b-4aa33b02d5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2f356948-3302-47d6-b21b-4aa33b02d5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c9e1ba69-b216-4ca7-a66d-92979a293931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2f356948-3302-47d6-b21b-4aa33b02d5cf" xlink:to="loc_us-gaap_RelatedPartyDomain_c9e1ba69-b216-4ca7-a66d-92979a293931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_3ce5da5c-2d70-49e1-9647-b4be6cd89614" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c9e1ba69-b216-4ca7-a66d-92979a293931" xlink:to="loc_srt_AffiliatedEntityMember_3ce5da5c-2d70-49e1-9647-b4be6cd89614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_12888fea-afff-47a5-a588-d96436f1185c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_VariableRateAxis_12888fea-afff-47a5-a588-d96436f1185c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_347fa156-d65c-429e-9e5f-1ba25438b027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_12888fea-afff-47a5-a588-d96436f1185c" xlink:to="loc_us-gaap_VariableRateDomain_347fa156-d65c-429e-9e5f-1ba25438b027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_5796e3c8-db9c-49a3-b583-afec1008a047" xlink:href="ibrx-20231231.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_347fa156-d65c-429e-9e5f-1ba25438b027" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_5796e3c8-db9c-49a3-b583-afec1008a047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_807b326b-d030-4f39-b674-234cc6a0d8d5" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ebf1c5b8-f18c-4f74-8ea2-b76850fb29db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ebf1c5b8-f18c-4f74-8ea2-b76850fb29db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f0e3060f-e05c-4539-93ac-4072fd11c853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f0e3060f-e05c-4539-93ac-4072fd11c853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5e97bf4b-8225-4025-a891-b94aabc146d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_LongTermDebt_5e97bf4b-8225-4025-a891-b94aabc146d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_f0f155f0-040d-4284-95cc-3b29182391c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_f0f155f0-040d-4284-95cc-3b29182391c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_280b5946-fb58-4430-8664-c82fbe5015d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_280b5946-fb58-4430-8664-c82fbe5015d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_739db45f-0fd0-4fc5-8269-7c0c8e8d6989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_739db45f-0fd0-4fc5-8269-7c0c8e8d6989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_45b167be-92ed-4571-95fe-a6610493177e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_45b167be-92ed-4571-95fe-a6610493177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_68ed2e44-8f18-411a-967e-e993de2f805a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_20e3600c-7425-4bc4-b8ca-e25ce39aad12" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_68ed2e44-8f18-411a-967e-e993de2f805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3fc1c9aa-6af3-43f7-8b28-4cc0eb641f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3fc1c9aa-6af3-43f7-8b28-4cc0eb641f8f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9322bb1-953e-4562-9051-330b5226ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9322bb1-953e-4562-9051-330b5226ce79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9322bb1-953e-4562-9051-330b5226ce79" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_7e09d7b1-151c-47aa-b355-a51c9aff66e1" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:to="loc_ibrx_PromissoryNotesPayableMember_7e09d7b1-151c-47aa-b355-a51c9aff66e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1083ccb4-510d-40ae-991f-d1c281b73669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_122fd2c0-45e3-4637-bd12-c59b3647f47d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1083ccb4-510d-40ae-991f-d1c281b73669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ef784eaf-9c31-493c-b0b6-826c7b19357b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ef784eaf-9c31-493c-b0b6-826c7b19357b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ef784eaf-9c31-493c-b0b6-826c7b19357b" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_47fb943b-3c8a-4a9e-99a6-8e6fb64ee23a" xlink:href="ibrx-20231231.xsd#ibrx_A300MillionDecember2021PromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_47fb943b-3c8a-4a9e-99a6-8e6fb64ee23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_be3ba60b-8259-4660-8028-03be6ccf067c" xlink:href="ibrx-20231231.xsd#ibrx_A125MillionAugust2022PromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_be3ba60b-8259-4660-8028-03be6ccf067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_81aa5aed-f102-49dc-aca7-2a0a692ab4c2" xlink:href="ibrx-20231231.xsd#ibrx_A50MillionDecember2022PromissoryNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_81aa5aed-f102-49dc-aca7-2a0a692ab4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_410a7dea-c5c1-438c-a9aa-8aadb858b403" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionMarch2023PromissoryNoteMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_410a7dea-c5c1-438c-a9aa-8aadb858b403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionJune2023PromissoryNoteMember_6db06e5a-2098-4fad-a4f2-9537f9190495" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionJune2023PromissoryNoteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A30MillionJune2023PromissoryNoteMember_6db06e5a-2098-4fad-a4f2-9537f9190495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_900c7b17-df33-4557-ba31-5a3aefa161a4" xlink:href="ibrx-20231231.xsd#ibrx_A200MillionSeptember2023PromissoryNoteMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_900c7b17-df33-4557-ba31-5a3aefa161a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member_dd96cacf-328b-4400-a28d-16e7300343e3" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member_dd96cacf-328b-4400-a28d-16e7300343e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_dcd00247-976e-44ed-b449-051ab8f7b9f5" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_dcd00247-976e-44ed-b449-051ab8f7b9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_3882b298-b19d-4c79-81ac-e2ce7dfdd2a6" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantWorksMember_3882b298-b19d-4c79-81ac-e2ce7dfdd2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_9a034b22-40dc-4c47-9c54-6b7fc7f157d2" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_NantCapitalMember_9a034b22-40dc-4c47-9c54-6b7fc7f157d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_d6dca311-12b5-4db3-89b8-da4ed39584d9" xlink:href="ibrx-20231231.xsd#ibrx_A505MillionPromissoryNoteDecember2023Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f6849d0-78cb-40b7-a4d5-96bbf5419e5a" xlink:to="loc_ibrx_A505MillionPromissoryNoteDecember2023Member_d6dca311-12b5-4db3-89b8-da4ed39584d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02f4f036-ac76-4041-a4ce-75993da077ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02f4f036-ac76-4041-a4ce-75993da077ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b967fe7d-04f1-4310-a07b-667c11d6d15f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02f4f036-ac76-4041-a4ce-75993da077ab" xlink:to="loc_us-gaap_RelatedPartyDomain_b967fe7d-04f1-4310-a07b-667c11d6d15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_a6297976-f970-4071-a631-8851ba4ead3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b967fe7d-04f1-4310-a07b-667c11d6d15f" xlink:to="loc_srt_AffiliatedEntityMember_a6297976-f970-4071-a631-8851ba4ead3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_VariableRateAxis_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e9a3b3c9-bb49-4957-b7a9-1dbecd6cb03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7ee4aff2-ba45-4c1f-93dd-7df59e72abe1" xlink:to="loc_us-gaap_VariableRateDomain_e9a3b3c9-bb49-4957-b7a9-1dbecd6cb03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_f759c621-486b-4ba6-94e6-69483edbcb9c" xlink:href="ibrx-20231231.xsd#ibrx_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e9a3b3c9-bb49-4957-b7a9-1dbecd6cb03a" xlink:to="loc_ibrx_SecuredOvernightFinancingRateSOFRMember_f759c621-486b-4ba6-94e6-69483edbcb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5587dc34-3a0d-4155-bb74-029508d572a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_srt_RangeAxis_5587dc34-3a0d-4155-bb74-029508d572a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5587dc34-3a0d-4155-bb74-029508d572a8" xlink:to="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a5122bf3-6b60-48c4-b531-1f1a0ffaa6d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:to="loc_srt_MinimumMember_a5122bf3-6b60-48c4-b531-1f1a0ffaa6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd8bbd0f-e5a6-4990-9442-4316d3fa6276" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_faacedc1-4f3b-4c85-8a6f-f9dce23f1bb5" xlink:to="loc_srt_MaximumMember_dd8bbd0f-e5a6-4990-9442-4316d3fa6276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b1699c3d-c231-45e5-a73d-5e902eb09056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b1699c3d-c231-45e5-a73d-5e902eb09056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b1699c3d-c231-45e5-a73d-5e902eb09056" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputMarketYieldMember_651721ef-a057-41eb-b138-7758117be0dc" xlink:href="ibrx-20231231.xsd#ibrx_MeasurementInputMarketYieldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:to="loc_ibrx_MeasurementInputMarketYieldMember_651721ef-a057-41eb-b138-7758117be0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e4c0e03e-fba3-4ad6-8b5d-9a2e46b4f30c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e4c0e03e-fba3-4ad6-8b5d-9a2e46b4f30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_abecea56-86a3-4330-8325-7b316565962a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a09c2d49-e222-4dd4-b42a-6cd711902bed" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_abecea56-86a3-4330-8325-7b316565962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ce2cb02b-4a83-435b-8ad1-83b692e0c1e8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_511ccbc4-8058-4f6b-a4f2-40713e1aaebd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_511ccbc4-8058-4f6b-a4f2-40713e1aaebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ValuationTechniqueBinomialLatticeModelMember_570dfdc6-dc13-4f20-aac1-04fcd6e660f4" xlink:href="ibrx-20231231.xsd#ibrx_ValuationTechniqueBinomialLatticeModelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_bd8db05c-5cba-41ff-a589-2bb1fc94282b" xlink:to="loc_ibrx_ValuationTechniqueBinomialLatticeModelMember_570dfdc6-dc13-4f20-aac1-04fcd6e660f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_6ae9d3fb-0777-4c3a-9ba6-588e14f49012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_6ae9d3fb-0777-4c3a-9ba6-588e14f49012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_be016726-1b39-4ee4-8f82-dd2525d1fa07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_6ae9d3fb-0777-4c3a-9ba6-588e14f49012" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_be016726-1b39-4ee4-8f82-dd2525d1fa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_a8439e55-9c2b-4ec6-a31f-524b77f4fb10" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_be016726-1b39-4ee4-8f82-dd2525d1fa07" xlink:to="loc_ibrx_PromissoryNotesPayableMember_a8439e55-9c2b-4ec6-a31f-524b77f4fb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_VestingAxis_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_5ee5167d-35f8-4f1d-8243-1d2bcd3bf421" xlink:to="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0b9de12b-05af-4f61-a51b-88dbfc8dff46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0b9de12b-05af-4f61-a51b-88dbfc8dff46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a8e3f6ae-8856-4603-b2db-f8a90a72c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_123256ab-b8f2-48b2-b771-f116318539ad" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a8e3f6ae-8856-4603-b2db-f8a90a72c1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_80af554e-f7ca-4ce2-ae20-208fa37be132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_80af554e-f7ca-4ce2-ae20-208fa37be132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc38c812-d18b-446a-bc00-77dcb16db968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_80af554e-f7ca-4ce2-ae20-208fa37be132" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc38c812-d18b-446a-bc00-77dcb16db968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_5e04e79f-8b34-4de5-9863-3af1b4c689ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc38c812-d18b-446a-bc00-77dcb16db968" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_5e04e79f-8b34-4de5-9863-3af1b4c689ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ee11800-cfe9-47c9-94b6-198649b3bd28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ee11800-cfe9-47c9-94b6-198649b3bd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fe2a186-8f80-4073-b978-c1c07dd9fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ee11800-cfe9-47c9-94b6-198649b3bd28" xlink:to="loc_us-gaap_EquityComponentDomain_6fe2a186-8f80-4073-b978-c1c07dd9fb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1606edb0-78e7-41e7-a756-d3ad482b6054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fe2a186-8f80-4073-b978-c1c07dd9fb99" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1606edb0-78e7-41e7-a756-d3ad482b6054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6aa3853c-4908-4953-8365-fbfb0e9e09be" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c8d11d5c-48c7-4f0a-b3b1-2baee5b9e4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c8d11d5c-48c7-4f0a-b3b1-2baee5b9e4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28883dc9-d939-4ff8-aa93-4643b962879c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_28883dc9-d939-4ff8-aa93-4643b962879c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1d6b0d9b-52cb-44c3-a726-151c70eb9719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1d6b0d9b-52cb-44c3-a726-151c70eb9719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_aeaad7c4-1078-4bac-997a-bcdc406c0208" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentPrepaymentAndAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_DebtInstrumentPrepaymentAndAccruedInterest_aeaad7c4-1078-4bac-997a-bcdc406c0208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_f62e66dd-adf2-4a32-860a-ad88321f4c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_f62e66dd-adf2-4a32-860a-ad88321f4c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_fe700926-4a2c-4b51-acd5-cd3ebbed6c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_fe700926-4a2c-4b51-acd5-cd3ebbed6c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentNumberOfAdvances_85675198-9366-4a0a-9fe2-765753ccafb6" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentNumberOfAdvances"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_DebtInstrumentNumberOfAdvances_85675198-9366-4a0a-9fe2-765753ccafb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DebtInstrumentFaceAmountPerTranche_ceb7f6c1-056a-4e4f-bc30-61995ace66f4" xlink:href="ibrx-20231231.xsd#ibrx_DebtInstrumentFaceAmountPerTranche"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_DebtInstrumentFaceAmountPerTranche_ceb7f6c1-056a-4e4f-bc30-61995ace66f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19caf8e4-5b54-4d9e-bd41-426324650097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19caf8e4-5b54-4d9e-bd41-426324650097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b4496821-686d-46e1-ba84-b4896e06c3ff" xlink:href="ibrx-20231231.xsd#ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty_b4496821-686d-46e1-ba84-b4896e06c3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f827cb88-cb61-4e3e-a855-52763add4987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_InterestExpenseDebt_f827cb88-cb61-4e3e-a855-52763add4987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_43aa4c2f-4580-4850-b0a2-ac71469f710f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_43aa4c2f-4580-4850-b0a2-ac71469f710f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_8ab193dc-7f44-446f-9225-2de718bbdc6e" xlink:href="ibrx-20231231.xsd#ibrx_LongTermDebtGrossIncludingAccruedInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_8ab193dc-7f44-446f-9225-2de718bbdc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_95b11184-0695-4b55-bb96-1176edf563ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_95b11184-0695-4b55-bb96-1176edf563ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_527a8980-374f-449c-9dde-434b1815da30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_527a8980-374f-449c-9dde-434b1815da30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4018d87b-6251-4298-996e-f0c414c61e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4018d87b-6251-4298-996e-f0c414c61e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ac3b5cec-08f7-4232-913d-9d3e0eb7deba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_ac3b5cec-08f7-4232-913d-9d3e0eb7deba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_ab4325f7-968a-44df-a78b-06e017a3c707" xlink:href="ibrx-20231231.xsd#ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature_ab4325f7-968a-44df-a78b-06e017a3c707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ee3424b2-196c-4e97-8cc6-12eaf31c849f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ee3424b2-196c-4e97-8cc6-12eaf31c849f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_bb2401a8-4edf-4a91-82ef-330cd661ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_bb2401a8-4edf-4a91-82ef-330cd661ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_51981117-7dba-4dd1-a133-c7efd1a84e56" xlink:href="ibrx-20231231.xsd#ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl_51981117-7dba-4dd1-a133-c7efd1a84e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_cc88c3a2-41d0-46e8-901d-62cafe5b2d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_cc88c3a2-41d0-46e8-901d-62cafe5b2d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_04e8afeb-fbba-4340-9574-d8018c9602b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_04e8afeb-fbba-4340-9574-d8018c9602b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3ccd10af-f291-4904-a518-4a826b384aad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_abce08cf-896d-4c01-a633-01885f2d4552" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3ccd10af-f291-4904-a518-4a826b384aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9d497e42-73a4-437b-aabb-7cc8a2f6d51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9d497e42-73a4-437b-aabb-7cc8a2f6d51f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_60eb8c13-b94f-4817-8630-53e5de5ed127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f7824be-8ef8-4f7c-8ddf-9b332c20c4dd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_60eb8c13-b94f-4817-8630-53e5de5ed127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_38223963-62fc-41e6-84f1-82b224ec0ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_60eb8c13-b94f-4817-8630-53e5de5ed127" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_38223963-62fc-41e6-84f1-82b224ec0ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e8002688-12a9-4196-a1d1-ff613f6a5a79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e8002688-12a9-4196-a1d1-ff613f6a5a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e8002688-12a9-4196-a1d1-ff613f6a5a79" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MeasurementInputExpectedMarketYieldMember_e67846aa-929b-4702-8ddc-295c9ad49b63" xlink:href="ibrx-20231231.xsd#ibrx_MeasurementInputExpectedMarketYieldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:to="loc_ibrx_MeasurementInputExpectedMarketYieldMember_e67846aa-929b-4702-8ddc-295c9ad49b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_ec40552b-65e5-4661-aca1-6e6a5c0adfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_ec40552b-65e5-4661-aca1-6e6a5c0adfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2ee1db34-09e1-41e6-a363-905dc71be810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c3ecfb55-d0c1-4142-991f-88eaf2b562f8" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2ee1db34-09e1-41e6-a363-905dc71be810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_45e73485-6b84-456b-b101-aec085b5a427" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3b0bff5c-1e29-4d5a-89c7-6d1d60c6566a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_45e73485-6b84-456b-b101-aec085b5a427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c5e2fb63-80d7-4859-a7cb-559e69e32680" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_45e73485-6b84-456b-b101-aec085b5a427" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c5e2fb63-80d7-4859-a7cb-559e69e32680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_329f4b22-d426-4661-861f-94a4667ce391" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_b68b7b08-129d-474f-ac01-bad5d0a32c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_b68b7b08-129d-474f-ac01-bad5d0a32c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a53a144-6fb0-4efa-8f78-63eecd133185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_7a53a144-6fb0-4efa-8f78-63eecd133185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_267b4585-420f-4744-81b5-5f5ee3247002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_267b4585-420f-4744-81b5-5f5ee3247002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5342aef0-ce2e-4bfd-b7b0-04039b81bf74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5342aef0-ce2e-4bfd-b7b0-04039b81bf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a4c91f88-15cc-4dc5-b6b2-46de1a308fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_68c4f0ec-c01c-4ea7-b5be-d3090871a304" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a4c91f88-15cc-4dc5-b6b2-46de1a308fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtRelatedPartyPromissoryNotesDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ee5d7bcc-de58-4400-9a88-5ced2d0e4ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ee5d7bcc-de58-4400-9a88-5ced2d0e4ebd" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6cab3735-5b7d-4d88-9438-13a8b2ed1a06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6cab3735-5b7d-4d88-9438-13a8b2ed1a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_68b0dacf-79d1-4f7b-ae2a-c6d22a010f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6cab3735-5b7d-4d88-9438-13a8b2ed1a06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_68b0dacf-79d1-4f7b-ae2a-c6d22a010f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_1807c321-5031-4267-bcd6-ad5a37d3e934" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_68b0dacf-79d1-4f7b-ae2a-c6d22a010f85" xlink:to="loc_ibrx_PromissoryNotesPayableMember_1807c321-5031-4267-bcd6-ad5a37d3e934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c32fdfea-23a4-465a-9a65-a420741750b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c32fdfea-23a4-465a-9a65-a420741750b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c32fdfea-23a4-465a-9a65-a420741750b8" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_75b8e8a6-8976-48f8-ac8a-d65ac507f9a2" xlink:href="ibrx-20231231.xsd#ibrx_A300MillionDecember2021PromissoryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A300MillionDecember2021PromissoryNoteMember_75b8e8a6-8976-48f8-ac8a-d65ac507f9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_b948059d-49bc-4f95-8fd6-042ca364ca8e" xlink:href="ibrx-20231231.xsd#ibrx_A125MillionAugust2022PromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A125MillionAugust2022PromissoryNoteMember_b948059d-49bc-4f95-8fd6-042ca364ca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_05beff0e-943a-4bba-92b5-8bb3dbcaed0b" xlink:href="ibrx-20231231.xsd#ibrx_A50MillionDecember2022PromissoryNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A50MillionDecember2022PromissoryNoteMember_05beff0e-943a-4bba-92b5-8bb3dbcaed0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_4db0046a-c225-45e2-acb0-74f8cafe9702" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionMarch2023PromissoryNoteMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A30MillionMarch2023PromissoryNoteMember_4db0046a-c225-45e2-acb0-74f8cafe9702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A30MillionJune2023PromissoryNoteMember_945f629a-e0a9-4272-b46d-912ce2aaa2c7" xlink:href="ibrx-20231231.xsd#ibrx_A30MillionJune2023PromissoryNoteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A30MillionJune2023PromissoryNoteMember_945f629a-e0a9-4272-b46d-912ce2aaa2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_5636488b-cc21-4040-b73f-ba0cddae8afa" xlink:href="ibrx-20231231.xsd#ibrx_A200MillionSeptember2023PromissoryNoteMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_A200MillionSeptember2023PromissoryNoteMember_5636488b-cc21-4040-b73f-ba0cddae8afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyFixedRateNotesMember_ba679868-3987-4f52-a88a-d4a0b2d07a40" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyFixedRateNotesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a9c541cc-45a8-40d2-9d48-049782b75a3b" xlink:to="loc_ibrx_RelatedPartyFixedRateNotesMember_ba679868-3987-4f52-a88a-d4a0b2d07a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b614745-fc86-4c52-98c2-5bde6d22087e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b614745-fc86-4c52-98c2-5bde6d22087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ca724064-3d52-48e8-893b-7af1d41659db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b614745-fc86-4c52-98c2-5bde6d22087e" xlink:to="loc_us-gaap_RelatedPartyDomain_ca724064-3d52-48e8-893b-7af1d41659db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_0f134f5a-0310-468c-81cd-28bb5f3a2ae1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ca724064-3d52-48e8-893b-7af1d41659db" xlink:to="loc_srt_AffiliatedEntityMember_0f134f5a-0310-468c-81cd-28bb5f3a2ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_803bdd6c-d474-4a2c-a1d3-44d539390ceb" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a7b2a095-ceda-4ef0-a573-21e264c59ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:to="loc_us-gaap_InterestExpenseDebt_a7b2a095-ceda-4ef0-a573-21e264c59ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9bad7dc4-0a42-42cc-bcd1-a03dd8bf1ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_89247371-bc35-4533-8948-087b8b1ea9d0" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9bad7dc4-0a42-42cc-bcd1-a03dd8bf1ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_de012b43-aa99-417d-ba98-c077ff48c46d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_de012b43-aa99-417d-ba98-c077ff48c46d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f09b0fbf-da52-4996-b82d-1ab884bd55ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f09b0fbf-da52-4996-b82d-1ab884bd55ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c4cf39e-909f-4f90-9ee7-cfb9b0edd849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f09b0fbf-da52-4996-b82d-1ab884bd55ae" xlink:to="loc_us-gaap_RelatedPartyDomain_3c4cf39e-909f-4f90-9ee7-cfb9b0edd849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_2cf81b97-fa43-42c4-8406-f6cd1da1e318" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3c4cf39e-909f-4f90-9ee7-cfb9b0edd849" xlink:to="loc_srt_AffiliatedEntityMember_2cf81b97-fa43-42c4-8406-f6cd1da1e318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b33a9b6a-9f8a-45a0-8618-ae58b787d406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_DebtInstrumentAxis_b33a9b6a-9f8a-45a0-8618-ae58b787d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc232eab-5994-46f3-be10-ea25f4cb5586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b33a9b6a-9f8a-45a0-8618-ae58b787d406" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc232eab-5994-46f3-be10-ea25f4cb5586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc232eab-5994-46f3-be10-ea25f4cb5586" xlink:to="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesPrincipalMember_1afcae29-137a-4ce5-aaa3-7b09caac8b2d" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesPrincipalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:to="loc_ibrx_RelatedPartyNotesPrincipalMember_1afcae29-137a-4ce5-aaa3-7b09caac8b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_RelatedPartyNotesInterestMember_1f545723-5ec3-4903-9e0d-dc9804f55471" xlink:href="ibrx-20231231.xsd#ibrx_RelatedPartyNotesInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_RelatedPartyNotesMember_b520bc63-469d-4d5b-8469-9e79365e95f7" xlink:to="loc_ibrx_RelatedPartyNotesInterestMember_1f545723-5ec3-4903-9e0d-dc9804f55471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bebbc3dd-0458-4cfb-ae2c-b6cd173ee1be" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_49c0bc42-652f-438e-a26e-f01f86990945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_49c0bc42-652f-438e-a26e-f01f86990945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PromissoryNotesPayableMember_febb7b55-7bee-46d1-91b4-1e5e78d75605" xlink:href="ibrx-20231231.xsd#ibrx_PromissoryNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_25dd952c-c842-449f-8098-66570bc16c0d" xlink:to="loc_ibrx_PromissoryNotesPayableMember_febb7b55-7bee-46d1-91b4-1e5e78d75605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9c1d6920-71c6-40e7-9cde-501e91e634da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a8c5c99f-f1e6-473f-9fce-abcaa0c4da69" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9c1d6920-71c6-40e7-9cde-501e91e634da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalThreeMember_3d895afe-0733-46d5-9c0e-576f06aeaf0b" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9c1d6920-71c6-40e7-9cde-501e91e634da" xlink:to="loc_ibrx_NantCapitalThreeMember_3d895afe-0733-46d5-9c0e-576f06aeaf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1b01705e-790a-4e95-96ef-1427f642dfc7" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bf858c0b-dc9c-4a86-903a-3a4fefbf1a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_bf858c0b-dc9c-4a86-903a-3a4fefbf1a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_dd41ff7b-c7a8-41d7-ad7c-0fd21ea41276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_dd41ff7b-c7a8-41d7-ad7c-0fd21ea41276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0d15d1db-6f06-4d42-9c9b-1a5d8f2bf401" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0d15d1db-6f06-4d42-9c9b-1a5d8f2bf401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c3d0eb95-e38a-41e5-a892-a8cba2349e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_LongTermDebt_c3d0eb95-e38a-41e5-a892-a8cba2349e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c4dedda-a785-4a3d-9399-88b872bb3953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c98127c3-e9cf-4a27-a401-8b5fa81c52c6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6c4dedda-a785-4a3d-9399-88b872bb3953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ebcddeb4-6feb-49e3-994a-96c4de0bb362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ebcddeb4-6feb-49e3-994a-96c4de0bb362" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8e5f4d02-867f-4451-9677-41bf3c26a129" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:to="loc_srt_CounterpartyNameAxis_8e5f4d02-867f-4451-9677-41bf3c26a129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8e5f4d02-867f-4451-9677-41bf3c26a129" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioInc.Member_7a2e8406-189c-41f1-8381-f37638bb1032" xlink:href="ibrx-20231231.xsd#ibrx_NantBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_NantBioInc.Member_7a2e8406-189c-41f1-8381-f37638bb1032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_5fd63d44-eb71-4854-b00c-cd661a133eea" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_NantWorksMember_5fd63d44-eb71-4854-b00c-cd661a133eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember_1686ac2f-3e5e-4425-8843-763b9dfc9806" xlink:href="ibrx-20231231.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_BrinkBiologicsIncMember_1686ac2f-3e5e-4425-8843-763b9dfc9806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_VariousMember_45349142-3a47-42af-80cd-883fb6837473" xlink:href="ibrx-20231231.xsd#ibrx_VariousMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_VariousMember_45349142-3a47-42af-80cd-883fb6837473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadMember_50c4485c-86a2-4c45-8675-3f80863ed2b3" xlink:href="ibrx-20231231.xsd#ibrx_DuleyRoadMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_DuleyRoadMember_50c4485c-86a2-4c45-8675-3f80863ed2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicMember_a0b51694-2a62-4a1d-942e-dbed7a1eff33" xlink:href="ibrx-20231231.xsd#ibrx_ImmunoOncologyClinicMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd0d91c5-dd28-4ecc-9598-5f3a02246b7d" xlink:to="loc_ibrx_ImmunoOncologyClinicMember_a0b51694-2a62-4a1d-942e-dbed7a1eff33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c49383a-2e8f-4392-8d73-7db5c5eeb68f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c49383a-2e8f-4392-8d73-7db5c5eeb68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_327c889b-17ca-4eb7-8090-4236247fb987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c49383a-2e8f-4392-8d73-7db5c5eeb68f" xlink:to="loc_us-gaap_RelatedPartyDomain_327c889b-17ca-4eb7-8090-4236247fb987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5762838b-f1e1-4725-861c-34949d579072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_327c889b-17ca-4eb7-8090-4236247fb987" xlink:to="loc_us-gaap_RelatedPartyMember_5762838b-f1e1-4725-861c-34949d579072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75011dd-b60d-4d16-8442-520b7ce24cf4" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7005853c-2891-4b92-acf4-348d376cb907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7005853c-2891-4b92-acf4-348d376cb907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1a10a704-83d7-4152-85da-1c6054dcd8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b0ca7275-1f84-4135-b8d8-f47a49173a32" xlink:to="loc_us-gaap_AccountsPayableCurrent_1a10a704-83d7-4152-85da-1c6054dcd8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#RelatedPartyAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6ace29f5-f0fa-45ad-9c33-21dc2bb7c42a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6ace29f5-f0fa-45ad-9c33-21dc2bb7c42a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_22fb7e53-5943-431a-8975-2e2cfaae24ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_srt_CounterpartyNameAxis_22fb7e53-5943-431a-8975-2e2cfaae24ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_22fb7e53-5943-431a-8975-2e2cfaae24ca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_000ad4b1-7758-448c-ba07-aad04927595c" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_NantWorksMember_000ad4b1-7758-448c-ba07-aad04927595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ImmunoOncologyClinicIncMember_d2fe3f41-46da-4f89-8422-c9d34961f6b7" xlink:href="ibrx-20231231.xsd#ibrx_ImmunoOncologyClinicIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_ImmunoOncologyClinicIncMember_d2fe3f41-46da-4f89-8422-c9d34961f6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BrinkBiologicsIncMember_ee41d185-6a65-4cc2-a609-e09e11ea2b09" xlink:href="ibrx-20231231.xsd#ibrx_BrinkBiologicsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_BrinkBiologicsIncMember_ee41d185-6a65-4cc2-a609-e09e11ea2b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioInc.Member_57e3d294-d59f-4dea-b4d6-2e39d1808d39" xlink:href="ibrx-20231231.xsd#ibrx_NantBioInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_NantBioInc.Member_57e3d294-d59f-4dea-b4d6-2e39d1808d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveDougStLLCMember_85f52ead-25a5-42ef-a65a-bec968c8f4d1" xlink:href="ibrx-20231231.xsd#ibrx_SixZeroFiveDougStLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_SixZeroFiveDougStLLCMember_85f52ead-25a5-42ef-a65a-bec968c8f4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DuleyRoadLLCMember_acaee542-a11a-4deb-827a-e5e55b2a16d9" xlink:href="ibrx-20231231.xsd#ibrx_DuleyRoadLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_DuleyRoadLLCMember_acaee542-a11a-4deb-827a-e5e55b2a16d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SixZeroFiveNashLLCMember_655eba33-a9ff-4ada-9994-2493fa907112" xlink:href="ibrx-20231231.xsd#ibrx_SixZeroFiveNashLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_SixZeroFiveNashLLCMember_655eba33-a9ff-4ada-9994-2493fa907112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalMember_08261290-c6a2-4a9d-a4ef-c0f0d10d4788" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_NantCapitalMember_08261290-c6a2-4a9d-a4ef-c0f0d10d4788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FourTwoZeroNashLLCMember_a765bc01-b602-4c76-a538-c3f063b31c83" xlink:href="ibrx-20231231.xsd#ibrx_FourTwoZeroNashLLCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_FourTwoZeroNashLLCMember_a765bc01-b602-4c76-a538-c3f063b31c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A23AlaskaLLCMember_d42ac68d-cd6c-4731-8e32-17b070f48193" xlink:href="ibrx-20231231.xsd#ibrx_A23AlaskaLLCMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4880f69b-f2db-4fc0-b4de-1990fe9f795f" xlink:to="loc_ibrx_A23AlaskaLLCMember_d42ac68d-cd6c-4731-8e32-17b070f48193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e6dc9f-7e4d-4782-852e-7ace003235a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e6dc9f-7e4d-4782-852e-7ace003235a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0a3e1ace-ab61-4769-9b97-e9d0e1f49dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e6dc9f-7e4d-4782-852e-7ace003235a0" xlink:to="loc_us-gaap_RelatedPartyDomain_0a3e1ace-ab61-4769-9b97-e9d0e1f49dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_443e16a4-0711-4a32-a9ee-263657d04957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0a3e1ace-ab61-4769-9b97-e9d0e1f49dc9" xlink:to="loc_us-gaap_RelatedPartyMember_443e16a4-0711-4a32-a9ee-263657d04957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afe9b74e-57b7-4ee6-8b8a-e45fef158152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afe9b74e-57b7-4ee6-8b8a-e45fef158152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60b65a7-523e-4767-a3d4-f57d32a1cfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afe9b74e-57b7-4ee6-8b8a-e45fef158152" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60b65a7-523e-4767-a3d4-f57d32a1cfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SharedServicesAgreementMember_cf0c615a-dd8a-469c-8926-9644f00f16da" xlink:href="ibrx-20231231.xsd#ibrx_SharedServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e60b65a7-523e-4767-a3d4-f57d32a1cfa8" xlink:to="loc_ibrx_SharedServicesAgreementMember_cf0c615a-dd8a-469c-8926-9644f00f16da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionTypeAxis_bc86a7c6-970e-418b-b030-399c92316e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_TransactionTypeAxis_bc86a7c6-970e-418b-b030-399c92316e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransactionDomain_fc9156fd-36f2-42db-84a7-6385ddf76ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_bc86a7c6-970e-418b-b030-399c92316e3f" xlink:to="loc_us-gaap_TransactionDomain_fc9156fd-36f2-42db-84a7-6385ddf76ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ReimbursementsMember_310242eb-00c9-4604-b88a-071af015b41a" xlink:href="ibrx-20231231.xsd#ibrx_ReimbursementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_fc9156fd-36f2-42db-84a7-6385ddf76ad4" xlink:to="loc_ibrx_ReimbursementsMember_310242eb-00c9-4604-b88a-071af015b41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_20882699-22ac-4d93-b5a1-27c4cc8a5d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_20882699-22ac-4d93-b5a1-27c4cc8a5d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_20882699-22ac-4d93-b5a1-27c4cc8a5d30" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc59728b-f27c-4f60-b2c8-7d43b4d66740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dc59728b-f27c-4f60-b2c8-7d43b4d66740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_55306700-d6bc-4da9-a1df-195e20a7518a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5433885f-6f72-4e74-a189-6d814a84875d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_55306700-d6bc-4da9-a1df-195e20a7518a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1f2ecac2-2926-4f69-b1d8-08cfeb699674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1f2ecac2-2926-4f69-b1d8-08cfeb699674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1f2ecac2-2926-4f69-b1d8-08cfeb699674" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCancerStemCellMember_cd1f4965-8731-49bc-aaca-7ccf06e209dc" xlink:href="ibrx-20231231.xsd#ibrx_NantCancerStemCellMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:to="loc_ibrx_NantCancerStemCellMember_cd1f4965-8731-49bc-aaca-7ccf06e209dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_FiveFiveSevenDougStLLCMember_bd5a95ed-ffa8-4f44-bd94-52e322da529e" xlink:href="ibrx-20231231.xsd#ibrx_FiveFiveSevenDougStLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_7e657884-f3dc-44b4-affe-b0a6c01899e0" xlink:to="loc_ibrx_FiveFiveSevenDougStLLCMember_bd5a95ed-ffa8-4f44-bd94-52e322da529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_46dad45b-6be1-45cc-9c93-c20e18aee155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_LeaseContractualTermAxis_46dad45b-6be1-45cc-9c93-c20e18aee155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_46dad45b-6be1-45cc-9c93-c20e18aee155" xlink:to="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SeptemberTwentyNineteenLeaseMember_37b56202-8715-4123-9ee2-66ebeeb98ba4" xlink:href="ibrx-20231231.xsd#ibrx_SeptemberTwentyNineteenLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_SeptemberTwentyNineteenLeaseMember_37b56202-8715-4123-9ee2-66ebeeb98ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_JulyTwentyNineteenLeaseMember_34c121ae-5434-4c92-88a2-a21018f81755" xlink:href="ibrx-20231231.xsd#ibrx_JulyTwentyNineteenLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_JulyTwentyNineteenLeaseMember_34c121ae-5434-4c92-88a2-a21018f81755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialPremisesMember_5c528815-5195-4079-a82c-bd70d99adec8" xlink:href="ibrx-20231231.xsd#ibrx_InitialPremisesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_InitialPremisesMember_5c528815-5195-4079-a82c-bd70d99adec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ExpansionPremisesMember_e6780fbc-52e1-4857-9d9d-1e20b662859a" xlink:href="ibrx-20231231.xsd#ibrx_ExpansionPremisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_ExpansionPremisesMember_e6780fbc-52e1-4857-9d9d-1e20b662859a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_InitialAndExpansionPremisesMember_a83cac63-0af2-4164-916d-db7b5bcc0cbb" xlink:href="ibrx-20231231.xsd#ibrx_InitialAndExpansionPremisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_5a28e02e-9ae0-43de-8cf4-4dbcb065a2dd" xlink:to="loc_ibrx_InitialAndExpansionPremisesMember_a83cac63-0af2-4164-916d-db7b5bcc0cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_0b040686-1317-4d31-a3b8-7eac46d2b07d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_0b040686-1317-4d31-a3b8-7eac46d2b07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f6d0cab-8cd7-41e3-b638-132fa2be7d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_0b040686-1317-4d31-a3b8-7eac46d2b07d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f6d0cab-8cd7-41e3-b638-132fa2be7d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DueToRelatedPartiesMember_2b261743-0f4f-4239-b059-0915e66b11df" xlink:href="ibrx-20231231.xsd#ibrx_DueToRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0f6d0cab-8cd7-41e3-b638-132fa2be7d56" xlink:to="loc_ibrx_DueToRelatedPartiesMember_2b261743-0f4f-4239-b059-0915e66b11df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a0c5b207-7de6-4cd1-afe4-31fe2b462203" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bb6a228-966b-433c-922a-dd3541fe149c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bb6a228-966b-433c-922a-dd3541fe149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0a2f63cb-897b-4e60-b717-656d338433bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0a2f63cb-897b-4e60-b717-656d338433bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_07d3b251-b3ab-442a-a663-f28cbd58fe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_07d3b251-b3ab-442a-a663-f28cbd58fe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c276457d-3ae7-431f-8b76-c50dcc556712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_AccountsPayableCurrent_c276457d-3ae7-431f-8b76-c50dcc556712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_643af4e0-3bd9-44d0-b0f6-dce876932a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_643af4e0-3bd9-44d0-b0f6-dce876932a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_bcbb1f52-0288-4ffd-a11c-bb9e325d98d5" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFeetOfFacilityLeased"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NumberOfSquareFeetOfFacilityLeased_bcbb1f52-0288-4ffd-a11c-bb9e325d98d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreaseToLicenseFee_3fa0b825-48d5-4e51-bbad-66608be11242" xlink:href="ibrx-20231231.xsd#ibrx_AnnualPercentageIncreaseToLicenseFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_AnnualPercentageIncreaseToLicenseFee_3fa0b825-48d5-4e51-bbad-66608be11242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MonthlyLicenseFee_2b52eb8c-bc59-4b3f-9396-2e7fdc9f077f" xlink:href="ibrx-20231231.xsd#ibrx_MonthlyLicenseFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_MonthlyLicenseFee_2b52eb8c-bc59-4b3f-9396-2e7fdc9f077f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_17b1bbc9-ab63-4355-92f7-31e9ea26d4e6" xlink:href="ibrx-20231231.xsd#ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased_17b1bbc9-ab63-4355-92f7-31e9ea26d4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_46ab1e69-8eba-4c01-a63c-9231a41ea915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_OperatingLeaseExpense_46ab1e69-8eba-4c01-a63c-9231a41ea915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrepaidExpenseWriteDown_1dbbe565-742e-4d8e-8981-6f3b2def762d" xlink:href="ibrx-20231231.xsd#ibrx_PrepaidExpenseWriteDown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_PrepaidExpenseWriteDown_1dbbe565-742e-4d8e-8981-6f3b2def762d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_721d6271-e7ce-43ef-b63c-f23f9aaccd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_Revenues_721d6271-e7ce-43ef-b63c-f23f9aaccd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SupplyAgreementTermOfContract_661fffbf-b01f-4641-a871-ff145f29efa0" xlink:href="ibrx-20231231.xsd#ibrx_SupplyAgreementTermOfContract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SupplyAgreementTermOfContract_661fffbf-b01f-4641-a871-ff145f29efa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfExtendedLeaseTerm_c84958c4-2467-4413-9ce2-e177750351df" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOfExtendedLeaseTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_PeriodOfExtendedLeaseTerm_c84958c4-2467-4413-9ce2-e177750351df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantBioRevenue_2dc6073d-d32b-42ff-b2a2-866547ad365e" xlink:href="ibrx-20231231.xsd#ibrx_NantBioRevenue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NantBioRevenue_2dc6073d-d32b-42ff-b2a2-866547ad365e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ca227d42-f7c3-4709-b0ed-64ea28ab85ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ca227d42-f7c3-4709-b0ed-64ea28ab85ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_OptionsToExtendNumberOfTerms_4225b0a4-3113-4069-a875-c53edfeb48d3" xlink:href="ibrx-20231231.xsd#ibrx_OptionsToExtendNumberOfTerms"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_OptionsToExtendNumberOfTerms_4225b0a4-3113-4069-a875-c53edfeb48d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfLeases_d1c9ec1f-e051-4a95-95ec-668ebd5131b4" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfLeases"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NumberOfLeases_d1c9ec1f-e051-4a95-95ec-668ebd5131b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0a5a4852-9183-4ee3-ace4-6985ecffc6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0a5a4852-9183-4ee3-ace4-6985ecffc6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LeaseRelatedPayables_3c8e4312-40db-465a-9e30-0b194e109b4d" xlink:href="ibrx-20231231.xsd#ibrx_LeaseRelatedPayables"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_LeaseRelatedPayables_3c8e4312-40db-465a-9e30-0b194e109b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_5e310466-3193-423c-94e0-9faac0172c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFromLessor"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_IncentiveFromLessor_5e310466-3193-423c-94e0-9faac0172c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NumberOfSquareFootOfFacilityLeased_7bec5370-470a-48f2-95da-7e56dcbba400" xlink:href="ibrx-20231231.xsd#ibrx_NumberOfSquareFootOfFacilityLeased"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_NumberOfSquareFootOfFacilityLeased_7bec5370-470a-48f2-95da-7e56dcbba400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionConsiderationTransferred_dc13afb8-dc08-435d-9116-92a929a3762e" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionConsiderationTransferred"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SaleLeasebackTransactionConsiderationTransferred_dc13afb8-dc08-435d-9116-92a929a3762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionPropertyTaxes_d4a5353c-8e77-46d0-b0b0-6fc338dbb1bc" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionPropertyTaxes"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SaleLeasebackTransactionPropertyTaxes_d4a5353c-8e77-46d0-b0b0-6fc338dbb1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleLeasebackTransactionNetProceeds_fb413e78-8204-43c2-8418-83fd66aa59ad" xlink:href="ibrx-20231231.xsd#ibrx_SaleLeasebackTransactionNetProceeds"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_SaleLeasebackTransactionNetProceeds_fb413e78-8204-43c2-8418-83fd66aa59ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionHistoricalCost_abf72c89-5265-4412-ae32-df538ba6e8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionHistoricalCost"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SaleLeasebackTransactionHistoricalCost_abf72c89-5265-4412-ae32-df538ba6e8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue_4bd65d9c-9566-4a77-80c0-ba61b18293b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SaleLeasebackTransactionNetBookValue_4bd65d9c-9566-4a77-80c0-ba61b18293b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_878915e4-2249-4c0d-a78e-71df25f9e32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_878915e4-2249-4c0d-a78e-71df25f9e32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_BaseMonthlyRent_040642ee-d848-46b8-a176-9e079c78d89e" xlink:href="ibrx-20231231.xsd#ibrx_BaseMonthlyRent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_BaseMonthlyRent_040642ee-d848-46b8-a176-9e079c78d89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AnnualPercentageIncreasesToBaseRent_a39ea233-6d52-4bce-9679-829c4675bc05" xlink:href="ibrx-20231231.xsd#ibrx_AnnualPercentageIncreasesToBaseRent"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_AnnualPercentageIncreasesToBaseRent_a39ea233-6d52-4bce-9679-829c4675bc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PeriodOfRentFreeLeaseTerm_d1bae3f6-86d0-40f0-aaa9-4c9446082ba9" xlink:href="ibrx-20231231.xsd#ibrx_PeriodOfRentFreeLeaseTerm"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_PeriodOfRentFreeLeaseTerm_d1bae3f6-86d0-40f0-aaa9-4c9446082ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LesseeOperatingLeasePrepaidExpense_9d7c7f79-7da2-4eba-89aa-436269979a79" xlink:href="ibrx-20231231.xsd#ibrx_LesseeOperatingLeasePrepaidExpense"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_LesseeOperatingLeasePrepaidExpense_9d7c7f79-7da2-4eba-89aa-436269979a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_b3c57d02-dba9-489a-86ac-e914b8cdb635" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_b3c57d02-dba9-489a-86ac-e914b8cdb635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MonthlyBaseRentParking_d30f268b-8c96-4d4c-bc21-f00e3ef9f7e7" xlink:href="ibrx-20231231.xsd#ibrx_MonthlyBaseRentParking"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_ibrx_MonthlyBaseRentParking_d30f268b-8c96-4d4c-bc21-f00e3ef9f7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_b64f8e8e-5c3b-4b8b-b039-ec57f72ed4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f24d1f54-6591-4b06-8c12-2bdace73a7eb" xlink:to="loc_us-gaap_SecurityDeposit_b64f8e8e-5c3b-4b8b-b039-ec57f72ed4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#WarrantLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/WarrantLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_66f8f83e-aa77-4154-83e2-552a8fd40bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66f8f83e-aa77-4154-83e2-552a8fd40bd4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0d7aae0a-541c-4d00-99df-bfda9cf42a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0d7aae0a-541c-4d00-99df-bfda9cf42a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38a04b1b-198e-484a-8745-571e79e8717b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0d7aae0a-541c-4d00-99df-bfda9cf42a2c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38a04b1b-198e-484a-8745-571e79e8717b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_2bb13e6f-b301-4cd1-bf45-2ef0612aab75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38a04b1b-198e-484a-8745-571e79e8717b" xlink:to="loc_us-gaap_PrivatePlacementMember_2bb13e6f-b301-4cd1-bf45-2ef0612aab75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_bed3b47c-223a-4182-b904-3883b031ebe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_bed3b47c-223a-4182-b904-3883b031ebe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_bed3b47c-223a-4182-b904-3883b031ebe3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_46783b48-5529-4c53-8784-af41294ea092" xlink:href="ibrx-20231231.xsd#ibrx_December2022WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:to="loc_ibrx_December2022WarrantsMember_46783b48-5529-4c53-8784-af41294ea092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_f1cb8a31-e535-46b4-81d7-e59774a44e3a" xlink:href="ibrx-20231231.xsd#ibrx_February2023WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:to="loc_ibrx_February2023WarrantsMember_f1cb8a31-e535-46b4-81d7-e59774a44e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_July2023WarrantsMember_bfaf8c69-6b72-4fdc-8094-d33fabcd6d8e" xlink:href="ibrx-20231231.xsd#ibrx_July2023WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_91a9d74c-eebe-45f2-af53-2b1bbddd6063" xlink:to="loc_ibrx_July2023WarrantsMember_bfaf8c69-6b72-4fdc-8094-d33fabcd6d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_38a8dbc5-0578-4a5a-8b46-57fc4fd25aa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9f3aaaea-1def-4c94-a8b7-0a1e286ab7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9f3aaaea-1def-4c94-a8b7-0a1e286ab7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c2136f89-3fa8-4ba5-a362-bf78173d60da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c2136f89-3fa8-4ba5-a362-bf78173d60da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6621a6ad-569d-4403-b7f5-156099998e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6621a6ad-569d-4403-b7f5-156099998e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_280660a3-a18c-4920-825e-069fc5bf8a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_280660a3-a18c-4920-825e-069fc5bf8a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_737e09c5-561d-4e60-af0c-c353a2ce9791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_DeferredOfferingCosts_737e09c5-561d-4e60-af0c-c353a2ce9791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TransactionCostsWarrantLiability_01fed098-f45a-4444-a3b8-cc5e9f39be29" xlink:href="ibrx-20231231.xsd#ibrx_TransactionCostsWarrantLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_ibrx_TransactionCostsWarrantLiability_01fed098-f45a-4444-a3b8-cc5e9f39be29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7e683b1a-42a6-4384-9690-45192ca807b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7e683b1a-42a6-4384-9690-45192ca807b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_475f1106-934e-4074-bec3-468d85454ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_475f1106-934e-4074-bec3-468d85454ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d985f867-a012-4edc-a814-8fdc8f70fd46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_11952484-5442-47ef-8e98-badeed2ec901" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d985f867-a012-4edc-a814-8fdc8f70fd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockholdersDeficitAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3ec69fd3-ad88-449f-86c0-d561af113753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3ec69fd3-ad88-449f-86c0-d561af113753" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec253984-a410-43d4-b3ef-46c4b7b62d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec253984-a410-43d4-b3ef-46c4b7b62d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d5c43ca-4e51-40c2-9156-1993d0190fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec253984-a410-43d4-b3ef-46c4b7b62d05" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d5c43ca-4e51-40c2-9156-1993d0190fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_514d7bf5-f112-4d45-ae8a-a7ae9caf09a4" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d5c43ca-4e51-40c2-9156-1993d0190fce" xlink:to="loc_ibrx_NantCellInc.Member_514d7bf5-f112-4d45-ae8a-a7ae9caf09a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4b93c467-ae3f-4f97-96bf-fffb064ee7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_PlanNameAxis_4b93c467-ae3f-4f97-96bf-fffb064ee7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3ab5e1a3-19c7-4f8c-a5ae-3eac43749759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4b93c467-ae3f-4f97-96bf-fffb064ee7ba" xlink:to="loc_us-gaap_PlanNameDomain_3ab5e1a3-19c7-4f8c-a5ae-3eac43749759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_b5470bcd-a6a9-43bd-8c1b-88f7151edeaf" xlink:href="ibrx-20231231.xsd#ibrx_TwoThousandFifteenShareRepurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3ab5e1a3-19c7-4f8c-a5ae-3eac43749759" xlink:to="loc_ibrx_TwoThousandFifteenShareRepurchasePlanMember_b5470bcd-a6a9-43bd-8c1b-88f7151edeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f06894ff-e93f-4937-a0ff-d1009af419ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f06894ff-e93f-4937-a0ff-d1009af419ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f06894ff-e93f-4937-a0ff-d1009af419ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023ShelfRegistrationStatementMember_2c534532-abea-4ed8-b09b-52befa6fae65" xlink:href="ibrx-20231231.xsd#ibrx_February2023ShelfRegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_ibrx_February2023ShelfRegistrationStatementMember_2c534532-abea-4ed8-b09b-52befa6fae65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_904d7e00-19fd-4676-bd7d-4ebb5ead9b48" xlink:href="ibrx-20231231.xsd#ibrx_PrivatePlacementAndAtTheMarketOfferingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_ibrx_PrivatePlacementAndAtTheMarketOfferingsMember_904d7e00-19fd-4676-bd7d-4ebb5ead9b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_1cefbef4-9075-4bde-b4a9-ed943853e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_us-gaap_PrivatePlacementMember_1cefbef4-9075-4bde-b4a9-ed943853e4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_StockPurchaseAndOptionAgreementMember_5c17f285-dc54-4ba1-b2e1-5b55b4a34670" xlink:href="ibrx-20231231.xsd#ibrx_StockPurchaseAndOptionAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248ae6a7-57af-4841-8a60-31c355231192" xlink:to="loc_ibrx_StockPurchaseAndOptionAgreementMember_5c17f285-dc54-4ba1-b2e1-5b55b4a34670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6a1ff11-98e7-4f38-8e0f-395f490a61d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_srt_RangeAxis_b6a1ff11-98e7-4f38-8e0f-395f490a61d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dceeaa8-b956-4869-a69a-2bdb3824c4aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b6a1ff11-98e7-4f38-8e0f-395f490a61d3" xlink:to="loc_srt_RangeMember_0dceeaa8-b956-4869-a69a-2bdb3824c4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f9aca63e-2ef2-415a-97c4-5a8c693b8fcf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0dceeaa8-b956-4869-a69a-2bdb3824c4aa" xlink:to="loc_srt_MaximumMember_f9aca63e-2ef2-415a-97c4-5a8c693b8fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3bb70744-633e-477a-af3c-1b76386eefa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3bb70744-633e-477a-af3c-1b76386eefa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c3b20f8-1533-4028-a564-d45c4c39b38e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3bb70744-633e-477a-af3c-1b76386eefa6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c3b20f8-1533-4028-a564-d45c4c39b38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_AtTheMarketOfferingProgramMember_fd498fd1-2858-44b9-b9f1-f01b6e739e1a" xlink:href="ibrx-20231231.xsd#ibrx_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c3b20f8-1533-4028-a564-d45c4c39b38e" xlink:to="loc_ibrx_AtTheMarketOfferingProgramMember_fd498fd1-2858-44b9-b9f1-f01b6e739e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_31b89cf8-34d1-44dd-8e7b-abd2464dfc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_31b89cf8-34d1-44dd-8e7b-abd2464dfc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_31b89cf8-34d1-44dd-8e7b-abd2464dfc83" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_February2023WarrantsMember_82bcd0c8-a5fc-456a-a573-ee8e2d7b9aa1" xlink:href="ibrx-20231231.xsd#ibrx_February2023WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:to="loc_ibrx_February2023WarrantsMember_82bcd0c8-a5fc-456a-a573-ee8e2d7b9aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_July2023WarrantsMember_31d3c53d-f6fa-448c-b9fc-4888706646fd" xlink:href="ibrx-20231231.xsd#ibrx_July2023WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:to="loc_ibrx_July2023WarrantsMember_31d3c53d-f6fa-448c-b9fc-4888706646fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_December2022WarrantsMember_807a8983-74ba-4366-bba1-fc18967245ba" xlink:href="ibrx-20231231.xsd#ibrx_December2022WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b44279a7-7751-4842-9e04-1d29e97f70db" xlink:to="loc_ibrx_December2022WarrantsMember_807a8983-74ba-4366-bba1-fc18967245ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_73c813a5-9f16-4ce2-acd4-40b4746a350d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_73c813a5-9f16-4ce2-acd4-40b4746a350d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7faf2eb4-f8a5-42b6-b9bd-d4f9f40b1e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_73c813a5-9f16-4ce2-acd4-40b4746a350d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7faf2eb4-f8a5-42b6-b9bd-d4f9f40b1e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_71721223-89f3-40cd-9224-e8bc2b6ebce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7faf2eb4-f8a5-42b6-b9bd-d4f9f40b1e86" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_71721223-89f3-40cd-9224-e8bc2b6ebce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0960a639-803e-43c0-9b7f-551b1612ee15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0960a639-803e-43c0-9b7f-551b1612ee15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0960a639-803e-43c0-9b7f-551b1612ee15" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_18118bfb-360e-491c-84b0-16213ad7d3aa" xlink:href="ibrx-20231231.xsd#ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember_18118bfb-360e-491c-84b0-16213ad7d3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksLLCMember_39ac9f9d-2a01-42a0-9b54-4ad505d99668" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantWorksLLCMember_39ac9f9d-2a01-42a0-9b54-4ad505d99668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_64a7c4ef-9ce4-45f2-a12d-aafcdbbc9abb" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantWorksMember_64a7c4ef-9ce4-45f2-a12d-aafcdbbc9abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksLLCMemberMember_c787e260-dbac-45d5-9436-2b94a3ca340d" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksLLCMemberMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0effcab9-1572-4a56-adef-72fc8483badc" xlink:to="loc_ibrx_NantWorksLLCMemberMember_c787e260-dbac-45d5-9436-2b94a3ca340d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40b7a099-1fba-4f27-b73f-587523d70348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40b7a099-1fba-4f27-b73f-587523d70348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_36a5aa4b-ede9-4303-9970-ca789a479834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_40b7a099-1fba-4f27-b73f-587523d70348" xlink:to="loc_us-gaap_RelatedPartyDomain_36a5aa4b-ede9-4303-9970-ca789a479834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_fd637ec9-4640-45a4-940c-bb812e4c4329" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_36a5aa4b-ede9-4303-9970-ca789a479834" xlink:to="loc_srt_AffiliatedEntityMember_fd637ec9-4640-45a4-940c-bb812e4c4329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_acb612f4-35b8-4772-ac19-e9c472ad865e" xlink:to="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ab096025-1740-4784-91bd-32edf1d87e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ab096025-1740-4784-91bd-32edf1d87e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_58dd1353-018f-43bd-8220-01be924158f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_58dd1353-018f-43bd-8220-01be924158f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6aa5c87b-038d-455b-b4e5-3a55809e9668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6aa5c87b-038d-455b-b4e5-3a55809e9668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e68c3b33-14a9-40de-bc15-bb2b257d1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockSharesIssued_e68c3b33-14a9-40de-bc15-bb2b257d1cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dfede270-5bd7-450b-b133-678b36453876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dfede270-5bd7-450b-b133-678b36453876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_3bfaab4a-3cbf-4030-9d99-48be911b30b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_TreasuryStockCommonShares_3bfaab4a-3cbf-4030-9d99-48be911b30b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_MergerExchangeRatio_07655f5d-cb58-4bed-8c1a-02296c8467e2" xlink:href="ibrx-20231231.xsd#ibrx_MergerExchangeRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_MergerExchangeRatio_07655f5d-cb58-4bed-8c1a-02296c8467e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93900498-708d-4360-acf6-7976c620c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93900498-708d-4360-acf6-7976c620c23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_320bac97-9e5f-47ef-b178-9ec25b907e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_320bac97-9e5f-47ef-b178-9ec25b907e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4e84bea5-589a-43f4-943f-9a8daea70716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_4e84bea5-589a-43f4-943f-9a8daea70716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11568e7b-a276-4517-9faf-0b83377315fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_11568e7b-a276-4517-9faf-0b83377315fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1c1bf15f-2211-4161-aa10-3ee10f382426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_1c1bf15f-2211-4161-aa10-3ee10f382426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_8b3f0a50-6d06-46f9-a3f0-c54617aab652" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_SaleOfStockMaximumAggregateOfferingPrice_8b3f0a50-6d06-46f9-a3f0-c54617aab652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3b59ddc8-bcf7-4096-aa35-d2ee26941441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3b59ddc8-bcf7-4096-aa35-d2ee26941441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_e2f1f4ff-efdf-492e-a3f6-d6ed4b017954" xlink:href="ibrx-20231231.xsd#ibrx_CommonStockValueAvailableForFutureStockIssuance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_CommonStockValueAvailableForFutureStockIssuance_e2f1f4ff-efdf-492e-a3f6-d6ed4b017954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_PercentageOfSalesAgentCommission_aea9c37f-1672-4eba-aab1-66fd369f5d44" xlink:href="ibrx-20231231.xsd#ibrx_PercentageOfSalesAgentCommission"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_PercentageOfSalesAgentCommission_aea9c37f-1672-4eba-aab1-66fd369f5d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ac282b7-2621-4008-b2e1-e8e01606a025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ac282b7-2621-4008-b2e1-e8e01606a025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_70b0ad9b-1be9-449d-9dd2-aab0aa0f6938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_70b0ad9b-1be9-449d-9dd2-aab0aa0f6938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_313edc9a-04b5-4b25-bae2-071bb686548a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_313edc9a-04b5-4b25-bae2-071bb686548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40911659-77cd-4e01-ae6f-10e7dcce6b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40911659-77cd-4e01-ae6f-10e7dcce6b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c0d2c2d1-ece2-45fb-a017-201bab1a3238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c0d2c2d1-ece2-45fb-a017-201bab1a3238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_10d400cf-c536-48e6-86d0-7b9588f31116" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DeferredOfferingCosts_10d400cf-c536-48e6-86d0-7b9588f31116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0ba5891b-51a9-41d1-a6c1-4acf0d0eb28f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0ba5891b-51a9-41d1-a6c1-4acf0d0eb28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_SaleOfStockAdditionalPurchaseOption_36d0d130-1d2d-48ea-a229-4816d5e10521" xlink:href="ibrx-20231231.xsd#ibrx_SaleOfStockAdditionalPurchaseOption"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_SaleOfStockAdditionalPurchaseOption_36d0d130-1d2d-48ea-a229-4816d5e10521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_cbbc5e96-38f9-4f7a-904a-b5b366682830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_cbbc5e96-38f9-4f7a-904a-b5b366682830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_9e09a6e0-45f1-4393-a7fc-52604dc834a8" xlink:href="ibrx-20231231.xsd#ibrx_LongTermDebtGrossIncludingAccruedInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_ibrx_LongTermDebtGrossIncludingAccruedInterest_9e09a6e0-45f1-4393-a7fc-52604dc834a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7ea7edf-3b2d-4b58-be8c-87de51383422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7ea7edf-3b2d-4b58-be8c-87de51383422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0dc010fd-f427-40a1-91ce-fc5580dce2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0dc010fd-f427-40a1-91ce-fc5580dce2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8e566468-e981-4408-8725-e0ec804a470b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8e566468-e981-4408-8725-e0ec804a470b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a54b9f96-ab20-47d8-82e0-a74160a06974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a54b9f96-ab20-47d8-82e0-a74160a06974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8be9f5c4-ea5f-4153-a102-20210d988431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4e349097-7d65-4068-8eaf-8ce508d482c8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8be9f5c4-ea5f-4153-a102-20210d988431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69322036-489f-4eef-8e81-2463a000a40a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69322036-489f-4eef-8e81-2463a000a40a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_912d7f42-e496-4629-8c58-683e731c9ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_PlanNameAxis_912d7f42-e496-4629-8c58-683e731c9ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_912d7f42-e496-4629-8c58-683e731c9ad9" xlink:to="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_A2014PlanMember_7d6b4e23-5d56-4ee6-818a-8332cd787dc1" xlink:href="ibrx-20231231.xsd#ibrx_A2014PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:to="loc_ibrx_A2014PlanMember_7d6b4e23-5d56-4ee6-818a-8332cd787dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellTwoThousandAndFifteenPlanMember_e7e23637-c2e1-4aec-98f9-fb77d479eee1" xlink:href="ibrx-20231231.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:to="loc_ibrx_NantCellTwoThousandAndFifteenPlanMember_e7e23637-c2e1-4aec-98f9-fb77d479eee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_6b315248-52af-4787-8244-2be43b5eda2e" xlink:href="ibrx-20231231.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_632bfa9b-8098-44c4-ab4f-bc021fb69ea8" xlink:to="loc_ibrx_TwoThousandFifteenEquityIncentivePlanMember_6b315248-52af-4787-8244-2be43b5eda2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6eafd773-a302-45ae-85a4-74de2a5050ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6eafd773-a302-45ae-85a4-74de2a5050ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f517bd0-8adf-45e8-a96f-b5db52d77ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6eafd773-a302-45ae-85a4-74de2a5050ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f517bd0-8adf-45e8-a96f-b5db52d77ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantCellInc.Member_f6ad1065-f51c-4d55-8eb5-2ff0addc9ac5" xlink:href="ibrx-20231231.xsd#ibrx_NantCellInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f517bd0-8adf-45e8-a96f-b5db52d77ec2" xlink:to="loc_ibrx_NantCellInc.Member_f6ad1065-f51c-4d55-8eb5-2ff0addc9ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f813fa9e-a173-4e5d-ac38-180001258d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_AwardTypeAxis_f813fa9e-a173-4e5d-ac38-180001258d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f813fa9e-a173-4e5d-ac38-180001258d84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7f6b8668-8496-4138-a155-5d8ebe4ec808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7f6b8668-8496-4138-a155-5d8ebe4ec808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d5f16825-1d78-4f87-9fb9-60486561d02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d5f16825-1d78-4f87-9fb9-60486561d02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_WarrantsMember_ab0d18f5-b8ef-4828-9bfa-f59ec7d3950d" xlink:href="ibrx-20231231.xsd#ibrx_WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6637ce4-8fb1-4fd5-8f6f-0bee9240bb5e" xlink:to="loc_ibrx_WarrantsMember_ab0d18f5-b8ef-4828-9bfa-f59ec7d3950d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2ed847f0-513c-4365-8de1-5ead84f6a0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2ed847f0-513c-4365-8de1-5ead84f6a0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_91025211-7b66-419f-8f52-9cc1204a85ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ed847f0-513c-4365-8de1-5ead84f6a0bc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_91025211-7b66-419f-8f52-9cc1204a85ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3101d62b-d16e-42e4-915d-d0b129125fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_91025211-7b66-419f-8f52-9cc1204a85ae" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3101d62b-d16e-42e4-915d-d0b129125fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34760a06-adb3-4d4e-b1a2-93a585556d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34760a06-adb3-4d4e-b1a2-93a585556d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc0e4417-c437-4be2-b72a-225d936be9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_34760a06-adb3-4d4e-b1a2-93a585556d60" xlink:to="loc_us-gaap_RelatedPartyDomain_cc0e4417-c437-4be2-b72a-225d936be9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_NantWorksMember_de98fd56-f526-4865-bf49-8d1d6dbd1822" xlink:href="ibrx-20231231.xsd#ibrx_NantWorksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cc0e4417-c437-4be2-b72a-225d936be9e6" xlink:to="loc_ibrx_NantWorksMember_de98fd56-f526-4865-bf49-8d1d6dbd1822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_VestingAxis_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_b9732da0-a0ec-43a7-8eb7-1d70e4cadc71" xlink:to="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_663b4680-6945-43f9-ad26-68fc7739ee27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_663b4680-6945-43f9-ad26-68fc7739ee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_eae10ed8-33d9-460a-9be9-e49c47804d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a85926d0-7c42-4233-94cb-bd59d9af48f2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_eae10ed8-33d9-460a-9be9-e49c47804d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d9829433-117e-483e-8aa8-fd0dce24dbc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_167a7243-83ee-4474-b3a1-c965eba2b59d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_167a7243-83ee-4474-b3a1-c965eba2b59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b50b8130-fb5e-427c-b113-813e40631c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b50b8130-fb5e-427c-b113-813e40631c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_011bad8a-cf12-4fda-8598-db12110a122e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_011bad8a-cf12-4fda-8598-db12110a122e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0c3034d0-d275-4687-8156-66518977c89e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0c3034d0-d275-4687-8156-66518977c89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_038eb8d9-cd0c-414c-80ea-0c2e93fa7fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_038eb8d9-cd0c-414c-80ea-0c2e93fa7fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c8f68c72-4e6c-4fe3-afd3-b8993365ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c8f68c72-4e6c-4fe3-afd3-b8993365ea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9445033b-cf8e-4d22-b9a9-21e191faac43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9445033b-cf8e-4d22-b9a9-21e191faac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6af0183d-d1b1-4532-828f-9b0600a9e44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_6af0183d-d1b1-4532-828f-9b0600a9e44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fe2172f0-4920-4f42-bf4d-739f0203896c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_fe2172f0-4920-4f42-bf4d-739f0203896c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_22853d25-2135-4082-9ac2-f34d567b9985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_22853d25-2135-4082-9ac2-f34d567b9985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d4663a06-9f8a-4437-836e-98991fb2c761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d4663a06-9f8a-4437-836e-98991fb2c761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb5c97cc-140d-4e83-b2ff-3816ea456a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb5c97cc-140d-4e83-b2ff-3816ea456a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_c31e947f-6a7b-45ae-905d-c73f3d948cb7" xlink:href="ibrx-20231231.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_c31e947f-6a7b-45ae-905d-c73f3d948cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_b921072d-20f6-4876-b88e-8ba1d7fffb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_Dividends_b921072d-20f6-4876-b88e-8ba1d7fffb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37685dec-91e3-4961-9a94-2a24ab682e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37685dec-91e3-4961-9a94-2a24ab682e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_756179e0-e3eb-4191-9257-97cf17be7304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_756179e0-e3eb-4191-9257-97cf17be7304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ceae677d-3cbb-45bd-9d98-504959290c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a25a0ab3-7a9c-41b8-94b6-5599949987fe" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ceae677d-3cbb-45bd-9d98-504959290c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2a961e8-fbcd-4c17-8a15-8da7908c81cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2a961e8-fbcd-4c17-8a15-8da7908c81cf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b6c623fb-59a0-410f-83fe-2cf2561ba596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:to="loc_us-gaap_AwardTypeAxis_b6c623fb-59a0-410f-83fe-2cf2561ba596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b6c623fb-59a0-410f-83fe-2cf2561ba596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b73c33b8-f953-45af-8840-7da15a29fce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:to="loc_us-gaap_StockOptionMember_b73c33b8-f953-45af-8840-7da15a29fce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_58a07a9e-36c3-4a73-bd0e-112c2236e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_adaa895c-7c20-4145-a567-25be3d9c6fd1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_58a07a9e-36c3-4a73-bd0e-112c2236e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f0491f3b-7c33-4939-95d2-28abedcc305a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f0491f3b-7c33-4939-95d2-28abedcc305a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f0491f3b-7c33-4939-95d2-28abedcc305a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f65b7631-0284-4ac1-a028-6bc6d25318bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f65b7631-0284-4ac1-a028-6bc6d25318bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b17fe36-f405-4752-a230-28c091a0b104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_64460fe3-8add-43c0-88ce-529337d953d7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b17fe36-f405-4752-a230-28c091a0b104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d7ccefe-70e8-4d74-9f46-c49b61529127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_368af43b-2773-450d-89d8-4770967c1f49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d7ccefe-70e8-4d74-9f46-c49b61529127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39953509-2957-488c-9a65-f6f46159d90f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8d7ccefe-70e8-4d74-9f46-c49b61529127" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39953509-2957-488c-9a65-f6f46159d90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2c89c5d-4eee-4a1e-a0ea-50c7c054ca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2c89c5d-4eee-4a1e-a0ea-50c7c054ca8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_274e38ed-41db-4b55-8cdb-537fc040a44d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2c89c5d-4eee-4a1e-a0ea-50c7c054ca8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_274e38ed-41db-4b55-8cdb-537fc040a44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5f13317b-1110-4333-a000-0dff73bf5e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2c89c5d-4eee-4a1e-a0ea-50c7c054ca8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5f13317b-1110-4333-a000-0dff73bf5e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12e26a92-4659-4a35-9ef2-2f46c755d65d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2c89c5d-4eee-4a1e-a0ea-50c7c054ca8a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_12e26a92-4659-4a35-9ef2-2f46c755d65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_82863e8d-c615-48c6-af6d-e5b1f825c7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2c89c5d-4eee-4a1e-a0ea-50c7c054ca8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_82863e8d-c615-48c6-af6d-e5b1f825c7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0567a8ab-afd5-4f2b-8197-9caaed7d9286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2c89c5d-4eee-4a1e-a0ea-50c7c054ca8a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0567a8ab-afd5-4f2b-8197-9caaed7d9286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_244829a2-2708-4713-bf48-fc3eed56cff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_244829a2-2708-4713-bf48-fc3eed56cff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_89aedc19-65fd-4762-ada0-8055ccc3ea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_89aedc19-65fd-4762-ada0-8055ccc3ea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b17b351f-e2bb-41cf-b753-cd189f074be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_89aedc19-65fd-4762-ada0-8055ccc3ea0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b17b351f-e2bb-41cf-b753-cd189f074be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e375ee10-3635-4dd1-9317-ed5613439af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_89aedc19-65fd-4762-ada0-8055ccc3ea0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e375ee10-3635-4dd1-9317-ed5613439af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bbbb402c-28fa-405d-8cf7-7837025d4e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_89aedc19-65fd-4762-ada0-8055ccc3ea0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bbbb402c-28fa-405d-8cf7-7837025d4e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e755a9a8-9abe-411c-b1f5-0740f9e940be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_89aedc19-65fd-4762-ada0-8055ccc3ea0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e755a9a8-9abe-411c-b1f5-0740f9e940be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d221c8b6-c404-46f0-88bb-d1f45c29f599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_89aedc19-65fd-4762-ada0-8055ccc3ea0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d221c8b6-c404-46f0-88bb-d1f45c29f599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3ed59752-7dc6-4835-9836-b50e31bc953a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3ed59752-7dc6-4835-9836-b50e31bc953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_dba36156-0f9e-4cbd-afa8-a6a8e5e2f8ce" xlink:href="ibrx-20231231.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_dba36156-0f9e-4cbd-afa8-a6a8e5e2f8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b3325ce-5709-4762-82c4-e7ac7db13297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_dba36156-0f9e-4cbd-afa8-a6a8e5e2f8ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3b3325ce-5709-4762-82c4-e7ac7db13297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_7baa2b98-0c82-4d8f-82f3-e769fc911d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_7baa2b98-0c82-4d8f-82f3-e769fc911d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_34c0783e-3ebd-4bf8-89dc-f8e0a90ffde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_34c0783e-3ebd-4bf8-89dc-f8e0a90ffde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4bf1d298-0b78-4214-9a4c-1f2594253631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_34c0783e-3ebd-4bf8-89dc-f8e0a90ffde0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4bf1d298-0b78-4214-9a4c-1f2594253631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_2489aaea-0c58-4d82-9831-678408e09299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32b8f834-f283-47a2-8b93-0f0df4e9b471" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_2489aaea-0c58-4d82-9831-678408e09299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c280ca25-acb5-4363-b27f-25485cc6960a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7310335-c3ef-4c24-a64c-e2b9bdfd9ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c280ca25-acb5-4363-b27f-25485cc6960a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7310335-c3ef-4c24-a64c-e2b9bdfd9ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7c7f399f-df99-4303-83cd-635c2fa00f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7310335-c3ef-4c24-a64c-e2b9bdfd9ae2" xlink:to="loc_us-gaap_AwardTypeAxis_7c7f399f-df99-4303-83cd-635c2fa00f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d3f3559-c7e5-4348-9acc-6c2327ab0c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7c7f399f-df99-4303-83cd-635c2fa00f4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d3f3559-c7e5-4348-9acc-6c2327ab0c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab6eb71b-b6ee-4366-b709-c7062176bd22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d3f3559-c7e5-4348-9acc-6c2327ab0c9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab6eb71b-b6ee-4366-b709-c7062176bd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7310335-c3ef-4c24-a64c-e2b9bdfd9ae2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eeac2859-a9f3-4f40-adb4-6559a02f60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eeac2859-a9f3-4f40-adb4-6559a02f60ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a9dc603-65b4-4403-aea3-0a5bb3d0ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7a9dc603-65b4-4403-aea3-0a5bb3d0ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f0c24ae8-62b5-4dee-b7e5-7af9fdf0bde3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f0c24ae8-62b5-4dee-b7e5-7af9fdf0bde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd8a8ab8-b0c1-434e-bc85-86555f787a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd8a8ab8-b0c1-434e-bc85-86555f787a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e3dcd73-f140-4079-8481-46b730617d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c1744ab3-8467-434d-b602-2b4bbfdf45aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e3dcd73-f140-4079-8481-46b730617d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#StockBasedCompensationRSUActivityunderEquityPlansDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd05cb6-5f13-4bfc-b4cd-49bed80712cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d6fcc6-8f4e-45ae-8466-4af9b59e39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bd05cb6-5f13-4bfc-b4cd-49bed80712cd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d6fcc6-8f4e-45ae-8466-4af9b59e39a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_69948394-94bf-49b2-865c-ef269b5b6ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d6fcc6-8f4e-45ae-8466-4af9b59e39a5" xlink:to="loc_us-gaap_AwardTypeAxis_69948394-94bf-49b2-865c-ef269b5b6ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0865baf-3a8f-49d0-b993-efebdce7b909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_69948394-94bf-49b2-865c-ef269b5b6ecb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0865baf-3a8f-49d0-b993-efebdce7b909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_05dc78c5-1c2a-445a-8510-7a22340bb917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0865baf-3a8f-49d0-b993-efebdce7b909" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_05dc78c5-1c2a-445a-8510-7a22340bb917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2d6fcc6-8f4e-45ae-8466-4af9b59e39a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c817dc37-3e6a-486b-b6fc-774796159591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c817dc37-3e6a-486b-b6fc-774796159591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e57fa07-66f3-40c5-a783-9173cbcd2cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6e57fa07-66f3-40c5-a783-9173cbcd2cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0af7b66e-522f-4407-b91e-23da64b4ec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0af7b66e-522f-4407-b91e-23da64b4ec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_38a945e6-aab3-4c4d-a3cc-443e0aaa1e11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_38a945e6-aab3-4c4d-a3cc-443e0aaa1e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a13ae78b-c6a6-4f9f-ab31-966799f81140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c60029e7-7548-4a49-accb-d96f0fab1b47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a13ae78b-c6a6-4f9f-ab31-966799f81140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b3e24671-232f-4f7c-b9ea-c63f37c39c52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595769b1-f592-4f87-96bf-280370555af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_595769b1-f592-4f87-96bf-280370555af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_edc31c9a-3413-4fac-b8b4-d45a79b1d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_edc31c9a-3413-4fac-b8b4-d45a79b1d6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5591f925-e9a6-4d37-9e77-39fdbbc12bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5591f925-e9a6-4d37-9e77-39fdbbc12bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6fcd53f-4e2b-44ea-a1b6-5e9f19876ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6fcd53f-4e2b-44ea-a1b6-5e9f19876ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_669efe52-4acc-494d-87a5-f9d5c81a360a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f549bf47-cfbf-47ca-ad3e-9684e9f2c447" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_669efe52-4acc-494d-87a5-f9d5c81a360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesLossBeforeTaxesDomesticandForeignDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7e90ae44-ab11-4518-9f3b-d622f1d89e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_87160bf7-cb26-4bed-8735-0e89c52f2525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e90ae44-ab11-4518-9f3b-d622f1d89e87" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_87160bf7-cb26-4bed-8735-0e89c52f2525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5e17c946-f077-441d-8c79-b9ee54cb38d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e90ae44-ab11-4518-9f3b-d622f1d89e87" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5e17c946-f077-441d-8c79-b9ee54cb38d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd4030eb-40f2-427d-ae9a-d6ef86e513bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7e90ae44-ab11-4518-9f3b-d622f1d89e87" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd4030eb-40f2-427d-ae9a-d6ef86e513bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5c3777df-086b-4d7c-8e5f-adb25ba89034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_12709951-4c44-46b4-b1fd-171ea2d39093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5c3777df-086b-4d7c-8e5f-adb25ba89034" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_12709951-4c44-46b4-b1fd-171ea2d39093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_be7f1c3a-4dbe-454e-985f-af71506fef68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_12709951-4c44-46b4-b1fd-171ea2d39093" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_be7f1c3a-4dbe-454e-985f-af71506fef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_635f6b36-79b2-4201-acde-332e85ef6074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_12709951-4c44-46b4-b1fd-171ea2d39093" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_635f6b36-79b2-4201-acde-332e85ef6074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_91f79ed4-3ece-40db-86e9-161c806e82d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_12709951-4c44-46b4-b1fd-171ea2d39093" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_91f79ed4-3ece-40db-86e9-161c806e82d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_909fcf33-5047-4f85-b5a6-bb68abb4b63b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_12709951-4c44-46b4-b1fd-171ea2d39093" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_909fcf33-5047-4f85-b5a6-bb68abb4b63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3850168b-dfe9-44af-b517-819f7f543509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5c3777df-086b-4d7c-8e5f-adb25ba89034" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3850168b-dfe9-44af-b517-819f7f543509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e1bc9cbd-42f6-4648-b075-7011167ec5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3850168b-dfe9-44af-b517-819f7f543509" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e1bc9cbd-42f6-4648-b075-7011167ec5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6475ab06-7c79-4a6c-9dc0-1e11f2d80bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3850168b-dfe9-44af-b517-819f7f543509" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6475ab06-7c79-4a6c-9dc0-1e11f2d80bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_90af2a02-ec35-464c-ac05-32ae89b7b4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3850168b-dfe9-44af-b517-819f7f543509" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_90af2a02-ec35-464c-ac05-32ae89b7b4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_ec2bf468-3978-4cdd-8d5a-a543a947aaf7" xlink:href="ibrx-20231231.xsd#ibrx_DeferredIncomeTaxExpenseBenefitNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3850168b-dfe9-44af-b517-819f7f543509" xlink:to="loc_ibrx_DeferredIncomeTaxExpenseBenefitNet_ec2bf468-3978-4cdd-8d5a-a543a947aaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ada72fb-5d0c-4c5d-a40b-f8ab2c025018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5c3777df-086b-4d7c-8e5f-adb25ba89034" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ada72fb-5d0c-4c5d-a40b-f8ab2c025018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3511491f-c41b-4062-99b5-d3be7f89e293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3511491f-c41b-4062-99b5-d3be7f89e293" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_911134fa-5905-4378-ac27-6e9362502c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_911134fa-5905-4378-ac27-6e9362502c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e9e100f4-76a5-41b2-8bbe-6714df39c228" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e9e100f4-76a5-41b2-8bbe-6714df39c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_99e4e6da-98a7-40e9-95b2-999f56a60fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_99e4e6da-98a7-40e9-95b2-999f56a60fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_a493dece-4b0b-4113-9f86-a5491d31655f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_a493dece-4b0b-4113-9f86-a5491d31655f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d4c96a19-891a-4f6a-8540-18f9da170d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d4c96a19-891a-4f6a-8540-18f9da170d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_e636b65c-f596-48a8-81ec-ea1a1c06484b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_e636b65c-f596-48a8-81ec-ea1a1c06484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_969bb3b1-73e3-4065-ba5b-4ccd90099b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_969bb3b1-73e3-4065-ba5b-4ccd90099b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetsValuationDiscount_10c3aa77-e2b9-4732-8748-31eb2cb14f8b" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetsValuationDiscount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_ibrx_DeferredTaxAssetsValuationDiscount_10c3aa77-e2b9-4732-8748-31eb2cb14f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_ab92a32f-533f-404a-94d8-02a9ac85ce74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_ab92a32f-533f-404a-94d8-02a9ac85ce74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_827bf85e-0e0a-4e05-a036-3128d2d83a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_827bf85e-0e0a-4e05-a036-3128d2d83a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_202869c9-dbf4-4ee0-8a9a-cf538e459039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_202869c9-dbf4-4ee0-8a9a-cf538e459039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_bf0265bf-3308-4eef-b228-05fe88304a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_bf0265bf-3308-4eef-b228-05fe88304a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_24c89189-dffe-454f-a806-8e8928df198d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_24c89189-dffe-454f-a806-8e8928df198d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_09fdedde-11bb-4b2e-89e4-27e62e9556b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_19b68659-b396-4f6b-ba7a-f883790fc24d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_09fdedde-11bb-4b2e-89e4-27e62e9556b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3511491f-c41b-4062-99b5-d3be7f89e293" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_09454153-0d6b-4ca6-a3b8-451ed71c90b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_09454153-0d6b-4ca6-a3b8-451ed71c90b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_94f1b6fa-8876-4952-a1aa-22e96904e2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_94f1b6fa-8876-4952-a1aa-22e96904e2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7a037bd4-2f62-456e-a644-a82e2f4e4710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7a037bd4-2f62-456e-a644-a82e2f4e4710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_aaad2e07-6aeb-42c2-88c5-d83611fd993a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_aaad2e07-6aeb-42c2-88c5-d83611fd993a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_6b846cf5-2556-4d07-90ea-5c80708be8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_6b846cf5-2556-4d07-90ea-5c80708be8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_77564550-7487-4b48-b160-dd35e4a25272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_7fa1e992-a953-4d6e-8e36-3f053e6b4b81" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_77564550-7487-4b48-b160-dd35e4a25272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b9fd2f52-3e5f-46ce-988f-eec3df12c768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3511491f-c41b-4062-99b5-d3be7f89e293" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b9fd2f52-3e5f-46ce-988f-eec3df12c768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5107dc3b-c39c-4c87-9011-a6a39eb2ada8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3511491f-c41b-4062-99b5-d3be7f89e293" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5107dc3b-c39c-4c87-9011-a6a39eb2ada8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_175b40c5-a6c8-462d-9db3-e75035db24f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxTable_85fbf8e9-0176-4c95-9023-ee94edcc50f3" xlink:href="ibrx-20231231.xsd#ibrx_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_175b40c5-a6c8-462d-9db3-e75035db24f0" xlink:to="loc_ibrx_IncomeTaxTable_85fbf8e9-0176-4c95-9023-ee94edcc50f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0d3f2da3-1700-4c9c-affa-cbac4b40fc85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxTable_85fbf8e9-0176-4c95-9023-ee94edcc50f3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0d3f2da3-1700-4c9c-affa-cbac4b40fc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0d3f2da3-1700-4c9c-affa-cbac4b40fc85" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_c91e3836-bf73-4c02-b633-c99a2261d406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:to="loc_us-gaap_DomesticCountryMember_c91e3836-bf73-4c02-b633-c99a2261d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_03332962-3588-49c0-b001-3e1b2c4e10b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ec05fd2d-1be1-4325-a4f9-b1a0f9e6b149" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_03332962-3588-49c0-b001-3e1b2c4e10b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:href="ibrx-20231231.xsd#ibrx_IncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxTable_85fbf8e9-0176-4c95-9023-ee94edcc50f3" xlink:to="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7d835fcd-be9d-438b-8465-42cd3bea7b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7d835fcd-be9d-438b-8465-42cd3bea7b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_506a783d-eea1-443a-b953-3054a0ec7e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_506a783d-eea1-443a-b953-3054a0ec7e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_2d353781-1da7-4222-8a0b-fec17f68bc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_2d353781-1da7-4222-8a0b-fec17f68bc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_6d2459c2-6055-462d-8ed8-db0e02cfd529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_6d2459c2-6055-462d-8ed8-db0e02cfd529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_245c05d0-84ec-4987-936a-ba17e59db2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_245c05d0-84ec-4987-936a-ba17e59db2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b1be6992-346d-4635-bc54-ca86adb425f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b1be6992-346d-4635-bc54-ca86adb425f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital_7ae93655-6c47-4f92-8c09-5fda2cff6607" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital_7ae93655-6c47-4f92-8c09-5fda2cff6607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations_ec1dd91d-d97c-455d-8922-160fbe9e59e2" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations_ec1dd91d-d97c-455d-8922-160fbe9e59e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0d97797f-7693-44db-aab6-74baf6ef6f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0d97797f-7693-44db-aab6-74baf6ef6f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_3f0b7dc6-1e6b-4c09-9004-59e6f617a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_3f0b7dc6-1e6b-4c09-9004-59e6f617a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed_34e4062a-3474-48cc-848d-b5ebf292bdd1" xlink:href="ibrx-20231231.xsd#ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed_34e4062a-3474-48cc-848d-b5ebf292bdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_645775bb-9258-4026-b5bd-cbf1d941c86a" xlink:href="ibrx-20231231.xsd#ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ibrx_IncomeTaxLineItems_e2ba5330-bc6c-4ecb-9fb8-c71779a4dadf" xlink:to="loc_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_645775bb-9258-4026-b5bd-cbf1d941c86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2a6814c4-0df8-46ba-b591-b2d04ea3c4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2a6814c4-0df8-46ba-b591-b2d04ea3c4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6edb42dc-c59b-479e-85fb-54d1f1826285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6edb42dc-c59b-479e-85fb-54d1f1826285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue_2babbd5e-5251-4a82-aa0b-858c9f3c8fc8" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue_2babbd5e-5251-4a82-aa0b-858c9f3c8fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue_19cae00e-fce6-4ef8-b8f3-22331a582df2" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue_19cae00e-fce6-4ef8-b8f3-22331a582df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss_7fb52c85-5433-4ef6-a48d-ba0fad7e58c0" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss_7fb52c85-5433-4ef6-a48d-ba0fad7e58c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_55c831d2-2e2e-450c-aeaf-6770d8e73268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_55c831d2-2e2e-450c-aeaf-6770d8e73268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7af96be6-7905-49cd-be10-76c39c9d4dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7af96be6-7905-49cd-be10-76c39c9d4dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e42d5023-2b9f-4df8-a35b-1568f102274b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_e42d5023-2b9f-4df8-a35b-1568f102274b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4405cdbe-7f15-4dee-9adb-dce44601c546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4405cdbe-7f15-4dee-9adb-dce44601c546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent_fed458bf-2480-4bbd-a378-c93ad9527bcf" xlink:href="ibrx-20231231.xsd#ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent_fed458bf-2480-4bbd-a378-c93ad9527bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f62036c2-85b4-4e50-9f35-3b3a8361a2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f62036c2-85b4-4e50-9f35-3b3a8361a2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_63839c7c-9fd9-417c-8c52-6fefa6abf148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_63839c7c-9fd9-417c-8c52-6fefa6abf148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0479aaa8-7727-45ef-87da-5664907ba06e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c5ea1504-a59b-4759-bf50-a452181f8e0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0479aaa8-7727-45ef-87da-5664907ba06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_904d6440-f303-431d-b7f1-c566b98357cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_972a4b82-e02b-4599-9f58-04977ca4fdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_904d6440-f303-431d-b7f1-c566b98357cd" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_972a4b82-e02b-4599-9f58-04977ca4fdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8ad768a6-df88-480b-bac4-4a8114cc03fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_972a4b82-e02b-4599-9f58-04977ca4fdf2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8ad768a6-df88-480b-bac4-4a8114cc03fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_613c762e-2082-4691-8bad-0b5645672c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_972a4b82-e02b-4599-9f58-04977ca4fdf2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_613c762e-2082-4691-8bad-0b5645672c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e852df5d-25bd-4d1c-b357-4d08fdc07c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_972a4b82-e02b-4599-9f58-04977ca4fdf2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e852df5d-25bd-4d1c-b357-4d08fdc07c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_61dd9cab-1477-4996-aef5-2ff80969ddcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_972a4b82-e02b-4599-9f58-04977ca4fdf2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_61dd9cab-1477-4996-aef5-2ff80969ddcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c704ea2e-8beb-46c0-a586-acd102ede2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_972a4b82-e02b-4599-9f58-04977ca4fdf2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c704ea2e-8beb-46c0-a586-acd102ede2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/role/EmployeeBenefitsDetails" xlink:type="simple" xlink:href="ibrx-20231231.xsd#EmployeeBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.immunitybio.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_1e912256-c6fc-4516-a370-9a925b327db7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9fd59dd9-424d-47b2-83ad-e9d25cb94e33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_1e912256-c6fc-4516-a370-9a925b327db7" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_9fd59dd9-424d-47b2-83ad-e9d25cb94e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ib_logoxfinalxcolorx02x2021a.jpg
<DESCRIPTION>2024 PIPELINE
<TEXT>
begin 644 ib_logoxfinalxcolorx02x2021a.jpg
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M;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
M !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D;V)E &3      ?_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@"? CN P$1
M  (1 0,1 ?_$ :(    & @,!              <(!@4$"0,* @$ "P$   8#
M 0$!            !@4$ P<"" $)  H+$  " 0,$ 0,# @,# P(&"74! @,$
M$042!B$'$R( "#$403(C%0E10A9A)#,74G&!&&*1)4.AL? F-'(*&<'1-2?A
M4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)
M2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(
MR<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1  (! P($! ,%! 0$!@8%;0$" Q$$
M(1(%,08 (A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3Q
MHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6U
MQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EY
MB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:  P# 0 "$0,1 #\ W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,><W/MK;, JMR;AP
M>WJ4@L*G.9:@Q,!5?U$35]13QV7\\\>[*K-A02?EU5F515B /GT!F=^8/Q7V
MX\D>5^0O4*317$M/0[[V_F*F)A]4DIL/75\Z2#_4E0W^'M];.[;A&_["/\/3
M#7EHO&1/V@_X.@PK_P"8_P#"C&LRU'>^%D*&Q-!MC?N54_\ !7Q>U*Q''^*D
MCVZ-MOC_ *&?VC_/TT=RL1QD'[#_ )NF3_AS[X-?\_N/_HM>WO\ [ ?=OW7?
M_P"^_P#C2_Y^J_O2P_WY_P 9;_-U-I/YF'PAK6TP]YT:&]O\KV+V?0+<_P"U
M5VR:=+?XWM[T=LOA_H?\U_S];&YV)_T3^3?YNA$PGS@^(N?T?8_(7K"#7;3_
M !O<=-MJU_\ 5_WC&*\?_(5K>VVL;Q>,;_D*_P"#IQ;ZS;A(OYFG^'H=]L]B
M=?[T17V=OK9V[4==2/MG<^$SR,MKZE;%UU4&6W-Q[3M'(GQJP^T$=*%DC?X&
M4_80>EC[IU?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7ND'O_ +2ZWZKQ1S?9.^MJ;'Q9#F*JW/G,?B!5-&+M#015D\4^0J3?B*!9
M)&)L%)]N1Q2RG3$I8_(5Z;DEBB&J5@H^9ZK?[3_F_?&C9GW-'U_C]X]MY.+4
ML,^*QK;4VR\B7#)-F=S1T^852W"O#BZB-A<AB+7,HMGNGS(50?M/[!C^?1;+
MO%JF(PSG]@_G_FZKT[&_G)?(;<AFI^O-H;!ZTH7+&&IEIJS>NXH ;A1_$,N]
M%@)0H-S?$W)'X''LQCV:W7^T9F/[!_G_ )]%TF]7+?V851^T_P";^71(]\?-
M#Y5]BM*=T=\]C/#/J\U!@<[+L[%3!OJDN(V>N"Q<L?\ 16A(']/:Z.RM(_@C
M7\Q7_#7I"][=R?%(WY&G^"G1;J_(Y#*U4M=DZZLR5;.=4U97U,U953-_JI:B
MH>260_XDGVI  %!@=)B234Y/43WOK77O?NO=>]^Z]U[W[KW7O?NO=<HY'B=)
M(G>.2-E>.2-BCHZD,KHZD,K*1<$<@^_=>Z'_ &)\K?DGUHT/]R^[NR,334Y4
MPXN;<^1S&"0K]/\ ?OYR7)8-N..:<W'!X]IY+2VE^.-2?LH?VC/2B.[N8O@D
M8#[<?L..CW]9?SC/D7M9J>F[&VWL?M3'1Z?N*EZ*39.YI[6!T9+ )+MV'4+W
M_P!P[<_3C@H)=FMGS&60_M'\\_SZ7Q;S<IB4*X_8?Y8_EU9AT_\ S9OB_P!C
MO2X[>51N#I[.SZ(RF[Z+^([9>I>W[=-NG BLCA@7\S9"FQT8MR?I<KFVBZCR
ME'7Y<?V'_)7HTAW>UDP]4;Y\/VC_ "TZLDV[N7;F[\12;@VIG\+N?!5Z>2AS
M6W\I0YG$UD?'KI<CCIZFDG7GZJY]EK*R'2X(8>1Z,E9774A!4^8ST]^Z]6Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[HB/R _F+_&CH)ZW#U>ZF["WM2>2)MG=>&ESE125273P
M9O.&HAV]A7BEXFBDJ7K(Q<BG:UBOM]MNKC(&E/4X_8.)_P '2"XW*UM\$ZG]
M!G]IX#_#\NJ6^[_YM7R.[)>MQG72XGI;;,Y>.-=OJF;WE+3/<%*O=N5IA'32
M_0K)CJ*@E0\:S[.X-HMHLR5=_G@?L_SD]$D^[W,N(Z(ORR?V_P"8#JLW<6YM
MQ[ORU5G]V;@S>Y\Y6MKK,SN'*UV9RM6]R=53D,C/4U<YNQ_4Y^OLS550:4 "
M^@QT6,[.=3DEOGGID]VZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T*?5?=W;72.:&?ZIW_N39->9(Y*F/$5
MS#%Y/Q?YN/-8.I%1A,W OXCJZ>:,'FUP/;,L$,ZZ95##_5P/$=.Q3S0-JB8J
M?E_E' ]75_'+^<?1U3T&VODQM5,:[&.G_P!)>Q:.>:B!X3[G<>SB\]9 H4:I
M9\;)/J8V2B4?0DN=F([K4U_HG_(?\_[>CRVWD'MNA3^D/\H_S?LZNSV/OW97
M9>VZ#=^P-T83=^V<DFJCS. R%/D:)V 4R4\CP.S4U93E@LL$H2:%_2ZJP(]D
MDD;Q,4D!##R/1W'(DJZXR&4^8Z5WNG5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NB2?)SY\=#?&.*LQ&;S)WIV-%&?M^N=HU
M%-5Y>GG9-47]Y<B6?';5IB64L*DM6&-M<5-,/:ZUV^XNLJ-,?J?\GK_JSTAN
MMPM[7#'5)Z#_ "^G^K'6O1\D?YB'R&^1;5V&J<\>N^O:DR1+L38]354%-64C
MW40[ESH9,QN0R1V$L4CQ4+L-2TR'V(K;;K>V[@-4GJ?\@\O\/SZ#MSN-S<]M
M=,?H/\I\_P#!\NB)>U_2#KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$O8'3';?:LP@ZVZTWQO
M@^3Q23[9VSE\M0TSWL?O<C24DE!0HIX+32QJ#]3[:DFAB_M65?M/3L<$TO\
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MJG)9;+5U)C,7CJ*%ZBLK\C7U$=+145)3Q!I)ZFJJ95CC1069V ')]Z)"@LV
M.M@%B%&2>MP?X.?%K'?%CI7&;:JH:6;L3=/VVX^R\O 4E\V>E@M3X*EJ5N9<
M1M:FE--!8Z))3-4*%,[* =?71NYRP_LQA?L]?S_V.AC8V@M(0I_M#EC\_3[!
M_L]'*]HNEO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3!NK=&!V3MK/[PW3DJ?#
M[<VQB,AG<YE*IBL%!B\9325=94R6!9O'!$2%4%G-E4$D#W9$9V"(*L30=5=U
M12[&B@5/6F9\K/D-G_DYW3NCL[+_ '%+BIY?X/LO!3R!QMW9N-EF&&QEE9XQ
M5S"5ZJL93I>MJ)66RE0!I:6RVL B''B3ZGS_ -7IT"[NY:ZG,IX< /0>7^S\
M^BY>U/2;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NKR/Y2'Q'.=S#_*'?F+OAL!45>+ZFH:V&\>2W!%Y*3,[R$<@TR4N N]'
M1/9E-<TT@TR4J$D6[WFE?I8SW'XOL\A^?G\OMZ/=HL]1^JD&!\/V^9_+R^?V
M=;"_L.]"+KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ$?YO?RLL*+XM;*
MR7+?P[<?;E322_0?M9#:^RY2I_/[64K$(^GV8#<RK[/]GM/^);_8O^4_Y/V]
M$&\7?"U0_-O\@_R_LZH.]B#H/]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]T9WXC_ !JW%\I.Y,%UYBQ4T6W:<IF]_;CBC!3;
MNT:2>):^>-W5XCE<BSK2T,9#:ZF568>))65+>7*VL)D/Q< /4_ZN/2JSMFNI
MA&/AXD^@_P!7#K<AVEM3;^Q=L8#9NT\7387;6V,30X/!XJD4K!0XW'4Z4U+
MI8L\C".,%W<L\CDLQ+$D@QW:1R[FK$U/0S1%C4(@HH%!TH?=>K=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=%V^4_R"P/QFZ6W7VCF/MZK(T< Q6SL)/(4.XMY9
M*.9,'B0%9)#3*\3U-6R'7'14\SJ"5 *FTMVNIQ$.'F?0>?\ J]>DUW<+:P&4
M\?(>I\O]7IUID;KW3G]\;FS^\=TY*HS&Y-T9?(9W.92J8-/79/)U,E765#V
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M H:%[HXJ)VFC)-,P]F>UVGU$^MQ^DF?M/D/\I_V>BS=+OZ>#0A_5?'V#S/\
MD'^QUJG^Q9T$^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN<<<DTB111O++
M(RI''&K/)([&RHB*"S,Q-@ +GW[KW0T[4^-?R%WR(GVETCVKGJ>:VBOH=A[E
M;%^K])?*R8Z/&Q!OP6E /MA[FWC^-T'YCI]+6YD^"-R/L/1F]F_RN_F;NZ2
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M^]I]E[;J--BVG&X-9]P0!SQ_Q=VL/ISS[+)=YN6_LPJ#]I_GC^71E%LULO\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!?R2[QP7QTZ8WMVOG/#.VW\:T6
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MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM8[^;/\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U53_->^2?\
MHEZ13J?;E?X-\=TQUF)JC!):IQ77M+H3=%8V@DQ'/M,F,C#@"6":J*'5#P:[
M3;>-/XK#]-,_GY?LX_LZ*=VN?!@\%?C?^0\_V\/V]:NWL5=!;JP#^7M\0I?E
M'VN:S<]+4)U%U[)19;?%0ID@7/5<KL^(V51U*:767,/ SUCQD/#0QR6:.66
MDOW&\^EAHG]LW#Y?/_5Y]&&W6?U4M7_L5X_/Y?G_ (.MM2@H*'%4-%B\91TN
M.QN-I*:@Q^/H8(J6BH:&CA2GI*.DI8%2&FI::"-4CC10J(H   ]A$DDU.2>A
M<  *# '4OWKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-^6RN.P6+R6;S%;3XW$8
M?'UF5RN1JY!#24&.Q]/)5UU;4RMZ8J>EIH6=V/"JI/O8!8A1DGK1(4%FPH'6
MF'\MN_\ (_)7O?>G9U0]1'@ZBK_@FR,=47#8G9.&DF@P5*8B3X*FL1WK:I 2
MHK*N8C@CV-;.W%M;K$/BXG[3Q_S?9T"KRX-U<-+^'@/L'#_/]O0+;&V5N7L?
M>&VMA[.QDV8W/NS,46#PF.AX,]=73+%&99#Z*>E@!,DTSVCAA1I'(520](ZQ
M(9'-% J>F8T:5Q&@JY-!UN:_&+X_[:^-'3FUNK=O>&IJ<? <CNK.I%XI=S;O
MR$<39S-S @2"*66-8:5'+-#100Q$G1<@NZN&NIC*WGP'H/(?ZO/H:6MNMK"(
MEX^9]3YG_5Y=& ]I^E'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3[_-T^2?
M^CSJK&]#[:K_ !;L[;B:KW.:>734XSKG'U6B>*325DB.[LO!]HIY62DI:R-A
MZA[.-GMO$E-PWP)P^W_8_P W1-O%SX<0MU^-^/V?[/\ GZUHO8GZ#/6Q%_*.
M^)O]V\!-\GM\8W3G=TTM7B.K*.KBM+B]KR,]-F-V+'(-457N22-J6D<!6&/2
M1U+1U@L'-WN]3?2QGM'Q?;Z?E_A^SH1[/::5^JD'<?A^SU_/R^7V]7>^R/H\
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J#6Y/&
MXU8VR.0H:!92RQ-6U<%*LC* 6$9GDC#E01>U[7]^H3UZH''J!_>G;'_/1X+_
M ,^^/_\ JCWNAZU4>HZD?QW!FE-<,SBOLA-]L:S^(TGVHJ- D\!J/-X1-XSJ
MT7U6YM[]0]>J.G-'615=&5T=0Z.A#*ZL 596!(96!N"."/>NM]19LCCZ:I@H
MZBNHX*NIM]M2S54$53478J/! [K++=A;T@\^_4Z]4=3/?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TQ[FW)A=
MG;<SV[-R5\.*V]MG#Y+/9O)U)(@H,5B:.:NKZN6P+%(*6!FL 2;6 )]V56=@
MBBK$T'56944NV% J>M+#Y)]WYOY$]T[X[7S/F@CW#E'CV_BYG#_P+:N.'V6W
M,,H5FA62DQD2&=DLLU4\LMKR'V-;:!;:!81Y#/S/F>@3<SM<SM,WF<?(>0Z7
M_P +?C3D?E%WCM_8S1U,.S,3IW+V-EH-<?V&TL?40BHHH*D<193<%1(E%2VN
MR/,TVEDADM2]NA:P&3\9P!\_]CCTY96INIPGX!D_9_L\.MQW%8K&X/%XW"8>
MAIL9B,/04>+Q6-HH4IZ/'X['T\=)0T5)!&!'#34M-$L<:* %50![!A)8ECDG
MH9@!0%7 '4_WKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=%O^17Q&^/7RQQ^U\7\@.OO[_4&RZS)U^VH/[U[WVK_#:O,04=/D
MI?+LK<NW)JS[F&@B&FH:54T74*2278II8:^&:5^S_+TS-;PW  F%0.&2/\!'
M5$77O\O+X>YS^:KWM\;<IU#]UTMLWXVX#?VV]F?W_P"T(/X;NVMR/5,%3EO[
MQ4^]H=UUGEBW+6CP5%?+3+YKB,%(])@US,+-90WZA:E:#Y_+HI2SMC?O"5_2
M"5 J>./.M?/H8OYD/Q#Z5ZK^/OQ=^)?0NV#UKM+O?YZ]:ID:1=Q[LW.RYG=>
MTLUL'(9G[[>6<W)E(U2EJ<>?$DH@4TP94#,Y9NUFD>1YI#4K&?3UKY=.WMO%
M'#';Q#2KRCU/$4\Z]'L_E4=QY3M;X>;)P.ZS+%V)T1DLQT#V!053ZJZAR_6T
MD..PR5>HF:2=MH3XX32-?R52S<D@GVQ=H$F)'PMD?GTJL)#); -\:=I_+_8I
MU35W]O?*=S_S&.LOE''73R=:=:_/GH'X>];S(^O'U=)LS)5&;[2KXI0/%412
M[DRWW--+&=,E-6@$G2K>UL:Z+8P_B,98_GPZ+9F,EZL_X%F5!^7'^?6UI[*.
MC_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NJ5/YP?R2_NKL? _'+;-?HSO8"4^Y=^M3R6EHMDXVM;^#XF4H0T;;E
MSU$9& -_M\>R."DXN=[-;:Y#<M\*X'V_[ _P]$F\W.A!;+\39/V>7[3_ (.M
M<U$>1UCC5G=V5$1%+.[L0JJJJ"69B; #DGV).@WUMU?R\_BZGQHZ*QT>>H%I
M^SNQ!1[K[ DD0"KQLDE.QP.T7:VI4VQCZEEF2[ 9">J96*,M@?N-U]5.=/\
M9+@?Y3^?^"G0PVZU^EMQJ_M6R?\ (/R_PUZ/G[0=+^O>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ9.I_^WX_R=_\
M4\VM_P"[?HWVN?\ Y)Z?Z?\ S]%L?_)4D_YIC_GWI0?S(I6R'R=_E:;34W-=
M\JFW;X_K<;&GV36-)I_YM+DR;_B_O5KB*9OZ%/VUZW>YG@7_ (97]E.BJ=I]
MQ3?RXOEG_,&2*5<9MCY$]!K\DNGUE/\ D9[N.1FV;+00)Q$:O+[[W)D:^K1
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M .C"S/\ U^]^_P!:WVZ_Z,NW_P#.%?\ -U[^O?.7_1RO/^<C=>_X=$_F(_\
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MJ^@K*=S'44E;1X#(5%+4P2+ZHYH)XU=6'(8 ^[(*N >%1U20D1L1QH>M!O\
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M?^_'_;U[_AQ3YT?]Y6=V_P#H<97_ *^^_?36_P# O[.O?6W?^_'_ &];D_\
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MYC-9"KRF4KZAK!IZW(5TT]753,!RTCLQ_K[D>*&*",0P*J1**!5   ] !@=
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M43U=75SRU-555,LD]34U,\C2SU%1/*SRS3S2N6=V)9F))-_>1BJJ*$0 (!0
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M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?,V_FH_\
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MWOW7NO>_=>Z][]U[KWOW7NOF;?S4?^WB_P QO_$Z;R_]RD]]-O:K_IW&S?\
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MT0'W('01Z][]U[KWOW7NOK=X_P#X 4/_ %!TW_6E/?(R3^T;_3'_  ]="T^
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MV"[=9=+P$H]33[PW!1U+5N[5@)8FGV)M^&IR2NZ/ U=%2T\MA4"\A>V7*/\
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MRW*^W>^EW+<I&FOIF+.[<2?\  %  *!0    !UE#9V=MM]JEG9H([:-:*HX
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M+LB2$G \511D^UT *_..G%@.HC]U=BENK2+>[==36X*24XZ":JWV*U:_Z:O
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MI&?MZ!O_ (>6_ED?]Y;;&_\ /!V%_P#8=[.?]9CW/_Z-$_\ O</_ %LZ+?\
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M7D<-XH!*D.2 PJ#A2,CY]!'_ ,/+?RR/^\MMC?\ G@["_P#L.]F_^LQ[G_\
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MV=%?^N5R/_T<8O\ >9/^@.O?\/+?RR/^\MMC?^>#L+_[#O?O]9CW/_Z-$_\
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M#_ULZI_KE<C_ /1QB_WF3_H#KW_#RW\LC_O+;8W_ )X.PO\ [#O?O]9CW/\
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MO?NO=>]^Z]U[W[KW6DA_PIX_[*VZ!_\ %=(?_?E[\]YO?=?_ .51W#_I9?\
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M "J6Y_\ 2ON/^K3=?+]]]1.L%NO>_=>Z][]U[JY_^0#_ -O/>F/_  T>X_\
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MEYNFEC%+6\'CKZ:F)$@^WQ S4\@PZIL]S-U&O7O?NO=>]^Z]UNQ?\)HODO\
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M:[)9*NE@HZ&CIXU+/)*ZHH%R1[V 2:#)ZT2%&IC11UKZ_,3^?-L#8D^4V/\
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MW+_I7W'_ %9?KY<WOJ5U@CU[W[KW7O?NO=>]^Z]U]9GK_P#X\/9/_AH[;_\
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MSR55=D<CD*R2:KKJZMJ96DEFE=I))&+,223[S:BABMXE@@54@10JJH 55 H
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MO'.>]1;'LD>NZDRS'"1H*:I)&SI1:_,DD*H+, <R]_W_ &[EO;'W3<WTP)@
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M"LDFJZZNK:F5I)9I7:221BS$DD^\VX88K>)8(%5($4*JJ %50* *!0  8 &
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M/'44]>]^Z]U[W[KW7TR/Y5O_ &[H^'/_ (@S9W_N-)[YE>ZW_3Q]Y_Y[I/\
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MH(XC!(_8>D5[6])>O>_=>Z][]U[JS5/Y-O\ ,TD1)$^)6^F215=&&>Z^LRL
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MMP&Z,15X3+TP9E<(\U!6R!6L=+$'\>UFW7]SM6X0;G9-IO+>9)4/HZ,&4_M
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M\P%X=7GT]/3T=/!24D$-+2TL,5/34U/$D%/3T\*+'#!!#$JQPPQ1J%55 55
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MMLU?[5A4OZB)<:O342$&<DC3UN>_$3^5]\-/A;0XVHZIZHQ>8W_111?<=O\
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MKK>HJJ;)UU#,0&2'<&_:JMIZA.0S8.%K^\)/O,<T?7<PVO*UNU8+&+Q)0/\
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M[J=[FY=I+F1BS,Q+,S,:EF)J22<DG)/67<444$2P0*J0HH"JH   %  !@ #
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M^J,1_&=]=B9V#"XF&0R1T-! $DJ\MGLS4QQS/18';N(IIZZNG".8J6G=@K,
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M_=>Z][]U[KWOW7NOFW_SE?\ MYM\M_\ P^L#_P"^^V=[Z4>S/_3L=H_YH/\
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M?NO=>]^Z]UOB?R@O^W<WQL_[5G8G_OW^P?8>O?\ <I_R_P  Z%VV?[@I^?\
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M9[0W4SM(VYNQ-Z[@:1B2SG,[ER>2+L3R68U-S[Z6;9!]-MMO;?[[@C7_ 'E
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M_P#*I;G_ -*^X_ZM-U\OWWU$ZP6Z][]U[KWOW7NKG_Y /_;SWIC_ ,-'N/\
M]];NGW"WW@?^G7WO_-:W_P"KZ=27[1_\KU:_\TYO^K3]?0H]\\NLPNO>_=>Z
M][]U[KWOW7NO>_=>Z^?=_P *$/\ MYAV/_XCKJ/_ -XNA]]!_N\_].RMO^>F
MX_ZN'K$+W@_Y7>?_ )HP_P#'!U23[F_J+^O>_=>Z][]U[H=/C+T/NCY/=_\
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MD6%70;OW;1Y"%00Q:@)_2K>X4]_]^;9/;JXMXFTW%_*EL/72U9)/R,<;(?\
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MTYL";)2&P )ES"5+7_-^>;^^C/L3<FY]K=L+&KQ^.A_VMQ+I_P",Z>L-?=2
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M_P!.XV;_ )X(_P#!UA!S[_RN>Y?\];_X>B ^Y Z"/7O?NO=>]^Z]U];O'_\
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M?NO=>]^Z]UOB?R@O^W<WQL_[5G8G_OW^P?8>O?\ <I_R_P  Z%VV?[@I^?\
MQX]64>TO2[KWOW7NO>_=>Z(C_,P[I?H?X0]^[SHJQJ+/Y7:$G7^UY8G\=6F>
M[%J8-G0U= _&FLPU#EY\@I_LBD)Y(L5%K'XEPJ^5:_LSTDOI?!M78<2*#\\=
M: /L1] [KWOW7NO>_=>Z&KXY=,9GY#][=5=*8)IHJWL;>F'V]/6P1B5\3AI9
M_N=QYTQD$/%@-O4U56N+&Z4YX/MN5Q%&9#Y#IV"(S3+$.+&G^?\ 8.OHO[/V
MGM_86T]L['VGC8,/M?9^ Q&V-NXFF733XW"8*@I\9BZ*(?71345,B GDVN>?
M898EB6/$GH:JJHH1<*!0=*/WKJW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW56?\X'XTP?(?X:[WRF-QZU6_.D4G[:VA/%$'K)*# 4
MDIWSA8V4&>2#)[0^YF6!+^>MHJ7@E19792^%. ?A;'^;^?1?N4'C6I(^-,C_
M "_RZT7_ &(.@GU[W[KW7O?NO=&0^(/=,_QX^3G2/<<=0U-1[*[ PE3N!T9E
M:79^4F;!;UI0RG@UFTLI6Q FX!>Y!'!:GC\6)D]1_/R_GT_;2^#.DOD&_EY_
MRZ^BTCI(B21NLD<BJZ.C!D=& 971E)5E93<$<$>PST->N7OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NOD8[VP\NWMY[NP$ZE9\
M'N?/8>93<%9<9E:NBD4AB6!#P'ZF_OIE:2B>UBF7@\:M^T ]87SH8IWC/%7(
M_8:=)GVHZ9Z][]U[KWOW7NOI;?R8-Q1[H_E@_$+)12+(M+L#-[=+*;@2;0[
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M5%343RLL<,$$*%G=B%5023;W9$>1Q'&"SL0 !DDG  'F3UIF5%+N0% J2>
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MST33254L[FKI]\[RI*M2TS3NPFQ]',#KN*F8&\2^SG<MQI6VMCC@2/\  /\
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MO?NO=>]^Z]U[W[KW7O?NO=:"'_"BI5'\Q[,D  MTSU8S$  LWV^:6[$?4Z5
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M?=VZ8J3/;YR%))8>+(8#:L./I+@G5!GI!;\^\5?O.<T?3[=8\HV[?J7#_43
M<?#2J1 _)Y"[?;$.I[]C]B\:\NN89AV0KX,9_IM1G(^:II'V2'K<E]X9]9)=
M>]^Z]U[W[KW7O?NO=>]^Z]T'7<'_ #*3M+_Q'6]__>9R?NZ?&/M'5)/[-O\
M2G_!U\UCV*.@-U[W[KW7O?NO=>]^Z]U]%OXO[:VY+\:/CO++M_"2RR]%]222
M228J@>221]@;?9W=V@+.[L222;D^PS,3XK9_$?\ #T-8%7P$P/@'^#H<_P"Z
MVV/^><P/_GHQ_P#]3^VZGU/3NE?0=>_NMMC_ )YS _\ GHQ__P!3^_5/J>O:
M5]!U[^ZVV/\ GG,#_P">C'__ %/[]4^IZ]I7T'7O[K;8_P"><P/_ )Z,?_\
M4_OU3ZGKVE?0=>_NMMC_ )YS _\ GHQ__P!3^_5/J>O:5]!U[^ZVV/\ GG,#
M_P">C'__ %/[]4^IZ]I7T'73;3VLZE'VU@'5A9E;#8YE8'Z@@TQ!!]^J?4]>
MTKZ#IBK^K.L<HK+D^N=AY%7X=:_:&WZM6'(LPJ,?(&X/Y][UN.!/[>M&.,\5
M'[!T&&?^('Q/W2KKN+XR] YEGO>:OZ@Z_GJE+?5HJMMO_=0N;_J1U;_'W<33
M#@[?M/3;6UNWQ1H?R'1:=[_RC_Y?.^HYON_CSA=NU<FHQU^R-R;SV?)3.U[O
M#083<-+@WM?A9:21!_J?;JWEROXJ_;0],/MMF_% #\B1_EIU7[V]_P )Y^F\
MS#55G1_=V_=B9%A)-!B.P<9A]^X%I+$QT<-;AXMFYK&TQ-AY93D9%^NE_I[4
MIN3C^T4'[,?Y^D<FRQ',3D'YY_S?Y>J/_E)_+!^77Q/IJ_<&]-AIO+KS'AY:
MCLOK.>IW5M:BID)O4YZ#[*AW'M>G12NJ?(T--2ZV"I,Y]KX;N&;"FC>AZ*KB
MPN;?+"J>HR/\X_/JO;VIZ1=>]^Z]U[W[KW7O?NO=&L^'7RY[+^&?<F&[4Z_J
MI*O'L\&-WYLJHJI8,+OS:3SJ]=A,DJB1(*V(7EH*P(\E%5A9 '0R12,SPI.F
MAN/D?0]*+:YDM91(G#S'J.M^CH[NG8/R'ZIV7W'UGE1EMG;XQ$63Q\CB-*W'
MU"N]-E,'EZ>.29:/-X+)PRTE9#J81U$+!69;,0[)&T3E'^(=#"&5)HQ*GPD=
M"Q[ITYU[W[KW7O?NO=>]^Z]U[W[KW6GK_P *$O\ LL+JO_Q6O:__ +]#MSV=
M[;_8'_3G_ .@UO/^Y*_Z0?X3U0[[,.BCKWOW7NO>_=>ZWQ/Y07_;N;XV?]JS
ML3_W[_8/L/7O^Y3_ )?X!T+ML_W!3\_^/'JRCVEZ7=>]^Z]U[W[KW6GY_P *
M#=Y-E_E;U=LN*8R4FS>C\97RQZCI@R^Z]Y;MEK%"?0,^*PU Q/U(('X'LZVU
M:0EO5O\ (.@UO+5N%3T3_"3U0M[,>BCKWOW7NO>_=>ZW"/\ A/OL&/ _%'LG
M?TT CK^P.Y\G1Q3:;&? [-VQMVBQ]WL"PBS66R8 ^@_UR?9+N35F"^07_#T)
M=F2ENS^;-_@'_%]7R>R[HWZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NM)7^>5L"/9GSWW-G(81#'VAUSUWOVRKHC>:
MFQM5U]42J  NJ6?8;,Y'ZI&+'DGV?;>VJW ]"1_E_P O05W9-%X3_$H/^3_)
MU3[[6]%O7O?NO=>]^Z]UNN?R*=Y/N?X%8?"-,91UWVIV/LY$)O\ ;I6U6,W_
M .$#^R"^^2]OZO[(MP6EQ7U /^3_ "="G:6U68'\+$?Y?\O5R'M#T9]>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?.E_G[]6R=:?S.
M.ZJ^.E-)BNT\%UUVEAUT:5FCR^SL9MS/52-P)!4[RVIDW)_U1(^HO[SF]F-Q
M&X>W]HA-9+9Y86_VKEE'Y(Z=8Q^XUG])S9.P%$F5)!^:A3_QI6ZIE]RIT!>O
M>_=>Z][]U[K:L_X2Y=Z0X3MWY)?'/)581.P-D;9[6VO!/)HC&5Z[RM1MS<E-
M1J2!)6Y7%;YHYG478PXLL+!&]XY?>'V<S;98;[&,P3/"Y^4H#*3\@8V'VO\
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MYZW_ ,/1 ?<@=!'KWOW7NO>_=>Z^MWC_ /@!0_\ 4'3?]:4]\C)/[1O],?\
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M_P TYO\ JT_7T*/?/+K,+KWOW7NO>_=>Z][]U[KWOW7NOGW?\*$/^WF'8_\
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M>]^Z]U[W[KW7O?NO=?,V_FH_]O%_F-_XG3>7_N4GOIM[5?\ 3N-F_P">"/\
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MO\W1!NUH%_QJ,8.&_P A_P A_+K6L]FO1%U[W[KW7O?NO=.F$S65VWFL1N+
MU]3BLY@,I09K#92CD,59C<KBZN*NQU?2RCF.IHZR!)$;\,H/O1 (H>'6P2I#
M#B.OHL_%?NZA^1_QUZ?[MH1 C]@[)Q65S%-2F]/CMTTROBMX8F W):+$;JQ]
M92J38D17(!X]AF:/PI6C]#_Q70UMY1/ LO\ $/Y^?\^A_P#;?3W7O?NO=>]^
MZ]U[W[KW6GK_ ,*$O^RPNJ__ !6O:_\ []#MSV=[;_8'_3G_  #H-;S_ +DK
M_I!_A/5#OLPZ*.O>_=>Z][]U[K?$_E!?]NYOC9_VK.Q/_?O]@^P]>_[E/^7^
M ="[;/\ <%/S_P"/'JRCVEZ7=>]^Z]U[W[KW6A?_ #;ZIZS^8E\EII"69,_L
MRE!+:O10]7['HHQ< <+'3@6_%K>Q#9"ELGV'_">@CN.;V3[1_@'5<?M5TAZ]
M[]U[KWOW7NOH!_RRZ-:#X$?%N!5TA^K<966L!ZLC79#(,W!(]351/]>>?8<N
MO]R'^WH8V I9Q_Z7H]/M/TKZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NM8O_A1Q2II^'U:!:35WW2NUOU);IJ6(%OQ
MH;78?G4?9KMGXQ]G^7HAWO\ T(_Z;_GWK6']FW1#U[W[KW7O?NO=;47_  G0
ME8[&^4T!_1'NSJV5?K^J;#[U1^+V^D"^RC<_B3[#_DZ$&R?!)]H_R];)7LKZ
M/.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJQOYP_Q
ML?Y0_P O?O[9F,H#D-X;*V^O<6PHXXC-5G<W6'EW%4T./A )ER.XMJ19/$PJ
M.2]>/<@^UV_#E[G:RNY&TVLS^!)Z:)>T$_)7T.?]+T$^=]J.[\M7,""L\:^*
MGKJC[J#YLNI1]O7S1/>?/6*O7O?NO=>]^Z]U[W[KW7T(?Y WS7@^4'PTQ/5.
MZ,L*KMOXO1XKK?.Q5,X>OS'71IYQU9N8*[-*\4.$H),+,Q+.:C#F5R/.@.$O
MO1RFW+W-3;E;K3;-QK*M!A9:_K)_O1$@^3T' ]9*^W&_#=MB6SF:M[:40^I3
M_0V_8-/VK7SZO3]P_P!2#U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= 9
M\F._]D_%KH7M/Y =ASB+:W5^TLCN.II1/'35.<R2!*3;VU\;+,&B&7W7N"JI
M<=2:AI-35)JL+GV<;!LMWS%O-MLMB/\ &;B4*#2H4<6<_P!%%!9OD#T7[KN5
MOM&W3;E<G]&%"WVG\*CYL:*/F>OED=R]L;P[V[8[&[FW_7?Q'>?9^\MP;VW%
M4J7\"Y+<&2GR$M)0QR,YIL9CUF%/2P@Z(*:)(ULJ@>^B>U;;:[/ML&U60TVE
MO$L:CY* *GU)XD^9)/6(E]>3[A>2WUR:SRN7;[6-:#Y#@!Y#'0:^U_23KWOW
M7NO>_=>ZW$/^$NOQL:EP_P A_EMFJ!DDRU1C>A]@5DL9C8T% <;O?LB:$N+S
MTM77R;=ACD2R"6CG0DL"%Q=^\-OVJ6QY:B;"@W$@^9K'%^8'BDCT8'[9N]I-
MKHEUO,@R2(4/R%'?^>@?D1UMR>\9^IHZ][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HJ/SR_[(;^9O_BJ
M/R)_]]#O#V+.0O\ E>ME_P"EM9_]I$?1!S7_ ,JMN7_2ON/^K+]?+F]]2NL$
M>O>_=>Z][]U[KWOW7NOK,]?_ /'A[)_\-';?_NFHO?)3</\ <^?_ )K/_P >
M/706S_W$B_YIK_QT=*[VDZ4=>]^Z]U[W[KW7O?NO=>]^Z]UI"_\ "G7_ ++%
MZ*_\5HQ?_OT>R_></W8/^5-O_P#I9M_U8AZQ=]\O^5DM/^>$?]79>M;+WDKU
M"G7O?NO=>]^Z]U]$K^0Y_P!NL/C3_P!1G=G_ +_[M'WSJ]^O^GJ[G_I;;_M$
M@ZS']I_^5"LOMG_[2)>K??</=2-U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW14?GE_P!D-_,W_P 51^1/_OH=X>Q9R%_RO6R_]+:S_P"TB/H@YK_Y
M5;<O^E?<?]67Z^7-[ZE=8(]>]^Z]U[W[KW5Q'\A/_MZ3\>/^U1W3_P"^/[$]
MPY[^_P#3K-Q_T]M_VDP]2/[3?\KY9_Z6;_JQ)U]#_P!\[.LQNO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K0&_X41?\ ;R3<_P#XB/JG_P!U
M5=[Z _=U_P"G:Q?\]D__ !X=8C>\?_*ZO_SS1?X#U1C[G7J*^O>_=>Z][]U[
MKZ=?\M;_ +=]_"__ ,5IZ>_]XC#^^8/N7_T\+>O^EG<?]76ZSEY)_P"50VS_
M )XH?^.#H[GL#]"CKWOW7NO>_=>Z][]U[K20_P"%/'_96W0/_BND/_OR]^>\
MWONO_P#*H[A_TLO^L,76+_OG_P K#:?\\7_663K6G]Y,=0EU[W[KW7O?NO=?
M1*_D.?\ ;K#XT_\ 49W9_P"_^[1]\ZO?K_IZNY_Z6V_[1(.LQ_:?_E0K+[9_
M^TB7JWWW#W4C=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5'YY?\
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MO=:0O_"G7_LL7HK_ ,5HQ?\ []'LOWG#]V#_ )4V_P#^EFW_ %8AZQ=]\O\
ME9+3_GA'_5V7K6R]Y*]0IU[W[KW7O?NO=?1*_D.?]NL/C3_U&=V?^_\ NT??
M.KWZ_P"GJ[G_ *6V_P"T2#K,?VG_ .5"LOMG_P"TB7JWWW#W4C=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5'YY?]D-_,W_Q5'Y$_P#OH=X>Q9R%
M_P KULO_ $MK/_M(CZ(.:_\ E5MR_P"E?<?]67Z^7-[ZE=8(]>]^Z]U[W[KW
M5Q'\A/\ [>D_'C_M4=T_^^/[$]PY[^_].LW'_3VW_:3#U(_M-_ROEG_I9O\
MJQ)U]#_WSLZS&Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM
M ;_A1%_V\DW/_P"(CZI_]U5=[Z _=U_Z=K%_SV3_ /'AUB-[Q_\ *ZO_ ,\T
M7^ ]48^YUZBOKWOW7NO>_=>Z^G7_ "UO^W??PO\ _%:>GO\ WB,/[Y@^Y?\
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M $MK/_M(CZ(.:_\ E5MR_P"E?<?]67Z^7-[ZE=8(]>]^Z]U[W[KW5Q'\A/\
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M7_I;6?\ VD1]$'-?_*K;E_TK[C_JR_7RYO?4KK!'KWOW7NO>_=>ZM\_D._\
M;U#XS_\ 4)W9_P"^ [2]P_[]?].JW/[;;_M+@ZD;VG_Y7VQ^R?\ [1Y>OHE^
M^=/68_7O?NO=>]^Z]U[W[KW7O?NO=?-O_G*_]O-OEO\ ^'U@?_??;.]]*/9G
M_IV.T?\ -!_^KLG6%?N5_P KQN/_ #57_JVG59'N3N@-U[W[KW7O?NO=?5J^
M/W_,ANDO_$1=;?\ O&X7WRAYA_Y+]]_SV3?]7&ZS\VC_ ))-K_SSQ_\ '%Z%
MWV3]&/7O?NO=>]^Z]U[W[KW7O?NO=?,V_FH_]O%_F-_XG3>7_N4GOIM[5?\
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M>]^Z]U[W[KW7O?NO=%1^>7_9#?S-_P#%4?D3_P"^AWA[%G(7_*];+_TMK/\
M[2(^B#FO_E5MR_Z5]Q_U9?KY<WOJ5U@CU[W[KW7O?NO=7$?R$_\ MZ3\>/\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z^:Y_-K^,'^RG?/#NW8&-Q_P##]D;MS/\
MI:ZUCCB\-&NRNQ9JK,QX['1V!%!M;<0R.%CO<D8V]S]3TL]H^:/ZV\A6.X2M
MJOH4^GF]?$A 6I^;IHD/^GZPG]PMB_J_S7=6B"EK(WBQ^FB2IH/DK:D_VO5;
M?N2N@5U[W[KW3EALQE-NYC%;@P==48O-8/)4.8Q&3I',57CLIC*J*MQ]=2RC
MF.HI*N!)$;\,H/MN:&*YA>WG4/!(I5E/ JPH0?D0:'IR*22&19HB5E1@01Q!
M!J"/F#U]2?XA]^XOY1_&/I#O[%&G [-Z^P6>R]+2$-3XO=D4!Q>]<'&P+7&
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M]KNBOKWOW7NO>_=>ZW4/Y#^U6V]\$*?+M&4&^>X.Q-THQ%O,E'#M[9)D!_M
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MY?\ *R6G_/"/^KLO6ME[R5ZA3KWOW7NO>_=>Z^B5_(<_[=8?&G_J,[L_]_\
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MWK_I9W'_ %=;K.7DG_E4-L_YXH?^.#H[GL#]"CKWOW7NO>_=>Z][]U[K0?\
M^%&T)C_F+2.55?N.BNL)@1:[A:S=<&IK<Z@8+<\V _%O>??W<#7VY ]+^?\
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M>Y.Z W7O?NO=>]^Z]U]6KX_?\R&Z2_\ $1=;?^\;A??*'F'_ )+]]_SV3?\
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MGHZ*CIYJNLK*N:.GI:2EIXVFJ*FIJ)F2*"G@B0L[L0JJ"20![LJL[!$!+DT
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*C\\O\ LAOYF_\
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MKWOW7NO>_=>Z^G7_ "UO^W??PO\ _%:>GO\ WB,/[Y@^Y?\ T\+>O^EG<?\
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM!'_A17_V\>R__B&.K/\
MK3F_>?WW<_\ IVZ?\]L_^%>L2/>7_E=&_P">:+_G[JB;W/'44]>]^Z]U[W[K
MW7TZ_P"6M_V[[^%__BM/3W_O$8?WS!]R_P#IX6]?]+.X_P"KK=9R\D_\JAMG
M_/%#_P <'1W/8'Z%'7O?NO=>]^Z]U[W[KW6B3_PI7QGV'S_V15Z0/XU\8.O,
MD6']LP]A]N8>Y_VH#% ?ZP'O/#[L\OB>WTZ?P;I,O_5&W;_G[K%+WM31S=$W
M\5C&?^JDP_R=:]WO(;J'^O>_=>Z][]U[KZ$_\@'<\>?_ )8?3.+2022;*W=W
M#MB<!M31R5/9^YMX)&_Y4BFW9&0/]21^/?/+[P-J;?W0O92*">&W<?E D?\
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M^8(/6!MU;365S)9W TW$4C(P]&4E6'Y$'I+>U72?KWOW7NK</Y'_ ,A'^/\
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M+SJS8.6[6[,Z]ZQP2LV9[#WMM;9.+TH7T5VZ,W186FE91_NN&6M#N38!5))
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M/QY/\?>:WW7;H/RYN=E7,=\CT_YJ1!?Y^%_+K&7WT@T[S8W5,/:LO^\2$_\
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M>,=<[($F)PF1@CE EIDW56"JS;PMS%-DW3\>^F?M=RD>2^2K/9I@!?E3+/\
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MZS'Z][]U[KWOW7NO>_=>Z][]U[KYM_\ .5_[>;?+?_P^L#_[[[9WOI1[,_\
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M />9R?NZ?&/M'5)/[-O]*?\ !U\UCV*.@-U[W[KW7O?NO=>]^Z]U]';XM_\
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M/EKF>0G:L+#,V3#Z)(?]]?PM_H? _I_!$G/?(7[PU[SLJ?X]QDC'^B>K*/\
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M?=TO&(-]ND2#TCA9_P";2)3[:'[.BZ?W?MP/\5L78_TI O\ ((W^$=5]=O\
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MMG_PKUB1[R_\KHW_ #S1?\_=43>YXZBGKWOW7NO>_=>Z^G7_ "UO^W??PO\
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H.NX/^92=I?^(ZWO\
M^\SD_=T^,?:.J2?V;?Z4_P"#KYK'L4= ;KWOW7NO>_=>Z][]U[K=RZ _FG_
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MDG2@RL<$D..W3MRJ+3;?W7ABY?R8S.XXK*HU,\$FN"33-%(JB2*59HQ(O ]
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M_I9W'_5UNLY>2?\ E4-L_P">*'_C@Z.Y[ _0HZ][]U[KWOW7NO>_=>ZTD/\
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M&!U7O[D/H']>]^Z]U<__ " ?^WGO3'_AH]Q_^^MW3[A;[P/_ $Z^]_YK6_\
MU?3J2_:/_E>K7_FG-_U:?KZ%'OGEUF%U[W[KW7O?NO=>]^Z]U[W[KW7S[O\
MA0A_V\P['_\ $==1_P#O%T/OH/\ =Y_Z=E;?\]-Q_P!7#UB%[P?\KO/_ ,T8
M?^.#JDGW-_47]>]^Z]U[W[KW7TZ_Y:W_ &[[^%__ (K3T]_[Q&']\P?<O_IX
M6]?]+.X_ZNMUG+R3_P JAMG_ #Q0_P#'!T=SV!^A1U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=%1^>7_9#?S-_\51^1/_OH=X>Q9R%_RO6R
M_P#2VL_^TB/H@YK_ .56W+_I7W'_ %9?KY<WOJ5U@CU[W[KW7O?NO=6^?R'?
M^WJ'QG_ZA.[/_? =I>X?]^O^G5;G]MM_VEP=2-[3_P#*^V/V3_\ :/+U]$OW
MSIZS'Z][]U[KWOW7NO>_=>Z][]U[KYM_\Y7_ +>;?+?_ ,/K _\ OOMG>^E'
MLS_T[':/^:#_ /5V3K"OW*_Y7C<?^:J_]6TZK(]R=T!NO>_=>Z][]U[KZM7Q
M^_YD-TE_XB+K;_WC<+[Y0\P_\E^^_P">R;_JXW6?FT?\DFU_YYX_^.+T+OLG
MZ,>O>_=>Z][]U[KWOW7NO>_=>ZTF/^%.?6-1@OE'T)VW'3/%C.Q>DJO9S3A?
MVJG.]9[RRU?D7U_F=,/V)C48?ZA%_P ?>;OW8-T6?E;<-H)K+;7PDIZ+-&H'
MY:H7/[>L8??*Q:+?K3<0.R:U*?:T3DG^4B]:S_O)GJ$.O>_=>Z][]U[KWOW7
MNC0]8?-OY@]+XREP?5?R=[TV-MZAB$-%MG!=G;NI]KTD:J%5:;;+Y67 P:%%
M@5IP0.!["VZ<D<G;U*9]UVNPGN&-2[01ES]KZ=9_;T>V/-',>V1B*POKN*$<
M%65](^Q:Z?Y="ODOYI?\Q3*P&GJOF1WU%&1;5C=]9+#3_P"PJ<0:&I!_QU^R
MJ/VK]N8FU+LU@3\XE8?L:HZ,'Y\YRD%&W*[I\G(_F*'I$;+^;GR8@[@ZK['[
M$^0W>6_XMA=E[%WQ-3[S[6W[NR&=-J;IQ>?:*2ES>>KXIHW%!8H5*D&UO:Z]
MY'Y9;9[O;=NVZPMS<6TL0,<$4=/$1DXJ@]>/26UYHWP;C;WMY>74PAG1Z/+(
M_P #!N#,?3KZ@4,T51#%402)-!/&DT,T3!XY8I5#QR1NI*NCHP((X(/OET05
M)5A1@<]9T@AA49!ZR>]=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZT\/^
M%-OQ@_A6[ND/EYM_':*+=5#-TIV/4P1:(EW!@XZ_<W7F1J2H/FK<O@7R](\C
M$:8<33H+\6S&^[%S1XMG?<GW#=\3"YA!_@:B3 ?)6\-@/61CUCC[X[%X=Q:\
MQ0KVR#P9#_26K1D_,KK%?1%'6J/[RPZ@#KWOW7NO>_=>Z][]U[KWOW7NMTW_
M (3/?&+^Z'2';7RKSV.\>8[AW&G7>PZF>*TB;!Z_GD?<60H)K"])N+?-4]+.
MI)_=V^AX_.%/WFN:/K-\M.5+=JPV<?C2@?[]E'8#\TB 8?*4]9->R&Q?3[7<
M;_,OZER_AQG_ (7'\1'R9S0_./K9Z]XO]3GU[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=!UW!_S*3M+_ ,1UO?\ ]YG)^[I\8^T=4D_LV_TI
M_P '7S6/8HZ W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=3,=CLAF,A0XG$T-9E,KE*RFQV,QF.I9ZW(9'(5LR4U'0T-'3)+4U=95U$BQ
MQ11JSR.P5020/>B0!4\.M@$F@X];F/\ *5_EH#XI[97N_N;%TTOR%WKB?!08
MB7Q52=2;4R$:/-@H9%+PMO+,QV&5J8R13Q 4<+:?N7J"2\NO&/AI_9#^?0FV
MZQ^G7Q9?[8C]@_S^O[.KK_:#HUZ][]U[KWOW7NO>_=>Z][]U[KWOW7NM/7_A
M0E_V6%U7_P"*U[7_ /?H=N>SO;?[ _Z<_P" =!K>?]R5_P!(/\)ZH=]F'11U
M[W[KW7O?NO=;XG\H+_MW-\;/^U9V)_[]_L'V'KW_ '*?\O\  .A=MG^X*?G_
M ,>/5E'M+TNZ][]U[KWOW7NO>_=>Z][]U[JKS^9[_+WQ'S;ZKCRNTX<?BN_^
MNJ*KJ.N\[4-'20;DQS,U57=>;AK6 5<9E9KR4,\ATX_('7J2&:J$BNTN3 ]&
M_LSQ_P _2"_LA=1U7$R\/G\C_JX]:.>Y]L;BV5N/.;1W;A<EMS<^VLI6X3/X
M',4LM#E,1EL=.]+74%=23JLL%333QLK*1]1_3V?@AAJ7(/03965BK"C#IB][
MZUU[W[KW7O?NO=*3:&\MV]?[CQ6\-B[FSVSMUX.I6LP^X]LY:NPF;QE2H*^:
MBR6.GIZNG=D8JVEP&4D&X)'O3*K#2P!'5E9D8,A(8>8ZO'^.7\_'Y"]=TU!M
M_OS9>W^]L)3+'!_>6CJ(MA=AI"H$?EK:S'8ZNVMG6@C4$*V-I)YFN9:EF;4"
M^7;HVS&2I_:.C6#>)D[9@''KP/\ F_EU;GUO_/1^".]:>G.[,YV+U'6NJK/3
M[UV#E,Q31SV 80UW7+[W$M,7X222. E>71.0$;;?<+\(#?8?\].C*/=K1_B+
M*?F/\U>C-X[^9_\  /*0+44WRBZWBC8!@N1ES6(GL1<:J;+8>BJ5//(* C\^
MV?I+D?@/3XO[,_Z(O3+N'^:[_+WVS#)-7_)C:-8$!_:V]@]\;JFD8?18XMM;
M6RK$L> 39?ZD#GWL6=R>"'^76FW&R7C(/RJ?\ Z))V[_ ,* OB_M2GJJ;J/K
MWLSMO,HK_:U.1I\?UUM&9K$(7RN3DS.YT]7)4X4>G^U?@*$VV4_&0H_;_J_;
MTEDWBW7^S5F/[!_G_EU1W\I_YN'R[^3]+DML/NBEZAZWR"RT]1L?JTUN&?*T
M,@,9I=R[MFJI]SYJ*:%BE1 D]+CZA6.NEM8!?#90Q9IJ;U/^;HIN-RN9^VNF
M/T'^4\?\G57_ +5](.O>_=>Z][]U[KWOW7NC9_#7X?=G_-'N#&=8]?4LE#B*
M9J;)=@;[JJ62;!;"VJ9_'497(%6B6KR=6$>+'4"R)+75(T@I$DTT3,\Z0)K;
MCY#UZ4VMM)=2>&G#S/H/]7#K?8Z$Z+Z[^-O4^T.F^KL0,3M+9^/6E@,I23)9
MC(S,9\MN'.5:1Q"NSF<KW>HJ9=*KK?3&J1*D:AV21I7+O\1Z%T,*01B*,44?
MZJ]##[IT[U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5._
MS4_D@_";YBS97=D.U)NANW<CYJB3L?J&DQV(I<QD9;N*K>>PY(5VKN5I9V,E
M1411X_*U+'UUMK>Y1Y3]W.;>5PML9!>;8N/"F)8J/2.3XT] "60>2= C?N0-
MAWPF8)]->G\<8 J?Z2?"WS.&/\76JQ\KO^$_WSR^.CY3.; VSC_DWU]1F::#
M.]0I42[WBH4OXFRW560;^]#9"4*28,*V=C06O-<V&1G+?O5R;OH6&]D;;[T_
MAFIX=?Z,P[*?.3PS\NH@WCVWYBVRLEL@N[8><?QT^<9[J_)=?V]4HY_;V?VI
MF*_;VZ<'F-M;@Q4[4N4P>?QE;A\QC:I "U-7XS(P4U;1SJ"+I(BL+_3W+$,\
M-S$L]NZR0L*AE(92/4$5!'V= .2*2%S%,K)(#D$$$?:#D=-'MWIOKWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZL@^+?\ICYX_+F6@K>M^C-P
M;:V57&)_])O:T=1UQL):28#3D*"OSM*F9W51@L QP=#E'4_5>#8"<Q>Y7)O+
M(*W]XDEV/]"AI+)7T(4Z4/\ S49.A3M')O,6]$-:V[) ?]$D[$IZ@G+#_2!N
MMH#X;?\ ";3XX=1R8C>/RKW;6_(S>M(T%8=D8N.LVATYCJQ-,@@JZ6&==V[X
M2FG0%7JJG'450ETGQ[J2/>/?-7OSONYAK7ER(6-H<>(:/.1\C\$=1Z!F'$..
MI9V/VMVNR*S[PYNIQG0*K$#\_P 3_F5!\UZV,]I[1VIL+;F(V?L?;.W]F[2P
M%&F/P6V-K8?';?V_AJ&,DQT>*PV)IZ3'8^E0L2(XHT4$DVY]P7<W5S>3M=7D
MCRW+FK.[%F8^I8DDG[3U)\,,-O$L%NBQPJ*!5 50/0 4 _+I0^V.G>O>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HJ/SR_P"R&_F;
M_P"*H_(G_P!]#O#V+.0O^5ZV7_I;6?\ VD1]$'-?_*K;E_TK[C_JR_7RYO?4
MKK!'KWOW7NO>_=>Z][]U[KZS/7__ !X>R?\ PT=M_P#NFHO?)3</]SY_^:S_
M /'CUT%L_P#<2+_FFO\ QT=*[VDZ4=>]^Z]U[W[KW7O?NO=>]^Z]UI"_\*=?
M^RQ>BO\ Q6C%_P#OT>R_></W8/\ E3;_ /Z6;?\ 5B'K%WWR_P"5DM/^>$?]
M79>M;+WDKU"G7O?NO=>]^Z]U]$K^0Y_VZP^-/_49W9_[_P"[1]\ZO?K_ *>K
MN?\ I;;_ +1(.LQ_:?\ Y4*R^V?_ +2)>K??</=2-U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW14?GE_V0W\S?_%4?D3_ .^AWA[%G(7_ "O6R_\
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MOMC]D_\ VCR]?1+]\Z>LQ^O>_=>Z][]U[KWOW7NO>_=>Z^;?_.5_[>;?+?\
M\/K _P#OOMG>^E'LS_T[':/^:#_]79.L*_<K_E>-Q_YJK_U;3JLCW)W0&Z][
M]U[KWOW7NOJU?'[_ )D-TE_XB+K;_P!XW"^^4/,/_)?OO^>R;_JXW6?FT?\
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MYIK_ ,='2N]I.E'7O?NO=>]^Z]U[W[KW7O?NO=:0O_"G7_LL7HK_ ,5HQ?\
M[]'LOWG#]V#_ )4V_P#^EFW_ %8AZQ=]\O\ E9+3_GA'_5V7K6R]Y*]0IU[W
M[KW7O?NO=?1*_D.?]NL/C3_U&=V?^_\ NT??.KWZ_P"GJ[G_ *6V_P"T2#K,
M?VG_ .5"LOMG_P"TB7JWWW#W4C=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T5'YY?]D-_,W_Q5'Y$_P#OH=X>Q9R%_P KULO_ $MK/_M(CZ(.:_\
ME5MR_P"E?<?]67Z^7-[ZE=8(]>]^Z]U[W[KW5Q'\A/\ [>D_'C_M4=T_^^/[
M$]PY[^_].LW'_3VW_:3#U(_M-_ROEG_I9O\ JQ)U]#_WSLZS&Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM ;_A1%_V\DW/_P"(CZI_]U5=
M[Z _=U_Z=K%_SV3_ /'AUB-[Q_\ *ZO_ ,\T7^ ]48^YUZBOKWOW7NO>_=>Z
M^G7_ "UO^W??PO\ _%:>GO\ WB,/[Y@^Y?\ T\+>O^EG<?\ 5UNLY>2?^50V
MS_GBA_XX.CN>P/T*.O>_=>Z][]U[KWOW7NM)#_A3Q_V5MT#_ .*Z0_\ OR]^
M>\WONO\ _*H[A_TLO^L,76+_ +Y_\K#:?\\7_663K6G]Y,=0EU[W[KW7O?NO
M=?1*_D.?]NL/C3_U&=V?^_\ NT??.KWZ_P"GJ[G_ *6V_P"T2#K,?VG_ .5"
MLOMG_P"TB7JWWW#W4C=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5
M'YY?]D-_,W_Q5'Y$_P#OH=X>Q9R%_P KULO_ $MK/_M(CZ(.:_\ E5MR_P"E
M?<?]67Z^7-[ZE=8(]>]^Z]U[W[KW5Q'\A/\ [>D_'C_M4=T_^^/[$]PY[^_]
M.LW'_3VW_:3#U(_M-_ROEG_I9O\ JQ)U]#_WSLZS&Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NM!'_A17_V\>R__B&.K/\ K3F_>?WW<_\
MIVZ?\]L_^%>L2/>7_E=&_P">:+_G[JB;W/'44]>]^Z]U[W[KW7TZ_P"6M_V[
M[^%__BM/3W_O$8?WS!]R_P#IX6]?]+.X_P"KK=9R\D_\JAMG_/%#_P <'1W/
M8'Z%'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T13YU_R\_C[\_NO$VEV[AI,7N_!
M051Z][8VY#2P[XV+6U%G>.EJIHVBS.VZV95^]Q57JI:@>M##4K%41#OD3W$Y
MA]O]Q^KVAP]G(1XT#U,4H'J!\+C\,B]PX'4I*D*<U\G;/S=9_3[BNFY0'PY5
MIKC/R/XE/XD.#Q%&HPT5OG3_ "H/E=\$\ID<IO+:LW873:5+KB.[]@T%;D=H
M-2/-HI$WA1A9LEU]EY%=%>'( 4CSL8Z6KJPI?WG=R)[L\I\^1+%92BWWFG=;
M2D"2M,^&<+*O'*=P&71*TZQ5YJ]O^8.5)&DN8_&VVN)XP2E/+6.,9^38KA6;
MCU69[DWH#]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U8I\&/Y8'RD
M^>F?I&ZVVI+M7JJ&M^WW'W=O2DK<=L'%1P2Z*^FPDWB6IWMN&G *C'XT2F.5
MD%5+2Q-YECGGKW1Y6Y!MR-SE$NZE:I;1D&5J\"PX1H?XWI45TAR*=#+E7D7?
MN;)A]%'X=@#W3N"(QZA?-V_HK7--149ZWNO@7_+F^/O\OW8+[<ZLQ+YW?V?H
MZ6/L/M_<=/3MO/>M3 5E-*K1^2+;>U:>J&JEQ-(W@BTJ\SU-3KJ'P.Y^]Q^8
M?<'</J=U?P]OC8^#;H3X<8/G_3D(^*1LG(4*M%&5W*?)FS\H6G@V"Z[MP/$F
M8=[GT_HI7@@P.)+-5B?GV .A;U\\S^?K_P!O0^]__#=Z9_\ ?/;)]]$/8#_I
MUMA_S4N?^TB7K#SW;_Y7N[_TD/\ U93JFOW,W4:]>]^Z]U<__(!_[>>],?\
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M_P"B*QG_ -M;W[_@I[O_ *,L?_94W_6CKW^L/;_]'-_^< _ZV]>_Z!:MI?\
M>:&XO_1%8S_[:WOW_!3W?_1EC_[*F_ZT=>_UA[?_ *.;_P#. ?\ 6WK98^./
M3L'QZZ#Z<Z+IL_+NJGZBZWVCUY#N6?')B)L[%M3"TF'3*RXJ.MR*8]ZY:3R&
M$5$PC+6UM:_O&?F3>6YBW^]WUHQ$UY<R3% =07Q&+:=5!6E:5H*^@ZFW9=M&
MS[1;;4K^(+>%(]5*:M"@5I4TK3A4_;T-/LEZ,^O>_=>Z][]U[KWOW7NJ7/YE
MO\G?"?S&NU]A]HY/OS*=33;'Z]38,>%H.NJ3>4>2C3<F<W%_%'KJC>>VFI7+
M9LQ>(12"T>K7ZK":O;/WCG]N-IN-KBV]+L3W'BZC,8Z=BIIH(WK\-:U'&E.H
MSYW]N(N<]PBOWNVMS%#X>D1AZ]S-6NM:?%2E/+JN'_H%JVE_WFAN+_T16,_^
MVM[DC_@I[O\ Z,L?_94W_6CH%_ZP]O\ ]'-_^< _ZV]>_P"@6K:7_>:&XO\
MT16,_P#MK>_?\%/=_P#1EC_[*F_ZT=>_UA[?_HYO_P X!_UMZ]_T"U;2_P"\
MT-Q?^B*QG_VUO?O^"GN_^C+'_P!E3?\ 6CKW^L/;_P#1S?\ YP#_ *V];!?P
M9^*M'\)_B_UO\::#>U3V)2]>3;SEBW?5X&+;-1E?[X;\W-OAU?"PY;.1T?V$
MFY#3"U5)Y!"']);2N/?/7-;\[\T7/,TD MGN!'^F'UA?#B2+XBJUKHK\(I6F
M:5ZE_E78%Y8V*'9$E,RPE^\KIKKD9_AJU*:J<36E>C;>PCT(>O>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"SO/K&+NSI/N+IF?,2;=@[;ZL[!ZQFW
M!#0KDY<%%OW:67VK)F(L:]50ID),8F5,ZP&>$2E-)=+Z@:[%NAV3>[/>E02-
M9W44X2NG5X4BR::T--6FE:&E:T/2#=;$;GM=SMI;0+B"2+52NGQ$*5I45I6M
M*BOKUK(_] M6TO\ O-#<7_HBL9_]M;WD[_P4]W_T98_^RIO^M'4'?ZP]O_T<
MW_YP#_K;U[_H%JVE_P!YH;B_]$5C/_MK>_?\%/=_]&6/_LJ;_K1U[_6'M_\
MHYO_ ,X!_P!;>O?] M6TO^\T-Q?^B*QG_P!M;W[_ (*>[_Z,L?\ V5-_UHZ]
M_K#V_P#T<W_YP#_K;T;OX*_R&MO?"/Y.]?\ R3H/DSF>Q:K8=)O*ECVC5]4T
M.V*?)C=^RMP;-=WS4._\[)2&@3/&H %+)Y#$$].K4 ASW[]W'/'*]QRU)MB6
MR7!C/B"<N5\.1)/A,2UKHI\0I6N>'0BY4]IX>5]]AWM+YIFA#C08@M=:,GQ>
M(U*:J\,TIUL#>\?.I>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NJ'_YA/\ (^P'SX^1%7\@,C\CLOUC4U6SML;1.UZ+K"BW9 B;:2M1*\9>
M??6WY&:L^\YC^W 33^IK\3S[>>^5QR!RZ.7X]M2Z43/)K,YC/?3&D1/PIQKG
MJ*.</:V+FW>3N[WK0,8E32(@_P -<U\1>-?3HCW_ $"U;2_[S0W%_P"B*QG_
M -M;V.?^"GN_^C+'_P!E3?\ 6CH+?ZP]O_T<W_YP#_K;U[_H%JVE_P!YH;B_
M]$5C/_MK>_?\%/=_]&6/_LJ;_K1U[_6'M_\ HYO_ ,X!_P!;>O?] M6TO^\T
M-Q?^B*QG_P!M;W[_ (*>[_Z,L?\ V5-_UHZ]_K#V_P#T<W_YP#_K;ULL?''I
MV#X]=!].=%TV?EW53]1=;[1Z\AW+/CDQ$V=BVIA:3#IE9<5'6Y%,>]<M)Y#"
M*B81EK:VM?WC/S)O+<Q;_>[ZT8B:\N9)B@.H+XC%M.J@K2M*T%?0=3;LNVC9
M]HMMJ5_$%O"D>JE-6A0*TJ:5IPJ?MZ&GV2]&?7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW4>JI:6OI:FAKJ:GK**L@FI:NCJH8ZBEJJ6HC:*>FJ:>97BG@G
MB<JZ,"K*2""#[LCO&P>,E74U!!H01P(/D1UIE5U*L 5(H0<@CT/5+7RP_D,?
M!CY)SY/<NT-MY'XW]A5[2U#Y[I]**BVC6ULER),QUC71OM44^IBSKB!A9I7.
MIYFYO-?*?OWSWRTJVUY*NY;<N-%Q4R ?T9Q^I7_FIX@ X#J,N8/:?E7>RT]L
MC65X<ZH:!"?G$>S_ 'C03YGK7[[W_P"$W7S;Z\GK*SIG<G6'R#P4;2?8TV/S
M2=:;XJ(TN5>LP&^*B':5(TB6LL6XJDZK@V%B<@MA^\GR1N*JF]176W3^9*^-
M$/L>(&0_G".HAW;V5YHLR6VUX+R+R ;PG_-7[!^4AZJV[$_EU_.WJJ:>/>_Q
M([\Q\%,7$^5Q76VY-U[?C*$WON7:5%G=OD&Q((J2& N+CW*>W>XW(>[*#8[O
MM[,>"M,D;_[Q(5?_ (ST!+SDWFO;R1=;==@#S$;.O^](&7^?17<QL/?.WI6@
MS^S-UX.==1:',;=R^,E4(+MJCK:.!QI YXX]BF&_L;@:K>:)U]5=6_P$]$,E
MI=0FDT4B'YJ1_A'43&[2W5F9(X<1MG<&5FE-HHL;A<E722$D@"..EII6<DJ1
MP/J/=Y;RTA%9I8T _B8#_">JI;SR&D:.Q^0)_P  Z,5L'X,?,[M&:"+87Q5^
M0.Y(JA@B9*DZFWM!@T+&RFIW#78:EP=&I/\ :FJ$'!YX]AS<.>N2]K!.X;KM
M\1'X3/$6_) Q8_D#T<VG*O,M^0+2PO'!\Q$^G\V*A1^9ZLRZ-_X3O_S ^T9Z
M.I[$Q?7GQ^P$KH]34[^WA0[BW']DUKRX_;/79W6CUEC<4]?6XP\'4RFP,9;[
M]XKV^VI67;GN-PN!P$491*_-YO#Q\T5_D#T.-J]G.;[\AKQ8;.$\?$<,U/DL
M>O/R8KU?[\3O^$]7PSZ%J,9N?N.;-?*'?- \=0J[YHX-O]7TU5%8K+3]9XRL
MKURJ&[!X<UDLO22"Q\"D7]X_<V_>'YTW]6M=F";78MC](EYR/G,P&GY&-(V'
M\1ZESE_V>Y:VDK/N1:_NA_&-,0/RB!-?L=G'RZO<P^'Q&WL5C\%@,5C<'A,3
M208_%8?#T-+C,5C*"EC6*FHL?CZ**"DHJ2GB4+''&BHB@  #W TTTUQ*T]P[
M23N269B69B>))-22?,G/4KQQQPQB*%52)10    #@ !@ >@Z<O;?5^O>_=>Z
MU_\ YW_R']O?.#Y-;Y^2%?\ )?,]<56]<?L^@DVE1]54.Z*?'#:6T<+M1)4S
M4V_L%)4FN3#B<@TR>,R:+M;4<@N0_?FXY&Y8@Y;CVQ+E(&D/B&<H3XDC2?"(
MFI353XC6E>HBYK]J(>:=\EWI[YH6E"#0(@U-"*GQ>(M:TKPZ)]_T"U;2_P"\
MT-Q?^B*QG_VUO8P_X*>[_P"C+'_V5-_UHZ#G^L/;_P#1S?\ YP#_ *V]>_Z!
M:MI?]YH;B_\ 1%8S_P"VM[]_P4]W_P!&6/\ [*F_ZT=>_P!8>W_Z.;_\X!_U
MMZ.-\#/Y$FW_ (-_)?9WR.H/DMF>R*K:.)W?BTVE6=5T6UX*X;LVQD]MO,V9
MAW]GI*<T*9(S!13/Y"FFZWU &\_>_%QSURS-RW)MB6RS/&WB"<N1X;J]-)B6
MM=-/B%./0DY3]J8>5M\BWI+YIVC5QH,06NM2OQ>(W"M>'5_?O'_J7.O>_=>Z
M][]U[KWOW7NO>_=>ZH/^?G\B[;_SL^2.XOD1D/DEF.M:G<&WMIX!MJ4?5M%N
MJ"E7:V&AQ"52YB??F DF:M6'R%/ME\9-KM]?<_>W_OM<<A\M1\NQ[8ERL<DC
M^(9S&3K8M32(GX5IQSU$O-WM5#S7O3[R]ZT#.B+H$0>FA:5KXB\?LZ)=_P!
MM6TO^\T-Q?\ HBL9_P#;6]C3_@I[O_HRQ_\ 94W_ %HZ#/\ K#V__1S?_G /
M^MO7O^@6K:7_ 'FAN+_T16,_^VM[]_P4]W_T98_^RIO^M'7O]8>W_P"CF_\
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M5T^(A2M*BM*UI45]>M9'_H%JVE_WFAN+_P!$5C/_ +:WO)W_ (*>[_Z,L?\
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MZ!:MI?\ >:&XO_1%8S_[:WOW_!3W?_1EC_[*F_ZT=>_UA[?_ *.;_P#. ?\
M6WK:5V%M9-C;%V7LF.M;)1[.VGMS:R9%X!2O7IM[#T>)6M>E66=:9JI:3R&,
M2.$+6U&U_>+&X79O[^>^*Z3-,\E*UIK8M2N*TK2M!U/%I!]+:Q6H.H1QJM>%
M=( K3RK3I6>TG2CKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JK7YD?R>OA3
M\T*[)[MW?L:KZV[7R9EGJNUNI9Z+:^X\M6N+_=[LQ,U!D-J[OGED5?+4UM"^
M1>-="548L1*G)GO'SMR5&MI9SBYVE<""X!=%'I&P(DC'H%;17)0] /F3VXY8
MYF=KBYB,&X-QEBHK$^KBA1_F6753&H=:_P#W%_PF'[_PE35U/1'R&ZL[!Q:O
M)+3X[LG$;FZUSRP&YCI(YL#2]B8?(5:7"^222@CDL6M'?3[R!V;[T'+\ZA=^
MVZ[MY?,PLDR5]:,86 ^0#$<,\>HBW+V,W>)BVU7EO-'Y"0-&WV=HD!/SJH^S
MHBFY_P"0;_-!V_-(F/Z)V_O&"/5>LVQW#U(D+J#^J.GW/O+;62?5^ (-7^'L
M>6OO][77 K)?R0MZ/;W'^%(W'\^@I/[2\]0FB6B2#U6:+_GYU/\ +H/E_DF?
MS1&E$(^*&X=9ORW873BQ<&W,[=BB ?\ )7/LP_U[O:T#5^]HZ?\ -&X_P>#7
MI'_K8<]UI^[WK_S4A_ZV="%MK^09_- SSH,AT7MW:$3L )]R]P]2NBJ3;6\.
MV=X[CK$4?T,6K_#V77/O][76X_3OY)CZ);W'_/\ &@_GTL@]I.>IOCM$C']*
M:+_GUV/\NC<=??\ "9+Y>9N2GE[([LZ#V#02E3-'@:G?._<Y2J?UB3'OM7:.
M&DE7\"/),I_U0]A'<?O.\GP C;;'<+B0?QB*)3^?B2-^U.A%9^QW,4I!O;JT
MA3^B7D8?EI0?\:ZV9/Y9_P#+_3^71TINGIV#MVO[>@W7V%5]C5&5JMGP;*IL
M9E\AMO;FVZ^EQV)BW'NF7[:HIML4SEI*IFU \"_O&3W-]P3[C;W%O+6:V;16
MXA"B0R%E#NX);0F07(PO4W\D<H_U,VN3;1<&Y$DQDJ4T $JJD :FQ11Y]6,>
MXXZ&?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:G?_"HJBZS&UOB;
MD9WT=R-G^R*+%1TZQ?Y3UFF.V]/N!\PZGSC[+=+XP8T.-!^XKM'.OWEG]UM]
MS^JW>-?^2-X<):OE-5PFGRRFO7]D=?+K'[WV6Q\#;W/_ "4M<@%/.*BZJ_8^
MG3]K]:?GO,/K'/KWOW7NO>_=>Z^@%_( ^,/^@3X(8'L+-8_[3>WR6S<_:V2D
MFBT5D6R8XCA.L\<S@ 2T%1@::7-4YY(&<?G\#GW]X'FC]_\ /DFW0M6QVQ!
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JNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ibrx-20231231_g1.jpg
<TEXT>
begin 644 ibrx-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X3O^17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(S.C S.C Q(# P.C W.C(T   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP.#HQ," P.#HP-#HP,@ R,#(R.C X.C$P(# X.C T.C R      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  *E$         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@!  #F P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HH ** "B@ HH ** "B@ HH ** "B@
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M(DB;E/'O2/-''C<P&>E',K7"SO8$FCD4E6X'7/%/XH335T#36XM%,044 %%
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M_6AUFG:I;ZG%YMM-%-&1D/$^Y3^-7J]:$N:-SS)QY78**HD** "B@ HH **
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MHLJ:TMVAC6%71@HX^[&Z_P#LPK<JHJQW4*3IW\V%%4;A10 44 %% !10 44
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MMRLV74(F[*KAA\V<<G/;L:]*A#37H0V:<D<']GJ87>&8-Y9DS\T;$8);UX_
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M:W22"9O+=0Z_C6>*@GKYL(LV;"Z-S$=V-R]2.]6Z\N2L[&@45(!10 44 %%
M!10 44 %% !10!5U*/S-/F&!D+D9]1S7GEXT,]S,UY=.(XRNVW4D'(Y##;SW
M_05UX:]G8EG(36]U'XVCU*: QV,4&4D8X,:'(+')Z\G\Q6%YLUY:ZSK#7#6F
MEF5@K _O)6&2J*3R!R,GO^=>M":C'3R1#)/#=F;E]*A!(ENB9)ASQ$#@#'N
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M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *J F,# 2(
M A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1
M @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152
MT? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0
M'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%
M! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D
M-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$
M/P#]4Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **3-&: %HHHH **2C<.E "T4FX&C(H 6BDHH 6BDW"C<* %HI,T;A0
MM%)1F@!:*;N I=PH 6BDS10 M%%% !1110 4444 %%%% !1110 4444 %%)1
MD4 +129HH 6BDS1F@!:*3<.*-PH 6BDS2T %%)FB@!:*3-&X4 +12;@#BC-
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M[\3_ !W\3_$;XG> 9[:TO_#OA&?68(K0;V0WP$T0D:3!Y&&7 &1UKRL=F%+
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M)!U5G ([]*^5O!^DO\#OVFM,\&:!J-S>>'=:M6FEL9I=_D.4D.1Z']T.?[K
M<G!K)USX::3\5OVP/%NC:VTXM%LX;D&V<*VY;>V Y(/!W&HEFE3V:Y*?O\W)
M:^E^][#CE--U'S5'R<G/>VMKVM:Y]@0:E;W3$0SQ2[>OEN&_E4^[=GUKY?\
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MN+Z3SHT\F/S;=LX9@6XC?A03P*SQ]&I+"<OQ3NM;?WD;8"M3CC.=>Y&TNO\
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M8_\ USC%?/7@S0O$'[3'Q TWQOX@M9-,\$Z1()-)L7)S<,I#!N<9&Y5RW0X
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MM+/(L4:]68XJO9:Y9Z@VV"=7?&=O0T<T4[7#E=KI%X#;FG4T-GK2U9(M%%%
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MVDMU>.ZE&4E.3NVN.,9QD$\[ ?2OGOXF>$;/]D7QWX=F\":C?RF,-?W5G?W
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M<C.3DX.*CT7P]\8/ NK6ESX+U"9+5'4?8%NT6,K@!MRRXC[')8\<DD8R-#X
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M'@L10CA)7:TDK'ET\I^NT*SQ4;1>L7?\C]'K2X2XMDD5@RL,Y&:GKYY_9_\
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MF3YG*QK]Y5.,_P">*\>O+VDO=9Z]"+C&TD0:UYMG'-/,XCB1&))<D*N,G.>
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M-^;"[U:X6QBN(1\\#$%I!GLP"L,]<^^,?._P=UR'78YDU<B76(?WLEQ,=S7
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M[0;"^LK*[LC+=1WT(51.H"JR.'YW(V"I7MG/.*]BUSX>W.I@&"=[">+E9X7
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M;6;=#.Z@,T+948<<\X^;T/S,/4]3ET_4]@O;.WO5C.Y3/$LFUB,9&<X../\
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MY#+I-HY&"T2DC\*OU%;QK'"J(-J*  OI[5+7T459)'UD5RQ2"BBBJ*"BBB@
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MV=H[A2!G@;7)KZG\)^#/#_@G138:#I%II%DSFX:&VBV@N1]XGJ3CC))P H&
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M+AO; 5 "3[FFH58;GSN'H<782K+GGSMZ-I)_C:R.*NOVW]:T_4/*?0K-K.%
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M@KJ_!>J+XJT.UUO2IU:TG4.JN"C)GJI!&00<C!QTKH+B\MUD+HRK)G(W9&X
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M)"/+H^K[OJ9NE^&]7UPF[66*UM6X1IE+LPQUV\<?4UM:;X%G293?WBW$"_\
M+*--N[V//2NQ6/:H X Z>E+MKT8X>G&VA[\,+2A;349'"L<851M51@ =JY7Q
M?X#M]>S=6H6VU!5P&Z))[, /UKKA05!K>R:L=+BFK'EFG_#/49I2MY)!:P@8
M)B)D8_3/2M#Q+\-[0:2LNF1,EY;#=UR9?4&O0MM(%]JA4TD9^RBE8^<[N3YM
MD@9)%."K+@@UKZ'<1KA7 +>]>QZIX?T[5EVWEE%<?[3(-WYUY3K?@/5](NYA
M:6TD]L6)B:$[N,\*0:Y:E%M61QU<.^2R)=2LX;R-4V*!G/N*T[CYM/7=+AD
MP0.3CM6/9+<Z?*L&HPM:S,H94D&,@G%;6FZ3_P )%>?9XV*VR\S2+W']T'UK
MR_8RE/E/'E0G*:@SS#QUX#TSQ?K5EJ:7NK:5K$,/V9KK2+Y[=Y8=V[RI2 0R
M[N<8R,FJ6F_#;2O#]XE^87U.[C.?M.H7#W!CZ;<*YVCD^F1SSS7O_P#PK/1&
M5MD,L1(QN20Y^OUJQ)X+L[?0;S3[="3<1D>9(<L6Q\ISCUKT8X91.W^RZ/-S
M2BK^AYC)?7"Q"9-R,V3C^5.\+J;Y7DN9@6<D/QZC_P"O_+T%2#[1#(ME);2+
M>*=IB R6;V]JZK2_AD/[.25[J:SOF.7$>"HSQ@CO^=81H.5XI6(CA743BE;\
MCA]2^&MOYGV;P[J6L:',Y+"WL;C]V23DMM=6"C_=VBN2_P"%6P^$_$N_7?M7
MB+4@/,CFU.Y,RX)/*IPGY@XQ7TCHGANUT2-O*WRRM]Z:0Y8^WL*J^*/!UIXF
M\IY2\5S%PDR$9'L?:NF&%486>XJ638:FFW!-_A]QY?#J+W4*000+!&N %4
M 9Z ?A5!OM$%VD:)Y[2-M6-5^\3P!CN>M=4WP^UR&8Q(+>6('Y9?,P/Q'6NO
M\.>"H-&9;F<_:KX='(^5/8#^M90P[OJC>C@^65N70Y31OA-;ZG?VM_KNF6,A
MMW$B120I(V\?Q$D'\NOO7I,=FD<:JJJJJ, (,8'MZ585<"AA7HPA&&QZ=.C"
MBK00V)=JGG))R:DI%Z4M6;A1110 44E% "T444 %%%% !1110 4444 %%%%
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M/3<L9*C\\5XQ^W0!_P *MTC'_08CY_[835ZY\4=<T?P_\.M2U#7M-DUC1XX
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M7JX50Y.:.Y[N5/#RH)T.FC)1TI:04M=Q[04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #2V#BN<\4>)HM.MY;>#]]>L-H5?X<\9-;\^[
M:^W[VTD<=\5Y!I\N^XD\S_CX$K"0D_-NR00?I7+B*CIQT.+%594H712CT<^<
MBQ@9!!9O7YOTY.?PK*T*S'C+7[G7+H,VE::S6^G0D;8W=01),1GYB<X!/ V]
M,C-=U#"NYT[D !<GICKU]ZX[X:WD%CIL_AR5ECU/3&>.6$Y!9=Q*N,]00PY]
M3[5X+J>T=SX7%5?:5J:J?#J_FME^;^1Z#X7\&VU]:F^OXWD,S%HX][8"^I (
MSGK^-=K:VL-G"L4"+%&O"JHP!7*^'=<>S,5A,A:-6$<3CJ.V#^@KKU[>M>_0
M<)03B?=X5TY07(.^Z*Y[Q=X1A\5VR*TC03PG,<BC(^A'<5T-(?K70U?1G6TI
M*S/%=>\&:CH-D\MUY<]N.&EC)P/3C%9NCZP]H/(==RY.TXX'%>O>+-0M;?39
M[:;$TDR%5@'))/>N L?"X6W3S%R54<Y]J\O$.G'W7N>-BE3A[I@^(-+.I&'4
M["-%U^P7-O(QP98NCQ-Z@KGOP2#ZY]-^''C"R\6>&[:>U?!7,3QNNUD925*L
M.S#&"*YE;6.Q,9Z,'&#^=87A>.VL?&OBNWLV6%&:WO&5#C9-(K!_Q(16/NV:
MXL/6]G+38^<HU_J.+4J?PS=FODW?^O(]R4\4M4-#NFO-)M9WSODC5CGUQ5^O
MH8OF29]W%W284444R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4@_C7J2]!FOHZ=15(\R/K<'BH8RBJL/Z8\=*6DS16AW#67YL\UYYXSM8-/\
M$-K+:HJ22QL94 X.#P<>_(/T%=SJ>IP:7:R3SOL11U]?:O.9/.U.\FO9V.]B
M0N?X%'0?3O\ C7#BZD8PY7N>;CJL8PY7N9'CZRCO/"=Y,FY+[2R;ZSG7JDJ@
MD8]5(RI'<$_AT>GNVN:3:Z@-T2W$2S*1P1N (_G7'>)KB34Y!X=MCLN+I/,N
MGR0;>VR 3_O'! 'UKJ))KQ;4)9:?<2VT2[5\I"5 '&/PKQX1E):(^.PJE7Q$
MW3U227SU_(U+:?4+63Y+^1U7G9)\P)_H*Z;0]4.HVK%P%DC;:VT<9Z\5Y[HZ
MZQK4Q6WM7AC!P9+A2BJ?H>M=RMO_ ,(OX?NY-^^5(WE+D?Q8_P <5ZV'C6YK
M3V/K<'&O%_O-BQJWB;3]%&+F9?,/2-!N;\A4^EZW9ZQ&6M90^.J]"/PKS;2+
M%M0\VXNI"92"[L[')S_*MCP/ [Z[<NAQ D)1^^<D8_D:]^>'4*;DV>I?4] !
MS2TU:=7 4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%)2,VW)Z"@!<5R'Q.TAM2\.--$
MI>:S<3JH[CH1^5;*^*]):\-K_:$'GC^'=_7I6DRB92&&5(QCL1_DU:;IR4K"
MW/!;76#'9R0AP$DZ_ATIVD>*+_1;B1M/F5 X)>-QE/J?3GCBL_Q'IYT35+^S
MDRGD.VSW4G*G\B*\IN+'Q'\2/$VH:3;ZI<>'/#NG.L-W/8G%W>3%%?RU;G8@
M5QDCYCN&.AKZFC'ZVN5Z16K9D_=/H+_A8GB'S%/G6_'&SRNOU^;V-07/B?6]
M6;+WTD0P1MM_D7MZ<]?>OE.UA\>MXCUC1?AKXCGETG35\N\U#7B+J*&<@%8K
M=V5BQ Y;=D#)[CF70_VF/'7P^\1:5X-\1:/!JWB>\U6"-;T(%BEL9,EI#Y9P
ML@/RCMECD87)]*.41UE0M)VO;K^)'M'U/J"[L;H$W]QNN"3AFF8L3QZGVJ[)
M9JJVMSI[;2_\/4=.0?SK4M+V/5&EM@C>7*,[6'0CO^58NF;;/6)+9R-K%LD=
M,C^O/Z5\9FV%52BZJ7+*/Y'G8VFG3<UNCD/!]W<:UX\\5ZE$6AA%S#9!%YW-
M OS2'W)<*/\ =KWGPSK;ZE;&.8 7,07>1T;CJ*\0\%+<6?BCQ7I\=N\T\.HM
M<,85+X27]XA/YX_"O9/".CW-FLUU=H(Y9554C!R5 R>?Q-?/X:,XSMT/-R7V
MG+>VEY??<Z?M222!,DG '))Z8H'3'2LGQ8L[>'[];92TQB.,=?<?E7J/1-GU
M;T1R?B*^3Q%JT1A.^TMP0K#HS'J??C I)&>!HS@+G)/]?\_2J>BZA;+:Q!0H
M"_+M],>M:,VKPS30@JIX8COV.*^<K-SDW+H?)8B3K2DYZ'E?P]OF\3Z+JFNQ
MY%S?:E<"1';#P)%*T0C;T.%SCL6)KU73_B%;Z;91QW-CY,:_*IMWW#';KC^=
M>9?#W28=*UKQHT$VR"]UZ:X$>1L!,408],Y+!CUZDUW6H>'XEB0YBG9N50/V
M]Z^ARRE3JTI)[G1DG+&A[JZO7N;K?$RR\P 6=P8VZ,<>GI69KWB:?7XDM4B:
MUM2^9.=S/CM]*\F^*/CBS^'^C6UU'#%)JNH7T.EZ;;W-QY44EU*3L#/V4!68
MX!.%XKE;7XO>(O#%N)=3T_2_$=HQ5/[2T"25+2.4LJB&1Y$*YW$_,&P!C(&1
M7TU'+TY:(]_F/>I$6ST[:/OL1G';':NH^']JT>CO<,N/M$ID7_=X _D:\'UC
MQEXL\/V<6H:UI&GW&D''GMIMP[RV49(!=@R_. " 2N ",]*^DM%N+:;2;22S
M=9;1HE,<B]&7'!KFQ\7327<N)?48%+5*/5[.:<PQW,3R_P!T-FK>[\Z\9IK<
MT'44E+2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8 >GW!D5UR]!7S]2*A-Q1N+11168!1110 4444 %%%% !1110 4444 %%%%
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M )HY_BT/'/"6C_%+3?">E>'7L-)\%6&F64=H^H-<G5[V?8 K.B$(J[B,Y8G
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M?V=EW8[@^A]:]&G449WOL1:Z/SC^+V@RZ/*)/)AFO=#U80LDSD*_S8.YCT#
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M;(AEA3+#*!07SP!M;@GK\K["E45N>S.BY]L>"UM8O#]N+60/E=\ASD[B.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,LE8EN1T'OCW]%^&MGX2'A6SD\&VVFPZ#=1;HFT^!8@_4%B  002<YP0<Y
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M$5W9ZCK,VL-;QM"IWA8B4'F@C!D_>*3CJ''4YKZ>U3X6W]OXBUK6_#OBB_\
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MPMO#Y#;X90K*(I,$$,7 7ZH>@QGVSP#X.7PK\*?"^E,D2O::;!!/$!@!P@W
MCZDY]23FO$J0]A;VL=S03P[XDB62'4],DCN59>55LAT/4'_/7%>L:3K%MJ]F
MLUNX8=&7^)#Z$5\Q>---C^&.L6OB72I1::?<W4-GJ&EJH,;^8X42QC^%_F.5
M'##& #N+>EVMW<6,WGVLIBE&.5)PPQT/K7#C,+&2YZ949'L(-+7&^%_&<VI7
M@M+U%65_N2+P#[?6NQKP9PE3=I&PM%%%0 4444 %%%% !1110 4444 %%%%
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M=O'I.N*-LL952)57:R,!SG^+/JQS6=^S#9Q>*O'5UX;N_$-YHUGJ5E*/L5N
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M4Y_?2D@_6NJ'2BN#FD61PPI;Q)'&@C11@*HX'TJ2EHJ0"BBB@ HHHH ****
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M2%F_O$Y)%1?#O2HKZ\O9+F%;A4C6/]XH*@GJ.G7 'YUZ1#$D<:I&BQH.BJ
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M+7D2DY.[- HI-PHW"I 6BDS1F@!:*2EH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "DI:* "BBB@ I"H.#BEHH Y[QEX3C\5V,<)E,$T3;XY ,C
MIC!'ITKD=,^$#>=NU&]#Q#I':Y4G\>PZ\"O3&^]0>@K15)05D%D<G+\+]"8I
MY4,ULJXRL4IPX'8YS^E=)I^G0:7:1V]O$(XHQ@**M?Q4M*52<E9L0@Z4M)2U
M PHHHH **** "BBB@ HHHH **** $V\YH Q2T4 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ibrx-20231231_g2.jpg
<TEXT>
begin 644 ibrx-20231231_g2.jpg
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M# P,# S_P@ 1" =N#'8# 1$  A$! Q$!_\0!0@ !  (" P$!
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M 0$  0 1(3%A\$%1$'&1H='Q(%"!L<'A,&!P@$"@D-"P_]H # ,!  (1 Q$
M  &_P
M
M
M
M
M
M
M
M
M
M         .H^8;[\V#YZ^@
M
M
M                                      .N^5V[<H?Z<]Y\>IOY]9)\
M>P
M
M
M                 !5_MPB?ISG?EUL#R[
M
M
M                                                   11[YU>[\)
M!\>[;<)'Z
M
M
M                         #JOE-9,>4^?N<^77O/H
M
M
M
M$&=.6+^_)OY]<Q\^@
M  #19G"O%Y7X3MXW^#(L=16'?\>@ !I,OC'TZ/.]-.     ZWKYK??GML;J
M.#Y4_2U<\TT[>H?<   :5+X[K$[5PO:Z<:B;GN/0      :9*XUCT-;D^?JU
M6;M,EX] # ]N=8M#6C]^,KS]SI3S=QB]H$N8,E0)&XQ>P           $8V$
M;H>_,NUDL 8KIXKE>U^AS>&P\.ECZ&QVZ-UANTAYSE[R_+W&L^//=-.  $$7
M,&0H,C=8G8    ?#[\K!H:VTV=LP*TW]=K4CD -HC=;)T-B!#]I$RG/U)E?)
M  %;+ZNGFFG9KE[   X%6-'5VJSEH    -?[<ZXWU=ITKELT?I8RBL=MC=0
M      -)E\8^G1YWIIP
M       &/?-$]^9+\>P                   !T7SO/H
M          Q?3SYQ;O.VSS5KM4;K7V[@=3W\O#D+H  0]:1('N8%V<E=
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M<[A%[   <"LV@K;.9^R    UOOS\^MO06&H["6*R5&\^/6+0UE^,7>[Q$[@
M     "'K2) ]S NSDKH
M      <2LMK C^3QLS1V4A>??Z"$+*#FN?258,H         5ON*V8ZZ9'\N
M/-M;. $7^O%=_?/OG=^?;5\^L*>_$Q>/>:?0!B7S+/H
M        TB7QHALJ+T:PFA[GGUC_ 'YK;?5UHL]9]#WYJOHZS09L>2Z^3:/.
MV<2V<6![F!=G)74>S8]8=#6]3WYL716,P5<O'>_-6-'5Z%-X2C72K%45A0?:
M47V^+F92XD"%( I!KJ69JJ94;3U/HUA-#F.7L05<08&N8.6Y^[7YJTJGI*N*
M;*+;;,VNI2N4_4D^KNBK+<YBU[OGU%5C%UB1RFVIFU7T=9H,V/)=?)M'G;/[
M_/H H9LZ*5JR7&-C%FVHFS]2SP!I4OC1K84GHUA-"!YS;K/7/REQ6F_KK#4D
M^1X$FK.BJ]"F\-@X=+4YRTVF-TJ=I:OZ$>3H\V5$VQ%'85VO*_Y_4.VL/8X_
M2VV9M<MS]Q-91:X7U=]?BS>?LI(@2<-U\50TE5K<CGDN?O;XW6U>;M *RZ"M
MC^;'NUDKH"NMY7R1 D07<0MQB]9.KY,4646Q5%85.TM7]"/)T>;*B;8BCL*\
M7E?),"3OL+O7*]KH;M8FSQ^EL\U:_7Y]JSHJO0IO#8.'2U.<M-AX=/-W>YST
MNP&D  JGI*O[^5I<[:"K6BK.)I<OA-E3-R_+W*];*K;?5T16D3L>?MCZ&QEF
MME>>NWH+M9*YQ73S6'0UG5]?)]I9\X5$T#@^5 U%3<++V]7-%69;E[AFUA;Q
M$[VRS5KV?/T"H.GJ>]X^VPS=J!6V^KHILHMRLK;UWO(&![\]2D\K"4<^;:F;
MCO?FK&CJ]"F\)1KI5HL[9Z[WYU7T=7J\GE+U7+LI06406D2![F!=G)74.VD.
MN][7_?S]LOG[*3($G#=?%4-)5ZS(Y2E72MFC],3U\R!![R9 DXOIYJYHJNV^
M9M@                                      !3^ZK=KX])^K)N%^_*M
M7=;=:BM!6ZXK=BX]-OX=L;Z\X'KSD2)(B6?%G>KG:;)X]7[\U21QD^#*AVQA
MSM5SM4[\MPC]N9I\CES^.A[\Z'*X3M5SM4[\NQ\^T:TU';[/V^T<>NWQ^VA2
MH^C\??#S]GCSTA'US^)(?SUL_P ^XDBCWXDCSZV_YZ
M        'X4PU=/"MM"E:ME2U62Y[IIW?\>J9:JGRO/U9W/6=4=+5;!PZ21
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M8V%'Z(X;04^U%3(4&1/=-.I#KJ61(,B1(,B'+2'=O)75>KNOTB9QMYF+8
M                    #XGT/T^1]@  ?,^@!\CZ@^)]CY'U!\SZ    \[]+
M2^A^:NM#]>-]\^Z-W]5<6DLL_P _=;KBMV+CT@VT@RC!E1Q,C]SS]D.)(U?M
MRUCOSWF+WU?ORQ73Q,==,C>9'Z7KS9^DL^W\]5<NZOM>?O:^?=KC]M*D\/TF
MJMFU&T%3<K.7%6KRKO+F;RB.HHK"YFZ@SWSWCS]CKUYN)S[P%ZYSIY]U0Z<K
M/\^M;??*U7CMLWSZ                          !K??G$UG$@ZWA:S(Y^
MA^'O_-??9V4ZV5E.?K7N_/!=N=H\[:0/<P+ 4D^DVNIILJ)HBJRBV6S]C5_1
M5GH-B+_/\>GR^_/K\^U:T59DN?JR=#8@5OOJZOEW G^DGZ)-X1=8Q?1[!Z*K
M>BJ^SY]6=S]E^'#[\C.?'K/H*V]&/N_/W;4%RLI<8'OXK/?UMT\G<^>VXH/2
M'!:'S5W^=E.ME93GZU[OSP7;GZ"8F_ KQ>5\!74"Q%%8U+TU3:+.V>+Z>;19
MZS TJ7Q\]=OGY@JYGZ9OC[L'23Y A2*/ZZEL-23Y0KI4)6T+0IO"++*+MD7K
M=7)W/F5^@9OT[_/M*//K;4%S\I<U;T57.5/.FBJF5YO*_4)/+<8O6L>AK9:K
M)8ABVAW2R=Q276TWI/@M%WO'JO%Y7ZW(YVKS=H!2S64TE5\FQ-'8 ?A^E2=+
M5;C%Z[9&ZUWO8%V\C<^97Z!F_3O\^TH\^MM07/RES5W15<[4TZ$;>%+M9,G.
MGF\'S]?>OZ^0E;0M"F\(LLHNV1>MS\I<^;N]SGI=@-( !5/25?W\K2YVT'GQ
MMZ"Y.5N-^A=ZHZ2JV+AUL916$26<2,K"-H<SA&=A&],,!I//7;T%VLE<UTO:
M^%+:%,U5,G6FG27 D@?+[\\S]_G/37\_TGGWMJ"X^5N-]A]ZG:6JV:/UL716
M 'GWMJ"UV;M96K90&G2N- MK0W]Q5]1_7TOHCAM /-#?YOTCP6C\YMWG?0;$
M7^?X]/E]^=+U\\W-[G/37\_THB&SB5TO:^Q%'80/<P)(@2=9D<K;YFV%(M=2
MSE3SJ7ZNF],_S_2=CY]@:Y@QY.CVPS5IYM[W.^D&#T5#ME1W$RUOOL/N
M                   !YUD^&<*TEYSX&7,&<C,E+BV!OI%Y5<^YWC72P!!A
M]RXYYS'J&   #SOTM+Z&YJZ^#YVGV@NBI[S9^VRGGU6ZXK=BX]((M8-X\Q=U
MWMZ_:./7>(O>LEU68[WYM]G[>(+"'UOOR<*R=3C14_;\_;/TEGVOGJKMW5]K
MS]L946.7Y^Z>Z&GV#CTL!56%2[ZIO?E[VC&GH[14=I!MI!DZBL]<^^9J\=(Q
M]>-*]?.7QOWSUJ/WS9/QUA;US^9-OGH                         !!-Q
M!T2;PMCFK4#S8WN<O[BK[S_VU#<C*W&Q\.G0]^>MZ^=7U\@>Y@6"I+"I&FJ;
MGY2Y&M]^>\1.U"-G17]Q5]LO#IH\OAU?7R'+6)DN?JR=#8@>=NYS\WU$W8.'
ML5@T-;<C*W$;6$;\+29VS^7WY!]O"V6/UK/H*V]&/N_/W;4%RLI<;M$[^<6\
MSL\TL_K^OEKLW:>:N^SER,K<;'PZ=#WYZWKY*];* H9LZ*Q-%8354S:OZ&LJ
M;IJJ\N.NYMJ9H&E2^-&MA2>C6$T( %']=2V&I)\!W,'])[I9VKR><2V<2ZV2
MN?-'?YSTT_/](//O;4%S<I<U<T57/--/F&KEUZNZ_3I7+=8O:%+:%:W-VHU6
M1RDR!)\[MSGO1?":'+\_==KROUV1SM7F[0"NUY7Q)9Q+R9"[ IGJJ>18,C4)
M/+<8O7;(W6N][ NWD;GS1W^<]-/S_2#S[VU!<W*7-7M%5SM33H3MX<JULJ>:
M:=B>GB,;&-!MO"_2>Z6=J\GG$MG$NAD[GS=WN<]+L!I  *IZ2K^_E:7.V@\^
M-O074R5SN<7M5'256Q<.O;\_:[WE?9_/6>UQNM#ME1>F& TGGKMZ"[62N>)P
M^H?M(=7]#6WYQ=[OD/N/E]^>9^_SGIK^?Z3S[VU!<[*7.[1.U4-)5;)PZV+H
MK "I>EJOAZ^6[S%L!6F_K8SL(UL<U:TFUM-Z%8B_'FCO\WZ18+1^=.ZSU_<5
M?;+PZ:/+X8?KYHML:/TW_/M+R(8M8<!74"P=)80/<P).KY6F2N-OLQ;"C.PI
M+ TD^F.KI_1W!Z'+<_=>;ROTF7QMYF+:FNJI]KC=H/MX/H?A]
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M#H:W4I7*;JB;4_2U4SU,RWF8MHUGQJ";6BMGF;6R5#8@
M       "BYDS(&@FFFN$[EG"O!LIHIN!8$Z1Y_%]"J)(AF2KA=\@ @<],#9@
M   :!(XQ)-C[Y'ZR]"D@19.BY/GZCN9'L)4V$838N6Y^]@Y=(FGQ.M]^3=6S
M='D\/G];_$D0;:090@R:L7E7OD7OLG'K]_GV48,KN^?L'V<+)>/4E0I,)V<+
M,<_<WUDWSXUF?]#LEH=#^^8&]\QL/S[8/QTC/UYDKSZC3UYBWUXWKYZG;QT
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MW#[[C%[0Q:PX?M(FWQ>MCZ*QUGORKC?5_P!?B<*B=',Z-8BCL*W7U=9>@L@
M(ILHOT^)2KI0KW=U\U5,W-<O<4647(\_6[1.U9M!6X3MXFBIF:1+XV$I)\$W
M$&;:F;T??RNE[78OIYFFIF2Y62P.!6?05MF\_95]NZ^9ZF;F^7N)[*+DN?J1
MH,@ 8KIXKW>0-,E<=HC];!4D_8N'3#]?$)6T*PM)8"M%_6V1H;$5UO:_1Y?"
M5ZV7.-1-QOOS7&^KM:D<Y?JY<S54S3I7'0YG";:F;'TV/ 5U![?G[8>CL-LC
M=<!VYQ)9Q=>[\\7T\?A;#-VO$\R_T#-^C>$T.;Y>P
M    !HIF#D88T$RYL)OY#9M9^G<-@-;(O,V;X1P2 1>9LF4T<W@
M          'P^_*2Z6EFRLFSK63@
M
M                                           !1C84F]P^\EU\FIFE
MJK=YBVV7AT@"Z@:Q(Y7:R5T
M                   !KW7GL/+H
M
M                                            !B.OBOEW Q'7Q+E7
M+E6NE:3+XP7<0;(T-CF>7L
M
M
M
M
M
M
M
M
M
M
M
M
M
M                   "&;6'\_OP                ;1'ZZO(Y
M          #8>'3"]O'P^_
M                                               -HC]=7D<@
M            -AX=,+V\?#[\                 VB/UU>1R
M      VB/UU>1R                 VB/UD*#(  'EO^B9CJ^_@
M        GZDGP#=P                  !--1,BNRBXKKY
M
M            GZDGP#=P                 )IJ)D5V47%=?(
M      $_4D^ ;N                 !/U)/@&[@                 3]2
M3[J9.Y  'EO^B9CJ^_@                GZDGP#=P
M !--1,BNRBXKKY
M                                       GZDGP#=P
M    )IJ)D5V47%=?(                $_4D^ ;N                 !/
MU)/@&[@                 3]23[J9.Y  'EO\ HF8ZOOX
M   )^I)\ W<                   3343(KLHN*Z^0
M
M       )^I)\ W<                 "::B9%=E%Q77R
M !/U)/@&[@                 3]23X!NX                 $_4D^ZF3
MN0 !Y;_HF8ZOOX                )^I)\ W<                   334
M3(KLHN*Z^0
M                                  )^I)\ W<                 "
M::B9%=E%Q77R                !/U)/@&[@                 3]23X!
MNX                 $_4D^ZF3N0 !Y;_HF8ZOOX                )^I
M)\ W<                   3343(KLHN*Z^0
M
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M,;[\U\O*_&]/( $SU,S6I'/8X_2&K:&
M                                      )^I)\ W<  #9H_2V^8MOAZ
M^5NOJZ.I\<  "RN?LH_G1\AS]0U;0P+3YNTJQI*L #9XW26:V77^[@  3343
M(KLHN*Z^0  !LT?I;?,6WP]?*W7U=,55,JQI*L    "?J2?&=A&TV7Q    G
MZDGP#=P   !/-+.F.JF8'OS@^WA9;E[ANVA@    6PS5KILKC&=A&TV7Q
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MR>4LULN'K2';G,6U6M'68#MSVF/UD.#(JWHJNQ=%8Y?EZKE?5\9V$8
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M59-!6R- D2M72J>ZBHLC0V6^PN]3M+5297R:K:2K
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MQ+E9+^/U =U L516%5-)5RK6RJJZ2K
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M+2YRTS7'W0G:47P]?.O]^?GT ^.Q\^_+[\^GS[\/7P    3343(KLHN*Z^0
M.QY^]?U\ M;FK3:XW7&=/-.M54=OQ]ZGOYV//WK_ 'X^@ !]_/WX>O@'W\_?
ME]^?I^GS^OOY^_+[\X_3X['S[U_7P
M                                   3]23X!NX     'U\OU]^/KY]_
M/WY??G'Z   '9\_>MZ^??S]^'WX^@  )IJ)D5V47%=?(      'W\_?A]^/K
MM>/O6]?/SZ[?C[U/?P     "?J2? -W        ['G[U_7Q\=KS]ZOOYS^/K
M\^]?U\      GZDGP#=P      !S^/T^?U]O/W\?/EZ=GS]Z_P!^?GT
M!/U)/NID[D  >6_Z)F.K[^                "?J2? -W        '8\_?G
M]^?/Z         $TU$R*[*+BNOD    =SQ]Z?OX
M                                                          )^
MI)\ W<                 "::B9%=E%Q77R                !/U)/@&[
M@                 3]23X!NX                 $_4D^ZF3N0 !Y;_HF
M8ZOOX                )^I)\ W<                   3343(KLHN*Z^
M0
M                         )^I)\ W<                 "::B9%=E%Q
M77R                !/U)/@&[@                 3]23X!NX
M          $_4D^ZF3N0 !Y;_HF8ZOOX                )^I)\ W<
M               3343(KLHN*Z^0
M                                                    )^I)\ W<
M                 "::B9%=E%Q77R                !/U)/@&[@
M            3]23X!NX                 $_4D^ZF3N0 !Y;_ *)F.K[^
M                "?J2? -W                   $TU$R*[*+BNOD
M
M                    "?J2? -W                  FFHF1791<5U\@
M               3]23X!NX                 $_4D^ ;N
M     !/U)/NID[D  >?VUH.OZ                "9*J7#=K$
M        $I5TF/YW#&^_(
M                                             $R54N&[6(
M          !*5=)C^=PQOOR                !,E5+ANUB
M     3)52X;M8@                $R54NTN=M  !YU[K/=7[\
M       %W\?=[3$[@                 #I':.8
M
M    !7XL"                 =([1S                 ,>9
M         QYD                 #L'>  !Y;_HF8ZOOX
M  /0?"Z#<84@                  8\[IS
M
M*S%F0                #'G=.8                !C#)@
M    &,,F                 =HR   /+?\ 1,QU??P                >
M@^%T&XPI                   QYW3F
M                                                         5F+
M,@                &/.Z<P                #&&3
M ,89,                 [1D   >6_Z)F.K[^                #T'PN@
MW&%(                  &/.Z<P
M                                                    "LQ9D
M              QYW3F                 8PR8                !C#)
M@                ':,@  #RW_1,QU??P                >@^%T&XPI
M     'X<3F<#F <#F?,^@/F?0     &/.Z<P
M
M"LQ9D                 QYW3F                 8PR8
M    !C#)@                ':,@  #RW_1,QU??P                >@
M^%T&XPI      $;GG*>L!0@OR#SL/@6?*XF7-P-;-Y+6@    &/.Z<P
M
M    #0*N#&M37['*D;/,D1K4U^R2Y&[6$SX_/GR\_/MZ^Q32U@F_0W&A5L+:
M9LG;YTKI\_, YFC[/OU-6@M\OWZC"1N/X9R3V  %0+:%\[:&
M    !\3ZGZ                 ? ^X                !\#[@
M      $Q5,V8:F8!VC(   \M_P!$S'5]_                !Z#X70;C"D
M     1N4A)D-(+\@\R3'$J%R"F1?4I>9,N      8\[IS
M                                                       (+S=-
MD>O2$\]3R=<66X3Y4:5%=D.O3:ILCK^?G:]>X@HJF<M%=2';3JAX7+;)+D6B
MV6CQ/#G6W)YZ9+ZWBVFK,W([82/RZWCSL,KO\_GS[>OL^::[ %*='5P[I*L
M
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MN$Z7"N?J-@E=[-:[0][K[ I3HZN'=)5@
M                                         ?7S]N9D;J9ZB;VC(
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M/F[V,W'\N>%C\?EY^64UV@Y_?H%*='5P[I*L
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M:/1PRY00]%@                      4IT=7#NDJP
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MW*?+R7;II5=$W6QE@"E.CJX=TE6
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M=:B1I$M9\+9^HN)O-6 *4Z.KAW258
M                                       F>GG7+R-SD/GW(   \M_T
M3,=7W\                'H/A=!N,*0      !Y@DF&M';/0HXF@%82VQ"Q
M.)L8     ,>=TY@            K465                     !"A(ILP
M       /@5\+%                       K-D,]C^7C,=^FM1.$TZ"WCVK
M@:)60I;O;5\:M#BV8U^AQ_+G5K&9RR>MT&KPXT64U;9W8:(<?BMF2S\BVL^&
M:"IVZ=)EJ\M(8S]3N$^5$])6</GRV>WT_=Z>P*4Z.KAW258
M                                                        $ST\
MZY>1N?M\^]HR   /+?\ 1,QU??P                >@^%T&XPI       '
MGZ>@)YJF[%SSB5\(:+UE0"="<      8\[IS
M                                            !U.?FI>(S$]Z:Z@#
M,4G/[]S4CKO]G.C>I@2U=V>%C\M6AQ;,:_0U<QN<UB'&E.YL]"K8.8[]=EER
M9WTMS#E!4P%FJ2<-%<Z-6PL9QYR;<6,'9VFEZ\M=IF281SU/;;<:?(]>@%*=
M'5P[I*L
M                3/3S;EY&Z^WSZ.T9   'EO\ HF8ZOOX
M   /0?"Z#<84@      "D1TC>BQQ3 XESB(2#3METS+@     QYW3F
M
M    "LN/SUEM?H/I]^@   ?+S\^OK[&-/7R=<6  _#A\^?3[]    K*2Z:^
M               #I':.8                !T#O@                &/
M,@              94D [  .T9   'EO^B9CJ^_@                ]!\+
MH-QA2                  !CSNG,
M                                                      K,67
M               ,>=TY@                &,,F                 8P
MR8             !^GZ  =HR   /+?\ 1,QU??P                >@^%T
M&XPI                   QYW3F
M                                                     5F+,@
M              &/.Z<P                #&&3                 ,89
M,                 [1D   >6_Z)F.K[^                #T'PN@W&%(
M                  &/.Z<P
M                                                "LQ9D
M          QYW3F                 8PR8                !C#)@
M             ':,@  #RW_1,QU??P                >@^%T&XPI
M              QYW3F
M                                            5F+,@
M     &/.Z<P                #&&3                 ,89,
M         [1D   >6_Z)F.K[^                "^F%T&XPI
M         ZQ]SD
M                                       1 2^
M=8^YR                 .F=P                 ZAVP
M   #(F<  !Y;_HF8ZOOX                /0?"Z#<84@
M    8\[IS
M                                  *S%F0                #'G=.
M8                !C#)@                &,,F                 =
MHR   /+?]$S'5]_                !Z#X70;C"D                  #
M'G=.8
M                             !68LR                 8\[IS
M             ,89,                 QADP                #M&0
M!Y;_ *)F.K[^                #T'PN@W&%(                  &/.Z
M<P
M                          "LQ9D                 QYW3F
M          8PR8                !C#)@                ':,@  #RW
M_1,QU??P                >@^%T&XPI                   QYW3F
M
M                      5F+,@                &/.Z<P
M     #&&3                 ,89,                 [1D   >6_Z)F.
MK[^                #T'PN@W&%(      QAJAOQ'Q((-(->)8(:-_,L0T3
M6=H     QYW3F
M                                      5F+,@                &
M/.Z<P                #&&3                 ,89,
M   [1D   >6_Z)F.K[^                #T'PN@W&%(      C<\N3UY*-
ME^0><)M9NAV"+"53>R&2\     !CSNG,
M                                                         IC?
MUL>7]<                !Q/T_0                #@<P
M  9[ATNKCKO/<>@&,,F                 =HR   /+?]$S'5]_
M        !Z#X70;C"D      1N5<,:?0MD?8H(=4D4NX4M+[E+CZES     #
M'G=.8
M                             !2G1U<.Z2K
M                              &XP^UZ<5?9[CT&,,F
M    =HR   /+?]$S'5]_   ,OR]SC3S>'U$5G$W2)VBZQB]3W\ $SU,R&+:&
M)GJ9D,6T,     #T'PN@W&%(      C<A8Z)7LNL?(K43Z5B+;E9R6BQA1@]
M"0    #'G=.9 9H!,1+)70TTM48PK";H60!#9,AI!VC;0        #6C%F\@
M  ATD8XFJ$8EES0S$&./PBDDLG @XBHM$;(1J0<9LLR?<  B$_02Z    1(2
M<58,T69/T$5DEG9  ,&=HR16LUHG4Q!+)R  !7$TTM,1J3(:0<3 '3)D-)*]
M DHG$T0@XL^0N<2;RKY,AV2"BRYF0                "E.CJX=TE6
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M0N89PJH;F1&8H$QFTE2242PI5,O2                 4IT=7#NDJP
M                                              !N,/M>G%7W;X],
MF                 =HR   /+?]$S'5]_   -YA=[WXV\TJ9QP7;GW_ !ZK
MC>UT[TTZ3*^3@N_BK>BJ[69NUZ_KY5O15=K,W:_3XTZ5QU[OSFVHFT6V-)HD
MW@   /0?"Z#<84@                  8\[IS/-XW0B0DPO.94^!Y]EV2GA
M8@FT\_3T"*WD>&3(X-K)[*$DWFBF0)P(0+W'F\6!/L:8385],@9\VX^1I9A2
M/B<S42_!08DLU8S9!Y.Q'!LYJ9Q,T0N3\6")2/B?8J 1D?A: B0K82V7=*/F
M2/P$M&&(D,27&(7-++\%+2UQ1@]"S@5P.V0J=<M>5',870*HF,)"+#F^GF"2
M6:0>E10@ON0&=,[1/QY]%^CMGGF=H] BMY^$6F /0(&EE9BYH!0<XDN D4UX
MJT>CA0XLR2V                 4IT=7#NDJP
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MRQ(18HWT                 I3HZN'=)5@
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M?LK6YBV_3&&3                 .T9   'EO\ HF8ZOOX
M   /0?"Z#<84@      #S!)+-'-@/0L&D%82PQ6$MH;R     #'G=.8
M       -$-[                   !HAO8   !@#4R2P#03?@        #0
MC?0                                 4IT=7#NDJP
M                                    !8K/V5K<Q;?H,89,
M         [1D   >6_Z)F.K[^                #T'PN@W&%(       \\
M"[)0,F$ET$;$'E^RJY-Y-8     ,>=TY@
M                                                         %0[
M&+A+*+\0                ?$^I^@                'P/N
M    9DD3ATG^CL/T QADP                #M&0  !Y;_HF8ZOOX
M          /0?"Z#<84@      "N!K1,))Y6 ^9:$U0K:;^6#/T     &/.Z
M<P
M                          "LA/YP                !T#N',
M           QID@             #)G<  ,89,                 [1D
M >6_Z)F.K[^                #T'PN@W&%(                  &/.Z<
MP
M                         "LQ9D                 QYW3F
M         8PR8                !C#)@                ':,@  #RW_
M $3,=7W\                'H/A=!N,*0                  ,>=TY@
M
M                      %9BS(                !CSNG,
M      QADP                #&&3                 .T9   'EO^B9C
MJ^_@                ]!\+H-QA2                  !CSNG,
M
M                  K,69                 ,>=TY@
M &,,F                 8PR8                !VC(   \M_T3,=7W\
M               'H/A=!N,*0                  ,>=TY@
M
M             %9BS(                !CSNG,                 QAD
MP                #&&3                 .T9   'EO^B9CJ^_@
M           OMA=!N,*0                  .H=DY
M
M        $-$R@                '4.R<@                #I'=
M            .F=P                 R!FP  >6_Z)F.K[^
M     #T'PN@W&%(                  &/.Z<P
M
M   "LQ9D                 QYW3F                 8PR8
M       !C#)@                ':,@  #RW_1,QU??P
M >@^%T&XPI                   QYW3F
M                                                           5
MF+,@                &/.Z<P                #&&3
M   ,89,                 [1D   >6_P"B9CJ^_@                ]!
M\+H-QA2                  !CSNG,
M                                                        K,69
M                 ,>=TY@                &,,F
M8PR8                !VC(   \M_T3,=7W\                'H/A=!N
M,*0                  ,>=TY@
M                                                   %9BS(
M            !CSNG,                 QADP                #&&3
M                .T9   'EO^B9CJ^_@                ]!\+H-QA2
M    -1*XEO"L)9X%3#5BW)3TE(W KV68)/     ,>=TY@
M
M         %3YL?>YO                 #JG8.0                !TSN
M        &=X])8JY8       &,,F                 =HR   /+?\ 1,QU
M??P                >@^%T&XPI      $;GF&>EA5XOR#SF-E.1:PJ668/
MH0&7:     ,>=TY@
M                                        %*='5P[I*L
M                                  /BU^7M[$T-B       ,89,
M             [1D   >6_Z)F.K[^                #T'PN@W&%(
M C<@XA(V0DX^Y")NQ&AZ#E,2]Q!I!9>\     QYW3F
M
M       4IT=7#NDJP
M 'Q:_+V]B:&Q       QADP                #M&0  !Y;_HF8ZOOX
M            /0?"Z#<84@     "-R%R6R@!ZJ'P/.(V EDBD[!LAQ/L71
M   ,>=TYE'#KF2+=E(3\+-FFD/'0+VF7**%KS4S)DJ@KH"Q8    -$*:'V+5
MD(%Q"LAMACR.2XI#Y58ZQ:(G I$8<N"5 -D)>*_%@B,S4RSY)(
M                                             !2G1U<.Z2K
M                                        #XM?E[>Q-#8@     #&&
M3                 .T9   'EO^B9CJ^_@                ]!\+H-QA2
M         .!\#M'4.T?IT3O      QYW3F>=A9,K$2&6>-Y(C*CGHL:.=LVX
M\]C#EEC%$6'1+)$1E@2 S,&D$\$V@ 'GL7W.Z>>!DCT"*9F]&*(D/0($'&OE
MD3YD8$3D?$[$&&O'H44&-()2+?F?
M                        *4Z.KAW258
M                   #XMCE[>P]#8@     8PR8                !VC(
M   \M_T3,=7W\                'H/A=!N,*0                  ,>=
MTYGG>6B*A&YERC;B$2K)>(I$3&6L*#%A"E!:<C0AHN,98K^9<B4G$[Y;0I^#
M:"T!YXGH*8XH,=\]!"E))A@B)#T"!!QKY9$%?"'R5C8B!S5CT,*$%DS:"LQ=
M4                                                        I3H
MZN'=)5@                                             ?7S]N9D;
MJ9ZB:     !C#)@                ':,@  #RW_1,QU??P
M    >@^%T&XPI       %'SI$KDZ%-#XERR&B'#-%U3]     !CSNG,\_P R
MYJI=PI$9$L&:41T8<MX2L4F+LGGZ;T:81V6Y-Q*DER2N9B"2RS0 !%A40ADF
MTDXCXPY<$CXJN2B61.H80GXQ)Y7$_%A"K)E"7B*"5R(SKEHB6P
M                                             "E.CJX=TE6
M                                        /KY^W,R-U,]1-      &
M,,F                 =HR   /+?]$S'5]_                !Z#X70;C
M"D       >=A<PIB9PNJ?A%16X]"R$B4C-@     QYW3F
M #&&3
M            !2G1U<.Z2K
M       ^OG[<S(W4SU$T      #&&3                 .T9   'EO^B9C
MJ^_@                ]!\+H-QA2       /-(L"0&9T]"#\(/(1+)E+"WY
M,8     ,>=TY@
M                                     %*='5P[I*L
M                               ?7S]N9D;J9ZB:       ,89,
M            [1D   >6_P"B9CJ^_@                ]!\+H-QA2
M  /,$E0TLM:5C/PLT5V,P1\7E)!     !CSNG,
M
M   J9)Y921R^0                .N?<_0                #JG:
M  /TSI)G+WO4/N       !C#)@                ':,@  #RW_ $3,=7W\
M                'H/A=!N,*0        !US\.R#'G=.8     !CSNG,
M
M                      K*60                 .@=PY@
M     &,,F       #ZGU        !C#)@                ':,@  #RW_1
M,QU??P                >@^%T&XPI                   QYW3F
M
M                    5F+,@                &/.Z<P
M   #&&3                 ,89,                 [1D   >6_Z)F.K[
M^                #T'PN@W&%(                  &/.Z<P
M
M               "LQ9D                 QYW3F                 8
MPR8                !C#)@                ':,@  #RW_1,QU??P
M             >@^%T&XPI                   QYW3F
M
M           5F+,@                &/.Z<P                #&&3
M               ,89,                 [1D   >?VUH.OZ
M      "X>2N=AB]@                 !TSM'(
M
M    @@G<                 Z9VCD                 = [X
M       !T#O@                '>,N  #S@WF=ZWKX
M+P8R\VB)W                  '1.V<P
M                                                         "O)
M88                 Z)VSF                 8XR(
M !CC(@                '<,H  #RW_ $3,=7W\                'H/A
M=!N,*0                  ,>=TY@
M                                                      %9BS(
M               !CSNG,                 QADP                #&
M&3                 .T9   'EO^B9CJ^_@                ]!\+H-QA
M2                  !CSNG,
M                                                  K,69
M           ,>=TY@                &,,F                 8PR8
M              !VC(   \M_T3,=7W\                'H/A=!N,*0
M               ,>=TY@
M                                             %9BS(
M      !CSNG,                 QADP                #&&3
M          .T9   'EO^B9CJ^_@                ]!\+H-QA2
M          !CSNG,
M                                         K,69
M  ,>=TY@                &,,F                 8PR8
M     !VC(   \M_T3,=7W\                'H/A=!N,*0
M      ,>=TY@
M                                    %0+:%\[:&
M !\3ZGZ                 ? ^X              !L\;K9G.6?-]&,,F
M               =HR   /+?]$S'5]_                !Z#X70;C"D
M               #'G=.8
M                                             !2G1U<.Z2K
M                                               GBCL+>Y2WYON,
M,F                 =HR   /+?]$S'5]_                !Z#X70;C"
MD      ?AQ.9P.8!P.9\SZ ^9]      8\[IS.!S.(.0  !\C'F5   /P_#\
M.8/B=0R(!Q .1P.8     .L?,[H        !\3IF2.!S.(/P',XGS!S.8/F?
M0X@Y                                         I3HZN'=)5@
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M<<L44=,.3L5I.)=TH.3V8 Z18(F8
M     %*='5P[I*L
M       ">*.PM7E+?*OH                ':,@  #RW_1,QU??P    ;I$
M[6ESEG2;74T@P9$_4D[']/.O=_%BZ*PZ7KS6#15ME\_9=GS]J;I:J)+2(
M !Z#X70;C"D      1N4A)D-(+\@\R3'$J%R"F1?4I>9,N      8\[IS*"F
ML%@S[%?3F98SQ@CT .!YS&VEI"@YLQL9T3?CH'Q,N:J7R*(%T#/F!*!F;,F;
MN;26,//T] C5BL!\SM$=F+,Z; =8O,>>9Z%'$UDIB:"6$(K,6;(9HVDBPQQ]
MB1BY8 !0,O,98\\#NGH$5P.!%Q@#T"!I968N:#@>>9NYNA^FBFA&^FB&RD_D
MZ                                      I3HZN'=)5@
M                                         "S&:M;09VS
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MP(:, >@0-+*S%S00F2P>:A88_#;2<2B99\F(H(>@0
M                  *4Z.KAW258
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MBPL^22                                     "E.CJX=TE6
M                                             -]@2+RXR]Y\O>3
M                .T9   'EO^B9CJ^_@        &3Y>K:YJU^94C3U/2]_
M     /0?"Z#<84@                  8\[IS                     *
MND?%IS?
M         "E.CJX=TE6
M          !OL"1>7&7N6Y>\89,                 [1D   >6_P"B9CJ^
M_@                ]!\+H-QA2                  !CSNG,
M
M                IA?UL6W]=^                 XGZ?H
M    !Q.0              /J;E&ZW5Q]WEN7L8PR8                !VC
M(   \M_T3,=7W\                'H/A=!N,*0                  ,>
M=TY@
M                            %8"63K@                Z1VSD
M             = [X             !^FUFPGZ 8PR8                !
MVC(   \M_P!$S'5]_                !Z#X70;C"D
M #'G=.8
M                               !68LP                 = [AS
M               ,89,              'Z  8PR8                !VC
M(   \M_T3,=7W\                'H/A=!N,*0                  ,>
M=TY@
M                            %9BS(                !CSNG,
M            QADP                #&&3                 .T9   '
MEO\ HF8ZOOX                /0?"Z#<84@                  8\[IS
M
M                         *S%F0                #'G=.8
M        !C#)@                &,,F                 =HR   /+?]
M$S'5]_                !Z#X70;C"D                  #'G=.8
M
M                    !68LR                 8\[IS
M    ,89,                 QADP                #M&0  !3+5TWP^@
M               !9/-VF4C]0                 !UC[G(
M
M             B E\                 ZQ]SD                 =,[@
M                !U#M@                &1,X  #RW_1,QU??P
M          >@^%T&XPI                   QYW3F
M
M        5F+,@                &/.Z<P                #&&3
M            ,89,                 [1D   >6_Z)F.K[^
M     #T'PN@W&%(                  &/.Z<P
M
M   "LQ9D                 QYW3F                 8PR8
M       !C#)@                ':,@  #RW_1,QU??P
M >@^%T&XPI                   QYW3F
M                                                           5
MF+,@                &/.Z<P                #&&3
M   ,89,                 [1D   >6_P"B9CJ^_@                ]!
M\+H-QA2                  !CSNG,
M                                                        K,69
M                 ,>=TY@                &,,F
M8PR8                !VC(   \M_T3,=7W\                'H/A=!N
M,*0     !P(U)-(^)!!I!KQ+!%)L!LQ#1-9V@    #'G=.8
M
M           !68LR                 8\[IS                 ,89,
M                QADP                #M&0  !Y;_HF8ZOOX
M         /0?"Z#<84@     #J'BV>OQ3<OR#SA-K)K(E--)=-](9+P
M&/.Z<P
M                              "E.CJX=TE6
M                       !EN/N\N+O=]A2        ,89,
M     [1D   >6_Z)F.K[^                #T'PN@W&%(      ZA0$QIL
M1;(^Q00ZI8(F(@<MZ5+/J7,     ,>=TY@
M                                                          %*
M='5P[I*L                                            9;C[O+B[
MW?84@       8PR8                !VC(   \M_T3,=7W\  W:'VEVLEQ
M-91=%F\ )+KY.H2N.#[>    !M$;KJ\GD!)=?)U"5QP?;P !Z#X70;C"D
M   =0HZ3,4+/0X^16HGTA\W\B4E$LD48/0D     QYW3F0V3(    :$9TV '
MS*L' M0?8  &CF3-E     !UB,37">B'R7"L)TBU!$1V263D  ?,J\=$M.1.
M3(1@;<:0=,F0C(A$$PDM$2$;$XD2FW$OD>&T$?D;$XFY@
M                            I3HZN'=)5@
M                      9;C[O+B[W?84@      #&&3
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MKGH$4S)W*XF /0(QA7XP)9PRQY_%@#($<$8%QSS@/1HJ&6 )K,L
M                                  "E.CJX=TE6
M                             ,MQ]WEQ=[OL*0      ,89,
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M7 P!Z! @XU\LB"EY^$-%U2!BWI7 F<KH?AN):
M                     %*='5P[I*L
M                "Q6?LK79BV      &,,F                 =HR   /
M+?\ 1,QU??P =GS]]",/?P5<P9NJ)L;3X^%[>)BJI<8V$;3I?&:JB;C^GF-I
M\;8.'31)O"9*J9T/?G%]/.&Z^.YY^RW62X%N8$L5LO?(7>%;>% US!CF?'
M]!\+H-QA2     !%9J@)B,Z: ;^#J&@$E Q)C32#B3"    #'G=.9Y^%DS.%
M=#XG;+A%)C7"P)#I:$K"7R*XD?FVF%([-Z-2+Y'GX=$VDV4W4A(LV5<,B30;
M$5U-(+(F?)Y*$EZRCI8D\WBZ1R!Q(P/0 H87U-%/B?4WLJ2?A#)M)BRRQ48O
MX5+(U+>DC$<&OED04;)4(2-E-$/1 JL3.5@)4,"6N
M                        !2G1U<.Z2K
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M.N;(#2"/">"(#8C?S5#-&LD>$\'(
M           %*='5P[I*L
M     ">*.PM[E+CF       8PR8                !VC(   \M_P!$S'5]
M_                !Z#X70;C"D      45+I%.R12)2SQGRB1(Y+Y6(F@U$
MUHU4](CM@   &/.Z<P 0L32      =$C$EP         XFBF^    T(WT
M                                                         I3H
MZN'=)5@                                           ">*.PM[E+C
MF       #&&3                 .T9   'EO\ HF8ZOOX
M   /0?"Z#<84@     "BI=(IV7'*1DY'S*V%B2NA]BR)#!.Q7,O*9D    QY
MW3F
M                            4_L8N&LHO                 'R/H?H
M                !\#[@      &0)"Y>[#T-CS        ,89,
M        [1D   >6_P"B9CJ^_@                ]!\+H-QA2      (G)
M/(U)+(M):(^,R;00>9(C,FPA,W<G,    &/.Z<P
M
M   "L18 X@                Z)VSF                 8XR(      !W
MC('Z        #&&3                 .T9   'EO\ HF8ZOOX
M       /0?"Z#<84@                  8\[IS
M
M     *S%F0                #'G=.8                !C#)@
M         &,,F                 =HR   /+?]$S'5]_
M  !Z#X70;C"D                  #'G=.8
M
M!68LR                 8\[IS                 ,89,
M     QADP                #M&0  !Y;_HF8ZOOX                /0
M?"Z#<84@                  8\[IS
M                                                        *S%F
M0                #'G=.8                !C#)@
M&,,F                 =HR   /+?\ 1,QU??P                >@^%T
M&XPI                   QYW3F
M                                                     5F+,@
M              &/.Z<P                #&&3                 ,89
M,                 [1D   4RU=-\/H                63S=IE(_4
M               =4[!R
M                                             (@)?
M      .J=@Y                 '3.X                 =,[@
M         !D3.   \M_T3,=7W\                'H/A=!N,*0
M          ,>=TY@
M                                        %9BS(
M !CSNG,                 QADP                #&&3
M     .T9   'EO\ HF8ZOOX                /0?"Z#<84@
M       8\[IS
M                                     *S%F0                #'
MG=.8                !C#)@                &,,F
M  =HR   /+?]$S'5]_                !Z#X70;C"D
M  #'G=.8
M                                !68LR                 8\[IS
M                ,89,                 QADP                #M&
M0  !Y;_HF8ZOOX                /0?"Z#<84@                  8\
M[IS
M                            *S%F0                #'G=.8
M           !C#)@                &,,F                 =HR   /
M+?\ 1,QU??P                >@^%T&XPI      &HE<2WA6$L\"IAJQ;D
MIZ2D;@5[+,$G@    &/.Z<P
M                                               "I\V/O<W@
M            !U3L'(                 Z9D?GV:J>;]OGT
M    #&&3                 .T9   'EO\ HF8ZOOX                /
M0?"Z#<84@     "-SS#/2PJ\7Y!YS&RG(M85++,'T(#+M     &/.Z<P
M
M                    "E.CJX=TE6
M      )GIYUR\C<_;Y]               &,,F                 =HR
M /+?]$S'5]_                !Z#X70;C"D      1N0<0D;(2<?<A$W8C
M0]!RF)>X@T@LO>     8\[IS
M                                                 *4:.KA[258
M                                   $ST\ZY>1N?M\^@
M   8PR8                !VC(   \M_P!$S'5]_-HC=;A9:W[OG[6+0UDW
M5$V';2)B.OB,+&,,KR]6=SUG4W357=\>K6YNTJ+IZD #>(??+\O486,8
M >@^%T&XPI      $;D+DME #U4/@><1L!+)%)V#9#B?8NB     8\[IS*2'
MX:F7C-E       !7<L.?I6LAXZ!=\\^#<2Q)5 OL? ID7_   *0'5,87S.R
M      :28,E(  &HE*3LE@RNYDS<SJ&_%ASS./3$  %-S63O$_G F0IT#;";
M3;"E9$))Q>0T4J02"9PAXM&5H-.+&$,F]EN0
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M] \_3T"!J)I95T[1?(HL7M/.XMJ5I,>>@P
M  !2C1U</:2K                                      FVEG7+R5T
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M)5@                                    #Z^?MS,C=3/430
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MD9@L&1&;D1<;F7-*/%X00^5D.Z;B:(6+(;+>D9%93M%\0
M             "E&CJX>TE6                                    !
M]?/VY61NIIJ)H              &,,F                 =HR   /+?]$S
M'5]_                !Z#X70;C"D  >?IZ!%$3Y%L#+%-R^I7,RQ.Q$10@
M]3#L'FD76)7//XSA+QIYHY-)0$]+"KQUC=#<RS8!CSNG,
M         C\J.<B^P                 .!TC(
M                   %*-'5P]I*L
M     ?7S]N5D;J::B:               ,89,                 [1D
M>6_Z)F.K[^                #T'PN@W&%(  \XS<C;C@3X;Z><9N!L)+9.
MP*+%X3L%#RRQ6<QIZ!%#3833S-&X$)&R'$[AN!<@ QYW3F
M
M           4HT=7#VDJP                                   /KY^
MW*R-U--1-                QADP                #M&0  !Y;_HF8ZO
MOX                /0?"Z#<84@ #S^/0$%02,3JEKB:"N964WXO,48+PG8
M*4$UDV%#2^10XCLWT^9)A+90 E(] B@):4ED&/.Z<P
M
M      "J9*!Q                !TSM'(                 ^1*)D@
M             8PR8                !VC(   \M_T3,=7W\
M      'H/A=!N,*0         /P^9]0 =8^I]     8\[IS
M
M            *S%EP                #'G=.8                !C3*
M                &,,F                 =HR   /+?\ 1,QU??P
M           >@^%T&XPI                   QYW3F
M
M         5F+,@                &/.Z<P                #&&3
M             ,89,                 [1D   >6_Z)F.K[^
M      #T'PN@W&%(                  &/.Z<P
M
M    "LQ9D                 QYW3F                 8PR8
M        !C#)@                ':,@  #RW_1,QU??P
M  >@^%T&XPI                   QYW3F
M
M5F+,@                &/.Z<P                #&&3
M    ,89,                 [1D   4)V=%U_7P                6ZRE
MQG8O8                  =0[)R
M                                                     (-)R
M              .H=DY                 '1.\                 =$[
MP                !WS,   \X-YG>MZ^                "\&,O-HB=P
M                !T3MG,
M                                               KR6&
M        .B=LY@                &.,B                 8XR(
M           !W#*   \M_P!$S'5]_                !Z#X70;C"D
M             #'G=.8
M                                           !68LR
M     8\[IS                 ,89,                 QADP
M        #M&0  !Y;_HF8ZOOX                /0?"Z#<84@
M         8\[IS
M                                       *S%F0
M#'G=.8                !C#)@                &,,F
M    =HR   /+?]$S'5]_                !Z#X70;C"D
M    #'G=.8
M                                  !68LR                 8\[I
MS                 ,89,                 QADP                #
MM&0  !Y;_HF8ZOOX                /0?"Z#<84@      <#F<#F <#F<#
MD?I\SZ      QYW3F
M                                          5F+,@
M   &/.Z<P                #&&3                 ,89,
M       [1D   >6_Z)F.K[^                #T'PN@W&%(      ZAX[G
ML*44+\@\[#X%QRGAV22S6S>2UH    !CSNG,
M
M IC?UL>7]<                !Q/T_0                #@=WQ]N5D;K?
M84@               #&&3                 .T9   'EO^B9CJ^_@
M            ]!\+H-QA2      .H>:I(IUB_(/,DQQ9$DX@<N(5(,F7
M  ,>=TY@
M                                %*-'5P]I*L
M                  9;C[O+B[W?84@               8PR8
M      !VC(   \M_T3,=7W\   '[\9;G[Q'3P^@  'Q]OGWX^O@      ]!\
M+H-QA2      .H4=,Z5\+/GZ1N6 *W%CR#R=2=3SR/1      QYW3F<#@?4_
M#]/T     ' Y@ '$^9]#]/PY 'X<3F     ?(_#[   _#B<P     ##F7/T
M  X',   '1/J=D         ZI\SO' YG Y'$',X' ',Y@^9]#@<C].!S
M                !2C1U</:2K
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MC2XA-I#Q2<]#RB9V2Q)!9GB[0                   !2C1U</:2K
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MW!YFDOD1ET"K!CC,&:)O(@(3)6- +2$,D:FX&X&)(?/2DPQ6@NF5U*?'H:5
M,V84SQ#AGBS!H9'YKY(1NA;$\\3T..H:.56(U)<.L8(QYL)O1HYA3YD@%RP
M#SO/0XY'G@=T] BF9.Y7$P!Z! @XU\LB".RJ!,9M! Y(!7<W0OH
M           4HT=7#VDJP                                     )4
MJY=Y,9>@             #&&3                 .T9   'EO^B9CJ^_@
M $C0)%K\U:TCUU+?/&7E5-)5W'RUQ6;05LC0)'U^?<3T\;)PZ4HUM-=[(77'
MZ_")+.)+M9+A*WA?A7^[@   #T'PN@W&%(     XGX<S@<C]  !P.1^G ',^
M9]    #'G=.900M&;802:48DBPDTOF4..):<HB;.?<ZIZ(E#2^Y6(U0%OBI1
MNI*AIY%)%9H9:TY&G&M$U$=F]D)G;+Q%+S'$N&K$<%T"B!8T@0^Y,9#Y*QK)
M^$3FY%IBK!$I-!?,H<?I? P)18]!RFA)Y3PMD0"<SF3H0^;Z:R1D;H7C*6EX
MCSR+_$?$$FB$2E@2X)2<Z1=LHR9DP9F"^@*DF-.^6Y*!%U2)BMY]#T,*+%J"
MKQ@#T"!!QKY9$ H<3H"#S"E]"A!Z%                    %*-'5P]I*L
M                                    ;Y D7FQE[EN7L
M   8PR8                !VC(   \M_P!$S'5]_   !8RAL)5K94+6T.![
MJ#;',VM8]#66!I+#8.'O4I7+[?/M>[NOL516&<X]/K\1G81MIC]8[G1Q&%C&
M   'H/A=!N,*0    !78J<>G1Y<%ZB7088S)U3\*DFJEVRDQABR978ON?H
M ,>=TYE8BS)]"&34R.#HDH%ERM )G(V(6,@6%*R&T%P  """33:B/S2"#3@6
M-(-)0,22"<"L1^DO%C2OAUBRP*OEH"!3(D#&0-^(Q+ &N$1G8)7-3-*,62N6
M@*T&M%B3<RN!#YNQ;DI@7(*7'W,X2X:$9 C8YFZEC2OA8TT,J.=DL\5I,63,
M6"*[G2(_+-%9#;382RX  -?*8& -T)J*ZFWEN"!"$S(ED3(F,): *T%C2E!M
M1-)6<E(LH                    4HT=7#VDJP
M               -\@2+RXR]R_+V              !C#)@
M   ':,@  #RW_1,QU??P                >@^%T&XPI     %=BFIZ2GF<
M>@1+I2H^IEB(SZFW&EEKROQ!A]3U6/T    QYW3F
M
M     4HT=7#VDJP                                   !OD"1>7&7N
M7Y>P              !C#)@                ':,@  #RW_1,QU??P
M            >@^%T&XPI     %=C0RO)/YEC0S$GH.5.*]F]'7+B%#22302
M=#,%FP   #'G=.8
M                                       !36VA:I;0P
M     /D?0_0                #B;EY^VNS5KE^7L               #&&
M3                 .T9   'EO^B9CJ^_@                ]!\+H-QA2
M     (I,@5Q)R-H-Z(8("+"$$'5)=)A-/-!,>6A*6ES#[    QYW3F
M
M                   5=)U                 .@=PY@
M  '7-R.8                ,89,                 [1D   >6_Z)F.K[
M^                #T'PN@W&%(                  &/.Z<P
M
M               "LQ9D                 QYW3F                 8
MPR8                !C#)@                ':,@  #RW_1,QU??P
M             >@^%T&XPI                   QYW3F
M
M           5F+,@                &/.Z<P                #&&3
M               ,89,                 [1D   >6_P"B9CJ^_@
M          ]!\+H-QA2                  !CSNG,
M
M        K,69                 ,>=TY@                &,,F
M            8PR8                !VC(   \M_T3,=7W\
M     'H/A=!N,*0                  ,>=TY@
M
M   %9BS(                !CSNG,                 QADP
M       #&&3                 .T9   %,M73?#Z                %D
M\W:92/U                  '5.P<@
M                                                       "("7P
M                #JG8.0                !TSN                 '
M3.X                 9$S@  /+?]$S'5]_                !Z#X70;C
M"D                  #'G=.8
M                                                  !68LR
M            8\[IS                 ,89,                 QADP
M               #M&0  !Y;_HF8ZOOX                /0?"Z#<84@
M                8\[IS
M                                              *S%F0
M       #'G=.8                !C#)@                &,,F
M           =HR   /+?]$S'5]_                !Z#X70;C"D
M           #'G=.8
M                                         !68LR
M   8\[IS                 ,89,                 QADP
M      #M&0  !Y;_ *)F.K[^                #T'PN@W&%(
M        &/.Z<P
M                                      "LQ9D
MQYW3F                 8PR8                !C#)@
M   ':,@  #RW_1,QU??P                >@^%T&XPI
M    QYW3F
M                                  57[<Y:E\0                .
MF=DY@      W:'WS'+V         ,89,                 QADP
M         #M&0  !Y;_HF8ZOOX                /0?"Z#<84@
M          8\[IS
M                                        *474"'M;3
M              ;C#[7IQ5]GN/0        #&&3                 ,89,
M                 [1D   >6_Z)F.K[^                #T'PN@W&%(
M                 &/.Z<P
M                                               "DEU B+6TP
M                      W&'VO3BK[/<>@        QADP
M   #&&3                 .T9   'EO^B9CJ^_@[_/U/E+.P_7Q!EQ"?0S
M''WN\3MF.7N&+:&)DJID/6D/9H_67ZN6-)E\8MLHH      'H/A=!N,*0
M !I1IA-!"A(YL@  (T,N;<16=4F,KJ6*/T   &/.Z<R&R9    #5S!'7)- !
MJ1J)+8-',F;*      "(R7   "&S:S>2N!8\ U$VX  ^1K9M(/D:V:42\ "'
MR$BRYNP,>:$8XEXU\P9NI4L&;+0         &"*M&\EAR'R8B&S:3M&IDND!
MF@ L@;65_.Z3,5?)\(M-=)%.V1J6=.0                   *274"(M;3
M                         ;C#[7IQ5]GN/0       #&&3
M      ,89,                 [1D   >6_Z)F.K[^"R%!8R'!D8?KXKI>U
M\B09'V^-#F\+#45AT_?RKVBK)ZI9U@:2?YZ;B@RG/U/M)/DV!)JWHJS8.'O5
M9/+M>?6^0N^3Y^L/U\:S(YXCKXEJLE07<PI,KY.3Y^J_W< #T'PN@W&%(
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M05/+DE428BN)/A+QNP                   *274"(M;3
M            #<8?:]6*OL[QZ       #&&3                 ,89,
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M&)<+7$K                    I)=0(BUM,
M  ))K95X,;>=_P >@      !C#)@                &,,F
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M52+BE6"XA5$L$9LJH6X)4*8ETC,&ME4C6SJ%A2OI: C$M(><Y+Y*)-X
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MW3F      "%B:0
M                               4DNH$1:VF
M     D:NE7?QEYD_'H        #&&3                 ,89,
M        [1D   >6_P"B9CJ^_@                ]!\+H-QA2
M         !CSNG,
M                                        J1[\[MV\?@
M      .H=DY      &PDI\.G>\_0        !C#)@                &,,
MF                 =HR   /+?]$S'5]_                !Z#X70;C"D
M                  #'G=.8
M                                                !64LJ
M          = [AS      .9R          ,89,                 QADP
M               #M&0  !Y;_HF8ZOOX                /0?"Z#<84@
M                8\[IS
M                                              *S%F0
M       #'G=.8                !C#)@                &,,F
M           =HR   /+?]$S'5]_                !Z#X70;C"D
M           #'G=.8
M                                         !68LR
M   8\[IS                 ,89,                 QADP
M      #M&0  !Y;_ *)F.K[^                #T'PN@W&%(
M        &/.Z<P
M                                      "LQ9D
MQYW3F                 8PR8                !C#)@
M   ':,@  #RW_1,QU??P                >@^%T&XPI
M    QYW3F
M                                  5F+,@                &/.Z<
MP                #&&3                 ,89,                 [
M1D   4IUM+U_OP                6<S5MEXW4                  =0[
M!S
M                           (:)E                 .H=@Y@
M          '2.Z                 =([H                !D#-@  \M
M_P!$S'5]_                !Z#X70;C"D                  #'G=.8
M
M                       !68LR                 8\[IS
M       ,89,                 QADP                #M&0  !Y;_HF
M8ZOOX                /0?"Z#<84@                  8\[IS
M
M                   *S%F0                #'G=.8
M  !C#)@                &,,F                 =HR   /+?]$S'5]_
M                !Z#X70;C"D                  #'G=.8
M
M              !68LR                 8\[IS                 ,8
M9,                 QADP                #M&0  !Y;_HF8ZOOX
M            /0?"Z#<84@                  8\[IS
M
M          *S%F0                #'G=.8                !C#)@
M              &,,F                 =HR   /+?]$S'5]_
M       !Z#X70;C"D      :B5Q+>%82SP*F&K%N2GI*1N!7LLP2>     8\
M[IS
M                            *S%F0                #'G=.8
M           !C#)@                &,,F                 =HR   /
M+?\ 1,QU??P                >@^%T&XPI      $;GF&>EA5XOR#SF-E.
M1:PJ668/H0&7:     ,>=TY@
M                                                %'M=2Z?81@
M              .)^GZ                 <"0(,BY61NNUY^@
M      8PR8                !VC(   \M_T3,=7W\                '
MH/A=!N,*0     !&Y!Q"1LA)Q]R$3=B-#T'*8E[B#2"R]X    !CSNG,
M
M                     HEM:&-+**
M      )8JI=UL?>=KS]               &,,F                 =HR
M /+?]$S'5]_     !8^@L>_X]5AT59?7%WM7]%62S62L=T\[1&ZT^U-1\_H
M    #T'PN@W&%(      C<A<ELH >JA\#SB-@)9(I.P;(<3[%T0    #'G=.
M92 ZIC"2BTAW@     5)+;   IP2F;R4I/1$J$=PVDL0   4W-9.\3^<"9"G
M0):,B2T4K(A).+R K ;V:>0\6L*UF'+HFR
M                           %$MK0QI910
M             )8JI=UL?>=KS]               QADP
M #M&0  !Y;_HF8ZOOX    !S^/0?$7_U^??/K;4'H_@]%"EO"EZKEQ;8QM]A
M=_/[;4'Q]      /0?"Z#<84@        #@? [1U#M'Z=$[P     ,>=TYGG
MT7F*,'P+3%?#Z'R.H3Z55,J7$*I&1)'(X-?/08  ^10,ZQ;T\QCUH/-XE<W4
MMF  #32I!>DJ2:H2\6#//T$[&6)V!Y^GH$#"%(2>"!B^11,M"1.2$32
M                                                42VM#&EE%
M                                  $L54NZV/O.UY^@
M #&&3                 .T9   'EO^B9CJ^_@    $O5<NY.5N/C]^57T=
M78.DL,WQ]ZQ(Y:S(Y[["[^?VVH/CZ      >@^%T&XPI
M   QYW3F><Y)I(Y$A.9 A%9(9><I>8@FX@DZI^G1/1<H>7P*DF-.^6Y*[E83
M2"[Y!QCSOG8-U+9@BT@D$YF8*PEPRN1'A+98P\^SF3L98G8'GZ>@0!!YCB""
M^Q0PG(A\O&
M   "B6UH8TLHH                                     %R<C=3?33@
M             !C#)@                ':,@  #RW_ $3,=7W\     M]E
M[:#;B%CO?FSN>LOI\^X?KXT:9PV7AUW:'V&IR>51=14@    #T'PN@W&%(
M   B<A\MP5!+!F]@  @0[A,I74QY8XJ,7./T   &/.Z<RCQ>$%/#-&BD9DN%
MQ2HYTB6S%$"'S)2-3!>8  HD7G-'*:DXE6B[I"9#1(Y<LSP !1<C$C$],2F1
MF"P9$9,Y6$W O,4@+P@$.G0(S-$)U*-D_%I"10
M                              "B6UH8TLHH
M                 LWF[2SN<M               ,89,
M  [1D   >6_Z)F.K[^                #T'PN@W&%(     KL4C/6$\C3T
M9)=(,())N(6,^?0KF>E!3LU Z1?@VT    QYW3F                    #
M@=(R
M       !1+:T,:644                                    "S>;M+.
M9RT_0              #&&3                 .T9   'EO^B9CJ^_@
M             ]!\+H-QA2     *[$#&UFHFXG6-=+_E-B.##DFDTE9#9"OQ
M)!>HW@    QYW3F
M                                        42VM#&EE%
M                         %F\W:6<SEI^@               QADP
M            #M&0  !Y;_HF8ZOOX                /0?"Z#<84@    "
MNQW2A!=4D(EPIL8\UXQ9]B0"R)74U@PI>8\YCTO/L   #'G=.8
M
M              !2#0UF)E\0                /F<S]
M  .R3'!D6(H;']                ,89,                 [1D   >6_
MZ)F.K[^                #T'PN@W&%(        '3.X=<YGU       !CS
MNG,
M                            JN3V                 =$[9S
M           /L;,?H                ,89,                 [1D
M>6_Z)F.K[^                #T'PN@W&%(                  &/.Z<P
M
M                        "LQ9D                 QYW3F
M        8PR8                !C#)@                ':,@  #RW_1
M,QU??P                >@^%T&XPI                   QYW3F
M
M                    5F+,@                &/.Z<P
M   #&&3                 ,89,                 [1D   >6_Z)F.K[
M^                #T'PN@W&%(                  &/.Z<P
M
M               "LQ9D                 QYW3F                 8
MPR8                !C#)@                ':,@  "A.SHNOZ^
M           "XV4N-DB]@                 !U#LG(
M
M         @TG(                 ZAV3D                 =$[P
M            !T3O                 '8.X
M
M
M
M
M
M
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M.8  /F?0        ' YGS/H?A^'3.Z?IP.8   /P^(/H<S@<P<#D?H
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M-:)&-W(6,26?(Q+=G Y&K RIS*L&X'1,$9DUDEDU<EHAT^9G# G;,T88PQM
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M(SI&YWRS!FP
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M\))-=.D;R=(G4ULB@VX^Y&)J)WSHED3-F5
M                       (P.)O)V2,R1#+$;GZ2.?H ,(:.;"9XC\VHZ9]
M#N@'1,<;@1T2<=LPY'A)AJYU3*'$V<P1^F1([).-*.!LAI9*!^F'(Z)#/PU,
MVLT\VDXF2,$;08(CPF@PIQ.D#F8@^Y]3NFH';)&->-+)1/L #Y&#,Z:N<C#F
M=-E-:-E-:,P8P^)TC'&X$=$G$>FYG4.@? WLQAU0=<S1BC]-2-E-?,Z?4R!^
M',CLE$^Q&!]20S7C4C.&QFD&Y&JG<,X:6;Z<C)'$C V$SA'YM1]09LC,D\CH
MVDXG1.)NIT",R1#7#="+39S<0 #X$7FYGU-2,X90[!H)N9\3.F",<#(F=,4?
M P!S-Q/L:P9XQALIAS03=3NFO&*,L:630#4C4S6B<"+S?#H'?-.!*1HQO0
M, :*?(E@BTVX[9J1LIR!S,(;2:V8(SAW#IF\FJ&T$6F_&7-8.R98P1@S9#2S
M9"#CJE@S(D?FU&(-D-+)0(Q-@-O-/-<-A,J? QY\#+&:(S)$.J=<C,T0E8E8
MZQB3MG(QAC3JG9.)]3=0
M
M
M                  ?AIAM)VP           = UXW
M
M
M
M
M
M
M
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M?AR    !P!^GS/J?$^X   /PX'T    !P/TY'R/J #\/PY X',XGZ?I\SZ
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M261";62&5A+/'Q-8-H.J?(K^3^=TU<VHU\[ACC!&Z&!-G.V
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M#5#>S(D8'S-V-%)1([,L=\^Y]#020CX'7.R=4[9HQM1^FT@
M                   &..X?4       '0->-P
M                               !B3L'>  -:-E
M
M    -:-E
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7(E9]W@L$I&LL[].;=_79N,++QB"SZ!DXW-X1ZE,9U%,T6C5]/2;%HFP9Y_
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MY5Q_]>]AX#ZA??O>P]QOK?8?_P!>]A[<_6_>7\_L+(/2'8V ^H7W[WY5Q_\
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MV;1CK)LIS>,Q)3[S8V('<+&\A<#(=PL=QU5#>:$.I%2T=-LQD^4,<49?>;'
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M/,MZ4BH7;R8RU*?VV?8PWV_RLV4PZJZ+<K=XT=T,8I*+.VC8B:J:Q G(,%E
MNZ;-2IJ)JEJ<A:T=M3+^[EN1HXO#0V)Y'N&)#9ZK9+;S-)!V\W _LH;K>C<+
M_K793]LS_NH9/ %R6'D]GV\?&X1@*67,\/V^2Q)^,[EYF;R>9VN- Q>!Y4I,
MXO&1\MNI*24=+[5RLY)IM\9Q+ Y+*8J#VQ>P\MO \7K7[/R PW%5\5;?@S.O
MKWXKQ7*JQ]:5H9QV&EXO>7\_X6.?7MQ/H0Q7U#N3^QVT\MW_ &/.OX^(;P$\
MUR1JKCZ"N:3,S'XHRQ^883R><^I?AXWZ=^+F'I7&\4+D^WVUF5F>MF7]T^R7
M?=(YUE.4S62N-STFK'$8)(J,)N=_T9G4I3#-<[R-@?:!M$HQ7PW/E%\(S6E*
M[I3;-UMIE^XKUM(X!B4F2&VSQG&'VXJV38L^VZ5W/DTYG&8K; L\PV^5D<=S
M,5I0U'&/YGM]*,=YCIFQR5QV;1=L9*6W%S3;MIBT1CN%N,\8X61WBFX>91&5
M91DLSM) M8K;Z6=O\*V7^B;1?61O6N?ABFJ;*,"+&-CJ,&TANM/91M_7$6F7
MSG46V;W^H-JO1HS+^U!.?1=E_HF]'T?<+^N<4V]ZJB85N^P3<++G<GF>8RNU
M:40QV4_RB-SJ:_.*4H6ABE.4S9&)CX/;Z4R=?-,73P-UN:XJ[P/%-O>JHF%;
MOL$W"S:1E<IRV5V@8-XN,R2?@\$Q;!%,S;RC%_M5-;M.5:3T!M/RY_[N]3@]
M5V+5-BR&8%I%[I;@?V4-UO1N%_UKLI^V9_W5[,D].[+_ $?V<):US;.\C<M(
MM*+8;5[0I%)B>[R93XG,NU_M%C+'<QQ!XWG<_'SVX:LHXSY\7>",;X+F1,M8
M?@S.OKWXLP1_(*J=AI>+WE_/^%CGU[<!-16$T;L8RFHCD6XZ1S1FV[95-D[_
M +'W(^F[9_HFJ1/<G<9@Y63V[CG35KG/J7X>-^G?BYAZ5V<]+[CP#G'Y;$Y8
ML[NAD^WLQ.S>.X--XVZV829JK[EMF*^(OD';K:W%'J<AC>=&I+;C3&<QT)/F
M*4Q<%*DAN5\-SY1?",T_M/(X%KDD0M*R,-#-T#N-F=I'2"V*;LND$,2R9%1#
M;R._Q'L/[GEMLIR0E(/&IK"8_ ,T/EC:1AHF73P9$D7N3CG]N;J>C-O/1G_W
M?D4_DN2Y>\VL0;L=L?3&R_T3:+ZR-Y(M1S#X7.MY['G+E!FWQK,)W,5\"Q)E
ME593:^$B6,\SBF6V;W^H-JO1HS+^U!-_YA=ESEK$;TKITC]POZYP?_&(Y7_:
M\$<L5NY)/$(]ALGY W?9.&LC#RS2;CIF6:PD9C6?S;W'H*)S#<)+/,,CL3;9
M_P#UM@_^,1RO^UXXQ(_>)PNDU0S')66881B>W4?D4'.8!BL",\123R#V/-N9
MUR[^V60!KMQ/-W(WEB57$=AV0-LB@U-P\<;3A5^M]S]T^]AF"2J:Z6[[]%#&
ML6;G:[=[*?MF?]U>S)/3NR_T?V4SF.ZK>HM'#/!6J[V,V<>IK8]O&]31QXL\
MVP7#XU^A*Q^Z52.<OIG,7U0H<B:>T9;F0_@S.OKWXK@(!S..63)M']B)>+WE
M_/\ A13I-C)_<:$'W&A!DF3H2<@AN#"KMTMQF%'"\\T4RS+<I83S7$,C98^'
MKM>?R@^4/8MICF0*9 IFQJ&R7X>-^G?BSS!64A<!QI]BT,]9MY!IBNVLICF4
M>R9VVDVTNK@N=9*J;'8HT"C@^?XX;"\!4@GF:X2URYMTSNN=MAF%,\1;?#<^
M47PC(,+E)7-!GV &RD^+0JT+C:^W.104BCMUDD_(9[AKW)6#5(R+9MALFCN!
M[)O:IR1^?$MU'U,,P=GB243ALFPSG-(-WD>/XK%.(/'^C9/[BY+M_,'GS8=G
M>1C$L&FL>;;?8K(8I'8+ALGC#\.FR#UNYVOGHA\M@>X.05QS'(_&(Z=VXD"S
M#C!L^R93)L+,^Q-QC3Y7!,*@G>.0 S3 I^>R'HG=$8CCF8QD@;;C+("1D-KL
MHF$,IQ=_-XGCL<M$0<WALG)9MF$!CV6RSO \I<--E4C48B5BF4TP^W&80#BN
MW.99 X+C$4GCT?A>XN,FDMK<AET)S%)B7PK'8Y:(@YO#9.2S;-<#)DYW&);G
M2Z,/B<7$0!=O\QQIU'[<34I+9AALGD$_[SEL@\;O=K9B+>K[;9M/NHB$S';Z
M6RO%F.5QR.#[D0I8W:R5?R#IM=8[>8A)8DC/;>94\R?HG=$87"Y3#B6:*/XK
M;[%)#%&'LS7 *9&LXQ3=&80Q;%V.*QTCMU-Q<O&[=SLI,3\&RR*,:X;N1CI<
M1V\7C)+-=OZ9&NYQ3=&71Q;&66*QGX,SKZ]^*H" <SCEDR;1[;^3V&EXO>7\
M_P#X;-VLP=(;A0[A%SN%$MT'+A5VX^'C?IWL9SY1?#V7E^ NY:5=8EN;.IXW
MC[/&8O\ 'N=?7OQ3 0#F<<LF3:/;#^3V&EXO>7\_L+&_3O8SGRB^'Y5YJFHK
MD-8]_0:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH'P
MT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH7M!H'
MPT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH'PT#
MX:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/A1B]J- ^&
M@?#0/AH'PT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#0/AH'PT#X:!\- ^&@?#
M0/AH'PT#X:!\- ^&@?#0/AH'PT#X:!\"QDD81.*R<BZ9,FT>V]G\GL-+Q>\O
MY_86-^G>QG/E%\/RKEJ<6<J1=3&Y28<I,.4F'*3#E)ARDPY28<I,.4F'*3#E
M)ARDPY28<I,.4F'*3#E)ARDPY28<I,.4F'*3#E)ARDPY28<I,.4F'*3#E)AR
MDPY28<I,.4F'*3!>)K;I$F[N4F'*3#E)ARDPY28<I,.4F'*3#E)ARDPY28<I
M,.4F'*3#E)ARDPY28<I,.4F'*3#E)ARDPY28<I,.4F'*3#E)ARDPY28<I,.4
MF'*3#E)ARDPY28-XDU2<I,.4F'*3#E)ARDPY28<I,.4F'*3#E)ARDPY28<I,
M.4F'*3#E)ARDPY28<I,.4F'*3#E)ARDPY28<I,.4F'*3#E)ARDPY34-694:>
MY_)[#2\7O+^?V%C?IWL9SY1?#\JY+UYV&Y\HOA[#:^7V'_)[#2\7O+^?V%C?
MIWL9SY1?#\JY+UYV&Y\HOA[#:^7V'_)[#2\7O+^?V%C?IWL9SY1?#\JY+UYV
M&Y\HOA[#:^7V'_)[#2\7O+^?V%C?IWL9SY1?#\JY+UYV&Y\HOA[#:^7V'_)[
M#2\7O*0&)7.G\0'3^(#I_$!T_B Z?Q =/X@.G\0'3^(#I_$!T_B Z?Q =/X@
M.G\0'3^(#I_$!T_B Z?Q =/X@.G\0'3^(#I_$!T_B Z?Q =/X@.G\0'3^(#I
M_$!T_B Z?Q =/X@.G\0'3^(#I_$!T_B CRD;1EQ<7%Q<7%Q<7%Q<7%Q<7%Q<
M7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<
M7%Q<7%Q<7%Q<7%Q<7%PJ=2I**+=UQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7#MLQ/DMQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<
M7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%PJ=2I**+=UQ<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%PB=0I;BXN+BXN+BXN+BXN+BXN+BXN+BXN+BX
MN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BX
MN+CC4O7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%
MQ<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7%Q<7#8ZAC^\OY_86-^G>QG/E%
M\/RKDO7G8;GRB^'L-KY?8?\ )[#2\7O+^?V%C?IWL9SY1?#\JY+UYV&Y\HOA
M[#:^7V'_ ">PTO%[R_G]A8WZ=[&<^47P_*N2]>=AN?*+X>PVOE]A_P GL-+Q
M>\OY_86-^G>QG/E%\/RKDO7G8;GRB^'L-KY?8?\ )[#2\7O+^?V%C?IWXIJT
M*6%S''<A<!YE,(PEO9,9'!P!8K.,6FEQ+9MC$(O#9'"9 1TZ;,4"[E8699%9
M%RE\-SY1?#\JY+UYV&Y\HOA[#:^7V'_)[#2\7O+^?V%C?IWXJ_D0Z\I%*P,T
MTR"*R_\ M;V8^P;9?N'NCBT%$QBV2NVFW&V^%Q<C$Y1'([=Y9N'!9'DSYSMW
MB'*=EWSI1M\-SY1?#\J\Z^O?AED]<QSF!GFTXV_X/\GL-+Q>\OY_86-^G?BK
M^1M+'-9:-QF0=;=97E_]JR&78W%NHW*L>EW$C=R[,\HA<KC'&=2+&3VWP"E*
M8=O52F@B^_EN:0&X<LIM++Q>E^&Y\HOA^5><_7OPTR>N8YS SS:<;?\  _D]
MAI>+WE_/]V'Q^3FS?;9[P3&.R<&;VP.,.Y].28*1C[X32&D7K;VP.,.Y].28
M*1C[W<;]._%7\C9+P;BXEU)$P4F\D\LE]OL;G)"/P"!AC;2RC.)>[ES$:RQB
M+@'CO:/:J?9N\>W)?)9/D67YC+8E/FEHPK# .^:W"^&Y\HOA&49M&8FK\'(\
MA:8S'14BC+QWL,8I"RF[N.,EHW=[''BQ#D5)[V0SS7&XR'E$)J-^(JJF@EC6
M5)9,VQO<2#R9^)+-(V+R$QBD+*[LXU'JQN[V./%DU$UDVV;1CK)LBRQ#&GE*
MTK3W3&*0LKNUC3!6.W@QUTJ@X0=(US:,IE(RC*F&)MD9)%>*Q;,(_+20>;1D
M],C*,J8XHU^\V.#[S8X,5S&.RTHR3-(;%E?N]B8@9UCD<?-;H8S#NL;S>"R@
MPR3)8[%V$:^3DX_),TAL65^[V)B!G6.1Q_X8SGZ]^&V3US'.8&>;3C;X_P#)
M[#2\7O+^?[C5N=VY<JL\6@NO,AU#W*L;D(>/CGDHY3VV>U3FL9DX,;:_M,M]
M1QN RSU*0V^E6B4='JR,A7;J4HM-XF[B%V^W$BHE-XO)P0C8Q[+.2;;/:D<8
M?*M9(\:>L#+03J*D6NW$BHG*X')QS?;7]IEOJ/W<;]._%.6ARXOAT9B5 ?;J
M -D'LR/;S'\D7C-H\;8KE*4A9K:K')5UC.!P>+*34%&9"SILS W8>$C(%G\-
MSY1?"-Z?WPDGM(UABV5Q^6-,ER-CB\=)Y_'14-)[OP3-SB^9P^5DR?.(3%@S
MWBA55MU5DG&&16YT+ 8_BVX4-E#@;E*.$L,VJ:8RI"9IA;&?BH-:2P7"L>GF
M>21>59A'8DG,YU&0+IUO+").,<R:+RAGDNY,'CKK+MP8C)\7QJ51A-NG6\,$
MDAUK"I8_]YXBY!S\7D3-UN5 ,9)OO-#*.)S=7'XE;%,[B<L-DV:PF+4:;Q0B
MJ[=P@[0&[4TJC'Q44E"0$8UDTF^*9$WR>'R_^UMWIUP@ABF$1..L,MPV-R*-
MVYB\BA8B(_N/,H8L[CFUD\:7Q[W=W)QR6F*X+#X\QR##X3(6NV,F]AI\W]UC
M>CZ-'^B-E/VVV_\ 8(<LF;TNX4/$ML/VPB8IUB;5@Q8^S*JM9?=)LEMD[7RU
M9OBV'[5XW'HX_N"P0P_)<BEG$7 93$98O'8CZ6RJK67W2;);9.UV;%E'(_AC
M.?KWX<9/7,<Y@9YM.-OC?R>PTO%[R_G^YC?=2>W H:N/@S5RFEMXR22B)S,)
MFLLQ43R7'=MZ5*V19)/=P\YGGD2C@V1/I)5^Q3:9_F<TZAHW#';N=D\B892]
M='9N'L'MXT(E$2^6S5)J6SY5\@JZ<4Q9M.2?-ET,WFB,6SA%AMK^TRWU'[N-
M^G>QG/E%\(WI_? Q:&+AO?B.X6X:A\ES#>5--&+Q>$81,#CS5&*W;PUHCE.?
M9/C;/)XO.(7I[;K;6%91N,3K1"+W9"Z"+I"6V<2JLX+NCA),>G&>?8WM0\6B
MY61_^8[H[NH:K(F\+%M8[;Y;DLUM!%H/5=W(1HX@Z_TYM3CL6M 98T3F=Q>7
M,-%B"?3>YC*):S.Z^Z[%J?$=KXAFSQ5BW1CMYV60PU<VR3</"LAB=G)!5Q"#
M(?\ U^[B_D;.-D'C1FJZVNS'+#D4W2W(_P"O<'V$.10L1_<8VV_]%G(<;F8@
MU7^Z>%A#<W#W"PSON3W-]A*\>]"G^-ZQO1]'C_\ &$[*?MMM_P"P?9N1Z*VI
M]'>R0VL<S.3Y-M5#)Q!Y]Y,[9X!W=';U=V@BZ5I&[P^E<1]+2&UCF9R?)MJH
M9.(VJGW4S!_AC.?KWX=PJ =&7^-_)[#2\7O+^?[B*IT%6SF/RN%IMLXU,P]9
M8Y![=R:2C*8P%XZDUE6F)X_MM^T/))Q>?97CE<A;XEBRD"%)1*5SW<K]GM[(
M)-9/)(G)'+N0B'$=$;=2*1V4K@+MU+Y="XY%13=&LABN-PQH/*\K99(\$,Q4
MC8O;@IB-\M]1^[C?IWXDQFF-P#O[GX2/N?A(C9)G+L@VR>$=S'L772:H0F7X
M_D2_L?/6T:SB)F.G6:V>X@@JGGV'K*?"<^47PC>G][]R,*$=FV+R[S=A@JP>
M;9-U)S(-ZOV$?^P8?W/%/28%N#EVX,1&PV3.9M[MAA'I'+O[6&Z$.\E<;PG<
MJ%I$Y-N/BR45L_%.F4+GQ5L3S7:&*.5AN?ZO&"-BO,NV\G4</D]T<RB7D37^
MG-JO1NX1'..9IU[B6@P(KG)<[QS^W-U/1FWGHS_[O8*-,(SR>RO"8N,V^D9"
M7B!EO_M6Z2_D;)>#-\63RF&QU9ZIENZ^-.)>-Q/<^&>L,MW-AF<=M/CKF*BH
MC^XZUI2FUE*R&5!3%\;54Z3Q<$Q?&DSC=3%G,LSQ3=&'=L3[H9!#RFTT8:0D
M=PTW>-YLUW'P]RVSC(2YY+NFY6D#LI^VPZ;BX'./N1A0B)N+GFVY'HK:GT=[
M&V:S&/YMEN?0#&%Q?#WCK;O;3,XEK#9C)(Y]E):4+3>'TKB/I9MFLQC^;9;G
MT QA=I(9>.@?PQG/U[\.8IBM7]:4H6GQOY/8:7B]Y?S_ '64@]C5>NLCX'K]
M[(JI*JH*)YOD::;^3?RBL;/2L01V[</G$=D\W%IR&4SDFFT=N&+B2G967+2M
M2U;YKD3=.2FY27JBLJW5+G.2%(^D'LDM&Y3-Q2+Z9DI%W3-\DHDVRO(&E&F2
M33$[MVX?./=QOT[\24Q+'9ISNICD+ ILMOL.49O97&\'CW.Y6)-7\67#*9K[
M-UYKEN-M6R^WV0TK2M)W*8/&R3>>XS/XUMDY*RP3;G%(;(6:&VV%$-\)SY1?
M")K%H'(C_;+!Q&X+BL,]W%S:"DX##83D&.36.0V1)ID*D1/&81*9F("'GT6.
MV^(1[B6AHV=:,63:.:.\9A'\K[)3 ,3EUF.VN'L%5UV[%KN-DL=E-(B.2B(N
M3QF$F7@C<9A(A].8E 9%5OMYB#9IR")Y/%1,?",WC-I(-Z[787=9,6<:V;8S
M"-)>4BF$TRCX]G%,^F83G<O Q$\BVVRPULL0A$R#=2 /*P>*S2>1X_"8U"8[
M0*X?C:TN)/;_ !*55C-O<2BE@EB\$A,[A3I8+&=N\>-C^.>]*X'BLPJPVXP^
M/.VVUC8[(7C)I(-U=K,-44AL8@L?HJF19.%QN%QTJ^W.&.5OME@XAH**Q]M)
M1K*79141'PC/V3..0N0)LMM,/8KTI2E)C \7G'$)B\'CI1,0D7/M6C1NQ:S.
M.0N0)LMM,/8KTI2E/PQG/U[\-XKBM9"M*4+3X_\ )[#2\7O+^?V%C?IWXN]G
ME1_[#>K]CC>WF-(1.._VXYS;%6CB*R*%G#95(L<AW%W.D,;G8#;><YUC&,,$
M<ZSC<+"X53'L.9OI#:^"VB?.6TBRF=JIE!8CE#X+GRB^'W(_;[%(Q_\ %<MT
M7C>%P?&H!U_PZTI6D)C<7CWP9/&XJ8??CG.?KWX:Q7%:R%:4H6G_  /Y/8:7
MB]Y?S^PL;]._%WL\J/\ V&]7[%C^RQW^W'NV>*/WAH>"V\B-N\(C\E9?:K#1
M@3A7$\XPAVCB.;;BSS&,QG$Y.3AMLL&RY+*(K=:6;S+R.:Z&/^"Y\HOA^5>5
MM=;E5<4K2O2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'
M2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'
M2M0?&*DITM4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK
M4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK
M4=*U'2M03&*GITK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'2M1TK4=*U'
M2M0CAIUJQ^ -T7%*4+3_ (/\GL-+Q>\OY_86-^G?BY1AT9EI44RHI91B,;EB
M22=$4F6&QC'(ADF.-,H80T0T@HP36 P\Y,9-A,)E(8[18VUIC^.L<<C)/:+&
MWJ^-[?0.-+?"<^47P_*N5+Q9U5BE4:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:
M!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:!$:
M!$:!$:!$:!$.&*5LK!'NT"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T
M"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T"(T
M"(T"(;,4N#0(C0(C0(C0(C0(C0(C0(C0(C0(C0(C0(C0(C0(C0(C0(A-N1/_
M (G\GL-+Q>\OY_86-^G>QG/E%\/RKDO7G8;GRB^'L-KY?8?\GL-+Q>\OY_86
M-^G>QG/E%\/RKDO7G8;GRB^'L-KY?8?\GL-+Q>\OY_86-^G>QG/E%\/RKDO7
MG8;GRB^'L-KY?8?\GL-+Q>\OY_86-^G>QG/E%\/RKDO7G8;GRB^'L-KY?8?\
MGL-+Q>\IF;,JG6K(=:LAUJR'6K(=:LAUJR'6K(=:LAUJR'6K(=:LAUJR'6K(
M=:LAUJR'6K(=:LAUJR'6K(=:LAUJR'6K(=:LAUJR'6K(=:LAUJR'6K(=:LAU
MJR'6K(=:LAUJR'6K(1ZA9",T]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1
MIZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-
M/4:>HT]1IZA5*I"40KW:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1I
MZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/
M4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZ
MC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4
M:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC
M3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:
M>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3
MU&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>
MHT]1IZC3U&GJ-/4:>HT]1IZAW()I9+IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>
MHT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U
M&GJ-/4:>H52J0E$*]VGJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>H
MT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZA%*I
MRZ>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZ
MC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ+5;VGJ-/4:>HT]1IZC3U
M&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>HT]1IZC3U&GJ-/4:>H
MT]1IZC3U&GJ-/4:>HT]1IZALE4A_>7\_L+&_3O8SGRB^'Y5R7KSL-SY1?#V&
MU\OL/^3V&EXO>7\_L+&_3O8SGRB^'Y5R7KSL-SY1?#V&U\OL/^3V&EXO>7\_
ML+&_3O8SGRB^'Y5R7KSL-SY1?#V&U\OL/^3V&EXO>7\_L+&_3O8SGRB^'Y5R
M7KSL-SY1?#V&U\OL/^3V&EXO>7\_L+&_3OQ9]\M%PF![D+Y"_#?,I57<+V9)
MN,[;3%-QLH@7CF68-(M/<+-9T^%9_P!1N<QS%GB+,V<;CHM<4REEE<=\-SY1
M?#\J\A>)1^8_<&&'W!AA]P88?<&&'W!AA]P88?<&&'W!AA]P88?<&&'W!AA]
MP88?<&&'W!AA]P88?<&&'W!AA]P88?<&&'W!AA]P88?<&&'W!AA]P88?<&&'
MW!AA]P88?<&&'W!AA]P88?<&&'W!AA]P88?<&&'W!A@KGT.<E-P(;N^X,,/N
M###[@PP^X,,/N###[@PP^X,,/N###[@PP^X,,/N###[@PP^X,,/N###[@PP^
MX,,/N###[@PP^X,,/N###[@PP^X,,/N###[@PP^X,,/N###[@PP^X,,/N###
M[@PP^X,,/N###[@PP^X,,/N##!'/8=,I,_A3G(<BI.P?Y/8:7B]Y?S^PL;].
M_%S#TJS@7G3.&Y,CE,,R_NGV0KQ/"=P-R\IAIZ/SJCR'VZQ%@G&XSFU.2;D3
MN$Q>0RN09GCL&CLS&/&[7X;GRB^'Y5YS]>_!6+Y0>).0Y%2=@?R>PTO%[R_G
M]A8WZ=^+F'I7:))-?$:ZK:W,HQ9)QO'D^=Y%#3>,YW.2K[%XI?<N7S+;YA!Q
MN6S3G(\$@U"JPNY__?F1EDB&F-N,:FEMN9.4B<E^&Y\HOA^5><_7OP7B^4'B
M3D.14G_/_D]AI>+WE_/$/$NIIZUP_'(MN6!Q"4+E.,&@%H7&X1SCN&,HEZ[R
MYK',Y;V,$R*OLQQ^'C88-BE.YR['8:.A/=@(-:?>Y7#MH-_\3&_3OQ<P]*[.
M>ELPQE'*(;;=!=KGH43*JG'.I;:F:R7<%7+VBF JUV^QS<@V+L,7:2F;YAN7
MC\JG)UWHCM#MMCDM63^&Y\HOA&X.39/'93H=Y@^RK<S$58>4;3<9_P #<',G
M.)-?9G.X">,&1:;P3)*Y;G^%NDI!!]$P.0;H9*'+O>.'2P7,2Y;'YGG65163
MP<F29A\AE2PD)MYF>2S>2>_N!DV41V4Z;>H)9YF>+222J:Z7Q\C-*%A,.//G
MA/>G)IEC\:CD^X^9JN4-W8%/!LU2RUI.9+G"V;&2WK3IA&?R$I*;HY/.X\XV
MVR5UD<('NY&1N,E][+=QWB$D6'WA5+ [C2\;*9Y)O8?%L!E'TSBXP;)YV7RZ
M=R>=:;B[GSTM 14"X6>08?-]X*O5<CW.1G"-]Z.,9'.ML;B&$CNKE*&%YQ)O
MI;/<W7QVKU[NY!M<:R,N40&JWI$QE6Z, E"91)-<(CI?='+28=G$NO-=MYS]
M>_!F+Y0>).0Y%2?\[^3V&EXO>7\\;<-"$C<VE%WLU$H3\>ZR"8R:29X]Z4P:
M+82CW+XQNSG(S#(:+9EA,/G4G<*M!9#,,&,@S9QN%3*4Q!F@9S//3F.XG$H1
M;-GA4T);&M+DBT/A^-MEL>Q6<CL$0C$&^9$@--B.))RY#,<)(OEN')1J.*8[
M#2$"RBL,:.'.&XVT<%@<4G&..XH5_+K(X,P<9GBL<R8>S&_3O_#,4IJ)(HH4
M"J""X_3V:9O17XCGRB^$;C+)-]Q.NL0&Y.<PDK$X2S/C^&I9'G&>2"\]G>!/
M,QS9OCT&RC-UYEI@&9R4L[VWR.:FY3<*5?PV,RV2SC?;5I([I90URC,<M@<D
MQ%EN0C-O\ORG+)V0=[D8,,NRQ?HB,=;EYJSQ?+<GC,IW9;3J,EBK+*&2 P!
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M&X'&X'&X'&X'&X'&X'&X'&X'&X'&X'&X'$K>XW XW XW XW XW XW XW XW
MXW XW XW XW XW XW XW XW XW XW XW XW XW XW XW XW XW XW XW XW
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M<O'8:1^[V)C',WALH<9'F4'B]([=K%WSBE:5IV1G/J#M6%FG4(ZCI%K*M?\
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MH.&@X:#AH.&@<EI:*6G#PT'#0<-!PT'#0<-!PT'#0<-!PT'#0<-!PT'=W?\
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M%@6!8%@6!8%@6!8%@6!8"R7 2B'^+ L"P+ L"P+ L"P+ L"P+ L"P+ L"P+
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MX7.L*1+Z5;RN;/$&$9F,OT9&LGE2'P3$O3HSJ/<%-&9;"R#?*<FH_&9FD&$
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M,!S <P',!S <P',!S <P',!S <P',!S <P',!S <P',!S <P',!S <P',!S
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MM1Z4H(]+4'/PEUQ0DYH>E7Y0DX*H#J4)37T%'1:EX_\ =-:ARF?E";PIJO\
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M,!S <P',!S <P',!S <P',!S <P',!S <P',!S <P',!S <P',!S <P',!S
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MI#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I#5I!8U#'_\
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M?A(Q*&%B@*E2GN*DXZ)DX:*H\=0J3CHF7AH:G?1)+@"J7&*!4G%1(G!0))<
M.3BIIS4!$.X))< 52XP6G=2H22X JEQ@M.ZBJ'%5%.I/8D7O.*CA'".'V5I[
M*T'<*4[8,2AA5N-/44;BE.[VF;T&GJ"MZ>PY>*B:7#4&)0PJW&GJ")4+[3-Z
M#3U!$:4]AB\0TX3)PT"B?&$TN'W#4[Z:?V'2H8:>HHW%*=WLJW":7#4Z'%4M
M.Z@,7BH5#NK[3-Z#3U!6]/>,A2HT]05"E!W#3_Y]IJ=]"H=U?=41XJD+PT,2
MAA5N*-Q1.E*%0[JBC?N]IT.*I:=U%$N*I"\- H3BHFGP>PZ=#"K<:<$3H7VF
M;C3U%BG<FGP>[6G>*MQIZBC<%+0OL43XPF3AH<O%1-'AJ*-^[VG0XJEIW442
MXJD+PT!T:&&GJ"M_88E#"K<4;BB=*4*AW5%&_=7W5$^,)I\'M.AQ5+3NH%$^
M,)DX!6G>*MQIZ@B5"@S?OK0&0XJEIW4,6AA5N-/4$2H7W:-_8=#BJ6G=0*)\
M83)P>[6G>*MQIZBC<%+0OL-3OH5#AK[*M^^OL,WH-/4$1I3V5IWBK<:>H(C0
MOL.7BHFEPU!TZ&&G%&X*2A?9WT%4*5&G"Q:%*V]M?U+3NI^,C.*UH@3AI^1)
M<O<9-:G=>*%#\=4B<-#GX0=?OH@7OK^,^&GY%*T[Q5N-,"I4+[#DXJ:<4IW?
M_E'7RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47R
MB^47RB^47RB^47RB^47RB^47RB^47RBJE*4OE%\HOE%\HOE%\HOE%\HOE%\H
MOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\H
MOE%\HOE%\H*K0POE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HO
ME%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HO
ME%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HO
ME%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HO
ME%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HO
ME%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HO
ME%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HOE%\HO
ME%\HOE%\HOE%\HOE%\HOE%\HN4[KY1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1
M?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y056AA?
M*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?
M*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y092A1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*
M+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*+Y1?*
M+E.Z^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^47RB^
M47RB^47RB^47RB^47RB^47RB^47RB^4%4H;LH_@[&0\5?U^59?+[#0\5?U[#
M<>+L/_Q]AM_%V2?P=C(>*OZ_*LOE]AH>*OZ]AN/%V'_X^PV_B[)/X.QD/%7]
M?E67R^PT/%7]>PW'B[#_ /'V&W\79)_!V,AXJ_K\JR^7V&AXJ_KV&X\78?\
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M7]?@)^)?]$>+O<?IW=Y:(D"A.&I4*=UDM11+O-:)0*(]U$T^(62!1/A]C?\
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MK>H63H#>!%3N!D:&"AZ%HW_17Q?_ *>\?P?#I3O!J\!;I@@?O!O]#F*4X)W
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M_:O_ &*+IVZJ\2A"-J<+2O\ LY5X:(>/W'/R/22XNS$O#\LW9^^M5"6VA_\
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M>'YIN?P:DKP_@UO3_"QN^I:&H#F-6B?@1+2M52]QBHTH. AA4G"8]*5I0I#
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M&2\/S36\7X,25X?PNB7O,<O$"$X0N7NJ?P4_V*I7_+C]$O#\9+P_--;Q?@U
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M)0A;3YJ=7#W;P#6'<0\$09D(8R?P?)$+I1W$.S]$_LE'S)$+:?-3JX=[>F^
M<\,L*,C,A&:,D0S+"C+"C(ED(HHS(6T^:G5PYV]-\/OFIU<-]O3?$#YJ/(HH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHR7$+]1[]1[]1[]1[]-GDSS9YL\V>;/-GF
MSS9YL\V>;/-GFSS9YL\V>;/-GFSS9YL\V>;/-GFSS9YL\V>;/-GFSS9YL\V>
M;&O4>_4>_4>_4>_4>^:F1H:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&
MAH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AIQD
M^:G5P7*OC!\U.K@R5?!TLR,S]D2?$^6+(;QAO:DE[U\U.K@V5?!J1)VMGQ>8
MQ02R.DS&SXF9.';TF9W,R(9^C*B%9W9G;U$)G=H=JLS$UJ3F=KQ?-3JX.[E?
M!DX-R(8AX]6/5A'03UC1D9B9[CPR_(Q_S!'294+%\U.K@Z%7!D&1J=S*%!#)
M1F-&2(9^S-$HEH?2\BBA):$:'=TG;F=W49(9FC)'2_T=B0LL7S4ZN#85<7/F
MIU<&0JXO?-3JX+A5Q@_4>_4>_4>_4>_39999999999999999999999999999
M99999998VO392*12*12*12*12*12*12*12*12*12*12*12*12*12*12*12*1
M2*12'ZCWZCWZCWZCWZCWS4<E(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%
M(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%(I%
M(I%(I%(I%(I%(KC%\U.K@N'PO?U+YJ=7!D/A2<8=;-XY$O"]Z^:G5P;#X4;Q
MZ>HG\8943)U(A#;P_19F0L,]R^:G5P=#X29F3.':-?D[CM1+9U[$%YCP]SWW
M+YJ=7!TOA.>G"7A*()Z3Y,?[)>$LGI,WF-,ED(A[E\U.K@V7Q<^:G5P9+XO?
M-1R:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:
MFIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:FIJ:F1+XP?J/?J/?J/?J/?IL
M\3Q/$\3Q/$\3Q/$\3Q/$\3Q/$\3Q/$\3Q/$\3Q/$\3Q/$\3Q/$\3Q/$\3Q'/
MJ/?J/?J/?J/?J/?-2$444444444444444444444444444444444444444444
M4444444440^0[YJ>WW6'R&?-3V^[0^)99DC\;$F1VXQA)11"^@?-3V^[P^)$
M?*SX"3,LS/(8S-9DLHE80QM#DE$$G=A1EGAF42B"(V'S4]OO$/B.&99GX))9
M*&,8D2QK%C'@CJ]S,4$O46$(@9.P^:GM]W_9+XC[B'A'N9D(8QB9#)Q8\)9"
M.KWP0A896=Q[[+YJ>WW;]DOB6BL,T9(AF1,845C#,L)(@A$HS(1*1F5A,;+Y
MJ>WW7]DOD*^:GM]T_9+Y#/FID6RV6RV6RV6RV6RV6RV6RV6RV6RV6RV6RV6R
MV6RV6RV6RV6RV6RV6RV6RV6RV6RV6RV6RV6RV6RV6S/D._4>_4>_4>_4>_39
MY,\F>3/)GDSR9Y,\F>3/)GDSR9Y,\F>3/)GDSR9Y,\F>3/)GDSR9Y,\F>3/)
MGDSR9Y,\F>3/)GDQKU'OU'OU'OU'OU'OU'OFHI12*12*12*12*12*12*12*1
M2*12*12*12*12*12*12*12*12*12*12*12*12*12*12*12*12*12*12*12*1
M2*12*12*12*12*12*12*12*12*12/C?&+YJ+@N5?#4=)'5A9F0C,:3W[YJ+@
MR5?#/]/YBT-C'OWS47!LJ^%_Z2B61^#W&=3_ $,>_?-1<'9<+9(4C13*U)2'
M^3-#R-13.]?-1<&]O3Q<^:BX,[>GB]\U%P7V]/&#YJ0S4U-34U-34U-34U-3
M4U-34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-3
M4U-34U-34U-34U-34U-34CIXQ?J/?J/?J/?ILLLLLLLLLLLLLLLLLLLLLLLL
MLLLLLLLLLLLL;7_HJ#__V@ ( 0,"!C\"_P G+GN)^NC"/HL]]/V'+#/9G<S]
M!&S&\CZ7,RPS^CGF1GA*(^D6XC=S]%*VGL9?7O:SPRPD6$;F-XOIEN;WF>&7
M&V6UD9_2Y8=O!5XY89[O+#/Z)K&-QEAGMP]MBW.6UEAGLY[G+%[$;:PG8RPS
MQG#+#/'+96TAXP9;.6TMW&.>S!.Q..9ELY89XY89[O+AF#/'/9C'/'/'/'/'
M(SV,R2<,L,^ LL<\8)>$HC<P2]Y)&S.TB=F"7A*(V8W#V,MJ7A*V,]S.U!+Q
M>[6UGN96,O"5BMI#V)>"W*WDO>/![4$O9SQC<P2]N">&Y9*)>#PEDHEX0(6#
M$2\($(@@C@V-F=E[*V8)V5N5N8V8PRPRV7]&ME[,[3W:W*WRVD/86"W*)PSW
M*P6\>T^.6/;0L&(6*%C))/ 6>XK#+8S**PR'LK=K<K8G8K#+;G:8MQ!+W*V7
MAF45AELO8G;6Y6X@E[*VD/86"W*QRW*P6S)&Q&#V'@_J)X5AX9$O<L>VL6(6
M*%L01P#&&>&6,[$[.>Q)#WL[,+:6$[$[$[$XY$[+%N8>Y6RR-J2'B]K/#+%;
ME;4(G"'LK:0]A8+8LA;"PSW2P6WGAEB]AX20]F'M1CEC.XGAJ-B-F",8,B7M
MP3P3GL989X1N<M]>QGCEA.,;.6&>UEAGA^MY&S,X7C.,;O+"-O+#/9C&\9QC
M8SVIG"]U.UELSNKPG=989F6,XWCELY;$;QXY>HF'LY$^HJ_^:VGFI/%L\'+F
MH^7:YJ/EVN:CY=KFH^7:YJ/E+&X@G>KZJ/KI>YG<3R+?T4;,_5S]BR(>]GZ:
M=_/U61!GL9X1A*PG8E89DK;6^@D@SPA&9*PS)6$F9EOWL2L?ULP]K,E;,&9D
M2\(((PSY$/:6UF9$&9EN\S(CZ%;>9D1A*^KSPS,B,)1+QS,OI_8RQS)1+P@S
M,B#,E8KZQ["PRP^3P>X]MM;V29(V&9LB<?8>.6_>&1\GN)G>O&\$>V"VER#>
MTMK,L>X6S\F9?1+:1\F9#PO"9^H@RV'!\GA#,A87];>"PR&9LB<5]="VI,L)
MPADD+'VVUO\ ,G#(9.Q[8=QE] \9,L&03A&&6$;4$[V=A<@WM+;SW*P@G&/H
MEM+"#,G""3+ZQDF6.6&9E]-[;A,RQG87W5?09_8HPCE ^7:YJ/EVN:CY=KFH
M^7:YJ/EVN:C7!.7V2/LF>W9999999999999999999999999999999999?^"#
MHSPHS))PDHHD@G&BB5CF3Z>$9GQ%A*V<]B-F".DS/T1H1TD=6RO3BB9)8A"6
M*PA[$D[/Q1\CIP^)FME>G'(AX98?(@R,R$9XP9$/#(SPGI)8EJ9T3TD]6RO4
M>O3M+),L,]C+9R,S+'+"-E>G"22,)6&8XQR)&D?+8A'RO'(4'RO"!;*]-\':
M1B\,AXRR$1AV[';TF=X(1V])W,[NHG97IOSV.TEXO&#(9!W,C""2&=V':B3M
M>':1L+T_YU_T)JBRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
MRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR_10
MN4>>W.,\XER@1E]#/-U<H$9X3AD?C<Y\X%Q9/W1;+,MS9?-]<5R_O\8P9<X5
MQ5+]$JXIE^B>RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
MRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR_^B35P
MY#]&:X=A^C)</0_1BN'X?HP7J/7J/7J/7J/S_P #'9999999999999999999
M999999999999999?^$)S]$RXJA^B5<5P_O"YV+BR']W6R\)PC"><*XMC[LL5
MLOG(N4TK&<<C-<XERMS,N<*]1Z**********************************
M************************************************************
M**********_Y_NRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR_P#$7KU'KE+'
MT$<VERHC;@@CF\N3JW.1#QEF1GLR?CFZN'IX#@RW.19&QF98/FVN'9? V9EL
MYXY\XUPY+]&:X;E^C6RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR
MRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR_\ 51111111111
M1111111111111111111111117^(O7J/7)_,RYWKDY)FL,S(SQS,L9>$&9D?L
M_9+()6$$XP2N:ZX.C@Z-M8K#,RV'N7S97)V%CD9[E/&620R2%LLGFPO4>O4>
MO\/E9999999999999999999999999999999999?^"@199999999999999999
M9999999999999999999999999999999999999999999999999999999?I&7J
M/7J/7*1K91.UGS?7!V7"TDD$D"YS+E#GL9X0S+9SYQ+U'K_#Y66666666666
M666666666666666666666667_@H,_P#C@SC/J%R/D9;S+8C<3Z=<\(,B'OEZ
M?()6X@E$;A;<>GS/<9XR29F6U'_'XHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHK_ 844444444444444444444444444444444445_B
M,+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
M++++++++++++++,_75F2MC,R_P"(ZO4GEZ+I?J.E^HZ7Z1)X*S_]+[O_V@ (
M 0$!!C\"_P#Y+J^^\AE'QEJ"1V8E]Y4WI$]V I"@I)R*%H__ !%K==4$-MB\
MM9V (4UAOD&19S@CEJWMKMP7'7%.K5G+69GC,)=NBFIU9'7=D;B<L)=36U"G
M/AA)N-JWTV]O_P#$6:*F7^YLGEJ']8H?B&QU$8C7HO)5;2TZLA_*5^+_ /$8
M*1E4JFK!F1E2WLGAZ@4ZG]SI^4^?C'81_P#B,<?=5=;:25+.X(=?2TM]QT\E
MI";Q"1D%FT(E6X)5!*OZU=0@R^2-&>W"6*9I++2,B$__ (C&<(IIK<=(6^A%
MI/Q42[/% 575)ID*M53-6JX3D'9C1-+=6G;=<4OMV#@_F^#5N%3RQ-JE1:M7
M<X8_<J!AE'_K%3A[%R)END7N%M7XEPEO$Z+0 YU0R;P\ V]F$5-*\E]ARU#B
M+1[MVO;:#ZFU(&C49#E&4.43E$BG"65.A:5$Y"D2R;OOBWGW$LM-B:W%F0 W
MXJC0J4XW2K#:G2)!1(GR?<E2C)*1-1AP-8:VIH*.B4I9F4[$[(367 TZ%J;?
M9!G=4/\ E[R,)IGN<5-U2G%-VH3=V"K;WNI58>B@;>33W9.%9!-Y 5^.*.M*
M-&:II+A;%LI^_P"GJU36NQBG3GK,'FU-3T[?P0H*6KCF.U"4XE1MNLG.<8FE
M8X"2#V(:JZ5P/,/":%CW-96I0'%4K2G @[-T1[+:](>Y'LMKTA[D>RVO2'N0
M!5844IV5M.S/$4CMP54+TUH$W:=?)<3OCN=043=$A].B2Y?4HC.GW(I\06T&
M%/7P6P9CDJ*?Q?RJGJ&Z=-07W=&4J,I63BNTM*FFYIHY753G?O>+[E=56/)8
M81E6KM#;@HPR@T@&1]\R_,3W8G<I4_DAM7C0!7T#3J-E3)*#Q*O1I:%Z:DZU
MA5BT;XZE&AJE14\Y2LDJ41*[+NP]5.4Z:=33Q:NI,Y\D&?9BHQ!#0>4Q<DVH
MR!O+"?QP:)RB0P-$IS2)43FRW-WW;=&W1HJ$K82[?4HC*5"78AFO6R&%.*6D
MM@S'),O>W%Y;B29;T4=*K#6TIJ7D-%06;+ZI3R>XK*!.'MNIIEW0X5D3[$>R
MVO2'N1[+:](>Y'LMKTA[D>RVO2'N124"\/;:34JNEP+,Q83M>XH@U2HJ>=Z2
M=Y1$KEWNQ45#E.FG4R[H[J3.=@/NZN@10-NIIE !PK()F ?QQ15I1HS5,H=*
M,LKPG+W@G:BFIU8:TE+[J&RH+-EXRVO>]/7U"6$? 'PE':2,I@IPW#T@?!=J
M#.?R$R[<3NTH_)T9\: ,0P]MQ&RM@E!XE7H+M"]>*-:RJQ:-\?R)VO;:#ZFU
M(&C49#E&4.43E$BG"65.A:5$Y"D2R;O\Y'JEXR;93>5W.&',8K$SKL0-](/]
M6@Y .#K6L,NI<+>>$G)_Q+KK4UCEJ*5I3BAMW1."M4WZRN=DE.ZK(!N"$'$;
M]=4$>4%XH;!W+LCV8E]W7-U+C@_I0JOH'%U%&D^6:5GM@[,QE$-X>XL\SQ W
M+FPETYI&_D]W5><:^>(>^QK^>CWS"$!1N*4\5)V#*Y*,2\^GYON7T(5)ZO\
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MZM%]M3]&N*;SSWSX9H:UU:*A]*5MA*"H24HI%HW1&@J'5/U0SJ5@7E)G\:9
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MR/C.*$YG>G*$U]>\JGI'-0VW*^N1E.W(($Z,U"A\)UQ1[ ($+:I:5FET[[:
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MN@ N-\.R8-(IE!IBC1EB7)N[4H;<14?]IG?=8.L'Y .T=N$--)#;;8"4(38
M!L=6KHM)HN=-*;TDKTKVS*R*2N^]M-S5P.:+079RW=(?="N^\>:^22WHM#?S
M9VSOIVX8P[3\YT)7Y:[<G>459)G;C05B#-%K+Z;%H.Y!YKB++B-C2I4@]B]
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ME-,ARHK?WWGG/-'_ %>CNW+WY2OC>Y535K":AE7P5=L'8@JP_$%,C^Q>3?\
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MB,:Q_P!$8UC_ *(QK'_1&-8_Z(QK'_1&-8_Z(QK'_1&-8_Z(QK'_ $1C6/\
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M_1&-8_Z(QK'_ $1C6/\ HC&L?]$8UC_HC&L?]$8UC_HC&L?]$8UC_HC&L?\
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M5.AEQ5@O(=5R9[LX3B517+IT)0$U#=DKJ=I1S8J:?#%H<IWJ1VFI"@\FQ);
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M\*64'?ZE1B;B=([JJ-CX[RLT;UDS!QSI#BSE/A[BSS1L"=Z5AT2)W4)&W_\
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M#%D4G/E4KJI4H5<O7Z:YEDK)>GDA5WHOHCL+74*(^B3%1T@QG$6AB_*728<
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MI#88NV71.V\1',J>@JJUC2:+GC5WE&<IH03:.*$)KW%O5CHO-T#$E.W?C&9
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MO3,5+#:6C,'-5=E.>2V*A5:[=IL-JW4MO.&Q#00APVG8!48<8P^AJ\4*/ZU
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MNW[QA/VE$(J:^>A6X&TW4WN403^*$MBI+!69!3C92GA.Q'W@S4K(PY!6JC^
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M,4%/4M)?8>2TEUE8O)4"R;"#'./NLV&>@+SI;GO7H;88:2RRTD)::0+J4@9
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M #U^-'J?YZ_&CU/\]?C1ZG^>OQH]3_/7XT>I_GK\:/4_SU^-'J?YZ_&CU/\
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M0E4[/=N@8Q6@!9D.<.;??1[8KO\ ,.>-'MBN_P PYXT>V*[_ ##GC1[8KO\
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M?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1>
MY]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X
M#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47
M@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1
M> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD7334?@.?61ZM1> Y]9'J
MU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>
MK47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61
MZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9
M'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GU
MD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?
M61(4U'X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#
MGUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@
M.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1>
M Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?61ZM1> Y]9'JU%
MX#GUD>K47@.?61ZM1> Y]9'JU%X#GUD>K47@.?60EK%FF6:=RP/LA0N'\J:E
M60%),TFT$=7Y/63@]V]WZNWUCPCS/6?A@;WX+%^9;_G4C#L17.A-C+Q_JOT>
MU 4DS2;01U/D]9.#W;W?J[?6/"/,^_V&?4E,3VO<320H;8ZG*4$SR3ZMV\+W
MQ=GWWA@;W4D2)[74M,HLM]X*UJ"$)SE*,@(N,5C+Z_BMN)4>P?>;#.+#/JE;
MBPVD95*,A!YO4M/RRZ-85VO<6F43G9MQ,6]24Q/:]]OO.H91\99"1V8O4[[;
MZ?C-J"AV/Y)?=6EM RJ49"/W>J9J)9=&M*NUU)$@':ZEIE$YV;<6$&)3$]KJ
M6F49Z>.,]/'%B@>J0% E.<.I,F0&4Q,&8.0_S37YEO\ G6C#L17.A-C+Q_JO
MT>U 4DS2;01'R>LG![M[OU=OWO"/M37SH9^V(^8OJ  3)R 1Y1M2)Y+PE!T;
M:ERRW1.+A00OXDK8%]I:;V;,$3C2/4CS*#D6M"DCC(ZAYO3.ORRZ-!5VH4WH
M5WT9Z+IF-\1=6DI5M&SWS"/,^_=(O]OJ/F&$HJE$81B1#=9/(A7P71WNSN0"
M#,&T$14=\Y_H^KB&#_>"Z'!,,4YY).31M*T=Z[9-2SMY(I,>Z/8P^6=*&GVU
MR!F;1> Y*DF6U#/29IM(JJYAOFK!M2'W1DW0FWB@=(.D6,U ?Q":J49ZKFPI
M5[8.P!L1_P"&XQ6&IP^KY- XHDI"E";2D3R!6:1MQAG1C!'%L5>*W=*^V;JS
MI%:-#:5;$SE@OTV./''&TWTKE)HN;0.<-^?!%;08FZ:BJPHMZ.J7G+;<G(*.
MR4E.7WSA@;W4IBV2'!0,E!3EGI',D)TZQ]ZT$FZ]/QOBN_*[<8AYVG^E3&!]
MX[],Y%^H>0PCX[B@D=F-)3O(?;^.VH*'&(FM80-LF4)%55LTQ7F!U:43WIP%
M)4%).10R=12U9J!,\$8@_5XBJBPFA((8S@VE9-Q"$3 G)-JH4[A&,/<^:%YE
M#X%U2AL7DRNQ7X#B[BWZO#$WV'W+7+@5<6E9V;IE!0%@K&5,[8+#-:PZ^,K*
M'$E7$#%^JJ&Z9!LONJ"!V8#C+B76SD6@WAQCJ: 8A3%[^QTJ+W%.,8^Q5'T:
MHQ;[=_=ICI5\CZ1SJ5&)N)TCNJHV/CO*S1O63,''.D.+.4^'N+/-&P)WI6'1
M(G=0D;?_ .6#7]&\5J%8A2#2-,N22M1'Q'$79':BHPO%%W\3PU(4E\YSS62:
MMU)L/!!6XL-H&52C(054M2U4I&4M+"^U ^VL]I<(_P!KI_G(BA\\_P#2'J=&
MO.X=]/U9H6%C<,XFM00-LF47E* 3\8FR$N5-2U3MJS7'%A(/"8#C3B74'(M!
MF.,05*-U(M),*%-5LU!1GAM:52WY0;BTKEED9]1+C 2O$ZXEN@0JU(EG+/>S
MXX;QWI5C%0CG@TE,SGNW%6@V\E .P .*%X]T9Q:I4N@27'F\QX-BU2DK1*<M
MD2A2ZJZ,2H%!JMN_"F.2Y+8O=L&+[[R&4?'6H)'9@FEJF:D#*6EI7VHFI02-
MLPERIJ6J=M6:XXL)!X3 <:<2Z@Y%H,QQCJ:%FNIW7?[)#B2KB!ZE^IJ&Z=/Q
MG5! [,!;2TN(.1:3,0 I8259H)RP:9-2TJI3G4X6+X^3E]T_B2TAQ\G14+!^
M&ZK)/<$IF#CF/XLY3X>ZI7-1G3D9'1-S"4)W8YST?QEY->QRFD/23>4/BN(E
M=AWHMTB*CB=->32ON:Q1:SVW-M0EECHOO4'^J7U*SS['SQ%+]CK?I'8Z0>=I
M^TN'/.O?Z)74?PE=2:1+RD*TP3?E<5>R3$8A7C'7'#14SKX;T %[1H*I3O[D
M5M4YB:J'FKP:"$M7Y\F<YWA%17-XHNM-13E@M*:")34E4\X_%ZE)T'P:H51M
MN716.))3?*TWU7B/@H1L0_C.#8W4_>.&-*J'2?)WDH%Y=PHM39;LP[B.*+\O
MA*G&ZZHEGI;0%Z20_),5]=B->Y18)1KNLTR+0F>:A"<DY9RO^!05]!7N5N!U
MCEU]A5EZ6<A:<DY9JHQ/%F'+R.8./4KHV;S?D^.8@XI]_N8>G3K:;:*%.7@@
M#E3TB=DRB@Q-?29=4BC<TBJ?1*3?W)Z4QT>PFD<4EVI<<<*4F5O)0C)OF/XN
M7Z!7UT5E._BAQ3G3B7$K*"B[(2E:M7\S5^9;_G8C#L17.A-C+Q_JOT>U 4DS
M243!'63@]V]WZNW[WA'VIKYT,_;$?,7U,*\]^(QAOGU?-C&.^8_IPG[0S]"F
M&\4K6=,Y3FY1B7*ON9;L\E@BH4*?1%HW*BF7RQ)0LWYPY@S?DZ32Z10&PV4!
MTI':$4Z$4T[_ "*2C:DD23E,X<Q"GI]!5M^1J4F5X#*+1E&U%=WK7T:??,(\
MS[]TB_V^H^88K= D?>M!B3[N'K^-Y)F\U\KMRA71K$E$8AAJ?W,KL4ME-ERW
M9;[6]%1WSG^CZM55]%*M.)O5:W!68:$*6$J<5>6S9G6VB[DR1A^%=(&/_%\-
MT@<<OLNSGDTB@>4J4[ (Z+8?A[NFH&W$\W=!F%A#4@N8V[T8.RBQ+5%3I3P-
MB.BE6BQT!FWS=1,=N!> ,C,3VXQ7#L-P-VFIF"6?OU2'%"1%JD\D)&7;,5KU
M+7)JL3J5(^\6)%)9"9W$R.7*;<G%[YPP-[J=%P1,$T$Q_B%0QC&'()P6O)DP
M,EPZU@[V5/!M&'ZZC<#U-5&F<9<&R"XF*/%'!>314M0X$?&4'G+J>$Q58_TE
MQ*HYHEPM,-MV$G*0W>F$(3/:BEZ0]&L1?YKI U4-NR)!-H"[L@I"I;4=$\4:
M3HT5Q6YH_BFX)C@,-XSTCQ>L<Q7%$"H\F4R0%B:0J\%3LVI2R1B'1!^I-12>
M5 1\"^@7TN)&Q-.7_EU"E0F%6$155O1QI=?A;_\ 9HTP+8,PEYL<J:=L<<:+
M&L#*%)L=<IER(_5.>-#F(8$&;Y/[V$MAMY*E6R<&6WLQCV$8;5&C.*/NL5SX
M_P#;@AQSYG#DAK&L*Q"J6]2O(34:4I^%D6@H"2F1A/2/I3C%6XJHFW0-M%(D
MAHW)F\E0$U V ;NS%7T4%6I^C?"TE)R*DSIVURV%7;(IL'0A^BZ+BZ'*M.K5
MR;ZUJ -I^"F<5511XC5,55,TI:'*A;9;44B<E<E,I[\=):.J=4^,-9>33K69
MD-N,J-W>!$8M]N_NTQTJ^1](OJ='J8$Z-1J75C8)&C XIF,.HV1)NFIFFT;R
M4@=1]ZFHJ>CO7EU#C3:4$[))NBV*]^MK7:3 ,-5-JG1*:0N80E(R7B!,JM[4
M?^2=%\3JF7<.(4^AQ0*KI(3-*DA/"#&'XHM-Q]RK:15)V-*W?2J6_EA'^UL?
M.1%#YY_Z0]3HUYW#OI^IC'V*H^C,8M]N_NTQA'VP_1F,,_P/T<4N,=(<4JKB
MV@QAE,R4\AAGR:;5!6UD W=F*; FJQ51AV(K0DH-@6AX$(*DY+R5?\6PGH;0
M5)IL-I%7:HC-*DIO.+6+)W<T#;WX.*=&L3K48QAJ2^W?4GREP3(3=2F1_P#R
M1TB.VY3=ISJ='\,=)YNIJF;*?//J"CQ2@ "0%@ A2%@*2H24DY"#%7]S88RA
MUME:J>B80EH.+2DW4V2%IBMQ7IQ45K+^DN,T\P%JV9S(4 BV0 C#,4P#%'DK
M6X9-N*&E0I-H,TW9I.]%+5D735.TKI2-B^DJBEQCI#BE5<6T&,,IF2GD,,^3
M3:H*VL@&[LQ38$U6*J,.Q%:$E!L"T/ A!4G)>2K_ (MAGH1AE2:>C04IJRG(
MI5W2.*7*4PA.QMPZ]@]=5KQ>E1I6M(4E+JDVW0$I!!.Q;%;7](J-]&)8<=!0
MFI$E/7Y!HKG;83;N"%=)NE&)U3IKE*YLAL@+4E!NWB2#(3G)($8?7896O5>!
MX@N512KE-01*\A<I)G(\E4HZ.5=$X4O"E2]2.IRA6EO((C",7K,7+]32."HJ
MZ4-V%P6@!=[85N6^ZP&CF=&$/.D;!)*4CBE%)1LI"6J5E#2 G))(EU,%K*?D
M*JW*)YZ[LS<T*N-*8Z+[U!_JE]2L\^Q\\12_8ZWZ1V.D'G:?M+ASSKW^B5U<
M>_VZJ^B5&,?;$_1CJ@D E.:=J*[#4X&[A&&O+73N5[B'"76YRD%*2E(O1C?W
M37BN4\PZ<0>2"DAYP!"D73:))X\NS"EC*]6O*5Q(3^* HY6:UE2>):?QQA:&
MTK<75LTU-R020E"I[&XW**-K!76\)PID+-+?N(4[>45%7*2I5L]P0GHSTT;
M>><#3584I0I"U9D[G)4E6W&'##J-=54X>BF30M7"4+="M-_2MA>+.UZ7T- K
MJ*5H,+*4C+R+DO!ATO-II\2HB$UC",TA6:M,]@_S-7YEO^=JJ-:"]0LIY+Y_
MJS\7=ZR<'NWN_5V_>\(^U-?.AI+:%.*YV@R2)_!7'JKW@*C"=*VIJ;UEX2V(
MHG0DE#51RSM7DF48A4K04M5#B TH_"N3G+CA/VAGZ%,8>/\ \Y/S#&-?X?\
MO(J@N7EF@A$]OFZ#^*,/K66U.,T]]#]T3NWI2/8BOJWVU-(K%-AA*K"0W>FK
M\Z*[O6OHT^^81YGW[I%_M]1\PQ5_[D[]$U%-TUP/R/EDJK;OP']A<MIS(=W?
MAC%D-ED5J'%*:/P5"D(4.,168I2](.9,5&CT=+Y3DW&TH.14K2)Q68DYCGWB
M11/-L4_+UA$TGE$[48Y5.R<Q-L-!M:K5!M=Z\1OD6QB;E8$WZ8)<HG#E2[>
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M-=?N<X<" T57-(F7*GRADLA;CJ@AIM)4XM60)&4F.D=33"[0:*24['+=FWV
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M*:YLI:I7 J<[Z$;<5_2#!\4I* OKO4SFF>;>3Y,(.8T>W'\8H_SM5]5&(_\
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M2?\ 1J[D>I/^C5W(]2?]&KN1ZD_Z-7<CU)_T:NY'J3_HU=R/4G_1J[D>I/\
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M%0[3/LLBG4$J#E[9W@8J*!U:5N4RKJEHR&R>S[W4UC%.>:4C:W'JA5B9($R
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MRJ;JIIRV6PY13J,1?9-U[FJ4E"5#*+RE)[$X6S0.N,U:!>515"0AR[MB1(/
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MNW[G"+V3G3?'.R#=R)J&RO>M_'U&ZA=.XAAW5/%)"5;QR0[62\M5O$%?Y*+
M..<5(HZI5+3TCJFV64@2-PRFJ>6<-+JFQ+$&2EY.Q?22DD?*$Q&*I.5+Z >(
MQ5)>%Y%.LOW3LE"!=[,4E-0+T+U7>4NHV0E,K!OSBJP^O=YPMIO3,/G.E, @
M[>41A;C2+B:T:9<OCR6%=J&ET2@W4U+NC2X0#=$B20#%1B6)*#[V&TR&&%R
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M_K(]6K? ;^LCU:M\!OZR/5JWP&_K(]6K? ;^LCU:M\!OZR/5JWP&_K(]6K?
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M-I7^;53Z4FF>F1);:@L6C;E*!A&+=%:O%#3$ABJ.DG:9RT@0ZE>Y**+'^D%
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MLIF7?<4.4V)N*=KZ9%0U4.K-XJ*$709G+8/=8;_N*?HG(P>@J7:@5%'1LLO
M,DB\A !MBJPC!:=];E>G1.U+R0A*4'+=$R23DC&45C>BJJ_][<9-BD!:FTI2
MK=DF$/4K'.:IKG:J:FR7UA2KJ>$Q6XKTXJ*UE_27&:>8"U;,YD* 1;( 1AF*
M8!BCR5K<,FW%#2H4FT&:;LTG>AKI4\MYNMHZ2G+#""G1?O#C<[P*2?A;<?\
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MWHF,2+3J@VE(L"RBPW>",3QVKQ05./O!=^A(*5)#BIJ=GD5/<R</6ISS+?\
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M", ^S?C/5T'/J?3Y-#I4WN*<^H7'W4,MC*M:@D<9C24[R'V_CMJ"AQB,,_W
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MW-#4,ST;D@J4Q(V*F,AAI&(U7.$LDEL7$)D3WJ1U$TU/5WF$6-MN)"[N\3;
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M!0M:"DIDW6&IE4AERJ),4Z\8H!5JI0H,*TCC9 5*>K4F>39A+:$A*$ )0D9
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MN1_#6'> .Y'\-8=X [D?PUAW@#N1_#6'> .Y'\-8=X [D?PUAW@#N1_#6'>
M.Y'\-8=X [D?PUAW@#N1_#6'> .Y'\-8=X [D?PUAW@#N1_#6'> .Y'\-8=X
M [D?PUAW@#N1_#6'> .Y'\-8=X [D?PUAW@#N1_#6'> .Y'\-8=X [D?PUAW
M@#N1_#6'> .Y'\-8=X [D?PUAW@#N1_#6'> .Y'\-8=X [D?PUAW@#N1_#6'
M> .Y'\-8=X [D?PUAW@#N1_#6'> .Y'\-8=X [D8?6)0*1+S4^;-6(3:<D:U
M4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U
M4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U43OE6X8'E
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51288:1IQ3ER58H>43.9L,:U4:U
M4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U
M4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U4:U43OE6X8'E51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K51K
M51K51K51K51K51K51K51K51K51K51K51K503?*;=B-:J-:J-:J-:J-:J-:J-
M:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-
M:J-:J-:J-:J-:J-:J-:J-:J-:J+E\Y,Z-:J-:J-:J-:J-:J-:J-:J-:J-:J-
M:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-:J-
M:J-:J-:J-:J-:J-:J";Y59L^[>[]7;ZQX1YGK/PP-[\%F'_JNT>LG# WNLA[
M[K)\GK)P>[>[]7;ZQX1YGK/PP-[\%F'_ *KM'K)PP-[K(>^ZR?)ZR<'NWN_5
MV^L>$>9ZS\,#>_!9A_ZKM'K)PP-[K(>^ZR?)ZR<'NWN_5V^L>$>9ZS\,#>_!
M9A_ZKM'K)PP-[K(>^ZR?)ZR<'NWN_5V^L>$>9]^Q7$:<)4_0TKKS25VIO(3,
M3E*'<+QENGIJMT7L/6P%)2N[G(-Y2K=D=1WHHIJF^[D%<G E6FY+&ERWI9=S
MJGH]T7PP8MB;:]&\M04I-\94)2@@F[LF=D4['3'H^BFI:C(^P%)5+9(Y:TJE
MM60O&7:A/W<AGG'.!:"@B8(VY[$5#_1CHTVYA].J5]Q*G%;Q4%H$]P0]A.)T
M?W=C-."=$)W%W<Z05:DIVC#;KC?.JVJ)%'1@W9RRJ4=@"/OA_HNP,)NWU>2<
M!T?QM85#?NRCGM,@L/-*T=92*,RVO?V0=@^^<,#>_!9A_P"J[1ZR<,#>ZR'O
MNLGR>LG![M[OU=OK'A'F??ND7^WU'S#">EV&N+#^%XBININ94)2EM3;J=Y2K
M8:K1)%8UY+$6!\%T;(W%91%1WSG^CZN,'I"A3+.(:<,5Y22).NAQ+F\96RBB
MP3!5_>]<Y4I=!82579!0D++2J>01T;P:H)34.*915IGL-H*KG 9<48)2MINR
MI&W'-UQP7UGC,='L6I?)&LYNJIE\+RA9<XV[(P_%JYZHTN'W BF24Z%:4+OR
M4DI)MV;8JVZRN:?JVDE)PQ!ON*418E21DGNQB^)O-J:I:\LHI)V7]%?O*&YR
MI<?OG# WOP65KC3RVUM:+1+2H@I\DG(=B/:];Z=SNQ[7K?3N=V/:];Z=SNQ[
M7K?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:
M];Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7
MK?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:]
M;Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ[7K
M?3N=V/:];Z=SNQ[7K?3N=V/:];Z=SNQ;BM8?U[G=CVM6^G<[L>UZWT[G=CVO
M6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZ
MWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6
M^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZW
MT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^
MG<[L>UZWT[G=CVO6^G<[L>UZWT[G=CVO6^G<[L>UZWT[G=BS%:P?KW.[%W$'
MW:VC>UFD45K1^4DGM0V^PX'6G1>;<3D(ZQ?)ZR<'NWN_5V^L>$>9]^Z1?[?4
M?,,8@P\@.LO8@\AUM5H4E3+0(,3%]S ,1X;].3\]H_\ %L+?8<#K+U];3J;0
MI*J.8(BLPV@Z.\^I:?1Z.JN.F]?;2LYMEA,HJ&<5P'[NHZ>D=J55%QU.KD9<
MNR,1Q?I'5NKH:%0#=$A4A-S(A/Q4@)ME:87T@Z,N/X95X7)Q:$NK,TY"4J)O
M B>W'1S$ZJVI9KG:6L<&12PBP\($XPAU-J7**G4G>+8CHI2IM<(9L'_J5$AV
MH2A;J$K78A!(!.]%;5OM/-5]:HK76(=5,*[TS3V(Q'H97U)JJ:GTJ::9F$+8
M/P)Y$J3L>^<,#>_!9B/ZKZ)'\R] _-W#G3RT;+9^,G\8AM]AP.M.B\VXG(1U
MA^3UDX/=O=^KM^^U=;B5/IV;P:ID$D6BU1L(W(8K\,IN;I:<N5202;%YJK2<
MALX>I2N+PQ"EK90I1O+RE/?06J5O14K[2'66[2!\$Y=T1SW$:05"WWE:$DJ$
MD)Y.P1LSBE>H*--.XY47%J!4;+JCLDQ05=70Z6H>2HN.:5T3DLC(% 0H#("?
M?L(\S[]TB_V^H^88J_\ <G?HFH>H5215M^5P]\_ ='XE9#%#35+:FJBFYRV\
MTK*E265@CJ+:6)H<24K&X8KF*ZA<K<$KR FH39I B=Q:%9+UMJ8_\=Z,835K
M<Q"0J5.!-^Z#.ZE*"JS;),)Z.30K%6_WQ*O@\YG.[/>-R?#'_C_23"ZKG6%^
M2IRV %71D2L+*<FP1L0.F&(4II<+H2%4:3.1+>J0@G.D>4H[<8=TPP5I3[V'
MA'.6VTWE)+*BM#DAE&P8FC!ZG[T*=02G07^_G>E\F*_I?CK:F*BO"^;,K3=4
MHO*O+<N_!&P/?.&!O=2@P; <0YN*VG8#3%QHS==<6C.<2=R/6T<=%XL4]%TS
MHP]3/F:GKB NYD*FU,\A4MKM1@=7@-?S=->I9+J4(7?1=24YZ3MQ3N*M4MM*
ME'=(]]Z1T&(UO.:6AO\ -6KB$W9/71:E(.3W>'X1T?J"S6%I516%"$.&Z<Q/
M*"OBDPA^K=TN(TCBF*Y4@+QRI5(2RI,8S6TCFAJ:6D<<8=D#=4D6&1F(HZ#&
M\1YU1UP4RE);:1==(F@S0E)RB7#U,,H,&J^:U;X4_5.74+.CS4"2PK*9\48K
MCE16ES%*=-26:JX@2N9O)";O8BIK,6JN=U+=<XRARZE'(#;9 D@ 95'W@]'N
MBE-SS$4KT3U3=TGE/B-(&4C9)XHYTK%@T[E%*76P?!2FY"<!Z;TV@=FE K[H
M0I!5D+@')*3\9,8CB.&O\WJV2SHGI)5*\\A)L4",AB@Q#$G^<UCRG@X]=2F=
MUU218D 9!U,>PW$:\U%%1MU!IF+C:;I0^E";4I!R&,%IL*KS2,U3<ZA%QM5X
MWY?#28JZ_#*CFU6VXRE#UU*K%+ -B@1&%8CB+W.*RHTVF>DE,[KRTBQ( R#J
M5AHJI HR\YS0?N>KO&YE3/)">CB\3_[LLI2EBY2RY2;XY5R62$WJI%V8O>IY
M/!ZK^'X74)J,<7R.1RDTWY2]B]M#CC#J_$7S4U;RG@X\0!.ZZI(S0!D$4N%8
M0P*K&\0M;21>#:5&ZGDC*I1R"/OJM?:J:5L7ZJDN,KN)_+2A*3(;-TPSB;2-
M"Y,M5=/.=QU.4=F8A_ ^A#2$MTI(7B"DI42$V*6=)-*4SR63/8ABLQTL8OAJ
MUW5D!%V9^#?0E*DG:F)11XI1DFGK&[Z)Y1L%)WC9_.S$?U7T2/YF:!^;N'.G
MEHV6S\9/XQ#;[#@=:=%YMQ.0CK!\GK)P>[>[]7;]\2E(O*49)2-N+93H*:\O
M\IX]U9A.DE_W"GN/?DN"PG@4(=IW1==866W$[129&*2H7F(98OG<-T$Q05R1
M:PZ65[S@F.RF,,IE#E(YNP1_ZCJ@E79,XHOM?]!487WB_I%0OOC[]A'F?Y(4
MJ 4DY08NL-(93\5"0D=CJ)TS*'KMJ;Z0J7'$A8!D'4TXIVP]_;71>X_?>&!O
M=3HRM:@E">8%2C8 !4JB9Q*E &SID=V,+PO#:AO$*IAY3CKK!OA,Q="+PRD[
MFU'0>C?F'J5C1.@["D,M@B&<1T8>J%H:9HF59%.*3.W< !,-XJ,?:PNGJO*4
MC&J)2<A\FV;-J9AKHITI>YV*@Z-#I *DJ4F;:DK %X*W8-%ASNGI@R@,X84
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MCS1KO56N'P;.& ,$Z/MNTF($50J'4@J6%I%W^L39**7I%CV%##':?1LLU3(
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MVMB+J:NJ#O\ :31+BNQ_XW7NJJJ5U,Z9RTA-DTJ&T#DEMPW3.U33=2]J6%+
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M+F@4K+<4T5#MQC-+4*4*5I]]YY*3*]=7= _.BHPO G4THJWM+5+?6;4@9MX
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M62[=S9W<FY!Q<4__ '!0NFHO*R7;N;.[DW(.+BG_ .X*%TU%Y62[=S9W<FY
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MFR!BG2^@MN/J4\6SE 5D[ ZCK#J;S3R"AU.2:5"1R0JFH&- RI9<4B\I7*(
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M2Q4OL%"7ED@ %9GDMR0EG&:FCJ,0_P#JCIB9':2D&?8A]C"'E.894-J")SM
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M64]N$MM(#;:!=0A(D !L 0:AVADXLS<T:E("N!)E%&ZW0I;7A_JA2I0NVSR
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M&@96M0(K["AK7\;FE@>JERZMOV JODOX+R4]6 VAN^$4*%"F]%1:+E.SX*K
M73,JAUFL&LDC-R'7X]9[AJ% @V0>M&=#BZO^#:XOA+M(R8.Y]7\=Y@L3(N1M
M.[ZRADN7H[VDT47HI\V^<TS&+.]P?$F G*5YT]<LW_\ $1V2A*]9TN+2FNWC
M#_9&XH]&K6@NLK!O,QR%=_61:?2CK?RIL^589*'BKP^:A:B?J&H;M5*J/6N9
M5[30.01>PB/3 I:ZN70FH":/OPF*.4CHF)EQI9OK%YJIYP736S[SI_Y&D48
M<K8+DYU;7Q194-@UJM>!.]);TE<Y/R^ F%#'N@;Y([Z_@RW'M5#+.HTSBO0[
M  +7Y^_O+2>'S-ZU*>/\[8CR*NO7?XR$2;(^",I2^;](;@0,-A74#88C>>B/
M[=/!\/&^N(RUS+3-*/8C7\T1LBAI0ZN.EGU)9;98+IHW30DTD&^@%'<T_P#:
M2PP/(?!D^3;T.0<U<!S9EQ!2VM -5S=5VHATW# XZ&2MPLZW&X#^3A8^D15U
M;><BKO54[M8U@UN:JYD-4DU.1LMRAW">?:$J4!E+SK;>&L5T+;G%L.SXU&/6
M-_&AJ(QO5KZ]+?7^/B/5\-$[2E7F@P*Z=B,4J"K=P.IB>ABMWDZ'L1OD46XH
MY .OP,-C&OPJJ7?\(MQ9-/\ P,('*RB7WRD_9*>:U77\2OW4'U*/@9E(RA5"
MNZ?OJYE'H%-L,ROH[V<23XER[>Y9QR:GU6%][%P.H:?4"32'8<MFO$V;C_<V
MD4PQU:@#56&&O[&-%<+N0XL@.'/^""UE6<%6XA&G(')SGQ#F? T B+ZP@]1R
MC>4=L*#11M_Y2!*\7T?BKZ32_O(IH(+>A F)]0U$;W&#X5C..\2L43ETE&*;
M60;+ETDJRRW,[X5<P&]63J:P49!>CR3DCA.3B)!#0?2QZMI,5Q5#"A0RO+X6
MQH4)JK7I=7K5%T%?-#U1EA:7#O")GIT+1Q#FY(0&:(;O.SS5KV_O%''\L,EO
M0Z=E^Q54!^5Y'.82> =L#ZD&NW!-?G%T04!WT;'57U0T^P&7"C7X&D5G2*U%
M'7>=S\!C\.7*CN!>X(>:Z+/UOFNS6&.NC;SMGOSV740!0= YJ\@RQ8]"P'J,
M?58XZYQ9AN57:W18XZHXZ2GYIR>\4Z-<H&,;R7R28JBX9 T3TP2C"E0WS^#7
M 8&F%_H?4(E7V3U4OJBB _YXYW;0]TW>]EAEW5CVW. PS\@*7,-.MXCX!=WA
MW8*9%UFP?HGU<?MG@ VIB_3K 5(M116S*+@)Y[G 8;YQ.1ZBK#W)%* &196A
MUZ(2:84!W@JU]8!0> SB%VS?#2!!Y/90+/M%MC<8:\X <2FT+"U2:<I?L55
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M2C>7N_4908RWZ\2PR(6Z=P!!2@.0C&,;=!8A/W'Z=&1MMN:7@Q,%-*0 _ D
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ME+P F1@'-:^RV>5)8TG ^L>5Q'HP@)51H?$2AZSQN4LPZOT'G"*;33-VK?K
MTO5K-,F"K2R6AAO9A]5^!A 3 YKR  []?K#J1_? @T'%'3.8R+8+%6!+*\.I
M*0TV-6D#-#K,\A8&\9!1I[>#=/@&0]90@;>F&70"^3>(R0"GZTLM>\UUTFSM
M;:VR;)$792Z2^ (Q1LHI/*$ZC/ZJ!\#X-=YEU7F0R-6WN[  W G]0 ^JR]_
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M? PT9#P=6M]7L<#ZQY7V*A/HZN[X%7:9BG9YSD$-R3#@? ^%^P@4*P-3V!E
MM31NYE7["E>;5DZU.6UZ(=6P?":?%H-Z$O=#>WP<&Z? ,AG31<.MWY]@NL3?
MH^OX8%Y,TZ_D& :%C') \P_!K6D[[R2';?T=D?#L #+2B/4WS[0!:")\(Z(J
M[D7AH(0M%?HK^O8HVU83;J7I/,N$8?: AN]*/OVWOMH;?S(CB GJ ^[MM(H1
M\U''W1W'$)#3VUL%MU^U2,@H%Z"GW2[515U57YAB;'0T^W8R#Z4G3S)P7JFX
M;,V>0RR.THW.XI?=$!^B, >ZYX-,J;;ZKZ*GU(9=.>Y7T?,ECZTX\W>LUK^6
MH9^XKQ@Y!FILMCN9WU-12528[DFXNR_U0=Q*^&H0\U\=ZF;3.R K"^&#J1"8
M+NV4# K(R0XV OQHYX;U*<?NK@;3LS6?N1 O!]8+22-*-<GWNQ(PVN@!"[ O
MIE8.N_,Z$, H#5,O>5&ZG\MVI9,6,"#W '+PO0%/I!/8$(VRX4N*R 07<;SU
MA/.O>E8.N_,Z$, H#5,O>5&ZG\MVI9,:7)ZKF .M(//$L^@G00W0CW!_@"F4
MDY"Y.J[ZD'^!"P<B,K^MKTCP@ [!P!?JN/J5]C#.I'ZZ+^7:1XQU3,>L<S:8
M+D&GQ),*F*,!>D/0".Q(@@92PX=USRCX4Z*MU/)S$VE]=[/86\DGY'LY7/W/
MMV9 2XH"C>\W6T;AR\Q&;H*G+,2F5.88R#K;6]HX[:2<3:5BA9K,6PL=)U>K
MM73D1:(#=<K%*["-+:'1=1>;.%=9L32?N?*+!_9 (/N]GWFDI]I8<*P.PM^Z
M_-@ RD;R F<7B"I*NL7[5V8^ "^@!@[V!P0@=#=[^\N::C<CZHE._8%TPZ\K
MDX@_,/08E%@'/FM2V U+&FWH6W:TBY"M1WN^EF7U'N>#IRD/K.(/S.(/S+RO
ML-NFIP61SUJ^@&K(J78%3OO)(RHTYR(/I!.P07OHEE%%>9*.^^$:&3\IP/I\
M*+5YAY:)-E?U0J>03TIUB+SKVE2IG'J:BM: LT<:C.JAG5 \2IWC/H6,1+,>
MAS@ \-1X]@G'5Z 6LR#8SW4#J].SYQ7H?!\&!,.DR(\HH"!SEDO;"?6'K7+
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M+*_ *(C2:,JA'3WNM@T#T=7B3>FC?G_'Q3H^/AKM:E'<./@J7C9UR3487BB
MF[%+7:*TVZUSE//!^1QH!1TOL%CFC'@7L+TH-IWTQ556UU?CUV<^.X.GP/'
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M+0EY_)&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P85-"[Q $!I%?)
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M?0]<3I4U0@NK5MUS\/!NC_AIW]K:D$32ICL_?P3/Y#%AV:WQN!=7R/R7[O\
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MBO2P'UGT@0D><U7?KV<"CU_9'H,98N(NRG*[G<4.S;_HAXVXH LUO3%W'(U
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MT1(/ILJ?5CED08KH 595:O<8_DU.Y/(NPE:UB98!$U&-F'5(A5P5X(H7@5T
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MYJ^2*/)A$RM'R.%K':R$!Y=+/O!Z66J#%N2/0_D("4L;4P=T)"C2*8>8P +
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M*UW5#T[K)O%:NEY'!?<CZLY$P.NO!H_5XK9E/5=5UNVN127%H69BJ-7G&G*
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M/K;F7(\V<1:FZY?).#='^UZ%A0WTGY3]FF# :'R6UOC<"ZOX*I0="$TH_4[
M\,KZ']H)D>E:%U/M!!U9#O>]&=9DEG?-+IQ3>32:AHIN#OI^E0VJWD69ARM6
M&V9,=(ZH$-DJ8 =='G9D\$UIJFG1JXTYPQ'N%E<Q8;), .NCSLR>":TU33HU
M<:<Y>,2TP]+P=Y%P8E)'G1Y2X!I#MUE4.<C544>3K_%Y+]W_ ,'-#M<,VL Z
MQL5%5EN)-CPU#0> :6:Y/5@_/1$19,BF70'.7;E'7)3-FALS=41VQYG!HG/2
M (URQ"- EUKV*9ED:@:2XCC5](<R$.NH(M%QQL=01>Y RKA17F?L+9DY-0[T
M^42U9TM_+J=R>1=ABE'U&709;E*8!@ALZ;G5MV,^$6$ZV5]<T%QZ'>@=Y# *
M/ , !H$NO(PSD=$[YB:L_1UO= BL$Z.%37N#M2%\O@3:",,?A0B,#Z)KQ;)8
M4W&YKC.N/:_*5C)R9I?._+;K9WF[MZ[@&R/--*^<B K0V'.9NDFM!06[3/S0
M#NMBYSK+G!)W<Y!53M> (#0>Z1T,5I4O\,X*]+!V(1^&C<\:75#D71R(=7W=
MB< D.AP!4#.NSW+6T#MY<%5  )B)L%FBP,VL,?Z5!5IH]P,1W5?,2VG+ZS9Z
MH6A</JS=@A\9NTK5;PC5472U77WB!G:!GA"IWL7UH!%%76"N8FEXY\MNMW>9
MBAX;US3FBZ\"+#/X"T%JMU5=6+=6W1&@JW2&8NU%<*\3ZJ<W163*H!V5S,-;
MJQ-:NM]FJ2QU@(AYHZ:37PRF)ZS UEGA$R&Q57TEVC_I65A"SH9FFI#J 42Q
MY30U.$U&T&.DSZX+MO;,WAB=<>L"B-5=->R#1;A?;\3V DL,.&@LPZ*D,,0
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M"ZOD?DOW?D^IW)Y%_EG!NC_:GH-U9;R>'T0Z!1:Q'1'Y-:WQN!=7R/R7[O\
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M&AI-'PD+:42GQS2$8<L'%BTJ5B!HBU>>PE(A0++<[UE11+BY9!+06N*T.<Y
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M6EQ2M!4]3'/S%CAB7(AB<FAIU;>LH>LBZ#T#1@<EXHN/++.U=Y42U16"BN.
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M((R:X'SFL06J(QO^.3S9I\./QA<G>EB;.VBJ  U$MWW?NITPU!:1BU26]P0
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MD, 5'G>K1JO-<L[G:9K73=&D:^6GPGJ])R9>_P#SS#+WE:L\'^(K[G7,S\T
M[K8N<ZRYP2=W.054[7AIHF#J P <NP96+?E!7/NP768NGO&:@:6X;B6I2_(F
M5<KL5)%M8;EKA=Y\[[+73-A'5(+U;11P79[D%7.3F=F?7!=M[9F\,3:/L+I$
M#IJ'6NL8=1#2$,<JBSDOC/U9R,Q%&ZHP(;J,D[J2;N-LZAP2TJ68(' J$H9,
M/,='E+-US ._'T876,^379\[E=;3+S^$IT64Y&:3=6%3.A5M)JEQ9=6$+7D=
MD&NCTN-R %74H)+%'A&Z!PS2X>^6W6[OV\_;-V5Y'4NGF2ZJCD<OM*P$P*#
M!!!UUCCF0VZV\+5G,E++D&AK;LTR[:>2!CQ=32=*I"\I0:K<Y^V;LKR.I=/,
MEU5'(Y?:5@)@4& #^L\6Z/\ 7'K-T99S>'T0Z!0:@#0#YI:WQN!=7R/R7[O_
M (=F:L8<PA>84O\ (I#-O9^W+%!$NF6)4U*?-PB:-:8I=^8&DE5@_01)*-9
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M-P$\):CK; GZ3]4A6FN=TK.E3O*6 @1497:72^I9HLQ5?]BI7"T')U97NJ"
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M)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B1,O4R
M3:\Y)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q
M)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$G
ML2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q
M)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$G
ML2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q
M)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$G
ML2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q
M)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)SJK_I6&U]T]B3V)/8D]
MB3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)
M/8D]B3V)/8D]B3V)/8D]B3V)$R]3(!-KSDGL2>Q)[$GL2>Q)[$GL2>Q)[$GL
M2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)
M[$GL2>Q(O,WR@\B>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$
MGL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$GL2>Q)[$G?Y8E>$]B3V)
M/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]B3V)/8D]
MB3V)/8D]B3V)/8D]B3V)/8D]B3V)'YGF .9\? NKY'Y+]WY/J=R>1?ZA%J=R
M>1?)/.OL?TBUOC<"ZOD?DOW?D^IW)Y%_J$6IW)Y%\D\Z^Q_2+6^-P+J^1^2_
M=^3ZG<GD7^H1:G<GD7R3SK['](M;XW NKY'Y+]W^>QQNM-]B 9+2V?@.-.B6
M=C(IU2CS@B69'1[.DDML8=:_EU.Y/(O]0BU.Y/(ODGG7V/Z1:WQN!=7R/R7[
MO\W%NJ&*B:0FP<L?>E:+,S.O J'T?@C82356IU(<N]!>E.-J?0;@.%HX-:\J
M8GO85@&Y9R@@A-61O.M*%6[ZI&6K9<5BCXZ7>8L,&8!2CJU#=5R6\11NE%U'
M,X.^Z)K>,!5=20991+MM_DU.Y/(O\L7'N5-LT$^2)4J5*E2I4J5*E2I4J5*E
M2I4J5*E2I4J5*E2I4J5*E%HSHI\EU4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5
M*E2I4J5*E2BT;T DZ636/DT!F.Y0=_('R?H_T:UOC<"ZOD?DOW?YN+=4PV 2
MWZ]5]X><KY0WJ%MTKN5W5T^"-23$J(E^M%LMIG6*4<4:$ $ #.>H/L GI. W
MTH#-'%!+A0'U@*^R4') WYD6Q*!RD39L^1>I'+#D!M.HS5R<?R-3N3R+_+.-
M]'^EI9;8=X/FN9,=R@[^0/D_1_HMK?&X%U?P@G(H,JS=PD_%_"UP970F_( '
M\_DOW?YN+=4X/TB_WY61%[*^K=C-CHT 8N?(BG)LY2JSS0ND%D<#G,*#).%A
M+#T0[LT&MM<X5^[K,/.IW2UM5;,H)4]ROAKR\$$TSEG>]_UGDOI VUX9S-QU
MH2XA=&(B\@%HPB.MQVRG)!I18T"Z?R:G<GD790YW2VI[(@B6-CS@-D.JU!$$
M;'1_E'1*=;9^(>R/5:GLR +0.I%!: :K + .B?!IEFC]=:;_ )$K,:BD]M?'
MIEFC]=:;_FSX&J.QRM:" 2QR)_ @"CH+7\)E7T+^+(>3M/&I/_D][!8(E96U
M/^+>S[C>?#LRYEZM2RLNJY9XW6FX(0C4.>S+F>JU/9D]F31^NM-]J:#.W2QL
M=C(IU2CS@B69'1[$!6ON6NA\KXWT?Z8EEMAW@^:YDQW*#OY ^3]'^B6M\;@7
M5_!OZ^]Z,\H@<L67,(F;,!YL(@C<QK0J3SPDL!?U)-3ET4,2I$MTE&HQ*PX3
M4@O5X@?J$4(]%4>@$QXBZBG>Q3=<^DTRQ4+6@8U@-<N*!82\2B&W1&K4%ZU"
M;Z&8],%@XZV!V9QS5<OO2'6 L(IX7\7DOW?YJ"!6=+%15>&D'>BM5<2\<&@4
M@ZB0C\?91 W4CD5>>W(0(UZ&E^B.M4%Z14V#&6HQ<I>CI+&PZ4EN%BN:K*__
M -A <LDW&.R8BH<Z5I5<L8;Q4 9$.=@D4K<B962[1:WA?=?1AOQU=I@AM).H
M92+G+:RZ ?QZG<GD7; JJ)4ZI-^WBIE"\ K/.BN<'6)&M@6S5];3.[A,J.]@
M/"FJ'G3W(D=9=""MCG*3HY8-*(L$01L<B0(";,4-R8=&%?O-NPHOZ>-C)HM7
MINY,=B@LU&AX&)XLM\9C.0<S5)HNKJZCD.EA\"0@O)6+UT@]AB:$YY+QK%W4
M\+3-J;Z^*"":.-;#ONQQG),X$Q1N6(]4#Z![UJ$^D$NI20+KR8A>@:X/U:3S
M GT@U1P;.102T9Z.)XD:".F5NZXXRZ$%;'.5M=OY>E$928\#JBL$"TJ!.]=[
M2 #2T^&&<8U-7<I,!6"";Y-JD>3JJ7G*[+F'ZJA1?T\;&31:O3=R8A\0VU '
M-6(I*A&[H89S)P%8NZX)=2D@77DQ#6L()]60#KB,?5)%K&61G!8W-27W0=2M
M0J>$O.?J(R<CD^;ZD=9=""MCG*3HY8-*(L$2B*+&'7%%L4Z6T<JY5#A=<K'Z
MS3+@(^N20!:=NCUQ8NEX>&,:9U(O;-6XXL1F5-NAIQ=-%&7X410<Z/8*U8(%
M>T+F-JH#=935,/B)&*C&M%!-C9"YD LO@:ND*X R8["., O?0F'J*UB'42)%
MB%T+'=K,O%JXVX&G:!Z\W-*481I<3"UI!X0C'<V=LLA0ZL&OMH !>6RF\%,<
MQ/?LKP17R";0EYS]1&3D<GS?4AHJ- A?UFMH$3EU2X!9;;:-DAZ"LP!S5FB%
M>E74;L616FU/2Y<#F-NL39(XRZ$'N'.'MFV);AIX?%4\B-*E'%E0'-'*X$BY
M8'E>^9 <<H51]FJRW2[@OKRE>C->0N&!P5HR)SK3X<?C"Y.]*H",K>@-<'46
M&\F:*STE>!K$9=[K[H=;KQCG%7_@[$PT8EA"="JW.M#44D6661]&P]75*S!6
MCJ+?/JE!!":LC>=:4*MWU2,M6RXK%'QTN\Q3"S=B?& '3+E#BHT;@4UTR8WE
M;+C15GHO)R8U^5<;Z/\ 34LML.\'S7,F.Y0=_('R?H_T.UOC<"ZOX""9<W2P
M:T!:8$^;LO5H?)57U($X,ZTQ'>UG;,!5I?HJ[IR#ZLJSOF5W3/K4;CM]G#E=
MB,%\HU5:4;*HRSB4%9E3*M<QDPBR^.<&H[!WPBP"(H$JHW:\B<"Z9A=?TTM(
M"#H-<^LRO,Y+309E=9Q?24(^I33(8+;=\&% QUU;%FMN;>\'#D.$LL!2*6;Z
MQI-\BG2-+?$_A\E^[\GU.Y/(NV BJV)S0[X;%2(K;Q;JVYQ52OH YEMG.V3:
M+,T@)5H.0:R9&EQ&TG,P6=7DNO+G*Y&,TN!^Z;<A$(3&OU6F+ 1E'C(#M"D+
M-#JQ+ W-MM[S@UL]6+-5YPA6E)AJ.8TL';5!<R=("UTK>(/62R;W+3K43JPN
M3C,%#]8$4%Z-12)D]$H$S0%9-+MV<U>;(9'4F:1SB_EXE!>5FM6BZG)'38XY
MA&""+J?'C-CKH5G;)9+??L %1(.:JOG';%K4 HZ4E.2UK$Y5$2WK5 P&LTSF
M?E7 *P'KI61\:4O"HZJ([&[EE0;*9$&AU1Y1TTIJ8MZI0[O#LP9[+5:F8M95
MX-0T(7L9!4JB]8I7/7$8ZZ<\K6ZUOVI3!4*:-E0L+0UE=?",NQ=,Q[.4M:3B
M4FIS HBG A">ZX+/Y08Y[/:QC[BGE.&MXTM*\A.)$]J%;,,:5ZA:5<!!JH;Z
M>"N%R<9@H?K B@O1J*1,GHE F: K)I=F0SA@*9H,&A6S6D" G5-; =>L28/L
M]@"B^:\6Y;FK1&Y%!WPK,+.NPAH -D7!!$'RQ4T7.^F'<F"!60C*X&IF<G7,
MD*MW451NXC6IPL"@I]-"&@ @KD6*.Z[0A,:_5:8L!&4>,@.T*0LT.K$&R?EC
M$<-(4Q0EUEB&3#C':/R9F72F %SNL\A*E61T?Z#"L.K\"/JOL),L7U'$E[L8
M6!O>GT$.':(8%L>"CF+\N=8*Y7W2CWO%500Y7,J6Z!!$[1L%BB<E7=57.+7]
M4F4V5#MSJ!/BEME4@&_JER5'TL2=7M0M1;1B+BJ?#P30W5O)31AF)$,BPM0]
M<MI98BWDAM!>CKSHF>ZY42USJB9.697B6ILGD*H<&\=GST[SKE'5LUH=ERW)
MH ^CR2OU['#73-U&1.^/&7HE@\^8\ZJ*HW<1K4X6!04^FA#0 05R+%'==NPN
M^==@J8<[&*-#2Y4X-TT,UN^,'7-T@SZ\4*RXP?*.S8L4] :*T0T:AUEX$Y<-
MNK+;:K7I4'<0Z198@Y*T;FB*P ARHTOW+0/&F<=T ":&5=(UG2NUP\B_B-WL
MMY9+UL(]T!,>@P <CLOMY$:*Z'(-K::?#C_"%R=Z6CCO5VM)*))M:VUS&T(
M (:!:/T SJ R^I@,T<4$N% ?6 K[(E *!UHU%=,;!B'L0VMI"8UPUC#M01]I
M5@"L2YT5\IXWT?Z<%C[39>M-&>7U_H=K?&X%U?P%1630*B\@0LYKX,*5%>=4
MG=7.#G+DHK61,?6+99:5!?(Q!=IR43A:5#8[TA?C>-;\[^29@*$Z.+XD47::
MN)J-/B6-^M %+UK><=>Q ASCNA;\)PWHG NF$DK52E]58*K&7K 7WP=9*T+L
MK;L1I!.0?"Q8/XD=^2_=_D!L!U<2SQNM-]E#G=+:@@M".B?&/9'JM01!&QT3
MLL\;K3<$(1J'/8O3'10_BU.Y/(NV U%5EITBAH*5\>3]P[-5R3KE:&G(!>,W
MRJ92YX 7 M.I#24#(,->,0#!J=80!=$/=[.*VP"J6V;-$X;UQ@Z0#FC+!:^7
M6F.8R5W$9?H$<-5H(%,L:;)=48MB1*CI0EL:P3428=+<J9![_L8"L8 E#Y2]
M':%"K8UI"(5EUUU[,8"C'K2W569!=&? #Z/8I&N["HK=- 0Q:O/82D0H%EN=
MZRHHEQ<L@EH+7,E.?;.G 3 PH'O]'LX%4"\_@V#A,)RBJ_08?P\.0:_?:$2+
M&J?3./=<U//LYM3JK[ P60'TF!L@8:',:VTF*^AB4'(Q"H47C +%[V8F6<MN
MI&KH'1,HG(2%H@V<K$M?+K3',9*[B,OT".&JT$"F6:T_&>5U#.J:*C#UN"JT
M[HY@RT,K2+0Q6PIKC%W>@YRK75@K0<HL;98D,96:AJHF/7'$QI=E89,PUOP!
M'NN9F[.B^BYU4<ZJ+05W6K%ZAH#CE#T4_P H4!E9DP@"Z(>[V<5MGEOS[+]/
M'MXRAWU22!:^^36[#5.PR?OU,I&CA.@O2,-H2GK"T\:BP2Z7( 7*M>\S4@J8
M%]!3QH3!PZI"M?-J/ID)L=%U5)= &+Z=\*R"MZMB_ G&[97,$"1C%!LZBL:V
M!@0F2=1E1=*RK4*BQ=" $+,O!R<0Z^U61$7/NF!'+3? 4B1ZLV9H5OGAB7M3
M*,U#KF(@M<1:"NZU8O4- <<H>BG^4* RLR>Q. )0(.RH-P70,'-T\!&EMR%E
M P* +3,<)[DL)0U%%WK<L[8L >.%N1J )K<E30K25@DUS'([5*K[IB45!K0[
MNP+6<4V2E84"M'L+(%3GP<C0=^!MRPIQJZ/A(>=J(TO]"U!: L)KU2"$#]4!
MG=W1=CR%SN@B69'1BJ21N '&]IWIMXD6Q/$^+O2T<=ZO@XK=+Q:9[VX00033
M.6=[W_6>2^D#;7A@&ZJW) ZC!WRL( E1R>I7/G J>"Z<:,9:SK\JXWT?Z;G
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MN50'@WLG,SI<;%5HIZNFJ6+"]D$'M<G!BSB'%(ZRHV(E(#&T63AJ_$@*]\2
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ML?TBUOC<"ZOD?DOW?D^IW)Y%_EF+XJ?FF.@%J/\ 8<GEW633OA,'[@3]F/\
MR>=?8_I%K?&X%U?(_)?N_)]3N3R+_+. =/FN.@%J/]AR>7=9-.^$P?N!/V8_
M\?G7V/Z1:WQN!=7;S7?J7[ <UP0=!6L]BXWW7"$=>,FJ#3W%NA-,/:,45_=S
M-"S4F#,-K.VCE7.JLPTR\=>UN#E-=Q=+6%U(BK:%>&Z2+="GN,_<9AVJG0RK
MIJ?_ (/)?N_R,',9$*#5GK%X0#4ES.J[K4[*CUV5O<W#57HROA%Q<2B2\<GX
MS>D%%VFI5/G$3 [3,$#0ZZ(\X"JD!K0O$!YH8<71]KNH"ZDYV?GA2QB*!;@-
M6?7*@0!V6ZZ%O5#0Q6W\.IW)Y%V,6]6;D$KK2^O\1^_N"PK6N9A9]&*X]9'3
M%B>KWG*2JZOAH^FM0$P%7JBU82FT#B6CM;5(ZN"!><HK=T*VA)=G)_G4\E4]
MZ@M>0?X'&>(H9^S\'2Z-6$<D4*=$['4J>6@ARE3L?@)P+L1J6)=E8W^(%.S!
MUH8 (3",W- !B.&'EV@IV8.M# !"81FYH ,1PP\IC\O]R //1?PJK;XD]*#O
M>/(8 LC- ];C"4I394O5#9T>2]M(&#+O*R%T=98GJ]YRDJNJ?5JG9@M>8.PS
M!Z+6P@OO92NIZUW@59ZPR49ZJ-M=J%"8;80FS55N:'_R:PTYS= 6CD"LH,RQ
M[T'Q 0!)5!=!FNAK."$SH%?I$ZZV5!T?:[KL0I8,G*I76E+F$HJ4-"KZPF-G
M$@R6F<#/"_E4_O=UR[#V8V!P%JON=J%"?5 \!QK3H]B1(87(U8<Q-<\R\*6
M\M'5M]"4V?H)M2(J*BALE[B&BC7G6KV5Y/)8&63VX,R['1V22Y(!TCFYME,%
M[=#N@;,)7RT9H02)KI>^\E'-@)@6&1'Y3P#I\VQT M1_L.3R[K)IWPF#]P)^
MS'_B\Z^Q_2+6^-P+J[02$"VIHOU(MQ0UN\(PY4KJS-<0HCIB.[E+F$C;;Z0;
MC5(3S"OH;;3) Q 3O0]V72XL "U(EV)/.(/ECU9,>9%KCBP :HP!S6-Z-0OV
M&0&AR$!!.2"3B_6$U6TE-"E(M,; ND"F"7D7PX4TM2L+LB6,A:SC9NHY51H$
M5U[* JE& 58JW4@+PY8BU>QKV5=#%8%VEPY@G-QY@EKO(^U8L4#OMM"FAKJ7
M0T5\FTF4N"NN406CD'?4ZH&\(:X^V78.X'#+4/=;C8Y-&M3 \B$H!SN/@>2_
M=_EP*<TM+?%OG:NSF>+Q4K9'\I[,9V$G/0&5Y&JA,T*?W<RKE),$4VI6=1KT
MK)8W, V@NU$-/4J\EE">8)%5HT#HT]!SV3'V<O=1[QK:YJ@BSUK$52/800.X
M"]E6443S] "YE)SS8Q<058&N;(//59>0?PZG<GD79QCK[4#=HJ%5@,.Q:<PE
M=VFV7FY=UQ.:&92.^.E-G51S;.G#7'/<BDUN1MDJRZ.,6%D&4V31R!YRMYJJ
M<X9*QPA !PI$LJ1&D4(CH]FQR@ 0U%"Z.LP$B<FSBG(AGDPW;82-1281<\I3
M:FL.6)H#.CV)MU]3LK=:=Z$!#81(+Y'E&_8(V=,/69X0USI@@W3"L^YY@;+S
M&<OIN[HUE7=%9<E@2@70NDZP><,;&VJD/"#*;)HY \Y6\U5.<,E8X0@T\Z-*
M&D!81T<,.V4)8*?)V+-J-82SH[ )H4[7G@<T,S>8.9P!:C &6+(K0%IJ:]Q,
M;@$F7241Y(CG-C*THL36+RXG+/-537E0C>;%_7$YH9B)OO(26>G#-Q9:*+M!
MN&Z11^8M]LA 9%/''8Z #X M5= CNLM:9KDU=<7DI$7TK$N:X;-+R&4\15Y,
MH-,E2Q+6@]9:COA6R&:[#9P*)N,KJ,# V'JM+:*CDPO:C^J,26U8"MV?#+0O
M$H+P &4N ,K@E$!%IJZ.8>5B LUU#DB:$>2)O>(<]*0B0CR*+3.LK98.M%JN
MV !E<5<>6SFT<N:'82A)CT)E:*,T@UDT87CU=JT&=(R[5F%:A34N6-<'AFQZ
MP W%P?ZT4!E74M(ND\YCQ1?<Q:-,"_I7(/(X^XMIU51:H/(3BX/]:* RKJ6D
M$3*T?(X6L0[%B9S)5 .:!]8-6'/US6^G93,>QF31$:0<(Y'#V,PDZ8+U= :X
M-;+JQ;R \#9)6I4DVG4 6<U;SE2WKK@-@#<#>X'(%/=U5#C93/ H^$M=0.8E
MD\@DR4^[XE.A<Q\#(L-U$"\M7:LPP(65]M%!I==]+E8)CTF1'D]G#G4",P<%
M,%$ .-*E8"B/,A"UISI1K7A<'"EM Z6"^]C*:H+=/,X:9EL$D+1%Q%@;M1HP
MP;L69H6GE>5TY7=7=7#(*]50\LFTM(%6M 12Z#A1-&(&[14*K 8=BTYA*[M-
MLO-R[KB<T,S"I'Q:DXP:W$^YB# +6V!1I8>8?H#K$#S+M685J%-2Y8UP/"Q&
ME6W,1OXE_"#QRXV+3NMTS6@U'45=W>[$I[4(1KFFI0+7#KA&RJK8+>:?1CGV
ML.&=<XQU? 69QSEBDTL6BXA+'6..8%6U<>C&CJLERB\TZJF!:W*G=*%97+5#
M@FIDR(854C;*N@SE@'SOH#LL6K:.A.BNMRC<&WO$6Z$#O"*MMUT,%0PX:DFM
M+E97>K&S.(^ "JN"6(4,^=\Z9'WC(0.@FN V@'U6Y%,QTP!TZH\&&5REW^IB
M,.U.^.34622@"P$OV#Y3P#I\WQT M1_L.3R[K)HX.F"Z'DG&/_#YU]C^D6M\
M;@75VVTV;+?A!_>LIL$KLGO,<2BQ:C]">$6S054#'?K=>],.RT#7LM@K5RK>
M-FJ9,+>=3'/7Z%V"VB[5;T7=GG'8:5 O5:E [WDC>2R'*LZFJ<8[X(Y<(HI"
MY6O.+]>SSDW!>CX;WDYOA1$%N5'>RH]-"@D79FKPF5U<4@1Y.0XHAQ\=J0T!
MX*)C5"G5@6!U#0 #(-'QN%FZO0&Z);Z$\FHN]EGC&"-)SEIM;^#R7[O\N!%X
M3C(E;.E3O8)%"U0TH[_N$RCRGT::L,%,#D5\PJ6F&&U#<Z2V%,A&X%Z,$7L1
MK4L"5A6''%QAU6M=[!+#O,^DI$);E\8EPW,=KBW5OK G*:5T(!6A%<9F"_)
M'5CT)CH%I<$"#=0$S+E5MZNPAS?LB?H^5^EFC4^GSL->!"9SJHI-#Y.RV/ZY
M?Q:G<GD79QCK[ I(YHH$!M*,0W4-!LSUA0!='?O)W'6GE*BBW<K=UP'<E"AJ
M0LNLBR-"B:Y38C7\BS0PR(D<N8@&8OHAO9+Q95/!4 XIK(Q'+!MY8(^J[-BW
MTP6(2)&QW\AI5O-?I)'OVQKJL.Z^]-%FNR4.X([5#U 6J[2^@9NI&U'/]$S
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M!^-9^)P>'9MB[.D 1=6EU1H$Y(^-#1;4W6WG_#J=R>1=ABE'U&709;EV0:@
M1^[Q JXQW@CB$@Z)-H)@BN V(+')R(@$+6$9=E8'MU^W*.RLL'-%E&\6QRAT
M4L'8H;!0*L+6)GG C/+*@C)5"*GJEN79K+YS4N"NLIS ;.4Y<)O 9$&#E-.I
MZV46) #-+IS\:DVN.N9W>QDYH5#H FZZS1X'T@7<'9C OVL 2+T/.[93M%6C
M1*@7@L0ESQ82 0K40:S<ZX\KMI>,O-F1&Q H+R1S5RU8$IXJ H V(=%+!V*&
MP4"K"UB9YP(SRRH(R3L5*1=K*[*LB4Y>PX9+08.4Z\3]EF!PM6!!$2RF# I6
MJ^<U)"4H\ I,X)J2]"ZU5E%>LM);0W*#-EK:$JOEURUBN5KLR.S+!M2+\R O
M6*@NP,:-E><T48[;"IN7.")>;D]8J%SSK6V!Z4)Y/O?2NSP>VF9#K\P#61K<
M$IIZ%G5U&I9H#W( "KZ=9AO<Y>+<Q@QPXPF+-@(S(E1Y3WP-J1DQ!K4FB]9>
M+,)1,)CT*&LEUM,EV)4BO046*2S.9://1GP*^L8:9RJ- O6MF'EJK27-47?5
M6T#X\LDR75W(2> 5[%5TEW'EC!H8#DZ*J8#7EW;R%6KD\V5]/R4,T"AH,S&[
M!(=S(]+J7<>6,&A@.3HJIW4V7VOFZ:0J=;#H:4VZ0PC0]UQ](VN0.+0CU8
M<CLM+=2;NMBQM [^K/.@@3/7 7K&UW2Q+S8>0Z%ND, BF&^MUALF:7X#0IA@
M6K$Z!R9EF08.3/J8TZTFR-!+;2YK;6P(UDNGF3.P#_5"ME)AW0#51\A+:\KK
MVZWLN_0^6Z"N79U1OM5E(MNFS:"VN:2GFHC#EK/"Y3]:J=.Y*<O8<,EH,'*?
M2VU] V1YNSJ=GD+*N16L8[P1Q"0=$FT$P17 ;$%CDY$^KMH2VC+ZS:SL6MA/
MJP\M5:2YJB[ZJV@?'EDF2ZNY"0$QZ# !R/B0'<#J*P$=YE.E:[%Y; G>O'!A
M*[Y,H=10)OQM M!9SEV>\[G5BQLQ?Q'<8,=K"E,+ZI6MF<S>-:M:6[YKJDP
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MLO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\
MME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_V
MR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9
M?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO
M^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_
M &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_
M[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9K@TI5T#ERE_P!LO^V7_;+_ +9?]LO^
MV7_;+_ME_P!LO^V7_;+_ +9?]LO^V7_;+_ME_P!LO^V7_;+_ +9?]LO^V7_;
M+_ME_P!LO^V7_;+_ +9?]LO^V7_;+_ME_P!LO^V7_;$37C)B,I388N7_ &R_
M[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]
MLO\ ME_VR_[9?]LO^V7_ &R_[9?]LO\ ME_VR_[9?]LO^V7_ &R_[9?]L?"*
ME=PE_P!LO^V7_;+_ +9?]LO^V7_;+_ME_P!LO^V7_;+_ +9?]LO^V7_;+_ME
M_P!LO^V7_;+_ +9?]LO^V7_;+_ME_P!LO^V7_;+_ +9?]LO^V7_;+_ME_P!L
MO^V7_;+]]^J7_;+_ +9?]LO^V7_;+_ME_P!LO^V7_;+_ +9?]LO^V7_;+_ME
M_P!LO^V7_;+_ +9?]LO^V7_;+_ME_P!LO^V7_;+_ +9?]LO^V7_;+_ME_P!L
MO^V7_;+_ +9?]L7*)E=X^/@75\C\E^[\GU.Y/(O]0BU.Y/(ODGG7V/Z1:WQN
M!=7R/R7[OR?4[D\B_P!0BU.Y/(ODGG7V/Z1:WQN!=7R/R7[OR?4[D\B_U"+4
M[D\B^2>=?8_I%K?&X%U?(_)?N_)]3N3R+_4(M3N3R+Y)YU]C^D6M\;@75\C\
ME^[_ #"-BU5!%)+.22QH'*A2:3S,@[7!,C.6RO\ 7^U'LA3+ODB)1[YHFU\6
M++E^0K\U2WT=U+U2G.R9>3#]%Y!C-:G5U@%#G7%T<NM6<9O#26^[M7KE'*U:
M.:! @/2ZK8BLWP9TG*>D9+*%4LT9Z")_)J=R>1?ZA%J=R>1?)/.OL?TBUOC<
M"ZOD?DOW?Y]10CEYM8AWAT&*)5\BF0Z7V-1^ I]^964(%3HM#KHRGV?L17R=
M7)B[Y3)K)RK?K7'@)^+>1_6/"&93QMD/I1FCV6V>=EJ@Q#^5&O&T5#EJ5*#!
MU1F6-14/79_)J=R>1?Y9SHG^?Q-Y+I\D2I4J5*E2I4J5*E2I4J5*E2I4J5*E
M2I4J5*E2I4J5*+1G13Y+JI4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5
M*E%HWH!-H? WWJ*]_-WP$%4+1S/Z-:WQN!=7R/R7[O\ /J/'#U(0=1&H!] <
M\@[J[TZ$@LM9E%.B,K]?>N ZCATE>,JR#DC4+'HHK*U\.02F[MFNO%Q1L99R
M)94J'. "9I,"9!SNL1';=;J2G>=UD\YQKCVL>@6V7Q;)$ (]!6D9ZNZHB\R
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M>(A-<T4'B?RJ JT&K#K%TM7\2@*M!JP>EUE?\9%BNBJAU$]5< 0!JL$$"1H
MFF7 :L]L?Q7& UM?\=1D=+5 :3:#)V;"<!?A4!5H,JP>ETC9V_<ISX=@*(-5
M@@@$ Z)V*HSH*Z^/[E.?#^ ZB>JJ:_)LMW*IR5;(KR=0X%ND/DRDRZ6 (J&E
M*?K-G+JY:MD,T%PL]H@1=;G*.^*4*+ PY'SOLE\ Z^S5IZD*!K72YP+^(-O5
M0# 8UUBEO,[[/H1)OJ,FP\[OXKB77"U Q9$V=Y%73-@U06G)]X<VH(@MX,EM
MSKJQ,(=E7-(ZN3I'P2#BO1F#,"K*KFF]?T10%6@RK$P T,1.3>GC!3E0C=;
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M]6B+=(I[H($NIXHE4-4^1_K9]-YD,NK06^X[S//LZ,UM]LZ'-7I[ND4XTI6
MYZ%[%]B! %IH!VB1+ 4P-1M0JZ>RAE]O9K5/@D#/OH?8!YRX1UA63=],A;VE
MH8@KRY#G1#+KW!?"8;2C7U];05MH.]CW+1KK(L2LE:XZ1>QGM6/-E@*+&2Y,
M+5A:AO 4Z8Q U2QR5CZ%VLYR@D-EQ,X@!TQWW"(*19 FY#HO,G6)^^%<LZNE
MQTBL!,^!I;+,5L;1WG?2T=\O3'-2V?46[B9$S38JG-[GVJAYKVU=@4]Q.V =
MAB@4E=-'98@R9E3ACR.Y4H;16T!*%*)VLE!(;+B9Q #ICON$04BR!-R'1>9'
M5\[D&SY +?"4=_ZB4HZ8.AJUTX;;*7['5Y&MSSF*T!<\'<;.D5E:)QU5T.WU
MS*_/$ULZ%<G-UN5QAKQ",U=-?5G.>P.H4- H\N<]@DP6+#@N77V0#&Z^R\Q7
M)7%DB!#ZAMTGDY5'(5\XT->V)M.:SUJPYW?7RJI1X0'   "-_ERC!-ZZZQE4
M]%+-\QU"9ET)4T8=C\!%5B$%8W#B:PY2[%;>SF38H[L12C3BQKZ@9=*@ZQ?<
M27)*R+I.DNH7;6")-'*=:5R)R3D2P5Y!>-\IYSV&&BMT+;Q9EM/N4Y03R\_0
MU7LRN4MC0-<K<I96W<-&K)6E+@&EN<S EX(0 .JW*%)!#FYP@9Z$XG;LLA,0
MYW0GUT[TRSA*B1SAD?6GE"@H;TVZ2 ?4S$_)7 M PD%S7?/).R8RP6]=59JZ
ME@).'YLF--/(MO-Z6YXK<JY)HG*>6[-+\DES'L, 5Q=4U]%0P#+,K.Q?+R=;
MYSKB\PN>]"[SFL]:L.=WU\JJ!L(#@ P! ,W6G1H_;;DZZI01N!VN##LW0F=$
M"T\[EZ0C;JCH&6,-2_B2I;LL<@S9 \J6-QVAQ!IQHD=#AX<H 5\1!U2I;Z2$
M'D)4O4 A9HY[2*1 @"TT [1(E@*8&HVH5=/9AHK="V\69;3[E.4$\O/T-5[,
MKE+8T#7*W*65MW#1JR5I2X!I;G,P)>"$ #JMR@00@YN<(&>A&AI)]6Q]#B/)
ME=@/@M7F"+=;O,1@NLT6SPHQ2_8ZO(UN><Q6@+G@[C9TAFA'^HE+RCKGK!MI
MH/<@9RT E0\I*-YD%.5C[=IP&;K3HT?MH2FBBH12PVI5==(D>Q.]^NWRJMHQ
MUQ^IPV<Y3QT5D;6'&2M<<IAXP!WK+K3!+J.UE'4Z 75-&Y>((C4<Q6.;&.4Y
M;],<QB15Z=\&'9NA,Z(%IYW+TA&W5'0,L8:EQ2O6<MRIT,ZVZ1ZLHK2-H+U\
M.U^=IXZ*R-K#C)6N.4P\8 [UEUI@EU+31C!9Q9-A;PVC2I!=RK!I&'DYAELI
M<9VYN!1 #FY0@9Z$&*VR"E:'$+*Q1HNP!S-3M2DL]T^BDI?1T@&A!L5$+*7K
M>5^>)K9T*Y.;K<KC#7B$9JZ:^K.<]O?4) +[1"?$HAEF=$Z$87ZH6R+49[F5
M%J_FH\&9A^A2\9JZYW<G,_52RMF967BSA/7\&9^P&0%(.*/8)?IZ"IH;)K/8
M\1C!L!8T!NU#@@&EDE/Y4" =28/!0E@@B,066&E65!XN1K(Q42TIP.2>2=EB
MRW5 8U5UF^9'E,Q--)"NE%*-.+&OJ!ETJ#K%]Q)<DK(NDZ=MV#9OZ4 /%^^(
MK.;!EC;,A-:O:#3Z!*NP*>XG; .PQ0*2NFCLL03-2NK9CT6C+F,9F[%&=0!:
MX[JC?EEMJ ],]P(R@6\6&2G/%,LD0I78% Y=*BRR@RL5RT++1G#;9=0NVL$2
M:.4ZTKD3DG(E@KR"\;Y3SGX!35TUHTA='4(7,+<9F[%&=0!:X[JC?EEMJ ],
M]P)Q.W99=4! E%RM=98"]=K0<D;TY\N-43'YZ!2-.7*-B&77N"^$PVF;7[K:
M.MM!WLH9%8U@YRZ--=;FN4]Z-8YH(K5*P:]+07$04GI'OW4$7FQH=C>4E MJ
M]L0;::#W(&<M )4/*2C>9!3E8^WR3)_H(5+WPVB.@#[=BVRL=WXZ"4FB:M;G
M]0M7:LQ!-0:D(3EE=U2JLN;4.@')3J3(+C3AGFU3!7C+"L-W/<63O'M1[5O:
MXOA#+K4U27+:"&F%"5/I=-&6Z-'*:A#2[1.YM]6:"E(*R$+.8W-A)L)+[8YG
M&<B$JZG$NOX97/JE66PE!PZAZ7>D9L2GQN:T#5?S*5^%&$MED8=$;E49#I;A
M8*GFNXX?K<#JA8R7N+@4.V0 JHTH34J6"#\W(KH%"B6G!^CM) 2T+.&I$$4L
MKNUA)8C59!SHHIRE%&:0=0X7AB<-MF7?ITF#81]-=)J/[K2JU"+;KI+":!J%
MT=Q^KX&-8.=D-$"_0CY,'47@$O+H"CKLR-=:5:K2P&0M=?Q0[%##-J], %,<
MXE&"K1"N1J,9@@V!K8I=^!YRM%UJ16--KT=.TD3@0MXE?5(IT[X[*IM7[FT"
M=X2L&3TY/OC49J<U'6&WAVN-.C)0 *%5E O+EI ^MCR![5S*^,H0._P*KC'>
M'Z&0P8 Y<R<<Z?";A'R'(HY(.91.< C746X30KK9CG#\E!ZT(CS"F&QI+>JC
M4$M6CK$47:\#1T(4R9=NRY(,--8UT+/HPC( A*ZXK >; (3*M:()M+&S63*,
M'-ZI7R^P37>H[*-YGZ]5B(WJ[DA,"R_/0&-=,\I<]G$*&C=#V&=$YL6.T "^
MIN1XX-05K$3F%5OT)5<;(A3< 5U?2&H-ZKAZ>J$CXZBE7M<UN=/69:*06\W2
M8[PD6:Z;AK;,^Y:VOWG-W&=O/MXMK]NP4>G )B1U5TUFPDV$A%T(&Q$5&!-"
M@;J[-\H]B$3NTY)TMN81_O2IT,+ZWM#IMA+(KM15GLH[AU[S-UK!Y@BQP:C6
M0UQ<YCE!Z6#%@4QF.VL9+J*ITHNT1F4JU76@G75Q*J(;U!EMZP<J'5:MMP?5
M,P;*'+Q;+!:77G"0G<:##IGZLYEV\?62 L)'E9=XFL!<=#K*!"+C7#-@4(H'
MT(7M 8:;QT,]\P<G6:Y6%G!1GE#&PD0<1SHDUG&.G;6/UA156K+<'U3,&RAR
M\6RP6EUYPD)W&@PZ9^K.9P*/R)X->SB]IX+!\]'3/06T'\9/L?O V8O"LJUI
MU11R!*FWF?UD4?\ -*JA9-*8K6X&1PUHZ3!H7-Y0BB3;.3.(:=S>,VVTQ'F:
MNN)8?RLYUTI&A")8>'Z3)N[?.Y]YJW.S\-/66GZ1AS,+  ,5>$"G<C7X*71;
MJ>)GG#-IH]1FVFVTP22E\Z='JVG90W?*26># L65R4-5;$-KJNE'@2AQ<]!F
MP!,KXRA [_ JN,=X?H9#!@#ES)QCIVUC]#PJW+1W:WUF#DZS7*PLX*,\H8V$
MB#B.=$FLX/T3>-F+/(8:.(P )PDZW!*+=W5[$(E;J!0#=F9YG*TI)X(62VT4
MSO%6P6VRIFC'2#,@.H91W> 8FO1<4(-OLYL"A% ^A"]H##3>.AGOF#DZS7*P
MLX*,\H8V$B#B.=$FLT#=0!*G4%734S%@ XI.Z##OB]"<-MG';>R^O&NG5-IW
M,PV-);U4:@EJT=8BB[7@:.A"F3+MV"U1;1&LXGZ03"GS70,<WX6L=#KPVV&N
MCOH%=[F73725- 4%";%DK.M1V28D*HA"KMU[)]L6/J@3!K<)0T(*%MU,1&:Y
M$<D1 6:><;KD& !["/IKI+.7OL0;0LH=;VGG/:/F*#MA!K/Y0YPCJPRK&)U:
MME4Q=TDK=>( )Y05 ./+W=*MDOEF+J-YT7U0LO'5135(.ZDR9AL&E62@J,>"
MDW3>IY9-:4%5;:MP?5,P;*'+Q;+!:77G"0G<:##IGZLYGDG9!W!"T$B,PB!'
M0YWJS,#"MP<>1KT>D>6[-+\DDE66PE!PZAZ7>D9L2GQN:T#5?S&NZ@%!DT)?
M=7;U>DR45Y:ZN^^4ACLWGV >B/?3B6%(9(Y/7;E#16NM4*Y2I0192@=T KP#
M08HE+T367]OD."MN(7IVI4NP>R.Q=TPP]MW5-FESOJ$E[<6Y:VRH24/<'5$'
M>JWJ)G";=:E3!HO.$T;@<].(YU8#E7G47#U5\E<M#5I==B0S::/49MIMM,$D
MI?.G1ZMIVOF*#MA!K/Y0YPCJPRK&)U:ME4Q=TDK=>( )Y05 ./+W=*MDOEF+
MJ-YT7U0KDE[T^>9EO=A#6_#N=A[0Q1*J]@+LTTE_CL1NBRY!/76<=M[+[SO3
MKZ"#EK:$3QR+"TP^XOR8"A^ <#@* QVG/29**\M=7??*0QV;S[ /1'OIQ+"D
M,D<GKMRAHK76@F[$TI8MY5VO6%NJ==Y!'G0$-OX.-O0SC'2>(]96A4"6DLPY
MTSGRE?+[!-=ZCLHWFCZ6^;U<%[D8!7@&@Q1*7HFLO[?(<%;<0O2<<Z? ?G>,
M=)XCUE_LO9WRZUM>\:XB650-XWP6QL0Y<YD0IQJ*G-V&%,GO>OSS,8Y88=\B
MI=7&)5ZN2*&&;5Z8 *8YQ*,%6B%<C48S&Q< 7O\ 3@=?'=&]01E/2&QI+>JC
M4$M6CK$47:\#1T(4R9=IP*/R)X->S$MB36X\2KQEETA6JS\U'E'E* 6$OLCZ
MS%$8=5I^C] )1U)UQP>#'P!S]9?0LP,P!#A/7'B7O$SI3R@+YT/2W-L6]@+*
M>*U90 M>4VTPB-?3 B@:B)_6\)91NZ$H[V!J-@2F(^LR$L4DT%C3G,N#6_1G
M@VWBPBOA?125BB9S>)9.K0) \B1/K**=]$H7L4KRAI*J47*H70#7,10-?X)^
M910H&_$:A=9#6X2AH04+;J8B,UR(Y(B LT\^VX(T-Z3 ^ZWZ2[5]:?;(NP.&
M9 =0RCN\ Q->BXH0;?9P^0Y%')!S*)S@$:ZBW":%=;,<X#M2(=N KXIO.N>&
M;K6#S!%C@U&LAKBYS'*#TL&+ IC,X;;&ZY!@ >PCZ:Z2SE[[$&T+*'6]IYSV
M!M,DZOB.ZYQ/T@,],:QX:V%U@$:ZBW":%=;,<XL$WK8O*,#ZP[J3)F&P:59*
M"HQX*3=-ZFL*TA.IS+-'#SF&VF&TMR=[AU?5F*OV;#;O5"Y7QE"!W^!5<0[Q
M]"V8, <N9V ^,W30X,3Y.%YWAU]"!RUM")XY%A:8?<7Y,!0_ .!P% 8FV"4.
MQ=TJP_(NOG\DNK0TY,XRP=Y5].SK]?9+JT-.3V$HOVW(NN%>QH%:(SI<DV9D
MA=_4S1?UAJH%!- ,!,%EAW$H=-#%5V%A1IWP:+.C6$ON@HW6*F7FPVJFF I&
M('"#@L"DP\SX;7RZ2PI,3H!@W<K?H=E0[#2X.0,C1ES(L8E=2F7FPBW*+B]7
M'T&"DH!3ZKZ!B$<DA5*6$2)4!6&7L8_2HF*E'S=57*[L)@S*+U!)W2X#9YJF
MZE#:ZE[BO)VN<<V G+B^A$&UT7.9)OPM++;6@YPY;_,-J-9YH"S3$5Z+=5=5
M>KF#N"K0<@5[ZS,U-W<S]$A<?ZM>]^@8%_/"W?E]1G*NFI$&VZ+G,NMX6E1;
M:T'.>*.#SJ+'(.S4+*W%IK?K P%G1O!I-0AT3A3++0@CGZ=?HU['!J\<.T%N
ME[P+D1XX*YH\S!_WS653(N@"Z<3)(7G9L6+!HIY0DQ\TC5S<'Z]C8&U2NHU6
MY.&C<68R);P+ZC5=W,[E3!$7),Z.(]X]D'J&"=0N45R</T1F$EJCU+SA0JH3
MGG!UE(23KY3I]>79;$F:R74 =9WP?R2K5?5[- Q7LODCJ)U,P:;H ZMG/ZW"
MM7$88 P!!"WD4YXQO8E"Z\RII=55XMQV(E';055-+:^+7L"XHN6V@!]&//F%
MA&B+:I''*8.0';W\\25K%7GTU]HWFN>K"UJ4.N\4=B8&=6VP=<]<]CX!'B&$
M1U)8LE^"M#]"65K:)=4_ J,K"NT+]P=A++*L?6SKZD&^XBF0&%8Z2D&V+QNJ
M+K/+HC\J582T&V;UNJ+K,BEF6G0MSI\5QNF[EU54=TBQQNMDYC/EF7G5-@N4
M2QY2B!#B[6N;.C$-T308%M>1SAUV1!>H).Z7#II2H.M*T;:2W4<6D)HT!2%\
M]90L7)1I3%];F,7FEEF R-&/Z+&<VT;)R\V8EMV(#Z9><,,NF0Q=-6L)V,"A
MC!=A@<C,AO8VNM.0[DNU>^1EK#QE2J[\BR^"!C2(&VBC7L\*DSU>%1;JKJN[
MF"&KSQY3I]729AX;>=U661G((%BL=4,G)E-5M[*)NG+>68EMV(#Z9><,,NF0
MQ=-6L71Z6L6F134T,F>5SZM09Z;3GUAAUJKCU.F\ 0QK."H4R)Q2#P([:S1N
MKYJ;/FU<PIHN#UI%&UU"ZOMLIY"4;74 #D',R*03DU<[]*HA?<$R.'236VG+
MK QL$,TMZ:T90L=V6:@UV&E;H\IWU;27AQX@+O5"(EB,/DYL%H*SZF_PY^TB
MEA269TE[4,WH6MN@@=%EOJ=7FM'BUG*8C/9:WZ+$H^V!!0BUS"2U1ZEYPH54
M)SS@ZP0U>>/*=/JZ3,/#;SNJRR,Y! L5CJADY,5J^=H W3:M6(&VBC7L\*DS
MU>%1;JKJN[F7N*\G:YQS8".9HY=LI2-(=/7T4;;JKZ=KFE6T5I>LMQG> GBW
M?-#N-]]C5>L;RSMAH486X673N'50!^XF.2LNU>^1EK#QE2J[\BR^"!C2(&VB
MC7L\*DSU>%1;JKJN[F>*>7[N,.00$6%:#-+>FM(?-56S C+&K2^>L"7,KN9^
MB11DAA, RAD-&7Y@PB565,O-@A;R*<\8WL2A=>94TNJJ\6X[-' 3<Q>=TY]A
M.34\=JRE#2<YC"%J98J\KJ,S6)]+ +*<CRFN?R^6RU.3I%S(L8E=2F7FS,U-
MW<S]$@V_=2OJ\^@PS%P=.2M8Y*7,80M3+%7E=1F:;/I@"RDL>4O*ZZ# MKR<
MYS4[Q>H!-TN5BO;*W!!C0Q$1,J6AU6GT& X&M4RF3IUHSKU7Y+U4UYO95G[.
MP= 1E:5V%:1+((Q-R<NY!]:[DNI8+O5P-)WR:=#6:%( :!]^4X.6<1DQ5DL,
M!:C>!OO98YV3+G0,RG""UD4([YW@0>3C.R5#ZU%EN2,Q+;L0'TR\X89=,ABZ
M:M8I$<ZNBNR5V+@UR!4LL[P]BBWTH;=FV7UTY:Q>;)B&715YW7G*7VP&8E7E
M:DI$<ZNBNR5!%N47%ZN/H,%)0"GU7T#*+YR*"S 4C1ES(L8E=2F7F]@)CT^1
M'DP/SK\.Z'Z$./=)H<P5 ]"B(O8!8.HC'3:287MJ-J1FV6/8M6FZW*W#C7BG
M3Z\I6X<:\4Z?7E+U=%(PIU!*Q3CG4LE#@\4MW_K+F181*ZE,O-E)\#154')U
MYSHO!$(+%?JSSP!]E>8F=OMS.H@N]7,FWX2E1926/*7)$S^A2BZCXJL_9V#H
M",K2NPK2)9!&)N3EW(/K7<EU+!=ZN!I.^33H:S0I #0/ORG!RSB%R,E00]'"
MWK+]R81)65,O-@Q["6NY'Z!%;?'.N:+GZC ES*[F?HD49(83 ,H9#1EO,:'1
ML,+:YNX & )'UU\26/66NDE6!%I3YCM<XYL!V F/3Y$>3 _.OP[H?H0X]TFA
MS!4#T*(<UHEU9Q]!E]@24Y9V.Y+2Y 8*Z^%T""&KSQY3I]72..SUSX=?HUFG
M(KWGDCJ)U,S!R [>_GB1!9J0NE="JCIM),+VU&U(S;+'L6K3=;E(23KY3I]>
M79E97Z6 64ECRFJ$H"@LW0<X(:O/'E.GU=(X[/7/AU^C6)#)7RFMT+K-.8-$
M]A!IK/U&/5^%:(HK60?4Y6FNN\0W1-!@6UY'.'J$+*@H=7*JVC@U>.':"W2]
MX%R(\<%<T>9B"<&Z9-$!#J,6"KYS.@5;2"%O(ISQC>Q*%UYE32ZJKQ;B71Z6
ML6F134T,F>5Q1@58@M.:ERA7A=MIT+;7'6$848I9NA.\8^S*#,-R5@R9E6&L
M_A1Z>%_Z_ 5:$1I!6@C[#X[I;";-X5=OT["=(:DX$I!I.?PHFPQ@H]0!SA;6
MH:*R*IEYO904IS=L1J?DU@JEA7O*Q@Y90!VV1'09!Z%$RB#DL^HHVNI87+"B
M*,^GH@E5A2P;JVZGK&3%62PP%J-YS4[Q>H!-TN5BO;*W!!C0QV62AP>*6[_U
M@RW"4HV+$3',S DJ7@@6Y*'.:VWKT=2KP-(;RSMAH486X673N'50!^XF.2LT
M#%>R^2.HG4S!IN@#JV<_K<YQS+G<6EJQ/H] GMM.76'79$%Z@D[I<.FE*@ZT
MK1MI,S4W=S/T2$1,J6AU6GT& X&M4RF3IUHSKU7Y+U4UYO9@&^1:6N.P3?"H
M<X[1L#FO>#3= '5LY_6X5R0S# & (&^]ECG9,N= S*<(+610COG>9FIN[F?H
MD%V(A0B6$,/6-@6E8-V4T.5N.4PDM4>I></SVF%0Z7-N=><1W!FDP+:\NL4+
MTUW-_1(^KT&.FTY]9XV>;\[2K++_ "^M#A31#G=[P , 2/KKXDL>LM=)*L"-
ML.L+DYL#@_HA@R12>PH'.8%XX= 4 &@'_AS<?L#UH,2F6 3ZY*^G]M-.*\ 1
M =&EF?1EX75JF7XFJ[9>D@LXL I_R1JNV7I(+.+ *?\ _,2__]H " $" P$_
M(?\ XN[?]&]3L21O_P!%U?\ 1W=V5?\ 1IB.[_HT<XPM_P!?9Z.L#K?3'K'=
MX^D8S9L^L0HI^,Q;4"I;/\B*C64_7\(7 K.7\3*24=@OG39E_GJT#,E\I3RS
MO.>#X=V6;V;V;V/^F,8^G9<M,RYO?_J%!:J%@;O\?#6BV)Z'K.]G.WUCE'T[
M"#;50!#>)5O%PJML_'8E,U+V]_QBV(^0? (YTWLWLWLWL0\KX"R-5!$-V?&1
MYTV@?X6?(/XVZ-S]!Z_J=[/64<H^G_B,6U J6S_9 N+E_8&$<YT((MRGG ?T
M)9TW[P:>OV?'H_6:/#G_ "'/T_F>0^&GZ&?2$I&+Z_8_P"^/E/N'95YZW_4M
MNO\ G+<9\8M1 :QB6V>H'D_#YLB":A.ZG<Q6AQU(I6C&5<I]V?;?;_U>0GY?
MQ\!#497S7FRE\WTB_L@VLSKSE4<CQ<=GRGVLT.&K*&MU.37U_7Q\Q,WK-$U_
M'I3S+[? #-43NIMK4WEN=U$=5/P=27])64JOK_ _/OX;;F[_ *_B)RH1@.+8
MET?J^DRW^,*T;.O./4E'Z3EW?^'1^LT>'/\ L68Q^\5N88+^!8&\1EH?^7$-
MU4$S08UFY8^)1*[0?.R6]8@.K'="GL4ARA-S=_UV:@&4K?A-GS9BM_1]8BIF
MC]9H\.?8KC3K-6MC-!/KZS!,\->R@%LI6O";/FRHM_261S:E]EGK&1MCI$.E
M\&[/LBO O6*SR'WBN^7:=H'FP7)?KZ3G \^SH!>W5[9)R30E6SU@1FWCI",T
M&$@Y=WI'9<NP7-!#%FV:@&4K?A-GS9BM_1]8BI^$A.>'I,:7>O?%NU/* 'O/
MA\V3R/P6R].Q_=GVWVG/1.>>$/=,U@GGQX]A0C[(XV@5;^A-GS8EU9Y]EJ'6
M.:Z+]6"Y7]?2$9T^)%6H=F?TZO2:Q;QM-&LXWC><G7LH!F&,K? CC GU]9S
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M[+@X/H3D%QXS N.CL%&R#4+\INH1H//M'#6?/*FE8KL*SE>]1PI7UOX& \H
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ML? N=6N4%*Y@&.FN+ASG<Y3=!=2\+KXN4,_+"F'B5!,Z/\7W":/=V)<->/\
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MZ_Q(<]B'7^'[A-'N_P# AU[4NIVYKK^;7X:'_@IKVA.78EP!I_[1+@5V(=8
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MW_5/P?G^U4=UY/3Y<<TG\'D8_'%>D;.GU]8G1TS/L$-Z%$LX4Y8,-^R*4$G
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M^;TF_P";TF_YO2;_ )O2;_F])O\ F])O^;TF_P";TF_YO2;_ )O2;_F])O\
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MX;_4X;_4X;_4X;_4X;_4X;_4X;_4X;_4X;_4IU#UN_GVD^1^=_YLTGR/SO\
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M\WI-_P WI-_S>DW_ #>DW_-Z3?\ -Z3?\WI-_P WI-_S>DW_ #>DW_-Z3?\
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MJ*KZ2NBYY9CB.KN92O1/S"P!\*)S049;M!,])1 ^%2].;6#U SRE,.>'6#1
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M;*/H?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2<
M?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2< ?2<
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MD5%]IC$9B'G %G89+ISNNX(+TAM]ISD31V'$T1IV+4I /SAE>B:*PVN8S14
M6=EVQ $.14&3FYKS[$H7%W; MX'DC4RI9?L0$AR*EG&C,0P:41Q9 #3MOF![
MV!14HW)8/8RI,%-+)0&L?O)>-0G*#H)JSR$JWI@>G9@.D^I2[8@"'(J#)S?P
MO.9^W9FW7XO(0A6;\W88A*.;*@3[$TXE0:0Q#:A$,TVCV 7DPNDEL2H9]B'F
MZ0'D0E9I,22QAZ^L#P0J?4DJ7.Y4"H"4D[NGX/@7D@S[_BU1K]\UY]J/8!>3
M"Z26Q*AGV)HS#G.7<Z0& AA)2G*)4&D,0VH1#--HZ3S7Q?D^ U81@$$[#7[X
MQA-0T(!H31690._LUYY27.!$A=)*,"'P:??V:L PPU1#Q:2[N? LX*/P&^XB
MH]\\I MJ#YRP_2"]UV7[$!(<BI9QHQ6KRG<L,+U134E^S25K<IKS[$M6-7!\
M$.GU9*9G<J%4!*2:%I-;,STF)Z]E&],C_47,=>QRUV5!BL/9I=\T9H=TYXK#
M"'E?PEVA23$)I]TU!K 8;=,1V!3-?L3RA-7NFJ/R?B"->X]H4DUX_)!(])W!
M<K0-9?+G]SLT7+TFF4=A@%=@T@6E((&_G&ND;IB9_6+M=BM]\,"IM1\"*C->
M?8CI]D-J;4=VQ9]\=]Y!0/A-;X*-R'8FU*54H7L6B'"_!J]MJSR$^E3 =9;,
MQ?7L5OOA@5-J/@14?@0TC/:,ZA%L)@O-*0Z?!Y".Z)W$[B<TS0>S[$TXH:P^
MF8OD0JF?8C!8[=6>0GV(.SI]\U0L>^7;FU-KL@[,=OO@HKL&+O/P? ,>Z//O
M^+5&OWS7GVHP6.W5GD)]B:,6/=#7P%#6'TS%\B%4S[$=)YKXOR? :L-=H:_?
MV;C'I([::/?V:\\I'NLT9C\DTK7X=/O[-6'M#7[_ (!3BL_ Z7=!9[YY2#'M
MU>^&D=]Y!0.U40V3?M-N.->?8CPARO:*^B*5:@5V&-;!94;[N4+EEM*,_J+Y
MGP8,@HKLTN^:,TN[LTN^:4\HS5]$TNZ:$^_/NS0S6[NR>0)J]TU1^3\3R!-2
M:_=/R3RT_+LH3 I])K?3-,,H@1=A[31-'S80C$4+X"#J:/=#3[X8:[(-:$L:
M+FO/L06X$#M28)J$DBN\E2]AFV:#V&M\%DQP6[F^S?9C9]"AU3$G:M69J]MJ
MSR'9AI8*YS6[!I]\,-=D&M"6-%_!JRG9OQ^O9G>OP>0^.?8FG%>@2IR(/E,#
MGV(S3[^W5GD)]B:?9I]\U0//*@.V12FH =$%/OE0]F*;S\'P6[$P[S^"^ARC
M0JS5&OWS7GVHS3[^W5GD)]B:,.+M+J=E2X_68KT"5.1!\I@<^Q'2>:^+\GP&
MK/(=IK]\>@YQ'M 140FCW]FO/*1+F36R<\BT,JGX-/O[-6>0[37[_@THJS^"
MHG(])Y2:?;YJ&D%=Y*E[#-L$0CH=^VB3&O/L0XN\S)VW0*DVDJ#V4$FM[*-R
M5K:5']2H6:QH-R<F6OMM+OFC-+N[-+OFA/*,U?1-/NFE/OS[LTLUNZ#5!"H"
MG-FJ/R?B>4)J37[I^2>6BUEU[,]TEAW^TJ8T]F^P'8Y1UV*"CYM<1N"=+V-Q
M4IV6:LT#I-V:0TG.S7GV(*4QJH!R,YQ<M<I29JS;$1YR[M-;U8<$M1@BSLNV
M59\& C ]9A8UL,UA)',\B"W,K-+FK/(=FA%K*L[,U9H'2;LTAI.=^"[&6=IN
MS2:)R#$T+I!$L[?(?'/L33E:W[(.81EM'#-/O[=6>0GV)I]FGWS5%Q'U1#LX
MAV,LK=,IB9JROR((UBW3\'P *8U4T4;\Y,T(@U$U1K]\UY]J,T^_MU9Y"?8F
MC-!U)W-!S6&89IK6_9!S",MHX=)YKXOR? :L\AVFOWS38&#I-A*,,!V:\\I+
M>.*U07.9.49\&GW]FK/(=IK]_P !FF,YE.)WX4]1,*J>4FGV^:AI,U9MB(\Y
M=VFMZLR7)AA%#G+NTSSJS7GV)80.[(!G$.YF;S94J9Z_6:9T@HCMFM[+*""I
M0OZFU:;S\)O03-HU@]BT'8ZP(UK=8Z$8*(E:+:B61TJP+DN9?B6K;8UK8U*=
M)0'2"RHZM8U*=)7]$P1EI<9IVAV"_A%D);+RGYP1F=%F^0^:&:.Q+B.B;Q :
MK@5V8RU]A%,Z+#G,R//L2XC54WB95R]@"F.^8:^S$S4MW=_!;$*_IV=XQY3.
MN@BB)<SY3/7+"TICLN(I&^U+B.B;Q :K@5\.<PF^3KB4JI205VVQ*9OXLE?8
M FF+R8O-BP.<HOL=EB_L[;"TIB9:^W&&N9V;[-1B\F#YLT'L2X#JJ'.8X*9V
M;OX3-,/FF^3KH)1V8V:F&OL!DK[+%_9VV%I3$RU]N,AHS>@&J!6D)IB\F+S8
ML#G*+[$94/V?%C9JIF9OML+2@.S&S4I5< 4SKH<YF6U98-P42XM* @E,Z+#K
M3+:OPT-_9V6%I3'9C9J4JOX3%,/FF^3KH)78L"5%NVX?LA$N(U5-XF5<O8 I
MA\T.M,EJ]N,M?9J,7R9U6$4=CI7-.Q \V  ZP=H7WTIC^Y,K05%L=7_A/(=8
M:!/G%AK.L VP:([D?W0-NC_A0S3!Y,(9[GV8J'6PS1_]6)55555555555#.K
MY/55555555555525$0_P*JJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJ
MJJJKY555555555555554/T_DE55555555555)41#Y)555555555553U/R2JJ
MJJJJJJJJJN[_ ))555555555553U'QNO]+IK?Y9YKT^2FM\DT.[Y)^?R34[O
MC=?Z736_RSS7I\E-;Y)H=WR3\_DFIW?&Z_TNFM_EGFO3Y*:WR30[ODGY_)-3
MN^-U_I=-;_+/->GR4UODFAW?)/S^2:G=\;K_ $NFM_EGFO3Y*:WR30[ODGY_
M)-3N^-U^*^L-(^&],4<L=*^)W$L8+W'_ *[77K+$_B=Q+'^8:W82W.\G>0*C
M^-&[ 6R^GQ-Q+*PTI\27?2'2QTK_  GS7I\5",[R=Y$?\%E8%Z.E? 7N/B$Q
MAHGQFM_#0C.\G>1'"]Q_(:W#</XM#N_A);G>2MEV0.E?R%[B&MPW#^'\_P"%
M@.9WDJ4TEM8:4_C&EE;4+W$-;AN'\&IW?&Z_&B@[Q!N\0"%FK01H@..\%%0!
M<<M#@=)SGW[$%A.<JO-#7SI$>TKPROR(2W#6(?\ Y M%"#JF AJ$K03S95HK
MP);AK$.!83G,SF@UN4X=T_QFMV_BBA:ISGW[$!JL%K#2PG!K&SSFK=)9@UG1
M"'4P%":$UY96&PLP1#5ND7@<S7ES;@Z4#057-+D2[!]X1K1E=JH832H**E"X
MY:.Z9?AK-!.[O\#\UZ?'-/OGT,T^^7DQ/6 7(%RT@:"J^S P[P45+\-9H)W=
M#7SI$>THQ-4:0EIIQ7;II?&:W\4T^^?0S3[XXVTT$[NA+33ADZ9HG[PX%_:<
MCG'>W9K37_BT.[^'2R]^SM3CE'!6" 0\7.??L0%(-']YAH57(N<94]FMW36F
MO_#^?\/ [IDU34OIV63++!$*7(EV#[RK'.4\_P 0*Y62M%?M+5&MW36FO_!J
M=WQNOQNM]9I$7F@X=XG&-?JFK]8;@J<9A8KF#S"EZTKL-6?:AAEN.NYI98XM
M\7+_ ,EHW(L2VBAQ..T:_5!.W0!DUI8XM\7+L'2@%>43S)'J?XS6[?P=C3('
MF%+UI4UHZYB8*[YS7AH]TIR0"GG-?LT)K]DZG>:LQ,'ESFKV0DG':4 <0"\"
M8(YGY(\7=V(N3+48*@Q[Y5;:/&?D_P #\UZ?' -L>BQW+EVF9@-*H1HBMQ$X
M[2@#CLORS62JVT>,_)/M0PBG>8-B8+ G\4TOC-;^* ;8]%CN56VCQGYHF"P)
M18TF2UF0%W08QZA^DU1V:TU_XM#N_ATLLB#6$=WFD3[D#&&8/,*7K2NSSFX=
MTO1L6%0M3388V.S6[IK37_A_/^'(;3O(F!IV3*=YJP"\"8(YE]E/K,5-/M*[
M-9;H ]LM4:W=-::_\&IW?&Z_&ZWUFLGW)<KI;,_ 70FK]9K)6WZS/1##L,0J
MZ(0I*CSS[<*1*.:B:TU9Q?3_ ,=L5- Y3<BW(6T8)<PUI)D6BS5$H]%S6FK.
M+Z0A2"\'9H3EA6G\9K=OX.Q)!YP[#$*NB:W9"RQ6\U8-G6627*,V"PE$T)K]
MEJ35@Y8W']1VNRNWE,_*["HE\7NF(903:H!ATFLE68O *C2?:FG/R?X'YKT^
M.:'?VZG=*9[#GYQ!NY3/RNS[D_+-9/M33GY)]N!D[+, 3 V8<YE!FE\9K?Q3
M0[^W[<TXZ7QRF!LPYS+2NL1HU!KO,$+Q63& 7V:TU_XM#N_ATLU>UUD^Y "\
MV'88A5T3'47,I<-0Y(4L)_*(Z'9K=TUIK_P_G_#P.[X+4[YJP:I?%[I04TGX
M@A9F"-=&:HE'HOMM4:W=-::_\&IW?&Z_QW\*WV7VJO;;_P"N] IH&.Z"6PL%
M/B5>Q;_D-;XK^#) N.= P=EO8*?P7\ U\(U\"W_@_FO3^2XM]@U_%;V#7\1K
M?^ :[13MM_FT.[_P7VV]JW_-^?\ XAJ7V"G\^IW?&Z_-*-?^<UOX[?Y#YKT^
M2FM\DT.[Y)^?R34[OC=?Z736_P L\UZ?)36^2:'=\D_/Y)J=WQNO]+IK?Y9Y
MKT^2FM\DT.[Y)^?R34[OC=?Z736_RSS7I\E-;Y)H=WR3\_DFIW?&].;<VYMS
M;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;CR#)
M-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<V
MYMS;FW-N;<OZ2ZXFW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;F
MW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<
MVYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;
MFW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;
M<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS
M;FW-N;<VYMS;FW-N;<VYMS;FW-N;</4S?I-N;<VYMS;FW-N;<VYMS;FW-N;<
MVYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;E_277$VYMS;FW-N;<VYMS;
MFW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N7\<IMS;FW-N;
M<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<Y=FY
MMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW
M-N;<OXY?&V:IN)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)N)
MN)N)N)N)N)N)N)N)N)N(E"_\V.OR/0_YL=?D>A_S8Z_(]#_FQU^1Z'_-CK\C
MT/\ -JPU=RT5H5*PU=RT.T*FEIHJLR@:N:/EHM%3U3!"^WU19:.I\ 0-<$(^
M.IJ;!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@F
MP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V"
M;!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38
M)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-
M@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$
MV";!-@FG=?XW7Y'H?YN'5A,WDG.QALZ_>*',B LU^_TFAWS\DLVFIO'A,"*V
M_!,MY_?LU^Z$7?3TCW&8P^28.F./XC(=XF)7AO*Z_F%K_#^3_#1J:!U_B=?D
M>A_FX89(67V#[K[P8*'OCR-XL6\_)-ADWWCZ3%]8MJ-8K3ANX0#G-?NFOW>D
M%EZ2R^TI17UYPB3]A]IT.C^8SAS+ID^DO2_@_)_APU- Z_PNOR/0_P V"5@'
M4[ BL HL._\ <N"_+.@\?P&'Y##NU+\.79A!@[H8]$3JB5%[H+1&;%?4]9^U
M;A5<^PAS<>/I*@8>T;KXS+5_)_AXU- Z_P #K\CT/]4_)_B U%M?C=?D>A_F
MHS5_&(HC2.5V!+505U@WF,5<$M7VK66(NL$M7-21.EF+66(NL$M7V5VY^'\G
M^(:AT^\"OC=?D>A_FEF\]);8E7%FP3H]@C98^HT3FVLZS4[NS"6)2VOW@ZM1
M.O,3?I7P)<K^B)8Y5-&]?(@#(ZAUF5_1$L<JF$:OVAKX;\G^'ZAT^\"OX'7Y
M'H?YI0],1J7^94NN&U])?@:$P$ ATBRE9)]U-3N[.0"<@'&6"(CTS51+7-\_
M@V!]YE-2:7U_,U?5/(38'WEOJ<8E^82_2V&;-/@_)_AVH=/O K^%U^1Z'^9D
M%>4\[,V?-F@\LG=QB/,<Z^T=<9T@CS)^>?>GW4U.[L7H3[P6@3K 0U9XSD0U
M[V4#ICL<QS^T>@%S&"4QI=_J8T?J4?,^Q'H!<Y84Y3OIT0M@ .7P?D_PW4.G
MW@5_$Z_(]#_-VV!K$K^*NP:Z'Q!7^1.OR/0_YL=?D>A_S8Z_(]#_ )L=?D>A
M_P V.OR/0_YL=?D>A_S8Z_(]#_FQU^1Z'_-CK\CT/^;'7Y'H?\V.OR/0_P!4
MPAF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;
MSQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;
MSQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;
MSQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;
MSQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;
MSQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\9O/&;SQF\\8W=W %GR]U^1Z'^
MJ?D_M+NR +/ESK_!CIODWR,5%J(*:^'*G;E3^;0_U3\G]J=V0!9\M=?X9:>J
M+!K*]B6@=8<Y@%ZDT6 ,,UYHL 89KS18]:.Z9CN/D?PZ'^J?D_M;NR +/ECK
M_##+A,3:=DSI;$M8&=](:89%S5AIAD7-65-0MUB8AF6V@5+_  Z'^J?D_MF0
M?+'7^&-40?-@IX=E2&9,2IFT.CI!=R:L.CI!=R:L^W36,)BEF:W=_%H?ZI^3
M^UW_ "T=?X$5DW_M-V:RP.A@QLUCUX!0QW9 *N6@XCNR 5<M!Q&;C?BJVP2E
MQ_%H?ZI^3^U7_+AU^1Z'^J?D_M-_R\=?D>A_JF-FJG!4X*G!4X*G!4X*G!4X
M*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X
M*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X
M*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X
M*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4-
M6M_,'7Y'H?\ -CK\CT/^;'7Y'H?\V.OR/0_YL=?D>A_S8Z_(]#_FQU^1Z'_-
MCK\CT/\ FQU^1Z'_ #8Z_(]#_FQU^1Z'^J5-S89L,V&;#-AFPS89L,V&;#-A
MFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V
M&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS
M89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPQ.OGKK\CT
M/]4_)_7-\?/'7Y'H?ZI^3^N[X^=NOR/0_P!4_)_7M\?.G7Y'H?ZI^3^O[X^<
MNOR/0_U3\G]>"YJ'7YRZ_(]#_5/R?UT+FH=?G3K\CT/]4_)_7 N:AU^=NOR/
M0_U3\G];"YJ'7YXZ_(]#_52;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]Y
MM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]Y
MM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]Y
MM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]Y
MM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]YM_>;?WFW]Y
MM_>;?WFW]YM_>;?WFW]YM_>,V'SUU^1Z'_-CK\CT/^;'7Y'H?\V.OR/0_P";
M'IS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;FW-N;<VYMS;F
MW-N;<01_YL;-7C-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>
M,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>
M,WGC-YXQ6+_YL=?D>A_S8Z_(]#_FQU^1Z'_-CK\CT/\ FQU^1Z'^J5-38)L$
MV";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP
M38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";
M!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)
ML$V";!-@FP38)L$V";!-@FP38)L$V";!-@FP38)L$M:^7W7Y'H?ZI^3^U;<^
M7.OR/0_U3\G]KVY\M=?X_,3[G;50+E2F):G8)TE/\NA_JGY/[9MSY8Z_Q^8G
MW.S1FEVD9:&(EZ?#-!3&M9K_ ,FA_JGY/[:W9\K=?X_,0W]4OTAJ1PC6>RTI
M^"#2XY16F(%><U_Y-#_5/R?VQ'M#-'RMU_CJ&;#-A@ER(LS"S3$%Z,- ES<:
M^:LLO&)K_P FA_JGY/[6CVAFCY8Z_P#D960<P@S"(K?Y-#_5/R?VI'M#-'RU
MU^1Z'^J803>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3
M>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3
M>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3
M>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3
M>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3
M>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA-YX3>>$WGA%\E$
M,T?+G7Y'H?\ -CK\CT/^;'7Y'H?\V.OR/0_YL=?D>A_S8_([;;;;;;;;;;;;
M;;;;: -?\V.OR/0_YL=?D>A_S8Z_(]#_ )L=?D>A_P V.OR/0_YL=?D>A_JG
MY/ZT[LAG?YZZ_(]#_5/R?UMW9#._SQU^+39O34_@?3_(P"S3X'T_&S0_U3\G
M]<=V0SO\[=?AL5$=U,MS-^<1T0ZTU>:6:L"MQ-&S$DRZQ$&MSFF:KI$*)O09
MU3R%1X%:L)O6:6:OQ:'^J?D_KKNR&=_G3K\/F.VM5RF\MZ8]7G-+"[# YI<P
MI=XF")TR*9T1=&J47EW3&&"HK+G4ZF>P#%',TLU?BT/]4_)_7FN_SIU^$:;[
M!WO7$^R($%LT13N)I8VUE#&LU;K$E4TDQ'6+6XMZX$'M-)I7,&+:8+HE--.,
MTQJ_%H?ZI^3^N[<^=NOQ,V3=CML&M(=>,VIJR(K9HK,*L1635G8'G-204R3?
MC-L$H8S;K-^<PEE3K$5OQ:'^J?D_KFW/GCK\CT/]4_)_6]N?/77Y'H?ZIC9T
MG!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*
MG!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*
MG!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*
MG!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4X*G!4(;6_GSK\CT/\ FQU^
M1Z'_ #8Z_(]#_FQU^1Z'_-CK\CT/^;'H9L9L9L9L9L9L9L9L9L9L9L9L9L9L
M9L9L9L9L9L9L9L9L9L9L9L9L9L9L9L9L9L9L9L9L90O_ #8Z_(]#_FQU^1Z'
M_-CK\CT/^;'7Y'H?\V.OR/0_U2IN;#-AFPS89L,V&;#-AFPS89L,V&;#-AFP
MS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;
M#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89L,V&;#-AFPS89
ML,V&;##<@W_377Y'H?ZI^3^EZ!T^T&_Z8Z_(]#_5/R?TS0.GV@W_ $MU['H(
M/GSG*U]);VB"I%F.D7:;$LX=FJ78/B:J!4=/Y=#_ %3\G]-T#I]H-_TIU[,Q
MC4\B,@&:>#NFAW1E!40'<T\>48B=%)BHPW8AEQX$QOG$4-E )&!ODFT)FT7!
M/(EF2/=<2MI-*EF/*(EJ^ !H?ZI^3^G.[:?TIU[,DEIO" I-?CG-#NFM-.6\
M<MV;J_ U LY@)KW: 9\X;CRE>GV)IU&=3I-.+#OBQ[YK]\+[E<1SE\9K]NA_
MJGY/Z:%S4.O]*=>QKH SYP9"NQ0<EFD-+9K5*A'(RF>4KTI#E$F>Y3#$E16-
M*'6&',0Y?688P+\R-%K4 P5=$,0&!2( [PA3SC"WG"$O.'M8MI.W0_U3\G],
M"YJ'7^ENOR/0_P!4_)_2PN:AU_ICK\CT/]4_)_2@N:AU_IKK\CT/^;'7Y'H?
M\V.OR/0_YL=?D>A_S8Z_(]#_ )L>C-O[3;^TV_M-O[3;^TV_M-O[3;^TV_M-
MO[3;^TV_M-O[3;^TV_M-O[3;^TV_M-O[3;^TV_M-O[3;^TV_M-O[3;^TV_M-
MO[3;^TV_M-O[3;^TV_M-O[1A'_FQLU>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>
M>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>
M>,WGC-YXS>>,WGC-YXS>>,WGC%8O_FQU^1Z'_-CK\CT/^;'7Y'H?\V.OR/0_
MYL=?D>A_JF$,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>
M>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>
M>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>
M>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>
M>,WGC-YXS>>,WGC -VPSO_377Y'H?ZI^3^EN[(9W_ICK_%L?Q5_/H?ZI^3^F
M.[(9W_I;K_ BHEN\YFA%FLMV6[-CLM*5F4L@7$.793.=7\6A_JGY/Z:[LAG?
M^E.O\!QF(=EWU3AO.55.<TF9HYF&J")U@"W*%4.O8[UG1P0J.QR0,86+^'0_
MU3\G].NO]*.O\%-$P:DR54Q[*>C^((=$LV)=6LPHQ.+].PUG8W>HNAB:?'/L
M=?NFAW?PZ'^J?D_IJ/:&:/Z4Z_PL*COHHHP=A@6N9B#(= E%5X962XJ942YC
M(O4&(825DN!<P+C^'0_U3\G],1[0S1_2W7Y'H?ZI^3^EH]H9H_ICK\CT/]4J
M:FX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$
MW";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX
M3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX2WE(9H_IKK\CT/^;'7Y'H
M?\V.OR/0_P";'7Y'H?\ -CK\CT/^;'Y'))))))))))))))))) !K3_FQU^1Z
M'_-CK\CT/^;'7Y'H?\V.OR/0_P";'7Y'H?ZH)<;_ -YO_>;_ -YO_>;_ -YO
M_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_
M -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO
M_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_ -YO_>;_
M -X39_9'7Y'H?ZIH=_S1W9 %G]C=?D>A_JFAW_-7=D 6?V)U[45$YIFC9^##
M0FV9P[:@>Q:";Y-\A-O_ (-#_5-#O^;.[( L_L+KVDM /3#KJC2Z(%;B:-F:
M<TII25'=$WHYC&([(2%@!&/98%C.B(?5$8U89JV)F>4T&/6BE,I"+9?P:'^J
M:'?\W=V0!9_8'7MN1']$H.LV%K# YI<PK-YI30[IK,+0=)1L>S1FDFEV.OW3
M[+[QK2 MP]!TF;G@R$LLMMTBH]T%1T^#0_U30[_F[O: */[ Z]H"]C#FX1;E
MI*&-9JW6"532FAW2A8:940]FC-)%3,&1\V?9?>?<FEFO-2!Y,;4XAF]/M?#H
M?ZIH=_S9WM %']A=?@#SG/.S16858BLFK()0X@U,>LT![7=DU9V T,YA+ U@
M5*:LCNV"4N(S9'KQ5RP(RQ\.A_JFAW_-7>T 4?V)U^1Z'^J:'?\ -'>T 4?V
M-U^1Z'^J!JFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3P
MFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3P
MFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3PFT\)M/";3P
M@!I_9'7Y'H?\V.OR/0_YL=?D>A_S8Z_(]#_FQU^1Z'_-B.F4Z93IE.F4Z93I
ME.F4Z93IE.F4Z93IE.F4Z93IE.F4Z93IE.F4Z93IE.F4Z93IE.F4Z93IE.F4
MZ93IE.F4Z93IE.F4Z90O_-CK\CT/^;'7Y'H?\V.OR/0_YL=?D>A_S8Z_(]#_
M )L=?D>A_JAV"S>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC
M-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC
M-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC
M-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC-YXS>>,WGC
M-YXS>>,WGC-YXS>>,1YB")9_377Y'H?ZIK\<OZ6CIT@B6?TQU_E)6*4=C0Q#
MPZ2TB'D0$I_/H?ZIK\<OZ8CIT@B6?TMU_E/#B.]B4U"BS&,-)-/OFG'^;0_U
M37XY?TU'3I!$L_I3K_)]*@BF :)F>L^S*%<QN\T^^:<?YM#_ %37XY?T[)/Z
M4Z_R//2V(J,0V:V)CK-(2JP1S@J$*><&+2=UXRWPO^70_P!4U^.7^,8Z_(]#
M_5-?CE_C&.OR/0_U37XY?XQCK\CT/]42BIN$W";A-PFX3<)N$W";A-PFX3<)
MN$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-P
MFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W";A-PFX3<)N$W
M";A-PFX3<)N$LW_3CK\CT/\ FQU^1Z'_ #8Z_(]#_FQU^1Z'_-CT9M_:;?VF
MW]IM_:;?VFW]IM_:;?VFW]IM_:;?VFW]IM_:;?VFW]IM_:;?VFW]IM_:;?VF
MW]IM_:;?VFW]IM_:;?VFW]IM_:;?VFW]IM_:;?VFW]IM_:,(_P#\5!__V@ ,
M P$  A$#$0  $
M
M
M
M
M
M
M
M
M
M                  /X
M
M
M                                    !X%
M
M
M                                                        .^
M
M
M
M               ._
M
M
M                                  ''P
M
M
M                                                      N
M                                          *[J  !*     )  &R
M   !Z      !@$ !;?"$0            $ !5,@R4   0     \ !;:@!"
M!L   -P    '<X        )0
M             P                    !P
M (ST    P    !T !2P   P.       !NP  ;?9B            . !HQF-U
M@  !P    %0 ;U: '   $0  !D    ,8]V        &
M                               N7 /          *V  94Q@ &
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M<]4!4&V: . !?90/Z@D8"&6!;E=(QX                        !)
M  !  (    YQ -S82YD;'PN4UQ^ AZ%1N
M BM9E6&XD':",@ 4I<T 4 >/HYE6 #<WP &EV,9\6T Q\"N4H<00 *@!!NXT
M P>P&I\6J   P !P+7PC66 *@T+ !0 *; &K04P$@Y0!.A(^D@
M                ! (()  (!    .F+AN?A)@_D_)S*I0-,5YAPV
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MF0DXU1RP  "!\ K1=6890!L"AL !2H . R2\,P!>.J TFQ$@
M            ( (   !)))(                    !(@
M
M
M  ))D$P
M   !@
M
M                      1>%@
M
M
M
M
M
M
M
M
M
M
M
M
M
M                        -;;;;;;;;;;;;;;;;:+;;;;;;;;;;;;;;;;;
M;>;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
M;;;;;;;;;;;;;;;;;;;;;;;;;;;:+;;;;;;;;;;;;;;;;;S;;;;;;;;;;;;;
M;;;;1;;;;;;;;;;;;;;;;;1;;;;;;;;;;;;;;;;;0  !P
M ,                  !V
M                                               (
M     .P                !                 !@                !
M   .                !@                  .P
M
M      !                 !V                 (
M ,                 (  !P                ,                  !
MV
M                          (                 .P
M  !                 !@                !   .                !
M@                  .P
M                                             !
M   !V                 (                 ,                 (
M !P                ,                  !V
M
M     (                 .P                !                 !
M@                !   .  -0 $4  -\     !@     %^    -P     .P
M4J    &AH  !@  +$
M                        !   56   ,$ ,  '0 !V    57@     D
M (    \7@     $@   ,    (]     *PD   (  !P  LMMBN634+5KP  ,
M    !L<.8]?660   !V"0"?B4[P)EH2^CV#P@+&
M                                            (  -*P;,>,HP M+>
M  .P   -*V!*7(\-    !     OX22!E:%H   !@    HEV&7(P M   !
M.  %1,O%LE!J-GH  !@     #$(7_P#0&L@   #L"3J*)],\3?*<# RZKGB2
M
M     0  ;ZGJ0'/R2^M2<  =@   ;ZQ-0&&,:    "    #O(-0KW8+0   #
M    +Y5.TI_@!:   "   <  (C!T4C?%V<?4  #     !-B/M3ZD3H    =@
M1#YS5\""+E182Z1E$R6@
M                        "  #("5W77NT7$$Y  #L   #("VD_K:#
M 0    8!:_ NE#8    8   ! *ZS1I0";    0  #@    0 8 #0      8
M      %:3@#2@    #L    /L,3   0 )TA,8
M                                            0     -!,    "8
M  =@      "8-A@     "        #<$      #       4A,3@     "
M<                #         @         =@    ,
M
M   "                 #L                 0                 8
M                0  #@                8                  #L
M
M                       0                 =@                "
M                 #                 "   <                #
M                =@
M                                          "
M#L                 0                 8                 0  #@
M                8                  #L
M
M  0                 =@                "                 #
M              "   ?;;;;;;;;;;;;;;;;9[;;;;;;;;;;;;;;;;;;4;;;;
M;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
M;;;;;;;;;;;;;;;;;;;;;9[;;;;;;;;;;;;;;;;:C;;;;;;;;;;;;;;;;;/;
M;;;;;;;;;;;;;;;;/;;;;;;;;;;;;;;;;;,   __ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#T                   0
M
M               "                 "                 "
M         "   <                #@                  0
M
M                                  "                  0
M           0                    #@                <
M         "
M                                                      0
M            "                 "                     <
M         #@                  0
M
M             "                  0                 0
M           #@                <      "  "" 0     "
M
M                                 0                 "
M         "                     <                #@     " 0"
M"00     0
M                   !E,WS&WV#6 !H  "@
M                                                  #@
M        <      0" 00 0     "
M                                       /K;WC=3X0CD;"@ 8
M
M    #0    <                #@     "2 """ 0     0  "0"0 "0
M             2 0"  2   "2  0    "20   "2 "0"0" 00         !X
M:X.>5Q"#Z"B!@#
M                        #0   #@                <       0 22"
M      " 2" 0 00 0" " 000"2220   "0  " 0"" 00" 0" 0   2   2
M 0 2 20 "         ,!ZO)D/ ! (XMD 8
M                                            #0   <
M      #@                  0"2 " "" 2" 0 0 "2 22  2  2""""  0
M0 "2"0" 02 ""0  ""0 " " ""2220                      #
M
M    #   #@                <       2 " "      "  22 2 220"""
M00 ""02 "0"00 ""020""  "2 2 "  "  2 22  0 0"2 0"0        @ !
M%C=0 ;KK=!  8
M                        2@  <                #@       ""2 "
M     0"" "00 222"  "  2 2"2000002  "" 2 ""0"20020 "0"   0"00
M 2 00000       "K:+H$:T@#IL).\ #
M                                           2@  #@
M     <       0 "0       "
M           2                       "> .8@K:@9+,J_P! &
M
M   $H   '                 X       $ $ @@     $
M                                                       "W4NB
MQ&RM <E=GVH P
M                      %H    X                '       $$$D$@
M     @
M                 9    "$  %    $
M                          @              @     '
M     X                  $
M                                                   $
M         @                 $                 $
M       X                '                   @
M
M                            $                  @
M     @                    '                 X
M   $
M                                                @
M      $                 $                     X
M   '                   @
M
M       $                  @                 @
M     '                 \DDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDD$DDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDD@DDDDDDDDDDDDDDDDD@   X                '
M  @
M                                              $
M     @                 @                    '
M  X                  $
M
M      @                 $                 $
M    X                '                   @
M
M                         $                  @
M  @                    '                 X
M$
M                                             @
M   $                 $                     X
M'       @  @ $      @
M
M    $                  @                 @
M  '                 X      @$ @$D      $
M
M      (                 $                 $               '
M$                     X                '      $ @ D $@     @
M
M                         &
M                  _ @                    '    DF8          X
M      DD@ @@D     $ $ D$D @$          @   $D D   @@@  $D
M $$ $  $ @D@  $D@$$   D@D@ @                 P
M                                      _$
M X   R.%M.)QZ9(   '       $  D@@@     @ $@ @D$ $$$@ $D@  @ D
M $ DD @ D$$  $$@$$$ D $D@ $ $DD  $@$ @ $$$  D$
M    &                                                     _@
M                    '   &4H;X(!#[>    X                  $ D
MD D  @$D$@ $@  @DD@ $D  @@ @@D $@@D@@$   D@DD$D D @$@  @$
M $D@D@@                 P
M                  4                     X   U-'O3"885    '
M      D $@@      @$@@@@D$$$ $@ @$$  D@D @@D$$ @$$ $ $$@  $
M$ DD@$ $DD   $D$ D  $DD@ $                 &
M                                     $@                    '
M    BPI<N%U'8    X        DD@ @     $ $@$@$     D$$ $@$@$@D$
M @D$ @D $$@  D$@@@ $@@@ @@@DD    D  D$  DD@$
M   P                                                    $$
M                   X                '       $D  @@      @
M          @                   $    $@ @         @
M                      &
M               $ @                    '                 X
M     $ @ @     $
M                                          6VVVVVVVVVVVVVVVVV
MRVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVV4 $                     X
M               '        $$DDD      @
M
M                   $                  @             $@  @
M                 '                 X                  $
M
M                                       @                 $
M               $                     X                '
M              @
M                                                          $
M                 @                 @                    '
M              X                  $
M
M                  @                 $                 $
M                X                '                   @
M
M                                     $                  @
M              @                    '                 8
M            $
M                                       @                 @
M               $                                       X
M            '                   @
M
M                $                  @                 @
M              '                 X                  $
M
M                                    @                 $
M            $                     X                '
M           @
M                                                       $
M              @                 @                    '
M           X                  $
M
M               @                 $                 $
M             X                '      $  $$ D      @
M
M                '2222222222222222262222222222222222222222222
M22@        @                    '                 X      @D
MD$ $     $
M                                    P
M                     'P       $                     X
M         '      $ @ $@       @
M                                                       "
M                                         'P       @
M           '                 X      @@$@ $D     $ $@$@ @$  $
M     $@  $ @@$@$$$@
M               0
M 'P      $                     X                '
M $      @$D$  @ $@DDDD  $$$$D $@@ D@@
M                                  "
M                     '0      @                    '
M        X                  $ $ @ @ @@  @ $D@@  @@ D D$@ @
M                                                      0
M                                         T      $
M          X                '       $DDD $      @ $$$D  $@  D
M   $$D $ $ $$@@@
M             "
MP       @                    '                 X       D $D$
M      $
M                                 0
M                   P       $                     X
M      '        $D$ @      @
M                                                    "
M                                      P        @
M        '                 X       @D$@@      $
M
M            BVVVVVVVVVVVVVVVVV2VVVVVVVVVVVVVVVVVRVVVVVVVR5
M      $                     X                '         $@ @
M     @
M                                @
M        @       $         @                    '
M     X                  $
M
M         @                 $                 $
M       X                '                   @
M
M                            $                  @
M     @                    '                 X
M   $
M                                                @
M      $                 $                     ^VVVVVVVVVVVVV
MVVVVDDDDDDDDDDDDDDDDDDD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDD
MDDDDDDD@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD   $                 X
M
M                                             $
M   $                     X                '
M  @
M                                              $
M     @                 @                    '
M  X                  $
M
M      @                 $                 $
M    X                '                   @
M
M                         $                  @
M  @                    '                 X
M$
M                                             @
M   $                 $                     X
M'                   @
M                                              %
M                                       O @
M  '                 X                  $
M
M      P                                                    G
M$                     X                '       @  @@$      @
M $@   D   $$ D  $       $            D@$D $$
M                         &
M                   G@                    '     !# <X7H     X
M      @$ @ D$     $  D@   @ @$$@@$$   @D D $D @$ D$   $$ @ $
MD     D                                      P
M                                       C
M X     ('L+$6     '      $ @$$ $      @ @  $$D$ $D$  @DD $ $
MDD $@ D@$ @  $ @$     @$D@@
M    &                                                      @
M                    '     %G/G(SP     X      D@ @@@$     $ D
M$@D   D$@@@DD D@    $@ DD@ $D@ D$$DD       $@D
M                        P
M                  Q                     X    $2_Y[AK     '
M     $ $D@@      @$$@$D$D@D$@ $ @ $$$ D@D D  D@@@     $DD @
M D$DD@                                     &
M                                     U@                    '
M         #+H     X                  $
M
M   P                                                    U$
M                   X                '                   @
M
M                      !@                $@
M               M @                    '                 X
M               $
M                                          DDDDDDDDDDDDDDDDDD
M@DDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDD $                     X
M               '                   @
M
M  DDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@  @
M                 '                 X                  $
M
M                                       @                 $
M               $                     X                '
M              @
M                                                          $
M                 @                 @                    '
M              X                  $
M
M                  @                 $                 $
M                .VVVVVVVVVVVVVVVVWDDDDDDDDDDDDDDDDDDD$DDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDD$DDDDDDDDDDDDDDDDD   '                 X
M            $
M                                                         @
M               $                 $                     X
M            '                   @
M
M                $                  @                 @
M              '                 X                  $
M
M                                    @                 $
M            $                     X                '
M           @
M                                                       $
M              @                 @                    '
M           X         $$ @     $
M
M               @                 $                 $
M             X                '       $@$$D@      @
M
M                &
M "8        @                    '                 X       $
M$$ D     $
M                                    0
M                     "8       $                     X  ]0 A
M    P A  '       $D  DD@     @$     @$ @  $@     $  DDD@  $D
M@@$  @D @@D                                            "
M                                         "8       @
M           '  UTM2./K]3Y_*(  X      $$ $@$$     $  $DD@D D@D
MDD@$ $ $ @@D  D  $$$$  D@$@@ DD
M               0
M "8      $                     X '@R8K8R*2&=%1  '
M        @   $D@@$$@D $  @$D$ $$ $ @$@  @@  D   $$
M                                  "
M                     "       @                    '  #)@>*@5
M$2L<Q(  X      D     $@    $ D@D@@@@DD@@$ $DDDD@  DD D  $ @D
M@D$@$DD@DD                                            0
M                                        $0      $
M          X  3@+H,E?G26*   '      $$$ $@ D     @ $$@    $@$
M$$ D D@  $  D    $D D   @@  @@
M             "
MP       @                    '                 X      $  $D
MD     $         $@         @    @
M                                 0
M                   P       $                     X
M      '       @  @$$D     @
M                                                    &MMMMMMM
MMMMMMMMMMMIMMMMMMMMMMMMMMMMMMMMMMMMMMMP        @
M        '                 X      D@ $$ @     $
M
M            @DDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDDDDD@DDDDDDDD@
M      $                     X                '
M     @
M                                                 $
M        @                 @                    '
M     X                  $
M
M         @                 $                 $
M       X                '                   @
M
M                            $                  @
M     @                    '                 X
M   $
M                                                @
M      $                 $                     .VVVVVVVVVVVVV
MVVVWDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD   '                 X                  $
M
M                           @                 $
M   $                     X                '
M  @
M                                              $
M     @                 @                    '
M  X                  $
M
M      @                 $                 $
M    X                '                   @
M
M                         $                  @
M  @                    '                 X      @  @@$@
M$
M                           Z22222222222222222R22222222222222
M2222E                $                     X
M'      $$@$@@ @     @
M                                              "
M                        E                @
M  '                 X      @$  D       $
M
M      0                                     E
M$                     X6!.(%0@  $(     '      $$ D  D@     @
M @        $@  $D     DD        @   $@@@    D$ D@  $@  DD
M                         "
M    E               @                    '%XUMAL.94):T>:I  X
M            @     $ @@$D$D @@@$ $@ @$  @ $@@$@$$$D$@$@D$ D @
M  $    @$ D$$ D                              0
M                        X              $
M XC@N."H#39=!2CIJ@'                   @ D $ $$D$$$@$$@$@@$D
M  $D@ $$DD@@ $ $@D@ D$@@$@$ @ D@$ @
M    "                                      T               @
M                    '#Y)P]*DJO<);'HR  X  $ @@$  $@  $   @$ @
M $D  @  @D$@ @D$$@ $ DDDD@D@@@$@ $@ D@@  $  $@D   $$D@
M                        0
M  1               $                     X                '
M$ @ $ $ $ @@ D$@ @                        $@
M                                           "
M                     1                @                    '
M                 X  D$$    $@    @$ $
M
M   0                                    1                $
M                   X                '     @$ @ @$ D @@$ @
M
M                      $$DDDDDDDDDDDDDDDD@$DDDDDDDDDDDDDDDDD$
M                 @                    '                 X
M       @ $     $
M
M@                                   $                     X
M               '                   @
M
M                   $                  @                 @
M                 '                 X                  $
M
M                                       @                 $
M               $                     X                '
M              @
M                                                          $
M                 @                 @                    &DDD
MDDDDDDDDDDDDDD,DDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M$DDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@   @                '
M
M                                                        @
M              @                    '                 X
M            $
M                                                         @
M               $                 $                     X
M            '                   @
M
M                $                  @                 @
M              '                 X                  $
M
M                                    @                 $
M            $                     X                '
M  @$$      @
M                                                       $
M              @                 @                    '
M           X      $$ @@$$     $
M                                                         (
M               $                 $?                $
M             X                '       D@$ DD      @
M
M                "                                     7
M           @                    '    \0   V       X
M@$ $     $ $ @     $   D$ $@     D   D               $@
M      $$ DD  $                      0
M              7               $                     X   $ZV=
MN9> '    '       @@$DD@      @ @$ $  D @  D  $$$$@ @$@$DDD$$
M @$@@@D@@$  $$$  D  @  D@@@ $$ @@                      "
M                                  7               @
M           '   #HK1<S+.E#    X                  $ $D@   $$@
M $@@ D$@@ $ D@@ $D@  D$@ @DDDD$@ $ @@@$D   @$$  $@$@D@@
M               0                                      0
M         $                     X   JSX "L8VI    '     $
M@$      @ D$@@$$D @$@@DD@ D$$@DD DD   $D  $$ D@@D$D$@DD@$D$
M$@@@D   D  $$@                    "
M             Q               @                    '    [XWGH
M;7=M    X      $@ $$$@D@   $ @$$@$$ D@  $@D @@D$ @  D$ $@D@@
MD@ @$$$ D$ D@@$D$ @   $@@D $  DD$                     0
M                                1               $
M          X                '       $ @ @DD@    @
M
M             "                                     1
M        @                    '                 X     $$@DD$
MD@    $
M                                 L                 @
M         $I                $                     X
M      '     $@D   D @@    @
M                                                    $@
M          $                                    @
M        '                 X                  $
M
M                              @                 $
M      $                     X                '
M     @
M                                                 $
M        @                 @                    '
M     X                  $
M
M         @                 $                 $
M       X                '                   @
M
M                            $                  @
M     @                    !VVVVVVVVVVVVVVVVV\DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@   X
M   '                   @
M
M       $                  @                 @
M     '                 X                  $
M
M                           @                 $
M   $                     X                '
M  @
M                                              $
M     @                 @                    '
M  X                  $
M
M      @                 $                 $
M    X                '                   @
M
M       '222222222222222226R2222222          @
M  @                    '                 X
M$
M                           0                         _
M   $                 $                     X
M'                   @
M                                              &
M             _         @                 @
M  ' W> 5H ,DP       X     $    $@$D@   $ @    @@ $ $@
M       @  @ @@  D $@            $D$$D@   @ @D$
M      0                          _        $
M$                     X&V6-X"<N$]B368  '       D$@@DD@@    @
M    @ DD $$@$ @$ $D DD@   $D @    @D   @D$ @D@ $$@  D  $D $D
M$@D$$@                   "                           _
M  @                 @                    ' M<8WOR@2AFAUWQ0 X
M     $@D  D D@    $    DD$ $ D$ $D D $D$@$$D$ $$@  @$D$ $ $$
M @@ $@ $ $D  $ D@ @ $$@$$                    0
M            &0       $                 $
M X&!:B]8D"0NVL,ZH '      @D@ D$D$@    @$D   D@$ $$ @$@ $@D
MD D$@  D$D$  DD@  @@$   $ D@@  $@DD@@$ @@@ D@
M    "                          $P        @                 @
M                    ' J0,6YJXY!FOKR[  X     $@@$D@@@$    $
M@ D@  @$ $ D$ $  @ @   D@  $ D $ $$D@ @  D@ @ @@  $@@DD $@$
M@                       0                         $P
M$                 $                     X                '
M                 @
M                                           "
M          P         @                 @                    '
M                 X                  $
M
M   0                 @      D          $                 $
M                   X                '                   @
M
M                       DDDDDDDDDDDDDDDDD@DDDDDDD           @
M                 @                    '                 X
M               $
M
M@                 $                 $                     X
M               '                   @
M
M                   $                  @                 @
M                 '                 X                  $
M
M                                       @                 $
M               $                     X                '
M              @
M                                                          $
M                 @                 @                    !;;;
M;;;;;;;;;;;;;;                   $@
M
M@                 D                 $                 $
M                X                '                   @
M
M                                     $                  @
M              @                    '                 X
M            $
M                                                         @
M               $                 $                     X
M            '                   @
M
M                $                  @                 @
M              '                 X                  $
M
M                                    @                 $
M            $                     X                '      $
M $$ D      @
M                                                       $
M              @                 @                    '
M           X      @D D$ $     $
M                                                         P
M               $                 $D                $
M             X                '      $ @ $@       @
M
M                $                                     \
M           @                    '      R&COH      X      @@$
M@ $D     $ D@@         D@$    $@@$D   $  $@
M
M              \               $                     X     )G
MUJ3      '            $      @ $ $D@D$ @  $DD@@   @   @ @$ @
M $
M                                  \               @
M           '     %%8328      X                  $  $@$ @ D
MD $D@$ $@D$ D$ $ $$ D
M
M         $                     X     (33\:P     '     $@@
M@  $    @$ @D$@@@D   $D@D@   @  D$$   @D$
M
M             H               @                    '
M        X     $$@D@$ D     $
M
M                                ,               $
M          X                '      $   @@$$@    @
M
M                                                   ,
M        @                    '                 X         $ $
M$@    $
M                                 MMMMMMMMMMMMMMMMMM%MMMMMMMM
MMMMMMMMMML,                $                     X
M      '         @         @
M
M                             $                 @
M        '                 X                  $
M
M                              @                 $
M      $                     X                '
M     @
M                                                 $
M        @                 @                    '
M     X                  $
M
M         @                 $                 $
M       TDDDDDDDDDDDDDDDDADDDDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDD@DDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDD
M
M
M
M
M
M
M                                 @ @D  $        $ $      $
M  D  DD$$ @@  $ @    @     @        $        @       $ D
M   D     $   D   @  D @@  $$ @  D     $          @@D
M D                                                  $@@$D
M$@D@$@  @@ $ D@@$@DD$$ @$$@$@ @$  @$ D $ D  @$$@ DD@@$@ $ D
M@@$$$D $D$  $$D   D@D$D@DDD@@   D@  @@ $D D  DD  D $D$$$D $
M$ $$D$ @$ $D D @DD$D$
M            @@@$ D @D@$D@$@ $ $$$@DD@ @   D @DDD D DD$@D$D@D
MD @@$DD@  $@ $@@$$$$DD  $@@$@$@$$@ @@   D$D@  D@D @@D@   @$@
M  $D   $ D D @$DD D$D$$$$DD @@$D D $ @$@@
M                               $D DD $  D@D@$$@$@ @@ $D  $ @
M@ @$$@$@$D @ @   $ $ @@$D$D@ $$D@  $ @D@D@ $DDDD@@ @$$D  $
M@ @@D$@@@D $D  $@ D $ @  $ $ DD@$ @  $$DD@@DD@@ $@DD$D@@$ D$
M                                                  $$@$   $$D
M$@  D @$ D@D$@ $@ @@$D  D@ @@   $$D $$$@$@@ @ D@D  $D@@D @$
M @$D@$  @$$  D    D@@@D $ D$@@@D$  $ D  $   $$@D DD  @@@ DD
M$ D$ $ @@@@@$@D D@@@@
M
M
M                   $@            @
M
M
M
M
M
M
M                                                    @$$@   @
M  @@    $@          @@    @       $D$@ @      $        $$
M$DD@  D @      $                @$$      @$    $    $$$   @@
M D     $      $  $      D$    $@      @    $ @      $@
M            D$$DD@$    $@ @ DD$D@@@ $$$  @@D@@$ @$@D@$D@$$@
M @$$ D$@   D @ D@  D@D@@ $ @$D  $$ @D@ @@ $$$$$@$$@$@@@D  $
M$D $ @@@@  $     $$$@D@$@ @DD $$$@ $$@D  @   $    D$D D $ D$
M  @D$ D D@@$D@                   DD@$ $$D$ $@ @@@$@@D $ @ @
M@@@D$@D $DDD DD$D@$D$$$ @$@ @D$@@ $@@D@D$@@D@@$D$@D$D   $D $
M$@ @$@$@@@@D$D@$   @ $DD@  DD@ $@D$D DD D$$$$   D$DDD @$@D@
M  @DDD@$@$D D$$ D@$@ D$@@$  $DD@D                  D$D@  @@
M   D@ DD$D$ @ D$D$   $D @ $ $$ $ $ @D@  DD@@@ @DD @ @ @$D D
MD@D $@@D@  @D@$DD DD@@$ @ @D@D@@@ @@$D$ $DDD  @ D  D@ @ $ $$
M $@D@ D D  $ $@D$D@$ $@ $@    D$ D@ $D @@D$$$$  $$$@D
M           $  @ $    $@  @  $$DD   D$@@$D   $@$$  $@@D$DD@
M@ @ D D$  @ @$$  D@$$@  D   @  D @$$  @$ @ @$@  $ $$ D@@$$
MD  $ D$  $@@D@  @$D$@$D  DD D$@ D$@$DD $  D@$$  @$D@@@$$D$@@
M  @@DD   D@$                                   @       $
M                                                      @
M
M                @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*HYKDU:/DI&G-<KR4FGNE1$MO"N%<ERXO?@.0H!BS=Y@CIM97L1,KU1_X$
M6JN "60'-A6)5;I=S#,"J&UEV6(M3L$IU9K,VNZ)RE!R'%BYA&CMF9\OE:M
MQ7 "JT$?43T[B [0"0MR\OKYE!PL9\X"PN^!>2I00(BQ$1P!N(?&2&\4Z_ :
M71^P/)=R51QXP[G66-53.J+!J&/^E5>(H!!M*"DUM0GG[ENZ,$*2]%6R7MG1
M"N4?R!  %JKH$0.M?8$3==.]01=D$$O3 N]87M8HVN=(A[[[HLJI=UEJ&PI4
M.*"G:RVB[BHWI,1<9%<)4%M]=! 5:ZH&T=:%[::/A)"/TF&&6C89+[K#I\!C
M2TT>=+A1KB7')4P*B^79<A94]=;4*.)AJ1FI2)@%K, !EJ5A'E=&04D)H++
MCF%UI;"O&]:$8Z(/P4'PJ8(1ZM>]B@G/8J2.E$.2/@KR=4!]SJ8YBN"QWY4:
MX;![T,?PJ$<:06 :YD<:P1K#*F &B&3%VN*5-'J^QP( KD$ZFJ\>\O\ E3D"
M5R#8L"BR$Q63.&@"T, 4P"PUTR#W%XG3 Z,S,@CY+<I"8J90HWGY,VA]@,@2
MP,(F1)K=H, V<6#F@,H,PE%:9(.$;1R5=4PX0XL.JC?JB]D-TT9*.4UX P G
MY@ZP+$1L3X$;RBT',34J4(@M-5Q= *%YRU!^LPHN/_FN]\0VE2*\DA1@):7H
M (LL^(SU#4924'V%BL.&U\K[@IZH.<W"^Y9X]YBQM:^TIF0-KLEAHAV54B)1
MB@EX'8_VTE=H%*VMPI1QP(*2"K=Z QV+'5CJ2QW$-Q)FA7,&M:VGR_J.'66<
M5XI6@0AN80^O76MLFH(# +A)'KQZH,!(5:I,"Y6="&41;2P@<6<"]#4Z!T"
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M2TE""UJ<WS<$QT:Q'"(Q68 AS,$+JN&!5M6RUKFE(I<(LQ4*(F')9O?=1OG
M+N3;:/=E*&Q:P-%9'"#V,DZVJ0>ET@V-,.&NL@?ES3H@40*3"@HM%4G'6T9
M5MK*TMHUBI@($?C5= L\S0@VY]J-XAP/=1CK44'5A0/'8Q;8KQ> MYL:+%YJ
M8HB3@N2+;PX/D.J:;*N88E@/[$!6+0E4<$Y0K  *P*S1<NA+:D1Q9G(@@Y-^
MPV0@;?AM-$04"AFD(W%,,+#2M(Z!+5JNJE)72Y9),%9'"E.I8#H40S>J**GF
MXJ]+>L6 1/%CJ+S1$^:1AL""LK6>VLA0[2^HV+NP!#<-TT3H4[$)KH6AD[@)
MHP3& RG)0'665!4,I2>C][V1 V[_ %!-!H9.DJ@U\0 01OU=6T1$"F"J*53.
M=S:B"+T8CUG66V!:[(*<,4M"4)&X&EETN6$(Y*.L&V]8^A+Y_LB+::B>8*:J
MAH%:'L;<+Z9AB$+ 2XP7[UDSR>*VB&Q2Z![,A5<MX'T!29<C087A<T4?*!DG
M6U2#TND&QIAPUUD#\N:=$"B!284%%HJDXZVC("MM96EM&L5,! C\:KH%GF:$
M&W/X6HW21;,H11D2P14=F?PI:T5BV4Q4@  !08 ^*D$%G2$JNZ.@O881$CDS
MX(QBLO#Z-4N1HY\D5+(7,D-M9#H"L9XH(65(YHK=[2H!%7BI\RU57C5M80>E
M1AQK6+HJBPM;=:\3.Z+1BL6 V)D(LJLR@$Y<GZ/#?6<5Z^RF<)!PCHJ#8'$U
M,?.DZJ1Q:G(N88C+[4RL17>&YQ<3&WAIA+ZWLR7-SO&&9D*X6898'"J6 5:Y
MKFEB= [#N59$D:VHR(-'1BM;"]#-1S64+ +88CF!=AEO1C[A:*Q=0JVAE"5-
MHHAB[&F,$'2[9A8&*5NBJN;BM+4*^V5#*ILQRD^*A(NA< >XJMR4. R]X_($
M=5.J&<A&W"7RNH+95:'NAI?1*<0X$G65<;:3<<JW H<@*AQ3K\%"+R-EV][-
M57,!5E>A1_B!C6?_ (KU]E,X2#A'14&P.)J8^=)U4CBU.1<PQ&7VIE8BN\-S
MBXF-O#3"7UO:UD6Q.G2D:Z+<O,=<CZR%GG-(.9 HI 'P['0*ME%957FSD</@
M.2(!(DJE,!Z)RR6(+5U98<XB*O%3YEJJO&K:P@]*C#C6L715%A:VZUXF=T6C
M%8L!L3(1959E )RY/T>&^O\  2&\4Z_":5$+GD_2(-V2PM4)L,O-*M)YJ0L>
MT(+U@9\]592O=AMTQ,!FI!*9I"42N_T"^:YJ\U*\X(!1ZG1QG*++'DL5+KG]
M$"? RVB>AT ]O(0[U/.6=NM_B1Z:JYA6-0T!F@099I5:(8@2[,U+5O0HJFO\
MUCS.A)8H\GMXIU?!?3VY8CI4$$$HMR,%.P (7R#&PWO$<-O@FH@@(YH*HK9)
M<)4&+>@ Y%? UP!+90[IE0>1=>GD?I\!'6F%VVFX2;RO#1L6CLECV)=.$N"'
MW 2M:Y!"TRV64^?(8.,UD-B2S W%Z!*6F*I3JTY6CM$YM0>A9Y,MJ1'%F<B"
M#DW[#9"!M^&TT1!0*&:0C<4PPL-*TCH$M6JZJ4E=+EDMB:3)6M A!:3I40R=
MU#C-+)-7D:(.H00_/+$*&^ 5!R03C]58(.2"<F-4(,+M5K9#(!9@7YIO-QU2
MG+01@':C>:+J?1Q"XRDYC(J5441;5YFA<H67<!0*G[+62V<;R$7JT@F,R\I>
M1J68^I*EAL65>W2522FIEV+]]3<\IVE)*G&E9YM@#T&J''$1YRX%@*E5:$0]
M"*E6 PX$G)C)BWI)UHQ3 Y.P1QS"9:<ZLX6Z09WW=J@TZ9H]4=FJ/O9&-33&
M]0)BQ0RQ$6Y [CYE* -LZ=01 ?@0%&1$PC 3"5&@#56%!6V 'FV:^-OPTV-U
M0-F>OP:7?RAZ6"W8[52_5]X0:=GLTN_E#TL%NQVMHDN2RPM:8<_PNQLBH "V
M4#44P@,3Y^R, &!5B.P=DF ?8,H:O(F@103HW:8RKE?@U!49T?K)J[,(,'+O
MO\ATP\UE*A<.<THWB6)?.PRE7WJXUSM!EJ3%@M@)<9UD(75H2!#TJ5VO0"T<
M[><QT]XN1F%.:9CKFJ*@QC7X?E.!-=(6H"QB-V5-<,R7ZER%:GA1( RES6H1
M8M3+,>3A'PK5D-+]+QW#W@735HNC6*L14*D:>T6U70U$H,E#,MQXH0^N<<ZP
ML_$+*.'-PQL88='3TZ^]% C?5$XEU76AY$;LJOP)4$5W@=TI%I1RHBRT:&2
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M\$Z.UK(5(3FS(<RD9JM684X=XA-X6*"I$)<*9 \PT=@-+J>2PV$H$(T! R
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M %JZY7/<@08WI;O[*U Y4.NI$X"[%S2623?(J 0O8=5]IFC])4V@-(D4S:V
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M&P@@S0T.0.S@7CIZ."^I/TF7*!RN^G;QF1=SS!>M$VX;Z#@MJZTN!,Y,E32
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M'U2A4AFW3?\ T>TED&9B@S491I+(,S%!FHRC2609F*#-1E&DL@S,4&:C*/\
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M?"O3ISF'>S!4SX](,T)2QAS1J8/*2DK,"ZN&HYKK#(OP)@1V1J :%U.$]/\
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M='*K9K"E:AA8  "9AL1:)S04/4C *F#.-IK@LYEM#Z!P7A4P&FKRHB=5:B4
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M+=(%@AIYN 6@HH+7E&)!$)D1FC,*(G.FK[1"5 HMZID06(6$OJQ17>;PEBE
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M< NR+L!:A&*4P,$*K"=86)/2VI60<A(%5I!)$,2$AO8*%4)8]C$J!3;U:'9
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MR1R!\;"A'2B:UKHEU2-$5EJ@0R4O!B"N)7N3%#1!!8E0.":J,%5A7D<XB<8
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MFRH"GY@ZT, !:L,9\%052VJYCG @-G00-&TWJUB*<+2AU>8",%2K:@1IJ'O
M3(GD[SR;%/AQ)EB4(-%U/*KE<3T2V746X=<]F+@0P^CJB+.H/*9<Q5*1GJ"V
M_D.[EB8EG'Y! $'"(ZC+G&#W8+K5, '6RGS91<P&VS:#INV..M:=85A'2(!
M!2.1&9J:<]6/H1WP%ME.%&LM94MJ#O0S#EES@KV985UE)I\LRR9ME0%0F03
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MDPJ%VNDZ*E2)S33AJJHC*0,L+7<.LNV.[F,3%A>:B@\^Q3<<RYD< &W( O2
MRBL97,(")J0W.<P"M8=.:"61@P!#('?^ G9@C&BYXM[-!/8(,=88H:O607;"
M^??$#C6ZP)"="9@A7&"O2:HMA+FG('O":QPYY%CI=WTBJD!J"3Z)49,%9BAX
MHYLL[QV?OST7/[D7D- ;<X?,P)%77'TA#=$R:$*!3$N3UHL 83/R)(30:&#C
M5]S5!F*[*0GF07,^:]^]\HT>O8FUER:(^3!L$D=UV 0LU*Q%#JU+>9Y?PV)B
M6<61 X$VE*VBPXE"X*HJ6$%)\@G*&T@=9+5@(2V]>2C7C::%QH?%2(_R(%(J
MAEL4:@&IB3$D%,FZE9<F#!%-:M6Z"4R)?EME%15>H-0A9_4%%MF-UH8Y(2HZ
MRVM P^P$1)WJ]JX5@U%F  !'\VF72)&A!,5C0UV5GX@KZ2K-"E=%F*IPKB!T
MBTQ*UE:I</* 0T!5]B;OL6"M8U!:5VE, ;1*H6RG5 '.&] /(L>4)S&7@K>(
MJ6\=]<-$'<XOT&:!K/:9T#)MK@ :JRF <H%4I13HA&(1"SN%=92-TCM+I^U\
MZF@VBBCJPM( JU69UFPUFH9T#)MK@ :JRF <H%4I13HA&(1"SN%=92-TCMV+
MBLGYRL0ZT/\ BJ:^LY[54N4H*#68A!4;3CP * ^=4B]!NX:AH&T:57<&-5)Y
MS:BSS--8!V#4)4-4+ T@LC%;J2O:(EL&\C((,53&*264'A '3&D+=I$BE7JC
MF(T%IRH$0Q@"@S0;IP/J5YS21(B2.,Q>,)NF]UQI*F\^=J>PHBH5"Q:I(50(
MH!47AL_EXKUG!.AV!IB*#&>M*A-"=(X5L-J'WFLTATM<)%K*TB5:9F\K4(EC
MA$341E&'))UM3#'3V+*OYPTT@V*R>=3,$6L2QJ$BA@E*BVQR20CRS19#05G&
M,3J3:L5NIWQBLE+-FB$NF$B><=IPZZ:YP   "(+(L!N8JT:80 "+YN[*J@5"
M9S:P5>:DVI$.%EL(:,__ -CLVIT#5@JH^Y'242P@YL9T6)O1X2VJ9:UE?0A-
M!452%%73ZHDTPU;!!(N%A OQ0QAH"6F"D!R*'3<T$ '4&Q!BC880-I#0?9A-
M2U0*^K4!=0@LMJW+4C :\,&M$'!.J[@WJ%C@K -:(RZ=46N6)TL=)1;*R0MQ
M$,3.U%EL$1*ROMYCYR$X6R5/DQNJ5W(58.:G(Y<IFTI"I1J0O@?^$10O"K:%
M]8:-(+Q,@W=:Q9)A&90SEJE(R12J7TS*B4!YUBLNX&2NA7K@>90,(-&V$M)S
M!G2]8#3#%%RI^V)J.%-&>-95>&)O!Q#/7-3!C:30#24< [H!J%"TJ;4VV7%=
M]CXOJF2T.@E@>,%*!Z&0Y*O-0EMT96$>C*)2 CJ45!?%45HBDI8]]VM5VH5B
M-#=2V;^N_$RX:-UL.,?I'"ME!9"=<,7/"JH18E@0KG"/DY(**FU1XTMQ'/\
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MP8A8R6H.3!ZU1:"9ODF!K!;L>*D#7GW3E0JY8T3IF1P,Z -"A)HO\YUP$ M
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M,QJO>)3+^VQ=+8@P5,E>R@L_H*M)S)@R-F@F6H5:@8ZRUM*P1BHB@*C2PAP
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MD$A40>D*2.J6RBQ2Q:&'V8SD,NO>#@U1-Q"6NW#NN59B"K;.###40"A>>&Y
M8M9Q;3P:6*$:AUI5IS@*O: )/0UJH>$2V,O*0>@!P2!U@D)5I#16#2H>!",C
MK(* 4TNT$S?,0R,9(:.5"(0':6THT<A,.@M0/8. )2EFF1U+4.9.<6^"U ?R
M YY!#39U798Z-FSQVT93'X3B[PR$1SULY_:#9[KY5 0K8.YM-XE<C8 4IK>,
M(EC6F)TUSR]^R]'&J)A7 R69.UXB7*X@J\%8+S($>Z[-:H0 P$IS*=+K0D>H
M<CLT)3/J.$:"G"L ,KWG#0J6U91P 8:5=E!*2Z;5<:B+FK^ **K+99:2#4,3
M+"*9C>5EY27S'W)=\CPVEEU:Z JXZ_@;]-0'%7HC+K9SR<23ZG6%4(<!D(I6
M;*!21F^RL86 >;H;1J6#!O.MS&P-4KW=IE  .877,[ VL_0M'@7-L^$E80VR
M9@Z+J@6YV'0<D;P  !:LRDB\ 67%')2AS@,$I=1-<"EI=-Q;^W4VMJ!X(9N,
M;0!( J*%!LE!^!5\I:,BE-0")D<G=GB**O   !*REUE\(B@J)<5CNGX5"C1@
MB#KABD8FL3MR>\!S1)(.%(WR0K@#5R,.NK-;:E&J]N5+659%43I\YP<F-M:8
MJ,D@.F:0]$Z/ G8K3D5FN,W%YAXX.9!WO8 \G <' .6-/+LL@T4HL,4$"UH[
M&B49XR=7)F(FVC\!D^L[ [NO\J\9L?W1&,][IDGR>Q3*1/5QO 8ZI(AZ /U'
M^)B,["<0@+UN@:VI0'27/9KY4M1/!:UN#02.)J51>]B&#,X;4U]$:U#@,+$,
M^X(4!)UE,T990P_&12MHI R4@Z#DB.#  +5C'0W*&,4%:P @EHD,B"@TT %S
M!;:)A_AZ84Z[BK\@W/5E7+8JCC^GR3S+[G_@I,(Z8*@B!;(?HRDE%K!UL&NE
MMUK3I*]:W9 #;<M>0\T[)](K/8G-F>I4S0N%P@P\$$UBCE'212@S6K N7+#2
MV8Z(P-XV]%RE:=%JG?607N'7V0AI;,=$8&\;>BY2M.BU3OK(+W#K[(2O"P2<
MSKH.J[,V@)CR<< MH:!?(8X5W(ZH0W33,YI08P^*?_47"Z*D!A;3+29#B  +
MU;UWP[^$@Y3"29L*S78C"NF6CWA,'4CR4L1T#$$H(%8M! ( L3(C!70%M+:B
M!4U<ABUR2LTUJ\=HI1_2O0Y'"#O'\W%>LX)T.Q 870^FS:(O(6(%2%M(^!:.
M-7*/C'(_.Q S=FY0]:">O,EP>NFQK3"+ =@7%XT#)>)E@2-&$;H887PTI-W0
ML5/-+BY32!)L*U88A([J&&P"(V"G<:063C[KHJ-I<[F$MB>LVO%$*%,A8S"P
M#($9+D8!9=Q".;79'X%=RD!>W 3=OI:T47>E!46(+7H#7,[)'F.T.66>B1AA
MZ*(!4ZU&K\>E-?D0J=$NPE)L_P"'T*8$TP92]_3UJP)C1:HP]?%]EK>L50 -
MQQ#_ &HLD+YYK"\1O([ UU?0,B5<2_GMB Q=M I@U<H4:NA"89>0%#):7W0-
MUAK,&0HP96DTL\XY(C35SB_5/)S#*FI/8<U1:JNZO @N\M9 PC72RF%,RG7J
M=M%4M57'NN%'@"VT(&F4FX%R^Q&FO#U]]3&4HZN%)!Y^I,A)^'U\45Z2MU@9
M;JQ"Y8;R+8&'M!((B6.I%PQ @RO2RI"@HWVPY*O<9D:0#4N@SF<NYZ#2Y,?M
M491(*078[*%9PP:_);KN Z /YIP"@'<EU;$ _#<CW[#XY21G,+I(J 75D(W:
M%7B,0(*+$EPG:U? \[(>!Y%_D5"N%%AJ:(6 70X-YTMB &7IQ.-*X+ R2!(O
M-N-JAI'1@:P!PI0<$(3B2RY04(> +4I>&L:(&>5EY27S'W(TFV:0!DC'X]8
MX5% TM)50066$:H>3RZOE SR_8V=?@HM HIRQZB:-/&%K'-_5G8E[)4;:]$L
M]89#"!M8T'))N3-*,X\D6945DX5&NU<(E.78L #',2+2R()-%>XYBH4M\J#J
M]U=06Y1ICZ+"5\D'.-J&A67T8M:UHDPL64MO^ET/O*RU=GCRDE"A5HTRN1(?
MH'$RU1+8RJ@46S'00?01R"K:@<"S>Q<X!12KT*'UBA4.6V:12(C8F'L*WRA%
MT5:N-;<9C<,F ;D%E@X&8$2S97:'#4*+S, !:JZ 0!(R4W@WJWO1CKV)FMOU
M72Y0VK;V!S/(0A$4 (C8]A:@=@J4G0/<Q"1(VW1Y[:+NHR0O$/'W2D%2H"7)
M^"NGA0,^M*EF%@&0(R7(P"R[B$<VNR/P*[E("]N F[?2UHHN]*#HD00O0&N9
MV,2M\H1=%6KC6W&>P%FA9!N<"=&RZJQ\/82^@J&'$!R0@X0686*]2"4 WGSE
M0!,93I5A"4+,FWZ_/JS6,Z$L0?BCQ"4 [4ZR1=SKL0.C,-4360BJ"!UJ'I$L
M$"5[PT]*,VQ$Z9*(R+ $ZY1MQ"@H)4!* I%ULW1=Z=# Y<:C8S57/_#TR)E5
M)+,L_6^YT$@  !08 .1./Z?)/,ON?STM17]&7@&Z(;=D@J&/6_$8BM"ZL4-"
MT*$,Z(*IASA4QA'"^1E8$(E11842L12D,7<IQH^B4=8S,D#*VP"9]:,43=E>
M8YPM-JP-8)<KE*\H6CYVMW1 *C-63.C7FUE;8500Z-8.C0VBP:L)<KE*\H6C
MYVMW1 *C-63.C7FUE;9B3(9#D(&<@Q>8O"RBB58B.X)B_$V<+>K0 =#!B:@J
ML^5/ZKDOO_ZB[8J5LL!W1PTSB!_4#=Y LF^(624374G2Q'+ "-D'^&D12H=\
M".!%-U '24:,I4:I0YR! (LALMX4KP5\*9"J%81B']J@,KI33"J=01 ?2, &
MSX6JV 8BL&-.'#.H8(&8,;B^APE!6+;JKS_+Q7K."=#L[PL@(5%DS;RP<(;&
MRU/!A(:7!"E6#SP/3L:VZQ+CN_$.-!(KN-@2;H:!RT**!P * ,1E6=?%-&K0
M)"KGIVYCC[%M"5U/DY$7DMOVCVS)=30QI$J6EF>JZBX= #E4KZ  _JRBB"E%
MN[E7PL#1- ZV;-?;$=;"[+IJ<JGB=MQ1@G#1C5G30*FQC24T.4TT>L.O"M +
M6XU,3&O3!D4(H95#]O?,:=QX%YW#(B&@:0:.B\BJEUY0[+3;X"Y$$A;B#S31
M<J6BV'LCM=EE!R2$"X^4R5@NK>7#$.49R\'!"@"H=#9MA03S I"@P2]G=T38
MAX45@HM3S8_:!E<8O,G0RT(^-?J[O/$D(DW'-=>HBX&%$5(3!2J3#B5_T8Z9
M!%SR<>=D>G)2VGKPU 6G, UL*LNFIRHA@ M',:ZL*NPI:%XX (Y(O-(6BJPJ
M@GSD"\ 4"%M.8?+*UBL*:SS",S^_: T.PJM&55R]A)&B&"F5&CI6*MN-IX8U
M!-9J57:R(D=/@FNL$"%8!@=;D,$NTUZLN\WB"-2V#*&90:AY+ &5AA2\ 46A
M.4)98--'5F%(-H8C,:_SFK05J4YG+7I8CAW)94K%=A><^CP]6:WE*^QHG' .
MN67CG2,PFH:$$K!F@\[A'SZ<"--T#LYK,O);*@V65U8)TK-+G?EEI:JO8B3(
M%@J3$1*8MC4/-J")R&- J!]Y_P#N710N30@. 9=PX9:5KF++2M/KRC'(&(TA
MK_3C)Y@0V"*I6'H,.8+W91URK,WZ1Q>9-)DNKG,]^<,?X!:-F(IRB.+"G6AQ
M"RB7B]1(;!4!RM0R#!*!8,%10Z"LIXGJ422]+JL5']^"*D.E.YYQ,Z,35[K5
ML !;"D 8V@(O( '9;PFW"W9L8-;<TS-.,*4N4]; >B0QY "*/(!1$S.^_P#*
MAX:< #I66T3DK8UBZ[+XE'VRCKRMS+:.5>6\(4M%LE%ESJ26-6A@%).DT><6
M-O"J 6JP+(B:8F:A88_<1EG4.6 #0H"A1HF28LGK!IYTA4UQ"3895!<3E4H&
M7C;'1=%(-KAY<M$ <1X#("A("M7"EC6Z,##5:=)HDZH!-1F.L4H2P!^J!^L%
M[(#%6**'2^N4 /2P*FW."4H)U$NM]HN54JYOC"IGJY98TR@4G*44;![R#2=
M2Q^[AD:CX7@HYL>V9+J:&-(E2TLSU747#H <JE?0 ']64404HMW<$V@(%[*%
M@L1AD[)$Q+.K P;S.DT2=4 FHS'7L+KGP+">ON5ZJ*ZHHQ-*+2D-1&"8O1PC
MC<10&U]JI4( %-67&.8NH8=]"5$*Z%E2Z(D&R[*BEAA0 "%ZUR/J<=(#T)9&
M""$+99,"Q8@>7/$4,1$:1C^2:A\2HZ)TA=PJ$.139HQ9H1=(1?+N*TT0 4=A
M?7: 8QC2V1>?^')D3*J2699^M]SH)   "@P <CLX_I\D\R^Y\ZI%[+V6  ;Z
MG7B^!&UH% 3-ONB+TE>3QI!TFXH !',X4,BJIQEJ[5VJF"IK<HW'2!6%T+'"
MZH5?K$ER BS=I K7S'.JZIDRZ%$S#I+%%C%NYI5URO\ EXKUG!.A_P"O71J7
MSA8&3U<_*<[DHJIH=GZ!IC^(J[D45I@]7)FRR49U=\,\X$ 0-D5V@U8 XV1U
M&-4U#_Y';R/$.&WFM-!8*_RY,B9522S+/UON=!(   4& #D=O']/DGF7W/G5
M(N!%?FB2:<.5 RQ^RJ" E5%?>3A99H J7<26 M"K<BO7*FA)6)+$F,M6JEI$
MRR(9BD @U?<M<6J;,[6]M]2[<@92)EE9_32.A!E5[VFOH-5Y0.9$)^42O3HA
M3H&8H+EPE11L5HH3#_+Q7K."=#_+$#[U7\L12%PCK3OZ7^1UUUUUUUUUUUUU
MUUUUUUUUUUUUUUUUUUUUUI<8#0UWM*WE36\^2:ZZZZZZZZZZZZZZZZZZZZZZ
MZZZZZZZZZZZZRC<=H!O1U_\ ;7777777777777777777777777777=++B[SK
MRPTXQ8D%CF;$%5FR   "@P <CX./Z?)/,ON?.J1<9A2.J#Q2NHN"QSD$>^A\
M&/B@K>42@*8(RJ/?WF4$E B)21FZCQ2W*)R+H!*\,)-S0'34O0$!S4@X6@X
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M=<1E!4O*SC^HTB_%>LX)T/\ 4-^*]9P3H?T@'Q_3Y)YE]S^HTB_%>LX)T/\
M4-^*]9P3H?T@'Q_3Y)YE]S^HTB_%>LX)T/\ 4-^*]9P3H?T@'Q_3Y)YE]S^H
MTB_%>LX)T/\ 4-^*]9P3H?T@'Q_3Y)YE]SYQ2+J*XW+A5"Q5<R7)XT(#NAN
M U9V!LJJD):OH/<:Y[6@(VO+(*-I@1!#@D:5%B0 KT16Z("4R_'6Y($&4!EB
M2NM\%8*P5A!H(!OZ&J^%F8Y# @Q2#U6.2>2B " _&$KZY-WZ$T-44B6(:)"#
M5 8(@'\?%>LX)T/\L$:![(1$<\Q\DCQX\>/'CQX\>/'CQX\>/'CQX\>/'CQX
M\>/'CQX\>.V"W"&.Y1^HFJY97R3'CQX\>/'CQX\>/'CQX\>/'CQX\>/'CQX\
M>/'CQX\= WRL*0YCI_XH\>/'CQX\>/'CQX\>/'CZJU?I"BO) %P; _\ AX_I
M\D\R^Y\YI%P*_P# '#=%G.'%(3++UMJA553*\T+=BX+U=H6K]\XTVV*]5PE!
M%MUI$) T&!HZZH3F^BMV9+PO#*D%4A8E6JOGE!4K CK6G4=[V(0,\P10NM:J
M<B8J&MBQ$A@BOF#9;8D&2-I V-%VOY.*]9P3H?\  Z9$"!!I$T1@+Q4  P_]
M+['_ ,+Q_3Y)YE]SYS2+@0[VGP(:3(=2$!>59,AEC$8B<[?8*%PC(](J>R=_
M3>MD/5G$3TR )@FRRM<1Y%#[*V(*N+(A)?NYQ)]^VJV@U N5/I;,%P!H"D(6
M(;8IUYY,R+ F32L,VT(/]:4F@1,:!'/-%I4UJ9:,"8JH7W/+U%<[! 7^2XKU
MG!.A_P $=D0($&D31& O%0 ##_TOL?\ P/']/DGF7W/G-(N!*(B"UU*X3U":
MK</%+!YPU&D*GE$!#S3M'3L*>U>CKN])+UXS))5JY1SK2T:@'$.1A6A1!!3U
M7$6L4L):&BHQ+NXN(!$ ;DZA4SSJ.9IL$E:E(BS':S^B24PR#:8"A@6,*L1J
M%47,1G-ZM=Y5"E"A07_(XKUG!.AV+Y_#U4"U5$:XS'.>:Y1RYYNP$_2>8*;8
M#+ O< \J0**(4S@, BU09N[ \*I@2]39P(J3+/:\)4MR(VYJA%Y\)=8LJ0T*
M\S;B?+08$&5V]I5&<RYH!YD&Y9_$&MS0$DY&!+R>*0Q:;=JR"LG9:#&!IX:E
M& :',4/0$W",.05#$R&[(*@!?;9EURS&'*%FPZ;$=+<WVT)D413$NDU^B[E@
M<%,*I)&#6O\ C/4UPD*5@-)L915(R#27("*Q2%'6\(3*1.I 936A&\KHE#C=
M#E@8FJ+ 0A(C5JL#=?)Z.Q;MRHWT,38'>/@*SKVIBV@O C=;I9JD$5Y9RQG1
M =?-7>]W;;3V/1^&J<'T!^"XA$<E*%G P;S2XF$^OPL6A?+$692I%1I,N'J=
MA9T4B2L50Y 9HK(T<S:'\LM8J2)B\6..P@"PY"5,\FIGK1,!HT8)'*/@<J@0
MM3U"UE_&@T276(;!,L*&Y2L>-<7,=?)8K3'OW,X%B^-RC6E*?"K0X$:X4*L!
MGLJ&1!T@6!<HIAOJ7_I_9$"!!I$T1@+Q4  P_P#2^Q_G>/Z?)/,ON?/J1>A*
M@SVH!$[Y>QX0+FB7V# *L^K:&Y#\@  #  :!V'@&B2.B+?'^7BO6<$Z'8A8A
M&:YLM$JH%Q WA8%L'G##+E4!7P+T*HD"*V.GJ2IFJ:'4/(CG0VTJEU5<O0K0
M$#PY(RV0(C2,KG,J--2Q3MCF'30JAX X<YY"9A$(-4T0P9C3Y]$$57I#'GXF
M='@8T!"\'9GE\9-=!2RQL@=J^095@9%R!!2*?X!<@6(C8D*\/$+ECE>C1:-5
M&#^XJC=BZ1BU(/7$ZRHR9(\A58Q'F"[=RV7E+6F)G$PZ:19:(*7)"VE@%X0Q
M2Q%=U/\ H#1H3!,Z#\0CY$6M!?H"M&K .I!B:$M55]1)O83>HM1B%& 7PJN:
M2SF)8N1#6>LTB2"% NJHM,JURQ-%CR1$B"(E)$6/>AE6=3V>\?R=.9D6O^4+
M]*E@&G1"[&*$EI[!-A7LMCI$FE 94:H5E*%L-A9W'P3R\RR-X.E,0&4[HSW/
M$,="/4- <CD#"H6B2E8 WI'L.QL@"6!TT6G0=1,/;D$2Y0(<#"A;:(Q4VX 0
M@ ]%QLUQ!&=%1C"/^H=D0($&D31&-9D"#2%+<H4^Q_F>/Z?)/,ON?U&D7XKU
MG!.AV'99-AP$:D'.&#Q8%^E@)XPO;\@6B64', D5)LN\B=YP/,1_?E7:CE5Y
M(=ED^,<%6$9.P9NP$0)^, )95FC"Z0*6,:T@*[2J:Q/?"OS+/*NU=/@I%@SU
M'24+=8DL@H3(VDSO022QJ9PQGF M]/=<V$HH6\*4$EP @N,"1E>24J:,FP"U
MI:^KL<:G)H"+,],HY(,2H/)HV\Z"TT"EW*$(I5&9H"B:+K$4O>4#$B_-FJKK
ML:% ]?XCI%I"C0)1^D*HVXBFEY.V1(3E&Y$PEVH\%V,A98G!G-9UME3P'&2F
MHP>C&:_:JH%V0269B@=@V,TGD("W&2"@=;K[]APUS<@,= /UAH$FH%2.B)_"
M+7_*%]XS2>BV#F8=9YQ1B%6DX%"@%!41;K7GE=:@'6)HLZCDK?N1E^.4]8-,
MZ$ZTPV;:C&E=!?OIKV,L+NV0T:$PJU,S1(';2G1H&5BPH<9I4JPIX)RL;%%T
M6K1#<L&6UK?^H=G7NA5 \J30$Y"]V.RF0#0?S8\?T^2>9?<^=4BY('WV-@[N
MJ*V(J-MX:ZL)1SK&L.[?OFPR+EF!"H%JU) %_ P.;FBT/)76Y+,OBU?0BYS?
MZ^NLR!ML.8BW=*"8J*O,@FB(CJWH-WT10#94#*EQ.D-E(5".;K%_F#D9?15C
M#5L@( "#8CHC_+Q7K."=#L9I?,?@CFB:/*R=(JH [X?>8@L$BVY1 -4HB"9X
M@:B1G%69&V0F@)85M,/28FV[.Z9JLH)IH7HG.:<"Q4R@)TS&94Y>0]GT(1L,
M*7C)PS+<4!KW17G*RP')7L.8'U',=36Z-J:M:X%LNECL#;SNY?;N*VP7#V-T
M9=H!8F+%!LO$O7R !:4%$L:2@7G-<B+)16*G6!T>K,BXKW )884#9 $18.0;
MJHKQV\CU"!H#+5_M)*(1,"7&49B*X9O*TT+3RG*8LW$_/,'BU H,12ZWM8-H
M54V@C$<'*#JJ-F\ 'XA3^'*/0N6*XO!HCLT+SM<W5EOO$9UAL,^Y4"5%,C4#
M9CEC&),45*SVBCB"M17X!"^F(0Z9;D#)%K;Y!!*R"1F+,Q:@R[;X402>@AB^
MYY7)N$12FF<F<7]]2C&DUP]@%[QF46$1:RV)D8L_A)"T:LLH%T(:I(WL;!RG
M(R=A??R$Q 62I:"Y3"F@OIPZ(N)!?L 4B]4PH5">D0)B(\W9$4;(P0%%E-=E
MP(KD25>PBIE4!O#ZPT!+@HR0  Y$V5*S?$$=*K23>NMU(*-T@4DZ(7.H%F*&
MLZ=:6;3('BI5-%MV'@Q!ER)N(6+1A_IW9U*K5P/*DT!.5?4#LID0:#^?'C^G
MR3S+[GSJD7(UPQ^I:M3* RD?#=X0+; ;(QT'S;6%I7&IK&@*LH,Y<59L=) /
MBTD7@9-&JB0DI-$6 5/((<34L+E@;RC6;'@V@A%I$"X0R E=P=O-$ZACE',<
MT,< :( WESE5_EXKUG!.A\CQ,V,XQT2 !%O_ &7LZE5JX'E2: G+'J!V4R :
M#_P8\?T^2>9?<^=4BY+&26RL+56L6;P-3(Q+DT!\)GH?!6"#+%%;<03HJ+0Q
M^=ND&ER8/L#"(V)#UCZ5%F  JPN2.^ Z#@N:/.5F1F.:=(/T;T01XC#Q-&,+
M:N4?GD."9C@+8Q&,9L1"U1EE &A_+Q7K."=#_@?LZE5JX'E2: G+'J!V4R :
M#_PX\?T^2>9?<^=4BYI-D54TSMYNZK%W"(4E:>2['@0.E"JPNI1;+ZA5VU@*
M*.<?4PIJ%G[!"0FHK1P8:8R+/B')C]'7%FXY9]CQ. 5=#:,-&@+#E[;DLXW=
M:;/(%M<U]BEG5@6C0H$B\"R2NB5:Y[66E%:!IJ*/Y.*]9P3H?Y9KL4_+54LA
MHD-F"I=\C                                        U+PN_#WN-1D
M%>8GR2                                        !'*0UX$Y'K_P"
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MK*@GVJ@!+ PB9$G!>KMMI"2AT$&Q:&%D/71><K[8?;&JYQT)7/*R0MTU,+!
MNXP;^TL:P N""XT0.X&(JI+91:XJWMI[$**#9 6)S%;IBDNI-<+EEPK[ HR>
M0$)_'Q7K."=#L7,)N!U$@(F1G+ '[""Z+'$ 4#)V>ES._5/*UOSQ-?--R^BC
MQEW#2A2Z%&9UTM:&@_+&(9HQEK10B=W8Q0'BT8@&N"!/1T5#F.H6[($+@6%^
MVVF!AZQS#6F$WL:BB\AP%UR1&-D6PR:G.(PT.,5"1H&\3$\B\-T?-<KEW_<=
M.MA/HP$QU1H U5A.S2!+E3/].Q0W(:(<EMGVB<YLKR64??L-K'=$-:$0PCTP
M013%AV03D4C9993-!7H6U@T02*8P>90'12T8NK)G$.NG/U6 =[$@Q;*&D#C?
M9\2E*T6] CRC4%4"'D68^K\"U0* +3 !&8;3@=:5-,$626"% 4%T, -0BH-2
MR&;Q*@HY'BFDQO# %_9&]4)]&&NF8>M"@ +5CE(M:=$?U2[ L,^.F1JZ[$8K
M=25[1$M@WD9!!BJ8Q22R@\( Z8TA;M(D4J]4<Q&@M.5 B&, 4&E40G77SQ.=
M/>%ZCGUC5J %VT6@994%'(\4TF-X8 O[(WJA/HP$P%1H U5CP3IK>C8?IV(R
M^D0] OS@7UL^^JU?1EWZBF4*9%6AB53R'P7;H47GXCX6P#>2$8PC>*T*6C33
M$7,,0:[)E'2WL"VUU"MI"XN,%4:Y)LSYJY/X&N8TL1C14[$, 6U;T0KBVD$!
M@[&FKNHU2RS2:&T%')=]**V@"$OAH5WNP^,)M8U-VYTM@1FO25'AR9!LRZ5:
M@70M@*&H68 A$W_*D:/H)J4$!&5_"]=F*&M#8 B:=WTNGGJ1WCF"$BBF0<D<
M]YH2E&V(A0&2]U'HG;LK*%#OI#G6<YJ+>2*A.2JHZ-/\Y3&)^^KL/E6OW&H
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M^ VYPNZ @K#.CIV'(J'H4H,/OT4!%>+/0VS;IA<P##&:F 8M$RG&#\!8B47
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MJAKFD@=%&D)VD82V*LO@?^$10O"K:%]8:-(+Q,@W=:P@9966L&8:Q3F2H)9
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MP@_1E4?P0^*.JY8JF4M8UARJPK=0Q8-%02K_ $[UCO(7VD1=Y !0J!!K=,$
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M(-%*+#%! M:.PA:;?!1C>IG=H:\,H C6F6WC&:"+V'CIV"4]\@ OF122Q:B
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MHHSQSK= ;T]?_!111111111111110=067:OI249&LY%<B'0')=79J=F#J H
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MZT"C2Y.G8=*,S&XC7)4TT-4GI.PB!1 KX6P@>ZWK8T)$"P@0@\' A,CCU0B
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MF1*TJU' 5E*SZD?R?1D-WMQ$1NYH=ST&F"ZRAIT+R"/OXLWR[,,_/B)'G4M
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M !.*_P 3BO\ $XK_ !.*_P 3BO\ $XK_ !.*_P 3BO\ $XK_ !.*_P 3BO\
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MO@E J:.:^DW,0'F4+58#,1RWOKP=68A%&QZV'0H4'-@2_4.C6C57=-R4V+!
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M::Y!:=GA4 @_NR+43?!6TEPGWI@)+W"C&?+>XZG_ +^/Z?)/,ON?STJ,"X6
M[T%TOGO,<5,5,TU!8-++Y'8Q]-S#].@FN5])<>*FC@Z;I1?U')5$U%!4!H"'
ML"#0Y]2WEHA4:# .I"1%U!O D%V*S, *U*O-*D'(HL.@T-%M%P*U-%'*:S,=
M:%L8D&[F]:T5AD[!]6*3,%D]&!A:E4U3MA",UZ@M@K@C5A:QL8N0*LP)2TU9
MJ%=V %BJ$'NYH)3D(.BEFASJG/(P!J#FJQ\P+\5ZS@G0[0M':?T (.,:[.P>
MCNS(6 SN'RU5B9=EM1AT8B(HP\\+M87TD@(G>M:>S0Q&9:K(]/I.28@L *:(
M&V<VYL 6Q"RK,QPCS+]8R#U&%JBLY-=GLP7% H%R!'YXE#4C"N "0.XZH*%@
M=4Z@M%9Q;=:!:27*$*U09<$5FG &J+4-"[:X"L584BADG((KA6UI 3P#:;0N
MW:PKJ(W+:U;4)!4+K\;P\YWNN*EG3SF()E(<5VBA%LL0.'PYV&)+H+448F]7
M$QG>=B*O6'R3H:%9)(DLHB#>:2Q042*?Q8:A=6-@XL&ZYI8<BW4G<7A RQ19
M:JA*C(V5M8I%S%MRS!=M3W$IV BVHT$ B6H%2X!@%@P['S:+P-2+JK::3X1@
M!'F5%[^FFQU['<7O=.\!]]00(="J8/'9FPQ@*KF"K.T)T4>AF(H5?(ADJ. %
MW2Z\(_R^0(O*[@&$24%92"FL@(VBF96J#+@BLTX U1:AH7;7 5BK"D51)N56
M(JIV#806518KX9@-2E8$\U@#7W-JT%%%4Y&<MD\6RB5^^=JLW6- WH9L%61C
MTT_(47 <""JP1'(J(P4F;HUX=0+5*^V$S=-V12*B&BU.8+J,CM\/)@CY1; #
MMG-N; %L0LJS,<(\R_6,@]1A:HMJIH#; #R"$1LJ>M/HKP$ ^H(8NKUGH-HE
M_6<*2W0?I'BU*"61U!1ZT=.RJO"HT479G-2/(^%19F:HSF=(_P!682R4L4(+
MZ&-V*LH#D)8+S7-Q %CCK#+8TA52@W(,\@XIO!8%T;70!]M5@3>1M5@7,5@[
M6Q+5A\.T6T/QTMDK1"S48;47C",6)>0BCD#0:$A0R[@7KHL+K("+!P4YHMH?
M>'9(/@*F$*TI+RMC2!L&Y")MPJ/I>T4MO(ZX T'97LAF9J0-:Z/>[-72YPP9
MN8$E@<4!@=JP(T:-U+LBD5$-%J<P749';X>3!'RBV &VF\+I);%13(0Q<:]3
M150FP-13 3J%+6)?,CP5420NA(1,IE4709]K" "ELX[=Y#"(74#TZA;U-560
M2BC>I%Q:%]9!-KB(3*A87%9+2T[@8&Y"K=F;]Z[@>H>2^)>IVJ?M8=T*'*&
M > * , &AV4M"[7M 8Z"G3^7ISG,5_RA@M1Q$Q<K-558N!_"  " & "%"630
M*G46N\@7<=JM,>](*73]="^,&U;YR#7#EPUN4IRZ<,H+,P*U 2Y473\*L-3(
MM!5'^\$6@'#T#=H!5\!E5'_OX_I\D\R^Y_/2PET=T%(CCH#+J5M<19 8M.6
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M41L*@+.1 ?SV'2*XFT%>0L2R#[0[BSVAU P[*5M00R:M3D$J9K&*/M49%7$
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M0-#'*<IB[_832&D1.1!R0XR,W0E[8!C5](?[.2*=-D>UMRQ)$W!#148&G9^
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M2.KP:TNPB3*-/X>*]9P3H?Y8"EI/K-!75\C                 - _;%/P
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M*S0U;. =?P>R-]V/"W&@:X@<4("&X:6P U8Y(ZA%(\NTX%@#4T^(XGKZDH/
MQH*)3E"F>2;Q9)NU<Q@!;K(U0"X8%')2;YJ-&PJ'N_\ $%[%&YE8,[J-P)8/
MOBC/=<WRM8FF&3\0;#(!D5.J/-*U'<@>'.!*N@1(PS(&.' &<:Y<=1ERGW=@
MM+>94Y1#2?N3P.:HT>K:J+] \Y8'2J!<*17B$HW93PJ0T6I.[]9>EQ4(72AV
M,&?Q& !41L BR>1[?"NO[FEDL66U%R3!#1U<^G-^+0IB.'_AXKUG!.AV(#"Z
M'TV;1%Y"]@(KA3^B"<!0MG2<H*LLEZ62"H5I2P7/;16243R!9;22+6O:&A@.
MG+(H9UZ<*U@(%19ESN6/WT#&7#;-$$"CY8MA2% I9)[4@=<F6:Q8.!0.;"12
M,3E8O:&AHF'E ?T,J'V"6@:Q3>(B?9X-6!541,TK&D-UOD93-!(KFX,+XX$.
ME-@<(10+X;*X -]NPUG,/H*TF E50M&C3#"]PNCN4&#;'5LQ>J? (,IFFJN9
M;1-%Q5S2L=(4$"CY8MA2% I9)[4@=<F6:Q8.!0N;"12$3E8O8I\BEG[8A SY
M*A2AP3M"92IS(%7U66H]_#OC @T%& 40+21D@L^*D2@B.&&"PK\*0"G"B#TD
M0W*TBB5FK#IS@M(1.UQ104,,@J^(I"N9 MKLKFRQ0:("I7BZ!ECZ+"5\D'.-
MJ&A67T8M:UHDPL64PQ^W0V\K+5\'+$I%;5]_DWW&/M=LPJ8#<C"\3A/1$\6K
MDM=%-'!&A$)F6I %JU-8+"WWMG*L[$J04#4 FH*38*CW0NV8)FH8 0VFD="R
M"6Z2II=<%# JHT7FO#]90I30(@"Q*IG"2;UW,Z&Z*+%B*,),';CC6TW6PNH%
MYLF/D'!&#-P^40"7)>F,D9GTNXMWPFTR&V9B(#Z,+E1#$%L;PS+BQJ<Z54,F
M!"U2:-:-.I/*R83)286.H0M7G,=_(_8MJ5B%!UHD0X?LYCST=56&U3@YM!UP
MR-.&&S\>K:,T2Q1B)RM1>*Z5ML,J;CM!9=DDO"]<&#P<6DH:;6]5!#9!A65M
MP <VZ*CNNV[5F5KN%+-*(?-RK=V/(H#90[?;0C3T.G0G2UL2Y!VI\>Z>R[>U
M,00HR\/>,@:'-7W704,(M"/,]F4^?[&4PGE@A)SQ/*"K+)>ED@J%:4L%SVT5
MDE$\@67?N;+79E%9%0$3L\JF<))O7<SH;HHL6(HPDP=N.-;2>5<4:JR#I^@,
MAA,":ITR<T@CVAPYX?&>T\C(673V![%'-E;6#E50G6"2+=P:ZW4' "PRD7HY
MXY@S* _ X.HQ#2T7+$##2LQT(VJFV-"#=6EE#TL C3@ '5,PN&O WY]"XZ+J
MSVJP"&$S0Q@^A1>B\U 6\&'8*$]1IT^ R$86:FP[+(:P#?*61MX$+(/JS6.,
M4\&F(HK< 6:(;+(K-7-!= ZA* - _*Z.U;B!+0V0U(%;#%$)&H;39=,%I*F1
M18TJYBQN%7*.:LW4/&CVC_U2$O/7X"&!;IS-$!RK2T,@[',MXK)FI#XNDR-V
M!L19_7T30'P465AD$Y<A8 BNP*!JJ;4*HJJJK\V!\?T^2>9?<_BI/6J4^N@(
MB6)&E8V8!0V8=9DFI1VJ#$83%-3L'A++271;7(&TQG0YU-A/-8])]%$1ZAEZ
M(1S;=9LJ^8$I)%8'^[6$]WRWWC9VM)VR(%B-DY22@=6,QN-THJ*(SM4N@&!R
M"7TJZQ+7&_9>.;RAK:@&36S-1652U"M,L U5R[ ;4:UZ,@<L3D$L  "DZ4[,
MNEX2FHL">NFODWHV8FDL$MIK*8L,Z1[],W.5R0Y2^>A-;N-&%A@S!XQ3U]"1
MH#2++O/G$@,$ZK86$YM$.T&@=O5[P Q=^5I>;J])J @7@[MR2W??^$OJ8S<B
MJ53<&]&R'9/B@8YLD=:TJ"LQ)T<$OJ&IU;A.-M^K#DP5>9 6@&M9&I=-N[]C
ML@-DY+-I5(95*$&-<B'45:[I?TX;3.ZWO:H8+55U55RRQ,IGLK,,KKFQ]N2]
M>P2U"D<TTIY(U= CI,KJZAUQM#KBJ415:K.;WW A*.:!*0 P.MPF VTUX67>
M;Q"U78?IY==%45AV&<]T=,:S0ZBR@7IG2CG&^&7)E+G^'BO6<$Z'9WA9 0J+
M)FWE["^1!V/R^M%-"AI;5'I>[(G^5"*KJ8'Z['7*!@<H!$8= J-8CA$=1EXJ
MV$K&(KRASN,D.L&69-&J$#1$.X5/0!P :*@78PBK8VZS"D1I^4V@0!L<,95-
MB+9A37,%K:,3Z!!;-4V4@VN78C"JV\<OG(Z(8L*E1G6IJJ7H=B;#(YLM=NO*
ME8K,L3%^6Y=M&#L#29CC'4X!=;7(*P.^#*J9-(50&8R,)Q[AA 51+GC9GN<#
MC;L TXUBF4*P<QAD!4@8./8  "!HB'<*GH X -%0+L815L;=9A2,IZIZO/ZT
ML<<PK3C4,XXW$4@VN>%X_P"L&E(9TN4,)T!*JJ%;<2]1,NI:5:.BDY$=&+7+
M @ A@$6H>LMVBV@Y51U\QD1VX^T,9:F&HWGL+NRV"7R)5U-MLPWBTQ=1L(T
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MC.P<H$-.IXQ>9- P.#5BO.;N\22BW L>7DIMRJ/><P,6016JN8P^ #P!0!@
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M&PH1P*F0]-2A7)98[9#0JYBHZ!>"!:F"Z0ZD2R4665,I:6K5@D,0_&#@M!1
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M\CNY8F)9W<U_F'V6V*L9A=.+D9CXZN&B@S00N3&9C;18@$/"+<B<Q RWAX;
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ML'O@KUK-IG!&@-Z/VT!$34_AXKUG!.A_E;HP>1( )DQ)E8.*^GR/ @0($"!
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M=,=SW03F6 #J"Q^-5Z L6@ +< [E@ ZB6/QVT=H(+Z6U! (B)8FB?R F$J-
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M?E0FK+#I':Z=UMGM/'GN*R/2LME4*<0^O0HR($H+NAZ2QYC2*-KG5Y54=-%
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MFR!:+)DI,:PC-_(,1JA<:B8K "*Z1L8TNB^XT\4A;E:BIS3\(2+"MNBHP4U
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M!^(+IY.6]=%'$;PEJ%Z.&@;RJ&S?.5#$=%4\N F%,)5#%.FB2U: ,JZ1@IJ
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MHMH8L]SL1+H1S'$NSY79K 4&" %3#%#"?8=J#R&3;;;;&: 4A4+IV6%(>CS
MEA1J4#BC.Q$VH@Q%/PEV!8!1J^'#U)=!M0*QXZ(8F51>(PN.1*' @!\C3 Z6
M#> [I8D8@/MTCGCY9V?'>F.=@N0+@ 958P4U 0Z9$?6!':"%M2H-$8 34[M0
M/0@4M;TB,3B0"=Z60T-XKE5[A&'3.(R&L4FO2U99-FB_1+X5[/A56\JC98N
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M(4D27*-<2P[K7H*329&A5(.0@,YN+Y]DK?A0LJT!58MEQX KA1@[I-65LPH
MX!FH@EQ2NQ"S!I2R%%D/!TY*X57+7,"0$):@P8'):.W/G:Q2V0:XKC (Y)Q?
MK"MW(KP%8-')=H<? !*5461- Z)=T")Z$_*JE)1Q&+$4;/7VJ6BK%M3LTHOH
M9,9#E9A6&"H\5F@#J"['$I>=$$6H2, *,5Y/\,.'1LE3^E#7Y/ 7HWJC\!$)
M\9!Z%3 PK'0X<\<)D44 ,0U]PI ^,Q<(EG4GOV*C+6NL1DD" U&T9CDV,@P<
MH,ZA10H MU$1S926K+0M<KE["Q".%6,K D:#>4((2ZU+%56&PD@B46GW2:M9
M8:M5%"O8]D@)"-J 7E<<%.IUM#. +:EOA,M.ACSHX@9&@UM/>'0[,2H8#B89
MO'>G)0[6[#IL&J4! 4(%E9',!+5.&63&&M!6T63-5 *K47SE2RK@F^K12FB%
M^B.,#5ZBJ]!6=Z'+ ;%<M6NF5!][T#PHC1OV]F=/>N0EH9OKRH\HM\;T:V3"
M2]5>D,0[)FJ3T*)*+:TPOA$:F7[Q=8D0P&JCF0]+["T--EM#2NRJG7\XBLHD
M-@&VU!QA*M5TE 6)FCH^ .9T)6*F#D#=Z^J:@1T:F.:+&6EM/9\Q"1QD(CTI
M_6;]&RD]4V<NDT)XND3FX2>0]EM+F*$(Q*:*:JFLQU_#)*)68"%F#&KX!+I%
M%W8U@8$%Q-2%,=>6IAT"HUB.$1U&%YZBCT  =T1>9@ +57 !V\^8QC2$<P\C
M5ZT].R;5@H]MQ$%K4NIK(2ZL%<NM7D&A;M6&YG%MP5B*BAU";R'J6(G^5Y4+
M(+F69DTY7@C5&CCK C+8CR<=#4:)S('Y!L$[2N'R%7-G"7Y@L/;'J6% C!I[
MXYFCJ('E**W]9")S-F7=CTL [ .V-DJ?TH:_)X"]&]4?@(A/C(/0J8&%,/<7
M@1*-$4T$:<_ @&)E"L:0J:FZA+/I%;)0HM47>43(^O-8BN]%C"J/!! 51A*I
M^0K%AB.QE:"N=8=R^>'=VI9PJ_9YH5+6 )82)*U**H%(#V4.;"<QW3I50.80
M>:E]J@.%7!X6J,L44G+%EB "I2K@N0B'*+#U2NC0Q+'@]6T@O1@-+5U6/L3&
ML G<OT]-"P4AU+T#BFDBSYPP%QX@*(X1)D9*BB8TX4-G0Y858[B8!UT3W>=>
M<0T>"X),V'E"6FXX*=3K:&< 6U+?":^SM12BK2?(=CNWC@7-1Y-Z73E'8'F-
M%4<O+16K*'9C"\1_ SD.@$P@=>6DPH0&:B1>810V+EOFVAYQD@@0D FT%0++
M"AO?78^BM:7'16(]V'9D")$K!;DDB!""<JPBR<ZE?36A:(*&S#@;*L(<-)S(
MS;-K&RG38-4H" H0+*R.8"6J<,LF,-:"MHLED4(56A?.5+,AS=@@RK[6\!@%
M6AK<NC@!H 40+"W*T([X=E#5EUI!$/BSIQGF*0K#,6(HV>OM4M%6+:NY#:1L
M*;K1TLPI<KI,M,PJA#:S2FSBQX1+;H^ H*6'&-:&PRT<S$4/VJ$P*B7FI!K@
M!S I>F_ 7 +\B3- BWQO1K9,)+U5Z0Q#LF:I/0HDHMK3!PT7DUU<67"\!5V8
M_&&D8AHTWE6\]O(0&<W%\^R5OPH65: JL6]EEK K(RDAT)05%#2G=^$A@+54
M8K=H#KQF(%+KN1H0(!!$L31(9<%.NF3Q0-5CLY@IL)B8R  "U[ _.6JD<^LG
M91=UDT9<_D,#!X2@*RS*"Y"(<HL/5*Z-#$2IABCI[Y$%.JNJR@XS@?!J'R")
M- B<H;4,&I6@HLIA<3_VP#ITLK7HIIV$&.+:PW5E:]G%.OYQ%91(; -MJ'F0
M/FDT*$M+-'1$B:M2@1 50 1Q2Z GKH0S-L- S+$L0K1*D1%)$RW?GV+P]DML
MK#*J8D4ZJ5:4*E2J[Y.6R2C1:>8K:L3*L]'QN$RQP<HQY4242!JHJ)IH0THV
M "IHP6G;:1$&P0X@Y6X5I **V6W)9)#S-/,MR[%!V&=SW5%-:X<X8/6DPT=9
M<MI1'419VZ3E[9>KH7BZBHT,->,ET6HQ2K=*"Y!%P>'PQCFI0Z'"&+VFPKN1
MC$ZJPCLHJ,1J=<&"UQTA2XUJ\$US,094COJ/(?CJ;H4B\S  6JN #MY\QC&D
M(YAY&KUIZ2TK,*GUB(Q U"9*$_4]B/1&(D&C7R14P1P&3V:,HLX<Z#?WB+Z)
M"X/"4!66907(1#E%AZI71H8C7,\4=#?(@IU5U6+E=)EIF%4(;6:4V<6/");=
M'P%!2QI3%KNV7)FY#%LRB6L9WBHT,->,ET6HP"WS%9R)AA]-(D7F$4-BY;YM
MH><9(($) )M!4"RPHXVETH0UD@&--8H]16P!!KS6*B+N O8_02ZC AJIEF\4
MT0&\!U&4X"4@]-1K 050<:2F1*%IJA[S/(02*!J$"8#X.D%.OYQ%91(; -MJ
M)$ 7\YW>8LO8)AF\=Z<E#M;L.FP:I0$!0@65D<P$M4X99,8:T%;19!B2+POB
M40E#94K$934=Q&!B$M:F R#9<!50650 A0+CAHO)KJXLN%X"KLNX)(BHTZ"'
M15M,6(HV>OM4M%6+:H#OW%%+DJBP#H3#-X[TY*':W8=-@U2@("A LK(Y@):I
MPRR8PUH*VBR$<D6@,IHAM&RI'>/60! .T+6M@+T.OIW, :9 6- ?#(M&@?\
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M@@1B@U5O"*V=@]JK2@N4G59Z$#2%<V]1RMQR#K&:198!E)T<A6;IPQC:67J
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MQ843:TA)AT;7Z#_%H0(6/?:^Q$U$)/GBU_P-QS407IEG#/YB9X '5= +_@U
M.R/=:7_"<J$B5>F$9FNA1CW(DS%RJ@MW9PS^8\%-0#Q(@0!:8 .;!@"JT!>O
MCV)*(HTCC\X 0!89$>9\0*\RJJUR"*%Y0C=:0("8ZA0!JK&)0*@0&N#6(37&
M@@LW.T1!@MJJ:WE?9JE$(%XRN(?$;<(G43_PY2M506\K:A=4+&%&PS(S%8!W
MK'8#3M7H _'F+E5!;NQ(1MB =:LOK!C&T(+Z6U$EB++&M=52S!5N-;TNEFJ4
M0@7C*XF$MW<*.="_"H% %I@ B@K+,*ZT+V+@):(FUI! ((EB:)_/LB0O1[+^
M#$G,AY&0;.P1!@6U5-;ROXU0MD+6NEI.&?S,')4Y[@?A$08%M536\K[<C] #
MN$VZ?%JU$(%XRN(=$[<(G43LUM]><F0<=F7$9%-=;7_&(@P6(J:VVOGV:%C#
MR*P+GL70Q843:T@P#MR \PNV _:T 6UK=((@P6(J:VVOG\9[+R>O*QD9FLD6
MSW(GP (I0 'HTL 12@ /1I>T5 JD(7:TE]1+(E--)C6<[5UK6M6G6'Q&W")U
M$CAZ +%T+0B\+U\"P@( *C0!JK%P$M$#>E^+6WUYR9!QV9<1D4UUM?P:I!"!
MRRL+F-J$39/X$;C1"FF V=I[+R>O*QD9FLD6SW(G\H)CJC0!JK%A&V(+Z67U
M^($PE1H U5A-<:""S<_C!-2@ O2U)31VJ@OI9<R,E2!WK&9#2M78&*!0!:8
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MHJDD<A"O6= ?%&NL!S0_KH_[CLLG):Q6N5UR:Q1^](@U5P 3?U5:^ZZE?+*
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ML2)%-6%M3K"A)$Y112S4:72B-?/"B7]84YAZ]@0EE:L&[)+=CV0J@L4X<X^
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MDZ5,&@#*Y,-TLBR5E+N@ T)D.;L$&5?:W@, JVCM^Z/ : %$:T,U9A%@?1P
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MI0$!0@65D<P$M4X99,8:T%;19+(H0JM"^<J69#F[!!E7VMX# *M#6Y=' #0
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M6G3%(F5C*:H%F!K\LCVIU+R+A=M79V9G<KCO)1T"@!IYTAS^!VZ\O[!FD66
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ME,5<:<IF/=@!9$.O<OCFC"M ;="P$<_!9R"T-:^TF601TF*\Y4[_ ) J#7@
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M=( E'("*NT",29$7'%K(EUYNC)JO5]*RJU XF+6@,2N!PDB(0Q,RM(IH'7X
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MT5**CJ%=-00;,/.5!EQ5S=EN!W#",J+O&F;ID2] "60#>:AHF&5OM30U*M:
M*+C5E'#'B7D7"[:NSLS.Y7!62#HZ &GG2'/L:>>=J/\ 3!-L&X(U5SLIZ1'F
MWG9P*<8AP8E<WQ;?858P(N+Z?""WY=ZEF?D72?\ '3F,#(1Y7.-VPX7>;H[.
MDMYZ<P@9![/A\$+KTJ8<DR=F2@?W;&4FZ5"VC,2J,M$:4$-K#S@9)A*T) &
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M87-8)B@#D+ M%=8EFY6@I6JI'0JU<Z(]:T\K,".L?S9274=$AO/Z';=Z6'<
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M)\&LAU!UX!:2QN:I)$$=>XE#6-+N*R6/#O?]<65]Y*]1X)AWSA4M;0>H&!K
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M/7)0%8Z+$1P@ER"#S%R\_B7E;>6>JC2%E%/^2+RMO+/51I"RBG__ #$O_]H
M" $" P$_$/\ XN@72;#_ -&!< S 5IV0V%?]%UK=>SD'_1ER^G90W_Z,"VH
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M>\_IXL6*N;_LKRBI 91T'7&H=Q]>QZ8B,@, \QZQV% :ZY+Y! N$E%Y/NO\
M!>Z$4M[U^$BQ;>]SS>Z!W0XLV8$.UH00+KTP/%M?* -3P=8 W/?3P<Q]=8FB
M=9Y@^\XAU?%H^#&R:)HE:IS72 M^3R,7JM^55UCDK0N[L*ZGJ)B\QK UO6QZ
M1%T-M#S3D$"X8<7D^Y<'=3O4 R^\OQ4$P[B"G+8U>B/1/S]NSR#]V<<ZL8F#
MJOL'-X8%K=VOPA^.X+U1.U6OY.IOY? %L#=J.O(7V,^B:)6%.:Z10RQIR!UZ
M'AGI4$4MWM^$(M(.\#M>I];CLZ#2=$^ DM53N,OB_:",U/H<GDOA\"I-1-AK
MXGV@(-2_HX]7TCM4 -:Y:ERO  I6>X/O!RW0,#\OEW0"AFXOS9Y2Y76Z][J;
M^78:4F@006O3 /KS\IBJ_?\ LKREFQ3FU>Y_#XQ$:95ZWGT#JO&T*.TO<\_I
M%%#.#FL7,!S?8F'NH^L1&G6>5^QGEGV[!XF]S>Y^?O \.\4 M;LW^41O(T'V
M3D^71[!IVN+>A+$FQ[CY=TKQN!?FSRBNR7A@-8'"?7GM&12D;#H;!*^I402M
MM5R\[A-U8(NO1T#GY)V:ZR#QCVP%UU<CO-']145^S7\#Z[1VJ/,U^KD=VO/I
M.:;67-&A!XTA9LYCO^<=OG_W)Y3[(U,0HY#0'\RB8=6 ]VJ^%;Q::36S?@A?
MTMF8BM7D=[P])?!;T%_('BD2F@U&)@$&M0@- =3!ZOT(E&'DF_!"^XSM,USS
MZ'>\H*PKTM_)$* Y,' 14VA-4!(]YB,>LH'UA* 952.DQ@.%VUK=?:*<(:5@
M)OS^@R[).@M^8'G$IH-1F-!PNVM;](](JIKTUS.0\O7GWP7C+63/-!P4I9F^
MP<!-5H1>NDC])J[&W4&8NB)41TEHNKYP?K&+?<Y/6\/+I*D;N#X/I,O=V;/"
MWW)=(GHY?D\R,V!R>RE71V'J^51"U)WAL=-WPJ><BU^-Q!6R6N8-1W-;YEW"
M4\KWG5Y5X3ROV,\L^T:A2 ^LIQ@\_E[W[Q92Y:5CN:OETE]'<MKO.&%:%!-S
M1..4Z##CO9/+$=%JAL'\OV(^:QH:YY'3=UY8E)[BVXJY+;T.C^']PP]4O#D&
MKC3DWUN8T3"U:^J%PBM%.>TN 75;?/MUC$'[^FL4; =Q@_$=JU*][+P<NS@Y
M-^,H]CQ!IXG8!N\SN.7U:^D9TM8&_H?KG+B#WT'<&"+4166[.F>G4TYQL5HO
MP\.74(Y$S*M5"K%U'*%3(H^4-"DZJ_?LX\Y^\O4Y7Y#SORF.F!?T8?P_7LI&
M9/!IZOK*P/)?3U7X2E71V'J^51"U)WAL=-WPJ><BU^-Q!6R6N8-1W-;YEW"4
M\KWG5Y5X?#=6XT=>ZY;+W@]@(-+3KOP6\G7XN/=8.EH WFZ\?5!Y M0=0;6V
M,'?<7XGY&@?8)JK)?&:O?^Q/+?8ARC:"EUJXW?M#MQ5AKG0.F,WN3/J.MOK$
M]15IUQR7G]>D#F!7Z!O[)H=_8S FA,4<[UKH%;PZQLJ'O'W@#,&Z^Y^( 6@C
MN'$\]^T5X47;R=:ZKIRPR]+>]ZQ*KK1ZCUW.N\ >J(^!/NQ>1+GN9?+SB)E'
M0'@!QO%:PZB#Z<^]MA57F)L?1W)6?GB?4?,FNLD\)8Y^ -!]=?#I%#!@&J]!
MY!MSVE+A[WS-'ZP-(Q#[)L^LT?!C&]7]@EW)'WKZ'Q><^QGD4..W3[7[,T._
ML9@30F*.=ZUT"MX=8V5#WC[P!F#=?<_$ +01W#B>8?:/(_81P=T/U:>%+WU%
M(YFM@U]'ZEMQ[WRZ?2 5!U.HF:7G9I?= Y5U;J^]->+#E&T%+K5QN_:';BK#
M7.@=,9O<F?4=;?6)ZBK3KCDO/Z](',"OT#?V3S!]YQ#J^+1\&-Y1^Z%J"ET7
M5Z .-^<#P!5T"'.JK73-S1-Q.['  =2%O+7?/TE,HO2UKKNK[I+(CWL9V@$6
M]<6+I6O1A*=;]13S.SR#]V<<ZLZ[BWO>*@!A "@!IWN_AB$6=RV/>0.2:FJK
M,H/"$,5EM/4[=1.+='L\D_=+=53<+T#>LWN5 M=[WK&[JJ=^C]?N2AN4O?G[
M ^#Z-7Q4;:4\GYOX.(*VF MS^TSAW4CMJ 5[C6.;N6*FMQE?+:%K>8E1-KT=
MR-UGR0B4U'1:H;!_+]B/FL:&N>1TW=>6)2>XMN*N2V]#H_A_<Q1HVUT8?'#N
MW "L1WCR^SQZQV"JLPKGGD=*UYRF8][PQTWK9PS^ZA-T8_D^I]KYSROV,\L^
MT6WN[CUT^L6,P* Q;R#C!&Z:Z#0^GY<P*BYJ;/IT=SZW%<K@/$?!)J"*OIR?
MJ9EYG.[AH?77PZ0M$8!JO,'D'C>TJ>/>^?7ZRST8-W0=_P!YYA]B7S<%?1D_
M)]90$ROP/G3V6Z8./ ^U^4K_ %5NXT\7[?U&[&-$\@_?LS/H.Q%^!^O. -H(
M\'L\_P#N3RGV0ANBX'8NZ*MK'T.E5B)I8+'G5@F^I7/7Z6Z"PFM*WYOD4&Q[
MU0;Y7BQ_&E>,,/5$?I5?=G ;16YR[7'+8-,=->49MHL77'+?ZS18.M5Z\^EJ
M?2M,P850([\SN\)49FU=VIX9\9Y=]F<2ZIP[J3S7X33,KI.I-;<M<C7+K=RX
M5@;U+Q8[=-/O*1:Y7W/#/CV KM#-WW/J;O>*2IV:'2S'6J8>4X/@?MX]@M13
M/L?!B^[LKESO0,I7,YHEL1BFY*],H:^<:2'2\>&GE, 3W6\L0&N70='N]512
MC'5T>G<\XS5A( '+[1+ME+RYO=.-/2+&-NG,3IO N\@? 3ROV,\L^T!<Y6\T
M1)"F37"/XG&GI.-/2-U!;S70.7=".J^U9P!6#'=YMYO9HC79Y&'G7W^"UC!H
M\SP/O*J+(M\PY>-/TGLS#+2B(#D?W3.L=7W&3T^L2L,S=VX>$5Y$%\4/QV#4
M16ML\]]R:W:<><_>9:\U]=/LET3)X-/)GZ37<0>K]#,Q=%0WT'C416ZL #E]
MHEVREY<WNG&GI%C&W3F)TW@7>0/@/@:C;4')U9V/N[0)1>@_+M]X^6U?V(Y'
M4.6\490PG+H./*$X!>3H%]W9.I"V.A2UU6F_+K\''NLT^RVIL^$]8]'PGK#&
M<[U]D/94-!IW[O?]*[-7O_8GEOL0\:K0,L")LN7P,><'J/=3[K]I613S7KL4
M>4\M^T:'?%(U$\GM5]T_=.'=9Y[]H<70/*_SV*$\Y^$)+E]Z0(X#>*Y#U[YQ
MIZ3C3TB)$+UW;A5.8O)-@B\B*SJJ^+V+R5O]1/5FCX-M,_,/W$.5:^"^OQ><
M^QGD4..W3[7[,T.^*1J)Y/:K[I^Z<.ZSS#[1Y'["5=4_(/5C],)]W\]B*S#%
M7+#QJM RP(FRY? QYP>H]U/NOVE9%/->NQ1Y3RW[1Y@^\XAU?%H^#&\H_=$0
M]1X8_'9HFXG=[ <'6P\#+Y!%]#\E_$<+$ZM'V?><2ZNSR#]V<<ZLK@:@Z(\N
M\\^4R0+UT?$IF89=,'X?O#6D[A]>9]2O@U$XMT>SR3]T=CU'ACL?BPXG=^#N
M*)X*-<YV\GY^!R.M]!M\B$AR^TSAW4BN-GBAVN^"PGF&< 5@QW>;>;V:(U 2
MT0>+'+U5X"]JE.0/@OW" KT3\?F>5^QGEGV@GF@'B_J.<BJ\ =I77-#NH?NL
M!7JGX_$+I / (B+55\>Q4Y%\D9YA]B:P"$[R"WV#/U)KE)'Z3/SFOKI]DISF
MKN8>>OU_J.G:M.#JD1&F+?99X?L#'Y>Z;\J^+?9Y_P#<GE/LGGT%5MGF$/)?
M8G#NI/-0X#:*W>K[S[R:/=^[/,'WG ;,\N^S.)=4X=U)YK\)IF5\%E/*OO.!
MV>P.)=8=EG9R7U*_(=T!G2G<] FF=[[?EY=DT9;K&',YDYNQY.TU_-B6ZA>=
M$O[PI0JH#%*6NB5]?@UW!OPFQ/R,,CG]K/G*\E@=UX\NQ J9H$-F'6Q\U5/*
M_8SRS[0=CG9XC7G$$4''2\^6>U$4F#5F<P3I#%$:^L$CI?4*?,BO\G]\>78N
M047;=:U6+AJ:-%+R[PGD8>=??X+;U'U,O(H^D2Q:A;MK#HG/3:>S0]F@&"%P
MAR&OJ;,O@<E]=3Q\JAG,HO"Q^Y%Z"D^R?GP[$0&K'-T"W*:=Y^9Y[[DUNTX\
MY^\%&R97L'>TX=(G--'>\X4@N[[?EY=AD<_M9\Y7DL#NO'EV(%3- ALPZV/F
MJO@(4];>+^*F7R8.ZO6^RR)AU]'U>;'3L>KT/KS?8^E_!Q[K/,?BU>_]B>6^
MQ+(-?/0-5]:M^G26A!U71MC5^N/MTDV \Z7SA.R#*M<N??-/N_:-#OG!NCV^
M6?NGF_WGGOVCROV.SS*'G/L(*7-KZ)^+C!Z4:Z(_FO'M1!"(YA<8NYI3M"/Y
M_:SYQWM4/![$Y 5^J/1FCX-:S@V<'1?" >:/U>Q^GP5XV#T>K]B44PM"M<&G
M<SSGV,\BAQVZ?:_9FAWS@W1[?+/W3S?[SS#[1Y'[""\^7^B'HQ2Y1\K/3Q[-
M05!X^D9AU*6_,ED&OGH&J^M6_3I+0@ZKHVQJ_7'VZ2; >=+YPG9!E6N7/OFG
MW?M'F#[SB'5\6CX,;RC]TX=U[-$W$[L+BRE&[G]*\:@!KDG=S=OO-8=R$*3@
M%7C+TTG"NKL\@_=G'.K#,#W)]ZF#<.CD\&R8 AUR>=CY0GFZGF).:&L[@-?2
MZ[=1.+='L\D_=.'=>SSL.)W?@O:R-.YQX,>,$FZ5]A^C=]^WP.RU#<L+]#'U
MV@U]2OH9?P?6<.ZD\@?9V\0Z)YA^\$CI?4*?,BO\G]\>78N047;=:U6+CX(<
M++R/,)UU(?42(C3V.)H4_4@-70/N_B>5^QGEGV@>HW\$]8X6B'@.T]SG?9 3
M'(>5_F 7S'VB:F0\'L?E]'U17D,\P^QV7@Y=G!R;\97PT;X>@8 6%/J8>1;]
M/ZD:ZAXNO=UB%01?Y,=>N;\X!JKO^RX@,-<GY?P>,N&V1H;/SX=:[//_ +D\
MI]D\[[#S"'DOL3AW4GFH<!M/,OO-+O32[OW9YP^\X#9@=3:^\'C5@W%9QULA
M&,XGEC(?5\LSS7X33-Q#JGE7WG [/8'$NL2@6V\NRA7JOVQ]94_\C@7NSIFN
M.XP>79',ICK%BIS2ZMO*EG9SI9\V<TQDZG,\(,J'[B?>7H(<%#\GUF>O(0A)
M3N'O6O /K$2U%'J^ASB)7*RT>%NXU3O'/<[14( *1T'+/4G7#Z5XW7G%O0HJ
MC0>LJ7S=[:T/S]">5^QGEGVAD:03O(:R I.CS7&2-!OT/(SK]/" 1KYN'EJ^
M$-!H+5\5>-I4^SN-/'7ZQP^%NXU3Z.?KM,8\,CC#1OKRSBO/-@[Z#QNH""'4
M&FP;$M7>(>KS'D?2"<XB\%]8@XL(CBQZ3&_ <9U[+?,'Z'J:/K.I(8[V#SBW
MVW&Q@[S7Q/M,=9+^KV/TEZZL=YZ-/TET.&D,T\DXT9D8.3D/Y/J$$*C(U-\E
MK%&M>,<AQ573F?73Z[06/6O$3\Q"0P2]+(;(I:PWV<><_?LRJX*_#SBP%6MW
M:"_ )TL7'<P>79:/"W<:IWCGN=HJ$ %(Z#EGJ3KA]*\;KSBWH451H/65+YN]
MM:'Y^A\#"ZM?>YGE9]8 V#0>3L\8GYA@^\*(!I7 N_+SG(N%]5>O.M:SI,"0
MGT'1WZ/T<:)3H-)V\>ZSS'XM7O\ V)Y;[$(36Z\;/))K\HAJ/=S'7$H M\'G
M$UHZC^&WWCH]$^Y^9H=\X-T>WRS]T\W^\\]^T>5^QV>90\Y]A.<8SN:)]27C
MX/W^R>3&^TIK]=7A9#N\KK]#KWT3*6CQWKYLUG%?=T/H8BI]1W#E.\<]SM,#
M/I.\/7OP_?)TW:#Q]+E'-K*ZOH<OW-'P9(:2SZ0/K^ ^G1Y^,7 ;S<VSR[J3
MN@&J._[+B :CDY][^#QB_ , <^@.*[IK\KPZ'T,3SGV,\BAQVZ?:_9FAWS@W
M1[?+/W3S?[SS#[1Y'["7 K&[/-]SZW#MJS+\.SZ,SU=RD\?68H8]3+5>5UTO
MQAE\@[ T/JY^F\(36Z\;/))K\HAJ/=S'7$H M\'G$UHZC^&WWCH]$^Y^9Y@^
M\XAU?%H^#&\H_=.'=>S1-Q.["+:M#>K'\3+9>5U'IN?F?8!QXZ0#3734;EZ]
M.1KKHH',/$>SR#]V<<ZL9;L#J6<_J9@L6MU?T,ZG3G]YFR;X''=<<K=6KRO5
M^GXA:Z-'<%#]:OMU$XMT>SR3]TX=U[/.PXG=^!D*3@[G1GB!-39.9OHP$);F
MT^C^'QC;5._]D: 5]1[WE]+[R8P$P?@.;'F(T'3U<W><.ZD\@?9V\0Z)YA^\
M</A;N-4^CGZ[3&/#(XPT;Z\LXKSS8.^@\;J @AU!IL&Q+5WB'J\QY'TAI,%.
MYR?##OWQ&0ZG1GKR9YGATF7)NT''='I=ZS\&QY^4 I=V>O-]#3QGE?L9Y9]H
M0K0<G58?+SEH-'">2;CYZQF=(?R-3[;P:GJWJ[C\OG+<P=!]@W?VS4'2\=T=
M<I,[QR]XU/KTAV)S+T[W1WS*/4ZW?D?J ,SJO-=>-)YA]CLO)YCN]#3](_34
MK:\,IK06]^CP/ZFQG<')^OI4/>O6"V;.6'GKYU\"X&Z8[Q_$1@@@4[$1K3;%
M= _'8G0BC'>/X@((-8=@(260'P;@BUCK7.O2.&LWBNDISFKXRI2E)1O+1 H9
MVN4'0QBM&\UTA[6T1T3H_?OA0VNE!YI]HV[-YUT P>?TABUCK7.O29%=!7*_
M6"<4(^+<L#DCX,8O2V:Z3++!I7*_6"64(^, %HNDURW2.[K<$0*=:YUT7I&!
M-2(&@93HC["Z^G9<N4Z2D>@BWV);8T;41T^<8J.IJN\X8U5EZK\/K,/-X=?Q
M'E&;J_(K[QTC<_'0V.PTE)HD'#WGF8I\H4<WZ>L1!WN7TY'G'26NK.5H.+K4
MK6G[2OT0;Z FE.O9A$O4U'O.&4<][K\FONP1G.]$#8N@Y][S\C;L-)2:) 7>
M9E]31\HU8M^GK^(D"W6FU]<8[CZ]AY<G@G1FI5[8?:$#BYEWE>AU['<W0O0#
MZ.OX@DK&WF=.1IGX-817W]3ZF(HL"4[66KQ!Z]XY=SR^VT48SM3Z16E;U7X>
ML2*3F\>4-)2-CO )O U?TK\_2%RZ!M;T$TK?K.K8SA=JZ6Z]9B*K+6M7OCL,
M:[::6:)]26'02\JO7%.6_::2DT2#A[SS,4^4*.;]/6(@[W+Z<CSCI+75^ 4;
M(.K#G=?5R?)ZLQ<WZ?>_Q& @\]?HY'GWR@5G=WF^MRUZ /W#J=-%VQ'26N5[
M<170UI=;YFC2E7E7TI]_BW)&\-:Y6Z3HJ,7>@&M'3I+YZZCH]_KK'&$[(_>
M&==P?:YIZ(#&#QEMF 2*V]'N.8J1FDVPO>5VNNXSA=JZ6Z]9B*K&M:O?$O\
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MBAH]>_L-BA6M]!ZP"#=,]#UBCJ'T(!HB=3TAD#8_ R70+^KQYP6URP?GCO\
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M"+]5C"<V\F 7M/*JF9M<R].]9?F]+S?6MNNDT._[">;_ !\6GW,\X_?^'S1
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M_P#2MI]S/./W_P L\F^2-/N9YQ^_R3RC[O\ 2+SC[GQZW?\ TK:?<SSC]_\
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MASB%NL_Q)=3L6@UP-5W^IX:?$& ?Y%K=_P C\G_S9K=_R/R?_-FMW_(_)_\
M-FMW_(_)_P#-FMW_ "/R?_-FMW_(_)_\V:W?\C\G_P V:W?\C\G_ ,V:W?\
M(_)_\V:W?\C\G_S9K=_R/R?^J95%WHITGN#UGN#UGN#UGN#UGN#UGN#UGN#U
MGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#U
MGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#U
MGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#U
MGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#U
MGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#U
MGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#UGN#U
MGN#UGN#UGN#UGN#UGN#UGN#U@U(<Q5AU\?+];O\ D?D_]4X'T_M/(IS.L.OC
MY=K=_P# P'5:G /I'D^9Z2C%?9EH@+YW+9<FOA;H(=_IVMT$._T_F\G_ *IP
M/I_:N13F=8=?'RW6[_X/-$()3AY/6:+"Z5R^D&KK97'=<^ZPD[5?>.,(]U^D
MS:;'*/5I-5TE\!>FG'E/)GW(]6DU727P%Z:<>4\F?<BU'!JND 8*_6)#I(U
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M.>I]I6BAI\Z_$<%9E]>4304GVF(*$'[GX_A\G_JG ^G].,)0:OXWO^E:W?\
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M7_X/)_ZIY1]GYMR*<SK#KX_L.MW]J%=:Q^?Q+MR>1;]8)BPVU\)JD&_7SEZ
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M/U>.^=1?L)H\=/A\G_JGE'V?FUB<'5_!#04']AUN_M&LD!K+O!\]8'30VQV
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M#UGN#UGN#UGN#UGN#UE!2G7*;GI#26/]-UN_Y'Y/_5/L_L_I>H!^6Y#26/\
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E]4X;ZIPWU3AOJG#?5.&^J<-]4X;ZIPWU3AOJAO4A_P#Q4'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ibrx-20231231_g3.jpg
<TEXT>
begin 644 ibrx-20231231_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@#
M( 5D P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME6>8;V^ K1J1\GJO)K=/R:3/HZ.(HXB'-3E=!1117J&P4444 %%%% !1110
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M^,O#/[8'PP_85^#NM)I&L^-Y1>>)?$JVL5Q/IFGCS2$MTF5XO/D$$OS2HZH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\W 0E7G+%S6LM(^4?^"%%%%?HAZ@4444 %%%% !1110 4444 %%%% !1110
M4444 ?-7[3G@;6?@W\1[#]H3X>Q>5'+> ZC&@^59SU+ ?P2KD-_M9YRPKWSX
M?^.-%^(_A"Q\9:#)FWO80VPG+1..&C;W5@0?I5CQ9X7T?QKX:O?"FO6_FVE_
M;M%,O< ]&'H0<$'L0#7SI^SOXIUCX!?&+4/@1XVN"+*^N]ME,W""<@>7(O\
MLRKM'^]M'8U^9S_XPOBM36F#QTK/M3K]'Y*IU\^RB>0_^$_&W_Y=U']TO^#_
M %L?3E%%%?IAZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ
M-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH
M V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ
M-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
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M* "BBB@ HHHH \+\ _\ *03Q_P#]B)I7_HQJ]TKPOP#_ ,I!/'__ &(FE?\
MHQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% 'FG[4_PF'Q1^&<\FG6N_5=(#76G[1EG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\%'O^":-O\8OV+?#=YJ*V_CN/Q!XA\.VMJ?MS7"6TUO<QO"A.^=/.BD(7.]
M77=N!(![B_\ P4PM/A_X]^&_AG]I#X.-X+TCXM:7'=^#/$5MXB%_#&[^41;W
MRF"$VT@$T.XH9HU,JY? 9E]"_:2_;$\,_ ;X@^"O@AH?AT^(_'OQ!U#[/X<T
M 7XM84C4_O+JZGV2&&!1GE8Y'8JP5&VMC\O_ /@II^T+X/\ VA/V0_V=O"'A
MS2M:B\8:39O8:KI5]H%W;/#=1VMI!+'')+&J2DRJA C9B R%@"0*]=^)^H^*
MK[_@OQ\+-!\873S3Z+X<L+1'=L@G^R[F:0CZS22GZDT ?</[-7[8_A?X^?$#
MQI\$=;\.GPYX]^'VH?9O$?A\WPNHGC)PEU:S[(S/ W'+1QNNY=R#<N>&\4?\
M%);"XU'XI7WP6^$A\7^'?@O&&\>ZV_B 63,Z^:9X["+R)!=-$L,A8R/ IV$*
MS94GY0^%7BWQ%X1_X+W?%:?PV&8W.@:FEQ&O1UCTVWG0$=QYL,?XUR?_  2H
MN)[_ /X)N?M:ZGJ$[2SW'A/4GGED;+.QT>\)8GN2230!^I_P1^,_@#]H;X4Z
M)\9_A?JQO=#U^S%Q93.FUUY*O&Z\[71U9&&3AE(R>M=57PK_ ,&]>N:MJW["
MVIZ?J,CM#IGQ#O[:P#'A8C:V<Q ]O,ED/U)K[JH ***\MO\ ]MC]E+2[Z?3-
M0^.6AQ7%M,T4\3RME'4D,I^7J""* .=\ _\ *03Q_P#]B)I7_HQJ]TKYE^"7
MQC^&'C_]N3QUXK\&^-++4-.N/!.G1PW=NY*.Z2$.!D=1N'YU]$?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 >3_MN?
M$4^&?AS#X(T^;%WK\VV0*>1;H07_ .^FV+[@M7;?L^_#H?##X5:9X=G@"7DD
M?VG4>.?/DP6!_P!T;4_X!7AB:MIOQ\_:S_M?4;Q#H.@/F%G/R/' WR@>H>4[
ML?W2?2OI7_A,?#'_ $&H/^^J_.>%_P#A>XDQN>RUIQ?L*/\ A@[SDO\ %+9^
MJ/*P?^TXNIB7LO=CZ+=_-FE16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U7Z,>J
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 '(_M+?"__ (6G\++S3K*WWZC8
M?Z7IN!\S2(#F,?[R[EQZE3VKG/V,/B@?&?PX/@_4[C=?^'RL(W'E[8Y\L_\
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
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MHA_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHK[8] A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH=1GN;73Y[JSLS<
M31PLT5N&"F5@"0N3TR>,^] $K21HRJ\B@N<("?O'&<#UX!_*EK\EOV4/VFO
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M&-7NE>%^ ?\ E()X_P#^Q$TK_P!&-7NE !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%^ ?^4@GC_\ [$32O_1C5[I7A?@'_E()X_\ ^Q$TK_T8U>Z4 %%%% !1110
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M_8R_X*'_  6^#<OQF\=:!H4EQXBO(O'4$NH1VNH^&)D\.ZK)(K"0^;'&MY#
M5##9*4B!#9 KT;_@AA\-OBW\,_V)/L7Q2LKZTM]2\5WE_P"%K/48FCDCTUXX
M0KB-_FC2259I%4@9#[^0X- 'EW[7/_!-K]B;PS\;_@I^SU\$/@7:Z7KOC3QH
M;W6[M=8OK@QZ#I\1FO%*S3NJF3*(K$=00.:K_M,_$;5O'/\ P7I^$/PPO+AC
MI7@_3T^QV9.8UN)K.YN9)@.S$>0N?2%?2O>?V=_^+_?\%&?BY^T%+^^T?X;Z
M;;?#SPO)U0W0/VK4V Z!TE9(\]2IQQTKR']M/X/WWP>_X*W_  ;_ &S-:5;7
MP7J[Q:1KFN3MMM].OQ#<6\?GR'Y8ED26$*S$ E'YXH Y7]GOXOZA\)O^"Y7Q
MK\)0RR?V-X@TFZGU"RC;"/-:V<%VDN/[X G4'_ILWK7"_P#!./Q-J_Q8_83_
M &R_BAXVG^V:OXBT'4[[4KF7DR3'3+Z;.3V#N2!VKUO]C3X%R?&__@J[\:_V
MM;2 7W@2Q^U:-I&M0MNM]3O9(H;>58)!Q*B1QSAF4D NG/->5?LR>&8/V)_V
M;/VP?V6OC3K-OH^O#0+F'PU!?S+%)KL-S97EK;36BL09Q(QB'R9*F0*P!XH
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M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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MQ_\ ]B)I7_HQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /"_ /\ RD$\?_\ 8B:5_P"C&KW2O"_
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MB:]%:,NVEVW<X,!5G!O"U?BAMYQZ,VZ***^^/3"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H) &
M2:*AU"QM]4L)],O%)AN(6BE"L02K @\CIP: /G"Y_P""BUIXPUK1A^SM\#M9
M\>:'JOC.\\-PZ_;ZK:645_=VVGW=[*+$3R SA5M67S)/)C8GY7;%>N?L_?M
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M_?5'_"8^&/\ H-0?]]5^BGJFE16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
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M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
M-*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH
M TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
M-*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH
M TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
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MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
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MLY_#O_A6?PETS0[B#R[VXC^UZB",'SI "5/NJ[4_X#7<UY/!&45<HX>IJO\
MQJK=6HWNYSU=_-*R?H89?0=#"KF^)ZOU9#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-17UQW$/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SX
MP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $
M/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A4U% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]
MG:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^
MA4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?V=I_
M_/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\
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M_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\
MY\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
M(?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_
M +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L
M[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA
M_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?
M[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[
M]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3
M_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?
M^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"
MIJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^
M?&'_ +]"IJ* (DL;*-@\=G$K#H5C (J6BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \+\ _\ *03Q_P#]B)I7_HQJ]TKPOP#_
M ,I!/'__ &(FE?\ HQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^8)_^,D/VN1 /WVA^'6Y[HT4#<^Q$DQQ[J?:O9_VBOB/_P *Q^%&I:[;S[+V
MX3[)IV#@^=(" P]U7<__  &N0_8G^')\*_#63QC?P;;S7Y?,0L.5MTR(Q^)+
MM[AE]*_.>)_^%_B7!Y%'6G#]_6_PQ=H1?^*6Z[69Y6,_VG%T\,ME[TO1;+YL
M]GHHHK]&/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ IL\$%U ]M<PI)'(A62.10592,$$'J"*=12:35F!\R_%OX-^,?V=O
M%G_"Y?@F\@TQ&+7U@H+BV4G+(R_QP'\UXY& U>Q?!/X[>$_C3H8N=,D6VU.!
M!]OTN1\O$?[R_P!],]&'T.#7;R1I*C12H&5@0RL,@CT-?/?QD_9<U_PMKG_"
MT_V?)I;.\MW,TNE6S893W,'8@\YB/!Y R#MK\UQ64YIP7BYX[)H.KA9N]3#K
M>+ZSH_K#KTTMR^1.C6P$W4PZO![Q[><?\OZ7T+17Q=K?[7_[0<FIR;/$Z:<4
M"QO9QZ5 0CJH5C^\C9@2P+$$\$D#  %5?^&N_P!H?_HH7_E)M/\ XU7F3\:>
M%83<?8UG;^[#]:B?WI,R>?X).W++[E_F?;=%?$G_  UW^T/_ -%"_P#*3:?_
M !JOJ3]G/Q?XB\>?!K1O%?BO4/M>H7?VC[1<>2D>[;<2HORH HPJ@<#M7T7"
M_B'DO%N82P>#IU(RC%S;FHI63BNDY.]Y+IWU.K!YIA\;5<()II7UM_F^YV]%
M%%?>'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M54_:&\0A% &;4X [FTA)KS>O2?VN_P#DX?Q#_P!NG_I)#7FU?P_Q9_R56/\
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M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M?^S-X1\>>(KCQ7XKTFRN]0N]GVBX\^YCW;45%^5)0HPJ@<#M6;_PQO\ "_\
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M;SMDW_?M\/\ I725]MAL7A<;257#U(SB^L6FOO5T>A"<*D>:+NO(Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBBN@HQ_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M6Y!(]C6I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %8GB_P"&O@'Q["8?&'A*QO\
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M+\ _\I!/'_\ V(FE?^C&KW2O"_ /_*03Q_\ ]B)I7_HQJ]TH **** "BBB@
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M (:O_:-7YI/@;\HY;_B4W@X_.E_X:\^._P#T0\_^ -U7TC11_JGQ.MLZJ?\
M@N ?4L9_T$/[D?-W_#7GQW_Z(>?_  !NJ/\ AKSX[_\ 1#S_ . -U7TC11_J
MIQ3_ -#JI_X+@'U+&?\ 00_N1\W?\-@?'*/YYO@@0H^]_H=R/UQ1_P -E_%_
M_HB9_P"_5Q_\37TC11_JKQ6MLZJ?^"J8?4L;_P!!#^Y'S=_PV7\7_P#HB9_[
M]7'_ ,31_P -E_%__HB9_P"_5Q_\37TC11_JMQ9_T.I_^"J8?4\;_P!!#_\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *BO[ZUTRQFU*]EV0V\32S/@G:J@DGCV
M%2TC*KJ4=001@@C@B@#X2^$/[=WQW_;4O/"7C'X)?%;P[X+TW6OBEJ'ARV\.
M2>'UU&ZAM8=#U&^AGU O,I/FO;(1'#Y04 CS'(:O?_ ?Q9_:U\1? K4UUCX2
M>'H_BA9>);K08K>.ZGBT4M&V4U)V;=,MJ8B)0B[G;*H""V5^!/VWO^">/C;]
MBWXP^%?VM_\ @G9XMN6EUS7;B30_#&GQ)</:2C3KR\E:U)REQ;&TAN0(F!;:
MVU?,WX'W+_P3._;5N_VZOV:H_BGK^@0:9KVEZK+I'B"WM,^0]S''%)YL08DA
M'25#M))5MRY( ) /FS3?VM_^"E7[,/\ P4+\#_LT_M0^*O#7CC0?B%=P)9#P
M]H\<"6T$TK1&6)EB253"REG67S 8U.#D[E]N_:]_;-\9>&?VP/AA^PK\'=:3
M2-9\;RB\\2^)5M8KB?3-/'FD);I,KQ>?(()?FE1U0!3L;=Q\L_MTV?[9'["_
M[?G@7]L36/B;;^/]+\0WB:#8O=:%#"UI:EP9-,$:@B(LCNR31D,Q\S=_$'U_
MCGIVJV'_  <1> ;K5%807FF6TVGENAB&FW49Q[>:DGXYH ^C/V/OVT?&GBC]
MK[XG_L*_&368]7UGP1,]WX:\3&UBMYM4T_,64N(X52+ST$\7S1(BN"QV+MY\
MR\-?MZ_'K]J'PC^T)\>O@E\1X_#'AKX-V4DW@[2H-'M+J/7Q;PW,\LM\\\;R
M;)4@&Q8'A*"099BI+>4_"[1/$WB#_@OA\5(_"N\2PZ#JC3.AQM#:9!$A)[#S
MI(OQQ7*?\$HT:T_X)J_M907,;)+%X1U%9(W&"I&CW@P1VYS0!^CW["_[5.F_
MMF?LS>'OCM:Z7'I]Y?));:UIL3EEM;V%RDJJ3SL. ZYR=DBYYS7KM?"?_!O/
MINK6/[#.KW6HHXAO/B-?S6!;H8A:649(]O,20?4&ONR@ HHKQ+5/VI?C+8:G
M<V%M^Q;XWNHX)WCCN8KFVVS*&(#C+="!D?6@"#P#_P I!/'_ /V(FE?^C&KW
M2OEGX!?$OQ=XP_;9\<>(==^#^LZ#=3>"]/232M0DC,L024A6)4XPV21_NFOH
M[_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_
M .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7
M_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=
M7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z
M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
MZ%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^
M^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[
MZ6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@
M#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8KXD_:[_Y.'\0_P#;I_Z2
M0U]2?$7XVZ9\+_#S^(?%.@W,*9V6\1E0//)CA%'?W/8<FOGSP3\.O%7[3'Q&
MO/B]XT\.SIHUS<@R1V8V_:!&JHL2,<' 55#./0XP3Q^0^*<7G]/#9#@??Q,J
MBGRK[,%&:<I/[*O);[ZVZ7\/.5]94,-3UFW>W96>K[;GBM%?8?\ PS3\#_\
MHAU[_P"#BY_^/4?\,T_ _P#Z(=>_^#BY_P#CU?GO_$%.*O\ G]1_\"G_ /*S
MR_\ 5_&?S1^]_P"1L?LB?\F\>'O^WO\ ]*YJ])KE/"%K:> _#MOX4\*?#^]M
M-/M-_P!GM_M!DV[G9V^9V+'+,3R>]:?_  DNK_\ 0H7O_?2U_1F1X*KEF2X;
M!U6G*E3A!M;7C%)VND[76ETO0^JP].5'#P@]TDON1L45C_\ "2ZO_P!"A>_]
M]+1_PDNK_P#0H7O_ 'TM>H;&Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%
M[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_W
MTM &Q1679Z]J5S=)!-X9NH59L-*[+A?<UJ4 %%%% !1110 4444 %%%% !11
M10!\@V'[(/[;'PUT_P"$_P ,_!WQU\+^)-$^'_B.X?1_$FM>%)$OM(LSHNHV
M47VB);U4O5C^TQQ($V-DH6RJO4\W_!,?Q9\+OV8O#WP/_9&_:F\0^ -<T7Q,
M^OZIXEB@W#7[QT".+J*-T'EX6,+'\Z;8PK+(?FKZWHH \)M_V5_B3\7=6\%:
M_P#MB?$'P]XH;P%JBZKH^E>&?#DEA;7.IHI2*]NC+/*9&0%F6.,1('8D[QM5
M7_M0_L7V'QQ^*_@3]H[P-XEM] ^('P\OO,TG4;RQ-S:W]J22]G<QJZ/L.Y]K
MJP*&1SALXKW.B@#PS]E[]B[3_@;\6/'?[1WCCQ+!K_Q ^(=]YFKZA9V)MK2P
MM004L[:-G=M@VIN=F)<QH<+C!X#7/^":VO>%[OXO>'OV?/BIIGASPK\;X-GB
MO2]3T"2ZETIW$R7,EBR3QKB5)Y1Y<@(0[2IP-M?65% '%_L\_ ?P#^S)\&M!
M^!WPSM)8M'T"T\F![A@TL[LQ>2:0@ %WD9W;  RW  P!VE%% !1110!X7X!_
MY2">/_\ L1-*_P#1C5[I7A?@'_E()X__ .Q$TK_T8U>Z4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<K\6_B]X3
M^#OAMM>\27&^63*V-A&P\VY<=E'8#C+'@?4@'+^.7[0/A3X+:3MNF6\UB>,F
MRTN-^3_MR'^!,]^IZ#N1Y'\*_@EXW_:%\4+\8/CE/*--D(:RL#E#<(#E55?^
M6</ZMU[[C\-Q!Q1B(8S^R,EBJN,EO_)27\U1^72.[TONE+SL3C)*?L,.KU']
MT?-_Y%;P%\.?'_[6?C(?$SXHS26OAV"0K:6L9*K*H/\ JH1V7(^:3J2,#G[O
MTYIFF:?HNGPZ3I-E';VUM$(X((4"K&H&  !T%/L[.TT^TBL+"VCA@AC"0PQ(
M%5% P% '  ':I*]/AKAG#\/T9SE)U<14UJ59?%-_I%=%T]37"82.%BVW>3W?
M5_\  "BBBOICL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/?[15['XL^,.ORZ989W6UG.NUPI_YYPCB,=MS?,>.#UKVGX?_"3_ (5AI/\
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\
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M **** "BBB@ HHHH **** "BBB@#POP#_P I!/'_ /V(FE?^C&KW2O"_ /\
MRD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB@ HHHH **** "BN+\>_M!?"3
MX<;X?$/B^W>Z3/\ H-D?/FSZ%5SL/^\17D>M_MB?$?X@W[>'?@7\.9S(W NI
MX3<3*#T;8OR1_5BPKY3-N->',GJ>QJUN>KLJ=-<\V^UHWL_\31Q5\PPM!\KE
M=]EJSZ'U;6-)T&PDU37-3M[.VB&9+BZF6-%'NS$ 5XW\1?VW? 'AYGTWP#I\
MVO7F=JS &*W#=/O$;GY[ 8/9JYG2OV4/C)\5+Y->^.WQ"FA7.X6:3>?*H[J
M/W47_ =WTKV/X=? ;X7?"]4E\+^&(C=J.=1N_P![<$^H8_=^B@#VKQ?KW'7$
M6F$HK!47]NK[U5KRI[1?E+Y,Y_:9CBO@C[./=ZO[NGS/$4\"_M3?M*N+GQMJ
M;>']"E.1;2HT*%?]F '?)Z@R''H:]6^%O[+7PL^&)CU!-,.JZDF"-0U)0Y1O
M5$^ZGL<%O>O2**]/*N!\GP&)^MXERQ.(_P"?E5\S_P"W4_=C;I977<VHY=0I
M3YYWG+O+7[NP4445]D=X4444 %%%% !1110 4444 %%%!( R3@#J: "BN2UC
MXZ_"30KPV&H>-[7S5;#"!'F /H3&K ?G6WX;\8>%_&%H;WPQKMM>QK]\P2 E
M/9AU7\0*\W#YSD^+Q#P]#$4YU%O&,XN2^2=SJJX''4:2J5*4HQ?5Q:7WM6-*
MBBBO2.4**** "BBB@ HHHH **** "BBB@ HJKJ6MZ+HP4ZOJ]K:A_NFYN%3/
MTW$5DW7Q7^&-GD3_ ! T?(ZA=1C8_D":XZ^8Y?A7:M6C%^<DOS9O3PN)K*].
M#?HFSH**XZZ^/_P>L_\ 6^.;8_\ 7**1_P#T%36==?M0_!RWSY6O7$^/^>5A
M*,_]]**\JMQ;PM0_B8ZBO^XD+_=>YV0R7.*GPX>?_@,O\CT*BN(\.?M#_"?Q
M#;SW4WBJVTM(&"[M9N8K;S,_W=[_ #8XSZ9'K1J'[2?[/^GHRGXV>$I)L'R[
M>/Q';,[MV4 .3R>.E>_ETO[8P4<9@4ZM*5[2BG).S:=FET::^1Y&-K4<NQ+P
M^*FJ<U:ZDTFKZK1OLT=O17A%_P#MK+"I,'@%(QV>?5?Z",?SK"O_ -N^\B?9
M%9>'X"3@+<7Q8Y_[Z6OA*?B3PIB';"SG5_P4JK_]M1]+4X8S;#J]=1I_XIP7
M_MQ]*45\S?$+]KKXJ?#I;8^/=/T[P]]M#FT6^TZ6)I0F-VT2,2<;ES]1ZUQ9
M_P""A-^=0A2;XE6NPS*'BM=*#;QD94$QG&>F<CZUWX/BO$YG&,L!E.-KQ>SI
MX:<EVW\NIP8O!9?ETW#&9CAJ4ENIUX1??9GV;17D/[4?[7OAC]ER?1[;Q%X0
MU#5&UJ.=K<V4J(J>48PP8L?^F@Z#M7SA\1_^"CNG_$G4[-=%T7Q#H$<8\IH[
M;5 R3%B/F8*4QC\>#7Z#B>&^+Y9'_:>79?/$Q?PQ@XIR][E=KOH[WTZ,^0EQ
M9PEA<W>7X_&QHS6_,I66G,KV5M5:VO4^[:BN;^QLQF\O88O^ND@7^=?&?[4"
M?$;X 7&C6FHMJ/B:36HYV46,TQ$7E&,$-D$G/F#MVKS'3/B#\7];NXHM/_9X
M\1R))*H>6.SN),*3R<"#TSW[5\A@,)XKYQ@XXK!9!^ZE>TIXNA#9M/W6U+=/
MH>YF&>^'V4XV6$Q6:/VL;7C'#UI[I-:QBX[-=3]";KQ[X%LL_;?&FDPXZ^;J
M,2_S:L?QK\4M#LOAQK/BWPCKEI?/80;$DMIED5)7(5,XXZL#BOFO]J'X*?%C
MX87FB6OP.\%ZCXJ%_'.=1E.GO*+9D,80'RR N[<W4\[3Z&N2\%Z5^WP]LWA*
M;X,26F@ZG<Q'5X!:1HSHK [@99"RD<' QG&*,+D?B9FV35L74HX:A!TJKC?$
M)U>>,9<B4>[FDE?U%C.(^#<MS>&#C]8JS4Z:DU0E[/EDXW;EV47=V\RU<7$]
MW.]U=3-)+(Y:21VRS,3DDD]233*?<6\]I.]K=0M'+&Y62-UPRL#@@@]"#3*_
MA27-S/FW/Z95K:;'HG[/?Q?M?AEK=U;>(+B;^RKR'+I$A?9,,;6 ]QD'\/2O
M7/\ AJSX1_\ /Y?_ /@$?\:^<;#X%?%WXU:!=VGPIU2PTV:WEC\W4=3GDCC
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MSQ&+Q]185_\ +JG"FI+33]Y)2;][5W6VGF>'?&K]L;QUI5[91_ ;PSI&IP/
MYOY->66-HY,C:%".N1C.:X.T_;/_ &PI]4MUO_!?@>"S-PGVDP17!D$>1NP6
MG(SC..*^F_\ A1GPC_Z$.P_[X/\ C1_PHSX1_P#0AV'_ 'P?\:^&PN8>)F%P
MZI<F FU]J5.LY/U]]+\#Z7%Y5PKB\0ZOM\7!/[,9TU%>GN-_B>%_M%_M6?%L
MZGIJ_LVWE@+0V[_VFVKV(WB3<-NW<>F,_E7%>"?BQ_P4I\<ZU;3Z(ME?:=#>
MQ#4GL;.P54CW#<I,N#DKD\<^E?5/_"C/A'_T(=A_WP?\:V/#/@WPOX-@EM?"
M^BPV4<SAI4A! 8@8R:]WAC/N.,MJPI9G0P-:BE)-JC-U&W>SYG*VC?W(\G/N
M'>'\R<ZV#Q6,I5&TTE5BH*UKKE4>J7WL\;_;"L/VPKC5-*N_V:M:^QZ9#8S/
MK3&6T7:ZL"I_? L?EW?=XX]:^=-%\=?MIOKME>:]\?B;6*[B>YA6Z=?,C5@6
M7"0C.1D5]_W$$-U ]K<1AXY$*R(>C C!%<O_ ,*,^$?_ $(=A_WP?\:]',.*
M.,\)A*.&R2E@U&*DI2K47*<KNZ?,GTU7W''#A/AW'8VKBLRQ&*O)IJ-.MRPC
M96:4;=;7];GS=^UOX^\??%C7-'N_@+\:[_PU:VUI)'J41U&\L_.<N"K 6Z-N
MXR,G%>6>'O!'QUBU^QU;Q/\ M4WUQ%;7D4LT)U74IO,57#%<.H!SC'-?<G_"
MC/A'_P!"'8?]\'_&C_A1GPC_ .A#L/\ O@_XUX6 XJ\9\MP$<)1JX'EBFKNC
M)RU;>K>^YZ&/X/\ #G,\PEC*\<5S2:=E5M'1):):+8^<?VJ]+\-?M/\ BO09
MO"7Q<OM 6U@:UEA;396$S/("IPLBCCIS5/PW_P $J-7TSQ%8>(]6_:",TEC>
MQ7(C'AYFWE7#$;FN>,X'.#]*^G+?X*?"FUG2ZM_ ]BDD;AHW"'*D'(/6NIKZ
M/A/C/Q+RC+98+'8FER+2'LJ:T3NY<SG%MW;T/*X@X'X#S;,OKM/#U'.6LN>I
M+=62LHR26W8^;/VX_@C\+/BMXMT'4/B#X^U/1I;.PDCABT_3%G\U#("26+#:
M0?8]:\D\,_LK?LH^'M9L]<?XL^+YIK*ZCGC"Z;"BED<,,_*>.*^U?$WP^\%^
M,IXKKQ1X=M[V2%"L3S*25!.<#FLW_A1GPC_Z$.P_[X/^->+7XK\9,'?"91CJ
M%/"QTA&4&Y)/5W:6NK?78]-\'^&F.K_7,QP<YXB6LI*6C:T5E?LET/GK]H/X
M@>'OB9XZM]>\/PL8;735MHYIHMKG+L[>X&2O_?-</7I/[27PM7P'XJ35]%T^
M.'2-011;1P1%5@D50&0G)R3C>#QG)&/E)/FU?Q?QN\Z_UHQ*S67-63LVK\MK
M+EY;ZJ/+:WD?T1P\LO644G@HVIM7Z7O?6]NM]QLT,5Q"]O<1*\;J5='&0P/!
M!'<5TGPS_P""<GPQUG2=&^+EC\1M5M(XIUO9K*:UCE1?*E)= 1@[<H1GDX]:
MP+>WGNYTM;6%I))'"QQHN69B<  #J:^OOAAX)N/"WPOL/!6NNDLBVCK=",%0
M/,9F9.">F_;N!YQGC.!^O?1[S_BC),QQZRVLX4ITTIK>+G?W+W35[.>VMF?G
M_BMP_P .YYAL*\QHJ<X3;B]4U&WO6LT]6H^6A\^_M9?#[P'^TMXFTGQ/X<_:
M-MO#[:58- MNVF3MYC,^[?O#*5[#&#TS7GGA#]G'XE>%?%.FZCIO[:>GR6%M
MJ$,EW!_;E];F2%74NH7D'*Y&"<=J^JI/V7?@ZYRNA7"<_P -_+_4FJTO[)_P
MFD'RQ:BG'\-[_BIK]IP7'OCAEN C@HT\'.G%-)6EL]=W&_7JS\YQW ?AAF68
M2QTWB(U9--M2M=JUM%*W3L>8_M8ZG\:O&_BG2=4_9P^/NB:38VVGLE];MXFC
MMC+,9"=Q5@5.%QR37 >"==_X*,:=XNTJVU'XIZ3?Z6^I0+J#1ZUHTY\@R+O.
M&.\_+G[OS>E?0LO[(7POD^YJ6LQ_[EU'_6,TRQ_9'\":;J5OJ5KXAU8M;SK*
MJ2/$0=K @'"#TJLOX_\ $[ X*&#JY-@:L%IS2UE9O5W=KM7T)S#@7@_'8^>,
MAFF+I2DT^6,K1TMI9)Z.VIS?[6OQ'_:Z\#>+-+C_ &=_ 1UC3'TXOJ+_ -F?
M:,3>8P"\,&'R@'CUKS;PA^V#^W:OC'2O#7CC]G*.WM;W48+>XO)/"VH0^7&\
MBHS[S(4 &<YQBOL.N ^,/P)@^+6I6>I2^)GL3:0&((MH) V6SG[PQ7UN*XL>
M5Y#[/#9/2Q5:*LKR]G*5WJW-Z72?;6UCQ?\ 57$8_.'7EFU;#TY.]DE.*LME
M&U[.W?K<X/\ :T_;)\1_LU^+M+T'2/A;_;]M?:;]JGN?M;PB(^8RA=RQN.BD
MUPG@'_@JKI?C+Q7I?A.[^"-U:S:IJ,%I')#KRRA6DD" X,*9^]FO0C^QI=P'
M-G\2\9Z_\2LK].DM,D_9&\7*P>#XE(S*05+02#!]?O'%?'X3C[,*&7QHXSA%
MSJ)->TCC8J[[\JC;3MY'N8SA'$ULQE7PG$:A2;3]F\+>RTTYG*^O?S-C]H?]
MM#X9?LT^*]/\)^.M!UN[EU"P^UQR:3!#($3>R8822H<Y4],U@>#_ /@I+^SA
MXSURQ\.V1U^VN]0NX[:V2ZTH8,DC!5!*.V.2!57Q#^QGXM\3.DFO^*=+U(QK
MMC;4(Y)"J]<#<K8&3T]ZW_A'^QG\-O![C5?&W@?0+W4[74([K3+RSMRK0%"&
M4YVKR&&>XKT>'.*\KQ_)A,UR3$4)\LKU56IRC=)M>[;KHMSFSK(N(L/7GB,N
MS2A4IW5J<J4U*VE_>3U>[V.O^*7[2WP0^"NNVOAOXG^.H]*O;VV^T6T4EE<2
M!X]Q7=NCC91R",$@\53\/_M<?LU>*;Z#3-$^,NBRW%S*L5O \YC>1V.%4!P"
M23@ >]-^.'[+/P<^.UV/$GCKP@;_ %BTT\VVGW)U&>(( 7=5*HX0C>Q))4GG
M'3BO#-/_ &#?$>@:Q:Z]H_@K2([NRNDN+6>"[ ,<B,&5@#@<$ \UT9OGW"^2
MX.BG@\;7K2B^9T8TI0C);+5J5G?UT8L)EW%V/QU5PKX2G137+[1U%-QZWLG&
MZ\M-CZEUWQ[X%\+W\>E>)O&FDZ==31^9#;7VHQ0R.F2-P5V!(R",CT-6=.\2
M>'=8Q_9&O65UGI]FND?/_?)-?+GQ7_93^+GQFU:#7_B9X536;NUM?L\$S:I%
M&4CW%MH".HZL3GWZUR^D?L)^)/"NOV7B72/A5+%=Z=>17-JZZLL@62-PZG!F
M(89 X-?+4>.^''A$\1@,QA5MK;"0E"_D_;Q=O^W3VZW#_$JQ;5"M@ITKZ7Q$
MXSMYKV,E?_MX^V**^3?BK\%OVA/C+XBM-:\2VVLV-]!;"SMKK3KTV\<8WE@[
MB%N<,Q)/7 ]JK?#[]C?]M;P5X]T35KS]I5KS1+35[:75+-/%&H@S6RRJ9$$;
M)L;*!A@D YZ\U];PCB,BXMP%6LJ\\-4IVO"O1E3<FTW[C4I<VVKLM6CPN(J^
M></XZG16$6(IS>DZ-12LM%>2:C;?HWHF?7=%>$_M/Q?'M?'UE=_#+Q/XEL--
M&D(KIHEFDT33^;+N+AXG&=OEXZ5Q.B_$/]KC0M0@N-4\8:]?V\4RM-:7WA>U
M42H""4+1VZL,C(R#D9KY3,>,N&,JQ,L/B:\HSCNO956MKV4HPE%[]]SZ+#91
MG>+BJE+#W@]GSTEUM=J4XM?=L?5E%?.'B/\ :8^/,E^ESH/AW3]/@6("2VOM
M'GG#-D_-N$D9 Q@8]NM1Z=^UU\7+.Y3_ (2+1- FC#CS8[;3[B!F'< M.^#[
MX./0UY2\3.!53YJF,Y7V=*M?\*;7XGH/A;B/VG+'#.2[J=*W_I:?X'TG17RQ
M\4?^"F"?#;5K2Q/P8>]BN8"[2?V]Y90Y(Q_J&!_2H_ __!5#P1XO\2:=X8N?
MA+JUK-J-[%;1O'J$4JHSN%#'(4X&<GZ5^I91D&;Y]P[3SW 4N?"3BYQG=*\8
MMIOE;4E:SWBMCX#,>*L@RG/)Y/BZ_)B8247!J3]Z5FES).+O=;,^JZ*\AC_;
M&\"'_7>&-67C^%8C_P"SBK,?[7_PQ=@&TC6TYZM:Q<?E+7YI#Q"X*GMCH?.Z
M_-'WTN&<^COAY?A_F>JT5YG%^UC\)Y/OMJ2?[UF/Z,:NZ9^TO\)M5O8=/MM6
MN1-<2K'$KV+\LQ  SCU-==+C7A&M)1ACJ5W_ 'TOS9C/(,Z@KRP\_P#P%G?U
MP?Q*_:$\$?#B[;1Y/-U#4$'SVEH1B+V=SPI]AD^U:7Q7^(^E> _"NHS1ZS9I
MJL=B9+.RDN$\UBQ*(X0G+*&R>F/E/I7R)<7$]W.]U=3-)+(Y:21VRS,3DDD]
M237QOB=Q[CN$_98/ Q2K5(\W-)748W:32V;;3U=TK;.^GN<(\.X;.N>O7=X0
M?+9/>5KM-]+)KSU/?M(_;*\/W-X(M;\%W5K"3@S07:S$>Y4JOZ&O6?#OB31/
M%FD1:[X>U&.ZM9AE)8S^8(/(([@\BOB6O2OV;/BG9^ /$EQIOB/5?L^DWL!9
MV<,5CF7[K8 /494X'/'I7Q'!/BUFU7-H83.IQE3J.W.U&#@^C=K1Y>CNM-[Z
M6?T&?\%X*&"E6P$6IQUY;N7,NMKW=^W?:Q]/45Q;_M#?!M!N/CB'\+:8_P D
MJYHGQL^$OB&[BT[3/B#I?VFXF$5M:7%R(9IG/14CDVLY/^R#7[]@LZR?,L0J
M&$Q-.I4:;Y83C*5EJW9-NR6K['YMB<%C<'2]KB*4H1T5Y1:5WLKM6UZ'445R
MWC/XW_"'X=ZHNA>-OB/H^FW[Q+)'875\BSNK9"E8\[CD@@8')&!62_[3OP:4
M97Q+,W^[I\W]5K7-,TRW)%3>85HT>=7CSR4>9+=QYK72ONC/!8>OF4IQPD74
M<':7*N;E?9VO9^IW]%>=R_M2?!Z-<IK-T_LMA)_4"JK_ +6GPI681A-492<&
M068P/?EL_I7C_P"NG"/_ $'T?_!D?\SO_L+.O^@:?_@+_P CTZBO)=>_;+^%
M>A6\UW_9.N7<,$)EDDMK2+  !)&'E4YP/2N1\ _\%*O@K\2?'VD?#WP[X0\3
MQW.LW\5I!/?6MLD:.[;06VSL<=.@KZGAZ#XLPU;$9.UB(4OC<&FHW3>NNFB;
M^1\]G6883AW$TL/F<O8SJ_ I)IRU2TTUU:1]$45Y7\7/VF&^%_C"3P?;^!FU
M&2.UBG,[:B(5(?=@ >6QXVURMA^VQK$NJ01:G\);>"R:4"YN(?$C231IW98S
M;*KGV+KGU%>!C>)N'<NKRH8K&4H3CO%SBI*ZNM+WV:9Z]#+\QQ4%.C0G*+T3
M4)-:.V]K;^9[]17SUXX_;.\61:KY7PV\!:=<67E#$^N7\D,N_G(V1(XV].=V
M3Z"LC1/VR?C0^OVA\1^$/"\>E^>/MZV,MR]QY??RRQ5=WU&*YH\:\%NC[1YE
M16E[<SO]R3=S2>3Y[&M[-8.J];74=/O;2L?3E%?*OQ:_:W_:IU#Q.L7[.?P:
M.JZ*;9?,N)=!N+J2*?)W*SQ2",<;2!C//TJC\._CG_P4+OO&^FW7Q$^$S6?A
MV.Y#ZRRZ*L)6W +.=SN2..]?H669&LWX>CG6'Q5'V$H.:;J6DTKW]UJ]]&K'
MQ>/XFHY=G<LJJX:LZL9*#M3;BF[6]Z]K:IW/KBBOD7XP_M&?M">)_%7V_P"$
M'Q&C\,Z3]F1?L%QH]M=/YH)W/ODC)P<CCMBL#P7\8?VH-(\::;KOC/XYS:QI
MEK=I)?:4FE00"ZC'6/<B_+GUKX"GQSX<RPOMIYS1B[7Y>3$.5^VE!QOT^*WF
M?65,HXNAB_8PRJM)7MS\U!1MWUK*5NOPW\C[9HKXK^.OQ+^,WQ0\:?V_X ^+
MNM>$=--I'$=)L;IV7>-VZ3<K)R<CC';K6-\(8OCAI?Q;\.ZUXC_:-\4:U:PZ
MO";C3+R_N#%.A8*5(:=EQ@_W36F&X[\+:^&C)YW!5)+2'L,2WS=(\WLN6[>E
M[V\[&5?)^.Z6+=.&43E33MS^VH)6ZRLZG-9+6UK^1]VT5\Y_M0_L<?%CX[_$
M_P#X2_PI\9SH6F'3H8#8&2<_O%+;GVHP7D%?RKR*+]DWQI^S;\7?#GC'4?B%
M<^)+FQG2_6".SD5'*L08R2['G!.<?A7VV9QX.R/A_P#M/,<T4&DO<5&I-\SV
MC>-]WI>UEN?-X;&\68_._J.#RMSAS6]HZU.*Y5O*SUVUMN]C[?O]=T32FV:I
MK%K;'&<7%PJ<?B:H6_Q'^'EYJ$6DVGCS1I;J=PD%M'JD+22,>@50V2?85\6?
MM"_#2;]H[XD'XB:WH6JV$[6$5L;6QC+*0F[#99"<_-^E9GPN_9UM_ACX^TGX
M@Z%H7B2YOM'O4N;>&=08W9>S!802/7!%?'T?$#PEEEZJ3S&M[9QOR+"U;*5O
MAYK:Z];'NULB\2%F+I4\OI>Q4K<[Q$+N-_BY>CMK:Y]L>+OC5\'O .HG1O&_
MQ3\/:3>J@<V>H:Q#%,%/1MC,&P<<''-9>A_M._L_>)O$-KX4\.?%S1+[4;Z8
M16EK:7@D:5R,@#;D5\P?'+X42_M"^/C\0_&'P^\017QLH[9H-.#+"40G!PT+
M-GYL$[L>U=Q^RM^Q?\*M,U6#XDW_ (8US3]7T35%DT];N\=58J P8JRC<,DC
MTXKULBXN\+\\IQP]*OB7B90;M[%Q@I)7MS22TO\ ,X,SRGQ&R_%RG]7P_P!7
M4TN;VMYN+>_*NMOE<]?^)O[5OP ^#GB%O"GQ(^(<>FZBL"S-:FPN96"-]T_N
MHV'-8W@_]N;]F?Q_XQL/ G@_QW->ZCJ=P(+.,:/=1J[GH"TD:@?C4_QN_9-^
M!_Q;U6\^(OC;P')JVLQ:9Y<"C4;F-9/+5BB;(9%SDG'')KQ#P9\&G\"^(+/Q
M7X-_94@L=0TZ=9K2Z-EJDC1N.C#S;A@:ZLXXI\-^'<#3AC:>,GB9P;_=PA*F
MI+T]ZU^^MC'"9/XBYIF,Y866$CAHS7QRJ*HX7_\  >:WRN>R_&S]MSX*? /Q
MB_@3QR-8?4$MHYREC8"1=CYQ\Q=1G@UR<O[?/A;XC^&+J3X0Z#J]O.LPB-_K
M%I$B)QDE LC[F'R_>  W#KTK'\9>&_'?Q*U__A*O&_[,VD:IJ'DK$;J_\-2R
M,47.%^=^@R:XKQ-H4_A[5WL;CP+9^'&*J_\ 9EAIPM8E&,;@@]<9)[FORCC[
MQ3X:7!3H9+A<32QL^6+JU(\L(K>;A_>=K1OJKMK5(^XX7X,XG_UI=7,L10G@
MX\SC3AK-_P JD]K*]W;>R6S*^LZKJ7B+4I-8UZ^EO+J48DN+AR[D=AD]AV'0
M5V'PF^.7BGX:7D%B]U)=Z,I"RZ=(V1&GK%G[A'H.#W'<</17\MX'/,WRW'+&
M8>O*-1.][O7UONNZ=TS]MQ&78'%8=T*M-..UK+3T[?(^XM-U&SU?3X-5TZ<2
MV]S"LL$B]&1AD'\C4U<;^S[]K_X4YH?VW._[.^W=_<\U]G_CN*[*O[CRC&RS
M'*L/BY*SJ0A-KMS13M\KG\^XV@L+C*E%.ZC)J_HV@HHHKT#F"BBB@ HHHH *
M**"0!DF@ HKYJN?^"BUIXPUK1A^SM\#M9\>:'JOC.\\-PZ_;ZK:645_=VVGW
M=[*+$3R SA5M67S)/)C8GY7;%>F?";]J;X;_ !<^#US\9].TOQ!I5C8:A<:?
MJNE:MH<HU&RO()/*EMFMH1([RJ_R[8]^3P,T >DT5\W?LI?\%+OA3^V+^T%X
MG^"/PI\%:Y!;>%M(:[N];UN+[*TTJW"0F)+8@R* 6))D*,"N"@ZUUW[27[8G
MAGX#?$'P5\$-#\.GQ'X]^(.H?9_#F@"_%K"D:G]Y=74^R0PP*,\K'([%6"HV
MUL 'L=%>-?LU?MC^%_CY\0/&GP1UOPZ?#GCWX?:A]F\1^'S?"ZB>,G"75K/L
MC,\#<<M'&Z[EW(-RYX;Q1_P4EL+C4?BE??!;X2'Q?X=^"\8;Q[K;^(!9,SKY
MIGCL(O(D%TT2PR%C(\"G80K-E20#Z>HKE?@C\9_ '[0WPIT3XS_"_5C>Z'K]
MF+BRF=-KKR5>-UYVNCJR,,G#*1D]:ZJ@ HHKXXT/]IC]HK4U^TW'Q%*0YXQI
M-IEOI^ZKX[BSC;*>#?8_783E[7FMR*+^'EO?FE'^96M?J:8:ABL;C887#4W.
M<K[6LDK7;;:26OZ;V/4_ /\ RD$\?_\ 8B:5_P"C&KW2OC+3_B/XXTOQ]J'Q
M1L=?9-?U2PBLK_4?LT1,L$1)1=A3RUP2>0H)[DU-KG[3/[16F+]IMOB(7ASS
MG2;3*_7]U7QR\;N%&_X-;_P&G_\ +#V\ZX9S?),$\54ASPCK+D=W%=VG9V76
MU[;O0^QZ***_8CP HJ*\O;/3X&NK^[B@B7[TDT@51]2>*X_Q'^T7\$O"VY=3
M^(VG.Z]8[*0W+9],1!L'ZUQ8S,LNR^/-BJT::[RDH_FT9U*M*DKSDEZNQVM%
M>$^)OV]/AYI^Z/PMX5U/4G'1YREO&WT/S-^:BL#_ (7[^UC\3OD^''PT_L^W
MD_U5TE@6_P#(LY$9_(5\CB/$;A>%3V6&G+$3_EI0E-_)V4?Q.*>:X-.T&Y/M
M%-_\ ^E'=(T,DC!5499B< "N(\8_M'_!CP1OCU;QS:33IP;;3R;A\^A\O(4_
M[Q%>1)^RW^T-\3'%Q\6OBIY$+G+6K7+W)3Z1J5C'X&NV\'?L4_!SPYLGUR&\
MUJ=>2;VX*1Y]DCV\>S%JP_MSCG-=,OR^-"+^W7EK_P""X>\GZLCZQF-;^%2Y
M5WD_T6IRWB#]N+5==O3HOPA^&=S>W#\0R7JM([?2&')/_?=9W_"M?VP/C>=_
MCCQ*V@Z;+]ZVEF\D%3V\F'YF^DA'UKZ*\/\ A;PUX4LQIWAC0+/3X/\ GE9V
MRQ@^YV@9/N:DU#Q!H.D?\A76[2U_Z^+E4_F1ZTGP9FF:KFSS,:E2/6G3_=4_
M1VUDO-V8/ 5:W^\U6_):+_@GDG@/]B/X6>&2EWXJN+K7KA<$K.?)@SZB-#D_
M1F(]J];T70=$\.6"Z7X?T>UL;9/N6]I L:#\% %4[_Q_X#TL*=3\;:1;;_N>
M?J42;OIEN:IW7Q?^%EG%YTOQ"T=EY_U.H1R'\D)->]EN7\*<.T^7"1I4O.ZN
M_63?,_FV>GALL]BK4:3^2=_OW.CHKC]2^/WP>TH*UUXZM6W=/LT<DWY^6K8_
M&N>\5?MH?LV>"X(KGQ)\16MUF)$/_$FO&+D#)'RPGU'6O9P&88#-<;#!X*M&
MK6G?EA"2E*5DV[1BVW9)MV6B39IC:=3+<++$XM.G3C;FE+W8J[25V[)7;25W
MNT>HT5P'QH_:7^%7P$T?2]<^(.HW<=OK._[ UI9-*7VJK'./N\.#S6)'^V3\
M,ID66+0->*N 5;[-!R#W_P!=3SG'X/A["4L3F<U1IU>90E/13<+*7+??ENKV
MVN3E\7FV*J8;!_O*E/E<XQU<5+6/-;;F2=K[GK5%>/:C^V1X.B _LGPEJ<Y[
MBY>.+_T$O69+^VEAOW/PUW#U;6<?^T37RD_$;@F"N\;'Y*3_ "1[JX8S]NWU
M>7X?YGNE%>#7_P"VC<[,6'@&*(_W[C4BP_((/YUY3/\ \%*/C[?SO#X=_9I$
MNUR%8)=3 @'K\B#/%?9<#XC"^(LJZR&HJOL>7G;O32YN;E_B*-_A?PWMUW1\
MMQ9C:?!*HO-XN'M>;ELN=OEM?X.:WQ+>U^FS/L^BO._BW\1?B?X:T_1;CX>^
M#3J#ZC:RR7J_V=-.UN0(BO$9&W[[?>!SM]C7G5U\5?VK+Q\6_A75;?/01>&'
MP/\ ON,U\OFO&& RG,)X.=&M.<;7Y*4IK57T:T9]%@\FQ&,PL<1&I",7_--1
M?W,^B:*\$N/$'[8UZ8S;Z;/;[AP([&UYZ==X./TJ'4=%_;+U%R;AKX9[V^HV
M<0_\<=:\R/'T:C_=Y7C)?]P;+[W)'9+AQP7O8N@O^XE_R3/H&BOF'XH?!W]N
MOQ9IMI'X,^*3:9.DQ-P?[<:'*%>A,2G)S_6N+_X8L_X*":MQK7[4NU#P4_X3
M'4W]ONB(#I[U^L\*Y;@.(<CIYAB\5'"2GS7I54_:1M)Q7,E=>\ES+79H_.>(
M<ZS')<VG@L+@9XF,;6J4VN25TGHWVO9Z;IGVE7AG[5_Q2U*SNH_AOH=VT*-
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M'AEWB'7C^]Q]&F_[E%R_]*DCZR>+X=IR_=X:<U_>J<O_ *3%G$77[9^GH?\
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M],L-I^22T33XI@/>3(<_B:MM8_M)7SDW'BS4HL]QXE11_P".2U],_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A7QE#PYP&'3C#&XI1;ORJLXQ7DE%+0_2XY[[."C
M3PM"-NU*/ZW/GP^"/CMJ$6VZ^-4,8*8*/K]R/P.Q"#^M9ES\!_'^HN6U+XDZ
M'-GJ9=3N7)_.&OI;^SM/_P"?&'_OT*/[.T__ )\8?^_0JX>&_#R?[R=:?^*M
M/]&C6?%&927NQA'TIQ_5,\'_ &E_V?;#]HKP)X7\)/\ &"#1Y]!7_2KH6;7
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M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZKYH_;";]H+Q[\4-(3X4^!;;4O#>D63"6:76+.$WDTI4
MO@22JZA B $CKOX((KZC_L[3_P#GQA_[]"C^SM/_ .?&'_OT*T@L#.G4HXS#
M4\13G%QE"HI.-GU]V46I+[+3O%ZJS2:Y<51Q-90>'Q$Z$XR4E*FXJ5T[V]Z,
MDXOJFK-:/1M/XZTSX5?%&]MA->^"FLY,?-%-J]DQS[%)V!KG/'WPT_:3DLWT
MWP%\-%65QAM0GU[3QL'^PIGY/N<8]*^Z/[.T_P#Y\8?^_0H_L[3_ /GQA_[]
M"OS[(_#/@O(\[CF7U55N5\T:564I4DUJO=3C*27:<I)_:31]+F_$G$&;93+
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /"_ /_ "D$\?\ _8B:5_Z,:O=*\+\ _P#*
M03Q__P!B)I7_ *,:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY0_:7_;K\0Z-^U9)^Q?\
M"[Q'HWAK5;?P-=Z[J/B;7+7[0\DRPM)#864)=$,[*/,+OO4*& 1B*^KZ^,_^
M"I?_  34^''[8NBWOQD\)^+8_#_Q"\):*Q:[4[X;VWB5YDAN44[HV'S;)5Y
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MBZ^*?_@=:4 ?5E%?*?\ P\$_:>_Z1=?%/_P.M*/^'@G[3W_2+KXI_P#@=:4
M?5E%?*?_  \$_:>_Z1=?%/\ \#K2C_AX)^T]_P!(NOBG_P"!UI0!]645\I_\
M/!/VGO\ I%U\4_\ P.M*/^'@G[3W_2+KXI_^!UI0!]645\I_\/!/VGO^D77Q
M3_\  ZTH_P"'@G[3W_2+KXI_^!UI0!]645\I_P##P3]I[_I%U\4__ ZTH_X>
M"?M/?](NOBG_ .!UI0!]645\I_\ #P3]I[_I%U\4_P#P.M*/^'@G[3W_ $BZ
M^*?_ ('6E 'U917RG_P\$_:>_P"D77Q3_P# ZTH_X>"?M/?](NOBG_X'6E '
MU917RG_P\$_:>_Z1=?%/_P #K2C_ (>"?M/?](NOBG_X'6E 'U917R#XP_X*
M7_M!>!O#%[XN\2?\$S?B796%A"9;JZN]2M4CC7.,LP!P.?0U<T[_ (*)?M*Z
MII\&IV7_  3!^*$D-Q"LL4D=_:E75@""#W!!H ^LJ*^4_P#AX)^T]_TBZ^*?
M_@=:4?\ #P3]I[_I%U\4_P#P.M* /JRBOE/_ (>"?M/?](NOBG_X'6E'_#P3
M]I[_ *1=?%/_ ,#K2@#ZLHKY3_X>"?M/?](NOBG_ .!UI1_P\$_:>_Z1=?%/
M_P #K2@#ZLHKY3_X>"?M/?\ 2+KXI_\ @=:4?\/!/VGO^D77Q3_\#K2@#ZLH
MKY3_ .'@G[3W_2+KXI_^!UI1_P /!/VGO^D77Q3_ / ZTH ^K**^4_\ AX)^
MT]_TBZ^*?_@=:4?\/!/VGO\ I%U\4_\ P.M* /JRBOE/_AX)^T]_TBZ^*?\
MX'6E'_#P3]I[_I%U\4__  .M* /JRBOE/_AX)^T]_P!(NOBG_P"!UI1_P\$_
M:>_Z1=?%/_P.M* /JRBOE/\ X>"?M/?](NOBG_X'6E'_  \$_:>_Z1=?%/\
M\#K2@#ZLHKY3_P"'@G[3W_2+KXI_^!UI1_P\$_:>_P"D77Q3_P# ZTH ^K**
M^4_^'@G[3W_2+KXI_P#@=:4?\/!/VGO^D77Q3_\  ZTH ^K**^4_^'@G[3W_
M $BZ^*?_ ('6E'_#P3]I[_I%U\4__ ZTH ^K**^4_P#AX)^T]_TBZ^*?_@=:
M4?\ #P3]I[_I%U\4_P#P.M* /JRBOE/_ (>"?M/?](NOBG_X'6E'_#P3]I[_
M *1=?%/_ ,#K2@#ZLHKY3_X>"?M/?](NOBG_ .!UI6/9?\%/?CS?^-KWX?VO
M_!-3XD/JFGV<=U=6*:I:F:**0D*[+C 4XX.3]* /L2BOE/\ X>"?M/?](NOB
MG_X'6E'_  \$_:>_Z1=?%/\ \#K2@#ZLHKY3_P"'@G[3W_2+KXI_^!UI1_P\
M$_:>_P"D77Q3_P# ZTH ^K**^4_^'@G[3W_2+KXI_P#@=:4?\/!/VGO^D77Q
M3_\  ZTH ^K**^4_^'@G[3W_ $BZ^*?_ ('6E'_#P3]I[_I%U\4__ ZTH ^K
M**^4_P#AX)^T]_TBZ^*?_@=:4?\ #P3]I[_I%U\4_P#P.M* /JRBOE/_ (>"
M?M/?](NOBG_X'6E'_#P3]I[_ *1=?%/_ ,#K2@#ZLHKY3_X>"?M/?](NOBG_
M .!UI1_P\$_:>_Z1=?%/_P #K2@#ZLHKY3_X>"?M/?\ 2+KXI_\ @=:4?\/!
M/VGO^D77Q3_\#K2@#ZLHKY3_ .'@G[3W_2+KXI_^!UI1_P /!/VGO^D77Q3_
M / ZTH ^K**^4_\ AX)^T]_TBZ^*?_@=:4?\/!/VGO\ I%U\4_\ P.M* /JR
MBOE/_AX)^T]_TBZ^*?\ X'6E'_#P3]I[_I%U\4__  .M* /JRBOE/_AX)^T]
M_P!(NOBG_P"!UI1_P\$_:>_Z1=?%/_P.M* /JRBOE/\ X>"?M/?](NOBG_X'
M6E'_  \$_:>_Z1=?%/\ \#K2@#ZLHKY3_P"'@G[3W_2+KXI_^!UI1_P\$_:>
M_P"D77Q3_P# ZTH ^K**^4_^'@G[3W_2+KXI_P#@=:5C^)?^"GOQY\)ZOI&B
M:Y_P34^)%K<ZY>&UTV&YU2U5[B4+N*1@ [FQS@D?6@#[$HKY3_X>"?M/?](N
MOBG_ .!UI1_P\$_:>_Z1=?%/_P #K2@#ZLHKY3_X>"?M/?\ 2+KXI_\ @=:4
M?\/!/VGO^D77Q3_\#K2@#ZLHKY3_ .'@G[3W_2+KXI_^!UI1_P /!/VGO^D7
M7Q3_ / ZTH ^K**^4_\ AX)^T]_TBZ^*?_@=:4?\/!/VGO\ I%U\4_\ P.M*
M /JRBOE/_AX)^T]_TBZ^*?\ X'6E'_#P3]I[_I%U\4__  .M* /JRBOE/_AX
M)^T]_P!(NOBG_P"!UI1_P\$_:>_Z1=?%/_P.M* /JRBOE/\ X>"?M/?](NOB
MG_X'6E'_  \$_:>_Z1=?%/\ \#K2@#ZLHKY3_P"'@G[3W_2+KXI_^!UI1_P\
M$_:>_P"D77Q3_P# ZTH ^K**^4_^'@G[3W_2+KXI_P#@=:4?\/!/VGO^D77Q
M3_\  ZTH ^K**^4_^'@G[3W_ $BZ^*?_ ('6E'_#P3]I[_I%U\4__ ZTH ^K
M**^4_P#AX)^T]_TBZ^*?_@=:4?\ #P3]I[_I%U\4_P#P.M* /JRBOE/_ (>"
M?M/?](NOBG_X'6E'_#P3]I[_ *1=?%/_ ,#K2@#ZLHKY3_X>"?M/?](NOBG_
M .!UI1_P\$_:>_Z1=?%/_P #K2@#ZLHKY3_X>"?M/?\ 2+KXI_\ @=:4?\/!
M/VGO^D77Q3_\#K2@#ZLHKY3_ .'@G[3W_2+KXI_^!UI1_P /!/VGO^D77Q3_
M / ZTH ^K**^._!'_!3WX\_$'2)=;\*_\$U/B1?6T-Y+:R366J6KHLL;;70D
M@?,#P1CCUK8_X>"?M/?](NOBG_X'6E 'U917RG_P\$_:>_Z1=?%/_P #K2C_
M (>"?M/?](NOBG_X'6E 'U917RG_ ,/!/VGO^D77Q3_\#K2C_AX)^T]_TBZ^
M*?\ X'6E 'U917RG_P /!/VGO^D77Q3_ / ZTH_X>"?M/?\ 2+KXI_\ @=:4
M ?5E%?*?_#P3]I[_ *1=?%/_ ,#K2C_AX)^T]_TBZ^*?_@=:4 ?5E%?*?_#P
M3]I[_I%U\4__  .M*/\ AX)^T]_TBZ^*?_@=:4 ?5E%?*?\ P\$_:>_Z1=?%
M/_P.M*/^'@G[3W_2+KXI_P#@=:4 ?5E%?*?_  \$_:>_Z1=?%/\ \#K2C_AX
M)^T]_P!(NOBG_P"!UI0!]645\I_\/!/VGO\ I%U\4_\ P.M*/^'@G[3W_2+K
MXI_^!UI0!]645\I_\/!/VGO^D77Q3_\  ZTH_P"'@G[3W_2+KXI_^!UI0!]6
M45\I_P##P3]I[_I%U\4__ ZTH_X>"?M/?](NOBG_ .!UI0!]645\I_\ #P3]
MI[_I%U\4_P#P.M*/^'@G[3W_ $BZ^*?_ ('6E 'U917RG_P\$_:>_P"D77Q3
M_P# ZTH_X>"?M/?](NOBG_X'6E 'U917RG_P\$_:>_Z1=?%/_P #K2C_ (>"
M?M/?](NOBG_X'6E 'U917RG_ ,/!/VGO^D77Q3_\#K2C_AX)^T]_TBZ^*?\
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MBTZ!;N6,)+=+"HD=1T4MC) ]*GH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*/VY_^31_'O\
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M(%9AB-EZ;WQU/_"XOV[?A1\#T_>Z;X%TZ\^('B*(_=,Z@V&F _[0EEN90/\
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M)&5F:ZO)%Y2"-$=CCEVV1K\TBU\ ?\%J?^3]_P!G+_L)6W_IT@K].6954LS
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MJ5W?V$]P\11I'C1("3%(K*J,P(RLI&#7W?7YB_\ !0/_ )3I_ 7_ +!N@_\
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M2R7LP  #2.L>-P$0#$5[W10   # %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5R_QC\'>,OB!\.M6\$^"?%^GZ'<ZMIT]F
M^HZCHKWZQ)+$R%EC2X@^8;LC+$<=*ZBB@#YB_P""<_\ P3X\7?\ !/W0=;\&
M6_QWL/%FBZYJ2WTT,G@Y[*XBF$7E_+*+V5=I 0X*$_*>>>/._P!I_P#X)-_M
M _M,?'O4_CK=_P#!0C5?#LUS#]CTG3=$\'S0IINGAMR6JNFI*7&?F9B!O<EL
M#@#[AHH ^-_A[_P2S\;?#_\ 9F\8_ #5_P!I>Z\6W_Q \2Z;+XG\4ZQITT-P
M=&MY(C+8H#<3,69%F4,7"XG(P,9/TG\>?AU\0OB/\'=5^&WP?^*4?@35-1M!
M:6_B*+1OMCV$)^5_)C$T.V39E5?=\F<@9 QVM% 'YMV/_!!#XOV.BKX6A_X*
M5>*$T@1&)]+@\,7"0&)L[D"?VGM .3Q@CGH:^L?VM?V'?!_[2FC^"-2T'6E\
M-^*OAGK5MJG@;7!9?:(K5X7B?[/-%N0R0N88L@,K QJ0>"K>YT4 >"_!3]BU
MO"O[3_BC]L[XP^)['7/'GB+3X=.LHM)T][>PT:RCCCC*0K))(\DCB)2TC$?>
M954 G/O5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?(G[9__!,WXB_MA?'?PE\;[S]I;2O#[^"'C?0M-@\ 27 +)<B<
M-,[:BN\Y5 =JH,+T&:]A_:C^!/QF_:&_9]O/@OX7^/MKX,U'64-OKWB+3?"S
MS&:T;<)((8FO%,&\%59S(YV[P -V5]:HH _/#P-_P0Q^)_AS7M#/BC_@H;XE
MUOP[I6H6DEWX8F\/7"6UY:PR(QM<'4G5%94V#Y&"Y'RG&*^POA'\!]7\$?'7
MXF?'7Q7K]M?W_CB]T^#3(K>)@-.TNRMO+A@RW\32O/*V."9!Z5Z;10!\<?MH
M_P#!,3XZ_M@?&V'XL1_MU:AX0L]*M6M?#6AZ+X2D']FPN!YO[Y-0C,DDC %W
MVKD*JX 4"NP_8#_X)]^)?V,=;\5>*/'G[2&J_$K5/$=K9VMM?:OITD#Z?! T
MS-&IDNIRP=I5)Y4#RQP<U]+T4 ?('QY_X)E?%#XZ?ME>%?VR[W]IW1M.U7P<
M;!=(T:'X=RR6[1VL\DX65CJ89MSRR D;>",8(S7USIT>H16,,>K74,]RL8$\
MUO 8HW;N51F<J/8LV/4U-10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '+_&/P=XR^('PZU;P3X)\7Z?H=SJVG3V;ZCJ.B
MO?K$DL3(66-+B#YANR,L1QTKPK_@G/\ \$^/%W_!/W0=;\&6_P =[#Q9HNN:
MDM]-#)X.>RN(IA%Y?RRB]E7:0$."A/RGGGCZ=HH ^'OVG_\ @DW^T#^TQ\>]
M3^.MW_P4(U7P[-<P_8])TW1/!\T*:;IX;<EJKIJ2EQGYF8@;W); X V?A[_P
M2S\;?#_]F;QC\ -7_:7NO%M_\0/$NFR^)_%.L:=-#<'1K>2(RV* W$S%F19E
M#%PN)R,#&3]D44 <5\>?AU\0OB/\'=5^&WP?^*4?@35-1M!:6_B*+1OMCV$)
M^5_)C$T.V39E5?=\F<@9 Q\(6/\ P00^+]CHJ^%H?^"E7BA-($1B?2X/#%PD
M!B;.Y G]I[0#D\8(YZ&OTDHH ^7_ -NW_@G]\4?VQ++PQX0\&?M5S?#SPMX7
M$4]GHNF>%GN));R/Y8[AIUO83^[3 C4*-I+-DDC;S7[&O_!*[QW^S'\>+/XV
M?$G]LC7OB0-,TRZM]+TG5])FB6VGG54,ZO)>S@$1^8F H)W]>,'[%HH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY$_;
M/_X)F_$7]L+X[^$OC?>?M+:5X??P0\;Z%IL'@"2X!9+D3AIG;45WG*H#M5!A
M>@S7UW10!Y+^U'\"?C-^T-^S[>?!?PO\?;7P9J.LH;?7O$6F^%GF,UHVX200
MQ->*8-X*JSF1SMW@ ;LK\E>!O^"&/Q/\.:]H9\4?\%#?$NM^'=*U"TDN_#$W
MAZX2VO+6&1&-K@ZDZHK*FP?(P7(^4XQ7Z'T4 >9?"/X#ZOX(^.OQ,^.OBO7[
M:_O_ !Q>Z?!ID5O$P&G:796WEPP9;^)I7GE;'!,@]*\%_;1_X)B?'7]L#XVP
M_%B/]NK4/"%GI5JUKX:T/1?"4@_LV%P/-_?)J$9DDD8 N^U<A57 "@5]CT4
M?(7[-/\ P2_^(/P \"?$K1-5_;1\3>(/$GCO08-+TKQE_9\MO>>'TC\]MT)>
M[F9MSRJQVO&1Y?!!.X;O@C]D/]L#6/@;J'[,_P"T=^UGI7BKPOJ5HUAJ&MV_
MA>5=?N[!^)+=KJ2Y:-2Z?(97BEDPS<EB'7Z@HH R_!/@OPO\.?!^E^ /!.C0
MZ=H^BV$5EIEC #L@@C0(B#/)P .3DGJ>:*U** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/$/[8OP]\2^'_B9:647C7P#K?]F>()=.C,<%]&Q<0W2QDGRRYBE5E!(W1DC
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MK;;]VW9YZYSZ8S0!9HJ&VU"PO25L[V&4K]X12!L?E4U !1110 4444 %%%%
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MZH_L7Q!_Z&L/_!$?\S[+ZOFG_/Y?^ H\2_X;^\'_ /1/]3_\"8Z/^&_O!_\
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M#O W@G0K;3-(TKXAZ=;:?86<02.")=/U *J@?Y)Y->O_  2_93^%%S_P4?\
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MF>&[:Q\?^)-/U?58XPMUJ&F:2]C#,0 "PA>:8IDY.-Y'->6?!3]BKX>?L_\
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MV8/VC8?"WA#XAMN\1>';GPV+JYL3YCR V4QE"(ZF641M(C"-9"&27 H ^?\
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M'7/BM\#?VPO@-X_3PA8>&? EC;7NCZ)I*A/$%FT!>,R2HZ\N)CO9UD+@+R"
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M/B%X5L;;QG+XO;08;"XLXS,T%X[I>SD$'?-9)!>3;STVQ 8P*_4SPEX2\,^
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M4I^ G['7BV:23P+=WFEZIK.C,Y$&J2SZA+$5E7I(HCMM@ST\Z3&,UZA^TO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT 4?_!4/_D3S?X8_LC_L^?!OQ2GC7X:^ WTS4D@>$7":S>2 QN/F5DDF96'
M/(." 1R :](HHKR\9CL;F%7VN*JRJ2M:\I.3MVNVW8]3!X# Y=1]EA*4:<;W
MM&*BK][))7"BBBN4ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723413136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUNITYBIO,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">43-1979754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3530 John Hopkins Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-5235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,952,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted herein, the information called for by Part&#160;III of this Annual Report is incorporated by reference to specified portions of the registrant&#8217;s definitive proxy statement to be filed in conjunction with the registrant&#8217;s 2024&#160;Annual Meeting of Stockholders, which is expected to be filed not later than 120&#160;days after the registrant&#8217;s fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> December&#160;31,&#160;2023.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728899072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los Angeles, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879722186992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 265,453<span></span>
</td>
<td class="nump">$ 104,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">2,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (including amounts with related parties)</a></td>
<td class="nump">25,603<span></span>
</td>
<td class="nump">31,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">294,084<span></span>
</td>
<td class="nump">140,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">146,082<span></span>
</td>
<td class="nump">143,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">17,093<span></span>
</td>
<td class="nump">20,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ConvertibleNoteReceivableNonCurrent', window );">Convertible note receivable</a></td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">6,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net (including amounts with related parties)</a></td>
<td class="nump">36,543<span></span>
</td>
<td class="nump">45,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets (including amounts with related parties)</a></td>
<td class="nump">2,880<span></span>
</td>
<td class="nump">4,860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">504,452<span></span>
</td>
<td class="nump">362,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">42,708<span></span>
</td>
<td class="nump">41,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Related-party promissory notes, net of discounts and deferred issuance costs (Note&#160;10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">431,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (including amounts with related parties)</a></td>
<td class="nump">5,244<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">58,283<span></span>
</td>
<td class="nump">500,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermNotesPayable', window );">Related-party nonconvertible note, net of discount (Note 10)</a></td>
<td class="nump">104,586<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Related-party convertible notes and accrued interest, net of discount (Note 10)</a></td>
<td class="nump">576,951<span></span>
</td>
<td class="nump">241,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Revenue interest liability (Note&#160;9)</a></td>
<td class="nump">155,415<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Derivative liabilities (Note&#160;9 and Note&#160;10)</a></td>
<td class="nump">35,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion (including amounts with related parties)</a></td>
<td class="nump">39,942<span></span>
</td>
<td class="nump">47,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">118,770<span></span>
</td>
<td class="nump">21,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,090,389<span></span>
</td>
<td class="nump">812,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001&#160;par value; 1,350,000,000 and 900,000,000&#160;shares authorized as of December&#160;31,&#160;2023 and 2022, respectively; 670,867,344 and 421,569,115 shares issued and outstanding as of December&#160;31,&#160;2023 and 2022, respectively; excluding 163,800&#160;treasury stock shares outstanding as of December&#160;31,&#160;2023 and 2022</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,374,620<span></span>
</td>
<td class="nump">1,930,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,961,684)<span></span>
</td>
<td class="num">(2,378,488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total ImmunityBio stockholders&#8217; deficit</a></td>
<td class="num">(586,987)<span></span>
</td>
<td class="num">(447,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(585,937)<span></span>
</td>
<td class="num">(449,820)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">504,452<span></span>
</td>
<td class="nump">362,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,195<span></span>
</td>
<td class="nump">21,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 3,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ConvertibleNoteReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible note receivable, non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ConvertibleNoteReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723419216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">670,867,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">670,867,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares outstanding (in shares)</a></td>
<td class="nump">163,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879724222928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">232,366<span></span>
</td>
<td class="nump">248,149<span></span>
</td>
<td class="nump">195,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">129,620<span></span>
</td>
<td class="nump">102,708<span></span>
</td>
<td class="nump">135,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">362,872<span></span>
</td>
<td class="nump">351,538<span></span>
</td>
<td class="nump">331,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(362,250)<span></span>
</td>
<td class="num">(351,298)<span></span>
</td>
<td class="num">(330,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Interest and investment income (loss), net</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="num">(3,090)<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense (including amounts with related parties)</a></td>
<td class="num">(129,198)<span></span>
</td>
<td class="num">(63,515)<span></span>
</td>
<td class="num">(14,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="num">(7,549)<span></span>
</td>
<td class="num">(12,107)<span></span>
</td>
<td class="num">(803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(47,600)<span></span>
</td>
<td class="nump">13,460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of related-party convertible note</a></td>
<td class="num">(36,203)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="num">(2,223)<span></span>
</td>
<td class="num">(736)<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(221,642)<span></span>
</td>
<td class="num">(65,988)<span></span>
</td>
<td class="num">(19,559)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes and noncontrolling interests</a></td>
<td class="num">(583,892)<span></span>
</td>
<td class="num">(417,286)<span></span>
</td>
<td class="num">(349,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">40<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(583,852)<span></span>
</td>
<td class="num">(417,320)<span></span>
</td>
<td class="num">(349,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(656)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
<td class="num">(3,058)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ImmunityBio common stockholders</a></td>
<td class="num">$ (583,196)<span></span>
</td>
<td class="num">$ (416,567)<span></span>
</td>
<td class="num">$ (346,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ImmunityBio common share - basic (in dollars per share)</a></td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (1.04)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ImmunityBio common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (1.04)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in computing net loss per share &#8211; basic (in shares)</a></td>
<td class="nump">508,635,592<span></span>
</td>
<td class="nump">399,900,374<span></span>
</td>
<td class="nump">389,234,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in computing net loss per share &#8211; diluted (in shares)</a></td>
<td class="nump">508,635,592<span></span>
</td>
<td class="nump">399,900,374<span></span>
</td>
<td class="nump">389,234,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879725940048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (583,852)<span></span>
</td>
<td class="num">$ (417,320)<span></span>
</td>
<td class="num">$ (349,848)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">60<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of net realized gains (losses) on available-for-sale securities included in net loss</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(218)<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(173)<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(584,025)<span></span>
</td>
<td class="num">(417,141)<span></span>
</td>
<td class="num">(349,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to ImmunityBio common stockholders</a></td>
<td class="num">$ (583,369)<span></span>
</td>
<td class="num">$ (416,388)<span></span>
</td>
<td class="num">$ (346,908)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879718208464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Offering Program</div></th>
<th class="th"><div>Registered Direct Offering</div></th>
<th class="th"><div>Revenue Interest Purchase Agreement</div></th>
<th class="th"><div>Total ImmunityBio Stockholders&#8217; Deficit</div></th>
<th class="th">
<div>Total ImmunityBio Stockholders&#8217; Deficit </div>
<div>ATM Offering Program</div>
</th>
<th class="th">
<div>Total ImmunityBio Stockholders&#8217; Deficit </div>
<div>Registered Direct Offering</div>
</th>
<th class="th">
<div>Total ImmunityBio Stockholders&#8217; Deficit </div>
<div>Revenue Interest Purchase Agreement</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM Offering Program</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Registered Direct Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Revenue Interest Purchase Agreement</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>ATM Offering Program</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Registered Direct Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Revenue Interest Purchase Agreement</div>
</th>
<th class="th"><div>Accumulated Deficit&#160;</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,243,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (118,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (119,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,495,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,615,131)<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 1,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Statements of Stockholders&#8217; Deficit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,295,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">57,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">5,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">873,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(4,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Sales of assets to an entity under common control</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty', window );">Gain on extinguishment of debt with related parties under common control</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(349,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(346,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(346,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,058)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,830,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="num">(243,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,961,921)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Statements of Stockholders&#8217; Deficit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,051,894<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,129<span></span>
</td>
<td class="nump">$ 13,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,129<span></span>
</td>
<td class="nump">$ 13,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,129<span></span>
</td>
<td class="nump">$ 13,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in exchange for notes payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,986,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in exchange for notes payable (Note&#160;10)</a></td>
<td class="nump">51,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">40,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Shares issued pursuant to litigation settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_StockIssuedDuringPeriodValueLitigationSettlement', window );">Shares issued pursuant to litigation settlement</a></td>
<td class="nump">10,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty', window );">Gain on extinguishment of debt with related parties under common control</a></td>
<td class="nump">82,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (417,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">$ (449,820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,930,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,378,488)<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Statements of Stockholders&#8217; Deficit [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,605,323<span></span>
</td>
<td class="nump">28,641,911<span></span>
</td>
<td class="nump">2,432,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,106<span></span>
</td>
<td class="nump">$ 36,931<span></span>
</td>
<td class="nump">$ 11,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,106<span></span>
</td>
<td class="nump">$ 36,931<span></span>
</td>
<td class="nump">$ 11,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,105<span></span>
</td>
<td class="nump">$ 36,928<span></span>
</td>
<td class="nump">$ 11,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in exchange for notes payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,291,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in exchange for notes payable (Note&#160;10)</a></td>
<td class="nump">269,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl', window );">Gain on debt extinguishment with related-parties under common control (Note 10)</a></td>
<td class="nump">36,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature', window );">Increase in fair value of embedded conversion feature from debt modification with entities under common control (Note 10)</a></td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 49,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">184,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,545,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,403,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(3,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty', window );">Gain on extinguishment of debt with related parties under common control</a></td>
<td class="nump">36,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement', window );">Change in ownership interest in a joint venture due to legal settlement (Note 7)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (583,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(583,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(583,196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(656)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">670,867,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,867,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="num">$ (585,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (586,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,374,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,961,684)<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>APIC, Debt Instrument, Convertible, Increase In Fair Value Of Embedded Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Gain (Loss) On Extinguishment Of Debt With Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Debt Extinguishment, Entities Under Common Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase (Decrease) From Legal Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_StockIssuedDuringPeriodValueLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_StockIssuedDuringPeriodValueLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728876736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_AtTheMarketOfferingProgramMember', window );">At-the-Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Commissions and offering costs</a></td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 4,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Commissions and offering costs</a></td>
<td class="nump">3,535<span></span>
</td>
<td class="nump">$ 1,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Commissions and offering costs</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879721936480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (583,852)<span></span>
</td>
<td class="num">$ (417,320)<span></span>
</td>
<td class="num">$ (349,848)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">49,163<span></span>
</td>
<td class="nump">40,179<span></span>
</td>
<td class="nump">57,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">47,600<span></span>
</td>
<td class="num">(13,460)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of related-party notes discounts</a></td>
<td class="nump">42,396<span></span>
</td>
<td class="nump">16,282<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of convertible note</a></td>
<td class="nump">36,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">18,512<span></span>
</td>
<td class="nump">18,260<span></span>
</td>
<td class="nump">14,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest items, net (including amounts with related parties)</a></td>
<td class="nump">9,189<span></span>
</td>
<td class="nump">11,746<span></span>
</td>
<td class="nump">12,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense related to operating lease right-of-use assets</a></td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
<td class="nump">4,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized losses on equity securities</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">4,190<span></span>
</td>
<td class="nump">4,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums, net of discounts, on marketable debt securities</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(407)<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,958<span></span>
</td>
<td class="num">(16,557)<span></span>
</td>
<td class="num">(2,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
<td class="num">(3,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(6,476)<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="num">(3,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">6,689<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
<td class="nump">5,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent', window );">Related parties</a></td>
<td class="num">(1,129)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(10,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,978)<span></span>
</td>
<td class="num">(4,319)<span></span>
</td>
<td class="num">(4,164)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(366,757)<span></span>
</td>
<td class="num">(337,509)<span></span>
</td>
<td class="num">(274,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(30,584)<span></span>
</td>
<td class="num">(78,162)<span></span>
</td>
<td class="num">(33,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable debt securities, available-for-sale</a></td>
<td class="num">(10,358)<span></span>
</td>
<td class="num">(34,312)<span></span>
</td>
<td class="num">(141,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable debt securities, available for sale</a></td>
<td class="nump">10,100<span></span>
</td>
<td class="nump">128,188<span></span>
</td>
<td class="nump">56,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of marketable debt and equity securities</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">33,812<span></span>
</td>
<td class="nump">13,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in joint venture &#8211; an equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(30,470)<span></span>
</td>
<td class="nump">27,297<span></span>
</td>
<td class="num">(84,886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party promissory notes net of issuance costs paid</a></td>
<td class="nump">258,700<span></span>
</td>
<td class="nump">174,125<span></span>
</td>
<td class="nump">338,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the RIPA, net of transaction costs</a></td>
<td class="nump">192,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">5,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(3,443)<span></span>
</td>
<td class="num">(616)<span></span>
</td>
<td class="num">(4,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments of finance leases</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Sale of assets to an entity under common control</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">558,341<span></span>
</td>
<td class="nump">233,613<span></span>
</td>
<td class="nump">505,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(292)<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">160,822<span></span>
</td>
<td class="num">(76,315)<span></span>
</td>
<td class="nump">146,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, beginning of year</a></td>
<td class="nump">104,965<span></span>
</td>
<td class="nump">181,280<span></span>
</td>
<td class="nump">35,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, end of year</a></td>
<td class="nump">265,787<span></span>
</td>
<td class="nump">104,965<span></span>
</td>
<td class="nump">181,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash, end of year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">265,453<span></span>
</td>
<td class="nump">104,641<span></span>
</td>
<td class="nump">181,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash (Note 2)</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, end of year</a></td>
<td class="nump">265,787<span></span>
</td>
<td class="nump">104,965<span></span>
</td>
<td class="nump">181,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">77,192<span></span>
</td>
<td class="nump">35,442<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of related-party convertible notes and accrued interest, net of unamortized discount, into equity</a></td>
<td class="nump">269,987<span></span>
</td>
<td class="nump">51,947<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IssuanceOfWarrants', window );">Initial measurement of warrants issued in connection with registered direct offerings accounted for as liabilities</a></td>
<td class="nump">49,534<span></span>
</td>
<td class="nump">35,096<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty', window );">Gain on extinguishment of debt with related parties under common control</a></td>
<td class="nump">36,110<span></span>
</td>
<td class="nump">82,858<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative', window );">Increase in fair value of embedded conversion feature from debt modification</a></td>
<td class="nump">31,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability', window );">Common stock issuance discount related to the revenue interest liability</a></td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable, accrued expenses and due to related parties</a></td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">12,693<span></span>
</td>
<td class="nump">11,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,798<span></span>
</td>
<td class="nump">23,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets disposed in exchange for operating lease liabilities</a></td>
<td class="num">(3,777)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued pursuant to litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,656<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Unpaid offering and transaction costs included in accounts payable and accrued expenses</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_StockIssuedCashlessExerciseOfStockOptions', window );">Cashless exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid', window );">Accrued investment in joint venture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_PrivatePlacementAndAtTheMarketOfferingsMember', window );">Private Placement and At The Market Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="nump">100,561<span></span>
</td>
<td class="nump">60,427<span></span>
</td>
<td class="nump">164,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember', window );">Stock Purchase and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="nump">$ 9,542<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Gain (Loss) On Extinguishment Of Debt With Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CommonStockDiscountOnSharesRevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Discount On Shares, Revenue Interest Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CommonStockDiscountOnSharesRevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in due to related parties current and non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_InvestmentsInJointVentureIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Joint Venture, Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_InvestmentsInJointVentureIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Disposed In Exchange for Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_StockIssuedCashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued, Cashless Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_StockIssuedCashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_TransactionCostsWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs, Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_TransactionCostsWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid Offering and Transaction Costs Included in Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_PrivatePlacementAndAtTheMarketOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_PrivatePlacementAndAtTheMarketOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879820831744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to the consolidated financial statements, the terms &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio and subsidiaries.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Using our proprietary platforms that amplify both the innate and adaptive branches of the immune system, our teams of clinical, scientific, and manufacturing experts, advance novel therapies and vaccines aimed at defeating urologic and other cancers, as well as infectious diseases. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations and is currently under review by the FDA for treatment in combination with BCG of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease and has a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including&#8212;NK cells, dendritic cells, and macrophages, as well as&#8212;the adaptive immune system comprising&#8212;B&#160;and T&#160;cells,&#8212;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally-infected. Our ultimate goal is to overcome the limitations of current treatments, such as checkpoint inhibitors, and/or reduce the need for standard high-dose chemotherapy in cancer by employing this coordinated approach to establish &#8220;immunological memory&#8221; that confers long-term benefit for the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary platforms for the development of biologic product candidates include: (i)&#160;antibody-cytokine fusion proteins, (ii)&#160;DNA, RNA, and recombinant protein vaccines, and (iii)&#160;cell therapies. These platforms have generated 9&#160;novel therapeutic agents for which clinical trials are either underway or planned in solid and liquid tumors. Specifically, our clinical focus includes bladder, lung, and colorectal cancers and GBM, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. In May&#160;2022, we announced the submission of a BLA to the FDA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. The CRL did not request new preclinical studies or Phase&#160;III clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company&#8217;s resubmission, as well as a safety update. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. As part of our resubmission, we provided an update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG unresponsive subjects with high-risk CIS disease. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;21,&#160;2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NantKwest and NantCell,&#160;Inc. (formerly known as ImmunityBio,&#160;Inc., a private company) (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NantCell)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into an Agreement and Plan of Merger (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), pursuant to which NantKwest and NantCell agreed to combine their businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;9,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the Effective Time), each share of NantCell common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $0.001&#160;per share, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted auto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matically </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the Exchange Ratio into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">newly issued shares of Company Common Stock, with cash paid in lieu of any fractional shares.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, RSU or warrant to purchase NantCell common stock was converted using the Exchange Ratio into an option, RSU or warrant, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71.5% </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the outstanding shares of Company Common Stock and the stockholders of NantKwest as of immediately prior to the Merger held approximately&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.5% o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Chairman and Global Chief Scientific and Medical Officer,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and his affiliates beneficially owned, in the aggregate, approxim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ately&#160;81.8% of th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e outstanding shares of Company Common Stock. Following the consummation of the Merger, the symbol for shares of the company&#8217;s common stock was changed to &#8220;IBRX.&#8221;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.0&#160;million of costs </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the Merger in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations, consisting of financial advisory, legal and other professional fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Treatment of the Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger represents a business combination pursuant to ASC&#160;805-50, which was accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We recast our prior period financial statements for the year ended December&#160;31,&#160;2021 to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the consolidated financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the impact of the change in reporting entity on our unaudited condensed consolidated statement of operations for the three&#160;months&#160;ended March&#160;31,&#160;2021 (in&#160;thousands):</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:50.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NantCell</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NantKwest</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intercompany<br/>Eliminations</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">ImmunityBio,<br/>Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (including amounts<br/>with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (including amounts<br/>with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(45,708)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(40,628)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(86,264)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net (including amounts <br/>with related parties)</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(848)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,637&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,789&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(46,556)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(33,997)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(80,481)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727828864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S.&#160;GAAP and pursuant to the rules and regulations of the SEC. Certain items in the prior years&#8217; consolidated financial statements have been reclassified to conform to the current presentation. These reclassifications had no effect on the reported results of operations. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a VIE for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities in which we have less than 100% ownership, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net loss attributable to noncontrolling interests, net of tax,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impacts the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the entity is within the scope of the variable interest model and meets the definition of a VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the company had an accumulated deficit of $3.0&#160;billion. We also had negative cash flows from operations of $366.8&#160;million during the year ended December&#160;31,&#160;2023. The company will likely need additional capital to further fund the development of, and to seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of our common stock under the ATM, of which we had $208.8&#160;million available for future issuance as of December&#160;31,&#160;2023, and a February&#160;2023 shelf registration statement, of which we had $565.6&#160;million available for future offerings as of December&#160;31,&#160;2023), a potential $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including upon approval of N-803 before June&#160;30,&#160;2024, and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek to sell additional equity, through one or more follow-on offerings, or in separate financings, or obtain incremental subordinated debt in compliance with our existing revenue interest liability. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the potential commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, CVR&#160;measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants, stock options, derivative liabilities, and convertible promissory notes, fair value measurements, revenue interest liability, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain judgments to determine whether transactions should be accounted for as acquisitions of assets or as business combinations. If it is determined that substantially all of the fair value of gross assets acquired in a transaction is concentrated in a single asset (or a group of similar assets), the transaction is treated as an acquisition of assets. We evaluate the inputs, processes, and outputs associated with the acquired set of activities and assets. If the assets in a transaction include an input and a substantive process that together significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which requires that assets acquired and liabilities assumed generally be recorded at their fair values as of the acquisition date. Excess of consideration over the fair value of net assets acquired is recorded as goodwill. Estimating fair value requires us to make significant judgments and assumptions. We perform impairment testing of goodwill annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions accounted for as asset acquisitions, the cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. In an asset acquisition, upfront payments allocated to in-process research and development projects at the acquisition date are expensed unless there is an alternative future use. In addition, product development milestones are expensed upon achievement. Any contingent consideration, such as payments upon achievement of various developmental, regulatory, and commercial milestones, generally is not recognized at the acquisition date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attempt to minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also monitor the creditworthiness of the borrower of the convertible promissory note. We believe that any concentration of credit risk in its convertible note receivable was mitigated in part by our ability to convert, if necessary, at the qualifying financing event or upon a payment default into shares of the senior class of equity securities of the borrower.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates developed by us will require approvals or clearances from the&#160;FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</span></div><div style="margin-top:12pt"><span id="i4643e1a07ce0428bbdfe8baf8b53beac_51425"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include highly liquid investments with an original maturity of three&#160;months or less from the date of purchase.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes a certificate of deposit held as a substitute letter of credit for one of our leased properties. This certificate of deposit is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash is included on the consolidated statements of cash flows as of December&#160;31,&#160;2023, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Other Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have typically invested our cash in a variety of financial instruments, including investment-grade short- to intermediate-term corporate debt securities, government-sponsored securities and European bonds; however, after our entry into the RIPA, we can no longer invest our excess funds in corporate or European bonds. Certain of our investments are subject to credit, liquidity, market, and interest-rate risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive income,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest and investment income (loss), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. Realized gains and losses from sales of securities and the amounts, net of tax, reclassified out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if any, are determined on a specific identification basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in mutual funds and equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and any unrealized gains and losses are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. Realized gains and losses from the sale of the securities are determined on a specific identification basis and the amounts are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluating Investments for Other-than-Temporary Impairments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether we have plans to sell the security or whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded during the years ended December&#160;31,&#160;2023, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method of Accounting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, we record our share of the income or loss of the other company as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">loss on equity method investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our consolidated statement of operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to operating expenses during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IT equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The lesser of the lease term or life of the asset</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal of property, plant and equipment, the cost and related accumulated depreciation are removed from the consolidated financial statements and the net amount, less any proceeds, is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review impairment of property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method of accounting in accordance with ASC&#160;805-50. These standards require that the total cost of acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition, with the excess purchase price recorded as goodwill. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration incurred in connection with a business combination are recorded at their fair values on the acquisition date and re-measured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair value are recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations and comprehensive loss. Changes in fair value reflect changes to our assumptions regarding probabilities of successful achievement of related milestones, the timing in which the milestones are expected to be achieved, and the discount rate used to estimate the fair value of the obligation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Control Transactions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions between us and entities where Dr.&#160;Soon-Shiong and his affiliates are the controlling stockholders are accounted for as common control transactions whereby the net assets acquired or transferred are accounted at their carrying value. Any difference between the carrying value and consideration recognized is treated as a capital transaction. Cash consideration up to the carrying value of the net assets acquired or transferred is presented as an investing activity on the consolidated statement of cash flows. Cash consideration in excess of the carrying value of the net assets acquired or transferred is presented as a financing activity on the consolidated statement of cash flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired in a business combination or an asset acquisition are initially recognized at their fair value on the acquisition date. Acquired indefinite-lived assets, such as IPR&amp;D, are not amortized until they become definite-lived assets, upon the successful completion of the associated research and development effort. At that time, we evaluate whether the recorded </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are impaired and make any necessary adjustments, and then determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned, the related IPR&amp;D assets is written-off and an impairment charge recorded. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired definite-lived intangible assets are amortized using the straight-line method over their respective estimated useful lives. The amortization of these intangible assets is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. Intangible assets are tested for impairment at least annually or more frequently if indicators of potential impairment exist. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent costs, including related legal costs, are expensed as incurred and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three tiers are defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities, and corporate bonds, as well as foreign municipal securities.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, no transfers were made into or out of the Level&#160;1, 2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of FASB ASC Topic&#160;808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;808). A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. To the extent the collaboration agreement is within the scope of ASC&#160;808, we also assess whether the arrangement contains multiple elements that are within the scope of other accounting literature. If we conclude that some or all aspects of the agreement are distinct and represent a transaction with a customer, we account for those aspects of the arrangement within the scope of FASB ASC Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;606). Amounts that are owed by collaboration partners within the scope of ASC&#160;808 are recognized as an offset to research and development expense as such amounts are incurred by the collaboration partner. The amounts owed to a collaboration partner are classified as research and development expense.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration arrangements require us to acquire certain equipment for exclusive use in the joint operating activities. These equipment purchases do not have an alternative use and are therefore expensed as incurred within research and development expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration arrangements are further discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements and Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing the consolidated financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate clinical trial and research agreement-related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research-related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Related Parties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have various agreements with related parties. These arrangements can be billed and settled in cash monthly, billed quarterly and settled in cash the following month, or estimated in advance and collected or paid upfront based on expected utilization. Monthly accruals are made for all quarterly billing arrangements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases other than short-term leases, at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At the commencement date, lease right-of-use assets and lease liabilities are determined based on the present value of lease payments to be made over the lease term. Leases are classified as either finance leases or operating leases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the rate implicit in lease contracts are not readily determinable, we utilize its incremental borrowing rate as a discount rate for purposes of determining the present value of lease payments, which is based on the estimated interest rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, we will remeasure the lease liability at the net present value of the remaining lease payments using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, the exercise of renewal is only assured for five&#160;of our cGMP facilities where we have made significant improvements or extended the lease.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We combine our lease components (e.g.,&#160;fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g.,&#160;common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term. The lease term includes the non-cancellable period of the lease and any additional periods covered by either options to renew or not to terminate when the company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC&#160;480 and ASC&#160;815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther expense, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounted for a convertible note issued on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the&#160;FVO&#160;election of ASC&#160;825 until it was amended and restated on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023. Prior to its extinguishment on December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the convertible note was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issuance-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of this convertible note were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations, except that changes in estimated fair value caused by changes in the instrument-specific credit risk were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with ASC&#160;470-50, when the convertible note was extinguished on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the cumulative amount previously recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting from changes in the instrument-specific credit risk were reclassified and reported in current earnings on the consolidated statement of operations. See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;10</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Modification and Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company evaluates amendments to its debt instruments in accordance with ASC&#160;470-50. This evaluation includes comparing (1)&#160;if applicable, the net present value of future cash flows of the amended debt to that of the original debt and (2)&#160;the change in fair value of an embedded conversion feature to that of the carrying amount of the debt immediately prior to amendment to determine, in each case, if a change greater than 10% occurred. In instances where the net present value of future cash flows or the fair value of an embedded conversion feature, if any, changed more than 10%, the company applies extinguishment accounting. In instances where the net present value of future cash flows and the fair value of an embedded conversion feature, if any, changed less than 10%, the company accounts for the amendment to the debt as a debt modification. Gains and losses on debt amendments that are considered extinguishments are recognized in current earnings or in additional paid-in capital if the transactions are with entities under common control. Debt amendments that are considered debt modifications are accounted for prospectively through yield adjustments, based on the revised terms. The increase in fair value of the embedded conversion feature from the debt modification was accounted for as an increase in debt discount with a corresponding increase in additional paid-in capital. Legal fees and other costs incurred with third parties that are directly related to debt modifications are expensed as incurred. Amounts paid by the company to the lenders, are reflected as additional debt discount and amortized as an adjustment of interest expense over remaining term of modified debt using the effective interest rate method.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize uncertain tax positions when the position will more likely than not be upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax benefit (expense),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31,&#160;2023 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program. As it is our intent for the repurchased shares to be retired, we have elected to account for the shares repurchased using the constructive retirement method. For shares repurchased in excess of par, we record the purchase price in excess of par value in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Interest Liability</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter. The RIPA is considered a sale of future revenues and is accounted for as a liability net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability, interest expense, and the time period for repayment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Embedded derivatives that are required to be bifurcated from the underlying debt instrument that do not meet the derivative scope exception and equity classification criteria are accounted for and valued as separate financial instruments. The terms of an embedded derivative related to a contingent exercisable prepayment feature of a convertible note have been evaluated and deemed to require bifurcation. This embedded derivative will be initially measured at fair value and will be remeasured to fair value at each reporting date until the derivative is settled. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains certain features that meet the definition of being an embedded derivative requiring bifurcation as a separate compound financial instrument apart from the RIPA. The derivative liability is initially measured at fair value upon issuance and is subject to remeasurement at each reporting period with changes in fair value recognized in other expense, net, on the consolidated statement of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have primarily generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. The nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies grant them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines. We have generated revenues from product sales of our proprietary GMP-in-a-Box bioreactors and related consumables, primarily to related parties. Additionally, we also generated revenues from grant programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreements with customers, we typically promise to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. Research and development data are provided throughout the term of the contract when and if available.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have sold our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies. The arrangements typically include delivery of bioreactors, consumables, and providing installation service and perpetual software licenses for using the equipment. We recognize revenue when customers obtain control and can benefit from the promised goods or services, generally upon installation of the bioreactors, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. Upfront payments and fees are recorded as deferred revenue upon receipt and recognized as revenue when we satisfy our performance obligations under these arrangements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue is typically paid for reimbursable costs incurred over the duration of the associated research project or clinical trial and is recognized either when expenses reimbursable under the grants have been incurred and payments under the grants become contractually due or when cash is received, depending on the certainty of payment and other factors specific to each grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December&#160;31,&#160;2023, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials costs, including CROs and related clinical manufacturing, including third-party CMOs, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classifies its research and development expenses as either external or internal. The&#160;company&#8217;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#8217;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#8217;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the preclinical studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates. We adjust the accruals in the period when actual costs become known.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation under the provisions of ASC&#160;718. We estimate fair value of each stock option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions, including, but not limited to, expected stock price volatility over the term of the awards and the expected term of the stock options. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;14</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale-Leaseback Transaction</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sale-leaseback transaction occurs when an entity sells an asset it owns and immediately leases the asset back from the buyer. The seller then becomes the lessee and the buyer becomes the lessor. When entering into a sale-leaseback transaction as a seller-lessee, the requirements in ASC&#160;606, and all related ASUs to such Topic are applied in determining whether the transfer of an asset shall be accounted for as a sale of the asset by assessing whether it satisfies a performance obligation under the contract by transferring control of an asset. If the company transfers control of an asset to the buyer-lessor, the transfer is accounted for as a sale and the company derecognizes the transferred asset. The subsequent leaseback of the asset is accounted for in accordance with FASB ASC&#160;Topic&#160;842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same manner as any third-party lease. If the company does not transfer control of an asset to the buyer-lessor, the sale-leaseback transaction is accounted for as a financing arrangement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net (loss) income and other comprehensive (loss) income. Our other comprehensive income or loss consists of net unrealized gains (losses) on marketable debt securities classified as available-for-sale, net of income taxes and foreign currency translation adjustments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests are recorded for the entities that we consolidate but are not wholly-owned by the company. Noncontrolling interests are classified as a separate component of equity on the consolidated balance sheet and consolidated statement of stockholders&#8217; deficit. Additionally, net loss attributable to noncontrolling interests is reflected separately from consolidated net loss on the consolidated statement of operations and the consolidated statement of stockholders&#8217; deficit. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the noncontrolling interests&#8217; share of loss based on the percentage of ownership interest retained by the respective noncontrolling interest holders. Noncontrolling interests recorded on the consolidated financial statements result from the company&#8217;s share of GlobeImmune, of which we controlled 69.1% as of December&#160;31,&#160;2023, 2022 and 2021, respectively, and NANTibody, of which we controlled 100.0% as of December&#160;31,&#160;2023 and 60.0% as of December&#160;31,&#160;2022 and 2021, respectively. Noncontrolling interest stockholders are common stockholders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GlobeImmune was determined to be a VIE as it does not have sufficient equity investment at risk to finance its operations without additional subordinated financial support and we are deemed the primary beneficiary of GlobeImmune and, accordingly, consolidate GlobeImmune into the company&#8217;s consolidated financial statements under the VIE model. The company also supports GlobeImmune through a promissory note agreement, in which the company provides advances to GlobeImmune from time to time up to $6.0&#160;million with a per annum interest rate of five&#160;percent (5%). As of December&#160;31,&#160;2023 and 2022, there were no outstanding advances due from GlobeImmune under the promissory note agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022, and 2021, GlobeImmune recognized no revenue, respectively, and recognized $0.3&#160;million, $0.5&#160;million, and $0.7&#160;million of operating expenses, respectively, during the years ended December&#160;31,&#160;2023, 2022 and 2021. As of both December&#160;31,&#160;2023 and 2022, the consolidated balance sheets included approximately $1.4&#160;million of total assets that can only be used to settle obligations of GlobeImmune, and no&#160;liabilities, respectively, related to GlobeImmune. The creditors of GlobeImmune do not have recourse to the general credit of the primary beneficiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and hold assets in Italy and South Korea. The functional currency of the subsidiary in Italy is the Euro, based on the nature of the transactions occurring within this entity, and accordingly, assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates prevailing as of the balance sheet dates, while the operating results are translated into U.S.&#160;dollars using the average exchange rates for the period correlating with those operating results. Adjustments resulting from translating the financial statements of the foreign subsidiary into U.S.&#160;dollars are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of comprehensive loss. Transaction gains and losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,471,837</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,274,965</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding third-party warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,732,820</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,090,909</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,820,435</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,262,926</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,124,930</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503,979</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,889</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding related-party warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,167,071</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,818,188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278,819</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dilutive securities exclude the option to purchase up to $10.0&#160;million of the company&#8217;s common stock pursuant to the SPOA entered in connection with the RIPA, as the exercise price is not yet determined. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_223" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_223" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_223" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Deficit,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Our CEO is the chief operating decision-maker of the company, and manages and allocates resources to our operations on a company-wide basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future-period financial results, allocating resources, and setting incentive targets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate a portion of our revenues from outside of the U.S. Information about our revenues by geographic region is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span id="i4643e1a07ce0428bbdfe8baf8b53beac_102909"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2023, the FASB issued ASU&#160;2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic&#160;740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1)&#160;disclose specific categories in the rate reconciliation, (2)&#160;provide additional information for reconciling items that meet a quantitative threshold, and (3)&#160;disclose more detailed information about income taxes paid, including by jurisdiction; pretax income (or loss) from continuing operations; and income tax expense (or benefit). The ASU is effective for fiscal years beginning after December&#160;15,&#160;2024, and interim periods beginning after December&#160;15,&#160;2025, with early adoption permitted. We are currently evaluating the impact of this standard on our disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2023, the FASB issued ASU&#160;2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic&#160;280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, and interim periods within fiscal years beginning after December&#160;15,&#160;2024 on a retrospective basis. We are currently evaluating the impact of this standard on our disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2023, the FASB issued ASU 2023-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations-Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a joint venture to initially measure all contributions received upon its formation at fair value. This ASU is applicable to joint venture entities with a formation date on or after January&#160;1,&#160;2025 on a prospective basis. We will apply this guidance prospectively in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2023, the FASB issued ASU&#160;2023-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Common Control Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC) and the SEC during the year ended December&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879719127376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Financial Statement Details</a></td>
<td class="text">Financial Statement Details<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid software license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance premium financing asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance claims receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid equipment maintenance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ERP system implementation cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture &amp; fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">230,458&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">212,911&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, depreciation expense related to property, plant and equipment totaled $16.5&#160;million, $16.3&#160;million and $14.2&#160;million, respectively.</span></div><div><span id="i5152da74782c4119b27351f18d5b573b_17470"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Definite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,825)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(886)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Organized workforce</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,935)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,613&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,935)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definite-Lived Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the Dunkirk Facility in 2022, we acquired definite-lived intangibles consisting of favorable leasehold rights and an organized workforce. During the year ended December&#160;31,&#160;2022, we wrote off the entire unamortized organized workforce intangible asset totaling $0.7&#160;million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> impairment of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements and Acquisition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023 and 2022, we recorded amortization expense of definite-lived intangible assets totaling $2.0&#160;million and $1.9&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we discontinued the research and development program associated with the&#160;Tarmogen platform based on results gathered from clinical data. We recorded a charge totaling $0.9&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">impairment of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations in connection with the writedown of the carrying value of Tarmogen to zero. No such impairments were recorded during the years&#160;ended December&#160;31,&#160;2022 and 2021. As of December&#160;31,&#160;2023 and 2022, the company had indefinite-lived IPR&amp;D intangible assets of $0.5&#160;million and $1.4&#160;million, respectively, which were obtained from business acquisitions.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense associated with our definite-lived intangible assets is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Definite-lived</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intangible</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Note Receivable</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we executed a convertible promissory note pursuant to which we advanced Riptide a principal amount of $5.0&#160;million. The note bears interest at a per annum rate of five percent&#160;(5%). Concurrent with the transaction, we entered into an exclusive license agreement with Riptide to obtain worldwide exclusive rights, with the right to sublicense, certain know-how related to RP-182, RP-233 and RP-183. We are required to pay a single-digit royalty on net sales of the licensed products on a country-by-country basis. Pursuant to the license agreement, we are also required to make cash milestone payments upon successful completion of certain clinical, regulatory and commercial milestones up to an aggregate amount of $47.0&#160;million for the first three&#160;indications of the licensed product with a maximum payment amount of $100.0&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a first amendment to the convertible promissory note with Riptide. Under the agreement, we extended the maturity of the promissory note to the earlier of (a)&#160;the later of (i)&#160;the completion of non-clinical IND enabling studies by the company, or (ii)&#160;December&#160;31,&#160;2020; and (b)&#160;when we accelerate the maturity of the note upon the occurrence of an event of default. No other terms and conditions of the promissory note were modified. Concurrently, we also entered into a first&#160;amendment to the exclusive license agreement with Riptide and extended the achievement dates for certain clinical trial milestones related to the licensed products. This option for receiving a 25%&#160;discount was determined to have an immaterial value at inception and life-to-date of the note, as the probability of a future qualifying event is remote. The convertible note receivable balance was $6.9&#160;million and $6.6&#160;million, which included accrued interest of $1.9&#160;million and $1.6&#160;million as of December&#160;31,&#160;2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional and service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued preclinical and clinical trial costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing obligation &#8211; current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued construction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Investment Income (Loss), Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and investment income (loss), net consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses from equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment accretion income (amortization expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and investment income (loss), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,090)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes interest from marketable securities, convertible notes receivable, other assets, and on bank deposits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on related-party notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,198&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,515&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,849&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879730109840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:34.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;<br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, 12&#160;of the securities were in an unrealized loss position. Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): </span></div><div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, we evaluated our securities for other-than-temporary impairment and did not recognize any other-than-temporary impairment losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, we held investments in marketable equity securities with readily determinable fair values of $0.9&#160;million and $2.5&#160;million, respectively. During the years ended December&#160;31,&#160;2023, 2022 and 2021, unrealized losses recorded on these securities totaled $1.6&#160;million, $4.2&#160;million, and $4.6&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest and investment income (loss), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org//325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728321120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recurring Valuations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">265,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">265,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,353&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock option purchase liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,024&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,403&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,621&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration is recorded at estimated fair value and revalued each reporting period until the related contingency is resolved. The fair value measurement is based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Contingent Consideration Related to Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the carrying amount of contingent consideration were as follows (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:60.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (increase) decrease in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock Option Purchase Liability</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the RIPA, we entered into an SPOA pursuant to which Oberland has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability at its fair value upon issuance. The fair value was estimated using probability-weighted scenarios over the likelihood of this option being exercised. As of December&#160;31,&#160;2023, the stock purchase option was outstanding. The fair value of the stock purchase option was estimated at $0.8 million at issuance. Due to the proximity of the inception date of the SPOA to December&#160;31,&#160;2023, the change in fair value was immaterial. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The debt incurred pursuant to the RIPA entered on December&#160;29,&#160;2023 contains embedded derivatives requiring bifurcation as a single compound derivative instrument. The company estimated the fair value of the derivative liability using a &#8220;with-and-without&#8221; method. The with-and-without methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the individual embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the derivative liability, which is estimated at $34.5&#160;million as of December&#160;31,&#160;2023. The estimated probability and timing of underlying events triggering the exercisability of the Put Option contained in the RIPA, forecasted cash flows and the discount rate are significant unobservable inputs used to determine the estimated fair value of the entire instrument with the embedded derivative. As of December&#160;31,&#160;2023, the discount rate used for valuation of the derivative liability was 12.1%. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">N</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ote</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;2023 debt extinguishment, the company identified an embedded derivative related to a contingently exercisable prepayment feature of the amended $505.0&#160;million December&#160;2023 promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment and accrued interest upon occurrence of a specified transaction (defined in the promissory note). This embedded derivative is recorded as a derivative liability on the consolidated balance sheet and is measured at fair value. Changes in the fair value of the derivative liability are reported as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">change in fair value of derivative,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. The fair value of the derivative liability is determined at each period end using a with and without method, which assesses the likelihood and timing of a specified transaction that if triggered could result in a repayment. The fair value of the embedded derivative is estimated at $0.8&#160;million as of December&#160;31,&#160;2023, and will be remeasured to fair value at each reporting date until the derivative is settled.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-Party Warrant Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;12,&#160;2022 registered direct offering of common stock, the company issued 9,090,909&#160;warrants (December&#160;2022&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023 and 2022, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the February&#160;15,&#160;2023 registered direct offering of common stock, the company issued 14,072,615&#160;warrants. The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">February&#160;17,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.2636</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, the company reduced the exercise price of the outstanding February&#160;2023&#160;Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extended the expiration date of the warrants until July&#160;24,&#160;2026. The effect of amending the terms of the warrants is reflected in a change in the fair value of warrant liability of $7.3&#160;million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">July 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the July&#160;20, 2023 registered direct offering of common stock, the company issued 14,569,296&#160;warrants (July&#160;2023&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">July&#160;25,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying amount of the warrant liabilities was as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2022<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">February&#160;2023<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July&#160;2023<br/>Warrants</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1044">Change in fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118,770&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;2022<br/>Warrants</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value at issuance, December&#160;12,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S.&#160;government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Recurring Valuations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. Except for the impairments discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5152da74782c4119b27351f18d5b573b_17470" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Details&#8212;Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were no other material non-financial assets or liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the years ended December&#160;31,&#160;2023, 2022 and 2021.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the promissory notes before and after amendments that were entered on December&#160;29,&#160;2023 and August&#160;31,&#160;2022, as they were accounted for under the debt extinguishment accounting model. We used discounted cash flow analyses for promissory notes without a holder conversion option and used binomial lattice models for promissory notes with a holder conversion option. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be a Level&#160;3 valuation. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related-Party Debt,</span> for more information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879716571440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration and License Agreements and Acquisition</a></td>
<td class="text">Collaboration and License Agreements and Acquisition<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Cancer Institute </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2015 NCI CRADA</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2015, Etubics entered into a CRADA with the HHS as represented by the NCI of the NIH to collaborate on the preclinical and clinical development of an adenovirus technology expressing TAAs for cancer immunotherapy. In January&#160;2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;2018, our subsidiary NantCell assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing TAAs and proprietary adenovirus technology expressing TAAs for cancer immunotherapy. Pursuant to the CRADA, the NCI provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA. During the term of the CRADA, we were required to make annual payments of $0.6&#160;million to the NCI for support of research activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2021, NantCell entered into a third&#160;amendment to the CRADA, which was effective as of March&#160;16,&#160;2021. The principal changes effected by the third&#160;amendment are the following: (i)&#160;assignment of the CRADA from NantCell to ImmunityBio; (ii)&#160;modification of the research plan; (iii)&#160;extension of the CRADA term through May&#160;2026; and (iv)&#160;an increase in funding for a total of $1.3&#160;million per year, payable in semi-annual installments from 2022 through 2025. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded R&amp;D expense of $1.3&#160;million, $1.2&#160;million, and $1.1&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the updated CRADA research plan, NCI and ImmunityBio will collaborate on the preclinical and clinical development of ImmunityBio&#8217;s proprietary adenovirus platform expressing TAAs; proprietary yeast platform expressing TAAs; proprietary agent N-803</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and derivatives, agent N-809 and derivatives, and/or TxM&#160;product candidates; proprietary recombinant NK&#160;cells and mAbs; proprietary RNA vaccines and adjuvants; and other proprietary agents owned or controlled by ImmunityBio as contemplated in the research plan, for cancer immunotherapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under any of the CRADAs, any party may unilaterally terminate the agreement by providing timely advance written notice to the other party before the desired termination date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of any of the CRADAs. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amyris Joint Venture</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2021, ImmunityBio and Amyris entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture is to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine-platform. As part of the limited liability agreement, Amyris contributed $1.0&#160;million in cash and rights to its license agreement with AAHI for an RNA platform for the field of COVID-19. ImmunityBio contributed $1.0&#160;million in cash and priority access to its manufacturing capacity for the joint venture product. Both parties agreed to enter into a separate manufacturing and supply agreement and a sublicense agreement following the execution of the joint venture agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint venture agreement stipulates the initial terms for equal representation in the management of the newly-formed joint venture. The joint venture is managed by a board of directors consisting of four&#160;directors: two appointed by the company and two&#160;appointed by Amyris. Both parties agreed to make additional capital contributions in cash, in proportion to their respective interests, as determined by the board of directors of the joint venture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered the joint venture entity as a VIE and determined that we are not the primary beneficiary of the VIE. We account for our investment in the joint venture using the equity method of accounting. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded our 50%&#160;share of net losses from the joint venture totaling $7.5&#160;million, $12.1&#160;million, and $0.8&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. During the years ended December&#160;31,&#160;2023 and 2022, such losses incurred included $7.5&#160;million and $11.9&#160;million, respectively, attributable to expenses incurred by us on behalf of the joint venture. We are not obligated to fund the joint venture&#8217;s potential future losses. In August&#160;2023, Amyris announced that it filed for Chapter&#160;11 bankruptcy protection. The Amyris bankruptcy case remains ongoing, and there can be no assurance that we will receive any recovery on account of our claims against Amyris, including for Amyris&#8217; portion of expenses incurred by the joint venture. As of December&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was zero.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3M IPC and AAHI License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M&#160;IPC and its affiliates and AAHI. In November&#160;2021 we obtained nonexclusive rights in the field of SARS-CoV-2 and in June&#160;2022 we modified those rights and expanded the scope of the license to include (1)&#160;SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than LMIC, and (2)&#160;oncology applications, when used in combination with our proprietary technology and/or IL-15 agonists. In consideration for the license, we agreed to make certain periodic license payments, including $2.25&#160;million each year through June&#160;2025. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. Beginning in April&#160;2026, the annual minimum licensing payment is $1.0&#160;million, which can be credited against any royalty payments due under this agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2023 and 2022, we made annual license maintenance fee payments of $2.25 million and $1.75&#160;million, respectively. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we expensed $2.0&#160;million, $1.0&#160;million, and $0.5&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAHI License Agreements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into two&#160;license agreements with AAHI pursuant to which we received a license to certain patents and know-how relating to AAHI&#8217;s (i)&#160;adjuvant formulations for the treatment, prevention and/or diagnosis of SARS-CoV-2 (the AAHI&#160;Adjuvant Formulation License Agreement) and (ii)&#160;RNA vaccine platform as further described below (the&#160;AAHI RNA License Agreement). Under both agreements, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $2.0&#160;million. In addition, under the AAHI Adjuvant Formulation License Agreement we owe milestone payments to a total of up to $2.5&#160;million based on the achievement of certain development and regulatory milestones for the first&#160;licensed product and royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low-single digit percentage, subject to certain royalty-reduction provisions. During the years ended December&#160;31,&#160;2023 and 2022, no&#160;milestone fees were incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we amended and restated the AAHI RNA License Agreement, pursuant to which AAHI granted us an exclusive, worldwide, sublicensable license to AAHI&#8217;s rights to an RNA&#160;vaccine platform for the development and commercialization of certain therapeutic, diagnostic, or prophylactic products for the prevention, treatment or diagnosis of any indication, other than those subject to pre-existing third-party license grants, including, without limitation, SARS-CoV-2. Pursuant to the terms of the amended and restated AAHI RNA License Agreement, we made a one-time, non-creditable, non-refundable, upfront payment to AAHI of $1.5&#160;million and a license maintenance fee of $3.0&#160;million in June&#160;2022. The company is required to pay license maintenance fees to AAHI of $5.5&#160;million annually from 2023 through 2030. The company may terminate the restated agreement without cause by paying AAHI a $10.0&#160;million one-time early termination fee. In addition, the milestone payments to AAHI based on the achievement of certain development and regulatory milestones for the first&#160;licensed product were amended to a total of up to $4.0&#160;million. We are required to pay royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low to mid-single digit percentage. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded $4.5&#160;million, $1.8&#160;million, and $1.5&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the license agreements, in May&#160;2021 we also entered into a sponsored research agreement with AAHI pursuant to which we will fund continued research of at least $2.0&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. As of December&#160;31,&#160;2023, $0.5&#160;million payable to AAHI in connection with the sponsored research agreement was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheet. During the year ended December&#160;31,&#160;2023, we recorded $1.2&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $3.7&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">loss on equity method investment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the year ended December&#160;31,&#160;2022, respectively, on the consolidated statements of operations related to the sponsored research agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viracta License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with Viracta under which we were granted exclusive worldwide rights to Viracta&#8217;s Phase&#160;II drug candidate, VRx-3996 (nanatinostat), for use in combination with our platform of NK&#160;cell therapies. In&#160;consideration for the license, we are obligated to pay Viracta mid-single digit percentage royalties on net sales of licensed products for therapeutic use and milestone payments ranging from $10.0&#160;million to $25.0&#160;million up to an aggregate maximum of $100.0 million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, at our sole discretion, in whole or on a product by product and/or country by country basis, at any time upon 90&#160;days&#8217; prior written notice. In&#160;addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party. To&#160;date, we have not had incurred any royalty or milestone payment obligations under this agreement, including during the years ended December&#160;31,&#160;2023, 2022 and 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dunkirk Facility Leasehold Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;14,&#160;2022, we completed the acquisition of the Dunkirk Facility (approximately 409,000 rentable square feet) from Athenex, which we believe will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our existing manufacturing capacity in the U.S. and the ability to scale production associated with certain of our product candidates. The company accounted for the transaction as an asset acquisition because the Dunkirk Facility&#8217;s integrated set of assets and activities does not meet the definition of a business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration for the acquisition was approximately $40.5&#160;million, including a cash payment of $40.0&#160;million, and transaction costs of approximately $0.5&#160;million. The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other depreciable assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">_______________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Definite-lived intangible assets consist of favorable leasehold rights totaling $20.4&#160;million and organized workforce totaling $0.8&#160;million as of the acquisition date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort&#160;Schuyler Management Corporation Lease, dated October&#160;1,&#160;2021 and as amended as of the February&#160;14,&#160;2022 closing date (as amended, the Dunkirk Lease), with the FSMC as landlord. The Dunkirk Facility, as well as certain equipment, is owned by the FSMC and is leased to us under the Dunkirk Lease. Our annual lease payment will be $2.00 per year&#160;for an initial 10-year term, with one&#160;option to renew the lease under substantially the same terms and conditions for an additional 10-year term. As part of the transaction, we assumed certain of Athenex&#8217;s obligations under various third-party agreements (the Facility Agreements), subject to the terms and conditions of the purchase agreement by and between the company and Athenex dated as of January&#160;7,&#160;2022, and committed to spend an aggregate of $1.52&#160;billion on operational expenses during the initial term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for one additional 10-year term. We also committed to hiring 450&#160;employees at the Dunkirk Facility within the first five years following the Commencement Date, with 300&#160;such employees to be hired within the first 2.5 years following the Commencement Date. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above. Failure to satisfy the obligations over the lease term may give rise to certain rights and remedies of governmental authorities including, for example, termination of the Dunkirk Lease and other Facility Agreements and potential recoupment of a percentage of the grant funding received by Athenex for construction of the facility and other benefits received, subject to the terms and conditions of the applicable agreements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that governmental funding will assist in funding a portion of the further build-out of the Dunkirk Facility, which we estimate to be approximately $8.0&#160;million&#160;to $10.0&#160;million of governmental funding remaining available as of December&#160;31,&#160;2023, there can be no assurance as to the final acceptance and timing of the requests for governmental funding that we submit, and we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, any future governmental funding will be subject to the eligibility of submitted expenses, as well as our compliance with the obligations that we are subject to pursuant to the agreements with parties regarding the Dunkirk Facility as described above. Further, on May&#160;14,&#160;2023, Athenex, together with certain of its subsidiaries, filed voluntary petitions for relief under Chapter&#160;11 of the United States Bankruptcy Court for the Southern District of Texas (the Athenex Proceedings). We do not know what, if any, impact the Athenex Proceedings will have on any portion of the potential governmental funding remaining for the Dunkirk Facility.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dunkirk Facility Workforce Reduction</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2022, the company initiated a workforce reduction at the Dunkirk Facility and recorded severance and retention benefits for the terminated employees totaling $1.0&#160;million during the year ended December&#160;31,&#160;2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1125">selling, general and administrative expense</span>, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations. The terminated employees were not required to render service through their termination date in December&#160;2022 to receive these benefits.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879720572768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VivaBioCell, S.p.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2015, NantWorks, a related party, acquired a 100% interest in VivaBioCell through its wholly-owned subsidiary, VBC Holdings for $0.7&#160;million, less working capital adjustments. In June&#160;2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of VBC, we are obligated to pay the former owners contingent consideration upon the achievement of certain milestones related to the GMP-in-a-Box technology. A clinical milestone totaling $0.8&#160;million was earned by the former owners of VivaBioCell, of which $0.4&#160;million was paid during the year ended December&#160;31,&#160;2021, with the remaining $0.3&#160;million clinical obligation, net of foreign exchange adjustment, settled during the year ended December&#160;31,&#160;2022. If a government agency unconditionally approves the GMP-in-a-Box technology for commercial sale (the regulatory milestone) in the future, we will be obligated to pay an additional approximately $2.2&#160;million to the former owners.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable. As of December&#160;31,&#160;2023, Dr.&#160;Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer, and his related party hold approximately $139.8&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Altor BioScience, LLC Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, NantCell announced it had entered into a definitive merger agreement to acquire Altor. An action captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gray v.&#160;Soon-Shiong, et&#160;al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (Gray) and Adam&#160;R.&#160;Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara&#160;Sturm Waldman and Douglas E. Henderson (Henderson)) filed a second&#160;amended complaint, including appraisal claims, and which the defendants subsequently moved to dismiss. In a second&#160;action, Dyad Pharmaceutical Corporation (Dyad) filed a petition in Delaware Chancery Court for appraisal in connection with the merger. The defendants moved to dismiss the appraisal petition in 2018. The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor from the action. The following claims remained: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the court issued a written order implementing its ruling on the defendants&#8217; motions (the Implementing Order). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o&#160;C. Boyden Gray, were dismissed. The plaintiffs then moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the court granted the plaintiffs&#8217; motion, and the plaintiffs filed the third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counterclaims against the plaintiffs. The defendants sought damages for attorneys&#8217; fees and costs incurred as a result of the breaches of &#8220;standstill&#8221; agreements and of stockholder releases. The plaintiffs filed an answer denying the counterclaims and asserting defenses. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the former Altor stockholders seeking appraisal met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date, given that those shares were the subject of the above-described appraisal claims. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March&#160;2022, the company agreed to the terms of a settlement with the appraisal petitioners, without any admission of liability or fault. The settlement provided that in exchange for complete releases, the appraisal petitioners, who as a group held 3,167,565&#160;dissenting Altor shares, collectively would receive an aggregate of 2,229,296&#160;shares of the company&#8217;s common stock issued in a private placement, plus an aggregate of $21.13&#160;in cash in lieu of fractional shares. The company&#8217;s Board of Directors approved the settlement and stock issuance in April&#160;2022, and the court approved the settlement and dismissed the appraisal petitioners&#8217; claims on July&#160;9,&#160;2022. On July&#160;9,&#160;2022, the company issued 2,229,296&#160;shares of its common stock with an aggregate market value of $10.7&#160;million, based on the closing price of its common stock on the Nasdaq as of July&#160;8,&#160;2022, to the appraisal petitioners pursuant to the court-approved settlement agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late April&#160;2022, the company also agreed to the terms of a settlement with the putative class plaintiffs without any admission of liability or fault. In exchange for class-wide releases, the company committed to make a settlement payment of $5.0&#160;million in cash by December&#160;31,&#160;2022. On December&#160;8,&#160;2022, the Delaware Court of Chancery entered a final judgment approving the settlement, and the company timely made the $5.0&#160;million settlement payment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sorrento Therapeutics, Inc. Litigation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sorrento, derivatively on behalf of NANTibody, filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company&#8217;s subsidiary NantCell, Dr.&#160;Soon-Shiong, and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol from NantPharma and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. Trial had been set to commence in Sorrento&#8217;s Superior Court action on August&#160;7,&#160;2023, but on July&#160;24,&#160;2023 the Superior Court vacated the August&#160;7,&#160;2023 trial date at the parties&#8217; request in light of the pending settlement discussed below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#8217;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April&#160;2021 and concluded in early August&#160;2021. After post-hearing briefing was concluded, the parties were notified on November&#160;30,&#160;2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February&#160;25,&#160;2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July&#160;2022, and summations took place on August&#160;2,&#160;2022. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two&#160;exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $156.8 million and NANTibody approximately $16.7 million, plus post-award interest accruing at a daily rate. On December&#160;21,&#160;2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January&#160;16,&#160;2023, Sorrento filed a response to the petitions and moved to vacate the award. On February&#160;7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento&#8217;s motion to vacate. The Superior Court entered judgments against Sorrento in the aggregate amount of approximately $176.4&#160;million plus 10% post-judgment interest, of which approximately $159.4&#160;million was payable to NantCell, and the remainder of which was payable to NANTibody. On February&#160;13,&#160;2023, Sorrento informed counsel to the company that it had filed a Chapter&#160;11 proceeding in the U.S. District Court for the Southern District of Texas, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In&#160;re:&#160;Sorrento Therapeutics,&#160;Inc., et&#160;al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Case No.&#160;23-90085 (DRJ), Docket Entry&#160;810. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;6,&#160;2023, Sorrento filed a motion in its Chapter&#160;11 proceeding for entry of an order approving and implementing a mediation settlement reached with the company and other entities. The settlement involved two&#160;possible scenarios: Either, if Sorrento were to raise an amount needed to pay its debtor in possession lender and its unsecured creditors by August&#160;31,&#160;2023, Sorrento would pay those obligations, including the judgments held by NantCell and NANTibody, by 2:00&#160;p.m.&#160;ET on August&#160;31,&#160;2023 and be free to proceed with pending litigation; or, failing that, the judgments would be released, the litigation claims would be released, including, without limitation, the Superior Court action discussed above, Sorrento would relinquish its interests in NANTibody and certain other entities, Sorrento would forfeit its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell (rights to PD-L1), and certain other provisions not impacting the company would be implemented as described in the motion. On August&#160;14,&#160;2023, the United States Bankruptcy Court for the Southern District of Texas issued an order approving the settlement described above, such that the settlement became binding on the parties. As of 2:00&#160;p.m. ET on August&#160;31,&#160;2023, Sorrento had not paid the judgments held by NantCell and NANTibody. Accordingly, in relevant part to the company and NantCell, a mutual release of claims became effective such that the aforementioned judgments were released, the litigation claims were released including, without limitation, the derivative litigation against NantCell described above, Sorrento relinquished its interests in NANTibody, and Sorrento forfeited its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell, including any royalties associated with the company&#8217;s engineered NK&#160;cell therapy in Phase&#160;II clinical trials, PD-L1 t-haNK. As a result of the settlement, the parties filed dismissals of the litigation matters discussed above. After the settlement, the company&#8217;s ownership in NANTibody increased from 60% to 100%, and, as a result, the carrying amount of the noncontrolling interest of $4.2&#160;million was adjusted and recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to the company, on the consolidated statement of stockholders&#8217; deficit. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shenzhen Beike Biotechnology Co. Ltd. Arbitration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill agreement under which, among other things, the parties affirmed they would perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration were indefinitely extended. The standstill agreement could be terminated by any party on ten&#160;calendar days&#8217; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We served an Answer and Counterclaims on May&#160;19,&#160;2023. Beike served a Reply to our counterclaims on June&#160;21,&#160;2023. Beike&#8217;s Statement of Claim is due on March&#160;22,&#160;2024, and the company&#8217;s Statement of Defense and Counterclaim is due on June&#160;21,&#160;2024. The hearing in the arbitration is scheduled to begin on June&#160;9,&#160;2025. Given that no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims asserted against the company lack merit and intend to defend the case, and to pursue or counterclaims, vigorously.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;30,&#160;2023, a putative securities class action complaint, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salzman v. ImmunityBio, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:23-cv-01216-BEN-WVG, was filed in the U.S.&#160;District Court for the Southern District of California against the company and three&#160;of its officers and/or directors, asserting violations of Sections&#160;10(b) and 20(a) of the Exchange Act. Stemming from the&#160;company&#8217;s disclosure on May&#160;11,&#160;2023 that it had received an FDA CRL stating, among other things, that it could not approve the company&#8217;s BLA for its product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, in its present form due to deficiencies related to its pre-license inspection of the company&#8217;s third-party CMOs, the complaint alleges that the defendants had previously made materially false and misleading statements and/or omitted material adverse facts regarding its third-party clinical manufacturing organizations and the prospects for regulatory approval of the BLA. On September&#160;27,&#160;2023, the court appointed a lead plaintiff, approved their selection of lead counsel, and re-captioned the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re. ImmunityBio, Inc. Securities Litigation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No.&#160;3:23-cv-01216. On November&#160;17,&#160;2023, lead plaintiff filed an amended complaint, which named the same defendants and asserted the same claims as the previous complaint. On January&#160;8, 2024, defendants filed a motion to dismiss the amended complaint. A hearing on the motion is currently scheduled for April&#160;23,&#160;2024.The company believes the lawsuit is without merit and intends to defend the case vigorously. The company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in this action. If an unfavorable outcome were to occur, it is possible that the impact could be material to the company&#8217;s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconditional Purchase Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unconditional purchase obligations are defined as an agreement to purchase goods or services that are enforceable and legally binding (non-cancelable, or cancelable only in certain circumstances). In the normal course of business, we enter into unconditional purchase obligation arrangements with a third-party CMO to reserve manufacturing slots in its cGMP manufacturing facility for the manufacture and supply of cGMP batches per FDA and EMA regulations for commercial use. The total amount of future non-cancelable purchase commitments related to the manufacture of cGMP batches is $2.0&#160;million and $0.9&#160;million for the years&#160;ending December&#160;31,&#160;2024 and 2025, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our total unconditional purchase obligation related to hosted software license subscription fees and implementation costs at $5.2&#160;million as of December&#160;31,&#160;2023. Payments by year are estimated as follows: 2024&#160;($1.6&#160;million), 2025&#160;($1.8&#160;million) and 2026&#160;($1.8&#160;million). Additionally, our total unconditional purchase obligation for laboratory cleanroom service costs are estimated at $1.9&#160;million as of December&#160;31,&#160;2023. Payments by year are estimated as follows: 2024&#160;($0.5&#160;million) and 2025&#160;($1.4&#160;million). The purchase obligation amounts do not represent the entire anticipated purchases in the future, but represent only those items for which we are contractually obligated. The majority of our goods and services are purchased as needed, with no unconditional commitment. For this reason, these amounts do not provide an indication of our expected future cash outflows related to purchases.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we did not enter into any significant contracts or material unconditional purchase commitments, other than those disclosed in these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723398496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Arrangements</a></td>
<td class="text">Lease Arrangements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease property in multiple facilities across the U.S. and Italy, including facilities located in El&#160;Segundo,&#160;CA and the Dunkirk Facility in upstate New&#160;York. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rentals at the Dunkirk Facility. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information about our related-party leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:f-1163">two</span> to ten years and often include one or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:f-1165">one</span> to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:33.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1170"><span style="-sec-ix-hidden:f-1171">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,601&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,923&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1178"><span style="-sec-ix-hidden:f-1179">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1184"><span style="-sec-ix-hidden:f-1185">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:71.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:60.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including right-of-use asset <br/>&#160;&#160;&#160;amortization and interest expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:59.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of December&#160;31,&#160;2023, including $11.5&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62,942&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,008&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we extended some existing related-party leases and terminated an existing related-party lease. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information regarding our related-party leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Lease Arrangements</a></td>
<td class="text">Lease Arrangements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease property in multiple facilities across the U.S. and Italy, including facilities located in El&#160;Segundo,&#160;CA and the Dunkirk Facility in upstate New&#160;York. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rentals at the Dunkirk Facility. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information about our related-party leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:f-1163">two</span> to ten years and often include one or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:f-1165">one</span> to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:33.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1170"><span style="-sec-ix-hidden:f-1171">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,601&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,923&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1178"><span style="-sec-ix-hidden:f-1179">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1184"><span style="-sec-ix-hidden:f-1185">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:71.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:60.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including right-of-use asset <br/>&#160;&#160;&#160;amortization and interest expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:59.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of December&#160;31,&#160;2023, including $11.5&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62,942&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,008&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, we extended some existing related-party leases and terminated an existing related-party lease. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information regarding our related-party leases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879717724608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementAbstract', window );"><strong>Revenue Interest Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Revenue Interest Purchase Agreement</a></td>
<td class="text">Revenue Interest Purchase Agreement<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland, to support the commercialization of Anktiva, our lead product candidate, to further the development of our product platforms, and to provide for other working capital needs. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing, less certain transaction expenses. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including following the receipt of approval by the FDA of the company&#8217;s BLA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on or before June&#160;30,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales during such quarter, which will be tiered payments initially ranging from 3.00% to 7.00% (or after funding of the Second&#160;Payment, 4.50% to 10.00%) of the company&#8217;s worldwide net sales, excluding those in China. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the aggregate Revenue Interest Payments made to Oberland as of December&#160;31,&#160;2029 equal or exceed the Cumulative Purchaser Payments as of that date, the initially tiered revenue interest rate will be decreased to a single rate of 1.50% (or after the funding of the Second Payment, 2.25%) of the company&#8217;s worldwide net sales, excluding those in China. If the aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then following the Test Date the initially tiered revenue interest rate will increase to a rate that, had such increased rate applied during the period from December&#160;29,&#160;2023 through December&#160;31,&#160;2029, it would have resulted in Oberland receiving aggregate Revenue Interest Payments (excluding certain payments detailed in the RIPA) equal to the Cumulative Purchaser Payments as of the Test Date. In addition, if aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then the company must make the True-Up Payment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oberland&#8217;s rights to receive Revenue Interest Payments under the RIPA shall terminate when Oberland has received payments (including any True-Up Payment) equal to 195.0% of the then Cumulative Purchaser Payments unless the RIPA is terminated prior to such date. If Oberland has not received total payments (including any True-Up Payment) equal to 195.0% of the then Cumulative Purchaser Payments on or before the twelfth&#160;anniversary of the RIPA, then the company shall be obligated to pay to Oberland an amount equal to 195.0% of the then Cumulative Purchaser Payments less the aggregate payments (including any True-Up Payments) made as of such date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA, the company has a Call Option to terminate the RIPA and repurchase the Revenue Interests at any time upon advance written notice, subject to certain limitations set forth in the RIPA. Additionally, Oberland has a Put Option enabling them to terminate the RIPA and to require the company to repurchase the Revenue Interests upon enumerated events, such as a bankruptcy event, failure to make a payment, an uncured material breach, default in certain third-party agreements, a breach or default under any subordination agreements with respect to indebtedness to existing stockholders, or subordinated notes during certain time periods, judgments in excess of certain amounts against the company, a material adverse effect, the loss of regulatory approval of our product candidates or a change of control. The required purchase price with respect to the Call Option and/or Put Option, as applicable, shall be (a)&#160;120.0% of the Cumulative Purchaser Payments as of such date, if Oberland exercises the Put Option (other than in connection with a change of control) on or prior to the first anniversary the Closing Date, (b)&#160;135.0% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised in connection with a change of control on or prior to the date that is eighteen (18)&#160;months after the Closing Date, and (c)&#160;in all other cases, (i)&#160;175.0% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised no later than the date that is thirty&#160;six (36)&#160;months after the Closing Date, and (ii)&#160;195.0% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised later than the date that is thirty&#160;six (36)&#160;months after the Closing Date, minus, in each case, the total payments made to Oberland on or prior to such date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company&#8217;s obligations under the RIPA are guaranteed by certain of its subsidiaries meeting materiality thresholds set forth in the RIPA. To secure the company&#8217;s obligations under the RIPA and the subsidiary guarantors&#8217; obligations under the guarantees, each of the company and the subsidiary guarantors has granted a security interest in substantially all its assets, subject to certain exceptions and limitations. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA contains affirmative and negative covenants and events of default, including covenants and restrictions that, among other things, restrict our ability to incur additional liens, incur additional indebtedness, make loans and investments, enter into transactions with affiliates, engage in mergers and acquisitions, engage in asset sales and exclusive licensing arrangements, and declare dividends to our stockholders, in each case, subject to certain exceptions set forth in the RIPA. As of December&#160;31,&#160;2023, the company was in compliance with all covenants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RIPA is considered a sale of future revenues and accounted for as long-term debt recorded at amortized cost using the effective interest rate method.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on December&#160;29,&#160;2023 and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $10.0&#160;million of our common stock at $4.1103&#160;per share in a private placement. Oberland also has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability estimated at fair value at issuance. The $200.0&#160;million received pursuant to the&#160;RIPA and $10.0&#160;million received pursuant to the SPOA were allocated among the resulting financial instruments on a relative fair value basis, with $197.1&#160;million allocated to the debt under the RIPA, $12.0&#160;million allocated to the common stock issued under the SPOA, and $0.8&#160;million allocated to the stock purchase option. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Put Option under the RIPA that is exercisable by Oberland upon certain contingent events and the Call Option that is exercisable by the company upon a change of control were determined to be embedded derivatives requiring bifurcation and separately accounted for as a single compound derivative instrument. The company recorded the initial fair value of the derivative liability of $34.5&#160;million as a debt discount, which will be amortized to interest expense over the expected term of the debt using the effective interest rate method.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the RIPA, as of December&#160;31,&#160;2023 $155.4&#160;million was recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">revenue interest liability,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales may materially impact the revenue interest liability, interest expense, other income, and the time period for repayment. During the year ended December&#160;31,&#160;2023, we recorded $0.3&#160;million of interest expense related to this arrangement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company incurred $7.5&#160;million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the debt.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the year ended December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability at inception</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the RIPA, gross</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the RIPA, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,509&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded contingent derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock purchase option</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability as of December&#160;31,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,415&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RevenueInterestPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RevenueInterestPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879720541520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Debt</a></td>
<td class="text">Related-Party Debt <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$505 million December 2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$505 million December 2023 Promissory Note Tranche 2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+7.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,951&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$200 million September&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued PIK<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized<br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300 million December&#160;2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$125 million August&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$50 million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party nonconvertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,099&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431,901&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2015 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2020 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2021 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NantMobile Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCSC Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$300.0&#160;million December 2021 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;17,&#160;2021, the company executed a $300.0&#160;million promissory note with N</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ant&#160;Capital, an af</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filiated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. The note bore an interest rate of Term&#160;SOFR plus 5.4%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances were due on December&#160;17,&#160;2022. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company and Nant&#160;Capital entered into an amended and restated promissory note, pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2023 and the interest rate was amended to Term&#160;SOFR plus 8.0%&#160;per annum. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which this existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Based on the terms of the amended and restated promissory note, the noteholder, at its sole discretion, may convert all of the Tranche&#160;2 $380.0&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$125.0&#160;million August 2022 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company executed a $125.0&#160;million promissory note with Nant&#160;Capital. The note bears an interest rate of Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note letter agreement pursuant to which the existing promissory note was amended to be included in the Tranche&#160;1 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025 and an interest rate of Term&#160;SOFR plus 8.0% per annum. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$50.0&#160;million December 2022 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12,&#160;2022, the company executed a $50.0&#160;million promissory note with Nant&#160;Capital. The note bore an interest rate of Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a specified transaction (as defined in the note), the noteholder can request the outstanding principal and interest due on the loan to be repaid in full upon consummation of such specified transaction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Pursuant to the terms of the amended and restated promissory note, the investor, in its sole discretion may convert all of the outstanding Tranche&#160;2 principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. The noteholder can request up to $50.0&#160;million of the Tranche&#160;2 principal amount and accrued interest to be repaid upon consummation of such specified transaction.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$30.0&#160;million March 2023 Promissory Note </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital. This note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest was originally due on December&#160;31,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. Upon receipt of a written notice of prepayment from the company, the noteholder may choose to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon into shares of the company&#8217;s common stock at a price of $2.28&#160;per share. Additionally, the noteholder may at its option convert the entire outstanding principal amount of the promissory note and accrued interest into shares of the company&#8217;s common stock at a conversion price of $2.28 per share, at the option of the noteholder. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of approximately $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the noteholder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of the $30.0&#160;million promissory note described above was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of this promissory note was extended to December&#160;31,&#160;2025. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$30.0&#160;million June 2023 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;13,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital, pursuant to which, the company could request up to three&#160;(3) advances of $10.0&#160;million each. The principal amount of each advance bore interest rate at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances was originally due on December&#160;31,&#160;2023. We may prepay the outstanding principal amount, together with any accrued interest, on any then-outstanding advances, at any time, in whole or in part, without premium or penalty, and without the prior consent of the noteholder upon five&#160;(5) days written notice to the noteholder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received net proceeds of approximately $29.9&#160;million from this promissory note, net of a $0.1&#160;million origination fee paid to Nant&#160;Capital. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Pursuant to the terms of the amended and restated promissory note the investor, in its sole discretion may convert all of the Tranche&#160;2 $380.0&#160;million principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$200.0&#160;million September 2023 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company executed a $200.0&#160;million convertible promissory note with Nant&#160;Capital. The note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a monthly basis. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;11,&#160;2026. We may prepay the outstanding principal amount, together with any accrued interest, at any time, in whole or in part, without premium or penalty upon five&#160;(5) days written notice to the noteholder. The noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $1.9350&#160;per share. The company received net proceeds of approximately $199.0&#160;million from this financing, net of a $1.0&#160;million origination fee paid to the noteholder. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Footnotes to Related-Party Debt Tables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Modification and Debt Extinguishments</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">August 2022 Debt Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company amended and restated the above fixed-rate notes payables held by Nant&#160;Capital, NantWorks, NantMobile and NCSC, which are entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and thereafter continued to bear interest at a per annum rate ranging from 3.0% to 6.0%, provided that the outstanding principal was and thereafter continued to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continued to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and thereafter continued to be able to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the noteholder, subject to an advance notice period of at least five business days during which the noteholder could convert the amount requested to be prepaid by the company into shares of the company&#8217;s common stock, as part of the amendment and restatement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gave each noteholder, at its sole option, at any time (other than when the noteholder is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above promissory notes were entered into or amended at the same time and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. ASC&#160;470-50 provides that a modification or an exchange that adds or eliminates a substantive conversion option as of the conversion date would always be considered substantial and require extinguishment accounting. Accordingly, as a result of the addition of the conversion feature to the fixed-rate promissory notes, the fixed-rate promissory notes and the variable-rate promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments. Under this model, the company calculated a gain on extinguishment of $82.9&#160;million, representing the difference between the fair value of the new and amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts plus the cash proceeds from the new promissory note. Since the debt was obtained from entities under common control, such gain was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022. Also, the difference between the face values of the new and amended promissory notes (and accrued interest on the date of the amendment) and the fair values of the new and restated promissory notes was recorded as a debt discount to be amortized to interest expense over the remaining term (or until conversion in the case of fixed-rate promissory notes) of the respective promissory notes. During the year ended December&#160;31,&#160;2022, we recorded amortization of related-party notes discounts totaling $16.3&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the promissory notes without a holder conversion option were estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair values of the fixed-rate promissory notes, which were each modified to include a holder conversion option, were determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included market yields from 18.0% to 24.8% and a risk-free rate of 4.1%, and the significant unobservable inputs used for the binomial lattice model included a volatility of 84.9%, a market yield of 17.4% and a risk-free rate of 3.5%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, the company received written notice from NantWorks, the holder of an existing convertible promissory note of NantCell, a wholly-owned subsidiary of the company, of its election to convert the NantCell promissory note into shares of the company&#8217;s common stock. As of such date, the holder of the NantCell note converted the entire $56.6&#160;million of outstanding principal and accrued and unpaid interest due under the note into 9,986,920&#160;shares of the company&#8217;s common stock at a price of $5.67&#160;per share in accordance with the terms of the promissory note. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">September&#160;11,&#160;2023 Debt Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the holders exchanged promissory notes totaling approximately $270.0&#160;million in aggregate principal amount and accrued and unpaid interest for an aggregate of 209,291,936&#160;shares of common stock at an exchange price of $1.29&#160;per share. As a result of the exchange, the company was forever released and discharged from all its obligations and liabilities under the notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a series of letter agreements pursuant to which the maturity date of the related-party nonconvertible notes described above totaling $505.0&#160;million in principal was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. In addition, the company entered into the $200.0&#160;million September 2023 promissory note with Nant&#160;Capital. No other material terms or conditions of these promissory notes were modified.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above promissory notes were entered into or amended at the same time on September&#160;11,&#160;2023 and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Pursuant to ASC&#160;470-50, as the terms of the amendment were not substantially different than the terms of the promissory notes prior to the amendment, the amendment was accounted for as a debt modification. The unamortized debt discounts from the promissory notes are being amortized as an adjustment to interest expense over the remaining term of modified promissory notes that are not recorded at fair value using the effective interest rate method. Also, a $29.6&#160;million increase in fair value of the embedded conversion feature from the debt modification was accounted for as a debt discount to the $200.0&#160;million convertible note that is not recorded at fair value, and a $1.6&#160;million increase in fair value of the embedded conversion feature related to the promissory note recorded at fair value was accounted for as interest expense during the year ended December&#160;31,&#160;2023. Such increase in fair values of the embedded conversion features totaling $31.2&#160;million has been recorded with a corresponding increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit.</span></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">December&#160;29,&#160;2023 Debt Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note and a letter amendment for the following outstanding promissory notes. Pursuant to the terms of the amended and restated promissory note, the amended $505.0&#160;million December&#160;2023 promissory note is comprised of a Tranche&#160;1 with principal amount of $125.0&#160;million which was previously the $125.0&#160;million August&#160;2022 promissory note before amendment, and a Tranche&#160;2 with principal amount of $380.0&#160;million, which is made up of the previous $300.0&#160;million December&#160;2021 promissory note, $50.0&#160;million December 2022 promissory note and $30.0&#160;million June&#160;2023 promissory note. In addition, the amendment allows Nant&#160;Capital, in its sole discretion, to convert all the Tranche&#160;2 principal amount of $380.0&#160;million of the amended promissory note into shares of common stock. The conversion price was subsequently determined at $8.2690&#160;per share based on the agreement. The maturity date of the amended promissory note is December&#160;31,&#160;2025. Pursuant to the terms of the letter amendment, the maturity date of the $30.0&#160;million March&#160;2023 promissory note was extended from December&#160;31,&#160;2024 to December&#160;31,&#160;2025. Also, in connection with the RIPA transaction, all outstanding related-party promissory notes became subordinated to the RIPA payment obligations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes before the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$125 million August&#160;2022 Promissory Note </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$2.2800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$200 million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$1.9350</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes<br/>&#160;&#160;&#160;before amendments</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,000&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes after the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$505 million December&#160;2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$50 million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$505 million December&#160;2023 Promissory Note &#8211; </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 2</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$8.2690</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+7.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total $505 million December&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">505,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$2.2800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$200 million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$1.9350</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes <br/>&#160;&#160;&#160;after amendments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">735,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above outstanding promissory notes were amended at the same time, with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Also, in accordance with ASC 470-50 the company used the debt terms that existed before the September&#160;11,&#160;2023 modification to determine whether the current modification is substantially different, as the September&#160;11,&#160;2023 modification was within a year of the current transaction, and the promissory notes, at that time, had been modified without being deemed to be substantially different. As the modifications (September&#160;11,&#160;2023 and December&#160;29,&#160;2023 on a cumulative basis) added a substantive conversion feature to the promissory notes, these promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of all the promissory notes before and after amendments. Under this model, the company calculated a loss on extinguishment of $318.8&#160;million, representing the difference between the fair value of the amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts. Since the debt was obtained from entities under common control, such loss was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, a debt premium totaling $354.9&#160;million, calculated as the difference between the fair values of certain promissory notes after modifications and their respective face values, was also recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collectively, net gain on debt extinguishment of $36.1&#160;million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit for the year ended December&#160;31,&#160;2023. Also, the difference between face values of certain new and amended promissory notes and their respective fair values of $53.1&#160;million was recorded as a debt discount to be amortized as interest expense over the remaining term. During the year&#160;ended December&#160;31,&#160;2023, we recorded amortization of related-party notes discounts totaling $0.5&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations related to the new and amended promissory notes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regard to the Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note, the company identified an embedded derivative related to a contingent exercisable prepayment feature of the promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment of the promissory note and accrued interest upon the occurrence of a specified transaction. After the debt extinguishment, the company concluded that this promissory note was issued at a substantial discount, so the embedded derivative that is contingent exercisable was required to be bifurcated and accounted separately from the debt host instrument. The fair value of the embedded derivative was estimated at $0.8&#160;million as of December&#160;31,&#160;2023, using a with and without method, which assesses the likelihood and timing of the specified transaction to be triggered and result in a repayment. Significant unobservable inputs used for the valuation included a volatility of 118.0%, a market yield of 23.2% and a risk-free rate of 4.8%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Tranche&#160;1 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, which had no noteholder conversion option, was estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair value of Tranche&#160;2 of the amended promissory note, which was modified to include a noteholder conversion option, was determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed were considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included a market yield of 23.2% and the significant unobservable inputs used for the binomial lattice model included a volatility of 118.0%, a market yield of 23.2% and a risk-free rate of 4.4%. The effective unamortized debt discount rate of the amended Tranche&#160;1 and Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note is 23.65% and 18.04%, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the $200.0&#160;million September 2023 promissory note was determined using the binomial lattice model. Significant unobservable inputs used for the valuation included a volatility of 119.3%, a market yield of 23.3% and a risk-free rate of 5.2%.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to December&#160;29,&#160;2023, the $30.0&#160;million March&#160;2023 promissory note was accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the note was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the convertible note was computed using the binomial lattice model with the following observable assumptions before it was modified on December&#160;29,&#160;2023. After the debt extinguishment, the note is accounted for under the amortized cost basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of this note was as follows (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value at issuance date, March&#160;31,&#160;2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on debt extinguishment with entities under common control</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying value, December&#160;29,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense for our related-party promissory notes during the year ended December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Expense</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt<br/>Discount<br/>Amortization</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$125 million August&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 million September&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related-Party Fixed-Rate Promissory Notes </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balances include the amortization of debt discount totaling $0.5&#160;million recorded during the period from December&#160;29,&#160;2023 to December&#160;31,&#160;2023. The interest expense recorded during this period was $0.4&#160;million.</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:33.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our promissory notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The weighted-average interest rate on our promissory notes as of December&#160;31,&#160;2023 was 13.09%.</span></div></td></tr></table></div>Related-Party Agreements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from related party&#8211;Brink</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,019&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;the Clinic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantWorks, LLC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shared Services Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated shared services agreement dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for these services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded $3.3&#160;million, $3.8&#160;million, and $4.4&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $2.2&#160;million, $0.9&#160;million, and $0.4&#160;million, respectively, of expense reimbursements under this arrangement in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, we had a receivable of $0.5&#160;million and a payable of $1.0&#160;million, respectively, for all agreements with NantWorks, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due from/due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. We also recorded $1.0&#160;million and $2.0&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of December&#160;31,&#160;2023 and 2022, respectively, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a facility license agreement with NantWorks for approximately 9,500&#160;rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In 2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing January&#160;1,&#160;2022, the license fee increased by 3% to approximately $56,120 per month. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by 36,830&#160;rentable square feet to an aggregate total of 46,330&#160;rentable square feet. Effective May&#160;1,&#160;2022, the license fee was approximately $273,700 per month and was subject to a 3%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#8217; prior written notice to the other party. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded license fee expense for this facility totaling $3.4&#160;million, $2.4&#160;million, and $0.7&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple agreements with t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that a previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we wrote down the remaining value of our prepaid asset and recorded approximately $4.4&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. While we have not yet finalized the potential transition, we continue discussions with potential partners around such alternative structures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded $2.2&#160;million, $2.4&#160;million, and $1.6&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, we owed the&#160;Clinic $0.1&#160;million, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brink Biologics, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into an agreement with Brink whereby we granted Brink worldwide exclusive licenses for the use of certain cell lines and intellectual property in non-clinical laboratory testing. Brink is a related party as our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, and our Chief Corporate Affairs Officer and member of our Board of Directors, collectively own more than 50%&#160;of Brink&#8217;s outstanding shares. During the years ended December&#160;31,&#160;2023 and 2022, we recognized revenue of an immaterial amount, respectively, and $0.4&#160;million during the year ended December&#160;31,&#160;2021 related to this license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantBio, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a supply agreement with NCSC, a 100%&#160;owned subsidiary of NantBio. Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement had an initial term of five years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#8217; prior written notice by NCSC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized no&#160;revenue, respectively, and $0.3&#160;million of revenue during the year ended December&#160;31,&#160;2021. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $0.1&#160;million of deferred revenue for bioreactors that were delivered but not installed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $0.9&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets related to this agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits related to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded a receivable from NantBio of $1.3&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due from related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Doug St, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 24,250&#160;rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease term was from July&#160;2016 through July&#160;2023. In June&#160;2023, we exercised the option to extend the lease for one&#160;additional three-year term through July&#160;2026. The base rent is approximately $72,385 per month, with annual increases of 3% that began in July&#160;2017. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded lease expense for this facility of $0.9&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duley Road, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 11,980&#160;rentable square feet of office and cGMP&#160;manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through October&#160;2034. The base rent is approximately $40,700 per month, with annual increases of&#160;3% that began in November&#160;2018. Effective October&#160;3, 2023, we exercised the first option to extend the lease for one&#160;additional five-year term through October&#160;31, 2029. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in 2019, we entered into two&#160;lease agreements with Duley&#160;Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately 5,650&#160;rentable square feet. The lease has a seven-year term that commenced in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488&#160;rentable square feet. The lease has a seven-year term that commenced in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive five-year periods through 2036. The base rent for the two&#160;leases is approximately $35,800 per month, with annual increases of&#160;3% per year.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded rent expense for these leases totaling $0.9&#160;million, $0.8&#160;million, and $1.0&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $0.1&#160;million and $1.4&#160;million of lease-related payables to Duley&#160;Road, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Nash, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but effective on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately 6,883&#160;rentable square feet (the Initial Premises) in a two&#160;story mixed use building containing approximately 64,643&#160;rentable square feet at 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2027</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and includes an option to extend the lease for one three-year term through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2030</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent is approximately $20,300 per month with an annual increase of 3%&#160;on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year during the initial term, and if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately 57,760&#160;rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has one&#160;option to extend the initial term for three years. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $170,400&#160;per month with annual increases of 3% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included the options to extend the lease term of both the Initial and Expansion Premises for three years as part of the initial term of the leases as it is reasonably certain that we will exercise the options, which implies expiration of both leases in December&#160;2030. During the years ended December&#160;31,&#160;2023, 2022, and 2021, we recorded rent expense for the Initial and Expansion Premises leases totaling $2.2&#160;million, respectively, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations. The terms of initial and amended leases provided for tenant improvement allowances totaling $2.9&#160;million for costs and expenses related to improvements made by us to the Initial and Expansion Premises, which were received from the landlord during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">557 Doug St, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a Membership Interest Purchase Agreement with Nant&#160;Capital (the Purchase Agreement). Nant&#160;Capital is a related party controlled by Dr.&#160;Soon-Shiong. The Purchase Agreement transferred all outstanding membership interests in 557 Doug St,&#160;LLC from the company to Nant&#160;Capital. The only asset owned by 557&#160;Doug St, LLC is the improved property located at 557&#160;South Douglas Street, El&#160;Segundo, California with a building area of approximately 36,434&#160;rentable square feet (the Douglas Property).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price under the purchase agreement was $22.0&#160;million, and after the offset prorated property taxes of $0.1&#160;million, the net proceeds from the sale were $21.9&#160;million. An independent appraisal of the Douglas Property assigned the Douglas Property a value of $22.0&#160;million. The net carrying value of the property was $20.5&#160;million as of the closing date. We accounted for the transfer as a sale of an asset to an entity under common control, recorded the transfer at book value and recognized the excess of net consideration over carrying book value of $1.4&#160;million as a capital contribution received from Nant&#160;Capital in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we entered into a lease agreement with Nant&#160;Capital under which we leased back 557&#160;South Douglas Street for an initial lease term of seven years, which commenced on September&#160;27,&#160;2021. The monthly base rent under the lease was approximately $81,976 per month with an annual increase of&#160;3% on October&#160;1 of each year beginning in 2022 during the initial term. For the first two years under the lease, we would not be charged rent; we would begin paying rent on October&#160;1,&#160;2023 at the current monthly base rent. We prepaid the first&#160;month rent and security deposit totaling $0.2&#160;million upon the execution of the lease. The lease was classified as an operating lease. During the year ended December&#160;31,&#160;2021, we recorded $0.3&#160;million of rent expense for the lease, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May&#160;31,&#160;2022, we executed a lease termination agreement with Nant&#160;Capital under which we received a full refund of the first month&#8217;s rent and security deposit totaling $0.2&#160;million that we paid upon execution of the lease. Prior to the termination of the lease, we recorded rent expense of $0.4&#160;million during the year ended December&#160;31,&#160;2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. During the year ended December&#160;31,&#160;2022, we recognized a gain of $0.6&#160;million on the disposal of this lease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">420 Nash, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately 19,125 rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $38,250 per month with an annual increase of 3% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. We received a rent abatement for the first month of the lease, and a one-time improvement allowance of $15,000 from the landlord that was credited against base rent obligations for the second month of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has options to extend the lease term for two&#160;additional consecutive periods of five years each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3% during the option term. We have included the first&#160;option to extend the lease term for five years as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. During the years ended December&#160;31,&#160;2023 and 2022, we recorded rent expense for this lease totaling $0.5&#160;million, respectively, and $0.1&#160;million during the year ended December&#160;31,&#160;2021 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23&#160;Alaska, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a 47,265&#160;rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the lease term began on May&#160;1,&#160;2022 and was to expire on April&#160;30,&#160;2027. The base rent was approximately $139,400&#160;per month with an annual increase of 3% on May&#160;1 of each year beginning in 2023 during the initial term. We were also required to pay $7,600&#160;per month for parking during the initial term. The company was responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company was responsible for the costs associated with the build-out of the premises and was to receive a one-time tenant improvement allowance of approximately $0.9&#160;million from the landlord. As of December&#160;31,&#160;2022, we re-evaluated plans for the future development of the facility and deemed it unlikely to claim any of the allowance during the reimbursement time frame. As such, during the year ended December&#160;31,&#160;2022 we wrote off the entire allowance receivable of $0.9&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August&#160;31, 2023, we executed a lease termination agreement with the lessor under which we received a full refund of the security deposit totaling $0.1&#160;million that we paid upon execution of the lease. During the years ended December&#160;31,&#160;2023 and 2022, we recorded $1.2&#160;million of rent expense for this lease, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. During the year&#160;ended December&#160;31,&#160;2023, we recognized a gain of $0.6&#160;million on the disposal of this lease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728800448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Agreements</a></td>
<td class="text">Related-Party Debt <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$505 million December 2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$505 million December 2023 Promissory Note Tranche 2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+7.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,951&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$200 million September&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued PIK<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized<br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300 million December&#160;2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$125 million August&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$50 million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party nonconvertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,099&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431,901&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2015 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2020 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2021 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NantMobile Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCSC Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$300.0&#160;million December 2021 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;17,&#160;2021, the company executed a $300.0&#160;million promissory note with N</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ant&#160;Capital, an af</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filiated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. The note bore an interest rate of Term&#160;SOFR plus 5.4%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances were due on December&#160;17,&#160;2022. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company and Nant&#160;Capital entered into an amended and restated promissory note, pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2023 and the interest rate was amended to Term&#160;SOFR plus 8.0%&#160;per annum. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which this existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Based on the terms of the amended and restated promissory note, the noteholder, at its sole discretion, may convert all of the Tranche&#160;2 $380.0&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$125.0&#160;million August 2022 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company executed a $125.0&#160;million promissory note with Nant&#160;Capital. The note bears an interest rate of Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note letter agreement pursuant to which the existing promissory note was amended to be included in the Tranche&#160;1 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025 and an interest rate of Term&#160;SOFR plus 8.0% per annum. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$50.0&#160;million December 2022 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12,&#160;2022, the company executed a $50.0&#160;million promissory note with Nant&#160;Capital. The note bore an interest rate of Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a specified transaction (as defined in the note), the noteholder can request the outstanding principal and interest due on the loan to be repaid in full upon consummation of such specified transaction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Pursuant to the terms of the amended and restated promissory note, the investor, in its sole discretion may convert all of the outstanding Tranche&#160;2 principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. The noteholder can request up to $50.0&#160;million of the Tranche&#160;2 principal amount and accrued interest to be repaid upon consummation of such specified transaction.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$30.0&#160;million March 2023 Promissory Note </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;31,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital. This note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest was originally due on December&#160;31,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. Upon receipt of a written notice of prepayment from the company, the noteholder may choose to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon into shares of the company&#8217;s common stock at a price of $2.28&#160;per share. Additionally, the noteholder may at its option convert the entire outstanding principal amount of the promissory note and accrued interest into shares of the company&#8217;s common stock at a conversion price of $2.28 per share, at the option of the noteholder. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company received net proceeds of approximately $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the noteholder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of the $30.0&#160;million promissory note described above was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of this promissory note was extended to December&#160;31,&#160;2025. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$30.0&#160;million June 2023 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;13,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital, pursuant to which, the company could request up to three&#160;(3) advances of $10.0&#160;million each. The principal amount of each advance bore interest rate at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances was originally due on December&#160;31,&#160;2023. We may prepay the outstanding principal amount, together with any accrued interest, on any then-outstanding advances, at any time, in whole or in part, without premium or penalty, and without the prior consent of the noteholder upon five&#160;(5) days written notice to the noteholder.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received net proceeds of approximately $29.9&#160;million from this promissory note, net of a $0.1&#160;million origination fee paid to Nant&#160;Capital. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Pursuant to the terms of the amended and restated promissory note the investor, in its sole discretion may convert all of the Tranche&#160;2 $380.0&#160;million principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">$200.0&#160;million September 2023 Promissory Note</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company executed a $200.0&#160;million convertible promissory note with Nant&#160;Capital. The note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a monthly basis. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;11,&#160;2026. We may prepay the outstanding principal amount, together with any accrued interest, at any time, in whole or in part, without premium or penalty upon five&#160;(5) days written notice to the noteholder. The noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#8217;s common stock at a conversion price of $1.9350&#160;per share. The company received net proceeds of approximately $199.0&#160;million from this financing, net of a $1.0&#160;million origination fee paid to the noteholder. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Footnotes to Related-Party Debt Tables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Modification and Debt Extinguishments</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">August 2022 Debt Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;31,&#160;2022, the company amended and restated the above fixed-rate notes payables held by Nant&#160;Capital, NantWorks, NantMobile and NCSC, which are entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and thereafter continued to bear interest at a per annum rate ranging from 3.0% to 6.0%, provided that the outstanding principal was and thereafter continued to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continued to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and thereafter continued to be able to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the noteholder, subject to an advance notice period of at least five business days during which the noteholder could convert the amount requested to be prepaid by the company into shares of the company&#8217;s common stock, as part of the amendment and restatement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gave each noteholder, at its sole option, at any time (other than when the noteholder is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#8217;s common stock at a price of $5.67&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above promissory notes were entered into or amended at the same time and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. ASC&#160;470-50 provides that a modification or an exchange that adds or eliminates a substantive conversion option as of the conversion date would always be considered substantial and require extinguishment accounting. Accordingly, as a result of the addition of the conversion feature to the fixed-rate promissory notes, the fixed-rate promissory notes and the variable-rate promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments. Under this model, the company calculated a gain on extinguishment of $82.9&#160;million, representing the difference between the fair value of the new and amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts plus the cash proceeds from the new promissory note. Since the debt was obtained from entities under common control, such gain was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022. Also, the difference between the face values of the new and amended promissory notes (and accrued interest on the date of the amendment) and the fair values of the new and restated promissory notes was recorded as a debt discount to be amortized to interest expense over the remaining term (or until conversion in the case of fixed-rate promissory notes) of the respective promissory notes. During the year ended December&#160;31,&#160;2022, we recorded amortization of related-party notes discounts totaling $16.3&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the promissory notes without a holder conversion option were estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair values of the fixed-rate promissory notes, which were each modified to include a holder conversion option, were determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included market yields from 18.0% to 24.8% and a risk-free rate of 4.1%, and the significant unobservable inputs used for the binomial lattice model included a volatility of 84.9%, a market yield of 17.4% and a risk-free rate of 3.5%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, the company received written notice from NantWorks, the holder of an existing convertible promissory note of NantCell, a wholly-owned subsidiary of the company, of its election to convert the NantCell promissory note into shares of the company&#8217;s common stock. As of such date, the holder of the NantCell note converted the entire $56.6&#160;million of outstanding principal and accrued and unpaid interest due under the note into 9,986,920&#160;shares of the company&#8217;s common stock at a price of $5.67&#160;per share in accordance with the terms of the promissory note. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">September&#160;11,&#160;2023 Debt Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the holders exchanged promissory notes totaling approximately $270.0&#160;million in aggregate principal amount and accrued and unpaid interest for an aggregate of 209,291,936&#160;shares of common stock at an exchange price of $1.29&#160;per share. As a result of the exchange, the company was forever released and discharged from all its obligations and liabilities under the notes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a series of letter agreements pursuant to which the maturity date of the related-party nonconvertible notes described above totaling $505.0&#160;million in principal was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. In addition, the company entered into the $200.0&#160;million September 2023 promissory note with Nant&#160;Capital. No other material terms or conditions of these promissory notes were modified.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above promissory notes were entered into or amended at the same time on September&#160;11,&#160;2023 and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Pursuant to ASC&#160;470-50, as the terms of the amendment were not substantially different than the terms of the promissory notes prior to the amendment, the amendment was accounted for as a debt modification. The unamortized debt discounts from the promissory notes are being amortized as an adjustment to interest expense over the remaining term of modified promissory notes that are not recorded at fair value using the effective interest rate method. Also, a $29.6&#160;million increase in fair value of the embedded conversion feature from the debt modification was accounted for as a debt discount to the $200.0&#160;million convertible note that is not recorded at fair value, and a $1.6&#160;million increase in fair value of the embedded conversion feature related to the promissory note recorded at fair value was accounted for as interest expense during the year ended December&#160;31,&#160;2023. Such increase in fair values of the embedded conversion features totaling $31.2&#160;million has been recorded with a corresponding increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit.</span></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt">December&#160;29,&#160;2023 Debt Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note and a letter amendment for the following outstanding promissory notes. Pursuant to the terms of the amended and restated promissory note, the amended $505.0&#160;million December&#160;2023 promissory note is comprised of a Tranche&#160;1 with principal amount of $125.0&#160;million which was previously the $125.0&#160;million August&#160;2022 promissory note before amendment, and a Tranche&#160;2 with principal amount of $380.0&#160;million, which is made up of the previous $300.0&#160;million December&#160;2021 promissory note, $50.0&#160;million December 2022 promissory note and $30.0&#160;million June&#160;2023 promissory note. In addition, the amendment allows Nant&#160;Capital, in its sole discretion, to convert all the Tranche&#160;2 principal amount of $380.0&#160;million of the amended promissory note into shares of common stock. The conversion price was subsequently determined at $8.2690&#160;per share based on the agreement. The maturity date of the amended promissory note is December&#160;31,&#160;2025. Pursuant to the terms of the letter amendment, the maturity date of the $30.0&#160;million March&#160;2023 promissory note was extended from December&#160;31,&#160;2024 to December&#160;31,&#160;2025. Also, in connection with the RIPA transaction, all outstanding related-party promissory notes became subordinated to the RIPA payment obligations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes before the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$125 million August&#160;2022 Promissory Note </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$2.2800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$200 million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$1.9350</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes<br/>&#160;&#160;&#160;before amendments</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,000&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes after the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$505 million December&#160;2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$50 million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$505 million December&#160;2023 Promissory Note &#8211; </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 2</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$8.2690</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+7.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total $505 million December&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">505,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$2.2800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$200 million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$1.9350</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes <br/>&#160;&#160;&#160;after amendments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">735,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since all of the above outstanding promissory notes were amended at the same time, with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Also, in accordance with ASC 470-50 the company used the debt terms that existed before the September&#160;11,&#160;2023 modification to determine whether the current modification is substantially different, as the September&#160;11,&#160;2023 modification was within a year of the current transaction, and the promissory notes, at that time, had been modified without being deemed to be substantially different. As the modifications (September&#160;11,&#160;2023 and December&#160;29,&#160;2023 on a cumulative basis) added a substantive conversion feature to the promissory notes, these promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of all the promissory notes before and after amendments. Under this model, the company calculated a loss on extinguishment of $318.8&#160;million, representing the difference between the fair value of the amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts. Since the debt was obtained from entities under common control, such loss was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, a debt premium totaling $354.9&#160;million, calculated as the difference between the fair values of certain promissory notes after modifications and their respective face values, was also recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collectively, net gain on debt extinguishment of $36.1&#160;million was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of stockholders&#8217; deficit for the year ended December&#160;31,&#160;2023. Also, the difference between face values of certain new and amended promissory notes and their respective fair values of $53.1&#160;million was recorded as a debt discount to be amortized as interest expense over the remaining term. During the year&#160;ended December&#160;31,&#160;2023, we recorded amortization of related-party notes discounts totaling $0.5&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest expense, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations related to the new and amended promissory notes. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regard to the Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note, the company identified an embedded derivative related to a contingent exercisable prepayment feature of the promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment of the promissory note and accrued interest upon the occurrence of a specified transaction. After the debt extinguishment, the company concluded that this promissory note was issued at a substantial discount, so the embedded derivative that is contingent exercisable was required to be bifurcated and accounted separately from the debt host instrument. The fair value of the embedded derivative was estimated at $0.8&#160;million as of December&#160;31,&#160;2023, using a with and without method, which assesses the likelihood and timing of the specified transaction to be triggered and result in a repayment. Significant unobservable inputs used for the valuation included a volatility of 118.0%, a market yield of 23.2% and a risk-free rate of 4.8%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Tranche&#160;1 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, which had no noteholder conversion option, was estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair value of Tranche&#160;2 of the amended promissory note, which was modified to include a noteholder conversion option, was determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed were considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included a market yield of 23.2% and the significant unobservable inputs used for the binomial lattice model included a volatility of 118.0%, a market yield of 23.2% and a risk-free rate of 4.4%. The effective unamortized debt discount rate of the amended Tranche&#160;1 and Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note is 23.65% and 18.04%, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the $200.0&#160;million September 2023 promissory note was determined using the binomial lattice model. Significant unobservable inputs used for the valuation included a volatility of 119.3%, a market yield of 23.3% and a risk-free rate of 5.2%.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to December&#160;29,&#160;2023, the $30.0&#160;million March&#160;2023 promissory note was accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the note was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the convertible note was computed using the binomial lattice model with the following observable assumptions before it was modified on December&#160;29,&#160;2023. After the debt extinguishment, the note is accounted for under the amortized cost basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of this note was as follows (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value at issuance date, March&#160;31,&#160;2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on debt extinguishment with entities under common control</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying value, December&#160;29,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense for our related-party promissory notes during the year ended December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Expense</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt<br/>Discount<br/>Amortization</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$125 million August&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 million September&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related-Party Fixed-Rate Promissory Notes </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balances include the amortization of debt discount totaling $0.5&#160;million recorded during the period from December&#160;29,&#160;2023 to December&#160;31,&#160;2023. The interest expense recorded during this period was $0.4&#160;million.</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:33.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our promissory notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The weighted-average interest rate on our promissory notes as of December&#160;31,&#160;2023 was 13.09%.</span></div></td></tr></table></div>Related-Party Agreements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from related party&#8211;Brink</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,019&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;the Clinic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantWorks, LLC</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shared Services Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated shared services agreement dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for these services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded $3.3&#160;million, $3.8&#160;million, and $4.4&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $2.2&#160;million, $0.9&#160;million, and $0.4&#160;million, respectively, of expense reimbursements under this arrangement in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, we had a receivable of $0.5&#160;million and a payable of $1.0&#160;million, respectively, for all agreements with NantWorks, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due from/due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets. We also recorded $1.0&#160;million and $2.0&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of December&#160;31,&#160;2023 and 2022, respectively, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prepaid expenses and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a facility license agreement with NantWorks for approximately 9,500&#160;rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In 2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing January&#160;1,&#160;2022, the license fee increased by 3% to approximately $56,120 per month. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by 36,830&#160;rentable square feet to an aggregate total of 46,330&#160;rentable square feet. Effective May&#160;1,&#160;2022, the license fee was approximately $273,700 per month and was subject to a 3%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#8217; prior written notice to the other party. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded license fee expense for this facility totaling $3.4&#160;million, $2.4&#160;million, and $0.7&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-Oncology Clinic, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple agreements with t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we completed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that a previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we wrote down the remaining value of our prepaid asset and recorded approximately $4.4&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. While we have not yet finalized the potential transition, we continue discussions with potential partners around such alternative structures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded $2.2&#160;million, $2.4&#160;million, and $1.6&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, we owed the&#160;Clinic $0.1&#160;million, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brink Biologics, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into an agreement with Brink whereby we granted Brink worldwide exclusive licenses for the use of certain cell lines and intellectual property in non-clinical laboratory testing. Brink is a related party as our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, and our Chief Corporate Affairs Officer and member of our Board of Directors, collectively own more than 50%&#160;of Brink&#8217;s outstanding shares. During the years ended December&#160;31,&#160;2023 and 2022, we recognized revenue of an immaterial amount, respectively, and $0.4&#160;million during the year ended December&#160;31,&#160;2021 related to this license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NantBio, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a supply agreement with NCSC, a 100%&#160;owned subsidiary of NantBio. Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement had an initial term of five years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#8217; prior written notice by NCSC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized no&#160;revenue, respectively, and $0.3&#160;million of revenue during the year ended December&#160;31,&#160;2021. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $0.1&#160;million of deferred revenue for bioreactors that were delivered but not installed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accrued expenses and other liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $0.9&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets related to this agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits related to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded a receivable from NantBio of $1.3&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due from related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Doug St, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 24,250&#160;rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease term was from July&#160;2016 through July&#160;2023. In June&#160;2023, we exercised the option to extend the lease for one&#160;additional three-year term through July&#160;2026. The base rent is approximately $72,385 per month, with annual increases of 3% that began in July&#160;2017. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded lease expense for this facility of $0.9&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duley Road, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 11,980&#160;rentable square feet of office and cGMP&#160;manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through October&#160;2034. The base rent is approximately $40,700 per month, with annual increases of&#160;3% that began in November&#160;2018. Effective October&#160;3, 2023, we exercised the first option to extend the lease for one&#160;additional five-year term through October&#160;31, 2029. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in 2019, we entered into two&#160;lease agreements with Duley&#160;Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately 5,650&#160;rentable square feet. The lease has a seven-year term that commenced in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488&#160;rentable square feet. The lease has a seven-year term that commenced in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive five-year periods through 2036. The base rent for the two&#160;leases is approximately $35,800 per month, with annual increases of&#160;3% per year.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2022 and 2021, we recorded rent expense for these leases totaling $0.9&#160;million, $0.8&#160;million, and $1.0&#160;million, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, we recorded $0.1&#160;million and $1.4&#160;million of lease-related payables to Duley&#160;Road, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">due to related parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">605 Nash, LLC </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, but effective on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1,&#160;2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately 6,883&#160;rentable square feet (the Initial Premises) in a two&#160;story mixed use building containing approximately 64,643&#160;rentable square feet at 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2027</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and includes an option to extend the lease for one three-year term through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;2030</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The base rent is approximately $20,300 per month with an annual increase of 3%&#160;on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each year during the initial term, and if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately 57,760&#160;rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has one&#160;option to extend the initial term for three years. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $170,400&#160;per month with annual increases of 3% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included the options to extend the lease term of both the Initial and Expansion Premises for three years as part of the initial term of the leases as it is reasonably certain that we will exercise the options, which implies expiration of both leases in December&#160;2030. During the years ended December&#160;31,&#160;2023, 2022, and 2021, we recorded rent expense for the Initial and Expansion Premises leases totaling $2.2&#160;million, respectively, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations. The terms of initial and amended leases provided for tenant improvement allowances totaling $2.9&#160;million for costs and expenses related to improvements made by us to the Initial and Expansion Premises, which were received from the landlord during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31,&#160;2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">557 Doug St, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a Membership Interest Purchase Agreement with Nant&#160;Capital (the Purchase Agreement). Nant&#160;Capital is a related party controlled by Dr.&#160;Soon-Shiong. The Purchase Agreement transferred all outstanding membership interests in 557 Doug St,&#160;LLC from the company to Nant&#160;Capital. The only asset owned by 557&#160;Doug St, LLC is the improved property located at 557&#160;South Douglas Street, El&#160;Segundo, California with a building area of approximately 36,434&#160;rentable square feet (the Douglas Property).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price under the purchase agreement was $22.0&#160;million, and after the offset prorated property taxes of $0.1&#160;million, the net proceeds from the sale were $21.9&#160;million. An independent appraisal of the Douglas Property assigned the Douglas Property a value of $22.0&#160;million. The net carrying value of the property was $20.5&#160;million as of the closing date. We accounted for the transfer as a sale of an asset to an entity under common control, recorded the transfer at book value and recognized the excess of net consideration over carrying book value of $1.4&#160;million as a capital contribution received from Nant&#160;Capital in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September&#160;2021, we entered into a lease agreement with Nant&#160;Capital under which we leased back 557&#160;South Douglas Street for an initial lease term of seven years, which commenced on September&#160;27,&#160;2021. The monthly base rent under the lease was approximately $81,976 per month with an annual increase of&#160;3% on October&#160;1 of each year beginning in 2022 during the initial term. For the first two years under the lease, we would not be charged rent; we would begin paying rent on October&#160;1,&#160;2023 at the current monthly base rent. We prepaid the first&#160;month rent and security deposit totaling $0.2&#160;million upon the execution of the lease. The lease was classified as an operating lease. During the year ended December&#160;31,&#160;2021, we recorded $0.3&#160;million of rent expense for the lease, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May&#160;31,&#160;2022, we executed a lease termination agreement with Nant&#160;Capital under which we received a full refund of the first month&#8217;s rent and security deposit totaling $0.2&#160;million that we paid upon execution of the lease. Prior to the termination of the lease, we recorded rent expense of $0.4&#160;million during the year ended December&#160;31,&#160;2022 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. During the year ended December&#160;31,&#160;2022, we recognized a gain of $0.6&#160;million on the disposal of this lease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">420 Nash, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately 19,125 rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $38,250 per month with an annual increase of 3% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. We received a rent abatement for the first month of the lease, and a one-time improvement allowance of $15,000 from the landlord that was credited against base rent obligations for the second month of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has options to extend the lease term for two&#160;additional consecutive periods of five years each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3% during the option term. We have included the first&#160;option to extend the lease term for five years as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. During the years ended December&#160;31,&#160;2023 and 2022, we recorded rent expense for this lease totaling $0.5&#160;million, respectively, and $0.1&#160;million during the year ended December&#160;31,&#160;2021 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">23&#160;Alaska, LLC</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a 47,265&#160;rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the lease term began on May&#160;1,&#160;2022 and was to expire on April&#160;30,&#160;2027. The base rent was approximately $139,400&#160;per month with an annual increase of 3% on May&#160;1 of each year beginning in 2023 during the initial term. We were also required to pay $7,600&#160;per month for parking during the initial term. The company was responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company was responsible for the costs associated with the build-out of the premises and was to receive a one-time tenant improvement allowance of approximately $0.9&#160;million from the landlord. As of December&#160;31,&#160;2022, we re-evaluated plans for the future development of the facility and deemed it unlikely to claim any of the allowance during the reimbursement time frame. As such, during the year ended December&#160;31,&#160;2022 we wrote off the entire allowance receivable of $0.9&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective August&#160;31, 2023, we executed a lease termination agreement with the lessor under which we received a full refund of the security deposit totaling $0.1&#160;million that we paid upon execution of the lease. During the years ended December&#160;31,&#160;2023 and 2022, we recorded $1.2&#160;million of rent expense for this lease, respectively, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statements of operations. During the year&#160;ended December&#160;31,&#160;2023, we recognized a gain of $0.6&#160;million on the disposal of this lease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879720541520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_WarrantLiabilityTextBlock', window );">Warrant Liabilities</a></td>
<td class="text">Warrant Liabilities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12,&#160;2022, in connection with the sale of 9,090,909&#160;shares of our common stock to an institutional investor, we entered into a warrant agreement that allows such investor to purchase up to 9,090,909&#160;shares at an exercise price of $6.60&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of the warrants was estimated at $35.1&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0&#160;million, $1.1&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was allocated to the warrants and recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations on the date of the transaction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, all 9,090,909&#160;underlying warrants were outstanding. As of December&#160;31,&#160;2023 and 2022, the estimated fair value of the warrants were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.1&#160;million and $21.6&#160;million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the year ended December&#160;31,&#160;2023, a decrease in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.5&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15,&#160;2023, in connection with the sale of 14,072,615&#160;shares of our common stock to certain institutional investors, we entered into a warrant agreement that allows such investors to purchase up to 14,072,615&#160;shares at an exercise price of $4.2636&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants was estimated at $23.7&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling $3.0&#160;million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was allocated to the warrants </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the date of the transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, the company amended the terms of the warrant, reducing the exercise price of the warrants from $4.2636&#160;per share to $3.2946&#160;per share and extending the expiration date of the warrants until July&#160;24,&#160;2026. Since the warrants were classified as liabilities and measured at fair value, we recognized the change of $7.3&#160;million in fair value of warrant liability in earnings due to the warrant modification.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, all 14,072,615&#160;underlying warrants were outstanding, with an estimated fair value of $50.0&#160;million. During the year ended December&#160;31,&#160;2023, an increase in fair value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.3&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">July&#160;2023 Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;20, 2023, in connection with the sale of 14,569,296&#160;shares of our common stock to certain institutional investors, we entered into a warrant agreement that allows such investors to purchase up to 14,569,296&#160;shares at an exercise price of $3.2946&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants was estimated at $25.8&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling $2.5&#160;million, $1.0&#160;million was allocated to the warrants </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the consolidated statement of operations </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the date of the transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, all 14,569,296&#160;underlying warrants were outstanding, with an estimated fair value of $51.7&#160;million. During the year ended December&#160;31,&#160;2023, an increase in fair value of $25.9&#160;million was recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879716751296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Deficit</a></td>
<td class="text">Stockholders&#8217; Deficit<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Authorized for Issuance</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the company was authorized to issue up to 1,350,000,000&#160;shares of its common stock, par value $0.0001&#160;per share, and 20,000,000&#160;shares of our preferred stock, par value $0.0001&#160;per share. As of December&#160;31,&#160;2023, there were 670,867,344&#160;shares of our common stock outstanding (excluding 163,800&#160;shares held by a majority owned subsidiary of the company that are treated as treasury shares for accounting purposes).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October&#160;18,&#160;2023, we amended and restated our Amended and Restated Certificate of Incorporation to increase the number of shares that the company is authorized to issue from 900,000,000&#160;shares of common stock, $0.0001&#160;par value per share, to 1,350,000,000&#160;shares of common stock, $0.0001&#160;par value per share. The number of shares of preferred stock, $0.0001&#160;par value per share, that the company is authorized to issue remained unchanged at 20,000,000&#160;shares. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Issued in Connection with the Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $0.001&#160;per share, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive 0.8190&#160;newly issued shares of common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $0.0001&#160;per share, resulting in the issuance of approximately 273.7&#160;million shares of Company Common Stock.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Merger was accounted for as a transaction between entities under common control, the outstanding shares presented on the consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock during the period ended December&#160;31,&#160;2021, and in connection with the conversion, those shares of common stock were recorded at the company&#8217;s par value of $0.0001&#160;per share. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2015 Share Repurchase Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program, which allows our CEO or CFO, to repurchase on behalf of the company, from time to time in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups, or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements, and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through approval of the Board of Directors upon repurchase. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, no&#160;shares of our common stock were repurchased under the program. Since the plan&#8217;s inception, we have repurchased a total of 6,403,489&#160;shares at a total cost of $31.7&#160;million. As of December&#160;31,&#160;2023, $18.3&#160;million remained authorized to use for share repurchases under the program. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During February&#160;2023, we filed a $750.0&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. During the year ended December&#160;31,&#160;2023, we sold shares of our common stock and warrants valued at $184.4&#160;million under the shelf. As of December&#160;31,&#160;2023, we had $565.6&#160;million available for use under the shelf. This available shelf is in addition to the Open Market Sale Agreement described below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sale Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April&#160;2021, we entered into the&#160;ATM under which we may offer and sell, from time to time at our sole discretion, shares of our common stock through our sales agent. We pay our sales agent a commission of up to 3.0%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the ATM, and also have provided them with customary indemnification and contribution rights. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, we received net proceeds of approximately $16.1&#160;million, $13.1&#160;million, and $164.5&#160;million, respectively, from the issuance of shares under the&#160;ATM. As of December&#160;31,&#160;2023, we had $208.8&#160;million available for future issuances under the ATM.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances and shall automatically terminate upon the issuance and sale of all of the shares.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Direct Offerings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Offerings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;15,&#160;2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,072,615&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,072,615&#160;shares of common stock at an exercise price of $4.2636&#160;per share, for a purchase price of $3.5530&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other offering costs of $3.0&#160;million, of which $2.0&#160;million was allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2023. The warrants became immediately exercisable on February&#160;17,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, pursuant to the terms of a letter amendment, the company and the investors agreed to reduce the exercise price of the outstanding February&#160;2023 Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extend the expiration date of the warrants to July&#160;24,&#160;2026. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_220" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">12</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">July 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;20, 2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,569,296&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,569,296&#160;shares of common stock at an exercise price of $3.2946&#160;per share, for a purchase price of $2.7455&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $37.5&#160;million, after deducting placement agent fees and other estimated offering costs of $2.5&#160;million, of which $12.7&#160;million was allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2023. The warrants became immediately exercisable on July&#160;25,&#160;2023 and expire on July&#160;24,&#160;2026.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Offering</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12,&#160;2022, we entered into a securities purchase agreement with an institutional investor for the sale of 9,090,909&#160;shares of our common stock, as well as warrants that allow such investor to purchase an additional 9,090,909&#160;shares of common stock at an exercise price of $6.60&#160;per share, for a purchase price of $5.50&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other offering costs of $3.0&#160;million, of which $1.9&#160;million was allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase and Option Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023 and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $10.0&#160;million of our common stock at $4.1103&#160;per share in a private placement, which resulted in the issuance of 2,432,894&#160;shares of common stock. We received net proceeds of approximately $9.5&#160;million, after deducting offering costs of $0.5&#160;million, which were allocated to the sale of our common stock and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional-paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit during the year ended December&#160;31,&#160;2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oberland also has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock, calculated from the date of exercise. The option is exercisable by Oberland any time after the closing of the SPOA, until the earliest of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;December&#160;29,&#160;2028, (ii)&#160;a change of control of the company, or (iii)&#160;a sale of substantially all of the company&#8217;s assets. Among other limitations, the option may only be exercised to the extent that the common stock issuable pursuant to such exercise would not exceed 19.9%&#160;of the common stock outstanding immediately after giving effect to such exercise. We have agreed to file a shelf registration statement allowing for the resale of the common stock acquired under the SPOA and to cause the registration statement to be effective no later than May&#160;15,&#160;2024, or if the SEC decides to review such registration statement, no later than June&#160;30,&#160;2024. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Promissory Notes into Common Stock </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the related-party purchasers exchanged all such fixed-rate promissory notes, representing approximately $270.0&#160;million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936&#160;shares of common stock at an exchange price of $1.29&#160;per share. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;12, 2022, the company received written notice from NantWorks, the holder of the existing note, of its election to convert the entire outstanding principal and accrued interest under the existing note into shares of the company&#8217;s common stock. As of such date, the entire outstanding principal amount and accrued and unpaid interest due under the existing note of approximately $56.6&#160;million and an unamortized debt discount of $4.7&#160;million were converted into 9,986,920&#160;shares of the company&#8217;s common stock at a price of $5.67&#160;per share in accordance with the terms of the Existing Note. We recorded a net increase of $51.9&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet related to this transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727802544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors adopted, and our stockholders approved, the 2015&#160;Plan. The 2015&#160;Plan, as amended, permits the grant of incentive stock options to the company&#8217;s employees, and the grant of non-statutory stock options, restricted stock, RSUs, stock appreciation rights, performance units and performance shares to the company&#8217;s employees, directors, and consultants. In addition, the number of shares reserved for future grant under the 2015&#160;Plan include shares subject to stock options granted under the 2014&#160;Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2014&#160;Plan that are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2015&#160;Plan pursuant to this provision is approximately 346,840&#160;shares as of December&#160;31,&#160;2023). Pursuant to the Merger, we assumed 7,121,110&#160;RSUs (adjusted for the Exchange Ratio) issued under the NC&#160;2015 Plan. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the 2015&#160;Plan is the only equity plan available for grant of equity awards to employees, directors, and consultants of the company. As of December&#160;31,&#160;2023, approximately 13.1&#160;million&#160;shares were available for future grants under the 2015&#160;Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation included on the consolidated statements of operations (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,163&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,179&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,181&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense in operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity and related information for the year ended December&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intrinsic</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in years)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,262,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">949,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(184,362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(207,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,820,435&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and exercisable as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,867,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the unrecognized compensation cost related to outstanding stock options was $8.4&#160;million, which is expected to be recognized over a remaining weighted-average period of 1.0 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31,&#160;2023, the total intrinsic value of stock options exercised was $0.3&#160;million. During the years ended December&#160;31,&#160;2023, 2022 and 2021, cash proceeds received from stock option exercises were $0.3&#160;million, $0.1&#160;million, and $5.4&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, a total of 3,445,499&#160;vested and exercisable stock options were outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.80</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S.&#160;Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends for the foreseeable future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the year ended December&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Units</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance as of December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,551,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,407,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,545,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, there was $38.2&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.2&#160;years. During the year ended December&#160;31,&#160;2023, the total intrinsic value of RSUs vested was $11.1&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of August&#160;25,&#160;2023, the Compensation Committee of the Board of Directors granted 5,727,159&#160;RSUs to eligible employees of the company, with the intention of retaining such employees (the &#8220;retention award&#8221;). The retention award vests according to the following schedule: &#189;&#160;(one-half) was to vest and vested on September&#160;1,&#160;2023 and &#189;&#160;(one-half) will vest on January&#160;31,&#160;2024, subject to the recipients continuing to be a &#8220;service provider&#8221; (as defined in the 2015&#160;Plan) through each applicable vesting date. With respect to RSUs granted, compensation cost was measured using the grant date fair value of $1.65&#160;per share, the closing price of the company&#8217;s common stock on August&#160;25,&#160;2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded to employees and consultants of affiliated companies are accounted for as stock-based compensation in accordance with FASB ASU 2018-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation (Topic&#160;718)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $4.0&#160;million. During the years ended December&#160;31,&#160;2023 and 2022, we recorded $0.4&#160;million, respectively, and $0.9&#160;million of deemed dividends during the year ended December&#160;31,&#160;2021 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheets, with a corresponding credit to stock-based compensation expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related-Party Warrants</span></div>In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#8217;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of 1,638,000&#160;warrants with an exercise price of $3.24&#160;per share were outstanding as of December&#160;31,&#160;2023. The fair value of $18.0&#160;million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723620128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California, and other states. From inception through December&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated NOLs. Our federal returns for tax years 2020 through 2022 remain open to examination, and our state returns remain subject to examination for tax years 2019 through 2022. The Italian and South Korean returns for tax years 2018 through 2022 remain open to examination. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the IRS or other respective tax authorities. No income tax returns are currently under examination by taxing authorities. There are no cumulative earnings in our Italian and South Korean subsidiaries as of December&#160;31,&#160;2023 that would be subject to U.S.&#160;income tax or foreign withholding tax. We plan to indefinitely reinvest any future earnings of our foreign subsidiaries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;9,&#160;2021, the company completed the Merger with NantCell. The Merger is accounted for as a transaction between entities under common control, and is considered a nontaxable transaction for U.S.&#160;income tax purposes, as it is intended to qualify as a &#8220;reorganization&#8221; (within the meaning of Section&#160;368(a) of the Code).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss before income taxes is as follows (in&#160;thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. loss before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(583,892)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,286)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,839)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense) consists of the following (in&#160;thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit (expense)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components that comprise our net deferred tax liabilities consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;E capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,722&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,363&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,426)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,766)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,296&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,597&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, we have federal NOLs of $1.6&#160;billion, state NOLs of $2.0&#160;billion, and foreign NOLs of $14.3&#160;million. Of the $1.6&#160;billion in federal NOLs, $1.2&#160;billion do not expire and will be able to be used to offset 80% of taxable income in future years. Of the $2.0&#160;billion in state NOLs, $50.7&#160;million do not expire and will be able to be used to offset 80% of taxable income in future years. The remaining federal NOL carryforwards expire beginning in 2024, the remaining state NOL carryforwards expire beginning in 2024, the South Korean NOL carryforwards expire beginning in 2024, and the Italian NOLs do not expire. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some or all of our deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of economic conditions, we recorded a valuation allowance of $648.4&#160;million and $491.8&#160;million as of December&#160;31,&#160;2023 and 2022, respectively. During the years ended December&#160;31,&#160;2023 and 2022, the valuation allowance increased by $156.6&#160;million and $116.6&#160;million, respectively, which was mainly driven by losses from which we cannot benefit. The portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital is $0.2&#160;million.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory income tax rate to our effective income tax rate is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections&#160;382 and 383 of the Code, annual use of our net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We have not recognized the deferred tax assets for federal and state NOLs and credits of $274.1&#160;million from our deferred tax asset schedules as of December&#160;31,&#160;2023 due to Section&#160;382/383 limitations. There is no impact to tax expense for the derecognition of net operating losses, and federal and state research and development credits due to the valuation allowance recorded against our deferred tax assets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, we also had federal research tax credit carryforwards of $47.7&#160;million and state research tax credits of $29.6&#160;million. The federal research tax credit carryforwards expire beginning in 2032 and certain state research tax credit carryforwards expire beginning in 2030. Our California research tax credits can be carried forward indefinitely. As of December&#160;31,&#160;2023, we also had federal other tax credits carryforwards of $1.3&#160;million and the tax credit carryforwards expire beginning in 2036 </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credits also are limited when there is a SRLY. These rules generally limit the use of the acquired or departing members&#8217; net operating loss and tax credit carryovers to the amount of taxable income such entity contributes to consolidated taxable income. The 80%&#160;limitation also applies to SRLY NOL carryovers and tax credits. Therefore, any SRLY NOLs and tax credits will be subject to this limitation, as well as Section&#160;382 and 383 limitations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023 and 2022, we have $164.6&#160;million and $77.6&#160;million of interest, respectively, that is temporarily disallowed pursuant to Section&#160;163(j) of the Code. This interest can be carried forward indefinitely and will be deductible when the company generates sufficient adjusted taxable income.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of changes to the amount of unrecognized tax benefits is as follows (in&#160;thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of December&#160;31,&#160;2023 is $15.1&#160;million that, if recognized, would not impact our income tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. We do not expect that the unrecognized tax benefits will change within 12&#160;months of December&#160;31,&#160;2023. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact our effective tax rate. We have not incurred any material interest or penalties as of the current reporting date with respect to income tax matters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Reduction Act of 2022</span></div>The Inflation Reduction Act 2022, which incorporates a corporate alternative minimum tax, was signed on August&#160;16,&#160;2022. The changes are effective for the tax years beginning after December&#160;31,&#160;2022. The new tax will require companies to compute two&#160;separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The company will be monitoring the impact of the act to determine if it will have an impact on the company for years beginning after December&#160;31,&#160;2022. We currently do not expect this act will have a material effect on our consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879716751296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Employee Benefits</a></td>
<td class="text">Employee Benefits<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, we adopted a 401(k)&#160;Plan covering all employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The company, at its discretion, may make certain contributions to the 401(k)&#160;Plan. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we made contributions totaling $2.8&#160;million, $2.7&#160;million, and $1.7&#160;million, respectively, to the 401(k)&#160;Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensated Absences</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our vacation policy, salaried employees are provided unlimited vacation leave. Therefore, we do not record an accrual for paid leave related to these employees since we are unable to reasonably estimate the compensated absences that these employees will take.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728220288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock', window );">Accounting Treatment of the Merger</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Treatment of the Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger represents a business combination pursuant to ASC&#160;805-50, which was accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We recast our prior period financial statements for the year ended December&#160;31,&#160;2021 to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the consolidated financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div>The consolidated financial statements have been prepared in accordance with U.S.&#160;GAAP and pursuant to the rules and regulations of the SEC. Certain items in the prior years&#8217; consolidated financial statements have been reclassified to conform to the current presentation. These reclassifications had no effect on the reported results of operations. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a VIE for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities in which we have less than 100% ownership, we record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">net loss attributable to noncontrolling interests, net of tax,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impacts the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the entity is within the scope of the variable interest model and meets the definition of a VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, CVR&#160;measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants, stock options, derivative liabilities, and convertible promissory notes, fair value measurements, revenue interest liability, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attempt to minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also monitor the creditworthiness of the borrower of the convertible promissory note. We believe that any concentration of credit risk in its convertible note receivable was mitigated in part by our ability to convert, if necessary, at the qualifying financing event or upon a payment default into shares of the senior class of equity securities of the borrower.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates developed by us will require approvals or clearances from the&#160;FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span id="i4643e1a07ce0428bbdfe8baf8b53beac_51425"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include highly liquid investments with an original maturity of three&#160;months or less from the date of purchase.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes a certificate of deposit held as a substitute letter of credit for one of our leased properties. This certificate of deposit is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other assets,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated balance sheet as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities and Other Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Other Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have typically invested our cash in a variety of financial instruments, including investment-grade short- to intermediate-term corporate debt securities, government-sponsored securities and European bonds; however, after our entry into the RIPA, we can no longer invest our excess funds in corporate or European bonds. Certain of our investments are subject to credit, liquidity, market, and interest-rate risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive income,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">interest and investment income (loss), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. Realized gains and losses from sales of securities and the amounts, net of tax, reclassified out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if any, are determined on a specific identification basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in mutual funds and equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and any unrealized gains and losses are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. Realized gains and losses from the sale of the securities are determined on a specific identification basis and the amounts are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluating Investments for Other-than-Temporary Impairments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether we have plans to sell the security or whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded during the years ended December&#160;31,&#160;2023, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method of Accounting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method of Accounting</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, we record our share of the income or loss of the other company as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">loss on equity method investment</span>, in our consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to operating expenses during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IT equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The lesser of the lease term or life of the asset</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon disposal of property, plant and equipment, the cost and related accumulated depreciation are removed from the consolidated financial statements and the net amount, less any proceeds, is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Property, Plant and Equipment, Net, Impairment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review impairment of property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method of accounting in accordance with ASC&#160;805-50. These standards require that the total cost of acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition, with the excess purchase price recorded as goodwill. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration incurred in connection with a business combination are recorded at their fair values on the acquisition date and re-measured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair value are recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">research and development expense,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statements of operations and comprehensive loss. Changes in fair value reflect changes to our assumptions regarding probabilities of successful achievement of related milestones, the timing in which the milestones are expected to be achieved, and the discount rate used to estimate the fair value of the obligation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonControlTransactionPolicyPolicyTextBlock', window );">Common Control Transactions</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Control Transactions</span></div>Transactions between us and entities where Dr.&#160;Soon-Shiong and his affiliates are the controlling stockholders are accounted for as common control transactions whereby the net assets acquired or transferred are accounted at their carrying value. Any difference between the carrying value and consideration recognized is treated as a capital transaction. Cash consideration up to the carrying value of the net assets acquired or transferred is presented as an investing activity on the consolidated statement of cash flows. Cash consideration in excess of the carrying value of the net assets acquired or transferred is presented as a financing activity on the consolidated statement of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired in a business combination or an asset acquisition are initially recognized at their fair value on the acquisition date. Acquired indefinite-lived assets, such as IPR&amp;D, are not amortized until they become definite-lived assets, upon the successful completion of the associated research and development effort. At that time, we evaluate whether the recorded </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are impaired and make any necessary adjustments, and then determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned, the related IPR&amp;D assets is written-off and an impairment charge recorded. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired definite-lived intangible assets are amortized using the straight-line method over their respective estimated useful lives. The amortization of these intangible assets is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense,</span> on the consolidated statement of operations. Intangible assets are tested for impairment at least annually or more frequently if indicators of potential impairment exist.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Patents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent costs, including related legal costs, are expensed as incurred and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three tiers are defined as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities, and corporate bonds, as well as foreign municipal securities.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31,&#160;2023, 2022 and 2021, no transfers were made into or out of the Level&#160;1, 2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of FASB ASC Topic&#160;808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;808). A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. To the extent the collaboration agreement is within the scope of ASC&#160;808, we also assess whether the arrangement contains multiple elements that are within the scope of other accounting literature. If we conclude that some or all aspects of the agreement are distinct and represent a transaction with a customer, we account for those aspects of the arrangement within the scope of FASB ASC Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC&#160;606). Amounts that are owed by collaboration partners within the scope of ASC&#160;808 are recognized as an offset to research and development expense as such amounts are incurred by the collaboration partner. The amounts owed to a collaboration partner are classified as research and development expense.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration arrangements require us to acquire certain equipment for exclusive use in the joint operating activities. These equipment purchases do not have an alternative use and are therefore expensed as incurred within research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock', window );">Preclinical and Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing the consolidated financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate clinical trial and research agreement-related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research-related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock', window );">Transactions with Related Parties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with Related Parties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have various agreements with related parties. These arrangements can be billed and settled in cash monthly, billed quarterly and settled in cash the following month, or estimated in advance and collected or paid upfront based on expected utilization. Monthly accruals are made for all quarterly billing arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease Obligations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases other than short-term leases, at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At the commencement date, lease right-of-use assets and lease liabilities are determined based on the present value of lease payments to be made over the lease term. Leases are classified as either finance leases or operating leases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the rate implicit in lease contracts are not readily determinable, we utilize its incremental borrowing rate as a discount rate for purposes of determining the present value of lease payments, which is based on the estimated interest rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, we will remeasure the lease liability at the net present value of the remaining lease payments using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, the exercise of renewal is only assured for five&#160;of our cGMP facilities where we have made significant improvements or extended the lease.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We combine our lease components (e.g.,&#160;fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g.,&#160;common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term. The lease term includes the non-cancellable period of the lease and any additional periods covered by either options to renew or not to terminate when the company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale-Leaseback Transaction</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sale-leaseback transaction occurs when an entity sells an asset it owns and immediately leases the asset back from the buyer. The seller then becomes the lessee and the buyer becomes the lessor. When entering into a sale-leaseback transaction as a seller-lessee, the requirements in ASC&#160;606, and all related ASUs to such Topic are applied in determining whether the transfer of an asset shall be accounted for as a sale of the asset by assessing whether it satisfies a performance obligation under the contract by transferring control of an asset. If the company transfers control of an asset to the buyer-lessor, the transfer is accounted for as a sale and the company derecognizes the transferred asset. The subsequent leaseback of the asset is accounted for in accordance with FASB ASC&#160;Topic&#160;842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the same manner as any third-party lease. If the company does not transfer control of an asset to the buyer-lessor, the sale-leaseback transaction is accounted for as a financing arrangement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC&#160;480 and ASC&#160;815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">additional paid-in capital,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of stockholders&#8217; deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ther expense, net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock', window );">Fair Value Option Election</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Option Election</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company accounted for a convertible note issued on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the&#160;FVO&#160;election of ASC&#160;825 until it was amended and restated on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023. Prior to its extinguishment on December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the convertible note was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issuance-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of this convertible note were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other&#160;expense, net,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations, except that changes in estimated fair value caused by changes in the instrument-specific credit risk were recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with ASC&#160;470-50, when the convertible note was extinguished on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;29,&#160;2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the cumulative amount previously recorded in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulting from changes in the instrument-specific credit risk were reclassified and reported in current earnings on the consolidated statement of operations. See </span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;10</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Debt</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Modification and Extinguishment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Modification and Extinguishment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company evaluates amendments to its debt instruments in accordance with ASC&#160;470-50. This evaluation includes comparing (1)&#160;if applicable, the net present value of future cash flows of the amended debt to that of the original debt and (2)&#160;the change in fair value of an embedded conversion feature to that of the carrying amount of the debt immediately prior to amendment to determine, in each case, if a change greater than 10% occurred. In instances where the net present value of future cash flows or the fair value of an embedded conversion feature, if any, changed more than 10%, the company applies extinguishment accounting. In instances where the net present value of future cash flows and the fair value of an embedded conversion feature, if any, changed less than 10%, the company accounts for the amendment to the debt as a debt modification. Gains and losses on debt amendments that are considered extinguishments are recognized in current earnings or in additional paid-in capital if the transactions are with entities under common control. Debt amendments that are considered debt modifications are accounted for prospectively through yield adjustments, based on the revised terms. The increase in fair value of the embedded conversion feature from the debt modification was accounted for as an increase in debt discount with a corresponding increase in additional paid-in capital. Legal fees and other costs incurred with third parties that are directly related to debt modifications are expensed as incurred. Amounts paid by the company to the lenders, are reflected as additional debt discount and amortized as an adjustment of interest expense over remaining term of modified debt using the effective interest rate method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Interest Liability</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter. The RIPA is considered a sale of future revenues and is accounted for as a liability net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability, interest expense, and the time period for repayment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize uncertain tax positions when the position will more likely than not be upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">income tax benefit (expense),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31,&#160;2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock', window );">Stock Repurchases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program. As it is our intent for the repurchased shares to be retired, we have elected to account for the shares repurchased using the constructive retirement method. For shares repurchased in excess of par, we record the purchase price in excess of par value in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">accumulated deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">Derivative Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Embedded derivatives that are required to be bifurcated from the underlying debt instrument that do not meet the derivative scope exception and equity classification criteria are accounted for and valued as separate financial instruments. The terms of an embedded derivative related to a contingent exercisable prepayment feature of a convertible note have been evaluated and deemed to require bifurcation. This embedded derivative will be initially measured at fair value and will be remeasured to fair value at each reporting date until the derivative is settled. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains certain features that meet the definition of being an embedded derivative requiring bifurcation as a separate compound financial instrument apart from the RIPA. The derivative liability is initially measured at fair value upon issuance and is subject to remeasurement at each reporting period with changes in fair value recognized in other expense, net, on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have primarily generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. The nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies grant them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines. We have generated revenues from product sales of our proprietary GMP-in-a-Box bioreactors and related consumables, primarily to related parties. Additionally, we also generated revenues from grant programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract&#8217;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreements with customers, we typically promise to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. Research and development data are provided throughout the term of the contract when and if available.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have sold our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies. The arrangements typically include delivery of bioreactors, consumables, and providing installation service and perpetual software licenses for using the equipment. We recognize revenue when customers obtain control and can benefit from the promised goods or services, generally upon installation of the bioreactors, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. Upfront payments and fees are recorded as deferred revenue upon receipt and recognized as revenue when we satisfy our performance obligations under these arrangements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue is typically paid for reimbursable costs incurred over the duration of the associated research project or clinical trial and is recognized either when expenses reimbursable under the grants have been incurred and payments under the grants become contractually due or when cash is received, depending on the certainty of payment and other factors specific to each grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials costs, including CROs and related clinical manufacturing, including third-party CMOs, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company classifies its research and development expenses as either external or internal. The&#160;company&#8217;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#8217;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#8217;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the preclinical studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates. We adjust the accruals in the period when actual costs become known.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation under the provisions of ASC&#160;718. We estimate fair value of each stock option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions, including, but not limited to, expected stock price volatility over the term of the awards and the expected term of the stock options. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;14</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span>, for more information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net (loss) income and other comprehensive (loss) income. Our other comprehensive income or loss consists of net unrealized gains (losses) on marketable debt securities classified as available-for-sale, net of income taxes and foreign currency translation adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests are recorded for the entities that we consolidate but are not wholly-owned by the company. Noncontrolling interests are classified as a separate component of equity on the consolidated balance sheet and consolidated statement of stockholders&#8217; deficit. Additionally, net loss attributable to noncontrolling interests is reflected separately from consolidated net loss on the consolidated statement of operations and the consolidated statement of stockholders&#8217; deficit. </span></div>We record the noncontrolling interests&#8217; share of loss based on the percentage of ownership interest retained by the respective noncontrolling interest holders.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currencies</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and hold assets in Italy and South Korea. The functional currency of the subsidiary in Italy is the Euro, based on the nature of the transactions occurring within this entity, and accordingly, assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates prevailing as of the balance sheet dates, while the operating results are translated into U.S.&#160;dollars using the average exchange rates for the period correlating with those operating results. Adjustments resulting from translating the financial statements of the foreign subsidiary into U.S.&#160;dollars are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other comprehensive (loss) income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on the consolidated statement of comprehensive loss. Transaction gains and losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other expense, net,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share of Common Stock</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div>We operate in one reporting segment focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Our CEO is the chief operating decision-maker of the company, and manages and allocates resources to our operations on a company-wide basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future-period financial results, allocating resources, and setting incentive targets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span id="i4643e1a07ce0428bbdfe8baf8b53beac_102909"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December&#160;2023, the FASB issued ASU&#160;2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic&#160;740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1)&#160;disclose specific categories in the rate reconciliation, (2)&#160;provide additional information for reconciling items that meet a quantitative threshold, and (3)&#160;disclose more detailed information about income taxes paid, including by jurisdiction; pretax income (or loss) from continuing operations; and income tax expense (or benefit). The ASU is effective for fiscal years beginning after December&#160;15,&#160;2024, and interim periods beginning after December&#160;15,&#160;2025, with early adoption permitted. We are currently evaluating the impact of this standard on our disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2023, the FASB issued ASU&#160;2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Topic&#160;280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, and interim periods within fiscal years beginning after December&#160;15,&#160;2024 on a retrospective basis. We are currently evaluating the impact of this standard on our disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2023, the FASB issued ASU 2023-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations-Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires a joint venture to initially measure all contributions received upon its formation at fair value. This ASU is applicable to joint venture entities with a formation date on or after January&#160;1,&#160;2025 on a prospective basis. We will apply this guidance prospectively in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2023, the FASB issued ASU&#160;2023-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Common Control Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC) and the SEC during the year ended December&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CommonControlTransactionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Control Transaction, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CommonControlTransactionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Fair Value Option Election</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preclinical and Clinical Trial Accruals, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_StockRepurchaseProgramPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Program, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_StockRepurchaseProgramPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 6<br> -SubTopic 50<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479455/805-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -SubTopic 15<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481051/815-15-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480526/815-10-35-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5B<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480588/815-10-25-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 15<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481116/815-15-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728093728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of Impact of Change in Reporting Entity on Unaudited Consolidated Statements of Operations</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the impact of the change in reporting entity on our unaudited condensed consolidated statement of operations for the three&#160;months&#160;ended March&#160;31,&#160;2021 (in&#160;thousands):</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:50.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Three Months Ended<br/>March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NantCell</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NantKwest</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intercompany<br/>Eliminations</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">ImmunityBio,<br/>Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (including amounts<br/>with related parties)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (including amounts<br/>with related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(45,708)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(40,628)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(86,264)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net (including amounts <br/>with related parties)</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(848)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,637&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,789&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(46,556)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(33,997)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(80,481)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879716589952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Estimated Useful Lives of Property, Plant and Equipment</a></td>
<td class="text">Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IT equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The lesser of the lease term or life of the asset</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture &amp; fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">230,458&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">212,911&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Securities Excluded from the Computation of Potentially Dilutive Securities</a></td>
<td class="text">The following table details those securities that have been excluded from the computation of potentially dilutive securities:<div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,471,837</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,274,965</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding third-party warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,732,820</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,090,909</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,820,435</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,262,926</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,124,930</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503,979</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,889</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding related-party warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,167,071</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,818,188</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,278,819</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Region</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate a portion of our revenues from outside of the U.S. Information about our revenues by geographic region is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728906624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid software license fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insurance premium financing asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance claims receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid equipment maintenance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ERP system implementation cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text">Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture &amp; fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IT equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The lesser of the lease term or life of the asset</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net, consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">68,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">67,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture &amp; fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gross property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">230,458&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">212,911&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">146,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">143,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Definite-lived: Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,825)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(886)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Favorable leasehold rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Organized workforce</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,935)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,613&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indefinite-lived: IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,935)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(681)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense associated with our definite-lived intangible assets is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Definite-lived</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intangible</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities consist of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional and service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued preclinical and clinical trial costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing obligation &#8211; current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued construction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeTableTextBlock', window );">Schedule of Interest and Investment (Loss) Income, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and investment income (loss), net consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses from equity securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment accretion income (amortization expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and investment income (loss), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,090)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of the following (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on related-party notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of related-party notes discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,198&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,515&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,849&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879829318064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-Sale Marketable Debt Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair <br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:34.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life<br/>(in years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;<br/>Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">970&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</a></td>
<td class="text">Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): <div style="margin-bottom:9pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December&#160;31,&#160;2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">More than 12 months</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879825269392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">265,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">265,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,353&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock option purchase liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,024&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,403&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,621&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration is recorded at estimated fair value and revalued each reporting period until the related contingency is resolved. The fair value measurement is based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Contingent Consideration Related to Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the carrying amount of contingent consideration were as follows (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:60.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (increase) decrease in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock Option Purchase Liability</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the RIPA, we entered into an SPOA pursuant to which Oberland has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability at its fair value upon issuance. The fair value was estimated using probability-weighted scenarios over the likelihood of this option being exercised. As of December&#160;31,&#160;2023, the stock purchase option was outstanding. The fair value of the stock purchase option was estimated at $0.8 million at issuance. Due to the proximity of the inception date of the SPOA to December&#160;31,&#160;2023, the change in fair value was immaterial. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The debt incurred pursuant to the RIPA entered on December&#160;29,&#160;2023 contains embedded derivatives requiring bifurcation as a single compound derivative instrument. The company estimated the fair value of the derivative liability using a &#8220;with-and-without&#8221; method. The with-and-without methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the individual embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the derivative liability, which is estimated at $34.5&#160;million as of December&#160;31,&#160;2023. The estimated probability and timing of underlying events triggering the exercisability of the Put Option contained in the RIPA, forecasted cash flows and the discount rate are significant unobservable inputs used to determine the estimated fair value of the entire instrument with the embedded derivative. As of December&#160;31,&#160;2023, the discount rate used for valuation of the derivative liability was 12.1%. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">N</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ote</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;2023 debt extinguishment, the company identified an embedded derivative related to a contingently exercisable prepayment feature of the amended $505.0&#160;million December&#160;2023 promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment and accrued interest upon occurrence of a specified transaction (defined in the promissory note). This embedded derivative is recorded as a derivative liability on the consolidated balance sheet and is measured at fair value. Changes in the fair value of the derivative liability are reported as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">change in fair value of derivative,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. The fair value of the derivative liability is determined at each period end using a with and without method, which assesses the likelihood and timing of a specified transaction that if triggered could result in a repayment. The fair value of the embedded derivative is estimated at $0.8&#160;million as of December&#160;31,&#160;2023, and will be remeasured to fair value at each reporting date until the derivative is settled.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-Party Warrant Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;12,&#160;2022 registered direct offering of common stock, the company issued 9,090,909&#160;warrants (December&#160;2022&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023 and 2022, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the February&#160;15,&#160;2023 registered direct offering of common stock, the company issued 14,072,615&#160;warrants. The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">February&#160;17,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.2636</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, the company reduced the exercise price of the outstanding February&#160;2023&#160;Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extended the expiration date of the warrants until July&#160;24,&#160;2026. The effect of amending the terms of the warrants is reflected in a change in the fair value of warrant liability of $7.3&#160;million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">July 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the July&#160;20, 2023 registered direct offering of common stock, the company issued 14,569,296&#160;warrants (July&#160;2023&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">July&#160;25,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying amount of the warrant liabilities was as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2022<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">February&#160;2023<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July&#160;2023<br/>Warrants</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1044">Change in fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118,770&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;2022<br/>Warrants</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value at issuance, December&#160;12,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S.&#160;government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.</span></div></td></tr></table></div>The estimated fair value of the convertible note was computed using the binomial lattice model with the following observable assumptions before it was modified on December&#160;29,&#160;2023. After the debt extinguishment, the note is accounted for under the amortized cost basis. <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of this note was as follows (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value at issuance date, March&#160;31,&#160;2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on debt extinguishment with entities under common control</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying value, December&#160;29,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879717772960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Schedule of Asset Acquisition</a></td>
<td class="text">The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other depreciable assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">_______________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span>Definite-lived intangible assets consist of favorable leasehold rights totaling $20.4&#160;million and organized workforce totaling $0.8&#160;million as of the acquisition date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879720585152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to our leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:33.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,543&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1170"><span style="-sec-ix-hidden:f-1171">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,601&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,923&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1178"><span style="-sec-ix-hidden:f-1179">Accrued expenses and other liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, less current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><span style="-sec-ix-hidden:f-1184"><span style="-sec-ix-hidden:f-1185">Other liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Information Regarding Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our lease terms is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:71.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 7pt 0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term:</span></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate:</span></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Finance leases</span></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:60.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease costs (including right-of-use asset <br/>&#160;&#160;&#160;amortization and interest expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Variable lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:59.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for operating leases (excluding variable lease costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Financing cash flow from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flow from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Operating</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Finance <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62,942&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,008&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879720033360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementAbstract', window );"><strong>Revenue Interest Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock', window );">Summarizes the Revenue Interest Liability Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the year ended December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability at inception</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the RIPA, gross</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the RIPA, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,509&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Embedded contingent derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock purchase option</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability as of December&#160;31,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,415&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RevenueInterestPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RevenueInterestPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summarizes the Revenue Interest Liability Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879717742880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock', window );">Schedule of Related-Party Promissory Notes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our related-party debt is summarized below (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31,&#160;2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized <br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$505 million December 2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$505 million December 2023 Promissory Note Tranche 2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+7.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">346,951&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$200 million September&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December&#160;31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Year</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accrued PIK<br/>Interest<br/>Added to<br/>Note</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less:<br/>Unamortized<br/>Discounts</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$300 million December&#160;2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$125 million August&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$50 million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2), (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+8.0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party nonconvertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,099&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431,901&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2015 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2020 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nant Capital 2021 Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NantMobile Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NCSC Note Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1), (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related-party convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,226&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes before the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$125 million August&#160;2022 Promissory Note </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$2.2800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$200 million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$1.9350</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes<br/>&#160;&#160;&#160;before amendments</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735,000&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Nant&#160;Capital promissory notes after the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Rate</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Nonconvertible Note:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$505 million December&#160;2023 Promissory Note &#8211; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%">Related-Party Convertible Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$50 million December&#160;2022 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$505 million December&#160;2023 Promissory Note &#8211; </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Tranche 2</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$8.2690</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+7.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total $505 million December&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">505,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$2.2800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$200 million September 2023 Promissory Note</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9/11/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$1.9350</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">SOFR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+8.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total related-party promissory notes <br/>&#160;&#160;&#160;after amendments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">735,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense for our related-party promissory notes during the year ended December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest<br/>Expense</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt<br/>Discount<br/>Amortization</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$300 million December&#160;2021 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$125 million August&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 million December&#160;2022 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30 million March&#160;2023 Promissory Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30 million June&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200 million September&#160;2023 Promissory Note </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related-Party Fixed-Rate Promissory Notes </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balances include the amortization of debt discount totaling $0.5&#160;million recorded during the period from December&#160;29,&#160;2023 to December&#160;31,&#160;2023. The interest expense recorded during this period was $0.4&#160;million.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Estimated Future Contractual Obligations for Related-Party Notes Payable</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future contractual obligations for our related-party debt as of December&#160;31,&#160;2023 (in&#160;thousands):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:33.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Payments (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible<br/>Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonconvertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,295&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest payments on our promissory notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The weighted-average interest rate on our promissory notes as of December&#160;31,&#160;2023 was 13.09%.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">265,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">265,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,353&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stock option purchase liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,942)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,024&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,403&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,621&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities at Fair Value:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,655)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration is recorded at estimated fair value and revalued each reporting period until the related contingency is resolved. The fair value measurement is based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies&#8212;Contingent Consideration Related to Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in the carrying amount of contingent consideration were as follows (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:60.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(972)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (increase) decrease in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock Option Purchase Liability</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the RIPA, we entered into an SPOA pursuant to which Oberland has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability at its fair value upon issuance. The fair value was estimated using probability-weighted scenarios over the likelihood of this option being exercised. As of December&#160;31,&#160;2023, the stock purchase option was outstanding. The fair value of the stock purchase option was estimated at $0.8 million at issuance. Due to the proximity of the inception date of the SPOA to December&#160;31,&#160;2023, the change in fair value was immaterial. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note&#160;9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for more information.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The debt incurred pursuant to the RIPA entered on December&#160;29,&#160;2023 contains embedded derivatives requiring bifurcation as a single compound derivative instrument. The company estimated the fair value of the derivative liability using a &#8220;with-and-without&#8221; method. The with-and-without methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the individual embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the derivative liability, which is estimated at $34.5&#160;million as of December&#160;31,&#160;2023. The estimated probability and timing of underlying events triggering the exercisability of the Put Option contained in the RIPA, forecasted cash flows and the discount rate are significant unobservable inputs used to determine the estimated fair value of the entire instrument with the embedded derivative. As of December&#160;31,&#160;2023, the discount rate used for valuation of the derivative liability was 12.1%. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">N</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ote</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;</a><a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Interest Purchase Agreement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;2023 debt extinguishment, the company identified an embedded derivative related to a contingently exercisable prepayment feature of the amended $505.0&#160;million December&#160;2023 promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment and accrued interest upon occurrence of a specified transaction (defined in the promissory note). This embedded derivative is recorded as a derivative liability on the consolidated balance sheet and is measured at fair value. Changes in the fair value of the derivative liability are reported as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">change in fair value of derivative,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> on the consolidated statement of operations. The fair value of the derivative liability is determined at each period end using a with and without method, which assesses the likelihood and timing of a specified transaction that if triggered could result in a repayment. The fair value of the embedded derivative is estimated at $0.8&#160;million as of December&#160;31,&#160;2023, and will be remeasured to fair value at each reporting date until the derivative is settled.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Third-Party Warrant Liabilities</span></td></tr></table></div><div style="margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">December 2022 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the December&#160;12,&#160;2022 registered direct offering of common stock, the company issued 9,090,909&#160;warrants (December&#160;2022&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023 and 2022, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$6.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">February 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the February&#160;15,&#160;2023 registered direct offering of common stock, the company issued 14,072,615&#160;warrants. The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">February&#160;17,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.2636</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July&#160;25,&#160;2023, the company reduced the exercise price of the outstanding February&#160;2023&#160;Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extended the expiration date of the warrants until July&#160;24,&#160;2026. The effect of amending the terms of the warrants is reflected in a change in the fair value of warrant liability of $7.3&#160;million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">July 2023 Warrants</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the July&#160;20, 2023 registered direct offering of common stock, the company issued 14,569,296&#160;warrants (July&#160;2023&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issuance Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">July&#160;25,<br/>2023</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.2946</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected average volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in the carrying amount of the warrant liabilities was as follows (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 2022<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">February&#160;2023<br/>Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July&#160;2023<br/>Warrants</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1044">Change in fair value</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value, December&#160;31,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118,770&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,958&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;2022<br/>Warrants</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value at issuance, December&#160;12,&#160;2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value, December&#160;31,&#160;2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S.&#160;government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.</span></div></td></tr></table></div>The estimated fair value of the convertible note was computed using the binomial lattice model with the following observable assumptions before it was modified on December&#160;29,&#160;2023. After the debt extinguishment, the note is accounted for under the amortized cost basis. <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected market yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of this note was as follows (in&#160;thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value at issuance date, March&#160;31,&#160;2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on debt extinguishment with entities under common control</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying value, December&#160;29,&#160;2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of related party notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (S-X 210.12-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879720216448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Outstanding Balances of Related Party Agreements</a></td>
<td class="text">Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):<div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due from related party&#8211;Brink</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due from related parties&#8211;Various</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due from related parties</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,019&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantBio</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;Duley Road</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;the Clinic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Due to related party&#8211;NantWorks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total due to related parties</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879726141680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expenses Related to Statement of Operations</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation included on the consolidated statements of operations (in&#160;thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,163&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,179&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,181&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense in operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,181&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity and Related Information under Equity Plans</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity and related information for the year ended December&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Intrinsic</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Value</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(in years)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,262,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">949,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(184,362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(207,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Outstanding as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,820,435&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested and exercisable as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,867,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.90 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.80</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of RSU Activity under Equity Plans</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the year ended December&#160;31,&#160;2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:71.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Units</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted-</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance as of December&#160;31,&#160;2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,551,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,407,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,545,644)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited/canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nonvested balance as of December&#160;31,&#160;2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,503,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728595600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Taxes, Domestic and Foreign</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss before income taxes is as follows (in&#160;thousands): </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. loss before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(583,892)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(417,286)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,839)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit (Provision)</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit (expense) consists of the following (in&#160;thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit (expense)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components that comprise our net deferred tax liabilities consist of the following (in&#160;thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;E capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682,722&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,363&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,527)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,426)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,766)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,296&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,597&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory income tax rate to our effective income tax rate is as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Changes to Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of changes to the amount of unrecognized tax benefits is as follows (in&#160;thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879726146816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForMergerRelatedCosts', window );">Merger-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember', window );">Executive Chairman and Global Chief Scientific and Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OwnershipPercentageByKeyExecutives', window );">Ownership percentage of outstanding shares of company</a></td>
<td class="nump">81.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ibrx_NantKwestMember', window );">NantKwest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger', window );">Ownership percentage held by stockholders upon consummation of merger</a></td>
<td class="nump">28.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member', window );">NantCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger', window );">Ownership percentage held by stockholders upon consummation of merger</a></td>
<td class="nump">71.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage acquired on fully diluted bases upon consummation of merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OwnershipPercentageByKeyExecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage by key executives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OwnershipPercentageByKeyExecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the reporting period for charges associated with the mergers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibrx_NantKwestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibrx_NantKwestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723455088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Consolidated Statements of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">41,128<span></span>
</td>
<td class="nump">232,366<span></span>
</td>
<td class="nump">248,149<span></span>
</td>
<td class="nump">195,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">45,275<span></span>
</td>
<td class="nump">129,620<span></span>
</td>
<td class="nump">102,708<span></span>
</td>
<td class="nump">135,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(86,264)<span></span>
</td>
<td class="num">(362,250)<span></span>
</td>
<td class="num">(351,298)<span></span>
</td>
<td class="num">(330,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="nump">5,789<span></span>
</td>
<td class="num">(221,642)<span></span>
</td>
<td class="num">(65,988)<span></span>
</td>
<td class="num">(19,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(80,481)<span></span>
</td>
<td class="num">$ (583,852)<span></span>
</td>
<td class="num">$ (417,320)<span></span>
</td>
<td class="num">$ (349,848)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember', window );">Reportable Legal Entities | NantCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">21,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">24,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(45,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="num">(848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(46,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember', window );">Reportable Legal Entities | NantKwest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">19,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">20,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(40,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="nump">6,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(33,997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember', window );">Intercompany Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NameChangeEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NameChangeEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NantCellInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NantCellInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NantKwestInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NantKwestInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879724009776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Aug. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,961,684,000)<span></span>
</td>
<td class="num">$ (2,378,488,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(366,757,000)<span></span>
</td>
<td class="num">(337,509,000)<span></span>
</td>
<td class="num">$ (274,419,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment', window );">Additional revenue interests, second payment</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Other than temporary impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="nump">622,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">934,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,872,000<span></span>
</td>
<td class="nump">351,538,000<span></span>
</td>
<td class="nump">331,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,452,000<span></span>
</td>
<td class="nump">362,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,090,389,000<span></span>
</td>
<td class="nump">812,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAdditionalPurchaseOption', window );">Sale of stock, additional purchase option</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PurchaseAgreementTotalInvestmentAmount', window );">Gross purchase price</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ibrx_GlobeImmuneIncMember', window );">GlobeImmune, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Advances to support operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ibrx_GlobeImmuneIncMember', window );">GlobeImmune, Inc. | Advances To Related Party | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Advances to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ibrx_GlobeImmuneIncMember', window );">GlobeImmune, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.10%<span></span>
</td>
<td class="nump">69.10%<span></span>
</td>
<td class="nump">69.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ibrx_NANTibodyLLCMember', window );">NANTibody, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember', window );">February 2023 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 565,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember', window );">Stock Purchase and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAdditionalPurchaseOption', window );">Sale of stock, additional purchase option</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CommonStockValueAvailableForFutureStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value available for future stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CommonStockValueAvailableForFutureStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Additional Revenue Interests, Second Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PurchaseAgreementTotalInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Total Investment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PurchaseAgreementTotalInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleOfStockAdditionalPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Purchase Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleOfStockAdditionalPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-8A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_GlobeImmuneIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_GlobeImmuneIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_AdvancesToRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_AdvancesToRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibrx_GlobeImmuneIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibrx_GlobeImmuneIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibrx_NANTibodyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibrx_NANTibodyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728237280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibrx_LaboratoryEquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibrx_LaboratoryEquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">IT equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723427440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">219,167,071<span></span>
</td>
<td class="nump">72,818,188<span></span>
</td>
<td class="nump">12,278,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyConvertibleNotesMember', window );">Related-party convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">162,471,837<span></span>
</td>
<td class="nump">46,274,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding third-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">37,732,820<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,820,435<span></span>
</td>
<td class="nump">9,262,926<span></span>
</td>
<td class="nump">4,124,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,503,979<span></span>
</td>
<td class="nump">6,551,388<span></span>
</td>
<td class="nump">6,515,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyWarrantsMember', window );">Outstanding related-party warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,638,000<span></span>
</td>
<td class="nump">1,638,000<span></span>
</td>
<td class="nump">1,638,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_RelatedPartyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723395696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879725892064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development costs</a></td>
<td class="nump">$ 7,847<span></span>
</td>
<td class="nump">$ 11,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidServices', window );">Prepaid services</a></td>
<td class="nump">5,869<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidSoftwareLicenseFees', window );">Prepaid software license fees</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_InsurancePremiumFinancingAsset', window );">Insurance premium financing asset</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance claims receivable</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidEquipmentMaintenance', window );">Prepaid equipment maintenance</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization', window );">ERP system implementation costs</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Prepaid supplies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (including amounts with related parties)</a></td>
<td class="nump">$ 25,603<span></span>
</td>
<td class="nump">$ 31,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_InsurancePremiumFinancingAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance premium financing asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_InsurancePremiumFinancingAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidEquipmentMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid equipment maintenance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidEquipmentMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidSoftwareLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid software license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidSoftwareLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of capitalized implementation cost from hosting arrangement that is service contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 40<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482558/350-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723675776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Property, Plant and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">$ 230,458<span></span>
</td>
<td class="nump">$ 212,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">84,376<span></span>
</td>
<td class="nump">69,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">146,082<span></span>
</td>
<td class="nump">143,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">72,552<span></span>
</td>
<td class="nump">68,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">69,915<span></span>
</td>
<td class="nump">67,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">84,436<span></span>
</td>
<td class="nump">72,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture &amp; fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property, plant and equipment</a></td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="nump">$ 1,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879722194704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ConvertibleNoteReceivableDiscountOptionPercent', window );">Convertible note receivable, discount option, percent</a></td>
<td class="nump">2500.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ConvertibleNoteReceivableNonCurrent', window );">Convertible note receivable</a></td>
<td class="nump">$ 6,879<span></span>
</td>
<td class="nump">6,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_IPRDMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_RiptideBioscienceIncMember', window );">Riptide Bioscience, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ConvertibleNoteReceivableNonCurrent', window );">Convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount', window );">Milestone payment, payable amount</a></td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_RiptideBioscienceIncMember', window );">Riptide Bioscience, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAmount', window );">Milestone payment, amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility | Organized workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Write off of remaining unamortized organized workforce intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsMilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Milestone Payment, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsMilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsMilestonePaymentPayableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsMilestonePaymentPayableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ConvertibleNoteReceivableDiscountOptionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Note Receivable, Discount Option, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ConvertibleNoteReceivableDiscountOptionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ConvertibleNoteReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible note receivable, non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ConvertibleNoteReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Statement Details [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_IPRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_IPRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_RiptideBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_RiptideBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727611600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (3,825)<span></span>
</td>
<td class="num">(1,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">16,573<span></span>
</td>
<td class="nump">18,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="num">(886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">21,804<span></span>
</td>
<td class="nump">22,619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="num">(886)<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">17,093<span></span>
</td>
<td class="nump">20,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">6,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 16,573<span></span>
</td>
<td class="nump">$ 18,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember', window );">Definite-lived: Favorable leasehold rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Life (in years)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,398<span></span>
</td>
<td class="nump">$ 20,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,825)<span></span>
</td>
<td class="num">(1,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">16,573<span></span>
</td>
<td class="nump">18,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 16,573<span></span>
</td>
<td class="nump">18,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember', window );">Organized workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite Lived Intangible Assets, Gross, Excluding Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723347072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Accrued Expenses and Other Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">$ 11,350<span></span>
</td>
<td class="nump">$ 12,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and service fees</a></td>
<td class="nump">9,829<span></span>
</td>
<td class="nump">6,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">1,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,241<span></span>
</td>
<td class="nump">6,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AccruedPreclinicalAndClinicalTrialCosts', window );">Accrued preclinical and clinical trial costs</a></td>
<td class="nump">4,218<span></span>
</td>
<td class="nump">4,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancingObligationCurrent', window );">Financing obligation &#8211; current portion</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Accrued construction costs</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">7,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">$ 42,708<span></span>
</td>
<td class="nump">$ 41,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedPreclinicalAndClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedPreclinicalAndClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancingObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Obligation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancingObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727795392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Interest and Investment Income (Loss), Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">Unrealized losses from equity securities</a></td>
<td class="num">$ (1,591)<span></span>
</td>
<td class="num">$ (4,190)<span></span>
</td>
<td class="num">$ (4,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Investment accretion income (amortization expense), net</a></td>
<td class="nump">1,844<span></span>
</td>
<td class="num">(1,486)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized gains (losses) on investments</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Interest and investment income (loss), net</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="num">$ (3,090)<span></span>
</td>
<td class="num">$ (4,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 6)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728481312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty', window );">Amortization of related-party notes discounts</a></td>
<td class="nump">$ 42,396<span></span>
</td>
<td class="nump">$ 16,282<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Other interest expense</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">129,198<span></span>
</td>
<td class="nump">63,515<span></span>
</td>
<td class="nump">14,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsLineItems', window );"><strong>Financial Statement Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="nump">$ 86,453<span></span>
</td>
<td class="nump">$ 47,145<span></span>
</td>
<td class="nump">$ 14,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AmortizationOfDebtDiscountPremiumRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount (Premium), Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AmortizationOfDebtDiscountPremiumRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Statement Details [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879843983360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Available-for-Sale Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,033<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Weighted- Average Remaining Contractual&#160;Life (in years)</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember', window );">Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Weighted- Average Remaining Contractual&#160;Life (in years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 891<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt securities period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879843274320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt securities, available-for-sale, unrealized loss position, number of positions | security</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">$ 930<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months, Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months, Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember', window );">Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">More than 12 months, Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">More than 12 months, Gross Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember', window );">Foreign bonds | Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Weighted- Average Remaining Contractual&#160;Life (in years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt securities period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879721507392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Investments in marketable equity securities with readily determinable fair values</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized losses on equity securities</a></td>
<td class="nump">1,591,000<span></span>
</td>
<td class="nump">4,190,000<span></span>
</td>
<td class="nump">4,615,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-8A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879725092240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 267,353<span></span>
</td>
<td class="nump">$ 108,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(154,942)<span></span>
</td>
<td class="num">(21,655)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">265,453<span></span>
</td>
<td class="nump">104,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Liabilities | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Noncurrent Liabilities | Stock option purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Noncurrent Liabilities | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(35,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Noncurrent Liabilities | Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(118,770)<span></span>
</td>
<td class="num">(21,636)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">266,408<span></span>
</td>
<td class="nump">66,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">265,453<span></span>
</td>
<td class="nump">63,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Liabilities | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Noncurrent Liabilities | Stock option purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Noncurrent Liabilities | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Noncurrent Liabilities | Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">41,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Liabilities | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Noncurrent Liabilities | Stock option purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Noncurrent Liabilities | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Noncurrent Liabilities | Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(154,942)<span></span>
</td>
<td class="num">(21,655)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Noncurrent Assets | Foreign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Liabilities | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Noncurrent Liabilities | Stock option purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Noncurrent Liabilities | Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">(35,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Noncurrent Liabilities | Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value</a></td>
<td class="num">$ (118,770)<span></span>
</td>
<td class="num">$ (21,636)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_StockOptionPurchaseLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_StockOptionPurchaseLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_DerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_DerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879730426608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 25, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>yr</div>
</th>
<th class="th">
<div>Jul. 20, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>yr </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>yr </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,770<span></span>
</td>
<td class="nump">$ 21,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue', window );">Fair value stock purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet', window );">Embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,600<span></span>
</td>
<td class="num">(13,460)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Change in fair value of warrant liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DebtInstrumentPrepaymentAndAccruedInterest', window );">Prepayment and accrued interest upon specified transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_ContingentConsiderationMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember', window );">Stock Purchase and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Risk-free rate | Embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Derivative liability, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,545)<span></span>
</td>
<td class="num">(13,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,100<span></span>
</td>
<td class="nump">$ 17,091<span></span>
</td>
<td class="nump">$ 21,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60<span></span>
</td>
<td class="nump">6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Expected average volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.190<span></span>
</td>
<td class="nump">0.994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.047<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,958<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Expected average volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,721<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,569,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,569,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants | Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants | Expected average volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants | Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,353<span></span>
</td>
<td class="nump">108,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="nump">41,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,453<span></span>
</td>
<td class="nump">104,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Cash and cash equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">40,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Government-sponsored securities | Cash and cash equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Current Assets | Corporate debt securities | Cash and cash equivalents | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DebtInstrumentPrepaymentAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment And Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DebtInstrumentPrepaymentAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value Of Stock Purchase Option At Issuance And Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480463/815-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_AgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879720803312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,549<span></span>
</td>
<td class="nump">$ 12,107<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,789<span></span>
</td>
<td class="num">(221,642)<span></span>
</td>
<td class="num">(65,988)<span></span>
</td>
<td class="num">(19,559)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember', window );">Amyris Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Advances to support operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
<td class="num">(11,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember', window );">Amyris Joint Venture | Amyris, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Advances to support operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalCancerInstituteMember', window );">National Cancer Institute (NCI) | 2015 CRADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities', window );">Annual payment for support of research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalCancerInstituteMember', window );">National Cancer Institute (NCI) | 2015 CRADA | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities', window );">Payment for support of research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalCancerInstituteMember', window );">National Cancer Institute (NCI) | 2015 CRADA, Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems', window );"><strong>Research and Development Arrangements with Federal Government [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsAnnualProjectFundingAmount', window );">Annual project funding amount</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual payment for support of research activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsAnnualProjectFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Annual Project Funding Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsAnnualProjectFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Payment For Support Of Research Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangements with the federal government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ibrx_AmyrisJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_AmyrisIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_AmyrisIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_CooperativeResearchAndDevelopmentAgreement2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_CooperativeResearchAndDevelopmentAgreement2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727951312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>licenseAgreement</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,128,000<span></span>
</td>
<td class="nump">$ 232,366,000<span></span>
</td>
<td class="nump">$ 248,149,000<span></span>
</td>
<td class="nump">$ 195,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,549,000<span></span>
</td>
<td class="nump">12,107,000<span></span>
</td>
<td class="nump">803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_A3MIPCAndAAHIAgreementMember', window );">3M IPC and Access to Advanced Health Institute License Agreement | License Agreement Terms | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsPeriodicLicensePayments', window );">Periodic license payments</a></td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment', window );">Annual minimum licensing payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember', window );">Access to Advanced Health Institute (AAHI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsNumberOfLicenseAgreements', window );">Number of license agreements | licenseAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment', window );">Non-refundable upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum', window );">Milestone payment, aggregate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestoneFees', window );">Milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember', window );">Access to Advanced Health Institute (AAHI) | License Agreement Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment', window );">Non-refundable upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum', window );">Milestone payment, aggregate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsTerminationFee', window );">Termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember', window );">Access to Advanced Health Institute (AAHI) | License Agreement Terms | 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember', window );">Access to Advanced Health Institute (AAHI) | License Agreement Terms | 2023 through 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember', window );">Access to Advanced Health Institute (AAHI) | Sponsored Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable', window );">License payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember', window );">Access to Advanced Health Institute (AAHI) | Sponsored Research Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities', window );">Annual payment for support of research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_ViractaMember', window );">Viracta | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum', window );">Milestone payment, aggregate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_ViractaMember', window );">Viracta | License Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAmount', window );">Milestone payment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_ViractaMember', window );">Viracta | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CollaborationAgreementsMilestonePaymentAmount', window );">Milestone payment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Annual Minimum Licensing Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual payment for support of research activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, License Maintenance Fees Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Milestone Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Milestone Payment, Aggregate Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsMilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Milestone Payment, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsMilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsNonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsNonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsNumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Number Of License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsNumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsPeriodicLicensePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Periodic License Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsPeriodicLicensePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborationAgreementsTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Termination Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborationAgreementsTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LicensingAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LicensingAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_A3MIPCAndAAHIAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_A3MIPCAndAAHIAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AAHIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis=ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_ViractaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_ViractaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879721992016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>employee </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Selling, general and administrative (including amounts with related parties)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration</a></td>
<td class="nump">$ 40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash payment to acquire assets</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseOperatingLeaseAnnualLeasePayment', window );">Annual lease payment</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options | renewal_options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm', window );">Commitment to spend, operational expenses, initial lease term</a></td>
<td class="nump">$ 1,520,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm', window );">Commitment to spend, operational expenses, renewal lease term</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears', window );">Commitment to hire, number of employees, first five years | employee</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears', window );">Commitment to hire, number of employees, first two and a half years | employee</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Severance and retention benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility | State Of New York | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestGovernmentFundingAvailable', window );">Government funding for leasehold build-out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility | State Of New York | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseholdInterestGovernmentFundingAvailable', window );">Government funding for leasehold build-out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseOperatingLeaseAnnualLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Operating Lease, Annual Lease Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseOperatingLeaseAnnualLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Commitment To Hire, Number Of Employees, First Five Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Commitment To Hire, Number Of Employees, First Two And A Half Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestGovernmentFundingAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Government Funding Available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestGovernmentFundingAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfSquareFeetOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of square feet of facility leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfSquareFeetOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_StateOfNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_StateOfNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879725997056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements and Acquisition - Acquisition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember', window );">Definite-lived: Favorable leasehold rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,398<span></span>
</td>
<td class="nump">20,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember', window );">Organized workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 10,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">6,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">21,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Other depreciable assets and prepaid expenses</a></td>
<td class="nump">2,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AssetAcquisitionFairValueOfAssetsAcquired', window );">Total consideration</a></td>
<td class="nump">40,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility | Definite-lived: Favorable leasehold rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember', window );">Dunkirk Facility | Organized workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AssetAcquisitionFairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Fair Value Of Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AssetAcquisitionFairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OffMarketFavorableLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ibrx_OrganizedWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibrx_DunkirkFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723500976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember', window );">Altor BioScience, LLC | Contingent Value Rights Obligation, Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ContingentValueRightsObligations', window );">Contingent value rights obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation', window );">Minimum net sales milestone contingent value rights obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember', window );">Altor BioScience, LLC | Dr Soon Shiong And Related Party | Contingent Value Rights Obligation, Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ContingentValueRightsObligations', window );">Contingent value rights obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember', window );">Altor BioScience, LLC | Altor Stockholders | Contingent Value Rights Obligation, Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ContingentValueRightsObligations', window );">Contingent value rights obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ibrx_VivaBioCellMember', window );">VivaBioCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PercentageOfWhollyOwnedSubsidiary', window );">Ownership percentage acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned', window );">Contingent consideration arrangements, earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements', window );">Contingent consideration arrangements, paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Maximum milestone payment due if certain conditions are met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BusinessCombinationContingentConsiderationArrangementsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BusinessCombinationContingentConsiderationArrangementsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Settlements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ContingentValueRightsObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ContingentValueRightsObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum net sales milestone contingent value rights obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PercentageOfWhollyOwnedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of wholly-owned subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PercentageOfWhollyOwnedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsObligationSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsObligationSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_DrSoonShiongAndRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_DrSoonShiongAndRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_AltorStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_AltorStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_VivaBioCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_VivaBioCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879726011328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Litigation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 07, 2023</div></th>
<th class="th"><div>Dec. 08, 2022</div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Jul. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Aug. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ibrx_NANTibodyLLCMember', window );">NANTibody, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ibrx_NANTibodyLLCMember', window );">NANTibody, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember', window );">Sorrento Therapeutics, Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party in litigation settlement</a></td>
<td class="nump">$ 176,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationSettlementInterestPercent', window );">Interest related to litigation settlement, as a percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember', window );">Sorrento Therapeutics, Inc. Litigation | NantCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party in litigation settlement</a></td>
<td class="nump">$ 159,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember', window );">Sorrento Therapeutics, Inc. Litigation | NANTibody, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Amount awarded from other party in litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares to be issued in private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Value of shares to be issued in private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember', window );">Altor BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationLineItems', window );"><strong>Litigation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfDissentingShares', window );">Dissenting shares to be released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,167,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LitigationSettlementNumberOfSharesToBeIssued', window );">Shares issued for litigation settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,229,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares', window );">Cash distributed in lieu of fractional shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payment for legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LitigationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LitigationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LitigationSettlementInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement Interest, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LitigationSettlementInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LitigationSettlementNumberOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number Of Shares To Be Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LitigationSettlementNumberOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfDissentingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Dissenting Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfDissentingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Cash Distributed In Lieu Of Fractional Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibrx_NANTibodyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibrx_NANTibodyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NANTibodyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NANTibodyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ibrx_SorrentoTherapeuticsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NantCellInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NantCellInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879722485952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Unconditional Purchase Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_CGMPBatchesMember', window );">cGMP Batches</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase commitment, 2024</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase commitment, 2025</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember', window );">Software License Subscription Fees and Implementation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase commitment, 2024</a></td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase commitment, 2025</a></td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Purchase commitment, 2026</a></td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total unconditional purchase obligation commitment</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_LaboratoryCleanroomServiceCostsMember', window );">Laboratory Cleanroom Service Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase commitment, 2024</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase commitment, 2025</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total unconditional purchase obligation commitment</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_CGMPBatchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_CGMPBatchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_LaboratoryCleanroomServiceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=ibrx_LaboratoryCleanroomServiceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879721511904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms', window );">Operating lease payments related to options to extend lease terms</a></td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments related to options to extend lease terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879725913424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Arrangements - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 36,543<span></span>
</td>
<td class="nump">$ 45,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">36,601<span></span>
</td>
<td class="nump">45,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">5,244<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">39,942<span></span>
</td>
<td class="nump">47,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 45,250<span></span>
</td>
<td class="nump">$ 50,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets (including amounts with related parties)<span></span>
</td>
<td class="text">Other assets (including amounts with related parties)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
<td class="text">Accrued expenses and other liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723663504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Arrangements - Summary of Information Regarding Leases (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Operating leases</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Finance leases</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Finance leases</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723037888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 11,123<span></span>
</td>
<td class="nump">$ 11,093<span></span>
</td>
<td class="nump">$ 7,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">3,060<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense', window );">Finance lease costs (including right-of-use asset amortization and interest expense)</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">3,521<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">2,862<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 18,820<span></span>
</td>
<td class="nump">$ 18,113<span></span>
</td>
<td class="nump">$ 10,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728296304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow Operating Activities Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases (excluding variable lease costs)</a></td>
<td class="nump">$ 9,538<span></span>
</td>
<td class="nump">$ 10,241<span></span>
</td>
<td class="nump">$ 9,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow from finance leases</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow from finance leases</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879724174688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Arrangements - Summary of Future Minimum Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 10,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">10,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">8,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">8,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">8,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">16,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">62,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">17,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable', window );">Less: Tenant improvement allowance receivable</a></td>
<td class="nump">670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">45,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable', window );">Less: Tenant improvement allowance receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearOne', window );">2024</a></td>
<td class="nump">10,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearTwo', window );">2025</a></td>
<td class="nump">10,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearThree', window );">2026</a></td>
<td class="nump">8,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearFour', window );">2027</a></td>
<td class="nump">8,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidYearFive', window );">2028</a></td>
<td class="nump">8,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">16,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityToBePaid', window );">Total future minimum lease payments</a></td>
<td class="nump">63,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityUndiscountedExcessInterest', window );">Less: Interest</a></td>
<td class="nump">17,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable', window );">Less: Tenant improvement allowance receivable</a></td>
<td class="nump">670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 45,250<span></span>
</td>
<td class="nump">$ 50,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Tenant Improvement Allowance Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Tenant Improvement Allowance Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, To Be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseLiabilityUndiscountedExcessInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Undiscounted Excess Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseLiabilityUndiscountedExcessInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727483504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment', window );">Additional revenue interests, second payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAdditionalPurchaseOption', window );">Sale of stock, additional purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Revenue interest liability (Note&#160;9)</a></td>
<td class="nump">$ 155,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,415<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,198<span></span>
</td>
<td class="nump">$ 63,515<span></span>
</td>
<td class="nump">$ 14,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember', window );">Stock Purchase and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issued in transaction (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAdditionalPurchaseOption', window );">Sale of stock, additional purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction', window );">Purchase price allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PurchaseAgreementTotalInvestmentAmount', window );">Gross purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage', window );">Revenue interest purchase agreement, payment received percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction', window );">Purchase price allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Revenue interest liability (Note&#160;9)</a></td>
<td class="nump">155,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 7,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice', window );">Required purchase price, as a percent</a></td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice', window );">Required purchase price, as a percent</a></td>
<td class="nump">1.350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice', window );">Required purchase price, as a percent</a></td>
<td class="nump">1.750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice', window );">Required purchase price, as a percent</a></td>
<td class="nump">1.950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Fair value of stock purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction', window );">Purchase price allocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TieredPaymentsAxis=ibrx_InitialPaymentMember', window );">Initial Payment | Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage', window );">Revenue interest purchase agreement, tiered revenue interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TieredPaymentsAxis=ibrx_InitialPaymentMember', window );">Initial Payment | Minimum | Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales', window );">Payments as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TieredPaymentsAxis=ibrx_InitialPaymentMember', window );">Initial Payment | Maximum | Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales', window );">Payments as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TieredPaymentsAxis=ibrx_SecondPaymentMember', window );">Second Payment | Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage', window );">Revenue interest purchase agreement, tiered revenue interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TieredPaymentsAxis=ibrx_SecondPaymentMember', window );">Second Payment | Minimum | Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales', window );">Payments as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TieredPaymentsAxis=ibrx_SecondPaymentMember', window );">Second Payment | Maximum | Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales', window );">Payments as a percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Additional Revenue Interests, Second Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PurchaseAgreementTotalInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Total Investment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PurchaseAgreementTotalInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Purchase Agreement, Payment Received Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleOfStockAdditionalPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Purchase Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleOfStockAdditionalPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionPeriodAxis=ibrx_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionPeriodAxis=ibrx_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionPeriodAxis=ibrx_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionPeriodAxis=ibrx_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionPeriodAxis=ibrx_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionPeriodAxis=ibrx_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionPeriodAxis=ibrx_PeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionPeriodAxis=ibrx_PeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_TieredPaymentsAxis=ibrx_InitialPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_TieredPaymentsAxis=ibrx_InitialPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_TieredPaymentsAxis=ibrx_SecondPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_TieredPaymentsAxis=ibrx_SecondPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727484832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement - Summary of the Revenue Interest Liability Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the RIPA, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,764<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Revenue interest liability at inception</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ProceedsFromIssuanceOfSecuredDebtGross', window );">Proceeds from the RIPA, gross</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Less: Issuance costs</a></td>
<td class="nump">7,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from the RIPA, net of transaction costs</a></td>
<td class="nump">192,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Revenue interest liability at end of period</a></td>
<td class="nump">155,415<span></span>
</td>
<td class="nump">$ 155,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Embedded contingent derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod', window );">Debt discount</a></td>
<td class="num">(34,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod', window );">Debt discount</a></td>
<td class="num">(2,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement | Fair value of stock purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod', window );">Debt discount</a></td>
<td class="num">$ (819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Discount Recorded In The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ProceedsFromIssuanceOfSecuredDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Secured Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ProceedsFromIssuanceOfSecuredDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ibrx_CommonStockRevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ibrx_CommonStockRevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879710072112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Debt - Summary of Related-Party Promissory Notes (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2023</div></th>
<th class="th"><div>Dec. 17, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Sep. 11, 2023</div></th>
<th class="th"><div>Jun. 13, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member', window );">$505 Million December 2023 Promissory Note - Tranche 1 | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember', window );">$300 Million December 2021 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember', window );">$300 Million December 2021 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember', window );">$50 Million December 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 8.2690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember', window );">$50 Million December 2022 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember', window );">$30 Million June 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 8.2690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember', window );">$30 Million June 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember', window );">$505 Million Promissory Note, December 2023, Tranche Two | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember', window );">$30 Million March 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember', window );">$30 Million March 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember', window );">$200 Million September 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember', window );">$125 Million August 2022 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital 2015 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalOneMember', window );">Nant Capital 2020 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember', window );">Nant Capital 2021 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember', window );">NantMobile | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellMember', window );">N C S C | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,000<span></span>
</td>
<td class="nump">$ 233,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,951<span></span>
</td>
<td class="nump">241,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $300 Million December 2021 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 8.2690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $300 Million December 2021 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $50 Million December 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $30 Million June 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $505 Million Promissory Note, December 2023, Tranche Two | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 8.2690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $30 Million March 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 2.2800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $200 Million September 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 1.9350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $200 Million September 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $125 Million August 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital 2015 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital 2020 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital 2021 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | NantMobile | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | N C S C | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,600<span></span>
</td>
<td class="nump">43,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $505 Million December 2023 Promissory Note - Tranche 1 | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $300 Million December 2021 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $50 Million December 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $30 Million June 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $30 Million March 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $125 Million August 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued PIK Interest Added to Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital 2015 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879703662464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Debt - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 13, 2023 </div>
<div>USD ($) </div>
<div>advance</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party promissory notes net of issuance costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,700<span></span>
</td>
<td class="nump">$ 174,125<span></span>
</td>
<td class="nump">$ 338,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty', window );">Gain on extinguishment of debt with related parties under common control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,110<span></span>
</td>
<td class="nump">82,858<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in exchange for notes payable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,291,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature', window );">Increase in fair value of embedded conversion feature from debt modification with entities under common control (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl', window );">Gain on debt extinguishment with related-parties under common control (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet', window );">Embedded derivative</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty', window );">Gain on extinguishment of debt with related parties under common control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature', window );">Increase in fair value of embedded conversion feature from debt modification with entities under common control (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl', window );">Gain on debt extinguishment with related-parties under common control (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty', window );">Gain on extinguishment of debt with related parties under common control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,453<span></span>
</td>
<td class="nump">$ 47,145<span></span>
</td>
<td class="nump">$ 14,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt premium</a></td>
<td class="nump">$ 354,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember', window );">$300 Million December 2021 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember', window );">$300 Million December 2021 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember', window );">$125 Million August 2022 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember', window );">$50 Million December 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember', window );">$50 Million December 2022 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember', window );">$30 Million March 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember', window );">$30 Million March 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember', window );">$30 Million June 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember', window );">$30 Million June 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember', window );">$200 Million September 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital 2015 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member', window );">$505&#160;million December 2023 Promissory Note | Affiliated Entity | Market yield | Embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member', window );">$505&#160;million December 2023 Promissory Note | Affiliated Entity | Risk-free interest rate | Embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member', window );">$505&#160;million December 2023 Promissory Note | Affiliated Entity | Expected average volatility | Embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">118.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">43,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $300 Million December 2021 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $125 Million August 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $50 Million December 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $30 Million March 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $30 Million June 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party promissory notes net of issuance costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DebtInstrumentNumberOfAdvances', window );">Number of advances | advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DebtInstrumentFaceAmountPerTranche', window );">Debt instrument, face amount, per tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $200 Million September 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Risk-free interest rate | Discounted cash flow analysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Minimum | Market yield | Discounted cash flow analysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Maximum | Market yield | Discounted cash flow analysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Nant Capital 2015 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DebtInstrumentPrepaymentAndAccruedInterest', window );">Prepayment and accrued interest upon specified transaction</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">23.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity | Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">18.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity | Minimum | Market yield | Discounted cash flow analysis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Expected average volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,000<span></span>
</td>
<td class="nump">233,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $300 Million December 2021 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">26,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $300 Million December 2021 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $125 Million August 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $50 Million December 2022 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">4,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $30 Million March 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party promissory notes net of issuance costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $30 Million June 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $200 Million September 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9350<span></span>
</td>
<td class="nump">$ 1.9350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party promissory notes net of issuance costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $200 Million September 2023 Promissory Note | Affiliated Entity | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023 | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023 | Affiliated Entity | Market yield | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023 | Affiliated Entity | Risk-free interest rate | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023 | Affiliated Entity | Expected average volatility | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">119.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LongTermDebtGrossIncludingAccruedInterest', window );">Aggregate principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Market yield | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Risk-free interest rate | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Expected average volatility | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">0.849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of convertible notes (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,986,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital 2015 Note Payable | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity | Market yield | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity | Risk-free interest rate | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | $505&#160;million December 2023 Promissory Note | Affiliated Entity | Expected average volatility | Binomial lattice model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="nump">118.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>APIC, Debt Instrument, Convertible, Increase In Fair Value Of Embedded Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Gain (Loss) On Extinguishment Of Debt With Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DebtInstrumentFaceAmountPerTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Per Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DebtInstrumentFaceAmountPerTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DebtInstrumentNumberOfAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Advances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DebtInstrumentNumberOfAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DebtInstrumentPrepaymentAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment And Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DebtInstrumentPrepaymentAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Debt Extinguishment, Entities Under Common Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LongTermDebtGrossIncludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Gross, Including Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LongTermDebtGrossIncludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480463/815-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ibrx_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A505MillionPromissoryNoteDecember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputMarketYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputMarketYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=ibrx_ValuationTechniqueBinomialLatticeModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=ibrx_ValuationTechniqueBinomialLatticeModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879725791968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Debt - Estimated Fair Value of Convertible Note (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Consideration paid</a></td>
<td class="nump">$ 49,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="nump">47,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants</a></td>
<td class="nump">118,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Consideration paid</a></td>
<td class="nump">29,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="nump">36,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment with entities under common control</a></td>
<td class="num">(36,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Expected market yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Expected average volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Significant unobservable inputs, Level 3 valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputExpectedMarketYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ibrx_MeasurementInputExpectedMarketYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879724995040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Debt - Related Party Promissory Notes (Details) - Affiliated Entity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,453<span></span>
</td>
<td class="nump">$ 47,145<span></span>
</td>
<td class="nump">$ 14,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">86,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">42,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $300 Million December 2021 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $125 Million August 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $50 Million December 2022 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $30 Million March 2023 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $30 Million June 2023 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | $200 Million September 2023 Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember', window );">Promissory Notes | Related Party Fixed Rate Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A300MillionDecember2021PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A125MillionAugust2022PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A50MillionDecember2022PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionMarch2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A30MillionJune2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_A200MillionSeptember2023PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_RelatedPartyFixedRateNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_RelatedPartyFixedRateNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879724487184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related-Party Debt - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details) - Affiliated Entity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Nant Capital Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">13.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 576,951<span></span>
</td>
<td class="nump">$ 241,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Related Party Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">96,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">631,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">218,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">946,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Related Party Notes - Principal | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Related Party Notes - Principal | Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Interest Payments | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">79,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">79,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">18,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">177,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Interest Payments | Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">16,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">16,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 33,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ibrx_PromissoryNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesPrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesPrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_RelatedPartyNotesInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879726039568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related-Party Agreements - Outstanding Balances of Related-Party Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total due from related parties</a></td>
<td class="nump">$ 2,019<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total due from related parties</a></td>
<td class="nump">2,019<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantBioInc.Member', window );">NantBio | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total due from related parties</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantWorksMember', window );">NantWorks | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total due from related parties</a></td>
<td class="nump">541<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_BrinkBiologicsIncMember', window );">Brink Biologics, Inc. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total due from related parties</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_VariousMember', window );">Various | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total due from related parties</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_DuleyRoadMember', window );">Duley Road, LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_ImmunoOncologyClinicMember', window );">Immuno-Oncology Clinic, Inc. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_NantBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_NantBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_BrinkBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_BrinkBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_VariousMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_VariousMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_DuleyRoadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_DuleyRoadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_ImmunoOncologyClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_ImmunoOncologyClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879702633024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2023 </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>May 01, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Sep. 27, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>lease </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_options</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,275,000<span></span>
</td>
<td class="nump">$ 129,620,000<span></span>
</td>
<td class="nump">$ 102,708,000<span></span>
</td>
<td class="nump">$ 135,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,128,000<span></span>
</td>
<td class="nump">232,366,000<span></span>
</td>
<td class="nump">248,149,000<span></span>
</td>
<td class="nump">195,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="nump">622,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">934,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Sale of assets to an entity under common control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,136,000<span></span>
</td>
<td class="nump">3,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantWorksMember', window );">NantWorks | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreaseToLicenseFee', window );">Annual percentage increase to base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyLicenseFee', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased', window );">Expansion of leased premises (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantWorksMember', window );">NantWorks | Related Party | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantWorksMember', window );">NantWorks | Related Party | Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantWorksMember', window );">NantWorks | Related Party | Shared Services Agreement | Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PrepaidExpenseWriteDown', window );">Partial write down of prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_BrinkBiologicsIncMember', window );">Brink Biologics, Inc. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantBioInc.Member', window );">NantBio | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943,000<span></span>
</td>
<td class="nump">943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantBioInc.Member', window );">NantBio | Related Party | N C S C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SupplyAgreementTermOfContract', window );">Supply agreement, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NantBioRevenue', window );">NantBio revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantBioInc.Member', window );">NantBio | Related Party | Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveDougStLLCMember', window );">605 Doug St, LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreaseToLicenseFee', window );">Annual percentage increase to base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyLicenseFee', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | renewal_options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveDougStLLCMember', window );">605 Doug St, LLC | Related Party | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreaseToLicenseFee', window );">Annual percentage increase to base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyLicenseFee', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,800<span></span>
</td>
<td class="nump">$ 40,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | renewal_options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfLeases', window );">Number of leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Related Party | Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LeaseRelatedPayables', window );">Lease-related payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Related Party | September 2019 Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Related Party | July 2019 Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Related Party | Initial Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreaseToLicenseFee', window );">Annual percentage increase to base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyLicenseFee', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | renewal_options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Related Party | Expansion Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreaseToLicenseFee', window );">Annual percentage increase to base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyLicenseFee', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | renewal_options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Related Party | Initial And Expansion Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Tenant improvements incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Related Party | Research and development | Initial And Expansion Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantCapitalMember', window );">Nant Capital 2015 Note Payable | Related Party | 557 Doug St, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleLeasebackTransactionConsiderationTransferred', window );">Sale-leaseback transaction, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleLeasebackTransactionPropertyTaxes', window );">Sale-leaseback transaction, property taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleLeasebackTransactionNetProceeds', window );">Sale leaseback transaction, net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionHistoricalCost', window );">Sale leaseback transaction, independent appraisal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionNetBookValue', window );">Sale leaseback transaction, net carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Sale of assets to an entity under common control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfRentFreeLeaseTerm', window );">Period of rent free lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LesseeOperatingLeasePrepaidExpense', window );">Prepayment of first month rent and security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantCapitalMember', window );">Nant Capital 2015 Note Payable | Related Party | Research and development | 557 Doug St, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_NantCapitalMember', window );">Nant Capital 2015 Note Payable | Related Party | Other income, net | 557 Doug St, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on disposal of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_FourTwoZeroNashLLCMember', window );">420 Nash, LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreaseToLicenseFee', window );">Annual percentage increase to base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyLicenseFee', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | renewal_options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Tenant improvements incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_FourTwoZeroNashLLCMember', window );">420 Nash, LLC | Related Party | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_A23AlaskaLLCMember', window );">23 Alaska, LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_NumberOfSquareFeetOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreaseToLicenseFee', window );">Annual percentage increase to base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyLicenseFee', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Tenant improvements incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on disposal of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MonthlyBaseRentParking', window );">Monthly base rent, parking</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibrx_A23AlaskaLLCMember', window );">23 Alaska, LLC | Related Party | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AnnualPercentageIncreaseToLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increase to base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AnnualPercentageIncreaseToLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AnnualPercentageIncreasesToBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AnnualPercentageIncreasesToBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base monthly rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase to Number Of Square Foot Of Facility Leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseRelatedPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease-related payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseRelatedPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LesseeOperatingLeasePrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Prepaid Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LesseeOperatingLeasePrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MonthlyBaseRentParking">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly Base Rent, Parking</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MonthlyBaseRentParking</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MonthlyLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MonthlyLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NantBioRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NantBio Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NantBioRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfSquareFeetOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of square feet of facility leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfSquareFeetOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of square foot of facility leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionsToExtendNumberOfTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options to extend number of terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionsToExtendNumberOfTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PeriodOfExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PeriodOfExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PeriodOfRentFreeLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Of Rent Free Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PeriodOfRentFreeLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidExpenseWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense, Write Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidExpenseWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleLeasebackTransactionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale-leaseback Transaction, Consideration Transferred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleLeasebackTransactionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleLeasebackTransactionNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Leaseback Transaction, Net Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleLeasebackTransactionNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleLeasebackTransactionPropertyTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale-leaseback Transaction, Property Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleLeasebackTransactionPropertyTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SupplyAgreementTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply Agreement, Term Of Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SupplyAgreementTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive received by lessee from lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481475/840-20-55-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481178/840-20-25-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479924/842-10-30-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionHistoricalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The historical cost of the asset(s) sold in connection with the sale of the property to another party and the lease of the property back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-50<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-52<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-51<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionHistoricalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionNetBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-50<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-52<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-51<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionNetBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_SharedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_SharedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ibrx_ReimbursementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ibrx_ReimbursementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_ImmunoOncologyClinicIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_ImmunoOncologyClinicIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_BrinkBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_BrinkBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_NantBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_NantBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveDougStLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_SixZeroFiveDougStLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_DuleyRoadLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_DuleyRoadLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ibrx_DueToRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ibrx_DueToRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_SeptemberTwentyNineteenLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_SeptemberTwentyNineteenLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_JulyTwentyNineteenLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_JulyTwentyNineteenLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_SixZeroFiveNashLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_SixZeroFiveNashLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_InitialPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_InitialPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_ExpansionPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_ExpansionPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_InitialAndExpansionPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_InitialAndExpansionPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_NantCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_NantCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_FiveFiveSevenDougStLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_FiveFiveSevenDougStLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_FourTwoZeroNashLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_FourTwoZeroNashLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibrx_A23AlaskaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibrx_A23AlaskaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879724263328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2023</div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Feb. 15, 2023</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,770<span></span>
</td>
<td class="nump">$ 21,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,600<span></span>
</td>
<td class="num">(13,460)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,100<span></span>
</td>
<td class="nump">17,091<span></span>
</td>
<td class="nump">21,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,545)<span></span>
</td>
<td class="num">(13,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember', window );">July 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,721<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_TransactionCostsWarrantLiability', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase (decrease) in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued in transaction (in shares)</a></td>
<td class="nump">2,432,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,569,296<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Placement agent fees and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | July 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,569,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,569,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_TransactionCostsWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs, Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_TransactionCostsWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879732240368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">108 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 20, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 25, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,867,344<span></span>
</td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,867,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,867,344<span></span>
</td>
<td class="nump">421,569,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670,867,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,800<span></span>
</td>
<td class="nump">163,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAdditionalPurchaseOption', window );">Sale of stock, additional purchase option</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in exchange for notes payable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,291,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LongTermDebtGrossIncludingAccruedInterest', window );">Aggregate principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | NantWorks, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of convertible notes (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,986,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | NantWorks, LLC Member | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_LongTermDebtGrossIncludingAccruedInterest', window );">Aggregate principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember', window );">February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember', window );">December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">$ 164,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_PercentageOfSalesAgentCommission', window );">Percentage of sales agent commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember', window );">February 2023 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockMaximumAggregateOfferingPrice', window );">Maximum offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_CommonStockValueAvailableForFutureStockIssuance', window );">Available for future stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">565,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_PrivatePlacementAndAtTheMarketOfferingsMember', window );">Private Placement and At The Market Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,561<span></span>
</td>
<td class="nump">60,427<span></span>
</td>
<td class="nump">164,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issued in transaction (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Placement agent fees and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_PrivatePlacementAndAtTheMarketOfferingsMember', window );">Private Placement and At The Market Offerings | February 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued in transaction (in shares) | shares</a></td>
<td class="nump">2,432,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,569,296<span></span>
</td>
<td class="nump">14,072,615<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issued in transaction (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Placement agent fees and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | July 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,569,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issued in transaction (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | December 2022 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,090,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember', window );">Stock Purchase and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sales of stock issued in transaction</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,542<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issued in transaction (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.1103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Placement agent fees and other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_SaleOfStockAdditionalPurchaseOption', window );">Sale of stock, additional purchase option</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percent of common stock outstanding after option exercise, maximum</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenShareRepurchasePlanMember', window );">2015 Share Repurchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,403,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member', window );">NantCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_CommonStockValueAvailableForFutureStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value available for future stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_CommonStockValueAvailableForFutureStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LongTermDebtGrossIncludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Gross, Including Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LongTermDebtGrossIncludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PercentageOfSalesAgentCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Sales Agent Commission</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PercentageOfSalesAgentCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleOfStockAdditionalPurchaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Additional Purchase Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleOfStockAdditionalPurchaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLLCMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLLCMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_February2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_December2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_February2023ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_PrivatePlacementAndAtTheMarketOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_PrivatePlacementAndAtTheMarketOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibrx_July2023WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibrx_StockPurchaseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenShareRepurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenShareRepurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879722964416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 25, 2023</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 5,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,867,252<span></span>
</td>
<td class="nump">3,445,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants of restricted stock (in units)</a></td>
<td class="nump">5,727,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,407,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue', window );">Estimated benefit at grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ibrx_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_A2014PlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember', window );">NC 2015 Plan | NantCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants of restricted stock (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,121,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ibrx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ibrx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_A2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_A2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_NantCellInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879718551424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expenses Related to Statement of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 49,163<span></span>
</td>
<td class="nump">$ 40,179<span></span>
</td>
<td class="nump">$ 57,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">17,341<span></span>
</td>
<td class="nump">11,669<span></span>
</td>
<td class="nump">18,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">31,822<span></span>
</td>
<td class="nump">28,510<span></span>
</td>
<td class="nump">38,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">13,884<span></span>
</td>
<td class="nump">13,280<span></span>
</td>
<td class="nump">11,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 35,279<span></span>
</td>
<td class="nump">$ 26,899<span></span>
</td>
<td class="nump">$ 45,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879723204080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity and Related Information under Equity Plans (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">9,262,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">949,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(184,362)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired/forfeited (in shares)</a></td>
<td class="num">(207,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">9,820,435<span></span>
</td>
<td class="nump">9,262,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options, Vested and exercisable (in shares)</a></td>
<td class="nump">5,867,252<span></span>
</td>
<td class="nump">3,445,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 9.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired/forfeited (in dollars per share)</a></td>
<td class="nump">5.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">9.46<span></span>
</td>
<td class="nump">$ 9.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 6,046<span></span>
</td>
<td class="nump">$ 4,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 4,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life, Vested and exercisable (in years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879718326896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model (Detail) - Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">116.20%<span></span>
</td>
<td class="nump">101.80%<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
<td class="nump">$ 16.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727752960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity under Equity Plans (Detail) - Outstanding RSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 25, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning balance (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,551,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in units)</a></td>
<td class="nump">5,727,159<span></span>
</td>
<td class="nump">6,407,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,545,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(909,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, ending balance (in units)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,503,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/canceled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727608496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Before Taxes, Domestic and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. loss before income taxes</a></td>
<td class="num">$ (581,136)<span></span>
</td>
<td class="num">$ (413,653)<span></span>
</td>
<td class="num">$ (347,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign loss before income taxes</a></td>
<td class="num">(2,756)<span></span>
</td>
<td class="num">(3,633)<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes and noncontrolling interests</a></td>
<td class="num">$ (583,892)<span></span>
</td>
<td class="num">$ (417,286)<span></span>
</td>
<td class="num">$ (349,839)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879721040912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Benefit (Provision) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DeferredIncomeTaxExpenseBenefitNet', window );">Total deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax benefit (expense)</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DeferredIncomeTaxExpenseBenefitNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Expense (Benefit), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DeferredIncomeTaxExpenseBenefitNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879724128832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 420,782<span></span>
</td>
<td class="nump">$ 362,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 R&amp;E capitalization</a></td>
<td class="nump">87,721<span></span>
</td>
<td class="nump">50,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">56,610<span></span>
</td>
<td class="nump">40,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest expense</a></td>
<td class="nump">39,859<span></span>
</td>
<td class="nump">19,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">22,554<span></span>
</td>
<td class="nump">20,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss</a></td>
<td class="nump">16,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Operating lease liabilities</a></td>
<td class="nump">11,605<span></span>
</td>
<td class="nump">12,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DeferredTaxAssetsValuationDiscount', window );">Valuation discount</a></td>
<td class="nump">9,095<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investments</a></td>
<td class="nump">7,544<span></span>
</td>
<td class="nump">5,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Amortization</a></td>
<td class="nump">3,715<span></span>
</td>
<td class="nump">3,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">2,944<span></span>
</td>
<td class="nump">1,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">682,722<span></span>
</td>
<td class="nump">523,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Debt discount</a></td>
<td class="num">(23,365)<span></span>
</td>
<td class="num">(16,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(9,380)<span></span>
</td>
<td class="num">(11,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(1,533)<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Indefinite-lived intangible assets</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(34,426)<span></span>
</td>
<td class="num">(31,766)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">648,296<span></span>
</td>
<td class="nump">491,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(648,444)<span></span>
</td>
<td class="num">(491,755)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (148)<span></span>
</td>
<td class="num">$ (158)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DeferredTaxAssetsValuationDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DeferredTaxAssetsValuationDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879727626592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating losses</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating losses</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating losses</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">648,444<span></span>
</td>
<td class="nump">$ 491,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="num">(156,600)<span></span>
</td>
<td class="nump">116,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital', window );">Portion of valuation allowance credited directly to contributed capital</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations', window );">Deferred tax assets not recognized due to limitations</a></td>
<td class="nump">274,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">56,610<span></span>
</td>
<td class="nump">40,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed', window );">Deferred tax assets, interest expense temporarily disallowed</a></td>
<td class="nump">164,600<span></span>
</td>
<td class="nump">$ 77,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would not impact effective tax rate</a></td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating losses not subject to expiration</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">47,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Other tax credits</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating losses not subject to expiration</a></td>
<td class="nump">50,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Not Recognized, Interest Expense Temporarily Disallowed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Not Recognized, Section 382/383 Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance, Tax Benefits Credited To Contributed Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879820772880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue', window );">Change in fair value of warrants</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue', window );">Change in fair value of convertible notes</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss', window );">Investment loss</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent items</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate adjustment</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent', window );">Section 162(m) limitation</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(30.20%)<span></span>
</td>
<td class="num">(33.00%)<span></span>
</td>
<td class="num">(32.70%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Convertible Notes, Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Investment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Warrants, Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Nondeductible Expense, Section 162(m) Limitation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879721514432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning of year</a></td>
<td class="nump">$ 16,252<span></span>
</td>
<td class="nump">$ 13,504<span></span>
</td>
<td class="nump">$ 20,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">18,976<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior years</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, end of year</a></td>
<td class="nump">$ 35,470<span></span>
</td>
<td class="nump">$ 16,252<span></span>
</td>
<td class="nump">$ 13,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139879728068880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Discretionary contributions</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>118
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M[([6A?K*'WYG74 -P(P7LOD?/'2VP0)DM52\[!IK!&5>M7_I]VX@!@T@F6F
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M!C.S$!\"C+T!_LD5+2:QN"#&-L24! F98+3-( G".':#3 X@D^.3>0DJ7G7
M78@3"TJ2P@E<APV9R9CT@#5])F.T*A#J<0EVNOZK)F%,H=AINE8:,W."31WC
M%@4)FN!UF>$H3-V08=#S5N %_:E2M+K/S0"W*3 +M',T@A 'Z317'69:"\TE
M*QP0+/078%[M]>@V2"NNF%Y>&=-%6+\[T4(+1I3$T\+ALHK0W*#VO B]5+3^
MHO. *E,0"J:U$1!&!)WQN[-:CH;Y5:6CPS"J"M&P-G<AVF8DC)-D)L:>#Z&?
M$+\TI? $);#K9Y0P21),P["M2!+-K%C8<R7TDV5;!.>+'[3Y+PP(":?+TV&'
M(X3#: 9@3Y4P?)'&*G)ZFQ=-^7,*+>BEW&.5UJF\C8/NJ1?ZN?=#EHF:.;EW
M, [.8;"IDJ X2*;3Y3"#"0IG9JNG5.CGU*]MOI^9?'\$.ZUQ<BFY>&PJ5K?F
M^1W8Y#)K5XD)3.^6F)[D#="V=;-QR+@TB^H/W:@=51BXEXY-NM:ZL4T(AFDP
M(S)A3\S0S\S3&C>8F->5 YN90T2F:L-AI27V7#GH&1SZ*7RLB9[+-9N3PP0E
M5@%VF 5!$LW, .JI&_FI>YQL1A)-*-+*MS:EP$PV(0?!!R1,HDE #KN9@4<]
MNR,_NX]CF0;2KA/:586\4DQ7'75L>#;7AW&4AE-EZ+!#!*)X;KX&NV6_*OC*
M]JS26Y\G_(?\>APN]=0-WF9Q&(8$AE/PMMW<W/1,C_Q,?\6$UEGFF&B\R >8
MF_EYMEPAF\-QB/%TP3C,YF+H>1[Y>=Y3K9;Z(RD/BW['17,P]IH:AAQJ($W)
M5#0XS$@\3,AQL+UF0/[]]3]4"/I\_4*.;3-,XGA*(0X[!",\(VU0S_+(S_)?
M7D+HR&9J"*U3"H>5%KDS 'LV1R_9(3\'T+'Q#=( )Q9&VS"!",9SX]@S,?(S
M\24ORUR9369;)W7U-)G.JNRP3$'LSE.O8[?, \Z3N=<[&@??,S9*O?KX1O'L
MVY87&R;DSS\E>CS?&T&59[ER'TAZ!<#1)Y(G\C8^DNP5 /8K #/SNE1),P9+
M\"9XJS?:L/6ORQ/8TZ)F[P%<XC!8ZJ_,OR9#TN#PWEK++16&96NUY2+_3Y<W
M*@VS7ND]=GG+1&N%X;)],,?/C2-SD+S4)5'N6'./4#R^!U$<+),H7F)"&AN"
MX#*,TB6$(>CZ,4+7]&%4?:VDT@]-G?WA/MGWIUJM"],R>0I+"5WL:RV_FQ%Z
MZOW'NG2>\]I**(HGR]YA,R""\<3W<@G[Y=*'S28W+*7+DSFD/,LKD-%=KLN5
M$Z9#T>"81&A:Z1V&,,5!.E?K<:]]L%_[Z!U=7=8M<W;+TXG4EB]G*(U@9!TW
M.BUQG)"YDPT\..GWZYTAUN[ EY=Z_6[-K=O>Z#?][CQTPK9R@=88.VR2F=,Q
MW.L;_))SC$]E65=:3W[,>9OR[L+HA&YKD3,M_=/$RF>'(2$Q1C-TBWO9@OVR
MY8]F!Z,$+PJS-)]DLON&Q:%=@M ::]OJ#)%T;K1[Y8+]RJ4=[6-'V-8H>H3#
M%%LC[# D)$W0C K&O:#!1PJ:IKH=&X>M8YQ'8@X[WY$8[O4.]NL=G2=/(OS:
M;!>=('] D,S3_*F\C0/N-0[V:YR7G@'BDVJ;4WD;7V+VVH;XM8VNPNVN:T<?
MYP[YB<VM*4RG>V*'%8(!G,E#TI,P>=&9Q7P2^ML?.Q^G\C:.MF=P\NK+?G+2
MV_Y3>1O'VZL \LRIQQ&7U,1QA6'?4CNLYJ^IR>"ZGYRD.A"O@CAZ=D[D;1QT
MKQ6(7RN\J#J$]N\K()Z>9CJL,(FF5X"KP4^#S.^R/E-QGU<2%.Q.-PO>QMJ+
M:'_JU+XHOFM^+73+E>)E\[AE5%.L,=#?WW&]+>]>S ^0#C\X6_\/4$L#!!0
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M5#7"JX:V&DB6EQW;@DG5_Y67J?H/@+@.4/>7C,GG@6X"FW\5T7]02P,$%
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M;8YJ#JJYJ.:AFH]J :J%J!:A6MSKTYQ0,:LYO*PQ%;N+3(O+[D6N;DW/6O,
M9&4Z41H9FJS\ND*U&:KI[4VBC>L/+3/0L":J6:AFH]H<U1Q4<U'-0S4?U0)4
M"U$MZOL1C-&P26O8U[>'51-P66HJ=M>:SC;+GD_/%5MS-%G/=8EJ5Z@V0S4=
MU0Q4,U'-0C5;;%9FRM/Q1!Z-%*5^.PQ:JXIJ+JIYJ.:C6H!J(:I%J!:C6D)I
MU6&A+&X5WZANK0X+O8:"9L'AN:3(4U&N3]?1HE54FZ&:WMXDDCB6Z]-UM"85
MU2Q4LX_:ZV>6**-ZYD9+4E'-136OY001Q^)T/&K<Y()6G*):B&I1VV=&G&KB
M5*H_8+?EG4K]ZD8;-GYUPE738UD!*CY5,?T'G[$KDD59EZAVA6HS5--1S4 U
M$]4L5+-1;8YJ#JJYJ.:AFH]J :J%J!:A6HQJ":55ES0J:UBE[AK6[WKP;K<]
M=-Q M2M4FZ&:CFH&JIFH9J&:C6ISJ5D&*XU4<3*MS>R<EC=.1X?_JF]TT?WS
M4,U'M0#50E2+4"U&M832JMF^+$J5NHM2!S]GM]L;G.&;Y86B+$JUC]'5\6W5
MI4I&H]J#L6?HONFH9O0[4K/?D5KHOMFH-D<UIZU!ZDD6+>]$-;]?MP<GNEVK
MOBU$]RU"M1C5$DJKID6I3(O=!9FGTF)QG27]=GVWV-RFAP+-S39+]\+#XH_%
MYW7ZYNR87>Z37>^37?"37?&37?*37?.37?237?6S6<,XG4ZTJ52_YHV&=5#-
M134/U7Q4"U M1+4(U6)42RBM.E:4U9]2=_7G>\<*+__Q:3?$4?MPT:Q<4\6I
M4IL+7G;OWN!Q "T)136]7X,8:% 3U2Q4LZ66)1SKJ1TM]$0U%]6\$V=';0[M
MHT$#5 M1+4*U&-422JOF[++2,W_9E;/?L\C%D:S\QG<DCJ?U=-P9>7 Z)K49
MJNG]&L1 @YJH9J&:C6IS5'-0S44UK]^)Y*-! U0+42U"M1C5$DJK9NZR[E+J
MKKM\]\H7W>[@BR]H72:JS5!-1S4#U4Q4LU#-EEK6\U3&VK@^/T<+,U'-134/
MU7Q4"U M1+4(U6)42RBM.AB4!9Q2=P'GH,4PI&81T[C^H,3N>(/3.EK,B6IZ
MC]8PT(@FJEFH9J/:'-4<5'-1S>MQ%OEHQ #50E2+4"U&M832JIFZK/24NBL]
MJ94QNL,,GL6C)9^H-D,U'=4,5#-1S4(U6VI9C%,2I:E6G\:C]9ZHYJ*:AVH^
MJ@6H%J):A&HQJB645AT<RGI/J;O>$UD9HSO&X)$!+1-%M1FJZ:AFH)J):A:J
MV5);=9^JC1HK8Z!A'51S4<U#-1_5 E0+42U"M1C5$DJK#@UEK:O4O=SINU?&
MD)KK-9YKHE:_WH-6IJ+:#-7T7NUAH#%-5+-0S4:U.:HYJ.:BFM?K//+1F &J
MA:@6H5J,:@FE57*W7%:2RMV5I/%ALBZL]OO'XH'IC[OB/LFL6!UCO<I6MT\W
MW+Q*ZV],\+NC#9W@H]H5JLU034<U ]5,5+-0S99;JD$E:=J\]H.&=5#-134/
MU7Q4"U M1+4(U6)42RBM.DB4!:AR=P'JP$&B=6!HJ;$;:6I]KM^](X,S/KK8
M*:KI_1K$0(.:J&:AFHUJ<U1S4,U%-:_?B>2C00-4"U$M0K48U1)*JR9RJ4SD
MW26S?^;B27*SD'$B3>K+TU]V[^'@#(]6Q**:WJ]!##2HB6H6JMFH-D<U!]5<
M5//ZG4@^&C1 M1#5(E2+42VAM&J&+PM=Y>Y"U^]>\DAN68JQ43_5O1.#DSA:
MSHIJ>I_F,-"0)JI9J&:CVAS5'%1S4<U#-1_5 E0+42U"M;C/ASFA0E83>%GU
MFK]\ZY>II]8[.F[ZNI3\7!''<OU9(9?=,0;G9U*;H9I^U*I+P(OYU]_Z P?0
ML":J6:AFH]H<U1Q4<U'-0S4?U0)4"U$MZOL1C-&P25O8L5JNFU#-OV7MJOQ&
M[6KOY8ZDUA3=K"A4)%'5IJ*HUI,T6IZ*:C-4TU'-0#43U2Q4L_N?3',TL(-J
M+JIYJ.:C6H!J(:I%J!:C6D)IU9Q?EJC*;Y2H=JYEU)[GM9:IN#*=-*?B:+4J
MJLU039=;%B!4E/S;26,JCI:LHIJ%:G;+6:)(]<R-%J*BFHMJ7LL)(D[ET51N
M_*X2K49%M1#5HK;/C"2/)\ID4I\\MS3>1*Y?NVCCE.FI27%9&2H_%1?]!U<S
MDM&B452[0K49JNFH9J":B6H6JMFH-D<U!]5<5/-0S4>U -5"5(M0+4:UA-*J
MHTM96BIWEY9^UVI&W?;@<0,M*46U&:KIJ&:@FHEJ%JK9J#:7FP6JJC929:DV
MLW-:WBA--$6<UDM9W;9W*K+46"#)0X_$1[4 U4)4BU M1K6$TJJ9O*P$E;LK
M00>O5-3M#<[>T\;7;5$3ZRNT7+6\3=:F<NV#-&O31'52>YN.'H+1[Q#,?H=@
M]3L$&SV$>5O0>C9KV?UZ&D,K(E'-/]%)M6OR07LG2;5O]F&_3HK00XA1+:&T
M2MI1RB)&Y7W+87[?2D#=08?F)E2[0K49JNFH9J":B6H6JME*V\J64VDJ-BZ0
MSM' #JJYJ.:AFH]J :J%J!:A6HQJ":551XNRFE%YWW*:W[T6D-*LQ)*TZ712
M7PRH>_\&#P5HD2.JZ3U;Q$"CFJAFH9JM-!>1E.H/HT(C.JCFHIIWXOS0ZK\0
M1*,&J!:B6H1J,:HEE%;-VU*9M_L5+QY*%6L5C*\K%\^[*A>?TKAP*H,W*ZUD
M313K]W1T[^C@!([6,**:WJ]!##2HB6H6JMFH-D<U!]5<5//ZG4@^&C1 M1#5
M(E2+42VAM&JB+VL8E3<6ZWR^VR3/]S>+U4[XLE@_'J;KZ?WG=+D\K >W^9+N
M]L5S1V[21?:XRV?LN^W]T]APOUVN;E;73X\E.8P,^1"Q>N^0T*P9DL5F163W
M(0T>$M"*2%33^S6(@08U4<U"-1O5YJCFH)J+:EZ_$\E'@P:H%J):A&HQJB64
M5AT2RJK(_&77D/">M4"/9.7FVZFHR?7,W1EY<.8FM1FJZ4=-ZVX0 PUJHIJ%
M:C:JS5'-0347U;Q^)Y*/!@U0+42U"-5B5$LHK9JYRWI*Y4]:"U1I69MQHLB:
M5,_?:!DEJLU034<U ]5,5+-0S>YY)LW1J ZJN:CFH9J/:@&JA:@6H5J,:@FE
M5?-\64.I@,M\*LVZ.*E^?^IE=\#!B1VMG$0U76F6;36:PT!#FJAFH9J-:G-4
M<U#-136OSVGDHR$#5 M1+4*U&-422JLFZ[*>4_GWK/39'6;P+9)HT2:JS5!-
M1S4#U4Q4LU#-5IHK?2JJHFJ*4I_*H_68J.:BFH=J/JH%J!:B6H1J,:HEE%8=
M'<IZ3.7?L-1G=XS!0P-:EXEJ,U334<U -1/5+%2SE;:E/I61/%$:MU>B:WVB
MFHMJ'JKYJ!:@6HAJ$:K%J)906G5L*"L\E3]IK4^E94U"65$:OXU%%_M$M1FJ
MZ?T:Q$"#FJAFH9J-:G-4<U#-136OWXGDHT$#5 M1+4*U&-422JND;[6LE%6[
M*V7_S 6 U&;]8MO-\]U[.#3#H]H,U714,U#-1#4+U6Q4FZ.:@VHNJGFHYJ-:
M@&HAJD6H%J-:0FG5\:*LE56[:V4OGZIABT'CZR;=[>]6#_D/65K\UJ#XVX7P
M?]O\YWSBOSG<A+]\3 _+@J:WBW5EV>C#+?;CUBM%:K,(L#%FH!6SJ#9#-;VE
M,<X5<5J_NQX-:J*:A6HVJLU1S4$U%]6\?B>2CP8-4"U$M0C58E1+6CJKTE?5
M["V5V;N[8O:[%X-3FU5[Y^*X?LVF>R\&9V>T'!;5]%[M8: Q352S4,U&M3FJ
M.:CFHIJ':CZJ!:@6HEJ$:G&O3W-"Q:SF\+(85NTNANU:#^ZX:641"G4B3]3Z
M/?+=,09G:+0Z%=5TM5E46#2).-7J21JM3T4U"]5L5)NCFH-J+JIYJ.:C6H!J
M(:I%?3^",1HV:0NKJ=J).719>9J_[,J__=>#DUM3M-+8*VT\FFACN7[/VF7W
MC@Q.TJ0V0S4=U0Q4,U'-0C6[_\DT1P,[J.:BFH=J/JH%J!:B6H1J,:HEE%;-
M^67-JCIH#=!>>5YMFXJK4[G^\,?NT(.S/%JNBFIZ>Y-HS:<_HF%-5+-0S6YI
MDOHJN7,THH-J+JIY+:TAR6-%JZ^AZ*-A U0+42UJ^\Q(4TW4)DI]\MQ\9_U6
MBZ3U/>JH-B6^V-^E:7:UR!:?/CPL;E-WL;M=;?;".KW)-QO]-,Z5W>KV[N6'
M;/OP\4P\$SYOLVQ[?WAYERZ6Z:YX0_[O-]MM]OS#1>Y_W>Y^/\3X]/]02P,$
M%     @ \H-S6'._Q.T, P  1PL  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6RM5F%SFD 0_2LW--,V,TU 0+2I,J/23O,A4R<V[><++' C</;NU/3?
M=P^0JE&:=/@BW+'OL>_=NNQHR\52I@"*/.59(<=&JM3JQC1EF$).Y35?08%/
M8BYRJG I$E.N!-"H!.69:5N69^:4%88_*O?FPA_QM<I8 7-!Y#K/J?@]A8QO
MQT;/V&W<LR15>L/T1RN:P +4PVHN<&4V+!'+H9",%T1 /#8FO9M@J./+@!\,
MMG+OGF@ECYPO]>(V&AN63@@R")5FH'C9P RR3!-A&K]J3J-YI0;NW^_8OY3:
M4<LCE3#CV4\6J71L# T204S7F;KGVZ]0Z^EKOI!GLOPEVSK6,DBXEHKG-1@S
MR%E17>E3[<,>H.>= =@UP#X&N&< 3@UP7@IP:X!;.E-)*7T(J*+^2/ M$3H:
MV?1-:6:)1OFLT,>^4 *?,L0I?\8+R3,6404162B\X)DJ27B,*QXN4YY%(.0[
M$D#,0J;(G H,2$&QD&:7Y(H\+ +R_N*27!!6D.\I7TM:1')D*LQ.O\,,ZTRF
M52;VF4QZ-KGCR"S)YR*"Z)# 1%F--GNG;6JW,@807A.G]X'8ENV<2&CV<KA]
M AZ\'-YK4>,T)^64?.X9OHFZ0MNO[JA8@CIE;RM<MX\;N:(AC WL#Q+$!@S_
M[9N>9WTZ94V79$%'9 >VN8UM;JMM,Y[G3.HN)0D6)A9V#((5"0FY5"?+M.(;
ME'RZ:VY\MS\8F9M]>Y['.)9]&!.<X/$&;A-TH*;?J.FWJKF'A$D% O^L 1/8
M.\FW6L\I):U<KZV(+LF"CL@.//0:#[V.*Z+B\_9/N^_TCTK">W;<O>''H[H)
M6C/[3]V#1O?@'[6S@6(-Y+;0!22QE:]%F.(WDTP2 67?/R6^E?2U1=0E6= 1
MV8&9P\;,8<=%-'S>#@;.40VUOO.U]G1$5MEC[HT8.8BD'-4DJET7JOHB-[O-
M-#@IAZ"C_2E.B=50]Y>F&C'QRY8PM#.#&"FMZP$V"5&-;=5"\54YR#QRA6-1
M>9OBI M"!^#SF'.U6^@7-+.S_P=02P,$%     @ \H-S6);U._PY#@  =$H
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M(?Z($@VT5@O<6NU^&"'>F]]AV^11M*4JL%458Z:JQD#4S/\(Z+2S<\A%*[3
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MC@6FAG<V8!: [*BI!BDI > <(Y ]6 X57A- @X0B* ,%JJ%9M,Z1[28AVMT
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ME^$\HU46L6WZ$,B53$P2\'B>/O4&R(\%_//=-?85J/!,.T5($":M$[8$FMS
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M6-U=]$/"2HE$N9ZY=49@,H[K3BB7*J/NB5;S&P(HLR77PH&J$22N Z!N!\:
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MD,7$L&A^30+(*D=/?_A)+U=/7Y&K<9+88G5 OTVZWX@(/CGM/H$H5V('Q69
MY^BY2AHLXA;B'G"MNBILSJZ$XS8F&CH@K$2C>M>SVY6L$.7T%#E@;Z!M$RM
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MV!2."/-3YB;V] %1R.M=M=$%PQ6J2#ALA"0'5$C;+F!EBA)P88:YG;/Q$QS
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M7&^Z'C1=DVX-1FS!#F.3 8D[3A+:IPR6)>V&F0$U=1R1L17),VG/A_G+;@M
MKDJ)A8<9"KIW6.B\:XZG;2;0V[&'8)H<!/:UGM)68/Z?Y?U1;P[W55M^L>Z+
M>JTSN4#_E?JU4%\.8<KMH/JM5*_-U/$@Z.GYH&MV$;XL3"B^=$+6BV>'^GVV
M/]@LY(3<=SY^/!B/QS#04NYZ:LJ+#'V;8_&)2] IS>V@BTE34Q!$E,3LYRRI
M?.,XH26H#JO9$ N'-"LPM737L@BV1^QE<@,N]R5$AJ9:&\UW/L7&M\$E<\ W
M7&UG&[F2"+7/@>MX;TF_CSZ.PE6-"I,)<-TZ@X.E?.BZKC++H8BY#W"WFW+=
M&J/JXWI_E>-OFJ3CI%&E!N(<*^H:GIWJAN9_*2+M4U",WE2&S)UD*2->083\
M"%8W]9)7^(?L?$GOATAQ.^.+^C#V$<9+A'5!W/OC=,HD3P[W;.7>>:\MV?F!
M[C61.!2>C[=[FJE@LJJ6C+NU04)?F$UF&L0Z^;T4^]7/(\RTI1A;M":53YS2
M[HK8Y%RD176?[021&9S5QT_4%<31.&\3<FT_IPD]=4^=C@?C\[/$*^V23-ZC
MA@>#R<49/)XE;H8%MS:A.DHJQ+#GB6YJ /@GD\?J-]\(I%E$JY-GI!8Q*VT3
M$#<9/'YTAKBVJ[-[\-W!Q?B1^K_^?[S7-QGR@Q,\-:%O*B=]E7C&""IB-W \
M.N^5X96;ZQ**R/F5'AA0EMZ?)]?C=ZAAI'X/EQ\9W3_)%$?J%8G1#'K3&WZ$
M7MH5/,5X*.!UW<K7-"S],5NTFP*?O.VF4ZXJMPJS\*SG@1)X^%O65!3()8Z?
MBNMU _7=R7:B<SR0F%NW:-#CDG<['G20__7'MU=$%W \+X"KQ0VV#\73(FL9
M_(\ABP#SRJ>H,'SI[X*%*EU$UJ)D!EYM.C+7XVBD?FM=O$3A,>?@W!RLIX9K
MK7$LLL)05A@0.AT/Y5(,"=^?CI)L-\^(?&/6@@V9O##23P(,O%G+W)"2/ETI
MX*(..R;3..FF.X-J/4M:F_C&1!+P?:*+$7@7"@0XES;>DJL/[N9'P^ON48Y[
MO=RNQ;9U(L\I:N",D7MO-)6>G9IF;4S9<P2^M!;&O=&*58;W1AX&M!#:G(37
M6/VHC3C%)F#6]]LFR-BAR]0519!P#$L)\DEGPF27OE:(X/B;!.V,2Z0PY;IM
M'CQ@5)K#VO[#MQUZ)X26B,MS[-\-E^IF?YP@(XW7^-2]FA$H%US7'ZV[HF8Q
MJF56S2O!FV3A9W ([A!TFX$)^,J"T]'.!G3%\5WT8R<,N$NB.$]$>\OEFF'8
MZ%N:^5N*A]7Z!M1Z>MH:<=\G V\DX2[.D:8(-X%T(,CO#\DHWRW-X,@!]MY5
M[+/Q%#5LS1@GCLBX/G&^[M9,3\' " S;0@:VP%ACZ]EF9TUD5 R(W^B@$F0N
M4QO]:\=D ,-![+F5NG).1/@-%'I?H 5@<-8/),?F.@]!WFJ"X8->%W9+QAQ7
MDY[,GC A""!./E%CI>U>:=NZIR?:W!:(;Y_$FU6:8_0182;3]QVV\2MG8?>.
M(1GS:^I(YX>"EA_J8(01#X0@7!#*FO>J!L;\/=&&$W!NH==^ZB9]K4:G\T[,
MO;]-G;:VR(?4,C]HT+%F01G%,-.[Y!;P?+15]?=;[;/][,IL&'-X X/T6.[P
MF-6!F3%=!P$#LY&A99E9-?(5SW<L$V!$O7!^M9 TNY>K,((&Y2$2BDN')FKI
M)U#HM0J95Z>NZK*JHP23 )M*5\ATF:E[*J(.XFBP/[3N:6_Z;E))(&76TNN4
M_=9SUT2@).>'  \;S=1L&ZN$2MD?9Q-I-$E_M(>A> Z/:FDKKWL$.)9&E'1&
M-KV1V[H]VQZ%"%/$E&)='J+QCHSTOC G=LZM2^I#>W!)8X^A)F^JN6%?V*Y>
MR9/CFZ*6CBL3D3=5@8*5D,'*- F4<N2=,X]SDI%);Q>_ESRM\['A2;F771OF
M"J)K8@'Y$>8";DKU"C[L;,9V]0GQT8.C$)?>NRJ#+5)*.>;LEE=<P]+,!WQ6
M$X;EB]$!E5O:OR>Q9[6HGWL]E;Q\LA4KNGCZ#1\.1]C6S&A75W_$BN=#O(??
MOB>?].L504D,SY*"J;O&/X1*)"7Y#GN-\.EB8'"F\?,L,73')D3HL^4]+!*J
ML_3-A^]LILO;BD7!.4]>(2G\RV T D:OWW,3\[M>^-N^:OITB&5N?I-=I%>
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MW3M5+ZG-4.H%;IV,GYT=2"/+?VCMAM^N-K=M:]?\)\!;H6NZ +\OK&W]!WI
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MN<R*2M2ZD#538GX^F :GEPGMMQM^*\2#[HT967(KY1U-WLW.!SXI)$J1&^+
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M7&R4^R'H)D8V]B?<K31&5G:X%'PF%&W ^ES"^&Y" M9_92_^ E!+ P04
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M/CW9"Q=D[1=O:GX=;F&\-R5_7"L)W=("_+XTQK=?Z(#T?N3YOP%02P,$%
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M!USLZ;#\&5E<R,_OBC5V1,A!D9+TZ_=?4'O7J=BB.1/8D^+4E'IN.ES%[M.
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M4BB%8+T#SU(4;(17CCW20?2<Z2#T 6.T\Y2<>LV:A^F@%Y2K8\C24ON\-["
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M+TK\C%Z39$H8 D !TU;=_2ZUT=^!%M(HZYS0 ,H/H)7\WTHK':N4VN8-P!F
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M&PZTP6566MV&Z0%=AP-N?*_K,*Z+UAPL1KI"7ET5-ZVXAHC132[]!G[&/2@
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MBZ:;GCLFI+MU5&XEDBDP7:U5'0Y5T=H2WSV.R\QSRI$6M'T&[RX2Z4W(PO7
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MV1SU+@ *U&M_S6$(C]X,]5U -]O=I%S4%PA;\_H:YCW3:^IM$+BBK5%X,@U
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M&XF"C\R$(IE#5!\)\04 +Z\-=RZV%'8G!-@=@*Z5(+F&?,SO# S+:E6Z^'C
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MCHY')/_C+T6CV7R19(OY?PJ-#I=['!KMJ_ (&F7IV70V^Y/1:'(6IS>_$HU
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MO%( =,>+=/%EQ/;PK9\XE7#"]QT.0<?5!^MTYSA=38(M=Y3=L18[A6JD&U(
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M= EM"E0[M2F F@=ID:BJ[M!"7:MGU+ #WT&OHQ@KN1J'AK"52!@494JCQ E
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M$@'>KQ4RP=W0 MU7U_/_ E!+ P04    " #R@W-8P?R(XM -  "A)@  &0
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ME6M9\@$CO9<GN0X6W\OU%+:KZSL0N)$UE-0TM5ZU,!L(R 8&@;ML5 D=D=Y
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MREP_)E9]MT>=8F7<[5K9-[!.P&YTSG2#A;><ST3@S0-?),@8/T)M!Q10=R]
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M#4H:NG/@6ZW1[9:D;#?/BNRP<2\W=8@;^6+6X(8>*'QM[AQ+^8!224W&2VO
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M=0$KA@_ROY/&S6BU-^]O'C>);L/@BG)4[<E365))+74+C7O5,3V@5SV:P+M
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MN@$+1_[ #FZ;]A,-[^?_"U!+ P04    " #R@W-8JLQ=;+D#  #7!P  &0
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M\DI^AT*RL>$JI(:P Y8X:9C@[GE.XH8C':DM"N@9.6F<L=1QO6#\*!K=*@"
M,]_Q0Y^NZ5:DEDMSGRO.*C" K6S)P<=W/->E:Q:QZY$>#JI%6[-E!RA8:;W
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MH]#-@U4:4#@OBK;N 5?N@I6(\UHJ(_[J7D#7((G),C_R7^%]JIMAC'+AVU4
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MJ:WD.?:!55(9_@]FM*9-'Q9*:@VUH/92NND%F>J.^9+&2 LV=3GC"E:LK%U
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M;;E+^F'!SQ(:9\#[&ZWM?N("] _=XC=02P,$%     @ \H-S6-(]W^=4$0
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MZD>XS7#U4V;0P@:;UK%8PU1SOO#.6*9^'JR^%.F>?I*[2HLBW='E5G 0#@?
M\W4*&Z&_X +U;[3?_0]02P,$%     @ \H-S6.F:YBP) P  1P<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&ULA551;],P$/XKIX 02&5)G+1KM[92
MNX'@ 9BV,1X0#VYR;:PE=K"=E?U[SDX;.M1E+['/N?ON^VS?>;I5^MX4B!;^
M5*4TLZ"PMCX+0Y,56'%SHFJ4]&>M=,4MF7H3FEHCSWU0588LBD9AQ84,YE._
M=J7G4]784DB\TF":JN+Z<8FEVLZ".-@O7(M-8=U".)_6?(,W:+_75YJLL$/)
M1872""5!XWH6+.*S9>K\O<.=P*TYF(-3LE+JWAF?\UD0.4)88F8= J?A 2^P
M+!T0T?B]PPRZE"[P<+Y'_^BUDY85-WBARA\BM\4L& >0XYHWI;U6VT^XTS-T
M>)DJC?_"MO4=4<:L,595NV"R*R';D?_9[<-!P#AZ)H#M ICGW2;R+"^YY?.I
M5EO0SIO0W,1+]=%$3DAW*#=6TU]!<79^C26WF+^_XMH^PF*C$6G+K8&WMWQ5
MHGDW#2VE<<YAMH-<MI#L&<B8P1<E;6'@@\PQ?PH0$K^.)-N37+)>Q$O,3B")
M!\ BEO3@)9WHQ.,E_:*A%7VKN33<7Q(#/Q<K8S59OXX);V'3X["N?LY,S3.<
M!50@!O4#!O,WK^)1=-Y#.NU(IWWH\QNJQ[PI$=0:OC766"YS(3>PY"67&1JW
M_E38O],\IJ4WVW$MOH9!&.#[(G9)U0&9U9X,V>25H\FTJ'W]D:<1&RG6(N/2
M4D$35;?EA:CIM@D)ME"-H3CS[@P67@Z=.U8KU-W9NP^#RP9AK5758I#<VLE]
M\VK,XOC\*X$OA8+7$ _8).W&%X-^N#X(PS0&O\C.^T.66LA[&#%@I_%Q3X%F
MYWO'M2!M$!/YA WA5EE>0OY,$%%F@RB>>.KC2>31K7I![21-=M\>]TNZ/X]P
MK7@.<3(B^#2)^_QM@7!!5T-D,#R%.)J\Q*7=Q/T&3L:C ZW_A;5*XX$C\AJ2
M03J:P+$R"0^:6X5ZXUNX@4PUTK9]KEOM7HE%VQS_N;=/S!>N-X**O,0UA48G
MI\, =-NV6\.JVK?*E;+4>/VTH)<.M7.@_VNE[-YP";JW<_X74$L#!!0    (
M /*#<UA+QZ,[L 4  &@.   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM
M;)57;6_;. S^*T+6#1W@.;;\FJXMT';;W8#;5K3KAL/A/B@VDPBUK4R2F_5^
M_9'RR[(AS>6^V+)-4@_)AZ1UNE'ZWJP +/M>5XTYFZRL79],IZ9802V,K];0
MX)>%TK6P^*B74[/6($JG5%=3'@3IM!:RF9R?NG?7^OQ4M;:2#5QK9MJZ%OKQ
M$BJU.9N$D^'%C5RN++V8GI^NQ1)NP=ZMKS4^34<KI:RA,5(U3,/B;'(1GEQF
M).\$ODC8F*TU(T_F2MW3P_OR;!(0(*B@L&1!X.T!KJ"JR!#"^-;;G(Q;DN+V
M>K#^SOF.OLR%@2M5?96E79U-\@DK82':RMZHS>_0^Y.0O4)5QEW9II<-)JQH
MC55UKXP(:MET=_&]C\,A"KQ7X YWMY%#^498<7ZJU89IDD9KM'"N.FT$)QM*
MRJW5^%6BGCV_M:JX?W6)?I7L2M68:R-<N(X_BWD%YN7IU.(V)#PM>I.7G4G^
MA,F0LP^JL2O#WC8EE#\;F"*^$20?0%[RO1;?0.&S*/08#WBTQUXT.ATY>]%3
M3J^$AM[I:_&('+/L0FO1+,&M_[J8&ZN1,'_O\KZS'>^V345T8M:B@+,)5HD!
M_0"3\Q?/PC1XO0=Y/"*/]UD_O\6B+-L*F%JP)U/W]CNMP; ;J(3%KU:A,*Z<
M<ZCY:0W:B9I=_NU%L-N_SRM@"U5AA<MFR2PQA[FOC37,.)QSA[/8QBF;HFJ1
M(0S7%BT4"$A5LG28S0#8$&(U(F;'DJ15:T13FI<G[$\0NF,:0YY /0<]<H4N
MG"YA'ZT=**"+UDDG@3MUVQRQ,/+R/.X6/ ]H$7HI&KVYO3,L2CR>S1A/O7PV
M8W'B)4F.(O',"].(%H$7XO<CEF1>F/_W_AB-P4L,8?_2G& .#3I8K!BZB^WF
M =OHVN41X61>%(<]KI3V"G,O#V?L%IL<6O'8$AJT6#E=46+[D,1KZH,4HIQB
MDWM)&+ H]Z*4[\._A[S)2-[D_Y$7B>A"<$&M6=I'AW,@[?NF&SDDT&)Z,<G?
M6A*ZKL1NXN[??1='NU$D_X&>I7WVNUDQ -(](+D%"%>.LH]$/MA-OA/VL74O
M7,5UK/KJI@24K]C% V9F"5BLH N)^;_6L@!VL5QJ6.)^Z+_5$H=?P;Z(JH5?
M>+_#T@W0$";GKK#]4OMJ,?5_R$6G2U!1[U-KL;2:DN2$JZU?@7,V\WC*O1E/
M,?TS/\^(#EX>YRSS.?L-^R2%8X9423+B//>Q @8_2G8<YC&QZ241TD_HTUIJ
M**<8M 5(TCWF0>9E048BB9]$!Z"*$%7. R^.$H<J)G"I%^ ]]5/V!0P9IGQ!
MA\0E^"E;B9>GF<<3[JK'3V+G8ACF""?>0_5TI'IZ,-6'3(V)>B>D[I.Z18T[
MQ_'+2F";0'6%PW>H#Z(&1>:#*J':Q?S]8!SS:<^'84_S4ZN3QK0(;X/!PBC*
MVK%=6$=P:L:DL:2LL]:XVL'W/^/LRV;=XZP))_[(V)63_5%UFX&TH@^%P*WK
M#L;!G9S&6^'&&NB:Z!-TW,8E-L%A.1O>WDAS_VJA@3HL:J"'3)-3L1^PY\C=
M%*^!G^%U-/R@L.)E10T@#%/D_',6!J&?]W?2>X/]H<3"9X\2JI*]>);SD+_&
M#[M67W]UNXNFB^U68HXXE<)1[',<-KAO'NQA8C8R,3N8B3BX?O3:PWKJ7N.'
M_PQL-5H",?;7LM4#HPYMI7>-M+L:J>M+[ W%=*O /JKFH6L-<X$^%D^U!(Z]
M)$E"+\IS-T=]GHV=+O5B;%=QY)J%G_&AV1S'7H*#/XUCZF.9'T7LW=#BI@5M
M5I'4+,"9.LLZ&>R4AT**6.8E0>3-W!@.N1_LGL+3K;__&O32G7$,_F2TC>T.
M N/;\1AUT9T>?HAW9[ /0B]QYK *%JB*58$C57?GFN[!JK4[2\R5Q9.)6Z[P
M* B:!/#[0BD[/- &X^'R_%]02P,$%     @ \H-S6-WV+K0$!P  +!,  !D
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MK%"XR W1$+.2&PV!>G)"_LN9:H--$"I>+[CJPV4OU%X"\GEZ.WU>Q"LRCK/
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MC*S=<L49NJXEP/>E1/_K'JR _H#L_']02P,$%     @ \H-S6+S$%MG-!
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MB/EZJ;]K@],"JI*AT/2T*)5,CJN2B44E.U/'_'=??R\'9PA4)4.AZ1E2*IG
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M _G]75&(QYNZ@?9X].P_4$L#!!0    ( /*#<UB0OOM310H  *YM   9
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M16>(4/2E9!N!:2ZFKE0GUL]UL_9TU\WI@F=.%Z+/C,I2H)3FD/?H%\-Z/Q@
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M$L>J-U+5CJ!Y^5+GB0I!TW)SB]$*,U4@SZ\I%8<=]9ZH>2\8_0=02P,$%
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M:I\L7+==L\QM]N;;JB:UA5;GN]*DGEF3!CMZ3_@]N$ 128A\5K7J#[Y&E/S
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MK4+]1F+.^,PZ,FZ4DYNAGM#J,9LZ ?MO?V.OU8$OM'H"]CK@OEK@?GO@S6Y
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M[[1TA%9.B]0:IEIL?$L71MA+E@B8BI4>N,?)<M&/EJ*.1IR*A5F,@LSCC;_
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MBI9&L_.[[(:3=7H$-B><DS"]7&'D89H,$.\7A/"7F\1!<8HZ^0E02P,$%
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M:,)X/H_"*$ 2^_!"58 $Y&_U^,"$P *4_C=X)F&*YQ$GDJBA28"$( NBC)"
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M:U V )\OI33W$[M!^_]!_"]02P,$%     @ \H-S6("M ;Y2"P  87X  !D
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M#9OQF]EX6]8S[F+!+P6,3&>5 YB28B>5-KGH(6!G9EB$G!0MF3D1$&]WZK@
M";,Q.8-HM(S<S,8;LB[5Z&*Y, /ZS&:5,9B1 BJ5-MEV *B9BXS!S)PQB(K(
MG04BS,9D#.J*>;_'K[2>%!?K?!G 9#:KM+^,E#*IM,FV \K,B"OW9>:=851$
M[B<07>:"Z#*5Z/2EPG6"2*WP#(@M&T-LP>0=;5R]M;,YJ:XLE%>>%:1EM 66
MW518%DLLD]=8-B,:+C/HJU ZV1^#7EJW-U?9Q'5;EXJD4C<P!A>,,2O@>ND.
MF?V<%%/VA6K*/G4Y9=\,7(9&)P]+*+WLC\*S*5O<!M7V4^P"X)@OU%[V9X5P
M+]TALY^3\LN^4'_9IR[ [)LY#I<9]%6HO.R/2?+3^KU=]7&\'?M)=%*/V1<*
M,ONS2OA[Z0Z9_9S49/:%HLP^=55FWYSUA\L,CI808,YP8 8$P;1*Y%1G8QP&
MZ>BH#?&LC5GE_S'JLSJ<,*9X6@=^I,4$WV?F-RQPF4%?!9XS'(^A_@&8OOUM
M:,M^(IU0H7@@!YM5PA\C/L/#S2$>XBD>^%$7$Q>*7K3B1<JU4J>JE#/Q^ S#
M^1G:OP9_>3O<T*K]W+K8U&7BF1UL5CF!C/B\#S<'?H@G?N#'8DR.#4U-9K5T
MN:'QR<,3^,]P*L>(*!J_.VYHS'[RG2P?"L> ,#ZKY$)&>VH(F;J!_01"Q0_7
MF!H\7%.!65?0W-#\Y $*"&DZW<,</B.WRPTMV<^]DQ5(X1@1QF>5E\AHSQHA
M4S>PGP"U^)$<DV/G66LBX9:NS+E64E?G?"D<_]T?OOXQK^_*;>.MB]ON0O]-
M_WI'_7R<^?.'MGK8GPA^7;5MM=G_>%_DW1-)+]#]_K:JVI</_2'CQU/E+_X/
M4$L#!!0    ( /*#<UB=7B$8BA@  #Z+ 0 9    >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;,W=?V_;1I['\:="^(I#"Z2V2/WN)0'2<&8X@[8;--?N'XO[
M@Y886X@L>4G9J8%]\$M*LLDAJ9'H>]]!6&#K.-1K*.?[M4;\<$9OOZW3K]EM
MDFR\O^Z6J^S=Q>UF<__3U54VNTWNXNQR?9^L\K_YLD[OXDW^Q_3F*KM/DWB^
M?=#=\BKH]497=_%B=?'^[?9[G]+W;]</F^5BE7Q*O>SA[BY.GWY.ENMO[R[\
MB^=O_+ZXN=T4W[AZ__8^ODD^)YL_[C^E^9^N7I3YXBY998OURDN3+^\N/O@_
M&3\8%X_8'O+G(OF65;[VBN=RO5Y_+?Z@Y^\N>L4I)<MDMBF,./_/8_(Q62X+
M*C^1?^[5BY=!BP=6OW[6Y?;9Y\_F.LZ2C^OEWQ?SS>V[B\F%-T^^Q _+S>_K
M;U&R?T;#PINME]GV_[UO^V-[%][L(=NL[_8/SL_@;K':_3?^:_^3J#P@" X\
M(-@_(*@]H#\Z\(#^_@']V@,&ATYIL'_ H'Y*TP,/&.X?,#QUA-'^ :/Z P8'
M'C#>/V!<?T#_P ,F^P=,3OVQ3O</F-8?,#GT#]=[_I?K;2MH]T^^K9<PWL3O
MWZ;K;UY:')][Q1?;HML^/B^3Q:IHD,^;-/_;1?ZXS7L9+U+OSWCYD'B_)G'V
MD"9Y]6\R[T?OPWR^*$HX7GIZM>O$HJ"_#Y--O%AF/WC?>5=>=ANG2>8M5MX?
MJ\4F>Y-_,__ZOV_7#UF\FF=OKS;Y.18C7<WVYZ-VYQ,<.!\_\'Y=KS:WF2=6
M\V1N U?YDWMYAL'S,_PY<(IA,KOT@ND;+^@%?>^/SZ'W_7<_M)S81S=C'I8Y
M,[29ZL_@*6U!PU/0WF%T]Y\66+AAF5Q?>G[]; ]J\H0?H1]LM:#3::H3X+Y?
M.\VG]"0[.MT.NMKZ=-MWU)0YY5]IO'_ZUJDY"K__TMK]K=X_WMH?LBS)F_K#
M:N[]LHBO%\N\L_.GO^_XN?>WE?=[,GM(T\7J9GO4;^M5^O*-G^-LD7G_^"7W
M/;U)[K+_:7FJ/^].9M!^,L7K_$_9?3Q+WEWD+^19DCXF%^__\S_\4>^_VGJ1
MQ$(2$R0F24R16$1BFL0,A%DM-7AIJ8%+W[748]%2;[SKY&:Q6A7]L?[B/25Q
MVZ__GYU<UZ8@L9#$!(E)$E,[;+S%BC<+C^\#?]0?O;UZK%8[.:0F,0-A5K4/
M7ZI]Z*SVC^O\?= \27<3O_MX,6\K<:?1M<1)+"0Q06*2Q-0.&U5*?# =]@>U
M$B>'U"1F(,PJ\=%+B8^<)?Y;LLG?L,S2?"*4>-_/D]U7/Q1O8KZ\_*YOJWHG
MV[7J22PD,4%BDL34J%GUXU&O5ZMZ<DA-8@;"K*H?OU3]^.1I3)+/]AT3&"?4
MM<Y)+"0Q06*2Q-2X4>>^/QF/ZX4^/F6>H\DS,Q!F5?#DI8(G)U:PEVW6LZ_>
M_4,ZNRU^B:_OB]E*6RD[Q:ZE3&(AB0D2DR2F)HU2_G'2^(U-CJA)S$"85>_3
MEWJ?.NM=W%TG\WDR]_+I^.(Q+C*%MA)W(EU+G,1"$A,D)DE,31LEWJQP<D!-
M8@;"K KW>V42T7._W;R-5S>)/?4NIB;?XC2-5QMO65ZY;*M]M]ZU^%$M1#6!
M:A+5U%ZK3D3:YN7[PZS7 K\_&-6.TRU<[1!#G;]=M97\S#\^$_ES-Y=^OK;^
M]*9R.7U[]?R-]\=J?5V,'E\O$T^O[A\VQ3'KU2Q_P/8"RQM/Q7GM?__+.LM^
M>.-]WL2;;197M(!>S=9W>3.DWL?U7?XT;HN$^C%Y_OX_Q%^;XCL%+58/=_M+
M-JV7Z=U/IW.;D%J(:@+5)*JI(T7UO_M5&*'GJE'-4)K=KD'9KH'S)_LI7=\M
MLFR=/GF_K3=)YOW+^V[8&^Y&N%LLE\6ESC"9)?F$*]WE<K6'Y(_X\.7+MFOS
M^9A8;?)^;VTTYXET;C12"U%-H)I$-85J$:II5#.49C=6&3;[9Y4V^VC<C&HA
MJ@E4DZBF4"U"-8UJAM+L[BIS9]\=/'_*6V.VN(^77GRW?EAM6EL"#9M1+40U
M@6H2U93?3)SS^46O^0X(S9Q1S5":7>QE[.R[<^=/:7(?/VW?^\3YJT,\FZ4/
M^<O&8K5)\N$VWL-]/D?+[I/9XLLB__XFGQ)G\>S095_W8)W; DVH44V@FD0U
MY3=3ZJ(I&EV!QM2H9BC-[HHRJ?;=4?7'=?Y6(W]7F'?%K'IC1FO-H_$TJH6H
M)E!-HII"M0C5-*H92K-;HXRS_?%9O?= 0W%4"U%-H)I$-85J$:II5#.49G=7
M&;7[IV;M)][TZO8Z]P<:M:.:0#6):LIOQNW^M#[=:AXSZ$WK&4SSH.DXJ*<P
M_Q?IN%_&X[X['S_M5E4WTKDPT8 <U02J2513?C,D;[P-:![2[S?JLGG0H%[A
MACIU>^E9F6D'[DS[U?>7NMVNI8IJ(:H)5).HIH*VF+I6JRW'#&O'Z)9C_$'M
M#FU#G;I=JF60'9P09)]V4ZA;ZER<:(:,:@+5)*JIO6;=\UG_1;H_QC4)T"U.
M8Q)@J%.WB[.,;0-W;/MY>Y/GI^>;/(O+@G_;WNCI?;A)D^U]$JV%BF:PJ!:B
MFD UB6H*U2)4TZAF*,WNDC*##<XJ@PW0#!;50E03J"913:%:A&H:U0REV=U5
M9K"!.X/]'"_S#LJG1;L5!XLLVZ52QP*HH)D(^LWHXZ-[],[UCP:NJ"913:%:
MA&H:U0REV?5?QK+!L5BV6'F0>)^6^1@'9UQHVHIJ(:H)5).HIE M0C6-:H;2
M[)XH0]E@=%8S+C371;40U02J2513J!:AFD8U0VEV=Y6Y;N!>I_SJ&1<:T*):
MB&H"U6307$4\&#=FJ@H=-$(UC6J&TNSZ+Y/7P)V\_K[(OO[X)4T2+XVW"P].
M7 ;J9CO7/QK HII -8EJ"M4B5-.H9BC-;I,R_ VF9S4)0U-D5 M13:":1#6%
M:A&J:50SE&9O(EE&V'UWA!V^O-2\+#M\>N/-%]FL6(BP?65JZQ*WVK5+4"U$
M-8%J$M747O/[U9LM+OV@'F*CHVI4,Y1FUW^9B_?=N7AU,6C@_7VW K=U!P(W
MU+GDT5@<U02J2513J!:AFD8U0VEV8Y29?#\XIVE7'\WR42U$-8%J$M44JD6H
MIE'-4)K=797-NYUI9O>[KMU>Y_Y@=^!FM^!F]^!F-^'N-V_*:MEP&!U4HYJA
M-+OPRYB][X[93[N5VXUTKG8T>T<U@6H2U=1><]W*W7)(?]B;UG>F1,_+4)I=
MPF52WG<GY:^^Z]OM=JYJ-#U'-8%J$M54O[E6^<?!<#"L5W;+86U[F*$G9RC-
M+NTR\.Z[5R%WN$O<+74N9C2L1C6!:G*OC:W?F'XCA6LYS!_WIHTK.\W#VG8&
M1I^"H32[2,O<N._.C<5?23I;Y+][[]/%K+IQ6N9]G_\.GJ^7RSC-O/LDW7W:
MS@_%+F '/GIG7\MHHHQJ(:H)5)-[;5JIOM'EJ%[):)Z,:AK5#*79?5'FR7UW
MGMQ^*3,O_I-N[7/CG7L 39513:":1#6%:A&J:50SE&8W2YDJ]\\J5>ZCJ3*J
MA:@F4$VBFD*U"-4TJAE*LS]'K4R5!T<61C]L7XBJ4[/UPR;;Q*MYT3/%-&TW
M&ROF9H?G9>Y1NG8-JH6H)E!-#IH+DJ>][?]J<[-3#XQ./5"C3\10FEW&93@\
M<(?#91EGQ>_[W>O"+%XN\U>%ZR?[;<=)]8Q&R*@6HII -3EHKG,^4,]H.HQJ
M&M4,I=F=4:;# _>*[8/O-6IOSE_>A+>V YKYHEJ(:@+5)*HI5(M03:.:H32[
M9\K,=W!6Z[<':&*,:B&J"523J*90+4(UC6J&TNSNJGQVLSM8WO?.=E_AQ?8#
M6(Y=]76#G1L$#9E13:":1#6UU_R!ZR)R=-)1&CTS0VEV09<Q\\ =,SNF6/?)
MK/ATDDV2WK46-IHSHUJ(:@+5)*HI5(M03:.:H32[4<K0>G!6J[0':/"-:B&J
M"523J*90+4(UC6J&TNSN*M/V@3MM;YM7/;7>$>*&.C<&FJ*CFD UB6IJT/*1
MTLU/8F@Y*F@<I=$S,Y1F%W(9CP]>&8^_S*?BQR2-;Q+O<;V,-]N5<*UEC@;E
MJ!:BFD UB6H*U2)4TZAF*,UNFS(H'YQ54#Y @W)4"U%-H)I$-85J$:II5#.4
M9G77L S*A^Z@O#&[:NL)M]&U)U M1#6!:A+5U+!EL;5_V?C0A;;#>I?3:6T_
M<(V>G*$TNXS+H'SXFE74U;G5?/&XF!>WE#\MDF7KFA_W$)VK' W'44V@FD0U
MA6H1JFE4,Y1FMTR9H _/:GWU$,W:42U$-8%J$M44JD6HIE'-4)K=7676/G2O
MKSYM7H4FY*@6HII -8EJ:J^Y5ID>/T2CYV0HS:[>,LL>NK/L@].I<LO EX_+
M/;1#DWN(SL6-IMNH)E!-HII"M0C5-*H92K-;IDS+A\.SFDZA$3NJA:@F4$VB
MFD*U"-4TJAE*L[NKC-B'[G7AITVGT& <U4)4$Z@F44WMM=KUI]Y@7)]3'3BN
M<9T*#;,IS:[C,LP>NL-LF5RG#W'Z5$RL^L[=_MQ0YV)&PVQ4$Z@F44VA6H1J
M&M4,I=F-48;CP\E939_0#!W50E03J"913:%:A&H:U0REV=U59NA#]^=7=][M
MS^UU[@\T!4<U@6H2U=1>JVZNT[@RA4;;J&8HS2KZ41EMC]S1]FD[_;F1KI6.
M:B&J"523J*9&S>7=07\TG=2J'1U4HYJA-+O:RP1\=&2I^&LW!72[G1L C;U1
M3:":1#4U:JXP#T9!?;._"!U4HYJA-+L!RCQ[Y%X1WF'K0+?4N>31+!K5Q%ZS
MMN?KC^OW64MT4-4RZ& Z'39^F3</JX=JZ'D92K,+M(R$1^Y(F-\VT#U@YSK>
M:9/*OT?_,I@.:HL<0W14@6H2U12J1:BF4<VT_-L/+H/J/IYVT9=)\LB=)'^\
MC5<WB3T+J93^RV?^+ Y4.!HB[[7J;YQQO_[+,$3'%*@F44VA6H1J&M4,I=E=
M4(;#(_=2ZO;+_J?NC.G&.S<!FO6BFD UB6H*U2)4TZAF*,UNEC+K'9W5<NH1
MFAJC6HAJ M4DJBE4BU!-HYJA-+N[R@1ZY$Z@H9TQW:-T[AHTGD8U,6I9SSSH
MC8.1/ZR_BT:CYY/'C4X^4J-G:"C-KN0R,AZYUU,?G%1UV0+0/4;G.D:#8%03
MJ"913:%:A&H:U0REV3U3!L&CLUI,/4)C9%0+44V@FD0UA6H1JFE4,Y1F==>X
M3)S''1=3'[V"ZP:[-@BJA:@F4$VBFMIK_O#(I>\('5:CFFE[$JYKN.,R6AZ[
MHV7'1.O(1H!NN'-YH]DRJ@E4DZBF4"U"-8UJAM+L1BDCZ/%9+:D>HS$VJH6H
M)E!-HII"M0C5-*H92K.[J\S/QQV75!_<"- -=6X,=%TUJ@E4DZBFQLU%T\&H
ML1$@.J9&-=/V#*J;%-J%7&;B8W<F?GP^==I&@.YA.I<YJ86H)E!-HII"M0C5
M-*H92K/;I@S1QV>UPGJ,INZH%J*:0#6):@K5(E33J&8HS>ZN,G4? RNLW4;G
MGD"S<E03J"9138U;5D[[E[UQOSZU0E-P5#-MSZ%W.1T?F%N5\?;X-0NLNVT$
MZ!ZB<Y6CV3:J"523J*90+4(UC6J&TNR6*7/T\5DMO1ZCB3NJA:@F4$VBFD*U
M"-4TJAE*L[NK3-S'[J77I\VKT)P<U4)4$Z@F44WM-==&@.B &M6,\_2MZIV4
MB?;$G6@?G$YUV C0/437XD:U$-4$JDE44Z@6H9I&-4-I=LN4:?G$/Z?IU 2-
MV%$M1#6!:A+5%*I%J*91S5":W5UEQ#YQK_(^:3KE-CKW!!J,HYI -8EJ:J\U
M-OCS:W,J=%2-:N;0<SAP3]6D#+,G[C#;/"Q/V 30C70N9#3(1C6!:A+5%*I%
MJ*91S5":W11E,#X9G-74"<W/42U$-8%J$M44JD6HIE'-4)K=765^/CFR"+WK
M)H!NKW-_H DXJ@E4DZBF]IIK$T!T0(UJAM+LHB]C[8D[UCYM$T WTKG2T5P;
MU02J2513>\VZW6XXZ=<78:"#:E0SE&97>YE^3XXL[G[M)H!NMW,#H)$WJ@E4
MDZBF)BT?BCV<3.KKO=%!-:H92K,;H,RR)T?6A)^^":!;ZESR: Z]U\9V(=3O
MG1;HH!+55,M3&/KCH''QIWE8?1- ]+P,I=D%6L;!$W<<W+SN<^HN4&ZX<[VB
M&3&J"523J*90+4(UC6J&TJQ&F9;)\[1W3M>"IFA(C6HAJ@E4DZBF4"U"-8UJ
MAM+L[BI#ZJE[2??G>)EW4#X[RC;KV5=OD64/>2/E;Q,V^6M2%L^*=\NM;8*F
MS:@6[K7J5*(_'C8F3>B@$M44JD6HIE'-4)I=_V6,/'7'R- N:.Y1.K<#&C2C
MFD UB6IJK]G[GPU'TV!:OW2$CJM1S5":W1%E(#W]_]Z=W#U@Y^9 P^OI:7N=
M"W14B6H*U2)4TZAF*,UNC3*6GCJ#N<J+15:\J]B]^YC%RV4^9;I^LOODI%<-
M-'=&M7"O'?]=*M!Q):HI5(M03:.:H32[-<I,>>K.E%LO9W79?]/M=^X%-&-&
M-8%J$M44JD6HIE'-4)K=+V4</3VKO<VG:*Z-:B&J"523J*90+4(UC6J&TNSN
M*N/OJ3O^[K[_IAOLW" [[>@^DB$ZK$ UB6KJU!])A ZK4<U0FEW69:@]=8?:
M!R991_;>=*.=2QO-MU%-H)I$-85J$:II5#.49C=)&:Q/SVIG\RF:QJ-:B&H"
MU22J*52+4$VCFJ$TJ[O\7AG'%U]WG5NU[[YY1.K:&\]<]9)4O]?XU#YV5,%R
MDN54V\^D96]-=E3-<@;C:C7M5VK:G8*[)U:G;<)Y9(SNU8YFXBPG6$ZRG&*Y
MB.4TRQF,JW5/4.F>L]KM_/ETL$9#TW:6$RPG64ZQ7,1RFN4,QM4:K5]IM(X;
MG[>W!QJW/W.U32;K]V^'[+""Y23+J0,_E.;.F^RXFN4,QM4J>E"I:'>B[IYX
M'=^A\XC?O=C1#)WE!,M)EE,L%[&<9CF#<;7.&58ZYZPV07\^':S1T(">Y03+
M2993+!>QG&8Y@W&U1AM5&@W8#_T(TKT]FBN@F]>YT-R<Y23+J1-^(!$[I&8Y
M@W&U0AY7"MD=BK?.M3ILWWG$[U[CZ.)PEA,L)UE.L5S$<IKE#,;5.F=2Z9RS
MVAC]^72P1D,C>Y83+"=93K%<Q'*:Y0S&U1IM6FDT8(_T(TCW]I@VK^446SL.
M&Q,N-$YG.<ERZN!/I;YO SNN9CF#<79)^Y6XW#^R<?K+:\<;KU+>V9OR=:*U
MR-ULYR)'N9#E!,M)EE,L%[&<9CF#<;6&J63Q_EEMF_Y\.EBCL;$]R@F6DRRG
M6"YB.<UR!N-JC5:)[7WWTO=]=]T]=U.\.;(WW!&P>ZNPP3O*"9:3+*>>.6MC
ML-&X/VP$D'[+FOC>I!<,:IMKL2=H,*Y6WI6PW'>'Y2=,O+Q_>;\DC\G2"]K+
MG0W242YD.<%RDN44RT4LIUG.8%RM=2JIO#\XKRD8&^*C7,AR@N4DRRF6BUA.
MLYS!N%JC54)\W[UJ_A53,#:&1[F0Y03+2993SUQU9C6M7S2,VHX:^*/Z[7.:
M/3F#<;72KL3FOCLV/VWZ]3'_JKC8NV^$_!MQ=NO%^>O(K/@B^>?#(N^%Y,"G
MXAPYA^[=@*YK9SG!<I+E%,M%+*=9SF!<K;LJ6;X_/J\9&AO]HUS(<H+E),LI
MEHM83K.<P;A:HU6B?]^]Y/X5,S0VO$>YD.4$RTF64\^<O3AR.&BY2-8\T.\-
M1O6P4[,G:#"N5MZ5P-UW!^[T+.W8%34VN4>YD.4$RTF64RP7L9QF.8-Q=I\%
ME;L @K/:Q/[Y=*A&0[F0Y03+2993+!>QG&8Y@W&U1JO</1"X5_)WGZ^YP>ZM
MPN;_*"=83K*<>N9<GW#X?(QU/:TWGC1F:NBI&8RK%78EK0_<:?TK9VIJ_9BD
MJ^+('[/[]2I;%TU1V;WX]7,Y]_EV[QOV9@"4$RPG64ZQ7,1RFN4,QM4ZL7)C
M0= _K[D<>QL"RH4L)UA.LIQBN8CE-,L9C*LU6N4VA,"9O[YF+L?>2(!R(<L)
MEI,LIU@N>N:LO=^"QN9OFAW68%RM!RIW" 0G?%;[*R[0K=/[=;&0TYLGUQMH
MPL?>>H!R(<L)EI,LIU@N8CG-<@;C:CU8N94A.*N]^I]/!VLT]JX&E!,L)UE.
ML5S$<IKE#,;5&JUR5T/@WJ'@%1,^]KX$E M93K"<9#G%<M$S5[T6.&E\\+EF
M1S48MVN!J^PV239AO(G?O[U+TIOD8[)<9MYL_;#*^>+:W\MWO33Y4G3(3Q^"
MBZO&]Y7_D_:+[U^5S/NW]_%-\FN<WBQ6F;=,ON1D[W*<OUBFBYO;ES]LUO=Y
M$UYXU^O-9GVW_?(VB>=)6AR0__V7]7KS_(=B@&_K].OVM-__&U!+ P04
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MD%1U2;N@,Q*[J@L)<R!A;@G#]J&\EZ,C@2%;](%@+2-@JRFG6.!K>S.RJQ=
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MGP9I\.7#*1\)7T>I0#%=J::LR\FHAWCYO$=Y(%E6/&[PP*1D2?%R0XD:Q/(
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M?IA[V'L^\)FM-\H<\!>S+5G3!ZJ^;N^%WO-;E8P5M)2,ETC0U=R[QE=)&)J
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MU7RH1J%: -5"E-:,5MW]8>F[/VYC*5+R)1(/\X@G<W[TI+W>.3L^T X/J.9
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M^:40\O5._OTB^^_VF?T/4$L#!!0    ( /*#<U@%Q954,@,  #,,   9
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;+677V_:,!# OXJ555,KK20._SM
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M!_1&7^_'J$^TB>A"JE)I>RUN5$(BZ'HF[A7(-7B]CQ]P(_A<PE;-V*I.>_4
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MCR7$M8%ZOF!,/@QT.]Y\?B7_ %!+ P04    " #R@W-8BV#5Y9X"  #P!P
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M?(56S\3PI:)4]DLV3>S4<TBZ4EI4+1@KJ!AO_O2I]6$'$$P. ((6$+P$C \
MPA806J%-95;6)=4TB:78$&FBD<TTK#<6C6H8-ZMXKR7.,L3IY ;0 W(N)>4Y
MX.IH18[)?;.D1"S)-6]VBK'\#G(J,\9S8E&*?+H$35GY.78UEF((W;1->]&D
M#0ZDO81T1$+_B 1>$/; YV^'!_MP%PWH7 @Z%P++%PZYH,BO\X72$G?6[SY%
M#<6XG\*<MC-5TQ1F#AXG!7(-3O+Q@Q]Y7_KTO1/9GMJP4QL.L2</=F]#=DS7
M(/&HXFDTY]TL;&FW@P99'9'O-<[J;E3U>3*<*"+/0*4B :D$UX4B?D R^MS'
M-'\;TW3+%/40[9DQ[LP8OX<95XQ3GL* %<-I3CL+3@Y:,,S@6PO(,-&>!9/.
M@LF_69 QE8H5UP37']ZV$9H,OF=3F*=CG7@CWSN-W?6NQ -ADRYL3T#4"8C^
M2\#KBQ?UUN5/7Y3_:EA3OKMS'YNW\!N5.>,*\R\1YXVF:(-LWI>FHT5MK^B%
MT'CAVV:!3S)($X#S2R'TMF-N_>Z13_X"4$L#!!0    ( /*#<UB@P=A4- ,
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M4 \!FO(Q(@!4&0 .A@!C>H%Z"M"4CY$!H H!T)X"3L47J < 3?D8](<*_W"
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MUZ?VK5>\T%!CBO<KOE&^#!-!(E@HI'4]4%M*7KRR4)Q(EN:_R<^9E"S.#U=
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MFR2H5J*:V&GU"6-1GS"B%1%4TZAF4,VBFJ.T,#951:0?KXC4)HQ9[WD31K1
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MKE6_M4C=\)C]_YZ_7&?OY\577JUCDW<HE[.<8#G)<HKE-,L9EK,LYUC.LUS
MN%8?J27OAN.37:UC\W@HE[.<8#G)<HKE-,L9EK,LYUC.LUS N%:#J*7[AO%T
MWW&K?/:.Q5ONY54^F^E#.<ERBN4TRQF6LRSG6,[ON&'\_1FP89O%.ZJ%^D;Q
M4%_75?Z6:V\NV5[HQT?M_%&-<H+E),LIEM,L9XY[ UAV5,=RGN4"QK6JN):H
M&W6_1?#KK+:YZ(?B;OWT9=P_ON*/'T;G3W&4RUE.L)QD.<5RFN4,RUF6<RSG
M62Y@7*N;U.)WHY/=4'C$!NY0+F<YP7*2Y13+:98S+&=9SK&<9[F <:T&40OZ
MC8Z]H7!D>Y^XT;T5L"F]T8$<W($;0 AV7,ERBN4TRQF6LRSG6,ZS7,"X5I'7
M8GJC:#R("^''Q^G>"!ZY>AHZ?3/I[>T;?-SC!'MXDN44RVF6,RQG6<ZQG&>Y
M@'&M J^E\T8OI?/^G+A^_#"ZUS^[S]_HP 9IFT#\_D2 3?BAG&(YS7*&Y2S+
M.9;S+!<PKM4G:D' 43P(V"FO'[>Z%SL;&!SMI]320Z7.!@%13K&<9CG#<I;E
M',MYE@L8URKU6F9P%,\,'G4I?VLTK@ =6#J?[Q[XTAH[?^&HNI^78Z-Z**=8
M3K.<.?;%M>RXCN7\L6^]@(W;*KE:O&X4W]BN\P7X_4V_]@N/#<JAG& YR7**
MY33+F2->?<L.Z5C.LUS N%;]UM)OHWCZ[027WK_RQI[Q ^X^!6=WV4,YP7*2
MY13+:98S+&=9SK&<9[F <<V^,ZX%]\9GI[I(/V9WV4.YG.4$RTF64RRG6<ZP
MG&4YQW*>Y0+&M1I$+1,XCF<"C[ZQ9]SIW@[84!_*"9:3+*=83K.<V7%I5E]]
MO#D;MQ<@Z+".Y3S+!8QKU7DMK3<^9K.\Y@+DQ^E\G9Q/[V;KZ<VW#W_[UV+Y
MZ^K;Q/OSQ[^?;T[F+S^4DX3SXN9F^P_3^>7#/X;%Q]E-L?VA^+U<BVQF&I.W
M:?KV80US;%PX?N3=.PN;!D0YP7*2Y13+:98S+&=9SK&<9[F <:T&5$L#CGLG
M6XFP&4&4RUE.L)QD.<5RFN4,RUF6<RSG62Y@7*M!U)*$XVB4Z;BX<-SHW@I(
M+M]Q+UT6$^RXDN44RVF6,RQG6<ZQG&>Y@'&M(J^E"<?Q-.%_CV5(^;,P7?Y:
MK),OL^+FLOSK/V;SQ>VL[#WE)&6]B3'?+BZ+F\,MB TJHES.<H+E),LIEM,L
M9UC.LIQC.<]R >-:C:H69QP/3[9<8<.-*)>SG& YR7**Y33+&9:S+.=8SK-<
MP+A6@ZB%(,?Q$.2'V?5\=C6[V$Q>[N>+CYLQIIMIS6Q^=[_)/OOB<W&3])+/
MTYO[Z:9S'$YJ;8=)&XN&WIM>.ZT5/YSN;8 -4Z*<9#G%<IKES)'O ,L.ZUC.
MLUS N%9]UQ*7XWCB\K_-2N7GV>K7[ZZ6Q::SU*_5=ENTL'LLHES.<H+E),LI
MEM,L9UC.LIQC.<]R >-:/:N6,AU/3K9H8>.@*)>SG& YR7**Y33+&9:S+.=8
MSK-<P+AF@YC4XJ"3^#Z.U*)E.TQCRCIXD[77+/&CZ=P%4$ZPG&0YQ7*:Y<QQ
M;P#+CNI8SK-<P+A6==>RG)/N^SO^)4L6\?M=<;'YR;0\GNEUD7Q>E!.3\F$/
M_]IAV1+_A3O/2E N9SG!<I+E%,MIEC,L9UG.L9QGN8!QK;Y5RZ9.3K:3Y(3-
MCJ)<SG*"Y23+*9;3+&=8SK*<8SG/<@'C6@VBEAV=Q'>2Q)8MO?U9:YI.]B^V
MQ(^G>Q]@(Z(H)UE.L9QF.7/L6\"RXSJ6\RP7,*Y5X;7PYR2:/#OQTN7HKZ+$
MC[+[=(+D<I83+"=93K&<9CG#<I;E',MYE@L8UVHVM1#J9'"R]08;_D2YG.4$
MRTF64RRG6<ZPG&4YQW*>Y0+&M1I$+?PYB>]EB6UJ'1^G>[M@HZ H)UA.LIQB
M.<URAN4LRSF6\RP7=MRD<2EJ.'I:T+7:0"WB.8E'/)_VQBA^OROFJR(I^T%S
MT^O'I<K=],OF;,3A#L#>_1KE<I83+"=93K&<9CG#<G;'-4YS#'OM;R(Z=EC/
M<@'C6BV@E@*=Q%.@[Z^OE\7U)FYY5WT]=7Z93"\NEO?E$F(7R3Q<^VSH$N7R
M'=?8_'1TZ,NJZ+B2Y=2A7V,P'+9_"\T.:UC.LIQC.<]R >-:55W+24ZZ[\9Y
MVK.-7_6-T_AOT[V/L-E,E!,L)UE.L9QF.<-REN4<RWF6"QC7:$K9697-W/SY
M-&<E=S+4(%@N9SG!<I+E%,MIEC,L9UG.L9QGN8!QK0:1UAI$/-X)I2!VPZ2]
MVI3Y[$TZZK=2$"\<3_<^@,8E64ZRG&(YS7+FV+> 9<=U+.=9+F!<J\*S6H7_
ME9MTGO#[I2_\8MUG(&@.D^4$RTF64RRG6<ZPG&4YQW*>Y0+&M?I3K]:?3K6'
MYT[&&@0:T&0YP7*2Y13+:98S+&=9SK&<9[F <:T&T:\UB&AVBUNB] _-3\_:
MM^4^?^%XNO<!DA,L)UE.L9QF.7/L6\"RXSJ6\RP7,*Y5X8-:A?^5&WB>^/ND
M+_QRW6<A:'R3Y03+2993+*=9SK"<93G'<I[E L:U>M2PUJ-.M7?G3L8:!!K8
M9#G!<I+E%,MIEC,L9UG.L9QGN8!QK08QJC6(/V7OSMTPK3GJN#_96Z:@L4V6
M$RPG64ZQG&8Y<^Q;P++C.I;S+!<PKE7AXUJ%_Y6[=SZ7\)K-9[?WMX=;!9H%
M9;F<Y03+2993+*=9SK"<93G'<I[E L:UVLZDUG9.M0'G3L8:!!KR9#G!<I+E
M%,MIEC,L9UG.L9QGN8!QS0:1UD*>:7P#SJ>OE/U<]HF#?2 .=.X#*)>SG& Y
MR7**Y33+&9:S+.=8SK-<V''M>U3W#G]G-$MK(<WTK]R#\]FOEOS^[,(C?KS=
M^PF;"44YP7*2Y13+:98S+&=9SK&<9[F <:VV4TN.IJ?:0G,G8PV"C6ZBG& Y
MR7**Y33+&9:S+.=8SK-<P+A6@ZA%-]/X%II'+#S8A";*Y2PG6$ZRG&(YS7*&
MY2S+.9;S+!=V7'OA,7QNX5&+7J;1Z->S"X^'I<;A@B>C:><LE[.<8#G)<HKE
M-,L9EK,LYUC.LUS N%9?J 4VTU-M=KF3L0;!IB513K"<9#G%<IKE#,M9EG,L
MYUDN8%RK0=32DNG1FUTNKI*+O6G$9N_+QRTN-QM>/K_9Y0OC=&\7;'82Y03+
M2993.ZZ^^]MD,AY.LO:V6.S AN4LRSF6\RP7,*[5"6JQR#0>BWSIVD62G:6#
MY,?R7\K9Q,.6E\=NK/_"R-U[ YNG1#G!<I+E%,MIEC,L9UG.L9QGN8!QK092
M2UVFXY.M-=A\),KE+"=83K*<8CG-<H;E+,LYEO,L%S"NU2!J^<@TOO'F3T^;
MZ+Z_7=S/#VZ;^X+1O16P24B4$RPG64ZQG&8YPW)VQS5N:3S(LF%KRVQV6,]R
M >.:-9[5(HY9/.+HB]7J^^27^?1V4:XE_EU.!_+9ZF)3[8=/&\2YSN6.<CG+
M"9:3+*=83K.<83F[XQH;AZ?C<;O:T5$]RP6,:U5[+>^8=<\[OAZ<#1X'N9W=
MW&RF_WEQ4=Q^+);)PTW#?UHN;F>KU6+YY?%DPK$G$>*'TKU3L%%&E!,L)UE.
ML9QF.<-REN4<RWF6"QC7ZBBU*&-VLBACQD8942YG.<%RDN44RVF6,RQG6<ZQ
MG&>Y@'&M!E&+,F;Q*.-1)Q'B1O=6T-N?+)X-]FZ6D[/C"I:3+*=83K.<83G+
M<H[E/,L%C&L5>2W.F$6#4:=:5WS-?7A>..3N/87D<I83+"=93K&<9CG#<I;E
M',MYE@L8U^H\M<!D=K+ 9,8&)E$N9SG!<I+E%,MIEC,L9UG.L9QGN8!QK091
M"TQF\< DM7O<=IBT?L$IZ[W)VIO'Q0^G>QM@@Y H)UE.L9QF.7/D.\"RPSJ6
M\RP7,*Y5W[489-8]!LDL/9!;[<2/OOLD@XU2HIQ@.<ERBN4TRQF6LRSG6,ZS
M7,"X5A.J12FSDT4I,S9*B7(YRPF6DRRG6$ZSG&$YRW*.Y3S+!8QK-8A:E#*+
M1RFQ5<AD?P[:?[-W+]#XT73O FR*$N4DRRF6TRQGCGL#6'94QW*>Y0+&-:N[
M5PM1]N(ARM.M0;![Z<1_@\[3#)3+64ZPG&0YQ7*:Y0S+699S+.=9+F!<JQ'5
M\IV]]%3KD!X;UT2YG.4$RTF64RRG6<ZPG&4YQW*>Y0+&M1I$+:[9B]^SG%J'
M;(>IST+3=-Q>AL0/IGL38".9*"=93K&<9CESU.MOV4$=RWF6"QCW6-MO5Y^*
M8IU/U]-W/]P6R^MBL]7T*GGX9E99\J]J/TV6Q559^NGW[[-7;_=^;M+O7;KY
M^=N*>??#7;F6"-/E]6R^2FZ*JY(\>S,:O$J6L^M/3W]9+^[*E>:KY.-BO5[<
M/OSQ4S&]+):;!Y3_?K4H%R[;OVP&^&VS>=WFL-_]?U!+ P04    " #R@W-8
MCU2JU<T$  #\&P  &0   'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6RUF6UO
MVS80Q[\*H15# S212-FRD]D&&BOI"K1%D+3=BV$O:.EL$Y%$CZ3M!-B''RDI
MDF4K:@S0;V(]W?_(GW3'NW"TY>)1+@$4>DJ33(Z=I5*K*]>5T1)2*B_X"C)]
M9\Y%2I4^%0M7K@30.#=*$Y=X7N"FE&7.9)1?NQ.3$5^KA&5P)Y!<IRD5S]>0
M\.W8P<[+A7NV6"ISP9V,5G0!#Z!^K.Z$/G,KE9BED$G&,R1@/G8^XJN0Y ;Y
M$S\9;.7.,3)3F7'^:$X^QV/',R."!")E)*C^V< 4DL0HZ7'\6XHZE4]CN'O\
MHGZ;3UY/9D8E3'GR%XO5<NP,'13#G*X3=<^W?T(YH;[1BW@B\[]H6S[K.2A:
M2\73TEB/(&59\4N?2A [!H2\8D!* [)G@'NO&/BE@?]6#[W2H)>3*::2<PBI
MHI.1X%LDS--:S1SD,'-K/7V6F??^H(2^R[2=FMQ#0A7$Z(X*]8Q"F"ETCFZD
M8FE^^98R@7[29 V(S]&49QL0BLT20-^X O0^!$59(L_0.\0R]'W)UY)FL1RY
M2H_->'"C<AS7Q3C(*^/ !'WEF5I*=)/%$#<%7#VI:F;D96;7I%,QA.@"^?@#
M(A[QT8^'$+U_=]8RL.D;9,BPD&DQ#]\^"M(^BL;L_.J]^;FN_Z;W]EW03-(B
MDO[^HA]%GQ6D\I^V]U#H]MIU39JYDBL:P=C1>42"V( S^?TW''A_M+&S*19:
M$FOP[%4\>UWJ$_UI2Q:#H#G#%65Q&[M"8Y!KF(RZF?0N^WYOY&YVH71Z.A:*
M);$&E'X%I=\)Y9M>=U@6Z?5$ZEB/H3@Z,Z$^-XEA8Q)#&Z="-MCE- @\;X]3
MI_-C.5D2:W **DY!)Z?;"H;)DELJ=#BJUB08'(#!>#@8[)/I='<LF>#@HR4X
M\(/*96/*@VK*@U_%2[449'HI:)UMI\2QJ<:F6&A)K(%N6*$;GBAU#VWRM"D6
M6A)K\+RL>%Y:2-V7!Y%'+H?]_<#K]'0L%$MB#2C8JPL[[S3)N]3=1>4'Q//W
M4'6[/Y:5+;4FK)TJ&'?"^J0[)*2_GM@4P/"D6+98,[G4#8[2!;E:(GW % .)
MUKH\%2CB::H?CW3)*GC22A$?4#SW Z]_@+%S8$=CM*36Q$AJC,320E@*[:Y*
MON<=E C=_HZF8TFM2:<NV7%G!7NX9J+_T,W32G? >C707?>CCMAG!DEK_NK6
M/C;Y6U4+;:DUN=:E.^Z=:$'%-DOUJ56UT)9:$VI=^N/NVO^!+3(V9Y$.8)WS
M^,QXH.;+9=EJK>0'] 4VD" _#_=\Z6V/<YM%_K14P_Y.VO NB-]OIHW0EM<F
MN[H=P-W]0&>@4WV++@!MN/YJ6<+4<RLWFRW U*I::$NM2;?N//#@5.%NM2&Q
MJA;:4FM"K7L2W%FB6PMWJRU*J=8(=WSA#_>C_13=!Z[;#_S+_N,@VN^9?#R?
M"P"DVY+V*MMFJS&UJA;:4FO^W[;N7(AWH@ G-GN2J56UT)9:$VK=X9#N#L=2
M@'=[.9HP;EO/O3[9BW!;7@MV[LYV20IBD6\[2=W,K3-5[)Q45ZNMK8_YAHY;
M/U[LBWVE8L$RB1*8:U/O8J +#U%L-14GBJ_RS9<95XJG^>$2J&XAS0/Z_ISK
MC%&>& ?5AM_D?U!+ P04    " #R@W-8T?7<U4,&  #/.0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970W-2YX;6RUFUUOVS84AO\*X05#"ZRU1%FRG24&4HM%
M,RQ#D+3;Q; +QJ9CH9+HB72<#/OQHSXJFI+"6=O136++Y$/J/1:/7A_QXL"S
MKV++F$3/29R*R]%6RMWY>"Q66Y90\9[O6*H^V? LH5*]S1['8I<QNBXZ)?$8
M.TXP3FB4CA87Q;';;''!]S*.4G:;(;%/$IJ]?& Q/UR.W-&W W?1XU;F!\:+
MBQU]9/=,?MG=9NK=N*:LHX2E(N(IRMCF<G3EGA,OR#L4+7Z-V$$<O4;YJ3QP
M_C5_<[V^'#GYC%C,5C)'4/7OB2U9'.<D-8\_*^BH'C/O>/SZ&_UC<?+J9!ZH
M8$L>_Q:MY?9R-!NA-=O0?2SO^.$3JT[(SWDK'HOB+SI4;9T16NV%Y$G56<T@
MB=+R/WVNA#CJX$Y>Z8"K#KC9(7BE@U=U\$X=85)UF)S:P:\Z%*<^+L^]$"ZD
MDBXN,GY 6=Y:T?(7A?I%;Z57E.9?E'N9J4\CU4\N[EA,)5NC6YK)%Q2R!XG>
M(?/@;<:32 B>O:!?N&0"O0F9I%$LWJJF5YM-%$=%:Y+*2#5_A[[<A^C-V5MT
MAJ(4?=[RO:#I6ER,I9IO/NIX5<UM6<X-OS(W%Z,;GLJM4.@U6YN L3K1^FSQ
MM[/]@*W$D*W>(\_] 6$'>UT3^G_=P].[XX[NY/3NKD4,KPZ]5_"\DT+_.:.I
MH.75^_O/JBFZEBP1?W3,\T/)G71S\Z7M7.SHBEV.U-HE6/;$1HOOOW,#Y\<N
MR2%A(22, ,&,X$SJX$QL],5U*IFB2L2>54X0#!7K<A&P=[LB8&EQ+>[H"WV(
M65>4K /TC5()FQ:P//D\+6;!Q%<7P=.Q_.U6DZD[\<U6I-W*G01SW<H0S*\%
M\ZV"-5>I+D6LA+Z*0,)"2!@!@AEA".HP! ,M*@%D<"!A(22, ,&,X$SKX$R'
M7E2F[2O<<<SK>UFV"?YEK;!.M:^J0#!#U5FMZLRJZE7",QG]18MO.=^HVU1U
M$[6.Q(KO4]FEX:REH=_2<-;2<(*]>=#0T#JQOAH"P0P-Y[6&\UZK-_H;G7F.
M@VZB.,YE5?<^+'E@67'OT[PC[=+8.ES?U002%D+""!#,B)GK:._@#+385V"@
M^(#20E :@:*9(3JR=^[02[Y]A-ZQ<ELKFUK76MD!=% "13.#@'40,&R&L/-Z
M2XY;DN/I/)@V)8<<E$#13,FUMW6M[JPSH;C8KQ/*U?YQKZZ*W(F?DD[LH_4.
M"*CG!:41*)H9-VU[W<E0*074[X+20E :@:*9(=)&V[4[;8B4 NK$*]KQ^N8&
M?OX;F;F^@9IL*)H9!&VS7:M1_ \I!=1?5[1CR?UY@)N*@SIG*)JIN/;.KMT\
M=V44O]NAG)92( WP$I06@M((%,T,G+;G[FRHE +IKY>@M!"41J!H9HBT^W?M
M]A\BI8 Z_HIVO+X%@3-OKF^@7AZ*9E;&M)G'5B?:/Z/8>7T5KVC&+U[364-P
MT"$)%,T47%MS;+?FW;]YU0GEAF:K;5%I/"6;V,?J'0Q(6@A*(U T,VK:RV,\
M4#;!H*8>E!:"T@@4S0R1]O[8[OT!LHE]A-ZQ\MIKFS]WFHL;J(^'HIDQT#X>
MV^O7_;,)J'VO:,>*M^0&]>10-%-N[<EQO^IW(Y?\M%<KT\FI!-2<@])"4!J!
MHIE!TQX>#U4KQZ!F'I06@M((%,T,D3;]>/"*N7V$WK%J%]>QTZH+@XY)H&AF
M#+1_Q\#U=3NOM^+M4CSV6\8$U(U#T4S!M1O'_8OQ^*@8?\]VLOZMZ[24 FK.
M06DA*(U T<PG.K6)]X:JR'N@;AZ4%H+2"!3-#)&V_=[@%7G["+UCU:[(S]Q9
MXZ'-$'1, D4S8Z!-O =<D+?S>BO>49#W9\TD#CHF@:*9BA\]:]Z['F^N51^C
M9_7Z3AUY_?E=^QB]HP#[Y#GLH^=#N'=/NW=OJ"J\!VKC06DA*(U T<P0:<?O
M#5Z%MX_0.U;M*OQL.F^63$#')% T,P;:P'O 17@[K[?B)<UXD+BUVR($'9-
MT4K%QT<;UQ*6/18[!@4J]"MW==5'ZUV)5\5>O,;QI7M.RKV%&E-N=;RAV6.4
M"A2SC4(Z[Z?J*Y.5NP?+-Y+OBNUQ#UQ*GA0OMXRN698W4)]ON+J.JC?Y /4>
MSL4_4$L#!!0    ( /*#<UB".XV'=04  -LD   9    >&PO=V]R:W-H965T
M<R]S:&5E=#<V+GAM;+6:6V_;-A3'OPJA%4,++)%(ZF)EMH$V:;$ :V<DZ?8P
M[(&VZ9BH+AY)QPVP#S]*5D7)DN@+I#PXDLWSUSE'AT<_41KO4OY-K"F5X'L<
M)6)BK:7<W-BV6*QI3,1UNJ&)^F65\IA(M<N?;;'AE"QSHSBRD>/X=DQ88DW'
M^7<S/AVG6QFQA,XX$-LX)OSU XW2W<2"UH\O'MCS6F9?V-/QACS31RJ_;F9<
M[=FERI+%-!$L30"GJXGU'M[<NDYFD(_XD]&=J&R#+)1YFG[+=NZ7$\O)/*(1
M7<A,@JA_+_261E&FI/SXMQ"URF-FAM7M'^J?\N!5,',BZ&T:_<66<CVQ1A98
MTA791O(AW?U&BX"\3&^11B+_!+MBK&.!Q5;(-"Z,E0<Q2_;_R?<B$14#Z'88
MH,( G6J "P.<![KW+ _KCD@R'?-T!W@V6JEE&WEN<FL5#4NRT_@HN?J5*3LY
M?: 1D71Y-2-<OH([.I?@"GP4DL79U^"S^N2,1. V3217.=^J[3_F$7LFV5D0
MH+ ',@5UJ1E/8R9$RE_!EU12 =[>44E8)-ZI [Q?K5C$<L./B61J^!7X^G@'
MWKYY!]X EH"G=;H5)%F*L2U5E)FO]J*(Z,,^(M01T1U=7 ,,?P'(0;C%_/9T
M<U0WMU5NRP2C,L$HUW,[]+Z01();LF%29>YIS2EM"\FHD4WE&[$A"SJQU%P5
ME+]0:_KS3]!W?FT+L">Q6KBX#!?GZMA<3V!?!$^<)(+L)^S?OZNAX%[26/S3
ME@+<9PIZ$JNEP"U3X!K/^'VBY@P5$CRH3+1%NC>'3FZ?]=F7J7,-L1..[9=J
M$,;#7!B$5P;A&8-0\_V%<LGF$05)-G_; C%*G'O*>A*K1>N7T?H#5:W?9PIZ
M$JNE("A3$!A/^%.J&E1;A'NSH%*L7N"''CPHUN8PY$(4Z&$UKT:E5R.C5X=7
MD38'C0KGGH*>Q&K!AF6PX4!5&/:9@I[$:BF CN81Y[(Z--N=&V2A5JU7%\/0
MZ:A76.$I:/2_?A([B]:L<G8T/:G58]:( ]% A0M[!9^^U.IIT.@#C5@Q5<3H
MM@:Y-_,KM1;Z[L@_Z*!F]4N]U]0"S=BBO/=:O7<;WOL8(GA(*V;Y2]W7O +-
MP*+<]UO=]QKN(SCR0N?0_2'X VH @<:+NZ'M^<WB<7T4>H?^#P$/4-,#-.-#
M2]M3]W0SSI(%VZ@[G__ 241I/LK9_: GM7I.-+O T5!ML5>FZ4NMG@9--=!(
M#-UM,6Q4=F-2#L$B2+,(,K-(5TLLS*J>N]!1?P?NF^4O=5^C"#*C2%=++,QJ
M+=%I<W\(JD"5A1/SRDEG2RSL:E>DUO0/@0-(XP RX\#QEGC*W8WY(&<O#0W!
M&$@S!G('ZHBH)[HHTC $JR#-*N@HJ[1V1-1DE49-#X$I2&,*,F-*9T=L4@I$
M7LN4'()2D*849*:4SHX8'$_\$"R!-$L@\T)(=S,<G9CY(2  :0A 9@@H%T5G
MY#6FB12G$J%9]^R)/P108 T4V!EJ=;S7U8^^U.IIT&""CX)):__#33 )PB 8
M'92R6?U2[S678#.7=/5 W,22(/2\P]M\L_JEWE>>SQQ=I&AM@;BY2-%VFVQ6
MO]1[#1#8O$C1V09Q<Y4"!D&8U5G=_R&N_%A?^;'YRM_6!D^A0+/LV=-_"(C
M&B+P4$];<*^/6_I2JZ=!PP@^"B/M7; )(] /G$87' )(L 82; :2SB[8PB.^
M[^-#[X? $:QQ!!]=DVCO@L?7),S*ESY;U@CA7OA\Q&T^T< 8!X?/Z<SRY[IO
M5]X\R5[[^4SX,TL$B.A*R3O7@>HT?/\FS7Y'IIO\991Y*F4:YYMK2I:49P/4
M[ZM4M<!B)WN_I7R?:?H_4$L#!!0    ( /*#<UA8!\F15P0   8:   9
M>&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;+5946^C.!#^*Q:W.NU*;<&&D*27
M(&T2G:Y2;[=JN[L/JWMPP4E0 >=LI]E*]^//!@HA$"]9.2\)AIDOWXQGXL]F
MLJ/LF:\)$>!'FF1\:JV%V%S;-@_7),7\BFY()I\L*4NQD$.VLOF&$1SE3FEB
M(\?Q[13'F15,\GMW+)C0K4CBC-PQP+=IBMGKC"1T-[6@]7;C/EZMA;IA!Y,-
M7I$'(KYL[I@<V15*%*<DXS'- "/+J?417L_14#GD%E]CLN-[UT"%\D3ILQK<
M1%/+48Q(0D*A(+#\>B%SDB0*2?+XMP2UJM]4COO7;^A_YL'+8)XP)W.:?(LC
ML9Y:(PM$9(FWB;BGN[](&=! X84TX?DGV)6VC@7"+1<T+9TE@S3.BF_\HTS$
MG@/TCCB@T@'U=7!+!S</M&"6A[7  @<31G> *6N)IB[RW.3>,IHX4]/X()A\
M&DL_$=R3! L27=YA)E[!QQ4C1$Z2X. 2?-X*+G 6Q=D*S'""LY!P0)?@J,O[
M!1$X3CY(WR\/"_#^W0?P#L09>%S3+9= ?&(+25G]L!V6]&8%/72$WH*$5\"%
M%P YR.UPG_=W1TUW6R:JRA:JLH5R/%>?+5"$_LAPQG%1CM]OI2FX$23E_W2%
M6>!ZW;BJ5Z_Y!H=D:LEFY(2]$"OX_3?H.W]T!6T(K)$"MTJ!JT,/'JG "8BV
M!"P9364G%QG9R(S$I'.&"[QACJ?^55X"Y,#QQ'[9#ZEM!$=CIS)J4/4JJIZ6
M:F.VNIAIW4^=%$-@C4@'5:2#,]7EP&0*#($U4N!7*? -UV6!Y^OKLFUTO"Z'
M%=5A3ZJ"]B$Z;'. KG] M&WD>OZXF^BH(CK2$OV$,S&+*?@/_+25M$"GUI$A
ML$;,XRKF\9E::6PR!8; &BF 3BT*',/-5 (VBA2-O8,B_9E5D^Z>AH%&&ZJ$
MVZ<Q]MQ#KGJC)M5:0$#MXIRWU#>ET?LTE1[KU)(RA=:,O-8-T#U38T&M(CDY
M#8;0FFFH-0G4BY)?:"VO58@##QY6:]OHR"H%:U$!M0OVZ6TUT' H:;9-QB/_
M"-%ZZ8?ZM7_&XNP9R)4JH:LXY!?@)I.ZOT^#:7%/KBQ#:,TLU*H"#L_58%J]
M<G(:#*$UTU!K%J@7+;_08*-64?KHL'#;-F@(CQ1NK36@=AT/OF(6R[UQKU(U
M*B],H35WT;6^0,ZY]M%:X7+R1MH06C,-M6Y!?75+WU)%;5$"T6&M=ABY:-!=
MJVCOZ$.O7!;;A+R">XJC"W![.^]3LWK$DR?K'/H%U?H%G4N_(*/ZQ11:,PVU
M?D%]]4L_48#:PJ2]>>TR\MPC?Z^H%C!(+V!NTG2;T<O/6:B4P2N82X,X["\/
M]/ G3]PYCD=0+9*0?Z[Z-:J23*$UTU"K)&3V\*6$VS^9' P/R[=M YW#LQ=[
M[Y!>O2'Y&[-5G'&0D*7T<JZ&LCQ8\=*A& BZR<_MGZ@0-,TOUP1'A"D#^7Q)
MJ7@;J%<!U:N?X']02P,$%     @ \H-S6-22G;6B*@  CV<# !D   !X;"]W
M;W)K<VAE971S+W-H965T-S@N>&ULO=UK<^)(GN_QMZ*HW3@Q$]'=!>+J/M45
M456ZWZ74GGUP8F-"9<LNHC$P M=E8U[\2A@L!")!75_O/!B#6_JD,%3^44J_
MS'??EL6?ZR]YOE&^/\X7ZS_>?-EL5K^_?;N^_9(_9NO?EJM\4?Z7^V7QF&W*
MI\7#V_6JR+.[[4Z/\[=JKS=^^YC-%F_>O]O^+BK>OUL^;>:S11X5ROKI\3$K
M?GS,Y\MO?[SIO]G_(ID]?-E4OWC[_MTJ>\A%OOF/5524S]Z^*'>SQWRQGBT7
M2I'?__'F0__WM#\<5'ML-_E_L_S;^N"Q4KV6S\OEG]43^^Z/-[WJD/)Y?KNI
MC*S\\37_E,_G%54>R#]WZIN71JL=#Q_O=6/[ZLM7\SE;YY^6\_^<W6V^_/%F
M^D:YR^^SI_DF67ZS\MTK&E7>[7*^WOZ_\FVW;>^-<ONTWBP?=SN71_ X6SS_
MS+[O_A('.PS.[:#N=E"/=E!'9W88['88'.TP5,_L,-SM,#QN87QFA]%NA]&U
M+8QW.XROW6&RVV%R_%>:GMEANMMA>OP:SK5PL]OAYFB'_O#<&]?;OW.]:]OH
MO[S9Q^_V^5WV;W?_Y/T^N\O^#>\?O^/G=]F_Y?WC]WQX[@_<W[_I_:O?]?[^
M;>\?O^_G#VS_QO>/WWFU?VZ7_5O?/W[O^V=?R_[-[Y^\^^=V4??OOKI]]]\^
M_X/?]A9:MLG>ORN6WY2BVK[TJ@?;+F>[?]E)S!95]R@V1?E?9^5^F_=)/L\V
M^=VO459L?B@?'HH\+SN_S5KY5?EP=S>K>K!LKMB+YXZXZL_^IN6;;#;_^[NW
MF[+]2GE[NVO+>FY+/=-67_&7B\V7M:(O[O*[EOU=^?Z#2_M[%]I7)<#;\@_W
M\M=3]W^]CZI4#&\WORF]P2^*VE,'9;58Y-^R^3^6J^H/M6XYP$]RSL]^*+W^
M5E.5_Q":\K=__[MRO_D__]:?3/]O"Z==<W3/7O_$N^)P=;DO\M5OBCHYX[=X
MAMS[L"I^[GA-N>]DBY_SK0O^4^D/>KM/P]Z_S-I7_)EW[,MAMS#.A;_NTT/)
M;%]]?]KVC^_29[/8[RX]"D_.:/GM"S.0,/[UC"IA@NL9V8L*KV;Z-Z<?K'E>
M?GV[XG,07=_*Y*]\?..K/R#2MR:YW(E=\<Z(ZU_L6-:GI-<[HS-.H^L?O!3.
MP18>R NG\EPXTR);K+/G+_S_WRLW5>Q-_KC^KY8#_OCL#MO=ZG3H]_4JN\W_
M>%.>[ZSSXFO^YGUYU.->VZO_1&(:B>DD9I"826(6B=DDYI"82V(>B?DD%I!8
M2&(1B<4DEI"8(+$4PAKU8?A2'X8RO?S6-B]_]?"+\E#6Y:(\A\H6=TIV5Y[$
MS=:;(JO&A)2_S1:W\Z>[<C,E>UP^5:==WV:;+V4I?ZXMJ[*VS/)U6_G\*&V]
M:Q4A,8W$=!(S2,PD,8O$;!)S2,Q]QB9;K!JX_?I^.%(GHUZO]^[MU\,*<;IA
M7[T9J[V3+?V6+7OJI#<]V3)HV7(P4D?CDRU#\C5')!:36$)B@L12"&MTW*.7
MCGLD[;B34LR*VR_;#OLN_YK/EZMJ2$S)OZ_RQ3IOZXRE8M?.F,0T$M-)S" Q
MD\0L$K-)S"$Q]QD;'W;&_;YZVG%ZIQNJ W4P/NTX_98MA]/^\.:T,S[=LG\S
MNAF=MAZ2KSDBL9C$$A(3))9"6*,S'K]TQN,+G?'7?/'4VN=*=^S:YY*81F(Z
MB1DD9I*816(VB3DDYHY;OH.>]H[>^*1W'*OJ:7=[NIDZ//V*')QN=C,8GG:T
MY N-2"PFL83$!(FE$-;H:"<O'>U$/ER1S7-E>:]DZW6^62N;9?GU5RF_]<XV
M/Y2GQ5U>*+?+Q\?EHORQV!3+>5N/+&VA:X],8AJ)Z21FD)A)8A:)V23FD)A+
M8M[DI*<][K(O;A&<;M$?#DZ'2$+RP",2BTDL(3%!8BF$-;KKZ4MW/;WPO?C@
MZF-;7RS=O6M?3&(:B>DD9I"826(6B=DDYI"82V(>B?DD%I!82&(1B<4DEI"8
M(+$4PAIEX.:E#-R\TDTH-V1](#&-Q'02,TC,)#&+Q&P2<TC,)3&/Q'P2"T@L
M)+&(Q&(22TA,D%@*88WZT.^]%(@J#B(Y44B7FVRNW#WEU9#.T7TE;75!SG4M
M#*BFH9J.:@:JF:AFH9J-:@ZJN:CF[;3&4$Q_T'+9LV7#P7#<<M43/;X0U2)4
MBU$M036!:BFE-3OX@_Q67]K!!]EB\Y]5F%;YEW)Q5$AN=>[=24U#-1W5#%0S
M4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E03J)926K-.J'6=4%]IJ&@'4T6#
MU#14TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M036!:BFE-8M&G7'M
M2R-2W4>/T&PKJFFHIJ.:@6HFJEFH9J.:@VHNJGD[378ST&Z3P]M!;Z:GXTL!
M>F AJD6H%J-:@FH"U5)*:_;L=3JUFEI)-FST]/@Y+ZH[/M?_?,J*7+E?+C?5
MT_OL=C:O[OK<SEIQI_Q+-OG"1WDKG3O\X<D_F>%X,#CZYZ"AC>JH9J":B6H6
MJMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ":0+6TI1N\&1U\*6AV^76NM2\/MGY8
M+)[*;_.KO+C-%YOL(5=FB]MB.S=1^>W^\VZ.HDUK-X\&7'=:7SW\:O1;;W#<
MS:/9550S4,U$-0O5;%1S4,U%-0_5_.L^Y '::(AJ$:K%J):@FD"UE-*:_7P=
MF>W+,[/;.2[G/R[TZ&A\MG^::U0G@\GQB:R&MJJCFH%J)JI9J&:CFH-J+JIY
MJ.:W?,I'X[YZ,EI#-AJB6H1J,:HEJ"90+:6T9I=>AW/[\G2N_GV5/<](O[S?
M#\R4#3W.UOFZFD7L91 GSS=_OS1D@\9T^Z=QQ<%X>CID@R9P4<U -1/5+%2S
M4<U!-1?5/%3S42U M1#5(E2+42U!-8%J*:4UZT.=!N[+X\!G;P+=/F^?SZRU
M-J"Q85334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M035!*JEE-8L
M(762N/]:4>(^FB5&-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+
M4$V@6DIIS=6OZG2Q*D\7>]NKQY*)D>7[=ZT-J*:AFHYJ!JJ9J&:AFHUJ#JJY
MJ.:I;2GA7LN4]BT;JFT;!BT;3EJV"]'7$:%:C&H)J@E42RFMV5?706'U+P:%
MR^?B2U:43T79Z.PV7]?K0+;VZ6B(&-4T5--1S4 U$]4L5+-1S4$U%]4\5/-1
M+4"U$-4B5(M1+4$U@6HII35KB%K7D-<*$:MHB!C5-%334<U -1/5+%2S4<U!
M-1?5/%3S42U M1#5(E2+42U!-8%J*:4UBT8=(E;E(>+77@E1WGSGTH*&CE%-
M1S4#U4Q4LU#-1C4'U5Q4\]33T/%@T#K&U++AM'6,Z73#8=M@5(B^D C58E1+
M4$V@6DIIS;Z^CA67#V5]O?:4*_?%\O&:R2+D5.=^F]0T5--1S4 U$]4L5+-1
MS4$U%]6\G7;8RXY:NVVRU0#50E2+4"U&M035!*JEE-8L '7(6)6'C+O.&"3G
M.A<!=.U<5--1S4 U$]4L5+-1S4$U%]4\5//5EB5V>ZW?\-$(,JI%J!:C6H)J
M M522FM6@3J"K,HCR%&1K[+9W?[.H/:>'TT@HYJ&:CJJ&:AFHIJ%:C:J.:CF
MHIJGGB[1V]I7^RT;JNV=.AI"1K4(U6)42U!-H%I*:<U.O0XAJ_(0\E^Z@6B[
M[>SQ\U.QWCYO+P5H)!G5-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+
M42U!-8%J*:4UBTJ=7%:GKW5'$9I51C4-U714,U#-1#4+U6Q4<U#-134/U7Q4
M"U M1+4(U6)42U!-H%I*:<VB46>556FLK2P:[5-:2)-H:$H9U314TU'-0#43
MU2Q4LU'-0347U;R=UAA%4EN'FTXWO&D=;3K=KOT>(30TC&HQJB6H)E MI;1&
M[SVH0\,#>6C8?GQ\6BQ_#1>WR_GRX8?RJ=Q@=ON+8B]N?[MF$4LYW[4G1S4-
MU714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U!-H%I*:<W246>8!_U7
M&BT:H*%E5--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U!-4$JJ64
MUBP::ETTI/FVOS1:)"<[EPLTKHQJ.JH9J&:BFH5J-JHYJ.:BFK?3+H\6M6W8
M.F]1RX;]<=MX$?I"(E2+42U!-8%J*:4U^^\Z/SQ@%R&6<YW[;C0/C&HZJAFH
M9J*:A6HVJCFHYJ*:-SA-[_9;N^[KM@O0HPM1+4*U&-425!.HEE):LWNO(\/E
M0UGW7HWES,H._ELQV^3*W?+;=I&;53-!T-K/2]W._3RI::BFHYJ!:B:J6:AF
MHYJ#:BZJ>:CFHUJPTR[/(($V&Z%:C&H)J@E42RFM60[J /% 'B#^6,P6?RH?
M9]6UX=GMNL-E831)C&H:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6H
MEJ":0+64TIHUHXX;#\:O=5D8#2&CFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%
MJ!:B6H1J,:HEJ"90+:6T9M&HX\P#>9PYR;_FBZ?VD24TCXQJ&JKIJ&:@FHEJ
M%JK9J.:@FHMJWN!T@>^3BP<7-PE:-FD? D(SP:@6HUJ":@+54DIK]LQU)GAP
M>37CC[/E58,^: @8U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M
M036!:BFE-:M$'0(>O-:"Q0,T"HQJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@
M6HAJ$:K%J):@FD"UE-(:16-89X^'\NQQUWM)Y5S74H%J&JKIJ&:@FHEJ%JK9
MJ.:@FHMJWO!TM>&;X>#T7M(KMPO0HPM1+4*U&-425!.HEE):LWNO\\'#RVL<
MMXP<E<\#Y9,BE$^M?3P:#48U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U
M"-5B5$M03:!:2FG->J'6]>*UUC,>H@%A5--034<U ]5,5+-0S48U!]5<5/-0
MS4>U -5"5(M0+4:U!-4$JJ64UBP:=1YYR.:1Y5SG4H'FD5%-1S4#U4Q4LU#-
M1C4'U5Q4\X:G.>.V"47]*[<+T*,+42U"M1C5$E03J)926K-[K_/(Y4-9]RZ>
M5JOY#R7;KV#SB[+)B\<JDWR[7&R*\OR@M9.7HIT[>5+34$U'-0/53%2S4,U&
M->?"AWBD_,BSHNWKB(L>AX=J/JH%J!:B6H1J,:HEJ"90+:6T9G&HT\E#>3HY
M7%6C0^77__S[)E_<E5_\YWFVSK<EHK4LH*%D5--034<U ]5,5+-0S48UY\+'
MM[\M"ZU5 <T?HYJ/:@&JA:@6H5J,:@FJ"51+*:U9%>K\\5"^W/'^LG/Q'"DK
M?]XN'Q:S_\[O6FL"FCE&-0W5=%0S4,U$-0O5;%1S4,U%-6]XNI[QR5#0Q4V"
MEDT&;>DR]-@C5(M1+4$U@6HII34[ZSKW.Y3G?K7\/B^JQ8J+\P%@.=&YBT8#
MP*BFHYJ!:B:J6:AFHYJ#:BZJ></3Z&[K%*)7;A>@1Q>B6H1J,:HEJ"90+:6T
M9I=>!X:'?RDP+%N7OK771\/$J*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6HQJ":H)5$LIK5E!ZC#Q\+7"Q$,T3(QJ&JKIJ&:@FHEJ%JK9J.:@FHMJ
M'JKYJ!:@6HAJ$:K%J):@FD"UE-(:16-4AXE'\C"Q]I0K]\7R\9J;0.54US*!
M:AJJZ:AFH)J):A:JV:CFH)J+:M[H-"#<;QNO]Z_=,$"/+T2U"-5B5$M03:!:
M2FG-SKV.$H_D4>)Q;Z1HRZ<'16Q^43SOTS6ST<G)SIT\FB1&-1W5#%0S4<U"
M-1O5'%1S4<U#-1_5 E0+42U"M1C5$E03J)926K-<J'6Y>*TD\0A-$J.:AFHZ
MJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6H)E MI;1FT:B3Q"-YDCAX
M>OR<%U6T;/W/IZS(E?OE<E,]O<]N9_-964BVZ8*[\MSC?E.V.YFVO8J/\E8Z
M5Q T8(QJ.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ"9&I]%R=:B.
MCH844ZK19FFH4\CE0UEI^+!8/&5S9947M_EBDSWDRFQQ6SQGS9;*Y^IG<>8V
M)KG<N1R0FH9J.JH9J&:BFK73^NK!I[;W6V_0_-#::*,.JKFHYJ&:CVH!JH6H
M%J%:C&H)J@E42RFM60[JW/%('MSTEXO-E_F/"QT_&C9&-0W5=%0S4,U$-6NG
M30[Z_8DZF(Z..WXT18QJ+JIYJ.:C6H!J(:I%J!:C6H)J M522FMV_'6T>"2/
M%G>=<$+.=:X!:+@8U714,U#-1#7KPD=D<':N'QL]#@?57%3S4,U'M0#50E2+
M4"U&M035!*JEE-8L"W6(>20/,3^7A74U%O1<&)3%R[6$JC2LE7]5IPGYMVS^
MC^7SMJW5 LTYHYJ&:CJJ&:AFHIHU:LGA'I\MH.%E5'-1S4,U']4"5 M1+4*U
M&-425!.HEE):LRS40>B1/ A]Z:;5[?-U^6WQ]HN2E47C+O^:SY>K<X%H>6N=
MRP,:B$8U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425!.HEE):LY+4
M@>C1:P6B1V@@&M4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4$U
M@6HII36*QK@.1(_E@6AO>VDB_[[*%^O6>?7D^W>M#:BFH9J.:@:JF:AFH9J-
M:@ZJN:CFC5N626X+05^Y77#E=B'Z*B)4BU$M036!:BFE-7OJ.MT\EJ>;M:=Y
M_D-)EMG=U>%FN=BY[T;#S:BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6
MHUJ":@+54DIK5@NUKA:O%6X>H^%F5--034<U ]5,5+-0S48U!]5<5/-0S4>U
M -5"5(M0+4:U!-4$JJ64UBP:=;AY_+\2;I:WTKF"H.%F5--1S4 U$]4L5+-1
MS4$U%]4\5/-1+4"U$-6B\6GDM]^_F1Z-C,5HHPFJ"51+*:U9&NIP<_E05AI^
M(MPLESN7 U+34$U'-0/53%2S4,U&-0?57%3S4,U'M0#5PIUV(?X>7;=9C!Y;
M@FH"U5)*:_;S=6IY#*26Y4;G'AU-+:.:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!
MJH7CTUS[8#0]OE@=M6PV[$V.-XO18TM03:!:2FG-'KV.(X_E6=/+=_B@^6-4
MTU!-1S4#U4Q4LU#-1C4'U5Q4\\:GRQ*WW^%SNMVT]0Z?T^V>5]@\N<4'C0BC
M6HQJ":H)5$LIK=E5UQ'A\341X>MGCKC C<[.,O!)OF?G7AK-_:*:@6HFJEFH
M9J.:@VHNJGFHYJ-:@&KA7_X7'OWE/6/T%22H)E MI;1F=U]'?\?RZ"\T(\2N
M%<GL 9_D!]*YNT=SO*AFH)J):A:JV:CFH)J+:AZJ^:@6H%K8\D]9/1Y>N;A)
MC!Y3@FH"U5)*:W;@=>)V+ UG'=POL_V>7O77VP>MO32:L44U#=5T5#-0S40U
M"]5L5'-0S44U#]5\5 M0+=QIT@X=#<ZB6H)J M522FOT_9,Z.#NYM)*P-(Y5
M/J_6&BZ_VA_^^LQ*P_*FNM8&5--034<U ]5,5+-0S48U!]5<5/-0S4>U -5"
M5(M0+4:U!-4$JJ64UBPC=:IW\IP#XW-:$S3<BVH:JNFH9J":B6H6JMFHYJ":
MBVH>JOFH%J!:B&H1JL6HEJ":0+64TII%0ZV+AC0']GQ+SZ_%KG2LLA_9Y_F9
M,PLTS(MJ&JKIJ&:@FHEJ%JK9J.:@FHMJWDX[O1?GZ-Z>MNV&;3?WH(<7HEJ$
M:C&J):@F4"VEM&;/7B=P)_($[N51)9&ORE."ZK*#VNO?*-ZYZPWRACKW_&@(
M%]5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M03:!:2FG-(E)G=<N'
MKS2F-$2+!JEIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C6H)J M52
M2FL6C3KX.Y$'?Z&Y?^2M=*X@:#08U714,U#-1#4+U6Q4<U#-134/U7Q4"U M
MW&F'0V:C\>@X&8RV&:-:@FH"U5)*:U:&.D \D0>([<5L,\OFVTC"R[VN2E:4
MYQ4/^;EUR.1FYSJ AHI134<U ]5,5+-0S48U!]5<5/-0S4>U -7""SW)Y'Q<
M#3V.&-425!.HEE):LS;4B>6)/$9X^7J%\S3_<>E2!;JD,:IIJ*:CFH%J)JI9
MJ&:CFH-J+JIYJ.:C6H!J(:I%J!:C6H)J M522FO6CSH"/9F^UJ4*=*%C5--0
M34<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U!-4$JJ64UBP:=>QZ<FWL
M^N<N5:");%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5PLEI(GL\G$Z/+U6@
MH6Q42U!-H%I*:8W*,*U#V5-Y*/LO7:J0FUWK *IIJ*:CFH%J)JI9J&:CFH-J
M+JIYJ.:C6H!JX86>1'*I CV.&-425!.HEE):LS;42>NI?/WD<6^D!-GZR[D+
M%?O:$17YXVS='J>3-]&Y5*"9:U334<U -1/5+%2S4<U!-1?5/%3S42U M1#5
M(E2+42U!-8%J*:4URX=:EX_76E!YBF:P44U#-1W5#%0S4<U"-1O5'%1S4<U#
M-1_5 E0+42U"M1C5$E03J)926K-HU''NZ?_*@LKR5CI7$#3+C6HZJAFH9DY/
MEZ0=3Z='*Q5::)LVJCFHYJ*:AVH^J@6H%J):A&HQJB6H)E MI;1F9:@SVN5#
M667XB?64Y7+G:D!J&JKIJ&:@FKG3+BQ<:Z&-VJCFH)J+:AZJ^:@6H%J(:A&J
MQ:B6H)I M932FN6@3E]/@667Y4;GCA_-5J.:CFH&JIG3T_5MU=[@>'(X"VW4
M1C4'U5Q4\U#-1[4 U4)4BU M1K4$U02JI936[/CK</54'HGLNN2GG.M< ]!<
M-:KIJ&:@FGGA31V<O7G$0H_#1C4'U5Q4\U#-1[4 U4)4BU M1K4$U02JI936
M+ MUKGIZS4K0/[TTJ+R5SM4"35:CFHYJ!JJ9.TVR0*N%-FBCFH-J+JIYJ.:C
M6H!J(:I%J!:C6H)J M522FN6A3HN/96O&'WI'E;]^RI;K*N;DB+97:QH=!K5
M-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!-8%J*:4U"T@=G9X^
M!_!>X2Y6-"V-:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H)I
MM932&D7CIDY5W\BSD-!=K/)6NE805--034<U8Z<U)E>>3,9'%YQ-M%$+U6Q4
M<U#-134/U7Q4"U M1+4(U6)42U!-H%I*:<W24(>J;^2AZI^XC54N=RX':)8:
MU714,W;:A1M/3;11"]5L5'-0S44U#]5\5 M0+42U"-5B5$M03:!:2FG-<J#6
MY4"^,/55M['*C<X=/YJ'1C4=U8R==GCC:7_2&Q[?>6JBK5JH9J.:@VHNJGFH
MYJ-:@&HAJD6H%J-:@FH"U5)*:_;\==+Y1IYT[GH?JYSK7 302#.JZ:AF7'@;
MSM]Y:J+'8:&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)J@E42RFM61;JF'/Y\')9
M^.G[6.6M=*X6I*:AFHYJQDZ3W'EJH@U:J&:CFH-J+JIYJ.:C6H!J(:I%J!:C
M6H)J M522FN6A3KN?"./.U\[%^N'LF!<=T^KO,'.%0+-1J.:CFH&JIFH9J&:
MC6H.JKFHYJ&:CVH!JH6H%J%:C&H)J@E42RFM64SJ"/7-<Q:/OZ?U!@U3HYJ&
M:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):@F4"VEM&;1J /6-_*
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M9<B^F(CE8I9+6$ZP7(IQ1SUX_Z 'EP>D@^HJPZ=L-=MD<T7M]4=*L-SDY7G
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M>77%8Y-];T]<7-"[5PHTXLUR^IYKS/;47B?0_#;+62QGLYS#<B[+>2SGLUS
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M;=IGYI,CG8L!RFDLI[.<P7(FRUDL9[.<PW(NRWDLY[-<P'(ART4L%^^Y2V'
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M-(#2&(HF7Q'4VJV&VF[]SO/(U/2Q9=#03G>UMMG=U3K0G"Z41J$T#TKSH;0
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M3NA[^2+3=;&SX4,J9;HJ/CX*'HI,)U"_+])4OGS1!>SVZYS]!5!+ P04
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M$H#]%6/R::(>T+9E9_\!4$L#!!0    ( /*#<UB+Q##2TP0  $(6   9
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MPX'(< S^CN;%X'LG<NAU#CAT4C%T*F^[>:G%$.HMACI9]=9>D2;@@Z38\O!
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MT@8>CP_L'YQVTO+$--Y+\9UG9CWQ1AYDN&0;81[D[B/6>@:6+Y5"NU_8U=C
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M%&B]A.7"_*)M/=:Q4%(*R8K:6'E09+3Z)S_K0.P9*-!V [<V<-\:A"<,O-K
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M5^K"!UP/4.\7C,G7AIZ@N4).?@-02P,$%     @ \H-S6'AR'5+K @  @@@
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MAPO LM@J@+P^HU1L!^H&]8>4^#]02P,$%     @ \H-S6,TH('GS!   T1,
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MBCQ\/SJ<:+&M/\$LA=:BK \WC.9,&@.XOQ)"OYR8KSK-5[SY_U!+ P04
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MAP*!T[0/PQYHZ=HB*I$:2<7N?OTN*47SA^P&0UYLDCKGZ)Y[2>K.MD)^5R6
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MQBMD?QU@:[JO0K"1XI6(C12?:T#L\P:,*+*O-I8'&-@J8+4#^>UYH*;LG""
M5<6\83L81Z((0Z 6[34:ALCLA/"QKP^V2X(@BNP(8'8'08 AL!MQ!', 'C D
M",KGX,[SR*N?4U[[C_C)7U!+ P04    " #R@W-8EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( /*#<UCM1M:;<08
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M59XA!V6GV-PVC+GW24&&')2=:9M;A]G_J  Y**->%3J.^47(1Q\3.2@C=A#
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MIZS?AV'_C^/G9]K9IG_-S^:_'-W\!%!+ 0(4 Q0    ( /*#<U@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ \H-S6$OCA5CN    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ \H-S6)E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #R
M@W-8@]JM&$L(  !3,0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ \H-S6'A&Z9(] @  OP4  !@
M         ("!CA   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( /*#<UA;+>>G+P@  'PF   8              " @0$3  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #R@W-8IO ?(R #  !A#
M&               @(%F&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ \H-S6-Z?P2NY!@  BAP  !@              ("!O!X  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /*#<UCD*.-<* 0
M 'T.   8              " @:LE  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " #R@W-8#4=ZK3(5  !A1@$ &               @($)
M*@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ \H-S6'._
MQ.T, P  1PL  !@              ("!<3\  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( /*#<UB6]3O\.0X  '1*   8
M  " @;-"  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #R
M@W-8P*7$UWX/  !Z)P  &0              @($B40  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /*#<UC\Q$G@4"D  "R%   9
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M970Q-2YX;6Q02P$"% ,4    " #R@W-8VXP?.M$;  !Z3P  &0
M    @(&9P   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M /*#<UC>LN8QPP8  *$=   9              " @:'<  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ \H-S6&CABIRM#0  *RD  !D
M             ("!F^,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " #R@W-84B:DOQ >  ![A0  &0              @(%_\0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /*#<U@CPUA6$QX
M (>%   9              " @<8/ 0!X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ \H-S6(V@<L<>!0  :Q(  !D              ("!
M$"X! 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #R@W-8
M,E2!/]0.   0,   &0              @(%E,P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( /*#<UAPY9,". L  ($=   9
M      " @7!" 0!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ \H-S6,'\B.+0#0  H28  !D              ("!WTT! 'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #R@W-8G***4F4#  ":!P
M&0              @('F6P$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( /*#<UA\T,G28CD  &/,   9              " @8)? 0!X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ \H-S6*K,76RY
M P  UP<  !D              ("!&YD! 'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " #R@W-87-AU44P%  "##   &0
M@($+G0$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /*#
M<UC\1F '(P@  $<7   9              " @8ZB 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ \H-S6!&&/2T_!   -0P  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( /*#<UC2/=_G5!$  *\]   9
M  " @3[( 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M\H-S6.F:YBP) P  1P<  !D              ("!R=D! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " #R@W-82\>C.[ %  !H#@  &0
M            @($)W0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( /*#<UC=]BZT! <  "P3   9              " @?#B 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ \H-S6+S$%MG-!
M0!T  !D              ("!*^H! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " #R@W-8+$S%]64'   J/0  &0              @($O
M[P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /*#<UB0
MOOM310H  *YM   9              " @<OV 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ \H-S6)/=L4L8 P  G X  !D
M     ("!1P$" 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /*#<UC#61#%I@4  /,E   9              "
M@1X5 @!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ \H-S
M6$HTIXQH!0  <B   !D              ("!^QH" 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " #R@W-842K5$U<#  "@"@  &0
M        @(&:( ( >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( /*#<UCS%!1S50,  #D*   9              " @2@D @!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ \H-S6!Q9].,^ P  O@L
M !D              ("!M"<" 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " #R@W-8__ALERH%  !1'0  &0              @($I*P(
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /*#<UA3E2MV
M]@0  '(7   9              " @8HP @!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ \H-S6!+<%5I1 P  *PP  !D
M ("!MS4" 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #R
M@W-8@*T!OE(+  !A?@  &0              @($_.0( >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( /*#<UB=7B$8BA@  #Z+ 0 9
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M970V,"YX;6Q02P$"% ,4    " #R@W-8_P)NS%4%  #9)0  &0
M    @(&G>@( >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M /*#<UB/5U!^= @  .=G   9              " @3.  @!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ \H-S6 7%E50R P  ,PP  !D
M             ("!WH@" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " #R@W-8U\,A^^@"  #_"0  &0              @(%'C ( >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( /*#<UAP;8;;I ,
M (H-   9              " @6:/ @!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ \H-S6(M@U>6> @  \ <  !D              ("!
M09," 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #R@W-8
MH,'85#0#  #J"0  &0              @($6E@( >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( /*#<UBTIJC4$@,  +<(   9
M      " @8&9 @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ \H-S6%BN;S?L!   C!T  !D              ("!RIP" 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #R@W-8J[U.OH,)   7:
M&0              @('MH0( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( /*#<UAPSCU'%P4  $0B   9              " @:>K @!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ \H-S6)W2&8%<
M(   +6(" !D              ("!]; " 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " #R@W-8:+/Q)>$Q  #1K , &0
M@(&(T0( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( /*#
M<UB/5*K5S00  /P;   9              " @: # P!X;"]W;W)K<VAE971S
M+W-H965T-S0N>&UL4$L! A0#%     @ \H-S6-'UW-5#!@  SSD  !D
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M=#<Y+GAM;%!+ 0(4 Q0    ( /*#<U@2VP\ ZAH  -#E 0 9
M  " @6U. P!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @
M\H-S6$]C6 /Y"   NU,  !D              ("!CFD# 'AL+W=O<FMS:&5E
M=',O<VAE970X,2YX;6Q02P$"% ,4    " #R@W-8R>IB(Q@$  "B%0  &0
M            @(&^<@, >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4
M Q0    ( /*#<UB+Q##2TP0  $(6   9              " @0UW P!X;"]W
M;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ \H-S6#U7'LR# P
ML H  !D              ("!%WP# 'AL+W=O<FMS:&5E=',O<VAE970X-"YX
M;6Q02P$"% ,4    " #R@W-8O7TXC;(#  !.#@  &0              @('1
M?P, >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( /*#<UAX
M<AU2ZP(  (((   9              " @;J# P!X;"]W;W)K<VAE971S+W-H
M965T.#8N>&UL4$L! A0#%     @ \H-S6#A9,R2O P  5!$  !D
M     ("!W(8# 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /*#<U@TH!;J=P(  (X&   9              "
M@1J= P!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ \H-S
M6"/@6#!G P  E1<   T              ( !R)\# 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #R@W-8EXJ[',     3 @  "P              @ %:HP,
M7W)E;',O+G)E;'-02P$"% ,4    " #R@W-8[4;6FW$&  #*/   #P
M        @ %#I , >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ \H-S6!Q&
MX;:K @  *S8  !H              ( !X:H# 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ \H-S6,T>9+Q  @  >C0  !,
M     ( !Q*T# %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &0 9 !S&P
&-; #

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>671</ContextCount>
  <ElementCount>621</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>188</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Stockholders' Deficit Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Financial Statement Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetails</Role>
      <ShortName>Financial Statement Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Collaboration and License Agreements and Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition</Role>
      <ShortName>Collaboration and License Agreements and Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Lease Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangements</Role>
      <ShortName>Lease Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Revenue Interest Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RevenueInterestPurchaseAgreement</Role>
      <ShortName>Revenue Interest Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Related-Party Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebt</Role>
      <ShortName>Related-Party Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Related-Party Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreements</Role>
      <ShortName>Related-Party Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/WarrantLiabilities</Role>
      <ShortName>Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Stockholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders??? Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Description of Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/DescriptionofBusinessTables</Role>
      <ShortName>Description of Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/DescriptionofBusiness</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Financial Statement Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsTables</Role>
      <ShortName>Financial Statement Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/FinancialStatementDetails</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/FinancialInstruments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Collaboration and License Agreements and Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables</Role>
      <ShortName>Collaboration and License Agreements and Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Lease Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsTables</Role>
      <ShortName>Lease Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/LeaseArrangements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Revenue Interest Purchase Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementTables</Role>
      <ShortName>Revenue Interest Purchase Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/RevenueInterestPurchaseAgreement</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Related-Party Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtTables</Role>
      <ShortName>Related-Party Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/RelatedPartyDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Related-Party Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsTables</Role>
      <ShortName>Related-Party Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/RelatedPartyAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/StockBasedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Consolidated Statements of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail</Role>
      <ShortName>Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Consolidated Statements of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail</Role>
      <ShortName>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail</Role>
      <ShortName>Financial Statement Details - Property, Plant and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Financial Statement Details - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail</Role>
      <ShortName>Financial Statement Details - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails</Role>
      <ShortName>Financial Statement Details - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail</Role>
      <ShortName>Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Financial Statement Details - Interest and Investment Income (Loss), Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail</Role>
      <ShortName>Financial Statement Details - Interest and Investment Income (Loss), Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Financial Statement Details - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails</Role>
      <ShortName>Financial Statement Details - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Financial Instruments - Available-for-Sale Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail</Role>
      <ShortName>Financial Instruments - Available-for-Sale Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail</Role>
      <ShortName>Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails</Role>
      <ShortName>Collaboration and License Agreements and Acquisition - Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Commitments and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Commitments and Contingencies - Litigation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Litigation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Commitments and Contingencies - Unconditional Purchase Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Unconditional Purchase Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Lease Arrangements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail</Role>
      <ShortName>Lease Arrangements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Lease Arrangements - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Lease Arrangements - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Lease Arrangements - Summary of Information Regarding Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail</Role>
      <ShortName>Lease Arrangements - Summary of Information Regarding Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Lease Arrangements - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail</Role>
      <ShortName>Lease Arrangements - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail</Role>
      <ShortName>Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail</Role>
      <ShortName>Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Revenue Interest Purchase Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Revenue Interest Purchase Agreement - Summary of the Revenue Interest Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails</Role>
      <ShortName>Revenue Interest Purchase Agreement - Summary of the Revenue Interest Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Related-Party Debt - Summary of Related-Party Promissory Notes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail</Role>
      <ShortName>Related-Party Debt - Summary of Related-Party Promissory Notes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Related-Party Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails</Role>
      <ShortName>Related-Party Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Related Party Debt - Estimated Fair Value of Convertible Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails</Role>
      <ShortName>Related Party Debt - Estimated Fair Value of Convertible Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Related Party Debt - Related Party Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails</Role>
      <ShortName>Related Party Debt - Related Party Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Related-Party Debt - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails</Role>
      <ShortName>Related-Party Debt - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Related-Party Agreements - Outstanding Balances of Related-Party Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail</Role>
      <ShortName>Related-Party Agreements - Outstanding Balances of Related-Party Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Related-Party Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail</Role>
      <ShortName>Related-Party Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/WarrantLiabilitiesDetails</Role>
      <ShortName>Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/WarrantLiabilities</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expenses Related to Statement of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expenses Related to Statement of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Stock-Based Compensation - Stock Option Activity and Related Information under Equity Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity and Related Information under Equity Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Stock-Based Compensation - Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Stock-Based Compensation - RSU Activity under Equity Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail</Role>
      <ShortName>Stock-Based Compensation - RSU Activity under Equity Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Income Taxes - Loss Before Taxes, Domestic and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails</Role>
      <ShortName>Income Taxes - Loss Before Taxes, Domestic and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Income Taxes - Components of Income Tax Benefit (Provision) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Benefit (Provision) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Income Taxes - Changes to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Changes to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ibrx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immunitybio.com/role/EmployeeBenefits</ParentRole>
      <Position>92</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:Revenues, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  ibrx-20231231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ibrx-20231231.htm">ibrx-20231231.htm</File>
    <File>ibrx-20231231.xsd</File>
    <File>ibrx-20231231_cal.xml</File>
    <File>ibrx-20231231_def.xml</File>
    <File>ibrx-20231231_lab.xml</File>
    <File>ibrx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ibrx-20231231_g1.jpg</File>
    <File>ibrx-20231231_g2.jpg</File>
    <File>ibrx-20231231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="1741">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>125
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ibrx-20231231.htm": {
   "nsprefix": "ibrx",
   "nsuri": "http://www.immunitybio.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ibrx-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "ibrx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ibrx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ibrx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ibrx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibrx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 483,
   "keyCustom": 138,
   "axisStandard": 48,
   "axisCustom": 3,
   "memberStandard": 56,
   "memberCustom": 114,
   "hidden": {
    "total": 18,
    "http://fasb.org/us-gaap/2023": 14,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 671,
   "entityCount": 1,
   "segmentCount": 188,
   "elementCount": 997,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1741,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://fasb.org/srt/2023": 2
   },
   "report": {
    "R1": {
     "role": "http://www.immunitybio.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.immunitybio.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Deficit",
     "shortName": "Consolidated Statements of Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
     "longName": "0000008 - Statement - Consolidated Statements of Stockholders' Deficit Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Deficit Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.immunitybio.com/role/DescriptionofBusiness",
     "longName": "0000010 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetails",
     "longName": "0000012 - Disclosure - Financial Statement Details",
     "shortName": "Financial Statement Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.immunitybio.com/role/FinancialInstruments",
     "longName": "0000013 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.immunitybio.com/role/FairValueMeasurements",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition",
     "longName": "0000015 - Disclosure - Collaboration and License Agreements and Acquisition",
     "shortName": "Collaboration and License Agreements and Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.immunitybio.com/role/CommitmentsandContingencies",
     "longName": "0000016 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.immunitybio.com/role/LeaseArrangements",
     "longName": "0000017 - Disclosure - Lease Arrangements",
     "shortName": "Lease Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreement",
     "longName": "0000018 - Disclosure - Revenue Interest Purchase Agreement",
     "shortName": "Revenue Interest Purchase Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.immunitybio.com/role/RelatedPartyDebt",
     "longName": "0000019 - Disclosure - Related-Party Debt",
     "shortName": "Related-Party Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreements",
     "longName": "0000020 - Disclosure - Related-Party Agreements",
     "shortName": "Related-Party Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://www.immunitybio.com/role/WarrantLiabilities",
     "longName": "0000021 - Disclosure - Warrant Liabilities",
     "shortName": "Warrant Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.immunitybio.com/role/StockholdersDeficit",
     "longName": "0000022 - Disclosure - Stockholders\u2019 Deficit",
     "shortName": "Stockholders\u2019 Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.immunitybio.com/role/StockBasedCompensation",
     "longName": "0000023 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.immunitybio.com/role/IncomeTaxes",
     "longName": "0000024 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.immunitybio.com/role/EmployeeBenefits",
     "longName": "0000025 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.immunitybio.com/role/DescriptionofBusinessTables",
     "longName": "9954472 - Disclosure - Description of Business (Tables)",
     "shortName": "Description of Business (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954473 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsTables",
     "longName": "9954474 - Disclosure - Financial Statement Details (Tables)",
     "shortName": "Financial Statement Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsTables",
     "longName": "9954475 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.immunitybio.com/role/FairValueMeasurementsTables",
     "longName": "9954476 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables",
     "longName": "9954477 - Disclosure - Collaboration and License Agreements and Acquisition (Tables)",
     "shortName": "Collaboration and License Agreements and Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.immunitybio.com/role/LeaseArrangementsTables",
     "longName": "9954478 - Disclosure - Lease Arrangements (Tables)",
     "shortName": "Lease Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementTables",
     "longName": "9954479 - Disclosure - Revenue Interest Purchase Agreement (Tables)",
     "shortName": "Revenue Interest Purchase Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:SummarizesTheRevenueInterestLiabilityActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:SummarizesTheRevenueInterestLiabilityActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtTables",
     "longName": "9954480 - Disclosure - Related-Party Debt (Tables)",
     "shortName": "Related-Party Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsTables",
     "longName": "9954481 - Disclosure - Related-Party Agreements (Tables)",
     "shortName": "Related-Party Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.immunitybio.com/role/StockBasedCompensationTables",
     "longName": "9954482 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.immunitybio.com/role/IncomeTaxesTables",
     "longName": "9954483 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
     "longName": "9954484 - Disclosure - Description of Business - Additional Information (Details)",
     "shortName": "Description of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-622",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:PaymentsForMergerRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
     "longName": "9954485 - Disclosure - Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Consolidated Statements of Operations (Detail)",
     "shortName": "Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Consolidated Statements of Operations (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails",
     "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail",
     "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails",
     "longName": "9954489 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail",
     "longName": "9954490 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ibrx:PrepaidResearchAndDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ibrx:PrepaidResearchAndDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
     "longName": "9954491 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)",
     "shortName": "Financial Statement Details - Property, Plant and Equipment, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
     "longName": "9954492 - Disclosure - Financial Statement Details - Additional Information (Detail)",
     "shortName": "Financial Statement Details - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails",
     "longName": "9954493 - Disclosure - Financial Statement Details - Intangible Assets, Net (Details)",
     "shortName": "Financial Statement Details - Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail",
     "longName": "9954494 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)",
     "shortName": "Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedBonusesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail",
     "longName": "9954495 - Disclosure - Financial Statement Details - Interest and Investment Income (Loss), Net (Detail)",
     "shortName": "Financial Statement Details - Interest and Investment Income (Loss), Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails",
     "longName": "9954496 - Disclosure - Financial Statement Details - Interest Expense (Details)",
     "shortName": "Financial Statement Details - Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:AmortizationOfDebtDiscountPremiumRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:AmortizationOfDebtDiscountPremiumRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail",
     "longName": "9954497 - Disclosure - Financial Instruments - Available-for-Sale Marketable Debt Securities (Detail)",
     "shortName": "Financial Instruments - Available-for-Sale Marketable Debt Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
     "longName": "9954498 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)",
     "shortName": "Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "security",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
     "longName": "9954499 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
     "longName": "9954500 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "9954501 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ibrx:EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
     "longName": "9954502 - Disclosure - Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)",
     "shortName": "Collaboration and License Agreements and Acquisition - Collaboration Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-311",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
     "longName": "9954503 - Disclosure - Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)",
     "shortName": "Collaboration and License Agreements and Acquisition - License Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-315",
      "name": "ibrx:CollaborationAgreementsPeriodicLicensePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
     "longName": "9954504 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)",
     "shortName": "Collaboration and License Agreements and Acquisition - Acquisition - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-371",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-339",
      "name": "ibrx:NumberOfSquareFeetOfFacilityLeased",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
     "longName": "9954505 - Disclosure - Collaboration and License Agreements and Acquisition - Acquisition (Details)",
     "shortName": "Collaboration and License Agreements and Acquisition - Acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-339",
      "name": "us-gaap:ConstructionInProgressGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
     "longName": "9954506 - Disclosure - Commitments and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-351",
      "name": "ibrx:ContingentValueRightsObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-351",
      "name": "ibrx:ContingentValueRightsObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
     "longName": "9954507 - Disclosure - Commitments and Contingencies - Litigation - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Litigation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:MinorityInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-366",
      "name": "us-gaap:MinorityInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails",
     "longName": "9954508 - Disclosure - Commitments and Contingencies - Unconditional Purchase Obligations (Details)",
     "shortName": "Commitments and Contingencies - Unconditional Purchase Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-367",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-367",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
     "longName": "9954509 - Disclosure - Lease Arrangements - Additional Information (Detail)",
     "shortName": "Lease Arrangements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails",
     "longName": "9954510 - Disclosure - Lease Arrangements - Supplemental Balance Sheet Information (Details)",
     "shortName": "Lease Arrangements - Supplemental Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail",
     "longName": "9954511 - Disclosure - Lease Arrangements - Summary of Information Regarding Leases (Detail)",
     "shortName": "Lease Arrangements - Summary of Information Regarding Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail",
     "longName": "9954512 - Disclosure - Lease Arrangements - Components of Lease Expense (Detail)",
     "shortName": "Lease Arrangements - Components of Lease Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail",
     "longName": "9954513 - Disclosure - Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)",
     "shortName": "Lease Arrangements - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail",
     "longName": "9954514 - Disclosure - Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)",
     "shortName": "Lease Arrangements - Summary of Future Minimum Lease Payments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
     "longName": "9954515 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)",
     "shortName": "Revenue Interest Purchase Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-96",
      "name": "ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails",
     "longName": "9954516 - Disclosure - Revenue Interest Purchase Agreement - Summary of the Revenue Interest Liability Activity (Details)",
     "shortName": "Revenue Interest Purchase Agreement - Summary of the Revenue Interest Liability Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ibrx:SummarizesTheRevenueInterestLiabilityActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
     "longName": "9954517 - Disclosure - Related-Party Debt - Summary of Related-Party Promissory Notes (Detail)",
     "shortName": "Related-Party Debt - Summary of Related-Party Promissory Notes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-466",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-391",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
     "longName": "9954518 - Disclosure - Related-Party Debt - Additional Information (Details)",
     "shortName": "Related-Party Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-466",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-160",
      "name": "ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
     "longName": "9954519 - Disclosure - Related Party Debt - Estimated Fair Value of Convertible Note (Details)",
     "shortName": "Related Party Debt - Estimated Fair Value of Convertible Note (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-498",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
     "longName": "9954520 - Disclosure - Related Party Debt - Related Party Promissory Notes (Details)",
     "shortName": "Related Party Debt - Related Party Promissory Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-160",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-506",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
     "longName": "9954521 - Disclosure - Related-Party Debt - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)",
     "shortName": "Related-Party Debt - Estimated Material Contractual Obligations Related to Related-Party Promissory Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-513",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-513",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail",
     "longName": "9954522 - Disclosure - Related-Party Agreements - Outstanding Balances of Related-Party Agreements (Detail)",
     "shortName": "Related-Party Agreements - Outstanding Balances of Related-Party Agreements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-514",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
     "longName": "9954523 - Disclosure - Related-Party Agreements - Additional Information (Detail)",
     "shortName": "Related-Party Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-536",
      "name": "ibrx:NumberOfSquareFeetOfFacilityLeased",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.immunitybio.com/role/WarrantLiabilitiesDetails",
     "longName": "9954524 - Disclosure - Warrant Liabilities (Details)",
     "shortName": "Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-605",
      "name": "ibrx:TransactionCostsWarrantLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
     "longName": "9954525 - Disclosure - Stockholders' Deficit - Additional Information (Detail)",
     "shortName": "Stockholders' Deficit - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-620",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "longName": "9954526 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-656",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail",
     "longName": "9954527 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expenses Related to Statement of Operations (Detail)",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expenses Related to Statement of Operations (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail",
     "longName": "9954528 - Disclosure - Stock-Based Compensation - Stock Option Activity and Related Information under Equity Plans (Detail)",
     "shortName": "Stock-Based Compensation - Stock Option Activity and Related Information under Equity Plans (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail",
     "longName": "9954529 - Disclosure - Stock-Based Compensation - Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model (Detail)",
     "shortName": "Stock-Based Compensation - Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-657",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-657",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail",
     "longName": "9954530 - Disclosure - Stock-Based Compensation - RSU Activity under Equity Plans (Detail)",
     "shortName": "Stock-Based Compensation - RSU Activity under Equity Plans (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-660",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-660",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails",
     "longName": "9954531 - Disclosure - Income Taxes - Loss Before Taxes, Domestic and Foreign (Details)",
     "shortName": "Income Taxes - Loss Before Taxes, Domestic and Foreign (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails",
     "longName": "9954532 - Disclosure - Income Taxes - Components of Income Tax Benefit (Provision) (Details)",
     "shortName": "Income Taxes - Components of Income Tax Benefit (Provision) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954533 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "9954534 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails",
     "longName": "9954535 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails",
     "longName": "9954536 - Disclosure - Income Taxes - Changes to Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Changes to Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.immunitybio.com/role/EmployeeBenefitsDetails",
     "longName": "9954537 - Disclosure - Employee Benefits (Details)",
     "shortName": "Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibrx-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ibrx_A125MillionAugust2022PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A125MillionAugust2022PromissoryNoteMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$125 Million August 2022 Promissory Note",
        "label": "$125 Million August 2022 Promissory Note [Member]",
        "documentation": "$125 Million August 2022 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A200MillionSeptember2023PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A200MillionSeptember2023PromissoryNoteMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$200 Million September 2023 Promissory Note",
        "label": "$200 Million September 2023 Promissory Note [Member]",
        "documentation": "$200 Million September 2023 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A2014PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A2014PlanMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Plan",
        "label": "2014 Plan [Member]",
        "documentation": "2014 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A23AlaskaLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A23AlaskaLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "23 Alaska, LLC",
        "label": "23 Alaska, LLC [Member]",
        "documentation": "23 Alaska, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A300MillionDecember2021PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A300MillionDecember2021PromissoryNoteMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$300 Million December 2021 Promissory Note",
        "label": "$300 Million December 2021 Promissory Note [Member]",
        "documentation": "$300 Million December 2021 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A30MillionJune2023PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A30MillionJune2023PromissoryNoteMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$30 Million June 2023 Promissory Note",
        "label": "$30 Million June 2023 Promissory Note [Member]",
        "documentation": "$30 Million June 2023 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A30MillionMarch2023PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A30MillionMarch2023PromissoryNoteMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$30 Million March 2023 Promissory Note",
        "label": "$30 Million March 2023 Promissory Note [Member]",
        "documentation": "$30 Million March 2023 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A3MIPCAndAAHIAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A3MIPCAndAAHIAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3M IPC and Access to Advanced Health Institute License Agreement",
        "label": "3M IPC and AAHI Agreement [Member]",
        "documentation": "3M IPC and AAHI Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A505MillionPromissoryNoteDecember2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A505MillionPromissoryNoteDecember2023Member",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$505\u00a0million December 2023 Promissory Note",
        "label": "$505 Million Promissory Note, December 2023 [Member]",
        "documentation": "$505 Million Promissory Note, December 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A505MillionPromissoryNoteDecember2023Tranche1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A505MillionPromissoryNoteDecember2023Tranche1Member",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$505 Million December 2023 Promissory Note - Tranche 1",
        "label": "$505 Million Promissory Note, December 2023, Tranche 1 [Member]",
        "documentation": "$505 Million Promissory Note, December 2023, Tranche 1"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A505MillionPromissoryNoteDecember2023TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A505MillionPromissoryNoteDecember2023TrancheTwoMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$505 Million Promissory Note, December 2023, Tranche Two",
        "label": "$505 Million Promissory Note, December 2023, Tranche Two [Member]",
        "documentation": "$505 Million Promissory Note, December 2023, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_A50MillionDecember2022PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "A50MillionDecember2022PromissoryNoteMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$50 Million December 2022 Promissory Note",
        "label": "$50 Million December 2022 Promissory Note [Member]",
        "documentation": "$50 Million December 2022 Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AAHIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AAHIMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Access to Advanced Health Institute (AAHI)",
        "label": "AAHI [Member]",
        "documentation": "AAHI"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of embedded conversion feature from debt modification with entities under common control (Note 10)",
        "label": "APIC, Debt Instrument, Convertible, Increase In Fair Value Of Embedded Conversion Feature",
        "documentation": "APIC, Debt Instrument, Convertible, Increase In Fair Value Of Embedded Conversion Feature"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Line Items]",
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Table]",
        "label": "Accounting Policies [Table]",
        "documentation": "Accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "verboseLabel": "Total due to related parties",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r913"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from related parties",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of premiums, net of discounts, on marketable debt securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses and other liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ibrx_AccruedPreclinicalAndClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AccruedPreclinicalAndClinicalTrialCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued preclinical and clinical trial costs",
        "label": "Accrued Preclinical And Clinical Trial Costs",
        "documentation": "Accrued preclinical and clinical trial costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional and service fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ibrx_AccruedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development costs",
        "label": "Accrued Research And Development Costs",
        "documentation": "Accrued research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r879"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r265",
      "r718"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r157",
      "r273",
      "r713",
      "r739",
      "r740"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29",
      "r55",
      "r595",
      "r598",
      "r645",
      "r735",
      "r736",
      "r966",
      "r967",
      "r968",
      "r981",
      "r982",
      "r983"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statement Details",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r913",
      "r1085"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r754",
      "r981",
      "r982",
      "r983",
      "r1056",
      "r1087"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net share settlement for RSUs vesting",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on extinguishment of debt with related parties under common control",
        "verboseLabel": "Gain on extinguishment of debt with related parties under common control",
        "label": "Adjustments To Additional Paid In Capital, Gain (Loss) On Extinguishment Of Debt With Related Party",
        "documentation": "Adjustments To Additional Paid In Capital, Gain (Loss) On Extinguishment Of Debt With Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of assets to an entity under common control",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r514"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions and offering costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r185"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AdvancesToRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AdvancesToRelatedPartyMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances To Related Party",
        "label": "Advances To Related Party [Member]",
        "documentation": "Advances To Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated Entity",
        "label": "Affiliated Entity [Member]",
        "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r796",
      "r871",
      "r918",
      "r1015",
      "r1066",
      "r1067",
      "r1069"
     ]
    },
    "us-gaap_AgencySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AgencySecuritiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government-sponsored securities",
        "label": "Agency Securities [Member]",
        "documentation": "Securities issued by government sponsored entities."
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r551"
     ]
    },
    "ibrx_AltorBioScienceLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AltorBioScienceLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Altor BioScience, LLC",
        "label": "Altor BioScience, LLC [Member]",
        "documentation": "Altor BioScience, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AltorStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AltorStockholdersMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Altor Stockholders",
        "label": "Altor Stockholders [Member]",
        "documentation": "Altor Stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r132",
      "r165",
      "r473"
     ]
    },
    "ibrx_AmortizationOfDebtDiscountPremiumRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AmortizationOfDebtDiscountPremiumRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of related-party notes discounts",
        "label": "Amortization Of Debt Discount (Premium), Related Party",
        "documentation": "Amortization Of Debt Discount (Premium), Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of related-party notes discounts",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r624",
      "r897",
      "r898",
      "r972"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r77",
      "r82"
     ]
    },
    "ibrx_AmyrisIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AmyrisIncMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amyris, Inc.",
        "label": "Amyris, Inc. [Member]",
        "documentation": "Amyris, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AmyrisJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AmyrisJointVentureMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amyris Joint Venture",
        "label": "Amyris Joint Venture [Member]",
        "documentation": "Amyris Joint Venture"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AnnualPercentageIncreaseToLicenseFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AnnualPercentageIncreaseToLicenseFee",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual percentage increase to base rent",
        "label": "Annual Percentage Increase to License Fee",
        "documentation": "Annual percentage increase to base rent."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AnnualPercentageIncreasesToBaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AnnualPercentageIncreasesToBaseRent",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of annual increases of base rent",
        "label": "Annual Percentage Increases To Base Rent",
        "documentation": "Annual percentage increases to base rent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ibrx_AssetAcquisitionFairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AssetAcquisitionFairValueOfAssetsAcquired",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Asset Acquisition, Fair Value Of Assets Acquired",
        "documentation": "Asset Acquisition, Fair Value Of Assets Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Line Items]",
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Table]",
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Asset Acquisition",
        "label": "Asset Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r269",
      "r308",
      "r340",
      "r355",
      "r361",
      "r404",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r449",
      "r450",
      "r588",
      "r592",
      "r614",
      "r710",
      "r789",
      "r913",
      "r928",
      "r1007",
      "r1008",
      "r1070"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r276",
      "r308",
      "r404",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r449",
      "r450",
      "r588",
      "r592",
      "r614",
      "r913",
      "r1007",
      "r1008",
      "r1070"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ibrx_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Offering Program",
        "verboseLabel": "At-the-Market",
        "label": "At The Market Offering Program [Member]",
        "documentation": "At-The-Market offering program."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.immunitybio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.immunitybio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.immunitybio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r412",
      "r709"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r412",
      "r701",
      "r987"
     ]
    },
    "ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesPeriod",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual\u00a0Life (in years)",
        "label": "Available For Sale Securities Debt Securities Period",
        "documentation": "Available for sale securities debt securities period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r124"
     ]
    },
    "ibrx_BaseMonthlyRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "BaseMonthlyRent",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base rent - monthly",
        "label": "Base Monthly Rent",
        "documentation": "Base monthly rent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_BrinkBiologicsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "BrinkBiologicsIncMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brink Biologics, Inc.",
        "label": "Brink Biologics, Inc. [Member]",
        "documentation": "Brink Biologics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r904",
      "r905"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r585",
      "r904",
      "r905"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, consideration transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r27"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum milestone payment due if certain conditions are met",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High",
        "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ibrx_BusinessCombinationContingentConsiderationArrangementsEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationArrangementsEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration arrangements, earned",
        "label": "Business Combination, Contingent Consideration Arrangements, Earned",
        "documentation": "Business Combination, Contingent Consideration Arrangements, Earned"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationArrangementsSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration arrangements, paid",
        "label": "Business Combination, Contingent Consideration Arrangements, Settlements",
        "documentation": "Business Combination, Contingent Consideration Arrangements, Settlements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Treatment of the Merger",
        "label": "Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ibrx_CGMPBatchesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CGMPBatchesMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "cGMP Batches",
        "label": "cGMP Batches [Member]",
        "documentation": "cGMP Batches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment purchases included in accounts payable, accrued expenses and due to related parties",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r263",
      "r876"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r199"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash, end of year:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of year",
        "totalLabel": "Cash, cash equivalents, and restricted cash, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r169",
      "r304"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r169"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Operating Activities Lessee [Abstract]",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r339",
      "r483",
      "r484",
      "r485",
      "r487",
      "r490",
      "r495",
      "r497",
      "r743",
      "r744",
      "r745",
      "r746",
      "r899",
      "r941",
      "r973"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ibrx_CollaborationAgreementsAnnualMinimumLicensingPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsAnnualMinimumLicensingPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual minimum licensing payment",
        "label": "Collaboration Agreements, Annual Minimum Licensing Payment",
        "documentation": "Collaboration Agreements, Annual Minimum Licensing Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual payment for support of research activities",
        "label": "Collaboration Agreements, Annual Payment For Support Of Research Activities",
        "documentation": "Annual payment for support of research activities."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsAnnualProjectFundingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsAnnualProjectFundingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual project funding amount",
        "label": "Collaboration Agreements, Annual Project Funding Amount",
        "documentation": "Collaboration Agreements, Annual Project Funding Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsLicenseMaintenanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsLicenseMaintenanceFees",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License maintenance fees",
        "label": "Collaboration Agreements, License Maintenance Fees",
        "documentation": "Collaboration Agreements, License Maintenance Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsLicenseMaintenanceFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsLicenseMaintenanceFeesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License payable",
        "label": "Collaboration Agreements, License Maintenance Fees Payable",
        "documentation": "Collaboration Agreements, License Maintenance Fees Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsMilestoneFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsMilestoneFees",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone fees",
        "label": "Collaboration Agreements, Milestone Fees",
        "documentation": "Collaboration Agreements, Milestone Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsMilestonePaymentAggregateMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsMilestonePaymentAggregateMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment, aggregate maximum",
        "label": "Collaboration Agreements, Milestone Payment, Aggregate Maximum",
        "documentation": "Collaboration Agreements, Milestone Payment, Aggregate Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsMilestonePaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsMilestonePaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment, amount",
        "label": "Collaboration Agreements, Milestone Payment, Amount",
        "documentation": "Collaboration Agreements, Milestone Payment, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsMilestonePaymentPayableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsMilestonePaymentPayableAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment, payable amount",
        "label": "Collaboration Agreements, Milestone Payment, Payable Amount",
        "documentation": "Milestone payment amount."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsNonrefundableUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsNonrefundableUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront cash payments",
        "label": "Collaboration Agreements, Nonrefundable Upfront Payment",
        "documentation": "Nonrefundable upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsNumberOfLicenseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsNumberOfLicenseAgreements",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of license agreements",
        "label": "Collaboration Agreements, Number Of License Agreements",
        "documentation": "Collaboration Agreements, Number Of License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsPaymentForSupportOfResearchActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsPaymentForSupportOfResearchActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for support of research activities",
        "label": "Collaboration Agreements, Payment For Support Of Research Activities",
        "documentation": "Collaboration Agreements, Payment For Support Of Research Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsPeriodicLicensePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsPeriodicLicensePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic license payments",
        "label": "Collaboration Agreements, Periodic License Payments",
        "documentation": "Collaboration Agreements, Periodic License Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborationAgreementsTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborationAgreementsTerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fee",
        "label": "Collaboration Agreements, Termination Fee",
        "documentation": "Collaboration Agreements, Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022",
        "label": "Collaborative Arrangement And Arrangement Other Than Collaborative, Fee One [Member]",
        "documentation": "Collaborative Arrangement And Arrangement Other Than Collaborative, Fee One"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Axis]",
        "label": "Collaborative Arrangement And Arrangement Other Than Collaborative, Fee Schedule [Axis]",
        "documentation": "Collaborative Arrangement And Arrangement Other Than Collaborative, Fee Schedule"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]",
        "label": "Collaborative Arrangement And Arrangement Other Than Collaborative, Fee Schedule [Domain]",
        "documentation": "Collaborative Arrangement and Arrangement Other than Collaborative, Fee Schedule [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 through 2030",
        "label": "Collaborative Arrangement And Arrangement Other Than Collaborative, Fee, Tranche Two [Member]",
        "documentation": "Collaborative Arrangement And Arrangement Other Than Collaborative, Fee, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r140",
      "r711",
      "r775"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r431",
      "r432",
      "r860",
      "r1004"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r861"
     ]
    },
    "ibrx_CommonControlTransactionPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CommonControlTransactionPolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Control Transactions",
        "label": "Common Control Transaction, Policy [Policy Text Block]",
        "documentation": "Common Control Transaction, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CommonStockDiscountOnSharesRevenueInterestLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CommonStockDiscountOnSharesRevenueInterestLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issuance discount related to the revenue interest liability",
        "label": "Common Stock, Discount On Shares, Revenue Interest Liability",
        "documentation": "Common Stock, Discount On Shares, Revenue Interest Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r916",
      "r917",
      "r919",
      "r920",
      "r921",
      "r922",
      "r981",
      "r982",
      "r1056",
      "r1084",
      "r1087"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ibrx_CommonStockRevenueInterestPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CommonStockRevenueInterestPurchaseAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Common Stock, Revenue Interest Purchase Agreement [Member]",
        "documentation": "Common Stock, Revenue Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r776"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r151",
      "r776",
      "r795",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001\u00a0par value; 1,350,000,000 and 900,000,000\u00a0shares authorized as of December\u00a031,\u00a02023 and 2022, respectively; 670,867,344 and 421,569,115 shares issued and outstanding as of December\u00a031,\u00a02023 and 2022, respectively; excluding 163,800\u00a0treasury stock shares outstanding as of December\u00a031,\u00a02023 and 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r712",
      "r913"
     ]
    },
    "ibrx_CommonStockValueAvailableForFutureStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CommonStockValueAvailableForFutureStockIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available for future stock issuance",
        "label": "Common Stock Value Available For Future Stock Issuance",
        "documentation": "Common stock value available for future stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefits",
        "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]",
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188"
     ]
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to ImmunityBio common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r282",
      "r284",
      "r294",
      "r705",
      "r729"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Comprehensive loss attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r115",
      "r119",
      "r282",
      "r284",
      "r293",
      "r704",
      "r728"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r195",
      "r282",
      "r284",
      "r292",
      "r703",
      "r727"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IT equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r229"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r315",
      "r588",
      "r589",
      "r592",
      "r593",
      "r654",
      "r871",
      "r956",
      "r959",
      "r960",
      "r1006",
      "r1009",
      "r1010"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r315",
      "r588",
      "r589",
      "r592",
      "r593",
      "r654",
      "r871",
      "r956",
      "r959",
      "r960",
      "r1006",
      "r1009",
      "r1010"
     ]
    },
    "srt_ConsolidationEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationEliminationsMember",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany Eliminations",
        "label": "Consolidation, Eliminations [Member]",
        "documentation": "Eliminating entries used in consolidating a parent entity and its subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Legal Entities",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r315",
      "r342",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r362",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r444",
      "r446",
      "r448",
      "r449",
      "r957",
      "r958",
      "r1007",
      "r1008"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r315",
      "r342",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r362",
      "r438",
      "r439",
      "r440",
      "r441",
      "r443",
      "r444",
      "r446",
      "r448",
      "r449",
      "r957",
      "r958",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r883"
     ]
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails": {
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued construction costs",
        "label": "Construction Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Contingent Consideration [Member]",
        "documentation": "Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ContingentValueRightsObligationSalesMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ContingentValueRightsObligationSalesMilestoneMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Value Rights Obligation, Sales Milestone",
        "label": "Contingent Value Rights Obligation, Sales Milestone [Member]",
        "documentation": "Contingent value rights obligation before December 31, 2026."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ContingentValueRightsObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ContingentValueRightsObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent value rights obligations",
        "label": "Contingent Value Rights Obligations",
        "documentation": "Contingent value rights obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r502"
     ]
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Contractual Obligations for Related-Party Notes Payable",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-party convertible notes and accrued interest, net of discount (Note 10)",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ibrx_ConvertibleNoteReceivableDiscountOptionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ConvertibleNoteReceivableDiscountOptionPercent",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note receivable, discount option, percent",
        "label": "Convertible Note Receivable, Discount Option, Percent",
        "documentation": "Convertible Note Receivable, Discount Option, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ConvertibleNoteReceivableNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ConvertibleNoteReceivableNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note receivable",
        "label": "Convertible Note Receivable Non Current",
        "documentation": "Convertible note receivable, non-current."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ConvertibleNotesFairValueOptionElectionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ConvertibleNotesFairValueOptionElectionPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Option Election",
        "label": "Convertible Notes, Fair Value Option Election [Policy Text Block]",
        "documentation": "Convertible Notes, Fair Value Option Election"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r201"
     ]
    },
    "ibrx_CooperativeResearchAndDevelopmentAgreement2015AmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CooperativeResearchAndDevelopmentAgreement2015AmendmentMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 CRADA, Amendment",
        "label": "Cooperative Research And Development Agreement, 2015 Amendment [Member]",
        "documentation": "Cooperative Research And Development Agreement, 2015 Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CooperativeResearchAndDevelopmentAgreement2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CooperativeResearchAndDevelopmentAgreement2015Member",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 CRADA",
        "label": "Cooperative Research And Development Agreement, 2015 [Member]",
        "documentation": "Cooperative research and development agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r901",
      "r903",
      "r1083"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r313",
      "r314",
      "r455",
      "r485",
      "r652",
      "r880",
      "r882"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_CurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CurrentAssetsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Current Assets [Member]",
        "documentation": "Current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r976",
      "r1049"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r976"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r574",
      "r579",
      "r976"
     ]
    },
    "ibrx_CurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "CurrentLiabilitiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Current Liabilities [Member]",
        "documentation": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r976",
      "r1049"
     ]
    },
    "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses from equity securities",
        "label": "Debt and Equity Securities, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r813",
      "r848",
      "r849",
      "r850",
      "r969",
      "r970"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of related-party convertible notes and accrued interest, net of unamortized discount, into equity",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Interest Purchase Agreement",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r306",
      "r451",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r467",
      "r474",
      "r475",
      "r477"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r146",
      "r147",
      "r201",
      "r203",
      "r315",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r625",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r974"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate spread",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Amount",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r203",
      "r478"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r454"
     ]
    },
    "ibrx_DebtInstrumentDebtDiscountRecordedInThePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DebtInstrumentDebtDiscountRecordedInThePeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount",
        "label": "Debt Instrument, Debt Discount Recorded In The Period",
        "documentation": "Debt Instrument, Debt Discount Recorded In The Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r135",
      "r452",
      "r625",
      "r895",
      "r896"
     ]
    },
    "ibrx_DebtInstrumentFaceAmountPerTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DebtInstrumentFaceAmountPerTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount, per tranche",
        "label": "Debt Instrument, Face Amount, Per Tranche",
        "documentation": "Debt Instrument, Face Amount, Per Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r133",
      "r480",
      "r625"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r453"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable inputs, Level 3 valuations",
        "label": "Debt Instrument, Measurement Input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r315",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r625",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r974"
     ]
    },
    "ibrx_DebtInstrumentNumberOfAdvances": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DebtInstrumentNumberOfAdvances",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of advances",
        "label": "Debt Instrument, Number Of Advances",
        "documentation": "Debt Instrument, Number Of Advances"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DebtInstrumentPrepaymentAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DebtInstrumentPrepaymentAndAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment and accrued interest upon specified transaction",
        "label": "Debt Instrument, Prepayment And Accrued Interest",
        "documentation": "Debt Instrument, Prepayment And Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt discount",
        "terseLabel": "Less: Unamortized Discounts",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r135",
      "r1012"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt premium",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r135",
      "r1012"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Modification and Extinguishment",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 12 months, Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r415",
      "r891"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "More than 12 months, Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r415"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months, Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r415",
      "r891"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less than 12 months, Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r415"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Available For Sale Securities [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r891",
      "r997"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, unrealized loss position, number of positions",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r414"
     ]
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r917",
      "r1091"
     ]
    },
    "ibrx_December2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "December2022WarrantsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2022 Warrants",
        "label": "December 2022 Warrants [Member]",
        "documentation": "December 2022 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "ibrx_DeferredIncomeTaxExpenseBenefitNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, net",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r1012"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "ibrx_DeferredIncomeTaxExpenseBenefitNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r976",
      "r1048"
     ]
    },
    "ibrx_DeferredIncomeTaxExpenseBenefitNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DeferredIncomeTaxExpenseBenefitNet",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit), Net",
        "documentation": "Deferred Income Tax Expense (Benefit), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r202",
      "r568"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement agent fees and other offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredRevenueArrangementByTypeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementByTypeTable",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue Arrangement, by Type [Table]",
        "label": "Deferred Revenue Arrangement, by Type [Table]",
        "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueArrangementLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue Arrangement [Line Items]",
        "label": "Deferred Revenue Arrangement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": "ibrx_DeferredIncomeTaxExpenseBenefitNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ibrx_DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, interest expense temporarily disallowed",
        "label": "Deferred Tax Asset Not Recognized, Interest Expense Temporarily Disallowed",
        "documentation": "Deferred Tax Asset Not Recognized, Interest Expense Temporarily Disallowed"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DeferredTaxAssetNotRecognizedSection382383Limitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DeferredTaxAssetNotRecognizedSection382383Limitations",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets not recognized due to limitations",
        "label": "Deferred Tax Asset Not Recognized, Section 382/383 Limitations",
        "documentation": "Deferred Tax Asset Not Recognized, Section 382/383 Limitations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 R&amp;E capitalization",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Deferred Tax Assets, Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses not subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ibrx_DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion of valuation allowance credited directly to contributed capital",
        "label": "Deferred Tax Assets, Valuation Allowance, Tax Benefits Credited To Contributed Capital",
        "documentation": "Deferred Tax Assets, Valuation Allowance, Tax Benefits Credited To Contributed Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DeferredTaxAssetsValuationDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DeferredTaxAssetsValuationDiscount",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation discount",
        "label": "Deferred Tax Assets, Valuation Discount",
        "documentation": "Deferred Tax Assets, Valuation Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1046"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt discount",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Indefinite-lived intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r1047"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discretionary contributions",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r83"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r344"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r767",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r808",
      "r809",
      "r810",
      "r811",
      "r814",
      "r815",
      "r816",
      "r817",
      "r840",
      "r841",
      "r842",
      "r843",
      "r915",
      "r917"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r125",
      "r126",
      "r764",
      "r767",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r808",
      "r809",
      "r810",
      "r811",
      "r814",
      "r815",
      "r816",
      "r817",
      "r840",
      "r841",
      "r842",
      "r843",
      "r882",
      "r915",
      "r917"
     ]
    },
    "ibrx_DerivativeLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DerivativeLiabilitiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities",
        "label": "Derivative Liabilities [Member]",
        "documentation": "Derivative Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesEmbeddedDerivatives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesEmbeddedDerivatives",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities",
        "label": "Derivatives, Embedded Derivatives [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r5",
      "r8",
      "r9"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r516",
      "r544",
      "r545",
      "r547",
      "r907"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed dividends",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r185"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935",
      "r937"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DrSoonShiongAndRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DrSoonShiongAndRelatedPartyMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr Soon Shiong And Related Party",
        "label": "Dr Soon Shiong And Related Party [Member]",
        "documentation": "Dr. Soon-Shiong and related party."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DueToRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DueToRelatedPartiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to Related Parties",
        "label": "Due To Related Parties [Member]",
        "documentation": "Due to related parties."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DuleyRoadLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DuleyRoadLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duley Road, LLC",
        "label": "Duley Road, LLC [Member]",
        "documentation": "Duley Road, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DuleyRoadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DuleyRoadMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duley Road, LLC",
        "label": "Duley Road [Member]",
        "documentation": "Duley Road."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_DunkirkFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "DunkirkFacilityMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dunkirk Facility",
        "label": "Dunkirk Facility [Member]",
        "documentation": "Dunkirk Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ImmunityBio common share - basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r329",
      "r331",
      "r333",
      "r334",
      "r335",
      "r337",
      "r603",
      "r604",
      "r706",
      "r730",
      "r885"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ImmunityBio common share - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r331",
      "r333",
      "r334",
      "r335",
      "r337",
      "r603",
      "r604",
      "r706",
      "r730",
      "r885"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Net Loss Per Share of Common Stock",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r560",
      "r581"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1050"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate adjustment",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r1044"
     ]
    },
    "ibrx_EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of convertible notes",
        "label": "Effective Income Tax Rate Reconciliation, Convertible Notes, Change In Fair Value",
        "documentation": "Effective Income Tax Rate Reconciliation, Convertible Notes, Change In Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment loss",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Investment Loss",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Investment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1050"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1050"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1050"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1050"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1050"
     ]
    },
    "ibrx_EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrants",
        "label": "Effective Income Tax Rate Reconciliation, Warrants, Change In Fair Value",
        "documentation": "Effective Income Tax Rate Reconciliation, Warrants, Change In Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesReconciliationofFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 162(m) limitation",
        "label": "Effective Income Tax Reconciliation, Nondeductible Expense, Section 162(m) Limitation, Percent",
        "documentation": "Effective Income Tax Reconciliation, Nondeductible Expense, Section 162(m) Limitation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities (Note\u00a09 and Note\u00a010)",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Embedded derivative",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative, Net",
        "documentation": "Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Embedded derivative",
        "label": "Embedded Derivative Financial Instruments [Member]",
        "documentation": "Derivative instrument embedded in host contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmbeddedDerivativeGainOnEmbeddedDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeGainOnEmbeddedDerivative",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in fair value of embedded conversion feature from debt modification",
        "label": "Embedded Derivative, Gain on Embedded Derivative",
        "documentation": "Increase in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, discount rate",
        "label": "Embedded Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure embedded derivative liability."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "ibrx_EmbeddedDerivativeRevenueInterestPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "EmbeddedDerivativeRevenueInterestPurchaseAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Embedded contingent derivative liability",
        "label": "Embedded Derivative, Revenue Interest Purchase Agreement [Member]",
        "documentation": "Embedded Derivative, Revenue Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to unvested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding stock options",
        "terseLabel": "Stock Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r258",
      "r286",
      "r287",
      "r288",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r328",
      "r338",
      "r405",
      "r406",
      "r499",
      "r548",
      "r549",
      "r550",
      "r575",
      "r576",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r602",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r645",
      "r735",
      "r736",
      "r737",
      "r754",
      "r820"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method of Accounting",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r130",
      "r402"
     ]
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesByIndustryAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector",
        "label": "Industry Sector [Axis]",
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r760",
      "r763",
      "r831",
      "r834",
      "r839",
      "r851",
      "r890",
      "r917"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized losses on equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r995"
     ]
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesIndustryMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector",
        "label": "Industry Sector [Domain]",
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r760",
      "r763",
      "r831",
      "r834",
      "r839",
      "r851",
      "r917"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r923",
      "r924",
      "r925",
      "r1091"
     ]
    },
    "ibrx_EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value stock purchase option",
        "label": "Estimated Fair Value Of Stock Purchase Option At Issuance And Change In Fair Value",
        "documentation": "Estimated Fair Value Of Stock Purchase Option At Issuance And Change In Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1092",
      "r1093",
      "r1094"
     ]
    },
    "ibrx_ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Chairman and Global Chief Scientific and Medical Officer",
        "label": "Executive Chairman And Global Chief Scientific And Medical Officer [Member]",
        "documentation": "Executive Chairman and principal stockholder, and affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ExpansionPremisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ExpansionPremisesMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expansion Premises",
        "label": "Expansion Premises [Member]",
        "documentation": "Amendment for expansion of premises, lease term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of Debt [Axis]",
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of Debt, Type [Domain]",
        "label": "Extinguishment of Debt, Type [Domain]",
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liabilities",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r21"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607",
      "r612"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607",
      "r612"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r129"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r607",
      "r658",
      "r659",
      "r660",
      "r895",
      "r896",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r198"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607",
      "r609",
      "r610",
      "r613"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r504",
      "r509",
      "r607",
      "r658",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r504",
      "r509",
      "r607",
      "r659",
      "r895",
      "r896",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r607",
      "r660",
      "r895",
      "r896",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net increase (decrease) in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, beginning of year",
        "periodEndLabel": "Fair value, end of year",
        "terseLabel": "Fair value of warrants",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r658",
      "r659",
      "r660",
      "r895",
      "r896",
      "r901",
      "r902",
      "r903"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r613"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r40"
     ]
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of related-party convertible note",
        "negatedTerseLabel": "Change in fair value of convertible note",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ibrx_FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of stock purchase option",
        "label": "Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement [Member]",
        "documentation": "Fair Value, Stock Purchase Option, Revenue Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_February2023ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "February2023ShelfRegistrationStatementMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 2023 Shelf Registration Statement",
        "label": "February 2023 Shelf Registration Statement [Member]",
        "documentation": "February 2023 Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_February2023WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "February2023WarrantsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 2023 Warrants",
        "label": "February 2023 Warrants [Member]",
        "documentation": "February 2023 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease costs (including right-of-use asset amortization and interest expense)",
        "label": "Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense",
        "documentation": "Finance Lease Costs, Right-Of-Use Asset Amortization And Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r640"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r644"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaidAfterYearFive",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ibrx_FinanceLeaseLiabilityTenantImprovementAllowanceReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FinanceLeaseLiabilityTenantImprovementAllowanceReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Tenant improvement allowance receivable",
        "label": "Finance Lease, Liability, Tenant Improvement Allowance Receivable",
        "documentation": "Finance Lease, Liability, Tenant Improvement Allowance Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityUndiscountedExcessInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments of finance leases",
        "terseLabel": "Financing cash flow from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r640"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": "ibrx_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finance lease assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate, Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r912"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term, Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r912"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r416",
      "r417",
      "r476",
      "r495",
      "r600",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r726",
      "r891",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "ibrx_FinancialStatementDetailsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FinancialStatementDetailsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statement Details [Abstract]",
        "label": "Financial Statement Details [Abstract]",
        "documentation": "Financial statement details."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_FinancialStatementDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FinancialStatementDetailsLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statement Details [Line Items]",
        "label": "Financial Statement Details [Line Items]",
        "documentation": "Financial Statement Details [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_FinancialStatementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FinancialStatementDetailsTable",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Statement Details [Table]",
        "label": "Financial Statement Details [Table]",
        "documentation": "Financial Statement Details [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_FinancingObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FinancingObligationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing obligation \u2013 current portion",
        "label": "Financing Obligation, Current",
        "documentation": "Financing Obligation, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r422"
     ]
    },
    "ibrx_FiniteLivedIntangibleAssetsAccumulatedImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "ibrx_IntangibleAssetsAccumulatedImpairment",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment",
        "label": "Finite-Lived Intangible Assets, Accumulated Impairment",
        "documentation": "Finite-Lived Intangible Assets, Accumulated Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r421",
      "r422",
      "r424",
      "r687",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense",
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails": {
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "verboseLabel": "Definite-lived intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r688"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r81"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r687"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-lived intangible assets",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible assets acquired",
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ibrx_FiveFiveSevenDougStLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FiveFiveSevenDougStLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "557 Doug St, LLC",
        "label": "Five Five Seven Doug St, LLC [Member]",
        "documentation": "Five Five Seven Doug St, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currencies",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_ForeignGovernmentDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignGovernmentDebtMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign bonds",
        "label": "Foreign Government Debt [Member]",
        "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity."
       }
      }
     },
     "auth_ref": [
      "r989",
      "r990"
     ]
    },
    "ibrx_FourTwoZeroNashLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "FourTwoZeroNashLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "420 Nash, LLC",
        "label": "Four Two Zero Nash, LLC [Member]",
        "documentation": "Four Two Zero Nash, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture &amp; fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and investment income (loss), net",
        "totalLabel": "Interest and investment income (loss), net",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r940"
     ]
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on disposal of lease",
        "label": "Gain (Loss) on Termination of Lease",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ibrx_GainOnDebtExtinguishmentEntitiesUnderCommonControl": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "GainOnDebtExtinguishmentEntitiesUnderCommonControl",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on debt extinguishment with related-parties under common control (Note 10)",
        "label": "Gain On Debt Extinguishment, Entities Under Common Control",
        "documentation": "Gain On Debt Extinguishment, Entities Under Common Control"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on debt extinguishment",
        "negatedTerseLabel": "Gain on debt extinguishment with entities under common control",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r88",
      "r89"
     ]
    },
    "ibrx_GlobeImmuneIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "GlobeImmuneIncMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GlobeImmune, Inc.",
        "label": "GlobeImmune, Inc. [Member]",
        "documentation": "GlobeImmune, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ERP system implementation costs",
        "label": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of capitalized implementation cost from hosting arrangement that is service contract."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r426"
     ]
    },
    "ibrx_IPRDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IPRDMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D",
        "label": "IPR&amp;D [Member]",
        "documentation": "IPR&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r934",
      "r935"
     ]
    },
    "ibrx_ImmunoOncologyClinicIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ImmunoOncologyClinicIncMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno-Oncology Clinic, Inc.",
        "label": "Immuno Oncology Clinic Inc [Member]",
        "documentation": "Immuno Oncology Clinic Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ImmunoOncologyClinicMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ImmunoOncologyClinicMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immuno-Oncology Clinic, Inc.",
        "label": "Immuno Oncology Clinic [Member]",
        "documentation": "Immuno-Oncology Clinic."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r36"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write off of remaining unamortized organized workforce intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1001"
     ]
    },
    "us-gaap_ImpairmentOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other than temporary impairment losses",
        "label": "Other than Temporary Impairment Losses, Investments",
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_IncentiveFromLessor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncentiveFromLessor",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvements incentive",
        "label": "Incentive from Lessor",
        "documentation": "Amount of incentive received by lessee from lessor."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r942"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r580"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes and noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r159",
      "r207",
      "r340",
      "r354",
      "r360",
      "r362",
      "r707",
      "r721",
      "r887"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesLossBeforeTaxesDomesticandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r580"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on equity method investment",
        "negatedTerseLabel": "Loss on equity method investment",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r160",
      "r206",
      "r345",
      "r400",
      "r720"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r804"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r804"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r555",
      "r561",
      "r565",
      "r572",
      "r577",
      "r582",
      "r583",
      "r584",
      "r748"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
      "http://www.immunitybio.com/role/IncomeTaxesComponentsofIncomeTaxBenefitProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (expense)",
        "negatedTerseLabel": "Income tax expense",
        "negatedTotalLabel": "Total income tax benefit (expense)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r235",
      "r327",
      "r328",
      "r346",
      "r559",
      "r578",
      "r733"
     ]
    },
    "ibrx_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "documentation": "Income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r557",
      "r558",
      "r565",
      "r566",
      "r571",
      "r573",
      "r742"
     ]
    },
    "ibrx_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "documentation": "Income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Increase Decrease In Due To Related Parties Current And Non Current",
        "documentation": "Increase decrease in due to related parties current and non current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r971"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Statements of Stockholders\u2019 Deficit [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_IncreaseToNumberOfSquareFootOfFacilityLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IncreaseToNumberOfSquareFootOfFacilityLeased",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expansion of leased premises (in square feet)",
        "label": "Increase to Number Of Square Foot Of Facility Leased",
        "documentation": "Increase to Number Of Square Foot Of Facility Leased"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_IndefiniteLivedIntangibleAssetsAccumulatedImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IndefiniteLivedIntangibleAssetsAccumulatedImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "ibrx_IntangibleAssetsAccumulatedImpairment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment",
        "label": "Indefinite-Lived Intangible Assets, Accumulated Impairment",
        "documentation": "Indefinite-Lived Intangible Assets, Accumulated Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r423"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Carrying Amount",
        "totalLabel": "Net Carrying Amount",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Indefinite Lived Intangible Assets, Gross, Excluding Goodwill",
        "documentation": "Indefinite Lived Intangible Assets, Gross, Excluding Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r176"
     ]
    },
    "ibrx_InitialAndExpansionPremisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "InitialAndExpansionPremisesMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial And Expansion Premises",
        "label": "Initial And Expansion Premises [Member]",
        "documentation": "Initial And Expansion Premises"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_InitialPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "InitialPaymentMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Payment",
        "label": "Initial Payment [Member]",
        "documentation": "Initial Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_InitialPremisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "InitialPremisesMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Premises",
        "label": "Initial Premises [Member]",
        "documentation": "Initial Premises."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_InsurancePremiumFinancingAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "InsurancePremiumFinancingAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance premium financing asset",
        "label": "Insurance Premium Financing Asset",
        "documentation": "Insurance premium financing asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceSettlementsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance claims receivable",
        "label": "Insurance Settlements Receivable, Current",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ibrx_IntangibleAssetsAccumulatedImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IntangibleAssetsAccumulatedImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Impairment",
        "label": "Intangible Assets, Accumulated Impairment",
        "documentation": "Intangible Assets, Accumulated Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Carrying Amount",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r80"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncomeTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest and Investment (Loss) Income, Net",
        "label": "Interest and Other Income [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and income classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense (including amounts with related parties)",
        "totalLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r209",
      "r289",
      "r343",
      "r623",
      "r805",
      "r926",
      "r1086"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on related-party notes payable",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r471",
      "r481",
      "r897",
      "r898"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r302",
      "r303"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued PIK Interest Added to Note",
        "label": "Interest Payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r1080"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1089"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment accretion income (amortization expense), net",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Investment Interest Rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r830",
      "r832",
      "r833",
      "r835",
      "r836",
      "r846",
      "r847",
      "r917",
      "r989",
      "r990"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r947",
      "r986"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r758",
      "r759",
      "r761",
      "r765",
      "r828",
      "r831",
      "r834",
      "r838",
      "r839",
      "r844",
      "r845",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r917"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r758",
      "r759",
      "r761",
      "r765",
      "r828",
      "r831",
      "r834",
      "r838",
      "r839",
      "r844",
      "r845",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r917"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to support operations",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ibrx_InvestmentsInJointVentureIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "InvestmentsInJointVentureIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued investment in joint venture",
        "label": "Investments In Joint Venture, Incurred But Not Yet Paid",
        "documentation": "Investments In Joint Venture, Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_IssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "IssuanceOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial measurement of warrants issued in connection with registered direct offerings accounted for as liabilities",
        "label": "Issuance Of Warrants",
        "documentation": "Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_July2023WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "July2023WarrantsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 2023 Warrants",
        "label": "July 2023 Warrants [Member]",
        "documentation": "July 2023 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_JulyTwentyNineteenLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "JulyTwentyNineteenLeaseMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 2019 Lease",
        "label": "July Twenty Nineteen Lease [Member]",
        "documentation": "July twenty nineteen lease."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LaboratoryCleanroomServiceCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LaboratoryCleanroomServiceCostsMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Cleanroom Service Costs",
        "label": "Laboratory Cleanroom Service Costs [Member]",
        "documentation": "Laboratory Cleanroom Service Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease expense",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r912"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information Regarding Leases",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ibrx_LeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Lease, Liability",
        "documentation": "Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityTenantImprovementAllowanceReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityTenantImprovementAllowanceReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Less: Tenant improvement allowance receivable",
        "label": "Lease, Liability, Tenant Improvement Allowance Receivable",
        "documentation": "Lease, Liability, Tenant Improvement Allowance Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaid",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lease, Liability, To Be Paid",
        "documentation": "Lease, Liability, To Be Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaidAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Lease, Liability, To Be Paid [Abstract]",
        "documentation": "Lease, Liability, To Be Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaidAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaidAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Thereafter",
        "label": "Lease, Liability, To Be Paid, After Year Five",
        "documentation": "Lease, Liability, To Be Paid, After Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaidYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaidYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "2028",
        "label": "Lease, Liability, To Be Paid, Year Five",
        "documentation": "Lease, Liability, To Be Paid, Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaidYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaidYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "2027",
        "label": "Lease, Liability, To Be Paid, Year Four",
        "documentation": "Lease, Liability, To Be Paid, Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaidYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaidYearOne",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "2024",
        "label": "Lease, Liability, To Be Paid, Year One",
        "documentation": "Lease, Liability, To Be Paid, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaidYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "2026",
        "label": "Lease, Liability, To Be Paid, Year Three",
        "documentation": "Lease, Liability, To Be Paid, Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityToBePaidYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityToBePaidYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "2025",
        "label": "Lease, Liability, To Be Paid, Year Two",
        "documentation": "Lease, Liability, To Be Paid, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseLiabilityUndiscountedExcessInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseLiabilityUndiscountedExcessInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_2": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Less: Interest",
        "label": "Lease, Liability, Undiscounted Excess Interest",
        "documentation": "Lease, Liability, Undiscounted Excess Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseOperatingLeaseAnnualLeasePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseOperatingLeaseAnnualLeasePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual lease payment",
        "label": "Lease, Operating Lease, Annual Lease Payment",
        "documentation": "Lease, Operating Lease, Annual Lease Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseRelatedPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseRelatedPayables",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease-related payables",
        "label": "Lease Related Payables",
        "documentation": "Lease-related payables."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease assets",
        "label": "Lease, Right-Of-Use Asset",
        "documentation": "Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails": {
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment to hire, number of employees, first five years",
        "label": "Leasehold Interest, Commitment To Hire, Number Of Employees, First Five Years",
        "documentation": "Leasehold Interest, Commitment To Hire, Number Of Employees, First Five Years"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment to hire, number of employees, first two and a half years",
        "label": "Leasehold Interest, Commitment To Hire, Number Of Employees, First Two And A Half Years",
        "documentation": "Leasehold Interest, Commitment To Hire, Number Of Employees, First Two And A Half Years"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseholdInterestGovernmentFundingAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseholdInterestGovernmentFundingAvailable",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government funding for leasehold build-out",
        "label": "Leasehold Interest, Government Funding Available",
        "documentation": "Leasehold Interest, Government Funding Available"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment to spend, operational expenses, initial lease term",
        "label": "Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term",
        "documentation": "Leasehold Interest, Operational Expenses, Commitment to Spend, Initial Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment to spend, operational expenses, renewal lease term",
        "label": "Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term",
        "documentation": "Leasehold Interest, Operational Expenses, Commitment to Spend, Renewal Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalCostsPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangements",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease Obligations",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaidAfterYearFive",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaidYearOne",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaidYearFive",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaidYearFour",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaidYearThree",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiabilityToBePaidYearTwo",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Tenant improvement allowance receivable",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable",
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ibrx_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of renewal options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LesseeOperatingLeasePrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LesseeOperatingLeasePrepaidExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment of first month rent and security deposit",
        "label": "Lessee, Operating Lease, Prepaid Expense",
        "documentation": "Lessee, Operating Lease, Prepaid Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Optional extended lease term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial term of lease arrangement",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangements",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r308",
      "r404",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r449",
      "r450",
      "r589",
      "r592",
      "r593",
      "r614",
      "r774",
      "r886",
      "r928",
      "r1007",
      "r1070",
      "r1071"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r205",
      "r716",
      "r913",
      "r975",
      "r996",
      "r1059"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r262",
      "r308",
      "r404",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r449",
      "r450",
      "r589",
      "r592",
      "r593",
      "r614",
      "r913",
      "r1007",
      "r1070",
      "r1071"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities measured at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ibrx_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "License Agreement [Member]",
        "documentation": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement Terms",
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LicensingAgreementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LicensingAgreementLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreement [Line Items]",
        "label": "Licensing Agreement [Line Items]",
        "documentation": "Licensing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LicensingAgreementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LicensingAgreementTable",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreement [Table]",
        "label": "Licensing Agreement [Table]",
        "documentation": "Licensing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LitigationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LitigationLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation [Line Items]",
        "label": "Litigation [Line Items]",
        "documentation": "Litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigation expense",
        "label": "Estimated Litigation Liability",
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r1005"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount awarded from other party in litigation settlement",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "documentation": "Amount awarded from other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LitigationSettlementInterestPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LitigationSettlementInterestPercent",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest related to litigation settlement, as a percent",
        "label": "Litigation Settlement Interest, Percent",
        "documentation": "Litigation Settlement Interest, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LitigationSettlementNumberOfSharesToBeIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LitigationSettlementNumberOfSharesToBeIssued",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for litigation settlement (in shares)",
        "label": "Litigation Settlement, Number Of Shares To Be Issued",
        "documentation": "Litigation Settlement, Number Of Shares To Be Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_LitigationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LitigationTable",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation [Table]",
        "label": "Litigation [Table]",
        "documentation": "Litigation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Revenue interest liability at inception",
        "periodEndLabel": "Revenue interest liability at end of period",
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r203",
      "r464",
      "r479",
      "r895",
      "r896",
      "r1081"
     ]
    },
    "ibrx_LongTermDebtGrossIncludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "LongTermDebtGrossIncludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal and accrued interest",
        "label": "Long-Term Debt, Gross, Including Accrued Interest",
        "documentation": "Long-Term Debt, Gross, Including Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r315",
      "r469"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r315",
      "r469"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r315",
      "r469"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Category of Item Purchased [Axis]",
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Purchase Commitment [Line Items]",
        "label": "Long-Term Purchase Commitment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentTable",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Purchase Commitment [Table]",
        "label": "Long-Term Purchase Commitment [Table]",
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r87"
     ]
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in marketable equity securities with readily determinable fair values",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r963"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities, noncurrent",
        "label": "Marketable Securities, Noncurrent",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities and Other Investments",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r511",
      "r685",
      "r734",
      "r766",
      "r767",
      "r829",
      "r832",
      "r836",
      "r837",
      "r846",
      "r872",
      "r873",
      "r889",
      "r899",
      "r906",
      "r914",
      "r1011",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share",
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ibrx_MeasurementInputExpectedMarketYieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "MeasurementInputExpectedMarketYieldMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected market yield",
        "label": "Measurement Input, Expected Market Yield [Member]",
        "documentation": "Measurement Input, Expected Market Yield"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ibrx_MeasurementInputMarketYieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "MeasurementInputMarketYieldMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market yield",
        "label": "Measurement Input, Market Yield [Member]",
        "documentation": "Measurement Input, Market Yield"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected average volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_MergerExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "MergerExchangeRatio",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger exchange ratio",
        "label": "Merger Exchange Ratio",
        "documentation": "Merger exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r511",
      "r685",
      "r734",
      "r766",
      "r767",
      "r829",
      "r832",
      "r836",
      "r837",
      "r846",
      "r872",
      "r873",
      "r889",
      "r899",
      "r906",
      "r914",
      "r1011",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "MinimumNetSalesMilestoneContingentValueRightsObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum net sales milestone contingent value rights obligation",
        "label": "Minimum Net Sales Milestone Contingent Value Rights Obligation",
        "documentation": "Minimum net sales milestone contingent value rights obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r204",
      "r308",
      "r404",
      "r438",
      "r441",
      "r442",
      "r443",
      "r449",
      "r450",
      "r614",
      "r715",
      "r778"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest by parent",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_MonthlyBaseRentParking": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "MonthlyBaseRentParking",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly base rent, parking",
        "label": "Monthly Base Rent, Parking",
        "documentation": "Monthly Base Rent, Parking"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_MonthlyLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "MonthlyLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly base rent",
        "label": "Monthly License Fee",
        "documentation": "Monthly base rent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MutualFundMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual funds",
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ibrx_NANTibodyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NANTibodyLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NANTibody, LLC",
        "label": "NANTibody, LLC [Member]",
        "documentation": "NANTibody, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name Change Event [Line Items]",
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name Change Event [Table]",
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantBioInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantBioInc.Member",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantBio",
        "label": "NantBio, Inc. [Member]",
        "documentation": "NantBio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantBioRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantBioRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantBio revenue recognized",
        "label": "NantBio Revenue",
        "documentation": "NantBio Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCancerStemCellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCancerStemCellMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "N C S C",
        "label": "NantCancerStemCell [Member]",
        "documentation": "NCSC."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCapitalMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nant Capital 2015 Note Payable",
        "label": "Nant Capital [Member]",
        "documentation": "NantCapital."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC",
        "label": "Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC [Member]",
        "documentation": "Nant Capital, NantCancerStemCell, LLC, and NantMobile, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023",
        "label": "Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023 [Member]",
        "documentation": "Nant Capital, NantWorks, LLC, NantCancerStemCell, LLC, and NantMobile, LLC, Executed 9/11/2023"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCapitalOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCapitalOneMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nant Capital 2020 Note Payable",
        "label": "Nant Capital One [Member]",
        "documentation": "Nant capital one."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCapitalThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCapitalThreeMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nant Capital Three",
        "label": "Nant Capital Three [Member]",
        "documentation": "Nant Capital Three"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCapitalTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCapitalTwoMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nant Capital 2021 Note Payable",
        "label": "Nant Capital Two [Member]",
        "documentation": "Nant capital two."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCellInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCellInc.Member",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantCell",
        "label": "NantCell, Inc. [Member]",
        "documentation": "NantCell, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantCellTwoThousandAndFifteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantCellTwoThousandAndFifteenPlanMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NC 2015 Plan",
        "label": "Nant Cell Two Thousand And Fifteen Plan [Member]",
        "documentation": "NantCell two thousand and fifteen plan."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantKwestInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantKwestInc.Member",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantKwest",
        "label": "NantKwest, Inc. [Member]",
        "documentation": "NantKwest, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantKwestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantKwestMember",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantKwest",
        "label": "NantKwest [Member]",
        "documentation": "NantKwest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantMobileMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantMobileMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantMobile",
        "label": "Nant Mobile [Member]",
        "documentation": "Nant Mobile."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantWorksLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantWorksLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantWorks, LLC",
        "label": "NantWorks, LLC [Member]",
        "documentation": "NantWorks, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantWorksLLCMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantWorksLLCMemberMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantWorks, LLC Member",
        "label": "NantWorks, LLC Member [Member]",
        "documentation": "NantWorks, LLC Member"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NantWorksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NantWorksMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NantWorks",
        "label": "NantWorks [Member]",
        "documentation": "NantWorks."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NationalCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NationalCancerInstituteMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "National Cancer Institute (NCI)",
        "label": "National Cancer Institute [Member]",
        "documentation": "National Cancer Institute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r236"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to ImmunityBio common stockholders",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r171",
      "r208",
      "r260",
      "r280",
      "r283",
      "r288",
      "r308",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r328",
      "r332",
      "r340",
      "r354",
      "r360",
      "r362",
      "r404",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r449",
      "r450",
      "r604",
      "r614",
      "r724",
      "r797",
      "r818",
      "r819",
      "r887",
      "r926",
      "r1007"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interests, net of tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r196",
      "r280",
      "r283",
      "r327",
      "r328",
      "r723",
      "r968"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NoncontrollingInterestIncreaseDecreaseFromLegalSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NoncontrollingInterestIncreaseDecreaseFromLegalSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in ownership interest in a joint venture due to legal settlement (Note 7)",
        "label": "Noncontrolling Interest, Increase (Decrease) From Legal Settlement",
        "documentation": "Noncontrolling Interest, Increase (Decrease) From Legal Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r499",
      "r981",
      "r982",
      "r983",
      "r1087"
     ]
    },
    "ibrx_NoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NoncurrentAssetsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent Assets",
        "label": "Noncurrent Assets [Member]",
        "documentation": "Noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent Liabilities",
        "label": "Noncurrent Liabilities [Member]",
        "documentation": "Noncurrent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "verboseLabel": "Other (expense) income, net (including amounts with related parties)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity under Equity Plans",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-party promissory notes, net of discounts and deferred issuance costs (Note\u00a010)",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ibrx_NumberOfDissentingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NumberOfDissentingShares",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dissenting shares to be released (in shares)",
        "label": "Number Of Dissenting Shares",
        "documentation": "Number Of Dissenting Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NumberOfLeases",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leases",
        "label": "Number Of Leases",
        "documentation": "Number Of Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ibrx_NumberOfSquareFeetOfFacilityLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NumberOfSquareFeetOfFacilityLeased",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of square foot of facility leased",
        "label": "Number Of Square Feet Of Facility Leased",
        "documentation": "Number of square feet of facility leased."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_NumberOfSquareFootOfFacilityLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "NumberOfSquareFootOfFacilityLeased",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of square foot of facility leased",
        "label": "Number Of Square Foot Of Facility Leased",
        "documentation": "Number of square foot of facility leased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffMarketFavorableLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffMarketFavorableLeaseMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-lived: Favorable leasehold rights",
        "label": "Off-Market Favorable Lease [Member]",
        "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r354",
      "r360",
      "r362",
      "r887"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r912"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail": {
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofFutureMinimumLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities (including amounts with related parties)",
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": "ibrx_LeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, less current portion (including amounts with related parties)",
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsScheduleofCashPaidforAmountsIncludedinMeasurementofLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating leases (excluding variable lease costs)",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r640"
     ]
    },
    "ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments related to options to extend lease terms",
        "label": "Operating Lease Payments Related To Options To Extend Lease Terms",
        "documentation": "Operating lease payments related to options to extend lease terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails": {
       "parentTag": "ibrx_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/LeaseArrangementsSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net (including amounts with related parties)",
        "verboseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense related to operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate, Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r912"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsSummaryofInformationRegardingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term, Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r912"
     ]
    },
    "ibrx_OptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OptionPeriodAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Period [Axis]",
        "label": "Option Period [Axis]",
        "documentation": "Option Period"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_OptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OptionPeriodDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Period [Domain]",
        "label": "Option Period [Domain]",
        "documentation": "Option Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_OptionsToExtendNumberOfTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OptionsToExtendNumberOfTerms",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to extend number of terms",
        "label": "Options To Extend Number Of Terms",
        "documentation": "Options to extend number of terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "documentation": "Organization consolidation and presentation of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_OrganizedWorkforceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OrganizedWorkforceMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organized workforce",
        "label": "Organized Workforce [Member]",
        "documentation": "Organized Workforce"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAccruedExpensesandOtherLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r913"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets (including amounts with related parties)",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gains (losses) on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income",
        "verboseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r39",
      "r281",
      "r284",
      "r291",
      "r616",
      "r617",
      "r622",
      "r702",
      "r725",
      "r966",
      "r967"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income, net of income taxes:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification of net realized gains (losses) on available-for-sale securities included in net loss",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r157",
      "r279",
      "r399"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-party nonconvertible note, net of discount (Note 10)",
        "label": "Other Notes Payable, Noncurrent",
        "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income, net (including amounts with related parties)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due from related parties",
        "terseLabel": "Total due from related parties",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage held by stockholders upon consummation of merger",
        "label": "Ownership Percentage Acquired On Fully Diluted Bases Upon Consummation Of Merger",
        "documentation": "Ownership percentage acquired on fully diluted bases upon consummation of merger."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_OwnershipPercentageByKeyExecutives": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "OwnershipPercentageByKeyExecutives",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage of outstanding shares of company",
        "label": "Ownership Percentage By Key Executives",
        "documentation": "Ownership percentage by key executives."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-cash interest items, net (including amounts with related parties)",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total ImmunityBio Stockholders\u2019 Deficit",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for legal settlement",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForMergerRelatedCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger-related costs",
        "label": "Payments for Merger Related Costs",
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails": {
       "parentTag": "us-gaap_ProceedsFromIssuanceOfSecuredDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance costs",
        "terseLabel": "Less: Issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net share settlement for RSUs vesting",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment in joint venture \u2013 an equity method investment",
        "label": "Payments to Acquire Interest in Joint Venture",
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable debt securities, available-for-sale",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment to acquire assets",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ibrx_PercentageOfSalesAgentCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PercentageOfSalesAgentCommission",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of sales agent commission",
        "label": "Percentage Of Sales Agent Commission",
        "documentation": "Percentage Of Sales Agent Commission"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PercentageOfWhollyOwnedSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PercentageOfWhollyOwnedSubsidiary",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage acquired",
        "label": "Percentage Of Wholly Owned Subsidiary",
        "documentation": "Percentage of wholly-owned subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PeriodFourMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period Four",
        "label": "Period Four [Member]",
        "documentation": "Period Four"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PeriodOfExtendedLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PeriodOfExtendedLeaseTerm",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Optional extended lease term",
        "label": "Period Of Extended Lease Term",
        "documentation": "Period of extended lease term."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PeriodOfRentFreeLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PeriodOfRentFreeLeaseTerm",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of rent free lease term",
        "label": "Period Of Rent Free Lease Term",
        "documentation": "Period Of Rent Free Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PeriodOneMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period One",
        "label": "Period One [Member]",
        "documentation": "Period One"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PeriodThreeMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period Three",
        "label": "Period Three [Member]",
        "documentation": "Period Three"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PeriodTwoMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period Two",
        "label": "Period Two [Member]",
        "documentation": "Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "ibrx_PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preclinical and Clinical Trial Accruals",
        "label": "Preclinical and Clinical Trial Accruals, Policy [Policy Text Block]",
        "documentation": "Preclinical and Clinical Trial Accruals, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r776"
     ]
    },
    "ibrx_PrepaidEquipmentMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PrepaidEquipmentMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid equipment maintenance",
        "label": "Prepaid Equipment Maintenance",
        "documentation": "Prepaid equipment maintenance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails": {
       "parentTag": "ibrx_AssetAcquisitionFairValueOfAssetsAcquired",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other depreciable assets and prepaid expenses",
        "label": "Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets (including amounts with related parties)",
        "totalLabel": "Prepaid expenses and other current assets (including amounts with related parties)",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense",
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r274",
      "r788",
      "r1079"
     ]
    },
    "ibrx_PrepaidExpenseWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PrepaidExpenseWriteDown",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partial write down of prepaid expense",
        "label": "Prepaid Expense, Write Down",
        "documentation": "Prepaid Expense, Write Down"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r892",
      "r998"
     ]
    },
    "ibrx_PrepaidResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PrepaidResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development costs",
        "label": "Prepaid Research And Development Costs",
        "documentation": "Prepaid Research And Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PrepaidServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PrepaidServices",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid services",
        "label": "Prepaid Services",
        "documentation": "Prepaid services."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PrepaidSoftwareLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PrepaidSoftwareLicenseFees",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid software license fees",
        "label": "Prepaid Software License Fees",
        "documentation": "Prepaid software license fees."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PrivatePlacementAndAtTheMarketOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PrivatePlacementAndAtTheMarketOfferingsMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement and At The Market Offerings",
        "label": "Private Placement And At The Market Offerings [Member]",
        "documentation": "Private Placement And At The Market Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Registered Direct Offering",
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributionsFromAffiliates",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of assets to an entity under common control",
        "label": "Proceeds from Contributions from Affiliates",
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the RIPA, net of transaction costs",
        "totalLabel": "Proceeds from the RIPA, net of transaction costs",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ibrx_ProceedsFromIssuanceOfSecuredDebtGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ProceedsFromIssuanceOfSecuredDebtGross",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails": {
       "parentTag": "us-gaap_ProceedsFromIssuanceOfSecuredDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the RIPA, gross",
        "label": "Proceeds From Issuance Of Secured Debt, Gross",
        "documentation": "Proceeds From Issuance Of Secured Debt, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable debt securities, available for sale",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r988"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of related-party promissory notes net of issuance costs paid",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of marketable debt and equity securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of property, plant and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercises of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r280",
      "r283",
      "r300",
      "r308",
      "r319",
      "r327",
      "r328",
      "r340",
      "r354",
      "r360",
      "r362",
      "r404",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r449",
      "r450",
      "r587",
      "r590",
      "r591",
      "r604",
      "r614",
      "r707",
      "r722",
      "r753",
      "r797",
      "r818",
      "r819",
      "r887",
      "r910",
      "r911",
      "r927",
      "r968",
      "r1007"
     ]
    },
    "ibrx_PromissoryNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PromissoryNotesPayableMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Notes",
        "label": "Promissory Notes Payable [Member]",
        "documentation": "Promissory Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross property, plant and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r264",
      "r719"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentImpairment",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Net, Impairment",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r708",
      "r719",
      "r913"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r230",
      "r234",
      "r717"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Estimated Useful Lives of Property, Plant and Equipment",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PurchaseAgreementAdditionalRevenueInterestsSecondPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PurchaseAgreementAdditionalRevenueInterestsSecondPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional revenue interests, second payment",
        "label": "Purchase Agreement, Additional Revenue Interests, Second Payment",
        "documentation": "Purchase Agreement, Additional Revenue Interests, Second Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_PurchaseAgreementTotalInvestmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "PurchaseAgreementTotalInvestmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross purchase price",
        "label": "Purchase Agreement, Total Investment Amount",
        "documentation": "Purchase Agreement, Total Investment Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unconditional purchase obligation commitment",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitment, 2024",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitment, 2025",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitment, 2026",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r503",
      "r511",
      "r539",
      "r540",
      "r541",
      "r661",
      "r685",
      "r734",
      "r766",
      "r767",
      "r829",
      "r832",
      "r836",
      "r837",
      "r846",
      "r872",
      "r873",
      "r889",
      "r899",
      "r906",
      "r914",
      "r917",
      "r1002",
      "r1011",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/LeaseArrangementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r503",
      "r511",
      "r539",
      "r540",
      "r541",
      "r661",
      "r685",
      "r734",
      "r766",
      "r767",
      "r829",
      "r832",
      "r836",
      "r837",
      "r846",
      "r872",
      "r873",
      "r889",
      "r899",
      "r906",
      "r914",
      "r917",
      "r1002",
      "r1011",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail": {
       "parentTag": "us-gaap_GainLossOnInvestments",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestandInvestmentIncomeLossNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net realized gains (losses) on investments",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ReimbursementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ReimbursementsMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursements",
        "label": "Reimbursements [Member]",
        "documentation": "Reimbursements."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RelatedPartyConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RelatedPartyConvertibleNotesMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-party convertible notes",
        "label": "Related Party Convertible Notes [Member]",
        "documentation": "Related Party Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r649",
      "r650",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r794",
      "r796",
      "r827"
     ]
    },
    "ibrx_RelatedPartyFixedRateNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RelatedPartyFixedRateNotesMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Fixed Rate Notes",
        "label": "Related Party Fixed Rate Notes [Member]",
        "documentation": "Related Party Fixed Rate Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r649",
      "r650",
      "r651",
      "r652",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r794",
      "r796",
      "r827"
     ]
    },
    "ibrx_RelatedPartyNotesInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RelatedPartyNotesInterestMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Payments",
        "label": "Related Party Notes - Interest [Member]",
        "documentation": "Related Party Notes - Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RelatedPartyNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RelatedPartyNotesMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Notes",
        "label": "Related Party Notes [Member]",
        "documentation": "Related Party Notes"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RelatedPartyNotesPrincipalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RelatedPartyNotesPrincipalMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Notes - Principal",
        "label": "Related Party Notes - Principal [Member]",
        "documentation": "Related Party Notes - Principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances to related party",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r649"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r1069"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r804"
     ]
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate with related party",
        "label": "Related Party Transaction, Rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FinancialStatementDetailsInterestExpenseDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r649",
      "r650",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r794",
      "r796",
      "r827",
      "r1069"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreements",
      "http://www.immunitybio.com/role/RelatedPartyDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related-Party Debt",
        "terseLabel": "Related-Party Agreements",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648",
      "r650",
      "r653",
      "r749",
      "r750",
      "r751",
      "r802",
      "r803",
      "r804",
      "r824",
      "r826"
     ]
    },
    "ibrx_RelatedPartyTransactionsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RelatedPartyTransactionsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transactions with Related Parties",
        "label": "Related Party Transactions, Policy [Policy Text Block]",
        "documentation": "Related Party Transactions, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RelatedPartyWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RelatedPartyWarrantsMember",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding related-party warrants",
        "label": "Related Party Warrants [Member]",
        "documentation": "Related Party Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ReportableLegalEntitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ReportableLegalEntitiesMember",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Legal Entities",
        "label": "Reportable Legal Entities [Member]",
        "documentation": "Legal entities of the consolidated entity reporting separate financial information in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r956",
      "r959",
      "r960",
      "r1006",
      "r1009",
      "r1010"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r455",
      "r485",
      "r652",
      "r881",
      "r882"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Abstract]",
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r1043"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r1043"
     ]
    },
    "ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementsWithFederalGovernmentLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangements with Federal Government [Line Items]",
        "label": "Research And Development Arrangements With Federal Government [Line Items]",
        "documentation": "Research and development arrangements with the federal government."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ResearchAndDevelopmentArrangementsWithFederalGovernmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ResearchAndDevelopmentArrangementsWithFederalGovernmentTable",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development Arrangements With Federal Government [Table]",
        "label": "Research And Development Arrangements With Federal Government [Table]",
        "documentation": "Research And Development Arrangements With Federal Government [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development (including amounts with related parties)",
        "verboseLabel": "Research and development expense",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r553",
      "r1078"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements and Acquisition",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r554"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash (Note 2)",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r223",
      "r304"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding RSUs",
        "verboseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance and retention benefits",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r429",
      "r430",
      "r1003"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r185",
      "r714",
      "r738",
      "r740",
      "r747",
      "r777",
      "r913"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r328",
      "r405",
      "r406",
      "r548",
      "r549",
      "r550",
      "r575",
      "r576",
      "r594",
      "r596",
      "r597",
      "r599",
      "r602",
      "r735",
      "r737",
      "r754",
      "r1087"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Geographic Region",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ibrx_RevenueInterestPurchaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RevenueInterestPurchaseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Purchase Agreement [Abstract]",
        "documentation": "Revenue Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RevenueInterestPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RevenueInterestPurchaseAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Interest Purchase Agreement",
        "label": "Revenue Interest Purchase Agreement [Member]",
        "documentation": "Revenue Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RevenueInterestPurchaseAgreementPaymentReceivedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RevenueInterestPurchaseAgreementPaymentReceivedPercentage",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue interest purchase agreement, payment received percentage",
        "label": "Revenue Interest Purchase Agreement, Payment Received Percentage",
        "documentation": "Revenue Interest Purchase Agreement, Payment Received Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments as a percentage of net sales",
        "label": "Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales",
        "documentation": "Revenue Interest Purchase Agreement, Payments, Percentage Of Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Required purchase price, as a percent",
        "label": "Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price",
        "documentation": "Revenue Interest Purchase Agreement, Percentage of Cumulative Purchaser Payments, Repurchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue interest purchase agreement, tiered revenue interest rate percentage",
        "label": "Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage",
        "documentation": "Revenue Interest Purchase Agreement, Tiered Revenue Interest Rate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r874",
      "r884"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r308",
      "r341",
      "r342",
      "r353",
      "r358",
      "r359",
      "r363",
      "r364",
      "r366",
      "r404",
      "r438",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r449",
      "r450",
      "r614",
      "r707",
      "r1007"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets disposed in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Disposed In Exchange for Operating Lease Liability",
        "documentation": "Right-of-Use Asset Disposed In Exchange for Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r912"
     ]
    },
    "ibrx_RiptideBioscienceIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "RiptideBioscienceIncMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Riptide Bioscience, Inc.",
        "label": "Riptide Bioscience, Inc. [Member]",
        "documentation": "Riptide Bioscience, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SaleLeasebackTransactionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SaleLeasebackTransactionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale-leaseback transaction, consideration transferred",
        "label": "Sale-leaseback Transaction, Consideration Transferred",
        "documentation": "Sale-leaseback Transaction, Consideration Transferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleLeasebackTransactionHistoricalCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleLeasebackTransactionHistoricalCost",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale leaseback transaction, independent appraisal value",
        "label": "Sale Leaseback Transaction, Historical Cost",
        "documentation": "The historical cost of the asset(s) sold in connection with the sale of the property to another party and the lease of the property back to the seller."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r1065"
     ]
    },
    "us-gaap_SaleLeasebackTransactionNetBookValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleLeasebackTransactionNetBookValue",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale leaseback transaction, net carrying value",
        "label": "Sale Leaseback Transaction, Net Book Value",
        "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r1065"
     ]
    },
    "ibrx_SaleLeasebackTransactionNetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SaleLeasebackTransactionNetProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale leaseback transaction, net proceeds",
        "label": "Sale Leaseback Transaction, Net Proceeds",
        "documentation": "Sale Leaseback Transaction, Net Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SaleLeasebackTransactionPropertyTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SaleLeasebackTransactionPropertyTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale-leaseback transaction, property taxes",
        "label": "Sale-leaseback Transaction, Property Taxes",
        "documentation": "Sale-leaseback Transaction, Property Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SaleOfStockAdditionalPurchaseOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SaleOfStockAdditionalPurchaseOption",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, additional purchase option",
        "label": "Sale Of Stock, Additional Purchase Option",
        "documentation": "Sale Of Stock, Additional Purchase Option"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price allocation",
        "label": "Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction",
        "documentation": "Sale Of Stock And Revenue Interest Purchase Agreement, Consideration Received On Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of stock issued in transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SaleOfStockMaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum offering",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of common stock outstanding after option exercise, maximum",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock issued in transaction (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Securities Excluded from the Computation of Potentially Dilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Marketable Debt Securities",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r585"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Benefit (Provision)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impact of Change in Reporting Entity on Unaudited Consolidated Statements of Operations",
        "label": "Condensed Income Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r980"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expenses Related to Statement of Operations",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialStatementDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsTables",
      "http://www.immunitybio.com/role/RelatedPartyDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Before Taxes, Domestic and Foreign",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets, Net",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ibrx_ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related-Party Promissory Notes",
        "label": "Schedule Of Related-Party Promissory Notes Table [Table Text Block]",
        "documentation": "Schedule of related party notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedFairValueofConvertibleNoteDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtEstimatedMaterialContractualObligationsRelatedtoRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtRelatedPartyPromissoryNotesDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r800",
      "r801",
      "r804"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Balances of Related Party Agreements",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r158"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity and Related Information under Equity Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r102"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Fair Value of Options Under Black-Scholes Option Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r183",
      "r184",
      "r185",
      "r270",
      "r271",
      "r272",
      "r339",
      "r483",
      "r484",
      "r485",
      "r487",
      "r490",
      "r495",
      "r497",
      "r743",
      "r744",
      "r745",
      "r746",
      "r899",
      "r941",
      "r973"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes to Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r1045"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ibrx_SecondPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SecondPaymentMember",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Payment",
        "label": "Second Payment [Member]",
        "documentation": "Second Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue interest liability (Note\u00a09)",
        "label": "Secured Long-Term Debt, Noncurrent",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ibrx_SecuredOvernightFinancingRateSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r364",
      "r365",
      "r757",
      "r760",
      "r762",
      "r831",
      "r834",
      "r839",
      "r851",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r875",
      "r900",
      "r917",
      "r1013",
      "r1082"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment and Geographic Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r364",
      "r888"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations",
      "http://www.immunitybio.com/role/DescriptionofBusinessScheduleofImpactofChangeinReportingEntityonUnauditedCondensedConsolidatedStatementsofOperationsDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative (including amounts with related parties)",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SeptemberTwentyNineteenLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SeptemberTwentyNineteenLeaseMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 2019 Lease",
        "label": "September Twenty Nineteen Lease [Member]",
        "documentation": "September twenty nineteen lease."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/canceled (in units)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants of restricted stock (in units)",
        "verboseLabel": "Granted (in units)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested, beginning balance (in units)",
        "periodEndLabel": "Nonvested, ending balance (in units)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested, beginning balance (in dollars per share)",
        "periodEndLabel": "Nonvested, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r529"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in units)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated benefit at grant date fair value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value",
        "documentation": "Share based compensation arrangement by share based payment award estimated benefit at grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "documentation": "Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock option exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired/forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired/forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and exercisable (in shares)",
        "terseLabel": "Number of Options, Vested and exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price, Vested and exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationRSUActivityunderEquityPlansDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail",
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Anniversary",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Anniversary",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationWeightedAverageFairValueofOptionsUnderBlackScholesOptionPricingModelDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life, Vested and exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested number of shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SharedServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SharedServicesAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shared Services Agreement",
        "label": "Shared Services Agreement [Member]",
        "documentation": "Shared services agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares to be issued in private placement (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ibrx_SharesIssuedCashDistributedInLieuOfFractionalShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SharesIssuedCashDistributedInLieuOfFractionalShares",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash distributed in lieu of fractional shares (in dollars per share)",
        "label": "Shares Issued, Cash Distributed In Lieu Of Fractional Shares",
        "documentation": "Shares Issued, Cash Distributed In Lieu Of Fractional Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net share settlement for RSUs vesting (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease costs",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r912"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r305"
     ]
    },
    "ibrx_SixZeroFiveDougStLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SixZeroFiveDougStLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "605 Doug St, LLC",
        "label": "Six Zero Five Doug St, LLC [Member]",
        "documentation": "Six Zero Five Doug St, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SixZeroFiveNashLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SixZeroFiveNashLLCMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "605 Nash, LLC",
        "label": "Six Zero Five Nash, LLC [Member]",
        "documentation": "Six Zero Five Nash, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPropertyPlantandEquipmentNetDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SoftwareLicenseSubscriptionFeesAndImplementationCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SoftwareLicenseSubscriptionFeesAndImplementationCostsMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesUnconditionalPurchaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software License Subscription Fees and Implementation Costs",
        "label": "Software License Subscription Fees And Implementation Costs [Member]",
        "documentation": "Software License Subscription Fees And Implementation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SorrentoTherapeuticsIncLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SorrentoTherapeuticsIncLitigationMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sorrento Therapeutics, Inc. Litigation",
        "label": "Sorrento Therapeutics, Inc. Litigation [Member]",
        "documentation": "Sorrento Therapeutics, Inc. Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SponsoredResearchAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SponsoredResearchAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsored Research Agreement",
        "label": "Sponsored Research Agreement [Member]",
        "documentation": "Sponsored research agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_StateOfNewYorkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "StateOfNewYorkMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Of New York",
        "label": "State Of New York [Member]",
        "documentation": "State Of New York"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total ImmunityBio Stockholders\u2019 (Deficit) Equity",
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r52",
      "r258",
      "r286",
      "r287",
      "r288",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r328",
      "r338",
      "r405",
      "r406",
      "r499",
      "r548",
      "r549",
      "r550",
      "r575",
      "r576",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r602",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r645",
      "r735",
      "r736",
      "r737",
      "r754",
      "r820"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r247",
      "r364",
      "r365",
      "r757",
      "r760",
      "r762",
      "r831",
      "r834",
      "r839",
      "r851",
      "r859",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r875",
      "r900",
      "r917",
      "r1013",
      "r1082"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r338",
      "r686",
      "r741",
      "r755",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r776",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r796",
      "r798",
      "r799",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r820",
      "r918"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r338",
      "r686",
      "r741",
      "r755",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r776",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r796",
      "r798",
      "r799",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r820",
      "r918"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued pursuant to litigation settlement",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "ibrx_StockIssuedCashlessExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "StockIssuedCashlessExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cashless exercise of stock options",
        "label": "Stock Issued, Cashless Exercise Of Stock Options",
        "documentation": "Stock Issued, Cashless Exercise Of Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in exchange for notes payable (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r51",
      "r94",
      "r185",
      "r468"
     ]
    },
    "ibrx_StockIssuedDuringPeriodSharesLitigationSettlement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesLitigationSettlement",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued pursuant to litigation settlement (in shares)",
        "label": "Stock Issued During Period, Shares, Litigation Settlement",
        "documentation": "Stock Issued During Period, Shares, Litigation Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r150",
      "r151",
      "r185",
      "r743",
      "r820",
      "r856"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units (RSUs) (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r185"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/StockBasedCompensationStockOptionActivityandRelatedInformationunderEquityPlansDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r150",
      "r151",
      "r185",
      "r525"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in exchange for notes payable (Note\u00a010)",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r52",
      "r185"
     ]
    },
    "ibrx_StockIssuedDuringPeriodValueLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "StockIssuedDuringPeriodValueLitigationSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued pursuant to litigation settlement",
        "label": "Stock Issued During Period, Value, Litigation Settlement",
        "documentation": "Stock Issued During Period, Value, Litigation Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r150",
      "r151",
      "r185",
      "r754",
      "r820",
      "r856",
      "r927"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of shares to be issued in private placement",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r52",
      "r185"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationStockBasedCompensationExpensesRelatedtoStatementofOperationsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ibrx_StockOptionPurchaseLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "StockOptionPurchaseLiabilityMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option purchase liability",
        "label": "Stock Option Purchase Liability [Member]",
        "documentation": "Stock Option Purchase Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_StockPurchaseAndOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "StockPurchaseAndOptionAgreementMember",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase and Option Agreement",
        "label": "Stock Purchase And Option Agreement [Member]",
        "documentation": "Stock Purchase And Option Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_StockRepurchaseProgramPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "StockRepurchaseProgramPolicyPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Repurchases",
        "label": "Stock Repurchase Program, Policy [Policy Text Block]",
        "documentation": "Stock Repurchase Program, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining authorized repurchase amount",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of common stock, shares (in shares)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r150",
      "r151",
      "r185"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of common stock, value",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r150",
      "r151",
      "r185"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total ImmunityBio stockholders\u2019 deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r154",
      "r155",
      "r173",
      "r778",
      "r795",
      "r821",
      "r822",
      "r913",
      "r928",
      "r975",
      "r996",
      "r1059",
      "r1087"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r117",
      "r258",
      "r259",
      "r287",
      "r316",
      "r317",
      "r318",
      "r320",
      "r326",
      "r405",
      "r406",
      "r499",
      "r548",
      "r549",
      "r550",
      "r575",
      "r576",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r602",
      "r616",
      "r618",
      "r622",
      "r645",
      "r736",
      "r737",
      "r752",
      "r778",
      "r795",
      "r821",
      "r822",
      "r857",
      "r927",
      "r975",
      "r996",
      "r1059",
      "r1087"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Deficit",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r307",
      "r482",
      "r484",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r499",
      "r601",
      "r823",
      "r825",
      "r858"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesLitigationAdditionalInformationDetail",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficit",
      "http://www.immunitybio.com/role/ConsolidatedStatementsofStockholdersDeficitParenthetical",
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_SummarizesTheRevenueInterestLiabilityActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SummarizesTheRevenueInterestLiabilityActivityTableTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarizes the Revenue Interest Liability Activity",
        "label": "Summarizes the Revenue Interest Liability Activity [Table Text Block]",
        "documentation": "Summarizes the Revenue Interest Liability Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/FinancialStatementDetailsPrepaidExpensesandOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid supplies",
        "label": "Prepaid Supplies",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r893",
      "r998"
     ]
    },
    "ibrx_SupplyAgreementTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "SupplyAgreementTermOfContract",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply agreement, term of contract",
        "label": "Supply Agreement, Term Of Contract",
        "documentation": "Supply Agreement, Term Of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of fixed assets",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r178"
     ]
    },
    "ibrx_TieredPaymentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "TieredPaymentsAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tiered Payments [Axis]",
        "label": "Tiered Payments [Axis]",
        "documentation": "Tiered Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_TieredPaymentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "TieredPaymentsDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tiered Payments [Domain]",
        "label": "Tiered Payments [Domain]",
        "documentation": "Tiered Payments [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r985",
      "r1068"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.immunitybio.com/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.immunitybio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_TransactionCostsWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "TransactionCostsWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.immunitybio.com/role/WarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs allocated to warrant liabilities",
        "label": "Transaction Costs, Warrant Liability",
        "documentation": "Transaction Costs, Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction",
        "label": "Transaction [Domain]",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction Type",
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.immunitybio.com/role/FinancialInstrumentsAccumulatedUnrealizedLossesonDebtSecuritiesClassifiedasAvailableforSaleinContinuousLossPositionDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/FinancialInstrumentsAvailableforSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RevenueInterestPurchaseAgreementSummaryoftheRevenueInterestLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r476",
      "r495",
      "r600",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r726",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares outstanding (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ibrx_TwoThousandFifteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Equity Incentive Plan",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand fifteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_TwoThousandFifteenShareRepurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "TwoThousandFifteenShareRepurchasePlanMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Share Repurchase Plan",
        "label": "Two Thousand Fifteen Share Repurchase Plan [Member]",
        "documentation": "2015 share repurchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionCollaborationAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/RelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/role/StockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid offering and transaction costs included in accounts payable and accrued expenses",
        "label": "Unpaid Offering and Transaction Costs Included in Accounts Payable and Accrued Expenses",
        "documentation": "Unpaid Offering and Transaction Costs Included in Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unrecognized tax benefits, beginning of year",
        "periodEndLabel": "Unrecognized tax benefits, end of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r562"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reductions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesChangestoUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ibrx_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would not impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate",
        "documentation": "Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r226",
      "r227",
      "r231",
      "r232"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ibrx_ValuationTechniqueBinomialLatticeModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ValuationTechniqueBinomialLatticeModelMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Binomial lattice model",
        "label": "Valuation Technique, Binomial Lattice Model [Member]",
        "documentation": "Valuation Technique, Binomial Lattice Model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted cash flow analysis",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/LeaseArrangementsComponentsofLeaseExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r912"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/RelatedPartyDebtSummaryofRelatedPartyPromissoryNotesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_VariousMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "VariousMember",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyAgreementsOutstandingBalancesofRelatedPartyAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Various",
        "label": "Various [Member]",
        "documentation": "Various."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.immunitybio.com/role/RelatedPartyDebtAdditionalInformationDetails",
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "ibrx_ViractaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "ViractaMember",
     "presentation": [
      "http://www.immunitybio.com/role/CollaborationandLicenseAgreementsandAcquisitionLicenseAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Viracta",
        "label": "Viracta [Member]",
        "documentation": "Viracta"
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_VivaBioCellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "VivaBioCellMember",
     "presentation": [
      "http://www.immunitybio.com/role/CommitmentsandContingenciesContingentConsiderationRelatedtoBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VivaBioCell",
        "label": "Viva Bio Cell [Member]",
        "documentation": "VivaBioCell."
       }
      }
     },
     "auth_ref": []
    },
    "ibrx_WarrantLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "WarrantLiabilityTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/WarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liabilities",
        "label": "Warrant Liability [Text Block]",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetail",
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesSecuritiesExcludedfromtheComputationofPotentiallyDilutiveSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding third-party warrants",
        "verboseLabel": "Warrant liabilities",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r916",
      "r919",
      "r920",
      "r921",
      "r922"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liabilities",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.immunitybio.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ibrx_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [Member]",
        "documentation": "Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.immunitybio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of warrants",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ibrx_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.immunitybio.com/20231231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.immunitybio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [Policy Text Block]",
        "documentation": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2013 diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r335"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.immunitybio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2013 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r335"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479455/805-10-15-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "6",
   "SubTopic": "50",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-6"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "15",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481116/815-15-25-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5B",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480588/815-10-25-5B"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480526/815-10-35-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "SubTopic": "15",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481051/815-15-35-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//985-730/tableOfContent"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-8A"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-1"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-6"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481475/840-20-55-3"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-50"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-51"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-52"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482558/350-40-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "(m)",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479092/842-20-40-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479924/842-10-30-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//321/tableOfContent"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//325/tableOfContent"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(S-X 210.12-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815-15/tableOfContent"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>126
<FILENAME>0001326110-24-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001326110-24-000037-xbrl.zip
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MR=ME" L+Q.="47*(LY%\(_GTXD5R@+91$Z,FY*+R*KD$0"H. 6/6SX]&:G[
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M(D$F-[VWK3(#L&)&]L^$K_ME<J@E*<U8%]7) 8*TA)V$02('XZU/,S03C_4
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M'X0;I7^HRKTG.R?>ME"/OO+>T%/%'.WD3SO>@8%&,AQ;(#K*UJDD;@]78/A
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M0]?[.2Z&X?!:KS2, AOB4>$]L@!QU:X+U.,07R"\(9,J)6P89=W#(Q=G36O
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M"^$_6?:WJUL$^3T'AAA#8& 7N!6-XL'&GS'E*;D)$6+3RW4IBX(#_TKXFDA
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MJ&;-8A*1]D'RX*[RB>W6^'8EVL%1[UJ4[3%]T&/*'3C9XS1HVXJC(>$[;<G
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M[S.=&0X$-P^YT_=X1@,&[GRHTQ=G9^N1--NBL)]L4=AK,)8M"GN3!O\=T17
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M@OMW@PIL0CW-:3T'+(PKR+A7;P;HDR%!_Z8_,F]__5[P O(VD8<+M-KF>:1
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M<X_$'/-7P8<%=#O5UY]9@G,&V7<1F8M;4,\*L5WT@>*$*12'#"#ZSTB=$^:
MLPDT:5Y&/O<\O*D#\0@H% .J. 7[Y)EWU+2G<"N5WM/IE\2$A:\\2.^)_:#W
MQ/GS#__3G6\Y*Q$WP>KH17$X//QKO2B.GQ[?W8OB<;IL=XOHYW*<HC/>[ALF
M]LYE0_\VN!CTK&"P!S>ME*L)42I7B#H%674_2>.KO,"A$"DSY>6,P0:#E#12
M)\B9GDX-<HRY3DYT48RXS 5 @:FRVT$:<+J'Q-_)06_X5*O+T9EMY/CHAL>]
MDT/]ADM0-5G?'G,N.Y)KA8UB[NKRBKLDU/F4CF!NM,L")(0V4&37_;J@%RGC
M1#K^HKZ.SM74PKS=DX3*"Z6DT]E<P!#YG)Q]H3A1.HOH-$,S39)OF]$-L1=I
M8][U=,"WC7D?<G:WC7G7LS'OSEDQ*<JY"+W3W6VCWL=?U/LUZFTLW//==6_<
M"RY3LD,;L<R#??$W>E(!129JG"\\VHN4X-OBVDQ]D]>]?;2IJJ)9;>MVTWS-
M*(/?_OSW-]'/"F%[S GO^;ZWY'M,L64,#/TBY8@K+!=8*MAKS#]TKP[>7;UO
M.3-$DN;)\(>>VX6W;EV]U7"_SXD^:] (1,;>[NCH![)P*BV;7L+RR5[0?1.2
M<-#3PS#S#A*&=/=:RZ!7#DY"T;U(CE6E E%>R 'Q=[EPG G!YT6F+CJ_SO '
M^843OGT.(C/W<JE<Q"'[62_:TU]HXO2NR]E W;,_:IJD'FF_A ND2;-.OF15
M!]'KXJ9_57(2=6FP+8HV6R*1+.B&:1SM[.__L-NC340+^2G5C_;PT<1,D0I.
M%5N],WR"3\<TK5>UB7:&QS\H P$;RF3"[PSW[4<8L+B9=PZ(]VW%E%7SZ,D/
MT$T9F;"#Z,*@;#G#0O*%HT)[4-%V+^-KDJZPN"TNLVQL%P?"5/AX5=62H*-C
MS%@R4T[EAB!<J/-YFI$'<'"TS2JXK,+3;59A#<:RS2ILTN ?LV?,E_J9)"5_
M6]::@0,1D>_ D<7A,S'R(MAWFQ>IXGJ*,(G]X_GY.6,O^EE\:3*%Z(NP]24"
M2V8%QYU%R[8M##;);.H;46.).D#3M(P7 *(RP495Z6<-U</H&M4<@!; 5%*K
MHE/$F#)RNR>@UM'%8GQ]HW<30[RY*\'49S.=K\FYL2A09S#AQ/,TTD8H+-ID
MU!:SK7-CPV&CV,#&K%EU\T>:L#\91.\;2("\"/N19LY<^1BWO%"]CQIKR*4<
M[(E)<7 LW1)(,Z8,5 ,FD:Y-<ZCVMHW8\H'I6OD"S>-,\^NSW6#B=@X:<]68
M']@VSOS. 9= 1=0UHI)7<1B'I[<!@Q4OW*85-7UL>A?L7-A8YET.A0,VK70J
M$%PDAW!.(X[,/VNA*:/%N<("< UQG%M?\@>7$N$&,^33U,!HR5">'JG9?'9.
MY[<"L7_C)KBI?8!U+WZ08U>/1FQ?GK6'V(LTW$+K%\]F)BYC)7<2=X.UJ]VI
M:=YHB.MV$%=L&[+3Z]C5-[7/4WCXW1$#3;L<^I0;L'0;M@T_"!P_*XXL!\BE
MUD>MVX;+L*O$J6Z%;[@3R"7XO">H?4%WR1&O5\;%DO;G.OTG;2Y7A>?(#M![
M=&V#+TPW/?YY.)6"-1+/(%\J1IR+3;JJSO8MHE7<#$9>:FV7K&Z?9"C]KB&:
MN*P$T?3/G-D@D=/V[5[@\=L(R7U)Y#H"3,QO:)).J40_.#K!(ISL=[$3QXB!
M6"W=*=%V DGT4W3T='#<H],Q.-C5NF+= 8[$GAYU]@'_NW\\.%XJ[O-W>CIX
MVHO^=TUBR$H^I&WH3(]H"_P?.K^G[3# ,OZNXX755BF+RR 1S3DLSF+[]!5&
M;Z,X+A;A8A WL6KHI\/!X0\NDM'CYUB& J2SJJ*W'+#@9%B61:'T:)R*+QJE
MP)97#S0Z.1P,5XYQX^21+T>S&!!FTF=4PY*";LOGSF"M;S7%V@5JQNZ;)'K_
M0<-S_ZQAZ!1Y'J<EU]II2<JUB3,$N>;!4G'XD90F;<C)0N(TCJH.ZW"5T<IF
M(.7.Z$+)R-+Z29UET=XM1=X7L+&D0U _B2E@P&I8Y:J'@U]T_U CD<('(9 .
M1T#7-%>/>RV9O -C1O?4KI]#R8U:_=AIX]A -WP%U%LLO7U%+J8P=>;Z*C8M
M$T,N[+R7,?R7_&=OL'=\])0.^T4]98M,?V[S0FQ_^5W?6"+K)<#<U_7)C,7E
MT*K";8D_D>W>Y']Q\)-QH[J=5Y0?2;)>!F<%OKZU;0)=*:3'Z3R0R5Q=&1#?
M1&,ZQ&)'H5-@_]+D9IS.(Y:-[JVD5U (B H"PAMW8,D#?1,WK02#>9JF<S80
MH^>O3RU9K\WY:9%",P7ODNV='>%P:CO3A4V5<*^<P%W)PO7,MWFLV(WQ:?_8
M\N2\?_';RU.NM* I2S0E\:BE"VY7'/0\=<$@>A=LF*?!-SVW1;1-#+_=V8?7
MV#TUD Y7<9G82GWL*M1ZL;G8VH 6E<>7JDN+^T*()@:Q<1894O$^URZ!,#\$
M]R&@D:(D1QQ1!SR)][,P*]'C4E8XXL8  MESGAR>PL5>W(*!MFBBH0< 6K0B
MFVD5$;"G5XIIPR42_4A(4HQH)X^T-0PNP\O;M((_0NJ&<Z*IKQTTX,FSTO>\
M[IJ==%?/)VF9]*%9%M'9FW<MN%PZ-U,D)6B\E4#GF,<!L?S@G@6)O_):WXEF
MS#-<K!B+\[N A$RQI)=F+'5NLH8CYYC)W"=L^?$II\WH]X0M"G3.1WN&G9:0
MJ;8QH[,W9W:VV6"M*DLD;.3]KNT"8+))$JD=RKHF MJJ37N"]4%L9IF;R;K%
M416/F;;8TX7((_ B>FN[_\(\LKZ;HP()C6JG@]E=LY+0:;. 4!/\X5 *-!F^
M@1^>K)NJO2]0=6MW=R_$2<3V/60\&Z>92-"\HXWL?:6#AK1!>]+<5GCZ1A-)
M8!QBNL+I<8$BVKAZG*T\TCWF#ZZD@M6452AL,,\W)O"C<YUB>__.A6_*/_DX
M 8/#K:O=M4,ZT1HTN'\PTXXT8*5Y['.WX\!69-G=G-+C.Z8T%+WQ" 3!R@"$
M*6Q,+?>I]$ ^;F^3"!7X7';CLCVJ,I%G^Z-[$ACV88SA\-85H,#&1%<%P,OL
MT8JFQ-^[F.#369EFRSOD<!#]P?W<;L)V)&9YX+H13$.R!VOBMT1/<9TI9&=T
M52, -S>F.5,,1$3$7N,E\55I+V'0I#X@:,LD ;]Q'=!^&,&Z>P%W/L=3:6'
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M)$W56/$Y<29_DJ+!.4?FR=X:>Z.M,1_;E+A+B1]N4^)K,)9M2GR3!K^V*?%
MS@=AWJ#D,YXBYX/O(>9A^\&@:LC_0/9[3>52MF/&:UG'OY5NAY)HV(Y#M=U8
M-PRB<\Y&318SN+:5V+&^!,N+?"?I^QVB?K6RDK<5)B=41"E2:I;9\""3K7D#
M=$X#);<9P2VV0\N['LV&OGC]TW@1/"76.4[4A<R*V+;<1(3::O7+A>76PAL8
M+F]UB7V+U:=7DDGS?JB/L+$AZ\(NX0K=,#N<<G[96+($]M!27OGQC,:S\ZOB
M/M6E:V>YBJ\66O=CLECSW%1D4JA[MV%&:DCDY<]&%75A[1\],,W'E78C;=)^
MUXYTG%X>X'+_]TB2;_8>O4>M9%C+I>4H72/,Q^)TFEYQ*3$9UL_]EQS&2$>9
M$5<ET##CDAN&:U6AWD?J>3DPF\)V$>53<#2BUSD=W^JMFSX?!E6,^_1_HX(<
MQ-F<M$G>]V&71A$F/):^J4:Q]!&^,Q2U2FJQELKHGFJ56&H6LY[[1$0PU V2
MDS4D0#-U*I6:K,XL49"M[GS44^?0 :<?/O:#R%=WP*R!U).DFOB.EF@6B^CL
M+9'>V-9.:VMM/,),5I\CLMU#7B3,V>K"\ZU;Z5OEMHP%K6)-.B1:$!<O$]7O
M@8NNY 16 */Z/!UKCA[7_LAT Q*9UW(P1/<99<?GOQ&7CS0K8@L9F2\5F*)P
M_&1.<Z;(\0J$ @#HS-F$4X^765$D'7B"VZ5#:.*$;<U=MIQQ!]&LOK167H,M
M2HU%)'^B+XK5K8MU<!I5ABQ3C%^FWT6G&W)+XTD2G_:!G:Y2@4D\ [ /6"D(
MJU;VI:7:/9 FK@*K4D!R!Z!C43YBMC$=NDYJ-&@TG"%N6S:!S>]J2,5>:(QE
MHBE!^AT&RP:[U31-,WO5"0;9-/L*9*Z7G[@LUN]5O*<DLYF*P;Y^MIC.)G1&
M$V-A;YIUY"G@7)("Q^RHZ3S7N=MQ+9Q%L'W3JKEK[7;F \T;&.A> /$X=I4O
M1YIM;4L)#*]1?(![,OWB#2*-060Z.M5\0]]%V%.$_O'&,X6+T:2.0?IFRJ4(
MHZ ,;%%OVHC>VYWQ5]&LCY[6?\>OO(PGV33_X0\3<NIZXH>S=[^?O^@/GT;*
M'14B-ER--Q =D]/D2 3^Z[-^%7]X>\I58:#MT;.:F RF"_WD!7U)*H2NZ7'"
MVFB61-C'+TX_7/3/BM_[^V3]I)],M',A$5V6^,4HGE5I$NV\W85XG],NU/MS
M&.:&F7R%\LE94IJM#QD+<;^+H@:N;PP(KZ61T]Q-B^#%-,/CBI]U[]=#VAIL
MSYQ IU] .0,K8Y9@X,("35H):M=<>P"69WI&W."*,88\7XM!](KA=7AD6)'/
M.HMKNT0'"RK'$74O+QBG+1B\RNP7= 81.V$X3CHSPJ1="-$85M4^GSG&3D\K
M9U%6P:L+$L/6ISH(U2!Z1[>%PJR86<R-IH'M$!&":ZP45+HS2;17-)#*PI2Z
MLNAI\E]_NSO4MG_TM[5%R;\AX3PF4TJC4;2B)#_$7J-I_%Z :'_HMN/=B@6U
M0)YT%-EDA];=V_X9#(&G*^0$"N>2L#@&\+&*X><-AJV7+TY=^>6K-^\=]%,V
M:@;>NSZ<+4/*/)CZ'A]0:^@U$W@MCRPX@H/H>>IHN^I9A;#%5 9;W.3ZS\9S
MZ*C,1(JDQIK$J1CI*+:A4PT<4Y_;6[!RO[+))@E!<A&0RZYS>0S/+#L9X%N-
M4!E.QV]IRG-O@BB!.H<JR7MD](K*))Y=/:N])H!(N2O#&E*_#"2-% <6\>R2
MS5!QJ:N7.4'M$3\%<"T&$XN?(*,=C70\-&,Z2Q!%[N:D<M+[PT[71;E"%@90
MJ1%'M[ DS)T$ ZBU2VAB>2(X[4D^)K39!'1M%GWL\4V '^<QTXM&=172G>8D
M->U:I49%LD/0";(,N@:!=S75<F,2A]%D+:KT^:7-/P<G47QS";<SWZGN*W=>
MM,8MGR/&[S[M@'ZJ9^@T#P:<^*.RT W*-CMM-3F_B@NW-D"/+1!P0+%94=67
M-0TM^'I>*!1^-O?N:U&J3@Z=!K>O^1A=DAH$MGIJA'A89X<6C":&YV!.Q[R'
M#UA5WDS(?9$=SV6%MHT H^/S."\DVY$9:3)0DJ>=I7\ZW[HAH](<C078<T_*
M^LH.3*#R\%\Q19E0);.]4CMHFMU#&EO#LX0<SGX?G+#<X$I$76BBIP8,GG6Y
M9&LL#Q?UAC1)+VD^X=+T!8/I'LQGWVO[FZ+\I 80'7NMMF&F(?Z*I;#$20))
M(934F+)%=/;F715N!9X2M/>8LUCDK1G,4M4BO+LQ[L'653&Y,F74L%Y([ +;
MN%I@"]MHXZGTDHUG]G0-L6M4H\](_<972)1L$0,>,7"T10RLP5BVB(%-&OQC
M(@96IEA7,4N9\CJENZNZ;#HZ;YA)=<-").]$ZZ_2#;8%%GG\L< "S6BBA=V!
MK@U-&6#^X""#'X>+7IJJI4NC81#>KDB022H5EA#V](%)$E*&,TH8 ;?IDL-I
MHR-JA+$= <,2B-OX6GC-U&(5TMJ>T&_KHWJ!$2M6 E/J,+>E6*X<G(%587G'
MG0E(_QVGF35-&Z'H;GLX;6(9W9/I*6PP]4&E/2%7E\;'7,>.E]N9GZ%58QL]
ML5'3>B0,Z5*J)MDI&=?9L@6T>="',_^^(_C'[YU%N6&G$48G!(MD ):<"N]W
M2O?&D0LQ,1TN OW"BRM)#;B6ZLI7P4: O:]-O*3R#7/6MZ[X/#S707"Q%_U<
MEW0P^3R<5LKG@,%:UM=F2$&.[KC& \,-6=&.!E1^[()Z#8>D9<3SRRJMM#TO
M;1-><RG6U7 =P#BC3'.KN1U0=T&VC?"E]SGH*$B-R\Q6O+NYW._1:O?W]_"?
MU^%/:%9)=HRX#2"[^8U[C^'.8FTA I!XT#3%TYY+/QST;%PG""#'T=F'USBB
MZ$-IKF(- =%USU^?XJXVD>'3'OL]%Y_D2Z5K!]]W$B<>[JM@LA3,"'66,!!,
MIU_J1LJ43@.M#IY$LCJ@W$[G%G',+"P*TDZ,"*E1L$LP>MM.IR-P14YTGXZS
MR3G')/%Q3_*O=9?NZK:+U ,^#Y4MDHV9FRG-[@7(7<9:&4[>/+R$X)Y"M:J*
MA%X9<SQ7-[)S+#<\.2#*E':'2=A&!5,SLA?XO7LJ=T2$RB^J=<5<4+Q)/8,*
M#3-"EIC#%3YS=/;FC-1!5:N:C,E_73CR3KP?/Y(VU3MZ9U^N<=#862T8/^//
M>3OX)"7&B1R;6VB=,;PC#8<9J77OZ7#\&G<\__B.YX=[$M$P#MY!=.!YC7%(
M81O;6$[O)GPZ4B:LZ*@%MWN-A_;1/8GF&-U?F>B2#(8R&AOE$N*\Z\[[%[^]
M/.6_=[G"*"B&"*;SD(03%^_=-$74TL!UUDS5F#1.)8]3DP3S%Q2$YD5T5<<E
M"5UCFC,E]$S9W*)%XZO27L)<>_H %H]:KF05.J[6P20VF:H;1T"FM#",,;#T
M)/Z!5B3HTHB49M*5#;0)&H5M'#8_M:T2,"LO)=+V7D)I@<FP:1;\'UK<;N-+
MDM5OZ70Q"VR"RVI8+@XYHPFE#W-TT)2,GQK]W#<#MBU)JU@C]!J#LU.%HAF9
MU-18A=\(8$8[OB:.C1HA&X;E[9M;<8']4I&\=JMV0U4"<?%'9)\'R11KZ*S,
M6"QK?(''6'.!9&U=8D0_VD\<VY;)&!@1H)$P%4VE'X=[JSD)P:._BV.DP>A3
MVO@6IHB7_E]<[[BQIO<?71D=H818:1YSRV:9C;@U&PN>C6#3H0^4-2REJKIQ
M]G0WXAO^ F\=)X7R3PF1Q>J3\D[XKR"WN^[-'B:;B6*:^<%V)2ZZSWD'5,*=
MY(XQ:8\<'3@R[1:,$,R?Y[3BJ>=#W?_7#_5?.-)V-3D(8 ]US\;R"ZPJ\D D
MKF"G,<3@'^23]+&/P5IM9^<[.^HV@<2-X"TC_K_=$6^DT5IIXB\YXN%9_N(S
MR]GE\;A/S^_3R+-QU]$-M*WVR(!#M??T&3IE[/:4B"+.U8NJ%)A,4ZUQ-8=\
MLMQA2\]H5+FCCCW-!49ZZ0("VL7>4V!AX%Q4^Y?)E1[O5'! Z?SB7726D3Q1
MILI6Y/>EVB@;=A[(CWMI+DL/I!P>]L+0 ARYD3K",?,9F$F1)1)W18A7G9H7
M=?XI+3_)3^U<M,VWB:#B-9U+>T+2\A)'Y8HQ?A)C.KQ#;*ODYDJT,#R1_T[I
MY2:5QCK%'W1USER'-U>OF?<T%TT#BV(98L7.E1&4!ERTXEQJV1J;M;82#"IM
M5L^-QW)UOJ^+7*A2<R&ZHK2Z?1ZSP2W^F/6O[=V#R,DI?9Z;S^Z.=B"7<?X)
MI!BCA<3"3,)'*KH@U_!\;J8Z1:>#Z -Z+KS4"-4=E07;?&&0KKH\?#I,CD;#
MY/CP<#B.AT^&^T_-\?AP[\#L/SWYOT>'1P<')]KJ9N]9F+)ZH-G]LG8WWWJ^
MO];HOGP%U.N5 "%,6JUSZ)-&8\8F?$,'D?SA61!-+9;27:$KK >[AQEXL)3J
MX\V9R(?O\,7^EP/AI&-H+9N80$&W*1F:9)CJ-W-8((D/9P#T6^8WH9[D2-M4
M<,TN7HXH'(QBQ!RFY!PL88EZ[9PE"6@.*U??0$:LDT3XIA)X>!\)_+"5<S V
MN#,[^<!%.55F^49":RF(96&IM0,),N4>:BMAW:.A&'F^R+2'WH4@FP+*+<VI
MSV5?FL\S-C/@($LQY7@AB,?/J>3"E]/\(Y5[C0*">="(&PQPC-D+QM$NI!N9
M<@X#:B4)YA8A%B#$CK<(L348RQ8AMDF#7TN$6+<^\'$!#NZ\MPD7C9FAI8)*
MQ0V+%9RC:H)4PO.T<'ZIZ!FS+/(CX/C'19868@O90BSU\>%I7Y8H4 6V.C.)
M=$VP@+%E--=20)=L.++6DJ D1.HS#5H%QM=IYM1:@-L69EJ-SP<X-@0*ZC3C
M<A*:;.UV0,^182V!MD!5APQ^G'/DRPY;VJ]P?\( H,)UO^=O7_2YGD&A]0KF
M0A)92E9<R3DT:-!]/L#-Z"1O7)E(8 JQ>:!@]<IDMD 2,9IE2#R7X#5-"[ G
M2%V.G7.NXZ@0IZ]GF35('"RP89^SR01*?YA=?B,)TWP>E/WPA9)8CT>?ZEEK
M TAIXE^N[?U6-7@/4''WS43-6&-T1D+17 '6@87CP)I$L@L?2^\B8:]\ 2EO
MJR8:K5%$@:(-:Y7CP1*F\WL3^2CTD[)&?"D<5_-T#O =(X!O+&!D#$[(23,S
M+TS+D8*/'*Y&@I".?;N2ENU<:@(LS3SHW&IQ2VA0DVE?"2<V7 D=2T;N%\%O
M5N0N'NE@L<+P*?E]@]F@UTOLMD'@$+YR_,DTIM6U\(KB$7-\(I5V'3OX'TJ6
MR/.%PN14@:;"Q>A6V7L%:%[.HA#X&#CG'<?IGG6P)^M;!XOFTF:>;N 1_(/3
MM"&_Q,B_B^@TK@SSQ,,5;9)1,SLTC?^AL6^_OV:3F)SDD:GGKIA.75U5QLIZ
MS&U"1G%BIG347)U>FM/1F[-,0_,QMXUPIRL!(VHM%L<"-1 C\<#.FX!W>=$E
M,BQLK@&KLC6([;HQ;5@E4Z1Y @N*=96*4NQ/R^,_<;F/2Z #@_9XCB^&T;.M
M<(*BQ#Z9A5^4:UXOP:-*R;UF%W3\DM%8W"(C&^@:AJ#'HT7/TA,IIKVGK:08
MIH]_ #?/_"%SK7+MB1G$_#:T2PK+9PU5#PN.IK#P^-!IK_$*VFIJOK M8N:&
M^^W48O[,3"E#F5L2Q@VTA03H8'.M",^,224)3U)=*MR!L1.JV$:N%KL;_1$2
M%*@U4QH^F.D(N2P'TF"=BJTI,K^FDS.7%)CFQ)8,-7%=;'4N6^P %\Z8-3)0
M 2[I+8T3I>M:.%H<M :7'V(;R=P6WLZ$9SQ\JI19AN.Q&Z4H=;.*@<ZR2-ZH
M)5N<).&B"C0XQ*&0^N$5,F>MFQJL*$E2/,%]%<P,R=7\JI^9\?RGH\/6V>@_
MHK;DB.[QLP>.YGY9DJ(Q6\/#P1%FQ\)(^V>+>?$)?FT32QILH\<0,IQV=Z?7
M SQ4/56A$%AY9$2H<YQX8D:?M#6J$+06Z/[Q2W&#ZI%>BX:*@\T*C(-*<^T#
M[CZBE3&?6FQ_:JP[DJZ NU?LU[34D:+52<= %830E&5L%3>4=8,2HHW>](-4
M_<]6>DHK%Y>.?J)I^;PUG^:Q@N,%-<5O7"&Q6* W&IKKA)]K@5@^&M EZ"P_
MIU&?BQ\K*E2N.'T5[=CO=WO12V75_Z48CVG?Y/W7L7SPH1C9EAWX"?^3KK\@
M?VF<ZM,N!J>#:$<^HN_^)^GTHFR,1$2XEF?DD!.\ F_.GY_UHK-7D94]X6]>
MFM*RC00K36_^=]K2%7ET2U_@=]&.?KW[X]^+25[1]/_W>#I[%NF_9"QOR.#Z
MI%^<%8-@K-$.?[=[/P&^E8-?10Z^ .Y5P*^T.!^,GM1\[D#UOPLJLGI,<=@6
M 2[%Y=-8J\SA+/UDO. 44:%X0>&&4M0G +A2[N/=I<8%#>/%&MFGHPD]Q%1=
M8N)Y6KS]:"Q?W<7/T8[]A$[J*Y.;HNMGX3G\A:RC/R=%#8ECN;=67ORJ3.?5
M'$$4>DSC&SY6/2YM)E&T)!U8L&SS>T%^[\DVO[<&8]GF]S9I\/?([_F3\Z5J
M^]')-&_1Y]]B;%]!T0?H_S!4NU9L?$TM'Q0=+V/D@84GOT7^-\#'BXW)N/==
M"7\N!3U=Q;SS"0+8?%@FT!<:T6[WX+0$31=T[3S0R&P(_Z@*]RR>QU-4AD:<
M</5:E]:B)L<#0;+0_/4?[^*:?%Z7B]7Z_B5-Q!WVPRM:I"3&XS+]_/4\H<_/
MWW)'SM:HWGXBER2^XY9O?R7+A=^:[)C&-^J71!>3HI1,,5U5<7VYJ9:,CH_Q
M)Y/HPYK>1'0F5>31:W+/8-GMR+6[C^N1-PB[F-ZA@Y<MW*)=%B=WZD1W%>UM
MJCNLZ;KZ_1;5E38Z%GH2=DL=:_G;7YN]79O_FB*N1Z[ZE0VGDW!-P*PZLJW)
M/W)VBLG:'!.:ZV3F<FT?E\X#1R(97.G]]LM%]+Q,R?S,^F\6J >]^&>=7EZZ
MM=QY_N9B-]IQO1;=#VW&%B9QBER=6LO+^R;:D0MV?_P5]76R:>ZXI3JDM_FC
MUA,?1*>^8J%3-)R=?H@^]AW$W\Y"N%[.+<C(I28+?_7II?E@.< )=/4#+DX;
MHD$GQ+V%CRKTHO=CVKI-1_]]41G:>N'Q&D1GSF?I?B?9E\MKW/5.23R;2R_?
M4):<)NG(*-*A[7B<UK0AZJIK%F;9B";!Q--E>=.8)O68:#*R^'-Q01)A\BL.
MI[L+WKPTHQ3A'C>*3K%S@8QKZJZ9KUJ:"[A_MPNOLP_TT9.39U'WN#<L4=CV
M>YOBJ.GV^G)0MR_&8QJ,GMM7T\M?R--,24JMW/JGLUD:=V\8%A=5YX91C98M
MD+ RTXZ9?_X[??_1W5C"E$MK]WH!(<Q(J.5+-BYSL/GT[F=6]_24ZW(I-]:A
M6[EJI*OJ\9?SWYE;DP';S'@04HMW9XB!7)*(M(=E=T6-O "]F13*"FRU9,,&
M1,2;^S-X:[%3MT6_I^GOT2\FSN:3$5[)63QQ] ^.@3-%;8D<VOP&!"&O+GYU
MLE^(XB<D]HJK--C#N[VE&*MH&UROJJ3+[JKP6,#1TR2-A5N]4VWN_F68Q\%P
M?6$>YV&>^KWFJ3?L*/W![>F1A!<J/Z38A>I8R6052TDGQW#_7I\^[3'V,E=0
MAC39Y:TM=IY+27O$A%31*-6SEC9?PEYE ('?^<@(,8$NL%%SP4=9@W1,)BGC
M,6-FY2OQ+MRR0!KB^EX/%@U(#P57NH"G$MN/)2V32.N#A*]O5M EEDB:4U+!
MA"AVPDV"HWF_7#3YJ12>V@-K5S!*39U+KKY==T'__D=-AC 915J25,\K9B\?
M^PN#*M'V8%:M2+@:KE5#IS3#*C46IJLY0XIR6P;=A)A5NWP>=E9""')KE9C>
MH4)W&25%=V3P$@@66L+5;[-BR(Z<09I@Y(40?=FLE=)["6(3KP3TLF8:]95Z
MV/(FOT*UK>U<*?ML]4);8$YJLH09&"7.WY#A<=YRRWA2I!>-].F1F>&^0.8S
M[?:*P3$.2M/X3+<.B-S(BP3IA%N*\"L%+F/?,'#288EZD>W-$PL-N6??]U :
MH(:D:9;%)A<E63BY$'4*.V78 R-$4"K"B'5?8F9&MC(.E>42"*J)BDN>W\9D
MV\/A0"^-F?=CM/0"77OAON+HF1QG;D1F;&9S+#Q=L6V#@H<TMNTS@4(&F\/A
M-YFNSZS *A4WN>UQ%PB:9[('(<%4Q-*;C<S2IK,RS0M$OH)GBV["B:Q"ZP[%
MSB") 2L("5B1FVG%9@;=4@X:9A!3?$/V472=%O;\38RP*(;CX:BX/FW%XL@(
M14"%DG13<5E.:_0<\4%+GIBD,25=<EU!4;Z93%PUNQ!5HS*]%"CR3]'.<%>C
M)L+=;[BY''N*04SF6;2SK]=-S11G-_@VZ%HGNV+G8.F>C,Q*1W1<LC"\0Y()
MYJFV*^(ZZMN&X0UBKU_9_,4L16^?[+]@9#ZTQ_GK_O!(R1D^*^L0F>4D-=*1
M?/DA_O'EJ 6V>";F<C">6U^W:SR6VT@!<\+#%(IC* $2QH[CD#%KFB*5]AY8
ML;.?3\D8_NUL*!O@>1F/)HNZ7"SO!VD+Y000'W"'M>N<V16+X=\FO'VW9'%?
MX\994GPNROJ2;@E%)O?O2]P/G=W\MY!V_ZBO&#[/%M#K./GP>1//*_=DN.,D
MMLA([V[]8/%%W.B%_O'"C+@_AFR^@V&#YE+;O3B)$!0]"<A?GJSG0RU"W!7Z
MPCZI9T=B,4ZV)#AHQ1W:%DI$+8#>1C_Q_2<R.&:&3-A:U$!7,$O#0_U,K>?V
M58WY:U@.S8>=[#?OK0^]CPD;ZC-A%.Y%9Q-Z>P0K:2\A]Y''-AAY6J.W2Y;&
M@^CGSXYV")CM+S2+>IZ7LVMR[K]B7[A@3,UHVQ "B/IY!I8;/GRTCT[PV?[>
MX5[[_0*4K3?M&B\!8EHRR[;@"P^^.-F"+]9@+%OPQ28-_C&+JV]5\DYOW4N"
M'CP=1.?CJ*&0Y!IVFNZG[\R_J&+8>+1#L'43J\=^,%3I?R#$U>R"61_45S2*
MEHR=O=.+?GZO45@9QMM"7^K@>&]X<$RZRW6R'4UB,A[S*U'.* 2<N5B&YQ"S
M&$FY7=I4APT]Z'A\-=D7HK-MUD>[5L_3_MF+@Y.0(+A%_6OYAI/",#^[/C9;
MJ.4FO=R<2VY+JFP)-H=5A-<M\*B]CRS595I"8DUK."#@^^0L 7[!7*57,:K"
M)/3O9VCC[&*TCS"?8_A</=O3] X;V:;B1EF<3AL+_],62OVO"^E./)7K[VTW
M6B4\ W.2)\^VL_Y LUYKTQS7_CT0;"R5A!6).<FWJ_#-5L%-_2_GOTO@9#OW
M#S3W#67MD5B!5A>FTFY7]E[:\.GZ*$,)$B%-U.?_-N-V#Q(\"I%NOD/M%\62
MY-[]^P26?D6;9/PO9P+Z#&'E "GW'NH*8(A)H*'<KQ5X&CZ]1^!I_^#K!)Z.
M3AXP\-0*.-USW99S U^R8-]VK0YO7ZI;)OYP^'4G_I%C?'YV_4EMK\*73OL=
MCNK1OQ[JNZ=+'#QIXUSB0QW[OG1@WGHS:V]5A&#VK>'\8-,,;;&=Z&\PT3^_
M>OE!M?-VOK_!?)^]L!;D\J1O?<&'FO5??OZPW['+MP[X0TZZ]N1IS_JF%7U\
M.?SBOM"+_;T>!R*>\G^&^UIGU3\YV/O*F(Q;GB3HQ*[L_VT_NL5!/KJ'@_RU
M_.,G?]E-^Z8 BUNG?W,2?DVOY&[WQ@W^Y"N[-XJCDZ[P'41( N4[/8U:[3HO
M4YDG6U6J+BX#]'Y<"=.K'+!O([&>$E\3K*M"K0TS1M\[..BQ<W\I3MA [-U;
ML-TORM2X]PI1UKSF(<)%+M[W=<)%&J#[%6W7'R]HU)K:6\44R3$YZ8</'>XY
M./!/ND.FS(,L?["?MV&31[ %3QN;"4AQE&5@+VR-\$>:>*XPD6J.=D9XM9K[
M]T-9/MVB+-=@+%N4Y28-_@LHKM;'3@Z-8Y="5^-907Z-E+K6U)KHEU\N>@^2
M8/>-RRW^4.HO\0.I^6E5^MS;N+[=IO;]TE<8U/Z"4'>@97AIN!K1:9)@K*Y7
M^FH+_&#O'K&#5FW&5RKQ^.N9]F]HD7_I?K@KN'"X1L&%+TR=NEJ2X39UNBFF
MJ!<;UT;;-\C.K2LIIAUE2@=&1PX[Z>/IZ=8_^#8(Q?A^BW,[D'0S0_N]AI8G
M;=ZIZ>WG+/9SZ3DJQ0MG&&V<% ]C!'!)[S?5_U_RQ!46PA?=XNO:$/O#+[8A
MOE*9Z/#H: .,B"];W=OMAR=J/QRS_> 'OB$VA(M:/MW:$!NBKH3@P%,=7)N)
M**: XP!6 U^2F\+,4IIK)2G8KLH#&Q%_=76^2[.BK9="M21_L^#_JVGQ-L"W
MR:IW]N[W\Q?](0FVBT9CFDX*%^Z@U;B9U>/,9]0,!\C*A@0@_,#8/=*V@?CJ
M.BWJ4F<KW]S*>MI:#AR\<1KJ<,\!A#<P\_RE*>;3TU_._V*@[!\U=^5LY#=P
M.=/5R'J*R>.;F'S=//3M(W"M43Q/TFH+=AE $ZVV78_^JNW:-)-M,?0CF*J=
MQ_J.^>PW%_.^=NK)ETB!KGWZ[4W4@V#H.7BM@]TJFW2^NI:^P:PD,W[_\OK]
MO>.3I\.37DCG=;\"^^B&]E<]FX UL)X5K D-FO3>4G<?]@YR=<)!*,@VQ\[2
M&8C;='M\00_#-9*+#\7F].K->WK!?MQ_7GS^.J& \(ZW2*R3+W:Y][_$TEGI
M<1]O@L/=F,,5@HJ-%,5BTA]/[A./?U3Q) ,^L@/^V@ZTIY2]3(&"XH!DS^ZC
MN(SG['+ WIL6.5-<\"O3P:@S;5U_?[#Q.HD',*-@4?B4 :YXG2;,A:=SR6LE
MC=VOXW+!&X&>9#TG&DI/>4GQ%4M?EA_T<UR@#+UZ$)87I=>XVHGJJHZY![(-
M@&;F"O6 V#Q%L%%M]\0ZGY<:V1/.$_IXP7M?&%%-,N"^;B6(BGM1Z_BR.]$P
M#M/,N-Z,PB!<<MMF4*5R@^&2-J&<0')/RLKG9NE?&8UD'EXM4V#?,8[R(N]S
M?_M*RAR79T4(:\(C(WVL]5#)EF4*]+S";3&@A 3X(K"L= Z%KY:/&5\AMLLH
M9EYVYDZE5[QX__$=0J&^'[>J4$_>(M?$MM^PM"A)02Q#.Y:.!U/>9J!)ER[$
M7O&VI(&EI:$+KNR2Z!J#+-CVT@Y'W#%:MDY\VQ?@+%5A8[2QL+C'C2&0<R_"
M!1M:IG +.[*PH_V]+>QH#<:RA1UMTN#7EMR-[)IXQOTI8C:TU5Z?JZ[WRHE$
M;U8@A$J"'FRZ:&FO%[Y\<1JRF<,GH\&)[A?]1-?/;2]I^1PR%DQC)&:S@KPV
M4+?3VX^A!EE1BKJ?%W.O]C"@$)0^[[QS+YJ2_F :,S(YR>US9*NJ@(LL*V[P
M>XQ;NG_$&7D<.;/!MTT/'!RF/_.-0IB+7=6LTQ%,S)VS@BHJ9SB.Z >E'6OC
M!M Y8DHJVI7I\TGG<<0R^(:6N!Z3-A73D91FZ\F#Z(\)62$@5IME-$S;+B&P
ME]N*M=*2"PMZA^8O3?#&//E.:U_5:( W-T:Z$W@[@.[R(XT0\R@-O:]*8YNE
M(3Q;D25<L5U/.\5VA!!BYV L;)V[H523HLY %Q==\4,M\??8_[MI MQ^/]E_
M25TZ5]2:=%V>%TBSQ3@DG[\H$S&+\#[."K,^IMT;68%^=UE\0PY!39.SF*$1
M2\:=*[C_PE\R_UI]W6/'.KW4)X!,'6>\Z/#QM27G[U\N^I:G7[QS6, +<B[Z
M^F=T&5>I[ BQSBNQS:>PK<;6OVF>.GK+P J7,5:C0CY,Y[KOR030X4L/A-3R
M^GMAX5JQM2LPVC\1L[XT4Y/8%5+L!UJMV=?R;H +.S6(]-WMO(NQ>6&:P.!O
M\-;YWD;H?(03*!:\MYWKW)J^ B.Y+K)K8TO(=(KQS5CWVS]KVJ!RBMX6-L@B
MS^7F++2.<>DVA=L *OMBR%D^(VG>=L1<WXYFG[():1=:XO*JY50%KTPO7.M9
M[CC M)$!T2#7FU[<O>X@.B/E<B7[QJ0LA@(GDPXO2PWZ*"VE3\VL-'-;DM/L
M#J-=()TC"6F<D#.3I]6DW60C;%?CFV&$6U*_ZF*6MUTG&,92--9QQ"(R9L%A
M=WL=A%8[;L=>D#\PO?9028O.FLTC1%1-8^G\P_JI1YHER_B/@AY>:LL8?,AZ
M2WK6L..O_1M%8V@KC-O>]I:N);:Q"3I^7&KWH6 .@X"3;CQ^)DL@Z2!RSY8D
MRST8R$N;^"P+KS[7-'>^ G<-\%9-!9N*1]*.6:D>6^Y+0/+64:NNCJ1AHKM^
MVIF["L,3XQIV7H\T>LD>[HUICA,W,9_IA/L'\\/"I 1?J :(?8_&[=U;-KI,
MD5..2$&:.Q5FFZAT](53"6ZS[K5V5_!VD%$;:_G'@^@-G92"]2;+ =YP81ZI
MBI*";4-OU-256)(X;W)J$;O0LQFT/TIS;914Y#;VW1GK[GXO$6(DC^,@?.4%
MRFTR $^^E&Z]=BB8)GI#DM\\D[E:*:RSR[3Z)-/H!. \M1UDFT<<*\ELO)=D
MQGP*UUW/D)IB=@T4 (<I8^D0OO\=2ZJS:J_R+R.-C%J+)$/%(KL=)['FYF;3
MG>AS/WS"H?ICMA2QT]-R5$\Q:GP@ 25Y+PU!=<C!L%VF2D'T@\+8K;WB!!SW
M,L.-FE:I<Z#\8@?6FS0I-'[^5[=4:H6OW$ZMW/ECEY1/:6L2<7=L=;9=$][H
MUI:U ]&>LMQ;&[T0$Z2NT /%1?/"N>!?5_2V,+G"%7Q9E]C%4%.B6<)?\>+E
M(ML-=RC6E-'RK1@H^E)4<07G+JY85(=3U>@%?LNT>4EP:3@L:)=%34VTG2*S
MC!XB#88T-.J26>AE);(0FW'9O^4 K6^XNC2$'GPUQ#:+JDK9BZ1%QV!05:Q"
MU=FO2[^V,<CPA(DOM/![4/859D9S'_0&9")+;#,2 X.G"'YI#->JG%O_V[O!
M2T),O;]+/(E&Y>JE[>9H&=";9C]#W-!RPI3%LG.#,1SP(-'HFVFCMQT.PHJR
M^J[[-#H*]I8PP$_N^*4M.F_D"=NW.6QE*?U+K&IMZ%)489+R\+YWZ1P4\[YC
M][D^@QQ>KP#K$K'KXNM+_0=;UG$H3+SGV^Q8R%BP\1@G9A[\GD?1U2!RN>'A
M<N.T%";D-':I 1S)'GQJCK!SP"7G!$JS-QT'.J9JU<TGJJI\2UDQ6+6;8OCC
M]@/#AG*&W+!B86Q'Q=*ZWO"[Z)5CAD30(2&W&!$OGW9,KM.*_N5;/OK9"/KK
MP<*X*JU+O*+;WNV='_%6= YI>H)&H-%LLJ@0\\!4UV7C9F::5E;_VZO8<H>E
M4Q9Y.EKZ43!!X0BJ!3I& QN5H;W>U<0U$K!O,K+& =>-V^PD]EYY16[QGW%@
M]NO=>N%"(JEEQS(EQ4/V164-#"0R1A,;BU)M!-4JRYV0"H',=N&)L9K-\KN6
M"E_>F[B;;P=(Z@HG"-TY64'_/_;>A;F-Z\H:_2NHJ9FOG+I-1I1D.X[JWBI:
MLF/-9]GZ)">^C[IUJPDTP+: ;J0;30KY]??LM1]GG],-BG*LF)A!:C*A2*#[
M//=S[;5E#)D*K7MX.!P!<NHVV)EM5',[-C5^[?&B:<CIND]W1<Q!I4YPI6_;
M($HXNEG0B+?#3M:T[&BF9:^&=#1T5;E!E=' Z(A9IU*)6X@/=SY[&^SWEV$K
M68Y=7)[/W@3K=_8M3VX&4/*C#X&2_]G\P<%^WP\BO?1;C<[E.ZZ>?G6Q^'Q^
ML?CBZ=.+97GQY<7CKZHOED\?/:D>?_6G_^]I^.WGC_[M_W@#1^1-A L=:- <
M4R*_ASF ,W+!M7SQ*#T1V,SI!'V2$_2!C-GG?_JW_^-[A"-?&W2O?R@'A;NL
M]K/+IJ%S_*8BNQ%BCCWOW[(U]!THH?]^P(.+P\"#CVA@__3?3FB%AYTL/Z$5
M'CY:8<K'__V*SYZ;V8K<:)"?WTMUQZ49^,=7J444D?.:HBQLQ1/17O#A@M,T
M]_.5S (9]74S *U ^+]&/#[@)[J=^E?<IIS5#@<&X7]N28D-3;V3]G#KBA.X
M L3N=DVP[$D#7GSY#*C;;@<+GES)<LL!5/GJJN3\N;C 35B/I"8+&48.&-*3
M--X?0VG:^3W_TE1DF7M\![57H2;#BEC@#+N><Q0] %);]1XK:/&URC#?<H$P
M?):17/""TGBNNK;D+- -S1Y9_C-98X3C8J-Q3*F#F\K953J!9 #$+=0UO:ZW
MY-5&/[2_)K\O##VX.QR;KRHB.>Q**VY8;Z_+JPI#F!$*X Y6M <:@Z-<2(Q
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M<=434B::T"0=OTS%DY.#3KHI1W"?S26WZI-Y9>X%#S,!?9\2U9:H?G)*5#^
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M32!JTD07C+"<+"*.<52O"7EOW,.<;%R!Q56Y40R?%G!F614GC)X)E!02AM$
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MM7RQ>(]&C'KM=7TU12YXI*'Y5Y9@.>+8_+?672E%32ES7L$-Y;(H@?09\US
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MB;0]IME3>)TD !%459H%*L;M7\;49YXVQN<$XYH:G+</P^V70E[D&ZR3!/L
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M*DDMAP#:YLP)3%TC!R$*\LM,#M(UX,44X.8_\WSA4L.3SF=?5^)[+:'JHGH
M3%2\.GPV]BCRF.5!&J 340T537"Y^Q*NW $(],MF]FUUU0W! !,;[='CI[[B
MLA]0Z+/$V>B&=26,PHK#"D]QCWP5XW)!6+7=MF4BN"M2:&!RFQN9/2)F847"
M5'"_I'5)GB=]^?9'J>I_\O1/G__Y\:.++]+Z"RS(J<6)PZX\/6%7'L!83MB5
M8QK\@\6N1%-$>;X1F(-932H\EX\77RA;N:NV5^4!<P7DQLQ?MKM6.L_J/>>M
MM#*&%$>4^0::6;5<ZLT>HS@ (PWRA>8DI_2P32@S^.M&FKB@^U^2:V'*9&M+
MN1"J9%8\!(T7'R$Q>2V#(X!7QLG&T/KY[%LF!O4]RS27=%AO]SGN1.$N8[M#
M"4/5*C\^H(:V2N56G,&0"#^0IPN+LIY8#+$<K];5[%#2.FFJJJU=80%(E:P#
M +=F[PAP%BY+[-]G; *-%>I%LH<P<;:(3RGQ3Q49U%:WR(3MZAW5NUK;6[CF
MA>]]68RZ9.)JHE&HN>^GE-<GRQ8,?;!IJRXIL@^;<A/LVB!I.^F'2<6=?&L1
M^$'"1]JJ+W'[,^FH79KF5-R/7EJG+?Q46TBZL=0R'^M!4' S: J'#^@L5DO;
M^UT+3N'K84=L:BY['3YPVJ1/M4E<55@;?X44A4BTJA< F$58X*$WW%26D05,
M0N=J0<CB4@--/W7:OT^FU03V#-M18J"]5@JA)313&J!D:$5-^:K%*0/Y2367
M=A /F]%7\^'>T-<'E,VCF-4(]*II^G5YJQG\L<?T(6]$TZ))R7C,X2//NB-2
M;,D@6B,;P,^OB-(A'.I;*1<;]0@WUAI*I*U60>\D'87^"8 +!4EO*P#C8IK3
MXTCP?H&F2#9R&IWR:[$I!_@G% G6)[D8&2 B]UPN8=B:90[YFNHQ;T%;R_*)
M]X/W3AX!@Z1)N#5!HJ48,P8DEM(3?C_31H1+4'T05((VJ=ZP@[W>R[-HQU*L
MVMVYMW4MS"@^'^5;8FS:IH(Q:18]6_F_]@H_)'\X/(9[26FVAGLM, 7:H80Z
M0Q$\BX'/]:D^MY2S1@M2"&L$/=#.D[4@OE<?PQMED@O$:5!:$Y\XL\2; 6X$
MF0CN^AB0WX1[3\DE3=[22U<T[T8 T-&I3\?:]EI2 T86NB[T76H8VVL!A9;%
M1);]0NN6?&74MEW7EN?@93."#\@#MK4H$]X17T.2&YZ&W-_7B9'FA+*]&Q"V
MOKI+$EM'6W=S>&67%9'RK0L.9O#6K%$,=$#NKZ4U5,ME^[=M!](<*C2K8ZI7
M*_^9)&.Z8^/QU8=@Q;X#[&=.2_J]+M'SF,3R37&/S QXE<8HI<N<R74/*X^Q
M2A?50L/C6#\R<>:ZI)1FJHC$1=.8I4$D2S0:W(56U(;09#Q_];:0\86UEE:F
MX4Y]]]U;UI]HL_&-"^ME+3>6JKQ;]*X0U6$PD.<@:0E/?RTW\BU+U>?$;M-'
M7JIO?WI>S'Z<SX>M\AN\C5 P/C[9F_E[WS0W==<VTF[G-2/.:%R78((J(B>/
MNZ91[/49:\BX2R"^;TP9?R1$I-$X=&UP%S;"#8%]\\'3^%81&$%VEL-"6O*0
MW4/B DSB\TC5<"4=N-V3<Q(,%ENU?3K/L>IT9C]NFF!2];.OA\6JVH5K%C:*
MH")Y>Y1'PH70,2HMTP9Z8%Y+X9Q;9+2V7H8CL$",^#F=7WHL&8 ;1I%)^/?R
M^27P5MS''9V8J"2NO"GK-;Y+RE/)I( ]ZV+K75D^H$KVL[?SH%Z&M=5-2C?G
MV=NJ8R1B?DX<OM )Z,G"JV!5-0N&W'!C],FC/;TM6/+G\?-OX^>Q)I!Y4W]]
M"<8U?.";]_CQ4KNORZLV5;7SP?CY=;U>G 6E7,-.DX[I.;N'J#P;V^NV[M'T
M!*J5]N^U?0]O_'7"S(36MJ6<FZ2HH@#3TQ]OXER%PC8]2D.S+&N&-R@1+Z[(
ML=F5/U=YBV$3VX2>0CW282.B\B*M$,BL""*6B5-FQMAF8RDG&2LU+C*0T<X=
M^8(1GWWX7$EV&5'8[P0%QF!"IG8F#I+R'V6WH/D$S[(28B>B*2E[E*XG7AB9
M9]3L466<!#W95@WO6$N2$/B1>'(8@&/^R6P[=/T@M(2*1L:Q3M;KP-KP31!+
M<^C0@U"L3/B7[6T#@=/)Z*2:.1T=4,F4%ZF5MYG7A!V'LNO(GEU$E/+D@GDI
MPD;S-6'R.?I+8*1?VKK!#]APYOD$1*W41A$ WQ&(.RU8YL0-,/@U_Q.994.P
MBD-_M9\:#5FIA" -:U5)@3UB#,%Z1J;X7=,*K>F"76[F7 !94^T'IL\YM52*
M")[/3PB>!S"6$X+GF 9_C"V5JA1Q3_FYZ[+;E/-JX$;%;/TR8[::!LXZ38W2
MP_H]$J,SM=N9<+L504O,Z2^PWE2/LQX)6H^T:&;8Q]Z?&G A&3XTSA0G*_#0
M5-AF/L#@<@@Q8J0PR[K;<,2;RQXJ[K' 6BQZMW,NUGA1;2NFFQ=>A:SHP(TB
M-Y?OAUV9"FD:[,&:Q5L8-(-"Q*P[)]J++-..]2HDA4NFQRC%F^9SBUDXSS5_
M5C-8;$MH;,MR606OV'(@8X-.%$K@2ZPO$R?OT"]9(.QK\6K"PB:GR@4#[>^9
M*5<9]PZ>S3ADK9E)H^-I/)$"ABF$7]%4CGR'(ZUAS^9[[9 I43S$!H-=$8N[
MN3<&M8MQZS-:&G*N71$XEBGFV>D@P<<9K_%RH"A@3.'ZJMNAEP&I[1OKL,C4
M#0YWC3BQL. NPJKVU#YJ?W1^S/-8EY)((G)9@N'56XR7!$D7)$B,05M^VT="
M>=GJ37!7QVL%M!<O^Y7>4P@RLBRK]R6%N1TWM0NZ(_Z;=G5@6QR'SS-!ZTF>
MSLGKZ=&0?<*FS+:M0FB0,PBN0!/[LM(H+)F?,@PG(MX+[(S:ZN4RUK?I_#2_
MQ24VY&P4;)E+31@?KW@$46WB/2R_SD=W G\D=.(H#*'!?@O&N38?2HSYP<AK
M+BNXU#'-E-TC]@K6WML4^)C&8RW^\L'8;!)!L:@HHK 5Z0OM,/B?0[^KM>#P
MC@CNAX.?/_*AC505]XUVYL&OR_\I\>)OGU\2G]:^K^=U252Y>XPZJ),F'* .
M]/SDH].&UC>E_<LL%/XG@J3QVHQC2/#S$R T?- *=%0//M3X6\?V6,X<;8!O
M=M(T_]4TS=&!XW]B*1;!(N$V;%IR-W;<48BR\RSC*!BFT4S2&C@\W'$1'"^-
M_AP6JBMFTJ:0Z@PI_:V$4W "]BK3P]8,C2XF(>G?:V4IN1X0<74#.@X^'^')
MG?@#PK2>(PRV0U"#)85TPSFH\!"$YC2UL6JI/Y!V6 G?IGH]QMQ,M+/;4L*)
M&=:I+S!W0 "/8;A#G)'JPJLL-V4.DTH'H7Y $EAUR?GLC9^V$7=?=6VY &_W
MLI;>0*XV %M!LZ >06DA==D'Q:^@&+X[ Y8&:3AB!X /0.NX. L*B!CSP[2E
M,9Y(=?9JZ2S8@$SL" 1*:3'\]0^?W-W2AS-/.845T%5I..@NO8RD#(8P]KIE
MP-L'9RG(LTZK*CN9!;.G!N7:D6P67QA+3<B.V!^HXR1$Z3CY69J2V<*%T74D
MFC&#!@B%,($K"H&K^"9,$*K:V\V&1+FSIP@.DCC,7'Z4/#YY)@V*'*UFUH35
M:V])';Y6@(.67Q/Y>I7>"6.-N4*[ZFK%6W%5)6$,N2.NTTQ<57$ TY9'$_"H
M>4<%M_L8 V\1[4:1ZW*O5><V1]R9.,/SV;=Y)&*]CF2?::JVY#C G#;:&P$3
M.Y6%1=P;8SV7\&H8AS$1 ,^(3'+-D95H-(333;Y]OPM.->\9/N%:9+FC;::Q
M=N5:<&5RN&[5V=7^C/Y7RI.)I%7_.FP&#NK/7%NT\" "XM&%T'H1%\8Y#Z;5
MC?2V'*AU&*/<_.V[UM6)M!XX $G2FM>^E%-3L\"C>Q?.PK95&9C,,3+^IZ*X
M=\=*Q2[V+A5LD&M6]2]:L-"UCI*$J9$JZ;3A8B[T"?$B%O8U^"#$H!+.QPIU
M?CLM_8?IG;R;@()T)VT/^NMR8PZ1H"P5QQ4M/2H,;-"W*9%F>+X9\KZ^KJ1C
MU?.)1#YL'T]@(ZV)&%D=A%YX+*G+=;58Q5ZNO'\S[1%+G4-D#\-7986(V$ ?
MQ+V0N+^W<4M-@#W=<M*]+OL@2H7^@7BNRWKCE 4+_JCP^ASE-L%C17L2&71Z
MT%>O&<$*<,> %LC\)I(3<MRB?T$PB%<PO9AN --3-P8N X]6%<P.9'%L54]I
MT,*#;N%1$7RDW =)>W3.OCI?O*181!81_ LL O:67<34VH'?R79K[[+&:.I+
MA[6WTZK9VVG[3FR[=60GHWL#F#)K&_DU47_P"*U3U=11D#91VBZ1=@E?DSRQ
M&8 .T0A>M3NL)L$B/[^,0@6)7?8KH(BK@Y/6J8P85V0R?E VL2 @J&EEN<MF
M5X2Q)EY3(1/%]8I?NF(;F260_#'!MFLI6W1&P2ZO;I(AF@O?P-R-V&[P@;7F
M8/S=7V5SM^)UY@=HFUF)-X4S8?QFY^10PX"(.I6V1,R)8,!2%SI#/^V"SFZ"
M*2$!!(P'*/E3EMRRY%^<LN0/8"RG+/DQ#?[!\EP$2WRV"]9G) $HS3RA^$@0
ML /)00G'-42 )392-.+.9W]3 \Q;4%G>UI>S'*A6V745'=1%N0GB0[/6HF&=
MS1AL_:%/# IK63:7.AS^*R'CX% ?JJ01)D773$(;%ZNC/)%2AW=?M^AD'K9I
MM7<V?7@G:9166!$1UNARY8M^-4TC 5>+S=_%=VW54!FOM7J,G!_ED@2E%HSE
M"%,^C)($SC9D2Y]M2/?+]/DW5_*;1;L& Y;S:5)=FN5+XK&)J7KJ'ETGBMA'
MTO53&D7./ 9%$?I55AO RJP07Y@@M(7Y=5-9H[FYQ!^T&L>!-)1OESTB>@@U
M .15Q3.8#4\J]UPD(J=7@/TD+%QPF%;(F("X4A+MEM^64RS4*G43FXS&7LSL
M7!QM<I .WW<O7U\&@4 7LIK,&(T. 6^R1GD_Y 1HB'<YD/E7O<?MI: 2&7#!
M(]ULM;2'_T9XFUD_OZXV4LBHF/^]]]6E Y):]$D*4(2D;W/ _MRS@\,BQZ->
M[K6]P3R\R,SM<#?IYV$+2E0&+"#ZPNP0[S@6L/=@!O@QA'R9(T?#5#'.IXF.
MV &!LZC6X;!W""4Y?X(DSG@1^F+LB3_+)MA>A5,]S,4ML"U-!2S":>[Y%'UO
MJ'3S^UJB8I:DO RW5PL4-*O$$P,G$Q>UB'1P3^2]M(/$ H=/(#(I$F@814>:
M=K8.AXRH.JIJT?]V\9&ZD=C^W8&28[O8?Z%22UX)IV#I"=AD7C7H4TU(>BU2
M2(M<:AD]ES[ANSP\A(BF)-;DIMZ$AR6EKT&6MD,WKR0"Z('6[E"(M]CU$H[,
MZO?<'W+:1J>JIBN#$FVU.10URK]KYS,&C#GOZ +H2+"P7NCG[;:::6=N#CPQ
M/&LM_<\@?HJ1.A[E3<+7ZLW5T%$P@N^&98.B8<&AK)@ 2IDX)9$/W2D!")?M
M=.6<00 W\\HUG:=<?B']HM?<K5B++:*U=%M-ED/+.LJGC[+D) ^%=E6,#I5:
MU17,8-H'JAH@C4G[-,[=.\P+[SV;9L!04(C)(L(<O1<IR9L[=2W8AJ8@-BY.
MVV^I>%23;#"R)S1PM 1UA*\-4_):],G;H>FOB1GU<K[3V-\B:9;@DRV-C35+
MR!DVT[J#!R,\F-_U7 Q?01L)2QI;SFQ-J6:CYL0&+_%'/T^) K!# (^P$Y:^
MD/+&EXVV&WJM9@'7$:H*B%FUPL?I^IAK!<IF*;-"=I3WC<-0&U\ZHZF*<#3J
M[2A_G.WR>/N2N#-7SUS76]<D3^R#8%2 80)%+F$8^8-A@=8;KEFA$"K=C;#D
ME+*D9H]:>3_[S[!I1DIX41@YX6-MYA[WO;U:BTW0CS@%Q]-V9CS$SB+--]LB
MLQ\YO;Y4X=4V9P[V9*=?N[S'OY6]0'OXF0T)3/&I:,R8]W,9YK@DW7=0G%,I
MH9062K./17!_:ZHOU*,)M@+<;H0_!6)-IFN_2[A%.%K+T%MFV*=ORA^=YD0Z
M:E^5::)3GFZC\P%>9BPPF#7XX28<=>15PX'2%2^FEIN.NIVVMIL^;!:X!FE_
M$+,HIY)HM)96:=-0J#M:.^EQ3__7#+CO&A_/M516!,;I88^(\ZQKD])HK(7*
MNUV[<"3DXHH)(%P0])XI#HBH&+W9$;-&+"U'<.CYU+E3^V4B A"["D1""D*.
MOXL%S78KE[-5O=R!-7!#D/<8%E'$N,_VCS3-E(995M@?4B?'IK!_9E,$VYB>
M!-P[!4=FQ1L>CGK5BKLU$<G2N)4<%G/_;R,T($5KP8LILL+M[U[^],WS[YR@
M%D%:W[@CET'O[&B)VJH6!_5PEMMB@5EP<$3N*%%^A!=<MTR) X\6,@^$.X6=
M5[V1A1NL0?Z"P&WG-5N-GHR#8V-89X<_-3GODF,Q]!1N>+U@>"R4O<PA:4)[
M.6'/R%(20*/GQ3;U;V^.E,",'UOOO8M L:BI&1D_.ZDKVNH%"F5\&4?+I:U$
M6"1MD;-ED]0@HBB%\DH5QN++Z$M>DYV"@L+7QY.?B@C$E&!IV#(!M=%!KJ[+
M]5(Z4?MA[<_M_-$=B28KU_Z0$DF)B$R1>$='K4+M_S<^,!.+*KZE]&+1NI^N
M-R*>%?PO!E9+:L_:2:#612'@R.$OZ[6-6$0MS5^BT:S%K)*(5M!B5XR!00D/
M,TMQL(&% C6BD9?;65H:"VO;[]R4%K(55$,-?(.^P8_J0'C4^YQ\LXA\,F(5
M6.SXVY1*+2I_GCXH:HJFA5P;H?_E@[VH"43)@ R8'@)/9KW#ZY$E 2@A: XM
MJ68=.O?98#8G,AL':1T.:"[JI4U35L1JL3M5,;O\[)>G_.P#&,LI/WM,@_^(
M*N8':J>^9%R_ ?W9"[TK/2;B&SXDM 3PLJI'HY&*"&L6GC3<V] ?B-8E];?&
M:47:C7*C:.2D)6%WV B%:E\K\%W4_:KM5M+V"C;&0.IIK?@LN$J#UGVT^;*@
MV=1Z@,7(H&@ >^NMJ;MQJ"UU9J)GUE$9#P]$33AR2&W(P:D:=EJ713ED96A!
M,=)UA43SLI8 @Y2Z5$(P6,P2_7J@N(,FIQ@Z*GS!/*NTE 9>V> !I.SEQ_H2
MR6<X3R[644>#_X#)6B3@-=@OM]=A86^I@84;A3^.I.WY2-X1;&?X(#*AX_.E
M9T7/#QU>5^1%=E]I1=^^)%\V7R#QSA=;#O"G)C:;PV7)?B>;<N^M<.#<1;64
M,GDU>:W01XU/Z=A&)B)B[D%<G''%EGKMGF/26U9L!#>5RXT@CMNA*URL#[]5
M J0YP>66 Z7J[C.R+$4!")U^F"1"<ORBA5]2R.GH(@ OQ^6@5L"8^,9\7F5-
M<WI !B.\3KN*W;;=>G&+WJH-(2Y07Z*EE7S$8O,[384['(0+S9+%B>AL9^4>
MDC6V,AL+D8;AN'/?+E&FLNZ9:0EI[;!6=+=]^%6)@QPRGR$D1FBD_XBGG5('
MF!E!*P8NCP"WZ%Y#8OU( $PNU&AY,H\[.7 9!@>+')S4]I9*%K!!X9*0! IN
M%TG<?3OPB>8SKB/$:A@+E^N;Z!V]]"O(5FH[W4&V@3/"4 +PV=^MM=UK4ZV"
MOU!Q#Y;>)86EWTL5WMGN*U%[3%@"@4LZJX%,IC"+LH:YX,$$(JO7 \KAVVH5
M_XI)F&V IY)<B[%@T;W1=>>U,8R4(62H7^6JU, 3T M-LCF%ZAZ<'V>L< Q2
MU.7Q\:<B$1#6'A-YH_E5.B]'1I3ZEHDV1J WPZ.Q#9#U-VZUG96"'U0_NE4I
M%T%3<>;2+<^L3)#<^PE #1IC9;^SO,^8O=/CW"8K,;A.;S$.: JDQZ(@O:1S
M+*H=#,\@>/\A+3IC&=]MI6QU:])UZ[JZL8Y;HY&KD !Y?+)"Z<(@]G8@J4Z5
M4H((] *-K 5-]'(WR\FUXUH!Q.D8IC2_)HG0K"+?.6@+"+#((GTG5'9G6<]J
M'G48'D>7\^%K2M8.3UJ^F5"Z-L&9"">J[38F@)<?6AZF#@@_:";8OPL%YS)&
ME)31Y*=;3'LZ__N<6:3 ;&.LJ$KT"<,AV'IV6XZBO])46M[CVJ^%[$%#;LG:
M6FB'Y;LBI38>"X4RL=;<EKE#/UXIA7")9>:@H,P92'=]+U3P")>]?@KOI##U
M[76E<3R^UN5.;WF9O-9J#S5RF^S8(LNV@TWW 'YN1LE=Q&/! 6+?N>LP1']2
MZ-T]/FA147:.6Y7#+,M"I)LPQ78AW7RUND>:R(1?4.TT%+D-)-DZJH5TIO?0
MR W<[>4$8EE;*2OU@P8 J!=B>4XB,,8W=4%PFH^S3C]27D2A7"@QB/#2&\>I
MXGH<\8F"Y1C^M4B36:#6E*:,6$_GFWN8YKQ2=F"/N_6)U.DS->($67)Q$A<5
M2A %YGD]=_MTN6BW$<3MWVX!_V34RO<O\B9^67B>9;QA'8R5/]S97X;@C"YT
M(C"<C6 C>9\]GFVZ)?N??&&@7D!",E1J@DE@0-*>6B:JR4C"Z@E86HE\=DPK
M"VC>ADHN.[[64NDJSOA8>60,&4Z]L=\PT1I 8-_:',#R!E?,9$)JO%IDKQ(?
M:>C33UL?B7Z ^\.J.\JK() !%R*G>Y8ZW7$- ,W'U)'EN4M9<=OQ7-1!Y");
M@G\[/4%!(9)-J9IB2:(R66$R3A7A#.U83*]IE9BRP@V%%A<N^H1&9#7S"91A
MV3AU>,  @GLI -!,N--$>E,P.HSSV:MP0]H;*76^_UQXP&#T'XVZ!CA$!GUH
MQCCA-AR1VN>IV>^/6\2<)0<N<@#J(2("@LDK(97ZRL<CQYJCAW@PJOJ/SVUR
M#2?>4&QJ<V3>DBHY-FRI+$2U6"J@V7QA$27Q$JBVX%#/&04>V3^L8<N-2A(C
MDZ! #E%5<P-8YIVA^^(,!NGG3D@22J\R8.".,.5=A\[.UU[!$A:\>:>.D;EC
M9KZRD%SWU2T%'!7E2F2JSDQ2$)CTZY-2XGFDEQI-J8_A(>D]OVJ%X4'4:0;X
M1FI=6&; %P%B$$:._!'E6-M2XIP(?T[9X*D/3.P20;_M/637\8(LV_G@HBV2
MFI;@B'PA=9MY2]COW92_@/DG;GZ8T:[&CZ?\MLMO_^F4WWX 8SGEMX]I\,?'
MTOWUGA08$P?&LME78,AY_.CB42P0NRU9M0 73*THRMLBX9KB(II&Q#QJL%R$
MCS(/A7"-*?<.FKHQH+IK;ZG%X3)12,)P30CC:^G*0'$0<J(D"Y85^X!Q$O&2
MA&!SY%YFRARJ(QNK:B%.K3.&$P\NWZLC747",?NV:"[)9-*77!&F?$JT.[*$
MJ/F!SI?29$=9JBM/B$OTQ,&X) T3:[TF+(HPJ5-;^$_5KM4@\11,I<-/E9BH
M6B,^O09I7*ETE 2N@<<9W8B][!TB^"J<N$5EY'<<FA"^5BZ"1]15DDX%^4*$
M(F_I+I9Z>,@44G0 U><+G[AR)C%:G3BPNLJC#4=A_"2*?VK#_ E/D6)XU:J/
M+'>4#M@,1%9VQ?<YJ4!@HMS@$;BR,*NJ0H.Z-]P)30JGZ! \?G)^\1\X31=/
MSA_]A[':B:^>/)[#:20G]6 "Y"LA.*D.B]CW]?YT2C[9*9'@/T7.F0,CN#"<
M]-.ST=ZJ8^-KH^YY,N# E6MRK+31+\L=1W9U7:XI_54WRZ'G'_H=\6$LH!?7
M:! NJ&UX6:?3\&E/@^5'7@>?F,/^+V+4;55NC>C5$RK(J4E/"7=JI+0-S I
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MQ:1+$CSQ\M7\HP-,*E14J $;'(?W"%2CCUF,&QNE2;AVW%<(ZGA%K5Q0)^=
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MW3T+[>Q&AROU!:KV.#?_4*M@L! _PO@N/F&F)?RW??#3+&'/X7ZOF5\#"8^
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MEI7JI@&]5V:<)7&IT=YF"ST?P6S*O!AOMX29)*&7(2 PPGON9CG'.Q\\=>1
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M*23O3[^O?MT;9,JKZVLTT6C,%W>U-TK!98(QCSO*MXDP+-X,5R:W/<]Y/#8
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M,*\N_T!$@B77NPZFT(QEL[FEW<,IVK Z&RI0WRFUM_V@[FI9'Q"/,Z'OR67
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ML>EM\F6YB:@FIL#HD:%:N\U*I^:NG#V_<]@[M*GL-OF*67F1O",A)FI<ILX
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MK!9U2<X_':UU=']\QU%X]&%BCB:3 >QZ<LA3$&$J30-@60(94]X,^P$?3>,
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M]AO]A TQK(DC[J??(<[!(33>#9)1Q4R5+@C^OE[GMTWKV% '#6%SM]/T[4W
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M"%64[XV^3NR?O].<:ENZ/T[.M'QGM[OPJK'%E:;'"<N+'*D:WI105AWX0I@
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M;Z!GD[9B+%)K%=LVF4QWF""<E_3Q7]SS>+_=.4M1LJ-(\YW\S!J)4@!X.'7
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MRYPB[(KT\J9MP[JY!P8=N>]>:/%Q)CUX:N#FOYATEI,^-5C:ANX_!_"42'0
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MD*G%2/#/8RLZ:K1$$\&P#RL_;]0#:;C=CCX9CI0ID?BPM*ZD^@$% :Q54)<
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M^)YX56&3YTE5J;*XKGIP=1D)A.;3A-M2YU#1*O$&;$C.P??1^8 1S"JY'NY
MHS4!@S:CMQ; *\K.CY5_D3*BH58Y49(\5#-6Y"U8WYP:J02M 5DF<=99U[:I
M3)#I!$5+V%4DFDJX%SGP[?+[Y=2>_VF6F,)]6]8'#MS."2!.^E&D#BS9PH3<
MBH'J>P6-U^1WQ+;AM*:?9DV560%0T.X..>"#*IT8JP+M)VD8MJI]1!DP<(T3
M'=#[_, 2@;!MRL8H*:8",,<(.*Z$$R2$**CL947PT,]E-">!>(-,9" .(EE'
M!55L1H*V:S\<Z IUX*Q2HU'/RK;HYRL+A<T.D+@U](0AJ["<"I@)Q*CT,A($
M!5>,(#F=AD]W&A+=6FET$)93RU.O^V&# *3X.T@GLLO\<[GT6QJ!69,]7@A6
M-1!C8CR9D>D3S#P%G(8+&/L6,PVY"!_4YQ"$_[2O/LV^$BVSM8/F&(+.LB%D
M?CW*!<Y4MPLU2<RBBR;"<9A?LQ"<_A=E($],1I]TP<LH>T9K8#!HEI\  T3R
M:Z%*8&!DNLQR+</U6%E8?$P32K?<_,^<EOL3>U&260NZ TR*C@5^9DJ?H\R7
M39%H!]Q)IR 1%2 ] 3065][9P&"9NFZ8V0**$^AP-'&2T4AH!X HAU[4]?0[
M!\7]>EEA _:P3F19BI7\XY,35O(1C.6$E3RFP9_(LA[NOI,$]GP!,7& 6.Y!
M\?[$E!14DTU+!8@ E=WJNO@GD@.%:HF$HB(TY &H/Q+.*4UU*@K&C1YX.4@[
M>I2[.GE3#^]-85F ,\/*W85,%,@G$?ZI2"K()<G6;&)DY*K<0:$*'0[*<(GH
MR5VV6M)Y<PJG/BG36UX"/C8RCUCZ77C2CE3Z_41D^&G#Q\\@B^8?]$EET8X-
MW?^<FLYA O'RN76S('W+/LXJ!@EP"EN*%0XU1R@]US:9P?0II,](6?8\3 #7
M&CY\R^Y$W9VD-^:V(5?H/E0LRQZ:WKD"A"WT(" Q KAN2H: ?$[ OS>52,^R
M:$AA)(463:J^MCT :9)RHD.SZP#?JBM(GR6*>&81(7>>> QSC\O"X7!5>6L$
M<0GNC,7AZ;PFR,N%8&-7P'F&BRV(+GCMPHC#E.:'S6*;W83;ANJI+")&?C6I
MLN#0=VZ%O?J-&PAUS.W6H*T*)&/]9#,15B5PRN"TD9@JS]P4[)>=(3N+A@-P
MQHC9G461P^\O2<)VX4F]<L#*NKL6-*_\>X0J9VA?#,;1.A[P0@&VVW\PM*A#
MF::RL8*@W<,Y.CK(SO-&6L@GI B6KHG\"^*]A][PSD%W@>2AN4/&3^.5,Y1#
M.*4-,,C!A^K6WXS@31'OD)]);V/@T\BV!BQ<W$+/H5HM7/QZK+Q[LWI_W=:H
M(]VB+F\W[@;A6-*0SO]8L#NIDO>F7,7(!BT'LT:K<^^YE5Q)H*=;7=OP&W?5
M#A5M3F%V @8%OT9GJ+FVE4DB?^O#^2((O<470+#=0M4DL HP9 (\C4R$/7E:
MJ"YKAE8"^MSB<.>YFT!81>+W?1 8\]];BRH87/]^&"5*[FX(VTJ:E/;4DMJ&
MFHH;@8;P?$UZ.>7UD;-JKK<,X2CB+>..1":$D%9&9HLMPOQQN4@R'7[203&E
M7-W-'WE4O$TO-DI@T?^3,&XZW';*60R\9!)=%5ZDX(AV*[+JYN[4*G05!N72
MZHXJ@(_(YSLPPS2UTI0"7H.TJ]QAPG'^A+F$6SZ8_/*A9G[QUK2_J;V<&73>
M:;5M;/#E+7!E[$PJ) =07;S%$&+2:':768H4G9A7'0UQVRF5,#\N3(M4SRUR
M1A \.W\I(2A4Q"UC+R;?:4L\\/K#A9+),0F>2M1/>$%@@34W,,SI$NU J@9>
M@DKW\^*0:;'WGW&&H%D]F9\H\'"5S8L1Q#[-1,PM&W%AD?=TU^]@1$F.?IK+
M&ZZ=<JD&O<-L2H0Y3!L7_DE8B@ZP$AZ=X0=J?JP';ZCK9(&$\N@JS00EF))7
M"H-)$QF"IZ%YHET1,!?WIG2T$!D8T2@1T\&1F7&6,R<?G*XYU1A0?WZX[MKQ
MZOH>,XI$4SJIEC=08,W"^$PPP*3A*9 J<H+EBD4U,WE+=7J-/QCB:CP\G)V<
M/H2SW@5Y;B+W34L>/V<'M1>*JUG^V:ZZ 77_:?%%]26Y:69 T@(-!Y;GCQ-)
M0[8)[[/WOV%Z%@L^-CB8:O!^SL:2[_U4RUPC'SUMPB_Z+W7>F="[C< ^4\('
M9,L,(0L^.%E%F[7P6Q@YR"F*HG)?T'4VPVA#6*W=SW%B* X1*;:+&E?MQ<84
MX]K+/1F%;2Z8K>;!V]WPRZ'9CZ>-?8JJP=\BQV19-N\A6 P7/  Z!3M\71*Q
ME](&2C$)=[U.NKG ?92VJ6K^OA&/(3PP'Q 9F!_OC5GER%9$,J?9&!S&4)KT
MAJ8A"#[D39 /C!M'RB.FY[QQP%8 @27*(U3<H$%9HS6,J9J?0R*,%_,)B![_
ML^T6B=F)2L\(W$.2J>G]_M3RC>"&Z(/"E7("_2CHY^($^GD$8SF!?HYI\)^3
M(.W@-8XJ#E*6H8[D;B]Y;S6#:'&3.QD"0&^DZQ;OP3)4H3#'QD^$QS<2HP4[
MC65;?*8\M%*R$14"9^H*NIJ!1!F+[7SS4M:C9]IM(+]Q?=4%864[?();-'M6
M23Z?],__Z%9N&_1>GCR]P%))U# ?N=]T4SS?[OT@SA=_:6\=)D7]HYZ/5V,_
M6+T8^E2J&5,-*!=#BDHPOLOK<C?($"XN]-9?H5C7X*38@0%"/."O+B:J3BM_
M42.U;KD%T0/-KW@?8=@;YUGBV.3M_&K^PW4M$LA"3J2$'OD9*9>9.$2\O,#"
M;:,!4]P*S;.20_8+9'DR:+\5MDR2D"?[;Q/UC,JAR/Z3/ ./C(I%C)F!GO^K
M%B:)8@[I;D:V(.'9URR7X\I@$T5G]ZVQW)FB^='$]+^2@W[MRIL*^T&X-T1F
MP@=F56N+& 6E:_T)QH3[CQVD^-KF3%BU_U7,W83F _-#2?VM$ZJ&[+!\S%IN
MX^1<X&=J&VCO=*#94I+&>K:V=FSYA5=!,X/RAG32PAJ..R9X5BIS3<3R H5\
MO9^=NMT[AUSLN"=<<^4G%_$8 HZTG$$PZ\C9[ ]PW3+"TOX0K5@_NV33G12H
MVO_EVXF:X_IK5NU!GO !IFF-@7>17")S$ AO#M91 :YSN[I<277>B  B5UJA
MT_L[+4K0A++*( F> ;BS7QU 3\#O<[[:IFYIGU#;LRT[XL28S<-ZYTBWC:=R
M10VJN'C5+DC0L/5^C^D>?WJJ]4A=BQ];YG.@0[G&-%CNS]0WZS>56*E6U&M
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M,O,D7X\)*/&&AN#<>Z$^[%N13MMZ[ ?HYNXQ[]>@**;RZ" FR3\Y..LF ,&
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M/3, .P)+^>GMA]HMB8P7?P!TH]&M,JG&V&7OW3#4TN\18>S90"5?5<N5P]N
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ME\;EM=_FA?1]]:+@3&%0$*''X@#]+__PS0;_QX?84TLZ?U?>>/1GWMM&3NJ
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ML,_\.?D_;?>^6/Q/!=Y\51:+2SA<Y;HM%G\;RFOX[Z8!U-]J'(K%B_;6?P2
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M/?\$!C4=WL$;/W[VM;S(I[?I\=R</3W]"N8B5TX!=C)%)2S81W%'JKS^^K@
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M^KRB\BK,.B2)!R #V+!<)2-77&$9>%;R%A5=-[!+PY'VD]&P2Q0O "\?4B-
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M56,<\MD3OJLS81LV\J1XQL*OK[C22>"G'EE9Y3J7UHC'CYX\SLSK47PF\<D
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M!B8^L7".?83-%CR"$#I35V&S*G/Z SEGP4=HMHQ-^S*;1OY&7/>%>#DZ!D@
MEU@9HX?5B'T@" D6\<(CR>J '8#A*^$Z'_@;^ S0!%!-Q^G[$:]"1QQGP52.
M!!FI6[O<P#[ )#YN]; M@/-6015A"VP'AG(Q@1.*PHMDWF:!;6F\CHN+$*P<
M':7[,Q,31\@+^3&"R/R:E/L"%1*W.:E1WK@AD(+@/4;$$_\>7&2I_#EOVM^;
MOI<<7*KVZ ]]DBOC)09[/TB$^$8CQ'_D-W=,DS2@1\_>L-C5=IP"07<FE4(P
MPH4=AVN<=T'W&X.I[@H+KO!G,"N^CK4.EKMFQA3W)+U)A T(DW.H6(NP&6(V
M)PBA)4(Z1>BCD>(&;1][$C3'<(MJHDG=G;#!QXU[GQOW^Y=OSH65\_^<+KYI
MRW#K[,"_@:N<2-SMGJ\:8F;HRY-ETP(S$VP&LWT:]$,B-^[)LDKW40#J/A>5
M23M@2:AQ256,@^.BHC< 2%+S0=DK]HDH?:F\$KC6 KVE,,9GQ>(L?KB;B#N@
MM=8:+,= O5SWAFL40+5,P=/0%JN;^D0&)EU+41C)[#PK9OUO6B"C1YI(DP*P
MZGT,+\/A1F6,9(4B2X5C$:V$/(F4L$?,)4:]EF +FJ%B41-[W51#C9>'>PM@
M0P0"O\*PF^$MBNN\[L<?D[<>4\).RT!1M$R$'2/6(XT.?FTDD-0@3[KF39L&
M,74')YWCB" PJAF,G&)E<DM[@":C&F6.#8B["%56(*I/P3@B/J(M.K\Y0$M3
MWK?"BC#MG:F#G"1"<D];Y9O\DL@+V7="A"G"[2^;ELJMF4&J1]A2\B'*K1*;
M3.-CM_/V8^S,9,A,0D2E S0X*GA>X3##&/&UKBB1OB[[2/\IQ&DUN78$U4&2
M3&E:Q=X#[11@R)3G$SFOA8*ZDY5(]E#> OZ=9RPY8H04(_3\B!%Z &,Y8H0.
M:?!WP A%Y_SS7\QT6=X4U URV88P. ;:$^F\ $2I=\ZKMI/=!O1!;5@>U&[G
M9@+VL@FL"K\E?>%Y[V70N#/WNFS$(;76+;[+.8:JK).>^S66Q8J\HG>NQQ=*
MK<BAOFX&S$+*LZE"0H_7GHVDEP$ZU\S(92,5%U+E2)$&0UT(I)LE/T*9NNU;
M<\655KO,1&^-,J&.G1'KS\%)H&P'X)X+*HN,",'IEJ26&8A !E# M.X<#!EN
MG8FX 2A;0.,3:[-;-P\2=$,SCSX>JIUT+4.2KN V$?+W/)R=NJQ)S("7,1R-
MHNV9D!@:H\ I,,+DGEN;30]6;VUQ%#Y:XN#!='%\2\3.M,Q*1$V9B+??O73.
MFL>M"2<V3C7N,!:%@:16\*LNM4'\JA2!B3*"E%V5K="'8+'F?;%#/FJ7O*>?
MI:Q9#=27T@0'(A<&UC/% A80+%83+0).U0/["9) A.>UF>Z[FQ)K#/1P;ON2
M-R2OMF@A[B(2 R2]5B,5WEL:KGS7I0BTPE&<*GUH\#@6Q/SF'^< '^1J:M3Y
M.W$VH[[PRZJY@&T=/,UFLU-0?56&H'*%I=HY^CSQB@^MF^-=K.XI+?P8*R-O
M-,8Y)"44[Q@F>=$J=-B]D5%;"ZV"U<C<WK\85I>%=!70GB<.$H.@AF>Z+W17
M0P^RE1TWRNT_ [K=A;"@V,9RS'B]8.PD\J>$_6B@R=ML/#<.P6VU,XK?<^;M
M$6IM7! ^]DQOB[?)NH)0*&=N%N(R95EGI*JE"&:$@!VAF3B.NILA:03S&H==
MW!8.IVC<6\WGBM +#70D01H'S[">1>H3!68?))$*;\7AYU S<2=XK0?7X)RV
MV;[U7B4(; NOW)=8G1(+F4N-N1N0 :B)D'=H+[$ $287=2-/SEX(=6Z(Q(&J
MR+/V9DQQNEY'5P#)=7150R3NR#U5%W"#8UX!F4%NF.&6*FJT+XN5,(>HVN3%
MSGTSL8%BZ[LW,!\1]HKV=G ^NCZ6,#>5+.KP]HVSH/@1#C8*TNJW^#S5)JV:
M$)+0#&^T<'Q,,CI_5R3,$#S "C'LH-Z+^QOOYMGC9*WI9!>:K7W3\O[44PWV
M$!0FTL9JT0 IB+9["=VI8XTW,R#-O=+:S?YF!.&,^>2U%PP^MRHN>J%J"[\@
MRK Q_QM?HGW:Z+L)1.M U[R[!T3F!>,(O5]'U!KH-JK\0FL=<DW;$D,^90MI
M82+7W%/[I:]^9_:9SUK?75GR8MRJ9=0O&B4,@:,6'-'\NN%Z0M%NNH]5XOL5
MO+IR,*?.RMVLJ"L3E:O_]1\ALKUX^N)L]=7R;!5"V[-U?O:7L\<OBF?KIX^>
M%(]?//]_3\/??O7H/_[WIRGOI'WDGY EX2?+M[\*FZ2J"DI(OD&BB'YW1__I
MP7C^J<YA:G8!NUW6]%_,!<'(0)0I@6(-\PDC303O%W;7D9R",L?$I+!'[I&1
M/,NKFN4VM(V&V2Q\PAQ(G)3=@EH.I"_%B;B+Y^O.FPK28TX>'E1BE@!=^W'C
MJQ L04,#(IZ05T6&N!-K,B$"U,S"Z.HI5H?F6+]&&TDVJ@2H@5".@0!2&#%1
M@(D=H1W#'#QEK7]P'"*V=1!NAINGV[]EQK178Q[^<8/37;87[XUZ8HZOFQ+<
MW#5D_I5PPY_P+9_P_6,&.PG_!L*,?/MS5)=^&'\->^'*)60C5EYT0&"X7+#A
MC@!FBX%RLAX\8 U!A)/Q;.!G_4SSD?4J2RCG#>>,HUORLH:.&&(0_"%%+* E
M9?DQ4/O)Y'% #C]&"3.1XUHJT]+"5S9N)=9E@>1QKLU.6LR ,@;ZQ;&DQMN'
MB"!(2!WJ9F* N+*!/T(3S7H:WH3  ]N&7!;X',XNBA;!S7_BJ-EH6)S+F_Q&
M>*7X)7!>YRK.'&2"'$ZP!:JP):A$) $A;KH/G)*BFCYMDO"FG6G\&):[[2V%
MQ:09%>)[X.R%7PE' IY,00[XJ)@2Q&7AX F87K&H:%)FHPCO=/%C0X2F7:_<
MH>!-7>:M.B=0=UGU5VZ=44:(XL5XFF0;PG"*8&LOZ0Z%$XJ:2N)&DK<=G(F!
M] 9Q(X$H;L49#+Y^^.AF<9*':]S"=4"+QT>,IV>\%@<7]YT[IGZ>5-^@JEN^
M&]8 &*.@%X$@T36(1HI,#:$98<;<@F$[4?A'3J>1XXO7)BU^FV]QOX_MJY#H
M(OG6XG((-BH8OD*X;HV(@CF8DC8)CKY1EL%NH'3>)3Y,#%F7^0?.?LKH;L%U
M Q4DSLA3M!G.(6PN,GBZNYAC%YY_RX,%(LTG(#WM+-Y]EPLJ8_Y%8;#<%#E<
MID!>Y7PMNB-B7X88+P#[O*)6S!.]4F2V72$\-?&R?6SNY54IM\I3(<C:7J+J
M'T^>/WH2HM;SU5= ;_C3CQ2-!4L"XE#.M:.P&-NZ!V2X6H+UO<A9((UXF,.R
M5JOF0],.%\#R9Y6!._B.2HSLG<34IA^[?#*/@(28C/AC!&S_>(7Z%\="_0,8
MR[%0?TB#/[Q"_0_!689;+..\%!<1\-J3TMKT3A$7.$[DB4;1!>@L%5S9Z+FY
MBBX9BGB0/!)C"7Y.6_BB-FD8B+=XNOB.J\1)IT(C++Q0;FKAAA+B I?CI#%@
M3Y)X&HCVD_N1_AE?&;M]B.T3U9OXUAXX/ 4'(GF#6R'39R/TJDM0BLJUQ3X8
M/G[H)@7,Z>_[JRU? 4PU+!Q5Z>5Z%[I2Y@8UUT&0Q"JN&!:FSB$5B@WM9;L<
M-M?<WHY?1&?*H*[CMS@%7507Q-U ;QG.*79 B KY;^]4?)P7(8H+O%XB5< Q
M!/\MO2-YCRXSAA_FB642LCNN,,^UYKMT=ETX@_W[SBEWJ:J\8HC_V(5I'*T-
M;EJ =;M<!Y7"H_RQ223\(H#C/+LI('SZ*R,Y/;CXZYV+3S'3XDP7[&.HH%5$
M>IT3^@1G'9:Q05C#)*@E9@D?UK+M8QE0$=4-YP.C=F]$2",H\QN6U!V9IUCM
MEY452)-VASDG.]:>:+KON,>92LUK;!\B&ZE':%D4*\+12B&K+4Z@GE;6CA%X
MJYD37QRAS@3$!?D<7V-$K/\:VK);B1QH)(@.'[>9L_D/!FU\ILA@SWUU,NE^
M,?EFZ3MWNQ"EM/%(4T.7'6XJ='ITDOVT/\ 2HN3NWT<A+V*W.=(N6[UM3Q=V
M"Y>)T7A#0T2S>,8G/Q\-DE*?=@<74;I4"+2("SX\L6ZNF?[W74/)6"R!T0\)
MD)JV2:0<@ 2I:<6?=5D5\2.$0I5-$MW]!-?"@P7V.AQJIIU'@M@-9IP=3@PQ
MA3'U,Q1#MY*]BC!HDWS1P=FEG[7E@*YNV0,Q%UD>DU:&TR:FS(IX3+ /-TJK
M0(M_OGWS[C7>\1?!^=T4DK]$PV'G'#K$H5M'KH'K9JG_[:P#]@[T)YA0P=6\
MY\K>;%4L/9?H8V*%H^@^7TM9"'&H>LVN51C3&E LU%(D!MC1?K,KX/]1+(QD
M^#0[9*FA:-<OWE(_:LK_+*MDUH@WA22'Q,S@$<:SYI+ET'J&8$$4+*#(@6\J
MV;5?=%_B [$*@;GRW7S*"BP*><"UIGUU^V<I6V.]*>C S\ZJ7$RP[86&'\!_
M!1V-4J"OUP(+1:N.?+EF9U-QB-(VC9!,Z[(-)Z)O3NB96%:)>7;;.[R/G;[Y
MM_F-ABH^#8P9]\9HQ""^>_N T7N(5@$4:>;>0LI!+N$;%;@DS>G>0L>!FV__
M8)Q1LJLYZ>PXST;C0/1<(J])+[#(#QB9:<48IS>6'N]UP7KOC02XXKBD"J$N
M#<RWY.C$SY8$@PT8_)A5ED5\DZ9S8U"E!/EK[@6[ENJ,)I$E0TZI9 LB7<Q(
MS7!0%1REXJ?2RF.E.H Y)8H:[:^I[9-I,RGGU6" ;Y>S<&EY-D&?,71-*-%[
M;]G9R>\&*$+GM<4(W[TAB_^&WNO'AB%O3YX].GOR++Q0*:L7QPVY]P#<>8%:
M4-FY^$AUS<.*;4*DWZPZ@K+",W'2^-W#HEVPJ\#S(,H*T ']\MLGS_&_2(4+
MS1+0H\&\+,$WINVR:HAVR@@J"9B+?I 5CIPR-G8:HL% *;,54X04#">1PX*$
MZ549?$W5]@I;#-QNI(+';V!; 7<E]# +-D.0>E% EMPK6H7-M<40B;F0I,_
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M%5;GD@!0WQ$G9-@"+Z_R,C@D83'_5C4787E?7I7%>O'6H*SPXC\ %B[\XVN
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M0^0N@8X)@*IPYT38>S"BZ[#Q"<("Y3.YCG/51<SA%^MB78;X!SB"%;%"HZ(
MB%,JTV%(Z(2D%GFGTC^:"!708,>4;XV!Q&C[[D:0JK&%40XVGH[D DX4TP8*
ML Q%$!V$ILWB E^F&V=:NO;1FRQ(M_C",@M>?DI"53A;*#C !\5@=C#4$%1<
M%GT\A"\]U4;!77QXW_,4Z_ZC\Z/49K*287EKR&(D)T@0TLYRPZO0J+!P:OWO
MS"!&Y'+#0?:L*$L-DE.2EXA\*9&<+.P0L:JT.[FE -RI2_R(6 2&*"L?(*,T
MATY9KTO'"=F#1T8@Z>1J"$!ZB:84CIT\&7',O(&A14UL?3:R,4DN2!AL6:LL
M Y6AP]ZX*K>=/76DH0LT<4WM-725D)%=<Y<XPVP[X"J+*>4@3A31P-!<+Z^8
M$DA.^P6T<5'IG5OGA+[32C,(1[++@_=^O]O"Q(:'$@57"/^:&TR?=,H&F>,1
M#]^'M2KZ&ZGGR#6#U%ZN'W9*U"GH$3K/IXMS>W.\V69[3' (K*0"$0K0>#+!
MJ'#?A0,]R%U7HKA9A7V&$*O0L&'?-,K7U\4/#]8&/:IHU-*N-F71.\ CF^C3
MN4*4M'@$$Y_"'0X\YDPF3#;-O"3B?NS\X15G0S&SF8CQ<<, BE@!H:V@,OGF
M&W"/V9"89'7VG.?=G8[Y^'52*M:&LD44$X?7/3S5'_31L^"XY[,'_B+ORHX$
MZYB!=;+E\2Z ]INV1)JK?%'E2U+YD[N5S0X8 N;1K9H.8\HP."#66O*\0L=Y
MV0^\V2$!$.SJ9<$) 'DN;K RF&5J8 9"M:C%[<\-L:SQ(LABMKPK=%C:<I5)
M;(O49L9ME9$8@C3XXN=7X2:.&Z/HY+G$((-PN_3(IJ.Z1'2P<L/87*9DB7GB
MT(K*)O.A *>\77R&%<\J9\9K[>^Y.^UKOKP"^7K](.YT<YR0>0@U$"YVK!^)
MW ?:YJ^NK*E($F"Z5D&U\ _,Z"H<N-:+"X*+3#NV#5M ED9$% W1_'$)#VX[
M3*0WCH) !N9Z<01S/8"Q',%<AS3XCP!S.6_KQ4/.* J' C@3UTU/C"SDS_-E
MQ+$Z90>Q&7GJ^D<Y!2'9=LD"8U(]L'Q@.F'G)XUB<]%+HC]$-#YN#O6^7%)V
M&F>()G;OW*-S%O[JV^!*0"J-AO3D+*/_>/SH\9-TKHDR167D 0/2&9?C0[FA
MYHN_O#A]^I]W&2KV2?<Y0FEF\FF)'\1H''^UJA0O9P^"=T;7 HQ;&-:F[%"!
M-\1;V%7%::L;C-\Y+<6CV?*NPV!_B92K&#EH]UL\S^A0\..@' ">'--_A&"#
MDJ^W%-^.-Y8SF!=/7YRMOEJ>K8+%/%OG9W\Y>_RB>+9^^NA)\?C%\__WU=.O
MGCQ]P67-1U\_7,/_$>]Q]OAK;_SO:9?,&O4'L6]^J]%]_ J\1$L!O8_WMID^
MW\LASS!;)ZZ3L"#+[_!EG9W_';X=7UU*%XZWD5UX>I7]#E\=,V:_P_=B5^-W
M^&;>>YKZ3+_'%X88)LY\_4[?,HP9ZJZU""V,/>_?X6L3S.=W]UJL3OI[M*Q"
ML.#R[)!  /JP#BH[R^+WN*"D!51"KICXRS1EH, )8+#_4)*>2 2\D%YV%?58
M%=N6)#4@@H8:1"+^_01QRT.*4CYI='MVEZCP7A-5BXNB:FY.YZ4$'FCY-YE$
M0D@*5-.%WVV$,A"R/U1F$>ZC5 XRD[-R@4RAH(U(0J$7NRR9GXS:AC;<- 8_
M>;&K\IMNDA.%/Q05<ZF@W,]&-&,H%RAZAE@4DR$2WH9I$Z\ E4*O@F^83JRY
M?)P!U<QH4)T,B5:B'*V"$$0<*S8DT=L0A>VZ&K#::Q/+13SC6C2(6#-3_19
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MH@U6&#3E-!:!>/+H9 5UP#8O$2!Q';SN#?!\PMB*U4D>[B7@9I@MN(1P(Z^
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M'+ =!NH8HD"[B=HK)IMMD"[QT1[H-^L2^&3C6Z^G7%(7Y%S]$>0U G+)1,,
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M0P7+%E=/AGK5T#2SX;F'LANXE1>)=Z4FA6,S]0ZLS;3+UHF&WJY0'*+ P>=
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MRG3$J4S(IT\4*AC3W_4V^EZ.6%H%]HW@[:GB)V(Z>H:W(0AO*>DT@7V-G>W
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MW+./;SZ]/:&?"7MX/A;EML&&H8"VW%Z<HQ&!2J6#B&3>#*-@JXK/F5."@J)
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M3T4/&@,BT'DZN8M@08P0+<B8\8LX,2$VB<9]L/248-&Z#28X^(?"1+CA*!-
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M<7?=BOFF]2"^9+:R\Y&0R$P^=_ZS-""N](=ZU"[$7.@-TAZE> T:SJ#LFS^
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MZOQG=@P91!\$&T8X4MWJ10/4A*5I)48@2NR#P=4/!*[==*&I _:SMXOK%;5
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MHG'+&%=J9[8J0S<8)<50Y^\TETGJY'+^WMRZ2DED(E0)JH;6UIN3C2XUET9
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MVSDHEH23@KTP5)1'HX28;5+ +FO%%[MIY4K1%1J62#I,A73:4<)2)$IN\?;
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M601Q_-SZ:LX?&>.9O#7!\7#-"%YB,GWJM'!#^,+9?(T##HLD[_J>"*_0.;-
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M.TR&XL:;C"DF"F8#J,.4;:&^H/<,J26* INZIK2;;2DA?13*,]!'0N71$$$
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M/84&@UNC_3A"OGK/;BY0:FIU[4GI8\PC,F=),5B5>.[20QITFE3?>; ^'NZ
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M ?S.SFCB94JBIS$?]TD9@[JDC!+@,KV>$;[9>P*3$BS+Y<; DH+SE2:"0\.
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M=A#@ ";%<*WZOA&\21#2><#?"LF/E;*$-PS^3N?NQ"BZP\7DR0,\:FSJ*[)
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MD-21U*DR=<I,2JN:).\UI22O%QJEK*@R=<K,6ZN<K- J)BLN:2CRYU_,-^V
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M1,?N*WE2/*3C8,>&[2LOAA-A0HOR:OB^X8*]:!LCVR%K\$TJNX*M4HZOLK_
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M*!U6EV\&TP[2%L]7,?5%'H+5 $L'U>![R*56W=K*GIEO[GNP:U:@C'UOJ@1
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M_WBK*L)V#'VXMT ,F8^R8JH,4^M>F.0/8RI 8-:;. <K$ :ZVLN9R"5+7,X
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M-1F568LR\5%>_I<][C'&S#[K=KOM=K/='8U&K&4VC7[/&NMFN_N_/> *Y&+
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M1P8Z+\8YW2 =;JU_1T%(LP]^>+?P^G@WP\%#T7OWSIC9H>$@$+]Z0?#@?EZ
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MOYKX\4O,C&=V-?*9\?/*&,,[WAC.JS$/$(Y9[ 'PLON^O&5K-V8\/ACR. ,
M=WL^Y8K?T"A O K69%1F+<K$1T'W7]L)U ->0MX'+OG';T9MWT&I\^+O4#>!
M^*%WR&&ZDXJ'7J[\O9].4;_./]J>JH!>O*9TNJ=H%-B6;?C9TMVJOL(WTABA
MI]QEU<*71"T\)6IA]55V%'X=K;%9IVI]U"=<@U^AM7BC]V(M:P.8W/#F"C\Y
MT19IUZO9CL)*X;;+MV@*=S97W?3%;-EO-#SJ82PJJ"@ %YM#.K?-;#=BUFTH
M/L-;,#"=9H@7/P+A^@G^Z=L4O4.%_C$*8+5!$!M18B%+[ /?B7OSPI[DF7C_
MG*?JC76$ZBY1I=4] E'R39][5Y@S;@Q@'!6PU;91Z3)@MVF@H*>F-S]DF9@^
MTC[$7_%;DG6UYJL1M:=:<\TK6_XD"I)/4%*(3[W(CS\%><E\?)O,JNC2("-4
MUAMH6:;25VBS-A!;(M'H43?8B<XV=^"MA\C/H'C[6U4(@?]B2X8V8LZ$Z\C!
M ,@],V5D SK-B0M+>I[',.&#+EXH?TD%!^R%.=Z,_D9"X^!D#-;#!OZ'3'I\
MVV?F"IFAV @,[XI?RQPG<@P?0>T;,QS*'$Z,4!F!RQ\R^AAD$$@=X 'Z'5."
M.7PS1819/ACM EL!MB6A5^%7^2R8 2NQ:^7/ !<!"%5FOC<#](6&/U=F8/*C
MPR>>9TQGCCV>PW/#"3W4=N&Q_.:&9<S0/5!&/G CL*SP1!87I-(C0F9,Z?MX
M&U7P'&V@,P[3X]L#9(O&X"I&E+V.B>8^<K5AO= ,$1?VU<EL!_[D!5PD!)AB
M /EA02'L.4[RPQM$/I(&9#=>Z.'O%!-OY.,] ^45-AC_UW;'#-W3B/IZ8.%K
M<*W<.N'$BYXGL'_F!.X9@#+G<AU6.4?!A*T\:(R)H8P-HHB@-N\W[7LFIH-X
M/NSW,] Q]&!K??9B T#YN_*[V/&00MPVQ_[)''OB>9;8>[R/%9DA+MPBT:>\
MVK!LGYF,*#R#"UYP+[]=]9LMY=VM^Q,(8KSG>TY+!)SR;4C1MWI;59G 5HC;
M6DK,K@?BO;6"))\;/Z(?%4Y\(L@/HO_\P"O<N!XB8+6VZ M 4/GA@Q(XZ<8L
M, KNDATH%%%R0V<NALH+)AC-"?)?/MU2YYP0:)P<?G'ERV4BC:?_>/<[BHX9
M?(2:/OGP*G*%.$-N^/;'_<<[_MW=_1/_ VZ-_^M%L#T&_NN')F9Y<EZG52+V
M#9#&KTH$;ZZ,&5.>/6 38KAWCY_^_')+?[_'1=R"I'3X/?26*OYHZNUK95?5
M714MAPHZE?94+03?^]CER ,Q04WMEP4%CT!Q.O,Q3D88 NR$:.5$3R4J4&SB
M@88+D-X8!7SALGE9FRPI#%ZC!!>*B/NW_R9]&*!*=4&YA2C.^ =<F)J@P":@
ME1=$N_@Q/B;15(NJ$K6V;P?I@SZF!4\_^)_\,>)KKD@]'W5=R*T"H +H[VN4
M2QPTI (!]S,/75Z0MH#\$5P.!+\R'=A;+K4-T"LV&;?" !!KP]T2;P<O:_!M
M\AEL'ZB&*7$%[)_O/4>,;P&?6(LO.?*LN?(Z8:3JX#]SHA4G#!(#T/]B^[B@
M*TXB9ETK"(+(">TIKH!>@*\*C1C8GE@Q34$4<;9&%<Y9.F5:V'92E+#WL#7F
MSQF=7MONQ![9H/DXF7XC90APXO=T&=KQ'H;,X$O#!S8$;%Y9'L8Q)VSJ<4T_
M)X' P86; .:(1_%0VF33\WP+-P65?[RML'K8;V/DV,$DML/YWI(BA%><PNW]
M>6R8DZX%]P+,\T!Q/'!4T8D HKEL;(=</,&"A?2I*9_G6GCQJV5-%Z!O8C+D
ML+\H'[Q1WMGO8V8);83>E3D/O9_P=&4<T4AE^'7(;!>H_\Z.+_[T[595ON-_
MD,? X."BGIM,>'5BTO$KX)?Q3XDE$O./. Z@DK[,Q #^CIG)4@;\5UFKD44H
M.$!,H [!=W^=V("7V"(%/ .[<@G';.(B4EFO8*MY)"I=T;"8'%%:GV/_%<&?
M802 @C4]S9A)TZ&!R;@-EMQ\[)E1LGT@#QW#@GNKBA.E[@'@ =@2+A:&*GW\
M^\<_5+%2<DJF'J&?*5,/E/[89W]%2#=:#?!^\FLEG,_B;7Q%&<(E"=T$60V'
M8CLX\MHGPN)^L%]V0/(EYDG.[O@+^-8%8?\"OZ%H*AN3D(<M3Z3 SKYKE1AC
M=QM9$<8U"DA8Z_W7*ZT#8@\C/L^>"QNG;..$:^7>5?XPYHG1H -AT01QP7$W
M&>E?C 9,[2 082!#^?CU-@Z!Q,92LI UIE+,UJE1=1CC*<_6/$8@8B-1KP]M
MFF^&5(; @]0Z;*D) 2W0XZ!;46$I=]^_(FTC=+V>#=1DG+.1YF/;X<)F"3#
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MDI7NJ0&4 'B1%C1B%V[)@(: _0DQ_2A]I!@1O6!E9-;YXH59A<O7+ ?P%AG
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M[)Q )'YG[IUGK^^!7A\CPA8%BZ@8V$D>7@"],,0>XR Y-* OWR7E5-H:'<M
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MEF8MS04Z+DJ5YD%CW#&;O2N0YCTF(.T>1%0^<] =BV!\X>R)X*EI?%W8:$2
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M4>0471Z5Z2>1FA\.=Y;_Q%-^Z\HKEX@+I5TP<5>;U'B3J^I<.0S2N![9U,+
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MVGTVTZ^.NM@YEE;J!8OTPCU;S PGXBJ<8:H,/&6<&NKT5R>X!ZZP9[!TX-N
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MA_ UHIJEJ78 U3I96E"N1'R_PTVM4RO&';<H]VOG6U!%GW1%7>W9_,W13LM
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M?T+B7).NV=4@4;*N&7!=T^L=H6M*?9G7W3VAU<"S50.E=EZ49[R>JDRUGFI
MB[$6XS,V=90GQN7!AFDQUF)\_6)<T"C?T3!2KE$^;%^#44ZA@]\"&QX&_YTY
M#V.YF\^;);RT*?]]2E6R&ZJ,'?\=OB:W)%Y7%Y;U>NWZ#G[AE<<6\,T']OK1
MF07W4B4K5XF-MJ-+[ EL:A/D7Z)L:<K@M7L7B$#T8$UF?QB^74XNY=][3RYG
M;=^QFXG'[)\W]AQ6^\I>/-I//I)<V=326=VH%$QN/G>+\_EIMFBU_\:9!_C>
MY870KX!=F8??@C79E5F+<>^AV/^7,Q\PQJ9#UN_WN]UVMS^93%AGVK:'@]G<
MFG;[_P3G^0?RM^'.__Z;7=L]&'5>/%;9\Y&QL(<,\4FH&*ECV]T;DZMY^ N;
MW0;R4ZN1?TT'_IJ^I@/G05SV;.\.Q$\T 9T]36FAC/\S_K\X9;:ME11VI$WI
M?( U+^RUSU[)'UY+\'9G18^FBUZ+>PD5C%HG&=W%5\[_'"FD5ILK)1%E%D\6
M?V[!GWY+?]YI];MFYE_:K>S/\^XTZK;,WFCKK7;$P"]?O51F77L-=D/\K337
MO,UMKLDP07)97]H[-[C-5];@4H*;US5D.+[AH;:<\8P$\P,P'P/X)<I-T"QM
MC]'/,X/9TWOX;>UZ>$-C#<MQ9V#G!L["".Z90;84FPF%!D^</O&'@+WTP&8M
MXP=\2;FYR(<L<6GPO8GMP\6XL-5Z$_AP2UB5[3%X@CN!O3^0(L$5^< ISARX
M!BX,7'JV"WQD+Q9YMW_AM%BK:=C&)_; %MR![<2^\>@$]\Z*[J7<X]Z!VWK3
M^Z>7]&!<#9##88^P4KY_Y-W%DS%Y,N!%@26%-VL9WQDS).>4:A?M\\[/9!8=
MN93]#V5SU,92R8"5;%:<=P.<Z0:J67$!;=#<Q99'/IQN^,H)0)M/]U).RZ43
MH,SX)&"ALIJ"YROB3WF:V?@F] VH@#<;'^[M^_"-Y<19T=_]BY(9/'1CZ8*^
M<%;<68<5M?:QFD85.CKN;:"[;PB].+4][PDUO[UT0>N#DQ*I^N3A\LA@Z[8/
M9%@LW$<?%/"*"T!P[VY@23/_Y:L]J7%V&W(T:O7ZPZ(F9!\,SV&G%!O2-%O=
M7K?0K?(_[PP&5[ZH7AG6=F;NUNP=U6S HS_G"5,.=Z&6D,W^O\SVC/<K-/G>
ML2E;3IAG=,QFVL@]D&!*>'W_2&"U26:UK<X^!;I[[/<9D<S2)"M*,C-+"A/!
M:Q%2.;5@[KA%O9]T)FBJ2_84? @]V*8Q86#_K-!L WOM"?1_C>%"=NZ>*B]K
MV1FZW]8*EAGOJ!8(4XM_1(&0OYS@_D\EX/*1@C'?P $&GVSA<,\*?MUX'I#L
MC>T[ODQ6/M&]LO*/9C7Z29]7'[46EF+"LB,E?S9AL1KC;EM+BY:62DO+#ARJ
MLTE+IS$>#:S+2TNIC2U[M&Q?TKR,AV'7MC,[J&L[@P*7[O;:;_^%)*6W ]#I
M4$G)$93O+ @6=!._0+GGL+SFU2U\?:D6#,V$O1W@2:=DPC2S]1KC3B=MX6A&
MNP)&VX%%=%Y&Z^-D@JHPVKE!72[),Y\9UERLIAZ\9?82.8)^PDQB?N=K75O$
M]RR7.M)JP*(7^.G$ O6[[:P^N;[_<35=;&9L]G'UWO8P>I@I7X/&.#WTHXZ.
MZG6S7I5-A6(,-VR,>T>/F=%L5T6V.Z_A4(SM$".[>_38OVI%&JIL/JCY*[::
M%<Y<75-7WGX4>V9->2<QN7: ZYTKI(G%HE9ZIG6-.O5TPZT6[4J)=E42X:-C
M$^%:M+5H:]&N8MI^='3:_N*RO7=WVR6*\G5CY_D$T+JFQL[O@3O]:7Q9DRKY
MNO&F]QB(_I2)-U['_LZ/*U2)*\9U);8Q4K/.MX]?;YO&(S.HU)G-#&<5N :L
M[OO7+[?&>N/Y&]$^^7CO3.^-+Q/F+; %"\B#7W,YP>#O:TFSS=K@M_C_V7O7
MYK:1)&WTKR!T=D[8<4@V[Q?[?14ARW:/9FW+8:F[8S]M@$!1Q!@$.+A(9O_Z
MDYEU0>%&$B0ED1(V9MVV1 )569E9>7DR$S>.OS5=X[^J*.M.+QWD&625]0TH
MU>L9G5@*8P"ZF#GWS+[V;@.@%'_5=EU0AHF&[H'Q!4JD)(P#)^/B!OR9X<<!
MK'RQ\/$L82T-K(\UC67@6 Q),&6P"Z#J @[#QM+/@,V QA[_+5*_UV[:YLJ(
M A.8S+LS[GTW7C"#'R2SFR:6J]XQ\<B"5QJP>BOF]6VSP%_04VWX)WZ8_6*!
MY80,*VJ=4'Q!'9,XN0<X1\LUP]"9.5CA"Z>:=-G'#3E1J)>ZQDNJ"4:VL%BN
M5A>?EE0(8[7='2S>GXKG->7.@.S,,P/'#ZDDEY;M.C^9Z\Q]GP(Y$2Y9K''*
M\#ER.W;+N CQ([(T1=3I=AK\+UB)T: GEN_8AXL\ C:&Y^;V0"]?]^5D@T">
M2IS=S_)U)EOC3(-?[S[)QRN;1/"ZU$I<25U$5^(4+CR;E^!=>>HKE;F^?W;>
M;HUS3&](?D=.4*?^,58L#*?[RUD@KPBZ.? )3BO)A_A34B?PE8UG9M%.TAE
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M/1W,ZP#GA [ NSZ60J=7 B4G';(6-?,J@.25< D%<G5RN(1!_^R\TVOT"Y+
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M@$DG;?Y(VUR%K;)IO)OZ3Q=K5=&W\:"RD+3$I2>^<R*0/6N+J-DWWVNJ6]+
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M U83/2\-4=28\8!_>#Z7/-3B\#C8B%>D!T#H=#5017))APAS(*LQ0"68],)
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MI^RC26 %T$N@>S!L);_!-0&7.A0Q?\4XJ)=P)O+YCKQE@7RT'K$\Y"LM[IL
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M\^]H&1SM3ECCA/!)'XA4J@IL.- 9K(E ]@:!K;E+CFY(0[24Q'06N27Q<A8
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MW.N.6L6+MC8E&LJ6D D/<;K58TG='9I0'=2.H.J#;=!49FDDK?JF=^@"=*"
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M*=6[RUC5P?J9TH<^$P3E#_L;;0B1'@*R9(XFG/NQ*T['FOL^1T[2.25DY$Z
MU"$X8XZ9-M?>R4ELZ;>/CRA\^@64U%VZE<%^ADAIJXFGLE!P[A0?UH!6(TU3
M?U 2X'CWOLLK<E7MC>6:CH!]NNS.I!;#"B_#T2CHCOCJ@X'#"QXYS!$5I)[C
M$4AF3.;0; 4O0OD6^HYF?ZP*WA-Q$ ^_ _PE7+J^Z@J\4*6.#7JTZ_Q$12F9
M5)L,8=K8O)@9;#9#]!4^(@Z2AKSH)TF %@ON91-B7!'!N@GAA1,&P\21P0LM
M%,AX_ ,)BU]05@NF'DBXE$V'M/:4.J,WM8P?!.^B2* $0'/GHF&XB@<)_\<W
MY:G-"$03:IU0]3*&9]ALQH=S>K;P'1?<A@IQ_:*/,Z=B0D%<$-#$(GR;@@;/
M>.CNA;@4QL&%^LGG3V'PER*LIN>!+K$H\DL32S)35F7S:6 9< WOX"R3(C?\
M $\A\)L-K"#/D*U^3:HC@ <=5XK\]P"$Y[[($&.B MIT6\^9[R:CEP,D*>/L
MF@^H3S!V ':>!#CB?!W2),YL!M>L:ZZP^MGXX*^ Q0S:Y!O\\RTO-[3-!=_<
M#['SOTS7AJ7RC'GRI(81/?CR6O>P6&&5,E<:I*X"M"^ELKXS\;+.53CZHOW5
M#)TK3Z!'WG3>"G=#3-B9P4[MV,)$C6'' I'RIBL^!18!P9P1H# %!83_6/M-
M3C;0U[XLGV7>OWVA]#G[RG[O2$0@E2/& XAO4&H!$_^1G!L@F)YN)Q^KO&OX
MY3KXY:"&7Q[!6FKXY2DM?D?X)8>0%")+>@7JX?F-#TS_8_5(4JI *E6:JUS3
MDHU.T<XH=3,9;U"1BPR:O*.T:'_)=?7!#*9F8(KK/HJ#A2&N/M+U'_WXSH7[
M]E/+^">!P4*@[QOUU[=OU942,DQUB->*KB;*G$]-<U@N ],)L9$=W9"B (9L
M=S'-0UZ)H2((>!L+_YY;]+83+IQ05*&DWRN:(7Q<@9WV?6Z"&V_1 $L,$FD]
M6M[@!Y*ER^J*=?;$3 1_^<I+!I'K-ZBVC>S*93F?>)C^>CC8L7X#B\ UG(:/
M4,0@=D6:'CXXX0Z1>*C6^$'S)Y-?<D.=!MSPQ#6^DK\JJ8T5W^3I0F:_,]Z8
M;^4$ Y8[.6KB@!-Q$B8DGD'JOY%V3\Y!X,\#+^$M/_DW4_$*Q55)D(F_AH8,
MKC-KJMA!)PEMP-.6B&:=+=2\1VIBAXXJ]T&)2;#0E/.+ "LD+"F'1G*K3M3Z
M7.G?OL8'OB49*_Z=OAR0A9D3+,@BQ&&5P!.94Y(,0W DLL[1^&Z(.*0'AP"?
MYRE2WA@I"N(P8DKW_0X;](7=?HN_,F:_37\36NZRI=OU#8YE59R?->'Q>9Z0
M2>0LEU&@S2=U "2E3B@E>HP\.MM.%*Q("!;$+3%MGY8+LY H!@7+YZ8[$S7(
M,>HIX4#P6$7I2QK%:M-?@F6,&S])3N^V==:2DYS3EUV:?QMJ\I5&<:[<*6&R
MYD")P9-W:D2$;3R0G[_I$8)CI=='X[&" N<O65ON@@BY5( 3"H:_:$@$/D[@
ML62^ZXS:0U!E.%:7)G-30\(MAK&K2D2YZN.Q>_QZM_T>FR'98>2X+OV@\UZO
M@B1W=*9S%D8=L< WS F/N#,]01]T$5<2+)'9NR(+M2SCL;(3+%A' J1S(>5"
M'S+V,VWC+ IGE-FHF;@R%8].FJ;EHDB\/EA$=/%;!%+1,C4%593B(>F<G*AR
MT;O(-:A;@R="JW.T-L6"Z(WX<5E)*^N/L?*UJ57"9HR"TSM@T "8$32^FH$U
M+ZL@2O)C29\&TM=:X%?9@7G;CBMK!UL?\&'.6% 2RNBP*V$L-%+9!%'F<J<]
M6TP=%#=L#E J1CDJN6VL7<?<YVH#TR1+8\Y<>\TL1V*'?(IML,TTQX^*SV_$
M8RK.<.R!^]=K=(:CQF!8-DE,$R8ADO2N!O8#Q_Y-P.!@5SQ0CBT1F71GL,-N
M/PE_)V@W->"2'GCK?V!79,15)PEU8.]V)XWN9%C6(Z="[I:;D@X?3N[<(T%
MWULBW;-TX[!:'[7O+* ]5J09IPNGR:49SGE!.F&NK[PO#HNO9_)UIBNYJ8 Z
M$QSET.J4@023!"I('8O)O%*/%9R3&GFIJ/;!-P.Z)S\ZP$4<:,WA?-Q&T(25
M$D**NE0RZ&1*#V37NL326?>PQ(TK%6MI)XC;UT<\NRLZ$DQ26,7KLE]E:B8Y
M8U26C++"!PD-U ^Z,O/WVU68GV/I-687V4:-F^%.^@E7M)KN5Q%HL*'VX0;?
MRK?ZD4"E(!R.;_-&Z9@ J PVZ'>H-\K&B@<%^]=O?&! W@DJ1QCQP6]F:)O_
MD?T6%9.,TTSBEW-AKMD&\793\;;.U]+ .5V+(2?1*8L!^]55,AN6<<3+2[GG
MIUG=E2R'JZQQ@$]K$F8O;1[(E:::ZBW,GRR]OIWGK@Y*\/:J=Z"Z)G_P)'UU
M:>B>G0\V0ARESI^NUH.XK[,%K..<<DS"@Z2S@20J3BCSPJ;H$O3OV+[CC$[,
M+YVDA+#Z!< / K$-&.DT;6YZ5R1W"5@_.^;VLQ]\0?C'/DC\?F\;PN>9Z/0
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M0T%L#&N$[CS4>%^8@P=@WK/<DJ$)UFB6E@QU&>ZG!RYOWO9>BUNKG3 =,M&
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M=PLRL^F7W.#,.9E2$YI'G/A!H,O"O8YTB*/H!.6,[1P>CRDM+/2=0+^"**+
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M&6Q_ 7N&$W#Y]MD/R\4]B:DM^)4PJLO-)46) _H_VBMK#<8*+17V'AZG]/S
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MA1B:]-'&AGV:]PYC]$H.P\F7R5:7)AR0>1_#Y71PGDOALBH!$1&RLU %@=*
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M!ZF<+.R77Q=NFO\+=L[_ =O'^#8^![O[PW:__,(.$IF-)I@<"B,W,4K MXZ
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M+.D7[M/F,IGBI,XGMBWE9DI:$PPP)X$[MO.24GHNT']CM).Y^_B'Q[I\HS@
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MVPB[M;$1J)6!RA>M<GKR5:IEIFJ!D.3]. 1E$YDHF$Z.8=U6YZ;B5TH9G-#
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M;Y7E@:0#JAKD$#F@J%JA87:RHO>G&]ZN/KVXFHRK!T7NDWW>1N +KS+]7-%
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M7/ULV;WM\7'G,9GJRJ*RJ5E;C%HQT(F(.-J_V'X4-[Y^1#FO-#8#9TH=((!
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M.%/1$6L>6SS4B-).$C)4:?!DY>8"D84F]V""O!X3I(=U:X%&%9W_Z+=(]BZ
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MLG[(>YB NS'K*>>]*Y\M4;3$/96J%<V5G96ME;<H6"GZEE V=6]P9T&A1'5
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M8A=>2/YQ#ZT7\@G0D;O1D9N*TOJGK@,2U70.L2'#/HZOCRU\]7WL1ZQ_ B?
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M\B>>^@FHG%Z),_0.%#SH<53P_&*T]CO@H'AVJ96N7V>E5J9/Y@\6/>G.L0
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M75^1:OH/3PP(D780T)(G+^'_COP8!& 2:0%+LC@(=W$,IRM/R^UOK]K^M-'
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M:KX0_F,><B7$O#45+LFZ>:2E90/&<1M&ARJ.'B)?5=7+Y?AJ];7HEG(U=^J
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MP15@?'YN93FQ=X"M[Q#R]@"A\QEPCGF Q_TT#'M?IPK4A..9@5X=HTJ*)JQ
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MFI(V(RBNO5#6JPJ)V]*+Q20],A><,]D]NHO\BZ=WZJK*B'%T9K>67KA+1:2
MJ:8T6&?9QCLO&[N8=Y;>F)7+YI):8?=!>GT0["X#G@]0/D%#8T%XH4?AO <Q
M6D[&<@_3F]HMB.$%H ;X:>![Q3O2 Z&"0P<?Z8.PRJ=J*'H#'W:&#5^:VIIB
M$/+4I-FWJ2 $!=4GR[""5=R*95$ 4$]6W2YW[W3C3<$)(Y:?VW#.$UXT137/
M3XSC&G&N>=K]W>=_<?&!PRSBY^<C"Y![AB]B#*>FA%KXI]?[S\3'<R7$,V;L
M1?SU(\Z9,4?WK8_+\-C\IH2 K>/T9/-& /!Y3V_X&6+:U&T93T!F@-A^\L(9
M,O*[DX3Q<?!/#NB]1!QTN6%")[3UOPG^F)[KDB;C\= 7#T$2((S*SVF.CA(*
M !-Q^/F2C5FD^#,P(DIT/.G^FTG \ 2DGDZ@@1#EF<'/X'_G04B&>/- 9-]8
M\U5]Q5<)?YA<<7$0_#:8]1J> GHXD<F_#VPT#B,O A)<^C%'5*Q?73/9H)E<
M^[53BB^ZTC(=M9;I')VU6J^N$G;>EZ]OX)DW%JZ$X4L#C:,$U4XRG8_6SR:D
MC1=-0?%HP[4^_/O'O!&( @D/2E]4YACEY$^E<YH&GFE$?J<=95LH0-0P\60P
M\'L^-P!YAM.BEID5S1GK>S$T,'M:WDN3Y7;P>S U_V _?X()#+  0S@<?A(K
M><!W/L##?AJ&O:^Y/8']8;!58WAN$DW8T5ZH!R#L".;VPKOB<6.ZX!28!'F;
M&#1L5Y*%'UQH#B/;Q-H'7W))\A1.8%K]^,?3,@K3G?7I8;X_H)*S?W!_2N9Y
M$OXCH,S0&\?L-/WC([#M>.B]G/H!7Q\?]%$^7;JCG/&"\XB_3WS]\=GO)T_H
MUVGJPH4GXY+RS?+K)GQULOBYTVI:K5;A5WK3*/Q\V:,,LVFZ9J5'+?_<,=H'
M/BGKM4<5N+E39@'=P/!7KX2A5SJ_#6>C9$'!YF_CU&S/:8-6H4_S7^@2N\*+
M.1EBT  LE(@>;).LN9A$>9>QVH1%H%4F!E-BO34BF4DDJTHR8WU93;^6C[0X
M)MFY^+[RB$-\4T5=>1!7\WY?AB ;.?</($T,RFQR$:$P1JP<-?YKHR6J'1==
MWZA>B'TOL<7*6<M6SC)KH5.@83J+F?3O<(]KN6JIDH%!0G&H0F&]E52T02JL
MAJ,KT0B!I(*D8I54&.TWD@HLEZ(W;$.)N^N[PY KKA$HGTU_#G/FT1A-5$ %
MUD%(.0YC^7'$AB(,)1R9O4D4H>.X"%P>^&692B*VEH1=![V(P39@8L%DB$'&
M3U$XNA D_\+3J^#77]*]J2R0+1V.J7:CTU*B5'>%8ZJ^-[0J,9VN)M=A!Y)&
MRUB\DDA,=P!,]T:JKH"OS*,SQU);E57$%O,_K\.O:G5YL0K<&H,01!QHK=>Q
M9W\+O[P7TOJ"%"^I?"RP;>P#<H(12^T&1RWEJ:HH"K.Q&KK5)I8[1)9[$S7V
MRJ6V/+<YV[[3I@2^.BS?S9W(]D/8P"_LS ")<+ Q@*B) ;.6Y%VR74F>JU2]
M7;*7U0 7N^.W[579('Y[][)-VX,6&S!<&33;/CIK-6Q[DS9&Y+@Y",>-TA!K
M1:X5"_KK9EFMK.^P60T/Y2A8.>B^)>*HK<'7OQ6VLVA]JW-T9CD-N[5QG&:K
M&ZEH]@N),(FP<LF9;7W+R9DDPB3"),)OFDK:-K:<2JJ:#!>:$:O+?>&_<3?\
M0!0)FKG[*G?4QGNIJ?OSE(=1_6]L>AWU;[-WB"4Y].D0KPM+GR3+AQ3=JGUC
MKC4<?C7)GKT(G/_O4W;W:.P]LN,NV/!?C[T!S/;4&SY[+S&2/']SV ^.\Q2<
M7_S2)0X&.[M*+5BLC^6?^':? E.S"'\%<_*4F8OV%*%J^,$?M!ACO39S7=>V
M==OM=KO,ZNE>N]4?F#W;_:MU=,9ONH.]^(\3;V_7H.WSY+',(S9RX6LH$)\Y
M%2/UL=$Q;33 Y%>L?YYD'SL%ZN']JQ!<![WAI#\M]-?UAKR:VLK2 Z\7E_/C
M[94R67)4/CQYR9_A9-B_"9-K7I8N*]@I2W56KNW1QI93SJL5^+" 1T/S![ER
MA0WM&:?"BQC*&GE8?BY7<EP2#PL&L:PD>5J+'"DZ#(-'_-_BPH?PKA&6M<M7
MU/&TP60X+"J&QZLJ]D,^'2S2A[_'JB.\BM'2;>5E06191UFQT3#ETF&WGE[;
M]:9V.2W1Q[[[,4A0+RN95##-!BP@F40L*W^!Q22!;*],<8[(B^2<+2H)FS#A
MQ,2R)L .("C><%HT)<12E($W3/RL;&(^<SUBXU!4=\+Z2IPN:3T77&INA^'1
M\,CR=8IV)_'\B:=^ NBCM_KRLM0!@Z'8F2Q$K)WW>/F1F:O@&=A:"JZ*"HN\
MOXY;I:Q!*V.%K&4DD-69GOS>$]_J""OV8%$<3\O^ ?P,^QZ(JJ@ D/S19(0,
M >. G;#EA<C<.Y\\3N(DK>4SE1M3%.E*90#KE$U9.BVMB0S&0_.Y2[L<IZT0
M2/G@ *B(P[GL1(P7+I-E?ORT@-AH#%!62YY#,3C&DF:X-%"1O8F@S&SIU1S?
MCR= B+3LVMA[X?-]!"2)LY/2A'/(D483J_(CF,\C/%]D(PQ]K^L/_>1%$D16
M(DJK%8$.\I,PPI7C(U,-D!9DX^+89_!2>!%#]0S:EH_EF@#8+ATQ6^AHD"8]
M5*/LGYF*P/)-<ZH6:_/T9MX^53QB;W$6J+QF:K<-_ #4(OZ(EUWDG>2:BQ)7
M4*0/.?IU7&-:"$)6ZB4L=R -N6-T2YR:K3E!/L9/=B[)Q9K*<)MB#Q;_6ZWJ
MU 5L/@MBT3<FZ%^-QL/PA3&)+;X !A+U&0%D!/=/()(_8?YM?E1!&:JVM8#\
M\$-\^VQUJO1U6HIE%DW8_ 87JR_YZ!7Z5YD#YA++CP%_(ZCF=0MQ%4CD2A6J
MWO\@N0ZFQ7E,W7!$P=%^.$;A]31;-SY\_5&P(ZX.F.$;X_H*$(_&Y*:+,HJ+
M/_9$(:_L9ZC.1MY7IHTC=BQT:Q@GQ[S*8HZ.L389IYAKY'WG&E8 ++0@92$Q
M!)!=H9BO[^YGU&M#PVIT6%[9CWL1$Z49L0@X?W=:!G;VC?)U\TM _)>I9Z%2
MV4Q%H\*:K:A.TTJ(!J?HR.NSA3<BK\&C*UD5KY?M1;;,<R4N0TIG=)D1Q(M>
M\C\ZYT2M;EW81V=F<UE"KC0N&A57^'HMVC==HH-+?*4\<Z-Z"4A#L9UTL0CO
MJ\N<*_NX1&CVSES(3D&0[/-NC#9>O&>*_'=T"G'\]<WKB4-U#"BL!]L4>P!'
ML7KF5!$C(A]'X3<?==DD2(L(9T.'#"#>3''<Y\SZ%E7I$7UZO5Z$#1L0;XX]
MOR^&S5V8CEGNO;&/YC,>,1&:[5RAP\\PSRK$?[T K$A\!)89H$WWQ9/[DIG]
M,P_FN#0!_=ZL8-O5T''N+'><5P#=MGU$[G:UO;WD;E?<W9Z3B1GKM#5?T/>X
MM=.C<K4?[>'J-ZW3U):9J!>_G-_\?'6O7=]HYS>7VN7U_?G/=U=7OUW=/-QK
M?UX__**=7US<_G[S<(X?W-ZD_[R^^9D/^'1]<WYS<7W^&8=>?+Z]__WNJA1\
M4.CDO0F#^5.GBBIME?!?O.ONGZ_8_MN;A[O;S_=\+[_<W5Y<7<(&WI?=P7=:
MUM74;X_>?T#2PS!&GSW'T>%0N/V^1&&/]>'C?4."V)VD/UU4+[^H<;8HCL#Z
M3/IR^65K#@>G6 Q#./"$-';F]9Y\]DW:PCY 31ZT :#$XPN TE)#&8WO0)@?
M2&()]J27EK]*SHZE$3H1D,#>"=K QU,KPI@0]JC@NI?_YNJ[#..@#YL[(V7C
M+AX%P3R+T0CLK5Z*/!$) RD!DZ#/L8'>W>&DSPM#8O>6JUL^ZN+3+>_:X(UA
M^>/(A]'<K.'N!@V0*-:71[,IEG?3'[V(/R1;SI32L@V4'V=]FQJ"WG&,?XK2
MZ#S^(UJ8X9IYF$W$I;A+'%XHNX@!5@9+RQ_XTT#F_=6%[,,1RY8>O.T44'JN
MI=5TW_ANA.48@D-HT=PCYZZ']8M-0(=/SX^ ZG&"S]Z_[A6_Y=B!![V0J+S1
M2<\?9_I@@3V84!>R@5M&F #V-?U]&7%[/=2(+BST]6NXRZ;^\?6G\A\:'[4/
M\/2^]$@"L]P!<\B@C.4=&\X'EO58R(O1C]J( 3EG'RYZ"^4FCJ*?118X/U72
M' OZ(*\(L&&#U 5]].9-7S2G&<13$JX>XJE^B%<HB"I"N"49O'R=#80:8H(!
MPTDRTSYFV: =$%M)#=K4IB(ZS420NX]<L81 #51Z(E:M/<%;>0^>C&B<JX5:
M P[ AB(I#<, YE;VO,/GX73E''+GG]#[4U)I 4-^$VU0."=.-P';$[UPY_2_
M)_U'_FO@+*EB4D=S#[WB:7:%\$< [60WRG$8Q[R_R1)B-+6?LL(JO,UE'NQL
M2UDUYGE Q 3A>3+W1B24E'Q.F<.)S<209>)'X=X-L=&B C[(E1ATRNB9.KGC
MR@CWC7?Y";QA"DBUVV_ V9^R4.I=FL"Q9\@T)]U<+.(QL#7G9?0@LAA38'W@
M<PPO<8GR PS5\'_W08@0F/@I;3(Y1-I,P\S3Y!;,5, .8_Q(]5<?D(,?EYPD
MS>EFO/I"WG=-'C93]3-];CP!+?2-*T+9LV@5!BFI>E\[$J8*5PA,EI& [RDD
MFVRT-XY$QH2<4E$@7VS;=TF?+&G"YYYA.'SY!/@JI[WGX!LF@HOPDTG 7PG'
M!CQZ/$3E=<MSS$J37.@;/"+0GN >;Y\M: ]^@'SP98QB+". 68@1WQ>D>E_@
MACA-B0OR9.TS&#AL\*,3SQ/9?&K@^1$_209#D2P!)S%0/_9D;0K>_M6/9TI3
MX$:*[JT?^?<?_&QZJ[;S@_=CVA0)=>#,6Z)\Q]@X.X5>.(]@#DE2:E,WV+Z&
M]J&;GQ\N$J;$_'$BJ,#;Z_;])+- NXQW&?32T[C@Y=X$-A<PFS=#N]QQ*\@+
M[TG"**5F3TYCEOUA^=CUF:\^FH*31/0D2S'R)$A?R=<)A[?8MX9HEQCE]Y(C
M!='&F:^XQW,F5R?(+,F)V2]CZB?6\V3W2-ZZ*T#[,\CCV;A109 Q/(_!);E#
MH@DE[HLV\N,<F;3S81QR2/]OV5.<[P!@PUF@,VNF@0#(M,P4V"/OS71R!-GQ
MXZ_I)DH0(CJ'\[0PF'-Z!'6G2\]E><(@6=FN(7+!)$;IL\>(B1^#;0/J-V-L
MSI&IQ@IGC"Y\,4_\\GD^WMYQ1XG&MG-"C.2;](0M,K>72\WN\NPUB3-L'?E<
M*'D""9Q?L \RC>0"[!\?; B^5_<(341FWFWTZ 5Y]8,_?@#MW'^&7>*C8GZF
M^P7([9A_],B-#^U3Y(W8<QA]U3Z8NF']. /5 3U,EUU$GG60=7D*86)G1N2]
MXS?>-/(\""89.M;Z(8O39&FD' ]8P_;&26H:"[B=LE*?X=$D+,]'3/2.>.=*
M0*2]_&$W\ %-3D^5T@3.V[93#X*8 ](>9YI/A,_-%/A3'*39M/*S73+%?,]-
MKMVXLT)R[_W5A5!0$A9,XCR.Y ?Q:.EL?<FM,^1>SC$U#+*[=#M-@;E0N'R?
M)E\B7/X^GIJ+*<1;.-W#)7Z94CWG%7+,B. 1MUJZC 7H3IV[OU0>2!3$(N)Y
M7PN::(;3E_\J#$WTIWFW Q_S%34 WQ%Z>$LDX/*SC2\G-<'0=.7H!GW @+6%
ML9QEG0W]KV@*\OSDN0$5@52SU-Z_H^?Q.K74/D\M-42@5_,(.XV&[QDOKPHA
M9+L7OP"2&A7&#1!I,R!#A<!!@Z.W%* TY@,RR,.ST7+AY,]/A3/DB"5-[=,D
MPA!<0QJ/Z$5,8W S T:3.)EQ.0V\W)W(*(VZQ\"]/?ZV.(G0TR7#%?QF;'H'
MD1NGJ<V+S^V*$;!6A)LI6I-8TH]XA (C#5-+F-]?*G "<(_.<#@W>Q&RF37S
MLAGD*9T2=9ZF^4>"^361/C\_D,%I[MV*O$F?WTZ-HC#BUUOY[8"IGA,N!M;G
ML==XZ0*$_2 ##D.?7ZODLTAC.'R5:9 +KQF@ZI*MZP?>9)B\I$2'01SS]</G
M0*PT1%]BWJ< ![@_&@,:X=/&^8.!R5-;M;1X/JJGQBS!<,=X=![=)R*:*K8$
M!-;O(U ']N!DB4,1X(RYJZ*+4;7A<!*GQO9SR%\9<F=).!;I&-V\0<!U7\3E
M8(:5Y360',\&+RFWYO?7&\8A.LM% P"@'/J_M0E8W-GE#-SMT5CZ-;L8)\7W
M<"WM/X4AKSLG/3K<7S1E:HPA"7(L)D+@?.3L>+)#/,$*(7WA=$RC?2@/W.'4
MUQY#F&HN_6$<(D1!=9]>\LU\/A_%@8 NQ<:6_$>K7$<EW4:E!52$'*?QM7D]
M.>.$@[.9JX*,/X6@X<L%,^-6H$;LLJF$K9T@Y^BJ)\C]M#Q![O;AEZL[[?KF
MT^W=;^</U[<W]4IN="S5]^YB^=Y-,U*UNZN?S^\N,6D5-O+J^N<;[9^_WUW?
M7UY?X)[>:P^_G#]H7^ZN_KBZ>8#=OO]R);[8O]U.>(:"WT-80SZ=G$^GM96+
M$XY+%R<4=T20)TA]3]#[J8?BL^3+^1WH_>OK]0_*CN('I:&O.BCOX+R[O;MO
M:%?_[^KB]X?K/ZZTVT^?KB^N[L35@(O;NR^W=^</5]K/MW]<W>&=C[V[YO'
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MQ+Z(M+#S:5K8)S\:;<Z=]?4 MK?B 6Q1Z135'5#D 20/X'H>P#_6/\T+RX#
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M7,,]Z9MMM]7F3:S-5CDG]N5DR&3BR%WH]:> ^GR8A)$&</J^Y_,KF[]YP60
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MN:K"!L'H-6#TKXI*MFJD(AA='4:K>FJH1JO?/%"OFDV^:AI?H_&U ]'4!H]
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M:5<KP6!P?[9.X)O&UV)\[<!W6U%M2.!;)? -W&+:9LN9@F_#D G1''?C=1Y
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MVG][H_%'[5^P=8_:Y\]?&KPHP!@;0<"O[MBC'X/!R_K:ETEWZ/>T\UX/?IK
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M-L3VXH+VN]>P-I$[HW/R_9_^'U!+ P04    " #U@W-8I6[@UU9#   WPP(
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M_.JRC_L;Y;/%+9]6\I.S)<-VO_FT5 *_L-*"3<B2C*(4'SJO[0DX8W+ =N?
M7<KWVO]N]'Z)RP\<[K3_M#?Z$YXPE.6+U4M<+#ZS9C_W$$.RWE?/%E\9AE:=
M ;;W :1AOU$+GV+WZ'0C8&-RQOJ1I+],NM'ES8(^LF_XXY\?64M?Q\FWEIZ2
MSY**!ZPU@#': N: D$V00E*(&5UGLFP :TS.6#^J])9'O]/QAN,M96+ZLK9K
M1OP2#]OJY(T2$(.)[892033D01,YU(Z*U;WMS.-HQN1>]:-%I]WO[$1-K"M>
MH&SA8F6]Y6V[FRX(05E9JLW.5S6(]]37":10C+.80-7(D8T.":(,'KQSVEA=
MI<%AEC%:UV@KR=X+ W;>W&[\?,@M^W4^RQ>8M*C>I6Q8>28/1A8'(:8*$H.2
M*12B> C/^!K1^/R>O1C0<?L[>CKSC[18?7YS@K,5&];FB7UL&3VL2R=%&>E*
M93!6MXNE*@!+R6"KM,47E%'TSF-X"L_X?)N]Z-!MZ[N1X=5LA;/WTW8UM%X>
M _GQSWQRUM*__CZ?ES^F)R>3B(K(1([:+$DP3%$(.C)0P=\@*S#&WC?^F^ :
MGX>S%SFZBV)ODK1$KLG+^>P3<[;A:I?0U[X7Z[%+TZ9KUDYG!P45NUZ"*@2G
M-)1:$WI9+8H[@=']'+%-'[:)U.WXI3[(W@Z4 O2V;>7K^OORG)D3M"4A6@/.
M&/9D8C40O4(HD5UM5QP;,S-H!M =0)M0PHV?$OTWOV_0>Z&6KMV7:DPQB?U8
MR3$6+]*Q6HJ1J>F2R=&48*0=(MZ]"V03^?LO2/Y[;_: B1FO9A<FZ<U\L=[B
MU6HQ36=K'_?=O.&=SU:\8_R)[]FBT8*6+?3)F24I6)[4=)CGT%P+7H OVE05
M2G"]TQ[Z(!\@L451<5$K FFII72R9D_*LE)/3=-S6"BPMS/U7&++V)) !N?8
MW3=N3S'UB]:GL_EBO0$7BTHB&5M= I]1@6$/#V(LA=?HLO!5>T6]->Q=#&.*
MR$= E;U$U(TH-Q+W)ABP2,F!@%0RL6&($8)/%KR.FDP--0G?F2,W'C]0LOD-
MPQ>=LV6=Y)QM;$G.#D)Q%5RN448?.!XZ4+[Y=A['$2H1MN+"AKGF.TJBK^MY
M8XTW\"17A??104Z%7SV-GE_A9$#4G'U!9W1WM^)Q-&/2D]THT6?O.W-A/GO_
MCA:G-U/B)]Y4EW.)X)6O8"HKX*0"0<Q&UF""SZ)WNO"C8,9T:-F7"?ON?+^X
MI)VF4[D$] .EU427JC55!<46R88X&$A8"&S5RCC*DF3O,K4'8(SI4+*7\/?=
M[7XY/=?G90]R45 *-2<%2A?+BT2.NHMW8%)MYR+LDH7>MQ?/0!K3:64O.O24
M0C=J_#LN%MB2B69E?6*V?'VV:B77+3:8Z!Q5+<I KC:SCLH98F"5A9YI6I$1
MF=[6X2D\8SJO[$6*;OO?C1$_GB8JI:5M+Z:?>"L^T4\X7:Q3S%[7^S^\<G@G
M+B$ZGSB$2ZZ ,9D8:"5(U4MFM ]8>P<<NV(=T\EG+R8=1&Y#1.*7-S8F*>><
MMQ"-#6!":2?T0; 2+*B#B2GFWF');C6-X0MCQIY[/83,6=T]6#L0!,EH0<<6
M'$EVDY(3; %U1<..4?6JMROZ'*:>)TY>1"U4BI QL3H/+@/_Q4(MU9(50GCJ
MG0?[Z(G3:,Y>]F?"$W3?:LL[NMNGI]/5*9V;=7;[VND0S7(#E%*@FHL&:S*R
M_Y]2:]I#[.2E)%CWBMC]5.X).",]?.G/B5XB&=L-8=*NJ@:[Y/6>9 U160&Y
MH**451;=RX^&N"$<S6%/?^8=0=!W2/JOW]W=XY_YZTX]KGY;\9_K]VI>+T["
M^:>WD6S?[.J13QV@Z]4F^#NUO[HN8/R)*7BN@\Y8QM>/_9[J?'%1Z/@._Z3E
MCW^N%LAOPW2&B\^O&.CR$7KHY$)LGKML\:%!W1C*7V8IO;51*]^]W'G Y72[
M'+O&.'$F:$$>H0;4K-M;P4/5[4ZFZ.BM0RE[M]IY ,:8G+"Q\/'1"[4=I=>Q
M8]-L?AO+15G5)+04HA(4"%,M&!L=L!=10;C$W\Z"^F?R/0IF3#[<6"G51Y(]
M2PGJ=+4FMC121)M:<FKQ[="7X_J6K6:3*LD9810.4#AP\?3]L^"'$W>6Y#-A
M*WX6H?41( A6>*BV6D>!8HV]7[&#6;3CZOT=V7<_[WX<PN]8TW$!]$(W?$\S
MXHV:8*"<)=L>-*U;H&!ED5@U0$!1E;1**=_[5.H1*%NJ>OAR:+3?KO?/W[\
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MZ\CQR2G]X1*]K5[=ASGPQV2<ENB*](DP90A>D#M4R"<*,5OR4\D35D8Q#/$
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MQQ!8%MH5)*=>M]X8#DB%>SKF'YH)NPB[!P:\"3659-74.]E2!\^!0$ZK0RW
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M-]*^-_16ON])1\BM:JR:25]R[2' ]*:K?,8WHY"ZHW.)RF(M.<$N!5W66[<
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M-!G5KX[6L&G/*X8M8-9;D]IA]_7XZUN3UZ5&N.O1O#RJWX3I_,N S#V)774
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M&D:CV>ORY%,8CBKZ.M8X?+4(+:T/3!HHV=(B8D[@7:(7P;G 5+:H1>O4F";
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MTNMQE_X^>XN?<'QQ6?=^U0.4^Q(%LPZR5 F4UAI\G>L5BS RTSDK4]IJ\WK
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MC2KI!XX)8>K4!5JT7QCUP1=/[ID3V1,3N6S=NF=+:*?%C3[TT4?^Y;5RI=M
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MDT@,BE$1!5J&L;?3=FCJ[+JU?0+,V4<= S%F=KT7KVX$F0F>A2! (L>:$._
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M=BIZQ\W/_J+'Z[1[?]%]%-*'03D:!YIZ+?H_FT^O:C3CLGZ9B=(7*<#:6M/
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MU&P?L?<W\LO_?36;5V/@!N:%S5J'PA#0REIFFCMPP4N(K A7R(CDOK<GT4V
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M8)TD6I;DHS:-=7\/POGI_1@9;]#Y\5W]5D[Y^[+8GV:SJS!>-<"]X*SHB$4
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MRVF2+%AW;CE37G)K6TLJ=09WTN1IY92&E<;K@?X8$MZD8L9A%J@H :-<K&I
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M@EG%K6:Q=1+^!)S7$PVT\LD >X(;H-T6VFT'-U!L\"2PXX0(S=S8C1X]?#!
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MT",09$M<<21^[&#Z0<0@PI?1/%Q<_W6<</IACI=5YN"GG][4 S7Z_L^3.+I
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M!#=L+J_Y\)?LR28&&^#^UV)HUTO+]U>+RXHX'4WR-;M^P:^+'\W.O?2,*>_
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MLB5@/@X_=C']()*\,Z0/_$Q+\/?X.UY,OE2,-QOTM\TS=;1&<F#"*5HR$X=
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M@FIFHAI;9_77T"7K)#8R (0>'4 P3-3\XZ??SL(*S7UUO2Y!WFU?L/+04+W
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M,Y]@L %P3S;,TPL P_[W\F\P''_:N$]V<; E /[/.@"DMCU2 .+3%.UI7@,
MP)(DW?MSG<]ZUK.>]:QG/>O_4FE:VIK8N3F]^F!AYVSW2L+$TMG.\14[&PL;
M"SL;&SL["SL/)Q_7OUF+@XV#4X#MZ<W^BHU-@(U7@(,+ $"(A/M;5()%&@G_
M=YLM.NI/&XZ-#0"(COZ'_1/F']'-/R(7Y)=_M/8Y<GG6LY[UK&<]Z_]N/44;
M' )L? +L;*^><C8N 3:.?UGV) 08N+]B"H2GC!CPXD\;@!4+0_)W.P6&[J\Z
M3Y$(+,S?[IY@9</"_LUF4/X+;?@?\_\Q?9QYG >( Y 0$! 17B A(B(B(R.A
MH.&BHZ&BHA%AXV#BDA%3D),1DY*^HF:A?47)1$5*2L=+S\3&SL7%14'++\S'
M(<3"R<7QQTI@D)&1T5#1"-'1"3E>D[[F^!_KL06 A?34LBTXF-< 6"P8."R8
MQPX Q5,K7\#\J;]U'@PL'/P+!$0D9!34IPJ5+Y\\AH.#A8=[\0+^R5D8[Z?/
M ?!8+[!?L[]#P%$V0J1TP.7PB\I HA(K;<53&3VBYOSDZ(^,@D] 2$3\AH:6
MCIZ!BYN'EX]?0/R]A*24M(RLJIJZAJ:6MHZQB:F9N86EE9.SBZN;NX=GP-?
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M^F8$/,CZ_F#!83K4Y5!")T19;Q&&*O>M.M[3161HVMG>:?^_#!O\?VME! ^
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MS:D[J[R\3I?KMB^CH]MK.6-P1)>\ 1=Q$&[4!E*3J:? "IZ5@!HHLIM;#N>
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M]I4>VL@!IHA \AE8F_=#>-4@^IQR6(\/1WSY&.Y5@[45<;D9"N$$[E'UW!G
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M?J*M@Y7U*+GWBUTA6I%$D!;G_HGH:VUYVC5S!N'\1'::*NN&Q8J91+8[N8-
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M@7^;88.2\NQXO&67K[6YZSK%IG73:)CV\O/BX)?.\+L8/=X)=9>26L6Z\2>
M.T0B_KPJ%]%&,'<=M20; $@C_JO^B;"ZXE^C/887K/44]YX\[+5! @S_0B!(
M-[>RXX5L\6ONM:MP?K,Z.5NOTBS)8Z_*HDG#JP<JJ^2K5F*\"X9-B8-QL)N^
MVZ(P^%LND2'KS8?XP+;9B\K);DF,NN9YR5^_]V8C1W<G[?LE2+G8@Q!HXW2U
M8DY8M\I=,4^JJ5Y(3-0I^]=E$1_%DVLH@L,6'E[[:QG4[O'(5'M'<E1].D 0
MT[!*01#WJY>46H;Z9L1<,-=KC8P.COYF$+5A5CNWO\J=RD?"@$W@KR!^L?8C
M8*$OX!\1,%0LPGAH^Z2X12Y&;$!7=:VT\-3/LV#_Z6*3OK\CN$EGS^2]C%]#
M2&FW/"IQHO2V#06N;[->)R$**MMH$L9(4Q7J/5A.0U(\I!6?QSS*PKS4HQVJ
M)!E]/R'K@I<KX?BOHLL_K\..N?WW1[@I&<SCWC<P7)(<I 1@8QH-$&1LM!CO
M+H%K$O]+V(BQ^JYGS0FWNF XWYKM?P)@!@!!G+@;[VK75XGLO]2%" S_-ECY
M %;<4L(I3YHE$+*ZP'*4Z=@I-<S_2?PP/7T\/ZWV<2NCZ/B6?OZ>"JUEB$J-
MKO 5VRP7@S!.+4\J38-MEO&.<_@^S6N$4Y[%9_RY'Y90UTI5G[K$713SF8XY
MUA)789JA)R,;)1!^ E GGWH>):#9N](+5EZAG@!A"",3LW]G'?7#T%2^[DT%
M#*>$GC&5EL^1ADN)U@?G=JC+@U!@-8GU3!Q!T9H?]R"9U:B7J_9Q9G3W9EC>
MDHT_6:DOQ21\A'\AJ[%"=UOX;:AVC#E$RC.&X/&Z2F3RWJ <DG>Y+?7*[J!T
MSF@0E:5YBNIP,/9;BPX^SA?N;W?H:_%6Z&%/.V][;L:9Y"7DR<3.DAG?:)/P
M.N$8HY^Y5?2\_)8[#-;,5[PW\^YC1,71AB+)^TRV30!T)ZX89@;7T%6\CIK?
M9FKQ5"-,9LA8K%PLGL_\[/D^G:'15Y)I_,TH=M0G;MC.V5<@67#H5VF>.#5>
MYTR\K2"3]Q%PN4EM5/'OKSRK]YD^MS-5T>+_P!$[(-P=GVZ.>2&/C=$*O_IF
M8>[B^3.1HZ@-7X'-"'<_'OXGP-OECH*#!1NZUMJ&C.TS+(HN02%V2R?SCA%M
MFRLK<U?[.8,R_?36@]FT1W9D43BHP*O<ED*(N91!=R2VF\+J+37.)C6B5Q8M
MUJ7D530'Z^FLS.L54RGE- $?4SH, UE-"G]C4VX6.B[NZ:4.,GD:05XM.<G8
M4+?.5S1H+_K0G[3!497Q\&(-9<G/XQ.PM?1]H'/]<3OS)&:ADD277T'.-[I#
MJ60Y1_N9K3*N;O4-\0 H2$S3!EE/T/=UE"_JC>II-F9D9;5 YN*YJ(^?VN7H
MLD64#ILHUN?-19@I FT[+\^-DA=.Y!<9*V)/,/%?H7#Y7)Y,ABF>M-=C978=
M-ZN.$&K,FM)]%_@$J(#*Z8Q-I<^0[&LMIU5\0QVDN]:8C&Z?]>EI*NI.M'=G
MG\VL7=RRE+&7K-ISIIU88=Y%GEH^WM!?5%'_LV94!9U%BXJA"& XM=OWOO?K
M4/6_IJX;A-&FC.CG-B2M/J1&@75>\:1;OH.>A/[ ,1*1"TEZ_LVEE^3^(TJC
M9LN+)T\ ^OT$$+&#BN+1$I^B^D5EZJ=I7. 5(9_U5YL7+8%8)!NF.-?=Z85Q
M&0\-A>J% Y[4G,?S,XK,[FN![?<%/_J '9W9,(^#2HHL)BK>/VN"5HU9?DHB
M&@>](C#4Z4^CS,+<RP934>@';B(U0Z.QJE*;.]VD'KUH>NY4N^\WBNJF_NBK
M4J@,,2,OL:687]M D?Z<ET;)?U(L/2J6!:U5)14$/>"DG53,I#$ S>>HG:24
M#WEV2!&+LBH^Q)\MWCW!.'G<_PKB.ZNF=-$53F6T"U$ W+TCS=EQ.0,&/RL]
M#LU_5J DYW\E+6"P(9:'=9WAM:(]I)1-E#C<CGG5\;X3'*#'\8-#]J%FYPV@
MNU%)CM;?N>"JN*/C@,[J4@TM>1*V,F!EH:KF*9G XEVTW=7BX)QF?LA<>N%V
M!<L\3;-_KG/\9__DF3V0S1\Z5_B+?O/S$9=6'C1C6_B)3O;GIJ;?B5(K)H;=
MC*=M*S)GEE@,@<ZFE&7%[!>2>D11H0)'MM7MD(P-4V0.9+,SG2"^<&Y)">97
M"MUX])")("+MHGXIWHNGR+#Y5R"["H)4GQ$W65^VV>8=MYM]:VBOR[4J$3O5
M)!YI@&MY;00BBL]\ KS#:"FO3*CRE;YVN?7(=W3_.^(%J<)T9'RW5,XELY>&
MA56_IW&OB5++WABJ]K&N[%H_LA$X7=C$YE5_+Q('2?LI/";[8]!+DP#?5H@B
M6R@*AC/JSJH*K/%Q\^8;#+"O6@ 9HA[^AG]OIO*X-(3G'[V_$KQ>)?[/_UB
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MA52R:,,JP76N 'A<^1U[\E:E]TQ1;KD1,,$KJ?\],X;T@,AYE8EVM/&L9(V
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M&3Q*$N/"G32R_QIG]Q"^M2_:W862087=?;[SJOB.1WZHE7:NK]+S5WM;C,5
M@/!D'+(,3K96Q\(2.%%>%13K67T-![_5-6$8>2C>>(^1.\'1YB6,)6R#><Q-
MXU6]RV=<%<E0WZJ3VF-8!JS[UB:9"G8B!K??6*6*H]35[;<?B:\#%!O"]1"H
MN_UHF]G/ E0>IR:S"SU_>D_-:/;;VP>/ *68E,>7G%CKV\E%G4E&>ZCHF$Q5
MVC,&D7T5Y+!Z*_#T3H+!93#+5TYEZ!K4=L/YZ+"BP+G>%KN"@3ID+5JT3ZDF
M_56"K U:Q6K (-Y*.C@P>F=XODHD,,?](G/&6R[:*^5T*5?)]E<PQBLO'(Q1
MYZ,#/80Z89[D902]BQJQMZY);$]OMEM%1N%_=\LH"5YOG-GY7HU&VPH4C7Z,
MI<@NHD:WI<X(&NJ(.US(]*I_E75):7-R=76F'E]O/:YX?5GA3J7C-O62G.]]
M_>0"GT!FZP&UPD]U3/9>,=OTU?!N%V.X_ JV51Q]9ADE-19FO(S^"LLUH@#B
M,9W?5H_KTLYF4'+&Y (AE1F0VA$8+FV) 6D4LISI3HZ!?$=]>A3T)LXC'.XU
M?!NA4"01X6&LX*K]DMJQ.(+#2$PV85;"3UY=:K/J^0%4;/PDU\^ZPNIA*27=
M/5<;&;OA[O:B?^ OQF9NGS %$(E;Y?MINH)IYJ@G/MQM?K,97LWA>U<>NJ2Q
MW4]!A/V<=H !$SH]);/CEY/ -2-A^>T)D/F(F>E/Q9//$.<M\A_(5;L)M(,<
M,_(";WDQM:#Y]*Z=*_0Y#-NB^#LXH@QIB I<YY027=\,$Y-\<Q*AW92\F#M8
M)1-P))*I>1'5R82AL8&1B=F'!Z&ZQ3EQI^):_3)A4S=E$;:_H#^HY"ANO[LO
M\YR$-E@R'U7%4G\M]C*525RL1+U(O_^NH+K^X5"#KM<WZX9G,SLUF:H<2]YE
M[OKPC'9T7_,)\+U9-?%.S)_>5PD-./@S+U.ZAUH!SIP]Y/G(6>2M_Z3*B)<@
MW8H+IV)/FY("$KY=V.<=$@S)Z\#V<*%-U/4X&EBC;L_^YE$9KCWN)N;3< [Z
M;TK@P7O9PNN(KCZ*FY7T80?\G4"DX_F4;MLSK9Y9HDBB\PA9"W71"RZ*18PO
MS]0;BG)U*;+%PG-[YI1K=K+%O 43 V(KXM@.+E=GX ^R@WXX(Q7KTE96JVT0
M"0S.8)ZX5]NU)U)K>:E)BG5U4$JO8A<B7>&:K:VOA)FWMWJ->T^ ZJLN"?*.
MV,/W"_E6S;'.$"VO/F?J)4+[8TG2>SK4=.Q6]:ZW1%P(L7, K+9.+J$1H++)
M\. %8^W03KBZIJSZV+,767:Y^P3H1X_-*UP&HTTNRXOW]*C?9+EEF3ZZ7,UR
M;S4JG_*),D#$ZJQLBP 7]%+.O8NI$E*&9_$8]P!45=>#_Q/ <'*M/OWQ%.B
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MD5U#&"8.1C4ISFA]F0*[^RFHQ_GU:MOIRDL[Z7T=W*E3F$G^;]F(95668U#
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MZ' UPN&YM>J[EV*A6F9$AA">UNZ/5TJJA!4?_<];F6=AL! B/XPO GR#;_H
MV"FI>3D^O'RA7/_=AMM&4,V;K*-"8:>M::(P0'>:P.1 ;BS&_F0N%U4I%$*
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M\,_4V)2\C>2@^'S*#Q?,@MN2X-I[,J=[8EB'\%W16I4ZO8:0(Z$Z95I;;S0
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M<0I+[WHNQ]PZ%5=#-.ID%W2D':'+KEM, ]DV<[_+! 5MIC'3-?:0,"B+XSP
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M5(1/'3_%+8Z\B-CZ6SE*R_CZ5;5 8*B FRR/\* EP(N$%D/_'K55+WOQPVM
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MG0J^GYN0IW#\'O:JYM:N<+1X.5>:;Z?,LI/PZ\F?LIL1_UJ:O@]VOI,HM%%
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MZOU8]P6 I_N8J(>!@>9\-2Z8O6[&.XAI^_[%"O-LNEC,_-X;IL&T*:1?[C:
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M>;JC2YS,B(98;O=ZH1N+TJ+SC_ 53Q3<^J*E(3!^BKE:^&3TD],E-(2D*BC
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M.%-KF9<2]79WSK5%I, "<3T(GS/<&/SG5-DMXJDNH_\5*#KJEJIPJ=JR<7Q
M\D'_Z:^:1B,Y21-ZSP6&A7;LMTW?ZKI GM7"'7B@N"_!%_MSF?3M>V;TGS7:
M.3KX4<;[$3;B H*7]U]KG'-9A-]D[*@#R<'.=]_ 5DC>Z$NFE^@@8[/][+28
MMU4#4Y'_6?YH)H*KX#ZV/?7J/#2X"+[+N96O!F4K19]TR%,::T2$"%0GT-S(
M#TNTDG.R/9%K.4>D+<0O++RHXUJ1XGI?9FK)BV'J9SR;-#\?Q7XDB7H O&@D
M>BMP5 +ZW51"Z-K7[T_[R+) FM:/?[<:=%1[5?RJB?PC;].@T(^T5DVDTA_H
M!DFT<2^&-_KO8#/F32%>6UUKJFBZAP$A#F)J@[%U@W#./>(!4$_R2884- W*
M!4Z;-88ET!U07PIHLBGW[^@]/M(.E4-);=#M=3OR,@8D*6 =D&HGQ)B:7GN[
MYI1DE>;';JXE8>\?!3)ZSG>+"0-) S*1+Q\ L26PMMPZP:?/9LSX#1-E3E_V
MY3.5BU6,>JWHVWX7&QF=]4J-:[W^=A<G/="1]L&3^*CHG3C3DO"N.5]+5*\,
M/QK>9FALM&+V +!U%OBU:2Z>TA'I?<3U<^LB^=ISX58:(WBX3@R6A7H<[I@9
MR@L->GJ8OCPC#HD6WH V),&A)*M&V)(>=Z+%V<+F6!S/.F-2"]M/_;@I=2K2
M$K'(/JN*8 =5LHY&=0@P=)MMVN$WQ6I(QN8/'?P6:QQ:Q"3K^1TH=I8'NDF/
M/=QD5%VS;TXS:FJKZ^1K97+(!'ZCL+1)YT)QU.LW?SJO$H4M2U?=?X=D%Y+!
MZH2G*P"V/6_XWKW<<!O,K]:$Y7+];EB/6U:?:"Y%.%W[A9>,;1X_(^(9Z.>*
MP*UP32#P(+GNS^7.39>HKMP?>7OAKR#2\*_)&)3WODYW/V9+T<"O&T+571Z9
MUV_>&8+H%*KF/TK%G)6*]_NP='E/W8N#^=KF?C3)<,VXKKFG\GN+?BEJL_&V
M\@JV/>4W,UUNO,AXZ]IPTQ2V;#_,O1I,&C+H:2XB^H3#W3O]VG!:0'K4'[P1
M/"WTZ6,]GY9$&IP;)F0&U9VV/]MH3XG"*'%G&C!>_9^-NOGZ;]C2HA&"<U0)
M%YAWA]HW_U"K1YD:3#V69!$%H_,=&#49"'%G._"P,:+VEUFJ GA;R!2PO+41
ML[MI&7KYER$QZ-/50@L6LF/RG;S/"/XJ];$]TQ9^C@;5YE'I3&N1@J@_2F7'
M._&\?TOK .2]3I6$="<MB?K3L6,A8.!:-WBP>/VW6F !GKU6F?][H]EL29LA
MD&,QXU53B:JO"-50%[=3M]WL&_>JW_YCQ2++3U48PJ^ TQW-2*7^.TVX.;4:
M#ZN!.J]V(I([]-3]M.2CRU?;U_*/W;P^;ED:%($LG+N^:H9P:[*!?_[5NP 8
MT"*[R=5_+"-,%N%O?4%7"IV%4@!B\93N):WG,EE,C7\V'8>%BLJ^)'+T-M,)
MEWRZU:LXE*&[8;^,&*M=-SP!I0>R?$A[_N5VJ >3PV C)KQP*XZ^WC=VN%A=
MT?X.-?ROI:L-\'182U^X=Y/4$N<H+6UX!VRWN8TVZ&^8<MVV2S.:>X.:=6>S
M7G/(XOH693/X!L=TPZM?^K MF);Z1*66U^V=A=R5=:?J'(-!>]7Z5O=8]'<A
MT6=8A\E2H.J5Q44"QK<X'S5\*^LO(741P216*!9218=R&A+;T8@*LT@$%=[]
MD!'71(OVH@P^*T"AOER]=B5C?E>['F]5#J@,R@8Q^%<%R(QZJQL=IR#S(BNO
M-0(,94JE5TBWJ(A7J4W#<U:=_9<3SY?"0Y_3C/O:^3I;'0;[:]R6ZE'+5_T&
MZQ4%"'Z(=*Q^]4T[:ZDX3<.OJ;6YARMA!S=,&:[W)0P/P)"V+T-^]\-=*A!=
M3,1\; 6E,C]0V6QQ*[X*SZ<O:DOF?.P:8_0U<=-S@6KKQ0/@5TUT!^O&58V4
M.G*(6K46;VLZ7$5ZIFZY->-=/H$DX?>$GFNZSNK[WK-&>&9U  B64'0P2C[L
M66*&NT7K>?8D76/;7)/&6D56;B8>;G50)-38=1=!T[+'] K3(9H)7=Y[ 7?*
M<ILC3>=K9<;2;H3W7!NLZ%NN[_O5UQ((*@+]NW &P.'HDPM!3%<K\C7[@C"1
MS(EZ0Y8Q*(2GT/X+87)$X4=<-N^%I*J0BN( 27-[0Z9I24,XCLU+9J4FZ8H\
MD7$/;)F<_)\**@UB#B/T@7BF8LK6)I.][3^-#8#R@2JH#-3KZ4+B7XRH/4M^
MBUIG/%@%LVV/OYI(_AG+]3\: DS.T7HD'.@^L&K<=_/'CQ09C+4C[UI[7_R,
M2[,,%=N(H1B@MEB.4FG\@NBKJU!G252QAEB,=@;>;;&LS;_/:;Y,,OU[:%X,
M?+8-=%Y-R2ERQ??3KV'+<4NVL4IC6LF;*?*ZG&<UQ<X5"10KAA>K"(V)/W.0
ME&JZ_HQW_PB4BNW%W.ACE0(WCV3EIUW.B=0^OF4-/D^SK:ZABV8Y[>7A#FQO
M?0D@,9T[>80=.=GL3$=CMA/.(VLJ)]QKA%-H<^<0 #8KU+#".]7R7#SI.@NC
M\(+7NKXL-;ZV-=5=YI$"_D&Y"4B0(V3$W&?UQ>!:1TXU\4FI5%)?-Z?0JC6-
MZ-=UWSI[_/X#KZ@9!N"N10D3%S9M ^M2F'L("S)(_1@.7"ZP!Z/?:13F!CO$
M&R3><F-Q-B9IG)E8%DXZ&%VM?AZ0$'6E6PDIT+R+E?\PG-(P!,M5](NH\>8>
M[*@:<7NE6S(6F-D#7=:9[/50SP^(1,H5F8KLN5%GA&F(DG>O+C]'=5=[FFL6
MRT9#I,"&\[P-"2S(8Y/#XKS1&(BA%2&5J,@[P&N+KZ@41%%()I)W271C,,R'
MNYOTP!B0N[Q,(;1GU_*5)?X!,,IN;9(R%8Q:_PVA6\(J!^A/:#Y%.-7NB6J[
MQ31@7[R\D[,&/"95F?"0FW@WX*HK6ERG [?:-]8\)M;T&ZOYB?5#;)STJ<58
M:0H0"8RHQ13K]7Z)8&L*W$ZBG91?B#W37-KMST,P2?V37E(*Y./5JP1JT?U;
M<592$,<$%8[C,KVAOVPVPG^92CRR=R..A4!U]S&>9$TM'U!>M<M+YR-IB-F%
MB?7ZU>VNK%)LFH:K\KHBAW)#E4KZ9^.(SO)GM#^3T3=^H1J!XJRLV6=[\Q42
MO@=JR(R[RP_%C<IK75CW?,2M!48D"DDDP*BFAK%K,*Z*OP2XJ2 3K'*%W6A5
MM'$]@G/3]^[IT7,E$7^_J;/TVL9IU&N^I=E*+^S;E0V,X:CQ-LJC=*7CGGQR
M\%HY=\$TDO%&4:HU'>4K,Z9ZST72Z&= &HT:8OVTLGM^?M^XC30MU_W\#5H<
M 2L*W):C?^'.(]GT!^?$W!OU %BFZ%TG^'N3F7V_;C#_TS?>242P8,7]94J'
MPVO^M+2IFPVF J/.&[U9_9$M[]:F1 T)[SR+LP&(']ACMD.Z^-9\05>%ES&B
M\ZP#:23O]KWG;,C%#?XGG@&%]]BGRJN2C7]NNO1NEG/XGQQ,PT+A01P)4KS%
MH&N>Y7$[Z"/5<N6USY^^N!:&C@Z]# (Z_^4AGD!]-)1K3]F.$:EPWWZ'PL5C
MK#C#T\<DQ741W8K.O&#4.(4/FI)X$^K'UA HM514^VW;N7"[D?1(X;:SKLA:
M I?U-5\8K6,%873%1^\'8&T?4]-:\YF;825=?<2"2YT X2Z;+Q*<(Q0ZC7]7
M]V>URD)H+]I!QO<)'JJFTD-X=^J]0[+FV&O]CPL&UW]2U<L^3 2;E-TM)UTJ
MG5="8_.H6=")H;R0ON6B>QT"-0)SN_8LK'+:2N[MQB-0')H#]@_[%H[!LL@0
M_ 7E^>E9\QX?1$V#R2CQ^V2:4N;T1#$:F>(N8S%?MV#Z)C_C@8&QY<_\E2=<
M/[BZ;"AJF<2JS%YYV[P0=1ED31DL*]F[EAAG'=KBQAE4W9%A#\#?'90!2JAW
MM89L8G-]!5?V86^F%:G"7UH3KQP?AM\.2'A<MD9X:\+R*!L(*)-7#O@%E=(]
M:=^.*.$QR\&YQ]]T6-DAUV,R9O:I+=PC>5XI)8UN/;+3&L3+OZ+TF7Q4+P1]
ME!36]09]%_FI\F#Y>T:QG4D[CXY/5KHVCA%9.F6U!%-!O+Y?)EL0\(B&5T?,
MLJFC+I8@(?S.=GJ8CU!1FD7N*FBA0D/H9%CCTJE!2?[;7?FM#3+O&=0NJN44
M+%Z:\MPNP3 NPG6/0$29[:VB[&Y:D'45F!:[E9DMTUT:D&3&,C'R)/!56TYM
M#-FWX_A3"-A*SEHU2?5:4 ]='(.Z(]_M7[[X1EQ68FK/Z?I64:_6JS"(]'VR
MTLM0N:&G71^Q=0^ Q^=AC.]]T,5=T'HV7^B?!$O!KYJ5WO$YQ%_M.&BO$D'&
MAN7FO5,Y_@=J&KN3#P":+A8S,!@;>DGV /BY[[B#^-"<G,P:*KIN=7?1P^:S
M)^"9_;?[4S=!*J/Q@L:-8\O9]IE(+8O8Q>F[W:12X4R[&YJ R[X7S<NA[75=
MP7RVS4UU]H''GK_?;UC>.$CI/P#Z#JOL!^'S+S*-]?.=A 05+J+7UM0Q\*/X
M6OB[":4-T-ZOZQ9W.TEIES\.;,=)Y?=L 9#@DZCLU?1\O]8$_=-G*%H_LK;A
M1N^5Z(N;G>8&'L9;A0(C$&G!N&L@^5![ -Y+<ME'4-6]Y37A)B,=.W(EEJ.$
M5HZ4V1#  X#N;-4=:9YT(WE@T$1WCH[K$^T]YS8J\(#W#M-O9N)Q?<[)WR!+
MF:6PH&([D%\J*O>_%98@<4)W%;EO2DO[(!#07Q(,605FO:<!]M+>YT=F554P
M?ZW*.N5?\'ZND0#AG6Q(>P&VHD_"O-'*[^W1.8'CL:OMECVUUFC.J9A4N,DZ
ML6A()/8)R_KDW3J##^U@,Q72H(!F\+N;8]92XI>&N9L"::>Y/L/_U2"+#IWQ
M:]QHS&Z8PP*[R9'T%S/X-T+W'@^!H.LS<[72\;?V,2D%J2)<(VL_NY)8.<ZK
M*08> $21C:7"Y_&'[I+Q0ZDDZ=$,#(G?N;LBV7N]U*P9W )E\MQ!GD(ZP_@=
MZ%M,_2,_)CG+8 8&AT.37]\LZK\L4PH<N1;&QQX))7WV\UBNFW5C,LG<Y0/'
M_:LL!VE(<2N4,4 8+.KIC%X9%FZXLE@G-0FXQOF_?-+7J()"G=DHXLJM*C#'
MYF(-W3'CVV&WK[<S;SB[I;V3N0)=+(Z8;,57Z#EJMO]6:E)CTY319F'FSLT6
MMDJ>E)X_,U/UI<DH">L=XFV8"@TX\ 8)QKD(0M2,T&Y515@O(QW1N9+41ZZ7
M8N]._P,&O3(YL?DA?' CT?*E2+CDO5O&8$#?P=K>_9FURI B!TCT Y2W*B J
MTO6DBPKR.P@2]3,PJG]-H-5H04EA)84<..G+J%7PQ 7=;L)8L?<=(ADHM&A.
M'S;]XFB62>/C+AYK_B75F7\H6*%H\7[QGC6XTYPL&&1W(?DD5>=#^S0CNG27
ML+(:QD!JZR:!:GY.ZS6WO;!ZWX42-Y$ONFOM8I5'C_9>T"GF3 L_ **K%]1%
MR5HU7PE&)A\?> &T)R#>L7652A1@//1Q35QPB-*'7[6=]=DTZ2]H5>))8UOP
M*Y^;XB0&&>1 UMH\YQK6GY@^L0\ R]'G,',X-6?%#$EYT]QQ=TP=O<+H5Q1A
M/Y[E!VA,C!XA8HA\ [<C$UDD7+5*!W/2D@:;PCZBD\N@D>K=0JG=NY9!(X/Y
MM^[9*%VLO9N/XW^9V1Z-LS:Q[+(=CNR)^EIXOVJI0$H8JNYXH6_2FA]:3>*X
M2S,,"Y-^A[+*1.6BYLL.23RJA'0$Z57ZG^JF="J_/)6NSPG&C(-!:*#^G,S3
M^]]T41&^-\/YT^<$@S-?AO,XPTN#G7KVHRPIQ'K>!AED:60/_$X7VW^]6B,\
M"WU^/E&2/@?H]R$:9I4^#9AX C''>BMD(I4&GL]?]QUJ-[1V>P=>&,8-;1:R
M)_/AI8H2 B!112$1R)IEHGNV6X/I>R#6;QKUWZ^.?T#^ #!TDFLG>Y.5W$.9
M0LM5\GA7NJ=&XNZSCTD""&7?7F:^JND)RJ?O=>9PO=' D/;@XD:FB3'DN7'_
M[M&ZG]3QS51#W#\7 $_*'T");U^IR) &!"LLY.?.[RP2%)GHXQS9OADK#3T&
M<#7U%?)M72^,&JP1_,+28S*-9CM$R]H.(N9&V3C)EY5'C.8H[:!Q' "<'$!!
M[ UVL28FVU%J-Y:7)UF%]F6-2[P_'K#$&/NM!UI/$B/EB5$;H%.*J7&C^E/#
MEF@R11@*JV[]DJJ\MG$;ZSV5RL<7@!8;U&DXT,?Z^MV.?'&MFW6\Y^]V]!D/
MAHM26!A9L&]E!Q=ND0FYD@Y.?(:I-GQ%#(X$6<9>NH>V-7\&&Q4F0.644J]]
M2%>EQ[I\QQX37KV!MJ>TD/7"04,0:3![=V9_4&3ZAJ1_=U+_BV\EC1E:MM;;
MV0[Q:-$_VNEXR96/(F5%A_-P[T4"XGIS>9V$>)1N^,:^;4>7#S-T&:Z4]R1^
M=F. !C76</F^+,!SDKSKI:^:G*\CFC@:P;*&51T>AS@/5$U%*&?(&*2%>MX'
MUCRZBX<Z\E@@3V*%.W'AU/.N$.:SO^>1BPK=3BSOZ,6&-E"TO6X!/=<%>NCL
M8?Y4A..R &E:2F[/'9[J5=LOPZ#J+^/ZY;MA>^A)Y&2,.=M<K_Z,SU]UKGG^
M!X"T=L[8 T!'F?:BAAF[6B:'OH2-^E?PQ\EC\ >+.F&@K,KJE*R"'&B@QZ*E
M>!]38,W/KB?[5:6.S9?Y>AN=<^[L1C9["'L?CIKRO&KNG0< XE ]=OZL-_EM
M0\;ITD'QL5IPH"!W)HXUP :0T\+VEU9,>)7)R#HD!YAY?L9J&XS7.TFWCAV5
MIXMO.LCD'Q?..:CY$FB=G._[9T1Y(QR;8P M=;85S?)8[P2'MJQX0?MJ[RGV
M1>X9L08_Y!G>4X/$=M+R4,ENXK<J1U<+4<YT=X,P5[4!"T1;<D.24EO&R$(O
MNE[!,YBE.:->0V,AX&M.A&8FC;2\ Z?V3CF*:=LQA-VA**\^!K%S%F+0[7FO
M[B7S"FOB71D02^3_?MY^ZEP;;XG=KMD(U1+E:5D9'Q0V'O;LT$RVC_?Q?C<1
MA&D?0A.CW/SK<^B/G*?V;WILT:+\@XUN<A#7M\W]MU*\M,CZA/WATSCOS]!(
MB;\9UC/&&#U8,A^0)Z'!+[X'&K"5UR]V/JZ9CP7V&YMG>A8K%9F8RHO(3#6K
M741^#7NV-MF:^.PQ<7B3H%EGH;\,UYQ"O6H/69N!S>^G@DD:!6?5.V>]V>KG
M#?QJ+GA?1 I3Z@QN![SG!U7SVD:TQ=2!ZG1-1:Y6I&2(TM%G,_@IB7S2>):2
M!J7+""70(WG\-YZO^\K_/BIWHGM2'$.A!'HQ/O@&$6-SDCU-A9RO/)3,9L,M
MXJ$T$)?['R8S/ J>,:F2:$V*-FZXEHU:,W'@;V^#V^(>ETGE57VTWF9G0K[%
MAL/F(<"Z#*=MQ12E8>*3+,0,U>8:R\(YD,R4(*Z51A46;8,;'=7<@G<X[FJR
MN*Q.+[TR9B]E!4>&G 9!J.+*C)4:C5_A8YITDS1R+AB]#\W/&>B*3D2#:<\L
MY$?!3W\?K%-)V=VUT1Q*@%-ZB_O%[I8-&YS!BY\.F-X?C$^HXBPW=@DYG:[>
M"F(2.M2Z-&N%RF.]/)X:)H&A_..RL"ZBF0XS7[?EIN]/8!E_/E 4)E'6.837
MH>SL)NNJ=0?S<'WB)I^M[U\[MC2WI\XK5[F=U%17@S/LW)2RN(&Z>>:K25-6
MGD+E$X(YV9ZG#X P.^ZB?'=5;/R::'-2?RYAFTE[M*L>QWSRT\;:]X7N$QZG
M>=^>CVQY>?!!1.Y*I#B=T BDP9+/;I:U2/)J%6Q&<.*4X20]YW;-1B*#(SQM
M=J?R?@)**0P,DZ7DF.IXEVILHB*ZY%ZUXR55W\X>*?9&!GW^CR$&LZX\ %SS
MPO3;3D+=P&8E;S(EJB(:O)ZSIGQ5MZ?)H!DV?UQT:</FWP,(>1/H=9!R <JF
ML$C2!<8P"-RJM6(N_QQN$G23F2T=2(PM]YO I\K67K!H!?Z(IY4-*$25>L[N
M=.7.R;Q81V#CC.=O)9%Q#P#"@Z"23.$5F0^B+[PZG,EL^5LF/'N7#P)H)E5O
M#[%TS?[9EY_^9C'N-'4L'!T_Z=)X=%47IA$";IP(YH&D!%0,&L/6V-+Z[REG
M>!J)=."/V]J[NUOYC9<:OGU6]BOS]\,?Q 6^%:\V=:76$"J55Z>'BBYLI6@'
MG9%AJ6$&:Z^C=*=O%5PR(&S3''SF2@!NBK2,1.5[:S^)4\$)+TF#B0= ,\?G
M&K<.WLU.G=]L^O5M >S9E*.EOD]4;(:NDN_9<,PSRRVPJ%Y92A[?A/>C"FTA
MWAK!*M:UK8X_!^J<]%:+<$$XK/&[/X25D'X%2-E86>)S'G(@P$+!LURNBZ"[
ML6\^^D!O7B^=)K(?H"B8-EA:R?=7.I=%[/-<1_;5HI?;?-WIY9]F:Q.4?]3(
MD<!_]6KQ$>)D,IH+;'D375%W"6!!REP>;$V@+:N)_MP8OU2(J%":<@]32S_O
MOL7S "C2+W_C!.B4O1;]6%3DS=2?%I=M(V/1R8W!TYHI$NRKQIR96V:,?9F'
MC15'M*WZT',@3\=C<N_)=>$N5WTJRA6FQ&&RQT&\<54R+,;895"P<*L%WBBY
M$,GF^><U;G!^AJY0S*?>E]7!^B61'!B'J(:KADD21XO%?5^.[S(E519WQ?9>
M5/Z_*AC'(RR0/4OQWMGG]..J8C;<P(E@XJOS>[TT]I8\'E:1LV')"M1=>PFQ
M N4?G\56]%E?TSWE;W",VY/SH][@;^W(3U)7*W;KC%&6XF(];,ANOJI[@H:\
M)O]8*2+;;H=/U>ZV]4XXGN1J[FQ3;C*A$K;G;'1WPB9+/EC5]L!D%'WG$[ :
MAGX@Y5;XKEU*N";&B.><(/ACM_6[1^)Z1[^@JP"1H-N2;&;M$<CT=30,JX1&
M#=Q389<:L,%:'9WHQNM)3\;O,(_ V.?\Z1F*6D/KO!_0-"$A_H/0IKRD!9/Y
M6^[B?7T)F?;G9(%39G$9,87_N7 2-!;J($(H=ZN)_+KIH8XG)+<B,[YD1..Y
M)4C'N8(X=?(3TB9Q 51RUZJF!FPA S+4_<0.XY. 48/192V\/2=HY?VO2UM3
MP'6K#C\(</L Z%%R(REX'FQ_:,U2F9%KZ_(GZ:?0JBYL_2GXN=73S')CT++(
MMV<4AL..M>K;\1F.JQH$(3O,O[Q4)FEJ<AX CJ#H#@OTQ0, ECS4G&:"[2P4
M93+WI+NJ^^_Y_=X3#0D'F?/SQH'<E(+]2\W2!K[%\HP,T,\7_$!%0D,4P$\Z
M8$(B+PKR*J!>9>J6HGI?A@DCDUDJ-5W5D,RS/#+SQQJ],M@8O5[K8O<GZ'R8
MK^RCFSH;HG-!^R"I]%8!$]4O2WPK6&QZ8!P*;5AF75R&%16U:%4T_&/EB9JJ
M9^[A$-DHE":\U'?TAJ92/3TK<N3)ER&_BA@<OSU#BE[<6H:=+HV%KM<6 9/]
M$-(97GKOO2#HXA@L8=KN%X$''Y7?R\>H;2G;A2D+'"E9[R*L,8_?6&-4[/0.
M]Y' Q"5?<9%K(ZQI;TQD>R[R7U\C+Y'+8)S=TRU05#_DN$[S]SX*W')$6N4<
M/7:UT [E3UQ'$@7"9!G DE(6CK%JPT(76?ETR3,E-]QB;*3U*!!#^'2K)@UD
MFHF^<>I8",4^<K <D=Z'Z-\2P=KAC["D/28=Z+$H9PJGO9@$8,7!W.B2OFM=
M-M6+;!=235(:G#ZBGJ0R\7.VG0[5Y(L7%W4K4YK$V%3V5$;-#ZF2Z7;;>K\8
M2;2@DZ8&E4X2 TTU]O4F+5:_,[')UV06_ $SZDF;B74@I!F7ME/)RJJ\0ZF3
M\P_XO4T$.5PVXMXFG8$/#I","S*K6AV(7PNI+.94%-?QZ&<DJ?) \=6E[A9_
MM U^)M0(QUK O9T-PJ;/J>R@K2QHDN;Y=CJTPW-=OY3:!FV%_VVJ^,=9'T2(
M\;P:Z"NL=HAOQ'F5\F(.9P,B]!O1#WF9.K(>W/,[AG7-RT-3<U(VW:9#0+G5
MKZ_&75/U$D@5(# YP*0[=D($L_!2QN0$,9Q3#<OVT8*W.<MY,S3H^:RB9G9J
MC!.YI)J^"7I*=2'7R0D?C2>U2=YQZ7\ZJ9RGI=B:^(@ZQT, [IGZVEQU=D;F
M+#2F6>TBB)=JV.B+<BY[.;8M=A2Y(ANKG)BHT9T7964K146-V=09_AS./_!*
MM^X 6W\'@FB"- IVS/R8NZ+^W7V'7A"14<,ZV=XE@1UR#^'2A.YGI8]SA._D
M7#D/\C]ZJGQ3,@L(K F#-FSO5*&[#=&^OYL6=%5GWCJHC;;*C,%Q(_A_?E^S
MQ)D<C6#W'.JMJ>@@^;GN?'D)>=M-+E]F\1]+4^-W#Y<JN.I[N7O6EJO<6X/^
M!T!#<R]!WN=NBNH.A4T3_09T=<NOJS)"6Y[XEC,F%CS\A#"#W(A(&>V\UKZY
M*"F^.0,!?:@L3V(@!Z@@&ZN$?"W%BRE07/!U]"Y<5#TM3-Y<D>DK+0]EDB?E
M/Y >"$&ABQ>TT][/-1X>2:A)=GJ=NBHJ%]*DVUB24[JDC<#B>L5&A<',H$UZ
M]\?#Z.Y!8TBY,$)=)_!^@:6OM&FAO$\AR8%=Y10[:5:()H*4[=<MFAFSPV:R
M;-+EF=\1;RCA80JD*NC*]"/.74/6T9OJ)HI@P1M?;)K1C!3P9\]\^?6'A;>3
M?@)&[&2_*N43<5GY=L7W$QOR:BW@G/].RV/0TY;397><NG/1F\1>M5IKPSBL
M(@@/.%,J"F'$]&^Z1L$FGQS<,[019C3'?7V+[S#T)61PL%0<U<(61'85OC'Z
M ""]?8P==O<6H#>SD6\+>+N!<AE17&)=D:C 35[[IAY(IE,FIU/2X2MT8R A
MNTR_V8;%0\VWN^+S+OJ^D$C_L0P@8&9/*]NT\$KZQYP1W6C-4AZAR=#LA$K'
M^2.91D\^^E-&F.=;S_T(8+3PID5C=TP#;W0">A=F3*9RY/[F[79@@:69QU02
M9\MF>C/F&%1Q%PV&"%V=YSU=T;R9MPIQC,!R,-MJG_0U3PD'^7J<!NI4SI?=
M*ZJ:WR7]8IS\OL-+(VP]+]JR9K"#$I-6ZA1AY&DDR7DT2"NIX7QRRWIJB!B6
MJMB"=[A;*PF?ZL1FU)1-Z[=EL\]LQQ2LLVXJF5[6C$\BC)'/9"15J9HZ,S)=
M*>-RD/*MLQ"-$DQ-2]=KL"?:H2_DS1JVP#0682FC]_/[)44=0Z!G8BNMV;J/
MO_"5$P:*U+TUQ&;68 O[V3N"$H92G]&$C=*5*M\7<M6@>HY4XP/M/.GNG_SV
MU8QE$J^;/NIWIINO"R#,I @;,TLTU]\-+>#)Y<.YK%G2C)3!F[IEWABGZ/=+
M8AET>H3@AH(_G?%?\J1A%^# 6O>>(G1-Y&"2L&55Q<'>U"*\Y=7R"CEMC*SO
M2MEC/U//,U+I--3"D>#FR:<'P%*VS1BO\ U<_T5=*F3RN:Q0-=Y+SYFR6T$#
M@^R.SB]FV211NN78J!]R*)+H>1GZ6:L;\_ 2N;NB8,?;7D].E_?5$GPT]LL!
MX@P&SS&[&FB-;QN\%.L6CD$NYAJ9XA2#=C3IAG"]]WQ:<AR.>/LFLD]OG623
MWH#ED!69W&]+O&D,;WN08@4)>B9B>XMN7>F;%LV9\47U6-#3),<>4U#V9[]A
MNOCV0>"$\CG]Y\#!*G5?"3TJ]K;:$U_OW9.EI)X4L#;V>_Z^_]CO_>G)+(V3
MKS]Q64,][WK6X^R[WST G";)')F(L4X>IR3U<8'6ZEP$?GI?3)F?\F7A.6F)
MRT0Q'NZXAW:1-6+Y-Q\ C[ E9MPEJY+.%.IL@\Y%%?*A,"!2*N5/CV\-'S8.
M0S$ ;'" -;J*,%^0[A")3.B+Q]!\2I5P\Q*<E/U@4#%R,!NGJ5P%U2$"/EO$
MIB&;X^F>I-34N+.+DIN:*FO!>VR'JG$0/=<>3T)V-X&, >'R4Y4-=VK]UP-W
M<QV<%*8( 8VTY$>9$U[/7Z*A=*=Y4=#ZOTSTZ.\1>=\O@.3<5;_G7!;>I/K8
M$=QJGPI(Y*1EGS\ (L^<KYL^>?/T*00&EJP.VP7Q&'C%4!24IT+TZ8.W&!9D
M1.DUFF(XGH7%"316R9I@\TL7V>>_BT1MCCK-'_AV+CJTVWH,,PW(LAS3<H3_
M/5D?+5KABGE?:WJ'FKH7-KBQE7PZ\>Z<+3EXBPF*/UN/854BL+98/8(S>,:>
M<>GID6LWQBE/H67B7N67A[1!4R45KS[Z>SW#0^.=UZA9M'&G8*$$C8WCFSK)
M8STO)]<&]6^';RNJS"F)&\\:M\>UL_-GM14L_^?IV'D)_%':N;-GBJ]Q=S6C
M/_S32PU'.CO'K$(B&3-F _7WQER<+M!.<R?T Z#ONB2Q<$;*")6@;&'Z(W%G
M4JF>A/%[')48LS]0X!W]G0W%L!@NPQT!9K*/!\E(5436@;XB<?6D.P4WHUY"
MV!B\A_[6/,&RAGB';'H7KV8DZ4S;IVFV)&32.$Y0)EFW&P9%4EV(ASBID7#*
M^W:GBA_P:*JUM$2N^I7V;N$TA,@6!2H-GA O!\3U2=AG0B*J?$/,YR<.A*PK
MI]IO-Y@&'=V_>O$/-E<O.SX ^,XT,XZ&G!0%]_ .31_W0CC QO73;S[H[N72
M?5DQ,R/]X [62V?1WS/F'R7<XC?',3[I&X:7-*0A+%IB@ !0U]-YR/-#&1:L
M;T5@9IO4)>E!-OLA,$.>(32P(I$@>K7 E_&K39ULO@7>[7O?!T!$+G67 [GD
MXG^)WLEFBG#Q!T"@NL.M.U:V&*R$'AB/@.$W>^R82*8*3'W &SG<SVOK;TM]
M=I4(]KZ0Q591+KL^ #Z=L]](KWWS95D>%J02>-HO9)N;2-.]0'O C?ARWYYI
MGGWYX_AVYA!+>RLP>^WG*+-$H*BGVKP7 K78M>"Z7P#6OUDG_=N,(8ER05E0
M&-5,TA7+K.(GM0P6G_<L:YI_CPBQK*:T\O*<_ "]+B_:GH97V\77#GZ@>  <
M')H3.DOPYK56U&'/-H0[33I5X?L[<C:G<2J_"-^.(2))WJMZ'Q/Y>AR8LV/=
MD56L@]DB>5++?ND"@\(PRS\)$TBR(5J<J5^[C \ W*,'0&-F/R+I.?9:D[S0
M#[,O@4SX!==33C< L>),0.-D*KV-UNN)<LRY,',+D<>W\H$%1@?Z.DEU)J$Z
M?X]>ENF/;#';XS7-) 8"?RKZE-N6]1F?WUR(D]]M7OKW6<31X<%.(MO\H_]*
MJU)1R+<AQ=D0[!4;3Q,U// O.4IIM[PM^,'.Z"AX4N+:R_D.>?0)7*(X9;.4
M3<W$Q'_6-HQ^F#0]U1#?0[>87BI="MD%Q?CW0RD@8[*4C:.2KXGK-O2@S0H.
M4#\,PMR$$?'?)UIYJ8 4-=)W/6Q680OK%G@RO"1 L&R8]T^1.,!SFF9?31Z9
M=^\BID)_;X8R$'_G/KO^2EL.655:#=%HY'$!DSC<X-U:8^R[Z@\-+G@"><?9
M[XO*L@Q##5ZFM"9)H;I OZ5X;Q[U_KC5B%-> !LY^!8L&O:6.OO7*MHLM2[2
M:#&$+IHA$*'T[ '#UY<#='^[J*;?"M/\%%@=&J5J[!(0S:5FG?):5Y ^W"%)
MZGX![ ]27PCW.5(X:8R;Z3:>I=PX_1'X\GP;HKM'4N6M53#1CBO-C0(>/=GD
M#8,PUJ-//HTW;I\WR)B2ON]%-6_=GK9PO#$DEQ-G2_7,R?N\W8@1'8 R<C&W
M+8"5RDW!/[Z/G>0-?W3HQB_(P3^180)38:+@1*HT/CPB1I9G(NIEIMNN/Z7(
MC3]X>2CA<B2#3MS#\^J[(V3P]@Y?Y:+T%ZHWM7VK1$25O[^+)_RL@<7+%=!X
M*O*%<[I-4__9!)8 K>,>#B5$_NKH%,TNZJ&8Z(WYSR:4)2GEE%A3IFKFI<'G
M6X]I3=C)LD%O+L63)\5QM@LZ[99/ A/WB4/T:>09KFNJ0O[1J.$?E=,2@PPF
MWQ$1>@ F31=+2/J5.TH3>)A'#>'#3@6PB2Z=(S[9W14]LX:,/).CLW0@?[;P
M:?CQIU#CEKV!V8KQCA2S-[Y 8->;I 2FMPWHDL]6 @'0#\GPMS:Z<9%:U*S3
MPO@BB54+,T!5R/CZ$Y^3J'N*^@5V1W=?M458V"8?4EAL)/P.-:$YY3GA IFP
MJ&=*0>>I-,XVZEYT!F9ZP2D%>F#$G?)\C*=*'#6Z>_ZR1,OTPWERLR73V?N7
MPMGO?\%,NN:DGY\@9J@:G6?G.%1SS@^N97FQ;$O?ZDS9RR>#!=]X(&"G'56W
MSPJ\935Z*+ &^;<XO^WKT81!WV?MN3N=D6:*REAZ,L0EZ--]C^ZY?;6_PEW.
M_,T?;VP]C/KZ *ZW-4.E0R#^C+EI*)3\ #^1)N>>S:"QGR916$^KO ! '-9E
M0V;,D)C#>-+:9O;!U:9WV;Q#?M6$-X>$'.XGNR-Q+ZRXL%D<!6(1CU2+U,U;
M5U66-3Z(4N4.SU9(Z<<W@:7 PX2T0\O%@*JI&;')_W_]WL.2RC>8DG*.PM1D
M03C!9'-2TB@EC$4$6$XD1OIX\5@OWVCC"TE[)_$S2SY1W-]*M#M=WP>%-3_.
MO)RKW&YLT13@I';"PZ,]ECZL(8C-)2^1DH'8-HZ!Z\J<NBFDK.Q=?'D<Y&:.
MEE35?7\."IC^"GJ%1*@ 87Q*6G+5X7U,M#,=!$4(IR"S!K^F6D[#.6J:2=/+
MW2[O[*6Y*GOT6IW,-\ZWK/!!*;MG&TG;YU1NXZ[NK"Q.(D/K'BA<3$U-(N?'
M(L>]=M:GC4!/(8F(G^_T].UNQMYI&<3G]H>2;'!O)W!LOLU"/0,K(!,$QV9X
MSUWEBAM:XG->1B!L/P7TLF?5YQYX#@13PT>'_P+QQEVIX*,).D@B 8['F%W5
M4EB0E=J]>6-]/C:(B%OI5UUSC%5#4X1- J7--F[2V5H;IWXN>5[CSZ-7#P >
M*)E0X9])/BP0DWIIBGF5O\%+A>BLB?.)[ACX&DI^O>*J=0#M/BO=L Q/EI;V
M-[6NO0I$M)";%%-Z+5V@_E)M :D[9!GS$NX90/K)7*"Z@#!ZGPZM__+L'+<%
MF5G+J28^HL4NJ@V0O$=9FV84 PNYM'6UK?,VL=0-K;-5W_\C&X+H_S<DV70V
MA)IN2!!'.=RT!77E?>UBG*" ,1'%(0WZ3ZC!1AB&7ZM+_3;>+R)*K@H5W$GI
MM4\E9.0I#I0X0DE$D6;4_=FR_22/0,N/AXL.]#,1PHP*9LTF8]J%\2K)?F']
MCI,,B?PIYE%H:OV96T^TO '61":?,:. IV@\O=6>@)6M-\M6.]FT0M#.@.T)
MHV#:F7[GYDF,+/[R!0)F0+&G _QKXMNEG+OLKPB@DA48JMAQV%FA+M&C^<LW
M71:5UC>K(?%'3=6XX(\LR?WLM+.?/I^)2LED16,;^XI$2$?;EY^NA>(?DUX_
M#>)N/?S]__1V7D]-,%X:#H+2BR 8FE'I( K2:U2$4 2E%RD" H'0FR&$HJ%(
M;X)2 R(@):$%D!ZZ"(CT#B%!:0*A2N?GM[-7.WNU,]]>O'_#>YXS9YX3NISX
MH^7FVCEM74I'NYO)H);6G]4W)(C;"3 -JDIN>[0@S,FMN=<5:/K[;-%-J7V!
M'@DN6$U1]Z.;SE>9J_K-5F^3OAN*6*;>WK+RB%*6<R+2T[KNB[ULJO-)TZ+V
M^OK")_'A)C-OXSC8+#\R);9X=:(E&XM*;79'.FR/D(R.#]!VME4-J*X&/H_J
MELK:Q+9 #WY;1PT(W78%2.*KV([G;)(9 M+-'#']"E5&'#^];.^#N?,<N^7N
M3C_H)P)J2HQKXO#6M"0S6^Q= /Z2;'GD'HA^TOG8\<,?5>$)C\415X<T)Y\;
M1/J6N4GZ\#;2N46PM1H1_>:@P:,#S  G?F5%.YG5".S2SMQGC27DE/1S%_.S
M)1!)^<PZC.8^P\V-*N![CQQ\$1J1VV#C[9Y0<1Q& +,'9@;@S9U]E)10W5-6
MV1]21J#XC4'@[%EV\!VM132GS:ED@[A =-=!MLIKT)<4@8*X*&7*+Q*4>?>R
MEMS(;JH'S+2',QUR#52)DWUE\R%.@T[5?UC=#2->&DB^[FWC;#^9F%3\T\'(
MC+>A1AI?R?HX?J[+\4MG0!?_/#-RLC/-4^J-EE6SJIU2QLQ],[A^'! RO\GR
MRW4''!4";+EU_D.QX$^H*O=JW8]#R4*.Z99*UQ;+]_JQD7$.WAS M\J[S?C?
MGTH1@^V@,$4(W@KVL'HD3V=A0_XE[D1'HW3)$C 01@)+&"@F:RHG=2&$(LHV
M\LG?L])8N@I7*Z9ZI&@213L;'U)"]WI5$)3S]1X,ATZ=:)::$P^6-<5W!]9<
M(QZ=#1HIUR03<+\9T,[I4SK(SDICDV<4U,W(<ISOT<>T!']7Q%(,8W89+$>K
MUY648+%VSNL,AK9\&>6/Q7E]UC1O;=+38K_>T2PJMMXW==?V>;CF.'A>6)1V
M3=$/#\I&/);D]RK1B.%BBLX%@$6/^M4#YVFF;JTU(8:'=*R];/]=H?K_B"!T
MEA$@+L"9+TTQ &_$'UC?,9MV@MZU!YHGOB0IM!T,>%D+'@:"(I!R DMR!I:S
MC]=>.DN45F2Q #C7((A]+*/Q*.YP7X<[1JL^&MKO=AC?JO_\45GNV(<,2.\_
MTBHQH4[TE;X"2(AL>G&;M-RXG#Z/:WTXJK.?Z2%W*-6-?H1)4<<"#S@:*043
M+'!-X^I7RFVM4>OTZ?;O33C0HBK>I,&2ND ,?N(W.+%N<QYN]GWLU@+&YS6$
M'$%# HBKC0C^ &W(IY%Q98L) -QX0O!?]J[<N]U22AUUL.V;=J82B.P78&,[
M&!_QVU!;%/]>NJBUC#(=TIG5.4#2JG[;KM+[ZNG9QD2 =P-C<] 4AYJ/&A"/
M:6CC>1]\.P,?GZ<>[[I4:%VZ#U#B;4Z8!R#(BH&4>T=/#V+.DGVY92X 83UM
M0X-%ZI2;8[Z\L@*3MMU/:K_I4>8>Q08!?:=0C6O>KBYM)F?'S7N2Q=?YD5-.
M9YE>7JPNB@7CV:RGJUZ.N?U%%6W4\<O 4QB67-Y^U I-X%HAK'/]H[C!4"3,
MU+C9Z:[-9&M&2)_O^N1 @-1 ]G8X,WY"5?Z0Y$4H3,7ZPG1ZV*PL$B.@% )F
M;(GTA2/K@Q9G?&30:]^M*X?>@UI#OE^E2X'=^Q'7.!5Z^GL./X36"V&I"Q#F
MOQPB2PVG]2-;CI/T[A4/066W5V4E.B[=T7Q;4I(^77(% 'KXVH)56Y"PXV*V
MM\O%I/'TED_*@'YK[)3#C%@=%F':52]=+N?SB8R>;J$O9YB"@WLD+%3SG!8'
M#/M;<)&J]@]O_W8TS*$AE5,EC6"0742;:1?@.>\  <VXJNM]')&G'.(^RG('
M!G5P-(A*J7F[G$.MHDG:HS9(9GRN^Z6RM39Z\_LB@\%,/R5?\=>;J!PFQ 5
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M\Y_4<Z.D C#W,B2)%^''VG7 K6#4RCF2-HGSD] "8,G+ J4KHOJ'C.MR(FL
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MVF0YEL;RELL-B4BIE-JM&2[G W(\-(O\BV(V6:S@+9H*GJQ3:%T=*J >'O#
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M>CV11]V#%\W?7S*BA]HLMKZ(R?[=,LA:M*,OM;!,XYA,S^:MS!X;^1I!W:3
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M-EAXH88"K! ]>_HW9P#O0W_^\B( 47+C:O-Y!,NBT/DB'+$QU/.\B&[?3)+
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MYB\J2]B]UOK&!2GR\9=8+V,6#.A$\_T#9CNMDVB*EA;EBR0U[Z>;-E6^/SZ
M6<QAWC[4D>]UGA2@RU*]_\)BDVY:-Y1EIC)8!\6E)+9:+A9Y:?4&DL[Z<)W(
M]-HZLM*S/'^GL^3J7P68/=#^HK%-ED=@PS-2P&_IF',ME@7PA:M;SN3X<C@)
M=M_MSE3D.P;2JBJPLC<BT&CN6_VRGHN'#9>EG#J,K=Z%F"]A"S)IU"7[)-_#
M;>[&X6X[3F)K-'H2%\":#4=L(A=WY-T3/B[PB'DDV"U:#K'W#>'MV^1RU*P8
MUPPV-&3E:G)2'GD% 6\B$]@N>=526BE1F%$Z4%'AW*(PZILG5]KQN8[5E+2S
M1#!/K,(Z'<>&;2(?UTNKX" L!0QT>:RJXPL0Q."5W0KNO.:"@N!^A#3:B5,B
M@]RB/K<9UJX1<IC(D>Y&)[5#?P\QB:WWC%$ 6&)4IIVLX@L"V@I2&@1*(\;'
M3LGLL2JMUT7:BL<31N-C"CWZIYJY'W/'?)R1*O+?/3[P+$U0LZ]I_ 30C4P.
M6<3J&?@H8+//9G]2,VNT?>A^:,(QCG[7Y]XM)V>[]Q'Y/[$O ,01X$1<>&WB
M'6HP5W[+K^5';%GF)%"$?@HBZB"WJ8MM$9VI9EW715#>"6=DV4JD9*>*V5&D
M7Q.@S-4/N5="].P6%2LNE5&Z>3:K(L4\GA7U[<E@T8F ]46K1UV:Z0^(L%]?
MAE$.6E1CL^)@"XPG8^W%[F,D,&)5@%TF!*$J&#K3E;#&E!]=NA86J!V+RB(4
M7!R.G&KUL,<9S:ZOW>FA_&TYFA3_MEW4C(4VUK>P7'1C#AW](AFKZFS 7KDW
MZDGWEE:6,04O8N:+M^@Y/,3G YGOVG5&8>ZJ_XXY_\;Z 8X.C[WMU?I?>WT[
M+#B_?!AA JEK)&RUJ%(1GZ_WG2WC[NY%4/U$YR4I>'W2R-[T4J*(86)O_*T\
M<>:)-M^.6,R=K6)$J^:G+ROU<#HBIE(,<1@"U=L#[LFT,V':)Y K.O,N-%YC
M<95G1A&P, V1><0^^&(9ZU9(#C6>4 Y\[?4^3FQA]8OYL2@\BC??1-3<1*I?
M!5=<L-.%#;[R8H+L0;^B;]+.T26^Q@O(*@/KZG J]%(/2</D3*<5#4>CK:90
M9TTZ,"&<7<QWR@][0=LF\R(;U?JU,2,TK^&+,HT(_6<3P]K3)D3HMP,8/-OY
MX X:6)JW2J(C;$U.@J7^!##C%2_TKY"-C-KH!9NU7CK2]TH+NS4?6G>VP<A4
M5>')[,YVEY5,-=$I*Q/?ZW(AA43]*KX_LQ$X_'QK>>$UG5Y'?VK+818):0DB
MWN#FSVE@UR1($20'$NH#/KLBK"GQ)0D,AU(]@=;!5@5FK.\2- AP13MCHEKB
M":=H^LNP#OG#L)K"A.MC] NSVY+0!OWEC VEQ<<MC,,D,B35([3HR$S;"(X(
M*.3IV[&>L@5>33%<CVI[$:,>*W</TFF 4^2M?!.49I=;Q+K]T4]9.['B4O'<
M^N5+(DEA%;GPM-.IWM/.FF+D*,N2UB_U I#[;SZZ5 NOQ^)737[S%NUL!!.+
M.LI--*X<ZB/K5U>U%*L(%"7(0*:,9]DQ.,E"?X7B,<_ ^B&P>AB9MXLL6#?R
MB#^Y:J-UM>8RO#$*2U%O<TV\]ET!KX^GI\SA'\:)0IZ(5^ >>5VL'90<-3]I
M3&[LJ+KA)GGB_#P\0UICJ](G?<Z60_]OZ'T M8?["!.%8]CA >F?JGV ^WVI
M1^4NP)LAU+ZJV!.8)5P)!! T6.G_YK[1*9@(?37&A6N265\\#XQ[>BB7?D=$
M_ACJOF#LDU:?^$$Y'+G[T_QY]])5;\9L6NM=+N>J--)+:]U94BV)ZZ0IZ+VS
M-2\6-53I:I!^U8?.5%J0?!SXR)S69:7?)*]3TDA0J5H^&J=?U>YP9VQC]W0Z
MN3F3AZ?:54KU9Y8&PK"QX37'7L<_%)L@@K4K37S6NC8H4.^B>8.)$,W-L\P&
M :C6\2=&1U1*B8\-Z)+WL'P.QR(%W)P<#*D[35R>SKI0X6KF%]JIZH_79;G+
MX7@E<9CL3=1[JUW:4>Z04Q<-!S-OABYN8248TQP:--R>8"T4PM;$!'LC1#.+
MS+5.G2SCIQ+\\M95E[U"=7W_A@\FLPNRT15?VP M_Y /!AM.1.%!;R^#3M5#
MCHW&:S)PYI+"$;O*Z?_,Z,B=H4 -:Y\'*P?+X,$[@<"BHI)@?J\D>WW "9?7
MX>[Q+GC(THB5(M]S#\%EN(1 C48$UWB^"!-Z/AXTD0*L_T=B/*ATV%^*E&".
M?'S_C:/_%/XGHM$_[OPG0-6P"YJ^KP(Y.(*S;_'\"BR/9*"JRXV_[3HR9?VF
MVG]MG._=(_0WZ<6"88*BUSFT!BIW")<%G6'D\;>"JB8W^XNN[M^D%[8,#RIY
M]CNU]'6NZJM4%M$/A$Q_W/E/ .[3,E(H^KXV,5^)V-<2^$,J^X][_PG(?QT'
M589R&0"_E[&O1!#1',Q ?%6G."Q#!U G'3TP_'IMF#.@!_NZ\Y\ >%-Z*);]
M78;T:QG[2@1YQ87^-/W*\NBY[2LO2=)^-+>8B^8S725H.!KC_T7T4SAV1HY$
M!,>^([9+T*@END]/I>1)%G&V/?^$4#Z=&6Z-W8.BREY0OO=\&1WQ')LC>/I+
MYX74 >V7?RI]N*#-DMU;*3&:ZJ\<+EVMV'\<57T4"^G^GQ#82]D2:N@KM,U_
MVA ",-4O-SSLU<;>\W]_(JA-3([!?-,D"KB)LOTTYK5OF)1FFB\ E5@)*A]1
M>\2%O2X_6YUS9O3BI%](H&YGOM?C0?E,0X8:C7;S$C\"?B1('21S Q,/PX+=
MKH/&7B'.G$^]K $0,6ZS0#2?$/H\/,<S/%M2P$6G\!#JY^)4L>QLF$:A+=<I
M2^U(YV@9L$JQ<A )2[M2[ #D.+O88+\,!AO;7A6USU2^5\PXQD4(\"+I&:5J
MF2:-$J8T#2D WIZ]?P KA_6R\*MF(E9C]H@&V%LT.**D<\"PFE<)'8TR_L;W
M@QBAWRG\M?#3AOE8-U%EWS-4YOOJ[TH7XSZ(Q1I16_CIG2R!7/'X+)/<N$SI
M^?RV!9J16\DKV4HZ*GPI.K2>64DR>\H[4\;5Z*L7@"IL.6OOB.PO0F=?'W+<
M%R*-<+MPR<(DE;:=*0%&2YK16A_P68GR'3"^$):^ZBSUQ$^2LE$45>95@/N1
MQP4UN%Q#U,/Z<#(ZS$.SCG*9K&M!04+"^C$!UV:"'SYH[^H+-!Y\$@B'][SG
M$N8*WM:##@1/=L5(OCOZM28(#"N(>/7YF:VT,+3Q!J$"XG93%P.*,W1OOJW,
MM*._?N6RA<7%MW&2KYY(^E92FMN*JMI0BIM(/3T,)S._U2;\.H8^;BG0Y3&E
M#BPG6%W@6KV5?4W!:I8J9L>%9>_+#\LCJJMV<Y&P)?=*'-;35!G3?N4(!?KK
MRIW]4-SZUY(SGS?EP#94YGL*?MK M>'#1#>MV55\&^]/ .*\X VG35D>F:+(
M^YMS!<NY&Z8V(T5K"UI]*N-=4T4#\W+1K;J;/=;/$\0JV>,IIP%_[#RR=<\[
MD=^48>*.%D!,,1F[/FN(5 Y)\12\<S-N>SO>OIY&.6V>)91X4:BA->'U/8$W
M3V7]O%D1O"9"PS.?*@K0L"DPO1 .I!]Z,H8867+U"G=.HDP?2N2V?J#DAQ3#
M5*SP#YJPE'0&#+%.SQ8E3RZ4&P2$O8HE\.NF;X)G8+ 7Q[C9 V_':TSKW*FK
M[$B@ _O\:<M->N[&9/T(C0SBZ$NDC>\0G'KZ!(F]\9<WDMV3GO625Z4\U-3'
M$+J7&?VT)O72U3EIWW!9MSR)9W[H].T,4(+PUX(YV$%3ANS)TYCO>8JVS'53
MJ)FO*&R1;9XG%+0M/>N<+6]=(Q<*?]ZQ@#?Z.G[5=+;V0Y"58;<SFT=R_0H.
M5RO;L]%;4A_O0LXV07EK%ZU>8H^58/;UT^"@"AM'2*9"D&?9M>IR>"'Z0X*(
M-)QX#;.+43-!C J*9G1Q/$D1)*R9K7QK]($9"==U4$NL;F582["5J^^48',_
M),=N"[.@"+]N(H-DCHRJ%]E%WAP?B!Y[Z0F:S E]G%H0LE!F))W!,LMMI*VP
MCE71=]12\(ET[F.",'EX7$7B+7HX7:7]>$+98E&T[K3A"D,WTAEN8&]<BAKJ
M)!6C5N[!QKJ1;(=7G&V6E8G*E).>@K-J:W*7;$";)6M<9L&1H48'#;5B<<L;
MN4N[5]'0CHYL3U#*MS,ZL1,;RS 8ZF(Q;-3RZNP4U>_RF7\ )1K'=%I/*]_$
M?2<\@IG>7A6_1Q'X3&:VV'ZEX&"!7#@\:&5)(;K3W7\"=Z"GBB(9A%%)EYWD
MV<2-C1I0^(9Q Z?\+N3U-%1^;0G+\E:J+(WY,:%#22QEOLD<&X25();.6/?.
M*U];2E5+T54O2?K10#LB0P1.$1<>TZM'">&YX?=XPH2I+KU-:1\,Q@BOCF-3
M9Q45E6F%RS"32T/#R9EAQ_'AF$]W1D]KB$\;%$2[.BE%&GKQ)!E][#GA/+FS
M),'$K5)U;%..!ULDCL*<;*M68DC\%WD1(H3\"DE?\DE?8+:B\9J4I=P(+^&\
M_"*!W5"!#(0NE>'DA30)@"&(#[Q''PAW)8TBWB*?P,B3$T>#D]F24EQ>U,Z.
M<@>1\ID$R^)[2:'S2_>7K"Z 7M6G8WB1H>E/K,5O<-Y9ANO"EF9WU.='00A3
MQ7Z)^[#RT=DY'*CP&@US^BM2S!_M@W_JH\E$-(-7[@NR-_@;M]._P%^2<?C'
MP#'-R==5RS\:#T+EPOE02F^S&E#UBK\BUBO-BW3G@,SSGXAFE7D)JJ6O-6&>
MQWG)YT!]> 7Z_:>I%(Z_U,>0E[L_XZ4""A'*92B35>$6-7&4Z2R:8E!/(=A_
M)*AY^!$J68,H]/ZK,QI9YPP0:MSD3[G9O\*_IS0 _V:7A* &^U^=7:K\1O+C
MN8N<T-^D%[./%8I>9_1VZ.Q2ABO4$#QF4$(*1VK:_&]VZ7OP;W;I%_AOSBYQ
M8%?';.53)</+<!A.1NU&!3<7F3REA$SO'S'BAR4'-?50J-6D!U"\B"CSY4@3
MX30_U>,:_;/??\:>P%Q)-DB.P75K(@4]'9,3RZ?5,,5(@XDU!_S/YF;@YD86
M-M9ET0+.2C_A4\%RDLYAW[@I)_".W.:5N0>Z$O8!I@5\;/W_\#P 7IHG#0V!
M:24_/P\R!ZUK,*MI6WQS-V UR".+K?QQUG4@#AV$M:+LUN+(IZ(>GM"/985M
M]S)9Q%Y+L^R6:8]X3I=*#XF%V&_&DQ@.A=VS1VZS?L07(OU89$&5YW4Z#6PX
M@</;:, 8DEO1Z_L4;$KTAY2^__SL,8+T8JM*V#]_@N9G/&, X*T7>M\@K\1*
M'R]D.,C>F27Y1=)AD<6X34L^>;Z4_B;$I;L:-/HR1OTUED$??3A6S 7?KA<9
M."]N^,(LE7CWK"S=B^"'O1[70)!.R0][X:KE0KB L;[H.R^Y5P26K6EB".SW
M%1D.4WYX\C^>&(.;&P4S,?]G)OZ[:C!NR=W\\4,;DXX;<UBT[6Z/165,\J^Q
M&"#?UG1@)TN?)S1LBG.@HL%IU+J9\L"< 68I</EZR#66&?X+UZ6H"<A_F3F\
M%]F.Z@UR1 ZCWI:'>#+CR%TZMW]XXC\>8O]V:/!GIW[):P6[AN=2[X=8^D<!
M=MWXRK\&$GR? *R+N3HMX838+^(5B @<IK%+I()*W8]LQ9]*F-1P8F?$4A::
MDD9TL@,NJ"O?)*3NEZ.81]?&%J"MN18CNDIPTX>%)OK5B?K-_+B;NN3WU<C9
M"C7)M7YX$7Y\^P4:?2:[@@>!"NR0TL^XGC!+!H[(AF8HN3Y8"EJA-]LDHYZ<
M?4?W:ZOXE63]&,!?[QMZ^2-7R:#G\5,^/U\_/1),W$#O@ZT';:*E)O0,AY!;
MY?^(<?S1*)U$3]#&5'S5['G\6?&G_"BX+FQE]M+AZ"<G]'TZ3UZ0X$>%"0'^
MF5B1UCA90^HJ]!V?M11'J.P$7*[+9S)V>R+,F#P'OX3M/QDV.@-?EOZR ?](
M+-:A 55&OS?Y[5@,(V?O,^+_V6CLW^CF"_PCT4W*A"9Z4^IY=+4[7=(C)FCB
MB-C*'?XFM8#[2%#7RN"R7$*$H,;XZ@Q3+^];J.IY1@  ], ]:<T#.CA'8 69
M!T+?6$,4W?C[^:5V ]_S91X:*^C\4@@KZ?DRP3PY5/4D.+;_-[_T/?@WO_0%
M_M5H7P 7=AR_9YS@/(H$9]7']SS""^/\#5.K[=JQQ(44SK[_-.E_[0T-S6->
M%,^HJL7CGR#[\_T;F.9%+V"J@-G9*1((K[QUY()D+;R>N$>#O8"76R?<#^:<
M40,0,=$EX,[$"'(?X$MOVSRFDI#V6U=[:+JN]N@?IH@$?/4UMJ_A+[X!3+ZV
MSO!><8;X^/N.(%H_C:5T8EG&^*J-'HEMREUTIL093Q^!>9[#-L>][6/0[-H2
M1BK@JYB=;X%?_YJPC_"2P1;]H;9,3?7EL?J8<L"7^#5.K)$ERS@.8V#=2>9>
MUV&R)39W&=[ZFZ0'[[V[R/KI8/+P7P4_AMSHT61[KCIPV9HJ"'+?0!#C*:+,
M!HD(L:M\"4(TY+2^-<^2VPK1LW5#U!>]O(@46<9"@">/]6VR6LQ_.U9 ,9<:
M;F'?>4EA %WNM057K%/JNWU]]'#]P.^FU?[BZVVW9\45[M)>>5!WCK]B%)A:
MT0T+QQBG!!U9TA?A@HIRK;N@(M=MP^5\'MWZ831<ZUC@F(O7:4ZMYO.(?O"3
M?^&>76I6L3K;NMI 7 S;FXN[@+?N7=:9&=>XRZX0]G'.IWK)U.3&MJ7#][(M
M7D@UM6I/J"F/88:<0AAZW.S5TT?TM(S'"E&]OC79+$T"1^-Z8&H,YN,NC5+"
M9Q;D+Z]Z!Q+4Z -NLX((C8!PM9#C(_?P">!Z22U,3!G-N8C=$VIJ2;(>FXL?
MF3_JD'_WW:]G_L7K'/1O[@SWFEDUG\=]BS?5$LJS>&J]QTDLX:0%"PX6DYAB
M-C JKU2%;(;J^;NVCFJ.7Y6R@*2+_LHM/>$@+_?[F@_L!5ZK\M->YTZY\<R(
M:N=1PG7V!"P=.0GS$2G D/0[I70;ROMIT6T):'8QP1DE_BG9J>*%*I'/3=K+
M\\V$ZC/9F+AO!B7;TV%=ODQH(-66;R;9*':-'?3>GA\=7HHEVZN*BH$&I$N;
M$\<TJQK<_.@)S#(F>VD9/CMF'#WQ'3R"DQO]]M?BS-H#4OU3A;['?7]-[*^L
M(^'+$WJ6.^R?QWZ=D["ZRJ/%U_W<KR!-QEF)98KO94SQ/CH1#_')G,=AZ2 >
MMXWN:F5(X;6RQP!H8WY'U$M:3(31]WJ.'X.&,A+[N"1[,A(DQ(8(OHDQ_9@Z
MDG(A8EMD$*R:0V>*'PTSU4..4F'6#.4[K;>[$M+\Z&MZKW/W,93H!>L_[8J+
MH[J?$E]R/9QEF&9.C&P TSS;JBZK5@DNT JYU(YJ3H-LH%'4))K.((RSM-,7
MP$-UG</QFF;$\SB'I3!A B)6)ZJ;I/0 .@L\//,BB5FSQQ&VB\I!* )2I/_<
M:L[H2]97=TY[-;QK/H_^1L[<^-"CLB9/+TZ1?8^?Z<P9^E&G#;E6XG4V9S/@
M+\%?DS;;8DI=;9/W6K'U__'7*UGX>R76IZYOS^.X4K*A5 LBSCGO &[51J%V
M2MM[6BNVY#_M8N#ZQLA!?5V#1\(*ZBL9T"&33X)&<4KJ_X;7WE \!R;2_SMA
MB8_O?]X+_?>MX1?X7_W64*;":>;,.?P%8(Q!+G&2IT)00WU]8^,G ):4"FI5
MT$L.H)UEIYZWYXN(MS=\SY>-9=[^&Z=^#_[[XM1_-<07.*<A$&$Y*/L%*#$M
M$.JE+RA:(72)B Z?I=3_2W);Z&ES8VO;LIT[&%RR^?%M40-23C.2QF<G _Z)
M'?C!Z[LP,?/O=^8V74>_B-E/R";<\]LXEZW$2@5>7^#)O$]-CLBPH@C,.9O
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M']RS8X&T*)9N8''IN!XGH?HH*LDN,._SK#/94!LF#4I&S5^A\\E/4)+2.)W
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M^]/LLIZ"S+"A!6(IK #<^?;C;(JX[J-L663[6N;<F:,_%.T' #"0C,;M2.0
M,)K1&.UGD9)G/O^XS6>._3PD;5M+SJ<**1HV<1QP]LVS0J%OOPH]QHB8%3,
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ML2#*0-:/=1>>+D A@<$5&Q@G$;8F&71)J]6<-9]*):S]?M]G6WG"]7AI@YZ
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M,_@)*Z12+&>T+6NOI*1T5* =IAY3TRV+/Z,KH$ TI8H5-;PI%GS_K@%<:+K
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M,%7!_-D_JISY"VEZY.+TO2*KG7=\YHC%R"5B^CGA8Q;%>N]D7J ^[;V2[2^
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M$ D.X:GGG.\[Y[Z[[O_>/7SGOVN]KVNM7MU[]]3NWEU=755=M0=^?6=00AN
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M8,7RBE;]0YN.D2;@2B#F(3RN#^39]62:+,?=D<=Q"\?HSN15=5'"-+#/M2M
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M+^XU)E.W?*F"24\\"]R?*8#LNHPK&>,P^T7YO.]1WI3&Q_JNM-O<+]:YR/8
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M_;MLY&?GG@9(4H;_M4MTU:>*[A^7U$7NG1*R7]!:]*KSE9["Z>)NK-C)_TR
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MPYY6I35D/:#&<;^6K<87]T#F>+9<A;+'D\^)RH-!5]VBV1NPXOJ/=MZNEAJ
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MB<W@52A^Q@EG=KXA+YJO6NNJ6K(9?,DO, X@JR6^HTVM19MJA:%3NJPY3$.
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M%7_<K-WNR0O>Y7%@2-BTM1R4E!D(=G!_Q3DXO^U+,6>>QL]V<\0D*ZI$9WC
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M=/_@Y@HZ%,L2D<@W9U<!0ZU]U3TK:4">0<RYJK6[_95^0,1C\Z@;5(#8+87
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MI6>GK$#WEUT<KPH\9QD=9_!7WQGO(A<%X-=;@6"8?\[$6LD7(B^(YJ=&I-[
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M(_*[B4>GGS" D.:D%TN$B(8ZT@9W"ZH3^D\S-&Y\=OA6#YLV&Y6ZGK=X7-M
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MF%C7R8*13Z>/HLN6OA ]6NA")]S#YF%\ /F?PRZI2=,3]I23Z\%/:^NB[FW
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M5[WB?VH"/X9#$DVO\?M=Y5$U3(I)C"-WY)R3]1NNVM-ZX!1I&%-BC'82J_O
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MK!\M"T_J[0S'4/>0+N3&$EN^$7ZW@8PKAXGZW[MO\0_KQ468\T<+I4!O7ZK
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MO1S@H5+O/6&L;6!BMRLNZK*>^B38-%-&!>C])-Z6(\V@GS66.K1\*464BH$
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M20?(ZDP]%5_0TQ2J)@.]7#RS-F(P05V93R*N<@UW17+XYQ1E34^NZ6Y<.^<
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M]CHRT$DVQWK^0:>M84D*VK$L)R%!]P.(WC?B:'17CDCQZUB-2F]=%DR(@*$
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MGG+)J7L# %@+C8D21U%1_307)8S<Q7,5EO@9&.=-*RJH!E=1=5:QKV)$^F+
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M@/Z<XGE+;T=0"^-+@,Q;,$+I5V3>FB(*@ :JI/7L&F[(KA\RK#,U#)< $;(
M",UQ^W6@IT6_/!=6NWWZ\H<X>*?,;\0*808(EZ+D7&G@$WX+!K:<'=ECI:&S
M"$P8*,#!:5M/NI=&@J!6[0%%[>I_5T^Y)$-)(UL.W:[]2W\A]POF$+C0%";I
M>V71TW1;*$ ZCPY;U,&^!4O61%PJ46BNISP??/&4@/-#:<CHKR453\&0(&-;
MH^XGL$P&[ISE1PL>"( %D2)4Y==PZ\/SD+\Q4")HR&T(\!6 ?&DZX3Y+',0<
M; -M"E^4]_9O_FVPOYT8=.DN%Z[TQ_K[$_T_,HO\.^'-UXTVMGGXPJB;XNT(
MO,&5?=UK^*'.%"/*8B%>:7L/TQ_VBOP?K[*D8/_[D_^J2L?G;%'PQY#Z_W$5
M0%?_S]/23$&X)/SS;#'QW;?\IU?F81K\3TN(-+&RM,$#@PUK(0]GIKC&8B5>
M:_N/5XF.E%_,UO_-+6IB,CI"*(]PJ:AN+Z,=%F(T#(Y$>T4+N\'1K;?OC!!>
MCHJ6G2Z">'XV:6@Q Z[3;$DK12B1D@;*^W>C8;$JX;DM^K8H\2$6%PII$K80
MRO_;\)\WZ%I?^Z3=LCD\OQ!!33BA"*T7[8%>TOJ<^QVGA@R;#Z,6?(<&W]8,
M#$ZN\RE<%9=9^-):9"3-=OD(];WA("3UC9Y%>(>X9,9(P4/K4P+/OL[9%-SR
M$%YYUH'PZIE\UWOZ/[=<IQ\;6 0-#&)^;H&[5>0YZD 1 JM"D*^,,H<,$T8R
M"X.M"/^H@9QEAV)#47#8465]LM_[3QD1)<IZ]W,2%H7;QN!^@1;OH,A\8C3D
M"M(PBK?J@D5&U75!"S/]E+*\'RT3)HLLA53T<KVP]7Z,U2,W0Z;P8V!P)1.#
MN-8U@/'%^ XU\,6"N_R_4:L844'Z+V8WSN0DDN').OL%.K_;YTZH18\)XM_@
M0K9V94L4@* $"1D>4K@PN&@M%P?K,PS)O$-?%43=\0;>4HMR=RQX5IC7D&Q6
M55H[/QNLY>EC8<V9>C\GM%X9R[/!L HT-!Y3H08;FN@[1'DA)C_TM5[A?SAL
M#X"]:K7O'D]^I<=<WJSC0ELE:V%Z7'Q*8!>-="O: ()N(,DAIP1O4_SN1<1-
M/-Q4XJU]?UV,ND?&::W$B*\:GU2N*;;D6S-YGQ( DR)7R4 )3:E]K10N3!%R
MJ1+VT_F=$Y1]']Q=?FR0+'H8<$I/:WRH.U+AMA"DA&0B$=VF37B2<GB2TGB2
M0E]J^2TC!FDX4I\W[<ME7GY7Y UTG?&>=I][NW%)8TWBOE%PN$0K=[N.#+10
MHO@%DBIN$L09C'IS-QTV+#E2:/9)%P/C#$87&]]'7!44- 98L_E;'<5J73NW
MH3$[D_E6>6^Y1@<^[%''WW?O%^*J<F?$_T\ZA:IR!6N;R,[6-K^A18T!N%T;
M0>"WA:C!(984(+>QM/!J.MM =@N/A2$.<3[(X'S0L%YK>9$%K:%O*1;<,CGE
MJJ32CU8A,P34H$PQ("-,R1+C.GY3.CADDH5I4TG (C]HM_S4[<-5<(8R3-Q&
MY42VYZDQ :VRML M8)-P-/1.$,!FNB9VJB9,;-VR?<T2DZ40!<MI:".^/V$H
M:!C 4*\L-7$B<BL%Z2* T\\T&@P3QACA,7^RX ^+P6.#TL>/3@GFW '2:]=R
MCDJPD(:Y?*<UBZP/)]3!:1'?7^:T.?.-5Y9ZU-OZ80I+5(Q*+OG5VZKIJD!V
M :]=HE N RFKC&;#C/K#"$H+\O8=8[ I]I<\8%J!M+_X3DX\XL63RH!OQ(H/
M4OZ+7D+LWT('UD_N)OY=]]&@?#)PB,$%($W,%ARKHI[[2M\ ]?^Q!D"5\-YO
M8M0?990CZ$R;U@^L.3/<@J@*2H.PL^<6PZ&%#_0MZ+/8>70SL>&4(((.O^Z'
M>T]Y:X.HSG6\OJGE<<)^KF3L4"+V2/'<8%K@?"U[3_&$)>G"F2 BR>; "@/[
M_"ZUQ&B^?]VJ@<3@!J$U9Z_7G^^>V_\T?J-'>BN+!CA>^0-.LKV@ZUU^__$.
M="Y"0/X5P,7_L@;2)BSON3D*:5FO803/K=$DL6&R+ ?>$3&U6OKV_<RO>&,'
MV?6IPV]>:=+@'0NCIA^5[NF#-YY3[\HM0&B&Q"W;U@?.K;?JHFE5TH88=I5L
M+S,P=O%$^'OM\67JHS? RVFUHKB]<ZAP9)81 $I>7;'[4E>']QE0E.](]&<7
MH%#0KC&$A1<!$+;FL2HA=,*1^S6RG7L-8V$.#4*AB0#6@#DF-LTM\3_A_M7.
M?]Y.>I[]4E#3XO]GG=S&J+/5(?XVWU>MTWC\ 2?]UN^CB?GU8>$)TD"Q5K)S
ME<E =@DYH]=IM0PIE50&T4\Q JUGG\2$Z*IV27-HI!6*5\\S\/K<^:0/#$B_
MT@.F_3!CT7NPW=BS&6"/TDB426ZGR3/$VIOLW$6/*!F4O#=0T,46B2HR1O@%
M#;5B2RX/L0(^RP#V&H;.;9(=X?\;==O7Q;VT]>?34SG32U\:<U9-9MXWJ,7!
M0HU*5- 3^1W8?&E<4;*2AN]CR\$C5HO=],"-;R?)2OX_U"@$]=8GA'&[L'/#
M?,QP2D  JU22FM[. TQ\FU[P_=(C[-DVD8_>"$W"7KF])$MZN:Z(89A$S/OR
MRR-6JH,B4&KR*0&O3J: 23B*3P'U9U+>O._QM#X/YS;:6HPT]K0S2KL GB2;
M-$P7L3WK9LM/6251TEW.;S_[K;<U-,DM8LE'EJC- (1< ((6@"]-4[]">FOB
MVM'-7R'=F>_;>:Z0II]ALRW\%[C43PDB87^;FBW6]*US&U2>!&\3+Y$/,:/$
M_N'J+<CNX,\K:1'_\?Z>/I3WOS]G_Q<--NV_@B-38KURS*],?9W/+^@20[UQ
MOEKN-!\(O1[,;\W@# ESAIB.Z0W;+T( Q(8(\M7X3&.C3.D]^/EL-OSL$+RA
MBK@=I(;GRL5:"$RK5I88BWE&Q0)E26UA'B^V$,Z@^ ^S6(D3A@&D-Q!\46#"
MC9#&D@L5X6$9RIM&LZHCE.:A)6]4*0@4@M^3)77A3WL:]"/77 B6W7KN-%1:
MT+7FV!\G3$C/J%I+3,YO34ONUSL6(N#NPT$ #KY3 N,C7HTC 9AOB?6, >R%
M,?<0#W1&=D, R[C.@Q6([5CXME73ZM(O$59_\]\(7N-L#E6F].OTA!*&&2/N
M@0W# +O&AD%5#(*+4,*+G)'#<FJR *I 'A$7HTHY/= Z#=!%?WA:%@')HC<\
M3LZ[KVJ\>H474#Q%*RVKA;,:*J&1%@0)0@\^9RVQA8N5GV.D$)AVQ(;7>50G
MX4VCQFV=OYH<_^IVLK])RT&B/CHB+\S%*VSM,5UA2>3\3/]XE4\!O7__C]FG
MZ+7L/]?^F_NG;MM]E7;;?[53C0(?G]M_!77F7T&]AC)H]E?T=CB/WIA'2#_!
M>Q ;H/PCV=4=7W_9^\NKG+G&$).0\,:II:-?>('R/#;O:7'21YT2/ L+&DHY
M)1"B/XZU)BRP2PTUC2HVQ)>GO?V"3^BN(/)=/(F=)Q[ZPN#%K4QBGHV$YXJ^
MQ&LQTA0**_5,%6"4=:$7HP0&[:+]EZ:_S4DM0FBMA4H.2K&Y-BT@_61=J'P)
MS@;S;=L3M_>+=;9S"''$KW88MAG&A-MA?.)KTK"MZ[9D(TH8];E9[9Z+/K"*
M$E0*_;&5J[\E;602GJ^!+4+B2G]M]J9;!W$,2%_<+RA.KGN3"^(;*';69;1D
MBQ0??.'<>_8/W2CEPC-;H/]"#:^>1!F^WPC^:R1]CJ9M '?#KF->8'4\"F4-
MKP@^9^CX;S<(+/ZG]JR#WQ?CHMN8H\08K('U!G[Y&W]X%>AB.BM_9AN*2H7@
M]>"7T;,2OVJH\]J&J. 4< J/(;*QSM\,$; H'HO!42,7%T+FJ+HG>)0Q@ Z:
M/L,N,RWC!<JD@K5-=#+'QNAFIDNK)9 P%XJP>_0;LL?D8(^!K!D]_2P%%,!M
M.J,0G:H$$7KR@ITM-52 1N+I\."0\Q(@S(4J!4*:I2.U32(* <;>A^1-ZKG\
M8N7U+U98=2U,HC\'H9L-5^4[T" AD]RA58..A9S?&@B+3.&2OH.C<? /R*6F
ML*:ETEA#C_Z+)GG&PJVEX3E+%B)NVXLGZ#T==/'JG[CM0K8*0M=:77L9-*+0
M A@AY'$4LIU.+]1H<DGVF'Y=1MR XR"Y7FJ'!^<!9!!CQ/<(SWABW1@WA*?Y
M_'KPR7KN85#PGM)YO/;S-Y;:"Q.<W$N-9C$V-!TUIKSE0&D V;W(4<B@/[1C
M+9Y?B*S^A5&$"G/KW ZRJ]#)Z-_T8%%?ZHW!1OK#N?7N#BW^9QO3VO6=?.<-
M@.'[6:$_*>7<Z_8I\/DZRWE*%O _<))O<HE1?Y?[ZWONS7J]&#GF[_LA-&W,
M^<^^BY_=4L/2?K6]LO]B)[U%Y9'=V2>=*;%F+>&6/6>&1?V*1PAB.J!1O;2:
MO$DT77*^,Q-B[VR#6H([AR3A <3(PV3?78,V8N61Y\JJ]<JL9WBRWB:$SC1B
MO8YO[7I/*RF4YIU_41"Q\FB1Z5'M,1[$V.,E,+(12'FK"J$,>#4) 08>Q!\/
MFU2B=5P\N)_X7IF<QV=K.FE9_Z1+>0J-9YNN^WY-^/Q\'C?Q$\FUQ-H6?S'!
MD&AS#HL,V#+J_K>'R=]M(/J\>B;9OT2>FU_^^R#B3U5"P[J<4P*U6[_^UAPA
MB3+A*8$ D[H[=3372K-D0Y]+Y\2N(K]ZS3YK#AU'MUJJ>9(DQCZNV%(\+JF%
MWRF&1F>E-Z$^?31=I**'WX?U\D,>R_2L*8TN;)+D 9#_<?2EA<X*5N78CL:-
M:&>Q+N583/O5K ,NFM8=_2EE;M+F8T.F5A&>@K=SH10[O)%?(P7\3@E>TH8D
MJ-/L<*BNY)T2^%Z_C#(+T+ZIL1"7OXL3V7G+]50XX=6[=2$V28QF#!>GR$W9
MP^5/+T WS0)48V(Z+>GW)3Z?),342W!%H\*!?+'TZ2R.]F>]/DT1OEI9\95C
MX%%P<WQ<@KJJ(I_6)N:)1ZIR.RO-^O$#S$VSZP]NYBLKT'2Q+H/Y;(7T4ND'
M0RN8Z(?#525H-X&=$2$GKM?OBF2_6I>3:)F+^T&DO-I:]#75"4_;__GD\X$@
M0HWVOE2Z8E*-'NKG-#'K>S-KH8MQ/\ZJGW,S[V3N:=2&Q6PM=W>(>$FTB'"E
MTX8[6K*R(YU)_!P^& P[^MD[17A^'3 ?_[2LU-G!KW7IK)*5&,$=HGCGQ';<
M]R[_@P@S/GYU.U;.X"#9((]5A2?:"N:3;R<+::KC!X"OYD*GN\Z:S+*O#ZHE
M2H<*BX3SJW=L!0<)N&LE-;N-+8M&+N9WL2FMYS2GI/I4:/T:2[U?V1:E\$3S
M+FUZ@M."']<I@:HDO^..->G*HDB? [4MA>7M#G<M1Q\H+9Z9K%'_>*ULSD(5
MY:2:@K<[W,J\)^))->$SA9%.[EH4.F<_SY.N7X\!L7X= -.SC//J9HWJ79CM
M[6L'IHND<W#@KE9T-E/;1M^M#3674*>P)&=05 ZU@R=V)2S[2NX$1/(4@T5#
MH7(\BM:LZ14F8@Q*X2+X&2SE=F.6.CM,8@R2WSS37_+9X4U$QRQONNVY^Z5@
MSJT5QWM=*XHTZW:C>,W2;)AQ+2N5>D8[/.#66V21P;Q]NQ91ULJUG!<#8ED'
MLZY$.(]?R[[0FUS-$'? A18)[4O&KG(;.*1K;=*L=_;:C87>NP>ET+.UBX@^
M)D<22?/%IV]F-7:$!MZ@V1F; (GT,4=Q=)25)9O;HV^">$C:RHE.;O M\8;[
MDS-'L:Z])<IJY>[="/I8***_;L>W^/S!F4 A$H[WDJ7+UL'-T;9;65_96P-5
M%4U_$BE*T-\=WV7)[N8A8V+//U[/E.>SW50P^7;.;1S1]5,"#SR_T4L"SYRH
MGW.*^&N9&%S[-*'4Q;N')<HJ* 8>YS2GTVRXWZW,:>9ET#/@3*!QY)H^\'"G
M&C!.UGY;<[?R^.P!,U[F6JE72-!8.^<<KJQNGCX;"%> KB9&,K5BE?@XN<UY
ME,*BVRAV6Q2!JTL*'JMJG/4V/YVC&119PN%J[)/@9NK#T*WD6U,MS=0DHG"S
M  C>&1.H&8]:*E,<.-_NJ:.R$\O""CEF<UYM.J72^4@88TDMV>L%4H<2U>FT
M%.B@$C'][+(2GO;QO;7,/%(&B7PSZ1H=9-SBG1\9 LOW&4 ]9&KT8;3E L\Y
M\V,2Q"CZ:53I0Q,NLR8'^+SM?24"5_:G4W55I;-WC$D0B<3PL 1K!GLDEG5^
M9.51#%2C:TOM?86G*8F!\_Y;9S1P#YN0(:%:P4,:BTPP:Z4/Z4PTR! FC>$F
MXV/-CQR+Q%S-!&:EJ]][Q>L4FL#2>G<3&)9*%Y<(C,)'% E)=<T^LA")\-'R
MWFS)5(<%J#+1UDP":7:^LJ)S8!B>0'D2K_8I049;Z=N>.7>W)ONT'7,;^Y4O
MRXDGP\,?H3GSA],Y017^3Y.^K=RV&EH\"6HDVST4J!E3^@>[_4GU'&DGY,9[
MDVK\AQL[LT;LCPEC'%8/3<1W\N*K#PV #SNS\</'W7U)5Z\L^ZS<<-JB7/99
MDZ#W+WW:'2.IX75E[6JG[NK3&H].RRYP(D7HU,RW@ QEI\Y5"4GZ*PD#CK[I
MM$..U[)(CV?802'<\M4'-1]/J ;,4]E[.Y_GJ22PJSNYA3[BY/;M(9/@0?40
M5?'U$PGS9B?JOV2)5#<"<YE?"U69Z(.SJW*K;ZLN^5[O8N>WQRJ&XE?44.C/
M6?_PU;2&^42 YA)&0Q9*>XC1]-'02N<Y(,%W">S@@XFC+UWDDK)]3CU-C?5A
M,@^.6UXO8<)>P^#K@%/HHQQN$_(#+K>G-3>_V\5]XF3CBH=??L))/^O+2CL<
MS;P%FO!?2RN;8F<IO8O2Z,Q7WMB*"N*F70N^0JK1^,UDAVJ4UVR+E:>.B&<"
MU#);D-)H%A!Y2M Q('@4";X*/DD8EV.B,./EBA>1]TAST)8TQUL^"J:HU'Y3
M9>N40'EJD.ONJ@0LT1^:CKF-/26PS9YA70OFXZ1*F@\Y( %U3#@9K"_>M(N1
M---P-N-R:]@%)@=D4TZ__],KLCHC<K8\<I-C#G36;?K)'ZZ\BQO+N[:NJ89_
M$;LV=6)2(47")$MYD*IH1^.^/\4.[25?_89P+4(%F !*Y_:E=Q.1?)]#@W9.
M">;=BQ_+ZF<H>*O2#P&OUH?RG!+4G!)P.YT2I*<G<JVETCT?@B_1/)_UX6+O
M#)D+C3'#/U>8:%1D06"-=V*;$@9$[_^\)*5R5=L$MG@HYP[KZO7L>2\%K9;W
M*G$+K"MQM9\0$3[!*Y\CT@6\KF87-9-[K[T#M65W:&NXJ&[3R]%>=+>2N&D:
M?!)IF>/:UXBAY>7UYG-TU-0V4GELUW9,4\-Q2N"R=$ -SZ;=WD2%O$]F5^[;
M;;YY2F"_<RC0-%[W#CUX=$H00+^VH^=>X7]<7)R1]8\,:)Q,-7?XG6MHMJ)'
MY'>O3IW_JO=_Y+IMF/![O#ND@GZ_R]SQP>]354!R__X;NU;ZU1@,_O.+>LA_
MF^-8H\E@;<A_K@(8'FI S:W%NPK,DR##0( I,6_?NW:A_X4.H<:)_0=AX@'W
M%IE4\Z@/>$[F.T\)]F,"/9S*-GM#:G+W.5_5@.1)?XPMS3XJ.KP_5Z%0D/8B
ME"^$]I3 BQ7-F<13FY#=XJ=Q(A7P*60LYZ*4X.C2;$#1X=VYBA4ZOVN#8L=]
MZ>,!>@GC\/L4J2!U$PW]WIA3@EW,$RT[BWQ.N!+1]O*V%\CX:<E/P^)$N:?H
MS9$;B*S.L-"*]0J3ML283CUR/MOQZB?ON  G(_OWN9WN U/"G>,J@WHE\C4&
M(DX)%LO9!;HW.F\CN]=73$2SWVA@FJIO6OB<4'V$]B=+\?8V"9C6GA*\T.:B
M,1_=47BBY<.%1UR<EF_?GQ)P318D5LN_8P><C.\[\3NPVHY_FH\['^US0A&Q
MKP#=\7G-LPGARNHA_@S7<#)FRRIXX.UU@_'XW>94S;N]-P[G.OYW9?][X?NK
MQ 3- I@@0Y0:]_]@@69/"R_#J+SC<0BP,Q;5+M.7D65E2KWZ.J)<))^BM]71
MD4<";J;J9B,M7UO!.<E*3GHT_3XJ(4C]5OBM<!!8E:Y&##_!_.NNNE9B1\&^
MN7*%WBA<V:[E6F97)-/B&>G#)X$_*/)CX/>"X<&LJLT4^7?Z6&,'OR--&7VV
MUJ/Q3X:=K?6D[Z\Z-Q3UZ%O_-_[0T3VG#WSU#;6[I'00]]>%CSJQE/^K#C+<
MI8_0-U=6%[&[^"<[_CF/?W+@GU_P3T[\L^/L&68ENX\>;OE<''&F"A]&CY]X
MT5&!WG &#'7^ 0&QTSV2\T\+?OG[H]J_%';_??85_Q?VW>@B)_T_=-Q4Y,5+
MJ>WVI SFS"Y-)P>#_/Q?[YX9M3F^[.M7'DTU'.%#(SJ#EQ[3IR8?OW+XG;80
M$&CJIHNWYX.F]U+W[DD/HQ,>9X7;!<O'1>@W<9_WV#<2A-OW)?'XG5'WVE/Y
M:=!UK])"E"E:+;__?[*0:M](^V?3?/F/6/C#OS+K@*$E+"H =&92'GO4$C'5
MD@*^EUF3*L\:XO=(/#M3#>)#'=*S5:>W0OA"*^ *34Z>B5=!XV?S1@,(=J[V
M]JC8BB1+2M8@#6?ABSP48YQOJQ/V^4@M]?"R5OKZ03K"DYI()9WTKL!Z0 (Y
M@KU505GUI$NC-X'<&1\5(OR?N#][V"("[.P-Q6\=*'H $I@8N#UWE"27*U[>
M'O/NNNN'>!51[FQ]H[GIHA@%S/]G+PDKT)]M\L9CR8_9#WXZO50<^]YWX_';
MO[]R_R]C=J%Z^!]T9-KC)=_L51K#B?=N">/U1V]Y)'=4<^CGHKGJ;1O0?&MG
M7G_#>-U%-:LDA_E%&U&%O$Y['SQ=UF<K/:NW,SPP!A7FY./D;D"6-<Y>U-LZ
M4O#=I_YLCL([&Q(H96<XU\QPG GM9SVS_H07Z:N*$D<Q0;VT PZ@-KPV0O),
M2502T!/=##1=ZG?5-<,#>_N!J1$#F\ \OCPV]DD!-R=?@T36# D-[6-V.+G(
M.2^,G@_Q"B(!O1'#V\1TK7'[GS',X._#)[/QK;&_,SUQ_F4 UN#[XW-@[=G:
M@['K#<?:9RL!8[7:V1],R=&M-_PXJ[=@U3<6EP0VPHUTLC1#;ZP?,SF"6I1Z
M\%V7P%A^1QWLN/2^PO,A;2?K5N87Z[M*NV<1AUTL=!Y)Y@>YFITTVW'(AQ7)
M3I)Y,<@7'^F?AH_BE&EM9Z&(52SZF_25C#_J2*?;:_ZS:S_X!U(>;=]?RECS
M=^'I7U_4\6L9V=^\(SJ=/NJYOP?CS!TUCQYH)7R-L>5C !U<.FMLP:D&O-XC
MDQ3IW63I';&O@)N!+X,3#8BR1@U2_1P-@,$\MC\-OZ[1[#UG376:3C0'WF5)
M$+G/='WZ>>G#ZRIB!K:DOR65[:-7=H/&Q"(/(_TTWN$C"4LZ1:;9>BI(OF$=
MQ,1J/N&_W.CB__3KCC;.0IBB/Y$KG9[%P*Q% J,93 OL#86H.]A>KSBC83,F
M%E^*Y_C1<>(^Q3XZX4&UI6AJCT/%V#]:D)Q5^'??WQJ;[>-_+-F5K;/IE*28
M_@]4KI?^-?#+3_[CH=U-F7:QC.C@.1M*#2UV,_-TTEYGI</O^=-=IBW*@_O1
MX+L<QS\-/!X48X,6@:D:T[NL0Z<$X/,V'RO11(98ANZAY(A]27#GD*'"EX]J
MS0T-BE;[J%I\M,=;+C/QSM9&R/<"2<,_Z(#)^[7]R0@7_PN0XAJT@%+^];],
M_>E+^#5_^,$"YF:TTM9QA(CD6%;O,=&#]LV;:9(BD@=RW]7](#R+3#B9AUNP
MZNQV&^N=MRTBO&;JWV6B%U._[Z9CTRX[5"7D#,Q%N!-;R]EFK^$G\9?'MILY
MU5"[1C],'3%S>IL]+V+=ZOI:X*Z(9+M'#\5&CX,KUPR)I9RKZ,3=[%[Z<MGO
M#F]366=265<WL2\D.Y1>="@^/+MXE&*Z!"C*^IY5="C>20O-EQ'7GM*Z+%D)
M'PNVIHL<BVT9[7&QIJN6G/@T1+?A7U65_=U$8CTE:AP\FA8\43+;,-.\HB+F
MI'CW(5%#K4#X7"+<3Y$/_W,K+(16C)0F\NISRMCT,7]A1[(QRY1WL2]:1"3&
M@M2KK7M7E,8G2C;Q9,Q$NP4H=H6)Z_WUGIOM?"ZS8P*:=?&N,_E'M8C&= M3
M1%34W/>J%K KZW'S>5%#HSU1DA;NP!AN*6;G,S+G=C6MHCI^AXG<J[S'J\Q2
M0KWUS@X']9) F"TV0<RKH[H<3\V21H.@G16;*EFN(+>L1>VO(%Z=2E^N@!?)
M++2'Z3O'W(.*&P41T>-]%.66*56DF5S+)05*8<&C%4R8%J6!9M?Y<+.&B-#X
M'=L5=;F["G L:C3V!0^+!-]*LR)]-EX'H6Y>WZS;_>9"9R[C=8/71<2/QY<E
M9:TE8]PV,3<V6Y1>M&]DWKVKA,X4\U8P?_!I:3UKQ,S1(6;&;^YM:JL[A]P3
M>,3;A)OYI2?WG;\7;#Q8]_K^:F[\/]PB;E>SE@Y0!XO^Z1-ZW-_ZU7N/K8ZC
MN3EV C-\?VZ;TSB59].&OA:P,V%-K!XY(+O:1ZIN_UJ2SY;?T7*W7)ASI%?I
M=9>EN*.]-H:4AV*?9B=UQ%&5-=WMIP3/@LF4HZJM\-+/%DEN\63M#DDQY(Y$
MAX2!&*FDQ-7>E*B#CK*R'NJDYE6EZI$=K<0;K"^Y/7<XY-RG6#D%:M.GZMV)
M_.]4IUV=&ACO+5]EZNM*?THWKM&53DV.<5JZVF/;O.D'EF!BWJX);N%*KQ!@
MW/Y<7=!#AF'E%7E:/7)*(.'1:;_L;SOAL$7-*M$<#Z4--U,?HF_("NN4J:S^
M.?'Z:N;=A=0!#$47ADSBH%TK5<XV/6W0WXU>HMV'>=+TL],.$"-W:]_G'>H_
MWE^(YG8T#_G]?7[W\TC0=,@K16!OHD=B%&^P9S[<[+L>,M0Q0"VT)'.'QY%T
M45)9]1X^)ED*#T;Q:]G1I J3^M-!^]HX>9#4\(PQZTPO+FPJ)S=%3*>Z7W,"
M-47,>G:B66KA(STM)4OAH2=;*R))(I*C/4X\DB)>F!NF2#+>&#[;%S-7X&P:
M/7:TF_5>#)S"&.**!IGF<74QBHB8"EH6GV4\1IHBU7#7FOBTFN]C6GBTHZ#E
M5W^GTYZ]-^9J(NMDA OOBI]/0EF#\KS-%C_J#_W.M*7_3B-[8D819Y6K;@-6
MG,0__*"LG+&? J:MS)4?68KT/'3X^=33JJFI7=SA$V,;[)CNC6#:0O8?R8/8
M"5S:8U99_7Z$[8&$E1)U?Q1V+S"&&;6]I/0DSOK5SU."B^R_"]AL]D /MW1J
MBSCSC=L\3M;?C9Y]!ACIP7C$"&0*1]]=[6&LV.]\IRO,VL$C_8FO>Z+W':9!
MXY\&ZW]UE>Z?+/_NZDX)6JT;--[ .CYKW$@3XG$CY7G9DU3\,(&:U5'=7R)0
MKJ[VB1\518T<DWJ[H]E-US?L:1_&TA_,/P^8L9(3Z\_ O@N,_2\^Z/V]$CZZ
M8/2[<,D&)V;]ZHO 3XGY)[.SZ:\E)20[)$4<L"2.&LO'B9U\MD0S1&_NOZ%Z
M3A5;%=4B*1KQ+F#,*BOLN;I_\D:J%D4B4X_ 2_*A)]L<32USOXNKTTX 1+_K
MDO_E95/@<&8&5@7W'>BK<F2^7'+ #&@1Q5][>$U_OCR;IK?ZX3S=_^N[*4X)
M9D)D^U!6<0FI/T4C)_205NLAW!S[3P*"37!DJFY,$T\"^CRS);324X>".G!_
ME]J%CTA^'X+:X,3_>[IZJWS;/+%:4N*4(')I6R M?S'P%>+@>=HBG9^P\K'8
M^W-T<>'".;K8OU;:N,FJT6X1K.'(MYLB4Z#G0QB?6Y 9Q11W2D![WWN8Z,9H
M?576,RY=VT:5!"=9GM22E3<3S.R>T!+S'O/T&?$TMR@7;WOOR83:S+(T0TM]
MY$T6K=KQFD%W=[S1FN<7VJP^R+:(V([BC'S@31OY)7_3V%54OH*SVQ1W2K#!
M(LAJ5.32G,X*F^K"+A'+YTPL[NOEQ/C0GA+@KG=,&H^,:\$^34?8:&L_[=#C
M*^#?(&,E?@GBLPPV)BH^&!ZZVC,;R[J",2MT%JF,B=3#+[?=(\JYI$/3<D&M
MX,A(^VW;!>-A_G1 E=%'BS?T\3YW50<F+7PF/;571F657TX/UQIMMHXCU(I-
M'X8K>^7:)@?]8)3U9^9VJ%-;91K>2R-SI\__?#%+OZM>\:*[(ZTA9-/&MD<?
M)\JQ,KXS3HVNNGIOR%Y.77^./ED32>8 #4.HS@K2=;U?BWZ\2]>C"R]I2R>0
MP:$^HZ$RD++Q+&X55?CFTRY83&*"-(N'='AU8?!S.,0\'=JZ'#IB12G/5/C-
MGG52_Y0@K3Z&/WW5T] ;XJD['CHY*O1U:LG8=B'7=79P,BG,GO[Q!9OGP!\0
M*4=T0:TE4W?@*0&RV&CD/0L2^J27PU57#_JM&0"PJ/VNH)^,,W*MZ_KD"4?<
M?99(;<=6C/!0;,'<,]N53D'?\C0J$?P0\O:11L7X5L0[CI[[ QRS_J*EFO[Q
MQ"8,L*R4RN4^6LV59F/R00NB2:0-7^O:\WE] QG5B,%\[;2A?$GD1%2 BBL)
MP_:Z)<G=Q/R<MJ.B[+RZ1T/,D_W)J&X3J'!E);KP>X;<;:/YP-WH55-CLTTS
M6U:3-Y^_!L=(A&B2:'R3.&K=M?,5--SGJO+[3/ST(O25@TYB2&MQ/R+OB0NT
M*LRLTOTY@HT-H:8G!^D2,J![?VU9R6A.WGEHL*T8+9G#R[IC]XH&K#)WW4L7
MU7FYA^S(XUYF/OBB*E(*;B!7,3&YZ]I?HQX56A+Z_BF$1U _S8ZUU)(K3!91
M4$W1P=LS-6%M">>W[-> O):N+$3,2ADQ/6A$ZPG4OLZ%<GQ%%][^C#6G7_X;
MZ20L5S=PK:KQ$:[OC.M"WJ01]K:%KOA'71T6$GH\E>B;K/KF]FJ;&CAY$6EX
M;6&UX)//Q=6E!=I;>(+Z%S 59"\N;;0Q.JO'#$M$0"2ZUS,;IK-0A4@3M@'8
M(>H!2F3,K^?^U-;V-IDM)T$ 'WM!3"' 8T+I:@"S"\7\)OVU">@*\"B+=2.7
M DSMVOJ@)%C?+^4)>:68-7"DHI@I=N,(_E]:YM'L$\0,_YCNG*^L;:]=N>2;
M5LJMD&,+JENR\B-E/6B/FFPZKZ#6NA^&9G,HA#,4Z#I)'URE>] ];Y^\6GSU
M<C"-Y^7M8:+'*GYY9;[7.G?L;'RM)K6?4R^"BA>NW%9CTTMU-E\)>7L]&>SG
M'ZW81R-S[0'?8(;ZB9ZO\3S;/H[CD.WDB=)/TEL&M0A%HZP0X<08[3[D]\.T
MSV%:2Z<$DU^G3(*^MPN83+FQC3.5USR&K>BTO/"/VC0+?LSAR?3\NK)?:S<#
MS"U7QSRE-83T)Y6W4#EG@UR3[/O92AF$-Y><>RRJ(&_ ^7&QEKN6(-12HN;;
MC[7B!,A;:+=/B(_/=[O$PL*$HO&,]L2?T8^Y[MC0DVE*,D$%RP$D;0K>Y*(-
MT,RO R\$QV,@8>JNW#,?8_,=&3N<WK6==,^[ (%3+UP0LWD]U:PLGXJV0MIB
M#O(.FG&828Q+IF4G/4/?I,PNX3.=O*)J,M<#A_&D,4@-+J.\Y+:VLZ<R$'II
MS'*E"*@PWYABTUUV2E"9\^(NVRD!]?%\[9,WB"<W6'3G&0&/AX75GA@EAW"3
M?$B=D#&.J2U<VPPC%%$6M8E4ZWM/YY2<4JO'OF!8*_]1LHL)]GH*5"-V6?72
MF!"R"'%[.'?5B0LD6#Q6+H9,CHO*LTOZ<)?LI]O.(&/. V7U2%1+Y=$WO8?=
MDPW"18"NZU57#M<XO&>3I^+4'LJ;?-H?W[U7<MB2,>$@>F_+=).1]=.!#_:U
MLMZG1RZPRAHW)];9]-V:H_'W!F%/R^,*.+ '7X8-"E'&\]=>7_AY5[YX@)I)
M?-7^MN(/[8(!H1V'+DAS#<MO)=>>N^;W+PS[WMR:MQV/62K55#2SJ\XR9G-Y
M^)@YE71\KQ$7\W/*^:/8*8%IX/9A4W(6*C GZV&#0IWV[C5(E[:<]1K#3_@^
M/(9S^<%1\QJ1:YN2QM3N%E5>3P89=#&S*GMKVUO]/C@^-@4UJQDKW*8WI%@<
M(YX%GP41\2T[#S,SNDO>ZQ1HM.XCLCHLH?O:^&YC*E.PEVO84/X2?WK+8\!$
MO2O[BPS(0C':F(\R:Z::0L8HG6]V4VALKY@S<CF(J^AG;, &]=/8("7.3W1:
M\4R)MMT!7''U[#K-109)7):)54]C6QB,)B8C/A]V@9-7;C@]RC;(["T0#1>O
M7[+0,L(I:!S>V/,ZC+*(N8%\J3BG[WJ_+L7+#=B32C4D:6Z]*XNV?$XLYRU8
M)@1J?::<B+7Q,7EH[5DXZ$6#GGPGLE7L)EY7%+9H@RIT[<B,IS?0+>SA3B-X
M=:=DV(BD6.A*N>!7TLL"OC6KCS^2CU^J[-3=YS-A/;ISYQUD6TW[SJ2P2WH5
MV8K9A"-^@Y2D-WSK/O-=G6<!%>1/!)Y-=,JV2IKJ-/!0%_YTB9&RW;;Z"F4?
MV-0_>^NT#RYLWOAI!WK<,NJKD";OV.IMD6"I]OOI @*W/4V^IMO(&! $ZI:K
M6*S7#U+I?L3QZA%AJ0?ET\9NHSQ)[FP+"5KUHEUUBQ^##/1@GH_"#&O3"+0E
MJ_B#KGA?01=YBY1]?OE<B&&*7B=UG%6(LTKC$2\K5:]>-K<-O>K$>_U4SXQ'
M",#;K'(%A5G+45RH_$!+K*S8#9Q.\R47H?H9&T7PM[LV?1KZSD=5VAD9JD[L
M@Y57?SZE9+L)@$7/A[[Q((^3-KH!F[D3T%,FF*DG69H2DR156J\<C9HSMD3;
MAH>.X/(T,6C8X)TQ?'85U)B-ON0H]K!5&W?O99J+1U2 0_*-E'1 ^^N+C5I1
MW>UO7@\.UOY\V.E6@%(3?^T:OE^RPA$*=.I^F)%212VI/DC%MTU<"DFYK/82
M0#/L#;,$%UL,@.^$;NI4:^T2Q@)>FGE="RPW*=X@]<WD^<K<$W)* #$E6,EF
ML1#P05*A9HN]J\SL4JM>=Z=B/HQG&S0/&_/1VS66,,FZ:U6RY_OHZ#)2&JYR
M%9P20+>H?,+O6^R!5F.MB&_X<$D_BGHK/9*2&>;*TE:F)@D5I#M(;Z0KX<WP
MZG'7GEZY58+0OO^(-Q\:;,CG3LM8,B+58I=%!I,2U._V<42H.1!+,A0Y9L\-
MRZ:D>,4SEI77,$@_#T4LI<)PF(>./GE+3HO TL%:2V^9*WO\&M@61E'6*OW0
MVK$)_1R#-,&!KRG&5+==J72B\X<ODTY$)< ^2CY*_OA1VUF(Y"".U^)MI6UW
M!A+60TE6B\O3Q4IUN>8EYAT:^8)4XI=;]W%\&U*Z/55D3JQ(B'ZQW%?ZMXUJ
M#<^!X!(1V<'@GVZ\O30^#3UKVIUV'+=35H^N=W#ZV+D79ADY9TFNLA+?N$FU
M%_ZB($>\@#?/$8.+PZ2Y<+Y!:8%?P*'PMV7C CPMR@^CCU,^#=ER.FNX3]B-
MBTQYE))C?>Z2-Z3B:DN+;D=R.KA7HW+7L@^,P57>;N%F]W3OBQ?8/KKGW!"1
M,P=<G22Z, :/&D)Z2'V;T1'(JFR[&P3XR+8'>+!\J[B 5W/R<8H3EZ4Z@T\H
M+C6[I.Z&\VVKG$=\=DL^.MU8W3N]!5(OY;YB'&XO^<C:;12#(EI%N6__)NL6
M3>\L-4SU\O40CPGB 2$5]-6C1S&#)57B:9 L"#P=%HX)'S*0M5!3%X8-[[*H
MQ=9(KE=DDV8(L=T)4)5*#_1>T&PU=RO/"2T@?^[QP(<KHUM#*D:1/\RG>6KI
M'N'CR<?TWQ<ER-8^M=(-Q@P@;46KJ?L:"!K-7ZMWFT0W)$-([^\^J6Z=+#"O
M>2I@[WVE^/4CJ1Y_!=Z5"Q5W8FYDU:FKJ\GUF!^!"#.?%B4O5U<G7OI^.TH\
MF>U)NQ#_L5QU#S(YJ8KERU[0FE(;%5O(#X#831E:.W^!<BJ3.OXIMOB"N&.U
M3VL,\%W"ZMCOSO&;EQ2:Y+XQZ1#<R.L&F[FT/'>6= M-Y'5P'H\1^/C^JX[)
MT[)C-NZBQBR@9>]$;1J_8;<9M/FR9V_16"'8@E'N1F*N(U_UJQJ  LA36\]D
M\K+4FS=Z=73EW@K\#AZ%98XP-MW,%:S$FVV%*]?]AO/ .*:$:Q\R9=3@E1DN
M$;HC+K3%L.H+EP0,BN35G4?&7V@CH C57C38%NS"^@8-H?D992;X@"8;@JC0
MT1DE,20OQ)CKV@W:%AML&DY<E.?/*!SG9!3E.;B%4>=N\7YPQ'?5ZN$[2A.8
M7($#5BHKH9IJ(<)E:9*B['/&B*TF9N'SH#^U<K?!9!WIQ;?TC&CHM'-3^PL]
M!>>H]A/&#.EUAK'1WTPU-1/J?@I] E7'*'\?'H\17HEY>G77[,:VQJYGS%KY
M\;Q)17!6E+$D%$:#I*LHAE%6F'T-7_0HFTH':A47<:^3<SL +[\L&^>@Q%UP
M(>MG( +VW<N_C6IIXQ$!#D>0U^DC(',3B8)?HS*B6J7"*G9BN7)OI7SVT8*_
M).BV?6 KPE^B638L5YPS^YMSB ^BVI=F0+F 0K>#M8B3L?W#?IJMCF#C?:MQ
M=T%X+]"U8/NZGFS.BQ?-)^U]O32)"X/#2BB$5H)"P3(I7_!'?'35?_:J_=T'
MX:=%SVZ2Q_+BHVN&?.&[+)=MGX\U5)_';^*1*\+6:,N6NCY\F/>:%PRQ<9"2
MS- +0V=XQ:?@XXS%LY*PV%KG#/X$8RM+2!&3MRZJT-[<&1Y5>>,FMX7J^ZL8
MR[91\.N7E&#NI<$ZP_@6]XJR&6B!: T)B J\*BC>FL.+D5JE[K'Z@&.O1;>S
MWS)PM@!H+;/JNN"N>AZ&;X0/"J C77)7JE^'KG%,<+_(X8GDK2S?!R>'[-7:
MU967,<P)4\F'%O,.I'\E9LE%(/-=$;4_4)#FV6B)UYBDL+(HQPNS=0N-V.E.
M[LVBEWX!:I7PP'LDQ.R&H,1Z>.[%3B]SMQ7V3Z]2C-T0X6STEE%A/ "$MFZ(
M _@(P9DHPOZBH8]6#)[O=AN-$=Q(U1\WL1=F*Z/:Y[] <F=6W*7X=FU,I&:5
MMLF *FW$8)7ZEV;8T:NL3ZTZ(US-&T8#?*.$M'K1%1G&(IW&-<7[M\:O"O+?
M&2>-*I7]TD>S._KE9_^05 E/]I>8[RJ)!M^$-U1$ZSX"]TK./;W>O!CZR],!
MM(=5=D03O^?I)G_R=+%K><B.G?O.$D=?"]D?IUHZ,=Y[M>OK6#A$5EFHRD'Z
MVJ6\\+*N/%W!/5A>\O)'R&\Z+0S="._*6LP$I&O<J--L+,SH9C(W.HW</>]=
MZ$K!,ZW1):,1A>)"5ZCP,_LH>09#@Y/-:2TN*K.<4.^7%_?SY975*Q(>B=$)
M=KL[5K4Y3T^&__ LI#>VGDW.<!)U3:@T3(!\S2&9D-_7=(UZ!,4]F+H82*EV
MZ_@GC:DL6L'TK:%[&\TVR<V#U)ZU!4Y76)(0OR;L1M)>R5+_TRIE]=K"GWT!
M>X[A5</Y>5L(U]!<E!9$D"FVGPT0872L_PEQQQKFM%%XZ\K#T$%@ ZAJ=+R(
MCI!,@3G1^!H+M1WCA>*?_5*B%G,;AF2@L=>V  DQ0;*K;O$I26V41@-U:8M3
MS"^]F8*Y"CTOF41PJ&T1Y19U]=A)&>L)CJ,O?F1E3N.I\+J L1610^8U96R#
M8)>SEQ(1VN&=C+)A$'-7DQL2:"?GJP[/4@Q';@1[AY'&3TJ8BT_>OKR(0OI>
M'P*+VETKJ3+B1;]'"96Y@QEUTM_"QF_?>RDG3$^S#:Z^@6&8"77EU6E9:,FT
M#'_!^_XQL=Q@ZNT%Y&%;6\VGT@6WW&()PZYO8.BP$:.<_JAWE$G;O%&*O<0H
M-IF/2L94)R7(JI*WP'T"%F=W&5WH+5:V7O\5)4FDICQU3;31VU_-F]@\,5MW
M3_T&;@AX!<24,BE3,/MFT^_NVLNE[U=^ZA;4.?DV]#!Z?ZQ;0J.TG='6<*LL
M$<R#Z0CKELEK?"D37IL038EL\)!#O<H<ES>9$$@_^#W)1%Y4*O(5RC/M<CVO
M?:[FBZC2JN+O/"B7H81/@E;J\(_IP$[D1LNB.1^EL:#(*F%RXB6R<.*'41JR
M#?EUB:_']/B/I Y]J@_H9IP\0787JX8%;85Z28:%'W,/,AD:)]1X<R@&SNDS
M3-/?EG]WC>KB7MWZBB-#/SK/O-ZY_WZLQX-(H8(BGX2'<U8&>BS/.$5&D$Z:
M<.%8NF<9!Z9 >#<NH$B9=AGD(F@-7BZ5;F5]GHO)L%G=@HD)S,CGW?P@GFG*
MX*XY$+?Z""E]*X!//>*%X0+4I%+K?1L0*A#!HP&INHU&CJK(D4Z(GU!LEO()
M#AKTV4U9^$O._(67,C*ZNRR^-(S>Y_8P*14UMUX@A1X_HVPF;8)&=5>0I"*&
MPBSW"69I+-#Y;OU=C\G(+'R3N;I=N<B1^EZIN680+P0(^.-Y>>MD0- 2?QM(
MO$!X]\E5IB6?2?VL]Q\PG@]T&R2N"*0/%-\ ]71_G8HE7' >ZD6\ZB^\C7+N
MOJ5&^:!'L\=3JSM]?8S*P#CW-:Q8/>OJ"T-A)G*OY4C,XQ(>J2\]7[8T(0+"
MZ0XLP46H433,6A.2Y2I\]?8D;3[2@4)*XL8XR+!5OLKXS7?#&X@>-_-+%#>&
MUHSLJ#>_U+V5%F*SS?,NU*<9]PE6#37$:>IQOV.^K7P0NVL(+,)8F0J]6$1W
MS K+>G!\,YA/-QY/Z[3+LE0SUR,@H=?VRTN.Y3-\SW7Q_J,/CJEAR;SD1C#
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MT\>09Q%],=<ZUSUKGX_>AHD#?F--XKVY<)85&.3"<*@.E7*:_IBGE;W0NW&
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M#T,A5P,OX9,_3KE8%+815X(\UJ0HW')G?D[J0UW+X!K%5^"M#/[^P.TXS1(
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MG/I5$4%=Y8W^'9N%\O6E\:OUUI]%1*70L,P(TJL914[#)U/@26,:1I2JJC0
MHN-KEC3'OY_X=S%F]]^[![1_=P^XV'H12!]'AA^V0=<MG6.\2D-]%U\J)=5_
M 3D;_;_.2@5?701A"GF7X_-8%>.*.^6$6%\/I/Y@5_=P*0)L3JP^R+.$S>4&
M3/LCBOW+=@X66[R9I>NX>"4@O[%FA+@C]"S)JW8 F5!5.6NW+'B3YI=G[QB+
MSI=PT/=F5A[5-WAD"B!0%,XIM^8J+ZF4%8>M(QZDB/%E?SP!([B+*W#,^JL-
M%2L;9U -Z+#";SHN3"$IUNS%[0Q.K^I-V4[#\D^F7Q(5AA0QL!3FNWWJX\&9
MMRKZT C<E_Q,$?C%!T"A?IC!IGZHK%JVIU?W!3RMBX$VO.?DG*U"DL[5]=/%
M?!/8[7&@*I=G?^QJZPY"I(PJ).1#*)V,,H?0>B:FUU_(?.&5O32;:,ND1+'/
M:76)"^+$?W:U]X!:*53\K87ZP;)F'"RO"\1![6.%'#+5A6!,OGF&7A056QA(
M'?G_""5AB/,AN9/1/#_%^V]-@T.C&<P5%C SMK2QF&GW@R3ZT?(KS1?=\;_H
M)J97RGU$@;2#%K<5[T]LO:P>.]6%"BW1@XBRL.['?KUWQ%912'<IQI20^ANK
MP85S\" V\N8#>:E;24J8L6;/"*@[BIVC(09)$?>R9/S")L)N3O7/ 4J[#W-"
M68)Z::OCA?+ZWQ;0ONPS E#]]..R RA?3S^X:O.#_&O]J^@&3RIQ#,FZ,'&F
MV4^W(GF&CK':A](I63T_=?2:I73Y&C_.J[A%?55(?I':2<-]X.R/Z=/*-'/@
MI:O]C:6N]%2'FP5\:F.D!.,-!T3<OVI]7.HC#C!2Q?VS*M!5XJ0=R:O^N7LS
M&JWW@SCFJL'O=0S^K=:E3LA=2-;W9/(5._>M]%ZIP3M>2M:?\8?K#V^HI87P
MEK6='A"K8\IQ@."#\Q<!#X97([(9QM]QO'$UZJ(TQ?<OF])M0199EXQ2V#BL
MP9\_#1\.?/4;:Y<=T3$8?TSP2P1%V!8^6*X;@L#YI."[(/7<$A4.-$*7HYPT
MA*9 >*UO55 *FN!L/4N^$T[A?-4%PTB=U!^TZ=W">;]"^96"KK,E'ZO.,]<P
M?B87$%QI+:Q2 :?9QLX,)NC-0#!VCRUD^_BV4BOEOY7=OR\NU$?-55RP?<]G
M(^LQ>X.",RYA*U1;U#9#2B.(W!*3*P+A6BZI*#:>+#ZT!JLSMYDB*N5_8Z$M
M]8[RAZLM?>U*CSV4WC3P^'I6ZS$Y+*6L+A=K$@W@9!7(>GXX8/!::/"B9Y-I
M0> R,YH_IIQZG,6-!1_T)X^^WZ0 A#<#W8+[3.6F8#!ESBPE@4[?>N_7*7Y=
MB%4!75F5?"=]!/)5*1F?03VA%91@R9&I44YS4'2(MNR?&1K1.7_W*?0QQ)F@
M#U<>\4&#D*=\I(VC30IOBJ >_B%CADG5F<CC]5+Z8 \>&'BUWGDOE3./4!:_
MS% @11"$"PLUX@Q%\FHHY0M<#Q5*U^F9<B1DPT(U2F6<&XSPGS$K^QO0>5L*
MQY*OE=!I(%&;#YV4THZ$,,P\B#!R5Q!1,5.]HCJS^F3M0HJR1Y=O 06PYCZ-
M(:%NONV#A1C 4JC(KNI1B%^B7I\;S80NHI*P@96!HTY9H@C(:<:VB4L5A[3:
M@<YF:X;G=9KD!#MJ3X#L70?;MZ:&],T5(O22R>5\U&FQ96]3#',9%^(<ZE6S
M5<6D9_!U%E<C=G2XWD2)@[0^:WD8X*) !!=1SB49>J9:W:KO5JO(T&F<:<&@
MB#4)HD/:4(X6=+#K=;,J/0Z;^D$#=:6AM$=/2C'X C_O'F,C9:%2CX4I7G<G
M&:_Q+MGZ2P A4G12>R["H "2J:03( MKM57IO5RX9OH#H*R]6A"O:DF3+WW?
M7PW<OAEVT'EE(R9$6H<'+Q;1M83#P:YU&K^Q1,JA7W>?_!%AVCM%ZPZ\OF!C
M!G)%XQ11F;4/]+"ZNJ+4T:+G9NV&K?5#[=^&WF0"7Q9K"Y4/@2L@<"J.^0A>
M=/AA XE1 :MU]B;A;--KJE+% SP/:+XCBW_*A5/8#I%I 2I-Q-'FH3782G7\
M-Y9^H=OE:)B.=H%N'7 &9?A9^$GMXYOQS _I*\UC7JR_L:AY1QT^B(>WV,H,
M3?P<O+6D+K/XM,?-<NK,2H]3_L^+?TM/:QL7=+6]QP. A94.+S2K]D;*'8D9
MOQ*-44>V 5X@,PT]?:+5MSCG&/"FH^H.)ZG$%.D>D7IB9P)AIUY"WGJ5<R#5
MF:DFQ 7YSX* G1CA _7;X^G>FZU?4;RA 2D=&/X+ ?_S/NYL[^U<)-T"SD05
MKXO0K)..ODRKP/<-]K4*P^1/EE]@>_:T^W%S/+E>1TOG?">QS>(?;U.\+?Q'
MC]J D2<:C7]^(IU<9%N2=8R,5W561+W?P0V??01DX>9^_2K!0AK+ES72R00=
M_E:!RVS,('70>^3.8Z>E_7#8?>CQ?,C1,IOOF)K&?60NX?[SE%*E'LM-=CIR
M\=82W@\_?F,M^T6@'$@#,D/)1')Z\$K?DGSE1Z+F#/U:WRQQ<4RB%Q2CRF5/
MDF[SW0MM:^REB>HV;K BC2CY@: 4.TFO06_4X;$<#-7E.:NQG:NG$)M2UB=)
M(%65PY<[*,YTE-[MO]!>UV>W\'2BD/WRZ[5NUPU_3EWWS12ERWS&U7IYU.7H
M'8G5XS_0O,QJW_YJ#VXF<C3.0UNJ>-URW]A)'"@[KG+0Y;7JE7+L51F,"$Z(
MG7ANUI:PO.!\/X405[:'I[L(!!7+3&(N3LEGHK81,>4[81K&:E31ZC:LT*'N
M'B@WC$@N;SD%+CQ4N5#@#U_CQE-&V:;FF%I.B49[/0ZIMW02KPO73%3N"EV2
MM85G^B_%YDR7>Y$D>=8=,DN&!;(%C9;74^HO4%[+'E8[[?[Q[50K5C=C58"5
MHK^1V_.K=G5JG]]8AVN=!])?B,-GF31*CFIWYED4I>. L/(2N&%KL=3#0TYQ
M<T?*21K#3"-9=PFY.3WJL# \Z'6?:G7SU4LG15)XM:#V?,JG@G_M4RJ"!6P$
MSO&YP>SF2+T!%^MPU+$W@:"1:HO#8V9"-=O!@2ZS9<#;8"NG^TA*WVH!2 D]
MV7ZTQH2ETJVV3G.E'+>$$*)65_GAYO^Q4?F70<Y"<([,?H7JWY5?/UB45@1G
MC71DH1?G&7T%/+&"12>GBP3!7W',_[J8IGNW@&T%[CQ)LI'\F2>I+4VJL/'+
M$5#Q(D>QQT[,7X4 4VH7+N"$/3VCBSZ9\0/JS!$M4=O>1*2!+S\;#/_&8NN7
MZK\<X0V[ZO/O\W0U:Y ^"Z<\A1W(N980"^7<:_GJR/$JA?;8.F I<EE 'YX>
M()1:BB"N_Z/@!6U$-Y@,VL<FEY T3<Z3P@\:=H;23F'OAAJC>Q^[VHN"@].?
M.M.@Y*1=/^BXICR),JA760^OWC=' <Q-2BNQRI.K4X*=$HQ%DFCGY=W!\5BA
M53NVL5%P/2&G(:1SNHDGR!FSAD76X%90D^1W95D^)GC:*WDA>'NF"+U?3+;K
M#Q_O>E7/&O?@W3-V>^.D!7UKVFYZYNLX"QUNMN%FUJ:*\&?9DN-MP($3BY??
M)[TP51N/$M2FH7'D8CMS.6AP8V%F5(X)OT5=3K/CC\\K'@-M\Y\TWM ]C";I
MH$D<*:>&*C[<6AJYV$Z%#+VLS)&4S\/.CVZS[BYW\ '0A!M259::*[%NZ9S&
M@ROK2DXQZ]F0R]%+A5ZI;@H6M/-.8N.;$44]EIH_H"_J_=7CX7X_$_?O='EV
M=R#&(A/>8JW4'B!X5*%!1DRI:[%&/EQ,:PJ$(&K3*ZM1] ,:/CJF$WBC_!NK
MHG%'IQAEK=NLN3P_N8=DC.-55T/6#Z+[?/K6^J"R#O8)8L8;*>HC-K4\AB^B
MIR8;M<(KT"T-Z?AQ  >%\.35)=S]S_(=F$NG]/XW6Z0!UW ;>^*&NI,DD5[A
MX-F9^HC956<Q 2@[P8K<C'&FBQJ]#@E<*M[C#41_%:!P++:'_I/L5S34E>%:
M8QU\UFS=C3^___PWUAN[+5%*NIL X0D6X+%#KFDH*"<F4QF:'O]S+D),8VHY
M 4*._6OG/:<;B:;:X)S,G.;8V!X992 _Z.;P!+:3!2V1?TG=30Z?':U@?6&K
M5*+'<@TF[UU[>/D$NGI&&2L9X,7U;HISJBG->CZR#6G"HF<-%XM1I&NK'G3/
MS")#P\/(D56X T?R.2P[1RH >,AO+(^NU&9<5N:-_9>.K'9VGHM/GWX&J/U\
M3PB!-$QD4"0H,PM9$^FH3>&U6+.-JL(*@Z5P+..+I(,P@.UY=LK>N!0I66>0
M_F\L%@/+:$(3<+F^RIP3]/68Z4[=S>CNKNP8UY*&D7^$\N-ASJ]]*>=)=V;1
MN#YD6[7(1_9E*.&!9?40OQ=KN8D1$YHE>80I5;;#:&KJ'S,O3E$^3I4.'3'9
M19+IMC7P!M3DM(CM6A>+!4CO<P#&-NHO^EV28\,N!EEV]8JCPBQ"'TS;.K:[
M*Q7!9HKC49\G QD)&NW]'!0GHY?$T.XR+:P-G)S3C"%F3VNX7$LM^#-CG[@A
M7TJ(G>,%?;AJ!JPN/V>53>!)6_@S$_FT65$W[P)=[K:(&5-(XP0/4[[09<%,
M7U@OV?L.AI*"ZP8TR8T8#^(^\Q".+86\ 4^(W(*GZ(#V5](P&G%R<Z8YVHYU
M]M3O(.A"7% ,%+Y;=Y(!X^<,<P2 H&CX- 8JJ#.6, ^F?C2<O+ 2(RX+7I+F
MGUR>O&]7W%R_W(?]'/.L!>25 >Z7TT[(N& H>&=MZJ2"TT$"STS;G2][^K$(
M5T:(^M-^/UT^RCDO8\<%=H^_TYNI=2Z_P-6B;Y(G'%&WP<R@70$*K^30;??0
MY3L[I$:U/&9D?N_ /JVOW3-8KF;^Z /5LR-_<RD!3D+#^22YKGE1"T0M4E11
M9@WM4:R"$/C *GG*5<H/P]16 O4#?#AR,7ZR\=@Z!X\DR!7V7,E%I#_:4$B+
MI'@5M!CJO><0M*0F5C HDZ?!B/K^9/$^/'!19.:+W834AF,*/GKRO=>=RAYK
MBH.\TV"?;Y.F<?<ZMIW2N$L/^);W:%\8:OJ]LLQQV2F?:5*SZ_;#SX\?G@-W
MW]0*NN#3:)X4>KS*3JR.F' )S=WP/6!>:J[RU[>\H(\$3-PEX[9>#>4YD&HH
M=,.^:G5ICNV(2RH*K3V(K5"UUTY_>="=T^.@\>0W5MFK2<9W8U8?7[2K>;ND
M26?A>I.@!=.<MKY3$'>[Y?8R-TP2S6-CZ(6P'O6*1^Q<-22JBADUGJJ?J,OM
M!1YO>W^%&$J2CQ13C5TWM&3B;;DL38MQ&!*NOA^I80)0X_H\).[.N"@:MB0[
M*'6ZIR:9D#Y5> ZU1HYESQTI?=;1:'FW[HQ?+A?:A>-,=DBM:[_]&VNJPDSY
M7O9G6\XJ9'/C<![YG*(&).^M;N',$<L>3-Q"Z,(W3D>/Q:D*4V;'+,\0ZD,#
MQ6Z//DCP>T1;##43FVQ%Y@PGI3]P// $&-WT9-2KZQ;&OD@ZB9//SDXXUZG8
MKA)9CNUD+6IAY?^1DK8(U1:SAB/(EH<]]MG?==.ZT+:L.^#)A4G)\049W;>U
ML^[R<4=6_,9:$OZXPFHK$4>ON>:%UYWP]ITNMN6KL(TG%5.EW,/Z;M3(8AL.
MGF4'4GQ8;UC#-X AH1RA#IXI7:2]H9X2K<9>)QLEU.'X86= X62&FMN0[+"?
MNP/0]:]7AZ*M&QY_OSKT>.\ 8//(=':8-YH<VM_\R.Z;(N*';@*2,C4#EK3K
M68S" 0Y+O5=#@&Q">P$*%Y,Z(__]<]V%2$*A&N8".?/WC7C>!"@!_E\%5BIQ
M#T3C1GS/.9<ZC'\Y,B^"RF9,&K/RC95QA_R(4A=4Y.TIM$/GL*A??$/*F<_)
MADE&2+TY!TYV42SD;@W$FR*;CYO=UUIQO8G+!'<U6K"XA'MJS2<!B.>6L526
MQEFMX/!%1>6[$N\E\SV<C0=U7JL$ @D+3N\0?QG(9[VJ:-7";0U .],'T,5(
M!1QTU%ZW./UI*UK6RVUIDLZ#O>-XJT.5\WN=\*F=XU&I,V5/W>VVG/YFU6+.
M)KEUQD(LMN63B=?<)7WYA[);3=%<C%:@E)<7W#+;;Y/ME09LF)5/J_I,",3!
M@C&HTMVTH3?+),.+<,.+&E15QJ?6MF7]\"'/+(8!1D<0 !WXLW-T23Y-M*W4
M8\QPK%*/\;)4>)M92EG65Q],FJ8B5)@4H8K<JF1NYZ@:,^)K(#:ZC!=L&3*<
M^/YA@VG,>ZJ1P.(ZT+T0')=Z,+(ND2RI!/.9%9B0H.UTN[UB NDG-Y*_WEX\
MS6%F,)2DJ1H_26G$T!S4IGUAFH9X<7@KW;YX'<6WYB6  C^U/"-TC^*9]_)0
M!8_;[K-GYE=>/LQ!NTWGC'9AC#3S119"=K\4\,@NA&Q1Z<%84W.Z B1PN)TE
M.A@UP[>SWR%?,'J11H QS[W5!GVN-XM4D$MX)(@I^B'XRHK/ML3$G\RGJ-7M
M<I-]W2\%HE>=&0[] 5W L<2KOI55C]\W_9.'C9%$L\.8&P5_)I!'6D(TA]59
MN8?TW43;"41LZ @,=(L:BCYBBLVDMORG@203.ZR^9HB<,M^T'/=V]KZ%2RZU
MI(=('R,=G0C854/N=FIKH+XN>9*5@^CELL3>(*K]6?B61V7.N9,LM:6.!N2R
M[Y?S+DWSZ*9XB=N,I\/?SVI% 2=B^),M"=DMLO5D"#$-;D$8YXZ-E]O7E&KX
M2IL/LA\\$Z\81*^3_<<:GO><W6XK(=G5O+9<<U5S"W<-=/++3:I$@@78#A &
M<W&* <#DAO)OQRK=QKU[H@-T=_QRNYK7M1<%3VKG#6$%G@V33%C_SUB0(2O[
M#H/?L1KTLC\Y2R+"V=U'<ZT4L",Y3;7=-IX)DRZ?-.WT/DD^MJQV7_89.PSZ
M=R6XE$,C _;RMYEHGX6<%2?P[3S"@'5@ FW3Q?7%B \F)-F5NSJY?B-7R-]8
MNV=I'Y9NBP_DSVZ/<G86)\V:W?1 !D,1,(?,ISP_DF/3P=7[,LP?$].FDC=9
MFU\8$97(>7UY5O05-[1#MK)"\_7AAI9O3B2ZW(5L:P?EJ?G(@Z)JF1]Q%D)I
ML]W<4RF$$+FM6GD).JL<)G\5L=Q"Z);O88@_F?" *\%)D9;\CEO A@#&S#ZK
M4,INE:4O6*S"[V39QW3P'D_@5:9N7DA$(O>8^HW.9@V>-4$==GD#*6Y9QI]%
MK0Y?D2Z7+A(WDIW3^9M]$4GC^B.7G>SZ'%"%\I&FRQA(,^*_=;H.1_[:=L#(
M5;[9N:_:[.$OL%?!M;/WV-G8#O=B,SM6JEO[$*J<4D,>.!3FU8\A7YW>+<6Y
M3DOV?\.F\KEJTF0A\U8%KY>7I&Z_KMOFKY F($ V:,$J::!;=:4TA:DH["S<
M5J^L9"KU^H'8M :OT?GN7-5&3=ASC9G'M,@W3J/1-^O*8Z9&C:)MFP$0Q%E"
MJ*8WR</+@O_%X .>KDV;\^IK*&/O>7VF*DH9((P\B7"3**%71QR47,?;RP%I
M63I05.5O5''%8<K>98=TI5OSBDP[SBNC_(.\^)4WGW-6;#3LS_3Y$NS$=^=W
M'X!#ED *6>7.?;$]#2]/'54C2&N*00E^% 4LC20RRMUJ *9CM$G9ER\?O2[J
M-PWKCW*+ZIQGIBB4F7>A35$+U6#S=I4]!+;7HD+J"I;D7(X2<+WL9V4=T=NA
M%#(R 8YPCQ1]C%NE-Y$"QLN]B,+;G!EQO'SHR3GX\6F]3$;=.2A9(7X0O!%,
MAN#<FA(BEOQ8^U;+^#LOAUQTMMXJ'*_ 3V7-F0S]LP:(-2]DL2A.5KJMZ[+$
MQ>^C.BH<AGH9_2>57D6LI<)S+Z(R4. V4"R:*4M=?XW2DT*XO!<#-3Y,[#-C
M5C0@*\0NM:1X=4'JN@WU^3(<)Y#RXAR(]4;^K66U4ABU)BPI%-#+5J7(#XG2
M-JP09^$YL_0P_FX16"1LHC&RA"C3$K#9Y:IMQ:<Y&+619S=2-/DABY7S56Z^
MZSNQ*G*FV2';S+^>I(A\KIW\101Q[P?W^5A&>*>/?CPS"/#LX#&92#NW.)(0
M1UY_)@YL>R^3+/GC$W!U5@Q$*#5#83!)F^GA"$,T)7+;8[3EQ1^:%8[[";;S
M26YLGZM_8UT)2AL]L10))!W= VALO9CJ0)$P)VH2?Z09?E:HZ"1Q]!!M7GR
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ML@'(-[(,]L$QO2&V1 43A@)\\!D<AYY:QB_"E0E8E,V0(''O5:OO_HG)I:Z
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M2688_H-SX6?>UG@6(\IXAD. *RC9L'"S.$P\82UUU3(\.U:\2"3Y!X1F6*7
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MDTX$++Q=-O:3[>-UUNIDD&5J1#%M*BI+T*4R,T.RB!SZXM[/7(K+[0G!ZE%
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MO?&DZE T;8]1 X7K+4O!;:'KM2(09ION0-A2(XV919+*E>CE*EQ_ @>=E5*
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MM+,5<]Q+D<-AKJX//7M' ^#U6"[8GIHE@"&:%.OP08MAQ.:4B,\:BB*F0!N
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MP#CLRV)C]F&7442@("U4YPW[Y@KB[N7,<S;'VESO8;[EZF M5M%R)H?:Z)"
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MH84:2@ES$'(4#V9#,Y@]*\&MZUM'P1&Q6<8W]$4,<"\&);^+.8A.P9LG"/G
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M4_UV?F_7423P$8,TP'M^XG/5HT45/=/UC!H^6 %LR*K/!)MS^@+M9,)1$=#
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M/(E-ILN-W1<W)%MBX+9>U3Z*5T MB*+M''2!0]=*O,+=/A=>5XV@2Z@-9M#
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MP?4]%KF?<\CUW]6X8Q5MW&'R;(4L71VT+D4 /6( \GHKID/EY4SN+VMWI8O
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M9_J( &93\R.X_IAGHP&K%#7"N1?;"Z/U@-<HNZPQFN,DEE,_5QI$^96*&W$
MXY8&+Y)<::55AGRN*6$ T0\WS.^UC_8JR%UQJMHXXB]V6^SP'TFSA:,^/71
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M2[-YT5Z>NAJ+P#HTFJ>? A'2.HG/&.])&:F:%+U_)OD1+WY9/ NT#AUU$RY
M)E[IDC,)8PGYW<[3LD4/1(4EC&"\/VG?$D9>V7"J4F64 UJ1GVD# 8):518N
MV3<XJ1;\64Q4QK-!;H]O-*JDK.3QG+%J?^Q P!KS(5EP+6XJ.\)N!.P7EX6>
M1OBE>:I^U%,XQNV >$.(8Y85O T'%F0*WFX"B ]B$YB=(UZ-L0%_#<&X16K(
M*XE+PE@%?%[&@ V/ C761\K!'H/<AC[R]!;OF1FV7*AH9D!W;D!G;OD#.E,0
MPL7['V+5# >TD;=E"_W'--3YNV4KJ<R9_:"JSOT/P,D.7)P!*XE^0TKZK9-
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M1P*#=GD-,(>["K!I/1"QEU$,]U!+F#1HG%1E!W>@(UMGINL=6*+%A*-MR7+
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MR:Z=PYP:,]A<%*:9!MW_\":0G_PYX[^!Z'0][,PPKC2%HE: K$*%0+ AMO:
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M>#.VQ #QA_KUYA.NA$1*/N.63D:1OR/;)N7'Q+<HG 9I2B-\Q$_G<Y,SQ((
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M!?N3"_8A'C>1ZM7,;UR-Y@0UJOMEZA6U894_V><)T!#.M[>.*/_&;>)@@?4
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MG2S@KZ\U@5CIJ!Y0S9"XD2T">DRUN4QO"?+BA8A7FI[Q:,/&R*7%WP#LS>;
MRFNY-:HR54=9FV=2)NO)'BHPTVX.M&3;P%)JW.KT.RC"__LSUF' >+6XXS>
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M=6BIN15QWA,AP=/-8 FYA&#=B[)<&U2'=S5\<8W2G"]N:@97GB]=EHUM!]-
M,C[*@3"7,2)H2N'=0)<QS DX:T8.BI4N2ZASL)2^SUS6CP4JSZ5'\;VI&TN
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M'IGM:H.NA2QW%6LUDR1S4IQ*6GVLTZ$'I.E+\I//!>/68JP:M0*2A,4WT]#
MHNJ3Q8T6S=E/L]8&,-#QKDQ9_@SK2\8T53T&='!*[:^/?FC2,DDRDQELDCB,
M6K\6'_R<9O.GX^.$R=&94:< S(>[!CY:+=*+QIJT8.,A,WKG9+J3N#)Z?'XL
M*R;66A@7H:"HG#'@Y9'Q)"5@8L/EW <6:&O2[@YI:+E\KQ1T.N[.B;U\[7&)
M/K:47!I38Z?U 5U<RS'@Z86CIU>W*6+SJ6X [:Y_(%<"9-(%^USP*N/K,\#Y
M"F\56YA?2-VR,I+_ZK4EHX/6R2A>(T@9 1J":DIG"3<29V/K%IV+&9'OV2+R
MS^QQWEAPJKH@W1IM7X1AM+5:E"RA7*>)N!-69M5@5[#)=(RP7)6='\@T:D8G
M<Z<.HV,'Q0*'<%XO&%6;V2\^^2J7_[$:O_&6 NTCLYSX8H/#B=>#%7UO34H[
MI=8E"WX#?-CMW:D&P 'Q:'RI\%ME]+T6S;RR@.<SC;'3&EH+:'?BE'P#R;<
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M"6*)O"GX)*GY-UD?^(.=3JL8LZ:,U57IEL'8RGH'_0>-256JR(<YR@=TF=]
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M/2\@+.$CFQ@J,?B^T5AKVJ.<P1_F /QL)-"UGM!AWD8\AHNJ9]*0V -%0]^
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MD20],HS*.;];:*/KBXAA\<&:KW>66(4;P(F3K%..W&618\'8H MDD CV,MC
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M&2<X'K3]1<27%JTH@1@3JPA].T"^8=>/HJL_4T8!T;>G 2UEIG4:8RVB[?"
MDB(JK\Y:)L_UGYS%B<L>Q2^Y(J^K]^T#\:X4?$/EK&;+4C$ 94FC-=NL0::Z
M,CD1BPK2\F18^K"8/69_H^"S&M<M[0$H';A>X56*ZEL95L-M,HFS%2[?I*F'
M5$]>_?:A@J/9-R_=XK%)#K?C6JH.]].HYR3J"</.-;K[M9T3AL/-4O%XN7D
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M_*1D0>D9>A)%(_%+;_G]G5\\&+P!9#?*4YVM%^[7Q6 E>11Y3(1OD_]4L<E
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M!Z[@"@_\=XNEP6%Y**PD>..IO6/%6@]B'UA5\HH0;B@D68);]K?VOC,7=Z?
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M+MW\B I%P/.31*=,7"6VFCJ6-P@;1.-?O/]LY^B+\O:=G+(F"_C 5_SBCD:
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M2KN?,.#LW0_\Q/HEG;%:15#4I BKT4M:<1Y3'L_S)OV#MDZQ[XTG#!!:'RC
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ML@UFDQE@N_DECG[1^CZ%_>K[O'< #XC>.9G2PX!%.OW+G\D!SO7U :25EZP
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MHU(QVU60L#+O-3'L714Y:-3?P98:RFB<6/HLO74SEV' 7WSYW3\!Z++WV83
MFG*)696.7ZI%=KGHGL@+T>UR&%)/ZV1@\OJ)ZP^-\/>1]R(T7Y4/B(]&9]X8
M'S&CW> ]^L/L+Y)_DT_7OY//^G]3/F6)5M/AN9G JX'<2+N:RZP_:,-1"!%E
MT69X<[WHYZ15+W9M$FO@_'??A^'90:]A=+O>% LKE7VD^L9&+%!=<'<\:9#?
M(L4A@\7YLWD*MP+RG]^"\2=W< C5@6^V^R'D$.7]J2)<K7$X<JZ;<$^G0VTJ
M&8@3Q((5B7JU./'11/&'N/$);;2Z69+_TC7ZLANVU310A8;J3677VZ]R!AF7
M-V4,[6/>V>0FYSC@7AK^(EE$1L3*_2))FU"Y^,GS^!TDOT;V!OLW#;O)O\NR
M ;RW]^934[.[>.#-9._DDFM]OJ3ELKDEEU\Z>?':[7(CYU<9XVVM?5N961>F
MW?D7*/\DW'@7]7(.Q$'\9"OOAWK1BE:J^H.)Z_$'$]?V+TS<^C^8N/_U"W-\
M"_\@$=_]@T1L_0>)^,T?>.+F/_#$U7?^>Q1N+-V)J1Q(#48#B+%*7AJ4.29G
ML[+J+__NLT]D^FZ3^'2D1X#C^IY]:%/'XX1ZN?F'F5.,Z>D YFNO_A5HKORU
M_[V@N;ZZ=/5@X5"W!R%G=P]RCM?GG[;<??G8+6+^*9]FSL5_L^)D]8SB9[RZ
M=,N![=%"W9+_R%Z0?R8%02:C-/_@/I+_UJ1A8JMQ6&PU[WEMR=!E#1FS?[07
M9K#;;9M_]+91K#E<@__HS/Q8,6GXAQM-_B(YMGLCEBII?5W3@:O"7>U'P?$-
MZ=K,4+K@O<NM'+F^TF)>HA%[+J^\!^NO1QSN#QQ4=,K=1TF/.BZ<IUQ3\P =
MRR0>WT]\(M#*POXXHGT\]_GO@HN\80%^5U'16'*Z>A^HRRNO_H'2I=$<NKF-
MM.!2C-:[I+>QRVUIMJ!W>QXL+WGPEYZS"%]JO=I_/!!W?QF41S+L_ %!UU:,
M!4#$ED^,-):-66D;+KJA#]\E1LNUSJ1!Q% 1QT/\1W^[*\4=GY4$,F;YQ\%5
MYCQ^</IS6(;VRKG"[V("(#$_>OGKW;29G^I1]WU#J6G,!]E_D?!/YL9%/YU_
MQ[*V9U1QN?D&_B7*UNL6FS%)_Y0;O8[F\MM;7LT\C\"76UE V6J4Y_X6F;](
MGIMPI;P.5.+RN>B!8IC3L0;2S9!I]!>"M5C]3#KD"BH<=(ME(=\/0_&+I.TW
M,Y42UU/!CU9N[+F]D,]N0V=F/D_ 1H5E5E!M[/U5IS,WN?7'+(YJX_P!GNSH
M%XG0;Y9Z$ 2+J%ZI-U+<\2/E#6]YXR<")OFL]XIEZ$A!F?*?^@1=N4\(<CY[
M:_6;AS_])1B\7DSM\869 2>D5ZS6XHG<54XGP^"1![@,\A9] P[HR5,O.B1A
MIA/LHF-4.%O7Q4'O:]HR25D!"QU7C2#/NRR,M(+W(<C,\[@*28LI>XA-266P
MW"O(QQ)ZA.&3H.KW<?,X^9JJPI30 "078NEQ%PH88'H]5(DAH[F]@TP!NFR2
ML?I$R9-9Z@N1R=3Z-$QL1KH[T1B3)RK6FK54^;KURQJZ?G@X1@T^; ^%!6E5
M^.A?GL&.5!031$^I&YSDN["T><I\^(&UIK<M6O?X9D3V@M,NP&.!#:Q/>OG]
M%P8)M6[QK)<T>JE**E'$PZ 4K?1NH:.;S^RV\>WA;X>>2_'.;YN+M O\(E'X
MT>OTM^M"$"HWJ#C%7]P::%+51)O&6UGAG=/@'<\+T2J<&44V)4XL/\,_%3U<
M6C>00]FM^,JO#Y%$R_HQS=RGZ"/2B7(9&56$/.!_(E@JV:A&YF#J  FS5 =3
M/KT??-SW@[L?WI&9OG=D6]EBJOP=03DU"U<Q63$5(E+QN%V67,-\"#0 Z1\C
MEQ:3S4.?X_6<S&9G5$QF1SH,X<QBH98F+[S+F9S**2E6K?-3C4SO8)-+TD.Q
MY,ZK*QJR-:ZVLR #/P@AO8?:=Q;?,B':7/'J4L<=G3< DU:J#!C.M-S?6X*/
M3;R,,"F3@V62WZCJH(=1;L_E&50!W@(5QY/>.PZ[W>&V%$@L-<#'[2BFDF2D
M-1LIR_MJA^$W8$WYV_80<,BH.[+^:G"!VE7PP'J7<EC,$W[Y[(HR? 6"C\8X
MWZM9@^4:%7AA+HE02:3_18)4-$;O1ZX''A*)V)GQG!$CTR?@N DUD5:Z:0WX
M=* ,RAKZPK8USMHN55R@I0?ZII+D,D .CP_OR"R7$D)1L[QC?,.>[(Q.X-"N
M-1[WVY"G*>*]<&7==TK2;:I@OQY+?DM#.+V17O[ @ZYKV*=C*M\("FO1VT=_
MLSP."UH04 ]+>K'S J+ G\[J;BDZ@DD9HWL+ ($YE%B<\CMEF6 )TPW-1C%L
MB:\VY&.>F9U<0X;6M.ADA!@B7M]8\K=Z"P2>,!,V=)^2WTKHN^9I..H'?&[S
MJ=[8,GGO+N3]5U%?!\C",]>B:3$?T[ON RH%AM[B$2,_E RXMW9ON*A9SMIY
MBK0:6[%3O4HCS#]GG054\<'39G6IH49"MP>D1: ZK'86%8[:&T/4F@E; 3AT
MH/AIF,T0E=87CU\D*3L.=Q!2LU=]P]^D4<-)AF&MXI$,U=!WDJ(_-*'5C0)@
M["'J^_!/3X%MF?!ERP"$G>4#@8Z<%U C*%P42QMC"'JP\_7#PTU78WB%,KEJ
M4<Z1F;3%VT9(5X>BI./:"!UU;B9A9/"#P #9BH9.Z!VMGV(FTR^&3+/(>I87
M8MH6^A*L<]F?R!JL[CEUA]Y2EOB8]54&HAG"OT]N7?RB>!Z]-S]DTA+@\*W*
MW*4WX&$LL #5BM02YQO5,!N#F<W(U;C2D(.PF8\R+C<'TDTKFTZL$RE9%G)2
ME-/5N5N;&C>6%_/=!Z6,[X^+VH?R,_Y6E4*ZL$18T\ZX9Y6)SX&.8WDH0U/5
M6VX!W60#F>WT!5DZKSN*K8VZ251B(9X]BH@4A,,X706SRN!+&,N1W3>]0;[F
M"@%*!H"',LGERJ9>%")AFCHP@_$L7=Z"2ZME#OA[U5>(W30H<NU6%NB'SC9"
MRP()7D[Z&B>Q-Z$G@'D#_QI&3.(\Y@7!Z^RMF?[[+Y!V@<;[PO:JS9+G/&2^
M&W_XD5)E2@/*%KHWB*YD=(H/LH4.K'8+@4#062@%0K&(X&N@X+@B/:O[>I<-
M9B ]EAYQ_&Q83:6HW?!W!69O@I>XY.5FERO /5N\E\&>Y5X4V5EUZCT'+>>#
M'W*"!\OM@[%5T!QO%N%RHSRSK7=6G*;&XPIC^;D!?BTGV!;Z&;C5:MN3H8@4
MZB!P@Q.I&]@$3Q54\2ZB8$"V-4)S@O*Z@5SD]=3)*'27=AP/U^^A'5V19+-
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M R@V1WY0_5NC#<2V&PQW;F7;U4095]IGXVPQ9 W[GK0/]=DE)M']\9!V.%0
M#,AT*(A.Z_,N5YJ)+8\QD[OQ^3G.Y%J#Y8-MIX4E$)#@54ZCV+2I)VQ$+CX7
M"90M^_AA;/I-S(I+A@N/"+5IYW14_O!U3YMFE<@]^E&G$'*YD]GQV#85L4"6
MU:>L3G->O#!X2"!K^YLTS!B Y/)M;&:>DPG@C#3*Y1IR0'WC["M+LD4,\.R1
M?]D5?NA4)">Z_U,!/E_;^RGPBPUWT?#\:V_> 5E[TRS9ERR!<'>5L5(!A3E$
MRTO0HR9>Q9<?])RSJ??=RK- -X<VQ4X9G&6K+E%XUF\"-[_:XR-N[P_04_RP
MDNN=IT+8#AI[[=.FK2LV>T[/X/ETBJ1<5N:>76^,58(\$\)(NT\U(L4%D4\]
M"$D_^DS0L1PW0Y\']81:^6.R0]EF<JGE;X9(DA6:C1X2#"!Q=8M]6K4K$UL1
M:?LY7OL&UW,1(FQ "*U4*&D-4:_O^5<15Q$SP>:,SM?<5^X[Y:PD*WX*77-?
M@4).]'=)V_$@CH9$HP$&PQ&B=TH:ZT>SY67!Q]&WT5D?S]2J3;G!OA)@C ]>
M$ 4N,[-@FZW^P&77(?05W($Y,PG?1;=XH"0P#7E[B(?BB7-^&4+4Y;>?@#\D
M!!4 %3JH^,N3_P,ZK.*/#J,R-I?Q+)[Y'8VBGC-*5^]E! 0C@O88O>EGR' @
M +-1,AO]%LG :SK#UED'MLL'TUFLBA_NI5%3]$_1BA8VE&#/IW+@UWF!-I;C
M3@URN6 K^ %%N)J&@$0&0FK"^1GB/!]7 @&4=>G 6\6\\A*3V9]34>2!=[MF
MU_0F8*TM;)R6Y&9;CX_(4Y0/-LGX>8=Z"19FNN?"N5.E$;](!A?>HS.)3[T"
MKYJRD2Y:J"NV9XES26$$EARKB;G?TL-_"&:]>MK3P*(?\\:_2HBY87^(RH+]
M7I1J*1>^ AHK8=Y].@3"?JCLN+*M6P7!:S.HX1#K(>-0S+=JCH9*1E^#R*LG
M"?N?6:%I&9UPK9$_ 269.VD?0I+X0R)>^$Q[218OOPP3SQ_!]%<W=GB/^O8"
MCBMKZAJ#"_ JEM$M19)"A!)B/X!0@/GDW8'A\GJ5?3; \37NHBYS<<#]37,:
M1D"F*,-,2VH/SN&??M_PQ8O+];-E3KDM!/$\QXRVMI*<E)1$&V]K&'7XPZ*<
M*PN^9NV:W7KKN"H S"NN0"JE\@ 87E%1V4^#!O-,P%JP#IC8M4AU6>^$Z;:R
M>WN6$^SIF"$1O8+& -_>^;[=6"5GEHO.<RRJ)4MM$PVT!\W<A Y F1VT@;DN
MG2UIRD*4[_#?6/XMPQ!0F-!F!8H7>.OU.PBR8%EELDN]XU\I$5+<XJ;C1B(\
M7R?&+QC/TW/76*S)NUX>IN;(0V'@K*X)>2W\+'PPX7O1//N U1.)6K<",_\I
MO$D;YK7PIKA?)_MSZ]Q ?UME]F8''2AI"\.FSL=O\KBI&Y,G+N.]*QGV9/J.
M$E/H/1CXB/#;4TA2OE2P%(T"++_@ WND'6%T18*]7YV4>6;+#[$^EI[M&&9O
M[,!%<SZ=Y_L:)^?3% FJN,O8OXBXTZP2#8+.D')KMY&D<UL@8J>J[2??O.;/
MF;^GJMH0*.O\S=Z1E4>4(+6?DTJUG-]V1SL6KA!O95,,PQMI]$N>E$1E%/\,
M.-#4=9<9AEV2R%SIM["2*D+M[A(@(]/*Y [Y<$M8'3>AJC<3Y9"CTI6C(7JS
MO_U+:>F*5RW.G[C#Q7JJ?7\ZWUDZTKI\"NM#-K^H:0 ==)9C*V;^TIIPH/L3
M69LW<VL1^8NDF/6FZ\_<DOC1R>^3;$\];LKQVD:^_3X0*.IY&?#8TR(RVZ>3
M;Z[D%XGLNR".T0^<E9,CH&)?"<R)V6ZR=:F,"N2],E^_<#EPCT?:9TY#E_!0
M=>7Y*[9[UUUY>8]^1X3F,+K3X:_U\75C=G",EX.#KZ^^ C/S'#9S,U:V?(Z:
M*BV\G/7#D\4-,XDY:-DB@W"+<FW2?0M'XL4XU$*<==I1 &CWI&6L?Y#F5DRT
M*3Y@!74LZ Y87*1.YL0_I!<^/VHIO"5UV2?8^6I9B8OLBRH0790I7F(1#=QL
MHG/05 )RA;F]J&R,0]U[DS8HXF @!BDIH7Y5E]\I>_039 .")52[U)P.]JS,
MN067TFGRA>2J8##7T\.T:I!0_?T2J%S\!+7%&!#"?J%@!3#X*B9Y)E3:-+,S
M63>2*M)R%B_D+5N8-OT8 '[O=7@Y]%JR;G.5],)9!EH_=#7KD8*<7I]PHU5*
M52?D?;TVF9ENE$.V5VY'"PH%?RP#L:SSB3!I $M\M$5UA\9) H955&!>^10K
M90SO-']0>AQX?9\=4#(0G")^D+ U'N_"5S$],+DD5,\KM'-Z6E%D^KYLMK'4
M;W]_D>G_AW^(JC72]Q_9TC_.#!JSVQ0$+->6;R,0*5?L;:"QBVNW1?5<8B#D
M65==I=U9JUI9)R$'@PK&$#RUY=/P[8PG$F^M AC&T<DRI(&*)=4'4M!W-LW\
M;BLD\R[_6N7NB[,@8KIRBJFSNS U( TR$P-5-/KVFCO?CPE3^T35ZM)VFM*!
M2K4:IK@QE;O\>#$9*C$T3S!E)2JW._M6^23A0?L#;B>V7!V) BMYF>3&%M0[
M )/)Y_";:H1J=_5FK+@##<LE>2%A->T';7&09\SC=FB]Z3E-LY3SL1^R>\Z1
M+O>W..W81J\LF#J_803Q%*5[92RBOX,;LJ^?\;P/S**"=/JJG-%:KCT3JP8%
M>CQA38(^S'1(>91&63(0)F>=ML<!1.L!].5'&NO\.'=&"&.!'K8A 0:R-8]A
M:J5L>Z#(H)-#P?LY=_+\7:](CQ3>4C=^Q^U1SRO^ F@_%;YL;E&L8:635J0B
M\!_R3M W'F?!E]E4J1^(>6^E&T8<1%V[3W\G%S'9XH#L)QA\[I&G'1JA#Z]^
MG9M:)G&F\C-YP'#1ZI/7H-A*ZZ?$N,ICTKT5@IAAH)5W,<7[ _V91!%)D-#W
MZT),@Q\(BSU<IF\(,[N><_)<KVR#DF4.RVW-!*,*J*V!$,A3<1["$*?0GY!G
MJ^=WR)/%\J4D>G_L0<_W3;;/*DF2UW]<1-W%L#]]22TE!]W;'-(&0QGH=ISQ
M98?-9OAG$-P6CE&+1^%Q5S:9_,7W/>Q!TFD7KI"O'\E3'JX$;<DFT3\8>"U\
M-8[HZ(KM+*^EJ]CI56:2S-Q@')0R21$DP$J)1B.EPVP]GDKQ:V-MU:0!7G!^
MQUQETK@-:DD5ADG1+[9[&$S1?!WI708.;NCE692=OH[5$U_2.VB>OGIP1*#!
M,<@W;UCO,*]WAM'O9=WSKVPW[?AZ?Y%LP'_\[M(IV1\E*L/^!S[E&*A<]033
MVW41F2K[AJ\_Q^L-82*+6W1""VVO0G]+LV(Z]IV6/#MK3$K#74X^WE"0MHYM
MM9!7$Y703^7BCE:><B*'#-+![UM6U]+)(5A=*S./5LG!Y"PQ_Y&X[3XS-PS]
MG8/95Q$A-<-6#O:.<F'&C<Y_O,/0^U%PP+^6B  W]Y?YO8(6IYEDW[A[D1 Y
M^HOD7O;?KB\M$E0!3RS+I=4[688=TQ4T6)A,XRUF! G(^R8?4O*&3&<(_"8^
M@XS;LJ9>FL9&WB7']=<?N>#N:C@A*BJ<$U@=Z67?@[ASI9X-Z=OR A$*YI=,
MS,[%Z?&NFK:LLAT_[ C7*/QU6KW'#12WV<O%,8?XV[4O>&KZU1S[:J=76=O'
M8AFQ)&H (>&A%@ED_;>H,2G-#6@+?@G4*9%8V#]0M\G./B#_88]:R^XNN*P7
MS@JR$84-L4>ZI ]8<*H4FI^GQX=CGV8+\9V._2()Y>4\ROWF7M)?3^WM&X>(
MB7_4Y ?SM;?D='!WBST.\E*<)S?6((7EWVF&?]$-@?*Z3EQV*1#IO^N"#N/S
M2PV)[3!5_.KW3&U8W6#950> .=VC0]+-I^U5M48 NR_*C+,C!$*]VNH54T1:
MO[!2QL*5#'6MOSUS+&@F=[PIG$/IM/5Q8]6]0J1_JFB\+]V&PCHP7F\QG-JK
MIZU8B"W$4C+67VPVM",FE:2^A7+DZJUGA,--[*%5=*:LU;W!@E"B"A>-PW*,
M1JAQY@ON^H?.,I?'\L RDA&Z,94)0 G& 7^$N:5\BPT2&_M47'IT1+CXX[!/
M36ZU^?*26?#M@9OJSBG$+48F>%8"2.0F_938];IE>H9'=:>>?C]/08*;B^#8
M>+<>^J]/#\F<P_=NI,M%AQ<%+2=K[%=][^$5>1>\JQ?^>CSR\.;%_:0ON2:[
M#F/+>VK;B_'9H9<&"\-G5*,;*%GB*V;E5\(5GG(U/FEGNU7US7I72K$,#S)]
M/*SC4]X@&)4*8^B*J7WV5**>ZA<)PY>2^/WGTW"G;N\G6[J?FA^MK6.I ]45
MHX2AZ2W*Q:R*GAK5]%+;6LR84RTQ;XG<2I"N*C&K]%H:CFPEGMQ8>#D/(>72
M/?\*=]:O_H8S/L5N1QR<F5?<OK\YPL:&8)/)5P-,3LLW,\=*!V%>HZA-B^;N
MS#]M#OZS16CV'1^O:J"*BLR(\;!M>;"HKX;OGRC8N?7@[I;HU5T^;N6]BF%3
MQ%*#&>J+<K 0=ZA?UUD**A-$,)9+6N7,B 4Z6D]<[V0:*EB,! !C5YNPXD1"
M-?22,?AY( "":%A)38!V2'<LGZP%84IBF7INE!LA"SER*J!V@6IJ0!H*38L(
M;/A<#R&'PZ;<,06WN8%G9C*W7^FDL[4*<6UKOSR/0:R_+@'AG&@;"O $>?GO
MAZK]#^:_*1JH)VOWF.0VJ_G.SA5"/R7FS&6C/=53B]F,C1?NVGNN@+WQ(-([
M$;+Q:E$>R#U;W4".E,0-&A$AM47J:GU=5JV2C[[QI$9+DUZ'8#G+C7+;X@K=
MF:*?1B>/-%Z,BR^&U><&[\P;RS3M]9H_8:98:F2R AG$O8V&B3[8VZOE?>2Y
MB6J5-S0"/#^_8K@JHB-QKSL-)KOL85; C66GD10O-!9AG<GVIC-.0EPG ,K&
MHD+)^@]DIT@O.U%2399-Y-!&_3^#X5LH_Z;LG9736^"*NTQNP\E2+RK[I :L
M0Y)+*GG#F;U3<'B,EV39SL_T9+Y'YUCS. T1N*3+ZXS'0XRH@(!F;Q$%9,-6
M@3=OHG"&$"_,=+?0>VW1S:_+NT8W#G)2CP:CU#\!]0#![+ ZGQ,0^FK$XUD@
M,<>/#8K8>#7^S4W^H51JQL_673TG7L';?@1>XT#F>9(5\W6FI$^)Q\.$@&9S
MS8>AX+4Z?7:1!)A_LGR5\'6ZTHP\]%I=[P==19FD1F39*Z#-''/^ZD*+;.;'
MLF4_$%U&0%8$6Y%/H-RT QQ]>V\PN=;-V'[UI=H)T"3E#7<N.G7&&4$$Z2H!
M=;@65&3,[*93,3/0C&O>FP.T)?YD'RFWVTH/-&S"[5<9GMU3\<HT,7->O$/%
M:2S5:&CVP216.0U3;34ZVYEI89C<_624F$&ZQ,V3PMQ6)6=57.U6O-<"GU7P
MDA3/J ?,-[-]2J$9;VNE02Y"J2VOT!9WW2#B.VQSF>L#9\D<01;P_O--3FV<
M8V8AUMU%75Y\-,.0!Q%^;I(E^UWG9-'7&7G5V.>C.!-U!2HUKOYSV#,-%'57
M!$B>R?(TQ.]>$YRL+1?.->>@ATUS3989>UH8AN'\<=7MD$<K3,>/"K$A$<*I
MFU2-2MP-107/, FU(9SB9!]<VGP./25,P66-AM(!0JV<^M1[/,'&0_U ZC)+
M7)F?6,0#R+)=*FR6)JNIICW<>,4[-%B$LZ^JA<OK[,VZ)!4-03J1BHXPJ+2=
M]Q-S^T;HZQT#JE21S@.H:MI^RT3G+H]R3PUG--#[X/T<9.K:4'NFKX,5S&PA
MM'%U 3(%I\Y8J5LPV50MWS:Q:+;O)05F'%,)EZ\NZ&UG<A?W?%3F\TJ]M8(4
MMN]$0NKVYX1PRZ?/3>DM+=5*RMUL#841$H,[]0IJ)BHV!EN9!;L[2^DFAWEE
M T:;O.;_L#?Q\_2FK+Z(%QM"5['$"R%2SHJ)_@@BV>^C7<N%S\**!,P>/5"3
MC(_TEEEMBNT.@"Z:CF":'[B"N3USEHQ,SDOSWUKLKE!1/@]'U@43F?9?+W2N
M]YDWQSL$8LE;JB5: *)W5C^+=YB:K*03< CC]4M!*U^5M4*<3>KO LHQW-9+
M&<]9(:L.O.$3W/9+E>X$%HW[/)B$'MEA=#QW'RLSBF]QTP&:.F_40F>6FEG=
M7^:E;#]=W5<OG*$74.5YZA>RX,>P8'\@*KN$W"AT^^;=]O[(&+5&QAE6C=X"
M\HE?G\1)2A+NBCS<6$2#E[1QBA\^)TKAZ_X'9^\9UV2WK7L#BM)%>E4I 1)Z
M[R@=0D^A"D@G@8#T)A8ZH0@A]"(E 1*J]*YTJ5(5J=*;H%+MSXL^Z^R]SEY[
MG[U^[T<"R7U/YIC7&&-F_J\;^JJMO50K[WF4]]1/RG^D$DG\7R2+C9"W,:W:
MKM3Q"CF@#"(3#F$TX0O0SZZ[%U?<??\M.4ICA=HN:IDQ%0R5=&DN*3YY%]*Q
M\"R4\WK<S_2/60XKC35;Q>S'MQ?9^KEV ;J9X(YTZ63W[H8(05?/.DVVAU1C
MBH_T<0^+LL7T21*:#Q82935Y\,Y/270$SW2['!)M#FY.(26Z/MNKFM9(_QR$
MH-'-U[1UV&UKROVP5X6Q8N!WEH[%31@",>B0&0J(]2:O<9 7"+NNA02G![8=
M**5CF\@V%V.:V7#/MM2+<.'7X"6T-AYE^IO1=X$-WKTS 0$H2,?TL*^)T"VF
M<IJTY43 L#:"K13J"5B*IL<SZ$;3_%R'CGWM/[C&@\Q_9R+#W85WH7@^")73
M_[(KGS:/CA%FLWO2ZUN5F*"1]NFQI!54.\X/C<3 8N[JMZ1XDNW576\EPY]/
M,(/3%6+>5-LDP/HC7:T<T/M=&OC"A+](,I*2A3S?R!V!)K*5YAF#@9IKV1\.
M>^%"7CN!Y3#1V\Q-K^3R5X6*OHN?S#*IN3[=BBLOK;S&ROV@)9]#G:'M(O66
MR%5,/N40;&;ZBZ3F*WJ/*5>]=K#^-O+CTQNC/RNZ5)3N[WEYV6=D8AN-#PW7
M M>*4Y=L#9"HL&$&= <C.Q4RW\L.\=57?2BLT_0Z>(NK3467SEJE#K(C9I\]
M+VV4ZZAVXG]EM_9[!0JC]=*X,M@\J]='3JN?,5J,NV(*J.)(_ZUB'F]UPRPV
M/4!?V7SS?:(T5<]3!4TDCPFI V13[?*3# E/Q>UTD^A6WF^#CP)T-TK_)6 =
M>UV_ZR:")&M45DY*2(_''VDHR7V/V3=JP8O:Q-LX]YI U- QK6M74NN#C?>:
MBJH&@()?4QX>$L$5.SL0+M35C)5N"+Z5ZYPIO,Q#O"*/Y[SZRD'=4/RHC:<#
M'Z5+D_ON$B*E=(HAG?@UI]EW6(*(SKPD HBR\[&Z?!*AI'9,!]BZ&] 32^]*
MYSIJ/O%#,/=(%^$X<^9$LK,?;^H5_59Q,$3Q&;GT=0/8E$#.5;J4:Q'1[]0D
M>-KPDAH]U<9%F13@E*I<2G11]'N4I(D>LQ^C_JU7<XI27VP-;W:%?:-_.[_P
MM>*?RS+_I+;A*"AP>X9CBK.>9];*Z\>_H>?TF8C[#:O]8GY]9G+Z.5I3\!07
MH^?@'.*;7220P\!$9C55_G*IW'8K995K*/E5^KY?( [>!XI.?^21R;.A. -D
M:TK@<]W)@3C\2^<A&6OE*;5P4#5@R< *L66XZ#R24YNM3-$N*M\BK34#G94J
M1%?0-5V[F*V;<78V7B)&?/JH7^1D/'!:LXDW:C4692AUBZ=# AJ73EH<[^\G
M'W?KO'O&;P2PNMHMC;YSZB'S>K(N@\@9X""8 E .7)T?$'4PJA+);RAJKU_%
M?LN_&=!_%U47+:I[[RKJJ8?D(-N@)-&K0AM\B%D=D@'9EOL=B#V8&9 W^HND
MQ?QICY>93?1)1';,OK7_SF)YK96#UI&54"FN]S[RKC5A4]](SI/QE8 @(CFQ
M\)8<?6.93JZ&2W&M#N73*Q_K#7%%[QYJ?'S2(\AU_E% QL+;MD/\X]WQ//\7
M7% 76CAT!M]ZT"J;(E\9'4X8GW(J"1L+!Q4_Y0JX/ DOW:^XR-\<+5&)<"KK
M-WM$4 [44^9==DY?:17!J_>9A]]6"0'],^DODA))L[/9GYP^\>=5/WF=J(_=
MMO\T9U6E@WL7K?IY*G@^TT?@0[5 &"-++];2AFFDIAQ(BLH'Y5*:F@&<LTWX
M[V$NU/9)?RD:/#PH _LP+8WSU89T,*0ZNOIF>=4EC8DJ3T^V\F8OR1NA4X=O
MYZ%]@OUGZF E^##@5Y\_.68@!IW--+;)<TGLZ[MH2=CP39>0L4I#[4-7PB,W
M_-UVG\+B,FUI>^:+7P^'1@]*G#2MU1$P-A_XAR\EK>[Z./$6 ,9[*N-I"K9S
MWDJ7.7Z"CPP;E03PLYUY'Q1\?J^L']NP0!CS'P-S]D.CI\VE<F)8TZF2!"6F
MZ%T9UM[@/ALOLYGS]PLAGR/:RACPI$!2X;3VYXT<UO,2S8\SLOF+[@*DGM$P
MFTY=68*C0[0(#Y!Y)1\?>E_TK.G+/B%68DMC^8NY*3X^)A>OF+8AQ84!"ZWU
M[6F^=&+ OT@.J5B-M#>=VX/D@GR][M@&W/*9B0=L8*(-PA6#'?PCKW&P4D#S
M&I<!BHH695Q#;Q@.1%\F47W5T!_*$#]FT#T+M1#[L:/)=(#/L&'01#!<(A16
ME6H;A)$Z"7R>2U@<TGI@)(PY&&?H%Q8J<U'DO)/R^ !UR^:E@2'&E. U(DZC
M,FT9ZOR-VJM*&VRF/P)@E.RF[H%>!*7W_3'8^=OF,*63HZ06-^K C%-:Q8X1
MUK<.S:MV!>.+<B..^RA^GH:#RW,\Q^HFA=O\P%^0="G!S_$+:.1>3C@ SI4D
MW8P5>S5J25/70ZA@,](4'H[62<M*$]9$^KBHMM  <#%D7E?N;"P- >]4E^ F
M9@2"]*PWQ"DY*;$<PVC@C-"8!_A-PJ#G$J^,[,E0N:=U]B9GG_4MI1Q:7HPK
MMJ515(U22D75EA8E'2#Z@3PQ=]!1W$]V9 UA(;:XKJT)7I*B"^A&K"@:^H7N
M^<_(*C[VC6S1+F9:EY&VNFQOC2606SF/I8ZY6TU(!A,W-T'3;<4.)HJ:/OW9
ME0WX6S=(7,C;J&#3T6[EUGCO\H6KK%M_D9R3B>4D# \%'GH>;BS&(D +4].=
ME5[.QCHA6HG2T:T&H1'Y%CF.WS[(_1">?K<0\\[3%H6+DLLOS+T,>SL]O;.W
M+SC.W5$2ZNK:XY)QA1_-7#O&IV;7J#.X" UB]#=Q4+;5-+C[)C]" RT.E$O,
MP$5RS3_)O\2*/K2#5"D3!3B^#V!A[F[%\EB,8,9,*E6/F9&(JE]'_^F'[&WC
M,]NY@ ZU9W=B$Q=9L821+H'K5OJ:Q>5>05Q3"@0[!CF@EN>@6D7)U"QUEX7>
M^[&A>Z;TL<^IC.^O(UJB[:T]1S[!>#J4BI_IZTS<0>4.,[0ZHJ[X?%A94%U_
M:2W1P)"7.=.8#!"*(Z$DO4=&)KQ[W2Q(4J>?=I/:\2\2*3&]48"72#*PQP9!
MB6J@Y&F()Y&_V@IA$4B/2*?MI7:ZYI3;L%93)8^MAN$_Q<]'\R"H-/JP:2F1
MUX3I\%N;7Q$A'K#--(7\%I/;.(,]':<,O.:F@,ZEDY,[77F#=\VL.*?KV+9/
MOCWT!&=M J4$[)F2JDL6>YZICU- %_$@YZ"^@U-.;_JR;0KG94\[B+-)J)8B
M^$B\]HC:2[XIS1GT[/?U&U<@WD"HN2&1_X-F%A&X:;>3]G09WD2:J^B)^O^_
MX !_+S@2C6>^,>L)TG9)X#LJ),.*G;1*B/EA#=^T)OV&7D+O[M>6!]'*PY!2
MW0>&"&'WJ?4_2Z^: 2/8RX$$2]R<"W&NT@P],Z8K:4A'[2*6,U);4Q79-QDD
MSYU$%HM:&MR]A8[NYN_K%XSZ(:_XT]@)MX: &P[+LTK[0,"3="QFZZ.=:3N?
MY#VI6,2*3FKFE.F>W%0%#3!1[=G%N.U_CUM1JCR-@^J;_XP<S;0RA7*4]2V5
M)1*?OFQ<&UZ$CLR%65;&_]M5XN@><X@SZ-T&_Q.J\H?H_1%IGX$9G)URH175
M%E.\@\%S+VO\32PABU!35C8Y^\8D3SE$YV1T+&I$1%'?\DU._CM[+V=G:99X
M-FT IS5'X+9/:QIV=-[5 3:;*%"4OJE1HC^JGU[4J%!7L AH2N%$D>W1I]XB
MF;M4CJ^AR\D 8_U?N]P6$\@3O?K")N'KL$1&CH8UBDP/Q7N']B7/V0Y!TVAF
M?P*&CPYV[O:?&'9U:6BI+;CEF!*^''7,J(3BP":4]JKI,P[54Y56.<C25+P7
M;I(K,M"FW:37%?6 /6&HF]MJ$-EAZX#['J4CELPDD$BACKK$11LD1-Q[25+O
M6(82-7S3W!3RH2EPP9O&W6,WS72N47I8/J[A3H ,AS;_&- ':?V P3G885BI
M]*1A_)7"XK O>P*4[SDM!-)<7.:LW[1EV.2;75#T^T'9U#&16GB72:#>#0JI
M""*'3,/J\.><MZN@^VW( :AISU&1&6Z+0X.FYZ[U3 %PH9>J+PM/:RXJ#UN#
M%0)N 7R# N6*#ATN)/4R\/!"4I77')(?F91M]1$*(&F\+I_UYJ/KOB-",B]G
MS/=U7Z0H-6^]S95\2@0.T)3[)QZ]**#CIHL^KAZB0+VKC]G5O2+295:M]E@(
M-GMR_4;ALFK)U74/-A>&Y4N].2DS+*L1,(,^<9PMSLL/4D/=RN\IUT_.V+,_
M=BL3F@&V1K_Z<,K4#Q4*3]^6>R[)VIJ#_UF0[GLP$('.9QI[ *-IWP9&FYN;
M(8AP8"O.1[&)FJ&0QZ@MJF6^+V,^JINSF.IKJGN:%*?//1]C\8E)?)E1]+JL
M>!+T'(S8FMHW8+!!,E[VBF3]FNKEZB+T^X^HA(#73<(40V!!,ZY.ZO;&.3'=
M.6X.5^\G:%W-+:132)/)A.&?O#0L;C6$[(SSIPLT9[2*@/SJ3K,#^7)-ZPL=
M/]N.#,/+ K3^(^7<"3:U!TJ#61H)*EH+O93X:B<CXW1R0/NP=G%WCI:L.MP$
MCW,\C*\89F@12U"_RO]/B8VWM*O@F:Z%E=K]@TW.:6DY1I'G^*H2ZE#(-#]6
M.*H4NIHDRLRF^4YF#X!\#QKJIO'[%GY;#F#HB\UF%$?KS"B,1!Q[X8KZ#B(=
M(HWNC#_!%-<E#%L('9;GE[,URU^4??RVS*SI& L_MR"!#8Z<G-MBE>><9MH'
M7S6QB-[4HE!K&_B#)6FNUN4/O;"&W99>RK8I 3A/EZO#&VZCK0)]S?@%<%2R
M7A"5MDCY3?BV95>[T3.JDS.Y52+8_ 3V(5YN<2AC'"I],^SXT?>HZN/_R%Q[
M',AY_QDI5%M59!.=&>O7>#^$L(^+"O2@1V@?V(L=2\%)4=XAY]64B-L2=A9+
MT^&8($[Z4Y+2W58WM/*9633K:O1U4]37.E O#XPQ%AD;X\ ^KKZ<K<U9-8%O
M7/U5#L%3-[V^)?=I@!4\1K428G)S11W#YIV&Z_1Z;1XPXQ[@^/)3CL6J@([X
M,>]&W9_,T2_K(KWGE=I\*=D,M)CQ.!UES&H"&[9W&3U[(\#[8!+Q(V5O<R%B
MEAR$F*H\$H4TSZ"B5.,@?K&<1GV@;].N]A%%%+U(MBDS.7JL=(A&G^L\S?J[
M%TUA@T]=?[W[>+-<&"'4  =V"LHD<^W31FN%=7*'@T ,TN#ZF*/HXHN[Z,0!
M^U,78H3=S3N 6UA,D<D0^/'(O?0IG1E@,ST7RM% XR*.:RU&$Z##&8N67-#(
M42##<+IC?J/!;2!4LK"FS$CSWIAT[>_JXM+8Q%4N_1P#(N3E>P$S*%37I#"T
M<KS((D.CJD!#C_Y<HFS"+X+I' C.YOXL,7B[;/K8$?8:J)\J]06'NN/8E:<6
ME5T\166\>B'^;C(""09EDZQ<;\#0_-U!21L>_QR)-]'F"85Z%"'S(%N.9^JH
MD1%(M_H<)I[>5D8J.QLE)B(8QX:[&52DTC>>JX/GW:U]C=$Z\NQ]\ NK4MKH
M108IZL'P)J<.&WQP.$_BE4GV]6;/];;IG7E$7XJC-8?935](>M"%I+^R:20'
MD>J;8C"^;%-^W.P"2#"7-;1?6>$6=!):FI^*FOF07^=;4,)WO72;@S*CU<"P
MQF6,#TDN&Z84J!'1(PY4*5I.;::MFVM;T*= *:O+4?QKTOCW*SQ),RNM'B1W
M*:DUH\K041V*PBB0S[ ?$$ D. W3F1]YPM9J6'"E6U]0?*%R) S&[BB^*!MF
MV9.9;TIM0\>9WD++V1V> E8._K.)I471?_*03!1[5,N%'$";8YCC)<$<E=9>
MA#["'? =\,;A!Y1Z97EQOD;BFX8J]X[ L2D^37O#G)A^0H%9Q\7\$@JG@ ((
M@P3(]/LTOEZ&N8AO.V($'0\P"X[_TZ7Y*/-I,WQ.QF2)QA1>3P REM>6U!H'
M.8YNR*W*W3>,'3+]$Y$W0',EN$G9N[GI^EV-=@Q\JT(C"AN1!AKC3R)^"\1O
M\>I-6CWYL41'/(XX2I<^BD\"H#CN!E,B,&#F'HC6%R<C?9U+WZ^)I)=[VPUU
M,^W5E$WG0&"#_X@CC;ERA+C4>\R"998D;DMP;/=N^W'A!!Y;G&J4D4"QD4"L
M3;A02NG_5,I^.1XS$UPE+E,^]"CZ'7L"*19JZA@<%J @ZJCN<TJF)RW]R5,2
MUL&38=<'LH%ZVG95Y*C[5V3FWG+,%R]L6M^#]M=CR9T_T)54*N6.J43$0C$(
MT]0AJM)"ISO#&7<AXL"[Q23/A/++?3%5G:+*4U/R4H)\*H34N1@"T&826L>_
MX"=@HV@X&OYQ[*(58F@?_X_FZ%)CPQ-O4E$I?0U\NTB'Q+&1PV[:CFA;(S-0
M6U $:SAXF8\&SK5CXP>.D4FV;$?E[W[HAX/<+>[.6X/9BSVS<W%WW^7'Z @)
M%;#:(2ZWY=5!9LQUW?XBZ54/&!7+J\Q.\X6N1=4;#[,A%*N:R.Z\OSEL(&O(
M6U22WLS I"QQPXVF3#.^4;A5T?NB:5M;D+Z7Y!B\UJN07:OS7,7'X1D44QA4
M[/IJHUPXE-\\)6C=LD!A(R6HV/D5:A"@;K/\\??/Y=P?PWZ#IF/O$A;L/F(+
MY=?Z<9^^SR[TG+V%'*R&>2P+&,8L>C .LN^NGR=#'J^<9ZN:+N@BD)>:65,*
M&PXB%;*E.)]7FG!9NG7.O!%\2J@TN=F>6UU4U%1WU4M<9LW6>)Y"M1K7?1G5
MUYVUN+>4U=DX<_$.'TGW7YI2SO*.ZO?R>QGE*'YCON=^ IJ!BOS<.YOT\FNG
MJT%>BB"JY=_T+@/5U>#OU> GRZK&%S?P2[UD6Q2A!OBL)AY\BUYO6"G351P5
MU@6)^#.^BP^:?];ZFY2M^ /V&F;3MF0U$QR?9%Z,1K4F[#\9VCP\Z0L2.T;%
MRV!'MUL)]:Q-G2L9(;0FZ^6"?T;VP\&[Y3>(C%%?WCO"7OEAR)[4LBDD^%!
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MPV_;C:FI=0]&C2E7BD6)LMGX:7=,1;1#7X'Y;*[$37PX,TT%7U)N[W.VLM_
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M\S6E9A_0C\:^S:'8NF[,JE)232ED&_O6K^9G=>]:WV]HRT@93_&T]]%7;:F
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MP ]/0:Y#D2(IXZ!C=?@0(N'I@FM*Z6FVG&-Q7?[C)2-7IGK(AZ'.C:%WDK\
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M==>MM^4* ]QSO\E? J'LJ1!#<\GI#OX&<*,K<<?:H*$JT%&@)S,I12^2:&8
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MJY7-&].0-(\TZ7:@I^> Y';NKTQ(S0N/[;B>CM?KJF 1 _K2;3872[U@3EV
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M&FV+<H<:U.Z0_U#GR5\ZT?_HY#3EF$0+_"H'Y.*<(YZ0Q9ZTDPDWDX$(/;3
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M-BWEJR8:KJ;*70QQ\G[#X9:=JS"CLC<&[H["D@U@]I7I\N6M^^U S(X$^O^
MV64K@Y K;&&<JD:$2C3ZN)54TLQP*H,.:[W XK\W?&2.)")E,>];O8R2DOS*
MZ6G$;PWJ"69OW'.K[/!]'"/)BLJ9.DZ=Z+?U.CGSROZ+;/*OG>2 <:QO:(RY
M8VM-,:DJX%V"T_Q*H&P/6%&7HR*U$=VL I+N7Z+TWE=K%?YWI=Q*D$& #Q[&
M^6*QL*$!2N:7I=1%Y2Q37(L9@OB0E#S:[$6H:['E@+3_H#_9:;5 BWL3_BY5
M'+,XU0XMNLK4!I1J6.,6[GIX_P+#I_Z (Z[4\_2[<U7Z'E<L%IK.5.E[J0<N
M3+,R_[< 4,+Z<OD3)=.QLBMZ/8KE!=$/"KEU#/:Z').F^7F82\Q +@4.ZC5:
M!=!+]BF#_5 Y. 5,ROE%>?+O?N5-I*!"ILVZF+XXL$V44FS!,=>U[)!Z8G8M
M3U?9"6M=!JTMQ!-1)@G@  5?O$;(U\S+9:<&W8%EB>/4+I:Q$OE:+)?&LBX4
MO#[T;XA@(<K&2D BN7HP)T/RMBP\=B1-<!5U^8[I> ?+A=O1[XZ![-5/F^:N
M:)9G4+],#<4RW$URR7+\G_&4PH]_+ [PE\4Q_H7OX:]U%_!BA?N[YY+@C%Q<
M.*$_N3S.[BEF##UUA"5)8GLZF;^@5,/,T'0(=< [^"]IJ[@$\>]X$IJJ'O//
MSCC[G(&#EIDOT275$"=PD;/-AHQ*P69#&@4%HDA7>%PPQCY-3OD;E;F)]6AD
MTBP,3I!Z\?!:^D9>.^3[!>KR0@FXJ'H A5C0A0!LBG,.H7(LH_9ZMR+L%9)I
M5W,[(4,[51BJ%' !P[*D>Y"6I)C]_A> (//7&@ 1"@H&ZCW%+\#>V=97DRA@
MAK=U'*ET6Y1#X;T>C5-T4N.9QT ?:/#V&U<,?:VV=V.Z':^/WTC&-$(-EB.V
M31>2^<>?L31'!3<SNO5Q[O/%X]R:D92> L*][X\G4M4=VD@15K)7*ZJB%BJ<
M9YQN;7\!)"^(CE LI^V6445=IUX;*>BA8NU:CN844:#HKWRK/[O] LPE)NUP
MY\AK>@2IK@ .TB$\,S(XEKKH AC'@)]]YU/,CBP-:'.MHX9XQ=MLOA.N J;[
M[*0E&:2SQ1OYQ1VY]OSOU;-ODK_0RSWDLS SU&VQ_0)0Z1.YUS/"'EFXNNAS
M;Y$A.IGR 28:D+S@/XF+)55K8BJFM5:3[<["W,R<JS>MKYC];*X6A8(-G%?-
M%1V]BY+<J&@M37(W(+V7G)F9TP2!<27]?F#>*']4^$Y;PB>M'/$+@+ HR* T
M)Y;@L-")$#F?4^4$E;J76[;=2&G?V@(, ;W:CI33V_\"5*1<QX6LP\RK9<PX
M_ARLWK4?TIU)(E0FGY)%KQ+<3.D>]:B):/!MTZ'[VKG<_R*EP6!T-VJ9^XBD
MSBG#+H[GI2_#;9(9.*!DEI"D^(*WAJO\B=Z'69H(7JL5FO&<WM[XTV$&0E4F
M2^U'$V"?_#,KS3L=M.+N71QZE?)[#3T6]>:=JGY#3F"D;@W1.!4OQ<K797]0
ML4B8Q=L6:_'8ZI]H=:SAW3+C89T/'T@/4; I]QT%^YI \IFEO65SDL>0SWWN
M"I^8KEP"9(/SP+X+*TS;OP!O2%/"ZW7G]^9S+KYB/$KM)4K5VK T-3ASDD1X
M/R3;WI?6?J]L/M"Q*-ZKQ\B)J"BLL"-N5:MZ9Y^MW3++#VLT2+4 G='5Z4%;
M1)OX$2F&7^8X*]L5G'N&GU-Y!+>@+WP'^2F5+ 5P:T-)S=<WQM%56>6N6@D1
MG->?U^9_SQJ<I3+:!?]"U?<QC'FT5652()XSYEX0 +UR='7%3!<YM=7*\/7[
M1=0M\&SE0URX;),PXH3:RT<9)UA4'MQ%-!"5[W'BQ<+ ]4U?1USK5,MG^D<J
MX\]OFNAMQ:L3,@)E+=MT6')X%9&XDIR+<+RY?@'6Y%$Q**XM7GCN^1&X74B^
M9&*JK<VB:?-JKD5Y;+#Q'5O4#DZW$P?_5,(33L;U=#RBK'O0N%SF#M//J<Y&
M4U-4DIITBW0I""P&JA#*3[=M$8UX,'>.-)P_+YHO\]X45\0Y:_7U,C_\%*9:
MNIX3E-,\#(/N\J+"J0!N]I^:^1'4;BE%-A+OJSK1[\/4]P^9$WT'5GI_I]S0
M_:VL?Q"!D3YSF^&]!21GR?.[W(]%,K7$D&R9"5RQ;LA5=;9TD;H#)^/QE366
M<K3;Q:7N*"UDR33PW "]&+*(Q!5I.FG5HYB;^,23K,"^5 &C:0KZV!B/.W@I
M'DO.Y_X3D=E2=T!K[PV$W,V]$/,P  T0U=<0MN@6?T#:4#0GM?TB@]5C++U7
M7S;_\Y:A*'0K'"GZ 4W"V35L5V=:<+A&E=\CS2Q7%WXR4Q8XR3QU%6'0[ZRE
M5-Z@FF242+V?@)T:E20N>M]XNJ:@C2N.C,/1TX?W*0*IJO7$TV\)7]28ZYUJ
M!EXF^G5T03Z*-.;A?CB\#>A*4&BIWOD*Q_5[P[BS.,3R&ZX&PH$OR2&6#X(#
M1B5\MXMBD*N'J(CW7..2L0;7-ZA,9.YG(DEKF5I)4N_\F7[SZX.)A!VCG<B<
MX^:'/OMF'?.Z^)Z+@N^/AA)0HK/\U6,<(XEB_7YQ@5I\9WFZH -M>P^=KU5\
M)PPO$+H>]5*#(G/B\8 4LXH."S3L!=A29 W>F9T5J)!R_%<RE6CM+^\T^BI*
M8'[Z''G-/BEN/>I8;NH\;NRPS8PA&PPIM4<]PVWN;H9FX^LV!$4_N'ZS#D:K
MC+T_@U)CEL1MIN] .NKL-^USY7];4O-N'*<(7C*]>*4$RS8":@NY]2%8Q0=U
M#]]A&XU<=/]1A>F;9!LO@?TTP)6AA8E9S7;"N%%3)$@[>=J4+MBK_S7)OAUV
MY0A? @<AD)A4\T%<N8'0I=0X OW*%VYED?-2UM.5,'\S*%&]"]8$:E8Q&S#*
MTSYKX  JN+]S]GR/07SV+ 6+R0NZTJ)K#J"CLV42%J/"A$HW@(*%&YGS"%0Q
M"P^LGS*1C"T G1;PC^V\4?H!N^P..O7&NJ& D5L5"\MF?:2/7RH2L-Q0HG2L
MO!/]!M;74:D]2#/*SZ*PJ _MU5: 9NGM@<LDU[7?&#997*U8QSTBJO48.U/X
M5KD-"V%%TD&@,14D=2V2%^"_W8=[(HR.<-,^8S$D9&D;"(IK/Q7COLQ_T)UB
M7WVWSMAAGYK,>HSS[0[BJ1R "-42,C]XERD+K3:RJ'_JPYKT++ :DG>*;TG0
M%ND+*GT5' E F*V5UPSI,E+DC1&%LP>@X>5]$]/P.Q5-UJ)2JKA' 7H0OO.F
MXW."N+)B87+5AM/SI_P"F$5MZL&4&P[OT:X5<I%U:;9&(&_I2IY\B4V9>&%<
M\IC('2T*!=V>X2 #6F9IY=]6>9OQ-IRXL*IEW0F[YE@PEN9H!2YZ#_6N0(W?
M*E#?OB$(1JW:021G88DM/0W#H;H(,H=F,KCGU;B9E@;$>!_3-D<]?(##\C%6
MFH\AHMP:6"DQC:.(25=H:#N9V*V8'?& APG4J &A@+"])LMV_556UO_Z8$H<
M28MJ"\$OK=D)D75$Z&?-]4MWU ^S \I#!O.W_+S/!"+6M'K]]KI7U1W+M69L
M%=MT_3D]#3#;*3B7^AWX@ACQ7W?6S)XE@B8U+.7NE)6&;8"22[_CC^U)%056
MZ_>;SE\>JI9##K=<@SJ:1E5^$+U.=>6IG@O.A"E/!JS-N$<-',-DP-]C]%?/
MK_#KC\+,RMG4<-5>X;$U&<AZ0T<MY9L,35NS<3B.:/:4A]F(GF7.SP1\7NJJ
M.]HOA84N;]T?(VQ]^J\V(13[^2U5"4?JNN%G=-?;,WY&Q&9/FR?]/@L"V\"I
M*S[R76?)L^2MA5K"2)&]9:J2]S RK<]"9UG#1U9^BP'68J/++Y.0 ZU5UKE0
M8AE)DIL>"O[\L,W;[D@A-YH'M<(@C\O*JP@F04F(O+ %$JL-JI^&.]]&XAX#
MKFE<E)OM/E2#QWPQ8(H?%CY=[_1=CAW["C>O![E%V^WRI=PO@*IYR2<&8\^2
M(_,2O'Q<%].\43;2#$FB"A*;.+T!.'",8LU+45&=;@P2E8=*7,2M$62'ZI-
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M/8WLCRW5E_T]0PQ=M1K[(FP; K$:<P9))"-K:;SR9U)OP]^T01::6M'[Z%[
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MXWNY?(/",Z2*V)6M$?&^S3E'4*O/ N&.:KN)53QYOM[M.ZJAMRV'9W3S^8C
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MLFW]WR8[#+);<X4\2HZQPR%RI6^Q_"P&4E2M0#0,88ZL/N>.LX!P3!]$Z>(
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MOXLS*1W<L21YKZ[]2+3S=819OA.A^OJ!9NE*F?PG0"7Z%\Y!GON32(G>)\)
M=]_XB??7$X\"R>,?ELA_X7RAR?6+/\5I'_VE6.Z,NK]-0M;"5L,U"4E_%?[L
M??,"Y#Q)\] ZP#;67Q3JI4Q;&ZKU9RYW\<9]#='+G3@PHKRO;_Q.OO*R]9L6
M>2__[)^OY50FM_8:^I:_$(+MT02$_H(X^*:JE3_A<"?HH9Q0_80'8G!^H-8;
M8?C*4JHT\4K4HG&(#CU0.H8N3QH3DQ*-JWH\RZUM"-88J[A:95N;JD>*L!17
M=7KWNHNZ/09&6TTL395YTS_YUZR^\1G(YM'>$?<&DX 4%FQJKBW5]M7WX\G.
MU]B82NS;%:VRO?S$%_!JUX2H+C+8E[^%L.8MGJ<V")&))PS4Y[K6K2<C',);
MUW*-R>X'DKUS@TM[WPQ+&T+!Z5PE@'6NX-5=>;C.7L#C;;Q),VK-0TO[FD]Y
M.06[R"V%)Q@.SXZ]^AG)UT:-"<'[6V(P+#(>J_' /P'8G,RW %$;[#O1?X;Q
M)P#CB.3]A?2?-O,["%MR&KB#^N<(0XS7QG \/L7ZCJYUVV]C?\4@#CYX?GDD
M<!$%J3Q0\\.4CI 7YT+@NU1;:?=K4@Y71+YOT6<J<X]2'2% @P @'U<(G0,_
M%1'%YIKPR;4)GJ;,=O9\64!2ZR*@E(.CP[3\F.B3. 44=>"/69X8N^/ZM8N&
M1J&A.\$\V25RB0/+Y3FG<1FY2X>?F4GYVJ\8*^DN6*M2@!IN;!'Y"[7V$@^@
M<,$[(IH2?@/<CB.BP* "G?YAAF'89DE-K9%<O8W]$,%8\SX]SU4'"%AH,Y^'
MP;C7"CZ8E)KA;#5O.-Q'Y11^!/O^ L%ZR]V T<3BH\G;,@1P !*'CUXO_+?-
MB#,FWRGDO0["\1L_5 .E5"YQI&JM;=>;&\?X%YM/&QL)D@ME B+^T!\/V$S6
M:_^+AWX"=I?*3NK%1I:"N]S<E6Q(I2 %!RI/Z9MGD$IP9*!R!H,I]TP8A="N
M9F#;5GFUK\Y9[RNWF1PTFP$RCUG^HK)&;"[%?A"B;H$6"2;H(4%V-0R1TG@1
M/0%ZK!'GSIMT$[ I.G/,^1.56WE2:[UL\^+(<]6%2MN"&H&/5@OY)'X[FREZ
M5!]]LY@,LSN'6D43BUS74 +.]B&,09@_ >1!<RA:4.;\F2\GKEWZX*C?^;(!
M)+VO9960&Z #I9DE K;IM(KVSAES:RMOZU:.V*A 63&NM8B[)0E6QB;UTWTH
M'_ODV?01YWX-@4-AI S2G".,QL6C*!]K"LL8P4-Q+%B1G(_LEE 3HFL:NZ9Q
MA^+&)@W5W"?V)P"-&ZHZXK>16/(#A &MVJ*!\^/!BO*8+\RX)R1;8FC28](0
MHD1K, %G5HW0%"H6\)\+6B$:0 :BC%!%'MHAZFK)Z\F;X-80L '.@X B)9R\
MP.Q(30>*SIMCZ>;ABXK))OK5]!]L\;VABWRU9DB4SBB$(('9Y4X,:)1ER)UO
M+Y(/8=V5C\,Z<==0];@0;U:!!(.%!\1&PS2XFP5H%2@@Y '7N!]=\9MGL3O4
M:C@5=A^[+,<M3S<-7<<8*9[Q+@M?J)(_<.+Z5,A,=7I(G&>D/HRFF:(H>MLA
M<!3);:78Y.4&<2WL/(Q(6@9=*!6UI'I"!VDP:^MJH3=QHC V&P4'N_D/Q?U8
M60JB3F5;__I"[4\6C? W&X9= RH)>0[G* PJN4L,<;-]TOI<)%S9=?[@R$@_
MPD GAM?SG0L:A6%8^DE<JYB/E&(POBV;2WIQB6Y282,RV_MYT&W0^&?0!3=!
M>!(3NB\>DAPBX\P61"+0 P&K=CQ3EWG>SLO(_<'D PA<!N] >88OVSEEQQS@
M3_Q+Z)K2M[N0<#,W5<> ,0)W\<V"RZ(^*\V=9 XAI>ZW,%BX(!G;<:0*55(?
MD&HA+H9A&]"&=G5]PE^8L0R,B=8/6^?[Q-6<]WH.&.W@/$\@/!O#3CV:3E@]
M,7R4+#H[UR$P+OL(>R$0L+Q4OL>)E\TO'9"+]\W[)P":L[ \WE9"2CJD[X33
M9S1W= =MB&!9U'$4>2G+WL%#6+'\<P,>6:QM([E4G!S.JQV:+BN3,A0HY=WC
M+0HT5FYYC*D4K$\',>/UQK8'%GXI_./7&K);E%: JQ9Y4B%A%[Y>$QPE!+^2
MK2$/$H6L4^9DX^O0@!)TWPDIF52P7)Y;'#7WY:S>Y+#<J?5.1UMMVC'*^<5W
MZV^N.MUC:&^3TR!,!1*'EWN:FS]D?R0\N[A@Y$\A:#"L'@TPT2'0(@06^R36
M1RC%O 5XSL"K-368A>99=D%CG:P"BCDZ3AE8>BX6GXVY.=GE+IBUH^9J4\>9
M FMF-9Y*LA,"=1B4\#2=BG#.SGVMY+FR8-F9' G-CWU7GCS$$FA@R\:1V:%6
MM(\WIUN-)*JC(_H][4X.I&Z.-:K2UUKX%]M/GNQKN[%19AV(BK88,FWT:\V<
ML]!*+8S'D 1GW.#IYNL@I*V<%[2,O-?+K_KMK<U3 4V;UK]Q[QY+[UYU(V*"
MU&NHKNSW@M"Z8=N6.P\*:#%"$%ZB*:[X)T6S]BICQT;!\=%7@GO7N=-BP<O+
M0H1V_5H7-6ZU=;"CTML"BEY0$&H#'?J2V46Q&9PU\^>SN \8@:(X];0YKY=B
MN3'[?&F&$M3(R*<K)1TN"VC-G2.5(^NR<&Y#2-N?OZ%'%=0IA PKW"-N&WB2
MHE7$4^ :TO(TS$[Y)2HL[$Y(9TYX#1XR35;3=;"&8FGYT-IZP>6M8JS#Q!(6
ME@A'#4/:"E!480_2"GQ->VC6+2J!X4(;;7A49VG5KY"6E<KB.U15:L[H(7],
M(#"C38FB=7C8Q)9A9,&+K9("V#YCBA9%GTP3I.!^ZX+D#.[X"1B0Q>X D(BQ
MK&Y)5S-:/U[,0[9 *!<$"HV:ILTIZNA<O'M*4>EK?PCOP/#QN(;$-M>!/*UX
MY4P#54">1+VRRJ&&&(.G)A?6IP]-:>D,\F8;#M\4(:3:3(*J.EF)S>S;G$.K
M55NXX!B/%4K;R,3O5RPFX+02F&(N[]C4M?"&+:"'WHH90M=C:TQ:(\]/$+"/
MPS1M%BO1L[:_-""R[WE.'GK,'(JW2Z@)ZU(U>*M]FB?0D<E;6S[N2ZQFVWJM
M)[7+$%%S$PO>W=TFN;G_T-I*&EFJX/'^!T+^N.F0_F>GWP[H7UBVOPC_XFL+
M5=F[EKLL7&4W'[K[O4\ARE58T$VC/LG65K#P9]"?O&[)G/"SF\_!,1QIF68P
MS*Y\GZ5D5B^BM[/$UW. )HF%\ 4!;H!2%^0U>8IOH?S8MP3(6RTZ2CK!Y^T^
M :(OW@ B!>NJ(RXKJW+%6=)##]PZA"K;H[JP:@Q$Q.6<R2-G!=:4$8#.P:'4
M%GJ K,TP%SM*15Y*,Y<^UO+0),E4\S2<]A>R55(V%[7J9'4*/DX.NK-[9/#(
M(I2G^@1Q;^<XYTQJG#51Z5?B,F"G#A:#)XX!B6PS[=I^#L%,$?VRVT:8$3^&
M"34"Y22O2W*E)II;YO@0T?S\7 DQR<("%:<J"^)Z+:FH4F5MP/D*%<2>4!0M
MKF:KHVXHV=9M<Y\?XW@R9NT./$I4[$R/VT/.6=P3EN0T[<8>8G2>&'!5*J>D
M48'B+  H=[GGH!VUI.3Q=%2SF%^EDCWZ,#+:+:IO^];7-)?XXX9+VTKP]+M!
MTUCS3?>I#V=6[Z27&SRO6C[[@7-31:0#I*X5,1B53@_DB]B*[8O<!(Q&K 4*
MQ&5RECW/U_N+5Y]D"D8-AZ#=(=_V>"5T(,^L/]:-(AR[-R:E,SUY'/F090KJ
M:'Q6K6XP?H)*F7H=.!M0P=1D9.28+=K!=L<!T$($ $=T%!-X;@JH[*,>&DAT
M'P(1B%TU/]5;0<8;K1,'XYON,T^Z=.>. &<^G(3'=A0@<?6R>1+%BL+$0TF]
M!GT90"J&)*6J:O"&I,7?JQ;OA#!(F1\<<\.HCTEYF*%?40U5M= H8.)TTSB5
M$?!9.(T6/^,I$0"DCL]C6LR0])H3T9//=LW8' VH+)8:? 4&_O[_3.8N9[#A
MR5:^&>U)>^)7M!R*QF.%36R]/M&-V=X"1[-3#1)[=OJPDG >*I^4ZTQ+']K7
MV Q=A^7/X<0(%Q*WE>>_)?X2%/004!"<)K2>L\$N$P8_ 9I5E4O/PYCJOD?5
M-RFK0&FW-UL?+.-H9)%/5UVO8L78K:R0L.9I\5\'ZC>$4\GZK-6YW"&+_0 G
MT'AR3Z7R80MW2)5WS[ G/P$1H.^UE="*]#;S"7 G8#X6)9/;/S/,3T!_41H7
M.D9I%\+F51BOY#-8BJ;MF% J<B$PP+NV+:[(G_L71UGAG5\,G/N^A!LOV9P$
M]-@VO0\8-H@OTGXU,3R-+UDM<J!6M7YTC4GUI((_2J67@PLZT7L(7(-#.C)W
MAT,N4(2U-YV+"Q5J)$;C._#:BGP<ULB&4J4N-N\D5"\J7XI+O-]YNT0*C:C>
MK6SM7HG5.DY/PZE"R86\_"Q3TI</*A2MA^:M^>%/O4H51CN;^*+<B\7F$)QG
M(L6MO;T2%$)?#Z4P(_8BX?+LS$G$B5UT EWD-2Z'JS=X <&$DG"RZ^$C@6Y^
M)CNZ#GX.,#X:Z\\ZMQ9%9+QMO9A /XIO6[/0.9:S)&Z'T<J=G\;WLJA4E<!N
M*.L8V>[_V&4F5[3(Z,#X['%01N)Y";5BRG;0/X(Z%YA7"X#*QM]Z\DIYTJ [
MW\Q@<.4JESQ(R4G:,RHR-]XRB[A_)Q*XX"9^N\/^$^#YW3[L< /[)X!O77]G
ME>AM]>Z%Z',%Q$29^WDET"9_9<3CGD1.0>80XZFK3.V[[&\$"05,5J-(Z#%"
MDVNG,S1X4\'F/$-;C+]2^9=A7V6\*OI0+UC@Q&OS3FB[-C<7?@QV:")+//09
M?("<;Z-(H,3=1)Q'X240X$_.W&26[+ENL*J>,G*=%H!5++B=N<J(GZ2Z=%<H
M?4W\"0A$A$C5(@AKT8&7K&?6@-!108@^KFK;L(E)5!5"/(:(=FV,/;LNH=IZ
M%(#A$CM89IAB=*MDBC7.BN2Z)6+%N-)V*;4,5E^6>%":X1'XVHT=I[]%N_P1
M2EA1OM13'$)TCMNXJJ4^)%*\QK*,WAJ7T@]'7&>Y]\'(DH+'S1V3*[H<@L'=
MX?SA$A'+APY P+1\K&;&(%*^B("\*FVYD7$4%.=V21]H:/S)+L"FI]^2$QT&
M6MW:6U]2HP_B2/,1KHOGL7[&]J&%!V^%BQYRJ$$Z"?2A./I%19L:IROPAHY)
M?*QTQCT4!B9T>JC')=$][0[]LE7P,'+4+ NJY\U/P$)!\7=(-1T_._L'W6?Y
M/I4&"[U0HOW99A+#403/N>P\U7'2%6B@+50-#,\.:JOW5D\=,,UV.5]*]WTH
MP'_7:='N-1RQ]@>3([XRE?%5)ADA10YWSEU=-Y/-\H4]5^!=%ZS6,'ZRM>&[
MD]>I_ U)OLC(+#;LM$D1^8":*@?L>3J!V26[$0"7Y@+C0&MH]]FK@FYVGA!&
M:C,6W?B"&U?M0SALT')9O] 0>CT68%E;MAEV!>>Z^I3-TM'K04[KHPEN'SVV
MG:*94?AOIO6PB,[; -1=#FNR)U@ @ !N[,^'U)\ R&%9QY:+'JX 1Q<(EK1H
M^@#4S_)R/P$J<UNL+1\A:48"S++X#,X:U>S:W^1BM,EXF"DB0@>MDC\NJ*+O
MP)K$!5L.8:,K$Z *C 2<+,&F9XIG[4&=R2GN!-HNK[OO>5/VD;2U.&[U_ 3\
M[KZP ".VJLV5HD_JALCH9=2!:ITJ\*_Y6B-H2NT@DPR*\IS,,!V$NP8#4TY\
M:9?D2_$<9G1J.0G@EF.REB6V0YAF='*2-EW:I7[L2K;0OZ9Q7_5O&%XS206"
MK85'\"ZP*HAERU&783Z3(_O;T7Y5(R/V3/4J5J($+W7,+Q."#8P'VB F"#"E
MY* 0BO$'X4*='F4G5P#XSZ%2O<AS957G):AA"=X!(>KB]@[>'2=BIK4RI/CI
MC4!M2FUY=#TZA ;R0JUYO;;(S'H',4041(CQ'BW) #S[!$.?@O)I9+SB"(XW
MY^RNV81,5I*C<OQ599[ZJN!,MUU,3Q9MO(Q-,:U*;7LV6LRKP7U548GYET<F
M!] >7RN..9']X+3RI]BL;$,G;24IJX!(^@(H1:D\5X&4P=IL*'HH_:I)CV*8
M #<48RXMM-J)P:)J/K&.H]2A@H1NM'Y33<L</A<KYDI^WD+L[S9G* 3Q;AYZ
MT4$&\[4X9SU? 7K1:5GIFML>EI[IRMR3["4G#<,^.8+K++SU*Q$ _J)4;33A
M<AOD7#'2P$,G M)+K[30!Q4<]T_BG/:JXYTYN.R&W3M&'73@R*P%FK-N?7VF
M:AT%TD*56,[!@G&[7 G*O$:L'J7;CO=1DX?DJ/0,U08Y9[W!MEH-=%23=,>P
M;-R+YS6T^$KA@[&27:IA6\M1BV(%?CKSC3+D1TX&$WQ[ 9/TC3%A89+I/P$H
M\B#]CRN?=-8^9]2VJASG+1VA^+U&(,PA7LPK/3!&"39XSB.+D(HV\$H:_[.>
MFT)C3RYT"G51,EOU <QQ83-RI-%Y1/6Y82VL !LH:.F29?Z+4V!C]L ;X8N[
MUTFJW8<UVV#;FI,%'(]W(4A=7GRB0TGE7,?<9X.I:3=W^*F'#.H/3RH8/B;U
M.53I'^7KIIX#0(>H>YN:IT[WI\R\VP/(!;HF"X2)-"7DN+N#0-EY*[9((8<M
M%VYR,X *"3I^8=:\;"*!X%X 5W!I,,4 8G=%(Z8X=>36D+NL&;TMF+%C9I'9
M;%N44>M'\KL5O4P0_,#!H5D?]^,J;$#!'.(!2%^CT8X'&<YYF=0EBK:5'R)B
M&?%RLA1)&G8G9*7TL*89NU*]4B;E55! <\&"1 "58[AQ")<>@#4Q :S8-@-Q
M8%LX P,G',B'C)&FD"#';0UXF,=,[Y[A-5?:A5WICS35YP[=Q<:A4O077IHF
MA(SY3W TJLBO5$R?<O&4]^.VS4.C,M\RFM$GE(D>:1VAC==IR!72C=WO&KZU
MPGJ-T5CO^Y:''@SG7R6('Z&F1$V5W0JKDV(YXEC.Y7;]QD;3NNC,-VE_T9E;
M#PW&;)6#4=YQ[CZGR(%'7OH^5E-9Z"(=:AA3+>JRG!9Q;@^S-J[CE,UX(.1>
M]8OX\"TF%DA^ZA[^_I&3^*OOS@JF&@N)&N*G!4)H*'4_G'Y]C.+JXP#FOJ:I
M2"[],9F=:72>#LOE72OGVS3!FP\IW/"P9:], 6U4,MH? 6 _R[S%=W2AUW-^
MAHD?@A!5:/-1?UDYX3\:/@%(^BWGQBY0  !KS+^<"G[3J;7QI%V.M4.R,Z$C
M/*X\,319:]E<\T6-;8Q'9!-%'[O[7T61G6P!<_ !!GZ[Z"!IE9PF)#=D2F<8
M3TT=S]!G],)$7I<#?)=P@J%W4\X6#<6Z3CY,D 1_<MW^Z'G7,O9.?.5;&Y!
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M7R1;K>3_%#8QB5)]Q'?#=U3+@(6W/^U<;C<31C?A7S<RF#/P 9V #E@1!:$
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M UX7R_$!S-^'WLQ-]/LQHKJW%LE@8_42HIX*_OH/Z?\P-2\(]0#U%;R0%D3
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MT1#*$?"M+P&3D4+P,3H'RG69MNU];#V/[+L)#4OPO"D>:&5&A^V9XF*)/^R
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MG->3:^:%+4/B=U0_R"NO^:!$B.>A5^S+QF(C,IM5@5_.8=WDUG=A0.YL?QX
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MF1LZL&;J9G"/;W]8*!OY0A8RW+T#,$]PB8.XX8XR?F<7'&EM/TXZ3)"E^0N
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M'^RYV;0T&8O[H7X@!87?<XGX1&$&NXVE3]C^VGLB]Z6P$WC53+HIP>4''EY
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MD&__1/<@EC$*2M'MO!7+&[E:]DXJU?^"6*QE-%7Q!>=?3/UG$<PO!DN,]@M
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M&6G82'B,]WKO0IG;0D\2S-@I.+^L*9.A_T)V9&6%B5TGH617M%H"GK8N_MA
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M$25EM1"M7;KTB,$P"R6@>\O%GM&*<B&HR+%'6T'GP1)K5'MAM:@#/L!>!U4
MU*\Z:])IUT86U()='@1+/I/:IDEP+%4[BKH$/Z?!,IUFJ<_-Z# .]93UY]"Q
M(.0KT54F-"I_(_N)X&?H)'%\JIA=<:5097YXM="8\UVR;U39<2TU_(XT":N^
M\E-X(O;J,0PKG^$%_K%KJT6X*C(NBHA^@"1[ F[Z$?CHA4DI?(:ZGNYXB5\\
M58!Q4BR CCU-X],A'J&N%F2]8CDVJW$R"/I*W^WL.7]*Q[?]'7:"%D,:'3%T
M+S=^'3@B<A)C7]-/OA.F.Y&=:[2.E^?=[F?IES?<[>SPI1ZOBC+FE!HO_PP;
M )>ZS^PZ>\X)1>@+_P+()2?$B)PT1%6AA\_M&&\*-*HG 7;TU5WP:PSD9@U$
M@*%4/KMH9)PH&<E<,A0""N#F5\7ET<3! N?DY3[GKPW0:UH(T[Q]*]QO$@.Z
M^_3O/- =M>EV&QTIV"+A[YS')-]&M4H)NQ8IC!00\,58I0VZBUI6:F[6Z.R@
MQ[8^^0K*$^"V YC6^Y9'^O,5U:Y]C&N(1=@D5FEQ+M"TA.F(*#U[J7ABC>3H
ME0$I.F=>@-=PH059305B/"]\;]1\5/@4.FV4=O4+\ LP?-6[^_IKR+]_7'W"
M03="47K48?=!55LL:!(Q)@\H#6/D6,J.*%R-U\CR_C;F77LO^(+&IP[@*B_R
M;<,HR)ELB:>TU[9*C/P=<DO;M;#TAZ:E+$R^,+2^V"Z;CJTQ\J8XJY!E)_H&
M+N\.%Z]7?27>'CB+TJ4PX%UN?/01L^UGB?$R7B$;0J&RFA2OSYVK*)@R!DU>
M/W/V"*!U@9;X^MG>W7DOV60M%O"[3P0LW^#\3LYF3CHFY>.5<HM_;&RXWQQ+
M=X:YOE.S_)6=>#XX-*L*?J$7XT?\ L*GVVVR%RS/8!#NV&M&;7B;G]MBK&O
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MWP#_@=H%H5[\IG;/_IED?-[M9U^21--QI_G;\3]8P@+K,L&S>;;?+.&-=$1
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M-AY$B"I8(M.LT;\_<EE@C03SV[O.2#H)/R<L8)-8Y=3JR?=] -E8C-+1#=C
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M2X4K.RB"JY%*-AUNMM+&'#QH)=[3TQ+8,NM>+_V8U4KGRE[=(5%)4_W!DMD
M9>3[-QE$LZUUVC)(B,&N2[K3:GSADS.T]I"VR:U(]C+(%:(EHFI54C8N_;UY
M#7!$=3;"X?&Y<]N@/AE>94E/%9@_&8U/_W,B8A-JZ.$K1!2S$V5TE3]\,9'&
M2<RRTN()S!*'O3YI^*(+5HRM2=)\V=RP&=/ZRJ-@ KR+G#"L%U'3\? ]=PA"
MO[P84\9*D1Z]GUUJM>!I^YRKUTI.(E9*8XZ,ZX )/22.9U#%E&M;#PC)^;ID
MN]6E[PGXLN[[HW$ 8SKA,]B^7S@[T46'D#)5K^LE'!K"V,5_:BJ5]??5'U*5
M!3B_W\_07](ZY TQE"KPAH\GV!H%:' 99AM#*W:#@4J5CF+(&Q]VGFV8RU U
M<^5;X2CL(2?B1,<_P@1U%X\#,J4_5(IM0_\"Q).EB\0)!X8^;!3Y^\H.?4_N
M:T*BP.'<(0EQ6@9E.T<82'DV"4:FTG6[ F.[/W)Z\J7I)H3.Z0A*8Q:X-2A*
MVK:E#P%.8]Z"A20;H#?#Q(XEVBU7M+ I3:N=YIE-^"N);>LP-<><C:P'%C_Z
ME\H:8[U&U.'K&))4T= XR'5(PBU.*HSI(@H."+GH_>C2GV\*H1S;_T@SO?"L
M^\HS0X<Y]R:QG2=,ZBR!K@M:[PC1)MT,3G10@DDD?LZ"\IQ_#P[&8ZI;+BD1
MW.DJ6YQ1?PJ'T(=^M(QRC?3."V JC:147!*0>%U[V#9E.YO5N>*=O+\XF;)[
MF@[C]/+N$..>3_8'YWOCK 8 M"WA+.,98%@X"10K2QM"#1S,FQ4"!6=ZPE;A
MLMHD--7E=F1#NHOSP^DGXL"B;.>;. -&384&!CI".I:\J\^,^.?D0U7)-3QB
M%Q;-)E,ID%%X3+*,FMJA-YBG7P27&)S5!4+6IYT#1<R&IDGA9-TWR1'$XJ@.
M>9C90!%O>[J-E<5?):N@9P**&R;51^:VW>?G=IAE7937'K&OJ$2GN.BRML'K
M99ZU=GH!"DZ\AD2_+[/)"Q)FX6SFJGNQ']J5_\>OH3%]2" @R'B3Y/ZS0#DF
MC0>_>2%T@];OJT9\]0PP<A:'CVAD.EY+FYI(;?;R<;)V!D.'!VML:OG(*;1+
MF%U#SE=KVANJ3'&6Y@[,'RB+S<#-I.<;AV3?,S&I0>ED&H[V&KI%G9@L06;
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M?[/&Q(K*95AXTLUG6-_>;+N,/)O$]GH9FU<YUXJ7DZ^9!EZ;T?"E"[^ODDG
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MA\-A$RI^#YKK4/XB''==IYR*EEN_PNR5ILD>!4N)V*G8(>,!C<NIA!$9F8_
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M/\,T*K^E@-6\C-:K9]D$Q]6PD_A>QK5GAD-"C86[SQI'J'GXES9GXBY*3 H
M;TL=W?QGIK1G[LVM:=VM^]4]204?[;>2_)3OHF])*W51.EGLH6/QF#2JK\=0
M>+) Y;"71C;MKKNN904* MDA$W46+4*J9<$G^L3&LK+>](94U/%=YBL^]'[?
M%2GV!X(%D>3L=/HVO=/ S&Q]ZF.F&S@WR[U]G-)*&:-!*J&0-HS=5/XZ(A)'
M=_MUX[JG0<%D9DX=AI\4RQEV7=I7GGVSW,DW_Y#_ZBM3+98R7N^82':N-L60
M?ZOHM?NZ9\W]:7F,XZ-=A'D\@:_M1F-F^9^+<,5K#*:/#OT4X^8[ZSL^=VU%
MCT=R=IV(?KSTC[XQ=B4_1]ECL0^9VI_6]SNI30.B-_[\_O 7BX]TV;!1?0 &
M6P09H4K2?1WT*?K+9R?!YQFGQ7'YHXHZNZ:!VH1=WB.'3W2U65>X)#"U";+M
M,XQ%5TMO>'I0H7Q*GS!6R[#CG[W+)K<H5_MC71JH3216^?C8I3UU\6FYSI!8
M0%.$9Q>W,RR32:27$.4>2_4[X$9?$A%9-E:TK*_.^&19\:&^F"TCAD=44\13
MU!S*;8VO."FZOJ,,O!0M&%2Y,2NWJLR$XZ[$X]ZGYN]=UA8?<0X\:RZ<\WYF
M6-N?)X\>N,-IK'AS',L0[OV%UZK%):_FBH6CSS!_:)?G@\Z##JJ3K+HJ'_H>
M/HO-B$XL&\M'#%:,J6B_Z'5?(U75L<O@N+7UQ>-3O*LGZG.K&J^)WTU>EILU
M*;-Z2-_,#--<)^75[&GQ0#HH\ I-[7A)RM=LS2@-9:S! M=8NFP\L:Y?RL5D
M<RK?N<<*-V^-J7Q^W!SV42(]7&5 O9 ;T7/=1G;'@52&;>RTTHQ\NXX9#))(
MQ?*W>ND(89OU_70DI>K$2K<DO3)NGD GRCRAV1AJ_4G\50OV<Y]IY:E-&YL9
MUC[T/G-'@8NI199+K$E6-M"G>.,CH8D7QHUW!,K29N;^ 5CI&-/[II;$PFI)
MF="W26D3I+=,1?QT8KOO?VT@$O%W7'@LWT0-=EQ^J5::*'9<_O^PRL:RIP?"
M$T2CE#"3@ZWY(K5WBLM-9F:]IRT2I\(0SPDV^PAIJ.=UUNW">I+Q%9@V44GZ
MUI6QD5>V1;PUD ,T/]%:"LE^JB;?87R;;^3I3)IJA#1+4Z.SY<9DG>2ZJ^TC
M7]?O?BK4-XY]\&',]7IKR_NZE^Q,NVRMXF\8GI3^U"9>9E)E+325(B9BBY;/
M'L]E6>FXRZ$62]9A\EYX0IK0[>(MA@9DH$2SS@E7/6?%YB9S&?L)<;312+_8
M$E+2F?=.2(7L62/OD;YUR8ZKD^J$INY?,SMH.Y:]BJUDZZ1/_"!^K9!)&A5-
MXTRG%861,9C<\V7Y[X.[KE]^WV0OL?N*A*Q OEZG(_8*C;C<;J]HS^0\5J5C
M]..,+\LX/G72)JVYS;A10O7HOC6RVI:.YV]6]G[E+NXXKWS+QMFCI OVF.D9
M>P7W'[.Q>MTN,G$EY7_UAZNA?DVQH4Q<V\+#:.KHM1C_Q.K>P8AUTBE&>95'
M3XT5^;/JWOO4+@)*PKQ_6] ][[)%C''-)\<B48/_G5?PR^@. @A5<V6.%HIY
MTN?D=D1\9HVVJC&A?S^T*#XDB-_U'B&_\5*?K];G$=+Z38^HV1M$W[V^N)ZL
MMDZM/(9FB@:<>)-RM%K*'?34U3L4A:(2JA\/Q[IO/+:M7Y^>7<_3U:L1U%QI
M50ICO7-?WXJAXL@HDV]^2;YZF\&94KW+FP_YHBYXRWKTAA7<VW#PEL^^:ZMC
MEG\XM-Y5.V5K]EKA$R=T1T"U,2Z32CWB;9WC-IGDNZ7V?>TTH30T59$9CM8#
M1F45X)A+OX[U=8YA:?9IXL3[N>V6(DVDM6W$2TH7=*GS2'D(28:WR"QO%/'T
M8\Z7W*OR^.CA%_D'^$0R+J5N;F<:9>)..X][W>-(J ?1!O7;XKBI[!N=!M3[
M<Y+NDP)7?0Z6T&PVW\G_A6D#NJ*PCZ%(4:Y 5Z%6\?CCF)2.C*:^TJQ@C6MO
M.=&IXX+=IC09CJ\-/KRJI6E<=5VZ_T#C3+(B?;03*6$T'1*[WCTJR@D]E5)=
MT=3CKZ>$OIK74>6;V==M2,U4[V9;Z?JI\WV!_)O!EY-^.H42IR]:HP^'G(M.
MC+E3M3:>AV'OKB&J'0U\">YFI0<<+6_WS+2=\$SB^_]JS1D?PMK?#AY.VV&3
MTRG;:JYTE-B;I@O6A7<5_AL]SG<>F SZZ2*T87G2EOR^IXNZ%6P]Y+;8U>TO
M%W"/F]/_.Z;0>3W"3DBM8BE+^CJOUKK4MYFXY#KLR@2GU?R>\B^YG2Z2RXOO
M7*^[:?SVUD;9#QS2++E"4U;@,!MF=1@['&T-O?R,LX]'?CB)SVRMU >]-]Z1
MS8_3-[?;-*XJ9[TF=;GEQ'B<?PLT=5D/N\6%#]/524P#*J5N[#4E-#JI+[JW
MR)[>&:U_WTS._&3*RP-OR_+>.?(5-@ZKL1:!F%+Z4]<TL"NN7=@-FN]>R\J+
M&.!*Q+@IW7GCJ9E.W'JH6"-R<OT#XU.MI9LT\K9>SPIZ8EU2;A]2-Y$!SEQ=
MTMT#]:]D/+Y.;9"[!'*;_.7.A-S'8;>&@(C3<%$F9^+[/J?_V9\*CZ2!SA_/
M;S&?73B!O^/B"*"<!GHUW. S-TB^GKD1/6 EEWQTRS2@4#<-*-K9'YH&=CP^
MG#+E=_ :0K]J4/<UPZ,SKP'="6:GVZ,K'X0R]DJ:J([LB-%[L5_%=#3[X4DV
M/25DR;GLRVU\I?HWO@3M[-A_>QHX>+NV^&4T.L)43=)[(L#7WLC0-)WMP;Z7
M@_OZS"^2.E.4$Z)G*IU5]UA#_VS"(C68IN?^63>F52Q"71O[M@M, _[J>]R.
M[/>('EIV>95M=N1;O=WQ&XZ1?ZJ*-AH5>IF6,[@IVTDE3<9#_V%J:IS,E;ZU
M"5:&^+R<)DQ8\9A#V4K-#G;5:$/S:>!+67>T1P/"RN!QQNHT%A'>$S?5-)/J
MJY>'3#A:3NV44!?N$3W:'<NCNB9JX'B)QQKAS7LFG/KSW:BHI@':Q--"S,6U
M1VCDGZ=/ ]1/QUFKO;^X4S0GX50KN%E']PSY4I:2DC__W,%+7OV%E<JY?'](
M.^JDO4:"E@MNY<NFB&?!QRU+[M4DOC#W1I]]VX$XNDLYG<?"8F>Y0:KB@Q&!
M;9RBQ1MK\UO3F(S//V\/,WQ5[&MWQ.Y1L':"X0K/O?HF?HEJSS"41B?5/N2+
M]K1(9%6K#IBOS(O.:9)>?4>HM1I_0N&>.,<$[V//HQT8X4.7[77OOJ (WF:8
M3&M27*@N=I/'1G(XN>@>+4JP788\6V>'0WQ6:!"IC;;E<*[F9O7#B%L=Z?>+
M[#?)JQ[R.*?IC2D*^);<Q: B9_V@!M;SOH;<=B'"]*W))_(%5BQW'+(LV4S1
MS1B'X><_,<%')KGF/)Y$[\55*QDRN4;)3[AV;B;\L@[D1H\D TK#DVHUEH<N
M\?CZ5?-*2O1WV!L)&V(>1(U7FU1[DYG:Z+2?]-VSLRS)6/6<KYMFLVNRPA<\
MK0JGE6J&6<''PX<,']S@:*C%<5\HMQA[N46)-.&#G(B]Q-E+FBYQ JN]';-6
MVJ_FC>Q*=Z<L7>,2+\Z@>#CW+;,]CPI61LS8B>-\CF58$2.@6V.?BZ!6D V*
MP/=WJ*Q:99^5=J;);V>"\3@M_=KSH=8Q LN9-=?J D*=&0:GJU=HQYS4V>:;
MP*^ERHY(=.W3$T;G4[M;E*SG^A"V+BJ,.NC+[DYOY-KS'IRB/4];7.O"T_0O
MO-K.&-%OS^09$\&%&F?8Q2Y[0X#JIKR@6DPU:=/S-O9[7*N'UK>T(9JV[S47
M8+OGE91(@^)R4>8ZV*6]#!<<E![?,+(J</GX% _8'85;W_D;K JBO!&:>].T
M&B](;7/9Y@89DDE9Y:2/AOER.0NZY65F;5)5+T:E2?;2X60EJ5Q'7C)HO,&9
MJ3&&8[L[JJ[L/M@@?[94A7]]C_GPD$46?XZVW(L;Z8][N!MB>M9T;8BIE[I!
M:4$3F3R)>5;UK0H8;^<[</,_TU13=BUBMSP)5I3J7N$3SK1M@T?B3$]>TT;=
MP*\,.B"XC8,SR7A-V<9)A4*[CI-5QK+G<VIBZX5,O&Q;S^=0..H_/W1-60 =
M7R=,ELQTK(RN>D61:VZ?9T47/J;/%>-WVM]LM]JIB0"E@:CLDZE4QGVMPY)"
M!Y]QA"L>QNTS*"6-Q9S)C+2\<3PL?-*PTWZ+2T]6P@-6))>@GHMWVY"<Q3%%
M^Q?1S@X?9+$C:E;N?J_L.<ICM:^=7NE](I,LZ=AM*<\Q[2R[T,(7@QU[QQO/
M:%E(H[1=44*^0[Y?Z(YR4!9MIHXF#[CX.2JWBU.HB#RE0TWL6J)T^(6F[0G1
MAOPZG157MKMX2TJX]&MSGVY^'Z%E>9^ZT'Z\X7HZ&6]_CS/)NL_]W2,/=F0Z
M5T5;S,3VB5FY[4U5ED8EZ\X7?>NU2^ZQ<.)',CFS+'(.74NJKWF4=^/B.[-A
M:*BL:Q<RD6$K?3!B.SXN?+B3RG4:P&F=+\EJ<Y US7!4$NBLZ#YWJ=Z1E.2!
M)E60:]EQL:IH0ZGU^4/GQS:$6)#:,U5F&^\8?[R].;34=^KZ:#39<O?S':7=
M>$'5]!35#'/U347Z\J5=>(;NDG0AP0/I]QV1%L-JFJ,R#*\8=EL.J[^62IU(
MW[1SF0M'6IE0SJ8SJPYW"JFQBM#Z*E V8+Z8#<NI9S!9WJ<R4V7F!844Z2-:
MR=T&>,_ +4]#^ Y'F'A46SJOW'GBP..,HB$CTS?7*@0X+2K";[\'1T3-N=!E
MK<+I9-'._%5'F-^$"NEGW]Y<D\F:9.*0E-TD+3[$$;GOJDJDM[062;2AH'IF
MVEY']!!'M$FT<P5)"1?)0X7--Q%O2:5'-88,(TJR>P[<X^^6<1];&[,]L8)Y
MLE_/Y6:1]%2=;A-G-9[_8R=OO+&J?Z7A,Z1VDVQ?V-IQNE+'I M]SF2)?2QQ
MF<Y.U-;KWM!IHF/J:Y*D;JB&"]^W>96Z-6%$"*QPTX!.X?$IJDVW9=ROG]S&
M&8QWR;!@ECW4E'!Z^7O4=@F6<;,@YOX.N0M/"Z/2L DB@5>'-)3O=,2<W/LP
MA+7\IFZBF2@GQ_[Q8[RC,4+IZ4+I+9Y]OA4#:M)ML=(3XRFJPNE7*U!<R,B:
M6S*<'QVW6ZBYMHURAE[0M>LHL0UEF2J-$QJR2F:YJ%EEZ.X?<7!'0Q2?D?7N
MJ%"+(I(;=7@YY>(BQR%,K, MW$G!R(,/\G>;)+ZG6W>RJ^Q A1?J =.&XH*'
M>Z+)D/S;3%8*)Q<=9K.1\N8I3"QM 4N-I[/D*BZLP),KIPN="XH:X7VI^^YX
M$8?/*P$AW@#YE+17SC8=:N+[Z^]3'UY];"UQ]:^B&Y27%/,RXKY3MMD'?S]S
M T4E3UF/,[#93_OMCHFF(@H/36%"7__VGN\;.TX;V:+#82;XRLD &XH"LT:B
M%B@S,&@3H??E9\'WYZN>^OA UB9<?(<SL\LD/N65/7YR&D#@C<2#/SHTJFOR
MW[JRVWQH]*:YX-YCWO[B#N9WOA1>YF!2H ;++?4%K!!V3^H.G"EMEXF5B';"
ME4S=.%MW[T[\AX)-F(3M4W$5<?T]$6]VOA/VJ$YEN9B\<7^=T36F33[[>6Z&
M*JHD\ZJ&N[+?/N9G:;0[BAU12LDE\<!/Q39DD@%E'/O2_!V+^Q3=$?;[?=&1
M=.%O349I\*MC[O%NO&Y%RWR7U-Z(Q\532X);O/ 5*/^\*[1.A>_C,UAFE'$X
M*85!F*>N/OOH]LQXTU-YP<5/**ZS%X[N'"R@5#&Z_W'SFDY5[\\1N62WS^A3
MVZ S=CT*OA4<L._8O<T1(_?W52/-+[R^4'2!)/+Z.$LH7T=G<FH<V*&LSSV.
MBN@H-^PS&$V1[5#%?;EI$]809W]\BD$HIR6BJ?UJL+V121SS."(PHV#5D'WU
M?BT&'I='K\R*/I/=9+S!$?8T[&EULG@^W[W5&I/1*T4LXDRL'CXOQ76\+%+9
M<X)4\*Z7>/@Q78/:%:H75)#HG9^3VW<^3,J1<S,U/ALK4..'#[XUQ;""D%%(
M=3*[0OIQUOMTO!OWJ'TT/O@,M]FKB#KUM<70)QX7O*\^AYV. LO%D"))6JEJ
M0"+[W:IZ%:/QH"VRFD?MW!JEO'3,&%I7,A<G4R6;76QRLZ5Z(M,H)Y3=]'QU
METO83;OD(M9)G9 ]!-(6O-TTN.>K(X2.IH?KUL)TNWG/-]*646_ZFM(>=GFY
MOQS;U%]_2PC4:0*_O3'(NB9IX(FE6ZACDGH@OI[M3=<H9VN?VJYNOZJQ0\*9
M!5)5\:_5K +-')R#^D<YXAU>MD_RXNN;KUB6-<6EO1:2S% >G0C22O]D-W59
MS:JO1+BM3^M $YZEGFUB2CFAKO?)-* :ES9JBA\8W7RG3XVZ.]#5C:V\:Z3.
M=4L[U<;&9P**W+9)/K6J3'S6T\#=*KW[N5.<UMQN89;V]+7=G([(F)&WZ8BC
M&=$,UMR)0O&YEUW6E^:I3 /H?KUH1HKB/H=+K#VZ.JMB8IU)NZ37"YSSZ<77
MYVP7?!K5I$A9Z[;^3LZ)*1[J[D;VQQ]4:NRQ;?JO]#XRUXK2-$Y, V=Q+0Z!
ML4*AE<Q:(R]#]Y;S65,=7^/58^'@?#R3>9-D[IJGV/4F=U!FN$]/5V@CK OD
MSI3:1+OFKF2(O-4OIR\A?UJE)W_"6_5$):@:-%$J4$C$(9D][Z#ZC?=OR0IM
M3)0[<UB\L-A,^/$NEK()DS2KC^=7)A2[C-,R)ZY,+GU^PG*-5,N=4ET/W;<4
M=OPK.#RK0O>NH>27%SY^Z=3:(D>;X]3!5*3[A![3=[">VI%J;'^+28UK&9?&
MH^:8)\8CED(,Z9E9$U7Q>4+CK6^*I$<=!;89K,(<3#US]=8X/W\W*2-?CN[5
MJ#HJYS:ZSDVY%<S;]YN_L&^+!>OF!>&-D4_'P#2N\0@U!L6913\56S44>='Z
M0QV^3'\D53+32Y7/M;C\4_")O10HJ8.M]?<02D)NCN?.[MO0NEJKYDZ=<%QF
MSY1;3E97N+"::EO-D0)NNF4'?>QIGMY>VRP%Z@);0@)3]W7R:!)BPA6ZYLX@
M7E[/3,S!YZ7P6%Q2Y1KW^-5GS[?0\,>VJW0(F[X[M_JX1)>Y\46>WI/0ELO:
M"_3O-EF+=3)/:NRJ XY4AHJEO2A(MKW*V,Q0>.F+FV]EYP2+WU;RL-V#L6IF
M[6%A6S)L])BWE48&+',L<BU")]5(1+4DYF8W%UL,;5?.,\>NQ?(A#2Z:-OFO
M<C#DW?F B6OYZ>:][Z1,FZ8!$K GK24YZL3MP'LHSH1$Y1KSAC0ZL<Y-)!<+
M^HJ.W'JOZ#L1U"E'$>_H86B0S-FKQN=;.;6)K'I IVO/L9B7KF9AW&@%/PY5
MW8!5MDQY-UV#M.TMU=P^ONF:8N&^CZFDJVNY)-VT_'"8U//+=[:D%!]G*1TX
MJJ/-HR;"5-U1V055N)M,XZMCDJ_"F.UWQCO>!IZBW<4OUZ@GOE"3+DT7#OU,
M\OZ[BGP]S)[?=K0DZQ#Z-N@XX)JRC38G.9?KL^=F+JG^SN>7-K5<MU33?3$P
M#>0=U7XCKO8J;?TQ)O9"X1OA*R\(R\>\M=EO4<QW8[T2'[F)9_-9<ZAW-G0H
MDT=*+M]^U^=.#27WWOZ]5%'&@0=C1"C1\F_PDZ$W*CQ"15G+[=.WI 67Y'=P
ML?>>CEL?S&"!.UQJR:Y[(8M+*-K"O.3U%'G+,VGQ:_7O$^HV7\F)CI1-AV*/
M!X$5.:ZURU5YJ.%(1PJPDRK,)EP6K[_ZSH267&9:9Y%8F_/)L#7\K5M+G^2:
ME3-W\V_OU17 Z9ND5L&#M[1(KTI7N@EX6FW/=/80 XM"86R.1M-9;LX^[\_V
ME@YJYDD3,M$]/9(9E%H9%MFW]%<]T=!2'G%?:4)1M</"1_'Z^+'9%9CGMJS>
M>.C6T'M0W PL,V/J<C] 22K-KO<BLTDX8\O(5NRC5FQVC95!?(]^EG"/GS.E
M6\.49=DH+\\0E1OC,P_]7$NW!N;.%9UIH^!(Z=$_]NRV6]'H-/"1^7+UYHFQ
MJ/HU246;JJ9L#HQT3LF!M:%BZ1PDE]X4'?U:6#)#5+_-MG(:X :['+MPAO*U
MNC[UDB8\],XO2>"!EMKW$3;'CQ4]3A-9S*,_YO6BXLUY+!A3O<OQZZ_]4Q]/
M# JZ!OWJJV[*=KF_FJ-^WN9?Y:ZYYI<+E'E1?XU)PJ,(GU^\O(/Y)JK;^[;1
MC-ZK:G)B[3=*>C4@TY*G?^FS6]'%S(UOI@&11&$''L9KNY,K:E,EM\>%XKE2
M-C$_CFF^_E:K@G_[N(NF<4Q"#XKJQ'9I"7P$JIHC6P2=K.9^E,'@_ZDCWFY*
M%*J>"*^]#**!-O?.%6>>NE;H32D\/LGAY3P16!07U]O(O^'A! -/ZW!'59?G
MH8$!?^NPG*8P"2/_CUM9/AKN.]?W9.JPY81,T(20A1F+FP]4\RV-YY1T73RZ
M,GH,KG7[;SQUSTJ&K?I(_:FQG?HZ#V-T[H@=;P1:A<?C,AUNK-0++.C<K.#B
M^)QMTNN=K81,6/':@CCU&\_X&B:B&W.TL.T3O(2F0^N0:R5O2%[&+3D-G&S(
MY/XLY8;P:N+O*L^D/A0FZ_&$:4#^BX_FZ:NI.X[N*Q^,?G"<\> XA8WUIS8N
MLG5OGXP4/G#C'#E5_D8"G#>A?E$APSF"*S^@[P<S'"/LQG1^HU*S/>J!QCX=
MT; 7!^DKANX8>S_)YCE8?DE"]X*N(6^RZKZ:0X]'P&3.72OK1F; -8?7?3H0
M6AUB;9(ML<U=1&?,CR'"4J)H5U<ANX^JY;#';4V)?@;7D![V_"GO4''MM\^<
MO4DVWK0+UW]+G\<5MB/I'?.(U>LIUINVXUE)#7:CZ[Q&8VEV[HB=,E:]NT9?
MV97,,PN[OI0[]DBTG;!DNC@0B;,.I? >*-)6/5@OXV'@TJ*UV]S%37!?A91G
M-:NC5<)+]E'/3-7#$4(C8.GL(2XSS\+E.\+8+-51%"UB)G7?P=J[?VU[)XMU
M%,9_JZOC<'R=VJZN%Y_5GZX\(Y$EM_=4L;QPMS%)G.3:/)E4)X0-$[M ;/T7
M(\4OFOW2N: [=$6S9-M;2@.@N<=5O:=.+OX#J1L#5*%%[PTLZ3//IY,]8:7=
M-\KPW=B+8'%5O :VH\2$O]S44:BL/QFLVL]7/^V-*/F?OOG5U2),"^K FIM*
M&)5)3;\/I#079V9?C&BJW\BX\OHRR\;\J,=:HZE0=QZ*M\>N='Y0-6(<?XN;
M.7^(_:J=ESA.[\9;@^6">F;)9*N3A'0&8YZ82/I?FI!@_1(=-'X@'4,IK=,^
MP5_@F?O.?F?;456=U?5*YN<4BG2@FZZ61II.V#GCAV=V3P/47F/Q35,U <[W
MJD:,M&7[#>*]C)5,=JJ$ITI(R#IP)!+NX[:5_&&QX7?J)O;#.1R:!GA8W,XP
M!KEUBIK<S_IL\++(J JGD6>/Y6J^^E'R/F(?#SE=A-_(K?>HV+Q>,[=;KNJ=
M^R8>0;T#RJ[,K0#N$;>,3&Z=T&Y(R-9RCR?=M2R248SKG^>DVE]?^*MCX/M!
M,Q:K5G3NJ.#AB.75)CDBJY/_*QP"$J/M,T)UL*BWG]!FKNKMZ9]:CQ/&\D1T
M55I><=1,1T[J]H]\ A9I4JO/38\2[Z7_S74(<D5)S+@.PJZO80<@UQ4X3#O"
MS3%M^/_SS;?:>?!'G6)=Y*\!-VN46\O+(CU!QT^B5Y;Z)J"3N7#OG4K0TOKO
M03P+.^@K,_2_RIZ*-.F#T-@<5'\]F70<DJL3N>-1#S1XM>/8$ZHYE=7[X#[>
M&6'3?#$SKX6SMN,M_M -XVO>E^-SA%:\?("?!E[#G?UAFFE^G9M_H9R;=J:2
MA2)%Y6F>S2.8TD_!>\/.Z-GHCPK!PCOWM)R0\YVJD2_0@$*?W%#XO$B ]',.
M]K(H\^AM[J>&EM, !\Q7I;^9B7\H"&.:C(^L?;[\^8:TF11N0"D\@)KB2YBL
MZ!4&Q\;_\=NJU_*"B@51"XO</LE9>S7>FY'H+TX*@PV1VO7*U.W*-^'D<$0P
MLX3%E4?$2DV]P47F519W&?BS!FZ;P3Q[.<F)SJK&>YHLY04VHJUT;ZE3*UI"
M+;+NY+Y-H=_Y)%?V3K$Y_NZE91P#JRNDSBJ>V9\<46ENDO0"[D%WT^^OKF_=
ME4D3UGEGW^:G:7';]&Q4*9.S6B[SQW[@H(C:NCF*SM8B6.]0&9/!S<3'Y5],
MDY=K%I86Z5\@2%C+3%#RTL6-DY^N8NCPICT@I"#I$^OW(%@@L>));H@:6Z[=
MA0,7G!ID.X7P^_@-WQD\81<J\RUCSEP)ES,]3=J^O5?P2-W%]V2I7GJ"%A:O
MSM=<3UEVCS%HKSUY9'F %EN][WO4-=_WB?61SW6U$A6L9M@^5G+EJR0_\#YZ
M&UQQ<2*V_S4S\L).BF-6K<4_@:Z?35X>_=7+F/(G"*""Z_A_9AKGK_5P*SLT
M,T?'?F:1?F,U9C0SKP\4D<2_HYH&5.TZG"BDG5NWZ"M;F;G?T+UXR3Z"OI@%
M'ULMS7&+5%&]F3#;E]E21YN)3FZN2A'P4]^P%8$_)1GG96M,*D]NH[Y.TSMJ
M1=C-'/OUE]>A7H[F:M1@V0RL H^A(Q2RI7Q,E(8/JKQ3X]+UW^1C,0+ F+"M
MN#-^(%ZO,'"_%<4R-5?Q(NJV.T+-3T_61=SN$486&W \>X>(%CLN%>ODXA.O
M&;4K:!>WY,>\#,OAY^,AN3:77UH.P;*Z[9J-1CO(T[V[.,%6LNWI*]:&FE/Q
MX"NXZ%[EFP8GJ<@%*U]IYL\-8?3;9'=N;:ZXBPE35N96H?WE)*2':'/)2#<
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MHF#":+B%(]%=XR/53J<B1*?#D8HHW)OBP]Q4!MIQB1<[W7=_%#SBU+N/FZ*
ME1I$%EYN18<Z <U)> WR"YYE&A!R2$4H#L$+=;?($E)[(M31_[D;CMGMR((J
MOW=;\%+\^]DB^,RPL*=<>F7P[[@)K#.D"'53(X#)S+69L3'Q2AMT)P6J1I5U
M8EG\ELOEW$CU=J2ECX;$=5(>7YMW6RGX@JK=E%:.=[>AEL;U0B,JMK)NO/74
M,9I!$$RXJ2GN"I!/ 25UGPL711SBNHE32<JF?0+I1=*C\:PMT*Q>]>GR0$<0
M%$-JX.&&&-J:.SX74Y14$NF*EWEN;B7CX;3[Q-.3V3P3=>0E ?7J7]3_Q 2K
MD% NO@3I2G_^/R!:(4>*6]F/%V('3.K?'9N,6^);#,4T,*'-.OT.6$Z" )!T
M)'0 0 O\H7\^D8S\ISF8A\C/8/_3+,Q#D@W_:0[F(>J)_S0'\Q B+^L_S<(\
M1(G[>1QD^DT L0EZP )'P?B(SY O H=%'.OQQ'Z+AD5HO]JJ ?Z"SS0 Z<.K
M* Q E@4 M:";W(:0#U)C,4R1S/4X,4\DWP'P!B8/L "DW "PG!KV1:0#P+$A
MPV^QQ "SET9V.  !Q=0&K/;BU@( **C)0"Y)F(8-""_A%L$4[T&2K)G'.SA$
MB !NOK>0'=R;GI%))W/*[\4)W:#T4/8+F[KP!F!1 L/4Z=Y%,Y\+NA=T71*'
MY"<;S^R]2;$NU?[Z58 $P4>;@SGO D@B3X,MLO+F2X9KIBK+MXX\-A%;L2!3
M2';^-77O>EG5;;<N8WVC3U5Z=MY8W9H9J4)^HN4L5Y&-AKNW-TS*IK=C 2JP
M1O1.A=4;&(V[%$3%>0.K<$#=2S*IH77G1"L @(G$%05XVE0@-([A@0:$2S#-
M%S03A?&9X_N4\N8INC)\QP)@$+4U4%NM&KZ&E3*XBA7G=4WST;Q<;=$-.?PH
MP-Y]*[ BM@C0(/>/"=\+B(IF(6*K7SH?P KT; F^EDL+W$20=0F1D"<S1Z^\
M";7X"1[GC;H&RSRV9Y$"RXXB;LON1'D$(R3HI0/GRP6%I& #*%#@4]N%<ZV-
M'#1-$Y'YL20[]X6=J)XG.@V6*@N@/K%"QRT H+2GW8O;M@)\%['A(AA&)BEP
MD*2$O/3,V<, F0&9@W66E#2BN' /%B #C,[<.+R&.DN;:3D@ *PYP<@M_9EC
M+99$C%\C:YY<E##N%"AW! 8<&$D840]'&QGVP@][,"CS[(*2>:H6T'W(AKEY
ME-_R4V)  R"FJ)#=,(1<AENV(@ ,$R#+:EAW2EK=\EP3L,6R+?TBHK'E&2*9
M"P#X2=8>L:&H4T)>S3( #LH4X!)ZRUOY/P;:8=P]Y\G$'4#1(]C<E4&ND"L
M,2K5VSHB \7RJ,/[:^<;?P @U[E2RXKE.?H4U5D,P)B[:@<3PE@(N!-'*PH
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M!D&D1=!*M&C^1.T^23QNF\WK6^CVE+&NHN5 FW7F)$DX"Y<75&/DAK;?YZG
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M0H'2[JO$^6N/_^I)'HR[>$Y!-JKXBRXT@*&F1#DH-9$W\L\:A12S4]>2%E\
M2H9T_OW,4I"]777'-*@^FSO3*M?"VG($&-08N5[:UI@L0E@I24PN@VKW:&3^
M'W<.1BZ%EUS3%<[U9G8&'!_I0U"X6IH\L".U^/P:I6AUUK =C"8-"((")EEB
M3I:8ZBWFD=Y:GH_D'P=T:OK/ C>1UC1LNG HMPGMM/>X='G*,G &FG(RJ>2
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MY$9.1V45J;D!)0:\4?"_;YV-!R##L#@'.CX?._U+PEK_B$/E6%37TJT^RHJ
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M\A%:PGA(DL]%[R\7@PU[ GG%7G?(D&>]!2^4G;\3+VU4I&)]Q-\;/^[' XC
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M>,BSB4HLTO75I0<3_W13W^0$:7X5NF&4I"0VM<_6EF;?BR)*<,1%!+F29'F
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ML(WJRK6(]'AY!+\C* AI#W)X?&365];0(^PA#G&B6'6&:*>2:,Q=M 1O$*N
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MF6G<]-J](Y*8T&E3_2"_)CR*3<GJYOGZ6W.9CU-*UT]<Y"S6NDYIE<?1K!Q
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MR)G1,8.*@C8+"YH\)HV?'U 4Q[DSA)N/7Y\KAJV(U-E',6K$?O$6"&F8_F;
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MECH6N(]AL;/3=#T7<IF84\G:WH+C<Y"?"HS>*Y< T!@*7ZKY>X#KQ6:BR('
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M! *X,)".=,X<#02@+U5D&\E*Q8,-*OBVKHTH)YJOUGX5[?.8N!<S)R=-QVO
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ME7[EO])]]P< 6*O7/&&^S10Q9E.@SZ/B_NC! )@V@^@](PF@X]5ZL#015*%
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M=QJA/*YZ>9#XM34ZW0CRBZ.H!3S5HHF/5[.#<YKY>3H2$[<<%J&W-2,G;_A
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M6H#RE#WRX;89)6]RY)W4(Z,N5*H3.-T:VLSTTH]NNC^^F$NE.6IF0ZX/TM8
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M-9&1)H:M9#:)4'VN2FG*)OUQAMIK4M56_NU:M$3Q,KDC>42A%[VJ"IX0V=
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M,')Z9&!JIUO+*M%JN<2$/08Q_D4Q'9$&1)*F%6AO1?3&T7 I^VW^QJ;3?BV
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M^ROQZ<[PF \M?MD[#![3I.\$QCUX:4YP)]CH$,=+8! .7$70F"O5J=P\2_B
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M3_RVVU,EQ!-Q-NGD2Z+1$!8XD@BB_>M$&BEL&[;AXD$0_WC1Z+\X[[<D3JG
M<_+,N26I'^&-6 Z7"I6I3*M6^^YO'PJ^_^FW3[7"T7=RZLN!3=E4:UT3]6*H
M)8UFTFX>M#:%\8OX8%\WJO'52E.P;4N0;H*)6SN%Z!!QR8!])U9FA1:+XE )
MPCSR9 Z0I)3N/\LN(4#9=@GRW)6[X(A!A9:&1RXHO,U[W5:N:M1MM5MB(G"P
M(.[QJBOML*]1O<Z0&SS0!3R?QH6QOL3Q&E, =E-60RNJ]+O0]AJ!)C[3%9'4
MM:I?(8ET1H?O_4T;$Q13+L7]@3V&XB[7S=C9C5+_WC6A\IEUCN^ TW_GUA"4
MDRUU;@4,_/ O\7'_CTLB_6=; S3S-Z\67C@^^^5>I&&?Z O6=_&_#-W:^G]Y
M($8F<EE&&0WM41K/^F7_GQ?PY<+3N:J< %,5:>P_4^[_AC_#JZ7:CE=5U_IN
MGWML^$\(>I6\S)&=C=4@^QK<DW^*1-W^0(RM3LW8@W^*-%2^;7U3;-_!N]E_
M0IB)<)!Z!UC<O?M_B)O_TQ;>OZ@DQX<3CM1,Q5_.@/Y#VH(V-+:<.&5EHDJK
MT?_]^/^2'MC>?J:F!O<I,-2_$_J?!=-,KK]\'3D[+_G#-K63XME0PVBD(!(-
MGGY:9H6X4ACU'SU#[1;1/-QKR+]\V!(^:2T;;N2FD\ !E[MCSI:N^WWE3R=7
MB=DVJC3V&!N #4"*R)Q<]^7*N98 39G SX&;':Y,UGOZ5I 4T>K/\ZRJJ[8\
M3X23G??+MTB4/*^'WY^?-;]B,7.5?6E/3LIJ2VY@L!2G$CZGI,7#%U9DKK!6
MJ@OK8\?2T3 ]=_\5X(I?%ROUB^=\E"+G 6FG%Z6+R-XK6W[OSE-_I:>62] V
M*EMGU:_PN_>9]I]F?K7LX0GZ9 3\,-J7 <K@J'_;U#/MMZF-F9)?0&C<3;"S
MS_\AB8QG 5<!-)I"RBPE6N=:(%SB4I)D2MUJY1_-_<I#\?M5,LS'J)PGQZ
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MS<-TCB[=-TRM$/$2Y=#+-<CFAV6/RB9X>E??!K1<;?^WM_W1ZM]8*9C[1^_
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ME/C,EWCJ06)1ZM!'VZ?!?WLF?P[32^;D2H-\;J^._KC%QK0NJ)EQ76=,V2W
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M(V05KG8*4MQ(EQ1BU4N<C?[.,*2)VSWG#O%D>NC4_'6BSAF3 K_WIJ"B-OH
MV?BGFTB(JOO+="/ &5VG*N[Q4MPS2=)3@=4KI(1;*3$+==$4^=]YHSE3.4SH
MO9\/DES<H>,9=76]L6W'W*WX\E7>2.SDC\_621]T4U#I].S<>IQUWZ%C<:(M
MU-*FL/C@[[LOMW(#Z[]&EIFO 7(YQ1IQJ&B#2^YL?I(*+S6(F$/VR+H'-#J*
M_66>VAF8>?!8+@)4A=KI@<0CF[_@CA9&6W:^^".>\K&B'2QOC(XW,[UX=LN$
M&2R\\I0NR5OD>;$\[V4$,HU#0@^7)*&\J^.ID\OMVIW/Z,#U\JUC$.ME9K+Q
M1J2V;8":U,JIER? SOPUTY.V#EAYH^1DN&97&GA./SO*05W?*3*56U\.S5V/
M#'=E'OV-3IV-9(P(.Z@<CF7P$7-TAJG*VAUN70[*@K!G,+5S@V:@ J\=TLL[
MJB9T7:YOA+M!,J7!/6()[.3@!I&I^:H'*F5>Y+A9-0'4L*!R\>1<FZ^ U++3
M*A("99=I2',2IP7.2,BOD3N3Q3.UN6UYYPEMPG,;B.F!M8]\8%OXBUXU8"F8
M708]O9#V+1R_FF>KQ?ZMK8;_4 HZHN""W#Q]9[YHB:[O8:WTD^I=7)J5"NXU
M;I]%Q:JVX?SV)F*- M))I57Q?&MQ(VC!6=U+6V7R*/'#2O@.H[Q4U)U!>] ?
MB4J8Y/MW]#J-Q9X2CUET6CWJKD/%RK>6&5EYLQWL;0+[P0[Y?SA7NL"57Q'[
MOYZS\\^-?3ZC/H/R$$M1+7?<<YNE1:6$%W*X8<HU$;O"I Z"2Y<76[\'PORT
M!\Z.8,>V*!NX#YGVNGW"K+JVY4LUY^=/ D#KS3?5?2I#3B7=><.R]>Q_Z= Q
MQI9*RTPS9R0$)U\B-*6R8.OBD,<?,L$:];1I-J7HCSY7$(G*D.*R#A8XM;1\
MVCGHYM=!C=#6CJ/JDEB^O:V1,'??S3&-7T'<.09^=/ZUD1DWO)611D;*H=C$
M>O-H=FX,?9!1J613K)+J"&:V14:['9?)8<B%?OW8Y>-7([\&19J+KD:=90Z*
M0/N0G3N%7/0^E/89G6Y;_-1MW#(TK7" S3& U]86>NG@5 $HKR'O;6\.AB$V
MQ$$ =R4H:=-_RBWCL_)G]$R+UH9GR$LS$]]X-:<OE2/Z-L%;9D)8F^W*@W=Y
M]65W>Y-2653>B"_Z*."Z<,P9ND.['\?5ZW3*AOF>5@_W9::8TH8UD;6C/F%#
MY'4A8:-4GX\F(0H,A+0?Z<+?3@(H(I_E ;;U)+97]\<5*D7S(^%/O8_1TO)U
M7Q)2,"L2.*XOUQ,N]$2T*FZ+$88$&6YYI)3/"QY=_3UA()$Y9AC/G>L.GL2J
MZ\;3K/3B1.V?PT*O3I)+B*LN!Z$%WOE$B+]'SN98.B3WY16@EA'<@J>OT[Z@
MA\5.,=&7_Q5*67X])4^W=A#]F;LX,>Z*B8CN(8>.R\& ?]E;?D0T$Z!("R_3
M7)%:M12KD@5,54FZKNL'9.A?0XF\!WV]J25; 8+7Y=Z!+0+[&<UR=L01%RN^
M0# ^J+(:6^9-N_SY6BPG$A[+1/JFH67ZK%C7G5, L.TCAN']7/+*96;C_Z,)
M\&7),>^9,>FXXT;=581&G5PXUZKI$)N!W'@; H ">A.7/-74)-/M"&J:Z19+
MJ%TNC=>U,[9.4HWZ26@G)ON0/KPP,\JJ;6:+';F:=K%?MO4RWB2&4(I 8EI;
MU4FY=2,R^2.VT"V9V&#=4L5"X7:_.J$W:QAVMH6.1M)3MH&266 UQGKA"DNR
M7O1?@,@;"&COK,_O8)D$E>*B-YQ]BZ[0BB%ZL%DL[:%VBW/"F;N7=(GK0O]W
MH46M@FF8CO;G/W2GX">E->".HMGJ7,MVI8&$\R/H,\]";K03D[,(;J6\%D;Z
MBC\<]G@E(#3/=%VV1(;Y6Z7!52B(HI3U+93C\^-_50L[_3LO+]-AH"**!NSP
MU J%J98,IP.&,"@2#^Y-F;]?27$O\Z7._%E$TQ+W3#U8#]6_-Q_-_6&R2.&&
M"B)4 ];D: )C1'+:^R %2KQ>T'-\Z_:AD]4K_J$[E<PD#("R7J7[V7$W<_+1
M,5L9X/K9 \!AZPXS?;>\6WN8^% &92QLD&L:!->M9+$>2JXM5(98W]&;#3_;
M,#$J5_V>/]Z4A/Q[6!$IQ](_@% %6Y7<\" $1U(H3GDPY!'D W-UX8I^4>3F
M8 U?/(-P+3'*:2?0;-KUAVK4)%0G;JW:K.JW:KT-C07F_4>WMMD$'RS[?;%Q
M%6E*"^)/;X*,=7 9TV;:?_\V7$]W!%>ZJV-K8PG3B:W1=7$KE*28P58IC9:(
MA%PU/8+OPA*/UV$T(\1>B-7=06"479-:SU+C+Y/LX[MO@]0RZZV*$4;6HB>P
MNWAF?FWKV-2=#^4W@7[Y@0&U<R(S@&G3-.VVT-T4?YFG&&3(6G[#3_Q<V.RV
MOS)!?J4;4(O?XG),N:1R)O$I-]EN1H^YJ[)D_,%@[DYK4@VFDKNRP<Q+PI,0
MD=1LB@N34_K]^O*A-AN?R3?FPJ!Z*#[QG<]J?5/3YCN^H;>TR5FGEHRQ9A/2
M1R!5[VWP]P*,QMK@NKAB7=[0^<QE?[M\5\4?P6:C[&3;T<JFUY9-(N-0-@OG
M;U4:M.F_ *H?\_A#-77RM..>GY9G>0\_I]GF.'F_M91N.Z3>^PZ]JL5?NWIP
M:Y5Q"8!@80%P[%_/W2(_E3S7T6Y$.355[H^KEHE;5W]RT&7Y5$S+#@/&NM]?
MS^B(2M'(W5:. JBT)7N;-*.AVNRY.\AS=.TRE;(QZU=FF%:Q_<0:S4#HO,\N
M^WE;E:UMXBZ+!(TW8>E\D\_5"T35NFO[]Y0Y-2RR-Q1CA(?K'H/W:9U<!'WH
MS5JA7O*+,R:0C+Y:$H]JN'8DJ.&6!HFG<XX7)V);(-65D3\%:=&QJK)@[?7>
MI/]9O7G2.J[K(+BG=,6>(]E'HH"8Y_WA$\62<4'9XV-<>VL#,I[)-&DT:-#7
MWI?A##DCJHMO#J'E@#L-&ES 26<X=+):@'HN !_D\TD6?9":^6GF2V2(R(!E
M$C24[ZI6:)_RJ#F(,\=KT;GLXXS:LMF9^\$K_F8YA,7-L+R24:U'2<?\U)S=
MTT1S@W59]^/X1]3D66MI-/N=Q1+@E=N4T% J:*,['G]FQ;+)*46F=XDAWH$T
MEL1LU>.8<THLH]B5*2%WS*9?!+.U%.KF G-*!"D>QR-\6S91)/S;1B7!UZMV
M.)V$SD+IEK$V3A(^5.!##.FT!DG[@694M<PY:_08 X;V.J2*UHVGZ)M(.!(#
MJ=^,F005Q'6UJ*!5%SL >W0^_9ANGU\1$&_6C&9'QTL.MUH8;U7OB*0HK#?[
MT85?HEUN7N=BQ$N).,;+)N[BC*JU=,#;2Z9O;NP8!=KH6I2:0Y<LD>V<!X3?
MJ=:2XAIYCU;;=\6P2J51/D=(V%,Z5X$IM Q1ALEF]'ICB(\ERG9G;(_2UBP(
MGG+_5_J*A]RW>T"Q'GS76H6=RRF;UX(<NVOD5ERIZK=F&L.N5BA(=/L1 2P2
M4V^9'J@C]R!::!=SJSOU5ARN8$:IYJ_*/U/;0 N@IA=V-T;\!ML!O6VPKW0Y
M3+(J,-;Y]@ 0Y ][%6">J.D#D?VQV P2F*&(;%.3-=<_%J9@Z2M/5._\4=T&
M]VYUU[5RG7*GLEFN)EMOV%^W>49K$M]3_.Z[783^J7(>'/%2 UB:KM3<D0T8
M>L%IF7@_+O6+7:13EL]9B-B5QH*Z2$V0Q>!2'.S-S"0MP_J@HR#*^6V5RV<>
MZ SV">J#+DC9R_8,$C T55=FEF$];GO;ECX)GJ3;S32I:WA@V%H0I)<3TY6,
M O(D00.J]AP_4#<-9/ 1/JZ72)S*6B2OYI[)/G$W4N1-,/6NRN#? @LG%MCJ
M*K,] YB>61%7\4R7T4G:]WDRKYV_FG4/GL.-R]I=U4V^Y?<KI,NK2KN_EG]6
M#'2&N@@%#'$-2ZBS?N! ^UFQZ)B3S(ND;73U\4V%9-;\R.D86=3A61==MS-_
MGKV9GX;LI]"O(K_(9'7DW)2\^-:0DQ<@&BS$Y-U,"AY+I^[Z#,.(ZCB!](?"
M=^LY$K&W"45O%E:ALCNMYGL\\*0YFWA[6P< Z@0.+O',^$HX6<]BEZ$46Y;D
MQDUISWG+M1/_:QE@Z MEMHA0%)C>K=F@FCW$A!48..48)U[6-0*E^9B-:,3O
MPC(@ :.!3_I@-9.:H<UOI2R+_B#(ZQO1?\Q!;*V\;4O+>2F#OF+ZAIN> _^?
M\HWS4?U3&&"QS+=SNNB;+=1UP\J"BQC_)FDJHU4RUCA8X)5(@,;]NO0Z:9"&
M_+]+$:P*^.7%1B=U:-[,,B"G0WMT!'8ECYH<"6YL2/$Y%9=XVUQ8R9EF"1W9
MG<<MS5MI WDV*T4&:[V7U(/R![NU^L#0'NF]8S#UXV?'X3O\7AW][4Y]488O
M/%\P!3 C::%0+5O<& ^9R5O9L$"T4!5'K"/$+D'UP(V9!!<;71>;SZHT=?F0
MC<4T[YAP/=I;]^LBU[;GY\%JHVH*TD5[VV>H<?K_N8L(J;S]W&Z#"U)\J?5'
MRV9'NE%@)#3I;@&J : ,$-:_GI0$JM$X@CX/&CJX8O/FPC*[YTRMU%I8:ZQ^
MM+LK5U5_0F[U8#;INRU2:L'I)7CI;)73@$\<N5@^HBUL_-9D4*VLJ:)C8$F$
M=3IW\Z??:,I89NS%#\2=K65+(WPJ@<&73H_EQ00+>R>8HCA>:_?I2/2MQFM)
MZOUD<0CJ*J'939P;W'U4C *Z(B^Q9_:3?XA>>[LYI RH[^)YWKPMCP;(-HS=
MW%2Y*!UNT%X=)+ DA3X#BT)_:2K&.QC;V9+YC[.4 ;YX?L$4HWOLWP]3E7IA
M)CD@U,'R6.,B/;9E6/'%8$7<RK&Z_:M ]>89!&-%D1Q;M%8M'8 A^N.)*>IJ
M<&J _-E/BQFZ,,_S=L7\C]UQ%<Q^2'4%"UB7J8ET+?V2LE@<TM9I_VF(')<I
M772,?5)P[I\)2E9FP/#B27:UZ%AU]^?VTS!J$\E.3Y/G;9,[%+>.05<()8>L
M*[9\!NX;"2:Q+-CK=!'\C6<2Z_H!4E,QT,E7>@E7(PLG<[LUCO-ZL/R_P08(
M+#T.5K+WN.V\1F<XZ_>R^]OUEY\#$U_W.SO@65CJ'?VNDD9(C(_(Q31-HS?3
M==E4Q>S$@-,=:Y+<TX']BJD@-$RI17EYB=JZ *Z*;#:43>D]N$PU'BFJGT[>
M"JH*O:=?J&+G#)PBUYE+V=RY919?H'Y7Q6#!JI+H F 4J],P$T>J0Y&8CG"J
MA$([*+AA4L#WI47H,#4_2$:-<E,8HH%A2@/@&4CA0OAR)HN$-["2O5+HT6??
MI*M:H!@CL+K,Q'AY#=]H'Q3G/"IR\WV)A#0I1FBM@N1[.7_8+L(_UR)0L;S)
M<F\ %O>$?$]*MY )W^S3K)EH)QMUZ*5S'_%QI/DN[O*XG?%*KK)2BZWW,6[3
M"[34OQET_W.DM^R5SGP L>X<*,-EM^'3=EVF%^H@G_!^J,S5?G><8[3QW ?J
MM6\D6^4P.:Q1P)NKZIUP:_MS]]HP18J^.X]F?Z9?*<=](^/BDJO>KPC-,^!?
M .3TENQG4\FBH!ZB3<3JYJ?R TK!C5A.\%\ D@:I%% J? 'CZ(W1.(!>F])Z
MI \=JOT"B1PR3N750@B2OH48:_E99>1*N09_U\]P7U>#J;0S31UGAB7 ]*Y@
M<E>=6".$GR$ANP)?]L.*>CM]>'?Y<DG3'UF7UO95%N>%I/,_G)4Y/*Y6"T5Z
MMM6_NE=IQ%>9P?B!R<'1&*'"$3^*RWR. PSNNY.%[K^(=N5I#EIU=SVDF\Q5
MA_&7=L<'U&X5Y'%9W 589#-P9_:GL@=\5LE$!X8MRP4GL$I$VD?;!/<VV8]7
M,'C--=6@QN:F9=F1W-YZQ.J6$,RW*^6'>.LRN3_0V:3F<Z2ZOIO3?!*=5WEL
MJMK9TKPO;C?>:0G1PW9Q(SLR+[;<MZIRZPTR*&ZITFWOG7+?,_\KO+A$'*4&
M:8)U/DE$M"TE\ FFM,DUZ^O*E3N7SZKB4JXL!*2A,PFG<A*I99RTH-10LX0_
M[6>UJ>8]GI;6+\8:0S4VR^UR^J_9-'?$,_;QY0$:8S$RK,W'E5JW [%YTITE
MRB K_?;("F(GNV ^BBI"S;WXPA>9T?G+K8X=1$*>K1>2H<T4V@(!EL+#O]K2
M2D BEN^STY7JS;:/QRYR".M$BJ<&AN?N.B8))HQF91.M[,9LFNQ4#9Q3$BD\
ML1I#"79')O4, JULSC2F<Z[B*%>FC,N=Z/<27,4BY*Z[QGW&;+6]@/\:]BQC
M65S,PO+>MB;FI-LZEHR2KE^!")S6L 1'SO#@I\V!='B3C+R5_-VZ)8O+O.PK
MSOX41@F42^[Q5%48H% O-F.,V5@PK\G=?<<[G0HG*,GH29[26*7YD@=0^K5'
M7]*<1+$"'4FWKVK30.TT!R9 ,)/_RTX;D\'II!Z[I&_F\ &FLRH>+TFU(]D*
MT?0*OE$0XF+; 3'0)Y^+:WQVZ'#2XVSL?(]>:5G,"[!6JJC.E_M5^/,<W#,4
M682D)\[4)-M5IP-JA]TQX_9[U7I]I3F7$[G)G%]L66Y$,R*78B9O"'UFN>PY
M^D2E[ILP8[E1R3D\C#G>A0U?]VVUOME,G=M42_$G?:CY#PFXS(A;[="?#$=[
MF]RFK2/BF3#(,[@#+=;BH1XE-22>#[?XV90AU7(#'^RT#%CNS?"W7+"5*PLR
M@39U+CF&RCQN,(^S6^U2,KDN98<&V%H5R<H]NH,6'_FZU+O1PL("'X,=2('Q
MB]IQ?-X!P?\[4PIKAHPVM8=<KDO4?^&FG9.;QS-.*VQJDFP*YWI.\R_C6-\J
M=5WUM"YJ7L>80B3BIJV'-IRG^^$\KER/(6]BUH!>IL8?N,YOR\R3QM\=6X[_
M4ASN0= _4;P)$&Q]VW2/T6RH$\3-@D')AB!;K]*N6@*W$A\*5-$-V].]&%*Z
M>; [6%]F)!P1F?=B[ZX3&V9==VGK+T#;XQ,)2PLVR[W3*K=L+:'25WYT *D$
M4/#-JNKK<5TT^I6#P=3,,0.@)EG 5@[[T6YL'V#F\Y0S)IWT!1YJ3!'-Y/LT
M:UN4:?_ B00JQ"_<7UCH)$=LT/TRH[8[O-7\":Q>U?(=:'H]H'B$.>(3OF_[
MX3N_I.[>@,*C:&-'QW>\#I_SEW\7<X/7M>D7CP1WR.XP=,L^-Y/BR2Y?@&,+
M>F299Z4UV0N>3!KJ%I9ZOS >&!*"#23&)<MOHN1_T^I5Z]2U:.@O5(W%U8VK
M+.J)_]]!F2;C9X.^PU"FSZ/"PF3G<JY]OA!R4%#P%T".#>P M6'NFW5+S&9=
M%3LP<3D.&._6- I\HLN&=3$TI-4W[C6LH\D9^0/O2&\1ZLP)^S7#U7 ]DK>.
M4!&K1.T#E[,4*:#U(TDM#HY*UY\@VT;6#("1_PX/*<,82*2[3FDYKV-^'^VO
MH/Q*\]V5%>ZXT,+_T@+(X/KV.H744BZJ!V;;\:2H&M8PDN@\*O4=HK7$<#'G
MP@,ZDZ5?*7O(@S_^&NS1@>  = B2L+=1^P-!"PYZ^E?T%!*-[]KKF%$Z88+Y
M=4EV-1+4%9 WG%,'AI8/=NSYG\P#%BCT@][$)>0SU4?$9S\@*&$S5G5:<),_
MRG&^\2/G(B^U_.N#,A=>T6HI;T][;EJ!IP_?KC1K#?:,SCII.%;\+P"E-9#G
MLBXC\BR%?Q'C#\-GUG#9O'-,*WTY$B+0TB]5^YU5</_H$(^1"(H[IZJ.>$UX
M"3L(;]C&;??-KAL9=HSCW[!6&4R-;7E'/-P2?J]3$"]"9]U.Q;T48_M2YK1C
M7@6Z/ ':A-ME,TIZ.A(#:A)Y8O?G!LWY"VO*\Y=MRD-CTW;BG)8K5Y'@"Q6G
M8$ST*(OPS-^=5V#0>9#NN98I4:CJTP%A:CJ_C8. \,*>5I^\55"D/]ZK-)29
M].G\"U 003N@*%#^OEC &@F*SE^3AY\W[ ;7,4LL-)QB;U_[[?C6@H0.#E.<
M+=9G$?@^/SS8^_:OSGT/:<"'?U W[6PZHP7\28.::X'/#R$ABX-_&I3BP=4
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MURWP34MA!4E'=%:9!0WU;(FP,/O4-1X\*/Q/4BZM@OH&W[SY7X[8Z4Q;T'J
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M!D"N58<Z.Q5?-])S@&^Z"LKWL#%;2+'4W[@E=I?4A>!;A&FQJL"7^0A>9U+
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M[9B>J+-04!AWBVQ<-*[E*,?:L<6TY?\E2.F3^%*=N[_4NHWN)XEYXM?[NDZ
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M_,48T/^LV2/3G>0NJ2]LTQLXKIKK6 I3/S5VG2P>7YV2\I/0_E C+J@%$6_
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M(6"#;FJ2NE3_V%\ 11V_=XP.@NN)!1CW0ZGEBAPX\<,^\B6]1X45]2;AB@&
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MWP T**&4IJE*^N9[L6,_&#I+ Q6<U@BB>W>*7HJ2NP>):TS F.DB,*\?[4S
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MMR1I$5>XWE.MKD*__='6.GSUQ!1*:7LU3]<,Q7/ZIGX@7;@G8 SL=+*/QVY
M A'=(G584%H_]ABF+,6@Q;ZG'RT=/S$FG7[TU>VG=+NC)/PC;MBLEZ^]YQ!O
MKTS$%3,*=RES1%TA-S817Q$Z03)8!H]V VIPEGC3#:\B:*]P.I>QI@N^LH$E
M:9/*_/2E#[3MCCV:P%3XR,J%27F[I@G+"'%.UI!6KHVNV"^(K+5VS5>!UDQ=
M.GOD;U*6DB[)OUP&'3!-EO.Q"4-DR#H@8SQ7\G_&)#4>1"N*]UF6J+J$ZIF8
M/+L('?B.* [%98[#P[AV I4=<%-?6VI7A=]]R+ZH+6\N@47_B' G7H CN.P)
MR;,:]R_0OL0[%P#Z79N1'8PTA[BO, $, 8QP!>[M =0$+BP1((1H2\N2MW[?
ML7M,:BX%G'!#'-V!,=?OG526V$16JMWCX&?=5RJ;BPL\(V9ALJ2QK;?W"&MW
M7!XJ7_* &2DWO+YUB6@.]Q_6EV6."A'=PXQ3&HWRZXGU6;*L0$&*W*WD/Y;-
M^E%BIQRULBJ\V.8BDGL#&K<<EV?CZ1@:ZC;*W]N(Y]QX.>"9+^H2>=C"E@"E
MTJYG]T"W/H/B:M3==&G9V=1\XY63OH]0,_2G UQ'XUNA@H7;4>8KCD&A\2\P
MF*#C74]H1^8;&ZK-9];)>YQ"&0GL3*R6G^\<783J\0?6@-*=])G!;:D914F@
M5-AZUN5L5RX+CK=E2^<6!4]-T>;*[>7=H" 1CR/Y3P!HA])(GP<13"S,,*.
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M037,2NVRSX2Z__ WJZ'3ZM-@%#A&\P%1]VE/2@T.P94(#5+(EL.QDT=8WBZ
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M]KO0Q!-;\P!1S!)RFP*I;H'I!C%^%']$&>#GH>4%T1D>]%;)YF"PO=7'O]W
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MN(J9))0L')0EPZA%F3LR(3,=M[MTUT5?%)[;3LC65%')F0=[DQ,,@B?574Z
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M8>N9@8;#S> '@EFAMZU$++ZD? .(G%M^F;0=&:U^;38%Y 7PX(X?*)$<4L:
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M3=9K\L(*L+%E*=",+P*L-R[I5S9BDY!@7HI!T,]*[W 882[0^'TLG^.[UV.
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M0'P?[X2U"\:$8$Z&\8[J*;1Y2)M^6?\&(-&8J9?*']X8^, $4S#RN][08]
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M8Z>.;EW^#.3#-</7J.?1FX;>@]0R'^=B3Q>(J\R1XD?BJ*7%7]NYD2,;]PT
MA?>?D7":6P6)5<,Q";LY I#M#T31LI'".9B;8EDON&9!3TO6L]UF07N44?7>
M.3FJ%*)"#!MZUY<?@4DD]P?*8O?,&@.?T_5 B]4];O339%ZOZ\!'<URS<\2<
M*A+(!7#ET"%7KG,T1HB;$PSU)WEYR,E9%34D4*7E[,,C0W\IZ80]D<D$!NMG
M)#J..BPF>T"LWASW5KMP["Z!D<F#C);+H5^\EYW'RVC;AWII9 ;;^$>C?#]6
M \M),JKBW97=P8UWLIY+A^ NV&LD&3L[D573BFJ]88.6H>->[,VQ;BN,/:TA
M@5T:T3TQ_&ELZWQO4L*AC61'LW\RMG8 07H?(_>K^WV_,RW?GA]OF M+F/^K
M_"@FQ[*Q6JO$7MB_,^H@Q .?M#/$A$BP7O%09D.GJ"&$LX<=%'(6(_\?-C/Y
MJB8Q_IUYF>.\JWI-G+&V+O\<4<4?V]%V2W;=H_F:U:G0GUA&W/>4*=?(\<L_
MX9[O>UI/!X)NLL6WS@[QZFS7,KF&-JVWW7UMM=[S7 !>3%*BR5WPK)0D<8M)
ME!V;P/$*^>5<Y/.[.9,3BR6Z65^>;U%Z3)W ?LI/^B5?L\;'.&5C8A ;LO49
MV+C#GJ0BKP7+$)]<94RPY(GLI=(P"9\,#>U'"\]2O-ACI1\B?]_M$<].2]%8
M&9 A,-PY?LOZB@)20&R@\5*B8K\?UX?2MQY/W[9SFJ#?#&%>U[T+7!5_G,^I
M@37Z2CZV[/+U_#$1=(/9JGR@ VP?D8Q]6!VWCTD"H'H0Z# ^2OTF[Z@R9I=[
MNW-$\O5NL1D2$VML8YH0KH-?P91#6(\R!/E]QB;BS:<#(_3]B71N/=QEP#:<
MU$=0T"K(I[?4 ,X7H&N]8TI8F8<K&L]U@^XI&F\8A2EQ9GLS5+'7V4TGI:[-
MZCF8YP[>["'JLU%.6%UE.O;;-U=[NS>TE%-#-J<0&!T]2MW[_0/^]Z9 ;27U
M'=!T([!*(Z[\ _)(GCSP>FWJ^<_\UY).F8F0W!XJ%;C4WS?T5UPW7-6 8Z=+
MZ<_)R6Z@E(R1!7J#S<(FBJ9G;T<EF_8$GS-+UE]@"B=YMIPPSY-]Z&[*+(V=
M0O+JGRL)36RFLY84Z&9(]-H^80(T%V+"Y 0M(T6TY3Z$/LOR7"T?*<J\'D7,
M%$F[>).H(RBR\K'.@)X68NO".VYTEY%UF.];G9VUE+X;=.FM7-5?D9'D^4/;
M&)]S)*S"JJOM=Q2$QHDOH^]T^3V2>.S(=$)\IZ=#4P"I98JU;@Y]XF*^)&#@
MZ?4+9E3$Q0]*3VI7OP$4_RSFS<WZ&?/2S2'^S,^C<Z2OE?4W["TE_P+O?VYK
M=/$6Q7]X.*DZ^\\;H26^,%B'/-D&ZOP/+=H<8RXO=N+WB=0CC$;^+$."L)A]
M;]1+H2SB\VP<A:>J\]^:_P:X'*ZR]@M*K;\H(SP7Z?8- *!0N+Q7)*#O3N5A
M 2O'PMD#$[13<,=]-67/ @AT;YL7?=J4C2%\G[CZ:'DF*?HJ<3.WS/0!<\'E
M^UJZ/K]SE1&5IKOP!-H41WQLR=S)N4W@UUM=G"NH+Z/BT0<^]UR54B<E?=Q[
M=8N/\0M:G]7F.LQW>$L9"4TOBAZC=_T_QJ9G>?0;.9Z8=61.*"D=*2GOH_BP
M<K6O/139[44VP+F6F9!^^*5/.O$3'Y2(6;^:DE%YKRT=_M(BX195:[P0'/']
M<46SM?-(AUOI38R_*C17GEY)QZ87S%C;,3[K&(6(F<7#=A)U>4O<Y#A >C5-
M*I*G"R,HUB06" @;9Q!55>2=>L<W7V!"'/Z@)]UY%"6YWR>YO!?9\'LJ.UGA
MGH#[&F4J*?H[/UVXXDK7Y^/$F(VEHD_"@,4(WI"U>W1:%$[?H^17Z94M7<G
M>F[HR!7W60VDM4$U*W0QYD1#P2'C-H9EOE-D%7<(KCD9BY\7R[5Q&>\'[SKH
M]MF,2PE<+I]U<P[J Q1CFTY]@G[?6K9?L1H^_D\$7_'W,.]WMY7G1M9DE_H*
MG;9SK.(.9FV4C)EE?(("YF"#ACU;$1(+_Y,ZGEZD='$[^+YXV[_ST9-53>>P
MG?NQ$HKQ2=,20J@1S(*-S)G=12?/2L9X_F%=CZFV$WS^WKPSYBPNF!#:$K;(
MLA]XM) 6W"I!'>C!>A&M?&,]Y<'0?V>SXRM\UR_DK3!:K*:$.(FV0B,W?SW4
MWDA3._"V^?F8!]]>,O?5DMOT&6D*&6)ZHG5>6K3X7,!K4U+"]T?'KBD ";N&
MG*=Q;/1K@&-E K3_H%RQ$1[X2^ST+[&B,Z?Y6KJ=:[L\TVER<&T6+L&)%NLH
MNXE^0U\[Z)O+0Q4I5V<'A [#V0IR7V:.5+W5M4-B3Y6\>W 5ZERG]YM;O2+"
M7OU_"\U97'W>X=R<I5PJ88VNS\P",Y]=6;4D]\,]H4-[33ZWW/ZS<%O^BC]'
M-AX\>RGHX+YG(5)U?R_\DM1;'%806_>?(9X=5!%_ZM_\N<[5<FYB^.&_S='[
MMXCMOY?(M,<_7N-3X;,Z#[5-!G\J[#,.!.=\=PLLB3@8>>%OL<W]1\"VD6SQ
MA\*G(A96]H:R5Z^_[%SYYO=_ALTVOVT>?I]U]\E#<W7979I7HMI\,Y_O<?58
M?GU>>N/\(J8/S\JWUE>H':RT#+L0/UOYV,S$2B?&Z5H_;( EW)3:^;-OS)&-
M/\C+ROZ--^_?=>YU_F>\&6+=-$.S+WL$W1"KJ3NM*<+LUWM\U[1CEH+S'=KO
M5>X_\IG_C(II4:UI]X1SVSG\W/=<^5;[G^'FO-JI^BY=:Z=-LEF9I_'2XNUE
M]YT_YY7\.;_UM_ )^2(6N=3=K_87J*VR#^_[>25^PRR;$G 9"W)!!,P%LGG_
M+JZ9('5ZC[QM0LF%V[(-U_3Z$G;QM2DN6=+&VKBAMG-3LO,EI<T\3/,3"[*>
MW6O^KG0_(7Q)"^O4#;5]9T7,SX3/7'7A=R:W:J^495IJPSM[EIT:>]O?N>AG
MR]Z)EIOT8+%(^ WWD*U3IK6&2E74@$K>4W;GS^;X\:U_T-;4_%L,VD8'.FD6
MV$G'%!<L^'<<DCI7F J:ZU4S7QJ<2-J!K_V;+Y%S4!NXOZ5O.)\X[[!M6S7/
M-\DWQC=(YK8PB&5DDC&DU+ DF6E.YT"W;&B('+U*3^55.7LFPSN!;_Z=?UG5
M4!<]X5+$?P90BRG0ZRS_&46O.7]+'M<=5;>RW+=ID293[3)_T>Q8VW<!!V-_
M&;TXO?OZ/JO_#.:@HN*W_>9?:0ODISTQF69_"33&/$%T$?/.RM]G3D^V_??Q
M9I8I(Z_&'V_ND^OE,_QS:L,*I(U/[2_+^I</+/F^U:=_N>M@KWLB4Z=^:3:P
M,::J]'+Z\CE;3\1K')VR^_R60R6_>^N%@W?^:/3+JEMJ7Q1X;?KA>^@&//4^
MO/!R_7I_<!/H9)U0L?=B__@U8:(+_96O1VR,DGD^W6*&I%'*8X\C>LMT=D8>
MTEN1'!^QC=MH3VGQUT:7O1R?$G;,>>BWYOZ'O8G"KEW>P )+'^:MW)+:XT__
MR -]!6E<VIU_\V]FK'SASWKV+["*"]@ULU]ZW?U.7?Q!6) &>BR.NJ]@-3B;
M#]254',7N6#R/O]7&8&F2-+US[;I-)_J:_NJ^)_A8T#]_YL 4$L#!!0    (
M /6#<UA'>^3/_R0! *;/ 0 4    :6)R>"TR,#(S,3(S,5]G,RYJ<&?LO0D\
ME%__-WZ)K$6R91U%4DBR%ADM"$G($C%%LB4D^Y@1(>N$4)3)+MMD)\MD+T+V
MK9@A63+,6,8PVW^Z_\_S^W[OY[[OY[F?W^]>?T]G7I]YG>OZ7.]SG<\YGW/.
MYZP7?9R. 0X8ZAGH 4Q[F(!;C!] 7P6XS]_Q=' "G "&8Z)/ 1>!/4P_W<__
M/3\="_//_[TL+,PLK'M96?] ;!SL#&)C967G8N?@_.D8OGU<G/M^7OP,Y/^'
M[MG+S+R7DXV5C?/_VM'? [SLS))[[S S'0'V\#(Q\S+1VP$0(XY[_Q ])N!_
M.*8]S"Q[6=D8T>!B/%!]@!%]9F9&I/<R8LS@AC#X  OOWH.'E<ZS\IG>9COB
MS7_Z46(6N]2%\A8!LP&\M++#@S .3D&A0\(B1V6.R1X_H:*JIJYQYNS%2[IZ
M^I<-#,VO6UA:6=^P<;SC=-?9Q=7-YZ&OGW] 8%#XXXC(J"?1,4G)SU)2TYZ_
M2,_.R<W++RA\4U11655=4UM7_ZZUK;VCL^O#Q^[!H>&1T;'QB4GL[-RW^>\+
MBTO+A/6-S2WB-FEG]Z=<3  ST_]T?U8N7H9<>W[F =M/N9CV^/]\@)=E[V$E
MUH/G3=EN>_,=.?V(G?]"8E9Y"X>4LAE>P.'! *>@M KV*.&G:'^0[*\3+.P_
M)=E_"/:;7)/ /F8F1N8Q\P)@@$K)CI$%?M'?CU!G252R<0 S,3BM+5WHB8+B
M%N0 J<=2Q/-QHU).KD=@T4U"@V?ZDICW:R=%Z82BK,BKE]D&W.?H $F.;463
MD$%,'X2"",5$%X+Y.%2'Y.%[;C3>I?8":Z.5"W+;++GF3"+6K.%MB7 X;P?@
M#^(">[Z!&LV>8VL#"]"8 F);BV=10LO38GAB@Z</:TY^;XACL*_;Z'H/'X=D
M2G./%#"P<D]M[%;N$!WP0)..'VL!C?OKW8#ZO Y W!@Y*=;A>#MW<?V)=,8M
M+T3@D1).OZ>&Q5JA8BNJZP64@QLT3G6LY\$?1&2Y$,X'$SD$]?"<B]<C&XW>
MQ[*GB7R93.GX\K;G !?1]I&W2F$&3(_\W#R4ZD\1<V"C*&V']X&_Y]G2@:7F
MW5#M[R3'N?,$*2PJJOEPO/H*?&I2/#^'"-;\M*Y%,H,HPEAQ#>4O]\UIB,L=
MFUOH4F2E]:'W>=)D29-<Y(Q@O<NE*KTRG[_8+ZN;G;I<ZC$K]E&N'. .3[H,
M)+*MM-$!F1'\!JW=XQ@=N#Q;UKEM,%@M%VO4I'^E-M.6*_Q<7/*%DM'UY]/*
M1PYJZTU(1]?=POF)<[SFB0$[KY$4_,-A,K1!07@EI!,YT=^.W+=E9[^KJ2!A
M]V"QH?I3W;I#700V&O?I<=$;T1;GFT^YL6O(JC1<-!89.G, *H"_>!&_1  A
M8)++(&?\]U#%CI+C(LAI.SN3BHO[.)6[NZ3*+3GCJ\LW(#AF_)$9XC ="'L7
MH&F*SPM3>X0WOU+^CC"*%H&6%A[M^3KEFA7%<TQ)>1\E9MV9!8#2@;GFZJ(?
M$+S7=MM7=7/_4ZY!=M7-F8?PY>)G5WT09%=Y9#P0DD=6A8W3A$@[!.9.)(LO
MFAO)';"-)681/7E)T!FNPLS37FF6E2MQ_<S>/?JB9?-?PA\L1!+T*?RIK7.F
MI+P0O"WV, $>!>/J%.UZ-T4*O:%\=B<_8.7(NK20\<&VPXY2[PMN<_:F')OG
MB;!7( @]AF.:9@0*\.-WU<^RYJ?QHO2M-Z<"/_-^"7S;11ICY !+85TF':!Q
MU)-MEH,>X^2W)?B&,P/OW*LL'UCC< A.,E!AVD7B]>? H6 7SXBSQSKA$;OE
M39^WR$K>3LKY8_:&C?<;<0]][]Q.CC0['31F >&D RU-0=]+BV&MDYG(P@\X
M[A<$;MKD>R6L@UJ-SX%SC1_O@,W<5XL V>Q&H^O4-[#3XV[^:H(SY9[QJSEA
M_@F:S\L\:CYE/>$^_95=&&0#$"?E/L .TH;3%]I1HLM('E_4H\F9*%^[$ZUR
M]25;HA\D+HK%77A5:'#->W@+I4<''J=9T8&L"]NT71M@/+N<#F"/CM"!Q6M-
M=* Y%4$R\(7O\BO"U_)>[X^1 ]$.VD%H$5PSY"677\A?R%_(7\A?R%_(7\A?
MR+\-\F2__7#9_22.1F5?SLK;>7XW%>M+#1FF3\Q_D-P'.N"B*$3[3 =XM$\$
M2'4BN;3YW;25\6'6RS6P,P.;(8:C<G4BEA7!FG4.=:FJKYYV>$5<W"-X5SOE
MQ[-K;-^WV]#CY Y(]5@G.A)T2$'[X-< (P.2/\&J8[+_"<6J1+71RJ9&R\+?
MW[U =Y^95IR#KZ__TR,%+V1:20N#= !3!:KLPDF1;T+%\=LM=&""<0N657;3
MM5D>8=$P K(=4O!X;.2J96N%$S(X[,#HEWCQ)-8O(:L+7_.PUWA.)K?!WUXZ
M*]2*C-R?0S']W+C?^7:>JPAU/FZ@>D6-H#<O(?PM(JI[7KTBK,4_E ,E2N(E
M&S L1,-&;S)O0.L9&N?Y65"\#4_<*D6)N2LX_T8+DVV DWKE_1>2?H\_#:S$
M'G[%S]O^."2O9&G0;=>B,TWPC<^=,=Y#'5^33_0(!GR)> 3LBHE9@/8$<+5"
M]FLI>6+66!:7' NF5!+*.80GOB5.&AQ-_)*6JN_G'"B6ZG?WKG22"_-&,,8_
M#(RIA[%_?K@6=@W*C=^.:%0M<HMI/DI034#E->?N_=2&2X_M4YR^<?+&C2\?
M!) :XTR<;,VP<3I0OIVPBO9 1B!KT:TF7+TH$^QQ(1,"(NJ>4_3)A7+J>FEO
M7<J ]$/;:.;#MSX)[%E@;6[,#M4^3XV'.R+$;L FZ0 _'? TB;472#Z?UC'8
MA BGG('+F]FUW+ER?O4^RY4EOG<MAZS;!*_UB8IQKL^PT#I XG3@CLD>V "Z
M$MX&>2R2%JL"CCW[\"WT[$A51L_UR$\W6WSNX^UWAJ1T;M^8TWSO]%3OLN2K
MZMW#ND! +85OC7@-,MY%M,$SDEVT5X_KJPV?PMH318_SZ]^;7M0:5$H>?**F
MEQMJV,D!O+2J&M %^$T90$@H?%XR$\R0E\^0#@S$VR_9"V% .Y>/(>C RJ5!
M]*:CU;MK3+K\_V 2R)BE T(D__<P\3H")&:+I\*5F*$]X/VM,</_;#:ED$NL
MDNG]VHW14B,>0PNWCWI*QC5?DXPLIX*D4TO+#4WC;.]_%+ENE0%OLZ/U@S:O
MH=>3_>E 9R$=B&R@9H(7L^#S,FMT(-XJBE;CA:*R#3#2["T=^);@68:A PO?
M8%LTY]R!F_J/P2[]X?9:! %TA-;Q.5#ULE PK=^3BO26P!7VS2AW\M^^GFGB
MAOLQW'+W#,S98*1E--ZZX"[VZ-$0\;(,J\JKTRZ3KVPL<@(,5+^M,I+;3V0O
MOZG.?T>2^!.EL8H@L=',..;H )E7!44]-++Z###5Y?^'DE4&; R^[BEQF [4
MFE#E(K-)E61+J KIUH;KM9NO'"UB3]R3O^D1WR2=O(JJ$WWN+X!%"\!.T 8@
M@HU,\#*W3&$/]5;)2V-[Y'02/^1?YWVU#EV'SFLO2.3L0:O,757^L.1D_:DF
M[I7;8)Z9@OG-+VFQQKVE1W(:J]\970\4C@1S%_8]@ZBDNQM[%$"N%L0/Z I0
MGD%-E\ 5QR@OP5%H'$,##610-3\V&$W+L4@MJSG%)S;P*"W>TGA-"V2O6EH^
M=G:]^](J+*#%J?N-&/?6RF# '+&+)/X":INKAL[KZ.F7=YC?L^VIIG49:34W
MB?;#M\4XME' EAIQ"C=,?>]\M=9/5X(^-390L$BZNKL:(F$:9WU/V2S<NWG)
M3D%P8>BZ53)%@?I66QAZ/NF<HFUBE;@NGD5]G7E?_&(%'KSVNGD"9<UR:E_N
M 7T6J]4)2]\4Y^>>GJ&E(HGK02B96I./N?TY.4]RGD2IGK%CZ(!]UMM_=/[^
M[0BZ0/:F3741G0D+;9"P9HGZ@175_NB@I4I$N[VTI0?X4K5^M'1=BL#<Z7I7
M"U/U[(6CSYG"F#:=!-81+3RQR)J4Q\VB!' T]&)6P%KKV;&._? VD8WFQ_>J
M%00U0QQH?9-+$D)*1DQD+9</ Y%F2QLU-R+!% $D\3LU'^Z C!S5EB49XW^T
MQ1;\$"D<Q!!.EA:JMN._J/#('K];6,0Z_JVM,>[TRZXP#H L$C,/8R&EV1"0
M+3RLI+;V-*3+L*\GI^M8VK:$34&&5LU 0\T(DY5\.P9@#=A3TV@1,FNLJ5/7
M@(^*PHRH'C4E&HD6TX&*#JF#;/TGNV1SWAP^A/'*)>B(\%NUT0&\B>?4-A%!
M+0)[P*.1;-JG7"8EHO(#CEVIKXUMVST26"SP36CI_NKV2?5/>F)W6"YP^S';
MU>*"R7=)/6W@&K8VGG$KS&I5NE[E7*#N0C34L*;\IDF^ZUSO885!IX#&'9:#
ME,&<(J# \3Z&>;E(;EYQG$P<(!3$@-W7HNG 6U2G\=USD!OX2_W^6!2?J'7I
M]Q$52L>SN@2!RXV;?!T;EYZ4<8G'UB)/X\=P/P@_B%EX!(Z#\ .3UAY 4<*B
MPOW,C#&X$_LE!I?/06W;?+0J9K0(C1E'+[-V/,+*2@O?/6$$A&SI!@JM*)*O
M+Z%KG%=ZL6L)H^]N!H7,KQMXE+J6GW&J;HKH-BPRT>1F+GO@=[E^0?5'U4\5
M8<+"F.C L[  .D!K-Y:C WJJP7E_IO'\!U:Z%HJ\)(0N/C7*9Q;,Z\8[.6%S
MZ4YF( \G^,VQ4#;IIWMU#9\M#OED&!ZWJ\TVN#^U(C-L,8[SL1N@*.?VH]QW
MGUFF^@VL9<[ZM[ZF UI,P\F/(!H!<W.H=CHP>:P=A9_"Z*;TYJ<_J+7:46I\
M\U(HD0[,Q\':OM]_N>!Q;435,QI4@TBX&ILM_P[R>',I7+-NYYJ??Q>/DO#D
M*WZ8/"R.%(Q?:(7LT]($139*Y<L?>,UZP^3T5=+\5W0TXMM9@$U@YUEY( HT
MFB+//W]1,;:J2.&8S50A7/[L&=^I1JNG"[;*R=>GXD]2G98FQ(1:9B9$WX.X
MLV,M"%J\[NEU;<*KCI\.U.9Z9W*#&R>T[G@LV8%P0HRF^P!I#=-7C@5S+,VX
MH=^1P1,XRC#";^K)JV;GPWH"!M^(9=,Q9$XMI>3;#VSJ[460E7EF!Q_7PV1R
M7]HV-,T[YZ3T+6+P^+9WIRR-;8VWJ";18&PBV 6^>PR]8UE%!^:JX&U'8 P3
M?M,$OE[J2@>ZW''OY!CU-RGL)4,IP,5PS#5&.CF_H*$8D4F'!-$!J7GT1#_1
MA]2# <>]4X^A6&'6&+8,TH6LVT6,8%@SMMVQZ[D1"3=",?ZH-[+9S1L1)(@B
M5K[96DLL3[;[JD=O_NJPU>4.FP$[S>4@:RUQ>8%C[&I#_F.[=@A54CE9GJ),
MRA*K'; ^F5CT]J@O%WMKE.<-*2SD1QN\VMXXCS0WE[827]R"G9&PT:[$1H6D
M#LI'/%6D*CU=CV/3MO5NZ=3>"M&W4/W*ID?03M:.F-U_6K1'\]F4:N-2O34<
MX144_@&EK(%I5)/BHV:EF"R/5Q.Q^)[N7+^D$#O4R/3H:53HXSR<2[/!MBW8
M8K@?S].NR$&Y@M^$'<7#"FO5UMI0!H=ABS]&K&%->N=9:W[,KX$H\J1P\HF
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M6PU)'"*HQ<Z)[QEJIXDWV\;*C5]Z:MC4LJ+OP'U>_#R+%8B3P"UUVN*4\.-
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MT<Q"LC01I3B0HG,9!BM""A=4O=PN?4NYG.E,(I7WO./X-38375-\5[0*1#C
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MU3[1/. AG1)[*E1:Z'+]N32<KLY*$8#A).LUWV \?H;6.WV2^H(.."B VNC
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MKD9*N 2AXM:TU+G1GD63-W3A_AX%7Z>[Y2^M,VM85#MM2*\[.L"L[EG22NG
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M^R-Y_Q<KX?_<7&JCXGOP^E,3$!T8C\Z#+W:B'OY90_IO09S:QPC<2*PB-R0
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MIN0[L&X0[Y9H<+R!AX*J;/JUJ2V^>S(.CP >#Z\W)Q<O3]:][WY[G0A/L#]
M$(J"8QI!;+!C 8C+J7TSG38"U9^.Z/AU>:4*J:U/?=NZXW0%L>O27$WTCT+?
MFIGXH8?&-TU7%K@W2T6]GS<)?[@F$)"Z=JUJ8$*'?>"BW#/Y1Q:F7S0E3:OB
MK&X3<HC!) L"L=\P=E;[D71M$&MN>E14=3#71P7/JH8\R>A;F3)6<?C3RM5O
MF9D?Z8"0D#W:_&XS_&C,NQGAZF(+WZ$JXX-;BFO\3H[!&;(*O,K4N>^:3$M\
M05:,FI9E\+.O9Q3ZK1 N'D_NL,P?LOS<>*[HQK)E!?[SIW2[S2NY(.) %!92
M -G+4'-T! 0HV;)N%@N 7;Z_1=6MYCFPO#V69 =Q2[MB</J+B9SRAT -%MS-
MIZ_WN*>2$.1]M#XXOY8Y*J 2@N_,<07'EF+"._TF99I\'3UG#V4=Z[;]\#K1
MTJ/^=@-33+F9X<MK;&%TH&4/3/P'C)4:%EE?,J5E,(L2ABR/'CD?]ID=AV-V
M_%Q=G+C,?FY_2/EURCDLCJO59C\R@J*8,^6Z>_^56^JHH*!7B==4:XR U*5K
M>PH!@ W@K-?9&Y#Z!@.9&K2[^MU.:@X==KC*]<MDAV+$M[N7>\2+KJY>/L0R
M5C.@ Y*G[!F J2_-U/0GR-.D2%-ZP[X1>/O,^YXJ5-6LZ+G32'F68V&L*YD[
M IO^XXV>=.!\@R*%%3QGK_\GYQ2S@G__@/[O+VSY?W%_<?\!7,@YVJA-;4RC
M)X&GC0XPEU;+EAT-G$NUB%0HJC3TDUG;-E?8#-JUI^T.&95GF*&?Z^]M-)8?
M5+^DRY($"Q79J27>+&\@U1-FVL&BU4^L.]RE,G08Q5.Z_I+ICPH!.5(I++BK
M^MAS?8ZG@S#BB6RSFN5GYY;0/6/7 P.3?:^?&ICVA.@6G^O7P:.C*:I9$Z1@
M@Y%[.=7E-9<5AE:Z'NMR:NYRUA,51>G Y_L]=( )01KM$-C>7&I]QB]9DE1A
MEW1.Y9E%(N*/GACX7Y]W5*)US,%W]T_ ,4IT0$3[]Q<_#[SXQ?T7X&H'4BNT
MA4F9'MS]LY_4O9JFXX_H>RN4Z(H[*#Z#TH'*PQ3UY,DF$&8[ 6I.,,?BHN+D
MMWH.2Q<Z-CR9\A'K:0L/[])"W!68='\G\VK66'"M;;>C+G64^!53%T<'#IZ2
MI$4V^U!?J#;I8]"=I<X8</0J>^0ZAAH]$Z$LVZVQ>5 7T2Z)ZE-"$^*\F[1L
M!B//#B],6"+>_S3!5G>_5G:_H74]/TY-3P<3%)JI"#A9*)X.+*H[T8'0+HK+
M'UVY.\10Q;:NP,L#9FCA?A#2/G@GXG?^&MG7^W[Q?O%^\?[]> V:)H)Y@^>(
MI6X$5NKLT7H6A*/-LW^#KPXP?4/76#%>B^4F752+=M>>:@HR=3W$EB@T_8RJ
M%AI%>V?9M=*$X2%9S;"I]!@]4;-;EB.2O\2)KP/705Z/F+99&S-FYT (<+7?
M"_PT\_>E=+DG9>_GO=!-==KM&/TM4XCQB:)""P X!> @K^Z \ V=&E\F?ER-
M(I_3'K/?TJ<#CUR0U_L5]].&$&]L<T-&=F/_,&I8^%];C;^-*\>(_@"MH.*G
M#WW=_SU-RVO:^,"\3LCGGRT_/ V,4\P+8;ZN98KM5>R@B3?AFZMY7KC#[^'[
MFO!MPA*/?=G*]S3#8TY?]N;6MV7YFCN"H0.I[M9H!?_U^MZXMA)+B>N[FUN+
M=RG'"51$^QK@VJQ2,9F_RD1\_HP.%+T(2 2SLDGDL#4]5-V K+R9/6>.5>\(
M<<?PQ-Z=E*GWJU!H??'960XGK7.*#OCJ!^V:U9/ 6IDAB:W53FZ?[PL(69B)
M&%)13>_LVV]Y\_!%F:6U5\&*O;)CY):YW__S!Q+_#]38,PO!I9$5*9*$*]I<
MI"A"P:6AK3,G>ZN(,RX;QL\R+R7/?NL\9!/.;W;J= H+YR3!"L>+5V^!LW\G
M;<_RQ 2=()UFB9]IKZDM]G:Q-+"4/H%?Y7DA;C7?+Q.J>59N 4$*YJ'P-= 2
MD QC$BT$IK@U069YNF8>0[BT%/)(;5VPTS'=0W:9AU0T4D==RZJ/YP-=^YNJ
M+@_UR^UAC^?-F S5Y)1+(9D2*K'^G=0C:S=(MV?'JZ6'4+D5(PKI'!ZK)2>?
M8C%UM2_,; /U'R8*-!6_(L62'6B]=( 3:E(8<+&383/DA)'UPH2K":[Y=G8=
M.?I*[28AJHTFXC%H?!7ND&28A@K3TK/K(O?S"MS/^C:7Y\RT^+OZ<QJ[^WK(
M)IW)N25L)VRP+_? >;$#;D'_U!F%\N;# <W][[791[0<0\+20S*ZB[I$9PY=
M8A1*)0N*^]U&+N(BH;K5)5V_M5>R\LORV)'965G:AE[!/=<$<NX9"<)8O[?E
M@PIN4+NC5<>A26V?U$2*S<[-^<ZQW1I!B[.E34$'8&VP XW-(FL=5/_3=F[J
M"AXL?6<\,SZ]H&Z?.8^\KKIY]!;T)-X"W8:*FC0)E^3*$%6]\2)(J^![(EI(
M'BXR4X@5>_%-ZUQ4J]&<X<;&RZ:EH&7<XM.W*MJE$7$2U!![+*.R&!2__5_=
M0=0/KT&&^NX_LF%(^H&]TN&?W\\(MO.,F>BI;EC\>O)J>'7PL=89D"L=X&MD
M*P@8,IE$NX<&$H[WIYS"#N%O>2^?"AY%Q&BI,_2OK;99:!2SH:"(2Q<>:S[D
M*/4YX351TJH?7#$6K6KR&"18C0B5.(ETNWFSO,(/>V6Y?I_R9R,)]C]4!)1I
M-,6AT4.$?+N<&->@UP@3FN^KVDB9&E]WHG4\/QX2DPX^_I#<G^>2'4.5_+EW
MZ^\VR?1?IJQAAT:D2>9^[<7S7OB*%B7C5G5)W#W_EI8.8UT I@+K!55#&-;W
M;71"LP#U.?R^(FM_=@<6'C.)B%$U$>S=EVSL0^R5NO;6]>9>F=5CJ=_/L"P;
M3(H=&&>"7Y@A"E%?P%2@  +K&:F:VT!RG 6)@F.1QOBMST:VI#S+IS8=*O)J
MYQ<JNM4.Z.B$NWR#[I"O0)VI<6A,%AW8V[R_AY#19<,:<;3K">H(8?C@,N_D
MLO:A%UJ:11^/O'VZ4]Y9^_3]]5,3QR\_VO]4;@"-B03M;U:@*%.CM3L(AMV[
M@S-F!+MY.A!1LG4H_8S4D+W&A;IXFLN@@:6KP&5A'O13S&>V--@8&&^,&L]H
M XO2.&']$!;MO9-+06OQ6BZ>O@W5HXIE^X*XD;SI!,->S:(7IY^4Z%_3^5Y,
M&P+S5GN*,3K)0; #E%.-=8YY 6 3D_*)Y.>CL^Z:&2]DF"MYOYT,.0PQW$9.
MS- 4MRG\SK,+N+V*:U7PR%V/VK9^KH\C^S^#W8;'N1\-6E[>&'[3)2[W >X!
M#M^>84-C2ND *QVXU^MJ.=82U-"1ZY[^#5<S<Q5]X(MMU\('F'7JI3^<<F.Z
M,QMZ!C*Q-DO+PF?0N%((J-9K/<>(ZD]4,MYL<<E.L6_83+3X)<V1,1S#H-U[
MT]6MC"AK4(R+*=;4QXSPT3$2:DA<.OI)E?A5LEE]6K)TUY7FC#/GPNLE_5"V
MU'CMO1\):!IG P%%K*X*A00<[,+9J"667I@JW=*<.!(Y;1%VOKTPL4OCKIG.
MR9<;]A;DTP%W><:1Q'O4MW G5/S9WF8$:O^>[Z#]Y^&G.V0:]O>FS)=6C<:T
M"[?'.8!D#%_L><L6 ^R:T]@5"?IVI'@RR]3B.]RW9"0[J8BL6Y5D*=\*/+4[
M\HT(J19@KBAD#I7#B>PXT]@7R.H!#41GZI,J. ]%9^#[D&\_[W+:66)>_I>L
M&QY76C5F]<V[T8G[CC[#O''(O2.RFQ[**8LZ. *^A0BW:2[P*;Y)*N[\<71X
M3256*';5XJ*RH"00(*S%/<S$]B?KZR#RE#TD<2PHD@[4]"=HB6>Y!7T:K9GF
M&II/,+YHF11HD&1F>_)+XGH<]Y>Q@9E_^FD6OY#_O9 "&Z!'X%D:;:PV\Q1\
MQE4;Y'.T?#GOMN;A+O(@;!NONH2LLOB>C!_"JA6@;&?L2K]\4+C'U'#?*3D.
ML6WE W_OCJ0BFGEM7-%<0ATVJ$FI=Z,+RK()9L\?/2@/3ZC?&0_60/61$#0A
MC5KFY-+;1M1L%+4A3X7J]"Y$5:O1BJRG]HH[<1O9X]F^S2D'^MW._S\Z+H!Z
M8.L/7[+\"^S_\27+WXX40/SN.('7OY#_?D@4$[5:6PQR7A!)0+=F9#4/.B5H
M+MW&IER\>QQ61'&FYJW(3:!_%W3Q,GJ_EFKI4IJ(=O[8@ZFO%P:,1>V4]I6<
MT@W0,DH<G)5/+>.\VF=(2%OO=1>&9A*7'OHXX'\(1#V<Z?FX*4G2)$CTS-:V
M?05WJC58WLB9".%$;IFCN-%7UL\].?>C )72O%\:R=*L.4,1)+R:;W7=C7]O
M)!KQ/+LJZOF=.<2KRQ=IHVSX]%W]WQU[$QM>V5T_?;6YHO1)[M>SY<L%XJ)T
MH+865VRW#W\HVD&64?S^/_;>/![J=^\??RM1E$E(UFFQ98TL99M4""&4$3(A
MR3K)-A@S1<@>BJ),92>&;!'&KI)]RSJ6D'W&,H;9?O,YO_M[GW/NL]SWN;_G
MW.=\[T=_7![>\WH_W\MUO:_7]7R]WN_K>?'ZH'+_6AUA"S2,_^5:YA?R%_(7
M\K^(_+!,%<_^/BX^IL:OF^&>&Y1\BLB7]V>S?L)KD75'J"K$^"@?F! BK2%9
M+; R CNRK=\O*FL /U^9/%:AIT9?#."5N;.GX>%8OKZN+B\+S+37I_"$>+QA
MG]R*94"J2_($GXY8[/;K8C:KF<0 9<JHD)QAK]$AO4Z9)^+F'YHT[7N&ND,;
M^.1X6?B>QR:GN8B$OW;FJSF<:_4VY,R3*'6 ';@.K9:(SKLUNB@8E^#FI961
M7)8>Y.L?%N\CYF0JHFO]>PD"S3])2F#_1)WX[YU2*BAT)6F#>U:W5LSA\B-?
MA^<_>E.EHJPPGZ]W>N6PG]80+W#P$/=#+E%L7"OQ/'4*9/_)NZ&*M+'<(:<
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M"J(LQO^!IA(I+M0PJH,9Y;<U@3<%0^F[&;_?[Z%R[GO\'^P+F5(DM-'8WC"
MNMR]OU"_4+]0OT?E'YV0(M!^++FYY3>OGV\\F6Y0L/EGOTDC5$93O2D7W=(%
MR:<(6%(>[2G2H)"<9D#4FDTN9^5/]9C#3./(V2II'E\T;,,LGYU+U'UQ7&?N
ML F@N<8,K"?CZ$H0PE41-Y(M$?I$F0(37J1+:\L5W_CHXKXYNA5USJ'<!6@/
MW:,,/QD:_BRAYOCX+K\N@/*D7J/%0URQ(]ND:V0P19#<-[F:,<6) Q8/-\R8
M\KKZ5R3>U'%R\1PL42G0/5O>_H531CH,4)J*BD^M]285T")KH!GT(69<C_9
M/YK@3K..KW_:E$'.:%(]>SGEP4)N8IM("R[U9V*-B_*CI\5W.=(>Z&!+<M^
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ME:;_MKI3Y#0#"*]C(2Y+@(\A#)G>?;8^&<'^(H.6<LR)NK^P6D98#PR*RER
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M2&]DWQ3+LF"F*UNQ8<P^4Y:FY3@-CS[99V&.,Q*1'[Z=/+UTK=K[<<C$!%^
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M>MZTU9LQ%4K;A3CY=['= 0BKQK:-[.^-'SZC7'<GH@!"&GH8-FW:,F[38,T
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M2='+Z!5AQ<^46M ;Y%[:"TT50J+4%LV]+0_Q*$7.K_W%2NF  SO.83YI%$B
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MK.UR1\,H*>R5V3_[0$@7917^K#YC4;!(JGA+7ZCZ>+VKSXLOR9<(FXI-O\P
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M!9&C$ Y<))=WB/GB[<8O9/$]WN;',<2GLHBW1UP,^ .X+1T06T'2I0. V70
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MWO(K[C2D@/D)\-BN53YAQ]>;V<)G?2)*GU?\H48<(,]M^(=:,&((U^ -O9W
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MQV M_WT.DWRF@ #:DA8[*16=6*IU?5VMK77KWH>E+?:/=T6XA,[^('\"(T$
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M*0FS#]D$V(Z\#C4LL*AM>3P46SHV;9.8?$8!6@=NEI05:]P'(]OMC!?V2'0
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M?ZOF1U*&VTXA_'[;/)\XY+KU=4+KSM*<Y44-29WI$2>&AL^2<9N&$5/V4G3
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MNW!2N^ASFN)V#MN:;.-BC\Z-]UD$SYF3:\,QDO*MT1L,#W(=+,%SR)7?70A
MDG<OWG^%#BL37+BR> +!'C1 <+2RS[13$;9/%?:+678/6AO!=_"*EPN !F$8
M\%H5FI"\IKC5U<8*Y=A>.AEOC.^/5+]VDEU<-3IF\X[BY$^'O9^B<:<^-QC)
MD[@Y])E;3I(S"?Y$&G\/+PGM!-<%1CZ@5%?!+V'!#$##]ML)LG)ISY5I=M'+
M.SY7DU1ZQAC/O;SD.Y^1/FR 0>#-]D]XMY^CI#T%<P#C9]O%"=]^:\H1KK-'
M>2^:635?>+EMH2*:+-3:? "+.P8Q7(&LY",;T%'J)@@0+!)Z8E^6Y2@^>1&(
M[CEMF&5ODVS0V*A$N(P:;?YZ;N3; -TNM$$638)YE?O@1XBBHT]ESEJ9B 57
M!(WT-O$$W$EWC</,P1LY'50,W 9J^N)::#(-#*%I9%HK>>!ZN5XD!MR'J"[%
MQ9;8.P2ANHB!RC+E\_\NTWR'3I:#V%53_[M,\[/W>T-,[I&+7V9KYR/+M0/]
M6!2[3CNX>J)WM;W!6>IS8MA!CYK13SN=+]4?UUM4([^*MM.X0GAHZ.!18S?T
M?% _L1L@N;.^(7"NR=8K3(>"FS)O9FGF?OM]S7--O97J\, (]/7$@J^2B@C8
M^G\^Q.\_OJP[CT&-6V0N.6(M!0GQ'(F&TJDKKL!8@X+U">F-KHT.)'=B(JZW
MW*E(/M\@\4'#@\KP:\HL3)]5Z/>9R+TT"R>/05])U&$HD:/A&#11Q$7W^QB$
MXUQC2]!D!_Q%R71X(72,NO-'1XFDZ-.%8@;.GF(RUQV=#%N+V O4SOOA:A3_
M%-D!DO_96DY]=UWZ@]M]$+]X;AHA-QZ/TJ/4(!Y+H1^/\ ^=+>W:C\#XVP2Q
M$G_U^'X/_*1>X^ UG_W2D[GV9*J:RU695_5F6AK]Q#7@*W8_'%H;4(^5B\HX
MDRLW55H_VLHG(/[ZO=71TX;&^TG\#H5&F[C[VNPYX3<T#4A0;RC^'LZ"&<T6
MVG?;HT')B7W"V?%N3[M(_2N22:]RP:D4;5>8^)43?<H@VS1ZH[;;83DTO2QD
M3I:5FV]<->@XI/S(7G%4_8EEB"F /!W.F_4,H\DDB?3-VY"=I&#K_-!)]/EB
M@!/_<<L._R-9MAK;1B/OM>KLJ_.69Y7*/PY4KO<4DN)?B2<%&18&J#.!\&R
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MN5R1#+.$_E.'CQQTGU:GP&LV+UF^Y5#6-^RX_Y'ND,*]!:YO;UI#G@X==E(
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M@.)^XK=N 6::BK-!)GH3]5_JK<2ZS!'^EPG="M+J(PTW/V:[^R=&K+-E5X.
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MQ]JWDUHBDWWOS<,UL-1]K;4DF3\_8SWP2R;("K&.@6O%DL-M%<BZ>*?OIJA
M] I"S[?W\<5A(&2-1U,^S:;*8*^@+2?U]X01:=$:"R\_!K$]!I[1-& RC7-V
M;'O3!H<'&V:Y&TGS;1A98VWH89=R<X3FA?GU^7FSN-'-"Y+?[%]U]G-O0_&5
M5*%CT&AD :W356#JQ:I=)T'\CUH?[MSJ/%O';H:C=U4^%GK)"?#\E_1)-U"2
MG)F^:;<L^<<Z!J[&PPG$RB89C]3&%G=4YO=_8=0>U78?M8:*C#ZJWW;V&">.
MJT4D)AE'W^X EWA%_\- K8PI2.*;YGMX[^;MLKBK7*QAK%.][Q_>0'#S76YD
MEKX"S?KIWSZ]Z.ECMI=\JL?&:&@SZ/.TV4)#2;[/?NWT$?@M!&\54^^)7JD!
MT^>/PGQPJ-R9KD%7_T"OB5ZN4J?FV7V!5C>]L^'W5'E 88,Y"6",;M^2$J4
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M9T'R=3:>I],*8(_/*.:&)I\_N)BQM&+)D@$TF,<!C] Y'/AG#C*BM^E5WRL
MU^WL]%/BAV%(AY*V58K!H1.11;+>UB>L0=,<7M%>&#0]@9G2G\#\HIB@?79
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M(Q:]O%234B.G[[VHKI_MUCS;I[QU.E=]Z,62H6]3T"^3D Y(4\93*F4?8OM
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M!6__-1RU&=/7>H8(UVL(-:I[2=#'=)SXA<-"ZL%Q&#]($ESF:.L$3 @9 DG
M^QU./F1.Z8LSJY?W0S>JJ5ZYYJOE>G9M3O-?YXI* ,Q?!A0M#$"NL\S0@2-X
M5\P>SNKS^B$VG"EH[^VNZ)_9F T;Z>OP_ZA(YN\EZEP#3[C]W=R/C1MVQ03"
M8Q@=1LGD@>\J#\],1D_L/0 6D-RN]X)$4W!TFSJYZ!GB09@)0\">4[X"TQ&(
M+T']BA0*X3<821].%K)1]GIY=Z.$>O 6:ND!N(B'\S44X6C5Z &*!)N/Y<"3
MS$>;@"6J3)/TB"9;=;X(OO*A<?GC']JU>M\,.YWK-QN3VO]<J'VC]>4=CGZ5
M" &$:"TK[W@"/YX>EC#\&68CV3W>B[SGGJ0Y.RO-TM/-,#>E/KB_('YZ8AS2
MV,*6\)EW7JVO145#R'7,BH3-KL.0QX/@!)C(7&RYRJ98T_/P6FCP9+W7H]OQ
M>YH?N!2&K([Q.-R;UYPZ+@0%IH)CHD], @*=%/"JF\+1?V([L9@CA]W.E7TR
MS+I^1=D^YGFR2IY1"5CA7T8VE@SP7Y\NYW;,E'1W7/]<X-J]F0#'(379EC$M
MSQ_! 6<W/J8T_WCF(FK8QZ'9HZ"]$SA^^!Q>;G"%1?_V^01,EB%@<;86N/%1
M1R'SG<>AKZFY\;=2CP1J?P*IV*C=+=RV819R8FM-38$1Z@1I1F]>) /+.$MM
M^RKA\K/_V7N7&[=)BH^F[8*6_J2*!4UJJ/MN^K*F9# =7I/6:!V6&U#$I *#
M-"&32)+;:J7K\OW6BT_&Q^54*SL.R219*^/?--Y^X*MJ.3 '_6P&D<1TF/"(
M]@$&EBW90IMX '.E)W9%Y"52_QB$ZYLHL<XGN >9T,;FK,@R4Q=ZKUA?NBS,
M;U;;0!7HKA.+'L70+WME; MTP^.& "Y$:#F,*T=?2C00,9\]IM]F:ER/A VI
MDC[*.52ZC@9S&+(=_(18>@A/=W1#A(C!8*GH<2(/"P.M&].-2=;'&-!$7%>?
M05?XB"6L?\^(=5)LG\P1?+.OTS6CKEIH+P90G<!B5Q]"5\M81[A#2/IF=^L+
M#%6QONV+Q5;-R.GXW,[\2TYFE9_EU>5[Z1]O/P _(0:NAC%G.#'$N:QFRIYH
M+52<VT]R!=8R\==G=YMQD>Z\;2%R&RE;[5!5>):-J$)I4!E(. I*_\G=MSRG
M<'>^I9TR+31GB!WIE#HL2U=-;UK#EB*.2W1+!?&A/F67U6FI&4^-F\]!%1\@
MAPAZW,YH!4X9W%_$D1D-+#$@CA-;09Z,4&.L3%/U;9N]+U*DC.9:O&:ZQ!7%
MDIRK_=[TS)3#\E<\6&#N"+'A?NIS]&D@AQ4XB\KI,)5_"WZ&"K&A_[KO<+I,
M*D.]MA\_:]X,SJR) 9GWPGK;(<>_[X"$T)*,5*[0#H@!YL&[F#YI5!_Q*^8W
M^?K;>PE;SA?>=#ON5OZ4]$1"]H][H+#@!Q,P6Y0./L =AC<&=&A"-:A1< ^E
M_O-9_1V"-OUO3SE]^*;XD@3$:-U]Z&4&&/(*&RU$\._A%(.ZZ2_17PK]>M::
ML[MN4QOFPJ54'M:4/93T9X4;YWJGY4TG'"'89R5&]V#H%\&RT22*/"R*4<25
M$[K(.$04E7-M4H !JJM2L]2*[-![F):^1R(:_'&^:>B/X27@)/@<CM*PWNF5
ML@/B8?F-=3!JL_,V!>$F65M"]LQ:@MW/_- BW:F.+C]BTRWQVS=V<4WU5GAM
M/W??.]8YM!5@R$MA!-!'VP$)_QCI>XFRZ9;.!((6C'= #9][VK(3S.Z K /"
MFW]]=<GJJWO.J]& *@F+"0"+HUT83D4LF^6(YX,]02=_R(\5M8N?RY/H5ZE5
M-3,0]W >S+RI(K'![A(P)M8[LR4T;/[N.@?L@.2C/W%- 1R21A1"S8:7$^(
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MM^4]6>GV9G];EW^7:_7BM0LA$M(4H3"!,HHCY1=&".:<J'^&.<IE'J49,H]
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MQ11#+.,<YI+I14V&H\BH+_)X5:8^>B;?0:G$ ,+_:UO5C6\LJZZY@VQ&%/-
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M7ZMPD= @#E/*($^HFN4H$Y $*(<)SM7_!*9"6(5O.6DQ4^@#>-+RM=OUK=7
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MN/I-J19</9XZBE1F(D",0>7/!3J.+X$XS"4,4\ZB.$\XP4:1RCZ4F9,I&E5
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M0_;.[8/YP_7-K97[;]HSMP_L=/UR#Z2X4?R9V(R;;:EW819AF,@X#AB,9!!
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M@."Y)(21Z%<I^& #RKER#E9CN)',?Y"RT-'$G[4D[8$3EJ2,I2',* X@$JF
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M_L=>8O"VWMR+KA>HHYLXT[?(3F/_?-\--SW_3_FU<&_$.>LNA>KB.0_3\[8
MG74CCOJ'SDO=<[C6KKO7P72[?2^X5T]'#<#,E</;_]HH)@>-[LWMP[?OI/[T
M8";J?%S5CZ)5GMH_1'7W7?WO[:,Z:G?B5[7T^HV2:8?/(B<\+_3 KE04ROY/
MTPC20L:09$)$F&9YD62+!]%4*YW/W:SM7J0_@V@NJO2Y@/;^Q9:=&T#%7577
M6I/2;AJ8R9SBNA=VT^JN$%T6E642U<^$Y(*FB&2I2&&>HUA]2:(88AGG,"ED
M3K.(B(21_DORMN;_/W]%MN+Y?$%$-RON_[MOAYW]]#.P.IUU->SJ>3 '=]C:
MDSZ!D]T_M90WH)/S8")-ES&P5J*"7E8S-F+[A=K*"WJ!@9$8:)'!WMP+."_O
M)]K"4#/X?@:1YIWK]S-(?,9L^ZEX\^D0M'EX6#[M)EY\$\V];NY:KQO"UHLX
MB1/,4 9IDE.(>(Y@F5$*LR@M&*(L(]BJ>\9E4A-'&#K:@&R)WP"UR+WV_UC/
M@$M#G%',QM\M89%PU/@="+=[$#1EG3[].C0(+@V!0H'AV0O('Q3';D V<HXW
M AI=8<8>0#:2'+;_L7K"37VUS7KQ13RL&C.H\8.X(\NW]=HTV]_VBT"YP$F1
MPJ3,)41)(B&5#.O^(E'!4TJ+TFIRSD5*DU^*;VD#0QQLJ=L=U\M C:NLH.*[
M7I>?D3S@Y$-K\<;L-[7(P'93O^WMMLOKSW)RK<7<'ES[!WPOTOOR^GU;^5O:
M=J\/5&#"1:DO2$KEO>MQ5U@P#K,T3R-.<BZ%TY"*$5H3G]U!8X@];?#'EKKC
M]<(89K:WN$&0<+VP]03!XV;VHGC!+F'/4YKYOO6BR,=7JY<?F7@Z#1V.B-A]
MAQ/E;Y X%E (C""B>0(I2W,HU.N:E%G!<^E4O7(=.U/[)":P0L^/5?%4$E?N
M@9T>F0]9_ZB6)ZC33:H9Q6+N036GF?DYY]2, N<]IF9\5?=B5V,>/2FU^I[K
M\EE9,4.W*ZM=1"B/HS3+8)EB9=CD7,_ERP6,!(TY9S%."V%;^3I*:6*UU=$V
M+_-#ZJ C;U\/.X[7N!X*BH*;BO$&P*EDUDHXK_K9\95G*Z:U$G!866OW@$<,
M]+=5O?Z^?!HV\B>9)(1GL,A(#E',$E@JVP226,HHEIPFJ7U_H*/E)SZ@/3VO
M 1#'4%B$,Z\2T.WL;67S&^)P8J/MXY172>D7FSS:R5!]>,[*,AI_/'YJOICC
M68X/XHSG/^7;$92N7^M[F*95^];]M-:YJ-M;FZY!QONVW0@>+P1G(LE) 3'5
M <<B%;",XT17ST62%[2("C?WQ8G\Q&IESTA_;:*9,7EQ]6HM6O>F.YX@6_HG
MDT'GIK!,N>R>D1NP8V5P;7[3-ZT!'3LA&X;ZH!"L9:@3\9F;AOH <]PVU&L5
MSTX@NK>5=EX6N)!)F?$(9H01B(2DD&11#O-,(1&+&.49=RF V:WLI$'<*UN^
MZ4>ZCG) =#U5'1MS[""P4P)>@KF=;T-"G^HVP#WA6;Y#];[8K3MO5XOGXASU
MJSCZ@-\1V8V<79ERVT;\1IH_A;F_V$_B7D0XQ3CE!<QS(2!".5,O:"1AE$8T
M3PF.R[S<=NZV.T!6=*V^@X?=NMV.UV?U]^\*2#,I\7[' >#Z%=0.IL631U(M
M]3]!N6I@2Y:.Q] .9KLC&@XZK^.[):\["/8,@#T'8,]"N,/M)'&@@V]'<U:E
MX 3#<X7A]K!'7H&.%YO&+))%I3+I(XA(64"4Z,Y:"1&0YUF:E+3@LB36.03;
M5:>^6-!N9KNN=&/ZWY1JW30.3; .Q1\_Q-Y".<;T3\L3K O-23&NN>W?K37?
MS?YS]@]N\8_^T7<DLTD#__I=B+7ND*]C&7VGA4*4N$R5JQN1&$$D,^7T$HE@
M(F),1%ZR.+,:K7J9U,1GIR<,#&6P)>TZ>_DL3G8OQ3#2NQVRTX)/T)SBLG#!
MYBB?)33S[.1+ A_/2[[XA$>8^T)!]:_-JCW1'$#R5!28Y<K/5"XF*G@.2U82
MF&-)HES!(6+[T5Q>+$Q\X@U1OXX+5\!J$5:?'"PW!;%G!YSING ##$\WX+CY
MPN1X.@3R)\?5+]@_#;YN]P)703-Z=^"W\GSW"U=)?G '<=U*?I;9ZU7=KI85
M[WI^;FA;\8HTR@?ZU)BRDO>FE,2X3/N/"K[-Y_RL_L">%JDL>$(R##&-$H@H
MQ9#*E,-<1 A%68$*NPR%H%Q-K/T_JN^&SD-?+9?Z/*G=$NK3:\O4ZK#XVQF'
MLZ/J]IHX8.\&#!G431:Z^L !C^9&9,?E+L'[!G2,@C_Z__TF_EJ#5^J\_AG0
M%@V*92"S-0Q/LUJX06%\;@R'7=PWJ\LH!L+62J6_(6OR>M/H^_A%FF&&!&$P
MQEQ"5!*IQTL32*.<B(+2@A>)6U+7:4+SY'0-:.N27 )ZZJXI76? &M=O(2%P
M4UF^TGOD<XV+=D4ZUYF%9\[F&A?O.)GKPN<]G-POHA7JB>^W-7\C'L5R]6 J
M;O<9P.T_JO7W=T(M1Y:_KAY%4YN*-!TZ7@A6R"3%#-(R40:0+/5PI**$-.>L
MP)@E,LJM?=UK.)GXN&]9 XHW,&!NF"G= LT>Z/D#>P;!'X9%EZG.5VV*A:<\
M%]1N:N6?"F4'_WDNM/W<Z&E1=W.G0R UZE5?16 ^YSH$#@<^=I %_5,"]W>,
MM]NK]'>KYBM9BNXPE33/BRQF,(F1L@I391]2S@LHTH0DDI*$<Z>6OQ8TI[Y2
M9-\%WRR%KHO?T0>* : Y&-R3N^DM%U#MO./ 4+EI?)/L]W60:7%[D&EAH JF
M83PD#IC8=XGB[-E\EA"<2N&S?=37=_R'6"[_HU[]J+\*TJYJP4U"8+-@>E)7
MCF,H<)I#A/0L/)(0R"-E>68H9YQ9Y19<I#2/]ZB)PS\U=; EWR6T.I<$G0/,
MUH$, (.7!^F!@(</>4&Z*YS(<RO/[$5>$/#8C;STP,S-+C_L9L/0A!:Q2"C,
MBCR&B"41)"4M(<,91I@SD5*G;L_7LS2UG:"I@PM-Y5[U3>7 B:9R5XSH";!?
M=C;&O+O@IHFN[NHWT9"@<)B]=!N]#R\S=B@<@,%:V!VO[!6PVP]H^0?11-?;
MMD04ZQ <R2&FLH!(%!DD.<40BX0(7&1<$OO4D_-T)E:)GS;K=DVZ1JI-QP3L
MII7^Z-EPBO&<1<LJ3A8" ]<HV&#B$=A2O=R_R4EVI^A5" Q\8U.GL @6;+HD
MV(50TMG'YPP479+A61CHXL>]-%)U3S?JG)M 4O\-*PN"2X(%3+,BA2BCRI(K
M$@E+FBNS3B0XS>P[89ZB,'G(?TC2Z=2=0,-*UUPGHZN6&5+STRXGY'32*]?)
MZZM1AE1#E8>/R7)!B9QX<$[U<9[O9XICY(,>*L,4L.UF,7Q;O1*?2<5OI3JH
M_RE(\ZYZ%(LBX81KY2&R%"EK)F,0LU1"+G(<1:1$"2(V59NV!)T4BD<QYW?1
M"*().APR&YPL=$M@Z=U435_Q.1A(\VT%7@F@6;@!A@F@N0":C<#8..BCP!CY
MJ:<P6+DI+P?!1W69S3KSJ38'J0XTG<MSOKFG]_=5EW]U6W/=U%=Y.J)FE6A/
M=*E,A2@(94KM19Q!A$@,RX3',$*,XPBE<6F78N%%?6(;:\ +4 X?.. F1/M/
M-ZCM@EF3 >BF54-BYY$&ZH%!L'1/%]HSIW5ZP'*<ONFSB(<-]KD1#TJUZ;D*
M)AO@-U+5:U'K0JI%EI$H*A&&I<Q+B)*(0T+*'-*RQ#(M,D0SJS3-2X0F5C ]
M92"VI,']GK:#J3$&E87Y%0@ -P6QE7U'%?P67'8'\RH0!GYFU>CW()03:"'A
MJ/TT]OQ\=I.%% ?VDLWG_7/(V:IY6'43),V@OM>ZUK!Y>KWB8D&+.,YDE,.(
M)!2BG$I(4Y' (L596B >9XF5961);YZ<@ ,6^LF;W:Q-PPC0G+AGEX_!.*Z_
M)@#'38V%P,4K[]Q"VJO2S\?6GST+W4+84\GH-H]YYA)T*49/;\3#JJW6"U[&
M&.-(PARE4AWV1&>:9P1F.(TS@=.LB)W<H&?K3WW+WU,#O"/G6"WW' P[1^4*
M$=V.Z$ZZGE+ 2_#3(H2ZT7ZV^KS7TZ=%.[IK/O,QG\EEZQ7[LVNM]V:CY^5^
M[B:BFI9['ZIU==<=9+%>+TV<=X&+(D(E+F&2INH-F^0I+%/"81YG64$31*/2
M*BW7C_P<F3<MJ Q'X&'3M!L]67&] LL=,Z#=<>/>KM,3= M_8E(H'<^^9J5O
MPPDZ9D#'S;9'IXYF[O#<LS0IAB[3U*;$TG/"6G!,'0>O^4(R/HS->=49![3Y
M2GPXM,U[%3\;Z98Q;6^UG\F33KN^K;FI[U5_;A0+VQAV)=IM/6F"(D+**((L
MBX0>!$YA65($LSB2-(W3#"5.V96N#$RLT7NZVU:I75QT9>KGEWM>W$PO9XSM
M;+,ID7-3X%M.0,^* :UK.K#%<\#.3;@:WVNA"&0$.I.?U4KT!>>Y&>F]CJ?W
MUE<_?9)OA!1J1?Z-_-6U<U&D!^1,O8CN5&$:52Q8&I<)-4E#C$.4<0)IG JH
MU!:1!<D(BYWZP7OR,;7EN:T-6TFPY<M,1^DX,R?P@Z_"\H7>TJ><'E!'^],-
MR[Z:;)KF*%>"$\JK]>1B7N_W.JB.O.0KEW-O>&LB7:(Q><D?R7W7_)52%.44
M(YBPPD2D4TAB4L!<8,%)7N0,6:FO<P0FOX[?DP2:YJ6&L7:HC&N6$+*ZJ0QG
M,9WZXH[)<D6+W)/+SM8M=TRH8>/<T<]Y75&O[JNV735/'_7(E-YZZ7--(R9I
MS&,&TS*1$$4<0UR6,8PEEUE1YADI[)N/C%&:_))Z2QH8VDYWLR/X6 220DGM
M=@"?"[QS/3RRD$<1<+J>#H.$[_WT:42"W4Q?%N["U?3( G/>35^6X]GEM,4#
MGL&7>EWQ:KG1K9CV]?!=GTK!WRG"NCALTWT1/LFWI*FK^J[]+!H3#_JP*Z',
MTC2+D4"0Y[B "*?*YREH">.LI&4N1!ESJT*)T(Q-':P9L#ELA[%E%&A.P8!5
MW4ECRZP.A_8EL?[EK\%VT#+D\P+[XA@*NK0E\OF6K/RWQ#U.%!B_4/&C4&S-
M&U<*#.91O"GT^M?&H8:5;]\:4K>ZB=ZJ;E\]'?R+:9R#2Y2E,4YA1DH"$8N8
M3GXL($F%3)@0-+%+?KR*B[EB4$JK'E99#OG2G0<._]6K6Y'?-KA&I"8"US\>
M=1[7&]U1P W8*Z)1'L $CT6Y\/!"D2@/F,['H7P6\\GI\&U%\+9=5_>:CU>B
M%K):WZY_U=7 ;]2?WI&J^3M9;L2B("+!"4=08A9#Q F"1*09S+B,HS0N$4U3
M^_R/*5F=.CESRP*@'0^ K,&=Y@+HWLE *C[ HV;$):UATKVS\/Y_FAUQ5+%7
MM\S9;V<O +A= R."[F,L@!8"_/VGVDZ7C):?95L]LU_,ME&S;6RXO>2P(4\[
M^-Q#O[W$;*^P/JVA4O]G@7P\NV92#F;,Q)D#R<.LG5DH>LYG[2>4?J++/GGH
MS4:\KS^*O];??HCEHS#SV]M%5,0X(DC 2+V3(2IR[:PP]=Y.8T2IE FR:XSH
M2'?JP'C/A58#?4G<#5!??>0X?=421#M_8P)H'*/G6U3V'-SHK%6ZK1(W]>&?
MZ@#!8T^90\U@M:0Z[Q16-RB.YK Z/NZG-MZ=GZ9T>[]JUM5_&])ONSRYHX/
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MB8HH<7J%6E.>VF?5?#C>2%B#9GE),044CFZML1KVMQ=[)M2[4]_V:#[ CI&
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M?X9M=?3L-+_P0K]\VO?+AR?ZY>M2D7YLR> KL&OUN5Z9/^OFGSLA;\#9[U%
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MJ0,& RYTJ19;KG0[,3/553$%I.)*O59W;/U/Q_B!);B6$83PD#G&$(9H:0Z
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M .LY ^L],X#LN''4:!/MF)WV>_E]<-.470G$ </;46J_:)[_IM1DOTM;OL&
M<9-X/6 =['F_ 1^[PA+%?^!*BLGP#5F&$9[)^6LX)@/Z9 '(=-0\)V'>4\&Y
MX&]$4ST2/7-N-X3FDSS^1T5UP3.9LKC0!25Z'%N$.,1%PB A99&F/-(SLYWF
M7SJS,+'*WM($?$?4<;2E.ZAVFG=:J-RTZ@ZE/;V;P10PK15/?D0Q%7!DI3<@
MH095NC,P[WA*;X".AE+ZK^0[6D%WV%T_?59?N[52@WK(UD,WA>N;6M%D@*:I
MC!'#"63<E+!2K89T^XDRHAF.912Y5<=8T)Q8^>@*P3ZQX=M!6H/K((;+X-GI
MG,"0N"F9LV@$RZKU$#/80(?+%&>>\6 -P?'8!_M'KRRP4>B+OK0B2:(\*O(2
MEOJ^%R5Q!$O=T;U0)@BF69((8M5R9H3&Q*?]L.I$D_4L-QF@,GZL \GJ=HR/
MQ;RVO&8@KV>!C9_<5Y38V&VS?XW-L4#653:#1U^FSN:8][.5-B<^ZM[%RI2@
M/+V]%\U=5=_]VJQ^K+]KUXS43XN(Y@5-40KC%)5Z0B:!E$<8BK1DJ,1%6D2)
M;2.K$3I3.S&&,MB2!AUMT!.W[V4UAM2XI@DHOZ-GXB>Z4T<K"\&\FEJ-K3M;
M7RL+X8:MK6P^[O'2O[U_:JKV?Z^J>OUWI7$WS5;A1RF3<984,$UB 5%1<DAR
M4D!,8UGF6<8R:O_:/T=EXN/9D06&+N@).[P*SV)C\?(/(;';@3PEK(\!<%9J
M!Q,@A/1^1H#3EKN9 9>$&C4$SCX\GREPB?\#8^#BAZ]+->UOW5ZOVG6K(W.1
MS$3,DQ*2@J<ZW"F5.4 2B M":"0YCG/FDQGYC,[$^L9,1Z[:=F/NC)DF:KIB
M^:5$/L?(+I(00'(WO=.-A-X*_;H3.FC\\8)(@=,;GU-YD93&,Z*>2V,\]W&_
M0_J\=D2M^/8OMMQP;7BL5OQ'M5PN2%)*5&01C-315 :\2&$IU:\EYEG$<,D3
MEKF<6!NB$Q_?08T3Z5-XG0^O%7:8,":%1)"Q*((HXP+2& EE:A$AL@P1FF&7
MJ7C!L7.?AS<;=G9:,#0B;BKQ1+&<OL+^9<<"V/)POC6BLY9T$3F0RK0B.:O^
M= 'AN3)U>C90I8WRX]IV4:0ED4D6PY*7.41)JB?U%#E,$"HHI4C]G].4S--D
M)M8 W_0C@&\+(?1PGDX37%D0TD'D9OSX"^YJ^YPH^S T)RST.)!IJMJ.CLC+
MEG,<"'JQ@N/PTQZAD*]DV:4!4L+^'"2'*#WPN5DQ(7B[B"C+\XA&D''UTD9I
MG$(LF(0\+9*,ETD1(:NJ5EN"$UL\F@.PW++09<UU/'3=?!]Z-AS"!S8H6L1/
M F/C=JP-+#OJPS2U[D7^>1I8' (L@>'QB[5<#9-;_,5!YM%0C,TZ\T5E'*0Z
M"-"X/.>A#,W2WU=+OAUS\GIU?U^9I+AOJ_]5->+C1H>#=%+*PW+U)$3[KFK:
M];OJT4P9;Q=E3I(XY@F,TIQ 1!*J_,.RA$QF)(_3/$+8*FDD"#<3J]$]-[HL
MX+OB1ZE/PY%.T!);GFZ U%RI_SX*\*3Y<E @5V^(A=*=$V8WC;SC;#?\Z 8,
M4/^V O_+H-XQJ"L&W^Y1-TP"S:4IT9@5=0>=/B?Z?@I_GEUP>RN$0FWTE7$U
MD?G>)Z'P.'C9!%O4MW.WLO#%;ACZ0:W.TZ!2YZ/X:_WMAU@^BM]6]?J[.GU(
MF>0I1E#D BO'.F<0IRB&&.%$),J49[%5EL&UC$S\_E%?6.3:X]L343L_? Z<
M7%\@FJ,;L./I0DF?J>7[5 =LV' M)L':BGNR,7/3\>O .FY)?N5Z(4SHGORJ
M)LM^.'@[U*-?U9_X%U&+'V1IGM5]TQ>$8I%C)B&.].1=61209@Q#63!>DHC'
M);=28>%8FM68;C4'-V"UYQ.(GM$;T'2<=1$,L+:>=!!P>WRLZJE!O]ZT'G (
MWN[@/MR9K]W.](QVZM1AVD3 /;C&QIYZ+\(9VM/LR97&]C7PN5G<7I1>T.R^
M!IEQV_NJE?T,\-MZ7?%JN=$U1U\%TPT.*M%VMV."OU-0Z%3$3?<M5UX :6KU
MEFT_BZ;KU_%T>@%3(!,QJLSP-(,HRE.(:,PA%32%B>",92B)1>[43&-"7J=.
M5QP0!GO*CB/J)]PJ.^/_)]D M[?@&>R#5T#- $X@1V%*3F?U)6: _+F[,0=)
MSWI/Y=V^K_^CJG>ODP5/BAAC(F IF=;"<0HITU5>N7(\..$,TV3Q*!JZLB[P
M/"+B<G"'I*S/[\=5#1EIOX.JIP@J/;6BN\;\I:JWB3?D7H\F;<&/:OU=^0]=
M]VH]TU3!ZSBG] 24=@KR.GC<])JF!:L::FH[8S)@0>=944+5;QX3F+=<\ZR
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M?G/_H6*ZBUM]U]_1+7!18(P2Y:RF^LSG/%?6;YG"(D(\IWF&([OWLC<'D\<
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MZEVT]C>E\10ES<C[^F&S7L@<,QX5I?9T<HA864 JLE0I(,YY5B@UE# 7W>-
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MJA'A>4+S-B6\*/!1@\++3WC&D<A2?)+&:_Y([M6/WQI2M[K)Q:I^L[HG5;U
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MCG=K\A<@AH<K^_L]@\S.? @(A)L6.MGQ+^@</$O1IFK\]XS:RW8 /"WZQ5:
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MM$0QS%F2%9QC(K!5[D-0KB;6/5L>C;T[X'(X!.D&;!G5#11Z5H'Z3V<@MS=
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MI$JEI=,9V8OJQ!M*1]N8;RU-GW%NKK@Y; -3H.%IR;)V#%Y7Q=KCLF,#]'R
MAI$I</(9<S<!7H%C[2+AYCG=SE/^\6EVK@^;<7J=IWR'T^I\;P[LT&=33/AZ
MTXS)&H0=[H6P_<LME;8;G%:Y((A2F&CK6R3-(/<BA8KB3' L<I(IKVY\CH0G
M5IT#-@Y3,3R=BLXXNOD&ID#'-Z8PX. P#7+/Q#QM\CRQB-42SY7LO.WO/,$X
M:77G>W]@]_*FOE,==HU9)#IG2<$93#*60"R3TMA>Q@K3*..29&E6*.35M?P<
ME<EC$DT=:S/@J&G2LCY*6ECNH[F>K<S/8N:F+VY&PD\Y=.3 <0NFB,W+QP2*
MU;3\+(UYFY6/B7G2I'ST8K^%*E6U>-W9BN:Y'[>?MV\VF_7FU7JS:0>G_;)D
M3PM.9"$1+V&>4PXQ124L"<90$DH(XR4NB5/EM!NYB9=NS\"YM@^@80?L^0%_
M6(X<O3Z.:(ZOY?@8^2WJJ/ X+W@_J<^L_%J)?WM:?_EW\Z!VT9L?]FO=\?&S
M+'H_4?O5[WE7@.]D. Z[&8*]&ZC5-UPCF9!%FL,L)27$>9I!FJ(,%ASE"=.:
MD,PII]^)VL1*H",/&OJ@80! L./!PR5P%38'ETE,,/Q6^Q4<0MS>5P'Q\(W$
M!";,)Q+ZH?CY0%SE'/5]7'W(?#X/5WD.?!W.-_V@E5%V@D);3KLP>"$N<@J+
M+,N-P92;(TZ6*ZA*R7,NLD1QVB=JNQUR9N3>:5$=9GG[*=\+=4XOJVI;_VBU
M38.7ZG8&^]%>U%^C2LG<;[Z 5JR_4!72Z;OXJY0:#3C_OZN>Z/25S%XT=(:%
ML"VK)?B;VGY:FT=^4?6V(=OYD!,I<Y;E @HLS";#I;''<XV,49[D0HFL2/R:
M)(Q2FSH9IM46+7'K3]M[(OTVA''(W%1X-"#\E.XA!@/"TSK6G:2-I-;&:<VJ
MB)S$/E8=;C<%M3^_X)!?R<%O.WUS</DO2GT4GY1\6:K7Z\^L6BVR,LLI*W*H
MTI1#3'0!:989S4#2+$M$CE/"/%JC1V1MOCC>8;BJ22@:_CZP10YN,A:)4J!G
M&OS1LNW7,CSFJW3P'GRW%Q0IE-CDVYV^F\<?_MUXM7K_3N\HM W\W.O(MUW\
M!'!>:24?D^*<;>8G0.JH!?T4% )]/-W#;*K[UI"N^%*U8Y5L$N)Z+?^LELNF
MQ; UI1I+:J&*0I.$8"BRI(0XRSED)+=M@4LJ"Y+IA.9>Y3#^/$R\*^Y6H;&K
M]SQUT\H\9L_>@K*C\V1:[#R=(&.PM;GZ'4==L_AI[/,;,(GEC C@8%ZG0CA$
M)\Z!&QX5IK/>K5=/MBGK:\6WO['MRZ9)&OF@GEO/0_V@=W[PMZO?#=''/]7R
MB_IMO=I^JA?FC"]*E@A8<&63:0@WYW^.H41$4)8CD2JG@1I1N)E8CYD/$_MI
MJMNP==-9LR'FI[TL6]#R!2QC-INW8>U;-Q/M816QVU,4""(IJ]MXF55M18'M
M6('%>6B8*FL4Y;WXKY>JKOKI#Y54;5KMH[$%ZZ[;B?V1B?:2>KM :<X15@5,
M"\T@+F@&&2L4I)*Q!#&,)2U]E%@@'Q.KKP$U( PYS\3 4'#=M-@,D/GIKX8A
M,."H:;RZYPD,F+H#0VPM7_%TVXW 1-)JH5S,JL]NA.I8D]WZN) "9JUM,E5?
M$_W(OGY@6_5!60":6L26C2]JL[6&89.E\.J3/>.^7>T[71*<V4)E!9'$A;')
M4 ZILD/.-"NYX#I!7+I7,<=@:6JW:T//1G"U[26Y2XH6>[[ RC+F4ST;Y54X
MN$]G!]@S*M2SUW=AL!W?+(?@D,5&/>[0;KB\ ]V+>;MR:?(YU3OP*6.>^UT$
MUC+/]DX\ZYMCPC=>Y!R%THR5SC&1.2QWCOKDD-!A.SU^T#ZPR[,L6%(DA!.H
M:8X@3M*B;::ALK(46F"6EN[;T"4J4^\L+=EABTN?<,\E:%RB:A$$]@R0G<H:
M-++XDM ^X:H(P@=&GCQ>N&?,Z(I,X^&?2S?/&,FYPO]A4.;:Q4$Y"EV1VQ=U
M8=)!/VHX35!^;WZ0]I>^RRBFI;+C%DE9Y!"3!$.N,@:SC(B$49'FR.F,?SLK
MDWLI40Y>?;A_?7\'=I2]8M2WP.RBV>8"SU/][=D"NT$L]\>#6'K6[D"#\XZ[
ML.'NMR#M%?V?"?'0:/\MR$<+Z4? Z$H(_Q8*<X;L(R!Q%**/\<1;<E@_*M%Y
MHG_Y\GOUM]5&L67UWTKV<PD7,E-,DX1#+8L"8DHRR%+*(),XX5*F.BF47\6$
M&V&GU75+L<.>)%@:>K9O[0JH-M6SWC$7DN1Z%5,WSV]$G&Y)>]TS< =^^3O\
M_>T=&$ WF"H:._/55?*H*;!7B7Z'7%A7(,XGQ3K?'6!Y_J98_;)I%-3;U?/+
M]C>V^:?:_I]*+66_&2NB*<8,TC(WUJ7*)>2)2"!#0N<%U23-W*W+J^0FMB!;
M>N";)>AASEQ'R<$XC"J[GR(8D 8-;1NT;I!HR(=8> X?CKL5%Q6:,$OM"D21
M3#%G04?-K>M/F<^D<I;HP&QRORM"*_^FT9?Y&V.H;;^]-V_=)E!:U=H8: NM
MD[10>0$SEA@%5Z0E+'.<0"6+A"G!4BZ<6G $T)Y8VQUVL:\-+TUK_^>.G3OP
M;!EJ\NU4S](-K?ZOX.QF,TV$GI^^/&K_S]I,Q?<[W!I6VE:J;ZX"=]LT #<(
MII@+<(7R]YL0X ;)Z*P QT>$M_RI;<QB\VR3L97\^=L'.XQ(&5'W:;LE924W
MUA,T!I2$F*<"<J;-3R5)DB(M4J*<9@-Y49U8X>SX $-&;#GSCA7_?C_7H1S7
M+),!Y*=3'+ !?T1-<PX2_*8&0->IS-X'R%GP<^V W&\.+*HP>JCI-L:9^.<@
MV>8_J]J\4MN_N<DSPRF5(B,"ID8WV"0^<P1#2L,DR7,I49(H[66AN)&=6%<T
MN^JRYP)L]VS<@6HEU;,R?UCKY/EYPRICO+3)+Y[U%&X NYDF\6'STR -8CL&
MAHEY=V#/0^0D/3^A8Y5%N!&=MQ+""XB3X@>_N\,-C[8[PIN5M'-4%SQ/\D05
M$JHR91"SS+879!R:O]:)2D2!N5.Y\D4*,QD47?\2\,:&3@Q9?ROB$!=WBR%8
MVC#KP%G0("O@K# W[?B'3YQ]=S\KT+F=_/R% 0[3KG?CZNF!+ZNG-@>IS0A8
M*$EP5D@$J<XIQ+G-M4\1ASA1'/%2%SQSFOYUA<[$2VY'&*QWE,'_^!>:(O0?
M0'0Y),8DLG_OX2\<P<W!=QH'#;\EN0=B3_0.=&3C2.[A(HV#0)AO- P)/\_H
M=?E&7:(CM\_G"[TNPX$3U.'RVYN#'XU8?UW53?<?FTEI=**P7R'1FI(D3:$@
MV(X&HQJR++6C"Q7-=8H8DUY3"_W(3ZS.>@8@:SD LF,!V$/='>@[;3<GD1L:
MBCO@[';*F Z]$/6W:T'>LP(Z7D#/3).=?0<Z?J9I4.Z.PP2=RQV(?[>6YN[
MC/4Z]WA*Q&D%OQMQNWTPX01KG!.8XD38F5$(EE0KF.1YD2"F&:/9PC#'US=-
M+MA3]%DV0[K>JV>*D04#X/Q5RHU@W*1#=K3OP)[ZQ",-3L6<<KC!@-KW'W-P
M*KK3P(,SMX4&8=4SJ^2;K[83I.I,F_N5''R_)<&Y1"B!2"!K>I0IY"+!D%"-
MLP1G4BNO#C'724X><FT8 *KEP'MR^E7$W%9\7!S\%GT/04<\9ES45:AHX="K
M!&>.@KH"<!K\=+XS)(G,=CA8?K-=73]87PO;_-.<:A8)4TF9$0+SW%9)9<08
MX51*F!4)IF6!LTPZ=5$=H3%UNEA+%'"[B6^:#.WGEK!/IM1Y=!R\'K?+[+=R
M>W$M0?"A$?=]+'%]LL%N%CLP!<Q??,_LKU'!QE.^SM\Z8Y[7*.^'R5WCEP;.
M45RRNG[0_V"V\=WV8?/!'EGNOU;U@BA$A)(<<FS^P"BED'.509VF-,UY0M+"
MJ\7)14H3*YN&KLTSZB@;>$!#&_QAJ3LF9U['R\V"B(*"G_H)!L!_XN$UX6*-
M.+Q(9]Z9AM?$/1EB>/6&VR9(&\OC@_JB5B_J[<JL%%5OWYMOXI-1&+MRF8.6
M)!^44-47)1]6@]#I0F*LJ/D#DKPP]@6G&-J4*B@0Y8(FJ%"I^]2DV-Q-?<[H
M.+)3WLT!FRV;C]XO)!/]A3B8--\39C]M=#"RN:G9Z[@%/;M@]Q(&%7R'G91Z
MGL'#:IBO\3U?4MC\[-E?5H0YVW.]M."AW%%!=1W>'8?H=QGR'16O2\/ XQ*9
M?V#!PTKU?0$0RP5#&B)JTP:15K!,>&(V27LL5[I(4Z>)XE&YFGA?-)]^.E_7
M^CW6#EO?]T#0TP"/-$? L!K6-"#2RYAO>D#02XD].,#[Y?P8HP).L)MR2L">
MV%]F0, )/C%G YP^/,PMLVO-U;F6?U8KI:OM@DC)>9I22#@U9[,42<@*+"#+
M,JV9S$0J/9L.7*#DM/!NZ3+0]:';LJ^ MR3!3UUTQW.BXB6LL,R9L%FYE)'"
M[-,RA8R)'"J1\"S-S9]B-]+RT=V/%0^P1_]]>(":NA('\L)*(<6HQLK8-.;@
MCP6ED**L@%25A&!>*$3+'5;K+5O.CM6.J#-6S2V@FOP[<W/\W0)%D-4Q:/38
MD00_=40C=J2X(E8DA]\E*K.Z^ZZ(>NSLNW;Y[2D_C?OP0?^M;N<]+ A2-$$I
MAGF**,2,)K"4)3%[A60HSX0M60A/]SFB-G.J#VLF6H1G^1QCY;9H(\GOMW"/
MLGL:NG"MX=_J;I3+'6#:G.'LQ,F7SR_MM._[SS9U_+_'?94WI?Y<D'^"M)]C
M2M\MY>>"R&/I/I=N"5OM?U>U'2C:Q)<8DB@3E$&4<[.Z4:8@Q44&49&5FJ8J
M5:SPB<<-GCVQ\Z"C%!1O&R+@MF8#Y?);HXXB>2^X,\Q'6F##)\^ZH,Z(=+R
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MPS([YG@+?DD=T4 ;S>>XG<I\J1S1$#G(XHCW5/_P[BN;OWS/S9&$B>U")YE
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MT_VR7S2#1\VR,$Y9[S_^,_\2V!:&59MF2.=@X=0?[,Q@VZJ_2Z//!"O,<55
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MG_S1,Q1[.E 4=&+.#KJ-H?DG"T4!\.S<H3A/#JQPOW$<[;V45=N4Z755"Z-
MFL&T_>K5DN>IRC"D(C&&'&8(,D$)) 1I07-)<>YTXIR%VXDU[C^4G1NB) 3W
M7]2&V>YVROK][='%3ABQ++RP)7A7:=4,%?^FV&;NF>+CK]--&?\P+\E/3\><
M);X7 0QDF$2YSX+V#S)#?)S7O]3\<"?88\\.=R,:E&"MA/FW2K"E32_J?GS<
M5.9W(39&K=6MR7]\,N76M.::P3))&,29UK!D3,,\4:6=(5[B7'KD6H=Q,?FQ
M?\=6FQ#7_])P!GK6O/*& ^%V\&G. :)W=-,%OR#_0$1LO=*SI\<X-%/;"^MH
MN=JWX7$E;3OPX7-F<-\F_U$R]XT/BWJ0L+N/K;05G]3#JA_D*V5AS@(BA9IE
M%&(J<LC+!,,R2W*BK8,W<>H3$$![8EW_2[6I;77#RISD-C7;.(ZX"P'Q)F/\
M5FC"3>N=R;RW6NY QPHPO$S1=LL?@VD-WK.4?P3S=0P21V-T]!$!IN6;K\]L
M53=%^NIS5>_*1GFIRY27&.J\-)9CD1@=DBH$&2ZP$GE.D>#.EN,%(A,KBQU5
MT)/UL%,NX>)@XD60UF_]GPH:D@)S26(/PRN"Y(%3+\TMLM%[>KVQZ8D='FMM
M<Q8;5NX&S<QC1;"OR#MJ-UVZ=SZSZ KW!U;/M6OC)+O??ZWJA39G5D:X@D0H
MHWET3B!'A88)ED8A9:C(W.J#QXA,K'DF2'1OH!E7/K$$]E,^%Y+<+=$)4]R'
M,D5.<&\>_5W3VX?"74MN/[@V[&CQ=[9I,KWMU(RNG@*E.DMSRJ J;4$9E1AR
M96<E)BFSB6VHS+U.$*<D)EZ!/<%VQ,W5D@M77-P.!;=)Z[?\/ 7U-NXORQ+)
MAC]#8%93_;* QQ;YR)6!G>U9M6E&WO]F+).737-8^T>U_?2WU9K7:O/%$GN[
M>GZQ$W*L--6R:LRB#[9WART9-\>#JM[UY+8]=VQ@LQV'8ZO3WK"-C7_5BR1C
M/"EM(VTL%,1(<5AF1$!!N4:9% 4M<\\V^7/Q[K-T@GKNV^R :C<P2_8#L^PX
M-6V$!%^LE)[]]V=[L6X*Z8=\67YZSHH &AGNP$ *\*<1 PSE *T@X% 2.[JG
MDP4TPAP,%[ "==DBH!?*OO]>K(A3!^9^$[%&&,S&][SS$.9^'2?#%69G(&RK
M,DIRGSESO]UN*OZRM<P]KG\W;-G\BO5RV?3#-=::JK>+)!$I3A($64$EQ&F1
M0X[-J0XA@5*&,DT2K]P4;PXFMC#MMF$3^@ ;\ *V:[ ZX,:HD9:=>I?QMV5?
M_;83?_#=MH5)(?53[Q;-@ZP]<'\$ZR%'H&<IGFH.1B.2BO6G/ZNJ#(;G6.6%
M/RAT"L7?U\N7U99MOOU2+<U"7Q0RI3G)M%%-!8(XYPFD&2F@4"E%:9F53#OY
MMB]2F-JQW4Y>V!$%+57?>1/'L(PKC2C">OJU/>4,F"QQ098;1DH</W'F61(7
M!#H=(G'I0G]/[@<;:.S#1H4V6SU)H" H-4LK49"KLH0Z,6LN%5BQW-EY.WCN
MQ O*#M"HZFV3B3$PQ-P]MD,(KCMI P7S6SP79(K<?N2,*#>X8X=/F\T#>T:$
MH=/UW#_/G O>3E5\NZJWFR8V5C=I[8^?V*I+/#3[IFV\K.3O+VV+5<[,'E<(
MF/&20UR2%)8")3#+B1:<R@)QOGAN\M[-9[+9NEG@L_'OLRB.I7"W.'N:=X"K
MIVK5)(ISMFSF#]K\\)=5M9TM/]S[%7.%&9*L@ 7),HAU:4?C900*C5!*F4W_
M%]TK?K.2?_D7W,L0\GK52OZUWJW;Z>V'?%N>>]3M-0'=H-^!-%UKGJV19U\Q
M,/@<6J%^@ J!T/?PO:L%O/G^$5*OIGL=T:H(@AD(2/MZ^'-ES.1/U?-[99:F
M.0<\J9^__6_U[<U7)5ZVE2&SR(C,,%<<DMQFD::IA(S*!.:X5%H2PC''SAE@
MU^E-;.+O& #/.PZL,V[]LJVWK-TA:OM::ONWMG"7K1RS2UT!'5?K$\#DIXSW
M".V)@Y^_ 4,>[.G'A<0CMRPN-&%I9F<_(K,__=- I'9\Q,HN<Y=X--',X3'S
MY9RYRW20?N9Q6VA[9;[=%VWMJTX*B1@I2P%)(LU)*B]LK2W.85:63*(L8[*D
M/E&,"W0F5GX?U!>U>E$[ISEX;R[\9./=NR8TOKV4S\/E9KE& ,%/M5F"@TI1
M\,<DO4VNB!6M<_)Y*C,W31X5];1?\OCE-TR/M]_N@_ZX-8_[M%Z:F^O6C-H5
M52=)PA65.11E64#,[ K.*89Y3A6G1&0H\RN&<:$Z@[^R/1P96V7(Q?_3GX<<
M2J%OP-3Q@!H;*7\'Z,T@A<V@=Q4ZYB3ZJS3GGT?O"L/9J?3.-X?44W?;WV[W
MVU=N=UMEOU/6'VW:17],6R1*)U*F!(JT:!H]*VB.1!DL!2$91V61BM2]GCJ0
MBXF5RZ"YPJ:S&P8Y#'7#"7AN6?$I_ W%W.'8- >2?LKGU, ZZ%IQ;) 98%O&
M>O?6',#Z5%3/ '!@1?540'N66-\(T'B)=>C#9RRQOE'^PQ+K6Q\6.EJX5N8F
M.\'GM2&S7#>]]+H6XVTU]T*FFFF2EC#7O(0XXP4LI::0E[1(E$1<EHG?@.&K
M-"<_&[8<-/T(!CR 5^O:?[3P=03=;,?(N/@I[XN0=/3G:97I 4&T,<37*<X\
MC-@9@M.1Q.ZWAJF+_;#CVIYON_Z;V\%DU=UYB?)"<$40Y(+8AKM4P)*G&@JD
M""E3F23:J^&N.^F)E<> D3O0>%GZGK+;P^&^@<=1#XS=],HTR/FIEXB@>2L5
M?_DCZ18/PK.J&'] CC5-P!."1P!6*QM57+4YL[8:VWQ8;SX_+]??U,8ZV#:J
M,9,VWX87W7]>OQASGVBBC.62P10SZ\I6":1"8IA*J@LMJ1T-ZN?*OH6=B173
M 74@!N3]IP;> KJK0WPN*'W]Y@U?8$BSZ1U^!WK>P"'2!U>V[$6=3Q@!IG@3
M#&]A9NX9AQ& .S,%,<93 ZVOS\^LVK1.0G,:-%]MQ9>J'0#U2[6JMFI9?5%R
MP5!JA\VGL"RS!&*2*U@R<V##&44,"Y(DW"DAV9/NQ.KM'V9CL>D+VOJV-[L^
MMR\K]GF]V5;_;=:LH<%6S4]_KC?_U&OS(.O'ZQCNIKIY6F..F#N:8O&1]+3#
M=@Q8%/<L=%/=[D#+!7QGV8AH@OG)'<O^<J0ZK_'E!\6)Y>5Y>T"DX&/U]?]5
MF_4OYCF_L_K3NW>ONBQ_FHB,**Y@@@NC5Q@K(,N+'&))<H:9)$0ZC5(?I3*Q
M%B%)#BR].V H>GB<+X+BX*J/(:IG'+#Z"BQ)8&GNY0UID751< ]7>@P PESE
M%X"(Y &_)M>HA_OBS?-YL*_Q?^"AOGIQF%%S+X0UC>IN/N.KE\W&!FI*K30B
M20J%% QBP11D+$\@2?,B06F>J<RI7G&<S-1AQ8ZH#1VZ#Y^\@DR*<H8$HS K
MD#36G2QAR>U<F9(GS+K8&&=^?4UNQR:H"4DWZ/ZE*77>J&733>N9;?S'W%]
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M DU^WS"I;X+3A8.(T<X88[1F/FDXB'UZWG"Y*<#Y>527<%+!T'VTN:T04Z6
M0J9V8+,H(4\4AD@G."MDR814S@Y0-YJ3GS\BE9;[P.C@&8T/CN])Y"HN(1%H
M1X \W*3Q@0ISE=[R(?FY2?TD'G65.CYJ/G>IGVP'+E//6P/[B*]7ZV=E-'#3
MW]=V >Y*,A:%SID2>0)EBB7$HF"0Y5D"DYPF2)N36*',0<R&2=T,H(N4O!3B
MCIYG)'?=]"!3?;W02GFZ42_C5&)>J!3E$.7$=EC-M:U ,X9B5I:*(5ZD'/F%
MO*,@%13U;CNU_=3!9$=N6.IMH_2?JJ:'O4UK9)_;('$SZ^$H..[9Q.\RKF[V
M9!2L_':2(<E=C_2.ZF7I_=N?7Y,L5IOSBW3F;6=^3=R3MN57;PC3B&^T5L*V
M,&H?^LB^VOE"A],>[K>_*/-$MK2=$5[,>_QV</$"(<4E*A#496$.CQIKR#*<
M054PA#*6:Z*\ZLLB\#2QV=G1!G5/W$Y5 -:R]],',=!WTQPS8^JG8W;,]0K&
MQJN;B6+'8W38%O38[Y@\ONFN[R 73SM%1"^2'HO!T:P:+R*$Q[HQYJ.#P_&?
MJ[8(STYE7Z^LFE:&NJH73*5$%QI#HK*F9E_9<OW<F$U"T0R5J"1>/=Q&:$WN
M6-M1;B)<8D@;_/3[VBS8PM,B&D/.U<<6!0]?#]LA% =DHX;NK\D6+WQ_D=+<
M(?QK(I\)XU^])6Q=/_0FUSL[E*^?<V6>V[7\J%^_J'U@GQ4)+3F'3$MS-$H9
ML\.G,H@QE2DI2:)+I^Y,(<0G7OD[5D##BZ<GW0M%MT4_%39^6N"=JFME[(TC
M> Z&^VW7@"OPGE725G35=A[&_U%L WXSV]!FJC9P(?!$4B1>I&?5+"&@'*N:
MH&>$VA1-*VYAK9>WJ_>;]9/Y$NM?-^NZ7F ED1(*PX3D$F)SSH(\Y1+23/$T
M3W I<\]PW45:D]L4>\IVYN5S1]O7BKB,E:L5$04!7ROB4/B>[!UH",>T(ZY*
M%\V.N$QI9COBJLBG=L3U6P*"<Z]LW_S-UA:'6A/9G$M4U4S6['.!V_[ZW:%U
M@04394D)%$+GQGA($T@+A"!!),.J()A1IT89 ;2G7^L],V!E#PN;'3MWNR(&
ML'YNC_K/5P[Q-P/M$,:;#CYO1;%#KCEF?1@@U_/2C1NY[OZX&3F/^-YT"(;%
M^>(BZ1?Y"\-B- +H^<CY(H%ALAY$! ,?$:"ANVHT8]8UK=F,.?>N6JFW6_6Y
M7A"I=9)K!#5)!<19H8R517,HI20ZT1PAZM1R\1JAB77OGC+H28,_+''04/=)
M AA#RT&G1L+ 3X'.)+Z'8HP$0Y@6',#QW%&/-3;$0:Y1C39V_WSJRT&* UWE
M<GUPRD([=>F#^7-3"?-3TY6\&>)4WUN_=[7]]MA,,-X-PI L$UCE&J)$4(@I
M09!IH[220F<EQQ3E7'I-/P]@8F*%UJ?2VN8Y'S[^#?1,@)>5[ JJS"^V(Y3G
M63((<+=#YM0P^NG$'3=@STX[J:"=>%?O,?VCX6F:1K.W@!(O*<"?A;GS!8)!
M.I-*$/ZL .OJ;5V_V-&7#_H?S(ZAV]:+@F54X+* 29XBFVVE(),%@HB05.48
MTU(ZM46[\/R)5<_;5;6MV!)\'LPU-EKHSXXZJ Q#9BE5*QLA6ZG6O=-E#SU5
MM4UPD^:\:TZ_]CZM-F;;J %KMQ#S3WJ] :P&R[UWT<,\.8.V@U%V&X9^>J>G
M!1XTZ*G=)J"'V76;H&'6EI? ?M;697%&C:PSM\UG6UWF^<"D&KDLS))ZOUD+
MI63]BV%G_W ;/%RO&@6X2'7.DI1P6.B$0)S*#/(D26!JFQX5!<D$\PK57Z4X
MM:+J/[QVIJ2A"FI+UL\@NHZ;F_43%0T_E=.3!O93!$-86O*MV1//IG$6-9(!
M<YW>K-:*L_C'IHG[C0%UNOU8IU_5^FG#GC]5@BV;^M"BR&C)508+E&&(-1*0
M9YA#2C.F2\Z1P$XSVD:I3+S4A^0\RFHO8C*^I*-)ZK>,AY3B%L->D^662M>+
MSYZOC/6:> <UJE<O#C@#_%*M[%H^B)I_>U3F+[=O/S]OUE_:03O+Y?I/>]W>
MU[O(,-*<"@DSVS(>)T1"RKF 1"94)PB)PFUQWL;&Q*O7)I+\3] R JH])X#U
MK QB91ZV<CCL#F>&6<#T4Q =2V?2<#IL!XR!'6>#&- LV'H<5V;!..Q4,QW6
M?D>@FR$:/2F%/WV^ ]7-"!R<NVY_6MCQ[-'<]J#O[5'OJ25A[1"!.2DDR6'2
M>+(%,V:94L9*2Y N2JPPU87/D>PLE<GS'I:&!5OX;4L<!K2;U.'A[VU%VO83
M6X&#F_P.;.>1=#NDW8R/G\*^'9IH=J 3 I'.:^=IS'I&&Q7S^%PV?G'H +.N
M_N+LX'N=9#FC!#(F;6?E!,&2E0IREB2X*)BDR"N -49L<F]Q7YWDFS<]BI#;
M<HXEMZ>'=U^0-?G8>Q<)HPT1&R$U\]BPZT*?#@ISN">PB/1HXMC;E7RIMYMO
M73N(M"C-_Q04<IG8: \2D*$40\ESAJDH5%$@K_K047*3+^>6F.VJ8[Y,SWK/
M<:#<UG0\\7U7]8'DX(_7:SOY)^):=I,L5@7E.+%YBR.=!#^I>W2[*VQ-__Q2
M5RM5UZ_6G[DY$32SZ^Y7LC'#^N8<#[J_ZM%8!C5K(IUU.]YTOU,E37-UF4!M
M[7@L"P(I+A$DE&,[MMC\X=63.!IG$VN*09+5XT:Q;1\G-GR"W]3F27DJCWAO
MQ$W/?!><_5123QP,>6R.#NUQ8=?$Q\"^NW;(Z3RSE*,C&4D%QN-K5FT9'<YC
MQ1J?0' GZ2Y!YQ6K;>=:^Q^K];^PI2TV^]W@U0U8*3#*A-(:(LTQQ"6Q8RUR
M\T>>,U'R4NF"^/7E<2?NL[Z#&O4,\M.$8:(K-4\]2\T]T'13D-,@Y*<!!]!8
MZFTQNOUAP,<=V',2M?^TI_3Q>E&[$IZ[+[4G(&=Z5/L^(4RQM(7+;2WWL7&0
MYX0S013$26%.:TS8;M180EE*4@B6:*D*/TTR0FURU=%0!0]\63VQ@/G+8T"Y
M*8E(POMIA;XPO24[K7'C(&"DA3]&:=:5[B#R\=)VN26D<NG^/]_V+9Q+KHC"
M".8I,>NVT&;=YIF&.,LE+GF:\M(I>>WHN=,?DJQ-OEV#>_G%QI,D^$_%EMM/
MX.VJWE;;%[/1_V2Y<=SLCU$97Z0WR.JW("V-D(:K TE\:HN") HL)3*T8I4.
MG; ]7BFTOWS&PJ 3'@_K@$[_.=3T;]JAVB963S;=?+TZWGY(3H5,*(*)P-18
M_"B%-!$<,D%53K'@BGI%1J]2G%@3]!UX!PSXVO?7(',UZR,"X6O-MQA,NF$[
MRQ?-7K]&;V8SW5'\4^O<]<:0!#E6;>R0.-6DN>Z<#$V%LV/7;<QXSG3*(.%Y
M";&B&61%9OY(,F4,^C15J=-@J4C\3*PN+(/@B^70.O>:M';PO'/W/;NKCUCP
M.U@:\X+JIWH:/!OF[KHBP)WSM.^&,%%3^0C8^V34S?H. E/KHKR+6/EUT0 ;
M3[2[G<R,&7?1,#E,O8OWV-N"?O?BOUZJNMGCWNV:&Y0LP04A!(J"*8B9=3&+
ME,(D8YE$4JNR=.J$X4)LXLUC%PL:T [H!^$$FU^P[58P N-GWC@$Q\#&!(P<
MUCI+ZKM$JL:$OA1\&KTG;'DW%=X_&ZTA[>13M:K;ULC[M+Z?O^TOZ3H:WO_)
M-K+--'C;M$=KVAPVH;#'3VS5*J=Z5U/^#U4]?3+_O?^B-NQ)_6H+-U^SK=JI
MM@_KY?*7]<8^=8%%DBCS_S#A*C5'V$0:C5)B* LB\YS9U "GZ8<_J'P3*[&>
M%0@Z9D###;#L@+T)X:?*?C (';7G#\;U= J[D0(V8H"AJ >ITOP;&%[7R0L:
M@>_ZSB@#F8>YU9W83<BP%?P.]**/?V>3-++]05]LI(WJ1Y-NUKWQ1Q/^PG;\
MH[(99@'L'GE?UZIIES[H8?Q;V\]$/IC#AHTS5ZLG<X%A<]/_:H2LZJ8SS )E
M:9[DI809XCG$>9%#SCF"9:JD4@E)"NYU&HC&V1Q^IU;AM9P"PPD8\ IZ9L'#
M"NS8;:X:,@P:CKO.2I[GC7AOT6U[_2[O)MQ]M0>='8-^#6[O#2HZ-)&VEGA\
MS;HI1(?S6)W')Q#8C*;=*8Q6W\VKV-K^TY5L&LS;,U]7>MG68UI6VLY<=C)*
MP01'JD20*UE";/0PI*E-V<D*FA%$TJQ0BY5ZLJ/JW-3O3?PX+>NR7=9#KIQ7
M=V_"VLY8NZDS6_OCGD'/IC8WX>^F-J?'-*P9S@#,/6/@@+-A.?>..;#G+F*K
MG!@@Q6JC<Q,O\[;8B0';2?N=* \-:1'8=M1[OU&?JWHW8STOE,X$P4;+%01B
M33GD!6.PD"G!&<$\XTYU8Y=)3&PK]HT">Z(^7>[.(N(08[Q93C]E<BQB2 #P
MO*P^3?UNE3FPK]^1[+%:*(^*,][7[^R=,[;V&^/\L+O?Z)6!$W.6K*YW[0(?
M-A_LL7H?B"E*KA5*4EA0G$+,4@S+4G*8,:T$H3A)I5,G(3=R$ZN6AKC-?.C(
M&Z! P\ -8:PK^+D9/?%0\5-$-P+B/U+'2<Y84W7&B<T[6,=)\)/9.FYW!<:U
MNE[@#_K]QDY)WGZS?;^WYNQFG7#/5K.W[@Y,2J33U-@11!7&HL@%+*D=9JXE
M89(43 DOIY4KX8F5P:X7^H,&/2--Z_-MXW;:\1+F;7)&US%6,P%FG@>@CNY=
MAQ'SPL@_AN$I<*S@@BO9>;W^GF"<N.-][P\IJEBM7HQITLZ584]VK/"F*=QX
M7%LO_P=;(5BF1&F$$"P4,<9$ALPI)2\T9 SG!!4IR9!3]K4KP8DUR)ZVW4)9
MPP^H>C;LWW&;6S9:01@&I,.1)C(\?LJB)0X& .W(@\>U]>+;E/7HL/A4>\2%
M)[ ,I(7I>0_3_NNQ(U#[KR?:F!EWH<>+2!R>,V-UB;M4AV4G'O?-G#K4!3O_
MWD0ZK9K^^JQLA>OCVO[5P\NVWIK]MUH]'45!WWPUTIBCX?M-)90M=BFUL=>@
MDBR'.+7J-DD+J#*DN"H9IGZ=V;^O.',E!O7Y&CUQT%"_ RWWC=VCVG]JQKO\
M5*V M+WU-K5=R*"V"'@6V7_G[\31!/W+O'V_O2I"=M N_V?PC?126D5N_]I<
MM9?T3'K0X>?V R0#17UMWSOW)XXP?XU4GZ@O+EIF3URN;DSD>;MZ-@3?J2]J
MF76>\U*G.>&DA"A5=H)PALRQ1)A?$XJ8T)0EN=,$80=:$^]D#2F0!6;'G('&
M;7^()+"?\AYFL+1T;?^&1O[K097PO)7+(L;.1#E#Z?ODEEP6^6*VR,@M01/!
M=P--=K-L5^WXM:,RGUW =5$D>5*4/(&ZD!IBF7%8(F5^946AD:"9*-S;.P0P
M,'4\8S">J!F@UC2+WPT%WZ@EZRP0VSYOTU6_57WU6S\K[9O7T&O_M^#@K9@8
M6\^HR&"\T7"^]:H;\7BFD/#=3%!Z#1&?%-+02>(30.L[4#P8ERM3Q?V?.^=H
M\6"IC^:+AS\G<,3!IDDP_-;0[,@W]!8(LU1E.(=YEDF(\[* -$4E9&F1(::8
M4?I>)MM%2A.K\9YNJ\CO6A="#=9[F[CQ,K1_[>E:N(R>FU47!1,_];N#H],2
M+=6[3D-$G%EP3;18<PLNTIEW=L$U<4_F%UR]X?MX10=GQ=]?F@.*4*J@)6$0
M491"S',&.4<2"F/^Y101:OYW\:PVU5I^W++-=AYWYPF?/DOFF%OGU7/@9>+J
MJ5JMK +A;-D8A\&*)/Y;T[1,)-<2&J$IQ$0A2"5-8)H22AFAFB#=O;4W*\>,
M[!_@G?6\AKTQU>K['_!US>,EOND%?#_'[\$[;!G_<5RX%S']0;RRI_S]I1RM
M%^&-[3N]3"BPH6VU[1J\?E"UVGQ1BY1APCC74-M$3YRRM.LMH%->%*7$V*T=
MYD4*$UO2]T)L[!3YY8XN4%\MTIX%_:?(N&F_F^3UTUYOZFWUN7'O[(G&/"M?
M%2E6?]J3Y\_;E?:2>">]:"]>&&@%6ZO:CFM6\O6+K9)[WU@/^TY&W:+OXQ]R
MH1#6FNH4YJG((<YP AG**52"%RF71<EH[A7.]^5@XL6[BX#N6M.U'>D\NT_[
M ^MHV4P)EZ?ETJ#3\@):9D#+S=UA![2.I5UP648T2D+AB&5T>-.?UZ@(A>?$
M: A^4.!8LJ^VANVEJC]9\^-!OU9\:R<9MG.K%CDG6.,\A:DL;3*X,1.8*!G4
MBBE"6*$SOS#I.+G)-<Z0N-4[EOP=L Q<G]05 I^;JHD'BJ=-<1,>_I/+G,2,
M-;ELG-B\D\N<!#^97.9VUZW5($W'E5?MQ(RVWK_)#=\WA.8X)5HP!9,R%1"K
MA,$2"01)D10)UTSEF9<*<"<]L3K8582L;46(>F95F\:ULOFX^_E8'8-=)Y/0
MLI"K,#M:)9. YVF.#' [!U%7'3)-8VY_ **7BEPE_)V*15P!N5PNXOR$[Q,)
M:)H^U6]7K4ETM2/4@FC;_3\IH+)]6#$3"E)IU)<03&29TK3,O(I99^9_K@QH
MUJ6D/C4EH=)VK-/[QN$_0L*S[XN?QW<]X>O\?I[M5BA@7GI_PG3K;/CCN+\#
M7\L/XASWY?XOY3H/?#6Q'>NA;(3M>K^K;3M6_-VZKA>EL)F(/(-%3AG$.5:V
M/Q6#!*%,Y1B5HLP7V_66+=WVI(.G>^T8.QK.>L;0 DM#!K#M=E/QEVUCYFW7
MX.WGSR^K:OOMYVH-Q"!)\=-Z:7#RM)D/\7)3Y<$H^"E:"T!+!_QD*5W>!KVU
MWED)(NFDPV?/JC'.BG6\GL]?%%*4O#0@?QQ\>5U&NRJR#.>D*8H3MDE2#GE:
M9%#21.*$I%S@TKT0^3R1J4-=EBKXZ+VJ1G$97URQI/5;8Z>"!LV$NR"Q3\GP
M[9('E@F[OVK/>N!QB<9K@"_<.V/=[SCWA[6^5ZX-#:#ONF!VA^0%UDE*<\(@
M95I"G(D4,IV74.=))@DG&<D3G^W\E,3$>_JCO05T$W-W)0)CW0M=H7';N6\3
MV$^U#&C=]3ZKF)'S2Y)$"YV?$)@Y=GY)P-/@^<4KPU;>:V.I?S%:](NR31=M
M__Q!D*60!(LT3V F;<^RG&2P5,IV+2H%1UJ1 CFU0'0A-O$NOR<->MJ!@:E1
MQ-R69BP<_!9I$ 3>B]5%MDC+=I34K O81>CCI>QT3V!Y;M,?M9WWO,MDZH[K
M]>L7]7\4VSS^N5X0BLSR%L9<EZR F&48\BQ14"<*,\0*DC#L5:KK1G?BI6Z^
MD]RS9M<1+[?5/0$*?@N]8Z"=OWXW;*9L>^$H\)Y5\@Y8-H#A(V)5KY_@L2I\
M':G.6^WK!\5)Y:_G[8%J8KU1U=.J-23$M\<-6]5&#5E'WOU*-K\NFP/6\<SX
M!2XPQDDB8"(+<_;7K(2<)]PH#ETRC!@I,?=2'*&<3*Q*.KXZDU9X&^_A"#NJ
MFCEP\U0^AY!] T.FFN#_D"W0C9J>=.3TS2C%TE3!?,RKNVZ%ZT2;W?S 0*^"
MJFNE'IZ;]O&KIW=M3[+=$J,\I9R4)60X1Q +02!-B!TI1(CD:<+SS&O^WSBY
MB3550VT8EO1U,XQCY>ARB(: I_NAH6MCK1WEUO2Q^3)3Z!,W,6/Y)L:)S>NG
M<!+\Q&?A=M<-F2]UF]:[R"0M$<<I%$DI(,Y(!FFN-$QED0B:%CP77N>9X<.G
M3IEK2]5; [UJ$]*K%7ANSH@*/"^9:+,-;BMD[)%R6\^A\ONMWKYA14LG<KK#
M$?<Q<Q'Z1\^?*' DU-DH_O$U-SOFS58]]/NW P;[H9N+I"1F-RT3B)/,IK.;
MPT"9Y&;]Z213"*=Y2KUZF[L2GGI;?7O_\]MW;Q_?OOD([G]_#3X^/KSZW__Y
M\.[UFP\?_\>_T!05_P%>O_GE[:NWC\%N_7%@O9W]T> *#@'L6IIOOTTREM57
MV/A1@G&RWRMVX 3&2$3![?[ Z2B#?*(/;3NM5^MZ6WM^Y]<>,]WW?9#^UY$&
M#>U)OG%706.-^+A&;MXA'X["GXSY<+TO[!N^_\*JI<W,,@?:CVRI;-W(1SN;
ML5T]0KQ\?FF(_KI9U_7?5AO%EM5_*VF3;WY6VIR"']G7!:6I4B2G,!7"[)2)
MR,U.F250JI1@(CC6E/A-3XS"E]/*N66*8D,<[*D#2][7H1;G%;CIFOE@#0SG
M\2W8\W,'=OQ"0QM:CLW?[;D$9U^ ;6UC606&UWC:*RITD51<')YFU8-183Q6
MEG$?'K5VOSW G*\Q3PO!4IQ@6,I20ZQR AGCW!PT$%>"F'_4:83B_1$6)CYR
M7*S>O^'H[P\SEZ3D:<ZALEU?,6,,4H$U%%R5"4&8<TK]=JF)@+YE2]I1FA5:
M1]_+I-]E@(<F4AE,S^Z@$F;R7@H.H$W;3&&,@1^AFX(#0([M%%R>%)!__K.A
M\,^?J_5R_52)^NU*=%G'*:4XD49-L9R:W2#G")89)5 GG"4L$9)(]T%8%XA,
MK.\;JF!'UK9?%Y?G%+E#,ZYF8@GLITC.RAJ2A7Y):(\L] C"AV6A^[UPOT3T
M*T*-)J)?NG>^1/0KW!\DHE^[-M1-M?JB-MO*F,7OUJNG1[7Y_/MZJVJSFS5#
M)J7&:5;D"4Q502'66D'*$]N\@0ND,XH$]K(^K]";6/5T/A+XS.S(3K'G!:PL
M$XT?EW6=X/IF]W=@I9J.)KON^#]9C@%*/"VG:U"[.@2C >CK#]RCU5 $'<D[
M\^M*Q,Z!=Y0SFCMPG-K,WD GT4^=@6ZWA2F*?5G=+X9AF\%;K5Z,%=2%N8W=
MTYZ1V^O,25G5K\T/];82BUQQG8E"09*S%&)2E)!KC"!22I4J89H)K\23&WB9
M6,'\[=\^_EM;V-IYF:JVQG-K>?!3%[< [J9*9H+13\T<%,4"NSC GC.P9ZT'
MN+N^X>X.]/S%TT,10(JDHV[A9%;]%0&R8]T6XY'A<;R-^J16=?6E>WR;M'><
MP(IXQO.,")C2K(28(PTY2S-(F"ZQ*LLBHUY*SI7PQ!KM@(W&@^YK]3CBYVK^
MQ$?%UPX: M*R<#=+6J^O[!%#I4YD9P^9^H!Q+G3J=7^ $V=O%P^2#KJ#.R.$
MTU)J2#(BC;HH-:28IS!/9$$(Y87D3A4%UPA-K![VE,& M(=C8PPC!X].),G]
M5,!YH4/<.F/2>[AV(J$0YM[Q_ 3\_#L.DHWZ>,;NG\_/XR#%@:_'Y?HP<\:&
M-<7Z:64#F\9,^EFME*YL!Z-N@OD'5;\L;=:RM;/>;ZKUIG5SFVO?K^NJ,;46
MA999EC ).1<4XM(ZH8N<0E&6FB92$%TX.:%C,C6QGKN7LNK.'4VT9[VR9SKP
MW),?CDQ\MAR";XKY]BN*\G+<[*BY(?=3L$/N[-$.]/PUON.&0[#CL#TD-CQV
M\;7FEAV;\0RPF*!%,LZBL#2KX183Q&.C+NJS PR^OU<VZXYU&SAA><ZP3"$M
M%(&8T0Q2Q0O(9)HG M$\8>XS9 \>/;&RZVAYV#&'@CO8;<'B^"F2CDR(:78H
MDH<Q%BQ:F/EU[67YV5MGF1^UL [OF,^F.LOI@15U_HI;2BN;4J[7JA:;JHGU
M-SV-%PEF/+.>[03IPHY7D;#$0D)):"+2-$VRS&_VT65:$R_\EG);3 @&M+L^
MW)Z-8\8P<[-2(B'AIS/ZXLJNFX0/#(&5E:,"1BVK/$_I.]14CHI\OJ!R_);
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M:XGF9WDE<H(IAHK+!.**,TB+5,]DC*N,"Z$JY!Y_79,V=AYDQZWQW<@'*ZL
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MSEWTR-[-"(9*2]9SL!4-]*+3DVW$ T@W)S8./'XN:Y_%V2IQ!XP:P.@!>D6
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M<JCC9PR9RCDD)#<$U)CDTFMM<CC\R!\;(\QRHGL2E!Y"X!;.AAOFY[NW-HW
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MJX)'R'<5.X>@.28B?IYL#XP'!:QL8(6#MZ. X1'FQ@0E+)J]"1R_B-75V,'
M].H@T\6?KO8<A)G.-X5%DS8::GWLV\W*LNZ7/&$%9QQ*+'*(L2@AS7@%<9E@
MHD21E\BK1O14Q!01GE\T=P8&M[CL-N/\_%(;N?:A52<N7H1TV91(L<X9 9-&
M+9<-/(X_!JX,FV9OY[1I] 0V!5P?M^32A9Y@0F4Y9$SH^<6%7H&A(H<BY13K
M $)/-Z\#%&>EC#S9K$S[*;"UA>%LW.<A<IN%-QON-Q%;FY=>-GM/QT&;(LW(
M\S(FG92#9A[/R^&+0_,I;-WV&3*?TZ[CD#DEW:Q7-CZZ?UIN%FLTHUR;EY4$
MIB65IIDT@43)"BJ>4U;2)*/"B23"5_#8$WBK@GFCN\/-T!YNUL'_KG76PC1@
M.DL@T598ZYLW"_JTU)?_M_Y'43?<J']G+EL"^5^;VO>TM/.3<4VAQ,?;-T7"
M3)C<JW 'MDJ G19WH-4C9NK#S_!HJ0U'L1.G+OS .$U->-X?PC383K!/*\GU
M)36G\_N%>-O]^'55T_G;9;-N9F7!4%8H!"5'.E+/>0Z)4!RF.<]T[) @A=PW
M 1V%CNR-^AS@\TX-ZW.V?UD;3;1C:KQHM%P1=<A+C("3GQ?I(=K3 &@50*\#
ML$J MR-!Y,,K&!^JL*2%SUL5BTO5T_AA5D''L2:D%/2S[I!/T//>P"57NW![
M+_4M=&X/VFHQ'Y=&!OW199'?R(54]>ZL=L$+GJI4:(_*=(Q7T002;,_'HE29
M)KV$>IUP"5%B['BO5>G?/%=G(6@Z+MY&QLAS;==J SIU[MH#\M9;6)7:/:U.
M*_!3I]??1CD]?PLRL5:((2I,NX"\ :23]>4M8P4U$I_KGY>KEO&^KQQHVF-]
M-?]8<R.P;]PR0QCE!4\RB$3!H?Y+ BNF?T)%GN5<($QR)^\4('O\_2<K%<Q;
ML7U5ET\ XPFF0Z@W'D2>/FE?CUW54','MKAUNO1U1"/BYM41?"S\0CN!Q\/1
MMQ]X"!)7^H![#3EE_^\06X_Z?@<-$=+.0P_Y78OY+O?*!GH6?RP8UPMJ2')1
M0$RH@*RL,!09+AB7+"M*=W<[(&ADW[J3[%_M=!4C!R\:R7+?5-O6Z#VI01U!
M!JSWZ0X2!X7 3B%GT8C5-.2Z9<,-1 ;NG["9R'4K#AN+.%P?MG!]9U/E7R3?
MK.R@;UX^+,1&!YLO]F!=@M**F&V(DA-J*O\3[94R!#FC,E=<<NK7$GQ8W,B^
MJ1<%M'S]BOFM2:\ Y;;ZC&>^GX,ZLCSZP4,WNR*M$J\(FW0]Z&;X\<K/\:Y;
MVO'6=+ZW2V#>T()G$B6"0KUVTU.9ER5D#"F8EBF3G%04(^7?=?=$SLAS>"MU
M;Q,KI-GN*3YN,SB"U7Y3]YS!T>?O%:NBML,]E?(*76\OFGJ^N>WERT-)3MO-
M[/:\AN7Z(YSR B$$"ZER'?_K.5J5E5X)2%F1@B"4Y5X;_J<B1O^Z]N3E6XF^
ME*8GH+C-R=M,]?V2=E9^OFYE ('I)4.B<9>>")B8MO22@:>,I1>O#-RAH<VC
M^9_Y]GZG<[.4_ZS'7]6&U\/\P_U"'/YB[\KM)D.)\XHKS&%&B)ZE):60)0I!
MI:=O254FD]RK7#6*5B-/;/T(]-/5BXXVDV48#[4>=_9/6VK3J7-G]RU66VV[
MRZ3^I;[G1=*5[S90E$?FYD,F?Q">25D+I?D3O-M'?*<2:"\QC^#HE_MWC+-S
M%!.[6%M)472:=F\I)HPGFTU1!_=SP4+6LW>+M5[RO+54J;:BLN61W&NG/"L1
M1@G.3,A35/J/Q+3A$R4L15YE2594/'<Z(NHF;F2GV2H 6@W:TMV>]72_7[J;
M0W0$<-C3Q8?%SX7=BHBS6_(S](R_:23_EV_+[_^J!VI=C?YAYV$<AY_$=?B9
MVOL$S[L"-CJVJZ8MY?S/<DWK>=/RFA.950(1!EEJ5C@\%Y"D#$%!J%!2EDE2
MNK?9')8U63IBU]J@$^]'">\"F\/V1SPP0K,4$^#@L1$2#X^PO9!;</';&'&S
M='!OY,H0TVV/N-ERL$/B>,MM+!COERM9?UNTW31.:G1F"<E0DFFW5B2*05RP
M E8IR:"JTI02GO&T*&<+VR53?/6GNAB6[O0ND_9=/M'!_7UN=0ACK[@"G]M"
M+2(:MS%/= J KK7-V4*]^(P2;F9'YHNX(O15V"#<@+C$]>!X=T#H<THV^:9>
M+)]JP[RX7M=<_K(4<MYMZ6<XR45F>+$IPQ!35IHE3P$3IM),)HED5>$<"/E(
M'CDLZ@6#>2L9/!G1'A& %XH.<=%8V/CYCATA[%:-.[#%JM,$6%5"BD>\0/,(
MHL8"+RRD\@ Q4F@58O]@H.4UX'1A5XB=!T%8T !A(=DG:FJG^_8"."VSBBA(
M4W.00I0YK I&89D(Q!!-6%51GZS\_N C>\JOAI,7?'AZVBST>OQ-O6PS(Z97
M@Q[L__RO*D7EOQM6JYK7GAO=!Q"Y!5>AAONYP5;*=0_G'22=4S]2*'0P]*0!
MSSFCCL.:L]<$EH_0>F7FL7SSLOWQ_ZGE2@_T^/)1?M>VFFH)R=*B0%3"/"%<
M1RXJ@4R4)EF;YKS +.%^W7G<Q(Z=S=&2@14-MK+MCLJO]W_W+#)Q0]%M5L;'
MQC.Y,P!+_%(4+V-C5::X"9VV4,4+B).Z%;^[_7Q%LUK/WBX7S7)>"_N]M]08
M/R^?:+V89661LM3PWN<X@3C)<DB)JB"2"2LDHSEWZ_HY)&1D/W @MN5:<9O^
M@\ ,3_98YOI-[3.6@M];H1'FM(M-0S-8W[\W>_7?=C-W<.A)YJF+<?VL=+HV
MI ]%O:Z_M1&WS8PSPE6.F0Y_N2ST5QD)2#/]D4[37!!>$H(]^FP=#3[RG-M)
M"]@P.,;!(2-P@W5^4RRJ83Y=(\(-#&P3L148B]7@@@G#O1^.[IFPV<-Y;0^[
M.URX)BQ6_VRV.!92O*.K1;WX9CAI-T\;RZG4K1AG)*T01RF&5:E,#^ZTU%]C
MDL(L3U29%5F9,Z_NN]=%CNPG]@0"$;(L=@#-+2R/"X6?4^EE@UXX^&D?F$Y^
MQ/T'=V,CA>0. B<-Q]T!. [%/>X<H1'WKJC+7G;_)UV)MG%LR2BKLHS!-*<Z
M6,"5=@VI7L)+G(NT2'*2%%X5YV%JC.PN_J[EFL;3EFUN6Q9I>W4#DW+3$^?S
ME]^:OXW4L_LR^FX^9GQ,_?R.2T_OO?+3]G*K6/2VO[=!,T7;[\M*_'7:@%\%
MRJLM^/71PFDS=P=PWE,N6^*[656H5!9Y @M<YE"O?!ADN5(09P1SG**<4*_,
M_R5!(WNI3QI(7C\;HK!A.D8_=-Q\3 R;_;R(I:;<)Z$T0D=AHARR*R+SY%DQ
MDS--#AE[CEER\/JPB7I 8[T[-2.R)&&L@()B/3>K-($5*264-)&X4%A@MWK/
M02ECYP0[JBYJ97N>9#D/B]OTO-E8O[EYQ/@^RH&109,B3<OS,B:=DX-F'D_(
MX8O#9J/M);D["97I\#XI%-5?1S,-"T$@(_J+6:(,E51@2C.O@/]P^+'S@U:8
MR^OH H7;U LWT#-%Z&R;]U0[;T*D.78T^*23Z[QAQ[/JPE6!1TB73\_+A3D0
M]:!.FD9M7RV<,[U^S@G,4Z9G&3,\"TE.8<8$%9)F:4&]*%.<I(X\^;9%KVOZ
M(^P+Z(:=V[2,CHC?;-V)-UF%,YWHQCEDZ6-TK$.43C*G/23I \/)(4BOFT,/
M.=X+H=^>QAY$>%A]6BV_Z\6=G"F!9(I0!6F>5Q"G.(<,T0RBBB+&%$WRW(E_
MY9J@D5U!=XROD]TSUBY7H)?O>Z3Q ES#KB F"'ZS/]S^@ .,P\;=<'3QPL 3
M'UH<-N_TN.*5ZV_A2Y*'?==[ML>?-W+&"UIE2&:0L\P4Z6<$4DD5Y%P(C C5
MDYK.UJ:.T^V#?DV@UP3>BG5^@=N*4[59;U82/-6+^FGS!.9&&4\>7&< W;[J
M,6'QF]*=9&!%WVU)"U_NP'H)F*%GK45LKJ7K=D8E71H0]PKL2]>-/T_#Y'!?
MX X:?Y1B,Y</JFNTW;S7JK_[H;^/"SI_NVG6RR?]J;3TW(MO'TV+[;Y5K"V[
MJ81"B"20%CK:Q[+4/^$\A66"M=\@"I&T]-I)NTF=D0. 7CD3_/;J ?.D0:\@
MV&K8,=DOOD&KY#8^]JF#B?2,'/?;)D/><]]M?-#]-^"B8!5K(^XV9:;=D(L"
MW,G&7)Q1PQSHKW)M.&-L2":D>//R6V/:5#T\2T.KO?AVS]?U=\MUN5WKIYRH
M0N 4$BF$=IIY#JG*$12%2 N%&$\RKTT!?Q5&=I1;R8!N17MF30)@=?-SXX+E
MY]NT+BU/5:\-8"_@)Z,0J!=_ SL8=TJ-DF$)QR22#PM08%*_%0[0L:^Z8:2;
M6N+^@ZY6=+%^6'VNOSVNN[K\-$%YGA($2Y*94PLYA8S@ J*2,"G2LA05"6B,
M>T[6V'N4?:O83K9)2UCIUVOZO5%S3-7&P<(S01L.0VCCW"$#X[;//2OI-9KH
M#IE\H97NX"TQ*H/>[EK([MIF?EK57*)9BG&:(L1@GN4ZWF!,1QXJ15"I/,EQ
MF2OM!L)+A08DCSWI=RUUGXT\6\DH3$\3O130#K6M:O0L:G2'U<T/C *6GU<X
M*3K:T^)NKU$NL(J,58;D8/HH=4E#<E^Q4,D!CN'*)9<! AD&5DLNI;"KJ%_H
MNJ/J_[22?9;4])&D\[GV:_??:3TWJZCWR]47.I<[9O\99JG$*)50E(D.+G!9
M0FJ(H1@KJHPQO<[)O,Y?1-%J9(^TT\M\A)_HZ@^Y-GH 8:9@LU7C#M!>1:#T
M-[JAOI3A<9Z1FPN;''D_]]:KUV:%=@K>@3T5;6K(*MEN7>O'\67O<6SUAOIQ
MP"]#C\.?FR$F?+%(':+H-"T;1$P83V@DH@X><)ZURUSUY.^?]+O^2!NY;<KV
M2>J7?[&FW^2#>ML>HJF_R_ZR5;\A\%D^=[^R7X)9@4F5)VD!<9:95%-!("$9
MAER4DI5)FE:Y>^OR<70<V25_-CSMIDJE%]K&BMH#:Y]@HD2CLL>YU)$>U+ G
M_HO [^>7.WW!MG%$K\JN):3M"-DI;?SR3NWMQ:MMCTASOF;[$(=#U<D>F\>I
MY-=_?&&'FU_Q,?J=F1X7X,&CUR.)GNX$][C8'1P$'UF4/Y_+;OM(KZ.$(<,4
M+3OFEE#7[A-]E3_6;S1@?\S2@E8IX@J6YB@'+C&&59%2R&7%J4!56B5.]6PA
MPB?<XO[P]$SYVL[G1WV-!/7"3-WERFY)=-5@RP7X;4$WHK8]-[9$'_8$9&>
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MP%*E19YF/.'"O0K(4>C8J;BWP)Q> 4:@9[[*!3'''%UD' )2=T8#H%4 O0Y
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M)=R+1LU!YD3E,I\^_+_;]N'@7H@VYOIUZ=MYP 5%-P\5&1L_9[2%HI,>DPC
MV:QHI_ZO2YSXB+\S!*?G^=UO#7,#[9)/VF#JTZK6J[]G.N\XK)J9JF1>9D3
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MM$6Z.LR4W9!<;3IJ@N1\6X W_-QRN7ZBJ_6+H7EI^E9+W;HI(4G%"\9A4>I
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MN^'L=_)#M2 +5I'Y9UV%JJN!J5) L=@L1464Z;'-:<13B*2*IFB:2HA0FJM
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M_]I4VM7:/\.=97&44AY3R"41$,4LA5BJL#:B(LT99@@)[M &]*)@HR_JU:U
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M_D']KIZ1 D4R*C#D2:Y"*IE3B"7F$".6)U%!B;J7"4>-2@GM&G5R02NXJ_D
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M[P_5@BR8\E"WA0+OQ)I4\WK;AS,B.4Y)F4%:H@*B.)*P3(H<<J&\<)3PS'!
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MA<!6(_!E(A3=QWMX1M/;Q(\K4;UJ!(@%)C9304QN^VJ#0BQL'IL=8G,;QYD
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M*B?*EV+!TQ_T'+^!LH /M&U;O [4M!RJ[.OAF&UYO ;DUE2ZQ7FHX@W8*ME
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M7\A:?+W[\*7+N2 HRGF&,E@DRH5&C B()<FA% PCP6C$,_.^@H9"0Q^&MUJ
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MZ)2E19>:!BZ?KR1-+G&L0REU6T<Q=U(HWLJ7V_L<Q@6EB $">0$0+A'(>8$
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M#Q FHS?*,* $58!6(L4ES&)LUL=QU$)@85,FH]9F)+]K<:1KW7UH!,PR.7#
MCL$CW+D^VRG+B;O2GFL:Y,!3RUS(.1Z[)T1&O/5\4WM[)COES<7DR,&%RV9(
MCN$>I$F.?M#G&8W?-IOR^VJ]EE'?>6[!^?M[EE>4T)B#-(\S@-)2@ )+%<IQ
M68F\2AE-"V^G-BR &7V/9Y_C>%N7,@K6:3MKG;:S.J3M,(W#Q^D.F_MAM^8,
M2Z_G$R"#E*C0ISX<^ AZ#L0&S__@9(@#?69G15P&=@FSI/--;4SYB4]=MZ:N
M+^&-:/Z_E6S<20%9_R5VN[5^C'=/8P)QACC@*.$ <<9 09%<E4JUQ$6>)"5G
MYK&8*XS  =N;9JVIRAI_K^7EGU=?E?PUS<CD7UGT[T:^C[Y)*"HSM-P+U<%X
MK4!&VQYE6].8V)0T=K\S)G'@$GQ;!HLGD/J6;T=-,I]WN%Y$"EFDH44';(N0
M:Q-Z+D&R8WP:CFS+@'8N1]-1K_/H"X;&<QDXC9]GC^98'?-1N^UR+<]RRHEJ
M;\%DU(Q*AN2OA*I354!<DB*&%!O]5)@8"[V"?WSB6(; DVR91;>^./ BT@&Z
M6YCXYZLHY92I9<M/&C@]*#1I<LW8I#Z^7W?RU:LGW5_D/ZHQ\*LG_P%02P,$
M%     @ ]H-S6'H^$';:20$ G.0. !4   !I8G)X+3(P,C,Q,C,Q7W!R92YX
M;6SDO5ES6TF2+OC>OR(GYW6\,O:EK;NO*;64Z;8R*9.47;?G!1:+AX0I$- %
M0*54OWX\#KB .PC$P3FL:V6EI$@*X<L7'NX>'N[_]C^^G\Y^^H;+U70Q__>?
M^5_8SS_A/"WR=/[YWW_^X],;<#__C__XEW_YM_\+X'_]^N'=3Z\6Z>P4Y^N?
M7BXQK#'_].=T_>6G]1?\Z6^+Y=^GW\)/[V=A71;+4X#_Z/[9R\77'\OIYR_K
MGP03ZN+7+GZZ_%=>LE7!&&"8/"@;)009!%C+C ^<!2WX__/Y7RU&5 H%Q.(=
M*%,XN&@9E)R3B*&(&&/WH;/I_.__6O^(884_$7OS5??7?__YRWK]]5]_^>7/
M/__\R_>XG/UEL?S\BV!,_G+QVS^?__KW6[__I^Q^FWOO?^E^>OFKJ^E=OT@?
MRW_Y7[^]^YB^X&F Z7RU#O-4%UA-_W75??/=(H5U)_5'Z?KIWM^H?X.+7X/Z
M+> ")/_+]U7^^3_^Y:>?-N)8+F;X <M/];]_?'A[;<GIZ>G9?+K^$:>+OZ3%
MZ2_U=WYYN2!,O ^?*\7=)ZQ_?,5__WDU/?TZN_S>ER66?_]Y&I??:64AN=BL
M^W]?_>-?KDCXNL05X:9C^1U]X_PSZFI[DX/?USC/N.'T8J'9(EW[I5F5\V)Y
M\2]G(>*L^^XDXW32??*+N%HO0UI/3);&<(F 5@=0KB X:Q.([$7@JDB-YCKW
ME?(5D=ZI987I+Y\7WWZA#_ZE2J1^T8FF$\NMY3;BV8_NBWWXB7YWPI-/3)<"
MB"P3V<J#=ZR TTY9DXV)# \B>WNUZU1OJ_7%,OVT6&9<DB&Y6"XLTRT57X?P
M^6_\\C4LZ8,@?9G.\L6_+LO%:0M=K1<-)+=1"Y'[\T_$=<'E$O.[C5;N9:[C
MC*B.BQ5VO]M"YR_F\[,P^X!?%\OUA.F,UJ(#9E("Q;, SSD94FY)#,%:R5@3
MW6^ONA,&Q/@QL+<D]\;"FH[:=DAXC\OI(K^>YU=T%D],"8YS@U <0U!9TV&9
M783(DTTL&J:";@*%:\ONA 4Y?BSL+\N!P?#R;%DE]6:Z2F'VWQB6%SP()8**
M9-),P"H1'<'Y&"!+5P0SPF<5#CO-[EEY)TBH\4*BB41'8B(^+<-\-:VR/S=S
MT1@6/5DX9U(!Y:.#H#R=@$8GQZU7] MMG(4;*^^$"CU>5#21Z,"H>#U?DV_]
M9CK#W\].(RXG2N00+"(8G14H[1)%7Q16R50BMR;)),1!:+BYXDXH,.-%P4$2
M'(7V/^#G:17"?/U[.,6)E3P6+CQDE)'B;V4A6I(&9XGX<D%SP1L@X/JJ.Z'
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M^D?7>2MTU[:KFD&]^LF+[]/5)"OO@[ (@OXD(7F$R N#*+6WS"F?_$.7Y?L
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M\L=JLP\FJ$N,:+$Z^<1,1DN2BJY.*9 D0O5(/^^]HOB'"!IF:ET/!J>=V,>
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MHED=&"IE5LQ)UKH;PVZ4#6NI^@%8#SH9 =+>GGX-T^4FR+C9E?UV2W:+6>;
M+# 3>:W#5[2-E  F'!8?C,W-V\@^B<!A4TK]X*X_#8T ?K=$-B&7(8L8%"0L
M#%2P%'1J^BI;SIFT7,7F$SIO$3%L'JD?&!TFZ1$4%%PR<%5<.'&:UTZ4!E*L
M,ZT5'?#>!PF<%96"45:DYF]$;Y,QK-7IU2_?4]8C@,OOB_GB.A<7@]8N!"2L
MT\5E#T%DPG_B#+QQ 3AZ%B1M,Q];@^=1HH:U/'U J:T>1G!D_35,YW5#G,S?
MSK_A:O-B<9*9\,(C^7F%U9[@+D,PFLY=+@,OQ?50[WDG(<.&=HV5O6@M^1'
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M-% L@\"RT*Z@0::;EW[>1<A(4'.XJF]6?QXL]1$8H,T L=^PUG--=+(E<!9
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M^EH#C+=X@-FCSKKPR3OI= !?W\$IZ^@K+A&,D5RIX%#%]E5;QY]U@<$GG5@
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MCA5 6?OM*UFKFR4%(R5ZGK6BF*1UW/ET*D?B@N^)BYL#-?M5T@A@N%42;8)
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MK)$J<F^E:=V[[0%R=JM4?6Y9_%;R'SX;=M[$Y187.>K(74S H\J@,#N(7DA
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M3F==>N &KU8(:7VTX)-4H%B@0$Y'"4ZGP.EO6;/69_XA] XS"^:HAKAG)8X
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MG-82E.09/+DP0(1[J:/$/:O/#X#@ R+V@]7+"KF?QND.H$*@QV7-P? <36&
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MM6#QRX_;/UE--=):T!U:!,CHZ\ 0E2 PAN"2%[EVTHJ^=:[U_M3UB+4C /'
M&AI$.IWA;C.0)D6;BG .1"9?5@4FB%%T0)%)C=E9[W+K^,%#*L9M"C"4O)^
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M.@/ )AN%LJKU^]H>9(T],V00_#R6\M12/!THU5_")5T(^.D+XO)=_>TJL1J
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MF#9T(!6SX*S/D*55="AM2*IU:443PL=5W=V@>  I]W_M[MQT+;V\V;3+HOC
M(D0RR,F^3K1IGR7DY$V17MG<O#57$\+''>_4/[2/E_*ITZ ' ?<NB^E"1JV5
MJH7FL=8)ZCI'5C$/1L3 K,(H;1D8O[MH&W>(TW@0;2*K9A?LF9+P;@[BW3.(
MB]GT+AM>7X;%8E(FF,.#U+7)]/5LNIQ,KV97JYX*'V:+R>H]K6WNWEF('33E
M[_SL/G^FH)2:*6,"Z!3HN"@RM>D !7"(@BNAO+_?HO>GR12\*]2M6/ZXJM'
M]V7[]\6%$#$KNCT@I#HM2]8^A/0E")XQT/^T\:WS[IL0_F*R#0_!X&'9AD.(
MN .K?)]XI8\Z:B<=R)J'KI(LX&WQ('E6&$)6,K=N7MHJ W:PD$<7F#Q</!T@
M;M>CM-/9^^P8I"(4;2.(FBQC 84M-F)P:HA1D4=GF8R:_WJ0R/?,,CF$_QW
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M.QIYM0G)M%"\!$ OD#:A(CAC&*!AV7#M;;[?B.#I&^'!"N,:)0->"Z?Q<FQ
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MGN!SNKR?*:PZ@OD=0.BID3**,U%,,& #XZ!J>78(S(',5B=IG&&B>09^KS.
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M^W+KQEZ=(<5=MI(.3:F5!4HE"3$80W\H)W24THO6A<6/$C).=>.XJNUTB70
MJ]M\6D</PLUW;C<WVYP:F>A><9Q#B@XWAY&S @RSXIR3GYY;=R,\D,21!R&<
M#HK[L<@!)32V[GL]FWU;Y?5_QQW'>.O-"\;UML.*"8DGSVE'3H&2(=:'5@?"
M,[2F*&]#V4LE'K/ZN.@:% NS<PKF92'O%7V1ZU\V.XW:1I,3\=7&!,I&#K'H
M *S8Y+(S4IL\  3OD3&B/SD\/HY'XRG"ZD CK^/BUX'R=_4?;)MQ%RL3PXC
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M-VCSVPL41[?Y#;=0[TOK5_+7M^]?5S[U5__Q]F9K7E=64?B:@J^=.;J 8B:
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M.^*_VA'_Y_DZG2_7ERN\J;A)5EL,=%:G[#(HO2&S90JL%B[R+"@6;$T(L)>
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M.'E.J$G<9S0"3U,#3 !1MPKZG<RR^H8SA9*C% )X"#6 JZ=OT@RBQ\!==+4
MLS&"?A!B$CE2&\0<I^ )(.1]^+YI)WFS7&V&?]QM7"^JUBW1 BBQ1U"F&/ F
M<L@^1IZEC\&V]C9/B-.GHW 4U+12^@3P\U#H_^K+\I)^_3.03?(;4N7&=V[H
M2V<ZAQ!C2)!YG4U:R'<&0U&:B1HM$Z50##>:_QDDXB"<N1>!LS&-TSLU>VAM
M;Q?TPW%]L>7'FC'-K=>495H52'>9T6G-*B,;_0MAA E.#+O9'?"Q0;#QDX;-
M*'J=@(_Z=;Y8KN87WZ^7<7,W?LNC]M/W]QL]SYA"+QU&4I22M7])@L?((*B
MU@=NBVP]^V</\8;=+[))HVQLJTP0<#.!V?-:N8W:E]J?E,#9C."X$2AT8:ZT
M[CS=E6$8=*9]-]U$OR^38>&?B[1<7+,+O+]<I<]AC7=(3:Y8!M;W%WDTQ\+0
MKYZ 9>$@!73A6> \2F5J^9/PAL!H97UWRX"^*%$<FF1:#_@ZZ4C?=\O%IX^X
M^G)MA-N/7[T[.D;_FWD 5F,"I7,!7R0CJ2V&+)57[4/\IT5Z2:0-^Z#GAWB_
MH64F<(P^OIR?OK\.%_AIN?I^5NIQ<OTW\J:N)1C/1)09DLVT3,R1CA8Z:113
MENG 31I6U=4$@$^*VA>83>$R&(KM;#=IB#ZRR.OJRQ02EUZ"X3G0XE@$)VN/
MAT@\&69YS*VOU@X4=:H0;0BCP=!M9]/>MR>O__'K^Y_"1?J,UP. +)<9>>&
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M**L\Q& =V(04^S-:CVW=QON4/'UHYD8^@XY2^B0@],B6^&VY2-LE!2TC1V9
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M106:U_MA%BAW];S4%E_A>+32F-;'U/'TM"=G(#T 1^W5/P$L/45ZB,4ZA:&
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M3@R^SZ[X>HF;(5;*@K<&:8D4>D:E/##-0W3%1E^&':Z'?7^2%5:-@3B&*::
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M$P6Y'1DKFUW!UD_EHQ#2>9?X*91O.\&?41'!S:]_)SG-U^OEZMLV^-*P>&#
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M4J;MRQ*-DU99.0@.MSYVFL#C"X'@> 9.+?J?R#C_]GX9\EZ?L:1(BR6RG((
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MIW>:7GR07)]/+SZ$R1W I(X4>%?>K.@H?<+KJ7RD?GVTJC9-CA84DEIVT05
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M>>M*RB>V,VWGBK$NL5;\[Q=*NQ/'L)04H@>N:V?IH V$VH_5BI*<<C*&W'J
MUI,;FE8M-1/[,#@=(8.I7:UM"6#X.M^$BZN_+A*N/FSP2ZT+_/77'VN8G;[_
MMV6<7R!]O4\1<YR[6")(PXAYGB=P*C+@1I#1D&V6=U,EGJJV/'C]+E%UC/3O
M56..*XH>T/:/Y>J/]??M2Q^2+SZ#"'6J$_V7CF%-&PM9,YV]-V98MO#]SYXV
MN#,B2DY@83<(V.W=J&"3(L)]0K6;K,!%AA!*RC$F'V(\3/P]!''&EOT1S.M&
M\->XW1&1K+,H#*NCTVN0.I/+J:0!$;T*,@6I[@9O!BN 'M)Q7TP-','.?JW9
M]0_?;O[DJF2911N8)UZ5&JDLPD*TD@PV9[60V3)YMZYD+-/V@=U-VT[MA=VF
M4Z73&>[VY<XFZ!!4!,Q8*Y&9!.\M@Q2L\T%9[V3KB=SW=]&E97NRO)^ U1',
MGSB#^$TIVZZ6F']>;.:;;]<I049:3+1YHVIWUZ!(\;($,3IR)E52\FZ3YJ-2
MB1]>O1_8'"//95/F=J!==H]X6V7\ZW572X52>>8MV&PT*&9JIGTHX!)JYK)R
M(HW4EOGV1H:!A9W;974ZTWM SO++EUHL3#1<C5IZ<[GYO%S-_R_F68@U9B4T
M<%L/01TJZ7G,( 7FPC/9?;QU;.^)[7212G.*L.^]-[3A?%\@(IW\;K6M/<_;
MIKB_XVI+W4R[G+G4$AAW9==W10A&7T;T0G'M2NNWSP';ZB(?9QQ0-9%$!^#Z
M?;_NPT?%A*"3LQ&8=)EN:ATA*M0@@]:.>;P?SVM0N?W4CKI(YVD(J8;\[P!-
M][3NU6C!&1J79)02>*T\5ZS6H">NR> 346B;>2K-9XH^O)4NAC:-><\=P?$>
M@7-SYD8NY'8(<C=TS)8. :-#P(DT8UV41FGI[(B7V[W]=#%[:4P('<O[#G#T
M<;4=9/%M2\V.L"U-,QE+"%$%D"G2O<PD Y\]'0U']S+G4;+8.B_CT<UT,9BI
M(8+:<'WJ-XV_X>H3KG[^*WVN16COJSQFS!JMB\Z08JT,B[CM9QB ">%-<LI8
MO-.X[9'GC <^O(LA2@U0T(1Y'>B.+2NNKL^?+K=%@KB:+_,5DG_#?VY_M)YY
MZ1E3WH%EU223=19=*@:LMR89P9*0K?L2#]M9%U.*&FJ5$>31"\IN]$Z]*D3]
M;O*_^;*\7&SX3 H60ZJ-?%&7JZ$YD5M'7R:AHV<66>M2SH%;ZV+64&N<-99(
M?T#+;Q;Y/6[FJX=.$_'/D7X.&K3SM6ZDM@NC_X(/+@<,EEG>VL0^9'\3Q[A'
MQUP[X9P-\*Z& G.NS571K+"F#E&DTU6(ARPZ*:V57)?6E<8';&\8[,XH*CZ6
M:/I#W4Z+O\?Z?DF4?5?GWW]GK]AYXK$0.2 $YZ"XX1 "9R 1.2NU?9(86?D=
ML-MAF#RCH/H+"6YJ[_)&(\==TZTWGSZM\%/8X/>F)/.$,Q=E84$S,)G1N3/%
M0Z#O0-+*<$O>M-'#7,ZA*PY#U!G$U,?C<P_Z[3M=/RX7ZSE)93^*%>=_8GZW
MN)'B,Y-1^YR3@YB*)?9Y0R=#:L@"41BON%*M ^X';7 8YLXH#C^>>*967#?"
MPU>#6/\,\XN:WO'+<O7+Y>9RA=>.>JUQF*$HO&S;]Y=<V_<+K.?*0#:8563<
M>CUL=->!"P^#U!G$Y4?G^M2((BLS5=E\JB>&SLWZS2?ZLE(\7Z_K\2"GQB=I
M"W!3\Z@Q!CH>D8,Q)4OCB\YJ&(2>6VD89LX@$M^>KQU<>60*)L2\_H48MP?Z
MNW+C9,QT2,*):$$846?E,7?5FQH=,FZ8"4RT?M1Y=E/#,'4&<?UQQ- !KF[V
M5+^L":GTQ8VW\[>WKFK+(JMS%J#F[]3!P1GHZA;UX+ 06#%>MLZ .61_P]!V
M3E'_L833 ? >[ 9T326FR]5\,\?UC^'B O,/W_:]?7:_6#O.2<S)!V JUE$.
M0D,,*(!9'J-Q1BO7^NGIQ"T/@^<9/1:\I A[1>S/?Y&A,:^AFGF]">[2R&?D
MT'!NM =K4YU5PS@$-&1V,+0Y)331M;Z6C]KHL/S4,WI6&%]<'6#RQ@VQ)>DZ
M]3:Q+)+(9'?4_D9*EPB!/!\""X]DY@8IQKRJ;^UE&++.Z>6@!=,[ ,]/NV7W
ML< ?EVO2RIQELEI3@:1E'9^ !IS)#&STVKDB.6_^_/G@1H;!YHR"^Z>SNP/,
M_!Z^;9N4[SBS]X&N:&$Q:.=Y!,UKHBVGDQ!,(B\HI,(RPRC<H)DCA[B@3^QG
M&(+.()C?G/E31[UNCCG->5Y%$B[VT[>N1F_-))V"S"6K/4!S/1@!@A U79*;
MK)$S+8;U3!ZPV#"DG$$(?A3N=J!V;EZY-R)[[_ZYH"4^S[^^*;3636\XQ9@T
M>@/2%:*JV ">J0!11VF,<<+)UDT,#]WC,-"=09#^180TM<JJ?2 _[OI _N=J
MN5Z_7:2+RUH7\":EU38:0ROA>C/SR'PP6(NY"ZE?Z24$6Q)H89C*R4D5AO5]
M&KSD,"2=2^A^'$[WH,2>2N*]:@I:GR9J//FZ0>CW,,HL60P6<P$9J\JN>>01
M70)G,VHNB5HA6JNTDW8\#)9G%/U_00%V -=Z_MXNUIO5Y9?MT]DU2=\IW;J_
MO$[<8YR5#$6)^H0?.'B>$$JJE9F9G.'<>B;8X,T- ^$9/0J,(Y;N\/;W1?BR
M),+^+YVU^3K5)+>90UW'.3A [^J4&49LLT(#,DR.# =E6>L,V6<W-0Q?9Q35
M;RN&3G#U_6SL#DRU(O8TWGQ3X[.@5?2E9B%%43MB9*).D(T1K.*&!6:\;=TL
MZ[ =#BO[/Z-(_8@"Z@!^-USP,">B=HUP9[7JL^BD $,MH>&:C%?.1$4'9]D[
MIV3KM,1'MC(,4&<4H&_!\F;(^8]_O\=6HO*/[8^V/ZG_ZCV6_U'__/O[M[<^
M?_[ER^5BOOD6Y\M_2\LO5RM<-9>J-0L_+K]\17*GM[*Z)OKMHBQ77[;?_ DW
M87YQFZ;U_,O7BSOVV'T/]/!%_OT[27>)W:UU#S9CD(=_;7"1,?_/$V\-NNTN
MENO+U55^S_4^=AWAMC'7K5Z*=:?[R.R;2#HKI,W,>"D$VT;T/4$-D9"+=%L*
M961@C 4RQUK?(B?M^&3G]GOOL[K&??G=F'#ZP[?OO[/;QYM_AE6^ZI1&!U%X
M5=MU<(O$/XG@ZCCODK<VJ\HQM7XQ;[;Y:5N'O2!F[[G&DXB_@^O]]XNP^"U\
MN1HMY+G(EKPM0.5K'87P=%^1FV^("BMY\B$/ZI1YR /8C?6G1=]$$+C[1G:L
M/#K"TJ[3J)$BEN C..;K*&8R7$)4!6(B>Z5$X_%N(+D9FGIHV7N\)!^!Q!%L
MG?K5X8U@7-7][X=#91,5"@DZ:U-5M ''70 GI4C9.IO3L$?1.Q_<AZ2/$="R
M$;>FEO1V, I>7'S\Y_+CY^7E.BQJ1?(O\[)!7-R@"2T19*2%5+/*5< $OKZ>
ME6AM5M8CXC $#%QPVKZ5K9 Q!G>G1LP-6G:$_/Q_+LF9>KNH3Z_S/_$&729*
MKH5RH$6H_3J<!2>4 A%1R:@Q!_&L1WCHHM.VIVR%G+&XW(&Y\</E>K[ ]?I-
M(HK6\^OY809#R=9*")+5-,9 YE?M2VY51A$TTRRT[L;\R%:F53Y]&+0MI-0I
MV.I?5[@_HJIH;F-FQ)I:MJG10?"&CJC.49/U9S&U?M]^=E/3VD5-1#\ 3L?+
M8>H[<'^ODS;^M_U !1,R9T8#D9% 9:W!8=0@2F$AUWJ3N^&C9PRD[Y_='QI.
MD-Q#YM&1;.Q O5PIV_V(Y^*XI-L>(7 Z)0IUAI"D ^X88UQHEUWK-[Q;&YC6
M].GCWCI>(AW Z7C&?2=[D>_8H-F09U'GV;D2R;DHF8Y4,;6+%-9V^"Q&W3I-
M9@PZIM6")\#J;LAZ:AEW@/.?OWR]6'[#JP8:5ZGA^]A),=&9^NJZ#;AQ8FK@
M= GH3-< JIKIT3KX^.AF)HYK3XZ3Y1A"ZP!][W&]6<W39C?QX>^+^6;]_L/?
M=\1D7;AQ=31-MN2R%U>;[D4/ABEGM.&9B=9/J$]N:&)GM#<4MA/>U$[$O@IX
MM_406>:N:(@.R8IVPH&/)9 A[#'9++T>.+;U]N=.;!/V I]3.=Z!VOHA7-2R
MNP^?$3>_UM_>^^4"R=RPA8'F,M7VV\2/C!PT!OH!>50L-@^</;*7:6>[].&!
M-)%3IWC;G4#/F="UX:>-IE[XOM )U )\2EPP%9P.K5V*QW<S<7BDB;0'0.@(
MUG< HD=R(G<:6'+&LQ$1,C=TS 36,8#D3&46N?#D2)7F.'IR0_U!Z1BI#TM+
M/4($'>#I@('*4MEM7C:$',E)SPHA\D \DT$[K;7)IG4M;N/QYJ,5X?9Q48XD
MR\Y0NCO!*3%4BEM(2MHZB4= M"* $#I[:2)Z;-W?Y(R'H1\D[^>'H1_"_*G=
MPOHH\H_EZH^]EY+1NU(3B4C?UQQ9LB-B49Z,"=+;.9('<[?^]HF'I1L?W \6
MCA'2W6>D8SG6@;+X+UQO:I5YQ7WT5HH<& 2&U6@,MCY_V1K.(.:DD)-M79US
M8_EIA^+U<2D=*XU^@+0[3F03>K%MZ924(,..V.%5BA"S]MF'HEQIG==P:P/3
MZI>CQ?@P'([@:0> >.0<;0\*G24Z;^\6N$\B,S(JXQ@8KW2=<.3I[B7U:5Q)
MUDJ/^+UEPKBOA ]MKPLP'0."88]_)TOD+,#V\9_+?;YK0,XP.Y R>U!DZH&O
M[8-1^:2L8RJ[YCU%AF]OVA>7EP3;<1+I%VS?+83'#(1?KRM]@]"!!?(N;/!T
M*_#HB+/1@-;>>^6]L^7%TR*>W?6T VO[L-!>6/:]H#T^3W&\2_'5*_VZJA3,
MMWNYS[BQP0HE@9A/(E!6092!0_)&TR>).A]G#/PWIJ/S)(W&6'SH*$P)C%X.
MQS$BV!=4[-M]K-]M/N/JX^>PV''G/[>/Q6\75^VV9E&SZ&KORA)UC93;!)%S
M8A.7J)B1/-G65;8O15OG.28O<(AZ ] Y'ZS;^N3FV*PM0V:,\QBR"Y *%S5_
M(P!9N0YRY()S%KBX6Q4VW4%ZAI;.LVLZ/3@M =+!0;E.C,35G_/Z?OL06WZK
M_:7J;;OEP/KC<A,N;OZ\=LGX;;GYW[AYCVGY:5%;G]W(M%S/6)),*O($L[":
M/+1:Y<>U 6,T=][:Y'SK4_,BA$V<,C3M$>H/.J_Y/%W=PZ1F=M^JO\=G3#J,
M+GM(F57YJ02.80"6!'I9@BVA=3#J92F<.-?@E9ZPT\'4P5$[6C@[U;(?;'1M
MY&Y9]W:Q6<T7ZWFZ&F.?7#$N;<==&N))00FA9 G1>2\E.97!C!)I&)FNB5]+
MS]3V&PLX'1RFFU,Z;]Z_>UKSS"NEF921#%M''F 6 J(/'@1'[GD)(2G9^"0\
MNZF)0\K3PKBMR#K X*GG\BHB^&:1?_[K*]8JFX_+^JT=/ZJ7=N6\S4PHC#N9
M(?-:A*&E "=< 1^982QX5*KUT*67HFW0B1BM=?N9*_91 '3TP?H35W'9NUOR
M_9.N_M'=,.*LH.!6%%:'RM-_:C^Z6%0&*WUA@DQ.;UH7^$Q&[*##-UI?^]?J
MK#2%6"_7W#$/7\_&[-]\^K3"3V&#MVW1*[4V$\)IF86FZU_6]N!.@ ])0)$J
M:V,CB;=YD^!I2!WVKCI:N_\>;L'.\77.QW#[GUVFT]4,Y.^CVV99F=KYV8 O
M+H"JV>!.&@1/;A\O421K6B=!CT+(L"/TW[D)8V&CEP/R F_+_\#**+K=R> E
M-FU_^!,IF5_"?'452\&HD[<I 5>L3AAW$J(H!:3C!H/2)MC6H8=NB!]V$/\[
MOZ$G#$Y=AG4\UTAQ?:FU33_@ LM\\V;S ">2Y.B5+4 DQZM6BI[I#,G*(K-7
M+L4[V?:/31D><YO#SLUK2V_H3/P=W&(_S?^<9USD6DHC.+,B$Q)++:VS!J)S
M""X&GFTI);K63SG7BP]#XVO-%#A.!AV 9S=G:]=[Y]UJ:]*]N]RL-V%1I^O.
MI#5.Y]KRG*,$Y0TGG\<K$$&H$(T3V/Q1Y+D]#8/::WTR;RJQ7A&X?^'9#BV]
M_N%Z]],UGUEMN/7( "7&VG*#B!3: ADPA=N(5K+6S5R/VN@PK+[6=^CQ9=L!
M@/<$_+;<?,#-Y@+K,TIMY++^?&U3?!_"-4L8T%B;0:98K8N8P6?O0#/EM1>>
M)=<Z4?VP'0Z#[&M]<QY1FF<W/?+A[]:GP\4:U[LF$9OE!]K"5C++\NXK>9=;
M[[/UD,D&>QEW%F5K9O4QLC**0 8$.B@Q95")6W"!UV9IP7KFDN.I=2)!+R,K
M!SWWO;FXV/4">U?N9A]N=WI542F-"T7)"*).:%":97 ^.U#6,F]LXD4UKTX:
M@Y"S'F5Y")8?'V4Y%2PZL'1NMUF/)ADA2P3M Z-;EA5PLB"(5 19<#%HW[IG
MUN'S%%Y@L.5D@'ARML(ATND 6L>7K#_1BCCD$)S7"6RJ:1-<:0C:6! ZHLP^
MF9)'>:IL3$=/LQ4.@M5+S%8X1,8]X/Q>>_YH99*27)3B=3WR=9R]4PQLIKLI
M"%\2-N^V\B\P2^$@7-P%ZDE"Z@!E3[?AURXP6^>C2).(F$ W3<P,@7.1A) &
M36[?[/)?:X;"*>AK)[PN$G/?+LAQQFNW]]>;7;@+4YX7,G<LG2Y07GKP.@L0
MCCXGIR29;CW-XXGM]#)8LA>#LI7D.E"(CY"RGP.KE&&U?LF%3(ZA3(RT>T+0
MPDMI,ZG\W+J[WI,;FO8Z;B;V87 Z0@8= (J4--(&/I/J_PG_Q(OEUTK3+MIW
M/2U11VLD!R:<(E6=. 3Z*YB83!9:<A=C^WOVN6UU":YC0'#_VFPJD0Y ]@$O
MZ$>?_A,7N H71-B;_&6^F-=P5ATRO8\M[XCSD5OBG8&BF"8%KP4$(1F=S<0\
M#RSRYD^B!VUPVNMU/."-)Z4N[+<VULCWQSF7;4I$#%B&9(=DJ\ 792 I'PW7
M=:I%Z\NV,0F]#'+MQ4Z<$B$=:.D=93?+N!YX 9Q)3UI$,P_":PN*U OX4$<I
M&Z*-UWZQK/5+VK"=36L03 J>NQ'T]I(\SS?_J]C7FT3W%_VKL,B[%[:WB[)<
M?=G^WN6"<'&5@UYC'^.\]Q^_CQ=XZV_$I#[>^:6(KCBIH A'^M\& 2YZ":RP
M7!3ZJ)J/MICXG?_$2OH;&9?OEQ<7ORQ7]8>S+)+S2=?ZB=J>-7"L<PT":)9L
M8EJEX%I'M,:AY*Q?^@]!<^L6"PV T8%1TY +NXX2PBJ4#HD!/$=046MPB?ZF
MI2V)*1:4ZJW/U#TB.G\G>P%DCG=8CH#)T>?DZ]9R_+ )JTT7I^5VJ=Y_KI;K
M]4P7+B6W$3CG#)24DL3"&) &*U;&HI%U4Q+Z.!F=O^V=WXDY%2H]W"W5>GZ[
M7E]B_NER1;R]HN6JW_##?;ZX0&&"%Z",]L1QJ<%C$2#(XTI6ZVQT\\OCX%V>
M:;OI$;$^KJ /A[*_@O)BV^(C=Z'ZB<\%YYO+VFI[VY9KOLL)OVY,[X0S$EV&
M9+@&Y9*!4$P&U)$7)W2RP75V$3Q+U)FVE>[W6F@+HU=QLN[;EDP;(C+$VJ>4
M6%!$!,>]!9]"P&RS)Q9U=I*.<T'ZJWWM]^2<!I,379"?%WV<E<%](8523OA
M%[)E]76(R]J)SD%)$C%KDTKI[3)JVEAT-%?EC"->HX"G!S^EG6:YTWWG5@ET
M581EIPB=)PV3N >C"VE#:P2$.AO7,:U3(C:16NSL>!U.Y;1^TAD?M)$!]:]S
MY&:1VR@U+X"BEFWS5"!:+2%E[GQA5D7L9EK<8:2]FA#U* B?YD >!+?S"6H_
M6A@QI '=;0:AM!J1,Y"F=E;-F8.7W$*U"KA4TH<R2N?>ER'OU03!NSB3$\'N
M'&['YUAS;Z[+TUJ+_J>82"!<":!J"SR7B@7KI&5"9X7BA>; CT3AJPG8G\6Y
M' ]\YW T3XW?/JW'K-;!!P>>=D;V!:^S:XL&LBQ8\>@5B[VYC2<1_&J>#[HX
MN-U \Q6<XZ$>01:")Q=K7C)3H$RI!2?D&V1>E$["%^U?LP-Z#@\4YW VQX#;
MZW[2&,HQ23Z K]59-J?:Q[<F(CAI(&J&DL?DM>PMD?<TBJ>]4\\X*ON"0#O;
MMOM/C]>Y%F..09HZ^[J:!J!2S! *V0[!!(<:17'IV7*2E]CHM'?<!&>E.^F_
M+E/QSF1=&:44NI8?6^:O+ HGD@*T(=D<N12^=8GL:,1,\Q[1'U[',_Q. ,\K
M.$7/)Q\\(L:9C2&(Z!VPY 2H[ HQJDABE/$E><ZSZ"UH<C2QTTY#?WW&76-X
MO8)S^";G>?U+N/@N[1LB5(E9)Q$DDI94L;C:7B!!<<B"9Z5D9)V=M2<)FG8L
M^QF?IW8PZ>7,Q.>9$9^_Q.^XB.^QMJ6A[_^X7&Q9<QDN/N+JBY@14TAS5+42
MK0,EN (?5 )>A/9*:&ED-^,WCR?SO+-8&H*\U=C.%T+<*SB4S]_X SG'9T(Y
M'P(&,@%T[452YP4[R<%8IQA)VXMQ@OQ=4#_H"+O7>D5V(8*# 'AVG6KN<.%Z
M.D\=K+)EY-]K]Y4?+D+ZXT/Z3)^SOOI^#;L2L_ZVS'C1NFM-PSV-V\%F+.;U
MT<TF"<=2$!I"BAH4W5 0A2T@M'(Z)>,-:_UXT\O4FN/3=*X:P:&5G$FI(4DL
MH))0$ S=]DB^;,PE^]"^'7VKS9]USYI#,/OX=)J7%'\'QM[MX10VV2*]+Y"+
M]\1")L')E,%(G40)C)7F+6:ZG$CSHB!X<@K-(1+I $[',^Z)60 \RR*U]I L
MUH.M:BY42F"2D,*&R))_\3CSF4^A.0A6+S&%YA 9=X#SZZ:;]P:=A&@P6AZ!
M_L1Z"QF(]1TI668$MR;FYCG?CVZF\R#0Z#AYK,WN24+K 'U'A]=^O>[RFKA5
MJDYX=<K8RL=,M#,!(JH8"[GH.G23G?7K07VC7V"^R)3FP0O+OA>T'Q,.NO;)
MWZS7EU_V-12[D- VO(,8R&L@;1)\D:"*8A!R5&!TG<XF"GD,K0=,C$=-Y]J^
M,2Y;Q0S;@J27XW*,(![BQ/OY^H]?5EB?YI$ M7E/COC,!I^3(9/1:&*#4O2W
M@$$""SI&F5E U4T+DZ%$G6F%:</#TPUD7ML9VFN3_UI>T,=<S#??MBPIC.[]
M@ Z,J.&J3(9GK#:M#<63O%C,V$U[TN%DG6E%:(?GJ %L7NM)^FG^YSSC(F\9
MDK.KO<8<D._'J\"((<EI<'0_ZV*=#;*;GG1#B3K3\LR.3]'1D#GG,S2DG\/V
MAS\15ZZY-S,H<\I60N%DZRIF/8G1$:-,M)(9;G/[7L$O2^*9EEA.?+Y> $YG
MET/Q_L/?]P-LQA[H\_Q2XV8\'$AJ'XD,-F:F4S106[S77,$$4:4,RD?,CEDN
M4FM=]EH2&9+(IJ1DP!6Z($FC8-4V!A19FE%[E#XT;RGUWXD,!V)VO$2&0\3?
M@9%T^WW3>*^<] H\L:\R3E3C+@$686CWT6!J'=A]E8D,!X'@R42&0R32 9Q&
M>;R,C$B.H8 ,KO(@,XC>2^(!QIS01L]>O&?)F2<R' 2KETAD.$3&'>#\/=*E
M,Z\>\M;H^SO9@FLR]';OXDSG9%W2P),(H.C\@].<@0U"2,5B]+QU'?63&^K\
MB6MTO-R?V-Y(>!T@L8%7'"4*\H<Y""F(E\62X>0Q0#*R2)ND3_K%^RW^RR0U
MG&(JO+#LSQGM5U[WVP6=_,NM5-YM/N/JX^>PV(5G?ELN_MP6P-R<#Y(,8\*C
M!:N5(Y$H#R&E"-F;PDJ(/*IN&F(<16'G-T-C_+8Z/N.#Z5_CJ.W&<R3';4[2
M@D1#-ZXS-:&0O'=KE?5UL+GVHY06OP1Q9WK 7@#A+W\8CX#;^33%/YH]M]\E
M9@:U+8%9,*:F;3$RA(-U$LCJE2FF+%+NID'H@;2=:;+2:SJ+)X#MZ*/X)Z[B
MLOM+\:KZ^IHS+!0;C4'0HMHUBGA$CB>2F9.#45%A4NELCN%MVLXTU^DU'<,3
MP';>(SJ?Y<RNZ?@-YD@7O-)H(-3$ 954AB!3(C9)9"$$COQ\K--[Y)UIRM1K
M.HRG0>Z5G\>[QGO@,J!UD1S\8,C?]P6(1QR\,=;[XCA7W31T&\57["^]ZC6=
MQ5/@=N[]ZX<SY]GDM9N"+EKY6)2%5.I3HTT!0I9(+'0*?1%)G6,,]1 6G*G?
M>39!UM'@^*\1A7T^%55[;8V/'(KV@N3O++&+N"<<DY9IK4/IYH&P(=VO/G8[
MWL'I4 D<A.)_N;CO\^S#G"1//H!4-;VR!+H$7%20E0Z6V)I-+F>C!,8H?.CO
M!O^7T@1CXOE5&P*W@X$#]*CVO'BA 7WUB;(D/8K6@O0EQYBXB+&;.J?6Q+_Z
MV/4K4 1CXOE5*X(; S>?YUI],L]:DMA11%"*W,' :_$%"9Y[9PV6;KI9-*7\
MU4?,7X$*& W)K_K\'^!+&>.)>DUN5.TBI[S*X&S04'S6R?$@VS<Z[H'N5Q^A
M?P5G?R04-XWNMR^S?KN@O^+'\!>N?UVNUS]@6:ZNOOR)OK_>S%-89!(<\61Q
M57:\/J;$^IAE6I57GTQBH]+JZWU\KU?]7H.*OC9E4A BYZ T=^"+C)"-$(5G
MY]&U?NQX8CNG7C57'UV9_0LIHSKE8;ZXG"\^O2-,;V6X$\(-R>Q%,7.6&Q8+
M*8<HR*J.6,^6U,#0U>>"(K1H709]PG:G#?6V0M1=)?M2\NO *CJ"U)VJF&GD
M-GEEH##R^I3B1&FROCYQH58I2I=;)_@<O]MI(Y$= ?48Z9TG3G_^BQA,DITO
MPNK;]D&63)Q41^Z0+78UAW7;,7"6LF*2(?DPK)!-(VR&@#Z0!,B#,:BYC*VK
M]T<D9]I06T=('T7^QQ^%Y29<O)0I6WV#Y:):^<MR_>T?<(%EOOE]M?QSOJ;E
MVIBS!RTU@DE[/*DO8-;J)*VUN0"KU3(JVP0.=:D-?86.P7DFU?F8M3]>KJH*
M^ 5)A82+#R2[6F#^*_V["UJOMKY;K'''^FL6<&&9]YK7=$Q5FW IB+QDX)9C
M$%EZYEOW'3UFG_T:LH=@Z*[6'%UB'5@&MVF\1]8LHBT\R4"LB[507"%X5_E7
M+-?,%"RF=<#]F2U-B[7Q,?$D"$\3T*E9VQ];P^YI_LV,U,5$:<#65C%*, XA
M900I!3I-E#';^@(8M+%IW:&I(-A06-T!<>?7W:?*\V(]9@42$QTOEB.04>N!
M&YX<,^B(=R/IOT>V-*V',IG^:R&@[F!W;;G<)8KYDHJ4H)FR-6E00]3!0(S&
MA1A5-+*U3_WTCJ9]?IX*="W$<S+F[GB^)S1GW:U^&!NETXP;%R$7.E5*A4*T
M<@N.^V*+5E(W;X-WU$;[#5&>XH*,+[,.?) [1#YVZI#'Y%/,9%L40P=:U9;P
M5H-EG'-C,>G4>K+DL)U-W+]V?(@\#<H6\NKG9MX3=XN/CY%HE-4A,K)Y:_!?
M!9/ Y\2@ELH6D1V+S4>2';*_:77B=,!L+KO^X+FSAQ^W4$(1@0G )'4]>XF<
M,:9!BH#.1UMME+%TY9,[F]9[F5!7MI/7]&"L3QK7E#U"TF](-T 2L2CC0'KK
MR [/&5S6 0+Q+'AE0RAW\E+N/Y8,7&M:!^7E<#4&Z_MQ41X['B+D8$6)H#-+
M1(W.$!2+4,C=$HD)XF/K*'27^FLL-Z,%WUNC:-0GWOT)HB_>K->X60<ZK?,0
MZ^BV.:[;/.X.7&2$9]UCR'N!!UVI.5>>%TB*UWP!(\#[J"'+^HKA/(KFKYEC
M/NA>OYV_*_<8_CT,Y:-Q1GN(TM=>'K7O8["!CI"3UK.2A&I=MS9H8_T^V1Z"
MDGN!N^8RZ2@^<DW(+FUG\:EF]/P85JMOY2HY?CWSY%M+50)H3^:CDG3YAR0L
M&/32D+XFK=TZK?" [4W\=ML>'(]8^ZTEU2,(WRY^7RT3KM?O28JTM<]D\/Z$
M?^+%\FNMD)BA1\Y846!-(/IX'?81(X*Q7.4B?1*BM<UVZ!XG?L=]>3BVE%F/
MF*2__$A?SS>WCMJ>V)GWJ-#D -X%2S<+>5U>QWJ]^*)-,*S$T97CTUN<^''W
MY1'94&(= G*?)'N3N%E07N;M8W4D5TK1+0"^.%-=<\^SY$;KUBU-ANQKXB?>
M%X?>R;+I$&_U..V_MW/E;Q4Z+O+.LU\_7 E9AQW.LDK>!.[!>1XJD^LH(L6
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MO!G"]C!BG,N5_?>-W_Z/^D>D:.&?__@_4$L#!!0    ( /:#<U@( P;>3 4
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M3F+>A3$MW@DX@RDC)],P!QD$RD"6P2Q!=W@BI&&3$8B V9Q^S/M/I)'%(!1
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M^7*7M0IOX:?[5/? ?B+\/U!+ P04    " #V@W-8H+=!%<T$  !B%0  'P
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M>CNTZNF]=L4J&@-1(JSZYH(7#)8>/%4M*[GF8\J!  DGJ6QU78IQ&"(P@V2
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MCJ; 4X%<<<G0RX;SQ7%\&1E(*;SUV*U!< T/SZH,@%_OO+G#8F78;BP64C!
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MI#\0WM]@@?4>OP%UP.X$ F?RN^584#5:+1K^C4O_,R,S]_WP9S(@_F0] C$
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MCJL D6NZA?'1X8A/O..LNXFAP/F@#L/Y:5RHNI585N,#@%L:ZNEB8;)%P*7
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MV3P)KB>9V-G>V1-?XN1K<"/Y>19DH?K-C//+6_[]E[<TR2_#V)__]HL?W(C
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MP .\;/?..X-!Z;SQD!&;6I>79YT30B!:U,*J+Z]Z@&#=@1A<P >B#:LZ&70
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M^,'5X"4H?_0]; AH.@LSF/&@53QC=#%A#"D'G6G;2#P+(KW2$6PC5:&'JXI
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M.A6RM>5BJ54/Q1EIO*PE G"Q0  VB(*FIGP@2-V!V^%SDPN;Z\_O7W79 &1
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M^RO6O&KP=VSL7$:@=21_%3:\*LRO"O/W*LQOA[$_AW\FV33\[?\ 4$L#!!0
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MX_S#S^= Y%?GG\\OKX)//W\^@P-]'IS^^/G\_#W0^<8YS*-R"A=F72Q^&)U
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MVUS.5]'7+8S-??:4E/NM0]5^ BC%SY].7>R3[8/1]K)UMSTUMYM4?W/<;G!
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M$W_2P\WK0Q%<(,B>2K!D>JDJ4,E%#$5F^L^H1$N2P<.Y;,IENHPRM.K?_/Q
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M.LIC#"R![U H*<J::'72E(2SERC@&L7"@._'Q7RNRC@%*?H_!E027X!;,6M
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M+Q64R%F;P(H@^D=Q*:V=(>@H<="1FEQ]Q:5 (,ZHYCLA2R=J3[=,IM.FDF=
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M$'"]US;ZZ,$9K)?CM(:Y$+K)W3M4J(Q</DY0/7LPBNN\DH!O##^I-B=Y./7
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M4*R'Y;W7,2*Y-PN,Q];>E)!2T.& RQI%V:I*M<Y!#UZC&85FW(HG%_.(!G.
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M606I%(M\X%3_]T:J<&,]8RSPFJ)+5C4XL$G)]R5:5#![QV8ZM5N!]7+=O5$
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ME,@C%IVLY5GW_+9A(0/-Q2:.#IO4D:=>+(4.![N.,(/!8"BF.0&Y3Z0MDEQ
MS[JU/YFR6Y49V &5>H[O.&O1">&#9 EOC#$Y/GAVA*W O\?FG%*S 26U:B74
M8N[>LF%W8D,'SPYWE.4+,F-3'EK7J!8C<DEHQMAN4D;7Z%6XRQJ0B3<*WC=9
MG4K\5LDC9![KU%5&^;#SR90DV%(5Y11FHBN_HYVW*C*FZ>[I7B':F<26_L/,
M<U<FJEQJME1E+.<3QQ>IQ5K57F>BHE 39XW)Z#K,L_6D#>>A<#<W6DT::>W.
M\:B]-1./&"T\G/9BO/[Q#%\A/ZU*"#WQAK%+HU/'PK@>R!WHXA;B+*B":8E^
M87U^VF,^M.2K#Z0?EV?6"LXN*$+.:I':HHA91 F>VXJ2I_C*7AOVS%D+3^T0
M0FJ])404U7ME6GT)I,#Z!KKQ)W5TX-VU[>OUZ.#(DI8I!W(#(2/F!2B,)0>#
MQ.BIX"S]7S&DPUN&=+)&[:E+.W/MFN!C9-C:&L?B3>X^1U[!.=QLHK\%\/.T
MF<,=TP";!+4=!2E,*\O_W>!6=Y+-P7.G5<HS<$6J;M8B\_K%F1?GA,^-1^BV
M)EBO=L-XA-H%3+5JQK\(>VUSSI?K8M;AZ%#D.??,?MFP[A/"J44D@/9T-]\2
M1P?0W&W$*(^X8\B<,<RC+\[]Z89#M?B5LQ02FBM4"7.HI8EQP2YTDX32M;M'
MSX!Q[8R\@?/ 4 *>F^M&(^]1[R2K#)+JO4JJDGB!>G%_1-56J($[2(DYZ%#>
MR?).4B''XQDUGFI.-MG4%C"@!1BRWLWJO^R1BW?(>O]5IY>CO$\9#+='K@>K
M;:ZC,YO,$W)2>^E>6B5;1"M$>.1[9(K57&OWZSKZRMJ??EX<%]H >$VQ+:5)
M Y)$J\H-!W/;/3X8F4N9K#ANII;_!7GM;4_D7[<> $H LO[/F8HRL@4E=BA9
M).E<UMI.IAK)!>O(X/>A8:4,KA,H)GEII,KRPE(V627 KSJD4JSG[TC 8+N5
MERXV9F,2_ ^Z ]"<Y"0][5SOFH@'#PD11XCQ!>2_C+Z&H#8E34R)0'J[0Q;C
M[?93Q;TJ+HMK^YWCPHCAX6).\:&8L$,[V2:A72>+[S^J+()QE-&*V4Z-UGI=
ME%\XUHUR@DP:F7;LRBY5T9+4(Z<%K0ZV>P\[L,5Y6FOXXA6#GU9P=;@4WUHV
M],QAI(5XICA-J1(ZIZ^B3'^6_=>*GP:]DMYTHT0"S@:>X>=SQ[-'P>1!-.53
MH#"X'_&TV<:)@Z:,RXD]FW\Z$21,'#\1KP?$+42I'QX9X$Q*24$/I//T8%O_
M-A?!.]'2@"[[<!<\=OB'PX=&9AIR$K_),;'9JGTX)1T2D]9[G;1:'6<(V@S5
M,>2;O04;;_.1=1X$PEPZ&>HF\\I%8:4"+W U6/N/+<&E(Q"=D>P8_[V7<='J
MZ1K./EXFI-B07T%R\@L-+,O&%0%M(*/PE-'SE=+QTA];2<%^IC''.8LY@N,J
MQ(K(6:=BNOK1#?8Z;>I9(2C_-D_9=+S6J\1<\^6E&T:^-L92/:6*5;H4JQU<
MIU@0=NRC[GKCM069&@X0BTV%"T*I$(1*A0EHP"<K%SL!"RW-=3"9VRS=O%H8
M^C$KQ@J>:W+%>7 #!_D6'.0*);'^, \OG CK$^,!NF)IT3 6^FS*._!!A]<K
MK27DBMW;&*]LP[[R@CT%B!UA0BMUVZ39T)<2H%3I7_PL9B-$ZMY;Z?WL<J-8
MIBPU*"!TZ* ].%8<A42^GJ[2%"$7#*-$!QS$HH2)I OB 1/)>7"<C/(EQJW6
MMC"V6YM9[+*ZP@T.8D<8$!9=$_-\,T;(CLIC9%X^)=O]@2]])"G]S*)NZ\W1
MQ_OG_<O]5F M-D6AM9ZVX.\B.<'8X>?4@.NHA.).WRTEW<%E;9 WUM])V1WC
M0W+ LCM((-Y=D@MJD-ERKYP9A[\)/_TMX_"6UVV:;805EV-L;[6C+?+Z137K
M])% K#MY6$91U.YL^)G<GBM>UA9V)P&$.=HFDLCF_6+*?7MZ=7;*?%NKF!A?
M1S1 SP^"WSVS;1T<Z*1#N+&!_>'D[,=U08]\0!A%$$&QE2^<P':K7A6]5:\P
M2=BD^H%^=00<$%C%SOL'!=G3B6!K.**F  VGY3L8Y5*5+9_R)S9$TM\@V\9*
M)_Z+[X)^R-4U%:^%Y6&OFH<KA)P0.*B4:Q9;F\MV/30K&^U%@3O&@V@-?4/L
MZS=C)TL)4'BC)A%(,'W@'H_=U'*R?_#B04TMPPFYQZTE :</QX(O53]\=G3\
M?&1T<?AP[$8AA XFLS:.M%"3M2*@L6584T%[.?R%,"PF:B0UB5LUV_]1CHQ*
M3A&%BP7M(UJCSU9<FJ_(58D97[[4*1DI')53L^N+,#1=1S<&M:"XRZ5"H=E%
MJ6SA0"GBX14BKGSSS,8P$UPRO*C]B US.4Y2K%/2 G3+U#2M=*F34L=K+@A-
M$IT;&O+#TRQRR2GR$O2<@JL43;<2MQRR87+B$"Y1IYDG%?]).A>X':/2:9IP
M)S0P@7ME F>?>L$#'OO5>+1_> B';[@=M^9@O.G%N; *IU_4]2VF_"/39&A$
MB;LM38RUP)W*A2<V*V#25!FIOJT<^Y.+KAH=#.%5C_686@33-[W*65LWMQ(6
M*0P8+SM"0D CNQX\W'9=8Q]'\1<.W=^3:4SH/Z_TI"+\[[<TNYSF7^#81^P7
MG(]UN#[965^?_1CLO([B-,M '#Z+LCE:9/9^;/[R_>'1T:LRS7=M/H&;9($)
M[23;ZF;VFIQ!5S$*AS*9YTT5DR%\&=%WXRQ**"(*8X@$/RJ.RCC-89*4*YW6
M#7\MP3N8?7X5X:<K#9N=5@3[\)!4(IAB6316V;H*0DJ&3GL7BQ<_FFJ\6+'$
MWPAFR]-]_FQT=/3,0<N=L(^%*4Y:1XJ42X/HS <9/3RP.)I'VI51Y!;&TF0;
MF1^X?,YZ31KLR,>^Q'[?1X+8^=+I:)!E[I5)(OYQOQAC2YH1^02EFI!$&G9;
MGA45,)0TQJAR#RJV X',!Y9C_/_;XLO=B$;*<4PX>ZIRP5\]8S"/RS,T&V#G
M@6COE6C9=H]A%,;DWA\:-@Y[<N\T#)^(Z78%U7M%IB?!KM5,J?6: 1K*P(2(
MD!&D8H-U3) @HE@Z*,^'+/%O_'UDDRP$G\@;D>.Z\')20^+AI9HIOGRSHI*
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MI]R4EUU@0E\050'KO6O\' /F;4(,.)C?*YSNY #[J<%4DJ9RE9!9A(%/B&)
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M&$V<12E!Q5 L 0LHG(/0;FUW/_BG6RNAXZXQ:[V!:F\!V]/7 2-Q..VL4[N
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MS$NL0QLOO9!8)EBXBUQ'*04[K=FZ!;GY#@,.LHS2C!I=O\V\W8PEO*F#H+!
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M:Z+(&6ERVI#(0D-R:W,L'O+:W6<+D#LXU.+$-I9BU@OJ9H"BC%&!I3,/[-K
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M3FZ"U-3IDDW@-6R"$HQ(N.9>$%G.=2DNA$H_I<1DF]1.N1S9\NQ]E^@RL9L
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MB5_>'EN0)U@4@H/>TZ!1(#4[6S1*^\6C4#VV4"7!)]C*HQ&DT##VQM$V5-0
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MQ<E:RF#+I(;Q,FTU2/\-!0T;?M,JA0E&%!.O2VBI'\TT$&VT'$MH*,([-<G
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M&R1-B^; U;0;-IUS!UWK$/P>>'"U:EV'*D*^"83MF,ZNLY/3%[L.KQ9J_WB
M??4#K$PVZ)1**(%=AKNH1"2I-(4_!W-N"=OB_?OW ;/\V_U6EPVU]"Z17X<[
M7DE G[@@X**UACXD%6;($V*W4MF'.,Z2+]18JX.10[H?_U*+33;*O>V=,*=T
MSU,=E(12=>J3N<=G0U5E/'[,[2&O' )62I_KU[F/#'+/I J).1CG\9;X7/7&
M,6>G8OX[V-/NTU-MD?;%M%N8^^SH8;!J2OPJ5%JNHMJ[PLD7_+HB#V&5E-R)
M EXCP&G'+ S/V9]:\A9EWD2G>9PUMF/@*@M'.C>R'8Y3TYT:W!Q/2F^'IE:V
M[0%)^"9?J#T =FYUHYWL%I>T&&SM&DV\F(U&9A/J*=7KMRR_E=S_")VW#X73
M=BAX>TMKG6/G]UMASENFY;)92TB*E+D)4%ZEMQ*@S-D.0.\NJBHE;T+B$_AH
M4<#U=T63<4RT3NL&J[-Z'MSG-%+TE"K0ZS1OX'E'N($/-_CA"#?XMISWSQX+
M*-I=7?)0M\=9VU'K(Y:F/45US\-$N+4R24VNO0HQ0CTEGS(F%K^-,VJ$%3[M
MIC5]Y@G8&6?/J03V]!2V#!XI487<?'P*K5)0>B#=L[,.1>!,J6 )1YH0-Q?U
M^G.H>SFKQN;,GPADS7WW> ]WPL F]NJ .X-I)8-\/YT=*/S?-R"H(RR%>DL%
MW:M#1,3(%*XB08\T9DK-M83.&RQ@N%Y<[R3W*PO.8TPE@_Y>87K[FT&8C[#F
MJDLTS\>IML-#8$.SB:G@2?9VFF-"EY$$XNKT0VL#T$7+I$M>(!VOU@6RJ25$
M%LB/T(RN!43@@/J:R(7HKX%.J_!F;*'[M)/T%B185JG8\J6!VG0+FABW3?#J
MB?M[=_L ?#-;=(3E6@-;=/=A:<HC>RLI^>_,/6SVM4.$!MMZW#L F0JIZ2 H
MB2=-?,!F0&4USMEZTJB,^ W?"$QKA/5[G[W4,VB(=5J[/2K1M")-D7S9X+$X
M.?[+?2]H (&MYB+(7B;1M?:%VMX\@AV"9*[2$W:ORZ)=8[$/22J@Q0XN1.W9
M@T AH?]/O!#;G^R\^8$W-FE(IJVD/CMI24RYIVT7T7;JZ3QR<O("GB &=$SQ
M/KX5F*K)5:&E_'"$UL0,D&15XIQ[=8F =C0^D2(?):*G:TOO)/7YL@I$Z3F7
MR7XF3&6<@.N<+FRZ@,E'B;: F$?!?7\SA\&\FQ.X&.7OI[FQO,9YX/0=ST^;
M&]/.UP?XK1@2P7PNDBEB8&4HU,$MYTH$=>>:'>">D;D BT;>"/5=P_OC;2;+
MQ2&4,72.;)%G<H!VH $&JS]=@(%0E^F&X=Z55AI=EX'B*-AVIA7@@6<#-6#N
MB]ZU6.^P-XAI[#<U!3NM-ID?BZI^IH&']ZATGY8D\5N ^HUG_97X&2/HL(M?
MG#+;O[;B](I'_, QE<@5F0U>4* \[ 6#+:+\QK8*7;G\-5FQY)JXIJ[2V&"^
MO'96H911^-5T^YC;!BHV4S3Z8K8K)#[73_H6@<8L0?9)02+B2,J$L&."LDB8
M=@:I*"1YR7D++Y%(W)=LRH12R+9?*O<MHCLB1L)\WN8X<LJAWG[!$!N,Y%PN
M_C80L./9%U*\(=OB[+2_:Y2_/_ &0M-#%(",7\.^4DEI^H7"+ZCU58)T3G%1
M5AJ);9UPG>J?Z+8HAU('(Z(V_#8$<422J%#L0S1T1!U5HAQ7%YLWE7%H9,,I
M,=LC&*%63GLUE 9\607-)BNBV/(,OT&&]4]%L385SO+%,(D:H;[<T/<P+CB8
M)2=7)_AROU_^&,0EFK%XKR@E.CA;[,T6H3=F\2%Q2U4[^JG_\T&"7D\>$O2D
M"N)V3/K!6G"F0-DT2N0314N;Q^E(._FX[YZT:2U&.NY8S;[>I69]WKW>BS3%
M5&2,I^)+TA+/<V[N?8%_>?OW)KW%UI-,0^;:R1A)24G+<7_GG[)B 7?:!I?;
M"O0HK"K^X_T:\[?8E.]'^.TW<?J.:&]QKXE_^<]WR-BAL1 \'+7=]MD/(B=^
M?+,K+BZK/WHEEV"EI7$:E185W7!O:I218KU.2LS59TYI.";BD31PM:*,O5.J
MUPOS,2P#S"@@%2 9'K]HTV'C%.QY8LY?L0:OHC(V%5X=VFJU89<"[ZZ2&JT+
M[!^["\(0!E)(LA+0@C$SU?V#&7WQP^FKX)?H)@DNKY'X[0V=]&]#I48)@P__
M$YR]/'WYPS<AY:,R,;T@P%[==X P[Q9-Y+@AU;@&V;DB,#AX]TE"FZLNFZH;
M\>MW<0XW:CT?JJ_<5$5S 4[/*JT[EU4=?\D19'SQ+*VDV^)(C]GE=1(WH$8H
MK;"</ZT(_LM_&N^AW0'C6,5U+%5Z6*D252B*2E$',(DKHU6<E#YF P7IME^G
M42]D@LU1AF2!Q9=Q<9=SRKM=\^0=BN-<*JT5?C$N_)M'^;2GE&P)ZPEC*+>D
MN7>M^IQ0 8B#9&1B9\6P3/8VR:.<@9 .@HM@MO#O%9Q#8B+Q!749P2\2/0-N
MT\J2O[MO]&V8*N.Q5<Y^\ .S/QQJJ_#.KQ)$PA;BAC%LH=P4U(QX <O.XO.V
MP5,=1) _FLS!_NKD[ S;GC^E![7C7#]X+[0$?1$M;ZY*\(GC9_(.*_K?WQ[_
MC?8V=GYYG\;.?^' [RLS'XK@O*J:-<@U>7>L".^171V)<FJ#E7"K&WW,3JEW
MP!2ETUL-T2="H^ BF,*VX8^<!-$2;04J9LTS[5D,1T##;/%H'K#RP(O1P(AP
M>G5(-H."#HB9<*.V1$G)Z,Y72%0H#!AW< 0EZ$KE40U[";LH)S1Z.<*X-CM!
MOEDB4L1[E"EI0?QK!6^ V@M1613$M3>PO2CZ@/R!9ASOTBHY"8)S5)]H8.F[
MI'+8VM=QZKNQ_XS60W%'%XQF>=?BQ^Z]NG/!T1 S&U4PPPM&#0HRB=E?[)N-
M 1%TWYW]E^8H^K7N^:?/[R]^>8M\-H\V]B?6R' X?GK[\=/;R[<?/I]_?O_;
MA\O@_,.;X+_//WTZ__#Y_=O+X+=WP>>?WP87O_WZ\?S#_TQ-&[LU%M(ER9C:
MG@%OJB7V PJ9(\=$$*,>BHCA'IH'4IBU8DT#(?VHA4T;J,ILW8SALQ(=IOK3
M!VU%Z3/W1'M1+: 7)Z=G][& GEXA_^;T3YH(<&TDF_FMBST"(RHROA*A=RG/
MF,2.:;.T)[?VQ5+?"EXEQ8ZWK;U!B#+I<,5H&?#0]4=Q,/,NGX?!+>R%F$!H
MS*XOP&2_;D%,.=(6J7L# ]+ZHP$#*4Z77'$-G_K=ZFR!8Q;=D2I(J;<7!7XQ
M)^'^'K]V>W2=!-Z\8;T!FD04:JK2VG$X#YK"37&7=)L^9TP(CZ@AZ7MG QD.
MI70D$'N_IG,)*GB+WFSKK1:*<*+ZBSL*@S"G!-VKHE@WJ5VX"?.MR/<P@_"/
M7'2$(7_9@_X8J!]M32"L($F))0S"Q%?AC3:B^@30DKZ$ZH<'3+->.B"GCR%E
M55?0T&X'RW[K"Y0; \,EVB5M)+V,S#Z"6U1QO3R= +CE"8[V_MDB^R1*,[2'
M>&M5A7 Q+;P$6_)EP^A7K0N/AI@&3H+S'1$Y+[+><OK0>9Y,N V-H6D'VD9I
M8#Z?EH%Y[I[ )T\J#Y.V,/^LI=1JE$J&$ULNT@>54 %2ON""0T.O]R^>N&Z4
MBE8Z;(410_4#N0K AA?Q3HR<H3'UQM5,+57*E@,U8N H&5IG\-!FO=:2J6$;
M"OUKC>!)4V(9JV>\G 2?K[7G,UE%\M9;[[4)3-%-QZG'._PV56@N,B-W IOW
M 0 ?]#"'D 2M0C5_;5<+VV;Y3XF//%D*G7&%#,)8!+;'T#=T+WV1#:DI618;
MZB3JMHR.XF(C<^(^P7!._%@@*,MM<5T?NJ:M6W;7^$^)<N_2]S[R7J*P<TQ[
M1.1A@<[1''XOIG7XO442HV4BN^KD'K1A(SF"/C^:X VKIM 6S3G'#@N^5^#%
M!X'+WN2PH>+C*?[!?*<INY!^+HGVG?JPB:X-F*K:<=JYH(_#L1410,*'RHV\
M"MV=JE-4N=;O10!RV6SJY1:[EQ.2 B[0&J)-F>;+=).QS8]G/#(I:"H*WQ,T
M9\G!A @UZ3))C)/,5V,ZJ\:8S(Y*CBGL\7OED)]^CU-#O$]N0[R)Z]A7TYK_
MW^Y@!U77Z69Z(>19-!K@D%2Z<X[*=KW!=&T%N@[CT'>Y4ZJ!;=\QO-G?"SX,
M/B57#9@O"#9^)UT%]9!POCIW(K"F,NX\OP'U&@4KI$X@+9\E4:E%=_M['[*5
MEQ<:!F9(&@/8"'H SZB:Q,GOD]K?\T)PDQ+GCHW3%>AB/!9:]^B^=4B6+QU[
M5YC9TY3_UIQJ4@,.)VV)F3AZF#U2+%AR$@&?5XBO&BEN^@26UA0AMZJ44+C1
M2Z%Z)+$C5'QHW?"HI?6GU&Q3)2013+1.HMCZ\B_9*8[_\3X78(4^[;A[$,?H
MOAWGA!CU,\U]-=J-=9YO[5G!$J,E6KHQ=/UL]M#I_CJEF/:K4:Z!XNJX6JSB
M#:4T0)4,?WI40(LQ&4A<[/AVNF?S8K1GLVCEC5'7FZ:LFBB70C(_" &'DQM6
MI' #MOQBB(0J&CP6\$AK4<W@@_!6=(#J3\WO!GX5,G 6UMH)WG;QK5(B=V'*
M2$^"MWYA9Q5ER?#OS4L[(8ZIRME(!8VD!ZR""M?16D%NDI4R+=B6C0P6JFU:
M)GBND0PPEJUJ2=4'6*++*&/SHN2%-=G;MFU6<=+!?1YEF9LLLP_%4HR0H\(K
M'/:RR&^3K8@$LL9U((*5:W3*S4V,G$]AN&%:9XF0XJC884@I-Z0D.\2RLQ=-
MVW=N8T<@&DWB% N$.)OX=Z+45EN9?F.GT1%E@3F,)^=?<^6S2T+:SIDC\KKN
MR:2WTPL.I35#U>'6A#8YXD(,+N1L_+B0)YH:W![L%(HU.[2!G!W8V4=AGT\F
M)97&-\,^<8L_G IJ"C+W%,Z1S>V8T#T!%*X@F)!E_:3FWI\VKJ<=]?UN6E'?
M=Z9=QZ5IU\&%\1^*0=S5Y-R?D<:'SYN8$EQ]BV""5Z3WTG7_15A>?H?=>39E
MLHDTK]5*M_UT?OZ14U]8NX657)1.(P!!63179'D0_H"99S!,528"]EAX8513
MJ>7T"88-K1?#PV>4T*<?A%HX0>2"QH@;?IW0V/=PV">"%5D518V/J)230[7Z
M%G3_LP25?HR[G^XPM\UH5E%:9ELM7QMN1DPFHQF,*<KN0 ;["O9M!8=MB$.G
M42Q%9?"4)F..30SA"=C'T-/TSO<_^Q+^F:SK:#3." ,NE& MO03KY!3YZ"BM
MX0353IAN+_F=FETB$K9_52^ 65JN4= ^=T(L4M30JN4U:@GV^BWX27F-V#2J
M=#'_#-52-DI0 6=X0U/I0&ZB\&;U%PZ[#Y,LQT;\1(MT(_>0?3=--O#=UCJ,
MWB?.[+3@-6\9D^'$AE9.935[P'/[0BU"^I[QNH2WH>VY@1F9,EEEB5::<#V=
MMJ/HZVK&LTL7LG)S$36FNXC1M@S9<6L*G;KP QH>M+J(=!SXR>WEIVR3.J B
M/WNV@+/4%DSE!G'&:=*[?>=&D$8>;\.MSD0]\4Q99-]>:W[F@^5<+>,$_SE'
M.(G)?W(153]!W(9!=V$F6.U%5*4]->+6U*7\_O*Z5Y_,33BWR-*8PB$]+D@X
MX#Y0Y N)A599<=>M;=KOJ%2>I^)[(U7;=YC>P?*4W+X#1N*EZ:UZJ)789P-B
M))3"^,NT7#9K)J<$WRXE8PBANK=IW!"=J[5-HJLKI%MEJS*JZ8;74<SH BR_
M<VKO%LE]RN\F':?[?EIQN@]%\'MNM8U#^S(]N*:3RP7-#U()K^11]*0X0J["
M%B$>"'YY'I1GA%,@Z#_^]>7W?^.=@)J1VO'Q!F)=ERZ#%0&D0,_'2=NS,@7F
MEV\OA#. ^_G)F.!4AE%1!5!3<G3$>#15[WYW>R@/!UYGBSGX.W&R@%U(-[,'
MNJF^XBMQ I>]$]A?*?];N^!LN#Q>U0]'[.TYN)M)J7/N.-D4O*2=P34>Z4V*
MI"V@GJHBN77)H\#Z*1NL;<!2'E@I[M(EJ<#0=B^/F=I7>D<N[HW1&9EV^F%:
MVNFRR.!H6FY-YN!=&368S(%!:N!B>GKJ\QZK"O9(= ,G,U%#W%T71.$@M&PI
MFG9T7".34+(B$14]A'9@4_?WH'++6RZ*6(E]['0R?B$2"C;G"X4XZ.W-_J0;
MXS_>P&:\(U" RT[7JJ=!( !U&;T"8P)[;])9KQ$'IPZGRTLDEG%?]_C[<1GQ
MJ9!X-CE!?NC!MU'6)$/X#$.>Y*R3\LDC25W=NVHIXBJ3J'9A+'518X'F6IN)
MN9KO"'8P8(?G1[##P-3T^&5MR>S5(%67_W MG(QH&CSDGG%A^TLWN<MFOT8O
M=QEM4A1V,A2D 2=X&SE1YIO&JFK<"$_-\F%#H3&PAF1S"I%DV',/?[WEKW7?
M;[(H)T>:K*\Z86P(_1"/_@7'8-V)6B3;PB3?M @;._!%@HWO_14#Q]#]61;K
MQ)@7VHX*6ZR!6H1CS>A86%L3L;Z+.!2,3W=M21=>+U%RIXRR_2MC7;9^^3#2
MHS89:;VGJ-3<EZ:9U/UURF7^,6@OKCR 8PR/&_4W=97P&&IPDH(EC#^MJ0ZD
M5<3^0$K>)["\7C]E)&I:5M\OL'NNCGPD]P]0O9\'OUG,[/20R:_A#48),/,P
M[0[I"1\A&/D2##+#VEMMP4%IH>5)I]F2 [!5DZ*_62[2FJ?$*1D/L?5[NL:4
MXFU2U:8^WG#JV>)R4X >Q6#EI!7=[!9.PS^:.*4@@,N"/ >/7\KND1*&W_5_
MY\5=EL17QO+5FCOT$,AV)92O%.#W)$&%7] _GS&"L.!7OL*P;TY];[&Q*&)[
MMW_=0+P^I.T..##/#9:<\>K$/.1%<6L2N,0C%AX0 4U7;L@@XGAFM@T?' 3E
M\;R''5U,?$>/=DMS((IR]']B7X;] CZVW1JV  N^KRX%%^Q06D;Y'HAT7[2M
M=2_Y\!R]XND8:&>G1P/MT!V.,@5^CDD=4WSG:*K=I^^#^#KN,99W4$5T,#'S
MZFU:9,J3PU77_ GZN1:XLT,]I!J:]ZV*UI%H3FZ3'G34BO#F7L.4PK^TFQ!7
M?X,><^T=? ]WR-Q%(KJ# [')J#8_ICQ%PO585%>N+R?3 $KQBNL)J=]]2%85
MNHW@#<(=.'G!'C<7PE.XRCJZ/[EJ^=R0Z#F11GS=0^V(7G6H'G"G@&R'1FR;
M)&1G_$4)TZ=7LA-C7[^0UEF20=-I-R&0H]9[2()V<F;LV3AY<L$K=8X1PZ?H
MLK1M#:ZU0XYY0/3.4'UZ@4/K_N86X6-9.,M[,FE*<0+?BOYZEV89=YK \\]V
MJPO]5G8*8V+*-<P"+.E \H]*AX(NPDACA+\0IM&"\L!)EI3*5^J^B:'#7#"\
MUT,X&]R6U[$) Y0R\G1^^)FWX[QZ^'&XY[9F;7?BFITST12>*+T>I[T<D#5G
M%.CPTEH,M ^P78W%%:0R,;RLF*J/+', TI*DM8HG^C!EBW1V]V@=V63ZOMX?
M>:?[_5\10^OX3LJC0A *"[$8A[QVQ)(C%MPWD]M$VO[69/+D3O,!GCUJ'S$;
MHIB5C4YCY4]B51SSO?A^F:[EO-U96W SFL*^N%! "WS8*F*S!A;;G9P=4/++
MPON8C5;;1\)G'UX)KY/)5OBI\X]1K=AYT)-Q J?K3?#;:H6VKH,&ZO[PHMAL
MF3" KPY-RU:V]V7^<<+1%I5W9UF1Z>6R_-"IR\=OAC9U;\4^H?/<FOW0S(R*
M3.B^A\X&YIO:=0U[JOUE6>,Y.01!B<AA@>@8>BF!TG#L9(F2FV5&Z(X)<),
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M/?TD>H0AZ-$J^VDO>CM7+(N-=$GJ?Q:;@C\FX$VHQ6>5 ML^H@C?-/E-6M[
M'*+N5$7>5=_D]R_3+#/$>G6!O8H.:QS=:N?$/:2UY6"+45!?0CKQ>#T'!Z[D
MA;<M#.4WA_1I>@R,MW(?(@%ZP80&[:)C\?CP/+:D@]*K8$5B2'[9HD#,P5X^
M!6Y#:OLRFH.D,P4J_CKS3AJUTU$*_<)]WNS<">UP5GK'NH34@)+ZEK5_)16,
MW:4DC"KN=KK$[RX)KVF:*7H]7G=($/;P,B-0KBGW&<SV:BNU$P/6W/;?]>0
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MDLR#J,D+A*J@P<GU *T++-]\F@LQ@9*!DQUKZ;@) U=SLV"\."-HCHS0[]S
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M!G>5+^%X&-&*_(YS$F$(M*C<XL)E-\B2)L*@%W0>N#>.:*AF>7!#PI'>P 4
MQQ0#(VS(3(#CJ62LMXI XW&VV-D6EJ-V5OSI/Z3-V,]A"3%"VV!Z9,EF8 &4
MO_J5G)U@_!G2S0OFB>5_Y%*,5(@)[&,\)52=G5'M!3]INFS1W/@14>*E;2 /
M*O'( 2T3>!?G/%!EJ.OT.^K/*M?LH5?;U")A#'Q&;$'=F*#2E+LGN*V734&L
M1$"YTVLQF-J!R_DA=PIC"4P54/NA&FS$Z@>39C5Z"_;=RWF,'<4XLIF%'$ER
M"<E+^,E&OD#J!W=G"+0S>U#_&71%^OJ;X3P_DUQ[@/@/;T4B4J>HO38Z,:1]
M%N>7 N7("O8X?FB::Y%E!N3LD5NE7C+=<R+0OB[+-0Y4./%SEMA**=@FO@S_
M@J]CEJ*%"&>YM<%MN0!P-O[:7U<U)6B.&!V\^QX]$K1!TTT',3>@SB'- $X>
MF+XISC:R76/PQ3D-G/BLF+L-@WP%C6@(XP@78/0T\#,MRQ*.-\)&D>H;(YJW
M1<7Y"1K*#$S&!,>ZYG9D]Q_$G2;;U_T!YR5.FJ=:2]VNS=YQ@@.?18^%ZY+3
M'48V@:0O7$!3K3:D0@>7R\Z^F2"I>.?+6Z:;51.ZR#MN(;M;>'RX].GU4HY.
MY6F?Y7A5$^.=Z+A?N*.E/[*]2/16TDZG!:@:?%4;FXA<1'[1&Y@!S_U %PX4
M<&[C'96+!"U1RK2^<>*J<4XGH>:,72&G.T[MHH/053U'CK2[#)P[QI*Q3Q ]
MA_R5Z@(=.QE*P$**(8$M35]G:,OX2U,]'F1G:P:V:67?<3XV:1C4F7G1+.%\
M!P["!663G:-'2%6&T:&?XMP\6%;JB0P&@%-7?BA M(!'? V<(QVV<G2$3EW#
M,ZG0PIX+"8*O0#IO'A^-@(IZQ7++ @5(5;+FPE#RN3RK)EW3/(LB<\50XE^,
MG>0?E:BBMFI0(:TG367GEL%A35KR:/VX'PF/!/SN GPMTFBHP*X/FCI#P4K6
MDR:9Z T0?*1ZE,E[I%RA^^>OF_X1GW\=D(MB7JWC!J\D8;KEU>'2"5<NT&FG
MR<&7(^>JV;H''M4R2*^YH_!E?$#W\GIV9.&J0Z8Q;:3UWG;$HZE#E7R(;^3"
M?>)F,@CCD%E'>$NEE('RUN4'>!K0"V.>!=%@H1L1^8V(5O/,J3EK^2@>'/ (
M8"$M:MDU562J:;69&A4:*;%)N'@ZEF)-^ _SQAG)TSM<1Z<\M^]P]=/^2UG"
M-CGRP?JCEUG?RR-B8E2U94SUB<80Q8[;'B5/&(5!W0!MMJ('S<[<+EHCTU7N
MSL3";>4EL,JSECH1?\W+)OP(/&T?M[J8MKJL+?=GM(PGN(ZK;K;A/DXJ;G0A
M^7!P4MH,TNB31T^/G3R2X]!9F$N$,( IPE84]DGP2)Q#ITJSELY:9X[;:UH$
M8M)1O3!Z%;322"I9;^3,+C CS_C<]1)[ 6WFCC88RGT:Z2LS,'0AT(HJB @/
M.L7;FR4/22\PY,[E:B%*/,]>-SU8:97;ZBT36YY._".IJ-]O?"S+ Z08&FA;
M<NISL 4Q+86+'-X0RSBXZ4&7ET2H\=VK0AT?.16)2*%_6G1WW$25HX1\#CFQ
M?:G8[;6VI**_Y 3Q-FP$>/-WS$FH[J\&PQ#Y>6\K3@FDW=A3IH=[?G),_F_)
MA.YV#/[YRKU?G4"Y=RSNV4GQ2)'+4\TR7O2C(Y12(8DT>U0?\$1YC <<JB17
ME:M+A$$49!"0J[1\X)/Z_?BD"H\E4#K)/)NZ\[YN,DPK<$W7O9CM(T+X?/5\
M0J!6[TN@?K3[3!G!JK;K$8%G\J;LAW=:+#(ZCCE6WDB.F AQRW4!Q_ZFQM 1
MW.-BB1Y)=^5.[H,0 H6/1_G>F,\5!X[J/41&U2RK.?[#KT=$S*H#@#3&;E17
M(%!] Q6K#E<L.&#H;[BKW,":I8Q;Z2*%%B_7S*Y=@+$PT?8D^MUJY5Y \HL4
M><-?KIKEW"0&4$1CFYW-2TC%]_3%6=&Y.74[S,-WZ0V</9MD[A[.SUJC%8$_
MU:RER?O,AQ^$^/4;E#)[L=!F3JE[>4L)WI,_7UR\44D2L HU^,3TMA^5DA+(
MBCEX/T9I!OE[.\&C,)W-QGGT?('EEEQT )PU3>_<1:AT8&^K?WFH[@FK:0,<
M0(^FVT?\GWB/V!N'OP_ZJ% 7--=B)X%+W+\N6_?F3601M+P/V]V-6VWR+;SR
M956>^3HIE534WW37VG :!9,C]NXD=I'6AP$:FZJNI*:J@^1N-'?SF6$CAX\,
MFMB=->#%."]AY[?]? R#<Q9@FV^PTH[;CP:\T%;'X/%S??'E!T8'MECP B'[
M/ NV!-6N7TQ$BDODR^>X,%D'^X4_.S((R^^[N+\8*.F(@*1"]';H@5.[JX&%
M^^[QWL,&SY&@,I=G<F $=CTX/;K!\>%/"LQO_Y,=$U31U$,AM\<O9(3)EOMD
M]I+[IU%X.&I.(B>.PV=G@L!FU.P4#)V^C*4< 1+0UD3W!2 PS=K,G %LP<+#
M(_L%HZ45>-2GC[__H;K,OL+_?O*]!19CV3EHR8)MN2YQ;YK#C_C3!K_D[FWF
MV$[YM<[\5GV73CR .':%->G!E&BJ\JXCU!0D %%O5!BX?<P9T:62^N<@]7HE
MBM:4.,)LDDPX2X/QK#$[/U1WVEIF#[X^<RL:4S^PE52*'99+<+LNN+8IS4%S
M1#51U^L^ Y3MQO-=K>!E$:T$<-[T88'2U\($-8!=#72,=#'*7 7'B(!+,.6,
M<,"Y\#_4V5>('ZPC[+[V!TK,1W#(Z@*JZ\EPX_S.Y]D7<9R-Z#P3,LI$UY4!
MCH3GDSH\<-Z%/13N7_Q=((_<'WR%K87^8.1[XJX;WA-.7#TSB!9)(=F*S?.U
M$C9:9W!A-A?CS +^EPZ94B/'S(RP#9U A;9GJIM>R)(-A(F=XE7)$1GU9E/Y
MFKN!?\,T=2>I=BT4!)^_T/IT^'FZP4Z_(NW" 64?CM'#S7)L5*-DN0HSN\A@
MP>EB:Y00Q4\H,?2FI)>U P')N3DN$ (GHZBPW2!72^^I2@7UN>-V7<7\&F&Q
MGYV9%2!IH,_-O7[.]3/@W"WFH)L2#M09\V3P'?=-''30SR;>?P+WY&]2Y!97
M:M%L=,])N.TM0R+Z"8OY6JT$"R__2?/"W8-SB'V\Q>>M^:,;U ]-T<[E%.?M
MRTC9 $X1X(7Q:>#"+^ _7BKW#+PZK(VA3].5,SA[43VTY8!/GMAW:07Q',;Y
M??,(7X#\YDR5C[28%:41BV7GA4YB9\O7BL 4LQ"273>^>1XN+8NWDJA<C"Q>
M(K8;8"#C&P(BW9C) *< )2Q<N^Y_)SLX]M&W"V%-]P:86 B9T7P-D*#).YF!
MBUL1@D&EU,7>@IU([F90,F&9N7C2SMV.T9>1;$^U0@/)]^G;/V%!E<MR?87X
M>D.9L+N/R6^MLR>3!R$^7PAZ?@*%H(&G>:3)"OI3+4(@1==!56J(;J*CFJD#
MD\=USB2 @_.:Z#!O)GL/'C+\3XE#$)ZQ 1B",''>F#:)D$ODBZ']&%$7IM)^
MF$061Y)%NA$3O(S#*RE"82"JW7&A9)"'GP(Q8RTJ?IQH\5_GZ\'?_[.H-]!=
M_R3/GCY^^E6.^-"ZA@6G".+ULJ C:KJ97QY89N%4>Y!L@P#?%R& /@JQ)GTT
MMIK1NSDDE '2VQ.K.@ S\H%_A7,A3I$$.D$1B6&-08B.;M$7&A&/:%\(/U44
MN@HG@%GF^!H9N[[</NIF5^5\$P:?@LSCMY9ZA</6?W(_IOC=:\9/AS1,%FW'
MH<"\@C:7ACK<8I%OQ6[S>,+"P+C"8/&LCPK"&^?40*QQS&G)T3FEA:0KD9M=
MW5(LI!,^C&1\*A5AC0HO;,N%R&(JZV1"P#26-G(1 GO?N^3YA$/-.1I5W(B"
M<&TL_,UOF  *<IE=N<RC/!)A\BB^T_UCG\QK/W6@B-*T=;E]-%MB0YESKFZJ
M97F)$8?_B91B?#680GIHE45V 7:&6'ZD8NK571=W\][?EF4]1/11ZHP>+)VT
M"015\&0++H(H^SW-<(G.6N@F@3? C0SNI.Q<U $'-==\*JFL>CVKNX:66=48
M3+JXM;,\=$2(E<0QX7N0ZQM)YT2<%\&N8810C;)B]3FMPSD)1*?6QAF5@Y;#
M/TU\3][=3_!@IQ_L],=,2V)92PK$)ZR"/&7GUKWXWE?E4GD&O/8U^L)?C+\Y
MJ@(,!6(P]<W&Q5C5JI+VKLP9!NB(,^7"8NJ"@I$N?-)'SX[JSH.;HK4L<M0)
M#J\Y2<E^Q@TNN?0[,G^0%I,(X<6H3L@GUP5K'RQ+:FG \X!"U#G[+\CHWIL*
M,#G_9\*GCM<DK>R^+(,(80)#LQ584W!-N?<]M:/#5SI2J.3F^#O"#/Y(>RM]
MU^SJR]GHX]GI0H49K4XTLT0JR+N>Q$'"Q:AY/8\P(&<8,O[\<VX4<]\F_ S)
MP$U[4_:X<U5$?#^E5]4CX0]XH\YOS;-E4V"F>^8<(:*B[)SA@C9N]:^^H$4T
MHE7T=52PW\V9MH/B/]1.D0#D+D+"U,+$#$@L7"B<I,B\T;EX:XX@6+P?I+/4
M_WWW\@6:0\1*MX2*=.?=;"L/8^"2=5,_^NW\W7G !3P1R \UO,/O;IQAM^)T
MS"LW_$O$:UW5@(W9PBQPC( #\74X@TV1'RM:CKJ@I6]X[RQ^.9#,$5'*[T]E
M^Y@_X0/P^_(AEUW><14>L><0TWFDF*9SW6'=( L%G<.YM;F6HX:6SK2HK_7C
M W+37Q3QWW@6CN1ZPVY^7ANY[5T-<A+I^OJ@F)ZHN--[#, #^4.2ZB%)-4Q2
M/4  % +P]0,$X' (P(GE-N_$47V>O-7AG"MC>9%?+#OKT0DV_G!V5N@(#58V
M$+-V$2]KSEK:L!M 2L -_%KPGCE?UQVUMZ5S"NGBM!>@W:3LF8+-?$$$4%AL
M/B*!!8P=T\,VX:&JDINE>^+%X#X8T, _VP+^R7<+,+#W(WTE]MC3XT0Z*:I2
M8"1UP2L HF$7<NL]66 &4Q^9??"%&Q\A:]P.-,V?>BZENZY.AEJH$]-WU.9Y
MIA<:YTP=M\L3I@8J*[NPO_.-\ OMY8=XH'CX_2@>LJ09\]W8BJB3!MJ!WMPG
M]I_E?(6M5XVF1>"EO6-Z)>T>3(^]@J.^;S<E$RXRNAWEBE3:"+WPL-,4RU,B
MF!?@W<%C !HX:<>,R=C@Y(<;YL*,'-YY%[OCN3LG?&H$KCH@<QW$][$+0'L)
M(&B9$M5AN6H;,]49BCE,KB4G[TNI+HRHMB#-[>3R=9L6VS:G%4*Q-.]=@H_*
MO!;^6R(^[3_!EJ3";XI]I06WEVX+B'/J\A;\;;=\E\6,>E6I]:H,J-VX(TFZ
MGB1M'[=U?$EYTS$5H;1KE"M-A<VM8^[3US:-=E\J,\#U<!,7<*V1:YM*I>>3
M"VIEW-\T5SK4_U$C1D6Q8K'@YN@PV[JGUV=7 G@*. W6H8-!YJ;X%=^59/O\
M4\?/>\\,\NEE,F(B1S<="(PW#8.$:>'#%)D3$)_ ^QWF[Y?7;UX!)21,LF5-
MW4'>Q30#2N4MC%Q1'L77S4\FD$!FY..B:T8_/T=/,;D]?@*3=,P4!DT2FM9;
MX/&V^P_54'U'=_:CIJW.-"&M[*KUN)OZC=T:13^_F]Y?IVYPU"F]KGIW4/WB
M\6P___S"37*?7=]6EY<E^$]??_5]PS^8T??/7;  !+B(XV]JC'BS_]M675^Y
MM_%7^B$".\SQR=X^5.A)[8B<M@0+C:@S#7N3)\@N0>E%H)=(YBUM"T&O*=R,
M9%A\0<.>)]1IL&O5Y2#^@,] WQOG.GLX'1Y.AR_W=(BK+YT;>H<VI.AV).+@
M C:FT&O9 BACT@8F(2*9.<^RT^;#?G9:?-B&,@HS=S\7MQ3(O_R O&V<B8T$
MV-ZH7 ]]6?@;W9\,Q=8)JN*-CM_Y3__Q?A!Z'2P6!1E13#=RG2=(-R[*.;0[
MY)3OS%&7@F0)H*#O]E2V+&Z1N^62B3R9>:^=HP*[!XRR5;"I@BCI)&QZBR$G
M2=&YV+0+9!_=*%_6-U7;U+"HW*!^QH%@@K:9*B.*H4>A#&[P>$M6_<D9M032
M=I KNZKPPTO(9LGUBTU_U;35/X2/,4VLH$DY5KZI2RBGPN-)UWIS6[NIN:K6
M(KUD9*V4J'9^4R!/*A RB.H2?UU;ZO%I3+\G1]+#I(7SZPP)JYLG266[J=+Y
MP;RN3HPAFKC MG?WF7\4P$252T)4#9EIA5@%,XR4#GQ?MLZ+;""'P)1__(49
MMXW"(A2./:_MM2BJ)<+=6*DG'RA%\V54K#EG2!QP(QRB#%TXH\6/?,&\%R\Q
M+?7 _>_Q7M^< -YK+&?#Z& (GWPVG'V8A"13:[=]RO:&F+)!"-19-O8 2MP[
M:*:6;C^"+A@[".Y:6W,=^,9ETR#?+64A(PHU3CR2K0@.$J,E%O8>2(-ZB6>2
M%#GL=\2$NF.D:=?LZ( 9,:A6EH=!PT2FE;O7_Q$-/Z ?91.EMAD,*@$E\# (
M!N'M6PW,H^7 L(-="\\%4 +L$JRGQB:?D6'-8\LJ+8#_F.1IRPK,KXU<E@H\
M?"S.#S*FA!K:94<G6O$AX^Y7DCV'W2*X9.9B?6;W'5PAMTU[3:J,E!4P.GC9
M&7._WP+K"QZ>\A_S8@65+G?TN8EPS^:.9IJ@<DYLQ<-CDN06E_:@@Z)M12AE
MREK7Y6VQU!0V5,24JUG4[7C\>M+%ZYI1D_'9]OL?7&,UF:.3BOW3?[RT H>J
M>&A\52Y+%>130FW\RLTN+1^4TPPYA-V.(D%S7!C>BP7[2KQ?PAH3 !77+IA:
MDF/8]P5I A/^$.[#OCF3= N=5]1'];[X 'MIM4:V/2S.47-@9&'@.=G)9N \
M# >91 &A0*!>E))'D*)L3K>*7<@PW5JI,&+7+N<H@C5W3WU)*#(O!(J>JVA"
M\VFBG,I#HFJ]OU%:E@*SO*2F#3II":=A'D(R%B[2*5%! $\R$H*FZ72'ACO-
MP%Y6JXY> ,(H-S7H1XMCZ>[KOB@7*K*?J[*6:=4)==98"*>*&LICW'@,7^Y8
M0Y/<[STO'Q_O50W]HN4<SX7P&<HE],AQ9J4"T.NB<,:!'L;^CEB!(W9O]\\&
M&NGH&#%RILR=56H'8U5W?;N1!E??A<&H V4?M;>\IQ$:67;FJU/+SM0+>!5
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MRA$#8?;"=/*TPVNJ^$P6H@I_25WL6#<\YP:L2&25/',L:OO@'.A4-T0X#$F
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M'<;08?<!$MN(_OB?B8??P!5_J:!.[D+"//O7Y[E[J_!_!/_XWPGUDF !+47
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M;KVL(.,.X4=CH?^MJIU6)0?[ICV)P[1WP%@$^W_0YAY)>W<:Z>P$[DD5'?.
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MSP>D*7I*<!S<:28:3T+L76#S9$H+>>8U8V1P5'R2\EHU3$*S%+/AF# <%*V
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M_8;7V%NVV9$LAZN'92937E*[(X,4/"*-$^7(">=U0.').^@DD'%G%6HW,*5
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MI3\"@[ @S;[<!B0!K3RQZ@;LZHL('WT@X&=. 72Q47F\X;ZH>4!L9_L^@.F
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M&S^L(Q?<Y*(GC]V8YNT?%X)*D6!01<5A.G1EABQ<H3[N^RR>FN0*R</11,/
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M!OTRW'"F43$OL>U\GI00?@LPJFF>*>E'<_X<)*,E_#693Z,__A]02P,$%
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M+*;P"AKQL$E>R\OU%>]!F/.SVZ8$_*LZ.-)DB=4BF,BBL[6V6^P*MB*,E^I
MTM9HU][^$&>%2T4&'@V77Q$@ Q(T+D79'^(&6T[&1T^EX2WPC[J!8\_4DGY8
MM%C\DA4+B$1(SNLR*\5E@51T5MM5L:JBRA*E]8:G3J,,:$4Q,FW^BN>3/7"I
M\[5DTH3PCI%9C3B?!)/IA.U.,_ZYFK%W%$U(00YMQ4 5[KYLC,#U9LG\X[G=
M#$5ZCT>RP/\\WVJ,G]$#H$@89ANMT-^0)!;:28(>N*;\*]17,)@;P,]6C2"V
M@A!4)W38@%9^G5S57+]WGEV".F"< ]O9B?^IE8#L7N(C4 XVXG!JOYV>*@A
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MJ?<*]T72[3$9M)@\*S!,)C' "Y,3P>M &\J8:D_8K&3:V=3DUL*LKF5M%8[
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MF#!C$XZ?,F>#5-H_].[N3](" +5VIJ]AK2'I4WMSM<062J88PO9J(L5@!B4
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MCI 95/X<XK@)W'#9@PNZH/P(LZ"GJ,%D6(XO(HK#A(E@1WLC9$<AH]Y(()I
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MKNVXK?9T&L]-4K\]X[I+"OSR2R1C#7$RX:^88SFPW8?X"SSI(SG5R%8\S*P
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M6P;J(UZV54/])! +#[>[2W/N79H3I2+A*--X5](^LAG[T7>:0/A"A8&*!R%
M*PO*8XWWRT&3$!M0()=L.E8>H5EOF5&6F"F@SZ_C,2,C$M"NY;(N#; 9'W08
M#:EPI>9M,3RJO9"_"0D@Y]1>]N@8%FU58".:85H1[,0R\(4CTF0GQGWM:8PE
M=&:$!SO6M0@H=>R\ >,?:3]N\7<MJ'%":LT$2044>7SM2D5E>\$5_("DKC+
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M6:Y<9\S1G=R:=-Y+9<F"85>J._%(>FPX&19VSE#V_33-FINPZ6]=X][,ZD?
M>-B=..XJS$&%/*:]URCJ(WM1+ZME"AP:=3I!TJ(1^NF.6JV1>6)SHV2DB^;C
M(8ER<VZ*($6TT01$-31WG;9'\]F#-4$XM9U)"%)[5UEN%0[R4]=0C6)?FK<#
M)*ZP^?"\I'H1=7KTAQAY"KS$'5")CQ!\5;U@3U#GH8=499J"K;O)1Q=IH-?#
M,)2X)X9C*MPK6/49I$91L2<#:\6C]L@8A+_,KMU<!D2>V+V<'A RV7TN_&12
MN:%T.EF S<G[EXY8\J5CKGSOT"(QYO3G9@H]\@92^GQTZT8]H\&S(OWNVT=/
MGA-_,(=KW :'BEQG%]1$F^\/9D\?"MGZ+$TN,[BBD*FQ>]5^S.!!4MR)O3+U
M>ASVB&<#M8[+)U;,[L"/;W?B$WHL+;T%+9 $Y$!<<Z^[I/T7-P/9DF)14I!:
ML57&K^>1]K2M5&&^#O58!XS1I*#7N%LC*EN1;@V3ZSKVK4%J7+6WX*C(BI9P
MW?XGAXJ?B\\UJ+2 C>XKUGD0Y-*%T 2[LUB+P<Y#!<+H^! .#%>J&RX\TSC?
M<CV=[II HWW:- WQ(+ZXW:9686#Q-@:FHCSKB(<0 WP=V9"[*<'H\"[ON@2<
M[J@$A'QT'2%0[!5?1P[4#?=7%%[LJ"@$70I*]&_:)6#9J#3*1_#JL.2:>R8P
M;E+=P5=(KZJRD8/5&HLM9XE[ &9&9=(I0AZ?G+=[U0G<3,G-V02!4W[L/[FL
M_?>D,M98J:&,(HY^2JQ78-#-V6)5HVI!N,L9LQU(F D^[G=ML4J,RFYD$!7%
M1$;J"#/&M4/#ZD*A..1J0L_2MTXC=Q73< @7[X;J,""?AK'W;4KAP2?6@"L!
M,,"T_"+%\#$D!AZKQ,#!M=CX$(I"#;EH.-X3(L^[]SF^[S(,$Q0:[,I)*0P8
M^,JC9EDN9JPVK@)EDM!1Q.0@Q#C@_'-KE@ SR'7$$5L,V+5%#LN.GCS=TU_#
M]  D0YZ!"\L8 "(QVB)H3;\.P"5Q_%<UZ@@].Z+B22FFHKN!?$8(5UE:-WQ'
MN_!"_C+:>]E7:T2J22&3%W:??%,D#(=X_^#0Z5A1GD^'4:B(K8KAFQ[ZZJ@P
M@H6O*E4=*5H.<]=V(+_6U4TS>*Q9++"J"BP3C%A3\'?-G&)T7#_9+U>9FX%X
MN<,0P'M(QV"U&BA D@"Q&WU6VE<XL,($ZBW)[8C3ZS7-2CY;F&@./;,8M%E(
M@/") FRY2;@NADITA(D[J8BZ!SIB:=ZHSJ@T&<XA"!+$RG!UNK'T88$.QJ62
MGE^2,.BF]5R43Z*&PCP1M@H>::?4_7A34R0[:B)Y=>3F8'W7M8J:4OT=S8P@
M&_.2"L ./Y? >UJFS(0@_8SQ.5F_;X;*/W5,4-R809507DE#6N^T0$@0L2=0
M*0;":H_NRJ<$,<MX7EC%(W7*T@W/*4/_$]UAS(<GX>_!X&!0^>QN4IE%KEH/
M\1=4K5U5B1"\$1\ECUY#"5POK06%[PD'*,PM88_TNK>[(!1JMRL7$<(59".M
M>>OP@^Y F2?S!CE!_1*=2._:50W6D@#-;C'IX ]A+/<>/O@^#C][=N_X_L/>
M9P\?/.JC8)[=>WS_L>H!'*A6!PZ!40RN.2V;QG"A[3+-F$FGAY@YW*["L.ZC
M!]%B/FM-T^H1<ZC3=6\?(A6+Z>APH.%9'ZEX;3>4'5@:_0[&3;7E.NI].,*G
MM/H4=/C-6JJW,?55;KMG(D:Y" Q:P\3#,/=>3]=HZ]FS.F[AC@R7411S3I,2
MLC>LRDI/?8W 2+^(3DFZCZF@W9XZLQ&\%3HB-/2D%J-C!.H"W='.SR'HWTB)
ML@+UWZ6Z/RO5#??:TJ9U43#?72\!>P>)PB$C@!T&$-2E8V9=).PVPEA4 RFU
M)7$D!.AB2.(>[.PED&\0#[BY#Q4"K[QS#1WM"FX4\+N;Z.'3^X]IO*\!D_W^
M BK77E16ANG3LSAZT18?L^IC3!^\^5=T_.C^HZ=[7):Q3<_L%>E%HM0(@CVH
MY&K&<">Y7TT6M.OH9 %N"2I*)W(A!V684NP71\"!8O]$+#0+C>IUAB.(-YPD
M\!N(GD5+*YOG5O7</HPQ$*);))=EKT.-PRYN",K5P_&78!;WP48]GXXTWZ13
MV/0:N)X-8 $I=JO0C&F KA877Z!T8#AAYST*X4'?(X^O\\BZ@2;).<4U*> .
M$05CW^/2Q.-HK%O%T-=VH]TQJNAI=H2-L,6B9$NHB;S36[KG4/0J[#F)4&;/
M][0\E+C\)+H'4UD ]EW1,?L[4?D"46&Z@,[YJKC%G6B0*>>,T*U1J(P3GL%G
M2'P>6+]D@4@@5&J,QBI$=JS<:)I"U:<2&-$?V _/CJ,PW$=1*08F<00NN'6W
MH#ZU&?):*'S3YQ2S"&R*6KW]A]N_N ![!'8%%S<.!GM!=WJD/!+<,3!^\.>*
ME7+-"\8^44C1D[(35J\I)8;G>0=4;96CAU6/Y-.@N!7RCKT9L6IU9NR>7XS$
M4N//I))=RR++YL'X?.R#=7RQ2]:QRY1MUR#^O6-5@$#Z)%ZGG\X74)5/*RHP
M'4&18.]WWSX[?LX.06K_>/C\+OSRIX1?WF)3)FL-8]<Q#!CW_2Z_ \)2%\X3
M.]I+WCBUJT070P]"(&E2I:X=6 85N'@/+N^$_F$EJ.OK#7<-(2A!+4PG8.A"
MZB^95^!EDE7VHID]R-Z[ 9T0#./XV<.GU$P=CE8N;,>ND$#Y#.5JYVVN:M40
MXP4G(7>?(JJ7O2C%G)"0DCI8=V[\5)8?:47>$7O%=L^/4PR%X"'QRO&?=2B?
M[+&"';XA]CASPV?R#>KBC%B-$8"BU)_ULOW.>=D'(?QCEX3P#5*4(&& R[]M
M%Q!_0LQW#=XTT.4J0YA@:]L:/0T77.<8'Q;M?NI"KJ7II-/-;"+IYH%!H"=H
ME]=M4(TYQUA(^4^*CTUVF00H0:["#\/_VIO3].#6KRC.*4=,G#&4*.B_(FXQ
M_0&,('J9?<*+NM_&@C,><FLT]E;Y)8BF+!DW)#>F#IW[%8'_.)UM>@,?HP:%
M.<>5.)E;94P9:9!+5LVO-.@+'%!&]J$@OP:<)RZN<,Z?,N/>=@^=NXS]'G5T
MG\Y^ZA;[4!"&V"-\QQ.,PU+GAPH30=PE'>/MBB-*T>>-X+9[Y!)AWDES2]R<
M]<&Z D$72Z"^(69:5/IS_,40<6[( X3$8"JUA,4H@OK%TR-GY9 [Y4!TG-RH
MV=7S(X]:DC?<LKF!NEC,+3B"&(A$FD]\F%%2)?@.R84:5=\_N\8SCUK8F4^0
M1P/"0D93^'JJ#-EVQ9X\AP[Q!1<;5$TVEUCO4P5#567B<'6A^7!.^?WDCK&O
M)LYJQZ_JG@A#/[&N([.I'9SY #^QZ9A@>'PD8SS3GIDGT$OG+@3PIX0 9(,3
M8@8P/Y+%@+7A\MS!:'9W8SDIORP);6T0FH>Z@1@0'8*-*0$)D6VW3HS?J9 !
MNT_0DQFWZQ@;D[UU[_#ND'@IBQ=A?HJ^J;./QW>Q@X/'F#1<$0A#A>IO,[8O
M>#SM9IQM3'JX8/=Z9Q'"$UG1 Y;T8NVP,T6OX$E.N!A<&P>&M#]"JXK@]VY"
M0J+#E0N^>Q:KH3P;#+/*?&4"T8/ W/K&/MU.WB,)AMH@KQEBN"--E[A&=CIJ
M'SZAGK6UI/F.H@_:H\&IY]YS;KSV4,N:7()9//<CX)VLD#JXL6'!UUT2\L]L
M9Q='JNL27QCR8X>=F'BQ["_;FL^#@]6AFXJ]4, 3TL#'W$+Y58"7</4(0)$/
M\#20K90<T[F!+)K[C7S@-"\Z[!Y8G.KC=U/Q&ERKB,M#WO($@L/SCQ'2HQJ,
M@-K/4B ,S68M*O.P:QUCC,$.L^)D-Z5T.4/RHPHK#]$E3JD,%(1XGJRRAJCT
MNH/!4R =?T99G5M7[#\)L[N6*[IG%3FN(UUUA^#4@;HM#E'0X0-U-U0/"7N6
M5;U=AIA*@F:\BW#H%#N&L4']@7Q&YINSYA9E%8_M^CB,E:CA\N8+E3.E+^UN
M7B592HT/Z6'J)<?TBVN3F&=6NZ2)S)1=3'3T5*FV3$0($;XAI>U Z2YQD=!A
ME2R-6/+)N3(S>H<2HBO=)8ZT7U"0O=_7AE'M#'UG6I26-:4>5BR%8-3ESB$]
MY6%C>?S-6>NUC::_2)U.*@"43T>9;H[3@A660V@=Z)UE.TPS=K-#!^K4).";
M']\ <(^MUCD:DR7PAQ"L13Z]<O1%*B3M">H(L(HG<%9<)CGH28YEN,.V")X3
M#S\HOM63_J  LD.CK]J9]8CL[2"(3V42[@Q8 U'+EM#?TCX+$$Y KA0!%0%[
M#U\\CLA#/.4^P#-%[3FAHZSJ-0_GBK5$\W*UO$D!O7!#Z).5K0'4VVMOGHD1
M4[85E?"#;5(0#V_38R,4$"H>#QB9J*X/F06-3)[Q4F]^?480R13"$6RM"!07
MU]K+A5!<$P"/EJ)V $!;W[A^1F89%"U[]VF>57-[Y&,Y01U3'I$S.WB*04*0
MDX_L2.,D';"[P1A;RI(S)[ZF?#]T^)8!X8 WQUB1FQ3Q8MP8\%)]PUO>;X-D
M*("<?SFBDZM,8:ZP6:P!V*[,+DU_P'/G3GJT@5#:<:6!BF8MYK.;N\J*!80]
MV8E=9K5?,AQMFHDA95],-0I=C.T^^$9WO&*P8>,[9<$8I>S=W-7I[6R='@6Z
M/5'!@)G<9:V]@3[ 4)HF-'"B%9+-XA91]R.5.P-AYNT%+2=P6X4R/B;1E8/G
MVU.C+>8@9J!@,D,(:?F6W-?RDN,Q@J\1Q/Y"FIA_WL[:"TMJ0J84QX81A_>.
M<7A'",3;BXF>T$Q+#,A9E=!7."M:TS]<W;'AZ%0QHMOFR-,U!\"#,;X\$N-]
M>+#,[&XKB40%]EE1%O<0[^=,26](U(ZW+>%XX[];Q^JW0K0@9^1 *+ 4K%PL
MC.=#PTW<'ZE*)0&!:'D]]D/O*VNM5SBBV;!+3;9020.5@NH#2+G!^YFRW0\$
M[*((!NVM@-*+8FQH]-*?4O31E(>W\RW&7G/8P=@+/78YI=TUY!+>SE4C$FN]
M8+RA()NMG4-T1U(.O :.TSXLZX16E; ^B%XF<WZ=*SSD_FK_"!T(Y;60K4P6
MRY <V-^OW\Y..@*!B*?N-:\H\:7)^Y&66X+Q0TXU?]'UG#?PI&GG^6:SRXXU
MN4IH2<*"Z4@M455\-&85AVZQ*>ALE%_NQ5:<E/U"&O:#1#?&"'HPUK&Q\P4+
ME1)&U5T:!=*+MKTL3RHFI<-/[8Z?7\L]@L".7+0JK3%C=R14J,\@F87)&I=C
M^?I!E<\(D_!6H#J,OB'UQ8&26+7D@=^UM6'B%OVI?8R5!&C"0YGX_=@XT]DY
MQT]="<[&0XRJB^TYEIND*H;BN&O5YW@3!T"%B<>==MQM['4+WC:=9.1L2]1.
MD3+'/BKU)\4V5",J?//N]/1[/?7C(7Z";KZ5[D(CT]FW$]JXW[/+#D[%4G!M
MJI&Z<-E+5W4H;K.*N/&N[2!C"6Y\;IBCQ;3N%IZJWE,'#+ZB6@Z&\G1JL#W<
MZG/KTR8E"]FGR4B",WZ".-G>U*M.:*+%X]O3B=Z%[A\BZT.D42.8?L89072$
M,2\8K21<:VXPH:Y:2*J63ZCSN+M2S;W6XNA4P$]I]((05RKV1P8N0FX$CM;/
M^?8ZT#&(B#V+SBT[;;% S=_EW;YVWFWK[4HZ[9\5EDT:&\;#Y[+K/XK]RBD"
MQ+Q2$)W \O9Q8M>=8R%[/$$=M88>Z"@*N"7)97(\D5HG];&WNC)(8DU6B:B<
MZH [,8Z$M+\R"^:TN^XY_U1D^SEWAA]A9]YN3'/1#6JZ (= 6D&UW1@5 Q_^
M80W6.LWFTNBBY]AQP5&G&<#8T2#YE,T$7TF?W<MY1/,D-T#D $DJ^,F7\WXU
MY;F?()I77^21(4F%A(D'FXW'3/L)ITO&A0F<7AI$DB(0!6.; .5>^9X@-'T8
MD<)@4\\!Z'-(]6LB#J-EF5)0(6R\10>=!P' S8#Y N3K3A=]?:HR"D];4=+B
M9-B^B8@]!(N=*%)S$YV "DW001"(<2>-UP\24.DL_G!?)3^R_!H[(&$@\*KP
M;8YNWCL<)<RAK>#?I37T( Q\,&L=/R=I9E9%VP3BVMGE:I?C20K6_4-[8%W7
MW?.+#P]A&T2=NO#DF&*WA@J>39E8!QA@054?YY'CYC">M/F./+.0*J!!>NI.
MJG[#IEM*P3//$.3-*,KH-#Z7**I:Y*#Z&)EOI3;9497?K ?] !F__=]%6^$C
MG9& 98J+K%H2$,*'ELAPO'G3.M],KF_+PKT"8W;LE%FMRHS>=2"]"C>R/DQ5
MF&OK2M\#!D0B)415X=FS/<E-$.3LE7V/3[44?$ ZZ+S$^LFVLGH%20+1:&M\
M@8>,R6I(^"6_"APKV/]/33'_A5>MRBLH=Z%KK/&SREW3)E\"'ON&,9FU7"Y+
MJEA%HZ2,\A( I75W(?PEA2SS($FWX\S]3:IT%(D^SD=;J2Y.V/R=^?43NSAV
M8U#ET]FE-R]$]L;J>(-%IX%"2F@LD=?OIT=Q?6+4,%(V3*8D&!F725ZSX&/5
M$4!J*!E.3$G%O=<$L^E-23>'W ?.UG$W!U(/)T%&M1I*Z\+UUM-Q7"JK[-0,
M^:YAHZ6?C0_0CD5&**%M=12VN]J'4J#E=**%QQM+@:"N%N$/V^4+^R7("MO-
MLQ0V&L%F1.=E:55066&FB%J+LO+B@L0#M36O3,+ ?/E'">$D>Q*B_J!D@4D/
M1XJVW6&V2+*<R9" ";9DBB7 RHV3:EO1;W,FR/A%]M\)XUO.<(?M@YP7TY'S
MS9Q'/R/-!Q-V6%<>SLCMBOR'0.+6!PGLOX,.J=C#U[>)66W.G,>JWVW,6# ,
MFM:>V6#.$R,]<_R<@?R2B]U(US_5BF_X=VC8"M/)"S/#*E-K5D!Y\+(L3 -U
M/^4LS\X3H<#0\2=Z"A*BT3WV8<N44]LRG$B:9J1#TEO;W*>46OO,5G:3DKW5
MU&1OW=('Z<WMK_\>+/^_=VGY7W(<X*1F>N0MG]4.FN8H(S:YDNC6,\$#M$KG
MT&&7&#2V;JR][4 \D7LD)(B4@F@!'/34^98G9SQ $,+0Y/<*CG:;. T'&SC$
M "] SBZ9X=*N2%QQ+,+A?ER<\@O<?S3%%YXQB :+X89:V)F8K&DC*HU[,SMH
M9ZR)4L((2GR7K_ZR?/4655>0O],-N21T%O:U9XE*@._V-H*.=QMMT#7 MX,Q
M*;\5%F)#UZ0 .. 3=PJUL(K,4P!!:(B35T$>E"BL^FU%))0D[<AY=U+<!F"5
M5I54<\4RS+ML* %R\V-M(H?8XRV227?.L*='C]<?82?!JEKGYB7DIU^ZSC3O
MG2!ON?7=YZ130>NOI P?$^^0FNT2(NFL!H3W#B6746"A2H?/;KRKNVIM()'>
MCBXX[#8#XJ0ZWE8Z3/''$*UEAJF;DJGV<Q6(V![=E<@,PD'/T29^O>Q%'; 4
MTH8=84_Z[?04>\?16X2M( YC[9L/3BB\DVL8U<7!%[Z6B,G%D[J70Z+0,H4,
MJ$3$7IBJ2C*Z8"4JK<N=+O=C9'S :>X23_[Q8PLC]5R$-@*+ XVM-+-W-UQ'
M4_MUBJ'*+*MQIM!T:5.69U-@DAH-'=^9F@V549"R>JN08'*CZ=)M1N5IY^L(
MXNH/[C]'ZP;H7FL/5BG**V8,X<U*>5!&Z:1XY?%S^%+=I$?\?N/['?$-=^V<
M^'Z7SHGT<@(.SM=)LHUL4X>AP,W)C(3<[V9PS\(6A,;!DX0@H'YR8<M:*>L.
M@B[@Q@N..G]PT%&*80Z</6H_W\.OQ%MMHL%+54,.!*0!-"_ZLYPL1O[%FWF5
M5.GDE+!0+-!ZHV@Y@-X-2I)6R;5F$_+-E.R<+K,6NOD-_*Q)/E$[/?E<Y6^Q
M>#%AZYG;5]B#H@1[!K(X\$G,+Y]!-PLX3%-\$>+"118E)JDET!RE?8B#(O18
M@MO0F3TVA5A=XUQQ*N<:.J&\W4/W8V\&<"K ^,<5F/9>T*C63KOS.4(;XB@Z
M$4@"+2Z,>PE1>-BM/'#H.RC)?# 'K_%JKKGQG4]@5O\ W 1C-B[QO)PE=::
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M5SZ4D[N,\ZXV:_1$W(7A.D$SDK/DULNA'(#DB"09(V57(PJXR^$D&"Z[MFG
MP7N'?M]4$;0O*G<Z.E>YNU 56E8J,-\DG\ N1$\N'O+SW"%KS]5V.:NH]6EN
M+C-"-@,C%D+?*=1EU4QCL-+\/ %UO:_&XE2]."*8=_H(E)NJP:6/7>OT;EMG
M9:2I$*9TMU;E")JB;6D/7ON4M#4";Y]9';,T^$GCZ7$V4-\ST=,XLP%=OS\"
M-)V(^?'WO410N-BI:UWB:)>"Q8\YKAGK<!77G0_+!2>/&_M*'2YT>$!%"&2
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MRLND<PI,]%W*=E=IC]<?60-[V#6Y2^JY/ZO4YE:A&+51H:Y08)U53> G =I
MC0*T\<BHF)7. I4&LU\V\($&1(41:M^ J*Q0 PT>U@EEG>ON"?&Q**\PO>RB
MC/Q$!$/XCGA*?3FE-<]-@G">59)Y> Q"V*FCDNF>#])>:1],VG1*)NUF#D:Q
MNU XWWGA/)G/,7.R76/VI+C&,"FC;\7J 6!N!0=EA_HCUI0A7=N/.YEQA(J\
M+/US>6,L99_YH(F.X_+#J>:=XW6ALVD-#[XXU5>3K9$U*A5)]:8C;N<([U6G
M7 B'C[N3!W]DIWZT78IKC!)&8Y1Z0]/!O4]HF"ON:GI6="!!ON'AD:E^".]-
M%M9P7FV8R5HR?>.-=/HO(AUN.&?8*W>2<3N31IR)PCGP-WX6+C-.%(<.('"9
M%(5'L$L/,6FE&38X]:5K-*]@A"E+Z_;3'+L$N9J#\,.L $8\*MX1D!%UBF*6
M.B&7F@_,)>9C18@Y25Z.7D;OCR+-I?!$C/:Y0A0[8Y@69)'E]$Z8\8T#G@4^
M;;&+(=&N=X=$<#YI0X<%PQU0 6>-R:.05C%VT:$J$>-,=%2RHR:<YIDGS9(H
MD,XPPT]!/>[#*;=3?9K_E^_W_987^IWS\-_YI'\?5#=-FJ'=R<].)SOK*"/>
MEU%>$JNCM>9[Q'1T#B#W8X>F!K:V(ZT,\A<"+1CH*U]8C55#8&,@EE4.HCB[
M);\#J$Z'H6+&O.$6T($9,7S*#O"<!6R3 L.AL#768>GWQ4R<]4QJJ\5]U)&*
M._QWJH[#?09C)=(<.Q%AD!$X38&&U!5ZD^F7S,I+(,H%UM%YMJ*:5I>ULIY&
MVD'P#,QMEZ#47-.C@(G'=6H>GI=] DU,"#,H7!]?IW.]VYUA2Q=O:^G$(]SS
M!AO6G>Q7T Q>N;*=7(^[[_0#9M9F:FM#,V4UM)VUK0;-<&>SWIT3-P?K%]_:
MLO;VN?6>5LB#@"B^2^J_FPWGH'5$V'Y?^$[7D"E7[:YE\?")FZ4B!A49K9$R
M49SP**?UM/*BFE2GO:X)>+9.V)A4[#\D;@.:>?<$[Z?=%+RO)'1Z"1$S9"T2
M=10R=<U-98=24P>G2@/>6O#@,-2>GA=I%W#A(S1D=]T%:9N6N,W41(,854#0
ML*GC@' ?>AIJ8\T3"D$@'J)3?PE^<END/:"H1H3-#+6T(DY#L*+*2V[T,)1[
MJSN9/S*G %^%\0YYIY@C8>ORQ.&]<.<!V4C%&M?O X$HR?3H9I1[X$DOIF.,
M?7]T?X,G_8ZY\B;4NW4?#/(IB0!YR:^Z!0]*Z]BS*G9A,*$EP4W/=8H5U60I
MYB)B\4)0!,<#Y60!ES+@' ^:-8XAL/!<'52.TK"/P?G",P]P6N(Y[^K"NSSM
MKI;6DD0"0> *@-%#'#K=KBV4!Q*^ST4&#:F">B%7!,)0'P@JA^!]IBIPR'R/
MVEBXW 51#/+Y_1KI:3HE(/:GO!'HQA_4#GC!8XB$/$#!./9!VTU(W7'X80QE
MZL@B1VDC"(?:"Z[!Q8X8>NWU+J,_P$>!I,)Y8XC![]+*&.,*TLSNYJR^X,9!
M</LK[A.+&8\X,HL%PK^AHM::_YS*KP8 W_W@(*5VD+\X'!/$&7U9 D^.=$KB
M=TT%(S?0\(%#.$B^"5CY"ER0*B.J;!@I2#S\\'.>NQ];8T)[0YA9AV)S+,R_
M9+D5H;(PE,LF33<":V9OX4U9W#LI/MHS-.E;%R'CML(M*E)NS]B<CJ$Q/\,*
M^,*S1'7+\XW3<KM+&^:V^>WT]-[#H-V3YF$3RB.8.O43<J(@UYGZD/YO[]]^
M^-6]^6\%-H%ZWR!O_FFYNJ;XPJ^0DS6T%]%Y+U7EHWY(?;CV&-SX8HE_D;&5
M=WUGW+K- VAH01D94^F^2@E*TR 8_G!*9_.P/-^BK^A$=,^S'>H,P[W.!)#\
MEON4;QVJY.-I_524KDG!8 ?\7#58[P+-K\##T<&XFT)38BQ5PX@Q3)/AO!A4
MK(WT^V;-3/R(847;@!+'LK&2L=*.X!6H/"J#!6R[)OG']Z<C^@\WB?XIF5!@
M^#E]>!=^V;,60%SQW#6?&<!H_P\83"/!-J5L[*\I:4:#B$LJL&8NO+W.WFN<
MVF E&MW&F^-U6UUBJLL_\]"9)X/GZX[;>I./&^CX?MHB6W?(/+[V56G4O1*>
MQ#64Y>,BZ '=C^Y3//\BJ05[#C@^X" @%!TRD@4Q0CFM?(^&D+(L%,-]T#N3
MJQ,>T3O.;2=_A+0-;'D01M/9R(#508\ 8\2$W$A<E^H8BL,T)M(!5;&A<4EM
M/R"9;4V9N$.<$-@L6+@_AU5$D5E" BW(ET-PHZQ$H)JV*FYG1U&0PFHY(-XK
MP)=:5$EK]Q-<X*FX0R'V^-:?DN)CU:Z:^37TX]7-A9 VGTK>&8QXD:3,GV!W
MQC))S5W_KG7]NS)=R::1NWD>P.5N*C8CPA*SUO<%DJ4PCO/1HKWC >>8?5YW
M?6[.H=;%,-&'-9EG5K]1#. 0 'QM5=U21H&< [OF"&#%]S,B#(/LQK#MJB_V
M07T.KV!2%OCAF=L]J_YXAZSZ$[L\*<H![?S?L64M__&+ZAAN]<A9,]\V)4./
M7;\#"5'DHTP+D\ +PI;"9KRIM$'']"'6N]E_.#;(E*J?G1DHU"U 5](07 $$
M_Q;=>^\ZMMXZR3>5;?Q@A[;Q>Z$#P9C**\ZP3&JW#G?>UCCWF"(\_E7(E </
MHE:.A34(*P,XGW,J,G7QZ5LPG8CJZ/(@:PJ)\@:0J-$;\>=9U7T?#S+@-]N]
M\^WA#FV,-Y3?V'* EI@8,-$"P8*,[3TO"V0/41^LP=B'9Y)#CCU74#;83?[!
M^'ET9]^OL^]U Q#HQM 68OU(7MK%*IQ!BZR\M(1AL =935PX8[FRE[N0$=>8
M=+Y65D;9MS+6K.KNZ9!'.Z1#3J$DTU3@GVQ9D72.5"GYI#"BJP8NVN6,V'KF
M:N2^0IWBJ%=PU@'GHKM<Q>:,0NE":-8>K< O&$<S!(;D_C8N4".($^@V(*=B
MG2"]L5#='D6O.J2-01NN)3$Z6'50+@; (<0MF+84^4BXBG<AG0THAEQP\%.]
M^5'T@EZ*BX3]"ZL?41T%=5'!ED^N7V8PAAEP5GZB<*9BEF2">"CJK4JK,ZAC
M:/"K W-T?A0!:]<#:[RG"_S7\7.XFC]L,OGP4)&ZN9 7<CZJ]X"B[Y;XBT;>
MIQ.WC'[7<0(I;G+DK'&G2&W3 S**KT*J$9U$"L'QX4;GF1.FV),U2K#<E7EC
MXA#7;&AFU\ZIFR474:?>]A3*8.Z0->^P>VKS\0ZIS7\:[&F[=94)Q0 T$CE
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MIB2"]>*!CMAUF/'6/0-[JFAA4M(PR5408AVL.\:=)P7]]:%/&71>,JCM]R:
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M1W/* ?RQ@S=!6ZXR4,364>#Z;+[U;5V=;KG2D8];WL,7\:EN78 R+-'%%#:
MI""[R^DVG@^VQ,AP@KBF.##P2"J<Y+9]Z,92MV^(<J;)TN[KSVU1,JE].<%
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M7UP%+T>C\^!R]-/9^&IT.7H5?#A_-;H,KMZ,]*5GHW$P/+T*+EX'!\^/CL(
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M"#Q3WF8HFF"?@%;'Q_?>@@NN8*?VPI(PI7.$:( %X= 3ULRC8L*J/Z]J\>C
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MX7UG+:)2)B9-J+(O1&,2W/6RRL%#8W^IK(K\OAML9@YK3*8Z;R\KN$V^3"
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M0^FR&2/606@)2N.!EJ'!0X!4!/F%\CRB.GD':(< !9!HL80A+)>KT1F8XT7
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MEO3*I1Q569LEAS.?<"^EJB-D#]=CQRYJ$EPBD*M,]#H&\UKX!Q#%O&"CG*G
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M2P$"% ,4    " #U@W-8_TVSU>_[!0"D-#X $0              @ $
M:6)R>"TR,#(S,3(S,2YH=&U02P$"% ,4    " #U@W-8,"AR<F$F  "=QP$
M$0              @ $>_ 4 :6)R>"TR,#(S,3(S,2YX<V102P$"% ,4
M" #U@W-8I6[@UU9#   WPP( %0              @ &N(@8 :6)R>"TR,#(S
M,3(S,5]C86PN>&UL4$L! A0#%     @ ]8-S6.I<?L02^P  S2P+ !4
M         ( !-V8& &EB<G@M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M /6#<UC!TJ()=U4! *VE 0 4              "  7QA!P!I8G)X+3(P,C,Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( /6#<UC5W:F0300' +7/"0 4
M      "  26W" !I8G)X+3(P,C,Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( /6#
M<UA'>^3/_R0! *;/ 0 4              "  :2[#P!I8G)X+3(P,C,Q,C,Q
M7V<S+FIP9U!+ 0(4 Q0    ( /:#<UC/:$X6?-X! '(P$@ 5
M  "  =7@$ !I8G)X+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #V@W-8
M>CX0=MI) 0"<Y X %0              @ &$OQ( :6)R>"TR,#(S,3(S,5]P
M<F4N>&UL4$L! A0#%     @ ]H-S6 @#!MY,!0  .",  !L
M ( !D0D4 &EB<G@M,C R,S$R,S%X,3!K97@Q,#0Q+FAT;5!+ 0(4 Q0    (
M /:#<UBX9*;6X00  )8^   ?              "  18/% !I8G)X+3(P,C,Q
M,C,Q>#$P:V5X:&EB:70R,3$N:'1M4$L! A0#%     @ ]H-S6,\(>ZY\!
M5!@  !\              ( !-!04 &EB<G@M,C R,S$R,S%X,3!K97AH:6)I
M=#(S,2YH=&U02P$"% ,4    " #V@W-86PL8 D$(   X+   'P
M    @ 'M&!0 :6)R>"TR,#(S,3(S,7@Q,&ME>&AI8FET,S$Q+FAT;5!+ 0(4
M Q0    ( /:#<UA6X6@5.0@  "DL   ?              "  6LA% !I8G)X
M+3(P,C,Q,C,Q>#$P:V5X:&EB:70S,3(N:'1M4$L! A0#%     @ ]H-S6*"W
M017-!   8A4  !\              ( !X2D4 &EB<G@M,C R,S$R,S%X,3!K
M97AH:6)I=#,R,2YH=&U02P$"% ,4    " #V@W-8$X%GBZ4$  !:$P  'P
M            @ 'K+A0 :6)R>"TR,#(S,3(S,7@Q,&ME>&AI8FET,S(R+FAT
M;5!+ 0(4 Q0    ( /:#<UB!<UI(4@X  "=$   >              "  <TS
M% !I8G)X+3(P,C,Q,C,Q>#$P:V5X:&EB:70T-RYH=&U02P$"% ,4    " #V
M@W-8&;-1NU04  !<=@  'P              @ %;0A0 :6)R>"TR,#(S,3(S
M,7@Q,&ME>&AI8FET.3<Q+FAT;5!+ 0(4 Q0    ( /:#<UA);Q3>-PH  )X^
M   ?              "  >Q6% !I8G)X,C R,S$R,S$M,3!K97AH:6)I=#$P
M,3,N:'1M4$L! A0#%     @ ]H-S6%1UZ547*@  :A<! !\
M ( !8&$4 &EB<G@R,#(S,3(S,2TQ,&ME>&AI8FET,3 Q-RYH=&U02P$"% ,4
M    " #V@W-8*>#FR^Z' 0"CV0L '@              @ &TBQ0 :6)R>#(P
M,C,Q,C,Q+3$P:V5X:&EB:70Q,#,N:'1M4$L! A0#%     @ ]H-S6-58)5IR
M>P  !IX# !X              ( !WA,6 &EB<G@R,#(S,3(S,2TQ,&ME>&AI
M8FET,3 T+FAT;5!+ 0(4 Q0    ( /:#<U@8Z\^,14L  -K_ 0 >
M      "  8R/%@!I8G)X,C R,S$R,S$M,3!K97AH:6)I=#$P-2YH=&U02P4&
2     !< %P!^!@  #=L6

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>ibrx-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ibrx="http://www.immunitybio.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ibrx-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantKwestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:ExecutiveChairmanAndGlobalChiefScientificAndMedicalOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:AdvancesToRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:GlobeImmuneIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:RelatedPartyWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:IPRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:RiptideBioscienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:StockOptionPurchaseLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-25</startDate>
            <endDate>2023-07-25</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015AmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalCancerInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreement2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:AmyrisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ibrx:AmyrisJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:A3MIPCAndAAHIAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeScheduleAxis">ibrx:CollaborativeArrangementAndArrangementOtherThanCollaborativeFeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AAHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:ViractaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:ViractaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:ViractaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OffMarketFavorableLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ibrx:OrganizedWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:StateOfNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibrx:DunkirkFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-04-30</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:DrSoonShiongAndRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsObligationSalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:AltorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-09</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-09</startDate>
            <endDate>2022-07-09</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-08</startDate>
            <endDate>2022-12-08</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibrx:SorrentoTherapeuticsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NANTibodyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">ibrx:CGMPBatchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">ibrx:SoftwareLicenseSubscriptionFeesAndImplementationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">ibrx:LaboratoryCleanroomServiceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:InitialPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:InitialPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:SecondPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:SecondPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:InitialPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:TieredPaymentsAxis">ibrx:SecondPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ibrx:OptionPeriodAxis">ibrx:PeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-30</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:EmbeddedDerivativeRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-30</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:CommonStockRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-30</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ibrx:FairValueStockPurchaseOptionRevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-30</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Tranche1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Tranche1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-13</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-17</startDate>
            <endDate>2021-12-17</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-13</startDate>
            <endDate>2023-06-13</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ibrx:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantCancerStemCellLLCAndNantMobileLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A505MillionPromissoryNoteDecember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputMarketYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalNantWorksLLCNantCancerStemCellLLCAndNantMobileLLCExecuted9112023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ibrx:ValuationTechniqueBinomialLatticeModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ibrx:MeasurementInputExpectedMarketYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A300MillionDecember2021PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A125MillionAugust2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A50MillionDecember2022PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionMarch2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A30MillionJune2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:A200MillionSeptember2023PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:RelatedPartyFixedRateNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesPrincipalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ibrx:PromissoryNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:RelatedPartyNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:VariousMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:VariousMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-01</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SeptemberTwentyNineteenLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:JulyTwentyNineteenLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ibrx:DueToRelatedPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:ExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:InitialAndExpansionPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-27</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-27</startDate>
            <endDate>2021-09-27</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:FiveFiveSevenDougStLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:FourTwoZeroNashLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-01</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-01</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:A23AlaskaLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibrx:BrinkBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:February2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenShareRepurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:February2023ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:PrivatePlacementAndAtTheMarketOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibrx:July2023WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibrx:StockPurchaseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLLCMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:A2014PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-25</startDate>
            <endDate>2023-08-25</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ibrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-25</startDate>
            <endDate>2023-08-25</endDate>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-25</startDate>
            <endDate>2023-08-25</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>ibrx:segment</measure>
    </unit>
    <unit id="security">
        <measure>ibrx:security</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="licenseagreement">
        <measure>ibrx:licenseAgreement</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal_options">
        <measure>ibrx:renewal_options</measure>
    </unit>
    <unit id="employee">
        <measure>ibrx:employee</measure>
    </unit>
    <unit id="advance">
        <measure>ibrx:advance</measure>
    </unit>
    <unit id="lease">
        <measure>ibrx:lease</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001326110</dei:EntityCentralIndexKey>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-1044">http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-10" id="f-1125">http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-370" id="f-1163">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-370" id="f-1165">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1170">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1171">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1178">http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1179">http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1184">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1185">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:Revenues contextRef="c-600" decimals="-5" id="f-1722" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-601" decimals="-5" id="f-1723" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-668"
      decimals="INF"
      id="f-1922"
      unitRef="number">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-669"
      decimals="INF"
      id="f-1923"
      unitRef="number">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-37507</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">IMMUNITYBIO,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">43-1979754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">3530 John Hopkins Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">696-5235</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">IBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">315900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">673952278</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As noted herein, the information called for by Part&#160;III of this Annual Report is incorporated by reference to specified portions of the registrant&#x2019;s definitive proxy statement to be filed in conjunction with the registrant&#x2019;s 2024&#160;Annual Meeting of Stockholders, which is expected to be filed not later than 120&#160;days after the registrant&#x2019;s fiscal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; December&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-36">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-37">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-38">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">265453000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-40" unitRef="usd">104641000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">1009000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">2543000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">2019000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">1890000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">25603000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">31503000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">294084000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">140577000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">891000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">840000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">146082000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">143659000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">17093000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">20003000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <ibrx:ConvertibleNoteReceivableNonCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">6879000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <ibrx:ConvertibleNoteReceivableNonCurrent contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">6629000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">36543000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">45788000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">2880000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">4860000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">504452000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">362356000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-63" unitRef="usd">9195000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-64" unitRef="usd">21016000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">42708000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">41825000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">431901000</us-gaap:NotesPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-69" unitRef="usd">1136000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-9" decimals="-3" id="f-70" unitRef="usd">3469000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">5244000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">2650000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">58283000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">500861000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLongTermNotesPayable contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">104586000</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:OtherLongTermNotesPayable contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">576951000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">241271000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:SecuredLongTermDebt contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">155415000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">0</us-gaap:SecuredLongTermDebt>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">35333000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">39942000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">47951000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">118770000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">21636000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">1109000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">457000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">1090389000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">812176000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-91" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-92" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-93"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-95" unitRef="shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-96" unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-97" unitRef="shares">670867344</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-98" unitRef="shares">670867344</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-99" unitRef="shares">421569115</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-100" unitRef="shares">421569115</us-gaap:CommonStockSharesIssued>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-101" unitRef="shares">163800</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="INF" id="f-102" unitRef="shares">163800</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">67000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">2374620000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">1930936000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">-2961684000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">-2378488000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">183000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">-586987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">-447327000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">1050000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">-2493000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-115" unitRef="usd">-585937000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">-449820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-117" unitRef="usd">504452000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">362356000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">622000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-3" id="f-120" unitRef="usd">240000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-121" unitRef="usd">934000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">232366000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-10" decimals="-3" id="f-123" unitRef="usd">248149000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="-3" id="f-124" unitRef="usd">195958000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">129620000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-10" decimals="-3" id="f-126" unitRef="usd">102708000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-11" decimals="-3" id="f-127" unitRef="usd">135256000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">886000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-10" decimals="-3" id="f-129" unitRef="usd">681000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-11" decimals="-3" id="f-130" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">362872000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-10" decimals="-3" id="f-132" unitRef="usd">351538000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-11" decimals="-3" id="f-133" unitRef="usd">331214000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">-362250000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-10" decimals="-3" id="f-135" unitRef="usd">-351298000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="-3" id="f-136" unitRef="usd">-330280000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">1131000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-10" decimals="-3" id="f-138" unitRef="usd">-3090000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-11" decimals="-3" id="f-139" unitRef="usd">-4100000</us-gaap:GainLossOnInvestments>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">129198000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-10" decimals="-3" id="f-141" unitRef="usd">63515000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-11" decimals="-3" id="f-142" unitRef="usd">14849000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-7549000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-10" decimals="-3" id="f-144" unitRef="usd">-12107000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-11" decimals="-3" id="f-145" unitRef="usd">-803000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">47600000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-10" decimals="-3" id="f-147" unitRef="usd">-13460000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-11" decimals="-3" id="f-148" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">-36203000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-10" decimals="-3" id="f-150" unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-11" decimals="-3" id="f-151" unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-2223000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-153" unitRef="usd">-736000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-11" decimals="-3" id="f-154" unitRef="usd">193000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">-221642000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-156" unitRef="usd">-65988000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-11" decimals="-3" id="f-157" unitRef="usd">-19559000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">-583892000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-159" unitRef="usd">-417286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-160" unitRef="usd">-349839000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">-40000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-162" unitRef="usd">34000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-163" unitRef="usd">9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">-583852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-10" decimals="-3" id="f-165" unitRef="usd">-417320000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-3" id="f-166" unitRef="usd">-349848000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">-656000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-168" unitRef="usd">-753000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-169" unitRef="usd">-3058000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">-583196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-171" unitRef="usd">-416567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-172" unitRef="usd">-346790000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">-1.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">-1.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-177"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-178"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-179" unitRef="shares">508635592</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-180" unitRef="shares">508635592</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-181" unitRef="shares">399900374</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-182" unitRef="shares">399900374</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-183" unitRef="shares">389234156</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-184" unitRef="shares">389234156</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-583852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-10" decimals="-3" id="f-186" unitRef="usd">-417320000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-3" id="f-187" unitRef="usd">-349848000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">60000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-10" decimals="-3" id="f-189" unitRef="usd">-183000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="c-11" decimals="-3" id="f-190" unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">15000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-10" decimals="-3" id="f-192" unitRef="usd">-124000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-11" decimals="-3" id="f-193" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">-218000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-10" decimals="-3" id="f-195" unitRef="usd">238000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-11" decimals="-3" id="f-196" unitRef="usd">-105000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-173000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-10" decimals="-3" id="f-198" unitRef="usd">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-11" decimals="-3" id="f-199" unitRef="usd">-118000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">-584025000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-201" unitRef="usd">-417141000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-202" unitRef="usd">-349966000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-656000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-204" unitRef="usd">-753000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-205" unitRef="usd">-3058000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-583369000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-10" decimals="-3" id="f-207" unitRef="usd">-416388000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-11" decimals="-3" id="f-208" unitRef="usd">-346908000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-209"
      unitRef="shares">382243142</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-210" unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-211" unitRef="usd">1495163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-212" unitRef="usd">-1615131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-213" unitRef="usd">122000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-214" unitRef="usd">-119808000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-215" unitRef="usd">1318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-216" unitRef="usd">-118490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-19" decimals="-3" id="f-217" unitRef="usd">4674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-20"
      decimals="INF"
      id="f-218"
      unitRef="shares">13295817</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-219" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-220" unitRef="usd">164528000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-221" unitRef="usd">164530000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-3" id="f-222" unitRef="usd">164530000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-223" unitRef="usd">57181000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-224" unitRef="usd">57181000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-225" unitRef="usd">57181000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-25"
      decimals="INF"
      id="f-226"
      unitRef="shares">1695638</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-23" decimals="-3" id="f-227" unitRef="usd">5461000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-24" decimals="-3" id="f-228" unitRef="usd">5461000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-11" decimals="-3" id="f-229" unitRef="usd">5461000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-25"
      decimals="INF"
      id="f-230"
      unitRef="shares">873058</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-25"
      decimals="INF"
      id="f-231"
      unitRef="shares">277611</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-23" decimals="-3" id="f-232" unitRef="usd">4064000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-24" decimals="-3" id="f-233" unitRef="usd">4064000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-11" decimals="-3" id="f-234" unitRef="usd">4064000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-23" decimals="-3" id="f-235" unitRef="usd">1435000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-24" decimals="-3" id="f-236" unitRef="usd">1435000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-11" decimals="-3" id="f-237" unitRef="usd">1435000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-26" decimals="-3" id="f-238" unitRef="usd">-118000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-24" decimals="-3" id="f-239" unitRef="usd">-118000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-11" decimals="-3" id="f-240" unitRef="usd">-118000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-27" decimals="-3" id="f-241" unitRef="usd">-346790000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-24" decimals="-3" id="f-242" unitRef="usd">-346790000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-243" unitRef="usd">-3058000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-3" id="f-244" unitRef="usd">-349848000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-245"
      unitRef="shares">397830044</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-246" unitRef="usd">40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-247" unitRef="usd">1719704000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-248" unitRef="usd">-1961921000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-249" unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-250" unitRef="usd">-242173000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-251" unitRef="usd">-1740000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-252" unitRef="usd">-243913000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-36" decimals="-3" id="f-253" unitRef="usd">302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-37"
      decimals="INF"
      id="f-254"
      unitRef="shares">2051894</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="-3" id="f-255" unitRef="usd">13129000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-39" decimals="-3" id="f-256" unitRef="usd">13129000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-36" decimals="-3" id="f-257" unitRef="usd">13129000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-40"
      decimals="INF"
      id="f-258"
      unitRef="shares">9986920</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-40" decimals="-3" id="f-259" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-41" decimals="-3" id="f-260" unitRef="usd">51946000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-42" decimals="-3" id="f-261" unitRef="usd">51947000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-10" decimals="-3" id="f-262" unitRef="usd">51947000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-43" decimals="-3" id="f-263" unitRef="usd">1897000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-44"
      decimals="INF"
      id="f-264"
      unitRef="shares">9090909</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-44" decimals="-3" id="f-265" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-45" decimals="-3" id="f-266" unitRef="usd">13006000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-46" decimals="-3" id="f-267" unitRef="usd">13007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-43" decimals="-3" id="f-268" unitRef="usd">13007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-269" unitRef="usd">40179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-270" unitRef="usd">40179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-10" decimals="-3" id="f-271" unitRef="usd">40179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-40"
      decimals="INF"
      id="f-272"
      unitRef="shares">14767</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-41" decimals="-3" id="f-273" unitRef="usd">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-42" decimals="-3" id="f-274" unitRef="usd">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-10" decimals="-3" id="f-275" unitRef="usd">74000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-40"
      decimals="INF"
      id="f-276"
      unitRef="shares">521296</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-40"
      decimals="INF"
      id="f-277"
      unitRef="shares">156011</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-41" decimals="-3" id="f-278" unitRef="usd">616000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-42" decimals="-3" id="f-279" unitRef="usd">616000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-10" decimals="-3" id="f-280" unitRef="usd">616000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <ibrx:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="c-40"
      decimals="INF"
      id="f-281"
      unitRef="shares">2229296</ibrx:StockIssuedDuringPeriodSharesLitigationSettlement>
    <ibrx:StockIssuedDuringPeriodValueLitigationSettlement contextRef="c-41" decimals="-3" id="f-282" unitRef="usd">10656000</ibrx:StockIssuedDuringPeriodValueLitigationSettlement>
    <ibrx:StockIssuedDuringPeriodValueLitigationSettlement contextRef="c-42" decimals="-3" id="f-283" unitRef="usd">10656000</ibrx:StockIssuedDuringPeriodValueLitigationSettlement>
    <ibrx:StockIssuedDuringPeriodValueLitigationSettlement contextRef="c-10" decimals="-3" id="f-284" unitRef="usd">10656000</ibrx:StockIssuedDuringPeriodValueLitigationSettlement>
    <ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty contextRef="c-41" decimals="-3" id="f-285" unitRef="usd">82858000</ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty>
    <ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty contextRef="c-42" decimals="-3" id="f-286" unitRef="usd">82858000</ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty>
    <ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty contextRef="c-10" decimals="-3" id="f-287" unitRef="usd">82858000</ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-47" decimals="-3" id="f-288" unitRef="usd">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-42" decimals="-3" id="f-289" unitRef="usd">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-10" decimals="-3" id="f-290" unitRef="usd">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-48" decimals="-3" id="f-291" unitRef="usd">-416567000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-42" decimals="-3" id="f-292" unitRef="usd">-416567000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-49" decimals="-3" id="f-293" unitRef="usd">-753000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-10" decimals="-3" id="f-294" unitRef="usd">-417320000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-50"
      decimals="INF"
      id="f-295"
      unitRef="shares">421569115</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-296" unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-297" unitRef="usd">1930936000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-298" unitRef="usd">-2378488000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-299" unitRef="usd">183000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-3" id="f-300" unitRef="usd">-447327000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-301" unitRef="usd">-2493000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-302" unitRef="usd">-449820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-56" decimals="-3" id="f-303" unitRef="usd">457000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-57"
      decimals="INF"
      id="f-304"
      unitRef="shares">5605323</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-57" decimals="-3" id="f-305" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-58" decimals="-3" id="f-306" unitRef="usd">16105000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-59" decimals="-3" id="f-307" unitRef="usd">16106000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-56" decimals="-3" id="f-308" unitRef="usd">16106000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-60"
      decimals="INF"
      id="f-309"
      unitRef="shares">209291936</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-60" decimals="-3" id="f-310" unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-61" decimals="-3" id="f-311" unitRef="usd">269966000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-62" decimals="-3" id="f-312" unitRef="usd">269987000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">269987000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-63" decimals="-3" id="f-314" unitRef="usd">3535000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-64"
      decimals="INF"
      id="f-315"
      unitRef="shares">28641911</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-64" decimals="-3" id="f-316" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-65" decimals="-3" id="f-317" unitRef="usd">36928000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-66" decimals="-3" id="f-318" unitRef="usd">36931000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-63" decimals="-3" id="f-319" unitRef="usd">36931000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-67" decimals="-3" id="f-320" unitRef="usd">473000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-68"
      decimals="INF"
      id="f-321"
      unitRef="shares">2432894</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-69" decimals="-3" id="f-322" unitRef="usd">11581000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-70" decimals="-3" id="f-323" unitRef="usd">11581000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-67" decimals="-3" id="f-324" unitRef="usd">11581000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl contextRef="c-61" decimals="-3" id="f-325" unitRef="usd">36110000</ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl>
    <ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl contextRef="c-62" decimals="-3" id="f-326" unitRef="usd">36110000</ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl>
    <ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">36110000</ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl>
    <ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature contextRef="c-61" decimals="-3" id="f-328" unitRef="usd">31179000</ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature>
    <ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature contextRef="c-62" decimals="-3" id="f-329" unitRef="usd">31179000</ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature>
    <ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">31179000</ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-61" decimals="-3" id="f-331" unitRef="usd">49163000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-62" decimals="-3" id="f-332" unitRef="usd">49163000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">49163000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-60"
      decimals="INF"
      id="f-334"
      unitRef="shares">184362</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-61" decimals="-3" id="f-335" unitRef="usd">294000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-62" decimals="-3" id="f-336" unitRef="usd">294000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">294000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c-60"
      decimals="INF"
      id="f-338"
      unitRef="shares">4545644</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-60"
      decimals="INF"
      id="f-339"
      unitRef="shares">1403841</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-61" decimals="-3" id="f-340" unitRef="usd">3443000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-62" decimals="-3" id="f-341" unitRef="usd">3443000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">3443000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement contextRef="c-61" decimals="-3" id="f-343" unitRef="usd">-4199000</ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement>
    <ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement contextRef="c-62" decimals="-3" id="f-344" unitRef="usd">-4199000</ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement>
    <ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement contextRef="c-71" decimals="-3" id="f-345" unitRef="usd">4199000</ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement>
    <ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">0</ibrx:NoncontrollingInterestIncreaseDecreaseFromLegalSettlement>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-72" decimals="-3" id="f-347" unitRef="usd">-173000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-62" decimals="-3" id="f-348" unitRef="usd">-173000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">-173000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-73" decimals="-3" id="f-350" unitRef="usd">-583196000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-62" decimals="-3" id="f-351" unitRef="usd">-583196000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-71" decimals="-3" id="f-352" unitRef="usd">-656000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-583852000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-74"
      decimals="INF"
      id="f-354"
      unitRef="shares">670867344</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-3" id="f-355" unitRef="usd">67000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-3" id="f-356" unitRef="usd">2374620000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-3" id="f-357" unitRef="usd">-2961684000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-3" id="f-358" unitRef="usd">10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-3" id="f-359" unitRef="usd">-586987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-3" id="f-360" unitRef="usd">1050000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-361" unitRef="usd">-585937000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">-583852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-10" decimals="-3" id="f-363" unitRef="usd">-417320000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-3" id="f-364" unitRef="usd">-349848000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">49163000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-10" decimals="-3" id="f-366" unitRef="usd">40179000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-11" decimals="-3" id="f-367" unitRef="usd">57181000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">47600000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-10" decimals="-3" id="f-369" unitRef="usd">-13460000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-11" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">42396000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-10" decimals="-3" id="f-372" unitRef="usd">16282000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-11" decimals="-3" id="f-373" unitRef="usd">62000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">-36203000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-10" decimals="-3" id="f-375" unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-11" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">18512000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-10" decimals="-3" id="f-378" unitRef="usd">18260000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-379" unitRef="usd">14238000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">9189000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-10" decimals="-3" id="f-381" unitRef="usd">11746000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-11" decimals="-3" id="f-382" unitRef="usd">12417000</us-gaap:PaidInKindInterest>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">6112000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-10" decimals="-3" id="f-384" unitRef="usd">5932000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-11" decimals="-3" id="f-385" unitRef="usd">4884000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <ibrx:TransactionCostsWarrantLiability contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">2010000</ibrx:TransactionCostsWarrantLiability>
    <ibrx:TransactionCostsWarrantLiability contextRef="c-10" decimals="-3" id="f-387" unitRef="usd">1082000</ibrx:TransactionCostsWarrantLiability>
    <ibrx:TransactionCostsWarrantLiability contextRef="c-11" decimals="-3" id="f-388" unitRef="usd">0</ibrx:TransactionCostsWarrantLiability>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">-1591000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-10" decimals="-3" id="f-390" unitRef="usd">-4190000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="-3" id="f-391" unitRef="usd">-4615000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">886000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-10" decimals="-3" id="f-393" unitRef="usd">681000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-11" decimals="-3" id="f-394" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">137000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-10" decimals="-3" id="f-396" unitRef="usd">-1318000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-11" decimals="-3" id="f-397" unitRef="usd">-403000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-10" decimals="-3" id="f-399" unitRef="usd">1333000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-11" decimals="-3" id="f-400" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-401" unitRef="usd">-407000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-10" decimals="-3" id="f-402" unitRef="usd">269000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-11" decimals="-3" id="f-403" unitRef="usd">741000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">-5958000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-10" decimals="-3" id="f-405" unitRef="usd">16557000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-11" decimals="-3" id="f-406" unitRef="usd">2249000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">-1913000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-10" decimals="-3" id="f-408" unitRef="usd">-1998000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-11" decimals="-3" id="f-409" unitRef="usd">3977000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">-6476000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-10" decimals="-3" id="f-411" unitRef="usd">8000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-11" decimals="-3" id="f-412" unitRef="usd">-3717000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-413" unitRef="usd">6689000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-10" decimals="-3" id="f-414" unitRef="usd">4102000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-11" decimals="-3" id="f-415" unitRef="usd">5182000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">-1129000</ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent>
    <ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent contextRef="c-10" decimals="-3" id="f-417" unitRef="usd">-1225000</ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent>
    <ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent contextRef="c-11" decimals="-3" id="f-418" unitRef="usd">-10187000</ibrx:IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-419" unitRef="usd">-2978000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-10" decimals="-3" id="f-420" unitRef="usd">-4319000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-11" decimals="-3" id="f-421" unitRef="usd">-4164000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">-366757000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-10" decimals="-3" id="f-423" unitRef="usd">-337509000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-11" decimals="-3" id="f-424" unitRef="usd">-274419000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">30584000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-10" decimals="-3" id="f-426" unitRef="usd">78162000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-427" unitRef="usd">33563000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-428" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-10" decimals="-3" id="f-429" unitRef="usd">21229000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-11" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-10" decimals="-3" id="f-432" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-433" unitRef="usd">20498000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-434" unitRef="usd">10358000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-10" decimals="-3" id="f-435" unitRef="usd">34312000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-11" decimals="-3" id="f-436" unitRef="usd">141750000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-437" unitRef="usd">10100000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-10" decimals="-3" id="f-438" unitRef="usd">128188000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-11" decimals="-3" id="f-439" unitRef="usd">56166000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-440" unitRef="usd">372000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-10" decimals="-3" id="f-441" unitRef="usd">33812000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-11" decimals="-3" id="f-442" unitRef="usd">13763000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c-10" decimals="-3" id="f-444" unitRef="usd">1000000</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c-11" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">-30470000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-10" decimals="-3" id="f-447" unitRef="usd">27297000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-11" decimals="-3" id="f-448" unitRef="usd">-84886000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-1" decimals="-3" id="f-449" unitRef="usd">258700000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-10" decimals="-3" id="f-450" unitRef="usd">174125000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-11" decimals="-3" id="f-451" unitRef="usd">338500000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-1" decimals="-3" id="f-452" unitRef="usd">192764000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-10" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-11" decimals="-3" id="f-454" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-80" decimals="-3" id="f-455" unitRef="usd">100561000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-81" decimals="-3" id="f-456" unitRef="usd">60427000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-82" decimals="-3" id="f-457" unitRef="usd">164530000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-83" decimals="-3" id="f-458" unitRef="usd">9542000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-84" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-85" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-461" unitRef="usd">294000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-10" decimals="-3" id="f-462" unitRef="usd">74000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-11" decimals="-3" id="f-463" unitRef="usd">5461000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-464" unitRef="usd">3443000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-10" decimals="-3" id="f-465" unitRef="usd">616000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-11" decimals="-3" id="f-466" unitRef="usd">4064000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-467" unitRef="usd">77000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-10" decimals="-3" id="f-468" unitRef="usd">58000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-11" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-1" decimals="-3" id="f-470" unitRef="usd">0</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-10" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-11" decimals="-3" id="f-472" unitRef="usd">1435000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-10" decimals="-3" id="f-474" unitRef="usd">339000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-11" decimals="-3" id="f-475" unitRef="usd">419000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-476" unitRef="usd">558341000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-10" decimals="-3" id="f-477" unitRef="usd">233613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-11" decimals="-3" id="f-478" unitRef="usd">505443000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-479" unitRef="usd">-292000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-10" decimals="-3" id="f-480" unitRef="usd">284000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-11" decimals="-3" id="f-481" unitRef="usd">48000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-482" unitRef="usd">160822000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-10" decimals="-3" id="f-483" unitRef="usd">-76315000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-11" decimals="-3" id="f-484" unitRef="usd">146186000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-485" unitRef="usd">104965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-35" decimals="-3" id="f-486" unitRef="usd">181280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-18" decimals="-3" id="f-487" unitRef="usd">35094000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-488" unitRef="usd">265787000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-489" unitRef="usd">104965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-35" decimals="-3" id="f-490" unitRef="usd">181280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-491" unitRef="usd">265453000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-492" unitRef="usd">104641000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-35" decimals="-3" id="f-493" unitRef="usd">181101000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-494" unitRef="usd">334000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-5" decimals="-3" id="f-495" unitRef="usd">324000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-35" decimals="-3" id="f-496" unitRef="usd">179000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-497" unitRef="usd">265787000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-498" unitRef="usd">104965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-35" decimals="-3" id="f-499" unitRef="usd">181280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-500" unitRef="usd">77192000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-10" decimals="-3" id="f-501" unitRef="usd">35442000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-11" decimals="-3" id="f-502" unitRef="usd">2106000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-503" unitRef="usd">8000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-10" decimals="-3" id="f-504" unitRef="usd">2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-11" decimals="-3" id="f-505" unitRef="usd">9000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-1" decimals="-3" id="f-506" unitRef="usd">269987000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-10" decimals="-3" id="f-507" unitRef="usd">51947000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-11" decimals="-3" id="f-508" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <ibrx:IssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-509" unitRef="usd">49534000</ibrx:IssuanceOfWarrants>
    <ibrx:IssuanceOfWarrants contextRef="c-10" decimals="-3" id="f-510" unitRef="usd">35096000</ibrx:IssuanceOfWarrants>
    <ibrx:IssuanceOfWarrants contextRef="c-11" decimals="-3" id="f-511" unitRef="usd">0</ibrx:IssuanceOfWarrants>
    <ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty contextRef="c-1" decimals="-3" id="f-512" unitRef="usd">36110000</ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty>
    <ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty contextRef="c-10" decimals="-3" id="f-513" unitRef="usd">82858000</ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty>
    <ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty contextRef="c-11" decimals="-3" id="f-514" unitRef="usd">0</ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty>
    <us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative contextRef="c-1" decimals="-3" id="f-515" unitRef="usd">31179000</us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative>
    <us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative contextRef="c-10" decimals="-3" id="f-516" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative>
    <us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative contextRef="c-11" decimals="-3" id="f-517" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainOnEmbeddedDerivative>
    <ibrx:CommonStockDiscountOnSharesRevenueInterestLiability contextRef="c-1" decimals="-3" id="f-518" unitRef="usd">2039000</ibrx:CommonStockDiscountOnSharesRevenueInterestLiability>
    <ibrx:CommonStockDiscountOnSharesRevenueInterestLiability contextRef="c-10" decimals="-3" id="f-519" unitRef="usd">0</ibrx:CommonStockDiscountOnSharesRevenueInterestLiability>
    <ibrx:CommonStockDiscountOnSharesRevenueInterestLiability contextRef="c-11" decimals="-3" id="f-520" unitRef="usd">0</ibrx:CommonStockDiscountOnSharesRevenueInterestLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-521" unitRef="usd">1156000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-10" decimals="-3" id="f-522" unitRef="usd">12693000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-11" decimals="-3" id="f-523" unitRef="usd">11654000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-524" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-10" decimals="-3" id="f-525" unitRef="usd">14798000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-11" decimals="-3" id="f-526" unitRef="usd">23069000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-527" unitRef="usd">3777000</ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability>
    <ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability contextRef="c-10" decimals="-3" id="f-528" unitRef="usd">0</ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability>
    <ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability contextRef="c-11" decimals="-3" id="f-529" unitRef="usd">0</ibrx:RightOfUseAssetDisposedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-10" decimals="-3" id="f-531" unitRef="usd">10656000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-11" decimals="-3" id="f-532" unitRef="usd">0</us-gaap:StockIssued1>
    <ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="c-1" decimals="-3" id="f-533" unitRef="usd">255000</ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses>
    <ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="c-10" decimals="-3" id="f-534" unitRef="usd">277000</ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses>
    <ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="c-11" decimals="-3" id="f-535" unitRef="usd">0</ibrx:UnpaidOfferingAndTransactionCostsIncludedInAccountsPayableAndAccruedExpenses>
    <ibrx:StockIssuedCashlessExerciseOfStockOptions contextRef="c-1" decimals="-3" id="f-536" unitRef="usd">0</ibrx:StockIssuedCashlessExerciseOfStockOptions>
    <ibrx:StockIssuedCashlessExerciseOfStockOptions contextRef="c-10" decimals="-3" id="f-537" unitRef="usd">0</ibrx:StockIssuedCashlessExerciseOfStockOptions>
    <ibrx:StockIssuedCashlessExerciseOfStockOptions contextRef="c-11" decimals="-3" id="f-538" unitRef="usd">1035000</ibrx:StockIssuedCashlessExerciseOfStockOptions>
    <ibrx:InvestmentsInJointVentureIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-539" unitRef="usd">0</ibrx:InvestmentsInJointVentureIncurredButNotYetPaid>
    <ibrx:InvestmentsInJointVentureIncurredButNotYetPaid contextRef="c-10" decimals="-3" id="f-540" unitRef="usd">0</ibrx:InvestmentsInJointVentureIncurredButNotYetPaid>
    <ibrx:InvestmentsInJointVentureIncurredButNotYetPaid contextRef="c-11" decimals="-3" id="f-541" unitRef="usd">1000000</ibrx:InvestmentsInJointVentureIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-542">Description of Business&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In these notes to the consolidated financial statements, the terms &#x201c;ImmunityBio,&#x201d; &#x201c;the company,&#x201d; &#x201c;the combined company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to ImmunityBio and subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Our Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Using our proprietary platforms that amplify both the innate and adaptive branches of the immune system, our teams of clinical, scientific, and manufacturing experts, advance novel therapies and vaccines aimed at defeating urologic and other cancers, as well as infectious diseases. Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, N-803 (Anktiva), our lead biologic commercial product candidate, has received &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Breakthrough Therapy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fast Track&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; designations and is currently under review by the FDA for treatment in combination with BCG of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease and has a new user fee goal date (PDUFA date) of April&#160;23,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including&#x2014;NK cells, dendritic cells, and macrophages, as well as&#x2014;the adaptive immune system comprising&#x2014;B&#160;and T&#160;cells,&#x2014;in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally-infected. Our ultimate goal is to overcome the limitations of current treatments, such as checkpoint inhibitors, and/or reduce the need for standard high-dose chemotherapy in cancer by employing this coordinated approach to establish &#x201c;immunological memory&#x201d; that confers long-term benefit for the patient. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our proprietary platforms for the development of biologic product candidates include: (i)&#160;antibody-cytokine fusion proteins, (ii)&#160;DNA, RNA, and recombinant protein vaccines, and (iii)&#160;cell therapies. These platforms have generated 9&#160;novel therapeutic agents for which clinical trials are either underway or planned in solid and liquid tumors. Specifically, our clinical focus includes bladder, lung, and colorectal cancers and GBM, which are among the most frequent and lethal cancer types, and where there are high failure rates for existing standards of care or no available effective treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. In May&#160;2022, we announced the submission of a BLA to the FDA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;9,&#160;2023, the FDA delivered a CRL to us regarding the BLA filed in May&#160;2022, indicating that the FDA had determined that it could not approve the original BLA submission in its initial form, and the FDA made recommendations to address the issues raised. The deficiencies in the CRL related to the FDA&#x2019;s pre-license inspection of the company&#x2019;s third-party CMOs, among other items. Satisfactory resolution of the observations noted at the pre-license inspection would be required before the BLA could be approved. At the time, the FDA further provided recommendations specific to additional CMC issues and assays to be resolved. The CRL did not request new preclinical studies or Phase&#160;III clinical trials to evaluate safety or efficacy. The FDA requested that the company provide updated duration of response data for the efficacy population as identified by the FDA in the company&#x2019;s resubmission, as well as a safety update. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;23,&#160;2023, we announced that we had completed the resubmission of the BLA addressing the issues in the CRL. As part of our resubmission, we provided an update of the duration of response regarding the responders identified by the FDA in the efficacy population for BCG unresponsive subjects with high-risk CIS disease. On October&#160;26,&#160;2023, we announced that the FDA had accepted our BLA resubmission for review and considered it as a complete response to the CRL. The FDA has set a new user fee goal date (PDUFA&#160;date) of April&#160;23,&#160;2024. While we believe the BLA resubmission addresses the issues identified in the CRL, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. It is unclear when the FDA will approve our BLA, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;21,&#160;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, NantKwest and NantCell,&#160;Inc. (formerly known as ImmunityBio,&#160;Inc., a private company) (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NantCell)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; entered into an Agreement and Plan of Merger (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merger Agreement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), pursuant to which NantKwest and NantCell agreed to combine their businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merger&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;9,&#160;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the Effective Time), each share of NantCell common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, par value $0.001&#160;per share, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted auto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;matically &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using the Exchange Ratio into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;newly issued shares of Company Common Stock, with cash paid in lieu of any fractional shares.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the Effective Time, each share of the company&#x2019;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, RSU or warrant to purchase NantCell common stock was converted using the Exchange Ratio into an option, RSU or warrant, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71.5% &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the outstanding shares of Company Common Stock and the stockholders of NantKwest as of immediately prior to the Merger held approximately&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.5% o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Executive Chairman and Global Chief Scientific and Medical Officer,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and his affiliates beneficially owned, in the aggregate, approxim&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ately&#160;81.8% of th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e outstanding shares of Company Common Stock. Following the consummation of the Merger, the symbol for shares of the company&#x2019;s common stock was changed to &#x201c;IBRX.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2021, w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$13.0&#160;million of costs &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;connection with the Merger in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general and administrative expense&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations, consisting of financial advisory, legal and other professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Treatment of the Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger represents a business combination pursuant to ASC&#160;805-50, which was accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We recast our prior period financial statements for the year ended December&#160;31,&#160;2021 to reflect the conveyance of NantCell&#x2019;s common shares as if the Merger had occurred as of the earliest date of the consolidated financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the impact of the change in reporting entity on our unaudited condensed consolidated statement of operations for the three&#160;months&#160;ended March&#160;31,&#160;2021 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NantCell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NantKwest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intercompany&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;ImmunityBio,&lt;br/&gt;Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development (including amounts&lt;br/&gt;with related parties)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative (including amounts&lt;br/&gt;with related parties)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(45,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(40,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(86,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net (including amounts &lt;br/&gt;with related parties)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(80,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-86"
      decimals="3"
      id="f-543"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger contextRef="c-86" decimals="3" id="f-544" unitRef="number">0.715</ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger>
    <ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger contextRef="c-87" decimals="3" id="f-545" unitRef="number">0.285</ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger>
    <ibrx:OwnershipPercentageByKeyExecutives contextRef="c-88" decimals="3" id="f-546" unitRef="number">0.818</ibrx:OwnershipPercentageByKeyExecutives>
    <us-gaap:PaymentsForMergerRelatedCosts contextRef="c-89" decimals="-5" id="f-547" unitRef="usd">13000000</us-gaap:PaymentsForMergerRelatedCosts>
    <us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock contextRef="c-1" id="f-548">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Treatment of the Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger represents a business combination pursuant to ASC&#160;805-50, which was accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of both the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We recast our prior period financial statements for the year ended December&#160;31,&#160;2021 to reflect the conveyance of NantCell&#x2019;s common shares as if the Merger had occurred as of the earliest date of the consolidated financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c-1" id="f-549">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the impact of the change in reporting entity on our unaudited condensed consolidated statement of operations for the three&#160;months&#160;ended March&#160;31,&#160;2021 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Three Months Ended&lt;br/&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NantCell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;NantKwest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intercompany&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;ImmunityBio,&lt;br/&gt;Inc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development (including amounts&lt;br/&gt;with related parties)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative (including amounts&lt;br/&gt;with related parties)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(45,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(40,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(86,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (expense) income, net (including amounts &lt;br/&gt;with related parties)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(33,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(80,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:Revenues contextRef="c-90" decimals="-3" id="f-550" unitRef="usd">183000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-91" decimals="-3" id="f-551" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-92" decimals="-3" id="f-552" unitRef="usd">-44000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-93" decimals="-3" id="f-553" unitRef="usd">139000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-90" decimals="-3" id="f-554" unitRef="usd">21509000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-91" decimals="-3" id="f-555" unitRef="usd">19725000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-92" decimals="-3" id="f-556" unitRef="usd">-106000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-93" decimals="-3" id="f-557" unitRef="usd">41128000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-90" decimals="-3" id="f-558" unitRef="usd">24382000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-91" decimals="-3" id="f-559" unitRef="usd">20903000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-92" decimals="-3" id="f-560" unitRef="usd">-10000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-93" decimals="-3" id="f-561" unitRef="usd">45275000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c-90" decimals="-3" id="f-562" unitRef="usd">-45708000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-91" decimals="-3" id="f-563" unitRef="usd">-40628000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-92" decimals="-3" id="f-564" unitRef="usd">72000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-93" decimals="-3" id="f-565" unitRef="usd">-86264000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-90" decimals="-3" id="f-566" unitRef="usd">-848000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-91" decimals="-3" id="f-567" unitRef="usd">6637000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-92" decimals="-3" id="f-568" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-93" decimals="-3" id="f-569" unitRef="usd">5789000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-90" decimals="-3" id="f-570" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-91" decimals="-3" id="f-571" unitRef="usd">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-92" decimals="-3" id="f-572" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-93" decimals="-3" id="f-573" unitRef="usd">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-90" decimals="-3" id="f-574" unitRef="usd">-46556000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-91" decimals="-3" id="f-575" unitRef="usd">-33997000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-92" decimals="-3" id="f-576" unitRef="usd">72000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-93" decimals="-3" id="f-577" unitRef="usd">-80481000</us-gaap:ProfitLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-578">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with U.S.&#160;GAAP and pursuant to the rules and regulations of the SEC. Certain items in the prior years&#x2019; consolidated financial statements have been reclassified to conform to the current presentation. These reclassifications had no effect on the reported results of operations. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a VIE for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities in which we have less than 100% ownership, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net loss attributable to noncontrolling interests, net of tax,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impacts the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the entity is within the scope of the variable interest model and meets the definition of a VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, the company had an accumulated deficit of $3.0&#160;billion. We also had negative cash flows from operations of $366.8&#160;million during the year ended December&#160;31,&#160;2023. The company will likely need additional capital to further fund the development of, and to seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings (including but not limited to the offering, issuance and sale by us of our common stock under the ATM, of which we had $208.8&#160;million available for future issuance as of December&#160;31,&#160;2023, and a February&#160;2023 shelf registration statement, of which we had $565.6&#160;million available for future offerings as of December&#160;31,&#160;2023), a potential $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including upon approval of N-803 before June&#160;30,&#160;2024, and our potential ability to borrow from affiliated entities, will be sufficient to fund our operations through at least the next 12&#160;months following the issuance date of the consolidated financial statements based primarily upon our Executive Chairman and Global Chief Scientific and Medical Officer&#x2019;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also seek to sell additional equity, through one or more follow-on offerings, or in separate financings, or obtain incremental subordinated debt in compliance with our existing revenue interest liability. However, we may not be able to secure such external financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the potential commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, CVR&#160;measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants, stock options, derivative liabilities, and convertible promissory notes, fair value measurements, revenue interest liability, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make certain judgments to determine whether transactions should be accounted for as acquisitions of assets or as business combinations. If it is determined that substantially all of the fair value of gross assets acquired in a transaction is concentrated in a single asset (or a group of similar assets), the transaction is treated as an acquisition of assets. We evaluate the inputs, processes, and outputs associated with the acquired set of activities and assets. If the assets in a transaction include an input and a substantive process that together significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which requires that assets acquired and liabilities assumed generally be recorded at their fair values as of the acquisition date. Excess of consideration over the fair value of net assets acquired is recorded as goodwill. Estimating fair value requires us to make significant judgments and assumptions. We perform impairment testing of goodwill annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In transactions accounted for as asset acquisitions, the cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. In an asset acquisition, upfront payments allocated to in-process research and development projects at the acquisition date are expensed unless there is an alternative future use. In addition, product development milestones are expensed upon achievement. Any contingent consideration, such as payments upon achievement of various developmental, regulatory, and commercial milestones, generally is not recognized at the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We attempt to minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also monitor the creditworthiness of the borrower of the convertible promissory note. We believe that any concentration of credit risk in its convertible note receivable was mitigated in part by our ability to convert, if necessary, at the qualifying financing event or upon a payment default into shares of the senior class of equity securities of the borrower.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product candidates developed by us will require approvals or clearances from the&#160;FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span id="i4643e1a07ce0428bbdfe8baf8b53beac_51425"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include highly liquid investments with an original maturity of three&#160;months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes a certificate of deposit held as a substitute letter of credit for one of our leased properties. This certificate of deposit is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheet as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash is included on the consolidated statements of cash flows as of December&#160;31,&#160;2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities and Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have typically invested our cash in a variety of financial instruments, including investment-grade short- to intermediate-term corporate debt securities, government-sponsored securities and European bonds; however, after our entry into the RIPA, we can no longer invest our excess funds in corporate or European bonds. Certain of our investments are subject to credit, liquidity, market, and interest-rate risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive income,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of stockholders&#x2019; deficit, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest and investment income (loss), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations. Realized gains and losses from sales of securities and the amounts, net of tax, reclassified out of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if any, are determined on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in mutual funds and equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and any unrealized gains and losses are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations. Realized gains and losses from the sale of the securities are determined on a specific identification basis and the amounts are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether we have plans to sell the security or whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded during the years ended December&#160;31,&#160;2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method of Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, we record our share of the income or loss of the other company as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;loss on equity method investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in our consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to operating expenses during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The lesser of the lease term or life of the asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon disposal of property, plant and equipment, the cost and related accumulated depreciation are removed from the consolidated financial statements and the net amount, less any proceeds, is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review impairment of property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for using the acquisition method of accounting in accordance with ASC&#160;805-50. These standards require that the total cost of acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition, with the excess purchase price recorded as goodwill. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration incurred in connection with a business combination are recorded at their fair values on the acquisition date and re-measured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair value are recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations and comprehensive loss. Changes in fair value reflect changes to our assumptions regarding probabilities of successful achievement of related milestones, the timing in which the milestones are expected to be achieved, and the discount rate used to estimate the fair value of the obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Control Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transactions between us and entities where Dr.&#160;Soon-Shiong and his affiliates are the controlling stockholders are accounted for as common control transactions whereby the net assets acquired or transferred are accounted at their carrying value. Any difference between the carrying value and consideration recognized is treated as a capital transaction. Cash consideration up to the carrying value of the net assets acquired or transferred is presented as an investing activity on the consolidated statement of cash flows. Cash consideration in excess of the carrying value of the net assets acquired or transferred is presented as a financing activity on the consolidated statement of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired in a business combination or an asset acquisition are initially recognized at their fair value on the acquisition date. Acquired indefinite-lived assets, such as IPR&amp;amp;D, are not amortized until they become definite-lived assets, upon the successful completion of the associated research and development effort. At that time, we evaluate whether the recorded &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are impaired and make any necessary adjustments, and then determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned, the related IPR&amp;amp;D assets is written-off and an impairment charge recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired definite-lived intangible assets are amortized using the straight-line method over their respective estimated useful lives. The amortization of these intangible assets is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general and administrative expense,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations. Intangible assets are tested for impairment at least annually or more frequently if indicators of potential impairment exist. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patent costs, including related legal costs, are expensed as incurred and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three tiers are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&#x2014;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&#x2014;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities, and corporate bonds, as well as foreign municipal securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, no transfers were made into or out of the Level&#160;1, 2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze our collaboration arrangements to assess whether they are within the scope of FASB ASC Topic&#160;808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;808). A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. To the extent the collaboration agreement is within the scope of ASC&#160;808, we also assess whether the arrangement contains multiple elements that are within the scope of other accounting literature. If we conclude that some or all aspects of the agreement are distinct and represent a transaction with a customer, we account for those aspects of the arrangement within the scope of FASB ASC Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;606). Amounts that are owed by collaboration partners within the scope of ASC&#160;808 are recognized as an offset to research and development expense as such amounts are incurred by the collaboration partner. The amounts owed to a collaboration partner are classified as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration arrangements require us to acquire certain equipment for exclusive use in the joint operating activities. These equipment purchases do not have an alternative use and are therefore expensed as incurred within research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration arrangements are further discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and License Agreements and Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the process of preparing the consolidated financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate clinical trial and research agreement-related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research-related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transactions with Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As outlined in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we have various agreements with related parties. These arrangements can be billed and settled in cash monthly, billed quarterly and settled in cash the following month, or estimated in advance and collected or paid upfront based on expected utilization. Monthly accruals are made for all quarterly billing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all leases other than short-term leases, at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At the commencement date, lease right-of-use assets and lease liabilities are determined based on the present value of lease payments to be made over the lease term. Leases are classified as either finance leases or operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the rate implicit in lease contracts are not readily determinable, we utilize its incremental borrowing rate as a discount rate for purposes of determining the present value of lease payments, which is based on the estimated interest rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, we will remeasure the lease liability at the net present value of the remaining lease payments using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, the exercise of renewal is only assured for five&#160;of our cGMP facilities where we have made significant improvements or extended the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We combine our lease components (e.g.,&#160;fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g.,&#160;common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term. The lease term includes the non-cancellable period of the lease and any additional periods covered by either options to renew or not to terminate when the company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC&#160;480 and ASC&#160;815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#x2019;s own stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of stockholders&#x2019; deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ther expense, net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Option Election&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounted for a convertible note issued on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the&#160;FVO&#160;election of ASC&#160;825 until it was amended and restated on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;29,&#160;2023. Prior to its extinguishment on December&#160;29,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the convertible note was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issuance-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of this convertible note were recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations, except that changes in estimated fair value caused by changes in the instrument-specific credit risk were recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other comprehensive (loss) income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In accordance with ASC&#160;470-50, when the convertible note was extinguished on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;29,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the cumulative amount previously recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other comprehensive (loss) income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; resulting from changes in the instrument-specific credit risk were reclassified and reported in current earnings on the consolidated statement of operations. See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;10&lt;/a&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Debt&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Modification and Extinguishment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company evaluates amendments to its debt instruments in accordance with ASC&#160;470-50. This evaluation includes comparing (1)&#160;if applicable, the net present value of future cash flows of the amended debt to that of the original debt and (2)&#160;the change in fair value of an embedded conversion feature to that of the carrying amount of the debt immediately prior to amendment to determine, in each case, if a change greater than 10% occurred. In instances where the net present value of future cash flows or the fair value of an embedded conversion feature, if any, changed more than 10%, the company applies extinguishment accounting. In instances where the net present value of future cash flows and the fair value of an embedded conversion feature, if any, changed less than 10%, the company accounts for the amendment to the debt as a debt modification. Gains and losses on debt amendments that are considered extinguishments are recognized in current earnings or in additional paid-in capital if the transactions are with entities under common control. Debt amendments that are considered debt modifications are accounted for prospectively through yield adjustments, based on the revised terms. The increase in fair value of the embedded conversion feature from the debt modification was accounted for as an increase in debt discount with a corresponding increase in additional paid-in capital. Legal fees and other costs incurred with third parties that are directly related to debt modifications are expensed as incurred. Amounts paid by the company to the lenders, are reflected as additional debt discount and amortized as an adjustment of interest expense over remaining term of modified debt using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize uncertain tax positions when the position will more likely than not be upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax benefit (expense),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31,&#160;2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program. As it is our intent for the repurchased shares to be retired, we have elected to account for the shares repurchased using the constructive retirement method. For shares repurchased in excess of par, we record the purchase price in excess of par value in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated deficit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Interest Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter. The RIPA is considered a sale of future revenues and is accounted for as a liability net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability, interest expense, and the time period for repayment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Embedded derivatives that are required to be bifurcated from the underlying debt instrument that do not meet the derivative scope exception and equity classification criteria are accounted for and valued as separate financial instruments. The terms of an embedded derivative related to a contingent exercisable prepayment feature of a convertible note have been evaluated and deemed to require bifurcation. This embedded derivative will be initially measured at fair value and will be remeasured to fair value at each reporting date until the derivative is settled. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the RIPA contains certain features that meet the definition of being an embedded derivative requiring bifurcation as a separate compound financial instrument apart from the RIPA. The derivative liability is initially measured at fair value upon issuance and is subject to remeasurement at each reporting period with changes in fair value recognized in other expense, net, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have primarily generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. The nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies grant them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines. We have generated revenues from product sales of our proprietary GMP-in-a-Box bioreactors and related consumables, primarily to related parties. Additionally, we also generated revenues from grant programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract&#x2019;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our license agreements with customers, we typically promise to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. Research and development data are provided throughout the term of the contract when and if available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have sold our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies. The arrangements typically include delivery of bioreactors, consumables, and providing installation service and perpetual software licenses for using the equipment. We recognize revenue when customers obtain control and can benefit from the promised goods or services, generally upon installation of the bioreactors, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. Upfront payments and fees are recorded as deferred revenue upon receipt and recognized as revenue when we satisfy our performance obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue is typically paid for reimbursable costs incurred over the duration of the associated research project or clinical trial and is recognized either when expenses reimbursable under the grants have been incurred and payments under the grants become contractually due or when cash is received, depending on the certainty of payment and other factors specific to each grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through December&#160;31,&#160;2023, we have generated minimal revenue from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables, and grant programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials costs, including CROs and related clinical manufacturing, including third-party CMOs, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company classifies its research and development expenses as either external or internal. The&#160;company&#x2019;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#x2019;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#x2019;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the preclinical studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates. We adjust the accruals in the period when actual costs become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based compensation under the provisions of ASC&#160;718. We estimate fair value of each stock option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions, including, but not limited to, expected stock price volatility over the term of the awards and the expected term of the stock options. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;14&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale-Leaseback Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A sale-leaseback transaction occurs when an entity sells an asset it owns and immediately leases the asset back from the buyer. The seller then becomes the lessee and the buyer becomes the lessor. When entering into a sale-leaseback transaction as a seller-lessee, the requirements in ASC&#160;606, and all related ASUs to such Topic are applied in determining whether the transfer of an asset shall be accounted for as a sale of the asset by assessing whether it satisfies a performance obligation under the contract by transferring control of an asset. If the company transfers control of an asset to the buyer-lessor, the transfer is accounted for as a sale and the company derecognizes the transferred asset. The subsequent leaseback of the asset is accounted for in accordance with FASB ASC&#160;Topic&#160;842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the same manner as any third-party lease. If the company does not transfer control of an asset to the buyer-lessor, the sale-leaseback transaction is accounted for as a financing arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net (loss) income and other comprehensive (loss) income. Our other comprehensive income or loss consists of net unrealized gains (losses) on marketable debt securities classified as available-for-sale, net of income taxes and foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests are recorded for the entities that we consolidate but are not wholly-owned by the company. Noncontrolling interests are classified as a separate component of equity on the consolidated balance sheet and consolidated statement of stockholders&#x2019; deficit. Additionally, net loss attributable to noncontrolling interests is reflected separately from consolidated net loss on the consolidated statement of operations and the consolidated statement of stockholders&#x2019; deficit. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record the noncontrolling interests&#x2019; share of loss based on the percentage of ownership interest retained by the respective noncontrolling interest holders. Noncontrolling interests recorded on the consolidated financial statements result from the company&#x2019;s share of GlobeImmune, of which we controlled 69.1% as of December&#160;31,&#160;2023, 2022 and 2021, respectively, and NANTibody, of which we controlled 100.0% as of December&#160;31,&#160;2023 and 60.0% as of December&#160;31,&#160;2022 and 2021, respectively. Noncontrolling interest stockholders are common stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GlobeImmune was determined to be a VIE as it does not have sufficient equity investment at risk to finance its operations without additional subordinated financial support and we are deemed the primary beneficiary of GlobeImmune and, accordingly, consolidate GlobeImmune into the company&#x2019;s consolidated financial statements under the VIE model. The company also supports GlobeImmune through a promissory note agreement, in which the company provides advances to GlobeImmune from time to time up to $6.0&#160;million with a per annum interest rate of five&#160;percent (5%). As of December&#160;31,&#160;2023 and 2022, there were no outstanding advances due from GlobeImmune under the promissory note agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022, and 2021, GlobeImmune recognized no revenue, respectively, and recognized $0.3&#160;million, $0.5&#160;million, and $0.7&#160;million of operating expenses, respectively, during the years ended December&#160;31,&#160;2023, 2022 and 2021. As of both December&#160;31,&#160;2023 and 2022, the consolidated balance sheets included approximately $1.4&#160;million of total assets that can only be used to settle obligations of GlobeImmune, and no&#160;liabilities, respectively, related to GlobeImmune. The creditors of GlobeImmune do not have recourse to the general credit of the primary beneficiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have operations and hold assets in Italy and South Korea. The functional currency of the subsidiary in Italy is the Euro, based on the nature of the transactions occurring within this entity, and accordingly, assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates prevailing as of the balance sheet dates, while the operating results are translated into U.S.&#160;dollars using the average exchange rates for the period correlating with those operating results. Adjustments resulting from translating the financial statements of the foreign subsidiary into U.S.&#160;dollars are recorded as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other comprehensive (loss) income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of comprehensive loss. Transaction gains and losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. The following table details those securities that have been excluded from the computation of potentially dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,471,837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,274,965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding third-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,732,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,090,909&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,820,435&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,262,926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,124,930&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503,979&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,551,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,889&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding related-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,167,071&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,818,188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278,819&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dilutive securities exclude the option to purchase up to $10.0&#160;million of the company&#x2019;s common stock pursuant to the SPOA entered in connection with the RIPA, as the exercise price is not yet determined. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_223" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_223" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_223" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;13&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Deficit,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one reporting segment focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Our CEO is the chief operating decision-maker of the company, and manages and allocates resources to our operations on a company-wide basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future-period financial results, allocating resources, and setting incentive targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate a portion of our revenues from outside of the U.S. Information about our revenues by geographic region is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span id="i4643e1a07ce0428bbdfe8baf8b53beac_102909"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Application of New or Revised Accounting Standards &#x2013; Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2023, the FASB issued ASU&#160;2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Topic&#160;740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1)&#160;disclose specific categories in the rate reconciliation, (2)&#160;provide additional information for reconciling items that meet a quantitative threshold, and (3)&#160;disclose more detailed information about income taxes paid, including by jurisdiction; pretax income (or loss) from continuing operations; and income tax expense (or benefit). The ASU is effective for fiscal years beginning after December&#160;15,&#160;2024, and interim periods beginning after December&#160;15,&#160;2025, with early adoption permitted. We are currently evaluating the impact of this standard on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November&#160;2023, the FASB issued ASU&#160;2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Topic&#160;280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, and interim periods within fiscal years beginning after December&#160;15,&#160;2024 on a retrospective basis. We are currently evaluating the impact of this standard on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2023, the FASB issued ASU 2023-05, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations-Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a joint venture to initially measure all contributions received upon its formation at fair value. This ASU is applicable to joint venture entities with a formation date on or after January&#160;1,&#160;2025 on a prospective basis. We will apply this guidance prospectively in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March&#160;2023, the FASB issued ASU&#160;2023-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Common Control Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC) and the SEC during the year ended December&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-579">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;The consolidated financial statements have been prepared in accordance with U.S.&#160;GAAP and pursuant to the rules and regulations of the SEC. Certain items in the prior years&#x2019; consolidated financial statements have been reclassified to conform to the current presentation. These reclassifications had no effect on the reported results of operations. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-580">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the company, its wholly-owned subsidiaries, and a VIE for which the company is the primary beneficiary. Any material intercompany transactions and balances have been eliminated upon consolidation. For consolidated entities in which we have less than 100% ownership, we record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;net loss attributable to noncontrolling interests, net of tax,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impacts the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the entity is within the scope of the variable interest model and meets the definition of a VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-8" id="f-581" unitRef="usd">-3000000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-582" unitRef="usd">-366800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance contextRef="c-94" decimals="-5" id="f-583" unitRef="usd">208800000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance contextRef="c-95" decimals="-5" id="f-584" unitRef="usd">565600000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment contextRef="c-96" decimals="-5" id="f-585" unitRef="usd">100000000</ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-586">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, CVR&#160;measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value calculation of warrants, stock options, derivative liabilities, and convertible promissory notes, fair value measurements, revenue interest liability, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-587">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-588">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We attempt to minimize credit risk associated with our cash and cash equivalents by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy. While we maintain cash deposits in FDIC insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also monitor the creditworthiness of the borrower of the convertible promissory note. We believe that any concentration of credit risk in its convertible note receivable was mitigated in part by our ability to convert, if necessary, at the qualifying financing event or upon a payment default into shares of the senior class of equity securities of the borrower.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product candidates developed by us will require approvals or clearances from the&#160;FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-589">&lt;div style="margin-top:12pt"&gt;&lt;span id="i4643e1a07ce0428bbdfe8baf8b53beac_51425"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include highly liquid investments with an original maturity of three&#160;months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes a certificate of deposit held as a substitute letter of credit for one of our leased properties. This certificate of deposit is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other assets,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheet as the landlord is the beneficiary of the account and we are not able to access the funds during the term of the lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-590">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities and Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have typically invested our cash in a variety of financial instruments, including investment-grade short- to intermediate-term corporate debt securities, government-sponsored securities and European bonds; however, after our entry into the RIPA, we can no longer invest our excess funds in corporate or European bonds. Certain of our investments are subject to credit, liquidity, market, and interest-rate risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. Marketable debt securities with remaining maturities of 12&#160;months or less are classified as short-term and marketable securities with remaining maturities greater than 12&#160;months are classified as long-term. All marketable debt securities are reported at fair value and any unrealized gains and losses are reported as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive income,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of stockholders&#x2019; deficit, with the exception of unrealized losses believed to be other-than-temporary, which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest and investment income (loss), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations. Realized gains and losses from sales of securities and the amounts, net of tax, reclassified out of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if any, are determined on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in mutual funds and equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and any unrealized gains and losses are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations. Realized gains and losses from the sale of the securities are determined on a specific identification basis and the amounts are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate whether declines in fair values of our investments below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the investment until a forecasted recovery occurs. Additionally, we assess whether we have plans to sell the security or whether it is more likely than not we will be required to sell any investment before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of our investments, duration and severity of the decline in value, and our strategy and intentions for holding the investment. There were no other-than-temporary impairments recorded during the years ended December&#160;31,&#160;2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ImpairmentOfInvestments contextRef="c-1" decimals="INF" id="f-591" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments contextRef="c-10" decimals="INF" id="f-592" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments contextRef="c-11" decimals="INF" id="f-593" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-594">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method of Accounting&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship. Under the equity method of accounting, we record our share of the income or loss of the other company as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;loss on equity method investment&lt;/span&gt;, in our consolidated statement of operations.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-595">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at historical cost less accumulated depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. All repairs and maintenance are charged to operating expenses during the financial period in which they are incurred. Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The lesser of the lease term or life of the asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon disposal of property, plant and equipment, the cost and related accumulated depreciation are removed from the consolidated financial statements and the net amount, less any proceeds, is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-596">Depreciation of property, plant and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The lesser of the lease term or life of the asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;67,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;230,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;212,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-97" id="f-597">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-98" id="f-598">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-99" id="f-599">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-100" id="f-600">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-101" id="f-601">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-102" id="f-602">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="c-1" id="f-603">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review impairment of property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to the future net cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected undiscounted future cash flows arising from the assets using a discount rate determined by management to be commensurate with the risk inherent to our current business model.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-604">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for using the acquisition method of accounting in accordance with ASC&#160;805-50. These standards require that the total cost of acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition, with the excess purchase price recorded as goodwill. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration incurred in connection with a business combination are recorded at their fair values on the acquisition date and re-measured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair value are recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations and comprehensive loss. Changes in fair value reflect changes to our assumptions regarding probabilities of successful achievement of related milestones, the timing in which the milestones are expected to be achieved, and the discount rate used to estimate the fair value of the obligation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <ibrx:CommonControlTransactionPolicyPolicyTextBlock contextRef="c-1" id="f-605">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Control Transactions&lt;/span&gt;&lt;/div&gt;Transactions between us and entities where Dr.&#160;Soon-Shiong and his affiliates are the controlling stockholders are accounted for as common control transactions whereby the net assets acquired or transferred are accounted at their carrying value. Any difference between the carrying value and consideration recognized is treated as a capital transaction. Cash consideration up to the carrying value of the net assets acquired or transferred is presented as an investing activity on the consolidated statement of cash flows. Cash consideration in excess of the carrying value of the net assets acquired or transferred is presented as a financing activity on the consolidated statement of cash flows.</ibrx:CommonControlTransactionPolicyPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-606">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired in a business combination or an asset acquisition are initially recognized at their fair value on the acquisition date. Acquired indefinite-lived assets, such as IPR&amp;amp;D, are not amortized until they become definite-lived assets, upon the successful completion of the associated research and development effort. At that time, we evaluate whether the recorded &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are impaired and make any necessary adjustments, and then determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned, the related IPR&amp;amp;D assets is written-off and an impairment charge recorded. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired definite-lived intangible assets are amortized using the straight-line method over their respective estimated useful lives. The amortization of these intangible assets is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general and administrative expense,&lt;/span&gt; on the consolidated statement of operations. Intangible assets are tested for impairment at least annually or more frequently if indicators of potential impairment exist.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:LegalCostsPolicyTextBlock contextRef="c-1" id="f-607">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patent costs, including related legal costs, are expensed as incurred and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-608">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three tiers are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&#x2014;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&#x2014;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities, and corporate bonds, as well as foreign municipal securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, no transfers were made into or out of the Level&#160;1, 2 or 3 categories. We will continue to review the fair value inputs on a quarterly basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-609">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We analyze our collaboration arrangements to assess whether they are within the scope of FASB ASC Topic&#160;808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;808). A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. To the extent the collaboration agreement is within the scope of ASC&#160;808, we also assess whether the arrangement contains multiple elements that are within the scope of other accounting literature. If we conclude that some or all aspects of the agreement are distinct and represent a transaction with a customer, we account for those aspects of the arrangement within the scope of FASB ASC Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC&#160;606). Amounts that are owed by collaboration partners within the scope of ASC&#160;808 are recognized as an offset to research and development expense as such amounts are incurred by the collaboration partner. The amounts owed to a collaboration partner are classified as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration arrangements require us to acquire certain equipment for exclusive use in the joint operating activities. These equipment purchases do not have an alternative use and are therefore expensed as incurred within research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <ibrx:PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock contextRef="c-1" id="f-610">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the process of preparing the consolidated financial statements, we are required to estimate expenses resulting from obligations under contracts with vendors, clinical research organizations and consultants. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate clinical trial and research agreement-related expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. In accruing clinical and research-related fees, we estimate the time period over which services will be performed and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;/div&gt;</ibrx:PreclinicalAndClinicalTrialAccrualsPolicyPolicyTextBlock>
    <ibrx:RelatedPartyTransactionsPolicyPolicyTextBlock contextRef="c-1" id="f-611">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transactions with Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As outlined in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we have various agreements with related parties. These arrangements can be billed and settled in cash monthly, billed quarterly and settled in cash the following month, or estimated in advance and collected or paid upfront based on expected utilization. Monthly accruals are made for all quarterly billing arrangements.&lt;/span&gt;&lt;/div&gt;</ibrx:RelatedPartyTransactionsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-612">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all leases other than short-term leases, at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. At the commencement date, lease right-of-use assets and lease liabilities are determined based on the present value of lease payments to be made over the lease term. Leases are classified as either finance leases or operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the rate implicit in lease contracts are not readily determinable, we utilize its incremental borrowing rate as a discount rate for purposes of determining the present value of lease payments, which is based on the estimated interest rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, we will remeasure the lease liability at the net present value of the remaining lease payments using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received, and initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We determine the lease term by assuming the exercise of renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. Several of our leases have renewal options, however, the exercise of renewal is only assured for five&#160;of our cGMP facilities where we have made significant improvements or extended the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We combine our lease components (e.g.,&#160;fixed payments including rent, real estate taxes and insurance costs) with non-lease components (e.g.,&#160;common-area maintenance costs and equipment maintenance costs) and as such, we account for lease and non-lease components as a single component. Lease expense also includes amounts relating to variable lease payments. Variable lease payments include amounts relating to common area maintenance and real estate taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not recognize right-of-use assets and lease liabilities for qualifying short-term leases with an initial lease term of 12&#160;months or less at lease inception. Such leases are expensed on a straight-line basis over the lease term. The lease term includes the non-cancellable period of the lease and any additional periods covered by either options to renew or not to terminate when the company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of operating right-of-use-assets and leasehold improvements is limited by the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale-Leaseback Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A sale-leaseback transaction occurs when an entity sells an asset it owns and immediately leases the asset back from the buyer. The seller then becomes the lessee and the buyer becomes the lessor. When entering into a sale-leaseback transaction as a seller-lessee, the requirements in ASC&#160;606, and all related ASUs to such Topic are applied in determining whether the transfer of an asset shall be accounted for as a sale of the asset by assessing whether it satisfies a performance obligation under the contract by transferring control of an asset. If the company transfers control of an asset to the buyer-lessor, the transfer is accounted for as a sale and the company derecognizes the transferred asset. The subsequent leaseback of the asset is accounted for in accordance with FASB ASC&#160;Topic&#160;842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the same manner as any third-party lease. If the company does not transfer control of an asset to the buyer-lessor, the sale-leaseback transaction is accounted for as a financing arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ibrx:WarrantsPolicyTextBlock contextRef="c-1" id="f-613">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC&#160;480 and ASC&#160;815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, meet the definition of a liability pursuant to ASC&#160;480, and whether the warrants meet all of the requirements for equity classification under ASC&#160;815, including whether the warrants are indexed to the&#160;company&#x2019;s own stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of stockholders&#x2019; deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ther expense, net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/div&gt;</ibrx:WarrantsPolicyTextBlock>
    <ibrx:ConvertibleNotesFairValueOptionElectionPolicyTextBlock contextRef="c-1" id="f-614">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Option Election&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company accounted for a convertible note issued on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the&#160;FVO&#160;election of ASC&#160;825 until it was amended and restated on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;29,&#160;2023. Prior to its extinguishment on December&#160;29,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the convertible note was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issuance-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of this convertible note were recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations, except that changes in estimated fair value caused by changes in the instrument-specific credit risk were recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other comprehensive (loss) income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In accordance with ASC&#160;470-50, when the convertible note was extinguished on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;29,&#160;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the cumulative amount previously recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other comprehensive (loss) income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; resulting from changes in the instrument-specific credit risk were reclassified and reported in current earnings on the consolidated statement of operations. See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;10&lt;/a&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Debt&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;</ibrx:ConvertibleNotesFairValueOptionElectionPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-615">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Modification and Extinguishment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company evaluates amendments to its debt instruments in accordance with ASC&#160;470-50. This evaluation includes comparing (1)&#160;if applicable, the net present value of future cash flows of the amended debt to that of the original debt and (2)&#160;the change in fair value of an embedded conversion feature to that of the carrying amount of the debt immediately prior to amendment to determine, in each case, if a change greater than 10% occurred. In instances where the net present value of future cash flows or the fair value of an embedded conversion feature, if any, changed more than 10%, the company applies extinguishment accounting. In instances where the net present value of future cash flows and the fair value of an embedded conversion feature, if any, changed less than 10%, the company accounts for the amendment to the debt as a debt modification. Gains and losses on debt amendments that are considered extinguishments are recognized in current earnings or in additional paid-in capital if the transactions are with entities under common control. Debt amendments that are considered debt modifications are accounted for prospectively through yield adjustments, based on the revised terms. The increase in fair value of the embedded conversion feature from the debt modification was accounted for as an increase in debt discount with a corresponding increase in additional paid-in capital. Legal fees and other costs incurred with third parties that are directly related to debt modifications are expensed as incurred. Amounts paid by the company to the lenders, are reflected as additional debt discount and amortized as an adjustment of interest expense over remaining term of modified debt using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Interest Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA. Under the RIPA, Oberland has the right to receive quarterly payments from us based on, among other things, a certain percentage of our worldwide net sales, excluding those in China, during such quarter. The RIPA is considered a sale of future revenues and is accounted for as a liability net of a debt discount comprised of deferred issuance costs, the fair value of a freestanding option agreement related to the SPOA, and the fair value of embedded derivatives requiring bifurcation on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. Interest expense is recognized over the estimated term on the consolidated statement of operations. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of actual and forecasted net sales. The company evaluates the interest rate quarterly based on actual and forecasted net sales utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales will materially impact the revenue interest liability, interest expense, and the time period for repayment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-616">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record valuation allowances to reduce deferred tax assets to the amount we believe is more likely than not to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize uncertain tax positions when the position will more likely than not be upheld on examination by the taxing authorities based solely upon the technical merits of the positions. We recognize interest and penalties, if any, related to unrecognized income tax uncertainties in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;income tax benefit (expense),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations. We did not have any accrued interest or penalties associated with uncertain tax positions as of December&#160;31,&#160;2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <ibrx:StockRepurchaseProgramPolicyPolicyTextBlock contextRef="c-1" id="f-617">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program. As it is our intent for the repurchased shares to be retired, we have elected to account for the shares repurchased using the constructive retirement method. For shares repurchased in excess of par, we record the purchase price in excess of par value in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accumulated deficit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</ibrx:StockRepurchaseProgramPolicyPolicyTextBlock>
    <ibrx:PurchaseAgreementTotalInvestmentAmount contextRef="c-103" decimals="-5" id="f-618" unitRef="usd">200000000</ibrx:PurchaseAgreementTotalInvestmentAmount>
    <ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment contextRef="c-96" decimals="-5" id="f-619" unitRef="usd">100000000</ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment>
    <us-gaap:DerivativesEmbeddedDerivatives contextRef="c-1" id="f-620">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Embedded derivatives that are required to be bifurcated from the underlying debt instrument that do not meet the derivative scope exception and equity classification criteria are accounted for and valued as separate financial instruments. The terms of an embedded derivative related to a contingent exercisable prepayment feature of a convertible note have been evaluated and deemed to require bifurcation. This embedded derivative will be initially measured at fair value and will be remeasured to fair value at each reporting date until the derivative is settled. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the RIPA contains certain features that meet the definition of being an embedded derivative requiring bifurcation as a separate compound financial instrument apart from the RIPA. The derivative liability is initially measured at fair value upon issuance and is subject to remeasurement at each reporting period with changes in fair value recognized in other expense, net, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesEmbeddedDerivatives>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-621">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have primarily generated revenues from non-exclusive license agreements related to our cell lines, the sale of our bioreactors and related consumables and grant programs. The nonexclusive license agreements with a limited number of pharmaceutical and biotechnology companies grant them the right to use our cell lines and intellectual property for non-clinical use. These agreements generally include upfront fees and annual research license fees for such use, as well as commercial license fees for sales of the licensee products developed or manufactured using our intellectual property and cell lines. We have generated revenues from product sales of our proprietary GMP-in-a-Box bioreactors and related consumables, primarily to related parties. Additionally, we also generated revenues from grant programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract&#x2019;s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our license agreements with customers, we typically promise to provide a license to use certain cell lines and related patents, the related know-how, and future research and development data that affect the license. We have concluded that these promises represent one performance obligation due to the highly interrelated nature of the promises. We provide the cell lines and know-how immediately upon entering into the contracts. Research and development data are provided throughout the term of the contract when and if available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have sold our proprietary GMP-in-a-Box bioreactors and related consumables to affiliated companies. The arrangements typically include delivery of bioreactors, consumables, and providing installation service and perpetual software licenses for using the equipment. We recognize revenue when customers obtain control and can benefit from the promised goods or services, generally upon installation of the bioreactors, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. Upfront payments and fees are recorded as deferred revenue upon receipt and recognized as revenue when we satisfy our performance obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grant revenue is typically paid for reimbursable costs incurred over the duration of the associated research project or clinical trial and is recognized either when expenses reimbursable under the grants have been incurred and payments under the grants become contractually due or when cash is received, depending on the certainty of payment and other factors specific to each grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:Revenues contextRef="c-104" decimals="-3" id="f-622" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-104" decimals="-3" id="f-623" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-624">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Major components of research and development costs include cash compensation and other personnel-related expenses, stock-based compensation, depreciation and amortization expense on research and development property and equipment and intangible assets, costs of preclinical studies, clinical trials costs, including CROs and related clinical manufacturing, including third-party CMOs, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on our behalf. Costs incurred in research and development are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company classifies its research and development expenses as either external or internal. The&#160;company&#x2019;s external research and development expenses support its various preclinical and clinical programs. The&#160;company&#x2019;s internal research and development expenses include payroll and benefits expenses, facilities and equipment expense, and other indirect research and development expenses incurred in support of its research and development activities. The&#160;company&#x2019;s external and internal resources are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs and are not allocated to specific product candidates or development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in research and development costs are clinical trial and research expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations and other vendors that conduct clinical trials and research on our behalf. We record accruals for estimated costs under these contracts. When evaluating the adequacy of the accrued liabilities, we analyze the progress of the preclinical studies or clinical trials, including the phase or completion of events, invoices received, contracted costs and purchase orders. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period based on the facts and circumstances known at that time. Although we do not expect the estimates to be materially different from the amounts actually incurred, if the estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. Actual results could differ from our estimates. We adjust the accruals in the period when actual costs become known.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based compensation under the provisions of ASC&#160;718. We estimate fair value of each stock option award on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions, including, but not limited to, expected stock price volatility over the term of the awards and the expected term of the stock options. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;14&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;, for more information.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-626">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income or loss is composed of net (loss) income and other comprehensive (loss) income. Our other comprehensive income or loss consists of net unrealized gains (losses) on marketable debt securities classified as available-for-sale, net of income taxes and foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="c-1" id="f-627">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interests are recorded for the entities that we consolidate but are not wholly-owned by the company. Noncontrolling interests are classified as a separate component of equity on the consolidated balance sheet and consolidated statement of stockholders&#x2019; deficit. Additionally, net loss attributable to noncontrolling interests is reflected separately from consolidated net loss on the consolidated statement of operations and the consolidated statement of stockholders&#x2019; deficit. &lt;/span&gt;&lt;/div&gt;We record the noncontrolling interests&#x2019; share of loss based on the percentage of ownership interest retained by the respective noncontrolling interest holders.</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-105"
      decimals="INF"
      id="f-628"
      unitRef="number">0.691</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-106"
      decimals="INF"
      id="f-629"
      unitRef="number">0.691</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-107"
      decimals="INF"
      id="f-630"
      unitRef="number">0.691</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-108"
      decimals="INF"
      id="f-631"
      unitRef="number">1.000</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-109"
      decimals="INF"
      id="f-632"
      unitRef="number">0.600</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-110"
      decimals="INF"
      id="f-633"
      unitRef="number">0.600</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-111" decimals="-5" id="f-634" unitRef="usd">6000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="c-112"
      decimals="INF"
      id="f-635"
      unitRef="number">0.05</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-113" decimals="INF" id="f-636" unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-114" decimals="INF" id="f-637" unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Revenues contextRef="c-112" decimals="INF" id="f-638" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-115" decimals="INF" id="f-639" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-116" decimals="INF" id="f-640" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c-112" decimals="-5" id="f-641" unitRef="usd">300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-115" decimals="-5" id="f-642" unitRef="usd">500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-116" decimals="-5" id="f-643" unitRef="usd">700000</us-gaap:OperatingExpenses>
    <us-gaap:Assets contextRef="c-114" decimals="-5" id="f-644" unitRef="usd">1400000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-113" decimals="-5" id="f-645" unitRef="usd">1400000</us-gaap:Assets>
    <us-gaap:Liabilities contextRef="c-113" decimals="-5" id="f-646" unitRef="usd">0</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-114" decimals="-5" id="f-647" unitRef="usd">0</us-gaap:Liabilities>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-648">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have operations and hold assets in Italy and South Korea. The functional currency of the subsidiary in Italy is the Euro, based on the nature of the transactions occurring within this entity, and accordingly, assets and liabilities of this subsidiary are translated into U.S.&#160;dollars at exchange rates prevailing as of the balance sheet dates, while the operating results are translated into U.S.&#160;dollars using the average exchange rates for the period correlating with those operating results. Adjustments resulting from translating the financial statements of the foreign subsidiary into U.S.&#160;dollars are recorded as a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other comprehensive (loss) income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of comprehensive loss. Transaction gains and losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-649">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-650">The following table details those securities that have been excluded from the computation of potentially dilutive securities:&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,471,837&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,274,965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding third-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,732,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,090,909&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,820,435&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,262,926&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,124,930&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503,979&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,551,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,889&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding related-party warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,638,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,167,071&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,818,188&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,278,819&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-117" decimals="0" id="f-651" unitRef="shares">162471837</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-118" decimals="0" id="f-652" unitRef="shares">46274965</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-119" decimals="0" id="f-653" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-120" decimals="0" id="f-654" unitRef="shares">37732820</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-121" decimals="0" id="f-655" unitRef="shares">9090909</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-122" decimals="0" id="f-656" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-123" decimals="0" id="f-657" unitRef="shares">9820435</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-124" decimals="0" id="f-658" unitRef="shares">9262926</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-125" decimals="0" id="f-659" unitRef="shares">4124930</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-126" decimals="0" id="f-660" unitRef="shares">7503979</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-127" decimals="0" id="f-661" unitRef="shares">6551388</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-128" decimals="0" id="f-662" unitRef="shares">6515889</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-129" decimals="0" id="f-663" unitRef="shares">1638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-130" decimals="0" id="f-664" unitRef="shares">1638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-131" decimals="0" id="f-665" unitRef="shares">1638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-666" unitRef="shares">219167071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-10" decimals="0" id="f-667" unitRef="shares">72818188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-11" decimals="0" id="f-668" unitRef="shares">12278819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ibrx:SaleOfStockAdditionalPurchaseOption contextRef="c-132" decimals="-5" id="f-669" unitRef="usd">10000000</ibrx:SaleOfStockAdditionalPurchaseOption>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-670">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographic Information&lt;/span&gt;&lt;/div&gt;We operate in one reporting segment focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Our CEO is the chief operating decision-maker of the company, and manages and allocates resources to our operations on a company-wide basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future-period financial results, allocating resources, and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-671"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-672"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-673">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate a portion of our revenues from outside of the U.S. Information about our revenues by geographic region is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.664%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues contextRef="c-133" decimals="-3" id="f-674" unitRef="usd">31000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-134" decimals="-3" id="f-675" unitRef="usd">42000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-135" decimals="-3" id="f-676" unitRef="usd">373000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-136" decimals="-3" id="f-677" unitRef="usd">591000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-137" decimals="-3" id="f-678" unitRef="usd">198000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-138" decimals="-3" id="f-679" unitRef="usd">561000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-680" unitRef="usd">622000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-3" id="f-681" unitRef="usd">240000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-682" unitRef="usd">934000</us-gaap:Revenues>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-683">&lt;div style="margin-top:12pt"&gt;&lt;span id="i4643e1a07ce0428bbdfe8baf8b53beac_102909"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Application of New or Revised Accounting Standards &#x2013; Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2023, the FASB issued ASU&#160;2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Topic&#160;740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1)&#160;disclose specific categories in the rate reconciliation, (2)&#160;provide additional information for reconciling items that meet a quantitative threshold, and (3)&#160;disclose more detailed information about income taxes paid, including by jurisdiction; pretax income (or loss) from continuing operations; and income tax expense (or benefit). The ASU is effective for fiscal years beginning after December&#160;15,&#160;2024, and interim periods beginning after December&#160;15,&#160;2025, with early adoption permitted. We are currently evaluating the impact of this standard on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November&#160;2023, the FASB issued ASU&#160;2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Topic&#160;280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, and interim periods within fiscal years beginning after December&#160;15,&#160;2024 on a retrospective basis. We are currently evaluating the impact of this standard on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2023, the FASB issued ASU 2023-05, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations-Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires a joint venture to initially measure all contributions received upon its formation at fair value. This ASU is applicable to joint venture entities with a formation date on or after January&#160;1,&#160;2025 on a prospective basis. We will apply this guidance prospectively in future reporting periods after the guidance is effective to any future arrangements meeting the definition of a joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March&#160;2023, the FASB issued ASU&#160;2023-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Common Control Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that leasehold improvements associated with common control leases be amortized over the useful life of the leasehold improvements to the common control group, regardless of the lease term. This ASU is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years. We are currently evaluating the impact of this standard on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC) and the SEC during the year ended December&#160;31,&#160;2023 did not, or are not expected to, have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-684">Financial Statement Details&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid software license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Insurance premium financing asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance claims receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid equipment maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ERP system implementation cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net, consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;68,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;67,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture &amp;amp; fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Gross property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;230,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;212,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;146,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;143,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, depreciation expense related to property, plant and equipment totaled $16.5&#160;million, $16.3&#160;million and $14.2&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span id="i5152da74782c4119b27351f18d5b573b_17470"&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Definite-lived: Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Organized workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Definite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the Dunkirk Facility in 2022, we acquired definite-lived intangibles consisting of favorable leasehold rights and an organized workforce. During the year ended December&#160;31,&#160;2022, we wrote off the entire unamortized organized workforce intangible asset totaling $0.7&#160;million in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_184" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and License Agreements and Acquisition, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023 and 2022, we recorded amortization expense of definite-lived intangible assets totaling $2.0&#160;million and $1.9&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2023, we discontinued the research and development program associated with the&#160;Tarmogen platform based on results gathered from clinical data. We recorded a charge totaling $0.9&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;impairment of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations in connection with the writedown of the carrying value of Tarmogen to zero. No such impairments were recorded during the years&#160;ended December&#160;31,&#160;2022 and 2021. As of December&#160;31,&#160;2023 and 2022, the company had indefinite-lived IPR&amp;amp;D intangible assets of $0.5&#160;million and $1.4&#160;million, respectively, which were obtained from business acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense associated with our definite-lived intangible assets is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.825%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Definite-lived&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Note Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we executed a convertible promissory note pursuant to which we advanced Riptide a principal amount of $5.0&#160;million. The note bears interest at a per annum rate of five percent&#160;(5%). Concurrent with the transaction, we entered into an exclusive license agreement with Riptide to obtain worldwide exclusive rights, with the right to sublicense, certain know-how related to RP-182, RP-233 and RP-183. We are required to pay a single-digit royalty on net sales of the licensed products on a country-by-country basis. Pursuant to the license agreement, we are also required to make cash milestone payments upon successful completion of certain clinical, regulatory and commercial milestones up to an aggregate amount of $47.0&#160;million for the first three&#160;indications of the licensed product with a maximum payment amount of $100.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, we entered into a first amendment to the convertible promissory note with Riptide. Under the agreement, we extended the maturity of the promissory note to the earlier of (a)&#160;the later of (i)&#160;the completion of non-clinical IND enabling studies by the company, or (ii)&#160;December&#160;31,&#160;2020; and (b)&#160;when we accelerate the maturity of the note upon the occurrence of an event of default. No other terms and conditions of the promissory note were modified. Concurrently, we also entered into a first&#160;amendment to the exclusive license agreement with Riptide and extended the achievement dates for certain clinical trial milestones related to the licensed products. This option for receiving a 25%&#160;discount was determined to have an immaterial value at inception and life-to-date of the note, as the probability of a future qualifying event is remote. The convertible note receivable balance was $6.9&#160;million and $6.6&#160;million, which included accrued interest of $1.9&#160;million and $1.6&#160;million as of December&#160;31,&#160;2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consist of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional and service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued preclinical and clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing obligation &#x2013; current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest and Investment Income (Loss), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and investment income (loss), net consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses from equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment accretion income (amortization expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains (losses) on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and investment income (loss), net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes interest from marketable securities, convertible notes receivable, other assets, and on bank deposits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on related-party notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of related-party notes discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-685">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid software license fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Insurance premium financing asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance claims receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid equipment maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ERP system implementation cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ibrx:PrepaidResearchAndDevelopmentCosts contextRef="c-4" decimals="-3" id="f-686" unitRef="usd">7847000</ibrx:PrepaidResearchAndDevelopmentCosts>
    <ibrx:PrepaidResearchAndDevelopmentCosts contextRef="c-5" decimals="-3" id="f-687" unitRef="usd">11704000</ibrx:PrepaidResearchAndDevelopmentCosts>
    <ibrx:PrepaidServices contextRef="c-4" decimals="-3" id="f-688" unitRef="usd">5869000</ibrx:PrepaidServices>
    <ibrx:PrepaidServices contextRef="c-5" decimals="-3" id="f-689" unitRef="usd">8013000</ibrx:PrepaidServices>
    <us-gaap:PrepaidInsurance contextRef="c-4" decimals="-3" id="f-690" unitRef="usd">2242000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-5" decimals="-3" id="f-691" unitRef="usd">2282000</us-gaap:PrepaidInsurance>
    <ibrx:PrepaidSoftwareLicenseFees contextRef="c-4" decimals="-3" id="f-692" unitRef="usd">2100000</ibrx:PrepaidSoftwareLicenseFees>
    <ibrx:PrepaidSoftwareLicenseFees contextRef="c-5" decimals="-3" id="f-693" unitRef="usd">2195000</ibrx:PrepaidSoftwareLicenseFees>
    <ibrx:InsurancePremiumFinancingAsset contextRef="c-4" decimals="-3" id="f-694" unitRef="usd">1475000</ibrx:InsurancePremiumFinancingAsset>
    <ibrx:InsurancePremiumFinancingAsset contextRef="c-5" decimals="-3" id="f-695" unitRef="usd">1417000</ibrx:InsurancePremiumFinancingAsset>
    <us-gaap:InsuranceSettlementsReceivableCurrent contextRef="c-4" decimals="-3" id="f-696" unitRef="usd">1149000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent contextRef="c-5" decimals="-3" id="f-697" unitRef="usd">0</us-gaap:InsuranceSettlementsReceivableCurrent>
    <ibrx:PrepaidEquipmentMaintenance contextRef="c-4" decimals="-3" id="f-698" unitRef="usd">1183000</ibrx:PrepaidEquipmentMaintenance>
    <ibrx:PrepaidEquipmentMaintenance contextRef="c-5" decimals="-3" id="f-699" unitRef="usd">833000</ibrx:PrepaidEquipmentMaintenance>
    <us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-700" unitRef="usd">1087000</us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization>
    <us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-701" unitRef="usd">920000</us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization>
    <us-gaap:Supplies contextRef="c-4" decimals="-3" id="f-702" unitRef="usd">0</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c-5" decimals="-3" id="f-703" unitRef="usd">2160000</us-gaap:Supplies>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-704" unitRef="usd">2651000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-705" unitRef="usd">1979000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">25603000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-707" unitRef="usd">31503000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-139" decimals="-3" id="f-708" unitRef="usd">72552000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-140" decimals="-3" id="f-709" unitRef="usd">68710000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-141" decimals="-3" id="f-710" unitRef="usd">69915000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-142" decimals="-3" id="f-711" unitRef="usd">67945000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-143" decimals="-3" id="f-712" unitRef="usd">84436000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-144" decimals="-3" id="f-713" unitRef="usd">72693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-98" decimals="-3" id="f-714" unitRef="usd">1666000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-145" decimals="-3" id="f-715" unitRef="usd">1657000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-101" decimals="-3" id="f-716" unitRef="usd">1889000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-146" decimals="-3" id="f-717" unitRef="usd">1906000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-718" unitRef="usd">230458000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-719" unitRef="usd">212911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-720" unitRef="usd">84376000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-721" unitRef="usd">69252000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-722" unitRef="usd">146082000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-723" unitRef="usd">143659000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-724" unitRef="usd">16500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-10" decimals="-5" id="f-725" unitRef="usd">16300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-11" decimals="-5" id="f-726" unitRef="usd">14200000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-727">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying amounts and accumulated amortization of intangible assets are as follows at the dates indicated (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Definite-lived: Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(3,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Favorable leasehold rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Organized workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Indefinite-lived: IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-147" id="f-728">P8Y1M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-147" decimals="-3" id="f-729" unitRef="usd">20398000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-147" decimals="-3" id="f-730" unitRef="usd">3825000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment contextRef="c-147" decimals="-3" id="f-731" unitRef="usd">0</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-147" decimals="-3" id="f-732" unitRef="usd">16573000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ibrx:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-3" id="f-733" unitRef="usd">1406000</ibrx:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill>
    <ibrx:IndefiniteLivedIntangibleAssetsAccumulatedImpairment contextRef="c-4" decimals="-3" id="f-734" unitRef="usd">886000</ibrx:IndefiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-735" unitRef="usd">520000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-3" id="f-736" unitRef="usd">21804000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-737" unitRef="usd">3825000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:IntangibleAssetsAccumulatedImpairment contextRef="c-4" decimals="-3" id="f-738" unitRef="usd">886000</ibrx:IntangibleAssetsAccumulatedImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-739" unitRef="usd">17093000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-148" id="f-740">P9Y1M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-148" decimals="-3" id="f-741" unitRef="usd">20398000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-148" decimals="-3" id="f-742" unitRef="usd">1785000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment contextRef="c-148" decimals="-3" id="f-743" unitRef="usd">0</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-148" decimals="-3" id="f-744" unitRef="usd">18613000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-149" decimals="-3" id="f-745" unitRef="usd">831000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-149" decimals="-3" id="f-746" unitRef="usd">150000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment contextRef="c-149" decimals="-3" id="f-747" unitRef="usd">681000</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-149" decimals="-3" id="f-748" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="-3" id="f-749" unitRef="usd">21229000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-750" unitRef="usd">1935000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment contextRef="c-5" decimals="-3" id="f-751" unitRef="usd">681000</ibrx:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-752" unitRef="usd">18613000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ibrx:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-3" id="f-753" unitRef="usd">1390000</ibrx:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-754" unitRef="usd">1390000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-3" id="f-755" unitRef="usd">22619000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-756" unitRef="usd">1935000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ibrx:IntangibleAssetsAccumulatedImpairment contextRef="c-5" decimals="-3" id="f-757" unitRef="usd">681000</ibrx:IntangibleAssetsAccumulatedImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-758" unitRef="usd">20003000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-150" decimals="-5" id="f-759" unitRef="usd">700000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-760" unitRef="usd">2000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-10" decimals="-5" id="f-761" unitRef="usd">1900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-151" decimals="-5" id="f-762" unitRef="usd">900000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-152" decimals="-5" id="f-763" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-153" decimals="-5" id="f-764" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-154" decimals="-5" id="f-765" unitRef="usd">500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-155" decimals="-5" id="f-766" unitRef="usd">1400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-767">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense associated with our definite-lived intangible assets is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.825%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Definite-lived&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-768" unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-769" unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-770" unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-771" unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-772" unitRef="usd">2040000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-3" id="f-773" unitRef="usd">6373000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-774" unitRef="usd">16573000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ibrx:ConvertibleNoteReceivableNonCurrent contextRef="c-156" decimals="-5" id="f-775" unitRef="usd">5000000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <us-gaap:InvestmentInterestRate
      contextRef="c-157"
      decimals="INF"
      id="f-776"
      unitRef="number">0.05</us-gaap:InvestmentInterestRate>
    <ibrx:CollaborationAgreementsMilestonePaymentPayableAmount contextRef="c-158" decimals="-5" id="f-777" unitRef="usd">47000000</ibrx:CollaborationAgreementsMilestonePaymentPayableAmount>
    <ibrx:CollaborationAgreementsMilestonePaymentAmount contextRef="c-159" decimals="-5" id="f-778" unitRef="usd">100000000</ibrx:CollaborationAgreementsMilestonePaymentAmount>
    <ibrx:ConvertibleNoteReceivableDiscountOptionPercent contextRef="c-4" decimals="2" id="f-779" unitRef="number">25</ibrx:ConvertibleNoteReceivableDiscountOptionPercent>
    <ibrx:ConvertibleNoteReceivableNonCurrent contextRef="c-4" decimals="-5" id="f-780" unitRef="usd">6900000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <ibrx:ConvertibleNoteReceivableNonCurrent contextRef="c-5" decimals="-5" id="f-781" unitRef="usd">6600000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <us-gaap:InterestReceivable contextRef="c-4" decimals="-5" id="f-782" unitRef="usd">1900000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable contextRef="c-5" decimals="-5" id="f-783" unitRef="usd">1600000</us-gaap:InterestReceivable>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-784">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other liabilities consist of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional and service fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued preclinical and clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing obligation &#x2013; current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.07pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;42,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent contextRef="c-4" decimals="-3" id="f-785" unitRef="usd">11350000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-5" decimals="-3" id="f-786" unitRef="usd">12068000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-787" unitRef="usd">9829000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-788" unitRef="usd">6685000</us-gaap:AccruedProfessionalFeesCurrent>
    <ibrx:AccruedResearchAndDevelopmentCosts contextRef="c-4" decimals="-3" id="f-789" unitRef="usd">7700000</ibrx:AccruedResearchAndDevelopmentCosts>
    <ibrx:AccruedResearchAndDevelopmentCosts contextRef="c-5" decimals="-3" id="f-790" unitRef="usd">1930000</ibrx:AccruedResearchAndDevelopmentCosts>
    <us-gaap:AccruedSalariesCurrent contextRef="c-4" decimals="-3" id="f-791" unitRef="usd">6241000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-5" decimals="-3" id="f-792" unitRef="usd">6040000</us-gaap:AccruedSalariesCurrent>
    <ibrx:AccruedPreclinicalAndClinicalTrialCosts contextRef="c-4" decimals="-3" id="f-793" unitRef="usd">4218000</ibrx:AccruedPreclinicalAndClinicalTrialCosts>
    <ibrx:AccruedPreclinicalAndClinicalTrialCosts contextRef="c-5" decimals="-3" id="f-794" unitRef="usd">4985000</ibrx:AccruedPreclinicalAndClinicalTrialCosts>
    <ibrx:FinancingObligationCurrent contextRef="c-4" decimals="-3" id="f-795" unitRef="usd">1475000</ibrx:FinancingObligationCurrent>
    <ibrx:FinancingObligationCurrent contextRef="c-5" decimals="-3" id="f-796" unitRef="usd">1417000</ibrx:FinancingObligationCurrent>
    <us-gaap:ConstructionPayableCurrent contextRef="c-4" decimals="-3" id="f-797" unitRef="usd">1179000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:ConstructionPayableCurrent contextRef="c-5" decimals="-3" id="f-798" unitRef="usd">7072000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-799" unitRef="usd">716000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-800" unitRef="usd">1628000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-801" unitRef="usd">42708000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-802" unitRef="usd">41825000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestAndOtherIncomeTableTextBlock contextRef="c-1" id="f-803">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and investment income (loss), net consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses from equity securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment accretion income (amortization expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized gains (losses) on investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest and investment income (loss), net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestAndOtherIncomeTableTextBlock>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-804" unitRef="usd">-1591000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-10" decimals="-3" id="f-805" unitRef="usd">-4190000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-11" decimals="-3" id="f-806" unitRef="usd">-4615000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c-1" decimals="-3" id="f-807" unitRef="usd">863000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-10" decimals="-3" id="f-808" unitRef="usd">2708000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c-11" decimals="-3" id="f-809" unitRef="usd">836000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-810" unitRef="usd">1844000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-10" decimals="-3" id="f-811" unitRef="usd">-1486000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-11" decimals="-3" id="f-812" unitRef="usd">-488000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-3" id="f-813" unitRef="usd">15000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-10" decimals="-3" id="f-814" unitRef="usd">-122000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-11" decimals="-3" id="f-815" unitRef="usd">167000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-816" unitRef="usd">1131000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-10" decimals="-3" id="f-817" unitRef="usd">-3090000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-11" decimals="-3" id="f-818" unitRef="usd">-4100000</us-gaap:GainLossOnInvestments>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c-1" id="f-819">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense consists of the following (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on related-party notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of related-party notes discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt contextRef="c-160" decimals="-3" id="f-820" unitRef="usd">86453000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-161" decimals="-3" id="f-821" unitRef="usd">47145000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-162" decimals="-3" id="f-822" unitRef="usd">14695000</us-gaap:InterestExpenseDebt>
    <ibrx:AmortizationOfDebtDiscountPremiumRelatedParty contextRef="c-1" decimals="-3" id="f-823" unitRef="usd">42396000</ibrx:AmortizationOfDebtDiscountPremiumRelatedParty>
    <ibrx:AmortizationOfDebtDiscountPremiumRelatedParty contextRef="c-10" decimals="-3" id="f-824" unitRef="usd">16282000</ibrx:AmortizationOfDebtDiscountPremiumRelatedParty>
    <ibrx:AmortizationOfDebtDiscountPremiumRelatedParty contextRef="c-11" decimals="-3" id="f-825" unitRef="usd">62000</ibrx:AmortizationOfDebtDiscountPremiumRelatedParty>
    <us-gaap:InterestExpenseOther contextRef="c-1" decimals="-3" id="f-826" unitRef="usd">349000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c-10" decimals="-3" id="f-827" unitRef="usd">88000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c-11" decimals="-3" id="f-828" unitRef="usd">92000</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-829" unitRef="usd">129198000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-10" decimals="-3" id="f-830" unitRef="usd">63515000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-11" decimals="-3" id="f-831" unitRef="usd">14849000</us-gaap:InterestExpense>
    <us-gaap:InvestmentTextBlock contextRef="c-1" id="f-832">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, 12&#160;of the securities were in an unrealized loss position. Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, we evaluated our securities for other-than-temporary impairment and did not recognize any other-than-temporary impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023 and 2022, we held investments in marketable equity securities with readily determinable fair values of $0.9&#160;million and $2.5&#160;million, respectively. During the years ended December&#160;31,&#160;2023, 2022 and 2021, unrealized losses recorded on these securities totaled $1.6&#160;million, $4.2&#160;million, and $4.6&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest and investment income (loss), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-833">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross &lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, the weighted-average remaining contractual life, amortized cost, gross unrealized gains, gross unrealized losses, and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod contextRef="c-163" id="f-834">P0Y9M18D</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-164" decimals="-3" id="f-835" unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-164" decimals="-3" id="f-836" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-164" decimals="-3" id="f-837" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-164" decimals="-3" id="f-838" unitRef="usd">54000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-165" decimals="-3" id="f-839" unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-165" decimals="-3" id="f-840" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-165" decimals="-3" id="f-841" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-165" decimals="-3" id="f-842" unitRef="usd">39000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-166" decimals="-3" id="f-843" unitRef="usd">94000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-166" decimals="-3" id="f-844" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-166" decimals="-3" id="f-845" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-166" decimals="-3" id="f-846" unitRef="usd">93000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod contextRef="c-167" id="f-847">P3Y3M18D</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-168" decimals="-3" id="f-848" unitRef="usd">939000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-168" decimals="-3" id="f-849" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-168" decimals="-3" id="f-850" unitRef="usd">48000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-168" decimals="-3" id="f-851" unitRef="usd">891000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-3" id="f-852" unitRef="usd">1033000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-853" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-854" unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-3" id="f-855" unitRef="usd">984000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-169" decimals="-3" id="f-856" unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-169" decimals="-3" id="f-857" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-169" decimals="-3" id="f-858" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-169" decimals="-3" id="f-859" unitRef="usd">36000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod contextRef="c-170" id="f-860">P4Y6M</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-171" decimals="-3" id="f-861" unitRef="usd">932000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-171" decimals="-3" id="f-862" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-171" decimals="-3" id="f-863" unitRef="usd">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-171" decimals="-3" id="f-864" unitRef="usd">840000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-865" unitRef="usd">970000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-3" id="f-866" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-3" id="f-867" unitRef="usd">94000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-868" unitRef="usd">876000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions contextRef="c-4" decimals="0" id="f-869" unitRef="security">12</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-870">Accumulated unrealized losses on marketable debt securities that have been in a continuous loss position for less than 12&#160;months and more than 12&#160;months were as follows (in&#160;thousands): &lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;More than 12 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-172" decimals="-3" id="f-871" unitRef="usd">39000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-172" decimals="-3" id="f-872" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-172" decimals="-3" id="f-873" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-172" decimals="-3" id="f-874" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-173" decimals="-3" id="f-875" unitRef="usd">891000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-173" decimals="-3" id="f-876" unitRef="usd">48000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-173" decimals="-3" id="f-877" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-173" decimals="-3" id="f-878" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-3" id="f-879" unitRef="usd">930000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-3" id="f-880" unitRef="usd">49000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-3" id="f-881" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-3" id="f-882" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-174" decimals="-3" id="f-883" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-174" decimals="-3" id="f-884" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-174" decimals="-3" id="f-885" unitRef="usd">36000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-174" decimals="-3" id="f-886" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-175" decimals="-3" id="f-887" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-175" decimals="-3" id="f-888" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-175" decimals="-3" id="f-889" unitRef="usd">840000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-175" decimals="-3" id="f-890" unitRef="usd">92000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-5" decimals="-3" id="f-891" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-5" decimals="-3" id="f-892" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-5" decimals="-3" id="f-893" unitRef="usd">876000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-5" decimals="-3" id="f-894" unitRef="usd">94000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:ImpairmentOfInvestments contextRef="c-176" decimals="INF" id="f-895" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments contextRef="c-177" decimals="INF" id="f-896" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments contextRef="c-178" decimals="INF" id="f-897" unitRef="usd">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:MarketableSecurities contextRef="c-4" decimals="-5" id="f-898" unitRef="usd">900000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-5" decimals="-5" id="f-899" unitRef="usd">2500000</us-gaap:MarketableSecurities>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-900" unitRef="usd">-1600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-10" decimals="-5" id="f-901" unitRef="usd">-4200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="-5" id="f-902" unitRef="usd">-4600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="c-1" id="f-903">Fair Value Measurements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recurring Valuations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;265,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;265,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock option purchase liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent consideration is recorded at estimated fair value and revalued each reporting period until the related contingency is resolved. The fair value measurement is based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&#x2014;Contingent Consideration Related to Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of contingent consideration were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (increase) decrease in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock Option Purchase Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the RIPA, we entered into an SPOA pursuant to which Oberland has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability at its fair value upon issuance. The fair value was estimated using probability-weighted scenarios over the likelihood of this option being exercised. As of December&#160;31,&#160;2023, the stock purchase option was outstanding. The fair value of the stock purchase option was estimated at $0.8 million at issuance. Due to the proximity of the inception date of the SPOA to December&#160;31,&#160;2023, the change in fair value was immaterial. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Interest Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The debt incurred pursuant to the RIPA entered on December&#160;29,&#160;2023 contains embedded derivatives requiring bifurcation as a single compound derivative instrument. The company estimated the fair value of the derivative liability using a &#x201c;with-and-without&#x201d; method. The with-and-without methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the individual embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the derivative liability, which is estimated at $34.5&#160;million as of December&#160;31,&#160;2023. The estimated probability and timing of underlying events triggering the exercisability of the Put Option contained in the RIPA, forecasted cash flows and the discount rate are significant unobservable inputs used to determine the estimated fair value of the entire instrument with the embedded derivative. As of December&#160;31,&#160;2023, the discount rate used for valuation of the derivative liability was 12.1%. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;N&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ote&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Interest Purchase Agreement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the December&#160;2023 debt extinguishment, the company identified an embedded derivative related to a contingently exercisable prepayment feature of the amended $505.0&#160;million December&#160;2023 promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment and accrued interest upon occurrence of a specified transaction (defined in the promissory note). This embedded derivative is recorded as a derivative liability on the consolidated balance sheet and is measured at fair value. Changes in the fair value of the derivative liability are reported as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;change in fair value of derivative,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations. The fair value of the derivative liability is determined at each period end using a with and without method, which assesses the likelihood and timing of a specified transaction that if triggered could result in a repayment. The fair value of the embedded derivative is estimated at $0.8&#160;million as of December&#160;31,&#160;2023, and will be remeasured to fair value at each reporting date until the derivative is settled.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Third-Party Warrant Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2022 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the December&#160;12,&#160;2022 registered direct offering of common stock, the company issued 9,090,909&#160;warrants (December&#160;2022&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023 and 2022, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;February 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the February&#160;15,&#160;2023 registered direct offering of common stock, the company issued 14,072,615&#160;warrants. The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issuance Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;February&#160;17,&lt;br/&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.2946&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.2636&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On July&#160;25,&#160;2023, the company reduced the exercise price of the outstanding February&#160;2023&#160;Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extended the expiration date of the warrants until July&#160;24,&#160;2026. The effect of amending the terms of the warrants is reflected in a change in the fair value of warrant liability of $7.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;July 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the July&#160;20, 2023 registered direct offering of common stock, the company issued 14,569,296&#160;warrants (July&#160;2023&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issuance Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;July&#160;25,&lt;br/&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.2946&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.2946&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of the warrant liabilities was as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.951%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 2022&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;February&#160;2023&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;July&#160;2023&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1044"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;2022&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value at issuance, December&#160;12,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value, December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S.&#160;government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Recurring Valuations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. Except for the impairments discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i5152da74782c4119b27351f18d5b573b_17470" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Statement Details&#x2014;Intangible Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were no other material non-financial assets or liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the years ended December&#160;31,&#160;2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measured the fair value of the promissory notes before and after amendments that were entered on December&#160;29,&#160;2023 and August&#160;31,&#160;2022, as they were accounted for under the debt extinguishment accounting model. We used discounted cash flow analyses for promissory notes without a holder conversion option and used binomial lattice models for promissory notes with a holder conversion option. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be a Level&#160;3 valuation. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Related-Party Debt,&lt;/span&gt; for more information.</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-904">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;265,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;265,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Stock option purchase liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities at Fair Value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contingent consideration is recorded at estimated fair value and revalued each reporting period until the related contingency is resolved. The fair value measurement is based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;7&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitments and Contingencies&#x2014;Contingent Consideration Related to Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of contingent consideration were as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (increase) decrease in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock Option Purchase Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the RIPA, we entered into an SPOA pursuant to which Oberland has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability at its fair value upon issuance. The fair value was estimated using probability-weighted scenarios over the likelihood of this option being exercised. As of December&#160;31,&#160;2023, the stock purchase option was outstanding. The fair value of the stock purchase option was estimated at $0.8 million at issuance. Due to the proximity of the inception date of the SPOA to December&#160;31,&#160;2023, the change in fair value was immaterial. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Interest Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The debt incurred pursuant to the RIPA entered on December&#160;29,&#160;2023 contains embedded derivatives requiring bifurcation as a single compound derivative instrument. The company estimated the fair value of the derivative liability using a &#x201c;with-and-without&#x201d; method. The with-and-without methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the individual embedded derivative. The difference between the entire instrument with the embedded derivative compared to the instrument without the embedded derivative is the fair value of the derivative liability, which is estimated at $34.5&#160;million as of December&#160;31,&#160;2023. The estimated probability and timing of underlying events triggering the exercisability of the Put Option contained in the RIPA, forecasted cash flows and the discount rate are significant unobservable inputs used to determine the estimated fair value of the entire instrument with the embedded derivative. As of December&#160;31,&#160;2023, the discount rate used for valuation of the derivative liability was 12.1%. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;N&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ote&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&#160;&lt;/a&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_952" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Interest Purchase Agreement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the December&#160;2023 debt extinguishment, the company identified an embedded derivative related to a contingently exercisable prepayment feature of the amended $505.0&#160;million December&#160;2023 promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment and accrued interest upon occurrence of a specified transaction (defined in the promissory note). This embedded derivative is recorded as a derivative liability on the consolidated balance sheet and is measured at fair value. Changes in the fair value of the derivative liability are reported as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;change in fair value of derivative,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of operations. The fair value of the derivative liability is determined at each period end using a with and without method, which assesses the likelihood and timing of a specified transaction that if triggered could result in a repayment. The fair value of the embedded derivative is estimated at $0.8&#160;million as of December&#160;31,&#160;2023, and will be remeasured to fair value at each reporting date until the derivative is settled.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Third-Party Warrant Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2022 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the December&#160;12,&#160;2022 registered direct offering of common stock, the company issued 9,090,909&#160;warrants (December&#160;2022&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023 and 2022, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$6.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;February 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the February&#160;15,&#160;2023 registered direct offering of common stock, the company issued 14,072,615&#160;warrants. The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issuance Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;February&#160;17,&lt;br/&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.2946&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.2636&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On July&#160;25,&#160;2023, the company reduced the exercise price of the outstanding February&#160;2023&#160;Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extended the expiration date of the warrants until July&#160;24,&#160;2026. The effect of amending the terms of the warrants is reflected in a change in the fair value of warrant liability of $7.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;July 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the July&#160;20, 2023 registered direct offering of common stock, the company issued 14,569,296&#160;warrants (July&#160;2023&#160;Warrants). The warrants were classified as a liability at their fair value upon issuance. As of December&#160;31,&#160;2023, all warrants were outstanding. The estimated fair value of the warrants was computed using the Black-Scholes option pricing model with the following unobservable assumptions at the following dates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issuance Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;July&#160;25,&lt;br/&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercise price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.2946&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.2946&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in the carrying amount of the warrant liabilities was as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.951%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 2022&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;February&#160;2023&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;July&#160;2023&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1044"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value, December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;2022&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value at issuance, December&#160;12,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value, December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, the Level&#160;2 measurements include $32.0&#160;million in U.S.&#160;government agency securities and $8.8&#160;million in corporate debt securities with original maturities of less than 90&#160;days.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The estimated fair value of the convertible note was computed using the binomial lattice model with the following observable assumptions before it was modified on December&#160;29,&#160;2023. After the debt extinguishment, the note is accounted for under the amortized cost basis. &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected market yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of this note was as follows (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value at issuance date, March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on debt extinguishment with entities under common control&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying value, December&#160;29,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-179" decimals="-3" id="f-905" unitRef="usd">265453000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-180" decimals="-3" id="f-906" unitRef="usd">265453000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-181" decimals="-3" id="f-907" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-182" decimals="-3" id="f-908" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-183" decimals="-3" id="f-909" unitRef="usd">916000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-184" decimals="-3" id="f-910" unitRef="usd">916000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-185" decimals="-3" id="f-911" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-186" decimals="-3" id="f-912" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-187" decimals="-3" id="f-913" unitRef="usd">54000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-188" decimals="-3" id="f-914" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-189" decimals="-3" id="f-915" unitRef="usd">54000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-190" decimals="-3" id="f-916" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-191" decimals="-3" id="f-917" unitRef="usd">39000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-192" decimals="-3" id="f-918" unitRef="usd">39000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-193" decimals="-3" id="f-919" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-194" decimals="-3" id="f-920" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-195" decimals="-3" id="f-921" unitRef="usd">891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-196" decimals="-3" id="f-922" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-197" decimals="-3" id="f-923" unitRef="usd">891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-198" decimals="-3" id="f-924" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-199" decimals="-3" id="f-925" unitRef="usd">267353000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-200" decimals="-3" id="f-926" unitRef="usd">266408000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-201" decimals="-3" id="f-927" unitRef="usd">945000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-202" decimals="-3" id="f-928" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-203" decimals="-3" id="f-929" unitRef="usd">20000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-204" decimals="-3" id="f-930" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-205" decimals="-3" id="f-931" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-206" decimals="-3" id="f-932" unitRef="usd">20000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-207" decimals="-3" id="f-933" unitRef="usd">819000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-208" decimals="-3" id="f-934" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-209" decimals="-3" id="f-935" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-210" decimals="-3" id="f-936" unitRef="usd">819000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-211" decimals="-3" id="f-937" unitRef="usd">35333000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-212" decimals="-3" id="f-938" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-213" decimals="-3" id="f-939" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-214" decimals="-3" id="f-940" unitRef="usd">35333000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-215" decimals="-3" id="f-941" unitRef="usd">118770000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-216" decimals="-3" id="f-942" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-217" decimals="-3" id="f-943" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-218" decimals="-3" id="f-944" unitRef="usd">118770000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-199" decimals="-3" id="f-945" unitRef="usd">154942000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-200" decimals="-3" id="f-946" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-201" decimals="-3" id="f-947" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-202" decimals="-3" id="f-948" unitRef="usd">154942000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-219" decimals="-3" id="f-949" unitRef="usd">104641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-220" decimals="-3" id="f-950" unitRef="usd">63860000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-221" decimals="-3" id="f-951" unitRef="usd">40781000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-222" decimals="-3" id="f-952" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-223" decimals="-3" id="f-953" unitRef="usd">2507000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-224" decimals="-3" id="f-954" unitRef="usd">2507000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-225" decimals="-3" id="f-955" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-226" decimals="-3" id="f-956" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-227" decimals="-3" id="f-957" unitRef="usd">36000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-228" decimals="-3" id="f-958" unitRef="usd">36000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-229" decimals="-3" id="f-959" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-230" decimals="-3" id="f-960" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-231" decimals="-3" id="f-961" unitRef="usd">840000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-232" decimals="-3" id="f-962" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-233" decimals="-3" id="f-963" unitRef="usd">840000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-234" decimals="-3" id="f-964" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-235" decimals="-3" id="f-965" unitRef="usd">108024000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-236" decimals="-3" id="f-966" unitRef="usd">66403000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-237" decimals="-3" id="f-967" unitRef="usd">41621000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-238" decimals="-3" id="f-968" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-239" decimals="-3" id="f-969" unitRef="usd">19000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-240" decimals="-3" id="f-970" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-241" decimals="-3" id="f-971" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-242" decimals="-3" id="f-972" unitRef="usd">19000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-243" decimals="-3" id="f-973" unitRef="usd">21636000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-244" decimals="-3" id="f-974" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-245" decimals="-3" id="f-975" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-246" decimals="-3" id="f-976" unitRef="usd">21636000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-235" decimals="-3" id="f-977" unitRef="usd">21655000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-236" decimals="-3" id="f-978" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-237" decimals="-3" id="f-979" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-238" decimals="-3" id="f-980" unitRef="usd">21655000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-247" decimals="-3" id="f-981" unitRef="usd">19000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-248" decimals="-3" id="f-982" unitRef="usd">409000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-249" decimals="-3" id="f-983" unitRef="usd">972000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-250" decimals="-3" id="f-984" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-251" decimals="-3" id="f-985" unitRef="usd">339000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-252" decimals="-3" id="f-986" unitRef="usd">419000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-250" decimals="-3" id="f-987" unitRef="usd">-1000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-251" decimals="-3" id="f-988" unitRef="usd">51000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-252" decimals="-3" id="f-989" unitRef="usd">144000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-253" decimals="-3" id="f-990" unitRef="usd">20000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-247" decimals="-3" id="f-991" unitRef="usd">19000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-248" decimals="-3" id="f-992" unitRef="usd">409000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-132" decimals="-5" id="f-993" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ibrx:EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue contextRef="c-4" decimals="-5" id="f-994" unitRef="usd">-800000</ibrx:EstimatedFairValueOfStockPurchaseOptionAtIssuanceAndChangeInFairValue>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-103" decimals="-3" id="f-995" unitRef="usd">34500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput contextRef="c-254" decimals="3" id="f-996" unitRef="number">0.121</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-997" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <ibrx:DebtInstrumentPrepaymentAndAccruedInterest contextRef="c-255" decimals="-5" id="f-998" unitRef="usd">50000000</ibrx:DebtInstrumentPrepaymentAndAccruedInterest>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet contextRef="c-4" decimals="-5" id="f-999" unitRef="usd">800000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-256"
      decimals="INF"
      id="f-1000"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-257"
      decimals="2"
      id="f-1001"
      unitRef="usdPerShare">6.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-258"
      decimals="2"
      id="f-1002"
      unitRef="usdPerShare">6.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-259" decimals="1" id="f-1003" unitRef="y">1000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-260" decimals="1" id="f-1004" unitRef="y">2000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-261"
      decimals="3"
      id="f-1005"
      unitRef="number">1.190</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-262"
      decimals="3"
      id="f-1006"
      unitRef="number">0.994</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-263"
      decimals="3"
      id="f-1007"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-264"
      decimals="3"
      id="f-1008"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-265"
      decimals="3"
      id="f-1009"
      unitRef="number">0.047</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-266"
      decimals="3"
      id="f-1010"
      unitRef="number">0.044</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-267"
      decimals="INF"
      id="f-1011"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-268"
      decimals="4"
      id="f-1012"
      unitRef="usdPerShare">3.2946</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-269"
      decimals="4"
      id="f-1013"
      unitRef="usdPerShare">4.2636</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-270" decimals="1" id="f-1014" unitRef="y">2600</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-271" decimals="1" id="f-1015" unitRef="y">2000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-272"
      decimals="3"
      id="f-1016"
      unitRef="number">1.073</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-273"
      decimals="3"
      id="f-1017"
      unitRef="number">0.970</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-274"
      decimals="3"
      id="f-1018"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-275"
      decimals="3"
      id="f-1019"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-276"
      decimals="3"
      id="f-1020"
      unitRef="number">0.041</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-277"
      decimals="3"
      id="f-1021"
      unitRef="number">0.046</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-278"
      decimals="4"
      id="f-1022"
      unitRef="usdPerShare">4.2636</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-279"
      decimals="4"
      id="f-1023"
      unitRef="usdPerShare">3.2946</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-280" decimals="-5" id="f-1024" unitRef="usd">7300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-281"
      decimals="INF"
      id="f-1025"
      unitRef="shares">14569296</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-282"
      decimals="4"
      id="f-1026"
      unitRef="usdPerShare">3.2946</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-283"
      decimals="4"
      id="f-1027"
      unitRef="usdPerShare">3.2946</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-284" decimals="1" id="f-1028" unitRef="y">2600</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-285" decimals="1" id="f-1029" unitRef="y">3000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-286"
      decimals="3"
      id="f-1030"
      unitRef="number">1.073</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-287"
      decimals="3"
      id="f-1031"
      unitRef="number">1.210</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-288"
      decimals="3"
      id="f-1032"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-289"
      decimals="3"
      id="f-1033"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-290"
      decimals="3"
      id="f-1034"
      unitRef="number">0.041</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-291"
      decimals="3"
      id="f-1035"
      unitRef="number">0.045</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-3" id="f-1036" unitRef="usd">21636000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-292" decimals="-3" id="f-1037" unitRef="usd">21636000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-293" decimals="-3" id="f-1038" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-294" decimals="-3" id="f-1039" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-1" decimals="-3" id="f-1040" unitRef="usd">49534000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-295" decimals="-3" id="f-1041" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-296" decimals="-3" id="f-1042" unitRef="usd">23698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-297" decimals="-3" id="f-1043" unitRef="usd">25836000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-1045" unitRef="usd">47600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-295" decimals="-3" id="f-1046" unitRef="usd">-4545000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-296" decimals="-3" id="f-1047" unitRef="usd">26260000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-297" decimals="-3" id="f-1048" unitRef="usd">25885000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-4" decimals="-3" id="f-1049" unitRef="usd">118770000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-298" decimals="-3" id="f-1050" unitRef="usd">17091000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-299" decimals="-3" id="f-1051" unitRef="usd">49958000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-300" decimals="-3" id="f-1052" unitRef="usd">51721000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-301" decimals="-3" id="f-1053" unitRef="usd">35096000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-301" decimals="-3" id="f-1054" unitRef="usd">-13460000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-292" decimals="-3" id="f-1055" unitRef="usd">21636000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-302" decimals="-5" id="f-1056" unitRef="usd">32000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-303" decimals="-5" id="f-1057" unitRef="usd">8800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c-1" id="f-1058">Collaboration and License Agreements and Acquisition&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;National Cancer Institute &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2015 NCI CRADA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May&#160;2015, Etubics entered into a CRADA with the HHS as represented by the NCI of the NIH to collaborate on the preclinical and clinical development of an adenovirus technology expressing TAAs for cancer immunotherapy. In January&#160;2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;2018, our subsidiary NantCell assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing TAAs and proprietary adenovirus technology expressing TAAs for cancer immunotherapy. Pursuant to the CRADA, the NCI provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA. During the term of the CRADA, we were required to make annual payments of $0.6&#160;million to the NCI for support of research activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November&#160;2021, NantCell entered into a third&#160;amendment to the CRADA, which was effective as of March&#160;16,&#160;2021. The principal changes effected by the third&#160;amendment are the following: (i)&#160;assignment of the CRADA from NantCell to ImmunityBio; (ii)&#160;modification of the research plan; (iii)&#160;extension of the CRADA term through May&#160;2026; and (iv)&#160;an increase in funding for a total of $1.3&#160;million per year, payable in semi-annual installments from 2022 through 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded R&amp;amp;D expense of $1.3&#160;million, $1.2&#160;million, and $1.1&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the updated CRADA research plan, NCI and ImmunityBio will collaborate on the preclinical and clinical development of ImmunityBio&#x2019;s proprietary adenovirus platform expressing TAAs; proprietary yeast platform expressing TAAs; proprietary agent N-803&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and derivatives, agent N-809 and derivatives, and/or TxM&#160;product candidates; proprietary recombinant NK&#160;cells and mAbs; proprietary RNA vaccines and adjuvants; and other proprietary agents owned or controlled by ImmunityBio as contemplated in the research plan, for cancer immunotherapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under any of the CRADAs, any party may unilaterally terminate the agreement by providing timely advance written notice to the other party before the desired termination date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of any of the CRADAs. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amyris Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December&#160;2021, ImmunityBio and Amyris entered into a 50:50 joint venture arrangement and formed a new limited liability company to conduct the business of the joint venture. The purpose of the joint venture is to accelerate commercialization of a next-generation COVID-19 vaccine utilizing an RNA vaccine-platform. As part of the limited liability agreement, Amyris contributed $1.0&#160;million in cash and rights to its license agreement with AAHI for an RNA platform for the field of COVID-19. ImmunityBio contributed $1.0&#160;million in cash and priority access to its manufacturing capacity for the joint venture product. Both parties agreed to enter into a separate manufacturing and supply agreement and a sublicense agreement following the execution of the joint venture agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The joint venture agreement stipulates the initial terms for equal representation in the management of the newly-formed joint venture. The joint venture is managed by a board of directors consisting of four&#160;directors: two appointed by the company and two&#160;appointed by Amyris. Both parties agreed to make additional capital contributions in cash, in proportion to their respective interests, as determined by the board of directors of the joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We considered the joint venture entity as a VIE and determined that we are not the primary beneficiary of the VIE. We account for our investment in the joint venture using the equity method of accounting. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded our 50%&#160;share of net losses from the joint venture totaling $7.5&#160;million, $12.1&#160;million, and $0.8&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations. During the years ended December&#160;31,&#160;2023 and 2022, such losses incurred included $7.5&#160;million and $11.9&#160;million, respectively, attributable to expenses incurred by us on behalf of the joint venture. We are not obligated to fund the joint venture&#x2019;s potential future losses. In August&#160;2023, Amyris announced that it filed for Chapter&#160;11 bankruptcy protection. The Amyris bankruptcy case remains ongoing, and there can be no assurance that we will receive any recovery on account of our claims against Amyris, including for Amyris&#x2019; portion of expenses incurred by the joint venture. As of December&#160;31,&#160;2023, the carrying amount of our equity investment in the joint venture was zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;3M IPC and AAHI License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have licensed rights to 3M-052, a synthetic TLR7/8 agonist, 3M-052 formulations and related technology from 3M&#160;IPC and its affiliates and AAHI. In November&#160;2021 we obtained nonexclusive rights in the field of SARS-CoV-2 and in June&#160;2022 we modified those rights and expanded the scope of the license to include (1)&#160;SARS-CoV-2 and other infectious diseases including malaria, HIV, tuberculosis, hookworm and varicella zoster on an exclusive basis in countries other than LMIC, and (2)&#160;oncology applications, when used in combination with our proprietary technology and/or IL-15 agonists. In consideration for the license, we agreed to make certain periodic license payments, including $2.25&#160;million each year through June&#160;2025. We have also agreed to make payments upon the achievement of certain regulatory milestone events and tiered royalties ranging from the low to high single-digits as a percentage of net sales. Beginning in April&#160;2026, the annual minimum licensing payment is $1.0&#160;million, which can be credited against any royalty payments due under this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June&#160;2023 and 2022, we made annual license maintenance fee payments of $2.25 million and $1.75&#160;million, respectively. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we expensed $2.0&#160;million, $1.0&#160;million, and $0.5&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AAHI License Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we entered into two&#160;license agreements with AAHI pursuant to which we received a license to certain patents and know-how relating to AAHI&#x2019;s (i)&#160;adjuvant formulations for the treatment, prevention and/or diagnosis of SARS-CoV-2 (the AAHI&#160;Adjuvant Formulation License Agreement) and (ii)&#160;RNA vaccine platform as further described below (the&#160;AAHI RNA License Agreement). Under both agreements, we were obligated to pay one-time, non-creditable, non-refundable upfront cash payments totaling $2.0&#160;million. In addition, under the AAHI Adjuvant Formulation License Agreement we owe milestone payments to a total of up to $2.5&#160;million based on the achievement of certain development and regulatory milestones for the first&#160;licensed product and royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low-single digit percentage, subject to certain royalty-reduction provisions. During the years ended December&#160;31,&#160;2023 and 2022, no&#160;milestone fees were incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September&#160;2021, we amended and restated the AAHI RNA License Agreement, pursuant to which AAHI granted us an exclusive, worldwide, sublicensable license to AAHI&#x2019;s rights to an RNA&#160;vaccine platform for the development and commercialization of certain therapeutic, diagnostic, or prophylactic products for the prevention, treatment or diagnosis of any indication, other than those subject to pre-existing third-party license grants, including, without limitation, SARS-CoV-2. Pursuant to the terms of the amended and restated AAHI RNA License Agreement, we made a one-time, non-creditable, non-refundable, upfront payment to AAHI of $1.5&#160;million and a license maintenance fee of $3.0&#160;million in June&#160;2022. The company is required to pay license maintenance fees to AAHI of $5.5&#160;million annually from 2023 through 2030. The company may terminate the restated agreement without cause by paying AAHI a $10.0&#160;million one-time early termination fee. In addition, the milestone payments to AAHI based on the achievement of certain development and regulatory milestones for the first&#160;licensed product were amended to a total of up to $4.0&#160;million. We are required to pay royalties on annual net sales of licensed products on a country-by-country and product-by-product basis of a low to mid-single digit percentage. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded $4.5&#160;million, $1.8&#160;million, and $1.5&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the license agreements, in May&#160;2021 we also entered into a sponsored research agreement with AAHI pursuant to which we will fund continued research of at least $2.0&#160;million per year, payable in four&#160;equal quarterly installments each year until May&#160;2024, or such year of earlier termination. As of December&#160;31,&#160;2023, $0.5&#160;million payable to AAHI in connection with the sponsored research agreement was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accrued expenses and other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated balance sheet. During the year ended December&#160;31,&#160;2023, we recorded $1.2&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $3.7&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;loss on equity method investment,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the year ended December&#160;31,&#160;2022, respectively, on the consolidated statements of operations related to the sponsored research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Viracta License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we entered into an agreement with Viracta under which we were granted exclusive worldwide rights to Viracta&#x2019;s Phase&#160;II drug candidate, VRx-3996 (nanatinostat), for use in combination with our platform of NK&#160;cell therapies. In&#160;consideration for the license, we are obligated to pay Viracta mid-single digit percentage royalties on net sales of licensed products for therapeutic use and milestone payments ranging from $10.0&#160;million to $25.0&#160;million up to an aggregate maximum of $100.0 million for various regulatory approvals and cumulative net sales levels. We may terminate the agreement, at our sole discretion, in whole or on a product by product and/or country by country basis, at any time upon 90&#160;days&#x2019; prior written notice. In&#160;addition, either party may terminate the agreement in the event of a material breach or for bankruptcy of the other party. To&#160;date, we have not had incurred any royalty or milestone payment obligations under this agreement, including during the years ended December&#160;31,&#160;2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dunkirk Facility Leasehold Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;14,&#160;2022, we completed the acquisition of the Dunkirk Facility (approximately 409,000 rentable square feet) from Athenex, which we believe will provide us with a state-of-the-art biotech production center that will substantially expand and diversify our existing manufacturing capacity in the U.S. and the ability to scale production associated with certain of our product candidates. The company accounted for the transaction as an asset acquisition because the Dunkirk Facility&#x2019;s integrated set of assets and activities does not meet the definition of a business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total consideration for the acquisition was approximately $40.5&#160;million, including a cash payment of $40.0&#160;million, and transaction costs of approximately $0.5&#160;million. The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other depreciable assets and prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Definite-lived intangible assets consist of favorable leasehold rights totaling $20.4&#160;million and organized workforce totaling $0.8&#160;million as of the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the Dunkirk transaction, the company became the tenant of the Dunkirk Facility under the Fort&#160;Schuyler Management Corporation Lease, dated October&#160;1,&#160;2021 and as amended as of the February&#160;14,&#160;2022 closing date (as amended, the Dunkirk Lease), with the FSMC as landlord. The Dunkirk Facility, as well as certain equipment, is owned by the FSMC and is leased to us under the Dunkirk Lease. Our annual lease payment will be $2.00 per year&#160;for an initial 10-year term, with one&#160;option to renew the lease under substantially the same terms and conditions for an additional 10-year term. As part of the transaction, we assumed certain of Athenex&#x2019;s obligations under various third-party agreements (the Facility Agreements), subject to the terms and conditions of the purchase agreement by and between the company and Athenex dated as of January&#160;7,&#160;2022, and committed to spend an aggregate of $1.52&#160;billion on operational expenses during the initial term, and an additional $1.50&#160;billion on operational expenses if we elect to renew the lease for one additional 10-year term. We also committed to hiring 450&#160;employees at the Dunkirk Facility within the first five years following the Commencement Date, with 300&#160;such employees to be hired within the first 2.5 years following the Commencement Date. We are eligible for certain sales-tax exemption savings during the development of the Dunkirk Facility, and certain property tax savings over the next 20 years, subject to certain terms and conditions, including performance of certain of the obligations described above. Failure to satisfy the obligations over the lease term may give rise to certain rights and remedies of governmental authorities including, for example, termination of the Dunkirk Lease and other Facility Agreements and potential recoupment of a percentage of the grant funding received by Athenex for construction of the facility and other benefits received, subject to the terms and conditions of the applicable agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although we believe that governmental funding will assist in funding a portion of the further build-out of the Dunkirk Facility, which we estimate to be approximately $8.0&#160;million&#160;to $10.0&#160;million of governmental funding remaining available as of December&#160;31,&#160;2023, there can be no assurance as to the final acceptance and timing of the requests for governmental funding that we submit, and we will need to plan and fund most of the additional build-out of, and purchase additional equipment for, the Dunkirk Facility in connection with our planned full operations. In addition, any future governmental funding will be subject to the eligibility of submitted expenses, as well as our compliance with the obligations that we are subject to pursuant to the agreements with parties regarding the Dunkirk Facility as described above. Further, on May&#160;14,&#160;2023, Athenex, together with certain of its subsidiaries, filed voluntary petitions for relief under Chapter&#160;11 of the United States Bankruptcy Court for the Southern District of Texas (the Athenex Proceedings). We do not know what, if any, impact the Athenex Proceedings will have on any portion of the potential governmental funding remaining for the Dunkirk Facility.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dunkirk Facility Workforce Reduction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September&#160;2022, the company initiated a workforce reduction at the Dunkirk Facility and recorded severance and retention benefits for the terminated employees totaling $1.0&#160;million during the year ended December&#160;31,&#160;2022 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1125"&gt;selling, general and administrative expense&lt;/span&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statement of operations. The terminated employees were not required to render service through their termination date in December&#160;2022 to receive these benefits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities contextRef="c-304" decimals="-5" id="f-1059" unitRef="usd">600000</ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities>
    <ibrx:CollaborationAgreementsAnnualProjectFundingAmount contextRef="c-305" decimals="-5" id="f-1060" unitRef="usd">1300000</ibrx:CollaborationAgreementsAnnualProjectFundingAmount>
    <ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities contextRef="c-306" decimals="-5" id="f-1061" unitRef="usd">1300000</ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities>
    <ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities contextRef="c-307" decimals="-5" id="f-1062" unitRef="usd">1200000</ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities>
    <ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities contextRef="c-308" decimals="-5" id="f-1063" unitRef="usd">1100000</ibrx:CollaborationAgreementsPaymentForSupportOfResearchActivities>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-309" decimals="-5" id="f-1064" unitRef="usd">1000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-310" decimals="-5" id="f-1065" unitRef="usd">1000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c-311"
      decimals="INF"
      id="f-1066"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-312" decimals="-5" id="f-1067" unitRef="usd">-7500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-313" decimals="-5" id="f-1068" unitRef="usd">-12100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-314" decimals="-5" id="f-1069" unitRef="usd">-800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-312" decimals="-5" id="f-1070" unitRef="usd">-7500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-313" decimals="-5" id="f-1071" unitRef="usd">-11900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-311" decimals="-5" id="f-1072" unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <ibrx:CollaborationAgreementsPeriodicLicensePayments contextRef="c-315" decimals="-4" id="f-1073" unitRef="usd">2250000</ibrx:CollaborationAgreementsPeriodicLicensePayments>
    <ibrx:CollaborationAgreementsAnnualMinimumLicensingPayment contextRef="c-316" decimals="-5" id="f-1074" unitRef="usd">1000000</ibrx:CollaborationAgreementsAnnualMinimumLicensingPayment>
    <ibrx:CollaborationAgreementsPeriodicLicensePayments contextRef="c-315" decimals="-4" id="f-1075" unitRef="usd">2250000</ibrx:CollaborationAgreementsPeriodicLicensePayments>
    <ibrx:CollaborationAgreementsLicenseMaintenanceFees contextRef="c-317" decimals="-4" id="f-1076" unitRef="usd">1750000</ibrx:CollaborationAgreementsLicenseMaintenanceFees>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-316" decimals="-5" id="f-1077" unitRef="usd">2000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-318" decimals="-5" id="f-1078" unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-319" decimals="-5" id="f-1079" unitRef="usd">500000</us-gaap:ResearchAndDevelopmentExpense>
    <ibrx:CollaborationAgreementsNumberOfLicenseAgreements
      contextRef="c-320"
      decimals="INF"
      id="f-1080"
      unitRef="licenseagreement">2</ibrx:CollaborationAgreementsNumberOfLicenseAgreements>
    <ibrx:CollaborationAgreementsNonrefundableUpfrontPayment contextRef="c-320" decimals="-5" id="f-1081" unitRef="usd">2000000</ibrx:CollaborationAgreementsNonrefundableUpfrontPayment>
    <ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum contextRef="c-321" decimals="-5" id="f-1082" unitRef="usd">2500000</ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum>
    <ibrx:CollaborationAgreementsMilestoneFees contextRef="c-322" decimals="INF" id="f-1083" unitRef="usd">0</ibrx:CollaborationAgreementsMilestoneFees>
    <ibrx:CollaborationAgreementsMilestoneFees contextRef="c-323" decimals="INF" id="f-1084" unitRef="usd">0</ibrx:CollaborationAgreementsMilestoneFees>
    <ibrx:CollaborationAgreementsNonrefundableUpfrontPayment contextRef="c-324" decimals="-5" id="f-1085" unitRef="usd">1500000</ibrx:CollaborationAgreementsNonrefundableUpfrontPayment>
    <ibrx:CollaborationAgreementsLicenseMaintenanceFees contextRef="c-325" decimals="-5" id="f-1086" unitRef="usd">3000000</ibrx:CollaborationAgreementsLicenseMaintenanceFees>
    <ibrx:CollaborationAgreementsLicenseMaintenanceFees contextRef="c-326" decimals="-5" id="f-1087" unitRef="usd">5500000</ibrx:CollaborationAgreementsLicenseMaintenanceFees>
    <ibrx:CollaborationAgreementsTerminationFee contextRef="c-327" decimals="-5" id="f-1088" unitRef="usd">10000000</ibrx:CollaborationAgreementsTerminationFee>
    <ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum contextRef="c-328" decimals="-5" id="f-1089" unitRef="usd">4000000</ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-329" decimals="-5" id="f-1090" unitRef="usd">4500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-330" decimals="-5" id="f-1091" unitRef="usd">1800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-331" decimals="-5" id="f-1092" unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities contextRef="c-332" decimals="-5" id="f-1093" unitRef="usd">2000000</ibrx:CollaborationAgreementsAnnualPaymentForSupportOfResearchActivities>
    <ibrx:CollaborationAgreementsLicenseMaintenanceFeesPayable contextRef="c-333" decimals="-3" id="f-1094" unitRef="usd">500000</ibrx:CollaborationAgreementsLicenseMaintenanceFeesPayable>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-334" decimals="-5" id="f-1095" unitRef="usd">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-335" decimals="-5" id="f-1096" unitRef="usd">-3700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ibrx:CollaborationAgreementsMilestonePaymentAmount contextRef="c-336" decimals="-5" id="f-1097" unitRef="usd">10000000</ibrx:CollaborationAgreementsMilestonePaymentAmount>
    <ibrx:CollaborationAgreementsMilestonePaymentAmount contextRef="c-337" decimals="-5" id="f-1098" unitRef="usd">25000000</ibrx:CollaborationAgreementsMilestonePaymentAmount>
    <ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum contextRef="c-338" decimals="-5" id="f-1099" unitRef="usd">100000000</ibrx:CollaborationAgreementsMilestonePaymentAggregateMaximum>
    <ibrx:NumberOfSquareFeetOfFacilityLeased
      contextRef="c-339"
      decimals="INF"
      id="f-1100"
      unitRef="sqft">409000</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-340" decimals="-5" id="f-1101" unitRef="usd">40500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-340" decimals="-5" id="f-1102" unitRef="usd">40000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost contextRef="c-340" decimals="-5" id="f-1103" unitRef="usd">500000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="c-1" id="f-1104">The following table summarizes the fair value of assets acquired as of the acquisition date (in&#160;thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other depreciable assets and prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Definite-lived intangible assets consist of favorable leasehold rights totaling $20.4&#160;million and organized workforce totaling $0.8&#160;million as of the acquisition date.</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:ConstructionInProgressGross contextRef="c-339" decimals="-3" id="f-1105" unitRef="usd">10043000</us-gaap:ConstructionInProgressGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-339" decimals="-3" id="f-1106" unitRef="usd">6253000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-339" decimals="-3" id="f-1107" unitRef="usd">21229000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c-339" decimals="-3" id="f-1108" unitRef="usd">2983000</us-gaap:PrepaidExpenseAndOtherAssets>
    <ibrx:AssetAcquisitionFairValueOfAssetsAcquired contextRef="c-339" decimals="-3" id="f-1109" unitRef="usd">40508000</ibrx:AssetAcquisitionFairValueOfAssetsAcquired>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-341" decimals="-5" id="f-1110" unitRef="usd">20400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-342" decimals="-5" id="f-1111" unitRef="usd">800000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <ibrx:LeaseOperatingLeaseAnnualLeasePayment contextRef="c-340" decimals="INF" id="f-1112" unitRef="usd">2.00</ibrx:LeaseOperatingLeaseAnnualLeasePayment>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-339" id="f-1113">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibrx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="c-339"
      decimals="INF"
      id="f-1114"
      unitRef="renewal_options">1</ibrx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-339" id="f-1115">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm contextRef="c-339" decimals="-7" id="f-1116" unitRef="usd">1520000000</ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendInitialLeaseTerm>
    <ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm contextRef="c-339" decimals="-7" id="f-1117" unitRef="usd">1500000000</ibrx:LeaseholdInterestOperationalExpensesCommitmentToSpendRenewalLeaseTerm>
    <ibrx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="c-339"
      decimals="INF"
      id="f-1118"
      unitRef="renewal_options">1</ibrx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-339" id="f-1119">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears
      contextRef="c-339"
      decimals="INF"
      id="f-1120"
      unitRef="employee">450</ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstFiveYears>
    <ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears
      contextRef="c-339"
      decimals="INF"
      id="f-1121"
      unitRef="employee">300</ibrx:LeaseholdInterestCommitmentToHireNumberOfEmployeesFirstTwoAndAHalfYears>
    <ibrx:LeaseholdInterestGovernmentFundingAvailable contextRef="c-343" decimals="-5" id="f-1122" unitRef="usd">8000000</ibrx:LeaseholdInterestGovernmentFundingAvailable>
    <ibrx:LeaseholdInterestGovernmentFundingAvailable contextRef="c-344" decimals="-5" id="f-1123" unitRef="usd">10000000</ibrx:LeaseholdInterestGovernmentFundingAvailable>
    <us-gaap:RestructuringCharges contextRef="c-345" decimals="-5" id="f-1124" unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1126">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VivaBioCell, S.p.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April&#160;2015, NantWorks, a related party, acquired a 100% interest in VivaBioCell through its wholly-owned subsidiary, VBC Holdings for $0.7&#160;million, less working capital adjustments. In June&#160;2015, NantWorks contributed its equity interest in VBC Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of VBC, we are obligated to pay the former owners contingent consideration upon the achievement of certain milestones related to the GMP-in-a-Box technology. A clinical milestone totaling $0.8&#160;million was earned by the former owners of VivaBioCell, of which $0.4&#160;million was paid during the year ended December&#160;31,&#160;2021, with the remaining $0.3&#160;million clinical obligation, net of foreign exchange adjustment, settled during the year ended December&#160;31,&#160;2022. If a government agency unconditionally approves the GMP-in-a-Box technology for commercial sale (the regulatory milestone) in the future, we will be obligated to pay an additional approximately $2.2&#160;million to the former owners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altor BioScience, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our 2017 acquisition of Altor, we issued CVRs under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million of contingent consideration upon calendar-year worldwide net sales of N-803 exceeding $1.0&#160;billion prior to December&#160;31,&#160;2026, with amounts payable in cash or shares of our common stock or a combination thereof. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable. As of December&#160;31,&#160;2023, Dr.&#160;Soon-Shiong, our Executive Chairman and Global Chief Scientific and Medical Officer, and his related party hold approximately $139.8&#160;million of net sales CVRs and they have both irrevocably agreed to receive shares of the company&#x2019;s common stock in satisfaction of their CVRs. We may be required to pay the other prior Altor stockholders up to $164.2&#160;million for their net sales CVRs should they choose to have their CVRs paid in cash instead of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altor BioScience, LLC Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, NantCell announced it had entered into a definitive merger agreement to acquire Altor. An action captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gray v.&#160;Soon-Shiong, et&#160;al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was filed in Delaware Chancery Court by plaintiffs Clayland Boyden Gray (Gray) and Adam&#160;R.&#160;Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for (1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion and permitted the merger to close. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the close of the merger, in 2017 the plaintiffs (joined by two&#160;additional minority stockholders, Barbara&#160;Sturm Waldman and Douglas E. Henderson (Henderson)) filed a second&#160;amended complaint, including appraisal claims, and which the defendants subsequently moved to dismiss. In a second&#160;action, Dyad Pharmaceutical Corporation (Dyad) filed a petition in Delaware Chancery Court for appraisal in connection with the merger. The defendants moved to dismiss the appraisal petition in 2018. The court issued an oral ruling in 2019 that dismissed certain claims and dismissed Altor from the action. The following claims remained: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience,&#160;LLC), and (b)&#160;Henderson&#x2019;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the court issued a written order implementing its ruling on the defendants&#x2019; motions (the Implementing Order). In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o&#160;C. Boyden Gray, were dismissed. The plaintiffs then moved for leave to file a third&#160;amended complaint to add two&#160;former Altor stockholders as plaintiffs and a fiduciary duty claim on behalf of a purported class of former Altor stockholders, which the defendants opposed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the court granted the plaintiffs&#x2019; motion, and the plaintiffs filed the third&#160;amended complaint. In 2020, the defendants answered the third&#160;amended complaint and asserted counterclaims against the plaintiffs. The defendants sought damages for attorneys&#x2019; fees and costs incurred as a result of the breaches of &#x201c;standstill&#x201d; agreements and of stockholder releases. The plaintiffs filed an answer denying the counterclaims and asserting defenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares of the former Altor stockholders seeking appraisal met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date, given that those shares were the subject of the above-described appraisal claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In late March&#160;2022, the company agreed to the terms of a settlement with the appraisal petitioners, without any admission of liability or fault. The settlement provided that in exchange for complete releases, the appraisal petitioners, who as a group held 3,167,565&#160;dissenting Altor shares, collectively would receive an aggregate of 2,229,296&#160;shares of the company&#x2019;s common stock issued in a private placement, plus an aggregate of $21.13&#160;in cash in lieu of fractional shares. The company&#x2019;s Board of Directors approved the settlement and stock issuance in April&#160;2022, and the court approved the settlement and dismissed the appraisal petitioners&#x2019; claims on July&#160;9,&#160;2022. On July&#160;9,&#160;2022, the company issued 2,229,296&#160;shares of its common stock with an aggregate market value of $10.7&#160;million, based on the closing price of its common stock on the Nasdaq as of July&#160;8,&#160;2022, to the appraisal petitioners pursuant to the court-approved settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In late April&#160;2022, the company also agreed to the terms of a settlement with the putative class plaintiffs without any admission of liability or fault. In exchange for class-wide releases, the company committed to make a settlement payment of $5.0&#160;million in cash by December&#160;31,&#160;2022. On December&#160;8,&#160;2022, the Delaware Court of Chancery entered a final judgment approving the settlement, and the company timely made the $5.0&#160;million settlement payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sorrento Therapeutics, Inc. Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sorrento, derivatively on behalf of NANTibody, filed an action in the Superior Court of California, Los Angeles County (the Superior Court) against the company&#x2019;s subsidiary NantCell, Dr.&#160;Soon-Shiong, and Charles&#160;Kim. The action alleged that the defendants improperly caused NANTibody to acquire IgDraSol from NantPharma and sought to have the transaction undone and the purchase amount returned to NANTibody. In 2019, we filed a demurrer to several causes of action alleged in the Superior Court action, and Sorrento filed an amended complaint, eliminating Mr.&#160;Kim as a defendant and dropping the causes of action we had challenged in our demurrer. Trial had been set to commence in Sorrento&#x2019;s Superior Court action on August&#160;7,&#160;2023, but on July&#160;24,&#160;2023 the Superior Court vacated the August&#160;7,&#160;2023 trial date at the parties&#x2019; request in light of the pending settlement discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in 2019, the company and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. Our claims alleged that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#x2019;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement. The Superior Court ruled that the company&#x2019;s claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#x2019;s claims could be pursued in Superior Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the company, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration. The hearings in the NANTibody arbitration commenced in April&#160;2021 and concluded in early August&#160;2021. After post-hearing briefing was concluded, the parties were notified on November&#160;30,&#160;2021 that the arbitrator in the NANTibody arbitration had passed away. A substitute arbitrator was appointed on February&#160;25,&#160;2022, and the parties worked with the substitute arbitrator to conclude the proceedings. Additional hearing sessions were held in May and July&#160;2022, and summations took place on August&#160;2,&#160;2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;2, 2022, the arbitrator issued a final award finding that Sorrento had breached the two&#160;exclusive license agreements with NantCell and NANTibody. The arbitrator awarded NantCell approximately $156.8 million and NANTibody approximately $16.7 million, plus post-award interest accruing at a daily rate. On December&#160;21,&#160;2022, NantCell and NANTibody filed petitions in the Superior Court to confirm the arbitration award; on January&#160;16,&#160;2023, Sorrento filed a response to the petitions and moved to vacate the award. On February&#160;7, 2023, after a hearing, the Superior Court entered orders confirming the arbitration award and denying Sorrento&#x2019;s motion to vacate. The Superior Court entered judgments against Sorrento in the aggregate amount of approximately $176.4&#160;million plus 10% post-judgment interest, of which approximately $159.4&#160;million was payable to NantCell, and the remainder of which was payable to NANTibody. On February&#160;13,&#160;2023, Sorrento informed counsel to the company that it had filed a Chapter&#160;11 proceeding in the U.S. District Court for the Southern District of Texas, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In&#160;re:&#160;Sorrento Therapeutics,&#160;Inc., et&#160;al.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Case No.&#160;23-90085 (DRJ), Docket Entry&#160;810. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;6,&#160;2023, Sorrento filed a motion in its Chapter&#160;11 proceeding for entry of an order approving and implementing a mediation settlement reached with the company and other entities. The settlement involved two&#160;possible scenarios: Either, if Sorrento were to raise an amount needed to pay its debtor in possession lender and its unsecured creditors by August&#160;31,&#160;2023, Sorrento would pay those obligations, including the judgments held by NantCell and NANTibody, by 2:00&#160;p.m.&#160;ET on August&#160;31,&#160;2023 and be free to proceed with pending litigation; or, failing that, the judgments would be released, the litigation claims would be released, including, without limitation, the Superior Court action discussed above, Sorrento would relinquish its interests in NANTibody and certain other entities, Sorrento would forfeit its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell (rights to PD-L1), and certain other provisions not impacting the company would be implemented as described in the motion. On August&#160;14,&#160;2023, the United States Bankruptcy Court for the Southern District of Texas issued an order approving the settlement described above, such that the settlement became binding on the parties. As of 2:00&#160;p.m. ET on August&#160;31,&#160;2023, Sorrento had not paid the judgments held by NantCell and NANTibody. Accordingly, in relevant part to the company and NantCell, a mutual release of claims became effective such that the aforementioned judgments were released, the litigation claims were released including, without limitation, the derivative litigation against NantCell described above, Sorrento relinquished its interests in NANTibody, and Sorrento forfeited its rights to any payments from NantCell arising out of its antibody exclusive license agreement with NantCell, including any royalties associated with the company&#x2019;s engineered NK&#160;cell therapy in Phase&#160;II clinical trials, PD-L1 t-haNK. As a result of the settlement, the parties filed dismissals of the litigation matters discussed above. After the settlement, the company&#x2019;s ownership in NANTibody increased from 60% to 100%, and, as a result, the carrying amount of the noncontrolling interest of $4.2&#160;million was adjusted and recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; attributable to the company, on the consolidated statement of stockholders&#x2019; deficit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shenzhen Beike Biotechnology Co. Ltd. Arbitration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration. The arbitration relates to a license, development, and commercialization agreement that Altor entered into with Beike in 2014, which agreement was amended and restated in 2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on N-803 in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to N-803. Beike is seeking specific performance and declaratory relief for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill agreement under which, among other things, the parties affirmed they would perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration were indefinitely extended. The standstill agreement could be terminated by any party on ten&#160;calendar days&#x2019; notice, and upon termination, the parties had the right to pursue claims arising from the license agreement in any appropriate tribunal. On March&#160;20,&#160;2023, we terminated the standstill agreement, and on &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April&#160;11,&#160;2023, Beike served an amended Request for Arbitration. We served an Answer and Counterclaims on May&#160;19,&#160;2023. Beike served a Reply to our counterclaims on June&#160;21,&#160;2023. Beike&#x2019;s Statement of Claim is due on March&#160;22,&#160;2024, and the company&#x2019;s Statement of Defense and Counterclaim is due on June&#160;21,&#160;2024. The hearing in the arbitration is scheduled to begin on June&#160;9,&#160;2025. Given that no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims asserted against the company lack merit and intend to defend the case, and to pursue or counterclaims, vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;30,&#160;2023, a putative securities class action complaint, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Salzman v. ImmunityBio, Inc. et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 3:23-cv-01216-BEN-WVG, was filed in the U.S.&#160;District Court for the Southern District of California against the company and three&#160;of its officers and/or directors, asserting violations of Sections&#160;10(b) and 20(a) of the Exchange Act. Stemming from the&#160;company&#x2019;s disclosure on May&#160;11,&#160;2023 that it had received an FDA CRL stating, among other things, that it could not approve the company&#x2019;s BLA for its product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease, in its present form due to deficiencies related to its pre-license inspection of the company&#x2019;s third-party CMOs, the complaint alleges that the defendants had previously made materially false and misleading statements and/or omitted material adverse facts regarding its third-party clinical manufacturing organizations and the prospects for regulatory approval of the BLA. On September&#160;27,&#160;2023, the court appointed a lead plaintiff, approved their selection of lead counsel, and re-captioned the case &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re. ImmunityBio, Inc. Securities Litigation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; No.&#160;3:23-cv-01216. On November&#160;17,&#160;2023, lead plaintiff filed an amended complaint, which named the same defendants and asserted the same claims as the previous complaint. On January&#160;8, 2024, defendants filed a motion to dismiss the amended complaint. A hearing on the motion is currently scheduled for April&#160;23,&#160;2024.The company believes the lawsuit is without merit and intends to defend the case vigorously. The company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in this action. If an unfavorable outcome were to occur, it is possible that the impact could be material to the company&#x2019;s results of operations in the period(s) in which any such outcome becomes probable and estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconditional Purchase Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unconditional purchase obligations are defined as an agreement to purchase goods or services that are enforceable and legally binding (non-cancelable, or cancelable only in certain circumstances). In the normal course of business, we enter into unconditional purchase obligation arrangements with a third-party CMO to reserve manufacturing slots in its cGMP manufacturing facility for the manufacture and supply of cGMP batches per FDA and EMA regulations for commercial use. The total amount of future non-cancelable purchase commitments related to the manufacture of cGMP batches is $2.0&#160;million and $0.9&#160;million for the years&#160;ending December&#160;31,&#160;2024 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate our total unconditional purchase obligation related to hosted software license subscription fees and implementation costs at $5.2&#160;million as of December&#160;31,&#160;2023. Payments by year are estimated as follows: 2024&#160;($1.6&#160;million), 2025&#160;($1.8&#160;million) and 2026&#160;($1.8&#160;million). Additionally, our total unconditional purchase obligation for laboratory cleanroom service costs are estimated at $1.9&#160;million as of December&#160;31,&#160;2023. Payments by year are estimated as follows: 2024&#160;($0.5&#160;million) and 2025&#160;($1.4&#160;million). The purchase obligation amounts do not represent the entire anticipated purchases in the future, but represent only those items for which we are contractually obligated. The majority of our goods and services are purchased as needed, with no unconditional commitment. For this reason, these amounts do not provide an indication of our expected future cash outflows related to purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2023, we did not enter into any significant contracts or material unconditional purchase commitments, other than those disclosed in these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ibrx:PercentageOfWhollyOwnedSubsidiary
      contextRef="c-346"
      decimals="INF"
      id="f-1127"
      unitRef="number">1</ibrx:PercentageOfWhollyOwnedSubsidiary>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-347" decimals="-5" id="f-1128" unitRef="usd">700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ibrx:BusinessCombinationContingentConsiderationArrangementsEarned contextRef="c-348" decimals="-5" id="f-1129" unitRef="usd">800000</ibrx:BusinessCombinationContingentConsiderationArrangementsEarned>
    <ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements contextRef="c-348" decimals="-5" id="f-1130" unitRef="usd">400000</ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements>
    <ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements contextRef="c-349" decimals="-5" id="f-1131" unitRef="usd">300000</ibrx:BusinessCombinationContingentConsiderationArrangementsSettlements>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="c-350" decimals="-5" id="f-1132" unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <ibrx:ContingentValueRightsObligations contextRef="c-351" decimals="-5" id="f-1133" unitRef="usd">304000000</ibrx:ContingentValueRightsObligations>
    <ibrx:MinimumNetSalesMilestoneContingentValueRightsObligation contextRef="c-352" decimals="-8" id="f-1134" unitRef="usd">1000000000</ibrx:MinimumNetSalesMilestoneContingentValueRightsObligation>
    <ibrx:ContingentValueRightsObligations contextRef="c-353" decimals="-5" id="f-1135" unitRef="usd">139800000</ibrx:ContingentValueRightsObligations>
    <ibrx:ContingentValueRightsObligations contextRef="c-354" decimals="-5" id="f-1136" unitRef="usd">164200000</ibrx:ContingentValueRightsObligations>
    <ibrx:NumberOfDissentingShares
      contextRef="c-355"
      decimals="INF"
      id="f-1137"
      unitRef="shares">3167565</ibrx:NumberOfDissentingShares>
    <ibrx:LitigationSettlementNumberOfSharesToBeIssued
      contextRef="c-355"
      decimals="INF"
      id="f-1138"
      unitRef="shares">2229296</ibrx:LitigationSettlementNumberOfSharesToBeIssued>
    <ibrx:SharesIssuedCashDistributedInLieuOfFractionalShares
      contextRef="c-355"
      decimals="INF"
      id="f-1139"
      unitRef="usdPerShare">21.13</ibrx:SharesIssuedCashDistributedInLieuOfFractionalShares>
    <us-gaap:SharesIssued
      contextRef="c-356"
      decimals="INF"
      id="f-1140"
      unitRef="shares">2229296</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-357" decimals="-5" id="f-1141" unitRef="usd">10700000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:LitigationReserve contextRef="c-358" decimals="-5" id="f-1142" unitRef="usd">5000000</us-gaap:LitigationReserve>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-359" decimals="-5" id="f-1143" unitRef="usd">5000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-360" decimals="-5" id="f-1144" unitRef="usd">156800000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-361" decimals="-5" id="f-1145" unitRef="usd">16700000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-362" decimals="-5" id="f-1146" unitRef="usd">176400000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <ibrx:LitigationSettlementInterestPercent
      contextRef="c-362"
      decimals="INF"
      id="f-1147"
      unitRef="number">0.10</ibrx:LitigationSettlementInterestPercent>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty contextRef="c-363" decimals="-5" id="f-1148" unitRef="usd">159400000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-364"
      decimals="2"
      id="f-1149"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-365"
      decimals="2"
      id="f-1150"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterest contextRef="c-366" decimals="-5" id="f-1151" unitRef="usd">4200000</us-gaap:MinorityInterest>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-367" decimals="-5" id="f-1152" unitRef="usd">2000000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-367" decimals="-5" id="f-1153" unitRef="usd">900000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligation contextRef="c-368" decimals="-5" id="f-1154" unitRef="usd">5200000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-368" decimals="-5" id="f-1155" unitRef="usd">1600000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-368" decimals="-5" id="f-1156" unitRef="usd">1800000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear contextRef="c-368" decimals="-5" id="f-1157" unitRef="usd">1800000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligation contextRef="c-369" decimals="-5" id="f-1158" unitRef="usd">1900000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-369" decimals="-5" id="f-1159" unitRef="usd">500000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-369" decimals="-5" id="f-1160" unitRef="usd">1400000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-1162">Lease Arrangements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease property in multiple facilities across the U.S. and Italy, including facilities located in El&#160;Segundo,&#160;CA and the Dunkirk Facility in upstate New&#160;York. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rentals at the Dunkirk Facility. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information about our related-party leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our leases generally have initial terms ranging from &lt;span style="-sec-ix-hidden:f-1163"&gt;two&lt;/span&gt; to ten years and often include one or more options to renew. These renewal terms can extend the lease term from &lt;span style="-sec-ix-hidden:f-1165"&gt;one&lt;/span&gt; to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to our leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1170"&gt;&lt;span style="-sec-ix-hidden:f-1171"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1178"&gt;&lt;span style="-sec-ix-hidden:f-1179"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1184"&gt;&lt;span style="-sec-ix-hidden:f-1185"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our lease terms is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs (including right-of-use asset &lt;br/&gt;&#160;&#160;&#160;amortization and interest expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for operating leases (excluding variable lease costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments as of December&#160;31,&#160;2023, including $11.5&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.331%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2023, we extended some existing related-party leases and terminated an existing related-party lease. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information regarding our related-party leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1161">Lease Arrangements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease property in multiple facilities across the U.S. and Italy, including facilities located in El&#160;Segundo,&#160;CA and the Dunkirk Facility in upstate New&#160;York. Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. All of our finance leases are related to equipment rentals at the Dunkirk Facility. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information about our related-party leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our leases generally have initial terms ranging from &lt;span style="-sec-ix-hidden:f-1163"&gt;two&lt;/span&gt; to ten years and often include one or more options to renew. These renewal terms can extend the lease term from &lt;span style="-sec-ix-hidden:f-1165"&gt;one&lt;/span&gt; to ten years, and are included in the lease term when it is reasonably certain that we will exercise the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to our leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1170"&gt;&lt;span style="-sec-ix-hidden:f-1171"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1178"&gt;&lt;span style="-sec-ix-hidden:f-1179"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1184"&gt;&lt;span style="-sec-ix-hidden:f-1185"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our lease terms is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs (including right-of-use asset &lt;br/&gt;&#160;&#160;&#160;amortization and interest expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for operating leases (excluding variable lease costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments as of December&#160;31,&#160;2023, including $11.5&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table (in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.331%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2023, we extended some existing related-party leases and terminated an existing related-party lease. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information regarding our related-party leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-371" id="f-1164">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-371" id="f-1166">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ibrx:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-1167">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to our leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1170"&gt;&lt;span style="-sec-ix-hidden:f-1171"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1178"&gt;&lt;span style="-sec-ix-hidden:f-1179"&gt;Accrued expenses and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&lt;span style="-sec-ix-hidden:f-1184"&gt;&lt;span style="-sec-ix-hidden:f-1185"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ibrx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-1168" unitRef="usd">36543000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1169" unitRef="usd">45788000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-1172" unitRef="usd">58000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1173" unitRef="usd">135000</us-gaap:FinanceLeaseRightOfUseAsset>
    <ibrx:LeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-1174" unitRef="usd">36601000</ibrx:LeaseRightOfUseAsset>
    <ibrx:LeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1175" unitRef="usd">45923000</ibrx:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-1176" unitRef="usd">5244000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1177" unitRef="usd">2650000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-1180" unitRef="usd">64000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1181" unitRef="usd">77000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-1182" unitRef="usd">39942000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1183" unitRef="usd">47951000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-1186" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1187" unitRef="usd">64000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <ibrx:LeaseLiability contextRef="c-4" decimals="-3" id="f-1188" unitRef="usd">45250000</ibrx:LeaseLiability>
    <ibrx:LeaseLiability contextRef="c-5" decimals="-3" id="f-1189" unitRef="usd">50742000</ibrx:LeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1190">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding our lease terms is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease costs (including right-of-use asset &lt;br/&gt;&#160;&#160;&#160;amortization and interest expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for operating leases (excluding variable lease costs)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flow from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1191">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1192">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1193">P0Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1194">P1Y9M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1195" unitRef="number">0.109</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1196" unitRef="number">0.105</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1197" unitRef="number">0.117</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1198" unitRef="number">0.117</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-1199" unitRef="usd">11123000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-10" decimals="-3" id="f-1200" unitRef="usd">11093000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-11" decimals="-3" id="f-1201" unitRef="usd">7977000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-1202" unitRef="usd">4088000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-10" decimals="-3" id="f-1203" unitRef="usd">3060000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-11" decimals="-3" id="f-1204" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense contextRef="c-1" decimals="-3" id="f-1205" unitRef="usd">88000</ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense>
    <ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense contextRef="c-10" decimals="-3" id="f-1206" unitRef="usd">80000</ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense>
    <ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense contextRef="c-11" decimals="-3" id="f-1207" unitRef="usd">0</ibrx:FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-1208" unitRef="usd">3521000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-10" decimals="-3" id="f-1209" unitRef="usd">3880000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-11" decimals="-3" id="f-1210" unitRef="usd">2862000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-1211" unitRef="usd">18820000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-10" decimals="-3" id="f-1212" unitRef="usd">18113000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-11" decimals="-3" id="f-1213" unitRef="usd">10839000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-1214" unitRef="usd">9538000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-10" decimals="-3" id="f-1215" unitRef="usd">10241000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-11" decimals="-3" id="f-1216" unitRef="usd">9034000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-1217" unitRef="usd">77000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-10" decimals="-3" id="f-1218" unitRef="usd">58000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-11" decimals="-3" id="f-1219" unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-1220" unitRef="usd">11000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-10" decimals="-3" id="f-1221" unitRef="usd">15000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-11" decimals="-3" id="f-1222" unitRef="usd">0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms contextRef="c-1" decimals="-5" id="f-1223" unitRef="usd">11500000</ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1224">&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.331%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Operating&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1225" unitRef="usd">10354000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1226" unitRef="usd">66000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <ibrx:LeaseLiabilityToBePaidYearOne contextRef="c-4" decimals="-3" id="f-1227" unitRef="usd">10420000</ibrx:LeaseLiabilityToBePaidYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-1228" unitRef="usd">10864000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-1229" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <ibrx:LeaseLiabilityToBePaidYearTwo contextRef="c-4" decimals="-3" id="f-1230" unitRef="usd">10864000</ibrx:LeaseLiabilityToBePaidYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-1231" unitRef="usd">8983000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-1232" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <ibrx:LeaseLiabilityToBePaidYearThree contextRef="c-4" decimals="-3" id="f-1233" unitRef="usd">8983000</ibrx:LeaseLiabilityToBePaidYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-1234" unitRef="usd">8220000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-1235" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ibrx:LeaseLiabilityToBePaidYearFour contextRef="c-4" decimals="-3" id="f-1236" unitRef="usd">8220000</ibrx:LeaseLiabilityToBePaidYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-1237" unitRef="usd">8465000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-1238" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <ibrx:LeaseLiabilityToBePaidYearFive contextRef="c-4" decimals="-3" id="f-1239" unitRef="usd">8465000</ibrx:LeaseLiabilityToBePaidYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-1240" unitRef="usd">16056000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-1241" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <ibrx:LeaseLiabilityToBePaidAfterYearFive contextRef="c-4" decimals="-3" id="f-1242" unitRef="usd">16056000</ibrx:LeaseLiabilityToBePaidAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-1243" unitRef="usd">62942000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-1244" unitRef="usd">66000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <ibrx:LeaseLiabilityToBePaid contextRef="c-4" decimals="-3" id="f-1245" unitRef="usd">63008000</ibrx:LeaseLiabilityToBePaid>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-1246" unitRef="usd">17086000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-1247" unitRef="usd">2000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <ibrx:LeaseLiabilityUndiscountedExcessInterest contextRef="c-4" decimals="-3" id="f-1248" unitRef="usd">17088000</ibrx:LeaseLiabilityUndiscountedExcessInterest>
    <ibrx:LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable contextRef="c-4" decimals="-3" id="f-1249" unitRef="usd">670000</ibrx:LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable>
    <ibrx:FinanceLeaseLiabilityTenantImprovementAllowanceReceivable contextRef="c-4" decimals="-3" id="f-1250" unitRef="usd">0</ibrx:FinanceLeaseLiabilityTenantImprovementAllowanceReceivable>
    <ibrx:LeaseLiabilityTenantImprovementAllowanceReceivable contextRef="c-4" decimals="-3" id="f-1251" unitRef="usd">670000</ibrx:LeaseLiabilityTenantImprovementAllowanceReceivable>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-1252" unitRef="usd">45186000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-4" decimals="-3" id="f-1253" unitRef="usd">64000</us-gaap:FinanceLeaseLiability>
    <ibrx:LeaseLiability contextRef="c-4" decimals="-3" id="f-1254" unitRef="usd">45250000</ibrx:LeaseLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1255">Revenue Interest Purchase Agreement&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023, we entered into the RIPA with Infinity and Oberland, to support the commercialization of Anktiva, our lead product candidate, to further the development of our product platforms, and to provide for other working capital needs. Pursuant to the RIPA, Oberland acquired certain Revenue Interests from us for a gross purchase price of $200.0&#160;million paid on closing, less certain transaction expenses. In addition, Oberland may purchase additional Revenue Interests from us in exchange for the $100.0&#160;million Second Payment upon satisfaction of certain conditions specified in the RIPA, including following the receipt of approval by the FDA of the company&#x2019;s BLA for Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1&#160;disease&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on or before June&#160;30,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the aforementioned payments, Oberland has the right to receive quarterly Revenue Interest Payments from us based on, among other things, a certain percentage of our net sales during such quarter, which will be tiered payments initially ranging from 3.00% to 7.00% (or after funding of the Second&#160;Payment, 4.50% to 10.00%) of the company&#x2019;s worldwide net sales, excluding those in China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the aggregate Revenue Interest Payments made to Oberland as of December&#160;31,&#160;2029 equal or exceed the Cumulative Purchaser Payments as of that date, the initially tiered revenue interest rate will be decreased to a single rate of 1.50% (or after the funding of the Second Payment, 2.25%) of the company&#x2019;s worldwide net sales, excluding those in China. If the aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then following the Test Date the initially tiered revenue interest rate will increase to a rate that, had such increased rate applied during the period from December&#160;29,&#160;2023 through December&#160;31,&#160;2029, it would have resulted in Oberland receiving aggregate Revenue Interest Payments (excluding certain payments detailed in the RIPA) equal to the Cumulative Purchaser Payments as of the Test Date. In addition, if aggregate Revenue Interest Payments made to Oberland as of the Test Date are less than the aggregate amount of Cumulative Purchaser Payments as of the Test Date, then the company must make the True-Up Payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oberland&#x2019;s rights to receive Revenue Interest Payments under the RIPA shall terminate when Oberland has received payments (including any True-Up Payment) equal to 195.0% of the then Cumulative Purchaser Payments unless the RIPA is terminated prior to such date. If Oberland has not received total payments (including any True-Up Payment) equal to 195.0% of the then Cumulative Purchaser Payments on or before the twelfth&#160;anniversary of the RIPA, then the company shall be obligated to pay to Oberland an amount equal to 195.0% of the then Cumulative Purchaser Payments less the aggregate payments (including any True-Up Payments) made as of such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the RIPA, the company has a Call Option to terminate the RIPA and repurchase the Revenue Interests at any time upon advance written notice, subject to certain limitations set forth in the RIPA. Additionally, Oberland has a Put Option enabling them to terminate the RIPA and to require the company to repurchase the Revenue Interests upon enumerated events, such as a bankruptcy event, failure to make a payment, an uncured material breach, default in certain third-party agreements, a breach or default under any subordination agreements with respect to indebtedness to existing stockholders, or subordinated notes during certain time periods, judgments in excess of certain amounts against the company, a material adverse effect, the loss of regulatory approval of our product candidates or a change of control. The required purchase price with respect to the Call Option and/or Put Option, as applicable, shall be (a)&#160;120.0% of the Cumulative Purchaser Payments as of such date, if Oberland exercises the Put Option (other than in connection with a change of control) on or prior to the first anniversary the Closing Date, (b)&#160;135.0% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised in connection with a change of control on or prior to the date that is eighteen (18)&#160;months after the Closing Date, and (c)&#160;in all other cases, (i)&#160;175.0% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised no later than the date that is thirty&#160;six (36)&#160;months after the Closing Date, and (ii)&#160;195.0% of the Cumulative Purchaser Payments as of such date, if the Put Option or the Call Option is exercised later than the date that is thirty&#160;six (36)&#160;months after the Closing Date, minus, in each case, the total payments made to Oberland on or prior to such date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company&#x2019;s obligations under the RIPA are guaranteed by certain of its subsidiaries meeting materiality thresholds set forth in the RIPA. To secure the company&#x2019;s obligations under the RIPA and the subsidiary guarantors&#x2019; obligations under the guarantees, each of the company and the subsidiary guarantors has granted a security interest in substantially all its assets, subject to certain exceptions and limitations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RIPA contains affirmative and negative covenants and events of default, including covenants and restrictions that, among other things, restrict our ability to incur additional liens, incur additional indebtedness, make loans and investments, enter into transactions with affiliates, engage in mergers and acquisitions, engage in asset sales and exclusive licensing arrangements, and declare dividends to our stockholders, in each case, subject to certain exceptions set forth in the RIPA. As of December&#160;31,&#160;2023, the company was in compliance with all covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RIPA is considered a sale of future revenues and accounted for as long-term debt recorded at amortized cost using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, on December&#160;29,&#160;2023 and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $10.0&#160;million of our common stock at $4.1103&#160;per share in a private placement. Oberland also has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock calculated from the date of exercise. This stock purchase option was classified as a liability estimated at fair value at issuance. The $200.0&#160;million received pursuant to the&#160;RIPA and $10.0&#160;million received pursuant to the SPOA were allocated among the resulting financial instruments on a relative fair value basis, with $197.1&#160;million allocated to the debt under the RIPA, $12.0&#160;million allocated to the common stock issued under the SPOA, and $0.8&#160;million allocated to the stock purchase option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Put Option under the RIPA that is exercisable by Oberland upon certain contingent events and the Call Option that is exercisable by the company upon a change of control were determined to be embedded derivatives requiring bifurcation and separately accounted for as a single compound derivative instrument. The company recorded the initial fair value of the derivative liability of $34.5&#160;million as a debt discount, which will be amortized to interest expense over the expected term of the debt using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the RIPA, as of December&#160;31,&#160;2023 $155.4&#160;million was recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;revenue interest liability,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheet. The company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method. A significant increase or decrease in actual or forecasted net sales may materially impact the revenue interest liability, interest expense, other income, and the time period for repayment. During the year ended December&#160;31,&#160;2023, we recorded $0.3&#160;million of interest expense related to this arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company incurred $7.5&#160;million of issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue interest liability activity during the year ended December&#160;31,&#160;2023 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue interest liability at inception&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from the RIPA, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from the RIPA, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded contingent derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock purchase option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue interest liability as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <ibrx:PurchaseAgreementTotalInvestmentAmount contextRef="c-103" decimals="-5" id="f-1256" unitRef="usd">200000000</ibrx:PurchaseAgreementTotalInvestmentAmount>
    <ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment contextRef="c-96" decimals="-5" id="f-1257" unitRef="usd">100000000</ibrx:PurchaseAgreementAdditionalRevenueInterestsSecondPayment>
    <ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales
      contextRef="c-372"
      decimals="2"
      id="f-1258"
      unitRef="number">0.0300</ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales>
    <ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales
      contextRef="c-373"
      decimals="2"
      id="f-1259"
      unitRef="number">0.0700</ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales>
    <ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales
      contextRef="c-374"
      decimals="3"
      id="f-1260"
      unitRef="number">0.0450</ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales>
    <ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales
      contextRef="c-375"
      decimals="1"
      id="f-1261"
      unitRef="number">0.1000</ibrx:RevenueInterestPurchaseAgreementPaymentsPercentageOfNetSales>
    <ibrx:RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage
      contextRef="c-376"
      decimals="3"
      id="f-1262"
      unitRef="number">0.0150</ibrx:RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage>
    <ibrx:RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage
      contextRef="c-377"
      decimals="4"
      id="f-1263"
      unitRef="number">0.0225</ibrx:RevenueInterestPurchaseAgreementTieredRevenueInterestRatePercentage>
    <ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage
      contextRef="c-378"
      decimals="2"
      id="f-1264"
      unitRef="number">1.950</ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage>
    <ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage
      contextRef="c-378"
      decimals="2"
      id="f-1265"
      unitRef="number">1.950</ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage>
    <ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage
      contextRef="c-378"
      decimals="2"
      id="f-1266"
      unitRef="number">1.950</ibrx:RevenueInterestPurchaseAgreementPaymentReceivedPercentage>
    <ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice
      contextRef="c-379"
      decimals="4"
      id="f-1267"
      unitRef="number">1.200</ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice>
    <ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice
      contextRef="c-380"
      decimals="4"
      id="f-1268"
      unitRef="number">1.350</ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice>
    <ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice
      contextRef="c-381"
      decimals="4"
      id="f-1269"
      unitRef="number">1.750</ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice>
    <ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice
      contextRef="c-382"
      decimals="4"
      id="f-1270"
      unitRef="number">1.950</ibrx:RevenueInterestPurchaseAgreementPercentageOfCumulativePurchaserPaymentsRepurchasePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-132" decimals="-5" id="f-1271" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-383"
      decimals="4"
      id="f-1272"
      unitRef="usdPerShare">4.1103</us-gaap:SaleOfStockPricePerShare>
    <ibrx:SaleOfStockAdditionalPurchaseOption contextRef="c-132" decimals="-5" id="f-1273" unitRef="usd">10000000</ibrx:SaleOfStockAdditionalPurchaseOption>
    <ibrx:PurchaseAgreementTotalInvestmentAmount contextRef="c-103" decimals="-5" id="f-1274" unitRef="usd">200000000</ibrx:PurchaseAgreementTotalInvestmentAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-132" decimals="-5" id="f-1275" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction contextRef="c-378" decimals="-3" id="f-1276" unitRef="usd">197100000</ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction>
    <ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction contextRef="c-132" decimals="-3" id="f-1277" unitRef="usd">12000000</ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction>
    <ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction contextRef="c-384" decimals="-3" id="f-1278" unitRef="usd">800000</ibrx:SaleOfStockAndRevenueInterestPurchaseAgreementConsiderationReceivedOnTransaction>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-103" decimals="-3" id="f-1279" unitRef="usd">34500000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SecuredLongTermDebt contextRef="c-385" decimals="-5" id="f-1280" unitRef="usd">155400000</us-gaap:SecuredLongTermDebt>
    <us-gaap:InterestExpense contextRef="c-386" decimals="-5" id="f-1281" unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-387" decimals="-5" id="f-1282" unitRef="usd">7500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <ibrx:SummarizesTheRevenueInterestLiabilityActivityTableTextBlock contextRef="c-1" id="f-1283">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue interest liability activity during the year ended December&#160;31,&#160;2023 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue interest liability at inception&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from the RIPA, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from the RIPA, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Embedded contingent derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of stock purchase option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue interest liability as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ibrx:SummarizesTheRevenueInterestLiabilityActivityTableTextBlock>
    <us-gaap:LongTermDebt contextRef="c-103" decimals="-3" id="f-1284" unitRef="usd">0</us-gaap:LongTermDebt>
    <ibrx:ProceedsFromIssuanceOfSecuredDebtGross contextRef="c-387" decimals="-3" id="f-1285" unitRef="usd">200000000</ibrx:ProceedsFromIssuanceOfSecuredDebtGross>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-387" decimals="-3" id="f-1286" unitRef="usd">7491000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-387" decimals="-3" id="f-1287" unitRef="usd">192509000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod contextRef="c-388" decimals="-3" id="f-1288" unitRef="usd">34500000</ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod>
    <ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod contextRef="c-389" decimals="-3" id="f-1289" unitRef="usd">2039000</ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod>
    <ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod contextRef="c-390" decimals="-3" id="f-1290" unitRef="usd">819000</ibrx:DebtInstrumentDebtDiscountRecordedInThePeriod>
    <us-gaap:InterestExpenseDebt contextRef="c-386" decimals="-3" id="f-1291" unitRef="usd">264000</us-gaap:InterestExpenseDebt>
    <us-gaap:LongTermDebt contextRef="c-385" decimals="-3" id="f-1292" unitRef="usd">155415000</us-gaap:LongTermDebt>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-1293">Related-Party Debt &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our related-party debt is summarized below (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.003%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized &lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$505 million December 2023 Promissory Note &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Tranche 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;273,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$505 million December 2023 Promissory Note Tranche 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+7.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$200 million September&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;610,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accrued PIK&lt;br/&gt;Interest&lt;br/&gt;Added to&lt;br/&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$125 million August&#160;2022 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total related-party nonconvertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nant Capital 2015 Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nant Capital 2020 Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nant Capital 2021 Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NantMobile Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NCSC Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;$300.0&#160;million December 2021 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;17,&#160;2021, the company executed a $300.0&#160;million promissory note with N&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ant&#160;Capital, an af&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;filiated entity under common control of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder. The note bore an interest rate of Term&#160;SOFR plus 5.4%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances were due on December&#160;17,&#160;2022. In the event of a default on the loan (as defined in both the original and amended and restated promissory notes), including if the company does not repay the loan at maturity, the company had the right, at its sole option, to convert the outstanding principal amount and accrued and unpaid interest due under this note into shares of the company&#x2019;s common stock at a price of $5.67&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;31,&#160;2022, the company and Nant&#160;Capital entered into an amended and restated promissory note, pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2023 and the interest rate was amended to Term&#160;SOFR plus 8.0%&#160;per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which this existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Based on the terms of the amended and restated promissory note, the noteholder, at its sole discretion, may convert all of the Tranche&#160;2 $380.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;$125.0&#160;million August 2022 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;31,&#160;2022, the company executed a $125.0&#160;million promissory note with Nant&#160;Capital. The note bears an interest rate of Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was extended to December&#160;31,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note letter agreement pursuant to which the existing promissory note was amended to be included in the Tranche&#160;1 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025 and an interest rate of Term&#160;SOFR plus 8.0% per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;$50.0&#160;million December 2022 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;12,&#160;2022, the company executed a $50.0&#160;million promissory note with Nant&#160;Capital. The note bore an interest rate of Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. In the event of a specified transaction (as defined in the note), the noteholder can request the outstanding principal and interest due on the loan to be repaid in full upon consummation of such specified transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Pursuant to the terms of the amended and restated promissory note, the investor, in its sole discretion may convert all of the outstanding Tranche&#160;2 principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. The noteholder can request up to $50.0&#160;million of the Tranche&#160;2 principal amount and accrued interest to be repaid upon consummation of such specified transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;$30.0&#160;million March 2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;31,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital. This note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest was originally due on December&#160;31,&#160;2023. The company may prepay the outstanding promissory note, at any time, in whole or in part, without penalty. Upon receipt of a written notice of prepayment from the company, the noteholder may choose to convert the outstanding principal amount to be prepaid and the accrued and unpaid interest thereon into shares of the company&#x2019;s common stock at a price of $2.28&#160;per share. Additionally, the noteholder may at its option convert the entire outstanding principal amount of the promissory note and accrued interest into shares of the company&#x2019;s common stock at a conversion price of $2.28 per share, at the option of the noteholder. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company received net proceeds of approximately $29.9&#160;million from this financing, net of a $0.1&#160;million origination fee paid to the noteholder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of the $30.0&#160;million promissory note described above was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into a letter agreement pursuant to which the maturity date of this promissory note was extended to December&#160;31,&#160;2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;$30.0&#160;million June 2023 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;13,&#160;2023, the company executed a $30.0&#160;million promissory note with Nant&#160;Capital, pursuant to which, the company could request up to three&#160;(3) advances of $10.0&#160;million each. The principal amount of each advance bore interest rate at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a quarterly basis. The outstanding principal amount and any accrued and unpaid interest on advances was originally due on December&#160;31,&#160;2023. We may prepay the outstanding principal amount, together with any accrued interest, on any then-outstanding advances, at any time, in whole or in part, without premium or penalty, and without the prior consent of the noteholder upon five&#160;(5) days written notice to the noteholder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received net proceeds of approximately $29.9&#160;million from this promissory note, net of a $0.1&#160;million origination fee paid to Nant&#160;Capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11, 2023, the company and Nant&#160;Capital entered into a letter amendment pursuant to which the maturity date of the promissory note was further extended to December&#160;31,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note pursuant to which the existing promissory note was amended to be included in the Tranche&#160;2 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, with a maturity date of December&#160;31,&#160;2025, and an interest rate of Term&#160;SOFR plus 7.5%&#160;per annum. Pursuant to the terms of the amended and restated promissory note the investor, in its sole discretion may convert all of the Tranche&#160;2 $380.0&#160;million principal amount into shares of common stock at a conversion price of $8.2690&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;$200.0&#160;million September 2023 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11, 2023, the company executed a $200.0&#160;million convertible promissory note with Nant&#160;Capital. The note bears interest at Term&#160;SOFR plus 8.0%&#160;per annum, payable on a monthly basis. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;11,&#160;2026. We may prepay the outstanding principal amount, together with any accrued interest, at any time, in whole or in part, without premium or penalty upon five&#160;(5) days written notice to the noteholder. The noteholder has the sole option to convert all (but not less than all) of the outstanding principal amount and accrued but unpaid interest into shares of the company&#x2019;s common stock at a conversion price of $1.9350&#160;per share. The company received net proceeds of approximately $199.0&#160;million from this financing, net of a $1.0&#160;million origination fee paid to the noteholder. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Footnotes to Related-Party Debt Tables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Modification and Debt Extinguishments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;August 2022 Debt Extinguishment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;31,&#160;2022, the company amended and restated the above fixed-rate notes payables held by Nant&#160;Capital, NantWorks, NantMobile and NCSC, which are entities affiliated with Dr. Soon-Shiong. Prior to the amendments and restatements, these notes bore and thereafter continued to bear interest at a per annum rate ranging from 3.0% to 6.0%, provided that the outstanding principal was and thereafter continued to be due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest was or continued to be payable either upon maturity or, with respect to one of the notes, on a quarterly basis. Prior to the amendments and restatements, the company could and thereafter continued to be able to prepay the outstanding principal (together with accrued and unpaid interest), either in whole or in part, at any time without premium or penalty and without the prior consent of the noteholder, subject to an advance notice period of at least five business days during which the noteholder could convert the amount requested to be prepaid by the company into shares of the company&#x2019;s common stock, as part of the amendment and restatement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of these fixed-rate promissory notes were amended and restated to include a conversion feature that gave each noteholder, at its sole option, at any time (other than when the noteholder is in receipt of a written notice of prepayment from the borrower), the right to convert the entire outstanding principal amount and accrued and unpaid interest due under each note at the time of conversion into shares of the company&#x2019;s common stock at a price of $5.67&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since all of the above promissory notes were entered into or amended at the same time and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. ASC&#160;470-50 provides that a modification or an exchange that adds or eliminates a substantive conversion option as of the conversion date would always be considered substantial and require extinguishment accounting. Accordingly, as a result of the addition of the conversion feature to the fixed-rate promissory notes, the fixed-rate promissory notes and the variable-rate promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of the fixed-rate promissory notes and variable-rate promissory notes before and after amendments. Under this model, the company calculated a gain on extinguishment of $82.9&#160;million, representing the difference between the fair value of the new and amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts plus the cash proceeds from the new promissory note. Since the debt was obtained from entities under common control, such gain was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of stockholders&#x2019; deficit during the year ended December&#160;31,&#160;2022. Also, the difference between the face values of the new and amended promissory notes (and accrued interest on the date of the amendment) and the fair values of the new and restated promissory notes was recorded as a debt discount to be amortized to interest expense over the remaining term (or until conversion in the case of fixed-rate promissory notes) of the respective promissory notes. During the year ended December&#160;31,&#160;2022, we recorded amortization of related-party notes discounts totaling $16.3&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the promissory notes without a holder conversion option were estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair values of the fixed-rate promissory notes, which were each modified to include a holder conversion option, were determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed are considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included market yields from 18.0% to 24.8% and a risk-free rate of 4.1%, and the significant unobservable inputs used for the binomial lattice model included a volatility of 84.9%, a market yield of 17.4% and a risk-free rate of 3.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;12, 2022, the company received written notice from NantWorks, the holder of an existing convertible promissory note of NantCell, a wholly-owned subsidiary of the company, of its election to convert the NantCell promissory note into shares of the company&#x2019;s common stock. As of such date, the holder of the NantCell note converted the entire $56.6&#160;million of outstanding principal and accrued and unpaid interest due under the note into 9,986,920&#160;shares of the company&#x2019;s common stock at a price of $5.67&#160;per share in accordance with the terms of the promissory note. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;September&#160;11,&#160;2023 Debt Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the holders exchanged promissory notes totaling approximately $270.0&#160;million in aggregate principal amount and accrued and unpaid interest for an aggregate of 209,291,936&#160;shares of common stock at an exchange price of $1.29&#160;per share. As a result of the exchange, the company was forever released and discharged from all its obligations and liabilities under the notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11,&#160;2023, the company and Nant&#160;Capital entered into a series of letter agreements pursuant to which the maturity date of the related-party nonconvertible notes described above totaling $505.0&#160;million in principal was extended from December&#160;31,&#160;2023 to December&#160;31,&#160;2024. In addition, the company entered into the $200.0&#160;million September 2023 promissory note with Nant&#160;Capital. No other material terms or conditions of these promissory notes were modified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since all of the above promissory notes were entered into or amended at the same time on September&#160;11,&#160;2023 and with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Pursuant to ASC&#160;470-50, as the terms of the amendment were not substantially different than the terms of the promissory notes prior to the amendment, the amendment was accounted for as a debt modification. The unamortized debt discounts from the promissory notes are being amortized as an adjustment to interest expense over the remaining term of modified promissory notes that are not recorded at fair value using the effective interest rate method. Also, a $29.6&#160;million increase in fair value of the embedded conversion feature from the debt modification was accounted for as a debt discount to the $200.0&#160;million convertible note that is not recorded at fair value, and a $1.6&#160;million increase in fair value of the embedded conversion feature related to the promissory note recorded at fair value was accounted for as interest expense during the year ended December&#160;31,&#160;2023. Such increase in fair values of the embedded conversion features totaling $31.2&#160;million has been recorded with a corresponding increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statement of stockholders&#x2019; deficit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;December&#160;29,&#160;2023 Debt Extinguishment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023 in connection with the RIPA, the company and Nant&#160;Capital entered into an amended and restated promissory note and a letter amendment for the following outstanding promissory notes. Pursuant to the terms of the amended and restated promissory note, the amended $505.0&#160;million December&#160;2023 promissory note is comprised of a Tranche&#160;1 with principal amount of $125.0&#160;million which was previously the $125.0&#160;million August&#160;2022 promissory note before amendment, and a Tranche&#160;2 with principal amount of $380.0&#160;million, which is made up of the previous $300.0&#160;million December&#160;2021 promissory note, $50.0&#160;million December 2022 promissory note and $30.0&#160;million June&#160;2023 promissory note. In addition, the amendment allows Nant&#160;Capital, in its sole discretion, to convert all the Tranche&#160;2 principal amount of $380.0&#160;million of the amended promissory note into shares of common stock. The conversion price was subsequently determined at $8.2690&#160;per share based on the agreement. The maturity date of the amended promissory note is December&#160;31,&#160;2025. Pursuant to the terms of the letter amendment, the maturity date of the $30.0&#160;million March&#160;2023 promissory note was extended from December&#160;31,&#160;2024 to December&#160;31,&#160;2025. Also, in connection with the RIPA transaction, all outstanding related-party promissory notes became subordinated to the RIPA payment obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Nant&#160;Capital promissory notes before the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Conversion&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$125 million August&#160;2022 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$2.2800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$200 million September 2023 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9/11/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$1.9350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total related-party promissory notes&lt;br/&gt;&#160;&#160;&#160;before amendments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Nant&#160;Capital promissory notes after the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Conversion&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$505 million December&#160;2023 Promissory Note &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Tranche 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$505 million December&#160;2023 Promissory Note &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Tranche 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$8.2690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+7.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total $505 million December&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;505,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$2.2800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$200 million September 2023 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9/11/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$1.9350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total related-party promissory notes &lt;br/&gt;&#160;&#160;&#160;after amendments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;735,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since all of the above outstanding promissory notes were amended at the same time, with entities under common control, the company determined that the promissory notes were required to be evaluated collectively to accurately capture the economics of the transactions entered in contemplation of each other and contemporaneously. Also, in accordance with ASC 470-50 the company used the debt terms that existed before the September&#160;11,&#160;2023 modification to determine whether the current modification is substantially different, as the September&#160;11,&#160;2023 modification was within a year of the current transaction, and the promissory notes, at that time, had been modified without being deemed to be substantially different. As the modifications (September&#160;11,&#160;2023 and December&#160;29,&#160;2023 on a cumulative basis) added a substantive conversion feature to the promissory notes, these promissory notes were determined to be extinguished given the contemporaneous nature of the amendments. The company performed a valuation of all the promissory notes before and after amendments. Under this model, the company calculated a loss on extinguishment of $318.8&#160;million, representing the difference between the fair value of the amended promissory notes and the carrying value of the extinguished debt, net of any unamortized related-party notes discounts. Since the debt was obtained from entities under common control, such loss was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, a debt premium totaling $354.9&#160;million, calculated as the difference between the fair values of certain promissory notes after modifications and their respective face values, was also recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collectively, net gain on debt extinguishment of $36.1&#160;million was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statement of stockholders&#x2019; deficit for the year ended December&#160;31,&#160;2023. Also, the difference between face values of certain new and amended promissory notes and their respective fair values of $53.1&#160;million was recorded as a debt discount to be amortized as interest expense over the remaining term. During the year&#160;ended December&#160;31,&#160;2023, we recorded amortization of related-party notes discounts totaling $0.5&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;interest expense, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statement of operations related to the new and amended promissory notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In regard to the Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note, the company identified an embedded derivative related to a contingent exercisable prepayment feature of the promissory note, which allows the noteholder to request up to a $50.0&#160;million prepayment of the promissory note and accrued interest upon the occurrence of a specified transaction. After the debt extinguishment, the company concluded that this promissory note was issued at a substantial discount, so the embedded derivative that is contingent exercisable was required to be bifurcated and accounted separately from the debt host instrument. The fair value of the embedded derivative was estimated at $0.8&#160;million as of December&#160;31,&#160;2023, using a with and without method, which assesses the likelihood and timing of the specified transaction to be triggered and result in a repayment. Significant unobservable inputs used for the valuation included a volatility of 118.0%, a market yield of 23.2% and a risk-free rate of 4.8%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Tranche&#160;1 principal amount of the amended $505.0&#160;million December&#160;2023 promissory note, which had no noteholder conversion option, was estimated using discounted cash flow analyses, based on market rates available to the company for similar debt at issuance after consideration of default and credit risk and the level of subordination. The fair value of Tranche&#160;2 of the amended promissory note, which was modified to include a noteholder conversion option, was determined based on a binomial lattice convertible note model. The analysis involved the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. Since certain of the factors analyzed were considered to be unobservable inputs, both the discounted cash flow model and the lattice model are considered to be Level&#160;3 valuations. Significant unobservable inputs used for the discounted cash flow analysis included a market yield of 23.2% and the significant unobservable inputs used for the binomial lattice model included a volatility of 118.0%, a market yield of 23.2% and a risk-free rate of 4.4%. The effective unamortized debt discount rate of the amended Tranche&#160;1 and Tranche&#160;2 principal amount of the $505.0&#160;million December&#160;2023 promissory note is 23.65% and 18.04%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the $200.0&#160;million September 2023 promissory note was determined using the binomial lattice model. Significant unobservable inputs used for the valuation included a volatility of 119.3%, a market yield of 23.3% and a risk-free rate of 5.2%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to December&#160;29,&#160;2023, the $30.0&#160;million March&#160;2023 promissory note was accounted for under the ASC&#160;825-10-15-4 FVO election. Under the FVO election, the note was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the convertible note was computed using the binomial lattice model with the following observable assumptions before it was modified on December&#160;29,&#160;2023. After the debt extinguishment, the note is accounted for under the amortized cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected market yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of this note was as follows (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value at issuance date, March&#160;31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on debt extinguishment with entities under common control&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying value, December&#160;29,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the interest expense for our related-party promissory notes during the year ended December&#160;31,&#160;2023 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;Discount&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$125 million August&#160;2022 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200 million September&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related-Party Fixed-Rate Promissory Notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balances include the amortization of debt discount totaling $0.5&#160;million recorded during the period from December&#160;29,&#160;2023 to December&#160;31,&#160;2023. The interest expense recorded during this period was $0.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future contractual obligations for our related-party debt as of December&#160;31,&#160;2023 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Payments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonconvertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonconvertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest payments on our promissory notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The weighted-average interest rate on our promissory notes as of December&#160;31,&#160;2023 was 13.09%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Related-Party Agreements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;NantBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;NantWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due from related party&#x2013;Brink&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related parties&#x2013;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due from related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;Duley Road&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;the Clinic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder founded and has a controlling interest in NantWorks, which is a collection of companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman, Global Chief Scientific and Medical Officer, and principal stockholder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NantWorks, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shared Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the amended and restated shared services agreement dated as of June&#160;2016, but effective as of August&#160;2015, NantWorks, a related party, provides corporate, general and administrative, certain research and development, and other support services. We are charged for these services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded $3.3&#160;million, $3.8&#160;million, and $4.4&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;selling, general and administrative expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $2.2&#160;million, $0.9&#160;million, and $0.4&#160;million, respectively, of expense reimbursements under this arrangement in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which were reimbursed to NantWorks based on those vendors&#x2019; invoiced amounts without markup by NantWorks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023 and 2022, we had a receivable of $0.5&#160;million and a payable of $1.0&#160;million, respectively, for all agreements with NantWorks, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due from/due to related parties,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets. We also recorded $1.0&#160;million and $2.0&#160;million of prepaid expenses for services that have been passed through to the company from NantWorks as of December&#160;31,&#160;2023 and 2022, respectively, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;prepaid expenses and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, we entered into a facility license agreement with NantWorks for approximately 9,500&#160;rentable square feet of office space in Culver&#160;City, California, which was converted to a research and development laboratory and a cGMP manufacturing facility. In 2020, we amended this agreement to extend the term of this license agreement through December&#160;31,&#160;2021. Commencing January&#160;1,&#160;2022, the license fee increased by 3% to approximately $56,120 per month. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;6,&#160;2022, we amended our facility license agreement with NantWorks to expand the licensed premises by 36,830&#160;rentable square feet to an aggregate total of 46,330&#160;rentable square feet. Effective May&#160;1,&#160;2022, the license fee was approximately $273,700 per month and was subject to a 3%&#160;increase commencing on January&#160;1 of each year. The space continues to be rented on a month-to-month basis, which can be terminated by either party with at least 30&#160;days&#x2019; prior written notice to the other party. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we recorded license fee expense for this facility totaling $3.4&#160;million, $2.4&#160;million, and $0.7&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Immuno-Oncology Clinic, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into multiple agreements with t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Clinic&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by an officer of the company and NantWorks manages the administrative operations of the Clinic. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we completed a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review of alternative structures that could support our more complex clinical trial requirements and made a decision to explore a potential transition of clinical trials at the Clinic to a new structure (including contracting with a new, non-affiliated professional corporation) to be determined and agreed upon by all parties. Based on this decision to explore a potential transition, we determined that it was more likely than not that a previously recorded prepaid asset would not result in the collection of fees for services performed by the Clinic as contemplated in the original agreements. As a result, during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we wrote down the remaining value of our prepaid asset and recorded approximately $4.4&#160;million in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations. While we have not yet finalized the potential transition, we continue discussions with potential partners around such alternative structures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2022 and 2021, we recorded $2.2&#160;million, $2.4&#160;million, and $1.6&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations related to clinical trial and transition services provided by the Clinic. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, we owed the&#160;Clinic $0.1&#160;million, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due to related parties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Brink Biologics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, we entered into an agreement with Brink whereby we granted Brink worldwide exclusive licenses for the use of certain cell lines and intellectual property in non-clinical laboratory testing. Brink is a related party as our Executive Chairman, Global Chief Scientific and Medical Officer and principal stockholder, and our Chief Corporate Affairs Officer and member of our Board of Directors, collectively own more than 50%&#160;of Brink&#x2019;s outstanding shares. During the years ended December&#160;31,&#160;2023 and 2022, we recognized revenue of an immaterial amount, respectively, and $0.4&#160;million during the year ended December&#160;31,&#160;2021 related to this license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NantBio, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, we entered into a supply agreement with NCSC, a 100%&#160;owned subsidiary of NantBio. Under this agreement, we agreed to supply VivaBioCell&#x2019;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement had an initial term of five years and renews automatically for successive one-year terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#x2019; prior written notice by NCSC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized no&#160;revenue, respectively, and $0.3&#160;million of revenue during the year ended December&#160;31,&#160;2021. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, we recorded $0.1&#160;million of deferred revenue for bioreactors that were delivered but not installed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;accrued expenses and other liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated balance sheets. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, we recorded $0.9&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due to related parties,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, we entered into a shared service agreement pursuant to which we are charged for services at cost, without mark-up or profit by NantBio, but including reasonable allocations of employee benefits related to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, we recorded a receivable from NantBio of $1.3&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due from related parties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets for amounts we paid on behalf of NantBio during the year ended December&#160;31,&#160;2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;605 Doug St, LLC &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 24,250&#160;rentable square feet in El&#160;Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease term was from July&#160;2016 through July&#160;2023. In June&#160;2023, we exercised the option to extend the lease for one&#160;additional three-year term through July&#160;2026. The base rent is approximately $72,385 per month, with annual increases of 3% that began in July&#160;2017. During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2022 and 2021, we recorded lease expense for this facility of $0.9&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Duley Road, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we entered into a lease agreement with Duley&#160;Road, a related party that is indirectly controlled by our Executive Chairman and Global Chief Scientific and Medical Officer, for approximately 11,980&#160;rentable square feet of office and cGMP&#160;manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through October&#160;2034. The base rent is approximately $40,700 per month, with annual increases of&#160;3% that began in November&#160;2018. Effective October&#160;3, 2023, we exercised the first option to extend the lease for one&#160;additional five-year term through October&#160;31, 2029. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective in 2019, we entered into two&#160;lease agreements with Duley&#160;Road for a second&#160;building located in El&#160;Segundo, California. The first&#160;lease is for the first&#160;floor of the building with approximately 5,650&#160;rentable square feet. The lease has a seven-year term that commenced in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488&#160;rentable square feet. The lease has a seven-year term that commenced in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive five-year periods through 2036. The base rent for the two&#160;leases is approximately $35,800 per month, with annual increases of&#160;3% per year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2022 and 2021, we recorded rent expense for these leases totaling $0.9&#160;million, $0.8&#160;million, and $1.0&#160;million, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, we recorded $0.1&#160;million and $1.4&#160;million of lease-related payables to Duley&#160;Road, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;due to related parties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;605 Nash, LLC &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;February&#160;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, but effective on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January&#160;1,&#160;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we entered into a lease agreement with 605&#160;Nash, a related party, whereby we leased approximately 6,883&#160;rentable square feet (the Initial Premises) in a two&#160;story mixed use building containing approximately 64,643&#160;rentable square feet at 605-607 Nash Street in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease term commenced in January&#160;2021 and expires in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;2027&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and includes an option to extend the lease for one three-year term through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;2030&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The base rent is approximately $20,300 per month with an annual increase of 3%&#160;on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January&#160;1&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each year during the initial term, and if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May&#160;2021, but effective on April&#160;1,&#160;2021, we entered into an amendment to our Initial Premises lease with 605&#160;Nash. The amendment expanded the leased square feet by approximately 57,760&#160;rentable square feet (the Expansion Premises). The lease term of the Expansion Premises commenced in April&#160;2021 and expires in March&#160;2028, whereby the company has one&#160;option to extend the initial term for three years. Per the terms of the amendment, the term of the Initial Premises lease was extended for an additional three&#160;months and now expires on March&#160;31,&#160;2028. Base rent for the Expansion Premises is approximately $170,400&#160;per month with annual increases of 3% on April&#160;1 of each year. We are responsible for the build out of the facility space and associated costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have included the options to extend the lease term of both the Initial and Expansion Premises for three years as part of the initial term of the leases as it is reasonably certain that we will exercise the options, which implies expiration of both leases in December&#160;2030. During the years ended December&#160;31,&#160;2023, 2022, and 2021, we recorded rent expense for the Initial and Expansion Premises leases totaling $2.2&#160;million, respectively, i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statements of operations. The terms of initial and amended leases provided for tenant improvement allowances totaling $2.9&#160;million for costs and expenses related to improvements made by us to the Initial and Expansion Premises, which were received from the landlord during the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;557 Doug St, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;27,&#160;2021, we entered into a Membership Interest Purchase Agreement with Nant&#160;Capital (the Purchase Agreement). Nant&#160;Capital is a related party controlled by Dr.&#160;Soon-Shiong. The Purchase Agreement transferred all outstanding membership interests in 557 Doug St,&#160;LLC from the company to Nant&#160;Capital. The only asset owned by 557&#160;Doug St, LLC is the improved property located at 557&#160;South Douglas Street, El&#160;Segundo, California with a building area of approximately 36,434&#160;rentable square feet (the Douglas Property).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price under the purchase agreement was $22.0&#160;million, and after the offset prorated property taxes of $0.1&#160;million, the net proceeds from the sale were $21.9&#160;million. An independent appraisal of the Douglas Property assigned the Douglas Property a value of $22.0&#160;million. The net carrying value of the property was $20.5&#160;million as of the closing date. We accounted for the transfer as a sale of an asset to an entity under common control, recorded the transfer at book value and recognized the excess of net consideration over carrying book value of $1.4&#160;million as a capital contribution received from Nant&#160;Capital in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of stockholders&#x2019; deficit during the year ended December&#160;31,&#160;2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September&#160;2021, we entered into a lease agreement with Nant&#160;Capital under which we leased back 557&#160;South Douglas Street for an initial lease term of seven years, which commenced on September&#160;27,&#160;2021. The monthly base rent under the lease was approximately $81,976 per month with an annual increase of&#160;3% on October&#160;1 of each year beginning in 2022 during the initial term. For the first two years under the lease, we would not be charged rent; we would begin paying rent on October&#160;1,&#160;2023 at the current monthly base rent. We prepaid the first&#160;month rent and security deposit totaling $0.2&#160;million upon the execution of the lease. The lease was classified as an operating lease. During the year ended December&#160;31,&#160;2021, we recorded $0.3&#160;million of rent expense for the lease, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective May&#160;31,&#160;2022, we executed a lease termination agreement with Nant&#160;Capital under which we received a full refund of the first month&#x2019;s rent and security deposit totaling $0.2&#160;million that we paid upon execution of the lease. Prior to the termination of the lease, we recorded rent expense of $0.4&#160;million during the year ended December&#160;31,&#160;2022 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations. During the year ended December&#160;31,&#160;2022, we recognized a gain of $0.6&#160;million on the disposal of this lease in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;420 Nash, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;27,&#160;2021, we entered into a lease agreement with 420&#160;Nash,&#160;LLC, a related party, whereby we leased an approximately 19,125 rentable square foot property located at 420&#160;Nash Street, El&#160;Segundo, California, to be used primarily for the warehousing and storage of drug manufacturing supplies, products and equipment and ancillary office space. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the lease agreement, the lease term began on October&#160;1,&#160;2021 and expires on September&#160;30,&#160;2026. The base rent is approximately $38,250 per month with an annual increase of 3% on October&#160;1 of each year beginning in 2022 during the initial term. The company is responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. We received a rent abatement for the first month of the lease, and a one-time improvement allowance of $15,000 from the landlord that was credited against base rent obligations for the second month of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has options to extend the lease term for two&#160;additional consecutive periods of five years each. At the beginning of each option term, the initial monthly base rent will be adjusted to market rent (as defined in the lease agreement) with an annual increase of 3% during the option term. We have included the first&#160;option to extend the lease term for five years as part of the initial term of the lease as it is reasonably certain that we will exercise the option, which implies lease expiration in September&#160;2031. During the years ended December&#160;31,&#160;2023 and 2022, we recorded rent expense for this lease totaling $0.5&#160;million, respectively, and $0.1&#160;million during the year ended December&#160;31,&#160;2021 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;23&#160;Alaska, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;6,&#160;2022, we entered into a lease agreement with 23&#160;Alaska,&#160;LLC, a related party, for a 47,265&#160;rentable square foot facility located at 2335&#160;Alaska Ave., El&#160;Segundo, California, to be used primarily for pharmaceutical development and manufacturing, research and development, and office space. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the lease term began on May&#160;1,&#160;2022 and was to expire on April&#160;30,&#160;2027. The base rent was approximately $139,400&#160;per month with an annual increase of 3% on May&#160;1 of each year beginning in 2023 during the initial term. We were also required to pay $7,600&#160;per month for parking during the initial term. The company was responsible for the payment of real property taxes, repairs and maintenance, improvements, insurance, and operating expenses during the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company was responsible for the costs associated with the build-out of the premises and was to receive a one-time tenant improvement allowance of approximately $0.9&#160;million from the landlord. As of December&#160;31,&#160;2022, we re-evaluated plans for the future development of the facility and deemed it unlikely to claim any of the allowance during the reimbursement time frame. As such, during the year ended December&#160;31,&#160;2022 we wrote off the entire allowance receivable of $0.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective August&#160;31, 2023, we executed a lease termination agreement with the lessor under which we received a full refund of the security deposit totaling $0.1&#160;million that we paid upon execution of the lease. During the years ended December&#160;31,&#160;2023 and 2022, we recorded $1.2&#160;million of rent expense for this lease, respectively, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statements of operations. During the year&#160;ended December&#160;31,&#160;2023, we recognized a gain of $0.6&#160;million on the disposal of this lease in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;research and development expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock contextRef="c-1" id="f-1294">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our related-party debt is summarized below (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.003%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.405%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized &lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$505 million December 2023 Promissory Note &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Tranche 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;273,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$505 million December 2023 Promissory Note Tranche 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+7.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;346,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$200 million September&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;610,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balances as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accrued PIK&lt;br/&gt;Interest&lt;br/&gt;Added to&lt;br/&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less:&lt;br/&gt;Unamortized&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$125 million August&#160;2022 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2), (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total related-party nonconvertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;475,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;431,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nant Capital 2015 Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nant Capital 2020 Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nant Capital 2021 Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NantMobile Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NCSC Note Payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1), (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total related-party convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Nant&#160;Capital promissory notes before the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Conversion&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$125 million August&#160;2022 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$2.2800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$200 million September 2023 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9/11/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$1.9350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total related-party promissory notes&lt;br/&gt;&#160;&#160;&#160;before amendments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Nant&#160;Capital promissory notes after the amendments on December&#160;29,&#160;2023 (principal amount in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;br/&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Conversion&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Nonconvertible Note:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$505 million December&#160;2023 Promissory Note &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Tranche 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:100%"&gt;Related-Party Convertible Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$505 million December&#160;2023 Promissory Note &#x2013; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Tranche 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$8.2690&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+7.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total $505 million December&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;505,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12/31/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$2.2800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$200 million September 2023 Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9/11/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$1.9350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;SOFR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;+8.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total related-party promissory notes &lt;br/&gt;&#160;&#160;&#160;after amendments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;735,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the interest expense for our related-party promissory notes during the year ended December&#160;31,&#160;2023 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.026%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt&lt;br/&gt;Discount&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$300 million December&#160;2021 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$125 million August&#160;2022 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$50 million December&#160;2022 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$30 million March&#160;2023 Promissory Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$30 million June&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$200 million September&#160;2023 Promissory Note &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Related-Party Fixed-Rate Promissory Notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:94.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balances include the amortization of debt discount totaling $0.5&#160;million recorded during the period from December&#160;29,&#160;2023 to December&#160;31,&#160;2023. The interest expense recorded during this period was $0.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ibrx:ScheduleOfRelatedPartyPromissoryNotesTableTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1295" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-391"
      decimals="3"
      id="f-1296"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-392" decimals="-3" id="f-1297" unitRef="usd">125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-393" decimals="-3" id="f-1298" unitRef="usd">20414000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-393" decimals="-3" id="f-1299" unitRef="usd">104586000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1300" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-395" decimals="-3" id="f-1301" unitRef="usd">300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-396" decimals="-3" id="f-1302" unitRef="usd">26091000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-396" decimals="-3" id="f-1303" unitRef="usd">273909000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1304" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-398" decimals="-3" id="f-1305" unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-399" decimals="-3" id="f-1306" unitRef="usd">4349000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-399" decimals="-3" id="f-1307" unitRef="usd">45651000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-400" decimals="-5" id="f-1308" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-401" decimals="-3" id="f-1309" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-402" decimals="-3" id="f-1310" unitRef="usd">2609000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-402" decimals="-3" id="f-1311" unitRef="usd">27391000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1312" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-403"
      decimals="3"
      id="f-1313"
      unitRef="number">7.5</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-404" decimals="-3" id="f-1314" unitRef="usd">380000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-405" decimals="-3" id="f-1315" unitRef="usd">33049000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-405" decimals="-3" id="f-1316" unitRef="usd">346951000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-406" decimals="-5" id="f-1317" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-407"
      decimals="3"
      id="f-1318"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-408" decimals="-3" id="f-1319" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-409" decimals="-3" id="f-1320" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-409" decimals="-3" id="f-1321" unitRef="usd">30000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1322" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-411"
      decimals="3"
      id="f-1323"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-412" decimals="-3" id="f-1324" unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-412" decimals="-3" id="f-1325" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-412" decimals="-3" id="f-1326" unitRef="usd">200000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-413" decimals="-3" id="f-1327" unitRef="usd">610000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-405" decimals="-3" id="f-1328" unitRef="usd">33049000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-413" decimals="-3" id="f-1329" unitRef="usd">576951000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1330" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-414"
      decimals="3"
      id="f-1331"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-415" decimals="-3" id="f-1332" unitRef="usd">300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-415" decimals="-3" id="f-1333" unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-415" decimals="-3" id="f-1334" unitRef="usd">35822000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-415" decimals="-3" id="f-1335" unitRef="usd">264178000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-416" decimals="-5" id="f-1336" unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-417"
      decimals="3"
      id="f-1337"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-418" decimals="-3" id="f-1338" unitRef="usd">125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-418" decimals="-3" id="f-1339" unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-418" decimals="-3" id="f-1340" unitRef="usd">7039000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-418" decimals="-3" id="f-1341" unitRef="usd">117961000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1342" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-419"
      decimals="3"
      id="f-1343"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-420" decimals="-3" id="f-1344" unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-420" decimals="-3" id="f-1345" unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-420" decimals="-3" id="f-1346" unitRef="usd">238000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-420" decimals="-3" id="f-1347" unitRef="usd">49762000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-421" decimals="-3" id="f-1348" unitRef="usd">475000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-421" decimals="-3" id="f-1349" unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-421" decimals="-3" id="f-1350" unitRef="usd">43099000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-421" decimals="-3" id="f-1351" unitRef="usd">431901000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-422"
      decimals="3"
      id="f-1352"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-423" decimals="-3" id="f-1353" unitRef="usd">55226000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-423" decimals="-3" id="f-1354" unitRef="usd">9320000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-423" decimals="-3" id="f-1355" unitRef="usd">5188000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-423" decimals="-3" id="f-1356" unitRef="usd">59358000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-424"
      decimals="3"
      id="f-1357"
      unitRef="number">0.060</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-425" decimals="-3" id="f-1358" unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-425" decimals="-3" id="f-1359" unitRef="usd">7039000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-425" decimals="-3" id="f-1360" unitRef="usd">4068000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-425" decimals="-3" id="f-1361" unitRef="usd">52971000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-426"
      decimals="3"
      id="f-1362"
      unitRef="number">0.060</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-427" decimals="-3" id="f-1363" unitRef="usd">40000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-427" decimals="-3" id="f-1364" unitRef="usd">0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-427" decimals="-3" id="f-1365" unitRef="usd">2580000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-427" decimals="-3" id="f-1366" unitRef="usd">37420000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-428"
      decimals="3"
      id="f-1367"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-429" decimals="-3" id="f-1368" unitRef="usd">55000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-429" decimals="-3" id="f-1369" unitRef="usd">5110000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-429" decimals="-3" id="f-1370" unitRef="usd">5978000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-429" decimals="-3" id="f-1371" unitRef="usd">54132000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-430"
      decimals="3"
      id="f-1372"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-431" decimals="-3" id="f-1373" unitRef="usd">33000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-431" decimals="-3" id="f-1374" unitRef="usd">7684000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-431" decimals="-3" id="f-1375" unitRef="usd">3294000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-431" decimals="-3" id="f-1376" unitRef="usd">37390000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-432" decimals="-3" id="f-1377" unitRef="usd">233226000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="c-432" decimals="-3" id="f-1378" unitRef="usd">29153000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-432" decimals="-3" id="f-1379" unitRef="usd">21108000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt contextRef="c-432" decimals="-3" id="f-1380" unitRef="usd">241271000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1381" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1382" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-433"
      decimals="INF"
      id="f-1383"
      unitRef="number">0.054</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-434"
      decimals="2"
      id="f-1384"
      unitRef="usdPerShare">5.67</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-435"
      decimals="3"
      id="f-1385"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1386" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-436"
      decimals="INF"
      id="f-1387"
      unitRef="number">0.075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-404" decimals="-5" id="f-1388" unitRef="usd">380000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-437"
      decimals="4"
      id="f-1389"
      unitRef="usdPerShare">8.2690</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-416" decimals="-5" id="f-1390" unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-416" decimals="-5" id="f-1391" unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-438"
      decimals="3"
      id="f-1392"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1393" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-438"
      decimals="3"
      id="f-1394"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1395" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1396" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-439"
      decimals="3"
      id="f-1397"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1398" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-440"
      decimals="INF"
      id="f-1399"
      unitRef="number">0.075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-441"
      decimals="3"
      id="f-1400"
      unitRef="usdPerShare">8.2690</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ibrx:DebtInstrumentPrepaymentAndAccruedInterest contextRef="c-255" decimals="-5" id="f-1401" unitRef="usd">50000000</ibrx:DebtInstrumentPrepaymentAndAccruedInterest>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-406" decimals="-5" id="f-1402" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-442" decimals="-5" id="f-1403" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-407"
      decimals="3"
      id="f-1404"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-443"
      decimals="2"
      id="f-1405"
      unitRef="usdPerShare">2.28</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-443"
      decimals="2"
      id="f-1406"
      unitRef="usdPerShare">2.28</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-444" decimals="-5" id="f-1407" unitRef="usd">29900000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-443" decimals="-5" id="f-1408" unitRef="usd">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-406" decimals="-5" id="f-1409" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-400" decimals="-5" id="f-1410" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-400" decimals="-5" id="f-1411" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <ibrx:DebtInstrumentNumberOfAdvances
      contextRef="c-400"
      decimals="INF"
      id="f-1412"
      unitRef="advance">3</ibrx:DebtInstrumentNumberOfAdvances>
    <ibrx:DebtInstrumentFaceAmountPerTranche contextRef="c-400" decimals="-5" id="f-1413" unitRef="usd">10000000</ibrx:DebtInstrumentFaceAmountPerTranche>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-445"
      decimals="INF"
      id="f-1414"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-446" decimals="-5" id="f-1415" unitRef="usd">29900000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-400" decimals="-5" id="f-1416" unitRef="usd">100000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1417" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-447"
      decimals="3"
      id="f-1418"
      unitRef="number">0.075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-404" decimals="-5" id="f-1419" unitRef="usd">380000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-448"
      decimals="3"
      id="f-1420"
      unitRef="usdPerShare">8.2690</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1421" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1422" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-449"
      decimals="3"
      id="f-1423"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-410"
      decimals="4"
      id="f-1424"
      unitRef="usdPerShare">1.9350</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c-450" decimals="-5" id="f-1425" unitRef="usd">199000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-410" decimals="-5" id="f-1426" unitRef="usd">1000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-451"
      decimals="INF"
      id="f-1427"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-452"
      decimals="INF"
      id="f-1428"
      unitRef="number">0.060</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-453"
      decimals="2"
      id="f-1429"
      unitRef="usdPerShare">5.67</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty contextRef="c-160" decimals="-5" id="f-1430" unitRef="usd">82900000</ibrx:AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty>
    <us-gaap:InterestExpenseDebt contextRef="c-454" decimals="-5" id="f-1431" unitRef="usd">16300000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-455"
      decimals="3"
      id="f-1432"
      unitRef="number">0.180</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-456"
      decimals="3"
      id="f-1433"
      unitRef="number">0.248</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-457"
      decimals="3"
      id="f-1434"
      unitRef="number">0.041</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-458"
      decimals="3"
      id="f-1435"
      unitRef="number">0.849</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-459"
      decimals="3"
      id="f-1436"
      unitRef="number">0.174</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-460"
      decimals="3"
      id="f-1437"
      unitRef="number">0.035</us-gaap:DebtInstrumentMeasurementInput>
    <ibrx:LongTermDebtGrossIncludingAccruedInterest contextRef="c-461" decimals="-5" id="f-1438" unitRef="usd">56600000</ibrx:LongTermDebtGrossIncludingAccruedInterest>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-462"
      decimals="INF"
      id="f-1439"
      unitRef="shares">9986920</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-463"
      decimals="2"
      id="f-1440"
      unitRef="usdPerShare">5.67</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ibrx:LongTermDebtGrossIncludingAccruedInterest contextRef="c-464" decimals="-5" id="f-1441" unitRef="usd">270000000</ibrx:LongTermDebtGrossIncludingAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-465"
      decimals="INF"
      id="f-1442"
      unitRef="shares">209291936</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-466"
      decimals="2"
      id="f-1443"
      unitRef="usdPerShare">1.29</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-467" decimals="-5" id="f-1444" unitRef="usd">505000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1445" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-468" decimals="-5" id="f-1446" unitRef="usd">29600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-469" decimals="-5" id="f-1447" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-470" decimals="-5" id="f-1448" unitRef="usd">1600000</us-gaap:InterestExpenseDebt>
    <ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature contextRef="c-1" decimals="-5" id="f-1449" unitRef="usd">31200000</ibrx:APICDebtInstrumentConvertibleIncreaseInFairValueOfEmbeddedConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1450" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-416" decimals="-5" id="f-1451" unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-416" decimals="-5" id="f-1452" unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-404" decimals="-5" id="f-1453" unitRef="usd">380000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1454" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1455" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-400" decimals="-5" id="f-1456" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-404" decimals="-5" id="f-1457" unitRef="usd">380000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-448"
      decimals="3"
      id="f-1458"
      unitRef="usdPerShare">8.2690</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-442" decimals="-5" id="f-1459" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-416" decimals="-5" id="f-1460" unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-392" decimals="-3" id="f-1461" unitRef="usd">125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-438"
      decimals="3"
      id="f-1462"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1463" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-395" decimals="-3" id="f-1464" unitRef="usd">300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-435"
      decimals="3"
      id="f-1465"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1466" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-398" decimals="-3" id="f-1467" unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-439"
      decimals="3"
      id="f-1468"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-400" decimals="-5" id="f-1469" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-401" decimals="-3" id="f-1470" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-445"
      decimals="INF"
      id="f-1471"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-406" decimals="-5" id="f-1472" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-408" decimals="-3" id="f-1473" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-408"
      decimals="4"
      id="f-1474"
      unitRef="usdPerShare">2.2800</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-407"
      decimals="3"
      id="f-1475"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1476" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-471" decimals="-3" id="f-1477" unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-472"
      decimals="4"
      id="f-1478"
      unitRef="usdPerShare">1.9350</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-473" decimals="-3" id="f-1479" unitRef="usd">735000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1480" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-474" decimals="-3" id="f-1481" unitRef="usd">125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-391"
      decimals="3"
      id="f-1482"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1483" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-437" decimals="-3" id="f-1484" unitRef="usd">300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1485" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-475" decimals="-3" id="f-1486" unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-400" decimals="-5" id="f-1487" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-476" decimals="-3" id="f-1488" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1489" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-404" decimals="-5" id="f-1490" unitRef="usd">380000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-404"
      decimals="4"
      id="f-1491"
      unitRef="usdPerShare">8.2690</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-403"
      decimals="3"
      id="f-1492"
      unitRef="number">7.5</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1493" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-477" decimals="-5" id="f-1494" unitRef="usd">505000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-406" decimals="-5" id="f-1495" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-478" decimals="-3" id="f-1496" unitRef="usd">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-478"
      decimals="4"
      id="f-1497"
      unitRef="usdPerShare">2.2800</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-407"
      decimals="3"
      id="f-1498"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1499" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-472" decimals="-3" id="f-1500" unitRef="usd">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-472"
      decimals="4"
      id="f-1501"
      unitRef="usdPerShare">1.9350</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-411"
      decimals="3"
      id="f-1502"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-479" decimals="-3" id="f-1503" unitRef="usd">735000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-480" decimals="-5" id="f-1504" unitRef="usd">-318800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-481" decimals="-5" id="f-1505" unitRef="usd">354900000</us-gaap:DebtInstrumentUnamortizedPremium>
    <ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl contextRef="c-61" decimals="-5" id="f-1506" unitRef="usd">36100000</ibrx:GainOnDebtExtinguishmentEntitiesUnderCommonControl>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-482" decimals="-5" id="f-1507" unitRef="usd">53100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="c-482" decimals="-5" id="f-1508" unitRef="usd">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1509" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <ibrx:DebtInstrumentPrepaymentAndAccruedInterest contextRef="c-255" decimals="-5" id="f-1510" unitRef="usd">50000000</ibrx:DebtInstrumentPrepaymentAndAccruedInterest>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet contextRef="c-4" decimals="-5" id="f-1511" unitRef="usd">800000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-483"
      decimals="3"
      id="f-1512"
      unitRef="number">118.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-484"
      decimals="3"
      id="f-1513"
      unitRef="number">23.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-485"
      decimals="3"
      id="f-1514"
      unitRef="number">4.8</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1515" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-486"
      decimals="3"
      id="f-1516"
      unitRef="number">23.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-487"
      decimals="3"
      id="f-1517"
      unitRef="number">118.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-488"
      decimals="3"
      id="f-1518"
      unitRef="number">23.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-489"
      decimals="3"
      id="f-1519"
      unitRef="number">4.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-255" decimals="-5" id="f-1520" unitRef="usd">505000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-490"
      decimals="4"
      id="f-1521"
      unitRef="number">0.2365</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-491"
      decimals="4"
      id="f-1522"
      unitRef="number">0.1804</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1523" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-492"
      decimals="3"
      id="f-1524"
      unitRef="number">119.3</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-493"
      decimals="3"
      id="f-1525"
      unitRef="number">23.3</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-494"
      decimals="3"
      id="f-1526"
      unitRef="number">5.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-406" decimals="-5" id="f-1527" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-495"
      decimals="3"
      id="f-1528"
      unitRef="number">0.235</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-496"
      decimals="3"
      id="f-1529"
      unitRef="number">1.380</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c-497"
      decimals="3"
      id="f-1530"
      unitRef="number">0.052</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-498" decimals="-3" id="f-1531" unitRef="usd">29850000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-498" decimals="-3" id="f-1532" unitRef="usd">36203000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-498" decimals="-3" id="f-1533" unitRef="usd">36053000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-499" decimals="-3" id="f-1534" unitRef="usd">30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-394" decimals="-5" id="f-1535" unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-500" decimals="-3" id="f-1536" unitRef="usd">39653000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-500" decimals="-3" id="f-1537" unitRef="usd">27967000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-416" decimals="-5" id="f-1538" unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-501" decimals="-3" id="f-1539" unitRef="usd">16521000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-501" decimals="-3" id="f-1540" unitRef="usd">5962000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-397" decimals="-5" id="f-1541" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-502" decimals="-3" id="f-1542" unitRef="usd">6609000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-502" decimals="-3" id="f-1543" unitRef="usd">478000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-406" decimals="-5" id="f-1544" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-503" decimals="-3" id="f-1545" unitRef="usd">4590000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-503" decimals="-3" id="f-1546" unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-400" decimals="-5" id="f-1547" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-504" decimals="-3" id="f-1548" unitRef="usd">2096000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-504" decimals="-3" id="f-1549" unitRef="usd">258000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-410" decimals="-5" id="f-1550" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-505" decimals="-3" id="f-1551" unitRef="usd">8185000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-505" decimals="-3" id="f-1552" unitRef="usd">2586000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="c-506" decimals="-3" id="f-1553" unitRef="usd">8799000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-506" decimals="-3" id="f-1554" unitRef="usd">5145000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="c-480" decimals="-3" id="f-1555" unitRef="usd">86453000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-480" decimals="-3" id="f-1556" unitRef="usd">42396000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-507" decimals="-5" id="f-1557" unitRef="usd">500000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt contextRef="c-507" decimals="-5" id="f-1558" unitRef="usd">400000</us-gaap:InterestExpenseDebt>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="c-1" id="f-1559">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future contractual obligations for our related-party debt as of December&#160;31,&#160;2023 (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Principal Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Payments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonconvertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Convertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonconvertible&lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;_______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.712%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest payments on our promissory notes are calculated based on Term&#160;SOFR plus the contractual spread per the loan agreements. The weighted-average interest rate on our promissory notes as of December&#160;31,&#160;2023 was 13.09%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-508" decimals="-3" id="f-1560" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-509" decimals="-3" id="f-1561" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-510" decimals="-3" id="f-1562" unitRef="usd">79778000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-511" decimals="-3" id="f-1563" unitRef="usd">16708000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-512" decimals="-3" id="f-1564" unitRef="usd">96486000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-508" decimals="-3" id="f-1565" unitRef="usd">410000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-509" decimals="-3" id="f-1566" unitRef="usd">125000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-510" decimals="-3" id="f-1567" unitRef="usd">79556000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-511" decimals="-3" id="f-1568" unitRef="usd">16663000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-512" decimals="-3" id="f-1569" unitRef="usd">631219000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-508" decimals="-3" id="f-1570" unitRef="usd">200000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-509" decimals="-3" id="f-1571" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-510" decimals="-3" id="f-1572" unitRef="usd">18590000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-511" decimals="-3" id="f-1573" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-512" decimals="-3" id="f-1574" unitRef="usd">218590000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c-508" decimals="-3" id="f-1575" unitRef="usd">610000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-509" decimals="-3" id="f-1576" unitRef="usd">125000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-510" decimals="-3" id="f-1577" unitRef="usd">177924000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-511" decimals="-3" id="f-1578" unitRef="usd">33371000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-512" decimals="-3" id="f-1579" unitRef="usd">946295000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-513"
      decimals="4"
      id="f-1580"
      unitRef="number">0.1309</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-1581">Below is a summary of outstanding balances and a description of significant relationships (in&#160;thousands):&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;NantBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related party&#x2013;NantWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due from related party&#x2013;Brink&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due from related parties&#x2013;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due from related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantBio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;Duley Road&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;the Clinic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Due to related party&#x2013;NantWorks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-514" decimals="-3" id="f-1582" unitRef="usd">1294000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-515" decimals="-3" id="f-1583" unitRef="usd">1294000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-516" decimals="-3" id="f-1584" unitRef="usd">541000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-517" decimals="-3" id="f-1585" unitRef="usd">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-518" decimals="-3" id="f-1586" unitRef="usd">62000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-519" decimals="-3" id="f-1587" unitRef="usd">271000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-520" decimals="-3" id="f-1588" unitRef="usd">122000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-521" decimals="-3" id="f-1589" unitRef="usd">325000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-8" decimals="-3" id="f-1590" unitRef="usd">2019000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-9" decimals="-3" id="f-1591" unitRef="usd">1890000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-514" decimals="-3" id="f-1592" unitRef="usd">943000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-515" decimals="-3" id="f-1593" unitRef="usd">943000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-522" decimals="-3" id="f-1594" unitRef="usd">136000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-523" decimals="-3" id="f-1595" unitRef="usd">1431000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-524" decimals="-3" id="f-1596" unitRef="usd">57000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-525" decimals="-3" id="f-1597" unitRef="usd">109000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-516" decimals="-3" id="f-1598" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-517" decimals="-3" id="f-1599" unitRef="usd">986000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-1600" unitRef="usd">1136000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-9" decimals="-3" id="f-1601" unitRef="usd">3469000</us-gaap:AccountsPayableCurrent>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-526" decimals="-5" id="f-1602" unitRef="usd">3300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-527" decimals="-5" id="f-1603" unitRef="usd">3800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-528" decimals="-5" id="f-1604" unitRef="usd">4400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-529" decimals="-5" id="f-1605" unitRef="usd">2200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-530" decimals="-5" id="f-1606" unitRef="usd">900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-531" decimals="-5" id="f-1607" unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-532" decimals="-5" id="f-1608" unitRef="usd">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-533" decimals="-5" id="f-1609" unitRef="usd">1000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c-532" decimals="-5" id="f-1610" unitRef="usd">1000000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c-533" decimals="-5" id="f-1611" unitRef="usd">2000000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-534" decimals="-2" id="f-1612" unitRef="sqft">9500</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-535"
      decimals="2"
      id="f-1613"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <ibrx:MonthlyLicenseFee contextRef="c-535" decimals="-1" id="f-1614" unitRef="usd">56120</ibrx:MonthlyLicenseFee>
    <ibrx:IncreaseToNumberOfSquareFootOfFacilityLeased
      contextRef="c-536"
      decimals="INF"
      id="f-1615"
      unitRef="sqft">36830</ibrx:IncreaseToNumberOfSquareFootOfFacilityLeased>
    <ibrx:NumberOfSquareFeetOfFacilityLeased
      contextRef="c-536"
      decimals="INF"
      id="f-1616"
      unitRef="sqft">46330</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:MonthlyLicenseFee contextRef="c-537" decimals="-2" id="f-1617" unitRef="usd">273700</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-537"
      decimals="INF"
      id="f-1618"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <us-gaap:OperatingLeaseExpense contextRef="c-538" decimals="-5" id="f-1619" unitRef="usd">3400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-539" decimals="-5" id="f-1620" unitRef="usd">2400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-540" decimals="-5" id="f-1621" unitRef="usd">700000</us-gaap:OperatingLeaseExpense>
    <ibrx:PrepaidExpenseWriteDown contextRef="c-541" decimals="-5" id="f-1622" unitRef="usd">4400000</ibrx:PrepaidExpenseWriteDown>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-542" decimals="-5" id="f-1623" unitRef="usd">2200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-543" decimals="-5" id="f-1624" unitRef="usd">2400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-541" decimals="-5" id="f-1625" unitRef="usd">1600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableCurrent contextRef="c-544" decimals="-5" id="f-1626" unitRef="usd">100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-545" decimals="-5" id="f-1627" unitRef="usd">100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:Revenues contextRef="c-546" decimals="-5" id="f-1628" unitRef="usd">400000</us-gaap:Revenues>
    <ibrx:SupplyAgreementTermOfContract contextRef="c-547" id="f-1629">P5Y</ibrx:SupplyAgreementTermOfContract>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-548" id="f-1630">P1Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:NantBioRevenue contextRef="c-549" decimals="-5" id="f-1631" unitRef="usd">0</ibrx:NantBioRevenue>
    <ibrx:NantBioRevenue contextRef="c-550" decimals="-5" id="f-1632" unitRef="usd">0</ibrx:NantBioRevenue>
    <ibrx:NantBioRevenue contextRef="c-551" decimals="-5" id="f-1633" unitRef="usd">300000</ibrx:NantBioRevenue>
    <us-gaap:ContractWithCustomerLiability contextRef="c-552" decimals="-5" id="f-1634" unitRef="usd">100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-553" decimals="-5" id="f-1635" unitRef="usd">100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AccountsPayableCurrent contextRef="c-553" decimals="-5" id="f-1636" unitRef="usd">900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-552" decimals="-5" id="f-1637" unitRef="usd">900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-554" decimals="-5" id="f-1638" unitRef="usd">1300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-555" decimals="-5" id="f-1639" unitRef="usd">1300000</us-gaap:AccountsReceivableNetCurrent>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-556" decimals="-1" id="f-1640" unitRef="sqft">24250</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="c-557"
      decimals="INF"
      id="f-1641"
      unitRef="renewal_options">1</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-557" id="f-1642">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:MonthlyLicenseFee contextRef="c-557" decimals="0" id="f-1643" unitRef="usd">72385</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-557"
      decimals="2"
      id="f-1644"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <us-gaap:OperatingLeaseExpense contextRef="c-558" decimals="-5" id="f-1645" unitRef="usd">900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-559" decimals="-5" id="f-1646" unitRef="usd">900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-560" decimals="-5" id="f-1647" unitRef="usd">900000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-561" decimals="-1" id="f-1648" unitRef="sqft">11980</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="c-562"
      decimals="INF"
      id="f-1649"
      unitRef="renewal_options">2</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-562" id="f-1650">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:MonthlyLicenseFee contextRef="c-562" decimals="-2" id="f-1651" unitRef="usd">40700</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-562"
      decimals="2"
      id="f-1652"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="c-563"
      decimals="INF"
      id="f-1653"
      unitRef="renewal_options">1</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-563" id="f-1654">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:NumberOfLeases
      contextRef="c-564"
      decimals="INF"
      id="f-1655"
      unitRef="lease">2</ibrx:NumberOfLeases>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-565" decimals="-1" id="f-1656" unitRef="sqft">5650</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-565" id="f-1657">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-566" decimals="0" id="f-1658" unitRef="sqft">6488</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-566" id="f-1659">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="c-564"
      decimals="INF"
      id="f-1660"
      unitRef="renewal_options">2</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-564" id="f-1661">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:NumberOfLeases
      contextRef="c-564"
      decimals="INF"
      id="f-1662"
      unitRef="lease">2</ibrx:NumberOfLeases>
    <ibrx:MonthlyLicenseFee contextRef="c-564" decimals="-2" id="f-1663" unitRef="usd">35800</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-564"
      decimals="2"
      id="f-1664"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <us-gaap:OperatingLeaseExpense contextRef="c-567" decimals="-5" id="f-1665" unitRef="usd">900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-568" decimals="-5" id="f-1666" unitRef="usd">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-569" decimals="-5" id="f-1667" unitRef="usd">1000000</us-gaap:OperatingLeaseExpense>
    <ibrx:LeaseRelatedPayables contextRef="c-570" decimals="-5" id="f-1668" unitRef="usd">100000</ibrx:LeaseRelatedPayables>
    <ibrx:LeaseRelatedPayables contextRef="c-571" decimals="-5" id="f-1669" unitRef="usd">1400000</ibrx:LeaseRelatedPayables>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-572" decimals="0" id="f-1670" unitRef="sqft">6883</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="c-573"
      decimals="INF"
      id="f-1671"
      unitRef="renewal_options">1</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-573" id="f-1672">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:MonthlyLicenseFee contextRef="c-573" decimals="-2" id="f-1673" unitRef="usd">20300</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-573"
      decimals="2"
      id="f-1674"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-574" decimals="-1" id="f-1675" unitRef="sqft">57760</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="c-575"
      decimals="INF"
      id="f-1676"
      unitRef="renewal_options">1</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-575" id="f-1677">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:MonthlyLicenseFee contextRef="c-575" decimals="-2" id="f-1678" unitRef="usd">170400</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-575"
      decimals="2"
      id="f-1679"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-575" id="f-1680">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <us-gaap:OperatingLeaseExpense contextRef="c-576" decimals="-5" id="f-1681" unitRef="usd">2200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-577" decimals="-5" id="f-1682" unitRef="usd">2200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-578" decimals="-5" id="f-1683" unitRef="usd">2200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncentiveFromLessor contextRef="c-579" decimals="-5" id="f-1684" unitRef="usd">2900000</us-gaap:IncentiveFromLessor>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="c-580"
      decimals="INF"
      id="f-1685"
      unitRef="sqft">36434</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:SaleLeasebackTransactionConsiderationTransferred contextRef="c-581" decimals="-5" id="f-1686" unitRef="usd">22000000</ibrx:SaleLeasebackTransactionConsiderationTransferred>
    <ibrx:SaleLeasebackTransactionPropertyTaxes contextRef="c-581" decimals="-5" id="f-1687" unitRef="usd">100000</ibrx:SaleLeasebackTransactionPropertyTaxes>
    <ibrx:SaleLeasebackTransactionNetProceeds contextRef="c-580" decimals="-5" id="f-1688" unitRef="usd">21900000</ibrx:SaleLeasebackTransactionNetProceeds>
    <us-gaap:SaleLeasebackTransactionHistoricalCost contextRef="c-580" decimals="-5" id="f-1689" unitRef="usd">22000000</us-gaap:SaleLeasebackTransactionHistoricalCost>
    <us-gaap:SaleLeasebackTransactionNetBookValue contextRef="c-580" decimals="-5" id="f-1690" unitRef="usd">20500000</us-gaap:SaleLeasebackTransactionNetBookValue>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-582" decimals="-5" id="f-1691" unitRef="usd">1400000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-583" id="f-1692">P7Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:BaseMonthlyRent contextRef="c-583" decimals="0" id="f-1693" unitRef="usd">81976</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="c-583"
      decimals="2"
      id="f-1694"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:PeriodOfRentFreeLeaseTerm contextRef="c-583" id="f-1695">P2Y</ibrx:PeriodOfRentFreeLeaseTerm>
    <ibrx:LesseeOperatingLeasePrepaidExpense contextRef="c-584" decimals="-5" id="f-1696" unitRef="usd">200000</ibrx:LesseeOperatingLeasePrepaidExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-585" decimals="-5" id="f-1697" unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <ibrx:LesseeOperatingLeasePrepaidExpense contextRef="c-584" decimals="-5" id="f-1698" unitRef="usd">200000</ibrx:LesseeOperatingLeasePrepaidExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-586" decimals="-5" id="f-1699" unitRef="usd">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:GainLossOnTerminationOfLease contextRef="c-587" decimals="-5" id="f-1700" unitRef="usd">600000</us-gaap:GainLossOnTerminationOfLease>
    <ibrx:NumberOfSquareFeetOfFacilityLeased contextRef="c-588" decimals="0" id="f-1701" unitRef="sqft">19125</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:MonthlyLicenseFee contextRef="c-589" decimals="-1" id="f-1702" unitRef="usd">38250</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-589"
      decimals="INF"
      id="f-1703"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <us-gaap:IncentiveFromLessor contextRef="c-588" decimals="-3" id="f-1704" unitRef="usd">15000</us-gaap:IncentiveFromLessor>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="c-589"
      decimals="INF"
      id="f-1705"
      unitRef="renewal_options">2</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-589" id="f-1706">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-589"
      decimals="INF"
      id="f-1707"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <ibrx:PeriodOfExtendedLeaseTerm contextRef="c-589" id="f-1708">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <us-gaap:OperatingLeaseExpense contextRef="c-590" decimals="-5" id="f-1709" unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-591" decimals="-5" id="f-1710" unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-592" decimals="-5" id="f-1711" unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfSquareFeetOfFacilityLeased
      contextRef="c-593"
      decimals="INF"
      id="f-1712"
      unitRef="sqft">47265</ibrx:NumberOfSquareFeetOfFacilityLeased>
    <ibrx:MonthlyLicenseFee contextRef="c-594" decimals="-2" id="f-1713" unitRef="usd">139400</ibrx:MonthlyLicenseFee>
    <ibrx:AnnualPercentageIncreaseToLicenseFee
      contextRef="c-594"
      decimals="INF"
      id="f-1714"
      unitRef="number">0.03</ibrx:AnnualPercentageIncreaseToLicenseFee>
    <ibrx:MonthlyBaseRentParking contextRef="c-594" decimals="-2" id="f-1715" unitRef="usd">7600</ibrx:MonthlyBaseRentParking>
    <us-gaap:IncentiveFromLessor contextRef="c-593" decimals="-5" id="f-1716" unitRef="usd">900000</us-gaap:IncentiveFromLessor>
    <us-gaap:IncentiveFromLessor contextRef="c-595" decimals="-5" id="f-1717" unitRef="usd">900000</us-gaap:IncentiveFromLessor>
    <us-gaap:SecurityDeposit contextRef="c-596" decimals="-5" id="f-1718" unitRef="usd">100000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseExpense contextRef="c-597" decimals="-5" id="f-1719" unitRef="usd">1200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-598" decimals="-5" id="f-1720" unitRef="usd">1200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:GainLossOnTerminationOfLease contextRef="c-599" decimals="-5" id="f-1721" unitRef="usd">600000</us-gaap:GainLossOnTerminationOfLease>
    <ibrx:WarrantLiabilityTextBlock contextRef="c-1" id="f-1724">Warrant Liabilities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;December 2022 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;12,&#160;2022, in connection with the sale of 9,090,909&#160;shares of our common stock to an institutional investor, we entered into a warrant agreement that allows such investor to purchase up to 9,090,909&#160;shares at an exercise price of $6.60&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of the warrants was estimated at $35.1&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.0&#160;million, $1.1&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was allocated to the warrants and recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statement of operations on the date of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023 and 2022, all 9,090,909&#160;underlying warrants were outstanding. As of December&#160;31,&#160;2023 and 2022, the estimated fair value of the warrants were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.1&#160;million and $21.6&#160;million, respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the year ended December&#160;31,&#160;2023, a decrease in fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.5&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;February 2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;15,&#160;2023, in connection with the sale of 14,072,615&#160;shares of our common stock to certain institutional investors, we entered into a warrant agreement that allows such investors to purchase up to 14,072,615&#160;shares at an exercise price of $4.2636&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants was estimated at $23.7&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling $3.0&#160;million, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was allocated to the warrants &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statement of operations &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the date of the transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;25,&#160;2023, the company amended the terms of the warrant, reducing the exercise price of the warrants from $4.2636&#160;per share to $3.2946&#160;per share and extending the expiration date of the warrants until July&#160;24,&#160;2026. Since the warrants were classified as liabilities and measured at fair value, we recognized the change of $7.3&#160;million in fair value of warrant liability in earnings due to the warrant modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, all 14,072,615&#160;underlying warrants were outstanding, with an estimated fair value of $50.0&#160;million. During the year ended December&#160;31,&#160;2023, an increase in fair value of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$26.3&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;July&#160;2023 Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;20, 2023, in connection with the sale of 14,569,296&#160;shares of our common stock to certain institutional investors, we entered into a warrant agreement that allows such investors to purchase up to 14,569,296&#160;shares at an exercise price of $3.2946&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classified the warrants as a liability at their fair value determined using the Black-Scholes option pricing model. The fair value of warrants was estimated at $25.8&#160;million at the issuance date. Of the placement agent fees and other offering costs totaling $2.5&#160;million, $1.0&#160;million was allocated to the warrants &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the consolidated statement of operations &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the date of the transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, all 14,569,296&#160;underlying warrants were outstanding, with an estimated fair value of $51.7&#160;million. During the year ended December&#160;31,&#160;2023, an increase in fair value of $25.9&#160;million was recorded in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;other&#160;expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</ibrx:WarrantLiabilityTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-602"
      decimals="INF"
      id="f-1725"
      unitRef="shares">9090909</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-256"
      decimals="INF"
      id="f-1726"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-603"
      decimals="2"
      id="f-1727"
      unitRef="usdPerShare">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-603" decimals="-5" id="f-1728" unitRef="usd">35100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DeferredOfferingCosts contextRef="c-604" decimals="-5" id="f-1729" unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <ibrx:TransactionCostsWarrantLiability contextRef="c-605" decimals="-5" id="f-1730" unitRef="usd">1100000</ibrx:TransactionCostsWarrantLiability>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-606"
      decimals="INF"
      id="f-1731"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-607"
      decimals="INF"
      id="f-1732"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-298" decimals="-5" id="f-1733" unitRef="usd">17100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-292" decimals="-5" id="f-1734" unitRef="usd">21600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-295" decimals="-5" id="f-1735" unitRef="usd">-4500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-608"
      decimals="INF"
      id="f-1736"
      unitRef="shares">14072615</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-609"
      decimals="INF"
      id="f-1737"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-278"
      decimals="4"
      id="f-1738"
      unitRef="usdPerShare">4.2636</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-610" decimals="-5" id="f-1739" unitRef="usd">23700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DeferredOfferingCosts contextRef="c-611" decimals="-5" id="f-1740" unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <ibrx:TransactionCostsWarrantLiability contextRef="c-612" decimals="-5" id="f-1741" unitRef="usd">1000000</ibrx:TransactionCostsWarrantLiability>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-278"
      decimals="4"
      id="f-1742"
      unitRef="usdPerShare">4.2636</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-279"
      decimals="4"
      id="f-1743"
      unitRef="usdPerShare">3.2946</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-280" decimals="-5" id="f-1744" unitRef="usd">7300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-613"
      decimals="INF"
      id="f-1745"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-614"
      decimals="INF"
      id="f-1746"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-299" decimals="-5" id="f-1747" unitRef="usd">50000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-296" decimals="-5" id="f-1748" unitRef="usd">26300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-615"
      decimals="INF"
      id="f-1749"
      unitRef="shares">14569296</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-281"
      decimals="INF"
      id="f-1750"
      unitRef="shares">14569296</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-281"
      decimals="4"
      id="f-1751"
      unitRef="usdPerShare">3.2946</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-616" decimals="-5" id="f-1752" unitRef="usd">25800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DeferredOfferingCosts contextRef="c-617" decimals="-5" id="f-1753" unitRef="usd">2500000</us-gaap:DeferredOfferingCosts>
    <ibrx:TransactionCostsWarrantLiability contextRef="c-618" decimals="-5" id="f-1754" unitRef="usd">1000000</ibrx:TransactionCostsWarrantLiability>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-619"
      decimals="INF"
      id="f-1755"
      unitRef="shares">14569296</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-300" decimals="-5" id="f-1756" unitRef="usd">51700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-297" decimals="-5" id="f-1757" unitRef="usd">25900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1758">Stockholders&#x2019; Deficit&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Authorized for Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, the company was authorized to issue up to 1,350,000,000&#160;shares of its common stock, par value $0.0001&#160;per share, and 20,000,000&#160;shares of our preferred stock, par value $0.0001&#160;per share. As of December&#160;31,&#160;2023, there were 670,867,344&#160;shares of our common stock outstanding (excluding 163,800&#160;shares held by a majority owned subsidiary of the company that are treated as treasury shares for accounting purposes).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective October&#160;18,&#160;2023, we amended and restated our Amended and Restated Certificate of Incorporation to increase the number of shares that the company is authorized to issue from 900,000,000&#160;shares of common stock, $0.0001&#160;par value per share, to 1,350,000,000&#160;shares of common stock, $0.0001&#160;par value per share. The number of shares of preferred stock, $0.0001&#160;par value per share, that the company is authorized to issue remained unchanged at 20,000,000&#160;shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Issued in Connection with the Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, par value $0.001&#160;per share, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive 0.8190&#160;newly issued shares of common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, par value $0.0001&#160;per share, resulting in the issuance of approximately 273.7&#160;million shares of Company Common Stock.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Merger was accounted for as a transaction between entities under common control, the outstanding shares presented on the consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock during the period ended December&#160;31,&#160;2021, and in connection with the conversion, those shares of common stock were recorded at the company&#x2019;s par value of $0.0001&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2015 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, the Board of Directors approved the 2015&#160;Share Repurchase Program, which allows our CEO or CFO, to repurchase on behalf of the company, from time to time in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups, or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements, and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through approval of the Board of Directors upon repurchase. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, no&#160;shares of our common stock were repurchased under the program. Since the plan&#x2019;s inception, we have repurchased a total of 6,403,489&#160;shares at a total cost of $31.7&#160;million. As of December&#160;31,&#160;2023, $18.3&#160;million remained authorized to use for share repurchases under the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During February&#160;2023, we filed a $750.0&#160;million shelf registration statement with the SEC on Form&#160;S-3 for the offering and sale of equity and equity-linked securities, including common stock, preferred stock, debt securities, depositary shares, warrants to purchase common stock, preferred stock or debt securities, subscription rights, purchase contracts, and units. During the year ended December&#160;31,&#160;2023, we sold shares of our common stock and warrants valued at $184.4&#160;million under the shelf. As of December&#160;31,&#160;2023, we had $565.6&#160;million available for use under the shelf. This available shelf is in addition to the Open Market Sale Agreement described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Open Market Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April&#160;2021, we entered into the&#160;ATM under which we may offer and sell, from time to time at our sole discretion, shares of our common stock through our sales agent. We pay our sales agent a commission of up to 3.0%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the ATM, and also have provided them with customary indemnification and contribution rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, we received net proceeds of approximately $16.1&#160;million, $13.1&#160;million, and $164.5&#160;million, respectively, from the issuance of shares under the&#160;ATM. As of December&#160;31,&#160;2023, we had $208.8&#160;million available for future issuances under the ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not obligated to sell any shares and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances and shall automatically terminate upon the issuance and sale of all of the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Registered Direct Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;February 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;15,&#160;2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,072,615&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,072,615&#160;shares of common stock at an exercise price of $4.2636&#160;per share, for a purchase price of $3.5530&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other offering costs of $3.0&#160;million, of which $2.0&#160;million was allocated to the sale of our common stock and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of stockholders&#x2019; deficit during the year ended December&#160;31,&#160;2023. The warrants became immediately exercisable on February&#160;17,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;25,&#160;2023, pursuant to the terms of a letter amendment, the company and the investors agreed to reduce the exercise price of the outstanding February&#160;2023 Warrants from $4.2636&#160;per share to $3.2946&#160;per share and extend the expiration date of the warrants to July&#160;24,&#160;2026. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;&lt;/a&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_220" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;12&lt;/a&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Liabilities,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;July 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;20, 2023, we entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 14,569,296&#160;shares of our common stock, as well as warrants that allow such investors to purchase an additional 14,569,296&#160;shares of common stock at an exercise price of $3.2946&#160;per share, for a purchase price of $2.7455&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $37.5&#160;million, after deducting placement agent fees and other estimated offering costs of $2.5&#160;million, of which $12.7&#160;million was allocated to the sale of our common stock and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on the consolidated statement of stockholders&#x2019; deficit during the year ended December&#160;31,&#160;2023. The warrants became immediately exercisable on July&#160;25,&#160;2023 and expire on July&#160;24,&#160;2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;12,&#160;2022, we entered into a securities purchase agreement with an institutional investor for the sale of 9,090,909&#160;shares of our common stock, as well as warrants that allow such investor to purchase an additional 9,090,909&#160;shares of common stock at an exercise price of $6.60&#160;per share, for a purchase price of $5.50&#160;per share and accompanying warrant. This transaction generated net proceeds of approximately $47.0&#160;million, after deducting placement agent fees and other offering costs of $3.0&#160;million, of which $1.9&#160;million was allocated to the sale of our common stock and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional-paid-in capital,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of stockholders&#x2019; deficit during the year ended December&#160;31,&#160;2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Purchase and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29,&#160;2023 and in connection with the RIPA, we entered into an SPOA with Oberland pursuant to which we sold an aggregate of approximately $10.0&#160;million of our common stock at $4.1103&#160;per share in a private placement, which resulted in the issuance of 2,432,894&#160;shares of common stock. We received net proceeds of approximately $9.5&#160;million, after deducting offering costs of $0.5&#160;million, which were allocated to the sale of our common stock and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional-paid-in capital,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated statement of stockholders&#x2019; deficit during the year ended December&#160;31,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oberland also has an option to purchase up to an additional $10.0&#160;million of our common stock, at a price per share to be determined by reference to the 30-day trailing volume weighted-average price of our common stock, calculated from the date of exercise. The option is exercisable by Oberland any time after the closing of the SPOA, until the earliest of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&#160;December&#160;29,&#160;2028, (ii)&#160;a change of control of the company, or (iii)&#160;a sale of substantially all of the company&#x2019;s assets. Among other limitations, the option may only be exercised to the extent that the common stock issuable pursuant to such exercise would not exceed 19.9%&#160;of the common stock outstanding immediately after giving effect to such exercise. We have agreed to file a shelf registration statement allowing for the resale of the common stock acquired under the SPOA and to cause the registration statement to be effective no later than May&#160;15,&#160;2024, or if the SEC decides to review such registration statement, no later than June&#160;30,&#160;2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion of Promissory Notes into Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;11, 2023, the company entered into a stock purchase agreement with Nant&#160;Capital, NantMobile and NCSC pursuant to which the related-party purchasers exchanged all such fixed-rate promissory notes, representing approximately $270.0&#160;million in aggregate principal amount and accrued and unpaid interest, in exchange for an aggregate of 209,291,936&#160;shares of common stock at an exchange price of $1.29&#160;per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;12, 2022, the company received written notice from NantWorks, the holder of the existing note, of its election to convert the entire outstanding principal and accrued interest under the existing note into shares of the company&#x2019;s common stock. As of such date, the entire outstanding principal amount and accrued and unpaid interest due under the existing note of approximately $56.6&#160;million and an unamortized debt discount of $4.7&#160;million were converted into 9,986,920&#160;shares of the company&#x2019;s common stock at a price of $5.67&#160;per share in accordance with the terms of the Existing Note. We recorded a net increase of $51.9&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheet related to this transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-4"
      decimals="INF"
      id="f-1759"
      unitRef="shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-1760"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-4"
      decimals="INF"
      id="f-1761"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-1762"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-1763"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-4"
      decimals="INF"
      id="f-1764"
      unitRef="shares">670867344</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-4"
      decimals="INF"
      id="f-1765"
      unitRef="shares">670867344</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-4"
      decimals="INF"
      id="f-1766"
      unitRef="shares">163800</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-620"
      decimals="INF"
      id="f-1767"
      unitRef="shares">900000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-1768"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-1769"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-4"
      decimals="INF"
      id="f-1770"
      unitRef="shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-1771"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-1772"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-1773"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-1774"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-620"
      decimals="INF"
      id="f-1775"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-86"
      decimals="3"
      id="f-1776"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ibrx:MergerExchangeRatio
      contextRef="c-621"
      decimals="INF"
      id="f-1777"
      unitRef="number">0.8190</ibrx:MergerExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-622"
      decimals="4"
      id="f-1778"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-621"
      decimals="-5"
      id="f-1779"
      unitRef="shares">273700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-622"
      decimals="4"
      id="f-1780"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-623" decimals="-5" id="f-1781" unitRef="usd">50000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-624"
      decimals="INF"
      id="f-1782"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-625"
      decimals="INF"
      id="f-1783"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-626"
      decimals="INF"
      id="f-1784"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-627"
      decimals="INF"
      id="f-1785"
      unitRef="shares">6403489</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-627" decimals="-5" id="f-1786" unitRef="usd">31700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-623" decimals="-5" id="f-1787" unitRef="usd">18300000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <ibrx:SaleOfStockMaximumAggregateOfferingPrice contextRef="c-628" decimals="-5" id="f-1788" unitRef="usd">750000000</ibrx:SaleOfStockMaximumAggregateOfferingPrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-629" decimals="-5" id="f-1789" unitRef="usd">184400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance contextRef="c-95" decimals="-5" id="f-1790" unitRef="usd">565600000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <ibrx:PercentageOfSalesAgentCommission
      contextRef="c-630"
      decimals="3"
      id="f-1791"
      unitRef="number">0.030</ibrx:PercentageOfSalesAgentCommission>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-631" decimals="-5" id="f-1792" unitRef="usd">16100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-632" decimals="-5" id="f-1793" unitRef="usd">13100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-633" decimals="-5" id="f-1794" unitRef="usd">164500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ibrx:CommonStockValueAvailableForFutureStockIssuance contextRef="c-94" decimals="-5" id="f-1795" unitRef="usd">208800000</ibrx:CommonStockValueAvailableForFutureStockIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-634"
      decimals="INF"
      id="f-1796"
      unitRef="shares">14072615</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-609"
      decimals="INF"
      id="f-1797"
      unitRef="shares">14072615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-278"
      decimals="4"
      id="f-1798"
      unitRef="usdPerShare">4.2636</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-611"
      decimals="4"
      id="f-1799"
      unitRef="usdPerShare">3.5530</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-634" decimals="-5" id="f-1800" unitRef="usd">47000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DeferredOfferingCosts contextRef="c-611" decimals="-5" id="f-1801" unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-80" decimals="-5" id="f-1802" unitRef="usd">2000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-278"
      decimals="4"
      id="f-1803"
      unitRef="usdPerShare">4.2636</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-279"
      decimals="4"
      id="f-1804"
      unitRef="usdPerShare">3.2946</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-615"
      decimals="INF"
      id="f-1805"
      unitRef="shares">14569296</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-281"
      decimals="INF"
      id="f-1806"
      unitRef="shares">14569296</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-281"
      decimals="4"
      id="f-1807"
      unitRef="usdPerShare">3.2946</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-281"
      decimals="4"
      id="f-1808"
      unitRef="usdPerShare">2.7455</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-635" decimals="-5" id="f-1809" unitRef="usd">37500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DeferredOfferingCosts contextRef="c-617" decimals="-5" id="f-1810" unitRef="usd">2500000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-635" decimals="-5" id="f-1811" unitRef="usd">12700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-602"
      decimals="INF"
      id="f-1812"
      unitRef="shares">9090909</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-256"
      decimals="INF"
      id="f-1813"
      unitRef="shares">9090909</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-603"
      decimals="2"
      id="f-1814"
      unitRef="usdPerShare">6.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-604"
      decimals="2"
      id="f-1815"
      unitRef="usdPerShare">5.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-602" decimals="-5" id="f-1816" unitRef="usd">47000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DeferredOfferingCosts contextRef="c-604" decimals="-5" id="f-1817" unitRef="usd">3000000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-43" decimals="-5" id="f-1818" unitRef="usd">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-132" decimals="-5" id="f-1819" unitRef="usd">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-383"
      decimals="4"
      id="f-1820"
      unitRef="usdPerShare">4.1103</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-636"
      decimals="INF"
      id="f-1821"
      unitRef="shares">2432894</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-83" decimals="-5" id="f-1822" unitRef="usd">9500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts contextRef="c-637" decimals="-5" id="f-1823" unitRef="usd">500000</us-gaap:DeferredOfferingCosts>
    <ibrx:SaleOfStockAdditionalPurchaseOption contextRef="c-638" decimals="-5" id="f-1824" unitRef="usd">10000000</ibrx:SaleOfStockAdditionalPurchaseOption>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="c-132"
      decimals="3"
      id="f-1825"
      unitRef="number">0.199</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <ibrx:LongTermDebtGrossIncludingAccruedInterest contextRef="c-464" decimals="-5" id="f-1826" unitRef="usd">270000000</ibrx:LongTermDebtGrossIncludingAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-465"
      decimals="INF"
      id="f-1827"
      unitRef="shares">209291936</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-466"
      decimals="2"
      id="f-1828"
      unitRef="usdPerShare">1.29</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <ibrx:LongTermDebtGrossIncludingAccruedInterest contextRef="c-639" decimals="-5" id="f-1829" unitRef="usd">56600000</ibrx:LongTermDebtGrossIncludingAccruedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-640" decimals="-5" id="f-1830" unitRef="usd">4700000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="c-462"
      decimals="INF"
      id="f-1831"
      unitRef="shares">9986920</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-463"
      decimals="2"
      id="f-1832"
      unitRef="usdPerShare">5.67</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:AdditionalPaidInCapital contextRef="c-641" decimals="-5" id="f-1833" unitRef="usd">51900000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1834">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, the Board of Directors adopted, and our stockholders approved, the 2015&#160;Plan. The 2015&#160;Plan, as amended, permits the grant of incentive stock options to the company&#x2019;s employees, and the grant of non-statutory stock options, restricted stock, RSUs, stock appreciation rights, performance units and performance shares to the company&#x2019;s employees, directors, and consultants. In addition, the number of shares reserved for future grant under the 2015&#160;Plan include shares subject to stock options granted under the 2014&#160;Plan that expire or terminate without having been exercised in full and shares issued pursuant to awards granted under the 2014&#160;Plan that are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2015&#160;Plan pursuant to this provision is approximately 346,840&#160;shares as of December&#160;31,&#160;2023). Pursuant to the Merger, we assumed 7,121,110&#160;RSUs (adjusted for the Exchange Ratio) issued under the NC&#160;2015 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, the 2015&#160;Plan is the only equity plan available for grant of equity awards to employees, directors, and consultants of the company. As of December&#160;31,&#160;2023, approximately 13.1&#160;million&#160;shares were available for future grants under the 2015&#160;Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation included on the consolidated statements of operations (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense in operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity and related information for the year ended December&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,262,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;949,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(184,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(207,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,820,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and exercisable as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,867,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, the unrecognized compensation cost related to outstanding stock options was $8.4&#160;million, which is expected to be recognized over a remaining weighted-average period of 1.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31,&#160;2023, the total intrinsic value of stock options exercised was $0.3&#160;million. During the years ended December&#160;31,&#160;2023, 2022 and 2021, cash proceeds received from stock option exercises were $0.3&#160;million, $0.1&#160;million, and $5.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2022, a total of 3,445,499&#160;vested and exercisable stock options were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.69 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S.&#160;Treasury&#x2019;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the year ended December&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance as of December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,551,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,407,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,545,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(909,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, there was $38.2&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.2&#160;years. During the year ended December&#160;31,&#160;2023, the total intrinsic value of RSUs vested was $11.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective as of August&#160;25,&#160;2023, the Compensation Committee of the Board of Directors granted 5,727,159&#160;RSUs to eligible employees of the company, with the intention of retaining such employees (the &#x201c;retention award&#x201d;). The retention award vests according to the following schedule: &#xbd;&#160;(one-half) was to vest and vested on September&#160;1,&#160;2023 and &#xbd;&#160;(one-half) will vest on January&#160;31,&#160;2024, subject to the recipients continuing to be a &#x201c;service provider&#x201d; (as defined in the 2015&#160;Plan) through each applicable vesting date. With respect to RSUs granted, compensation cost was measured using the grant date fair value of $1.65&#160;per share, the closing price of the company&#x2019;s common stock on August&#160;25,&#160;2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs awarded to employees and consultants of affiliated companies are accounted for as stock-based compensation in accordance with FASB ASU 2018-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation (Topic&#160;718)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if7eeec8e66644046bbbe3c0a87df2c46_205" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note&#160;11&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related-Party Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $4.0&#160;million. During the years ended December&#160;31,&#160;2023 and 2022, we recorded $0.4&#160;million, respectively, and $0.9&#160;million of deemed dividends during the year ended December&#160;31,&#160;2021 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;additional paid-in capital,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the consolidated balance sheets, with a corresponding credit to stock-based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related-Party Warrants&lt;/span&gt;&lt;/div&gt;In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#x2019;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of 1,638,000&#160;warrants with an exercise price of $3.24&#160;per share were outstanding as of December&#160;31,&#160;2023. The fair value of $18.0&#160;million assigned to the warrants will be recognized in equity upon achievement of a performance-based vesting condition pertaining to building manufacturing capacity to support supply requirements for one of our product candidates.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c-642"
      decimals="INF"
      id="f-1835"
      unitRef="shares">346840</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-643"
      decimals="INF"
      id="f-1836"
      unitRef="shares">7121110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-644"
      decimals="-5"
      id="f-1837"
      unitRef="shares">13100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1838">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation included on the consolidated statements of operations (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense in operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-645" decimals="-3" id="f-1839" unitRef="usd">13884000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-646" decimals="-3" id="f-1840" unitRef="usd">13280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-647" decimals="-3" id="f-1841" unitRef="usd">11623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-648" decimals="-3" id="f-1842" unitRef="usd">35279000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-649" decimals="-3" id="f-1843" unitRef="usd">26899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-650" decimals="-3" id="f-1844" unitRef="usd">45558000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-1845" unitRef="usd">49163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-10" decimals="-3" id="f-1846" unitRef="usd">40179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-1847" unitRef="usd">57181000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-651" decimals="-3" id="f-1848" unitRef="usd">17341000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-652" decimals="-3" id="f-1849" unitRef="usd">11669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-653" decimals="-3" id="f-1850" unitRef="usd">18819000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-654" decimals="-3" id="f-1851" unitRef="usd">31822000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-655" decimals="-3" id="f-1852" unitRef="usd">28510000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-89" decimals="-3" id="f-1853" unitRef="usd">38362000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-1854" unitRef="usd">49163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-10" decimals="-3" id="f-1855" unitRef="usd">40179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-1856" unitRef="usd">57181000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1857">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity and related information for the year ended December&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,262,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;949,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(184,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(207,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,820,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested and exercisable as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,867,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1858"
      unitRef="shares">9262926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1859"
      unitRef="usdPerShare">9.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-1860" unitRef="usd">4848000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-10" id="f-1861">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-1"
      decimals="INF"
      id="f-1862"
      unitRef="shares">949578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1863"
      unitRef="usdPerShare">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-1"
      decimals="INF"
      id="f-1864"
      unitRef="shares">184362</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1865"
      unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-1"
      decimals="INF"
      id="f-1866"
      unitRef="shares">207707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1867"
      unitRef="usdPerShare">5.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-4"
      decimals="INF"
      id="f-1868"
      unitRef="shares">9820435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1869"
      unitRef="usdPerShare">9.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-1870" unitRef="usd">6046000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1871">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="c-4"
      decimals="INF"
      id="f-1872"
      unitRef="shares">5867252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1873"
      unitRef="usdPerShare">11.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-4" decimals="-3" id="f-1874" unitRef="usd">4118000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1875">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-656" decimals="-5" id="f-1876" unitRef="usd">8400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-657" id="f-1877">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-657" decimals="-5" id="f-1878" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-657" decimals="-5" id="f-1879" unitRef="usd">300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-658" decimals="-5" id="f-1880" unitRef="usd">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-659" decimals="-5" id="f-1881" unitRef="usd">5400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1882"
      unitRef="shares">3445499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1883">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.69 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.90 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-657" id="f-1884">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-658" id="f-1885">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-659" id="f-1886">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-657"
      decimals="3"
      id="f-1887"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-658"
      decimals="3"
      id="f-1888"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-659"
      decimals="3"
      id="f-1889"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-657"
      decimals="3"
      id="f-1890"
      unitRef="number">1.162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-658"
      decimals="3"
      id="f-1891"
      unitRef="number">1.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-659"
      decimals="3"
      id="f-1892"
      unitRef="number">1.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-657"
      decimals="3"
      id="f-1893"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-658"
      decimals="3"
      id="f-1894"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-659"
      decimals="3"
      id="f-1895"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-657"
      decimals="2"
      id="f-1896"
      unitRef="usdPerShare">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-658"
      decimals="2"
      id="f-1897"
      unitRef="usdPerShare">4.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-659"
      decimals="2"
      id="f-1898"
      unitRef="usdPerShare">16.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-1899">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the year ended December&#160;31,&#160;2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.281%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance as of December&#160;31,&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,551,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,407,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,545,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited/canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(909,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Nonvested balance as of December&#160;31,&#160;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,503,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-660"
      decimals="INF"
      id="f-1900"
      unitRef="shares">6551388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-660"
      decimals="2"
      id="f-1901"
      unitRef="usdPerShare">18.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-648"
      decimals="INF"
      id="f-1902"
      unitRef="shares">6407432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-648"
      decimals="2"
      id="f-1903"
      unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-648"
      decimals="INF"
      id="f-1904"
      unitRef="shares">4545644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-648"
      decimals="2"
      id="f-1905"
      unitRef="usdPerShare">7.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-648"
      decimals="INF"
      id="f-1906"
      unitRef="shares">909197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-648"
      decimals="2"
      id="f-1907"
      unitRef="usdPerShare">7.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-661"
      decimals="INF"
      id="f-1908"
      unitRef="shares">7503979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-661"
      decimals="2"
      id="f-1909"
      unitRef="usdPerShare">12.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-661" decimals="-5" id="f-1910" unitRef="usd">38200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-648" id="f-1911">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-648" decimals="-5" id="f-1912" unitRef="usd">11100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-662"
      decimals="INF"
      id="f-1913"
      unitRef="shares">5727159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-662"
      decimals="2"
      id="f-1914"
      unitRef="usdPerShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue contextRef="c-663" decimals="-5" id="f-1915" unitRef="usd">4000000</ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue>
    <us-gaap:Dividends contextRef="c-664" decimals="-5" id="f-1916" unitRef="usd">400000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-665" decimals="-5" id="f-1917" unitRef="usd">400000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-666" decimals="-5" id="f-1918" unitRef="usd">900000</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-667"
      decimals="INF"
      id="f-1919"
      unitRef="shares">1638000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-667"
      decimals="2"
      id="f-1920"
      unitRef="usdPerShare">3.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-667" decimals="-5" id="f-1921" unitRef="usd">18000000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1924">Income Taxes&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S.&#160;federal income tax, as well as income tax in Italy, South Korea, California, and other states. From inception through December&#160;31,&#160;2023, we have not been required to pay U.S.&#160;federal and state income taxes because of current and accumulated NOLs. Our federal returns for tax years 2020 through 2022 remain open to examination, and our state returns remain subject to examination for tax years 2019 through 2022. The Italian and South Korean returns for tax years 2018 through 2022 remain open to examination. Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the IRS or other respective tax authorities. No income tax returns are currently under examination by taxing authorities. There are no cumulative earnings in our Italian and South Korean subsidiaries as of December&#160;31,&#160;2023 that would be subject to U.S.&#160;income tax or foreign withholding tax. We plan to indefinitely reinvest any future earnings of our foreign subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;9,&#160;2021, the company completed the Merger with NantCell. The Merger is accounted for as a transaction between entities under common control, and is considered a nontaxable transaction for U.S.&#160;income tax purposes, as it is intended to qualify as a &#x201c;reorganization&#x201d; (within the meaning of Section&#160;368(a) of the Code).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our loss before income taxes is as follows (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(583,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit (expense) consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components that comprise our net deferred tax liabilities consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.457%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 R&amp;amp;E capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(648,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, we have federal NOLs of $1.6&#160;billion, state NOLs of $2.0&#160;billion, and foreign NOLs of $14.3&#160;million. Of the $1.6&#160;billion in federal NOLs, $1.2&#160;billion do not expire and will be able to be used to offset 80% of taxable income in future years. Of the $2.0&#160;billion in state NOLs, $50.7&#160;million do not expire and will be able to be used to offset 80% of taxable income in future years. The remaining federal NOL carryforwards expire beginning in 2024, the remaining state NOL carryforwards expire beginning in 2024, the South Korean NOL carryforwards expire beginning in 2024, and the Italian NOLs do not expire. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some or all of our deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical operating results and the uncertainty of economic conditions, we recorded a valuation allowance of $648.4&#160;million and $491.8&#160;million as of December&#160;31,&#160;2023 and 2022, respectively. During the years ended December&#160;31,&#160;2023 and 2022, the valuation allowance increased by $156.6&#160;million and $116.6&#160;million, respectively, which was mainly driven by losses from which we cannot benefit. The portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be credited directly to contributed capital is $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal statutory income tax rate to our effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rate adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Sections&#160;382 and 383 of the Code, annual use of our net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. We have not recognized the deferred tax assets for federal and state NOLs and credits of $274.1&#160;million from our deferred tax asset schedules as of December&#160;31,&#160;2023 due to Section&#160;382/383 limitations. There is no impact to tax expense for the derecognition of net operating losses, and federal and state research and development credits due to the valuation allowance recorded against our deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023, we also had federal research tax credit carryforwards of $47.7&#160;million and state research tax credits of $29.6&#160;million. The federal research tax credit carryforwards expire beginning in 2032 and certain state research tax credit carryforwards expire beginning in 2030. Our California research tax credits can be carried forward indefinitely. As of December&#160;31,&#160;2023, we also had federal other tax credits carryforwards of $1.3&#160;million and the tax credit carryforwards expire beginning in 2036 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses and tax credits also are limited when there is a SRLY. These rules generally limit the use of the acquired or departing members&#x2019; net operating loss and tax credit carryovers to the amount of taxable income such entity contributes to consolidated taxable income. The 80%&#160;limitation also applies to SRLY NOL carryovers and tax credits. Therefore, any SRLY NOLs and tax credits will be subject to this limitation, as well as Section&#160;382 and 383 limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31,&#160;2023 and 2022, we have $164.6&#160;million and $77.6&#160;million of interest, respectively, that is temporarily disallowed pursuant to Section&#160;163(j) of the Code. This interest can be carried forward indefinitely and will be deductible when the company generates sufficient adjusted taxable income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of changes to the amount of unrecognized tax benefits is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits as of December&#160;31,&#160;2023 is $15.1&#160;million that, if recognized, would not impact our income tax benefit or effective tax rate as long as the deferred tax asset remains subject to a full valuation allowance. We do not expect that the unrecognized tax benefits will change within 12&#160;months of December&#160;31,&#160;2023. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact our effective tax rate. We have not incurred any material interest or penalties as of the current reporting date with respect to income tax matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inflation Reduction Act of 2022&lt;/span&gt;&lt;/div&gt;The Inflation Reduction Act 2022, which incorporates a corporate alternative minimum tax, was signed on August&#160;16,&#160;2022. The changes are effective for the tax years beginning after December&#160;31,&#160;2022. The new tax will require companies to compute two&#160;separate calculations for federal income tax purposes and pay the greater of the new minimum tax or their regular tax liability. The company will be monitoring the impact of the act to determine if it will have an impact on the company for years beginning after December&#160;31,&#160;2022. We currently do not expect this act will have a material effect on our consolidated financial statements.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1925">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our loss before income taxes is as follows (in&#160;thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(583,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(417,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-1926" unitRef="usd">-581136000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-10" decimals="-3" id="f-1927" unitRef="usd">-413653000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-11" decimals="-3" id="f-1928" unitRef="usd">-347226000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-1929" unitRef="usd">-2756000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-10" decimals="-3" id="f-1930" unitRef="usd">-3633000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-11" decimals="-3" id="f-1931" unitRef="usd">-2613000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1932" unitRef="usd">-583892000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-1933" unitRef="usd">-417286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-1934" unitRef="usd">-349839000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1935">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit (expense) consists of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1936" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1937" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1938" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1939" unitRef="usd">-26000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1940" unitRef="usd">38000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1941" unitRef="usd">9000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1942" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1943" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1944" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1945" unitRef="usd">-26000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1946" unitRef="usd">38000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1947" unitRef="usd">9000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1948" unitRef="usd">-5000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1949" unitRef="usd">-2000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1950" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1951" unitRef="usd">-9000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1952" unitRef="usd">-2000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1953" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1954" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1955" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1956" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <ibrx:DeferredIncomeTaxExpenseBenefitNet contextRef="c-1" decimals="-3" id="f-1957" unitRef="usd">-14000</ibrx:DeferredIncomeTaxExpenseBenefitNet>
    <ibrx:DeferredIncomeTaxExpenseBenefitNet contextRef="c-10" decimals="-3" id="f-1958" unitRef="usd">-4000</ibrx:DeferredIncomeTaxExpenseBenefitNet>
    <ibrx:DeferredIncomeTaxExpenseBenefitNet contextRef="c-11" decimals="-3" id="f-1959" unitRef="usd">0</ibrx:DeferredIncomeTaxExpenseBenefitNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1960" unitRef="usd">-40000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-1961" unitRef="usd">34000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-1962" unitRef="usd">9000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1963">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components that comprise our net deferred tax liabilities consist of the following (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.457%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 R&amp;amp;E capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(648,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-1964" unitRef="usd">420782000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-1965" unitRef="usd">362360000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-1966" unitRef="usd">87721000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-1967" unitRef="usd">50571000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-1968" unitRef="usd">56610000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-1969" unitRef="usd">40954000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-4" decimals="-3" id="f-1970" unitRef="usd">39859000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-5" decimals="-3" id="f-1971" unitRef="usd">19974000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-1972" unitRef="usd">22554000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-1973" unitRef="usd">20927000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-4" decimals="-3" id="f-1974" unitRef="usd">16192000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-5" decimals="-3" id="f-1975" unitRef="usd">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="c-4" decimals="-3" id="f-1976" unitRef="usd">11605000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="c-5" decimals="-3" id="f-1977" unitRef="usd">12986000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <ibrx:DeferredTaxAssetsValuationDiscount contextRef="c-4" decimals="-3" id="f-1978" unitRef="usd">9095000</ibrx:DeferredTaxAssetsValuationDiscount>
    <ibrx:DeferredTaxAssetsValuationDiscount contextRef="c-5" decimals="-3" id="f-1979" unitRef="usd">0</ibrx:DeferredTaxAssetsValuationDiscount>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-4" decimals="-3" id="f-1980" unitRef="usd">7544000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-5" decimals="-3" id="f-1981" unitRef="usd">5886000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-4" decimals="-3" id="f-1982" unitRef="usd">3715000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-1983" unitRef="usd">3969000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-4" decimals="-3" id="f-1984" unitRef="usd">3262000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-5" decimals="-3" id="f-1985" unitRef="usd">3398000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-4" decimals="-3" id="f-1986" unitRef="usd">2944000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-3" id="f-1987" unitRef="usd">1640000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-1988" unitRef="usd">839000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-1989" unitRef="usd">698000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-1990" unitRef="usd">682722000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-1991" unitRef="usd">523363000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements contextRef="c-4" decimals="-3" id="f-1992" unitRef="usd">23365000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements contextRef="c-5" decimals="-3" id="f-1993" unitRef="usd">16527000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-1994" unitRef="usd">9380000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-1995" unitRef="usd">11747000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-1996" unitRef="usd">1533000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-1997" unitRef="usd">3300000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-3" id="f-1998" unitRef="usd">148000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-1999" unitRef="usd">192000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-2000" unitRef="usd">34426000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-2001" unitRef="usd">31766000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-2002" unitRef="usd">648296000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-2003" unitRef="usd">491597000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-2004" unitRef="usd">648444000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-2005" unitRef="usd">491755000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-3" id="f-2006" unitRef="usd">148000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-2007" unitRef="usd">158000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-4" decimals="-8" id="f-2008" unitRef="usd">1600000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-4" decimals="-8" id="f-2009" unitRef="usd">2000000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c-4" decimals="-5" id="f-2010" unitRef="usd">14300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-4" decimals="-8" id="f-2011" unitRef="usd">1600000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-670" decimals="-8" id="f-2012" unitRef="usd">1200000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-4" decimals="-8" id="f-2013" unitRef="usd">2000000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-671" decimals="-5" id="f-2014" unitRef="usd">50700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-5" id="f-2015" unitRef="usd">648400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-2016" unitRef="usd">491800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-2017" unitRef="usd">-156600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-10" decimals="-5" id="f-2018" unitRef="usd">116600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <ibrx:DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital contextRef="c-4" decimals="-5" id="f-2019" unitRef="usd">200000</ibrx:DeferredTaxAssetsValuationAllowanceTaxBenefitsCreditedToContributedCapital>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-2020">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal statutory income tax rate to our effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rate adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-2021" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-10" decimals="3" id="f-2022" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-11" decimals="3" id="f-2023" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-2024" unitRef="number">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-10" decimals="3" id="f-2025" unitRef="number">0.095</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-11" decimals="3" id="f-2026" unitRef="number">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue contextRef="c-1" decimals="3" id="f-2027" unitRef="number">-0.018</ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue>
    <ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue contextRef="c-10" decimals="3" id="f-2028" unitRef="number">0.005</ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue>
    <ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue contextRef="c-11" decimals="3" id="f-2029" unitRef="number">0</ibrx:EffectiveIncomeTaxRateReconciliationWarrantsChangeInFairValue>
    <ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue contextRef="c-1" decimals="3" id="f-2030" unitRef="number">-0.013</ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue>
    <ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue contextRef="c-10" decimals="3" id="f-2031" unitRef="number">0</ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue>
    <ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue contextRef="c-11" decimals="3" id="f-2032" unitRef="number">0</ibrx:EffectiveIncomeTaxRateReconciliationConvertibleNotesChangeInFairValue>
    <ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss contextRef="c-1" decimals="3" id="f-2033" unitRef="number">0.021</ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss>
    <ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss contextRef="c-10" decimals="3" id="f-2034" unitRef="number">0</ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss>
    <ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss contextRef="c-11" decimals="3" id="f-2035" unitRef="number">0</ibrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInvestmentLoss>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-2036" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-10" decimals="3" id="f-2037" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-11" decimals="3" id="f-2038" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-2039" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-10" decimals="3" id="f-2040" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-11" decimals="3" id="f-2041" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-2042" unitRef="number">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-10" decimals="3" id="f-2043" unitRef="number">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-11" decimals="3" id="f-2044" unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-2045" unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-10" decimals="3" id="f-2046" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-11" decimals="3" id="f-2047" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent contextRef="c-1" decimals="3" id="f-2048" unitRef="number">-0.004</ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent>
    <ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent contextRef="c-10" decimals="3" id="f-2049" unitRef="number">-0.021</ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent>
    <ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent contextRef="c-11" decimals="3" id="f-2050" unitRef="number">0</ibrx:EffectiveIncomeTaxReconciliationNondeductibleExpenseSection162mLimitationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-2051" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-10" decimals="3" id="f-2052" unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-11" decimals="3" id="f-2053" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-2054" unitRef="number">-0.302</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="3" id="f-2055" unitRef="number">-0.330</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="3" id="f-2056" unitRef="number">-0.327</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-2057" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-10" decimals="3" id="f-2058" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-11" decimals="3" id="f-2059" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <ibrx:DeferredTaxAssetNotRecognizedSection382383Limitations contextRef="c-4" decimals="-5" id="f-2060" unitRef="usd">274100000</ibrx:DeferredTaxAssetNotRecognizedSection382383Limitations>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-670" decimals="-5" id="f-2061" unitRef="usd">47700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-671" decimals="-5" id="f-2062" unitRef="usd">29600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c-670" decimals="-5" id="f-2063" unitRef="usd">1300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <ibrx:DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed contextRef="c-4" decimals="-5" id="f-2064" unitRef="usd">164600000</ibrx:DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed>
    <ibrx:DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed contextRef="c-5" decimals="-5" id="f-2065" unitRef="usd">77600000</ibrx:DeferredTaxAssetNotRecognizedInterestExpenseTemporarilyDisallowed>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-2066">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of changes to the amount of unrecognized tax benefits is as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-2067" unitRef="usd">16252000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-35" decimals="-3" id="f-2068" unitRef="usd">13504000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-18" decimals="-3" id="f-2069" unitRef="usd">20413000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-2070" unitRef="usd">18976000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-10" decimals="-3" id="f-2071" unitRef="usd">1710000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-2072" unitRef="usd">536000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-2073" unitRef="usd">242000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-10" decimals="-3" id="f-2074" unitRef="usd">1038000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-2075" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-2076" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-10" decimals="-3" id="f-2077" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-2078" unitRef="usd">7445000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-2079" unitRef="usd">35470000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-2080" unitRef="usd">16252000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-35" decimals="-3" id="f-2081" unitRef="usd">13504000</us-gaap:UnrecognizedTaxBenefits>
    <ibrx:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate contextRef="c-4" decimals="-5" id="f-2082" unitRef="usd">15100000</ibrx:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="c-1" id="f-2083">Employee Benefits&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, we adopted a 401(k)&#160;Plan covering all employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the IRS. The company, at its discretion, may make certain contributions to the 401(k)&#160;Plan. During the years ended December&#160;31,&#160;2023, 2022 and 2021, we made contributions totaling $2.8&#160;million, $2.7&#160;million, and $1.7&#160;million, respectively, to the 401(k)&#160;Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensated Absences&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our vacation policy, salaried employees are provided unlimited vacation leave. Therefore, we do not record an accrual for paid leave related to these employees since we are unable to reasonably estimate the compensated absences that these employees will take.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-2084" unitRef="usd">2800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-10" decimals="-5" id="f-2085" unitRef="usd">2700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-11" decimals="-5" id="f-2086" unitRef="usd">1700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
